A Comprehensive Dna Test For The Detection Of Translocations In Acute Leukemia

van den Berg, Eva; Alimohamed, Mohamed; Johansson, Lennart F; de Boer, E. N.; Splinter, E.; Klous, P.; Bosga, A. G.; van Min, M.; Mulder, Anthonius; Vellenga, Edo

Published in:
Haematologica

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 13-02-2019
Este medicamento no se encuentra comercializado en España.
22nd Congress of the European Hematology Association

Madrid, Spain
June 22-25, 2017

ABSTRACT BOOK
Become an EHA member

Support our mission to promote excellence in patient care, research and education in hematology.

Join your fellow EHA members worldwide and enjoy membership benefits for both professional and personal development within the field of hematology.

**BECOME A MEMBER!**
- Full Membership € 155/year
- Junior Membership € 20/year
- Health Care Affiliated Professional Membership € 90/year
- Emeritus Membership € 90/year

**ENJOY OUR MEMBERSHIP BENEFITS ALL-YEAR ROUND**

- Monthly subscription to Haematologica
- Access to EHA Membership Directory
- Unlimited access to the EHA Learning Center
- Discount on EHA Congress and other EHA events
- Nomination and voting rights
- Access to the CV Passport online
- Subscription to EHA newsletters

ALREADY A MEMBER? RENEW YOUR MEMBERSHIP NOW!

[ehaweb.org/eha-membership](http://ehaweb.org/eha-membership)
EHA Board and Organization 22nd Congress

Executive Board
AR Green, United Kingdom [President]
P Sonneveld, the Netherlands [President Elect]
C Chomienne, France [Past President]
M Muckenthaler, Germany [Secretary]
A Engert, Germany [Treasurer]

Councilors
S Fröhling, Germany
G Gaidano, Italy
J Gribben, United Kingdom
S Izraeli, Israel
E Macintyre, France
MV Mateos, Spain
HA Papadaki, Greece
K Porkka, Finland
F Rodeghiero, Italy
V Sexl, Austria

Scientific Program Committee 22nd Congress
S Izraeli, Israel [Chair]
S Eichinger, Austria
A Engert, Germany
A Fielding, United Kingdom
S Fröhling, Germany
K Grønbæk, Denmark
J Jansen, the Netherlands
JJ Kiladjian, France
N Kröger, Germany
H Ludwig, Austria
C Moreno, Spain
M Muckenthaler, Germany
G Ossenkoppele, the Netherlands
JA Pérez-Simón, Spain
D Rees, United Kingdom
A Reiter, Germany
F Rodeghiero, Italy
S Soverini, Italy
S Stanworth, United Kingdom
CH Toh, United Kingdom
MM van den Heuvel-Eibrink, the Netherlands

Local Representative 22nd Congress
A Alegre, Spain

Scientific Program Committee Advisory Board 22nd Congress
I Aurer, Croatia
H Avet-Loiseau, France
C Bonini, Italy
JP Bourquin, Switzerland
M Delforge, Belgium
B Eichhorst, Germany
N Gökbuget, Germany
JB Hansen, Norway
H Hasle, Denmark
H Hasselbalch, Denmark
T Holyoake, United Kingdom
M Hutchings, Denmark
A Iolascon, Italy
PA Kyrie, Austria
T Lapidot, Israel
JI Martin-Subero, Spain
A Nagler, Israel
M Olsson, Sweden
RA Padua, France
D Pospíšilová, Czech Republic
D Prati, Italy
S Saußele, Germany
H Tamary, Israel
A Undas, Poland

EHA Executive Office
Koninginnegracht 12b
2514 AA The Hague
The Netherlands
Tel: +31 (0)70 345 55 63
Fax: +31 (0)70 392 36 63
E-mail: info@ehaweb.org
Website: www.ehaweb.org
Abstract Reviewers

EHA would like to thank the following persons for their time and efforts reviewing abstracts for this Congress.

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Wahab O</td>
<td>USA</td>
</tr>
<tr>
<td>Abdul-Kadir R</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Abken H</td>
<td>Germany</td>
</tr>
<tr>
<td>Ades L</td>
<td>France</td>
</tr>
<tr>
<td>Alegre A</td>
<td>Spain</td>
</tr>
<tr>
<td>Alessi MC</td>
<td>France</td>
</tr>
<tr>
<td>Almeida A, Portugal</td>
<td></td>
</tr>
<tr>
<td>Almeida JM</td>
<td>Spain</td>
</tr>
<tr>
<td>Alvarez-Larran A</td>
<td>Spain</td>
</tr>
<tr>
<td>Andre M</td>
<td>Belgium</td>
</tr>
<tr>
<td>Asp J</td>
<td>Sweden</td>
</tr>
<tr>
<td>Auer I</td>
<td>Croatia</td>
</tr>
<tr>
<td>Avet-Loiseau H</td>
<td>France</td>
</tr>
<tr>
<td>Barcellini W</td>
<td>Italy</td>
</tr>
<tr>
<td>Bartels M</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Beilhack A</td>
<td>Germany</td>
</tr>
<tr>
<td>Berntorp E</td>
<td>Sweden</td>
</tr>
<tr>
<td>Bhatia R</td>
<td>USA</td>
</tr>
<tr>
<td>Bierings M</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Bocchia M</td>
<td>Italy</td>
</tr>
<tr>
<td>Bodo I</td>
<td>Hungary</td>
</tr>
<tr>
<td>Boelevs JJ</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Boll N</td>
<td>Italy</td>
</tr>
<tr>
<td>Bondanza A</td>
<td>Italy</td>
</tr>
<tr>
<td>Bonfazi F</td>
<td>Italy</td>
</tr>
<tr>
<td>Bonini C</td>
<td>Italy</td>
</tr>
<tr>
<td>Bennet D</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Bonetain F</td>
<td>France</td>
</tr>
<tr>
<td>Bornhauser B</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Bosch F</td>
<td>Spain</td>
</tr>
<tr>
<td>Bourquin JP</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Boursac D</td>
<td>France</td>
</tr>
<tr>
<td>Brakkan SK</td>
<td>Norway</td>
</tr>
<tr>
<td>Brandt DM</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Breuins D</td>
<td>Belgium</td>
</tr>
<tr>
<td>Burnett A</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Caballero P</td>
<td>Spain</td>
</tr>
<tr>
<td>Caballero P</td>
<td>Spain</td>
</tr>
<tr>
<td>Cahn A</td>
<td>Sweden</td>
</tr>
<tr>
<td>Canesi A</td>
<td>Italy</td>
</tr>
<tr>
<td>Canaani J</td>
<td>USA</td>
</tr>
<tr>
<td>Cazzola M</td>
<td>Italy</td>
</tr>
<tr>
<td>Chakraverty R</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chalandon Y</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Chiapella A</td>
<td>Italy</td>
</tr>
<tr>
<td>Chiarietti S</td>
<td>Italy</td>
</tr>
<tr>
<td>Ching WJ</td>
<td>Singapore</td>
</tr>
<tr>
<td>Ciceni F</td>
<td>Italy</td>
</tr>
<tr>
<td>Clappier E</td>
<td>France</td>
</tr>
<tr>
<td>Colombati R</td>
<td>Italy</td>
</tr>
<tr>
<td>Colomer D</td>
<td>Spain</td>
</tr>
<tr>
<td>Copland M</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Craddock C</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Curti A</td>
<td>Italy</td>
</tr>
<tr>
<td>Da Costa L</td>
<td>France</td>
</tr>
<tr>
<td>Damm F</td>
<td>Germany</td>
</tr>
<tr>
<td>Davies A</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>de Bont E, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>de Botton S</td>
<td>France</td>
</tr>
<tr>
<td>de la Fuente A</td>
<td>Spain</td>
</tr>
<tr>
<td>de la Rubia J</td>
<td>Spain</td>
</tr>
<tr>
<td>De Meerlooste B</td>
<td>Belgium</td>
</tr>
<tr>
<td>de Montalembert M</td>
<td>France</td>
</tr>
<tr>
<td>Delforge M</td>
<td>Belgium</td>
</tr>
<tr>
<td>den Boer M, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Devos T</td>
<td>Belgium</td>
</tr>
<tr>
<td>Dokal I, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Dolstra H</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Dreyling M</td>
<td>Germany</td>
</tr>
<tr>
<td>Duhren U</td>
<td>Germany</td>
</tr>
<tr>
<td>Eaves C</td>
<td>Canada</td>
</tr>
<tr>
<td>Edgren S</td>
<td>Sweden</td>
</tr>
<tr>
<td>Eichorst B</td>
<td>Germany</td>
</tr>
<tr>
<td>Eichinger S</td>
<td>Austria</td>
</tr>
<tr>
<td>Elitzur S</td>
<td>Israel</td>
</tr>
<tr>
<td>Engellhardt M</td>
<td>Germany</td>
</tr>
<tr>
<td>Englert A</td>
<td>Germany</td>
</tr>
<tr>
<td>Facon T</td>
<td>France</td>
</tr>
<tr>
<td>Federico M</td>
<td>Italy</td>
</tr>
<tr>
<td>Fibbe W, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Fielding A</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Frohling S</td>
<td>Germany</td>
</tr>
<tr>
<td>Ganser A</td>
<td>Germany</td>
</tr>
<tr>
<td>Garcia-Marcio J</td>
<td>Spain</td>
</tr>
<tr>
<td>Ganzburg Y</td>
<td>Spain</td>
</tr>
<tr>
<td>Giralt S</td>
<td>USA</td>
</tr>
<tr>
<td>Gin N</td>
<td>USA</td>
</tr>
<tr>
<td>Gisselbrecht C</td>
<td>France</td>
</tr>
<tr>
<td>Gökübüret N</td>
<td>Germany</td>
</tr>
<tr>
<td>Goldschmidt H</td>
<td>Germany</td>
</tr>
<tr>
<td>Gomes da Silva M</td>
<td>Portugal</td>
</tr>
<tr>
<td>Goudemond J</td>
<td>France</td>
</tr>
<tr>
<td>Grebien F</td>
<td>Austria</td>
</tr>
<tr>
<td>Greinix H</td>
<td>Austria</td>
</tr>
<tr>
<td>Gronbaek K</td>
<td>Denmark</td>
</tr>
<tr>
<td>Groschel S</td>
<td>Germany</td>
</tr>
<tr>
<td>Gutierrez N</td>
<td>Spain</td>
</tr>
<tr>
<td>Hagenbeek A</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Hansen JB</td>
<td>Norway</td>
</tr>
<tr>
<td>Harrison C</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Hasle H, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Hasselbalch H</td>
<td>Denmark</td>
</tr>
<tr>
<td>Heemskerk JWM, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Herrmann C</td>
<td>Belgium</td>
</tr>
<tr>
<td>Hermouet S</td>
<td>France</td>
</tr>
<tr>
<td>Heß G, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Heyman M</td>
<td>Sweden</td>
</tr>
<tr>
<td>Holte H</td>
<td>Norway</td>
</tr>
<tr>
<td>Horvathova M</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Hough T, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Huls G, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Hunault-Berger M</td>
<td>France</td>
</tr>
<tr>
<td>Hutingships M</td>
<td>Denmark</td>
</tr>
<tr>
<td>Iolascon A</td>
<td>Italy</td>
</tr>
<tr>
<td>Ionova T</td>
<td>Russia</td>
</tr>
<tr>
<td>Israelli S</td>
<td>Israel</td>
</tr>
<tr>
<td>Jansen J, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Janssen J, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Jeremias I, Germany</td>
<td></td>
</tr>
<tr>
<td>Jerkeman M</td>
<td>Sweden</td>
</tr>
<tr>
<td>Johnson P, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Jurgczak W</td>
<td>Poland</td>
</tr>
<tr>
<td>Karlsson S</td>
<td>Norway</td>
</tr>
<tr>
<td>Kaspers GJ, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Kather AP, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Kattamis A</td>
<td>Greece</td>
</tr>
<tr>
<td>Kildjian JJ</td>
<td>France</td>
</tr>
<tr>
<td>Krause D</td>
<td>Germany</td>
</tr>
<tr>
<td>Kristinsson S</td>
<td>Sweden</td>
</tr>
<tr>
<td>Kröger N, Germany</td>
<td></td>
</tr>
<tr>
<td>Kruger W, Germany</td>
<td></td>
</tr>
<tr>
<td>Kuhn M, Germany</td>
<td></td>
</tr>
<tr>
<td>Kyrie PA, Austria</td>
<td></td>
</tr>
<tr>
<td>Lamy T, France</td>
<td></td>
</tr>
<tr>
<td>Lane S, Australia</td>
<td></td>
</tr>
<tr>
<td>Laperche S, France</td>
<td></td>
</tr>
<tr>
<td>Lapidot T, Israel</td>
<td></td>
</tr>
<tr>
<td>Leblanc T, France</td>
<td></td>
</tr>
<tr>
<td>Lehmann S, Sweden</td>
<td></td>
</tr>
<tr>
<td>Lippert E, France</td>
<td></td>
</tr>
<tr>
<td>Ljungman P, Sweden</td>
<td></td>
</tr>
<tr>
<td>Lo Celso C, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Lucas C, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Ludwig H, Austria</td>
<td></td>
</tr>
<tr>
<td>Luminari S, Italy</td>
<td></td>
</tr>
<tr>
<td>Macintyre E, France</td>
<td></td>
</tr>
<tr>
<td>Maertens J, Belgium</td>
<td></td>
</tr>
<tr>
<td>Maguer-Satta V, France</td>
<td></td>
</tr>
<tr>
<td>Manz M, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Martin-Subero Ji, Spain</td>
<td></td>
</tr>
<tr>
<td>Mayer J, the Czech Republic</td>
<td></td>
</tr>
<tr>
<td>McMahan C, Ireland</td>
<td></td>
</tr>
<tr>
<td>Medyouth H, Germany</td>
<td></td>
</tr>
<tr>
<td>Mendez-Ferrer S, United</td>
<td>Kingdom</td>
</tr>
<tr>
<td>Mercher T, France</td>
<td></td>
</tr>
<tr>
<td>Mesa R, USA</td>
<td></td>
</tr>
<tr>
<td>Micahlet M, France</td>
<td></td>
</tr>
<tr>
<td>Micaux L, Belgium</td>
<td></td>
</tr>
<tr>
<td>Mocca A, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Mulder-Tidow C, Germany</td>
<td></td>
</tr>
<tr>
<td>Mulligan S, Australia</td>
<td></td>
</tr>
<tr>
<td>Munshi N, USA</td>
<td></td>
</tr>
<tr>
<td>Muus P, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Nagler A, Israel</td>
<td></td>
</tr>
<tr>
<td>Nicolin F, France</td>
<td></td>
</tr>
<tr>
<td>Niemann C, Denmark</td>
<td></td>
</tr>
<tr>
<td>Nomdedeau J, Spain</td>
<td></td>
</tr>
<tr>
<td>Norden A, France</td>
<td></td>
</tr>
<tr>
<td>Oakes C, USA</td>
<td></td>
</tr>
<tr>
<td>Olavarría E, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Oliva E, Italy</td>
<td></td>
</tr>
<tr>
<td>Olsson M, Sweden</td>
<td></td>
</tr>
<tr>
<td>Oriel A, Spain</td>
<td></td>
</tr>
<tr>
<td>Ossenkoppele G, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Padua R, France</td>
<td></td>
</tr>
<tr>
<td>Papaemmanuil E</td>
<td>USA</td>
</tr>
<tr>
<td>Pellegratti A, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Pérez-Simón JA, Spain</td>
<td></td>
</tr>
<tr>
<td>Petrucci MT, Italy</td>
<td></td>
</tr>
<tr>
<td>Plesner TH, Denmark</td>
<td></td>
</tr>
<tr>
<td>Porka K, Finland</td>
<td></td>
</tr>
<tr>
<td>Porto G, Portugal</td>
<td></td>
</tr>
<tr>
<td>Pospíšilova D, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>Pott C, Germany</td>
<td></td>
</tr>
<tr>
<td>Prati D, Italy</td>
<td></td>
</tr>
<tr>
<td>Premawardhena A, Sri Lanka</td>
<td></td>
</tr>
<tr>
<td>Preudhomme C, France</td>
<td></td>
</tr>
<tr>
<td>Puissant A, France</td>
<td></td>
</tr>
<tr>
<td>Raaimakers M, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Racil Z, Germany</td>
<td></td>
</tr>
<tr>
<td>Raemaekers J, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Raje N, USA</td>
<td></td>
</tr>
<tr>
<td>Ramenghi U, Italy</td>
<td></td>
</tr>
<tr>
<td>Ravandi F, USA</td>
<td></td>
</tr>
<tr>
<td>Rees D, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Reiter A, Germany</td>
<td></td>
</tr>
<tr>
<td>Renela R, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Risitano A, Italy</td>
<td></td>
</tr>
<tr>
<td>Riva N, Italy</td>
<td></td>
</tr>
<tr>
<td>Roberts I, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Rodeghiero F, Italy</td>
<td></td>
</tr>
<tr>
<td>Rosendaal FR, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Rosenquist R, Sweden</td>
<td></td>
</tr>
<tr>
<td>Rosinol L, Spain</td>
<td></td>
</tr>
<tr>
<td>Rovo A, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Rowe I, Ireland</td>
<td></td>
</tr>
<tr>
<td>Ruutu T, Finland</td>
<td></td>
</tr>
<tr>
<td>Salles G, France</td>
<td></td>
</tr>
<tr>
<td>San Miguel J, Spain</td>
<td></td>
</tr>
<tr>
<td>Sanchez M, Spain</td>
<td></td>
</tr>
<tr>
<td>Sander B, Sweden</td>
<td></td>
</tr>
<tr>
<td>Santini V, Italy</td>
<td></td>
</tr>
<tr>
<td>Sanz O, Spain</td>
<td></td>
</tr>
<tr>
<td>Saussele S, Germany</td>
<td></td>
</tr>
<tr>
<td>Savage K, Canada</td>
<td></td>
</tr>
<tr>
<td>Schneider R, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Schrezenmeier H, Germany</td>
<td></td>
</tr>
<tr>
<td>Schuh A, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Sekeres M, USA</td>
<td></td>
</tr>
<tr>
<td>Selleslag D, Belgium</td>
<td></td>
</tr>
<tr>
<td>Shipilberg O, Israel</td>
<td></td>
</tr>
<tr>
<td>Skov V, Denmark</td>
<td></td>
</tr>
<tr>
<td>Socie G, France</td>
<td></td>
</tr>
<tr>
<td>Sonneveld P, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Souverini S, Italy</td>
<td></td>
</tr>
<tr>
<td>Spina M, Italy</td>
<td></td>
</tr>
<tr>
<td>Stanworth S, United</td>
<td>Kingdom</td>
</tr>
<tr>
<td>Steele A, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Suttrop M, Germany</td>
<td></td>
</tr>
<tr>
<td>Tadmor T, Israel</td>
<td></td>
</tr>
<tr>
<td>Taher A, Lebanon</td>
<td></td>
</tr>
<tr>
<td>Tamary H, Israel</td>
<td></td>
</tr>
<tr>
<td>te Boekhorst P, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Teshima T, Japan</td>
<td></td>
</tr>
<tr>
<td>Thompson A, United</td>
<td>Kingdom</td>
</tr>
<tr>
<td>Toh CH, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Tothova Z, USA</td>
<td></td>
</tr>
<tr>
<td>Trka J, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>Trumper L, Germany</td>
<td></td>
</tr>
<tr>
<td>Ugo V, France</td>
<td></td>
</tr>
<tr>
<td>Undas A, Poland</td>
<td></td>
</tr>
<tr>
<td>Uyl-de Groot C, the</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Vago L, Italy</td>
<td></td>
</tr>
<tr>
<td>van den Heuvel-Eibrink MM, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>van der Velden V, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>van Duin M, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>van Tendelo V, Belgium</td>
<td></td>
</tr>
<tr>
<td>Venditti A, Italy</td>
<td></td>
</tr>
<tr>
<td>Verma A, USA</td>
<td></td>
</tr>
<tr>
<td>von Lilienfeld-Toal M, the Netherlands</td>
<td></td>
</tr>
<tr>
<td>Watata C, Poland</td>
<td></td>
</tr>
<tr>
<td>Windygard J, Poland</td>
<td></td>
</tr>
<tr>
<td>Wolodarski M, Germany</td>
<td></td>
</tr>
<tr>
<td>Yacobovich J, Israel</td>
<td></td>
</tr>
<tr>
<td>Yerushalmi R, Israel</td>
<td></td>
</tr>
<tr>
<td>Zenz T, Germany</td>
<td></td>
</tr>
</tbody>
</table>

Journal of the European Hematology Association

Owned & published by the Ferrata Storti Foundation
Word of Welcome

On behalf of the EHA Board and the Scientific Program Committee we are pleased to introduce to you this year’s Abstract Program. The richness of the program is a testament to EHA’s spirit: unity through diversity.

The Scientific Program Committee has compiled an exciting program of Simultaneous Oral and Poster Sessions from close to 2500 submitted abstracts representing all fields of hematology. For the second year, a number of presenters will have the opportunity to pitch their abstract. These Poster pitches are an exciting opportunity to promote basic science and research, and to invite delegates to the poster walks.

The six Best Abstracts will be presented during the Presidential Symposium on Friday afternoon. This will be a session not to miss. During this plenary session EHA is also awarding, for the first time, the best abstracts by trainees in four categories in basic and clinical hematology research. These awardees and the travel grant winners can be found on the next page. YoungEHA are the future of hematology!

The late breaking abstract submission is an integral part of the scientific program. The late breaking submission is intended for abstracts with “hot” data that were not available by the time of the regular submission deadline. Only few abstracts, with the most exciting results are selected for a presentation in the Late Breaking Oral Session on Sunday morning.

A selection of abstracts will be presented during the regular Poster Walks. The Poster Session consists of two parts: the Poster Walk and dedicated Poster Browsing Time. This setup guarantees sufficient time for discussion of the important research presented, so look out for the Poster Walk Moderators in their red baseball caps! There will also be E-posters available on the E-poster screens, for which a specific time is allocated during the Poster Browsing Time at the end of each Walk. The Simultaneous Oral Sessions are spread over three days (Friday to Sunday) providing you with ample opportunity to attend a number of these important sessions.

All posters can be viewed on the E-poster screens from Friday morning to Saturday evening. All the abstracts are also available on the EHA Learning Center, for which you have complimentary access after the congress: learningcenter.ehaweb.org.

On behalf of the EHA Board, the committees and all the people involved in this year’s EHA Congress, we thank you for coming to Madrid and wish you a great meeting.

Shai Izraeli
Chair Scientific Program Committee 22nd Congress
Travel Grant Winners

For this Congress 140 travel grants have been awarded to junior members of EHA, based on the mean score of their abstracts.

EHA congratulates the following persons with their travel grants:

Agrawal M, Germany
Anagnostou T, USA
Arriazu E, Spain
Barcia Duran JG, USA
Beekman R, Spain
Bhoi S, Sweden
Binder M, USA
Birgisdóttir AM, Iceland
Blunt M, United Kingdom
Botelho J, United Kingdom
Bouillon AS, Belgium
Brockelmann P, Germany
Buffiere A, France
Burney C, United Kingdom
Cabal-Hierro L, USA
Caraffini V, Austria
Casado Izquierdo P, United Kingdom
Cerchione C, Italy
Chaudhry G, India
Chitre S, United Kingdom
Cleyrat C, USA
De Bie J, Belgium
De la Morena-Barrio ME, Spain
De Paepe K, United Kingdom
De Rosa G, Italy
Di Marcantonio D, USA
Dimohamed A, the Netherlands
Dominguez Rodriguez M, Spain
Durán-Ferrer M, Spain
Eisfeld AK, USA
Escriba García L, Spain
Eskekund C, Denmark
Fancelli L, Belgium
Farina F, Italy
Fattizzo B, Italy
Fernandez MC, Spain
Ferrero S, Italy
Figueroa R, Spain
Flasinski M, Germany
Gabella M, Italy
Ganuza Fernandez M, USA
Garcia Ramirez P, Spain
Geelen J, the Netherlands
Giannoni L, Italy
Gugliotta G, Italy
Hansen J, Denmark
Hasibeder A, Germany
Healey M, United Kingdom
Hermetet F, France
Herrmann O, Germany
Hu B, USA
Iskander D, United Kingdom
Jafar S, United Kingdom
Jentsch M, Germany
Jetani H, Germany
Kampen K, Belgium
Karamitros D, United Kingdom
Kardosova M, Czech Republic
Karjalainen R, Finland
Karsa M, Australia
Kim JC, Republic of Korea
Kim T, Canada
Koning MT, the Netherlands
Laurea de Orte E, Spain
Li X, China
Lippert L, Germany
Machnicki MM, Poland
Maekawa T, Japan
Manier S, France
Mannion N, United Kingdom
Manta L, Germany
Marchesini M, Italy
McKerrell T, United Kingdom
McPherson S, United Kingdom
Medano Dominguez M, Spain
Meyer-Pannwitt V, Germany
Milani P, Italy
Miller K, USA
Mitchell RJ, United Kingdom
Mora B, Italy
Morales Hernandez A, USA
Morita K, Japan
Nadeu F, Spain
Nasso D, Italy
Norfo R, United Kingdom
O’Byrne S, United Kingdom
O’Byrne S, United Kingdom
Ordonez R, Spain
Papaioannou D, USA
Passaro D, United Kingdom
Pawlyn C, United Kingdom
Pei X, China
Peric Z, Croatia
Plevka K, Czech Republic
Pozzo F, Italy
Prassek W, Germany
Puglise N, Italy
Rentz F, Hungary
Ribeiro D, Portugal
Rotolo A, United Kingdom
Saeed BRM, Germany
Schwartzman O, Israel
Seyfried F, Germany
Short N, USA
Smith J, United Kingdom
Song Y, China
Stamatopoulos B, Belgium
Stege C, the Netherlands
Stieglitz E, USA
Sud A, United Kingdom
Suksangpleng T, Thailand
Sullima S, Belgium
Suzuki K, Japan
Swan M, Czech Republic
Sverrisdottir IS, Iceland
Talati C, USA
Theis F, Germany
Thivakan K, Germany
Thompson P, USA
Thorsteinsson S, Iceland
Tissino E, Italy
Toda J, Japan
Unnikrishnan A, Australia
Uras I, Austria
Van de Wijngaert Z, France
Van den Bergh M, USA
van Doornewert B, the Netherlands
van Straaten S, the Netherlands
Vermaat J, the Netherlands
Versluis J, the Netherlands
Vinas L, Spain
Vinch F, Germany
Viswanathan GK, India
Wannez A, Belgium
Weigl A, Germany
Wiggers C, the Netherlands
Zaninetti C, Italy

YoungEHA Best Abstract Awards

One of the primary missions of the European Hematology Association is to support young hematology clinicians and researchers. This year we are proud to announce the launching of the YoungEHA Best Abstract Awards. These will be awarded to the highest ranking abstracts in the following four categories: Clinicians or medical students training for a PhD degree, PhD research students, postdoctoral fellows and clinical hematology trainees. We are honored that these outstanding YoungEHA trainees will be presenting during the EHA congress – they are the future of Hematology!

**CLINICAL TRAINEE AWARD**
K C Pawlyn, United Kingdom

**MD-PHD AWARD**
K O Schwartzman, Israel

**PHD RESEARCH STUDENT AWARD**
K JB Barcia Duran, USA

**POSTDOCTORAL RESEARCH TRAINEE AWARD**
K F Vinchi, Italy
Information for readers, authors and subscribers

Haematologica (print edition, pISSN 0890-6078, eISSN 1592-8721) publishes peer-reviewed papers on all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community following the recommendations of the World Association of Medical Editors (www.wame.org) and the International Committee of Medical Journal Editors (www.icmje.org).

Haematologica publishes editorials, research articles, review articles, guideline articles and letters. Manuscripts should be prepared according to our guidelines (www.haematologica.org/information-for-authors), and the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, prepared by the International Committee of Medical Journal Editors (www.icmje.org).

Manuscripts should be submitted online at http://www.haematologica.org/.

Conflict of interests. According to the International Committee of Medical Journal Editors (http://www.icmje.org/#conflicts), “Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making”. The ad hoc journal’s policy is reported in detail online (www.haematologica.org/content/policies).

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Ferrata Storti Foundation. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

Detailed information about subscriptions is available online at www.haematologica.org. Haematologica is an open access journal. Access to the online journal is free. Use of the Haematologica App (available on the App Store and on Google Play) is free.

For subscriptions to the printed issue of the journal, please contact: Haematologica Office, via Giuseppe Belli 4, 27100 Pavia, Italy (phone +39.0382.27129, fax +39.0382.394705, E-mail: info@haematologica.org).

Rates of the International edition for the year 2017 are as following:

<table>
<thead>
<tr>
<th></th>
<th>Institutional</th>
<th>Personal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euro</td>
<td>500</td>
<td>450</td>
</tr>
</tbody>
</table>

Advertisements. Contact the Advertising Manager, Haematologica Office, via Giuseppe Belli 4, 27100 Pavia, Italy (phone +39.0382.27129, fax +39.0382.394705, E-mail: marketing@haematologica.org).

Disclaimer. Whilst every effort is made by the publishers and the editorial board to see that no inaccurate or misleading data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles or advertisements herein are the responsibility of the contributor or advisor concerned. Accordingly, the publisher, the editorial board and their respective employees, officers and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion or statement. Whilst all due care is taken to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this journal, should only be followed in conjunction with the drug manufacturer's own published literature.

Direttore responsabile: Prof. Edoardo Ascari; Autorizzazione del Tribunale di Pavia n. 63 del 5 marzo 1955.
Printing: Tipografia PI-ME, via Vigentina 136, Pavia, Italy. Printed in June 2017.
# TABLE OF CONTENTS

## Simultaneous sessions I

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>New advances in plasma cell disorders and implications for therapy</td>
<td>S100 - S104</td>
<td>1</td>
</tr>
<tr>
<td>Aggressive Non-Hodgkin lymphoma - 1st line</td>
<td>S105 - S109</td>
<td>4</td>
</tr>
<tr>
<td>MRD directed treatment in AML</td>
<td>S110 - S114</td>
<td>6</td>
</tr>
<tr>
<td>New insights into chronic lymphocytic leukemia biology</td>
<td>S115 - S118</td>
<td>9</td>
</tr>
<tr>
<td>Pathogenesis of MDS</td>
<td>S119 - S123</td>
<td>11</td>
</tr>
<tr>
<td>Lymphoma biology</td>
<td>S124 - S127</td>
<td>13</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>S128 - S132</td>
<td>15</td>
</tr>
<tr>
<td>AML. Biology I: Towards molecular therapies</td>
<td>S133 - S137</td>
<td>17</td>
</tr>
<tr>
<td>Hematopoiesis, stem cells and microenvironment</td>
<td>S138 - S140</td>
<td>19</td>
</tr>
<tr>
<td>Gene therapy, cellular immunotherapy and vaccination 1</td>
<td>S141 - S145</td>
<td>21</td>
</tr>
</tbody>
</table>

## Presidential Symposium

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best abstracts</td>
<td>S146 - S150</td>
<td>23</td>
</tr>
</tbody>
</table>

## Poster sessions I

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoblastic leukemia - Biology 1</td>
<td>P151 - P159</td>
<td>26</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia - Clinical 1</td>
<td>P160 - P170</td>
<td>30</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Biology 2</td>
<td>P171 - P180</td>
<td>35</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Clinical 1</td>
<td>P181 - P190</td>
<td>39</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Clinical 2</td>
<td>P191 - P199</td>
<td>43</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Clinical 3</td>
<td>P200 - P207</td>
<td>48</td>
</tr>
<tr>
<td>Bone marrow failure syndromes incl. PNH - Biology</td>
<td>P208 - P215</td>
<td>52</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia and related disorders - Biology 1</td>
<td>P216 - P223</td>
<td>56</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia and related disorders - Clinical</td>
<td>P226 - P233</td>
<td>60</td>
</tr>
<tr>
<td>Chronic myeloid leukemia - Clinical 1</td>
<td>P234 - P241</td>
<td>64</td>
</tr>
<tr>
<td>Hematopoiesis, stem cells and microenvironment</td>
<td>P242 - P249</td>
<td>69</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>P250 - P257</td>
<td>74</td>
</tr>
<tr>
<td>Iron metabolism, deficiency and overload</td>
<td>P258 - P265</td>
<td>77</td>
</tr>
<tr>
<td>Lymphoma biology</td>
<td>P266 - P273</td>
<td>81</td>
</tr>
<tr>
<td>Myelodysplastic syndromes – Clinical 1</td>
<td>P274 - P281</td>
<td>85</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies - Biology</td>
<td>P282 - P289</td>
<td>89</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies - Clinical 1</td>
<td>P290 - P297</td>
<td>93</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies - Clinical 2</td>
<td>P300 - P307</td>
<td>97</td>
</tr>
<tr>
<td>Myeloproliferative neoplasms - Clinical 1</td>
<td>P308 - P315</td>
<td>101</td>
</tr>
<tr>
<td>Platelet disorders: Basic</td>
<td>P316 - P323</td>
<td>102</td>
</tr>
<tr>
<td>Quality of life, palliative care, ethics and health economics 1</td>
<td>P324 - P331</td>
<td>106</td>
</tr>
<tr>
<td>Stem cell transplantation - Clinical 1</td>
<td>P332 - P339</td>
<td>110</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>P340 - P347</td>
<td>113</td>
</tr>
<tr>
<td>Transfusion medicine</td>
<td>P348 - P355</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>P356 - P363</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>P364 - P371</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>P372 - P379</td>
<td>129</td>
</tr>
<tr>
<td></td>
<td>P380 - P387</td>
<td>133</td>
</tr>
<tr>
<td></td>
<td>P388 - P395</td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>P396 - P403</td>
<td>141</td>
</tr>
</tbody>
</table>

Owned & published by the Ferrata Storti Foundation

Journal of the European Hematology Association

haematologica
# Table of Contents

## Simultaneous sessions II

- Front-line combinations in multiple myeloma and amyloidosis S407 - S411 p. 142
- Hodgkin and indolent lymphoma - Clinical S412 - S416 p. 145
- Biology of MPN: JAK2 and beyond S417 - S421 p. 148
- Clinical trials including treatment discontinuation in CML S422 - S426 p. 150
- AML: Biology II. Epigenetic targets S427 - S430 p. 153
- Acquired and inherited platelet disorders S431 - S435 p. 155
- Acute lymphoblastic leukemia - Biology S436 - S440 p. 157
- Thrombotic disorders S441 - S445 p. 160
- Stem cell transplantation - Experimental S446 - S450 p. 162
- Sickle cell disease, enzymes S451 - S455 p. 164
- New drugs for rescue in relapsed/refractory multiple myeloma S456 - S460 p. 167
- Improving prognostication and front-line therapy in chronic lymphocytic leukemia S461 - S465 p. 170
- Aggressive Non-Hodgkin lymphoma - Relapsed/refractory S466 - S470 p. 172
- Targeted treatment of AML S471 - S475 p. 175
- Immunotherapy in ALL S476 - S480 p. 178
- Biology and disease monitoring in CML S481 - S485 p. 183
- Prognostic markers and new treatment in MDS S486 - S490 p. 183
- Stem cell transplantation - Clinical I S491 - S495 p. 185
- Bone marrow failure and PNH S496 - S500 p. 188
- Quality of life, palliative care, ethics and health economics S501 - S505 p. 190

## Poster sessions II

- Acute lymphoblastic leukemia - Biology 2 P506 - P514 p. 193
- Acute lymphoblastic leukemia - Clinical 2 P515 - P525 p. 196
- Acute myeloid leukemia - Biology 3 P526 - P535 p. 201
- Acute myeloid leukemia - Biology 4 P536 - P545 p. 205
- Acute myeloid leukemia - Clinical 4 P546 - P553 p. 209
- Acute myeloid leukemia - Clinical 5 P554 - P562 p. 213
- Aggressive Non-Hodgkin lymphoma - Relapsed/refractory P563 - P572 p. 218
- Bone marrow failure syndromes incl. PNH - Clinical P573 - P582 p. 223
- Chronic lymphocytic leukemia and related disorders - Biology 2 P583 - P590 p. 227
- Chronic myeloid leukemia - Biology P591 - P600 p. 231
- Chronic myeloid leukemia - Clinical 2 P601 - P611 p. 235
- Enzymes and sickle cell disease P612 - P620 p. 241
- Gene therapy, cellular immunotherapy and vaccination P621 - P631 p. 245
- Indolent Non-Hodgkin lymphoma - Clinical P632 - P641 p. 249
- Infectious diseases, supportive care P642 - P651 p. 253
- Myelodysplastic syndromes - Biology P652 - P661 p. 258
- Myelodysplastic syndromes - Clinical 2 P662 - P668 p. 262
- Myeloma and other monoclonal gammopathies - Clinical 3 P669 - P678 p. 266
- Myeloma and other monoclonal gammopathies - Clinical 4 P679 - P688 p. 271
- Myeloproliferative neoplasms - Biology P689 - P698 p. 275
- Myeloproliferative neoplasms - Clinical 2 P699 - P708 p. 279
- Other Non-malignant hematopoietic disorders P709 - P718 p. 285
- Platelet disorders: Clinical P719 - P727 p. 290
- Quality of life, palliative care, ethics and health economics 2 P728 - P737 p. 295
- Stem cell transplantation - Clinical 2 P738 - P748 p. 299
- Stem cell transplantation - Experimental P749 - P758 p. 304
- Thrombotic disorders P759 - P765 p. 307
Simultaneous sessions III

Targeted therapies in relapsed in chronic lymphocytic leukemia
Follicular lymphoma - Clinical
Changing the strategy of therapy in multiple myeloma
Old and new drugs in MPN
Childhood and more intensive treatment of AML
Stem cell transplantation - Clinical 2
Biomarkers in ALL
Infectious diseases, supportive care
Iron: Deficiency and overload
Gene therapy, cellular immunotherapy and vaccination 2

E-posters

Acute lymphoblastic leukemia - Biology
Acute lymphoblastic leukemia - Clinical
Acute myeloid leukemia - Biology
Acute myeloid leukemia - Clinical
Aggressive Non-Hodgkin lymphoma - Clinical
Bleeding disorders (congenital and acquired)
Bone marrow failure syndromes incl. PNH - Clinical
Chronic lymphocytic leukemia and related disorders - Biology
Chronic lymphocytic leukemia and related disorders - Clinical
Chronic myeloid leukemia - Biology
Chronic myeloid leukemia - Clinical
Enzymopathies, membranopathies and other anemias
Gene therapy, cellular immunotherapy and vaccination
Hematopoiesis, stem cells and microenvironment
Hodgkin lymphoma - Clinical
Indolent Non-Hodgkin lymphoma -Clinical
Infectious diseases, supportive care
Iron metabolism, deficiency and overload
Myelodysplastic syndromes - Biology
Myelodysplastic syndromes - Clinical
Myeloma and other monoclonal gammopathies - Biology
Myeloma and other monoclonal gammopathies - Clinical
Myeloproliferative neoplasms - Biology
Myeloproliferative neoplasms - Clinical
Non-Hodgkin & Hodgkin lymphoma - Biology
Other Non-malignant hematopoietic disorders
Platelets disorders
Quality of life, palliative care, ethics and health economics
Sickle cell disease
Stem cell transplantation - Clinical
Stem cell transplantation - Experimental
Thalassemias
Thrombosis and vascular biology
Transfusion medicine
# Table of Contents

## Publication Only

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoblastic leukemia - Biology</td>
<td>PB1611 - PB1628 p. 653</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia - Clinical</td>
<td>PB1629 - PB1649 p. 660</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Biology</td>
<td>PB1650 - PB1672 p. 668</td>
</tr>
<tr>
<td>Acute myeloid leukemia - Clinical</td>
<td>PB1673 - PB1704 p. 675</td>
</tr>
<tr>
<td>Aggressive Non-Hodgkin lymphoma - Clinical</td>
<td>PB1705 - PB1742 p. 687</td>
</tr>
<tr>
<td>Bleeding disorders (congenital and acquired)</td>
<td>PB1743 - PB1770 p. 701</td>
</tr>
<tr>
<td>Bone marrow failure syndromes incl. PNH - Clinical</td>
<td>PB1771 - PB1759 p. 704</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia and related disorders - Biology</td>
<td>PB1760 - PB1775 p. 707</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia and related disorders - Clinical</td>
<td>PB1776 - PB1801 p. 713</td>
</tr>
<tr>
<td>Chronic myeloid leukemia - Biology</td>
<td>PB1802 - PB1813 p. 723</td>
</tr>
<tr>
<td>Chronic myeloid leukemia - Clinical</td>
<td>PB1814 - PB1838 p. 727</td>
</tr>
<tr>
<td>Enzymopathies, membranopathies and other anemias</td>
<td>PB1839 - PB1848 p. 737</td>
</tr>
<tr>
<td>Gene therapy, cellular immunotherapy and vaccination</td>
<td>PB1849 - PB1851 p. 741</td>
</tr>
<tr>
<td>Hematopoiesis, stem cells and microenvironment</td>
<td>PB1852 - PB1860 p. 742</td>
</tr>
<tr>
<td>Hodgkin lymphoma - Clinical</td>
<td>PB1861 - PB1868 p. 745</td>
</tr>
<tr>
<td>Indolent Non-Hodgkin lymphoma - Clinical</td>
<td>PB1869 - PB1888 p. 748</td>
</tr>
<tr>
<td>Infectious diseases, supportive care</td>
<td>PB1889 - PB1900 p. 755</td>
</tr>
<tr>
<td>Iron metabolism, deficiency and overload</td>
<td>PB1901 - PB1909 p. 760</td>
</tr>
<tr>
<td>Myelodysplastic syndromes - Biology</td>
<td>PB1910 - PB1917 p. 763</td>
</tr>
<tr>
<td>Myelodysplastic syndromes - Clinical</td>
<td>PB1918 - PB1932 p. 766</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies - Biology</td>
<td>PB1933 - PB1947 p. 771</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies - Clinical</td>
<td>PB1948 - PB2022 p. 776</td>
</tr>
<tr>
<td>Myeloproliferative neoplasms - Biology</td>
<td>PB2023 - PB2031 p. 805</td>
</tr>
<tr>
<td>Myeloproliferative neoplasms - Clinical</td>
<td>PB2032 - PB2063 p. 809</td>
</tr>
<tr>
<td>Non-Hodgkin &amp; Hodgkin lymphoma - Biology</td>
<td>PB2064 - PB2081 p. 821</td>
</tr>
<tr>
<td>Other Non-malignant hematopoietic disorders</td>
<td>PB2082 - PB2094 p. 827</td>
</tr>
<tr>
<td>Platelets disorders</td>
<td>PB2095 - PB2125 p. 832</td>
</tr>
<tr>
<td>Quality of life, palliative care, ethics and health economics</td>
<td>PB2126 - PB2139 p. 843</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>PB2140 - PB2156 p. 848</td>
</tr>
<tr>
<td>Stem cell transplantation - Clinical</td>
<td>PB2157 - PB2187 p. 854</td>
</tr>
<tr>
<td>Thalassemias</td>
<td>PB2188 - PB2202 p. 866</td>
</tr>
<tr>
<td>Thrombosis and vascular biology</td>
<td>PB2203 - PB2227 p. 871</td>
</tr>
<tr>
<td>Transfusion medicine</td>
<td>PB2228 - PB2240 p. 878</td>
</tr>
</tbody>
</table>

## Late Breaking Oral Session

The best abstracts selected from the late breaking abstract submission are presented during this oral session.

A complete session overview is available via the mobile app or the online program at ehaweb.org
New advances in plasma cell disorders and implications for therapy

S100
NEXT GENERATION SEQUENCING METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
C. Chiu1, D. Soong1, L. Spicka2, M. Beksaç3, M. Schaefer4, N. J. Bahlis5, M. A. Dimopoulos6
1Janssen Research & Development, LLC, Spring House, PA, United States, 2First Faculty of Medicine, Charles University, Prague, Czech Republic, 3ANKARA University, Ankara, Turkey, 4Janssen Research & Development, LLC, Ranir, NJ, United States, 5Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada, 6National and Kapodistrian University of Athens, Athens, Greece

Background: Cytogenetic risk status in multiple myeloma (MM) studies is traditionally determined by using fluorescence in situ hybridization (FISH) or karyotyping to assess chromosomal abnormalities. However, these technologies have limited resolution and a narrow target range, and reproducible interpretation may be confounded by inter-laboratory variation.

Aims: To describe the NGS methodology used to determine cytogenetic risk status in the daratumumab phase 3 CASTOR and POLLUX studies in RRMM.

Methods: Bone marrow aspirates were collected at screening and assessed centrally via NGS. Whole exome sequencing (exome-sequ) and RNA sequencing (RNA-sequ) was performed using the illumina HiSeq platform to identify the presence or absence of defined risk markers: t(4;14), t(14;16), or del17p. The use of RNA-sequ allowed for investigation of chromosomal translocations in expressed genomic locations at a higher resolution than FISH, and exome-sequ data was used to derive the copy number status in coding regions across the genome. RNA-sequ was performed using total RNA and rRNA removal to capture translocations involving coding and intronic regions. Translocation calls were made using two fusion callers, and gene expression was quantified to allow for evaluation of genes associated with translocation events. For t(14;14) translocations, the detected events involved RNA-sequ reads fuses between IgH and WHSC1 or FGFR3. For t(14;16), the detected translocations involved IgH and WWOX, Manual inspection of patients with t(4;14) showed higher WHSC1 or FGFR3 expression, whereas t(14;16) patients showed higher MAF and CCND2 expression. For del17p detection, exome data of each tumor was compared against 100 peripheral blood mononuclear cell (PBMC) control samples from CASTOR and POLLUX studies. Copy number variation data from two callers were combined to utilize information on relative read depth, systematic biases (observed in pooled normal controls), as well as SNP allele frequency (indicative of loss of heterozygosity events). A del17p event was detected when >50% of the 17p region was deleted.

Results: Based on the RNA-Seq and exome results, cytogenetic risk status in the CASTOR and POLLUX studies was defined as high risk with either t(4;14), t(14;16), or del17p, and standard risk with the confirmed absence of these molecular abnormalities. Comparisons of NGS with FISH showed high concordance for t(4;14), t(14;16), and del17p in both studies (Table 1).

PFS analyses investigating differences between treatment groups and between risk groups using FISH-derived risk and NGS-derived risk showed consistent results between FISH and NGS, with improvements in PFS being associated with the addition of daratumumab to standard-of-care regimens in both high- and standard-risk subgroups (Figure 1).

Summary/Conclusions: These studies represent the first, comprehensive use of NGS in global phase 3 clinical trials in RRMM. The NGS methodology accurately identified the presence of defined risk populations t(4;14), t(14;16), and del17p and showed good concordance with FISH. As FISH was performed locally with different probes and pathologists, the high degree of concordance between FISH and NGS is notable and supports the use of NGS for determining cytogenetic risk in patients with RRMM. The utility of NGS in these clinical studies extends far beyond the detection of cytogenetic abnormalities and additional analysis are planned to interrogate these datasets in the identification of novel biomarkers.

Table 1.

<table>
<thead>
<tr>
<th>Concordance rate between FISH and NGS</th>
<th>POLUX</th>
<th>CASTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(4;14)</td>
<td>100%</td>
<td>92%</td>
</tr>
<tr>
<td>t(14;16)</td>
<td>100%</td>
<td>97%</td>
</tr>
<tr>
<td>del17p</td>
<td>100%</td>
<td>99%</td>
</tr>
</tbody>
</table>

Figure 1.

S101
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTezOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
1Clinica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain, 2Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Abteilung fuer Innere Medizin II, Tuebingen, Germany, 3St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom, 4Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, 5Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 6Division of Hematology, Mayo Clinic, Rochester, MN, United States, 7Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, 8Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France, 9University of Melbourne, St. Vincent’s Hospital, Victoria, Australia, 10mandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Brazil, 11Division of Hematology/Oncology, Columbia University, New York, NY, United States, 12Department of HaematologyOncology, University Hospital Ostrava and Faculty of Medicine and Faculty of Science, University of Ostrava, Ostrava Czech Republic, 13Department of Hematology, Erasmus MC, Rotterdam, Netherlands, 14Janssen Research & Development, LLC, Spring House, PA, 15Janssen Research & Development, Ranir, NJ, United States, 16National and Kapodistrian University of Athens, Athens, Greece

Background: Daratumumab (D) is a human CD38-targeting monoclonal antibody that exerts its antimyeloma activity through both direct (on-tumor) and indirect (immunomodulatory) mechanisms of action. Two randomized phase 3 trials in patients with relapsed or refractory multiple myeloma (RRMM) demonstrated that combining D with the standard-of-care regimens lenalidomide + dexamethasone (Rd, POLLUX) or bortezomib + dexamethasone (Vd, CASTOR)
significantly improved progression-free survival (PFS) and achieved higher overall response rates (ORRs) compared with the respective standard-of-care regimen alone (Dimopoulos MA et al., N Engl J Med 2016;375(14):1319-1331; Palumbo A et al., N Engl J Med 2016;375(8):754-766.). Due to its novel mechanisms of action, addition of D to standard-of-care regimens may benefit RRMM patients who have poor prognoses resulting from high-risk cytogenetic abnormalities.

**Aims:** To examine the efficacy of DRd and DvD in RRMM patients with standard or high cytogenetic risk status.

**Methods:** Bone marrow aspirates were collected at screening visits from 311/569 patients from POLLUX and from 353/498 patients from CASTOR, and cytogenetic abnormalities were detected via next-generation sequencing (NGS). Patients were considered to be of high cytogenetic risk if they had ≥1 of the following abnormalities: t(4;14), t(14;16), or del17p; patients were considered to be of standard cytogenetic risk if they lacked these abnormalities. Minimal residual disease (MRD) was assessed at suspected complete response (CR) at 3 sensitivity thresholds (10−4, 10−5, and 10−6) using the ClonoSEQ™ NGS-based assay (Adaptive Biotechnologies, Seattle, WA). Efficacy analyses included PFS, ORR, and MRD-negative rates.

**Results:** For POLLUX, the median follow-up was 17.3 months. Treating high-risk patients with DRd significantly prolonged median PFS vs Rd (top panel Figure 1) and numerically increased ORR (85% vs 67%; P=0.14). Responses to DRd vs Rd included CR or better in 33% vs 6% of these patients, and very good partial responses (VGPR) or better in 63% vs 31%. In standard-risk patients, DRd vs Rd also resulted in significant improvements in median PFS (Figure 1) as well as ORR (95% vs 82%; P=0.0020). Responses to DRd vs Rd included CR or better in 32% vs 24% of these patients, and VGPR or better in 84% vs 51%. At 10−5 sensitivity threshold, MRD-negative rates for DRd vs Rd were 18% vs 0% (P=0.0027) among high-risk patients and 30% vs 10% (P=0.0001) for standard-risk patients. For CASTOR, the median follow-up was 13.0 months. Treating both high- and standard-risk patients with DvD vs Vd significantly prolonged median PFS (bottom panel Figure 1) and increased ORR (high risk: 82% vs 62%; P=0.039; standard risk: 85% vs 64%; P=0.0003). Responses to DvD vs Vd among high-risk patients included CR or better in 30% vs 9% of patients and VGPR or better in 64% vs 34%; among standard-risk patients, responses included CR or better in 25% vs 8% of patients and VGPR or better in 64% vs 27%. At 10−5 sensitivity threshold, MRD-negative rates for DvD vs Vd were 14% vs 0% (P=0.0018) among high-risk patients and 12% vs 2% (P=0.0011) for standard-risk patients.

**Summary/Conclusions:** Adding D to Rd or Vd improved treatment outcomes irrespective of cytogenetic risk status in patients with RRMM. Both DRd and DvD appear to benefit RRMM patients who have poor prognoses due to high-risk cytogenetic abnormalities. Updated data, including analyses based on individual cytogenetic abnormalities, will be presented at the meeting based on longer follow-up.

**S102**

**MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM THE EMM02/H095 PHASE 3 TRIAL**

S. Oliva1, D. Hofste op Bruinink2, L. Rihova3, S. Spada1, B. van der Holt4, R. Troia1, M. Gambella1, L. Pantani5, S. Grammatico5, M. Gilestro2, R. Omedè1, V. van der Velden6, M. Boccadoro5, P. Sonneveld7, M. Cavo5, P. Zhang1, Y. Zhang1, F. Wang1, B. Lei1, L. Gu1, Y. Yang1, J. Bai1, R. Zhang1, Q. Zhuang2, F.X. Fan2

1Hematology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 2Nanjing Legend Biotech, Nanjing, China

**Background:** Multiple myeloma (MM) is still an incurable disease and patients may relapse despite achievement of complete remission (CR). Available data show that MRD detection is a sensitive strategy to appropriately measure response in MM patients.

**Aims:** We evaluated MRD by MFC in patients with newly diagnosed MM enrolled in the EMM02/H095 phase 3 trial.

**Methods:** Patients were ≥65 years of age and treatment consisted of Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction, mobilization and stem cell collection, intensification with Bortezomib-Melphalan-Prednisone (VMP) or High-Dose-Melphalan (HDM) followed by stem cell transplant, consolidation with Bortezomib-Lenalidomide-Dexamethasone (VRD) vs no consolidation, and Lenalidomide maintenance. MRD was assessed in patients achieving at least a very good partial response (VGPR) before starting maintenance (after HDM, VMP or VRD) and during maintenance every 6–12 months; samples were centralized to 3 European labs. MFC was performed on bone marrow according to Euroflow-based methods (8 colors, 2 tubes) with a sensitivity of 10−5. Quality checks were done to compare sensitivity and to show correlation between protocols (Hofste op Bruinink D, ASH 2016 abstract 2072).

**Results:** A total of 316 patients could be evaluated before maintenance: median age was 57 years (IQR: 52-62), 18% (57/316) had ISS III and 22% (70/316) had high risk cytogenetic abnormalities defined as presence of either one among del17, t(4;14) or t(14;16); 63% (199/316) had received HDM and 37% (117/316) VMP thereafter 51% (160/316) had received VRD. After a median follow-up of 30 months from MRD enrolment, 76% (239/316) patients were MRD-negative: 64% (153/239) in the HDM vs 36% (86/239) in the VMP groups. The 3-year PFS was 50% in MRD-positive vs 77% in MRD-negative patients (HR 2.87, 95% CI: 1.75 - 4.72, p<0.001). Subgroup analyses were carried out to assess the risk factors for MRD-positivity according to baseline characteristics and therapies: high risk cytogenetic abnormalities were the most important risk factors (HR 9.87, 95% CI: 4.3 – 22.63; interaction-p=0.001). Finally, 48% of MRD positive patients at pre-maintenance who had a second MRD evaluation after at least 1 year of lenalidomide became MRD-negative.

**Summary/Conclusions:** MRD by MFC is a strong prognostic factor in MM patients receiving intensification with novel agents or transplant; lenalidomide maintenance further improved depth of response; high risk cytogenetic abnormalities are the most important prognostic factors in MRD-positive patients.

**S103**

**PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

W. Zhang1, W. Zhao2, J. Liu1, A. He1, Y. Chen1, X. Cao2, N. Yang2, B. Wang1, P. Zhang1, Y. Zhang1, F. Wang1, B. Lei1, L. Gu1, Y. Yang1, J. Bai1, R. Zhang1, X. Wang1, X. Ma1, J. Wang1, J. Wang1, L. Wei1, J. Zhang1, X. Zang1, C. Zhuang1, F.X. Fan2

1Hematology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 2Nanjing Legend Biotech, Nanjing, China

**Background:** Immunotherapy has emerged as a potentially curative treatment in hematological malignancies. Uniformly expressed in plasma cells, B-cell maturation antigen (BCMA) is an appropriate target antigens for CAR T-cell therapies in multiple myeloma.

**Aims:** This phase I, open-label trial was conducted to assess the efficacy and
Neud001 is a novel investigational monoclonal antibody that targets misfolded LC and may neutralize circulating LC aggregates and clear insoluble deposits. Patients' survival depends upon rapid suppression of the misfolded protein.

Methods: All patients underwent leukapheresis to obtain peripheral blood mononuclear cells and their T cells were engineered to express anti-BCMA CAR. Three doses of 300 mg/m² cyclophosphamide were administered on day -5, -4, and -3 (before the recruitment, patients took the same chemotherapy to identify they were refractory to cyclophosphamide monotherapy) and engineered T cells were reinfused on day 0, 2, and 6. This trial was divided into the dose escalation stage and expansion cohort. Toxicity and responses were assessed according to the Common Terminology Criteria for Adverse Events (version 4.0) and International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma, respectively.

Results: As of the February 20th, 2017 data cut-off, 22 patients had been enrolled, two of whom were diagnosed as plasma cell leukemia. The male:female ratio was 11:11 and median age was 53.5 years. Chromosomal abnormalities were detectable by FISH in eight patients, two of whom involved in the deficiency of p53. Eleven patients were triple refractory (chemotherapy, proteasome inhibitors, and immunomodulatory drugs), 11 resisted to double prior treatments (chemotherapy and proteasome inhibitors/ immunomodulatory drugs), and four relapsed after autologous hematopoietic stem cell transplant. The median number of infused CAR T cells was 4.0×10^6 (range, 1.5×10^6-7.0×10^6) per kg. The median follow-up was 131.5 (range, 29-327) days. 100% of patients achieved an objective response. The first six patients achieved complete responses with flow MRD-negative; 14 patients achieved very good partial responses; one patient, with renal failure, achieved partial response; all these 22 patients had kept their best response at the end of follow-up. The pictures we enclosed were the subcutaneous nodules in one patient with extramedullary plasmacytoma. We found that the nodules were obviously decreased after the infusion and disappeared finally. Another one achieved transient partial response, which last for 12 days.

Discussion: We explored the potential impact on organ response of the number and type of organs affected and the number of, type of, and time since previous therapies at baseline. Depth of patients' best HR also was not related to the attainment of NEOD001 organ response (responder/stable: 35.6/36.6 months [cardiac] and 30.6/32.5 months [renal]; P>0.05). Depth of patients' best HR also was not related to the attainment of NEOD001 organ response (percentage of patients with organ response in CR/VGPR/PR after PCD: 47.1/66.7/42.9% [cardiac] and 68.8/63.6/62.5% [renal]; P>0.05). Similarly, time or depth of patients' last HR did not impact the NEOD001 organ response rate (P>0.05). Patients with NEOD001 organ responses were no more likely to have had their last PCD therapy <6 than 36 months from their first NEOD001 dose. Patients' previous PCD treatment type was not related to the corticosteroid for spinal meningioma. He terminally died with renal failure, achieved partial response; all these 22 patients had kept their best response at the end of follow-up. The pictures we enclosed were the subcutaneous nodules in one patient with extramedullary plasmacytoma. We found that the nodules were obviously decreased after the infusion and disappeared finally. Another one achieved transient partial response, which last for 12 days. He then took the secondary infusion but failed since the post-operation large-volume infusion.

Figure 1. Case #6

Summary/Conclusions: Our findings demonstrated the safety and amelioration activity of LCAR-B38M anti-BCMA CAR T cells.

S104

Patients with Light Chain Amyloidosis Treated with Neud001 Achieve Rapid Organ Responses That Are Independent of Previous Plasma Cell–Directed Therapies


1Mayo Clinic, Rochester; 2Tufts Medical Center, Boston; 3Memorial Sloan Kettering Cancer Center, New York; 4Boston University School of Medicine and Boston Medical Center, Boston; 5University of Pennsylvania, Philadelphia; 6Karmanos Cancer Institute, Detroit; 7JW Consulting, Hillsborough; 8Prothena Biosciences Inc, South San Francisco; 9Stanford University School of Medicine, Stanford, United States

Background: Light chain (AL) amyloidosis is a rare and often fatal disease caused by the accumulation of misfolded light chain (LC) aggregates that can lead to progressive failure of critical organs, causing significant morbidity and mortality. Patients' survival depends upon rapid suppression of the misfolded LC and stabilization or recovery of organ function. Current therapies limit LC production; however, ~75% of patients have persistent organ dysfunction. Neud001 is a novel investigational monoclonal antibody that targets misfolded LC and may neutralize circulating LC aggregates and clear insoluble deposits.

Aims: To assess the association between responses and time, depth, number or type of previous plasma cell–directed (PCD) treatments and organ response.

Methods: Inclusion criteria for this trial were: completed ≥1 PCD treatment before enrollment, attained partial hematologic response (HR) or better to any previous therapy, and have persistent organ dysfunction. Neud001 was administered intravenously every 28 days. During the dose-escalation phase, 27 patients received Neud001 at 0.5, 1, 2, 4, 5, 16, or 24 mg/kg in a 3+3 study design. In the expansion phase, 42 additional patients with renal, cardiac, or nerve involvement were enrolled and treated (24 mg/kg). We assessed cardiac and renal best responses based on consensus criteria. Peripheral nervous system (PN) responses were assessed at month 10 (after 9 infusions) using the Neuropathy Impairment Score—Lower Limbs (NIS-LL). We explored the potential impact on organ response of the number and type of organs affected and the number of, type of, and time since previous therapies at baseline.

Results: In the overall population (N=69), the median age was 61 years (61% male). Median (range) time since diagnosis was 2.9 (0.4-16.0) years, and 45% of patients underwent ≥3 previous PCD regimens. Median time to first best response was 1.8 (cardiac), 3.7 (renal), and 1.0 (PN) months. Best response rate indicating organ response was observed in 53% of cardiac-evaluable patients (n=19/36) and 64% of renal-evaluable patients (n=23/36). PN responses were observed in 82% (n=9/11) of PN-evaluable patients. Time from patients' best HR to previous PCD treatment was not related to the attainment of Neud001 organ response (responder/stable: 35.6/36.6 months [cardiac] and 30.6/32.5 months [renal]; P>0.05). Depth of patients' best HR also was not related to the attainment of Neud001 organ response (percentage of patients with organ response in CR/VGPR/PR after PCD: 47.1/66.7/42.9% [cardiac] and 68.8/63.6/62.5% [renal]; P>0.05). Similarly, time or depth of patients' last HR did not impact the Neud001 organ response rate (P>0.05). Patients with Neud001 organ responses were no more likely to have had their last PCD therapy <6 than 36 months from their first Neud001 dose. Patients' previous PCD treatment type was not related to the corticosteroid for spinal meningioma. He terminally died with renal failure, achieved partial response; all these 22 patients had kept their best response at the end of follow-up. The pictures we enclosed were the subcutaneous nodules in one patient with extramedullary plasmacytoma. We found that the nodules were obviously decreased after the infusion and disappeared finally. Another one achieved transient partial response, which last for 12 days. He then took the secondary infusion but failed since the post-operation large-volume infusion. We assessed cardiac and renal best responses based on consensus criteria. Peripheral nervous system (PN) responses were assessed at month 10 (after 9 infusions) using the Neuropathy Impairment Score—Lower Limbs (NIS-LL). We explored the potential impact on organ response of the number and type of organs affected and the number of, type of, and time since previous therapies at baseline.

Summary/Conclusions: Neud001 specifically targets disease-causing, misfolded LC aggregates in AL amyloidosis. Organ responses in patients treated with monthly Neud001 infusions were achieved rapidly and independently of time since previous chemotherapy, depth of hematologic response, or predominant type of PCD treatment.
A. Chen8, T. Lamy9, L. Wang10, E. Penuel10, J. Hirata10, C. Lee10, G. Salles11
4. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands,
5. Department of Hematology, Ankara University School of Medicine, Ankara, Turkey,
6. Department of Hematology, University Hospital of Amiens, Amiens, France,
7. Department of Hematology, Haematology and Blood Transfusion, University of Milano-Bicocca, Milan, Italy, 8. University of Maastricht, Maastricht, The Netherlands,
9. Department of Hematology, St George's University of London, London, United Kingdom, 10. Department of Hematology, University of Freiburg, Freiburg, Germany,
11. Department of Hematology, University of Erlangen, Erlangen, Germany,
12. Department of Internal Medicine I, University Hospital Saarland, Homburg, Saarland, Germany.
When pts in the SC group were asked, if given the option, which treatment they would prefer, 90.8% stated a preference for SC over IV. Median administration time (6 minutes SC vs 2.6–3.0 hours IV) and chair/bed and overall hospital times were shorter with SC than with IV treatment.

Table 1. Efficacy endpoints in the intent-to-treat population.

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Rituximab plus CHOP</th>
<th>Rituximab plus IV CHOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%) of Failure treatment</td>
<td>518 (32.5%)</td>
<td>518 (32.5%)</td>
</tr>
<tr>
<td>N (%) of Death</td>
<td>318 (20.1%)</td>
<td>318 (20.1%)</td>
</tr>
<tr>
<td>N (%) of Progression</td>
<td>232 (14.8%)</td>
<td>232 (14.8%)</td>
</tr>
</tbody>
</table>

Figure 1. Patient satisfaction at cycle 3 and cycle 7 of treatment.

Summary/Conclusions: Rituximab SC had similar efficacy and safety to the IV form, with improvements in patient satisfaction ratings, and administration/hospital time savings. Our findings support the use of rituximab SC in this setting.

S108
ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CANCERS USING A COMPREHENSIVE NGS PANEL COMPRISED OF DNA AND RNA TARGETS TREATING 704 GENES

A.R. Carson1, B.A. Patay1, V. McClain1, Z. Xie1, T. Stenzel1,2,3, J.E. Miller1,2,3
1Invivoscribe, 2LabPMM LLC, San Diego, United States, 3LabPMM GmbH, Martinsried, Germany

Background: As next-generation sequencing (NGS) methodologies improve, so does the ability to characterize hematopoietic and lymphoid neoplasms. This promises to revolutionize oncology, allowing more accurate and precise classification of patients and potentially leading to novel targeted and combination therapies with improved outcomes.

Aims: We constructed a custom targeted sequencing panel, MyHEME™, to comprehensively identify and characterize DNA and RNA changes in a broad range of hematologic malignancies, including Non-Hodgkin lymphoma (NHL).

Methods: The MyHEME targeted sequencing panel is comprised of two independent bait sets that target a combined 704 genes known or predicted to contribute to hematologic cancers (DNA baits for 571 genes and RNA baits for 361 genes; 228 genes are found in common between the two bait sets). Libraries were constructed using 1μg of DNA or 0.1μg of RNA and sequenced on an Illumina platform. Sequenced reads are analyzed using proprietary MyInformatics™ software to identify single nucleotide variants (SNVs), indels and structural variants (SVs). Both the MyHEME panel and MyInformatics software were created under ISO13485 design control. To characterize the performance metrics of the MyHEME panel, we used the NIST human reference sample NA12278 along with combinations of hematologic cancer derived cell lines with known pathogenic variants at various allelic frequencies.

Results: Analytical validation of the MyHEME panel established an average read depth of 1,175X (with a median read depth of 1,088X) for the DNA targets and an average transcripts per million (TPM) of 2,256 (with a median TPM of 743) for the RNA targets. For the DNA targets, we established sensitivity >95% (99.8% for SNVs at a 2.5% limit of detection (LOD)); 100% for coding indels at a 5.0% LOD) and specificity >95% (95.5% for SNVs at a 2.5% LOD; 97.7% for coding indels at a 5.0% LOD). We also show the ability to cross-confirm results between the 228 genes common to both the DNA and RNA targets. Importantly, novel gene fusions, which are generally difficult to detect and validate, were cross-confirmed when observed in both the DNA and RNA targets. For example, we identified a novel t(9;22) translocation causing a NUP214-XXR3 gene fusion using both the DNA and RNA targets. Additionally, while RNA data provides the fused exons of the transcripts, DNA data gives the precise genomic breakpoint coordinate.

Summary/Conclusions: MyHEME is an extensive panel for sensitively and specifically identifying SNV, indel and SV mutations in 704 target genes. This panel can comprehensively characterize mutations in multiple diverse hematologic cancer samples, including Non-Hodgkin lymphoma (NHL), AML, ALL, and Multiple Myeloma. By utilizing a high depth of coverage, MyHEME can accurately detect clones present down to 5% of a patient’s sample. In addition, by targeting both DNA and RNA, MyHEME contains a built in validation method to cross-confirm novel variants of interest.

S109
TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDKN2A, HAVE INDEPENDENT PROGNOSTIC VALUE IN MANTLE CELL LYMPHOMA TREATED BY THE NORDIC (MCL2 AND MCL3) REGIMEN

C.W. Eskelund1, C. Dahl2, J. W. Hansen1, M. Westman1, C. Montano1, C. Freiburghausen1, S. Ek3, A. Pedersen1, L. B. Pedersen1, C. Niemann1, R. Røyt4, P. Brown1, A. Kolstad5, C.H. Geisler1, M.K. Andersen1, P. Guldberg1, M. Jerkeman1, K. Grønbæk1
1University Hospital of Copenhagen, 2Danish Cancer Society, Copenhagen, Denmark, 3University Hospital of Lund, Lund, Sweden, 4University Hospital of Helsinki, Helsinki, Finland, 5University Hospital of Oslo, Oslo, Norway

Background: During the past decades, the outcome of MCL treatment has improved substantially in younger patients. However, the course of disease remains heterogeneous, and there is a need for better stratification of patients with poor responses from those with durable responses. The Nordic trials, MCL2 and MCL3, represent standard-of-care regimens for younger MCL patients.

Aims: Preliminary analyses of diagnostic samples from MCL2 and MCL3, show that TP53 mutations are associated with significantly poorer outcome. Recently, deletions of TP53 and CDKN2A was shown to confer negative impact in a cohort similar to the Nordic (Delfau-Larue et al., 2015). Thus, in this study we aim to describe the prevalence and impact of deletions of TP53 and CDKN2A in the light of TP53 mutations.

Methods: Fresh frozen DNA from diagnostic bone marrow samples from MCL2 and MCL3 were analyzed. In both trials, patients received intensified first-line induction therapy with alternating courses of R-CHOP and R-hd-Cytarabine and consolidation with high-dose therapy and ASCT. (Geisler et al., 2008; Kolstad et al., 2014). Targeted NGS of ATM, CCND1, TP53, KMT2D, NOTCH1, NOTCH2, WHSC1 and BIRC3 was performed ion Torrent Technology. Cut-off for calling a mutation was set to a variant allele frequency >3% and median coverage was >2700X. Copy Number Variations (CNVs) of TP53 and CDKN2A were measured by droplet digital PCR by commercially available assays, and RPP30 used as a standard control.

Results: We investigated the presence of CDKN2A and TP53 deletions in diagnostic samples from 175 and 157 patients, respectively. Patients were treated and <66 years (median 58, range 37-65). Fifty-three percent were either MIPI intermediate- or high-risk, 17% had blastoid morphology and 42% had del-CDKN2A, and 83% had bone marrow involvement at diagnosis. After a median follow-up of 9.2 years, median overall (OS), progression-free survival (PFS) and cumulated incidence of relapse (CIR) of all patients were 12.4 and 8.2 and 1.0 and 1.2 years (p<0.0001 for all three outcomes), respectively. In univariate analyses, median OS was 11.0 years for patients with TP53 deletion versus 38.2 years for patients without deletion (p=0.01). Del-TP53 was significantly associated with significantly poorer outcome. Recently, TP53 was significantly associated with poor OS (p=0.01), but not PFS and CIR, whereas del-CDKN2A was significant for CIR (p=0.02), but not OS and PFS. Patients with both deletions did significantly worse for all three endpoints. In MVA, (including all factors with significance in univariate analyses: MIPI, blastoid morphology, KIT-D816V, del-CDKN2A and del-CDKN2A) only mutations of TP53 remained a significant predictor of outcome.

Summary/Conclusions: Here we evaluate the impact of TP53- and CDKN2A-deletions in the context of TP53 mutations of younger, optimally treated MCL patients. In line with previous reports, both deletions were associated with poorer outcome; however, in multivariate analyses only TP53 mutations was an independent prognostic factor, substantiating its role as a biomarker for response to the standard-of-care immune-chemotherapy.

haematologica | 2017: 102(s2) | 5
S110

DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES SURVIVAL IN FLT3 MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA


Background: Mutations in Fms-like tyrosine kinase 3 (FLT3) are common in patients with acute myeloid leukemia (AML) and are associated with an aggressive disease course and a poor prognosis. Notably, FLT3 internal tandem duplications (ITD) predict early relapse and short overall survival (OS) after chemotherapy. Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase 1/2 study (NCT02014558), specifically at doses ≥80 mg/d. Aims: To assess molecular response to gilteritinib in a CHRYSALIS subpopulation.

Methods: This exploratory analysis evaluated molecular response in patients aged ≥18 years with FLT3mut+R/R AML who had been treated with 120 or 200 mg/d gilteritinib. These doses were identified due to their ability to induce high clinical response rates, and consistent, potent FLT3 inhibition in correlative assays. Molecular response was assessed in patients who had bone marrow aspirates obtained at baseline and at ≥1 additional time point. FLT3-ITD and total FLT3 were quantified by next-generation sequencing to assess molecular response. A Cox regression model of OS by Kaplan-Meier estimation established a FLT3-ITD-to-total FLT3 ratio (ITD signal ratio) of 10−2 as the threshold for improved survival.

Results: Of the 147 FLT3-ITDmut+ patients who had received gilteritinib 120 or 200 mg/d, 80 patients had bone marrow aspirates at baseline and at ≥1 additional time point, and were included in this analysis. The composite response rate (defined as CR plus CRi plus PR) for these 80 patients was 55%. During response, 20 patients (25%) had an ITD signal ratio of ≤10−2. Of these 20 patients, 18 had an ITD signal ratio of ≤10−3 (major molecular response [MMR]) and 13 had an ITD signal ratio of ≤10−4 (minimal residual disease [MRD]) negative. The median time to achieve minimum ITD signal ratio was 54 days. Elimination of morphologic leukemia was observed in 80% of patients with ITD signal ratios <10−2. Patients who had an ITD signal ratio ≤10−2, MMR, or were patients, 18 had an ITD signal ratio of ≤10−3 (major molecular response [MMR]) improved survival.

Aims/Conclusions: Molecular responses to gilteritinib in FLT3-ITDmut+R/R AML correlated with clinical response and improved OS. This is the first demonstration of a robust molecular response to a FLT3 inhibitor in AML. These data suggest that the ITD signal ratio may predict a durable clinical benefit of gilteritinib therapy and validate FLT3 as a critical therapeutic target in AML.

S111

RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP


Background: A comprehensive AML risk assessment, based on the integration of cytogenetic/genetic data and minimal residual disease (MRD) status, can help optimize patient’s (pts) therapeutic post-remission allocation. Aims: To evaluate the feasibility and results of a phase II trial of intensive chemotherapy in which risk-assignment and post-remission therapy of young patients with AML was based on pre-treatment cytogenetic/genetic data and post-consolidation levels of MRD. Methods: Between January 2012 and May 2015, 515 pts with de novo AML, 18 to 60 years old, seen at 55 GIMEMA institutions were enrolled in the trial. Induction consisted of i.v. daunorubicin 50 mg/m2 daily on days 1,3 and 5; i.v. cytarabine 100 mg/m2 as a daily continuous infusion, days 1 to 10. All pts in CR/CRi after 1-2 induction cycles, received 1 consolidation course consisting of i.v. daunorubicin 50 mg/m2 daily for 6 and i.v. cytarabine 300 mg/m2 every 12 hours on days 1 to 6. In pts belonging to ELN low or intermediate-risk category, peripheral blood stem cell collection was attempted by initiating, on day 20 from the start of consolidation therapy, G-CSF until completion of stem cell collection. Post-consolidation therapy was based on risk-allocation. Low-risk pts (NPM1 positive FLT3-ITD negative or c-Kit mutations) were to receive AuSCT; intermediate-risk pts (intermediate karyotype or FLT3-TKD positive or c-Kit mutations) were to receive AuSCT; high-risk pts (adverse karyotype or FLT3-ITD positive) were to receive ASCT. Results: Of 500/515 pts started treatment and were available for the analysis. Median age was 49 (18-61) years and 52% were males. Of 429 evaluable pts, ELN cytogenetic distribution was: low-risk 11%, intermediate-risk 73% and poor-risk 16%. RUNX1/RUNX1T1 was detected in 49% of pts, CBFbeta/MYH11 in 7% of 496, FLT3-ITD in 25% of 497 and NPM1 in 37% of 499. In 494 evaluable pts, complete remission rate (CR) was 73% (361), 18% had refractory AML and 9% died early during induction. Three hundred-41 pts completed the consolidation phase and were risk allocated: 114 (33%) to the low-risk category (=AuSCT), 122 (36%) to the intermediate-risk category (=AuSCT or ASCT), 122 (35%) to the intermediate-risk category (=AuSCT or ASCT). In 27 pts (8%) belonging to the intermediate-risk category, a leukemia associated phenotype was not found and they were to receive AuSCT. Overall, 109 (33%) and 123 (36%) of 341 pts received AuSCT and ASCT, respectively. Median follow-up was 27.9 months. At 3 years, overall survival (OS) and progression free survival (PFS) of the whole series was 55.9% and 49.3%, respectively; cumulative incidence of relapse was 32.9%. At the same time point of 24 months, OS and DFS in the low-risk category was 74.8% and 63.8%, respectively; in the high-risk category 42.5% and 44.8%, respectively; in the intermediate-risk category MRD negative 78.6% and 61.4%, respectively; in the intermediate-risk category MRD positive 69.8% and 66.6%, respectively (Figure 1).

Summary/Conclusions: A program of risk-adapted, MRD-driven therapy is feasible in a multicenter, cooperative setting. In the intermediate-risk category,
ASCT can be avoided if MRD is not detectable; if MRD is positive, ASCT can prolong OS and DFS to equalize those of the low-risk category. ASCT was delivered to 2/3 of pts in the high-risk category, using all the available sources of stem cells.

Figure 1.

S112

**GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION**

J. Versluis1,2, B. Kalin3, W. Zeijlmaker1, J. Passweg1, C. Graux4, M. Manz5, M.-C. Vekemans5, B. Biemond5, M.-C. Legede5, M. van Manwijk Kooy1, J. Janssen6, T. Pabst6, B. Lowenberg7, M. Jongen-Lavrencic7, G.J. Schuurhuizen1, G. Ossenkoppele7, J. Cornelissen1

1Erasmus Medical Center Cancer Institute, Rotterdam, 2VU University Medical Center, Amsterdam, Netherlands, 3University Hospital Basel, Basel, Switzerland, 4Mont-Godinne, Yvoir, Belgium, 5University Hospital Zürich, Zürich, Switzerland, 6Cliniques Universitaires Saint-Luc, Brussels, Belgium, 7Academic Medical Center, University of Amsterdam, Amsterdam, 8Medisch Spectrum Twente, Enschede, 9Isala Hospital, Zwolle, Netherlands, 10Inselspital, Bern University Hospital, Bern, Switzerland

**Background:** The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted strategies of AML treatment. The presence of MRD after induction treatment has firmly been shown to predict for relapse and overall outcome, irrespective of type of post-remission treatment (PRT). Currently it is unknown whether and how the presence or absence of MRD should guide the application of allogeneic hematopoietic stem cell transplantation (alloHSCT) as PRT.

**Aims:** We addressed whether and to what extent alloHSCT quantitatively reduces relapse as compared to conventional post-remission treatment (PRT) in upfront treated patients with MRD positive or MRD negative AML in first hematological complete remission (CR1).

**Methods:** A total of 1,511 patients were treated in subsequent HOVON-SAKK AML trials of whom 547 patients obtained a CR1, received PRT and had available flow cytometric MRD prior to PRT. MRD positivity was defined by more than 0.1% cells with a leukemia associated phenotype within the white blood cell population. MRD status was not known by clinicians during AML treatment. PRT consisted of alloHSCT (n=282), or conventional PRT by a third cycle of chemotherapy (n=160) or autologous HSCT (n=105). Endpoints of the study included overall survival (OS), relapse-free survival (RFS), and cumulative incidences of relapse and non-relapse mortality (NRM) at 4 years. A time-dependent covariate alloHSCT with the cumulative incidence of relapse as primary endpoint.

**Results:** MRD was positive in 129 (24%) patients after induction chemotherapy before proceeding to PRT. The latest European LeukemiaNet risk classification was similarly distributed among MRD negative and MRD positive patients. No differences were present in transplant characteristics in MRD positive and MRD negative patients. OS and RFS was significantly better in patients without MRD prior to PRT as compared to MRD positive patients (65±2% compared to 50±5% at 4 years, p=0.002, and 58±3% compared to 38±4%, p<0.001, respectively).

**Summary/Conclusions:** The graft-versus-leukemia effect of alloHSCT is equally present in MRD positive and MRD negative patients, which advocates a personalized application of alloHSCT taking the risk of relapse determined by AML risk group and MRD status as well as the counterbalancing risk of NRM into account.
all different currently used risk categories. These data urge to include both MRD and LSC in future AML risk classification to better inform post-remission treatment.

DEFINITION OF PARTIAL RESPONSE IN YOUNGER AML PATIENTS AFTER FIRST INDUCTION COURSE MAY BE EXTENDED BY INCLUSION OF IMMUNOPHENOTYPIC DETECTION OF MEASURABLE RESIDUAL DISEASE IN CR


1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, 2King’s College London School of Medicine, London, 3Centre for Trials Research, Cardiff University, Cardiff, 4North Bristol NHS Trust, Bristol, 5University Hospital of Wales, 6Cardiff University School of Medicine, Cardiff, 7Isle of Arran, Isle of Arran, 8Nottingham University Hospital, Nottingham, United Kingdom

Background: In AML response by morphology after a first cycle of induction therapy is used to guide further therapy including second cycles of induction and choice of consolidation. It is still uncertain how the quality of response post cycle 1 with inclusion of MRD assessment impacts on outcomes within AML risk subgroups including NPM1 wild type standard risk and whether this adds information to MRD status in CR post cycle 2.

Aims: To quantify the effect of MRD positivity for response after each cycle of induction therapy in younger patients with AML.

Methods: As part of the UK NCRI AML17 trial (ISRCTN: 55675535) for patients with AML or high risk MDS up to the age of 60, prospective flow cytometric MRD (MFC-MRD) monitoring was performed after each course of induction. Any level of MRD detected was considered MRD+ (sensitivity thresholds: ~0.02% by tracking diagnostic leukemic aberrant phenotypes /LAIP, ~0.05-0.1% by “different-from normal” blast LAIP). Clinicians were not informed of MFC-MRD results. Following their first cycle of induction with daunorubicin/ara-C based therapy, patients were allocated a risk group by a validated score (comprising cytogenetics, WBC, age, secondary disease, blast response to cycle 1 and mutation status). Poor risk patients received intensified therapy in cycle 2 with a view of proceeding to SCT.

Results: MFC-MRD results after either induction course are available for 1555 patients randomised from 4/09-12/14 (median age 51, range 0-73). Cycle 1 (C1) response data with MFC-MRD was available for 1,400 patients. 70% achieved morphological CR at this time-point; 14% had resistant disease (RD) and 16% were in partial remission (PR) according to clinician. Of patients in CR (n=984) 56% had detectable MFC-MRD (MRD+). Excluding poor-risk patients 14% of patients did not achieve CR (7% RD, 7% PR), 51% of patients in CR were MRD+. 5 year OS for MRD- vs MRD+ was 63% vs 44% vs 37% vs 25% for all patients; 69% vs 51% vs 50% vs 30% excluding poor risk patients and 66% vs 49% vs 49% vs 30% for standard risk alone (Figure 1). The similar OS in this group between CR MRD+ and PR at C1 was maintained in NPM1/wt standard risk patients and if censored at stem cell transplant. 771 patients were in CR post cycle 2 (C2) and provided MFC-MRD data. As expected, there were significant differences in 5 year OS between CR MFC MRD+ vs CR MFC MRD- for all patients (35% vs 83%) and excluding poor-risk (38% vs 70%, n=512). Importantly post cycle 2 MFC-MRD status also differentiated OS for NPM1/wt standard risk patients with 5 year OS of 32% vs 64% (P=0.002) for MRD+ vs MRD- (Figure 1). In stratified analyses, there was some evidence that the effect of MRD positivity on OS was lower in poor-risk patients (test for trend p=0.02 for both C1 and C2). The effect of MFC-MRD status on relapse and OS appeared greater at C2 (relapse, OR 2.00(1.56-2.55), p<0.001; survival, OR 1.80(1.42-2.28) p<0.001) than C1 (relapse, OR 1.69(1.37-2.07), p<0.001; survival, OR 1.46(1.19-1.79) p<0.001). In patients with data for both time points, C2 MRD remained significant on OS when adjusting for C1 response. 24 patients converted from C1 MRD- to C2 MRD+, with a poor prognosis (15 relapses, 13 deaths). C1 MRD-/C2 MRD− had the best prognosis.

Figure 1.

Summary/Conclusions: MFC-MRD in CR post cycle 1 has similar outcomes to partial remission in younger patients with AML, particularly in patients with good and standard risk disease. Assessment of MFC-MRD post cycle 2 appears to provide additional discrimination to cycle 1: MFC-MRD in courses 1-2 may be useful in further stratifying standard risk patients.
New insights into chronic lymphocytic leukemia biology

S115

CLINICAL IMPACT OF THE SUBCLONAL ARCHITECTURE AND MUTATIONAL COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA

FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA

FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA

may improve the stratification of CLL patients.

presentation of the mutations and not only their presence or absence. In addition, the clinical evaluation of gene mutations should consider the quantitative driver mutations is related to the size of the mutated population. Therefore, clonal population

Leukemogenesis", DKFZ, Heidelberg, 2Internal Medicine III, Ulm University, Spain

Recent studies have revealed the presence and prognostic impact of small mutated subclones in chronic lymphocytic leukemia (CLL) (Rossi et al 2014, Nadeu et al 2016, Rasi et al 2016). Although these studies focused only on a small subset of 5 genes, their results opened a new perspective where the proportion of cells carrying each specific driver mutation may be relevant to the evolution of this disease. Moreover, the subclonal and mutational complexity estimated by the presence of subclonal driver alterations (Landau et al 2013, Landau et al 2015) or the accumulation of driver alterations (Puente et al 2015) have been proposed as promising indicators of clinical behavior.

The goal of this study was to determine the relevance of the quantitative subclonal architecture and mutational complexity in the evolution of CLL integrating the deep sequencing analysis of a large panel of driver genes and DNA copy number alterations (CNA).

Methods: The mutational status of 28 driver genes was investigated in 406 previously untreated CLL patients by targeted deep next-generation sequencing (NGS). Mutations present in less than 1% of tumor cells were identified. All low frequency mutations were verified by allele-specific PCR or a second round of NGS. CNA were analyzed by SNP-arrays. Alterations were classified as clonal if their CCF was ≥85%, and subclonal otherwise. All patients gave informed consent.

Results: Using a highly sensitive NGS strategy we observed that small subclonal mutations were the sole alteration in 22% of the mutated cases, and were frequently detected in nearly all investigated genes. We identified three gene-specific patterns that linked the magnitude of the mutated clones (or mutated cancer cell fraction, CCF) with the prognosis of the patients: i) CCF-independent pattern: mutations at any CCF had prognostic value, ii) CCF-gradual pattern: the poor prognostic impact was a continuous variable directly related to the size of the clone, and iii) CCF-clonal pattern: only mutations with a CCF above a certain threshold impacted the outcome of the patients. Combining mutations and driver CNA, we identified at least one driver alteration in 66% of the patients. The subclonal mutational complexity (accumulation of 1 to ≥4 driver alterations), but not the presence of subclonal driver populations, gradually shortened the time to first treatment independently of the IGHV mutational status and Binet stage. Conversely, the subclonal complexity, defined as the accumulation of driver alterations with the presence of at least one driver subclone, predicted for a worse overall survival independently of the IGHV and Binet stage. Patients with a pure clonal population (presence of one or more driver alterations in all tumor cells) had a similar overall survival than patients without any alteration.

Summary/Conclusions: Our study shows that the prognostic impact of different driver mutations is related to the size of the mutated population. Therefore, the clinical evaluation of gene mutations should consider the quantitative representation of the mutations and not only their presence or absence. In addition, the mutational complexity predicts for shorter time to first treatment independently of the IGHV and Binet stage, whereas the subclonal complexity confers an independent adverse impact for overall survival. Altogether, the integration of the subclonal architecture and mutational complexity in prognostic indexes may improve the stratification of CLL patients.

S116

FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA AND c-MYC IN CLL CELLS

with recurrent mutations that are of pathogenic and prognostic relevance. Mutations in FBXW7 are among the most common mutations in CLL, yet their functional consequences are unknown. FBXW7 is an E3 ubiquitin ligase that ubiquitylates oncoproteins like NOTCH1, HIF1-α and c-MYC and thereby targets them for proteasomal degradation.

Aims: 2.5-4% of CLL patients harbor FBXW7 mutations. Approximately 60% of FBXW7 mutations alter arginine residues that are involved in substrate targeting. In T-cell acute lymphoblastic leukemia these arginine mutations are associated with chemotherapy resistance. In CLL however, the role of dysfunctional FBXW7 is unclear. We therefore aimed to delineate the prevalence of FBXW7 mutations in CLL patient cohorts and characterize its functional role.

Methods: FBXW7 mutations were identified via the PolyPhen-2 software. all but one missense mutation in FBXW7 were predicted to be most likely damaging. No mutations in FBXW7 were found in the CLL, MCL and LCL cell lines analyzed. To determine the functional consequence of FBXW7 mutations in CLL, we induced either a heterozygous or a homozygous truncation of FBXW7 in the CLL cell line, resulting in the loss of the substrate binding site of the WD40 domain. The homozygous truncation of FBXW7 resulted in an increase of NOTCH1, HIF1-α and c-MYC protein levels, whereas no difference of Cyclin E protein amount was detectable. In addition, an elevation of NOTCH1 activity was found in both the heterozygously and homozygously truncated mutant cell lines in comparison to the wildtype HG3 cell line. To confirm this finding, protein levels of 5 CLL patients with FBXW7 mutations were analyzed with a similar outcome.

Summary/Conclusions: Mutations in FBXW7 are frequently found in CLL, especially missense and nonsense mutations affecting the WD40 domain. We hypothesize that this has functional consequences on FBXW7 substrate binding and thereby accounts for accumulation of oncoproteins, which may lead to truncation of the WD40 domain of FBXW7 in the HG3 cell line resulted in the accumulation of protein substrates and corresponding increase of their activity implicated in the pathogenesis of CLL. Taken together our data show that FBXW7 can target proteins for degradation that are commonly dysregulated in CLL and that drive disease progression.

S117

INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA

leukemia (CLL), such as the genome, transcriptome and layers of the epigenome, like histone modifications, remain relatively unexplored.

Background: Different omics studies have focused on the analysis of individual layers of information in chronic lymphocytic leukemia (CLL), such as the genome, transcriptome and DNA methylation. Combining the information from all these layers of information may provide a more complete understanding of CLL biology.

Aims: The aim of this study was to extensively map and analyse the epigenome

Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease...
of CLL in relation to the mutational, transcriptional and three-dimensional (3D) chromatin landscape.

**Methods:** Seven CLL patients with distinct clinico-pathological features and five mature B-cell subpopulations were extensively analysed using (i) ChIP-seq of six different histone marks with non-overlapping features (H3K27ac, H3K4me1, H3K4me3, H3K9me3, H3K27me3 and H3K36me3); (ii) single stranded RNA-seq; (iii) transposase-accessible chromatin assays (ATAC-seq) and iv) whole-genome bisulfite sequencing (WGBS), creating a unique reference epigenome for CLL. These data were complemented with the 3D chromatin landscape in one CLL case measured by high-throughput chromatin conformation capture (HiC-seq) and promoter capture Hi-C (PCHi-C). Furthermore, we mapped the active chromatin landscape of 100 CLL patients by H3K27ac ChIP-seq and ATAC-seq. Whole-genome sequencing data was available for 44 of these patients. We applied a broad range of bioinformatic tools to analyze the data in an integrative way.

**Results:** CLL is distinct from normal B cells for all layers of the reference epigenome (47 CLLs) and the active chromatin landscape (100 CLLs). CLL though is closer to naive and memory B cells than to germinal center B cells and plasma cells. Interestingly, in CLL we not only saw activation of regions that are active in naive and memory B cells, but also an unexpected activation of genomic regions that are specifically active in germinal center B cells and plasma cells. Changes in activation in these and other regions could furthermore distinguish the two major clinical subgroups of CLL with unmutated and mutated immunoglobulin heavy chains (IgVH). CLLs did not only differ from normal B cells regarding the separate layers of information, but also using combined patterns of histone marks, which for example can define regulatory elements as active promoters (H3K4me3 and H3K27ac) or active enhancers (H3K27ac and H3K4me1). More specifically, we detected 534 genomic regions with de novo gain (n=498) or loss (n=36) of active regulatory regions in CLL. Large regions (>10kb) showing de novo gain of regulatory elements in CLL (n=51), were located into, close to, or interacted in 3D space with genes important for CLL pathogenesis, e.g., LEF1, BCL2 and FMO3. Interestingly, non-coding somatic mutations in IGHV mutated CLLs accumulate in these and other active regulatory regions, likely off-target effects of the somatic hypermutation machinery. Besides changes in regulatory elements, we observed that CLLs lose poised promoters, which are replaced by repressive active regions. This change, mainly occurring in developmental genes, does not affect gene expression levels, as these genes are already silent in normal B cells. It may however represent loss of plasticity during CLL pathogenesis in which these genes become permanently inactive.

**Summary/Conclusions:** With this integrative study, we generated new conceptual avenues to understand the complex link among the epigenetic, transcriptional, and 3D chromatin landscape in CLL. In addition we provide the community with an extensive resource of epigenetic information of this lymphoid neoplasm.

**S118 THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR CROSS-TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS**

C. Paiav1, T. Rowland1, B. Sreekantham1, O. Danilova1, A. Danilov1,1

1Oregon Health and Science University, Portland, United States

**Background:** Although small molecule inhibitors of BCR-associated kinases (BCRi) revolutionized therapy in CLL, they provide incomplete responses. Tumor necrosis factor receptor superfamily ligands BAFF and APRIL induce NFκB, which in turn upregulates pro-survival Bcl-2 family proteins and thereby drives anti-apoptotic responses, potentially accounting for resistance to BCRi. The exact roles of the individual NFκB pathways, as well as the implications of targeting BCR in context of BAFF signaling in CLL remain understudied.

**Aims:** We explored the mechanistic underpinnings of CLL cell survival in response to BAFF signaling.

**Methods:** We established a novel BAFF-expressing stromal co-culture model and screened inhibitors of Bruton tyrosine kinase (BTK), ibrutinib; phosphoinoside-3 kinase (PI3K, idelalisib) and spleen tyrosine kinase (SYK, entosple tinib). We quantified CLL cell apoptosis, migration, NFκB activity, protein and mRNA expression by flow cytometry, immunoblotting, ELISA, RT-PCR and immunocytochemistry.

**Results:** CLL cells co-cultured with BAFF-expressing stroma were resistant to spontaneous apoptosis (12.3±3.2% after 24 h, vs 34.8±6.2% off stroma) and chemotherapy agents (bendamustine, fludarabine). Gene expression profiling exposed the NFκB pathway gene targets as the most significantly upregulated upon BAFF stimulation (p<0.0001). We and others have shown that BAFF-expressing stroma induces canonical and non-canonical NFκB in CLL. By contrast, while BAFF led to strong activation of the non-canonical NFκB with processing of p100 (to p52) by 4 h and a 5-fold increase in p52 DNA-binding activity by 24 h, canonical NFκB (RelA) activation was less pronounced. BAFF predominantly induced Mcl-1, compared to CD40L which strongly upregulated Bcl-X. BCR is a major driver of canonical NFκB signaling in CLL. Thus, we studied whether BAFF co-opted BCR signaling in CLL. BAFF induced rapid (15 min) phosphorylation of the proximal BCR kinases SYK and LYN, sustained for up to 4 h, as well as ERK, in CLL cells. AKT activation occurred late (>2h), suggesting that BAFF induced AKT independent of BCR. BAFF-mediated BCR activation did not correlate with IGHV mutational status. Like IgM, BAFF induced CLL cell chemotaxis. SYK inhibition effectively antagonized survival and chemotaxis of BAFF-stimulated CLL cells. By contrast, targeting BTK or PI3K was less effective. All BCRi’s fully blocked canonical NFκB activation in BAFF-stimulated CLL cells (suggesting its dependence on BCR signaling), but none inhibited the non-canonical pathway. By contrast, pevonedistat, an inhibitor of Nedd8-activating enzyme which we have previously shown to abrogate TNFR-mediated NFκB activation, blocked both canonical and non-canonical NFκB activity in BAFF-stimulated CLL cells. SYK inhibitor entosple tinib, but not other BCRi’s, decreased Mcl-1 expression in CLL cells co-cultured with BAFF-expressing stroma and abrogated BAFF-mediated upregulation of pSTAT3, a transcription factor which regulates Mcl-1. This was accompanied by a decrease in Mcl-1 transcript. BAFF receptor signals via the TRAF complex to induce non-canonical NFκB activation in neoplastic B-cells. We supposed that TRAF complex could be directly responsible for SYK activation by BAFF. Indeed, IP experiments demonstrated that SYK directly complexed with TRAF2/3 in BAFF-stimulated neoplastic B-cells.

**Summary/Conclusions:** Thus, BAFF-mediated induction of BCR-associated kinases and Mcl-1 contributes to CLL cell survival. SYK inhibition is a promising therapeutic strategy uniquely poised to antagonize crosstalk between BAFF and BCR, thereby disrupting the pro-survival microenvironment signaling in CLL.
S119

LOW MYBL2 EXPRESSION OBSERVED IN MYELODYSLASTIC SYNDROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOIETIC STEM CELLS

R. Bayley1, L. Cancian1, C. Ward1, G. Völpe1, S. Dumen1, G. Gajjar1, G. Stewart2, E. Petersmann1, P. Garcia1.

1Institute of Cancer and Genomic Science, University of Birmingham, Birmingham, United Kingdom

Background: MYBL2 is a transcription factor with roles in the cell cycle and genome integrity. MYBL2 is located on chromosome 20, within a region commonly deleted in human blood disorders (del20q). Our published data shows that reduced levels of MYBL2 predispose to development of myelodysplastic syndromes (MDS)-like disease in mouse models during ageing, indicating that MYBL2 could be acting as a tumour suppressor gene within del20q abnormality. Moreover, our previous work demonstrated that regardless of del20q deletion, MYBL2 expression is reduced in CD34+ bone marrow cells from MDS patients with worse prognosis. Because it has been shown that the cell of origin of MDS is the haematopoietic stem cell (HSC) and given the role of MYBL2 in DNA replication fork progression and maintenance of genome integrity, we hypothesised that low MYBL2 levels in HSC could contribute to elevated somatic mutations through changes in DNA repair pathways and drive disease development.

Aims: The aim of this study was to determine if low MYBL2 levels affect the double strand break (DSB) DNA repair damage response in HSC.

Methods: In this study we used our mouse model in which animals express ~50% normal levels of MYBL2 (Myb2+/−). We characterised the activity of HSCs from young (7 weeks) and old (70 weeks) animals to respond to in vivo ionising radiation (IR) via the DDR that led to DNA replication, apoptosis and colony formation being impaired. We measured the activation of the two main DNA repair pathways operating in the cells to deal with DSB: the error prone non-homologous-end-joining (NHEJ) and the error-free homologous recombination (HR) by assessing 53BP1 and Rad51 recruitment by immunofluorescence, respectively. Finally, we analysed the frequency of chromosome abnormalities present in the progeny of Myb2−/− HSC that have previously been irradiated to determine the long term effects of changes in DNA repair.

Results: We observed that Myb2−/− HSCs had limited proliferative potential and displayed an increased sensitivity to ionizing radiation which increased during ageing. Myb2−/− HSCs also displayed altered kinetics of 53BP1 and Rad51 recruitment and clearance, including retention of 53BP1 foci at later time points following irradiation and decreased levels of Rad51 foci when compared to Myb2+/−HSCs. Using plasmid functional assays, we showed that Myb2−/− HSCs repair quite efficiently by NHEJ, but this efficiency is disrupted when cells are challenged with ionising radiation. Furthermore, Myb2−/− HSCs have increased sensitivity to inhibition of DNA-PKc (required for NHEJ) but not ATM (required by HR). We also observed that after ionizing irradiation Myb2−/− HSC progeny displayed an increased percentage of chromatids with fragile telomeres. Moreover, by making use of publicly available RNA-seq data from young and old C57Bl/6 mice, we have identified a clear association between low MYBL2 levels and low expression of DNA-repair genes in patients with worse prognosis.

Summary/Conclusions: In summary, we have shown that decreased expression of MYBL2 leads to an imbalance in the DSB DNA-repair pathway choice, ultimately resulting in increased genomic instability of the blood cell progeny. These findings are supported by a signature of deregulated DNA-repair genes which strongly associates with low MYBL2 levels in MDS patient samples, providing a mechanistic understanding for the progression of blood disorders occurring during ageing. This study demonstrates a novel role for MYBL2 in DSB repair in HSCs and suggests that low levels of MYBL2 in human MDS could contribute to the emergence of further genetic abnormalities by deregulation of DNA-repair pathways.

S120

A NOVEL GENETIC AND MORPHOLOGIC PHENOTYPE OF ARID2-MEDIATED MYELODYSLASTIC SYNDROMES


1Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, United States; 2Division of Hematology, Department of Internal Medicine, Shinshu University, Matsumoto, Japan; 3First Department of Internal Medicine, University of Tokushima, Tokushima, Japan; 4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, United States; 5Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; 6Clinical Research Center, Nagoya Medical Center, Nagoya, Japan; 7Laboratory of Sequence Analysis, Human Genome Center, The University of Tokyo, Tokyo, Japan.

Background: Clinical heterogeneity of myelodysplastic syndromes (MDS) and related myeloid neoplasms reflects molecular diversity. Most common genetic associations with distinct clinical or pathomorphologic phenotypes have been described, but many other rare or somatic lesions exist and their clinical context still remains elusive. AT rich interactive domain 2 (ARID2), which is located on chromosome 12q, encodes a component of the SWI/SNF complex that is involved in chromatin remodeling. In recent years multiple groups detect- ed ARID2 mutations in a variety of solid tumors.

Aims: In this study, we present whole exome sequencing-guided identification of novel ARID2 mutations in myeloid neoplasms. Specifically, in addition to copy number analysis and deep targeted and exome sequencing, here we include RNA sequencing and splicing analyses of the roles of splicing events in MDS and other myeloid neoplasms and gene expression.

Methods: Bone marrow aspirates or blood samples were collected from 1,473 patients with MDS (n = 445), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) (n = 201), myeloproliferative neoplasms (MPN) (n = 56), sAML (n = 221), and primary acute myeloid leukemia (pAML) (n = 540) at the Cleveland Clinic and The University of Tokyo; the registered data at the Cancer Genome Atlas were also included. Diagnoses were classified using World Health Organization criteria. Informed consent for sample collection was obtained according to a protocol approved by each Institutional Review Board in accordance with the Declaration of Helsinki.

Results: By comprehensive genetic investigation of these cases, we characterized here cases (10%) in which decreased expression of ARID2 mediated their clinical effects in MDS and other myeloid neoplasms via multiple kinds of genetic lesions. We showed that insufficient ARID2 expression mainly in MDS arose from ARID2 mutations, deletions, and missplicing due to U2AF1 mutations that yielded defective pre-mRNA transcripts. Our whole exome analyses showed that ARID2 mutations and deletions occurred as initial events of MDS or myelodysplasia/myeloproliferative neoplasms, and not during progression to acute myeloid leukemia. Morphologically, progressive maturation in myeloid and erythroid lineages and hypoproliferative megakaryocytes (indicated by arrow heads in Figure 1) were common in cases with ARID2 mutations and deletions, and were also found in cases with U2AF1 mutations. Functionally, we utilized in vitro knockdown models of ARID2 expression in hematopoietic cell lines and bone marrow mononuclear cells. Since no homozygous deletion or mutation of ARID2 was identified, we transduced shRNA in neo-plastic and healthy hematopoietic cells to obtain disease models with partial reduc- tion of ARID2 expression. Two myeloid cell lines (HL60 and KG62) in which ARID2 expression was knocked down showed significantly lower cell counts compared to those with normal ARID2 expression, compatible with more apoptotic cells in knockdown experiments. Flow cytometric analysis of the cell lines with reduced ARID2 expression revealed increased cell-surface maturation markers, CD11b and glycoprotein A (GPA), suggesting that reduced expression of ARID2 resulted in more differentiation in myeloid and erythroid lineages. Knockdown of ARID2 failed to reduce colony formation in bone marrow mononuclear cells. These results indicate that reduced ARID2 expression might induce more differentiation in myeloid/erythroid lineages and more apoptosis to reduce cell populations without reduction of proliferation capacity in hematopoietic progenitor cells. Finally, we examined morphological findings associated with knockdown ARID2 expression. Compared to control cells, KG62 cells with reduced ARID2 expression formed more hypoproliferative megakaryocytes, which confirmed morphological findings seen in ARID2 and U2AF1 defects.

Figure 1.

Summary/Conclusions: ARID2 is a MDS-suppressor gene whose expression is attenuated by multiple mechanisms as it shapes the distinct morphological phenotype of a subset of myelodysplasia.
The value of NGS panel sequencing to molecularly define myeloid malignancies and clarify borderline cases: A study on 39 genes in 1143 patients

C. Baer1, K. Perglerová2, W. Kern1, C. Haferlach1, T. Haferlach1

1MLL Munich Leukemia Laboratory, Munich, Germany, 2MLL2 s.r.o., Prague, Czech Republic

Background: The 2016 revision of the WHO classification for myeloid malignancies includes numerous molecular markers for classification and prognostication. Next generation sequencing allows analyzing relevant genes in one panel.

Aims: Exploit clinical usefulness of panel sequencing in routine diagnostics in order to describe genetic changes and use respective patterns in cases with undifferentiated myeloid neoplasms.

Methods: According to WHO 2016, 1143 patients were morphologically categorized as AML (n=261), MDS (n=176), MPN (n=19), CMML (n=51) or AML/MDS (n=21) and MDS/MPN overlap (n=28). Patients, who did not fulfill all characteristic criteria or had insufficient sample quality, were classified as “possible” AML (n=28), MDS (n=211), MPN (n=58), CMML (n=14) and as reactive (n=193) or unclear (n=136). DNA was isolated from BM (n=958) or PB (n=185) for NextSeq or MiSeq sequencing after TruSeq library preparation (all Illumina, CA). Data was analyzed with SeqNext 4.3 (JSI Medical Systems, Kippenheim, Germany). FLT3-ITD and KMT2A-PTD data was obtained according to standard protocols.

Results: Analyzing 39 genes, we found ≥1 molecular change in 90% of patients (500/556) with a definitive morphologic diagnosis (median: 2 genes; max: 7).

In de novo AML, 212/229 (93%) patients showed ≥1 molecular hit, of which 211 (92%) had aberrations that define WHO categories or have prognostic (according to ELN/MRC) or predictive value. Additionally, one mutation was found in 166/229 patients (72%), including information of adverse impact (e.g. of 68 NPM1 positive patients, 17 had DNMT3A mutations and 20 FLT3-ITD). Following NPM1, RUNX1 was the second most frequently mutated gene (46/225; 20%) and mutations were significantly more common in patients with ≥3 aberrations (37/57; 65%) than with 2 (20/76; 26%). A similar RUNX1 (f pattern was found in s-AML and t-AML. In the cohort of “possible AML” (including MDS patients), 199/918 (21%) patients had ≥1 molecular hit. Most frequently mutated were ASXL1 (16/48; 33%), TET2 (32%; 14/44) and SRSF2 (29%; 14/48); 16% had all three mutated. This combination is the most frequently occurring three-way interaction in CMML (10/44; 23%). In MDS, 124/157 (79%) cases showed mutations, of which 108 had ≥1 prognostic change (according to Bejar, 2015). The prognostically favorable SF3B1 mutation was present in 31/157 (20%) and significantly enriched among cases with ring sideroblasts (p<0.001). Overall, TET2 showed the highest mutation rate (25%) and was also the most commonly mutated gene in cases with “possible” MDS (3/69; 42%). A similar pattern was observed in the case of RUNX1 (8% of all molecular markers for clonal disease in 47% (91/199), 36% (43/118) or 17% (36/211) of cases, respectively (excluding sole ASXL1, DNMT3A, TET2 mutations with <10% burden), which is observed in clonal hematopoiesis of indeterminate potential (CHIP), too. However, using panel sequencing in cases with possible MDS, unclear or reactive morphology revealed at least one molecular marker for clonal disease in 47% (91/199), 36% (43/118) or 17% (36/211) of cases, respectively (excluding sole ASXL1, DNMT3A, TET2 mutations with <10% burden).

Summary/Conclusions: WHO 2016 requires information on numerous genes for diagnosis, prognosis and therapeutic decisions. This challenges conventional cytomorphology which is performed at least once in clinical disease in 47% (91/199), 36% (43/118) or 17% (36/211) of cases, respectively (excluding sole ASXL1, DNMT3A, TET2 mutations with <10% burden). De novo AML, 212/229 (93%) patients showed ≥1 molecular hit, of which 211 (92%) had aberrations that define WHO categories or have prognostic (according to ELN/MRC) or predictive value. Additionally, one mutation was found in 166/229 patients (72%), including information of adverse impact (e.g. of 68 NPM1 positive patients, 17 had DNMT3A mutations and 20 FLT3-ITD). Following NPM1, RUNX1 was the second most frequently mutated gene (46/225; 20%) and mutations were significantly more common in patients with ≥3 aberrations (37/57; 65%) than with 2 (20/76; 26%). A similar pattern was observed in the case of RUNX1 (f pattern was found in s-AML and t-AML. In the cohort of “possible AML” (including MDS patients), 199/918 (21%) patients had ≥1 molecular hit. Most frequently mutated were ASXL1 (16/48; 33%), TET2 (32%; 14/44) and SRSF2 (29%; 14/48); 16% had all three mutated. This combination is the most frequently occurring three-way interaction in CMML (10/44; 23%). In MDS, 124/157 (79%) cases showed mutations, of which 108 had ≥1 prognostic change (according to Bejar, 2015). The prognostically favorable SF3B1 mutation was present in 31/157 (20%) and significantly enriched among cases with ring sideroblasts (p<0.001). Overall, TET2 showed the highest mutation rate (25%) and was also the most commonly mutated gene in cases with “possible” MDS (3/69; 42%). A similar pattern was observed in the case of RUNX1 (8% of all molecular markers for clonal disease in 47% (91/199), 36% (43/118) or 17% (36/211) of cases, respectively (excluding sole ASXL1, DNMT3A, TET2 mutations with <10% burden).
Results: Unsupervised clustering of gene expression data of bone marrow blasts compared to those in the Class-I subgroup (median 2% vs 11%, *P* <0.01). Pathway analysis revealed up-regulation of many signaling pathways in the Class-II subgroup. The Class-I subtype showed highly significant up-regulation of the genes related to erythrocyte lineages. The erythroid signature was rather suppressed in the Class-II subtype, which was characterized by increased expression of genes related to progenitor cells. Compared to the Class-I subtype, the Class-II subtype was associated with a significantly shorter survival in both univariate (hazard ratio [HR] 5.0 [95% CI, 1.8–14], *P* <0.001) and multivariate analysis (HR 6.8 [95% CI, 1.5–32], *P* =0.015). High frequency of leukemic transformation in the Class-II subgroup (38%) contrasted to no leukemic transformation in the Class-I subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of BMMNCs. The model was applied to 114 patients with BMMNC samples, of whom 47 (41%) were predicted to be the Class-II subgroup. Compared to the predicted Class-I subgroup, the Class-II subgroup was associated with a significantly shorter survival in univariate analysis (HR 7.2 [95% CI, 3.0–17], *P* <0.001). Again, association was more pronounced for leukemic transformation (HR 18 [95% CI, 4.2–80], *P* <0.001) than for overall survival. Multivariate analysis also demonstrated that the predicted Class-II subgroup was independently associated with leukemic transformation (HR 7.3 [95% CI, 1.3–41], *P* =0.024). Finally, we compared the prognostic value of our model with that of the LSC17 score, which has recently been proposed to predict a subset of poor risk acute myeloblastic leukemia based on the expression of 17 genes related to a leukemic stem cell signature. Our model outperformed the LSC17 score in predicting clinical outcomes of myelodysplasia, especially leukemia progression.

Summary/Conclusions: Comprehensive transcriptomic analysis identified two subgroups of myelodysplasia with biological and clinical relevance, which could improve risk prediction and treatment stratification of myelodysplasia.

**Background:** Checkpoint blockade using anti-PD-1/PD-L1 antibodies is a highly promising therapy for cancer, frequently showing dramatic anti-tumor responses in a wide variety of tumor types. Particularly, an exceptional response to anti-PD-1 antibodies has been demonstrated for classical Hodgkin lymphoma (HL), which is characterized by frequent copy number gains/amplifications in PD-L1 and PD-L2, suggesting a link between these genetic alterations and the therapeutic response to these agents. Recently, we have reported frequent structural variations (SVs) in adult T-cell leukemia/lymphoma (ATL) caused by human T-cell leukemia virus type-1 (HTLV-1). These SVs invariably affect 3′-untranslated region (UTR) of PD-L1, leading to promiscuous PD-L1 overexpression. Providing critical viral antigens in an endogenous context to virally infected cells, we hypothesized that a deregulated PD-1/PD-L1 axis might play a critical role in evasion from anti-viral immunity before these cells are clonally selected for neoplastic proliferation.

Aims: Epstein-Barr virus is a DNA tumor virus closely associated with various human cancers, including B- and natural killer (NK)-T-cell lymphomas, in which genetic alterations involving PD-L1/PD-L2 may also be relevant to cancer evolution. In this study, to assess this hypothesis, we interrogated a variety of lymphomas for genetic abnormalities affecting PD-L1 and PD-L2, especially focusing on EBV-associated lymphomas.

Methods: SVs and other genetic lesions affecting PD-L1 and PD-L2 were analyzed using targeted-capture sequencing with cRNA baits designed for capturing the entire sequences of PD-L1 and PD-L2 genes, including exons, introns, and 5′- and 3′-UTRs. More than 400 samples were analyzed obtained from different subtypes of non-Hodgkin lymphomas, including EBV-associated lymphomas (such as EBV-positive diffuse large B-cell lymphoma (DLBCL) and NK/T-cell malignancies).

Results: SVs and/or focal copy number gains involving PD-L1 genes were successfully detected in various B-cell and T/NK-cell lymphomas, albeit at generally low frequencies (<10%). These lesions were the most frequently observed in PMBCs, accounting for more than 60% of the cases. Of note, high frequency (17–57%) of PD-L1/PD-L2 involving abnormalities were observed in mature NK/T-cell neoplasms, including extranodal NK/T-cell lymphoma, aggressive NK cell leukemia, and EBV-positive T-cell lymphoproliferative disorder, all of which were positive for EBV. Moreover, a substantial proportion (22%) of EBV-positive DLBCL cases possessed these lesions, whereas EBV-negative cases rarely exhibited these alterations (2%, *P*<0.01). For both PD-L1 and PD-L2 SVs, despite a large diversity of SV type (deletions, inversions, tandem duplications, and translocations), most of SVs resulted in 3′-UTR truncation, while the replacement of PD-L1 or PD-L2 promoter with an ectopic regulatory element was rarely observed. Interestingly, PD-L1 SVs were detected in both B- and T-cell lymphomas, whereas PD-L2 SVs were found exclusively in B-cell lymphomas.

Summary/Conclusions: We delineate the entire picture of genetic alterations involving PD-L1/PD-L2, and confirm the clinical relevance and EBV-associated lymphomas. Our finding help to understand their pathogenesis and develop a new diagnostic strategy to identify patients who potentially benefit from PD-1/PD-L1 blockade therapy in non-Hodgkin lymphomas.

**Methods:** We performed transcriptome sequencing of bone marrow mononuclear cells (BMMNCs) and CD34+ cells obtained from patients with myelodysplasia. Consensus clustering was used to identify stable patient clusters. A classifier of the gene expression-based subgroups was constructed using the 100 CD34+ cell samples as a training set, followed by validation in an independent cohort of 183 MDS patients. Another classifier was constructed using BMMNC samples from 51 patients, who had been assigned to the subgroups by the gene expression data of their CD34+ cells. Prognostic significance of the model was tested in 114 patients of myelodysplasia.

**Background:** Recent somatic mutations of N-terminal region of FOXO1,
shown previously to increase FOXO1 nuclear localization and activity, have been linked to diminished survival in DLBCL patients uniformly treated with rituximab-based immunotherapy. Although the contribution of FOXO1 mutations to the therapeutic resistance of B-NHLs becomes apparent, the molecular mechanism underlying this phenomenon has not been explained so far. The diminished levels of CD20 on the cell surface of tumor cells are among several potential mechanisms underlying the resistance to treatment with anti-CD20 monoclonal antibodies.

**Aims:** We have recently reported that the tonic BCR signaling activates FOXO1, and that inhibitors of the downstream BCR signaling pathways downregulate CD20 expression. Therefore, here we sought to determine whether FOXO1 might regulate the abundance of CD20 on the surface of tumor cells thus influencing the response to rituximab-based therapies.

**Methods:** We used CRISPR/Cas9 genome editing technology and lentiviral transduction to study the role of FOXO1 protein in CD20 regulation. qRT-PCR and Dual Luciferase Assays was done to determine the influence of FOXO1 on CD20 expression. To get insight into molecular interaction between FOXO1 and CD20 promoter we performed EMSA and ChIP experiments. For animal studies we used SCID Fox Chase mice model. All in vivo experiments were carried out at the animal facility of The Francis Crick Institute in accordance with the guidelines and were approved by the Ethics Committee.

**Results:** To determine the potential role of FOXO1 protein in CD20 regulation, we disrupted FOXO1 focus using the CRISPR/Cas9 genome editing technology in Raji cells. In *in vitro* complement-dependent cytotoxicity assay we show that ablation of FOXO1 results in upregulation of CD20 levels and improved resistance to rituximab efficacy. To see whether FOXO1-dependent up-regulation of CD20 transcription was linked to tumor cell survival, we analyzed apoptosis induced by DM-KG (Figure 1C). Contrary to that, exposing viable primary CLL, FL and DLBCL cells to DM-KG significantly induced apoptosis (p<0.01) in all cell lines examined (n=17). Interestingly, we also observed that in cell lines and primary tumors, DM-KG consistently activated the kinase AMPK, with consequent marked inhibition of mTORC1. Importantly, these signals were also engaged in normal B cells, but they did not result in growth inhibition or apoptosis, thus highlighting the unique sensitivity of cancer cells to the modulation of energy metabolism.

**Summary/Conclusions:** Collectively, our results indicate that FOXO1 is a strong negative regulator of CD20 expression and add new insights into the mechanisms underlying the contribution of FOXO1 mutations to the resistance of B-NHLs to R-CHOP therapy. In light of current knowledge and our observations presented in this study, FOXO1 inhibition represents a novel strategy to increase the efficacy of anti-CD20 monoclonal antibodies.

**Acknowledgements:** Abstract supported by national grants: NCN, Poland, projects no: 2013/11/B/NZ5/02240 (BP) and 2015/18/E/NZ6/00702 (MW); MNiSW, Poland, project no: D/2014/07/34 (NMJ) and European Comission (Horizon 2020, project no: 692180-STREAM-H2020-TWINN-2015, CSA action (JG).
**Thalassemia**

**S128**

**TIGET-BTHAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS GENETICALLY MODIFIED WITH GLOBE LENTIVIRAL VECTOR**


1Haematology and BMT Unit, 2Pediatric Immunohematology, 3San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milano, 4Pediatric Department, San Gerardo Hospital, Monza, 5Pediatric Clinic/DH, Fondazione IRCCS Ca’ Granda, Milano, 6Department of Biomedical Science and Biotechnology, University of Cagliari, Cagliari, 7Blood Transfusion Service, San Raffaele Scientific Institute, Milano, 8Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Policlinico S. Matteo, Pavia, 9Rare Disease Center, Fondazione IRCCS Ca’ Granda, Milano, Italy

**Background:** Gene therapy for transfusion dependent beta-thalassemia, as an alternative cure to allogeneic HSCT, is based on the autologous transplantation of hematopoietic stem cells (HSCs) engineered by lentiviral vectors expressing a transcriptionally regulated human beta-globin gene.

**Aims:** Our contribution to this field was devoted to the clinical development of a gene therapy protocol based on high-titer vector GLOBE, use of lenograstim and plerixafor as source of HSCs and a conditioning regimen based on myeloablative treosulfan and thiotepa favoring efficient engraftment of corrected cells with reduced toxicity (TIGET-BTHAL; EudraCT number 2014-004860-39).

**Methods:** The efficacy and safety of clinical studies, the clinical trial TIGET-BTHAL was approved and started in 2015 at Scientific Institute San Raffaele, Milano, Italy. The clinical study foresees treatment of 10 patients: 3 adults followed by 7 minors, with a staggered enrolment strategy based on evaluation of safety and preliminary efficacy in adult patients by an independent data safety monitoring board before inclusion of pediatric subjects. The chosen route of administration of gene modified HSCs is intraosseous in the posterior-superior iliac crests, bilaterally, with the aim of enhancing engraftment and minimizing first-pass intravenous filter.

**Results:** As of February 2017, seven patients (3 adults and 4 pediatric patients) with different genotypes (β0/β0, β+/β+ and β0/β+) have been treated with GLOBE-transduced CD34+ cells at a dose of 16x10⁶-19.5x10⁶ cells/kg and a vector copy number (VCN)/cell ranging from 0.7 to 1.5. The procedure was well tolerated by all patients, with no product-related adverse events. Multilineage engraftment of gene-marked cells was observed in all tested peripheral blood and bone marrow samples. Polyclonal vector integrations profiles have been detected in the first 3 patients tested.

**Summary/Conclusions:** So far, the clinical outcome indicates reduction in transfusion requirement in adult patients and greater clinical benefit in younger patients. Follow up analysis are ongoing and updated clinical outcome will be presented.
S130 DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, PHASE 2B CLINICAL STUDY


Background: Thalassemia is a heterogeneous group of hereditary disorders characterized by decreased production of hemoglobin due to defective production of beta-globin chains. Worldwide, an estimated 200,000 patients have beta-thalassemia major (TM). Thalassemia major patients have a life expectancy of 50-55 years, but the quality of life is significantly reduced due to complications related to the disease. Bone disease is one of the most common complications in TM patients, with an increased risk of fractures and osteoporosis. The aim of this study was to assess the effects of denosumab, a human monoclonal antibody that targets and binds to RANKL, on lumbar spine (L1-L4) BMD in patients with TM and osteoporosis as compared to placebo.

Materials and Methods: A double-blind, placebo-controlled, randomized clinical trial was conducted at 9 major centers in France. Patients (n=1) were randomized to receive denosumab (60 mg SC every 6 months for 12 months) or placebo. L1-L4 BMD was measured at baseline and at 12 months. Results: L1-L4 BMD was higher in the denosumab arm than in the placebo arm (6.02±5.30% vs 0.81±0.105 g/cm², p<0.008) and a significant decrease in their WR BMD (0.52±0.099 g/cm² vs 0.54±0.095 g/cm², p=0.004) and a significant decrease in their WR BMD (0.52±0.099 g/cm² vs 0.54±0.095 g/cm², p=0.004). The percentage increase in L1-L4 BMD was higher in DMB arm than in placebo arm (6.02±5.30% vs 3.11±5.46%, respectively; p=0.03), while the advantage of DMB regarding WR BMD was much higher compared to placebo (-0.22±0.45% vs -4.15±5.58%, respectively; p=0.02) as well as in FN BMD (p<0.001). No grade 3 or 4 toxicity was observed in this trial. Conclusion: Denosumab increased lumbar BMD in TM patients. Denosumab is an effective and safe treatment for the management of TM-induced osteoporosis.
SDS values increased with time, especially in females. Although gonadal dys-
function was observed in 60% of women aged at least 13 years at the last eval-
uation, 12/27 aged more than 20 years experimented at least one successful
pregnancy. 93 patients had stopped their immunosuppressive treatment two
years after HSCT. 37 were treated with iron chelation therapy and/or phle-
botomies. At least half of patients are receiving a long-term hormonal treatment
or antibiotic prophylaxis at the last visit. Decrease in serum ferritin values after
transplant was significantly influenced by age at transplant and pre-transplant
serum ferritin value. The median hemoglobin value was 12.5 g/dL (86-165) at a
mean age of 18 years and Hb values were significantly influenced by age, the
sex of the donor and the presence of donor thalassemia trait.

**Summary/Conclusions:** A comprehensive and regular long-term follow-up
should be established for all patients receiving allogenic HSCT for beta-tha-
lassemia major. In this national cohort, endocrinological complications were
frequent after transplant. Fertility can be partly preserved, but this result has to
be reevaluated with the more recent use of intravenous busulfan.

---

**S132**

**CD34**+AND HUMAN INDUCED PLURIPOTENT STEM CELL
DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS

M.-J. Claessen1,2*, E. Varga3, M. Hansen4, P. Burger5, S. Heshuis1,6, T. Wust1,6,
J. Eernstman1, M. Thiell,1, E. Heideveld1, E. Sellink1, M. von Lindern1, E. van den Akker1

**Background:** Donor-derived red blood cells (RBC) are the most common form
of cellular therapy. However, the source of cells is dependent on donor avail-
ability with a potential risk of allo-immunization and blood borne diseases.

**Aims:** We aim to produce unlimited numbers of cultured RBC with a defined ‘universal donor’ phenotype for transfusion purposes.

**Methods:** To this end we prepare for a clinical test using autologous cultured
RBC to test their in vivo stability. In parallel we develop methods for unlimited
production of cultured RBC. An immortal source to produce in vitro cultured
RBCs (cRBC), such as iPSCs would allow selection of ‘universal donor’ RBC, or
provide an autologous end product with the absence of immune reactions.

**Results:** The in vitro production of RBC has proven to be successful, however
there are barriers to overcome prior to clinical application. e.g.: xeno-free cul-
turing methods, scale up cultures to obtain transfusion units (1-2*1012 erythro-
cytes), and for iPSC we need virus- and transgene-free reprogramming proto-
cols. To solve the above mentioned issues a customized humanized GMP-
grade medium (Celluin) was generated in order to control erythroid culture
parameters and to reduce culture costs. This medium allowed 1*108 times ery-
thropoiesis, allowing directed colony differentiation using a feeder-free monolayer approach.

**Summary/Conclusions:** Here we showed that our monolayer approach is sim-
ple, highly controlled and compatible with upscaling. Avoiding virus-, integrative
reprogramming, feeders and with our GMP-grade media we maintained a cost
effective system moving toward clinical application.

---

**S133**

**FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL
EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC
INTEGRITY**

A. Skucha1*, J. Ebner2, J. Schmiöller2, A. César Razquin1, T. Eder1, A. Stukalov1, S. Vittori1, M. Muhan3, R. Roth5, B. Geyer4, P. Valient5, K. Bennett1, J. Zuber5, G. Superli-Furga1,6, F. Grebien2

**Background:** The frequent occurrence of chromosomal rearrangements in
AML frequently harbors chromosomal rearrangements involving the Mixed Lineage Leukemia (MLL) gene. More than 65 different MLL fusion genes exist and many of them have been described to act as strong cancer drivers. While critical effectors of several distinct MLL fusion proteins (MLL-FPs) were identified, it is not clear if transforming mech-
isms are conserved across the entire family of MLL fusions.

**Aims:** We hypothesized that common oncogenic mechanisms are encoded in stable physical and genetic MLL-fusion-specific interaction networks. Thus, we aimed to identify common critical effectors of different MLL fusion proteins that are presumed to employ different mechanisms of oncogenic transformation.

**Methods:** Protein complexes of 7 molecularly distinct, affinity-tagged MLL-FPs (MLL-AF4, MLL-AF9, MLL-ENL, MLL-CBP, MLL-EEN, MLL-GAS7 and MLL-
AF1p) were purified from stable cell lines allowing for inducible, single-copy transfection and characterized by mass spectrometry. Data analysis identified a comprehensive protein-protein interaction network, which was func-
tionally interrogated by a subtractive shRNA screening approach. Validation experiments included detailed RNAi- and CRISPR/Cas9-mediated loss of func-
tion experiments in cell lines and primary cells in vitro and in vivo, using read-
outs for changes in proliferation, differentiation, apoptosis and DNA damage.

**Results:** Characterization of the protein complexes nucleated by 7 MLL fusion proteins by affinity purification coupled to mass spectrometry (AP-MS) revealed a densely interconnected protein-protein interaction network of 963 proteins, comprising previously known MLL-interacting protein complexes (such as PRC2 or SWI/SNF), as well as new interaction partners of MLL, 128 proteins were found to interact with ≥5 of all 7 MLL-fusions. This subset of con-
served MLL-interaction partners was highly enriched for proteins with function in chromatin metabolism and transcriptional control. Systematic functional
investigation of the conserved MLL-fusion interactome using subtractive shRNA
screens identified the methyltransferase SETD2 as a critical effector of MLL
fusion proteins. Both RNAi-based suppression and CRISPR/Cas9-mediated mutagenesis of SETD2 induced myeloid differentiation and apoptosis in human
and mouse MLL-rearranged cell lines, while having only modest effects on the
proliferation of MLL-wild-type leukemia cells. Depletion of SETD2 in MLL-fusion
lent to changes in proliferation, differentiation, apoptosis and DNA damage.

**Summary/Conclusions:** In summary, our data highlight the functional rele-
ance of combined proteomic-genomic cellular screening to identify critical
effectors of MLL-FPs. In addition, our study identifies a novel role for SETD2
in the maintenance of genomic integrity during initiation and progression of
MLL-rearranged AML and establishes SETD2 as a therapeutic target in
leukemia with low genonomic complexity.

---

**S134**

**CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO
SMALL-MOLECULE-MEDIATED INHIBITION OF THE MENIN-MLL
INTERACTION**

L. Schmidt1*, E. Heyes1, T. Eder1, J. Grembecka2, F. Grebien1

1Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria, 2Department of Pathology, University of Michigan, Ann Arbor, United States

**Background:** The CEBPA gene - encoding for the transcription factor C/EBPa
- is mutated in 9% of patients with acute myeloid leukemia (AML). CEBPA

---

**N-terminal mutations lead to selective loss of full length C/EBPa p42 expression
without affecting translation as a balance of the shorter p30 isoform. As a balance
of C/EBPa isoforms is crucial for hematopoietic homeostasis, depletion of p42
leads to increased cell growth and blocks myeloid differentiation, resulting in
the development of AML. We have recently shown that the p30 variant of

---

**AML Biology I: Towards molecular therapies**
C/EBPα can act as a gain-of-function allele with distinct molecular properties. However, the mechanism of C/EBPα p30-induced leukemogenesis is incompletely understood.

**Aims:** We hypothesized that the interaction between the oncogenic C/EBPα p30 isoform and the MLL/SET histone methyltransferase complex is required for p30-dependent epigenetic and transcriptomic changes that contribute to leukemogenesis. Therefore, we aimed to investigate the sensitivity of CEBPα mutant MLL to perturbation of MLL/SET function.

**Methods:** We used CRISPR/Cas9-mediated mutagenesis to interfere with the MLL/SET complex in myeloid progenitor cells from a Cebpa<sup>−/−</sup>AML mouse model. Cellular competition assays were used to assess changes in proliferative capacity. Further, MLL activity was inhibited by blocking small molecules that block the Menin-MLL interaction. In both cases, proliferation, myeloid differentiation and apoptosis were used as readouts. Global changes in gene expression were measured by RNA-seq.

**Results:** We initially confirmed, via ChIP, that CEBPα and MLL co-localize on the Cebpa<sup>−/−</sup>AML promoters, indicating functional cooperation in gene regulation. To investigate the importance of different, annotated functional domains within the MLL protein in the context of CEBPα p30 expression, we introduced targeted mutations across the MLL gene in Cebpa<sup>−/−</sup> cells using the CRISPR/Cas9 system. This analysis revealed a strong dependence of Cebpα<sup>p30</sup> expression on the presence of an intact MLL protein. Surprisingly, loss of the enzymatic activity of Mll by mutually targeting of the SET domain did not significantly affect cell survival. In contrast, cells were particularly sensitive to mutations of the Menin-biding motif in Mll. Mll targeting strongly induced myeloid differentiation in Cebpa<sup>−/−</sup> cells as measured by increased levels of CD11b and macrophage markers. To further investigate functional cooperativity upon pharmacological perturbation of the MLL/SET complex, we used MI-643, a potent small-molecule inhibitor of the Menin-MLL interaction. Inhibitor treatment led to a time- and dose-dependent impairment of proliferation, induction of cell cycle arrest and increased apoptosis in Cebpa<sup>−/−</sup> cells. RNA-seq analysis showed that inhibitor treatment induced expression changes associated with myeloid differentiation, which could be confirmed by flow cytometry. Importantly, expression of C/EBPα p30 was associated with hypersensitivity to Menin-MLL inhibition, as Cebpa<sup>−/−</sup> cells were 2-6 fold more sensitive than other leukemia cell lines of mouse and human origin.

**Summary/Conclusions:** Our data show that CEBPα-mutated AML is highly sensitive to perturbation of the MLL/SET complex, either via genetic ablation of MLL or through pharmacological inhibition of the Menin-MLL interaction. Our data indicate that leukemic mutations of CEBPα selectively cooperate with the MLL/SET complex to regulate gene expression. These findings expand our understanding of the and may inform new therapeutic strategies for N-terminal CEBPα mutated AML.

---

**S135**

**INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKAEMIA**

J. Chen<sup>1</sup>, A. Ambesi-Impiombato<sup>4</sup>, A.A. Ferrando<sup>4</sup>, I. Mantzaris<sup>1</sup>, E. Gavathiotis<sup>1</sup>, M. Giannakakou<sup>1</sup>, P. Gallipoli<sup>1,∗</sup>, A. S. Costa<sup>2</sup>, K. Tzelepis<sup>3</sup>, G. Giotopoulos<sup>1</sup>, S. Vohra<sup>1</sup>, G. Vassiliou<sup>1</sup>, C. Frezza<sup>2</sup>, B. Huntly<sup>1</sup>, 1Haematology, 2MRC Cancer Unit, 3Wellcome Trust/Sanger Institute, UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

**Background:** FLT3 tyrosine kinase (TK) activating mutations (FLT<sup>3m</sup>) are amongst the most frequent in AML and are associated with a poor outcome. FLT<sup>3m</sup> cells promote constitutive activation of survival/proliferation pathways and induce chemoresistance, as shown by increased cell proliferation, increased glycolysis and increased ROS levels. FLT3 TK represents a valid therapeutic target and several FLT3 TK inhibitors (TKI) have been developed. However, despite showing activity in the preclinical setting, FLT3 TKI have displayed limited efficacy in clinical trials. Resistance mechanisms to FLT3 TKI include receptor mutations and cell intrinsic adaptive mechanisms. Amongst the latter, metabolic adaptations may play a significant role although the exact mechanisms remain ill-defined.

**Aims:** We hypothesised that metabolic adaptations facilitate FLT3 TKI resistance and aimed to identify early metabolic changes in FLT<sup>3m</sup>-AML, following TKI treatment, in an attempt to unravel novel therapeutic vulnerabilities.

**Methods:** Liquid chromatography coupled to mass spectrometry (LC/MS), using stable isotope-based carbon flux tracing, and oxygen consumption rate/extracellular acidification rate as measured by an extracellular flux analyser (Seahorse, Agilent Technologies) were used to assess metabolic changes in primary FLT3<sup>mut</sup> cells. Gene silencing was performed using CRISPR-Cas9 gene editing and active oxygen species (ROS) in various culture conditions were measured by flow cytometry.

**Results:** We hypothesised that metabolic adaptations facilitate FLT3 TKI resistance and aimed to identify early metabolic changes in FLT<sup>3m</sup>-AML, following TKI treatment, in an attempt to unveil novel therapeutic vulnerabilities.

**Conclusions:** We present a novel approach for the specific therapeutic targeting of these patients and overall approaches for the specific therapeutic targeting of these patients are thus far unexplored.
These data predict that a combined inhibition of glutamine metabolism and FLT3 TK inhibition by respectively counteracting oxidative damage and sustaining macromolecule biosynthesis and cellular energetics. These data predict that a combined inhibition of glutamine metabolism and FLT3 TK activity may improve the eradication of FLT3mut AML cells.

**Summary/Conclusions:** Our data suggest that upon AC220 treatment, glutamine metabolism becomes a critical metabolic dependency in FLT3mut AML. Glutamine metabolism is mostly channelled towards glutathione production, and mine metabolism becomes a critical metabolic dependency in FLT3 mut AML.

**Background:** The molecular pathways and microenvironmental cues that choreograph the conversion of endothelial cells (ECs) into long-term repopulating hematopoietic stem cells (HSCs) remain poorly defined. This is due to lack of models that recreate the ephemeral transition of an endothelial cell to a hemogenic state to the emergence of HSCs. The molecular pathways and microenvironmental cues that choreograph the conversion of endothelial cells (ECs) into long-term repopulating HSCs that give rise to all hematopoietic lineages, including functional T cells in vivo. To provide a platform to deconvolute the process by which endothelial-to-hematopoietic transition is possible.

**Methods:** Here, we have developed a modular in vitro model in which—by precise, conditional expression of transcription factors: FosB, Gfi1, Runx1, and Spi1 (FGS), and reintroduction of a proper inductive niche—adult mouse ECs were reprogrammed into HSCs (rEC-HSCs) with multi-lineage engraftment potential (rEC-MPPs). Adult, non-lymphytic ECs isolated from various organs of Runx1-IRES-GFP reporter mice were transduced with FGS and co-cultured in direct contact with vascular niche.

**Results:** Within 14 days, ECs initiated a hematopoietic program, turning on the endogenous expression of Runx1 and transitioning into hematopoietic cells. Expansion of these cells for another 14 days resulted in generation of rEC-HSCs and rEC-MPPs. Transplantation of rEC-HSCs and rEC-MPPs (CD45.2+) into lethally irradiated mice (CD45.1+) reconstituted both the short-term (rEC-MPPs) and long-term hematopoiesis, with secondary engraftment potential (rEC-HSCs). rEC-HSCs gave rise to both functional myeloid and lymphoid cells with full complement of polarized T cell subsets. rEC-HSC-derived T cells undergo T-cell receptor (TCR) rearrangement and restore adaptive immune function in Rag1−/− mice.

**Summary/Conclusions:** This multi-phasic, step-wise approach provided an interrogable model to decipher pathways involved in EC transition into hematopoietic cells. This will provide cues to devise strategies to convert autologous ECs into large numbers of HSCs for genetic modification and subsequent treatment of both genetic and acquired hematological disorders.

**Background:** Recent reports show that mesenchymal stem cells (MSC) rescue injured target cell and promote target cell recovery from a variety of stress including oxidative tress. ultraviolet radiation, ischemia/reperfusion [SI/R] and cytosine arabinoside (CytA) however, it is still unclear if bone marrow mesenchymal stem cells (BM/MSC) can also form TNT to communicate and rescue injured bone marrow -derived endothelial cells (BMdEC) and promote it recovery from chemotherapy stress . In our study, we set out to test the hypothesis that BM/MSC can rescue suffering endothelial cells by transferring mitochondria to endothelial cells through nanotubes.

**Aims:** To investigate the novel intercellular communication TNT between BM/MSC and BMdECs or HUVEC, illuminating its constituent and investigating the significance of transport of mitochondria through TNT between BM/MSC and BMdECs or HUVEC suffering from chemotherapy stress of cytotoxic arabinoside.

**Methods:** We established two direct co-culture system for human primary bone marrow mesenchymal stem cells (BM/MSCs) and bone marrow-derived endothelial cells (BMdECs) or Human umbilical cord vein endothelial cells (HUVECs) respectively.

**Results:** Firstly, We observed the TNTs formed between BM/MSCs and endothelial cells including the TNT structure between BM/MSCs and HUVECs or BMdECs are composed with F-actin, microtubule in addition to membrane. Live cell imaging showed the two xeno-genetic cells form TNTs by retaining a thin thread of membrane upon dislodge-
ment. Besides, we observed that TNTs were more likely to occur between healthy bone marrow resident macrophage stem cell and endothelial cell contacts (Ara-C) treatment. Single-cell analysis showed that stressed endothelial cells and cell lines in the early stages of apoptosis caused by cytamine (Ara-C) treatment form TNT to interact with untreated BMMSCs and then mesenchymal stem cells transport mitochondria to injured endothelial cell or cell line via TNTs. This was inferred by incubating with an F-actin-depolymerizing drug and tubline -depolymerizing drug, indicated that these TNTs transferring mitochondria have a distinct cytoketal composition which formed with F-actin and microtubule. Our results also suggest that the delivery of functional mitochondria from uninjured BMMSCs to HSC of TNTs can mediate the recovery of injured HUEVCs from the apoptosis, contribute to proliferation and remodel the formation of capillary-like structures in Matrigel®-coated plates of HUEVCs suffer from chemotherapy stress of Ara-C.

Summary/Conclusions: BMSCS can transfer mitochondria via TNTs formed between BMMSCs and HUEVC, rescued endothelial cells suffering stress, which can alleviate apoptosis of stressed endothelial cells, relieve its proliferation inhibition and alter its formation of capillary-like structures. Our study offers the clues to help know about cell-cell communication of niche components in the HSC niche in bone marrow.

S139
SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/ TGF-β SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC STEM CELLS IN C57BL/6J MICE BONE MARROW
F. Hermetet1,2,*, J.-P. Pais de Barros2,3, L. Delva1,2, R. Quéré1,2
1Signalining and Physiology in Hematological Research, UMR1231 Inserm / Université Bourgogne Franche-Comté / AgroSup, Dijon, France

Background: Some studies show that a high-fat diet (HFD) induces major perturbations in murine hematopoietic stem cells (HSC) and hematopoietic system homeostasis. However, it is currently difficult to say whether these alterations are related to direct effects such as changes in lipid metabolism in HSC or indirect “side effects” on HSC, such as phathophysiology related to obesity or indirect “side effects” on HSC such as pathophysiology related to obesity or indirect “side effects” on HSC such as pathophysiology related to obesity or high-fat-induced obesity significantly alters hematopoiesis in bone marrow (BM), with a decreased proliferation of HSC, a general suppression of progenitors, an enhancement of lymphopoiesis, and an activation of myeloid cell production from BM progenitors. Inflammation also affects HSC homeostasis, as Interferon alpha is well-known to activate dormant HSC in vivo.

Aims: Our strategy is to characterize the impact of a short-term HFD on HSC and hematopoiesis in non-obese C57BL/6J mice.

Methods: In a prospective study, C57BL/6J mice were fed a control diet (4% fat) or a high-fat diet (42% fat), over a short period of 4 weeks, to investigate the direct impact of such a diet on hematopoiesis.

Results: While fat intake led to an increase in plasma cholesterol levels, mice did not develop obesity, and no inflammatory monocytes and no modulation of pro-angiogenic-inflammatory cytokine levels were detected in blood and BM, respectively. While the high-fat diet impact was observed after an extended diet over several months or a diet in blood and BM. However, we noted an increase in the number of progenitors and a loss of more than 50% of the most primitive HSC (SLAM). We validated this loss via transplantation of BM isolated from HFD-fed mice (Ly1) in competition with control BM (Ly2), in lethally irradiated recipient mice which only recognize 2% of the recipient hematopoiesis from HFD HSC. To further investigate lipid metabolism in HSC, we quantified the major lipid constituents of HSC plasma membrane such as lipid rafts (LR), which are important for signal transduction in immune cells and BMSCs. We observed that the level of cholesterol was very rich in fat (>60 kJ% of fat). For example, HFD-induced obesity significantly alters hematopoiesis in bone marrow (BM), with a decreased proliferation of HSC, a general suppression of progenitors, an enhancement of lymphopoiesis, and an activation of myeloid cell production from BM progenitors. Inflammation also affects HSC homeostasis, as Interferon alpha is well-known to activate dormant HSC in vivo.

Conclusions: The LMPP gave rise to both GM and B cell engraftment, the GMP myeloid progenitors. For example, the expression of 72 genes in 919 single LMPP, MLP and GMP shows that the 3 populations form a transcriptional continuum. In conclusion, HFD markedly and rapidly affects primordial and cell lines in the early stages of apoptosis caused by cytamine (Ara-C) treatment. Single-cell analysis showed that stressed endothelial cells and cell lines in the early stages of apoptosis caused by cytamine (Ara-C) treatment form TNT to interact with untreated BMMSCs and then mesenchymal stem cells transport mitochondria to injured endothelial cell or cell line via TNTs. This was inferred by incubating with an F-actin-depolymerizing drug and tubline -depolymerizing drug, indicated that these TNTs transferring mitochondria have a distinct cytoketal composition which formed with F-actin and microtubule. Our results also suggest that the delivery of functional mitochondria from uninjured BMMSCs to HSC of TNTs can mediate the recovery of injured HUEVCs from the apoptosis, contribute to proliferation and remodel the formation of capillary-like structures in Matrigel®-coated plates of HUEVCs suffer from chemotherapy stress of Ara-C.

S140
A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR RECONSTITUTION BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS
D. Karamitros1,2,*, B. Stolova1,2, Z. Aboukhalil1, A. Reinisch3, F. Hamey4, M. Samitsch1, L. Quek1,2,5, G. Otto1, E. Repapi1, J. Donoodee1,2, B. Usukhbayar1,2, J. Calvo3, S. Taylor1, N. Garo3, E. Six7, F. Pflumio6, C. Porcher1, R. Mejati1, B. Goggens1, P. Vyas1,2,5

1MRC, MHU, WIMM/NDCLS University of Oxford, 2Oxford Biomedical Research Centre, Oxford, United Kingdom, 3Division of Hematology, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, United States, 4Department of Haematology , Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, 5Department of Haematology, OUH NHS Trust, Oxford, United Kingdom, 6UMR967, INSERM/CEA/Universite Paris 7/Universite Paris 11, 7UMR1163, Paris Descartes–Sorbonne Paris Cite University, Imagine Institute , , Paris, France

Background: Human hematopoiesis produces 10 billion new, terminally mature, blood cells daily; a production that is also rapidly responsive to external change. Disregulation of this complex process can lead to hematopoietic and immune deficiencies and blood cancers. In humans the hematopoietic progenitor hierarchy producing lymphoid and granulocytic-monocytic (myeloid) lineages is unclear. Multiple progenitor populations give rise to lymphoid and myeloid cells but they remain incompletely characterized at the immunophenotypic, transcriptional and functional level.

Aims: Here, we aimed to understand the clonal functional output and transcriptional programs of current primary human lympho-myeloid containing progenitor populations - the lymphoid-primed multi-potential progenitor (LMP1), the lymphoid progenitor (MLP2) and granulocyte-macrophage progenitor (GMP).

Methods: We devised a FACS-staining and sorting strategy to prospectively purified each hematopoietic stem and progenitor cell (HSPC) population. We compared functional and transcriptional programs between LMP, MLP and GMP in vitro by quantitative CFU assays, single cell liquid cultures or limit dilution analysis and in vivo by transplantation into humanized ows. We performed RNA sequencing and single cell RT-PCR analysis to understand the relationship between functional and transcriptional heterogeneity.

Results: Our study comprehensively characterized the LMP, MLP and GMP single cell population in myeloid populations. Both LMP and MLP are very rare within the mononuclear fraction (1 in 10^4 to 1 in 10^5). We cultured 3806 single LMP, GMP and MLP cells (isolated from 21 cord blood units and equivalent to ~10^11 mononuclear cells) under three different culture conditions. We observed functional and transcriptional heterogeneity in the three lympho-myeloid progenitor populations - the lymphoid-primed multi-potential progenitor (LMP1), the lymphoid progenitor (MLP2) and granulocyte-macrophage progenitor (GMP).

Conclusions: We devised a FACS-staining and sorting strategy to prospectively purified each hematopoietic stem and progenitor cell (HSPC) population. We compared functional and transcriptional programs between LMP, MLP and GMP in vitro by quantitative CFU assays, single cell liquid cultures or limit dilution analysis and in vivo by transplantation into humanized ows. We performed RNA sequencing and single cell RT-PCR analysis to understand the relationship between functional and transcriptional heterogeneity.
Gene therapy, immunotherapy and vaccination

S141

WILMS’ TUMOR 1 RNA-ELECTROPORATED DENDRITIC CELL VACCINATION AS POST-REMISSION TREATMENT TO PREVENT OR DELAY RELAPSE IN ACUTE MYELOID LEUKAEMIA: FINAL RESULTS OF A PHASE II STUDY IN 30 PATIENTS

Z. Berrernani1,†, S. Anguille1, A. Van de Velde1, V. Van Tendeloo1, N. Coels1, G. Nijss1, B. Stein1, E. Lion1, A. Van Driessche1, I. Vandenbosch1, A. Verlinden1, A. Gadisseur1, W. Schroyens1, K. Vermeulen2, M.-B. Maes2, K. Deitersen2, R. Malfait2, E. Smits3
1Hematology, 2Laboratory Hematology, 3Center for Cell Therapy and Regenerative Medicine, ANTWERP UNIVERSITY HOSPITAL, Edegem, Belgium

Background: Relapse is a major problem in acute myeloid leukaemia (AML) and adversely impacts survival.

Aims: The aim of this phase II study was to determine the clinical efficacy of dendritic cell (DC) vaccine therapy in AML and, more specifically, whether this form of immunotherapy can be applied in the post-remission adjuvant setting to decrease the risk of relapse following chemotherapy and to improve survival.

Methods: We vaccinated 30 AML patients in remission following polychemotherapy, but at very high risk of relapse with autologous DCs loaded with the WTI gene. WTI peptide complex (WT1) antigen by means of mRNA electroporation, a technique that allows for human leukocyte antigen haplotype-independent, multi-epitope antigen presentation to T-cells. The vaccines were administered intra-dermally. WTI mRNA levels in blood and marrow were followed as a measure of minimal residual disease. Circulating WTI-specific CD8+T-cells obtained before and after the 4th dose were stained with WT1 peptide-HLA-A*0201 tetramers. To assess cell-mediated immunity in vivo, delayed type hypersensitivity (DTH) skin testing was performed 2 weeks after the 4th DC vaccination by intradermal injection; DTH-infiltrating lymphocytes collected from skin biopsies were expanded for 2-3 weeks in medium with interleukin-2, harvested and tested for WTI-specific reactivity.

Results: There was a demonstrable anti-leukemic response in 13/30 patients (overall response rate 43%). Nine patients achieved molecular remission as demonstrated by normalization of WTI transcript levels, 5 of which are sustained after a median follow-up of 109.4 months, including 1 patient who went from CR2 to CR after receiving DC vaccination by intradermal injection. 2 of the remaining 4 responding patients, the clinical response was characterized by stable disease as demonstrated by elevated but stable WT1 transcript levels in blood for 3-12 months and stable blood values without blasts. Five-year overall survival was 40%, as compared to 24.7% in the SEER data of the National Cancer Institute; it was significantly higher in responders than in non-responders (53.8% vs 25.0%; P=0.01). In patients receiving DCs in first complete remission (CR1), there was a vaccine-induced relapse reduction rate of 25% and the 5-year relapse-free survival was significantly higher in responders than in non-responders (50% vs 7.7%; P=0.0001). In patients ≤55 and >65 years who received DCs in CR1, 5-year overall survival was 69.2% and 30.8% respectively. Of the 30 patients, 11 are alive in CR, including 5 who relapsed after DC vaccination; 2 proceeded to allogeneic stem cell transplantation, while the other 3 patients were brought back into CR by chemotherapy alone, 2 of them surviving more than 7 and 4 years respectively after reaching CR. Long-term clinical response was correlated with increased circulating frequencies of poly-epitope WTI-specific tetramer+CD8+T-cells. Long-term overall survival was correlated with interferon-γ and tumor necrosis factor-alpha WT1-specific responses in DTH-infiltrating lymphocytes.

Summary/Conclusions: Vaccination of AML patients with WTI mRNA-electroporated DCs can be an effective and non-toxic strategy to prevent or delay leukemia relapse under standard chemotherapy, translating into improved overall survival rates, which are correlated with the induction of WT1-specific CD8+ T-cell responses.

S142

FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS

1Hematology, 2Laboratory Hematology, 3Center for Cell Therapy and Regenerative Medicine, ANTWERP UNIVERSITY HOSPITAL, Edegem, Belgium

Aims: The primary objective is to determine the maximally tolerated dose of bb2121 in subjects with MM whose tumors express BCMA to redirect T cells to MM. bb2121 consists of autologous T cells transduced with a lentiviral vector encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory motif and a CD3-zeta T cell activation domain. We will report updated safety and efficacy results following promising initial results (Berdeja et al. ENA 2016).

Methods: CRB-401 (NCT02659892) is a multi-center phase 1 dose escalation trial of bb2121 in patients with relapsed and/or refractory MM who have received ≥3 prior regimens, including a proteasome inhibitor and an immunomodulatory agent. A two-stage, 3+3 design was performed and the recombinant protein expression of sNTX pts.

Background: To test the safety and efficacy of the CAR T cell modality in relapsed/refractory multiple myeloma (MM), we have designed a second-generation CAR construct targeting B cell maturation antigen (BCMA) to redirect T cells to MM. bb2121 consists of autologous T cells transduced with a lentiviral vector encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory motif and a CD3-zeta T cell activation domain. We will report updated safety and efficacy results following promising initial results (Berdeja et al. ENA 2016).

Aims: The primary objective is to determine the maximally tolerated dose of bb2121 in subjects with MM whose tumors express BCMA, to determine and test a recommended phase 2 dose for future studies. The secondary objective is to provide preliminary efficacy data on the anti-tumor effects of treatment with bb2121 in subjects with MM whose tumors express BCMA.

Methods: CRB-401 (NCT02659892) is a multi-center phase 1 dose escalation trial of bb2121 in patients with relapsed and/or refractory MM who have received ≥3 prior regimens, including a proteasome inhibitor and an immunomodulatory agent. A two-stage, 3+3 design was performed and the recombinant protein expression of sNTX pts.

Background: To test the safety and efficacy of the CAR T cell modality in relapsed/refractory multiple myeloma (MM), we have designed a second-generation CAR construct targeting B cell maturation antigen (BCMA) to redirect T cells to MM. bb2121 consists of autologous T cells transduced with a lentiviral vector encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory motif and a CD3-zeta T cell activation domain. We will report updated safety and efficacy results following promising initial results (Berdeja et al. ENA 2016).

Aims: The primary objective is to determine the maximally tolerated dose of bb2121 in subjects with MM whose tumors express BCMA, to determine and test a recommended phase 2 dose for future studies. The secondary objective is to provide preliminary efficacy data on the anti-tumor effects of treatment with bb2121 in subjects with MM whose tumors express BCMA.
Background: Fanconi anemia (FA), is a monogenic inherited syndrome associated with bone marrow failure (BMF), that has been considered a candidate disorder for hematopoietic stem cell (HSC) gene therapy. Up to date, three clinical trials have been performed, all of which failed to demonstrate engraftment of corrected HSCs.

Aims: To demonstrate engraftment of gene-corrected HSCs in non-conditioned Fanconi anemia patients.

Methods: To improve previous results, we proposed a new approach based on two clinical trials. First, to increase the HSC collection, we designed a trial employing a plerixafor plus G-CSF mobilization regimen. Second, to improve the quality of corrected HSCs, cells were pre-stimulated for only 8-10 hours and transduced with a new lentiviral vector (PGK-FANCA.Wpre) for 12-14h, a substantially shorter duration than in previous trials. To avoid chemotherapy-induced damage, a conditioning regimen was not included in the trial, based on the expected proliﬁerative advantage of autologous corrected HSCs.

Results: Eight patients have been included so far in the HSC collection trial. No severe adverse events (SAE) related to the procedure have been reported. The most relevant AE has been the transfusion of packed red blood cells and platelets. Six FA patients aged 3-6 years underwent collections after mobilization of significant numbers of CD34+cells (10 to 70 CD34+cells/µL) to peripheral blood. Two patients (15 and 16 years) failed to mobilize. On average, 5 million CD34+cells/Kg were collected, with 45% recovery after immunoselection. In the ﬁrst patient included in the gene therapy trial, fresh immunoselected CD34+cells were transduced with the therapeutic vector. Subsequently, two patients were infused with transduced CD34+cells that remained cryopreserved for almost 2 years. Infused cell products contained 0.5 to 1.4 million CD34+cells/kg, and vector copy numbers per cell (VCN/cell) that ranged between 0.17 to 0.45. To-date, there has been no SAE related to the procedure. Engraftment of gene corrected cells has been observed in the three patients. Notably, increased gene marking levels and signiﬁcant phenotypic correction in the hematopoietic progenitor cells, deduced from the acquired resistance of the colony forming cells to mitomycin C (15% of BM CFcs survived to 10 nM MMC), have been demonstrated after 9 months of follow up in one of the patients.

Summary/Conclusions: Our preliminary results show that 1) HSCs collection is both safe and efﬁcient in very young FA patients after mobilization with G-CSF and plerixafor, and 2) Engraftment and proliferation advantage of gene-corrected HSPCs has been demonstrated in FA patients even in the absence of conditioning regimens. The long-term follow up of patients included in these clinical trials will demonstrate the feasibility of restoring the hematopoietic function of FA patients by means of a gene therapy approach in the absence of conditioning.

S145

TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR T CELLS CONFRONTS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA

H. Jatan1, H. Garcia-Cadenas2, T. Nerreter1, J. Sierra2, W. Herr3, S. Thomas3, H. Einsele1, M. Hudecek1

1Internal Medicine II, University Hospital Würzburg, Würzburg, Germany, 2Servicio de Hematología, Hospital de La Santa Creu i Sant Pau, Barcelona, Spain, 3Klinik und Poliklinik für Innere Medizin III, Universitätssklinikum Regensburg, Regensburg, Germany

Background: Adoptive immunotherapy with chimeric antigen receptor (CAR)-modified T cells has therapeutic potential in hematologic malignancies. We are pursuing FLT3-like tyrosine kinase 3 (FLT3) as a novel CAR target in acute myeloid leukemia (AML). FLT3 is a homodimeric transmembrane protein with uniform expression on AML, irrespective of cytogenetic and histomorphologic subtype. FLT3 provides survival signals to AML blasts and is a key driver of leukemia-genesis in AML cases with internal tandem duplication (FLT3-ITD). These attributes suggest FLT3 may be an ‘Achilles heel’, making AML blasts susceptible to CAR T-cell mediated recognition and elimination.

Aims: We therefore explored the anti-leukemia efficacy of FLT3-CAR modiﬁed T cells against FLT3-ITD+ and FLT3 wild type AML in pre-clinical models in vitro and in vivo.

Methods: A FLT3-CAR comprising a single-chain variable fragment (4G8), fused to an IgG-Fc spacer, and signaling module with CD3 zeta and CD28 was encoded in a lentiviral vector (epHIV7) for gene-transfer into CD8+ and CD4+ T cells of healthy donors (n=4) and AML patients. CAR T-cell mediated cytolytic activity was evaluated in FACS/luminescence-based assays, cytokine production analyzed by ELISA and proliferation assessed by CFSE dye dilution. Immunodeﬁcient NSG mice were engrafted with AML cell line (Molm-13) or primary AML blasts and treated with 5x10^6 CAR-modiﬁed or control T cells (CD8:CD4 ratio=1:1).

Results: We conﬁrmed speciﬁc recognition and high-level cytolytic activity of CD8+ FLT3-CAR T cells against a panel of AML cell lines including THP-1 (FLT3 wild type), and Molm-13 (FLT3-ITD heterozygous). Both CD8+ and CD4+ FLT3-CAR T cells produced IFN-γ and IL-2, and underwent proliferation after antigen stimulation.FLT3-CAR T cells that we prepared from AML patients exerted speciﬁc anti-leukemia reactivity against autologous primary AML blasts, with near-complete cytolysis within 24 hours of co-culture. Further, FLT3-CAR T cells conferred a potent anti-leukemia effect in vivo models of systemic leukemia, both with AML cell lines (Molm-13) and primary AML blasts. A single dose of FLT3-CAR T cells conferred complete eradication of leukemia from peripheral blood, bone marrow and spleen, as conﬁrmed by bioluminescence imaging and ﬂow cytometry. FLT3 is not expressed in any normal solid tissues and mature hematopoietic cells, but shows limited expression in hematopoietic progenitors and hematopoietic stem cells (HSCs). Preliminary data show that FLT3-CAR T cells recognize FLT3+/high normal HSCs and interfere with normal hematopoiesis, but preserve a proportion of HSCs capable of reconstituting hematopoietic lineages. Studies to assess recognition of normal HSCs in vivo are ongoing.

Summary/Conclusions: Collectively, our data demonstrate that T cells expressing a FLT3-specific CAR mediate potent reactivity against FLT3 wild type and FLT3-ITD+AML in vitro and in vivo, and establish FLT3 as a novel CAR target in AML. FLT3-ITD positivity identiﬁes a high-risk AML subgroup that may particularly beneﬁt from adoptive therapy with FLT3-CAR T cells, e.g. in order to achieve ‘minimal residual disease’ (MRD) negativity prior to allogeneic HSC transplantation. Our data further suggest that in contrast to CD33 and CD123, which are pursued as alternative CAR targets in AML, targeting of FLT3 may preserve a fraction of normal HSC and enable the implementation of CAR therapy outside the transplant setting.
S146

BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS

M. Algen1,2, S. Naik2, N. Kapoor3, K. Mahadeo4, V. Aquino5, A. Woolfrey6, A. Bertane1, P. Merli1, A. Woolfrey7, F. Galaverrina1, K. Mahadeo8, S. Baumeister9, E. Nemecek9, W. Qasim10, D. Pagliara1, G. Li Pir1, L. Krishnamurthi11, D. Jacobsohn12, M. Slatter13, J. Weinberg14, A. Moseley14, F. Locatelli1
1Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Texas Children’s Hospital, Houston, 3Children’s Hospital of Los Angeles, Los Angeles, 4Fred Hutchinson Cancer Research Center, Seattle, 5Children’s Hospital at Montefiore, Bronx, 6Dana Farber Cancer Institute, Boston, 7Oregon Health & Science University, Portland, United States, 8Great Ormond Street Hospital, London, United Kingdom, 9Children’s Hospital of Atlanta, Atlanta, 10Children’s National Health System, Washington, DC, United States, 11Great North Children’s Hospital, Newcastle, United Kingdom, 12Bellicum Pharmaceuticals Inc., Houston, United States

Background: Allogeneic hematopoietic stem cell transplant (HSCT) offers curative therapy for children who lack an available HLA-identical donor with hematopoietic disorders such as Primary Immune Disorders (PIDs), hemoglobinopathies, erythroid disorders and acute leukemias. Γ-Β T cell depletion mitigates the risk of GVHD after haplo-HSCT, but is associated with extended immunodeficiency, leading to complications due to infections . We have performed αβ TCR-depleted haplo-HSCT with post-transplant infusion of BPX-501 gene modified T cells to allow for more rapid immune reconstitution. Upon occurrence of GVHD, administration of rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis of the transduced BPX-501 cells and mitigates the GVHD.

Aims: This study was performed to determine the impact of BPX-501 T cell infusion on outcomes (treatment related mortality (TRM), disease recurrence, GVHD incidence and immune reconstitution) after HSCT.

Methods: We report on a large multicenter, prospective Phase I-II study enrolling children receiving αβ T cell depleted Haplo-HSCT. Patients were infused with BPX-501 T cells 2 weeks post-transplant. 104 patients have >100 day follow-up, 81 patients have follow up >180 days and 51 with >1 year follow-up. All patients received myeloablative therapy and low dose ATG prior to transplant. No pharmacologic GvHD prophylaxis was given (Table 1).

Results: Cumulative incidence of TRM remains very low at 100 days (0%), 180 days (1.6%) and 1 year (2.8%). Of the 81 patients with >180 day follow-up, 20 patients had acute GvHD 1-3 (24.7%) (Figure 1A); 10 with Grade 1, 8 with Grade 2, 2 with Grade 3 and 1 Grade 4 skin. Mild GvHD was seen in 2 patients, moderate GvHD in 2 patients and one case of severe cGvHD in a malignant patient, attributed to the allograft, not BPX-501. Rimiducid was used in 4 patients with Grade 2 GvHD with rapid resolution of symptoms, as it did in the severe cGvHD patient. In both malignant and non-malignant patients, CD3, CD4, CD8 (Figure 2B) and B cells (Figure 3C) immune reconstitution was brisk. CD3+/CD19+ T-cells were detectable at one year via flow cytometry analysis of peripheral blood. In Wiskott-Aldrich patients, platelet recovery remains in the normal range at 180 days with mean platelet counts of 246.3±103/μL. At 180 days and 1 year, the patients with hemoglobinopathies remain transfusion-free with a normal mean HbG value of 11.4 g/dL.

Summary/Conclusions: These data suggest that infusion of BPX-501 modified T cells may facilitate T cell depleted Haplo-HSCT in children who would benefit from HSCT for either malignant or non-malignant conditions. The availability of a suicide gene mechanism in donor T cells infused after T depleted Haplo-HSCT, results in low rates of infection and rapidly reversible GvHD when the dimmer is infused to activate the suicide switch. Rapid cellular and humoral immune reconstitution makes BPX-501 after T depletion a safe and viable option for children who do not have a matched donor transplant and in whom transplantation has been deemed curative.
for a selected guide RNA confirmed no detectable genomic cleavage at over 5000x predicted off-target sites with a detection sensitivity of 0.2%, supporting its safety for clinical use. Finally, we have demonstrated editing rates of >85% at clinical scale in a GMP-capable manufacturing facility to enable clinical development for SCD and β-Thal. Required safety toxicology studies are ongoing.

**Summary/Conclusions:** Using CRISPR/Cas9 we successfully created gene deletions in leukemic cells from both patient samples and cell lines. We have also dissected the genotype-phenotype relationship for specific genetic modifications, identifying the editing strategies which are most promising for re-expressing HBF. We have optimized the conditions for modifying HSPCs, including at clinical scale in a GMP-compliant setting, and demonstrated potential off-target editing. These experiments support the further development of specific CRISPR/Cas9 editing strategies of HSPCs to treat SCD and β-Thal patients.

---

**S148**

**EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL**

A. García-Ramírez1, F. Auer2, G. Rodríguez Hernández1, S. Bhatia1, I. García-Ramírez1, D. Schäfer2, C. Vicente-Dueñas1, A. Borkhardt1, I. Sánchez-García2, J. Hauer2.

1Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cancer, CSIC/ Universidad de Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. 2Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany.

**Background:** B-cell precursor acute lymphoblastic leukemia (BCP-ALL) of childhood remains a major cause of death in high-income countries. It has a yet unexplained peak incidence between 2-6 years of age and a potential trigger was theorized a century ago with several possibilities of exposure to infection in infancy. Recently in vitro and in vivo evidence strengthened the causal role of exposure to infection in BCP-ALL (1, 2). However, it remains unclear which BCP-ALL subtype can be triggered by exposure to infection and how the pre-leukemic clone evolves to BCP-ALL.

**Aims:** Aiming to understand the role of infection exposure in the etiology of childhood BCP-ALL.

**Methods:** We have developed and characterized two independent GEMMs, in addition to the Pax5+/−-infected model (1), which were exposed to a common infection environment. These represent childhood BCP-ABL1p190 BCP-ALL and the most common subtype ETV6-RUNX1 BCP-ALL. Both model systems ensure Sca1-directed expression of BCR-ABL1p190 or ETV6-RUNX1 in HSCs in mice and B220+/− and CD19+B220+IgM-cell surface phenotype and manifested with blast cells in the peripheral blood (PB) and clonal immature BCR rearrangement. Whole exome (WES) and whole genome sequencing (WGS) was performed of murine BCP-ALL on a HiSeq 2500 (Illumina) platform.

**Results:** Pax5+/− and Sca1-ETV6-RUNX1 mice develop BCP-ALL only after exposure to infection whereas both BCP-ABL1p190 and ETV6-RUNX1 BCP-ALL independent of exposure to common infection. The molecular mechanism leading to BCP-ALL identified in the infection dependent GEMMs is determined by the genetic predisposition (Pax5+/− or ETV6-RUNX1). Pax5+/− mice acquire constitutive activating Jak3 mutations (6/9) in a susceptible B-cell precursor population (intermediate and immature B cells) (1). On the other hand Sca1-ETV6-RUNX1 mice develop BCP-ALL at a low penetrance (10.75%; 10 out of 93) with a CD19+B220+IgM-cell surface phenotype and manifested with blast cells in the peripheral blood (PB) and clonal immature BCR rearrangement. High expression of Recombination Activating Gene 1 (Rag1) and loss of function mutations in Btk were identified in murine BCP-ALL and are well known in the context of human ETV6-RUNX1 leukemia. Additionally we identified a high proportion of mutations in genes implicated in histone modification, i.e. Kdm5c (no. 40) causing a premature stop. CRISPR-Cas9 knock down studies of KDM5C in a precursor B-cell line revealed facilitated Rag1/2 binding to the pro-hoechst complex (H3K4me3) as a potential molecular mechanism (2). Rag1 off target activity in pre-leukemic ETV6-RUNX1 HSC/PC after exposure to infection. In contrast to Pax5+/− and Sca1-ETV6-RUNX1 mice, Sca1-BCR-ABL1p190 mice develop BCP-ALL independent of exposure to common pathogens by reprogramming of a HSC/PC and subsequent loss of Pax5. Summary/Conclusions: In summary, exposure to common pathogens can trigger childhood BCP-ALL based on Pax5 loss of function or in the common ETV6-RUNX1 rearrangement. However the underlying molecular mechanism (Jak-Stat signaling in Pax5+/− mice and histone modification in ETV6-RUNX1 mice) triggered by exposure to common infection is determined by the genetic predisposition. Both BCP-ABL1p190 and BCP-ALL emerge on the basis of a potent oncogene such as BCR-ABL1p190 can develop independent of exposure to infection. These findings are important for encouraging the prospect of novel interventions that might help to prevent or treat a significant proportion of childhood BCP-ALLs.

**References**

Background: The German Hodgkin Study Group (GHSG) applies the intensive eBEACOPP regimen (dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) to all newly diagnosed advanced-stage HL patients regardless of their individual risk-profile. However, some patients might not be in need of such an intensive treatment to achieve cure. Unfortunately, baseline risk factors as defined in the international prognostic score cannot identify these patients reliably. Recent clinical research suggests that early metabolic response assessment after 2 cycles of therapy using FDG-PET (PET-2) can better predict the individual outcome. In particular, a rapid response as determined by PET-2 negativity might allow reducing the overall treatment intensity.

Aims: To assess the feasibility of decreasing the number of eBEACOPP cycles in patients with negative PET-2 without loss of efficacy as determined by progression-free survival (PFS).

Methods: Between 05/2008 and 07/2014, we recruited patients with newly diagnosed, advanced-stage HL aged 18–60 years. All patients gave written consent before study entry. PET-2 was centrally assessed with FDG uptake not higher than the mediastinal blood pool defined as negative. Patients with negative PET-2 were randomly assigned to receive 6 or 2 additional cycles (i.e. 8 or 4 cycles of eBEACOPP in total, respectively). PET-positive residues after chemotherapy were irradiated. Based on the results of our previous HD15 trial, the protocol was amended in June 2011 and the standard therapy was reduced from 8 to 6 cycles of eBEACOPP in total. The trial was designed to exclude inferiority of 6% or more of the experimental treatment (4 cycles of eBEACOPP) compared with the pooled standard treatment (8 or 6x cycles of eBEACOPP) at 5 years.

Results: We enrolled 2,101 patients. 1,005 patients with negative PET-2 were randomly assigned to either 8/6 cycles of eBEACOPP (n=504) or 4 cycles of eBEACOPP (n=501). With a median follow-up of 55 months, estimated 5-year PFS in the per-protocol set was 90.8% (87.9–93.7) with 8/6 cycles of eBEACOPP and 92.2% (89.4–95.0) with 4 cycles eBEACOPP (difference +1.4%, 95% CI -2.7–5.4, excluding the non-inferiority margin of -6%). In the standard arm, 95% of patients had at least one acute hematological toxicity of CTCAE grade 3-4 compared with 90% in the experimental arm, including severe infections in 75 (15%) and 38 (8%), respectively. Acute severe organ toxicities were documented for 91 (18%) and 38 (8%), respectively. 25 patients (5%) in the standard group (8/6 cycles of eBEACOPP and 9 (2%) in the experimental group (4 cycles of eBEACOPP) died; most frequent cause of death was second malignancy (11 and 1 patient, respectively). No patient in the experimental group died from treatment-related toxicities. Estimated 5-year overall survival (OS) in the per-protocol set was 95.4% (93.4–97.4) with standard eBEACOPP, and 97.7% (96.2–99.3) with 4 cycles of eBEACOPP (log-rank p=0.004).

Summary/Conclusions: Metabolic response assessment using FDG-PET after 2 cycles of eBEACOPP allows the reduction from therapy with 8/6 to only 4 cycles without loss of efficacy as determined by PFS in advanced-stage HL patients. Furthermore, the abbreviated treatment with 4 cycles of eBEACOPP is associated with improved tolerability and consequently leads to a significant OS benefit over standard therapy. PET-guided reduced therapy with eBEACOPP combines outstanding efficacy with high safety. We therefore recommend this treatment strategy for advanced-stage HL patients.
Acute lymphoblastic leukemia - Biology 1

P151

TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

J. De Bie1,*, S. Demeyer1, E. Geerdens1, A. Uyttebroeck2, N. Boeckx3, J. Cools1
1CME, KU Leuven, 2Pediatric Oncology, 3Laboratory Medicine, UZ Leuven, Leuven, Belgium

Background: Acute lymphoblastic leukemia (ALL) is a common childhood malignancy caused by clonal proliferation of immature B or T lymphoid cells. ALL patients are primarily young children who respond well to chemotherapy, with survival rates above 85%. However, if relapse develops, survival rates drop to 15-50%. Recent studies have shown that at diagnosis, different ALL subtypes and subclones are present that are likely the result of clonal branched evolution. Understanding this clonal evolution and the order at which mutations are acquired can provide improved insights into the origins of leukemia relapse.

Aims: To use single-cell sequencing to investigate (i) the heterogeneity of leukemic T-ALL cells present at diagnosis and (ii) unravel the order in which mutations were acquired during leukemia evolution.

Methods: Bone marrow samples taken at diagnosis and remission from 4 T-ALL patients underwent whole genome and RNA sequencing. Somatic mutations, indels and chromosomal translocations were confirmed using Sanger sequencing. Primers were designed to specifically target these genetic alterations, and included 46 primers against heterozygous SNPs for quality control assessment. A total of 1517 single cells (average of 379 cells per patient), were sorted using flow cytometry or a microfluidic device and analyzed with targeted sequencing. Cells were discarded from further analysis if locus and allelic drop-out exceeded 33.3%. Jaccard hierarchical clustering was applied to identify subclones and a new graph-based algorithm was developed to determine the order of mutation acquisition. Single CD34+CD38− hematopoietic stem/progenitor cells (HSPCs) from the same samples were also isolated to test for the presence of mutations in early progenitors.

Results: We detected between 2 and 4 separate clones in each T-ALL patient sample. Every patient harboured one dominant clone comprising 46 to 98% of all single cells that was highly mutated, accompanied by a number of smaller subclones carrying fewer mutations. No mutually exclusive mutations, fusion genes or deletions were observed between the clones arguing against independent leukemic clonal initiation events. Instead, a more stepwise clonal hierarchy was observed, indicating that the accumulation of mutations can occur in progenitor cells or in committed T-cells. During remission, we could no longer detect HSPCs with all leukemic mutations.

Summary/Conclusions: We demonstrate that T-ALL patients have limited heterogeneity at diagnosis and that targeted single cell sequencing can be used to determine the cell of origin and the order of mutation acquisition. These data also illustrate that HSPCs at remission carry a few early, pre-leukemic mutations, while highly mutated HSPCs are eradicated during treatment, which is in line with long term remission in T-ALL.

P152

BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL

K. Kampen1,*, T. Girardi1, J. Verbeeck1, J. Op de Beeck1, A. Uyttebroeck2, P. Vermeersch3, A. Moorman4, A. Moorman5, C. Harrison5, J. Meijerink6, D. Lemort7, E. Cools1, K. De Keersmaecker1
1Oncology, KU Leuven, LKI Leuven Cancer Institute, 2Pediatric Oncology & Hematology, 3Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium, 4Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, Ashmore and Cartier Islands, 5Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 6Pediatric Oncology & Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, 7Center for Human Genetics, LKI - Leuven, Belgium

Background: The ribosomal protein L10 (RPL10) R98S mutation occurs in 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases. RPL10 R98S leads to a proliferation defect in lymphoid cells due to a peroxisomal contribution in pediatric T-ALL remains unclear. Treatment intensification and risk stratification has reduced the relapse rate of T-ALL to ~15% but further improvements will require strategies that focus on specific subtypes as RPL10 R98S; if the long-term sequelae of toxic therapy are to be avoided.

Aims: 1) Explore the oncogenic contribution of the RPL10 R98S mutation in pediatric T-ALL. 2) Define new therapeutic opportunities for RPL10 R98S defective T-ALL. 3) Identify a biomarker indicative of the RPL10 R98S mutation in T-ALL.

Methods: Quantitative label-free proteomics was used to screen for protein differences between RPL10 WT and R98S expressing Ba/F3 cells. Hits were confirmed by western blot in lineage negative (lin) bone marrow (BM) cells extracted from RPL10 WT and R98S knock-in mice and in RPL10 WT and R98S pediatric T-ALL samples. Serial re-plating was established by plating 2000 cells/ml in Methocult. Oxidative stress and mitochondrial activity was determined by Dihydroethidium and mitotracker. Viable cell counts were determined by Annexin V exclusion. Chromatin immunoprecipitation was performed using the Imprint ChIP kit followed by qRT-PCR. Human pediatric T-ALL samples were transplanted into NOD-SCID/IL2γ−/− (NSG) mice for in vitro and in vivo inhibitor studies.

Results: The RPL10 R98S mutation provided a cell survival advantage in Ba/F3 cells and in serial re-plating assays of lin-BM cells derived from RPL10 R98S knock-in mice. Proteomic profiling revealed metabolic reprogramming in RPL10 R98S cells through enhanced expression of peroxisomal enzymes Acox1, Acox3 and Paox. This expression facilitated peroxisomal β-oxidation of long chain fatty acids which are substrates for PPARγ and which were consequently upregulated together with CPT1A. Peroxisomal hyperactivation causes high intracellular H2O2 levels, increasing the observed elevated levels of reactive oxygen species (ROS) in RPL10 R98S cells that could not be scavenged by the increased catalase expression. High ROS levels and enhanced PPARγ binding drives the constitutive overexpression of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), responsible for the leukemia cell survival benefit of RPL10 R98S cells. Bcl-2 targeted therapy using venetoclax (ABT-199) reduced the expansion of RPL10 R98S knock-in BM cells by 50%, while RPL10 WT BM cells were not inhibited by ABT-199. In vivo, DMSO or ABT-199 50mg/kg therapy was started after the engraftment of >2% human cells in the blood of mice xenografted with T-ALL samples and was maintained 1/wk till disease end stage. RPL10 R98S xenografted mice that received ABT-199 therapy presented a complete inhibition of human CD45+ leukemia progression in the blood, which was characterized by a 70-85% reduction in spleen weights, and 20-50% reduction of bone marrow engraftment. Spleen weights of ABT-199 treated RPL10 R98S xenografted mice were only slightly increased as compared to ungrafted weights of healthy NSG mice. In contrast, mice xenografted with RPL10 WT T-ALL samples showed poor in vivo responses to ABT-199 treatment and all animals showed progressive disease. Bcl-2 overexpression induced by peroxisomal hyperactivation was defined as new target in RPL10 R98S defective T-ALL. Additionally, due to peroxisomal hyperactivation, a peroxisomal oxidase involved in purine degradation may have contributed to the metabolic output of purine degradation, uric acid, was elevated above reference levels in the blood of RPL10 R98S mutant pediatric T-ALL patients at diagnosis (Figure 1).

Figure 1.
Summary/Conclusions: Uric acid provides an indicative biomarker of RPL10 R98S mutations in pediatric T-ALL patients, which may be used for screening, providing early diagnosis and appropriate selection of patients in whom a Bcl-2 targeted therapeutic approach could be considered.

P153

TRANSLATE ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM

L. Fancello1,*, K. Kampen1, T. Girardi1, J. Op de Beeck1, J. Verbeek1, P. Vermeersch2, D. Cassiman3, F. Loayza Puch4, R. Agami5, K. de Keersmaecker1

1Department of Oncology, KU Leuven - University of Leuven, 2Department of Laboratory Medicine, 3Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium, 4Division of Biological Stress Response, The Netherlands Cancer Institute, Amsterdam, Netherlands

Background: We previously described a recurrent arginine-to-serine mutation on residue 98 (R98S) in ribosomal protein L10 (RPL10), with a frequency of 8.6% in pediatric T-ALL cases. The R98S mutated residue contacts the catalytic core (peptidyltransferase center, PTC) of the ribosome and causes ribosome biogenesis, Ptd RNA, and translational defects in PRL10-WT mouse lymphoid Ba/F3 cells. These observations suggest that the RPL10-R98S mutation may contribute to T-ALL pathogenesis by inducing translational changes.

Aims: The spectrum of translated proteins (translatome) of RPL10 R98S mutants was investigated in order to identify translational changes caused by the mutation and potentially driving oncogenesis.

Methods: We performed ribosome footprinting (RNA sequencing of ribosome bound RNA), polysomal RNA sequencing, total RNA sequencing and mass spectrometry based quantitative proteomics on engineered RPL10-R98S or RPL10-WT mouse lymphoid Ba/F3 cells.

Results: RPL10 R98S cells showed significant upregulation for 3% (n=178) of the measured proteins and a downregulation of 1% (n=68). Moreover, polysomal RNA sequencing and ribosome footprinting showed respectively 57 and 22 genes with significantly higher translational efficiency in RPL10 R98S, and 22 and 29 genes, with reduced translational efficiency. Among them, we also found genes involved in T cell differentiation and proliferation. In particular, Mapk6 presented reduced translational efficiency in the ribosome footprinting, potentially due to differences in ribosome occupancy of an upstream ORF, whereas the transcription factor Ikaros, a master regulator of the upregulated transcriptome, was overexpressed at the transcriptional and protein level. Interestingly, the results from the mass spectrometry and the polysomal RNA sequencing datasets showed a significant enrichment and upregulation of members of the JAK-STAT signaling pathway with Casaf2/2, Jak1 and several Stats being 1-3 fold elevated at the protein level and higher translation efficiency for Lfgr, Cbl, Ifit3, Ifi14, Ikaros and Ino.

P154

REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN

M. Karsa1,*, K. Somers1, A. Mariana1,2, T. Failes1,2, G. M. Arndt1,2, U. R. Kees3, M. Haber1, M. O. Norris1, R. Sutton1, R. B. Lock1, M. J. Henderson1

1Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, 2ACRF Drug Discovery Centre for Childhood Cancer, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, 3Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

Background: Remarkable improvements made in the treatment of childhood acute lymphoblastic leukaemia (ALL) in past decades have resulted in 5-year survival rates approaching 90%. However, prognosis remains dismal for certain subgroups of high-risk patients, including poor responders to induction therapy, infants with ALL that harbor rearrangement of the Mixed Lineage Leukaemia (MLL/KAETZ2) gene, and children with Philadelphia chromosome positive ALL. In particular, infant ALL patients with ML1 disease have survival rates below 50% despite the use of intensified treatments, necessitating the development of more effective, less toxic therapeutics for them.

Aims: The aim of this study is to identify candidates that target MLL-rearranged leukaemia cells using drug-repurposing, whereby an approved drug is applied to treat a disease other than the one for which it was originally intended. This drug discovery strategy is gaining popularity as it potentially avoids the lengthy process of drug development and FDA approval.

Methods: 3707 approved drugs and pharmacologically active compounds were initially screened against an infant ALL cell line with MLL-rearrangement, PER-485 and a paediatric leukaemia cell line wild-type for MLL, CEM, using a resazurin-based cell viability assay. Hit compounds were further tested in a panel of infant leukemic cell lines and seven solid tumor cell lines. Compounds were subsequently evaluated in vitro for cytotoxic activity against a panel of 20 paediatric high-risk ALL patient-derived xenograft (PDX) cells. Apoptosis was measured by Annexin V positivity and PARP cleavage.

Results: The screen resulted in the identification of two FDA-approved drugs that were preferentially cytotoxic against MLL-rearranged ALL and other leukaemia cell lines, compared to solid tumours and normal cells. Auranofin was originally developed for rheumatoid arthritis and was later fast-tracked into Phase II clinical trial for adult chronic lymphocytic leukaemia, while Disulfiram, which was developed for treatment of chronic alcoholism, is currently in several clinical trials for cancers including metastatic melanoma and glioblastoma. These drugs also showed potent activity in high-risk paediatric leukaemia PDX cell cultured translated in vitro, including MLL-rearranged ALL and Philadelphia-positive ALL with IC50 values between 100-400 nM for Auranofin and 30-60 nM for Disulfiram. Induction of apoptosis was evident at 6 hours post Auranofin treatment, or after 12 hours Disulfiram treatment. Each drug significantly increased intracellular ROS as early as one hour post-treatment (p<0.01), which was accompanied by induction of Nrf2, a master regulator of the antioxidant response. Incubation with ROS scavenger N-acetyl cysteine prior to treatment with either drug prevented the increase in cellular ROS levels (p<0.05) and rescued cells from apoptosis (p<0.0001), indicating involvement of reduction-oxidation and increased ROS generation as mechanisms of leukaemia cell killing induced by these drugs.

Summary/Conclusions: In summary, we have identified two FDA-approved drugs that demonstrated potent anti-leukaemia activity through induction of ROS, potentially opening up new avenues for clinical treatment of high-risk paediatric ALL. We will now be testing these potential therapeutics in vivo using relevant PDX models of high-risk paediatric ALL.

P155

TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKAEMIA

M. Pogodzinski1,*, F. Yang2,3, H. Sun2, J. Hof1, C. Eckert1, B.-B. Zhou4, M. Naam- Schwabe5

1Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2College of Life Sciences, Beijing Normal University, Beijing, 3Oncology and Hematology, Shanghai Childrens Medical Center, Shanghai, China

Background: Polychemotherapy resistance is a major challenge in the treatment of children with relapsed acute lymphoblastic leukaemia (ALL). Mutation of TP53 is tightly associated with poor response to treatment in ALL relapse patients.

Aims: We studied mutations of TP53 in ALL relapses and in six ALL cell lines to shed light on mechanisms and pathways mediating TP53 dependent drug resistance in relapsed ALL. First, we analyzed the spectrum of TP53 mutations in ALL relapses and correlated it to treatment response of patients. Second, we studied drug sensitivity in TP53 wild type (wt) versus TP53 mutant ALL cell lines.

Methods: TP53 was sequenced by the method of Sanger sequencing. Drug sensitivity was determined by IC50 in ALL cell lines. Drugs included in the study were DNA damage inducing agents as topoisomerase II inhibitors, alkylating agents, nucleotide analoga, and other agents, most of which are used in relapse treatment protocols.

Results: We identified 20 different TP53 mutations in 34 patients. We classified TP53 mutations into ‘hot spot’ (R175, Q245, R248, R273 and R282), non-hot spot and frameshift, respectively. We found that hot spot TP53 mutations were enriched in ALL relapse patients with non-response to treatment compared to good responding patients (64 versus 27%). In ALL cell lines, we confirmed TP53 mutations in Jurkat (R166) and Lu100527 and identified R248P in MHH. Three ALL cell lines were TP53 wt (SUP-B15, UOC-B6, NALM-6) and used as controls. Topoisomerase II inhibitors upregulated expression of wt p53. In contrast, nucleotide analoga showed no p53 induc-
tion, IC50 measurements showed that TP53 mutations lead to resistance against topoisomerase II inhibitors and alkylating agents, but not against other drugs. The upstream pathway of p53 (CHK1, CHK2) and DNA damage recognition (γH2AX) were not impaired in the six ALL cell lines. To study the effect of TP53 mutation on resistance to treatment in more detail, we focused on the R248P mutation, located in hot spot codon 248, that we found in a relapsed patient with non-response to treatment but without in-frame R248P. Using a CRISPR/Cas9 knockout (KO) of endogenous p53 and lentiviral based re-expression in NALM-6, we generated p53 KO, and KO+wt p53, KO+R248P and KO+GFP cell lines. The KO cells showed a similar resistance to DNA damage inducing drugs as KO+R248P cells. Overexpression of wt p53 in KO cells did not sensitize to DNA damage inducing drugs. In contrast, to wt p53, R248P did not inhibit cell proliferation under drug treatment. We found that this mutant was unable to induce downstream targets of p53 (p21, BAX). Moreover, ChIP-seq showed that R248P cannot bind the promoter and induce expression of typical p53 targets MDM2, p21, BAX, BCCJPUMA, FA7, and CASP9. This result indicates that R248P is defined by the consensus element of p53. However, the binding motif analysis showed that the R248P mutant still binds DNA at a different and purine-rich sequence. In summary, R248P leads to loss of wt p53 function and mediates resistance to topoisomerase II inhibitors and alkylating agents.

**Summary/Conclusions:** Overall, our results show that mutations affecting TP53 hot spots, in particular codon 248, are associated with resistance of ALL cells to chemotherapy and reveal first insights into underlying mechanisms and pathways.

**P156**

**GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBlastic LEUKAEMIA**

D. Ribeiro1,2, I. Lopes1, C. Custódia1, J. Silva1, M. Abreu1, J. Barata1,2

1Biomarker Sciences, Gilead Sciences, Inc., Foster City, 2Division of Oncology, University of Oxford, Oxford, UK

**Background:** T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive immature T-cell malignancies that are considered one disease entity according to the World Health Organization (WHO). Both T-ALL and T-LBL are often characterized by improper T-cell receptor (TCR) reorganizations leading to aberrant activation of proto-oncogenes.

**Aims:** Despite some genetic and phenotypic similarities between T-ALL and T-LBL, T-ALL risk group stratification cannot be extrapolated to T-LBL patients. Therefore, it is our goal to find new T-ALL markers and develop new targeted therapies based on those T-LBL specific markers.

**Methods:** We used an IL-7-dependent leukemia T-cell line (TAIL7) and “primary” cells from patient-derived xenografts (PDX). We used inhibitors of PI3K (LY294002), mTOR (rapamycin), MEK1/2 (UO126) and ULK1/2 (MRT68921). Analysis of viability and cell size was performed by flow cytometry. Signaling pathway activation and LC3-II-IL conversion was performed by western blot analysis. LC3 puncta formation was assessed by confocal microscopy. Autophagosome/lysosome formation was analyzed by electron microscopy.

**Results:** Drugs that target the PI3K/Akt/mTOR pathway (a master negative regulator of autophagy) could serve as a novel therapeutic strategy in this aggressive T-cell neoplasm.

**Summary/Conclusions:** Our results suggest that IL-7 makes use of a flexible strategy to promote T-ALL cell viability by recruiting both pro- and anti-autophagy mechanisms and functions in order to consistently promote T-ALL cell viability. In this scenario, IL-7-mediated viability relies on the latter pathway, as we previously described. In contrast, under stress conditions (serum starvation) IL-7 promotes autophagy in leukemia cells. In this situation, IL-7-mediated survival partially relies on autophagy activation and LC3-II-IL conversion was performed by western blot analysis. LC3 puncta formation was assessed by confocal microscopy. Autophagosome/lysosome formation was analyzed by electron microscopy.

**Background:** T-cell acute lymphoblastic leukemia (T-ALL) constitutes an aggressive subset of ALL, the most frequent childhood malignancy. T-ALL cases are high risk and a significant fraction of the patients still relapse despite intensive chemotherapy, prompting the need for a deeper understanding of T-ALL biology in order to develop novel therapies. Autophagy is a homeostatic intracellular process characterized by the sequestration of cytoplasmic compartments within double-membrane vesicles (autophagosomes) to promote their degradation. Importantly, autophagy is upregulated during starvation, cellular stress or in rapidly dividing cells, such as cancer cells, as a compensatory mechanism to provide nutrients and stress relief. By mitigating stress and allowing cell survival, autophagy may serve as a pro-tumoral mechanism. On the other hand, persistent autophagy can lead to cell death and thereby prevent tumor growth. Interleukin-7 (IL-7) is essential for normal T-cell development but there is considerable evidence that IL-7-mediated signaling can also contribute to leukemogenesis. A majority of T-ALL patients expresses the IL-7 receptor and IL-7 accelerates T-ALL disease progression in vivo and promotes T-ALL cell proliferation, survival and metabolic activation in vitro via PI3K/Akt/mTOR pathway (a master negative regulator of autophagy). IL-7 can also activate MEK/Erk pathway (which has been implicated in promotion of autophagy).

**Aims:** Since IL-7 has the ability to activate signaling pathways with potentially opposing roles in autophagy regulation, our goal was to explore the actual impact of IL-7 on the autophagic process in T-ALL cells and elucidate its molecular mechanisms and functions.

**Methods:** We used an IL-7-dependent leukemia T-cell line (TAIL7) and “primary” cells from patient-derived xenografts (PDX). We used inhibitors of PI3K (LY294002), mTOR (rapamycin), MEK1/2 (UO126) and ULK1/2 (MRT68921). Analysis of viability and cell size was performed by flow cytometry. Signaling pathway activation and LC3-II-IL conversion was performed by western blot analysis. LC3 puncta formation was assessed by confocal microscopy. Autophagosome/lysosome formation was analyzed by electron microscopy.

**Results:** We show that in optimal culture conditions (medium with serum) IL-7 inhibits autophagy in T-ALL, albeit in a common manner that involves triggering both pro- (via MEK/Erk) and anti- (via PI3K/Akt/mTOR) autophagic signaling. In this scenario, IL-7-mediated viability relies on the latter pathway, as we previously described. In contrast, under stress conditions (serum starvation) IL-7 promotes autophagy in leukemia cells. In this situation, IL-7-mediated survival partially relies on autophagy activation and strictly requires MEK/Erk activation. Mechanistically, we provide evidence that depending on culture conditions, IL-7 can balance the relative activation of PI3K/Akt/mTOR and MEK/Erk pathways towards or against autophagy in order to consistently promote T-ALL cell viability.

**Summary/Conclusions:** Our results suggest that IL-7 makes use of a flexible strategy to promote T-ALL cell viability by recruiting both pro- and anti-autophagy pathways, which are recruited to prevent tumor cell death depending on the microenvironmental conditions. Our data strengthen the notion that combination therapies against PI3K/Akt/mTOR and MEK/Erk pathways may be of particular relevance in the context of T-ALL.
and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, 3Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States

Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy of childhood and is highly curable with modern risk-adapted chemotherapy. However, 15-20% of children and >60% of adults with B-ALL develop chemoresistance and relapse, indicating need for new therapies. Addition of kinase inhibitors to chemotherapy for patients with \( BCR-ABL1 \)-rearranged (Ph+) B-ALL has dramatically improved event-free and overall survival, and similar approaches are now under active clinical investigation in patients with \( BCR-ABL1 \)-like (Philadelphia chromosome-like or Ph-like) B-ALL. Recent studies have demonstrated activated spleen tyrosine kinase (SYK) signaling in various genetic subtypes of B-ALL and preclinical activity of the SYK/FLT3/AKIR inhibitor fostamatinib. However, SYK activation in B-ALL and potential correlation with specific leukemia-associated mutations remains incompletely characterized. We hypothesized that constitutive activation of SYK signaling occurs across a genetic spectrum of infant and high-risk childhood B-ALL and can be therapeutically targeted \textit{in vivo} with the selective SYK inhibitor entospletinib (ento).

**Aims:** (1) Assess basal SYK signaling activation in childhood B-ALL specimens. (2) Quantify treatment efficacy, pharmacokinetics (PK), and pharmacodynamic (PD) effects of ento in childhood B-ALL patient-derived xenograft (PDX) models.

**Methods:** Total and phosphorylated (p) SYK levels were assessed by Simple Western analysis of splenocyte lysates from NSG mice well-engrafted with primary pediatric B-ALL specimens \((n=19 \text{ Ph-like}, n=4 \text{ infant } KMT2A\text{-rearranged (R)}, n=4 \text{ infant non-}KMT2A\text{-R PDX models})\) to identify leukemias with constitutive SYK signaling activation. To assess \textit{in vivo} activity of SYK inhibition, selected B-ALL PDX models with high basal pSYK \((n=2)\) were treated with continuous oral control \((0.03\% \text{ chow})\), or ento \((0.07\% \text{ ento} \text{ arms})\) daily for 21-28 days, and peripheral blood and spleens were harvested for downstream studies. Flow cytometric analyses of murine tissues were performed to assess initial human ALL engraftment and to measure ento treatment responses. PK and PD assessments were performed in terminal peripheral blood and spleens, respectively.

**Results:** Constitutive pSYK signaling was observed in \(10/19\) Ph-like, \(4/4\) KMT2A-R, and \(1/4\) non-KMT2A-R B-ALL specimens. Ento treatment of KMT2A-MLLT3 \((\text{ALL3103})\) and Ph-like NUP214-ABL1 \((\text{NH011})\) PDX models significantly inhibited ALL proliferation \textit{in vivo} versus control animals at both 0.03% and 0.07% chow formulations (representative data in Figure 1; p<0.05). Steady state concentrations were maintained throughout the study duration with terminal PK values of 3.3 (±0.5) and 7.9 (±1.0) \muM (0.03% and 0.07% ento arms, respectively). PD studies demonstrated dose-dependent \textit{in vivo} inhibition of pERK measured in human leukemia cells within spleens of ento-treated mice. PD inhibition of SYK target phosphoproteins was more pronounced in 0.07% ento-treated animals.

**Summary/Conclusions:** Constitutive activation of SYK signaling occurs frequently in childhood Ph-like and infant KMT2A-R childhood B-ALL. Ento treatment of B-ALL PDX models potently inhibited SYK pathway signaling proteins and significantly inhibited leukemia proliferation \textit{in vivo}.

---

**P159**

PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION

R. Lehal1,*, D. Weber1, V. Frismantas2, J.-P. Bourquin2, M. Bauer1, M. Murone1, F. Radtke3

1Cellestia Biotech AG, Basel, 2University Children’s Hospital, Zürich, 3Swiss Institute for Experimental Cancer Research, EPFL, Lausanne, Switzerland

**Background:** NOTCH signalling is a developmental pathway known to play critical roles during embryonic development as well as for the regulation of self-renewing tissues. Aberrant activation of NOTCH signalling leads to deregulation of the self-renewal process resulting in sustained proliferation, evasion of cell death, loss of differentiation capacity, invasion and metastasis, all of which are hallmarks of cancer. When the NOTCH pathway is inappropriately activated by genetic lesions (over expression of NOTCH ligands/receptors, GOF mutations in NOTCH receptors as well as chromosomal translocations), it becomes a major driver for NOTCH-dependent cancers and resistance to standard of care treatment. Over 250,000 patients are annually diagnosed with NOTCH dependent cancers, with no specific therapy available to date.

**Aims:** Given the importance of NOTCH signalling in human cancers, several therapeutic approaches have been utilized to block NOTCH signalling. Two of these strategies are: a) the use of monoclonal blocking antibodies (mAbs) against NOTCH ligands and receptors and b) the use of small molecule gamma-secretase inhibitors (GSIs). However, these approaches can only be effective if tumor cells express full-length ligand or receptor molecules. As validation of NOTCH as a therapeutic target, clinical activity of these in clinical studies were was observed in various trials for some of these inhibitors (mAbs, GSIs), but treatment and exposure were usually limited due to toxicities, mainly related to gastro-intestinal adverse events. On the contrary, in human cancers harboring NOTCH gene fusion due to chromosomal translocations or specific NOTCH mutations, the use of mAbs and GSIs will have very limited clinical benefits. Cellestia has decided to follow a disruptive approach, by blocking NOTCH signalling in the most downstream part of the NOTCH cascade, at the level of the NOTCH transcriptional activation complex, using small molecule inhibitors.

**Methods:** Here we report the pharmacological characterization of CB-103, a first-in-class orally-active small molecule inhibitor of the NOTCH transcriptional activation complex.

**Results:** We demonstrate that \textit{in vitro} CB-103 potently inhibits NOTCH signalling in various leukemic and lymphoma cell lines, and T-ALL blasts derived from relapse/refractory patients. In addition, CB-103 exhibited anti-tumor efficacy in multiple \textit{in vivo} models of NOTCH-driven T-ALL using T-ALL cell lines and patients derived xenograft models.

**Summary/Conclusions:** Toxicology studies have been completed and clinical development of CB-103 with a first-in-human Phase I/IIA clinical study in advanced solid tumors and haematological malignancies is under preparation.
Acute lymphoblastic leukemia - Clinical 1

P160

IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL


1UCL Cancer Institute, 2CRUK and UCL Cancer Trial Centre, UCL, 3Barts Cancer Institute, QMUL, London, 4Leukemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, United Kingdom

Background: The IKZF1 gene encodes the IKAROS zinc finger transcription factor and master regulator of lymphocyte differentiation. IKZF1 lesions are common in acute lymphoblastic leukaemia (ALL) and have been reported as independent prognostic factors for poor outcome. IKZF1Δ4-7, resulting in the dominant negative Iκ6 isoform is the most common single IKZF1 deletion.

Aims: We aimed to generate and validate a simple, PCR-based screening assay for IKZF1Δ4-7 using an endpoint PCR assay using primers located in introns 3 and 7. The lower limit of detection was determined by serial dilution of DNA from the IK6-expressing cell line SUP-B15 and calculated to be 0.001%. A total of 95 samples were also tested using the MLPA P335 kit to detect the full spectrum of IKZF1 deletion. Sanger sequencing confirmed the breakpoints in 27 cases.

Results: The median age of the patients tested was 46 years (range 25-65). Overall IKZF1Δ4-7 was detected in 97/490 (20%) patients but the frequency varied by genetic subtype. Patients with BCR-ABL1 fusion had the highest IKZF1Δ4-7 frequency (46/150, 31%) followed by patients with B-other ALL (29/154, 19%). Patients with other classic cytogenetic abnormalities harboured significantly fewer IKZF1Δ4-7 – low hypodiploid (3/26), MLL gene fusions (3/31), t(1;19) and iAMP21 (0/3). MLPA did not detect any IKZF1Δ4-7 deletions that were not detected by PCR but did identify several samples with alternative IKZF1 deletions affecting different exons (see Table 1). By contrast, the PCR assay did detect six IKZF1Δ4-7 deletions undetected by MLPA, consistent with the higher sensitivity of this approach. Interestingly, three of these samples harboured alternative IKZF1 deletions in addition to IKZF1Δ4-7. In 70 (14%) cases, we observed a “faint” PCR band. Since the biological relevance of this was not clear, the “faint” bands were not included in the main analysis. Interestingly the frequency of these “faint” bands was similar across all genetic subtypes: BCR-ABL1 (14%), B-other (15%), MLL (21%), low hypodiploid (19%). We examined the impact of IKZF1Δ4-7 on achievement of CR, persistence of minimal residual disease (MRD) at t = x ≥ 10-4 (lgT/CR quantitation by EuroMRD criteria) after courses 1 and 2 of therapy, EFS, OS and time to relapse, at a median follow-up of 23.1 months. Two thirds of patients (44/66) with IKZF1Δ4-7 were MRD positive at the end of phase 1 compared with 147/273 (54%) patients without the deletion (p=0.059). However, this relationship between IKZF1Δ4-7 and MRD did not persist after phase 2. We did not identify any association between IKZF1Δ4-7 and any of the other outcome parameters tested.

Table 1.

Summary/Conclusions: IKZF1Δ4-7 can be detected by a simple and cheap PCR assay, which is more sensitive than MLPA. The frequency of IKZF1Δ4-7 was broadly comparable with previous studies. However, we did not find an association between IKZF1Δ4-7 and clinical outcome in the large clinical trial sample set. We are in the process of evaluating the impact of other IKZF1 lesions.

P161

PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKAEMIA, UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY

G. Tsaar1,2, A. Popov2, T. Riger1, A. Solodovnikov1, A. Kustanovich3, O. Aleinkova3, Y. Olshanskaya4, N. Myakova2, T. Verzhbitskaya1, E. Shorkov4, O. Strenueva1, O. Araakev1, A. Vaslova1, S. Tsverenk2, L. Saveliev1

1Regional Children Hospital #1, Research Institute of Medical Cell Technologies, Ekaterinburg, 2National Research Institute of Pediatric Hematology, Oncology and Immunology, named after Dmitry Rogachev, Moscow, Russian Federation, 3Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus, 4PET Technology, 5Ural State Medical University, Ekaterinburg, Russian Federation

Background: Fusion gene transcripts (FGTs) are rarely used for minimal residual disease (MRD) monitoring in acute lymphoblastic leukemia (ALL) cases, except of Ph-positive ALL. However in infant ALL, where MLL gene rearrangements are found the majority of cases, MLL FGTs are attractive targets for MRD detection.

Aims: To estimate prognostic significance of MLL by qualitative detection of different MLL FGTs in infant ALL treated by MLL-Baby protocol.

Methods: Seventy six infants (27 boys and 49 girls) with median age of 5.8 months (range 0.3-11.83) were included in the current study. Among them there were 39 (51.3%) MLL-AF4-positive cases, 14 (18.4%) MLL-MLLT1-positive, 12 (15.8%) MLL-MLLT3-positive, 6 (7.9%) MLL-MLLT10-negative, 4 (5.3%) MLL-EFS15-positive cases. MDR detection was performed in BM samples by real-time quantitative PCR and nested RT-PCR with sensitivity non-less than 1E-04. MRD negativity was defined as absence of FGTs in the both assays. Median of follow-up period in the observed group was 6.4 months. Informative consent was obtained in all cases. Results: We confirmed our earlier finding that the most informative TP for the MRD detection was TP4. The lower limit of detection was determined by serial dilution of DNA from the MLL·MLT11·SUP-B15 cell line and calculated to be 0.001%. MLL-positive patients stratified to high-risk arm of MLL-Baby protocol (EFS 0.05±0.04 vs 0.78±0.07 p<0.0001; cumulative incidence of relapse 0.78±0.10 vs 0.11±0.07 p<0.0001, respectively) and for all others MLL-rearranged patients treated by intermediate risk (IMR) arm (EFS 0.00 vs 0.71±0.11 p<0.0001; cumulative incidence of relapse 1.0 vs 0.29±0.10 p<0.0001, respectively). There were no significant differences in initial patients’ characteristics and treatment response criteria (on days 8, 15, 36) among 38 MMRD-positive and 38 MMRD-negative patients. Multivariate analysis revealed that initial CNS disease (hazard ratio (HR) 2.703, 95% CI 1.255-5.284, p=0.011), m1 status of BM on day 15 (HR 3.909, 95% CI 1.465-6.515, p=0.003) and MRRD positivity at TP4 (HR 6.950 95% CI 2.617-18.456) were significant covariates with negative impact on hazard of unfavorable event. Based on dismal outcome of MRRD-positive IMR patients we tried to augment their therapy and relocated 5 of them from IMR group to HR arm after TP4. Although all infants had subsequently relapsed, we also wanted to find out which characteristics might predict relapse in IMR patients who were MRRD-negative at TP4 (n=5). Of note, all these 5 relapsed patients (100%) had initial CNS disease while CNS disease was detected only in 2 out of 19 IMR patients (10.5%) who stayed in complete hematological and molecular remission (p=0.003). Also 5 relapsed IMR patients who were MRRD-negative at TP4 had breakpoint positions within intron 11 of MLL gene and they were MRRD-positive by flow cytometry (MRRD ≥0.1%) on day 15. None of MRRD-negative patients by flow cytometry (MRRD <0.1%) on day 15 relapsed later on (p<0.001).

Summary/Conclusions: MDR monitoring by detection of MLL FGTs was feasible and had significant prognostic impact. MRRD positivity at TP4 was independent factor of unfavorable outcome in infants with MLL-rearranged ALL enrolled into MLL-Baby protocol irrespective of treatment arm. Treatment intensification for MRRD-positive at TP4 IMR patients did not improve their outcome. MRRD-positivity at TP4 in IMR group was associated with MRRD-positivity by flow cytometry on day 15, MLL breakpoint positions within intron 11 gene and initial CNS disease.

P162

PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY

B. Petroskova1, G. Rymkiewicz2, K. Domanska-Czyz1, J. Romejko-Jarosinska1, K. Blachnio2, L. Poplawska1, W. Michalski3, J. Walewski1

1Department of Lymphoid Malignancies, 2Department of Pathology and Laboratory Diagnostics, 3Department of Biostatistics, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland, Warszawa, Poland
Background: Risk factors for T-LBL have not been systematically evaluated, in contrast to T-ALL.

Aims: Our aim was to define immunophenotype of T-LBL/ALL in 71 consecutive patients by use of the flow cytometry (FCM) of tissue aspirates if peripheral blood (PB) and bone marrow (BM) were uninvolved. We also evaluated prognostic value of immunophenotype according to WHO 2008 subtype and ETP (Early T-Cell Phenotype) definition in adult patients with T-LBL/ALL treated on uniform ALL protocol.

Methods: Between 1997 and 2015, 71 adult patients with T-LBL/ALL were treated according to the GMAIL 05/93 and T-LBL/2004 protocols. Immunophenotype was determined by immunohistochimical staining and by FCM of cellular suspension obtained from lymph nodes (n=31), mediastinal mass (n=12) or nasopharyngeal/perimandibular infiltration (n=2) by fine needle aspiration biopsy (FNAB), as well as of BM (n=10), PB (n=7) and pleural fluid (n=9). Disease subtype was defined according to WHO 2008 classification:

- CD2 negative or dim (CD2-)
- CD2+ but CD5 negative
- CD5 weaker (20-71%): 54%
- CD34/HLA-DR expression

Results: Patient characteristics: ALL (BM+ >20%): n=26(37%), LBL: n=45(63%). BM+<20% (L). 7%: 28(37%); 3: 72(93%); 2: 9(12%); 1: 3(4%). BM+<20% involvement (LBL): 27%, pre-T: 17%, cortical: 55%, medullary/mature: 28%. Among LBL pts, ETP was expressed in 100%/50%/50%/75%/14% of ETP pts. 4 pts(31%) with CD2, CD1a and 3 or less positive pTAg present was 64% (0.511, 0.776), 66% (0.512, 0.803) and 64% (0.5, 0.782) compared to 11% (0.034, 0.256), 32% (0.152, 0.494) and 27% (0.097, 0.452) for pts without CD2, CD1a and 3 or less pTAg, respectively. OS and DFS in pts with CD2 expression as well as on WHO subtype. ETP is a non-uniform category with CD2 expression as well as on WHO subtype. ETP is a non-uniform category (CD2+/CD2-). Not consistent with CD2 positive pTAg (CD2+), only 19/ pts with pre-T phenotype. 3/7 pts were rescued with allo-HCT (Figure 1).

Summary/Conclusions: Survival of T-LBL/ALL pts depends on CD1a and CD2 expression as well as on WHO subtype. ETP is a non-uniform category by pro-7/pre-T-cell origin. ETP phenotype was non-significant factor for OS/DFS (p=0.15/0.09) unless consistent with pro-T subtype (CD2+), only 19/ pts with pre-T phenotype. 3/7 pts were rescued with allo-HCT (Figure 1).

REFERENCES:


1Hematology, Ospedale dell’Angelo, Mestre Venezia, 2ASST Papa Giovanni XXIII, Bergamo, Italy, 3Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, 4Hematology, Città della Salute e della Scienza, Torino, 5Hematology, Spedali Civili di Brescia, Brescia, 6Hematology Division and BMT Unit, Ospedale San Gerardo, Monza, 7Hematology and BMT Unit, Central Hospital of Bolzano, Bolzano, 8Hematology, Ospedale S.Croce, Cuneo, 9Hematology, Ospedale A. Buscino, Cagliari, 10Oncohematology Unit, University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Fondazione IRCCS Ospedale San Raffaele, Milano, 11Hematology, Ospedale S. Croce, Cuneo, 12Ematologia e Medicina Trasfusionale, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, 13Clinical and Experimental Medicine, University of Insubria, Varese, 14Hematology Unit, AOUS, University of Siena, Siena, 15Hematology, Ospedale San Bortolo, Vicenza, 16University of Milan, Milan, Italy

haematologica | 2017; 102(s2) | 31
Background: The outcome for older adults with acute lymphoblastic leukaemia (ALL) is unsatisfactory. The UKALL12/ECOG2993 study showed that high risk cytogenetic abnormalities, were common, as well as lower rates of complete remission (CR) and 5 year overall survival (OS) in those aged 55–65 years of age as compared to younger persons. There are few studies which focus on older patients with ALL, despite an increasing incidence with age.

Aims: A trial to establish age-appropriate baseline chemotherapy from which to design widely-applicable studies of novel agents in older people with ALL.

Methods: UKALL60+ offers five ‘Arms’ to be decided by investigator and patient choice; Arm A= Philadelphia chromosome positive (Ph+), Arm B= Non-intensive (designed to be delivered primarily out of hospital), Arm C= Intensive, Arm D= Intensive+ and Arm E= Registration only (in which treatment is at investigators discretion, including no active therapy). Any elderly patient with newly diagnosed ALL is eligible. There are no exclusions for co-morbidities, including prior malignancies. Baseline characteristics of each group including Charlson index, ECOG, Karnofsky and CRASH scores are being collected.

Results: After IRB approval, we performed a retrospective study of patients (pts) age ≥60 diagnosed with ALL from 2000 to 2016 at Mayo Clinic Rochester. Statistical analysis was performed using JMP 10.0 software.

Predictors of survival

Predictors of survival were 20% for CDKN2A del in this disease group. Further studies are needed to confirm this finding, as it could be a target for novel therapies.

Aims: Describe clinical outcomes and prognostic factors of elderly ALL.

Methods: After IRB approval, we performed a retrospective study of patients (pts) age ≥60 diagnosed with ALL from 2000 to 2016 at Mayo Clinic Rochester. Statistical analysis was performed using JMP 10.0 software.

Results: Out of 210 adult ALL pts, we identified 63 (30%) consecutive pts with elderly ALL. The average age at time of diagnosis was 67 (60-82), & 38 (60%) were males. Median follow up was 16.1 months (0.2-126), during which time 40 (63%) deaths occurred; 25 (3%) related to the disease, & 15 (27%) secondary to infection or other causes. Baseline characteristics at time of diagnosis: 54 (86%) pts had B-cell phenotype, 19 (35%) were Ph+. Only 9 (14%) pts had T-cell phenotype. 20 (31%) pts had a Charlson Comorbidity Index ≥2 & 17 (27%) presented with ECOG PS ≥2. Median Hgb was 10.6 g/dl (4.9-18.5), WBC 6.2 x 10⁹/l (0.5-160.8), PLT 51 x 10⁹/l (4-750), peripheral blast 30% (0-95), marrow blast 87.5% (0-100), & LDH 381.5 U/L (141-8440). Lymphoblastic lymphoma was only evident in 3 (5%) pts. Among pts with available data, 34/58 (59%) had B symptoms, 16/57 (28%) lymphadenopathy, 7/57 (12%) splenomegaly, 6/60 (10%) pleural effusions & 10/45 (22%) of pts had CNS leukemia. Cytogenetics at time of diagnosis: Of 48 pts with available data, 20 (41%) had complex cytogenetics (≥5 abnormalities), 18 (38%) had a monosomic karyotype, 8 (17%) were hypodiploid, 4 (8%) were hyperdiploid, & 2 (4%) were a mix of hypo- & hyper-diploid. FISH studies were available for 50 pts: 10 (20%) had CDKN2A del, 3 (6%) 11q(4,11) MLL-AF4, 2 (4%) 11(13,19) E2A-PBX1, 1 (2%) KLF1 deletion. Treatment and Outcomes: Of 48 pts received palliative therapy only, which included TKIs, chemotherapy, or hospice. The other 53 (84%) received induction chemotherapy. Only 12 (23%) had an up-front dose reduction due to comorbidities. 32 (60%) received Hyper-CVAD, concomitantly with rituximab in 12 (31%) pts. & TKIs in 9 (28%) pts. 21 (40%) pts received other regimens, of which 14 (67%) had asparaginase-based chemotherapy. Only 2 (4%) pts who received induction chemotherapy died within the first 60 days; both received Hyper-CVAD. Median number of cycles to achieve CR was 1 (1-8) with CR/CRi rate of 93%, & median time to CR1 was 34 days (19-459), 3 pts who underwent palliative chemotherapy achieved CR (all had Ph+ disease & received TKIs). 7 pts (13%) had primary induction failure. 50% of pts relapsed within a median time of 12.6 (3.6-72.8) months. Only 10 pts underwent allogeneic hematopoietic stem cell transplantation (HSCT), of which 2 (20%) relapsed in less than 180 days. Median survival after HSCT was not reached. Predictors of survival: Elderly ALL has worse mOS compared to our adult ALL cohort, 17.2 (IQR; 11.7-32.9) vs 52.1 (IQR; 27.6-169.9) mon (p=0.0016). In a univariate analysis model which included multiple variables, only ECOG PS ≥2, WBC>30,000, CDKN2A del, & CNS leukemia were statistically significant, however only CNS leukemia (p=0.0009) & WBC (p=0.0168) retained statistical significance in multivariate mode, with a trend in CDKN2A del (p=0.06) (Figure 1).

Figure 1.

Summary/Conclusions: All elderly pts with ALL have worse survival compared to younger adults. However, this was not reflected by a low CR rate, or a high rate of mortality during induction, but by grim disease overall. We report for the first time the incidence of 20% for CDKN2A del in this disease group. Further studies are needed to confirm this finding, as it could be a target for novel therapies.

P166

MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED AT THE “SAPIENZA” UNIVERSITY BETWEEN 1996 AND 2016

S. Chiaretti 1, V. Gianfelici 1, R. Agrippino 1, L. Elia 1, F. Paoloni 1, S. Capria 1

Background: Elderly acute lymphoblastic leukemia/lymphoma (ALL) is a rare disease with a poor prognosis and is underrepresented in clinical trials. This poor outcome is likely due to comorbidities, early death during induction, lower rates of complete remission, and higher risk of relapse with poor biological features (Gokbuget, Blood, 2013).

Aims: Describe clinical outcomes and prognostic factors of elderly ALL.

Methods: After IRB approval, we performed a retrospective study of patients (pts) age ≥60 diagnosed with ALL from 2000 to 2016 at Mayo Clinic Rochester. Statistical analysis was performed using JMP 10.0 software.

Results: Out of 210 adult ALL pts, we identified 63 (30%) consecutive pts with elderly ALL. The average age at time of diagnosis was 67 (60-82), & 38 (60%) were males. Median follow up was 16.1 months (0.2-126), during which time 40 (63%) deaths occurred; 25 (3%) related to the disease, & 15 (27%) secondary to infection or other causes. Baseline characteristics at time of diagnosis: 54 (86%) pts had B-cell phenotype, 19 (35%) were Ph+. Only 9 (14%) pts had T-cell phenotype. 20 (31%) pts had a Charlson Comorbidity Index ≥2 & 17 (27%) presented with ECOG PS ≥2. Median Hgb was 10.6 g/dl (4.9-18.5), WBC 6.2 x 10⁹/l (0.5-160.8), PLT 51 x 10⁹/l (4-750), peripheral blast 30% (0-95), marrow blast 87.5% (0-100), & LDH 381.5 U/L (141-8440). Lymphoblastic lymphoma was only evident in 3 (5%) pts. Among pts with available data, 34/58 (59%) had B symptoms, 16/57 (28%) lymphadenopathy, 7/57 (12%) splenomegaly, 6/60 (10%) pleural effusions & 10/45 (22%) of pts had CNS leukemia. Cytogenetics at time of diagnosis: Of 48 pts with available data, 20 (41%) had complex cytogenetics (≥5 abnormalities), 18 (38%) had a monosomic karyotype, 8 (17%) were hypodiploid, 4 (8%) were hyperdiploid, & 2 (4%) were a mix of hypo- & hyper-diploid. FISH studies were available for 50 pts: 10 (20%) had CDKN2A del, 3 (6%) 11q(4,11) MLL-AF4, 2 (4%) 11(13,19) E2A-PBX1, 1 (2%) KLF1 deletion. Treatment and Outcomes: Of 48 pts received palliative therapy only, which included TKIs, chemotherapy, or hospice. The other 53 (84%) received induction chemotherapy. Only 12 (23%) had an up-front dose reduction due to comorbidities. 32 (60%) received Hyper-CVAD, concomitantly with rituximab in 12 (31%) pts. & TKIs in 9 (28%) pts. 21 (40%) pts received other regimens, of which 14 (67%) had asparaginase-based chemotherapy. Only 2 (4%) pts who received induction chemotherapy died within the first 60 days; both received Hyper-CVAD. Median number of cycles to achieve CR was 1 (1-8) with CR/CRi rate of 93%, & median time to CR1 was 34 days (19-459), 3 pts who underwent palliative chemotherapy achieved CR (all had Ph+ disease & received TKIs). 7 pts (13%) had primary induction failure. 50% of pts relapsed within a median time of 12.6 (3.6-72.8) months. Only 10 pts underw
C. Minotti1, A.P. Iori1, F. Mancini1, M.S. De Propris1, A. Guarni1, A. Vitale1, R. Foa1
1Division of Hematology, Department of Cellular Biotechnologies and Hema- 
siology, Sapienza University of Rome, 2GIMEMA Data Center, Rome, Italy

Background: The outcome of adults and elderly (>60 years) patients with Ph+
ALL has improved since the introduction of tyrosine kinase inhibitors (TKI), 
used alone or in combination with chemotherapy during induction. Before 2005, 
all these patients were treated with chemotherapy; from 2005, a TKI-based 
“chemo-free” induction strategy was applied.

Aims: To evaluate the outcome of patients followed from 1996 at a single Cen-
ter, and to correlate the short- and long-term responses with: a) induction treat-
ment (chemotherapy or TKI); b) age; c) TKI used (imatinib or dasatinib); d) 
fusion protein; e) allogeneic stem cell transplant (SCT).

Methods: Sixty-eight patients (29M/39F) were treated; median age was 50 
years (28-88) and 16 were elderly patients; 43 cases had the p190 protein, 19 
the p210 and 6 had both; the latter 2 groups were merged together for further 
analyses. Fifty-two patients were enrolled in clinical trials. Median follow-up is 
105 months (13-224).

Results: As induction, 28 patients received chemotherapy, 2 chemotherapy+TKI 
(considered as “chemotherapy+TKI group”) and 38 TKI alone (24 imatinib and 
14 dasatinib). All cases received TKI during consolidation/maintenance when it 
became available. All elderly patients but 1 received a TKI alone (plus steroids).
Upon induction, 44 patients received consolidation chemotherapy, including 5 
elderly. A SCT - carried out virtually only in adults - was performed in first complete 
remission (CR) in 13 cases (5 in the chemotherapy+TKI and 8 in the TKI group). 
Overall, 91% patients achieved a CR, OS and DFS at 100 months are 42% and 
45.5%, respectively. Among the 30 patients in the chemotherapy+TKI group, 25 
(83%) achieved a CR, 4 were refractory and 1 died in induction; in the TKI group 
(n=38), 37 (97%) achieved a CR and 1 was refractory. Differences are statistically 
significant (p=0.03). Refractoriness was more frequent in p210+ than in p190+ 
cases (12% vs 5%): this finding did not translate into significantly different OS 
and DFS (30% vs 48% and 32% vs 51%, respectively). When patients were strat-
ified by age, adults had a significantly better OS and DFS at 100 months than 
elderly (53% vs 19%, p=0.04, and 57% vs 20%, p=0.03, respectively), even 
morbidly-affected patients. In univariate analysis we treated the TKI group alone 
(75% vs 20%, p=0.01 and 73% vs 21.4%, p=0.017, respectively). The TKI used (imatinib or dasatinib) 
did not impact in adults, while a significant advantage in OS and DFS was 
observed for elderly patients receiving dasatinib (Figure 1): this might be due to 
the greater activity of dasatinib and also highlights the importance of consolidation 
therapy based on a TKI alone. Since age holds strong prognostic significance, our 
study further underlines the benefit of an induc-
tion strategy based on a TKI alone. Considering adults only, 
the greater activity of dasatinib and also highlights the importance of consolidation 
as shown for elderly patients receiving dasatinib (Figure 1): this might be due to 
the standard-risk group. In univariate analysis, CD9 positivity, age <1 year, 
white cell count ≥100 x 10^9/L and poor prednisone response were associated with 
lower RFS rate (P=0.029). Subgroup analysis showed remarkably 
poorer outcomes in CD9+ patients of the high-risk group (P=0.045). A similar 
trend was also observed in patients of the intermediate-risk group but not in 
the standard-risk group. In univariate analysis, CD9 positivity, age <1 year, 
white cell count ≥100 x 10^9/L and poor prednisone response were associated with 
lower RFS rates (HR=3.9; P=0.015) remained as inde-
pendent prognostic factors for lower RFS rates.

Summary/Conclusions: Our data indicate that expression of CD9 was signif-
ically associated with inferior survival outcomes in pediatric B-ALL. 
the standard-risk group. In univariate analysis, CD9 positivity, age <1 year, 
white cell count ≥100 x 10^9/L and poor prednisone response were associated with 
lower RFS rates (HR=3.9; P=0.015) remained as inde-
pendent prognostic factors for lower RFS rates.

Figure 1. 

Summary/Conclusions: This study further underlines the benefit of an induc-
tion based on a TKI alone. Since age holds strong prognostic significance, our 
results suggest that while the benefit followed by consolidation chemotherapy is 
the optimal choice for adults, in elderly cases dasatinib is more appropriate, 
since patients are often unfit to receive further chemotherapy. Finally, the advan-
tage of SCT needs to be carefully redefined in the TKI era.

P167 

THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING 
SURVIVAL OUTCOMES OF PEDIATRIC B- Precursor ACUTE 
LYMPHOBLASTIC LEUKEMIA

K.T. Leung1, K.Y.Y. Chan1, C. Zhang1, A.W.K. Leung1, F.W.T. Cheng1, 
J.W.S. Yu1, T.F. Leung1, K. Li1, C.K. Li1
1Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong

Background: B-precursor acute lymphoblastic leukemia (B-ALL) is the most 
common childhood malignancy, accounting for approximately 30% of pediatric 
cancers. With advances in risk-adapted chemotherapy, the overall cure rate of 
newly diagnosed B-ALL is approaching 85% in most developed countries. How-
ever, relapse still occurs in ~20% of patients and a significant portion of them 
are not initially classified in the high-risk disease entity, underscoring the need 
for development of additional informative prognostic biomarkers.

Aims: CD9, a tetraspanin family protein, regulates multiple physiologic process-

s including cell migration and adhesion, and has been associated with metas-
tasis and progression of various types of cancers. In this study, we aim to eval-
uate its expression pattern and prognostic significance in pediatric B-ALL.

Methods: Cell surface CD9 expression on leukaemic blasts at disease presen-
tation was characterized by multicolor flow cytometry in a cohort of pediatric B-
ALL patients. The CD9 expression status was correlated with clinical parame-
ters, including age, sex, white cell count, cytogenetics and prednisone 
response. Kaplan-Meier survival analysis was performed to investigate the pos-
sible association of CD9 expression with clinical outcomes. The potential role 
of CD9 expression as a predictor of 5-year survival outcomes was evaluated using 
Cox regression models.

Results: Among 118 cases tested, blasts of 92 patients (78.0%) were CD9+ 
(≥20% of CD9-expressing blasts). There were no significant differences in age, 
sex and white cell count between CD9+ and CD9- patients. Major cytogenetics 
subgroups were similarly distributed except for hyperdiploidy (all patients were 
CD9+, P=0.022) and ETV6-RUNX1 translocation (higher prevalence in CD9- 
patients, P=0.001). Significantly more CD9+ patients were stratified into the 
intermediate-risk group (P=0.044) and a higher proportion of CD9- patients 
was stratified into the high-risk group (P=0.025). Besides, CD9- patients had 
poorer prednisone response (P=0.014). The 5-year overall survival (OS) and 
relapse-free survival (RFS) rates of CD9+ patients were significantly lower than 
those in CD9- patients (P=0.029). Subgroup analysis revealed remarkably 
poorer outcomes in CD9+ patients of the high-risk group (P=0.045). A similar 
trend was also observed in patients of the intermediate-risk group but not in 
the standard-risk group. In univariate analysis, CD9 positivity, age <1 year, 
white cell count ≥100 x 10^9/L and poor prednisone response were associated with 
lower RFS rates (HR=3.9; P=0.015) remained as inde-
pendent prognostic factors for lower RFS rates.

Summary/Conclusions: Our data indicate that expression of CD9 was signif-
ically associated with inferior survival outcomes in pediatric B-ALL. 
The observed difference was most prominent for patients in the high-risk 
group, suggesting that CD9 expression could potentially be used in conjunction 
with other known prognostic factors for refinement of risk group stratification. 
Our study also lays the foundation for future development of CD9-targeted therapy 
for high-risk and relapsed/refractory pediatric B-ALL.

P168 

PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL 
HDAC EXPRESSION

N. Vega-Garcia1, R. Malatesta1, C. Estella1, M. Torrebbedell12, S. Gassiot1, 
A. Catalá1, R. Berrueco1, A. Ruíz-Llobet1, A. Alonso-Saladrigues1, 
M. Mesegue1, M. Trabazo1, S. Rives1, M. Camos1,2
1Hematology Laboratory, Institut de Recerca Pediàtrica Hospital Sant Joan de 
Deu, Barcelona, 2Centro de Investigación Biomédica en Red de Enfermedades 
Raras (CIBERER), Instituto de Salud Carlos III, Madrid, 3Clinical Department 
of Pediatric Hematology and Oncology, Institut de Recerca Pediàtrica Hospital 
Sant Joan de Deu, Barcelona, Spain

Background: Overexpression of histone deacetylases (HDACs) is a common 
feature in acute leukemias. Consequently, HDAC inhibitors (HDACi) have 
emerged as promising targeted therapy. However, non-specific HDACi may 
lead to accumulation of double stranded DNA lesions, so more selective isoform 
specific HDACi are needed. Expression patterns of HDACs in childhood 
leukemia have been scarcely studied.

Aims: To analyze the expression of HDAC isoforms in different subtypes of 
pediatric leukemia and correlate them with prognosis and clinico-biological fea-
tures.

Methods: We evaluated the mRNA gene expression profile of class I, II and IV 
HDAC genes (HDAC 1-11) by quantitative PCR in 126 leukemic pediatric sam-
ples and a pool of non-neoplastic samples as calibrator. Patients were treated 
according to the Spanish Hemato-Oncology Cooperative Group protocols in a 
single center. The HDAC expression levels in different groups were compared 
by the Mann-Whitney test. The level of significance was set up at p<0.05. The 
analyses were performed with SPSS 24.0.
Results: Our series included 69 boys and 57 girls diagnosed with acute leukemia, with a median age of 6.1 years (range 0-17.4 years). We included 12 infant patients (<1 year old). Eighty-two (65%) patients had B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 24 patients T-cell ALL and 20 patients had acute myeloblastic leukemia (AML). Globally, we found higher expression levels of class I HDAC isozymes (HDAC 1, 2, 3 & 8) in leukemic samples as compared to non-leukemic samples, as previously reported. Interestingly, some HDAC isoforms associated with specific genetic aberrations. Those patients with rearrangement of MLL (KMT2A) gene (n=18, including 9 BCP-ALL and 9 AML; 7 infants and 11 pediatric) showed a significantly higher expression of HDAC9 (p=0.0001) and a statistically significant underexpression of HDAC1 and HDAC3 (p=0.003 & p=0.02, respectively, see Figure 1). Infants (n=12) had also a significantly lower expression of HDAC7 (p=0.043). In the same line, all pediatric patients with pro-B phenotype (CD10 negative) had low levels of HDAC7, but differences did not reach a statistical significance. After a median follow-up of 5.9 years, 15 patients died, with an overall survival (OS) of 68% for BCP-ALL, 79% for T-ALL and 55% for AML patients (p=0.0001). In the BCP-ALL subgroup, the expression of HDACs did not predict outcome, and only CNS infiltration and leukocytosis were unfavorable risk factors for OS. Again, CNS+, high WBC count and presence of minimal residual disease (MRD) post-induction were predictive for worse event free survival (EFS). Although the number of cases is low and these results must be taken with caution, T-ALL patients with the highest expression of HDAC3 (upper quartile) significantly correlated with worse OS (94% vs 25%, p=0.001) and a trend towards worse EFS (89% vs 53%, p=0.06). The only significant risk factor for EFS in this subgroup was the presence of MRD after induction (p=0.003).

Summary/Conclusions: We have observed a specific pattern of HDACs expression in pediatric patients with ALL rearrangement. Our study, if further confirmed, suggests that specific HDACi would potentially be a useful targeted treatment for pediatric patients with ALL rearranged leukemia.

Summary/Conclusions: Our study shows that minimal disseminated disease is seen in more than one-fourth of cases (28.8%) of T-LBL with <25% blasts in PB and BM. This underlines the importance of flowcytometry evaluation of bone marrow in cases with <25% blasts identified by morphology. The identification of minimal disseminated disease in T-LBL is important as studies have shown inferior event free survival in T-LBL with minimal disseminated disease as compared to patients without minimal disseminated disease.

MINIMAL DISSEMINATED DISEASE DETECTION BY FLOWCYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA

G.K. Viswanathan1, P. Tembhare1, N. Patkar1, S. Gujral1, P.G. Subramanian1

1Hematopathology Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Tata Memorial Centre (TMC), Mumbai, India

Background: T-cell acute lymphoblastic lymphoma (T-LBL) with minimal disseminated disease (MDD) is defined as the presence of T-LBL with <25% blasts in the peripheral blood (PB) and/or bone marrow (BM) by morphology and the presence of immunophenotypically abnormal T-lymphoblasts in bone marrow by flowcytometry. Published literature regarding the prevalence and clinical significance of this rare subgroup is sparse. In this study we analysed the presence of minimal disseminated disease in bone marrow in cases of T-LBL with <25% blasts in PB and BM using 8-10 colour flowcytometric immunophenotyping and evaluate the clinical and immunophenotypic features.

Aims: To evaluate the prevalence of minimal disseminated disease in bone marrow in cases of T-cell acute lymphoblastic lymphoma with <25% blasts in PB and BM using 8-10 colour flowcytometric immunophenotyping and evaluate the clinical and immunophenotypic features.

Methods: A retrospective analysis of 42 cases of T-LBL with predominantly lymphomatous presentation with <25% blasts in peripheral and bone marrow. The following parameters were taken into account including complete hemogram, peripheral blood examination, bone marrow morphology and immunophenotyping, CSF analysis, pleural fluid morphology and immunopheno-

Figure 1.

INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE III RANDOMIZED CONTROLLED TRIAL

G. Garcia-Manero 1, N. Short1, H. Kantarjian1, S. O'Brien1, F. Ravandi1, D. Thomas1, G. Garcia-Manero1, N. Daver1, G. Borthakur1, N. Jain1, M. Konopleva1, K. Sasaki1, N. Pemmaraju1, Y. Alvarado1, J. Jacob1, R. Garris1, P. Thompson1, J. Cortes1, E. Jabbour1

The University of Texas MD Anderson Cancer Center, Houston, Texas, The University of Texas MD Anderson Cancer Center, Houston, 2The University of Texas MD Anderson Cancer Center, Houston, 3The University of Texas MD Anderson Cancer Center, Houston, 4The University of Texas MD Anderson Cancer Center, Houston

Background: Older patients (pts) with acute lymphoblastic leukemia (ALL) have poor tolerance of intensive chemotherapy, and novel strategies are needed in this population. In pts with relapsed/refractory ALL, inotuzumab ozogamicin (InO), an anti-CD22 antibody-drug conjugate, has been shown to improve survival compared to salvage chemotherapy.

Aims: We designed a phase III trial to evaluate the safety and efficacy of low-intensity chemotherapy (mini-hyper-CVD) plus InO as frontline treatment for older pts with newly diagnosed ALL.

Methods: Pts ≥60 years of age with newly diagnosed Philadelphia chromosome-negative pre-B received mini-hyper-CVD (compared to hyper-CVAD: no anthracycline, 50% dose reductions of cyclophosphamide and dexamethasone, 75% dose reduction of methotrexate, 85% dose reduction of cytarabine). InO was given on day 3 of the first 4 cycles. The first 6 pts received InO at a dose of 1.3 mg/m2 for cycle 1 followed by 0.8 mg/m2 for cycles 2-4; pts 7-34 received 1.8 mg/m2 for cycle 1 followed by 1.3 mg/m2 for cycles 2-4. Due to concern for veno-occlusive disease (VOD), the protocol was amended so that pts 35+ received InO at a dose of 1.3 mg/m2 for cycle 1 followed by 1.0 mg/m2 for cycles 2-4. Ruxolitinib was given during the first 4 cycles in pts with CD20 expression ≥20%; all pts received IT chemotherapy prophylaxis with the first 4 cycles. Pts in CR after 8 cycles then received POMP maintenance for up to 3 years.
Results: Between 4/2012 and 12/2016, 47 pts have been treated, 4 of whom had received 1 cycle of prior therapy and were in CR at the time of enrollment. The median age was 68 years (range, 60-81), and median CD22 expression was 97% (range, 72-100%). Of 43 pts evaluable for response, 42 responded (ORR=98%). Best response was CR in 36 pts (84%), CRp in 5 (12%) and CRi in 1 (2%). MRD negativity by 6-color multiparameter flow cytometry was achieved in 31 of 41 evaluable pts (76%) on day 21 and in 44 of 46 evaluable pts (96%) within 12 weeks of treatment. The median follow-up was 24 months (range, 15-55 months). 3 pts (6%) underwent allogeneic stem cell transplantation (ASCT) in first remission. Of the 46 responders, 6 pts (13%) have relapsed. 16 pts have died, 1 due to resistant disease, 4 after relapse, 1 after ASCT and 10 in CR/CRp. 21 pts remain on treatment (consolidation, n=3; POMP maintenance, n=19), and 5 pts have completed all therapy. The 3-year continuous CR and OS rates were 72% and 54%, respectively. Compared to a historical cohort of 79 older pts treated at our institution with hyper-CVAD ± rituximab, mini-hyper-CVD+InO resulted in significantly improved OS (3-year OS rate: 54% vs 31%; median OS not reached versus 16 months; P=0.007).

Summary/Conclusions: Treatment was overall well-tolerated. The median times to platelet and ANC recovery in cycle 1 were 22 days (range, 11-91 days) and 16 days (range, 0-49 days), respectively. In cycles 2-8, the median times to platelet and ANC recovery were 22 days and 17 days, respectively. Prolonged thrombocytopenia (i.e. lasting >6 weeks) occurred in 37 pts (79%) at some point during therapy; 8 pts (17%) experienced prolonged thrombocytopenia during induction and 36 (77%) during 1 or more subsequent courses. Grade ≥3 transaminase elevation (n=15) was seen in 11 pts, grade ≥3 bilirubinemia in 8 (17%) and hemorrhage in 7 (15%). 4 pts (9%) developed VOD (1 after ASCT, 3 unrelated to ASCT).

Summary/Conclusions: The combination of InO with mini-hyper-CVD is safe and effective in older pts with newly diagnosed ALL, resulting in a promising 3-year CR and OS rate of 77% during 1 or more subsequent courses.

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy that is derived from plasmacytoid dendritic cell precursors. BPDCN tends to occur in elderly people with frequent skin involvement and is associated with an aggressive clinical course and a poor prognosis. Although optimized diagnostics and therapies should improve patient outcomes, the pathobiological and genetic aspects of BPDCN remain unclear.

Aims: We planned this study to identify a critical genetic event in BPDCN, which could provide better understanding of BPDCN pathogenesis.

Methods: We enrolled fourteen patients (five children and nine adults) with BPDCN who were treated in our institutions. We primarily performed RNA sequencing-based comprehensive transcriptome analysis with their samples at the onset to detect gene fusions. These results were then used as the basis for genetic validation studies and functional analyses with an exogenous expression model.

Results: We identified a recurring gene rearrangement that involved the MYB proto-oncogene in all five pediatric patients (100%) and four of nine adult patients (44%) with BPDCN. The resulting fusion genes included MYB-ZFAT (four patients), MYB-PLEKHO1 (three patients), MYB-OCPS (one patient), and MYB-MIR3134 (one patient), none of which have been previously reported to our knowledge. The translocations corresponding to these fusions were not detected by the metaphase analysis except in one patient with t(1;16), who harbored MYB-PLEKHO1. These fusion genes were detectable at diagnosis and relapse but not at remission. Fluorescence in situ hybridization (FISH) analysis efficiently detected the breaking apart of MYB in formalin-fixed, paraffin-embedded sections. Consequent to the rearrangement, the negative regulatory domain of MYB was truncated, leading to constitutive MYB transcriptional activation, as described in other malignancies.

Exogenous MYB-PLEKHO1 expression in HEK 293T cells led to the upregulation of several known downstream MYB targets. Gene set enrichment analysis also confirmed the activation of MYB target gene sets. The identified significantly upregulated genes included cell surface molecule-encoding genes such as NCAM1 (also termed CD56), CD68, S1PR1, and CXCR4, possibly providing targets for antibody-mediated anticancer therapies. We performed tumor-germline sequencing of paired tumor–germline sets. The identified significantly upregulated genes included cell surface molecule-encoding genes such as NCAM1 (also termed CD56), CD68, S1PR1, and CXCR4, possibly providing targets for antibody-mediated anticancer therapies. We performed tumor-germline sequencing of paired tumor–germline sets. The identified significantly upregulated genes included cell surface molecule-encoding genes such as NCAM1 (also termed CD56), CD68, S1PR1, and CXCR4, possibly providing targets for antibody-mediated anticancer therapies. We performed tumor-germline sequencing of paired tumor–germline sets.

Summary/Conclusions: We identified a high frequency of MYB rearrangements that promoted the MYB transcriptional activity in BPDCN. MYB split FISH analysis can constitute a valuable diagnostic tool for detecting MYB rearrangements. We expect that our findings provide critical insights regarding BPDCN pathogenesis and contribute to molecular biology-oriented diagnostic techniques and molecular-targeted therapies for this intractable malignancy.
Background: The branched chain amino acids (BCAAs) valine, leucine, and isoleucine are essential AA for the human body. The activity of BCAA metabolism involves several aspects of the function of the enzyme BCAA Transaminase 1 (BCAT1) have recently been associated with aggressiveness in several cancer entities. However, the mechanistic role of BCAT1 in this process remains uncertain.

Aims: To elucidate the mechanistic link between BCAT1 function and epigenetic deregulation in leukemia stem cells (LSCs) and consequences on clinical outcome.

Methods: High-resolution proteomics of LSCs, Knockdown and overexpression of BCAT1 in AML patient samples and AML cell lines, Gene set enrichment analysis, BCAAs tracing experiments, Xenotransplantations, Metabolomics, DNA methylation arrays, correlative and mechanistic link to clinical data sets.

Results: We performed high-resolution proteomic analysis of human acute myeloid leukemia (AML) stem cell (LSC) and non-LSC populations, which have been functionally validated by xenotransplantation into NSG mice, and we found the BCAA pathway enriched and BCAT1 overexpressed in LSCs. We show that BCAT1, which transfers α-amino groups from BCAAs to α-ketoglutarate (αKG), is a central player in regulating αKG homeostasis. To test its role in the branched boxyc acid (TCA) cycle αKG is an essential co-factor for αKG-dependent dioxygenases such as EGLN1 and the TET family of DNA demethylases. Knockdown (KD) of BCAT1 in leukemia cells caused accumulation of αKG resulting in HIF1α protein degradation mediated by EGLN1. This resulted in a growth and survival defect and abrogated leukemia-initiating potential. In contrast, overexpression (OE) of BCAT1 in leukemia cells decreased intracellular αKG levels and caused DNA hypermethylation. BCAT1(high) AML samples displayed a DNA hypermethylation phenotype similar to IDH1mut cases, in which TET2 is inhibited by the oncometabolite 2-hydroxylglutarate. High levels of BCAT1 were strongly correlated with αKG levels and IDH1(TET2)mut, but not IDH1(TET2)wt AMLs. Gene sets characteristic for IDH1mut AML were enriched both in IDH1(TET2)mut-BCAT1(high) patient samples and in BCAT1-CE leukemia cells. BCAT1(high) samples showed enriched RISC signatures for lncRNA and paired sample analysis revealed a significant increase of BCAT1 levels upon relapse of the disease.

Summary: In summary, BCAT1 reduces dioxygenase activity by limiting intracellular αKG, thus linking BCAA catabolism to HIF1α stability and DNA hypermethylation. Our results suggest the BCAA-BCAT1-αKG pathway as a therapeutic target to compromise LSC function in IDH wtTET2 wtAML patients.

P174
THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA
D. Papaiouannou1,*, A. Petri2, S. Terreri3, C. Thue3, S. Volinia4, P. Yan2, R. Bundshuh2, G. Singh5, S. Kauppinen2, C. Bloomfield1, D. Adrienne5, R. Garzon1
1Comprehensive Cancer Center, The Ohio State University, Columbus, United States, 2Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark, 3Institute of Genetics and Biophysics (IGB-ABT), National Council of Research (CNR), Naples, 4Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy, 5Department of Physics, Department of Chemistry & Biochemistry, Division of Hematology, Department of Internal Medicine, Center for RNA Biology, 6Department of Molecular Genetics, Center for RNA Biology, The Ohio State University, Columbus, United States

Background: Background: The prognostic significance of long non-coding RNA expression (lncRNAs) in older (>60 years) patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) was recently reported (Garzon et al., 2014). The IncRNA HOXB-AS3, which is embedded in the HOXB locus, is highly expressed in the AML cell line OCI-AML3, but not in healthy donors (Garzon et al., 2014). The lncRNA HOXB-AS3 was recently shown to be amplified among the IncRNAs that associated with mutated NPM1 (NPM1mut) in CN-AML.

Aims: Aims: Our aims were to evaluate the biologic significance of HOXB-AS3 expression in NPM1mut AML.

Methods: Methods: HOXB-AS3 expression profiling was performed by real-time PCR. Knock-down (KD) of HOXB-AS3 was performed in vitro and in vivo in a pt-derived xenograft (PDX) model with locked nucleic acid-modified gappers. Comparative proteomic analysis was conducted with a modified version of the RNA antisense purification (RAP) protocol (McHugh et al., 2015). Direct visualization of the HOXB-AS3 was performed using custom-designed Baseos and Feedbacken (Advanced Cell Diagnostics, Newark, CA) according to the manufacturer’s instructions.

Results: Results: Of 6 AML cell lines that were tested, only OCI-AML3 cells, which harbor NPM1mut, showed detectable levels of HOXB-AS3 expression. Five- and 3-prime Rapid Amplification of cDNA Ends (RACE) assays in OCI-AML3 cells identified a novel transcript previously annotated (NR_033201/NR_033203/ENST00000491264) and 1 novel variant of HOXB-AS3. NPM1mut pt samples exhibited higher expression of HOXB-AS3 compared to those with wild-type (WT) NPM1 (P<0.001) and healthy donors (P=0.001). In vitro KDO HOXB-AS3 led to decreased proliferation of OCI-AML3 cells, as measured by BrdU-based cell cycle analysis (S-phase average% in control vs KD: 24% vs 16%, P=0.02). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002). HOXB-AS3 KD in NPM1mut pt blasts (n=5) led to a decrease in the number of formed colonies by OCI-AML3 cells in colony-forming assays (P=0.002).
Summary/Conclusions: Conclusions: HOXB-AS3 is strongly associated with NPM1 mutations in AML. HOXB-AS3 interacts with EPB1 and NPM1 and regulates ribosomal biogenesis in the leukemic blasts. From a therapeutic standpoint, HOXB-AS3 constitutes a promising target, as in vivo anti-HOXB-AS3 treatment prolonged survival in a murine PDX model.

P175

A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA

D. Moujalled1,2,*, G. Pomilio1,2, C. Ghirardi3, D. Segal4, T.-C. Teh1,2, J. Salmon1,2, S. Rijal1, P. Lan4, L. Kraus-Berthier5, A. Roberts4, D. Huang5, A.L. Maragno5, G. Lessene6, O. Genest6, A. Wei7

1Australian Centre for Blood Diseases, Monash University, 2Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia, 3Oncology R&D Unit, Institut de Recherches Servier, Croissy Sur Seine, France, 4The Walter and Eliza Hall Institute, Melbourne, Australia, 5Oncology R&D Unit, Institut de Recherches, Croisy Sur Seine, France

Background: Identification of a chemotherapy-free option for acute myeloid leukemia (AML) represents a highly desired and important research objective. Perturbation of cell survival is an essential hallmark of cancer now amenable to precision targeting by small molecule BH3-mimetics able to inhibit pro-survival BCL-2 (e.g. S63845) and BCL-XL (e.g. S55746) in AML cell lines (Lehar, Nat. Biotech 2009). (B) Dual BH3-mimetic targeting of BCL-2 and MCL1 represents a novel approach to treating AML without need for additional chemotherapy and with an acceptable therapeutic safety margin. Our results support the translational investigation of dual BH3-mimetic targeting of BCL-2 and MCL1 in the clinic for the treatment of patients with AML.

P176

THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA


1Medical and Molecular Genetics, King's College London, London, United Kingdom, 2Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway, 3School of Veterinary Medicine, University of Surrey, Guildford, 4Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff, 5Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London, United Kingdom, 6Helen Diller Comprehensive Cancer Center, University of California, San Francisco, United States

Background: Acute promyelocytic leukemia (APL) is driven by the oncogenic PML-RARα which is generated by fusion of the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARA) genes, and which strongly interferes with downstream signalling and the architecture of multiprotein structures known as PML nuclear bodies (NBs). NB disruption is a diagnostic hallmark of APL; however, the importance of this phenomenon has only been studied in vitro.

Aims: The aim of this study was to decipher the impact of Pml NB disruption in APL pathogenesis.

Methods: We engineered a knock-in mouse model with NB disruption achieved through mutation of key zinc-binding cysteine residues (C62A/C65A) in the PML Ring domain.

Results: While no leukemias or tumors developed in PmlC62A/C65A mice, the forced dimerization of RARα - mediated artificially by linking RARα to the dimerization domain of the NFκB p50 subunit - in cooperation with NB disruption was associated with doubling in the rate of leukemia (p<0.0001), with a reduced latency period (p=0.008). Moreover, response to targeted therapy with ATRA significantly improved survival of the PmlC62A/C65A-WT mice transplanted with PmlC62A/C65A-PmL-RARα leukemic blasts, but not with PmlC62A/C65A-P50-RARα, revealing the essential role of NBs for an effective response to differentiating drug. While formation of the PML-RARA fusion is considered an initiating event in APL pathogenesis, it is insufficient for the full leukemic phenotype. Moreover, whole exome sequencing analyses have consistently identified presence of cooperating mutations. Since Pml and Pml NBs have established roles in DNA repair and in the maintenance of genomic stability, we speculated that loss of NB integrity could affect these functions. Here, whole exome sequencing revealed a trend of higher genomic instability in PmlC62A/C65A mice compared to PmlWT.

Figure 1. (A) Loewe Score (0 → Additive, 1 → Weak Synergy, 2 → Synergy, 3 → Strong Synergy) in AML cell lines (Lehar. Nat. Biotech 2009). (B) LC50 of primary AML after 48h treatment (C) NS mice engrafted with MV4;11 AML and treated with i) vehicle, ii) S55746 100 mg/kg (x 4 wks), iii) S63845 50mg/kg IV (x 4 wks) or iv) combined S55746 and S63845. (D) CD45+ staining of NRGs sternums showing 2 representative examples of PDX AML one week after treatment with i) vehicle x5d, ii) S55746 100 mg/kg/d x 5d, iii) S63845 25mg/kg IV x 2d and iv) S55746+S63845.

A smaller fraction of AML samples were also sensitised to combined S55746+S63845, but not from treatment with either BH3-mimetic alone. Similar in vivo efficacy was observed with xenografted OCI-AML3 cells harboring mutant NPM1 and DNMT3A. Patient-derived xenografts showed rapid reduction of established AML in the bone marrow one week of treatment with S55746 and S63845 (Figure 1D). Safety and tolerability of this approach was confirmed using normal CD34+ stem and progenitor cells in short-term cell culture (48h) and long-term (2-3 weeks) clonogenic assays and from histological and immunohistochemical examination of mice receiving treated for up to 8 weeks at doses shown to be highly efficacious against AML.

Summary/Conclusions: Dual BH3-mimetic targeting of BCL-2 and MCL1 induces rapid and synergistic cytoreduction of human AML cell line and primary AML samples in vitro and in vivo across a diverse range of AML genotypes. We provide further support for the dual pharmacological approach that both dual pharmacological targeting of BCL-2 and MCL1 represents a novel approach to treating AML without need for additional chemotherapy and with an acceptable therapeutic safety margin. Our results support the translational investigation of dual BH3-mimetic targeting of BCL-2 and MCL1 in the clinic for the treatment of patients with AML.

Figure 1. (A) Loewe Score (0 → Additive, 1 → Weak Synergy, 2 → Synergy, 3 → Strong Synergy) in AML cell lines (Lehar. Nat. Biotech 2009). (B) LC50 of primary AML after 48h treatment (C) NS mice engrafted with MV4;11 AML and treated with i) vehicle, ii) S55746 100 mg/kg (x 4 wks), iii) S63845 50mg/kg IV (x 4 wks) or iv) combined S55746 and S63845. (D) CD45+ staining of NRGs sternums showing 2 representative examples of PDX AML one week after treatment with i) vehicle x5d, ii) S55746 100 mg/kg/d x 5d, iii) S63845 25mg/kg IV x 2d and iv) S55746+S63845.

A smaller fraction of AML samples were also sensitised to combined A1155463 and S63845 therapy. Bioluminescent imaging showed rapid and sustained clearance of xenografted MV4;11 AML (FLT3-ITD mutant and MLL re-arranged) cells, translating into significant prolongation of survival (Figure 1C) from combined S55746+S63845, but not from treatment with either BH3-mimetic-alone. Similar in vivo efficacy was observed with xenografted OCI-AML3 cells harboring mutant NPM1 and DNMT3A. Patient-derived xenografts showed rapid reduction of established AML in the bone marrow one week of treatment with S55746 and S63845 (Figure 1D). Safety and tolerability of this approach was confirmed using normal CD34+ stem and progenitor cells in short-term cell culture (48h) and long-term (2-3 weeks) clonogenic assays and from histological and immunohistochemical examination of mice receiving treated for up to 8 weeks at doses shown to be highly efficacious against AML.

Summary/Conclusions: Dual BH3-mimetic targeting of BCL-2 and MCL1 represents a novel approach to treating AML without need for additional chemotherapy and with an acceptable therapeutic safety margin. Our results support the translational investigation of dual BH3-mimetic targeting of BCL-2 and MCL1 in the clinic for the treatment of patients with AML.

Figure 1. (A) Loewe Score (0 → Additive, 1 → Weak Synergy, 2 → Synergy, 3 → Strong Synergy) in AML cell lines (Lehar. Nat. Biotech 2009). (B) LC50 of primary AML after 48h treatment (C) NS mice engrafted with MV4;11 AML and treated with i) vehicle, ii) S55746 100 mg/kg (x 4 wks), iii) S63845 50mg/kg IV (x 4 wks) or iv) combined S55746 and S63845. (D) CD45+ staining of NRGs sternums showing 2 representative examples of PDX AML one week after treatment with i) vehicle x5d, ii) S55746 100 mg/kg/d x 5d, iii) S63845 25mg/kg IV x 2d and iv) S55746+S63845.
of Pml Nb to the effectiveness of DNA damage repair processes, and the manner in which their disruption mediated by the PML-RARα oncoprotein can assist APL pathogenesis.

P177

DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENESIS

D. Roder1, 2, B. Swarz1, Z. Swarz2, 3, S. Knöl1, J.-H. Klaussmann1, D. Heckl1, 2
1Pediatric Hematology & Oncology, 2Experimental Hematology, 3Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Background: Loss of function mutations in EZH2 (including the chromosomal abnormalities -7/-7q) and other PRC2 subunits have been identified in adults with MDS, MPN and AML. Moreover children with JMML and up to 30% of children with Down syndrome related AML present with mutations in PRC2 subunits. Since myeloid neoplasms are elicited by accumulation of cooperating mutations and the study of isolated mutations are unlikely to unveil the molecular processes guiding transformation, we set out to decipher the oncogenic network guided by loss of PRC2-activity.

Aims: Through identification of collaborating mutations driving AML with loss of PRC2 function followed by molecular profiling we aimed to identify novel collaborating mutations.

Methods: To model the complex interplay of mutational networks we performed CRISPR-Cas9 screenings with oncogenic/tumor suppressor pools in vitro and in vivo. Cellular resources generated were subjected to mutational and molecular profiling. Results: To this end, a 96-well based CRISPR-Cas9 immortalization assay allowing fast and quantifiable genetic cooperation screenings was established. Four out of six CRISPR-Cas9 pools tested—comprised of five genes each and representing 148 mutation combinations—reproductively transformed LSK cells was achieved. The results of our screening and a newly established in vitro CRISPR-Cas9 immortalization assay for high throughput screening of sgRNA pools, delivered potential cooperating partners of EzH2 loss in AML and provides rich cellular resources to identify molecular mechanisms of oncogenic synergies and dependencies.

P178

Abstract withdrawn.

P179

ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTILINEAGE ENGRAFTED MICE

B.R.M. Saeed1, 2, L. Manta1, S. Raffel1, 2, P.T. Pyl3, W. Wang1, V. Eckstein1, A. Trumpp2, W. Huber3, A.D. Ho1, C. Lutz1
1Pediatric Hematology & Oncology, 2Experimental Hematology, 3Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Background: Mutations in genes that haven't been described in AML yet. Tracking of these mutations in various non-leukemic cellular compartments including HSC and leukemic HSC. To reconstruct the sequence of pre-leukemic mutations single-cell HSC were seeded and the resulting colonies analyzed for the presence of the respective leukemic specific mutations. Based on the different mutational data, combined with the cellular context in which these were detectable the leukemic evolution of most patients could be reconstructed. In one patient we detected a DMNT3A mutation in myeloid and lymphoid cells, whereas NPM1 and FLT3-ITD mutations were only detectable in leukemic cells proving the pre-leukemic status of DMNT3A in this case. In another patient we found NPM1 and IDH2 in T- and B-cells whereas Trisomy 8 and a STAG2 deletion were only detectable in leukemic cells. By analyzing colonies from single cell HSC we were able to detect complex pre-leukemic hierarchies with one example in which a ZNF536 mutation could be identified as initiating event that hasn't been described in leukemia yet.

Summary/Conclusions: WES can identify leukemia specific mutations including mutations in genes that haven't been described in AML yet. Tracking of these mutations in various non-leukemic cellular compartments including HSC and multi-lineage engrafted mice allows reconstruction of the individual leukemic evolution. A better understanding of these processes may pave the way for new treatment strategies with the aim to target the relevant leukemic mutations.

P180

THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EP C2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A 'COMPLEX' STORY

M. Mannion1, 2,*, X. Huang1
1Paull O'Gorman Leukaemia Research Centre, 2Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow, United Kingdom

Background: The Enhancers of Polycomb (EPC) proteins EPC1 and EPC2 are required for the survival of MLL-rearranged acute myeloid leukemia (AML). Most importantly, loss of EPC1 or EPC2 in MLL leukemia stem cells, but not normal hematopoietic stem cells and progenitor cells, leads to the induction of cellular apoptosis. To date little is known about the functional contribution of EPC1 and EPC2 in AML. EPC1 and EPC2 are two major chromatin modifying complexes encompassing opposing epigenetic activities and both are known to be deregulated in AML. AML is a disease biology is complex and understanding the contribution of the homologous chromatin regulatory proteins EPC1 and EPC2 in AML in search for novel therapeutic targets.

Methods: Mass spectrometry (MS) analysis was performed on immunoprecipitated protein using EPC1 antibody from human THP1 MLL-AF9 AML cell line. Chromatin immunoprecipitation (ChIP) was performed using HighCell ChIP Kit and iPure kit v2 (Diagenode) followed by NextSeq500 Illumina sequencing in THP1 cells. ChIP enriched regions were identified using SICER peak calling and ChiPpeakAnno. Lentiviral supernatants were prepared and THP1 cells were infected with viral particles containing pLKO.1 puro lentiviral vectors expressing shRNAs. RNA was extracted 72 hr following lentiviral transductions and whole transcriptome sequencing was performed. DESeq2 was used for differential expression analysis.

Results: MS analysis identified the core N44 complex components (TIP60, ING3, RUVBL1, RUVBL2, EP400 and DMAP1) and also revealed additional components. A comparison of the interacting proteins with the PML-RARα oncoprotein can assist APL pathogenesis.
Acute myeloid leukemia - Biology 2

P181

STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX

R. Karjalainen1,2,3, M. Popa4, M. Liu1, K.K. Jawarappa1, M. Kontro2,4, A. Parsons1, K. Porrka1, K. Wennerberg1, E. McCormack1,2, B.T. Gjertsen1, C.A. Heckman1
1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland, 2Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway, 3Hematology Research Unit Helsinki, University of Helsinki, 4Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, 5Department of Internal Medicine, Haukeland University Hospital, Bergen, Norway

Background: The bone marrow (BM) microenvironment is known to protect AML cells from drug therapy. We showed earlier that conditioned medium (CM) from the BM stromal cell line HS-5 increased cell viability and led to resistance to specific drug classes.

Aims: Here, we investigate the mechanisms stimulating the BM stromal cell induced resistance to venetoclax and its reversal by ruxolitinib.

Methods: Phospho-flow analysis was done by stimulating AML patient cells with GM-CSF, G-CSF, IL-6, IL-8 or MIP-3α (10 ng/mL) for 20 min, after which the cells were stained with Alexa 647-anti-phospho-Stat5 (pY694), PE188 CF594-anti-phospho-Stat3 (pY705), BV421-anti-phospho-Akt (pS473) and PE-anti-phospho-Erk1/2 (pT202/pY204). For co-culture and transwell assays AML cells were added directly to MSCs from AML patients or separated by a 0.4 μm pore membrane. Vehicle (DMSO), ruxolitinib (300 nM), venetoclax (100 nM) or their combination were incubated for 48h and AML cells labeled with PE-Annexin V, 7AAD, PE-Cy7-CD34, BV605-CD45. In vivo drug efficacy was tested on NSG mice inoculated i.v. with MOLM-13 K5AML cells. Mice were divided into control, venetoclax (25 mg/kg, i.p.), ruxolitinib (50 mg/kg BM), and combination groups (all n=6) and treated for 3 weeks, 5 days a week with 2 days off.

Results: To identify the factors contributing to BM mediated drug resistance of AML cells, we analyzed the effect of IL-6, IL-8, MIP-3α, GM-CSF and G-CSF, cytokines enriched in the HS-5 CM, on proliferation of MNCs collected from AML patients. GM-CSF and to some extent G-CSF alone conferred resistance to venetoclax similar to CM that we showed earlier to reduce sensitivity to BCL2 inhibitors. To identify the impact of stroma-derived factors on cellular signaling we stimulated AML patient cells with CM and analyzed the phosphorylation of STAT3, STAT5, ERK and AKT. Compared to control conditions, CM rapidly induced phosphorylation of STAT5 in primary AML cells. When the effect of individual cytokines was tested, we noted that GM-CSF and G-CSF alone could mimic the effect of CM on cellular signaling. Gene expression data showed the receptor for GM-CSF (CSFR2A) is more highly expressed in AML patient cells compared to healthy controls. Taken together, these results show that cytokines such as GM-CSF from BM stromal cells increase JAK/STAT signaling, which may lead to enhanced survival of AML cells. To determine whether the protective effect of stroma on BCL2 inhibition was dependent on cell-to-cell interactions we cultured AML patient cells either in direct contact with BMSCs or separated from stroma with a 0.4 μm pore membrane. 48h treatment with 100 nM venetoclax did not result in significant reduction of CD34+ AML cells regardless of whether AML cells were directly cultured with stroma or separated by a membrane, further indicating that stroma-derived soluble factors are sufficient to reduce sensitivity to venetoclax. Since the most abundant cytokines secreted by HS-5 cells, GM-CSF and G-CSF led to increased phosphorylation of STAT5, a downstream effector of JAKs, we tested a combination of venetoclax and JAK1/2 inhibitor ruxolitinib. We found that ruxolitinib potentiated sensitivity to venetoclax when tested with AML patient cells in HS-5 CM and in co-culture and transwell assays. Significantly, the combination was more effective at reducing tumor burden in a xenograft mouse model of AML than either drug alone.

Summary/Conclusions: In conclusion, our data demonstrate that BM secreted soluble factors drive cytoprotection against BCL2 antagonist venetoclax that can be overcome by combined blockade of JAK/STAT and BCL2 pathways with ruxolitinib and venetoclax in ex vivo co-culture models and in vivo in an AML mouse model.

P182

IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING

F.G. Rücker1, X. Gong1, A. Dolnik1, M. Hoyos1, S. Grasediek1, J. Biscocho2, T. Blätte1, J. Swoboda1, A.S. Pollack2, A. Turciano1, H. Döhner1, K. Döhner1, J.R. Pollack2, L. Bullinger1
1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany, 2Department of Pathology, Stanford University, Stanford, United States

Background: Acute myeloid leukemia with complex karyotype (CK-AML), defined as having ≥3 acquired cytogenetic aberrations in the absence of WHO-designated recurring translocations or inversions, represents about 15% of
adult AML cases. Despite having poor outcomes, CK-AML is the least understood of the molecular subtypes, except for the finding that about two-thirds of cases carry TP53 alterations. In particular, because cytogenetic alterations appear to be distinct among different patients, it is unclear whether they are cause of leukemogenesis, or merely reflect a state of genomic instability.

**Aims:** We have hypothesized that cytogenetic aberrations in CK-AML create gene fusions that are not recurrent across patients, nonetheless deliver cancer genes that contribute to leukemogenesis in individual patients.

**Methods:** We performed a transcriptome analysis using Illumina paired-end (101bpX2) RNA sequencing of 65 CK-AML cases to identify gene fusions using multiple independent algorithms (as paired reads that flank, or single-reads that span fusions) that are not recurrent across patients, and identified gene fusions in part independently validated by array-based genomic profiling and/or long range PCR performed by use of long-read Oxford Nanopore sequencing technology.

**Results:** We identified 54 gene fusion events in 30 of the 65 cases (46%) with up to four fusions per case. All fusions are supported by 10-50+ junction-spanning reads, and most are independently validated by genome-wide breakpoints from array-based genomic profiling and/or long range PCR, respectively. About 35% of the fusions were in-frame, encoding chimeric proteins. The remained encode either C-terminally truncated 5' fusion partners, or else N-terminally truncated (or rarely full-length) 3' fusion partners that we observed in the 5' partner contributed only the 5'UTR. In many instances, the fusions are predicted to lead to the overexpression or chimeric activation of known or putative novel cancer genes. Of the 54 fusions, only three (RUNX1-MECOM, MN1-ETV6, and ETV6-MN1) were previously reported in AML. The most frequently affected genes were RUNX1 (n=6), KMT2A, and MECOM (n=5 each). Identified gene fusions were classified into six functional fusion clusters. Many of the fusions contained at least one known AML gene (n=16; e.g. RUNX1, MECOM, DEK, ETV6, KMT2A) together with a novel fusion partner, clearly suggesting pathogenic relevance. Other fusions were predicted to disrupt known tumor suppressors (n=4; e.g. TP53) or to activate known oncogenes (n=3; e.g. MYB). Others encoded chimeric proteins of unclear pathogenic relevance, but that could nonetheless encode novel epitopes created by the fusion junction (n=26).

**Summary/Conclusions:** Detailed molecular characterization of CK-AML revealed a high incidence of novel gene fusions in about 50% of cases. The affected genes suggest a more general role in leukemogenesis than reflecting a state of genomic instability. Furthermore, identifying gene fusions in each individual patient might lead to more effective, personalized treatments that target the gene fusion itself, enable immunologic therapies against the fusion junction epitopes, and provide private patient-specific biomarkers to track leukemic burden for the monitoring of disease remission and relapse.

**P183**

H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENOMIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE

S. Carbone1,2,3,4, P. Ferrando4, J. Verweij5, F. Bertsch6,7, L. Pappino1, N. Seigneurin2, N. Vey1,2,3, E. Duprez2,3,4,1,2
1Hematology, Paoli-Calmettes Institute, 2INSERM 1068, Cancer research center, 3Aix-Marseille University, 4Oncology, 5Cell therapy facility, Paoli-Calmettes Institute, Marseille, 6Hematology, Toulouse Cancer University Institute, Toulouse, France

**Background:** NPM1 mutation (NPM1mut) is the most frequent genetic alteration found in cytogenetically normal acute myeloid leukemia (CN-AML). Patients harboring NPM1mut without FLT3 internal tandem duplication (FLT3-ITD) are considered to have favorable outcome. Yet, some of them relapse and become resistant to chemotherapy. Little is known about biological processes underlying treatment failure. Our group previously described a new epigenetic biomarker corresponding to an abnormal gain of the repressive H3K27me3 histone mark within the HIST1 locus on the 6p22 region as H3K27me3high. This epigenetic biomarker had an impact on clinical outcome as CN-AML patients with H3K27me3 HIST1 high had a higher overall survival (OS) and leukemia-free survival (LFS) than H3K27me3 HIST1low patients (Tiben et al., 2015).

**Aims:** We studied the impact of H3K27me3 HIST1 in an NPM1mut CN-AML cohort. Firstly, we asked whether H3K27me3 HIST1 could help to define NPM1mut CN-AML patients independently of known genetic alterations. Secondly, we studied gene expression profile (GEP) related to H3K27me3 HIST1 to explore biological pathways associated with treatment failure.

**Methods:** Blood or bone marrow samples with at least 70% blast involvement collected from 2017 to 2021. H3K27me3 HIST1 high and low patients were recovered from the Paoli-Calmettes Cancer Institute Biobank and analyzed as training set. A validation set of samples collected during the conduct of two GOELAMS clinical trials (LAM2006IR and LAM2007SA) was used for validation. We performed H3K27me3 HIST profiling by chromatin immunoprecipitation followed by quantitative polymerase chain reaction (qPCR). We generated a training set of samples with very high and low gene expression of H3K27me3 HIST1 by qPCR in primary AML samples. We then sequenced frequently mutated genes in AML (FLT3, CEBPO, DNMT3A, IDH1, IDH2, MLL, EZH2, TET2, P53, WT1 and ASXL1). GEP was done on Affymetrix whole-transcript DNA microarray and we used gene set enrichment analysis (GSEA, Subramanian et al., 2005) along with the Gene Ontology database as statistical methodology.

**Results:** We pooled the 103 samples of patients with NPM1mut CN-AML of the training and validation sets together. Median age was 60 (37-76) and median leucocyte count was 76 G/L (10-352). ChiP-QPCR Profiling identified 74 H3K27me3 HIST1high and 29 H3K27me3 HIST1low patients. FLT3-ITD was found in 33 (43%) of H3K27me3 HIST1high and 18 (38%) of H3K27me3 HIST1low patients. We confirmed that H3K27me3 HIST1high was associated with higher 5-year OS and LFS rates: 37% and 44% versus 17% and 19% (p=0.005 and .01) for the H3K27me3 HIST1high and the H3K27me3 HIST1low patients, independently of other genetic alterations. Combining our biomarker with FLT3 mutational status, we identified two subgroups of patients with very different outcome: 49% and 56% versus 18% and 18% (p=0.004 and .01) for the H3K27me3 FLT3wt HIST1high and the FLT3mut H3K27me3 HIST1low patients, respectively (Figure 1). We performed GEP for 27 NPM1mut patients (12 H3K27me3 HIST1low and 15 H3K27me3 HIST1high). GSEA analysis revealed a strong enrichment in immune functions and leukocyte activation in the H3K27me3 HIST1high group, evolving differentiated AML. While H3K27me3 HIST1low samples had GSEA associated with chromatin remodeling factors and DNA replication. Considering only FLT3wt patients, the H3K27me3 HIST1low subgroup had a gene expression signature characterized by a high expression level of genes from the HIST1 cluster which expression is known to be upregulated during S-phase of cell cycle.

**Summary/Conclusions:** The biomarker H3K27me3 HIST1 high is correlated with a better LFS and OS in NPM1mut CN-AML patient, independently of other known genetic alterations in particular FLT3-ITD. The worse outcome of FLT3-ITD-H3K27me3 HIST1low patients is concomitant with high expression of replication-dependent HIST1 genes that could explain treatment failure.

**P184**

FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS AND INHIBITION BY KINASE INHIBITORS

K. Tarbock1,2, T.A. Hylland2, J.A. Pollard2, M.E. Hansen3, R. Ries2, S. Siewal2, S. Meshinchi1
1Hematology/Oncology, Seattle Children’s Hospital, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 3Pediatric Hematology/Oncology, Maine Medical Center, Portland, 4University of Rochester, Rochester, 5Arog Pharmaceuticals, Dallas, United States

**Background:** Somatic mutations in FLT3 are among the most common events in AML, with FLT3-ITD mutations in the juxtaparamembrane domain (JMD) as well as D835 missense mutations in the kinase domain (KD) the predominant events. Sequencing of FLT3 in a cohort of 788 children with de novo AML treated on the Children’s Oncology Group (COG) protocols demonstrated that in addition to the previously described FLT3 mutations (ITD and D835), numerous other variants, including several novel variants, were present in 8% of patients at diagnosis, leading to a cumulative FLT3 mutation prevalence of 27% in children and young adults. These variants mostly occurred in the JMD and ITD regions, and were present in 8% of patients who might be amenable to FLT3 inhibitor therapy.

**Aims:** We evaluated the oncogenic capability of each of these mutations by assessing their ability to result in aberrant FLT3 and STAT5 phosphorylation, as well as response to the tyrosine kinase inhibitors crenolanib and quizartinib.

**Methods:** Point mutations were introduced into HEK293 cells using retroviral transduction. Following transduction, phosphorylation status of FLT3 (pFLT3) and downstream STAT5 (pSTAT5) were evaluated by immunoblotting. Phosphorylation status was quantified by chemiluminescence analysis and the quan-
lity of protein expression was normalized to actin. That ratio of phosphorylated protein to total protein for FLT3 and STAT5 was determined and normalized to that observed in the D835Y mutation as a positive control. A value of >10% pFLT3 was considered positive. All mutations that resulted in FLT3 phosphorylation were subsequently evaluated for inhibition by crenolanib and quizarinib following 60-minute exposure to the compounds.

Results: A total of 24 non-ITD and non-ALM AML FLT3 mutations were evaluated for autonomous FLT3 and STAT5 phosphorylation. Eleven mutations resulted in pFLT3 and pSTAT5, including 4 mutations with >50% pFL3. All mutations that demonstrated aberrant pFL3 also had aberrant pSTAT5, however a direct correlation of pFLT3 and pSTAT5 was not always observed. Overall, 87% (n=86 patients) of all non-ITD mutations evaluated resulted in autonomous FLT3 activation. Excluding D835 mutations, 64% (n=39) of patients harbored an activating mutation. Many of the mutations that were not found to be activating had the lowest prevalence, often present in only one patient. Evaluation of inhibition of mutant FLT3 phosphorylation demonstrated that in every case of aberrant activation, crenolanib resulted in potent inhibition of phosphorylation of FLT3 and STAT5 with an IC50 range of 1.3-13.9 nM and 0.6-6.5 nM respectively. Many of the mutations tested were exclusively sensitive to crenolanib, with 9 of 10 mutations tested demonstrating an IC50 of pFLT3 inhibition ≥5.6 nM. Inhibition of downstream kinases is necessary for optimal efficacy of any FLT3 inhibitor and phosphorylation of STAT5 was potently inhibited by crenolanib in all cases. Quizarinib inhibited pFL3 and pSTAT5 with an IC50 range of 1.8-15.1 nM and 1-33.9 nM respectively, demonstrating less effective inhibition specifically at mutations including DB35Y, D839E, N676K, M664I.

Summary/Conclusions: We have previously presented that FLT3 mutations, including novel mutations in addition to the FLT3/ITD and D835, are prevalent in children and young adults with AML. Here we demonstrate that many of the non-ITD/D835 mutations also result in aberrant FLT3 phosphorylation and are amenable to inhibition by FLT3 inhibitors. Crenolanib resulted in potent inhibition of FLT3 and downstream STAT5 in all mutations tested. This data supports expanding the cohort of pediatric patients with activating FLT3 mutations who may benefit from FLT3 inhibitor therapy beyond those with FLT3/ITD.

P185
Abstract withdrawn.

P186
THE BCL-2 INHIBITOR VENETOCLAX INHIBITS NRF2 ANTIOXIDANT PATHWAY ACTIVATION INDUCED BY HYPMETHYLATING AGENTS IN ACUTE MYELOID LEUKEMIA
L.X.T. Nguyen1, A. Khahala1, E. Troade1, B. Kumar1, S. Forman1, G. Marcucci1, V. Pullarkat2
1City of Hope Medical Center, Duarte, United States, 2Hematology, City of Hope Medical Center, Duarte, United States

Background: The selective Bcl-2 inhibitor Venetoclax (ABT-199) has shown potent synergistic activity against Acute Myeloid Leukemia (AML) in preclinical and early clinical studies and impressive results have been achieved using the combination of hypomethylating agents (HMA) with venetoclax suggesting synergy between these agents.

Induction of Reactive Oxygen Species (ROS) is important for the cytotoxicity of various AML therapies including HMA. Induction of ROS by various cytotoxic therapies concurrently activates the Nrf2 antioxidant response pathway which in turn results in induction of antioxidant enzymes that neutralize ROS. Upon ROS induction, the transcription factor Nrf2 is released from its adaptor protein Keap1 in the cytoplasm whereby Nrf2 enters the nucleus and binds to antioxidant response element sequences in the promoters of various genes. Nrf2 pathway activation has been shown to mediate chemoresistance in various cancers including AML. Low ROS levels have been shown to be a hallmark of leukemia stem cells and are critical to their self renewal capacity. In this study, we examined whether Nrf2 inhibition is an additional mechanism responsible for the markedly enhanced antileukemic activity in AML seen with the combination of HMAs and venetoclax.

Aims: To determine the effect of venetoclax on ROS levels after HMA exposure in AML cells and to examine the effect of Bcl-2 inhibition on NRF2 antioxidant pathway activation in response to HMA

Methods: The effect of combination of venetoclax and HMA on ROS levels and apoptosis was measured by flow cytometry. Effect of venetoclax and HMA on Nrf2 nuclear translocation was analyzed by immunostaining after cellular fractionation. Effect of venetoclax treatment on the association of Bcl2 with Nrf2 was examined in cell lines that demonstrated increased nuclear translocation of Nrf2 (Figure 1) and induction of downstream antioxidant enzymes including HO-1 and NQO1. Immunofluorescence studies confirmed the inhibition of nuclear translocation of Nrf2 by venetoclax. Immunoprecipitation studies indicated that Bcl-2, Keap1 and Nrf2 associate in a protein complex in the cytoplasm and that treatment with venetoclax leads to dissociation of Bcl-2 from the Nrf2/Keap1 complex and targets Nrf2 to ubiquitination and proteasomal degradation.

Results: A total of 24 non-ITD and non-ALM AML FLT3 mutations were evaluated for autonomous FLT3 and STAT5 phosphorylation. Eleven mutations resulted in pFLT3 and pSTAT5, including 4 mutations with >50% pFL3. All mutations that demonstrated aberrant pFL3 also had aberrant pSTAT5, however a direct correlation of pFLT3 and pSTAT5 was not always observed. Overall, 87% (n=86 patients) of all non-ITD mutations evaluated resulted in autonomous FLT3 activation. Excluding D835 mutations, 64% (n=39) of patients harbored an activating mutation. Many of the mutations that were not found to be activating had the lowest prevalence, often present in only one patient. Evaluation of inhibition of mutant FLT3 phosphorylation demonstrated that in every case of aberrant activation, crenolanib resulted in potent inhibition of phosphorylation of FLT3 and STAT5 with an IC50 range of 1.3-13.9 nM and 0.6-6.5 nM respectively. Many of the mutations tested were exclusively sensitive to crenolanib, with 9 of 10 mutations tested demonstrating an IC50 of pFLT3 inhibition ≥5.6 nM. Inhibition of downstream kinases is necessary for optimal efficacy of any FLT3 inhibitor and phosphorylation of STAT5 was potently inhibited by crenolanib in all cases. Quizarinib inhibited pFL3 and pSTAT5 with an IC50 range of 1.8-15.1 nM and 1-33.9 nM respectively, demonstrating less effective inhibition specifically at mutations including DB35Y, D839E, N676K, M664I.

Summary/Conclusions: We have previously presented that FLT3 mutations, including novel mutations in addition to the FLT3/ITD and D835, are prevalent in children and young adults with AML. Here we demonstrate that many of the non-ITD/D835 mutations also result in aberrant FLT3 phosphorylation and are amenable to inhibition by FLT3 inhibitors. Crenolanib resulted in potent inhibition of FLT3 and downstream STAT5 in all mutations tested. This data supports expanding the cohort of pediatric patients with activating FLT3 mutations who may benefit from FLT3 inhibitor therapy beyond those with FLT3/ITD.

P187
UNRAVELING EPigenOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML
C. Wiggers1,2, M. Baak1, M. Creyghton1, M. Bartels2
1Hubrecht Institute, 2Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands

Background: In comparison with pediatric acute lymphoblastic leukemia, pediatric acute myeloid leukemia (AML) is characterized by a high relapse rate (~30%), and lower overall survival rates of 60-70%. It is therefore crucial to increase our insights in pathophysiological mechanisms underlying AML relapse, including chemotherapy resistance, clonal evolution, and clonal selection. There is increasing evidence that epigenetic deregulation is involved in the initiation and progression of cancers, including adult AML. Epigenetic regulation involves the activity of non-coding regulatory DNA elements such as enhancers, which interact with promoters to fine-tune gene expression. Importantly, epigenetic signatures at enhancers are highly cell state specific. Since little is known concerning the epigenetic landscape of pediatric AML, it is crucial to gain more insights into the epigenome of relapsed and non-relapsed AML in children.

Aims: To identify differential epigenomic regulatory pathways involved in AML relapse by exploring the epigenome of relapsed (RP) and non-relapsed pediatric AML patients (NRP).

Methods: The epigenome of 20 AML patients, harboring known molecular aberrations (including MLL-rearrangement, CBF-related and Fli3-ITD), was analyzed in triplicate using the dually marked active regulatory markers Chromatin-Immunoprecipitation-sequencing (ChIP-seq) experiments. Additionally, single-cell RNA-seq data were generated for selected AML patients to analyze clonal heterogeneity.

Results: All genomic regions that were significantly enriched by H3K27ac were analyzed, resulting in ~30.000 active promoters and enhancers per sample. Genome-wide Pearson correlation of all enriched regions showed subclustering of patients based on molecular aberration. Interestingly, epigenomic analysis showed that the initial diagnosis (Dx) and the patient’s relapse (Rel) sample were highly correlated. Also, single-cell RNA-seq analysis identified two highly identical homogeneous populations at Dx and Rel. Following the fact that no major differences were observed between AML cells at diagnosis and relapse, NRPCs were analyzed. Here striking differences in H3K27ac enrichment were observed in MLL-rearranged patients between NRPs and RPs. Enhancers and promoters were differentially enriched at diagnosis, of which Sphk1, a kinase involved in proliferation and survival, was significantly more enriched in RPs, while the promoter of transcription factor ELF1 and nearby located enhancers were active in NRPs only.

Figure 1.

Summary/Conclusions: In conclusion, inhibition of Nrf2 pathway may explain the marked potentiation of HMA activity by venetoclax that is observed in clinical trials. We show that ROS induction at least partially mediates the cytotoxicity of HMA and ROS induction after HMA treatment is augmented by venetoclax. We demonstrate for the first time that venetoclax is a potent inhibitor of Nrf2 activation via disruption of the association between Nrf2, Keap-1 and Bcl-2.
Summary/Conclusions: Analysis of promoters and especially enhancers is a highly useful approach to identify cell state specific regulation. Here, we analyzed pediatric AML patients at diagnosis and at relapse to gain more insight into specific cell states which are involved in relapse. Our data revealed high similarity between diagnosis and relapse samples, while, strikingly, in the WHO intermediate-risk group containing MLL-rearranged patients, differential epigenomic regulation was observed between NRPs and RPs. Taken together, our preliminary data suggests that already at diagnosis, AML cells display an epigenetic fingerprint associated with the development of AML relapse during the course of disease. We are currently validating these data.

MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RARA AGONIST, WITH HYPOMYTHERALY OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS
M. Mckeown1, K. Austigen2, C. Fiores2, E. Lee1, D. Smith1, C. Fritz3, T. Lodiego1, E. Di Tomaso1, E. Olson2
1Translational Medicine, 2Biology, Syros Pharmaceuticals, Cambridge, United States

Background: FLT3 internal tandem duplication (ITD) mutations account for ~20-25% of adult AML cases and are associated with worse prognosis. Although FLT3 inhibitors show clinical activity, relapse occurs quickly. Venetoclax is a potent, selective inhibitor of the anti-apoptotic protein BCL-2 that demonstrated monotherapy activity in relapsed/refractory AML (ORR 19%); however, no activity was seen in FLT3 mutant cases (Konopleva, Can Disc and RBCS1186; P190). The combination of the anti-apoptotic proteins BCL-XL, BCL-2, and MCL-1, but not BCL-2, and FLT3 inhibition synergizes with the dual BCL-2/BCL-XL inhibitor ABT-737 in vitro in FLT3-ITD+ cells (Kohl, Leukemia 2007).
Aims: Expression of BCL-XL and MCL-1 are known resistance factors to venetoclax, therefore targeting pathways that regulate BCL-XL or MCL-1 in combination with venetoclax may enhance cell death and improve efficacy. Based on this hypothesis, we interrogated if selective inhibition of BCL-2 by venetoclax in combination with quazartinib, a potent FLT3 inhibitor, resulted in synergistic anti-tumor effects in FLT3-ITD+ AML models.
Methods: FLT3-ITD+ (Molm13 and MV4;11) and wild type (HL60 and OCIAML2) cell lines were evaluated in vitro. Preliminary antitumor effects measured by cell titer glo and apoptosis by Annexin V staining. In vivo efficacy was determined in a MV4;11 xenograft model.
Results: Sensitivity to venetoclax was initially assessed in vitro. Dose dependent growth inhibition and induction of apoptosis was observed in the MV4;11, Molm13 and HL60 cell lines following 48hr venetoclax treatment, with the MV4;11 cell line most sensitive. Modulation of BCL-2, BCL-XL and MCL-1 expression by FLT3 inhibition was determined following 8-24hr treatment with quazartinib. Quazartinib reduced BCL-XL and MCL-1 protein, but not BCL-2, in the FLT3-ITD+ cell lines. Quazartinib had no affect on expression of these three proteins in the FLT3 wt cell lines SY-1425 could induce sensitivity to the anti-CD38 therapeutic antibody daratumumab (DARA).
Aims: We sought to investigate mechanistically informed combinations of SY-1425 in biomarker dependent and with potential novel agents in AML and MDS patients (Phase 2 study, NCT02807558). Based on the RARα mediated myeloid gene activation of SY-1425, epigenetic priming with hypomyelinating agents (HMA)s and CD38 induction were explored.
Methods: HMA synergy was tested in vitro in AML cell lines over a range of concentrations for SY-1425 and azacitidine. In vivo studies used a disseminated patient derived xenograft (PDx) model of AML expressing high levels of RARA. SY-1425 induction of CD38 was assessed by Hk327ac ChiP-seq, RARA ChiP-seq, and RNAseq. Antibody dependent cell-mediated cytotoxicity (ADCC) was tested in an ex vivo co-culture model of human NK cells and AML cell lines.
Results: SY-1425 acts as a repressive transcription factor until bound by SY-1425 leading to potent, targeted activation of myeloid genes. HMAs can further prime this activation by depleting repressive methylation of these target genes. The combination of SY-1425 and azacitidine showed synergy in RARA-high AML cell lines, but not in RARA-low AML cell lines, with combination indices less than 0.5. Co-administration in a RARA-high AML PDx demonstrated superior reduction of tumor burden (<1% detectable tumor cells) vs either treatment alone over 16 weeks (63% vs 41% in SY-1425 alone and 8% with azacitidine). Various combination regimens evaluated in the PDx model over two cycles (56 days) found that 1 week of azacitidine followed by 3 weeks of SY-1425 maximized for anti-tumor activity (<5% AML cells in periphery, bone marrow and spleen) and tolerability (<8% weight loss). RARα binds directly to the CD38 locus and induces Hk327 acetylation, promoting Hk327ChiP-seq enrichment of the modified H3K27ac mRNAs transcripts in RARA-high models. SY-1425 treatment of four RARA-high AML cell lines and three RARA-high primary AML patient samples induced cell surface CD38 to high levels comparable to those of DARA sensitive multiple myeloma cells. In contrast, no CD38 induction was observed in RARA-low cell lines. SY-1425 in vitro only RARA-high AML cell lines treated with SY-1425 and DARA were six fold more sensitive to NK cell mediated ADCC compared to single agent controls and exhibited a 5-10 fold increase in NK cell-dependent activation measured by IFNγ secretion.
Summary/Conclusions: This in vitro combination is highly promising and should be explored further in a clinical trial. We are currently planning a clinical trial to test the combination of SY-1425 and azacitidine in AML patients who have not had a response to frontline chemotherapy.
Acute myeloid leukemia - Clinical 1

P191
ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM: STAGE 1 AND STAGE 2 RESULTS
N. Pemmaraju1, K. Sweet2, A. Lane3, A. Stein4, S. Vasu5, W. Blum5, D. Rizzieri6, E. Wang7, M. Duvic1, J. Chen8, S. Shmeshi4, P. McDonald6, C. Brooks6, J. Lance1, H. Kantarjian1, M. Konopleva1
1MD Anderson Cancer Center, Houston, TX, 2H. Lee Moffitt Cancer Center, Tampa, FL, 3Dana-Farber Cancer Institute, Boston, MA, 4City of Hope National Medical Center, Duarte, CA, 5The Ohio State University Medical Center, Columbus, OH, 6Duke University Medical Center, Durham, NC, 7Roswell Park Cancer Institute, Buffalo, NY, 8Sterling Therapeutics, New York, New York, United States

Background: SL-401 is a targeted therapy directed to interleukin-3 receptor α (CD123), a target overexpressed on a variety of cancers including blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive malignancy with poor outcomes and unmet medical need.

Aims: This Phase 2 trial is a single-arm, open-label, study designed to generate efficacy and safety data to support potential registration in BPDCN.

Methods: In this ongoing Phase 2 single-arm trial, patients with BPDCN (n=32) or relapsed/refractory (R/R) AML (n=48) received SL-401 as a daily IV infusion at 7, 9, 12, or 16 ug/kg/day for days 1-5 of a 21-day cycle in stage 1. In stages 2 and 3, patients received SL-401 at the dose determined in stage 1.

Results: 32 adult BPDCN patients received SL-401 in stage 1 (n=9) and stage 2 (n=23), including 19 first-line and 13 R/R patients. Stage 3 patients will be reported separately. Median age was 72 years (range: 30-85 years). In stage 1, 12 ug/kg was the highest tested dose for BPDCN; MTD was not reached in BPDCN. Median follow-up was 4.3 months (range: 0.5-22.9 months). ORR of 84% (27/32) was observed in all patients: 90% (18/19) in first-line and 69% (9/13) in R/R. 88% (14/16) of first-line patients treated at 12 ug/kg had a complete remission (CR) (n=10), CR with incomplete hematologic recovery (CRi) (n=1) or clinical CR (CRC; residual skin disease) (n=3) based on investigator assessment. 56% (9/16) of these patients were progression free for 4 to 22.9 months (ongoing), including 3 patients on SL-401 in remission (4 to 18 months, ongoing) and 7 patients who were bridged to stem cell transplant (SCT; 3 auto-SCT and 4 allo-SCT). A R/R patient was also bridged to allo-SCT. Overall, most common ≥Grade 3 treatment-related AEs were transaminase elevation (22%) and thrombocytopenia (16%). Safety precautions, including daily monitoring of albumin and body weight during study drug infusions, have been implemented to minimize risk of severe capillary leak syndrome (CLS). Three patients had Grade 5 CLS: BPDCN (7 ug/kg); R/R AML (16 ug/kg); BPDCN (12 ug/kg) out of 118 patients who received SL-401 across all trials and regimens; 3/89 (3.4%) patients of which were enrolled in this clinical trial.

Summary/Conclusions: SL-401 continues to demonstrate single agent activity, including multiple CRs, in patients with BPDCN, with 25% (8/32) of patients bridged to SCT after a major response from SL-401. SL-401 side effect profile consists largely of transaminitis and thrombocytopenia. CLS can be fatal. Side effects have generally tended to decrease in frequency and severity with increasing cycles. Updated data, including detailed safety analysis across all ongoing SL-401 studies will be presented at the meeting.

P192
PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
K. Takahashi1, F. Wang1, K. Patel1, C. Bueso-Ramos1, G. Issa1, X. Song1, J. Zhang1, C. Gumbs1, F. Ravandi2, T. Kadia1, N. Daver1, C. DiNardo1, M. Konopleva1, M. Andreeff1, J. Cortes1, G. Garcia-Manero1, E. Jabbour1, A. Furtreal1, H. Kantarjian1
1Leukemia, UT MD Anderson Cancer Center, Houston, United States

Background: Persistence of somatic mutations at the time of complete remission (CR) was associated with poor outcome in patients (pts) with AML.

Aims: To analyze differential pattern of mutation clearance based on the genes with affected pathway and to assess prognostic impact of mutation clearance in AML patients.

Methods: We studied 95 pts with AML who were treated with frontline induction and subsequently achieved CR. We sequenced pre-treatment and CR bone marrow samples by targeted capture sequencing of 295 genes (median 280x coverage). We defined 3 levels of mutation clearance (MC) based on variant allele frequency (VAF): 1) MC2.5, persistent mutation with VAF≥2.5%, 2) MC1.0, persistent mutation with VAF<1%, and 3) complete mutation clearance (CMC).

Results: In the pre-treatment samples, we detected 597 mutations in 78 genes in 87 (92%) patients. In the matching CR samples, 62 (10%) and 82 (14%) mutations persisted at VAF≥5% and ≥1%, respectively, which corresponded to 43 (49%), 34 (39%), and 30 (34%) patients achieving MC2.5, MC1.0 and CMC, respectively. Table 1 shows the differential patterns of MC based on the mutations and pathways. Mutations associated with clonal hematopoiesis of
indeterminate therapy (CHIP), DNA methylation, and splicing pathways had low rate of MC, whereas mutations in transcription factors or receptor tyrosine kinase (RTK) had high rate of MC. Pts who achieved MC 1.0 (median 31.2 vs 12.5 months, P=0.04) or CMC (median 31.2 vs 12.5 months, P=0.049) had significantly better relapse-free survival (RFS).

Table 1.

<table>
<thead>
<tr>
<th>Gene</th>
<th>MCL0 (%)</th>
<th>MCL1 (%)</th>
<th>MCL2 (%)</th>
<th>Pathway</th>
<th>MCL0 (%)</th>
<th>MCL1 (%)</th>
<th>MCL2 (%)</th>
<th>Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNMT3A</td>
<td>21%</td>
<td>17%</td>
<td>14%</td>
<td>CHIP-associated</td>
<td>33%</td>
<td>24%</td>
<td>22%</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>100%</td>
<td>97%</td>
<td>94%</td>
<td></td>
<td>39%</td>
<td>35%</td>
<td>33%</td>
<td></td>
</tr>
<tr>
<td>TET2</td>
<td>15%</td>
<td>55%</td>
<td>55%</td>
<td>RTK pathway</td>
<td>88%</td>
<td>87%</td>
<td>86%</td>
<td></td>
</tr>
<tr>
<td>IDH1</td>
<td>100%</td>
<td>99%</td>
<td>98%</td>
<td>Erythroid Factors</td>
<td>87%</td>
<td>85%</td>
<td>84%</td>
<td></td>
</tr>
<tr>
<td>CDCA8</td>
<td>100%</td>
<td>89%</td>
<td>89%</td>
<td>Chromatin-remodeling</td>
<td>67%</td>
<td>58%</td>
<td>49%</td>
<td></td>
</tr>
<tr>
<td>IDH2</td>
<td>38%</td>
<td>44%</td>
<td>38%</td>
<td>Splicing</td>
<td>33%</td>
<td>17%</td>
<td>17%</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Somatic mutations associated with CHIP, DNA methylation, and splicing pathways persisted frequently in CR samples suggesting preleukemic origin. Pts with deeper MC had significantly better RFS. Somatic mutation clearance may help risk prediction of AML.

P194

IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS

U. Borate1,*, B. Wilmot1, B. Norris1, P. Lo1, D. Bottomly1, S. McWeeney1, J. Tyner1, A. Agarwal1
1Oregon Health & Science University, Portland, United States

Background: RUNX1 plays a vital role in leukemogenesis through its interaction with core binding factor-β complex and other genes involved in hematopoiesis (1,2). Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is linked to germline RUNX1 mutations (3). This autosomal dominant disorder is characterized by thrombocytopenia and potential for transformation to AML. AML patients with somatic RUNX1 mutations have a poor prognosis (6,7) independent of other risk factors. The role of co-occurring mutations in leukemogenesis in FPD/AML patients with germline RUNX1 mutations and AML patients with de novo somatic RUNX1 mutations is not fully understood.

Aims: In order to further characterize co-occurring mutations in patients with both germline and somatic RUNX1 mutations, we analyzed a large cohort of AML tumor samples along with several paired normal tissue samples.

Methods: We sequenced a cohort of 482 diagnostic bone marrow or peripheral blood samples from AML patients by deep whole-exome sequencing. Samples were collected through the "Beat AML" project, an ongoing program at Oregon Health & Science University in collaboration with the Leukemia & Lymphoma Society. RUNX1 mutations were classified using VarScan which defined somatic and germline mutations as follows: somatic if p <0.1 and germline if not called as somatic and normal variant allele frequency >0.1.

Results: Twenty AML samples had 21 germline RUNX1 mutations with a total of 6 different germline variants; 31 other patient samples had 38 somatic RUNX1 mutations with 31 unique somatic variants. One sample had 2 RUNX1 germline mutations; 6 samples had >1 somatic RUNX1 mutations. The most common germline variant, missense mutation p.L56S, was found in 16% (76/434) of the cohort. RUNX1 mutations were classified as known and novel. Significantly, the germline variants occurred mutually exclusive of the somatic variants. Out of 20 patients with germline RUNX1 mutations, 16 had co-occurring known pathogenic mutations in AML-related genes. Most significantly, 62% (10/16) and 51% (14/27) of patients with germline or somatic RUNX1 mutations, respectively, had 7 co-occurring AML-related pathogenic mutations that were exclusive to their cohort (Table 1). Both germline and somatic RUNX1 mutational cohorts had 12 overlapping co-occurring mutations. The most common mutations, for both groups, were in FLT3 (14/43), ASXL1 (8/43), and IDH2 (7/43) (Table 1). Patient demographics and treatment-related outcomes were similar for both cohorts.
Table 1.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Frequency</th>
<th>Negative</th>
<th>Positive</th>
<th>Two Positive</th>
<th>Three Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD25</td>
<td>92%</td>
<td>7%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>CD96</td>
<td>85%</td>
<td>15%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>CD123</td>
<td>90%</td>
<td>10%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>CD34</td>
<td>70%</td>
<td>30%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The incidence of RUNX1 mutations seen in our 482-patient Beat AML cohort (4.3% germline, 6.4% somatic) is consistent with results from other studies (8). Our study suggests that germline and somatic RUNX1 mutations in AML patients are mutually exclusive, as are several co-occurring pathogenic mutations that contribute to leukemogenesis. Our study adds to the already described mutually exclusive mutations in germline RUNX1 by identifying WT1, CHEK2, CCND3, and others. Similarly, in samples with somatic RUNX1 mutations, we found mutually exclusive mutations in CBL, JAK2, MLL, EZH2, and others in addition to the previously described IDH1 (8). Further characterization of these results and analyses of additional samples using our whole-exome sequencing and our bioinformatics platform will help us better elucidate the molecular events underlying AML progression and help us establish novel prognostic/therapeutic markers aimed at early intervention in patients, or their family members, who carry RUNX1 mutations.

P195

Abstract withdrawn.

P196

MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA

T. Yabushita1, Y. Shimomura1, D. Kato1, Y. Ono1, N. Hiramoto1, S. Yoshikawa1, N. Yonetani1, A. Matsushita1, H. Hashimoto2, T. Ishikawa1
1Hematology, Kobe City Medical Center General Hospital, 2Hematology, Institute of Biomedical Research and Innovation Hospital, Kobe City, Japan

Background: Acute myeloid leukemia (AML) is believed to originate from a small population of leukemic stem cells (LSCs). Current chemotherapy regimens target the majority of more mature leukemic blasts, but cannot efficiently eliminate LSCs, resulting in early treatment failure and relapse. Thus, the expression of LSC-specific markers could be used as a predictive factor of clinical outcomes in AML patients. Recently, the clinical impact of individual LSC markers has been documented in several reports, but the combined effect of different LSC markers remains unexamined.

Aims: This study aimed to estimate the prognostic impact of the expression of multiple LSC markers on the outcome of AML patients.

Methods: Ninety consecutive patients diagnosed with de novo AML at our institution and eligible for intensive chemotherapy were enrolled from September 2010 to March 2016. We excluded 10 patients with acute promyelocytic leukemia. This study was approved by the institutional review board of the Ethics Committee and complied with the Declaration of Helsinki. We analyzed the expression of three LSC markers, CD25, CD96, and CD123, in de novo AML patients. The expression of these markers on gated leukemic blasts was evaluated using 6-color flow cytometry. When over 20% of leukemic blasts were positive for any marker, the sample was defined as positive for that marker. We stratified de novo AML patients into two groups: LSCHigh was defined as positivity for two or three LSC markers, and LSCLow was defined as negativity for all markers or positivity for a single LSC marker. The primary endpoint was overall survival (OS). The secondary endpoint was progression-free survival (PFS). OS and PFS were estimated using the Kaplan-Meier method, and assessed using the log-rank test. Multivariate analysis using Cox proportional hazard ratio was performed for OS and PFS.

Results: The median follow-up for patients still alive at the end of the study was 38.9 months (range: 1.5-64.8 months). The median patient age was 60 years (range: 17-78 years). There was no statistical significance between LSCHigh patients (n=30) and LSCLow patients (n=50) in sex, age, laboratory data, NPM1 mutation, or European Leukemia Net karyotype risk group. FLT3 mutation was associated with the LSCHigh group (p=0.003). Three-year OS and PFS were significantly better in the LSCHigh group than in the LSCLow group (Figure 1) (OS: 65.0% vs 18.2%, p<0.001; PFS: 49.3% vs 19.4%, p<0.001). In multivariate analysis, controlled for age and karyotype (Table 1), being in the LSCHigh group was an independent prognostic factor for OS (hazard ratio: 3.17; 95% CI: 1.64-6.15; p<0.001) and PFS (hazard ratio: 2.25; 95% CI: 1.24-4.08; p<0.007). Three-year OS and PFS were significantly better in the LSCHigh group than in the LSCLow group (Figure 1) (OS: 65.0% vs 18.2%, p<0.001; PFS: 49.3% vs 19.4%, p<0.001). In multivariate analysis, controlled for age and karyotype (Table 1), being in the LSCHigh group was an independent prognostic factor for OS (hazard ratio: 3.17; 95% CI: 1.64-6.15; p<0.001) and PFS (hazard ratio: 2.25; 95% CI: 1.24-4.08; p<0.007). Being in the LSCHigh group had incremental value for OS compared with the karyotype risk (Harrell's C index: 0.80 vs 0.70; p=0.028). Moreover, this classification based on LSC marker expression allowed subgroups with unfavorable prognosis to be identified among patients in the intermediate karyotype risk group (3y-OS 54.6% vs 14.5%, p=0.013), as well as those in the favorable karyotype risk group (3y-OS 94.1% vs 50.0%, p=0.021).

P197

NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA

V. Mcclain1,*, A.R. Carson1, B.A. Patay1, L. Chamberlain1, C. Chander1, S. Zheng1, W. Huang1, O. Kiya1, D. Hubbard2, D. Caguioa2, Z. Xie1, J. Thornes2, T. Stenzel1, J. E. Miller1,2
1Invivoscribe, 2LabPMM LLC, San Diego, United States

Background: Many personalized therapies for acute myeloid leukemia (AML) have been developed targeting specific biomarkers. Unfortunately, the efficacies of these therapies are inconsistent, while the need to determine successful therapies prior to patient relapse is critical. Minimal residual disease (MRD) monitoring can help determine effective treatments and predict potential relapse. While there are now several MRD tests available on the market, most target single or small numbers of biomarkers, which can limit detection of residual AML heterogeneity. Thus, full characterization of a sample may require testing with multiple MRD assays, which can be impractical in a clinical setting. We have developed a targeted capture-based assay (MyMRD™), which allows characterization of the entire therapeutic AML biomarker repertoire and can inform...
the molecular remission status of a patient’s malignancy. This targeted panel can identify the mutations in driver clones that cause relapse in ~90% of all AML patients, as well as common drivers in myeloid proliferative neoplasms (MPN) and myelodysplastic syndromes (MDS).

**Aims:** To establish a sensitive and reliable targeted NGS assay to comprehensively detect and monitor the majority of known driver mutations in AML and myeloid malignancies.

**Methods:** Whole genome libraries, made from DNA extracted from cell lines and clinical samples, were hybridized with MyMRD probes targeting mutation hotspots in 23 genes associated with AML. In addition to single nucleotide variants (SNVs) and indels in 21 of these genes, 5 structural variant (SV) breakpoints that are commonly targeted. Enriched libraries were sequenced with the MiSeq® platform and analyzed using proprietary Invivoscribe (IVS) MyInformatics™ software. To validate mutations detected by the MyMRD assay, samples were additionally tested with IVS developed capillary electrophoresis (CE) assays and NGS-based assays targeting common mutations in FLT3 and NPM1.

**Results:** The linearity and limit of detection (LOD) of the MyMRD assay were assessed using data generated from contrived cell line DNA containing known AML driver mutations with a range of variant allele frequencies (VAFs). The assay shows strong linearity (R²=0.96 – 0.99) in the entire range of tested VAFs (0.01% – 99%). Overall, we established a LOD of 0.5% for >95% of the targeted sites in the assay with lower LODs for specific mutations of interest (e.g. 0.1% for a 30bp FLT3 ITD and 0.2% for FLT3 p.D835Y). In addition, using clinical samples the MyMRD assay shows excellent concordance with the standard FLT3 CE assay for variants with VAFs above the CE detection threshold (5%). Sanger sequencing was the only method actually covering the entire coding region of CEBPA. Both NGS amplicon-based panels failed to fully cover the coding region of the gene, and therefore have likely missed mutations. Crucially, even when any of the three methods detected more than one variant, cloning studies confirmed biCEBPA mutations only in a fraction of the cases. In summary, none of the amplicon-based tested methods can reliably determine if multiple mutations affect two different alleles; therefore biCEBPA mutations would still need additional confirmation. We are currently exploring the ability of capture-based NGS approaches coupled to appropriately tailored bioinformatic analysis of sequencing data to detect biCEBPA mutations.

**P198:** IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?

M. Hernandez-Mercado¹,²,³, M.J. Larroyo², I. Vazquez³, A. Mañu³, F.J. Gracia-Aznare³, M. Calasanz³

¹Biomedical Engineering, School of Engineering, University of Navarra, ²Molecular Oncology, Biodonostia HRI, Donostia University Hospital, San Sebastian, ³Haematology and Haemotherapy, Clinic of the University of Navarra, Pamplona, Spain

**Background:** CEBPA encodes a leucine zipper transcription factor that is important for normal myeloid cell differentiation. Biallelic CEBPA (biCEBPA) mutations are associated with favourable prognosis in patients with acute myeloid leukaemia (AML); therefore, accurate molecular testing of this gene is crucial in the clinical setting. Molecular pathology labs routinely analyse CEBPA through fluorescence-based multiplex-PCR fragment analysis or, more frequently, Sanger sequencing. Lately, it is increasingly common to use next-generation sequencing (NGS) technology in the pathology labs, and CEBPA gene is indeed included in the majority of NGS panels commercially available for testing of patients with neoplasias of the myeloid lineage.

**Aims:** We set ourselves to compare the performance of two different NGS targeted panels to detect CEBPA molecular aberrations, with a particular focus on biCEBPA mutations.

**Methods:** DNA specimens from 173 myeloid cases were subjected to Sanger (n=92) or to NGS (n=81) sequencing, including the TruSight Myeloid Sequencing Panel (illumina) (n=59), and the IonAmpSeq AML Community Panel (thera-capt) (n=34). Both NGS panels are designed to cover CEBPA through overlapping amplicons (6 or 9). However, we found that an average of 3.5 amplicons were covered <500x, and more worryingly, we realised that at least one of those amplicons was shallowly (<100x) covered in 97% of the cases. Indeed both panels showed significantly lower average coverage levels of this gene compared to the panel as a whole (Figure 1). This might not be surprising, since CEBPA is encoded within a CpG-rich region, and therefore its amplification needs tailored PCR conditions, hard to address in the multiplexed PCR step included in their library prep protocols. Therefore, both NGS approaches are prone to miss variants. In contrast, Sanger sequencing protocol (which includes optimized PCR conditions for correct amplification of the CEBPA gene) managed to cover the whole length of the gene. We were able to detect 26 variants affecting 20 AML cases through Sanger sequencing. Cases showing two variants were manually curated (through Chromas or IGV tools) to confirm if they affected different alleles. However, in 6 cases both mutations laid on different amplicons, which made not possible to univocally conclude if and how they are biallelic. These inconclusive cases were subjected to DMSO-PU-P PCR in order to amplify the whole length of CEBPA coding region, followed by cloning. Colony sequencing showed independent clones harbouring different variants (i.e. bona fide biCEBPA mutations) in the majority of the cases, but crucially, not in all of them. This result highlights the need of implementing techniques able to accurately assess CEBPA biallelism, others than plain calling of more than one variant.

**Summary/Conclusions:** IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS? Since AML patients with biCEBPA mutations have relatively favourable overall survival, it is important in the clinical setting to accurately assess CEBPA molecular status. In our study, we have tested the ability of three different assays to detect CEBPA mutations in 173 samples. Sanger sequencing was the only method actually covering the entire coding region of CEBPA. Both NGS amplicon-based panels failed to fully cover the coding region of the gene, and therefore have likely missed mutations. Crucially, even when any of the three methods detected more than one variant, cloning studies confirmed biCEBPA mutations only in a fraction of the cases. In summary, none of the amplicon-based tested methods can reliably determine if multiple mutations affect two different alleles; therefore biCEBPA mutations would still need additional confirmation. We are currently exploring the ability of capture-based NGS approaches coupled to appropriately tailored bioinformatic analysis of sequencing data to detect biCEBPA mutations.
(18–83 years). All patients were treated with standard induction and consolida-
tion protocols.

Results: Median time between two investigations was 2.8 months (range for all 0.1–115 months). A complete molecular remission was reached in 90/130 pts (69%) after a median of 5 months. 19/130 (14.6%) pts reached low level MRD and 20/130 (15.4%) high level MRD. Median event free survival (EFS) of patients with CMR was not reached (EFS at 2 years 82%). 16 (18%) of those patients relapsed in the course of follow up with a median time to relapse of 12.7 months (range 4.1 to 38.3 months). Median EFS for patients with CMR was not reached (EFS at 2 years 66%). The 7/130 (5%) patients with a <3 log fold reduction had a median EFS of 14.7 months (2 groups, p=0.017). A total of 59/185 patients received allogeneic SCT. Among the 130 patients diagnosed at our laboratory 34 (26%) received allogeneic SCT, 12 (9%) were transplanted in first CR and 17 (13%) were transplanted for relapse. Following allogeneic SCT 11/17 patients (65%) reached a second CR with CMR.

Summary/Conclusions: Our data shows that MRD testing is routinely per-
formed in RUNX1-RUNX1T1 AML outside of clinical studies. Defining MRD
levels by RUNX1-RUNX1T1/ABL resulted in a better classifier for high and low risk patients than log fold change. However, despite CMR 16/90 (18%) patients relapsed with a maximum time from first achievement of CMR of 38.3 months. We conclude that 1) MRD monitoring could serve to guide BMT deci-
sions in RUNX1-RUNX1T1 positive AML, 2) allogeneic BMT can rescue the majority of relapsed patients and 3) molecular monitoring can reliably identify patients with high risk for relapse.
Acute myeloid leukemia - Clinical 2

P200

NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELOPROLIFERATIVE SYNDROMES

G. Oyong-Bravo1, C. Benton1, T. Kadia1, F. Ravandi1, J. Cortes1, N. Daver1, K. Takahashi1, C. DiNardo1, E. Jabbour1, G. Borthakur1, N. Pemmaraju1, M. Konopleva1, A. Alfonso1, S. Pierce1, C. Bueso-Ramos2, S. Kornblau1, K. Patel2, H. Kantarjian1, M. Andreff2, G. Garcia-Manero1

1Leukemia, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Mutations in TP53 can be detected in up to 16-19% patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). TP53 mutations confer adverse prognosis irrespective of currently available therapies. The clinical impact of the type and number of TP53 abnormalities is unclear.

Aims: To evaluate the prognostic impact of the number of TP53 abnormalities in AML and MDS.

Methods: We evaluated 1401 patients with previously untreated AML or MDS treated at The University of Texas MD Anderson Cancer Center from 2012 to 2016. Sequencing data was obtained by use of a 28 or 53-gene targeted PCR-based next generation sequencing platform. Response was defined following 2003 IWG criteria for patients with AML and 2006 revised IWG criteria for patients with MDS. Generalized linear models were used to study the association of overall response (OR), complete response (CR) and risk factors, Kaplan-Meier produce limit method was used to estimate the median overall survival (OS).

Results: A total of 593 (42%) patients had MDS and 808 (56%) had AML. In a total of 984 (70%) patients, data on therapy with sufficient follow up and response evaluation was available, with 494 (35%) patients receiving therapy with hypomethylating agents (HMAs) and 373 (27%) with chemotherapy regimens. A total of 384 mutations in TP53, involving 208 unique mutations, were detected among 300 (21%) patients with R273H, R248W, Y220C and R175H being the most prevalent. Overall frequency of TP53 mutations was higher among patients with MDS (25%, n=146) compared to AML (19%, n=154) (p=0.012) with 251 (84%) of detected mutations happening in patients with complex karyotype (p<0.001). Among patients with TP53-mutant disease, 221 (74%) had 1 detectable mutation, 76 (25%) had 2 and 3 (1%) had 3. Additionally, 188 (13%) patients had TP53 deletions evidenced by presence of monosomy 17 or del(17p). In 167 (89%) of these patients, chr17 abnormalities were detected in the context of a complex karyotype and in 127 (42%) a co-occurring TP53 mutation was detected. Correlation between TP53 mutations and deletions (r=0.443, p<0.001) was observed with 172 (12%) patients having 1 TP53 abnormality. 169 (12%) of these patients had deletions. Patients with multiple detectable TP53 mutations were less likely to have co-occurring chr17 abnormalities (79% vs 22%, OR 0.28, CI 0.15-0.50, p=0.03). Median follow up was 8.6 months (range 0-167 months). Presence of a TP53 mutation adversely impacted OS (MDS: 12.4 vs 111.7 months, HR=5.98, CI 4.28-8.35, p<0.001; AML: 5.3 vs 16.9 months, HR=2.81, CI 2.26-3.50, p<0.001). Increasing number of TP53 abnormalities negatively impacted OS of patients with AML (Figure 1A) but not that of patients with MDS (Figure 1B). No difference in survival was observed between patients with two TP53 mutations and those with TP53 mutation+deletion (p=0.730). Presence and number of TP53 mutations did not predict for response (OR: 0.6 vs 63%, p=0.498; CR: 34 vs 36%, p=0.695) to HMAs, but was associated with significantly lower likelihood of response to intensive chemotherapy (OR: 41 vs 86%, p<0.001; CR: 33 vs 75%, p<0.001).

Summary/Conclusions: Presence of multiple TP53 abnormalities can be observed in up to 13% patients with AML and MDS. Second TP53 abnormalities more commonly involve TP53 deletions with additional TP53 mutations being less common and generally mutually exclusive with TP53 deletions. The number of TP53 abnormalities impacts the survival of patients with AML but not that of patients with MDS. Presence and number of TP53 mutations do not seem to impact response to HMAs but are associated with lower responses to chemotherapy.

P201

VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA-FRONTLINE (AML-FRONTLINE) VERSUS SECOND-Line (AML-SECOND): RESULTS FROM THE JAVELIN AML-101 STUDY

M. Konopleva1, A. Alfonso1, S. Pierce 1, C. Bueso-Ramos 2, S. Kornblau 1, M. O’Meara14, P. Ho14, A. Fathi15

1Department of Leukemia, MD Anderson, Houston, 2Gehr Family Center for Leukemia Research, City of Hope, Duarte, 3Hematologic Malignancy Program, Moffit Cancer Center, Tampa, 4Hematology, Memorial Sloan Kettering, New York City, 5Leukemia, John Theurer Cancer Center, Hackensack, 7Hematology, Fred Hutchinson Cancer Center, Seattle, 8Hematology and Oncology, Dana-Farber Cancer Institute, Boston, 9Hematology and Oncology, Huntsman Cancer Institute, Salt Lake City, 10Hematology and Oncology, Winship Cancer Institute, Atlanta, 11Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, 12Hematology and Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, 13Clinical Development, Seattle Genetics, Inc., Bothell, 14Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, United States

Background: Treatment of AML among the elderly is challenging. HMAs are commonly used, but yield suboptimal response rates and modest survival. Durations of response were difficult to achieve; in a study of MRD response by flow cytometry in patients treated with single-agent HMA therapy at MD Anderson Cancer Center, only 13/58 (22%) responding patients achieved minimal residual disease (MRD) negativity (F Ravandi, MD, unpublished data, Jan 2017).

Aims: To assess the safety and efficacy of vadastuximab talirine (VAD; SGN-CD33A; 33A) in a CD33-directed antibody conjugated to 2 molecules of a pyrrolobenzodiazepine (PBD) dimer. Upon binding, 33A is internalized and transported to the lysosomes where PBD dimer is released via proteolytic cleavage of the linker, crosslinking DNA, and leading to cell death.

Methods: Fifty-three patients (median age 75 years [range, 60-87]) were treated with VAD (per MRC); patients were either unfit for (40; 75%) or declined (13; 25%) intensive therapy. The median treatment duration is currently 19.3 weeks (range, 2-86) with 8 patients still on treatment; no DLTs were reported. Adverse events (AEs) ≥Grade 3 reported in ≥15% of patients were thrombocytopenia (55%), febrile neutropenia (49%), anemia (46%), neutropenia (42%), pneumonia (19%), and leukopenia (17%); no ≥Grade 4 bleeding events were observed.

Results: Fifty-three patients (median age 75 years [range, 60-87]) were treated with VAD (33A+HMA). Patients had a complex karyotype (39%); 19% of patients (7/37) had secondary AML (18/22, 82%), and age ≥75 years (18/26, 69%). Of all responding patients, 86 (86) with 8 patients still on treatment; no DLTs were reported. Adverse events (AEs) ≥Grade 3 reported in ≥15% of patients were thrombocytopenia (55%), febrile neutropenia (49%), anemia (46%), neutropenia (42%), pneumonia (19%), and leukopenia (17%); no ≥Grade 4 bleeding events were observed. Treatment-emergent (TE) liver lab elevations (≥Grade 3) were rare: ALT (8%), AST (2%), and total bilirubin (2%). Other non-heme TEAEs reported in ≥25% of patients regardless of relationship to study treatment were fatigue (60%), nausea (49%), constipation (43%), peripheral edema (42%), poor appetite (40%), dyspnea (34%), pyrexia (32%), diarrhea, vomiting (28% each), and dizziness (26%). Thirty- and 60-day mortality rates were 2% and 8%, respectively, with no treatment-related deaths reported. A total of 39/103 (38%) of doses were delayed due to AEs mostly from myelosuppression (neutropenia 18%, thrombocytopenia 7%, and febrile neutropenia 3%). High remission rates (37/49 (76%) CR+CRi) were maintained across adverse disease subsets including acute cytogenetics (16/18, 89%), TP53-mutated (6/7, 86%), secondary AML (18/22, 82%), and age ≥75 years (18/26, 69%). Of all responding patients, 19/37 (51%) achieved MRD negativity. Two patients went on to subsequent allo-HSCT, and no additional MDS/AML was observed. The median time to MRD-negative survival was 9.1 months (range, 0.1-19.4+ months) and OS continues to evolve with 15 patients (28%) alive (11.3 month median follow-up) (Figure 1).

Summary/Conclusions: 33A+HMA is well tolerated with a safety profile consistent with on-target myelosuppression. The CR+CRi rate of 76% and low early mortality in older AML patients with poor risk factors is particularly encouraging, and activity appears markedly improved compared to the historical experience of HMA monotherapy. The MRD clearance rate among responding patients who received 33A+HMA is higher than the rate observed with single
patients older than 60 years with IR-FMP AML had remarkable EFS of 36±3% and OS 54±10% at 8 years (Figure 1).

Figure 1.

P202

ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS


Background: Acute myeloid leukemia (AML) with intermediate-risk (IR) cytogenetics includes a substantial proportion of patients with favorable molecular profile (FMP), in which AML cells harbor the NPM1 mutation or CEBPA biallelic mutation without internal tandem duplication of the FLT3 gene (FLT3-ITD). The role of allogeneic hematopoietic transplantation (allo-HCT) in first complete remission (CR) in these patients remains controversial.

Aims: To analyze the results and prognostic factors of IR-FMP AML patients in a large series of patients treated by the Spanish CETLAM group.

Methods: Patients with primary AML diagnosed at 19 institutions from the Spanish CETLAM group and treated between 2003 and 2017. Induction chemotherapy included idarubicin and cytarabine (standard or intermediate-dose) in all cases, consolidation with intermediate or high-dose cytarabine (HDAC) and, depending on the protocol, additional HDAC, autologous or allogeneic hematopoietic transplantation.

Results: Two hundred-twenty-one patients were analyzed. Median age of the series was 54 years (range 18 to 72). 152 patients had an age up to 60 years and 69 (31%) were older. Median WBC count was 19±10×10⁹/l (range 0.55-282). One-hundred eighty-two patients had a normal karyotype and it was observed in only 2 patients of the NPM1+/FLT3-ITD- group (1%).

Two hundred eighty-one patients had NPM1 mutated and FLT3-ITD wild type (NPM1+/FLT3-ITD-) and 30 CEBPA biallelic mut/FLT3-ITD wild type (CEBPα+/FLT3-ITD-). There were significant differences in the main clinical or biological parameters in these two groups. The CR rate in the overall group was very high (92%) without significant differences between the two molecular groups. Chemo-resistance was observed in only 2 patients of the NPM1+/FLT3-ITD- group (1%). Death during induction was observed in 16 patients (7%), all of them with NPM1+/FLT3-ITD-. Induction results according to age were similar in both groups. Event-free survival and overall survival are reported at 8 years and were 52±8% and 70±4%, respectively. In univariate comparisons, better EFS and OS was observed in CEBPα+/FLT3-ITD- patients compared to those with NPM1+/FLT3-ITD- (p=0.03 and p=0.02, respectively). When analyzing post-transplantation treatment, patients treated with HDAC only had an excellent prognosis, even better than those receiving an autologous or allogeneic transplantation. One patient died in CR in the HDAC group, another in the autologous transplant group and 7 in the allo-HCT group (p<0001). In multivariate analysis of pretransplant characteristics, age up to 60 years and CEBPα+/FLT3-ITD- association to improved EFS (RR=0.42) and OS (RR=0.29). Interestingly, in a subgroup of 123 patients with data on MRD after consolidation chemotherapy (flow citometry, cut-off: 0.12%), positivity was associated with worse EFS (0.02).

Figure 1.

P203

GMI-1271, A POTENT E-SELECTIN ANTAGONIST, COMBINED WITH INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS WITH UNTREATED AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE


Background: The outcomes for elderly patients (pts) with acute myeloid leukemia (AML) remain poor due to limited tolerance of intensive cytotoxic chemotherapy and low response rate, therefore newer and less toxic therapies are urgently needed.

Aims: To analyze the results and prognostic factors of IR-FMP AML patients in a large series of patients treated by the Spanish CETLAM group.

Methods: Patients with primary AML diagnosed at 19 institutions from the Spanish CETLAM group and treated between 2003 and 2017. Induction chemotherapy included idarubicin and cytarabine (standard or intermediate-dose) in all cases, consolidation with intermediate or high-dose cytarabine (HDAC) and, depending on the protocol, additional HDAC, autologous or allogeneic hematopoietic transplantation.

Results: Two hundred-twenty-one patients were analyzed. Median age of the series was 54 years (range 18 to 72). 152 patients had an age up to 60 years and 69 (31%) were older. Median WBC count was 19±10×10⁹/l (range 0.55-282). One-hundred eighty-two patients had a normal karyotype and it was abnormal in 34 (5 patients no metaphases). One hundred ninety-one patients had NPM1 mutated and FLT3-ITD wild type (NPM1+/FLT3-ITD-) and 30 CEBPA biallelic mut/FLT3-ITD wild type (CEBPα+/FLT3-ITD-). There were significant differences in the main clinical or biological parameters in these two groups. The CR rate in the overall group was very high (92%) without significant differences between the two molecular groups. Chemo-resistance was observed in only 2 patients of the NPM1+/FLT3-ITD- group (1%). Death during induction was observed in 16 patients (7%), all of them with NPM1+/FLT3-ITD-. Induction results according to age were similar in both groups. Event-free survival and overall survival are reported at 8 years and were 52±8% and 70±4%, respectively. In univariate comparisons, better EFS and OS was observed in CEBPα+/FLT3-ITD- patients compared to those with NPM1+/FLT3-ITD- (p=0.03 and p=0.02, respectively). When analyzing post-transplantation treatment, patients treated with HDAC only had an excellent prognosis, even better than those receiving an autologous or allogeneic transplantation. One patient died in CR in the HDAC group, another in the autologous transplant group and 7 in the allo-HCT group (p<0001). In multivariate analysis of pretransplant characteristics, age up to 60 years and CEBPα+/FLT3-ITD- association to improved EFS (RR=0.42) and OS (RR=0.29). Interestingly, in a subgroup of 123 patients with data on MRD after consolidation chemotherapy (flow citometry, cut-off: 0.12%), positivity was associated with worse EFS (0.02).

Figure 1.

Summary/Conclusions: Patients with primary AML, IR cytogenetics and FMP have a good outcome. Best results are achieved in patients with CEBPα+/FLT3-ITD-, particularly if age is up to 60 years. In this subset, OS at 8 years is 96±7%, comparable to current results achieved in acute promyelocytic leukemia. Patients above 60 years treated intensively may achieve a long term survival of more than 50%. Chemotherapy without subsequent consolidation is a valid option. MRD monitoring after treatment has to be taken into account since in the subset of patients analyzed this was an independent prognostic factor for EFS.
Results: 24 pts have been enrolled to date and 17 are evaluable for response. The median age was 68 years (range, 60-79) with 58% male pts and 25% with high-risk cytogenetics (by SWOG). 50% (12/24) were pts with secondary AML (sAML), half of whom had prior hypomethylating therapy (50%; 6/12). This study had a rolling safety run-in and the first 3 pts had no DLT, allowing enrollment to proceed. Common Gr 3/4 AEs included febrile neutropenia (47%), pneumonia (20%), nausea (13%), and non-fatal respiratory failure (13%). 2 pts died of sepsis within 60 days. The remission rate (CR/CRi) was 12/17 (71%). CR/CRi rate was 75% for pts with de novo disease and 67% for pts with sAML. The PK profile in this elderly population was consistent with that of younger adults (median age <60 years) with similar AML. No drug-drug interactions were apparent. The median E-selig exposure at baseline was 29% (range, 2-67%) of blasts in the bone marrow.

Summary/Conclusions: The addition of a novel E-selectin antagonist, GMI-1274, to standard induction chemotherapy in untreated elderly pts with AML, including patients with secondary AML, demonstrates a high remission rate with acceptable side effect profile resulting in low induction mortality. This study compares favorably to previous studies (Lancet, ASCO 2016). E-selectin ligand was expressed on leukemic blasts in the majority of pts, therefore supporting its relevance as a target. A randomized trial is being planned.

P204

A PHASE 2 STUDY OF GLASDEGB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKAEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME

J.E. Cortes1, B.D. Smith2, E.S. Wang3, A. Merchant4, V.G. Oehler5, J.E. Cortes1,*, B.D. Smith2, E.S. Wang3, A. Merchant4, V.G. Oehler5,

Background: The addition of a novel E-selectin antagonist, GMI-1274, to standard induction chemotherapy in untreated elderly pts with AML, including patients with secondary AML, demonstrates a high remission rate with acceptable side effect profile resulting in low induction mortality. This study compares favorably to previous studies (Lancet, ASCO 2016). E-selectin ligand was expressed on leukemic blasts in the majority of pts, therefore supporting its relevance as a target. A randomized trial is being planned.

Summary/Conclusions: The addition of a novel E-selectin antagonist, GMI-1274, to standard induction chemotherapy in untreated elderly pts with AML, including patients with secondary AML, demonstrates a high remission rate with acceptable side effect profile resulting in low induction mortality. This study compares favorably to previous studies (Lancet, ASCO 2016). E-selectin ligand was expressed on leukemic blasts in the majority of pts, therefore supporting its relevance as a target. A randomized trial is being planned.

Summary/Conclusions: The addition of a novel E-selectin antagonist, GMI-1274, to standard induction chemotherapy in untreated elderly pts with AML, including patients with secondary AML, demonstrates a high remission rate with acceptable side effect profile resulting in low induction mortality. This study compares favorably to previous studies (Lancet, ASCO 2016). E-selectin ligand was expressed on leukemic blasts in the majority of pts, therefore supporting its relevance as a target. A randomized trial is being planned.

P205

CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKAEMIA CELLS


Background: Acute myeloid leukaemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Nevertheless, outcome for most patients is poor, and it is necessary to develop more effective treatment strategies. Our group showed that the inactivation of the tumor suppressor PP2A is a recurrent event in AML, and that overexpression of SET, an endogenous inhibitor of PP2A, is a poor prognostic factor in this disease. Furthermore, the anticancer activity of FTY720, a PP2A-activating drug (PPA) acting on its interaction with SET, FTYY720 is a relatively non-toxic drug currently used in patients with relapsing multiple sclerosis; however, this drug cannot be used in cancer patients due to its toxicity at the needed anti-neoplastic dose. Therefore, investigation of alternative agents for reactivation of PP2A is warranted.

Aims: To test the efficacy of CM942, a FTY720 analogue, on AML cell lines and primary patient samples, and investigate its mechanism of action.

Methods: AML cell lines and 29 de novo AML samples were analyzed by treatment with FTY720 and CM942, MTS (viability), apoptosis, cell cycle and PP2A activity assays, and western blot.

Results: CM942 exhibited notable cytotoxicity on all human AML cell lines with SET overexpression (n=10), but no effects on cell lines and primary samples (n=29) treated with CM942, providing mechanistic insights into the anti-tumor mechanism of this new molecule. Our analyses in primary AML samples showed that 7 out of 29 (24%) samples treated with CM942 had a significant reduction in proliferation. By western blot analyses we found that those patients responding to CM942 treatment had SET overexpression. Of note, treatment of peripheral blood mononuclear cells from healthy donors with CM942 had no effects on cell viability. Therefore, although FTY720 and CM942 have similar effects inhibiting cellular proliferation, CM942 was less toxic when assayed on normal peripheral blood cells.

Summary/Conclusions: CM942 inhibits growth of AML cells in both cell lines and primary patient samples, exerting its antileukemic effects through reactivation of PP2A activity. Although treatment with FTY720 was somewhat more effective than CM942 in primary samples of AML, fewer cytotoxic effects were observed after CM942 treatment in peripheral blood from healthy donors. Further experiments would be necessary to confirm the in vivo anti-tumor activity of CM942 in AML models. New compounds have been developed for the treatment of AML, although few have been translated into clinical practice; nevertheless, it is unlikely that any of these compounds, when used alone, will cure the disease, so combination strategies are imperative. Our results indicate that PADs may be a valid therapeutic option for AML, especially for treating leukemias characterized by SET-dependant inactivation of PP2A.
CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA

L. Manta1*, B. Saeed2*, A. Possolo3, P. Pyly*, T. Stiehl4, K. Barth-Miesala1, V. Eckstein1, W. Huber5, A.D. Ho1, C. Lutz1

1Department of Medicine V, University of Heidelberg, 2Multi-omics and statistical computing, European Molecular Biology Laboratory, 3Interdisciplinary Center for Scientific Computing & Institute of Applied Mathematics, University of Heidelberg, Heidelberg, Germany

Background: Clonal heterogeneity occurs in many cancers, including Acute Myeloid Leukemia (AML). In cases of relapse, chemotherapy has triggered clonal selection with minor or evolved sub-clones driving relapse. A better understanding of the underlying clonal architecture, the extent of genetic heterogeneity and its response to therapy is necessary to better understand mechanisms of therapy escape and relapse.

Aims: In this study we aim to define the clonal architecture of AML during the course of therapy and in leukemia propagating cells. In this study we aim to define the clonal architecture of AML during the course of therapy and in leukemia propagating cells.

Methods: We sequenced 12 AML samples at the time of diagnosis and in one case also at the time of relapse with at least 80% blasts per sample. 6/12 patients displayed a normal karyotype while the other 6 patients showed various cytogenetic abnormalities (inversion 16 (2), trisomy 8 (1), add(19)(p13.3) (1), complex aberrant karyotype (2)). Whole-exome sequencing (WES) was performed with the appropriate germ line controls. WES data were clustered using empirical Bayesian clustering.

Results: WES identified more than 3000 variants in total. By setting distinct filtration criteria (5% allelic frequency (AF) > 0.1 reads coverage), reads support of the detected variant, SIFT score < 0.05, and GMAF < 5%, 64 leukemia specific mutations were detected (2-18 mutations/AML). As expected, these included recurrently mutated genes like DNMT3A (in 4 patients), IDH1 and 2 (each in one patient), KIT and NRAS (both in 2 patients). Categorization of identified mutations showed that these mutations affected genes involved in various cellular processes including transcriptional regulation (15), cell differentiation (6), cell cycling (5), apoptosis/survival signals (5), proliferation (3), cell growth (3) and splicing (3). Empirical Bayesian clustering of all detected variants according to their respective AF resulted in 2-5 different clusters per AML.

Based on this cluster analysis we were able to predict the founding cluster/clone. Assuming that most of the mutations are heterozygous and considering the blast percentage at diagnosis, mutations of the biggest clusters present in every cancer cell and the mutations of the smaller clusters in tumor heterogeneity. Using a combinatorial approach, clonal selection with minor or evolved sub-clones driving relapse.

Summary/Conclusions: WES can identify leukemia specific mutations that are involved in various cellular functions including mutations that have been shown to be recurrently mutated in AML like DNMT3A. Sequencing data can also be used in combination with mathematical modelling approaches to reconstruct the clonal architecture of AML at the time of diagnosis and relapse allowing estimations of the clonal complexity at these time points.

TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE

K. Takahashi1, Y. Abaza1, F. Wang1, C. Gumbs1, S. Xingzh1, A. Futreal1, E. Alatal2, S. Khaled2, M. Arellano3, M. Patnaik4, E. Palmesino5, G. Garcia-Manero1

1University of Texas MD Anderson Cancer Center, Houston, 2Medical College of Wisconsin, Milwaukee, 3Stanford University, Stanford, 4City of Hope, Duarte, 5Emory University School of Medicine, Atlanta, 6Mayo Clinic, Rochester, United States, 7Helsinn, Pazzallo, Switzerland

Background: In a phase 2 study of 50 elderly patients (≥65 years) with AML who were not eligible for intensive chemotherapy, treatment with the investigational HDAC inhibitor pracinostat+azacitidine (AZA) was well tolerated and led to 42% complete remission (CR) rate and a median overall survival (OS) of 19.1 months (Blood 2016; 128:100). Responses were durable (median CR+CRi 17.2 months), blast clearance was rapid (median 8 weeks), and maximum clinical benefit required prolonged therapy (>6 months) in some patients.

Aims: Our aim was to understand the impact of somatic mutations and their clearance on disease response and survival outcomes in AML patients treated with pracinostat+AZA.

Methods: 88 samples from 41 study patients were sequenced. Pre-treatment samples were available for analysis for all 41 patients, and a median of 3 longitudinal samples were analyzed from 19 patients between Cycle 2 and 9. Longitudinal mutations were detected by SureSelect targeted exome sequencing (Agilent) of 295 genes that are recurrently mutated in hematologic malignancies (median coverage 507x [range: 111-777x]). Longitudinal mutation clearance was analyzed by tracking variant allele frequency (VAF). Informed consent was obtained from all patients.

Results: At baseline, 98 mutations in 28 genes were detected in 38 (93%) patients, with the most frequent being in SRSF2 (27%), DNMT3A (20%), IDH2 (17%), RUNX1 (17%), and TET2 (17%). The median number of mutations detected per patient was 2 (range: 0-6). Among the 33 patients with evaluable treatment response, CR was observed in 13 (39%) patients. The rate of CR was significantly higher in patients with mutations in NPM1 or in one of the DNA methylation pathway genes, while patients with TP53 mutation had a trend for poor CR (Table 1). The median follow up duration of the 41 patients was 23.8 months (95% CI: 20.4-27.1 months) with median OS of 18.1 months (95% CI: 10.1-26.1 months), patients with CEBPA mutation had a trend toward better OS, whereas patients with NPM1 mutation had significantly worse OS (Table). Considering mutations associated with AML oncology (Lindsley RC, Blood 2015;125:1367-76), median OS was 17.7 months in 20 patients with mutations typically associated with secondary AML and 18.1 months in 18 patients with mutations typically associated with de novo AML. Among the 19 patients whose longitudinal specimens were analyzed, 10 achieved CR. Of those 10 patients, 9 (90%) had persistently detectable mutations in their bone marrow at the time of CR, however, in 7 of them, continued exposure to pracinostat+AZA lowered the VAF or cleared residual mutations. Mutations in genes associated with DNA methylation, RNA splicing, clonal hematopoiesis of indeterminate potential (CHIP), and receptor tyrosine kinase (RTK) pathways had poor clearance of mutation, while transcription factors or cohesin had better clearance with pracinostat+AZA treatment. In 2 patients, relapsed samples were sequenced and showed re-expansion of the founder clone.

Summary/Conclusions: WES can identify leukemia-specific mutations that are involved in various cellular functions including mutations that have been shown to be recurrently mutated in AML like DNMT3A. Sequencing data can also be used in combination with mathematical modelling approaches to reconstruct the clonal architecture of AML at the time of diagnosis and relapse allowing estimations of the clonal complexity at these time points.
**Summary/Conclusions:** Mutations in *NPM1* and DNA methylation pathway were associated with a better response to pracinostat+AZA, while *TP53* mutation was associated with a trend toward poor response. Persistent mutation at the time of CR suggests residual preleukemic clonal hematopoiesis in this elderly population. Benefit of prolonged exposure to pracinostat+AZA was also confirmed at molecular level where continued decline of mutation VAF was seen after achieving CR.

**Background:** Effects on overall survival (OS) are of primary importance when evaluating AML treatments (Tx). Though complete remission (CR) rates are lower with azacitidine (AZA) than with intensive chemotherapy (IC), OS is similar with AZA and IC (Dombret et al., *Blood*, 2015). The 2017 European LeukemiaNet (ELN) recommendations acknowledge that hypomethylating agents, including AZA, may alter the natural course of AML in some patients (pts) who do not achieve CR (Döhner et al., *Blood*, 2017). According to IWG criteria for AML (Cheson et al., *J Clin Oncol*, 2003), stable disease (SD) is considered non-response to Tx. Yet AML is a progressive disease; potentially, stable health status may reflect delayed disease progression and result in improved OS.

**Aims:** This post hoc analysis evaluated OS outcomes among older pts with AML treated with AZA or conventional care regimens (CCR) who maintained SD, with or without hematologic improvement (HI), in the phase 3 AZA-AML-001 study.

**Methods:** Pts aged ≥65 years with AML (>30% marrow blasts), ECOG PS score ≤2, NCCN-defined intermediate- or poor-risk cytogenetics, and WBC count ≤15x10^9/L received AZA (75mg/m^2x7 days [d]/28d cycle) or a CCR (IC [standard 7+3 regimen], low-dose cytarabine [20mg BID x 10d/28d cycle], or best supportive care). OS was assessed using Kaplan-Meier methods for pts with SD at 2-, 4-, and 6-month landmarks. SD was protocol-defined as the absence of an IWG-defined AML response and no progressive disease (PD), whether or not HI was attained. Pts with SD could have had an IWG-defined response or PD at any time other than at the specified landmarks. OS was also evaluated in pts with HI as their best response; attainment of HI must have begun on or before, and been sustained past, each landmark, and lasted for ≥56 consecutive days.

**Results:** Median OS for all SD pts was 2.1-2.5 months longer with AZA vs CCR, and estimated 1-year survival was ~15% higher at each landmark in the AZA arm (Table 1). Hazard ratios for OS among all SD pts treated with AZA vs CCR ranged from 0.81–0.88. Median OS among pts with SD and no HI ranged from 12.6–13.3 months in the AZA arm and from 11.1-12.2 months in the CCR arm. Within Tx arms, AZA-treated pts with HI had meaningfully improved OS at all landmarks, ranging from 3.7 to 7.9 months longer than OS for pts without HI (Table 1). In contrast, HI attained with CCR did not largely influence OS; differences between pts who attained HI vs no HI ranged from -0.2 to 2.9 months. Median durations of HI in the AZA vs CCR arms, respectively, were 183 vs 166.
Madrid, Spain, June 22 – 25, 2017
days at 2 months, 176 vs 148 days at 4 months, and 176 vs 138 days at 6
months. Estimated 1-year survival within the AZA arm was 4.9%–27.4% greater
for pts with HI than for pts with no HI, but for CCR-treated pts with HI, 1-year
survival was 0%–10.3% greater. Between Tx arms, 1-year survival with AZA in
pts with HI was 9.6%–33.3% greater than for CCR-treated pts with HI.
Summary/Conclusions: Maintaining SD during AZA or CCR Tx is associated
with relatively favorable OS outcomes, as median OS in pts with SD exceeded
that for all pts in the AZA-AML-001 trial (10.4 months with AZA vs 6.5 months
with CCR; Dombret et al., Blood, 2015). Pts with SD who also attained HI during
early AZA Tx had meaningfully improved OS, whereas similar CCR-treated pts
did not, suggesting that HI with AZA is qualitatively different from HI with CCR.
The prognostic relevance of HI in AML requires further study.
P209

A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE
WITH EITHER CLOFARABINE OR FLUDARABINE IN ADULTS WITH
NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
N. Short1,*, H. Kantarjian1, F. Ravandi1, X. Huang1, L. Xiao1,
G. Garcia-Manero1, W. Plunkett1, V. Gandhi1, K. Sasaki1, N. Pemmaraju1,
N. Daver1, G. Borthakur1, N. Jain1, M. Konopleva1, Z. Estrov1, T. Kadia1,
W. Wierda1, C. DiNardo1, M. Brandt1, S. O’Brien2, J. Cortes1, E. Jabbour1
1The University of Texas MD Anderson Cancer Center, Houston, 2The University of California - Irvine, Orange, United States

Background: Fludarabine and clofarabine are purine nucleoside analogues
with clinical activity in acute myeloid leukemia (AML).
Aims: We designed a randomized phase II trial to evaluate the efficacy and
safety of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine
(FIA) in adults with newly diagnosed AML. The primary objective was to compare the EFS rates of the two regimens.
Methods: Adults with newly diagnosed AML deemed suitable for intensive
chemotherapy were randomized using a Bayesian adaptive design to receive
CIA or FIA. All patients (pts) received idarubicin 10 mg/m2 IV on D1-3 and
cytarabine 1 g/m2 IV daily on D1-5. Clofarabine and fludarabine were given at
doses of 15 mg/m2 and 30 mg/m2, respectively, IV daily on D1-5. Pts with FLT3ITD mutations could receive concomitant sorafenib. Responding pts could
receive up to 6 cycles of consolidation at attenuated doses. Outcomes were
compared to a historical cohort of pts <60 years of age who received idarubicin
and cytarabine (IA) without a nucleoside analogue.
Results: Between 8/2011 and 6/2016, 182 pts were enrolled (CIA, n=106; FIA,
n=76; Table 1).
Table 1.

The imbalance of the arms was due to the better performance of CIA during
the initial period of the trial. Treatment arms were well-balanced after randomization. 12 pts (55%) in the CIA arm and 8 (53%) in the FIA arm received
sorafenib. The composite CR/CRp rate was similar between the two arms (80%
for CIA vs 82% for FIA; P=0.84). CR was achieved in 72% and 74% in the CIA
and FIA arms, respectively. MRD negativity rates at remission by multiparameter
flow cytometry were higher in the CIA arm (80% vs 65%; P=0.07). 37 pts (35%)
in the CIA arm and 28 (38%) in the FIA arm underwent allogeneic stem cell
transplant in first remission. The median duration of follow-up was 27 months
(range, 1-58). Median EFS for pts who received CIA and FIA were 13 months
and 12 months, respectively; the 2-year EFS rate was 44% in both arms
(P=0.91). Median OS were 24 months and not reached, and the 2-year OS
rates were 51% and 57%, respectively (P=0.23). No differences in EFS or OS
were observed according to baseline factors, including cytogenetics, mutations

or ELN risk group. CIA was generally associated with more adverse events
compared to FIA, including a higher rate of transaminase elevation (29% vs
4%), hyperbilirubinemia (26% vs 9%), and rash (29% vs 12%). Early mortality
was similar in the 2 arms (60-day mortality: 4% for CIA vs 1% for FIA; P=0.32).
We compared outcomes of pts treated with either CIA/FIA to a historical cohort
treated with IA (n=92). Pts in the CIA/FIA group with FLT3 mutations who
received sorafenib (n=20) were excluded from this analysis. The two cohorts
were similar with respect to pretreatment characteristics analyzed, including
age, cytogenetics, and ELN risk. No differences were observed in CR/CRp
rates, EFS or OS between the two groups. However, among pts <50 years of
age, the median EFS for pts who received FIA (n=36), CIA (n=28) and IA (n=34)
was not reached, 10 months and 9 months, and the 2-year EFS rates were
58%, 33% and 30%, respectively (P=0.05 for FIA vs IA; P=0.79 for CIA vs IA).
For these pts <50 years of age, the median OS was not reached, 22 months
and 15 months, and the 2-year OS rates were 72%, 46% and 36%, respectively
(P=0.009 for FIA vs IA; P=0.23 for CIA vs IA).
Summary/Conclusions: CIA and FIA have similar efficacy in younger pts with
newly diagnosed AML, although FIA is associated with a better toxicity profile.
FIA may improve outcomes compared to IA in pts <50 years of age.
P210

OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3
MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351
VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK
ACUTE MYELOID LEUKEMIA
B.C. Medeiros1,*, D. Hogge2, L.F. Newell3, D.L. Bixby4, S.R. Solomon5,
S.A. Strickland6, T.L. Lin7, H. Erba8, B.L. Powell9, N. Podoltsev10, R. Ryan11,
M. Chiarella11, A.C. Louie11, J. E. Lancet12
1Stanford University School of Medicine, Stanford, CA, United States, 2Gordon
and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada,
3Oregon Health and Science Univ, Portland, OR, 4University of Michigan, Ann
Arbor, MI, 5BMT Group of Georgia, Atlanta, GA, 6Vanderbilt-Ingram Cancer
Center, Nashville, TN, 7University of Kansas Medical Center, Kansas City, KS,
8University of Alabama at Birmingham, Birmingham, AL, 9Wake Forest Baptist
Comprehensive Cancer Center, Winston-Salem, NC, 10Yale Univ. School of
Medicine, New Haven, CT, 11Jazz Pharmaceuticals, Palo Alto, CA, 12H. Lee
Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Background: Approximately 20% to 30% of patients with acute myeloid
leukemia (AML) have FLT3 mutations; these patients often experience rapid
post-induction relapse, highlighting the need for therapies that provide an
improved bridge to stem cell transplantation. CPX-351 is a liposomal formulation
that delivers a synergistic 5:1 molar ratio of cytarabine and daunorubicin. CPX351 demonstrated significantly prolonged overall survival (OS) versus cytarabine/daunorubicin (7+3) in a randomized, open-label, controlled phase 3 trial
in patients aged 60 to 75 years with newly diagnosed, high-risk AML (Lancet,
et al. ASCO 2016). A study of the ex vivo cytotoxicity of CPX-351 found that
AML blasts with the FLT3-ITD phenotype were 5-fold more sensitive to CPX351 than those with wild type FLT3 (Gordon, et al. Leuk Res. 2017;53:39-49).
Aims: The current analysis of the phase 3 trial therefore investigated outcomes
in the subset of patients with FLT3 mutations.
Methods: Enrolled patients were randomized 1:1 to receive induction with 1 to
2 cycles of CPX-351 (100 units/m2 [cytarabine 100 mg/m2+daunorubicin 44
mg/m2] on Days 1, 3, and 5 [2nd induction: Days 1 and 3 only]) or 7+3 (cytarabine 100 mg/m2/day x 7 days [2nd induction: x 5 days]+daunorubicin 60 mg/m2
on Days 1, 2, and 3 [2nd induction: Days 1 and 2 only]). Patients who achieved
complete remission (CR) or CR with incomplete platelet or neutrophil recovery
(CRi) could receive up to 2 consolidation cycles.
Results: Of the 274 patients who were assessed for FLT3 mutations and
received study treatment, 22/138 (16%) patients in the CPX-351 arm and
20/136 (15%) patients in the 7+3 arm had baseline FLT3 mutations. AML subtypes in FLT3+ patients were: therapy-related AML (19%); AML after myelodysplastic syndrome (MDS) with (38%) or without (10%) prior hypomethylating
agents; AML after chronic myelomonocytic leukemia (12%); and de novo AML
with MDS karyotype (21%). In FLT3+ patients, median OS was longer with
CPX-351 (10.25 months) versus 7+3 (4.55 months; hazard ratio=0.57 [95%
CI: 0.24, 1.33]; P=0.093; see Figure 1), and the rate of CR+CRi was higher
(68% vs 25%). A greater number of FLT3+ patients treated with CPX-351 were
able to undergo stem cell transplantation (n=10/22 [45%]; 4 patients were alive
as of this analysis, after a median post-transplant follow up of 692 days [range:
96-769]) compared with 7+3 (n=2/20 [10%]; neither patient was still alive). The
adverse event profile (reported during treatment or within 30 days of discontinuation) of CPX-351 in FLT3+ patients was comparable to that of 7+3 and consistent with the overall study population. Serious treatment-emergent adverse
events (TEAEs) were experienced by 7 (32%) FLT3+ patients in the CPX-351
arm and 10 (50%) patients in the 7+3 arm; individual serious TEAEs in ≥2
patients included febrile neutropenia (n=2 in each arm), respiratory failure (n=1
in each arm), cardiac failure (n=2 with CPX-351), and cerebral hemorrhage
(n=2 with 7+3).
Summary/Conclusions: CPX-351 demonstrated numerical improvement in
median OS in older patients with newly diagnosed, FLT3+ high-risk AML and

haematologica | 2017; 102(s2) | 53


allowed more patients to undergo stem cell transplantation. The safety of CPX-351 in this subpopulation was in line with the previous studies and the overall phase 3 population. This analysis was limited by small number of patients.

Figure 1.

P211

NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA IN REMISSION

T. Kadia1, H. Kantarjian1, E. Jabbour2, F. Ravandi3, N. Daver1, P. Cardenas4, M. Brandt1, M. Konopleva5, J. Cortes1
1Leukemia, 2MD Anderson Cancer Center, Houston, United States

Background: Dose intensification and newer drug combinations during induction have led to high rates of complete remission (CR) in pts with newly diagnosed AML. However, disease relapse remains a major source of failure. With the exception of allogeneic (allo) stem cell transplant (SCT), there are few options for post-consolidation maintenance of remission in high-risk pts. Prior attempts at developing maintenance therapy using cytotoxic drugs have been unsuccessful. Immune mediated disease control by engaging tumor-specific cytotoxic T-cells may be important in suppressing leukemia relapse, as is seen with graft vs leukemia effect following allo SCT. Immune checkpoint inhibitors may be effective in restoring host immune surveillance in the setting of post-remission maintenance.

Aims: We designed a pilot phase II clinical trial studying the efficacy and safety of nivolumab (nivo) as maintenance therapy in AML pts with high-risk disease in remission, who were not being considered for SCT.

Methods: AML pts ≥18 years with a high-risk feature in 1st CR (CR1) or any patient in 2nd CR (CR2) who had received induction and at least 1 consolidation cycle were eligible for enrollment. Pts should be within 12 months of achieving CR, have PS ≤2, and adequate organ function. Pts were treated with nivo 3mg/kg IV every 2 weeks for 6 months. 1 cycle was 4 weeks. After 6 months, nivo could be given every 4 weeks until 12 months on study, and then every 3 months until relapse. All pts had baseline cytokine and molecular testing, and minimal residual disease (MRD) assessment by flow cytometry. Peripheral blood and bone marrow samples were collected at baseline and during treatment for immune correlates studies to explore immune repertoire and biomarkers for response.

Results: Eight pts have been treated, with a median age of 60 years (range, 49-71). 7 pts were in CR and 1 in CRi at the time of enrollment; 5 pts (63%) were in CR1, 2 pts (25%) were in CR2, and 1 pt (13%) in CR4 was inadvertently enrolled and treated on the trial. Baseline characteristics are outlined in Table 1. AML-related mutations detected at start of therapy include: IDH2 (n=2), NPM1 (2), TET2 (1), and DNMT3a. High risk features at the time of enrollment were as follows: 2 (25%) persistent MRD, 2 (25%) adverse karyotype, 1 (13%) adverse mutational profile, and 3 pts (38%) in CR2 or beyond. Pts have received a median of 4 (1 – 13) cycles of therapy. With a median followup of 6+ months (1 – 14), the 6- and 12-month estimated RFS were 88% and 73%, respectively. The 6- and 12-month estimated OS were 100% (Figure 1). The one patient who died was discovered to actually be in CR4. This patient relapsed approximately 8 months after achieving CR4. The regimen was well tolerated overall, with 4 pts having possible immune-related events. 1 patient had grade 3 pneumonitis leading to hypothyroidism, treated successfully with steroids and thyroid hormone supplementation, who continues on treatment. 1 patient had grade 4 transaminase elevation which responded to dose interruption and who continues on treatment (Table 1).

Summary/Conclusions: Nivo appears to be a feasible maintenance strategy in high-risk AML pts who are not candidates for SCT. The study continues to surpass the pre-specified expected rate of 6-month relapse-free survival of high-risk pts based on a historical cohort. Correlative studies profiling the immune repertoire of pts before and during treatment are being finalized and will be summarized.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>60 (60-71)</td>
</tr>
<tr>
<td>WBC [×10^9/L]</td>
<td>3.8 (1.9-8.0)</td>
</tr>
<tr>
<td>Platelets [×10^9/L]</td>
<td>125 (20-272)</td>
</tr>
<tr>
<td>Hb</td>
<td>11.0 (9.5-13.5)</td>
</tr>
<tr>
<td>Albumin</td>
<td>3.9 (4.0-6.0)</td>
</tr>
<tr>
<td>Ht</td>
<td>0.62 (0.58-0.7)</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.65 (0.58-0.8)</td>
</tr>
</tbody>
</table>

Figure 1.

P212

HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA

S.-Y. Hung1, C.-C. Lin1,2,3, H.-A. Hou1, W.-C. Chou1,2, H.-F. Tien1
1Division of Hematology, Department of Internal Medicine, 2Department of Laboratory medicine, National Taiwan University Hospital, 3Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan, Republic of China

Background: Long non-coding RNAs (IncRNAs) are non-protein coding RNAs longer than 200 nucleotides. Recently, a number of IncRNAs have been shown to play important roles in cancer biology. IncRNA KIAA0125 is one of the 11 genes in an expression signature significantly associated with prognosis in cytogenetically normal acute myeloid leukemia (AML) patients as shown in our previous report. It is also among another set of 17 leukemia stem cell (LSC) genes, identified through xenotransplantation model in NSG mice, which predict inferior treatment response in AML.

Aims: KIAA0125 gene is localized on chromosome 14q32.33; its functions remain unexplored. One study reported that it might be involved in neurogenesis including induction of astrocytosis, preventing formation of dopaminergic neurons. Another study showed that it could potentiate cell invasion and migration in gallbladder cancer. Its clinical significance in hematologic malignancies has not been explored yet. Since independent studies have reported KIAA0125 as an important gene for unfavorable prognosis, in this study we aimed to investigate its clinical relevance in AML.

Methods: We performed global mRNA arrays for bone marrow samples from 347 newly diagnosed de novo AML patients in the National Taiwan University Hospital, who had adequate cryopreserved cells and detailed demographic, clinical, and genetic data for analysis. The KIAA0125 expression level extracted from the array data was analyzed for its clinical relevance. We also validated our findings by analyzing the public databases of AML.

Results: The 347 patients were divided into two groups based on the median level of KIAA0125 expression on the arrays. Higher KIAA0125 expression was inversely associated with favorable karyotypes including t(8;21) and t(15;17). Patients with M1 by the French-American-British classification more frequently had higher KIAA0125 expression (p < 0.001), while those with M3 (acute promyelocytic leukemia) had significantly lower levels of KIAA0125 expression (p < 0.001). To investigate the association of gene mutations with KIAA0125 expression in AML, we analyzed mutations of 17 AML-associated genes. We found that patients with higher KIAA0125 expression had significantly higher incidence of FLT3-ITD (28.7% vs 19.7%, p=0.048), and mutations of RUNX1 (18.4% vs 10.4%, p=0.034), and DNMT3A (24.1% vs 13.9%, p=0.015), compared to those with lower KIAA0125 expression. Among the 227 patients who received standard chemotherapy, those with higher KIAA0125 expression had a lower complete remission rate (61.2% vs 84.7%, p < 0.001), and shorter overall survival (median OS, 23.7 months vs 116.8 months, p < 0.001) than those with lower KIAA0125 expression after a median follow-up of 57.0 months. The prognostic significance could be validated in another two independent cohorts, TCGA and GSE12417. In multivariate analyses, higher expression of KIAA0125 remained to be an unfavorable prognostic factor for OS independent of age, white blood cell counts, karyotype, FLT3-ITD, CEBPA double mutations,
RUNX1 mutation, MLL-PTD, WT1 mutation, and TP53 mutation (p=0.011).

Summary/Conclusions: Higher expression of KIAA0125 in AML patients was correlated with mutations of RUNX1, NMT3A, and FLT3-ITD but negatively associated with favorable karyotypes such as t(8;21) and t(15;17). Higher expression of KIAA0125 appeared to be an independent unfavorable prognostic factor in our cohort, and its negative prognostic impact could be validated in another two large independent cohorts of AML. The close association of KIAA0125 expression with LSC signatures might in part explain its unfavorable impact on the survival of AML patients.

P213
LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR

O. Pérez-López1,*, T. Caballero-Velázquez1, I. Álvarez-Laderas1, P. Hernández-Díaz1, A. M. Márquez-Mattio1, J. González-Campos1, R. Morales-Camacho1, C. Prats-Martín1, M.T. Vargas-de los Monteros1, R. Bernai-Ruíz2, J.A. Pérez-Simón1

1Virgen del Rocío University Hospital, Sevilla, Spain

Background: There is a growing interest on the identification of leukemic stem cells (SC) as a potential prognostic factor in patients with acute myeloid leukemia (AML). Several studies identify these cells as CD34+CD38-Lin- although there is a controversy about its phenotypic identification and prognostic value.

Aims: To identify SC in a cohort of patients with AML and evaluate their prognostic value in a series of newly diagnosed AML patients.

Methods: The presence of SC (CD34+CD38-Lin-) in bone marrow samples was prospectively evaluated in a consecutive series of 67 newly diagnosed AML patients by flow cytometry, between May 2013 and June 2016. All patients received intensive chemotherapy according to PETHEMA protocol. We evaluated response, relapse rate and overall survival (OS) and event free survival (EFS).

Results: Out of the 67 patients [34 men/33 women; median age 54 (0-78)], 58 (86.6%) have SC at diagnosis, 37.9% of them (n=22) achieved complete remission (CR) with a negative minimal residual disease (MRD) vs 77.8% (7/9) among patients without SC (p=0.03). Among patients who obtained CR with a negative MRD (n=29), no one suffer a leukemic relapse in the non SC vs 5/22 (22.7%) in the SC group (p=0.02). Considering the intermediate risk group according to cytogenetic/ molecular features, 100% of patients without SC at diagnosis achieve a negative MRD (5/15 vs 14/41; 34.1%) among those in the SC group (p=0.008). OS at 9 months was 89 vs 56% (p=0.043), and the EFS 78 vs 48% (p=0.054) in the non SC and SC group, respectively (Figure 1).

Figure 1.

Summary/Conclusions: SC can be detected in a considerable group of patients with AML at diagnosis. The presence of SC is a prognostic factor in terms of response, OS and EFS. Accordingly, SC detection could help to identify prognosis subgroup of patients with different prognostic among those in the intermediate risk group by genetics/molecular assays.

P214
POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY

C. Frairia1,*, S. Aydin1, E. Audisio1, L. Riera2, S. Aliberti2, B. Allione3, R. Morales-Camacho1, C. Prats-Martín1, M.T. Vargas-de los Monteros1, R. Bernai-Ruíz2, J.A. Pérez-Simón1

1Virgen del Rocío University Hospital, Sevilla, Spain

Background: In acute myeloid leukemia (AML) the detection of residual leukemic cells at a submicroscopic level (minimal residual disease - MRD) is still under investigation. In about 30-40% of AML lacking a specific molecular target, quantitative real-time polymerase chain reaction (QRT-PCR) has been used to detect transcripts commonly overexpressed in AML. Among a large number of candidates, Wilms tumor gene 1 (WT1) has been proposed as a promising MRD marker.

After the standardization of QRT-PCR on behalf of the European LeukemiaNet (ELN), subsequent studies investigated the role of WT1 expression in AML with controversial results.

Aims: To assess the role of WT1 expression as a MRD marker after intensive induction chemotherapy and before allogeneic hematopoietic cell transplantation HCT (allo-HCT) in a large cohort of AML patients treated in a single institution.

Methods: The present retrospective cohort study included adult patients with untreated AML consecutively diagnosed between 2004 and 2014 in the Hematology Unit of the University-Hospital Città della Salute e della Scienza di Torino, Italy. The study was approved by the Ethical Committee and was registered at www.clinicaltrials.gov as NCT02714790. Among 255 enrolled patients, MRD was investigated in those in first complete remission (CR) with an available diagnosis and at two further time-points: after induction (n=117) and prior allo-HCT (n=65).

Results: Patients with baseline WT1 <250 copies were excluded. All patients underwent intensive induction chemotherapy with curative intent and subsequent consolidation chemotherapy according to the AML risk assessment (autologous peripheral stem cell transplantation for low risk and allo-HCT for intermediate and high risk patients). Effect of post induction WT1 expression on disease-free survival (DFS) and overall survival (OS) and of pre allo-HCT WT1 expression on relapse (CIR) were investigated.

Results: Baseline WT1 expression were not found significantly associated with demographical, clinical and disease biological features at diagnosis. Baseline BM WT1 expression lacked even to show an association with response to induction chemotherapy (CR 1.16; 95% CI 0.90-1.50, p<0.244).

OS and DFS were significantly shorter in patients in first CR with >350 WT1 copies after induction compared to those with ≤350 (OS 17 vs 95 months vs <150 copies; p=0.018 and 3-year DFS rates 15% vs 55% with a HR of 2.81; 95% CI 1.14-6.93, p=0.025).

Adding the BM WT1 in the model along with other factors determines an increase of the C-statistic from 0.696 to 0.7193 for OS (NR=0.384) and from 0.7413 to 0.7920 (NR=0.4037) for DFS. Before allo-HCT, patients with WT1 >150 copies (n=18) had a significantly higher CIR compared to those with WT1 ≤150 (n=47), HR 4.61; 95% CI 1.72-12.31, p=0.002.

Summary/Conclusions: The results of the present study showed that BM WT1 is associated with survival in patients in CR in two decisive time-point for treatment planning: after induction treatment and before allo-HCT. The prognostic role of WT1 resulted independent from other well-established risk factors. Therefore, WT1 may represent an additional MRD tool for risk stratification in patients nowadays classified in CR, especially in the high risk MRD positive subgroup which may have a role. Published evidences so far supported these suggestions, but mainly due to methodological issues, the role of WT1 is still a matter of debate. Perspective randomized studies are required to confirm these results.

P215
DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)

A.T. Fathi1,2,*, C.D. DiNardo 3, I. Kline4, L. Kenvin4, I. Gupta4, E.C. Attar5, E.M. Stein67, S. de Botton8

1Massachusetts General Hospital Cancer Center, 2Harvard Medical School, Boston, 3The University of Texas MD Anderson Cancer Center, Houston, 4Cellgene Corporation, Summit, 5Agios Pharmaceuticals, Inc, Cambridge, 6Memorial Sloan Kettering Cancer Center, 7Weill Cornell Medical College, New York, United States, 8Institut Gustave Roussy, Villejuif, France

Background: Enasidenib (AG-221) is an oral, selective, small-molecule inhibitor of miDH2 enzymes. Preclinical studies showed that exposing myeloblasts from patients (pts) with acute myeloid leukemia (AML) to enasidenib ex vivo resulted in differentiation of leukemic marrow blasts into mature, fully functional neutrophils (Yen et al, 2017). Enasidenib can inhibit 100 mg daily in a phase 1 dose-escalation and expansion study (NCT01915498). This dose is currently used in a多中心 multicenter, randomized, phase 3 trial comparing enasidenib with conventional care regimens in R/R AML pts (NCT02577406).
Methods: An independent Differentiation Syndrome Review Committee (DSRC) was formed to review potential cases of IDH-DS. The DSRC identified and agreed upon a series of signs and symptoms possibly characteristic of IDH-DS, including fever, lung infiltrates, pleural or pericardial effusions, rapid weight gain, edema, and azotemia. In all, 27 cases (8 of investigator-reported IDH-DS and 19 with characteristics suggestive of IDH-DS) were identified and retrospectively reviewed by the DSRC to determine their consistency with IDH-DS.

Results: The DSRC determined 13 cases (11.9% of 109 R/R AML pts in the enasidenib 100 mg/day dosing cohort) to be consistent with IDH-DS. Median time to onset was 30 days (range 7-116). Manifestations of IDH-DS in >2 pts were dyspnea (n=10), pyrexia (9), lung infiltrates (8), pleural effusion (5), and kidney injury (3). IDH-DS was effectively managed with systemic corticosteroids in 12/13 cases. Leukocytosis accompanied 4/13 cases, for which hydroxyurea was employed for cytoreduction. Enasidenib was interrupted for 9 pts (for a median of 7 days), but dose reductions or enasidenib discontinuation were not required for pts with IDH-DS. Six of the 13 pts had clinical responses (2 complete remissions [CR], 2 CRs with incomplete hematologic recovery, 1 partial remission, and 1 morphologic leukemia-free state), 6 pts had stable disease, and 1 pt had progressive disease.

Summary/Conclusions: Systemic corticosteroids, close hemodynamic management, and hydroxyurea (in the presence of leukocytosis) are effective IDH-DS management strategies; they should be administered promptly when IDH-DS is suspected, and continued until improvement. Enasidenib interruption can be considered if initial intervention is unsuccessful. IDH-DS represents a novel clinical finding in pts with mAML treated with enasidenib, and is likely due to its suggested mechanism of action, myeloblast differentiation.

Aggressive Non-Hodgkin lymphoma - 1st line

P216

Abstract withdrawn.

P217

OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION GROUP


1Hematology, University Hospital Hôtel-Dieu, Nantes, 2Hematology, CHU, Montpellier, 3Hematology, La Pitié Salpêtrière APHP, Paris, 4Anatomopathology, University Hospital Hôtel-Dieu, Nantes, 5Hematology, CHU, Lyon, 6Hematology, Saint Antoine APHP, Paris, 7Hematology, CHU, Rennes, 11Hematology, CHU, Strasbourg, 12Hematology, Loire Cancerology Institute, Saint Etienne, 13Hematology, CHU, Clermont-Ferrand, 14Hematology, CHD, La Roche sur Yon, 15Hematology, CHU, Angers, 16Hematology, Hospital, Bayonne, 17Hematology, Polyclinic Bordeaux Nord Aquitaine, Bordeaux, 18Hematology, Hospital, Le Mans, 19Hematology, CHU, Limoges, 20Hematology, Paoli Calmette Institute, Marseille, 21Hematology, Catherine de Sienne Centre, Nantes, 22Hematology, Cancerology Centre, Mougins, 23Hematology, Hospital, Pau, 24Hematology, CHU, Tours, 25Anatomopathology, CHU, Lyon, 26Statistic, University Hospital Hôtel-Dieu, Nantes, France

Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumina of vessels, classically reported with poor responses to chemotherapy. Due to its low incidence and rarity of tumor cells, diagnosis of IVLBCL remains difficult and many issues remain unresolved, regarding both clinical features and therapeutic strategies.

Aims: Our work aims to describe clinical presentation and outcome of IVLBCL patients treated in French LYSA centers between 2000 and 2016.

Methods: All LYSA centers were asked to report and update clinical data about IVLBCL patients treated. No central pathology review was performed for the present study, but all cases were classified by LYSA pathologists. Local investigators reported disease characteristics and updated patients’ outcome (clinical examination, standard biological parameters, bone marrow biopsy, CT scan at baseline, CT response evaluation and outcome).

Results: We identify 65 IVLBCL patients treated in 23 LYSA centers during the studied period. Median age was 67.8 years (range 22-91). In note, two third of patients presented with IP3 score >3 (67%) and all patients had a stage IV disease. As expected in Western patients, cutaneous and CNS involvement were highly frequent, respectively 33% and 39%. But interestingly, hemophagocytic syndrome were observed in nearly half of the patients (41%), while it was mainly described in Asian series. Despite classically delayed diagnosis in IVLBCL, only 2 cases were confirmed post-mortem and almost all alive patients at diagnosis (n=58) were treated with rituximab-containing chemotherapy regimen (92%). Regarding first line treatment, 83% of patients were treated with anthracycline-based regimens, with CNS prophylaxis for half of them (47%), and seven patients underwent autologous stem cell transplantation upfront. The median progression free survival was 28.4 months and median overall survival was 63.8 months (Figure 1). Pathological features (including cell of origin characterization, C-MYC expression, adhesion protein expression level) investigation is ongoing and will be presented at the time of the meeting.

Figure 1.
Summary/Conclusions: The present study is the largest European IVLBCL series. It shows that despite the use of modern immune-chemotherapy, IVLBCL remains an aggressive lymphoma entity. In particular, these patients are highly exposed to early relapse and therefore should be considered for innovative frontline therapies.

P218

OUTCOME OF ELDERLY DLBCL PATIENTS (≥80 YEARS) TREATED WITH ANTHRACCYLINE BASED CHEMOTHERAPY: R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY


1Charles University Hospital, Prague, 2University Hospital, Brno, 3University Hospital, Hradec Kralove, 4University Hospital, Olomouc, 5University Hospital Kralovske Vinohrady, 6CLSG Data Center, Prague, 7University Hospital, Pilsen, 8University Hospital Motol, Prague, Czech Republic

Background: Management of elderly patients (above ≥80y) is difficult and only limited number of patients could be treated by curative approach with anthracyline based chemotherapy. Dose reduction of particular drugs is used very often and it varies based on pts characteristics and center preferences. There is however lack of randomized or at least non-randomized historical comparisons.

Aims: The objective of this study is to analyze elderly DLBCL patients prospectively registered in NiHL Lymphoma Project and treated anthracyline based regimen in real world outside of clinical trials.

Methods: Patients (pts.) with informed consent are prospectively followed in multicenter Lymphoma Project since 1999. Diagnostic, therapeutic and follow up data are prospectively collected. There were 399 DLBL pts older than 80year diagnosed in period 1999-2014 identified. Among 372 pts. with pathology review and essential data there were 112 pts. (30.1%) treated with R-CHOPlike chemotherapy. Analysis of clinical prognostic factors, therapy and toxicity was performed. Pearson, Kaplan-Meier and log rank tests were used.

Results: Median age was 81 years (80-88), 51.8% of men. Proportion of pts ≥85 was 14.3%, with PS ≥2 (ECOG) 34.0%, with higher LDH 64.3%, with high or intermediate high IPI 49.1%, with bulky disease (≥10 cm) 17.0%, with lower albumin 27.7%, with Charlson Comorbidity Score (CCS) ≥25%. According to treatment choice of physician (intent to treat), pts. could be divided into 3 groups R-CHOP (CHOPlike chemotherapy). Analysis of clinical prognostic factors, therapy and toxicity was performed. Pearson, Kaplan-Meier and log rank tests were used.

Summary/Conclusions: According to treatment choice of physician (intent to treat), pts. could be divided into 3 groups R-CHOP (CHOPlike chemotherapy) – A - 50 mg/m2) or R-MiniCHOP (miniCH) (CF 400 mg/ m2, A 25 mg/m2, Peyrade 2011) or modified R-CHOP (modiCH) (CF 750 mg/m2 and A 25 mg/m2) for any other dose between CHOP and miniCHOP. There were 21 pts (15.8%) treated with CH, 38 (33.9%) with miniCH and 53 (47.3%) with modiCH. There were no significant differences between the subgroups, except higher proportion of bulk in modiCH vs miniCH and CH (35% vs 12.9% vs 7.7% resp.; p 0.04) and cardiac comorbidity (60.5% vs 33.3% vs 30.2% resp.; p 0.02). Six and more cycles were administered in 71.4%, 63.1% and 58.5% pts. in CH, miniCH and modiCH resp. Following proportion of pts. received >80% (>50%) of original CHOP dose. For cyclophosphamide it was 66.7% (81%), 0% (50%) and 62.2% (79.2%) resp. and for A it was 57% (76.1%), 2.6% (15.8%) and 13.2% (49%) resp. for CH, miniCH and modiCH resp. There were observed 11 treatment related deaths (6 cardiac toxicity and infection), 5 in miniCH and 6 in modiCH groups. The overall response rate was 76.8% with 58.9% CR/CRu. Median PFS and OS were 2.8y and 4.6y vs 3.5y vs 0.8 y. There was numerically (not significantly) better OS median for R-CHOP (4.6y) vs R-miniCHOP (3.2y) and R-modiCHOP (2.9y) (Figure 1B).

Figure 1.

Summary/Conclusions: Only one third of elderly DLBCL pts (≥80y) is treated with anthracycline based regimen. Performance status, albumin and beta2microglobulin levels were significantly associated with prognosis. In minority of these pts full dose of R-CHOP could be safely used and there is trend to better overall survival. Supported by AZV 16-31092A.

P219

IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015

A. Dinnohamed1,2,3,4, M. van der Meulen4, O. Visser2, J. Doorduin3, J. Bromberg4

1Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, 2Public Health, Erasmus University Medical Center, 3Hematology, 4Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, 4Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

Background: PCNSL is a rare, aggressive form of an extranodal non-Hodgkin lymphoma that exclusively affects the CNS. Recent findings from the few available prospective studies demonstrated improved outcome in PCNSL. However, the results from such studies are inherent to patient selection. Population-based studies that assess long-term patterns of incidence, treatment and survival in PCNSL are virtually lacking.

Aims: The aim of this comprehensive nationwide population-based study was to assess trends in incidence, primary treatment and survival among adult PCNSL patients (pts) diagnosed during a 27-year period in the Netherlands.

Methods: We selected all adult (≥18 years) pts diagnosed with PCNSL of the diffuse large-B-cell type in the Netherlands between 1989-2015 from the nationwide Netherlands Cancer Registry with survival follow-up through February, 2016. Pts diagnosed without pathological or cytological confirmation (n=50) and pts diagnosed at autopsy were excluded (n=32). Age-standardized incidence rates (ASIR) were calculated per 1,000,000 person-years and standardized according to the European standard population. Data on primary treatment (i.e. no therapy, chemotherapy (CT) alone, radiotherapy (RT) alone, and CT+RT) were available for individual pts. Pts were categorized into 4 periods (1989-1994, 1995-2000, 2001-2007 and 2008-2014) and 3 age groups (18-60, 61-70 and >70 years). We calculated relative survival (RS) and the relative excess risk of mortality as measures of disease-specific survival.

Results: We included a total of 1,673 newly diagnosed PCNSL pts in the study (median age, 65 years; age range, 19-89 years; 53% males). The ASIR of PCNSL increased from 3.0 in the first period (1989-1996) to 4.4 in the last period (2009-2015), which was consistently higher among males than in females throughout the entire study (4.8 vs 4.0 in the last period). The age-specific incidence rates were 2.3, 9.0 and 10.9 in the first period for the three age groups (18-60, 61-70 and >70 years), as compared with 2.7, 18.7 and 19.5 in the last period. The application of CT+RT increased exclusively among pts age 18-60. More specifically, the proportions for the three age groups were 26, 18 and 4% in the first period, as compared with 60, 10 and 4% in the last period. The use of RT alone among pts age >60 decreased with each period, following the wider use of CT alone over time, especially for pts age 61-70 years. The proportions of CT alone for the three age groups were 11, 8 and 2% in the first period, as compared with 31, 64 and 32% in the last period. Of note, 38 and 26% of pts age >70 received no therapy, chemotherapy (CT) alone, radiotherapy (RT) alone, and CT+RT were available for individual pts. Pts were categorized into 4 periods (1989-1994, 1995-2000, 2001-2007 and 2008-2014) and 3 age groups (18-60, 61-70 and >70 years). We calculated relative survival (RS) and the relative excess risk of mortality as measures of disease-specific survival.

Figure 1.

Summary/Conclusions: The incidence of PCNSL steadily increases among
PT20

CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C-ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL+C)


1Russian National Research Medical University named after N.I. Pirogov, 2National Research Center for Haematology, 3National Research Center for Oncology named after N.N. Blochin, 4City Clinical Hospital named after C.P. Botkin, 5City Clinical Hospital named after V.M. Buyanov, Moscow, Russian Federation

Background: In the WHO classification (2008), hepatitis C virus distinguishes as one of the etiological factors of multistage etiopathogenesis DLBCL.

Aims: The purpose of this study was an evaluation of clinical features and results of treatment of diffuse krepnokletochnoy lymphoma associated with hepatitis C in comparison with a control group of patients with diffuse large lymphoma without viral hepatitis markers.

Methods: It was included 521 patients with DLBCL: 98 patients with DLBCL and markers of hepatitis C (DLBCL+C) and a control group of 422 patients with DLBCL without markers of hepatitis C (DLBCL-C).

Results: Patient’s age ranged from 21 to 76 years (median was 47 years) in DLBCL+C; ranged from 23 to 81 years (median 61) in DLBCL-C (p=0.02). The male:female ratio was 1:1.3 in patients with DLBCL+C; 1:1.7 in the group DLBCL-C. Stage I and II were in 11% patients with DLBCL+C; and 48% patients with DLBCL-C; III and stage IV were detected in 89% patients with DLBCL+C and 52% of DLBCL-C(p=0.00002). Extranodal lesions detected in 72% in DLBCL+C and in 26% in C DLBCL-C (p=0.006). In comparable groups localization of extranodal lesions was: spleen (52% to 23%), bone marrow involvement (43% and 27%), liver involvement (36% and 64%) in DLBCL-C; 36% and 64% in DLBCL-C. Hepatitis C virus RNA in blood was detected by PCR. Viral RNA was found in 78% (74 patients). High viral load was in 21% of patients. In 22% of cases markers of hepatitis C virus in blood were identified by ELISA. All patients received chemotherapy according to the scheme CHOP/R-CHOP. The frequency of complete remission was 60% in the group of patients with DLBCL+C and 63% of DLBCL-C. Median overall survival (OS) was 46 months in group DLBCL+C and 71 months in DLBCL-C (p=0.0003).

Median progression-free survival (PFS) was 28 months in DLBCL+C 47 months in the control group (p=0.0002). According to the immunohistochemical variant of DLBCL-C Group A was in 19% of cases in DLBCL+C; 11% in controls. Group B was in 24% in DLBCL+C and 73% in controls (p=0.00002). In the comparison group of patients with markers of hepatitis C in the group DLBCL +C and in controls the difference was statistically significant (p=0.0002). GCB non-GCB histological variants ratio was 55%/45% in DLBCL-C; 36%/64% in DLBCL-C group (p=0.001). Hepatitis C virus RNA in blood was detected by PCR. Viral RNA was found in 78% (74 patients). High viral load was in 21% of patients. In 22% of cases markers of hepatitis C virus in blood were identified by ELISA. All patients received chemotherapy according to the scheme CHOP/R-CHOP. The frequency of complete remission was 60% in the group of patients with DLBCL+C and 63% of DLBCL-C. Median overall survival (OS) was 46 months in group DLBCL+C and 71 months in DLBCL-C (p=0.0003).

Conclusion: The study is a prospective, clinical, single-centre study. The study aims to include 70 consecutive chemotherapy-naive lymphoma patients scheduled for intended curative chemotherapy without planned mediastinal radiation therapy. All patients undergo routine clinical examinations, but with supplementary imaging, including 1) baseline 82Rb PET and MR (prior to treatment); 2) acute 82Rb PET and MR (within 1 week of the first treatment); 3) subacute 123I-MIBG (after 2-3 months of therapy) and (4) late MR (1 year after the start of treatment). 82Rb PET imaging is performed at rest and during pharmacological stress testing with adenosine. It is primarily used to evaluate the acute effects of doxorubicin on myocardial perfusion. 123I MIBG is used for detection of doxorubicin-induced subacute changes in the myocardial adrenergic neurons. Cardiac MR is performed with late gadolinium enhancement and provides information on acute and late changes in left ventricular, atrial and ventricular volumes, myocardial mass and interstitial fibrosis. Statistical analyses were done in R (version 3.2.0) as paired difference tests using Wilcoxon signed rank test. P-values <0.05 were considered significant.

Results: As of March 1st 2017, 61 patients have been included. In 33 cases, the time of intended follow-up has been reached. Four patients died prior to follow-up, including one patient who died before the acute imaging procedures. Four patients were excluded due to compliance problems. One patient was excluded due to disease downstaging resulting in omission of doxorubicin from the treatment plan. Of the 24 patients with complete data from both the baseline and late MR scans, 16 had lower LVEF values at follow-up: 0-5% (n=3), 6-10% (n=8), 10-15% (n=4) and >20% (n=1). Mean LVEF at follow-up was significantly lower (57.1%) compared to baseline LVEF. (62.0%; p<0.01) and acute LVEF (64.3%; p<0.002). The LVEF decline from baseline to follow-up was paralleled by an increase in mean left ventricular end diastolic volume (LVEDV) of 10.0ml (p=0.03). Interestingly, an increase in LVEDV was already registered at the acute MR scan (7.3ml; p<0.03). The increase in LVEDV from the acute MR to follow-up was not significant. We also registered an acute increase of 7.4ml in mean stroke volume (SV) (p<0.02). However, from the acute MR to follow-up we found a significant decline in SV (p<0.02). There was no difference in SV from baseline to follow-up (p=0.7). The acute changes in LVEDV did not predict LV EF declines from baseline to follow-up (Figure 1).

Figure 1.

Summary/Conclusions: Our preliminary show that cardiac MR can be used for detection of declining LV function 1 year after after doxorubicin exposure. It appears that cardiac MR may also provide information on acute functional changes in LVEDV and SV. We hope that our 82 Rb PET and 123I MIBG data will provide additional early signs of doxorubicin cardiodotoxicity that can be used to predict subsequent development of HF.
Background: We conducted this clinical trial to address the efficacy and safety of our regiment for newly diagnosed stage IV (n=49) and relapsed (n=11) ENKTL from 2010 to 2016. The median age at recruitment was 38 years and the median follow-up period was 13.4 months. Patients were treated with GLIDE (gemcitabine 800 mg/m2 D1, L-asparaginase 6000 U/m2 D1, L-asparaginase 6000 U/m2 D4,D8,12 or peg-asparaginase 2500 u/m2 D4,11; ifosfamide 1000 mg/m2 D1-3; dexamethasone 20mg D1-4; etoposide 100 mg/m2 D1-3) every 4 weeks, and responses were evaluated with PET/CT every 2 cycles. Patients achieving CR underwent ASCT or continued with GLIDE up to 6 cycles. Others finished 6 cycles of GLIDE. Overall response rate (ORR), CR, OS and progression free survival (PFS) were calculated using standard methods. Statistical analysis was done using Fishers exact test or Chi-square test / Kruskal-Wallis test. Kaplan-Meier method was used for time-to-event analysis including overall survival and progression free survival. The Log-rank test was used to evaluate the difference in time-to-event endpoints between patient groups.

Results: Fifty-seven patients had finished planned treatment with 1 withdraw of informed consent after cycle 1, and 2 death of sepsis during cycle 1 and cycle 2 respectively. Twenty-one patients underwent ASCT. The ORR was 81.4% and the CR was 69.5% with early CR (CR after 2 cycles) of 57.6%. Estimated 5-year OS and PFS rates of the whole cohort and patients underwent ASCT were 68.7%, 54.0%, 79.6% and 85.2% respectively. Univariate analysis revealed that ECOG ≤1, IPI≤2, early CR and ASCT were associated with less relapse and death. Multivariate analysis showed ECOG ≥2 was an independent risk factor for disease progression (HR=4.321, 95% CI 1.127–16.572, P=0.033) and death (HR=4.265, 2.150–993.190, P=0.014) and ASCT was associated with better OS, PFS and DFS (HR=0.058, 95% CI 0.007–0.495, P=0.009) and OS (HR=0.019, 95% CI 0.001–0.596, P=0.024). Figure 1 highlights the OS and PFS of whole cohort (A) and ASCT patients (B). Myelosuppression was the most common adverse reaction (AE). The incidences of level 4 neutropenia, thrombocytopenia and anemia were 46.6%, 28.6% and 5.3% respectively. The most common non-hematologic AE was fever with neutropenia (36.8% of total cycles), while others were mild and manageable.

Summary/Conclusions: GLIDE is an effective regimen for newly diagnosed stage IV and relapsed ENKTL. Up-front ASCT after achieving CR can reduce relapse and prolong survival. Treatment related adverse reactions and support care need concerns.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic of relapse</th>
<th>Group 1</th>
<th>Group 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapse-free survival, n</td>
<td>25 (88.6)</td>
<td>37 (82.6)</td>
<td>0.182</td>
</tr>
<tr>
<td>Median time to relapse, months</td>
<td>10 (6-21)</td>
<td>8 (6-19)</td>
<td>0.239</td>
</tr>
<tr>
<td>Time to treatment failure, months</td>
<td>9 (6-21)</td>
<td>6 (6-15)</td>
<td>0.246</td>
</tr>
<tr>
<td>Time to death, months</td>
<td>21 (15-27)</td>
<td>20 (14-26)</td>
<td>0.852</td>
</tr>
<tr>
<td>ECOG score</td>
<td>0 to 1</td>
<td>0 to 1</td>
<td>0.955</td>
</tr>
</tbody>
</table>

Note: AE = adverse effect, CR = complete remission, OS = overall survival, PFS = progression free survival, DFS = disease free survival.
Bone marrow failure syndromes incl. PNH - Biology

P226
IDENTIFICATION OF A NOVEL GERMLINE MECOM / EV1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY

T. Ripperger1,2,3, W. Hofmann1, J.C. Koch1, K. Shireeshan3, H. Haase3, G. Wull3, P.R. Issing4, M. Karnebogen5, G. Schmidt1, B. Auber1, B. Schlegelberger1, T. Illig1,2,4, B. Zirm5, D. Steiennann1

1Department of Human Genetics, Hannover Medical School, Hannover, 2Department of Neurology, 3Department of Hematology and Oncology, University Medical Centre, Goettingen, 4Department of Orthoholymphology, Head, Neck and Facial Plastic Surgery, Klinikum Bad Hersfeld, Bad Hersfeld, 5Healthpark Lengern, Division of Surgery and Orthopedics, Bovenden, 6Unified Biobank, Hannover Medical School, Hannover, 7Genetic Counseling and Diagnostics, Genetikum, Stuttgart, Germany

Background: Radioulnar synostosis and amegakaryocytic thrombocytopenia (RUSAT), one of the rare bone marrow failure syndromes, is caused by a point mutation in HOXA11. In three simplex patients, de novo missense variants in MECOM have recently been reported as an alternative cause in individuals with RUSAT. MECOM, identified as a common ecotropic viral integration site 1 (EV1) in murine myeloid leukemia, is known as a key transcriptional regulator in hematopoiesis and is frequently involved in sporadic myeloid leukemia.

Aims: To screen for the causative genetic alteration in a family with four affected individuals out of three generations with radioulnar synostosis, incompletely penetrant congenital thrombocytopenia, hearing impairment due to dysplastic middle ear bones, patellar hypoplasia, and hand and foot dysmorphisms. Notably, two of four affected individuals in our family developed adult onset myeloid malignancies (i.e. myelodysplastic syndrome (MDS) with excess blasts and MDS/myeloproliferative neoplasm-unclassifiable). No HOXA11 mutation was identified in this family.

Methods: Whole exome sequencing was performed in three affected individuals using a Nextera Rapid Capture kit and a NextSeq 500 instrument (Illumina, Munich, Germany). Identified sequence variants were filtered for those that are de novo by carrier analysis. In all three subjects, it was decided to be diagnostic of MECOM. Autosomal dominant inheritance was assumed and the following filter criteria were applied: (i) presence in both affected family members and two of the four affected individuals; (ii) not being a known variant (gVCF, 1000G, ESP6500, ExAC), and (iv) not listed in our in-house database of recurrent variants.

Results: Following this approach, a novel MECOM missense variant (i.e. Cys766Gly, UniProtKB Q03112-1) was identified. The missense mutation affects a heavily conserved cysteine residue in C2-H2-zinc finger motif 9 in the C-terminal zinc finger domain of MECOM. This residue is crucial for the tetrahedral coordination of a zinc ion stabilizing the zinc finger conformation and thus, is essential for DNA binding of the C-terminal zinc finger domain.

Summary/Conclusions: Our findings confirm the causality of MECOM missense mutations targeting the C-terminal zinc finger domain in subjects with RUSAT and indicate that MECOM needs to be considered in RUSAT pedigrees with no HOXA11 mutation. We report here for the first time that MECOM germline mutations are associated with an increased risk for adult onset myeloid malignancies. This extends the RUSAT-associated phenotype and proposes that MECOM germline mutations can cause a genetic predisposition to adult onset myeloid malignancy.

[BZ and DS contributed equally to this work].
generated by ENU mutagenesis were characterized in terms of their hematopoietic and non-hematopoietic phenotypes during embryonic development and adulthood.

**Results:** The rad51f mutant fish developed key features of FA, including hypocellular kidney marrow (equivalent to mammalian bone marrow), sensitivity to crosslinking agents and decreased size. Interestingly, although mutants can survive to adulthood, they develop exclusively as sterile males. We show that some of the hematological symptoms stem from both decreased proliferation and increased apoptosis of embryonic hematopoietic stem and progenitor cells. Co-mutation of p53 was able to rescue the embryonic and adult hematopoietic defects seen in the single mutants, but led to early tumor development in the adult double mutants. We further establish that prolonged inflammatory stress can exacerbate the hematological impairment, leading to an additional decrease in kidney marrow cell numbers linked to excess p53 expression (Figure 1).

![Figure 1. Example image of a p53, rad51 double mutant fish with a tumor behind the eye (A). Histological analysis showed the tumour to be a malignant peripheral nerve sheath tumor (B). The scale bar is 500 and 10μm respectively.](image)

**Summary/Conclusions:** We demonstrate that zebrafish lacking functional rad51f can be viable and develop symptoms resembling FA. These findings strengthen the assignment of RAD51F as a Fanconi gene and provide more evidence for the notion that aberrant p53 signaling during embryogenesis leads to the hematological defects seen during later stages of life in FA patients. Further research on this novel zebrafish FA model will lead to a deeper understanding of the molecular basis of bone marrow failure in FA and the cellular role of the RAD51F protein.

**P228**

**A NOVEL TELOMERASE RNA COMPONENT VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS**

C. Burney1,2, A. Mumford2, N. Roy3, A. Schuh3, M. Proven3, A. Mumford2, N. Roy3

1Department of Haematology, University Hospitals Bristol NHS Trust, 2School of cellular and molecular medicine, University of Bristol, Bristol, 3BRC Blood Theme and BRC/NHS Translational Molecular Diagnostics Centre, John Radcliffe Hospital, 4Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

**Background:** Telomerase RNA component (TERC), encoded by the TERC gene, is an essential component of telomerase, a polymerase that adds the telomeric repeat to the 3’ lagging strand of DNA during cell replication. TERC variants have been causally associated with several hematological disorders, including autosomal dominant dyskeratosis congenita (DKC), aplastic anaemia, myelodysplastic syndrome and acute leukaemia, sometimes accompanied by non-hematological phenotypes. In order to determine the pathogenicity of this variant, telomere lengths were assessed and found to be short in both Case I.1 and II.2 (Table 1). There were no other likely pathogenic variants in the Oxford Red Cell Panel genes. Together, these observations suggest that the n.181A>C substitution is causally associated with the macrocytosis phenotype.

**Table 1.**

<table>
<thead>
<tr>
<th>Parameter (normal range)</th>
<th>I.1 (Indice cases)</th>
<th>I.2</th>
<th>I.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin (g/dL)</td>
<td>13.9</td>
<td>10.9</td>
<td>17.2</td>
</tr>
<tr>
<td>Mean cell haemoglobin</td>
<td>130.8</td>
<td>115.0</td>
<td>170.4</td>
</tr>
<tr>
<td>Total red cell count (10^12/L)</td>
<td>4.36 ± 0.19</td>
<td>4.05 ± 0.20</td>
<td>4.38 ± 0.21</td>
</tr>
<tr>
<td>Mean platelet count (10^12/L)</td>
<td>300.00</td>
<td>300.00</td>
<td>300.00</td>
</tr>
<tr>
<td>Mean platelet volume (fL)</td>
<td>8.80</td>
<td>8.80</td>
<td>8.80</td>
</tr>
<tr>
<td>Serum iron (μg/dL)</td>
<td>130.0</td>
<td>100.0</td>
<td>170.0</td>
</tr>
<tr>
<td>Serum transferrin (μg/dL)</td>
<td>420.0</td>
<td>300.0</td>
<td>420.0</td>
</tr>
<tr>
<td>Serum ferritin (μg/dL)</td>
<td>300.0</td>
<td>200.0</td>
<td>300.0</td>
</tr>
<tr>
<td>Severe lymphopenia (%)</td>
<td>10.0</td>
<td>2.0</td>
<td>7.0</td>
</tr>
<tr>
<td>Severe neutropenia (%)</td>
<td>10.0</td>
<td>2.0</td>
<td>7.0</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** This report demonstrates a likely causal association between a newly identified TERC variant, short telomere length and a relatively mild hematological phenotype that is largely restricted to red cells. This emphasizes the phenotypic heterogeneity associated with TERC variants, justifies the rationale of screening multiple genes simultaneously and suggests that TERC variant could potentially underlie a broader range of unexplained heritable blood cell abnormalities.

**P229**

**GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS**

C. Carrascoso1,2, H.A. Zittersteijn1,2, L. Pintado-Berniches3, M.L. Lozano1,2, L. Sastre3, J.A. Buener1,2, R. Perona23, G. Guenchea1,2

1Division of HematoPOietic Innovative Therapies, Centro de Investigaciones Estructurales Medicinales (CIBMED and CEBARMAT) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), 2Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 3Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain

**Background:** X-linked Dyskeratosis congenita (XDC) is an inherited syndrome caused by mutations in the DKC1 gene that encodes for the dyskerin nucleolar protein. These mutations reduce the telomerase activity leading to premature telomere length attrition. Several organs can be affected in these patients, although the bone marrow failure (BMF) is the main cause of death in XDC patients. Other mutations have also been causally associated with telomere shortening and a more severe hematopoietic phenotypic spectrum. These mutations may cause an early onset of clinical symptoms, and there is an urgent need for new treatments that could delay the onset of BMF. Since hematopoietic stem cells (HSCs) are the building blocks of the hematopoietic system, they must be studied to develop new therapeutic strategies for XDC patients.

**Methods:** In this study, we generated functional hematopoietic stem cells (HSCs) in vitro from XDC patients using the human umbilical cord blood (HUCB) as a source of HSCs. We used the plasmid pCMV-hTERT to overexpress telomerase reverse transcriptase (TERT) in the HUCB cells, and we also used the plasmid pCMV-hDKC1 to overexpress dyskerin. After transfection, the HUCB cells were cultured under conditions that promote hematopoietic cell differentiation. We then isolated the HSCs from the differentiated cells and characterized their hematopoietic potential.

**Results:** We were able to generate functional HSCs from XDC patients using the plasmids pCMV-hTERT and pCMV-hDKC1. The HSCs showed normal hematopoietic differentiation potential, and we were able to generate all hematopoietic lineages. We also observed an increase in the telomere length of the HSCs, which was consistent with the overexpression of TERT and DKC1.

**Summary/Conclusions:** This study demonstrates the potential of using gene therapy to generate functional HSCs from XDC patients. This approach could provide a new therapeutic strategy for XDC patients and may lead to the development of new treatments for other hematopoietic disorders.
Aims: Because of the difficulties associated to the use of primary HSCs from DC patients for experimental studies, this study was focused on the generation of X-DC-like human HSCs by flow cytometry. The generated X-DC-HSCs showed an inhibited telomerase activity, as well as a reduced clonogenic and hematopoietic reconstitutuion potential in NSG mice. Additionally, an increase in DNA damage and senescence was observed in DKC1-interfered CD34+ cells.

Methods: CD34+ cells were obtained by immunomagnetic purification from healthy human umbilical cord blood samples. The generated X-DC-HSCs were then selected for 2 days with puromycin, and cultured in vitro or transplanted into immunodeficient NSG mice to evaluate the effects of shRNAs.

Results: Based on the inhibition of DKC1 gene expression, 3 shRNAs were selected among 7 designed shRNAs. Interted HSCs showed an inhibited telomerase activity, as well as a reduced clonogenic and hematopoietic reconstitutuion potential in NSG mice. Additionally, an increase in DNA damage and senescence was observed in DKC1-interfered CD34+ cells.

Summary/Conclusions: In vitro and in vivo data obtained from DKC1-interfered X-DC-HSCs suggested that these cells will be useful in the study of primary X-DC-HSCs. The generation of X-DC-like HSCs will facilitate the understanding of the molecular basis of the HSCS defects characteristic of X-DC and contribute to the development of new experimental therapies for the treatment of the BMF of X-DC patients.

P230 STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECUILIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY

F. Beier1,*, M. Kirschner1, A.-S. Bouillon1, I. Halfmeyer1, M.S. Ventura Ferreira1, A. Maurer1, S. Willop1, F. Thou1, A. Röth1, U. Platzecker4, W. Blau2, F. A. Ayuk1, S. Corbacioglu1, H. Schrezenmeier1, M. G. Manz2, T. Eggermann10, K. Zerres10, S. Koschnieder1, M. Schmemionek1, S. Isfort1, T. Panse1, T.H. Brümmendorf1

1Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, 2Department with Hematology, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, 3Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, 4Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, 5Department of Haematology and Oncology, Justus-Liebig Universität Giessen, Giessen, 6Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, 7Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital Regensburg, Regensburg, 8Institute of Transfusion Medicine, University of Ulm, Ulm, Germany, 9Department of Hematology and Oncology, University Department of Hematology and Oncology, University of Mannheim, Mannheim, 10Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease characterized by complement-mediated hemolysis (Brodsky et al., Br J Haematol, 2004; Hugel et al., Blood, 1999). Eculizumab, a human anti-C5 monoclonal antibody, used in the treatment of PNH seems to decrease the thrombosis frequency (relative reduction of 85% of thromboembolic event rate with the introduction of the treatment in the patients) (Hillmen et al., Blood, 2007; Kelly et al., Ther Clin Risk Manag, 2009; Weitz et al. Thromb Res, 2012; Al-Jafar et al. Hemato Rep, 2015).

Aims: The general purpose of this project is a better understanding about the role of EVs in thrombosis in the context of PNH patients under eculizumab. We aimed to study whether eculizumab can modulate EV production and on their procoagulant activity, in order to check, if the antithrombotic activity of the eculizumab could be in part explained by its interaction with the EVs.

Methods: We conducted a pilot prospective open label longitudinal clinical study with six PNH patients treated with eculizumab. The study was led according to the Declaration of Helsinki and approved by the local Ethics Committee. Informed consent was obtained for each patient. The aim was to measure, by flow cytometry, the production of EVs in patient’s platelet-free plasma (PFP) before the start of eculizumab, after 4 weeks and after 11 weeks of treatment. We also assessed the procoagulant activity in PFP by STA®-Procoag-PPL assay and by thrombin generation assay (TGA). A more sensitive version of TGA was also performed to study the procoagulant profile induced by the EVs (use of EVs pelleted from PFP). We used mixed-effects linear regression for flow cytometry results. We compared the results after 4 weeks or 11 weeks of treatment against the inclusion value.

Results: We observed a decrease in platelet EVs with the eculizumab treatment (p<0.05). STA®-Procoag-PPL assay showed a decrease of the procoagulant profile induced by procoagulant phospholipids (PL) with the treatment. These results were not confirmed by TGA on PFP, due to a lack of sensitivity. By this way, we performed a more sensitive version of TGA that allows to observe variation in the procoagulant profile induced by the EV with the eculizumab (p<0.05).

Summary/Conclusions: Eculizumab has an impact on the amount and the procoagulant profile induced by the procoagulant PL and the EVs. The anti-thrombotic performance of the eculizumab can be in part explained by its action on EVs.

P231 TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA – PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY

F. Beier1,*, M. Kirschner1, A.-S. Bouillon1, I. Halfmeyer1, M.S. Ventura Ferreira1, S. Giammarco1,*, S. Simona2, C. Dufour3, R. Peffault de Latour4, G. Socie5, J. Passweg6, A. Baigalupoi1

1Hematology, Università Cattolica del Sacro Cuore, Rome, 2Hematology, University of Florence, 3Department of Medicine and Surgery, University of Pisa, 4Hematology, Hôpital Saint-Antoine, AP-HP, Paris, 5Hematology, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, 6Hematology, University Hospital Regensburg, Regensburg, Germany

Background: Classical Dyskeratosis Congenita (DKC) is a multisystem disorder caused by defective telomere maintenance, mostly due to mutations in genes related to functional activity of telomerase or accessibility of the telomeres themselves. Clinical characteristics are mucocutaneous abnormalities, bone marrow failure, an increased predisposition to cancer and other variable features. While classical DKC is typically diagnosed in childhood or adolescence, the incidence of cryptic DKC variants typically presenting with a clinically more heterogeneous picture within the spectrum of bone marrow failure, is currently unknown. The prevalence of DKC in the general population is unknown. Accelerated shortening of Telomere length (TL) in peripheral blood leukocytes represents the functional read-out of altered telomere maintenance and thus allows for a screening of patients with suspected DKC. On the basis of TL measured below the 1% percentile of age adjusted healthy controls, next-generation-sequencing (NGS) analysis for underlying mutations was triggered.

Aims: In this study, we report the first results of such a clinical routine screening for telomeropathies carried out within the Aachen Telomeropathy Registry (ATR).

Methods: 184 patients from 52 participating centers (80% academic centers) within Germany, Austria and Switzerland were screened for premature telomere shortening and included with informed consent into the ATR since November 2014. Inclusion criteria and reason for screening was either the clinical suspicion of the treating physician for a telomere maintenance disorder and/or the recommendations of the German Society of Hematology and Oncology (DGHO) published via Onkopedia. TL analysis of peripheral blood granulocytes and lymphocytes was carried out using combined fluorescence in situ hybridization and flow cytometry (flow-FISH). Mutations in genes suspected to cause telomeropathies (i.e. TERT, TERC, DKC1, NOP10, NHP2, US2, TERT, RTLE1, TIN2, TCAB1) were analyzed by NGS using customized primer panels and amplicon-based sequencing on a Miseq sequencer (Illumina) in all patients with TL in lymphocytes below the 1% percentile of healthy controls.

Results: Underlying initial diagnosis by the treating physician for screening was aplastic anemia (AA, n=72, 39% of cases), unexplained cytopenia (UC, n=66, 36%), myelodysplastic syndrome (MDS, n=34, 18%), atypical squamous cell carcinoma of the head-and-neck (SCCHN, n=10, 6%), paroxysmal nocturnal hemoglobinuria (PNH, n=9, 5%), acute myeloid leukemia (AML, n=5, 3%) as well as other disorders (e.g. lung fibrosis, Dragon-Blackfan-Anemia, LGMD, etc.). Median age at diagnosis was 57.0 (range 1.5 to 88) years. TL screening revealed 20% (38/184) patients with lymphocyte TL and 16% (30/184) of patients with granulocyte TL below the 1% percentile. NGS screening identified typical mutations associated with altered telomere maintenance in 15 out of 38 patients (40%) representing 8.2% of the total patient population. Median age of patients with mutations was 45.0 y (range 21 to 68 y). 12 of 20 patients with mutations were detected in RTLE1 (n=3), TERC (n=6), TERT (n=2), DKC1 (n=3). Mutations were observed in 5% of all AA, 12% of all UC, 50% of all MDS, 13% of all SCCHN, 20% of all screened AML patients.

Summary/Conclusions: We provide the first analysis of a routine TL screening that started in the Aachen Telomeropathy Registry in patients up to the age of 88 y. TL screening is feasible in a routine clinical setting identifying approximately 20% of all samples to reside below the 1% percentile. Genetic testing confirmed the diagnosis of cryptic DKC in a variety of initial diagnoses. This study highlights both the diagnostic value of TL screening for cryptic DKC as well as the importance of comprehensively underlined patients. Preliminary mapping of DKC however is of utmost importance given its significant clinical implications towards prognosis, treatment and family counseling.
versità Cattolica del Sacro Cuore, roma, 1Hematology, Istituto Giannina Gaslini, Genova, Italy, 2Hematology, Hôpital St Louis, 3Hematology, Hôpital Saint-Louis, Paris, France, 4Hematology, Universitätsspital Basel, Basel, Switzerland

Background: Mortality following HSCT in SAA pts over the age of 40 is reported to be in the order of 50%, without taking in to account long term sequelae such as chronic GvHD, known to be more frequent in older patients. This has prompted international guidelines to recommend first line immunosuppressive therapy above 40 years of age. The question is whether this is still true in 2017.

Aims: Assess whether TRM in SAA patients grafted 2010-2015 is reduced, as compared to the era 2001-2009.

Methods: We used the WPSAA-EBMT registry, and identified 748 pts aged 40 years or more, with acquired SAA, grafted between 2001 and 2015. We divided pts in 2 transplant eras:2001-2009 (n=327) and 2010-2015 (n=407). In the more recent period (2010-2015) pts were older (53 vs 49 year, p<0.01), were more often grafted from alternative donors (ALT) (64% vs 43%, p<0.01), with a greater use of BM (54% vs 41%, p<0.01), and with a longer interval dx-tx (317 vs 258 days, p<0.01), and more often received a fludarabine containing regimen (55% vs 42%, p<0.01).

Results: The overall survival 5 year survival of pts grafted in 2001-2009 was 57%, compared with 55% for pts grafted 2010-2015 (p=0.7). In multivariate analysis, including the interval diagnosis transplant, patient’s age, donor type, stem cell source and conditioning regimen, the lack of improved survival in 2010-2015 was confirmed (p=0.3). A very strong age effect was shown both in univariate and multivariate analysis: survival of pts aged 40-50 years, 51-60 years and >61 years, was respectively 64%, 54%, 41% (p<0.0001) and this was confirmed in multivariate analysis. The conditioning regimen, also proved to be a significant predictor, with improved survival for ALT transplants receiving FLU containing regimens (56% vs 46%, p<0.001). In general pts receiving either CY200 or a FLU containing regimen, did significantly better than pts receiving other preparative regimens (58% vs 50%, p<0.02). The use of a sibling donor (SIB) did not prove to predict survival in multivariate analysis. Pts receiving Campath in the conditioning, did significantly better than pts not receiving Campath (65% vs 54%, p<0.01); similarly survival of patients with ATG was superior 59% vs 41% compared to patients not receiving ATG (p<0.01). When pts receiving either Campath or ATG (n=564) were compared to patients not receiving either (n=161), the difference in survival was 61% vs 41% (p<0.0001), and this was significant also in multivariate analysis. Combined primary and secondary graft failure was reduced from 16% to 12% in the two time periods (p=0.02), acute GvHD grade II-IV was reduced from 15% to 10% (p<0.01) and chronic GvHD was also reduced from 32% to 26% (p=0.01). Infections remain the leading cause of death in both transplant eras (18% and 22% respectively), followed by GvHD (5% and 4%) and graft failure (5% and 2%), whereas PTLD have been reduced from 3% to 0.5% (Figure 1).

Figure 1.

Summary/Conclusions: HSCT in pts with acquired SAA aged 40 and over, continues to carry a significant risk of TRM also in 2010-2015, ranging from 36% in younger pts (40-50) to 59% in older pts (>60 years). Survival is predicted in multivariate analysis, by two crucial predictors:patients age and the use of either Campath or ATG, the latter giving a 20% survival advantage over no Campath/ATG. ALT and SIB donors produce similar survival. This study gives further support to current guidelines, suggesting first line therapy with ATG+Csa, in pts over the age of 40.

P233

CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM

D. Iskander1, C. Miller2, M. Alkini2, Y. Harrington2, Q. Al-Oqaily1, I. Roberts4, A. Karadimitris1, J. de la Fuente9
1Centre for Haematology, Imperial College London, 2Department of Paediatrics, St. Mary’s Hospital, Imperial College Healthcare Trust, 3Imperial Molecular Pathology Laboratory, Imperial College Healthcare Trust and Academic Health Sciences Centre, London, 4Department of Paediatrics, Children’s Hospital and Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and John Radcliffe Hospital, Oxford, 5Department of Paediatrics, St. Mary’s Hospital, Imperial College Healthcare Trust, London, UK, London, United Kingdom

Background: Diamond-Blackfan anaemia (DBA) is an inherited bone marrow failure syndrome (BMFS) caused by mono-allelic, loss-of-function mutations in ribosomal protein (RP) genes. DBA is rare and has a wide spectrum of clinical manifestations, hence the utility of patient registries.

Aims: We evaluated the clinical and genetic spectrum of DBA in a large cohort of patients in the UK, aiming to identify novel features of the disease.

Methods: We performed a retrospective analysis of data from 103 confirmed cases of DBA, including 4 multiplex families. All living patients had undergone a bone marrow assessment at our specialised centre during the last 5 years. Data were collected from family interviews, patient records and referring clinicians.

Results: The 103 patients with DBA were born in a 48-year period (1967-2015), i.e., an incidence of 3 per million live births. Demographic and clinical characteristics are shown in Table 1. NGS analysis of 80 RP genes plus GATA-1 identified pathogenic mutations in 71% of cases and 7 putative novel mutations, currently undergoing validation. To date, mutation screening of both parents has been performed in 32 families with DBA. Twenty-five mutations are sporadic while 7 are autosomal dominant; in 3 of the latter, the parent is a silent ‘carrier’ without anaemia. In one case of an affected child, the causative mutation was identified in the peripheral blood of both parents but was present in 7/22 embryos generated for in vitro fertilisation, suggesting germline mosaicism. 80.5% of cases in our cohort presented within the first year of life. For the first time we report a high rate of perinatal problems in DBA. Prematurity +/- intrauterine growth restriction (IUGR) occurred in 3/87 (35.6%) of evaluable patients. Specific abnormalities included: hydronephrosis (3/87), prematurity (22/87) and IUGR (16/87). In addition to congenital anomalies classically associated with DBA, we identified abnormalities of the spine and axial skeleton in 9.2% of patients. These did not correlate with a particular genotype. Our cohort exhibited multiple comorbidities, including some not previously reported to be associated with DBA: hepatic (10.7%), neuropsychiatric (17.4%) and gastrointestinal (GI) disorders (25.7%). These complications were not associated with particular treatment regimens. In terms of the natural history of DBA, a lower proportion of our patients (22%) than previously reported in the literature (40%) were able to maintain a normal Hb on long-term steroids. Three patients failed to respond to a metoclopramide trial. In total there were 4 incidents of malignancy (MDS, B-ALL, BCC and cervical intraepithelial neoplasia) in 4 different patients. The lower incidence in our cohort compared with that reported by the North American DBA registry may be explained by differences in the median ages of the 2 cohorts (12y versus 18y, respectively) and the shorter follow-up of our patients.

Summary/Conclusions: This retrospective analysis of the UK’s DBA cohort confirmed several findings from other registries but also revealed novel features, including a high prevalence of i) prematurity birth and neonatal complications ii) abnormalities of the axial skeleton and iii) neuropsychiatric disorders. Prospective longitudinal studies are warranted to better characterise these co-morbidities and to confirm whether they are intrinsic to DBA or arise as complications of treatment. Above all, the observed clinical heterogeneity in our cohort highlights the need for novel therapies that target the multisystem manifestations of DBA, not just the anaemia.
BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS

M. Miano1,*, A. Grossi2, L. Fanciullo1, M. Lanciotti1, F. Fioredda1, E. Palmisani1, F. Piem1, S. Giardino1, E. Cappelli4, T. Lanza1, P. Terranova1, M. Calvillo1, C. Micalizzi1, F. Giona4, M. Santopietro4, K. Zhang5, I. Ceccherini2, C. Dufour1
1Haematology Unit, 2Molecular Genetic Unit, 3Stem Cell Transplantation Unit, IRCCS Istituto Giannina Gaslini, Genova, 4Haematology, Dep. of Cellular Biotechnologies and Haematology, La Sapienza University, Roma, Italy, 5Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States

Background: Differential diagnosis between acquired and congenital forms of Marrow Failure (MF) has always represented a crucial point in the diagnostic work-up, since genetic forms do require a different therapeutic approach. It is also known that patients with congenital MF may also show immunodeficiency that, in some cases, can represent the first or revalent sign of the disease and therefore can be misinterpreted as a Primary Immunodeficiency (PID). On the other hand, patients with PIDs may also show MF as a result of an immune-mediated attack of marrow precursors thus generating a phenotypic overlap that can impair the correct diagnosis.

Aims: In this report we analyzed all patients with MF evaluated in our Unit with the aim to identify the type and incidence of underlying molecular defects, in particular those related to PIDs.

Methods: We retrospectively evaluated all diagnosis performed in patients with single/multi-lineage MF followed in our Unit. DEB test was used to screen Fanconi Anemia (FA). Other congenital MFs have been searched by Sanger and/or NGS molecular analysis depending on the available tools over the years.

Results: Between 2009-2016, 88 patients have been studied for single-lineage (25) or multilineage (63) MF. 48 (64%) were classified as having an acquired MF; 27 (30%) were diagnosed with a congenital MF (FA 11, Dissekeratosis Congenita 5, Severe Congenital Neutropenia 6, Blackfan-Diamond Anemia 3, Congenital Megakaryocytic Thrombocytopenia 2), and the remaining 13 patients (14%) were found to have an underlying PID. Table 1 shows clinical characteristics and mutations of patients with PIDs.

Table 1.

Summary/Conclusions: This report shows that patients presenting with single/multi-lineage MF may have an underlying PID in a considerable number of cases. We also show that MF represented the most relevant clinical sign in patients with PI3KCD, TACI, or CD40L mutations, thus widening their clinical phenotype. We conclude that an accurate immunological work-up should be performed in all patients with MF and that PIDs-related genes should be included in the molecular screening of MF in order to identify specific disorders that may potentially receive targeted treatment and/or the appropriate conditioning regimen for SCT.

COVERSIN, A NOVEL C5 COMPLEMENT INHIBITOR, FOR THE TREATMENT OF PNH: RESULTS OF A PHASE 2 CLINICAL TRIAL

A. Hill1,*, W. Weston-Davies2, M. Numm2,3, T. Robak4, A. Szmigielska-Kaplon4, J. Windys5, A. Helman5
1St James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, 2Akari Therapeutics Plc, 3Haemostasis Research Unit, University College London, London, London, United Kingdom, 4Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, 5Department of Disorders of Haemostasis and Internal Medicine, Institute of Haematology and Transfusion Medicine, Warsaw, 6Department of Haematology, Gdansk University Hospital, Gdansk, Poland

Background: Paroxysmal nocturnal haemoglobinuria (PNH) leads to episodic haemorrhage secondary to an acquired deficiency of PIGA anchor molecules on the surface of erythrocytes which play a critical role in protecting the cells from complement mediated lysis. Until the advent of eculizumab, a monoclonal anti-body which prevents the cleavage of C5 to C5a and C5b, PNH was associated with considerable morbidity and a poor long-term prognosis. However, eculizumab needs to be administered by health care professionals by intravenous infusion which may interfere with the life-styles, occupations and personal privacy of patients and the interval dosing has led to concerning breakthrough haemolysis. Coversin is a protein suitable for small-volume subcuta-neous (SC) injection which can be self-administered by patients.

Aims: The aim of this study is to investigate the safety and efficacy of the complement C5 inhibitor Coversin in the treatment of PNH.

Methods: A Phase 2 single arm open label trial of Coversin is currently ongoing under which patients, either newly diagnosed with PNH or who have not previously had access to complement inhibitors, are treated for 90 days. Coversin is supplied as a lyophilised powder, reconstituted with water for injection to give a buffered aqueous solution of Coversin 30mg/mL. The trial population consists of up to 10 adult patients with a diagnosis of PNH confirmed by flow cytometry. Treatment commences with an ablating regime (AR) consisting of a fixed dose of 60mg followed by 3 doses of 30mg q12 hours delivered by SC injection. After being suitably instructed patients are encouraged to self-inject the drug. Following the AR, a dose of 15mg q12 hours is given for a further 26 days when, if the patient’s disease is well controlled, they switch to 30mg q24 hours for the remainder of the trial. The dose can be increased by two incremental steps according to a pre-specified algorithm for patients not satisfactorily controlled on the basis of serum lactate dehydrogenase (LDH) or clinical grounds at any time during the 90-day period. The primary endpoints are safety and reduction of serum LDH to ≤1.8 X the upper limit of normal (ULN) for the local laboratory. Secondary endpoints include LDH at 28, 60 and 90 days, terminal complement activity assessed by CH50 ELISA (Quidel®), sheep erythrocyte haemolysis assay, PK (free and bound Coversin levels), anti-drug antibodies (ADA) and quality of life.

Results: The trial is still ongoing and has currently enrolled 5 patients, four of whom remain on Coversin. Three patients have required single dose increases during the initial 28-day period, one of whom was later withdrawn when a co-morbidity was suspected. Two patients have moved to a single daily dose. Updated results of these and any patients enrolled subsequently will be presented. To date 2 patients have achieved the primary efficacy endpoint, two have not yet reached the 28-day point. There have been no serious or significant adverse events and the drug has been well-tolerated. A few mild injection site reactions have been recorded but these appear to diminish with time. There has been no evidence of the formation of neutralising antibodies.

Summary/Conclusions: It currently appears that treatment with Coversin is safe and effective in controlling hemolysis in PNH and that patients are capable of self-administering the drug. Coversin may be an effective alternative for patients with PNH who prefer the independence of self-administration. The relatively short dose interval may also help to reduce breakthrough events due to trough levels of drugs administered at two weekly intervals or longer.
Chronic lymphocytic leukemia and related disorders - Biology 1

P236

GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA

G. Tiao1, M. R. Impaglio1,2,3, S. Kasaer1,2,3, W. Pohl1,2,3, A. Kamburov1, D.-A. Landau1,2,3, E. Tausch4, A. Taylor-Weiner1, C. Cibulskis1, S. Bahtl1, S.M. Fernandez2, K. Hoang2, E. Rheinbay1, H.T. Kim2, J. Bahl1, S. Robrecht1, K. Fischer6, M. Hallek6, S. Gabriel1, E. Lander1, S. Stilgenbauer4, C. Wu1,2,3, A. Kiezun1, G. Getz1,7,8, J. Brown1,2,3
1Cancer Program, Broad Institute of MIT and Harvard, Cambridge, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States, 3Department of Medicine, Brigham and Women’s Hospital, Boston, United States, 4Department of Internal Medicine III, Ulm University, Ulm, Germany, 5Department of Computational Biology and Biostatistics, Dana-Farber Cancer Institute, Boston, United States, 6Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany, 7Department of Pathology, Massachusetts General Hospital, Boston, United States.

Background: CLL is a highly heritable cancer. Although GWAS have identified ~30 independent SNPs associated with CLL, these are estimated to account for only 5-10% of the inherited component of CLL.

Methods: We hypothesized that this missing heritability might arise from rare coding variants (MAF <0.01), and sought to identify these through an exome-wide association study comparing rare germline variants between CLL patients and controls.

Results: We investigated 516 CLL patients of European descent who were compared to 8,920 ethnically matched, non-cancer population controls. CLL cohorts included 235 CLL patients from DFCI (128 previously reported, 107 unpublished exomes), and 281 CLL patients enrolled on the CLL8 trial of the German CLL Study Group (WES data reported previously). An additional 130 CLL patients in an extension cohort included 24 from our published whole-genome sequencing study and 106 from an early publication of the ICGC. Non-cancer controls came from 3 sources: 2,520 from the 1000 Genomes Project; 6,852 from the Exome Sequencing Project; and 7,611 from a study of genetic risk for myocardial infarction. We combined these heterogeneous datasets by: (i) processing sequencing data from all cohorts together and consistently; (ii) jointly calling the variants across all cases and controls; and (iii) analyzing only ethnically matched, unrelated samples over DNA sites with sequencing coverage sufficient to achieve high-confidence genotype calls. This quality control resulted in 8,920 controls available for the association analysis. We further controlled for population stratification by correcting for three principal components.

Summary/Conclusions: We aimed to perform a detailed analysis of the second significant gene in the Chronic Lymphocytic Leukemia (CLL) genome-wide association study (GWAS) (p<1 x 10^-6) reported previously. To do so, we performed an exome-wide association study (EWA) in a large cohort of 516 CLL patients and 8,920 matched, non-cancer population controls. We used the Office of Biomedical Informatics (OBI) genetics repository and the Genome Aggregation Database (gnomAD) to identify rare coding variants in CLL patients and controls. We then performed a joint analysis of rare variants across all cases and controls, and controlled for population stratification. Our analysis identified 20,442 rare variants in both cases and controls, and we identified 131 novel rare coding variants that were enriched in CLL cases compared to controls. These variants were enriched in known gene regions and were predicted by PolyPhen2 to be possibly damaging. We also identified several rare variants that were predicted to be damaging in patients but not in controls. These findings suggest that rare coding variants contribute to the heritability of CLL and may be important for understanding the genetic basis of this disease.

P237

DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL

B. Tesar1,2, L. Werner3, N. Pochet4, S. Fernandes1, M. R. Impaglio1,2, J. Kiltigaard1,2, C. Thompson1, M. Hanna4, A. Friedman1, D. Neuberg3, M. Freedman2, L. Core6, J. Brown1,2,3

Background: Genome-wide association studies (GWAS) have identified multiple loci that are statistically associated with CLL susceptibility. These single nucleotide polymorphisms (SNPs) are primarily located in non-protein coding genomic regions. Data suggest that these variants are enriched in regulatory elements.

Methods: To investigate SNP allele-specific impacts on gene expression, we selected 15 SNPs from 13 loci that achieved genome wide significance in initial CLL GWAS studies. We investigated either the published GWAS SNP (if present on the Affymetrix 6.0 SNP array) or proxy SNP(s) chosen using the SNP Annotation and Proxy Search (SNAP) software, based on their high linkage disequilibrium (LD) (r^2>0.85) with the selected GWAS SNP. Genotypes were determined in tumor (n=146) and saliva (n=79) DNA from CLL patients (who had provided written informed consent); tumor and saliva DNAs were concordant in at least 96% of cases (except rs477184 at 92%). Given the high concordance with saliva, which is likely related to the stable genome of CLL, SNP genotypes from tumor samples were used for the analysis in order to significantly increase our sample size. Allele-specific gene expression was then evaluated using the RNA-Seq expression arrays allowing Affymetrix CL1U133 Plus 2.0 array gene expression data, focusing on genes within 1 Mb in either direction from a given SNP. In order to elucidate whether these associations were due to functional effects on transcription, we used a novel assay called precision-run on sequencing (PRO-seq). PRO-seq efficiently maps active transcription regulatory elements and provides allele-specific and quantitative direct maps of transcriptionally-engaged RNA polymerases. The algorithm, discriminatory regulator-element detection from GRO/PRO-seq (dREG), is then used to predict the presence of TREs from raw PRO-seq data, allowing for identification of functional elements in the vicinity of SNPs and quantification of their allele-specific effects on enhancer activity and gene transcription.

Results: Our gene expression analysis demonstrated 6 significant SNP-gene associations: rs674313 (6p21.3) with HLA-DOA1 (p < 0.0001), rs872071 (6p2.5) with HLA-DOA1 (p<0.01), rs4771718 (15q23; proxy for rs1766508) with TLE3 (p<0.009), rs783540 (15q25.2) with CPEB1 (p<0.01), rs305088 (16q24.1; proxy for rs305061) with COX14NB/EMC8 (p<0.03) and rs4802322 (18q13.32; proxy for rs11083846) with FKRP (p<0.0001). Two associations were successfully validated in a completely independent gene expression replication analysis (n=54): rs674313 with HLA-DOA1 (p<0.0001) and rs4771718 with TLE3 (p<0.0116). To annotate candidate regulatory elements, we evaluated transcription level at or near all six significant SNPs and quantification of their allele-specific effects on enhancer activity and gene transcription.

Summary/Conclusions: We conclude that PRO-seq and dREG analysis identifies evidence of active differential transcription based on genotype in the region of 5 out of 6 GWAS-identified SNPs that we have investigated so far.
It appeared that in all 13 patients with a 17p deletion the other (38%) patients with mutations was confirmed in 51% (22/43) of the cases, where by no cytogenetic abnormality in 17p locus was observed (median TP53 VAF 43.5%, range 10.5–51.3%). Applying a VAF cut-off of 55% indicating fully expanded heterozygous mutation (taking into account the potential unequal representation of forward and reverse strands in NGS data), 7/29 (24%) cases below the cut-off still harbored 17p CN-LOH. These results show that it is not possible to use an arbitrary VAF cut-off (>50%) to identify biallelic mutations due to CN-LOH. When we compared genomic complexity of leukemia clones with monoallelic vs biallelic TP53mut demonstrated by the Cytoscan array, the latter group exhibited significantly more genomic abnormalities (p=0.0388) and also preference for different recurrent chromosome aberrations (p=0.0011: 17p locus excluded from this analysis). However, there was no significant difference in overall survival between the groups (p=0.5856).

Summary/Conclusions: cn-LOH in 17p locus is present in approximately half of the patients with single dominant TP53mut and results in biallelic TP53 gene inactivation despite the absence of del(17p); truly monoallelic TP53 gene mutations with an intact second allele occur in CLL with comparable frequency. Although 17p cn-LOH is associated with increased genomic instability, it does not have worse impact on clinical outcome than truly monoallelic TP53mut.

Supported by the projects AZV-MZCR 15-3183A, 15-30015A, 15-29733A, the EU Horizon2020 project No. 692298, and MEYS CEITEC 2020 LG1601.

P239
INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS
M. Stevens-Kroef1,*, A. Eijkelenboom 1, L. Kroeze 1, D. Olde Weghuis 1, P. Groenen 1
1Radboud university medical center, Nijmegen, Netherlands

Background: 5-cell chronic lymphocytic leukemia (CLL) exhibits a highly heterogeneous clinical course, with overall survival rates varying from several months to decades. Mutation status of the IGHSV genes and specific genomic abnormalities, such as deletion of 11q22 on the 13q14 region provide prognostic information. However, more importantly deletion of 17p and/or the presence of a TP53 mutation, which are both associated with a poor prognosis identify a poor outcome group with the highest risk of disease progression. Additionally, we identified a sub-group of 97 relapsed/refractory pts who had serial FISH analysis performed in bone marrow ≥1 year apart, to determine whether there were changes in copy number composition of CNAs detected by FISH during treatment in the absence of disease progression.

Methods: We analyzed 336 pts treated on investigational studies with ibrutinib or rituximab for CLL. In pts who progressed, we analyzed FISH and/or NGS results pre-treatment and at progression, to identify CCE. Additionally, we identified a sub-group of 97 relapsed/refractory pts who had serial FISH analysis performed in bone marrow ≥1 year apart, to determine whether there were changes in copy number composition of CNAs detected by FISH during treatment in the absence of disease progression.

Results: In total, 37 of 336 pts (11%) progressed during ibrutinib-based therapy. Of these pts, 15 had FISH analysis both pre-treatment and at progression: pre-treatment, 10 had del(17p), 1 had del(11q) and 4 had isolated del(13q). All 4 of the pts with isolated del(13q) pre-treatment had new sub-clonal FISH abnormalities detected at progression: two pts had del(17p), 1 had del(11q) and 1 pt developed two additional copies of all targeted regions at progression, suggestive of tetraploidy. The pt with del(11q) pre-treatment who progressed developed Richter Transformation (RT) in the bone marrow at progression, without either del(11q) or del(17p) identified by FISH, suggesting that the RT arose from a common ancestral clone without del(11q) or was clonally unrelated. Median FISH%del(17p) pre-treatment in those with del(17p) was 72%; only 1 pt had <50% del(17p) pre-treatment. All these pts had persistence of del(17p), at progression, without significant changes in alleleic frequency. Two pts with del(17p) pre-treatment had additional abnormalities detected by FISH at progression: sub-clonal biallelic del(13q) was seen in 2 pts, one of whom also developed t(11;14) in 12. In the absence of disease progression, the only CCE detected was emergence of small sub-clones with biallelic del(13q) in two patients who initially had monoclonal del(13q). Notably, in responding pts, there was no expansion of high-risk sub-clones. Conventional karyotyping was performed in 10/37 patients who progressed both pre-treatment and at progression. In 4 pts, CCE was identified at progression, including 17 new abnormalities in one pt. All 4 pts had complex karyotype and del(17p) by FISH pre-treatment and 3 of 4 had evidence of multiple, related, complex sub-clones pre-treatment. Figure 1 shows inferred clonal evolution pattern for one pt.

Figure 1.
Summary/Conclusions: Emergence of high-risk clones containing del(17p) and or del(11q) may be seen at disease progression in ibrutinib-treated patients. Analogous to allelic expansion of TP53 mutations after chemotherapy, we hypothesize that small del(17p) or del(11q) subclones were present prior to therapy in these pts, below the sensitivity of existing FISH techniques and expanded under the selective pressure of ibrutinib treatment. Development of a more sensitive technique to identify small subclones with del(17p) or del(11q) may therefore be important. Additionally, complex CCE occurred at progression in several cases, indicating genomic instability and potentially contributing to therapeutic failure.

Pairwise association showed statistically significant co-occurrence between tri(12) and mutations in KRAS/BCOR (both q<0.05), NOTCH1 mutation and ZMYM3 (q=0.01)/SPEN (q=0.05) mutations, and TP53 mutation and del(17p) (q<0.01)/complex karyotypes (q<0.05). When correlating with clinical response to lenalidomide, worse overall response (OR) in the untreated group was associated with del(17p) (p=0.019) and KRAS mutation (p=0.05), whereas as mutation in SF3B1 (p=0.026), MGA (del(1q), p=0.035), DDX3X (p<0.001), complex karyotype (p=0.035) and del(17p) (p=0.031) were associated with worse OR in R/R group. In the untreated group, del(17p) and TP53 were associated with worse progression-free (PFS) (p=0.002 and 0.003, respectively).

Methods: Peripheral blood samples were collected at multiple time-points over a 10-year period from 6 CLL cohort #4 patients. The clonotypicIGHV-IGHD-IGHJ and IGKV-IGKJ rearrangements were amplified by PCR using cDNA and sequenced on the MiSeq (Illumina). Our experimental design involved paired-end sequencing, thus allowing sequencing of the CDR3 reads, so as to increase the accuracy of results. To maintain stringency, raw NGS reads were subject to purpose-built, bioinformatics algorithms, which filtered for: (i) length and quality filtering of raw quality reads resulting in non-filtered paired reads or local alignment; and, (ii) length and quality filtering of stitched sequences. No base calls of Q-score<30 were allowed in the 75 nucleotide stretch preceding the GXG motif, further increasing CDR3 reading reliability. Data was then analyzed using the IMGT/High-QUEST database and clonotype computation was performed using an in-house bioinformatics pipeline.

Results: Overall, 48 samples were analyzed, producing 12,386,554 and 4,506,464 total reads for heavy and light chain, respectively. In addition to filtering out poor quality, incomplete, out-of-frame and unproductive rearrangements, the filtered reads were processed using the IMGT Clonoseq tool with known reading frames, usage of subset #4-specific V- and J-genes, CDR3 length and landmark residues. Applying these strict criteria resulted in 84.1% (median 401,133 reads/sample) and 90.3% (median 141,549.5 reads/sample) of the total sequences obtained for the heavy and light chain, respectively, passing filters. Clonotype computation was solely based on the filtered and previously sequenced CDR3 sequences which at later time-points had often disappeared and hence been selected against; and, (ii) that despite the high intensity of ID, certain residues remained essentially unaltered alluding to strong functional constraints.

Summary/Conclusions: Detailed molecular immunoprofiling by NGS afforded the possibility to gain novel insights into the pathogenesis of CLL subset #4, thus providing a comprehensive understanding of how these patients continue to acquire SMGs within their Ig genes; an observation best explained by a clear role for antigen selection in clonal evolution.
P243

FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE
K. Szarc Vel Szić1,2, K. Loose1, G. Andreix2, A. Heumüller1, N. Glaser3, S. Hild1, J. Duyster1, H. Busch2, M. Börries2, R. Claus1

1Division Hematology, Oncology and Stem Cell Transplantation, University Freiburg Medical Center, 2Institute of Molecular Medicine and Cell Research, University Freiburg, 3Center for Chronic Immunodeficiency, University Freiburg Medical Center, Freiburg, Germany

Background: During normal hematopoiesis, a coordinated epigenetic and transcriptional programming is necessary to achieve lineage development. B cell differentiation is predominantly related to loss of DNA methylation at the enhancers and promoters of B cell-specific genes; e.g., transcription factors (TFs). In chronic lymphocytic leukemia (CLL), failure of proper epigenetic pro- gramming contributes to deregulation of B cell transcriptional programs and results in CLL phenotypes with highly variable outcomes. The mechanisms leading to failed epigenetic programming and to establishment of a CLL epigenome are not well understood. Genomic sites of failed epigenetic pro- gramming coincide with binding sites of key B cell TFs. Active DNA demethy- lation through TET-dioxenogene mediated conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and subsequent products is one of the mechanisms involved in physiological epigenetic B cell programming, and deregulation of this process could contribute to establishment of the CLL epigenome.

Aims: Here, we investigated the role of TET2-mediated DNA demethylation through differential SHCmC acquisition in healthy and in CLL B cells. We further studied mechanisms and TFs involved in regulation of SHCMC conversion during CLL pathogenesis.

Methods: Clonal B cell specimens from 122 CLL patients were subjected to DNA methylation profiling using Illumina 450k arrays. 17 CLL and 4 healthy B cell samples (CD19+) were used for DNA methylation profiling using Illumina Epic arrays and for hydroxymethylated DNA immunoprecipitation (hMeDIP) using a monoclonal SHCMC mouse antibody and the NEBNext Ultra DNA Library Prep Kit for analysis on an Illumina HiSeq2000 sequencer. Global SHCMC levels were quantified by dot blots. TET2, and EBF1 mRNA and protein expression was evaluated by qPCR and Western Blot, respectively.

Results: By dot blot, we found decreased 5hmC levels in CLL as compared to CD19+ B lymphocytes. SHCMC was further reduced in IGHV unmethylated com- pared to IGHV mutated CLL patients. To identify distinct regions with gain or loss of SHCMC, we performed genome-wide SHCMC profiling by hMeDIP. We con- firmed a significantly lower number of hydroxymethylated peaks in CLL (137114) compared to HBC (249421) which remained stable when separating to good (133234, p<0.0102) or bad prognosis CLL (140441; p<0.0161) patients (defined by the IGHV mutation status, Rai/Binet stages, CD38 positivity, del(11q) and del(17p)). Differential binding analysis (DBA) revealed 5988 signifi- cantly differentially hydroxymethylated reads between CLL and HBC samples (FDR<0.05). Pathway analysis showed that regions which lost hydroxymethylation in CLL were involved in B cell receptor (BCR) Class I P13K, CXCR-4, c-Mec and IL3 signaling. To further identify mechanisms that are involved in failed hypomethylation and 5hmC loss in CLL, we aimed at profiling sequence characteristics at the respective genomic sites. In our genome-wide DNA methylation data set, we confirmed highly significant enrichment of the EBF1 motif at the respective sites in 122 CLL patients. EBF1 mRNA and protein expression was significantly reduced in the majority of 17 CLL samples com- pared to HBC. TET2, a potential interaction partner of EBF1, was upregulated in CLL samples on RNA level and expressed to different degree on protein lev- el.

Summary/Conclusions: Here, we demonstrate that 5hmC loss in CLL con- tributes to a disease specific epigenotype as described earlier. First evidences indicate that alterations of an interaction between the EBF1 and TET2 are mechanistically involved in insufficient hydroxymethylation and consequently failed DNA hypomethylation.

P244

DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?
S. Bhoi1,*, L. Mansouri1, G. Castellano2, L.-A. Sutton1, N. Papakonstantinou3, J. Duyster1, H. Busch2, M. Börries2, R. Claus1

1Department of Immunology, Genetics, Science for Life Labo- ratory, Uppsala University, Uppsala, Sweden, 2Institut d'Investigaciones Bio- médiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 3Institute of Applied Biosciences , Centre for Research and Technology-Hellas, Thessaloniki, Greece, 4Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain, 5Department of Immunotechnology, Lund University, Lund, Sweden, 6Department of Internal Medicine – Hematology and Oncology, Uni- versity Hospital Brno and Faculty of Medicine, Masaryk University, 7Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, 8Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, 9Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala University, Uppsala, 10Department of Medicine, Clinical Epidemiology Unit, Karolinska, Stockholm, Sweden, 11Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, 12Department of Immunology, Erasmus MC, University Medical Center, Rot- terdam, Netherlands, 13Pitie-Salpetriere and University Pierre et Marie Curie, Université Pierre et Marie Curie, Paris, France, 14Hematology Department, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, 15Division of Dental Oncology and Oral Pathology, University Hospital Zurich, Zürich, Switzerland, 16Division of Molecular Medicine, Centro Operative San Raffaele Scientific Institute, Milan, Italy, 17Department of Molecular Med- icine and Surgery , Karolinska Institutet, Stockholm, Sweden

Background: Subsets of CLL patients carrying stereotyped B cell receptors (BcRs) display distinct biological and clinical features; however, the DNA methyla- tion landscape for these patients remains largely unexplored.

Aims: To investigate the DNA methylation profiles in three major stereotyped subsets.

Methods: By applying high-resolution 450K methylation arrays, we studied the clinically aggressive subsets #1 (Clan1 genes/IGK/D1-39, IGHV unmethylated, n=37) and #2 (IGHV3-21/IGKV3-20, mixed IGHV mutation status, n=35) and the indolent subset #4 (IGHV4-34/IGKV2-30, IGHV mutated, n=28). In addition, a series of sorted normal subpopulations spanning different stages of B-cell differ- entiation (e.g. naive, central, transitional, memory) were analyzed.

Results: Unsupervised principal component analysis demonstrated that the investigated subsets formed distinct subgroups and these findings were cor- porobated by hierarchical clustering analysis. We next explored if and how these subsets match to the recently proposed epigenetic classification of CLL, which divides cases into four groups: (i) naïve like CLL (n-CLL), (ii) pro-prognostic, (iii) intermediate like CLL (i-CLL) and (iv) aggressive like (a-CLL). The classification revealed that subset #1 clustered with n-CLL, subset #4 with m-CLL, while subset #2 clustered separately with i-CLL. We have recently shown that the number of epigenetic changes that a tumor acquired, compared to its cellular origin (i.e. epigenetic burden), may be a powerful predictor of clinical aggressiveness (Queiroz et al., Cancer Cell 2017). Following this approach in CLL, when comparing specific subsets vs their non-subset cases matched by epigenetic subgroup, we noted a signif- icant difference in the epigenetic burden amongst the various groupings; more specifically, in subset #1 cases in n-CLL (T2K vs 67K, p<0.05) and in subset #2 vs i- CLL (76K vs 68K, p=0.001), while no difference was observed between subset #4 vs m-CLL (83K vs 82K, p>0.05). This implies that subsets #1 and #2 have a higher epigenetic burden than n-CLL, which is in line with the more aggressive disease seen in these two subsets compared to the broader cate- gory of n-CLL patients. Focusing on subset #2, we observed that almost all cases clustered separately from i-CLL in supervised clustering analysis, pro- viding further support that subset #2 forms a distinct subgroup of i-CLL. Subset #2 cases frequently carry del(11q) and harbor SF3B1 mutations, however, nei- ther the IGHV mutation status nor the presence of del(11q) or SF3B1 mutations had any impact on the epigenetic burden within subset #2.

Summary/Conclusions: Stereotyped CLL subsets differed significantly in their methylation profiles. That said, subset #1 and #4 clustered at large with n-CLL and m-CLL categories, respectively, implying common cellular origin. In con- trast, subset #2 emerged as the first defined member of the i-CLL group, which in turn alludes to a distinct cellular origin for subset #2 and i-CLL patients. Both subsets #1 and #2 displayed a higher epigenetic burden compared to n-CLL and i-CLL, respectively, which is likely reflected in the poor outcome asso- ciated with these two subsets.
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS

B. Stamatopoulos1,*, T. Smith2, D. Sims2, A. Heger2, H. Dreau3, A. Schuh4

1Laboratory of Clinical Cell Therapy, J. Bordet Institute, University of Brussels, Brussels, Belgium, 2Computational Genomics Analysis and Training Programme, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, 3Molecular Diagnostic Centre, Oxford University Hospitals, 4Department of Oncology, University of Oxford, Oxford, United Kingdom

Background: The immunoglobulin heavy-chain gene (IgHV) mutational status is currently considered the gold standard of prognostication in Chronic Lymphocytic Leukemia (CLL): unmutated (UM) immunoglobulin heavy chain region (IgHV) is associated with poor prognosis while patients with mutated IgHM (M) have more indolent disease. An exception are patients with IgLV3-21/IGHV2-1 who have poor prognosis irrespective of the IgHV mutational status. Interestingly, IgLV3-21 is co-expressed with IgLV3-21 in the majority of cases.

Aims: Here we aimed to study the impact of the light chain IgLV3-21 on CLL prognosis. This light chain has never been characterized independently of the heavy chain IgHV3-21.

Methods: Based on 405 CLL patients from 3 independent cohorts (A. an initial cohort of 32 patients with aggressive CLL, and 2 cohorts of CLL patients where samples were obtained at diagnosis (B: n=270 and C: n=103), we analyzed the impact of the presence of IgLV3-21 on treatment-free (TFS) and overall (OS) survival. IgLV3-21 positivity was determined by real-time PCR and confirmed by Sanger sequencing.

Results: Among the 32 patients with aggressive CLL, we found that 9 (28%) patients who had an IgLV3-21 rearrangement, but only 1 patient carried the heavy chain IgHV3-21: IgLV3-21 patients had a median TFS of 17 months compared to 44 months in patients with another light chain (P=0.0270). Similarly, IgLV3-21 patients had a shorter median OS (88 months > vs >192 months, P=0.0287). We verified these results in 2 independent cohort obtained at diagnosis. In cohort B (n=270), 30 (11%) expressed an IgLV3-21 light chain and 10 (4%) an IgHV3-21 (of which 8/10 also carried the light chain IgLV3-21 rearrangement). Patients with IgLV3-21 had a median TFS/OS of 29/183 months compared to patients without IgLV3-21 who had a median TFS/OS of 88/292 months (P=0.0003/P=0.0142). In cohort C (n=103), 9 (9%) expressed an IgLV3-21 light chain but only 1 (1%) had a heavy chain IgHV3-21. In this cohort, IgLV3-21 patients had a median TFS of 21 months not statistically different from IgHV3-21 patients (28 months) while IgHV3-21 patients had a median TFS of 93 months (P<0.0001). We then pooled the 3 populations (n=405) in order to increase the under-represented subgroups and analyzed the association of the IgLV3-21 with the IgHV mutational status: patients with either IgLV3-21 or IgHV3-21 (with a M or UM IgHV) displayed a prognosis similar to UM patients: median TFS was 129, 48, 36, 24, 23 months for M, IgLV3-21/M (P=0.0005), UM (P<0.0001), IgLV3-21/UM (P<0.0001) and IgLV3-21 (P<0.0001) patients, respectively (Figure 1A). Similar results were observed for OS with a median OS of 292, 88, 174, 90 and 183 months M, IgLV3-21/M (P=0.0001), UM (P<0.0001), IgLV3-21/UM (P<0.0001) and IgLV3-21 (P=0.0021) patients, respectively (Figure 1B). If all IgLV3-21 (n=48) were considered independently of their heavy chain, IgLV3-21 median TFS (24 months) was similar to UM patients (36 months, P=0.5824) and statistically different from M patients (129 months – P<0.0001, Figure 1C). Similar results were observed for OS (Figure 1D).

Figure 1.

Summary/Conclusions: Our results highlight for the first time the independent prognostic significance of the light chain IgVT3-21 in CLL. The presence of an IgLV3-21 light chain confers a poor prognosis similar to UM patient irrespective of concurrent expression of IgHV3-21 heavy chain or IgHV mutational status.
P247
DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH VENETOCLAX AND RITUXIMAB
M.A. Anderson1,*, D.M. Brander 2, S. Ma 3, J.F. Seymour 4, M.Y. Choi 5, T.J. Kipps 5, L. Zhou 6, K. Balbarin 6, B. Prine 6, M. Verdugo 6, S.Y. Kim 6, L.L. Lash 6, A.W. Roberts 1
1Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Cancer and Hematology Division, Melbourne, Australia, 2Duke University Medical Center, Durham, 3Northwestern University, Chicago, United States, 4Peter MacCallum Cancer Centre, , Melbourne, Australia, 5University of California San Diego, San Diego, 6AbbVie, Inc., North Chicago, United States

Background: Venetoclax is a potent BCL-2 inhibitor that is approved as monotherapy for certain patients with relapsed or refractory chronic lymphocytic leukemia (CLL) in the United States, the European Union, and other countries.

Aims: Venetoclax combined with rituximab is being assessed in an ongoing Phase 1b study.

Methods: Minimal residual disease (MRD) was assessed in bone marrow using 24-color flow cytometry (minimum sensitivity: 0.01%). Patients who achieved complete remission (CR) or MRD-negativity could stop venetoclax and remain on study. Patients who manifested progressive disease while off therapy could re-initiate venetoclax and rituximab.

Results: Forty-nine patients, with a median of 2 (range: 1–5) prior regimens, were enrolled. As of July 2016, the overall response rate was 86%, the CR rate was 51%, and the bone marrow MRD-negativity rate was 57% (28/49) [Seymour et al. Lancet Oncol 2017]. The 24-month estimate for progression free survival was 78.8% and that for duration of response was 87.8% (100% for patients with MRD-negative CR). Of the 28 patients attaining MRD-negativity, 22 achieved the status at 7 months, which was the first mandatory time point for assessment. The remaining six patients achieved MRD-negativity at the second assessment, which ranged from 12 to 22 months, since the timing of this test was not mandated. Twenty (41%) patients discontinued the study. Eleven had progressive disease while on therapy: five with Richter’s transformation between 1–9 months and six with CLL progression after a median of 26.4 months (range: 12–37). The other nine patients: withdrew consent (n=3), failed to report for follow-up evaluations (n=1), discontinued due to adverse events related to venetoclax (n=2; tumor lysis syndrome and worsening of peripheral neuropathy), or discontinued due to adverse events considered not related to therapy (n=3). Seventeen patients with MRD-negative CR had incomplete response off venetoclax of 13 months (range: 3–34).

Summary/Conclusions: Venetoclax with rituximab induces deep and durable responses, with 51% patients achieving CR and 57% achieving marrow MRD-negativity. Patients on continued therapy have durable responses. Additionally, responses are sustained at a median of 13 months among patients who achieve bone marrow MRD-negativity and elected per protocol to stop therapy, demonstrating that it is possible to discontinue venetoclax and maintain prolonged treatment free remission. The 2 patients who progressed at 2 years off therapy responded to the reintroduction of venetoclax.

P248
PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE WITH OR WITHOUT OATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL

CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE WITH OR WITHOUT OATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL

M.A. Anderson1,*, D.M. Brander 2, S. Ma 3, J.F. Seymour 4, M.Y. Choi 5, T.J. Kipps 5, L. Zhou 6, K. Balbarin 6, B. Prine 6, M. Verdugo 6, S.Y. Kim 6, L.L. Lash 6, A.W. Roberts 1
1Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Cancer and Hematology Division, Melbourne, Australia, 2Duke University Medical Center, Durham, 3Northwestern University, Chicago, United States, 4Peter MacCallum Cancer Centre, , Melbourne, Australia, 5University of California San Diego, San Diego, 6AbbVie, Inc., North Chicago, United States

Background: Recurrent mutations in genes such as TP53, SF3B1 and NOTCH1 are frequent in CLL and have in previous studies been associated with outcome. SF3B1mut, TP53mut, BIRC3mut and XPO1mut were adverse prognostic factors in patient cohorts with different therapies, and NOTCH1mut associated with poor outcome when rituximab was added to standard chemotherapy. In the COMPLEMENT-2 trial (relapsed/refractory CLL, FC vs FC+ofatumumab 1–14-16, 18), NOTCH1mut was identified as a predictive factor in the context of chemoimmunotherapy.

Aims: We assessed the incidence and clinical associations of mutations in TP53, SF3B1, NOTCH1, ATM, BIRC3, FBXW7, MYD88, EGR2 and XPO1 in the COMPLEMENT-2 trial (relapsed/refractory CLL, FC vs FC+ofatumumab 1–14-16, 18).

Methods: Baseline samples were available from 325 of 365 patients (89%) representative of the full analysis set of the clinical trial. Mutation analyses were performed via custom targeted Next Generation Sequencing (tNGS) for TP53, ATM, BIRC3, FBXW7, MYD88, EGR2 and XPO1 in the COMPLEMENT-2 trial (relapsed/refractory CLL, FC vs FC+ofatumumab 1–14-16, 18). We used targeted tNGS to identify somatic mutations present in 365 samples of CLL patients included in the COMPLEMENT-2 trial. The list of genes investigated included TP53, SF3B1, NOTCH1, ATM, BIRC3, FBXW7, MYD88, EGR2 and XPO1.

Results: In total we identified 365 mutations across the 9 genes in 202 of 325 patients (62.2%), with incidences of SF3B1mut 19.7%, TP53mut 18.8%, NOTCH1mut 16.3%, ATMmut 13.8%, XPO1mut 11.4%, BIRC3mut 4.9%, EGR2mut 3.1%, FBXW7mut 2.7% and MYD88mut 0.9%. We identified a variety of associations of mutational subgroups with genetic, clinical and laboratory parameters, such as TP53mut with del17p (p<0.01), NOTCH1mut, FBXW7mut and BIRC3mut with +1q2 (p=0.01, p=0.01 and p=0.05) and ATMmut with del11q (p=0.01). XPO1mut and ATMmut associated with unmutated IGHV. CD79B expression on cell surface measured via flow cytometry was lower in ATMmut patients, whereas CD20 expression did not differ among the different mutational subgroups. TP53mut, EGR2mut and SF3B1mut patients had worse overall response to therapy (88% p<0.01, 50% p=0.02 and 72% p=0.05 respectively, vs 81% overall). Similar to the full analysis set, FCO as compared to FC resulted in significant improved PFS (median 28.1 months, HR=0.67, p<0.01) and OS (HR=0.53, p<0.01 and HR 1.85, p<0.01 respectively), but only TP53mut for decreased OS (HR 2.11 p<0.01). All other mutations, in particular SF3B1mut and NOTCH1mut, did not significantly impact PFS or OS. To identify factors of independent clinical
impact, we performed multivariable Cox regressions for PFS and OS including treatment, IGHV status and all cytogenetic and mutational subgroups. For PFS, the following independent prognostic factors were identified: FCO therapy (HR 0.64 p<0.01), del17p (HR 5.08 p<0.01), unmutated IGHV (HR 2.0 p<0.01), TP53mut (HR 1.75 p<0.01) and XPO1mut (1.86 p<0.01). Del17p (HR 4.79 p<0.01), unmutated IGHV (HR 1.69 p<0.04) and TP53mut (HR 1.76 p<0.03) were identified as independent prognostic factors for OS. With focus on the predictive value of gene mutations, we found a beneficial effect of the addition of ofatumumab to chemotherapy irrespective of TP53 mutation (HR 0.52 p=0.02 for TP53mut and HR 0.68, p=0.02 for TP53m)nt. Regarding NOTCH1, ofatumumab 48% was only beneficial in NOTCH1mut but not in NOTCH1m patients (HR 0.64, p=0.01 and HR 0.86, p=0.67) (Figure 1).

Summary/Conclusions: In the COMPLEMENT-2 trial evaluating FCO against FC in relapsed/refractory CLL patients, we found TP53mut and XPO1mut but not SF3B1mut or NOTCH1mut as independent prognostic factors for PFS. Notably, a benefit of ofatumumab addition to FC chemotherapy obtained among NOTCH1mut but not among NOTCH1m patients indicating NOTCH1 mutation status as a predictive marker in the context of type-1 CD20 antibody addition to chemotherapy.

P249
RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
A. Danilov1,7, H. Yimer2, M. Boxer3, N. Di Bella4, S. Babu5, J. Lf6, Y. Mun6, S. Sketino6, J. Sharram3
1Oregon Health and Science University, Portland, 2Texas Oncology, Tyler, 3Arizona Oncology, Tucson, 4Rocky Mountain Cancer Centers, Aurora, 5Fort Wayne Medical Oncology, Fort Wayne, 6Genentech Inc., South San Francisco, 7Williamette Valley Cancer Institute and Research Center, Eugene, United States

Background: Bendamustine (B) plus rituximab (R; BR) is a commonly used first-line (1L) treatment for chronic lymphocytic leukemia (CLL). The CLL10 study reported an overall response rate (ORR) of 96% and complete response (CR) rate of 31% with BR. Obinutuzumab (GA101; G) is a glycoengineered, type II anti CD20 monoclonal antibody. A randomized Phase III trial in 1L CLL pts showed that G significantly improved progression-free survival (PFS) and CR rate compared with R, when used in combination with chlorambucil (Goede 2014). B plus G (BG) was evaluated in a subgroup of CLL pts in the GREEN study (Stilgenbauer 2015).

Aims: The aim of this Phase II study (NCT02320487) is to evaluate the efficacy and safety of BG as 1L treatment for CLL pts.

Methods: 102 pts with previously untreated CLL received BG, consisting of 6 cycles of G (cycle [C] 1: 100 mg/day (D); 900 mg QD, C2–6: 1000 mg D1 and B (80mg/m2 C1, D2 and C2–6, D1 and D2). Each cycle was 28 days. The primary endpoint was CR assessed using iwCLL criteria. Secondary endpoints included ORR, PFS, overall survival, and minimal residual disease (MRD). Median follow-up at the time of analysis was 11 months.

Results: Median pt age was 61 yrs (range 35–90); 68.6% were male; 44.1% had Rai stage 3–4. For evaluated pts, IgVH status was 32.9% mutated and 67.1% unmutated. The incidences of trisomy 12, normal cytogenetics, and deletions of 13q, 11q, and 17p were 23.4%, 37.5%, 17.2%, 15.6%, and 6.3%, respectively. Investigator-assessed CR rate was 49.0% (95% CI 39.0–59.1) and ORR was 89.2% (95% CI 81.5–94.5) after 6 cycles. MRD negativity in blood, as measured by flow cytometry, was achieved in 42.9% of pts at the end of induction response assessment and in 75.5% of pts at any time following treatment. MRD negativity in bone marrow (BM) was 60.8% in pts with BM samples. The most common adverse events (all grades [Gr]) were infusion reactions (72.5%), pyrexia (36.3%), neutropenia (34.3%), fatigue (34.3%), constipation (52.0%), and nausea (36.3%). The most common grade 3–4 adverse events were neutropenia (26.5%). Incidence of Gr 3–4 infections was 11.8%. Incidence of tumor lysis syndrome was 4.9% (all Gr 3). Three pts died; none were deemed related to study treatment or CLL by investigators.

Summary/Conclusions: BG is an effective regimen for 1L treatment of CLL pts inducing a high CR rate after 6 cycles of therapy. No unexpected safety signals were observed.

P250
RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014
A. Dinmohamed1,2,3, O. Visser4, W. Posthuma5, R. Raymakers5, J. Doorduijn3
1Research, Netherlands Comprehensive Cancer Organisation (IKNL), 2Public Health, Erasmus University Medical Center, Utrecht, 3Hematology, Erasmus Medical Cancer Institute, Rotterdam, 4Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, 5Internal Medicine, Reinier de Graaf Gasthuis, Delft, 6Hematology, Utrecht University Medical Center, Utrecht, Netherlands

Background: The introduction of cladribine and pentostatin has revolutionized the management of HCL as from the late 80s. As a result of that revolution, HCL patients (pts) are rarely included in clinical trials. Population-based studies can inform on issues related to outcomes of HCL pts managed in daily practice. At present, however, population-based studies that assess patterns of incidence, treatment and survival in HCL are very scarce.

Aims: The aim of this comprehensive nationwide population-based study was to assess trends in incidence, primary treatment and survival among HCL pts diagnosed in the Netherlands.

Methods: We selected all adult (≥18 years) pts diagnosed with classic HCL in the Netherlands between 1989-2014 from the nationwide Netherlands Cancer Registry with survival follow-up through February, 2016. Age-standardized incidence rates (ASR) were calculated per 1,000,000 person-years and standardized according to the European standard population. Data on primary treatment (i.e. no therapy, chemotherapy [CT] and immunotherapy [IT]) were available for individual pts. Pts were categorized in 2 periods (1989-2000 and 2001-2014) and 3 age groups (18-59, 60-69 and ≥70 years). We calculated relative survival (RS) and the relative excess risk of mortality as measures of disease-specific survival.

Results: We included a total of 1,427 newly diagnosed HCL pts in the study (median age, 59 years; age range, 22–95 years; 77% males). The annual ASR of HCL remained quite stable over time and was 3.1 and 3.3 in the first and last period, respectively. Men had a higher overall incidence than women (5.3 vs 1.1 in 2013-2014). The age-specific incidence rates for males were 5.5, 15.0 and 15.3 in 2001-2014 for the three age groups. The corresponding rates for females were 1.2, 3.1 and 5.5. The application of CT increased over time for all age groups. The proportions of CT for the three age groups were 56, 51 and 34% in 1989-2000, as compared with 81, 73 and 53% in 2001-2014. The corresponding proportions for IT were 21, 13 and 17% in 1989-2000, as compared with 2, 1 and 4% in 2001-2014. Lastly, the corresponding proportions for pts who did not receive therapy were 23, 36 and 49% in 1989-2000, as compared with 17, 26 and 42% in 2001-2014. Overall, when corrected for age and sex, pts diagnosed in 2001-2014 had 49% lower excess mortality during the first 10 years after HCL diagnosis, as compared with pts diagnosed in 1989-2000 (P<.005). Ten-year RS (95% confidence intervals) was impressive for pts age 18-59, namely 92% (88% - 96%) and 98% (94% - 100%; P=.176) in the first and last period, respectively (Figure 1a). Most of the significant improvement was observed in pts age ≥60. More specifically, 10-year RS for pts age 60-69 increased from 82% (71% - 92%) to 99% (89% - 100%; P=.009; Figure 1b), and for pts age ≥70 from 67% (49% - 86%) to 95% (84% - 99%; P=.036; Figure 1c) between the first and last periods. In addition, older age (P<.001), but not sex (P=.058), was associated with higher excess mortality.

Figure 1.

Summary/Conclusions: The incidence of HCL remained stable during a 26-year period in the Netherlands. RS for pts diagnosed in the period 2001-2014 eventually reached a plateau, indicating that by then their survival is comparable to that of the general population. Survival was already excellent for younger patients throughout the entire study period. Survival improvement was most pronounced for pts age ≥70. This could be explained by the increased use CT over time. Population-based cancer registries are useful instruments to assess outcomes of pts rarely included in clinical trials.
CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG

V. Goede1,2, J. Bahlo1, S. Robrecht1, O. Al-Sawafi1, A.-M. Frank1, C.-M. Wendtner3, S. Stilgenbauer4, K. Fischer1, B. Eichhorst1, M. Hallek1,5
1Dept. of Internal Medicine, University Hospital Cologne, 2Oncogeneics Unit, St. Marien Hospital, Cologne, 3Klinikum Munich-Schwabing, Munich, 4University Hospital Ulm, Ulm, 5Centre of Integrated Oncology (CIO) Cologne-Bonn, Cologne, Germany

Background: CLL-IPI is a prognostication tool to stratify patients with chronic lymphocytic leukemia (CLL) for low, intermediate, high, or very high risk. CLL-IPI uses age, Binet stage, beta-2-microglobulin, TP53 mutation, and IGHV mutational status, but not comorbidity as weighted factors to model prognosis. CIRS is a tool which allows assessing and quantifying burden of comorbidity in individual patients.

Aims: To validate CIRS in CLL and to assess whether CIRS is of further value when estimating prognosis by CLL-IPI in CLL.

Methods: This is a comprehensive evaluation of CIRS in 2158 patients pooled from the CLL8, CLL10, and CLL11 trials of the German CLL Study Group (GCLLSG). Median observation time was 55 months. All patients had CIRS data prospectively assessed prior to study treatment (689 FCR, 409 FC, 279 BR, 333 GCLB, 330 RCLB, 118 CLB).

Results: Median age was 64 years; 69% of patients were males, and 50% had ECOG performance score of 1 or higher. Complete information on age, Binet stage, beta-2-microglobulin, TP53 mutation, and IGHV mutational status was available in 1761 of the 2158 patients. Distribution of CLL-IPI risk groups was as follows: 275 (16%) low risk, 653 (37%) intermediate risk, 712 (40%) high risk, 121 (7%) very high risk. The median total CIRS score was 3 (range 0-22); 81% of the patients had a total CIRS score of at least 1 and 28% of greater than 6. Comorbidities were most frequently captured under the following CIRS organ categories: cardiac, blood pressure, respiratory, musculoskeletal, and endocrine/metabolic. A severity score of >2 and >3 in at least one CIRS organ category was present in 46% and 11% of the patients, respectively. There was a positive correlation between total CIRS score and age (rs=0.5, p<0.001) as well as ECOG performance score (rs=0.4, p<0.001) and an inverse association between total CIRS score and creatinine clearance (rs=-0.3, p<0.001). In univariate analysis, increased total CIRS score was associated with shorter overall survival (OS); with poorer OS determined by severity rather than numbers of comorbidities (log-rank: p<0.001, Figure 1A and 1B). In multivariate analysis, total CIRS score was an independent risk factor for OS when used as continuous or categorical variable together with age, gender, Binet stage, ECOG performance score, thymidine kinase, beta-2-microglobulin, IGHV, and 17p deletion (adjusted for treatment intensity). Total CIRS score also remained an independent risk factor for OS when added to the CLL-IPI. Weight of CIRS was highest in the CLL and lower in the CLL10 and CLL11 trials as expressed by the hazard ratios (Figure 1C). There was no significant association between total CIRS score and progression-free survival or time-to-next treatment. However, increased total CIRS score was associated with higher risk of grade 3/4 adverse events as well as premature treatment discontinuation during or after treatment with FCR / FC / BR but not GCLB / RCLB / CLB.

Summary/Conclusions: Findings suggest that CIRS provides prognostic information beyond the CLL-IPI. It provides additional comorbidity assessment (e.g. by CIRS) in addition to the CLL-IPI therefore appears reasonable when estimating overall prognosis and deciding treatment in CLL.

A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA

1Haematology, Hull and East Yorkshire NHS Trust, 2Haematology, Hull York Medical School, Hull, 3Clinical Trials Research Unit, University of Leeds, 4St James Institute of Oncology, 5Haematological Malignancy Diagnostic Service, St James University Hospital, Leeds, 6Haematology, The Christie NHS Foundation Trust, Manchester, 7Haematology, University College London Hospital London, London, 8Haematology, Birmingham Heartlands Hospital, Birmingham, 9Haematology, Torbay District Hospital, Torquay, United Kingdom

Background: The outcome of CLL patients relapsing after chemotherapy (CIT) has been transformed by targeted therapies, however a proportion of such patients may be successfully retreated with CIT. CD20-monoclonal-antibody-based CIT has been successfully deployed for the retreatment of relapsed patients but the optimum dosage of antibody is unknown.

Aims: COSMIC (Chemotherapy plus Ofatumumab at Standard or Mega dose in CLL) was a phase II randomised study assessing the efficacy of standard (sOf) and high (megaOf) dose of ofatumumab in combination with either fludarabine cyclophosphamide (FC) or bendamustine (B). The primary endpoint was complete response (CR/CRi) rate independently assessed 3 months post-therapy. Secondary endpoints were the proportion of participants with undetectable minimal residual disease (MRD); overall response rate; progression-free survival; overall survival; time to MDR relapse; dynamics of MDR relapse; safety and toxicity. Using the A’Hem exact one-stage design with 80% power and 1-sided type 1 error of 5%, 10 CRs were required from 37 recruits in either arm to justify further investigation in a phase III study. Total sample size was intended to be 82 allowing for drop-outs.

Methods: CLL patients relapsing after a minimum of 6 months from the most recent course of chemotherapy, and fit for FC or B, were eligible. Treatment comprised sOf (total 6.3g of ofatumumab: 0.3g day 1 cycle 1, 1.0g day 8 cycle 1, 1.0g day 1 monthly cycles 2-6), or megaOf (total 22.3g of ofatumumab: 0.3g day 1, 1.0g weekly for 2 cycles + 0.3g day 1 cycles 3-6) given in combination with FC or B at conventional doses. The choice of FC or B was decided pre-randomisation by the local investigator.

Results: Recruitment was slow with 61 patients randomised and treated, sOf (32: 21 FC and 11 B), and megaOf (29: 17 FC and 12 B). 77% were previously treated with purine analogues and 79% had experienced a remission of greater than 24 months after their most recent therapy. 26% had an 11q deletion and 67% had unmutated VH genes or expressed VH3-21. With 61 participants, there was 71% power to observe 8 CRs from 28 participants in either arm. In the intention-to-treat (ITT) population b(18%) sOf and 77% megaOf patients as assessed by CR/CRi; 22%(69%) sOf and 21(72%) megaOf did not; and 4(12%) sOf and 1(4%) megaOf were unassessable. Rates were similar between FC(26%) and B(19%). Overall responses (CR/CRi+PR) were achieved in 20(63%) sOf and 20(69%) megaOf patients. In the ITT population, 4(13%) sOf and 6(21%) megaOf patients were MRD negative in marrow 3 months post-therapy. Overall, therapy was deliverable with 66% of participants receiving the proscribed 6 cycles of CIT (19(59%) sOf, 21(72%) megaOf). 42 serious adverse reactions were reported (21 sOf, 21 megaOf), 28(67%) being grade 3 or above (13(62%) sOf, 15(71%) megaOf), with the commonest events related to infections (45%) and cytopenias (21%). There was one treatment-related death (sOf-FC).

Summary/Conclusions: The CR rates observed in both treatment arms failed to meet pre-specified levels for the primary endpoint. Response rates observed in both arms are comparable to those obtained in previous studies of CIT in this group and suggest that dose escalation of ofatumumab in relapsed CLL does not lead to a worthwhile improvement in outcomes. However, CIT’s deliverable with acceptable toxicity and should still be considered an option, particularly for patients with long-remissions to first line therapy and who do not possess high-risk cytogenetic markers.
FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA: DURABLE REMISSEIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/ CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)

J. Brown1,*, S. O’Brien2, C.D. Kinglsey3, H. Eradat4, J. Hirata5, T.J. Kipps9

1Dana-Farber Cancer Institute (CLL Research Consortium), Boston, 2MD Anderson Cancer Center, Houston, Texas, 3University of Texas, Houston, 4Cleveland Cancer Institute, 5University of California, Los Angeles, 6Fred Hutchinson Cancer Research Center, 7University of Washington, Seattle, 8University of California, 9Mooreres Cancer Center (CLL Research Consortium), University of California, San Diego, United States

Background: GALTON was an open-label, parallel-arm, non-randomized, multicenter, Phase Ib study (NCT01302247) investigating safety and preliminary efficacy of G-FC or G-B in previously untreated CLL. Aims: We report final results for the planned 36-months (mo) follow-up (35/41 pts; median observation 40.4 (17.6–43.6) mo); initial results were reported previously (Brown et al. 2015).

Methods: Eligible pts met iwCLL 2008 criteria for therapy, were considered fit for chemoimmunotherapy by the investigator, and provided informed consent. Each center selected treatment (G-FC or G-B) for their pts. G was administered intravenously (IV; 100mg/day [D] 1, 900mg/D2, 1000mg/D8 and 15 cycle [C] 1; 1000mg D1 C2–6) with FC (fludarabine 25mg/m2 IV and cyclophosphamide 250mg/m2 IV D2–C1, D1–3 C2–6 or B (90mg/m2 IV D2–C3, D1–2 C2–6). Each cycle was 28 days. The primary endpoint was safety and tolerability of G-chemotherapy.

Results: 21 pts were enrolled in the G-FC arm and 20 in the G-B arm. Median age was 60 (25–80) years, 78% of pts were male, and around one-third had Rai stage III/IV disease. Median time from diagnosis to therapy was 24 mo (G-FC: 14 mo cut-off, 37 patients were alive in follow-up; G-FC (n=18; 2 lost to follow-up) and G-B (n=19; 1 event of progressive disease occurred in each arm, and 1 pt per arm died due to an adverse event (AE; G-B: respiratory failure; G-FC: unknown in the setting of unresolved Grade (Gr) 4 pancytopenia); neither was considered treatment related. Due to the small number of events, median PFS and OS could not be estimated; however, 3-year OS was 95% for each arm (95% CI G-FC, 68–99; G-B, 70–99). Post-treatment, 10/41 pts (24.4%) experienced ≥1 Gr3–5 AE: 2/21 pts (9.5%) in the G-FC arm and 8/20 pts (40.0%) in the G-B arm. 7 serious AEs were reported in 4 pts, all in the G-B arm; these included pneumonitis and respiratory failure (as noted above, in both Gr5). Gr4 leukopenia/neutropenia, small cell lung cancer and Gr4 pneumothorax, and melanoma. During follow-up, 6 pts had ≥1 Gr3–4 AE of neutropenia, including 4/20 pts (20.0%) in the G-B arm and 2/21 pts (9.5%) in the G-FC arm. At end of treatment, all pts were B-cell depleted (B-cell count <0.07x109/L). Within 6–12 mo of follow-up, very few pts had recovered (G-FC: 2/19 pts [10.5%]; G-B: 0/20 pts). At 36 mo follow-up, 9/19 pts (47.3%) in the G-FC arm had recovered, 3/19 (15.8%) were still depleted, and 7/19 did not have data available. In the G-B arm, 6/20 pts (30%) had recovered, 1 was still depleted, and 13/20 had no available data. In a single center exploratory analysis, 9 pts (G-FC) underwent 4-color flow cytometry to detect minimal residual disease (MRD) 8–14 mo after therapy; all were negative. 8 of these pts (G-FC) who were MRD-negative by 4-color flow cytometry were also tested with the ClonoSEQ immunoglobulin sequencing assay; 4 were MRD-positive and 4 MRD-negative. 4 pts who were MRD-positive always had both assays remain in remission, while only 2/4 pts who were positive by ClonoSEQ died after follow-up, one of Richter’s transformation complicated by pneumonia and the other related to MDS. Another pt who was MRD positive by ClonoSEQ underwent autologous stem cell transplantation and remains in remission.

Summary/Conclusions: We conclude that G plus either FC or B results in excellent long-term disease control in previously untreated pts with CLL, and has comparable side-effects to other chemo-immunotherapies. We thank N Crompton, N Tyson, M Rahman (Roche Products Ltd) and R Moraru-Zamfir (F. Hoffmann-La Roche Ltd) for their support.

P254

THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REPLACED INTENSITY CONDITIONING ALLOGENIC STEM CELL TRANSPLANTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE

T. Anagnostou1,*, T.D. Shanafelt1, M.S. Patnaik1, K.G. Chauffee1, S.A. Parikh1, D.A. Gastineau1, W. Ding1, T.G. Cal1, M.R. Litzow1, N.E. Kay1, M. Contel1, D.A. Bowen1, W.J. Hogan1, S.J. Kenderian1, T. Anderson Cancer Center, University of Texas, Houston, 2Mayo Clinic, Rochester, United States

Background: Allogeneic stem cell transplant (SCT) remains the only potentially curative option for chronic lymphocytic leukemia (CLL) patients. However, up to 40% of patients treated with Reduced Intensity Conditioning (RIC) - SCT relapse after transplantation. Recently the CLL International Prognostic Index (CLL-IPI) was validated as a predictor of 5 year overall survival in CLL patients. Aims: In this analysis, we aimed to elucidate the factors that may predict the outcomes following RIC SCT, including the CLL-IPI.

Methods: This is a retrospective analysis of all CLL patients who underwent RIC-SCT at Mayo Clinic between 2006-2013. The study was approved by the Institutional Review Board. The prognostic value of several CLL, patient and transplant related variables were analyzed. Continuous variables were reported as mean and compared using the T-test. Dichotomous outcomes were compared using the chi-square test. Survival was estimated and compared using the Kaplan Meier and Log Rank tests.

Results: Between 2006 and 2013, 50 patients with a median age of 56 years old underwent RIC-SCT for the treatment of CLL. The median time from diagnosis to RIC-SCT was 4.7 (0.6-22.9) years. Fourteen (28%) patients had 17p deletion at time of transplantation. CLL-IPI prognostic score calculated prior to transplant was intermediate in 30%, high in 42% and very high in 28% of patients. Disease status at the time of transplant was partial or complete remission in the majority of patients (39 patients, 78%). The overall transplant related mortality (TRM) was 6% and the 5-year non-relapse mortality was 14%. Relapse rates at 5 years were 54%. Acute graft versus host disease (GVHD) developed in 30 (60%) of patients and chronic GVHD was noted in 32 patients (64%). We evaluated the impact of CLL characteristics, disease status, and patient and transplant characteristics on clinical outcomes. Development of chronic GVHD post-transplant was the dominant predictor of both disease-free survival (DFS) (HR 0.29, 95% CI=0.10-0.69, P=0.006) and OS (HR 0.04, 95% CI=0.01-0.19, P<0.0001, Figure 1A). Very high CLL-IPI risk category (28% of patients) was associated with high relapse rates (82%) post RIC-SCT. DFS was also different between different CLL-IPI categories (18.2% in very high 52.9% in high vs 66.7% in intermediate; p=0.04, Figure 1B). However, there was no significant difference in overall survival suggesting potential benefits from novel therapies in relapsed patients. Given that development of chronic GVHD was the most significant predictor for OS, we evaluated what pre-treatment and disease (including CLL-IPI), and transplant characteristics predicted for subsequent development of chronic GVHD. ZAP70 over expression (OR 0.09 [95% CI 0.01-0.79], p=0.03), disease status at transplant (progression versus remission OR 0.22 [95% CI 0.05-0.92], p=0.038), and alemtuzumab exposure within 3 months of transplantation were associated with lower rates of chronic GVHD (OR 0.08 [95% CI 0.01-0.79], p=0.03). CLL-IPI was not a significant predictor for the development of chronic GVHD in our analysis.

Figure 1.
Background: The human leukocyte antigen-G (HLA-G) gene encodes a tolerogenic protein known to promote tumor immune-escape mechanisms.

Aims: We investigated the potential role of HLA-G polymorphisms and soluble HLA-G molecules in susceptibility to chronic myeloid leukemia (CML), as well as in achievement and maintenance of deep molecular remission (MR4.5) in 68 patients treated with tyrosine kinase inhibitors (TKIs).

Methods: The entire HLA-G gene was amplified by long-range PCR and sequenced using next-generation sequencing (NGS) with Illumina’s Nextera® technology and a 300 bp paired-end read protocol. The BioVendor® HLA-G ELISA (RD194070100R sHLA-G ELISA - EXBIO Praha a.s. BioVendor) immunocassay was used for the quantitative measurement of HLA-G1 and HLA-G5 soluble forms in EDTA-plasma samples.

Results: The frequency of the G*01:03 allele was significantly associated to CML. Patients carrying the G*01:01:02 allele had a significantly higher mean value of soluble HLA-G compared to patients carrying G*01:01:03 allele (10.29 ± 4.46; p = 0.001). Patients carrying the G*01:01:01 or G*01:01:02 allele had a significantly higher mean value of soluble HLA-G compared to patients carrying G*01:01:03 allele (10.29 ± 4.46; p = 0.001). Moreover patients carrying the G*01:01:03 allele had significantly higher rates of MR4.5 (100% vs 65%), with earlier achievement of deep MR4.5 (median of 8 vs 58 months; p = 0.001). TKIs were discontinued in 24 patients after 2 years of confirmed MR4.5. Treatment free remission (TFR) was 57.7%. None of the patients homozygous for the G*01:01:01 or G*01:01:02 allele remained in TFR (0% vs 68.4%, p = 0.023) (Figure 1). All patients carrying the G*01:01:03 allele remained in TFR.

Figure 1.

Summary/Conclusions: HLA-G alleles with higher secretion of soluble HLA-

**P255**

**IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL**


**Aims:** In a substudy of the EUROSKI trial, expression levels of the influx transporter OCT1 and the efflux transporter ABCG2 were analyzed for their correlation with treatment free remission (TFR) of chronic myeloid leukemia (CML) patients while on tyrosine kinase inhibitor (TKI) therapy. The predictive significance of the efflux and influx channel transcript levels was determined.

**Results:** During the trial of the EUROSKI (European Study of Imatinib, Nilotinib, and Dasatinib in CML), the expression of the ABCG2/GUS transcript level above 4.5‰ (n=93) had a 30-times higher risk of relapse (p=0.04). Moreover patients carrying the G*01:01:03 allele had significantly higher rates of MR4.5 (100% vs 65%), with earlier achievement of deep MR4.5 (median of 8 vs 58 months; p = 0.001). TKIs were discontinued in 24 patients after 2 years of confirmed MR4.5. Treatment free remission (TFR) was 57.7%. None of the patients homozygous for the G*01:01:01 or G*01:01:02 allele remained in TFR (0% vs 68.4%, p = 0.023) (Figure 1). All patients carrying the G*01:01:03 allele remained in TFR.

**Summary/Conclusions:** Here we investigated for the first time the impact of pharmacokinetics in the context of a CML discontinuation trial. ABCG2 but not OCT1 and ABCB1 (MDR1) predicted treatment-free remission after TKI discontinuation. High expression of the ABCG2 efflux transporter correlated with a two-times higher risk of relapse in multivariate analysis. Further prospective validation is warranted.
G would seem to be associated with lower EFS and TFR, possibly because of a stronger inhibitory effect on the immune system in favor of tumor escape mechanisms. Conversely, the allele associated to lower levels of SHLA-G promoted achievement of MR4.5 and TFR, suggesting increased cooperation of the host immune system in CML cell clearance.

P257

DURABLE TREATMENT-FREE REMISSION AFTER STOPPING SECOND-LINE NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ENESTOP 96-WK UPDATE


1SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia, 2Hemocentro do Rio de Janeiro - HEMORIO, Rio de Janeiro, Brazil, 3Department of Hematology, Akita University Hospital, Akita, Japan, 4Rambam Health Care Campus, Haifa, Israel, 5Hospital Das Clinicas da UFMG, Belo Horizonte, Brazil, 6Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation, 7Mayo Clinic, Jacksonville, United States, 8Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, 9National Research Center for Hematology, Moscow, Russian Federation, 10University Hospital La Paz, Madrid, Spain, 11Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina, 12Centre Hospitalier Lyon Sud, Pierre Bénite, France, 13Onkologische Praxis Hellbronn, Hellbronn, Germany, 14Department of Hematology, Jagiellonian University Hospital, Krakow, Poland, 15Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of, 16Novartis Pharma S.A.S., Rueil-Malmaison, France, 17Novartis Healthcare Pvt Ltd, Hyderabad, India, 18Novartis Institutes for Biomedical Research, Cambridge, 19Novartis Pharmaceuticals Corporation, East Hanover, United States, 20Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France

Background: ENESTop (NCT01698905) is evaluating the ability to stop treatment and remain in TFR in pts with CML-CP who achieved a sustained deep molecular response (MR) after switching from imatinib (IM) to NIL. In the primary analysis, 57.9% of pts (73/126) who stopped treatment remained in TFR (no loss of major MR, BCR-ABL1 ≤0.1% on the International Scale (IS), no confirmed loss of MR4 [BCR-ABL1 ≤0.01%], and no treatment reinitiation) at 4 wk. Aims: To evaluate the proportion of pts remaining in TFR at 96 wk after stopping second-line NIL in ENESTop.

Methods: Eligible pts had ≥3 y of prior tyrosine kinase inhibitor treatment (>4 wk IM, then ≥2 y NIL) and achieved MR4.5 (BCR-ABL1 ≤0.0032%) after switching to NIL. All pts provided informed consent. Enrolled pts continued NIL for 1 y in the consolidation phase (MR assessed every 12 wk). Pts without confirmed loss of MR4.5 during consolidation were eligible to enter the TFR phase (MR assessed every 12 wk for the first 48 wk and every 24 wk for the second 48 wk, then every 12 wk). Pts with loss of MR4 or confirmed loss of MR4 reinitiated therapy. This analysis was conducted when all pts who entered the TFR phase had completed 96 wk of TFR, reinitiated treatment, or discontinued from the study (data cutoff, 7 Nov 2016).

Results: In the consolidation phase, 67 of the 126 pts (53.2% [95% CI, 44.1% - 62.1%]) who entered the TFR phase remained in TFR. Four pts who were in TFR at 48 wk reinitiated NIL due to confirmed loss of MR4 at 60 wk. 72, 90, and 96 wk, respectively. Two other pts discontinued from the study between 48 and 96 wk due to pregnancy (last BCR-ABL1 of 0.0035% at 60 wk) and pt decision (maintained MR4.5 through 90 wk), respectively. Based on Kaplan-Meier analysis, the median duration of treatment-free survival has not been reached and the curve appeared to plateau (Figure 1). Of 56 pts who reinitiated NIL by the data cutoff, 52 (92.9%) regained MR4 and MR4.5, and the time by which 50% of pts regained MR4 was 12.0 and 13.1 wk, respectively. The time by which 50% of pts regained MR4 was shorter for pts with BCR-ABL1 of ≥0.01% (19.3 wk) vs <0.01% (21.2 wk), respectively. The median confirmed loss of MR4 (n=22) at 11.0 wk) vs loss of MMR (n=34; 16.0 wk). Two of the 4 re-treated pts who did not regain MR4 were ongoing in the treatment reinitiation phase (duration, 87.9 and 6.9 wk, respectively; the other 2 discontinued from the study before 48 wk, 1 wk due to regaining MMR (reinitiation duration, 20 wk) and 1 due to an adverse event (AE) after regaining MMR. Two deaths occurred after the first 48 wk of TFR, both in post-treatment follow-up-1: 1 due to cardiopulmonary failure 111 days after pt discontinued treatment due to an AE, and 1 due to adenocarcinoma 77 days after pt discontinued treatment due to initiation of chemotherapy for secondary malignancy. Among pts who remained in TFR at 96 wk (n=77), rates of all-grade AEs were 82.2% and 63.0% during the first and second 48 wk of TFR, respectively, vs 79.5% during the consolidation phase. Rates of musculoskeletal pain-related AEs were 47.9% and 15.1% during the first and second 48 wk of TFR, respectively, vs 13.7% during the consolidation phase. Summary: Updated 96-wk analyses from ENESTop showed stability of the TFR rate, with few pts reinitiating treatment between 48 and 96 wk after stopping second-line NIL. Rates of overall and musculoskeletal pain-related AEs decreased in the second 48 wk of TFR vs the first 48 wk. Overall, these results demonstrate the durability of TFR after stopping NIL in pts who achieved a sustained deep MR after switching from IM to NIL.

Figure 1.

P258

NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS

S. Sadig1, E. Owen1, T. Foster1, K. Knight2, L. Wang2, M. Pirmohamed1, R. Clark3, S. Pushpakom3, M. Villalta3, J. Klug3, E. Leaf3, M. Davis3, F. Keshaviah1, L. Finlayson1, S. Sadiq1, E. Owen1, T. Foster1, K. Knight2, L. Wang2, M. Pirmohamed1, R. Clark3, S. Pushpakom3, M. Villalta3, J. Klug3, E. Leaf3, M. Davis3, F. Keshaviah1

1Molecular and Clinical Pharmacology, University of Liverpool, 2Royal Liverpool and Broadgreen University Hospitals NHS Trust, 3Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

Background: Impaired glucose and lipid metabolism is an adverse effect associated with nilotinib (NILO), a tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML). Indeed the 5-year safety analysis of the ENESTnd trial observed elevations in blood glucose and lipid levels in the NILO arms; importantly NILO-treated patients also showed an increased incidence of arterial occlusive diseases. Adipose tissue is a key regulator of lipid and glucose homeostasis; dysregulation of adipogenesis, altered adipocyte lipid accumulation and reduced insulin sensitivity are implicated in the pathogenesis of metabolic disease. We investigated the effect of NILO on adipose tissue to explain the mechanisms behind NILO-associated metabolic adverse effects.

Aims: i) To study the effect of NILO and imatinib (IMA) on adipocyte function and adipokine secretion using an in vitro adipocyte model; ii) To utilise the in vitro model to explore potential therapeutic strategies to reverse NILO-mediated effects, and iii) To validate the in vitro results in a pilot patient cohort.

Methods: Differentiating 3T3-F442A mouse adipocytes were incubated with clinically relevant concentrations of NILO (1-20µM) and IMA (5µM); in the presence or absence of telmisartan (1-10µM), an angiotensin receptor blocker with potential beneficial effects on insulin sensitivity and lipid homeostasis. Cytoxicity and adipogenesis were assessed by MTT assay and Oil Red O staining, respectively. Expression of adipogenic genes, hormone sensitive lipase regulatory receptor gamma (PPARY), lipin1 (LIPIN1), sterol regulatory element-binding protein 1 (SREBP1) and glucose transporter 4 (GLUT4) were investigated by quantitative PCR and secreted adiponectin was measured by ELISA. Plasma samples were collected from 30 CML patients on neither NILO (first line, n=6; patients for first line, n=15) at baseline and at 3 and 12 months of therapy, and adiponectin was measured by ELISA. Data are presented as mean ± SD for 20µM incubations but full concentration response relationships were measured.

Results: Neither NILO nor IMA were cytotoxic to the adipocytes at clinically relevant concentrations. A dose dependent reduction in lipid accumulation was observed for NILO (for 20µM, 0.76 ± 0.005 absorbance units; p<0.01) but not IMA (0.98 ± 0.007), compared to vehicle control. NILO, but not IMA, resulted in significant downregulation of GLUT4 mRNA (NILO, 93%; IMA, 79%; p<0.01) and of secreted adiponectin (NILO, 5.99±0.31ng/ml; IMA, 79.2±0.79ng/ml). Co-incubation with telmisartan resulted in significant reversal of NILO-mediated effects on lipid accumulation, adipogenic gene expression and adiponectin secretion. In the patient cohort, IMA resulted in a significant increase in adiponectin levels at 3 (38.4±7.1mg/l; p<0.01) and 12 (36.7±2.7mg/l; p<0.01) month time points compared to baseline (27.3±5.7mg/l). In contrast, second line NILO showed a trend for reduction in adiponectin at both 3 (15.2±1.8mg/l; p=NS) and 12
Summary/Conclusions: A BCR-ABL transcript level measured at 1 month after initiation of a TKI may be used as an early indicator to reliably predict the MMR achievement by 12 months in patients with CP-CML. The level obtained at 3 months appears to accurately predict the MMR. Further studies are needed to evaluate the association between the transcript level at 1 month and long-term clinical outcomes.

P260

Abstract withdrawn.

P261

A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL
G.-N. Franke1,*, J. Maier1, M. Cross1, S. Tzonev2, D. Shelton2, K. Wildenberger1, D. Niedenwieser1, T. Lange1
1Abt. Hämatologie und internistische Onkologie, Universitätsklinikum Leipzig AöR, Leipzig, Germany, 2Digital Biology Center, Bio-Rad Laboratories, Pleasanton, United States, 3Askepios Klinikum Weißentals, Weißentals, Germany

Background: Digital PCR (dPCR) generates an absolute read out that is largely robust to variations in PCR efficiency and should reduce the requirement for standardisation by laboratory-specific conversion factors. DPCR is an appealing technology for quantitative detection of specific mutations with simultaneous measurement of the reference gene and is particularly suitable for minimal residual disease (MRD) diagnostics in chronic myeloid leukaemia (CML). However, a limitation of the dPCR assays compared to standard quantitative PCR (qPCR) is the background (termed lower limit of blank, LoB) of 1 or 2 positive droplets for BCR-ABL (Franke et al. ASH 2015, Cross et al, Leukemia 2016). The resulting false positive rate (FPR) limits the sensitivity and the ability to detect deep molecular remissions. This has hindered the definition of the lower limit of detection (LoD). We report here on the LoB and the LoD of a newly developed assay.

Aims: Determination of LoB, LoD, linearity and precision of an optimized BCR-ABL digital PCR assay.

Methods: The assay was developed by Bio-Rad laboratories and consisted of a reverse transcriptase reaction followed by a duplex PCR detecting ABL and both the b2/a2 and b3/a2 transcripts of BCR-ABL. Digital droplet PCR was performed using the Bio-Rad QX200 system. LoB and cross-hybridisation were assessed in non-template controls (NTC), BCR-ABL negative cell lines and healthy wild-type donor samples. LoB, precision and linearity were measured in serial dilutions of patient’s cDNA in healthy donor’s cDNA to simulate MMR, MR4, MR4.5, MR5 and MR5.5. Finally, the assay was tested on a certified CAP MR4.7 sample.

Results: The specificity was >95% for both BCR-ABL and ABL in NTC and wild type samples. Extensive NTC analysis yielded no false positives for BCR-ABL PCR (n=0/176; LoB=0) and 1% false positives in ABL PCR (n=2/176; 1-2 positive droplets, LoD=0). The BCR-ABL assays of healthy donors were positive in 2% (n=5/254) with 1 positive droplet/positive sample. For 2 wells analysis, the detection rate for BCR-ABL for MR4.5 and MR5 was 100 and 88%, resulting in a LoD between 6 and 3 BCR-ABL copies/2 wells. Although the ABL copy number was only 20000 for 2 wells, the MR4.5-detection rate was 42%. However, in a more refined analysis, the detection rate was 100% for MR5 and 67% for MR4.5 with an average of 6 and 2 BCR-ABL copies/4 wells (see Table 1). The MR4.5 sample was analyzed repeatedly, with 59 of 60 replicates evaluable. A total of 89 BCR-ABL copies (1.51/replicate) and 4,329,846 ABL copies (73387/replicate) were detected, resulting in a ratio of 0.0021 (MR4.5). The false negative rate was below 3% when combining any pair of replicates, indicating an LoD of 4.5 for assays carried out in duplicate.

Table 1.

<table>
<thead>
<tr>
<th>Sample</th>
<th>BCR-ABL Copies</th>
<th>ABL Copies</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR4.5</td>
<td>59</td>
<td>4,329,846</td>
<td>0.0021</td>
</tr>
<tr>
<td>MR5</td>
<td>66</td>
<td>4,329,846</td>
<td>0.0014</td>
</tr>
<tr>
<td>LoD</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Summary/Conclusions: We report here on an optimized digital PCR assay with a LoB of zero and a LoD of 3 copies/2 wells. This highly sensitive and specific assay allows accurate detection of MRD in BCR-ABL positive diseases with a detection rate of 100% for MR5 and 67% for MR5.5 in a 4 wells analysis.

P262

VALIDATION OF THE EUTOS LONG TERM SURVIVAL SCORE IN DUTCH CML-PATIENTS
I. Geelen1,*, N. Thielen2,3, J. Janssen2, M. Hoogendoorn4, O. Visser5, J. Cornelissen5, P. Westerweel1
1Albert Schweitzer Hospital, Dordrecht, 2Department of Hematology, VU Med-
Background: Risk scores in chronic myeloid leukemia (CML) use baseline characteristics of CML patients in chronic phase to predict outcome and can be used to make decisions regarding first line TKI choice and monitoring frequencies. Until recently, risk stratification of CML patients was used based on scores developed in the pre-imatinib era (Sokal and Hasford risk score) with overall survival as the end point of interest. After the introduction of imatinib, the EUTOS score was established to predict the chance of achieving CCyR at 18 months, as a proxy for survival. However, since the major causes of death of CML patients are no longer CML-related, the need for baseline risk prediction has shifted from overall survival towards disease specific mortality. Therefore, recently the EUTOS long-term survival (ELTS) score was introduced to predict the risk of death of CML in patients treated with first line imatinib.

Aims: The primary objective of this study was to perform a validation of the ELTS score in an independent cohort of "real-world" population-based CML patients.

Methods: Data from chronic phase CML patients were derived from the PHAROS-CML population based registry and Hemobase. Patients were stratified into a low, intermediate and high risk group according to the ELTS score. Data on "death due to CML" were provided by the Netherlands comprehensive cancer organization (IKNL) in combination with details from the patient records and a competing risk analysis was performed, to take death due to other causes into account.

Results: In total 349 patients were eligible for analysis; 273 patients (78%) were treated with first line imatinib and 76 patients (22%) were treated with a first line second generation TKI (2GTKI). Sokal, Hasford and EUTOS risk scores all did not predict differences in risk of "death due to CML". The ELTS score identified 163 patients as low risk (47%), 127 patients as intermediate risk (36%) and 59 patients as high risk (17%) at diagnosis. The 5 year cumulative incidence of "death due to CML" was indeed significantly higher in the high risk group (11%) compared to both the intermediate risk group (2%, p=0.02) and the low risk group (1%, p<0.001). Between the intermediate and low risk group no statistically significant difference in risk of dying from CML was observed. A subgroup analysis of only imatinib treated patients showed similar results.

Summary/Conclusions: In the current study based on a "real-world" population-based CML patient cohort, we were able to validate the predictive value of ELTS high risk stratification for "death due to CML" in the current TKI era. Therefore, the ELTS score should be preferred over Sokal, Hasford and EUTOS scores in clinical practice.
**Hematopoiesis, stem cells and microenvironment**

**P264**

**ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE**

D. Passaro1,2, A. Di Tullio1, A. Abarrategi1, K. Rouault-Pierre1, K. Foster1, L. Ariza-McNaughton1, P. Chakravarty2, L. Bhaw3, G. Diana4, F. Lassailly5, J. Gribben6, D. Bonnet7

1Hematopoietic Stem Cell Laboratory, 2Bioinformatics Unit, 3Advanced Sequencing Unit, The Francis Crick Institute, 4MRC Centre for Developmental Neurobiology, King’s College, 5Hematopoietic Stem Cell Lab, The Francis Crick Institute, 6Department of Haematology, Barts Cancer Institute - Queen Mary University of London, 7Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom

Background: The biological and clinical behavior of hematological malignancies is not only determined by the properties of the leukemic cells themselves, but it is also highly affected by the interaction with the microenvironment, pointing to the existence of an active crosstalk between the two compartments. Previous studies showed that acute myeloid leukemia (AML) actively modify endothelial cells ex vivo via several pathways, mainly mediated by VEGF. However, anti-VEGF therapies haven’t produced successful results in clinical trials.

Aims: Our aim is to perform an extensive study of the vascular niche in the bone marrow (BM) of AML xenografts to provide a global picture of the vascular architecture and design new therapeutic strategies.

Methods: We combined the use of mouse models of AML, human AML derived xenografts (PDX) and direct analysis of patients derived samples to study the vascular niche in AML disease. We used two-photon confocal microscopy as a powerful tool to functionally image the BM vasculature in vivo. We used RNA-sequencing to study the AML-associated transcriptomic profile in vascular endothelial cells.

Results: We found several abnormalities in the vascular architecture and function in PDX, such as increased number of endothelial cells, increased microvascular density (MVD), loss of normal sinusoidal architecture and increased hypoxia. Moreover, vascular permeability was increased as measured via two-photon imaging. Interestingly, induction chemotherapy failed to normalize the vascular permeability in the BM, although it significantly reduced the AML engraftment. Via high-throughput transcriptomic analysis, we showed that AML-induced hypoxic environment altered the molecular signature of vascular endothelial cells, activating pro-angiogenic pathways and positively regulating the response to hypoxia. We identified increased nitric oxide (NO) as a major mediator of the AML-induced vascular leakiness in the BM. Notably, increased NO levels were found also in BM aspirates of patients at diagnosis compared to healthy donors, and failure in reducing NO levels after chemotherapy appeared to be associated with a higher incidence of unsuccessful treatment. Strikingly, inhibition of NO production in mouse models of AML and in AML-derived PDX reduced vascular permeability, preserved normal HSC function and significantly improved treatment response (Figure 1).

Summary/Conclusions: We have shown an altered highly permeable vascular niche in the BM of AML PDX, mainly caused by increased NO production by the endothelial niche, contributing to disease progression and treatment failure. Our data call for clinical trials incorporating NOS inhibitors during the remission phase, to target the abnormal vascular niche and improve AML treatment response.

**P265**

**BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS**

H.-J. Prins1, T. Csikos 1, R. de Jong-Korlaar 1, R. Ruiter 1, S. van Veen1, H. Yuan1, J. de Bruijn2, G. Ossenkoppele1, R. Groen1

1Hematology, VU University Medical Center, Amsterdam, 2Xpand Biotechnolgy BV, BIlthoven, Netherlands

Background: Previously, we have reported that our human bone marrow-like scaffold (huBM-sc) xenograft model allows the engraftment and outgrowth of normal and malignant hematopoiesis (e.g. multiple myeloma (MM) and acute lymphoblastic leukemia (ALL) (Groen et al. Blood 2012; Gutierrez et al. JCI 2014) and more recently acute myeloid leukemia (AML); Antonelli et al. Blood 2016). These studies show that i) engraftment is not correlated with prognostic risk-groups, ii) there is preferential outgrowth in humanized scaffolds compared to the murine BM, iii) the huBM-sc environment results in better maintenance of self-renewal potential and less clonal drift of the leukemic cells. Although the presence of human osteoblasts and bone mimics a human BM niche more closely than the murine BM in standard xenotransplant models (e.g. NOD-SCID/NSG mice), still some essential components of the human BM niche, i.e. human blood vessels, are missing.

Aims: To implement human vasculature in the huBM-sc xenograft model in order to create a multi-tissue compartment that “maximaly humanizes” the BM-like niche of our scaffolds.

Methods: Towards successful implementation of a human vascular system inside our scaffold material we have developed: i) scaffolds material composition (bovine collagen type I-phosphate (BCP) vs tricalcium phosphate (TCP)); ii) scaffold shape (particles vs tubes); iii) different types of matrigel for cord blood-derived endothelial progenitor cells (CB-EPCs) embedding.

Results: Histological analysis of these fully humanized scaffolds showed a large hematopoietic vascular compartment (CD31-positive vessels, CD146, LEPR and nestin-positive stromal niche cells. Comparison of the composition and the shapes of the scaffolds indicated superiority of TCP and tubeshaped scaffolds in supporting the formation of vessels. Engraftment of BM-derived CD34+ cells in the CB-EPC embedded huBM-sc resulted in increased multidimensional hematopoietic engraftment, as compared to huBM-sc without CB-EPCs. Moreover, we observed that incorporation of CB-EPCs provides faster kinetics of engraftment of both patient-derived MM and AML cells, and proved to be essential for the engraftment of blast cells from myelofibrosis patients.

Summary/Conclusions: Thus, with the addition of human CB-EPCs and BM stromal cells, our scaffold systems now simulate both endosteal and vascular niches of the BM, thereby more closely recapitulating the human hematopoietic microenvironment.

**P266**

**MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS**

A. Gomáriz1, P. Heilbing1, S. Isringhausen1, U. Suessbier1, A. Becker2, A. Boss3, T. Nagasawa4, G. Paul5, O. Göksel6, G. Zekely7, S. Stoma6, N. Nerellyke6, M. Manz1, C. Nombela Arrieta1

1Hematology, University and University Hospital Zurich, 2Radiology, University Hospital Zurich, 3Radiology, University Hospital Zurich, 4Frontier Biosciences, Osaka University, Osaka, Japan, 5Computer Vision, 6SCOPE M, ETH, Zurich, Switzerland

Background: Adult bone marrow (BM) cavities host continuous, demand adapted and high throughput blood cell production, which is maintained by a scaffold of stromal cells, our scaffold systems now simulate both endosteal and vascular niches of the BM, thereby more closely recapitulating the human hematopoietic microenvironment.

Aims: To perform a detailed quantitative and structural analysis of the BM stromal infrastructure, with a special focus on sinusoidal microvasculature and the CAR cell mesenchymal component, both of which are essential regulators of HSC maintenance.

Figure 1.
Methods: We have developed i) advanced microscopy techniques allowing multiscale 3D visualization of entire bone marrow cavities with cellular and subcellular detail ii) customized computational tools enabling the detection and quantification of discrete cell subsets/structures in 3D images of the BM in an unbiased fashion, as well as a rigorous spatial statistical analysis of cellular interactions.

Results: Using 3D-quantitative microscopy (3D-QM) we uncover that BM stromal cells are in fact 15-20 fold more abundant than previously reported. The massive underestimation of these relevant cell subsets results from the highly inefficient isolation of these cellular types with currently employed flow cytometry protocols. Our image-based analyses further reveals that sinusoidal and CAR cell stromal networks occupy a disproportionately large fraction of the BM space, consequently constraining the tissue volume available for hematopoietic cell distribution. In fact, the vast majority of BM resident hematopoietic cells are unavoidably in direct contact with the CAR cellular projections and in close proximity of the sinusoidal endothelial surface.

Summary/Conclusions: Collectively, our quantitative description of stromal microarchitecture, challenges current models of cell type-specific niche interactions in the BM, which are based in largely inaccurate estimations of cell frequency and spatial confinement of stromal cells in this organ.

P267

TEMPLATED VDJ INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPertoire DIVERSIFICATION

M.T. Koning1, I. Trollmann1, R. Rademaker2, R. Toes3, H. Veelken1

1Department of Hematology, Leiden University Medical Center, Leiden, 2Gen-Mab, Utrecht, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.

Background: Recently, large LAIR1 insertions at the V-D junction were described as a novel mechanism to generate antibodies against P. falciparum RIFIN antigens on infected erythrocytes (Tan et al., Nature 2016). These templated insertions potentially add a novel biological mechanism used by the immune system to generate B-cell receptor repertoire diversity.

Aims: We investigated whether templated insertions occur in the B-cell repertoire of healthy donors and whether such insertions could be functionally exploited to explore their biological function.

Methods: We obtained >52,000 unique full-length VDJ sequences of IgM, IgG, IgA, and IgE isotypes by unbiased ARTISAN PCR (Koning et al., BJH 2016) from 6 healthy donors. Abnormally long sequences and junctions were searched for templated insertions by BLAST. Identified VDJ carrying templated insertions were co-expressed with a panel of 172 light chains on multiple myeloma cell lines and assessed for surface expression of transgenic immunoglobulin. The VDJ described by Tan et al. were included as controls.

Results: Six unique VDJ sequences, all from the same donor, carried a templated insertion in-frame (E=10-37–0). These sequences represented all VDJ described by Tan et al. and IgE isotypes positioned in a germline configuration of IgE joining region adjacent to IGHD3-22. Somatic hypermutation correlated strongly between the the IGHV segment and the templated insertions (r=0.9944; p<0.001). All templated insertions harboured cryptic RSS sites at their termini. All three IgG VDJ carrying templated insertions and the IgG rearrangement with the templated insertion gave rise to detectable surface immunoglobulin after coexpression with at least one light chain in the panel. The IgG VDJ carrying the LAIR1 templated insertion produced no detectable surface immunoglobulin. In contrast, the VDJ sequences carrying LAIR1 templated insertions as described by Tan et al. could be expressed with the majority of the light chains. The IgA rearrangement remains to be tested in this system.

Summary/Conclusions: Templated insertions represent a novel antibody diversification mechanism. Their presence in naïve B-cells, their exclusive positioning in VDJ junctions, and the universal presence of cryptic RSS sites point to primary VDJ recombination or secondary V gene editing as the generating mechanism. Certain loci (e.g. LAIR1) and individuals appear to have increased susceptibility. The available data suggest RAG to be involved in these insertions. We propose that templated insertions represent inserted signal sequences from aberrantly rearranged chromosomal sequences with cryptic RSS sites.

P268

TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION

S. Solier1, L. Meziani2, M. Mondini2, C. Lacout1, P.M.-C. Deng1, J.-C. Martineau2, P. Vandenvoort3, E. Deutsch2, O. Herminie2, N. Drön1, C. Dupuy2, J. El-Benna3, E. Ribakovsky1, N. Droin1, C. Dupuy7, J. El-Benna3, N. Droin1, C. Dupuy7, J. El-Benna3, C. Dupuy7

1INSERM UMR1170, 2INSERM UMR1030, Gustave Roussy, Villejuif, 3INSERM UMR773, Université Paris 7 Denis Diderot, Paris, France, 4Department of Cell Biology, University of Geneva, Genève, Switzerland, 5Laboratory and Cell Death Unit, VIB, Inflammation Research Center, Ghent, Belgium, 6Clinical Hematology Department, Faculty of Medicine and AP-HP Necker-Enfants Malades, Paris, 7CNRS UMR8220, Gustave Roussy, VILLEUIF, France

Background: Caspases, which are key effectors of apoptosis, have demonstrated non-apoptotic functions. One of these functions is the differentiation into macrophages of peripheral blood monocytes exposed to Colony-Stimulating Factor-1 (CSF1). Conversely, GM-CSF induces the differentiation of monocytes into macrophages in a caspase-independent manner. Macrophages generated by CSF1 and GM-CSF have different polarities.

Aims: Macrophage polarization plays an important role in the pathogenesis of diverse human diseases as cancer, leading us to explore if caspase inhibition would affect macrophage polarization.

Methods: To explore the role of caspases in CSF1 differentiation, we used human monocytes sorted from buffy coats or from blood of NOX2-deficient patients treated by cytokines, and we generated monocyte-restricted caspase-8, -9 knockouts and caspase-8 and -9 double knockout mice, which were treated with bleomycin to induce pulmonary fibrosis.

Results: Caspase activation is involved in the generation of M2 polarized macrophages. Caspase inhibition delays the ex vivo differentiation of peripheral blood monocytes exposed to CSF1 and modifies the phenotype of generated macrophages, e.g. cell shape, surface markers and cytokine secretion. In mice, caspase knock-out also modified the phenotype of monocytes induced to differentiate into macrophages. Caspase activation appeared to be prominent at the mitochondria level and responsible for the NOX2-dependent generation of cytotoxic radical oxygen species (ROS). Activation of the NOX2 complex is associated with p47phox cleavage by caspases. Mice treated with bleomycin typically develop a pulmonary fibrosis. Bleomycin-induced lung fibrosis was delayed in monocyte-restricted caspase-8 knockout mice and prevented by treatment with a caspase inhibitory molecule, including zVAD-fmk and the clinically developed IDN6556. This effect was associated with a change in the phagocytic activity of lung-infiltrating macrophages.

Summary/Conclusions: Caspase inhibition in monocytes prevents the development of bleomycin-induced lung fibrosis by modifying macrophage polarization, suggesting that caspase inhibitory molecules may be an exciting thera-peutic strategy to modulate macrophage polarization with diverse applications including cancer treatment.

P269

MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOYTIC MICROENVIRONMENT VIA CXCL13

K. Beider1, V. Voevoeda1, H. Bilmer1, E. Rosenberg1, H. Mager1, O. Ostrovsky1, E. Rabkovskiy1, A. Shimon1, L. Weiss1, M. Abraham2, A. Peled1, A. Nagler1

1Hematology Division, Bone Marrow Transplantation, SHEBA MEDICAL CENTER, Ramat-Gan, 2Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, 3Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel

Background: Previous studies including our work revealed a role of MM-educated M2-like macrophages (MΦ) in MM survival and drug resistance. However, the mechanism by which neoplastic plasma cells shape BM microenvironment and affect MΦ polarization is still poorly defined.

Aims: To investigate tumour-induced effects on MΦ in the myeloid compartment of the BM niche that are initiated by MM cells.

Methods: We utilized our in vivo xenograft model of BM-disseminated human myeloma. The CRI/SPR/cas9 technology was used to knockdown CXCL13 expression in MM cell lines.

Results: BM analysis of mice inoculated with human CXC44-expressing RPMI8226 cells revealed a significant increase in M2 in MM in comparison to non-injected controls (p<0.01). Characterization of MM-associated changes in the BM milieu revealed murine chemotractant CXCL13 being one of the most profoundly increased factors upon MM development. Elevated CXCL13 was documented in blood of MM-bearing animals comparing to healthy controls. IHC staining identified myeloid cells as the main source of increased murine CXCL13 detected in MM-occupied BM. Murine BM CXCL13 mRNA expression strongly correlated with human β2-microglobulin mRNA levels (p<0.0001 R²=0.64), indicating the interrelation between tumor burden and CXCL13 induction. CXCL13 promotes survival of MM cells, and anti-MM treatments resulted in CXCL13 expression in MM cell lines and primary human CD138+ cells. Mechanistically, TGFB signaling was involved in CXCL13 induction in both MM cells and MΦ, as TGFB receptor inhibitor SB431542 interfered with CXCL13 induction. Osteo-
clastogenic assays were used to elucidate the down-stream effects of the elevated CXCL13. Recombinant CXCL13 was added to mouse BM aspirates produced by co-cultured MM-MΦ increased RANKL expression and induced TRAP⁺ osteoclast (OC) formation in vitro, while CXCL13 neutralization blocked these activities. We next abrogated CXCL13 expression in MM cell lines using the CRISPR/Cas9 technology. The loss of CXCL13 had no effect on MM in vitro growth or drug sensitivity. However, mice inoculated with CXCL13-silenced MM cells developed significantly weaker BM disease compared to mice receiving the non-manipulated cells. Reduced tumor load correlated with decreased numbers of M2c-MΦ in MM, decreased bone disease, and lower expression of OC-associated genes. Finally, the presence of CXCL13 in primary MM samples was evaluated. 739 genes were significantly differentially expressed in the two populations. A new population of MM-MΦ emerged from the pre-existing MM-MΦ pool. The emergence of MM-MΦ was the result of increased bone resorption and osteoclastogenesis, which in turn increased CXCL13 expression. Recombinant CXCL13 as well as medium produced by co-cultured MM-MΦ increased RANKL expression and induced TRAP⁺ osteoclasts from BM aspirates from MM patients (n=24) in comparison to normal BM (n=5) and were in correlation with gene expression signature associated with OC activation and M2c MΦ phenotype (Figure 1).

Figure 1. Summary/Conclusions: Our findings suggest that bidirectional interactions of MΦ with MM tumor cells result in M2c MΦ polarization, CXCL13 induction and subsequent OC activation, enhancing their ability to support bone resorption and MM progression. CXCL13 may thus serve as potential novel target for the diagnosis and treatment of MM.

P270
RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR
S. O’Byrne1, N. Elliott1, G. Buck2, L. Liu1, B. Povinelli2, N. Fordham2, E. Louka2, K. Bartolovic2, A. Karadimitris3, A. Mead2, I. Roberts1, A. Roy3, E. Louka2, K. Bartolovic2, A. Karadimitris3, A. Mead2, I. Roberts1, A. Roy3
1Experimental Hematology, 2Department of Computational Biology, 3Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, United States

Aims: To determine B cell developmental pathways in human second trimester fetal bone marrow. The cellular hierarchy of normal human fetal B-lymphopoiesis remains poorly defined. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias. We have previously identified a novel population of PreProB progenitors (CD34⁺CD19⁺CD10⁻) in fetal liver (FL) [1] that was further expanded in fetal bone marrow (FBM) [2], and co-exists with adult-type CD34⁺CD19⁺CD10⁺ ProB progenitors. Increasing evidence indicates that infant ALL and many cases of childhood ALL arise in fetal life, suggesting that ontogeny-related changes in B-cell development may be important for in utero leukemia initiation. Therefore, understanding the human fetal B cell hierarchy, especially the differences between PreProB and ProB progenitors may be key to understanding the origins of infant and childhood leukemias.
development. We thereby report for the first time that the clonal origin of blood is much more complex than previously thought, with hundreds of precursors contributing to the establishment of the mammalian blood system at multiple stages of ontogeny.

P272
A20 RESTRAINTS THYMIC REGULATORY T CELL DEVELOPMENT
T. Haas 1, J. C. Fischer 1, V. Otten 1, S. Spoeller 1, H. Poock 1
1Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, TU München, München, Germany

Background: Maintaining immune tolerance requires the production of Foxp3 expressing regulatory (Treg) cells in the thymus. Activation of NF-κB transcription factors is critically required for Treg cell development, partly via initiating Foxp3 expression. NF-κ B activation is controlled by a negative feedback regulation through the ubiquitin editing enzyme A20, which reduces pro-inflammatory signaling in myeloid cells and B cells. In naive CD4+ T cells, A20 prevents necroptosis and promotes inflammation.

Aims: This study is aimed at analyzing the role of the NF-κB regulator A20 in Treg cell development and function.

Methods: We used A20fl/fl CD4Cre mice, which specifically lack A20 in T cells, to analyze the Treg cell compartment in vivo. We characterized expansion and differentiation of A20-deficient Treg cells in vitro. We performed competitive bone marrow engraftment between WT and A20-deficient bone marrow in vivo to analyze whether one bone marrow compartment would outperform another or would favor development of certain T cell or other immune cell subsets. We performed allogeneic hematopoietic stem cell transplantation with WT BM+T cells vs WT vs A20-deficient Treg cells to analyze whether A20-deficient T reg cells would reduce GVHD to the same extent as WT Treg cells.

Results: Using mice deficient for A20 in T lineage cells, we show that thymic and peripheral Treg cell compartments are quantitatively enlarged due to a cell-intrinsic developmental advantage of A20-deficient T cells. A20−/− Treg cells efficiently suppressed effector T cell mediated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, demonstrating normal suppressive functionality. Holding thymic production of natural Treg cells in check, A20 thus integrates reduced regulatory T cell activity and increased effector T cell survival into an efficient CD4+ T cell response.

Summary/Conclusions: In light of the largely anti-inflammatory effects that have been attributed to A20 in many cell types, this proinflammatory aspect of A20 physiology in effector and regulatory CD4+ T cells is particularly important since it may contribute to a change of perception of the functions of A20 as a negative regulator of NF-κB in the context of inflammation. Whether targeted modulation of A20 activity allows the induction of Treg cell mediated immune tolerance or, alternatively, boosting of favorable T cell immunity is a question of translational relevance that needs to be addressed in the future.

P273
THE TRANSCRIPTION FACTOR C/EBPγ REGULATES MAST CELL DEVELOPMENT AND FUNCTION
M. Kardosova 1,*, L. Potuckova 2, I. Halova 2, P. Zjablovskaja 1, L. Draberova 2, P. Draber 1, M. Alberich-Jorda 1, P. Zjablovskaja 1, L. Draberova 2, P. Draber 1, M. Alberich-Jorda 1

1Hematoncology, 2Laboratory of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Background: Mast cells are key effector cells involved in protection against infection and allergic responses. Defects in mast cells are related to immunological disorders, and therefore it is critically to fully understand the transcriptional network that controls their generation and activity. Differentiation of progenitors to mature mast cells is promoted by several transcription factors, such as GATA1, GATA2, STAT5, and MITF, and requires downregulation of C/EBPα. Recently, we identified another member of the C/EBP family of transcription factors, C/EBPγ, as a direct C/EBPα target gene. However, the role of C/EBPγ in mast cells remains so far elusive.

Aims: In this study we aim to determine the role of the transcription factor C/EBPγ in mast cell development and function. Next, we investigate the mechanism by which C/EBPγ is controlling these processes.

Methods: In order to determine the role of C/EBPγ in murine mast cells, we generated Cebpg conditional knockout mice, which allow excision of Cebpg in the hematopoietic system from the early embryogenesis. We employed Cebpgfl/fl Vav-1Cre- and Cebpgfl/fl Vav-1Cre+ mice, referred here as WT and Cebpg KO, respectively. Excision of Cebpg was assessed by RT-PCR and western blot analysis in bone marrow and spleen cells. Using flow cytometry, we enumerated mast cell counts in the peritoneal cavity of healthy WT and Cebpg KO mice. To elucidate whether C/EBPγ plays a role in mast cell response to bacterial infection, we challenged these mice intraperitoneally with lipopolysaccharide (LPS). Subsequently, we used intraperitoneal injection of distilled water to eradicate peritoneal mast cells and then monitored repopulation of peritoneum over time. To further explore the role of C/EBPγ in mast cells in vitro, we established bone marrow derived mast cells (BMMCs) and determined their growth (cell numbers), morphology (toluidine blue staining), and transcription factors expression (RT-PCR) at different time points. Degranulation potential of BMMCs was specified by measuring the percentage of b-glucuronidase released to the supernatant upon anti-TNP IgE sensitization and TNP-BSA activation. To investigate the effects of absence of Cebpg during mast cell differentiation, we employed transwell migration assays.

Results: We verified efficient ablation of Cebpg on mRNA and protein level in bone marrow and spleen of Cebpg KO mice. Analysis of peritoneal cavity of WT and Cebpg KO mice showed similar frequency and numbers of mast cells in steady state conditions. However, Cebpg deficient mice exhibit increased number of peritoneal mast cells after LPS stimulation in comparison to WT control littermates. Surprisingly, mice lacking Cebpg presented defective peritoneal mast cell repopulation. Since mast cells are scarce and difficult to isolate from in vivo models, we employed BMMCs to investigate the effects of Cebpg ablation in mast cell development and function. We observed that bone marrow from Cebpg KO mice generated reduced number of BMMCs in comparison to WT controls. Functionally, we demonstrated that deletion of Cebpg reduced mast cell migration towards antigen, SCF or PGE, and impaired degranulation upon FcγRI-mediated activation. Further, BMMCs exhibit increased expression of C/EBPα in the absence of C/EBPγ.

Summary/Conclusions: In summary, we revealed C/EBPγ as important transcription factor which suppresses C/EBPα expression, thereby favoring mast cell development and function. Our data identifies a new component of the mast cell transcriptional network and provides a better understanding of mast cells in normal physiological conditions and disease.

P274
TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING

1CEA, INSERM, Paris, 2CEA, Evry, France

Background: One of the main complications of anti-cancer therapies or bone marrow transplantation protocols is their deleterious effect on the blood system, leading to prolonged neutropenia and increased risk for infections. Manipulating hematopoietic stem cells differentiation pathways to favor production of specific lineage-committed progenitors might optimize blood recovery.

Aims: In this study we aimed 1) to determine and quantify the contribution of medullary progenitor populations (MPP) to the repopulation of the T cell pathway using the barcode cellular labelling strategy that we have previously developed and 2) to decipher the heterogeneity of these MPP at the transcriptional level.

Methods: Three different MPP subsets, of the following phenotypes: VCAM1+Flt3 (MPP1); VCAM1-Flt3+ (MPP2) and VCAM-1Flt3+ILR7 (CLP), were tagged with different barcodes carried by a collection of lentivirus and transplanted in mice. Barcoded cells in recipient mice were analyzed by flow cytometry. For whole transcriptome strand-specific sequencing, three biological replicates, per cell population, were sequenced at high depth of coverage (2 x 120 million reads).

Results: The results allowed the in vivo dynamic tracking of the progeny of the barcoded progenitors in transplanted recipients. Moreover, transcriptome-wide profiling was used to identify, by cluster analysis of RNAseq profiles together with gene ontology annotation, unique co-expressed markers for the prospective isolation of these populations. Unsupervised classification correctly classified reference surface markers, currently used to purify progenitors, which validate our bioinformatic methodology. Transcriptional regulation of these cell surface markers was further assessed by searching for co-expressed transcription factors and enriched binding sites in their promoters. Their grouping enabled to establish undescribed regulatory networks, specific to each progenitor cell.

Summary/Conclusions: Collectively, the cellular barcoding tool and the molecular changes observed at RNA and functional levels as they occur in vivo in the context of physiologic commitment processes, highlighted data that contribute to a deeper understanding of the dynamic of T lineage differentiation and the lineage restriction process.
Hodgkin lymphoma

P275
LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP
D.A. Eichenerauer1,*, A. Plütschow1, M. Fuchs1, B. von Tresckow1, V. Diehl2, P. Borchmann1, A. Engert1
1First Department of Internal Medicine, 2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany

Background: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity accounting for approximately 5% of all Hodgkin lymphoma (HL) cases. Pathological and clinical features differ from classical HL (cHL). Pathologically, the malignant lymphocyte predominant (LP) cells stain consistently positive for CD20 and are negative for CD30. Clinically, NLPHL often has a rather indolent course. Despite of these differences, the first-line treatment of NLPHL is mostly very similar to cHL. However, analyses on the long-term course of patients with NLPHL who were treated identically to cHL are scarce.

Aims: To shed more light on characteristics and outcome of NLPHL patients treated identically to cHL, we performed an analysis using the database of the German Hodgkin Study Group (GHSG).

Methods: A total of 471 patients with NLPHL who had received first-line treatment within the randomized GHSG HD7-HD15 trials for newly diagnosed HL were identified. The studies were conducted between 1993 and 2009. Patients at all stages (early favorable: HD7, HD10, HD12; early unfavorable: HD8, HD11, HD14; advanced: HD9, HD12, HD15) were included.

Results: Among the 471 NLPHL patients, the median age was 39 years; 76% of patients were male; 53% of patients had early favorable, 16% had early unfavorable and 31% had advanced-stage disease. Study treatment consisted of ABVD- or BEACOPP-based chemotherapy alone, radiotherapy (RT) alone or combined-modality treatment (CMT). After a median observation of 9.2 years, the 8-year progression-free survival (PFS) rate for the whole patient group was 81.3% (83.2% for early favorable, 85.2% for early unfavorable, 76.2% for advanced stages). 80 of 471 patients (17%) had refractory disease or relapsed during the course of follow-up (primary disease progression). In patients with relapse, 6 patients; late relapse: 66 patients). Second malignancies including histological transformation into aggressive B-cell non-Hodgkin lymphoma (NHL) occurred in 48/471 patients (10%) (solid tumor: 25 patients; leukemia: 7 patients; NHL: 13 patients; unspecified malignancy: 4 patients). For all 471 patients included in the present analysis, the 8-year overall survival of the 192 patients early relapse: 6 patients; late relapse: 66 patients was 99.5% for early favorable, 98.6% for early unfavorable, 87.4% for advanced stages). A total of 43 deaths were observed during follow-up resulting in a death rate of 9%. However, only a minority of these deaths was NLPHL-related (n=10). In contrast, most patients died from second malignancies (n=20) or due to other causes (n=13) such as heart failure and lung disease.

Summary/Conclusions: Taken together, the results from this large analysis on NLPHL patients prospectively treated and followed within randomized clinical studies for newly diagnosed HL indicate an excellent lymphoma-specific outcome. Nonetheless, further treatment optimization is necessary as the majority of the observed deaths were not NHL-related but due to second malignancies or other treatment-related late effects. Thus, future clinical trials including NLPHL patients should evaluate whether it is possible to reduce the treatment intensity without compromising efficacy. This goal may be achieved by the partial replacement of conventional chemotherapy by targeted drugs such as anti-CD20 antibodies as well as the reduction of RT fields and doses.

P276
ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16–59
J. Russell1,*, A. Collins2, A. Fowler3, M. Karanth4, C. Saha2, V. Shyamsundar1, N. Grigoropoulos1, B. Uttenthal1, G. Follows1
1Hematology, University of Naples Federico II, Naples, 2Department of Medicine and Surgery, University Medical School, Salerno, Salerno, 3Department of Hematology, University of Molise, Campobasso, Italy

Background: Hodgkin lymphoma is a rare entity accounting for approximately 5% of all Hodgkin lymphoma (HL) cases. Pathological and clinical features differ from classical HL (cHL). Pathologically, the malignant lymphocyte predominant (LP) cells stain consistently positive for CD20 and are negative for CD30. Clinically, NLPHL often has a rather indolent course. Despite of these differences, the first-line treatment of NLPHL is mostly very similar to cHL. However, analyses on the long-term course of patients with NLPHL who were treated identically to cHL are scarce.

Aims: To shed more light on characteristics and outcome of NLPHL patients treated identically to cHL, we performed an analysis using the database of the German Hodgkin Study Group (GHSG).

Methods: A total of 471 patients with NLPHL who had received first-line treatment within the randomized GHSG HD7-HD15 trials for newly diagnosed HL were identified. The studies were conducted between 1993 and 2009. Patients at all stages (early favorable: HD7, HD10, HD12; early unfavorable: HD8, HD11, HD14; advanced: HD9, HD12, HD15) were included.

Results: Among the 471 NLPHL patients, the median age was 39 years; 76% of patients were male; 53% of patients had early favorable, 16% had early unfavorable and 31% had advanced-stage disease. Study treatment consisted of ABVD- or BEACOPP-based chemotherapy alone, radiotherapy (RT) alone or combined-modality treatment (CMT). After a median observation of 9.2 years, the 8-year progression-free survival (PFS) rate for the whole patient group was 81.3% (83.2% for early favorable, 85.2% for early unfavorable, 76.2% for advanced stages). 80 of 471 patients (17%) had refractory disease or relapsed during the course of follow-up (primary disease progression). In patients with relapse, 6 patients; late relapse: 66 patients). Second malignancies including histological transformation into aggressive B-cell non-Hodgkin lymphoma (NHL) occurred in 48/471 patients (10%) (solid tumor: 25 patients; leukemia: 7 patients; NHL: 13 patients; unspecified malignancy: 4 patients). For all 471 patients included in the present analysis, the 8-year overall survival of the 192 patients early relapse: 6 patients; late relapse: 66 patients was 99.5% for early favorable, 98.6% for early unfavorable, 87.4% for advanced stages). A total of 43 deaths were observed during follow-up resulting in a death rate of 9%. However, only a minority of these deaths was NLPHL-related (n=10). In contrast, most patients died from second malignancies (n=20) or due to other causes (n=13) such as heart failure and lung disease.

Summary/Conclusions: Taken together, the results from this large analysis on NLPHL patients prospectively treated and followed within randomized clinical studies for newly diagnosed HL indicate an excellent lymphoma-specific outcome. Nonetheless, further treatment optimization is necessary as the majority of the observed deaths were not NHL-related but due to second malignancies or other treatment-related late effects. Thus, future clinical trials including NLPHL patients should evaluate whether it is possible to reduce the treatment intensity without compromising efficacy. This goal may be achieved by the partial replacement of conventional chemotherapy by targeted drugs such as anti-CD20 antibodies as well as the reduction of RT fields and doses.

P277
IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION
N. Pugliese1,*, L. Simeone1, R. Della Pepa1, C. Giordano1, I. Cappuccio1, I. Zacheo1, G. Campagna1, C. Cerchione1, P. Zeppe2, C. Salvatore3, F. Pane1, M. Picardi1
1Hematology, University of Naples Federico II, Naples, 2Department of Medicine and Surgery, University Medical School, Salerno, Salerno, 3Department of Economics, University of Molise, Campobasso, Italy

Background: Despite the high complete response (CR) rate to anthracycline-including first-line therapy, approximately one-third of patients with advanced-stage Hodgkin lymphoma (HL) relapses. Many relapses (30–50%) are clinically asymptomatic, without any physical and/or laboratory signs. For patients at high-risk of relapse, a close monitoring, based on imaging procedures is justified if an early detection of recurrence would allow a timely administration of salvage therapy and a survival improvement.

Aims: The purpose of this study was to evaluate the response rate to salvage therapy of relapsed HL by comparing patients who received surveillance with conventional clinical assessments versus patients who received surveillance with imaging procedures. The primary end-point was to assess the rate of CR to salvage therapy at first relapse (confirmed by FDG PET/TC performed before and after ASCT). Secondary endpoints were: the overall rate of recurrence after first relapse (confirmed by FDG PET/TC performed before and after ASCT). Secondary endpoints were: the overall rate of recurrence after first relapse (confirmed by FDG PET/TC performed before and after ASCT). Secondary endpoints were: the overall rate of recurrence after first relapse (confirmed by FDG PET/TC performed before and after ASCT). Secondary endpoints were: the overall rate of recurrence after first relapse (confirmed by FDG PET/TC performed before and after ASCT).

Methods: Between June 2001 and December 2009, we analyzed 306 patients with high-risk HL in CR after anthracycline-including induction treatment. In this case-control study, the first cases (n=150) consisted of patients who received a conventional follow-up program including symptom assessment, blood tests and physical examination; in these patients imaging procedures were performed only in case of suspected relapse (Historical group). Subsequent patients (n=156) received routine imaging procedures comprising ultrasound (US) for the evaluation of abdominal, and pelvic lymph nodes (SMAP US), and chest radiography (CXR), as integrated part of the follow-up strategy (Imaging group). Follow-up procedures were performed at 4, 8, 12, 16, 20, 24, 30, 36, 48, 60, 84, and 108
months after treatment discontinuation in both groups. Relapses were documented by histologic examination in both groups. When relapse was documented, all patients received salvage therapy with high dose chemotherapy (DHAP), for at least two courses, followed, in case of CR, by ASCT.

Results: After a median 62-months observation (range, 4–108), 83 patients, evenly distributed in the two groups, had a relapse of disease. Of these, 28 of 43 patients (67.4%) of the historical cohort vs 17 of 40 patients (42.5%) of the imaging cohort, showed a larger spread of disease at restaging, i.e. stage superior to IIB, and a more frequent extranodal involvement, 10/43 (23.3%) patients in the historical group vs 3/40 (7.5%) patients in the imaging group (p=0.01).

Furthermore, if we considered only asymptomatic patients, one recurrence was detected in 16 of 43 patients in the imaging group and 17 of 40 patients in the historical group, p=0.02. CR rate with second line therapy were higher in the imaging group (27, 67.5%) compared with the historical group (19, 44.2%; p=0.032). The 3-years DFS was 75% in the imaging group and 36% in the historical group, p=0.02.

Summary/Conclusions: This is the first prospective case-control study using SMAP-US plus CXR to monitor patients with advanced stage HL. We show that SMAP-US plus CXR is a valuable tool to improve follow-up in patients with a high risk of recurrence. Our data indicate that the early detection of HL recurrence allows to begin rescue therapy in patients with a more limited disease and, consequently, increases its effectiveness in terms of probability to response and DFS.

P279

CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.

H. Saseed1, R. Shrestha1, J. Nee2, E. Durbin2, M. Ziai1, R. Ramali1, G. Monohon1, R. Herzig1, R. Fleischman1, G. Hildebrandt1
1Internal Medicine-Division of Hematology and BMT, 2Kentucky Cancer Registry, University of Kentucky- Markey Cancer Center, Lexington, United States

Background: Early stage classical Hodgkin Lymphoma (cHL) has been shown to have an excellent outcome. Recent studies have therefore focused on decreasing the toxicity that results from the addition of radiation therapy to chemotherapy. However, it remains unclear whether omitting radiation as part of the initial therapy of cHL is associated with a similar survival benefit.

Aims: The primary aim of this study is thus to investigate the outcomes observed in a statewide cancer registry for cHL patients treated with chemotherapy alone vs patients treated with both chemotherapy and radiation.

Methods: All adult patients (older than 18) diagnosed with cHL in Kentucky Cancer Registry (KCR) from 2005–2014 were retrospectively reviewed. Baseline characteristics including age at diagnosis, gender, histology, stage, B symptoms, extranodal involvement, and the site involved were collected. First line treatment modalities as well as overall survival outcomes were reviewed.

Stage I and II patients without B symptoms were considered favorable, while those with B symptoms were considered unfavorable. Patients with stage III and IV disease were given an advanced stage designation. To adjust for selection bias, patient deaths during the first 6 months of diagnosis were censored for overall survival analysis.

Results: A total of 961 patients were identified. Median age was 41 (range 18–91) and 60.9% (n=585) were younger than 50. The group included a mild predominance of males (55.5%). Only 1.7% (n=16) had extranodal involvement at presentation. Of those with known histology (78.6%), the most common was nodular sclerosis (71.2%), followed by mixed cellularity (22.8%), lymphocyte rich (3.8%) and lymphocyte depleted (1.9%). Median follow up time was 45 months (range 0–136). The 10-year overall survival for the favorable group (n=329) was 77% (95% CI: 71.1–88.8) versus 68% for the unfavorable group (n=144) and 42% for the advanced group (372) (p<0.001). There was no statistical difference in survival between stage I (n=170), and stage II (n=385) disease (p=0.99). Treatment modalities were then compared for the favorable risk group alone. Those who received chemotherapy alone (n=145) were compared to those who received combined chemoradiation and radiation (n=148) as their primary therapy. The 10-year overall survival for the cohort receiving chemotherapy and radiation was 87% compared to 75% for those receiving only chemotherapy (p<0.001) (Figure 1). When adjusted by multivariate analysis for risk factors affecting 10 year survival of the favorable cohort, only age <50 and the treatment modality were independently associated with a statistically significant difference in overall survival (HR of 0.11 (p<0.001) and 3.94 (p<0.001), respectively).

Figure 1.

Summary/Conclusions: Our large data cohort shows the presence of B symptoms to be prog nostic than the number of nodal regions involved for early stage disease. Although the use of radiation as part of initial therapy for early stage disease might have increase long term toxicity, it continued to provide superior survival at 10 years.

25th Annual Congress of the International Society for Hematology
Madrid, Spain, June 22 – 25, 2017

haematologica | 2017; 102(s2) | 83
Background: Patients with Hodgkin Lymphoma (HL) who relapse after autologous Stem Cell Transplantation (auto-SCT) have a dismal prognosis. Advanced disease stage, presence of B-symptoms, extranodal involvement at the time of relapse and duration of remission of less than 12 months are parameters associated with decreased overall survival (OS). Brentuximab Vedotin (BV), an anti-CD30 monoclonal antibody conjugated to a microtubule-disrupting agent, has shown clinical efficacy in HL. Although in the setting of post-auto-SCT relapse, BV produces an overall response rate of approximately 75% with a median progression free survival (PFS) of 9 months, the impact of BV on OS has not been addressed in previously published studies.

Aims: To examine the impact of treatment with BV on OS of patients with HL relapsed after auto-SCT.

Methods: Data for patients with HL who underwent auto-SCT in Greece during the last 20 years were collected. Study group consisted of 214 patients who experienced post-auto-SCT relapse. In order to examine the impact of BV on OS, patients were divided in 2 cohorts depending of the date of BV availability in their hospital (January/2013). Cohort 1 consisted of 178 patients who relapsed before January/2013, while Cohort 2 consisted of 36 patients relapsed after BV became available. Patient’s characteristics are shown in Table 1.

Table 1. Patients characteristics.

The following variables were included in a multivariate Cox proportional hazard regression analysis model: 1) age of patient, 2) Sex, 3) B-symptoms (yes vs no), 4) Stage of disease (I-II vs III-IV), 5) extranodal disease, 6) time from auto-SCT to relapse (≤12 vs >12 months), 7) Relapse before or after BV availability (Cohort 1 vs Cohort 2). In order to exclude any confounding effect of subsequent treatments, analysis was performed by censoring patients at the time of allogeneic SCT or treatment with immune checkpoint inhibitors (IC-inhibitors).

Results: In multivariate analysis the following variables were statistically associated with OS: 1) The presence of B-symptoms [HR=2.07, (95% CI, 1.39-3.07), p<0.001] and 2) Relapse in less than 12 months after auto-SCT [HR=3.35, (95% CI, 2.35-4.85), p<0.001] were associated with decreased OS, while 3) Response after 1st salvage [HR=0.46, (95% CI, 0.31-0.68), p<0.001], and 4) BV availability [HR=0.36, (95% CI, 0.16-0.79), p=0.011] were associated with increased OS (Figure 1). Similar results were obtained when analysis was performed without censoring patients at the time of allo-SCT or treatment with IC-inhibitors (data not shown).

Summary/Conclusions: Patients in Cohort 2 survived longer even when censored for allo-SCT or treatment with IC-inhibitors. All patients in Cohort 2 treated with BV while only 18% of patients in Cohort 1 received treatment with BV. The results of our study strongly suggest that BV improves OS in patients with HL relapsed after auto-SCT. To our knowledge this is the first study showing an OS advantage of treatment with BV.
tion was defined as imaging at or before week 12 of treatment, whereas late radiological evaluation was performed at or after week 16. Response evaluation was performed according to the Lugano Classification and its update regarding immunomodulatory therapy.

Results: Between 06/2015-11/2016, 87 patients were enrolled in a name-based program in Turkey. Two, 19, and 5 patients who had not yet received nivolumab, had not reach the time for early radiological evaluation, and who died before any radiological evaluation were excluded from the analysis. Thus, 63 patients from 23 centers were retrospectively analyzed. Median follow-up was 6 months, median age was 29 (18-75) and patients had a median 5 (2-11) previous lines of therapy. 44 patients (70%) had been treated by stem cell transplantation (SCT) and 45 (76%) patients had been treated by BV. The ORR was 66% with 15 CR (95%CI 0.020-0.28; CR 26%, PR 42%, SD 12%, PD 20%) among 59 patients evaluated in 12 weeks of nivolumab treatment. The ORR was 67% with 9 (24%) patients with CR after 16 weeks of treatment (95%CI 0.004-0.26; CR 24%, PR 43%, SD 6%, PD 27%). Estimated OS was 95% (95%CI 0.80-0.98) and estimated PFS was 71% (95%CI 0.65-0.82) at 12-months. Median OS was not reached, while, according to the late response rates, the median PFS was 14 months. However, it was only 3 months in patients with PD at the late radiological evaluation. Regarding responses to last treatment prior to nivolumab, we detected that 28 (67%) of 42 PD cases had objective early responses and 70% of PD cases had ORR in the late response evaluation (CR in 4, PR in 12 pts). 8 patients underwent transplantation following nivolumab. Among 5 patients who had been treated by allo-SCT, 4 had CR at the time of transplantation and they are alive with ongoing response. Safety profile was acceptable and only two patients required cessation of nivolumab due to serious adverse events: one due to autoimmune encephalitis and one due to aggravation of graft versus host disease. At the time of analysis, 40 cases were still on nivolumab treatment (64%). Among the 40 cases with early objective responses to nivolumab, 35 (88%) showed ongoing objective responses. All 24 cases with objective responses in the late evaluation had ongoing responses at the time of analysis (Figure 1).

Summary/Conclusions: In conclusion PD-1 blockers are new options to meet the unmet need in patients with chHL refractory to BV treatment, and possibly a bridge for these patients before transplantation.

GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
V. Spina1,*, A. Bruscaggin1, M. Di Trani2, M. Martini3, S. Locatelli2, E. Cupelli4, C. Deambrogi6, F. Diop6, G. Stüssi 5, F. Cavalli5, F. Bertoni1,5, E. Zucca 5, G. Forestieri 1, A. Condoluci 1,5, A. Cuccaro 4, A. Moccia 5, A. Stathis 5, M. L. Aracca3, and Research Center, Milan, 2Division of Pathology and Histology, 3Institute of Hematology, Catholic University of the Sacred Heart, Rome, Italy, 4Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, 5Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

Background: In classical Hodgkin lymphoma (cHL) the low representation (1-5%) of Reed-Sternberg cells (RS) challenged tumor genotyping on the diagnostic tissue biopsy. Consistently, the mutational profile of newly diagnosed cHL is poorly characterized, and the genetics of refractory disease is completely unknown. Cell free DNA (cfDNA) is shed into the blood by tumor cells undergoing apoptosis and can be used as source of tumor DNA for the identification of somatic mutations. In addition cfDNA is representative of the entire tumor heterogeneity, thus allowing the identification of mutations from tumor cells residing in non-biopsied sites.

Aims: This study aims: i) at providing the evidence that the mutational profile of cHL can be tracked by using plasma cfDNA; and ii) at characterizing the genetics of newly diagnosed cHL and, for comparative purposes, of refractory cHL.

Methods: The study includes 28 newly diagnosed cHL and 9 chemorefractory cHL. All cases were provided with cfDNA from plasma collected at baseline, before treatment start, and paired DNA from granulocytes as source of germline DNA to filter out polymorphisms and sequencing noise. Paired genomic DNA from formalin fixed paraffin embedded (FFPE) tumor tissue biopsies was available for 17 patients, including 3 cases for which RS enriched areas were macrodissected. A targeted resequencing panel optimized to include the coding exons and splice sites of 77 genes (192Kb) that are recurrently mutated in B-cell lymphomas was used for genotyping. Libraries were prepared from plasma cfDNA, germline gDNA and tumor gDNA according to the CAPP-seq targeted enrichment strategy (Nimblegen) and subjected to ultra-deep-next generation sequencing (NGS) on the MiSeq platform (Illumina). The sequencing was tailored to obtain a depth of coverage >2000x in >80% of the target region in all samples, which allowed a sensitivity of 3x10-3. The somatic function of VarScan2 was used to call non-synonymous somatic mutations, and a stringent bioinformatic pipeline was applied to suppress the background noise and to filter out sequencing errors.

Results: In newly diagnosed cHL, genotyping of plasma cfDNA identified non-synonymous somatic mutations in STAT6 (43%), TNFAIP3 (43%), ITPKB (32%) B2M (21%), GNA13 (14%), CIITA (7%), XPO1 (7%) and CD58 (4%) among the most recurrently affected genes (Figure 1-A-B). In refractory cHL patients, genotyping of plasma cfDNA identified non-synonymous somatic mutations in ITPKB (44%), TNFAIP3 (33%), KMT2D (33%), B2M (33%), GNA13 (33%), XPO1 (22%), TET2 (22%), IKKβB (22%), BIRC3 (22%) and STAT6 (22%) among the most recurrently affected genes. Mutations of KMT2D (33%) and TET2 (22%) were enriched in refractory chHL patients compared to newly diagnosed cases, suggesting that they contributed to the chemorefractory phenotype (Figure 1-C-D). By using high sensitivity techniques, most of the mutations discovered in cfDNA were also identified in pair tumor DNA from the tissue biopsy and/or macrodissected RS cells, thus confirming their tumor origin (Figure 1-F). By pathway analysis, the mutational profile pointed to the involvement of PI3K/AKT signaling, cytotoxicity, NF-kB signaling, and the immune escape in cHL. ITPKB (a negative regulator of the PI3K/AKT signaling pathway) was specifically mutated in cHL across aggressive B cell lymphomas.

Figure 1.

Summary/Conclusions: This study provides the evidence that cHL can be genotyped using plasma cfDNA as source of tumor DNA, pointed to a non-overlapping genotype between newly diagnosed and refractory cases, and identified ITPKB as a new gene specifically involved in ~30-50% of cHL patients.
Background: Doxorubicin (DXR) induced cardiotoxicity is related to several mechanisms, including interference of mitochondrial respiratory chain and acceleration of glycolysis. We previously reported that this treatment may enhance myocardial FDG uptake.

Aims: The present study aimed to verify whether this metabolic response on serial PET/CT imaging can predict myocardial function, non-invasively evaluated by follow-up echocardiography (ECHO).

Methods: 18F-FDG PET/CT of 25 patients affected by Hodgkin Disease (HD), treated following ABVD scheme were analyzed. Inclusion criteria were: 1) availability of 4 consecutive PET/CT scan for staging (PET1), interim (PET2), post-therapy (PET3) and six months follow-up evaluation (PET4); 2) full remission after two ABVD cycles; 3) normal baseline EKG and ECHO findings and 4) no concurrent treatment with external thoracic radiotherapy. A volume of interest (VOI) was manually drawn on the left ventricular myocardium. Average standardized uptake value within this region was normalized for the corresponding blood pool index measured in the inferior vena cava to obtain LV-SUV. All patients showed signs or symptoms potentially related to DXR cardiotoxicity.

Results: LV-SUV progressively increased from PET1 to PET4 in 6 patients (24%, 2 females, mean age 39±17, termed “increasers”) being 1.34±0.9, 3.34±2.6, 4.32±2.8 and 4.43±1.5 respectively. In the remaining 19 patients (76%, 7 females, 36±14), FDG uptake showed a largely variable response without any progressive increase. Accordingly, the ratio between PET4 and PET1 LV-SUV in the two subgroups was 3.05±0.8 and 1.06±0.4, respectively (p=0.001). Up to six months after therapy discontinuation, none of the 25 patients showed signs or symptoms potentially related to DXR cardiotoxicity. However, late follow-up ECHO detected the appearance of first-degree diastolic impairment with respect to baseline in 9 of the 25 examined patients (36%, 4 females, mean age 36±18). This finding occurred in 5/6 “increasers” (83%) and in only 4/19 non-increasing (21%) (p<0.001).

Summary/Conclusions: The present data indicate that DXR related myocardial damage can be preceded by an enhanced glucose uptake. 18F-FDG PET/CT imaging might represent a useful tool to identify high-risk patients and to implement personalized program to monitor and prevent DXR-induced cardiotoxicity.

Iron metabolism, deficiency and overload

P284

ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM β-TALASSEMIA AND HEMOCROMATOSIS COHORT STUDIES

F. Vinciguerra1, G. Portoli1, A. Silva2, R. Sparta1, G.M. Vercellotti1, J.D. Belcher3, E. Fibach4, H. Zeid5, R. Rasras6, M.W. Hentze7, H. Ghosh8, M.U. Muckenthaler9, E.A. Rachmilewitz9

1Molecular Medicine Partnership Unit (MMPU), University of Heidelberg & EMBL, Heidelberg, Germany, 2University of Porto, Porto, Portugal, 3Vascular Biology Center, University of Minnesota, Minneapolis, United States, 4Department of Hematology, The Hebrew University Hadassah Medical Center, Jerusalem, Israel, 5Department of internal Medicine, AShifa hospital, 6Laboratory department, European Hospital of Gaza, Gaza, Palestinian Territory, Occupied, 7European Molecular Biology Laboratory (EMBL), Heidelberg, Germany, 8Department of Hematology, Assuta Medical Center, Tel Aviv, 9The Edith Wolfson Medical Center, Holon, Israel

Background: Increasing evidence from animal studies suggests that free heme exerts vasculotoxic, pro-inflammatory and pro-atherogenic effects due to its ability to trigger endothelial and immune cells activation. Moreover, we recently demonstrated a role for iron in the pathogenesis of atherosclerosis, analyzing a mouse model of type IV hereditary hemochromatosis, hallmarked by severe iron overload. We also showed that iron-deficient diet and chelation therapy prevent atherosclerosis progression in those mice.

Aims: Here we aimed at evaluating the clinical relevance of these findings and determining the parameters of vascular dysfunction correlated with iron levels and suggest a predisposition to vascular dysfunction and atherogenesis in iron-overloaded individuals.

Methods: To this purpose we examined serum samples from a cohort of patients with β-thalassemia major and intermedia, who received recurrent blood transfusions but inconsistent chelation therapy, and a cohort of patients with hereditary hemochromatosis (HFE C282Y homozygous mutation), treated with phlebotomy.

Results: β-thalassemia patients show high systemic heme and iron levels, which correlate with a severe drop in the plasma scavengers for hemoglobin and heme, Haptoglobin and Hemopexin, respectively. Hemochromatotic patients show increased systemic iron levels and reduced hepatic hepcidin levels. Consistently, in the two cohorts, transferrin saturation, non-transferrin bound iron (NTBI) and serum ferritin are elevated. Interestingly, both thalassemic and hemochromatotic patients present with high systemic levels of soluble adhesion molecules (sVCAM-1, sICAM-1, s-E-Selectin, s-P-Selectin) and reduced nitrotyrosine levels, hallmarks of endothelial activation and vascular dysfunction. In addition, they show increased serum lipid peroxidation, elevated circulating oxidized LDLs and high pro-inflammatory cytokines, which are known to promote atherosclerosis. All parameters significantly correlate with increased systemic heme and iron indices, including NTBI, as well as decreased scavenger levels.

Summary/Conclusions: These results emphasize the involvement of serum hemoglobin, heme and iron in the pathogenesis of vascular dysfunction in β-thalassemia and hemochromatosis and suggest a pro-atherosclerotic role for these molecules. These findings are relevant, on one side, for cardiovascular diseases and vasculopathy, when iron parameters are altered, and on the other, for iron overload disorders, where premature atherosclerosis might develop. Finally, our data highlight the key protective role of heme/iron scavengers and support the potential therapeutic benefit of chelation therapy to counteract heme/iron-driven vascular toxicity and atherosclerosis in hemolytic and iron-overload conditions.
P286

MEDIATION BY PATIENT-REPORTED OUTCOMES ON THE ASSOCIATION BETWEEN FILM-COATED VERSUS DISPERSIBLE FORMULATIONS OF DEFERASIROX AND SERUM FERRITIN REDUCTION: A POST HOC ANALYSIS OF THE ECLIPSE TRIAL

A. Taher1, R. Origa2, S. Perrotta3, A. Kourakis4, K. Belhoul5, V. Huang6, J. Han7, A. Bruderle7, P. Bobbi8, M.S. Du9, J.B. Porte10

1American University of Beirut Medical Center, Beirut, Lebanon, 2Ospedale Pediatrico Micronetico A’Cao, University of Cagliari, Cagliari, 3Second University of Naples, Naples, Italy, 4Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece, 5Dubai Health Authority, Dubai Thalassemia Center, Dubai, United Arab Emirates, 6Novartis Pharmaceuticals Corporation, East Hanover, United States, 7Novartis Pharma AG, Basel, Switzerland, 8Analysis Group, Boston, United States, 9University College London, London, United Kingdom

Background: The ECLIPSE clinical trial (NCT02125877) demonstrated that a new film-coated tablet (FCT) formulation of deferasirox (DFX) had a similar safety profile, with fewer patients (pts) experiencing severe gastrointestinal (GI)-related adverse events (AEs), and more favorable patient-reported outcomes (PROs) compared to the dispersible tablet (DT). PROs of FCT pts showed better adherence, satisfaction, palatability and fewer concerns about iron chelation therapy (ICT). The ECLIPSE trial results and supports previous evidence of improved adherence to DFX FCT over DT.

Aims: To estimate the proportion of the association between tx with DFX FCT versus DFX DT and SF reduction from baseline that is mediated through PROs, in a post hoc analysis.

Methods: The ECLIPSE trial was a phase II, randomized open-label study in pts with transfusion-dependent thalassemia or myelodysplastic syndrome who were randomized to receive DFX FCT (N=87) or DT (N=86) at average planned doses of 30.7 mg/kg/day (±10% deviation from target) and 28.7 mg/kg/day, respectively. PROs were assessed at weeks 2, 3, 13, and 24 (end of tx) using the Palatability and modified Satiety score, other PRO scores, and frequency of GI-related AEs during tx. Adherence was adjusted for confounders including age, sex, race, underlying hematological disease, prior use of DFX DT, and baseline level of iron overload severity, and frequency of GI-related AEs during tx. Comparison between the two periods was performed with a Wilcoxon sign-rank test for continuous data and McNemar’s test for dichotomized data.

Results: Of the 606 eligible pts, 56% were female, 64% were <35 years old, and 42% had transfusions during the baseline period. The median durations of the DFX DT and DFX FCT periods were 359.0 days and 290.0 days, respectively. Compared with adherence to DFX DT, adherence to DFX FCT was significantly improved across all measures. Mean MPR of DFX FCT vs DFX DT was 0.80 vs 0.76 (p<0.001); 60.9% pts had a mean MPR 20.8 during the DFX FCT period compared to 54.3% during the DFX DT period (p<0.01). Mean 3-month PDC of DFX FCT vs DFX DT was 0.83 vs 0.71 (p<0.001); 50.0% pts had mean 3-month PDC of 20.8 during the DFX FCT period compared to 34.5% during the DFX DT period (p<0.001). The proportion of pts with 3-month persistence to DFX FCT vs DFX DT (without a gap ≥30 days) was 87.2% vs 63.4% (p<0.01). Similarly consistent and significant results for PDC and persistence were observed using a 6-month time interval and/or a 60-day gap between claims.

Summary/Conclusions: Adherence and persistence to ICT was significantly improved in pts who switched from DFX DT to DFX FCT. Reasons for switching, which may contribute to improved adherence, were not examined in this study. Nevertheless, since the majority of pts were already adherent to DFX DT, this suggests that DFX FCT can be further augmented with this formulation. This real-world study complements the ECLIPSE trial results and supports previous evidence of improved adherence to DFX FCT.

P287

ASSessment of the performance of a widely available T2^R2^ LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMAIA PATIENTS

N. Tran1, N. Tran2, N. Pham3, C. Ca1, P. Nguyen4, T. Pham5, L. Trinh6, C. Tran7, T. Hai8, T. Pham1, N. Vien9, T. Pham1, N. Huynh1, N. Nguyen1, T. Nguyen2, N. Tran2, N. Pham3

1Blood Transfusion, Hanoi, Vietnam, 2School of Physics, The University of Western Australia, Crawley, 3Resonance Health, Claremont, Australia

Background: Measurements of liver iron concentration (LIC) by magnetic resonance imaging (MRI) have become established and validated in several research intensive centers. While the validity of spin density projection assisted (SDPA) R2-MRI together with a core laboratory service has been validated in routine clinical practice settings, methods relying on b-hemoglobin as an endogenous target of acquisition protocols and data analysis have not yet been validated in this way.

Aims: To determine the limits of agreement between measurements of LIC by a widely available T2^R2^ MRI method and a reference standard based on T2^R2^ MRI method in a routine clinical practice setting.

Methods: 70 pts referred by the National Institute of Haematology and Blood Transfusion, Hanoi, Vietnam for routine LIC measurement by MRI were prospectively recruited with informed consent. Patients were randomised to be scanned in either a Philips Ingenia or a Siemens Avanto 1.5T scanner. The LIC of each patient was measured twice, once by a T2^R2^ technique using freely available software and protocols (Iron Health Calculator: http://www.ironcalculator.com) and once by SDPA R2-MRI using a quality controlled core laboratory data analysis service (FerrScan®). Analyses using the T2^R2^ data analysis method were blinded from the SDPA R2-MRI results and vice versa. Reported data were analysed using the statistical methods of Bland and Altman.

Results: A plot of the T2^R2^ LIC against the SDPA R2-MRI LIC (Figure 1) shows the very large majority of data falling below the line of equality indicating that the T2^R2^ method is underestimated the LIC relative to the SDPA R2-MRI validated reference standard. The geometric mean ratio of T2^R2^ LIC to SDPA R2-MRI LIC was 0.44 (95% CI 0.36 –0.55) indicating severe underestimation of LIC by the T2^R2^ method. The geometric mean ratios of the two LIC measurements were significantly different for the two scanners (0.28 for Philips and 0.68 for Siemens, p<0.0001) indicating that the bias of the T2^R2^ method against the reference standard is not universal but is dependent on both/either scanner type and/or data acquisition method. Bland Altman analysis indicates that 95% of pairs of measurements are predicted to have differences between 3.73 and 0.05 indicating a very large random variability between the T2^R2^ method and the reference standard. The performance of the T2^R2^ method with regards to predicting SDPA R2-MRI LIC values above the clinically relevant thresholds of 7 and 15 mg Fe/g dw is characterized in the Table 1 showing positive predictive values (PPVs) and negative predictive values (NPVs) together with their 95% CIs.

Table 1.

<table>
<thead>
<tr>
<th>LIC Threshold (mg Fe/g dw)</th>
<th>Positive Predictive Value</th>
<th>Negative Predictive Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;7 mg Fe/g dw</td>
<td>0.00 (0.00 – 1.00)</td>
<td>0.23 (0.09 – 0.44)</td>
</tr>
<tr>
<td>&gt;15 mg Fe/g dw</td>
<td>0.98 (0.89 – 1.00)</td>
<td>0.40 (0.26 – 0.54)</td>
</tr>
</tbody>
</table>
Mean (SD) duration of deferasirox exposure in group A was 7.5 (1.7) years; mean daily deferasirox dose was 1280 mg.

In both subgroups analyzed, mean SCR was within normal limits and remained stable over time during the retrospective period (Figure 1). Analysis in adults showed mean SCR values were stable over time. As expected in growing children who are gaining height and weight, pediatric mean SCR absolute values increased from baseline in proportion with an almost linear increase in muscle mass over time.

Summary/Conclusions: The data indicate that the T2*/R2* method of measurement of LIC is not safe for routine clinical measurement of LIC because of the extremely poor NPIVs which could result in inappropriate clinical decision making. The severe discrepancies of the T2*/R2* method from the reference standard are likely caused by several factors including non-optimal curve fitting algorithms, lack of a method to identify non-analysable data, and the use of a calibration curve from the literature generated from data acquisition and analysis methods different from those used locally. These or similar pitfalls are likely to be encountered in many MR centres using non-regulated MR methods of LIC measurement.

P288
SIMILAR TRENDS IN RENAL FUNCTION AS MEASURED BY SERUM CREATININE DURING LONG-TERM IRON CHELATION TREATMENT WITH OR WITHOUT DEFERASIROX IN PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS

R. Origa1,*, A. Piga2, I. Tartagliona3, G. Della Corte4, A. Brueederle5, J. Han6, C. Castiglioni6, G.L. Foriero7. For the Kidney Chart Review Study Investigators8
1Ospedale Pediatrico Microcitemico 'A Cao', University of Cagliari, Cagliari, Italy, 2University of Turin, Orbassano, Turin, 3Università della Campania ‘Luigi Vanvitelli’, Naples, 4Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, United States, 7Novartis Farma SpA, Origgio, 8Ospedale Galliera, Genoa, Italy

Background: Regular transfusion and iron chelation therapy (ICT) are often indicated for patients with β thalassemia, sickle cell disease (SCD) and other anemias, and can be lifelong requirements. As most patients now survive into adulthood and many experience prolonged exposure to ICT, there is increased risk of age-, disease- or drug-related complications, including changes in renal function. Evidence suggests that some patients receiving ICT experience changes in markers of renal function, mostly within normal limits, non-progressive and reversible with dose reduction and/or interruption. Recently, we reported a retrospective analysis of patients with transfusion-dependent anemia during a decade of deferasirox treatment indicating stable and a lack of any progressive worsening of renal function (Origa R et al. Blood 2016).

Aims: To assess serum creatinine (SCR) during long-term deferasirox treatment in subgroups of Italian patients with transfusional hemosiderosis who participated in the deferasirox registration studies and who were then followed retrospectively.

Methods: Italian patients with β thalassemia, SCD, myelodysplastic syndromes or other anemias who received ≥1 deferasirox dose in the registration studies (studies 105, 106, 107, 108 or 109), had ≥1 post-baseline (BL) SCR measurement, and had medical records available were included. SCR values were collected retrospectively in 3-month periods from registration trial end until the latest patient assessment. Primary endpoint was SCR over time. SCR values during the retrospective period were evaluated by subgroups: those who received only deferasirox and those who received no deferasirox but other ICT during the retrospective period.

Results: 282 patients were included in the retrospective study who received ≥1 deferasirox dose in registration studies; of these, during the retrospective period, 98 (35%) received only deferasirox (group A) and 82 (22%) received no deferasirox but other ICT (group B). In group A, mean (SD) age at first quarter was 25.9 (12.1) years and 36 (37%) were male; in group B, mean (SD) age at first quarter was 27.0 (10.9) years and 25 (40%) were male. The proportion of pediatric patients was 28% (n=27) in group A and 19% (n=12) in group B.

Mean (SD) duration of deferasirox exposure in group A was 7.5 (1.7) years; mean daily deferasirox dose was 1280 mg.

In both subgroups analyzed, mean SCR was within normal limits and remained stable over time during the retrospective period (Figure 1). Analysis in adults showed mean SCR values were stable over time. As expected in growing children who are gaining height and weight, pediatric mean SCR absolute values increased from baseline in proportion with an almost linear increase in muscle mass over time.

Summary/Conclusions: This retrospective study of long-term renal safety in patients receiving iron chelation for transfusional iron overload suggests that long-term deferasirox treatment, or administration of ≥1 deferasirox dose followed by other chelators, did not have an overall detrimental long-term effect on renal function as monitored by SCR. This analysis provides no evidence of progressive renal function worsening over time, which is consistent with previous results demonstrating deferasirox has a mild, generally reversible renal hemodynamic effect.

P289
WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS

M. Giansily Blaizot1, S. Cunat1, O. Guillot1, G. Mouliol1, P. Aguilar Martinez1,*, 1Hematology, Hopital Saint Eloi, Montpellier Cedex 5, France

Background: Despite thorough clinical and biological phenotypic investigations, a number of red cell disorders remain uncharacterized. In addition, some of them are accompanied by overt iron overload and can be initially misdiagnosed as disorders of genes involved in iron metabolism. Next Generation Sequencing (NGS) has become an attractive technique to decipher constitutional disorders as it allows analyzing a large number of disease-causing genes. However an initial complete clinical, biological and morphological assessment is mandatory to correctly orientate towards the correct gene panel and to interpret the various molecular variations identified. We have set up in our center, a specialized outpatient consultation for both iron and red cell disorders. Specialized phenotypic investigations including biological and morphological tests followed by standard or second level genotyping can be prescribed.

Aims: The aims of this study was to characterize the molecular background of patients with iron or red cell disorders, or with a possible combination of both, and to propose key steps towards this genetic diagnosis.
Methods: A cohort of 25 well characterized patients was analyzed. Eighteen were initially referred to our center for unexplained hyperferritinaemia (HF), two for proven iron overload (IO) by MRI, 2 for chronic hemolysis and 3 for aferen- erative anaemia. A set of phenotypic tests was systematically assessed, including CBC, reticulocyte count, serum haptoglobin and measure of the Liver Iron Content (LIC) by MRI. For all patients with HF, causes linked to hepatic disease, inflammatory and neoplastic disorders were ruled out and standard HFE mutational screening was performed. Phenotypic investigations failed to clearly identify the cause of the disorder. Therefore, each patient was tested for a panel of 32 genes involved either in iron homeostasis or hereditary anemias, using NGS. Libraries were obtained using the Custom SureSelectXTarget Enrichment system (Agilent, Santa Clara CA USA) and sequenced on a MiSeq platform (Illumina, San Diego, CA, USA). Each deleterious variation was independently checked using conven- tional Sanger sequencing. Written informed consent was obtained from all the patients for NGS genetic analyses.

Results: Initial phenotypic reassessment allowing classifying the patients into 5 different groups: 1/ isolated hyperferritinaemia (n=11); 2/ HF and IO (n=90 µmol/g dry weight) (n=17); 3/ hemolytic anaemia (HA) without IO (n=2); 4/ HA and IO (n=2); 5/ aferenaric anaemia with IO (n=3). Among patients with an initial diagnosis of iron disorder, the reticulocyte count identified 2 undiagnosed chronically fully compensated haemolytic. Systematic screening using the gene panel identified a total of 14 sequence variations of clinical significance in 9 dif- ferent genes and 9 patients. An isolated mutation was found in 7 and 2 patients with an initial diagnosis of iron or of red cell disorder respectively. A combined aferenity of red cell and iron genes was identified in 3 patients who displayed IO and compensated haemolytic or anemia. Digestion involving an HFE C282Y mutation was found in 3/4 patients with IO (without anemia or haemolysis). No sequence variation of clinical significance was found in the sequenced genes of eleven of the studied patients.

Summary/Conclusions: On the phenotypic point of view, the present study highlights the importance to check for hematological data (CBC and reticulocytes) in patients with HF, because this can allow discovering fully compensated hemolytic and bringing towards a red cell disorder. On the other hand, it also underlines the importance to systematically check for IO all patients with a red cell disorder, who may display high LIC. Our present genotypic data (and pre- viously reported findings) show the frequency of combined inherited disorders of iron and red cells, making the combined search for both disorders quite relevant in clinical practice. This is now possible with the use of NGS analysis, which allows sequencing large numbers of genes. For those patients with no identified mutation, approaches using whole exome or genome can be proposed as the next step.

P290

CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET

A. Vitrano1, R. Rosso3, A. Quota3, D. Fiorino3, E. Olivara3, C. Gerardin2, G. Roccamori1, V. Spadola1, A. Filosa1, L. Tese1, A. Calvarusso, F. Pitolo1, L. Mistretta1, F. Cassarà1, A. Maggio1,3

1Campus of Hematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervelo, Palermo, 2Ospedale Vittorio Emanuele, Catania, 3UOS Talassemia P.O. “Giovanni Paolo II”, Sciacca, 4Centro di Prevenzione e Curare della Microcitemia, P.O. S’Agata Militeo, Sant’Agata Militeo (ME), 5A.O. “M. Pateron Aarezzo”, Ragusa, 6U.O.D. Malattie Rare del Globulo Rosso, A.O.R.N. “A. Cardarelli”, Napoli, 7La Sapienza University Radiologia, AOOR Villa Sofia-Cervello, Palermo, Italy

Background: The liver plays a central role in iron regulation and remains the primary site of iron storage, with liver iron concentration (LIC) being a strong surrogare of total body iron. Both R2 and T2* can accurately measure LIC. R2 MRI has been used in the study of haematological disorders and the measurement has been shown to be a sensitive indicator of iron balance.

Aims: The aim of the study was to evaluate longitudinal changes in LIC mea- surements across different iron chelation regimens in a real-life cohort of patients with transfusional iron overload included in LICNET.

Methods: This was a retrospective cohort study in patients with haematological disorders attending 9 Italian centres participating in the LICNET who had two R2 MRI scans recorded in the database and receiving the same iron chelation in between. Bivariate comparisons were made using the chi-squared and Fisher- er’s exact tests for categorical variables and the Wilcoxon or Mann–Whitney tests for continuous variables.

Results: A total of 130 patients were evaluated in this analysis, with a median (range) age years of 35 (range: 6–78) and including 60 (46.2%) men. The underlying diagnoses were regularly transfused thalassaemia major (n=86, 66.2%), thalassaemia Intermedia (n=33, 25.4%), sickle cell disease (n=6, 4.6%), myelodysplastic syndrome (n=3, 2.3%), and Diamond-Blackfan anaemia (n=2, 1.5%). The median duration (range) between the first and second MRI was 483 days (184-1076) and was comparable between iron chelation regimens. Median pre-transfusion hemoglobin level and blood requirement were similar at both MRIs.The median change in LIC (range) in mg Fe/g dw was not signif- icant in patients receiving DFP (n=29, median change -1.9, p=0.55), DFO (n=32, median change -0.5, p= 0.151), DFO+DFP (n=10, median change -2.2, p=0.074), or other combinations (n=7, median change -1.3, p=1.000), while it decreased significantly on DFO monotherapy (n=32, median change - 1.4,p=0.002). Among oral chelators, DFX showed to be more effective, during the period of the study, in stabilizing iron body burden in 65.4% patients even if they had baseline LIC values <7mg Fe/g dw (median 4.0 mg Fe/g dw) and with similar response as combined treatment DFO+DFP (Figure 1).

Figure 1.

Summary/Conclusions: This cohort study suggests that stabilization of LIC is achievable, during a median of 483 days, with different iron chelation regi- mens in real life experience, with considerable proportions of patients shifting to more favourable LIC categories. Therefore, the prospective determination of LIC by MRI has to be strongly recommended for management and prevention of iron overload and subsequent complications in haematological disorders.

P291

IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL-TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA

M. Elia1, R. El-Farrash1, H. Tahah2, E. Ismail2, N. Mohamed1,2

1Pediatrics Department, 2Audiology Department, 3Clinical Pathology Depart- ment, Faculty of Medicine-Ain Shams University, 4Ministry of Health, Cairo, Egypt

Background: Iron deficiency is the most important cause of nutritional anemia and is the most common micronutrient deficiency worldwide, especially in develop- ing countries. Iron is crucial for fetal brain development; hence, there is a parameter need for diagnostic neurofunctional screening that could identify low CNS iron stores. However, there are insufficient data regarding the effects of maternal iron deficiency anemia (IDA) on auditory neural maturation.

Aims: To evaluate the effect of maternal IDA on auditory neural myelination in full term neonates using the auditory brainstem evoked response (ABR) as noninvasive neurophysiological assessment tool.

Methods: This prospective case-control study was conducted at Ain Shams University Hospitals and included 100 neonates. Out of 223 pregnant women, 50 were diagnosed as having IDA anemia and 50 healthy mothers were enrolled as a control group. Neonates were studied focusing on anthropometric measures, hematologic profiles and iron status. Auditory brainstem response (ABR) measurements were done for the studied neonates within 48 hours after birth and at 3 months.

Results: Hemoglobin and iron profile were lower in neonates born to anemic mothers compared with controls. Of 100 neonates screened for ABR, 25 failed the test (all of them were born to anemic mothers). Neonatal birth weight, crown-heel length, BM1, Talassemia, Gela (CL), TA “Blanchet Malacrin-Morelli”, Reggio Calabria, 6U.O. of Talassemia P.O. “Giovanni Paolo II”, 7Sciaccia, 8Centro di Prevenzione e Curare della Microcitemia, P.O. S’Agata Militeo, Sant’Agata Militeo (ME), 9A.O. “M. Pateron Aarezzo”, Ragusa, 10U.O.D. Malattie Rare del Globulo Rosso, A.O.R.N. “A. Cardarelli”, Napoli, 11UOC Radiologia, AOOR Villa Sofia-Cervello, Palermo, Italy

Background: Iron deficiency is the most important cause of nutritional anemia and is the most common micronutrient deficiency worldwide, especially in develop- ing countries. Iron is crucial for fetal brain development; hence, there is a parameter need for diagnostic neurofunctional screening that could identify low CNS iron stores. However, there are insufficient data regarding the effects of maternal iron deficiency anemia (IDA) on auditory neural maturation.

Aims: To evaluate the effect of maternal IDA on auditory neural myelination in full term neonates using the auditory brainstem evoked response (ABR) as noninvasive neurophysiological assessment tool.

Methods: This prospective case-control study was conducted at Ain Shams University Hospitals and included 100 neonates. Out of 223 pregnant women, 50 were diagnosed as having IDA anemia and 50 healthy mothers were enrolled as a control group. Neonates were studied focusing on anthropometric measures, hematologic profiles and iron status. Auditory brainstem response (ABR) measurements were done for the studied neonates within 48 hours after birth and at 3 months.

Results: Hemoglobin and iron profile were lower in neonates born to anemic mothers compared with controls. Of 100 neonates screened for ABR, 25 failed the test (all of them were born to anemic mothers). Neonatal birth weight, crown-
Summary/Conclusions: In this study of pediatric cancer survivors, the gradients between SF and LIC and the SF cut-offs identified for predicting clinically important LIC values are considerably lower than observed for thalassemia or adult HSCT patients. This difference in the relationship between SF and LIC for different patient and age groups highlights the difficulty in relying on SF to screen for and define iron overload.

Summary/Conclusions: IDA during late pregnancy adversely affects cord blood iron and hearing status. ABR results are closely related to the severity of maternal and neonatal iron status. Antenatal screening of pregnant mothers is needed to improve fetal iron status and prevent abnormal auditory maturation.

P292
THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS M. House1,2, K. Sadak3, J. Lee1, A. Smith3, T. St. Pierre1,2,*

Background: There is increasing recognition that pediatric cancer survivors are at risk of transfusion-related iron overload related to intensive treatment regimes and improved survival rates. Current screening approaches rely on serum ferritin (SF). However, little is known about the SF to liver iron concentration (LIC) relationship in pediatric cancer survivors and whether SF thresholds derived from other iron overload disorders or age groups are appropriate.

Aims: The aim of this study was to investigate the relationship between SF and LIC in pediatric cancer survivors and to determine SF thresholds for predicting clinically significant LICs in this patient group.

Methods: In this retrospective study, patient data were extracted on survivors with elevated ferritin or iron overload from the University of Minnesota Childhood Cancer Survivor Program research database. All patients were enrolled into the database via an informed consent process according to the guidelines of the University of Minnesota Institutional Review Board. Survivors were retrospectively selected once they reached 18 years of age. Seventeen individual survivors were identified where both SF and LIC data were available and the time between the SF and LIC measurement was less than 30 days. Eleven of the 17 survivors had multiple SF measurements producing a final dataset with 34 pairs of SF and LIC measurements. Blood for serum ferritin was collected during antenatal screening and analyzed by the University of Minnesota Medical Center, Fairview CLIA-certified clinical laboratory. Liver iron concentration measurements were made using spin density projection-assisted R2-MRI (FerriScan®). Linear regression was used to determine the relationship between SF and LIC. Receiver operating characteristic (ROC) curve analysis was used to assess the sensitivity and specificity of SF concentrations for predicting LIC.

Results: The average age of the cohort (6 females and 11 males) at their first SF/LIC measurement was 18.3 years (range 9 to 30.3 years). Acute lymphoblastic leukemia (N=5) and acute myeloid leukemia (N=4) were the most common diseases and 15 of the 17 survivors had received a hematopoietic stem cell transplant (HSCT). The average length of time between the final treatment and the first SF/LIC measurement was 5.4 years (range 0 to 12.5 years). A linear fit to all 34 LIC-SF measurement pairs (Figure 1) produced a gradient of 63 ± 15 (mg ferritin/L)/(g dry liver tissue)/(mg Fe)/(L serum) and an intercept of 509 ± 157 (mg ferritin/L) (r²=0.36). The ROC curve analysis (Table 1) indicated that, in this cohort, a SF cut-off of 1270 mg/L potentially has good sensitivity and specificity for predicting a LIC above 15 mg Fe/g and a SF cut-off of 1076 mg/L has poor diagnostic performance for predicting a LIC above 7 mg Fe/g.

Table 1. ROC Curve Analysis.

AUC, area under the receiver operating characteristic curve.

Figure 1.
Methods: Prospective randomized controlled study conducted in department of Obstetrics & Gynecology, in a tertiary care hospital in Delhi, India. 60 women having Iron deficiency Anaemia with Hb 6-8 g% were randomized 1:1 into two groups and were given 1000mg parenteral iron on day 0 and 8. 200mg Iron Sucrose complex was given in second group on alternate days for 5 doses. Haematological parameters - Hb, Reticulocyte count, RBC indices, S. ferritin; clinical parameters - fatigue, dyspnoea on exertion and adverse effects were studied on day 0, 7, 14 & 28.

Results: Two FCM infusions vs five ISC infusions were required. On day 28 Hb increment ≥3 g/dl seen in 63.33% and MCV>80FL seen in 100% of FCM group vs 0% and 43.33% in ISC group. FCM group had 3.17 g/dl increase in Hb vs 1.9 g/dl in ISC group. S. Ferritin increased to 147ng/ml in FCM group vs 98 ng/ml in ISC group. Significant improvement in RBC indices & retic count was seen in FCM group. Earlier and significant improvement in fatigability & dyspnoea on exertion was observed in FCM group. Both groups had similar safety profile except for thrombophlebitis was observed in 6.67% FCM group vs 50.00% ISC group.

Summary/Conclusions: Intravenous Ferric Carboxymaltose is more effective and safer than Iron Sucrose complex in treatment of Iron deficiency anaemia.
phoid neoplasms characterized by highly infiltrated tumor cells in lymphoid tissues and extra nodal sites. The patients have short responses to current therapies and frequent relapses. However, recent studies have identified a subset of MCL with indolent clinical behavior that tends to present with leukemic disease instead of extensive nodal infiltration, and that is characterized by the absence of the transcription factor SOX11 (SRY (Sex determining region-Y)-box 11). SOX11 oncogenic pathways driven MCL tumor progression are poorly known.

Aims: The goal of our study was to identify the spectrum of genes regulated by SOX11 in malignant lymphoid cells and provide insights on how the constitutive overexpression of SOX11 may contribute to the oncogenic development of MCL. Methods: We transiently transfected stable transgenic DLBCL-silenced MCL cell lines with reduced SOX11 protein levels by infecting MCL cell lines with lentiviral particles carrying shRNA plasmids specifically targeting SOX11. SOX11-positive MCL cell line was infected with the empty vector and used as a control. These two MCL cell lines were injected in two different mice models to analyze in vivo the impact of SOX11, subcutaneous (sc) and intraperitoneal (iv) xenograft tumor models. To analyze the crosstalk between MCL and microenvironment, we did in vitro cocultures experiments using accessory cells at the tumor microenvironment, as endothelial and bone marrow mesenchymal cells.

Results: In the sc mice model, we observed that SOX11 silencing reduced tumor growth compared to SOX11-positive control tumors. We analyzed the gene expression profiling of these xenograft tumors and of SOX11-positive and negative primary cases and we observed than different microenvironment-related signatures were enriched in SOX11-positive compared with SOX11-negative cells, as angiogenesis, migration and stromal stimulation. By CHIP-chip analyses, we identified AICDA as one of the key modulators of epigenetic mechanisms involved in these signatures, between these PDGFA. This data indicated a role for SOX11 in the crosstalk of MCL with tumor microenvironment. We found that SOX11 promotes angiogenesis in MCL cells through PDGFA regulation, promoting tumor growth and vasculature. Inhibition of PDGFA on endothelial cells decreased angiogenesis on xenografts and, angiogenesis, invasion and inter-tumor cytosine methylation heterogeneity, of SCID mice with a PDGFA inhibitor reduced tumor growth and angiogenesis of SOX11-positive MCL xenograft tumors. We also observed that SOX11 promotes migration, pseudoemperipolesis (migration of tumor cells beneath stromal cells) and cell adhesion mediated-drug resistance (CAM-DR) in MCL cells, increasing angiogenesis and proliferation; and that these mechanisms were reduced in SOX11-negative cells. In the iv mice model, we observed that SOX11-positive cells were able to migrated and infiltrated bone marrow and lymph nodes, whereas SOX11-negative cells were retained in peripheral blood.

Summary/Conclusions: In conclusion, our results show that SOX11 is regulating essential processes involved in aggressiveness of MCL tumor cells, as angiogenesis, invasion and drug resistance. Inhibition of SOX11-target genes may represent an efficient strategy for the treatment of aggressive MCL.

AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESE

P.M. Dominguez 1,*, M. Teater 2, D. Redmond 2, Z. Chen 2, D. Ennishi 3, P.M. Dominguez 1,*, M. Teater 2, D. Redmond 2, Z. Chen 2, D. Ennishi 3, 1Department of Medicine, 2Weill Cornell Medicine, New York, United States, 3British Columbia Cancer Agency, Vancouver, Canada, 4NYU School of Medicine, New York, United States

Background: Diffuse large B-cell lymphomas (DLBCLs) are aggressive tumors derived from germinal center (GC) or post-GC B cells. Previous work from our group established that inferior outcome in DLBCL is associated with higher degrees of intra-tumor and inter-tumor cytosine methylation heterogeneity, although the molecules driving this epigenetic perturbation remain unknown.

Aims: We investigated the contribution of activation-induced cytokine deaminase (AICDA) to cytosine methylation heterogeneity in DLBCLs. AICDA is highly expressed in GC B cells where it drives somatic hypermutation (SHM) and also mediates DNA hypomethylation and epigenetic heterogeneity. AICDA is also expressed in a subset of DLBCLs and high level of AICDA in CHOP-treated DLBCL patients is associated with unfavorable prognosis. Thus, we hypothesized that AICDA contributes to epigenetic heterogeneity in DLBCL by facilitating epigenetic plasticity through the redistribution of cytosine methylation.

Methods: We expressed AICDA in malignant lymphoid cells and investigated the impact of AICDA on the methylation and transcription of neoplastic B cells. AIM2. To determine the contribution of AICDA-mediated epigenetic modifications to DLBCL pathogenesis.

Results: We observed more aggressive lymphoma phenotype in VavP-Bcl2/+Aicda mice (n=7) compared to VavP-Bcl2-/+ mice (n=8), based on greater disruption of the splenic architecture and higher degree of B-cell infiltration in organs such as lung, liver and kidney. Notably, the overexpression of AICDA reduced significantly the lifespan of the mice (Log-rank test p=0.0289). Necroplastic B cells from VavP-Bcl2/+Aicda (n=4) and VavP-Bcl2-/+ mice (n=4) displayed similar mutation and indel burdens, suggesting that the more aggressive phenotype in AICDA-overexpressing mice was not likely due to increased mutagenesis. We profiled then the DNA methylation landscape of neoplastic B cells from VavP-Bcl2/+Aicda and VavP-Bcl2-/+ mice. A principal component analysis of all CpGs, represented by its mean DNA methylation and heterogeneity (interquartile range) differences across replicates, revealed methylation loss signatures of AICDA overexpression in VavP-Bcl2/+Aicda lymphomas compared to VavP-Bcl2-/+ (49,750 AICDA-perturbed CpGs). These altered CpGs were depleted in promoters and enriched in introns and intergenic regions. We observed a remarkably similar pattern of focal heterogeneity and demethylation in primary DLBCLs with high AICDA expression to low AICDA expression (p=0.0001). AICDA and, more specifically, AICDA-mediated epigenetic heterogeneity in Aicda-/- cells compared to Aicda+/+ GC B cells (64,332 AICDA-perturbed CpGs), suggesting a conserved epigenetic function of AICDA in GC B cells and human and mouse GC-derived lymphomas. Finally, we found significant overlap between genes affected by AICDA-perturbed CpGs in human AICDA high DLBCLs and murine VavP-Bcl2/+Aicda lymphomas (P=2.21e-23) and with the genes affected by AICDA in GC B cells (P=8.48e-33).

Summary/Conclusions: Our results demonstrate that AICDA acts as a methylome modifier in GC-derived lymphomas, introducing epigenetic heterogeneity, and that AICDA overexpression is associated with higher cytosine demethylation in an evolving environment. These findings are relevant not only for B-cell lymphomas, but also for other types of cancer expressing cytosine deaminases.

P298

XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

M. Crespo 1,*, I. Jiménez 1, J. Carabia 3, S. Bobillo 1, P. Abrisqueta 1, C. Palacio 1, C.D. Carpio 1, J. Castellví 1, J. Seoane 4, F. Bosch 1

1Experimental Hematology, 2Hematology, Vall d’Hebron Institute of Oncology, 3Pathology, Vall d’Hebron Research Institute, 4Gene Expression and Cancer Laboratory, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Background: Primary central nervous system lymphoma (PCNSL) is an non-Hodgkin lymphoma localized in the CNS. Approximately 95% of PCNSL are classified as diffuse large B-cell lymphoma (DLBCL), being most of them related to activated B-cell type (ABC-DLBCL). PCNSL is associated with poor prognosis, particularly because of the difficulty to drugs to cross the blood brain barrier. High dose methotrexate is the most effective treatment, but relapse is very common and salvage treatment options are scarce. Also, in patients with systemic lymphoma, the secondary infiltration of the CNS is a fatal event, with a global overall survival of less than six months. Therefore, the development of new drugs with ability to penetrate the CNS is highly needed. Selinexor (KPT-330) is a Selective Inhibitor of Nuclear Export (SINE) that inactivates XPO-1 protein and induces anti-tumor effects mainly due to forcing nuclear retention and activation of tumor suppressors. Selinexor has shown excellent brain penetration and promising results in pre-clinical models of glioblastoma and can inhibit both BCR and NF-κB signaling in malignant B-cells.

Aims: In order to provide a pre-clinical rationale for the design of new therapies for patients with CNS lymphoma our main aim is to assess the role of XPO-1 inhibition in intracerebral xenograft murine models.

Methods: We in vitro tested the sensitivity of DLBCL cell lines to selinexor and etbrutin by MTS and AnnexinV/PI assay. We established an orthotopic xenograft model of PCNSL with stereotactic injection of OCI-Ly10 (ABC, MYD88 and CD79b mut) cells expressing luciferase into the cerebral parenchyma of nude athymic mice. We longitudinally quantified intracerebral tumoral growth by bioluminescence detection.

Results: To compare the sensitivity of DLBCL cell lines to selinexor we determined the IC50 in terms of survival and proliferation in 4 ABC and 5 GCB DLBL cell lines. DLBCL cell lines had equivalent sensitivity to selinexor, regardless of cell of origin (COO). In detail, survival by AnnexinV/PI exclusion showed that mean ID50 for ABC cell lines was 4.98 µM +/- 3.6 and 6.3 µM +/- 3.8 for GCB (p=0.9). Proliferation by MTS was also blocked by selinexor (mean ID50 for ABC-DLBCL was 1.35 µM +/- 0.7 vs 16.16 µM +/- 11.17 for GCB-DLCL (p=0.41)). Since SINE compounds have been shown to inhibit activation of the tumor suppressors, Selinexor has shown potential in glioblastoma and in a novel approach of depleting microenvironmental stromal elements, we used a SINE inhibitor in xenograft model of PCNSL by stereotactic injection of OCI-Ly10 cells expressing luciferase into the cerebral parenchyma of nude athymic mice. Eleven days after the injection of cells all animals developed detectable tumors confined to the CNS. Tumor size

92 | haematologica | 2017; 102(s2)
was measured and animals were randomly distributed into drug or vehicle group. At this time point mice were treated with 5mg/kg of selinexor or vehicle via oral gavage three times a week; subsequently, bioluminescence was assessed twice a week. Treatment with selinexor significantly increased mice survival, with a median survival of 48 days in the treatment group compared to 34 days in the vehicle group (p<0.0001; Figure 1A). Mice in the treatment group showed a significantly slower increase of tumor growth and increases survival. Our results provide preclinical evidence for the development of selinexor as new therapeutic option for PCNSL or DLBCL with CNS involvement.

**Summary/Conclusions:** Selinexor inhibits proliferation and survival of DLBCL cell lines regardless of COO and it can synergize with triltninib. Treatment of mice with CNS confined ABC-DLBCL with selinexor significantly reduces tumor growth and increases survival. Our results provide preclinical evidence for the development of selinexor as new therapeutic option for PCNSL or DLBCL with CNS involvement.

**P299**

**MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOS: OTHERWISE MISCLASSIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING**

Y. Watanat1,*, Y. Sato2, K. Nishida2, H. Miyoshi3, Y. Shiraishi4, K. Chiba5, H. Tanaka2, H. Ueno1, N. Kakuchi1, Y. Shiozawa1, T. Yoshizato1, K. Yoshida1, M. Sanada3, S. Miyano4, K. Ohshima1, T. Yoshino1, S. Ogawa1, K. Kataoka1, 1Department of Pathology and Tumor biology, Kyoto university, Kyoto, 2Department of Pathology,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 3Department of Pathology, Kurume University School of Medicine, Fukuoka, 4Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, 5Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan.

**Background:** Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous group of mature T-cell neoplasms. In particular, accounting for the majority of PTCL-NOS, PTCL-NOS not other specified (PTCL-NOS) is a diagnosis of exclusion and such, is expected to include many heterogeneous tumors. In fact, recent genetic studies have suggested that a subset of PTCL-NOS is closely related to angioimmunoblastic T-cell lymphoma (AITL); both lymphoma types show follicular helper T-cell (TFH) phenotypes and share mutational targets in common, such as RHOA, TET2, DNMT3A, and IDH2. However, with the lack of comprehensive genetic analyses, the molecular pathogenesis is poorly understood in the majority of PTCL-NOS cases.

**Aims:** The aim of this study is to extensively dissect the dynamics of DNA methylation in B-cell neoplasias in the light of normal B cell maturation program. The ultimate goal of this study was to generate new clinically relevant knowledge regarding diagnostic and prognostic value.

**Methods:** Our dataset included whole-genome bisulfite sequencing data (n=57) and high-density methylation arrays (n=1161) from acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) as well as from ten different normal B cell subpopulations. As DNA methylation estimates in neoplastic samples are influenced both by tumor cell content and composition of the micro environment, we developed a new method to deconvolute and in silico purify the methylation signal of tumors arising in different niches (bone marrow, peripheral blood and lymph node). The data were analyzed by a series of bioinformatic and biostatistical approaches and correlated with clinical variables.

**Results:** The initial bioinformatic approach to purify DNA methylation signals in B cell tumors revealed that samples with less than 55% tumor cell content could not be accurately purified. This strategy reduced the initial 1,044 tumor samples to 866. An unsupervised principal component analysis of in silico purified data revealed that each type of B-cell neoplasia clusters separately. ALLs clustered closer to precursor B cells, CLL and MCL closer to mature B cells and both DLBCL and MM showed the largest deviation from normal B cells.

**Conclusion:** We then performed a differential analysis and determined in each sample vs normal B cell maturation stages, and thoroughly annotated the results to biological and clinical features. From the clinical perspective, we identified that for tumor samples with similar cellular origin, the higher the epigenetic deviation from healthy B cells (number of DNA methylation changes) the worse the clinical outcome for the patients. Furthermore, for each tumor entity, we could identify from 5 to 19 epigenetic biomarkers that could classify each entity with high sensitivity and specificity.

**Summary/Conclusions:** In this study, we show that in silico purification of DNA methylation data is a powerful strategy to accurately measure DNA methylation alterations in tumor cells. Using a large dataset, we have developed a set of epigenetic biomarkers with high differential diagnostic power and identified that the epigenetic drift is a universal prognostic factor that can be applied to different B cell tumors.
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subset of peripheral T-cell lymphoma with follicular helper T-cell (TFH) features. We and others previously found mutations of RHOA, encoding p.Gly17Val (G17V RHOA), in AITL/TFH lymphoma samples compared to those with WT or mock. Finally, phospho-VAV1 was co-blocked by the dasatinib treatment. The levels of IL-2 mRNA were higher in Jurkat cells expressing each WT cDNA or mock. Phosphorylation was blocked by the dasatinib at 1-10 nM concentrations. The G17V RHOA, VAV1-STAP2 and various specific binding partners of the G17V RHOA mutant were examined by high throughput screening in Jurkat cells. Nuclear factor of activated T cell (NFAT) activity in response to TCR stimulation was examined in Jurkat cells expressing wild-type (WT) and G17V RHOA mutant, and WT and various VAV1 mutants. Phosphorylation of VAV1 occurs within seconds in response to antigen stimulation of the TCRs by Syk and Src-family tyrosine kinases and initiates downstream TCR signaling. We aimed at clarifying the downstream signaling of the G17V RHOA mutant in AITL/TFH lymphoma.

Methods: Proteomic screening was performed to identify G17V RHOA-specific binding partners. Binding was validated by co-immunoprecipitation of G17V RHOA and the candidate partners. Simultaneously, RNA sequencing identified 2 in-flame deletion mutations in an acidic region of phosphotyrosine dioxygenase 2 in up to 70% of AITL and other TFH lymphoma (a sub-group of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)) samples. RHOA, a small GTPase, is converted from the GDP-bound inactive form to the active GTP-bound form by guanine nucleotide exchange factors (GNEFs). It has been shown that the G17V variant binds the SH2 domain of STAT3, which encodes the SH2 domain, was performed using 19 to 24 of STAT3, which encode the SH2 domain, was performed using primers from the previous report (N Engl J Med 2012; 366: 1905-13). EBV-negative T- and NK-cell lines and PBMCs from healthy donors were used as negative controls. Cell survival and apoptosis were examined by an XTT assay and Annexin V assay, respectively. The mRNA expression of cytokines was examined by TaqMan® Gene Expression Assays. Results: STAT3 was constitutively phosphorylated on Y705 and S727 and was localized in the nucleus in EBV-negative T- or NK-cell lines and PBMCs from the CAEBV patients, as indicated by western blotting. The microarray analysis of EBV-positive T or NK cell lines from CAEBV patients showed that the expression of STAT3-responsive genes, including interferon-γ, were upregulated in these cells compared with EBV-negative cells. No mutation was detected in the SH2 domain of STAT3 in patient-derived cells by direct sequencing. The JAK inhibitors ruxolitinib and tofacitinib suppressed STAT3 activation and cell survival by inducing apoptosis of the cell lines and PBMCs from CAEBV patients. Ruxolitinib also inhibited the mRNA expression of TNF-α and interferon-γ in CAEBV patient-derived cells. Summary/Conclusions: STAT3 is constitutively activated in EBV-positive T or NK cell lines derived from CAEBV patients. Inhibition by ruxolitinib could be an attractive and effective treatment for CAEBV by suppressing not only EBV-infected cell survival but also the accompanying inflammation.

Background: Folicular lymphoma (FL) is the most common low grade B cell malignancy accounting for ~20% of all non-Hodgkin lymphomas. Approximately 30% of the FL cases suffer a histological transformation to a much more aggressive subtype of lymphoma drastically reducing the overall survival from 10 years to just 14 months. Despite being a critical event during disease progression it is molecularly poorly understood and no biomarkers exist to predict this event. Previous studies have suggested the possibility that deregulation of microRNA expression (miRNAs, small endogenously produced non-coding RNAs) could be implicated in the development of FL disease as well as in the transformation event. We hypothesise that mutations in miRNA binding sites may also have a role in this process. We set ourselves to find predictive biomarkers of transformation for FL, with a special focus on sequence variants affecting miRNA binding sites. Methods: We interrogated whole genome sequencing (WGS HiSeq, Illumina) data from sequentially obtained samples of 6 FL patients that underwent trans-
formation using a bespoke bioinformatic pipeline based on TargetScan prediction algorithm in order to identify mutations in putative miRNA binding sites. Once identified, in order to validate them and test their recurrence in an extended cohort (60 samples from 31 FL patients who underwent transformation plus 21 samples of non-transformed FL patients) we designed an Ampliseq (Ion Torrent, Life Technologies) NGS custom panel. Finally, we selected a number of variants for assessing the variant effect on the miRNA:mRNA interaction, by means of a combination of an in silico predictive algorithm and in vitro luciferase assays.

Results: 36% of somatic variants from WGS data arose in 3’UTR, and 68% of these were putative miRNA-binding sites (525 mutations in 497 genes). Interestingly, the ontology analysis showed that these mutations were not randomly distributed but rather there was enrichment in genes associated with hematological malignances (P=2.18x10-4). We then validated 85% of these mutations using targeted resequencing and found a total of 103 recurrent variants located in putative miRNA binding sites. QC criteria filtering led us to prioritise 38 variants in 25 genes to be functionally tested. Crucially, ontology analysis showed that these genes were highly enriched for GC-like B-cell lymphoma genes (P=4.39x10-5), strongly suggesting that these variants may have a biological significance in the disease. We then performed an in silico approach based on TargetScan miRNA target prediction algorithm to evaluate the effect of the mutations on the binding of the miRNAs to their target sites. Based on these results we prioritized some of these genes to perform luciferase assays. We experimentally demonstrated not only that the majority of these loci are bona fide miRNA targets sites, but also that the presence of a number of these variants cause a dysregulation of the normal miRNA regulatory activity (Figure 1).

PFS (A) and OS (B) by TP53 and/or KMT2D mutational status

Figure 1.

Summary/Conclusions: Our data show that the identified mutations do not occur randomly, but preferentially in putative microRNA binding sites of genes related to lymphomagenesis, supporting their role in FL pathogenesis. Furthermore, the presence of some of the identified variants in microRNA binding sites indeed promotes a dysregulation of the normal miRNA regulatory activity, suggesting that they might have a biological significance in FL.

Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milano, 11Department of Hematology, Ospedale Generale, Bolzano, 12Clinica Humanitatis/Gavazzeni, Bergamo, 13SC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, 14Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

Background: Within the landscape of mutated genes in mantle cell lymphoma (MCL), only TP53 disruption has been so far associated with outcome.

Aims: Here we present the clinical update of the deep sequencing MCL gene panel analysis in the prospective FIL-MCL0208 phase III trial (NCT02354313), high-dose immunochemotherapy followed by autologous transplantation for untreated, advanced stage <65 years MCL) based on the data from the second interim analysis.

Methods: A targeted resequencing gene panel, including coding exons and splice sites of the ATM, BIRC3, CCND1, KMT2D, TP53, TRAP1, WHSC1, and NOTCH1 genes was analyzed in tumor DNA from baseline bone marrow CD19+ purified MCL cells and, to filter out polymorphisms, in the paired normal genomic DNA (55% of cases) using a TruSeq Custom Amplicon target enrichment system followed by deep next generation sequencing (Illumina, median depth of coverage 235x). Variants represented in >10% of the alleles were called with VarScan2 with the somatic function when the paired germline DNA was available. For patients lacking germline DNA, a bioinformatics pipeline including a number of stringent filters was applied to protect against the misclassification of polymorphisms as somatic variants. Clinical data were updated at the time of the second interim analysis (January, 2017).

Results: Out of the 300 enrolled patients, 174 were evaluable for mutations. Median follow-up of the cohort was 36 months, and 3-years PFS and OS were 67% and 86%, respectively. Patients not included in the study, due to unavailable tumor DNA (n=126) showed superimposable clinical features and outcome. Mutations of TP53 (8% of cases) and KMT2D (11% of cases) associated with an increase in the hazard of progression both in univariate analysis as well as after adjusting for MIPI, Ki67 and blastoid variant: HR 3.87 (95% CI 1.64 to 9.13), p<0.002 and HR 3.66 (95% CI 1.77 to 7.56), p=0.001, respectively. These results translated into an increase of the hazard of death in both TP53 and KMT2D mutated patients both in univariate analysis as well as adjusting for MIPI, Ki67 and blastoid variant HR 4.26 (95% CI 1.34 to 13.57), p=0.014 and HR 3.09 (95% CI 1.07 to 8.86), p=0.036, respectively. On these bases, a survival model was proposed based on the TP53 and KMT2D mutation status: 3-years PFS and OS were 26% and 64% for patients carrying either TP53 or KMT2D mutations or both vs 75% and 92% for patients without any of these mutations (Figure 1).

Summary/Conclusions: The updated clinical results of the FIL-MCL0208 trial show that: i) both TP53 and KMT2D mutations independently associate with shorter PFS and OS in younger MCL patients receiving high-dose therapy; ii) KMT2D mutations seem to be as detrimental as TP53 mutations, at least in terms of PFS; iii) given the negative prognostic impact of these mutations, they might be used to select high-risk patients for novel therapeutic approaches.
Multifaced aspects of bleeding disorders

P305

A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE.

S. Jaafar1,2, T. T. Yue1

1Haematology, Royal Free Hospital/NHS, 2Haematology, katharina dornandy haemophilia centroreyal free hospital, london, United Kingdom

Background: Von Willebrand Disorder (VWD) has a prevalence of approximately 1% in the general population and is due to quantitative deficiencies or qualitative defects of the Von Willebrand Factor (VWF) protein. VWF is a large multimeric protein with multiple functions. It carries and protects factor VIII and helps in the binding of FVIII, platelets and the vascular endothelium at sites of injury. VWF binding to platelets is through several receptors most notably the glycoprotein 1b (GP1b) and collagen exposed at site of injury is important for VWF adhesion to the subendothelial matrix forming an adhesive anchor. Classification of VWD is based on the quantitative deficiencies (Type 1 and 3) and VWD type 2 are qualitative defects of the VWF protein with or without quantitative deficiency as well. Type 2 VWD is further subdivided into type 2A,2B,2M and 2N. These subtypes vary depend on a number of laboratory assays that measure the FVIII activity, VWF protein level (VWF:Ag assay) and the function of the protein i.e its ability to bind to 1) FVIII (VWF binding assays) 2) platelets (VWF Rcof assay) and 3) collagen (VWF:CB assay). Other tests include ristocetin induced platelet aggregation (RIPA), multimer analysis, assay ratios and VWF genetic analysis. No single commercially available laboratory method can achieve to test all the parameters required to clinch the accurate diagnosis of the subtypes of VWD. Use of those multiple assays with VWF Rcof/VWF:Ag ratio, VWF CB (VWF-CB) / VWF Ag ratio have helped in the better identification of VWD and the subtypes.

Aims: To assess recent various VWF investigation panels and assay ratios, VWF genetic analysis, multimeric patterns of the VWF protein in accurate diagnosis of the VWD subtypes. VWD 2A and 2M shows similarities in certain aspects and it is important to differentiate these 2 subtypes as new therapies become available and personalized treatment approaches of VWD become a reality.

Methods: Clinicians who have made a diagnosis of VWD for individuals referred for a bleeding state work up would classify the subtypes of the VWD according to the results of the investigations available at the time of seeing the patients. All patients with an inherited bleeding disorder would then be registered in the centre and details would be put into a database. We have looked back into the database from the period of 2000 to end of 2016 and focussed on the VWD types 2A and 2M. Current VWD diagnostic panel in our centre includes the following tests: FVIII one stage assay, VWF:Ag Elisa, VWF rcof, Platelet agglutination method, VWF CB Elisa methods. VWF multimeric analysis by gel chromatography and VWF exon 27/28 genetic mutations are routinely done. New information and new set of results for the registered patients have been taken into account the classification of VWD type 2A and 2M and the database are updated.

Results: In the VWD database 36 patients classified as 2M and 19 patients as type 2A have been recorded from 2000 to end of 2016. With the updated results and genetic analysis and the response to DDAVP, around 30% of the patients have had their subtypes changed. This exercise confirms that no singular test or combination of tests can be used to accurately diagnose the VWD and its subtypes and illustrates the importance of DDAVP testing and the difficulty of interpreting assay ratios for accurate diagnosis. VWF levels are <10% in some cases.

Summary/Conclusions: VWD may be misdiagnosed, underdiagnosed or undiagnosed. Appropriate and complete investigative panel is necessary for complete classification of VWD and its subtypes.

P306

RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS

C. Santoro1, F. Mazzaro2, E. Baldacci2, G. Ferrara1, F. Malaspina3, R.C. Santoro1, S. Pasca2, G. Castaman4, F. Peyvandi1, R. Foà1, D. Vasiliev1

1Cellular Biotechnology and Hematology, Hematology Sapienza University, Rome, 2OncoHaematology Department, Haemostasis and Thrombosis Service- Pugliese-Ciaccio Hospital, Catanzaro, 3Center for Hemorrhagic and Thrombotic Diseases, University Hospital of Udine, Udine, 4Center for Bleeding Disorders, Careggi University Hospital, Florence, Florence

Background: Dysfibrinogenemia (DF) and hypofibrinogenemia (HDF) patients (pts) experience hemorrhages or thromboses, and the clinical management can be difficult.

Aims: Aim of this study is to obtain information on DF/HDF clinical phenotype and management.

Methods: This is a spontaneous, retrospective, multicenter national study. Data is collected from clinical records.

Results: Forty-one pts have been enrolled in 3 centers: 35 DF (85%), 6 HDF (15%); 18M, 23F. Median follow-up: 7.4 months (1-203). Median age at diagnosis: 36 years (range 3-81). Median fibrinogen activity/antigen level: 53 mg/dL (0-156) and 250 mg/dL (66-380), respectively. Fourteen pts experienced hemorrhagic/apoplastic, hematomas, ecchymoses, menometrorrhagia, and gastro-intestinal (presence of esophageal ulcers). No specific therapy was administered. A portal venous thrombosis occurred in 1 DF splenectomized patient in absence of replacement therapy; he was treated with warfarin without anti-hemorrhagic prophylaxis. Forty-one minor/major surgeries were performed in 23 pts. In 10/41 (24%) cases, prophylaxis was administered; fresh frozen plasma in 3, fibrinogen concentrate (FC) in 1, tranexamic acid in 6; in 5/41 (12%) cases, low molecular weight heparin (LMWH) was administered; no hemorrhage occurred. Thirteen pregnancies were initiated in 9 women. In 1 case, LMWH prophylaxis was administered during pregnancy, and in 1 other during puerperium. In 2 cases, FC was also administered at the time of spontaneous delivery (SD). Nine SD and 4 cesarian sections were performed without complications.

Summary/Conclusions: Pts from this case series experienced few hemorrhagic/thrombotic events. The majority was asymptomatic and the most severe events were related to concomitant pathologies. Nonetheless, this study has the potential to collect data from a numerous population of pts who live in the same country, and therefore to provide useful information to better characterize and manage these rare diseases.

P307

OSTEOPOROSIS IN PATIENTS WITH HEMOPHILIA


1National Research Center for Hematology, Moscow, Russian Federation

Background: Osteoporosis is often a co-morbidity of hemophilia, which exacerbates the hemophilic arthropathy and affects the long-term stability of the components after the arthroplasty. We present our results for the presence of osteoporosis in 148 patients with haemophilia and hemarthroplasty.

Aims: To prevent progression of hemophilic arthropathy and increase the long-term stability of the components after the arthroplasty.

Methods: In the period from 2015 to 2016, the presence of osteoporosis surveyed 148 patients with haemophilia who are hospitalized in the department of reconstructive orthopedics for patients with hemophilia (Moscow, Russia): 121 (81.8%) - hemophilia A, 21 (14.2%) - and hemophilia B 6 (4%) – haemophilia with inhibitor. The average age of the patients was 39.3 years (range 10 to 69 years). 121 patients with hemophilic arthropathy performed primary total arthroplasty (98 knee, 20 hip, 3 shoulder joints); 18 patients underwent revision arthroplasty (5 - purulent infection, 7 - instability of the implants, 4 - fractures, 2 - loss of motion in the operated joint). 40 patients underwent ultrasound densitometry. Vertebral fractures were ruled out. As a result of ultrasound densitometry in 17.5% (7 patients) of cases revealed osteopenia and 20% (8) -Thighest index. 105 patients underwent histological study in which 93 (88.6%) bone resorption, 58 (55.2%) intraosseous hemorrhage which 53 (50.5%) cases were accompanied by bone resorption. In total (histologically and of ultrasound densitometry) 99(66.9%) patients with haemophilia had osteopenia or osteoporosis.

Summary/Conclusions: The data indicate that osteoporosis at patients with haemophilia considerably more common than in the general population. Intraosseous hemorrhage identified in more than half of the cases, exacerbate the decline in bone mineral density.
patient, with the rate of recurrent haemorrhagic events in joint(s) from 6 to 13 per year. The control group consisted of 255 age-matched healthy men. Gene polymorphism of apolipoprotein E (ApoE e2/e3/e4), paraoxonase (PON1 Gln192Arg), methyleneretahydroxyaducte reductase (MTHFR C677T), catalase (CAT C-262T) and plasmatoglucine peroxidase (GPX3 T-65C) was studied by PCR-RFLP technique. Statistical differences between the patient and control group, were assessed by Fisher’s exact test. Odds ratios (OR) with their 95% confidence intervals (CI) and p-value were calculated by using GraphPad Prism 5.0 software.

Results: We found abnormal distribution of ApoE genotypes in the patient group. Absence of ApoE e3 allele was observed in 7 (9.1%) men with SH and 9 (3.1%) controls (OR=3.4, 95% CI: 1.2-9.7, p=0.025). In particular, the frequency of ApoE e2/e2 genotype was 10-fold increased in patients when compared to healthy men (4.2% vs 0.4%, OR=11.2, 95% CI: 1.1-109.5, p=0.034). ApoE e2/e4 and e4/e4 genotypes were also more prevalent in SH than in the control group (2.8% vs 0.8% and 2.8% vs 0.2%, respectively). In the patient group, we observed the positive association between the PON1 192Gln/Gin variant and heterozygous GPX3 -65TC genotype (OR=5.8, 95% CI: 1.3-25.7, p=0.021). Simultaneous presence of these genetic variants was more than 5-fold found in SH than in controls (8.5% vs 1.6%, 95% CI: 1.3-22.8, p=0.016).

Summary/Conclusions: Our results indicate that OS-provoking variants of ApoE, PON1 and GPX3 genes are frequently seen in SH patients with chronic arthropathy and joint(s) destruction.

P309
THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY
A. Noroozi-Aghideh1,*, N. Lashgari 2, A. Dorgalaleh 3, Z. Kashanikhatib 4, S. Alizadeh5
1Pediatrics, Keimyung University School of Medicine and Dongsan Medical Center, 2Pediatrics, Yeungnam University, College of Medicine, Daegu, Korea, 3Hematology, Russian Research Institute of Hematology, Saint-Petersburg, Russia, Federation

Background: Congenital factor XIII deficiency (CFXIIID) is a rare bleeding disorder. Intracerebral hemorrhage (ICH) is a leading cause of mortality and morbidity in this disorder. Matrix metalloproteinase-2 (MMP-2) and MMP-9 are reported to be associated with ICH.

Aims: The purpose of this study was to investigate the association of MMP-2 and MMP-9 methylation and their expression with ICH.

Methods: Patients with abnormal clot solubility test as well as a positive family history of FXIII deficiency were included in the study. Methylation status was analyzed by Bisulfite Sequencing PCR. Gene expression in mRNA and protein levels was assayed by Quantitative real-time RT-PCR and ELISA, respectively.

Results: We found an unmutated profile for both MMP-2 and MMP-9 in patients with ICH. Both of these genes were partially methylated in controls. Percent of methylated CGs are also higher for MMP-9 than MMP-2. Higher expression of MMP-9 in both of mRNA and protein levels was found in ICH compared to non-ICH group. However, there were no significant differences in MMP-2 expression and methylation between the groups.

Summary/Conclusions: Our findings showed that gene methylation contributes effectively in regulation of MMP-9 expression. Furthermore, our data suggest that MMP-2 expression in CFXIIID may not be controlled by gene methylation alone because methylation status of this gene did not correlate with minimal cutaneous hemorrhages to severe life-threatening bleeding. It is well known, that there is no stable correlation between the platelets count or other parameter(s) and the hemorrhage grade in ITP patients. Possibly, the genetically-based individual mechanisms of immune response impairment could affect the severity of hemorrhage during course of ITP.

Aims: To reveal genetic risk factor(s) for severe HS in patients with chronic ITP.

Methods: A total of 67 patients (58 women and 9 men) with chronic ITP were involved in the study. The median age of the group was 57 years (range: 24-77). The mean duration of ITP was 7 years (2-48). Hemorrhage was graded according to WHO scale. Taking into account the severity of HS, all the patients were divided into two groups. The first group included 40 patients with HS of 0-1 grade and the second consisted of 27 patients with HS of 2-3 grade. All patients of the second group needed the use of different methods of emergency haemostatic therapy and we consider it as a “severe ITP”. We analyzed DNA polymorphism of 8 genes responsible for the formation of a human platelet alloantigen systems (HPA-1, -2, -3 and -5) and associated with impaired immune response (IL-1B, IL-6, IL-10 and TNF-A). The differences in genotype frequencies between the groups 1 and 2 were assessed by Fisher’s exact method. Odds ratios (OR), their 95% confidence intervals (CI) and p-values were calculated with GraphPad Prism 5.0 software.

Results: The frequency of HPA-3a/3a (GpIIb 2622TT, 844 Ile/ile) genotype was more than 2-fold increased in ITP patients with severe HS (55.6% vs 25.0% in the group with HS of 0-1 grade; OR=3.8, 95% CI: 1.3-10.7, p=0.02). HPA-1a/1a and HPA-2a/2a genotypes were also more frequently seen in patients with HS of 2-3 grade compared to the group with HS 0-1 (77.8% vs 72.5% and 92.6% vs 80.0%, respectively), but these differences were not statistically significant (p=0.78 and p=0.19, respectively). Moreover, in the group with “severe ITP” we found almost 2-fold increase of the IL-6 -174CC genotype frequency (26.9% vs 15.0% in HS 0-1; OR=2.1, 95% CI: 0.6-7.1, p=0.34). Patients positive for IL-10 -1082A allele were a higher frequency of severe HS compared to the group with HS of 0-1 grade (48.1% vs 26.3% in HS 0-1; OR=2.6, 95% CI: 0.9-7.4, p=0.11).

Summary/Conclusions: Our data indicate that HPA-3a/3a variant could be a possible risk factor for severe HS in ITP patients.
P312

AN ALGORITHM TO IDENTIFY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA

A. Kreuger1,2, R. middelburg1, J.L. Kerkhoffs1, J. van der Bom1
1Center for Clinical Transfusion Research, Sanquin Research, Amsterdam, 2clinical epidemiology, LUMC, Leiden, 3Hematology, Hagaziekenhuis, den haag, Netherlands

Background: Many patients with a hematological malignancy have an increased risk of hemorrhages. Research addressing the causes of these hemorrhages, especially those on major hemorrhages, are hampered by the difficulty to find sufficient and representative cases of major hemorrhage. Unfortunately, electronic health records generally do not codify hemorrhages.

Aims: The aim of this study was to develop an algorithm that can be used to find patients who suffered from major hemorrhages (WHO grade 3 or 4) within electronic health records.

Methods: An algorithm was developed using electronic health record data of a cohort of patients with acute leukemia, who received platelet transfusions between June 2011 and December 2015 at the Leiden University Medical Center in the Netherlands. Chart review was performed for a stratified, random sample of observation days. Discriminative performance of three indicators was assessed: CT-brain, drop in hemoglobin level and transfusion need within 24 hours. The cut off values for hemoglobin drop and transfusion need with the best discriminating capacity and CT-brain were entered in the final algorithm. The C-statistic was calculated and calibration plots were made. The algorithm will be externally validated in two other academic hospitals.

Results: The derivation cohort consisted of 255 patients comprising 10,638 observation days and chart review was performed for 353 days. The incidence of major hemorrhage was 0.22 per 100 observation days. The final algorithm consisted of information on CT-brain (yes/no), a hemoglobin drop of ≥2.8 g/dl and the need of six or more transfusions (yes/no). The C-statistic of the algorithm consisted of information on CT-brain (yes/no), a hemoglobin drop of ≥2.8 g/dl and the need of six or more transfusions (yes/no). The C-statistic of the algorithm was 0.93 (95% confidence interval (CI) 0.86 to 0.99). The incidence of bleedings with all grades of severity was 8.4 per 100 days. The algorithm for bleedings of all grades had a c-statistic of 0.54 (CI 0.53 to 0.55). The results of the external validation are not available yet.

Summary/Conclusions: An algorithm using information on CT-brain, hemoglobin drop and transfusion can accurately identify cases of major hemorrhage within electronic health care data. External validation will be performed.

Myelodysplastic syndromes – Clinical 1

P313

MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES

M. Shiokel1,2, M. Isii1, M. Ohwashi1, N. Morii1, K. Yoshinaga1, J. Tanaka1
1Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan

Background: Previously we determined common deleted region (CDR) of del(20q) observed in MDS by CGH-array. Our data showed that the PTPN1 gene is located within CDR of del(20q). The PTPN1 gene encodes PTP-1B, a non-receptor type protein tyrosine phosphatase, which is involved in multiple physiological and pathological cellular processes via dephosphorylation of several tyrosine kinases, and other molecules. Although roles of PTP-1B in normal and pathological hematopoiesis has not been elucidated, it may function negative regulator for cellular processes mediated by tyrosine kinases, including JAK2, and SRC. We hypothesized that the PTPN1 gene is a target gene disrupted by del(20q), resulting in haplo-insufficiency, and involved in MDS molecular pathogenesis.

Aims: We attempted to examine PTPN1 expression level in bone marrow cells of MDS patients with or without del(20q), and to investigate its clinical and biological significance.

Methods: Total RNA was extracted for cDNA synthesis from bone marrow samples taken at the time of diagnosis with written informed consent from patients and control subjects were used for the present study. Real-time RT-PCR was carried out to quantify PTPN1 expression by the TaqMan probe method using an ABI 7500 real-time PCR system (Applied Biosystems). Data including patients' demographic, disease status, medical history, clinical and laboratory findings, and outcome, were collected from medical records and laboratory data base. A non-parametric Mann-Whitney-Wilcoxon test was used to examine whether expression levels among groups are statistically different. The Kaplan-Meier model was used to analyze the impact of PTPN1 expression on overall survival, and log-rank test was used for statistical analysis. We also examined the effect of 5-azacytidine treatment on PTPN1 expression in primary bone marrow cells from MDS patients. Bone marrow cells were cultured with or without 5mM of 5-azacytidine for 48 hours. Expression level of PTPN1 was examined by quantitative RT-PCR described as above.

Results: A total of 118 MDS patients, 71 males and 47 females with median age of 68 years (range: 20-91 years) and 19 control subjects were included in the present study. The patients were classified as RCUD (n=18), RCMRD (n=58), RARS (n=8), RAEB-1 (n=20) and RAEB-2 (n=14) according to WHO classification. Relative PTPN1 expression level was significantly decreased in MDS patients with del(20q) (P<0.001) compared with control subjects. Moreover, relative PTPN1 expression level in MDS patients without del(20q) also significantly decreased (P<0.001). Expression patterns of PTPN1 among five WHO-subtypes, were statistically different (P=0.0201). Median values of relative PTPN1 expression level in RCUD, RCMRD, RAEB-1, and RAEB-2 were 1.52, 1.95, 1.91(P<0.001), and 1.26 respectively. Relative PTPN1 expression level in WHO-subtypes with high blast counts (RAEB-1 and RAEB-2) was significantly lower than that in WHO-subtypes with less blast counts (RCUD, RCMRD, RARS) (median value: 1.41 vs 1.89, P=0.0074). To investigate prognostic implication of PTPN1 expression in MDS, we analyzed impact of PTPN1 expression on overall survival (OS). Based on PTPN1 expression level, 118 patients were divided into four groups, high (Q1), intermediate (Q2, Q3), and low (Q4) quartiles. Kaplan-Meier analysis demonstrated that the lowest quartile (Q4) showed significantly worse survival compared with remaining quartiles (Q1, Q2, Q3) (P=0.048). The estimated 5-year OS rates in Q1-3 group and Q4 group were 69% and 49.8%, respectively. We examined whether PTPN1 expression is induced by 5-azacytidine in primary bone marrow cells of 17 MDS patients. Real-time PCR analyses indicated that 5-azacytidine treatment significantly induced PTPN1 expression.

Summary/Conclusions: The present study demonstrated that PTPN1 expression is reduced in MDS patients with haplo-insufficiency due to del(20q) and methylation of promoter region of the PTPN1 gene. Low PTPN1 expression is associated with advanced disease and poorer clinical outcome, indicating that PTPN1 expression level could be a useful prognostic marker in MDS.
Aims: The purpose of this study is to elucidate the clonal dynamics and molecular signatures that correlate with response to azacitidine therapy for MDS, focusing on the role of TP53-mutations.

Methods: We conducted a prospective multicenter trial of azacitidine treatment for high-risk MDS patients, in which the efficacy was compared between the 5- and 7-day regimens. A total of 107 patients were enrolled between 2013 and 2016. For all cases, a bone marrow specimens collected before treatment was analyzed for mutations using targeted-capture sequencing. Mutations were also interrogated after 4 cycles of azacitidine therapy in 48 (45%) cases. An additional case was analyzed for mutations in a patient who received azacitidine therapy for MDS and whose bone marrow specimens were available both before and after therapy. RNA baits were designed for detection of both oncogenic variants in 67 known driver genes in myeloid neoplasms and copy number alterations on the same platform. Response was evaluated according to the IWG 2006 criteria.

Results: On average, 2.7 mutations (range 0-9) were detected per sample before azacitidine treatment. TP53 represented the most common mutation target (50% of 222 cases total), followed by ASXL1, RUNX1, TET2, and SRSF2. TP53-mutated cases had significantly lower number of driver mutations (1.7 vs 3.1/sample, p<0.001) and higher number of copy number changes (9.6 vs 2.1, p<0.001), compared with unmutated cases. Clinical response was observed in 25 cases in the on-protocol cohort, including 6 complete remission (CR) (3.6%) and 19 marrow CR (17.8%) and 7 (29%) cases (all CR) in the off-protocol cohort. Notably, CR was obtained almost exclusively in TP53-mutated cases (5/6 and 5/7 CR cases in the on- and off-protocol cohort. No other mutations were associated with clinical response. Median treatment duration was 119 days (range: 81–721), which lasted for a median duration of 217 days (range 10–783). ΔTCF was evaluable for 62 cases who had one or more follow-up specimens and carried at least one mutation in either pre- or post-treatment with an average of –0.075 (range: –0.75–0.72). ΔTCF was significantly lower in responders than non-responders (0.18 vs –0.0002, p=0.0068) and in TP53-mutated cases (–0.25 vs 0.0006, p=0.001).

Summary/Conclusions: Our study revealed a significant positive association of TP53 mutations with favorable responses to azacitidine for MDS, although the response was transient and the expected response rate seems to be much lower compared to that reported for decitabine. Given that decitabine is not approved for MDS in non-metro areas (e.g. EU and Japan), our results suggest a potential role of azacitidine as a key agent to improve the notoriously dismal clinical outcomes of TP53-mutated tumors. Further study should be warranted to confirm its efficacy and to develop an optimal post-remission therapy to overcome the short remission period.
with non complex del(7q) (P=ns for complex vs non complex, chi-square test). The ORR was 37.5% in “de novo” and 38.4% in secondary MDS, respectively (P=ns). Impact of AZA treatment compared to BSC on overall survival: Results of this multivariable analysis of OS at different time points are presented in Table 2. Chromosome 7 cytogenetic categories and IPSS retained a poor prognosis over time with a constant value of poor prognosis. AZA treatment had a favorable impact on OS during the first 3 years of treatment, compared to BSC, confirming results obtained in univariable analysis. Nevertheless, the benefit of AZA treatment as compared to BSC approach decreased as time spans and the HR value increased over time: HR of 0.3 at 6 months, 0.5 at 1 year and 0.7 at 2 and 3 years after treatment. (Figure 1). This benefit was present in all chromosome 7 categories with a a trend towards better impact among patients with complex karyotype but no significant differences between the 3 categories (-7, del(7q) and CK).

Figure 1.

Summary/Conclusions: This study confirms the benefit of AZA treatment on outcome in patients with HR-MDS and cytogenetic abnormalities involving chromosome 7.

P317

UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A TOLL-LIKE RECEPTOR 2 ANTIBODY, IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING AGENT THERAPY

G. García-Manero1,*, G. Montalbán-Bravo1, H. Yang1, Y. Wei1, Y. Alvarado1, C. DiNardo1, N. Daver1, M. Koriolpeva1, K. Hearn1, R. Miller2, S. Arbe-Barnes3, P. McRae4, T. Kearney5, R. Keogh6, H. Kantarjian1, M. Reilly7,1
1Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States, 2Opsona Therapeutics, Dublin, Ireland

Background: Alterations of innate immune signaling, including overexpression of TLR2, are common in MDS. Significant TLR2 overexpression in MDS bone marrow CD34+ cells, especially after HMA therapy, has been reported. OPN-305 is a fully humanized antagonistic IgG4 kappa monoclonal antibody to TLR2 which significantly increases the formation of erythrocytoid colonies (CFU-E) in BM CD34+ cells isolated from pts with lower-risk MDS in vitro.

Aims: To evaluate the potential therapeutic value of OPN-305 in patients (pts) with MDS.

Methods: We designed a phase I/II trial of OPN-305 for pts with Low or Int-1 risk MDS by IPSS after failure to prior therapy with a HMA (n=4 cycles). Pts whose WBC count was to be transfusion dependent (≤2 units in 8 weeks). Pts with isolated del(5q) should have received therapy with lenalidomide. Because, OPN-305 had not been previously used in pts with hematological malignancies, the study had an initial phase of N=10 pts using OPN-305 at a dose of 5 mg/kg every 4 weeks for a maximum of 9 cycles. Therapy could be repeated as long as there was no excess toxicity or progression. If after 16 weeks of therapy, there was no response, azacitidine on a 3 day schedule, could be added to OPN-305. Responses were evaluated following the revised 2006 IWG criteria. This initial cohort allowed evaluation of toxicity, pharmacokinetic analysis, receptor occupancy, and sequential analysis of cytokine profile. An extension dose escalation phase to 10mg/kg was planned for N=30 pts.

Summary/Conclusions: Treatment with OPN-305 in pts with previously treated lower-risk MDS was well tolerated with no significant toxicities and 53% ORR including 20% transduction independence, and potential association between TLR2 levels and response.

P318

IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS

1Hematology Department, University Hospital of Salamanca, 2Department of Statistics, 3Centro de Investigación del Cáncer, IIBMCC Instituto de Biología molecular y celular del cáncer, University of Salamanca, 4Molecular Biology Department, University Hospital of Salamanca, Salamanca, 5Hematology, University Hospital La Fe, Valencia, 6Hematology and Medical Oncology Department, University Hospital Doctor Negrín, Las Palmas de Gran Canaria, 7Hematology and Cellular Therapy, University Hospital Vall d’Hebron, Barcelona, 8Area of Genetic and Cellular Therapy, IBSAL Instituto BioSanitario de Salamanca, Salamanca, Spain

Background: Approximately 90% of patients with Myelodysplastic Syndromes (MDS) have somatic mutations in driver genes detected by Next Generation Sequencing (NGS). In the last years, several studies have related these mutations with prognosis, disease characteristics and response to therapy, including allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Development of Chronic Graft Versus Host Disease (cGVHD) has been reported as one of the most powerful antineoplastic mechanisms after HSCT.

Aims: To evaluate the impact of specific somatic mutations in patients with MDS undergoing HSCT and if the development of cGVHD can modify their clinical course.

Methods: The results of HSCT in 115 MDS patients from five centres in Spain were retrospectively analyzed. Bone marrow samples were collected a median of 27 days prior to transplant and DNA was screened for somatic mutations by NGS, using a NextSeq platform (Illumina). Two myeloid genes panels that included the most frequently mutated genes in myeloid malignancies were used.

Results: Median age was 53 years (range from 19 to 70). Fifty-eight percent were male and 79.13% were classified as de novo MDS. According to WHO 2008 classification 4 (3.5%) were RCUD, 2 (1.8%) RARS, 22 (19.5%) ROMD, 28 (24.8%) RAEB-1, 32 (28.3%) RAEB-2, 12 (10.6%) Unclassifiable MDS, 9 (8%) CMML and 4 (3.5%) were AML (FAB RAEB-T). Among patients with calculated Revised IPSS (R-IPSS) (85 of 115 patients) 2 (2.4%) had very low risk, 15 (17.6%) low risk, 21 (24.7%) intermediate risk, 22 (25.9%) high risk and 16 (18.6%) had very high risk; 9 patients with CMML (10.6%) were categorized among responders or non-responders or based on OPN-305 dosing. A trend to increased response was observed in patients with higher TLR2 expression, among responders or non-responders or based on OPN-305 dosing. 

Summary/Conclusions: Treatment with OPN-305 in pts with previously treated lower-risk MDS was well tolerated with no significant toxicities and 53% ORR including 20% transduction independence, and potential association between TLR2 levels and response.
We also observed the unfavourable impact of TP53 mutations on relapse risk: CIR was 41.7% (95% CI 22.5-77.1) at 1 year for TP53 mutated vs 9.8% (95% CI 5.3-18.1) at 1 year for non TP53 mutated patients (p=0.006).

Summary/Conclusions: We conclude that the number of mutated genes prior to transplant could be a prognostic factor of OS and CIR. Mutations in some genes, like TET2 and TP53, could also have an adverse impact on outcome. However, cGVHD could ameliorate the poor prognosis of somatic mutations in transplanted patients with MDS.

P319

VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME: A PHASE 1/COHORT EXPANSION STUDY

M.A. Jacoby1,*, M.J. Walter1, J.F. DiPersio1, C.N. Abboud1, P. Westervelt1, A.F. Cashen1, K. Stockerl-Goldstein1, T. Fletcher1, G.L. Uy1

1Medicine, Washington University Medical School, St. Louis, United States

Background: Although hypomethylating agents are the mainstay of treatment for myelodysplastic syndromes (MDS), these agents result in remissions in a minority of patients and are not curative. Vosaroxin is a first-in-class quinolone derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin is active with a tolerable safety profile in acute myeloid leukemia (AML) and the novel combination of vosaroxin and azacitidine was found to be synergistic in primary myeloblasts.

Aims: This phase 1/cohort expansion study was designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of vosaroxin when given in combination with azacitidine, and to evaluate the efficacy and safety of the combination treatment.

Methods: Patients with MDS ≥18 years old with cytopenias requiring transfusions, an IPSS score of intermediate (INT)-1 or greater, or chronic myelomonocytic leukemia were eligible. Vosaroxin (initial dose: 50 mg/m2/d) was administered on Days 1 and 4, and azacitidine (75 mg/m2/d) on Days 1-7 of a 28-day cycle, in an outpatient setting, for up to 6 cycles in a 3+3 design (additional cycles were permitted if a clear benefit for the patient was demonstrated). Once the MTD was determined, an expansion cohort of 20 evaluable patients (≥1 cycle) was enrolled.

Results: A total of 35 patients enrolled in the dose escalation (n=13) and expansion (n=22) phases. The median age of the entire cohort was 66 years (range 38-77) with IPSS scores of low (n=1); INT-1 (n=13); INT-2 (n=15); and high risk (n=6). The median ECOG score for the entire cohort was 1 (range 0-2). In the dose escalation phase, at the initial dose of vosaroxin 50 mg/m2/d (n=6), the median number of total cycles was 2 (range: 1-4); 2 of 6 patients experienced a DLT at this dose (grade 4 hyperbilirubinemia and grade 4 neutropenia >42 days). At the de-escalated dose of 34 mg/m2/d (n=7), the median number of cycles was 2 (range: 1-18); 1 patient experienced a DLT at this dose (grade 4 mucositis). The MTD of vosaroxin was determined to be 34 mg/m2/d and this dose was used in the expansion phase. Incidences of grade 3 non-hematologic adverse events considered possibly, probably, or definitely drug-related for the total cohort (n=35) included infections (n=38), non-neutropenic fever (n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colic/dysphagia; n=4). Two deaths were considered possibly treatment-related (sepsis and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treatment was observed, even with prolonged therapy. Of the 35 enrolled patients, 32 have completed ≥1 cycle and are evaluable for response. Among these patients, median number of cycles completed is 3 (range, 1-18), with 5 still continuing with therapy. Best response rates are shown in the Table 1. The median number of cycles to best response was 1 (range: 1-6). Sixteen patients have received transplant to date.

Summary/Conclusions: The MTD of vosaroxin in MDS patients was 34 mg/m2/d when given on Days 1 and 4 with a fixed dose of 75 mg/m2 of azacitidine on Days 1-7. The major non-hematologic toxicities were infections, febrile neutropenia, and bleeding. The combination of vosaroxin and azacitidine showed promising activity with responses rates comparable or better than those generally observed with azacitidine alone. Additionally, the transplant rate observed was encouraging in this patient population.
Myeloma and other monoclonal gammopathies - Biology

P320
ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE

S. Barrio1, M. Da-Via1,2, T. Stühmer1, A. Gartano-Trojaola1, L. Brunis3, I. Cuenca4, M. Schreder1, R. Tiber1, P. Sonneveld3, M.S. Raab1, J. Martinez-Lopez2, A. Rosenwald3, R.C. Bargoo1, E. Braggio1, A.K. Stewart1,10, H. Einsele1, K.M. Kortüm1
1Hematology, Würzburg University Hospital, Würzburg, Germany. 2Hematology-Oncology, IRCCS Policlinico San Matteo, Pavia, Italy. 3Hematology, Mayo Clinic, Scottsdale, United States. 4Hematology, Doce de Octubre University Hospital, Madrid, Spain. 5Hematology, Erasmus Medical Center, Rotterdam, Netherlands. 6Hematology, Heidelberg University Hospital, 7German Cancer Research Center, Heidelberg, 8Pathology Institut, Würzburg University Hospital, 9Comprehensive Cancer Center Mainfranken , Würzburg University Hospital, Würzburg, Germany. 10Center of Individualized Medicine, Mayo Clinic, Rochester, United States

Background: The amount of genomic data available in Multiple Myeloma (MM) is exponentially increasing, however, hardly any of that information is translated into the clinic. A number of genes has been associated with resistance to commonly used anti-MM compounds. This, most importantly, includes immunomodulators (IMiDs) and proteasome inhibitors (Ps). However, no mutation screening has yet been attempted to our MM routine diagnostic workflows. We investigated 458 MM patients by targeted sequencing, including the largest cohort of previously treated MM patients so far. We identified an increased mutation incidence in treated patients, yet unreported mutations and functionally validated a subset.

Aims: To describe the mutational spectrum in genes of pathways targeted by standard of care (SOC) therapies in a cohort of pretreated and previously untreated patients.

Methods: Tumor-germ line paired samples of five contributing sites were pooled (Würzburg, Heidelberg, Madrid, Rotterdam and Mayo Clinic). Analysis included 310 untreated and 148 IMID and/or PI treated patients. Targeted sequencing was performed using the MIP (v2.0 or v3.0) gene selection, that includes most commonly mutated MM genes, actionable drug targets and genes being associated with drug resistance. Average sequencing depth increased 700X. Functional analyses of PSMB5 mutations were conducted using Sleeping beauty vectors transposed into AMO1 cell line.

Results: Our analysis included five genes each with known association to drug response to IMiDs (CRBN, CUL4B, IKZF1, IKZF3 and IRF4) and Ps (PSMB5, PSMB8, PSMB9, PSMD1 and XBPF1). Based on the increased sequencing depth, the mutation incidence in untreated patients is higher than in the CoMM-Pass dataset (IMiDs: 5.8% vs 3.9%; Ps: 1.9% vs 1.4%). Furthermore, pretreated patients showed a significant mutational increase compared with untreated pts (IMiDs: 19.7%, Z-score: -4.2; Ps: 7.3%, Z-score: -2.6, p=0.009). We observed a Gly159Arg mutation within the Lenalidomide (Len) degron sequence of IKZF3 in a patient progressing on Len and Pomalidomide (Pom), as well as two XPB1 truncating mutations in PI refractory patients. Of note, among three treated cases with mutations in the β5 (PSMB5) or βi (PSMB8) PI binding subunit of the proteasome, one patient harbored not less than 4 subclonal mutations. This is the first description of PSMB5 mutations in human MM, identified in a patient with long term history of PI treatment. All mutations were located in or close to the Bor binding site of PSMB5. The functional analysis demonstrated induction of resistance not only to Bor (IC50wt=2 nM vs IC50mut=4.5-8 nM), but also to the second generation PI ixazomib (IC50wt=5.2 nM vs IC50mut=N/A) and Carfilzomib (IC50wt=8 nM vs IC50mut=13-22 nM). Of interest, the P97 blockade of the protein homeostasis by the investigational compound CB5083 remains still possible in the mutated cell lines and the resistance can be overcome. Finally, Pom treatment eradicated two of the PSMB5 containing subclones (Figure 1).

Summary/Conclusions: Under the selective pressure of anti-MM therapy the incidence of mutations in genes associated with drug resistance increases in MM. Resistance mechanisms evolve in parallel in competing (sub)clones of the disease, mimicking phenotype and behavior. Remarkably, despite our restrictive gene selection, a quarter of our treated cohort is affected by at least one mutation. Aim of future therapy may be the eradication of selected clones or subclones, which, according to our data, appears possible.

P321
ILF2-YB1 INTERACTION MODULATES RNA SPlicing TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA

M. Marchesini1,2, O. Gogol1, E. Fiorni1, M. D’Ancia2, P. Storti1, L. Nezi1, M. Kemaili3, I. Ganan-Gomez1, M.T. Fulciniti1, L. Zhang1, N. Giulian1, Z. Bohannan1, K. Clise-Dwyer7, N. Munshi5, R. Orlowsky8, G. Garcia-Manero1, R.A. DePinho9, S. Colla1
1Leukemia, MDAnderson Cancer Center, Houston, United States. 2Neurology, University of Milan, Milan, Italy. 3Clinical and Experimental Medicine, University of Parma, Parma, Italy. 4Genomic Medicine, MD Anderson Cancer Center, Houston, TX. 5Hematology, Mayo Clinic, Scottsdale, United States. 6Pathology Institut, Würzburg University Hospital, Würzburg, Germany. 7Stem cell transplantationa and cellular therapy, 8Cancer Biology, MD Anderson Cancer Center, Houston, United States

Background: The 1q21 amplification, which occurs in approximately 40% of de novo and 70% of relapsed Multiple Myeloma (MM), is among the most frequent chromosomal aberrations in MM patients and is considered a very high-risk genetic feature that is especially correlated with disease progression and drug resistance. The 1q21 amplicon contains many genes, and while it is unlikely that all contribute to the pathobiology of high-risk MM, the critical genes that do drive this high-risk phenotype have not yet been fully clarified. Identifying such genes and their contributions to this phenotype would enable the development of new and effective targeted therapy strategies for high-risk MM and thus improve their survival outcomes.

Aims: In our study we wanted to investigate the biological and molecular mechanisms behind the 1q21 amplification’s contribution to high-risk MM with the ultimate goal of obtaining a list of validated therapeutic targets to inform the design of novel translational clinical trials for this subgroup of patients.

Methods: We conducted a high-resolution analysis of recurrent copy number alterations and expression profiles in a collection of 254 MM samples included in MMRC database. To define the discrete minimal 1q21 region that is recurrently amplified in MM, we used Genomic Identification of Significant Targets in Cancer, a systematic method that identifies regions of genome that are recurrently amplified or deleted across a set of samples. These regions were enlisted into an in vitro screening strategy that employed a single-shRNA-per-96-well approach and GFP-competitive cell growth assay to identify 1q21 genes whose loss of function resulted in the selective death and/or growth inhibition of MM cells carrying the 1q21 amplification but not MM cells without the 1q21 amplification.

Results: We identified MCL1, UBAP2L, INTS3, LASS2, KRTCAP2 and ILF2 as potential 1q21-specific vulnerability targets whose expression is driven by copy number functionally validated, both in vitro and in vivo, Interleukin-2- enhancer binding factor 2 (ILF2) as a key 1q21 amplification-specific gene. Our results show that ILF2 impacts homologous recombination (HR) and induces resistance to DNA damaging agents routinely used in the treatment of MM, which is consistent with the observation that ILF2 expression correlates with poor survival in MM patient treated with high-dose melphalan followed by tandem autologous transplantation. On the mechanistic level, ILF2 interacts with numerous RNA binding proteins directly involved in the regulation of DNA Damage Response (DDR) by modulating alternative splicing of specific pre-mRNAs. RNA sequencing experiment confirmed that ILF2 knockdown results in aberrant splicing of genes involved in the DDR pathways and, strikingly, ILF2 RIP-seq analysis showed that ILF2 directly binds to transcripts involved in the regulation of the HR pathway, including components of BRCA1 protein complex. Furthermore, we found that ILF2 mediates drug resistance in dose-dependent manner by modulating YB-1 nuclear localization and interaction with the splicing factor U2AF65 to promote mRNA processing and stabilization of DDR genes in response to DNA damage (Figure 1).

Summary/Conclusions: In our study, we reveal an intimate relationship among 1q21 amplification, mRNA splicing and DNA repair in the control of DDR in MM. On the basis of our findings, we propose that 1q21-driven ILF2 overexpression deregulates HR by stabilizing the mRNA splicing of critical HR
factors, which enables genomic instability, promotes adaptive mechanisms to genotoxic stress, and enhances cell survival, thereby promoting drug resistance and disease progression. Given that 1q21 amplification is one of the most frequent copy number alterations in cancer, synthetic lethality approaches based on targeting gain-of-function associated to ILF2 may have a broad spectrum of application to potentiate the sensitivity of cancer cells to chemothapeutic agents.

Figure 1.

P322

PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

M. D’agostino1,2, S. Oliva1, S. Spada1, M. Gambella1, M. DeRome2, M. Cavo3, M. Aglietta1, M. Offidani1, J. Yesil2, D. Oddolo1, C. Cerrato1, A. Belotti1, A. Ledda1, L. Canepa3, M. Grasso3, R. Foà3, D. Auclair2, P. Musto1, A. Evangelista4, F. Gay1, A. Palumbo5, M. Boccadoro1, A. Larocca1
1Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy, 2Multiple Myeloma Research Foundation, (MMRF), United States, 3Italian Multiple Myeloma Network, GIMEMA, 4Unit of Clinical Epidemiology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO Piemonte, Torino, Italy, 5Myeloma Unit, Division of Hematology, University of Torino - Currently Takeda Pharmaceuticals Co., Torino, Zurigo, Italy, Switzerland

Background: High throughput techniques, such as next generation sequencing, are becoming an appealing approach to characterize multiple myeloma (MM) genomic profiles and better define risk assessment. However, the clinical relevance of such approaches is still largely unknown. The Multiple Myeloma Research Foundation (MMRF) CoMMpass trial (NCT01454297) has collected data from 1154 newly-diagnosed MM patients enrolled worldwide. Comprehensive analysis of somatic mutations in MM cells at diagnosis could unravel prognostically relevant disease characteristics not detectable with traditional approaches.

Aims: We analyzed data from the interim analysis 8 cohort (August 2015) to create a prognostic model.

Methods: CD138+ purified MM specimens from bone marrow aspirates and peripheral blood cells were collected at diagnosis. Whole exome libraries from both tumor and constitutional DNA samples were created. Somatic single nucleotide variants (SNV) were identified, only nonsynonymous SNV were included in the analysis. We evaluated the impact on progression free survival (PFS) of recurrently mutated genes (with at least a nonsynonymous SNV with an allele frequency of more than 5% in more than 10 patients) in a multivariable analysis. Median age at diagnosis was 64 years (range 27-93), all patients received novel agents as first line treatment, 236 (45.6%) received autologous stem cell transplantation (ASCT). The most recurrent mutated genes were KRAS (25%) and NRAS (19.5%). Consistently with other works, DNA allele frequency stem cell transplantation (ASCT). The most recurrent mutated genes were KRAS (25%) and NRAS (19.5%). Consistently with other works, DNA allele frequency

Figure 2.

Summary/Conclusions: The use of a prognostic model based on the mutational status of 9 recurrently mutated genes could improve risk assessment of newly-diagnosed MM patients. Longer follow-up and validation in independent cohorts of patients are needed to confirm our findings. Updated results with a longer follow-up will be presented at the meeting.

P323

TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA

S. Manier1,2, D. Huynh2, J. Park2, K. Salem3, X. Leleu3, I. Ghobrial4
1Hematology, Lille Hospital, Lille, France, 2Medical Oncology, Dana-Farber Cancer Institute, Boston, United States, 3Hematology, University of Lille 2, Lille, France, 4Medical Oncology, Dana-Farber Cancer Institute- Harvard Medical School, Boston, United States

Background: Gain of 1q is one of the most frequent copy number variations across cancer types and in Multiple Myeloma (MM). Gain of 1q is associated with a poor outcome, indicating it is a potential driver in MM progression and resistance to treatment. While the whole 1q arm can be amplified in some cases, a specific minimal amplified region has been identified by CGH array, including approximately 500 genes in the 1q21.1-23.3 region. However, the driver genes in the 1q region are unknown.

Aims: We hypothesize that specific genes present in the 1q minimal amplified region are critical regulators of clonal evolution and tumor progression in MM.

Methods: To explore gene dependency in 1q21.1-23.3 in MM, lung, breast and
Methods: We used 14 cell lines including MM, lung, and breast cancer cell lines. We designed a pooled library targeted shRNA/shRNAs screen containing 6 shRNAs along with their matched control for each of the 500 genes in the 1q21.23-3 region, including IncRNA and mRNA in addition to protein coding genes. The pooled library contained 6500 shRNAs, including C911 controls as a control. We used the RIGER software to call hits, using the Kolmogorov-Smirnov algorithm. To complement the 1q-targeted shRNA screening, we studied the IMiD-resistant cell lines, we treated OPM2 and NCI-H929 continuously with increasing doses of either lenalidomide or pomalidomide for 4-6 months, until cell viation decreased in chromatin accessibility and to a much lesser extent with DNA methylation changes. Interestingly, neither CRBN nor any of the other molecules involved in the CRBN pathway (IKZF1, IKZF3, IRF4) exhibited changes in either promoter DNA methylation or chromatin accessibility. We then treated the IMiD-resistant cells with the combination of 5-Aza-2-deoxycytidine (a DNMT1 inhibitor) and EPZ-6438 (an EZH2 inhibitor) for 48 hours, before exposing the cells again to IMiDs, and found that resistant cells treated with this combination showed increased sensitivity to 5-Aza-2-deoxycytidine and EPZ-6438, significantly increased apoptotic response, similar to the sensitive cell lines. Even more interestingly, we found that the treatment with 5-Aza and EPZ-6438 almost completely restored the global chromatin accessibility changes associated with acquired IMiD resistance back to the initial state, even though the cells we observed the changes in chromatin accessibility, we found that the treatment with 5-Aza and EPZ-6438 was also effective in sensitizing the majority of cell lines with intrinsic resistance to IMiDs. We also observed that treatment with the combination of 5-Aza and EPZ-6438 failed to induce a significant upregulation of CRBN in the IMiD-resistant cell lines, thus suggesting that the process involved in acquiring resistance to IMiDs is CRBN-independent. Moreover, we show that the degradation of IKZF1 is abrogated on the resistant cell lines, and remains as such despite their resensitization, meaning that the CRBN-IKZF1/IKZF3 pathway might be bypassed and other important regulatory networks might be as important for sensitivity to IMiDs. Therefore, we are currently performing RNA-seq, which might, in combination with accessibility data, give information about the regulatory mechanisms behind acquired IMiD resistance.

Summary/Conclusions: In conclusion, our study is the first one to ever show that acquired IMiD-resistance is mainly an epigenetic event that is potentially reversible through a combination of two epigenetic compounds, 5-Aza-2-deoxycytidine and EPZ-6438. These drugs have been shown to have low levels of toxicity, thus making them very good candidates for a prospective phase I study to examine their potential as "IMiD-resensitizers," which may improve the outcome treatment of MM patients with drug-resistant myeloma clones and a potentially high-risk disease.

P325 MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANCER ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA

R. Ordoñez1,*, M. Kulis2, N. Russiniol2, R. Beekman3, C. Meydan4, N. Verdaguer-Dot2, A. Carrasco1, T. Ezponda1, J.H. Martens5, H.G. Stunnenberg5, B. Paiva6, J. San Miguel7, A. Meilicke8, E. Camacho9, F. Prosper9, Y. Agirre1, J.I. Martin-Suber2

1Oncohematology, Center for Applied Medical Research (CIMA), Pamplona, 2Departamento de Fundamentos Clinicos, Universitat de Barcelona, 3Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 4Dept. of Medicine, Weill Cornell Medical College, New York, United States, 5Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands, 6Cen- ter for Applied Medical Research (CIMA), 7Clinica Universitaria de Navarra, Pamplona, 8Hospital Clinic, Barcelona, Spain

Background: Most of the published omics studies in multiple myeloma (MM) have focused on the analysis of the genome, transcriptome and DNA methy- lome. Over the last years, the chromatin structure and histone modifications are emerging as essential epigenetic layers to understand gene deregulation in MM. Although this field remains widely unexplored in MM.

Aims: We herein aim to elaborate a comprehensive description of the MM genome including multiple layers of information.

Methods: We performed ChIP-seq of six histone modifications with non-overlapping functions (H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3, and H3K9me3), ATAC-seq for chromatin accessibility, Whole Genome Bisulfite Sequencing (WGBS) for DNA methylation, and RNA-seq for gene transcription in purified bone marrow plasma cells from 4 MM patients and, as healthy controls, naive B cells, germinal center B cells, memory B cells and plasma cells. Data were extensively mined using a battery of different bioinformatic tools.

Results: We performed a quantitative comparison of MM and healthy controls. HiChromatin interaction networks across chromosomes and regions with differential expression were detected over 13000 with differentially expressed genes. We identified 15000 pairs with significantly increased activity in MM as compared to normal controls. These findings were further validated by ChIP-seq in another collection of 10 MM patients. We next focused on the genes that gained novo activity in MM and were completely inactive (i.e. hypochromatic) in normal
Summary/Conclusions: Our data identifies for the first time a subgroup of MM patients (6.25%) with no morphological evidence of MDS/AML prior to transformation to MDS/AML. Aims: To ascertain baseline mutation landscape [especially low-level clones with variant allele frequency (VAF) ≥5%] of MDS/AML associated gene mutations in HSCs prior to ASCT in order to predict patients at risk of clonal evolution, transformation to MDS/AML.

Methods: DNA was isolated from mononuclear cells (MNCs) collected by leukapheresis prior to ASCT from 128 MM patients. A customised amplicon-based Illumina MiSeq panel was used for the sensitive interrogation of 24 most common genes harboring mutations in MDS/AML (splicing factor genes; KIT, JAK2, SF3B1, SRSF2, U2AF1 and ZRSR2, genes implicated in epigenetic regulations; TET2, IDH1/2, ASXL1, EZH2 & DNMT3A, known oncogenes/gene involved in cell signalling/transcription regulation and cohesion complex; TP53, FLT3, NRAS, KIT, ETV6, RUNX1, CCBL, C-KIT, JAK2, MPL, CEBPA, STAG2, GATA2, KDM6A and NPM1). Variant analysis was performed using Illumina Variant Studio (≥5% VAF & read depth ≥150X thresholds for multiple Mycoplasma for the lack of germ line material to confirm the somatic nature of the variants. SNPs occurring at a frequency of ≥0.001% in the healthy population [e.g. dbSNP132, UCSC genome browser, Exome sequencing project (esp6500), Exome Aggregation Consortium (EAC) were excluded.

Results: Seven patients (6.25%) contained heterozygous somatic mutations (VAF range 7-50%) in DNMT3A, IDH1, IDH2, TET2, ETV6 and CBL genes (Table 1). Four missense mutations identified in DNMT3A were aggregated in the Mds3a domain responsible for its methyltransferase activity indicating a strong intention to abrogate this function. Previous studies confirm R882 variant in the Mtase domain responsible for its methyltransferase activity indicating a strong intention to abrogate this function. Prior oncoprotein R882 variant (for ~60% DNMT3A mutations) as a founder lesion in MDS/AML. The signaling lymphocytic activation molecule family 3 (SLAMF3) is a member of the immunoglobulin superfamily expressed on T, B, and natural killer cells and modulates the activation and cytotoxicity of these cells via self-ligand binding. SLAMF3 is also expressed on plasma cells from patients with multiple myeloma (MM), although its role in MM pathogenesis remains unclear.

Aims: To clarify this, we investigated the expression and functions of SLAMF3 in MM.

Materials: 1) Two hundred thirty patients comprising 153 newly diagnosed (19 asymptomatic and 134 symptomatic) MM patients, 30 refractory/refractory MM patients, and 47 patients with monoclonal gammopathy of undetermined significance were enrolled. SLAMF3 and CD138 expression levels on clonal plasma cells were analyzed using flow cytometry (FCM). Soluble SLAMF3 (sSLAMF3) assay levels were measured using ELISA. 2) Drug sensitivity to anti-myeloma agents (melphalan and bortezomib) and the proliferation potential in MM cell lines KMS18 and U266 were analyzed using FCM and the MTT assay. SLAMF3 knockdown MM cell lines were obtained using the lentiviral shRNA system and siRNA. Stable transduced KMS34 cell lines expressing full-length SLAMF3 and cytoplasmic domain-truncated SLAMF3 (sASM) were established through corresponding vectors. Single-nucleotide polymorphism (SNP) genotyping was analyzed by real-time PCR. The adaptor protein of SLAMF3 was identified by Western blotting and immunoprecipitation.

Results: 1) SLAMF3 was highly expressed on plasma cells in almost all MM patients, even in relapsed/refractory disease, although CD138 expression levels were decreased in some with advanced disease. 2) The proliferative potential and percentage of antitymelyoma agent-induced apoptosis in SLAMF3-positive MM cells were significantly higher and lower than in SLAMF3-negative MM cells, respectively. The cell proliferation and drug resistance in SLAMF3-expressing KMS34 cells were comparable in comparison with SLAMF3-negative KMS34 cells. That malignant potential of MM cells was cancelled by SLAMF3 knockdown. Furthermore, the proliferation of MM cells and resistance to antitymelyoma agents were inhibited by anti-SLAMF3 antibody. Adaptor proteins, SHP2 and GRB2, were expressed in MM cell lines, but neither SAP nor EAT-2 were. SLAMF3 interacted directly with SHP2 and GRB2, and SHP2 also interacted with GRB2. SHP2 inhibitor-treated or SHP2/GRB-knockdown cells had characteristics similar to SLAMF3-knockdown cells. 3) The frequency of GG genotypes of SLAMF3 SNP rs509749 in MM patients was 63.6% (n=28), of AG 29.5% (n=13), and of AA 6.8% (n=3). Patients with GG genotypes tended to have shorter overall survival times than patients with AG genotypes. 4) sSLAMF3 levels were significantly higher in symptomatic MM than in asymptomatic MM and markedly increased in advanced MM. MM patients with high levels (≥3.3 ng/ml; n=62) of sSLAMF3 progressed to the
advanced stage significantly more often and had shorter progression-free survival times than those with low levels (3.3 vs. 9.3 months, p=0.032).

Summary/Conclusions: This study revealed that SLAMF3 molecules consistently expressed on MM cells may transmit positive signals mediated via the complex of SHP2 and GRB2 by self-ligand interaction between MM cells and induce a high malignant potential in MM. Furthermore, high levels of serum sSLAMF3 may reflect MM disease progression and be a useful prognostic factor in MM. Thus, SLAMF3 molecules may be a new potential target for future immunotherapy and chemotherapy.

P328

TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE, STRO-001

M. Lupher1, A. Molina1,*
S. Krueger2, S. Matheny 1, T. Kline 1, A. Yam 1, R. Stafford 1, T. Hallam 1, M. Lusher1, A. Molina1,*
1Sutro Biopharma, South San Francisco, 2MI Biorsearch, Ann Arbor, United States

Background: CD74 is a transmembrane glycoprotein involved in MHC protein formation and transport. CD74 expression has been observed in up to 90% of B-cell malignancies, including multiple myeloma (MM), with minimal expression in normal tissues. CD74 is rapidly internalized, making it an attractive target for ADCs. STRO-001 is a novel ADC comprised of an aglycosylated anti-CD74 IgG1 human antibody (SP7219) conjugated covalently to the non-natural amino acid para-azido-methyl-L-phenylalanine (pAMF) with a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead. Highly efficient site-specific conjugation enabled by novel cell-free antibody production and click chemistry results in a well-defined homogeneous ADC drug product with a drug-antibody ratio (DAR) of 2.

Aims: The in vitro cytotoxicity and in vivo efficacy of STRO-001 was investigated in MM cell lines and xenografts. An exploratory toxicity study was conducted in a non-human primate model.

Methods: DISCO-Alexa647-conjugated SP7219 staining and flow cytometry were used for detection and quantitation of CD74 expression on MM cell lines. STRO-001 was used to determine the EC50 and percent span of killing in MM cell lines. The anti-tumor activity of STRO-001 was evaluated in the disseminated ARP-1 and MM.1S MM models. In vivo bioluminescence imaging (BLI) for animals bearing MM.1S-luc cells was performed using an IVIS Spectrum. BLI images were collected 7, 14, 21, and 28 days post-tumor inoculation. STRO-001 was administered to cynomolgus monkeys in an exploratory dose-escalating study of repeat IV doses of 1, 3, 10, and 30 mg/kg on days 1 and 15.

Results: In vitro cytotoxicity assays show nanomolar potency of STRO-001 in five MM cell lines: MC/CAR (EC50 0.8 nM), ARD (EC50 6.5 nM), MM.1S (EC50 10–11 nM), U266B1 (EC50 8.5–9.3 nM), and ARP-1 (EC50 4.3–22 nM). CD74 cell surface expression is required for STRO-001 cytotoxic activity but expression level, as measured by antibody-binding capacity, does not correlate strongly with in vitro potency (R²=0.5837 for MM cell lines). STRO-001 inhibits the growth of CD138+ plasma cells in bone marrow (BM) and migration of visceral tumors (p=0.002 for kidney; p=0.0001 for ovary) after 4 weekly doses of 3 mg/kg in the ARP-1 disseminated MM xenograft model. STRO-001 dosed at 3 mg/kg and 10 mg/kg weekly x 3 also eradicates malignant BM plasma cells by day 32 post-inoculation (p<0.0001) and prolongs survival in the MM.1S disseminated model. At termination of the study, 129 days post-inoculation, 100% of the mice treated with STRO-001 survived and showed no evidence of disease with no CD138+ cells in their bone marrow, while mean survival of vehicle-treated control animals was 35 days with almost 50% of their bone marrow containing myeloma cells. BLI of luciferase-expressing MM.1S (MM.1S-luc) tumor cell lines enabled non-invasive quantification of tumor burden. Single doses of 1, 3, and 10 mg/kg STRO-001 (administered on day 7 post-inoculation) resulted in eradication of myeloma by day 28 based on bioluminescence signal and quantification of CD138+ cells in bone marrow. In addition, STRO-001 produced a dose-dependent reduction in normal B-cells in cynomolgus monkeys, providing pharmacodynamic evidence of B-cell targeting (Figure 1).

Summary/Conclusions: STRO-001 demonstrates potent in vitro cytotoxicity in MM cell lines and reduces tumor burden in MM xenograft models, including significant prolongation of survival in the MM.1S model. Based on these encouraging observations, STRO-001 is advancing to the clinic for the treatment of CD74-expressing B-cell malignancies.

P329

GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING

1Hematología traslacional, Hospital 12 de Octubre, Madrid, 2Centro de Investigacion Medica Aplicada, Pamplona, 3Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investiga- cion Biomédica (IBMC-SMC), 4Hospital General Universitario Gregorio Marañón, Madrid, 5Hospital Universitario de Salamanca, 6Hospital Clinico Universitario Valladolid, Valladolid, 7Hospital Virgen del Puerta, Plasencia, 8Hospital German Trias i Pujol, Badalona, 9Hospital de Cabueñes, Gijon, 10Complejo Hospitalario de Leon, Leon, 11Hospital Universitario de Burgos, Burgos, 12Hospital Clinico Universitario Lozano Blesa, Zaragoza, 13Hospital Rio Carrión, Palencia, 14Clinica Universidad de Navarra, Pamplona, Spain

Background: Immunoglobulin light-chain amyloidosis (AL) is a heterogeneous and multifactorial disease with high genetic complexity. Until now, no common factor or unique mutation associated with this disease has been described. Whole exome sequencing in Multiple Myeloma (MM) patient’s tests allowed to know important known important genes and pathways that are involved in the disease. However, few evidences through next generation sequencing (NGS) analysis were described in AL. Consequently, the application of NGS technologies permits unraveling the genomic landscape of AL to better disentangle the biology of the disease, allowing the identification of new therapeutic targets as in MM.

Aims: Genotype characterization of novel molecular alterations in AL plasma cell by whole-exome sequencing technology.

Methods: We studied 40 paired samples (sorted pathological plasma cells and peripheral blood) from 20 patients with AL. Whole exome and regulatory regions were captured using Agilent’s SureSelect Human All Exon V6+UTR kit and sequenced on the Illumina NextSeq 500 platform with pair-end sequencing technique with a global mean depth coverage of 70x, on target coverage of 96.5% and a Phred quality score of 91.3% up to Q30. Data were analyzed with Strelka software to discard germinal mutations, wANNOVAR for functional annotation, and a data reduction strategy to identify candidate variants.

Results: After analysis of patient samples we got an average of 76 (range 18-177) mutations per patient. 28.4% of the mutations was located on regulatory regions (5 UTR, 3’ UTR). So far, we did not identify recurrent mutations between the patients, although some patients presented different mutations on the same gene.

The mutation pattern was very heterogeneous between patients. We identified alterations in genes involved in extracellular matrix (MMP2), cell proliferation, differentiation and development (TFGA), transcription factors (ZFHX3, HNRPNP), adherent junction function (RASSF8), GTPases (RAPGEF2, RAB40A), and genes of the collagenase family (COL9A1, COL1A2) among others.

Summary/Conclusions: Taken together, these results suggest that the mutation pattern in AL is heterogeneous with no common mutated gene among all patients. However, we described novel mutations in the context of AL in regulatory genes or over-representing cancer-related pathways that can help to elucidate the molecular biology of the disease.
Myeloma and other monoclonal gammapathies - Clinical 1

P330
IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY
S. Thorsteinsdottir1,2, P.W. Dickman3, I. Turesson3, O. Landgren3, M. Hultcrantz5,6, M. Bjorkholm5, S.Y. Kristinsson1,4
1Department of Internal Medicine, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 2Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 3Department of Hematology and Coagulation Disorders, Skane University Hospital, Malmö, Sweden, 4Myeloma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, United States, 5Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, 6Myeloma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, Sweden

Background: Multiple myeloma (MM) is generally considered an incurable disease, however advances in the treatment options for MM have been great in recent years. Recent studies on these new agents indicate an improvement in survival, nevertheless population-based studies have had contradicting findings, especially in the elderly patients.

Aims: The aim of the study was to evaluate the survival of all patients diagnosed with MM in Sweden in the years 1973 to 2013 and to relate the survival pattern to trends in treatment strategies.

Methods: Patients diagnosed with MM in the period from January 1, 1973 to December 31, 2013 were identified from the Swedish Cancer Registry. Information on sex, date of birth, date of diagnosis, and date of death was collected. Relative survival ratios (RSRs) were used to provide a measure of excess mortality of MM patients compared to a comparable group from the general population. RSRs with 95% confidence intervals (CIs) were found for 1-, 5-, and 10-year survival for 4 calendar periods; 1973-1982, 1983-1992, 1993-2002, and 2003-2013 and furthermore for 6 age categories at diagnosis (0-40, 41-50, 51-60, 61-70, 71-80 and >80). Short-term survival, as defined by RSR of less than 3 months, was also defined for all calendar periods.

Results: A total of 21,465 patients (54% males, median age at diagnosis 72 years) with MM were recorded in the time period. Overall, the 1- and 5- and 10-year RSRs improved in the whole period, with the greatest improvement in the two most recent calendar periods. The 1-year RSR increased significantly between all calendar periods (0.69, 0.74, 0.77 and 0.82, respectively). The 5-year RSR increased significantly between the two last calendar periods (0.28, 0.31, 0.33 and 0.41, respectively; Figure 1) as well as the 10-year RSR (0.10, 0.12, 0.14 and 0.20, respectively). Short-term survival increased significantly between the first two and last two calendar periods (the RSR were 0.83, 0.88, 0.89 and 0.93 respectively). Females had a lower excess mortality compared to males (excess mortality ratio 0.91).

Figure 1.

Summary/Conclusions: In this population-based study, based on more than 21,000 MM patients diagnosed during more than a 40-year period, we showed that with an increased use of novel agents in MM patients, survival has improved significantly. This is especially prominent during the last 10 years. Our findings are important, since new agents are approved based on clinical trials, where certain groups, such as older patients and patients with significant comorbidities are often excluded.

P331
PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
1Department of Internal Medicine, 2Division of Hematology, 3Department of Laboratory Medicine and Pathology, 4Department of Nephrology and Hypertension, Mayo Clinic, Rochester, United States

Background: Cytogenetic evaluation using fluorescence in situ hybridization (FISH) at the time of diagnosis is essential for initial risk stratification in multiple myeloma. The presence of specific cytogenetic high-risk abnormalities (HRA) is known to confer a poor prognosis, less is known about the cumulative effect of multiple such abnormalities.

Aims: To evaluate the prognostic implications of the presence of multiple HRA at the time of diagnosis.

Methods: We studied 1181 patients who were diagnosed with multiple myeloma between July 2005 and July 2015 at Mayo Clinic Rochester, underwent FISH evaluation within 6 months of diagnosis, and received first-line therapy with at least 1 novel agent (immunomodulator or proteasome inhibitor). HRA were defined as t(4;14), t(14;16), del(17p), and gain(1q). Bone marrow aspirates were evaluated for deletions, monosomies, trisomies, and tetrasonomies using chromosome- or centromere-specific FISH probes. IGH rearrangements were evaluated using an IGH break-apart probe and evaluating up to 5 potential partners (FGFR3, CCND1, CCND3, MAF, and MAFB). Kaplan-Meier overall survival estimates were calculated and the log-rank test was used to compare overall survival in patients with and without HRA (stratified by the number of HRA). A multivariable-adjusted Cox regression model was used to assess the effect of HRA on overall survival adjusting for age, sex, International Staging System (ISS) stage, and first-line therapy (immunomodulator, proteasome inhibitor, upfront autologous hematopoietic stem cell transplantation). Patients diagnosed after 2014 (approximately 15% of the cohort) routinely underwent evaluation for gain(1q), therefore the hazard ratios represent conservative effect estimates. P-values below 0.05 were considered statistically significant.

Results: The median age at diagnosis was 65 years (28 - 95), 708 (60%) of the patients were male. There were 375 HRA in 327 patients (28% of the cohort): 170 (45%) del(17p), 110 (29%) t(4;14), 45 (12%) t(14;16), 8 (2%) t(14;20), and 42 (12%) gain(1q). Of the 280 patients with 1 HRA 130 (46%) had del(17p), 120 (43%) had a high-risk translocation, and 30 (11%) had gain(1q). Of the 46 patients with 2 HRA 34 (76%) had del(17p) and a high-risk translocation, 6 (13%) had a high-risk translocation and gain(1q), 5 (11%) had del(17p) and gain(1q), and 1 had 2 high-risk translocations. There was 1 patient with 3 HRA: del(17p) and t(4;14) and gain(1q). The median overall survival was 6.6 years (6.0 - 8.0) for the entire cohort (n=1181), 8.3 years (6.7 - 8.9) for those without HRA (n=854, 72%), 4.8 years (3.9 - 5.6) for those with one HRA (n=280, 24%), and 2.7 years (2.1 - 3.8) for those with 2 or more (2+) HRA (n=47, 4%). Figure 1 shows the Kaplan-Meier overall survival estimates stratified by the number of HRA (n=1181). The presence of 1 HRA (versus 0, HR 1.57, 95% CI 1.26 - 1.96, p <0.001, n=1181) and the presence of 2+ HRA (versus 1, HR 3.37, 95% CI 2.21 - 5.14, p <0.001, n=1181) were of prognostic significance after adjusting for age, sex, ISS stage, and first-line therapy. When adjusting for the revised ISS instead of the ISS the hazard was attenuated for 1 HRA (HR 1.21, 95% CI 0.92 - 1.60, p=0.180, n=1087) and 2+ HRA (versus 1, HR 2.82, 95% CI 1.81 - 4.40, p <0.001, n=1087).

Figure 1.

Summary/Conclusions: Approximately 1 in 4 patients with newly diagnosed multiple myeloma presented with 1 HRA at the time of diagnosis, approximately 1 in 25 with 2 or more HRA. These patients experienced inferior overall survival suggesting a cumulative effect of multiple HRA.
LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB

P.L. McCarthy1, S.A. Holstein2, S.-H. Jung3, M. Cooper4, C.J. Gibson5, E.A. Stadtmueller6, B. Winograd2, P. Richardson7

1Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, 2University of Nebraska Medical Center, Omaha, NE, 3Alliance Statistics and Data Center, Duke University, Durham, NC, United States, 4BresMed, Sheffield, United Kingdom, 5Cellgene Corporation, Summit, NJ, 6Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 7Dana-Farber/Partners CancerCare, Boston, MA, United States

Background: At a prespecified interim analysis (December 2009), the phase 3 CALGB/ECOG 100104 (Alliance) study results surpassed the prespecified superiority boundary (significantly improved progression-free survival [PFS] for lenalidomide [LEN] maintenance vs placebo [PBO] after SCT) and the majority of PBO arm patients without progressive disease (PD) crossed over to LEN maintenance. An updated analysis (cutoff March 2015) showed significantly longer overall survival [OS] with LEN maintenance (HR, 0.56; 95% CI, 0.42-0.76). However, the crossover from PBO to LEN makes it difficult to assess the true treatment effect of LEN.

Aims: To examine the effect of LEN vs PBO on OS and PFS from randomization, adjusting for effects of crossover.

Methods: The rank-preserving structural failure time model (RPSFTM; Robins, *Commun Stat Theory Methods*, 1991) was used for crossover adjustment; the iterative parameter estimation (IPE; Branson, Stat Med, 2002) algorithm was used as validation. Survival was partitioned assuming a residual LEN effect after discontinuation. A landmark analysis was also performed at the Dec 2009 interim for patients who remained on treatment. Patients in the trial provided informed consent.

Results: Patients were randomized to LEN maintenance (n=231) and PBO (n=229) (intent-to-treat [ITT] population); 76 patients without PD crossed over from PBO to LEN. The median time from randomization to crossover was 11.5 months. The relative treatment effect for OS and PFS increased for LEN vs PBO when adjusting for crossover using RPSFTM and IPE (Table 1). The landmark analysis at the Dec 2009 interim (PBO crossover, n=76) showed the treatment effect is not dissimilar to the ITT analysis (HR 0.53; 95% CI, 0.25-0.76). Sensitivity analyses showed consistent results. Updated data will be presented at the meeting.

Table 1.

Summary/Conclusions: Adjusting for the potential diluting effects of crossover reduced median OS and PFS with PBO, and improved the treatment effect in the ITT analyses for OS and PFS for LEN vs PBO maintenance after SCT. The statistical significance of the ITT analyses was maintained throughout.

P334

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RVD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX


1National and Kapodistrian University of Athen, Athens, Greece, 2Hematology, University Hospital Hôtel-Dieu, Nantes, France, 3Karolinska Institute and the Department of Clinical Medicine, Karolinska University Hospital at Huddinge, Stockholm, Sweden, 4Vejle Hospital and University of Southern Denmark, Vejle, Denmark, 5University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany, 6Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 7Department of Lymphoma/Hematoma, The University of Texas MD Anderson Cancer Center, Houston, United States, 8Department of Haematology, University College London Hospitals NHS Trust, London, United Kingdom, 9Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, 10Institut Català d’Oncologia, HGTIP, Barcelona, Spain, 11Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, 12Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain, 13Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 14Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, 15Janssen Research & Development, LLC, Spring House, PA, United States, 16Janssen Research & Development, Beere, Belgium, 17Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada

Aims: To provide updated efficacy and safety data from POLLUX, a multicenter, phase 3, randomized study of DRR vs Rd in RRMM.

Methods: Eligible patients with ≥1 prior line of therapy were randomly assigned to Rd (25 mg PO lenalidomide on Days 1-21 of each 4-week [Q4W] cycle) or DRR (Rd plus daratumumab) given with or without IV dexamethasone at 10 mg weekly for Cycles 1 and 2, every 2 weeks for Cycles 3-6, then Q4W until disease progression). Patients who were refractory to lenalidomide were excluded. Progression-free survival (PFS) was the primary endpoint.
marrow samples were collected, and minimal residual disease (MRD) was assessed at the time of suspected complete response (CR) and at 3 and 6 months after suspected CR at 3 different sensitivity thresholds (10⁻⁴, 10⁻⁵, and 10⁻⁶) using the ClonoSEQ™ next-generation sequencing-based assay ( Adaptive Biotechnologies, Seattle, WA). Additional reflex testing using an anti-idio- type antibody was used to confirm CRs in cases in which daratumumab interference with serum M-protein quantitation was suspected in patients with possible CR.

Results: Patients received a median (range) of 1 (1-11) prior lines of therapy; 55% of patients had received immunomodulatory agents (IMiDs), and 18% had been exposed to lenalidomide. After median follow-up of 17.3 months, DRd significantly prolonged PFS compared with Rd alone (median: not reached vs 17.5 months; hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.28-0.50; P<0.0001), with 18-month PFS rates of 76% and 49%, respectively. Responses continued to deepen in the DRd group with longer follow-up, with significantly higher overall response rate (ORR; 93% vs 76%) and rates of very good partial response (VGPR) or better (78% vs 45%) and CR or better (46% vs 20%) with DRd versus Rd alone (P<0.0001 for all), and MRD negativity was achieved with prolonged PFS at 10⁻⁶ (Figure 1). Overall survival (OS) data are immature, with 40 (14%) deaths in the DRd group and 56 (20%) deaths in the Rd group (HR, 0.63; 95% CI, 0.42-0.95). Neutropenia was the most common grade 3 or 4 treatment-emergent adverse event (53% with DRd vs 38% with Rd), and no new safety signals were reported with longer follow up. We will present updated efficacy and safety data based on approximately 25 months follow up at the meeting.

Figure 1.

Summary/Conclusions: DRd significantly improved outcomes compared with Rd alone, including PFS, ORR, depth of response, and MRD-negative rates, with a favorable safety profile that was maintained after longer follow up. These updated data continue to support the use of DRd in patients with RRMM who received ≥1 prior therapy.

P335

DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELapsed or REFractory MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES

M.-V. Mateos1, A. Spencer2, A. Nooka3, L. Pour4, K. Weisel5, M.-V. Mateos1,*, A. Spencer2, A. Nooka3, L. Pour4, K. Weisel5, M. Cavo6, M. A. Dimopoulos16

1University of Salamanca/IBSAL, Salamanca, Spain, 2Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia, 3Winship Cancer Institute, Emory University, Atlanta, GA, United States, 4Department of Internal Medicine, Harvard Medical and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic, 5Universitätsklinikum Tuebingen der Eberhard-Karls-Universität, Abteilung fuer Innere Medizin II, Tuebingen, Germany, 6Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, Italy, 7Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States, 8St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom, 9Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 10Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHR), Tours, France, 11Levine Cancer Institute/Carolina’s Healthcare System, Charlotte, NC, United States, 12Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic Of, 13Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada, 14Winship Cancer Institute, Emory University, Atlanta, GA, United States, 15Jansen Research & Development, LLC, Spring House, PA, 16Jansen Research & Development, LLC, Raritan, NJ, United States, 17National and Kapodistrian University of Athens, Athens, Greece

Background: Daratumumab (D) used in combination with bortezomb and dex- amethasone (Vd; CASTOR) or lenalidomide and dexamethasone (Rd; POLLUX) significantly prolongs progression-free survival (PFS) with a manageable safety profile compared with either Vd or Rd alone in patients (pts) with RRMM.

Aims: Here in this subgroup analysis we investigated the safety and efficacy of DVD and DRd in elderly pts aged ≥75 years from the CASTOR and POLLUX phase 3 studies.

Methods: Overall, pts enrolled in the CASTOR and POLLUX studies had ≥1 prior line of therapy. Pts in CASTOR received up to 8 cycles of Vd with or without D; pts in the Dvd group then continued to receive D monotherapy q4w until disease progression or unacceptable toxicity. Pts in POLLUX were treated until progression. Dosing schedules for D (16 mg/kg) were different between CASTOR (qw in Cycles 1-3, q3w for Cycles 4-8, and q4w thereafter) and POLLUX (qw for Cycles 1-2, q2w for Cycles 3-6, and q4w thereafter). All elderly pts received a reduced dose of dexamethasone (20 mg once weekly vs 40 mg once weekly) in both studies.

Results: In CASTOR, 23/251 pts in the DVD group and 35/247 pts in the Vd group were ≥75 years; the median (range) age for this group of pts was 78 (75-88) and 78 (75-85) years, respectively, with 100% and 94% with an ECOG status ≤1. At a median follow-up of 13.0 months, discontinuation rates due to treatment-emergent adverse events (TEAEs) were similar with DVD and Vd (15% vs 20%). Common (≥10%) grade 3/4 TEAEs for Vd were thrombocyto- penia (45% vs 37% with Vd), fatigue (15% vs 11%), pneumonia (15% vs 17%), and anemia (10% vs 11%). Infusion-related reactions (IRR) occurred in 13 (65%) pts; with 10% having grade 3/4 IRR, but no pts discontinued due to IRR. Median PFS was significantly prolonged with DVD versus Vd (not reached [NR] vs 8.1 months; hazard ratio [HR], 0.27; 95% confidence intervals [CI], 0.12-0.61; P=0.0007), consistent with the overall PFS observed in CAS- TOR (Figure). Higher overall response rate (ORR; 95% vs 79%) and rates of complete response (CR) or better (25% vs 3%) and very good partial response (VGPR) or better (70% vs 18%) were achieved with DVD versus Vd, respectively, consistent with the overall population. In the POLLUX study, 29/286 pts in the DRd group and 35/283 pts in the Rd group were aged ≥75 years; the median (range) age for this group of pts was 77 (75-89) and 78 (75-87) years, respectively, with 86% and 91% with an ECOG status ≤1. At a median follow-up of 17.3 months, 10% of pts in the DRd group and 11% in the Rd group discontinued due to TEAEs. Common (≥10%) grade 3/4 TEAEs for DRd were neutropenia (45% vs 31% with Rd), hypokalemia (14% vs 3%), and pneumonia (10% vs 11%). D-associated IRR occurred in 12 (41%) pts in the DRd group, with 4 (14%) pts having grade 3/4 IRR. No patient discontin- uated DRd due to IRR. Median PFS was significantly prolonged with DRd compared with Rd in the elderly subgroup (NR vs 11.4 months; HR, 0.19; 95% CI, 0.06-0.55; P=0.0007), consistent with the overall PFS observed in POLLUX (Figure 1). ORR was higher with DRd versus Rd (93% vs 77%), and rates of CR or better (52% vs 9%) and VGPR or better (72% vs 41%) were also higher with DRd versus Rd.

Figure 1.

Summary/Conclusions: The results in elderly pts were consistent with those observed in the overall study populations in terms of efficacy. Rates of most common grade 3/4 hematologic TEAEs for DRd in elderly were similar to that of the overall populations, and IRR were manageable. This subgroup analysis supports the addition of D to standard-of-care regimens in elderly pts with RRMM.
Summary/Conclusions: The all oral ixThalDex regimen showed an ORR of 63% with no difference in pts with high-risk cytogenetics, a CBR of 67%, and a PFS of 10.4 mos in pts with RRMM. The regimen was well tolerated and was associated with a low incidence of mainly grade ≥2 PNP, which required dose reduction in one patient only. Response rates improved with continuation of therapy and treatment was associated with an increase in health related QoL.

P337 EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS

Background: Growth differentiation factor-15 (GDF-15), is a member of the TGF-beta family, and is involved in several pathological conditions, including inflammation, cancer, cardiovascular, pulmonary and renal diseases. Serum GDF-15 levels add prognostic information to conventional prognostic factors, such as NT-proBNP and troponins, in cardiovascular disorders and has also shown to be associated with renal damage and risk of end stage renal disease in patients with diabetes. Increased serum GDF-15 levels have also been shown to correlate with early death and shorter survival independently of other cardiac biomarkers and Mayo stage. Because GDF-15 was also associated with renal outcomes we evaluated the prognostic value of GDF-15 levels in two independent cohorts of patients with AL amyloidosis and renal involvement who were treated in two different centers (Pavia Amyloidosis Center and Department of Clinical Therapeutics, Clinical Therapeutics, Athens). Aims: To evaluate the prognostic value of GDF-15 levels in independent cohorts of patients with AL amyloidosis and renal involvement.

Methods: Circulating levels of GDF-15 were measured by a novel pre-commercial immunoasay (Rutacell Diagnostics) in two different centers. The Pavia cohort included 135 and the Athens cohort included 76 patients with AL amyloidosis and renal involvement. Standard criteria were used for the diagnosis, evaluation of organ involvement and cardiac biomarker-based risk stratification. Renal staging was based on the system proposed by Palladini et al., based on baseline proteinuria ≥5 g/day and eGFR <50 ml/min.

Results: Median age and involved FLC levels were similar between the two cohorts. However, heart involvement was more common in Pavia cohort (72% vs 53%; p=0.005). Mayo stage disposition was also different (17%, 46% & 37% for stage 1, 2 & 3 in Pavia vs 30%, 43% & 27% in Athens cohort, p=0.08, but stage 3B was similar, 13% vs 12%). Also there were differences in peripheral nerve involvement (9% in Pavia vs 21% in Athens cohort, p=0.025). Median eGFR and renal stage distribution (26%, 54%, 20% vs 20%, 54%, 26% for renal stage-1, 2 & 3 respectively) were similar between the two cohorts (p=0.544). Median follow up for the Pavia cohort was 18 months and for the Athens cohort was 45 months (p<0.001). Survival at 2 years was 59% for Pavia and 56% for Athens cohort. Median GDF-15 levels was 3454 pg/ml in Pavia (range 624 to >100000) and 4152 pg/ml (range 626 – 71475) in Athens cohort (p=0.09), while 93% and 94% of patients in the two cohorts had GDF-15 levels ≥1200 pg/ml (the upper limit of normal for individuals without cardiovascular disease). We then evaluated the prognostic significance regarding renal outcomes (dialysis): GDF-15 <4000 pg/ml was associated with a HR of 6 (95% CI 2015.6, p=0.001) in Athens cohort (progression to dialysis within 2 years in 7% vs 47%); while, by applying the same cutoff in patients in Pavia cohort, 2-year dialysis rate was 10% vs 37% (HR: 3.95, CI 1.6-15, p=0.004). Although renal stage discriminated 3 groups in univariate analysis in each cohort, in multivariate analysis, GDF-15 ≥4000 pg/ml outperformed renal stage by eGFR and proteinuria and was the only independent prognostic factor for progression to dialysis in each cohort (Figure 1).
Summary/Conclusions: Our study validated and confirmed in two independent cohorts, with differences in their characteristics, the prognostic value of GDF-15, which emerges as a novel biomarker with prognostic implications for different outcomes in patients with AL amyloidosis. Importantly, GDF-15 emerges as a strong biomarker for renal outcomes in patients with AL amyloidosis.

**P338**

AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

M.A. Dimopoulos1-4, S. Grosicki2, W. Jędrzejczak2, H. Nash3, A. Gruber4, M. Hansson5, C. Byrne6, R. Labokta2, Z. Deng9, H. Yang9, N. Grzasko8, S. Kumar8

1National and Kapodistrian University of Athens School of Medicine, Athens, Greece, 2Silesian Medical University, Katowice, 3Medical University of Warsaw, Warsaw, Poland, 4Karolinska University Hospital, Stockholm, 5Skåne University Hospital, Lund, Sweden, 6Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States, 7St. John Cancer Center, Medical University of Lublin, Lublin, Poland, 8Mayo Clinic, Rochester, United States

Background: Proteasome inhibitor (PI)-based combinations are standards of care in all lines of MM therapy. As the treatment paradigm moves to focus more on extended therapy, new combinations are needed that will be efficacious and tolerable, while giving pts the flexibility of taking their treatment at home. Combinations of ixazomib, the first oral PI, with immunomodulatory drugs (IMiDs) are feasible and effective; however, there may be pts for whom the use of IMiDs is not desirable. Therefore, triplet combinations of ixazomib with alkylators have been studied.

Aims: This phase 2 study (NCT02046070) evaluated the safety and efficacy of the all-oral IC regimen in transplant-ineligible pts with NDMM. Primary endpoint was rate of CR+VGPR during induction. Secondary endpoints included tolerability and toxicity, overall response rate (CR+VGPR+PR) throughout treatment, time to response, PFS, and quality of life (QoL).

Methods: Adult pts with NDMM who were transplant-ineligible were randomized (1:1) to receive oral ixazomib 4.0 mg plus oral cyclophosphamide 300 mg/m2 (Arm A) or 400 mg/m2 (Arm B) on days 1, 8, 15, and dexamethasone 40 mg on days 1, 8, 15, and 22, for up to 13 28-day cycles as induction. Pts with ≥SD and an acceptable toxicity profile then received single-agent ixazomib maintenance therapy until PD, death, or unacceptable toxicity.

Results: 70 NDMM pts were enrolled (n=36 Arm A; n=34 Arm B): median age 73 years (range 61–87); 47% male; 31%/33%/32% ISS stage I/II/III MM; 50% had a cardiovascular/pulmonary comorbidity; 9% had high-risk cytogenetics (t(4;14), t(14;16), del 17p). At data cut-off (29 June 2016), pts had received a median of 19 cycles; 66% had completed 13 IC induction cycles and proceeded to ixazomib maintenance therapy; 10% were ongoing on therapy, and 31% had discontinued due to AEs (24%), PD (16%), patient withdrawal (3%), or other reasons (10%).

Summary/Conclusions: Based on this phase 2 study, ICd is an active treatment regimen for pts with NDMM who are ineligible for transplant. This trial captured a population of pts that was elderly and with multiple comorbidities. In this context, the results with ICd, an all-oral triplet including a PI and alkylator, provide evidence of clinical efficacy with a manageable safety profile. With a median follow-up of ~18 months, median PFS was not reached and outcomes appear comparable to other regimens in elderly transplant-ineligible pts with NDMM. The preferred cyclophosphamide dose for ICd phase 3 studies is 300 mg/m2, based on the similar PFS, higher response rate, and numerically lower rate of AEs vs 400mg/m2. Updated PFS results will be presented at the meeting.

**P339**

THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)

J. San Miguel1-5, M.A. Echeveste Gutierrez2, I. Špicka3, M.-V. Mateos4, K. Song5, M. Craig5, J. Blade7, R. Hajek5, C. Chen9, N. Gupta15, C. Byrne1, V. Lu10, H. van de Velde10, S. Lonial11

1Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA) Hospital Universitario Virgen del Rocio, Pamplona, 2Hospital Universitario Donostia, San Sebastian, Spain, 31st Department of Internal Medicine, Division of Hematology, General Faculty Hospital, Charles University, Prague, Czech Republic, 4Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain, 5Division of Hematology, University of British Columbia, Vancouver, Canada, 6Department of Medicine, West Virginia University, Morgantown, United States, 7Department of Hematology, Hospital Clínico de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 8Department of Haematology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Ostrava, Czech Republic, 9Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, Canada, 10Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, 11Winship Cancer Institute of Emory University, Atlanta, United States

Background: Bortezomib-MP is a standard-of-care regimen for elderly NDMM pts. Whereas bortezomib is administered IV or SC, ixazomib is an oral proteasome inhibitor with a safety profile amenable to extended dosing that is approved in the US and EU, in combination with lenalidomide-dexamethasone, for the treatment of MM pts who have received at least 1 prior therapy. Based on the demonstrated feasibility and efficacy of a proteasome inhibitor-MP combination, the all-oral ixazomib-MP (IMP) regimen was evaluated in elderly, transplant-ineligible NDMM pts.

Aims: Primary phase 1 objectives were to determine the safety, MTD, and recommended phase 2 dose (RP2D) of ixazomib in combination with MP. The primary phase 2 objective was to determine the rate of CR+VGPR, secondary objectives included PFS and OS.

Methods: In phase 1, pts were enrolled to 4 arms – Arm A: ixazomib 3.0–3.7 mg (days 1, 4, 8, 11, 22, 25, 29, 32) plus M 9 mg/m2 and P 60 mg/m2 (days 1–4) in 42-day cycles (max 9 cycles); Arm B: ixazomib 3.0–4.0 mg (days 1, 8, 15) plus M 6 mg/m2 and P 60 mg/m2 (days 1–4) in 28-day cycles (max 13 cycles); Arm C: ixazomib 3.0–4.0 mg (days 1, 8, 15, 22, 29) plus M 4.0 mg/m2 (days 1, 8, 22, 29) plus M 9 mg/m2 and P 60 mg/m2 (days 1–4) in 42-day cycles (max 9 cycles). In phase 2, an expansion cohort was enrolled at the RP2D. On all arms, after IMP induction, pts could receive maintenance with single-agent ixazomib (days 1, 8, 15, 28-29 cycles).

Results: 61 pts were enrolled, 11, 34, 11, and 5 to Arms A, B, C, and D (median age 74 yrs; 31% ISS stage III, 56% creatinine clearance ≤60 mL/min). Among
Myeloma and other monoclonal gammopathies - Clinical 2

P340

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN – PREDNISONE – BORTEZOMIB IN PATIENTS ≥75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY


1Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, 2Internal Medicine, Albert Schweitzer ziekenhuis, Dordrecht, 3Internal Medicine, Meander Medisch Centrum, Amersfoort, 4Internal Medicine, ZNB, Leeuwarden, 5Internal Medicine, Haga Ziekenhuis, Den Haag, 6Internal Medicine, Sint Jans Dal, Harderwijk, 7Internal Medicine, MCA, Alkmaar, 8Internal Medicine, Tergooi ziekenhuizen, Hilversum, 9Internal Medicine, Groene Hart ziekenhuis, Gouda, 10Internal Medicine, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, 11Hematology, UMCU, Utrecht, 12HOVON Data Center, 13Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Background: There is a high rate of toxicity-related discontinuation in elderly patients with NDMM, negatively affecting outcome. In order to predict feasibility of treatment the IMWG developed the frailty score based on age, (instrumental) Activities of Daily Living and the Charlson comorbidity index.

Methods: Patients were treated with 9 cycles of MPV: Mel 6 mg/m², day 1-4; Pred 30 mg/m², day 1-4; and Bort 1.3 mg/m² day 1, 8, 15 and 22 of a 35-day cycle. This first planned analysis was restricted to the first 140 consecutive patients out of 240 planned patients.

Results: Of the 139/140 eligible patients none were fit (because of age ≥75 years), 30/139 (22%) were unfit, 100/139 (72%) were frail, and 9/139 (6%) unknown. The median follow up was 17.0 months. The discontinuation rate of MPV in the total population was 42%; 27% in unfit and 46% in frail patients (p=0.09). When also patients were included who discontinued bortezomib only these numbers were 27% in unfit and 52% in frail (p=0.02). Importantly, 6 cycles of MPV were found to be feasible in 70% of patients, both in unfit (80%) and frail (69%) patients. Age >80 years was associated with a significantly higher discontinuation rate of MPV or bortezomib only (70% versus 35% in patients aged 75-80 years, p=0.01). WHO performance was not associated with discontinuation rate. Response on protocol was ≥PR 73%, ≥VGPR 38% and ≥CR 11%, not significantly different in unfit versus frail patients. After 6 cycles response was ≥PR 69%, ≥VGPR 35% and ≥CR 2%. Median progression free survival (PFS) was 17 months: 20 for unfit and 16 months for frail patients (p=0.13). Overall survival at 18 months was 76%: 89% for unfit and 72% for frail patients (p=0.22). Frail patients were found to have significantly less grip strength and lower walking speed as compared to unfit patients (Table 1).

Table 1.

However, 58% and 59% of frail patients had an intermediate or high walking speed and grip strength respectively. Vice versa, 8% of patients with low
walking speed and 12% of patients with low grip strength, were not frail but unfit according to the IMWG frailty index. Discontinuation rate in patients with highest and lowest walking speed was 16/41 (39%) and 18/41 (44%). These numbers were 14/42 (33%) versus 17/43 (40%) for patients with the highest versus the lowest grip strength. PFS was not significantly different between patients with highest versus lowest walking speed (p=0.38). However, in contrast to comparable PFS in unfit and frail patients, there was a trend for better PFS in patients with highest versus lowest grip strength (20 versus 17 months, p=0.05).

Summary/Conclusions: Nine cycles of dose-adjusted MPV results in a high discontinuation rate of 42% in NDMM patients ≥75 years: 27% in unfit versus 46% in frail patients. Importantly, 6 cycles of MPV were found to be feasible with comparable response rate, also in frail. Preliminary analyses showed that functional geriatric assessments differed within IMWG frailty groups and that grip strength was associated with PFS, whereas frailty was not. Therefore, functional assessments will hopefully be complementary to the IMWG frailty score in guiding future therapy in unfit and frail patients.

P341
THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE IS EFFECTIVE AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA

M. de Theije1, A. Günter1, M. Offidani2, M. Engelhardt3, S. Gentili4, V. Montefusco5, F. Patriarca6, E. Angeliucci7, N. Schub1, M. Astolfi8, W. Poenisch9, H. Einsele10, P. Corradini4, A. Palumbo11, F. Gay7

Materials and Methods: In a single-arm, phase 1/2, multicenter study (NCT02056756), 60 untreated patients were randomized to receive Carfilzomib (Carf) 27–70 mg/m² on day 1 and 8, Benda 70 mg/m² on day 1 and 8, plus dexamethasone (DEX) 40 mg for 2 days plus DEX until progression. With this scientific rationale a CBd combination of Carfilzomib and Benda was developed. The phase 1 part of the trial suggested Carf at the 27 mg/m² level for the phase 2 part. Forty-one patients were evaluated for response and efficacy. At last data cut-off, the median follow-up was 5.95 months. Number of prior treatment lines ranged from 2 to 9, and ≥85% of patients had received previously transplan
tative therapy prior to study entry. Hematological toxicity was well manageable. Non-hematological adverse events (AEs) were relatively low, with grade 3 or 4 AEs in 39% of all treated patients. No grade 5 AEs were reported. One death was either progression of AL (N=16), sepsis (n=4), heart transplant rejection (mostly due to renal complications after HTx). Complete remission (CR) was achieved in 7 patients (24% of all transplanted pts, N=29; 2 patients have not finished treatment yet, very good partial remission (VR) in 17% and partial remission (PR) in 7 patients (24%). Overall, 25 patients died. Cause of death was either progression of AL (N=16), sepsis (n=4), heart transplant rejection (n=3) or other (n=2). Patients that underwent HTx had a median survival of 46 months (2-177, 1-year survival: 77%).

Summary/Conclusions: HTx in patients treated with chemotherapy is a feasible treatment approach in patients with advanced cardiac amyloidosis. Patients who reach HTx have a nearly 50% chance for a very good hematologic remission (VGPR or better) and consecutively a favorable survival probability with a median OS of nearly 6 years in our series.

P343
CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS: SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP

U. Hegenbart1, K. Haack1, A. Kristen1, P. Blum2, C. Kimmich1, H. Katus2, A. D. Ho3, A. Ruhrwara4, P. Raake2, S. Schönfeld1

1Amyloidosis Center, 2Div. of Cardiology, 3University Hospital, Heidelberg, Germany, 4Cardiac Surgery, University Hospital, Heidelberg, Germany

Background: Survival rates for patients with light-chain (AL) amyloidosis are gravely reduced by advanced cardiac involvement at Mayo cardiac stage IV with a median survival of 6.5 months. High-dose Melphalan (HDIM) and autol
crophic stem cell transplantation (ASCT) or other intensive chemotherapy regimen cannot be applied to those patients due to the high risk of therapy-related mor
tality. One approach to improve the catastrophic prognosis of those patients is to perform a heart transplantation followed by intense chemotherapy.

Aims: Our aim was to examine the cases of cardiac AL patients treated with heart transplantation (HTx) at our center and to evaluate the clinical outcome of this treatment approach.

Methods: Data from 41 patients (21m, 20f) suffering from cardiac AL who were treated in our hospital between 2002 and 2017 were retrospectively analyzed. All patients were high-urgency listed for orthotopic HTx due to poor prospective of survival. Prior to 2009, 10 patients were listed, 8 of them with multiple organ involvement. Thereafter, we excluded patients with multiple organ involvement. All data are derived as medians with range or absolute numbers. Survival curves were calculated using the Kaplan-Meier method.

Results: Median age was 51 years (35-63) at diagnosis. Amyloidogenic lambda light-chains (LC) were detected in 31 and lambda-kappa light-chains in 17 patients. Median dFLC was 331 (69-2752) and median plasma cells in bone marrow were 13% (5-35). Median NT-proBNP was 6.332 ng/l (1.500-53.194), median cTNT 0.11 µg/l (0.01-0.52) and median hsTNT was 60 ng/l (28-448) at diagnosis. Median NYHA stage was 3 (2-3) and median Mayo 2004 stage was 3 (2-3). Serum creatinine was at 1.94 mg/dl (1.17-4.45), proteinuria at 0.1 g/day (0-10.7). Patients stayed on the high-urgency waiting list for a median of 26 (range 3-54) before 2009, and a median of 64 days (8-259) after 2009. 35 patients were treated with chemotherapy prior to HTx (mostly dexa w/o Bortezomib) to reduce dFLC during the waiting time. Eight patients died before receiving HTx with a median survival (start point: HU listing) of 28 days (6-177). With a median of 5 months after HTx (4-29), 18 patients received ASCT. HDIM was used with either 200 mg/m² (N=10) or reduced dosage (N=8) in patients with reduced kidney function (mostly due to renal complications after HTx). Complete remission (CR) was achieved in 7 patients (24% of all transplanted pts, n=29; 2 patients have not finished treatment yet, very good partial remission (VR) in 17% and partial remission (PR) in 7 patients (24%). Overall, 25 patients died. Cause of death was either progression of AL (N=16), sepsis (n=4), heart transplant rejection (n=3) or other (n=2). Patients that underwent HTx had a median survival of 46 months (2-177, 1-year survival: 77%).

Summary/Conclusions: HTx in patients treated with chemotherapy is a feasible treatment approach in patients with advanced cardiac amyloidosis. Patients who reach HTx have a nearly 50% chance for a very good hematologic remission (VGPR or better) and consecutively a favorable survival probability with a median OS of nearly 6 years in our series.
or unacceptable toxicity. Supportive care was allowed; thrombophlebitis was required for all pts on hemodialysis. The primary endpoint was overall response rate (ORR). Key secondary endpoints included safety, renal response, time to myeloma response, time to renal response, duration of response, progression-free survival (PFS), time to progression, and overall survival (OS). All pts provided informed consent.

Results: Enrolment has been completed with 81 pts (33 in cohort A; 34 in cohort B; 14 in cohort C), of which 13 (16.0%) were still on treatment as of January 28, 2017. Median follow-up for OS was 7.8 months. A total of 68 pts (84.0%) discontinued treatment; 39 (48.1%) due to PD. Median age was 72 yrs (range, 52-86 yrs). 60.5% of pts were male, and median time from diagnosis was 3.8 yrs (range, 0.03-19.44 yrs). Pts received a median of 4 (range, 1-10) prior anti-myeloma therapies. All pts had prior treatment with LEN (100%) and nearly all with BORT (97.5%). Median relative dose intensity of POM was 0.94 in both cohorts A and B, and 0.99 in cohort C. ORR was 39.4%, 29.4%, and 14.3% in cohorts A, B, and C respectively. PFS and OS results are presented in the Table 1. Grade 3/4 anemia and thrombocytopenia occurred more frequently in cohort C, likely due to severe RI requiring dialysis (Table 1). AEs leading to dose reductions were 18.2%, 14.7%, and 14.3% in cohorts A, B, and C, respectively.

Table 1.

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Grade 3/4 TEAEs, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>Anemia</td>
<td>20.6</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>22.0</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>13.6</td>
</tr>
</tbody>
</table>

Summary/Conclusions: POM+LoDEX is efficacious in pts with RRMM with moderate or severe RI, including those on hemodialysis, who had more advanced disease due to worse renal function. The safety profile was acceptable among the three groups and no new safety signals were observed. This study demonstrates that POM+LoDEX can be administered in pts with moderate or severe RI, including those on hemodialysis.

P345

ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM


Background: Treatment with autologous transplantation (ASCT) remains the standard of care upfront for Multiple Myeloma patients considered eligible for transplant. Peripheral blood stem cell (PBSC) collection, also called mobilisation, is needed prior to ASCT. The optimal methodology for mobilizing PBSC has yet to be defined, with either G-CSF alone, also called steady state procedure, or use of Plerixafor, a CXCR4 antagonist (Mozobil®)+G-CSF or high dose cyclophosphamide (used at a dose of 1.5 to 6g/m² IV for mobilization) versus Plerixafor+G-CSF or high dose cyclophosphamide. The 2 latter have demonstrated similar PBSC collection rates. Because of the intense competition for hospital resources and the staff required to manage patients preparing for mobilization and transplantation, it is important to quantify the total impact of mobilization on staff resource and hospital costs.

Aims: We aimed at better evaluate the respective cost of the 2 techniques of mobilization for the French health care system, high dose cyclophosphamide (n=57) versus plerixafor (n=55).

Methods: This is an observational cohort database analysis of 112 consecutive patients with MM treated upfront with ASCT between 2009 and 2013 and that had been mobilized with either high dose cyclophosphamide or plerixafor from 15 IFM centers. Patients must have successfully underwent ASCT. This study was not aimed at evaluating the suitability or advisability of one therapy versus another. A cost-consequences analysis of the different regimens of mobilization 1) without transplantation and 2) with transplantation is needed prior to ASCT. The optimal methodology for mobilizing PBSC has yet to be defined, with either G-CSF alone, also called steady state procedure, or use of Plerixafor, a CXCR4 antagonist (Mozobil®)+G-CSF or high dose cyclophosphamide (used at a dose of 1.5 to 6g/m² IV for mobilization) versus Plerixafor+G-CSF or high dose cyclophosphamide. The 2 latter have demonstrated similar PBSC collection rates. Because of the intense competition for hospital resources and the staff required to manage patients preparing for mobilization and transplantation, it is important to quantify the total impact of mobilization on staff resource and hospital costs.

Background: Treatment with autologous transplantation (ASCT) remains the standard of care upfront for Multiple Myeloma patients considered eligible for transplant. Peripheral blood stem cell (PBSC) collection, also called mobilisation, is needed prior to ASCT. The optimal methodology for mobilizing PBSC has yet to be defined, with either G-CSF alone, also called steady state procedure, or use of Plerixafor, a CXCR4 antagonist (Mozobil®)+G-CSF or high dose cyclophosphamide (used at a dose of 1.5 to 6g/m² IV for mobilization) versus Plerixafor+G-CSF or high dose cyclophosphamide. The 2 latter have demonstrated similar PBSC collection rates. Because of the intense competition for hospital resources and the staff required to manage patients preparing for mobilization and transplantation, it is important to quantify the total impact of mobilization on staff resource and hospital costs.

Aims: To determine the safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with RRMM.

Methods: Patients with RRMM who have failed ≥2 prior lines of therapy including a proteasome inhibitor and immunomodulatory drug (IMiD) received pembrolizumab 10 mg/kg every 2 weeks or 200 mg fixed dose every 3 weeks. Primary end points were safety, tolerability, and objective response rate (ORR) as determined by investigators, per International Myeloma Working Group 2006 criteria.

Results: At data cutoff of January 2, 2017, 30 patients were treated. The median (range) duration of follow-up was 15 (1-32) months. 28 (93%) patients discontinued the study; the most common reason was disease progression in 14 (47%) patients and clinical progression in 9 (30%) patients. 2 (7%) patients are still on treatment. Median (range) age was 70 (56-81) years. 21 (70%) patients had an ECOG performance status of 1. Patients received a median (range) of 4 (2-10) prior lines of therapy. 20 (67%) patients were lenalidomide refractory, 10 (33%) were double-refractory. 9 (30%) were triple refractory, and 11 (37%) were quadruple refractory. Among patients who received pembrolizumab at 10 mg/kg, the median (range) of pembrolizumab exposure was 6 (2-15) cycles; among those who received 200-mg fixed dose of pembrolizumab, the exposure was 3 (2-6) cycles. No patient experienced a response. Seventeen (57%; 95% CI, 37-75%) patients had stable disease. 13 (43%; 95% CI, 26-63%) patients had progressive disease as their best response. Treatment-related adverse events (TRAEs) occurred in 12 (40%) patients. The most common TRAE was anaemia (n=5, 17%); arthralgia, aspartate aminotransferase increased, fatigue, hyperglycemia, hypothyroidism, myalgia, pruritus, and blurred vision occurred in 1 patient each. A grade 3 TRAE (myalgia) occurred in 1 (6%) patient. There were no grade 4 TRAEs. 1 (3%) patient had an immune-related adverse event (grade 1 pruritus).

Conclusion: The safety profile of pembrolizumab in RRMM was consistent with that observed with other cancers. Best response observed while on pembrolizumab monotherapy was stable disease. Recent results of ongoing studies, such as KEYNOTE-023 (NCT02036802), demonstrate promising efficacy of pembrolizumab in combination with IMiDs (lenalidomide) and dexamethasone in patients with RRMM.
Summary/Conclusions: For a long time HD cyclophosphamide was recommended for mobilization upfront in Myeloma therapy, as it was needed to improve response rate and depth of response, despite only 10% of the patients improving. With the progress made recently with the induction regimens, the choice for the mobilization regimen is now based more on safety and cost saving. In that regards, one must acknowledge that plerixafor has become one, if not the, most attractive option for Myeloma.

P347

A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK

O. Gamage1,2, M. Zaw1, S. Gurung1, G. Pratt3, S. Shafeek1, A. Macwahonne1, S. Lee1, S. Basu1
1Department of clinical Haematology, Royal Wolverhampton NHS Trust, Wolverhampton, 2Department of Haematology, University Hospital, Birmingham, UK, Birmingham, 3Department of Haematology, Worcestershire Acute Hospital Trust, Worcester, United Kingdom

Background: Recent International Myeloma Working Group (IMWG) guidelines recommend that conventional skeletal surveys should be supplanted by low dose whole body computed tomography (CT), whole body magnetic resonance imaging (MRI) and or 18fluoro-deoxyglucose (18F-FDG/PET). However, resource, funding and radiology capacity issues, have posed significant challenges to implementing these recommendations. The risk of progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) to a neoplastic plasma cell disorder is approximately 1% per year and even lower in low risk MGUS. It is thus not necessary to perform imaging in unselected MGUS patients.

Aims: To look at all skeletal surveys requested across 3 large hospitals in UK over a year and analyze their justification, effectiveness and utility. To decide if a rational clinico–biochemical algorithm could be used to reduce the number of imaging requests, thereby avoiding unnecessary radiation exposure, and make a possible switch to modern imaging methods cost effective.

Methods: A total of 397 skeletal surveys were performed across three hospitals over one year. The data set was analyzed for clinical indications, paraprotein level, rationale for requesting the skeletal survey, the diagnostic yield and also the number of follow up CT/PET or MRI required.

A pragmatic algorithm was developed and applied to see if the requests were justified and could have been safely reduced. (Figure 1).

Results: Of the 397 analyzable skeletal surveys performed, 266 were on myeloma, 81 for MUGS, 48 were for non-paraprotein related indications. Of the 266 myelomas, 30% of skeletal surveys were reported as positive according to IMWG criteria. A detailed analysis of 130 myeloma patients revealed a significant proportion of false negatives (6%) and false positives (7%), highlighting the insensitivity and poor specificity of this imaging modality. More importantly, more than a third (38%) of myeloma patients required follow up imaging with MRI, PET or WBLC irrespective of the initial skeletal survey result, indicating a significant duplication rate and waste of resources. In the MGUS group, majority of skeletal surveys were negative (91%) but 9% were reported as positive. Follow up imaging with CT and MRI was performed in 23% of the MGUS group. However none these were positive. When the clinico-biochemical algorithm was applied, the number of requests was reduced by at least a quarter (24%), avoiding unnecessary radiation exposure and precious resources.

Figure 1.

Summary/Conclusions: - Skeletal survey has very limited role in investigation of paraproteinaemia and should be abandoned. - Our pragmatic clinico-biochemical imaging algorithm reduced imaging requests significantly (24%) allowing the preferred imaging modalities to be performed productively in a cost effective way in face of ever increasing health care cost and demands.

P348

SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES

T. Dejoie1, M. Attia2, P. Moreau3, H. Avel-Loiseau4
1Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, 2Institut Universitaire du Cancer-Oncopole, Toulouse, 3Department of Hema-

Figure 1.

Summary/Conclusions: - Our systematic review and NMA included most of the recommended induction treatments for transplant-eligible myeloma patients and identified VRD as being most effective in achievement of 3VGPR. NMA can provide an overview of the best treatment and each regimen’s relative efficacy in case of lacking head-to-head RCTs, thereby supporting clinical decision-making.
Background: In multiple myeloma (MM), abnormal serum free light chain ratios (FLCr) after therapy associate with poor prognosis, independent of depth of response. However the value of FLCr in the context of minimal residual disease (MRD) remains unclear. A proportion of MRD-negative patients experience early relapse and conversely, some MRD-positive patients can endure long-term survival; which may result from improved immunosurveillance following normal plasma-cell recovery. Aims: We hypothesised that serum FLCr levels and ratios add clinical value at the time of MRD assessment.

Methods: The study included 275 intact immunoglobulin MM patients from the IFM2009 clinical trial who achieved at least a very good partial response (VGPR) after consolidation therapy. Median PFS from the end of consolidation was 38.3 months; median OS was not reached. Serum FLCrs were measured using 4-colour multiparametric flow cytometry (MFC). We defined immunosuppression as levels of both the uninvolved (polychain) FLC+uninvolved heavy-light chain (HL; measured with Heyvityle) below their normal range. MRD assessment in bone marrow samples was based on 4-colour multiparametric flow cytometry (MFC).

Results: At the end of consolidation, 78/275 (29%) patients were MRD-positive, 79/275 (29%) had abnormal FLCr, 16/275 (6%) had elevated iFLC, with immunosuppression identified in 52/275 (19%). Using Cox regression all the variables associated with shorter PFS (p<0.001 for all) and OS (p<0.050 for all; except elevated iFLC which showed a trend towards shorter OS (p=0.070)). Among 196 MRD-negative patients, 37/196 (19%) had abnormal FLCr, 2/196 (1%) had elevated iFLC with immunosuppression identified in 23/196 (12%). Median PFS for MRD-negative patients was not reached; however both an abnormal FLCr (median PFS: 31.4 months; p<0.001) and immunosuppression (median PFS: 31.4 months; p=0.050) identified a group of patients with poorer outcomes. On the other hand, median PFS for MRD-positive patients was 21.3 months; 42%(53%) of these patients had abnormal FLCr and dismal outcomes (median PFS 12.6 vs 30.7 months for abnormal vs normal FLCr, respectively; p=0.054). Absolute FLCr measurements did not reach statistical significance for PFS in these patients.

Summary/Conclusions: Serum FLCr measurements in combination with low-sensitivity MFC bone marrow assessment at the end of consolidation therapy render the most powerful prognostic information in MM patients achieving deep responses. In those where disease is no longer detected using MFC, abnormal FLCr confer poor prognosis, which may partly be due to inefficient immune recovery. Absolute FLCr measurements were informative, supporting the rationale of evaluating biomarkers of the tumour and immune system recovery. Our results warrant further studies to validate the clinical utility of FLCr measurements in combination with next-generation (8-colours) flow cytometry.

P349
THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
1Duke University Medical Center, Durham, 2Indiana University Simon Cancer Center, Indianapolis, 3Mount Sinai Hospital, New York, 4Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, 5MD Anderson Cancer Center, Houston, 6US Oncology Research, Maryland Oncology Hematology, Columbia, 7Providence Cancer Institute, Southfield, 8Steeplechase Cancer Center, Somerville, 9University of South Carolina, Columbia, 10Wake Forest University School of Medicine, Winston-Salem, 11Celgene Corporation, Summit, 12US Oncology Research, Rocky Mountain Cancer Centers, Denver, United States

Background: The cytogenetic abnormality t(11;14) is common, occurring in approximately 20% of patients with newly diagnosed multiple myeloma (NDMM) (Avet-Loiseau, Leukemia, 2013). Historically, t(11;14) has been associated with standard-risk multiple myeloma (MM) and generally favorable outcomes (Avet-Loiseau, Leukemia, 2013). However more recent retrospective studies have reported the presence of t(11;14) to be a poor prognostic factor (Kaufman, Leukemia, 2016). Connect MM is a largely community-based, US prospective observational cohort study that collects data on management and natural history of patients with NDMM in clinical practice.

Aims: This analysis assessed the impact of t(11;14) on survival outcomes in African American and non-African American patients in a mostly community-based setting.

Methods: Adult patients with NDMM within 60 days of diagnosis were eligible for enrollment in the registry. Patients who completed induction and were tested for t(11;14) by fluorescence in situ hybridization or cytogenetics were grouped by race (African American and non-African American). Endpoints were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier analyses were adjusted for cohort, age, International Staging System stage, transplant intent, presence of t(14;14), diabetes history, and baseline levels of hemoglobin, platelets, calcium, and creatinine. Data cut-off was Jul 7, 2016.

Results: 3011 patients were enrolled in 2 cohorts. Cohort 1 enrolled 1493 patients from Sep 2009–Dec 2011; median follow-up was 39.3 months. Cohort 2 enrolled 1518 patients from Dec 2012–Apr 2016; median follow-up was 16.4 months. A total of 1539 (52%) patients were tested for t(11;14). Of these, 363 (24%) were positive for t(11;14). By race, 53 (26%) of 205 African American and 310 (23%) of 1334 non-African American patients were positive for t(11;14). First-line bortezomib exposure was similar across all groups. In African American patients, the presence of t(11;14) resulted in a trend toward shorter PFS compared to those without t(11;14) (Table 1). Additionally, African American patients with t(11;14) had significantly higher risk of death compared to African American patients without t(11;14). A higher rate of early mortality was observed vs non-African American patients. In non-African American patients, no differences in PFS or OS were noted based on the presence or absence of t(11;14). For OS, the interaction between race and t(11;14) status was statistically significant (P=0.004).

Table 1.

<table>
<thead>
<tr>
<th>African American</th>
<th>Non-African American</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(11;14)</td>
<td>yes</td>
</tr>
<tr>
<td>Median PFS, months</td>
<td>22.68</td>
</tr>
<tr>
<td>Median OS, months</td>
<td>Not reached</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In Connect MM, the effect of t(11;14) on OS was significantly different between African American and non-African American patients. Specifically, t(11;14) was associated with poorer survival outcomes in African American patients, and not in non-African American patients. Thus, the presence of t(11;14) may be a risk factor for poor prognosis in African American patients. Additional analyses will be conducted to elucidate the role of induction treatment, transplant and maintenance in African American and non-African American patients with t(11;14).
MYELOPROLIFERATIVE NEOPLASMS - CLINICAL 1

P350

RAS-PATHWAY MUTATION PATTERNS DEFINE EPIGENETIC SUBCLASSES IN JUVENILE MYELOMONOCYTIC LEUKEMIA

D. Lipka1-3, T. Witte1, R. Toth1, J. Yang2, M. Wiesendahl4, P. Nöllke1, A. Català1,2, D. Lipka5, Z. Gu3, J. Park1, B. Strahm1, M. Wodarczak5,5, A. Yoshimi10, R. Claus7, M. Lübbert7, H. Busch8,8, M. Boerries6,8,10, A. Català11, B. De Moerloose12, M. Dworzak13, H. Hasle14, L. Focattelli15, R. Masseti16, M. Schmugge17, O. Smith18, J. Stary19, M. Ussowicz20, M. van den Heuvel-Eibrink21, Y. Assenov3, M. Schlesner3, C. Niemann3, C. Flotow3, C. Flass1-2, Division of Epigenomics and Cancer Risk Factors, 15Division of Cell and Molecular Biology, Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, 16Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, 17German Cancer Research Center (DKFZ), Heidelberg, 18Department of Pediatrics and Adolescent Medicine, University of Freiburg Medical Center, 19German Cancer Consortium (DKTK), 20Division of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, 21Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, 22German Cancer Research Center (DKFZ), Heidelberg, Germany, 23Department of Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain, 24Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium, 25St. Anna Children’s Hospital and Children’s Cancer Research Institute, Medical University of Vienna, Vienna, Austria, 26Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark, 27Department of Pediatric Hematology and Oncology, Bambino Gesù Children’s Hospital, University of Rome, 28Department of Pediatric Oncology and Hematology, University of Bologna, Bologna, Italy, 29Department of Hematology and Oncology, University Children’s Hospital, Zurich, Switzerland, 30Paediatric Oncology and Haematology, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland, 31Department of Pediatric Hematology and Oncology, Charles University and University Hospital Masaryk, Brno, Czech Republic, 32Department of Pediatric Oncology, Istituto Nazionale Tumori Foundation, Institute of Cancer Research and Treatment, 33Division of Theoretical Bioinformatics, 34Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, 35Heidelberg, Germany, 36Division of Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium, 37Specialised, Experimental and Diagnostic Medicine, Policlinico S. Orsola-Malpighi, Bologna, 38Hematology, Università Cattolica del Sacro Cuore, Roma, Italy, 39Hematology, Ospedale S. Bortolo, Vicenza, Italy, 40Medicine, Well Cornell Medical College, New York, United States, 41Hematology, Centro Oncologico Ematologico Subalpino (COES). Torino, 42Hematology, Università di Bari, Bari, Italy, 43Cytogenetics and Medical Genetics Laboratory, Ospedale di Circolo, ASST Sette Laghi, Varese, 44From Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy

Background: Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood. While some cases show spontaneous remission, allelic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for the majority of patients, however, the 5-year event-free survival reaches only about 50%. Hyperactive RAS signaling is assumed to be the main driving event in JMML. It is caused by genetic alterations in CBL, KRAS, NF1, NRAS, or PTPN11 in about 90% of patients. So far, there is no clear understanding of how RAS pathway mutations relate to the heterogeneous disease biology and variable clinical outcome seen in JMML patients. As a consequence, established clinical and genetic markers fail to fully represent the observed disease heterogeneity. Therefore, we aimed to understand the genetic pathogenesis of JMML and to identify differences among putative subgroups with distinct biological and clinical features.

Aims: We hypothesized that DNA methylation profiling, either alone or in combination with genetic alterations, might provide a molecular basis for disease classification.

Methods: Genome wide DNA methylation analysis using the HumanMethylation450 BeadChip was performed in a discovery cohort of 20 JMML patients. We developed a strategy to eliminate methylation events that attribute to epigenetic changes in normal hematopoiesis. The clinical relevance of our findings was assessed in an unselected sample set consisting of 148 consecutive patients with JMML (n=130) or Noonan syndrome associated myeloproliferative disorder (n=18) registered in the EWOG-MDS 1998 & 2006 trials. Data integration was performed in a subset of patients with available exome sequencing (n=50) and expression profiling (n=15) data.

Results: Systematic DNA methylation analysis of JMML samples identified three subgroups with low, intermediate and high methylation levels (LM, IM, and HM). Detailed analysis of the validation cohort not excluding the Noonan patients identified an association of methylation groups with clinical features. The HM subgroup (n=41) was enriched for high-risk characteristics: All HM cases had elevated levels of Hbf; 88% were older than 2 years at diagnosis, 74% had low platelets (<70×10^9/L), and 66% carried somatic PTPN11 mutations. In contrast, the LM subgroup (n=62) was enriched for patients with low-risk disease: All 18 patients with Noonan syndrome, 13/14 patients with CBL syndrome, and 15/19 patients with NRAS mutations were assigned to the LM group. The IM group (n=45) was enriched for cases with monosomy 7 and somatic KRAS mutations. The unfavorable risk profile in the HM group translated into near 5-year survival (HM 57%, LM 87%, log rank p<0.01) and a high incidence of relapse after HSCT (HM 48%, LM 9%, Gray’s test p=0.01). In a multivariate Cox regression model, only methylation group (HM vs LM: RR 10.9 [1.8-66.2]) and PTPN11 mutation status (PTPN11-mutant vs other: RR 3.3 [1.2-8.9]) remained as independent prognostic factors for CIR (p=0.01). JMML patients with IM phenotype was significantly methylated compared to patients with HM phenotype (P=0.012), even adjusting for SMF diagnosis type (P=0.02). When investigating OS according to different cytogenetic abnormalities, we found that patients with HM had inferior OS respect to those with sole abnormality (P<0.001) and patients with HM had inferior OS respect to those with sole abnormality (P<0.001) and patients with HM had inferior OS respect to those with sole abnormality (P<0.001).

Summary/Conclusions: Our integrated approach identified three JMML subgroups characterized by distinct clinical and biological features. We provide evidence for a molecular mechanism by which additional genetic events, presumably further activating the RAS-Raf-MEK-ERK pathway, mediate DNA hypermethylatyion via up-regulation of DNMTs in more aggressive JMML cases.

P351

CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND TRANSTHIEMIC ACID THERAPY: PHENOTYPIC MYELOPROLIFERATIVE SYNDROMES WITH GENETIC SIMILARITY TO JMML - CLINICAL 2

IN JUVENILE MYELOMONOCYTIC LEUKEMIA

Summary/Conclusions: Our integrated approach identified three JMML subgroups characterized by distinct clinical and biological features. We provide evidence for a molecular mechanism by which additional genetic events, presumably further activating the RAS-Raf-MEK-ERK pathway, mediate DNA hypermethylatyion via up-regulation of DNMTs in more aggressive JMML cases.
MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE


1Leukemia, University of Texas MD Anderson Cancer Center, Houston, 2Hematology and Medical Oncology, Cleveland Clinic, Cleveland, 3Malignant Hematology, Moffit Cancer Center, Tampa, 4Medicine, Vanderbilt University/Vanderbilt-Ingram Cancer Center, Nashville, 5Hematopathology, University of Texas MD Anderson Cancer Center, Houston, 6Hematopathology, Vanderbilt University/Vanderbilt-Ingram Cancer Center, Nashville, 7Translational Hematology and Oncology, Cleveland Clinic, Cleveland, 8United States of America

Background: MDS/MPN-U is a rare, poorly characterized myeloid neoplasm within the MDS/MPN category in the World Health Organization (WHO) classification. A median survival of 12.4 months from time of referral was previously reported for a cohort of 85 patients with MDS/MPN-U seen at the MD Anderson Cancer Center (MDACC, DiNardo et al. Leukemia 2014). The International Prognostic Scoring System (IPSS) for MDS (Greenberg et al. Blood 1987) discriminated amongst prognostically distinct categories in that cohort, while neither the IPSS for primary myelofibrosis (PMF, Cervantes et al. Blood 2009) nor the revised IPSS (IPSS-R) for MDS (Greenberg et al. Blood 2012) did. Median survival of 21.4 months from the time of diagnosis was reported in a multi-institutional cohort (n=69, Wang et al. Blood 2014). Information on the genomic landscape of MDS/MPN-U is limited to one report on the frequency of SETBP1 mutations (8.3%, Meggedorfer et al. Leukemia 2013).

Aims: To describe the mutational landscape of MDS/MPN-U using targeted multi-gene sequencing.

Methods: Targeted sequencing was performed on DNA from 97 patients with MDS/MPN-U (diagnosed per WHO 2008 criteria but excluding refractory anemia with ringed sideroblasts and thrombocytosis) seen across 4 US institutions (MDACC, 43; Cleveland Clinic, 29; Moffit Cancer Center, 16; Vanderbilt University, 9). Gene panels varied between institutions, with 20 genes (ASXL1, CBL, DNMT3A, ETV6, EZH2, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, PHF6, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2) in common.

Results: Mutational frequencies for the 20 genes tested in all 97 patients were as follows: TET2, 28% (ASXL1, 27%; JAK2, 25%; SRSF2, 22%; EZH2, 15%; SF3B1, 12%; RUNX1, 12%; ZRSR2, 11%; SETBP1, 11%; U2AF1, 11%; NRAS, 10%; DNMT3A, 9%; TP53, 8%; CBL, 4%; ETV6, 4%; NPM1, 4%; IDH2, 2%; KIT, 2%; PHF6, 1% and IDH1, 0%. In 10% of patients, the frequency of mutations in ten other genes of interest in hematologic malignancies was assessed: BRAF, 0% (n=52); CSF3R, 4% (n=52); CALR, 4% (n=53); MPL, 3% (n=88); MLL, 1% (n=99); TET2, 3% (n=72); CEBPA, 4% (n=87); KRAS, 4% (n=81); TP53N11, 4% (n=82) and FLT3, 2% (n=82). Median survival for the whole cohort (n=97) was 12.4 months (range, 1-173). The 43 MDACC patients in this analysis were included in the cohort of 85 previously reported by DiNardo et al. Median age was 70 years (21-89). Median (range) values for leukocytes, neutrophils, hemoglobin, platelets and bone marrow blasts at the time of sample collection for sequencing were 13.4 (1-179) x 10^9/L, 7.9 (0.4-152.4) x 10^9/L, 9.1 (3.1-15) g/dL, 123 (6-1168) x 10^9/L and 2% (0-17), respectively. Upon univariate analysis (n=97), only the presence of EZH2 and ZRSR2 mutations were associated with trends towards statistical significance for survival. Mutated EZH2 adversely affected survival (p=0.066) and ZRSR2 mutation had a favorable impact on survival (p=0.074). The IPSS-R for MDS was useful to differentiate between risk groups with different survival times (p=0.065) while the dynamic IPSS for PMF (Passamonti et al. Blood 2010) was not (p=0.39). On multivariate analysis, only EZH2 mutations and IPSS-R very low risk (versus all other categories combined) were statistically significantly associated with inferior and superior survival, respectively.

Summary/Conclusions: In this cohort of 97 patients with WHO-defined MDS/MPN-U, mutations in genes encoding epigenetic regulators (e.g., TET2, ASXL1, EZH2), spliceosome components (e.g., SRSF2, SF3B1, ZRSR2, U2AF1) or signaling molecules (e.g., JAK2, NRAS), the transcription factor NKX3.1 and SETBP1 were found at frequencies ≥10%. Although the analysis is limited by small numbers, EZH2 mutations were independently associated with poor survival. This represents the largest cohort of patients with MDS/MPN-U interrogated for mutations in multiple genes to date.
Background: Mastocytosis is a clonal disease characterized by heterogeneous manifestations and a normal life expectancy in the majority of cases. In such a condition, it is important to ascertain if other diseases, and particularly solid malignancies, can worsen the prognosis.

Aims: To assess incidence and outcome of secondary primary malignancies (SPM) in adult mastocytosis

Methods: We performed a retrospective analysis of 826 adult (>18 years at diagnosis) mastocytosis patients diagnosed and regularly followed in 6 Italian Institutions. SPM were defined as de novo cancers diagnosed after mastocytosis. We excluded from the analysis non-melanoma skin cancers due to the possible under-reporting of such neoplasms by patients themselves. Also, we did not consider newly hematological neoplasms, as they mainly represent a progression from Systemic Mastocytosis (SM) to SM with an Associated Hematological Neoplasm (AHN). Standardized Incidence Ratio (SIR) was calculated as the ratio between the observed cases in our cohort and the expected cases in the sex- and age-matched general Italian population in the same time period (these data were retrieved from http://www.registri-tumor.it). Times to event (patient-years) were calculated from the diagnosis of mastocytosis to the date of SPM diagnosis, death, or last contact, whichever comes first. Survival curves were estimated according to the Kaplan-Meier method.

Results: Males were 450 (54%). Median age at diagnosis was 49.3 years (range 19-84). Median follow-up was 2.3 years (range 0-41). Subtype diagnoses were: Cutaneous Mastocytosis (n=46), Indolent SM (n=633), Smoldering SM (n=10), SM-AHN (n=34), Aggressive SM (n=47) and Mast cell leukemia (n=2). Fifty-four patients were classified as having mastocytosis in the skin. Overall, 42 patients had a history of malignancies prior to the diagnosis of mastocytosis: in these patients we did not detect any relapse of their prior malignancy after the diagnosis of mastocytosis. A total of 35 SPM were diagnosed in 34 patients (4.1%). Median age at SPM was 56.4 years (range 35-78). The median time from diagnosis of SPM to SPM was 22 months. The overall rate of SPM was 12.8 per 1,000 person-years (95%CI: 9.1-17.6) while the rate in the general adult population was 7.6 per 1,000 person-years (95% CI: 7.5-7.7) resulting in an increased hazard ratio of 1.7 (95%CI: 1.2-2.3). The risk for SPM was higher than expected in females (SIR 1.93, 95% CI: 1.2-3.1) while it was not significantly increased in males (SIR 1.48, 95% CI: 0.9-2.4). We found a clearly increased risk for melanoma (n=8, SIR 15.9, 95%CI: 7.9-31.9) and thyroid cancer (n=3, SIR 9, 95%CI: 2.9-27.9) while a non-significant increased risk was found for prostate cancer in males (n=5, SIR 2.06, 95% CI: 0.8-4.9) and breast cancer in females (n=3, SIR 1.7, 95%CI: 0.5-5.3). All the other malignancies were sporadic (one or two cases for each cancer type) and comparison to the general population was not significant. The death rate in patients with SPM was 14.7% with a median overall survival (OS) from SPM diagnosis of 38 months. OS was significantly inferior in patients with SPM as compared to patients without secondary neoplasia (5-year OS 77.6% vs 93.7% respectively; p<0.01) (Figure 1).

Figure 1. Summary/Conclusions: Patients with mastocytosis may have a significantly higher risk of developing a secondary non hematological cancer as compared to the matched general population. Careful follow-up of these patients is warranted as the rate of malignancies may increase over time and reduce life expectancy.
The diagnosis of prePMF have been added (anemia, leukocytosis >11 x10^9/L, the bone marrow biopsy and an explicit definition of minor clinical criteria for "true" essential thrombocythemia (ET) as these two entities have different clinical phenotype at disease onset.

Methods: To explore the clinical course of patients with CSF3R-mutated CNL and identify risk factor(s) associated with survival.

Results: Data of 47 patients with CSF3R-mutated CNL were collected and analyzed. 35 (76%) patients were male. Median age was 62 years (range: 16-92 years). At diagnosis, 17 (36%) patients had fatigue, 2 (4%) had fever, 8 (17%) experienced diarrhea or abdominal discomfort, 20 (43%) were asymptomatic and leukocytosis had been mostly an incidental laboratory finding. 20 (43%) patients had palpable splenomegaly, and 4 (9%), palpable hepatomegaly. PB parameters, median and (range), were: WBC 42.4×10^9/L (14.4-217.0), platelets 165×10^9/L (17-570), blast percentage 0% (0-10), neutrophil percentage 82% (70-99). The median of blast cells in bone marrow were 1% (range, 0-12%). 46 (98%) patients were in the chronic phase and 1 (2%) in the accelerated phase at diagnosis. Most of the CSF3R mutations was T618I (n=45, 96%), others were T568M (n=1, 2%); 244 (73.2%) patients and 41 (67.2%) patients were screened for ASXL1 and SETBP1 mutations, respectively. 21 (61.8%) patients harbored ASXL1 mutation and 22 (53.7%) harbored SETBP1 mutation. All patients were BCR-ABL1, PDGFR and FGR mutation negative. 2 were CALR mutation and JAK2V617F mutation positive, respectively. Hydroxyurea was the most frequently used therapy (n=48). Other therapies included interferon-a (n=7), hypomethylating agents (n=4), thalidomide (n=2), ruxolitinib (n=1), imatinib (n=3), dasatinib (n=1), chemotherapy (n=6), and transplant (n=2). With a median follow up of 17 months (range, 2-103 months), 7 patients progressed to blastic phase or acute myeloid leukemia (n=6) or myelodysplastic syndrome (n=1), 17 patients died. Survival rate at 30 months was 87%. Median survival was 39 months (95% CI 8.5-69.5). Multivariate analysis showed that WBC >40×10^9/L (HR=3.26, 95% CI 1.14-9.30, p= 0.027) was the sole risk factor for survival. However, SETBP1 or ASXL1 mutation was not associated with survival.

Summary/Conclusions: High WBC count was independently predictive of shortened survival in patients with CSF3R-mutated CNL.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>(Mean±SD)</th>
<th>(Median)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>42.4±18.6</td>
<td>31</td>
<td>14-217</td>
</tr>
<tr>
<td>Platelets</td>
<td>165±50</td>
<td>105</td>
<td>17-570</td>
</tr>
</tbody>
</table>

Summary/Conclusions: ET and prePMF diagnosed according to 2016 WHO criteria are two entities with a different clinical phenotype at diagnosis and a different outcome. The clinical phenotype at disease onset of MPNu and ET is similar.

P357

CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREBRYOPLIFOTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA

E. Rumili1,2, E. Boveni3, M. Bellini1, D. Pietra4, V. Ferretti1, E. Roncoroni2, C. Cavalloni1, M. Ciboddo1,*, I. Casetti1, P. Benvenuti1, C. Astori2, M. Cazzolato1,2

1Department of Molecular Medicine, University of Pavia, 2Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, 3Anatomical Pathology Section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Background: The World Health Organization (WHO) classification system for myeloid neoplasms was recently revised in 2016. The revised WHO criteria underscore the importance of differentiating preBPFM (prePMF) from "true" essential thrombocytopenia (ET) as these two entities have different clinical outcomes. For these reasons, standardization of morphologic findings in the bone marrow biopsy and an explicit definition of minor clinical criteria for the diagnosis of prePMF have been added (anemia, leukocytosis >11 x10^9/L, palpable splenomegaly and LDH).

Aims: To compare the clinical phenotype at diagnosis and the outcome of ET and prePMF diagnosed according to the new 2016 WHO criteria.

Methods: We identified in our database all patients affected with ET, prePMF and MPF diagnosis according to 2008 WHO criteria who satisfied these two requirements: a bone marrow fibrosis grade 0-1 at diagnosis and at least one DNA sample to define the mutational status. Firstly, the bone marrow morphology of all 404 identified patients was reviewed by an expert pathologist. Then, we reclassified patients according to the new 2016 WHO criteria as follows: patient with ET morphology were classified as ET, patients with PMF morphology and JAK2V617F negative were classified as ET (cumulative incidence of overt myelofibrosis at 10 years 86.6%, P<0.001) and a trend to a higher incidence of leukemic evolution (cumulative incidence of acute myeloid leukemia at 10 years 2.3% vs 1.9%, P=0.07) compared to ET patients, while they did not differ in terms of thrombotic complications (cumulative incidence of thrombosis at 10 years 18.5% vs 18%, P=0.9). Finally, we analyzed the subgroup of "old" ET diagnosed according to 2008 WHO criteria. Of 358 "old" ET, 268 were reclassified as ET, 25 as MPNu and 65 as prePMF. The "old" ET reclassified as prePMF had a higher risk of overt myelofibrotic evolution compared to the "old" ET reclassified as ET (cumulative incidence of overt myelofibrosis at 10 years 9.7% vs 0%, P=0.03).

Table 1.
Background: The minimal effective treatment in Essential Thrombocytopeny (ET) patients is tailored mainly on the basis of thrombotic risk scores (primarily non-nocere). The Revised International Prognostic Score for Thrombosis in ET (R-IPSET-Th) is based on different combinations of Age >60 yrs, absence of JAK2 mutations, no Prior Thrombosis (PrTh+), or Age >60 with JAK2+. The risk-by-arm interaction, age, sex, and body mass index (BMI) were assessed using Rules-Based Medicine, Inc. (Austin, TX) Human Biomarker Kit (BMK) data. Of these key BMKs in altered cellular signaling and potentially targetable pathways for symptom reduction.

Methods: Biomarker levels at baseline, week 4 and 24 were measured along with MF symptoms (MFSAF 2.0-Mesa JCO 2013; collected during blinded phase of COMFORT-I). Patients were randomized to ruxolitinib vs placebo. BMKs were assessed using Rules-Based Medicine, Inc. (Austin, TX) Human Biomarker Kit (BMK) data. Associations between the individual symptoms measured within the MFSAF and log2-transformed biomarker data were investigated at baseline using Spearman correlations. Mixed models were used to assess symptom and BMK changes over time. Models included terms for visit, arm, visit-by-arm interaction, age, sex, and body mass index (BMI).

Results: A total of 309 subjects were randomized in COMFORT-I with median age of 68 (range 40-91). Approximately 46% of patients were female and 50% had primary myelofibrosis (61% high risk). All 309 subjects had BMKs measured at one or more of the three visits included in this analysis, with 308 showing biomarker evaluation paired with MFSAF symptom scores at the same visit. Correlations of Baseline Biomarkers and Symptoms. Total symptom score (TSS) statistically significantly (p<0.05) correlated with 20 BMKs at baseline (Table 1). For individual symptoms, spleen-related symptoms appeared to statistically significantly correlate more frequently with BMKs at baseline: abdominal discomfort (23 BMKs), feeling full (20 BMKs), and pain under left ribs (19 BMKs). Night sweats, itchiness, and bone or muscle pain significantly correlated with 15, 14, and 10 BMKs each. The BMKs with the strongest correlations (absolute |r| > 0.50) associated with TSS over time. Like at baseline, BMKs appeared to be more often statistically significantly (p<0.05) associated with spleen-related symptoms over time including 25 and 24 BMKs for abdominal discomfort and feeling full, respectively. Night sweats, pain under left ribs, bone or muscle pain, and itchiness were associated with 20, 12, 12, and 9 BMKs each. Strongest associations (p<0.001) between symptoms and BMKs over time included VCA1 (4/6 symptoms+TSS), B2MICG (3/6 symptoms+TSS), LEPTIN (3/6 symptoms+TSS), TIMP1 (2/6 symptoms+TSS), TNFRII (2/6 symptoms+TSS), INTLK18 (2/6 symptoms+TSS), and VWD (1/6 symptoms).

Summary/Conclusions: Spleen-related symptoms demonstrate close association with BMKs at baseline as well as BMKs over time, after taking into account age, sex, BMI, and treatment. At baseline and over time, abdominal symptoms remained the most frequently correlated or associated symptoms with biomarker levels. More research is needed to determine the role of some of these key BMKs in altered cellular signaling and potentially targetable pathways for symptom reduction.

Table 1.

Study Population
<table>
<thead>
<tr>
<th>Study Group</th>
<th>Number of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>309</td>
</tr>
<tr>
<td>Week 4</td>
<td>285</td>
</tr>
<tr>
<td>Week 24</td>
<td>270</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptom Description</th>
<th>Baseline Correlation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal discomfort</td>
<td>23 BMKs</td>
</tr>
<tr>
<td>Feeling full</td>
<td>20 BMKs</td>
</tr>
<tr>
<td>Pain under left ribs</td>
<td>19 BMKs</td>
</tr>
<tr>
<td>Night sweats</td>
<td>15 BMKs</td>
</tr>
<tr>
<td>Itchiness</td>
<td>14 BMKs</td>
</tr>
<tr>
<td>Bone or muscle pain</td>
<td>10 BMKs</td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: In this study of the Registro Italiano Trombocitemia (RIT), we confirmed that the Revised International Prognostic Score for Thrombosis in ET (R-IPSET-Th) separated ET patients in 4 groups with increasing risk of thrombosis during the follow-up (p<0.001). According to the R-IPSET-Th score, severe complications seem to have occurred in this cohort of ET patients (anti-platelets in almost all cases, and cytoreduction in around 2/3 of VLR and LR cases), probably because other adjunctive risk factors have been considered.
Platelet disorders: Basic

P360
NOVEL HETEROZYGOUS ITGB3 p.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN aIIb3 CAUSES AUTOSONAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL aIIb3 LOCALIZATION

N. Miyashita1,*, M. Onozawa2, K. Hayasaki3, S. Kunishima1, T. Teshima1
1Department of Hematology, Hokkaido University Graduate School of Medicine, 2Department of Hematology, 3Clinical Laboratory, Hokkaido University Hospital, Sapporo, Japan

Background: Congenital macrothrombocytopenia is a rare platelet disorder and its cause is genetically heterogeneous. Recently, integrin αIIb and β3 mutations have been identified in congenital macrothrombocytopenia patients with platelet aggregation dysfunction. Here, we found a novel, heterozygous ITGB3 mutation in a pedigree and examined how this mutation contributed congenital macrothrombocytopenia.

Aims: To detect gene mutations responsible for the congenital macrothrombocytopenia in this pedigree and reveal the molecular pathophysiology.

Methods: Whole exome sequencing (WES) was performed to detect gene mutations. Expression and activation state of αIIbβ3 in platelets was evaluated by flow cytometry (FCM) and western blotting (WB). The effects of mutations on αIIbβ3 activation state, phosphorylation of FAK, and morphological changes were analyzed in transfected cells by WB and immunofluorescence staining.

Results: The patients were 56-year-old Japanese woman and 2 of her 3 sons. They had no bleeding tendencies and near-normal bleeding time (Duke’s method). Hematological examination revealed their decreased platelet counts (58-86 x 10^9/l) with increase of mean platelet volume (12.8-14.5 fl). In all affected family members, giant platelets were observed on the peripheral blood smears. Platelet aggregation induced by ADP (1-10 μM) and collagen (2 μg/ml) was obviously reduced although that induced by ristocetin (1.5 mg/ml) was within normal limit. The family pedigree indicates that the inheritance pattern is autosomal dominant. Common congenital macrothrombocytopenias, such as MYH9 disorders, Bernard-Soulier syndrome and type 2B von Willebrand disease were excluded by the absent leucocyte inclusion bodies, normal ristocetin induced platelet aggregation and normal platelet GP Ibα/IX expression, normal von Willebrand factor assays, respectively. WES revealed that all affected family members had a heterozygous ITGB3 p.T746del mutation. FCM showed decreased surface expression level of αIIbβ3 in the affected member’s platelets. However WB of platelet lysates showed that there was no difference in the total amount of αIIbβ3 among the affected and unaffected members and normal controls. FCM showed a constitutive activation of αIIbβ3 on the patient’s platelets as reflected by the spontaneous binding of PAC-1 antibody. Immunofluorescence staining using CHO cells showed membrane localization of αIIbβ3 in wild-type αIIbβ3-expressing cells and cytoplasmic localization in αIIbβ3 (p.T746del) transfected cells. Further, immunofluorescence staining of CHO cells showed spontaneous tyrosine phosphorylation of FAK and morphological changes, such as rhomboid changes, elongated changes, abnormal cytoplasmic protrusions, and membrane ruffling, in transfected cells. FAK inhibitor (1,2,4,5-Benzotetraamine tetrahydrochloride) hindered the localization change of αIIbβ3 and the morphological changes in transfected cells by dose dependent manner.

Summary/Conclusions: The autosomal dominant heterozygous ITGB3 p.T746del mutation was found to be responsible for constitutive activation of αIIbβ3 in the patients’ platelets as well as transfected cells. It is considered that ITGB3 p.T746del mutation unclips the highly conserved membrane proximal complex of αIIb and β3 cytoplasmic tails and renders the activated form. Activation of αIIbβ3 leads to phosphorylation of FAK causing morphological changes in transfected cells, which is considered to reflect abnormal thrombopoiesis leading to the production of giant platelets. We conclude that platelet aggregation dysfunction is due to decrease of αIIbβ3 expression on the platelet membrane surface due to cytoplasmic localization. These results suggest that the gain-of-function mutation around membrane region of αIIbβ3 leads to macrothrombocytopenia with impaired surface αIIbβ3 expression.

P361
CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELMETROPA

J. Bastida1,*, J. Hernandez-Sanchez2, A. Rodriguez2, D. Alonso-Lopez2, E. Lumbraeras2, M. Lopez-Parra1, R. Bueno2, A. Veiga1, J. Hernandez-Rivas1, J. Gonzalez-Porras1
1Department of Hematology, Hospital Universitario de Salamanca-IBSAL, 2Department of Hematology, IBSAL, IBMMC, CIC, Universidad de Salamanca-CSIC, Salamanca, Spain

Background: Emtrombopag (ETP) is an orally bioavailable, small non-peptide molecule thrombopoietin receptor agonist that stimulates platelet production by a mechanism similar, but not identical to, endogenous thrombopoietin. ETP interacts with the transmembrane domain of thrombopoietin receptor, initiating a JAK/STAT signaling pathway inducing the proliferation and differentiation of the megakaryocytes to increase platelets production.

Aims: To assess the gene expression profile (GEP) and the underlying signaling pathways modified before and during the ETP treatment in chronic immune thrombocytopenia (ITPc) patients.

Methods: ITPc patients (n=14) treated with ETP were evaluated. Complete response (CR) was defined as a platelet count of ≥100x10^3/mm^3 and treatment failure was defined as a platelet count of ≤20x10^3/mm^3 for 4 consecutive weeks at the highest recommended dose of ETP, a major bleeding event, or the need to change therapy. RNA was isolated from mononucleated cells pre/post ETP treatment. The “paired” GEP of the ITPc patients included the semi-supervised analysis cluster samples before and after (28 day) the treatment with ETP. This paired GEP was showed in Figure 1. The GEP workflow consisted of the following steps: 28-paired samples were hybridized to GeneChip Human Gene 2.0 ST Array (Affymetrix’s). The robust microarray analysis (RMA) algorithm was used for background correction and normalization, while signal expression was calculated by significance analysis of each microarray to provide a robust statistical inference by a permutation method. P-values were provided and adjusted by multiples testing using a false discovery rate (FDR). The pathways and upstream regulators related with the most differentially expressed genes were analyzed by in silico analysis tools: Advista Bio’s PathwayGuide (http://www.advistabio.com/pathwayguide) and DAVID Bioinformatics Resources.

Results: The median age of the 14 ITPc patients enrolled in the study was 77 years (range: 35-87y), 64% patients (n=9) were treated with ETP after ≥2 lines of treatments. Only 3 patients were splenectomized. Median platelet (P) and white blood cell counts (WBC) increased after treated by ETP at day 28. (P and WBC pre: 14,15x10^3/mm^3 and 6,85x10^3/mm^3 vs P and WBC post: 132x10^3/mm^3 and 9,1x10^3/mm^3). All but two patients achieved CR (85,7%) and other 2 were considered failure of treatment. Regarding the gene expression profile, in silico analysis showed that the expression of 147 genes was modified after ETP treatment; all of them were overexpressed after treatment. Semi-supervised cluster analysis showed 2 groups: pre and post ETP treatment (Figure 1). Pathway analysis revealed that 38 genes were involved in the maintenance of hemostasis, most of them related to platelet activation (PTGS1, GP1BA or GP6). Interestingly, the paired GEP pointed out E2F1 and GFI1B as possible leaders of the increase of the megakaryopoiesis. Other signaling pathways overexpressed by ETP treatment are downstream routes of PI3K/Akt (GFI1B, JAM3, ITGB3 and ITGA2B) and platelet activation (GP6, GP9, GP1BA or PTGS1).

Summary/Conclusions: In ITPc patients, ETP can induce overexpression of genes involved in platelet activation and megakaryopoiesis and also alter key/relevant/signaling pathways such as JAK/STAT and PI3K/Akt.

P362
DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRE-SPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA

N. Miyashita1,*, M. Onozawa2, K. Hayasaki3, S. Kunishima4, T. Teshima1
1Department of Hematology, Hospital Universitario de Salamanca-IBSAL, 2Department of Hematology, IBSAL, IBMMC, CIC, Universidad de Salamanca-CSIC, Salamanca, Spain

Background: Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The autoantibodies produced by autoreactive B cells against-antigens, specifically immunoglobulin G (IgG)

Figure 1.

Summary/Conclusions: In ITPc patients, ETP can induce overexpression of genes involved in platelet activation and megakaryopoiesis and also alter key/relevant/signaling pathways such as JAK/STAT and PI3K/Akt.

1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin, 2Second Affiliated Hospital of Kunming medical University, Kunming, China

122 | haematologica | 2017; 102(s2)
antibodies against glycoprotein Ibα (GPIbα)Illa and/or GPIbαIX are considered to play a crucial role. B cell homeostasis and function are controlled by cell surface receptor-ligand interactions. The activation of PI3K is initiated by engagement of the pre-B cell receptor (BCR) and the BCR. The phosphatase and tensin homolog (PTEN) suppress the activity of the PI3K pathway. As a consequence, loss of PTEN function leads to excessive PI3 (3, 4, 5) P3 at the plasma membrane and to recruitment and activation of Akt family members that potently drive cell survival and proliferation. PTEN regulates normal signaling through the B cell receptor (BCR). In immune thrombocytopenia (ITP), enhanced BCR signaling contributes to increased B cell activity, but the role of PTEN in human ITP has remained unclear. Both IL-21/IL-21R signaling and PI3K-PTEN molecules are involved in maintaining normal humoral immunity and deletion of autoreactive B cells. In this study, we want to determine whether abnormalities in PTEN might contribute to increase B cell responsiveness in this disease and IL-21-mediated PTEN induction was defective. Meanwhile, we want to evaluate the relation between the expression of PTEN in B cells and the prognosis of ITP, which will provide a theoretical basis of new treatment strategy for the ITP patients.

Aims: PTEN is involved in maintaining normal B cell function. Since B cell overactivity is characteristic of autoimmune thrombocytopenia (ITP), we sought to determine whether abnormalities in PTEN might contribute to increase B cell responsiveness in this disease.

Methods: 1. This study recruited 28 newly-diagnosed CITP patients and 26 sex and age matched health volunteers as health controls (HC). Peripheral blood mononuclear cells were isolated from collected anti-coagulated blood. 2. Flow cytometry and real-time quantitative PCR were used for detecting the level of PTEN from PBMC cells of HC and CITP patients. 3. The relationship between PTEN levels and the disease severity of CITP was analyzed. 4. PBMC cells were incubated with human rL-2 rL-2r1 CD40L or anti-igM alone or in combination for 72 h and after that the PTEN level was detected by flow cytometry. The proportion and surface activated marker of B cells were determined by flow cytometry.

Results: 1. Compared to HC the expression of PTEN was diminished in each CITP B cell population except IgD-CD38low/memory B cells. In addition, PTEN mRNA was also decreased in ITP B cells. 2. The level of PTEN in B cells was slightly correlated with blood platelet count (p<0.008) and also directly correlated with the production of platelet-specific antibody (P=0.03). 3. The capacity of IL-21 to induce PTEN expression in B cells of HC was found by flow cytometry. Importantly, we found that CD40L and anti-igM were the most potent inducers of PTEN expression in normal B cells, followed by IL-21 and IL-2. Neither IL-21 alone nor CD40L plus anti-igM nor the three in combination stimulated PTEN protein up-regulation in B cells in CITP patients. 4. These immature B cells in CITP patients had a greater expression of CD95 but less PTEN compared to HC suggesting that down-regulation of PTEN was associated with an increasing proportion of immature B cells with a more activated phenotype in CITP patients (Figure 1).

Figure 1.

Summary/Conclusions: Immune thrombocytopenia B cell showed decreased levels of PTEN and the decrease was associated with low platelet count and positive serum platelet-specific antibody. The capacity of IL-21 to induce PTEN was defect in CITP. Together, these data suggesting that the defective PTEN expression, regulation and function contribute to B cell hyper-responsiveness in CITP.

P363

A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCYTOPENIA

J. Xue1, J. Zhang1, Q. Wang1, L. Xu1, X. Zhu1, Y. He1, Y. Kong1, Y. Chang1, X. Zhao1, X. Zhao1, M. Lv1, L. Xu1, K. Liu1, X. Huang1, X. Zhang1.

1Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China

Background: Immune thrombocytopenia (ITP) is a common autoimmune disorder characterized by increased bleeding tendency and isolated thrombocytopenia. The precise pathogenesis of the decreased thrombopoiesis in ITP remains unknown. It has been demonstrated that megakaryocytes (MKs) in ITP show impaired proplatelets formation (PFF) (Br J Haematol 2014;165:854-64). However, the pathogenesis of the impaired PFF in ITP is not entirely understood. Additionally, the lipid mediator sphingosine 1-phosphate (S1P) plays a critical role in megakaryocytic PFF in the bone marrow (BM) niche (J Exp Med. 2012;210:2317-40). It has been demonstrated that cell-surface S1P receptors (S1PR) on MKs trigger the activation of Gi/Rac GTPase signaling. Sphingosine kinase 2 (Sphk2) is the major isoenzyme regulating intracellular synthesis of S1P in MKs. Additionally, intracellular S1P influences the expression of Src family kinase (SFK) in MKs, including 6 members (Fyn, Lyn, Src, Yes, Fgr, and Hck), which mutually regulate each other with Rac GTPase.

Aims: To determine whether the S1P levels in both the BM niche and within MKs, as well as S1PR expression of MKs contribute to the defective thrombopoiesis in ITP through impaired PFF.

Methods: The PPF of ITP-MKs was measured by an in vitro PPF assay using HSCs from the BM. (FASEB J. 2010;24:4701-10). Additionally, all-trans-retinoic acid (ATRA), the S1p1-specific agonist SEW2871, and extracellular S1P were used as interference factors. The concentration of S1P in the plasma and BM was measured by ELISA. The concentration of intracellular S1P was measured using liquid chromatography-mass spectrometry (LC/MS) analysis. Intracellular Sphk2, SFKs and cell-surface S1PR were measured using PCR and western blotting. The location of Sphk2 was analysed by immunofluorescence using an anti-human Sphk2 antibody. The activities of Rac-GTP were quantified by pull-down assay.

Results: Significantly fewer numbers of proplatelet-forming MKs were observed in ITP cultures. The concentration of S1P in the plasma and in BM of patients with ITP was measured, of which the results showed no significant difference in the plasma/BM S1P ratio. Decreased expression of S1PR1 and S1PR4 was observed in ITP-MKs. We found that downstream Gi/Rac GTPase signalling activated by S1PR1 was down-regulated. ITP-MKs exhibited decreased intracellular Sphk2, indicating less biosynthesis of intracellular S1P. Immunostaining of Sphk2 in ITP MKs was performed, showing that less Sphk2 was primarily localized to the nucleus of ITP MKs. Intracellular S1P of ITP MKs was further explored showing a decrease of megakaryocytic S1P production ascribed to significantly reduced Sphk2 expression. Additionally, the gene expression and protein levels of family of SFKs were examined in ITP MKs, and the overall mRNA expression was significantly limited in ITP MKs. The total Src protein levels and p-SFKs (phospho-tyrosine-418) were significantly reduced in ITP MKs, indicating significant reduction of SFK activity. ATRA, SEW2871 and extracellular S1P enhanced Rac GTPase activity and SFK expression, which rescued the defect of PFF in ITP.

Summary/Conclusions: Decreased intracellular S1P ascribed to significantly reduced Sphk2, results in down-regulated SFK expression and activity, and decreased S1PR1 and S1PR4 down-regulate Gi/Rac GTPase signaling in ITP-MKs. Therefore, abnormal S1P/S1PR possibly plays a role in the pathogenesis of impaired PPF in ITP, which may be therapeutically regulated by ATRA.

P364

ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA

I. Marthaler,1 R. Jouni1, J. Alex2, A. Greinacher2, T. Bakhoum1

1Center for Clinical Transfusion Medicine, University Hospital of Tübingen, Tübingen, 2Transfusion Medicine, Universitätmedizin Greifswald, Greifswald, Germany

Background: Immune thrombocytopenia (ITP) is a bleeding disease caused by autoantibodies (AAbs) directed against platelet (PLT) glycoproteins (GPI). A novel mechanism of antibody-mediated PLT destruction based on Fc-independent PLT clearance via Ashwell-Morell receptors (AMRs), which recognize glycan modifications on the surface of PLTs, has been suggested.

Aims: In this study we investigated the effects of human AAbs from ITP patients on the glycan pattern of human PLTs and the consequent impact on their survival in vivo.

Methods: Monoclonal platelet antigen capture assay (MAIPA) and lectin binding assays were used to evaluate antibodies from ITP sera and healthy donors.

Results: In this study, we investigated the effects of human AAbs from ITP patients on the glycan pattern of human PLTs and the consequent impact on their survival in vivo.

Summary/Conclusions: Increased glycan modulation and decreased survival in vivo.
tin (PNA) that bind to galactose, N-acetyllactosamine and N-acetylgalactosamine residues, respectively. The NOD/SCID mouse model was used to study the impact of different glycan patterns on the survival of human PLTs.

**Results:** In this work 37 sera from ITP patients and 25 sera from healthy donors were analyzed. In the LBA, after incubation with AAbs, different patterns of glycan modification were observed. 17/37 sera caused a significant increase in PNA binding compared to healthy donors (median fold increase (FI): 1.21; range: 1.08 - 1.40). 9/37 sera induced higher ECL binding (median FI: 1.02, range: 1.08 - 1.15). In contrast, 8/37 sera showed strong decrease in RCA binding (median FI: 0.52, range: 0.50 - 0.59). Sera from healthy donors did not induced significant change. Interestingly, not only GP- Ib/IX AAbs but also GP-IIb/IIIa AAbs were able to modify glycan pattern. In NOD/SCID mice the administration of AAbs induced an accelerated clearance of human PLTs from the circulation. The destruction of human PLTs by ITP-AAbs was decreased but not completely prevented by a specific neuraminidase inhibitor that blocks glycan changes on PLT surface (survival of human PLTs after 5h: 48%, range 41.53% - 59%, vs 22-40%).

**Summary/Conclusions:** Our results demonstrate that AAbs from ITP patients are able to induce cleavage of glycan moieties on the PLT surface in distinct manners. Antibody-mediated modification of glycan patterns seems to contribute to AAb-mediated PLT destruction.

**P365**

**NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA**

P. Noris1,2, D. De Rocco2, F. Melazzini1, C. Marconi3, A. Pecci4, R. Bottega2, C. Gnan2, F. Palombo4, P. Giordano5, M.S. Coccioli 6, A.C. Glembotsky 7, C. Gnan2, F. Palombo4, P. Giordano5, M.S. Coccioli 6, A.C. Glembotsky 7, E. Cigalini1, P.G. Heller7, M. Seri3, A. Savoia28

1Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, 2Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, 3Department of Medical and Surgical Science, Policlinico Sant’Orsola Malpighi and University of Bologna, 4Department of Medical and Surgical Science, Policlinico Sant’Orsola Malpighi and University of Bologna, 5Department of Biomedical Science and Human Oncology, Clinical Pediatrics “B. Trambusti”, University of Bari, 6U.O.C of Pediatrics, Hospital “D. Camberlingo”, Francavilla Fontana, Bari, Italy, 7Institute of Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, 8Amgen Inc., Thousand Oaks, United States

**Background:** Familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML) is a rare autosomal dominant inherited thrombocytopenia (IT) caused by mutations in the hematopoietic transcription factor RUNX1; an important hallmark of this IT is the increased risk of developing myeloid neoplasms, such as AML and myelodysplastic syndromes (MDS). FPD/AML is caused by different mutations of RUNX1 encoding the DNA binding subunit (known as core binding factor-alpha, CBF-alpha) of the CBF transcription complex. The N-terminus domain of RUNX1 (runt-homologous domain) mediates DNA binding and heterodimerization to CBF-beta, the other subunit of the CBF complex. The C-terminus of RUNX1 includes domains that are involved in transcription activation and repression. This IT is characterized by impaired megakaryopoiesis and moderate thrombocytopenia, with normal-sized and dysfunctional platelets.

**Aims:** To unravel the molecular basis of ITs and to improve our knowledge on the molecular basis and clinical-laboratory picture of FPD/AML.

**Methods:** Whole exome sequencing (WES) was performed in 86 propositi with an unknown IT after the diagnostic workup based on the most updated diagnostic algorithm for ITs (Clin Genet 2016;89:141). RUNX1 variants identified by WES were confirmed by Sanger sequencing in the propositi and all available family members, which also undergo clinical-laboratory characterization. The study was approved by the Institutional Review Board of the IRCCS Policlinico S. Matteo Foundation; all patients gave written informed consent.

**Results:** We identified three pedigrees (families 1-3) with different RUNX1 heterozygous mutations, all segregating with thrombocytopenia in the respective families: the novel variants c.578T>A and c.967+2_5del, and the known ANKRD26 and RUNX1 mutations in all patients with an autosomal dominant IT and normal platelet size.

**Summary/Conclusions:** FPD/AML is an IT lacking pathognomonic laboratory criteria: it is characterized by a mild functional defect and, much more importantly, by a normal platelet size, similarly to the other ITs predisposing to hematological malignancies (ANKRD26 and ETV6-related thrombocytopenias). Given the importance of recognizing these diseases for patients counseling, follow-up, and therapeutic approach, we recommend a systematic screening for RUNX1, ANKRD26, and ETV6 mutations in all patients with an autosomal dominant IT and normal platelet size.
first 6 months was 50% (0%, 83.3%); that of months 7-12 was 92% (33%, 100%). Overall, 80% (114/143) of patients had a platelet response. The median (Q1, Q3) time of an increase in platelet counts ≥20×10^9/L above baseline was 60% (25%, 84%). The median dose increased to 10 μg/kg by week 32. Median (min–max) treatment duration to date was 25 (1-67) weeks for a total exposure to date of 79 patient-years. Median (min–max) average weekly romiplostim dose was 6.1 (0.4-9.0) μg/kg. 32 patients (22%) discontinued treatment for lack of efficacy (n=17), required other therapy (n=5), patient request (n=4), noncompliance (n=2), adverse event (AE) (n=2) (interstitial lung disease in a 15 y old boy and abdominal pain, vomiting, and headache related to treatment per investigator in a 9 y old girl), administrative decision (n=1), and investigator decision (n=1). 34 (23%) patients received rescue medications. 15 (10.3%) patients had serious AEs (SAEs) including epistaxis (n=4), petechiae (n=2), decreased platelet count (n=2), and thrombocytopenia (n=2). A case of abdominal pain was the only SAE deemed treatment-related by the investigator. TCTAEC grade 3 bleeding was seen in 8 patients (6%) and included epistaxis (n=5), ecchymosis (n=2), petechiae (n=2), and 1 case each of hematemesis, hematomata, SC hemorrhage, injection site hemorrhage, and mouth hemorrhage. No grade 4 or 5 bleeding was observed. No neutralizing antibodies against romiplostim or TPO were identified. Of 30 patients with baseline bone marrow biopsies (bone marrow biopsies were obtained at European sites), all had modified Bauermeister scores of grade 0 (no reticulin) or 1 (fine fibers) and bone marrows typical for ITP. Of these 30 patients, 21 had evaluable on-study biopsies obtained after ~1 year of treatment, with no increases in 2 or more grades, findings of collagen, or bone marrow abnormalities (Figure 1).

Summary/Conclusions: In this year 1 dataset of an ongoing open-label study of romiplostim in children with ITP, the time in the first 6 months with a platelet response was 50%, with 80% of children having a platelet response at some point on study. The median romiplostim dose reached 10 μg/kg and there were no new safety signals. No effects of romiplostim were observed on the bone marrow in the subset of patients with bone marrow biopsies. Future datacuts for years 2 and 3 in this study, the largest of romiplostim in children with ITP with 79 patient-years of exposure to date, will provide more information on platelet response, dose requirements, and safety.

P368
NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?
N. Binsaleh1, C. Wigley1, K. Whitehead1, D. Moreno-Martinez1, S. Danielis1, S. Jones1, M. van Rensburg2, L. Pilkington2, D. Barker2, N. Dempsey-Hibbert1
1School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, 2School of Chemical Sciences, University of Auckland, Auckland, New Zealand

Background: Platelet hyperactivity is associated with a number of disorders including Acute Coronary Syndromes (ACS) and manifests as increased platelet activation and often inappropriate thrombus formation. The thienopyridine class of anti-platelet drugs, of which clopidogrel and prasugrel are the most well known, target the P2Y12 receptor on platelets, blocking the effects of the platelet agonist ADP. However, the effects of these drugs are variable amongst patients, with some patients responding well and some remaining at risk of thrombosis. This variability highlights a need for a refinement of this class of P2Y12 inhibitor. Aims: The aim of this study was to assess the efficacy of six novel thiopyridine derivatives synthesized by our group by examining their potential as in-vitro inhibitors of platelet function.

Methods: Healthy human platelets were isolated and incubated with novel thiopyridine compounds (D,J0081, D,J0199, D,J0201, D,J0206, D,J0171, D,J0097) (10μM, 30min) prior to stimulation with ADP (10μM) and analysis of alpha granule secretion (CD62P expression), GPIIb/IIIa activation (PAC1 expression) and platelet leukocyte aggregate (PLA) formation using flow cytometry. Furthermore, light transmission aggregometry (LTA) was used to assess ADP-induced platelet aggregation after these treatments. As clopidogrel is usually prescribed in combination with the COX-1 inhibitor acetylsalicylic acid (ASA), significant reduction in ADP-mediated platelet aggregation (P<0.001), CD62P expression (p<0.001), PAC1 expression (p<0.01) and PLA formation (p<0.05). These compounds were also shown to enhance the inhibitory effects of ASA. D,J0171 and D,J0199 were particularly potent, displaying greater inhibitory effect than clopidogrel.

Summary/Conclusions: The study demonstrates the potential for new thiopyridine compounds as modulators of platelet function and points to the possibility of future use in patients at risk of platelet hyperactivity and thrombosis.

Quality of life, palliative care, ethics and health economics
P370

ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM

P. Toulon1,*, N. De Poorter2, M. Brionne-François3, M. Smaïhi4, L. Abecassis5
1Hematology, Pasteur University Hospital, Nice, 2Hematology, General Hospital, Grasse, 3Hematology, University Hospital, Caen, 4Hematology, Simone Veil Hospital, Eaubonne, 5Hematology, General Hospital, Aulnay, France

Background: The diagnosis of venous thromboembolism (VTE) can be safely excluded in the case of D-dimer levels below a well defined cut-off value in patients with a low or intermediate pre-test probability (PTP), as the test negative predictive value (NPV) is close to 100%. As ageing is associated with increased D-dimer levels, the question arose whether D-dimer measurement was useful to rule out VTE in elderly patients.

Aims: The aim of the present study was to evaluate the clinical performance of a diagnosis strategy based on age-adjusted cut-off values calculated by multiplying the patient’s age by 10 in patients aged over 50, and to evaluate its economic impact.

Methods: We included 1255 consecutive outpatients with non-high PTP of VTE referred to the emergency departments at 5 French centres (2 university hospitals, and 3 general hospitals, in whom D-dimer testing was prescribed. The same standardized procedure was used in the 5 centres i.e. D-dimer measurement in patients with a non-high PTP, and imaging techniques (usually computed pulmonary angiography in case of suspected PE and Doppler ultrasonography in case of suspected DVT) in the case of D-dimer above the cut-off level. D-dimer levels were evaluated using the same fully automated latex-based assay (Hemoglobin Liat, Diasorin, Italy). The usual cut-off level for VTE exclusion being 500 ng/mL (fibrinogen equivalent units, FEU).

Results: VTE diagnosis was established by objective testing in 115 patients (9.2%): 88 of the 1082 patients referred for suspected PE (8.1%) and 27 of the 173 patients referred for suspected DVT (15.6%). D-dimer levels were above 500 ng/mL in all patients with VTE and in 521 of the 1140 patients without VTE (45.7%), leading to test NPV and sensitivity of 100%. The overall test specificity was 54.3%, even though it significantly decreased in an age-dependent manner over 60 years old. This is due to increased D-dimer levels in older patients particularly in those above 80 years. Using age-adjusted cut-off levels, calculated by multiplying the patient’s age by 10 in patients aged over 50, and to evaluate its economic impact. Such an improvement in test performance was found both in patients with suspected PE and DVT (Table). As such an increase in test specificity would have led to exclude VTE in a higher percentage of patients in the studied population, we evaluated the cost-effectiveness of both strategies, taking into account the local reimbursement rates of D-dimer measurement and Doppler ultrasonography (16.20, 58.72, and 75.60 Euros respectively).

Summary/Conclusions: The use of age-adjusted cut-off levels for D-dimer, in patients aged over 50 years old, led to a significant increase in the test specificity, but correlate to slightly decreased NPV and sensitivity. Even though some patients with D-dimer levels above 500 ng/mL but below the age-adjusted cut-off level would be misdiagnosed, such a strategy was found to be safe in our studied population with a high NPV (99.9%) and sensitivity (99.1%), and cost-effective.

P371

IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKAEMIA AND MYELODYSPLASIA SYNDROME

S. Lachance1,*, J. Bibeaü2, N. Ladjemil3, J. Lachaine4
1Hematology, Pasteur University Hospital, Montréal, Hôpital Maisonneuve-Rosemont, 2Peripharm Inc., 3Peripharm, Montréal, 4Pharmacie, Université de Montréal, Montréal, Canada

Background: Relapse following allogeneic hematopoietic stem cell transplant (aHSCT) is associated to a very poor outcome and remains an unmet medical needs. The impact of treatment approach on costs and survival remains unknown. The development of innovative cellular therapy for the treatment of relapse following aHSCT may change its dismal outcome but the cost of such intervention has prohibited its large-scale development.

Aims: The objective of this study was to measure the economic burden associated with the management of relapse following aHSCT and to evaluate the impact of treatment choice on survival and health care costs.

Methods: A retrospective medical chart review was conducted at Maison-Neuve-Rosemont Hospital (MHR) after research and ethic committee approval. Patients were selected using the Hematopoietic Stem Cell Transplant (HSCT) program database. Eligible patients were diagnosed with acute leukemia (AL) or MDS and relapsed following a HSCT between January 1st 2011 and December 31st 2014. Patients’ and disease characteristics and relapse-related health care resource utilization were collected from the date of post transplant relapse until death or last follow-up. Canadian unit costs for each intervention/treatment were obtained from literature and governmental publications.

Results: During the study period, 645 HSCT were performed at MHR, 303 were allogeneic. A total of 36 patients met the inclusion criteria and were included in the analysis. 32 recipients were diagnosed with AL and 4 with MDS. Treatment approaches following aHSCT relapse were divided in three groups according to patient and physician choices: group 1 received supportive care (n=9), group 2 received chemotherapy or tyrosine kinase inhibitors (n=21) and group 3 received a cellular based therapy, either donor lymphocyte infusion (DLI) or a second aHSCT (n=6). The median cost of care per patient per month was C$20,239 (SD=17,079). The median survival following relapse for the entire cohort was 12.4 months (SD=2.8). For group 1, 2 and 3, the mean cost of care per patient per month was C$17,436 (SD=16,447), C$22,914 (SD=18,474) and C$15,082 (SD=12,954), respectively. The median survival was 4.0 months (SD=2.0), 7.2 months (SD=1.6), and 46.6 months (SD=8.4), for treatment group 1, 2 and 3 respectively (Figure1).

Figure 1. Survival according to treatment group.

Summary/Conclusions: Relapse following aHSCT is associated to a poor prognosis and survival and to significant use of health care resources. Despite the selection bias, only patients who received cellular based therapy, either DLI or another HSCT, enjoyed a prolonged survival. Healthcare resources devoted to the care of patients in relapse post aHSCT provide a comparative basis for cost efficiency analysis in the development of innovative cellular therapy.

P372

ACUTE MYELOID LEUKAEMIA TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION

M. Hagiwara1,*, A. Sharma1, K. Chung2, T. E. Delea1
1Policy Analysis Inc., Brookline, MA, 2Jazz Pharmaceuticals, Palo Alto, CA, United States

Background: AML is a rapidly progressive hematologic malignancy that accounts for 25% of all leukemias in the Western world, with an estimated 5-year survival of 26%, and is associated with high HRU and costs.

Aims: To estimate HRU and costs among newly-diagnosed AML patients (pts) in a US commercially insured population by receipt of chemotherapy (CT) or stem cell transplant (SCT).

Methods: This was a retrospective observational study using the PharMetricsPlus® database. Pts were adults with AML (ICD-9-CM code 205.0x respectively) and received chemotherapy (CT) or stem cell transplant (SCT). 19593 pts were included (n=19593) from 16 healthcare plans in 10 US states.

Figure 1. Survival according to treatment group.

Summary/Conclusions: Relapse following aHSCT is associated to a poor prognosis and survival and to significant use of health care resources. Despite the selection bias, only patients who received cellular based therapy, either DLI or another HSCT, enjoyed a prolonged survival. Healthcare resources devoted to the care of patients in relapse post aHSCT provide a comparative basis for cost efficiency analysis in the development of innovative cellular therapy.
not continuously enrolled for 12-months (mos) before the first AML claim (index date); evidence of acute promyelocytic leukemia anytime during the study period; missing enrollment information; or ≥1 hospitalizations during follow-up (FU) with missing cost. Tpts were classified as treated or untreated, with treatment defined based on receipt of CT (inpatient or outpatient) or SCT. For treated pts, FU was partitioned into 2 periods: index date to 6 mos and >6 mos post index date. Mean HRU and costs over the FU period were calculated by receipt of treatment and, for treated pts, by time since index date.

**Results:** 10,197 pts met study criteria including 6,862 treated pts (67%) and 3,335 untreated pts (33%). Mean age was 55 and 60 years in treated and untreated pts, respectively. Mean follow-up was 19.3 mos in treated pts and 18.1 mos in untreated pts. Mean total costs were higher for treated pts ($386,711) vs untreated pts ($83,274). In treated pts, mean total costs were $166,156 during the first 6 mos (mean duration 3.9 mos), and $220,555 during the remaining follow-up period (mean duration 19 mos), 26% of treated pts had SCT. Costs of inpatient and outpatient CT during the first 6 mos were $86,188, representing 22% of the total cost for treated pts (Table 1).

| Table 1. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Treated Pts     | Unrevenued Pts  |                |                |                |                |
| SCL/BCR transfusions/patient | $262,139 | $281,573         |                |                |                |                |
| Ofactinavir gabaacide, tna | 188    | 209             |                |                |                |                |
| Outpatient pharmacy claims, tna | 17     | 19              |                |                |                |                |
| Emergency department visits, tna | 1.7   | 0.6             |                |                |                |                |
| Hemoglobin, mean | 9.6   | 9.6             |                |                |                |                |
| Hemoglobin, min | 7.0   | 7.0             |                |                |                |                |
| Hypertension, mean | 16    | 16              |                |                |                |                |
| Hypertension, min | 11    | 11              |                |                |                |                |
| Total costs, tna | 386,711 | 83,274          |                |                |                |                |
| SCT (n=981) | 54,236 | 16,326          |                |                |                |                |
| CT (n=981) | 10,399 | 3,577           |                |                |                |                |
| Other unts & tna | 24,877 | 13,388          |                |                |                |                |
| Other cost  | 10,605 | 31,379          |                |                |                |                |
| Pharmacy | 20,208 | 4,792           |                |                |                |                |

**Summary/Conclusions:** HRU and costs of managing AML pts are consider- able, with greatest HRU and cost in pts receiving CT or SCT.

**P373**

**HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS WITH PERIPHERAL NERVE INVOLVEMENT**

M. Yokota1, S.D. Guthrie 2, T.P. Quock2, K.L. McCausland 1,*, M.K. White 1, M. Bayliss1

1Optum, Lincoln, 2Prothena Biosciences Inc, South San Francisco, United States

**Background:** In light chain (AL) amyloidosis, misfolded light chains accumulate and cause progressive peripheral neuropathy (PN) and failure of critical organs such as the heart and kidneys. Consequently, a progressive, ascending sen- sorimotor neuropathy is often a related clinical finding.

**Aims:** This study describes disease characteristics and health-related quality of life (HRQoL) in AL amyloidosis patients with peripheral nerve involvement (AL-PN).

**Methods:** An online survey was administered to AL-PN (n=126) and non- nerve–affected (n=215) patients to assess patient characteristics and HRQoL (based on the SF-36v2 Health Survey [SF-36v2]). The survey measures eight health domains including physical (PF), role physical (RP) due to health-related physical limitations, bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), mental health (MH), in addition to physical (PCS) and mental component summary (MCS) measures. Patient characteristics were compared using chi-square tests. Differences in symptomatic and HRQoL burden were tested with multivariable logistic and linear models, respectively. Differences in mean HRQoL between AL-PN and non-AL-PN patients were compared to established minimally important differences (MIDs).

**Results:** Compared to non-nerve–affected patients, greater proportions of AL-PN patients visited ≥6 doctors (42.1% vs 19.5%, p <0.001) and ≥6 specialists (24.6 vs 9.9%, p <0.001). AL-PN patients also had symptoms for ≥1 year prior to receiving a diagnosis (50.8 vs 39.1%, p=0.035), relative to non-nerve–affect- ed patients. Nearly all AL-PN patients (97.6%) reported multi-system involvement. Gastrointestinal involvement was more prevalent in AL-PN patients versus non-AL-PN patients (68.3 vs 28.8%, p <0.001). There were greater odds of experiencing numbness (OR=4.23, 95% CI: 2.45–7.30, p <0.001) and fatigue (OR=3.09, 95% CI: 1.36–7.02, p <0.01) among AL-PN patients as compared to non-AL-PN patients, even after controlling for other types of organ involve- ment. Similar findings were observed for gastrointestinal symptoms, such as alternating bouts of constipation or diarrhea (OR=1.92, 95% CI: 1.12–3.34, p=0.019) and early safety/feeling fullness in the stomach (OR=1.80, 95% CI: 1.03–3.16, p=0.04). With the exception of RE, MH, and MCS, there were sig- niﬁcant differences in SF-36v2 scores among AL-PN patients as compared to non-AL-PN patients (p <0.05 for all). These signiﬁcant differences also exceed- ed the thresholds for clinically meaningful differences between the two groups.

**Summary/Conclusions:** This study suggests that the burden of illness from AL amyloidosis may be greater for those with PN involvement versus those without. AL-PN patients also experienced more complicated journeys to dia- gnosisis and significantly worse symptoms related to nervous systems and phys- ical HROQL. The SF36v2, a reliable and valid assessment of HROQL in AL amyloidosis studies, was sensitive to differences in HROQL between AL-PN and non-AL-PN patients. Future research should examine whether improve- ments in neuropathy symptoms following treatment subsequently lead to improvements in HROQL among patients with AL-PN. These findings are helpful for patient-focused drug development and supportive treatments.

**P374**

**ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE**

R. Pugh2, C. Bygrave3, H. Cosh3, W. Ingram3, J. Keil3

1Faculty of Life Sciences and Education, University of South Wales, Pontypridd, 2Tenovus, 3Haematology, University Hospital of Wales, Cardiff, United Kingdom

**Background:** Deciding how service for people with haematological cancers are to be delivered is going to be an important challenge in the coming years. Clinics have limited clinic capacity in terms of staff and bed space to cope with increased demand. In Wales many day units are already at capacity, over- crowded and have long waits for treatment. Ambulatory care, including diagno- sis, observation, consultation, intervention, and rehabilitation, has the potential to improve patient experience, if traditionally-based hospital services are moved into the community. We used a Mobile Unit – a 34-tonne articulated lorry which opens out to become a bespoke clinical space - to deliver treatments in a community setting to a range of haematology patients for a period of 12 months in South Wales.

**Aims:** We aimed to explore whether the administration of cytotoxic therapy on a Mobile Unit in a community setting for patients with haematological cancers could prove to be a safe and efficient alternative to hospital therapy, and in par- ticular whether this model of service delivery would be acceptable to patients. Our target group was patients with myeloma, aiming for up to 20 a day once or twice a week.

**Methods:** The first drugs administered on the Mobile Unit were zoledronate infusions, followed by bortezomib. When twice weekly doses were required, patients collected an additional injection pack which they could self-administer in the safety of their homes, thereby avoiding another trip to hospital. For high-dose bortezomib infusions, taking between 1-2 hours, were also administered. There was a con- sultant review clinic on board for patients receiving bortezomib which further reduced the numbers of hospital visits for patients and also a nurse-led Quality of Life clinic.

**Results:** In one year 548 treatments were administered on 91 days to a total of 54 individual patients. All 54 patients had a diagnosis of myeloma. 56% are female and 44% are male with an age range of 46 to 90 years of age, with 48% over 70 years of age. 37 patients are married and all but 4 classified themselves as White British. The greatest number of patients treated in a single day was 16. Improve patient experience, if traditionally-based hospital services are moved into the community.

**Summary/Conclusions:** Treatment in the community alleviates the stress of treatment and with minimal waiting times it gives some patients the ability to maintain family life and where possible to continue to work. It is both feasible and acceptable to begin to ambulate many different sorts of treatments. The possibilities opening up for haematology include rituximab maintenance; com- munity blood transfusions; delivering pentamidine for patients at risk of pneumo- cystis infection; late effects clinics for teenage and young adult cancer patients; and myeloproliferative neoplasm clinics, possibly near community pharmacies to facilitate dispensing medicines such as hydroxyurea.

**P375**

**THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST- LINE NITROBENZ OR GENERIC IMATINIB IN TREATING CHRONIC PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA**

D. Tran1, S. Brown1, N. Goyert1, P. Brandt2,2, D. Grimal1

1Cornerstone Research Institute, Burlington, Canada, 2Global Value & Access, Novartis Pharmaceuticals Corporation, East Hanover, United States

**Background:** The 2013 European LeukemiaNet (ELN) guidelines recommend switching from first-line therapy as early as 6 months with poor molecular response. They also recognize the possibility of treatment-free remission (TFR), requiring deep MR (MR4 or MR4.5). These emerging shifts in practice will dramatically change chronic myeloid leukemia (CML) treatment patterns. Occurring in parallel to this is the introduction of generic imatinib in Europe,
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (>65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES


1Hematology and Oncology, Mayo Clinic, Scottsdale, 2Hematology and Oncology, Oregon Health and Science University, Portland, 3Internal Medicine, 4Bio-statistics, Mayo Clinic, Scottsdale, 5Arizona State University, Phoenix, 6Hematology and Oncology, University of California, Irvine, Irvine, United States

Background: Cachexia, weight loss, and malnutrition in cancer patients are important contributors of adverse outcomes of cancer patients. MPN patients have abnormal cytokine expression (e.g., IL-1, IL-6, IL-8, and TNF-a) that contributes to symptom burden (e.g., fatigue, pruritus, night sweats, bone pain) and predicts for treatment toxicity. The aim of this project was to determine the nutritional needs and preferences of MPN patients in order to create a tailored MPN dietary intervention.

Methods: An internet-based survey was hosted by the Mayo Clinic Survey Center and promoted nationally through Mayo Clinic blogs and websites during February of 2017. The survey included data on demographics, MPN characteristics, nutritional habits, supplement use, and symptom burden using the MPN-SAF TSS/MPN-10 (Emanuel 2012).

Results: Demographics and symptom burden: 919 international MPN patients took the survey. Among those taking supplements, 16.6% took supplements with the intent of reducing inflammation. Half (47.5%) of those individuals followed a specific diet or had dietary restrictions. On average, MPN patients ate 2.1 meals outside the home per week. Among those taking supplements, 31.4% of respondents had tried alternative medicine to help treat their MPN. Among these, 44.8% were under the care of a naturopath and 60.2% endorsed that their treatment plan included dietary change. Nutritional Education Preferences: Overall, 34.4% of patients endorsed A logistic regression model and a full multiple linear regression model were calculated to determine the weights for each dimension, and its contribution to the final score; the ROC curve analysis was used to calculate the cut-off points that defined three groups: “go-on” (low probability to develop toxicity regardless of intensive or attenuated therapy), “slow-go” (high probability to develop toxicity with intensive therapy but low probability with attenuated therapy), and “stop-go” (high probability to develop toxicity regardless of intensive or attenuated therapy). Results: A total of 108 patients (women, 53.7%; median age [IQR], 78 [73-83] years) out of 360 included in the main study were evaluated. During treatment administration, 61 (56.5%) patients developed treatment-related toxicities, requiring discontinuation/modification of the initial therapy. The coefficients for the dimensions are: 7 for number of drugs, -10 for gait speed, 2 for mood, 23 for activities of daily living, 6 for subjective health status, 27 for nutrition, -5 for mental status, and 1 for comorbidities. The sum of the GAH scale score, ranging from 0 to 68, plus a factor derived from the treatment intensity (34 points for intensive therapy or 0 for attenuated) leads to a maximum score of 100 points, with a cut-off point set at 47. Figure 1 shows the GAH scale scores for treatment toxicity prediction and the classification of patients according to their score. Among the 97 (89.8%) patients that received intensive therapy, 26 patients were classified as go-on, 48 as slow-go, and 23 as no-go. The proportion of patients that developed toxicities for each group was 34.6%, 56.3%, and 78.3%, respectively, with a statistically significant difference (P<0.002).
using diet to help control their symptoms or MPN disease. Patients most often utilized books (28.2%), websites (27.1%), health care providers such as physicians, NPs, or naturopaths (28.2%), online forums (23.2%), friends (12.2%), nutritionists (9.5%), phone or tablet applications (9.1%), or videos (4.2%) for nutritional education. The vast majority (95.9%) of MPN patients endorsed being willing to eat only certain foods if it helped to control symptom burden and or could help their MPN to stabilize or reduce the risk of their MPN getting worse (98.0%).

Table 1.

<table>
<thead>
<tr>
<th>Frequency of dietary allergies, intolerances, restrictions and supplement use among a large international cohort of MPN patients (N=419).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food Allergies and Intolerances</td>
</tr>
<tr>
<td>Milk</td>
</tr>
<tr>
<td>Wheat</td>
</tr>
<tr>
<td>Peanut</td>
</tr>
<tr>
<td>Seafood</td>
</tr>
<tr>
<td>Egg</td>
</tr>
<tr>
<td>Fish</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

Summary/Conclusions: There remains an unmet need for symptom burden improvement in low-risk MPN patients or among those who have reoccurrence of symptoms while on JAK inhibitor therapy. Nutritional interventions for MPN patients have not previously been investigated and have the potential to be paired with traditional interventions to allow MPN patients to self-manage symptom burden. This study represents the first evaluation of MPN-related nutritional habits and preferences. These results will be used to inform the creation of an MPN nutritional intervention with the goal of improving symptom burden and reducing inflammation.

P378

DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE

C. Karamanidou1,*, A. Kocheli1, V. Kourtakis1, P. Ghia2, K. Stamatopoulos1
1Institute of Applied Biosciences, CERTH, Thessaloniki, Greece, 2Division of Experimental Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy

Background: Despite recent progress in prognostication and management, chronic lymphocytic leukemia (CLL) remains unpredictable at diagnosis, while virtually incurable, posing challenges to physicians on how to properly communicate the actual nature of the disease. Moreover, the great majority (~85%) of patients do not need treatment at diagnosis, creating a major cognitive dissonance between the perception of leukemia diagnosis and the “wait & watch” strategy usually applied, that may become a major reason of anxiety and quality of life (QoL) impairment for patients and frustration for physicians. Evidently, both patients and physicians need parameters that would allow co-decision making tailored to each particular case.

Aims: To identify physicians’ needs in order to improve their communication skills and thus facilitate CLL patient empowerment through a patient-centered-ness model.

Methods: An in-depth qualitative study with semi-structured interviews was conducted within hematologists (n=30) all over Greece. Data collection was considered as completed when saturation was reached i.e. no new themes emerged as assessed by the investigators. Content analysis was performed separately by a hematologist and a health psychologist with 98% inter-rater reliability score.

Results: None of the participants had ever received formal communication training, but rather adopted the techniques of senior physicians or developed their own through experience alone, thus frequently doubting their approaches (n=12/30, 40%). The most popular communication technique mentioned was adaptation of the quality and quantity of information provided according to each patient’s characteristics (n=29/30, 96.7%); followed by the use of caregivers as mediators for the communication of difficult issues (n=24/30, 80%); balance of realism and hope (n=21/30, 70%); careful choice of wording (e.g. lymphocytosis instead of leukemia) (n=18/30, 60%); gradual disclosure (n=17/30, 56.7%); and, descriptions through pictorial representations or metaphors (n=16/30, 53.3%). Even though physicians did not systematically assess patients’ anxiety and depression levels, they often found themselves dealing with patients’ emotions (n=29/30, 96.7%) through lengthy discussions. With regards to decision making, some mentioned that physicians should make all the decisions (n=9/30, 30%) and that patients are not always willing to take part in the decision-making process (n=8/30, 26.7%); while others were keener on stirring patients towards a decision (n=15/30, 50%), taking into account patients’ preferences (n=10/30, 33.3%). Most physicians felt uncomfortable delivering bad news such as initial diagnosis, relapse and poor prognosis (n=25/30, 83.3%). Self-reported needs included (i) communication skills training (n=20/30, 66.7%); (ii) psychological support (n=7/30, 23.3%); and, (iii) working in a multidisciplinary team (n=8/30, 26.7%).

Summary/Conclusions: In the absence of structured communication guidance there is great uncertainty among physicians concerning their skills on communicating CLL nature and handling difficult situations, leading to distress endangering their engagement in a healthy relationship with the patient. Additional studies are warranted at European level for identifying physician needs in different countries aiming at improving their communication skills to support and empower CLL patients for participating in their own care and enhance their QoL.
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

O. Ringdén1, A. Boumendi2, M. Labopin2, B. Sadeghi1, B. Savani3, M. Mohy4, A. Nagler5

1LAMBED, Translational Cell therapy Research, Karolinska Institutet, Stockholm, Sweden, 2Hôpital Saint Antoine, Paris, France, 3Division of Hematology/Oncology, Medical Center Drive, Nashville, United States, 4Hôpital Saint Antoine, Paris, France, 5Chaim Sheba Medical Center, Tel-Hashomer, Israel

Background: The average age of patients (pts) with AML is about 67 years. Historically, many of these pts were not considered as viable candidates for allogeneic transplantation (HCT) because of concerns about increased transplantation-related toxicity and excessive non-relapse mortality (NRM), a challenging problem especially in older individuals. However the development of reduced-intensity conditioning (RIC) regimens and the improvement in HCT supporting care allowed the successful application of HCT in older pts with AML.

Aims: Compare outcome of allo SCT in acute myeloid leukemia AML patients aged above 70 vs younger patients.

Methods: AML patients aged between 50 and 90 years old receiving a first or second allo SCT between 2004 and 2014 with MSD or UD donor were included in the study. Comparison of outcomes of patients aged above 70 with that of patients between 50-70 years were performed for the whole group and separately according to disease status at SCT (CR1, CR2, above).

Results: Altogether N=16874 pts were included in the study, N=713 were aged above 70 years old (median 72, IQR 71-73) and N=16161 between 50 and 70 (median 59, IQR 55-63). Older pts were more often male (62 vs 55%, p<0.001), had more often secondary AML (42% vs 28%, p<0.001), more advanced disease (42% vs 27%, p<0.001), more often peripheral blood stem cell grafts (96 vs 91%, p<0.001), more often unrelated donors (79% vs 59%, p<0.001) and poorer Karnofsky score (36% below 90 vs 29%, p<0.001), received more often reduced intensity conditioning (80 vs 63%, p<0.001). Incidence of acute GVHD II/III, IV/chronic GVHD and relapse were the same in the two groups in multivariate analysis. Non-relapse mortality (NRM) at two years was 34% (95% CI 31-38%) in pts above 24% (25%<32%) in those below 70 years of age (p<0.001). Overall survival and leukemia-free survival (LFS) at 2 years was 38% (95%CI 34-42) vs 50% (95%CI 49-50) p=0.001 and 33% (95%CI 29-37) vs 44% (95%CI 43-45) in the two groups, respectively (p=0.001). Among pts in CR1, 2 years survival was 43% (95%CI 37-51) vs 57% (95%CI 56-58) (p=0.001), in CR2 it was 36% (95%CI 27-47) vs 52% (95%CI 50-54) (p=0.002) and in advanced disease 35% (95%CI 29-41) vs 33% (95%CI 31-34) (p=0.036) in pts above and below 70 years of age, respectively. Among pts older than 70 years of age a Karnofsky score >80% was associated with improved survival and LFS in multivariate analysis (HR 0.7 95%CI 0.5-0.9 , p=0.005 and HR 0.7 95%CI 0.5-0.9 , p=0.003 respectively).

Summary/Conclusions: In AML with CR1, CR2 status at allo SCT, pts above 70 years of age have worse NRM, survival and LFS compared to pts 50-70 years of age. In pts above 70 years of age Karnofsky score is of significant importance for outcome.

BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS

M. Jentzsch1,*, M. Bill1, J. Schulz1, J. Grimm1, J. Häntschel1, S. Beinicke1, D. Niederwieser1, S. Schwind1

1Hämatoologie und int. Onkologie, UNIVERSITÄTSKLINIKUM LEIPZIG, Leipzig, Germany

Background: Acute myeloid leukemia (AML) patients (pts) that relapse after allogeneic stem cell transplantation (HCT) have a dismal prognosis. Identification of pts at high risk of relapse may allow preemptive therapy & improve outcomes. At diagnosis high expression of the AML associated genes BAALC (brain and acute leukemia, cytoplasmic) & MN1 (meningioma 1) adversely impact AML pts outcomes, but little is known about their usability for residual disease detection. Recently, we demonstrated a higher cumulative incidence of relapse (CIR) for pts with high pre-HSCT BAALC copy numbers in 82 AML pts (ASH 2016, #517). Until today no study assessed the prognostic impact of MN1 copy numbers prior to H SCT.

Aims: Assess the prognostic impact of peripheral blood (PB) pre-HSCT BAALC & MN1 copy numbers in an expanded set of AML pts in hematologic CR using digital droplet (dd) PCR.

Methods: We identified 118 AML pts (median age at H SCT 64 [range 31-76] years [y]) in first (55%) or second complete remission (CR, 23%) or CR with incomplete recovery (22%) with PB prior to HSCT (median 7, range 0-29 days) available. All pts received non-myeloablative (NMA) conditioning (fluadarabine 3x30 mg & 200 cGy total body irradiation). At diagnosis karyotypes & NPM1, CEBPA gene mutations (mut) & presence of FLT3-TKD & FLT3-ITD were assessed. Quantification of BAALC & MN1 normalized to ABL1 copy numbers in pre-HSCT PB of the AML pts & in PB of healthy controls (n=7, median age 63 [range 40-82y]) was performed by ddPCR. Median follow up after H SCT for pts alive was 1.8y.

Results: European LeukemiaNet (ELN) 2010 classification was 20% favorable, 25% intermediate-1, 24% intermediate-II, 31% adverse. AML pts & healthy controls did not differ in age (P=1) or mean BAALC (P=0.37, Figure 1A) or MN1 (P=0.96, Figure 1B) copy numbers. BAALC & MN1 copy numbers correlated well in pts (R=0.8) & healthy controls (R=0.75). The previously determined cut-off of 0.14 BAALC copy numbers (in 82 pts; ASH 2016, #517) defined pts with high (27%) & low (73%) pre-HSCT BAALC copy numbers. A cut-off of 0.74 MN1 copy numbers was determined using the R package ‘OptimalCutPoints’ & defined pts with high (12%) & low (88%) pre-HSCT MN1 copy numbers. Applying these cut-offs, 71% of the pts had low BAALC & MN1 copy numbers & 10% had high BAALC & MN1 copy numbers, 2% had high MN1 but low BAALC & 17% had high BAALC but low MN1 copy numbers. Pts with high & low pre-HSCT MN1 copy numbers did not differ significantly in pre-treatment characteristics or remission status at HCT (CR vs CRi) while pts with high pre-HSCT BAALC copy numbers were less often in CRi at HCT (P=0.02). Both high pre-HSCT BAALC & MN1 copy numbers significantly associated with higher CIR (P=0.02, Figure 1C & P<0.001, Figure 1D, respectively). In multivariate analyses, high pre-HSCT BAALC (Hazard Ratio [HR] 2.5, Confidence Interval [CI] 1.1-5.7, P<0.001) & high pre-HSCT MN1 copy numbers (HR 5.6, CI 2.6-12.2, P<0.001) retained their prognostic impact on CIR after adjustment for ELN 2010 genetic risk groups.

Figure 1.

Summary/Conclusions: High pre-HSCT copy numbers of BAALC & MN1 associated with higher CIR in univariate & multivariate models and might indicate residual disease burden in these AML pts. High copy number pts should be closely monitored for relapse in the post-transplant period. Prospective clinical trials are needed to validate the determined cut-offs, to evaluate if BAALC or MN1 copy numbers or a combination of the genes represents the most suitable prognosticator pre-HSCT and whether AML pts with high pre-HSCT BAALC or MN1 copy numbers benefit from additional pre- or post-HSCT treatment.
Sickle Cell Disease (SCD) and Diamond-Blackfan Anemia (DBA). Bertain et al (Blood, 2014) have previously shown that αβ TCR depleted haplo-transplantation in children with multiple types of non-malignant disorders was feasible. An ongoing Phase II/III trial evaluates the safety and efficacy of post-transplant infusion of donor T-cells transduced with the iC9 suicide gene (BPX-501 cells). (ClinicalTrials.gov identifier: NCT02058569). The iC9 vector contains the sequence for the CD19 marker, so that the BPX-501 cells (CD3+CD19+) can be tracked in peripheral blood. We report on 15 children with hemoglobinopathies and ED.

Aims: This study was performed to determine the clinical impact of infusing BPX-501 T cells post αβ T-cell depleted haplo-identical HSCT in pediatric patients with hemoglobinopathies.

Methods: Fourteen patients were transplanted from a parent and one patient was transplanted from a sibling. Conditioning regimen included busulfan, thiotepa and fludarabine. Low dose ATG was administered to prevent graft-versus-host disease (GVHD) and graft failure. No post-transplantation GVHD prophylaxis was given. Median follow-up is 387 days (range 126-631 days). Six patients were males and nine females, and median age at diagnosis and at HSCT was 0.8 and 8.9 years (range 2.5-19.2), respectively. Two patients had DBA and four with SCD. All 9 TM patients were β0/β0, and among the those with TM, 4 patients belonged to class I and 3 to class II of the Pesaro classification. All 15 patients were transfusion-dependent and receiving iron-chelation therapy before haplo-HSCT. 13/15 patients maintained full donor chimerism. The patients with secondary graft failure were re-transplanted from the same donor and maintained full donor chimerism.

Results: All patients are alive and well with no Treatment Related Mortality (TRM). Initial chimerism was resistant to treatment or grade IV GVHD. One patient had acute skin GVHD Grade IV. No chronic GVHD was observed. Median time to neutrophil recovery was 14 days (range 10-32 days), while median time to platelet recovery was 11 days (range 8-12 days). Median time to last RBC transfusion was 8 days (5 – 34 days). See Figure 1 for individual Hemoglobin levels. Median time of infusion of 1x10^6 BPX-501 T cells/kg was 14 days after HSCT (range 10-26). BPX-501 cells expanded after infusion and still persist in all patients. Immune reconstitution was normal cellular and humoral immunity present at 180 days post HSCT. All patients remain transfusion-free with a median hemoglobin of 11 or greater after 6 months.

Methods: Using these standardized MSC products altogether 52 patients were treated between December 2014 and December 2016. Patients were male (n=31, 60%) or female (n=21, 40%) and were transplanted for leukemia (n=38, 73%), non-malignant (n=14, 27%) diseases. Median age was 8 years (range: 0.5-52 years). Stem cell source was MSD (n=9, 17%), MUD (n=33, 63%) or MMFD (n=7, 13%) or non-malignant (n=14, 27%) diseases. Median age was 8y (range: 0.5-52 years). Stem cell source was MSD (n=9, 17%), MUD (n=33, 63%) or MMFD (n=7, 13%). All patients are alive and well with no Treatment Related Mortality (TRM) and in 13/15 patients maintained full donor chimerism. The patients with secondary graft failure were re-transplanted from the same donor and maintained full donor chimerism.

Results: All patients are alive and well with no Treatment Related Mortality (TRM). Initial chimerism was resistant to treatment or grade IV GVHD. One patient had acute skin GVHD Grade IV. No chronic GVHD was observed. Median time to neutrophil recovery was 14 days (range 10-32 days), while median time to platelet recovery was 11 days (range 8-12 days). Median time to last RBC transfusion was 8 days (5 – 34 days). See Figure 1 for individual Hemoglobin levels. Median time of infusion of 1x10^6 BPX-501 T cells/kg was 14 days after HSCT (range 10-26). BPX-501 cells expanded after infusion and still persist in all patients. Immune reconstitution was normal cellular and humoral immunity present at 180 days post HSCT. All patients remain transfusion-free with a median hemoglobin of 11 or greater after 6 months.

Summary/Conclusions: These data suggest that Haplo-HSCT combined with infusion of BPX-501 T cells with a suicide gene may be a safe and curative option for children with hemoglobinopathies and ED who lack a matched donor. Infusion of gene modified T cells with an inducible suicide mechanism, combined with selective αβ T-cell depletion, offers the potential to rapidly reverse GVHD and eliminate the need for the use of GVHD prophylaxis. Additionally, this approach results in rapid hematological and immune reconstitution for Haplo-HSCT recipients.

P382

EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCs OF MULTIPLE DONORS

B. Pades1, J. Kuc1, S. Baktiari1, O. Basu2, G. Bug3, M. Dennis4, J. Greil5, K. Källay6, P. Lang5, G. Lucchini8, R. Pol9, A. Schulz10, K.-W. Sykora11, I. von Luetich12, P. Remény13, L. Gopcsa13, A. Jarisch1, J. Soerenson1, E. Salzmann1, E. Seifried14, T. Kligiene1, H. Boenig14, S. Kuci1,

Background: All clinical data published thus far on the use of MSCs were generated using cells expanded from individual bone marrow donors hence suffer from huge inter-donor differences in MSC generation, expansion and immunomodulatory potential. To control these variables and to be able to administer to all patients highly similar MSC products, we established a proprietary pooling procedure and generated a large bank of MSC end-of-passage-1 vials from which end-of-passage-2 MSC products are expanded for clinical use. The manufacturing process is fully GMP-compliant and generates an animal serum-free product with negligible potency. Importantly, they showed a significantly higher allo-suppressive potential than the mean allo-suppressive potential of MSCs generated from individual donors. All tested individual MSC doses were equipotent in suppression of the allo-antigen-driven reaction in mixed lymphocyte reactions (Kuc et al. Haematologica 2016: 101 (8): 885-894).

Aims: A "hospital exemption" issued by the national regulatory authority Pau-Ehrich-Institute (Number: PEI: A11748.01.1) licenses the clinical use of these products for patients with steroid refractory GVHD. On the basis of this licence patients were with severe GVHD were treated who were either non responsive (n=5) or treatment resistant (n=2) to treatment with steroids for 7 days.

Methods: Using these standardized MSC products altogether 52 patients were treated between December 2014 and December 2016. Patients were male (n=31, 60%) or female (n=21, 40%) and were transplanted for leukemia (n=38, 73%), non-malignant (n=14, 27%) diseases. Median age was 8 years (range: 0.5-52 years). Stem cell source was MSD (n=9, 17%), MUD (n=33, 63%) or MMFD (n=7, 13%) or female (n=21, 40%) and were transplanted for leukemia (n=38, 73%), non-malignant (n=14, 27%) diseases. Median age was 8 years (range: 0.5-52 years). Stem cell source was MSD (n=9, 17%), MUD (n=33, 63%) or MMFD (n=7, 13%). All patients are alive and well with no Treatment Related Mortality (TRM) and in 13/15 patients maintained full donor chimerism. The patients with secondary graft failure were re-transplanted from the same donor and maintained full donor chimerism.

Results: Response was defined as either complete response (CR) in patients in who showed overall GVHD grade less according to the Glucksberg criteria, or non response (NR) at day 28 after first MSC transfusion. At day +28, 12 patients (23%) achieved CR, 29 patients (57%) PR (overall response= 80%), 8 patients (17%) NR, and in 2 patients (4%) no data were available at day +28. At the last follow up of GVHD, 29 patients (56%) were in CR, 13 patients (25%) in PR, 9 patients (17%) in NR, and for 1 patient (2%) no data were available. At 2 years these response rates resulted in a non-relapse mortality rate (NRM) of 27±6%, cumulative relapse incidence (CIR) of 14±4%, and overall survival rate (OS) of 92%±6%. Patients with aGVHD III and IV had an OS survival probability at 2 years of 77±12% and 59±35%, respectively thus dramatically in excess of expected survival rates for patients with such severe aGVHD. There was no difference between younger (n=40) and older patients (n=12) than 16 years.

Summary/Conclusions: Treatment with standardized equipotent MSCs from the "FRANKFURT MSC-BANK" offers an excellent chance to overcome treatment-resistant and steroid-refractory acute GVHD.

P383

HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE, COMPLICATIONS

T. Morishita1, T. Ohbiki1, M. Osaki1, M. Yoshino1, S. Ikeno1, M. Nakashima1, T. Sato1, Y. Kagaya1, Y. Ozawa1, K. Miyamura1, T. Kligiene1, H. Boenig14, S. Kuci1,

Background: Noninfectious transplantation-related complications (TRC) such as GVHD and endothelial cell damage (TRC-EC) including sinusoidal obstructive syndrome (SOS), transplant-associated microangiopathy (TAM), idiopathic pneumonia syndrome (IPS) are dismal complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Calcineurin inhibitors such as tacrolimus (TAC) have been broadly used to manage post-transplantation complications. Higher blood levels of TAC are expected to reduce the risk of GVHD, but may increase the risk of endothelial damage. Since TAC-EC often develops in patients with severe aGVHD, it is difficult to judge appropriateness of immunosuppression clinically.

Aims: Here we evaluated the impact of TAC blood levels upon TRC-EC occurrence and prognosis after allo-HSCT.

Methods: Two hundred sixty-one consecutive patients (pts) who received TAC as a GVHD prophylaxis after allo-HSCT at our institute from 2009 to 2015 were candidates for this retrospective study. Pts who received haploidentical allo-HSCT.
and pts with unavailable TAC concentration data were excluded. A total of 253 pts was eligible. All pts received standard GVHD prophylaxis by continuous intravenous (iv) TAC with starting dose of 0.02 mg/kg/day from 1 day before allo-HSCT (day -1) and iv methotrexate on day 1, 3, 6 at dose of 10 mg/m2, 7mg/m2, respectively. TAC dosage was adjusted to target the serum concentration of 8-12 ng/ml until at least day 30 and then tapered. TAC was rapidly tapered with any time-point selected were not significant factors for OS. By Cox proportionality/hazards regression models, TRC-EC diagnosis (HR: 1.90, 95%CI, 1.16-3.11, P=0.011) and high disease risk at transplant (HR: 1.76, 95%CI, 1.14-2.73, P=0.011) were significantly associated with poor OS (Figure 1).

Summary/Conclusions: Higher peak TAC concentrations during 22-28 days after allo-HSCT increased the risk of TRC-EC. And the development of TRC-EC was associated with poor OS.

P384

IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLOIDENTICAL TRANPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT


1Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie, Ospedale Civile, Pescara, 1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, 2Department of Hematology, Tokyo Women’s Medical University, Tokyo, 3Department of Hematology, Institute of Medical Science, The University of Tokyo, Tokyo, 4Department of Hematology and Clinical Research Institute, National Hospital Organization Kuyushu Medical Center, Fukuoka, 5Department of Hematology, Kumamoto University Hospital, Kumamoto, 6Department of Hematology, Sasebo General Hospital, Sasebo, 7Department of Hematology, National Hospital Organization Kyushu Cancer Center Hospital, Fukuoka, 8Department of Hematology and Oncology, Institute of Medical Science, Tohoku University, Sendai, Japan, 9Department of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan, 10Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan, 11Department of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel

Background: T-cell replete haplo-identical stem cell transplantation (haploSCT) is a valid therapeutic option for adult patients (pts) with high risk acute leukemia (AHL). T-cell replete transplantation (loSCT) is a valid therapeutic option for adult patients with AML older than 45 years (yrs) undergoing haploSCT. The aim of the study was to confirm the efficacy and feasibility of RIC among a population for which the choice of conditioning intensity is more related to center strategy than pts comorbidities or disease status.

Methods: We retrospectively compared the outcomes of 614 pts with de novo or secondary AML transplanted between 2007 and 2015 from an haplo-identical donor using either RIC (n=365) or MAC (n=249) regimens. Age was categorized in three subgroups (45-55 yrs, 55-60 yrs, >60 yrs). Patients receiving a previous allogeneic transplantation were excluded. RIC was defined according to EBMT definitions.

Results: The median follow up for MAC and RIC was 24 and 20 months, respectively and the median year of transplant was 2013 for both. Pts receiving a RIC were older (55 yrs in MAC vs 61 yrs in RIC, p<0.001). Secondary AML was more frequent in RIC vs MAC (31% vs 22%) while 77% of MAC and 68% of RIC were transplant for de novo AML, p=0.01. No differences were found on disease status and Karyotypic performance status (KPS) at transplant: pts were in CR1 (MAC: 44%, RIC: 40.5%), CR2/3 (MAC: 17%, RIC: 17%) or had active disease (MAC: 40%; RIC: 43%), p=0.68; 12% of pts in both groups had KPS>80, p=0.95. The most frequently used MAC regimen was TBF (56%), while in RIC it was mirTBF (27%) and low dose TBI+Fludarabine (24%). RIC regimens were more frequently associated with as detection of stem cell source (MAC 42% vs RIC 55%, p=0.002). Post-transplant cyclophosphamide was used in 69% of both RIC and MAC, p=0.39. Main outcomes were not different according to conditioning regimen: at 2 yrs was 26% vs 32% (p=0.29), NRM 31% vs 34% (p=0.62), aGVHD II-IV 24% vs 31% (p=0.05), and cGVHD 27% vs 26% vs 39% (p=0.17), OS 46% vs 39% (p=0.15), GRFS 36% vs 28% (p=0.10) for MAC vs RIC, respectively. The results according to RIC and MAC were not different in any of the three age subgroups. 338 patients died; main causes of death were infections and GVHD to be followed by disease recurrence. In multivariate analysis, the type of conditioning regimen was not associated with risk of relapse or treatment failure: RI (HR: 1.22, p=0.28), NRM (HR: 0.92, p=0.63), acute GVHD grade II-IV (HR: 1.14, p=0.48), chronic GVHD (HR: 1.26, p=0.30), LFS (HR: 1.03, p=0.77), GRFS (HR: 1.07, p=0.55), OS (HR: 1.05, p=0.68). Disease status was associated with outcomes (active disease vs CR): RI (HR: 2.44, p<0.001), LFS (HR: 1.75, p<0.001), GRFS (HR: 1.72, p<0.01), OS (HR: 1.71, p<0.001) as well as KPS>90: NRM (HR: 0.53, p=0.0002), LFS (HR: 0.67, p=0.001), GRFS (HR: 0.74, p=0.014), OS (HR: 0.62, p=0.0002).

Summary/Conclusions: In our study no differences were found between RIC and MAC regimens for haplo-SCT in adults with AML including older patients. Disease status and performance status were the major predictors of transplantation outcome, while conditioning intensity had no effect. These results may serve as the background for a well designed randomized study comparing RIC vs MAC for haplo-SCT in adult pts with AML.

P385

ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS

S. Fuji1, S. Kurosawa1, Y. Inamato1, T. Murata2, A. Utsunomiya3, K. Uchiyama4, S. Yamasaki1, Y. Inoue1, Y. Morichi1, I. Choo1, M. Ogata1, M. Hidaka1, T. Yamaguchi1, T. Fukuda1

1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, 2Crecon Medical Assessment Inc, Tokyo, 3Department of Hematology, Imamura Bun-in Hospital, Kagoshima, 4Department of Hematology/Oncology, Institute of Medical Science, The University of Tokyo, Tokyo, 5Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, 6Department of Hematology, Kumamoto University Hospital, Kumamoto, 7Department of Hematology, Sasebo City General Hospital, Sasebo, 8Department of Hematology, National Hospital Organization Kyushu Cancer Center Hospital, Fukuoka, 9Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, 10Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, 11Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan

Background: Patients with aggressive adult T cell leukemia-lymphoma (ATL) represent a stringent challenge for physicians because of the controversial indication regarding the indication of up-front allogeneic hematopoietic stem cell transplantation (allo-HSCT) as no prospective randomized controlled trial (RCT) has been conducted due to a rarity of patients with ATL even in Japan.

Summary/Conclusions: Higher peak TAC concentrations during 22-28 days after allo-HSCT increased the risk of TRC-EC. And the development of TRC-EC was associated with poor OS.
Decision analysis is a computerized modeling analysis which can simulate the clinical outcomes of different therapeutic strategies and identify an appropriate therapeutic strategy.

Aims: The aim of this study is to compare the life expectancy (LE) of chemotherapy followed by up-front allo-HSCT to that of chemotherapy alone using decision analysis in patients with aggressive ATL using database constructed by a nationwide survey.

Methods: We constructed a Markov decision analysis model to compare the outcomes in 2 therapeutic strategies: chemotherapy followed by up-front allo-HSCT vs chemotherapy alone. The transition probabilities between each health states were calculated from the database of 1,792 patients and patients were stratified into low-, intermediate- and high-risk groups according to the risk stratification system which we developed previously (Fuji S et al. 18th International Conference on Human Retrovirology). The model simulated the LE, quality-adjusted LE (QALE) and survival curve after diagnosis of aggressive ATL. Since QoL data for patients with aggressive ATL are lacking, estimates from a similar decision analysis study of patients with acute myeloid leukemia were used. In terms of the timing of up-front allo-HSCT, it was set as all patients receive up-front allo-HSCT from 2 to 6 months if ATL did not progress before allo-HSCT. We used the TreeAge Pro 2016 software package for decision analysis (TreeAge Software Inc., Williamstown, MA).

Results: In all patients, up-front allo-HSCT was associated with higher LE in comparison to chemotherapy alone (2.26 years vs 1.75 years). Stratified into 3 groups according to the prognostic scoring system, LE of up-front allo-HSCT was higher compared to that of chemotherapy alone in the intermediate- (2.27 years vs 1.66 years) and high-risk groups (1.50 years vs 0.91 years). The estimated survival curve depicted by TreeAge showed the superiority of up-front allo-HSCT as shown in Figure 1A-D. The Monte Carlo simulation showed that the probability of superiority of up-front allo-HSCT was 100% in all patients, 97.1% in the low-risk group, 100% in the intermediate-risk group, and 100% in the high-risk group in terms of LE, and was 99.8% in all patients, 75.2% in the low-risk group, 100% in the intermediate-risk group, and 100% in the high-risk group in terms of QALE.

Figure 1.

Summary/Conclusions: Based on decision analysis, up-front allo-HSCT was associated with higher LE and QALE in the intermediate- and high-risk groups in comparison to chemotherapy alone in patients with aggressive ATL. In the absence of prospective randomized controlled trials, our results suggest that up-front allo-HSCT for aggressive ATL is the favored treatment strategy in the intermediate- and high-risk groups.

P386
OUTCOMES OF THIOTEPA BASED REDUCED-INTENSITY CONDITIONING VERSUS STANDARD REDUCED-INTENSITY CONDITIONING IN ADULT PATIENTS UNDERGOING DOUBLE-UNIT CORD-BLOOD HEMATOPOIETIC STEM CELL TRANSPLANT

P. Sharma1, D. Poliya1, C. Smith1, E. Purev1, M. Kamdar1, B. Haverkos1, D. Sherbenou1, J. Gutman1

1Division of Hematology, University of Colorado, Denver, United States

Background: Cord blood transplantation (CBT) is an established alternative source for hematopoietic stem-cells in patients without matched donor. However, the most commonly used high-dose total-body-irradiation (TBI) myeloablative conditioning (MAC) results in high treatment related mortality (TRM). Non-myeloablative and reduced-intensity conditioning (RIC) have been studied to decrease TRM and provide curative chance to the elderly and those with comorbidities. However, these strategies are associated with higher relapse-rate and graft rejection. A novel-RIC using addition of thiopeta and higher dose of TBI to standard RIC has shown to result in sustained donor engraftment. Our study compares transplant-related-outcomes in patients who underwent first double-unit CBT with standard-RIC regimen of fludarabine (Flu, 200mg/m²), cyclophosphamide (Cy, 50mg/kg), and TBI (200cGy or 300cGy) versus this standard-RIC regimen with addition of thiopeta (10mg/kg) and increased dose of TBI (400cGy).

Aims: 1. To compare transplant related outcomes in CBT recipients who received standard-RIC (FluCyTBI) to those who received novel-RIC (FluCy with addition of thiopeta and increased dose of TBI). 2. To identify optimal conditioning regimen in patients undergoing UCT.

Methods: After IRB approval, consecutive patients undergoing CBT from 08/2009 to 08/2016 were evaluated and data retrospectively abstracted. Patient selection, graft-versus-host disease prophylaxis and transfusions were per institutional standards and conditioning regimens were compared as described.

Results: 3 of 99 patients who underwent allogeneic double-CBT, 52 received standard-RIC and 47 received novel-RIC. Median age at transplant was 67 years (range, 24-74) and 54 years (range, 25-67) in standard-RIC and novel-RIC cohort respectively. Acute myeloid leukemia was the major indication for transplant in both cohorts. Median hematopoietic stem-cell transplant-comorbidity-index (HSCT-CI) was 3 (range, 0-6) and 1 (range, 0-6) in standard-RIC and novel-RIC groups respectively. Four patients suffered engraftment failure (2 in each cohort). Median neutrophil engraftment was 13 days (range, 6-42) and 21 days (range, 12-43) while median platelet engraftment was 37 days (range, 26-70) and 38 days (range, 24-74) in standard-RIC and novel-RIC groups respectively. Fifty-three suffered acute GVHD which occurred in 21 (40%) patients (grade 2-4: n=15, 29%; grade 3-4: n=2, 4% in standard-RIC group and in 32 (68%) patients (grade 2-4: n=29, 62%; grade 3-4: n=5, 11%) in novel-RIC group. Chronic-GVHD (cGVHD) occurred in 18 patients (n=7, 14% in standard-RIC; n=11, 23% in novel-RIC group). The one-year cumulative incidence of relapse was 36% (n=15) in standard-RIC while it was 15% (n=5) in novel-RIC cohort. Median relapse free survival (RFS) was significantly improved in novel-RIC cohort compared to standard-RIC (HR, 0.32, CI:0.11- 0.76, p=0.01). Median RFS was 29 months in standard-RIC cohort while median RFS was not reached in novel-RIC cohort. The one-year cumulative incidence of transplant related mortality (TRM) was 22% (n=10) in those who received standard-RIC while it was 16% (n=7) in those who received novel-RIC. TRM was not significantly different between the standard-RIC and novel-RIC cohorts. Median follow-up in standard-RCI cohort was 9.3 months (range, 0.16- 79) and 13 months (range, 1.4- 38) in novel-RCI cohort. The overall survival (OS) was significantly better in novel-RCI cohort compared to standard-RCI (HR 0.49, CI: 0.25- 0.94, p= 0.03). Median OS was 17 months in standard-RIC cohort while median OS was not reached in novel-RIC group (Figure 1).

Figure 1.

Summary/Conclusions: In our study, RIC consisting of FluCy with addition of thiopeta and increased dose of TBI in patients undergoing double-cord UCT was associated with improved OS and improved RFS without increase in TRM as compared to standard RIC. While older and more comorbid patients might experience increased TRM with the thiopeta based regimen, these data suggest that consideration of this regimen may be appropriate in fit, older patients.

P387
INTERFERON-α IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

X.-D. Mo1, X.-H. Zhang1, L.-P. Xu1, Y. Wang1, C.-H. Yan1, H. Chen1, W. Han1, F.-R. Wang1, J.-Z. Wang1, K.-Y. Liu1, X.-J. Huang1

1Peking University People’s Hospital, Institute of Hematology, Beijing, China

Background: Post-transplant relapse is a major cause of transplant failure. Because impending relapse can be indicated by minimal residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HCT), MRD-directed intervention may be a reasonable option for relapse prophylaxis.

Aims: We investigated the efficacy of MRD-directed interferon-α (IFN-α) treatment in acute leukemia patients who were positive for MRD after allo-HSCT.
Methods: A total of 107 patients who were MRD-positive after allo-HSCT were enrolled. MRD-positive status was defined as positivity for leukemia-associated aberrant immune phenotypes or positivity for Wilms’ tumor gene 1 in a single bone marrow sample. Recombinant human IFN-α-2b injections were administered subcutaneously 2–3 times per week for 6 months.

Results: The 2-year cumulative incidence of severe acute and chronic graft-versus-host disease (GvHD) was 27% (n=11) and 8% (n=3), respectively. Anemia, neutropenia, and thrombocytopenia occurred in 76 (71%), 58 (54%), and 26 (24%), respectively. The 2-year cumulative incidence of relapse and NRM after IFN-α treatment was 11.5% and 4.3%, respectively. The 2-year probabilities of event-free survival and disease-free survival after IFN-α treatment were 66.5% and 82.4%, respectively. Persistent MRD after IFN-α treatment was significantly associated with higher relapse risk and poorer survival.

Summary/Conclusions: These data confirmed that MRD-directed IFN-α treatment is effective for patients who were MRD-positive after allo-HSCT.

P389

IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME


1Department of Hematology, Kanagawa Cancer Center, Yokohama, 2Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, 3Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 4Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, 5Department of Hematology, Red Cross Nagoya First Hospital, Nagoya, 6Division of Hematology, Saitama Medical Center Jichi Medical University, Omiya, 7Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, 8Department of Hematology, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, 9Department of Hematology, Toranomon Hospital, Tokyo, 10Department of Hematology, Nagano Red Cross Hospital, Nagano, 11Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, 12Division of Hematopoietic stem cell transplantation, National Cancer Center Hospital, 13Blood Service Headquarters, Japanese Red Cross Society, Tokyo, 14Japan Data Center for Hematopoietic Stem Cell Transplantation (JDSCT) Program, 15Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, 16Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan

Background: Myelodysplastic syndrome (MDS) is a heterogeneous myeloid stem cell disorder with ineffective hematopoiesis, dysplastic cell morphology, and a propensity for progression to acute myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available. In recent years, azacitidine (AZA) has been increasingly used as a pre-transplant induction therapy in high-risk MDS patients. However, the benefits of pretransplant therapy in these patients are unclear, and the optimal therapy regimen remains unknown.

Aims: We conducted a retrospective analysis to elucidate the clinical impact of treatment with AZA on outcomes after allo-HSCT in high-risk MDS patients.

Methods: Clinical data were collected from the registry database of the Japanese Society for Hematopoietic Cell Transplantation. We selected patients with high-risk MDS at diagnosis (IPSS intermediate 2 or high), aged 16 years or older, who underwent their first transplantation between January 2009 and December 2014 and received AZA or best supportive care (BSC) before allo-HSCT. Patients who received conventional chemotherapy or immunosuppressive therapy prior to allo-HSCT were excluded. We compared overall survival (OS), relapse, non-relapse mortality (NRM), and hematopoietic recovery after allo-HSCT in patients who were pretreated with AZA or BSC. OS was estimated by the Kaplan–Meier method, and a log-rank test was used for comparisons. Relapse and NRM were considered competing risk events and were compared using Gray’s test. The cumulative neutrophil and platelet recoveries were also compared by Gray’s test, considering death without these events as a competing risk. In a multivariate analysis, the Cox proportional hazard model and Fine-Gray methods were used for OS and cumulative incidence of relapse and NRM and hematopoietic recovery, respectively, using the following variables: age, gender, performance status at transplantation, marrow blast at diagnosis, cytogenetic risk, donor source, donor-recipient genotypic match, patient’s age, and donor age.

Results: Of the 485 patients, 161 patients (33.2%) received AZA and 324 patients (66.8%) received BSC before allo-HSCT. The median age was 60 (18–70) and 56 (18–74) years, respectively (P=0.002). A higher proportion of BSC patients received cord blood transplantation (P=0.005). Bone marrow failed in 14.6% of AZA patients and in 17.9% of BSC patients.

No differences were observed in other factors. The 2-year OS rate (46.7% and 50.8%, P=0.66), relapse (31.5% and 28.6%, P=0.59), NRM (26.5% and 26.1%, P=0.99), 30-day neutrophil engraftment (82.8% and 83.6%, P=0.18), and 30-day platelet engraftment (72.0% and 69.4%, P=0.36) were not significantly different between the AZA and BSC groups. In multivariate analysis, AZA and BSC showed comparable OS (HR, 1.16; P=0.31), relapse (HR, 1.13; P=0.50), NRM (HR, 0.92; P=0.64), neutrophil engraftment (HR, 1.01; P=0.89), and platelet engraftment (HR, 1.07; P=0.59). These data confirmed that pretransplant AZA and BSC provide similar outcomes of allo-HSCT in high-risk MDS patients. Further analysis is needed to clarify the role of pretransplant therapy in high-risk MDS and to identify the subset of patients who may benefit from pretransplant AZA.
LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT
Y. Han1,2, Y. Tang1, Y. Zhao1, M. Huang1, J. Chen1, J. Qi1, Y. Wang1, X. Wu1, X. Ma1, F. Chen1, X. He1, C. Ruan1, D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background: Isolated thrombocytopenia is a common complication of hematopoietic stem-cell transplantation (HSCT), which was defined as consistent low platelet counts with recovery of the other two cell lines after transplantation. This status leads to an increased risk of life-threatening hemorrhage, frequent requirements of platelet transfusion and extended hospital stays, representing a challenging clinical problem. Previous studies have demonstrated that decitabine, a hypomethylating agent, may increase platelet counts by promoting megakaryocyte maturation and platelet release in mouse models.

Aims: In order to investigate the role of decitabine in patients after HSCT suffering from isolated thrombocytopenia, we conduct a clinical trial to validate this effect in post-HSCT setting.

Methods: We performed a prospective open-label study to evaluate the treatment of low-dose decitabine in patients with hematological malignancies who received allogeneic HSCT and suffered from isolated thrombocytopenia. The inclusion criteria were: (1) Platelet count ≤30 × 10⁹/L persistently at day 60 post-HSCT or later; (2) Recovered neutrophil and hemoglobin; (3) Full donor chimerism; and (4) No response to conventional treatments for a duration of at least 4 weeks. Patients with malignancy relapse, active infections, uncontrolled graft-versus-host disease, severe organ damage or transplant-related thrombosis were excluded. From July 2013 to July 2016, 38 patients were randomly assigned into either the control group to receive conventional treatment only, or the test group to receive additional decitabine (15mg/m², intravenously daily for 3 consecutive days).

Results: Major response was observed in 16 out of 19 patients (84.2%) in decitabine group, with a median time of 22 days to achieve platelet transfusion-independence. Two patients (10.5%) showed a minor response and 1 patient (5.3%) failed. In contrast, 3 out of 19 patients in the control group (15.8%) showed a major response, 2 patients (10.5%) showed a minor response, 14 patients (73.7%) did not show any improvement, of which 1 patient died of severe hemorrhage in week 5. For bone marrow morphological analysis, all 38 patients showed low levels of megakaryocytes at week 0. However, the megakaryocyte counts in decitabine group were significantly increased at week 4, while no significant difference was recorded in control group. After decitabine treatment, we did not observe a change in anti-platelet antibodies levels and T cell subsets ratios. However, reactive oxygen species (ROS) and megakaryocyte counts increased in the test group. No considerable myelosuppression, febrile neutropenia, and nonhematologic toxicities associated with the treatment were observed.

Summary/Conclusions: Our data showed an encouraging efficacy of decitabine in patients after HSCT suffering from isolated thrombocytopenia, which leads to remarkably increased megakaryocyte counts. Decitabine may improve isolated thrombocytopenia via regulating ROS and megakaryocyte reconstitution.

Thalassemia

A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA
A. Mattei1, M. Winter2, E. Beneduce1, E. Federti1, A. Scicolora1, A. Macias-garcia3, A. Iolascon1, T. Singier2, O. Khwaja3, A. Korn4, J.-J. Chen2, A. Harmeyer1, C. Brugnara3, L. De Franceschi1
1Medicine, University of Verona, Verona, Italy, 2Pharmaceutical Research and Early Development, Hoffmann-La Roche , Basel, Switzerland, 3MIT, MIT, Cambridge, United States, 4Biotechnologie Avanzate-CEINGE, Federico II University, Naples, Italy, 5Lab of Medicine, Children’s hospital Harvard Medical School, Boston, United States

Background: The anemia of β-thalassemia is due to combination of reduced red cell survival in the peripheral circulation and ineffective erythropoiesis, the latter due to unbalanced hemoglobin chain synthesis, and hemichrome-induced oxidative damage. Here we used a specific and selective inhibitor of the plasma membrane expressed glycine transporter GlyT1 (RO4917838) in a mouse model for β-thalassemia (Hbb3th3/mice). A previous study in Wistar rats has shown that RO4917838 induces a dose-dependent decrease in MCH, Hb, soluble transferrin receptor, and increase in absolute reticulocytes and RBC counts (Winter et al. Exp Hematol, DOI: 10.1016/j.exphem.2016.07.003). This has been linked to the ability of RO4917838 to reduce glycine bioavailability in erythroblasts and decreased heme biosynthesis.

Aims: To evaluate the impact of the glycine transporter GlyT1 selective inhibitor RO4917838 on anemia of a mouse model for β-thalassemia.

Methods: Wild-type control (WT) C57Bl/6J, and Hbb3th3/mice (β-β) aged between 3 to 4 months were treated daily with either vehicle or RO4917838 at dosages of 3, 10, 30 mg/kg/d for 4-6 weeks by gavage. Hematological parameters, analysis of erythropoiesis, molecular studies of sorted erythroid precursors, indices of hemolysis, hepcidin liver expression and Pears staining were carried out.

Results: RO4917838 administration was associated with an improvement of β-Thal hematologic phenotype, as supported by (i) the amelioration of red cell morphology; (ii) the increase in Hb levels; (iii) the reduction in reticulocyte count
and in the percentage of circulating erythroblasts; (iv) the increase in β Thal red cell survival. RO4917838 induced a significant reduction in extramedullary erythrocytosis as well as in the amount of insoluble alpha chain aggregates in circulating red cells. It is of note that in β-Thal sorted erythroblasts we found a reduction in HRI and in phospho-eIF2α, indicating a reduction in free heme, which shall resulted in the activation of HRI, in RO4917838 treated β -Thal mice (10 mg/kg/d, 6 weeks). Finally, in β-Thal mice treated with RO4917838 (4 weeks at 30 mg/kg/d) a reduction in liver and spleen iron-overload was identified, which was associated with increased hepcidin liver expression.

Summary/Conclusions: Our data suggest that RO4917838 ameliorates anemia and ineffective erythropoiesis by reduction of heme biosynthesis in a mouse model for β-thalassemia. RO4917838 is a potential, novel therapeutic approach for the treatment of anemia in patients affected by beta-thalassemia.

P393
MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?
M.R. Storno1, M. Giuliano1, G. Fioretti2, S. Puozone1, R. Sessa1, L. Vicari2, M.P. Ottiano1, M. Caldora3, S. Costantini4, C. Matarrese2, A. Sarappa5, G. Amendola5, A. Filosa5, P. Izzo5, M. Grossi5,1
1Dep. Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 2UOSC Genetica Medica, AORN A. Cardarelli, 3UOC Patologia Clinica, P.O. Pellegrini, ASL NA1, 4UOSD Malattie rare del globulo rosso, AORN A. Cardarelli, Naples, 5UOC Pediatría-TIN, P.O. Umberto I, Nocera Int., Italy

Background: Kruppel-like factor 1 (KLF1) is a pleiotropic erythroid transcriptional factor that plays a key role in erythropoiesis (Sietiecka M, Blood 2011; 118: 2044-521). Accordingly, KLF1 mutations have been found to be responsible for a variety of hematological disorders. KLF1 also contributes directly or indirectly to regulate the expression of genes in the beta-globin gene cluster and the fetal-to-adult globin gene switching (Waye JS et al. Int. J. Lab. Hem. 2015; 37: 78-84). It has been reported that mutations leading to KLF1 haploinsufficiency may lead to increased fetal-globin (HbF) levels with ameliorative effects on the severity of beta-thalassemia (Liu D. et al. Blood 2014; 124: 803-811; Perkins A.

Aims: This study aimed at providing a functional characterization of known and novel mutations in the KLF1 gene associated with atypical beta-thalassemia phenotypes.

Methods: Hematological parameters were measured using an automated hematologic analyzer (Beckman Coulter) and high performance liquid chromatography (Variant II, Bio-Rad Laboratories). Screening of KLF1 mutations was performed by Sanger sequencing on an Applied Biosystems 3730 DNA analyzer. Functional studies were performed by gene reporter assays and expression vectors for KLF1 mutants in the human K562 erythroleukemia cell line. This study was performed on 19 adult subjects, including 11 beta-thalassemia heterozygotes with an unexpected phenotype of intermediate thalassemia. This study was performed on 19 adult subjects, including 11 beta-thalassemia heterozygotes with an unexpected phenotype of intermediate thalassemia.

Our data suggest that RO4917838 ameliorates anemia and ineffective erythropoiesis by reduction of heme biosynthesis in a mouse model for beta-thalassemia. RO4917838 is a potential, novel therapeutic approach for the treatment of anemia in patients affected by beta-thalassemia. RO4917838 was associated with increased hepcidin liver expression.

Summary/Conclusions: Our data suggest that RO4917838 ameliorates anemia and ineffective erythropoiesis by reduction of heme biosynthesis in a mouse model for β-thalassemia. RO4917838 is a potential, novel therapeutic approach for the treatment of anemia in patients affected by beta-thalassemia.

P394
SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR
A. Meloni1,*, A. Natale2, S. Santarone3, M. Di Ianni4, S. Angelini5, L. Pistoia1, L. Cuccia1, A. Spasiano1, A. Pepe5, P. Di Bartolomeo5
1 Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Bone Marrow Transplant Center, Pescara, 3University of L’Aquila, L’Aquila, 4Tor Vergata University, Roma, 5ARNAS Civico “Benferratelli-Di Cristina”, Palermo, 6AORN A. Cardarelli, Napoli, Italy

Background: Secondary solid tumors (SST) have been described after HCT, in particular for patients affected by hematologic malignancies. There is limited information about the incidence of SST following HCT for thalassemia major (TM).

Aims: The aim of this study was to determine the incidence of SST in 134 patients with TM who received HCT in our Center between 1983 and 2013.

Methods: 117 patients survived more than 3 years after HCT and were enrolled in the study. Of them, 57 were males and 60 females. Their median age at time of HCT was 10 years (1-29). As conditioning regimen, they received Busulfan (14 mg/Kg) and Cyclophosphamide (200 mg/Kg). The GVHD prophylaxis included Cyclosporine and Methotrexate. All patients received bone marrow cells from an HLA identical donor.

Results: At time of this report, 112 patients were cured, whereas 5 patients rejected their graft and are now under regular transfusion treatment. Overall, the median follow-up after HCT was 24 years (3-34). Seven patients developed malignancy 3 to 28 years (median 16.4 years) after HCT including 2 patients with 2 cases of the tumor and in addition 4 of them received chemotherapy and/or radiotherapy. Of relevance, the 3 patients with cancer of the oral cavity were affected by severe chronic GVHD with buccal cavity involvement. Two patients (1 with parotid and 1 with tongue carcinoma) died of tumor progression and 5 are living.

Using the event rate measure, we observed an event rate of 0.102 at 30 years for the transplant group and 0.041 for the nontransplant group (p=0.106).

Summary/Conclusions: This study shows that the magnitude of increased risk of SST is twofold to threefold for patients treated with HCT as compared with an age-matched nontransplant TM patients or with stem cell donors. Notably, among the transplanted patients we didn’t observe any case of HCC, which is one of the most frequent solid tumor in nontransplant TM patients, whereas we observed 4 cases of head/neck cancers. In our series, cGVHD seems to be a strong risk factor in the development of new solid tumors. Patients with cGVHD, especially those with involvement of the oral cavity, must receive a very long careful monitoring and surveillance in order to prevent the development of secondary cancers.

Figure 1. Results: Of the 19 patients who were tested, 15 were found to be positive for mutations in the KLF1 gene. More in detail, we found 7 mutations, comprising a nucleotide variation (c.-251 C>G) already reported as a single nucleotide polymorphism and a known mutation (c.-148 G>A) in the proximal promoter region, 3 nucleotide variants with no effect on HbF levels (S102P, F182L and M39L), (Radmilovic M. et al. Ann. Hematol 2013; 92: 53-58) and 2 novel mutations (C94X and P173Pfs*236), all of them in the proline-rich domain in exon 2. Functional studies were performed in K562 cells in order to clarify the pathogenic significance of these mutations and to better define the role of KLF1 in atypical thalassemia phenotypes. Interestingly, the c.-251 C>G polymorphism was found to be associated with an increased transcriptional activity of the KLF1 promoter (Figure 1A), thus allowing us to exclude for this nucleotide variation the condition of a neutral polymorphism. Furthermore, unexpectedly, the novel P395
VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING DEVELOPED IN A REGIONS WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES
T. Suksangpleng1,*, S. Riolueang1, J. Korchuenjiti1, W. Korchuenjiti1, J. Poolam2, V. Viprakasit1,3

22nd Congress of the European Hematology Association
Background: Newborn screening program for thalassemia (thal) and hemoglobinopathies (NBS-Hbs) is crucial for early detecting patients with serious hemoglobinopathies (Hb variants) e.g. Sickle cell anemia (Hb SS). NBS-Hbs has been incorporated into a routine neonatal service in several developed countries. However its role on early detection other forms of globin disorders remains unclear. Moreover, NBS-Hbs can detect several types of thalassemia and Hb variants carriers. This application could be useful for the national prevention and control programs in many developing countries including Thailand where these conditions are highly prevalent especially β-thal major. Hb E/β-thal and Hb Bart’s hydrops fetalis caused by α°-thalassemia (α°-thal). Recently a new capillary electrophoresis (CE) has been developed specifically for NBS-Hbs. However there is a limited data on validation of this technology on detecting several types of thalassemia and Hb variants found in Southeast Asia.

Aims: To evaluate and validate a new CE system to screen globin disorders in newborn to initiate the national NBS-Hbs for Thailand.

Methods: After informed consent, 1,213 blood samples of 2-day old newborns were collected by heel prick puncture into 5-dried blood spots. After elution, dried blood samples were analyzed by Capillaries 2 NEONAT FAST® (SEBIA, Evry, France). All samples were also extracted for DNA and genotyped by our extensive PCR based panel to detect >98% of abnormal globin alleles found in Thailand using α°-thal GAP-PCR, α-thal ARMS-PCR, β-thal ARMS-PCR, and PCR-RFLP for Hb E. We compared CE data with each globin genotypes and use a ROC curve to set up new diagnostic criteria using Hbs from CE for future cases.

Results: Identification of Hb Bart’s provided 100% of sensitivity, specificity and accuracy in most individuals with α-thal. Using ROC analysis, we proposed different cut-off values of Hb Bart’s to differentiate Hb H disease, α°-thal and non-deletional α°-thal traits; ≥9.40%, ≥0.85%, ≥0.45%, respectively with excellent accuracy. Interaction of Hb E with these α-thal genotypes has no effect on these cut-off values (Table 1). However, there was a limitation to identify deletional α-thal trait’s ≥20.10% (detectable level). A cut-off level to distinguish Hb EE from Hb E trait was suggested at ≥24.95% vs ≥0.7%. Two patients with Hb E/β-thalassemia were identified through this study with different CE pattern from Hb EE. 11 β-thalassemia traits was identified and they had a lower level of Hb A as compared to their gestational age (GAs) sex matched controls with normal β globin genotypes (n=148). We recommend Hb A level ≤10.35%; a cut-off to primarily consider for β-thalassemia carrier followed by molecular analysis.

Summary/Conclusions: This newborn CE platform showed a high efficiency for detecting several types of thalassemia and Hb variants in particular α-thal, β-thal and Hb E using cut-off levels of each Hb species described herein. Besides early detecting of Hb S, we can now apply this NBS into a routine service in order to early detect Hb H disease, Hb E/β-thalassemia and the major common thalassemia carriers. This NBS-Hbs approach can reinforce and leverage our current program on prevention and control for severe thalassemia syndromes in our region. Moreover, due to population migration from The East to the West, our new diagnostic guideline by CE could be useful and applicable for existing NBS programs currently available in several European countries.

P397
INCREASING INCIDENCE OF MALIGNANCIES IN AGING THALASSEMIC PATIENTS AT A SINGLE INSTITUTION'S LONGITUDINAL EXPERIENCE
E. Repousi1,* M. Moraki1, D. Kyriakopoulou1, P. Delaporta1, A. Kafourou1, E. Katamis1
1Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece

Background: The introduction of close monitoring, regular blood transfusions and systematic iron chelation in the management of thalassemia have significantly changed the clinical phenotype of the patients and improved their survival. The patients, who have benefited of the current therapeutic regimen, are reaching middle age and they may have started developing problems commonly seen in older people. Recent observations suggest an increased incidence of malignancies in the aging group of thalassemic patients.

Aims: The purpose of this study is to determine the longitudinal changes in the incidence of malignancies, along with possible correlations to different aspects of the disease.

Methods: A retrospective study in the largest Thalassemia Unit in Greece, which has been conducted spanning an observation period from 2001-2016. The occurrence and type of cancer, as well as hospitalization due to non-transfusion related complications, were recorded. Hb levels and capacity, transfusion and chelation therapy were collected. Survival analysis was performed using SPSS v. 20 software package. A p-values of <0.05 was considered statistically significant.

Results: A total of 591 patients were included. The incidence of malignancies increased from 0/51 in 2001-2005 to 7/51 in 2011-2015 (p<0.05). The overall incidence of malignancies was 13/591 (2.2%). The most common malignancies were lung cancer, breast cancer, colorectal cancer, prostate cancer and lymphoma, respectively. There was no correlation between malignancies and transfusion, chelation therapy and Hb levels. The incidence of malignancies increased with age (p<0.001).

Summary/Conclusions: The current study confirms that the long-term survival of patients with thalassemia is associated with an increased risk for malignancies. This is the first study to report on the incidence of malignancies in patients with thalassemia at a single institution, using a large prospective dataset.
with malignancies were identified (incidence: 4.6%). The mean age of the diagnosis of the malignancy was 41.8 years (36.6 years for thyroid gland cancer, 45.8 years for liver, 38 years for hematologic malignancies and 46 for renal cancer). 24 patients were transfusion dependent (TD) (7% of the patients) and 3 non transfusion dependent (1.8%). Liver cancer had the highest incidence 29.6%, followed by thyroid gland cancer 25.9%, hematologic malignancies 11.1% and renal cancer 14.8%. HCV infection was found in 56.7% of the patients and a statistical significant relationship between HCV infection and cancer (p=0.001) was detected. No correlation between liver failure and cancer was detected. In the TD group, the age specific ratio of cancer increased with age with the patients >50 years having the highest ratio of 42.3, compared to 36.9 in the 20-45 age group and 41.4 in 45-49 years age group respectively.

In regards to chelation therapy, at the time of diagnosis 40.9% of the patients were receiving deferasirox (DFX), 22.7% deferiprone (DFP), 22.7% deferoxamine (DFO). 9.1% no chelation therapy and 4.5% DFO/DFP. No statistical significant difference was observed between the different chelation therapy regimens (p=0.119). As the utilization of different types of chelation changed throughout the years, according to the availability of the chelating agents, we analyzed separately, the patients that developed malignancies in the period after 2010 when longitudinal exposure to all three chelators can be assumed. Even though the results showed a difference (p=0.027) between the different groups, with 47.1% of those patients receiving DFX at the time of the diagnosis compared to 27.1% receiving DFP and to 11.8% receiving DFO, this distribution reflects the overall distribution of chelator usage during that period. Apart from the incidence, there was no statistical significant difference between TD and NTD patients with cancer regarding the gender, age and year of diagnosis. The cancer mortality rate was 48%, but varied significantly with the type of cancer with liver cancer and hematological malignancies having a mortality of 66%. Overall only 2% of the deaths occurring in our group of patients were attributed to cancer.

Summary/Conclusions: This retrospective study has confirmed the increased incidence of malignancies in thalassemia patients in Greece, which is, at least, partially related to the aging of this population. Based on these observations, adaptation of monitoring guidelines is essential for optimal management of thalassemic patients. Periodic screening for malignancies, especially hepatic, thyroid and hematologic, will allow early detection and timely, and thus, more efficacious treatment of the neoplasia.

P398 SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL

M. Elalfy1,*, B. Helal2, V. Berdoukas3, F. Tricta4, M. Tarif1, H. Awad5, A. Adly1

1AinShams university, 2Ain Shams University, Cairo, Egypt, 3Oasis International Hospital, Beijing, China, Beijing, China, 4ApoPharma Inc., Toronto, Canada, 5National Research Center, Cairo, Egypt

Background: Early exposure to Iron toxicity is the main risk factor for morbidity and mortality in patients with transfusion-dependent thalassemia. Current practice is to start chelation therapy only after 10-20 transfusions, or when the serum ferritin (SF) level rises above 1,000 µg/L.

Aims: To evaluate the safety and efficacy of the early use of low-dose deferiprone in minimally transfused pediatric thalassemia patients and to evaluate if it can postpone iron overload in this group of patients.

Methods: In the current trial (ClinicalTrials.gov Identifier: NCT02173951), sixty-four children recently diagnosed with thalassemia major who had begun receiving blood transfusions in first year of life to keep pre-transfusion Hb above 10 gm/dl, had not yet started iron chelation therapy and had SF ≥400 µg/L or transferrin saturation (TSAT) ≥70% or labile plasma iron (LPI) ≥0.6 µM were randomized to start deferiprone (DFP) at a sub-therapeutic dose (50 mg/kg/day) or no chelation (NC). Median age at 1st transfusion ≥0.2 µM were randomized to start deferiprone (DFP) at a sub-therapeutic dose (50 mg/kg/day) or no chelation (NC). Median age at 1st transfusion was 4.5 years (range: 1.4-14.2) and mean age was 22.3±7.5 years.

Results: Table 1. Summary of the efficacy results of SF, TSAT, and LPI.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>3 months</th>
<th>6 months</th>
<th>9 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF (µg/L)</td>
<td>ES-DFP</td>
<td>NC</td>
<td>ES-DFP</td>
<td>NC</td>
<td>ES-DFP</td>
</tr>
<tr>
<td>% patients with SF ≥1000 µg/L</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>TSAT (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>LPI (µM)</td>
<td>0.28±0.07</td>
<td>0.16±0.10</td>
<td>0.20±0.08</td>
<td>0.16±0.10</td>
<td>0.20±0.08</td>
</tr>
</tbody>
</table>

All NC patients were removed from the trial prior to completing 7 months of follow-up (9-11 transfusions) due to confirmed SF ≥1000 µg/L. Mean ± SD time of follow up was 10.4±4.9 and 5.9±2.5 months for DFP and NC respectively. Most common adverse events in patients on DFP versus NC were diarrhea (19% vs 13%, p=0.73), vomiting (13% vs 13%, p=1.00), abdominal colic (13% vs 13%), elevated liver enzymes (6% vs 3%, p=1.00) and neutropenia (6% vs 6%). All adverse events were mild in severity and did not require interruption of DFP use. There were no cases of agranulocytosis or moderate neutropenia, no arthralgia and no serious infections in DFP-treated patients. DFP therapy was associated with a significant reduction in the rate of iron accumulation as measured by SF (P<0.0001), LPI (P=0.001) and TSAT (P<0.001) (Figure 1, a, b, c). LPI≥0.6 µM appeared as early as after 5 transfusions in NC children and was delayed to at least 10 transfusions with DFP therapy. TSAT≥70% appeared after 10 transfusions in NC children and was delayed to at least 17 transfusions with DFP therapy. The results of this study show that LPI and TSAT may reach values ≥0.6 µM and ≥70%, respectively, after 5-10 transfusions in children with TM and all NC children had SF ≥1000 µg/L after 8-9 transfusions.

Summary/Conclusions: A sub-therapeutic dose of deferiprone for a mean of 12 months in children with TM and low iron overload was not associated with safety concerns and able to significantly reduce the rate of iron accumulation as measured by SF, LPI and TSAT.

P399 LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR

M. Casale1,*, A. Meloni2, A. Filosa1, L. Pistola3, F. Sorrentino3, A. Quartar4, A. Carolo1, M. C. Cirotto1, V. Positano2, E. Grassedonio1, M. Missirelli8, A. Pepe2

1AORN A. Cardarelli, Napoli, 2Fondazione G. Monasterio CNR-Regional Toscana, Pisa, 3Ospedale “Sant’Eugenio”, Roma, 4Ospedale “A. Perrino”, Brindisi, 5Azienda Ospedaliera “Sant’Antonio ed SS. Tommasi, 6ASL N.1 Sassari, Sassari, 7Polilorino “Paolo Giaccone”, Palermo, 8Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy

Background: No studies are available in literature evaluating, on repeated magnetic resonance (MR) imaging assessments, changes in myocardial and hepatic iron overload, biventricular function, and development of macroscopic myocardial fibrosis in pediatric patients with thalassemia major (TM).

Aims: This is the first longitudinal prospective MRI study in pediatric TM patients.

Methods: We considered 68 TM patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) project with less than 18 years at the first MRI assessment. Changes in myocardial (MR) and liver iron concentration, biventricular function, and late gadolinium enhancement (LGE) images were acquired to detect myocardial fibrosis. All patients had a 1st MRI study performed at the age of 12±3 years

Results: At the baseline MRI, 16 (23.5%) patients showed myocardial iron overload (MIO; global heart T2*<20 ms) and 54 patients liver iron overload

Figure 1.
(79%). Figure 1 shows the changes in iron levels. Twenty-five patients changed the chelation regimen after the baseline MRI. Globally, a worsening in cardiac iron was found in 3% of the patients while a worsening in hepatic iron in the 21% of the patients (P=0.003). The LV end-diastolic volume index and all RV volumes as well as the LV mass index were significantly lower at the FU MRI. No significant improvement in left or right global systolic function was found. For 40 patients the presence of myocardial fibrosis was investigated at both baseline and FU scans. Six patients (15.0%) had myocardial fibrosis at the baseline MRI and myocardial fibrosis was detected for all of them also at the FU. The extent of myocardial fibrosis was comparable between the two scans (0.77±0.42% vs 0.79±0.51%; P=0.686). At the Fu 4 new occurrences of myocardial fibrosis were detected. In patients with baseline MI0 no significant correlation was found between the percentage change in cardiac iron and the changes in hepatic iron or the baseline hepatic iron.

Summary/Conclusions: Magnetic resonance imaging in children with TM demonstrated a good control of cardiac iron overload in terms of prevention and treatment but the need for further improvement of liver iron overload. Myocardial fibrosis appears mainly multifocal, non progressive and not reversible over a 18- month period. A prompt and aggressive approach to iron overload and a chelation regimen consistent with the high iron intake and the high rate of severe liver iron overload is recommended in children.

Table 1.

<table>
<thead>
<tr>
<th>MRI-RI-R2*</th>
<th>Heart</th>
<th>Liver</th>
<th>Pancreas</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50 Hz</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>&gt;50 Hz</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>&gt;100 Hz</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 1. Multi-organ MRI R2* evaluations at baseline and after f.u. of pancreatic-R2*>100Hz.

Summary/Conclusions: In this experience we observed that the regular multi-organ assessment of iron overload by R2* is concomitant with a reduction of the iron burden in this cohort of well treated patients confirming that is a careful method to tailoring the iron chelation therapy. However pancreatic-R2* remains above the cut-off for the prediction of cardiac iron overload, so this parameter should be considered with caution in the tuning of the chelation therapy, in order to avoid over-chelation risk. Ferritin values trend agree with R2* values confirming the reliability of this parameter. These results were obtained with a prevalent use of oral chelation regimen (90% of patients).
**Transfusion medicine**

**P401**

**DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION**

T. Mizukami1,2, K. Nojima1, R. Sobata2, W. Kuribayashi2, C. Matsumoto2, Y. Yano1, E. Sasaki1, K. Furuhata1, Y. Hiradate1, K. Ohkuma1, S. Matsuoka1, M. Satake1, I. Hamaguchi1

1Department of Safety Research on Blood and Biologicals, National Institute of Infectious Diseases, 2Central Blood Institute, Japanese Red Cross, 3Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Tokyo, Japan

**Background:** Adult T-cell leukemia (ATL) is a malignant disease caused by infection with human T-lymphotropic virus (HTLV-1). The prevention of HTLV-1 infection is the most effective strategy to eradicate ATL. However, there is no effective vaccine or anti-viral agent for HTLV-1.

**Aims:** The aim of this study was to develop an effective HTLV-1 hyperimmune globulin (HTLV-IG) isolated from HTLV-1 positive carriers screened at the Japanese Red Cross.

**Methods:** We developed two in vitro and in vivo screening methods to evaluate and characterize the anti-viral effect of HTLV-1 positive plasma and HTLV-IG. The anti-viral effect of HTLV-IG isolated from an HTLV-1 carrier with a proviral load (PVL) >4 inhibited both HTLV-1 infection and synctia formation. We purified HTLV-IG from the HTLV-1 positive plasma (PVL >4) and evaluated its effect in a humanized mouse model. NOG (Nod.Cg-Fkdcisl2tgtn1SugJrc) mice were treated with HTLV-IG for 5 days before HTLV-1 infection. During the monitoring period of 40 days after post-infection, HTLV-1 infection was observed in untreated infected mice, but not in HTLV-IG-treated mice. The inhibitory effect of HTLV-1 was observed at the early stage of HTLV-1 infection. Treatment with HTLV-IG at 20 days after HTLV-1 infection had a partial inhibitory effect. HTLV-1 gp46 expression in HTLV-1 infected cells was slightly reduced and the localization of the cells was changed in each tissue after the first line of treatment. These data suggest HTLV-IG is effective at the early phase of HTLV-1 infection. We also assessed the viral safety of HTLV-1 during the HTLV-IG manufacturing process. High log reduction values of HTLV-1 were observed during the Cohn fractionation process. Virus safety was assessed by PCR based assay and in vitro and in vivo infection assay. We next assess the viral safety of HTLV-1 during the HTLV-1 manufacturing process. High log reduction values of HTLV-1 can be seen during the Cohn fractionation process. Virus safety was assessed with PCR based assay and in vitro and in vivo infection assay.

**Summary/Conclusions:** These data suggest HTLV-IG is effective and safe for the prevention of HTLV-1 infection.

**P402**

**THE COMBINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSLANTATION**

M.L. Lozano1, F. De Arriba1, M. Solá1, A. Sánchez-Fuentes1, N. Revilla1, F. Omarto1, A. Jerez1, I. Heras1, P. Imiesta1, O. Lopez-Godino1, M.D. Garcia-Malo1, V. Vicente1

1Hematology and Clinical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain

**Background:** The use of high dose of chemotherapy followed by autologous stem cell transplantation (ASCT) has improved the prognosis of patients with multiple myeloma (MM) and plasma cell dyscrasia. However, there is controversy over the effect of infusion of atypical plasma cells (PC) on the apheresis product.

**Aims:** To analyze whether MM patients with an MM plasma cell reinfusion could negatively affect responses to ASCT.

**Methods:** Patients (n=114) undergoing ASCT (n=120) for MM between June 2003 and February 2016 were enrolled in a retrospective study to analyze the prognostic value of aberrant (CD38++CD138+CD19-CD45weak) to normal phenotype (CD38++CD138+CD19+CD45+) plasma cells (AT-PCT ratio) in the autograft by flow cytometry. The Durie-Salmon stage at diagnosis, pre-ASCT monoclonal component, and response (0.08 vs 0.08 ×10^6/kg). There was no difference between the type of autograft (autologous hematopoietic+G-CSF) and the degree of apheresis contamination (median AT-PCT ratio 0.5 vs 0.8; P=0.86). There was a statistical trend between the degree of infiltration of PC in the bone marrow before ASCT and the detection of atypical PC in the graft (p=0.06). At day +100, 94% of patients with CR or VGPR to induction therapy maintained the response, and 49% of patients in PR, SD or PD achieved post-ASCT CR or VGPR (p=1.24^-7). There was no association between the content of atypical PC in the graft and the response to day +100. However, the percentage of pre-ASCT PC in the bone marrow was significantly related to the response at day +100 (CR or VGPR vs PR, SD or PD), p=0.003, as well as the pre-ASCT monoclonal component (p=4.03^-7).

<table>
<thead>
<tr>
<th>Median age, yr (range)</th>
<th>Male (%)</th>
<th>Plasma cell dyscrasia, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Multiple myeloma, IgG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Multiple myeloma, IgA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Bence-Jones multiple myeloma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Plasma cell leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Other: Non secretory myeloma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Complete response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Very good partial response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Partial response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Stable disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Progressive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Other plasma cell leukaemia or plasmacytoma</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** infusion of PC with atypical phenotype does not appear to affect the response at day +100 following ASCT, in patients with MM or plasma cell dyscrasia. Conversely, the quality of response to induction therapy was significantly associated to 100-day outcome after transplantation. These data support that in vivo persistent residual cells, but not those being infused with the graft, are the main source of relapse in MM.

**P403**

**EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL**

R. Moli1,*, D. Warcel1, S. Clark1, M. Sekhar1

1Haematology, Royal Free Hospital, London, United Kingdom

**Background:** Therapeutic plasma exchange (TPE) is used to treat a number of haematological, renal and neurological conditions. Pathogenic antibodies or other plasma molecules are removed, and plasma volume is replaced with fluid. Haemoglobin, albumin solution (HAS) is usually preferred, except in cases of Thrombotic Thrombocytopenic Purpura (TTP) and related conditions. TPE may result in dilutional coagulopathy, and reactions such as hypersensitivity can occur. The British Society for Haematology (BSH) published a 2015 guideline to assist the use of TPE in UK clinical practice, providing evidence-based indications and recommended schedules.

**Aims:** To evaluate the use of elective TPE at a large tertiary London hospital, compare clinical practice against BSH guideline recommendations, and explore the effect of TPE on coagulation test results.

**Methods:** Data was collected prospectively over a 2 month period, using patient notes and electronic transfusion records. A data collection form recorded the indication, treatment schedule, replacement fluid, complications, the presence of a written treatment plan, and frequency and results of coagulation testing.

**Results:** 24 plasma exchanges took place over the period of data collection; there were no cases of TTP. Adherence to BSH guidelines was variable; although most cases (88%) had an evidence-based clinical indication for TPE, just 4% had a full written treatment plan, and only 17% of courses followed recommended scheduling. 75% of patients had received at least one prior course, some outside guideline indications for repeat courses. Most patients (83%) initially received human albumin solution (HAS), usually preferred, except in cases of TTP. Most patients (85%) received human albumin solution (HAS), usually preferred, except in cases of TTP. Fibrinogen levels showed some correction by the next day but usually still abnormal. A prolonged APTT and PT was also seen in most patients immediately following TPE, which almost always corrected by the next day.
Summary/Conclusions: TPE use was generally compliant with BSH guidelines regarding clinical indication and initial replacement fluid. However many patients were changed from HAS to FFP to achieve the predicted coagulopathy. This is a recognised complication of TPE, and the guidelines suggest that if possible, TPE can take place on alternate days to ameliorate this. Fluid change to FFP is recommended only for those at increased haemorrhagic risk. Almost all the TPE used in our study took place over 3 to 5 subsequent days, reflected in the high frequency of fibrinogen monitoring, and the level that should prompt change to the TPE schedule, require further exploration. The following are planned to enhance adherence to BSH guidelines and improve patient care. 1. Documented treatment plans with clinical indication, proposed treatment schedule, replacement fluid. 2. Local trust guidelines to include recommended TPE schedules, agreed parameters to monitor response, frequency of fibrinogen monitoring, common complications and their management. Where possible, TPE should take place on alternate days to reduce dilutional coagulopathy. 3. Education of staff involved with service provision, and strengthening of the role of apheresis nurse as lead.

P404

A COMPREHENSIVE PROTEOME STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MISAROL PATHOGEN REDUCTION TECHNOLOGY

D. Warcel1,*, R. Moll1, A. Li1

Background: Platelet concentrates (PCs) represent a blood transfusion product with a major concern for safety as their storage temperature (20-24°C) allows bacterial growth, which will occur in less than a week. This necessitates complete microbiological testing. Pathogen reduction technologies (PRTs) provide an additional layer of safety to the blood transfusion products from known and unknown pathogens (such as bacteria, viruses and parasites). In this context, PRTs (such as Mirasol technology) have been developed and are implemented in many countries. However, several studies have shown in vitro that Mirasol PRT induces a certain level of platelet shape change, hyperactivation, basal degradation and increased oxidative damage during storage. It has been suggested that Mirasol PRT might accelerate what has been described as the platelet storage lesion (PSL), but supportive molecular signatures have not been obtained.

Aims: We aimed at dissecting the influence of both variables, i.e. Mirasol PRT and storage time, at the proteome level.

Methods: We present comprehensive proteomics data analysis of control PCs and PCs treated with Mirasol PRT at storage day 2, 6 and 8. Our workflow was set to perform proteomics analysis using a gel-free and label-free quantification (LFQ) approach. Semi-quantification was based on LFQ signal intensities of identified proteins using MaxQuant/Perseus software platform.

Results: We identified marginal differences between Mirasol PRT and untreated PCs during storage. However, those significant changes at the proteome level were specifically related to the functional aspects previously described to affect platelets upon Mirasol PRT, and in addition, the effect of Mirasol PRT on the platelet proteome appeared not to be exclusively related to proteomic changes due to PSL.

Summary/Conclusions: In summary, semi-quantitative proteomics allow to discern between treatment changes due to Mirasol PRT or PSL, and proves to be a methodology suitable to phenotype platelets in an unbiased manner, in various physiological contexts.

P405

USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING

D. Warcel1,*, R. Moll1, A. Li1

1Haematology, Royal Free Hospital, London, United Kingdom

Background: UK guidelines to provide evidence-based support for decisions to transfuse packed red cells were published in 2015 by NICE (National institute for Health, and Care Excellence). The guidelines specified Hemoglobin (Hb) targets for transfusion, use of single unit transfusion to avoid over-transfusion, information provision to patients for informed consent, and avoidance of pre-operative transfusion by timely identification of iron deficiency for referral through an anemia pathway. A local baseline audit of NICE compliance at our London teaching hospital showed low overall compliance with these recommendations.

Aims: To determine knowledge amongst the prescriber group of transfusion recommendations for stable patients, to gain insight into current patterns of decision-making for transfusion and to impart knowledge of the key NICE guidelines.

Methods: An online survey, designed to both evaluate and inform participants, was targeted at doctors of different training grades and specialties during a two week period. The outcomes of this are being used to guide further training.

Results: Of 141 participants who took part in the survey, 31% (43) had been qualified for less than two years and 47% (65) were consultants. Specialties included Surgery, Anesthesitcs, Internal Medicine, Hemato-Oncology and Intensive Care. 60% (84) had prescribed blood within the last month. Despite only 51% (72) awareness of the NICE guidelines, a significant majority (73%, 103) selected the correct Hb threshold of ≤70g/L for transfusion in patients without acute coronary syndromes (ACS). A correct 70g/L Hb threshold held at all. Ferritin measurement was inconsistent with only 47% (66) routinely measuring this prior to transfusion, and only 31% (44) aware that a ferritin result over 30 days old should be rechecked. This highlighted potentially inadequate identification of iron deficiency anemia. In addition only 40% (57) were aware of the existence of a hospital anaemia clinic for referral. When reflecting on consent methods, 96% (135) of participants expressed some difficulty in obtaining patient consent, and 90% (127) gave an opportunity to ask patients questions and ensured the patient was content to proceed. Provision of written information was poor (26%, 37) and only 55% (78) recorded the discussion in patients’ notes. Exploring barriers to consent, 24% (32) expressed difficulty in obtaining a patient information leaflet, and issues relating to lack of time and confidence were 16% (22) and 9% (12) respectively.

Summary/Conclusions: Although the majority of participants expressed awareness of the NICE guidance, knowledge was not reflected in subsequent questions. The survey allowed simultaneous assessment of knowledge and provision of key information as a factsheet. Almost all participants felt that completion of the survey had been helpful, and as a tool to reach a highly mobile group, the survey is a constructive and supportive method to facilitate implementation of national guidance by medical staff. We were also able to identify areas that need further development including the clinical referral pathway for the anaemia clinic and improving the availability of patient information leaflets on hospital wards. At present we are not aware of any hospital transfusion service which routinely distributes information to all hospital staff, and carrying out structured case based discussion sessions with junior doctors to enhance knowledge and confidence.
Front-line combinations in multiple myeloma and amyloidosis

S407

QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY


1The Institute of Cancer Research, London, United Kingdom, 2Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, United States, 3Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, 4Heart of England NHS Foundation Trust, Birmingham, 5Leicester Royal Infirmary, Leicester, 6Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, 7University Hospitals of North Midlands, Stoke-on-Trent, 8Kant and Canterbury NHS Trust, Canterbury, 9Southampton Hospital, Southampton, 10University of Leeds, Leeds, 11The Royal Marsden Hospital, London, 12Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, 13Haematological Malignancy Diagnostic Service (HMDS), St James’s University Hospital, Leeds, 14Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, Leeds, 15Department of Haematology, Newcastle University, Newcastle, United Kingdom

Background: Combining anti-myeloma induction therapies limits the impact of clonal heterogeneity on resistance to therapy, maximising response and associated clinical outcomes. Triplett combinations induce deeper, longer remissions than doublets and those containing an immunomodulatory agent, a proteasome inhibitor (PI) or both are the current standard of care in Europe/US. Potential approaches to further improve outcomes include response-adapted induction, treating suboptimal responders with sequential treatment using an agent with a different mechanism of action, or intensifying therapy for all patients by the use of quadrplet combinations upfront.

Aims: The UK NCRI Myeloma XI trial is a large, phase III study comparing, in transplant eligible (TE) patients, the induction quadruplet carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRD) to the sequential strategy of triplet immunomodulatory combinations (with thalidomide or lenalidomide) followed by additional pre-transplant consolidation with PI triplet therapy for those with a suboptimal response.

Methods: In 2013, the TE pathway of the Myeloma XI study was amended to include KCRD given in 28 day cycles (carfilzomib 36mg/m2 IV d1-2,8-9,15-16 (20mg/m2 #1d1-2), cyclophosphamide (cyclo) 500mg PO d1, lenalidomide (len) 25mg PO d1-21, dexamethasone (dex) 40mg PO d1-4,8,9,15-16). Patients were randomised to this up-front quadruplet or the sequential strategy of CRD (cyclo 500mg PO d1, len 25mg PO d1-21 PO daily, dex 40mg PO d1,4,8,12-15) or CTD (cyclo 500mg PO d1,8,15 thalidomide 100-200mg PO daily, dex 40mg PO d1-4,12-15) given to max. response. Patients with VGPR/CR proceeded straight to ASCT, those with PR/MR were randomised to sequential CVD (cyclo 500mg d1,8,15, bortezomib 1.3mg/m2 IVSC d1,4,8,11, dex 20mg PO d1,2,4,5,8,9,11,12) or nothing and those with SD/PD all received sequential CVD. At day 100 post ASCT there was a maintenance randomisation between lenalidomide and observation. The trial has now closed to recruitment and all patients have completed induction therapy. This analysis compares responses and toxicity of the different regimens.

Results: 2568 TE patients underwent induction randomisation (CTD 1021, CRD 1021, KCRD 526). Patients were comparable with respect to age (median 59 years), sex and other key laboratory parameters. Patients were mandated to receive a minimum of 4 cycles of initial induction with therapy continued to maximum response. The median number of cycles delivered was CTD: 5, CRD: 5, KCRD: 4. Grade ≥3 haematological toxicities differed between the groups. (Neutropenia CTD: 12%, CRD: 22%, KCRD: 16%; Thrombocytopenia CTD: 3.4%, CRD: 4.5%, KCRD: 8.1%; Anaemia CTD: 6.7%, CRD: 9.6%, KCRD 10%). Grade ≥2 neurological toxicity was greater with the thalidomide-containing regimen (Sensory neuropathy CTD: 9.5%, CRD: 3.4%, KCRD: 2.3%). There was no statistically significant difference in rates of investigator reported, all-grade, thromboembolic events between regimens (CTD: 11.8%, CRD 11.1%, KCRD 14.7%). Response to initial induction and following ASCT is shown in Table 1 indicating deeper responses with the quadruplet compared to triplets both at the end of first induction regimen (p<0.0001) and, importantly, post-ASCT (p<0.0001). These differences were observed despite the use of randomised pre-transplant consolidation for suboptimal responders to triplet immunomodulatory therapy.

Summary/Conclusions: Induction therapy with KCRD, an outpatient delivered quadruplet regimen, was associated with deeper responses than immunomodulatory triplet therapy (CRD/CTD) and was well tolerated. Deeper responses persisted after ASCT, with an impressive response rate ≥VGPR of 92% with KCRD.

Table 1.

<table>
<thead>
<tr>
<th>Response at end of first induction therapy</th>
<th>CTD (n=1021)</th>
<th>CRD (n=1021)</th>
<th>KCRD (n=526)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP</td>
<td>46.8%</td>
<td>52.8%</td>
<td>58.7%</td>
</tr>
<tr>
<td>VGPR</td>
<td>29.5%</td>
<td>27.6%</td>
<td>34.9%</td>
</tr>
<tr>
<td>PR/MR</td>
<td>23.7%</td>
<td>34.9%</td>
<td>33.2%</td>
</tr>
<tr>
<td>VGPR (number completing ASCT to date)</td>
<td>647%</td>
<td>672%</td>
<td>632%</td>
</tr>
<tr>
<td>PR/MR (number completing ASCT to date)</td>
<td>20.9%</td>
<td>23.7%</td>
<td>34.9%</td>
</tr>
</tbody>
</table>

Table 1. Treatment exposure and safety data.

<table>
<thead>
<tr>
<th>Treatment exposure</th>
<th>n=1021</th>
<th>n=1021</th>
<th>n=526</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median number of treatment cycles (range)</td>
<td>17 (7-31)</td>
<td>17 (7-31)</td>
<td>17 (7-31)</td>
</tr>
<tr>
<td>AE (% any)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AEs at onset during induction (cycles 1-12)</td>
<td>3 of 1021</td>
<td>3 of 1021</td>
<td>3 of 526</td>
</tr>
<tr>
<td>AEs at onset during maintenance (cycles 13-24)</td>
<td>3 of 1021</td>
<td>3 of 1021</td>
<td>3 of 526</td>
</tr>
</tbody>
</table>

Background: Quadruplet combinations that include a proteasome inhibitor (PI) may have been proven superior to doublets in newly diagnosed multiple myeloma (NDMM) (San Miguel et al, N Engl J Med 2008, Durie et al, Lancet 2017). The all-oral combination of the novel PI ixazomib plus lenalidomide-dexamethasone (IRd) was evaluated as an induction regimen in NDMM patients, followed by single-agent ixazomib maintenance.

Aims: Here we report updated efficacy and long-term safety data for patients who did not withdraw from the study in order to receive stem cell transplantation (SCT).

S408

DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT

S. Kumar1, J. Berdeja2, R. Niewczyk3, S. Loriai4, J. Laubach4, M. Hamadani5, A.K. Stewart5, P. Har8, V. Roy9, R. Vesco10,1, J. Kaufman11, D. Berg12, E. Liao12, V. Rajkumar1, P. Richardson5

1Mayo Clinic, Rochester, 2Sarah Cannon Research Institute, Nashville, 3Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, 4Department of Medicine and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, 5Dana-Farber Cancer Institute, Boston, 6West Virginia University, Mary Babb Randolph Cancer Center, Morgantown, 7Mayo Clinic College of Medicine, Scottsdale, 8Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, 9Mayo Clinic, Jacksonville, 10Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, 11Winship Cancer Institute of Emory University, Atlanta, 12Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States
Methods: In this phase 1/2 study (NCT01217957), patients with NDMM received weekly oral ixazomib (1.8-3.5mg/m²; days 1, 8, 15) and dexamethasone (40mg, days 1, 8, 15, and 22) for up to 12-28 day induction cycles, followed by maintenance therapy with weekly single-agent ixazomib, at the last tolerated dose given during induction, until disease progression or toxicity.

Results: Of the 42 enrolled patients, 42 continued on study treatment without early withdrawal for SCT; the long-term follow-up of these 42 patients is reported here. Baseline patient characteristics included: median age, 68 years (range 34-86); ISS stage I/II/III in 40%/4%/17%. As of October 18, 2016, with median follow-up of 56 months, the confirmed overall response rate (ORR, ≥ partial response [PR]) was 80%, complete plus very good partial response (CR+VGPR) rate was 63%, and CR rate was 32%. Median time to first response was rapid (0.95 months), while median time to CR was 5.6 months. Median progression-free survival (PFS) in these patients not receiving SCT was 25.3 months. Median overall survival (OS) has not been reached at a median follow-up of 3 years. OS at 3 years was 87%. Safety findings are summarized in the Table; 74% of patients had grade ≥3 treatment-related adverse events (AEs), and 26% of the patients had treatment-related serious AEs. Among treatment-related AEs of interest, grade ≥3 rash and peripheral neuropathy were infrequent. There was one treatment-related death due to respiratory syncytial viral pneumonia. After completing 12 cycles of induction therapy with IRd, 25 patients went on to receive maintenance single-agent ixazomib. In these 25 patients, at the end of the induction period ORR was 100%, including 44% VGPR and 32% CR. Responses deepened during maintenance, at data cut-off, the response rates in this maintenance therapy population were 50% VGPR, 32%, and 38% CR. Patients who received maintenance therapy was 24 months. The occurrence of the most common treatment-related grade ≥3 AEs (neutropenia, thrombocytopenia, and fatigue) was confined almost exclusively to the induction period. During the maintenance period no patients reported onset of grade ≥3 peripheral neuropathy or rash. Summary/Conclusions: In patients with NDMM, weekly ixazomib plus Rd, followed by single-agent ixazomib maintenance, was highly active, resulting in deep and durable responses, long PFS, and a high 3-year OS estimate. IrD followed by single-agent ixazomib maintenance also showed an acceptable safety profile, with less toxicity reported during the maintenance (single-agent ixazomib) vs induction (IRd) periods, with no evidence of cumulative toxicities.
Table 1.

<table>
<thead>
<tr>
<th>Grade 3-4 AE/s/SAE</th>
<th>KCd</th>
<th>KRd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematological</td>
<td>13%</td>
<td>9%</td>
</tr>
<tr>
<td>Cardiac</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>0%</td>
<td>3%</td>
</tr>
<tr>
<td>AST/ALT/GGT</td>
<td>0%</td>
<td>3%</td>
</tr>
<tr>
<td>Dermatological</td>
<td>0%</td>
<td>6%</td>
</tr>
<tr>
<td>Infections</td>
<td>0%</td>
<td>9%</td>
</tr>
<tr>
<td>Acute Kidney Injury</td>
<td>p value &lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Safety profile was acceptable; more patients required plerixafor in the KRd arm. Rate of VGPR was higher with KRd. Updated data on a higher number of patients will be presented at the meeting. The trial is registered at Clinicaltrials.gov: NCT02203643

S411

HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS

M. Minnema1,*, K. Nasserinejad2, B. Hazenberg3, U. Hegenbart4, L. Noens5, P. Ypma6, S. Zweegman7, L. Tick8, A. Broijl9, H. Koene10, G. Bos11, N. Thuss2, P. Sonneveld2, S. Schonland4

1Haematology, UMC UTRECHT, Utrecht, 2HOVON data center, ErasmusMC, Rotterdam, 3Rheumatology, UMCG, Groningen, Netherlands, 4Amyloidosis Center, University of Heidelberg, Heidelberg, Germany, 5Haematology, UZ Gent, Gent, Belgium, 6Internal Medicine, HAGA hospitals, the Hague, 7Haematology, VU medical center, Amsterdam, 8Internal Medicine, Maxima Medical Center, Eindhoven, 9Haematology, ErasmusMC, Rotterdam, 10Internal Medicine, st Antonius Hospital, Nieuwegein, 11Haematology, University Hospital Maastricht, Maastricht, Netherlands

Background: Bortezomib (B) has been reported to be very effective in AL amyloidosis with overall response rates (ORR) varying between 50-80%. However, there are no prospective data from multicenter studies on B treatment in de novo patients. We investigated the efficacy and safety of B-Dexamethasone (BD) induction treatment followed by HDM+SCT in de novo AL amyloidosis patients.

Aims: The primary aim was to improve the hematological CR rate at 6 months after SCT on intention to treat analysis from 30 to 50%. Secondary aims were OS, PFS, hematological response rate after BD treatment, organ responses, safety and prognostic factors for survival.

Methods: Patients with biopsy proven AL amyloidosis, aged between 18-70 years, with detectable M-protein and/or level of involved FLC >50mg/L, WHO performance status 0-2, NYHA stage 1-2 and ejection fraction >45% were included. Major exclusion criteria were symptomatic orthostatic hypotension, NT proBNP level >5000 pg/ml, Troponin T > 0.06 ugl, Bilirubin >2x ULN, eGFR<30 ml/min, CTCAE grade peripheral sensory neuropathy > grade 2 or > grade 1 with pain. Inclusion and exclusion criteria were installed both at entry and before stem cell mobilization (SCM). B was given subcutaneously 1.3mg/m² twice a week in a 21-day cycle, D 20mg orally on each B day and the following day. HDM dosage was 200mg/m². Hematological responses were defined according to consensus criteria with the addition of very good partial response (VGPR), defined as the difference between involved and uninvolved FLC<40mg/L. Cardiac, renal and liver response and progression criteria were defined according to consensus criteria with addition of NT proBNP.

Results: Median age was 59 years (range 26-70) and 60% were male. NYHA stage was 1 in 56% and 2 in 42% of patients. Mayo cardiac risk score was 1 (30%), II (36%), III (34%). Organ involvement was 82% renal, 66% heart, 28% liver, 14% neurological, 8% gastrointestinal and 38% of patients had 3 or more organs involved. Bone marrow plasmacells were >10% in 28% of patients. The median FU for patients alive is 24 (10-55) months. Twelve of 50 (24%) patients could not proceed to SCM. Four patients due to B related toxicity, 3 patients did not fulfill criteria to proceed, 2 patients died (both amyloidosis related) and 3 miscellaneous. Of these 38 patients, 3 went subsequently off protocol because of ineligibility for HDM. Thirty-five out of 50 patients (70%) received HDM + SCT, one patient died of a cardiac arrest after the SCT procedure. The ORR after induction was 80%, ≥VGPR in 54% and CR in 6% of patients. The ORR in the 35 patients at 6 months after SCT was 80%, ≥VGPR in 51% and CR in 43% of patients. On intention to treat analysis the CR rate at 6 months after SCT was 30%. Organ responses at 6 months after SCT were 16/29 renal, 2/8 liver and 13/23 heart. No baseline characteristics were identified to be predictive for OS or PFS. BD doses were reduced and delayed after 2 cycles in almost half of patients, mostly because of neurotoxicity. Sensory neuropathy grade 2 or higher was seen in 36% of patients and autonomic neuropathy, mostly dizziness and collapse, in 22%.

Summary/Conclusions: This final analysis demonstrates that the primary aim of improving CR rate at 6 months after SCT from 30 to 50% was not met. This was mainly caused by the high dropout rate before SCT. This may be due to patient selection, but we also demonstrate that BD, given twice weekly sc, despite good efficacy, cannot prevent early amyloidosis related toxicity and can induce grade 2 or higher neurotoxicity.

Trial registration www.trialregister.nl (NTR 3220), EudraCT 2010-021445-42, supported by the Dutch Cancer Society (UU 2010-4884) and by an unrestricted grant from Janssen-Cilag.
Hodgkin and indolent lymphoma - Clinical

S412
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
1University Hospital of Cologne, Cologne, Germany, 2University of Texas MD Anderson Cancer Center, Houston, United States, 3Humanitas Cancer Center – Humanitas University, Rozzano–Milan, Italy, 4Dana-Farber Cancer Institute, Boston, 5Mayo Clinic, Rochester, United States, 6Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy, 7University of California, Los Angeles, Los Angeles, United States, 8Cedars Sinai Medical Center, Los Angeles, United States, 9Catholic University of Sacred Heart, Rome, Italy, 10Columbia Cancer Center, Churchhill Hospital, Oxford, United Kingdon, 11Barbara Ann Karmanos Cancer Institute, Detroit, 12Winship Cancer Institute, Emory University, Atlanta, United States, 13Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, 14University of Toronto and Princess Margaret Cancer Centre, Toronto, 15British Columbia Cancer Agency, Vancouver, Canada, 16Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic, 17Brigham and Women’s Hospital, Boston, 18Bristol-Myers Squibb, Lawrenceville, 19Memorial Sloan Kettering Cancer Center, New York, United States

Background: Nivolumab, a fully human IgG4 monoclonal antibody targeting programmed death-1, is an immune checkpoint inhibitor that augments T-cell activation and antitumor responses. Nivolumab is indicated for pts with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) following autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV) treatment. The multicohort phase 2 CheckMate 205 trial (NCT02181738) enrolled pts with RR cHL after ASCT. Initial analyses revealed high objective response rates (ORR), encouraging duration of response (DOR) and an acceptable safety profile (Younes A et al, Lancer Oncol 2016). Durable responses to therapy are valuable in pts with progressive disease after failure of ASCT due to their limited treatment options.

Aims: To report extended follow-up data for all pts with RR cHL after failure of ASCT in CheckMate 205.

Methods: This was a single-arm multicenter trial enrolled pts (age ≥18 y) with RR cHL after ASCT into 1 of 3 independent cohorts (Cohort A: BV-naïve; Cohort B: BV only after ASCT; Cohort C: BV before and/or after ASCT). All pts received nivolumab 3mg/kg every 2 wk until disease progression or unacceptable toxicity. Pts in Cohort C with a persistent complete response (CR) for 1 y were to discontinue nivolumab and could resume at relapse. Primary endpoint was ORR per Independent Radiology Review Committee. Secondary endpoints included DOR; progression-free survival (PFS), overall survival (OS), and safety were assessed irrespective of BV treatment history.

Results: In total, 243 pts were treated: 63 in Cohort A (BV-naive), 80 in Cohort B (BV after ASCT), and 100 in Cohort C (BV before [n=53], after [n=58], or before and after [n=32]). Median (range) age was 34 (18-72) y and 77% of pts had advanced (stage III+) disease at study entry. BV-naïve pts had fewer prior lines of therapy (median of 2 vs 4 with prior BV). At Dec 2016 database lock, median (min, max) follow-up was 19 (1, 25), 23 (2, 27) and 16 (1, 20) mo in Cohorts A, B, and C, respectively. Overall, 40% of pts were still on treatment; the most common reason for discontinuation was disease progression (26%). ORR was 65% in Cohort A, 68% in Cohort B, and 73% in Cohort C with 29%, 13%, and 12% CR, respectively. Median (95% CI) DOR was 20 (13, 20), 16 (8, 20), and 15 (9, 17) mo in Cohorts A, B, and C, respectively. DOR for patients with CR was 20 months for BV-naive patients (Cohort A) and ≥15 mo for BV-treated patients (Cohorts B and C). DOR for patients with partial response (PR) was 17 and ≥11 months, respectively. PFS by cohort is shown (Figure 1). Prolonged median PFS was seen for patients with CR (≥17 mo in each cohort), PR (<15 mo in each cohort), and stable disease (<9 mo in each cohort). Median OS was not reached in any cohort. The most common drug-related serious AEs were neutropenia (12%), fatigue (11%), and infusion reactions (13%); and rash (12%), grade 3-4 drug-related AEs in ≥3% of pts were pts (2%) and pneumonitis (1%). To facilitate translation to practice, efficacy results by sequencing of prior BV treatment will be presented.

Summary/Conclusion: With extended follow-up, high and durable rates of CR and PR to nivolumab therapy were observed in pts with RR cHL after ASCT, irrespective of BV treatment history.

Study funding: BMS; medical writing support: M Thomas (Caudex), funded by BMS.

S413
EARLY CHEMOTHERAPY INTENSIFICATION WITH ESCALATED BEACOPP IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A POSITIVE INTERIM PET-CT AFTER 2 PET-CT CYCLES: LONG-TERM RESULTS OF THE GITIL/FIL HD 0607 TRIAL
1Department recherche innovation et statistique, Centre A. Lacassagne, Nice, France, 2Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, 3Ematologia, Università degli Studi di Milano, Milano, 4Ematologia, Università Federico II, Napoli, 5Divisione Universitaria Ematologia, Ospedale Ferratocatania, Catania, 6UOC Oncoematologia, Policlinico Tor Vergata, Roma, 7Ematologia, Ospedale R.Binaghi, Cagliari, 8Divisione di Medicina, UOC di Ematologia, Università di Padova, Padova, 9Ematologia, Ospedale S. Gerardo, Monza, 10Ematologia, A.O. S. Croce e Carle, Cuneo, 11Ematologia e oncologia ematrix pediatrica, Fondazione IRCCS Istituto Nazionale dei Tumori, 12Università degli Studi di Milano, Milano, 13Ematologia, Ospedale S. Camillo, Roma, 14Ematologia, Ospedale Mauriziano Umberto I di Torino, 15Ematologia Universitaria, AOU Città della Salute e della Scienza di Torino, Torino, 16Divi- sione Universitaria di Ematologia, Ospedale San Carlo, Potenza, 17Ematologia, Presidio Ospedaliero S. Bortolo, Vicenza, 18Divisione Universitaria Medicina Interna, AO San Luigi, Orbassano, 19Divisione di Medicina, Unità di Ematologia, Azienda Ospedaliera Universitaria Integrata, Verona, 20Divisione Universitaria Ematologia, Nuovo Ospedale Torrette, Ancona, 21Unit of Lymphoid Malignancy, Ospedale San Paolo, IRCCS, Ospedale S. Gerardo, Monza, 22Azienda Ospedaliera Universitaria S. Martino, Genova, 23Ematologia, Ospedale Centrale di Bolzano, Bolzano, Italy, 24The Sheba Center, Tel Hashomer, Israel, 25RCCS - Istituto di Ricerche Farmacologie Mario Negri, Milano, 26Fisica Sanitaria, A.O. S. Croce e Carle, Cuneo, Italy

Background: Interim 2-[18F]fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) performed after 2 chemotherapy cycles (PET2) is the most powerful predictor of treatment outcome in ABVD-treated, advanced-stage classical Hodgkin Lymphoma (cHL). Preliminary reports showed that treatment with PET2 result could increase the efficacy of standard ABVD.

Aims: To confirm in a prospective setting the favorable prognosis of advanced stage PET2 negative patients treated with ABVD, as well as the safety and efficacy of escalated BEACOPP given to PET2 positive patients.

Methods: We conducted a prospective clinical trial (HD0607 ClinicalTriail.gov identifier 00795613), in which advanced-stage (IIB-IVB) cHL patients were treated with 2 ABVD courses, and PET2 performed afterwards. The latter was blindly and independently reviewed by a panel of nuclear medicine experts, using the Deauville 5-point scale (5-PS). PET2+ patients (5-PS 4-5) were randomized to either BEACOPP escalated (BE+BB) or BEACOPP baseline (BE+BB+R) therapy. Toxicity was assessed with the CTC-NCI version 4.0. PFS at 4 years (PFS4y) in the PET2 positive cohort was compared to the PET2 negative cohort.

Results: A total of 124 patients (PET2− cohort: 64 PET2+ cohort: 60) were consecutively enrolled in 24 Italian and 1 Israeli centers. The median age was 31 years (14-60); 35% had stage IIB, 32% stage III and 32% stage IV. The International Prognostic Score (IPS) was 0-1 in 36.6%, 2-3 in 51%, >3 in 12.5%.
Overall, 150 (19.2%) proved PET2+ (97 score 4, 53 score 5) and 630 (80.5%) PET2-. PET2+ patients were more frequently male (56.7% vs 47.1%, p=0.03), had higher IPS score (P=0.002) and bulky disease (28.0% vs 17.9%; p=0.002). Out of 149 PET2+ patients randomized to Be+Bb vs Be+Bb+R (76) or Be+Bb+R (73), 136 were evaluable for response: 93 obtained CR and 43 had a treatment failure. Of the remaining 13 patients, 3 died, 7 withdrew their consent and 3 stopped treatment for toxicity. As per study protocol, 627 out of 630 PET2- patients continued with 4 ABVD cycles and 3 withdrew their consent. Overall, 330 (38.6%) died, due to early death (n=2), resistant disease (n=18; 12 with a positive and 6 with a negative PET2), transplant related toxicity (n=5), infections (n=4) and pulmonary fibrosis (n=1). After a median follow-up of 1303 days (2-2857), the 4-Y OS for all 782 patients was 83% (95% CI 80%>86%) and 96% (95% CI 94%>97%), respectively. For PET2+ and PET2- patients, the 4-Y OS was 95% (95% CI 60%>96%) and 87% (95% CI 84%>89%), while the 4-Y OS was 95% (95% CI 82%>93%) and 97% (95% CI 95%>98%) (Figure 1, Panel A and B). No outcome difference was observed for Be+Bb vs Be+Bb+R patients, with a 4-Y PFS of 69% (95% CI 57%>79%) and 68% (95% CI 55%>76%), respectively (p=0.973). Consolida-
dation RxT in PET2- patients in CR after 6 ABVD and LNM did not translate in to a significant benefit, with a 4-Y PFS of 96% (95% CI 91%>98%) for RxT and 93% (95% CI 87%>96%) for NFT (p=0.288).

Figure 1.

Summary/Conclusions: These data suggest that 1) an early switch from ABVD to escalated BEACOPP can be safely done in PET2+ advanced-stage cHL; 2) the long-term outcome for the entire patient cohort is superior to standard ABVD; 3) no clinical benefit is associated with post ABVD RxT in PET2- patients with ≥3 tumor events were identified. The dates of occurrence of 3rd relapse ranged between 15th of January 1993 and 21th of June 2013. The sample consis-
ted of 51 male (74%) and 18 female (26%) patients. At time of 3rd relapse the age of the patients ranged from 20 to 79 years (mean 39.2 years, standard deviation (SD) 14.0 years) and the majority of patients presented with stage III or IV disease (67%). Time from end of 3rd-line treatment to 3rd relapse was ≤3 months (i.e. GHSG definition of refractory disease) in 15 cases (22%), ≤12 months (early relapse) in 19 cases (28%) and >12 months (late relapse) in 35 cases (51%). All 69 patients were pretreated with chemotherapy, 35 (50.7%) with BEACOPP, 30 (43.5%) with ABVD and no BEACOPP, and 32 (46.6%) with another type of chemotherapy. The number of prior chemotherapies ranged from one to three (median 3). Pretreatment with radiotherapy was observed in 57 (82.6%) patients, with salvage chemotherapy aimed to induce a remission prior to a stem-cell transplantation (SCT) in 58 (84.1%), and with high dose chemotherapy followed by autologous SCT in 50 (72.5%) patients. Patients with 6 months (early relapse) in 19 cases (28%) and >12 months (late relapse) in 35 cases (51%). All 69 patients were pretreated with chemotherapy, 35 (50.7%) with BEACOPP, 30 (43.5%) with ABVD and no BEACOPP, and 32 (46.6%) with another type of chemotherapy. The number of prior chemotherapies ranged from one to three (median 3). Pretreatment with radiotherapy was observed in 57 (82.6%) patients, with salvage chemotherapy aimed to induce a remission prior to a stem-cell transplantation (SCT) in 58 (84.1%), and with high dose chemotherapy followed by autologous SCT in 50 (72.5%) patients. Patients with 6 months (early relapse) in 19 cases (28%) and >12 months (late relapse) in 35 cases (51%). All 69 patients were pretreated with chemotherapy, 35 (50.7%) with BEACOPP, 30 (43.5%) with ABVD and no BEACOPP, and 32 (46.6%) with another type of chemotherapy. The number of prior chemotherapies ranged from one to three (median 3). Pretreatment with radiotherapy was observed in 57 (82.6%) patients, with salvage chemotherapy aimed to induce a remission prior to a stem-cell transplantation (SCT) in 58 (84.1%), and with high dose chemotherapy followed by autologous SCT in 50 (72.5%) patients.

Table 1.

<table>
<thead>
<tr>
<th>Progression Free Survival (PFS)</th>
<th>Overall Survival (OS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>Lower limit</td>
</tr>
<tr>
<td>6 months</td>
<td>76.3</td>
</tr>
<tr>
<td>12 months</td>
<td>58.8</td>
</tr>
<tr>
<td>18 months</td>
<td>47.4</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Patients with a 3rd relapse or progression of cHL have a dismal, mostly palliative prognosis due to frequent tumor progression. Within one year half of the patients have a PFS event and one fourth die.

S415

A REVISED STAGING SYSTEM FOR WALденström’S MACROGLOBULINEMIA

E. Kastritis1, M. Gavirotipoulou1, M.C. Kyrtsis1, E. Haghjusari2, E. Katodritou2, P. Repoussi3, A. Symeonidis4, M. Michael5, A. Pouli1, N. Giannakoulas6, D. Christoulas7, A. Megalakakia1, P. Tsigdoi2, S. Giannoulis1, P. Panagiota1, E. Veressou1, E. Spanoudakis1, E. Terpos1, M.A. Dimopoulos1

1Greek Myeloma Study Group, Athens, 2Greek Myeloma Study Group, Thes-
saloniki, 3Greek Myeloma Study Group, Piraeus, 4Greek Myeloma Study Group, Paatras, Greece, 5Greek Myeloma Study Group, Nicosia, Cyprus, 6Greek Myeloma Study Group, Larissa, 7Greek Myeloma Study Group, Alexand-
troupolis, Greece

Background: Waldenström’s macroglobulinemia (WM) is a rare low-grade B-
cell lymphoma characterized by the lymphoplasmacytic bone marrow infiltration and hyperviscosity syndrome. Most cases of monosomy 13 and IgM-immunoglobulin-secreting indolent lymphoma that has heterogeneous clinical manifestations and patients with this disease may have a prolonged disease course; however, there are groups of patients with poor outcomes after a relatively short disease course. In order to develop a robust staging system a collaborative effort resulted in the formulation of the International Prognostic Scoring System for WM (IPSS-
WM) which was developed in 2009 based on data of patients that were treated primarily without rituximab and mainly with alkylators and nucleoside analogues. IPSSWM is based on five covariates (age, hemoglobin, platelet counts, IgM levels and b2 microglobulin) and stratifies WM patients into 3 broad risk groups. IPSSWM does not take into account other non-IM related mortality, which is common and quite different among patients over the age of 75 years and does not include LDH, which is a well identified prognostic factor both in lymphomas and multiple myeloma.
S416
SPLenic MARGINAL ZONE LYMPHOMA (SMZL) TREATED WITH RITUXIMAB (R) MONOTHERAPY: A LONG TERM FOLLOW-UP STUDY ON 104 PATIENTS
C. Kalpadakis1, G. Pangalis2, T. Vassilakopoulos3, S. Sachanas2, M. Moschogiannis2, P. Tsigkirdis1, X. Yiakoumis2, D. Rontogianni2, F. Kontopodi2, S. Kyriakakis1, M. Psylaki1, A. Dimitrokopoulou1, E. Koulouri1, M.-C. Kyrtsonis1, M. Siakantaris5, P. Korkolopoulou9, T. Tzenou3, H. Papadaki1, M. Angelopolou3
1Department of Haematology, University Hospital, University of Crete, Heraklion, 2Department of Haematology, Athens Medical Center-Psychikon Branch, 3Department of Haematology, University of Athens, Laikon General Hospital, 4Department of Anatomic Pathology, Evangelismos General Hospital, University of Athens, 52nd Department of Internal Medicine, University of Athens, 6Immunology Laboratory, Laikon General Hospital, 71st Department of Propedeutics, University of Athens, Laikon General Hospital, 8First Department of Internal Medicine, 9Department of Pathology, University of Athens, Athens, Greece

Background: Rituximab monotherapy has been used successfully in the treatment of SMZL and it can replace splenectomy, at least in 1st line.

Aims: To present our data on the outcome of R monotherapy treated pts after a long term follow-up.

Methods: The diagnosis of SMZL was based on the WHO criteria. Criteria for treatment initiation included: bulky/symptomatic splenomegaly, cytopenias or presence of B-symptoms. All pts received 6 weekly cycles of R as 1st line therapy at a dose of 375mg/m2 (induction phase). None of the pts had been splenectomised before R treatment. Maintenance with R at a dose of 375mg/m2 every 2 months for 1-2 years was given according to physician’s discretion. Response assessment was based on the SLSG consensus criteria. Survival curves were estimated using the Kaplan Meier method and compared by log-rank test.

Results: 104 pts with SMZL were included. 45% were males with a median age of 66 y (41-91). At diagnosis all pts had bone marrow infiltration with a median % of infiltration of 40 (10-85). Anemia and thrombocytopenia were present in 30% and 19%, respectively. 40% had absolute lymphocytosis. LDH was elevated in 43%. According to the SLSG prognostic system, 39% were classified in group A, 56% in group B and 5% in group C. The median time from diagnosis to treatment initiation was 2 months (0-203). 71 pts received R maintenance. The overall response rate 2 months after the end of induction treatment was 93% (CR, CRu and PR in 42%, 21% and 30%, respectively). Maintenance therapy improved the quality of response in 19 of them, 52 pts maintained their initial response and one relapsed during maintenance phase. The 5- and 10- year PFS, OS and CSS were 70% and 64%, 93% and 88%, 99% and 93%, respectively. Maintenance therapy was associated with better PFS (p=0.008).

Summary/Conclusions: The present study includes a large number of pts with a long follow-up, confirms that R monotherapy is very effective in SMZL with minimal toxicity and is recommended as the treatment of choice for this disease.

Table 1.

<table>
<thead>
<tr>
<th>Parameter</th>
<th># of cases</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>47</td>
<td>45</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>66 (41-91)</td>
<td>7</td>
</tr>
<tr>
<td>B-symptoms</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Elevated LDH</td>
<td>44/102</td>
<td>43</td>
</tr>
<tr>
<td>Anemia</td>
<td>31/102</td>
<td>30</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>19/102</td>
<td>19</td>
</tr>
<tr>
<td>Lymphocytosis</td>
<td>40/102</td>
<td>40</td>
</tr>
<tr>
<td>SLSG prognostic system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group A</td>
<td>39/102</td>
<td>39</td>
</tr>
<tr>
<td>Group B</td>
<td>56/102</td>
<td>56</td>
</tr>
<tr>
<td>Group C</td>
<td>5/102</td>
<td>5</td>
</tr>
<tr>
<td>5-year PFS</td>
<td>85%</td>
<td>85</td>
</tr>
<tr>
<td>10-year PFS</td>
<td>74%</td>
<td>74</td>
</tr>
<tr>
<td>5-year OS</td>
<td>93%</td>
<td>93</td>
</tr>
<tr>
<td>10-year OS</td>
<td>88%</td>
<td>88</td>
</tr>
<tr>
<td>5-year CSS</td>
<td>99%</td>
<td>99</td>
</tr>
<tr>
<td>10-year CSS</td>
<td>93%</td>
<td>93</td>
</tr>
</tbody>
</table>
Biology of MPN: JAK2 and beyond

S417
YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT POTENTIATES THE TRANSFORMING ACTIVITY OF THE JAK2-V617F MUTATION
S. Sulima1, Y. Khan2, J. Briggs2, S. Vereecke1, J. Jones2, V. Advani2, J. Verbeeck1, K. De Keersmaecker1, J. Dinman2
1Department of Oncology, LKI, KU Leuven, Leuven, Belgium, 2Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, United States

Background: The JAK-STAT pathway is a critical controller of cellular proliferation, differentiation, survival and apoptosis in response to external stimuli. Promiscuous activation of this pathway is an important driver in the pathogenesis of BCR/ABL-negative chronic myeloproliferative neoplasms. The JAK2-V617F allele is the most common and characterized mutation linked to this class of leukemia. The increased activation of JAK-STAT signaling in JAK2-V617F cells can be partially explained by increased JAK2 autophosphorylation. It is unclear however if these effects are sufficient to fully account for the strong activation of the JAK-STAT pathway induced by JAK2-V617F. We recently described programmed -1 ribosomal frameshifting (-1 PRF) as a novel mechanism regulating the expression of -10% of human genes, including cytokine receptors (Blewe AT et al., Nature, 2014). In this process, cis-acting mRNA elements (-1 PRF signals, which consist of a slippery site followed by a pseudo-knot) direct translating ribosomes to slip by one base in the 5' direction, establishing a new reading frame. This directs ribosomes towards premature termination codons, resulting in destabilization of the -1 PRF signal-containing mRNA via nonsense-mediated mRNA decay (Figure 1). There is thus an inverse relationship between -1 PRF efficiency and mRNA stability.

Aims: To investigate whether the JAK2-V617F mutation, shown here to be located in the pseudoknot of a -1 PRF signal in the JAK2 mRNA, impacts disease progression through ablation of -1 PRF.

Methods: Computationally predicted -1 PRF signals were validated using dual luciferase reporters and proteomic analysis of a -1 PRF fusion protein. -1 PRF as well as mRNA abundance and decay were assayed in HEK293T and HeLa cells. Transformation assays were performed in HEK293T cells expressing Ba/F3 cells, in vivo experiments were performed in BALB/c mice.

Figure 1.

Results: We demonstrate in human cell lines that the JAK2-V617F mutation structurally disrupts the -1 PRF signal in the JAK2 mRNA, leading to ~2-fold lower rates of -1 PRF and increased abundance of the JAK2 mRNA and protein. The transforming potential of a series of mutants designed to manipulate -1 PRF independent of V617F was assayed in a Ba/F3 cell model. Silent protein coding changes in the pseudoknot of the -1 PRF signal at position V617 (V617m) or the slippery site (SSm), both of which drastically reduced frameshifting, increased JAK2 expression and led to transforming activity, albeit less than V617F. Importantly, the V617F+SSm combination conferred an additive effect on cellular transformation. Ba/F3 cells expressing these JAK2 variants were also introduced into mice. Whereas mice injected with wild type JAK2 remained healthy, both V617m and SSm induced similar leukemia phenotypes as V617F and V617F+SSm, with a ~2-fold longer disease latency of 8-10 weeks. Increased JAK2 mRNA abundance in JAK2-V617F homzygous patients as well as the presence of three additional -1 PRF signals in the JAK2 mRNA further suggest a prominent role for -1 PRF in controlling JAK2 production.

Conclusions: We demonstrate that the JAK2-V617F mutation diminishes -1 PRF on the JAK2 transcript, stabilizing the mRNA and increasing JAK2 expression, contributing to its transforming activity in vitro and disease onset in vivo. We suggest that -1 PRF normally provides a layer of control by limiting JAK2 translation. Defective -1 PRF synergizes with the transforming activity of the JAK2-V617F protein by causing its overexpression, explaining why this particular mutation causes such aggressive malignancies. In support of this, the combination of ruxolitinib and an HSP-90 inhibitor, which reduce kinase activity and JAK2 expression respectively, leads to increased therapeutic efficacy in myeloproliferative neoplasms (Bhagvat N et al., Blood, 2014).

S418
EFFECTIVENESS OF LSD1 INHIBITION FOR THE TREATMENT OF MPN
J.S. Jutzi1,*, H. Rienhoff2, H.L. Pahl1
1Clinic for Hematology, University Medical Center, Freiburg, Germany, 2Imago Biosciences, San Francisco, United States

Background: Treatment of MPN with JAK1/2 inhibitors ameliorates symptoms and splenomegaly but does not meaningfully reduce the JAK2V617F allele burden. Though curative, stem cell transplantation is associated with extensive morbidity and mortality highlighting the need for novel effective therapies. The histone “lysine-specific demethylase 1A” (LSD1/KDM1A) is being explored as a drug target in AML with the demethylators already in clinical trials. LSD1 induces monocytic differentiation and reduces engraftment of AML cell in vivo. LSD1 is over-expressed in a number of myeloid diseases including MPN. Preliminary data in a mutant mpl mouse model of MPN showed that a 28-day course of LSD1 inhibition had a beneficial impact on spleen size, cytokines and mutant cell burden. In a mutant JAK2 mouse model of MPN, we have characterized the disease-modifying activity of the LSD1 inhibitor (IMG-7289), a compound in clinical development for myeloid diseases (NCT02842827).

Aims: We assessed the pharmacodynamic effects of continuous daily treatment with IMG-7289 in a JAK2V617F knock-in murine MPN with established disease. Animals were treated for up to 56 days. Outcome measures included complete blood counts (CBC), hematological phenotype, overall survival, spleen size, bone marrow morphology and the JAK2V617F allele burden. Moreover, pro-inflammatory cytokine were monitored during the course of treatment as well as chromatin changes by western blotting and ChIPseq.

Methods: JAK2V617F-L2 mice were crossed to MxCre mice and displayed a fulminant MPN phenotype without did induction. CBC and BM FACS analysis were conducted as previously described. We designed a qPCR assay to quantitate murine JAK2V617F allele burden.

Results: IMG-7289 treatment was exceptionally well tolerated and mice showed drastic decreases in platelet count (208 vs 2063*10^3/μl), reticulocytes (800 vs 1674*10^3/μl), monocytes and neutrophils 14 days after the start of treatment. HCT and WBC started to decrease after 28 days. While the JAK2 mutant allele burden increased over time in untreated mice, it decreased in IMG-7289 treated mice drastically in peripheral blood as well as in spleen. We observed a drastic increase in the pro-inflammatory cytokine CXCL5 in untreated mice during the course of investigation while CXCL5 levels of treated mice decreased to levels of wild-type littermates. Moreover, treated mice showed a highly significantly increased survival over untreated mice, even in a late stage of disease. Lastly, we were able to show that global H3K9me2, which is generally associated with gene expression silencing, was increased in the bone marrow of IMG-7289 treated mice compared to control mice. The remaining pathophysiological data and functional data on epigenetic regulation will be presented.

Summary/Conclusions: The LSD1 inhibitor IMG-7289 normalizes or stabilizes elevated CBCs in a JAK2V617F MPN mouse model. It decreases JAK2 mutant allele burden, pro-inflammatory cytokine levels and confers a clear survival advantage. Our preliminary data show that LSD1 is a potent target with disease-modifying potential in MPN. Clinical studies with IMG-7289 testing this hypothesis have just begun. Owing to its mode of action, altering epigenetics, the potential reversibility of drug-induced epigenetic remodeling, a long treatment period in MPN patients may be necessary to eliminate disease. Combining IMG-7289 with JAK1/2 inhibitors might accelerate treatment effects.

S419
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
V. Caraffini1, O. Geiger1, A. Rosenberger1, S. Hatzl1, B. Perfler1, J.L. Berg1,
Background: myelomonocytic leukemia (CML) is characterized by increased proliferation and myelomonocytic lineage commitment of hematopoietic stem cells (HSCs). Mutations in the RAS signaling cascade are frequent in CML patients and lead to a CML-like myeloproliferative disorder (CML-MPD) in mice via causing hypersensitivity to GM-CSF. Loss of RAF kinase inhibitor protein (RKIP), a negative regulator of RAS signaling, is frequent in myelomonocytic and monocytic subtypes of acute myeloid leukemia (AML) and is often associated with RAS mutations. Moreover, RKIP loss has recently been shown to increase the proliferation of AML cell lines.

Aims: In this work, we aimed at investigating the role of RKIP in the development of CML.

Methods: RKIP expression was measured by immunoblot and quantitative real-time PCR in 23 primary CML patient samples as well as in CD34+ HSCs, B-lymphocytes, granulocytes and monocytes of four healthy donors. Sequence analysis of CML patient samples was done with an Ion Torrent Next Generation Sequencing platform using an amplicon panel covering 39 genes recurrently mutated in myeloid neoplasms. Effects of RKIP on GM-CSF-induced myelomonocytic differentiation were studied in human CD34+ HSCs lentivirally transduced with RKIP shRNA, as well as in a genetic mouse model for RKIP deletion (RKIP-/-). Effects of RKIP on CML development were initially studied in the same RKIP-/- model. Additionally, these mice were crossed with animals exhibiting a somatically inducible mutation in NRAS (RKIP+/−×Cre-NRASG12D) and the severity of CML-MPD onset was studied at an age of six months.

Results: Loss of RKIP protein expression was observed in 6/23 (26%) CML patient specimens and was associated with decreased mRNA levels as well (P<0.001). Patients with RKIP loss exhibited an increased percentage of myelomonocytic cells in the peripheral blood (56% vs 75%, P=0.0226). One or more mutations affecting the RAS signaling pathway were detected in all specimens with RKIP loss. In addition to the previously demonstrated induction of proliferation, we then aimed to delineate a role of RKIP loss in myeloid lineage commitment. When studying healthy donors, we observed that RKIP expression was high in HSCs and lymphoid cells, but significantly decreased in cells belonging to the myeloid lineage (monocytes, P=0.001 and granulocytes, P<0.001). In functional experiments, knockdown of RKIP increased the GM-CSF-induced myelomonocytic lineage commitment of both, human and murine HSCs (P<0.05 and P=0.0295, respectively). These results could be corroborated in vivo, as intraperitoneal injection of GM-CSF caused a significant increase of myelomonocytic cells in the intraperitoneal cavity (P=0.006), bone marrow (P=0.007) and peripheral blood (P=0.027) in RKIP−/− mice when compared to their wildtype littermates. In a final step, we evaluated the potential of RKIP loss to cause CML-MPD in mice. While it proved to be insufficient to cause the disease as a single event in RKIP−/− mice, it aggravated the CML-MPD phenotype in animals carrying an additional mutation in NRAS. In this case, the deletion caused worsening of leucocytosis (P=0.036) and splenomegaly (P=0.035), which was associated with increased levels of myelomonocytic cells in the bone marrow (P=0.028), peripheral blood (P=0.002) and spleen (P=0.025).

Summary/Conclusions: RKIP loss is a frequent event in CML and is associated with mutations affecting the RAS signaling cascade. Loss of RKIP is functionally involved in myelomonocytic lineage commitment of HSCs and aggravates CML-MPD development in mice carrying an additional mutation in NRAS.

S420 JAK2 V617F HAEMATOPOIETIC CLONES WITH DIFFERENT EXPANSION KINETICS ARE DETECTABLE SEVERAL YEARS PRIOR TO MPN DIAGNOSIS

T. Mckerrell1,2, N. Park1, J. Chi3, G. Collord4, T. Moreno5, H. Ponstingl6, J. Dias5, P. Gerasimou6, K. Melanthiou7, C. Prokopiou8, M. Antoniades7, A. Mead1

1MRC Molecular Haematology Unit, 2Computational Biology Research Group, 3Wellcome Trust Sanger Institute, Cambridge, United Kingdom. 4Department of Haematology, University of Cambridge, 5Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 6The Center for the study of haematological malignancies (CSH)/Karaiskakio Foundation, Nicosia, Cyprus, 7Instituto de Biomedicina y Biotecnología de Cantabria (UC-CSIC), Santander, Spain, 8Cancer Molecular Diagnosis Laboratory, University of Cambridge, Cambridge, United Kingdom. 4Theselaboratories for the study of haematological malignancies (CSH)/Karaiskakio Foundation, 2Haematology, Nicosia General Hospital, Nicosia, 3Haematology, Limassol General Hospital, Limassol, Cyprus

Background: JAK2 V617F is the most common somatic mutation in the classical myeloproliferative neoplasms (MPNs) and is also frequent amongst healthy individuals with age-related clonal haemopoiesis (ARCH).

Aims: To investigate the pre-clinical clonal evolution of MPNs.

Methods: We identified 12 individuals with JAK2 V617F mutant MPN from whom blood DNA was available from the time of MPN diagnosis and also from an earlier time point of between 4.5-15.2 years previously (median 10.2 years) when blood was donated for registration to the Cyprus Bone Marrow Donor Registry. We used deep DNA sequencing to interrogate all 24 samples at 15 myeloid mutation hotspots including JAK2 V617F, using an established multiplex PCR/MiSeq sequencing protocol that reliably detects nucleotide substitutions present at a variant allele fraction (VAF) ≥0.008. Additionally, for 12 samples with sufficient DNA available, we performed targeted DNA capture for all exons of 41 genes routinely mutated in myeloid neoplasms using a custom RNA-bait library followed by sequencing on Illumina HiSeq 2500. Finally, we genotyped archival Registry samples for the rs12343867 single nucleotide polymorphism (SNP) (G/T) linked to the JAK2 46/1 haplotype.

Results: Amplicon sequencing returned a median coverage of 6641 reads per nucleotide (nt) at the studied hotspots. This confirmed the presence of JAK2 V617F in all 12 diagnostic and 9 of 12 archival samples. The remaining 3 samples were JAK2 V617F negative at the sensitivity of our assay (VAF>0.008). The only other hotspot mutation identified was SRSF2 P95R in one patient, P3, whom had a diagnosis of myelofibrosis. Pulldown sequencing of all exons of 41 genes from 12 samples with sufficient DNA returned an average coverage of 1978 reads per nt and showed a close correlation in JAK2 V617F and SRSF2 P95R VAF quantitations with amplicon sequencing. The JAK2 V617F VAF at diagnosis differed between patients as expected, however the average rate of clonal growth also varied widely between individuals, ranging from 0.36 to 6.2% per annum (Figure 1). Targeted exon capture from 12 of 24 samples, only identified one co-mutation with a VAF >0.02, the SRSF2 P95R in patient P3. As this locus was also amplified by amplicon sequencing, we were able to quantify the SRSF2 P95R VAF both in the diagnostic and the archival DNA sample taken 12.6 years earlier. In the P3 diagnostic sample the VAFs for JAK2 V617F and SRSF2 P95R were similar (0.37 and 0.41 respectively) indicating that they co-occurred in most cells of the neoplastic clone. In the archival sample from P3, the SRSF2 P95R was detectable at a VAF of 0.06, however the JAK2 V617F was absent/undetectable at the sensitivity of our assay (VAF>0.008) indicating the SRSF2 P95R was the clone-founding mutation in this neoplasm. The genotyping results for the rs12343867 SNP revealed a tentative association in our small cohort between homozygosity for the risk allele (C) linked to the JAK2 46/1 haplotype and the average annual increase in JAK2 V617F VAF. This will need to be verified in larger studies.

Summary/Conclusions: Our findings reveal that JAK2 V617F neoplasms develop from clonal haematopoiesis over many years. The rate of clonal expansion of JAK2 V617F clones in the pre-clinical phase was highly variable and although it was tentatively associated with the 46/1 haplotype, the high variability observed suggests that other factors likely influence clonal progression.

S421 DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM

R. Norton1, C. Di Genua1, C. Booth1, A. Giustacchini1, B. Povinelli2, N. Gray2, E. Repeti2, E. Solleix3, L. Jamieson3, N. Tran1, A. Green4, S.E. Jacobsen5, A. Mead1

1MRC Molecular Haematology Unit, 2Computational Biology Research Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, 3Nuffield Department of Clinical Neurosciences, University of Oxford, 4Nuffield Department of Medicine, University of Oxford, 5Center for Integrative Haematology, University of Cambridge, Cambridge, United Kingdom. 4Theselaboratories for the study of haematological malignancies (CSH)/Karaiskakio Foundation, Nicosia, Cyprus, 5Instituto de Biomedicina y Biotecnología de Cantabria (UC-CSIC), Santander, Spain, 6Cancer Molecular Diagnosis Laboratory, University of Cambridge, Cambridge, United Kingdom.
Background: The hematopoietic stem cell (HSC) compartment in mice encompasses a broad range of heterogeneous cell types including highly lineage-biased HSCs, such as platelet-biased HSCs (PMID:23934107). Myeloproliferative neoplasms (MPNs) are a heterogeneous spectrum of clonal hematopoietic disorders, that includes essential thrombocytopenia (ET), a MPN subtype usually presenting with isolated thrombocytosis. Most ET patients carry a gain-of-function point mutation in JAK2 (JAK2V617F), with several other collaborating hits reported to co-occur with JAK2V617F at lower frequencies, including loss-of-function mutations of the epigenetic regulator EZH2, which are more frequent in advanced MPN.

Aims: Although it is broadly accepted that MPNs are propagated by counterparts of HSCs, the impact of collaborating MPN-associated mutations arising in different HSC subsets remains unclear. We aimed to explore the possibility that platelet-biased HSCs might selectively promote development of an ET phenotype.

Methods: We generated a novel mouse model of MPN that carries a conditional knock-in of heterozygous human JAK2V617F (hJAK2V617F) and the conditional knock-out (KO) of EZH2 together with an inducible Mx1-Cre transgene. To analyse platelet-biased HSC subsets upon onset of the mutation(s), we also crossed the vwf-eGFP transgene, which is selectively expressed in platelet-biased HSCs.

Results: Compared to wild-type and single mutant mice, EZH2-KO hJAK2V617F mice showed increased platelet counts, including a subset of mice which became acutely unwell with an extreme thrombocytosis. Strikingly, in serial bone marrow (BM) transplantation assays, EZH2-KO fully rescued the previously described hJAK2V617F-associated transplantation defect (PMID:20489053). EZH2-KO hJAK2V617F BM recipients showed long-term serial engraftment that was fully restricted to the platelet and myeloid lineages with a persistent thrombocytosis and absence of lymphoid reconstitution. RNA-sequencing revealed upregulation of several signaling pathways, including Hedgehog, and increased inflammation associated gene expression in EZH2-KO hJAK2V617F HSCs. Unexpectedly in this mouse model of thrombocytosis, phenotypic analysis of the HSC compartment in the BM showed that vwf-eGFP+ve HSCs were selectively lost (fold change[FC]=0.12 p=0.009), while vwf-eGFP–ve HSC numbers remained unaffected (FC=1.06 p=0.88) in EZH2-KO hJAK2V617F mice. To assess a differential contribution of vwf-eGFP+ve HSCs vs vwf-eGFP–ve HSCs in the ability to propagate MPN, we sorted HSCs according to vwf-eGFP expression and transplanted them into recipient mice. Unlike their normal counterparts, which showed lymphoid-biased reconstitution, vwf-eGFP+ve HSCs from Ezh2-KO hJAK2V617F mice primarily gave rise to platelets and myeloid cells. In contrast, vwf-eGFP–ve HSCs from Ezh2-KO hJAK2V617F mice engrafted poorly without recapitulating the disease in recipients.

Summary/Conclusions: In this novel Ezh2-KO hJAK2V617F mouse model, Ez2-2 loss collaborates to worsen thrombocytosis and rescue the HSC function defect in hJAK2V617F mice. We also observed a striking disruption of phenotypic and functional HSC heterogeneity in Ezh2-KO hJAK2V617F mice with an unexpected and selective loss of vwf-eGFP+ve HSCs together with subversion of vwf-eGFP–ve HSCs towards platelet-myeloid lineage commitment. This previously undescribed disruption of HSC heterogeneity in myeloid malignancy together with the clonal advantage conferred to HSCs by EZH2-KO helps to explain how this collaborating mutation might promote the development of more advanced MPN.
Methods: Pts aged <18 years were recruited into 3 separate cohorts: (1) IM-resistant/intolerant CML-CP treated with DAS tablets 60mg/m² QD, (2) IM-resistant/intolerant CML-AP/BP or Ph+ ALL (enrollment closed early due to poor response), and (3) newly diagnosed CML-CP treated with DAS tablets 60mg/m² or DAS 72mg/m² powder for oral suspension (PFOS) QD for 1 year. PFOS dose was increased by 20% to match the exposure of the tablet in order to maintain efficacy based on the findings from a bioequivalence study in adults. Primary objectives were major cytogenetic response (MCyR) for CML-CP resistant/intolerant to IM and complete cytogenetic response (CCyR) for newly diagnosed CML-CP (MCyR >30% and CCyR >55% considered of clinical interest). Study cohorts were not designed to be comparative.

Results: From 145 pts enrolled, 130 were treated; 54% were aged ≥12-<18 years. Within the IM-resistant/intolerant group, 25 were resistant, 2 were intolerant, and 2 were undetermined. For pts with CML-CP (n=113), 48% of pts with IM-resistant/intolerant CML-CP and 73% with newly diagnosed CML-CP remained on treatment at the time of this analysis (table 1). Cumulative rate of MCyR for newly treated pts was 96.5% as 3 months, 97.2% for IM-resistant/intolerant CML-CP, and a cumulative rate of CCyR >55% was reached as early as 6 months for newly diagnosed CML-CP (table). Estimated progression-free survival (PFS) by 48 months was 78% for IM-resistant/intolerant CML-CP and 93% for newly diagnosed CML-CP (table). Reasons for progression were loss of MCyR (n=3 IM-resistant/intolerant; n=4 newly diagnosed), loss of complete hematologic response (n=2 each), and development of CML-BP (n=2 IM-resistant/intolerant; n=1 newly diagnosed). One death was reported in the IM-resistant/intolerant CML-CP cohort 1 year after stopping DAS (gastrointestinal bleeding). Adverse events (AEs) were consistent with reports in DAS-treated adults, except no DAS-related myelosuppression, edema/hypertension, or pulmonary arterial hypertension were reported here. Sensitiveness in a newly diagnosed pt was the only DAS-related AE that led to discontinuation.

Summary/Conclusions: Results from the largest prospective and registrational trial of pediatric pts with CML-CP demonstrate that DAS is a safe and effective treatment for pediatric CML-CP. Target responses to first- or second-line that DAS were met as early as 3 and 6 months, respectively, and deep responses were observed. Efficacy and safety of DAS in pediatric pts were similar to those observed in adults; however, unlike in adults, no cases of pleural/pericardial effusion were reported.

Figure 1.

Summary/Conclusions: The present 24 month RFS of 77% for the overall 24 months in patients in stable MR4 appears better than in any comparable study to date, and implies that the initial 12 months of dose reduction may be responsible, perhaps via improved compliance in the few months prior to stopping or through an as yet undefined mechanism.

ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKAEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV


1Medical Faculty Mannheim, Ruprecht Karls University Heidelberg, Mannheim, 2Medical Faculty, Ludwig-Maximilians University of Munich, 3Medical Faculty, Ludwig-Maximilians University of Munich, Munich, 4Medical Clinic 5, University Hospital Erlangen, 5Medical Department, Ludwig-Maximilians University of Munich, Munich, 6Medical Department of Haematology, University Hospital Giessen, Giessen, 7Oncology Department, University Hospital Hamburg, Hamburg, 8Medical Department of Haematology, University Hospital Schwabing, Munich, Germany, 9Medical Department of Haematology, University Hospital Basel, Basel, 10Department of Surgery, University Hospital Basel, Basel, Switzerland, 11Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, 12Department of Haematology and Oncology, MHP Munich, Munich, 13Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, 14Institute of Medical Oncology, University of Ulm, Ulm, 15Medical Department, University Hospital Ulm, Ulm, 16Medical Department, University Hospital Heidelberg, Mannheim, 17Department of Medicine V, University Hospital Heidelberg, Heidelberg, 18Ambulant Treatment Center, Hospital Nuremberg North, Nuremberg, 19Medical Department, University Hospital Kiel, Kiel, 20Medical Department, University Hospital Wuerzburg, Wuerzburg, 21Medical Department, University Hospital Wuerzburg, Wuerzburg, 22Medical Department, University Hospital Heidelberg, Heidelberg, 23Medical Department, University Hospital Bern, Bern, 24Department of Surgery, University Hospital Basel, Basel, Switzerland, 25Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, 26Department of Haematology and Oncology, MHP Munich, Munich, 27Institute of Cell and Molecular Pathology, Hannover Medical School, Han-
LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL

S425 and gene expression associated with intrinsic vs extrinsic cellular resistance but not by treatment optimization. Faster response does not necessarily translate into better disease control.

Aims: To assess the efficacy and safety of BOS versus imatinib (IM) for first-line treatment of chronic phase (CP) CML in the BFORE trial (NCT02130557).

Methods: In this ongoing, multinational, phase 3, open-label study, 536 patients with newly diagnosed CP CML were randomized 1:1 to BOS 400mg once daily (n=268) or IM 400mg once daily (n=268 [3 not treated]). Informed consent was obtained from all patients. Per protocol, efficacy was assessed in a modified intent-to-treat (mITT) population of 487 Ph+ patients (BOS, n=246; IM, n=241) with the following prespecified subgroups: Ph+ patients and those with known Ph status and/or BCR-ABL transcript type were excluded from this population.

Results: After ≥12 months of follow-up, 78.0% of BOS and 73.2% of IM patients remain on treatment with median treatment durations of 14.1 months and 13.8 months, respectively. Major molecular response (MMR) rate at 12 months (primary endpoint) was significantly higher with BOS versus IM in the mITT population (47.2% vs 36.9%; P=0.02) as well as in the ITT population of all randomized patients (46.6% vs 36.2%; P<0.02). In the mITT population, time to MMR was shorter for BOS (hazard ratio=1.34 based on cumulative incidence; P=0.02). Rate of complete cytogenetic response (CCyR) by 12 months was also significantly higher with BOS versus IM (77.2% vs 66.4%; P=0.038); time to CCyR shorter for BOS (hazard ratio=1.38; P<0.001). Rate of BCR-ABL transcripts ≤1% (Intl. Scale) at 3 months was higher with BOS versus IM (75.2% vs 57.3%; P<0.001); rates of deep molecular response over time were also generally higher with BOS (Table). Results for molecular endpoints were similar in the ITT population. The only baseline characteristic identified as a significant predictor of MMR at 12 months besides treatment arm was Sokal risk group (high vs low; P = 0.0001 and intermediate vs low; P = 0.05 [mITT]). On-treatment progression to accelerated or blast phase occurred in 4 patients (1.6%) receiving BOS and 6 patients (2.5%) receiving IM in the mITT population. One BOS-treated and 4 IM-treated patients discontinued treatment due to progression to accelerated or blast phase. Among all treated patients, there were no deaths within 28 days of last dose of BOS and 4 with IM. Safety data for treated patients were consistent with the known safety profiles of BOS and IM. Discontinuation due to drug-related toxicity occurred with 12.7% of BOS patients and 10.4% of IM patients. Grade ≥3 adverse events were more frequent in BOS than IM (19.0% vs 15.2%), including anemia (19.0% vs 15.2%), neutropenia (18.0% vs 14.6%), and increased alanine (19.0% vs 15.2%) and aspartate (9.7% vs 6.8%) aminotransferase levels. Cardiovascular events were infrequent in both groups (all grades: 3.0%, 1.5%, and 0% BOS vs 0.4%, 1.1%, and 0.4% IM; grade ≥3: 1.5%, 0.5%, and 0% BOS vs 0%, 0%, and 0.4% IM).

Table 1.

<table>
<thead>
<tr>
<th>Response</th>
<th>BOS (n=246)</th>
<th>IM (n=241)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMR, %</td>
<td>47.2</td>
<td>36.9</td>
<td>0.02</td>
</tr>
<tr>
<td>CCyR, %</td>
<td>77.2</td>
<td>66.4</td>
<td>0.038</td>
</tr>
<tr>
<td>N&lt;1%, Intl. Scale</td>
<td>75.2</td>
<td>57.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Grade ≥3 events</td>
<td>12.7</td>
<td>10.4</td>
<td>NS</td>
</tr>
<tr>
<td>Anemia, %</td>
<td>19.0</td>
<td>15.2</td>
<td>0.001</td>
</tr>
<tr>
<td>Neutropenia, %</td>
<td>18.0</td>
<td>14.6</td>
<td>0.038</td>
</tr>
<tr>
<td>Alanine, %</td>
<td>19.0</td>
<td>15.2</td>
<td>0.001</td>
</tr>
<tr>
<td>Aspartate, %</td>
<td>9.7</td>
<td>6.8</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Patients on BOS had significantly higher rates of 12-month MMR and CCyR and achieved responses faster than those on IM. Consistent with the known safety profile, higher incidences of gastrointestinal events and transaminase elevations were observed with BOS. Primary results from this study suggest BOS may be an important treatment option for patients with newly diagnosed CP CML.
CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHERE AS DETECTABILITY OF BCR-ABL1 WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS


1Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), LMU München, München, Germany, 2Bergonie Cancer Institute INSERM Unit 916, University of Bordeaux, Bordeaux, 3Inserm CIC 1402, CHU de Poitiers, Poitiers, France, 4Section of Hematology, Skane University Hospital, Lund, Sweden, 5Instituto Portugues de Oncologia de Lisboa de Francisco Gentil, Lisboa, Portugal, 6Department of Hematology, VU University Medical Center, Amsterdam, Netherlands, 7Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic, 8Department of Hematology and Hematology Research Unit Helsinki, Helsinki University Central Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland, 9Dept of Propaedeutic Med, University of Athens and Hellenic Society of Hematology, Athens, Greece, 10Department of Medical Science, Upstate University and Hematology Section, Upstate Hospital, Syracuse, New York, Sweden, 11Hematology (Biology) and EA7435 GHELTER, CHU and University Clermont Auvergne, Clermont-Ferrand, France, 12Department of Clinical Genetics, Laboratory Medicine, Office for Medical Services and Department of Clinical Genetics, Lund University, Lund, Sweden, 13Department of Clinical Chemistry, Central Hospital Hospital, Turku, Finland, 14Institute of Hematology and Blood Transfusion, Prague, Czech Republic, 15Institute for Hematology and Oncology (IHO), Mannheim, 16Institute Medical II, University Hospital Jena, Jena, 17III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany, 18Dept of Hematology, St Olavs Hospital, Trondheim, Norway

Background: With imatinib (IM), most patients with chronic myeloid leukemia (CML) achieve deep molecular responses. Six months after stopping tyrosine kinase inhibitor in deep response in the EURO-SKI trial, 61% of the patients were in major molecular remission (3-log reduction in BCR-ABL1 level) in major molecular remission (3-log reduction in BCR-ABL1 levels) (Mahon ASH 2016). Between patients with and without BCR-ABL1, the difference in RFS at 6 months was not significant when assessing BCR-ABL1 detectability at the MR4.5 level (at least a 4.5-log reduction in BCR-ABL1) (Pfirrmann ASH 2016).

Aims: For 91 of 448 patients of the EURO-SKI learning sample, the sensitivity to investigate undetectable disease at the MR4.5 level was not given. Aim was to determine whether RFS probabilities would be different when comparing detectable and undetectable disease at the MR4 level.

Methods: Detectability of BCR-ABL1 depends on the number of control gene transcripts. To reduce bias when comparing “MR4 detectable disease” (MR4 but still detectable BCR-ABL1 transcritps; i.e. 0.01- 0.0033% IS) and “MR4 undetectable disease” (MR4 without detectable BCR-ABL1; based on 10,000-31,999 ABL1 or 24,000-76,999 GUS8 copy numbers), two samples with similar sensitivity of identifying BCR-ABL1 were to be identified using propensity score (PS) matching (Rosenbaum, Rubin 1983). Apart from type (ABL1 or GUSB) and treatment (IM or placebo), results suggest little or no impact of control transcripts and other factors, results suggest little or no impact of detectability of BCR-ABL1 on RFS. Time in deep response seems to be more important. In daily routine, many labs produce reliable outcome at the MR4 but not always at the MR4.5 level. Discontinuation at the MR4 level, irrespective of detectability of BCR-ABL1 residual disease, appears safe, with a good chance of success when performed as in EURO-SKI. With PS matching, bias and differences but also power was reduced. To judge whether molecular response on the MR4 level is sufficient, further data is welcome.

AML Biology II: Epigenetic targets

S427

ETO2-GLIS2 RECRUITS ETO2/ERG COMPLEX AT SUPER-ENHANCERS TO CONTROL TRANSCRIPTION AND DRIVE LEUKEMIC PROPERTIES IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA

C. Thirant1,2, G. Ignacimouotto1,3, C. Lopez1,4, M. Diop5, L. Le Moué4,2, C. Thiollier2,3, A. Siret1,2, P. Dessen5, Z. Aid1,2, J. Rivière1,2, P. Rameau3, F. Lefebvre2, M. Khalafé2, G. Leverger2, P. Ballerini3, A. Petit4, H. Raslav1,2, C. L. Carmichael1, B. T. Kile3, E. Soiler10,11, J. D. Crispino11, C. Wickham12, F. Piumo13, J. Schwaller14, W. Vaischenker1,2, C. Lobry1,2, N. Droni1,2, O.A. Bernard1,2, S. Malinge1,2, T. Mercher1, Logistic regression was used to compare RFS at 6 months. Signifi- cant differences but also power was reduced. To judge whether molecular response on the MR4 level is sufficient, further data is welcome.

Results: For 91 of 448 patients of the EURO-SKI learning sample, the sensitivity to investigate undetectable disease at the MR4.5 level was not given. Aim was to determine whether RFS probabilities would be different when comparing detectable and undetectable disease at the MR4 level.

Methods: Detectability of BCR-ABL1 depends on the number of control gene transcripts. To reduce bias when comparing “MR4 detectable disease” (MR4 but still detectable BCR-ABL1 transcritps; i.e. 0.01- 0.0033% IS) and “MR4 undetectable disease” (MR4 without detectable BCR-ABL1; based on 10,000-31,999 ABL1 or 24,000-76,999 GUS8 copy numbers), two samples with similar sensitivity of identifying BCR-ABL1 were to be identified using propensity score (PS) matching (Rosenbaum, Rubin 1983). Apart from type (ABL1 or GUSB) and treatment (IM or placebo), results suggest little or no impact of control transcripts and other factors, results suggest little or no impact of detectability of BCR-ABL1 on RFS. Time in deep response seems to be more important. In daily routine, many labs produce reliable outcome at the MR4 but not always at the MR4.5 level. Discontinuation at the MR4 level, irrespective of detectability of BCR-ABL1 residual disease, appears safe, with a good chance of success when performed as in EURO-SKI. With PS matching, bias and differences but also power was reduced. To judge whether molecular response on the MR4 level is sufficient, further data is welcome.
Background: Acute myeloid leukemia (AML) is characterized by rapid growth and block in differentiation of myeloid progenitors. The AML blast is defined by having “open” chromatin. We hypothesized that alterations of chromatin compartment may promote AML. Reversing those changes could represent a novel therapeutic approach.

Aims: Gain of chr2(q22) is the most common focal amplification in complex karyotype AML. HMGN1 is a chromatin-regulatory protein on 21q22 known to affect lymphoid development, and our preliminary data suggested that HMGN1 could directly mediate a myeloid differentiation block. Since HMGN1 is known to decompact chromatin and alter histone marks, our goal was to define and therapeutically target the mechanisms by which HMGN1 overexpression disrupts myeloid differentiation and promotes clonal dominance.

Methods: We immortalized bone marrow progenitors from wild-type (WT) or OE-HMGN1 mice (transgenic overexpressing HMGN1) with an estrogen receptor-HoxB8 fusion protein. Using exogenous estrogen to control nuclear translocation of HoxB8, we analyzed synchronized myeloid differentiation by flow cytometry, RNAseq, and TMT proteomic analysis. We performed MINT-Chip-seq (MNase Indexed T7-chromatin IP) to measure the histone marks H3K27ac, H3K27me3, H3K4me3 and total Histone H3. We also measured histone marks in hematopoietic stem and progenitor subpopulations in vivo. We performed competitive bone marrow transplantation with CD45.1 WT and CD45.2 OE-HMGN1 donors and measured the relative contribution to hematopoiesis over time.

Results: Synchronized differentiation in WT cells progressed over 6 days from myeloid progenitors to mature neutrophils and monocytes, analyzed by cell surface markers, morphology, and gene and protein expression. OE-HMGN1 cells proliferated faster and remained as undifferentiated myeloblasts (84% CD11b+Gr1+ in WT vs 4% in OE-HMGN1, p<0.002; Fig A). Gene set enrichment analysis revealed more similarity to undifferentiated hematopoiesis and leukemia signatures in OE-HMGN1 cells. MINT-Chip indicated a broader and locus-specific levels of H3K27ac in OE-HMGN1 cells (Fig B, upper panel), consistent with an increase in gene transcription, confirmed by RNA-seq. We found a specific increase in HoxA cluster expression in OE-HMGN1 cells, highest at HoxA7 and HoxA9, genes known to be important in AML pathogenesis. In agreement with gene expression, among the most differentially measured histone peaks genome-wide were higher H3K27ac at HoxA genes progenitors at all differentiation time points analyzed (Fig B, lower panel). Competitive trans-plantation demonstrated an advantage to OE-HMGN1 stem and progenitor cells. The clonal dominance of OE-HMGN1 over WT cells extended to all populations analyzed (long- and short-term HSCs, multipotent progenitors, CMP, GMP and MEP; Fig C) and to mature lineages (myeloid, B and T cells). MINT-Chip and MINT-Labeling studies revealed a marked increase in H3K27ac peaks at cell cycle and leukemia-related genes in the context of OE-HMGN1, H3K27 acetylation is catalyzed by the CBP/p300 histone acetyl transferase (HAT), suggesting that HAT inhibition could target leukemias with HMGN1 overexpression. Indeed, treatment of myeloid progenitors with the CBP/p300 inhibitor C646 rescued the differentiation block in OE-HMGN1 cells (93% CD11b+Gr1+ in WT vs 89% in OE-HMGN1, p<NS).

S429

PIWIL4 ACTS AS A PIRNA BINDING, EPIGENETICALLY ACTIVE AND GROWTH REGULATORY PROTEIN IN HUMAN ACUTE MYELOID LEUKAEMIA

S. Bameza1,*, M. Mulaw1, N. Végil1, M. Feuring-Buske1, F. Zhou2, C. Rohde1, A. Aravin3, J. Hoell4, A. Kloetgen4, A. Borkhardt4, C. Plass5, C. Müller-Tidow2, V.P. Rawat1, C. Buske1

1University of Ulm, Institute for Experimental Cancer Research, Ulm, 2Department of Pathology IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Göttingen, 3Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States, 4Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, 5Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany

Background: PIwi proteins are critically important for maintaining the self-renewing stem cell population in lower organisms through epigenetic silencing of transposable elements via DNA methylation and H3K9me3 marks, in close interaction with a novel class of non-coding RNA called piwi interacting RNA (piRNA).

Aims: There are neither precise data on the function of Piwi proteins in human acute myeloid leukemia (AML), nor are there reports on expression of piRNAs in this disease. We employed functional techniques and NGS to understand the function of human PIWI-like protein, PIWIL4 and its association in AML.

Methods: We assessed the expression of human PIWIL genes in AML and healthy bone marrow cells using qRT-PCR. Murine stem progenitors were transduced with AML specific oncogenes to evaluate the effect on PIWIL expression. shRNA mediated knockdown (KD) of PIWIL4 was performed on AML cell lines (LKS) and primary cell line (THP-1). We performed ChIP-seq (MNase Indexed T7-chromatin IP) to map chromatin-binding sites of PIWIL4 and performed RNA-seq to analyze the transcriptome. We performed PAR-CLIP and microarray to identify piRNAs that physically bind to PIWIL4 and to test the impact of PIWIL4 KD on piRNA expression.

Results: Among the family of human PIWIL genes, PIWIL4 showed the highest expression level and was ubiquitously expressed in healthy hematopoietic stem/progenitors, mature lymphoid and myeloid cells. Importantly, PIWIL4 was aberrantly higher expressed in more than 89% of the AML patients (n=68; p<0.0001) compared to normal CD34+ BM and total BM cells (n=3). Overexpression of AML specific oncogenes in murine stem progenitors, within 96h post-transduction, induced a 6 to 8 fold increase in PIWIL4 expression compared to GFP control (n=3, p<0.0001). Knockdown (KD) of PIWIL4 in AML cell lines significantly impaired proliferation and clonogenic growth in vitro (n=3; p<0.001) and delayed onset of leukemia in NSG mice (n=8; p<0.0001). PIWIL4 KD in primary AML patient BM cells lead to 5-fold decrease in clonogenicity (n=3; p<0.001), but had no impact on clonogenicity of healthy stem progenitors in vitro (n=4). Western blot and ChIP-seq (n=2; MACS1.4, p<0.01, FDR<0.01) in THP-1 cell line revealed a marked global reduction in repressive H3K9me3 marks upon PIWIL4 KD. Over 500 promoter and 650 gene body associated loci exhibited loss of H3K9me3 marks. RNA-seq analyses revealed gene set enrichment analyses revealed ~4000 differentially expressed genes upon PIWIL4 depletion. 30% of the loci that lost H3K9me3 marks at promoters and gene body were differentially expressed in RNA-seq (fold>0.05, adj. p<0.01). These genes belonged to pathways associated with RNA metabolism, transcription and cell death. Moreover, these genes were enriched for binding sites of SETDB1, an H3K9me3 establishing histone methyltransferase (ENRICHR, p<0.01, FDR<0.01). Notably, using IP/LC-MS, PIWIL4 was found to associate with SETDB1 in 293T cells. 560 unique piRNAs were found to physically bind to PIWIL4 and 981 unique piRNAs were differentially expressed upon PIWIL4 depletion in THP-1 cells.

Summary/Conclusions: Thus, collectively, we could show for the first time that PIWIL4 expression is deregulated in human AML and acts as a piRNA binding, epigenetically active growth regulatory protein in human AML.

S430

METTL3 CONTROLS TRANSLATION OF TARGET mRNAs BY N6 METHYLATION OF ADENOSINE RESIDUES IN THEIR CODING SEQUENCE AND CONSTITUTES A NOVEL THERAPEUTIC VULNERABILITY OF ACUTE MYELOID LEUKAEMIA

K. Tzelepis1,*, J. Barberi1, L. Pandoftis1, J. Shi2, S.C. Robson2, V. Migliori2, A.J. Bannister2, N. Han2, E. De Braekeleer4, H. Ponstingl5, C.R. Vakoc6, G. Valsesia1, T. Kozjakovic1

1Haematological Cancer Genetics, Wellcome Trust Sanger Institute, 2Gurdon Institute, Cambridge, United Kingdom, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, 4Wellcome Trust Sanger Institute, 5Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 6Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States

Background: Acute myeloid leukaemia (AML) patient survival remains below 30% and there have been no major new anti-AML therapies for decades.
Aims: To identify novel therapeutic vulnerabilities of AML. Methods: A CRISPR-Cas9 drop-out screen was used to identify genetic vulnerabilities of AML. Downstream, we study the function of the RNA methyltransferase METTL3, a novel therapeutic vulnerability of AML. These included in-vitro and in-vivo validation of METTL3 as a therapeutic target using CRISPR/gRNA or shRNA, and investigation of its function using Chip-seq, RNA-IP-seq, ribosome footprinting (RFP) and bioinformatic analyses. Results: We performed a genome-wide CRISPR screen on AML cells from Flt3ITD+/−/RosαCas9/+ mice transformed with MLL-AF9 lentivirus and identified >1500 cell-essential genes of which ~250 were AML-specific and included many MLL-AF9 interactors and several putative RNA methyltransferase genes: METTL1, METTL3, METTL14 and METTL16 (Fig 1A). Focusing on METTL3, we show that its disruption with Cas9/gRNA promoted differentiation of murine and human MLL-AF9 AML cells and inhibited their growth in vitro and in vivo (Fig 1B), but did not affect primary murine haematopoietic stem/progenitor cells. To investigate METTL3 function we performed chromatin immunoprecipitation (ChIP) for METTL3 and H3K4me3 and identified 126 METTL3 peaks, localized mainly to promoters with bimodal H3K4me3. METTL3 binding was highest at transcription start sites (TSS) (Fig 1C) and the most enriched transcription factor motif at METTL3 sites was that for the NFκB complex. Using available ChIP-seq datasets we found that NFκB, NFκB, H3R2me2s, WDR5 and KLF9 showed strong co-binding with METTL3. Also shRNA knock-down (KD) of WDR5, led to reduced METTL3 binding to target genes SP1 and SP2. To investigate if/how METTL3 controls expression of target genes we first noted that their mRNA levels were unaffected by METTL3 KD. As METTL3 is an N6-methyladenosine (m6A) methyltransferase, we then performed RNAseq as IP with an m6A-specific antibody (m6A-IP). This identified >4000 METTL3-dependent m6A peaks on poly-A+ RNA. m6A peaks were seen on 72.4% of METTL3-bound gene transcripts and were located in the coding region (CDS) in contrast to STOP codon enrichment in the general transcriptome (Fig 1D). Also, METTL3-bound transcripts were enriched for the [GAG]n motif, which was almost always in the +2 reading frame (Fig1E). As this raised the possibility that m6A may regulate translation of these transcripts, we performed RFP on wild-type (WT) and METTL3 KD MOLM13 cells, to evaluate translational efficiency (TE). Strikingly, upon METTL3 KD, m6A-marked genes had increased TE whereas transcripts with METTL3 at their TSS had reduced TE (Fig1F). We then mapped ribosomal pausing sites on mRNAs from METTL3-bound TSSs and found that GAN codons were more occupied (paused) in METTL3 KD vs WT cells (Fig1G). To understand consequences at the protein level, we studied METTL3 targets SP1 and SP2. Remarkably, in contrast to their mRNA levels, SP1 and SP2 proteins were markedly reduced upon METTL3 KD (Fig1H). SP1 and SP2 targets including c-MYC, were also downregulated upon METTL3 KD and simultaneous SP1/SP2 gRNA KD markedly reduced proliferation of MLL-AF9/Flt3ITD−/− cells. A combination of ORAL ALTS TRANS RETINOIC ACID AND DANAZOL VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL TRIAL F.-E. Feng1,2,3, M. Wang1,2,3, R. Feng4, J.-M. Zhang1,2,3, H. Jiang1,2,3, Q. Jiang1,2,3, J. Lu1,2,3, H. Liu4, J. Peng5, M. Hou6, J.-L. Shen6, J.-W. Wang7, L.-P. Xu1,2,3, K.-Y. Liu1,2,3, X.-J. Huang1,2,3, Y.-H. Zhang1,2,3

Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by increased platelet destruction and impaired platelet production. Despite decades of basic and clinical research, the treatment of severe, corticosteroid-resistant or relapsed disease remains a great challenge. Our preliminary study indicated the effectiveness of all-trans retinoic acid (ATRA) for ITP (Wang M, et al. ASH 2012, Abstract #3338). This has been coupled with previous discoveries of an immune-modulation effect of ATRA in ITP, including its role to induce changes in Treg cells (Ruan CQ 2016), and to correct the imbalance of aberrant macrophage polarization (unpublished data), indicating ATRA as a potential therapeutic regimen. Danazol has been used in the treatment of ITP for more than 30 years. Apart from its haemoapoietic stimulatory and immune-modulatory effect, it has recently been shown to reverse abnormal thrombopoiesis in patients with thrombocytopenia (Towsley DM 2016). The combination of ATRA and danazol may work synergistically based on the mechanism of action targeting both increased platelet destruction and insufficient platelet production. Aims: To investigate the efficacy and safety of ATRA plus danazol in patients with corticosteroid-resistant or relapsed ITP. Methods: A multicentre prospective study was performed in non-splenectomized corticosteroid resistant/relapsed ITP patients. Participants were at least 18 years of age, had a platelet count of < 30x10^9/L at enrolment, and did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or relapsed during steroid-tapering or after its discontinuation. Written informed consents were obtained from all of the participants. The primary endpoint was a sustained response. The secondary endpoints included overall response, time of response, duration of response, incidence of bleeding symptoms and safety. Results: From 2012 to 2016, 130 consecutive patients were enrolled from 5 different tertiary medical centres in China. Thirty-seven patients were ineligible and excluded, leaving 93 patients randomized to the ATRA+danazol group (n=45) and the danazol group (n=48). At 12 months follow-up, sustained partial or complete response was achieved in 71.6% of patients in the danazol group, significantly higher than 47.2% for danazol monotherapy (<0.001). Additionally, 92.5% and 42.5% of patients receiving ATRA+danazol achieved at least one response (R), while only 58.3% and 11.1% of patients with danazol monotherapy achieved R and CR, respectively. In patients achieving CR or R, the median time to treatment response was 30.5 days with a peak platelet count of 155x10^9/L in the danazol+ATRA group compared with 49 days with a peak PLT of 69x10^9/L in the danazol group. Multivariate analysis revealed that the initial response at day 28 and the median ITP duration were the potential variables associated with a sustained response. There was no treatment-related death due to adverse events. One patient receiving danazol monotherapy died from intracranial haemorrhage 4 weeks after study enrollment.

Summary/Conclusions: Our findings demonstrate that the combination of ATRA and danazol is safe and effective in achieving a rapid and long-lasting response, making it a potential promising therapeutic option for patients with corticosteroid-resistant or relapsed ITP.
chain IIA (NNMHC-IIA), and represents the most frequent inherited thrombocyto-
penia worldwide. NNMHC-IIA comprises two distinct domains, the N-termi-
nal globular head domain (HD) and the C-terminal tail domain (TD), and
causative mutations hit either the HD or the TD. All patients present at birth
with macrothrombocytopenia and only some of them develop during life addi-
tional manifestations, including nephropathy often leading to end-stage renal
disease (ESRD), sensorineural deafness, and/or cataract. Thus, the search for
genotype-phenotype correlations in MYH9-RD has been an important
research topic since the identification of the disorder. In 2008, the analysis of
108 patients allowed to conclude that the mutations affecting the HD were
associated with evolution to early-onset ESRD and deafness, whereas the risk of
newborn manifestations was much lower for patients carrying mutations
of the TD. In 2014, raising to 255 the number of patients, we sug-
gested that evolution to juvenile ESRD associated only with the most frequent
among HD mutations, i.e. substitution of the arginine 702 (R702). Conversely,
the R702 substitutions were almost exclusively found in a distinct hydropho-
bic region at the interface between the SH3 and the motor domain (SH3/MD interface),
but they were associated with a much less severe evolution.

Aims: To improve prognostic assessment of patients with MYH9-RD.

Methods: All the consecutive patients enrolled in the Italian registry for MYH9-
RD until June 2016 were included. The association of MYH9 genotype with phenotype was assessed by a generalized linear regression model (event-free survival analysis).

Results: We enrolled 350 patients belonging to 199 MYH9-RD pedigrees.
Mutational screening allowed us to identify 6 novel causative mutations in the HD
in 6 different pedigrees. Interestingly all of these variants were localized in the
hydrophobic region of the SH3/MD interface. By raising the number of
patients with mutations in this region from 14 to 26, and increasing the obser-
vation time, we could demonstrate that the mutations in the SH3/MD interface
are associated with evolution to a milder phenotype, characterized by development of hearing impair-
ment only (“auditory” phenotype). Our study confirmed a genotype-phenotype
model for MYH9-RD that overcomes the previously reported dualism between
HD vs TD mutation.

Summary/Conclusions: Mutations in the HD of the NMMHC-IIA are almost
all localized in a specific region at the SH3/MD interface, which therefore rep-
resents a critical region for MYH9-RD pathogenesis. Most importantly, patients with
HD mutations developed into two different phenotypic subgroups: patients with
R702 substitutions were expected to develop early a severe and progressive
neurological syndrome, whereas mutations in the SH3/MD interface are associated with
mutation to a milder phenotype, characterized by development of hearing impair-
ment only (“auditory” phenotype). Our study confirmed a genotype-phenotype
model for MYH9-RD that overcomes the previously reported dualism between
HD vs TD mutation.

S434

POSITION OF THE GFI1B ZINC FINGER MUTATION DECOUPLES CD34
EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GF1B-RELATED
PLATELET DISORDERS

W. Stevenson1,*, D. Rabbolini1, M.-C. Morel-Kopp1, Q. Chen1, S. Gabrielli1,
C. Ward2
1Haematology, University of Sydney, Sydney, Australia

Background: GF1B is a transcription factor that plays an important role in
haematopoiesis. Families with a mutation of the fifth DNA-binding zinc-finger
domain (GFI1B-RD) experience bleeding and have a platelet phenotype charact-
ised by macrothrombocytopenia, increased CD34 expression and alpha-
granule deficiency.

Aims: To explore the function of other zinc finger domains of GF1B we have charact-
erised two unrelated families with a GF1B variant, C168F, predicted to disrupt the first Zn-finger domain and compare the phenotype with a previously
described pedigree with the H294fs mutation that disrupts the fifth Zn-finger
domain.

Methods: Clinical platelet phenotypes were determined by light and transmit-
sion electron microscopy and functional studies performed by light transmission
and whole blood impedance aggregometry. Platelet protein expression was
measured by flow cytometry and western blotting. DNA-binding of variants was
determined by gel mobility shift assays (EMSA) and changes in gene trans-
cription by luciferase assays. Cellular phenotypes were then studied in patient
specific IPSCs derived megakaryocytes. 

Results: Individuals with both C168F and H294fs are thrombocytopenic (mean platelet count =107 x10⁹/L, n=8) but lack the collagen induced aggregation defects and bleeding symptoms observed in individuals with H294fs (ISTH BAT, P=0.015). Alpha granule content observed by microscopy and quantitated by
western blotting of granule related proteins, P-selectin and fibrinogen, were
similar between C168F and control platelets and this was significantly greater
than that observed for the H294fs mutation (P<0.01). EMSA studies indicate
that the C168F variant retains the ability to bind DNA whereas the H294fs
mutation altering GFI1B Zn finger 1 cause thrombocytopenia with increased CD34 expression but these platelets retain rela-
tively normal alpha-granule content and function.

Summary/Conclusions: Mutations affecting GF1B Zn finger 1 cause throm-
boctopenia with increased CD34 expression but these platelets retain the
alpha-granule content and function of wildtype platelets. A mutation that alters the 5th Zn-finger domain is associated with
biphasic platelet phenotype, similar to that observed in patients with the H294fs
mutation. This highlights that additional zinc finger domains of GFI1B may
have a role in the pathogenesis of GF1B-RD that may be related to the distinct
clinical presentation associated with this disorder.
Results: Treatment.

≥50K/μL at 4 of 6 biweekly visits over Weeks 14-24; intermediate response to splenectomy, and 32% rituximab. Stable response (SR) was defined as a platelet count ≥50K/μL at 4 of 6 biweekly visits over Weeks 14-24; intermediate response to splenectomy, and 32% rituximab. Stable response (SR) was defined as a platelet count ≥50K/μL at 4 of 6 biweekly visits over Weeks 14-24; intermediate response to splenectomy, and 32% rituximab.

Background: ITP is characterized by autoantibody-directed platelet destruction mediated by activated monocyte Fc receptors which signal through spleen tyrosine kinase (Syk). A Phase 2 trial of the oral Syk inhibitor Fostamatinib (FOSTA) in 16 patients (pts) with refractory ITP provided preliminary efficacy and safety data (Podolanczuk et al., 2009).

Aims: To evaluate the efficacy and safety of FOSTA in adult cITP in 2 parallel, identical, multi-center, randomized, double-blind phase 3 studies (S047 and S048) of 24 weeks duration, followed by an open label study (S049).

Methods: 150 pts with 3 platelet count (cts) <30K/μL were enrolled (76 in S047, 74 in S048) with a 2:1 randomization to FOSTA 100mg or placebo bid, stratified by prior splenectomy and baseline platelet count <15K/μL. Sixty-one % of pts were female; median age was 54 (20-88); 93% were Caucasian; 93% had cITP; median disease duration: 8.5 y; median baseline platelet c: 16K/μL. Prior therapies received by pts included 94% steroids, 47% TPO-RAs, 35% splenectomy, and 32% rituximab. Stable response (SR) was defined as a platelet count ≥50K/μL at 4 of 6 biweekly visits over Weeks 14-24; intermediate response (IR) as at least 2 consecutive bi-weekly platelet counts ≥50K/μL both without rescue treatment.

Results: Across both studies, a SR occurred in 18/101 (18%) FOSTA vs 1/49 (2%) placebo pts (p<0.0001). The median platelet cts were 95K, 49K, 20.5K, and 17.5K/μL in SR, IR, non-responders (NR) and Placebo pts, respectively. In SR and IR, median time to first platelet count ≥50K/μL was 2 weeks. Age (< or ≥65 y), gender, baseline platelet c <15K/μL, prior TPO-RA or splenectomy did not substantially affect response. In S049, 941 (22%) pts newly treated with FOSTA have a SR, consistent with S047 and S048. Forty-four of 101 (54%) FOSTA pts and 14/49 (29%) placebo pts had a platelet count ≥20K/μL (p=0.005). Three of 18 (17%) SR and 1/11 (9%) IR to FOSTA compared to 26/72 (36%) NR and 22/49 (45%) of the placebo group received ≥1 rescue medication, respectively. In S047-048, serious bleeding occurred in 5.6% of the NR and 10.2% of placebo pts (p=0.007); 11 additional FOSTA and no placebo patients died. Most common AEs were: diarrhea (29% vs 15%), nausea (19% vs 8%), hypertension (20% vs 8%), ALT/AST increase (10% vs 2%). Serious AEs were reported in 13% FOSTA vs 21% placebo pts.

Summary/Conclusions: Fostamatinib substantially improves platelet cts in certain pts with heavily pre-treated, severe cITP of long disease duration. AEs are mostly mild or moderate in severity. Given its unique mechanism of action based on inhibition of Syk, FOSTA could, if approved, be an important alternative as single agent and be a useful component of combination therapy for pts with difficult to treat ITP.

References


Acute lymphoblastic leukemia - Biology

S436

The YING and YANG of JAK SIGNALING: LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2-JAK-STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (CBL-ALL) OF MICE WITH GAIN OF JAK2 R683G


Background: Children with Down syndrome (DS) are prone to development of high risk B cell precursor (BCP) acute lymphoblastic leukemias (DS-ALL) that differ genetically from most sporadic pediatric ALLs. Chromosomal rearrangements causing increased expression of CRLF2, the receptor for thymic stromal lymphopoietin (TSLP), characterize about half of DS-ALLs. Aims: Understanding the pathogenesis of relapse of DS-ALL relating to their CRLF2 status.

Methods: Integrative genomic analysis of matched diagnosis remission and relapse DS-ALLs, pharmacological inhibition and genetic CRISPR mediated silencing.

Results: Genomic analysis of 25 matched diagnosis remission and relapse DS-ALLs revealed lesions affecting known driver genes in the samples. In 80% of the patients we detected activating mutations in genes whose protein products are involved in signaling, including receptors (CRLF2, IL7R, FLRT3), or downstream effector enzymes (JAK1/2, KRAS and NRAS). In contrast to a previous report, we observed that lesions in CRLF2 are early events during DS-ALL evolution, as is evident by its high allelic frequency, and are maintained at relapse. The genetic make-up of these DS-ALLs was characterized by enhanced RAS signaling coupled by mutations in chromatin remodeling genes, in particular CREBBP. In contrast to a previous report, we observed that lesions in CRLF2 are early events during DS-ALL evolution, as is evident by its high allelic frequency, and are maintained at relapse.

Summary/Conclusions: Integrative genomic analysis of matched diagnosis remission and relapse DS-ALLs, pharmacological inhibition and genetic CRISPR mediated silencing.

Discussion: The YING and YANG of JAK SIGNALING: LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2-JAK-STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (CBL-ALL) OF MICE WITH GAIN OF JAK2 R683G transduced ALL cells. To test directly the effect of JAK inhibition, we treated CRLF2/JAK2R683G transduced cells with increasing doses of ruxolitinib, a JAK inhibitor currently in clinical trials for CRLF2-JAK-STAT ALLs. Strikingly while high doses (>2μM) were cytotoxic, low doses (0.25μM) enhanced the survival of CRLF2/JAK2R683G expressing ALL cells.

Summary/Conclusions: These observations suggest that genetic or pharmacological restraining of JAK-STAT signaling may be beneficial to leukemic B cell precursors by enhancing the fitness of JAK-STAT ‘driven’ ALL. This and the reduction of JAK-mutated clones at relapse suggest that the pharmacological effect of JAK2 specific inhibitors may be limited. Rather, combined signaling inhibitors or direct targeting of the TSLP receptor may be a useful therapeutic strategy for DS-ALL.
TNF RECEPTOR 2 IS REQUIRED FOR RIP1-DEPENDENT CELL DEATH IN LEUKEMIA

J. Aguadé-Gorgorió1,1, S. McM bord2,3, M. Dobay1, C. Mezzaterra1, G. Cario1, C. Eckert1, A. von Stackelberg2, M. Stanulla8, M. Schrappe4, J.-P. Bourquin1, B. Bornhauser1
1Department of Oncology and Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland, 2Cancer Immunology, National Research Council of Canada, Ottawa, Canada, 3SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland, 4Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, 5Department of Pediatric Oncology/Hematology, Charité Medical University Berlin, Berlin, 6Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

Background: Persistence of residual leukemia cells, due to deficiencies in apoptotic programs, is a major driver of relapse. Activation of alternative non-apoptotic cell death pathways such as necroptosis represents an attractive strategy to eliminate residual leukemia cells and prevent relapse. We have previously shown that SMAC-mimetics (SM) potently induce cell death by simultaneous RIP1-dependent apoptosis and necroptosis in a subset of refractory acute lymphoblastic leukemia (B-ALL) patient-derived samples. The molecular signals that drive sensitivity to RIP1-dependent cell death remained elusive so far.

Aims: The aim of this project was to understand the mechanisms that determine the specific vulnerability to necroptosis in ALL.

Methods: To identify molecular determinants of sensitivity to SM, we correlated the gene expression profiles of 17 primary samples with high and low sensitivity to SM with the IC50 in response to two SM compounds, birinapant and LCL161. We confirmed the top scoring genes including TNF receptor 1 (TNFR1) and TNFR2 by quantitative RT-PCR in patient-derived xenografts. We further validated our results by quantifying the expression of the candidate genes in an independent cohort of relapsed primary B-ALL and by screening samples with different expression levels of TNFR1 and 2 for their response to SM in vitro. To assess the mechanistic role of TNFR1 and 2 in the response to SM, we generated knockout lines for TNFR1 and TNFR2 knockdown cells using the CRISPR/Cas9 gene editing technology, and evaluated their response to SM in vitro and in vivo using a CRISPR selection model. Additionally, we overexpressed TNFR2 and evaluated the cell death phenotype. To determine the mechanism of TNFR2-mediated sensitization to SM, we investigated the formation of the pro-death RIP1-TNFR1 complex in wild type versus TNFR2ko and in SM sensitive and resistant ALL by immunoprecipitation in primary ALL samples.

Results: Comparative gene expression profiling indicated a correlation of the expression of TNFR2 with sensitivity to SM in primary ALL. Using an independent cohort of relapsed ALL samples, we found that high TNFR2 expression predicted sensitivity to SM in an ex vivo model of the bone marrow. Deletion of either TNFR1 or TNFR2 using CRISPR/Cas9 in patient-derived ALL conferred resistance to treatment with SM in vivo in the xenograft model, indicating that TNFR1 and 2 are both functionally required for cell death. In agreement with an important role for TNFR2 in the response to SM, the overexpression of TNFR2 leads to increased sensitivity to the TNFR1/RIP1 death axis. On the mechanistic level, recruitment of RIP1 to TNFR1 is a key event in the activation of cell death, which is abolished in TNFR2-deficient leukemia and does not occur in SM resistant cases.

Summary/Conclusions: Taken together, our data reveal a novel function of TNFR2 in cell death signaling, as TNFR2 predicts sensitivity to SMAC mimetics and plays a key role in activating the TNFR1/RIP1 cell death pathway, which underlies the switch from RIP1-controlled cell death to cell death and characterizes a distinct vulnerability in ALL.

THERAPEUTIC TARGETING OF ONCOCENIC MYB ACTIVITY IN T-ALL

T. Pieters1,1, S. T’Sas1, J. Morscic1, F. Mathijsens1, K. Lemeire2, T. Hochepie2, B. Lintemans1, L. Reune1, J. Haigh1, G. Berx4, S. Goossens1, P. Van Vlierberghe1
1Center for Medical Genetics, Ghent University, 2Ghent University, Ghent, Belgium, 3Monash University and Alfred Health Centre, Melbourne, Australia

Background: T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that accounts for 10%–15% of pediatric and 25% of adult ALL cases. The prognosis of T-ALL has gradually improved, however, the outcome of T-ALL patients with primary resistant or relapsed leukemia remains poor. Thus, further advances in the treatment of T-ALL require the development of effective and highly specific molecularly targeted antileukemic drugs. The proto-oncogene MYB (encodes c-MYB) is aberrantly activated in a subset of T-ALL patients through T-cell receptor driven translocations or genomic duplications of the MYB locus itself. Recently, a new genetic mechanism for the generation of oncogenic super-enhancers in malignant T cells was identified, and suggests a general role for MYB in the regulation of T-cell specific super-enhancer activity.

Aims: We want to identify the role of enhanced MYB activity in super-enhancer driven oncogenic transcription in the context of malignant T-cell development and investigate the in vivo role of cMyb in the initiation and maintenance of T-ALL.

Methods: To evaluate if cMyb could act as a bona fide oncogene in the pathogenesis of T-ALL, we developed a conditional R26-driven cMyb overexpression mouse model. For this, we used a targeting vector that contained a floxed stop cassette followed by the cMyb gene and a EGFP/luciferase reporter, which was subsequently targeted in mESCs using recombinase-mediated cassette exchange (RMCE).

Results: Here, we report a novel conditional Myb knockin mouse model (R26-Myb). To study the in vivo oncogenic capacity of Myb, we initially crossed this conditional Myb knockin model with Vav1Cre mice, in order to obtain hematopoietic specific expression of Myb and the EGFP/luciferase from the ROSA26-promoter. Notably, Vav1-Cre+/R26-Myb+/mice developed T-cell lymphomas with a median latency of 77 weeks, suggesting that Myb can act as a bona fide oncogene in malignant T-cell transformation (Figure 1A). Next, we crossed our Myb transgenic model with Pten conditional knockout mice, to allow comparative analysis of tumors with and without T-cell specific Myb expression. Genetic inactivation of Pten is frequently observed in human T-ALL, and T-cell specific deletion of Pten (using Lck-Cre) results in T-cell leukemia/lymphoma development with an average of 17 weeks. Using this strategy, we obtained mice that overexpress R26-driven cMyb and lack Pten in developing T-cells and found that cMyb expression synergizes with Pten deletion, resulting in fully penetrant and accelerated T-ALL formation (median survival of 84 days instead of 118; p = 0.0003; Figure 1B). Finally, we used this novel murine T-ALL model to identify new therapeutic strategies for MYB dependent T-ALL. Importantly, the tumor cells from the cMyb knockin mice are luciferase-positive and are therefore suitable for in vivo drug testing using bioluminescence. Using this model, we evaluated the in vivo anti-leukemic efficacy of a variety of small molecules and identified new drugs that impede Myb protein stability or Myb-mediated transcription in Myb driven tumorigenesis.
THE T-CELL LEUKEMIA ASSOCIATED RIBOSOMAL RPL10 R98S MUTATION ENHANCES JAK-STAT SIGNALING

T. Girard1, S.O. Sulima1, S. Vereecken2, Y. Khan2, L. Fancello1, Z. Flickinger2, C. Schwab3, J. Op de Beeck1, J. Verbeeck1, J. Royaert1, E. Geerdens4,5, C. Vicente4,5, S. Bornschein4,5, C. J. Harrison6, J. P. Meijerink7, J. Cools4,5, J.D. Dinman8, K.R. Kampen1, K. De Keersmaecker1

1Department of Oncology, LKI, KU Leuven, Leuven, Belgium, 2Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, United States, 3Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Center for Human Genetics, LKI, KU Leuven, 5Center for Cancer Biology, VIB, Leuven, Belgium, 6Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 7Department of Pediatric Oncology/Hematology, Erasmus Medical Center, Rotterdam, Netherlands

Background: Several somatic ribosome defects have recently been discovered in cancer, yet their underlying oncogenic mechanisms remain poorly understood. Alterations in ribosomal protein genes RPL5, RPL10, and RPL22 have been described in ~20% of T-cell acute lymphoblastic leukemia (T-ALL) cases. Whereas RPL5 and RPL22 show heterozygous inactivating mutations and deletions, RPL10 contains a clear mutational hotspot at residue arginine 98 (R98), with 8% of pediatric T-ALL patients harboring this RPL10 R98S missense mutation.

Aims: Investigating the pathogenic role of the recurrent R98S mutation in ribosomal protein L10 (RPL10) in T-ALL.

Methods: A label-free quantitative proteomics experiment was performed to screen for differentially expressed proteins in engineered mouse lymphoid Ba/F3 cells expressing RPL10 WT or RPL10 R98S. Differences in protein expression were further validated in hematopoietic cells derived from a transgenic RPL10 R98S knock-in mouse model and in material derived from xenografted T-ALL patient samples.

Results: The differential proteome screen revealed overexpression of several Jak-Stat signaling components (Csf2rb/2, Jak1, Stat1, Stat3, Stat5a/b, and Stat6) in engineered RPL10 R98S mouse lymphoid cells, which we confirmed in hematopoietic cells derived from a transgenic RPL10 R98S mouse model. The relevance of this overexpression was illustrated by enhanced Jak-Stat pathway activation upon cytokine stimulation in RPL10 R98S lymphoid cells, as well as increased sensitivity of these cells to clinically used JAK-STAT inhibitors ruxolitinib and pimozide. RPL10 R98S positive leukemia patients likewise showed overexpression of IL7RA, Jak1 and Stat5, increased sensitivity to pimozide, as well as a mutually exclusive mutation pattern between RPL10 R98S and JAK-STAT lesions, suggesting that RPL10-R98S also modulates the cascade in human T-ALL. Programmed -1 ribosomal frameshifting (<1 PRF) recently emerged as a post-transcriptional mechanism regulating expression of cytokine receptors. We identified -1 PRF signals in mouse and human Jak-Stat genes and observed RPL10 R98S associated frameshifting reduction in several of these, which may contribute to their overexpression. Altered levels of -1 PRF can however only partially explain observed JAK-STAT protein expression changes, and transcriptional changes and altered protein stability.

are also involved. Indeed, our data point to altered proteasome activity and composition in RPL10 R98S cells, with upregulation of immunoproteasome specific catalytic subunits, which may explain the increased stability of particular proteins such as Jak1. Of further medical interest, RPL10 R98S cells showed reduced proteasome activity and enhanced sensitivity to the clinically used proteasome inhibitors bortezomib and carfilzomib.

Summary/Conclusions: We explored the molecular mechanism by which the RPL10 R98S mutation contributes to the pathogenesis of T-ALL. We propose a model in which R98S associated decreases in -1 PRF levels, combined with changes in the degradation of particular proteins and potential other mechanisms such as transcriptional regulation, leads to selective upregulation of the JAK-STAT cascade (Figure 1). Besides expanding the relevance of the JAK-STAT cascade in T-ALL and leukemia in general, our results have therapeutic potential since cells harboring the RPL10 R98S mutation are sensitized towards clinically used JAK-STAT and proteasome inhibitors.

S440

NFATC3-PLA2G15 IS A NOVEL INTERGENICALLY SPLICED CHIMERA THAT IS ASSOCIATED WITH AGGRESSIVE T-ACUTE LYMPHOBLASTIC LEUKAEMIA BIOLOGY

J. Bond1,2,*, C. Trang-Quang3,4, A. Bergon5, M. Belhocine5, G. Hypolite1,2, W. Goma6, J. Ghysdael1,4, E. Macintyre1,2, N. Boissel6, S. Spiculiga6, V. Asnafi1,2

1Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INERM), Institut national de recherche médicale (INSERM) U1151, 2Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, Paris, 3Institut Curie, PSL Research University, CNRS UMR 7594, 4Université Paris-Saclay, Orsay, 5Technological Advances for Genomics and Clinics (TAGC), INSERM U1090, Aix-Marsselle University UMR-S 1090, Marseille, 6Université Paris Diderot, Institut Universitaire d’HématoLogie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, Paris, France

Background: Transcriptional read-through of a single mRNA between contiguous loci, or cis-splicing of adjacent genes (cis-SAGE), results in transcription of intergenically-spliced chimeric RNAs (ISCs) in the absence of structural genomic changes. Recent advances in high-throughput RNA-sequencing analyses have permitted identification of aberrant ISC expression as a potential cancer driver, but knowledge of leukaemia-related ISC is lacking.

Aims: To examine whether cis-SAGE generates biologically important ISCs in T-acute lymphoblastic leukemia (T-ALL).

Methods: We performed RNA-sequencing of 12 cases of T-ALL and normal thymic RNA, and used targeted analysis pipelines to detect T-ALL-specific fusion chimeras.

Results: We identified 140 T-ALL-specific fusions, of which 55 involved genes located within 30kb of each other, in the same transcriptional orientation. This distance is consistent with that previously observed for cis-SAGE, suggesting that ISC expression is common in T-ALL. In total, putative ISCs were detected in 10/12 samples, with a median of 4 (range 0-15) per patient. We performed further analysis on the candidate ISC NFATC3-PLA2G15, which includes the Nuclear Factor of Activated T-cells (NFAT) family member NFATC3, a critical regulator of normal thymopoiesis and known modulator of T-ALL biology. We found that primary T-ALLs exhibited a wide range of NFATC3-PLA2G15 expression, while levels in normal tissue were either very low or undetectable. 5’ RACE PCR analysis of leukemic cDNA revealed that fusion transcription was initiated in exon 1 of NFATC3. We also performed array comparative genomic hybridization of 115 diagnostic T-ALL samples, and found no evidence of microdeletions that would result in NFATC3-PLA2G15 expression, providing strong evidence that NFATC3-PLA2G15 is a true ISC that is generated by cis-SAGE. We found that the NFATC3-PLA2G15 fusion had lower activity than wild-type NFATC3 in both luciferase reporter experiments and proliferation and survival complementation assays in NFAT-null all cell lines in vitro. Gene set enrichment analysis revealed that primary T-ALL blasts with elevated NFATC3-PLA2G15 levels had reduced transcription of canonical NFAT target genes in vivo, suggesting that these cases may have lower activity of normal physiological NFAT pathways. Strikingly, we found that higher NFATC3-PLA2G15 levels strongly correlated with both shorter time to leukemia development (p=0.01) and survival (p=0.003) in patient-derived T-ALL xenografts in immunodeficient mice. These findings were corroborated by survival analyses of human T-ALL patients treated as part of the Francophone multinational GRAALL-2003 and -2005 studies, as cases with the highest quartile of NFATC3-PLA2G15 expression had significantly reduced 5 year overall survival (52.6%, 95% CI 33.3% - 68.7%) compared with NFATC3-PLA2G15 low cases (69.8%, 95% CI 58.8% - 78.3%, p=0.047).

Summary/Conclusions: Our results suggest that ISC expression is common in T-ALL, and that high expression of the NFATC3-PLA2G15 ISC correlates with reduced canonical NFAT pathway activity and poor patient outcome.
**Thrombotic disorders**

**ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A POPULATION-BASED STUDY**

A. G. Kristjansson1,2,3, A. Garg1,2,3, M. McCallum3, S. Dixon3, S. Y. Kristinsson1,3

*1Epidemiology and Biostatistics, 2Medicine, Western University, 3Institute for Clinical Evaluative Sciences, London, Canada*

**Background:** Cancer patients have a higher risk of venous thromboembolism (VTE) which conveys a higher subsequent mortality risk; conversely, they also have a higher risk for bleeding due to many factors including abnormal tumor anatomy and the use of chemotherapy agents with the associated risk for thrombocytopenia. However, the consequences of a recurrent VTE or a major bleeding event (MB) might be different in terms of mortality. As a result, the risk of VTE recurrence or a MB event might bear different weights. A previous systematic review has suggested that the case fatality rates of VTE recurrence and MB are similar. However, heterogeneity in study design, outcomes and in particular the types of populations included, limited the interpretation and applicability of the results. Clinical decision making uses estimations of risk and benefit for any given intervention. In the case of VTE, anticoagulants are the cornerstone of treatment having a proven benefit in reducing the risk of recurrent VTE events with an associated increase in the risk of bleeding. Therefore, determining the risk-benefit of anticoagulants might allow for better informed treatment decisions, in particular in a population at high risk for both ends of the spectrum. Therefore, herein we sought to estimate the risk and benefit of anticoagulant therapy in cancer patients developing a VTE using data from administrative databases.

**Aims:** To estimate the case fatality rates of VTE recurrence and MB, as well as the case fatality rate-ratio for MB and VTE recurrence in cancer patients developing a VTE treated with anticoagulants.

**Methods:** We conducted a retrospective population-based cohort study in Ontario, Canada using de-identified linked administrative healthcare databases housed at the Institute for Clinical Evaluative Sciences (ICES). We included patients over 65 years of age with a diagnosis of cancer defined using provincial, ICD-9 and ICD-10 codes for major malignancies and who developed a VTE event within 6 months of the initial cancer diagnosis. VTE was identified through a Cox proportional hazards model using a combination of diagnostic codes for deep vein thrombosis (DVT) and pulmonary embolism (PE) and codes identifying diagnostic procedures for VTE (i.e. ultrasound, CT pulmonary angiography, lung scintigraphy) within 7 days of each other. Recurrent VTE and MB events were assessed within 180 days from the index date. MB was identified using a previously validated algorithm and included upper and lower gastrointestinal and intracranial bleeding events. Treatment was classified based on the first available prescription within 7 days of the index VTE. We estimated mortality within 7 days of the VTE recurrence or MB events using an unadjusted Cox proportional hazards model and competing risk analysis. Ratios of the mortality for MB compared to VTE recurrence were calculated and 95% confidence intervals were estimated using non-parametric models.

**Results:** Between 2004 and 2014 there were 6967 VTE events identified in cancer patients over 65 years of age and treated with an anticoagulant. Mean age was 75 years, and 47.6% patients were women. Of all patients, 59.9% received prescriptions for LMWH alone, 15.3% for LMWH followed by warfarin, 22.1% for warfarin and 2.7% for rivaroxaban. At 180 days after the index VTE event there were 235 (3%) MB events and 1184 (17%) VTE recurrences. Within 7 days of the outcome event there were 26 (11%) deaths after MB and 6 (0.5%) after VTE. The mortality ratio for MB versus VTE was 21.8 (95% CI 9.53). In exploratory analyses we did not find differences according to type of anticoagulant prescription.

**Summary/Conclusions:** In this large, population-based, study based on more than 40,000 patients with NHL and almost 116,000 controls, we demonstrated that there is an increased risk of thrombosis in patients with NHL when compared to controls. This is true for all types of thrombosis. We therefore conclude that hypercoagulability seems to increase with diagnosis of NHL. Several factors may contribute to this prothrombotic state, including chemotherapy and other treatment related factors as well as the disease itself. Considering that the increase in the incidence of thrombosis was highest before and around the time of diagnosis for NHL patients, that indicates that the tumor itself may have a great impact on the hypercoagulability of these patients.

---

**RISK OF THROMBOSIS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A POPULATION-BASED COHORT STUDY**

A.M. Birgisdottir1,1,2, I.S. Sverrisdottir1, O. Landgren2, M. Björkholm3, S.Y. Kristinsson1,3

1Faculty of Medicine, University of Iceland and Landspitali University Hospital, Reykjavik, Iceland, 2Department of Medicine, Haukavita Hospital, Memorial Sloan –Kettering Cancer Center, New York, United States, 3Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

**Background:** Lymphoma is a malignancy that originates in lymph nodes and lymphoid tissue. The main category of lymphomas is non-Hodgkin’s lymphoma (NHL), NHL comprise about 3% of all cancers in Sweden. Some are aggressive and fast growing, while others are more indolent and do not necessarily require treatment. It is well known that cancer increases the risk of thrombosis, especially as it promotes thromboembolism, but data are scarce on the risk of thrombosis in NHL patients.

**Aims:** The aim of this study is to evaluate the risk of thrombosis in NHL patients compared to controls and to study time trends in the risk of thromboembolism with recent advances in the treatment of these diseases.

**Methods:** The study population consisted of individuals diagnosed with NHL in Sweden 1980-2013 (n=40,354), and up to four matched controls (n=115,677). The risk of the first thrombosis was evaluated after the diagnosis of NHL (and corresponding date for controls) and the ones that occurred less than 30 days prior to diagnosis of NHL. Kaplan-Meier survival analysis was used to estimate the risk of thrombosis and a log-rank test performed to assess statistical significance. Cox regression analysis was used to calculate hazard ratios (HRs) and 95% confidence intervals (CI) (adjusting for age, sex, year of diagnosis, and previous history of thrombosis). Risk of deep vein thrombosis, pulmonary embolism and arterial thrombosis was evaluated. Arterial thrombosis was defined as cerebral infarct, transient ischemic attack, angina pectoris, myocardial infarction, and arterial embolism and thrombosis.

**Results:** NHL patients had a statistically significant increase in risk of any type of thrombosis compared to controls (HR: 1.58; 95% CI: 1.53-1.62). The risk was significantly increased for all three types of thrombosis; deep vein thrombosis (HR: 3.11; 95% CI: 2.95-3.39) and arterial thrombosis (HR: 1.20; 95% CI: 1.16-1.23). The risk of thrombosis did not change during the study period for the NHL patients. There was an increased risk of thrombosis for NHL patients when compared to controls, independent of previous history of thrombosis (HR: 1.64; 95% CI: 1.59-1.68) no previous history, HR: 1.43; 95% CI: 1.37-1.50 if previous history of thrombosis). The incidence of thrombosis for NHL patients started to increase about five months before the diagnosis of NHL, and reached its peak a month before diagnosis. The incidence stayed increased for the first year after diagnosis.

**Summary/Conclusions:** In this large, population-based, study based on more than 40,000 patients with NHL and almost 116,000 controls, we demonstrated that there is an increased risk of thrombosis in patients with NHL when compared to controls. This is true for all types of thrombosis. We therefore conclude that hypercoagulability seems to increase with diagnosis of NHL. Several factors may contribute to this prothrombotic state, including chemotherapy and other treatment related factors as well as the disease itself. Considering that the increase in the incidence of thrombosis was highest before and around the time of diagnosis for NHL patients, that indicates that the tumor itself may have a great impact on the hypercoagulability of these patients.

---

**COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTS**

D. Antic1,2, N. Milić1,2, N. Nikolovski1, M. Todorovčić1, J. Bila1, P. Djurdjevic1, B. Andjelic1, V. Djurasinović1, A. Sretenović1, M. Smiljanić1, V. Vuković1, J. Jelčić1, B. Mihaljević1

1Clinic for hematology, Clinical Center of Serbia, 2Medical school Belgrade, Belgrade, Serbia

**Background:** Actual guidelines recommend Padua and Khorana score for thromboembolic (TE) risk estimation for cancer patients in general. These existing models are quite limited for designation of lymphoma patients for TE events, as their development is not based on features specific for hematological patients.

**Aims:** The aim of this study was to compare diagnostic performance of these suggested predictive models, as well as Thrombosis lymphoma (Tholy) score, developed by our group, which is more specific for lymphoma patients.

**Methods:** The study population included all consecutive patients with a confirmed diagnosis of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and chronic lymphocytic leukemia (CLL) were included. All patients who were treated in the Lymphoma Departments of Clinical Center Belgrade and Clinical Center Kragujevac in period from 2006 to 2014. Data for newly diagnosed and relapsed patients who had completed a minimum of one chemotherapy cycle were prospectively collected for all venous and arterial TE events from time of diagnosis to 3 months after the last cycle of therapy. Data for specific thromboembolic, gastrointestinal, and pulmonary events were collected. The Tholy score was developed by our group, which is more specific for lymphoma patients.

**Results:** The study population included 319 patients with NHL or CLL, 22 patients with HL, and 7 patients with other lymphomas. The Tholy score was divided based on a split-sample random method into the model developing and validation sets. The Tholy score was divided into tertiles, based on the distribution of predicted risk of thrombosis of the model developing set. The prediction performance of the Tholy score was not significantly different from Padua score, but it was better than the Khorana score, for the development and validation sets. For all three scores, the area under the curve (AUC) was significantly higher for the total population compared with the relapsed patients, and higher in the relapse group compared with the non-relapse group.
and validation cohorts. The ThroLy model was developed using data solely from a derivation cohort, which included 1236 patients. Variables were evaluated by univariate logistic regression analysis, while the model was developed using a stepwise multivariate logistic regression analysis. Once a final model was defined, patients were divided into low risk and at risk groups. The final model was assessed in the validation cohort (584 patients). The studied population was also divided, based on Khorana and Padua score, into low risk and at risk groups.

Results: The study population included 1820 eligible lymphoma patients. The mean patient’s age was 53.1 years (range, 15–87 years). Most patients (83%) were newly diagnosed and had advanced stage disease: Ann Arbor stage III, 14.7% and stage IV, 44%. A total of 778 patients (42.7%) had high-grade lymphoma; 351 (19.3%) had low-grade lymphoma; 266 (14.6%) had HL; 156 (8.6%) had other forms; and 269 (14.8%) had CLL/SLL. Of all the patients included in the study, 99 (5.4%) developed at least one TE during the follow-up period. There were 73 patients with venous TE (73.7%), and 25 with arterial TE (25.3%), while 1 patient had both. Patients with aggressive NHL had significantly higher rates of developing TE compared to patients with any other lymphoma type (RR=1.5; 95% CI for RR 1.1–2.4; p=0.027). The incidence of thromboembolism was 81 (5.3%) in the newly diagnosed patients and 18 (6.2%) in relapsed patients. Overall, 35.4% (35/99) of the patients with thromboembolism experienced the event before the start of chemotherapy. The majority of patients (64.6%) had TE events during chemotherapy or within 3 months after chemotherapy. For patients classified at risk according to ThroLy score in derivation cohort, the model produced negative predictive value (NPV) of 98.5%, positive predictive value (PPV) of 25.1%, sensitivity of 75.4%, and specificity of 87.5%. In validation cohort PPV for ThroLy score was 28.9%. Padua and Khorana score had PPV of 15.5% and 14.8% in derivation, and 11.5% and 14.8% in validation cohort, respectively.

Summary/Conclusions: Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. ThroLy score is more specific for lymphoma patients than suggested Padua and Khorana score, but external validation in large prospective cohort studies is required.

Table 1.

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2 and both.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Mean 81.24</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 75.6%</td>
</tr>
<tr>
<td>Cancer</td>
<td>Hodgkin's</td>
</tr>
<tr>
<td>Status</td>
<td>35.4%</td>
</tr>
<tr>
<td>Survival</td>
<td>18 (6.2%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The new e-alert system further increases the use of VTE prophylaxis in hospitalised cancer patients, although this was not associated with a reduction in the VTE incidence. A relevant number of VTE events occur despite prophylaxis with standard LMWH. Identification of risk factors for thromboprophylaxis failure is needed. This work has been funded by a biomedical research grant with the Laboratory of Pharmaceutical ROVI and an aid to the research projects of the Instituto de Salud Carlos III and the FEDER (PI13 / 01029).

S444

IMPACT OF A NEW ELECTRONIC ALERT SYSTEM (V2.0) FOR VENOUS THROMBOEMBOLISM PREVENTION IN HOSPITALISED CANCER PATIENTS

R. Figueroa1, A. Alfonso1, V. Sara1, M.C. Nicolás1, M. Marcos Jubilar1, J. López Picazo2, I. Gil-Bazó2, A. García-Mouriz2, J.A. Páramo1, J. Hermida3, R. Lecumberri3

1Hematology, 2Medical Oncology, 3Informatics Department, Clínica universidad de Navarra, 4Division of Cardiovascular Sciences, Centro de Investigación Médica Aplicada, Pamplona (Navarra), Spain

Background: Onco-hematologic hospitalised patients constitute a group at high risk of venous thromboembolism (VTE). Current clinical practice guidelines recommend prophylaxis with low molecular weight heparin (LMWH) during hospitalisation, unless contraindicated. However, its underuse is a worldwide problem. Electronic alert systems (e-alerts) can improve the use of appropriate thromboprophylaxis and reduce the incidence of VTE.

Aims: To evaluate the impact of a new version (v2.0) of our e-alert system for VTE prevention compared with the initial software version. Secondary endpoints try to identify predictive factors for prophylaxis use and thrombotic events.

Methods: Prospective study including consecutive adult cancer patients admitted to our centre. From April 2014 to June 2015 (first period) the initial e-alert system version remained operative and from July 2015 to December 2016 (second period) the new version was active. The v2.0 displayed a second warning that asked physicians about the reason why LMWH was not prescribed.

Results: 1251 patients were included, 782 patients in the first period and 469 in the second one (main clinical features are shown in Table 1). E-alerts v2.0 was associated with an increase of appropriate LMWH prophylaxis during hospitalisation (65.2% vs 72.2%; p=0.015). However, this improvement did not result in a reduction of VTE during admission or follow up (2.3% vs 2.3%; p=0.89). Interestingly, almost 80% of VTE events occurred despite LMWH use. No differences in the rate of major bleeding (2.8% vs 3.2%; p=0.83), and mortality (10.6% vs 14.3%; p=0.07) were observed, either. The main reason for not prescribing LMWH prophylaxis was bleeding risk, but in 17% of cases physicians did not consider that the patient really had a high VTE risk. No significant correlation was found between any of the clinical variables analyzed and the risk of VTE. Prophylaxis use was more frequent among patients with solid cancer (vs hematologic), advanced stage, active chemotherapy treatment and longer hospital stay.

Summary/Conclusions: The new e-alert system further increases the use of VTE prophylaxis in hospitalised cancer patients, although this was not associated with a reduction in the VTE incidence. A relevant number of VTE events occur despite prophylaxis with standard LMWH. Identification of risk factors for thromboprophylaxis failure is needed.

This work has been funded by a biomedical research grant with the Laboratory of Pharmaceutical ROVI and an aid to the research projects of the Instituto de Salud Carlos III and the FEDER (PI13 / 01029).

S445

IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1 GENE DEFECT CAUSING ANTIITHROMBIN DEFICIENCY HARDLY DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF EXON 6

M.E. De La Morena-Barrio1, B. de la Morena-Barrio1, J. Padilla1, R. Teruel1,2, S. Asenjo3, E. Wypasek4, A. Miñano1, V. Vicente1,2, J. Corral1,2

1Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, 2Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Murcia, 3Servicio de Hematología, Hospital Clínico San Carlos, Madrid, Spain, 4The John Paul II Hospital, Krakow, Poland; Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

Background: Antithrombin (AT) deficiency was the first thrombophilia described 50 years ago and so far the strongest one. Up to 78% of cases are explained by point mutations or small deletion/insertions in exons or flanking regions of SERPINC1 that are easily detected by sequencing analysis. A low proportion of cases (2%) is explained by gross gene defects, mainly deletions, which are detected by multiplex ligation-dependent probe amplification (MLPA) analysis. However, the molecular base of AT deficiency is unknown using current methods in 20% of cases.

Aims: To identify new SERPINC1 defects causing AT deficiency.

Methods: We studied 271 unrelated cases with AT deficiency. Functional and biochemical assays characterized plasma AT. Genetic analyses involved Sanger and Next Generation Sequencing (NGS) (PGM, Ion Torrent), MLPA and specific PCR designs.

Results: Sanger sequencing of PCR amplicons with primers flanking the 7 exons and further analysis with SeqscapeTM detected pathogenic mutations in 173 cases. Whole gene sequencing identified 5 mutations in regulatory regions. MLPA analysis revealed 5 cases with whole or partial deletion of the gene. Moreover, 13 cases had disorders of glycosylation. Interestingly, the analysis of the PCR product and the electropherogram of exon 6 of a 42 year-old male patient (P1) with deep venous thrombosis and 75% of anti-FXa activity

haematologica | 2017; 102(s2) | 161
with no apparent gene defect by either Sanger sequencing of 7 exons or by NGS analysis of the whole gene using the Ion Torrent platform, revealed a 193 bp insertion, which corresponded to a tandem duplication involving exon 6. Family studies revealed the same duplication in 5 relatives, all with AT deficiency (60-75%). The first MLPA analysis of this case failed to detect the duplication and only after a fine readjustment, it was detected. MLPA analysis under the new conditions of the remaining 59 cases with unknown molecular base for their AT deficiency identified one additional case, P2, with potential duplication of exon 6. P2 was a 17-year-old female with 41% of anti-FXa activity, who developed deep venous thrombosis. Sanger and NGS sequencing also failed to detect any genetic defect in P2. A set of primers specific to detect tandem duplications of exon 6 was designed with forward primer from 3’ end of exon 6, and reverse primer from 5’ of exon 6. This set of primers only rendered amplification in the two cases with exon 6 duplication. The second patient (P2) had a new 863 bp duplication in tandem of exon 6. Sanger sequencing of the specific amplicons in the two cases with tandem duplication of exon 6 revealed Alu sequences surrounding these duplications. Finally, one out of 5 cases with gene deletions involved breakpoints affecting intron 5 (deletion of exons 2-5).

**Summary/Conclusions:** Our study identified a new and relatively frequent SERPINC1 gene defect causing AT deficiency that is hardly identified by current molecular methods: duplication of exon 6. This genetic defect was detected in 1% of our cohort, and represents nearly half of the total gross gene defects causing AT deficiency. The small size of this exon makes difficult the identification of this defect by MLPA. The presence of 6 Alu elements up and downstream exon 6 makes this region a hotspot for unequal recombination that may cause deletions, tandem duplications and potentially transpositions, which may produce AT deficiency (both severe and mild) by an aberrant splicing. We also developed a simple and specific method to detect duplications in tandem of exon 6.

**Background:** The epitHELial lining of the gastrointestinal (GI) tract represents the first line of defense mediating protection from microbial challenge. Next to producing antimicrobial molecules, Paneth cells contribute to this defense by providing a supportive niche for intestinal stem cells (ISCs) maintaining the epithelium. Loss of intestinal barrier function by total body irradiation (TBI) or chemotherapy (CTx) is an essential step in enhancing the development of intestinal graft-versus-host disease (GVHD). We hypothesized that activation of these pathways can initiate epithelial repair, we hypothesized that activation of these pathways during conditioning therapy may protect epithelial integrity and could be exploit ed interventionaly to promote intestinal barrier function and prevent GVHD.

**Aims:** We aimed at characterizing the role of RIG-I/MAVS and STING during allo-HSCT, and at understanding mechanisms by which activation of these pathways can promote barrier function to enhance healing after genotoxic tissue damage.

**Methods:** We used an integrated approach with pathophysiologic mechanistic studies on IECs in experimental mouse models (MHC-mismatched and minor histocompatibility antigen (miHA)-mismatched transplants to model highly aggressive GVHD; genotoxic stress induced by TBI and CTx) and evaluation of immune-mediated regenerative strategies to promote epithelial barrier function (organoid cultures, barrier function test)

**Results:** Mice lacking MAVS were more sensitive to total body irradiation (TBI)- and chemotherapy induced intestinal barrier damage, and, like RIG-I-deficient mice, developed worse graft transplantation (allo-HSCT). This phenotype was not associated with changes in the intestinal microbiota, but with reduced epithelial integrity and regeneration. Conversely, targeted activation of the RIG-I pathway during damage promoted these processes and ameliorated GVHD. Mechanistically, IFN-I (RIG-I-induced or recombinant) could promote growth of intestinal organoid cultures and production of RegIIIγ. Importantly, our findings were not confined to RIG-I/MAVS signaling, as interventional engagement of the STING pathway also protected from loss of barrier function and GVHD and led to IFN-I-dependent intestinal organoid growth. Consistent with this, STING-deficient animals suffered from worse GVHD.

**Summary/Conclusions:** Our studies may have the potential to develop novel targeted therapies (i) to promote intestinal barrier integrity, (ii) to prevent the development of GVHD, and (iii) for the regenerative response of other tissues.
T cells were isolated, again with different tissue specificities. In addition, also 11 HLA-DPB1*03:01 reactive cells could be isolated which all recognized biliary epithelial cells with or without co-stimulation. From patient 4, 26 HLA-DPB1*01:01 reactive T cells recognized only hematopoietic target cells, whereas other clones again showed recognition of GVHD target cells with differences in tissue specificity. 32 HLA-DPB1*04:01 reactive T cells were found in all 4 patients. A total of 33 HLA-DPB1*04:01 reactive T cells were isolated from patient 1 who suffered GVHD of skin and colon, but not liver. Within these 33 clones, 3 clones recognized only hematopoietic target cells, 9 clones recognized hematopoietic, skin and colon derived target cells and 5 clones recognized hematopoietic and colon derived cells only. None of the T cell clones recognized biliary epithelial cells. From patient 2 total of 230 HLA-DPB1*03:01 reactive CD4 T cell clones were isolated, of which 27 recognized only hematopoietic target cells and 96 clones also recognized GVHD target cells with differences in tissue specificity. 32 HLA-DPB1*03:01 reactive T cell clones were found from patient 3, of which 6 recognized only hematopoietic target cells, whereas other clones again showed various tissue specificities. From patient 4, 26 HLA-DPB1*01:01 reactive T cells could be isolated which all recognized biliary epithelial cells with or without co-recognition of other target cells. In addition, also 11 HLA-DPB1*03:01 reactive T cells were isolated, again with different tissue specificities.

Summary/Conclusions: These results illustrate that donor CD4 T cells directed against mismatched HLA-DR show differential recognition of target cells including restriction-specificity for cells of hematopoietic origin. Donor CD4 T cells recognizing hematopoietic target antigens in the context of patient specific HLA-DR alleles can be used to mediate tumor specific immune responses after HLA 10/10 matched unrelated stem cell transplantation.

S448

MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS

Aims: To investigate if IL-C3s can contribute to the therapeutic effect of MSCs, we studied the interaction between MSCs and IL-C3s in vitro.

Methods: IL-C3s isolated from human tonsils were CellTrace-labeled and cultured with bone-marrow derived MSCs for 5 days in the presence of IL-2. Results: Co-culture with MSCs significantly enhanced the proliferation of IL-C3s and their IL-22 production. Reciprocally, IL-C3s promoted ICAM-1 and VCAM-1 expression on MSCs. These experiments revealed that the interaction is mainly dependent on cell-cell contact or close proximity of MSCs and IL-C3s. Addition of blocking antibodies against ICAM-1, VCAM-1, or their integrin ligands, did not affect IL-C3 proliferation, suggesting that IL-C3 stimulation is ICAM/VCAM independent. Soluble factors also contributed to the interaction, as IL-C3s proliferated slightly better in the presence of MSC culture supernatant compared to IL-2 only. Based on experiments with blocking antibodies, we found IL-7 to be the likely candidate for this effect.

Summary/Conclusions: We show that via cell-cell contact and IL-7, MSCs promote the proliferation and IL-22 production by IL-C3s in vitro, suggesting IL-C3s may play a role in the control of GVHD upon MSC therapy.

S449

ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVIRONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Aims: To compare the T cell subsets in the BM immune microenvironment, including Th17, Tc17, Th1, Tc1, Th2, Tc2 cells and regulatory T cells (Tregs), are involved in the pathogenesis of PGF remains to be explored.

Methods: This prospective nested case-control study enrolled 20 patients with poor graft function (PGF) after allo-HSCT, and 20 healthy donors (HD). Th17, Th1, Th1, Th2, Tc2 cells and regulatory T cells (Tregs), were involved in the pathogenesis of PGF remains to be explored.

Background: Poor graft function (PGF) remains a life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the underlying mechanisms have yet to be elucidated. Considerable evidence from murine studies has demonstrated that effective hematopoiesis depends on the specific bone marrow (BM) microenvironment, where hematopoietic stem cells reside. In this regard, we previously reported that PGF patients had impaired BM endothelial and vascular microenvironment (BBMT 2013; BMT 2016; Oncotarget 2016; Blood 2016). Moreover, our pilot study showed that both CD4+ and CD8+ T cells were polarized towards a type 1 immune response in the BM microenvironment of PGF patients (N=10) compared to those in matched good graft function (GGF) patients (N=20) (BBMT 2016). Nevertheless, whether abnormalities of T cell subsets in the BM immune microenvironment, including Th17, Th1, Th2, Tc17, Tc2 cells and regulatory T cells (Tregs), are involved in the pathogenesis of PGF remains to be explored.

Summary/Conclusions: These results illustrate that donor CD4 T cells directed against mismatched HLA-DR show differential recognition of target cells including restriction-specificity for cells of hematopoietic origin. Donor CD4 T cells recognizing hematopoietic target antigens in the context of patient specific HLA-DR alleles can be used to mediate tumor specific immune responses after HLA 10/10 matched unrelated stem cell transplantation.

S450

HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Aims: To investigate if IL-C3s can contribute to the therapeutic effect of MSCs, we studied the interaction between MSCs and IL-C3s in vitro.

Methods: In a randomized clinical trial we treat patients 3 months after T cell depleted alloSC from HLA 10/10 matched, HLA-DR mismatched, donors with 0.25-0.50 x 10^9/kg donor CD4 T cells to promote immune reconstitution. In 4 patients, Graft-versus-Leukemia reactivity and/or organ specific GVHD occurred after the infusion. To characterize the immune responses in these patients, in vivo activated T cells were clonally isolated and tested for reactivity against a panel of target cells, including patient and donor derived hematopoietic cells, third party hematopoietic cells as well as different GVHD target cells (patient skin fibroblasts, third party colon carcinoma cells, biliary epithelial cells and lung fibroblasts) expressing the mismatched, patient variant, HLA-DR molecule.

Results: Allo-HLA-DR directed CD4 T cells showing differential recognition of target cells were found in all 4 patients. A total of 33 HLA-DPB1*04:01 reactive CD4 T cell clones were isolated from patient 1 who suffered GVHD of skin and colon, but not liver. Within these 33 clones, 3 clones recognized only hematopoietic target cells, 9 clones recognized hematopoietic, skin and colon derived target cells and 5 clones recognized hematopoietic and colon derived cells only. None of the T cell clones recognized biliary epithelial cells. From patient 2 total of 230 HLA-DPB1*03:01 reactive CD4 T cell clones were isolated, of which 27 recognized only hematopoietic target cells and 96 clones also recognized GVHD target cells with differences in tissue specificity. 32 HLA-DPB1*03:01 reactive T cell clones were found from patient 3, of which 6 recognized only hematopoietic target cells, whereas other clones again showed various tissue specificities. From patient 4, 26 HLA-DPB1*01:01 reactive T cells could be isolated which all recognized biliary epithelial cells with or without co-recognition of other target cells. In addition, also 11 HLA-DPB1*03:01 reactive T cells were isolated, again with different tissue specificities.

Summary/Conclusions: These results illustrate that donor CD4 T cells directed against mismatched HLA-DR show differential recognition of target cells including restriction-specificity for cells of hematopoietic origin. Donor CD4 T cells recognizing hematopoietic target antigens in the context of patient specific HLA-DR alleles can be used to mediate tumor specific immune responses after HLA 10/10 matched unrelated stem cell transplantation.
Sickle cell disease, enzymes

S451

EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY


1Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Boston, United States, 2Allergy / Immunology, UTH ealth McGovern Medical School, Houston, 3Division of Pediatrics, Dana-Farber Cancer Institute, Boston, United States

Background: Pyruvate kinase (PK) deficiency is a congenital hemolytic anemia caused by deficiency of the glycolytic enzyme, red cell PK (PK-R). AG-348 is a novel, first-in-class PK-R activator under clinical development. This study presents preliminary results from the ongoing DRIVE PK study (NCT02476916), an open-label dose-ranging trial of AG-348 in transfusion-independent adults with PK deficiency.

Methods: After providing informed consent, patients were randomized to AG-348 50mg or 300mg orally twice daily (BID) for 6 months (Core Period). At the end of the Core Period, patients can continue on treatment for another 2 years in the Extension Period. Transfusion independence is defined as ≤3 units of red blood cells transfused in the 12 months preceding the first dose of AG-348 and no transfusions in the 4 months preceding the first dose. Patients are followed weekly for Weeks 1-3, every 3 weeks for Weeks 4-12, monthly for Weeks 13-24 and then every 3 months until the end of the study. Hormone and iron status are evaluated at Baseline, Week 12 and End of Core Period, and then every 6 months in the Extension Period.

Results: As of 18 Jan 2017, goal enrolment has been met and all 52 patients are evaluable for safety and efficacy; 24 have completed the Core Period and 23 are ongoing in the Core Period. Five patients discontinued from the Core Period, owing to adverse events (AEs) (n=2) or consent withdrawal (n=3). Of the 32 patients evaluable for efficacy at 23 Sep 2016, 15 (47%) had a maximal increase in hemoglobin (Hb) >1 g/dL. Hb responses were seen across a range of four doses, and were rapid and sustained. For a subset of patients (n=8), the rate of glycolytic metabolism in peripheral blood samples was assessed before and after treatment, and a positive correlation was observed between increases in glycolytic flux through the PK-R pathway and increases in Hb.

Summary/Conclusions: AG-348 is a novel, first-in-class PK-R activator undergoing clinical testing in patients with PK deficiency. The ongoing DRIVE PK study has now met goal enrolment of 52 patients, and data from these patients will be available at the time of presentation. Chronic daily dosing with AG-348 is well tolerated and has demonstrated clinically relevant, durable increases in Hb across a range of doses from <25mg BID to 300mg BID. These data highlight the potential of AG-348 to be the first disease-altering treatment for patients with PK deficiency.
Aims: The aim of this study was to make a worldwide inventory of all cases of PKD that have been treated by HSCT, and to evaluate indication, procedures employed, and outcome. Methods: This is an international case series. Queries were sent to national and international databanks and to physicians involved in HSCT on PKD patients. The latter were asked to complete a questionnaire on disease characteristics, pre-transplant condition, transplant regimen and post-transplant outcome. Two additional cases were reported from a recently published report (Kim. 2016. Bone Marrow Transplantation).

Results: From 1996 to 2016 a total of 16 PKD-patients were reported to have been treated by stem cell transplantation. Eight patients were treated in the EU and eight in Asian centres, respectively. No patient resulted to be transplanted in the US. Median age at transplantation was 6.5 years. (10 patients (62.5%) were <10 years; 6 (37.5%) >10 years), seven patients (43.8%) were splenectomized. Nine out of ten patients (90%) younger than ten years old survived transplantation, whereas two out of six (33.3%) patients older than ten survived. Patients younger than ten years old were less often splenectomized (p=0.001). All Asian patients (8/8) survived transplantation, whereas three out of eight European patients survived. Patients treated in Asian hospitals differed from European patients in that they were younger (p=0.001), less often splenectomized (p=0.041) and had a lower ferritin level (p=0.048). They were more often transplanted with peripheral blood stem cells (p=0.014) and more often conditioned on a cyclophosphamide (p=0.007) regimen.

Summary/Conclusions: This is the first study on outcome of HSCT in PKD patients. Due to the still relatively small number of cases no definite conclusions on the safety of HSCT in PKD can be drawn. However, we observed a better survival for patients transplanted before the age of ten. This difference could also explain difference in survival between patients transplanted in Europe versus Asia. The high rate of severe GVHD in this cohort is a reason for concern. The strong decline in survival of patients older than ten years of age indicates the need for very careful selection of HSCT-candidates.

Background: Pyruvate kinase deficiency (PKD) is the most common glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia. PKD does not have a specific curative treatment. Therefore treatment is mainly supportive, consisting of regular red blood cell transfusions, splenectomy and chelation therapy for iron overload: phlebotomy (14) and/or Deferasirox (6) and/or Deferoxamine (6) and/or iron infusion. Hyperferritinemia and/or a chelation therapy were noticed for 26 patients among all cases. 71 patients (69%) were already followed for unexplained hemolysis. Results: Clinical features: Most of HX diagnosis was made in adults (median age 31.5 years, range 0-88), children less than 10 years representing only 21% of all cases. 71 patients (69%) were already followed for unexplained hemolysis. Haematologica | 2017; 102(s2) | 165

Results: This is the first study on outcome of HSCT in PKD patients. Due to the still relatively small number of cases no definite conclusions on the safety of HSCT in PKD can be drawn. However, we observed a better survival for patients transplanted before the age of ten. This difference could also explain difference in survival between patients transplanted in Europe versus Asia. The high rate of severe GVHD in this cohort is a reason for concern. The strong decline in survival of patients older than ten years of age indicates the need for very careful selection of HSCT-candidates.

Background: Dehydrated hereditary stomatocytosis, also called hereditary xerocytosis (HX), is a dominant non-spherocytic hereditary hemolytic anemia characterized by an increased leak of monovalent cations through the red cell membrane leading to dehydration and a shortened red cell survival. HX is difficult to diagnose because of its rarity and the heterogeneity in its clinical presentation. Aims: Our study aims to characterize the clinical and biological features at HX diagnosis in a retrospective series of 103 patients. Methods: HX diagnosis was based on the typical left-shifted curve of osmolar gradient ektacytometry performed at CHU Biérot from 1993 to 2016. All patients were from European origin. They were referred to our center for: chronic non-spherocytic hemolysis (30), thrombotic events after splenectomy (8), hyperferritinemia (15), hematologic investigations (3), and/or iron overload (1). Ten patients (9.7%) presented with thrombotic episodes in a family study (54) after diagnosis in a first-degree probands. PIEZ02 and KCNN4 were analyzed by Sanger sequencing of the exons and intron-exon junctions.

Results: Clinical features: Most of HX diagnosis was made in adults (median age 31.5 years, range 0-88), children less than 10 years representing only 21% of all cases. 71 patients (69%) were already followed for unexplained hemolysis. Haematologica | 2017; 102(s2) | 165

Background: Dehydrated hereditary stomatocytosis, also called hereditary xerocytosis (HX), is a dominant non-spherocytic hereditary hemolytic anemia characterized by an increased leak of monovalent cations through the red cell membrane leading to dehydration and a shortened red cell survival. HX is difficult to diagnose because of its rarity and the heterogeneity in its clinical presentation. Aims: Our study aims to characterize the clinical and biological features at HX diagnosis in a retrospective series of 103 patients. Methods: HX diagnosis was based on the typical left-shifted curve of osmolar gradient ektacytometry performed at CHU Biérot from 1993 to 2016. All patients were from European origin. They were referred to our center for: chronic non-spherocytic hemolysis (30), thrombotic events after splenectomy (8), hyperferritinemia (15), hematologic investigations (3), and/or iron overload (1). Ten patients (9.7%) presented with thrombotic episodes in a family study (54) after diagnosis in a first-degree probands. PIEZ02 and KCNN4 were analyzed by Sanger sequencing of the exons and intron-exon junctions.

Results: Clinical features: Most of HX diagnosis was made in adults (median age 31.5 years, range 0-88), children less than 10 years representing only 21% of all cases. 71 patients (69%) were already followed for unexplained hemolysis. Haematologica | 2017; 102(s2) | 165

Results: Clinical features: Most of HX diagnosis was made in adults (median age 31.5 years, range 0-88), children less than 10 years representing only 21% of all cases. 71 patients (69%) were already followed for unexplained hemolysis. Hyperferritinemia and/or a chelation therapy were noticed for 26 patients among the 55 for which this data was available (47%). 19 patients were treated for iron overload: phlebotomy (14) and/or Deferasirox (6) and/or Deferoxamine (6) and/or Deferrirone (1). A perinatal edema history was noted in 17 (16.5%) patients. A history of thrombosis was noted in 15 (14.6%) patients, corresponding to a total number of 17 thrombotic events including post-embolic pulmonary hypertension (2), arterial events (3), pulmonary embolism (4), portal thrombosis (4), splenic infarcts (2) and deep venous throm-
Sickle Cell Center, Medical College of Georgia, Augusta University, Augusta, This and was well tolerated in the 52-week SUSTAIN study (Ataga KI et al. N Engl J Med 2017:376:429-439).

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.

Table 1.

<table>
<thead>
<tr>
<th>SCPC event-free patients by prior SCPC events, genotype and HU use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizanlizumab 5.0mg/kg</strong></td>
</tr>
</tbody>
</table>
| Genotype | HbSS | HbSp–thalassaemia, and HbSβ+–thalassaemia (n=12/66; 18.2%) groups. In each of the prior SCPC events, SCD genotype and HU use subgroups, a greater proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo 2.5mg/kg or placebo arms (Table 1). In subpopulations considered to be at increased risk of experiencing a SCPC (patients with 5-10 SCPC events in the previous year and/or with the homozygous HbSS genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo arm (28.0% vs 4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-free during the study, compared with 17.5% in the placebo arm, possibly suggesting an additive effect.

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.

Table 1.

<table>
<thead>
<tr>
<th>SCPC event-free patients by prior SCPC events, genotype and HU use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizanlizumab 5.0mg/kg</strong></td>
</tr>
</tbody>
</table>
| Genotype | HbSS | HbSp–thalassaemia, and HbSβ+–thalassaemia (n=12/66; 18.2%) groups. In each of the prior SCPC events, SCD genotype and HU use subgroups, a greater proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo 2.5mg/kg or placebo arms (Table 1). In subpopulations considered to be at increased risk of experiencing a SCPC (patients with 5-10 SCPC events in the previous year and/or with the homozygous HbSS genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo arm (28.0% vs 4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-free during the study, compared with 17.5% in the placebo arm, possibly suggesting an additive effect.

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.

Table 1.

<table>
<thead>
<tr>
<th>SCPC event-free patients by prior SCPC events, genotype and HU use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizanlizumab 5.0mg/kg</strong></td>
</tr>
</tbody>
</table>
| Genotype | HbSS | HbSp–thalassaemia, and HbSβ+–thalassaemia (n=12/66; 18.2%) groups. In each of the prior SCPC events, SCD genotype and HU use subgroups, a greater proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo 2.5mg/kg or placebo arms (Table 1). In subpopulations considered to be at increased risk of experiencing a SCPC (patients with 5-10 SCPC events in the previous year and/or with the homozygous HbSS genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo arm (28.0% vs 4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-free during the study, compared with 17.5% in the placebo arm, possibly suggesting an additive effect.

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.

Table 1.

<table>
<thead>
<tr>
<th>SCPC event-free patients by prior SCPC events, genotype and HU use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizanlizumab 5.0mg/kg</strong></td>
</tr>
</tbody>
</table>
| Genotype | HbSS | HbSp–thalassaemia, and HbSβ+–thalassaemia (n=12/66; 18.2%) groups. In each of the prior SCPC events, SCD genotype and HU use subgroups, a greater proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo 2.5mg/kg or placebo arms (Table 1). In subpopulations considered to be at increased risk of experiencing a SCPC (patients with 5-10 SCPC events in the previous year and/or with the homozygous HbSS genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo arm (28.0% vs 4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-free during the study, compared with 17.5% in the placebo arm, possibly suggesting an additive effect.

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.

Table 1.

<table>
<thead>
<tr>
<th>SCPC event-free patients by prior SCPC events, genotype and HU use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizanlizumab 5.0mg/kg</strong></td>
</tr>
</tbody>
</table>
| Genotype | HbSS | HbSp–thalassaemia, and HbSβ+–thalassaemia (n=12/66; 18.2%) groups. In each of the prior SCPC events, SCD genotype and HU use subgroups, a greater proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo 2.5mg/kg or placebo arms (Table 1). In subpopulations considered to be at increased risk of experiencing a SCPC (patients with 5-10 SCPC events in the previous year and/or with the homozygous HbSS genotype), a higher proportion of patients treated with crizanlizumab 5.0mg/kg were SCPC event-free compared with those in the placebo arm (28.0% vs 4.2% and 31.9% vs 17.0%, respectively). Additionally, 33.3% of patients who were taking HU and treated with crizanlizumab 5.0mg/kg were SCPC event-free during the study, compared with 17.5% in the placebo arm, possibly suggesting an additive effect.

Summary/Conclusions: Treatment with crizanlizumab 5.0mg/kg appears to increase the likelihood of adult patients with SCD being SCPC event-free while on treatment, even in high-risk subpopulations. Crizanlizumab 5.0mg/kg was also effective in those who had experienced at least two SCPCs in the previous year despite taking HU, suggesting that this dose is effective as a disease-modifying agent that meets an unmet medical need.
mine whether ex vivo Hpx addition to human SCD sera would prevent NET formation.

Methods: Patient serum and plasma samples were obtained from 32 incidents of VOC in 24 adult SCD patients, with informed consent. Moreover, steady state samples were obtained at least 4 weeks after discharge from the hospital. Patients having had a blood transfusion in the 3 months prior to admission were excluded. NET formation by human neutrophils from healthy donors was studied using confocal fluorescence microscopy and staining for extracellular DNA with the cell nonpermeable dye Sytox Green. The presence of extracellular DNA that stains positive for citrullinated histone H3 confirmed the formation of NETs (Figure 1A).

Results: Indeed, we found that hemin (ferriprotoporphyrin IX) activated neutrophils to generate reactive oxygen species and release NETs, which was prevented by addition of plasma-derived Hpx. Moreover, exposure of neutrophils to sera from patients with SCD promoted NET formation, which was significantly enhanced during VOC. However, we observed that circulating free heme levels were elevated in SCD patient serum irrespective of disease state, and serum concentrations of Hpx were reduced in both VOC and steady state compared to healthy donor serum. Strikingly, addition of Hpx in supraphysiological concentrations failed to prevent the formation of NETs in all SCD sera tested. We and others (Chen et al. Blood 2014) have found that, in contrast to heme, protoporphyrin IX does not trigger NET formation, revealing that the iron atom is required for the release of NETs. This observation led us to investigate whether free iron may directly induce NET formation. When neutrophils were exposed to Fe-NTA or serum from a thalassemia patient with iron overload, NETs were formed. Scavenging of free iron by addition of the iron-chelator deferoxamine or the specific iron-binding protein apotransferrin prevented NET release (Figure 1B). Moreover, we found that sequestration of free iron prevented NET formation induced by a subset (6 out of 11 tested), but not all, sera of patients with VOC (Figure 1C and D). In addition, sickled red blood cells (RBCs) are known to bind to neutrophils in vitro. Here, we found that neutrophils released NETs in response to sickled RBCs, even in the presence of Hpx. By contrast, blocking of complement C5 activation completely prevented the formation of NETs when neutrophils were exposed to sickled RBCs (Figure 1E).

Summary/Conclusions: In summary, we observed that sequestration of free iron with these iron binding compounds may be explored therapeutically to prevent or treat VOC development in SCD. Finally, complement activation in the presence of sickled RBCs activates neutrophils to release NETs, which may also contribute to VOC and SCD pathogenesis. Therefore, anti-CS IgG may represent an alternative therapeutic strategy to prevent VOC in SCD.

New drugs for rescue in relapsed/refractory multiple myeloma

S456 PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA


1Institut d’Investigació Biomèdica de Barcelona-IDIBELL, Bellvitge University, L’Hospitalet de Llobregat and Gregorio Marañon University Hospital, Madrid, Spain, 2M. D. Anderson Cancer Center, Texas, United States, 3Department of Medicine, Mayo Clinic, Rochester, United States, 4Institute of Hematology and Immunology, Charles University, Prague, Czech Republic, 5Department of Hematology, University Hospitals of Liège, Liège, Belgium, 6Department of Hematology, Aarhus University Hospital, Aarhus, Denmark, 7Department of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 8Department of Hematology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States, 9Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States, 10Department of Medicine, Charles University, Faculty of Medicine in Prague and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 21Winship Cancer Institute, Emory University, Atlanta, United States, 3Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Canada, 4University Hospital Nantes, France, 5University Hospital of Salamanca—Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain, 6Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain, 7Daan-Farber Cancer Institute, Boston, United States, 8Institute of Haematology, Assuta Medical Centers, Tel Aviv, Israel, 9Medical University of Silesia, Katowice, Poland, 10Charles University in Prague and General Teaching Hospital, Prague, Czech Republic, 11Medical University of Lublin, Lublin, Poland, 12Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, 13CROSS Cancer Institute and University of Alberta, Edmonton, Canada, 14Princess Margaret Hospital, Toronto, Canada, 15Ankara University, Ankara, Turkey, 16Bristol-Myers Squibb, Lawrenceville, 17AbbVie Biore- apapeutics Inc. (ABR), Redwood City, United States, 18University of Tübingen, Tübingen, Germany

Background: Elotuzumab is an immunostimulatory monoclonal antibody that targets SLAMF7, a glycoprotein highly expressed on multiple myeloma (MM) cells and natural killer cells. Elotuzumab exerts a dual effect, directly activating natural killer cells and mediating MM cell death via antibody-dependent cell-mediated cytotoxicity. In a 3-year follow-up of ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ELd) demonstrated a sustained 27% reduction in the risk of disease progression/death and an overall survival (OS) trend towards benefit compared with lenalidomide/dexamethasone (Ld) alone in patients with relapsed/refractory (RR) MM (Dimopoulos et al, ASH 2015).

Aims: To evaluate the long-term efficacy and safety of ELd following extended 4-year follow-up (median 46 months).

Methods: RRMM patients with 1-3 prior lines of therapy randomized 1:1 received ELd or Ld in 28-day cycles until disease progression/unacceptable toxicity or consent withdrawal. Co-primary endpoints were progression-free survival (PFS) and overall response rate (ORR); OS was a secondary endpoint (analysis not prespecified for this data cut) and safety an exploratory endpoint. Written informed consent was obtained for all patients.

Results: In total, 464 RRMM patients were randomized: 321 to ELd and 325 to Ld. At 4-year follow-up (data cut-off: Oct 18, 2016), nearly twice as many patients remained on ELd therapy vs Ld (17% vs 9%). With the extended follow-up, ELd demonstrated a sustained relative improvement of 50% in PFS rates vs Ld (21% vs 14%) and maintained reduction in the risk of progression/death of 29% for ELd vs Ld (all randomized patients: HR 0.71; 95% CI 0.59, 0.86). Patients with very good partial response (VGPR) (ELd 14% vs Ld 9% [29%]) had the greatest reduction (35%) in risk of progression/death (HR 0.65; 95% CI 0.46, 0.94). ORR was greater with ELd (79% vs 66%) and the duration of response benefit was maintained over time (HR 0.77; 95% CI 0.62, 0.95). Early separation of the Kaplan–Meier survival curves, which remained consistently separated over time, supports a sustained OS benefit in favor of ELd vs Ld (Figure). Grade 3-4 adverse events in >5% of patients were generally comparable between ELd and Ld arms—vascular diseases (10% vs 8%; mostly venous-related), second primary malignancies (SPMs; 9% vs 6%) and cardiac disorders (5% vs 8%); the exception was a
S457
A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PLANNED SECOND INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF ENDEAVOR

Summary/Conclusions: At 4 years, ELd has the longest median follow-up of an immune-oncology agent in MM. The data continue to show that adding elotuzumab to Ld results in durable long-term responses, clinically relevant improvement in PFS, sustained reduction in risk of progression/death, and a survival trend in favor of ELd. Overall, these data continue to support the durability of ELd. Updated safety and tolerability, including rate of SPMs, was consistent with previous findings despite longer exposure, with minimal incremental AEs compared with Ld therapy.

Background: Isatuximab (ISA) is a anti-CD38 monoclonal antibody, which kills tumor cells via multiple mechanisms. Here, we report preliminary data from the dose-escalation cohorts, and the first 3 patients (pts) of the expansion cohort, of a Phase 1b study of ISA plus Pom/Dex in pts with RRMM (NCCT02283775).

Aims: To evaluate combination therapy with ISA plus Pom/Dex in pts with RRMM.

Methods: Pts with RRMM (≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor) were sequentially enrolled to ISA 5, 10, or 20mg/kg (4-weekly doses, then every 2 weeks until disease progression or intolerable toxicity) with Pom 4mg (Days 1–21) and Dex 40mg (Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles). An expansion cohort was initiated at ISA 10mg/kg (plus Pom/Dex) based on preliminary safety, efficacy, and PK data. Primary objective: Determine maximum tolerated dose (MTD). All patients were required to provide informed consent.

Results: 26 pts were analyzed (5mg/kg [n=8]; 10mg/kg [n=12]; 20mg/kg [n=6]). Median age 65 (42–80) yrs. Median 4.0 (2–11) prior treatment regimens, with 20 (77%) pts refractory to prior immunomodulatory drug therapy. At data cut-off (Nov 8, 2016), median duration of ISA therapy was 19.0 wks and 16 pts remained on treatment. 2 pts at 10mg/kg discontinued therapy due to adverse events (AEs) (grade [Gr] 5 perforated bowel; Gr 3 infusion-associated reaction [IAR]). Dose-limiting toxicities reported in 1 pt at each dose level (Gr 4 neutropenia; Gr 4 neutropenic infection; Gr 3 confusing state), and MTD has not been reached. Most common TEAEs, besides IARs, were fatigue (62%), diarrhea (23%), hypocalcemia (23%), and anemia (15%). Most frequent laboratory abnormalities (laboratory assessment) was neutropenia (Gr 3, 40%; Gr 4, 52%). Gr 3/4 thrombocytopenia was reported in 8 (32%) pts (Gr 3, 16%; Gr 4, 16%). IARs occurred in 12 (46%) pts (Gr ≥3 in 1 pt); only with 1st infusion in 9/12 pts (16 %) pts achieved at least PR (5, 8, and 3 pts at 5, 10, and 20mg/kg), including 1 CR, 8 VGPR, and 7 PR. Clinical benefit rate (mCR) was 73%. Median time to 1st response, 4.2 wks; median duration of response, 25.6wks. The PK parameters of ISA were not affected by co-administration with Pom/Dex.

Summary/Conclusions: The combination of ISA and Pom/Dex was manageable and clinically active in heavily pretreated RRMM. A Phase III trial of this combination therapy is planned.

S458
OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL

Summary/Conclusions: At 4 years, ELd has the longest median follow-up of an immune-oncology agent in MM. The data continue to show that adding elotuzumab to Ld results in durable long-term responses, clinically relevant improvement in PFS, sustained reduction in risk of progression/death, and a survival trend in favor of ELd. Overall, these data continue to support the durability of ELd. Updated safety and tolerability, including rate of SPMs, was consistent with previous findings despite longer exposure, with minimal incremental AEs compared with Ld therapy.

Background: Isatuximab (ISA) is a anti-CD38 monoclonal antibody, which kills tumor cells via multiple mechanisms. Here, we report preliminary data from the dose-escalation cohorts, and the first 3 patients (pts) of the expansion cohort, of a Phase 1b study of ISA plus Pom/Dex in pts with RRMM (NCCT02283775).

Aims: To evaluate combination therapy with ISA plus Pom/Dex in pts with RRMM.

Methods: Pts with RRMM (≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor) were sequentially enrolled to ISA 5, 10, or 20mg/kg (4-weekly doses, then every 2 weeks until disease progression or intolerable toxicity) with Pom 4mg (Days 1–21) and Dex 40mg (Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles). An expansion cohort was initiated at ISA 10mg/kg (plus Pom/Dex) based on preliminary safety, efficacy, and PK data. Primary objective: Determine maximum tolerated dose (MTD). All patients were required to provide informed consent.

Results: 26 pts were analyzed (5mg/kg [n=8]; 10mg/kg [n=12]; 20mg/kg [n=6]). Median age 65 (42–80) yrs. Median 4.0 (2–11) prior treatment regimens, with 20 (77%) pts refractory to prior immunomodulatory drug therapy. At data cut-off (Nov 8, 2016), median duration of ISA therapy was 19.0 wks and 16 pts remained on treatment. 2 pts at 10mg/kg discontinued therapy due to adverse events (AEs) (grade [Gr] 5 perforated bowel; Gr 3 infusion-associated reaction [IAR]). Dose-limiting toxicities reported in 1 pt at each dose level (Gr 4 neutropenia; Gr 4 neutropenic infection; Gr 3 confusing state), and MTD has not been reached. Most common TEAEs, besides IARs, were fatigue (62%), diarrhea (23%), hypocalcemia (23%), and anemia (15%). Most frequent laboratory abnormalities (laboratory assessment) was neutropenia (Gr 3, 40%; Gr 4, 52%). Gr 3/4 thrombocytopenia was reported in 8 (32%) pts (Gr 3, 16%; Gr 4, 16%). IARs occurred in 12 (46%) pts (Gr ≥3 in 1 pt); only with 1st infusion in 9/12 pts (16 %) pts achieved at least PR (5, 8, and 3 pts at 5, 10, and 20mg/kg), including 1 CR, 8 VGPR, and 7 PR. Clinical benefit rate (mCR) was 73%. Median time to 1st response, 4.2 wks; median duration of response, 25.6wks. The PK parameters of ISA were not affected by co-administration with Pom/Dex.

Summary/Conclusions: The combination of ISA and Pom/Dex was manageable and clinically active in heavily pretreated RRMM. A Phase III trial of this combination therapy is planned.
and 11: 20mg PO/IV dexamethasone on Days 1-2, 4-5, 8-9, and 11-12) with or without daratumumab (18mg/kg IV once weekly in Cycles 1-3, every 3 weeks for Cycles 4-8, then every 4 weeks until progression). Patients who were refractory to bortezomib were excluded. Progression-free survival (PFS) was the primary endpoint. Minimal residual disease (MRD) was assessed at suspected complete response (CR) and at 6 and 12 months after first dose at 3 sensitivity thresholds (10−3, 10−4, and 10−5) using the ClonoSEQ™ next-generation sequencing (NGS)-based assay (Adaptive Biotechnologies, Seattle, WA).

Results: A total of 498 patients were randomized with median (range) age of 64 (30-88) years. Patients received a median (range) of 2 (1-10) prior lines of therapy; 66% of patients previously received bortezomib, and 21% were refractory to lenalidomide in their last prior line of therapy. After median follow-up of 13.0 months, DVD significantly prolonged PFS compared with Vd alone (median: 7.9 months, DVD: 18.3%; P<0.0001). Overall response rate (ORR; 84% vs 63%) and rates of very good partial response (VGPR) or better (62% vs 29%) were higher with DVD compared with Vd (P<0.0001 for all). MRD-negative rates were more than 4 times higher at all 3 sensitivity thresholds with DVD versus Vd: 18.3% versus 3.6% at 10−6 (P<0.0001), 10.4% versus 2.4% at 10−5 (P<0.001), and 4.4% versus 0.8% at 10−4 (P<0.01). MRD-negative patients had prolonged PFS compared with MRD-positive patients at 10−4 sensitivity threshold (Figure). At the clinical cut-off date, 37 (15%) deaths in the DVD group and 58 (24%) in the Vd group have been observed (HR, 0.63; 95% CI, 0.42-0.96), and follow up is ongoing. Thrombocytopenia was the most common grade 3 or 4 treatment-emergent adverse event (45% with DVD vs 33% with Vd). No new safety signals were reported after median treatment duration of 11 months with daratumumab. Updated efficacy and safety data with longer follow up will be presented at the meeting.

Figure 1.

Summary/Conclusions: DVD is superior to Vd in terms of PFS, ORR, depth of response, and MRD-negative rates, with no new safety signals reported. These updated data further support the use of DVD as a standard of care in R/R MM, with the greatest benefit observed in patients with 1 prior line of therapy.

S460

A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA


1CHU de Nantes, Hotel Dieu–HME, Nantes, France, 2Mayo Clinic, Jacksonville, United States, 3Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, 4The University of Arizona Cancer Center, Tucson, United States, 5CHRU Lille, Hospital Huriez, Lille, France, 6Mayo Clinic, Rochester, 7AbbVie, Inc., North Chicago, United States, 8Peter MacCallum Cancer Centre, Melbourne, Australia

Background: Venetoclax (VEN) is a potent, selective, orally bioavailable small-molecular inhibitor of BCL-2. When combined, VEN can enhance the activity of bortezomib in multiple myeloma (MM) cell lines and xenograft models.

Aims: The objectives of the study are to evaluate safety and preliminary efficacy of VEN with bortezomib and dexamethasone in relapsed/refractory (RR) MM.

Methods: Phase 1b study of patients (pts) with R/R MM who received daily VEN (50-1200mg for dose escalation cohorts; 800mg in safety expansion) with standard bortezomib (1.3mg/m2 SC) and dexamethasone (20mg PO).

Results: As of 19Aug2016, 86 pts were enrolled. Median age was 64 years; 9 (14%) pts had t(11;14), 5 (8%) had t(4;14), 15 (23%) had del(17p), and 30 (45%) had del(13q) abnormalities. Median number of prior therapies was 3 (range: 1-13), with 39% of pts refractory to prior bortezomib, 14% to carfilzomib, 53% to lenalidomide, and 21% to pomalidomide. Median time on study was 5.9 months (range: 0.3-28.9). Forty-six (70%) pts discontinued, with 36 due to disease progression (PD). Common AEs in ≥30% of pts were diarrhea (46%), constipation (41%), thrombocytopenia (39%), nausea (38%), peripheral neuropathy (33%), and insomnia (32%). Common grade 3/4 AEs in ≥10% of pts were thrombocytopenia (29%), anemia (15%) and neutropenia (14%). Serious AEs in ≥2 pts were febrile neutropenia, thrombocytopenia, cardiac failure, pyrexia, influenza, lower respiratory tract infection, pneumonia, sepsis, acute kidney injury, respiratory failure, embolism, and hypotension. Dose-limiting toxicities were grade 3 cardiac failure in the 300mg cohort (possibly related to dexamethasone) and grade 3 thrombocytopenia during the first cycle in the safety expansion. No events of laboratory or clinical TLS were reported. Four deaths were due to PD and 1 due to respiratory syncytial virus infection. Overall response rate (ORR) for all pts was 67% (44/66); 28 (42%) pts achieved very good partial response (VGPR) or better (3 stringent complete response (sCR), 10 CR, 15 VGPR). Pts non-refractory to prior proteasome inhibitors (PI) or immunomodulatory drugs (IMiDs) had higher ORR than refractory pts (PI, 92% vs 32%; IMiDs, 82% vs 57%). Among pts refractory to any 2 or more (n=15), 3 or more (n=7), or all 4 (n=4) prior therapies (bortezomib, carfilzomib, lenalidomide, pomalidomide), ORR was 40%, 43%, and 25%, respectively. Median time to progression (~10 vs 3 months) and duration of response (~10 vs 7 months) were longer for pts not refractory to any of these therapies versus refractory pts. ORR for pts with or without cytogenetic abnormalities, respectively, was as follows: 78% vs 65% for t(11;14), 60% vs 67% for t(4;14), 47% vs 73% for del(17p), and 63% vs 69% for del(13q).

Summary/Conclusions: VEN combined with bortezomib and dexamethasone has an acceptable safety profile with promising anti-myeloma activity, and the highest response rates were observed in R/R MM pts who were not refractory to PI or IMiDs. These data support the ongoing phase 3 trial with this regimen in R/R MM.
Improving prognostication and front-line therapy in chronic lymphocytic leukemia

CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT: A RETROSPECTIVE STUDY ON BEHALF OF ERIC

Summary/Conclusions: CK defined by the presence of ≥3 numerical and/or structural abnormalities should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with ≥5 chromosomal aberrations emerges as prognostically adverse, independently of clinical stage, IG somatic hypermutation and TP53 status. Prospective clinical validation is warranted before finally incorporating high-CK in risk stratification in CLL.

IS FOR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS

Background: Chemoimmunotherapy (CIT) is the standard treatment for young and fit treatment-naïve patients with CLL. The median progression-free-survival (PFS) in patients treated with CIT is about 5-6 years and the overall survival (OS) is increased by 5-10% compared to those treated with chemotherapy only. Patients with mutated IGHV genes (M-CLL) and/or unfavorable cytogenetic alterations (i.e. del(17p)/TP53 mutation, and del(11q)) have a better outcome than those with unmutated IGHV genes (U-CLL) or poor FISH cytogenetics and show a plateau in survival curves, suggesting that a fraction of these patients may have a survival similar to general population. Nevertheless, the possibility that some M-CLL patients without unfavorable cytogenetics are overtreated is of concern because of the treatment toxicity related to CIT, particularly for frail patients.

Aims: The aim of this study was to analyse the outcome of M-CLL patients with no unfavorable cytogenetics according to the type of therapy.

Methods: We analysed 816 CLL patients from Sant Pau Hospital, Barcelona, Spain; Uppsala University Hospital, Sweden and IRCCS San Raffaele Scientific University, Milan, Italy for whom IGHV mutational status was available. Endpoints were OS and TFS.

Table 1.

Results: 488 patients had mutated IGHV genes (400 without unfavorable FISH cytogenetics; 26 had either del(11q) and/or del(17p), and in 62 cases FISH was not available) and 328 patients carried unmutated IGHV genes. The main clinical and biological characteristics at diagnosis are shown in Table 1. OS at 5 and 10 years was 93% (CI, 95-91) and 81% (CI, 85-77) for M-CLL cases and 78% (CI, 83-73) and 46% (CI, 52-38) for U-CLL cases (<0.05). TFS at 5 and 10 years was 78% (CI, 68-84) and 28% (CI, 33-23) and 10% (CI, 14-6) for M-CLL and U-CLL, respectively (<0.05). After a median follow-up of 8 years (range, 1-26), 424 patients [161 M-CLL (136 without poor-prognostic FISH cytogenetics, 13 with either del(11q) and/or del(17p) and 12 cases in whom FISH information was not available] and 263 U-CLL required therapy. Front-line treatments were administered by purine analogue (PA)-based therapy (n=83), alkylating agents (n=212), anti-CD20 moAbs with PA or bendamustine (n=75), anti-CD20 moAbs with alkylating agents (n=21), BCR-signal inhibitors or BCL2 antiprototipic agents (n=9), others (n=23), and unknown (n=1). The...
Table 1.

<table>
<thead>
<tr>
<th>ORR</th>
<th>N=18</th>
<th>Marrow MRD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18/18 (100)</td>
<td>14/14 (100)</td>
</tr>
<tr>
<td>CR/CR</td>
<td>7 (39)</td>
<td>5/7 (71)</td>
</tr>
<tr>
<td>PR</td>
<td>11 (61)</td>
<td>6/11 (54)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: IFCG achieves high rate of MRD-neg remission after 3 courses. Pt enrollment continues, and updated results will be presented at the EHA meeting.

S464

BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)

P. Cramer1,*, J. von Tresckow1, J. Bahlo1, S. Robbrecht1, O. Al Saawi1, P. Langerbeins1, A. Engelke1, A.-M. Fink1, K. Fischer1, T. Seiler1, L. Fischer von Weikersthal1, H. Hebart1, K.-A. Kreuzer3, M. Ritgen1, M. Kneba1, C.-M. Wendtner1, S. Stilgenbauer1, B. Eichorst1, M. Hallek1

1Department I of Internal Medicine and German CLL Study Group, University Hospital Cologne, Cologne, 2Department III of Internal Medicine, University Hospital Munich, Ludwig-Maximilians University, Campus Großhadern, Munich, 3Gesundheitszentrum St. Marien, Amberg, 4Staufferklinikum, Schwäbisch-Gmünd, 5Department of Internal Medicine, University Hospital Cologne, Cologne, 6Department II of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, 7Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, 8Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany

Background: Based on the theoretical “sequential triple-T” concept [Hallek M., Blood 2013; 122(23): 3723-34] of a tailored and targeted treatment aiming for total eradication of minimal residual disease (MRD), the GCLLSG designed the CLL2-BAG trial.

Aims: This prospective, open-label, multicenter phase-II trial investigates a sequential treatment with a B debulking, followed by G and A as induction and maintenance therapy in an all-comer population of physically fit and unfit, treatment-naïve (TN) and relapsed/refractory (R/R) CLL pts.

Methods: Pts with an absolute lymphocyte count (ALC) ≥25.000/µl and/or lymph nodes (LN) ≥5cm were to receive 2 cycles of B as debulking (70mg/m² d1 & d2 28 days), unless contraindicated. In the induction G (1000mg) was administered 3 times in cycle 1 (days 1/2, 8 & 15) and every 4 weeks in cycles 2-6. A was added in cycle 2 with a dose ramp-up (to 400mg daily) over 5 weeks and several safety precautions. In the maintenance therapy, daily intake of A was continued and G administered every 3 months until achievement of a MRD-negative complete response or for up to 24 months. The primary endpoint is the overall response rate (ORR) at the end of induction therapy; secondary endpoints include MRD evaluations, safety and survival parameters. This primary endpoint analysis is based on uncensored data, the final analysis will be presented at the meeting.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>Efficacy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CR/CR</td>
<td>7 (39)</td>
<td>5/7 (71)</td>
</tr>
<tr>
<td>PR</td>
<td>11 (61)</td>
<td>6/11 (54)</td>
</tr>
</tbody>
</table>

Results: Between May 2015 and January 2016, 66 pts were enrolled. Two R/R pts died of a sepsis and 1 TN pt discontinued due to toxicity during the first induction cycle; these 3 pts with <2 induction cycles were excluded from the analysis as predefined by protocol. 34 pts were treatment-naïve and 29 had R/R CLL (median number of prior therapies: 2, range: 1-8). Median age was 59 (28-77) years, the median CIRS score was 2 (0-14) and 16 pts (25%) had a creatinine clearance of 30-70ml/min. 11 of 59 pts (19%) had a del(17p) and 45 of 61 (74%) had an unmutated IGHV status. Risk categories for TLS at baseline were: low (ALC ≥25.000/µl & LN <5cm): 9 pts (15%), Intermediate (ALC ≥25.000/µl or LN 5-10cm): 35 (58%) and high (ALC ≥25.000/µl & LN >10cm): 16 (27%), 3 missing. 45 pts (71%) received B debulking, 18 (29%) pts immediately started with the induction. 60 pts completed 6 induction cycles with G and A. All TN (100%) and all but two of the R/R pts (93%) respond-
ed (table 1); with an ORR of 97%, at the end of induction, the primary endpoint was met. MRD negativity (<10−4) by flow cytometry in peripheral blood (PB) was achieved in 56 pts (89%); MRD assessment from bone marrow was available in 8 pts (4 TN and 4 R/R, among them 4 with a CR and 4 with a PR) and were all negative. As of January 9th, 2017, 38 serious adverse events (SAEs) were reported in 37 pts, including 69 SAEs (83%) related to study treatment. 66% of the SAEs (60%) were Grade 3-4 and 1 had a fatal adverse event (SAE, Grade 5). Most SAEs occurred in the R/R cohort (61 SAEs, 74%) and during the induction phase (63 SAEs, 76%). Most common SAEs were infections (27 in 16 pts; including 13 CTC°3-5) and hematological disorders (18 in 10 pts; CTC°3-4), followed by infusion-related reactions (6 in 6 pts), laboratory TLS (6 in 5 pts), diarrhea/colitis (4 in 4 pts), and transaminase elevation (9.8%). Serious adverse events were reported in 46 (45.1%), including pyrexia (10.8%), diarrhea/colitis (11.8%). AEs of special interest included serious adverse events as a result of therapy, however the frequency of Gr ≥3 ALT/AST was increased compared to the relapsed setting. There was no significant effect of age on the risk of ALT/AST elevations or diarrhea/colitis. The occurrence of CMV and PJP infections is consistent with current IDELA labeling and speaks to the benefit of potential risk mitigation through PJP prophylaxis and CMV monitoring during treatment. NCT02044822.

Aggressive Non-Hodgkin lymphoma - Relapsed/refractory

S466

CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXIATABEGENATE CILOLEUC (AXI-CEL: KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)


1In Lee Moffitt Cancer Center & Research Institute, Tampa. 2The University of Texas MD Anderson Cancer Center, Houston, Texas. 3Washington University, St. Louis. 4University of Miami, Miami. 5Stanford University, Stanford, 6Dana-Farber Cancer Institute, Boston. 7Montefiore Medical Center, Bronx, 8Vanderbilt University Medical Center, Nashville, 9City of Hope, Duarte, 10Mayo Clinic, Rochester, 11University of California at Los Angeles, Los Angeles, 12University of Rochester School of Medicine, Rochester, 13Kite Pharma, Santa Monica, United States

Background: Outcomes for pts with refractory aggressive NHL are poor with current therapies (Crump, ASCO 2016). Results from the interim analysis of (n=62) pts in ZUMA-1, a global, phase 2 study of CC-122 in combination with obinutuzumab (GA101) showed a manageable safety profile. 80% of pts entered the ZUMA-1 study with poor prognosis NHL. In pts with refractory aggressive NHL, the ORR was 89% in pts with refractory aggressive NHL and 68% in pts with refractory indolent NHL in ZUMA-1 (pregun). A phase 3 study of CC-122 in combination with obinutuzumab is ongoing. Here we present results from the primary analysis of the ZUMA-1 trial.

Aims: Here we present results from the primary analysis of the ZUMA-1 trial. Methods: Pts received a target dose of 2 × 106 anti-CD19 CAR T cells/kg after low-dose conditioning with cyclophosphamide and fludarabine. Eligible pts (218 y) with large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) or transformed follicular lymphoma (TFL); an ECOG performance status (PS) 0-1, and refractory disease (progressive or stable disease as best response to last prior therapy, or relapsed ≤12m of autologous stem cell transplant [ASCT]). The primary endpoint for this analysis was ORR in the combined DLBCL, PMBCL, and TFL cohort. Used PS was duration of response (DOR), overall survival (OS), and frequency of adverse events (AEs). The primary analysis was triggered when 92 pts had at least 6m of follow-up.

Results: As of January 27, 2017, 111 pts from 22 institutions were enrolled: 101 pts (91%) received axi-cel. Median age was 58 y (range, 23-76), 67% male, 85% stage III-IV, 47% PS 0-1, 77% refractory to ≥2nd line of therapy, and 21% relapsed <12m of ASCT. Axicel was successfully manufactured in 110/111 (99%) pts with an average turnaround time from apheresis to the clinic site of 17 d. With an ORR of 82% (n=92; P<0.0001) the study met the primary endpoint. The ORR in the mITT analysis set of 101 pts was 82% (CR 54%, PR 28%). was consistent across key covariates including disease subtype, refractory status, stage, and IPI score. At a median follow up of 8.7 m, 44% of pts were in response and 39% were in CR. The median DOR was 6.2m overall and not reached for pts who achieved a CR. Median OS was not reached; 80% of pts remained alive at 6 m. The most common Gr ≥3 treatment-emergent AEs were neutropenia (66%), leukopenia (44%), anemia (43%), febrile neutropenia (29%), diarrhea (27%), and encephalopathy (21%). Gr ≥3 cytokine release syndrome (CRS) and neurologic events (NE) occurred in 13% and 28% of pts, respectively. All CRS and NE resolved except for 1 gr1 memory impairment. As previously reported, there were 3 Gr 5 AEs (3%). Peak CAR T levels and AUC post-axi-CEL were associated with durable responses. Additionally, this pres-
Background: CC-122 is a cereblon modulating agent that degrades Aiolos and Ikaros, resulting in potent anti-lymphoma and immunomodulatory effects on T- and NK-cell function. Phase 1 clinical data revealed promising activity of CC-122 against follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Preclinical combination of CC-122 with obinutuzumab has shown synergism in FL and additive effects in DLBCL vs either single agent (Chiu, ASH 2015), supporting further study of this combination’s therapeutic potential.

Aims: The current phase Ib study (EUDRACT 2014-003333-26; NCT02417285) evaluates the safety and efficacy of CC-122 plus obinutuzumab in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).

Methods: Patients at study entry must have R/R CD20+ B-cell NHL after ≥1 prior regimens for FL/marginal zone lymphoma (M/ZL) and ≥2 regimens and/or ASCT for DLBCL. CC-122 was given orally (5 of 7 d) for 28-d cycles in escalating doses plus a fixed dose of intravenous obinutuzumab 1000mg on d2,8,15 of cycle (c1) and d1 of c2-c8, upon informed consent. CC-122 was continued until progressive disease (PD) or unacceptable toxicity. CC-122 active ingredient in capsule formulation (AIC) 1, 2, 3, and 4mg and CC-122 formulated capsules (F6) 3 and 4mg were evaluated in separate cohorts. Primary endpoints included safety and tolerability, non- tolerated dose (NTD), and maximum tolerated dose (MTD). Response was assessed using the international Cheson 2007 criteria every 2 cycles to c6, every 3 cycles to c12, and every 6 cycles thereafter.

Results: As of January 12, 2017, 34 R/R B-cell NHL patients with DLBCL (n=10), FL (n=15), or M/ZL (n=9) were enrolled. At study entry, median age was 60 y (26-81), most patients were male (86%), and Ann Arbor was extended stage III/IV in 76% of patients. Of the 18 DLBCL patients, 8 had transformed FL. Of the 16 FL/MZL patients, 44% relapsed in <12 months after first-line treatment. The median number of prior regimens was 4 (range, 1-11), and 13 (38%) patients had received prior SCT. One patient experienced a dose-limiting toxic effect (DLT) of grade 4 neutropenia (CC-122 dose level AIC 3mg); no dose was yet an NTD. Median CC-122 duration was 22 wks (range, 3-71) equivalent to 6 cycles (range, 1-18). CC-122 dose reduction or temporary interruption occurred in 10 (29%) or 26 (76%) of patients, respectively, primarily due to adverse events (AEs). Most patients (96%) had 1 wk of interruption due to AEs. The most common ≥10% grade 3/4 treatment-emergent AEs (TEAEs) were neutropenia (50%) and thrombocytopenia (21%). Fifteen patients (44%) had ≥1 serious TEAE, including 2 each of febrile neutropenia (related to CC-122), cytokine release syndrome (related to obinutuzumab), and pneumonia. Three deaths occurred during the study (2 PD; 1 AE). Overall response rate (ORR) was 59%, including 26% CR and 32% PR (Table 1). Median time to best response was 57 d, and median duration of response was not yet reached. In evaluable patients, 6-mo progression-free survival (PFS) was 63%.

Summary/Conclusions: The combination of CC-122 and obinutuzumab was well tolerated and demonstrates promising response rates and durable remissions in R/R patients with B-cell NHL. CC-122 doses of ≥3mg and obinutuzumab showed best response rates to date. The study is ongoing to establish the phase II recommended dose.

S468

POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OGINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY

M. Matasar1,*, A.F. Herrera2, M. Kamdar3, A. Mehta4, S. Assouline5, I. Fleury6, PHASE 1B/2 STUDY OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A

Background: Transplant ineligible patients (pts) with relapsed/refractory (R/R) FL or DLBCL have poor outcomes. Polatuzumab vedotin (pola) is an antibody drug conjugate that targets delivery of the microtubule inhibitor MMAE to cells expressing CD79b. Pola + rituximab (R) previously showed promising responses in R/R FL and DLBCL, but data are limited to pola without substituting obinutuzumab (G) for R could improve outcomes. We report updated results from the Phase 1b/2 (P1b2) study evaluating pola + BR or BG in R/R FL and DLBCL and the expansion cohorts evaluating pola + BG in R/R FL and DLBCL (OmiciaTrials.gov NCT02257567).

Aims: The primary aim is to assess safety and tolerability of pola + BR/BG in R/R FL and DLBCL. Secondary aims include assessing safety and efficacy of pola + BG in an expansion cohort.

Methods: All pts provided informed consent to participate in the study and were treated with pola (1.5mg/kg) + B (90mg/m2) and R (375mg/m2) or G (1000mg) every 28 days (FL) or 21 days (DLBCL) for 6 cycles. Responses were assessed by modified Lugano criteria after 3 cycles, end of treatment (tx), and every 6 months for 2 years during follow-up (fu).

Results: As of 14 Nov 2016, 65 pts were enrolled: 24 pts (12 FL, 12 DLBCL) in P1b and 41 pts (20 FL and 21 DLBCL) in P2. In safety evaluable pts, FL pts (N=32) were median age 63 yr (37-86), 82% ECOG 0-1 and 63% Stage III/IV, 75% Stage I-IV, 2 (1-7) median lines of prior tx, 38% refractory to last tx, 3% prior transplant (BMT). DLBCL pts (N=32) were median age 66 (30-86), 88% ECOG 0-1 and 13% ECOG 2, 59% IPI 3-5, 75% Stage III/IV, 2 (1-7) median lines of prior tx, 15% prior transplant (BMT). DLTs were 16% and hypokalemia (9%). AEs led to study tx discontinuation in 5 pts. B was stopped in 2 pts due to Gr 3 thromboctyopenia. Of 4 deaths: 2 were PD and 2 were Gr 5 AEs, 1 tx related (PML), 1 tx unrelated. In DLBCL, 88% (28/32) had Gr 3/4 AEs and 41% (13/32) had serious AEs (SAEs). The only SAE occurring in ≥10% was infection (22%). The most common Gr 3/4 non-heme AEs were infection (16%) and hypokalemia (9%). AEs led to study tx discontinuation in 8 pts. There were 13 deaths: 9 PD, 4 AE (all unrelated to tx). Responses by modified Lugano 2014 criteria are shown in Table1. Median duration of response (DoR) (DoR) for FL P1b pts was 16 months (mo)(median fu 14.5 mo). Median DoR for FL P2 (median fu 6.5 mo) and DLBCL P1b/2 (median fu 13.7 mo P1b, 6.4 mo P2) have not been reached.

Summary/Conclusions: Updated evaluation of pola + BR shows promising durable responses and an acceptable safety profile in heavily pre-treated R/R FL and DLBCL pts. Safety and efficacy data will be updated at the time of presentation.

S469

SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY, DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY

M. Maerevoet1,*, J. Westin 2, C. Thieblemont 3, J. Zijlstra 4, B.T. Hill 5, Center, Seoul, Korea, Republic Of, 6Hospital Universitari Vall d’Hebron, Barcelona, Spain, 10Manchester Academic Health Science Centre, The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom, 11Winship Cancer Institute of Emory University, Atlanta, United States, 12Roche, Shanghai, China, 13Genentech, Inc., South San Francisco, United States, 14BC Cancer Agency, Vancouver, Canada.

Background: Lymphoma Phase III Consortia, Amsterdam, Netherlands. 5Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 6Academic Medical Center, Amsterdam, Netherlands. 7Institute of Hematology “Seraglio,” University of Bologna, Bologna, Italy. 8Celgene Institute for Translational Research Europe, Seville, Spain. 9Celgene Corporation, San Francisco, CA. 10Celgene Corporation, Berkeley Heights, NJ, United States.

Translational Research Europe, Seville, Spain, 9Celgene Corporation, San Francisco, CA, 10Memorial Sloan Kettering Cancer Center, New York, 11City of Hope, Duarte, University of Colorado, Denver, 12Department of Medicine, University of Birmingham, Birmingham, United States. 13Memorial Sloan Kettering Cancer Center, New York, 2City of Hope, Duarte, University of Colorado, Denver, 13Department of Medicine, University of Birmingham, Birmingham, United States. 14Memorial Sloan Kettering Cancer Center, New York, 2City of Hope, Duarte, University of Colorado, Denver, 13Department of Medicine, University of Birmingham, Birmingham, United States. 15Memorial Sloan Kettering Cancer Center, New York, 2City of Hope, Duarte, University of Colorado, Denver, 13Department of Medicine, University of Birmingham, Birmingham, United States.
Background: Patients (pts) with persistent DLBCL after two or more lines of therapy have limited effective treatment options. The nuclear export protein exportin1 (XPO1) is upregulated in hematologic malignancies, including DLBCL, and has pleiotropic effects on tumorigenesis including functional downregulation of tumor suppressor proteins (TSPs) and increased export and translation of mRNAs for oncoproteins c-Myc and key survival proteins such as Bcl-2. Selinexor (SEL), an oral XPO1 inhibitor, causes sequestration of TSPs including p53, p21, and IκBα, the latter of which serves to suppress NF-κB transcription, along with reductions in c-Myc and Bcl-2 family proteins. In a Phase I clinical study, pts with relapsed/refractory (R/R) DLBCL treated with SEL presented an overall response rate (ORR) of 32% including 4 CRs. Interestingly, 2 of these pts remain in CR for >1 year.

Aims: In this clinical study we assess the efficacy of single agent SEL in pts with R/R DLBCL, after two or more regimens.

Methods: Pts with R/R DLBCL were randomized to 60 or 100mg of SEL twice weekly (8 doses) per 28-day cycle. Pts were stratified by DLBCL subtype (GCB or non-GCB). The primary objectives are to determine the ORR and evaluate the safety of 60 vs 100mg doses. Disease response was assessed by an Independent Central Radiological Review (ICRR), using the Lugano Classification (Cheson, 2014).

Results: 72 pts were enrolled: 37 pts on 60mg (24 M/13 F, median age 71 yrs) and 35 pts on 100mg (23 M/12 F, median age 68 yrs). Both groups had a median of 3 prior treatment regimens. The most common related adverse effects (AEs) across both dose groups (Grade 3/4 AEs) were: fatigue (47%), nausea (46%), anorexia (42%), and vomiting (33%). Common Grade 3/4 AEs were: thrombocytopenia (39%), fatigue (18%), neutropenia (18%), and anemia (13%). These were managed with dose interruption/reduction, platelet stimulators, and/or standard supportive care. Grade 3/4 fatigue (26% v 11%) and thrombocytopenia (48% v 32%) were higher in 100mg arm as compared to the 60mg arm. Among the 63 evaluable pts (9 pts performing response), the ICRR determined ORR was 28.5% (Table 1). Nine responders, including 6 pts in CR, remain on treatment. Responders on the 60mg arm have a median time on treatment of 8.9 months as compared with 3.8 months on the 100mg arm.

Table 1. Independent Central Radiological Review-Best Response.

<table>
<thead>
<tr>
<th>Category</th>
<th>N</th>
<th>ORR (%)</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>SD (%)</th>
<th>ORR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Doses</td>
<td>63</td>
<td>18 (28.5%)</td>
<td>7 (11.1%)</td>
<td>11 (17.4%)</td>
<td>11 (17.4%)</td>
<td>27 (42.9%)</td>
</tr>
<tr>
<td>60mg</td>
<td>32</td>
<td>9 (28.1%)</td>
<td>4 (12.5%)</td>
<td>5 (15.6%)</td>
<td>3 (9.4%)</td>
<td>12 (37.5%)</td>
</tr>
<tr>
<td>100mg</td>
<td>31</td>
<td>9 (29%)</td>
<td>7 (22.5%)</td>
<td>6 (19.4%)</td>
<td>3 (9.7%)</td>
<td>12 (38.7%)</td>
</tr>
<tr>
<td>All patients</td>
<td>63</td>
<td>18 (28.5%)</td>
<td>7 (11.1%)</td>
<td>11 (17.4%)</td>
<td>1 (1.6%)</td>
<td>27 (42.9%)</td>
</tr>
<tr>
<td>Non-GCB Subset</td>
<td>31</td>
<td>11 (35.4%)</td>
<td>4 (12.9%)</td>
<td>6 (19.4%)</td>
<td>2 (6.5%)</td>
<td>13 (41.9%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: SEL monotherapy shows activity in pts with R/R DLBCL including in pts with GCB subtype. 60mg SEL twice weekly was more tolerable than 100mg twice weekly, with fewer interruptions due to toxicity. Objective responses to SEL were durable at 60mg BIW, suggesting these responses were associated with clinical benefit.

S470

L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)–A SINGLE-ARM PHASE II STUDY

K. Maddocks1,*, E. González Barca2, W. Jurczak3, A.M. Liberati4, J. Duell5, L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS S470 were associated with clinical benefit. Tolerability responses to SEL were durable at 60mg BIW, suggesting these responses were endurable at 100mg twice weekly, with fewer interruptions due to toxicity. Objective responses to SEL were durable at 60mg BIW, suggesting these responses were associated with clinical benefit.

Background: The Fc-enhanced CD19 antibody MOR208 and the immunomodulatory drug LEN have demonstrated single agent activity in patients with R-R DLBCL. MOR208 and LEN have shown synergy in vitro and in vivo in preclinical lymphoma models.

Aims: This ongoing phase II study was designed to assess the safety and efficacy of MOR208 plus LEN in patients with R-R DLBCL.

Methods: Patients ≥18 years of age with R-R DLBCL. ECOG performance status 0-2, adequate organ function, having previously received at least 1 but not more than 3 prior therapies, including at least 1 CD20-targeting regimen and who are not candidates for autologous stem cell transplant (ASCT), are eligible.

Treatment comprises up to 12, 28-day cycles of MOR208 12mg/kg IV, administered weekly during cycles 1-3 (loading dose day 4 of cycle 1) and every second week during cycles 4-12 plus LEN 25mg administered po days 1-21 of each cycle. Patients progression-free after 12 cycles receive up to 12 additional cycles of MOR208 12mg/kg IV, administered every second week. The primary endpoint is the overall response rate (ORR) by central radiology assessment. Secondary endpoints include disease control, duration of response, progression-free and overall survival, safety, and response by cell of origin and other biomarkers. A preplanned safety evaluation was undertaken.

Results: 31 of 80 planned patients were enrolled prior to data cutoff (3 January 2017). Median age was 74 years (range 47–82); 45% of patients received ≥2 prior lines of therapy; 23% had rituximab refractory disease; 74% had Ann Arbor stage ≥III disease; 65% had elevated lactate dehydrogenase level, and 52% had a poor revised International Prognostic Index (3–5). The most common treatment-emergent adverse events (any grade) were neutropenia (39/26), anemia (23/0) thrombocytopenia (16/6), infections (26/10) diarrhea (13/0), pyrexia (13/0), and rashes (13/6). Of 26 response evaluable patients (median follow-up 3.3 months), ORR (investigator assessed) was 58% (15 patients), with 7 (27%) complete responses. Median time to response was 1.8 months.

Summary/Conclusions: The combination of MOR208 plus LEN is well tolerated and shows promising activity in patients with R-R DLBCL. Accrual and follow-up of patients is ongoing, as are cell of origin and other biomarker analyses.
ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY

E.M. Stein1,2,3, C.D. DiNardo3, D.A. Pollyea4, A.T. Fathi5,6, G.J. Roboz2,7, J.K. Altman8, A. Stein13, M.A. Sekeres14, R.T. Swords15, B.C. Medeiros16, R.D. Knight17, S. Agresta18, S. de Botton19, M.S. Tallman1,2

1Memorial Sloan Kettering Cancer Center, 2Well Cornell Medical College, New York, 3The University of Texas MD Anderson Cancer Center, Houston, 4University of Colorado School of Medicine, Aurora, 5Massachusetts General Hospital Cancer Center, 6Harvard Medical School, Boston, 7New York Presbyterian Hospital, New York, 8Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, 9Dana-Farber Cancer Institute, Boston, 10Sarah Cannon Research Institute, Nashville, 11University of Texas Southwestern Medical Center, Dallas, 12Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, 13City of Hope Comprehensive Cancer Center, Duarte, 14Cleveland Clinic Taussig Cancer Institute, Cleveland, 15Sylvester Comprehensive Cancer Center, University of Miami, Miami, 16Stanford Comprehensive Cancer Center, Stanford University, Stanford, 17Celgene Corporation, Summit, 18Aigios Pharmaceuticals, Inc., Cambridge, United States, 19Institut Gustave Roussy, Villejuif, France

Background: Recurrent mutations in isocitrate dehydrogenase 2 (mIDH2) occur in ~12% of AML patients (pts). mIDH2 proteins synthesize an oncometabolite, 2-hydroxyglutarate (2HG), causing DNA and histone hypermethylation and blocked myeloid differentiation. Enasidenib (AG-221) is an oral, selective, small-molecule inhibitor of mIDH2 proteins. Differentiation of myeloblasts, not cytotoxicity, appears to drive the clinical efficacy of enasidenib. In preclinical studies, bone marrow blasts from pts with mIDH2-exposed to enasidenib ex vivo were shown to produce mature, fully functioning neutrophils with conserved mIDH2 allele frequency, indicating differentiation of mature cells from the mIDH2 blasts (Yen et al, Cancer Discov, 2017). Additionally, no apoptosis was observed in mIDH2-R140 erythroleukemia (TF-1) cells treated with enasidenib for 7 days in vitro.

Table 1.

Aims: Evaluate the maximum tolerated dose (MTD), pharmacokinetic (PK) and pharmacodynamic (PD) profiles, safety, and clinical activity of enasidenib in pts with mIDH2-defined AML, or with mIDH2 WHO-defined AML, or with mIDH2 MDS with refractory anemia with excess blasts, and ECOG PS scores ≤2. Pts were relapsed or refractory (R/R) to prior anti-cancer therapy, or had untreated AML if aged ≥60 years and not eligible for standard-of-care treatment (TX). Safety for all pts and clinical efficacy in the largest pt subgroup, those with R/R AML, from the phase 1 dose-escalation and expansion phases are reported.

Results: In all, 239 pts received enasidenib. Median age was 70 yrs. In the dose-escalation phase (n=113), pts received daily enasidenib doses of 50-650 mg. The MTD was not reached. Median 2HG reductions from baseline at cycle 2 day 1 were 92%, 90%, and 93% for pts receiving <100 mg, 100 mg, and >100 mg/day, respectively. Enasidenib 100 mg QD was chosen for the expansion phase (n=126) based on PK/PD profiles and demonstrated efficacy. Median number of enasidenib cycles was 5 (range 1-25). Grade 3-4 investigator-reported Tx-related adverse events included indirect hyperbilirubinemia (12%) and IDH-inhibitor-associated differentiation syndrome (IDH-DS; ie, retinoic acid syndrome) (7%). Of 176 R/R AML pts, 94 (53%) had received ≥2 prior AML-directed Tx. Overall response rate (ORR; complete remission [CR] + CR with incomplete count recovery - count recovery-confirmed AML-fresh leukemia [CRi-ALF] + complete remission-confirmed AML-fresh leukemia [CR-ALF]) in R/R AML pts was 40.3%, including 34 pts (19.3%) who attained CR (Table). Median time to 1st response was 1.9 months (mos); 87.3% of responding pts attained a 1st response by cycle 5. Median response duration was 5.8 mos. Of pts who achieved CR, 7 pts (21%) did so by cycle 3, 23 (88%) by cycle 5, and 29 (82%) by cycle 7. Median duration of CR was 8.8 mos. ORR with enasidenib 100 mg/day was 39.5% (Table). Seventeen pts (11%) proceeded to stem cell transplant. Response was associated with cellular differentiation, typically with no evidence of aplasia. Median overall survival (OS) of R/R AML pts was 9.3 mos. For pts who attained CR, OS was 19.7 mos. Pts who had received ≥2 prior AML Tx had a median OS of 8.0 mos.

Summary/Conclusions: Enasidenib was well tolerated, induced CRs in R/R pts with AML, and was associated with OS of >9 mos in pts who had failed prior AML Tx. A randomized phase 3 study of enasidenib vs conventional care in older pts with late-stage R/R AML is ongoing (NCT02577406).

S472

SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (≥65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)


1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, 2University of Colorado School of Medicine, Aurora, 3UC Davis Comprehensive Cancer Center, Sacramento, 4Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, United States, 5The Alfred Hospital, and Monash University, Melbourne, Australia, 6Emory University, Atlanta, 7Division of Hematology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 8Northwestern University Feinberg School of Medicine, 9University of Chicago Medical Center, Chicago, United States, 10Centre Hospitalier Universitaire (CHU) de Bordeaux, INSERM U1038, Université de Bordeaux, Bordeaux, 11Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse and Université de Toulouse III, Toulouse, France, 12Peter MacCallum Cancer Centre, Melbourne, Australia, 13Abbvie Inc., North Chicago, 14Dana-Farber Cancer Institute, Boston, 15University of Texas MD Anderson Cancer Center, Houston, United States

Background: Newly diagnosed patients (pts) with AML aged ≥65 years and ineligible for standard induction therapy have limited treatment options, and low overall survival. VEN is an orally bioavailable, selective BCL-2 inhibitor that has displayed single-agent activity in pts with relapsed/refractory AML. VEN at escalating doses combined with hypomethylating agents (HMAs) has demonstrated antileukemic activity, with an overall response rate (ORR) including complete remission [CR] and CR with incomplete marrow recovery of 60%. Combining VEN with HMAs, such as decitabine (DEC) or azacitidine (AZA), may provide a novel low-intensity approach for treating AML. Preliminary results from the expansion stage of a phase 1b trial comparing 2 doses of VEN plus either DEC or AZA (NCT02203773) are reported.

Aims: To evaluate the safety and efficacy of VEN at 400 mg vs 800 mg doses plus DEC or AZA.

Methods: This open-label, nonrandomized, two-stage phase 1b study evaluated the safety and efficacy of VEN plus DEC or AZA in treatment-naive pts ≥65 years with AML. Eligibility criteria: ECOG PS ≤2; eligible for standard induction therapy; intermediate- or poor-risk karyotype. Pts received DEC (Arm D, 20mg/m²/d [d]; intravenously [IV]) on 1–5, or AZA (Arm E, 75mg/m²/d; subcutaneous or IV) on 1–7 of each 28-d cycle (C) in combination with once-daily oral VEN. The dose-expansion stage consisted of 2 VEN dose cohorts (continuous 400-mg and interrupted 800-mg dosing) in each arm (D1, D2, E1, and E2, respectively) to determine optimal dose. Tumor lysis syndrome (TLS) prophylaxis was administered in C1 to all pts during VEN dose ramp-up until final dose was reached. All pts provided informed consent.
Results: As of 13/09/16, 100 pts were enrolled in the expansion stage; 25 pts in each arm. Overall, 61% pts were male; 50% had ECOG PS 1 and 15% ECOG PS 2; mean age was 73.9 (range 65–86); 53% had adverse karyotype; and 22% had secondary AML. Median time on study was 6 (4–9), 6 (0.2–9), 5 (0.5–9), and 4 (1–8) mo for arms D1, D2, E1, and E2, respectively. The incidence of adverse events (AEs) was generally comparable between the 4 arms. Overall, the most common treatment-emergent AEs (TEAEs; in ≥30% of pts) were nausea (59%), diarrhea (42%), febrile neutropenia (FN; 41%), constipation (39%), fatigue, and decreased white blood cell count (31% each). The most frequent grade 3/4 TEAE and serious AE was FN (41% and 29%, respectively). No TLS was observed. Overall, 29 pts discontinued the study for ≥1 reason, including progressive disease (PD) per protocol (n=10), “other” (n=10; 9/10 proceeded to stem cell transplantation) and AEs not related to progression (n=10). A total of 16 deaths occurred; 12 pts died within 30 d of initiating VEN and HMA due to AEs (n=12) and PD (n=1). The ORR was 68%, with rates of 76% (19/25), 71% (17/24), 68% (17/25), and 60% (15/25) observed in arms D1, D2, E1, and E2, respectively. The Kaplan-Meier survival curve for all pts with a median follow-up time of 5.4 mo is shown.

Summary/Conclusions: Overall, the safety profile was favorable when combining VEN at either dose with DEC or AZA in treatment-naïve elderly AML pts. Promising activity with high ORRs was observed at the lower 400-mg VEN dose in both HMA arms. A Phase 3 study of VEN plus AZA is planned.

S473

UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ≥65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY


1The Alfred Hospital and Monash University, Melbourne, Australia, 2Vanderbilt-Ingram Cancer Center, Nashville, 3Weill Cornell Medical College, New York, 4University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, United States, 5Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 6University of Kansas Medical Center, Kansas City, United States, 7Bologna University School of Medicine, Bologna, Italy, 8University of Washington, Seattle, and Fred Hutchinson Cancer Research Center, Seattle, United States, 9Calvary Mater Hospital Newcastle and School of Medicine and Public Health, University of Newcastle, Callaghan, Waratah, Australia, 10AbbVie, Inc, North Chicago, United States

Background: Incidence of acute myeloid leukemia (AML) increases with age, and patients (pts) ≥65 years have a poor prognosis, with 5-year survival rates of <10%. Treatment with low-dose cytarabine (LDAC) in this population results in modest complete remission (CR)/CR with incomplete blood count recovery (CRi) rates of 11–19%, and 3–20% with azacytidine (AZA) in patients (pts) ≥65 years on treatment with 7–10% CR and 10–16% CRi. A phase 1/2 study of VEN in pts ≥65 years with untreated AML, ineligible for standard induction chemotherapy, with an ECOG performance status of 0-2 received oral VEN QD on days (d) 1-28 and subcutaneous LDAC 20mg/m2 QD on d 1–10 of each 28-d cycle. Safety target dose evaluation followed a 3+3 design, ranging from 600–800mg; 18 pts were enrolled and the RP2D was established as 600mg. Safety and efficacy of VEN at RP2D were evaluated in the expansion phase. All pts were hospitalized and received prophylaxis before a dose ramp-up of VEN during cycle 1 to mitigate the risk of tumor lysis syndrome (TLS). Adverse events (AEs) were graded by NCI CTCAE V4.0. Pts enrolled as of May 2016 are included in this analysis; data cutoff was August 2016. All pts provided informed consent.

Results: In total, 61 pts, including 8 from phase 1, were treated at the RP2D of 600mg (median age 74 years; ECOG 1–2 70%; adverse karyotypes 31%; secondary AML 44%; prior hypomethylating agent [HMA] 28%). AEs (all grade; ≥30% pts; excluding cytopenias) were nausea (72%), hypokalemia (46%), diarrhea (44%), fatigue (43%), and decreased appetite (41%). Grade 3/4 AEs (≥10% pts) were febrile neutropenia (34%), hypokalemia (15%), hypophosphatemia (13%), and hypertension (10%). No pts had clinical TLS; 1 pt had laboratory TLS, which was managed. The 30-d and 60-d mortality rates were 3% and 15%, respectively. The CR/CRi rate was 54% (33/61; 21% CR and 33% CRi). The overall response rate (ORR; CR+CRi+partial remission) was 61% (37/61). VEN+LDAC was shown to be active across a wide range of cytogenetic mutations and pt profiles (ORR: 70% in pts ≥75 years; 52% in secondary AML 47% in pts with adverse karyotypes; 53% in pts with prior HMA). Among response-evaluable pts, those achieving an objective response have longer survival than pts who do not achieve an objective response (Figure 1).

Figure 1.

Summary/Conclusions: VEN (RP2D 600mg) and LDAC exhibited an accept-able safety profile and durable efficacy in pts aged ≥65 years with untreated AML who are ineligible for or unable to receive intensive induction chemother-apy. ORR highly correlated with overall survival, with better survival observed in responders compared with nonresponders. A planned phase 3 randomized trial has commenced.

S474

PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)

N. Daver1, S. Basu2, G. Garcia-Manero1, J. Cortes1, F. Ravandi1, E. Jabbour1, N. Pemmaraju1, S. Hendrickson 1, T. Gordon 1, M. Brandt 1, S. Pierce 1, J. Matthews1, S. Kornblau1, W. Flores1, M. Konopleva1, H. Kantarjian1, P. Sharma2

1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, United States, 2Immunotherapy Platform, University of British Columbia, Vancouver, Canada, 3Immunotherapy Platform, University of California, Los Angeles, 4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, United States

Background: Blocking PD-1/PD-L1 pathways enhances anti-leukemia responses in murine AML (Zhang et al. Blood 2009). PD-1 positive CD8 T-cells are increased in bone marrow (BM) of pts with AML (Daver et al. AARC 2016). AZA up-regulates PD-1 and interferon-gamma signaling in AML and the up-regulation of PD-1 has been associated with emergence of resistance to AZA (Yang et al., Leukemia 2013).

Aims: To assess the best response to Aza+Nivo at the end of 3 courses of combination therapy.

Methods: Pts were eligible if they had AML and failed prior therapy, had ade-quate performance status (ECOG ≤2), and organ function. The first six pts
received AZA 75mg/m² Days 1-7 with nivolumab 3mg/kg on Day 1 and 14. Courses were repeated every 4-5 days indefinitely. Only one of six pts had a dose limiting toxicity (grade 3 pneumonitis) and this dose was RP2D. 60 additional pts have been treated at the RP2D.

Results: 66 pts with a median age of 71 years (range, 44-90), secondary AML (39%), poor risk cytogenetics (35%), median number of prior regimens 2 (range, 1-7) have been enrolled. All 66 pts had baseline next generation sequencing: TP53 (n=14), DNMT3A (n=12), ASXL1 (n=10), TET2 (N=9), and RAS (n=9), IDH2 (n=9), IDH1 (n=6), CEBPA (n=7). 63 pts are evaluable for response: 14 (22%) achieved complete remission (CR)/complete remission with insufficient recovery of counts (CRi) (3 CR, 11 CRi), 7 (11%) had hematologic improvement (HI) (5 HI, 2 (11%) had 25% BM blast reduction, 5 pts (8%) had stable disease >6 months, and 24 (38%) had progression. 3 pts are too early for response assessment (<3 courses). The median number of courses to CR/CRi/HI was 2 (range, 1-4+). The med OS among the CR/CRi/HI patients was 15.3 months (range, 2.29-27.9+ months), the mOS of patients who had died was 5.7 months (range, 4.67-17.45+ months), and NRI was 5.0 months (range 0.29-16.16). The 4- and 8-week mortality were 5% and 11%, respectively. The median OS for the 63 evaluable pts on Azac+Nivo compares favorably to historical median OS with AZA-based salvage protocols in similar pts treated at MDACC (P=0.10) (Fig 1A and Fig 1B). Grade 3/4 and Grade 2 immune toxicities were observed in 8 (12%) and 7 (11%) pts, respectively. The most common Grade 3/4 AE on treatment included pneumonitis, colitis, nephritis, skin rash, and hypophysitis. One pt died from grade 4 pneumonitis/epiglottitis. In the remaining 14 cases the toxicities responded rapidly to steroids and 13 of these pts were successfully rechallenged with nivolumab. Time to onset of toxicities ranged from 4 days to 3.5 months. Multicolor flow-cytometry studies and Mass-cytometry (CyTOF) studies are conducted by the Immunotherapy Platform on baseline and on-treatment BM aspirate (end of cycle 1, 2, 4, 8). Baseline and end of cycle (EOC) 1 and 2 BM was evaluated in 6 responders and 19 non-responders. Pts who achieved a response had a baseline higher live total CD3 (P=0.10), CD8+ T-cells (P=0.02), and lower live CD4+Foxp3+PD1+T-regulatory (T-reg) cells (P=0.01) infiltrate in BM. Patients who had a response had progressive increase in BM CD3+ cells and BM CD8+ cells, with increased ICOS (activation) marker on BM CD4-effector cells at EOC 1 and EOC 2 as compared to those who had no response. The CTLA4 on CD8 T-cells went up in both responders and non-responders after PD1 based therapy.

Figure 1. OS with Azac+Nivo compared to historical survival with AZA-based salvage protocols in similar pts treated at MDACC in (a) all salvage and (b) first relapse only

Summary/Conclusions: Full dose AZA and nivolumab are tolerable and produce an encouraging response rate with durable responses in relapsed AML with poor risk features. Immune mediated toxicities occur and may be adequately managed with early recognition and systemic steroids. Up-regulation of CTLA4 in both responders and non-responders after PD1 based therapy suggest role for combination therapy.

S475

QUIZARTINIB AND BRIDGE TO TRANSPLANT IN FLT3-ITD AML PATIENTS AFTER FAILURE OF SALVAGE CHEMOTHERAPY: A HISTORICAL COMPARISON WITH UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) DATA

R. Hills1,*, G. Gammon2, D. Trone3, A. Burnett4

1Centre for Trials Research, Cardiff University, Cardiff, United Kingdom, 2formerly Daichi Sankyo, 3Daiichi Sankyo, San Diego, United States, 4Blackwaterfoot, Isle of Arran, United Kingdom

Background: The presence of a FMS-like tyrosine kinase 3 (FLT3) Internal Tandem Duplication (ITD) mutation in pts with AML is associated with an increased early relapse rate and a dismal prognosis. Quizartinib is a potent, selective FLT3 inhibitor that confers median overall survival (mOS) of 23 weeks and remission rate of 46% in a single-arm phase 2 study (AC220-002) in pts with AML with a FLT3-ITD mutation who were relapsed or refractory (R/R) to second line therapy. (Levis, et al, ASH 2012) As context, a study of AML pts, regardless of FLT3 mutation status, receiving second-salvage therapies, reported mOS of only 1.5 months. (Giles F, et al. Cancer 104 (3), 2005). Such poor-risk pts may benefit from a stem cell transplant (SCT), if available.

Aims: The primary aim was to compare SCT rates and outcomes of pts on quizartinib from an exploratory selected cohort in the AC220-002 study with those from a historical cohort of 1388 AML pts with confirmed FLT3-ITD mutations in the UK NCRI database.

Methods: Within AC220-002, 58 pts with a FLT3-ITD mutation were identified who had received intensive chemotherapy, and were relapsed (n=53), or refractory (n=5) to salvage therapy prior to entry. Applying the same entry criteria to the NCRI database, we identified 118 pts who received only recognized chemotherapy regimens prior to eligibility (relapsed n=99; refractory n=19). To avoid biases where those dying early would predominantly contribute to the NCRI group (reflecting that pts in AC220-002 had to be fit enough to be enrolled), pts in this cohort entered analysis 14 days following being identified as R/R. Multivariable Cox/logistic regression was used to compare remission rates and survival stratified for known prognostic factors. A landmark analysis excluding deaths before day 90 (allowing for those too unfit for SCT) was performed on the pooled sample (n=176) of the AC220-002 and NCRI cohorts to compare survival between transplanted and non-transplanted pts.

Results: Overall, quizartinib-treated pts had significantly greater remission rates, consisting mainly of complete remission without normal blood counts (CRI), vs NCRI pts (40% vs 3%, adjusted OR 0.05 (0.01-0.21), p<0.0001) and improved mOS (140d vs 54d, adjusted HR 0.38 (0.25-0.58) p<0.0001). A greater proportion of pts in AC220-002 proceeded to SCT: 23/54 (40%) vs 9/118 (8%). Comparing survival in SCT vs non-SCT in a landmark analysis, 18-month survival was significantly greater in the SCT group (29% vs 7%, adjusted HR 0.36 (0.20-0.65) p<0.0005). Significance persisted in sensitivity analyses with the landmark set at 120 or 150 days indicating an association between long-term survival and SCT. A similar analysis in an unmatched cohort consisting of SCT-naive pts in first relapse also found better survival for SCT vs no-SCT, confirming a potential benefit of SCT in this poor risk population.

Summary/Conclusions: When compared to a large historical cohort, quizartinib was associated with greater remission rates and opportunity to receive SCT in pts who relapsed after salvage therapy. While varying practice patterns and patient factors obviously influence treatment choices and outcomes, pts with AML with FLT3-ITD mutation appeared to benefit with longer survival with SCT. This data suggests quizartinib may show promise in potentially improving long-term survival by bridging patients to SCT.
Immunotherapy in ALL

S476

GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS

J. Buechner1, S.A. Grupp2,3, S.L. Maude3, M. Boyer4, H. Bittencourt5,6,7, T. Taran23, T. Huseby1, M. Leung1, T. Baehrecke4, S. Stredney2, S. Rives4, R. Geyer1, J. Buechner1, S.A. Grupp2,3, S.L. Maude3, M. Boyer4, H. Bittencourt5,6,7, T. Taran23, T. Huseby1, M. Leung1, T. Baehrecke4, S. Stredney2, S. Rives4, R. Geyer1

1 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 2 Department of Pediatrics and Hospital of University of Utah, Salt Lake City, Utah, Salt Lake City, Utah, 3 Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, 4 Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas, 5 Department of Pediatric Hematology-OncoLOGY and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium, 6 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 7 Department of Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 8 Division of Hematology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, 9 Pauline Allen Gill Center for Cancer and Blood Disorders, Children’s Health, Dallas, Texas, 10 Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany, 11 Adult and Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, 12 Children’s Mercy Hospital and Clinics, Kansas City, MO, 13 Alacron Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, 14 Division of Hematology Oncology/Blood and Marrow Transplant, Children’s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, 15 Department of Pediatric Hematology-Oncoligy and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium, 16 Cancer Research Institute Ghent (CRIG), Ghent University, 17 Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 18 Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 19 Lucile Packard Children’s Hospital Stanford, Palo Alto, Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, NC, 20 Oregon Health & Science University, Portland, Oregon, 21 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 22 Hospital Sant Joan de Déu, Barcelona, Spain

Background: The CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, CTL019, is an investigational therapy that reprograms cytotoxic T cells to eliminate target cells, resulted in high response rates and a manageable safety profile in pediatric/young adult patients (pts) with R/R B-cell ALL in a single-center trial.

Aims: We report an updated interim analysis from the first multicenter global pivotal trial of CAR T-cell therapy for R/R B-cell ALL, to evaluate the cellular kinetics of CTL019 in pediatric/young adult pts with (tumor burden at enrollment generally had higher expansion, based on box plots and summary statistics. Extrinsic factors (prior lines of therapy, stem cell source, therapy use or protocol) and baseline cytogenetics, disease characteristics, and disease status did not reach significance. Relationships between manufacturing specifications, therapies for cytokine release syndrome (CRS) management, and anti-CAR19 antibodies on cellular kinetics, based on graphical analysis.AUC0-28d increased with pres.

Results: At November 2016, 88 pts were enrolled. There were 7 (8%) manufacturing failures, 9 (10%) pts were not infused due to death or adverse events (AEs), and 4 pts (5%) were pending infusion at the time of data cutoff. Following lymphodepleting chemotherapy in most pts (fludarabine/cyclophosphamide [n=64] or other [=1]), 68 pts were infused with a single dose of CTL019 (median dose, 3.0×10^6/kg; range, 0.25-6.4×10^6/kg). Median age was 6.4 mo. Median age was 12 y (range, 3-23 y); 59% of pts had prior autologous stem cell transplant (alloSCT). Five infused patients had not reached 3 mo of follow-up; among 63 evaluable pts, 52 (83% [95% CI, 71%-91%]) achieved CR/CRi within 3 mo of CTL019 infusion, all of whom had minimal residual disease–negative marrow. The relapse-free probability at 6 mo after remission onset was 75% (95% CI, 57%-87%; median DOR not reached). The probability of survival was 95% (95% CI, 77%-94%) at 6 mo and 79% (95% CI, 63%-89%) at 12 mo. Seven pts (13% of responders) proceeded to alloSCT within 6 months while in remission. Cytokine release syndrome (CRS) was graded using the U Penn scale and managed using a protocol-specific algorithm. CRS occurred in 78% of pts (21% grade 3; 27% grade 4); no CRS-associated deaths occurred. 38% of pts received tocilizumab for treatment of CRS or with or without other anti-cytokine therapy. Most CRS grade 3/4 nonhematologic AEs (>5%) other than CRS were hypotension (22%), hypoxia (18%), and infections (15%). The number of patients treated with CTL019 in the global registration trial was 88. Within 8 weeks of infusion was 69%. 15% of pts experienced grade 3 neutrophilic chimeric AEs, with no grade 4 events and no cerebral edema reported. Grade 3/4 neutropenia with high (>383.3) fever occurred in 60% of pts. 2 pts died within 30 days of infusion (ALL progression, n=1; cerebral hemorrhage, n=1), and 9 pts died >30 days after infusion (ALL relapse/progression, n=6; HHV-6 encephalitis, pneumonia, systemic mycosis, n=1 each). CTL019 expansion in vivo correlated with CRS severity, and persistence of CTL019 along with B-cell aplasia in peripheral blood was observed for ≥1 year in some responders. Summary/Conclusions: The ELIANA study confirmed the efficacy of a single infusion of CTL019, without additional therapy, observed in a previous interim analysis and a prior single-center CTL019 trial. AEs were effectively and reproducibly managed globally by appropriately trained personnel at study sites.

S477

CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

K. Thudium Mueller1, E. Waldron1, S.A. Grupp2,3, J. Levine4, T.W. Laetsch5, M.A. Pulispehr6, M. Boyer7, K. August8, J. Hamilton1, R. Awashti1, D. Sicker1, A. Chakraborty1, B.L. Levine1, C.H. June12, L. Tomassian1, M. Leung1, T. Taran23, S. Stredney2, S. Rives4, S. Rives4

1 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 2 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 3 Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, 4 University of Michigan, Ann Arbor, 5 Icahn School of Medicine at Mount Sinai, New York, 6 Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas, 7 Pauline Allen Gill Center for Cancer and Blood Disorders, Children’s Health, Dallas, Texas, 8 Division of Hematology Oncology/Blood and Marrow Transplant, Children’s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, 9 University of Utah, Salt Lake City, 10 Children’s Mercy Kansas City, Kansas City, United States, 11 Novartis Pharma AG, Basel, Switzerland, 12 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

Background: CTL019 is an investigational therapy whereby autologous T cells are genetically engineered with a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant B cells. Data from 2 phase 2 studies (ELIANA, NCT02435849 and ENSIGN; NCT02228096) in pediatric and young adult R/R B-cell ALL were pooled to evaluate cellular kinetics of CTL019. Aims: We report cellular kinetics, humoral immunogenicity, AUC0-28d (exposure)-response analysis and impact of intrinsic/extrinsic and manufacturing factors on CTL019 expansion. Methods: Cellular kinetic parameters of CTL019 post infusion were derived using traditional pharmacokinetic principles and reported by response category (complete response [CR]/CRi with incomplete blood count recovery [CR]) vs no response [NR]) using 2 assays of peripheral blood cells: qPCR and flow cytometry. AUC0-28d-response relationships were evaluated by logistic regression. Relationships between manufacturing specifications, therapies for cytokine release syndrome (CRS) management, and anti-CAR19 antibodies on cellular kinetics were explored using summary statistics and graphical- and model-based analyses.

Results: Data from 79 pts (ELIANA, n=50; ENSIGN, n=29) were pooled for analysis. Using qPCR, pts with CR/CRi (n=62) had ≥2-fold higher CTL019 expansion than pts with NR (n=7) (Cmax, 73.5% higher geometric [geometric mean]; AUC0-28d, 104% higher geometric mean). Table 1. Pts with NR had delayed Tmax compared with pts with CR/CRi (20 vs 10 days). Intrinsic pt factors including baseline cytogenetics, disease characteristics, and disease status did not appear to affect Cmax or AUC0-28d with the exception that pts with a higher tumor burden at enrollment generally had higher expansion, based on box plots and summary statistics. Extrinsic factors (prior lines of therapy, stem cell transplant) and parameters related to the manufactured product (% T cells, transduction efficiency, cell viability, total cell count), did not appear to impact cellular kinetics, based on graphical analysis. AUC0-28d increased with pres.

Figure 1. Results: Data from 79 pts (ELIANA, n=50; ENSIGN, n=29) were pooled for analysis. Using qPCR, pts with CR/CRi (n=62) had ≥2-fold higher CTL019 expansion than pts with NR (n=7) (Cmax, 73.5% higher geometric [geometric mean]; AUC0-28d, 104% higher geometric mean). Table 1. Pts with NR had delayed Tmax compared with pts with CR/CRi (20 vs 10 days). Intrinsic pt factors including baseline cytogenetics, disease characteristics, and disease status did not appear to affect Cmax or AUC0-28d with the exception that pts with a higher tumor burden at enrollment generally had higher expansion, based on box plots and summary statistics. Extrinsic factors (prior lines of therapy, stem cell transplant) and parameters related to the manufactured product (% T cells, transduction efficiency, cell viability, total cell count), did not appear to impact cellular kinetics, based on graphical analysis. AUC0-28d increased with pres.
ence and severity of CRS. Pts who received anti-cytokine agents for grade 3/4 CRS also had higher expansion. CR/CRi pts treated with tocilizumab and steroids (n=17) had 89% higher AUC0-28d than CR pts who did not receive tocilizumab and steroids (n=45). Experience is limited in NR pts with (n=4) and without (n=4) tocilizumab. Moderate correlation was observed between trans-gene levels and CAR surface expression in peripheral blood (r=0.592) by qPCR and flow cytometry, respectively, when matched by time points from the cellular kinetic profile. Slower B-cell recovery was observed in pts with AUC0-28d above the median. Post-dose anti-CAR19 antibody responses were determined from the fold change of anti-CAR19 antibodies above the baseline pre-dose value. Pts with treatment-induced or boosted anti-CAR19 antibody responses generally had lower expansion, based on box plots, compared with pts with treatment-unaffectected anti-CAR19 antibody responses, although AUC0-28d was variable. The boosted levels of anti-CAR19 did not impact clinical response or relapse.

Table 1.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>S1 (n=159)</th>
<th>S2+ (n=146)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR rate</td>
<td>74%</td>
<td>71%</td>
<td>0.60</td>
</tr>
<tr>
<td>Relapse</td>
<td>26%</td>
<td>29%</td>
<td>0.25</td>
</tr>
<tr>
<td>OS rate</td>
<td>56%</td>
<td>53%</td>
<td>0.94</td>
</tr>
</tbody>
</table>

Summary/Conclusions: There was increased expansion of CTL019 in pts with higher tumor burden at enrollment, which correlated with higher CRS grade. There was no relationship between dose and expansion, supporting the wide dose range used. Expansion was not attenuated by tocilizumab, steroids, or cytokines, indicating therapies for CRS do not abrogate CTL019 proliferation. Cellular kinetics are important to understand the determinants of tumor response with CAR T-cell therapy.

S478
BLINATUMOMAB VS SOC CHEMOTHERAPY IN FIRST SALVAGE COMPARED WITH SECOND OR GREATER SALVAGE IN A PHASE 3 STUDY
H. Dombret1,*, M.S. Topp2, A. Schuh3, A. Wei4, G. Martinelli5, S. Durrant6, C.L. Bacon7, K. Nie8, Z. Zimmerman9, H. Kantarjian10
1Hôpital Saint-Louis, Paris, France, 2Universitätsklinikum Würzburg, Würzburg, Germany, 3Princess Margaret Cancer Center, University Health Network, Toronto, Canada, 4Alfred Hospital, Monash University, Victoria, Australia, 5Institute of Hematology and Medical Oncology “L. e A. Seragnoili”, S. Orsola University Hospital, Bologna, Italy, 6Clinical Haematology and BMT, Royal Brisbane Hospital, Herston, Australia, 7St. James’s Hospital, Dublin, Ireland, 8Global Biostatistical Sciences, 9Global Development, Amgen, Thousand Oaks, CA, 10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) often relapse following standard induction/consolidation chemotherapy (CTX). Prognosis following second and successive CTX salvage regimens (S2+) is poor compared with first salvage (S1) or frontline therapy, with less favorable outcomes among patients with shorter CR duration. Blinatumomab links cytotoxic CD3-positive T cells and CD19-positive B cells to induce tumor cell lysis. In a randomized phase 3 trial of blinatumomab vs investigator’s choice of 4 standard of care CTX (SOC) regimens, median OS was 7.7 months in the blinatumomab group vs 4.0 months with SOC (Kantarjian H, et al., NEJM 2017). Here, we evaluate outcomes by salvage status for patients in this study (NCT02013167).

Aims: To evaluate responses to blinatumomab vs SOC in patients with relapsed/refractory ALL by prior salvage therapy status.

Methods: Patients with relapsed/refractory (R/R) BCP-ALL in this international multicenter trial were randomized 2:1 to blinatumomab (n=271) or SOC (n=134). For this analysis, salvage status was adjudicated separately from prior randomization. Blinatumomab was given by continuous IV infusion (9 µg/d in week 1 of cycle 1, then 28 µg/d) in cycles of 4 weeks, 2 weeks off. The primary endpoint was overall survival (OS), determined from time of randomization until death due to any cause. Adverse events (AE) of interest were coded according to MedDRA version 16.0.

Results: At baseline, patient characteristics were balanced between groups within salvage designations. The rate of complete remission, with or without full hematologic recovery (CR/CRi/CRv) in both the S1 and S2+ groups was higher in the blinatumomab arm compared with the SOC arm (Table 1). Patients randomized to blinatumomab had a median (95% CI) of 11.1 (8.2, 17) months overall survival for S1 vs S2+ subgroup, compared with 5.5 (3.7, 9.0) months vs 3.0 (2.1, 4.0) months in the SOC arm (Figure 1). For both S1 and S2+ subgroups, blinatumomab patients had longer median survival time. Grade 3 or worse AEs were experienced by 61% and 83% of S1 patients in the blinatumomab and SOC group, respectively. These percentages were 68% and 75%, respectively, in S2+ patients. Grade 4 or worse AEs occurred in 34% and 51% S1 patients, and in 36% and 54% S2+ patients. Neurologic events of grade ≥3 occurred in 9% and 9% of S1 patients, and in 10% and 9% S2+ patients, respectively. Grade ≥3 cytokine release syndrome (CRS) was observed in 4% S1 and 5% S2+ patients receiving blinatumomab, and in no SOC patients.

Table 1.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No prior salvage (n=271)</th>
<th>Any prior salvage (n=134)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR rate</td>
<td>74%</td>
<td>71%</td>
<td>0.60</td>
</tr>
<tr>
<td>Relapse</td>
<td>26%</td>
<td>29%</td>
<td>0.25</td>
</tr>
<tr>
<td>OS rate</td>
<td>56%</td>
<td>53%</td>
<td>0.94</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Patients in this trial receiving blinatumomab for R/R ALL achieved improved OS and remission rates compared with SOC regardless of prior salvage therapy. Improved OS compared with SOC in S1 patients supports earlier use of blinatumomab.

S479
DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL AFTER CD19 CAR (19-28Z) T CELL THERAPY
J. Park1,*, I. Riviere 1, X. Wang 1, B. Senechal 1, Y. Wang 1, T. Purdon 1, R. Brentjens1, M. Sadelain1
1Memorial Sloan-Kettering Cancer Center, New York, United States

Background: CD19-specific chimeric antigen receptor (CAR) T cells have demonstrated high initial responses in patients with relapsed B-ALL. However, clinical characteristics associated with the durability of response remain undefined.

Aims: We performed a retrospective analysis of our phase I clinical trial of 19-28z CAR T cells in adult patients with relapsed B-ALL (NCT01044069) with a focus to identify those patients who optimally benefit from 19-28z CAR T cell therapy with durable long-term survival and reduced toxicities.

Methods: Adults with relapsed B-ALL were infused with autologous T cells expressing the 19-28z CAR following conditioning chemotherapy. Disease burden was assessed by bone marrow biopsy immediately prior to T cell infusion; patients with ≤5% blasts were classified as minimal residual disease (MRD) cohort vs patients with >5% blasts as morphologic disease cohort. Response assessment occurred at 4 weeks. Median follow-up duration was 18 months (range, 0.2-57.3).

Results: 51 adults received 19-28z CAR T cells; 20 in the MRD and 31 in the therapy with durable cohort. Complete remission (CR) rates were comparable (95% and 77%, respectively). However, median event-free and overall survivals widely diverged among the 42 patients who achieved MRD-negative CR: not reached (NR) (95% confidence interval [CI]: 4.2-7.5) vs 6.3 months (95% CI, 4.8-9.0) (p=0.0005), and NR (95% CI, 15.3-NR) vs 17 months (95% CI, 8.5-36.2) (p=0.0189), in the MRD and morphologic cohorts, respectively. Subsequent allogeneic HSCT in either cohort did not improve survival (p=0.8). MRD cohort patients developed substantially less severe cytokine release syndrome (CRS) and neurotoxicity, and both toxicities significantly correlated with peak haematologica | 2017; 102(s2) | 179

Madrid, Spain, June 22 – 25, 2017
CART cell expansion (p=0.0326 and p=0.0001, respectively). No case of cerebral edema was observed.

Summary/Conclusions: Despite comparable initial CR rates regardless of pre-treatment disease burden, durability of 19-28z CART cell mediated remissions and survival in adult patients with relapsed B-ALL positively correlated to a low disease burden and do not appear to be enhanced by allogeneic retransplant. Our findings strongly support the early incorporation of CD19 CART therapy before morphologic relapse in B-ALL.

S480

STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INFUSION IN ETV6-RUNX1-POSITIVE PATIENTS

K. Ferrero1, S. Chiesa2, M. Zimmermann2, G. Mann3, M.G. Valsecchi4, C.R. Bartram5, A. Biondi6, R. Panzer-Grümmayer7, R. Beier7, G. Cario7, F. Locatelli8, G. Basso9, F. Nig Gill10, M. Arico11, V. Conter12, M. Schrappe1 Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, 2Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany, 3CCRI, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria, 4School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy, 5Institute of Human Genetics, Ruprecht-Karls University, Heidelberg, Germany, 6M.Tettamanti Research Center, Pediatric Clinic, University of Milano Bicocca, Monza, Italy, 7Dept. of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany, 8Department of Pediatrics and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, 9Department SDB, University of Padova, Padova, Italy, 10Pediatric Hematology/Oncology, University Hospital Zürich, Zürich, Switzerland, 11Azienda Sanitaria Provinciale Ragusa, Ragusa, 12Department of Pediatrics, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy

Background: ETV6-RUNX1 fusion is a common genetic aberration in childhood acute lymphoblastic leukemia (ALL) and is associated with good prognosis in the context of contemporary treatment regimens. The required treatment intensity for this well-described biologic subgroup with low risk of relapse is not known so far. In trial AIEOP-BFM ALL 2000, feasibility of reduced delay of intensified treatment to reduce the burden of chemotherapy was tested in a randomized approach in the standard-risk group. Treatment reduction was not successful in the total cohort (8-year probability of disease-free survival 8y-pDFS, ± standard error) 89.2±1.3% for reduced intensified treatment, 92.3±1.2% for the standard treatment (log-rank P=0.04) due to evidence of more relapses observed in patients treated less intensively.

Aims: The retrospective subgroup analysis presented here focuses on the ETV6-RUNX1-positive patients included in the group of randomized standard-risk patients.

Methods: From 07/2000 to 06/2006, 4741 eligible patients with ALL (age range 1-17 years) were enrolled in the trial AIEOP-BFM ALL 2000 (NCT 00430118 (BFM) and NCT 00613547 (AIEOP)). Of those, 1164 patients were considered at standard risk of relapse, defined by lack of genetic high-risk criteria and absence of minimal residual disease at day 33 and week 12 of treatment (tested by immunoglobulin/T-cell receptor gene rearrangement polymerase chain reaction). They were randomly assigned to either receive the reduced-intensity protocol (P-III) or intensified treatment (P-III) for delayed intensification. P-III is shorter than P-II (duration 29 vs 49 days), the dose of dexamethasone in P-III is 30% lower, and the dose of vincristine, doxorubicin, and cyclophosphamide are reduced by 50% as compared to P-II. The intention was to prove non-inferiority of the reduced-intensity treatment compared to standard treatment.

Results: ETV6-RUNX1-positive patients (n=367) accounted for 34% of randomized standard-risk patients (Age: 6 years n=260, 6 to <10 years n=79, ≥10 years n=28; early cytologic response evaluation in bone marrow on day 15 of induction treatment: M1 n=218, M2 n=74). Of those, 188 were treated with the experimental P III, 179 received the standard P-II. With a median follow-up of 6.8 years, the as-treated analysis showed an 8y-pDFS of 94.5±1.7% for P-III and 94.1±1.8% for patients with P-II (log-rank P=0.74). Cumulative incidence of relapse at 8 years was 3.3±1.3% and 4.3±1.6% (Gray P=0.09), and 8-year overall survival was 96.9±1.4% and 98.8±0.9% (P=0.27) for P III and PII, respectively. Analysis of ETV6-RUNX1-positive patients by age groups or treatment response on day 15 allowed no further refinement of prognostic subgroup.

Summary/Conclusions: There was no evidence of prognostic disadvantage in ETV6-RUNX1-positive standard-risk patients when treated with the reduced-intensity experimental arm. No clear age- or response-dependent differences could be revealed for this group, which is in line with the biologic understanding of this genetic subgroup. Hence, it might be postulated that treatment reduction might be feasible in this well-defined biologic subgroup. However, the present data is not a sufficiently powered non-inferiority study question focused on the subgroup of ETV6-RUNX1-positive patients, but reflects a subgroup analysis with descriptive character. Therefore, any decision for treatment reduction should be considered carefully.

Biology and disease monitoring in CML

S481

A SECOND GENERATION LYSOSOMOTROPIC AGENT DRIVES LEUKAEMIC STEM CELL DIFFERENTIATION AND SENSITIZES THEM TO TYROSINE KINASE INHIBITOR TREATMENT IN VITRO AND IN VIVO

P. Baquer1,*, E. Kuntz2, R. Mitchell1, A. Ianniciello1, K.M. Ryan2, E. Gottlieb3, R.K. Attarzadeh1, T.L. Holyoake4, G.V. Helgason1

1Wolfson Wohl Cancer Research Centre, Institute of Cancer Science, University of Glasgow, 2Cancer Research UK, Beatson Institute, Glasgow, United Kingdom, 3Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, 4Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

Background: Autophagy is a conserved catabolic process that delivers cytoplasmic constituents to the lysosomes. We have previously shown that the lysosomotropic agent hydroxchloroquine (HCQ) inhibits autophagy and sensitizes Chronic Myeloid Leukaemia (CML) stem cells (LSCs) to tyrosine kinase inhibitors (TKIs) treatment. However, the biological effects of autophagy inhibition in LSCs in vivo are currently unknown and remain to be investigated. Furthermore, recent clinical studies showed that maximum tolerated dose of HCQ does not achieve consistent autophagy inhibition in cancer patients. Therefore further pre-clinical studies using more potent 2nd generation lysosomotropic agents, alone and in combination with TKIs, are vital.

Aims: Here we aim to investigate the functional effects of autophagy inhibition in LSCs both in vitro and in vivo using the highly potent lysosomotropic agent Lysosomotropic Agent (Lys05). Additionally, we aim to address whether Lys05 achieves autophagy inhibition in the most primitive LSC populations in vivo and whether it targets LSCs more effectively than HCQ when combined with TKIs.

Methods: In this study, we used primary stem-cell enriched samples (CD34+ cells) derived from CML patients at diagnosis. For in vivo studies, we used a human patient-derived xenograft (PDX) model and an inducible transgenic CML model in which the expression of BCR-ABL is induced at a stem/progenitor level (Scl-Tva-BCR-ABL). To accurately measure autophagy flow in long term LSCs in vivo, we generated the transgenic mouse Scl-Tva-BCR-ABL/GFP-LC3 by crossing the Scl-Tva-BCR-ABL model with a mouse bearing the autophagy reporter GFP-LC3 fused to GFP.

Results: Firstly, we show that Lys05 targets LSCs more potently than HCQ in vitro by achieving a 60% and a 35% reduction in number of CD34+CD38– and CFSEimmCD34+CD133+ cells respectively. Interestingly, Lys05 promoted a 40% loss of quiescent cells and induced myeloid differentiation of CD34+ cells. Functional long-term culture initiating cell (LT-CIC) assay demonstrated that, while HCQ had moderate effects, Lys05 decreased the number of LSC-derived colonies by 80%. Additionally, we show that Lys05 inhibits autophagy flow more efficiently than HCQ both in the Scl-Tva-BCR-ABL/GFP-LC3 model and in patient-derived progenitor cells. Analysis of bone marrow (BM) cells from Lys05-treated leukemic mice (but not from HCQ-treated mice), showed a statistically significant 35% decrease (p=0.0469) in the most primitive population Linc-Sca–c-kit+CD48–CD150+ followed by a 50% increase (p=0.0231) of progenitors Lin–Sca–c-kit+.

This result indicates differentiation of LSCs towards a more progenitor phenotype following potent autophagy inhibition. Finally, to test the in vivo generational switch hypothesis, both Lys05 and HCQ treatment were administered to mice over a period of 3 weeks and the effects evaluated.

Conclusion: Overall, we demonstrate that lysosomal inhibition induces loss of quiescence and drives differentiation of LSCs in vitro and in vivo. Furthermore, our results show that Lys05 achieves autophagy inhibition in LSCs and effectively sensitizes LSCs to TKIs in vitro and in vivo. Therefore, 2nd generation lysosomotropic agents should be considered as a potential alternative to HCQ in order to eliminate LSCs and achieve cure for CML patients.

S482

FC GAMMA RECEPTOR 2B IS CRITICAL FOR BCR-ABL MEDIATED LEUKEMOGENESIS

O. Hermann1,2, S. Langer3, C.C. Wessling3, M. Huber5, S. LfT, T.H. Brummendorf1, B. Koschmieder1, M. Schiemke1

1Institute of Internal Medicine – Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen, 2Institute of Transfusion Medicine, University Hospital Essen, Essen, 3Department of Neurosurgery, University of Bonn, Bonn, 4Institute of Biochemistry and Molecular Immunology, University Hospital RWTH Aachen, Aachen, Germany, 5University of Massachusetts Medical School, Worcester, United States

Background: Chronic myeloid leukemia (CML) is provoked by the chromoso-
MAL TRANSCRIPTION (9.22) that gives rise to the oncogenic tyrosine kinase Bcr-Abl. Implementation of tyrosine kinase inhibitor (TKI) therapy resulted in significant clinical success but with TKIs failing to eradicate the disease initiating leukemic stem cell population (LSC), this treatment is not curative in the vast majority of patients. By using a transgenic CML mouse model, we previously showed that LSC persist despite complete Bcr-Abl kinase inhibition due to a lack of depletion. In this study, we identified the TIM carrying Fc gamma receptor IIb (FcRyIIb; CD32) to be 2.8-fold upregulated in Bcr-Abl+ versus control LSK (lin-;Sca-1+; c-kit+) cells using microarray and qRT-PCR.

Methods: In this study, we first aimed to validate Bcr-Abl mediated FcRyIIb upregulation on mRNA and protein level in leukemic cells. Next, we tested the effect of shRNA-mediated FcRyIIb knock-down and depletion on CFU (colony forming unit) capacity, proliferation and leukemic signaling in vitro. Finally, we studied the disease-initiating potential of primitive CML stem and progenitor cells upon FcRyIIb knock down.

Results: Bcr-Abl increased FcRyIIb mRNA (12.3-fold, p≤0.001) and protein expression in primary murine lineage negative (lin-) BM cells. Reduction of FcRyIIb in immortalized SCLT/A-Bcr-Abl progenitor cells significantly reduced CFU (colony forming unit) capacity (1.28-fold, p≤0.05) and decreased spontaneous transformation rate in these cells (2.27-fold, p≤0.001). Moreover, transplantation of SCLT/A-Bcr-Abl shRNA:FcRyIIb BM cells (CD45.1+) into FVB/FVB wildtype (WT) CD45.2+ recipients reduced spleen weight (352 ± 59.13mg) as compared to scrambled shRNA (586.1 ± 101.72mg). FACS analysis revealed a decrease in GFP+;CD45.1+ BM cells (1.43-fold, p≤0.001) upon FcRyIIb knock down. Likewise, donor-derived Gr-1+ cells (Gr-1+; CD45.1+; GFP+) were reduced in the BM (1.28-fold, p≤0.01) of these mice. Flow-cytometric analysis of the stem cell compartment revealed decreased leukemic BM LSK cells (lin-; c-kit+; Sca-1+; CD45.1+; GFP+, 1.38-fold, p≤0.01) in mice transplanted with shRNA:FcRyIIb vs scrambled control. We also observed similar effects upon FcRyIIb depletion (FcRyIIb-/-) vs wildtype (FcRyIIb+/+), combined with virally induced Bcr-Abl expression. Interestingly, Bc-Abl signaling induces FcRyIIb phosphorylation in leukemic cells. Analysis of downstream signal pathways showed decreased levels of p-ERK, p-BTK, p-PLCγ1 in FcRyIIb-/-, compared to FcRyIIb+/+ Bcr-Abl transduced immortalized primary murine BM cells.

Summary/Conclusions: FcRyIIb is upregulated in LSC derived from transgenic CML mice upon Bcr-Abl expression. Complete depletion or knock down of the receptor reduces CFU capacity and cell growth in CML cells and significantly impairs CML development and LSC burden in vivo, presumably due to impaired leukemic downstream signaling. Our data demonstrate that FcRyIIb is critical and disease specific making it a potential novel therapeutic target in CML stem cells.

S483 MYC-DEPENDENT REPRESSION MECHANISM OF THE MIR-150 TRANSCRIPTIONAL REGULATION IN CHRONIC MYELOID LEUKEMIA

P. Hlinka1, K. Sovova1, F. Sovova1, H. Klamova1, P. Pecherkov1, Z. Sovova1, J. Kobliha1, T. Stipka1, D. Perrot2, K. Machova Polakova1,4
1Institute of Hematology and Blood Transfusion, 2Institute of Pathological Physiology, 31st Medical faculty, Charles University in Prague, Czech Republic, 4Department of Medicine, Greenbaum Cancer Center, University of Maryland Baltimore, Baltimore, United States, 4Institute of Clinical and Experimental Hematology of the 1st Medical faculty, Charles University and Institute of Hema- tology and Blood Transfusion, Prague, 3BIoCEV, Biotechnology and Biomed- icine Center of the Academy of Sciences and Charles University, Vestec, Czech Republic

Background: The expression of miRNAs is regulated at transcriptional and posttranscriptional levels. Dysregulation of miRNAs could directly induce or be a consequence of oncogenic pathways. Chronic myeloid leukemia (CML) is characterized by overexpression of MYC-150 levels leading to an insufficient repression of its target, oncogene MYB. CML treatment with imatinib normalizes miR-150 levels. Thus miR-150 is crucial for CML biology, however, little is known about its upstream transcriptional regulation. BCR-ABL is an inhibitor of oncogene MYB, CML treatment with imatinib normalizes miR-150 levels. Therefore, BCR-ABL is crucial for CML biology, but little is known about its upstream transcriptional regulation. BCR-ABL is an inhibitor of oncogene MYB, which is required for BCR-ABL-dependent leukemogenesis in CML blast crisis. The aim of this study was to characterize transcriptional regulation of miR-150 in 150/MYB regulatory links in CML, sustained in CML resistant cells. We low down levels of miR-150 to be a hallmark of CML and impaired signaling pathway MYB/BCR-ABL1/MYC/miR-150/miR-155/PJ.1 leading to a progressive cell differentiation block.

Aims: To define potential mechanisms of the miR-150 transcription regulation via the oncogenic transcription factor MYC in CML.

Methods: Primary bone marrow cells from CML (N=28), CML cell lines K562 and KCL-22 and imatinib resistant (K562R, KCL-22R). Expression analysis: RT-PCR. Protein levels: WB. ChIP: chromatin from the cell lines. SIRNA inhibi- tion: AMAXA electroporation. DNA methylation analysis: Methylation DNA immunoprecipitation.

Results: We observed that unlike MLL-AML diagnosis (Jiang et al. 2012), CML is not characterized by a block of miR-150 maturation and that miR-150 levels negatively correlated with MYC mRNA levels in CML HSPCs (p≤0.001). Role of miR-150 overexpression by imatinib induced was downregulated and restored miR-150 levels in K562 and KCL22. Imatinib resistance in K562R and KCL-22R was characterized by further miR-150 downregulation. To assess the MYC role on regulating miR-150 levels we tested the MYC binding sites upstream the miR-150 gene. We detected MYC binding to the upstream CpG of the MYC150 gene in K562 and KCL-22. We also found a depletion of MYC from the miR-150 locus after the imatinib treatment. We suggested potentially synergistic route for imatinib-induced BCR-ABL1 inhibition. This could be processed not only directly but also through an inhibition of a mutual positive regulatory loop between MYC and BCR-ABL1 (Xie et al. 2002). We also noticed upregulation of MYC downstream signaling which is adjacent to the studied miR-150 CpG to become activated by imatinib. We observed MYC levels dependent regulation of both genes, but FCGRT is activated by MYC. This different MYC regulatory role may be facilitated by the detected transcription factor CTCF binding to an insulator site between miR-150 promoter and the CpG. An activation of the insulator via CTFC binding could be an interaction between enhancers and promoters (Bell et al. 2000). CTCF was previously described to be an inhibitor of MYC transcription and we show CTFC transcription to be induced by imatinib. CTFC binding to DNA is prevented by DNA methylation. We did not detect DNA methylation within miR150 upstream region.

Conclusions: The presented data characterize transcriptional regulation of transcription factors-dependent epigenetic changes within the promoter and distal enhancers. We outlined a new insight into MYC/MIR150/BCR-ABL1/Imatinib regulation loop in CML. Our work revealed a MYC role in miR-150 repression underlying the CML leukemogenesis, where MYC functions as a pivotal gatekeeper and its repression is probably required for CML establishment and is enforced in imatinib resistant CML.

Support: LH15104 of MSMT and 00023736 of MZCR

S484 COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT:
AN ALLG CML9 SUB-STUDY

I.S. Pagani1, P. Dang1, I.O. Kommers2, J. Goyne1, V.A. Saunders1, J.A. Prime3, D.L. White1, S. Branford3, T.P. Hughes1, T.P. Hughes1, D.M. Ross1,2
1Cancer Theme, South Australian Health and Medical Research Institute (saHmi), Adelaide, Australia, 2School of Medicine, Vrije Universiteit Medical Center, Amsterdam, Netherlands, 3Department of Genetics and Molecular Pathology, Centre for Cancer Biology,SA Pathology, 4Department of Haema- tology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

Background: Real-time reverse transcription quantitative PCR (RQ-PCR) for BCR-ABL1 mRNA is widely used for the monitoring of chronic myeloid leukaemia (CML). Pre-analytical factors, such as the rate of degradation of the target mRNA, and methodological factors, such as the choice of control gene, may influence the final result. In contrast the genomic DNA is stable, and the number of copies of BCR-ABL1 DNA is directly proportional to the number of CML cells. Measuring both DNA and RNA may enable us to understand the contribution of expression and cell number to the RQ-PCR response.

Aims: To compare BCR-ABL1 DNA Q-PCR and routine RQ-PCR monitoring of CML.

Methods: Fifty-nine newly diagnosed chronic phase CML patients from the ALLG CML9 (TIDEL II) trial were included in this sub-study. Samples were tested prior to commencing TKI treatment (baseline), at 1, 2, and 3 months, and every 3 months to 24 months (total 568 samples). Since we wanted to compare the sensitivity of the Q-PCR methods we selected the patient who had achieved the number of 100% of copies of BCR-ABL1 DNA is directly proportional to the number of CML cells. Measuring both DNA and RNA may enable us to understand the contribution of expression and cell number to the RQ-PCR response.

Results: We first demonstrated that DNA dPCR and real-time RQ-PCR gave comparable results: 45 samples from 6 patients were quantified by both meth- ods. The median bias was -0.15 (1.4-fold) in DNA and RQ-PCR. The mean detection limit of RQ-PCR was 5.0-log, and 6.4-log for DNA methods. We first demonstrated that DNA dPCR and real-time RQ-PCR gave comparable results: 45 samples from 6 patients were quantified by both methods. The median bias was -0.15 (1.4-fold) in DNA and RQ-PCR. The mean detection limit of RQ-PCR was 5.0-log, and 6.4-log for DNA methods.

Support: LH15104 of MSMT and 00023736 of MZCR
and ii) verify accuracy and inter-laboratory reproducibility of results. The second storage and a common pipeline of data analysis, interpretation and reporting, BCR-ABL1 KD mutation screening.

A multicenter, multilaboratory prospective study (‘NEXT-IN-CML’) has been conducted to assess the feasibility, cost, turnaround times and clinical utility of a next generation amplicon deep sequencing (Deep Seq) strategy for routine therapeutic reassessment and is recommended in case of Failure and Warning. In chronic myeloid leukemia

KINASE DOMAIN MUTATION SCREENING: THE ‘NEXT-IN-CML’ STUDY

S485

ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPION DEEP SEQUENCING FOR BCR-ABL1

Background: Benchtop next generation sequencers are gradually replacing Sanger sequencers in diagnostics labs because of greater throughput, better sensitivity and increasing cost-effectiveness. In chronic myeloid leukemia (CML) patients (pts) on tyrosine kinase inhibitor (TKI) therapy, BCR-ABL1 kinase domain (KD) mutation screening is a precious tool for timely and rational therapeutic reassessment and is recommended in case of Failure and Warning. A multicenter, multilaboratory prospective study (‘NEXT-IN-CML’) has been conducted to assess the feasibility, cost, turnaround times and clinical utility of a next generation amplicon deep sequencing (Deep Seq) strategy for routine BCR-ABL1 KD mutation screening.

Aims: The first phase of the study was aimed to i) create a network of 4 labs achieving MMR by 12 months, in comparison with 33% (20/60) of patients with e13a2 transcripts. BCR-ABL1 mRNA expression levels were significantly lower in e13a2 patients than in e14a2 patients in all follow-up samples analysed (ratio of BCR-ABL1 mRNA:DNA for e13a2 0.44 vs e14a2 0.57; p=0.016).

Figure 1.

Summary/Conclusions: In the first 1-3 months BCR-ABL1 mRNA fell more rapidly than DNA, likely reflecting the time taken for normal haematopoietic cells to recover. At later time-points there was good agreement between methods, indicating that later reduction in BCR-ABL1 IS is closely related to depletion of leukaemic cells. Normalised to BCR-ABL1 DNA the expression of e13a2 BCR-ABL1 mRNA was lower than that of e14a2, an observation that requires confirmation. DNA methods were more sensitive: following the achievement of MMR by 12 months, in comparison with 63% (median 0.002%, range 0.0003-0.07%). Finally, 88% (15/17) of patients with low burden mutations <3% were occasionally called by one or two labs only, suggesting that this value should be taken as a threshold below which mutation detection is not reproducible and sequencing artifacts and errors cannot be ruled out. In the second phase of the study, pts positive for mutations were 25/159 (16%; 23 Failures and 2 Warnings) by Sanger Seq and 52/159 (33%; 48 Failures and 4 Warnings) by Deep Seq. Among the pts with low burden mutations detectable by Deep Seq, 4 had a T315I; 34 had other known TKI-resistant mutations; 14 had only mutations with unknown clinical significance. Pts positive for mutations by Deep Seq were more frequent in the High and Intermediate Sokal risk group. The number of positive pts and the number of mutations per pt were not significantly higher in those receiving 2nd- or subsequent-line TKI therapy than in those receiving 1st-line TKI therapy. Compound mutations found were only in 2 out of 52 mutated pts (both in blastic phase). Summary/Conclusions: 1) Results of the ‘NEXT-IN-CML’, the first prospective study evaluating the routine diagnostic use of Deep Seq of BCR-ABL1, show that this technology can successfully be implemented in national lab networks and is feasible, robust and reproducible; 2) in a relatively large, nonselected cohort of CML pts analysed for mutations because of a Failure or Warning response, Deep Seq confirmed that enhancing sensitivity enables to detect BCR-ABL1 KD mutations in twice as many pts as compared to Sanger Seq (33% vs 16%). All the pts who need to be switched to another TKI would benefit from sensitive BCR-ABL1 KD mutation screening by Deep Seq.

Background: Benecthop next generation sequencers are gradually replacing Sanger sequencers in diagnostics labs because of greater throughput, better sensitivity and increasing cost-effectiveness. In chronic myeloid leukemia (CML) patients (pts) on tyrosine kinase inhibitor (TKI) therapy, BCR-ABL1 kinase domain (KD) mutation screening is a precious tool for timely and rational therapeutic reassessment and is recommended in case of Failure and Warning. A multicenter, multilaboratory prospective study (‘NEXT-IN-CML’) has been conducted to assess the feasibility, cost, turnaround times and clinical utility of a next generation amplicon deep sequencing (Deep Seq) strategy for routine BCR-ABL1 KD mutation screening.

Aims: The first phase of the study was aimed to i) create a network of 4 labs achieving MMR by 12 months, in comparison with 33% (20/60) of patients with e13a2 transcripts. BCR-ABL1 mRNA expression levels were significantly lower in e13a2 patients than in e14a2 patients in all follow-up samples analysed (ratio of BCR-ABL1 mRNA:DNA for e13a2 0.44 vs e14a2 0.57; p=0.016).

Figure 1.

Summary/Conclusions: In the first 1-3 months BCR-ABL1 mRNA fell more rapidly than DNA, likely reflecting the time taken for normal haematopoietic cells to recover. At later time-points there was good agreement between methods, indicating that later reduction in BCR-ABL1 IS is closely related to depletion of leukaemic cells. Normalised to BCR-ABL1 DNA the expression of e13a2 BCR-ABL1 mRNA was lower than that of e14a2, an observation that requires confirmation. DNA methods were more sensitive: following the achievement of MMR by 12 months, in comparison with 63% (median 0.002%, range 0.0003-0.07%). Finally, 88% (15/17) of patients with low burden mutations <3% were occasionally called by one or two labs only, suggesting that this value should be taken as a threshold below which mutation detection is not reproducible and sequencing artifacts and errors cannot be ruled out. In the second phase of the study, pts positive for mutations were 25/159 (16%; 23 Failures and 2 Warnings) by Sanger Seq and 52/159 (33%; 48 Failures and 4 Warnings) by Deep Seq. Among the pts with low burden mutations detectable by Deep Seq, 4 had a T315I; 34 had other known TKI-resistant mutations; 14 had only mutations with unknown clinical significance. Pts positive for mutations by Deep Seq were more frequent in the High and Intermediate Sokal risk group. The number of positive pts and the number of mutations per pt were not significantly higher in those receiving 2nd- or subsequent-line TKI therapy than in those receiving 1st-line TKI therapy. Compound mutations found were only in 2 out of 52 mutated pts (both in blastic phase). Summary/Conclusions: 1) Results of the ‘NEXT-IN-CML’, the first prospective study evaluating the routine diagnostic use of Deep Seq of BCR-ABL1, show that this technology can successfully be implemented in national lab networks and is feasible, robust and reproducible; 2) in a relatively large, nonselected cohort of CML pts analysed for mutations because of a Failure or Warning response, Deep Seq confirmed that enhancing sensitivity enables to detect BCR-ABL1 KD mutations in twice as many pts as compared to Sanger Seq (33% vs 16%). All the pts who need to be switched to another TKI would benefit from sensitive BCR-ABL1 KD mutation screening by Deep Seq.

Background: Benecthop next generation sequencers are gradually replacing Sanger sequencers in diagnostics labs because of greater throughput, better sensitivity and increasing cost-effectiveness. In chronic myeloid leukemia (CML) patients (pts) on tyrosine kinase inhibitor (TKI) therapy, BCR-ABL1 kinase domain (KD) mutation screening is a precious tool for timely and rational therapeutic reassessment and is recommended in case of Failure and Warning. A multicenter, multilaboratory prospective study (‘NEXT-IN-CML’) has been conducted to assess the feasibility, cost, turnaround times and clinical utility of a next generation amplicon deep sequencing (Deep Seq) strategy for routine BCR-ABL1 KD mutation screening.

Aims: The first phase of the study was aimed to i) create a network of 4 labs achieving MMR by 12 months, in comparison with 33% (20/60) of patients with e13a2 transcripts. BCR-ABL1 mRNA expression levels were significantly lower in e13a2 patients than in e14a2 patients in all follow-up samples analysed (ratio of BCR-ABL1 mRNA:DNA for e13a2 0.44 vs e14a2 0.57; p=0.016).

Figure 1.

Summary/Conclusions: In the first 1-3 months BCR-ABL1 mRNA fell more rapidly than DNA, likely reflecting the time taken for normal haematopoietic cells to recover. At later time-points there was good agreement between methods, indicating that later reduction in BCR-ABL1 IS is closely related to depletion of leukaemic cells. Normalised to BCR-ABL1 DNA the expression of e13a2 BCR-ABL1 mRNA was lower than that of e14a2, an observation that requires confirmation. DNA methods were more sensitive: following the achievement of MMR by 12 months, in comparison with 63% (median 0.002%, range 0.0003-0.07%). Finally, 88% (15/17) of patients with low burden mutations <3% were occasionally called by one or two labs only, suggesting that this value should be taken as a threshold below which mutation detection is not reproducible and sequencing artifacts and errors cannot be ruled out. In the second phase of the study, pts positive for mutations were 25/159 (16%; 23 Failures and 2 Warnings) by Sanger Seq and 52/159 (33%; 48 Failures and 4 Warnings) by Deep Seq. Among the pts with low burden mutations detectable by Deep Seq, 4 had a T315I; 34 had other known TKI-resistant mutations; 14 had only mutations with unknown clinical significance. Pts positive for mutations by Deep Seq were more frequent in the High and Intermediate Sokal risk group. The number of positive pts and the number of mutations per pt were not significantly higher in those receiving 2nd- or subsequent-line TKI therapy than in those receiving 1st-line TKI therapy. Compound mutations found were only in 2 out of 52 mutated pts (both in blastic phase).

Summary/Conclusions: 1) Results of the ‘NEXT-IN-CML’, the first prospective study evaluating the routine diagnostic use of Deep Seq of BCR-ABL1, show that this technology can successfully be implemented in national lab networks and is feasible, robust and reproducible; 2) in a relatively large, nonselected cohort of CML pts analysed for mutations because of a Failure or Warning response, Deep Seq confirmed that enhancing sensitivity enables to detect BCR-ABL1 KD mutations in twice as many pts as compared to Sanger Seq (33% vs 16%). All the pts who need to be switched to another TKI would benefit from sensitive BCR-ABL1 KD mutation screening by Deep Seq.
Prognostic markers and new treatment in MDS

S486

PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS


Background: Cytopenia is a hallmark in myelodysplastic syndrome (MDS), however, many patients with persistent cytopenia do not fulfill the criteria for MDS. These patients are now classified as idiopathic cytopenia of undetermined significance (ICUS) or if a mutation is detected as clonal cytopenia of undetermined significance (CCUS). Little is known about these new entities in regards to survival and prognosis.

Aims: In this study we want to compare ICUS patients with MDS patients having low- or very low-risk disease according to the IPSS-R. We also wanted to investigate if sequencing of the cohort could bring additional information in regards to overall survival.

Methods: All patients underwent a bone marrow biopsy, cytogenetics and a broad range of blood tests. Furthermore, all ICUS patients underwent a blinded morphology review by two experienced pathologists; these review data will be ready for presentation at EHA. ICUS was defined as persistent cytopenia for more than six months, no chromosomal aberrations and common causes of cytopenia were ruled out. The patients were sequenced with a targeted sequencing panel, either using a customized Haloplex panel or a customized sequencing panel for the Ion Torrent platform. We analyzed 20 genes which are the most commonly mutated genes in MDS.

Results: So far we included 157 patients, 122 were classified as ICUS and 35 as MDS and the median age is 65 and 68 years, respectively (p=0.27). We have sequenced 78% of the ICUS patients and 74% of the MDS patients. In total 53% and 73% of the ICUS and MDS patients had at least one mutation detected, respectively. If the patients carried a mutation, the median number of mutations was two in both the CCUS and the MDS group. The most commonly mutated genes were TET2, SRSF2, DNMT3A and ASXL1 in 38 patients (31%), n=16 (13%), n=10 (8%), n=10 (8%), respectively. There were no significant differences in the distribution between the two groups. Mutations in NRAS, KRAS, TP53 were only identified in one patient each. The overall survival between the ICUS and the low-risk MDS patients did not differ (p=0.18) (figure 1). We also subdivided the ICUS patients into non-clonal ICUS and CCUS, but observed no difference between these two groups (p=0.355).

Eight of the patients categorized as ICUS progressed to a myeloid neoplasm during the follow up, and of these seven had a detectable mutation at time of enrollment, only one ICUS patient without a detectable mutation progressed (p=0.06).

Summary/Conclusions: We here demonstrate that low-risk MDS and ICUS patients share similar survival patterns, however, larger studies with longer follow up are needed. Mutations are most commonly found in the epigenetic regulators in this cohort of ICUS and low-risk MDS, while mutations in classical tumor suppressors and oncogenes such as TP53 and NRAS are rare. Mutational screening seems promising in detecting patients at risk of progression, however, other biomarkers for prognostication are warranted.

S487

AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILOMUB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)

Garcia-Manero1,*, N. Daver1, G. Montalban-Bravo1, E. Jabbour1, C. Di Nardo1, G. Garcia-Manero1,*, N. Daver1, G. Montalban-Bravo1, E. Jabbour1, C. Di Nardo1, S. Kornblau1, P. Bose1, Y. Alvarado1, M. Ohanian1, G. Borthakur1, J. Cortes1, K. Naqui1, N. Pemmaraju1, X. Huang2, G. Nogueras-Gonzalez2, C. Bueso-Ramos2, Y. Gasior1, V. Bayer1, S. Pierce1, H. Yang1, S. Colla1, H. Kantarjian1

Background: Outcomes of pts with MDS after hypomethylating agent (HMA) failure remain poor. Upregulation of PD-1/PD-L1 and CTLA-4 in MDS CD34+ cells after exposure and loss of response to HMA have been reported. Nivo and Ipi in allo or monoclonal aignted grade 33 non-hematologic AEs. Therefore, the stopping rule for toxicity was not met in any of the cohorts. Delays of therapy due to AEs were required in 9 pts due to: rash (N=1), adrenal insufficiency (N=1), colitis (N=1), thyroiditis (N=2), pneumonitis (N=3), and nephritis (N=1). Early 8-week mortality occurred in 1 patient due to: adrenal insufficiency (N=1), colitis (N=1), thyroiditis (N=2), pneumonitis (N=3), and nephritis (N=1).

Results: A total of 63 pts have been enrolled, 54 (86%) are evaluable for response and toxicity including 21 treated with frontline AZA+Nivo, and 15 and 18 with Nivo or Ipi after HMA failure, respectively Median age is 69 years (range 39-85). The median number of treatment cycles was 3 (range 1-11). A total of 3 (27%) pts in the AZA+Nivo cohort, 6 (40%) in the Nivo cohort, and 3 (33%) in the Ipi cohort having received 3 cycles. The stopping rule for toxicity was not met in any of the cohorts. Delays of therapy due to AEs were required in 9 pts due to: rash (N=1), adrenal insufficiency (N=1), colitis (N=1), thyroiditis (N=2), pneumonitis (N=3), and nephritis (N=1). Early 8-week mortality occurred in 1 patient due to: adrenal insufficiency (N=1), colitis (N=1), thyroiditis (N=2), pneumonitis (N=3), and nephritis (N=1). The ORR was 80% (13/21) in the AZA+Nivo cohort including 6 CR. The ORR was 0% and 30% (5/18) in the Nivo and Ipi arms, respectively. The stopping rule for response was met on the Nivo arm, and enrollment after patient 15 was stopped. Immunophenotypic analysis of stem cell and progenitor compartments was performed in 27 pts, including PD-1 and PD-L1 expression analysis in 16 pts. Increased PD-1 and PD-L1 expression on progenitor and stem cell compartments was observed in 3 and 4 pts, respectively. Treatment with PD-1 inhibitors could not overcome the aberrant differentiation patterns. No differences in response were observed based on PD-1 bone marrow expression.

Summary/Conclusions: Preliminary results indicate that PD-1 blockade with Nivo in combination with AZA in untreated high-risk MDS pts is associated with a tolerable safety profile and clinical activity. Single-agent Ipi is capable of inducing responses in previously treated MDS pts. Single-agent Nivo did not show clinical activity.

S488

ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS

S. Navada1,*, G. Garcia-Manero2, K. Kearn3, R. Ochimara-Reissig1, E. Demakos1, P. Fenaux3, M. Petrone4, P. Bzyszewski4, S. Fruchtman4, L. Silverman1

Background: Azacitidine (AZA) is first line therapy for patients (pts) with higher risk MDS and demonstrated efficacy in older pts with AML (Dombret et al, Blood
Hypomethylating agents (HMA) remain the standard of care for the treatment of myelodysplastic syndromes (MDS) however, loss of response to therapy is associated with poor outcomes. Multiple studies have tried to identify biomarkers of response but the impact of the mutational architecture present at the time of diagnosis in response outcomes is unclear.

Aims: To evaluate the impact of the mutational architecture present at the time of diagnosis in response outcomes.

Methods: We evaluated 222 previously untreated patients with MDS or CMML that received HMA therapy. A total of 143 patients (79%) had MDS and 43 (19%) had CMML, including 108 (49%) with lower-risk based on IPSS and 114 (51%) with higher-risk disease. Therapy consisted in azacitidine monotherapy in 60 (27%) patients, decitabine monotherapy in 57 (26%), guadecitabine in 46 (21%) and combinations in 59 (27%). The ORR was 61% (135/222) with 80 (36%) patients achieving CR. A total of 161 (73%) patients had at least one detectable mutation. Median number of mutations was 1 (range 0-5). Frequencies of detected mutations are shown in Figure 1A. Among 70 (32%) patients evaluable for clonal heterogeneity, as indicated in Figure 1B. By univariate analysis, presence of mutations in ASXL1 (OR 0.45, CI 0.22-0.93, p=0.03) and RUNX1 (0.44, CI 0.20-0.96, p=0.038) as well as that of TP53 mutations with VAF ≥0.31 (OR 0.21, CI 0.05-0.8, p=0.024) predicted for a lower likelihood of achieving response. Analysis of functional pathways revealed that patients with mutations in chromosome 1 (OR 0.43, CI 0.21-0.86, p=0.017) and signaling genes (OR 0.48, CI 0.23-1.00, p=0.049) had lower likelihood of achieving response. Additionally, patients with ASXL1 mutations (OR 0.24, CI 0.09-0.64, p=0.005), particularly in the absence of co-occurring TET2, as well as those with increased number of mutations, particularly if more than 3 (OR 0.21, CI 0.06-0.73, p=0.014), or signaling gene mutations (OR 0.32, CI 0.13-0.80, p=0.016), had a lower likelihood of achieving a CR. A longer time to response was observed in patients with DNM73A mutations with VAF ≥0.35 (3.4 vs 1 months, OR 0.22, CI 0.06-0.76, p=0.017). Among patients who achieved CR, presence of 3 or more mutations (2.6 vs 1.3 months, OR 1.35, CI 1.00-1.83, p=0.049) and TP53 mutations with VAF ≥0.31 (0 vs 3.7 months, OR 2.03, CI 1.03-3.98, p=0.040) predicted for shorter CR duration. Presence of clonal heterogeneity, as well as the identified pairwise co-mutation patterns did not predict for any of the response outcomes.

Summary/Conclusions: The combination of oral RIG and standard-dose AZA was well tolerated in repetitive cycles in pts with AML and MDS. Response was observed both in HMA-treatment-naive pts (85%) and in pts failing HMA therapy (62%), suggesting the addition of RIG can overcome HMA clinical resistance by acting as a chromatin modifying agent. In AML, responses were seen in 37.5% of evaluable pts. Based on these results, continued study in AML is warranted. A Phase III study of the combination of oral RIG and AZA in pts with treatment naive MDS is planned.

**Table 1.**

Summary/Conclusions: The type, number and burden of mutations at the time of diagnosis may predict response to therapy with HMA in patients with MDS and CMML.
STUDY OF THE EFFECT OF miRNAs TARGETING RPS14 ON CELLULAR BIOLOGICAL BEHAVIOR OF MYELODYSPLASTIC SYNDROMES

Y. Nie1, B. Xiong1, X. Zuo1, S. Wang2
1Zhongnan Hospital of Wuhan University, Wuhan, 2Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin, China

Background: As key factors in gene post-transcriptional regulation, microRNAs (miRNAs) have been identified to play important roles in carcinogenesis in various tumors. Myelodysplastic syndrome (MDS) is a group of clonal myeloid disorders characterized by refractory quantitative and qualitative abnormalities of hemocytes and its pathogenesis is poorly understood. Some studies have shown that abnormal expressions of some miRNAs have close relationship with the pathogenesis of MDS. Recently, low RPS14 expression is found common in all kinds of myelodysplastic syndromes including patients without 5q deletion, but its mechanism remains unclear.

Aims: To determine the cause of RPS14 reduction in MDS except 5q- syndrome, influence of miRNAs on RPS14 expression was analyzed, and the role of specific miRNA on proliferation, differentiation and apoptosis of hematopoietic stem cells were evaluated. This research will help reveal the pathogenesis of MDS from a new angle and provide new ideas for the diagnosis, treatment and prognosis evaluation of MDS.

Methods: Firstly, we predicted that miR-223 may target 3'UTR of RPS14 by bioinformatics software, then verified if the special miRNA could target RPS14 by assay of luciferase activity. Secondly, the miRNA expression level of miR223 were detected in the bone marrow BM selected from 28 MDS patients including ten RCUD patients, ten RCMD patients, four RAEB-1 patients and four RAEB-2 patients, meanwhile, the miR223 expression status were tested in four kinds of cell lines including SKM-1, HL-60, K562 and THP-1. Cell lines through qRT-PCR and RPS14 expression was detected by means of immunofluorescence (IF). Thirdly, constructing lentivirus which carried miR223 overexpression vector and inhibitor were infected to the SKM-1 cell line and K562 cell line which had the highest level of RPS14, then apoptotic analysis was detected by flow cytometry method and proliferation was tested by CCK-8 assay. Fourthly, hemin (50μM,) was used to induce erythroid differentiation of K562 cells which carried miR223 overexpression. We used flow cytometry method CD71 and CD235a makers and qRT-PCR (CD235 and r-globin) to detect the erythroid proliferation.

Results: 1.We verified miR-223 could target RPS14 by assay of luciferase activity. 2. Ten MDS patients had higher miR-223 expression compared with health controls. We demonstrated that miR223 could promote cell proliferation, inhibit cell apoptosis and suppress terminal erythropoiesis through target RPS14.

Summary/Conclusions: MDS patients had higher miR-223 expression compared with health controls. We demonstrated that miR223 could promote cell proliferation, inhibit cell apoptosis and suppress terminal erythropoiesis through target RPS14.
serial samples, we inferred the clonal relationships between original and relapsed samples in 20 patients (Fig B). Mutations from initial diagnosis reappeared in 17 patients. The relapse clone of 13 patients was identical to or clonally evolved from the initial AML clone (7 and 6 patients, respectively). Relapse clones of 4 patients evolved from an inferred ancestral clone, distinct from the initial AML clone. The remaining 3 patients’ relapse clones appear to be independent of the initial AML clone. As was assessed whether the mutation status at pre- and post-HCT has any impact on OS and relapse after HCT. With a follow-up duration of 6.9 years, patients with VAF ≥0.2% at day 21 in any gene showed worse OS (HR 2.9; p=0.006) as well as increased risk of relapse (HR 5.3; p=0.0003) (Fig C-D). Multivariate analyses verified that VAF ≥0.2% at day 21 remained an independent risk factor (HR 1.32; 95% CI 1.30-2.33; p<0.01), OS (HR 1.80; 95% CI 1.32-2.45; p<0.01) and GRFS (HR 1.32; 95% CI 1.01-1.72; p<0.05) and higher NRM (HR 3.03; 95% CI 1.98-4.70; p<0.01) vs HAPLO HSCT to those from MSD.

Aims: The following factors were included in the propensity score model: patient, year of HSCT, time from diagnosis to HSCT, conditioning (RIC), source of stem cells (BMP/B), cytogenetic group, patient and donor CMV serology status.

Results: We identified 2654 pts (HAPLO=185; MSD=2469) for int-AML (HAPLO=122; MSD=1888) or high-risk AML (HAPLO=63; MSD=581). Median follow-up (months) was 16 (1-209), with a median of 24 months for HAPLO recipients. 74% received PC'TY and 26% ATG. Conditioning regimen was myeloablative in 50% vs 52% (p=0.52) of HAPLO and MSD pts, respectively. HAPLO pts had a longer interval from diagnosis to HSCT (6 vs 4 months; p<0.01), had more often high-risk AML (34% vs 23%; p<0.01), bone marrow as stem cell source (49% vs 19%; p<0.01) and CMV positive donors (72% vs 61%; p=0.01). Graft failure occurred more frequently after HAPLO (3% vs 1%; p=0.002). For pts with int-AML CI of aGVHD and cGVHD was 29% vs 1% (p=0.03) and 30% vs 36% (p=0.02) in HAPLO and MSD pts, respectively. At two years, NRM and RI were 26% vs 10% (p=0.01) and 30% vs 20% (p=0.52) for HAPLO and MSD pts, respectively. In multivariate analysis HAPLO was associated with reduced LFS (HR 1.74; 95% CI 1.30-2.33; p<0.01), OS (HR 1.80; 95% CI 1.32-2.45; p<0.01) and GRFS (HR 1.32; 95% CI 1.01-1.72; p<0.05) and higher NRM (HR 3.03; 95% CI 1.98-4.70; p<0.01) vs MSD.

Summary/Conclusions: With an ORR of 67% and a sustained response rate of ≥20 weeks of 71%, treatment with ibr resulted in clinically meaningful and durable responses in pts who failed at least 1 prior treatment for cGVHD. Most responders were able to reduce steroid dose. PD and biomarker changes support a beneficial effect of ibr on immune cell subsets in pts with cGVHD. The interactions of ibr with those previously reported for pts with B cell malignancies and those seen in cGVHD pts on concomitant steroids. Responses in this pretreated, high-risk population support study of ibr for frontline treatment of cGVHD.
cliated to lower LFS. Donor CMV seropositivity was associated with lower GRFS and higher NRM and aGVHD. In high-risk-AML aGVHD and cGVHD were 36% vs 24% (p=0.03) and 39% vs 33% (p=0.80) for HAPLO and MSD pts, respectively. At two years, NRM and RI were 18% vs 10% (p=0.16) and 21% vs 36% (p=0.02) while LFS and OS were 61% vs 55% (p=0.14) and 67% vs 66% (p=0.26) in HAPLO and MSD pts; GRFS was 44% vs 40% (p=0.17). In multivariate analysis risk of grade IV aGVHD (HR: 2.20; 95% CI: 1.29-3.74; p<0.01) was increased after Haplo as compared to MSD and no difference was observed in LFS, OS and GRFS, respectively. Conditioning regimen was associated with lower NRM and higher GRFS; while younger age and donor CMV status was associated with lower RI, higher LFS and OS. Results were confirmed in the analysis of the with the the propensity score technique as for RI, NRM, LFS, OS and GRFS

Summary/Conclusions: As per our registry based study in intermediate risk AML results of HSCT from matched sibling donor are superior to those of HAPLO-HSCT, while in high risk-AML relapse is lower in the HAPLO transplants and NRM, LFS and OS is similar

S494

INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED RISK FACTORS

M. Heuser1, R. Gadbdouline1, P. Loeffeld1, V. Dobbermacl1, H. Kreimeyer1, M. Pankratz1, M. Flintrop1, V. Panagiota1, H. Kreimeyer1, M. Wichmann1, R. Shaswar1, U. Platzbecker2, C. Thiede2, T. Schroeder3, G. Kobbe3, R. Geffers4, B. Schlegelberger1, G. Göhring1, H.-H. Kreipe1, U. Gemming1, A. Gansen1, N. Kroeger5, C. Koenecke1, F. Thol1

1Hannover Medical School, Hannover, 2Universitätsklinikum Carl Gustav Carus, Dresden, 3Heinrich Heine University, Düsseldorf, 4Helmholtz Centre for Infection Research, Braunschweig, 5University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Background: Prediction of individual outcomes after allogeneic hematopoietic cell transplantation (alloHCT) is difficult, as it is influenced by a multitude of risk factors.

Aims: To develop a tool that predicts individual outcomes of patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia from MDS (sAML) after alloHCT.

Methods: We integrated molecular data with available prognostic factors in patients undergoing alloHCT for MDS and sAML to evaluate their impact on prognosis. 304 patients with MDS or sAML who underwent alloHCT were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM).

Results: In multivariate analysis, mutated NRAS, U2AF1, IDH2, TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status treated but not in CR, IPSS-R cytogenetic risk, HCT-CI >2 and female donor sex. Mutated NRAS, IDH1, EZH2 and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The addition of molecular information significantly improved the risk prediction for OS and CIR as assessed by the Akaike information criterion. Internal and cross validation confirmed the robustness of our comprehensive risk model. We developed an interactive risk prediction tool to provide personalized predictions for OS, CIR and NRM outcome after alloHCT. An individualized prediction for a 53-year-old male with sAML with trisomy 11, mutated NRAS, IDH2 and DMMT3A and complete remission after double induction is shown in Figure 1. The probability of CIR at 2 years was 45% and the patient relapsed after 0.61 years. The probability of OS at 2 years was 41% and the patient died after 0.88 years.

Summary/Conclusions: We combine molecular, cytogenetic, patient- and transplantation associated risk factors into a comprehensive risk score to provide personalized predictions for outcome after alloHCT. Upon validation in larger patient cohorts, this will improve patient information before alloHCT and provide a platform to improve treatment strategies for patients with high risk of CIR or NRM.

S495

IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ALPHA-BETA T-CELL DEPLETED HAPLO-HSCT

P. Merli1,2, A. Bertaina3, F. Galaverna3, M. Algen1, D. Pagliara1, G. Li Pira1, J. Weinberg2, A. Moseley2, F. Locatelli1

1Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Bellিকum Pharmaceuticals Inc., Houston, United States

Background: HLA-haploidentical allogeneic hematopoietic stem cell transplant (haplo-HSCT) offers an option for children with acute leukemia in need of a transplant and lacking an available HLA-identical donor. However, performing haploidentical-HSCT without any graft manipulation has historically been associated with a high risk of acute and chronic graft-versus-host disease (GVHD). T cell depletion reduces the risk of GVHD, but leads to delayed immune reconstitution, predisposing to serious infection and leukemia relapse due to the lack of a T cell-mediated graft-versus-leukemia (GvL). To address these challenges, we have infused mature BPX-501 T cells (donor peripheral lymphocytes which have been modified with the iCas9 suicide gene) after θ T-cell depleted haplo HSCT to facilitate immune reconstitution and GvL effect. BPX-501 T-cells are genetically modified with the iCas9 suicide safety switch and a truncated CD19 marker. In the event of GVHD, the switch is activated by an infusion of the drug rimiducid (AP1903) resulting in rapid T cell apoptosis and GVHD reversal.

Aims: This study was performed to evaluate both safety and efficacy of BPX-501 T cell infusion post θ T-cell depleted haplo HSCT in pediatric patients with high risk ALL and AML in CR1 and CR2.

Methods: A prospective Phase II study enrolling children with hematopoietic disorder who lack a matched donor. 38 patients have been enrolled and treated with θ TCR deleted haplo HSCT after a myeloablative preparative regimen followed by BPX-T cell infusion to date; of them, 24 had ALL and 14 AML (21% CR1, 79% CR2). Median follow-up is 11 months (range 3-24).

Results: All patients engrafted and no secondary graft failure was recorded. Median time to neutrophil and platelet recovery was 16 days (range 8-33) and 11 days (range 7-19), respectively. With a median follow-up of 11 months (range 3-24 months), the cumulative incidence of NRM and relapse was 3.7% and 12.0%, respectively, while the disease-free survival probability was 84.2% (Fig 1). All aGVHD resolved (5 Grade I skin, 5 Grade II skin, 2 Grade III GI). One child received rimiducid to treat steroid-resistant grade II skin with complete resolution in 24 hours (Fig 2). There were 3 cases of chronic GVHD, 2 were mild; 1 severe and fatal in a patient whose donor had VZV reactivation during mobilization. CD3+ T cells reached 500 cells/μl by day 90, with normalized resolution in 24 hours (Fig 2). There were 3 cases of chronic GVHD, 2 were mild; 1 severe and fatal in a patient whose donor had VZV reactivation during mobilization. CD3+ T cells reached 500 cells/μl by day 90, with normalized resolution in 24 hours (Fig 2).

Figures.
Bone marrow failure and PNH

S496

HEREDITARY HEMATOLOGIC MALIGNANCIES: GENETIC COUNSELING IMPLEMENTATION IN A LARGE LEUKAEMIA CENTER
C. Dimaro1,2, S. Bannert2, K. Takahashi1, C. Benton1, M. Routhbort3, N. Permaraju1, N. Daver4, T. Kadla5, G. Garcia-Manero5, K. Patel6, H. Kantarjian1, A. Yacoub7
1Leukemia, 2Clinical Cancer Genetics, 3Hematopathology, 4Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Hematologic malignancies have rarely been targets for genetic evaluation, even in familial cases. Over the past decade, more than 12 genes have been identified to cause inherited predispositions to hematologic malignancies. Genetic counseling, testing, and surveillance protocols for these families are not well-established. Additionally, many families with high incidence of blood cancers do not have described syndromes suggesting additional genes remain to be identified.

Aims: To identify individuals with inherited susceptibilities to hematologic malignancies, the Hereditary Hematologic Malignancy Clinic (HHMC) was established in 2014 at The University of Texas M. D. Anderson Cancer Center. The clinic at Backfan, together with both clinical and research testing for patients with hematologic malignancies suspected to have inherited predisposition syndromes

Methods: Individuals were referred to the HHMC for several indications: (1) bone marrow failure/aplastic anemia/hypocellular MDS, (2) personal history of hematologic malignancy with ≥1 first-degree relative or ≥2 second-degree relatives with hematologic malignancy, (3) personal history of multiple primary cancers, (4) germline evaluation of presumed somatic mutations identified on next-generation leukemia prognostic panels, (5) management and/or surveillance of a previously-identified genetic syndrome, or (6) solid tumor heredity. Genetic counseling is available for patients with active hematologic malignancy. Over the past 3 years, 152 probands were evaluated (n=152). Skin biopsies were performed to obtain germline DNA, and next-generation sequencing approaches on both a clinical and research basis were utilized.

Results: Clinical genetic testing was performed in 97/152 individuals (64%). Research testing was performed in 46/152 (30%), particularly in patients negative for known susceptibility genes or without features suggestive of a clinical syndrome. Nine (6%) individuals did not undergo genetic testing. Clinical testing identified 23/97 (24%) individuals with a germline susceptibility to hematologic malignancy. Seven probands (7%) were identified to have RUNX1 mutations associated with familial platelet disorder with myeloid malignancy (FPD-AML). Six (6%) were identified to have the telomerase disorder dyskeratosis congenita; only one of them met clinical diagnostic criteria with the “classic triad” of symptoms. Three (3%) patients were identified to have Li-Fraumeni syndrome due to constitutional TP53 mutations. Two adults (2%) were diagnosed with Diamond-Blackfan anemia and two of these individuals developed adult-onset myelodysplastic syndrome after a long latency period and prior spontaneous remission of their childhood anemia. Two young adults (2%) with Fanconi anemia were diagnosed, and one patient each with DDX47 mutation and CBL (Noo-nan-like syndrome with JMML) were identified. Counseling, testing, and surveillance of identified mutation carriers in many affected families is ongoing.

Summary/Conclusions: Individuals with hereditary susceptibilities to hematologic malignancies are not as rare as previously thought. Clinical evaluation of these patients through genetic counseling and testing is high yield for identified at-risk families. Research-based sequencing for novel mutations is indicated and ongoing.

S497

SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM ANALYSIS OF THE SCNIR EUROPE
C. Zeidler1,2, M. Klmiankou1, A. Nickel1, S. Mellor-Heineke1, J. Skokowa1, K. Welte3
1SCNIR, Medical School Hannover, Hannover, 2Department of Hematology, Oncology, Clinical Immunology, 3Department of General Pediatrics and Pediatric Hematology and Oncology; University of Tuebingen, Tuebingen, Germany

Background: Leukemia predisposition is well known in congenital neutropenia (CN) subtypes. By taking all patients with known and unclassified CN together the incidence of secondary leukemia accounts for more than 10 percent. Advanced molecular diagnostics and the identification of inherited and acquired gene mutations have improved our understanding of leukemic transformation in CN patients.

Aims: In the European SCNIR 449 patients with congenital neutropenia and 91 patients with cyclic neutropenia (CyN) have been enrolled since 1994. These 449 cases were analyzed by case-matched molecular genetic subtypes: ELANE, HAX1, G6PT, G6PC3, WAS, SBSD, TAZ1 and p14 or no identified mutation, respectively. Our aim is to assess the risk of leukemic transformation within these genetic subgroups.

Methods: Here we report the leukemia incidence of genetic subtypes analyzing all available long-term data from the European Branch of the Severe Chronic Neutropenia Registry (SCNIR). In addition, we analyzed 91 patients with CyN with or without ELANE mutations.

Results: Results from genetic testing were available for 314 of 449 CN patients, of whom 118 patients revealed ELANE, 48 HAX1, 71 SBSD, 28 G6PT, 9 G6PC3, 7 WAS, 5 TAZ1 mutations and 27 other rare gene mutations (e.g. p14, CXCR4). 135 patients remain unclassified. In addition, 48 of 91 patients with CyN revealed ELANE mutations. Secondary myelodysplastic syndrome (MDS) or leukemia occurred in 49 of the 449 CN patients and in 1 of the 48 ELANE-CyN patients. Acquired CSF3R nonsense truncating mutations have been detected in the bone marrow cells of about 80% of CN patients who progress to MDS or acute myeloid leukemia (AML) and around 30-35% of non-leukemic CN patients, supporting the association between the acquisition of CSF3R mutations and leukemic transformation. These mutations have been shown to be acquired in hematopoietic cells only and therefore are not the primary cause of transformation. At the time of first detection of CSF3R mutations, and of malign transformation is highly variable. Some patients progressed to MDS/AML within a few months. In others, CSF3R mutant clones persisted for many years without progression to leukemia. The distribution by genetic subtypes and the frequency of CSF3R mutations is shown in the table below.

Table 1.

<table>
<thead>
<tr>
<th>Gene Mutation</th>
<th>Patients</th>
<th>MDS/Leukemia n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CN</td>
<td>445</td>
<td>49 (11.0)</td>
</tr>
<tr>
<td>ELANE</td>
<td>118</td>
<td>17 (14.4)</td>
</tr>
<tr>
<td>HAX1</td>
<td>48</td>
<td>6 (12.5)</td>
</tr>
<tr>
<td>SBSD</td>
<td>72</td>
<td>6 (8.5)</td>
</tr>
<tr>
<td>SLCO1A4</td>
<td>28</td>
<td>1 (5.6)</td>
</tr>
<tr>
<td>WAS</td>
<td>7</td>
<td>2 (28.6)</td>
</tr>
<tr>
<td>JAG1N</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>unclassified</td>
<td>36</td>
<td>16 (11.8)</td>
</tr>
<tr>
<td>Total CyN</td>
<td>91</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>ELANE CyN</td>
<td>48</td>
<td>1 (0.2)</td>
</tr>
</tbody>
</table>

*Gene mutations without leukemia: (G6PC3 n=9, TAZ1 n=5, p14 n=4, digenic mutations n=4, CDH1 n=4, CDKR4 n=3, germine extracellular CSF3R n=2, C16orf57 n=2, Pearson syndrome n=2, LYST n=1)

All subgroups benefit from G-CSF treatment. However, patients requiring main- tenance doses of G-CSF above 8µg/kg/day are at greater risk of leukemic transformation.

Summary/Conclusions: Conclusion: The incidence of secondary AML reflects the genetic heterogeneity of CN.

S498

EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
B. Höchsmann1,2, F. Sicre de Fontbrune3, J. Wu Lee4, A. Kulagina5, P. Hillmen5, A. Wilson6, J. Marantz2, H. Schrezenmeier1
1Institute for Clinical Transfusion Medicine and Immunogenetics, University Hospital Ulm, Ulm, Germany, 2Department of Internal Medicine IV, 3Hôpital Saint Louis, Paris, France, 4Seol St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of, 5Pavlou First Saint Petersburg State Medical University, St. Petersburg, Russian Federation, 6St. James’s University Hospital, Leeds, United Kingdom, 7Alexion Pharmaceutical Inc., Lexington, MA, United States

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, life-threatening disease caused by somatic phosphatidylinositol glycan class A (PIGA) gene mutation in bone marrow stem cells. The International PNH Registry (NCT01374360) is a prospective, multinational, observational study to record the natural history of PNH and collect data on long-term efficacy and safety of treatment with eculizumab (ecu), a humanized monoclonal antibody approved for treatment of PNH.

Aims: Evaluate the effect of ecul in patients with PNH with or without high disease activity (HDA).

Methods: Patients enrolled in the Registry as of December 5, 2016, were stratified by HDA and ecu treatment status into 4 groups: HDA/ecu-treated; HDA/never ecu-treated; no-HDA/ecu-treated; no-HDA/never ecu-treated. HDA is defined as lactate dehydrogenase (LDH) ratio ≥1.5x upper limit of normal within 6 months of baseline and history of any of the following: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia (hemoglobin <100 g/L), major adverse vascular event (MAVE; including thromboembolism [TE]), dysphagia, or erectile dysfunction. Patients were assessed at baseline (date of enrollment in never ecu-treated patients; date of initiation of ecu in ecu-treated patients) and at last follow up by case-matched molecular genetic subtypes: ELANE, HAX1, G6PT, G6PC3, WAS, SBSD, TAZ1 and p14 or no identified mutation, respectively. Our aim is to assess the risk of leukemic transformation within these genetic subgroups.
Results: 4717 patients were enrolled; of these, 2670 had non-missing data on euc and HDA status, and were included in the current analysis (HDA/euc-treated, n=778; HDA/never euc-treated, n=636; no-HDA/euc-treated, n=111; no-HDA/never euc-treated, n=1138). Median (min, max) duration of follow-up after baseline was longer for the ecu-treated patients compared with the never euc-treated patients for both the HDA and no-HDA groups (see Table). Results for changes from baseline to last follow-up in outcomes of interest are summarized in the Table. Data show that patients in the ecu-treated cohort had high burden of disease at baseline. Specifically, in the HDA population, a higher proportion of ecu-treated patients had a history of MAVE (33.3%) vs never euc-treated patients (13.7%). A similar disparity at baseline was also observed in the no-HDA population (33.0% vs 11.0%, respectively). Following ecu treatment, the divergence in the proportion of patients with MAVE has substantially narrowed for the HDA patients (3.9% for ecu-treated vs 3.3% for never ecu-treated) despite longer follow-up for the treated patients. Similar findings were seen in no-HDA patients (5.3% vs 2.1%, respectively). In patients with no-HDA, treatment with ecu was associated with meaningful improvements in mean (standard deviation [SD]) reduction from baseline in LDH ratio (-5.0 [3.7] vs -0.4 [2.3]) and proportion of red blood cell transfusion-free patients (37.6% vs 15.8%). The FACIT-Fatigue data, while limited, showed the HDA/ecu-treated group experienced a greater mean (SD) score improvement than the HDA/never ecu-treated group (4.1 [10.3] vs 0.5 [6.8] points).

Table 1.

Summary/Conclusions: Our analysis of real-world data from the International PNH Registry has demonstrated that treatment with eculizumab was associated with improved outcomes in patients with HDA. Our findings are consistent with the notion that patients with HDA, including those with a history of MAVE, should be treated with eculizumab.

S499

CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC CELLS USING CRISPR-CAS9

C. Clever et al.

Background: Thrombopoietin (Tpo) and its receptor, Mpl, are the principal regulators of early/late thrombopoiesis and hematopoietic stem cells maintenance. Mutations in MPL can drastically impair its function and be a contributing factor in multiple hematologic malignancies, including congenital amegakaryocytic thrombocytopenia (CAML). CAMT is a rare inherited syndrome characterized by thrombocytopenia at birth, progressing to bone marrow failure and pancytopenia. The functional impact of CAMT mutations on MPL is yet to be determined. Here we report unique familial cases of CAMT presenting with a previously unreported MPL mutation: T814C (W272R) in the background of the activating MPL G117T (K39N or Baltimore) mutation.

Aims: To describe the characterization of this novel MPL mutant and the use of genome editing as a novel therapeutic option for CAMT.

Methods: Human megakaryoblastic UT-7 and murine Ba/F3 cells stably expressing human wild-type (WT) MPL or mutant MPL fused to mNeonGreen were used as models. Confocal microscopy, proliferation and surface biotinylation assays, as well as co-immunoprecipitation and western blotting analysis, were used to elucidate the function and trafficking of MPL mutants. Multiplex, flow-based, CRISPR-Cas9 gene editing was used to repair mutant MPL and rescue its function. Cord blood from the younger male sibling was used as a source of primary homozygous MPL K39N/W272R CD34+ cells. CD34+ cells were edited using ribonucleoproteins electroporation followed by sequencing and functional assays such as flow cytometry and single colony assays.

Results: Consanguineous parents and their eldest daughter, both heterozygous for MPL K39N/W272R, do not present any signs of disease. Their monozygotic twin daughters presented at birth with severe thrombocytopenia leading to a diagnosis of BMT type 1. Whole blood sequencing revealed a homozygous double MPL K39N/W272R mutation, as their younger male sibling. One of the twins died after bone marrow transplant. Confocal microscopy shows that a significant fraction of chimeric WT MPL protein reaches the cell surface. Significant surface expression is also noted for MPL K39N. In contrast, the chimeric MPL protein bearing the W272R mutation, alone or together with the K39N mutation, showed no detectable surface expression of the Tpo receptor while being strongly co-localized with ER marker calreculin. Both WT and K39N-mutated MPL were found signaling competent, while single or double mutants bearing W272R were unresponsive to Tpo. Tpo-induced signaling was partially rescued by the expression of the CAMT-specific R885H/C polymorphism (forcing binding of MPL to the cell surface). Genome editing performed on cells carrying the W272R mutation restored the WT sequence and the response to Tpo, with similar cell proliferation as WT MPL cells. Finally, when applied to primary MPL K39N/W272R CD34+ cells, CRISPR-based gene editing rescued surface expression of MPL and response to Tpo, as assessed by flow cytometry. Newly edited CD34+ cells were able to generate a similar number of megakaryocytic colonies as control CD34+ cells in a single colony assay. Non-edited cells failed to do so.

Summary/Conclusions: We report a new double in cis mutation of MPL (K39N/W272R) in the context of CAMT. Function of the deficient MPL receptor could be rescued using two separate approaches: gene correction, in cis, using CRISPR-Cas9 and CRISPR-Cas9 genome engineering. Successful editing of primary hematopoietic stem cells indicates direct therapeutic applications for gene editing in this disease.
Summary/Conclusions: Both treatment with MPT-T and MPR-R controlled pain and resulted in an improvement in global QoL, as compared to baseline after 9ID and during maintenance. Treatment with thalidomide initially resulted in less pain and disease symptoms. At all treatment stages thalidomide caused less diarrhea, fatigue and insomnia as compared to treatment with lenalidomide. In contrast, therapy with lenalidomide resulted in less side effects of treatment, less constipation and less neuropathy as compared to thalidomide at all stages of treatment. In addition, long term maintenance therapy with lenalidomide resulted in better global QoL, better physical functioning and less pain.

Background: We recently reported the results of the phase III randomized HOVON87/NMSG18 study showing comparable efficacy of treatment with melphalan, prednisolone and thalidomide following by thalidomide maintenance (MPT-T) versus melphalan, prednisolone and lenalidomide followed by lenalidomide maintenance (MPR-R) (Zweegman S et al. Blood 2016;127(9):1109-1116). As not only efficacy but also potential toxicity affecting quality of life (QoL) guides the choice of treatment, health-related (HR) QoL is important.

Aims: To evaluate the HRQoL results of the HOVON87/NMSG18 study.

Methods: Two validated HRQoL instruments (EORTC QLQ-C30 and MY20) were collected at baseline, after 3 and 9 induction cycles (3ID and 9ID) and after 6 and 12 months of maintenance therapy (6MT and 12MT). The subscales global QoL, physical functioning, pain, fatigue, constipation, diarrhea, nausea/vomiting, insomnia, disease symptoms, side effects of treatment and neuropathy, and/or meaningful improvements in HRQoL are important for previous literature were used. To determine clinically relevant superiority of one arm, a difference in score of ≥1 standard error of contrast, therapy with lenalidomide resulted in less side effects of treatment, less constipation and less neuropathy as compared to thalidomide at all stages of treatment. In addition, long term maintenance therapy with lenalidomide resulted in better global QoL, better physical functioning and less pain.

Background: Maintenance of pretreatment health-related quality of life (HRQoL) and/or meaningful improvements in HRQoL are important for previously untreated indolent non-Hodgkin lymphoma (iNHL) patients (pts). GALLI-
UM (NCT01332806) is an open-label, randomized Phase III study of obinutuzumab (GA101; G) plus chemotherapy (chemo) followed by G maintenance (G-chemo) compared with rituximab (R) plus chemo followed by R maintenance (R-chemo) in pts with previously untreated NHL. In GALLIUM, G-chemo produced a clinically meaningful improvement in investigator-assessed progression-free survival (PFS) among follicular lymphoma (FL) pts (34% reduction in risk of a PFS event relative to R-chemo). Grade 3-5 and serious adverse events were more common with G-chemo.

**Aims:** To compare changes in HRQoL in FL pts receiving G-chemo and R-chemo during GALLIUM.

---

**Results:** 277 responses were returned with 1 response excluded (non-haematological malignancy). Haematological diagnoses included acute leukaemia (n=40), chronic leukaemia (n=35), lymphoma (n=62), myeloma (n=102), MDS (n=15), MPD (n=12), other (n=2) and not specified (n=7). 257 (93.1%) patients had received antitumor cancer therapy, 218 (79%) were receiving treatment at the time of survey and 54% had ongoing symptoms related to their treatment or cancer. 197 (71.4% patients did not want access to a support group, 23 (19%) wanted access, 51 (8.3%) were not aware of the possibility and 6 (1.8%) did not respond. 51.8% of patients were aware of the existing support groups, 38.8% were not sure, 2.9% were not aware and 1.8% did not respond. The cohort of patients who did or did not want access to a support group was another 88% of patients had been given a key worker (oncological and nurse specialist, research nurse, advanced nursing practitioner or nurse clinician); of the those 88% were satisfied and 1% were partly satisfied with the support they had received with 11% not responding. 93% (n=231) of patients were satisfied with the information they had received at diagnosis and 90% (n=224) felt the diagnosis had been given sensitively. Only 20% of patients currently on treatment wanted access to a support group and 24% not on treatment wanted access to a support group. Date of diagnosis was divided into three groups. Gp A: before 2005 (n=15), Gp B: after 2006 (n=229) and not stated (n=14). There was no difference in the three groups when asked if they wanted access to support group (13%, 22%, 7% respectively; p=0.3) or awareness that support group was available (40%, 57%, 50% respectively; p=0.6). There were additional comments from patients that support from family and online forums in addition to key workers was extremely valuable to them. On univariate analysis patients who were satisfied with their key worker support did not want access to a support group (p=0.04). There was no effect on wanting access to a support group and diagnosis (p=0.67), treating hospital (p=0.5), information given (p=0.6), need for in-patient treatment (p=0.3), quality of care (p=0.8) or satisfaction with overall care (p=0.8).

**Summary/Conclusions:** Our results suggest that a large majority of patients with hematological malignancy do not want access to a cancer support group but providing satisfactory support through key workers and other healthcare professionals is likely to achieve better patient experiences.

**Acknowledgements:** We would like to acknowledge the members of the GMCPB and patients for their contribution to the survey.

---

**Figure 1.**

**Methods:** Enrolled pts were aged ≥18 years with documented, previously untreated FL (grades 1-3a), advanced disease (stage III/IV or stage II with tumor diameter ≥7cm), ECOG performance status 0-2, and requiring treatment according to GELF criteria. Pts were randomized 1:1 to R 375mg/m² on day (D) 1 of each cycle (C) or G 1000mg on D1, 8, and 15 of C1 and D1 of C2-8, for 6 or 8 cycles depending on chemo (CHOP, CVP or bendamustine). Respondents continued to receive R or G every 2 months (mo) for 2 years or until progression. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire (Webster et al. 2005) was used to assess overall HRQoL, physical and functional well-being, and distress and treatment-related symptoms. FACT-Lym was administered on D1 of C1 and C3 during induction, at the end of induction, and at mo 2 and 12 during maintenance/follow-up. For each FACT-Lym scale, mean and 95% confidence interval (CI) were derived for recorded scores at each visit and changes from baseline. Minimally important differences (MID) were used to calculate the proportion of pts reporting improvement on the FACT-Lym lymphoma subscale (LYMS; ≥3 points), Trial Outcome Index (TOI; ≥6 points), and lymphoma total score (Lym-Total; ≥7 points). All pts gave informed consent.

**Results:** Of 1202 FL pts randomized (median age, 59 yrs; 53.2% female; median observation time, 34.5 mo (range 0-54.5), 566/601 (92.5% G-chemo) and 550/601 (91.5% R-chemo) completed all FACT-Lym scales at baseline. Baseline demographics and disease characteristics were balanced between arms. At baseline, mean HRQoL scores were similar in the two treatment arms, with all pts having some impairment of physical function, functional wellbeing, emotional and social function. Over the course of treatment, mean HRQoL was similar in the two treatment arms. From end of induction onwards, pts in both arms experienced clinically meaningful improvements from baseline in LYMS scores (Figure), and the summary scales that included this subscale (TOI, Lym-Total). On each summary scale, ~50% of patients in each arm reported clinically meaningful improvements. There were no clear differences between arms in HRQoL scores over the course of therapy.

**Summary/Conclusions:** In previously untreated FL pts in GALLIUM, G-chemo and R-chemo produced similar improvements in HRQoL. These results suggest that lymphoma-related symptoms were reduced by both treatments and that the resulting improvements in well-being were not abrogated by treatment-related side effects. When viewed in the context of longer PFSs, these results further support the relative benefit of G-chemo over R-chemo in GALLIUM.
Background: Pharmacologic therapy stabilizes hematologic counts and splenomegaly in myeloproliferative neoplasms (MPN), however only partial symptom improvement typically occurs. Evidenced-based integrative care may address this need, however data is limited in patients with MPNs.

Methods: Patients were recruited via social media. Informed consent and approval were obtained. Patients with MPNs (polycythemia vera, essential thrombocytosis, primary myelofibrosis) were eligible. We surveyed patients about symptom burden, quality of life, depression, and fatigue in MPN patients. Interactions of integrative therapies with symptoms were assessed. All surveys were conducted by mail and online. Data was collected from March 2016 to February 2017. Results: A total of 1087 patient surveys were consented. Of these, 888 had 10 or more responses. There were 338 essential thrombocytosis (ET), 188 myelofibrosis (MF), 315 polycythemia vera (PV), and 17 other. In MF: DIPSS risk categories included low (8%), Int-1 (19%), Int-2 (29%), high (12%), and unknown (32%). Symptom association: Overall, patients had lower MPN related symptoms when participating in aerobic activity (p<0.001), massage (p=0.001), yoga (p=0.02), strength training (p=0.001), breathing exercises (p=0.001), and support groups (p=0.001). Overall quality of life was higher with aerobic activity (p<0.001), massage (p=0.02), yoga (p=0.02), strength training (p=0.001), breathing exercises (p=0.001), and support groups (p=0.001). Depression (PHQ-9 total >3 category) was lower in aerobic activity group (p=0.001), yoga (p=0.001), strength training (p=0.001), and meditation (p=0.2). Fatigue was lower in aerobic activity (p<0.001), massage (p=0.04), strength training (p<0.001), breathing exercises (p<0.001), and support groups (p=0.001). In subgroup analysis, ET and PV patients had lower symptom burden (MPN-SAF TSS) with aerobic activity (p<0.001, <0.001), massage (p=0.01, 0.02), and strength training (p=0.03, 0.02). Support groups were found to be associated with lower symptoms in ET patients (p=0.03). In MP, breathing exercises (p<0.001) and support groups (p=0.03) were associated with lower symptom burden. See Table #1.

Table 1.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Overall</th>
<th>ET</th>
<th>PV</th>
<th>MF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerobic Activity</td>
<td>0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Massage</td>
<td>0.01</td>
<td>0.02</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>Yoga</td>
<td>0.01</td>
<td>0.02</td>
<td>0.07</td>
<td>0.25</td>
</tr>
<tr>
<td>Nutrition</td>
<td>0.10</td>
<td>0.18</td>
<td>0.35</td>
<td>0.56</td>
</tr>
<tr>
<td>Sleep</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Appetite</td>
<td>0.18</td>
<td>0.58</td>
<td>0.58</td>
<td>0.30</td>
</tr>
<tr>
<td>Medication</td>
<td>0.01</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>Depression score</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anxiety score</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>Support groups</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Integrative therapies are associated with improved symptom burden, quality of life, depression, and fatigue in MPN patients. Interestingly, unique patterns were associated within MPN subtypes. Further studies are needed to understand the benefits of integrative therapies in MPN patients.
Acute lymphoblastic leukemia - Biology 2

P506

T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT

L Liu1*, Y Chang1, X Xu1, X Zhang3, Y Wang4, K Liu5, X Huang1
1Peking University People’s Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Background: B cell acute lymphoblastic leukemia (B-ALL) relapse contributes to the predominant mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the mechanism of B-ALL relapse after allo-HSCT remains unknown. Eradication of leukemia in allo-HSCT settings largely relies on graft-versus-leukemia (GVL) effects mediated by donor T cells. T cell exhaustion characterized by increased expression of inhibitory receptors including PD-1 and Tim-3 and impaired function may blunt the GVL effects and was reported in acute myeloid leukemia relapse after allo-HSCT, whether T cell exhaustion is involved in B-ALL relapse after allo-HSCT remains unknown.

Aims: To evaluate whether T cell exhaustion is involved in B-ALL relapse after allo-HSCT; and investigate the correlation of inhibitory ligands on leukemic cells, leukemic load and T cell exhaustion, as well as the impact of treatment outcome on T cell exhaustion.

Methods: Our study enrolled 18 B-ALL patients who underwent first hematologic relapse after allo-HSCT and 18 matched B-ALL patients in remission (without minimal residual disease MRD) and 14 healthy donors from April 2016 to November 2016 at the Peking University People’s Hospital. In the remission group, the methods used for the study were matched transplantation protocol and post-transplant time were matched in relapsed patients. In our study, all patients had achieved full donor chimerism before relapse or bone marrow collection. Peripheral blood (PB) were collected at the same day of bone marrow collection in relapsed patients. For patients who received induction therapy, we prospectively collected BM at least once after therapy.

Results: In the current study, we observed that increased co-expression of PD-1 and Tim-3 was observed in both CD4+ and CD8+ T cells in relapse settings. Moreover, both CD4+ and CD8+ T cells exhibited compromised proliferative capacity, cytokine production and cytotoxic potentials such as degranulation and granzyme B production (preferentially on CD4+ T cells) in relapsed patients. In addition, T cells in the tumor site are more easily exhausted than those in peripheral blood. Reversal of T cell exhaustion was associated with effective anti-leukemic response in relapsed patients who underwent re-induction therapy.

Summary/Conclusions: In conclusion, our study suggested that T cells experienced a comprehensive functional impairment in B-ALL relapse settings after allo-HSCT and reversal of T cell exhaustion was associated with effective anti-leukemic responses. These results also provide a foundation for the development of novel effective leukemia therapeutics, such as anti-PD-1 or PD-L1 therapy, by targeting T cell exhaustion

P507

RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL

Y Kong1, Y-L. Wu2, Y. Song2, M-M. Shi12, X-N. Cao1, H-Y. Zhao1, Z-Q. Lin1, Y-Y. Lai1, H. Jiang1, G. Jiang1, X-J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology, 2Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

Background: Relapse remains the major cause of treatment failure in patients with acute lymphoblastic leukemia (Ph-ALL), even in the modern era of tyrosine kinase inhibitors (TKIs). Relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs), which are defined by their ability to initiate human leukemia and self-renew in immunocompromised mice. Using an anti-CD122-conditioned NOD/SCID-hu/Slc mouse model, xenografting assay was used to be enriched in the CD34+CD38−CD58- fraction in human Ph+ALL(YK,...,XJH). Leukemia. 2014). Furthermore, a cohort study demonstrated that Ph+ALL patients with LPCs phenotype at diagnosis exhibited a significantly higher cumulative incidence of relapse than did the group with other phenotypes, even when receiving uniform front-line imatinib-based therapy pre- and post-allo-transplant (YK,...,XJH). BMT. 2015). Therefore, it is imperative to identify novel therapeutic strategies based on LPCs to improve the prognosis of Ph+ALL patients.

Aims: To identify the potential molecular basis of LPC-mediated relapse, RNA sequencing(RNA-seq) and real-time reverse transcription-PCR (qRT-PCR) were performed to analyze the gene expression profiles and functional characteristics of cells of other phenotypes from patients with de novo Ph+ALL. In order to assess the effects of the selective BCR-ABL and/or JAK2 inhibition therapy by the treatment with single agents or a combination of ruxolitinib and imatinib or nilotinib on Ph+ALL LPCs, drug-induced apoptosis of LPCs was investigated in vitro, as well as in vivo using sublethally irradiated and anti-CD122-conditioned NOD/SCID xenograft mouse assay. Moreover, western blot analyses were performed on the BM cells harvested from the different groups of recipient mice.

Methods: RNA-seq and qRT-PCR, we found that JAK2 was more highly expressed in the sorted LPCs than in the cells of other phenotypes in patients with de novo Ph+ALL in vitro study, cotreatment with nilotinib and ruxolitinib induced significantly higher levels of apoptosis in LPCs. In humanized Ph+ALL mice model, treatment with the nilotinib and ruxolitinib combination, compared with either ruxolitinib or TKIs alone, led to the most significant reduction in human Ph+ALL engraftment in the recipients. Further evidence that the most effective anti-LPCs effect was achieved with the combination treatment was derived by the engraftment analysis of BCR/ABL expressing cells using a qRT-PCR assay and HE and IHC with anti-hCD19 staining. Moreover, the combination of nilotinib and ruxolitinib more effectively reduced the LPCs capacity through a higher expression of phospho-CrKL, JAK2 and STAT5 activities at the molecular level.

Summary/Conclusions: JAK2 was more highly expressed in the sorted LPCs than in other cell phenotypes in patients with de novo Ph+ALL. Furthermore, selective BCR-ABL/JAK2 dual inhibition with nilotinib/ruxolitinib more effectively eliminated LPCs than either ruxolitinib or TKIs alone. Therefore, this pre-clinical study appears to provide scientific rationale for simultaneously targeting BCR-ABL and JAK2 activities, which represents a promising anti-LPCs therapeutic approach for patients with de novo Ph+ALL.

P508

PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE B-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING

F. Seyfried1, S. Demiri1, R. Hör1, J. Ryan1, A. Scheffold1, M. Villalobos-Ortiz2, S. Köhler1, J. Zinngrebe1, S. Stilgenbauer3, A. Letai2, K.-M. Debatin1, L. H. Meyer1
1Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany, 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States, 3Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany

Background: Although survival rates of pediatric BCP-ALL patients have continuously improved during the past decades, therapy-related toxicity and relapse occurring in 10-20 % of patients are associated with poor outcome, clearly emphasizing the need of novel, targeted treatment strategies. Deregulated survival pathways and cell death resistance contribute to treatment failure and relccurrence of the disease. ABT-199 (venetoclax) is a small molecule inhibitor of BCL-2 demonstrating anti-cancer activity among different malignancies. However, predictive biomarkers are required for up-front identification of patients who would benefit from BCL-2 directed therapies.

Aims: The aims of this study were to assess the efficacy of ABT-199 in BCP-ALL, to functionally evaluate factors mediating ABT-199 susceptibility or resistance and to identify markers indicative of successful anti-leukemia activity.

Methods: The activity of ABT-199 was assessed by cell viability assays in BCP-ALL cell lines (N=6) and patient-derived xenograft (pdx) samples (N=27), analyzing half maximal effective concentrations (EC50). Expression of apoptosis regulators was detected by western blot analysis. MCL-1 deficient cell lines were generated by CRISPR/Cas9 gene editing. BH3 profiling was used to measure the mitochondrial dependence of leukemia cells on anti-apoptotic BCL-2 family proteins. In vivo treatment of ABT-199 was performed in a set of three distinct ALL rdds.

Results: Different sensitivities of ABT-199 were observed in a series of BCP-ALL rdds and cell lines with heterogeneous anti-leukemia activities upon drug exposure. The majority of BCP-ALL samples showed sensitivity to ABT-199-induced cell death in the nanomolar range (EC50 <1µM) with four out of six cell lines and 20 of 27 rdds, while ABT-199 insensitivities with EC50s of more than 1µM were identified in 26% of pdx leukemias. ABT-199 induces apoptosis by selectively inhibiting BCL-2, thereby sensitizing leukemia cells to pro-apoptotic molecules; however, the sequestration of drug-released BIM by anti-apoptotic MCL-1 might lead to resistance. Therefore, we investigated protein expression of both regulators and found the ratio (BCL-2/MCL-1) to be cor-
related with ABT-199 sensitivity (t = 0.71, p = 0.000), highlighting the importance of functional assessment of the direct target molecule and additional resistance mediating molecules. In line, MCL-1 knockout in two ABT-199-resistant cell lines led to sensitization towards ABT-199, however, resulted in different effects of sensitization, emphasizing that ABT-199 resistance is determined by the interplay of several apoptosis regulators. Therefore, we characterized the functional dependence of pdx leukemias on anti-apoptotic BCL-2 family members. Mitochondrial dependence on BCL-2 (mitochondrial priming by the BAD-peptide measuring BCL-2, BCL-XL and BCL-W, and subtracting the response to the HRK-peptide measuring BCL-XL) was found to be tightly correlated with ABT-199 sensitivity. In contrast, ABT-199-resistant samples were characterized by low BCL-2-dependence and addition to other BCL-2 family members, including BAX, BAK, BCL-XL or MCL-1. Finally, we evaluated prediction of in vivo ABT-199 sensitivity in a pre-clinical ALL pdx mouse model by functional BH3 profiling. Strikingly, high mitochondrial BCL-2-dependency was clearly associated with prolonged leukemia-free survival upon ABT-199-therapy (two pdds, log rank p = 0.0035 and <0.0001), in contrast to another leukemia with low BCL-2-dependence and in vivo ABT-199 resistance (log rank p = 0.144).

Summary/Conclusions: SCP-ALL displays heterogeneous ABT-199 sensitivities characterized by the level of the target molecule but also other interacting regulators. Functionally, mitochondrial BCL-2-dependence assessed by the BH3 profiling assay is clearly associated with ABT-199 sensitivity. Importantly, in vivo anti-leukemia activity of ABT-199 therapy in individual pxd leukemias is predicted by mitochondrial BCL-2-dependence, emphasizing the utility of identification of patients and guidance of future clinical application by functional assessment of apoptosis signaling.

**P509**

**CD45RA- MEMORY T CELLS EXPRESSING AN NKGD2-CAR TARGET PEDIATRIC ACUTE LEUKEMIA**

L. Baz,1 C. de la Cruz,1 T. Colosimo,2 C. D. Mallory,1 A. Janik,3 L. Oteiza,1 S. Perov,2 A. Vultur4 and R. K. Greer1

1Clinical Research, CNIO, Madrid, Spain, 2Haematology, St.Jude Children’s Research Hospital, Memphis, United States, 3Infectious diseases and Immunity, IDIAP, 4Pediatric Oncology, INGEMMI, Madrid, Spain

**Aims:** The aim of this study was to analyze the CD45RA expressing on pediatric acute leukemia cells and determine their susceptibility to an NKGD2 CAR T cell based immunotherapy.

**Methods:** The expression of NKGD2 was analyzed in Peripheral Blood Mononuclear Cells (PBMCs) from patients suffering from acute leukemia, as well as in leukemia cell lines, by flow cytometry (FCM) using specific monoclonal antibodies directed against MICA, MICB, ULBP-1, ULBP-2, ULBP-3 and ULBP-4. The expression of CD45RA, CD27 and CD127 on T-cell reporter cells were measured. PBMC resistance to CD45RA-microbeads expressed on T cells was measured by AutoMACS device. The HL20I4r-MNDantsCD19bbz lentiviral vector was derived from the clinical vector CL204r-EE-1a-hgOpt27 but contained the extracellular domain of NKGD2, the hinge region of CD8a and the signaling domains of 4-1BB and CD3-z. The cassette was driven by MDR promoter. Vital supernatant was produced by transient transfection of HEK293T cells with the vector genome plasmid and lentiviral packaging helper plasmids pCAGG-HGpcp, pCAGGS-vgsv and pCAGGS-RTR2. Cytogenetic studies and array Comparative Genomic Hybridization were performed to analyze the genetic stability of lentiviral-transduced memory T cells. The in vitro cytotoxicity of CD45RA-NKGD2-CAR redirected NK cells against leukemia cells, healthy PBMC and Mesenchymal stromal cells (MSCs) was evaluated by performing conventional 4-hour europium-TDA release assays or by FCM using CFSE and 7AAD labeling of target cells.

**Results:** NKGD2 were heterogeneously expressed in leukemia primary cells and cell lines. For B cell ALL primary samples, we found expression of MICA, MICB, ULBP-1, ULBP-2 and ULBP-4 in refractory and resistant samples. Lentiviral transduction of NKGD2-4-1BB-CD3z increased NKGD2 surface expression in CD45RA-memory T cells, which became consistently more cytotoxic than untransduced cells against leukemia cells. Additionally, no chromosomal aberrations nor cytotoxic activity against healthy PBMC or Mesenchymal stromal cells was observed in NKGD2 CAR expressing T cells.

**Summary/Conclusions:** Our results show NKGD2-CAR redirected CD45RA-memory T cells target NKGD2 expressing leukemia cells in vitro and could be a promising and safe immunotherapeutic approach for pediatric acute leukemia patients.

**P510**

**A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR**

A. Gonzalez-Munillo1,2, C. Sánchez-Valdepeñas1, C. Robledo2, A. Castillo1, L. Abad1, C. Hernandez-Marques1, D. Ruano1, L. Madero1, J. Alonso2, M. Ramirez1

1Pediatric Hematology & Oncology, Hospital Universitario Niño Jesús, Madrid, 2Institute of Investigacion en Enfermedades Raras, Instituto de Salud Carlos III, Majadahonda, Spain

**Background:** Genetic mutations are crucial events during leukemogenesis and provide specific markers for backtracking the cellular origin of acute leukemias up to immature uni- or multi-potent progenitor cells in the hierarchy of the hematopoietic system.

**Aims:** To characterize the clonal architecture and cell of origin in a case of pediatric acute leukemia identified as B-ALL.

**Methods:** Bone marrow cells obtained at diagnosis were used for all studies. Immunophenotyping was done by flow cytometry. T- and B-cell leukemia purification was performed by immunomagnetics methods and DNA extracted afterward. TCR-gamma gene rearrangement was studied in T- and B-lymphocytic cells independently by PCR sequencing. Somatic mutations in purified T- and B-leukemic cells were identified by deep-sequencing using a panel of 160 genes frequently mutated in cancer (Human comprehensive cancer panel, Qiagen). Mutations were validated by Sanger sequencing. Myeloid and erythroid clonogenic progenitors were isolated from methylcellulose cultures, DNA extracted, and assessed for the presence of the H3F3A p.K28N mutation by Sanger sequencing.

**Results:** The patient was a 10 years old boy. At diagnosis, the bone marrow was infiltrated by 60% leukemic cells, with 2 immunophenotypically different populations: a common B-ALL (54%) and a pro-T-ALL (6%). The patient showed no bone marrow lesions, no liver or spleen enlargement, and full body X-rays showed no tumor. TCR-gamma rearrangement was detected in purified (>95% pure) T-ALL and B-ALL cells, suggesting a common origin for both leukemic subpopulations. The B-ALL cells presented a c.35G>A p.G12D mutation in the KRAS gene, absent in the T-ALL. The T-ALL cells presented a c.35G>A (p.G12D) mutation in the NRAS gene, absent in the B-ALL. A c.1126_1127insTAGA (p.P376Lfs*10) mutation in the WT1 gene was also detected only in the T-ALL. A c.849G>T (p.K28N) mutation in the H3F3A gene was detected in both the B-ALL and T-ALL subpopulations, confirming the involvement of a Common Lymphoid Progenitor in the process of leukemogenesis. The presence of the H3F3A p.K28N mutation in the myeloid compartment would point to a multipotent myeloid-lymphoid rather than a lymphoid-restricted progenitor as the cell origin of the leukemia. Therefore, we cultured myeloid-erythroid-committed progenitor cells in clonogenic cultures and sequenced the H3F3A gene. None of the 122 myeloid or erythroid clonogenic progenitors (41 CFU-GM, 73 BFU-E and 8 CFU-GEMM) presented the p.K28N mutation in the H3F3A gene.

**Summary/Conclusions:** Our results indicate the involvement of a Common Lymphoid Progenitor as the cell origin of this case of biphenal ALL, as well as the crucial role of H3F3A and RAS family genes in the leukemogenesis process coupled with B and T differentiation.

**P511**

**CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSRP2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS**

S.-J. Wang1,1, P.-Z. Wang2, R. Gale3, Y.-Z. Qin1, Y.-R. Liu1, Y.-Y. Lai1, H. Jiang1, Q. Jiang1, X.-H. Zhang1, B. Jiang3, L.-P. Xu1, X.-J. Huang4, K.-Y. Liu4, G.-R. Ruam1,2,4 Peking University Peoples Hospital and Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, and Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center., Beijing, China, 2Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom, 3Peking University Peoples Hospital and Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Sciences, Beijing, China

**Background:** Outcome of adults with B-cell acute lymphoblastic leukemia (ALL) remains poor and relapse is the major cause of treatment-failure. Currently, the best biomarkers in B-ALL especially in those with normal cytogenetics and studying their clinical significance and biological function will be helpful for risk-stratification, treatment decision and targeted therapy. CSRP2 (cysteine and glycine rich protein 2) maps to chromosome subband 12q21.1. which is frequently abnormal in diverse cancers. Increased CSRP2 transcript levels were associated with de-differentiation in hepatocellular carcinoma and CSRP2 was identified as a new invadopodia actin bundling factor that critically promotes breast cancer cell invasion and metastasis. However, the clinical significance and biological function of CSRP2 in B-cell ALL remains unknown.
Aims: To identify novel biomarkers in B-cell ALL based on bioinformatics analyses; to examine the expression and clinical significance of CSRP2 in adults with B-ALL; to explore effects of CSRP2 on biological function of B-cell ALL.

Methods: We did bio-informatics analyses to identify mRNA transcripts aberrantly-expressed in B-cell ALL. RT-qPCR (real-time quantitative polymerase chain reaction) was used to examine CSRP2 transcript levels in bone marrow samples from 236 adults with B-cell ALL compared with samples from normal. A prognostic value was assessed in 168 subjects. CSRP2-knockdown and CSRP2-over-expression cell models were constructed to study the biological function of CSRP2 in B-cell ALL.

Results: We selected 9 candidate genes for validation 7 of which proved significantly-associated with B-cell ALL. CSRP2 was the most differentially expressed gene in our validation studies. CSRP2 was over-expressed in 228 out of 236 adults (97%) with newly-diagnosed B-cell ALL. In subjects with normal cytogenetics: those with high CSRP2 transcript levels had a higher 5-year cumulative incidence of relapse (CIR) and worse relapse-free survival (RFS) compared with subjects with low transcript levels (56% [95% confidence interval 53-59%] vs 19% [18-20%]; P=0.011 and 41% [17-65%] vs 80% [66-96%]; P=0.007). In multivariate analyses a high CSRP2 transcript level was independently-associated with CIR (HR=5.32 [1.64-17.28]; P=0.005) and RFS (HR=5.56 [1.87-16.53]; P=0.002). Functional analyses indicated CSRP2 promoted cell proliferation, cycle-cell progression, in vitro colony formation and migration. Abnormal CSRP2 expression was associated with resistance to chemotherapy; sensitivity was restored by down-regulating CSRP2 expression. CSRP2 activated ERK1/2 signaling pathway, regulated cell-cycle related protein and activated CREB signaling pathway, whose activation was associated with poor prognosis in adults with B-cell ALL.

Summary/Conclusions: CSRP2 was widely over-expressed in adults with B-cell ALL. Determination of CSRP2 transcript levels in subjects with normal cytogenetics might inform therapy-decisions. Consideration could be given to down-regulating CSRP2 expression as a way to reverse drug resistance.

P512

THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

A. Alhammer1,2, M. Case1, E. Matheson3, H. Blair4, J. Vormoor4, J. Irving1
1Newcastle University, Northern Institute for Cancer research, Newcastle upon Tyne, United Kingdom, 2Al-Nahrain University, Biotechnology research Center, Baghdad, Iraq

Background: Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children and adolescents and relapsed ALL remains one of the leading causes of cancer-related deaths in children. Components of the precursor-B cell receptor (Pre-BCR) signalling pathway are hijacked in ALL cells and this causes of cancer-related deaths in children. The precursor-B cell receptor (Pre-BCR) signalling pathway is hijacked in ALL cells and this dependence may be therapeutically targeted. A number of tyrosine kinase inhibitors (TKIs) targeting effectors of this signalling pathway are showing great promise in the clinic and warrant preclinical evaluation in paediatric ALL. They include Dasatinib (BCR-ABL/SRC inhibitor), Fostamatinib R406 (SYK inhibitor), Ibrutinib (BTK inhibitor) and CAL-101 (PI3K-δ inhibitor).

Aims: To preclinically evaluate these candidate TKIs, as novel, targeted drugs for Pre-BCR signalling.

Methods: ALL cell lines (Reh, Nalm-6, PreB 697 and its glucocorticoid resistant descendant, R3F9) and 36 primary-derived xenograft (PDX) cells from 16 ALL were used in the study. Cell viability was assessed by Resazurin. Pre-BCR expression (μHc, VpreB and A5) and functionality using a Calcium flux assay were detected by Flow cytometry. Intracellular phospho-flow cytometry was used to detect constitutive phosphorylation and activation in response to anti-Ig antibody, as well as drug pharmacodynamic measures (p-BTK, p-Syk, p-AKT, p-ERK, p-PLC-Y2, p-BLNK). Apoptosis and cell cycle were analysed by flow cytometry using Annexin V and Propidium iodide. RQ-PCR was used to measure mRNA expression. Caspase activity induction, G0/RX expression and phosphorylation were detected by western blotting.

Results: ALL cell lines were modestly sensitive to Dasatinib (mean GI50 5.33 µM, range 2.45-12.5 µM) and R406 (mean GI50 6.42 µM, range 2.88-17.73 µM). However, cells were resistant to Ibrutinib (mean GI50 19.5 µM, range 11.47-18.3 µM) and CAL-101 (mean GI50 52.08 µM, range 25-77.83 µM). Cell cycle arrest and significant apoptosis was seen with R406 and Ibrutinib treatment, while Dasatinib and CAL-101 were cytostatic, causing G1 arrest with no substantial cell death. Pharmacodynamic assays confirmed inhibition of the relevant drug targets. PDX cells showed greater sensitivity than the cell lines to Dasatinib (4 out of 16 patient samples <0.5pM, R406 (7 out of 16 patient samples <0.5pM), Ibrutinib (3 out of 15 patient samples <5µM) and CAL-101 (3 out of 15 patient samples <2pM). Pre-BCR positive ALL cell lines and PDX cells were sensitive to R406 and Dasatinib, with a Ph+ PDX confirming sensitivity to the latter. Combining TKIs with the glucocorticoid (GC), Dexamethasone showed synergism in ALL cell lines and was particularly notable for Dasatinib and R406 in PreB cell receptor positive lines. Synergism was associated with significantly enhanced apoptosis, an increase in expression of the GR target gene, GILZ and for Dasatinib, enhanced expression of the pro-apoptotic, Bim. Control REH cells (GC receptor negative) showed no synergism.

Summary/Conclusions: Significant sensitivity of TKIs targeting Pre-BCR signalling have been identified at clinically achievable concentrations. Dasatinib and R406 sensitivity was associated with Pre-BCR positive ALL and combination with Dexamethasone showed significant synergism in GC resistant cell lines and PDX samples. TKIs were also effective in some Pre-BCR negative ALL cells, however, predictive biomarkers need to be established. Confirmation of these data in preclinical models in vivo may define new therapies for high risk ALLs.

P513

BMP4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME

A. Entrena1, C. Martinez-Laperche2, G. Melen2, A. Varas1, A. Vicente1, M. Ramirez2
1School of Medicine, Universtitad Complutense, 2Pediatric Hematology & Oncology, Hospital Universitario Niño Jesus, Madrid, Spain

Background: Leukemic relapses among children with acute lymphoblastic leukaemia (ALL) from low/intermediate-risk groups is a challenge for the cure of this disease. New biomarkers are needed for identifying children at high risk of relapses. Bone Morphogenetic Proteins (BMPs) are multifunctional secreted growth factors that belong to the TGF-β superfamily and are well-known for their indispensable roles in vertebrate development. In the cellular context, BMPs regulate fundamental processes such as cell proliferation, differentiation, migration and survival. In last years, important new information has been generated on the contribution of BMP family members, such as BMP4, in cancer pathogenesis.

Aims: Here we have evaluated the relevance of BMP4 signaling in ALL.

Methods: The expression levels of BMP4 related genes (bmp-4, and bmp-receptors, signaling mediators, inhibitors and targets) in ALL blasts obtained at the time of diagnosis (n=56), and the BMP-4 levels in central system fluid samples (CSF), were quantified by RT-qPCR or ELISA. The engrafting potential of primary ALL cells, exhibiting high or low BMP4 levels, were assessed in xenotransplantation experiments using unirradiated NSG mice.

Results: BMP4 was expressed at significantly higher levels in ALL blasts of children who later relapsed (17.78 versus 26.68, arbitrary units, AU, p<0.05). Relapses among children with high BMP-4 expression occurred significantly later than those with low BMP-4 expression (845 days versus 282 days, p<0.05). The difference in the cumulative incidence of relapses (CIR) was quasi-significant between both groups (p=0.031). The ratio Smad7:Smad1, suggesting inhibition of the Smad-dependent signaling pathway, was significantly higher in ALL blasts of children who later relapsed (14.33 versus 5.13, AU, p<0.05). CIR was significantly higher (p<0.05) in the group of children with the Smad-dependent pathway inhibited. All these differences were detected considering the whole population, as well as only the low/intermediate-risk groups. BMP4 levels were significantly higher in CSF samples of children with leukemic infiltration of the central nervous system (16.0 pg/ml versus 3.4 pg/ml, p<0.001), as well as in the group of children who relapsed (10.6 pg/ml versus 1.8 pg/ml, p<0.001). Hematopoietic engraftment (marrow, spleen and peripheral blood) and CNS leukaemia occurred only in ALL samples with high BMP4 levels. Even more, no signs of disease were detected in mice transplanted with primary ALL blasts expressing low levels of BMP4. In independent preclinical pharmacological blockade of the canonical BMP signaling pathway significantly decreased infiltration of CNS and consistently resulted in amelioration of clinical parameters including neurologic score.

Summary/Conclusions: These results indicate that high BMP4 levels are required for both bone marrow engraftment and CNS infiltration by B-ALL cells. BMP4 levels in leukemia cells could be a useful biomarker to identify children with poor outcome in the childhood B-ALL of low-/intermediate-risk groups. Furthermore, BMP4 could be a new therapeutic target to blockade leukemic CNS disease.

P514

TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

A. Buffere1,2, C.-H. Nguyen2, B. Uzan3,7, N.-S. Bastie14, D. Delva1, F. Pflumio3, R. Quentin1
1Signaling And Physiology In Hematological Research, UMR1231 Inserm, Université Bourgogne Franche-Comté, AgroSup, Dijon, 2Institut Curie, PSL Research University, URMR187 U1196, CNRS-Institut Curie, Inserm, Centre National de la Recherche Scientifique, Orsay, Commission à l’Energie Atomique et aux Energies Alternatives (CEA), DSM, 3RCM-SCSR-LSHL, Inserm UMR 967, Fontenay-aux-Roses, 4Clinical Hospital Department, François Mitterrand University Hospital, Dijon, France

Background: T-cell acute lymphoblastic leukaemia (T-ALL) is a hematological malignancy characterized by immature T-cell excessive proliferation. To achieve remission, patients typically undergo 2 years of chemotherapy, associated with acute and chronic side effects. To enable reduced chemotherapy intensity and haematologica | 2017; 102(s2) | 195 Madrid, Spain, June 22 – 25, 2017
Acute lymphoblastic leukemia - Clinical 2

P515 SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL

M. Kuhnen1,*, M. Kunstreich2, K. Krull1, J. Klasen-Sansone3, F. Schramm4, G. Escherich5, A. Moerick6, M. Schrappe5, D. Klee6, A. Borkhardt1
1Department of Pediatric Oncology, Hematology and Clin. Immunology, University Children’s Hospital, Medical Faculty, Heinrich Heine University, 2Department of Pediatric Oncology, Hematology and Clin. Immunology, University Children’s Hospital, Medical Faculty, Heinrich Heine University Duesseldorf, 3Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich Heine University Duesseldorf, 4Clinic of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, 5Department of Pediatrics, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany

Background: Cure rates for acute lymphoblastic leukemia (ALL) have increased to ~90% in the last decades, but come at a high cost as a substantial proportion of these children sustain toxic side-effects. Osteonecrosis (ON) is one of the most common and debilitating side effects, which severely impacts quality of life.

Aims: To analyze whether systematic magnetic resonance imaging (MRI) screening of adolescents can identify those with asymptomatic ON (stage I and II), who subsequently develop symptomatic ON.

Methods: Children diagnosed with ALL aged ≥10 years, who were enrolled in the Osteonecrosis Prevention and Long-term Observation (OPAL) registry, which includes all patients with ALL or lymphoblastic lymphoma (LBL), were analyzed. Standardized MRI screening of the hips and knees was scheduled at diagnosis and 6, 9, 12, 15, 18 and 24 months into therapy. All patients were assessed according to a standardized case report form recording symptoms and activities of daily living and functional impairments of the hips and knees based on modified Harris Hip and Knee Society scores every 3 months from diagnosis to the end of antileukemic treatment.

Results: Between 03/2013-12/2016, 64 patients (pts) were enrolled, median age at ALL diagnosis was 15 years (range 10-17), median time under evaluation was 11 months (range 0-45). 31 (48.4%) pts were male, 33 (51.6%) female.

Aims: To study whether a new compound named Pyrido[4,3-b]Quinoxaline (PyQ) has an antitumoral effect on Acute Myeloblastic Leukemia (AML). It strongly interacts with tumor alpha-chain (IL-7Rα) and downstream IL-7 signaling offers a potentially effective therapeutic strategy for T-ALL. The IL-7Rα is recruited and concentrated into lipid rafts thereby amplifying its downstream signaling pathway. The IL-7/STAT5 signaling pathway mediates downregulation of pro-apoptotic signals on human T-cells such as BAD and BIM. Moreover, we have previously reported that PyQ delocalizes the IL-7Rα away from lipid rafts on the cell surface of human T-ALL cells. We have also proved that PyQ delayed T-ALL progression in vivo when cocultured with murine stromal MS5 cells and in vivo when transplanted into immunodeficient NOD/SCID/γc−/− (NSG) mice. We also work on primary T-ALL blasts isolated from 10 patients suffering of T-ALL and maintained frozen in a biobank.

Results: In this study, we have shown that PyQ delocalizes the IL-7Rα away from lipid rafts on the cell surface of human T-ALL cells. We have also proved that localization of the IL-7Rα on lipid rafts plays a crucial role in human T-ALL maintenance in vitro. Its delocalization leads to IL-7 signaling pathway inactivation, upregulation of BAD and BIM genes involved in apoptosis and T-ALL cells apoptosis. We furthermore assessed effect of PyQ on 10 samples of primary T-ALL blasts. All of them were sensitive to IL-7-dependent cell survival and revealed a marked response to PyQ treatment (Mean IC50=5.7 ng/mL). For this work, T-ALL cells were co-cultured on murine stromal MS5 cells and PyQ has affected mainly T-ALL cell growth. No effect was observed on the stromal feeder cells, suggesting that injection of PyQ in vivo would not impact the stromal microenvironment in bone marrow. Finally, we provided evidence that PyQ delayed T-ALL progression in vivo, after treatment of immunodeficient mice xenografted with T-ALL cells.

Summary/Conclusions: The findings of this study highlight the importance of the IL-7Rα localization in maintenance of T-ALL cells and may lead to the design of a new generation of anti-cancer drugs able to modulate the protein positioning into lipid rafts.

P516 FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS

D.F. Lang1,2, H. Pfeifer1, W. Bethge1, M. Bornhäuser1, M. Stadler4, D. Beelen5, V. Vucinic6, T. Burmeister7, M. Stelljes8, C. Faul2, P. Dregere8, K. Wendelin10, E. Lange11, N. Goebkuget1, C. Wabbel1, D. Hoelzer1, O. Ottmann12
P157

ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)


1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, 2Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, 3Division of Hematology Oncology/Blood and Marrow Transplant, Children’s Hospital of Los Angeles, USC Keck School of Medicine, Los Angeles, United States, 4Hospital Sant Joan de Déu, Barcelona, Spain, 5Children’s Mercy Hospital and Clinics, Kansas City, 6Adult and Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, United States, 7Oslo University Hospital Rikshospitalet, Oslo, Norway, 8Department of Pediatrics, The University of Texas Southwestern Medical Center, 9Pauline Allen Gill Center for Cancer and Blood Disorders, Children’s Health, Dallas, United States, 10Department of Pediatrics, Faculty of Medicine, University of Montreal, 11Hematology Oncology Division, CHU Sainte-Justine, 12Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, Canada, 13Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, United States, 14Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, 15Cancer Research Institute Ghent (CRIG), Ghent, Belgium, 16Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, 17Cincinnati Children’s Hospital Medical Center, Cincinnati, 18Division of Pediatric Hematology and Marrow Transplant, Duke University Medical Center, Durham, United States, 19Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany, 20Department of Pediatrics, Stanford University School of Medicine, Stanford, 21Novartis Pharmaceuticals Corporation, East Hanover, 22Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 23University of Michigan, Ann Arbor, 24Icahn School of Medicine at Mount Sinai, New York, United States

Background: The CD19-targeted chimeric antigen receptor (CAR) T-cell therapy CTL019, an investigational therapy that uses reprogrammed cytotoxic T cells to recognize and eliminate target cells, has shown high response rates in clinical trials for pediatric/young adult R/R B-ALL. The safety profile in this population has been limited to a single-center trial.

Aims: To identify any new safety issues with CTL019 emerging from use in multicenter trials.

Methods: Pooled data from 2 single-arm, multicenter phase 2 trials of CTL019 therapy in pediatric/young adult patients (pts) with R/R B-ALL (NCT02435849 and NCT02228096) were used to further characterize the safety of CTL019.

Table 1.

Results: 123 pts were enrolled, 26 were not infused and not included in this analysis (10 deaths, 9 manufacturing failures, 3 adverse events [AEs], 4 pts prematurely discontinued). 97 pts received a single infusion of transduced CTL019 cells (median dose, 3.2×10^6 [range, 0.2-5.4×10^6] cells/kg). Median age was 12y (range, 3-25). During the first 8 wk after infusion, 98% of pts experienced an AE of any grade (G), 82% experienced G3/4 AEs, and 72% experienced a serious AE (SAE). Common nonhematologic G3/4 AEs (≥10%) during the first 8 wk were cytokine release syndrome (CRS; 44%), hypotension (24%), decreased appetite (21%), increased AST (19%) and ALT (12%), hypoxia (10%), hypokalemia (13%), hypophosphatemia (11%), and pulmonary edema (10%). Rates of G3/4 AEs and SAEs decreased substantially >8 wk post infusion. 21 pts died post infusion: 16 (76%) from B-cell leukemia/lymphoma (including infusion-related death), 1 from CNS, 1 from SAA, and embolic infectious stroke (n=1) (both ≤30 days); and infection (n=3, >30 days). Safety events were similar across pt subgroups based on age, sex, prior allogeneic stem cell transplant (alloSCT) (n=37), and Down syndrome (n=7). CRS was the most common CRIS, occurring in 81% of pts (Table 2). Al phCRS events occurred <8 wk post infusion. CRS was managed with supportive care, and 34% of pts were treated with anti-IL-6 agents. No deaths were attributed to CRS. Pts with ≥50% bone marrow (BM) blasts at enrolment (n=68) were...
twice as likely to develop G3/4 CRS than pts with <50% BM blasts (n=29) (63% vs 24%). Earlier-onset fever correlated with severity of CRS. CRS grade correlated with serum IL-6 levels. CRS-associated coagulopathy with fibrinogen levels <1.0 g/L was observed in 10% of pts. Neuropsychiatric AEs occurred during or shortly after CRS resolution, were self-limiting, and were more likely in pts with severe CRS or history of CNS leukemia or other CNS diseases. No G4 neuropsychiatric events were observed. Other AEs of special interest within the first 8 wk included G3/4 neutropenia with high (>38.3 C) fever (61%) and infections (G3/4, 22%). Prolonged G3/4 neutropenia (not resolved >28 days) occurred in 59 pts (61%). 36% of pts with prolonged G3/4 neutropenia had G3/4 infections after day 28. One pt with prior alloSCT was diagnosed with unconfirmed gut GVHD. Responding pts developed prolonged B-cell aplasia that was managed with immunoglobulin replacement. Tumor lysis syndrome was uncommon (3%).

Summary/Conclusions: This pooled analysis of global experience with CTL019 across 25 sites and 11 countries found no new safety issues. CRS and neuropsychiatric events, which are class effects of CAR T-cell therapy, were effectively managed. CTL019 appears similarly safe in pts with Down syndrome or prior alloSCT and across age groups. Prolonged follow-up will be required to determine the long-term safety of B-cell aplasia.

P519

PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETIC SUBGROUPS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBластIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN

E. Alvarez1,2, A. Advani3, R. Varela1, W. Stewart1, M. Liedtke1, N. Gökbuget2, G. Martinielli3, S. O’Brien6, J. Liang White5, T. Wang2, M.L. Paccagnella1, B. Steigh5, E. Vendandren10, D.J. DeAngelo11, H.M. Kantarjian1

1MD Anderson Cancer Center, Houston, 2Cleveland Clinic, Cleveland, United States, 3University of Nebraska Medical Center, Omaha, Nebraska, United States, 4University of Chicago, Chicago, 5Stanford Cancer Institute, Stanford, United States, 6Geoth University, Frankfurt, Germany, 7Institute Seràgnolí, DIMES, University of Bologna, Bologna, Italy, 8University of California, Irvine, Orange, 9Pfizer Inc, Groton, 10Pfizer Inc, Cambridge, 11 Dana-Farber Cancer Institute, Boston, United States

Background: In the phase 3 INO-VATE study of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) patients, inotuzumab ozogamicin (InO) showed improved complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rates versus standard care (SC; 80.7% vs 29.4%; P<0.001) (NCT01564784; Kantarjian NEJM 2016 [data cutoff date: Oct 2, 2014]). Aims: To assess the impact of baseline karyotype on response and toxicities in R/R ALL patients receiving InO from the INO-VATE study Methods: Full study details have been previously published. At screening, karyotyping was performed locally, and abnormalities were categorized according to International System for Cytogenetic Nomenclature. CR/CRi and minimal residual disease (MRD) negativity rates (defined as <0.01% bone marrow blasts as assessed at a central laboratory) were compared using a chi-square test for each cytogenetic subgroup. Survival estimates were compared using a log-rank test. Data as of March 8, 2016, are presented. Informed consent was obtained from all patients. All analyses presented were not adjusted for multiple testing.

Results: Of 326 patients randomized, 284 had cytogenetic data at screening (HR=0.34; P<0.001; SC: 140). Of the 186 InO-treated patients, 21.3% had normal diploid karyotype (≥20 metaphases), 17.1% complex (≥25 abnormalities), 13.4% Philadelphia-chromosome positive (Ph+) disease, 6.7% diploid (≤20 or unknown metaphases), 4.9% hyperdiploid (>50, 4.9% aberrations involving mixed lineage leukemia (MLL), 1.8% low hypodiploid/near-triploidy, 1.2% Del (9p), 16.5% other chromosome abnormalities, and 12.2% missing. Of 164 InO-treated patients, CR/CRi rate was 73% (95% confidence interval [CI] 66–80; Table) and MRD negativity rate was 95% (95% CI, 51–67). With InO, CR/CRi and MRD negativity rates were similar between the various cytogenetic subgroups. CR/CRi rate was significantly higher with InO compared to SC in diploid (≥20 metaphases), complex, other, and missing cytogenetic subgroups (P<0.015) and numerically higher in the other cytogenetic subgroups. With InO, more patients with diploid (≥20 metaphases) karyotype proceeded to stem cell transplant versus other cytogenetic subgroups. With InO, the duration of remission (DoR) was significantly different between cytogenetic subgroups (P<0.0001), with diploid (≥20 metaphases) and other subgroups having the longest median DoR numerically and MLL subgroup having the shortest median DoR numerically; no significant differences in DoR were seen between cytogenetic subgroups with SC (P=0.1763). Significant differences in PFS were seen between cytogenetic subgroups with InO (P=0.0063); no significant differences were seen between cytogenetic subgroups with SC (P=0.5427). With InO and SC arms, overall survival (OS) differences between cytogenetic subgroups were not significant (P=0.1629 and 0.3040, respectively); however, although not statistically significant based on 97.5% CI for hazard ratio (HR), OS was numerically longer (HR <1) with InO versus SC in diploid (≥20 metaphases), MLL, complex, other, and missing cytogenetic subgroups. Generally, adverse event profiles did not vary by cytogenetic subgroup.

Summary/Conclusions: In patients with diploid (≥20 metaphases), complex, other, and missing cytogenetic karyotypes, CR/CRi rates were significantly higher with InO versus SC (P<0.001). MLL, complex, other, and missing cytogenetic subgroups, OS favored InO versus SC, though not statistically significant. Safety profiles generally were similar to the overall study population.
LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS
P520
largely unsatisfactory, this regimen with full-dose CLO plus attenuated CY
proved feasible and yielded an appreciable CR rate in adult patients suffering
Summary/Conclusions:
CR affected DFS/OS probabilities.

Sheffield Children’s Hospital, Sheffield, United Kingdom, 5Department of Pae-
diatric Haematology and Oncology, University Children’s Hospital Münster,
Research (Munich) GmbH, Munich, Germany, 4Department of Haematology,
tology-Oncology, University of Pavia, Pavia, Italy, 3Global Development, Amgen

vanni XXIII, Bergamo, 10Ospedali Riuniti Villa Sofia-Cervello, Palermo, 11A.O.
G. Specchia7, E. Cerqui8, C. Micò9, F. Fabbiano10, F. Ronco11, A.M. Scattolin12,

CILOLEUCEL (AXI-CEL)
PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION
OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE
CILIOLEUCEL (AXI-CEL)
P522

1Bambino Gesù Children’s Hospital, Rome, 2Department of Pediatric Hema-
tology-Oncology, University of Pavia, Pavia, Italy, 3Global Development, Amgen
Research (Munich) GmbH, Munich, Germany, 2Department of Haematology,
Sheffield Children’s Hospital, Sheffield, United Kingdom, 1Department of Pae-
diatric Haematology and Oncology, University Children’s Hospital Münster,
Münster, Germany, 6Department of Stem Cell Transplantation, St. Anna
Children’s Hospital, Vienna, Austria, 7Department of Pediatric Hematology, Robert
Debré Hospital, Paris, France, 8Department of Pediatrics, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH, United States, 9LB Biostatistics, Lon-
don, United Kingdom, 10Department of General Paediatrics and Haematology/Oncology, Children’s Hospital, University of Tübingen, Tübingen,
Germany

Background: Blinatumomab, a bispecific T-cell engager antibody construct,
has shown antileukaemia activity and tolerability in patients with relapsed/refrac-
tory B-precursor acute lymphoblastic leukaemia (ALL).

Aims: We further evaluated safety and efficacy of blinatumomab in pediatric
and adolescent patients with relapsed/refractory B-precursor ALL enrolled in
an expanded access study (NCT02187354).

Methods: Eligible patients (aged >28 days to <18 years) had ≥5% blasts and
relapse after an allogeneic hematopoietic stem cell transplantation [alloHSCT].
Blinatumomab was dosed by continuous intravenous infusion (4 weeks on/2 weeks
off) up for five cycles (≥5 to <25% blasts: 15µg/m²/day; ≥25% blasts: 5µg/m²/day
on days 1-7, then 75µg/m²/day on days 1-7 in cycle 1, then 15 µg/m²/day). The pri-
mary endpoint was incidence of treatment-emergent (TE) and treatment-related
(TR) adverse events (AEs). Key efficacy endpoints were complete response
and minimal residual disease (MRD, measured by polymerase chain reaction
or flow cytometry) response within the first two cycles, relapse-free survival,
overall survival, and incidence of alloHSCT.

Results: Among the first 40 treated patients (median age, 9 [range, 1–17
years], 24% [60%] had experienced ≥2 relapses, 20 (50%) had relapsed after
alloHSCT, and 5 (13%) were primary refractory; 18 (45%) had ≥50% blasts
and 21 (53%) had prior alloHSCT. Safety and key efficacy outcomes are shown
in the table. Twenty-five patients (63%) achieved a complete response within
the first two cycles; 19 of whom had an MRD response. Eight patients relapsed
and 20 died after treatment. Regardless of causality, the most frequent TEAEs
were pyrexia (78%), cytokine release syndrome (CRS; 23%), vomiting (23%),
and anemia (20%). All nine CRS events were grade 1 or 2, and one tumor lysis
syndrome was grade 3. Ten (25%) patients interrupted treatment and two (5%)
discontinued due to TRAEs; 13 (33%) patients had grade ≥3 TRAEs, including
two of three neurologic events (depressed level of consciousness and
headache; both grade 3). Two patients experienced fatal AEs, both of which
were considered unrelated to blinatumomab.

Table 1.

| All TEAEs | 40 (100) |
| Grade 3 | 15 (38) |
| Grade 4 | 2 (5) |
| Fatal | 5 (13) |
| Complete response | 22 (56) |
| <50% blasts | 21 (53) |
| ≥50% blasts | 22 (56) |

Summary/Conclusions: Blinatumomab showed antileukaemia activity in pedia-
tric and adolescent patients with high-risk relapsed/refractory B-precursor ALL,
including t(17;19) and AEs were consistent with those previously reported for
relapsed/refractory ALL.

P521
BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBlastic LEUKEMIA
FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY
F. Locatelli1,*, G. Zugaiger2, A. Vora3, C. Rossig5, C. Peters5, B. Brethoren,
M. O'Brien6, L. Belton6, R. Handgretinger10

A modified schedule combining full-dose CLO with attenuated CY (given
tomorrow) allowed with a reference CLO-

Summary/Conclusions:
CR affected DFS/OS probabilities.

Background: Blinatumomab, a bispecific T-cell engager antibody construct,
has shown antileukaemia activity and tolerability in patients with relapsed/refrac-
tory B-precursor acute lymphoblastic leukaemia (ALL).

Aims: We further evaluated safety and efficacy of blinatumomab in pediatric
and adolescent patients with relapsed/refractory B-precursor ALL enrolled in
an expanded access study (NCT02187354).

Methods: Eligible patients (aged >28 days to <18 years) had ≥5% blasts and
relapse after an allogeneic hematopoietic stem cell transplantation [alloHSCT].
Blinatumomab was dosed by continuous intravenous infusion (4 weeks on/2 weeks
off) up for five cycles (≥5 to <25% blasts: 15µg/m²/day; ≥25% blasts: 5µg/m²/day
on days 1-7, then 75µg/m²/day on days 1-7 in cycle 1, then 15 µg/m²/day). The pri-
mary endpoint was incidence of treatment-emergent (TE) and treatment-related
(TR) adverse events (AEs). Key efficacy endpoints were complete response
and minimal residual disease (MRD, measured by polymerase chain reaction
or flow cytometry) response within the first two cycles, relapse-free survival,
overall survival, and incidence of alloHSCT.

Results: Among the first 40 treated patients (median age, 9 [range, 1–17
years], 24% [60%] had experienced ≥2 relapses, 20 (50%) had relapsed after
alloHSCT, and 5 (13%) were primary refractory; 18 (45%) had ≥50% blasts
and 21 (53%) had prior alloHSCT. Safety and key efficacy outcomes are shown
in the table. Twenty-five patients (63%) achieved a complete response within
the first two cycles; 19 of whom had an MRD response. Eight patients relapsed
and 20 died after treatment. Regardless of causality, the most frequent TEAEs
were pyrexia (78%), cytokine release syndrome (CRS; 23%), vomiting (23%),
and anemia (20%). All nine CRS events were grade 1 or 2, and one tumor lysis
syndrome was grade 3. Ten (25%) patients interrupted treatment and two (5%)
discontinued due to TRAEs; 13 (33%) patients had grade ≥3 TRAEs, including
two of three neurologic events (depressed level of consciousness and
headache; both grade 3). Two patients experienced fatal AEs, both of which
were considered unrelated to blinatumomab.

Table 1.

| All TEAEs | 40 (100) |
| Grade 3 | 15 (38) |
| Grade 4 | 2 (5) |
| Fatal | 5 (13) |
| Complete response | 22 (56) |
| <50% blasts | 21 (53) |
| ≥50% blasts | 22 (56) |

Summary/Conclusions: Blinatumomab showed antileukaemia activity in pedia-
tric and adolescent patients with high-risk relapsed/refractory B-precursor ALL,
including t(17;19) and AEs were consistent with those previously reported for
relapsed/refractory ALL.

PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION
OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE
CILIOLEUCEL (AXI-CEL)
P522

1H. Lee Moffitt Cancer Center, Tampa, 2Kite Pharma, Santa Monica, 3University
of Texas MD Anderson Cancer Center, Houston, 4Washington University School
of Medicine in St. Louis, Saint Louis, 5University of Miami Health System,
Sylvester Comprehensive Cancer Center, Miami, 6Stanford University School
of Medicine, Stanford, 7Abraxxeon Biopharma, 8Cell Genesys Inc., CA, MA, Boston,
9Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, 10Van-
derbilt-Ingram Cancer Center, Nashville, 11City of Hope National Medical Cen-
ter, Duarte, 12Mayo Clinic, Rochester, 13UCLA David Geffen School of Medicine,
Los Angeles, 14University of Rochester Medical Center, Rochester, United
States

Background: The incidence of acute lymphoblastic leukaemia (ALL) is increas-
ing, with nearly 6600 new diagnoses expected in 2016, of which >40% will

haematologica | 2017; 102(s2) | 199

Madrid, Spain, June 22 – 25, 2017
LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM AN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY

M.S. Topp1,*, R.A. Larson2, A. Schuh3, W. Stevenson4, E. Lech-Maranda5, K. Nie6, Z. Zimmerman7, W. Kormany8, A.S. Stein9,10
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 2Department of Medicine, University of Chicago Medical Center, Chicago, IL, United States, 3Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, 4Royal North Shore Hospital, University of Sydney, Sydney, Australia, 5Department of Hematology, Institute of Hematology and Transfusion Medicine and Centre of Postgraduate Medical Education, Warsaw, Poland, 6Global Biostatistical Sciences, 7Global Development, 8Global Development, 9Global Safety, Amgen Inc, Thousand Oaks, CA, 10Geher Family Center for Leukemia Research, City of Hope, Duarte, CA, United States

Background: Blinatumomab, a bispecific T-cell engager antibody construct, has shown improved overall survival vs standard of care (SOC) chemotherapy in patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in a randomized phase 3 study (N Engl J Med 2017;367:836-847).

Aims: We compared the incidence of adverse events (AEs) observed with blinatumomab vs SOC after adjusting for varying treatment exposure times for a more comprehensive evaluation of safety and tolerability.

Methods: Adults (aged ≥18 years) with relapsed/refractory B-precursor ALL (refractory to primary induction therapy or salvage therapy, first relapse <1 year, second or later relapse, or relapse after allogeneic hematopoietic stem cell transplantation) were randomized to receive either blinatumomab or SOC (1 of 4 predefined regimens). Blinatumomab was dosed by continuous intravenous infusion (4 weeks on/2 weeks off) for up to five induction cycles (9 months total exposure time) or 3 cycles (1−190 days) followed by 4 maintenance cycles (4 weeks on/8 weeks off) allowed for up to 12 months. Exposure-adjusted event rates were calculated as the number of events x total exposure time (shown in the table).

Results: Median (range) number of cycles were 1 (1−4) for SOC and 2 (1−9) for blinatumomab. The highest exposure-adjusted event rates (per 100 patient-years) were for pyrexia (507 SOC vs 376 blinatumomab), anemia (987 vs 229), thrombocytopenia (750 vs 126), and neutropenia (351 vs 121), all of which were lower for blinatumomab than for SOC. Febrile neutropenia (365 vs 93) and delayed cytotoxic/antineoplastic AE (1216 vs 45) were also lower for blinatumomab than for SOC (p<0.0001). Exposure-adjusted event rates for neurologic events were 743 for SOC vs 472 for blinatumomab, with median time (range) to onset of 7 (1−43) days and 7 (1−190) days, respectively, and grade ≥3 cytokine release syndrome (CRS) rates were 0 for SOC vs 10 for blinatumomab. The most frequent grade ≥3 AEs of SOC vs blinatumomab were for pyrexia (80 vs 20%) and neutropenia (80 vs 40%), which were lower for blinatumomab than for SOC (p<0.0001).

P524

EXPOSURE-ADJUSTED ADVERSE EVENT COMPARING BLINATUMOMAB VS STANDARD OF CARE IN ADULTS WITH RELAPSED/REFRACTORY B-precursor ACUTE LYMPHOBластIC LEUKEMIA: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

M.S. Topp1,*, R.A. Larson2, A. Schuh3, W. Stevenson4, E. Lech-Maranda5, K. Nie6, Z. Zimmerman7, W. Kormany8, A.S. Stein9,10
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 2Department of Medicine, University of Chicago Medical Center, Chicago, IL, United States, 3Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, 4Royal North Shore Hospital, University of Sydney, Sydney, Australia, 5Department of Hematology, Institute of Hematology and Transfusion Medicine and Centre of Postgraduate Medical Education, Warsaw, Poland, 6Global Biostatistical Sciences, 7Global Development, 8Global Development, 9Global Safety, Amgen Inc, Thousand Oaks, CA, 10Geher Family Center for Leukemia Research, City of Hope, Duarte, CA, United States

Background: Blinatumomab, a bispecific T-cell engager antibody construct, has shown improved overall survival vs standard of care (SOC) chemotherapy in patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in a randomized phase 3 study (N Engl J Med 2017;367:836-847).

Aims: We compared the incidence of adverse events (AEs) observed with blinatumomab vs SOC after adjusting for varying treatment exposure times for a more comprehensive evaluation of safety and tolerability.

Methods: Adults (aged ≥18 years) with relapsed/refractory B-precursor ALL (refractory to primary induction therapy or salvage therapy, first relapse <1 year, second or later relapse, or relapse after allogeneic hematopoietic stem cell transplantation) were randomized to receive either blinatumomab or SOC (1 of 4 predefined regimens). Blinatumomab was dosed by continuous intravenous infusion (4 weeks on/2 weeks off) for up to five induction cycles (9 months total exposure time) or 3 cycles (1−190 days) followed by 4 maintenance cycles (4 weeks on/8 weeks off) allowed for up to 12 months. Exposure-adjusted event rates were calculated as the number of events x total exposure time (shown in the table).

Results: Median (range) number of cycles were 1 (1−4) for SOC and 2 (1−9) for blinatumomab. The highest exposure-adjusted event rates (per 100 patient-years) were for pyrexia (507 SOC vs 376 blinatumomab), anemia (987 vs 229), thrombocytopenia (750 vs 126), and neutropenia (351 vs 121), all of which were lower for blinatumomab than for SOC. Febrile neutropenia (365 vs 93) and delayed cytotoxic/antineoplastic AE (1216 vs 45) were also lower for blinatumomab than for SOC (p<0.0001). Exposure-adjusted event rates for neurologic events were 743 for SOC vs 472 for blinatumomab, with median time (range) to onset of 7 (1−43) days and 7 (1−190) days, respectively, and grade ≥3 cytokine release syndrome (CRS) rates were 0 for SOC vs 10 for blinatumomab. The most frequent grade ≥3 AEs of SOC vs blinatumomab were for pyrexia (80 vs 20%) and neutropenia (80 vs 40%), which were lower for blinatumomab than for SOC (p<0.0001).
Acute myeloid leukemia - Biology 3

P526

DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS

S. Adams1,*, A. Wilhelm1, L. Harvey1, L. Flaherty1, K. Watkins1, S. Sikka1, P. Shah1, W. Li1, Y. Kovtun1, C. Sloss1, K. Lai1, M. Miller1, G. Payne1
1ImmunoGen, Waltham, United States

Background: Antibody-drug conjugates (ADCs) targeting CD33 are promising therapeutics in AML, where challenges are achieving efficacy while maintaining tolerability. Here, we report the payload/ linker design and selection resulting in a high-Therapeutic Index (TI) ADC with favorable preclinical toxicity profile across multiple species and tumor model and disseminated AML models and in multi-dose regimens, IMGN779, the final ADC design, is comprised of an indolino-benzodiazepine mono-imine DNA-alkylating payload, DGN462, coupled by a cleavable N-succinimidyl-4-(2-pyridyldithio)-2-sulfobutanoate (s-SPDB) linker to a CD33-targeting antibody.

Aim: Select the best ADC out of multiple preclinical anti-CD33 ADC candidates, and assess its activity in vitro and in vivo in AML models.

Methods: Unconjugated payloads were evaluated in vitro for cytotoxicity on human AML cell lines. Payloads were compared, as CD33-targeting conjugates, in vitro for cytotoxicity on human AML cell lines and in vivo for tolerability in mice and Ti in human AML xenografts. ADCs with cleavable and non-cleavable linkers were evaluated for cytotoxicity on MDR-positive and -negative AML cell lines, for tolerability in mice and Ti in AML xenografts. IMGN779, the final ADC design, was evaluated in vivo for toxicity in rats and cynomolgous monkeys. IMGN779’s antitumor activity was evaluated in disseminated models and in fractionated- and multi-dose regimens in AML xenografts.

Results: First, we selected a high affinity antibody to CD33 with retained ADC activity. Next, given concerns for long-term toxicity of DNA crosslinkers, we prepared DNA alkylating (single strand DNA damage) and DNA crosslinking (double strand DNA damage) versions of our novel IgG payload class. Both versions had comparable IC50s on human AML cell lines as free drugs (12-260 vs. 5-77 PM) and as CD33-targeting ADCs (0.7 vs. 0.5 PM). However, in vivo, the CD33-targeting DNA alkylating ADC had a 5-fold higher TMD (maximally tolerated dose) in mice and 5-fold larger Ti in AML xenograft models (TMD 950 vs. 180 µg/kg, by payload, Ti of 95 vs. 19). In addition, the DNA crosslinking version led to delayed systemic toxicity at TMD, not seen in the DNA alkylating version even at its 5-fold higher TMD. Thus we selected the DNA alkylating version for further development. To determine the optimal linker design, we created ADCs with three different linkers, one non-cleavable and two cleavable, and based on improved in vitro efficacy (IC50) and in vivo safety/efficacy (MTD, Ti), the s-SPDB cleavable linker with the DNA alkylating payload was chosen as the lead clinical compound, and named IMGN779. In multiple species, IMGN779 had a consistent toxicity profile (mice, rats and monkeys), producing reversible cytoxicities with no or minor changes in transaminases and without histologic evidence of hepatotoxicity. Importantly, IMGN779 was highly active at a single dose 10 µg/kg (payload) in an MV4-11 (FLT3-ITD+) disseminated AML xenograft model, producing a 90% increased life span, and was well-tolerated and highly active in repeat dosing regimens (10 or 30 µg/kg, qw x 3 and q3d x 3) in a HL60 AML xenograft model. Similarly, in a MV4-11 xenograft model, a single dose of 5 µg/kg (payload) caused a 90% increase in life span, and was well-tolerated and highly active in repeat dosing regimens (10 or 30 µg/kg, qw x 3 and q3d x 3) in a HL60 AML xenograft model. Similarly, in a MV4-11 xenograft model, a single dose of 5 µg/kg (payload) caused a 90% increase in life span, and was well-tolerated and highly active in repeat dosing regimens (10 or 30 µg/kg, qw x 3 and q3d x 3).

Summary/Conclusions: IMGN779, designed as the next generation CD33-targeting ADC, utilizes a novel DNA alkylating DGNN462 payload and a cleavable disulfide linker, selected to maximize anti-AML activity and preclinical safety. IMGN779 is highly active in multiple AML xenograft models, including models with poor prognostic factors, and is well-tolerated in preclinical repeat dosing regimens, where an additional benefit was achieved for a fractionating the dosing regimen over a single high dose. These results provide the foundation for the clinical evaluation of IMGN779 in AML.

P527

THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION

K. Hetzner1,*, M. Garcia-Cuellar1, C. Bütter2, R. Slany1
1Biology, Institute of Genetics, 2Biology, Institute of Hum.Genetics, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany

Background: In mixed lineage leukemia ENL is frequently found juxtaposed to MLL creating MLL-ENL fusion proteins that initiate leukemogenic transfor- mation. Interestingly, murine ENL also protected survival in a mouse model of the pediatric neoplasm, in its wild-type configuration ENL serves as a scaffolding factor in protein complexes that stimulate transcriptional elongation but, paradoxically, it also co-purifies with polycomb repressive complex 1 (PRC1).

Haematologica | 2017; 102(s2) | 201

Madrid, Spain, June 22 – 25, 2017

Table 1.

<table>
<thead>
<tr>
<th>Standard of Care</th>
<th>HI-MRD_Equivalent</th>
<th>HI-MRD</th>
<th>HI-MRD_Equivalent</th>
<th>HI-MRD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total responders, years</td>
<td>Number of Events</td>
<td>Exposure-adjusted Event Rate (95% CI)</td>
<td>Number of Events</td>
<td>Exposure-adjusted Event Rate (95% CI)</td>
</tr>
<tr>
<td>AS Alk</td>
<td>2017</td>
<td>8370</td>
<td>4036</td>
<td>0.14 (0.12–0.16)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>615</td>
<td>513</td>
<td>597</td>
<td>0.14 (0.11–0.16)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>115</td>
<td>781</td>
<td>319</td>
<td>0.14 (0.11–0.16)</td>
</tr>
<tr>
<td>Fuit</td>
<td>17</td>
<td>128</td>
<td>31</td>
<td>0.14 (0.11–0.16)</td>
</tr>
<tr>
<td>Neurologic events</td>
<td>10</td>
<td>419</td>
<td>60</td>
<td>0.14 (0.11–0.16)</td>
</tr>
<tr>
<td>CR</td>
<td>50</td>
<td>50</td>
<td>30</td>
<td>0.14 (0.11–0.16)</td>
</tr>
<tr>
<td>All autol</td>
<td>211</td>
<td>211</td>
<td>30</td>
<td>0.14 (0.11–0.16)</td>
</tr>
</tbody>
</table>

aPer 100 patient-years

Summary/Conclusions: In this study, blinatumomab showed an AE profile consistent with that previously reported for relapsed/refractory AML, including similar rates of manageable CRS and neurologic events. Exposure-adjusted event rates were generally higher in SOC vs blinatumomab, including for cytopenias and infections.
Aims: This work examines how ENL influences PRC1 repressive activity. Methods: The effect of ENL on transcriptional activity of model promoters and endogenous transcriptional control elements was studied by biochemical and molecular biology methods.

Results: Here we demonstrate that ENL overcomes polycomb induced silencing through recruitment of polymerase associated factor 1 (PAF1) and a chromatin remodelling complex. The capacity of ENL to bind to PAF1 could not only lead to a significant and dose-dependent increase in mitochondrial-produced ROS.

Discussion: Using a combination of experiments we showed that PKCε supports AML by maintaining mitochondrial redox homeostasis to support AML cell survival and disease progression and thus may represent a foundation for designing and developing novel therapeutic strategies.

P528
PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS

D. Di Marcarantonio1,2, E. Martinez1, J. Vadamkath1, S. Sidoli2, E. Masselli3, F. Ferraro1, M. D. Milsom1, C. Schoil1, S. Frohling1, B. A. Garcia1, P. Mirandola1, G. Gobbi1, T. Skorski6, R. Garzon2, M. Vitale5, S. M. Sykes1

Blood Cell Development and Function, Fox Chase Cancer Center, 1Department of Biology, Chemistry and Physics, University of Pennsylvania, Philadelphia, United States, 2Department of Medicine and Surgery, University of Parma, Italy, 3Experimental Hematology Group, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) and German Cancer Research Center (DKFZ), 4Department of Translational Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 5Department of Microbiology and Immunology, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania, 6Division of Hematology, The Ohio State University, Columbus, United States

Background: Although numerous genetic mutations contribute to the etiology and pathophysiology of acute myeloid leukemia (AML), the molecular machinery that is not mutated but supports AML biology remains largely unknown. Several studies have shown that AML cells, irrespective of genetic sub-type, display an oxidized intracellular redox environment compared to their healthy counterparts. The redox environment of AML cells is largely due to the elevated reactive oxygen species (ROS) levels, which are a class of free radical molecules. Though ROS are by-products of several cellular processes, in excess, they can damage DNA and destroy organelles, resulting in the activation of genetic mutations or cell death. As a result, ROS homeostasis is tightly regulated by an array of molecular pathways. Although ROS is elevated in AML cells, the role of ROS and the identity of its regulators remain largely unknown. Here we report that the serine/threonine kinase, PKCε regulates the ROS-neutralizing enzyme SOD2 to support mitochondrial redox homeostasis and AML progression.

Aims: The goal of this study was to identify and subsequently assess how targeting key ROS-regulatory pathways impacts AML biology.

Methods: Loss-of-function studies for PKCε and SOD2 were performed with recombinant lentiviruses expressing gene-targeting shRNAs. Recombinant retroviruses expressing either PKCε or SOD2/Catalase were used for gain-of-function assays. Cytoplasmic and mitochondrial superoxides and peroxides were measured using redox-sensitive GFP (roGFP) probes followed by flow cytometric analysis. Mitochondrial superoxides were also assessed by flow cytometric analysis of MitoSox stained cells. Proteomic analysis was achieved using nano LC-MS/MS. Annexin-V staining was analyzed by flow cytometry to measure apoptosis and in vitro and in vivo proliferation was measured using FACS-based purification of shRNA-expressing cells followed by: 1) growth in cytokine-enriched media or 2) transplantation into syngenic mice for survival analysis.

Results: We have discovered that inhibition of PKCε: 1) promoted the death of primary AML cell lines in vitro, 2) inhibited cell proliferation driven by MLL-AF9 in vivo (p=0.0014) and 3) obstructed the growth of 5 out of 7 PD-AML samples in vitro. At the molecular level, we observed that PKCε inhibition led to a significant and dose-dependent increase in mitochondrial-produced superoxides—a specific type of ROS. Moreover, we found that enforced expression of PKCε can protect AML cells from lethal effects of superoxide-inducing agents 2-thiophenyltrifluoroacetoxy and Antimycin A. To identify potential ROS-regulatory enzymes downstream of PKCε, we performed whole cell proteomics and found that the mitochondrial superoxide-neutralizing enzyme SOD2 is decreased in AML cells depleted of PKCε. Similar to PKCε inhibition, we also observed reduced inhibition of SOD2 reduced the expansion of AML cell lines and PD-AMLS in vitro as well as significantly extended the onset of MLL-AF9-driven AML in vivo (p=0.0042). Finally, we also found that enforced expression of SOD2 in tandem with another anti-oxidant enzyme Catalase, reverses the anti-leukemia effects of PKCε inhibition confirming that PKCε supports AML pathophysiology by maintaining mitochondrial redox homeostasis.

Summary/Conclusions: Our results indicate that PKCε and SOD2 regulate mitochondrial redox homeostasis to support AML cell survival and disease progression and thus may represent a foundation for designing and developing novel therapeutic strategies.

P529
Abstract withdrawn.

P530
ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2

R. Pandey3, S. Ramdas1, R. Chan1, R. Kapur1

1Indiana University School of Medicine, Indianapolis, United States

Background: SHP2, a protein tyrosine phosphatase coded by Ptnp11, is an essential protein that integrates signals from several different tyrosine kinase receptors with all the major intracellular signaling pathways such as ERK, PI3K and STAT pathways and regulates cell survival, proliferation and differentiation. One of the SHP2 dependent cytokine receptor kinase, FLT3 when mutated to be constitutively activated co-operators with other genetic lesions like loss of Tet2 and Dnmt3a leading to transformation of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML) in mouse models. Tet2 and Dnmt3a are involved in regulation hematopoietic stem cell (HSC) self-renewal and differentiation programs through regulation of DNA methylation. One their own each of them leads to MPD but when present in combination, leads to AML. These mouse models of AML have a more pronounced stem cell phenotype as compared to traditional chimeric mice or FLT3 targeted kinase inhibitor. Aims: Inhibition of SHP2 catalytic activity by a small molecule allosteric inhibitor has been recently demonstrated to retard the growth of receptor tyrosine kinase driven malignancies. Therefore, we wanted to investigate the role of SHP2 in leukaemogenesis driven by loss of an epigenetic regulator (Tet2) and aberrant cytokine receptor tyrosine kinase (Flt3-ITD) signalling.

Methods: Mice were intercrossed to generate Ptnp11F/FTet2-/-Flt3ITD+/+ or Ptnp11F/FTet2-/-Flt3ITD+/+ mice. Deletion of Ptnp11 was induced at 8-10 week of age by injecting poly IC and changes in the hematopoietic compartment were analyzed by flow cytometry. Cell autonomous and non-autonomous effects of Ptnp11 on leukaemogenesis were also evaluated in transplantation models.

Results: After ploy IC induced deletion of Ptnp11 there was a significant difference in the median survival between leukemic mice with with deletion of Ptnp11 versus non-deleted (n=8). Though the Ptnp11 deleted leukemic mice showed almost complete loss of long term HSC with concomitant increase in short term proliferating HSC in the bone marrow, they were still able to home and engraft in lethally irradiated recipient mice. These results indicate that loss of Ptnp11 does not impair the engraftment of leukemic stem cells though in normal mice deletion of Ptnp11 impairs the ability to stem cells to home to bone marrow niche and engraft. Deletion of Ptnp11 in both primary mice and secondary recipients was also associated with deregulation of myeloid and lymphoid cell distribution both in the periphery and bone marrow. Mice with deletion of Ptnp11 in the context of Flt3ITD did not generate immature or mature B- or T-cell. The effects of Ptnp11 deletion were more severe in in vivo mice as compared to mice that received Ptnp11 deleted cells or when Ptnp11 was deletet after transplantation suggesting a role for SHP2 function in the bone marrow microenvironment in this model of leukaemogenesis.

Summary/Conclusions: SHP2 has been recognized as a proto-oncogene on the basis of its ability to induce hematopoietic malignancies when it is constitutively active and loss of SHP2 catalytic activity is associated with inhibition of tyrosine kinase driven malignancies. Our results demonstrate that the role of SHP2 in AML is dependent upon the presence of other genetic mutations. SHP2 regulates AML with loss of Tet2 with concomitant expression of Flt3-ITD through influence on both leukemic cells and the bone marrow microenvironment.

P531
CLUSTER REGULATION OF RUNX FAMILY BY “GENE SWITCH” TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS

K. Morita1, K. Suzuki1, S. Maeda1, A. Matsuo1, Y. Mitsuda1, A. Yano1
Background: Although Runx-related transcription factor 1 (RUNX1) has been generally considered to be a tumor suppressor, a growing body of evidence suggests its pro-oncogenic property in acute myeloid leukemia (AML).

Aims: Demonstrate the anti-tumor potential of cluster regulation of RUNX with a “gene-switch” in AML as well as in distal-prognostic solid tumors arising from diverse origins in vivo.

Methods: To assess the effect of RUNX-inhibition in AML cells, we performed series of shRNA-mediated RUNX knockdown experiments. To achieve cluster regulation, we have computationally designed an agent which could irreversibly block the RUNX cluster genes expression profiling through dismantling protein-DNA interactions sequence-specifically (CROX-1).

Results: Firstly, shRNA-mediated silencing of RUNX1 stimulated cell cycle arrest at G0/G1 phase and induced apoptosis in AML cells bearing wild-type p53. Besides, RUNX1 depletion induced remarkable induction of p53 as well as its target gene products and additive knockdown of p53 in these cell lines reverted the phenotype of RUNX1-depletion, indicating that RUNX1 is functionally dependent on proficient p53 pathway. In addition, cycloheximide chase assay revealed that RUNX1 negatively regulates the protein stability of p53 in AML cells. In vivo data analysis and ChIP-seq experiments together with series of knockdown and restore experiments identified BCL11A and TRIM24 as critical mediators of p53 pathway activation in RUNX1-inhibited AML cells.

Though RUNX1-depleted AML cells exhibited drastically slowed proliferation rate, a small sub-population of leukemia cells retained the proliferation potential even after silencing of RUNX1. Analysis of these residual AML cells revealed the reciprocal up-regulation of RUNX2 and RUNX3 expressions, suggesting that RUNX2 and RUNX3 might compensate for the loss of RUNX1 functions. As expected, additional knockdown of RUNX2 and RUNX3 in RUNX1-depleted AML cells effectively suppressed their proliferations. Thus the simultaneous targeting of RUNX family members as a cluster provides more stringent control of leukemia cells. Finally, we examined the antitumor potency of CROX-1-mediated cluster regulations of RUNX. CROX-1 treatment was indeed highly effective against leukemia as well as distal-prognostic solid tumors arising from diverse origins in vitro. Moreover, this reagent was exceptionally well-tolerated in mice and exhibited excellent efficacy against xenograft mice models of AML, acute lymphoblastic leukemia, lung and gastric cancers, extending their overall survival periods in vivo. Since RUNX family take part in diverse physiologic functions not only in AML cells but also in normal hematopoietic cells and in various other vital organ tissues, we might expect criticisms in targeting whole RUNX family that it could trigger undesirable side-effects in vivo. Intriguingly, however, our drug was well-tolerated in vivo and through these experiments, we have coincidently found that the amount of total RUNX expressions was consistently higher in malignant tissues compared to their normal counterparts, and we believe that this gap offers pharmacological window to be targeted again and again. Furthermore, we found that higher expressions of estimated total RUNX amount demarcate significantly poorer-prognostic patient cohorts in a wide variety of cancers, underpinning the rationality of RUNX-inhibition strategies in cancer treatment.

Summary/Conclusions: This work identified the crucial role of RUNX cluster in the maintenance and the progression of cancer cells, and this indicated gene switch technology-dependent its modulation would be a novel strategy to control malignancies.

P532
PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELLS DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS

P. Casado-Izquierdo1, E. H. Wilkes2, F. Miraki-Moud1, M. M. Hadi1, A. Rio-Machin1, V. Rajeeve1, R. Pike1, I. Sameena1, S. Marfa1, N. Lea4, G. Mufti1, J. Gribben1, J. Fitzgibbon1, P. R. Cutillas1
1Centre for Haemato-Oncology, 2Flow Cytometry Core Facility, 3Tissue Bank, Barts Cancer Institute, 4Haematological Medicine, King’s College London School of Medicine, London, United Kingdom

Background: Kinase signalling is frequently deregulated in cancer cells. In the case of AML, the high recurrence of activating mutations in kinases and other kinase signalling regulators including FLT3 and RAS has stimulated the investigation of treatments based on kinase inhibitors. The success of kinase inhibitors depends of an accurate stratification of patients into response groups. The impact of genetic mutations on the sensitivity of primary AML to kinase inhibitors remains poorly defined and these have not been translated into effective therapies. The activity of a kinase can be affected by factors other than gene mutations and the sensitivity of leukemic cells to kinase inhibition depends not only on the activity of the targeted kinase. Thus, the integrative analysis of different biochemical features could improve the implementation of precision medicine therapies based on kinase inhibitors.

Aims: By the integration of multiple omics approaches, we aimed to generate molecular signatures, which can rationalize why some primary AML cells are resistant to treatment with different kinase inhibitors while others are sensitive to the same treatments.

Methods: In this investigation, we used a multomics approach to stratify 36 AML biopsies as a function of their cellular sensitivity to “ex vivo” treatment with TAK-715, silmitasertib, PF03758309, midostaurin and trametinib, which target P38, angiopoietin-like 2 (ANGPTL2) and MEK, respectively. The same samples were analysed using different omics platforms: (i) mass spectrometry for phosphoproteomics, proteomics and kinicomic profiling, (ii) mass cytometry for immunophenotyping and (iii) next generation sequencing for mutational profiling.

Results: Our integrative analysis identified two independent signatures that stratified our cohort of patients in sets of differentiated and undifferentiated cases. The phosphoproteomics signature divided our set of AML cases in the M1-like and M4-like groups (Figure 1A). The mass cytometry signature, which represented myelomonocytic markers that were co-expressed at the cell surface, split our cohort of patient in the CD56+ and CD56- groups. Remarkably, the M4-like and CD56- groups representing the non-differentiated cases, showed a high degree of overlap. Differentiated groups over-phosphorylated 3 times as many proteins as the non-differentiated groups, including kinases at sites linked to their activity. Mutations in genes involved in kinase signalling were also more frequent in differentiated cases. Kinase activity analysis using KSEA estimation demonstrated that differentiated groups presented an enriched activity for PAK, MEK, ERK or PKC. Ontology analysis showed that non-differentiated cells over-phosphorylated nuclear proteins with DNA binding properties, while the differentiated cells increased the phosphorylation of membrane and cytoplasmic proteins linked to the small GTPase signalling. More interestingly, cases in differentiated groups were more sensitive to PF03758309, trametinib and midostaurin than those in the non-differentiated sets (Figure 1B for groups defined by the phosphoproteomics signature). Finally, differentiated cases as defined by the mass cytometry signature in our cohort of patients, or by a CD marker mRNA expression signature in the ATCG database, presented with significantly reduced survival when compared to the groups of non-differentiated cases.

Summary/Conclusions: Our data indicate that differentiated cells activate pro-survival kinases like PAK, PKCD or MEK which make them more sensitive to the inhibitors PF03758309, midostaurin or the FDA-approved drug trametinib. Since patients with differentiated cells present a reduced overall survival treatment with these compounds may benefit patients in this higher risk group.
Background: Based on the prognostic significance, as well as the association with certain biological and clinical features, acute myeloid leukemia (AML) with biallelic mutations in the CCAAT enhancer-binding protein-alpha (CEBPA) gene has been included as a distinct entity into the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. CEBPA mutations (CEBPA mut) are found in about 20% of AML with normal cytogenetics, and approximately 60% of the mutated patients (pts) carry biallelic mutations. Several studies showed that CEBPA mut occur almost exclusively mutual with regard to other AML associated gene mutations such as NPM1 or FLT3-ITD mutations. Recently, mutations in the t(6;12) FUS/ETV6 gene family member 2 (TET2 mut) were described as a frequent concurrent mutation of CEBPA mut. Both genes are involved in the control of proliferation (CEBPA, TET2) and differentiation (CEBPA) of myeloid progenitors. Preliminary data suggest that pts harboring the CEBPA/ET2 mut genotype have a significantly worse overall survival (OS).

Aims: To evaluate the frequency and the clinical impact of TET2 mut within a large cohort of CEBPA mut AML pts.

Methods: In total 200 AML pts (age 18 to 78 years) with CEBPA mut (n=113) or CEBPA single mutations (CEBPA smt) (n=87) were analysed for the presence of TET2 mut. All pts were enrolled in one of six AMLSG treatment trials applying intensive therapy (AMLHG93 n=14; AMLHG98A (NCT0146120) n=53; AMLHG98B n=12; AMLSG 07-04 (NCT00151242) n=74; AMLSG 06-04 (NCT00151255) n=25 and AMLSG 12-09 (NCT01180322) n=22). TET2 mut screening was performed using a DNA-based PCR-assay covering exons 3 to 9 followed by Sanger sequencing.

Results: In total we detected 52 TET2 mut, 39 of the 200 pts (19.5%); in 16 pts TET2 mut were homozygous (6.5%). The median follow-up of the 200 pts was 76.3 months (95% CI: 68.5–84.2). TET2 mut were restricted to the cytogenetic intermediate-risk group (100%), and pts with TET2 mut were significantly older than pts with TET2 wild-type (p = 0.001). Furthermore, TET2 mut were more frequent in secondary/therapy-related AML (p = 0.04), and there was a significant association with SRSF2 gene mutations (p = 0.01). With regard to outcome, pts with TET2 mut had a significantly shorter event-free (EFS), relapse-free (RFS), and OS compared to TET2 wt pts (p < 0.001, p < 0.001 and p = 0.001, respectively). Furthermore, pts with TET2 mut were significantly older (68 y vs 51 y, p = 0.001) and had a higher rate of secondary malignancies (p = 0.03), and pts with TET2 mut had a significantly shorter RFS (p = 0.02) and OS (p = 0.05), and in trend a shorter EFS (p = 0.09).

Summary/Conclusions: In our study on a large cohort of CEBPA mut AML pts we could confirm the high incidence of concomitant TET2 mut (19.5%). Pts with concurrent TET2 mut were significantly older and had an inferior outcome.
Acute myeloid leukemia - Biology 4

P536

P38B MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA

E. Arriazu1, C. Vicente1, R. Pippa1, N. Marcote2, I. Igea2, L. Leon1, S. Chocarro1, M. Soto1, A.R. Nebreda2, M.D. Odero1,3,4

1Oncohematology, Center for applied medical research University of Navarre, Pamplona, 2Institute for Research in Biomedicine, Barcelona, 3Instituto de Investigación Sanitaria de Navarra (IdiSNA), Navarra, 4Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain

Background: Despite improvements in our understanding of the molecular evolution of acute myeloid leukemia (AML), the overall cure rates remain low, and most patients die from the disease despite achieving initial remission upon treatment. It is therefore necessary to open new therapeutic perspectives aimed at molecular targets. PP2A phosphatase inactivation is a recurrent event in hematological tumors. Our group has reported that SET, an endogenous inhibitor of PP2A, is overexpressed in 28% of patients with AML. Furthermore, the anticanine activity of PP2A activating drugs (PADs) depends on the interaction/sequestration of SET, pointing out the significance of this oncogene in AML. Drug inhibition of several MAPKs in AML cell lines showed that only p38 inhibitors activate PP2A and decrease SET protein.

Aims: Therefore, we hypothesized that p38 could regulate SET at postranslational level, leading to PP2A inactivation.

Methods: AML cell lines and primary human samples were analyzed by western blot, immunoprecipitation, immunofluorescence, treatment with pharmacological inhibitors and siRNA. Phosphorylation assays by in vitro kinase assay with recombinant proteins were performed.

Results: Knockdown of the two major isoforms of p38-MAPK, p38a and p38β, demonstrated that only p38β was able to reduce SET protein levels and increase PP2A activity. To decipher this mechanism of action, we performed protein immunoprecipitation and immunofluorescence in the AML cell lines HL-60 and MOLM-13. p38β co-localized and bound to SET mostly in the cytoplasm stabilizing it, since treatment with cicloheximide in the absence of p38β induced SET degradation. The stabilization role was in coordination with SETBP1, which co-localized with both SET and p38β. Interestingly, 12 out of 14 AML cell lines tested showed high expression of p38β protein levels as well as 5 out of 7 AML primary patient samples. Furthermore, expression analysis in a large series of adult de novo AML cases previously reported (Cancer Genome Atlas Research Network, 2013) showed a positive correlation between p38β (MAPK11) and SET (R²=0.416, p<0.001), but not between p38α and SET. We and others have shown that PADs retain SET in the nucleus. Our results showed that p38 phosphorylates SET not directly, but through the activation of casein kinase 2 (CK2), leading to the retention of SET in the nucleus and, therefore, contributing to the inactivation of PP2A in AML cells. Of note, CK2 is overexpressed in both AML cell lines and patient samples.

Summary/Conclusions: p38 is able to activate CK2 which phosphorylates SET and, as consequence, facilities its trafficking to the cytoplasm, contributing to PP2A inactivation in AML cells. Moreover, p38β binds to SET in the cytoplasm, contributing to its stability and leading to PP2A inactivation. In this regard, we have preliminary evidences that combination therapy with PADs and the CK2 inhibitor CX4945 reduces significantly the viability of AML cells, supporting that novel treatment modalities that can target multiple components of the same pathway may help to achieve a more sustained therapeutic benefit.

P537

GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA

J. Takeda1, L.-Y. Shin2, K. Chiba3, Y. Shiraishi3, Y. Shiizawa4, H. Makishima1, T. Yoshizato1, Y. Nagata5, A. Hangashi5, K. Ishiyama5, A. Takao-Kondo6, K. Kataoka1, M. Sanada7, H. Tanaka3, K. Usuki10, S. Miyawaki11, S. Miyano3, E. Arriazu1,*, C. Vicente1, R. Pippa1, N. Marcote2, I. Igea2, L. Leon1, S. Chocarro1, M. Soto1, A.R. Nebreda2, M.D. Odero1,3,4

1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China, 3Human Genome Institute, Institute of Medical Science, The University of Tokyo, 4Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, 5Department of Urology, Kansazawa University, Kanazawa, 6Department of Hematology, NTT Medical Center, Tokyo, 7Department of Hematology, Kanazawa University, Kanazawa, 8Department of Hematology / Oncology, Graduate School of Medicine, Kyoto University, Tokyo, 9Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, 10Department of Hematology, NTT Medical Center, Tokyo, 11Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 12Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Summary/Conclusions: Differences in the allelic composition were found between diagnosis and relapse regardless of the CBF-AML subtype. Our data suggest that the KIT clone might be successfully eradicated under dasatinib treatment whereas persistence of KIT mutant clones was more commonly seen under conventional chemotherapy. The frequent loss of KIT and NRAS mutations during therapy suggests that relapse is triggered by alternative genetic lesions. Relapsed disease may represent a distinct biology which is characterized by mutations that cluster in different pathways. Further analyses are ongoing including study cohort expansion, as well as inclusion of RNA sequencing results.

diagnosis. 8.9 variants per patient were found as compared to 5.7 at relapse. 52% variants were present at diagnosis, 26% at relapse only, and 22% were present at both, diagnosis and relapse. With regard to the most commonly altered signaling genes KIT and NRAS we found the following pattern: The median VAF at diagnosis was 23% and 26% for KIT and NRAS, respectively. Of note, the initial KIT and NRAS clone was lost (VAF <5%) in 71% (exon 17, n=9; exon 8, n=2; exon 11, n=1) and 100% of cases (exon 2, n=5; exon 3, n=3). Comparing the VAF kinetics between patients treated with and without dasatinib, baseline KIT mutations became subclonal (VAF <5%) in all patients receiving dasatinib (n=8), whereas they were still detectable in 4/6 (67%) patients who were intensively treated without the addition of dasatinib. NRAS became subclonal (n=8) irrespective of the treatment regimen. In one KIT mutated patient treated with dasatinib the baseline KITΔD186V mutation (exon 17) was lost at the time of relapse, but a KITΔD184V mutation (exon 8) was acquired instead. Gene set enrichment analyses revealed different mutation signatures at diagnosis and relapse: At diagnosis, there was a significant enrichment for genes associated with MYC overexpression. Variants that were recurrently present at diagnosis and relapse showed enrichment for genes affected in KRAS overexpression models. Relapse samples were additionally enriched for gene mutations involved in the mitotic spindle assembly.

Results: The median VAF at diagnosis was 23% and 26% for KIT and NRAS, respectively. Of note, the initial KIT and NRAS clone was lost (VAF <5%) in 71% (exon 17, n=9; exon 8, n=2; exon 11, n=1) and 100% of cases (exon 2, n=5; exon 3, n=3). Comparing the VAF kinetics between patients treated with and without dasatinib, baseline KIT mutations became subclonal (VAF <5%) in all patients receiving dasatinib (n=8), whereas they were still detectable in 4/6 (67%) patients who were intensively treated without the addition of dasatinib. NRAS became subclonal (n=8) irrespective of the treatment regimen. In one KIT mutated patient treated with dasatinib the baseline KITΔD186V mutation (exon 17) was lost at the time of relapse, but a KITΔD184V mutation (exon 8) was acquired instead. Gene set enrichment analyses revealed different mutation signatures at diagnosis and relapse: At diagnosis, there was a significant enrichment for genes associated with MYC overexpression. Variants that were recurrently present at diagnosis and relapse showed enrichment for genes affected in KRAS overexpression models. Relapse samples were additionally enriched for gene mutations involved in the mitotic spindle assembly.

Summary/Conclusions: Differences in the allelic composition were found between diagnosis and relapse regardless of the CBF-AML subtype. Our data suggest that the KIT clone might be successfully eradicated under dasatinib treatment whereas persistence of KIT mutant clones was more commonly seen under conventional chemotherapy. The frequent loss of KIT and NRAS mutations during therapy suggests that relapse is triggered by alternative genetic lesions. Relapsed disease may represent a distinct biology which is characterized by mutations that cluster in different pathways. Further analyses are ongoing including study cohort expansion, as well as inclusion of RNA sequencing results.
Background: Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia (AML) characterized by the predominance of erythroid components with increased ring sideroblasts as well as frequent myelodysplasia. However, due to its rarity, the molecular pathology of AEL has not been fully elucidated, except for frequent TPS3 mutations.

Aims: This study was designed to clarify the mutation profile of AEL distinct from other types of AML and myelodysplasia.

Methods: We performed a comprehensive genetic study, in which paired tumor/normal DNA from 22 AEL cases were analyzed using whole exome sequencing (WES). Whole-exome sequencing data from 3 AELs generated by The Cancer Genome Atlas (TCGA) was also included in the analysis. Subsequently, a total of 84 cases were screened for mutations in 67 driver genes associated with myeloid malignancies using targeted-capture sequencing, in which RNA baits were also designed for a total of 1158 single nucleotide polymorphism sites to allow for genome wide copy number abnormalities and other allelic imbalances.

Results: Median age at diagnosis was 58.5 (21-87) years old. Among the 77 patients with clinical information available, 62 patients were diagnosed with de novo AML, 13 with secondary AML, and 2 with treatment-related AML. On average, 18.4 and 3.4 mutations were detected per sample in whole-exome and targeted-capture sequencing in AEL, as compared to 12.2 and 2.9 mutations (P<0.05) in other AML, respectively. Both platforms being combined, most frequently observed was TP53 mutations (n=26, 31%) with complex karyotype being accompanied in most cases (25 cases), which were associated with a significantly shorter overall survival (P<0.001). Other frequently mutated genes were those encoding major components of the cohesin complex, including STAG2 (24%), SMC1A (4.8%) and RAD21 (2.4%), which were mutated in as high as 30% of the cases. The splicing machinery (18%) and epigenetic regulators (45%) were also common targets of mutations, including SRSF2 (12%), U2AF1 (4.8%), WT1 (15%), TET2 (19%) and IDH1/2 (12%). TP53 mutations were mutually exclusive with cohesin mutations (p<0.01) and those in epigenetic regulators (p<0.01). Compared with other AML subtypes, TPS3 mutations (0%) were significantly less frequent in AEL, compared to de novo AML and MDS. The frequency of these mutations was not statistically different between de novo AML and secondary AEL.

Conclusion: We identified in-frame internal duplications of STAG2, which are characteristic of AEL, and thought to be involved in its pathophysiology. Mutations in STAG2 are predominantly present in cytogenetic MDS and AML not otherwise specified.

STAG2 on the spatio-temporal genomic architecture in hematological malignancies. The cohesin complex plays pivotal roles within the cohesin complex function of STAG2, with an increase in binding peaks from ~17,000 to 25,000, within the cohesin complex. The open chromatin regions identified through ChIP-Seq and ATAC-seq profiling of AML cell lines and primary samples to provide information on gene activity in relation to chromatin state and transcription factor occupancy. An enrichment for transcription factors relevant for myeloid transcriptional programmes was observed. This increase in enrichment aids in the suggestion that the impact of mutated/altered cohesin complex function relates directly to the specific cell type and maturation state at which it occurs.

Summary/Conclusions: STAG2 mutation carries specific gene expression signatures and specific subsets of concurrent mutations with clinical value.

P538

EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITECTURE IN MDS/AML

J. Smith1,* K. Savage1, K. Mills1

1Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, United Kingdom

Background: The Cohesin complex is an evolutionarily conserved multimeric ATP-dependent CAK complex that plays a central role in chromatin architecture and higher order structure. The cohesin complex is required for the spatial regulation of gene expression and is frequently altered in cancer. There is an emerging body of literature on the role of STAG2 on the spatio-temporal genomic architecture in hematological malignancies. The cohesin complex plays pivotal roles within the cohesin complex function of STAG2, with an increase in binding peaks from ~17,000 to 25,000, within the cohesin complex. The open chromatin regions identified through ChIP-Seq and ATAC-seq profiling of AML cell lines and primary samples to provide information on gene activity in relation to chromatin state and transcription factor occupancy. An enrichment for transcription factors relevant for myeloid transcriptional programmes was observed. This increase in enrichment aids in the suggestion that the impact of mutated/altered cohesin complex function relates directly to the specific cell type and maturation state at which it occurs.

Summary/Conclusions: This research into the aberrant and non-canonical role of STAG2 on the spatio-temporal genomic architecture in hematological malignancies and begins to yield insight into the clinical implications of mutations within the cohesin complex.

P539

THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES

A. Al Hina1,2, F. Kavelaars1, T. Grob1, M. Sanders1, P. Valk1

1Hematology, Erasmus University Medical Center, Rotterdam, Netherlands. 2National Genetic Centre, Muscat, Oman

Background: Partial tandem duplications (PTDs) in the Mixed Lineage Leukemia (MLL) gene, currently known as Lysine Methyltransferase 2A (KMT2A) are acquired in-frame internal duplications present in 5–11% of acute myeloid leukemia (AML). MLL-PTDs are predominantly present in cytogenetic normal AML and occasionally in AML with trisomy of chromosome 11. MLL-PTD AML is now considered as a poor prognostic marker in AML.

Aims: Evaluate the mutational landscape, prognostic value and gene expression signatures of MLL-PTD AMLs in comparison to a well-characterized AML cohort without MLL-PTD.

Methods: cDNA of 2310 AML patients enrolled in the adult HOVON-SACK clinical trials (from 1995 to 2013) were analyzed for the presence of an MLL-PTD. Mutational screening based on next generation sequencing (NGS) was performed using the Illumina TruSeq Myeloid panel on the Illumina HiSeq2500. An independent cohort of 632 de novo AML patients without MLL-PTD served as control. The gene expression profiling was assessed of all AML cases using Affymetrix Hu6000 2 plus 2.0 GeneChips as previously described (Verhaak et al., 2009).

Results: MLL-PTD was detected in 118 (5.1%) out of 2310 AML patients. MLL-PTDs were significantly associated with trisomy 11: 7% vs 1% (p=0.0037), normal karyotype: 65% vs 53% (p=0.0102) and complex karyotype: 1% vs 14% (p=0.0003). MLL-PTD AMLs harbored more than 10% of the cases. The splicing machinery (18%) and epigenetic regulators (45%) were also common targets of mutations, including SRSF2 (12%), U2AF1 (4.8%), WT1 (15%), TET2 (19%) and IDH1/2 (12%). TP53 mutations were mutually exclusive with cohesin mutations (p<0.01) and those in epigenetic regulators (p<0.01). Compared with other AML subtypes, TPS3 mutations (0%) were significantly less frequent in AML, compared to de novo AML and MDS. The frequency of these mutations was not statistically different between de novo AML and secondary AEL.

Summary/Conclusions: MLL-PTD AML carries specific gene expression signatures and specific subsets of concurrent mutations with clinical value.
NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKAEMIA

I.-J. Lau1,2, A. Thomas1, J. Kerry1, L. Godfrey1, C. Nerlov1, P. Vyas2, T. Milne1 1MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Background: Mutations involving the MYL gene at 11q23 are found in 10% of adult and 18% of childhood acute myeloid leukaemia (AML) cases. The most frequently occurring MLL mutations are chromosome translocations that fuse the MLL gene in-frame with a second partner gene, creating novel fusion proteins (MLL-FFPs). MLL-AF9 is the most common MLL-FFP in AML. Despite much progress in the overall management of AML, patients carrying MLL-rearrangements still have a poor survival prognosis and limited response to existing therapy. This is in part due to the low therapeutic indices and narrow therapeutic windows of current chemotherapeutic agents, therefore underscoring the need to develop improved, targeted therapies. MYB is a direct downstream target of MLL-AF9. Recent studies indicate that MLL-AF9 leukaemia cells are more affected by MYB knockdown compared to normal hematopoietic stem progenitor cells. This is despite the fact that MYB is known to be essential for the establishment of definitive haematopoiesis. This suggests that a therapeutic window may be achieved through targeting MYB. Therefore, by understanding more about the role of MYB in MLL-AF9 leukaemia and the network it regulates, we may be able to exploit this knowledge to target MYB directly by interfering with its function or indirectly via its downstream targets.

Aims: To understand the molecular function of MYB in MLL-AF9 leukaemia.

Methods: We performed genome-wide MLL, MLL-AF9, H3K27ac, H3K4me3 and H3K4me1 chromatin immunoprecipitation (ChIP-seq) and ATAC-seq and Assay for Transposase-Accessible Chromatin with high throughput sequencing (ATAC-seq) in two MLL-AF9 leukemia models to identify putative regulatory regions of MYB and those of a direct MYB gene target, BCL2. The chromatin conformation capture technique, Capture-C (one vs all) was used to further characterize interactions from the MYB promoter. We then performed siRNA knockdown of MYB and assessed the effect of MYB loss on its downstream druggable target BCL2, using RT qPCR, Western blotting and ChIP qPCR.

Results: We identified MLL-AF9 binding to novel putative enhancers of MYB as defined by regions co-bound by H3K27ac, H3K4me1 and marked by open chromatin on ATAC-seq. Furthermore, Capture-C from the MYB promoter identified novel putative enhancer-promoter interacting domains 100-200kb apart that are co-bound by MYB but not MLL-AF9. This suggests long-range autoregulation of MYB. Next, siRNA knockdown of MYB results in loss of MYB binding at the BCL2 promoter and its downstream enhancer by ChIP qPCR. There is a corresponding loss of BCL2 mRNA and protein expression in MYB knockdown cells compared with control, confirming that BCL2 is directly regulated by MYB.

Summary/Conclusions: We have identified for the first time, regulation of MYB by MLL-AF9 via putative enhancers, and also an autoregulatory role of MYB involving long-range cis-interactions. Furthermore, we confirm that BCL2 is directly regulated by MYB in MLL-AF9 leukaemia, suggesting a molecular rational for using BCL2 inhibitors in MLL-AF9 leukaemia therapy.

CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA

S. Chitre1,2, J. Gaken1, A. Venus1, G. Mufli1 1Haematological Medicine, Kings College London, London, United Kingdom

Background: Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by clonal evolution of myeloid precursors in bone marrow and peripheral blood resulting in accumulation of leukemic blasts and severe impairment of normal haematopoiesis. Despite advances in our understanding of AML biology, development of novel therapies has been limited with 43% relapse rate. The majority of patients never attaining clinical remission (CR) with frontline induction treatment. Chimeric antigen receptor (CARs) T cells specific for tumour-associated antigens are emerging to be an effective form of immunotherapy for AML. A small number of in vitro and in vivo studies have evaluated the efficacy and specificity of CAR T cell immunotherapy in AML by targeting interleukin three receptor alpha (IL3RA, CD123). A molecule over expressed on AML blasts and leukaemia stem cells (LSC) compared to normal haematopoietic stem cells (HSCs).

Aims: In this study, we investigated the efficacy of a second generation CAR expressing a single variable fragments (scFv) with different affinities for CD123 and evaluated the cytotoxic effect of different co-stimulatory domains (CD28 versus 41BB) using a co-culture assay. Furthermore, we also evaluated the cytotoxic effects of a dual targeting CAR (against CD123 and CD33) using the same assay conditions.

Methods: Six CAR T cell constructs (two high, two moderate & two low affinity) were transduced (MOI 1:5) into peripheral blood mononuclear cells (PBMCs) from healthy donors and their cytotoxicity was examined by flowcytometry on leukemic cell lines; KG1 (CD123+, CD34+, CD33+) [Fig:1a], Kasumi-1 (CD123+, CD34+, CD33+), U937 (CD123+, CD34-, CD33+), K562 (CD123+, CD34+, CD33+) and AML mononuclear cells (MNCs).

Results: Flowcytometric analysis confirmed the expansion of T cells from PBMCs and the cytotoxicity of the six CARCD123 constructs against CD123+ve cells. The high affinity CARCD123 (4nM kD & 4nM kD K13Q) T cells demonstrated enhanced cytotoxicity compared to moderate (5nM kD, 5nM kD A105G) and low affinity (10nM kD, 10nM kD V24G) CARCD123 in both leukaemic cell lines and also in allogenic AML MNCs. Both the highest affinity CARCD123 constructs were also tested in cell lines using increasing effector: target ratios: target ratios (1:2, 1:4 & 1:10) displaying consistent cytotoxicity and were also effective against autologous AML MNCs (target cells) and PBMCs (effector cells) from two patients. T cell activation was confirmed by ELISA and showed increased IFN-γ (500-2000 fold) and TNF-α (150-200 fold) levels. Previous studies have confirmed the distinction in CAR efficiency using CD28 versus 41BB co-stimulatory domains; CD28 co-stimulation augmented, whereas 4-1BB co-stimulation reduced T cell exhaustion induced by continuous CAR signaling. To confirm persistence of the CAR cytotoxicity, we constructed a high affinity CAR substituting CD28 with a 4-1BB co-stimulatory domain and obtained similar cytotoxicity results on K562 and U937 cell lines. Furthermore, a novel a dual targeting CAR in which the activation domain (CD3ζ) is directed against CD33 and the costimulatory domain (CD28) directed against CD123 enhanced the specificity of the CAR towards leukaemic cells; reducing “on-target but off-organ effects”. Results obtained in co-culture assay against KG1 [Fig:1b] and K562 cell lines [Fig:1c] with varying effector: target ratios were demonstrated results similar to the high affinity single targeting CAR.

TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML

I. Uras1, P. Valenti2, V. Sext1 1Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, 2Department of Internal Medicine I, Division of Hematology and Hemosctology, 3Louis Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

Background: Acute myeloid leukaemia (AML) is a clonal hematologic disorder marked by clinical and biological heterogeneity. AML remains incurable for a significant proportion of adult patients while no therapeutic option exists for patients with relapsed and refractory AML. Mutations of the fms-like tyrosine kinase 3 (FLT3) gene are among the most frequent events in AML and usually involves internal tandem duplication (ITD) of the juxtamembrane domain coding region or point mutations of the tyrosine kinase domain. There have been considerable efforts to develop FLT3 tyrosine kinase inhibitors (TKI). The clinical impact of FLT3-TKI has been limited as resistant clones have emerged rapidly.
We have recently discovered that FLT3-ITD+ AML cells are highly sensitive to the FDA- & EMA-approved CDK4/6 kinase inhibitor palbociclib (IBRANCE by Pfizer). The effect is ascribed to the transcriptional activity of CDK6 on FLT3 and PIM1 - a feature not shared by CDK4.

**Aims:** Palbociclib impaired the viability of murine Ba/F3 cells with FLT3-ITD. The effect was specific to FLT3-ITD+ patient samples and to xenograft models, where palbociclib treatment effectively repressed FLT3-D835Y driven tumor formation in vivo at clinically relevant concentrations. Besides FLT3 itself, which is regulated by CDK6, transcriptional targets of CDK6 in AML included Aurora kinases (AURK) and AKT. Thus CDK6 inhibition in AML cells, two signalling nodes critical for survival of tumor cells. Dual targeting with palbociclib and AURK or AKT inhibitors resulted in synergistic cytotoxicity.

**Summary/Conclusions:** Palbociclib represents a viable therapeutic option for treatment of resistant clones in FLT3-D835Y+ AML. Inhibitory effects are specific to cell cycle inhibition as well as by transcriptional activity of CDK6 on important signalling pathways including Aurora kinases and AKT. Our findings provide the basis for the design of synergistic combination therapies with a CDK4/6 inhibitor which could be readily translated to patients with AML.

**P543**

**CANNABINOID DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT**

M. Medrano,1,2 M.V. Barbado,1 N. Campillio,2 F.J. Hidalgo3, T. Caballero1, I. Alvarez1, O. Lopez1, J.I. Pirat1, J.A. Perez-Simon1

1Instituto de Biomedicina de Seville, Seville, 2CIB/CSIC, Madrid, 3G/CSIC, Seville, Spain

**Background:** Endocannabinoid system is a set of ligands, receptors and endogenous enzymes which modulate a variety of physiological effects. There are two well-characterized cannabinoid receptors, CB1 (mainly expressed in Central Nervous System) and CB2 (mainly in hematopoietic cells). Here, we tested the effect of the cannabinoid WIN-55 212-2 in acute myeloid leukemia (AML) in vitro and in vivo and studied the molecular signaling pathways involved in this effect, specially the role of sphingolipids. Moreover, we synthesized a new family of twelve cannabinoids that are specific to CB2 receptor.

**Aims:** Development of new compounds derived from cannabinoid with CB2 selectivity and evaluation of their anti-tumor effect in AML in vitro and in vivo. To deepen in the knowledge of lipid metabolism in AML.

**Methods:** For the design and synthesis of new cannabinoids, computational techniques of docking, analytical and spectroscopic techniques such as mass spectrometry (MS) were used. To assess the anti-leukemia effect of the different cannabinoids, we analyzed cell viability by MTT and flow cytometry using six human AML cell lines, primary cells from healthy donors (hematopoietic progenitor cells (HPC) and lymphocytes) and blasts from AML patients. Mitochondrial damage was assessed by flow cytometry using TMRE and by MitoxSOXM Red. In addition, we performed western blot and immunocytochemistry assays to determine the expression of different proteins to elucidate the molecular signaling pathways involved in the effect of these drugs. Moreover, we analyzed the transcript levels by RT-qPCR and in the amounts of certain sphingolipids in untreated and cannabinoid treated leukemic progenitor cells. Remarkably, we observed significant differences in the amounts of certain sphingolipids in untreated versus treated leukemic cells. More specifically in ceramide C16:0, C18:0 and C18:1. Also we observed a significantly increased survival among mice treated with WIN-55 cannabinoid as compared to both the control group and the group treated with ARA-C and we confirmed that cannabinoids did not affect the viability of the different populations of hematopoietic progenitor and, moreover, an increased platelet count was observed in treated mice.

**Summary/Conclusions:** Our findings indicate that cannabinoids display a highly selective proapoptotic effect on leukemic cells. Several pathways are involved in this effect, the modification in the sphingolipids pattern playing a main role.

**P544**

**PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

E. Sala1,2,*, F. Biavasco1,2, G. Bucci3,2, C. Toffalori2, L. Zanotti2, D. Biancolini3, E. Antonini4, M.G. Carrabba 1, B. Gentner1,5, C. Tresoldi 4, M. Bernardi1, D. Lazarevic3, G. Tonon2, F. Ciceri1, L. Vago1,2

1Hematology and Bone Marrow Transplantation Unit; Division of Regenerative Medicine, Stem Cells and Gene Therapy, 2Unit of Immunogenetics, Leukemia Genomic and Immunobiology; Division of Regenerative Medicine, Stem Cells and Gene Therapy, 3Center for Translational Genomics and Bioinformatics, 4Immunohematology and Transfusion Medicine Unit; Division of Regenerative Medicine, Stem Cells and Gene Therapy, 5Translational stem cell and leukemia research Unit; SR-TIGET, Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milano, Italy

**Background:** Acute Myeloid Leukemia (AML) is a clinically and biologically heterogeneous disease that is known to dynamically evolve over time. Unravelling its mutational profile may provide relevant insights into the inception, propagation, and recurrence of the disease, and deliver new rationales for precision medicine approaches: still, whereas a comprehensive description of AML mutations at disease presentation is now available thanks to large-scale studies, a satisfying genomic characterization of AML at relapse, particularly after allogeneic stem-cell transplantation (allo-HSCT), is still needed.

**Aims:** To characterize the genetic profile of relapsed AML, highlighting the evolutionary trajectories in the two different settings of relapse after chemotherapy (CT) and after allo-HSCT.

**Methods:** For our custom-designed targeted Next Generation Sequencing panel we took advantage of the HaloPlex High Sensitivity (HS) technology, allowing a more precise definition of mutations and clonal architecture through a molecular barcoding system. We included in our panel 192 genes and miRNAs known to be involved in the pathogenesis of myeloid malignancies (n=112), in the DNA damage response (n=50), or in immune-related processes (n=30). Sequencing was performed on an Illumina HiSeq2500 instrument. Variant calling was performed using a pipeline based on the FreeBayes algorithm, and FLT3-ITD status was inferred using Pindel.

**Results:** We sequenced a total of 138 AML samples, including 79 diagnoses, 36 relapses after CT and 23 relapses after allo-HSCT. Sequencing yielded uniform and consistent coverage of all target amplicons and a 612x mean depth-of-sequencing, resulting on average in 117 unique barcodes for each region. Among the 79 diagnosis samples we identified 293 mutations (204 of which definable as oncogenic), with a median of 3 oncogenic mutations per patient (range 0-8), and mutation frequencies in line with the largest published dataset (Papaemmanuil, N Engl J Med, 2016; r2=0.83). In relapses after CT and after allo-HSCT the median number of oncogenic mutations per patient was 3 (range 0-4) and 2 (range 0-6), respectively. Comparing mutation frequencies at relapse
with the Papaemmanuil dataset, we observed a weaker correlation for relapses after CT ($r^2=0.69$) and an even more marked deviation for post-transplant relapses ($r^2=0.45$). This difference was mainly explained by the enrichment in both relapse cohorts for FLT3-ITD (25% in diagnoses vs 55% and 48% at relapses after CT and allo-HSCT, $p<0.01$ for both comparisons) and WT1 mutations (5% vs 25% and 22%, $p<0.01$ for both comparisons). For 24 cases it was possible to longitudinally compare the mutational profile of AML at diagnosis and relapse in the same patient: we observed higher stability in relapses after CT, with 50% of cases carrying the same pattern of mutations present at diagnosis, whereas at relapses after allo-HSCT changes were more frequent, with 70% of patients displaying new gains or losses.

**Summary/Conclusions:** Taken together, our data evidence that the genomic landscape of AML at relapse can be significantly different from the one documented at diagnosis, suggesting that the selective pressure mediated not only by intensive chemotherapy, but also by the graft-versus-leukemia effect, can be potent drivers of clonal evolution. From the practical standpoint, the pattern of emergence of novel mutations that we documented should be taken into account not only for targeted salvage approaches, but also for the design of post-remission strategies aiming to prevent relapse.

---

**P545**

Abstract withdrawn.

---

**Acute myeloid leukemia - Clinical 4**

**P546**

**AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?**


1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University of Munich, Munich, 2Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, 3Laboratory for Leukemia Diagnostics, Department of Internal Medicine III; German Cancer Consortium (DKTK), partner site Munich; German Cancer Research Center (DKFZ, Heidelberg), University of Munich, Munich, 4Department of Internal Medicine III, Hospital Leverkusen, Leverkusen, 5Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster, 6Department of Medicine, Hematology, Oncology, Tumor Immunology, Charité University Medicine Berlin, Berlin, 7Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany

**Background:** Acute myeloid leukemia (AML) is a disease of the elderly (median age at diagnosis ~68 years). The prognosis of elderly patients (pts) is poor. Advanced age often leads to the judgement that pts are unfit for induction chemotherapy, although several trials have revealed a positive impact of intensive induction therapy in terms of sustained remissions and long-term survival in a subset of elderly pts.

**Aims:** We sought to validate existing risk classification systems and identify genetic factors associated with clinical outcomes in very old AML pts who received induction chemotherapy.

**Methods:** We identified 151 AML pts aged ≥75 years who received intensive induction therapy in the AMLCG-1999 trial with suitable material for genetic

---

**Figure 1.**

Methods: We identified 151 AML pts aged ≥75 years who received intensive induction therapy in the AMLCG-1999 trial with suitable material for genetic
analyses, 81% of pts had de novo AML, 15% secondary AML, 3% therapy-related AML and 2% high-risk MDS. Recurrent gene mutations in AML were studied from bone marrow aspirates or peripheral blood using a targeted leukemia genotyping assay covering 68 genes. We analyzed known mutational hotspots or the entire coding sequence of the genes by multiplexed amplicon sequencing (Agilent Technologies, mean target coverage of 460 x). We studied associations of the genotypes with other potential prognostic factors which might influence the clinical outcome.

Results: The median age in the total cohort was 76 years (y) (range: 75-86). 44% of pts reached complete remission (CR) and 4% CR with incomplete blood count recovery (CRi). The median overall survival (OS) was 6 months with a 3-year OS rate of 21%. Acute leukemia to the ELN 2013 classification, 20 pts were evaluable in the favorable, 39% and 25% in the intermediate I or II group, respectively, and 15% in the adverse group (ELN 2017 data will be presented at the meeting). Pts in the favorable and intermediate I/II groups had significantly longer OS compared to the adverse group (median OS 6.5 vs 1.2 months, p=0.05). Figure). Likewise, pts in the favorable and intermediate MRC cytogenetic risk categories had longer OS than those in the adverse category (median OS 6.5 vs 1.2 months, p=0.01). By targeted sequencing, we detected 622 leukemia-associated mutations in 66 genes. The median number of mutated genes per patient was four. The most commonly mutated genes were TET2 (42%), DNMT3A (35%), NPM1 (32%), SRSF2 (25%) and ASXL1 (21%). Both NPM1 or EZH2 (5%) mutated pts showed a non-significant trend towards longer OS (NPM1: p=0.03; EZH2: p=0.05). FLT3-ITD mutations were identified in 29 pts (19%), but had no impact on OS (p=0.29). The NPM1 mutated/FLT3-ITD-negative genotype also did not associate with OS. Notably, none of the IDH1 mutated pts (9%; all within the ELN favorable/intermediate groups) reached CR, and consequently the OS in this group was significantly shorter than for IDH1 wild-type pts (p<0.01; Figure). The positive impact of mutated NPM1 on OS was reversed when it co-occurred with IDH1 mutations (p=0.014).

Summary/Conclusions: Among very old (≥75 y), intensively treated AML pts, adverse-risk cytogenetics predict inferior survival. On the other hand, 3-year OS was 24% for MRC/ELN favorable and intermediate-risk pts, suggesting that even in this age group, selected pts without medical contraindications benefit from intensive induction chemotherapy. The spectrum of driver gene mutations in elderly pts differs from that in younger pts. While NPM1 and FLT3-ITD mutations had no significant impact on OS in intensely treated pts aged ≥75 y, our data imply IDH1 mutations as a novel marker for chemoresistance disease and inferior prognosis in this age group.

P547

GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE


1 Dana-Farber Cancer Institute, Boston, 2 UC Davis Comprehensive Cancer Center, Sacramento, 3 Univ of Rochester James P Wilmot Cancer Ctr, Rochester, United States, 4 National University of Ireland, Galway, Ireland, 5 University of Michigan Comprehensive Cancer Center, Ann Arbor, 6 Cleveland Clinic, Cleveland, United States, 7 Princess Alexandra Hospital, Brisbane, Australia, 8 GlycoMimetics, Inc., Rockville, 9 Fred Hutchinson Cancer Research Center, U of Washington, Seattle, United States

Background: Expression of the adhesion molecule E-selectin (E-sel) in the vascularature of the bone marrow is associated with infiltrative disease, relapse, and poor survival in AML. GMI-1271 is a novel antagonist of E-sel that downregulates cell survival pathways and enhances chemotherapy response with improved survival compared to chemotherapy alone (Becker ASH 2013; Winkele et al. 2014). Protection from common toxicities (neutropenia and mucositis) has been observed in preclinical models, also affording survival benefit (Winkler ASH 2014). Protection from common toxicities (neutropenia and mucositis) has been observed in preclinical models, also affording survival benefit (Winkler ASH 2014). Protection from common toxicities (neutropenia and mucositis) has been observed in preclinical models, also affording survival benefit (Winkler ASH 2014).

Aims: We assessed GMI-1271 plus salvage chemotherapy with mitoxantrone, etoposide, and cytarabine (MEC) for the treatment of patients (pts) with relapsed/refractory AML.

Methods: A Phase (Ph) 1 trial in pts with R/R AML escalated GMI-1271 across Ph1 (30-150mg/kg) to Ph2 (120mg/kg). In Ph1, pts were given GMI-1271 24 hrs prior to MEC chemotherapy. Response and CR rates of 50% and 33%, respectively, and a 3-fold increase in median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML, median OS of the responding compared to the non-responding newly-diagnosed patients. Notably, 67% of the responding patients had secondary AML.
refractory to hypomethylating agents. To the best of our knowledge, this is the only experimental drug permitting high-dose cytarabine, considered a cornerstone of leukemia therapy, to be given to a population of patients that currently do not have this option. A Phase II study is planned to confirm these encouraging results.

**P549**

**FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNancies**

K. Morita1,2,*, F. Wang 3, K. Patel 4, C. Bueso-Ramos 3, A. Abou Zahr 3,

RNA sequencing may be a valuable tool in routine diagnostics for patients with boring rearrangements involving (n=3),

fusions with high accuracy and to characterize rare gene fusions providing the
terms in calling algorithms and may also have biological reasons. It was report-

one of the partner genes. Failure to detect gene fusions should initiate improve-

In addition, RNA sequencing was able to identify known and novel fusions in

Results:

er’s protocol with ~50ng RNA extracted from fresh/frozen samples. Sequencing

Targeted RNA sequencing was performed using the TruSight RNA Fusion panel

Feasibility and Benefit of Targeted RNA Sequencing for the Detection of Recurrent Fusion Transcripts and the Identification of Novel Fusion Transcripts in Myeloid Malignancies

Background: Genes fusions are frequent genetic abnormalities in myeloid malignancies. The impact of the detection of such gene fusions is rising due to an increasing number of drugs targeting them as has been impressively shown for e.g. BCR-ABL1 and PML-RARA. Further, they can be used as biomarkers for disease monitoring.

Aims: Evaluation of targeted RNA sequencing for the detection of recurrent and novel fusion transcripts.

Methods: 102 cases with myeloid malignancies harboring 105 translocations identified by chromosome banding analysis were selected. Recurrent fusion genes had been confirmed by FISH and/or RT-PCR. In cases with suspected novel fusions the rearrangement of one partner gene had been confirmed by FISH. The following recurrent rearrangements identified by standard diagnostic procedures were present: PML-RARA (n=11), RUNX1-RUNX1T1 (n=7), CSF3R-MYH11 (n=3), KMT2A-ELL (n=4), KMT2A-MLLT1 (n=4), KMT2A-MLLT10 (n=3), KMT2A-MLLT3 (n=2), BCR-ABL1 (n=3), NUP98-NSD1 (n=3), DEK-NUP214 (n=1), and KAT6A-CREBBP (n=1). Further, cases harboring known fusions (KMT2A (n=14), RUNX1 (n=21), ETV6 (n=10), PDGFRB (n=10), RARA, n=2), NPM1 (n=2) and NUP98 (n=1) were included. Targeted RNA sequencing was performed using the TruSight RNA Fusion panel (Illuima, San Diego, CA) consisting of 7690 probes covering 507 genes known

Fusion, which could not be suspected by

were less frequently observed in myeloid-T than in myeloid-B included

Mutations. Genes in which mutations were enriched in myeloid-T than in myeloid-B included RUNX1 (6% vs 46%), ASXL1 (0% vs 23%), TET2 (0% vs 15%), SRSF2 (6% vs 23%), and FLI1 (11% vs 23%). Myeloid-T and myeloid-B showed distinct pattern of promoter CpG methylation. Overexpression of one of the novel translocations such as

were mutated in hematologic malignancies (median 393x coverage, N=31), RNA sequencing revealed several other known translocations such as NUP98-NSD1 and KMT2A-MLLT4, in addition to the novel translocations such as FOXP1-DNAJC15, FLI1-IPT46, and ITPR2-ARID5B. Unsupervised hierarchical clustering of all MPAL, AML, B-ALL and T-ALL by promoter CpG methylation pattern revealed that myeloid-T consistently showed similar methylation pattern with T-ALL, while myeloid-B showed random similarity with either B-ALL or AML.

Summary/Conclusions: MPAL is genetically heterogeneous disease and myeloid-T and myeloid-B shows distinct patterns of mutation landscapes, coding and gene expression changes. Therapy for MPAL may need to be personalized based on genomic profiles.

**Background: Mixed phenotype acute leukemia (MPAL) is a rare subgroup of acute leukemia characterized by blasts that show immunophenotypes of both myeloid and lymphoid lineages and therefore not traceable to single lineage of origin. Diagnosis of MPAL is challenging due to the possible discrepancy between immunophenotype and morphology. Clinically, MPAL has poor prognosis and poses therapeutic challenges. Genetic basis of MPAL is not well understood.

Aims: To clarify the underlying pathogenesis of MPAL and provide clue on future personalized therapy in MPAL, we performed comprehensive molecular characterization of adult MPAL.

Methods: We studied 31 adult patients with adult MPAL (median age 53) that met 2008 WHO classification criteria for de novo acute myeloid leukemia--promyelocytic type. Patients were studied by targeted capture exome sequencing of 295 genes that are recurrently mutated in hematologic malignancies (median 393x coverage, N=31), RNA sequencing (N=24), and Infinium methylation EPIC array (Illuima, N=31). Mutational landscape was compared to that of 194 AML, 71 B-ALL, and 6 T-ALL. The following fusions were found:

In frame fusion transcripts but to termination of transcription.

Results: Among 31 MPAL cases, 18 (58%) had myeloid-T and 13 (42%) had myeloid-B phenotype. Four cases had Philadelphia chromosome, 1 had 11q23 abnormality, and 8 had complex karyotype. MPAL had similar numbers of mutations (median 2 [range: 0-8]) with AML (median range: 0-7, P=0.79) or T-ALL (median range [3 range: 0-8], P=0.92) but had significantly higher number of mutations compared to B-ALL (median range: 0-4, P<0.001). Consistent with the mixed immunophenotypic features, MPAL had both AML-type and ALL-type mutations. However, NPM1 mutation was specific to AML and was not found in MPAL cases. Myeloid-T and myeloid-B showed distinct pattern of somatic mutations. Genes in which mutations were enriched in myeloid-T than in myeloid-B included RUNX1 (6% vs 46%), ASXL1 (0% vs 23%), TET2 (0% vs 15%), SRSF2 (6% vs 23%), and FLI1 (11% vs 23%). Myeloid-T and myeloid-B showed distinct pattern of promoter CpG methylation. Overexpression of one of the novel translocations such as

were amplified and was overexpressed. RNA sequencing revealed several

known translocations such as NUP98-NSD1 and KMT2A-MLLT4, in addition to the novel translocations such as FOXP1-DNAJC15, FLI1-IPT46, and ITPR2-ARID5B. Unsupervised hierarchical clustering of all MPAL, AML, B-ALL and T-ALL by promoter CpG methylation pattern revealed that myeloid-T consistently showed similar methylation pattern with T-ALL, while myeloid-B showed random similarity with either B-ALL or AML.

Summary/Conclusions: MPAL is genetically heterogeneous disease and myeloid-T and myeloid-B shows distinct patterns of mutation landscapes, coding and gene expression changes. Therapy for MPAL may need to be personalized based on genomic profiles.

**P550**

**COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)**

K. Morita1,2,*, F. Wang 3, K. Patel 4, C. Bueso-Ramos 3, A. Abou Zahr 3,

Background: Standard remission induction chemotherapy for acute myeloid leukemia (AML) which consists of anthracycline for 3 days plus cytarabine for 7 days was first introduced in 1970’s and has been used for a long time. Several modification or intensification for this conventional regimen did not prove the effect for higher complete remission (CR) rate or lower relapse rate which led to superior overall survival (OS) rate.

Aims: We tried to find out possible benefit of early intensification of standard induction chemotherapy in adult AML patients.

Methods: This prospective study enrolled 1195 adult AML patients from 2002 to 2013. All patients were initially treated with idarubicin (12mg/m2) plus cytarabine (100mg/m2) or BHAC (300mg/m2) induction chemotherapy (3+7), and among them, 731 (61.2%) patients received additional early augmentation using cytarabine 3 days (3+10, n=363) or anthracycline 2 days plus cytarabine 3 days (2+10, n=368). The decision for augmentation was based on the follow-up BM blast counts on the 7th day of 3+7 chemotherapy: totally 3+10 for blast counts 5-20% and 5+10 for blast counts >20% (early intensified group). The rest 464 with blast counts <5% finished with 3+7 regi-
men (standard group). Re-induction and consolidation therapy was performed according to a consistent strategy and pre-remission therapy was mainly based on hematopoietic cell transplantation.

**Results:** Early intensified group was consisted of younger patients (median age, 37 years old [range 17–69] vs 45 years in 3+7 vs 43 years in 3+10 subgroup) and larger proportion of t(8;21) (n=102 [27.7%] vs 3+7 [n=33, 7.1%] vs 3+10, 12.9%), P<0.001. Also, initial blast burden was higher in two intensified groups (73.3% in 3+10 and 70.1% in 3+10) compared to 3+7 subgroup (66.8%, P<0.001). Early death rate at 8 weeks was higher in patients older than 55 years (10.8% vs 3.7%, P=0.001) especially when they were treated with intensified chemotherapy (21.7% vs 15.7% in 3+10 vs 6.3% in standard group, P<0.038). CR rate after induction was higher in young patients especially in 3+10 subgroup (79.8%, P<0.001) and we also found that patients with favorable to intermediate-risk karyotype might benefit with intensified chemotherapy in the context of CR rate (79.7% vs 68.3%, P<0.001, although final CR rates became similar after re-induction. Next, we found that pre-HCT relapse rate was lower in patients younger than 55 years (4% vs 9%, P=0.002) and favorable to intermediate-risk group (8.9% vs 20.2%, P<0.001) after intensified induction. In young patients with favorable to intermediate-risk karyotype, intensified group showed superior 5-year OS (55.0% vs 45.5%, P=0.010) and lower long-term relapse rate (32.2% vs 38.0%, P=0.084), but multivariate analysis revealed no effects for both OS and CR. In patients older than 55 years, intensified group showed inferior 5-year OS (19.2% vs 22.8%, P=0.014) with higher early death rate (17.6% vs 6.3%, P=0.015), and multivariate analysis also showed intensified induction was related inferior OS (HR=1.89, 95%CI; 1.14–3.15, P<0.013).

**Summary/Conclusions:** Our data revealed that intensified induction chemotherapy was not influential for poor-risk karyotype, while higher post-induction CR rate and low post-HCT relapse was shown in young patients with favorable to intermediate-risk karyotype although it was not influential for final OS and CR rate. In elderly patients, intensified induction chemotherapy was related with higher early death rate which finally showed poor OS.

---

**Table 1.**

<table>
<thead>
<tr>
<th>Table 1: Treatment outcomes according to induction regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>&lt;55 years</td>
</tr>
<tr>
<td>≥55 years</td>
</tr>
</tbody>
</table>

**Table 2.**

<table>
<thead>
<tr>
<th>Table 2: Novel FLT3 mutations in adult AML patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pt no</strong></td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>--</td>
</tr>
</tbody>
</table>

---

**P552**

**VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML**

E. Wang1,*, R. Stone2, R. Collins3, T. Agrawal4, V. Urity4, M. Tallman5

1Department of Medicine, Roswell Park Cancer Institute, Buffalo, 2Department of Texas Southwestern Medical Center, 4Arog Pharmaceuticals, Inc., Dallas, 3Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, United States

**Background:** Patients (pts) with FLT3-internal tandem duplication (ITD) and FLT3-D835 mutant AML have a high relapse rate. These relapses are typically due to outgrowth of mutant FLT clones. Previously available PCR-based tests only checked for presence of FLT3-ITD and FLT3-D835/836 mutations. Whole genome sequencing of 799 pediatric AML samples from CGH trials have shown novel FLT3 variants in many AML cases that also include activating mutations in the juxtamembrane (JM) and transmembrane domains in 7.8% of these samples (Tarlock et al. ASH 2015). Some of these mutations result in autophosphorylation of FLT3 and therefore may be oncogenic.

**Aims:** Identify novel FLT3 mutations in pts with FLT3 mutant AML and further investigate whether these novel clones are sensitive to induction chemotherapy plus a potent pan-FLT3 inhibitor, crenolanib.

**Methods:** Pts with newly diagnosed FLT3 mutant AML were enrolled and treated with cytarabine/anthracycline/crenolanib induction followed by high dose cytarabine (HiDAC) consolidation. Crenolanib 100mg TID was started on day 9 of induction chemotherapy. Crenolanib was continued and cycled 21 days in 3+10 cycles of HiDAC consolidation followed by crenolanib maintenance. Bone marrow samples were collected at baseline and at the time of remission assessment. Sequencing of the entire FLT3 gene was performed through FoundationOne Heme panel (n=18) and MSKCC multigene panel (n=5). Sequencing of exons 14, 15, 16, and 20 was performed through the Rapid Heme Panel at Dana-Farber Cancer Institute in additional 6 pts.

**Results:** Out of 29 newly diagnosed FLT3 mutant AML patients with full/partial FLT3 gene sequencing performed, 4 pts were found to have novel FLT3 mutations consisting of V491L, V592L, D593H, A680V, and N841I/T/K (Table 1). The majority of these novel mutations were located at the JM, kinase domain 1 and the activation loop (kinase domain 2). The allele fractions of these FLT3 variants ranged as high as 29% (higher than that of FLT3-ITD in p13), suggesting that some of these clones may have been potentially driving clinical leukemia progression in some pts. All 4 pts had NPM1 mutations, and two also had DNMT3A mutations. All 4 pts achieved CR with full count recovery (3/4 pts achieved CR after just one cycle of cytarabine/anthracycline/crenolanib induction). The pt with FLT3-D835Yand N841T achieved a CR after cytarabine/anthracycline/crenolanib induction and one cycle of HiDAC consolidation. All pts treated with FLT3-ve and have remained FLT3-ve out of 4 pts received 1-4 cycles of HiDAC consolidation followed by crenolanib maintenance. Only one pt underwent allo SCT. With a median follow up of 13 months, one pt relapsed (at 6.4-month following treatment). This 61F pt was found to have FLT3-ITD, D593H and I836del FLT3 abnormalities at the time of diagnosis. A full FoundationOne gene panel done at the time of relapse, showed no residual FLT3 mutant clones.

**Summary/Conclusions:** This abstract reports multiple novel variant FLT3 mutations in adult pts with newly diagnosed FLT3-ITD or FLT3-D835 mutant AML. The allelic burden of these FLT3 variant mutations can sometime be higher than that of FLT3-ITD. Detailed FLT3 analyses in this subset of pts suggests that crenolanib in combination with standard induction chemotherapy has the ability to eradicate variant FLT3 clones. All 4 pts treated with chemother-apy followed by crenolanib showed clearance of FLT3-ITD, TKD, as well as other novel variants. To achieve maximal clinical benefit, a potent pan-FLT3 inhibitor with the ability to inhibit ITD, D835, as well as other activating mutations maybe beneficial.

---

**P553**

**PATIENTS WITH ACUTE MYELOID LEUKAEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH “7+3” DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD**

D.M. Gupta1,*, D. S. Devlin2, D. M. Tallman2, D. E. Stein2

1Mount Sinai Hospital, 2Memorial Sloan Kettering Cancer Center, New York, United States

**Background:** Mutations in isocitrate dehydrogenase isoforms 1 and 2 (IDH1/IDH2) occur in 8-12% of patients with acute myeloid leukemia (AML). Mutant IDH enzymes catalyze the conversion of alpha ketoglutarate to beta hydroxylglutarate. Increased concentrations of intracellular 2-HG lead to histone hypermethylation and a block in cellular differentiation and may also lead to suppression of homologous recombination. Previous studies of outcomes in patients with FLT3-ITD has shown the majority of patients with FLT3-ITD have a complex karyotype which is generally resistant to standard induction regimens. In this study, we investigated the outcomes of patients giv-en induction chemotherapy with daunorubicin and cytarabine (7+3), the most common regimen used in the United States.
Aims: To delineate the complete remission rate in AML patients with IDH1 or IDH2 mutations who receive standard 7+3 induction chemotherapy.

Methods: After receipt of IRB approval, an institutional database of genomic abnormalities in all patients with AML was queried for patients with IDH1 or IDH2 mutations between the years of 2010 and 2016. Pathology records of patients identified as having an IDH1/IDH2 mutation were reviewed to confirm the presence of an IDH mutation. After confirmation of IDH mutational status, all patients who received standard induction chemotherapy with 7+3 were included in this retrospective chart review.

Results: Between 2010 and 2016, 82 patients with IDH1/IDH2 mutations who had been treated with 7+3 induction chemotherapy were seen at MSKCC. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Of those with IDH2 mutations IDH2 R140Q mutations were present in 34 (69.3%) and IDH2 R172K mutations were present in 15 (30.6%). The median age of all patients treated was 63, 56 patients (68%) had de novo AML, 16 (20%) had AML with myelodysplasia related changes, 5 (6%) had a known prior history of MDS and 5 (6%) had therapy related AML. Nearly half of the patients (49%) had karyotypic abnormalities. Of the 82 patients who received induction chemotherapy with 7+3, 51 achieved a complete remission (CR) after 1 cycle and 16 after 2 cycles for a CR rate of 82%. The strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations. Aims: The presence of an IDH2 R172K mutation was predictive of non-significance. The presence of an NPM1 mutation was the strongest predictor of response to induction chemotherapy was the presence of an NPM1 mutation. There was a trend towards decreased response to induction chemotherapy in patients with a complex karyotype (p=0.079) that did not reach statistical significance. The presence of an IDH2 R172K mutation was predictive of non-response to one cycle of (7+3) of 7+3 but when two cycles of induction chemotherapy were given, response rates were equivalent to patients with R140Q mutations. Co-occurring mutations in FLT3 (ITD or TKD), DNMT3A or NRAS were not predictive of responses to induction chemotherapy.

Summary/Conclusions: Induction chemotherapy with 7+3 leads to a robust CR rate of 82% in patients with AML that harbor and IDH1 or IDH2 mutation. CR is not affected if IDH2 is mutated, although those with IDH2 R172 mutations required two cycles of chemotherapy to achieve a remission. Karyotypic abnormalities did not influence the response to induction chemotherapy, nor did the presence of co-occurring FLT3-ITD, FLT3-TKD or NRAS mutations. Of these, 33 (40.2%) had IDH1 mutations and 49 (59.8%) had IDH2 mutations.
However, the correlation is only valid for CYT-IDA while the PM Test was applied to up to 45 treatments. Any such treatment identified as sensitive means the PM Test can provide a valuable guideline to hematologists. This means the PM Test can suggest sensitive treatments for the vast majority of patients.

Figure 1.

Summary/Conclusions: We have developed a novel ex vivo PM test for induction treatment in AML patients to guide hematologists selecting the right treatment to achieve CR in individual patients leveraging up to 45 different validated chemotherapeutic regimes. Assuming a similar response rate for all these treatments, our test could estimate a net prediction for sensitivity to AML treatment higher than 80% in 1st line. This PM Test will be evaluated in an interventional clinical trial on relapse/refractory patients that is expected to begin in the next few months in collaboration with the PETHEMA group from Spain.

P555

RESPONSE-ADAPTED AZA CITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP


1Department of Hematology and Oncology, University Hospital of Leipzig, 2Department of Hematology and Oncology, University of Leipzig, Leipzig, 3Department of Hematology and Oncology, Klinikum Chemnitz, Chemnitz, 4Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, 5Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, 6Department of Hematology and Oncology, University Hospital of Halle, Halle (Saale), 7Department of Hematology and Oncology, Helios Klinikum Erfurt, Erfurt, 8Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany

Background: AML treatment in elderly patients (pts) >60 years (y) with intensive chemotherapy (IC) or azacitidine (AZA) are not necessarily mutually exclusive. Aims: Results of the multicenter DRKS00004519 (RAS-AZIC) study of the East German Study Group (OSSHO) which evaluated first-line treatment with AZA followed by response-based AZA or IC in pts >60y with AML are presented.

Methods: pts >60y with newly diagnosed AML (n=112) were included. Recruitment was completed in May, 2016. In the phase I part, safety of upfront AZA (75mg/m²/day s.c.) for 7 days followed by IC (mitoxantrone 10mg/m²/day on day (d) 1-3 and cytarabine 1g/m²/BID on d 1, 3, 5, 7) on d17 was established through a 3+3 design. In the multicenter phase II part (figure), upfront AZA was sequentially followed by AZA or IC based on d15 bone marrow (BM) blasts (<45 vs 345%) and CR/CRi on d56 which were both previously identified as early predictors for long-term response to AZA in AML (Al-Ali et al. Leuk Lymph 2011). The primary endpoint was response (CR/CRi, and PR) at d90 according to the International Working Group criteria. Based on the optimal two-stage design (Simon. Control Clin Trials 1989), protocol treatment was non-inferior to standard IC if, on an intention-to-treat basis, an OR of 61% was reached. Adverse events (AEs) were reported according to the NCI CTCAE 4.03. All pts gave written informed consent.

Results: Median age was 70y (52% males), de novo AML was present in 65% of pts. Median BM blasts and WBC were 50% and 4.4x10⁹/L respectively. Genetic risk was high in 30%, intermediate in 55%, and favorable in 15%. FLT3 and NPM1 were mutated in 12% and 22% respectively. All pts received first-line AZA. Only lower baseline blasts correlated with blasts <45% on d15 (p=0.0005). Yet, 40% of pts with baseline blasts >50% reached this goal. Protocol assigned treatment on d15 was applied to 101 (90.2%) pts (54.5% continued with AZA; 46.5% received IC). Of 192 AZA cycles given till d56, 33.6% were applied in an outpatient setting. Until d90, one IC cycle was needed in 77 (68%) pts. The primary endpoint was response (CR/CRi) as CR/CRi were achieved in 62.5% [CR/CRi (n=43%); PR (4.5%)] and 8.9% respectively. The probabilities of achieving CR/CRi with AZA alone, two AZA cycles + one IC, and one AZA cycle + one IC were 28.3%; 53.3%, and 58.3% respectively. Age, WBC, and type of AML had no impact on response in the three treatment scenarios. Similarly, response was not influenced by baseline BM blasts. CR/CRi was lower in high risk genetics (48%) compared to other risk categories (78%) (p=0.007). This negative association was particularly marked in pts with high-risk genetics and d15 BM blasts >45% [CR/CRi 38.5% vs 84% in other genetic categories (p=0.009)]. Interestingly, the impact of genetics on OR was not seen in the two AZA cycles + one IC cohort (p=1.0). OR with AZA alone was remarkably high (70%) in pts with favorable genetics including those with NPM1mut/FLT3wt (p=0.003). Protocol therapy was generally well tolerated. Constipation grade 1+2 was the most frequently reported AE under AZA (48%). The most frequent grade 3+4 non-hematologic AE was infection [IC (47%); AZA (20%)].
a late complication of cytotoxic or radiation therapy and is associated with a poor prognosis. CPX-351 is a liposomal formulation that delivers a synergetic 5:1 molar ratio of cytarabine and daunorubicin. In a randomized, open-label, controlled phase 3 trial in patients aged 60 to 75 years with newly diagnosed, secondary AML (eg, tAML or AML after myelodysplastic syndrome), CPX-351 significantly improved overall survival (OS) versus cytarabine/daunorubicin (7+3).

Aims: The current analysis of this phase 3 study evaluated outcomes in the subgroup of patients with tAML.

Methods: Enrolled patients were randomized 1:1 to receive induction with 1 to 2 cycles of CPX-351 (100 units/m² [cytarabine 100mg/m² + daunorubicin 440mg/m²] on Days 1, 3, and 5 [2nd induction: Days 1 and 3 only]) or 7+3 (cytarabine 100mg/m²/day x 7 days [2nd induction: x 5 days] + daunorubicin 60mg/m² on Days 1, 2, and 3 [2nd induction: Days 1 and 2 only]). Patients who achieved complete remission (CR) or CR with incomplete platelet or neutrophil recovery (CRi) could receive up to 2 cycles of consolidation therapy. Note, the study was not powered for this subgroup analysis.

Results: A total of 304 patients were enrolled and received study treatment, including 62 (20%) patients with tAML (CPX-351 arm, n=30; 7+3 arm, n=32). Characteristics of tAML patients were similar between the CPX-351 and 7+3 arms: median age was 69.0 versus 67.5 years, and 47% versus 53% were male. Prior treatment in patients with tAML included prior non-anthracycline chemotherapy alone (26%), radiation alone (26%), non-anthracycline chemotherapy + radiation (32%), non-anthracycline + anthracycline chemotherapy (5%), and non-anthracycline + anthracycline chemotherapy + radiation (11%). CPX-351 was associated with a significant OS benefit versus 7+3 in older tAML patients and numerically longer event-free survival and remission duration (Figure). Additionally, a greater proportion of tAML patients in the CPX-351 arm versus the 7+3 arm achieved CR+CRi (47% vs 38%, respectively; odds ratio=1.33 [95% CI: 0.47, 3.81]) and proceeded to stem cell transplantation (37% vs 27%; odds ratio=1.54 [95% CI: 0.53, 4.49]). Serious treatment-emergent adverse events (TEAEs) were reported for 18/30 (60%) of tAML patients in the CPX-351 arm and 12/32 (38%) of tAML patients in the 7+3 arm; the observed difference in serious TEAEs in this subgroup population appeared to primarily be due to the incidence of febrile neutropenia (n=6/30 [20%] vs n=0/32 [0%]). These (10%) patients in the CPX-351 arm and 5 (16%) patients in the 7+3 arm experienced a TEAE that resulted in death during the treatment period; there was no pattern in the individual TEAEs that led to death.

Summary/Conclusions: CPX-351 is associated with improved efficacy and a safety profile comparable to 7+3 in older patients with newly diagnosed tAML. Outcomes in the tAML subgroup mirrored the overall study population, indicating CPX-351 may represent a new therapeutic option for this difficult to treat population.

P557
HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
S. Carabatos1,2, M.V. Larcher3, E. Bérard-de-Millay1, F. Vergez2,3,7, S. Tavitian1,2,3,*, X. Thomas 4, E. Bérard 5,6, F. Vergez 2,3,7, S. Tavitian 1,2,3, X. Thomas 4
1Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, 2Université Toulouse III Paul Sabatier, 3Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, 4Service d’hématologie, Centre Hospitalier Universitaire de Lyon, Lyon, 5Service d’Épidémiologie, Centre Hospitalier Universitaire de Lyon, Lyon, 6Institut Universitaire de France, 7Laboratory of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse.

Background: The prognostic impact of ferritinemia has been studied in myelodysplastic syndromes and acute myeloid leukaemia (AML) patients undergoing allogeneic stem cell transplantation (SCT). In this context, high levels of serum ferritinemia have been correlated to a shorter overall survival (OS) and an increased relapse risk. We have previously shown that hyperferritinemia at diagnosis has a strong prognostic impact in a cohort of 162 AML patients with intermediate cytogenetic risk and younger than 60.

Aims: We now extend the analysis to all age and cytogenetic risk, in order to confirm the impact of hyperferritinemia in AML.

Methods: This study included 525 adult AML patients (excluding acute promyelocytic leukemia) treated by intensive chemotherapy in Toulouse and Lyon University Hospitals between January 1st, 2005 and December 31st, 2014 who had ferritinemia documented at AML diagnosis. Ferritin level was measured by spectrophotometry. Primary outcome was disease-free survival (DFS). To avoid the loss of information and the reduction in power introduced by the categorization of ferritinemia and to deal with the non-linearity in the relationship between outcomes and ferritinemia, we explored the relationship between ferritinemia and outcomes using restricted cubic spline.

Results: Median age at diagnosis was 59.4 years (interquartile range [IQR], 47.8-66.4); 303 of them (57.7%) were men. Disease status was de novo in 83.2% (N=437). Median white blood cell count (WBC) was 10.0x10^9/L (IQR, 2.5-41.5). Cytogenetic risk was favorable, intermediate and adverse in 9.2% (N=48), 71.8% (N=374) and 19% (N=99) respectively; ELN classification was favorable, intermediate-I, intermediate-II, adverse and unknown in 21.0% (N=110), 25.5% (N=134), 22.3% (N=117), 18.9% (N=99) and 12.4% (N=65) respectively. Median ferritinemia at AML diagnosis was 715 µg/L (IQR, 372-1304), ranging from 34µg/L to 70759 µg/L (upper normal limit [UNL]; 300µg/L). 421 patients achieved complete remission (CR; 80.2%). Early death and treatment failure rates were 7.8% (N=41) and 12% (N=63) respectively. 169 patients underwent allogeneic HSCT in first CR (32.2%). Median DFS was 19.8 months (IQR, 8.4-Not Reached). Ferritinemia had a significant impact on DFS: median DFS was 21.2 months in patients with ferritinemia ≤2100 µg/L (7-fold UNL), and 17.7 months with ferritinemia >2100 µg/L (HR, 1.6 [95%CI, 1.1-2.3], p=0.0253). After adjustment for age, AML status and cytogenetics or ELN classification, relapse or death rate significantly (p=0.0122) increased from ferritinemia superior or equal to 2141 µg/L (Figure 1). Ferritinemia had also a significant impact on early deaths, CR rate, EFS and OS after adjustment (24-fold UNL, p<0.0001; ≥7-fold UNL, p=0.004; ≥3-fold UNL, p<0.0001 and ≥2-fold UNL, p<0.001 respectively).

Summary/Conclusions: In conclusion, hyperferritinemia is a prognostic marker independent from well-acknowledged factors, such as cytogenetics and molecular abnormalities. Ferritinemia should be included at AML diagnosis workup as it provides reproducible information on short and long-term outcome for AML patients of any subgroup. The putative link between hyperferritinemia, inflammation and chemoresistance should be investigated.

P558
NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE—IMPACT OF AGE ON MUTATIONAL LOAD
L. Pleyer1,2,3,*, F.J. Gassner1,2, S. Burgstaller4, H. Wedler5, T.N. Hartmann1,2,3, H. Pichler1,2,3, S. Pichler1,2,3, T. Hartmann1,2,3, L. Pleyer1,2,3,*, F.J. Gassner1,2, S. Burgstaller4, H. Wedler5, T.N. Hartmann1,2,3, H. Pichler1,2,3, S. Pichler1,2,3, T. Hartmann1,2,3
1Institute of Pathology, Paracelsus Medical University, 2Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials, 3Cancer Cluster, Salzburg, 4Department of Internal Medicine IV/Department of Internal Medicine V, 5Department of Pathology, Paracelsus Medical University, Salzburg, Austria

Background: Recent publications have shown the prognostic value of per- and molecular analyses in patients (pts) with acute myeloid leukaemia (AML) (Papaemmanuil et al, NEJM 2016). While recent data has been published on pts with myelodysplastic syndromes (MDS) and AML treated with decitabine, (Welch et al, NEJM 2016; Duncavage et al, Blood 2017) data on
AML pts treated with azacitidine (AZA) has only been presented in abstract form thus far (Tang et al, ASH 2016). Data on the impact of age on mutational load in AML are scarce.

Aims: To assess the mutational landscape in elderly AML pts treated with AZA; specifically, whether age has an impact on mutational load.

Methods: We analysed 474 bone marrow FFPE specimens from 157 AML pts in the Austrian Registry of Hematologic Agents from two centers (Salzburg, Wels-Grieskirchen) using a 53-gene panel (all exons). NGS was performed by Qiagen. Minimum coverage: 1,500x. All mutations were checked against COSMIC-v79, ClinVar, ICGC, DoCn, dbSNP and Varsome databases. For comparison of categorical variables Chi-squared test was used, for comparison of means Students’ T-test was used.

Results: The rate of secondary (s)AML was significantly lower in pts <75 (n=85), vs ≥75 years (n=54) (66.0 vs 77.8%, P<0.001). There was no significant difference in the rate of adverse cytogenetics or monosomal karyotype before AZA treatment between pts < vs ≥75 years, respectively (data not shown). Mutational load (average number of mutated genes and mutations per pt) assessed at/after initiation of AZA, was significantly higher in pts <75 vs pts ≥75 years (10.2 vs 8.6 mutated genes/pt; P=0.030 and 12.9 vs 10.5 mutations/pt; P=0.012, Figure 1A). This also held true when mutational load was assessed at any timepoint during the course of AML (including during/after AZA treatment) (Figure 1B). In total, 139 pts had more than one marrow sample with NGS results. Analysis of paired samples revealed that mutational load was significantly higher during/post-AZA vs before AZA in both age groups (Figure 1C-D). In total, 60.4%, 15.8%, 8.6%, 3.6% and 11.5% of pts acquired 1, 0, 2, 3, 4-13 additional mutations, respectively. No relevant differences between pts < vs ≥75 years were found (data not shown). When comparing the delta of mutations before vs during/after AZA according to age group, no significant difference was found (Figure 1E).

Table 1.

Summary/Conclusions: The observed mutational load per pt in our cohort is higher than that observed by others using targeted re-sequencing methods, which report an average of only 2-4 mutations per pt (Duncanave et al, Blood 2017; Conte et al, Leuk 2013; Au et al, Diagn Pathol 2016; Grove & Vassiliou, Dis Model Mech 2014). It seems however, that a higher mutational load (average number of mutated genes and mutations per pt) assessed at/after initiation of AZA, was significantly higher in pts <75 vs ≥75 years (10.2 vs 8.6 mutated genes/pt; P=0.030 and 12.9 vs 10.5 mutations/pt; P=0.012, Figure 1A). This also held true when mutational load was assessed at any timepoint during the course of AML (including during/after AZA treatment) (Figure 1B). In total, 139 pts had more than one marrow sample with NGS results. Analysis of paired samples revealed that mutational load was significantly higher during/post-AZA vs before AZA in both age groups (Figure 1C-D). In total, 60.4%, 15.8%, 8.6%, 3.6% and 11.5% of pts acquired 1, 0, 2, 3, 4-13 additional mutations, respectively. No relevant differences between pts < vs ≥75 years were found (data not shown). When comparing the delta of mutations before vs during/after AZA according to age group, no significant difference was found (Figure 1E).
AML showed higher therapy-related mortality (TRM) rate. However, multivariate rate and inferior survival outcome compared to normocellular AML, and hypo-survival outcome compared to normocellular karyotype was poorer. In untreated group (n=207), hypo-AML showed longer OS (p<0.001) compared to normocellular.

Results: Signal ratio was assessed in 152 patients with FLT3-ITD and -TKD mutations who had received ≥80mg gilteritinib. Of these patients, 136 had FLT3-ITD mutations with or without concomitant TKD mutations, and 16 had FLT3-TKD mutations only. Median ITD and TKD signal ratios were 0.84 and 0.5, respectively. Patients with FLT3-ITD signal ratios that were above or below the median ITD signal ratio had OS durations of 216 and 213 days, respectively. No significant difference in median OS was observed between patients in the highest and lowest FLT3-ITD signal ratio quartiles (Figure 1). Patients with TKD signal ratios that were above the median value (0.5) had a median OS of 202 days; those with TKD signal ratios below the median value had a significantly shorter median OS of 33.5 days (P=0.0004; Figure 1).

Aims: As the characteristics and outcomes are not well recognized.

Methods: Hypocellular (<20%) bone marrow (BM) which was identified with at least two myelodysplasia-related change (AML-MRC) accounts for small proportion of adult AML. As the characteristics and outcomes are not well recognized.

Background: Hypocellular acute myeloid leukemia (hypo-AML) and AML with myelodysplasia-related change (AML-MRC) accounts for small proportion of adult AML. As the characteristics and outcomes are not well recognized.

Aims: We tried to analyze these specific groups and compared to normocellular AML.

Methods: After exclusion of secondary AML, therapy-related AML, and AML M3, we retrospectively analyzed 1593 AML cases between 2002 and 2013. We found 101 (6.3%) patients with hypo-AML and 164 (10.3%) patients with de novo AML-MRC. Hypo-AML was diagnosed with blast counts ≥20% within hypocellular (<20%) bone marrow (BM) which was identified with at least two biopsy specimens and age-related correction was considered. De novo AML-MRC was defined with multilineage dysplasia ≥10% for each lineage with blast counts ≥20% without history of antecedent hematologic disease. Patients (n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group.

Results: Patients with hypo-AML were older (p=0.001) and significantly presented lower leukocyte and PB/BM blast counts (p<0.001). Patients with AML-MRC were older and lower hemoglobin level with lower PB/BM blast counts (p=0.001) compared to normocellular de novo AML. In both groups, the risk of karyotype was poorer. In untreated group (n=207), hypo-AML showed longer survival outcome compared to normocellular de novo AML and AML-MRC. In treated group (n=1386), hypo-AML and AML-MRC both showed higher relapse rate and inferior survival outcome compared to normocellular AML, and hypo-AML showed higher therapy-related mortality (TRM) rate. However, multivariate

Figure 1. MS}_{\text{OS}} (n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group. Hypo-AML was diagnosed with blast counts ≥20% within de novo AML. Evaluation of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IMGN779 are secondary objectives.

Methods: Adult patients (≥ 18 years) with relapsed or refractory CD33+ AML (defined by ≥20% of AML blasts expressing CD33 by flow cytometry) were eligible for enrollment. Informed consent was obtained from all patients. Dose-escalation, which follows a standard 3+3 design, began with a starting dose of 0.02mg/kg. IMGN779 was administered intravenously once every 2 weeks on days 1 and 15 as part of a 28-day cycle. Adverse events (AEs) were evaluated using NCI-CTC v4.03.

Results: As of February 2017, a total of 17 patients (9 female, 8 male) with a median age of 62 years have received IMGN779 treatment. Five dose levels have been completed, with escalation proceeding from 0.02–0.26mg/kg. AEs as of February 2017, a total of 17 patients (9 female, 8 male) with a median age of 62 years have received IMGN779 treatment. Five dose levels have been completed, with escalation proceeding from 0.02–0.26mg/kg. AEs were as expected for this relapsed/refractory AML population including cytopenias and constitutional symptoms. No relationship between frequency or severity of AEs and dose levels was observed. Median ITD signal ratio (ie, FLT3-ITD:wild-type FLT3) was calculated from patients with ITD mutations (with/without concomitant TKD mutations); median TKD signal ratio (i.e., FLT3-TKD: wild-type FLT3) was calculated from all patients with a TKD mutation. Median OS estimates were derived and stratified based on ITD and TKD signal ratios that fell above or below median signal ratio values reported for the trial.

Results: Signal ratio was assessed in 152 patients with FLT3-ITD and -TKD mutations who had received ≥80mg gilteritinib. Of these patients, 136 had FLT3-ITD mutations with or without concomitant TKD mutations, and 16 had FLT3-TKD mutations only. Median ITD and TKD signal ratios were 0.84 and 0.5, respectively. Patients with FLT3-ITD signal ratios that were above or below the median ITD signal ratio had OS durations of 216 and 213 days, respectively. No significant difference in median OS was observed between patients in the highest and lowest FLT3-ITD signal ratio quartiles (Figure 1). Patients with TKD signal ratios that were above the median value (0.5) had a median OS of 202 days; those with TKD signal ratios below the median value had significantly shorter median OS of 33.5 days (P=0.0004; Figure 1).

Figure 2. MS}_{\text{OS}} (n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group. Hypo-AML was diagnosed with blast counts ≥20% within de novo AML. Evaluation of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IMGN779 are secondary objectives.

Methods: Adult patients (≥ 18 years) with relapsed or refractory CD33+ AML (defined by ≥20% of AML blasts expressing CD33 by flow cytometry) were eligible for enrollment. Informed consent was obtained from all patients. Dose-escalation, which follows a standard 3+3 design, began with a starting dose of 0.02mg/kg. IMGN779 was administered intravenously once every 2 weeks on days 1 and 15 as part of a 28-day cycle. Adverse events (AEs) were evaluated using NCI-CTC v4.03.

Results: As of February 2017, a total of 17 patients (9 female, 8 male) with a median age of 62 years have received IMGN779 treatment. Five dose levels have been completed, with escalation proceeding from 0.02–0.26mg/kg. AEs were as expected for this relapsed/refractory AML population including cytopenias and constitutional symptoms. No relationship between frequency or severity of AEs and dose levels was observed.

Figure 1. MS}_{\text{OS}} (n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group. Hypo-AML was diagnosed with blast counts ≥20% within de novo AML. Evaluation of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IMGN779 are secondary objectives.

Methods: Adult patients (≥ 18 years) with relapsed or refractory CD33+ AML (defined by ≥20% of AML blasts expressing CD33 by flow cytometry) were eligible for enrollment. Informed consent was obtained from all patients. Dose-escalation, which follows a standard 3+3 design, began with a starting dose of 0.02mg/kg. IMGN779 was administered intravenously once every 2 weeks on days 1 and 15 as part of a 28-day cycle. Adverse events (AEs) were evaluated using NCI-CTC v4.03.

Results: As of February 2017, a total of 17 patients (9 female, 8 male) with a median age of 62 years have received IMGN779 treatment. Five dose levels have been completed, with escalation proceeding from 0.02–0.26mg/kg. AEs were as expected for this relapsed/refractory AML population including cytopenias and constitutional symptoms. No relationship between frequency or severity of AEs and dose levels was observed.

Figure 2. MS}_{\text{OS}} (n=20) with both AML-MRC and hypo-AML were distributed in AML-MRC group. Hypo-AML was diagnosed with blast counts ≥20% within de novo AML. Evaluation of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IMGN779 are secondary objectives.
Summary/Conclusions: This is the first clinical experience of the next-generation CD33-targeting ADC, IMGN779, in AML patients. No DLTs have been noted to date. AEs were generally consistent with the underlying disease. PK and PD are favorable and dose escalation is continuing.

Aggressive Non-Hodgkin lymphoma - Relapsed/refractory

**P563**

**COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA**

M.A. Lunning1,2, P. Bierman1, G.R. Bociek1, M.T. Schreider2, T. Siddiqi3, S. Blume1, K. Cutter2, E.K. Paul2, D. Bu2, P. Sportelli2, H.P. Miskin2, M. Purdom2, M.S. Weiss3, J.M. Vose1

1University of Nebraska Medical Center, Omaha, NE, 2Clearview Cancer Institute, Huntsville, AL, 3City of Hope National Medical Center, Duarte, CA, 4TG Therapeutics, Inc., New York, NY, United States

Background: TGR-1202 is a next generation, once daily, PI3Kδ inhibitor, active in patients (pts) with rel/ref hematologic malignancies that has demonstrated a notably differentiated safety profile, including in long-term follow up (Burriss, 2016). Ublituximab (UTX) is a novel glycoengineered mAb targeting a unique epitope on the CD20 antigen. Bendamustine (Benda) is an active chemotherapy agent in pts with lymphoma. The combination of UTX + TGR-1202 is tolerable and active in pts with rel/ref hematologic malignancies and is under Phase 3 testing for patients with CLL and Phase 2b testing for patients with DLBCL.

Aims: This Phase 1 trial evaluates the safety and efficacy of UTX + TGR-1202 + Benda in pts with advanced Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).

Methods: Eligible pts had rel/ref DLBCL or FL with an ECOG PS ≤2 w/o limit to number of prior therapies. ANC of >750 and Platelets >50,000 was permitted. Pts refractory to prior PI3Kδ, Benda, or anti-CD20 therapy were eligible. UTX was dosed on Days 1, 8, 15 of Cycle 1, Day 1 of Cycle 2-6, followed by Cycle 9 & 12. TGR-1202 was started at 800mg QD with a -1 dose reduction cohort at 600mg if not tolerated in ≥2/6 pts. Benda was dosed at 90mg/m2 on Days 1 & 2 of Cycles 1-6 only. Primary endpoints included safety and efficacy (Cheson 2007).

Results: Twenty-three pts were evaluable for safety: 15 diffuse large B-cell (DLBCL) and 8 follicular (FL). Med age 68 yo (range 31-81); 12 M/11 F; median prior treatment regimens=2 (range 1-6); 12 pts (52%) were refractory to their immediate prior treatment and to prior CD20 therapy, and 7 patients had progressed post-transplant. ECOG PS 0/1/2 (3/18/2). Initially 2/4 pts at 800mg TGR-1202 experienced AEs in Cycle 1 that led to treatment interruption (rash, neutropenia) thus the 600mg dose of TGR-1202 was explored. No additional Cycle 1 treatment delays were reported at the 600mg dose level, which was later expanded and the 800mg TGR-1202 dose is now being evaluated with stricter eligibility criteria to require an ANC of ≥1.0, and the use of growth factor support in cycle 1 is now encouraged. The most common AE’s included diarrhea (39%; G3/4 4%), decreased appetite (35%; G3/4 4%), nausea (30%; G3/4 4%), and neutropenia (22%). The only Grade 3/4 AE reported in >10% of pts was neutropenia (22%). Two pts had a TGR-1202 dose reduction. Nineteen pts (11 DLBCL/8 FL) were evaluable for efficacy: ORR amongst all pts was 79% (15/19) with 42% (8/19) achieving a complete response (CR), of which 5 were DLBCL and 3 FL. ORR in the respective groups as follows:

**Table 1.**

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>ORR (%</th>
<th>CR ( % )</th>
<th>PR ( % )</th>
<th>SD ( % )</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLBCL</td>
<td>17</td>
<td>59%</td>
<td>5 (30%)</td>
<td>3 (18%)</td>
<td>9 (53%)</td>
</tr>
<tr>
<td>FL</td>
<td>8</td>
<td>88%</td>
<td>5 (63%)</td>
<td>3 (38%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Median follow-up time on study is 6 mos for all pts (range 1-14+ mos).

Summary/Conclusions: The combination of UTX, TGR-1202, and bendamustine has exhibited manageable toxicity with significant activity in advanced DLBCL and FL pts including an encouraging 42% CR rate (45% in DLBCL and 38% in FL). Enrollment continues at the 800mg TGR-1202 dose level with the use of growth factor prophylaxis. Safety and efficacy data for all pts will be updated at the meeting. Based upon the early activity of the triplet, future registration directed studies are being planned.

**P564**

**VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)**


1Dana-Farber Cancer Institute, Boston, United States, 2Royal Melbourne Hospital, Parkville VIC, 3Peter MacCallum Cancer Centre, East Melbourne VIC, 4University of Texas MD Anderson Cancer Center, Houston, 5University of Arizona Cancer center, Tucson, Australia, 6AbbVie, Inc., North Chicago, 7Memorial Sloan-Kettering Cancer Center, New York City, United States

Background: Venetoclax (VEN) is a novel BH3 mimetic that targets the Bcl-2 protein complex, resulting in tumor cell apoptosis when the Bcl-2 inhibitor is combined with an alkylating agent or an antibody targeting CD20. In a recently published, single-arm, phase 1 trial, patients (pts) with rel/ref DLBCL and FL who had received at least 2 prior lines of therapy were treated with VEN at a dose of 300mg QD orally. The primary endpoints were safety and ORR. The ORR was 47% (95% CI 29-65%). Pts with rel/ref DLBCL or FL who were enrolled in this first-in-patients trial have been updated at the meeting. Based upon the early activity of the triplet, future registration directed studies are being planned.
Background: VEN is a selective orally bioavailable BCL-2 inhibitor. The dose-escalation Phase 1 study of VEN in 106 patients (pts) with relapsed/refractory NHL reported an ORR of 44%. Most pts had diffuse large B-cell/follicular lymphoma.

Aims: We report on updated results in pts with less common NHL subtypes.

Methods: VEN was administered and continued until progressive disease (PD). An acceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheon ISG response criteria, utilizing CT scans beginning at wk 6.

Results: 35 of 106 pts had mantle cell lymphoma (MCL, n=28), marginal zone lymphoma (MZL, n=3) or Waldenström macroglobulinemia (WM, n=4). Most common acceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheon ISG response criteria, utilizing CT scans beginning at wk 6.

Results: 35 of 106 pts had mantle cell lymphoma (MCL, n=28), marginal zone lymphoma (MZL, n=3) or Waldenström macroglobulinemia (WM, n=4). Most common acceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheon ISG response criteria, utilizing CT scans beginning at wk 6.

Results: 35 of 106 pts had mantle cell lymphoma (MCL, n=28), marginal zone lymphoma (MZL, n=3) or Waldenström macroglobulinemia (WM, n=4). Most common acceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheon ISG response criteria, utilizing CT scans beginning at wk 6.

Results: 35 of 106 pts had mantle cell lymphoma (MCL, n=28), marginal zone lymphoma (MZL, n=3) or Waldenström macroglobulinemia (WM, n=4). Most common acceptable toxicity, in dose cohorts ranging from 300-1200mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheon ISG response criteria, utilizing CT scans beginning at wk 6.
and other extranodal localizations (12%). In patients harboring a MYD88 mutation, the frequency of double carcinomas at IP sites (67%, Chi-square \( P=0.001 \)) was compared to nodal (13%) particularly in DLBCL patients with IP localizations. Interestingly, there was hardly any overlap between the presence of translocations (BCL2, BCL6 and MYC) or EBV and that of MYD88 and/or CD79B mutations, indicating that these tumors represent distinct DLBLC subgroups. In a recent study by Wilson et al. (Nat. Med. 2015), indicates that these patients are more sensitive to treatment with Bruton’s Kinase inhibitors. Our study highlights the importance of investigating the mutational status of MYD88 and CD79B in larger prospective clinical trials with molecularly targeted agents, particularly in DLBCL patients with IP localizations.

**Results:**

As of June 2015, 311 of 499 pts (62%) achieved a documented CR, 235 (60%) with relapsed NHL or Hodgkin lymphoma (HL) should be treated in a manner similar to immunocompetent pts. 

**Background:** The outcome of HIV-associated lymphoma has undergone significant improvement in recent years beginning with the widespread use of combination antiretroviral therapy (ART). However, among AIDS-related deaths, non-Hodgkin lymphoma (NHL) is the most frequent event. HIV-positive patients (pts) with relapsed NHL or Hodgkin lymphoma (HL) were diagnosed at participating centers in Germany and Austria since January 2005. Data on HIV-infection and lymphoma characteristics, treatments and outcomes were recorded. Pts with indolent lymphomas and primary central nervous system lymphomas were excluded from the present analysis.

**Results:** Of 499 pts (463 males, 36 females) 394 had aggressive NHL and 105 HL. The median age at lymphoma diagnosis was 45.6 yrs (range, 22–74.7). 344 pts (69%) were diagnosed with advanced stage (III/IV) lymphoma and the median CD4-cell count was 271/μl (266/μl in NHL and 287/μl in HL). As of June 2015, 311 of 499 pts (62%) achieved a documented CR, 235 (60%) with NHL and 76 (72%) with HL. After a median follow-up of 17 months for NHL and 30 months for HL pts, 31 of 235 NHL (13%) and 6 of 76 HL (11%) experienced a relapse. Incidence of relapse was 6.9/100 patient years (PY) within the 1st year after primary diagnosis and 1.3/100 PY thereafter (\( P=0.0062 \)). Median time to relapse was 7.3 months in NHL and 18.0 months in HL. Relapses beyond 12 months occurred in 6 of 31 NHL cases (19%) and in all 8 HL cases (100%) (\( P=0.045 \)). Median overall survival (OS) of all relapsed pts was 29.0 months (95% CI 14.1-44.2 months) after primary lymphoma diagnosis. In pts with HL, OS was not reached, whereas it was 15 months in pts with NHL (\( P=0.024 \)). Regarding the entire cohort of 311 pts with a documented CR, the 2-year OS rate was 57% in pts with relapse as compared to 97% in those without (\( P<0.001 \)). The majority of relapsed pts died of lymphoma (86%).

**Summary/Conclusions:** Relapses from CR are relatively rare in pts with HIV-associated NHL and HL. In pts with NHL the majority of relapses occur within the first year after primary diagnosis, whereas in HL most relapses occur beyond 12 months. Overall, pts with relapsed HIV-related NHL have a worse outcome than pts with relapsed HL.
Background: Nodal peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of neoplasms, which include PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (ATL), anaplastic large-cell lymphoma (ALCL), anaplastic lymphoma kinase-positive (ALK-ALCL), and ALCL-ALK-. Clinical assessments before and after treatment are essential to predict survival in nodal PTCL. However, limited data is available regarding the prognostic relevance of National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and post-treatment PET-CT scan.

Methods: In this retrospective cohort study, patients with newly diagnosed nodal PTCL were consecutively enrolled from 11 hospitals in South Korea. Patients were eligible if they were histologically diagnosed with nodal PTCL from Jan 2005 to June 2016, received systemic chemotherapy, and had the results of PET-CT scan at the time of diagnosis and at the end of treatment. Post-treatment PET-CT was assessed using 5-point Deauville score. The study excluded ALCL-ALK+ due to well-known better survival.

Results: A total of 396 patients were screened for eligibility. Seventy patients were excluded from the analysis due to following reasons: unavailable pre- or post-treatment PET scans, no systemic treatment, uncertain histology, and ALCL-ALK+. Thus, 326 patients were analyzed. The median age was 61 years (range, 18-86) and 209 (64%) were male. PTCL-NOS (N=172, 53%) was the most common subtype included, and ATL (N=111, 34%) and ALCL-ALK- (N=43, 13%) followed. Three-fourths of patients (N=242) had stage III/IV. Majority of patients received anthracycline-based therapy. Patients were categorized into low (N=42, 13%), low-intermediate (Li, N=108, 33%), high-intermediate (Hi, N=136, 42%), and high (N=40, 12%) risk groups according to NCCN-IPI. Based on the Deauville criteria, post-treatment PET-CT scan was scored as 1 (N=130, 40%), 2 (N=47, 14%), 3 (N=60, 18%), 4 (N=27, 8%), and 5 (N=62, 19%). Because the number of progression in Deauville score 3 (40/60, 67%) was significantly different from score 2 (21/47, 45%; P=0.023) and 4 (24/27, 89%; P=0.030), we categorized patients into 3 groups: Deauville score 1-2, 3, and 4-5. With a median follow-up of 54.7 months (IQR, 30.2-84.5), 5-year PFS rate was 35.7% (95% CI, 30.0-41.4) and OS rate was 47.1% (95% CI, 40.8-53.4). NCCN-IPI risk and post-treatment PET-CT scan were independently associated with PFS in the multivariate analysis (for Li NCCN-IPI, hazard ratio [HR] 1.615, 95% CI 0.963-2.671; for Li NCCN-IPI and Deauville score 1-2, HR 1.426-1.756; for Hi NCCN-IPI 4.475, 95% CI 2.231-8.977; P<0.001; for post-treatment Deauville score 3, HR 1.895, 95% CI 1.281-2.801; score 4-5, HR 6.916, 95% CI 4.948-9.667; P<0.001). We stratified patients into 5 groups based on risk of progression: a low (low NCCN-IPI and Deauville score 1-2), low (low NCCN-IPI and Deauville score 3, or Li NCCN-IPI and Deauville score 1-2), low-intermediate (Hi NCCN-IPI and Deauville score 1-2), high (high NCCN-IPI and Deauville score 1-2), or low-intermediate (Hi NCCN-IPI and Deauville score 3), and very high (Deauville score 4-5). The risk model showed a strong association with PFS and OS (Figure 1).

Summary/Conclusions: This study proposes a new risk stratification model incorporating baseline NCCN-IPI in combination with post-treatment Deauville score on PET-CT scan in patients with newly diagnosed nodal PTCL.

LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES

F. Farina1,2,3,*, M. Ceccon1, S. Mori2, L. Verga2, L. M. Borin2, L. Mologni1, D. Fontana1, G. Geeta1, R. Piazzza1, C. Gambacorti-Passerini1,2
1School of medicine, Milano Bicocca University, 2Haematology Department and Clinical Research Unit, San Gerardo Hospital, Monza, 3Haematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy

Background: Anaplastic large cell lymphoma (ALCL) is an aggressive disease with over 60% ALK-tyrosine kinase (TK) receptor positivity due to oncogenic fusions proteins containing ALK, mainly NPM-ALK. Crizotinib, an ALK inhibitor, proved to be effective in ALK positive tumors and in particular in ALK+ ALCL, with Objective Response Rates (ORR) in the 80-90% range. Long-term data on the safety and efficacy of crizotinib are lacking.

Aims: In this work, we analysed long-term clinical outcomes in 16 patients treated with crizotinib for ALK positive ALCL and we evaluated the presence of TK domain-point mutations in patients who relapsed during crizotinib treatment.

Methods: 16 patients were treated at the Clinical Research Unit, S. Gerardo Hospital, Monza (Italy) from June 2010 to December 2015 with a median follow up of 7.3 months (range 2.4-72 months). Survival curves were obtained using GraphPad Prism 5; differences were evaluated with Mantel-Cox test and Gehan-Breslow-Wilcoxon test. In 4/7 relapsed patients the TK domain of ALK were amplified from peripheral blood samples obtained at the time of crizotinib-relapse and subjected to deep sequencing. Subsequently we profiled in vitro the activity of 26392 generation ALK inhibitors (brigatinib, alecibitin, ceritinib and lorlatinib) with a murine Ba/F3 cell model and obtained their level of sensitivity/resistance to the drugs.

Results: Median age at diagnosis was 25.5 years (range 16-38 years) and 8/16 patients were male. Median previous line-therapies were 2.5 (range 1-5). In the Intention-To-Treat population which includes 1 patients who died after the first crizotinib dose, 13/16 patients (81.25%, 95% CI 53-95%) and 8/16 patients (50%, 95% CI 25-75%) achieved a OR and a complete response (CR) after 1 month of therapy, respectively. Median overall survival and progression free survival (PFS) were 7.53 months and 4.57 months respectively (fig 1a). Median time to progression was 50 days (range 47-137 days); OS and PFS from 1 and 3 years from treatment were 44%. In 7 patients were still on treatment and in CR (median treatment duration 44 months [range 15-72 months]). There was a significant difference in 3 years PFS between patients in whom CR was obtained after 4 weeks of crizotinib and those who didn't (PFS at 3 years 87.5% vs 0%, p<0.001-fig 1c); patients with less than 2 previous lines of therapy showed a borderline better 3 years PFS (66% vs 33%, p=0.08-fig 1b). Crizotinib was well tolerated and there were no cumulative adverse events (AEs) over this long-term follow-up. The only G3 AEs reported were transient neutropenia and creatine-kinase elevation. The deep sequencing of 4 NPM-ALK in relapsed patients demonstrated the presence in 2/4 samples of ALK mutations G1298A and G1156Y, which were not present in samples before crizotinib treatment. The level of in vitro resistance of these mutations showed a high level of resistance to crizotinib (resistance index for G1156Y and G1298A: 9.59-15.4 respectively). The sensitivity in vitro of these mutations to ALK-Inhibitors was also evaluated: all inhibitors, except alclebint for G1298A, with active with a therapeutic index (TI)>20 (fig 1d). TI values, as previously reported by Mologni L. et al (OncoTarget. 2015 Mar 20;6(8):5720-34), provide a view of the therapeutic impact of a mutation: the bigger the value, the more targetable is the mutation with the inhibitor.
PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARINIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

T. Witzig1, L. Sokol2, E. Jacobsen3, R. Advani4, R. Mondejar5, M. Piris6, F. Burrows7, C. Melvin7, V. Mishra7, C. Scholtz2, A. Guadarrama1

1Mayo Clinic, Rochester, 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, 3Dana Farber Cancer Institute, Boston, 4Stanford University Medical Center, Stanford, United States, 5IDIVAL Instituto de Investigación Marqués de Valdecilla, Santander, 6Fundación Jiménez Díaz, Madrid, Spain, 7Kura Oncology, La Jolla, United States

Background: Tipifarnib is a potent and selective inhibitor of farnesyltransferase (FT). FT catalyzes post-translational attachment of farnesyl groups required for localization of signaling molecules to the inner cell membrane. CXCL12 is a chemokine that is essential for hematopoietic stem cell (HSC) homing to the bone marrow and lymphoid organs and for maintenance of HSCs and immune cell progenitors. CXCL12 is known to signal in part through HRAS, a signaling protein that is uniquely farnesylated. Tipifarnib has previously been shown to be well tolerated and to have a 41% response rate (7 responses out of 17 patients) in patients (pts) with T-cell Non-Hodgkin Lymphoma, including 4 objective responses in 8 pts with peripheral T-cell lymphoma (PTCL) (Witzig et al., 2011). Building on this prior experience, we report herein the preliminary efficacy, safety and biomarker data from our ongoing Phase 2 study in PTCL.

Aims: This Phase 2 study is a multi-institutional, single-arm, open-label, two-stage (11+7) study designed to determine the efficacy and safety of tipifarnib in pts with relapsed/refractory (R/R) PTCL.

Methods: Pts with R/R PTCL after prior cytotoxic systemic therapy, aged ≥ 18 years old, and with a performance status of 0-2 were eligible. Informed consent was obtained. The following subtypes of PTCL were eligible for enrollment: PTCL-NOS, ALK-positive and -negative anaplastic large cell lymphoma (ALCL), hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma (EATL), extranodal natural killer (NK) T-cell lymphoma, nasal type and subcutaneous panniculitis-like T-cell lymphoma. The primary endpoint of the study is overall response rate. Secondary endpoints include safety and tolerability, duration of response (DOR) and progression free survival (PFS). Based on activity observed in the first 18 pts in the study, the protocol has been amended and enrollment is ongoing to an expansion cohort in PTCL (N=12). Enrolled pts are treated with tipifarnib 600mg administered orally twice daily on days 1-7 and 15-21 of 28-day treatment cycles until progression of disease or unacceptable toxicity. Biomarker studies included gene expression profiling of pre-treatment tumor biopsies by RNASeq and DNA next-generation sequencing (NGS). Clinical trial information: NCT02464228.

Results: At data cut-off (2/15/2017), 18 pts (2 ATL, 1 ALK-ALCL, 15 PTCL-NOS) were treated with tipifarnib. Most common treatment-related AEs (grade ≥3) were myelosuppression, including neutropenia (61%), anemia (39%) and thrombocytopenia (39%). 3 pts achieved a partial response (2 ATL; 1 PTCL-NOS) and 3 additional pts experienced stable disease >6 months. Tumor DNA from 18 pts was sequenced using NGS. A high rate of CXCL12 3'UTR single nucleotide variation (SNV) was observed. Seven of 16 pts carried the rs2839695 variant while an additional patient carried a novel variant. The presence of 3'UTR SNVs was associated with low levels of CXCL12 gene expression and disease progression (Figure) while all pts deriving clinical benefit from tipifarnib carried reference (wild-type) 3'UTR CXCL12 and had tumors that expressed high levels of mRNA for this chemokine. Testing of circulating CXCL12 levels is ongoing.

Summary/Conclusions: Although this study is ongoing, these preliminary data indicate that tipifarnib is generally well-tolerated and has antitumor activity, particularly in pts with AITL histology, absence of 3'UTR CXCL12 SNV and high levels of CXCL12 gene expression.

Figure 1.

Summary/Conclusions: ALK point mutations in patients (pts) with T-cell Non-Hodgkin Lymphoma, including 4 objective responses in 8 pts with peripheral T-cell lymphoma (PTCL) (Witzig et al., 2011). Building on this prior experience, we report herein the preliminary efficacy, safety and biomarker data from our ongoing Phase 2 study in PTCL.

Aims: This Phase 2 study is a multi-institutional, single-arm, open-label, two-stage (11+7) study designed to determine the efficacy and safety of tipifarnib in pts with relapsed/refractory (R/R) PTCL.

Methods: Pts with R/R PTCL after prior cytotoxic systemic therapy, aged ≥ 18 years old, and with a performance status of 0-2 were eligible. Informed consent was obtained. The following subtypes of PTCL were eligible for enrollment: PTCL-NOS, ALK-positive and -negative anaplastic large cell lymphoma (ALCL), hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma (EATL), extranodal natural killer (NK) T-cell lymphoma, nasal type and subcutaneous panniculitis-like T-cell lymphoma. The primary endpoint of the study is overall response rate. Secondary endpoints include safety and tolerability, duration of response (DOR) and progression free survival (PFS). Based on activity observed in the first 18 pts in the study, the protocol has been amended and enrollment is ongoing to an expansion cohort in PTCL (N=12). Enrolled pts are treated with tipifarnib 600mg administered orally twice daily on days 1-7 and 15-21 of 28-day treatment cycles until progression of disease or unacceptable toxicity. Biomarker studies included gene expression profiling of pre-treatment tumor biopsies by RNASeq and DNA next-generation sequencing (NGS). Clinical trial information: NCT02464228.

Results: At data cut-off (2/15/2017), 18 pts (2 ATL, 1 ALK-ALCL, 15 PTCL-NOS) were treated with tipifarnib. Most common treatment-related AEs (grade ≥3) were myelosuppression, including neutropenia (61%), anemia (39%) and thrombocytopenia (39%). 3 pts achieved a partial response (2 ATL; 1 PTCL-NOS) and 3 additional pts experienced stable disease >6 months. Tumor DNA from 18 pts was sequenced using NGS. A high rate of CXCL12 3'UTR single nucleotide variation (SNV) was observed. Seven of 16 pts carried the rs2839695 variant while an additional patient carried a novel variant. The presence of 3'UTR SNVs was associated with low levels of CXCL12 gene expression and disease progression (Figure) while all pts deriving clinical benefit from tipifarnib carried reference (wild-type) 3'UTR CXCL12 and had tumors that expressed high levels of mRNA for this chemokine. Testing of circulating CXCL12 levels is ongoing.

Summary/Conclusions: Although this study is ongoing, these preliminary data indicate that tipifarnib is generally well-tolerated and has antitumor activity, particularly in pts with AITL histology, absence of 3'UTR CXCL12 SNV and high levels of CXCL12 gene expression.

Figure 1.
Bone marrow failure syndromes incl. PNH - Clinical

P573

ANALYSIS OF MICRONAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

F. Fioredda1,*, F. Pierri1, C. Micalizzi1, M. Calvillo1, E. Palmisani1, I. Ceccherini2, N. García-Barberá2, C. Martínez2, J.C. Espín3, V. Vicente1,2, I. Martínez1,2,*

Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disease caused by the lack of glycosyl biosulfated protein anchored proteins at the cell membrane that leads to intravascular hemolysis upon complement activation. Patients have intravascular haemolysis with high risk of thrombosis, and a variable degree of bone marrow failure. Treatment with Eculizumab reduces intravascular hemolysis and also the thrombotic risk. The mechanism of thrombosis in PNH is still unknown. Exosomes are extracellular vesicles released by cells and whose secretion is closely related with the inflammatory status. Exosomes participate in cell communication by activating signaling pathways and transferring genetic material, i.e. miRNA, and proteins to host cells.

Aims: To describe the microRNAome, proteome and metabolome of exosomes from PNH patients to identify potential biomarkers of the disease and to investigate its relationship with the mechanism of thrombosis in these patients.

Methods: Plasma exosomes were isolated from 5 healthy controls and from 9 PNH patients (6 with Eculizumab, 3 with thrombosis –ET– and 3 without Eculizumab) using Total Exosome Isolation kit (ThermoFisher). miRNA expression was evaluated by plasma/serum focus miRNAs PCR panel V4 (Exiqon). Proteomic analysis of exosomes was performed at the OMIcs core facilities. Untargeted metabolomic analysis was performed by using combination of gas chromatography and liquid chromatography (LC) with mass spectrometry (MS). Additionally, latest advances were used combining LC-MS-solid phase extraction-nuclear magnetic resonance (UPLC-QTOF_SPE_NMR) on line for unequivocal structural elucidation of unknown metabolites.

Results: Mir-16-5p and mir-451a had lower levels in patients vs controls. Eculizumab treatment increased their expression, particularly in the group with thrombosis. Eculizumab also decreased mir-223-3p (the most abundant miRNA in platelets and that has been associated with its activity) and increased mir-15a-5p levels (0.5- and 3.12-fold respectively). Those proteins differentially expressed in patients and controls were related with the complement system and the immune response. We identified an increase in the plasma hemo-globin levels in patients vs controls (4.9-fold), which is related with platelet activation. It is also noteworthy the decrease (1.5-fold) of the anticoagulant Protein S in patients vs controls. When the analysis was performed among the 3 groups of patients, only Ig heavy chain V4 region HG3 increased in 3.9-fold in the Eculizumab group vs without Eculizumab group, which could be related with the treatment. We identified quite few metabolites inside the exosomes, all of them associated with cell toxicity or immune response. The levels of Cholesterol, HydroxyTerbinafine-glucuronide and Diacyl-glycerol decreased in 17.3, 17.6 and 19.4-fold, respectively in patients treated with Eculizumab. Interestingly, the Aminoethylphosphonic acid, Cholesterol and PGF2 increased 16.7-, 21- and 19.4-fold in patients with thrombosis.

Summary/Conclusions: Our study supports that exosomes contain material that may influence the pathological status of the PNH patients. In concordance, most of the proteins, miRNAs and metabolites are related with the complement system or the inflammatory response. In future experiments, some of the proteins, miRNAs and metabolites should be validated to define whether they could be considered biomarkers.

P574

Abstract withdrawn.

P575

SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNEDEFICIENCY AS CAUSATIVE AGENTS. A SINGLE CENTER DATA

F. Fioredda1,*, F. Pierri1, C. Micalizzi1, M. Calvillo1, E. Palmisani1, I. Ceccherini2, A. Grossi3, M. Lanciotti1, P. Terranova1, T. Lanza1, M. Miano1, C. Dufour1

Background: Severe Chronic Neutropenia may be a primary disease, usually defined as congenital (CN), or a condition mainly secondary to autoimmune disturbances (SN). CN rises in early infancy, has a narrow block at pro/myelocyte, classically carries genes ELANE/HAX1 mutations in 70% of cases and is G-CSF dependent. SN is accompanied by extraheamotological signs and/or positivity of autoimmune markers; bone marrow has a normal morphology or is "left shifted". In spite of these categorization many cases do not fit any group and share features of both of them. These "Overlap Neutropenia" (ON) patients are a diagnostic and management challenge.

Aims: Investigate the genetic background of this ON from a cohort of chronic neutropenia subjects screened at Haematology Unit of Gaslini Hospital and characterize their clinical phenotype.

Methods: Patients with severe chronic neutropenia were seen prospectively in our center and diagnosed/followed-up according to published guidelines(3,4). Genetic diagnosis includes classical Sanger technique for commonest severe chronic neutropenia genes and an enlarged NGS panel including also those genes responsible for PID.

Results: From 2008 to 2016, 24 patients (13 males) with median age at last follow of 18yrs (range 28 mo-51y) had a complete work up for severe chronic neutropenia (Table 1). Ten/24 subjects (43%) were diagnosed as classical CN with ELANE mutation found in the majority (80%) of cases. Seven/24 (29%) were diagnosed as SN and the remaining 7/24 (29%) as ON. A PID genes mutation was found in a total of 8/24 patients (30%) with 5 patients belonging to 7 SN subjects (71%) and 3 to the 7 ON subjects (42%). Table 1 shows clinical hematological characteristic of the 3 categories of patients.

Summary/Conclusions: A considerable portion (30%) of subjects affected with severe chronic neutropenia have been identified as PID. In the group of ON subjects a mutated PID gene was found in 3/7 patients and mutations of ELANE in 2/7 patients. No mutation was found in the remaining 2. The phenotype of ON subjects is characterized by extra-hematological autoimmune symptoms, by maturation block and by the frequent involvement of more than one hematopoietic lineage. This phenomenon may suggest to access to an enlarged genetic panel including PID genes for genetic diagnosis. An accurate immunological and genetic work may support diagnosis and management of these difficult patients.

Table 1.

References

P576

TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS

J. Tjon1, L. de Wreede2, F. Falkenburg1, M. de Grooth3, H. Koene4,
Acquired aplastic anemia (AA) is a rare disease characterized by bone marrow failure that results in pancytopenia and infections and graft-versus-host disease (GVHD) and was considered a barrier to the wider application of haplo-SCT in SAA patients. We provided the kinetics for immune recovery in SAA

Background: We aim to provide the kinetics for immune reconstitution in SAA patients after they complete haplo-SCT. Our results may be useful for differentiating and assessing the impact of immune cell subset recovery on transplant outcomes. We examined immune cell subset counts and immunoglobulins in 81 SAA patients from day 30 to day 365 after haplo-SCT. The immune cells analyzed in this study including lymphocyte, monocyte, CD3+ T cell, CD8+ T cell, CD4+ T cell, CD4-CD8- T cell, CD8+CD28+ T cell, CD4+CD28- T cell, CD4+ memory T cell and CD4+ naïve T cells. Simultaneously, we determined which factors influence immune reconstitution and analyzed the effect of immune cell subsets on transplant outcomes.

Results: (i) The reconstitution of different immune cell subsets occurred at different rates after haplo-SCT. Monocytes were the first to recover, followed by CD8+ T and CD19+ B cells, and finally CD4+ T cells. Early CD4+ T cell recovery occurred at the expense of memory cells, whereas naïve CD4+ T cells rose only 9 months after SCT. (ii) In the multivariate analysis, lower recipient age, female gender, high mononuclear cell counts and CD4+ T cell counts in the graft were associated with improved immune recovery after transplant. (iii) A CD4/CD8 ratio less than 0.567 on day 30 post-transplantation was associated with lower treatment related mortality and higher overall survival after haplo-SCT in SAA patients.

Summary/Conclusions: We provided the kinetics for immune recovery in SAA patients who received haplo-SCT. In general, our study demonstrated that the recovery of monocyte and CD8+ T cells was fast in SAA patients, whereas the recovery of the CD4+ T cell subset was delayed. In addition, our data suggested that the CD4/CD8 ratio may be useful for predicting transplant outcomes in SAA patients after they complete haplo-SCT. Our results may be useful for making better predictions and modulating the IR of SAA patients, which would subsequently improve the outcomes after transplantation.

Methods: To evaluate the safety and efficacy of first line treatment using ATGAM and ciclosporin in adult patients with acquired aplastic anemia in the Netherlands.

Aims: To evaluate the kinetics for immune reconstitution in SAA patients after they complete haplo-SCT. Our results may be useful for differentiating and assessing the impact of immune cell subset recovery on transplant outcomes.

Results: (i) The reconstitution of different immune cell subsets occurred at different rates after haplo-SCT. Monocytes were the first to recover, followed by CD8+ T and CD19+ B cells, and finally CD4+ T cells. Early CD4+ T cell recovery occurred at the expense of memory cells, whereas naïve CD4+ T cells rose only 9 months after SCT. (ii) In the multivariate analysis, lower recipient age, female gender, high mononuclear cell counts and CD4+ T cell counts in the graft were associated with improved immune recovery after transplant. (iii) A CD4/CD8 ratio less than 0.567 on day 30 post-transplantation was associated with lower treatment related mortality and higher overall survival after haplo-SCT in SAA patients.

Summary/Conclusions: We provided the kinetics for immune recovery in SAA patients who received haplo-SCT. In general, our study demonstrated that the recovery of monocyte and CD8+ T cells was fast in SAA patients, whereas the recovery of the CD4+ T cell subset was delayed. In addition, our data suggested that the CD4/CD8 ratio may be useful for predicting transplant outcomes in SAA patients after they complete haplo-SCT. Our results may be useful for making better predictions and modulating the IR of SAA patients, which would subsequently improve the outcomes after transplantation.

Methods: To evaluate the safety and efficacy of first line treatment using ATGAM and ciclosporin in adult patients with acquired aplastic anemia in the Netherlands.

Aims: To evaluate the kinetics for immune reconstitution in SAA patients after they complete haplo-SCT. Our results may be useful for differentiating and assessing the impact of immune cell subset recovery on transplant outcomes.

Results: (i) The reconstitution of different immune cell subsets occurred at different rates after haplo-SCT. Monocytes were the first to recover, followed by CD8+ T and CD19+ B cells, and finally CD4+ T cells. Early CD4+ T cell recovery occurred at the expense of memory cells, whereas naïve CD4+ T cells rose only 9 months after SCT. (ii) In the multivariate analysis, lower recipient age, female gender, high mononuclear cell counts and CD4+ T cell counts in the graft were associated with improved immune recovery after transplant. (iii) A CD4/CD8 ratio less than 0.567 on day 30 post-transplantation was associated with lower treatment related mortality and higher overall survival after haplo-SCT in SAA patients.

Summary/Conclusions: We provided the kinetics for immune recovery in SAA patients who received haplo-SCT. In general, our study demonstrated that the recovery of monocyte and CD8+ T cells was fast in SAA patients, whereas the recovery of the CD4+ T cell subset was delayed. In addition, our data suggested that the CD4/CD8 ratio may be useful for predicting transplant outcomes in SAA patients after they complete haplo-SCT. Our results may be useful for making better predictions and modulating the IR of SAA patients, which would subsequently improve the outcomes after transplantation.

Methods: To evaluate the safety and efficacy of first line treatment using ATGAM and ciclosporin in adult patients with acquired aplastic anemia in the Netherlands.

Aims: To evaluate the kinetics for immune reconstitution in SAA patients after they complete haplo-SCT. Our results may be useful for differentiating and assessing the impact of immune cell subset recovery on transplant outcomes.
tation and past medical history—and were asked to provide their differential diagnosis and the tests they would order to establish the diagnosis in free-text format. To reduce bias, Delphi panelists were blinded to the fact that the study was focused on PNH. Responses mentioned by ≥50% of Delphi panelists in the first round were included in the second-round questionnaire. For each case in the second-round questionnaire, Delphi panelists were presented with a series of consensus statements regarding potential diagnoses and the need for specific tests/data from a multiple-choice list and asked to respond with their level of agreement on a 4-point Likert scale. Consensus in the second round was attained if ≥80% of Delphi panelists agreed on a given screening or diagnostic approach.

Results: Twelve Delphi panelists from 6 countries, all of whom were clinicians with expertise in PNH, were recruited. Consensus was reached on 22 of 23 PNH screening and diagnostic decision points identified by the Delphi panelists. Specifically, consensus was gained on the core symptoms and signs of PNH at presentation, including hemolysis, bone marrow dysfunction, and thrombosis. Consensus was reached in 36 of 38 screening and diagnostic tests required at each decision point to narrow the differential diagnosis and to confirm the diagnosis of PNH. The level of agreement on screening and diagnostic decision points and tests was sufficient to enable the development of a screening and diagnostic algorithm (Figure) that is consistent with the published literature and with the real-world experience of the international expert advisory committee.

Summary/Conclusions: The modified Delphi methodology facilitated development of a consensus-based, clinically relevant PNH screening and diagnostic algorithm. This algorithm provides clinicians with varying levels of expertise detailed guidance on how to screen for and diagnose PNH.

P579

DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS

B. Van Dooijeweert1,*, M. Bierings2, A. MacInnes3, M. Bartels4
1Pediatric Haematology, clinical research, 2Pediatric Haematology and Stem Cell Transplantation, Wilhelmina Children’s Hospital, Utrecht, 3EuroDBA, genetic, metabolic diseases, AMC, Amsterdam, 4Pediatric Haematology and Oncology, Wilhelmina Children’s Hospital, Utrecht, Netherlands

Background: Diamond-Blackfan anemia (DBA) is a rare genetic disorder, characterized by bone marrow failure (anemia), congenital anomalies and a pre-disposition for malignancies. DBA is characterized by a highly heterogeneous nature, both clinically and genetically. Most of our understanding of this disorder stems from molecular studies combined with extensive data-input from international patient registries.

Aims: The aim of our retrospective study was to create an overview of the pediatric DBA population in the Netherlands.

Methods: Forty-four patients (age 0-18y) diagnosed with DBA from all Dutch pediatric hematologists included in this study. Molecular genetic tests were collected from patient records.

Results: Congenital malformations were present in 19/41 patients (46.3%), varying from craniofacial and cardiac defects to urogenital and developmental disorders. An underlying genetic defect was identified in 23 patients (56.1%), the majority of which were found in the RPS19 gene (n=10; 45%). No significant diversities in malformations, course of disease or response to treatment were observed when comparing patients with or without identified genetic defects.

In agreement with previous reports, two patients harboring defects in RPL11 displayed a more severe phenotype, including craniofacial malformations, thumb abnormalities, and cardiac defects. In contrast, our patient with a mutation in RPL5 has no associated congenital abnormalities, while previous studies reported a very high frequency (83%) of associated congenital defects. Furthermore we observed a relatively high number (12/23) of novel mutations in well-known DBA-genes, defined as novel variants. In addition, we have identified a novel RPS19 gene defect in RPL9, in a patient with multiple congenital abnormalities (craniofacial defects, cardiac defects, colitis) in addition to severe anemia. Thirty-four (34/44) patients were treated with glucocorticoids, of which in thirty-one (31/34) patients a complete response was observed (91.2%). However, in 29% discontinuation was prompted by high-dosage-dependence, side effects, a weaning response, or a combination of these factors. Five patients (12.2%) were successfully transplanted with hematopoietic stem cells from either matched sibling donors (n=3) or matched unrelated donors (n=2), including two cases after the age of 10 years. Eleven patients (26.8%) were treatment-independent, defined as acceptable hemoglobin levels without any therapy. No malignancies were thus far reported.

Summary/Conclusions: In line with previous reports, the Dutch pediatric DBA population is both clinically and genetically heterogeneous, with RPS19 being the most frequently mutated gene. Interestingly, the majority of mutations in our cohort have not been described before, probably further underlying clinical heterogeneity. In addition, we have identified a novel RPS19 gene defect in RPL9, associated with a more severe phenotype, based on multiple associated congenital defects. While we created a comprehensive overview of the Dutch pediatric DBA population, limitations of our study include a relatively small number of patients, and the lack of complete genetic analysis (for all DBA candidate genes) in a relevant number of patients. Overall, to increase our understanding of genotype-phenotype correlation in DBA, and underlying pathophysiological mechanisms more generally, it crucial to further extend our clinical, and functional analysis of DBA-candidate genes, as well as compare, and share data from international registries.

P580

NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES

E. Galvez1,2, E. Sebastian1, L. Madero1, A. Catalá2, C. Bellende2, C. Diaz de Heredia2, A. Galera3, D. Plaza3, E. Badei2, E. Vallespin3, P. Labunzina3, R. Perona3,1Hospital Infantil Niño Jesús, Madrid, 2Grupo fallos medulares SEHOP, Barcelona, 3Grupo fallos medulares SEHOP, Madrid, 4Grupo fallos medulares SEHOP, Valencia, 5CIBERER, Madrid, 6CIBERER, Barcelona, Spain

Background: Inherited bone marrow failure syndromes (IBMFSs) are a heterogeneous group of genetic disorders, with similar clinical presentations, resulting in complex diagnosis. Molecular characterization is essential in order to establish diagnosis, treatment and prognosis. Next-generation sequencing (NGS) techniques seem to be a useful platform for genetically defining different IBMFSs.

Aims: To design a NGS panel with the objective of making a specific, fast and cost-effective diagnosis for these pathologies.

Methods: We developed a NGS panel of 164 genes involved in different IBMFSs. A total of 120 samples have been processed. Patients were classified into two groups based on the clinical presentation: classified IBMFS (CBMFS) for those with a clinical picture typical of some of these disorders, and unclassified IBMFS (UBMFS) for the others. For the NGS study the NextSeq platform of Illumina (Roche) has been used. Bioinformatic analysis has been oriented to the identification of point polymorphisms (SNPs) and insertions / deletions of small DNA fragments.

Results: Of the 120 samples processed, 10% (12/120) was not suitable for analysis. A total of 108 patients were studied. In 59.3% (64/108) causal mutations were detected. From the total samples analyzed (108), 75% (81/108) were included in the CBMFS patient group, obtaining a diagnostic yield of 64.2% (52/81). The remaining 27 patients (25%) were included in the UBMFS group and we found causal mutation in 37% (10/27). Therefore, it remains a percentage of patients without a genetic diagnosis, which seems more evident in the UBMFS group. This could be explained by the fact that the causal gene has not been described or due to the limitations of the technique.

Summary/Conclusions: NGS techniques are a fast and cost-effective option for the diagnosis of IBMFSs patients. In our series, we have reached a diagnosis rate of 93.3%, coinciding with that described in the literature. Undiagnosed patients should be included in new research projects.

P581

APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY

E. Nevill1,*, D. Sanford1, D. Foresti1, D. Hogge1, Y. Abou Mourad1, R. Broady1, M. Bennett1, M. Power1, G. Toze1, K. Song1, S. Nantel1, S. Narayanan1, A. Gerrie1, H. Sutherland1, B. Dalal2, T. Nevill1
1Leukemia/BMT Program of BC, 2Division of Hematopathology, Vancouver General Hospital, Vancouver, Canada

Background: Aplastic anemia (AA) is a bone marrow failure syndrome that can be successfully treated with either immunosuppressive therapy (IST) or autologous bone marrow transplantation (BMT). In ~50% of patients (pts) with AA, a clone deficient in glycosylphosphatidylinositol (GPI)-linked antigens—a paroxysmal nocturnal hemoglobinuria (PNH) clone—can be detected (Young, Blood, 2011). In recent years, new sensitive techniques have been developed to test for PNH clones that have primarily focused on evaluating peripheral blood white cells. Neutrophils are routinely tested for expression of GPI with fluorescent eosinyl (FLAER); monocytes may also be analyzed but are not always evaluated in PNH testing. Our centre has previously reported that 60% of PNH positive tests show a higher monocyte clone than granulocyte clone and that there was >10% difference in 20% of these discrepant results (Razavi, ISLH Proceedings, 2015). Whether pts with discordant monocyte and granulocyte PNH clones have different clinical characteristics and/or response to IST has not been reported to date.

Aims: To compare the granulocyte and monocyte PNH clones in pts with AA to determine whether there are differences in clinical presentation and/or response to IST for pts with discordant clone sizes.

Methods: A retrospective review was performed on all patients >16 treated with IST at VGH, the tertiary referral centre for the Province of BC, between 11/09 and 10/15. All patients had central pathology review and metaphase cytogenetic analysis that confirmed a diagnosis of AA. High-sensitivity flow cytometry testing with a sensitivity of 0.1% was done on all patients.
to detect the presence of a PNH clone. Granulocytes, monocytes and erythrocytes were interrogated with multi-colour flow panels including CD59 and FLAER. The criteria for determining discordant granulocyte and monocyte clone sizes was dependant upon the absolute size of the smaller clone. For clones 0.1-10%, discordance was defined as when the larger clone was either ≥2 x the smaller clone or at least 1% (absolute value) greater. For smaller clones >10%, the larger clone had to be ≥110% its size. IST was uniform - Cyclosporine (CSA, 2.5mg/kg p.o. b.i.d.), anti-thymocyte globulin (ATG; ATGAM® 40mg/kg IV daily x 4 days) and (Methyl)prednisolone 1mg/kg/dx 10 days). CSA doses were adjusted to maintain whole blood trough CSA level of 200-300 μg/L for 12-months followed by slow taper based upon hematologic response. Non-responders at 6 months were eligible to proceed to either a second cycle of ATG or BMT, if a suitable donor was available. Severity of AA [very severe (VSA), severe (SA) or non-severe (NSA)] and response to IST ([none, partial (PR) or complete (CR)]) were determined according to published criteria (Marsh, Br J Haematol, 2009). Statistical comparisons were done using a standard Chi square analysis.

Results: 30 pts with AA and a PNH clone were identified, 18 females and 12 males with median age of 50.5 years (range 17-71). There were 14 pts with NSA, 13 with SAA and 3 with VSA. Responses were seen in 20/30 pts (66.7%) including 13 PR and 7 CR. Six pts relapsed with CSA tapering and 5 responded to intensified IST. 2 pts required Eculizumab after evolving to a classic PNH phenotype. Six pts underwent BMT for primary non-response and 4 pts have died (2 post-BMT, 1 from complications of AA and 1 from breast Ca); 26 pts remain alive and well with a median follow-up of 48 mos (15-86). There were 17 pts (56%) with concordant granulocyte and monocyte clone sizes (Group 1), 4 pts (13%) had granulocyte-dominant disease (Group 2) and 9 pts (30%) had monocyte-dominant disease (Group 3). Group 3 pts were significantly more likely to have NSA and showed a trend toward an inferior response rate to IST (Table 1).

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (yrs)</td>
<td>48.5</td>
<td>41.3</td>
<td>NS</td>
</tr>
<tr>
<td>Severity of AA</td>
<td>VSA/SAA</td>
<td>VSA/SAA</td>
<td>VSA/SAA</td>
</tr>
<tr>
<td>NSA</td>
<td>10/7</td>
<td>2/9</td>
<td>0.028</td>
</tr>
<tr>
<td>Response rate (%)</td>
<td>12/17 (70.6%)</td>
<td>4/4 (100%)</td>
<td>4/4 (100%)</td>
</tr>
<tr>
<td>CSA</td>
<td>4/4</td>
<td>7/7</td>
<td></td>
</tr>
<tr>
<td>CsA</td>
<td>0/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months CR</td>
<td>4/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months PR</td>
<td>4/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months CR</td>
<td>4/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months PR</td>
<td>4/4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Flow cytometry for a PNH clone is routinely done in AA although it may be important to evaluate both granulocyte and monocyte clone sizes. Pts with a larger monocyte than granulocyte clone size more frequently have NSA and appear to have a lower response rate to IST. This may have therapeutic implications and could identify a population of pts requiring a unique therapeutic approach.

P582
RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 29 YEARS
M. Oelmüller1, F. Alashkar1, D. Herich-Terhürne1, U. Dührsen1, A. Röth1
1Department of Hematology, University Hospital Essen, Essen, Germany

Background: Aplastic anemia (AA) is a rare, usually acquired disorder characterized by bone marrow failure with bi- or pancytopenia and marrow hypoplasia. The classification into the three main subtypes is of prognostic and therapeutic relevance. Depending on disease severity, patient's age, and the availability of a potential HLA-identical donor, different therapeutic strategies are favored. Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine (CsA) is considered as the mainstay of IST. A hematologic recovery is seen in up to 60-70% of the pts following horse-ATG (hATG) treatment, compared to 35-53% in rabbit-ATG (rATG) treated pts, considering hATG as first-line therapy in AA pts.

Aims: As response rates vary according to the different studies and the source of ATG being used, our aim was to retrospectively evaluate response rates in pts with AA receiving IST at the Department of Hematology at the University Hospital of Essen between 1988 until 2015.

Methods: In this single-center, retrospective analysis, approved by the institutional review board of the University Hospital Essen, 33 pts were included. When treated or monitored at the Department of Hematology between 1988 until 2015. 73% of the pts (49/67) were treated with hATG (ATGAM® (44/49) vs >50 yrs: 43% (13/30); p<0.001). In primary refractory pts (34% (23/67)) (52% (12/23) in first-line treated hATG pts vs 48% (11/23) rATG treated pts) a second course with either hATG (3/9) or rATG (6/9) was initiated, achieving an overall hematologic recovery at 6 months in 3 pts (33% (1/3) hATG vs 33% (2/6) rATG treated pts). A disease relapse (median: 13 months after primary ATG therapy) was seen in 11 out of the 44 pts with primary hematologic recovery (25%) (82% (9/11) in first-line treated hATG pts vs two rATG treated pts). A salvage therapy with rATG was initiated in two pts, whereas in one other pt a second course with hATG was started. An overall response following relapse therapy was observed in 33% of the pts (1/3). Four refractory as well as relapsed pts were treated with eltrombopag respectively (final results are still awaited). A secondary HSCT (hematopoietic stem cell transplantation) was performed in 11 out of the 67 pts (16%), either being primary refractory or due to a disease relapse.

Summary/Conclusions: Our data are able to independently confirm the findings of previous studies concerning hematologic recovery rates in pts with acquired AA following IST with ATG by providing further evidence that rATG plus CsA is inferior to hATG plus CsA when administered as a first-line treatment. In addition, we were able to observe in pts ≤50 yrs, irrespective gender, an overall higher hematologic recovery. For this reason, it remains unclear why ATGAM® is still not approved in Germany as first-line therapy in pts with AA, as the only hATG product registered in Europe (Lymphoglobulin®) was withdrawn from the market in 2007.
Chronic lymphocytic leukemia and related disorders - Biology 2

P583
NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
F. Pozzo1,1*, T. Bitto1, E. Vendramini1, R. Bomben2, P. Builian3, F.M. Rossi4, A. Zucchetto5, E. Tissino5, M. Degani5, G. D’Arena6, F. Di Raimondo6, F. Zaija6, G. Pozzato7, D. Rossi8, G. Gaidano8, G. Del Poeta9, V. Gattel1, M. Dal Bo1
1Clinical and experimental Onco-hematology unit, Centro di Riferimento Oncologico, Aviano, 2Onco-Hematology Department, Centro di Riferimento Oncologico–Department of Translational Medicine, University of Eastern Piedmont, Novara, 3Division of Hematology–Department of Translational Medicine, University of Eastern Piedmont, Novara, 4Division of Hematology, S.Eugenio Hospital and University of Tor Vergata, Rome, Italy

Background: Stabilizing mutations of NOTCH1 have been identified in about 10% of chronic lymphocytic leukemia (CLL) cases at diagnosis, with a higher frequency in unmutated IGHV-UM (IGHV-UM)-immunocompromised or advanced disease phase CLL, and have been associated with particularly unfavourable prognosis (Rossi et al, Blood, 2012; Del Poeta et al, Br J Haematol, 2013; Stilgenbauer et al, Blood, 2014). In CLL, all NOTCH1-mut cases were previously found higher in NOTCH1-wt cases in the IGHV UM subgroup. ii) Western blotting in 11 CLL cases (5 NOTCH1-mut) confirmed a higher NPM1 protein expression in NOTCH1-mut cases, with a direct correlation with NOTCH1 expression (r=0.814). In NOTCH1-mut cases, the NPM1high subpopulation, isolated by cell sorting, showed a higher NOTCH1 mutational load than the NPM1low subpopulation. iii) EDTA treatment of 12 CLL cases (6 NOTCH1-mut) activated NOTCH1 signaling (Rand et al, Mol Cell Biol, 2010), as from HES1 and DTX1 induction, and upregulated NPM1 and other RNPs. The same results were confirmed by co-culture of CLL cells with the JAGGED1-expressing M2-10B4 stromal cells. Inhibition of NOTCH1 signaling by gamma-secretase-inhibitor L-685,458 or by siRNA for NOTCH1 reduced NPM1 expression (Fig. A). iv) Previous studies identified MYC as a direct transcriptional target of NOTCH1 (Browne et al, PNAS 2014) and, in turn, a transcriptional activator of both NPM1 and RNPs. ChIP assays on MEC1-cells, transfected with exogenous NICD, revealed increased NICD binding to the MYC promoter, along with higher expression of MYC, NPM1, and RNPs. Of note, after 48 h culture, NOTCH1-mut CLL cases showed increased MYC transcript levels than NOTCH1-wt cases. MYC expression was further increased upon NOTCH1 activation by EDTA or by stromal cells co-cultures (Fig. B). MYC silencing by siRNA efficiently reduced NPM1 transcript and protein expression. Moreover, Cpg-ODN-2 treatment, to induce MYC overexpression, also increased NPM1 transcript and protein levels in CLL cells. v) NPM1 silencing by siRNA was able to reduce proliferation rates and cell size of both NICO-transfected cells and control cells. In keeping with a NOTCH1-driven regulation of cell growth/protein biosynthesis, activation of NOTCH1 signaling in 12 CLL cases (6 NOTCH1-mut) by EDTA or stromal cells co-culture, induced an increase in cell size.

Summary/Conclusions: NOTCH1 mutations in CLL are associated with the overexpression of MYC and MYC-related genes involved in protein biosynthesis including NPM1, which are allegedly responsible for cell growth and/or proliferation advantages of NOTCH1-mut CLL.

P584
CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP
I. Criado1,*, A. Rodríguez-Caballero1, L. Gutierrez1, C.E. Pedreira1, W.G. Nieto1, C. Teodosio1, V. Herraez 1, A. Romero-Furones 2, P. Fernández-Navarro 3, J. Almeida1, A. Orfao1
1Department of Medicine, Center for Cancer Research, 2Centro de Atención primaria de Salud Miguel Arrigo, 3Centro de Atención Primaria de Salud de Ledesma, Salamanca, Spain

Background: The presence of very low numbers of clonal B cells in peripheral blood (PB) of otherwise healthy individuals (low-count monoclonal B lymphocytosis-MBLlo) is a common finding in the general population. The majority of clonal B cells from MBLlo subjects show a phenotype overlapping with CLL (chronic lymphocytic leukemia) cells, the former might represent either the normal counterpart of CLL or the earliest stages of the disease. Little information exists about both the clinical outcome of MBLlo subjects and the biological features of their B-cell clones over time.

Aims: To gain insight into the biological and clinical significance of the presence of CLL-like MBLlo clones, we re-evaluated the biological features of clonal B cells and the clinical outcome of MBLlo individuals after 7 years of follow-up.

Methods: The baseline study was conducted in 2008, when 80 out of 639 (12.5%) healthy individuals (>40y) were found to carry at least 1 MBLlo clone. A GEP of these clonal B-cell population, using high-sensitive flow cytometry. A subset of them (n=49) has been followed for a median period of 84 months (range: 67-95 months). Besides physical examination and flow cytometry analyses, the most frequent CLL-related cytogenetic alterations [del(13q14.3(D13S25)), trisomy 12, del11q(ATM) and del17q(TP53)] were studied at baseline and at follow-up.

Results: A total of 64 CLL-like MBLlo clones (median size: 0.44 cells/ul, range: 0.027-66 cells/ul) were detected in PB of the 49 subjects at recruitment (in 15 cases ≥2 B-cell clones were detected in the same subject). In all subjects, B-cell clones persisted at reevaluation, phenotypically identical vs baseline. Interestingly, we found a near 6-fold overgrowth of CLL-like MBLlo clones after 7 years follow-up vs baseline (median size: 1.22 cells/ul, range: 0.046–789 cells/ul; p<0.001); in line with this, most clones (45/64; 70%) increased their size, while the remaining 30% maintained stable or slightly decreased numbers compared to time 0. From the genetic point of view, only 8/32 (25%) clones showed a subclone carrying one of the most common aberrations (del(13q), del11q, del17q) at baseline. Three clones (8%) harbored a near 6-fold overgrowth after 7 years. The same results were being present in 7/8 cases and trisomy 12 in the remaining one. Strikingly, re-evaluation after 7 years showed 36/56 clones (64%; p<0.01 vs baseline) with cytogenetic alterations; again, the most common abnormality was del13q(D13S25) (34/36) followed by trisomy 12 (36) and del17p(TP53) (13/36). The statistical analysis (p<0.05) was found between 0.05 and 0.10 in the over-time in the size of these clones and the presence of cytogenetic lesions. Three subjects developed lymphomacytosis (median: 5.3x109lymphocytes/l; range: 4.1x109-5.9x109/l) after 7 years; in these cases the clone size increased sub-
Summary/Conclusions: Our results suggest that CLL-like MBLlo is not a transient condition, as all clones detected at recruitment were systematically present also at follow-up with an increase in frequency of cytogenetic lesions. Despite, B-cell clones slightly increased in size of the majority of MBLlo when compared to MBLhi/CLL. More recent studies however revealed an important role of LADs in the regulation of gene expression and recombination. Aims: Given the apparent topological coincidence between LADs and Ig variable clusters, we hypothesised that nuclear lamina might play a paramount role in the dynamics of Ig-encoding variable genome domains. In particular, here we tested whether Lamin B1, a principal LAD-associated component of the nuclear envelope, had any restrictive role on somatic hypermutation (SHM) and the expression of Ig genes. Due to the strong involvement of IgV mutations in the pathogenesis of B-cell malignancies, we also tested whether nuclear lamina is involved in the pathogenesis of germinal centre lymphomas and chronic lymphocytic leukaemia (CLL).

Methods: We used BL2 and naïve B cells as in vitro and ex vivo models for somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation. ChIP-Seq, ChIP-PCR and ImageStream analyses were performed to establish Lamin B1 genome and nuclear binding dynamics in somatic hypermutation.

Results: We have found that genome binding of Lamin B1, a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B cell activation and formation of lymphoid germinal centres. ChIP-Seq analyses revealed a more frequent and heavy variable immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells. RNAi-mediated reduction of Lamin B1 resulted in spontaneous SHM as well as kappa-light chain aberrant surface expression. Finally, Lamin B1 expression level correlated with progression-free and overall survival in chronic lymphocytic leukemia, and was strongly involved in transformation of follicular lymphoma.

Summary/Conclusions: In summary, here we report that Lamin B1 is a negative epigenetic regulator of SHM in normal B-cells and a "mutational gatekeeper", suppressing the aberrant mutations that drive lymphoid malignancy.
Background: B cell receptor (BCR) mediated signalling is crucial for the pathogenesis of chronic lymphocytic leukemia (CLL). Drugs such as ibrutinib and idelalisib which inhibit BCR associated kinases have proved effective for the treatment of CLL but only suppress the disease without being curative. Some patients have developed resistance to these drugs following mutations, progress on therapy for unknown reasons, or cannot tolerate these drugs due to adverse events. We have shown that microenvironmental signals (e.g., IL-4) can increase BCR expression and signalling, and can partially reverse the effects of BCR-kinase inhibition. GAB1, PTPN22 and FOXP1 can positively regulate BCR signalling in CLL but the effect of IL-4 on these proteins has not previously been investigated. Here we show that IL-4 promotes BCR signalling and can allow the development of novel drugs that overcome resistance to kinase inhibitors. Cerdulatinib (cerd) is an inhibitor of both Syk (pivotal to BCR signalling) and JAK1/3 (integral for IL-4 signalling). Inhibition of Syk has been shown to induce apoptosis of CLL samples resistant to ibrutinib. Cerd is currently in phase II clinical trials in patients with relapsed/refractory B cell malignancies including CLL.

Aims: To investigate the effect of IL-4 on the regulation of BCR signalling in CLL and how this is modified by cerdulatinib.

Methods: Eighteen primary CLL samples were treated with IL-4 +/-cerd (1μM) and expression of FOXP1, GAB1, PTPN22, SOCS1 and SOCS3 assessed by immunoblotting. The effect of cerd on apoptosis was assessed by flow cytometry and PI/Annexin V staining.

Results: Primary human CLL cells treated with IL-4 for 24hr significantly increased expression of positive regulators of BCR signalling FOXP1 and GAB1 in CLL samples with un-mutated IGHV (U-CLL); no change in expression in FOXP1 or GAB1 was seen in CLL samples with mutated IGHV (M-CLL). There was a 40% increase in PTPN22 expression in IL-4-treated U-CLL samples vs no change in M-CLL. Cerd, at therapeutic concentrations, blocked IL-4 mediated increases in FOXP1, GAB1 and PTPN22 and pSTAT6 (a positive control for IL-4 signalling). After 24hr IL-4 selectively increased expression of the negative regulators of IL-4 signalling, SOCS1 and SOCS3 in U-CLL, but not M-CLL cases, and this could be blocked by cerd. Cerd potently inhibited the expression of other cytokines known to play a role in CLL biology (IL-6, IL-10, IL-15, IL-21 and IFNγ) which utilise either JAK1 or JAK3 for activation of STAT proteins. IL-4, CD40L and BCR ligation signals to CLL cells in lymph nodes can promote resistance to therapies such as the BCL2-inhibitor venetoclax. We have shown that cerd can overcome IL-4/CD40L induced expression of pro-survival proteins MCL1 and BCLXL and that cerd in combination with veneto-clax induced apoptosis in a synergistic manner in the presence of IL-4/CD40L. We now extend these results to assess the importance of this drug combination in the presence of BCR stimulation. The combination of cerd and venetclox in the presence of either BCR signalling (bead immobilised anti-IgM) alone, or combined with IL-4 and CD40L, induced synergistic killing, with greater CLL cell death than with either drug alone.

Summary/Conclusions: These results provide evidence that IL-4 may increase BCR signalling by upregulating the expression of positive regulators of BCR signalling in U-CLL and that this can be overcome by cerd. These results support the continued use of cerd in clinical trials for the treatment of CLL, alone or in possible combination with venetoclax.
University of Birmingham, Birmingham, 4University of Leeds, Leeds, 5Nottingham University Hospitals NHS Trust, Nottingham, 6University Hospital of Wales, Cardiff, 7Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, 8Belfast City Hospital HSC Trust, Belfast, 9Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, 10Kings College Hospital NHS Foundation Trust, London, 11Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, 12The Christie NHS Foundation Trust, Manchester, United Kingdom

Background: Ibrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor which has advanced the clinical management of CLL. Ibrutinib binds irreversibly to the cysteine 481 residue of the BTK protein, rendering it inactive. Btk inhibition affects the phosphorylation of other intracellular kinases resulting in an immediate redistribution of CLL cells and subsequent apoptosis. We investigated the impact of ibrutinib on the phosphorylation of upstream and downstream kinases in the B-cell receptor pathway in real time in the IcICLLe study (ISRCTN12695342).

Aims: The IcICLLe trial was a single arm, multi-centre feasibility study of ibrutinib in two cohorts of CLL patients: (A) 20 treatment-naive (TN) requiring treatment (according to IWCLL criteria); and (B) 20 relapsed/refractory (RR). All patients received continuous oral therapy with ibrutinib (420mg once daily) from registration until disease progression. The primary endpoint of the trial was the proportion of patients achieving minimal residual disease (MRD) negative remission (depletion of CLL ≤0.01% in peripheral blood (PB) & bone marrow (BM)) within 6 months of trial treatment. Exploratory endpoints included the assessment of phosphorylation of intracellular kinases in the B-cell receptor pathway.

Methods: A panel of markers was assessed on PB & BM taken at screening, 1 & 6 months. PB was also taken at baseline (0 hours), 4 & 24 hours, 7 & 14 days, and 2, 8 & 12 months. The phosphorylation of Syk Y348, Btk Y551, ERK1/2, Akt S473 was assessed in 4 conditions at each time point: unstimulated, Syk inhibitor (5μM) or Btk inhibitor (10μM), or in combination. Baseline stimulation of ERK1/2 gave a 1.5-2 fold increase in phosphorylation after 6 months of therapy although the degree of phosphorylation decreased at later time points. Syk, Akt and ERK1/2 phosphorylation was unaffected by the addition of ibrutinib in vitro. The pattern of phosphorylation was found to be relatively consistent in responding patients. One patient with progressive CLL had sustained phosphorylation in all markers despite ibrutinib therapy.

Results: The phosphorylation of Btk, Syk, Akt and ERK1/2 was analysed in cells at the specified time points and conditions for 20 TN and 20 RR CLL patients. Baseline phosphorylation of all kinases was similar in both PB & BM. Phospho-Btk showed no stimulation on addition of IgM/IgD 4h after initiating therapy. There was a strong (2-4 fold) increase in phosphorylation of Syk kinase with IgM/IgD even in the presence of ibrutinib in vitro. This effect was profound in the first 2 months of ibrutinib therapy with a general decrease in phosphorylation after 6 months. Baseline stimulation of ERK1/2 gave a 1.5-2 fold increase in phosphorylation but the effect was abrogated within 1 month of ibrutinib therapy. Akt S473 phosphorylation was maintained after 6-12 months of therapy although the degree of phosphorylation decreased at later time points. Syk, Akt and ERK1/2 phosphorylation was unaffected by the addition of ibrutinib in vitro. The pattern of phosphorylation was found to be relatively consistent in responding patients. One patient with progressive CLL had sustained phosphorylation in all markers despite ibrutinib therapy.

Summary/Conclusions: The effect of ibrutinib on the phosphorylation of various kinases in the B-cell receptor pathway was analysed in real time. Syk continued to be phosphorylated over the course of treatment, which is logical as this kinase is upstream of Btk. That the degree of phosphorylation declined over time (even with stimulation) suggests a general inhibitory effect of ibrutinib on CLL cells. ERK1/2 phosphorylation is effectively blocked and there is partial reduction of phosphorylation of Akt S473. Combinations of Btk inhibitor with a Syk or PI3 kinase inhibitor may result in complete BCR blockade. Phosphorylation patterns may also act as an adjunct to ascertain the response to therapy.

P590

EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53

S. Post(1), H. J. Lee(2), M. Malard(3), X. Zhang(4), M. Hombaker(1)

1Leukemia, 2Lymphoma, MD Anderson, Houston, United States, 3CNIO, Madrid, Spain

Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with survival ranging from months to decades. CLL patients harboring TP53 alterations are well known to be refractory to standard therapies; however, recent studies indicate that ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, suppresses the B-cell receptor (BCR) signaling pathway and is an effective treatment option for these patients. Unfortunately, many patients with TP53 alterations will ultimately fail ibrutinib-based therapies. Similarly, we have used a mouse model of refractory p53 mutant CLL (Eμ-TCL1;p53R172H) and reported that while ibrutinib is effective in reducing the CD5+CD19+ population and extending survival, these mice eventually succumb to the disease (Lee HJ, BCJ 2016). These incomplete therapeutic responses indicate that ibrutinib provides only a temporary respite for this refractory disease, and highlights our need to develop more potent and targeted combinations.

Aims: Ibrutinib is effective in delaying (but not eliminating) leukemic progression in p53 mutant CLL, suggesting that combinational therapies that inhibit BCR signaling and activate apoptotic programs may be effective therapeutic strategies. Thus, agents that do not require activation of p53 but are effective in blocking oncogenic pathways (BTK and BCL-2) are attractive options. Currently, ibrutinib and ABT-199 meet this criteria and thus, we hypothesize that simultaneous inhibition of the BTK- and BCL-2-pathways will be an effective strategy in treating p53 mutated CLL.

Methods: To test this, we used RNA-Seq to examine expression changes in B-cells from Eμ-TCL1 mice carrying either wild type or a single p53R172H hotspot mutation (corresponding to p53R172H in humans) following ibrutinib treatment. qRT-PCR and IHC were used to validate expression of key targets within pathways amenable to combinational therapy. Hematopoietic tissues were subjected to combinational therapies to interrogate efficacy.

Results: We have shown that ibrutinib downregulates the BTK- and ERK-pathways regardless of p53 status. However, less is known in regards to global expression changes in p53 mutant CLL following BTK inhibition. To investigate this, we performed RNA-Seq analyses using malignant B-cells from untreated and ibrutinib treated Eμ-TCL1;p53R172H and Eμ-TCL1 mice. Pathway analyses revealed that CLL cells harboring a single p53 mutant allele retained a partial ability to activate p53-dependent programs. qRT-PCR revealed robust activation of p53-dependent anti-proliferative targets like p21, but only modest activation of pro-apoptotic targets (e.g.; PUMA), suggesting these p53 mutant CLL cells retain diminished capacity to activate apoptosis or overcome apoptotic inhibitors. To explore this altered bi-modal p53 activation, we performed IHC and observed that apoptotic activation was hampered by increased BCL-2 expression. To examine whether this BCL-2-dependent inhibition could be overcome, malignant B-cells were treated with ibrutinib alone, ABT-199 (a BCL-2 inhibitor) alone, or in combination. Here, we confirmed that ABT-199 was sufficient to activate apoptosis, regardless of p53 status, and that its use in combination with ibrutinib drastically reduced cell viability.

Summary/Conclusions: Together, these data indicate that patients with a partially attenuated p53 pathway may retain the ability to activate apoptosis if molecular barriers are removed (e.g.; BCL-2 via ABT-199). Furthermore, these results suggest that combinations with BTK- and BCL-2 inhibitors may be therapeutically beneficial for patients with mutated TP53.
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disease which arises in a haemopoietic stem or multipotent progenitor cell with the t(9;22)(q34;q11) chromosomal translocation. Tyrosine kinase inhibitors (TKIs) which arise in a haemopoietic stem or multipotent progenitor cell with the t(9;22)(q34;q11) chromosomal translocation. Tyrosine kinase inhibitors (TKIs) are effective for the treatment of CML, and the outcome of patients who fail the treatment due to primary or acquired resistance is still uncertain. Our findings indicate that TKIs, being an indispensable role in CML maintenance, while normal hematopoietic stem/progenitors were not affected by STAP-1 deficiency. Although a majority of patients have a durable response to BCR-ABL tyrosine kinase inhibitors, the outcome of patients who fail the treatment due to primary or acquired resistance is still uncertain. Our findings in mice and human suggest that STAP-1 could be a novel target for CML. Further analysis will be needed to clarify the molecular mechanisms by which STAP-1 regulates the progression of CML and maintains survival of LSCs.

Methods: We generated STAP-1 deficient mice of the C57Bl/6J genetic background. For establishment of CML mouse model, we infected Lineage (Lin)- Sca-1+ c-kit+ (LSK) fractions of bone marrow (BM) cells from STAP-1+/+ and STAP-1−/− mice, infected them with retrovirus carrying MSCV-BCR-ABL-ires-GFP, and transplanted into congenic recipients, that were named Wild type (WT) and STAP-1−/− CML mice, respectively. Human BM samples were collected after informed consent, using protocols approved by the Investigational Review Board of Osaka University Hospital.

Results: Using Western blot and immunoprecipitation assay, we confirmed that STAP-1 binds to BCR-ABL. LSCs from STAP-1−/− mice showed significantly longer survival than WT CML mice (Fig. 1). STAP-1−/− CML mice displayed less splenomegaly and lung hemorrhages compared to WT, suggesting that loss of STAP-1 attenuates CML progression. To investigate how STAP-1 regulates CML progression, we evaluated leukemic stem cells (LSCs) in CML mice. The absolute numbers of STAP-1−/− LSCs (GFP+ LSK) in BM and spleen were significantly lower than those of control (WT vs STAP-1−/−: 2000 ± 694.07 cells vs 412.57 ± 114.07 cells in BM, p=0.0291; 12.9 ± 1.75 x104 cells vs 4.09 ± 0.72 x104 cells in Spleen, p=0.0009). In colony-forming assay in vitro, STAP-1−/− LSCs generated less colonies in the first and second plating compared to WT LSCs. These data indicated that deletion of STAP-1 would impair self-renewal capacity of LSCs. When we transplanted STAP-1−/− or STAP-1+/− mice without BCR-ABL transduction in the presence of competing BM cells, deletion of STAP-1 had no effects on engraftment at 28 days after transplantation. Furthermore, we measured the expression of STAP-1 in BM cells derived from patients in the chronic phase of CML. As a result, STAP-1 mRNA was abundant in the LSC (CD34+ CD38−) compartment.

Summary/Conclusions: In this study, we utilized CML mouse model and showed that STAP-1 is required for progression of CML. Our findings indicate that STAP-1 has an indispensable role in LSC maintenance, while normal hematopoietic stem/progenitors were not affected by STAP-1 deficiency. Although a majority of patients have a durable response to BCR-ABL tyrosine kinase inhibitors, the outcome of patients who fail the treatment due to primary or acquired resistance is still uncertain. Our findings in mice and human suggest that STAP-1 could be a novel target for CML. Further analysis will be needed to clarify the molecular mechanisms by which STAP-1 regulates the progression of CML and maintains survival of LSCs.
cell division and telomere length (TL) in peripheral blood cells has been shown to correlate with disease stage, response to treatment and duration of CP in CML patients. However, the use of TL as a routine clinical biomarker in CML has been complicated by considerable inter-individual, mostly genetic variability in TL ideally requiring non-clonal control cells.

**Aims:** Based on these considerations, we used a modified Q-FISH technique in a recently developed study to investigate if BCR-ABL+ LSC or BCR-ABL- control cells within the CD34+38- hematopoietic stem cell compartment of diagnostic patients with CML in CP.

**Methods:** 15 patients (median age: 59 years; range: 41-72 years) diagnosed with CML in CP of the NCT00852566 study (Nordic CML Study Group) were retrospectively analyzed. Patients treated with TKI were available for 14 patients. Of those, 2 (14%) belonged to the Sokol high risk group, 5 (36%) to intermediate and 7 (50%) to the low risk group. CD34+38- cells sorted from bone marrow samples were tested with the standard FISH method using dual fusion dual colour BCR-ABL FISH staining following standard procedures. After capturing the BCR-ABL staining using confocal microscopy, samples were re-processed for TL analysis by Q-FISH using established protocols. TL staining was analyzed in all previously captured cells allowing the identification of BCR-ABL+/−cells within the same sample. Analysis and quantification of BCR-ABL FISH staining and TL measurement by Q-FISH were performed in blinded fashion.

**Results:** Overall, we observed significantly shortened TL in the BCR-ABL+ compared to BCR-ABL- cells (4.9 arbitrary units (a.u.) range: 53.7-16.9 a.u., p=0.04). Next, we correlated the clone size (i.e. the proportion of BCR-ABL+ positive cells within the CD34+38- compartment) with the degree of telomere shortening in LSC. Mean clone size of the patients was 59.9 ± 32.0 % S.D. Of note, we found a significant negative correlation (R²=0.36, p=0.02) between TL and clone size strongly supporting the notion that increased expansion of the BCR-ABL+ LSC pool leads to accelerated telomere shortening. Corroborating this trend, a statistical data analysis (R²=0.07) of Sokol (R²=0.04, p=0.38) score did not reveal any statistically significant correlation with the degree of telomere shortening probably due to the small sample size analyzed in this pilot study.

**Summary/Conclusions:** In this study, we provide further evidence for accelerated telomere shortening in BCR-ABL+ LSC as compared to their normal CD34+CD38- counterpart in CP CML samples at diagnosis. Interestingly, the degree of TL shortening linearly correlates with the clone size of the BCR-ABL+ LSC compartment. Thus, this retrospective study (now on the LSC level) further supports a role of TL as a prognostic and predictive biomarker in newly diagnosed patients with CML pending confirmation in prospective trials.

P594

**GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDIENTLY OF BCR-ABL1 MUTATIONS**


1Department of Immunology, 2Postgraduate School of Molecular Medicine, Medical University of Warsaw, 3Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, 4Department of Hematology, The University Hospital, Cracow, 5Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, 6Department of Hematology, Military Institute of Medicine, 7Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, 8Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Center and Institute, 9Department of Medical Genetics, Medical University of Gdansk, 10Department of Laboratory Diagnostics, Institute of Medical Genetics, Medical University of Gdansk, 11Department of Immunology, and Hematology, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, United States

**Background:** Blastic phase of chronic myeloid leukemia (BP-CML) remains mostly incurable even with newer generation tyrosine kinase inhibitors (TKI) and represents an unmet clinical need. Although in recent years a dramatic reduction in the transformation of chronic phase (CP-CML) to BP-CML has been observed, still up to 5% of patients will progress to BP-CML despite treatment with TKI. Prospective identification of such patients may have a significant clinical impact. There are only few reports to date which use next-generation sequencing (NGS) to look for somatic mutations - other than those affecting kinase domain of BCR/ABL 1 - at the time of diagnosis (Dx) which could have a prognostic/predictive value.

**Aims/Methods:** We analyzed the mutational spectrum of somatic mutations in two groups of CML patients with clinically different disease course: first group (BP) comprised of 11 patients who progressed to BP-CML despite treatment with TKI and/or allo-HSCT (one patient) and died (paired samples from DX and BP were analyzed); second group (MMR) included DX samples from 36 patients who achieved molecular response, did not reach MR4.5 and TKI within 6 months and remained in MMR for at least 48 months from DX.

**Methods:** Targeted enrichment strategy using custom designed capture probes (SeqCap EZ, Roche NimbleGen) followed by NGS on Illumina platform was employed. More than 1200 genes implicated in human cancer were included. Common variants (>1%) gathered in large genomic databases and our internal database were filtered out and the subsequent analysis was focused on putative protein damaging variants, supported by variant effect prediction tools such as PolyPhen-2, SIFT or CHASM. All reported variants were reconfirmed by Sanger sequencing.

**Results:** The BP group comprised of paired samples from 11 CML patients who progressed to BP and died despite treatment with TKI. Median age at diagnosis was 53y (range 26-77), median time to progression for 9 patients (2 were diagnosed in accelerated phase or BP) was 17,5 months (mo) (range 4-108) and median survival was 22 mo (range 10-116). None of those patients harbored BCR/ABL1 mutation at the time of Dx and progression to BP-CML 4 patients had additional chromosomal alterations at progression to BP including two frequent (trisomy 8 and monosomy 7). Targeted enrichment followed by NGS allowed us to achieve deep coverage (>80% ge50). Median number of rare variants was 26 (range 18-38) and 29 (range 23-32) for Dx and progression samples, respectively. In BP-CML samples we detected new and previously described mutations in selected genes, which are frequently mutated in myeloid malignancies, namely in RUNX1 (36%, 4/11), DNMT3A (27%/311) IDH1/IDH2 (18%, 2/11) and ASXL1 (18%, 2/11). In BP patients (54%, 6/11) mutations in these genes (excluding IDH2, detected only in BP sample) were preexisting at the time of Dx. These results were compared to second, control group that comprised of diagnostic samples from 36 patients (median age at diagnosis 53y, range 23-75) who were optimal responders to TKI and remained in MMR for at least 48mo (median time in MMR: 73mo; range 48-128). In MMR group, the median number of rare variants was lower than in BP patients (26 vs. 36, 5%) frameshift mutation in ASXL1 (p.Gly643_Gly644fs) was detected, identical as in one of BP patients. Additionally, one patient harbored RUNX1 mutation (p. Arg201Cln) which was not detected in the BP group.

**Summary/Conclusions:** Our results provide new insights into the already complex genomic landscape of BP-CML. We suggest that a significant number of patients with poor disease outcome may harbor preexisting mutations in DNMT3A, RUNX1 and IDH1. In contrast, mutations in ASXL1 may be present at Dx in patients who will remain in long-term remission.

P595

**INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE**


1Hematology and Oncology, Medizinische Universität Innsbruck, Innsbruck, Austria, 2Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, 3Bioinformatics, Medizinische Universität Innsbruck, Innsbruck, Austria, 4Northwestern University, Chicago, United States, 5Universitätsklinikum Jena, Jena, Germany, 6Vrije Universiteit Medical Center, Amsterdam, Netherlands, 7Biological Chemistry, Medizinische Universität Innsbruck, Innsbruck, Austria, 8Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany

**Background:** Indolamine 2,3 dioxygenase (IDO1) is the rate-limiting enzyme in the metabolism of the essential amino acid tryptophan (TRP). IDO1 is induced mainly by interferons during infection and inflammation. Strong IDO1 activity depletes tryptophan, which results in reduced T cell activation and proliferation as well as expansion of immunosuppressive regulatory T cells. Deregulation of IDO1 activity has been linked to cancer immune evasion, but its role in chronic phase (CP) CML has not been investigated in detail.

**Aims:** Determination of IDO1 levels and activity in plasma CML-CP patients in the course of tyrosine kinase inhibitor therapy and their correlation with clinical and immunological parameters as well as molecular response.

**Methods:** A large panel of immune and inflammatory cytokines and chemokines of the IDO-pathway (soluble ID1=1sIDO1 and kynurenine/tryptophan ratio=kYN/TRP) as a product of IDO1 activity) as well as various leukocyte populations such as plasmacytoid dendritic cells (pDC) were analyzed alongside the prospective pan-european ENEST1st clinical study (NCT01061177). This substudy included 68 patients, followed chronologically. 25% of patients were subsequently treated with 300mg BID nilotinib and longitudinally analyzed at months 6 and 12 of therapy. Molecular responses were quantified in central EUTOS reference laboratories.

**Results:** Soluble IDO (sIDO1) levels and KYN/TRP ratio are significantly upregulated in newly diagnosed CP-CML and drop during nilotinib therapy; sIDO1 levels significantly correlate with increased KYN/TRP, suggesting increased IDO1 activity at diagnosis. Increased sIDO1 is linked to a pro-inflammatory status in CML patients, as it positively correlates with increased serum neopterin levels as well as to various other pro-inflammatory markers, such as IFN-α, IL-12, IL-15, IFN-g, IL-6, IL-8, TNFα, TGFβ, sVEGF-A, sVCAM-1 and sTNFR-1. Albeit being an IFN-regulated marker, in CML patients, as it positively correlates with increased serum neopterin levels as well as to various other pro-inflammatory markers, such as IFN-α, IL-12, IL-15, IFN-g, IL-6, IL-8, TNFα, TGFβ, sVEGF-A, sVCAM-1 and sTNFR-1.
of the KYN/TRP ratio to BCR-ABL transcript levels. Patients having a high KYN/TRP ratio (> mean +2SD of post therapy levels) reach deep molecular response rates (i.e. MR4.5) significantly earlier and at higher rates. Moreover, combining KYN/TRP with sCD62L levels, a recently identified predictive biomarker, resulted in a score robustly predicting the odds of achieving deep molecular response.

Summary/Conclusions: CML diagnosis in CP is linked to an increased inflammatory status, as shown by increased levels of sIDO and its metabolites kynurenine leading to an increased KYN/TRP ratio. In solid cancer increased IDO expression/activity is linked to inferior outcome by favoring immune evasion. In contrast, in CML an increased KYN/TRP ratio is associated with improved outcomes, mainly due to its role in anti-inflammatory therapy. The reason could be that IDO activity may reflect endogenous IFN-α production, a known factor favoring immune-mediated CML-control. The predictive potential of KYN/TRP is currently verified in an independent cohort.

P596

BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB

K. Byrgazov1,*, C. Lucini1, D. Printz1, M. Koenig1, P. Valent2, O. Hantschel3, T. Lion1

1Children’s Cancer Research Institute, 2Medical University of Vienna, Vienna, Austria, 3Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland

Background: Despite the dramatic improvement of prognosis in CML patients due to the introduction of tyrosine kinase inhibitors (TKIs), resistance to treatment occurs in a considerable proportion of patients. The best-characterized mechanism of resistance to TKIs is the acquisition of mutations in the BCR-ABL1 tyrosine kinase domain (TKD) affecting TKI binding. The third-generation TKI ponatinib exerts strong anti-neoplastic effects even in advanced CML stages and is capable of suppressing the kinase activity of BCR-ABL1 carrying any single mutation including T315I. Nevertheless, resistance to ponatinib can evolve in sub-clones carrying BCR-ABL1 variants with two or more mutations on the same allele, if the IC50 values for this TKI exceed the maximum achievable effective plasma levels (efcave). These co-called compound mutations (CMs) are associated with increased oncogenic potential in comparison to individual mutations, and represent a powerful mechanism of potential resistance to all currently available TKIs. The occurrence of compound mutations has been linked mainly to sequential treatment with different TKIs, and the identification of their responsiveness to ponatinib is of paramount importance for the subsequent clinical management.

Aims: 1. To determine the spectrum of highly TKI-resistant CMs. 2. Measure the responses of BCR-ABL1 CMs to ponatinib

Methods: We have established a BCR-ABL1 protein model facilitating assessment of the presumptive impact of 27 different CMs involving important functional sites of the BCR-ABL1 TKD, and including constellations expected to display distinct from GvHD is controversial. Another interesting observation is about 40 percent of persons with CML and a deep molecular response to tyrosine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell, some ascribe this therapy-free remission (TFR) a result of immune surveillance. Immune surveillance refers to a process whereby the innate and adaptive immune systems recognize and eliminate cancer cells on the basis of cancer-specific or related antigens or other molecules. Substantial data support the concept of immune surveillance in rodents but data in humans are less convincing and apply mostly to virus-induced cancers.

P597

IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO

R.P. Gale1,*, G. Opelz2

1Haematology Research Centre, Imperial College London, London, United Kingdom, 2Institute of Immunology, University of Heidelberg, Heidelberg, Germany

Background: Immune surveillance refers to a process whereby the innate and adaptive immune systems recognize and eliminate cancer cells on the basis of cancer-specific or related antigens or other molecules. Substantial data support the concept of immune surveillance in rodents but data in humans are less convincing and apply mostly to virus-induced cancers. However, considerable data indicate a strong anti-leukaemia effect in persons with chronic myeloid leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most, if not all, of this anti-leukaemia effect is confounded with graft-versus-host disease (GvHD) and whether there is a specific anti-leukaemia effect distinct from GvHD is controversial. Another interesting observation is about 40 percent of persons with CML and a deep molecular response to tyrosine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell, some ascribe this therapy-free remission (TFR) a result of immune surveillance. Immune surveillance refers to a process whereby the innate and adaptive immune systems recognize and eliminate cancer cells on the basis of cancer-specific or related antigens or other molecules. Substantial data support the concept of immune surveillance in rodents but data in humans are less convincing and apply mostly to virus-induced cancers. However, considerable data indicate a strong anti-leukaemia effect in persons with chronic myeloid leukaemia (CML) receiving an allogeneic haematopoietic cell transplant. Most, if not all, of this anti-leukaemia effect is confounded with graft-versus-host disease (GvHD) and whether there is a specific anti-leukaemia effect distinct from GvHD is controversial. Another interesting observation is about 40 percent of persons with CML and a deep molecular response to tyrosine kinase-inhibitors (TKIs) remain in molecular remission when TKI-therapy is stopped. Because TKI-therapy is very unlikely to eradicate every CML cell, some ascribe this therapy-free remission (TFR) a result of immune surveillance.
Methods: To test these hypotheses, we studied whether there was an increased incidence in CML in persons receiving immune suppression, after solid organ transplants. IF immune surveillance is important in CML we would expect an increased incidence in this setting. We used a dataset from the Collaborative Transplant Study (CTS) which collects information on recipients of solid organ transplants beginning in 1985 from >300 transplant centers worldwide. Cancer incidence data were checked annually by questionnaire. Data for expected CML incidence were obtained from a cohort of identical size matched for age and sex from Cancer Incidence in Five Continents monitored for the same duration as the transplant cohort. Data collection and processing were approved by the Data Protection Agency in Germany and all participating centers were in accordance with ethical and privacy regulations. The CTS dataset consisted of 441,332 recipients of kidney (N=355,606), liver (N=47,846) and heart (N=37,880) transplants. Amongst kidney transplant recipients the standardized incidence ratio (SIR) for developing CML was 1.54 (95% confidence interval, 1.1, 2.1; p<0.01) representing 39 cases in 1,682,491 person-years at risk (4.7 per 100,000). Amongst liver transplant recipients the SIR was 1.72 (0.6, 4.0; p=0.34) representing 5 cases in 182,833 person-years at risk vs. 3 expected (2 excess cases). Amongst heart transplant recipients the SIR was 3.47 (1.8, 6.1; p=0.0005) representing 12 cases in 173,015 person-years at risk. One excess case was detected in 9 patients (11 CML and 1 ALL) and 2 negative samples (K Cohen=0.690; p <0.02): 77 samples were concordant by the “Labnet” method, 51 (81%) samples exceeded the 100,000 copies of BCR-ABL1 KD mutation (MR3<0.032%, MR4<0.001%). Consequently, the molecular monitoring plays a crucial role in the clinical management of CML patients, with a consequent research of sensitive and standardized molecular techniques. The automated methods offer advantages in terms of reduced time for analysis, decreased manual steps, and reduction of possible errors and contamination. The aim of the present study was to compare the ultra-fast real-time PCR technique MinION (Oxford Nanopore, Oxford, UK) with the “Labnet” method that includes the “classical” manual real-time PCR techniques standardized in the Italian network (57 centers), according to the European guidelines [Cross N, 2015]. We compared the sensitivity of the two methods (based on the number of ABL1 detected copies) in the classification of molecular responses, with particular attention to the deep molecular subgroups.

Results: MinION data analysis on the Group 2 was able to detect mutation only in a ALL case. Results from MinION and SS showed 92% concordance in all cases included in this study. Notably, mutations that were initially undetectable by SS became evident thanks to the indications coming from MinION analysis.

Summary/Conclusions: Our findings demonstrate multiple advantages by using MinION approach, first of all the sensitivity: our comparison of MinION to SS identified mutations below the detection limit of SS (generally estimated around <20%) in 2 (22%) among the mutated cases, including mutations known to be clinically important. Another point on the side of the nanopore technology is the costs profile. Therefore, the main advantage of this technology is to allow a more efficient and sensitive analysis than SS at very competitive costs. In conclusion, we demonstrated that MinION is suitable for employment in hematology laboratory for detecting BCR-ABL1 KD mutations in Ph+ leukemias.

Background: The chronic myeloid leukaemia (CML) is characterized by the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene. The production of tyrosine kinase inhibitors (TKIs) significantly improved the survival, but 15% of patients don’t reach the optimal responses at the defined end-points or develop secondary resistance. The 2013 ELN guidelines identified as fundamental the early molecular response (BCR-ABL1/ABL1 % s10%, IS), the MR3 (<0.1%) and the deep molecular response (MR4<0.01%, MR5<0.001%) [31]. Consequently, the molecular monitoring plays a crucial role in the clinical management of CML patients, with a consequent research of sensitive and standardized molecular techniques. The automated methods offer advantages in terms of reduced time for analysis, decreased manual steps, and reduction of possible errors and contamination. The aim of the present study was to compare the ultra-fast real-time PCR technique MinION (Oxford Nanopore, Oxford, UK) with the “Labnet” method that includes the “classical” manual real-time PCR techniques standardized in the Italian network (57 centers), according to the European guidelines [Cross N, 2015]. We compared the sensitivity of the two methods (based on the number of ABL1 detected copies) in the classification of molecular responses, with particular attention to the deep molecular subgroups.

Results: Firstly we compared the number of detected ABL1 copies, that are fundamental for definition of the molecular response categories, especially for the so-called MR4+/MR5. By the “Labnet” method, 51 (81%) samples exceeded the 100,000 copies of ABL1, while by the automated method 81 samples (94.2%) reached >100,000 ABL1 copies. Then, we compared the two methods in discriminating positive and negative samples (K Cohen=0.690; p<0.02): 77 samples were concordant (89.5%) and only 9 (10.4%) were discordant. Of the 18 negative samples with the “Labnet” method, 2 (11.1%) were in MR4.0, 10 (55.5%) in MR4.5 and 6 (33.4%) in MR5.0. On the other hand, of the 19 negative samples with the method “Ultra”, 1 (5.3%) was in MR4.5 and 18 (94.7%) in MR5.0, confirming the higher sensitivity of the automated method. In the cohort of positive cases by the two methods, the median values of transcript expression were superimposable (p=0.55) and the linear regression coefficient was very satisfying (Pearson’s r=0.9399; p-value <0.0001). Finally we compared the results produced by the two methods according to the “molecular classes” (MR1 vs MR2+MR3 vs MR4+MR4.5 vs MR5). This comparison showed a good concordance of results. Overall, the comparison of the two methods demonstrated high concordance between “Ultra” and “Labnet” methods using assay comparison criteria proposed by Müller et al. [Leukemia 2009] (Table 1).
and apoptosis in IM sensitive and resistant cell lines. The advantage of using AK and Plk1 inhibitors in

Summary/Conclusions:
• significant increase of gadd45a expression levels;
• AK/A and Plk1 activation is only partly dependent on BCR-ABL1 TK phosphorylation of both proteins in parental K562, but not in IM-resistant K562, indicating that AK/A and Plk1 overexpression is always associated with defects in centrosome duplication, bipolar spindle and chromosomal segregation and aneuploidy, suggesting that it may enhance other oncogenic events by promoting genomic instability, one major trait of chronic myeloid leukemia (CML).

Background: Cell response to stress is a central component of genomic stability. The integrity of signaling pathways involved in cell cycle arrest, chromatin remodeling and DNA repair, are critical for the maintenance fidelity of replicated DNA. In this context, Gadd45 proteins function as stress sensors and de- transcripion regulators. Gadd45α, in particular, intervenes in G2/M checkpoint induction and DNA repair, and it is required for efficient coordination of centrosome duplication hence preventing abnormal mitosis and aneuploidy. Such evidences let assume a putative role of Gadd45α in cancer development and progression. We report that Gadd45α interacts with Aurora Kinase A (AKA), a key component of centrosome cycle and polar spindle assembly required for regulated progression from G2 to M and throughout M. AK/A is a member of a serine-threonine kinase family active during mitosis and it is frequently overexpressed in human cancers where correlates with a poor prognosis. Notably, AK/A overexpression is always associated with defects in centrosome duplication, bipolar spindle and chromosomal segregation and aneuploidy, suggesting that it may enhance other oncogenic events by promoting genomic instability, one major trait of chronic myeloid leukemia (CML).

Methods: K562 cell line is a human cell line generated from a CML patient in blast crisis. Drug resistance was induced in K562 cell line by the exposure to progressively increasing doses of Imatinib (IM). It was validated by dose-response curves showing a significant difference in LD50 of IM-sensitive and IM-resistant cells. By mean of cytofluorimetric and immunofluorescence microscope analyses we investigated the events leading to AK/Plk1 deregulation. Protein expression and activation were detected by western blotting and immunoprecipitation. Apoptotic cell death was measured by using an Annexin V/PI staining; cell cycle distribution was observed by PI staining and subsequent microscope analyses.

Results: Preliminary experiments were aimed to determine whether IM resistance in a BCR-ABL1 cell context is associated with the over-expression and hyper-activation of AK/A/Plk1 axis. In our in vivo model drug resistance was associated with increased expression and phosphorylation of AK/A (Y282) and Plk1 (T210). 24h exposure to IM significantly reduced expression and phosphorylation of both proteins in parental K562, but not in IM-resistant K562, indicating that AK/A and Plk1 activation is only partly dependent on BCR-ABL1 TK activity. Subsequent experiments showed that the inhibition of AK/A and Plk1 in response to specific inhibitors (Danusertib and Volasertib respectively) was associated with:
• significant increase of gadd45a expression levels;
• reduction of cell survival;
• G2/M checkpoint arrest.

Summary/Conclusions:
• The advantage of using AK and Plk1 inhibitors in CML therapy mostly arises from effects independent from TK activity of Bcr-Abl protein. We proved that the AK and Plk1 inhibitors induce growth arrest and apoptosis in IM sensitive and resistant cell lines.
Background: The t(9;22) translocation in chronic myeloid leukemia (CML) generally occurs in intron 12 or 13 of the BCR gene resulting in two different transcripts, the e13a2 or e14a2. It has been suggested that the two variants represent separate disease entities and that the transcript variants hold a prognostic value regarding treatment response, where e14a2 predicts a faster and deeper treatment response. However, no difference in overall survival has been observed and the issue remains controversial.

Methods: Transcript levels from 124 BCR-ABL1 positive patient samples were screen for BCR-ABL1 e13a2 and e14a2 transcript variants using either PCR with agarose gel separation or a droplet digital PCR (ddPCR) assay measuring the amount of e13a2 and e14a2 transcripts. The BCR-ABL1 level was determined by qPCR using the QuantaStudio instrument (Life Technologies) and expressed in the International Scale (IS) using the EAC primers and assay conditions with GUSB and BCR as reference genes. Samples were re-measured by digital droplet PCR (ddPCR) on a QuantaLife instrument (Bio-Rad) using modified EAC primers multiplexed with GUSB and BCR as reference genes and expressed as %IS.

Results: Transcript levels from 124 BCR-ABL1 positive patient samples were determined using the EAC qPCR assay (median: 0.08% IS; range: 0.001–159% IS) and ddPCR (median: 0.01% IS; range: 0.0002–124% IS). These included 59 samples with the e13a2 variant and 65 with the longer e14a2 variant. Comparing the expression levels obtained by the two techniques revealed ddPCR/qPCR ratio differences for e13a2 (median: 0.68, range: 0.35 – 3.2) and e14a2 (median: 3.43, range: 0–8.8), and a consistent 4.5 fold (>0.5 log) underestimation of the levels of the e14a2 compared to e13a2 when using qPCR (figure 1).

Summary/Conclusions: When we compared the BCR-ABL1 levels using qPCR and ddPCR, we observed a discrepancy between the e13a2 and e14a2 break transition variants. Since ddPCR is an endpoint measurement and not sensitive to variations in primer efficiencies, the most likely explanation for the discrepancy is a decreased qPCR efficiency of the longer e14a2 variant compared to e13a2 variant. Thus in qPCR analyses using the EAC protocol this may, at least on some analysis platforms, result in a consistently underestimation of the e14a2 transcripts.

Table 1.

<table>
<thead>
<tr>
<th>Result</th>
<th>e13a2 (median)</th>
<th>e14a2 (median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median %Ph+</td>
<td>0.08% IS</td>
<td>3.43% IS</td>
</tr>
<tr>
<td>Range</td>
<td>0.001–159% IS</td>
<td>0–8.8</td>
</tr>
<tr>
<td>ddPCR/qPCR ratio</td>
<td>0.68</td>
<td>4.5 fold (&gt;0.5 log)</td>
</tr>
</tbody>
</table>

Note: The discrepancy is a decreased qPCR efficiency of the longer e14a2 variant compared to e13a2 variant.

P603

5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA (CP-CML)


Background: Ponatinib is an oral tyrosine kinase inhibitor (TKI) approved for pts with CP-CML or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other TKI therapy is indicated, or for pts with T315I. The ponatinib PACE trial (NCT01207440) enrolled pts with CML or Ph+ ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. Long-term results in these heavily pretreated pts provide value in informing treatment decisions.

Aims: To report 5-yr efficacy and safety, and the association of early landmark molecular responses with survival outcomes at 4 yts past landmark, in heavily pretreated pts with CP-CML from PACE.

Methods: Ponatinib starting dose was 45mg/day. Dose reductions were instructed in Oct '13 to manage risk of arterial occlusive events (AOEs) observed with longer follow-up. Outcome measures were: 5-yr efficacy (n=267) and safety (n=270); post-landmark analysis (n=267) of the association of molecular responses (BCR-ABL1 ≤0.1% [major molecular response (MMR)], >0.1–1%, >1%–10% and >10%) and cytogenetic responses (major [MCyR] and complete [CCyR]) at 3-6- 12-mos with progression-free survival (PFS) and overall survival (OS) 4 yts past landmark (log-rank P values). Data cutoff: 3 Oct ’16.

Results: Baseline characteristics of the CP-CML pts included: median time from diagnosis, 7 yrs (range, 0.5–27 yrs); median age, 60 yrs (18–94 yrs); median %Ph+, 100% (2.5–100%); and ≤10% Ph+, 20 pts (7%). At initiation of study closure, 99 pts (37%) were ongoing; among these pts, minimum follow-up was 52 mos, and most (78%) had 15mg/d as their last ponatinib dose. In efficacy-evaluable CP-CML pts, cumulative response rates of the last TrKi dose were: MCyR, 60%; CCyR, 64%; MMR, 40%; and MR4.5, 24%. Among pts who achieved MCyR (n=148) or MMR (n=108), the Kaplan-Meier (KM) estimated probability of remaining in response at 5 yrs was 74% (95% CI, 62–83) and 61% (95% CI, 51–70), respectively. Maintenance of response was high regardless of dose reductions in Oct ’13. KM estimated 5-yrs for PFS/OS were 49%/77%. Among pts with 3-, 6- and 12-mo landmark responses, achievement of MCyR or MMR at 3-, 6- and 12-mo was associated with achievement of PFS/OS overall or treatment-emergent adverse events (AEs) in ≥24% of CP-CML pts were rash 47%, abdominal pain 46%, and thrombocytopenia 46%. Most newly occurring AEs were observed within the first yr. The incidence of any AOE/serious AOE for CP-CML pts was
29%/23%. Among CP-CML pts with no prior AEs who had a prospective dose reduction, 17% (11/63) had a first AOE occurring after Oct ’13.

Summary/Conclusions: Long-term 5-y results from PACE demonstrate that irrespective of dose reductions, ponatinib continues to show deep, lasting, clinically meaningful responses over time in heavily-pretreated pts with CP-CML. Achieving early cytogenetic response and deep reduction in BCR-ABL1 levels was associated with improved survival 4 yrs past landmark, demonstrating the prognostic value of early and deep response to ponatinib.

P604
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE

Methods: We analyzed 345 patients ≥ 18 years of age with CP CML enrolled in 2 clinical trials of the GIMEMA CML WP. Patients that sometimes receive imatinib (IM) at reduced doses based on physicians’ judgment. However, data on long-term follow-up of these patients are still lacking.

Aim: To investigate the treatment response and outcome in a cohort of very elderly patients with newly diagnosed CML in chronic phase; among these, 121 patients (46%) were older than 80 yrs.

Background: Very elderly (>75 yrs) people are a substantial proportion of chronic myeloid leukemia (CML) patients that sometimes receive Imatinib (IM) at reduced doses based on physicians’ judgment. However, data on long-term follow-up of these patients are still lacking. Aims: To investigate the characteristics of ATEs and their impact on the long-term outcome of CML patients treated with nilotinib first-line.

Methods: We analyzed 345 patients ≥ 18 years of age with CP CML enrolled in clinical trials of the GIMEMA CML WP investigating nilotinib as first-line treatment. Patients were treated with: nilotinib 400-600 mg BID (n=73); rotation of nilotinib 400 mg BID / imatinib 400 mg OD (3-month periods for each drug)(n=123); nilotinib 300 mg BID (n=149). The median follow-up was 58 (22-82) months. The median age at CML diagnosis was 53 (18–86) years. We compared the molecular response rates and the long-term outcome of patients treated with ATEs. Definitions: ATEs: peripheral arterial obstructive disease (PAOD), coronary syndromes, significant carotid stenosis and ischemic stroke, or other significant ischemic events; major molecular response (MRM): BCR-ABL ≤ 0.1% (IS), with 10,000 ABL copies; MR4: BCR-ABL≤0.01% (IS), with >10,000 ABL copies. Results: Overall, 30,545 (8.7%) patients had ATEs during treatment with nilotinib.

The median age at CML diagnosis of these patients was 64 (43-85) years, and the median age at ATEs was 67 (47-89) years. The median duration of nilotinib treatment at ATE was 25 (1-78) months. ATEs were: 14 coronary dissections, 28 coronary occlusions, 7 peripheral arterial occlusions, 25 carotid stenosis, 8 strokes, 10 transient ischemic attacks, 6 peripheral arterial occlusions.

Summary/Conclusions: The long term follow-up of very elderly CML patients treated with IM suggests that any effort to treat these patients with standard doses should be made, in order to achieve cytogenetic and molecular responses as in younger subjects.
ease (including 7 acute myocardial infarction), 8 PAOD, 4 carotid stenosis (asymptomatic), 2 avascular necrosis of femoral heads, 1 optic artery ischemia, 1 aneurysm of the left common iliac artery. Overall, 21 patients were hospitalized for the management of ATEs; 15 patients received medical treatment only, while the remaining required invasive interventions: 9 coronary angioplasty with stent positioning, 3 lower limbs amputations, 2 peripheral vascular bypasses, and 1 prosthesis of femoral head. No patient died for ATEs. Overall, 24 patients (80% of patients with ATEs, and 7% of the whole cohort) permanently discontinued nilotinib because of ATEs. The median follow-up after ATE was 15 (1-58) months. Of the 30 patients with ATEs, 26 (87%) achieved a MMR and 18 (60%) obtained a MR4, during nilotinib treatment. These rates were comparable to those observed in patients without ATEs (MR3: 260/315, 83%; MR4: 113/315, 64%). The 5-year progression-free survival and overall survival were similar in patients with or without ATEs (PFS: 96% vs 92%, p=0.55; OS: 96% vs 93%, p=0.79).

Summary/Conclusions: After a median follow-up of 58 months, 8.7% of patients treated front-line with nilotinib had ATEs, being coronary disease and PAOD the most common. ATEs were more frequent in elderly patients (median age at ATEs: 67 years). Half of the patients required invasive procedures, including major surgeries in 6 patients. The other patients were successfully managed with medical treatment. Importantly, no patients died for ATEs, and ATEs did not affect the rates of MMR, MR4 and 5-year PFS and OS, which were all comparable to those observed in patients without ATEs. Taken together, these data suggests that ATEs, despite being sometimes associated with significant morbidity, did not significantly impact on response rates and on long-term outcome of CML patients treated with nilotinib front-line.

P606

ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS

Q. Jiang1,*, L. Zuo2, X. Ren1, X. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology, 2Peking University People’s Hospital, Department of Nephrology, Beijing, China

Background: Long-term use of tyrosine kinase inhibitors (TKIs) may lead to chronic renal injury.

Aims: To evaluate the incidence of chronic kidney disease (CKD) in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) receiving TKIs, and to identify the factors associated with the onset of CKD.

Methods: Data of CML-CP patients treated with TKIs as first-line or second- or third-line therapy for at least 3 months were analyzed. Glomerular filtration rate (GFR) was followed from the initiation of TKI-therapy. CKD was defined as persistent GFR less than 60 ml/min/1.73 m2 or persistent more than 30% GFR reduction from baseline. CKD-free survival was used to evaluate the onset of CKD. Patients’ characteristics and TKI used were analyzed to identify the factors associated with the onset of CKD by Cox regression model in those receiving first-line and second- or third-line TKI-therapy, respectively.

Results: 587 patients were included in this study. 383 (65%) were male. Median age was 40 (17-84) years. 468 patients were received nilotinib (n=363), nilotinib (n=88) or dasatinib (n=13) as first-line TKI-therapy. With a median follow-up of 35 months (range, 3-185 months), 136 of 416 (33%) patients with normal GFR at baseline developed CKD. Probabilities of CKD-free survival at 4 years were 62%, 78% and 100% in the patients receiving imatinib, nilotinib and dasatinib, respectively (p=0.004). Multivariate analysis showed that imatinib use (HR=2.5, 95% CI 1.4-4.3, p=0.002), male gender (HR=1.1, 95% CI 1.1-1.4, p=0.003), and prior administration of hydroxyurea, interferon or chemotherapy (HR=1.7, 95% CI 1.1-2.8, p=0.010) were factors associated with incident of CKD. In 48 patients with abnormal GFR or prior CKD before first-line TKI-therapy, 8 of 42 (19%) developed ≥30% GFR reduction from baseline during nilotinib or dasatinib-therapy. In 123 patients receiving nilotinib (n=59) or dasatinib (n=64) as second- or third-line TKI-therapy after imatinib-failure, 13 of 110 (12%) with normal GFR at baseline developed CKD with a median follow-up of 19 months (range, 3-149 months). Probabilities of CKD-free survival at 3 years were 74% and 90% in those receiving nilotinib and dasatinib, respectively (p=0.059). Multivariate analysis showed that nilotinib use (HR=3.6, 95% CI 1.5-10.1, p=0.047) and a history of diabetes mellitus, hypertension or other renal diseases (HR=3.8, 95% CI 1.3-11.6, p=0.019) were factors associated with incident of CKD. 3 of 13 (23%) patients with abnormal GFR or prior CKD before second- or third-line TKI-therapy developed ≥30% GFR reduction from baseline during nilotinib (n=1) or dasatinib (n=2) therapy.

Summary/Conclusions: Our study showed that nilotinib and dasatinib were associated with less chronic renal injury compared with imatinib as first-line TKI-therapy, while dasatinib was related to less loss of renal function compared with nilotinib as second- or third-line TKI-therapy after imatinib-failure in CML-CP patients.

P607

COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY qPCR AND DIGITAL-PCR (dPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS

S. Bernardi1,2,*, M. Malagoli2, N. Polverelli2, C. Zanagio12, F. Cattinà12, V. Cancelli2, M. Trimboli1, E. Codarini2, M.T. Bochicchio1, G. Ruggeri2, L. Franceschini2, S. Perucchi12, F. Castagneri1, S. Sovenni1, M. Fogli2, C. Venturi1, S. Lavorgna6, C. Gaganì1, B. Rambaldi1, L. Caimi1, G. Rossi1, M.T. Vosò1, G. Rosti1, G. Martinelli1, M. Baccarani1, D. Russo2
1Lab CREA-AI, AO Spedali Civili di Brescia, 2Unit of Bone Marrow Transplantation, University of Brescia, Brescia, 3Division of Hematology and Bone Marrow Transplantation, University-Hospital of Udine, Udine, 4Institute of Hematology “Land A Seràgnoli”, University of Bologna, Bologna, 5Chair of Biochemistry, University of Brescia, Brescia, 6Department of Biomedicine and Prevention, University of Tor Vergata, Roma, 7Division of Hematology, AO Spedali Civili di Brescia, Brescia, Italy

Background: Quantification of BCR-ABL1 transcript by qPCR is mandatory to monitor the response to TKIs therapy in CML patients. The achievement of Major or Deep Molecular Response (MMR or DMR) with TKIs is crucial for long-term survival and for treatment free remission (TFR). Currently, up to 30-40% of CML patients treated with TKIs can achieve DMR, but 50-60% of深 responders who discontinue the treatment lose their DMR and re-challenge sequent TKIs therapy. qPCR has some intrinsic limitations and it does not appear to be an optimal assay to select the best candidates to TKIs discontinuation. Digital PCR (dPCR) can give an absolute quantification of target nucleic acids by partitioning the PCR reaction mix over a large number of wells, each containing a single copy or no copies of the target region.

Aims: The aim was to comparatively monitor the BCR-ABL1 transcript levels by dPCR and qPCR in 57 CML patients treated with TKIs and achieving MMR or DMR in at least 3 time points.

Methods: Using qPCR and dPCR (Q303 Digital PCR System by Life Technologies), we comparatively analyzed 228 peripheral blood samples from 57 CML patients with MMR (n=14) or DMR (n=43). qPCR analysis were performed according to the last International Guidelines while absolute quantification of BCR-ABL1 transcript were obtained by dPCR and results were expressed as number of BCR-ABL1 copies/ul of reaction. Patients were divided into 3 groups corresponding to the MR classes at the first time point: MR3.0, MR4.0 and MR4.5-5.0 groups. dPCR Positive Predictive Value (PPV) was also preliminary evaluated in 14 patients undergoing TKI discontinuation.

Figure 1.

Results: Analyzing comparatively the time course of MR in the patients of the three groups (MR3.0, MR4.0 and MR4.5-5.0) it was observed a similar trend, but the dPCR allowed to appreciate that, at the time of starting the monitoring the patients showed different levels of BCR-ABL1 copies/ml. Furthermore, those patients with MR4.5-5.0 undetectable by qPCR resulted with detectable BCR-ABL1 transcript levels when assessed by dPCR. Secondly, while MRD quantitations measured by qPCR appear to be more homogeneous, nearly due to a normalization effect of qPCR, the quantitations of MRD measured by dPCR appear to be more heterogeneous because of the high sensitivity and accuracy of dPCR. Therefore, dPCR values, reflecting the great heterogeneity of MRD level in patients belonging to the same MR group, suggest a higher accuracy in patients stratification (Figure 1a). dPCR value of 0.468 copies/ul, previously reported as value discriminating between major responders and deep responders, was used as threshold for dPCR data analysis. Patients with absolute value of BCR-ABL1 lower than 0.468copies/ul at the first time point presented more stable disease levels than the patients with absolute value of BCR-ABL1 higher than 0.468copies/ul (Figure 1b). In 14 CML patients who...
discontinued TKIs, a preliminary analysis showed that 80% of patient with BCR-ABL1<0.468 copies/ul at discontinuation, maintained stable TFR (PPV of 80%).

Summary/Conclusions: This study suggests that dPCR is more precise and sensitive than qPCR when detecting levels of BCR-ABL1 transcript and that dPCR seems to be more robust and accurate for CML patients stratification. Larger and prospective studies are warranted to confirm the higher sensitivity and accuracy of dPCR and its usefulness to better select the candidates for TFR.

P608

OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA
C. Tekieli,1, L. Iseaume,1, S. Shams,1, A. Kuykendall1, J. Chavez,2, B. Shah,2, K. Sweed2, J. Pinilla-Ibarz2
1Department of Malignant Hematology, University of South Florida/Moffitt Cancer Center, 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, United States

Background: Primary goal of management in chronic myeloid leukemia (CML) is to prevent disease progression to blast phase CML (BP-CML). Current notion for management of BP-CML usually involves initiation of intensive chemotherapy regimen with addition of tyrosine kinase inhibitor (TKI). Despite treatment with intensive induction chemotherapy, outcome remains dismal.

Aims: We aimed to describe our experience with management of BP-CML and its outcome.

Methods: We included 58 patients from Moffitt Cancer Center from 2001 till 2016 with diagnosis of BP-CML and performed a retrospective chart review. Data elements including age, gender, peripheral blood and bone marrow parameters, phase of CML, treatment, cytogenetics and vital status were collected.

Survival analysis using Kaplan-Meier method with log-rank test to determine significance by calculating two-sided p values was performed.

P609

EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS
J.L. Steegmann1,1, V. Garcia-Gutierrez2, B. Colom3, F. Sanchez-Guijo4, R. Ayala5, C. Boque6, F. Casado3, B. Xicoy8, I. Montero9, C. Soto10, R. de Paz10, A. Kreutzman1, J. Martinez-Lope2z, C. Muñoz3
1Servicio de Hematologia, Hospital Universitario de la Princesa/ IIS-IP Madrid, 2Servicio de Hematologia, Hospital Universitario Ramon y Cajal, 3Servicio de Immunologia, Hospital Universitario de la Princesa, Madrid, 4Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, 5Servicio de Hematologia, Hospital Duran i Reynals, Barcelona, 6Servicio de Hematologia, Hospital Virgen de la Salud, Toledo, 7Servicio de Hematologia, Hospital Germans Trias i Pujol, Barcelona, 8Servicio de Hematologia, Hospital Universitario Virgen del Rocio, Sevilla, 9Servicio de Hematologia, Hospital Povisa, Vigo, 10Servicio de Hematologia, Hospital Universitario La Paz, Madrid, Spain

Background: European LeukemiaNet (ELN) recommendations (2013) advised closely monitoring for patients with late warning response (patients with complete cytogenetic response without major molecular response after 12 months of treatment). Our trial, DASAPOST, has been the first one evaluating efficacy and safety of dasatinib in patients with late warning responses, and preliminary results have been reported (Garcia-Gutierrez et al, ASH 2016; P5450). Besides, many studies suggest that dasatinib may augment responses due to its immunomodulating effect. Although NK and CD8 cells seem to be involved, the specific mechanism remains to be clarified.

Aims: To evaluate the efficacy and safety of switching change to dasatinib in patients treated with imatinib first line during at least 18 months and having a late warning response, and to study the association between response to dasatinib and immune robustness, both baselines and during the therapy, and dasatinib-induced lymphocyte “mobilization”.

Methods: Phase II, open, multicenter DASAPOST study (NCT01802450). Patients previously treated with imatinib after at least 18 months, with CCyR but without MMR, were included. All BCR-ABL1/ABL (IS) measurements were centralized in a MATOS laboratory. Analysis of interest were done both previous to the dose, and 2 hours after.

Results: From April 2013 to May 2015, 18 patients were enrolled in 12 centers. Median age was 59 years (39-77). The ratio of men to women was 13/5, and the Sokal risk groups were 30% and 14% for low, intermediate and high risk, respectively. Median time from diagnosis to switch to dasatinib was 2.6 years (1.6–2.3) and median time while on imatinib to achieve CCyR 1.4 years (0.2–12). Median exposure to imatinib was 2.4 years (1.6–14). Eight patients (44%) obtained MMR at 3 months, and 12 (66.7%) obtained MMR at 6 and 12 months. Of interest 9/18 patients (50%) achieved MR4 by 12 months. There were 3 study discontinuations because of toxicity (16%). Table 1 shows the median number of the most relevant lymphocyte populations in the pre-dose sample at baseline. Table 2 shows that the absolute number of CD8 cells was significantly superior at baseline in those patients having a MMR at 3 months, with a trend in the same direction of absolute lymphocyte count and percentage. There were no significant associations with response when considering CD4 T cells, NK cells, or the degree of mobilization after dasatinib dose either in total lymphocyte number or in subpopulations. Besides, lymphocyte number or proportions at 3 or 6 months were not associated with MMR at 6 or 12 months (data not shown).

Table 1.

<table>
<thead>
<tr>
<th>Lymphocytes</th>
<th>Baseline</th>
<th>CD8</th>
<th>CD4</th>
<th>NK</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (x 10^6)</td>
<td>1.30 (0.8-2.24)</td>
<td>0.40 (0.12-1.48)</td>
<td>0.90 (0.12-1.29)</td>
<td>0.02 (0.00-0.77)</td>
</tr>
<tr>
<td>Percentage</td>
<td>27.6 (14.5-53.9)</td>
<td>9.6 (2.9-33)</td>
<td>14.0 (6.7-22.3)</td>
<td></td>
</tr>
</tbody>
</table>

Table 2.

<table>
<thead>
<tr>
<th>Lymphocyte Baseline</th>
<th>CD8 Baseline</th>
<th>CD4 Baseline</th>
<th>NK Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMR 3m</td>
<td>0.25</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>No MMR 3m</td>
<td>0.16</td>
<td>0.06</td>
<td></td>
</tr>
</tbody>
</table>
Summary/Conclusions: Our study shows that in patients treated with imatinib and with late warning responses, switching to dasatinib induced MMR in 2 out every 3 patients, and MR4 in half of the patients, with a good safety profile. Contrarily to other group reports, we have not found any significant association between response and lymphocyte mobilization in any point studied. Interestingly, the absolute number of CD8 at baseline was significantly associated with the early attainment of MMR at 3 months, a finding which underscores the prognostic importance of baseline immune status, the relevance of CD8 cells in the antileukemic effect, and which suggest that this quite simple variable must be included in future studies with dasatinib in second line.

P610

GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB

G. Caocci1,*, C. Mammì2, C. Labate2, S. Rodi2, D. Ielo3, M. Priolo2, M. Postorino2, G. Tripepi5, F. Ronco3, C. Laganà2, B. Martino3

1Hematology, Department of Medical Sciences, University of Cagliari, Cagliari, 2Operative Unit of Medical Genetics, 3Operative Unit of Hematology, 4Operative Unit of Nephrology, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, 5Epidemiology Research Unit, CNR-IBIM, Reggio Calabria, Italy

Background: Impaired fasting glucose (IFG) and type 2 diabetes (T2D) represent adverse events in Chronic Myeloid Leukemia (CML) patients treated with the second-generation tyrosine kinase inhibitor (TKI) nilotinib. A genetic risk score (uGRS) for the prediction of insulin resistance, consisting of 10 multiple single-nucleotide polymorphisms (SNPs), has been proposed.

Aims: We evaluated the uGRS predictivity in 45 CML patients treated with nilotinib.

Methods: Patients were genotyped for IRS1, GRB14, ARL15, PPARG, PEPD, ANKRD55/ MAP3K1, PDGFC, LYPLAL1, RSPO3, and FAM13A1 genes. The uGRS was based on the sum of the risk alleles within the set of selected SNPs.

Results: MR3.0 and CMR were achieved in 91% and 84% of the patients, respectively. Before treatment, none of the patients had abnormal blood glucose. During treatment and subsequently follow-up of 84.4 months (range 1-298), 5 patients (11%) developed diabetes requiring oral treatment, after a median of 11 months (range 3-95) since nilotinib. Nine patients (20%) developed prediabetes. Prediabetes/diabetes-free survival was significantly higher in patients with an uGRS below 10 compared to higher scores (100% vs 18%; p=0.004) (Figure). Each increment of 1 unit on the uGRS caused a 42% increase in the prediabetes/diabetes risk (HR=1.42; CI: 1.04-1.94; p=0.026).

Summary/Conclusions: Although nilotinib is not associated with a higher incidence of T2D compared to a general population, it could be an early “highlighter” of genetic predisposition to the disorder. The presence of more than 10 allelic variants associated to insulin secretion, processing, sensitivity and clearance is predictive of prediabetes/diabetes developing. In clinical practice uGRS could help tailor the best TKI therapy.

P611

THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 PATIENTS TREATED WITH NILOTINIB

G. Caocci1,*, M. Gniot1,*, M. Komarnicki1, K. Lewandowski1

1Hematology, Poznan University of Medical Sciences, Poznań, Poland

Background: The quantitative PCR of BCR-ABL transcript has been the most useful technique for monitoring therapy in CML patients for over a decade. The numerous standardization projects have been undertaken in order to harmonize the molecular response results in laboratories all over the world. However, our data suggest that using the most common protocol may lead to overestimation of e13a2 transcript.

Aims: The goal of the study was to verify the observation that e14a2 transcript amplifies less efficiently than e13a2. The secondary goal was to validate the modification of Europe Against Cancer (EAC) protocol developed in 2011 which corrects observed artifacts.

Methods: The BCR-ABL measurements acquired using EAC and in-house modified EAC protocol have been compared with results from SA Pathology in Adelaide. The Adelaide protocol (Branford and Hughes 2006) consists of separate, optimized reactions for e13a2 and e14a2 transcripts, therefore it should be considered free of any PCR efficiency-related artifacts. The data originated from four independent sample batches exchanged between Poznan and Adelaide since 2009.

Results: The analysis of retrospective EAC protocol data showed that when e13a2 and e14a2 samples entered the exponential phase at the same time, the latter would cross the threshold approximately 2.2 cycles after the first one. Re-analysis of data from sample exchanges from 2009 revealed that after establishing a conversion factor (CF), all of the e14a2 measurements in Poznan were underestimated according to Adelaide. At the same time, almost all of e13a2 samples were overestimated (fig. 1). Still, the bias between methods was acceptable and a valid conversion factor (CF) was calculated. The method modification introduced 2011 eliminated this difference and increased concordance between laboratories. The last sample batch revealed significant difference between non-modified and modified EAC protocols in e13a2 measurements: 4.56 (+/- 0.96). Reanalysis of sample batch from 2009 (presented on fig.1) using 4.57 (2x2.28) factor (e13a2 results divided by 2.28, e14a2 results multiplied by 2.28) resulted in almost perfect data alignment. The results of modified EAC protocol, after CF recalibration, showed very good concordance with Adelaide (100% results of e14a2 and 88% of e13a2 within 2-fold of reference laboratory).

Figure 1. The EAC protocol, the e14a2 transcript amplifies less efficiently than e13a2. Since commonly used plasmids, including ERM-AD623, are based on e14a2, the standard curve is being shifted towards the latter cycles. It leads to overestimation of e13a2 by mean factor of 4.5 (over 0.5 log), which could be clinically significant. The reports of worse outcome of e13a2 patients are probably caused by this artifact, which can be easily eliminated by implementing an additional forward primer to EAC protocol. This overestimation cannot be detected in case of lab to lab validation when two centers are using EAC protocol. In case of method validation in Adelaide, those differences were not as obvious as well. The shift of 4.5 (fig. 1) means that results are 2.25 times different from the perfect concordance line and could easily fit into accepted 2-fold and 3-fold compartments. The CF calculated by Adelaide would depend on the percentage of each transcripts among the exchanged samples. The observed artifact should be also taken into consideration in clinical trials that rely on surrogate endpoints such as molecular response level at certain time points. Uneven transcript variant distribution between compared groups may lead to improper conclusions.
Enzymes and sickle cell disease

P612

ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA

K. Saito1, T. Fujiwara1, M. Morita2, Y. Okitsu1, N. Fukuhara1, Y. Onishi1, Y. M. Shimizu1, H. Hargatz1

1Hematology and Rheumatology, 2Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, 3Cell Engineering Division, RIKEN BioResource Center, Tsukuba, 4Molecular Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan

Background: Congenital sideroblastic anemia (CSA) is an inherited sideroblastic anemia characterized by the presence of bone marrow ring sideroblasts, reflecting excess mitochondrial iron deposition. The most common form of CSA is X-linked sideroblastic anemia (XLSA), which is attributed to mutations in the X-linked gene erythroid-specific 5-aminolevulinic acid synthase (ALAS2). ALAS2 resides on chromosome X and encodes the enzyme that catalyzes the first and rate-limiting steps in the heme biosynthesis pathway in erythroid cells. This pathway converts glycine and acetyl-coenzyme A to 5-aminolevulinic acid (ALA), which requires pyridoxal 5'-phosphate (PLP) as a cofactor. Although PLP has been used for treating XLSA, a marked proportion of patients with XLSA remain refractory to treatment (Ohta et al. Ann Hematol 2013). Thus, there is a need to establish a model of XLSA to reveal the detailed molecular mechanism contributing to RS formation as well as to explore novel therapeutic strategies.

Aims: We explored to establish a novel model of XLSA by CRISPR/Cas9-based genome editing.

Methods: We targeted the GATA-1-binding region of intron 1 of the human ALAS2 gene based on both in vivo mice and human induced pluripotent stem cell-derived erythroid HiDEP cells (Kurita et al. PLoS One 2013). The mutation diminished the binding of transcription factor GATA-1, which would lead to decreased transcription of the ALAS2 gene, thereby causing XLSA (Kaneko et al. Haematologica 2014). Western blotting and quantitative chromatin immunoprecipitation (ChIP) analysis were performed using antibodies against GATA-1 (DSPhD, Cell Signaling Technologies) and TAL1 (C-21, Santa Cruz). For transcription profiling, Human Oligo chip 25K (Toray) was used. Quantitative ChIP analysis demonstrated that the chromatin occupancies of TAL1 in ALAS2 cells, which harbored 19-bp deletion within the intron 1 enhancer region of ALAS2, including GATA binding domain. Whereas wild-type HiDEP cells exhibited red color, the XLSA clone appeared pink/pale color, which were accompanied by the significantly decreased intracellular heme concentration. Despite no obvious changes in the expression of GATA-1 protein in the XLSA clone, quantitative real-time–polymerase chain reaction (RT–PCR) analysis demonstrated significantly downregulated expression of ALAS2 as well as globin genes (HBA, HBG, and HBB) in the XLSA clone. Microarray analysis revealed >2-fold up- and down-regulation of 619 and 274 genes caused by the 19-bp deletion, respectively. The downregulated gene ensemble included globins (HBZ, HBG, HBE, HBB, HB M, and HBQ) as well as genes involved in heme/iron metabolism (ALAS2, transferrin receptor: TFRC, coproporphyrinogen oxidase: CPOX, and mitoferrin 1: MFRT1). GO analysis revealed significant enrichment of cellular iron homeostasis (p=0.018), regulation of transcription (p=0.0021), and innate immune response (p=0.0018), implying that heme was involved in various biological processes in erythroid cells. Interestingly, ALA treatment significantly improved compromised heme production as well as downregulation of globin genes observed in the XLSA clone, suggesting that ALA may represent a novel therapeutic option for PLP-refractory XLSA.

Summary/Conclusions: The XLSA model established from HiDEP cells can be used as an important tool for clarifying the molecular etiology of XLSA and to explore novel therapeutic strategies.

P613

BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL

S. Berentsen1, U. Randen2, M. Oklam3, H. Birgins4, T.H.A. Tvedt5, J. B. Anthonsen6, 7Department of Infectious Diseases, Rikshospitalet University Hospital, Oslo, Norway, 8Department of Hematology and Stem Cell Transplantation, Turku University Hospital, Turku, Finland, 9Department of Haematology, Hertlev Hospital, University of Copenhagen, Herlev, Denmark, 10Department of Medisicne, Haukeland University Hospital, Bergen, 11Medical Department, Drammen Hospital, Vestre Viken Trust, Drammen, 12Department of Medicine, Akershus University Hospital, Nordbyhagen, 13Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, 14Department of Hematology, Oslo University Hospital, Oslo, Norway

Background: Primary cold agglutinin disease (CAD) is an autoimmune hemolytic anemia in which a well-defined clonal lymphoproliferative bone marrow disorder (LPD) causes production of monoclonal cold agglutinins. Major clinical manifestations are anemia and, in some patients, cold-induced circulatory symptoms. Pharmacological therapy, although not indicated in patients with very mild disease, seems required in a majority of cases. Corticosteroids are ineffective. Rituximab monotherapy has resulted in approximately 50% response rate and 1-year median response duration. Fludarabine and rituximab combination therapy showed 70% response rate (20% complete responses) and very long response duration, but considerable toxicity.

Aims: We wanted to investigate whether bendamustine and rituximab combination therapy can result in favorable response rates and duration with an acceptable toxicity profile.

Methods: We conducted a prospective, uncontrolled multicenter trial with 16 participating hospitals from Norway, Finland and Denmark. Essential inclusion criteria were verified CAD with symptomatic anemia and/or severe cold-induced circulatory symptoms. Eligible patients received 4 cycles of rituximab 375mg/m² day 1 and bendamustine 90mg/m² day 1-2 with 28 days interval. Outcomes were evaluated into complete response (CR), partial response (PR), and non-response (NR). The definition of CR included normalization of hemoglobin (Hb) levels with no hemolysis, complete histologic resolution of the bone marrow LDH and disappearance of monoclonal serum protein. The criteria for PR included increase in Hb levels by at least 2.0 g/dL or to the normal range, transfusion independence, at least 50% reduction of IgM and improvement of any circulatory symptoms.

Results: Forty-four patients (19 men and 25 women) were included, with a median age of 74 years (range, 48-86) and median disease duration 4 years (range, 0–18). Seventeen patients had received previous therapy. At baseline, median Hb level was 9.5 g/dL (range, 4.5–14.8), bilirubin 45micromol/L, lactate dehydrogenase (LDH) 468 U/L, haptoglobin undetectable, IgM 4.1g/L(1.0-27.2), CA 15042 (64-65536). Monoclonal IgM kappa was detected in 38 patients, IgG kappa in 1 and IgA kappa in 1. We observed CR in 16 patients (36%), PR in 15 (34%), while the remaining 13 (30%) were non-responders. Hb levels increased by a median of 4 g/dL in the responders; 4 g/dL in patients not achieving CR and 3.9g/dL in those achieving PR. Median post-therapy Hb levels were 14.2g/dL (CR), 12.5g/dL (PR) and 10.5g/dL (NR). Acrocyanosis and Raynaud symptoms resolved completely in 16 patients and improved in 11 (47% and 32%, respectively, of those with such symptoms at baseline). Histologic regresion of the LPD was complete in 17 patients (39%), partial in 5 (11%) and not evaluable in 18 (41%). Median time to response was 2 months (0.5-12). Only 3 responders experienced relapse; 2 after PR and 1 after CR. Median observed response duration was 32 months (range, 1-62) during median 32 months follow-up. A response, complete or partial, lasted longer than 1 year in 12 patients (43%). Neutropenia grade >3 occurred in 14 patients (47%), of which 8 (18%) had grade 4. Three patients (7%) experienced 1-3 episodes of febrile neutropenia, which was readily manageable. Non-hematologic toxicity occurred in 17 patients (39%), mostly consisting of mild nausea or rash. Three non-neutropenic serious adverse events (SAE) were recorded; 1 was considered probably therapy-related.

Summary/Conclusions: Bendamustine and rituximab combination therapy resulted in high response rates, a high rate of CR, long response duration and few relapses during the observation period, with a favorable safety profile. It might be considered in the first line for reasonably fit patients with CAD requiring therapy.

P614

EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS

B. van Orschot1, P.A. Kosinski2, J. Hilton3, K. Johnson2, V. Chubukov2, L. Deng2, G. Pasterkamp1, S. van Straaten14, C. Kung3, R. van Wijk1,*

1Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, Netherlands, 2Agios Pharmaceuticals, Inc., 3KSQ Therapeutics, Cambridge, MA, United States, 4Department of Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands

Background: Pyruvate kinase (PK) deficiency is a rare hereditary disorder affecting red blood cell (RBC) glycolysis. It is caused by mutations in the PKLR gene. PK-deficient RBCs are characterized by changes in metabolism associated with defective glycolysis, including a build-up of the upstream metabolite 2,3-diphosphoglycerate, and deficiency in the PK product ATP. It is hypothesized that insufficient energy production affects red cell homeostasis, promoting...
premature removal of PK-deficient RBCs from the circulation. Affected patients display chronic hemolytic anemia of variable severity. Treatment of PK-deficient patients is generally supportive, focusing on the anaemia and iron overload state, and there are no approved drugs that directly target mutated PK. AG-348 is an allosteric activator of the RBC isomor of PK (PK-R) and in clinical development for the treatment of PK deficiency.

Aims: To evaluate the effect of AG-348 treatment on PK-R enzymatic function, RBC metabolism and deformability.

Methods: Observational case-control study, approved by the Institutional Review Board. All patients gave informed consent. Enrolled patients (N=15) were adults, transfusion-independent and compound heterozygous or homozygous for PKLR mutations. Baseline metabolic profiling was performed by LC-MS/MS. Purified RBCs from patients and healthy control subjects were incubated with AG-348 (up to 10 μM) for 24 hours at 37°C. After 6 and 24 hours PK-R activity, ATP levels and RBC deformability (by Lorrca) were measured. For determination of PK-R thermal stability, RBC lysates were incubated for 2 hours with 2 μM AG-348 (10°C) prior to test. Baseline protein levels of PK-R were assessed using antibodies against PK-R.

Results: Baseline patient characteristics show strongly reduced PK-R activity in all patient cells, in particular taking into account the degree of reticulocytosis (Table 1). Distinct metabolic changes were consistent with a block of glycolysis at PK-R step. Treatment of PK-deficient RBCs with AG-348 resulted in increased enzymatic activity in all patient cells after 24 hours (mean increase 1.8-fold, range 1.2-3.4). Similar increases were observed in control cells (mean fold increase 2.3, range 1.2-7.1). ATP levels in PK-deficient cells increased upon AG-348 treatment (mean increase 2.2 fold, range 0-2.2) similar to control cells (mean increase 1.6 fold, range 1.4-1.8). Generally, PK-R thermal stability was strongly reduced in PK-deficient patient cells, illustrated by a mean loss of activity of 72% (19% for control cells) after incubation at 53°C for 60 minutes. Ex vivo treatment with AG-348 prior to incubation resulted in residual activity 4 to >10-fold higher than residual activity of vehicle-treated samples. Baseline protein level analyses suggests that a certain level of PK-R protein is required for cells to respond to AG-348 treatment ex-vivo, as treatment effects were minimal in patient cells with very low or undetectable levels of PK-R. In approximately half of the patients, ex vivo treatment with AG-348 was associated with an increase in RBC deformability, although there doesn’t appear to be a clear correlation with enzymatic or metabolic response.

Summary/Conclusions: These data support the hypothesis that drug intervention with AG-348 effectively upregulates PK-R enzymatic activity and increases stability in PK-deficient RBCs over a broad range of PKLR genotypes. The combination of AG-348 with ATP levels and RBC biochemical profile suggests that glycolytic pathway activity may be restored. AG-348 treatment may represent an attractive way to correct the underlying pathologies of PK deficiency.

P615
IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING

M.D.M. Maufu Pereira1,2, E. LLaudet Planas1, V. Rizzuto1, J. L. Vives Corrons1
1Red Blood Cell Pathology And Hematopoietic Defects, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Background: Red blood cell (RBC) membrane proteins deficiency or structural alterations lead to RBC membrane disorders such as hereditary spherocytosis, hereditary elliptocytosis or hereditary xerocytosis among others. Genetic analysis of these patients was not usually performed before next-generation sequencing (NGS). Here we present metabolic profiling by Sanger by several membrane related genes, considering that they all contain a high number of coding regions.

Aims: The aim of this study is to perform the molecular diagnosis of the patients included in the study as well as to identify new pathogenic mutations leading to RBC membrane disorders.

Methods: 116 patients from 74 unrelated families were studied with a next generation sequencing (NGS) based panel that contained genes already described as disease causing for RBC membrane disorders (ANK1, EPB41, EPB42, SLCA4A1, SPTA1, SPTB, PIEZO1, KCNN4, RHAG) as well as for enzyme deficiencies (ADA, AK1, ALDOA, BPGM, CYB5A, G6PD, GCLC, GPI, GSR, GSS, HK1, NTS3CA, PFKM, PKG1, PKLR, TP11), hemoglobinopathies (HBA1, HBA2, HBH) and congenital disserethropoietic anemias (CDAN1, C15orf41, SEC23B, KLFL1, GATA1, KIF23).

Results: A total of 74 pathogenic variants leading to RBC membrane disorders were identified, of which 14 had already been reported as disease causing. Of the remaining 60 variants, 42 had never been identified neither by 1000G or ExAC projects and therefore are novel mutations. Beta-spectrin, ankyrin and alpha-spectrin were the proteins that gathered most part of the mutations, we identified 23 variants in SPTB, 20 variants in ANK1 and 16 variants in SPTA. 48% (36/74) of the identified variants were missense changes, mostly from SPTB gene (11 genes), while a 38% (28/74) of the variants were nonsense or frameshift mutations, mostly from PKLR (9 variants). Of special interest, only 2 variants were identified in more than one unrelated family: 1) SPTB c.647T> A, leading to splicing disorder, was identified in 8 patients of 2 unrelated families, 2) SPTA1 c460_462dupTTG, leading to elliptocytosis, was identified in 6 patients from 5 different unrelated families.

Conclusion: These data support the hypothesis that drug inter-
Results: Table 1 shows clinical and laboratory characteristics of AIHA cases at onset and distribution of thermal types. Hb values were significantly lower in IgG+C wAIHA and atypical cases (p<0.001), LDH higher in IgG+C wAIHA, mixed and atypical forms (p=0.01), and Hb and LDH values were negatively correlated (r=-0.25, p=0.001). Absolute reticulocytes were reduced in CAD, mixed and IgG+C wAIHA (p<0.001) together with inadequate reticulocytosis (p=0.01). Moreover, the reticulocyte index was lower in cases with Hb<6 g/dl (65 vs 98, p=0.01), along with more frequent inadequate reticulocytosis (87 vs 70%, p=0.01). First line therapy was administered in almost all cases but 25 CAD. A second therapy line was mostly required in IgG+C wAIHA, mixed, and to a lesser extent in CAD (p=0.005). The ultra-refractory cases requiring 4 or more lines of therapy were mainly mixed, atypical and CAD. Considering anemia severity, patients with Hb>8 g/dl, more frequently required treatment after first-line (51 vs 33%, p=0.004; p=0.03), or even 3 or more therapy lines (52/71, 73% vs 19/71, 26%, p=0.001). The following hazard ratios (HR) emerged from multivariate Cox regression analysis: HR 3.2 (95% CI 1.4-7.9, 2.9 (1.4-6.2), 3.4 (1.6-7.5), for Hb <6, 6-8, and 8-10 g/dl, compared to patients with Hb >10, respectively. As regards complications, infections were observed in 14% of cases, mostly mixed AIHA (p=0.02); thrombosis occurred in 10% and acute renal failure in 3% of patients, with no relationship with AIHA type/Hb values. Evans’ syndrome was more frequent in mixed or atypical cases (p=0.04) and in severe forms (74% with Hb<8 g/dl vs 26%, p=0.005), and was associated with higher relapse risk (HR 2.3, 95% CI 1.4-3.9). Seventy patients died during the follow-up, and 12 because of AIHA-related acute complications. Higher mortality was observed for infections (HR 5.8, 95% CI), acute renal failure (HR 7.6, 95% CI) and Evans’ syndrome (HR 8.3, 95% CI).

Summary/Conclusions: In conclusion, we found that severity of anemia at onset was the major determinant of relapse risk. The lowest Hb levels were observed in patients with IgG+C wAIHA and atypical cases along with higher LDH levels and inadequate reticulocytosis, advising strict clinical observation in these patients.

P617
HEMЕ BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE
S. Sadoudi1, S. Le Jeune2, D. Charue1, L. Kiger3, L. Roumenina4, C. Boulanger1, O. Blanc-Brude1,*
1INSERM UMRs970 ParCC, INSERM, Paris, 2Hôpital Avicenne, Médecine Interne, Assistance Publique-Hôpitaux de Paris, Bobigny, 3Institut Mondor de Recherche Biomédicale, Hôpital Henri Mondor, INSERM, Créteil, 4Centre de Recherche des Cordeliers, INSERM, Paris, France

Background: Intravascular hemolysis, such as in sickle cell disease (SCD), is characterized by damage to red blood cells and extracellular vesicles in plasma, along with inflammation and tissue injury. Stressed leukocytes, platelets, endothelial and red blood cells shed microparticles (MP) that bear externalized phosphatidylserine (PS) at their surface and promote tissue injury. Conversely, intracellular annexin-A5 acts as an inhibitor of externalized PS, and is a key player in the process of transendothelial vesicle trafficking, promote cell membrane repair, protect against PS-mediated effects and enforce anti-inflammatory and anti-thrombotic control.

Aims: We investigated a possible functional relationship between intravascular hemolysis and annexins. We hypothesized that annexins, and annexin-A5 activity in particular, is blocked by intracellular heme as it is released in plasma during intravascular hemolysis.

Methods: In order to test the heme-annexin-A5 relationship, we measured PS, PS+, CD235a+ and annexin-A5+ circulating MP in adult SCD patient and matched control plasmas. We explored annexin-A5 expression in plasma and blood cells by Western blots and ELISA, and also quantified the PS-binding functionality of plasma annexin-A5 using a self-designed immunocapture assay and purified PS+ MP. Moreover, we investigated molecular interactions between purified heme and recombinant human annexin-A5 by surface plasmon resonance (BiaCore and Proteon), absorbance shift assay and protein autofluorescence quenching. Finally, we put forward a model of heme-annexin-A5 docking by 3D molecular rendering.

Results: Immunocapture of plasma annexin-A5 revealed an association with heme (Abs398 nm signature) during SCD, especially during acute hemolytic events. In SCD plasma, we found increased total annexin-A5, but virtually unde-}

haematologica | 2017; 102(s2) | 243

 Madrid, Spain, June 22 – 25, 2017
ening anemia) considered related to study drug were reported in 2/10 patients. Increases in mean arterial pressure were anticipated due to the oncotic effects of this colloidal drug, but with no consistent pattern to the changes. Changes in ECG intervals were seen in a few subjects, but those changes were not considered clinically meaningful. There were no clinically meaningful changes in laboratory values, physical examinations, or concomitant medications. There were no statistically significant changes from Baseline in leg ulcer pain and wound surface area for either Cohort. All of the wound assessments remained relatively consistent throughout the study. There were slight decreases in total VCSS at most time points, indicating slight improvement in vascular status. Results were similar for the individual scores. Summary/Conclusions: The administration of 4 or 6 once-weekly infusions of PEG-COHb at a dose of 320mg/kg was generally well tolerated. Slight improvements in total and individual VCSS are promising and may warrant further study with prolonged repeated doses of PEG-COHb.

P619
NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE
K. Gardner1,2,*, C. Sharpe3,4, M. Awogbade1
1Haematological Medicine, King’s College Hospital, 2Molecular Haematology, King’s College London, 3Renal Medicine, King’s College Hospital, 4Renal Medicine, King’s College London, London, United Kingdom

Background: Sickle cell disease (SCD) is characterized by chronic hemolysis and inflammation. Elevated levels of erythropoietin (EPO) drive expansion of erythropoiesis to compensate for increased red cell destruction. EPO is produced in response to anemia and tissue hypoxia. Previous studies in SCD suggest that EPO is inappropriate low for the degree of anemia but the reasons are unclear.

Aims: To perform a retrospective analysis of data collected as part of routine clinical care to examine the relationship between serum EPO and degree of anemia, inflammation status, hemoglobin status, alpha globin status, and renal function.

Methods: King’s College Hospital (London, UK) has a large SCD population. All patients with HbSS or HbSBthalassemia who had a serum EPO level measured between 2007 and 2013 were included. Sickle genotype, alpha globin genotype, “baseline” HbF (no hydroxycarbamide, transfusion or pregnancy) and demographic data were recorded. Other clinical variables were obtained from the same day as EPO levels (medications, laboratory values and oxygen saturation). Serum EPO was measured by chemiluminescence immunoassay (Siemens Immulite XPi). Exclusion criteria were: active vaso-occlusive crisis, transfusion within 8 weeks, chelation, erythropoiesis stimulating agent therapy, home oxygen, pregnancy and renal disease (eGFR<60mls/min or urine albumin creatinine ratio>30). Data analysis was performed in IBM SPSS Statistics 22.

Skewed variables were log transformed and estimated GFR was calculated using the MDRD formula. Normalized variables were correlated with Ln EPO using Pearson’s correlation, ordinal variables using one way ANOVA, and binary variables using independent samples 2-tailed t-test. Multivariate linear regression using Ln EPO as the outcome was performed.

Results: 245 adult (≥17 years) SCD patients (all of African or African-Caribbean origin) met the inclusion criteria. Of the 245, 241 had HbSS and 4 HbSβ0, 100 patients had no renal disease (eGFR>60mls/min or urine albumin creatinine ratio<30). Univariate analysis revealed a weak/moderate negative association between Ln EPO and HbF (r=-0.38, p<0.001). Significant associations were also seen between Ln EPO and negative correlation with PCV, oxygen saturations, Ln HbF, and positive correlation with Ln CRP, LDH, STFR, Ln uACR, cystatin C. One way ANOVA showed alpha globin status to be associated with EPO (higher EPO with more alpha chains). There was no significant association between EPO and: age, sex, eGFR, white cell count, and use of hydroxycarbamide. Multivariate linear regression (N=175) revealed alpha globin status, Hb, HbF and CrP to be independently associated with Ln EPO level, see table.

Summary/Conclusions: In our SCD cohort without renal dysfunction EPO was elevated. Unlike the non-sickle setting where Ln EPO is very strongly (negatively) correlated with Hb levels, in our SCD cohort we have found only a mild/moderate correlation. Instead, additional associations were seen between EPO and alpha globin status, CrP and HbF. Our findings suggest that in addition to Hb, other SCD severity markers influence EPO production. This may provide explanation for relative EPO deficiency, and have implications for considering therapeutic EPO in SCD.
Gene therapy, cellular immunotherapy and vaccination

P621
DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR ADULT T-CELL LEUKEMIA

K. Kawamura1, Y. Tanaka1, Y. Ishihara1, H. Nakasone2, S. Kako1, S. Kobayashi1, T. Ohmori2, K. Uchimaru3, S. Okamoto2, J. Mineno2, H. Shikui3, S. Nishimura4, Y. Kanda5
1Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, 2Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, 3Department of Biochemistry, Jichi Medical University, Tochigi, 4Department of Comparative Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 5Center for Cell and Gene Therapy, Takara Bio Inc, Shiga, 6Department for Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, 7Center for Molecular Medicine, 8Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Background: Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm caused by HTLV-1 virus infection and its prognosis remains very poor. Tax, which is the most important regulatory protein of HTLV-1, is associated with the development of ATL and is also a biologically active protein for CD8+ cytotoxic T-cells (CTLs). We previously analyzed the Tax-specific T-cell receptor (TCR) repertoire, phenotypes and functions of Tax-specific CTLs at the single-cell level in HLA-A24+ ATL patients who underwent allogeneic stem cell transplantation (allo-SCT). We found that a particular amino acid change in the TCR-β sequence motif (PDR) in the CDR3 region of TCR-β was conserved in different patients and also within the same patient before and after allo-SCT, and the PDR(+)-specific T-cell CTL clone selected expanded in ATL long-term survivors as less-differentiated effector memory CTLs. Actually, the PDR(+) CTL showed not only strong binding activity for the Tax-tetramer but also strong killing activity against patients' HTLV-1-infected T-cells without any reaction against normal cells.

Aims: Currently, we are planning a redirected T-cell immunotherapy using the PDR(+) TCR genes for ATL. Therefore, we prepared donor-derived PDR(+) TCR-transduced T-cells and evaluated their cytotoxic efficiency against HTLV-1-infected T-cells and ATL-cells both in vitro and in vivo mouse model.

Methods: HLA-A24:02 restricted and Tax301-309-specific TCR-α/β genes were cloned from an established PDR(+) CTL clone and integrated into a retroviral vector (Tax-siTCR vector) encoding small-interfering RNAs (siRNAs) to knockdown endogenous TCR genes for the efficient expression of therapeutic TCRs. Then, CD8+ T-cells of healthy volunteers were transfected with Tax-siTCR vector (Tax-siTCRs). First, cytotoxicity and cytokine production capability of the Tax-siTCRs against HTLV-1-infected T-cells or ATL-cells were evaluated using calcine-AM-based assay and flow-cytometric analysis, respectively. Next, to evaluate the in vivo anti-ATL effects by the Tax-siTCRs, the bioluminescence assay (in vivo imaging system) was performed. We generated a luciferase-gene transduced HLA-A24+HTLV-1 infected cell-line, MT-2 (Luc-MT-2), and injected 1×10⁶Luc-MT-2 cells into six-week-old NOD/Shi-scid,IL-2RγKO Jic (NOS) mice intraperitoneally. After the 3 weeks, 2×10⁵Tax-siTCRs were administered intraperitoneally, for a total of 3 times of administration, non-integrated T-cells (Mock) were administered in the same way. These mice were monitored for tumor growth using IVIS system weekly.

Results: Tax-siTCRs showed specific and strong killing activity against both HTLV-1 infected T-cells and patients' ATL-cells without any reaction against control normal-cells. In addition, Tax-siTCRs produced a sufficient amount of cytokines such as IFN-γ, TNF-α, and IL-2 against HTLV-1 infected T-cells. In mice experiments, the bioluminescence of Luc-MT-2 in the mice treated with Tax-siTCRs had started to reduce gradually after 7 weeks, and finally became undetectable after 9 weeks. In addition, macroscopic anatomical findings in the treated mice were normal after 12 weeks. In contrast, the amount of bioluminescence in the mice treated with Mock or in the control mice without treatment had rapidly increased and all mice died by 9 weeks.

Summary/Conclusions: We confirmed that Tax-siTCRs could exert a strong anti-ATL effect without significant reaction against normal cells both in vitro and in vivo. The therapy using this PDR+ Tax-siTCRs has a potential to be a novel immunotherapy for ATL patients.

P622
Abstract withdrawn.

P623
NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM PROGENITOR CELLS

F.J. Roman-Rodriguez1,2, B. Diez1,2, L. Alvarez1,2, C. Risueño1,2, R. Torres-Ruiz3, M. Corton2, C. Diaz de Heredia4, J. Sevilla5, C. Ayuso2, J. Bueren1,2, P. Rio1,2
1Division of Hematopoietic Innovative Therapies, CIEMAT/CIBERER, 2Advanced Therapies Unit, IIS-Fundacion Jimenez Diaz (IIS-FJD, UAM), 3Molecular CytoGenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, 4Department of Haematology and Oncology, Hospital Universitario Vall d’Hebron, Barcelona, 5Onco-Hematologa Pediatrica, Hospital del Niño Jesus, Madrid, Spain

Background: Allogeneic transplantation of hematopoietic stem and progenitor cells (HSPCs) is the only current curative treatment for the bone marrow failure of patients with Fanconia Anemia (FA). However, the risks of GVHD and increased incidence of subsequent cancer, and the limited availability of matched donors hamper the widespread application of this therapy in FA patients. For this reason correction of patients' HSPCs by gene therapy is considered a promising therapeutic alternative for these patients. In this context, gene editing constitutes a new step in the development of safe gene therapy approaches. Since non-homologous end joining (NHEJ) is the preferred DNA repair mechanism in HSPCs, and given that this mechanism has an important role in the maintenance of genomic stability, we have tested the efficacy of a NHEJ-mediated gene editing approach to generate compensatory mutations that can restore the FANCA protein function in HSPCs from FA patients, mimicking reversions observed in mosaic patients.

Aims: To demonstrate the feasibility of using a NHEJ-based gene editing strategy to correct FA-A HSPCs as a result of the insertions and deletions (INDELs) generated in edited FANCA sequences in these cells.

Methods: Two different FANCA mutations from FA-A patient-derived lymphoblastic cell lines (LCLs) and primary HSPCs were targeted by the CRISPR/Cas9 system. INDELs generated as a consequence of the NHEJ mechanism were analyzed at different time points.

Results: Initial studies conducted in a FA-A LCLs carrying the biallelic c.295C>T point mutation that generates a premature stop codon (p.Q99X) showed targeting efficiencies around 20%. Next Generation Sequencing (NGS) not only revealed the presence of frame-restoring repair events, but also that these events were conserved in different patients and also within the same patient before and after allo-SCT, and the PDR(+)-specific T-cell CTL clone selected expanded in ATL long-term survivors as less-differentiated effector memory CTLs. Actually, the PDR(+) CTL showed not only strong binding activity for the Tax-tetramer but also strong killing activity against patients' HTLV-1-infected T-cells without any reaction against normal cells.

Summary/Conclusions: Our results demonstrate the feasibility of the approach, a second FANCA gene correction was obtained, producing a frameshift and a premature stop codon (-p.R1187FesX2B)- with even higher gene targeting efficiencies. Finally similar studies were conducted in three HSPCs samples from FA-A patients harboring the c.295C>T mutation, that showed targeting efficiencies up to 36%. Moreover, NGS detected the presence of corrective NHEJ-repair events immediately after editing and evidence to 50-fold expansion of corrected cells after nine days in culture, confirming the functionality and proliferative advantage conferred by the frame restored alleles.

Aims: We tested the hypothesis that bi-specific CAR NK cell-targeting CAR INVARIANT NKT CELLS EXPRESSION FOR CD1D+ B CELL MALIGNANCIES

A. Rotolo1, O. Dubois1, K. Goudevenou1, K. Petev1, G.W. Cheung2, M. Pule2, J. Mahera5, A. Karadimitris1
1Medicine, Imperial College London, London, UK, 2University College London, 3King’s College London, London, United Kingdom

Background: Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm caused by HTLV-1 virus infection and its prognosis remains very poor. Tax, which is the most important regulatory protein of HTLV-1, is associated with the development of ATL and is also a biologically active protein for CD8+ cytotoxic T-cells (CTLs). We previously analyzed the Tax-specific T-cell receptor (TCR) repertoire, phenotypes and functions of Tax-specific CTLs at the single-cell level in HLA-A24+ ATL patients who underwent allogeneic stem cell transplantation (allo-SCT). We found that a particular amino acid change in the TCR-β sequence motif (PDR) in the CDR3 region of TCR-β was conserved in different patients and also within the same patient before and after allo-SCT, and the PDR(+)-specific T-cell CTL clone selected expanded in ATL long-term survivors as less-differentiated effector memory CTLs. Actually, the PDR(+) CTL showed not only strong binding activity for the Tax-tetramer but also strong killing activity against patients' HTLV-1-infected T-cells without any reaction against normal cells.

Aims: We tested the hypothesis that bi-specific CAR NK cell-targeting CAR INVARIANT NKT CELLS EXPRESSION FOR CD1D+ B CELL MALIGNANCIES

Methods: We optimized a novel protocol for manufacturing 2nd (CAR2) and 3rd (CAR3) iNKT cells expressing CAR19. Their in vitro reactivity was assessed in cytotoxicity (flow cytometry-based) and cytokine and cytotoxic granule release assays (intracellular staining and Luminex technology). In vivo reactivity was assessed in NSG xenograft assays, with monitoring of 1T1C1D1 tumour cell expansion and immune biomarkers.

Results: Our optimized protocol for selection, lentiviral transduction and clinical scale expansion of CARiNKT cells within 3 weeks is suitable for frozen and fresh lymphocytes, derived from either healthy donors or cancer, including lym-

haematologica | 2017; 102(s2) | 245
phoma patients. The manufacturing process consistently allows high CAR transduction efficiency of both T and NK cells (75.31%±4.294 and 76.95%±14.76 respectively, n=8) and ensures the preservation of CD4− iNKT cells, which have a higher cytotoxic potential and anti-tumour activity. In vitro validation, using singly- or dual-positive CD19 and CD19 targets, demonstrated that CARiNKT19 cells are CD19-specific, retain their natural CD19 specificity, and exert additive dual-specific cytotoxicity against CD19+CD19+ targets. Additional functional dissection showed that activated CARiNKT19 cells, both fresh and cryopreserved, have the ability to produce cytotoxic granules and IFNγ faster and in larger amounts than same donor activated CAR19 cells. Likewise, CAR2- and CAR3-iNKT cells are equally or more effective than their CAR1 counterparts in killing CD19+CD19− lymphoproliferative and cancer cell lines (B-lymphoblastoid C1RC1d and lymphopoma-derived Farage cells) and consistently more effective against primary MCL, MZL and CLL cells. Finally, in an in vivo NSG xenograft model of lymphoma, while survival of T- and NKT cell-treated animals was the same as that of untreated animals (P=0.23), both CAR19- and CAR19 cell-treated animals had significantly and comparably improved overall survival (P<0.001). However, compared to CAR19, CARiNKT19 immunotherapy led to a better disease control, with earlier, more profound and sustained responses resulting in a significantly improved tumour free-survival (P=0.03).

Surrogate cytokines: In our pre-clinical in vitro and in vivo lymphoma models, CARiNKT19 are more effective than CAR19 cells against CD19+CD19+ B cell malignancies. Further, dual targeting by CARiNKT19 cells may mitigate against CD19-focused tumour escape after CAR immunotherapy, while the previously demonstrated role of donor iNKT cells in protection from aGVHD supports the development of CARiNKT19 cells for 'off-the-shelf' use.

**Summary/Conclusions:** T cells transduced with NKp44-based CARs show enhanced activities against various tumor cells. The extracellular hinge region of NKp44 appears to play an important role in ligand binding and/or recognition. NKp44-based CARs may represent a promising candidate for novel immune therapies targeting a wide range of cancers.

**P626**

**NKp30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS**

P. Pichl 1, S.A. Khan 1, M. Theobald 1, U. Hartwig 1, 2

1III. Dept. of Medicine - Hematology, Internal Oncology & Pneumology, University Medical Center Mainz, Mainz, Germany
2German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany

**Background:** Adoptive cellular therapy (ACT) of chimeric antigen receptor (CAR) redirected T cells has evolved as a highly effective individualized immunotherapy for leukemia and solid cancer. In particular, clinical trials using CD19 expressing T lymphocytes to combat CD19+ lymphomas have revealed compelling results. However, suitable antigens for an effective and specific CAR-mediated therapy to acute myeloid leukemia (AML) are still warranted as e.g. CD33 and CD123 CAR expressing T cells induce potent immune responses in AML. In contrast, B7H6, a member of the B7 family, is frequently co-expressed in various tumor cell lines including AML blasts while not detectable on normal tissues, and is recognized by the natural killer (NK) cell activating receptor NKp30. Moreover, NKp30 recognizes human leukocyte antigens (HLA)-B-associated transcript 3, a nuclear factor that is secreted and translocated to the cell surface in stressed and transformed cells.

**Aims:** In the current study, we thus explored the use of human T cells redirected to express a NKp30-CAR for inducing effective antileukemic immunity in vitro and in vivo in the xenogenic mouse model of AML. We thus aimed to enable the development of an effective ACT approach utilizing the NKp30 receptor for AML.

**Methods:** Human T cells from healthy donors were stimulated with anti-CD3/CD28 beads and recombinant interleukin-2. Human NK cells were stimulated using K562-mb15-41BBL feeder cells, as previously reported (Imai C, 2005). Activated T cells or NK cells were then subjected to retroviral transduction with the CAR gene and the phenotypic and functional characteristics of CAR-T cells engrafted with the NKp30 receptor fused to the CD3ζ chain signaling domain (kindly provided by Dr. D. Masch, Dept. of Internal Medicine 3, Medical University Regensburg, Germany) by retroviral gene transfer. Transduced T cells were further selectively expanded utilizing puromycin resistance present on the retroviral backbone, and NKp30 expression was determined by flow cytometry. IFN-γ ELISPOT analyses and cytotoxicity assays were performed to assess antileukemic responses to leukemia lines and primary AML blasts in vitro and in vivo using NSG xenografts and adoptive transfer of redirected T cells. Expression of B7H6 in target cells was confirmed by RNA-based RT PCR.

**Results:** Following transduction and puromycin selection ≥90% of CD3+ T cells expressed the NKp30 CAR. In addition, most T cells displayed an effector-mem- rory phenotype. Upon co-culture with the B7H6 expressing targets such as K562 and HL-60 (myelogenous leukemia cell lines), NALM 16 (pre-B-ALL) and patient-derived AML samples (e.g. MZ506 and MZ5087) NKp30 redirected T cells elicited potent IFN-γ release and exhibited cytolytic activity to both leukemia lines and primary AML blasts in vitro. These responses were specific as e.g. no reactivity to B7H6 negative myeloma line U266 was observed. We then evaluated antitumoral responses of NKp30 redirected T cells in vivo. Upon adoptive transfer of NKp30-CAR T cells into NSG mice engrafted with K562 significant reduc- tion of tumor burden was observed. Moreover, injection of 1 - 5x106 HLA- A2-expressing MZ506-30-CAR redirected T cells into NSG mice showing up to 5% engraftment of patient derived AML blasts and thus resembling a clinically relevant minimal residual disease status at time of ACT resulted in clear leukemiam regression. Further experiments e.g. to elaborate to what extent CD4+ and CD8+ T cells contribute to this antileukemic immunity are in progress.

**Summary/Conclusions:** These studies demonstrate that human T lymphocytes can be successfully redirected to acute leukemia by NK cell activating receptor based CARs such as the NKp30-CAR. As its ligand B7H6 has not been reported to be expressed on CD34+ HSC, this antigen might be an interest- ing target for adoptive immunotherapy to AML.

**P627**

**PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANS- FER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA**

H. Echchannahuıı 1, 2, E. Amann 1, 2, E. Antunes 1, M. Theobald 1, 2

1Third Department of Medicine (Hematology, Oncology & Hemostasis), University Medical Center Mainz, Mainz, Germany
2German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany

**Background:** Adoptive cellular therapy (ACT) based on T-cell receptors (TCR) or chimeric antigen receptor (CAR)-engineered T cells has achieved tremendous success in the treatment of cancer, especially B-cell malignancies. The
impressive therapeutic results recently obtained with checkpoint inhibitors have opened a new era in the field of cancer immunotherapy. Yet, clinical responses are still often observed either transiently or in a minority of patients. This under- scores the need for an improved understanding of underlying factors limiting the efficacy of T cell-based immunotherapy and its wide application.

**Aims:** We explored an immunotherapeutic combination strategy to unleash the full power of anti-tumor function of adoptively transferred antigen-specific T cells. We propose to target multiple myeloma (MM) tumor cells in our established xenograft in vivo adoptive cell therapy model by T cells equipped with two optimized TCRs specific for HLA-A2.1-restricted MM2 and p53 peptides in combination with checkpoint inhibitors.

**Methods:** Human T cells from healthy donors were retrovirally transduced with MM2- and p53-specific TCRs and expression levels were analyzed by flow cytometry. MM2 and p53 protein expression in MM cell lines was determined by Western blot. The therapeutic efficacy of adoptive TCR transfer was evaluated in NOG-scid IL2R gamma chainnull (NSG) mice engrafted with HLA-A2.1-expressing MM cell line. In the adoptive transfer approach, mice were treated (ip) with anti-PD-1 (Nivolumab). Tumor growth was monitored and intratumoral alterations (in particular expression of relevant tumor and T cell antigens) in ex-vivo tumors were analyzed by flow cytometry. Tumor-infiltrating lymphocytes (TILs) were also characterized by flow cytometry.

**Results:** Adoptive transfer of dual MM2/p53-specific TCR-equipped T cells showed a superior anti-tumor response in vivo compared to single TCR treatment, demonstrating the need to target multiple MM antigens to circumvent tumor escape mechanisms associated with down-regulation of antigen. Yet, we observed a strong up-regulation of PD-1 expression in tumor cells in vivo and in TILs in tumors compared to cell lines which may limit the efficacy of antigen-specific TILs. Accordingly, in vivo ACT experiments combined with anti-PD-1 inhibitor, demonstrated the synergistic therapeutic potential of this approach as compared to single agent. Yet, it does not result in complete tumor eradication suggesting that targeting one single immune checkpoint receptor is not sufficient to cure this tumor resistant MM disease.

**Summary/Conclusions:** Combination checkpoint inhibitor approach has demonstrated promising potential in our ACT experimental MM model and forms the basis for a novel multi-modal immunotherapeutic combination treatment for multiple myeloma.

**P628 ENGINEERED T CELLS TOWARDS BAFF RECEPTOR: A NOVEL STRATEGY TO EFFICIENTLY TARGET B-CELL ACUTE LYMPHOBластIC LEUKEMIA N. Turazzi1,*, G. Fazio1, V. Rossi1, A. Rolink2, G. Cazzaniga1, A. Biondi3, C.F. Magnani1, E. Biag1

**Background:** Multiple myeloma (MM) is a malignant B-cell neoplasm of plasma cells. Although characterized by impressive response to novel agents, the resistance to current treatments is associated with deleterious mutations and emergence of alternatively spliced RNA isoforms, as effect of selective pressure. MM4,5 In the context of B-ALL leukemic cells expressed both BAFF and BAFF-R, R suggesting the presence of an autocrine signalling loop6,7. BAFF is also expressed in bone marrow microenvironment by endothelial cells which support the proliferation and the survival of primary B-ALL blasts.8

**Aims:** In the current study, we aimed to develop a chimeric antigen receptor (CAR) immune therapeutic approach targeting the BAFF-R molecule.

**Methods:** We characterized the expression of BAFF-R in B-ALL primary samples. As immunotherapeutic approach to target BAFF-R molecule, we developed six anti-BAFF-R.CARs that differ for the inversion of the VH and VL and the length of the spacer domain have been generated. Cytokine-induced Killer (CIK) cells, engineered using an improved Sleeping Beauty (SB) transposon system, stably expressed anti-BAFF- CARs, and maintained their characteristic phenotype. Among the newly constructed CARs, the shortest VHL anti-BAFFR.CAR exerted the highest antileukemic activity towards target cells, such as NALM-6, with an in vitro killing efficiency of 90% at 6 days post-infusion. Effectors function in terms of cytokine release by intracellular staining (8,9±2% of IFN-γ and 16,4±5% of IL-2 producing cells). Importantly, we also detected a specific cytotoxic activity towards primary B-ALL blasts (average 65,6±4,5%, n=9). Combining the IV.vsh.CAR with CD19.CAR we detected a superior antitumor activity towards ALL targets (average 72,2±2,9% of the tumor lysed by IV.vsh.CAR in NALM-6 and primary B-ALL blasts) compared to single population per se. Furthermore, by using a sample collected from a patient relapsed with CD19 negative disease, we demonstrated the ability of the IV.vsh.CAR to lyse CD19-negative blasts.

**Summary/Conclusions:** Taken together, these findings make this receptor a suitable target to re-direct the adoptive CAR strategy in case of relapse after CD19-targeting therapies or for a double targeted approach. Being restricted to mature B cells, but absent on precursors and plasmablasts, our strategy could have an inferior toxicity concerning the emergence of B-cell aplasia observed in patients treated with anti-CD19 CAR-modified T cells.

**P629 EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY B. Mir1, S. Khan1, M. Theobald1, U. Hartwig1,2

**Background:** T cell receptor (TCR) - or chimeric antigen receptor (CAR) redirected T cells have substantially improved adoptive cellular therapy (ACT) for hematological malignancies such as B-ALL, B lymphoma, chronic lymphocytic leukemia and MZ653 and NALM-16 in vitro. Studies to examine their cytotoxic potential potential of ex vivo expanded redirected lymphocytes limits their therapeutic potential and consistent efficacy. Invariant (type I) natural killer T (INKT) cells have been demonstrated not only to promote effector functions of dendritic cells (DC), natural killer (NK) cells and T cells but also to localize to tumors and have inherent antitumor properties. Moreover, as these cells are further restricted to the monomorphic, HLA class I-like CD1 molecule expressed only on few cells with limited alloreactive potential, all these features make INKT cells as attractive alternative carriers for redirected cellular therapy.

**Aims:** In the current proof of concept study we therefore explored human, AML-reactive TCR- and CD19 CAR-redirected INKT cells for their potential to induce antitumoral responses to leukemia cell lines as well as patient derived, primary AML blasts.

**Methods:** INKT cells expressing the invariant TCR composed of the VZ42Ja18/VB11 chains were immunologically isolated from PBMC derived from adult healthy donors using V B11-Ab (VB11-conjugated, anti-INKT microbeads (Miltenyi Biotech) and expanded in vitro upon coculture with autologous monocytes (Mo) loaded DC with low amounts of interleukin (IL)-2. INKT cells were retrovirally transduced on day 6 after stimulation and selected for TCR or CAR expression utilizing a virally transduced puromycin resistance. While phenotypic analyses on INKT markers and on the percentage of redirected cells were performed by flow cytometry functional assay for antileukemic cytotoxicity EL. In vitro cytotoxicity was assessed using CD19* NALM-16 (pre-B ALL) and primary AML (M2653) cells as targets.

**Results:** Following isolation of 0.7 - 0.8 x10^6 VZ42Ja18/VB11* INKT cells from PBMC we achieved on average a 120-fold expansion 21-28 days after stimulation with GalCer loaded, irradiated autologous DC and 25 U IL-2. Additional use of lenalidomide to promote expansion as described previously had no effect. Expanded INKT cells were mainly CD4+ (83%) and about 80% of cells expressed the natural killer receptor CD161 described as iNKT maturation marker. Upon coculture with autologous AML blasts, primary AML cells showed a superior anti-tumor response compared to single TCR treated cells. Importantly, we also detected a specific cytotoxic activity towards ALL targets as well as patient derived, primary AML blasts.

**Summary/Conclusions:** These studies demonstrate that purified human VZ42Ja18/VB11* INKT cells expanded from PBMC can be successfully redirected to recognize normal or leukemic AML cells but achieve good responses only in combination with redirected T cells as combination immunotherapy.

**P630 SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR) M.C. Rotiroti1, S. Arcangeli1, C.F. Magnani1, C. Cappuzzello1, A. Biondi1, S. Tettamanti1, E. Biag1
Background: Acute Myeloid Leukemia (AML) is an aggressive malignancy still associated with high relapse rates when treated with conventional chemotherapeutic and hematopoietic transplantation regimens. In search for alternative therapies of interest has been placed on anti-CD33-specific immunotherapies and in particular on T cells redirected with Chimeric Antigen Receptors (CARs) that have shown exciting results in cancer therapy, especially in the context of B-cell malignancies. CD33 is the only validated target in AML so far and represents a suitable antigen to be targeted with CAR-T cells, being broadly expressed on AML blasts.

Aims: The aim of the present study is to preclinically evaluate the efficacy and safety profiles of CD33 CAR redirected Cytokine Induced Killer (CIK) cells alone and in combination with standard chemotherapeutic agents.

Methods: Here we proved the feasibility of harnessing Cytokine Induced Killer (CIK) cells as part of an immunotherapy protocol with a third generation anti-CD33 CAR through the non-viral Sleeping-Beauty transposon system, starting from fresh and frozen healthy mononuclear cells (PBMCs) and also from frozen primary AML samples. The in vitro anti-AML activity of CD33.CAR.CIK cells is assessed by means of cyto-toxicity, proliferation and cytokine production assays upon challenge with AML cell lines or primary samples. The in vivo efficacy of CD33.CAR.CIK cells is evaluated in NSG mice transplanted with AML cell lines (MA9-NRas) and primary samples. Moreover, to investigate the potential benefit of CD33.CAR CIK cell immunotherapy in combination with standard-of-care treatments, xenograft chemotherapy models are exploited, by using standard AML induction therapy drugs (Ara-C and doxorubicin).

Results: CD33.CAR.CIK cells were able to induce a potent anti-leukemic activity as compared to unmanipulated CIK cells, in terms of specific killing (up to 70%), proliferation (up to 40% of Ki67+CAR-CIK cells) and cytokine production (up to 30% for both IL-2 and IFN-gamma producing CAR-CIK cells) when challenged with both AML cell lines and primary leukemic cells. By treating AML-NRas cell grafted mice with the already established “5+3” induction chemotheraphy protocol, we confirmed that chemotherapy is able to significantly reduce the leukemic burden from around 20% to 0.1% in the bone marrow. Since the AML disease is not totally eradicated, this model will be therefore suitable to further investigate the efficacy of the CD333.CAR.CIK cells immunotherapy on the chemotherapy resistant/residual AML cells.

Summary/Conclusions: Having demonstrated the significant in vitro anti-leukemic activity of SB-modified CD33.CAR.CIK cells we next aim to assess their efficacy in vivo, particularly against the resistant/residual AML cells that were not eradicated by standard chemotherapy treatment. Moreover, envisaging a safer clinical translation of this immunotherapeutic approach, a transient CAR expression, by using CD33.CAR coding mRNA, is under investigation, in order to limit the potential myelotoxicity due to the long-term off-target effect on normal hematopoietic stem/myeloid progenitor cells. Finally, if successful, our results will provide the preclinical validation of CD33.CAR.CIK cell immunotherapy, supporting its development to the clinic.
P632

A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

M. Van den Bergh1, L. Isenalumhe1, E. Wang2, B. Schabie1, Z. Ma1, L. Zhang1, L. S. Yeleswaram1, H. Brooks2

1University of Alabama Birmingham, Birmingham, AL, 2Indiana Blood & Marrow Transplantation, LLC, Indianapolis, IN, 3Hematology/Oncology Associates of Treasure Coast, Port St Lucie, FL, 4University of Michigan, Ann Arbor, MI, 5Hackensack University Medical Center, Hackensack, NJ, 6Greenville Health System Cancer Institute, Greenville, SC, 7Department of Medicine-Gastroenterology, Cleveland, OH, 8Utah Cancer Specialists-Network, Salt Lake City, UT, 9University of Arizona Cancer Center, Tucson, AZ, 10Incyte Corporation, Wilmington, DE, 11Incyte Corporation, Wilmington, DE, 12Karmanos Cancer Center, Detroit, MI, United States

Background: Large granular lymphocytic leukemia (LGLL) is a rare clonal lymphoproliferative disorder of post-thymic T-cell or natural killer (NK)-cell lineage associated with cytopenias, splenomegaly, autoimmune disorders, and recurrent mucocutaneous infections. Treatment is dictated by the presence of these manifestations and consists of immunosuppressive therapy.

Aims: The main aim of this study is to evaluate clinical features, hematological parameters, and survival data of patients with LGLL. The secondary aim is to assess response rates and duration of response to various first line immunosuppressive therapies in LGLL.

Methods: This is a retrospective analysis of clinical and laboratory features, treatment modalities, and outcomes of LGLL patients evaluated at Moffitt Cancer Center between January 1, 1995 and May 1, 2016. Continuous and categorical variables were tested via Kruskal-Wallis ANOVA and Fisher’s Exact Test, respectively. Kaplan-Meier curves were used for overall survival (OS), P-values were two-sided with significance set at <0.05.

Results: We identified 261 patients with LGLL (91.6% T-cell, 8.4% NK-cell). Median age was 66 years [21-90] and M:F ratio was 1:2.1. Median follow up was 3.07 years [0-21.88]. 42.9% of LGLL patients presented with anemia, 37.1% with neutropenia, 30.7% with thrombocytopenia, 29.1% with bicytopenia and 6.9% with pancytopenia. Transfusion dependence was noted in 20.3%, splenomegaly in 27.2%, and bone marrow involvement in 69.3%. 24.9% had autoimmune diseases and 9.2% had autoimmune cytopenias. 45.6% were observed while the remainder required at least one line of therapy. 5-year and 10-year OS were 75.0% and 63.1%, respectively. There was no statistically significant difference in OS, complete response rate or duration of response based on first line agent (methotrexate, cyclophosphamide, cyclosporine A). However, there was a statistically significant improved partial response with methotrexate versus other therapies (p=0.01). A marginally significant association between severe anemia/transfusion dependence and poor overall response rate (p=0.075) to any immunosuppressive therapy was noted. There was no statistically significant difference in OS based on absolute LGL count. Mean number of therapies was 1.08 (range 0-6) and was higher in patients with LGL count <0.5 k/μL (p=0.0078), bone marrow involvement (p<0.0001), and splenomegaly (p<0.0001).

Summary/Conclusions: In the large retrospective study, we described the frequency of LGLL-associated manifestations and their impact on the course of LGLL. Severe anemia/transfusion dependence, lower LGL counts, bone involvement, and splenomegaly were suggestive of more aggressive disease. We confirmed that there is no difference in overall survival among first line immunosuppressive therapies.

P634

ONGOING PHASE 1/2 STUDY OF INCBO50465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/ REFRAC TORY B-CELL MALIGNANCIES (CIITADEL-101)


1University of Alabama Birmingham, Birmingham, AL, 2Indiana Blood & Marrow Transplantation, LLC, Indianapolis, IN, 3Hematology/Oncology Associates of Treasure Coast, Port St Lucie, FL, 4University of Michigan, Ann Arbor, MI, 5Hackensack University Medical Center, Hackensack, NJ, 6Greenville Health System Cancer Institute, Greenville, SC, 7Department of Medicine-Gastroenterology, Cleveland, OH, 8Utah Cancer Specialists-Network, Salt Lake City, UT, 9University of Arizona Cancer Center, Tucson, AZ, 10Incyte Corporation, Wilmington, DE, 11Incyte Corporation, Wilmington, DE, 12Karmanos Cancer Center, Detroit, MI, United States

Background: PI3K pathway is activated in a wide variety of hematological malignancies. In PI3Kδ selective inhibitor of PI3Kδ (INCBO50465) demonstrated manageable toxicities with no clinically meaningful transaminases or PJP. Objective response rates were generally high and most responses (90%) were observed at the 9-week disease assessment. Different dosing regimens/schedules, long-term safety, and disease-specific cohorts are being evaluated.

Methods: In this phase 2/1 study, eligible patients ≥18 years of age had relapsed/refractory lymphoid B-cell malignancies (excluding Burkitt’s lymphoma and precursor B-cell lymphoblastic leukemia/lymphoma), Eastern Cooperative Oncology Group performance status score ≤2 (≤1 during dose escalation), normal liver and kidney function, and had not received autologous hematopoietic stem-cell transplant (HSCT) within 3 months or allogeneic HSCT within 6 months of screening. The protocol was initiated with a single-patient cohort, treated with oral INCBO50465 5mg QD. Subsequent cohorts used a 3+3 design and evaluated doses of 10–45mg QD. Based on PK/pharmacodynamics, the 20 and 30mg QD cohorts were expanded. Responses were assessed every 9 weeks using the Lugano Classification or International Working Group on Chronic Lymphocytic Lymphoma (CLL) criteria.

Results: As of the data cutoff (Nov 1, 2016), 52 patients were treated (median age 65 years, range [39-88]). Baseline disease subtypes included diffuse large B-cell lymphoma (DLBCL; n=14), follicular lymphoma (FL; n=10), Hodgkin lymphoma (HL; n=9), marginal zone lymphoma (MZL; n=8), CLL (n=6), and mantle cell lymphoma (MCL; n=5). Sixty-two percent (n=32) of patients had ≥3 prior systemic regimens; 31% (n=16) had prior HSCT. Median duration of therapy was 11 months (range, 0.6–13.4); no DLTs were identified. Seventy-seven percent of patients discontinued therapy, most commonly due to disease progression (31%) and AE (25%). Thirty-three percent of patients had dose interruption and 4% had dose reduction. Most common nonhematologic AEs (all grade; grade ≥3) were nausea (38%; 0%), diarrhea (31%; 6%), and vomiting (25%; 0%). Grade ≥3 hematologic AEs included neutropenia (21%), lymphopenia (17%), thrombocytopenia (10%), and anemia (4%). Forty percent of patients had serious AEs (SAEs), most frequently colitis, diarrhea, and hypotension (all n=3). One patient had grade 3 pneumonitis; none had Pneumocystis jirovecii pneumonia (PJP) or grade ≥2 elevated transaminase. Objective responses occurred at all doses (Table 1), except 5mg QD; 90% of the objective responses were observed at the 9-week disease assessment.

Table 1.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Objective Response, n (%)</th>
<th>Complete Response, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20mg</td>
<td>11/13 (85%)</td>
<td>4/13 (31%)</td>
</tr>
<tr>
<td>30mg</td>
<td>11/13 (85%)</td>
<td>4/13 (31%)</td>
</tr>
<tr>
<td>40mg</td>
<td>11/13 (85%)</td>
<td>4/13 (31%)</td>
</tr>
<tr>
<td>50mg</td>
<td>11/13 (85%)</td>
<td>4/13 (31%)</td>
</tr>
<tr>
<td>60mg</td>
<td>11/13 (85%)</td>
<td>4/13 (31%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In patients with relapsed/refractory B-cell malignancies, INCBO50465 demonstrated manageable toxicities with no clinically meaningful transaminases or PJP. Objective response rates were generally high and most responses (90%) were observed at the 9-week disease assessment. Different dosing regimens/schedules, long-term safety, and disease-specific cohorts are being evaluated.
lymphoma (IFL). Upon informed consent, patients receive 12 cycles of R² induction with daratumumab, 21 d of 28 d of rituximab, 375mg/m² weekly cycle 1 [d1, 8, 15, 22], then d1 of odd cycles. Responders to induction (≥SD) are randomized: 1:1 to maintenance with either R² or rituximab alone (18 cycles); following R² maintenance, optional single-agent lenalidomide (10mg/d, 21 of 28 d) can be given until PD. The primary endpoint is progression-free survival (PFS).

**Results:** As of April 14, 2016, 106 patients with R/R FL have been enrolled, including 103 with grade 1-3a FL, 2 with tFL, and 1 unknown grade. Median age of patients with FL was 66 y (range, 41-91); most had ECOG PS of 0-1 (99%) and stage III/IV disease at study entry (80%). Patients received a median of 2 prior therapies (≥2, 30%; 103 (97%) patients had received prior rituximab-containing treatment, of which 35% were rituximab refractory (defined as best response of SD/PD to rituximab/rituximab-containing regimen or a CR/PR of <6 mo after the last rituximab dose). The most common prior regimens were rituximab alone (40%), R-CHOP/R-CHOP-like (38%), and bendamustine plus rituximab (35%). Premature discontinuation of lenalidomide occurred in 39 (37%) patients during the induction period, mainly due to AEs (n=20); the most common treatment-related AE leading to early discontinuation in the induction period was neutropenia in 8 patients. Four (4%) patients’ conditions continued the study. Common grade 3/4 treatment-emergent AEs during induction were fatigue (79%), nausea (76%), vomiting (65%), and headache (62%). At a median induction duration of 23 weeks (range, 0.4-51), the most common AEs were chemotherapy-related (n=104) and included 27% neutropenia, 7% leukopenia, and 6% fatigue. At the median induction duration of 23 weeks (range, 0.4-51), 83 FL patients were evaluable for response with an overall response rate (ORR) of 65%; those who were rituximab refractory had improved ORR compared to rituximab refractory patients (70% vs 55%; Table 1). The median time to response during the induction phase was 2.8 mo. Twenty patients have completed 2 cycles of induction and 16 proceeded to maintenance (n=6 R², n=10 rituximab alone). Enrollment is ongoing.

**Table 1.**

<table>
<thead>
<tr>
<th>Safety population</th>
<th>CT-P10 (N=97)</th>
<th>RTX (N=99)</th>
<th>Difference</th>
<th>lower bound of 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS (ITT)</td>
<td>34 (35)</td>
<td>34 (36)</td>
<td>0.094</td>
<td>-0.034</td>
</tr>
<tr>
<td>Serious Toxicity</td>
<td>5 (5)</td>
<td>4 (4)</td>
<td>0.474</td>
<td>0.069</td>
</tr>
<tr>
<td>Infusion-related reaction</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>0.785</td>
<td>-0.285</td>
</tr>
</tbody>
</table>

* Difference was calculated using percentages not the round off values.

**Summary/Conclusions:** R² induction therapy shows favorable activity and a tolerable safety profile in patients with advanced-stage, R/R FL. The study is ongoing to determine the effect of R² vs rituximab maintenance in FL patients, and updated results will be presented.

**P635**

**A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVPP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA**


1Clinica di Ematologia, 2Istituto di Anatomia Patologica, 3Clinica di Dermatologia, Ospedale di Macerata, Macerata, 4Clinica di Dermatologia, Ospedale di Jesi, Jesi, Italy

**Background:** Early stage Mycosis Fungoides (MF) has an indolent, relapsing course, with patients frequently undergoing multiple therapies. Current guidelines consider the utility of combination therapies (skin-directed therapies plus systemic biologic response modifiers) to increase the therapeutic efficacy. Recently, time to next treatment (TTNT) was applied as a new relevant measure of the durability of response of PUVA, interferon-alpha (IFN-α) and retinoids as monotherapies in early MF (Hughes et al, AJH 2016; Hanel et al, AJH 2016), but it has not been yet investigated in combination therapies.

**Aims:** We aimed to evaluate TTNT together with the usual time-event measures (OS and EFS) in the series of 89 early MF patients treated for 14 months with CT-P10 (infusion (IFN) 6-18 MU weekly) and PUVA, which was first reported in 2005 (Rupoli et al, EJH 2005). The follow-up was prolonged until October 2016, in order to evaluate prospectively the regimen activity and influence on the further course of the disease.

**Methods:** The design, rationale, safety and efficacy results for this protocol were previously published. Clinical stages IA-IIA patients who had received no previous treatment, or had been submitted to a 4-month wash-out after systemic therapy or a 4-week wash-out after topical therapy, were included in the study. Survival curves for each efficacy endpoint were calculated according to Kaplan-Meier.

**Results:** Eighty-nine patients (56 men and 33 women) with a median age of 60 years (range, 17-80) were recruited. Disease stage IA in 22 patients, IB in 55, IIA in 11, and IIB in 1 patient. The majority of patients had generalized skin disease (75% T2 vs 25% T1). The protocol proved to be highly effective, well tolerated and able to induce complete clearing of skin lesions in 84% of cases (99% of patients). The median follow-up time was 175 months (range 4-259). Updated data showed that the median overall survival (OS) was not reached, whilst the median event-free survival (EFS) was 142 months (95% CI, 130-153). Estimated OS rates at 1, 2, 5, 10, 15 and 20 years.
were 99%, 98%, 92%, 89%, 78% and 51%; at 1, 2, 5, 10, 15 and 20 years 98%, 97%, 88%, 67%, 19%, 0%, were free from events. Median TTNT was not reached thus indicating clinical benefit with IFN-α and PUV. Kaplan-Meier estimated rates of 97% at 1 year, and 91% at 2 years, respectively whereas 5-, 10-, 20-year TTNT remained almost unchanged with 62% of patients that still had not required further treatment.

Summary/Conclusions: There has been an ongoing debate about whether patients would benefit from adding PUV to IFN-α in the treatment of early stage MF. We chose to initiate the combination treatment of MF as early as possible in the course of the disease to induce a permanent remission or even a cure. In our experience, this regimen set the realistic goal of achieving high rates of complete clearing and durable responses (median TTNT not reached) with only 38% of patients requiring a subsequent systemic treatment within 20 years. Here, we suggest a synergistic or additive effect between PUV and IFN-α compared with either agent alone. With respect to Hughes et al. (Blood 2015), our combination treatment provides a longer TTNT than PUV or IFN-α monotherapy (36.3 months and 15.7 months, respectively). At 2 years, 91% of patients receiving PUV plus IFN-α were free from further treatment as compared to 54.2% and 29.1% treated with PUV or IFN-α monotherapy, respectively.

P637

PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN’S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL Lymphoma (CTCL): NUMBER NEEDED TO TREAT ANALYSIS


1Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States; 2The University of Melbourne, Victoria, Australia; 3Augsburg; and Si Thomas Nash Foundation Trust, London, United Kingdom; 4Memorial Sloan Kettering Cancer Center, New York, New York; 5The University of Texas MD Anderson Cancer Center, Houston, Texas; 6Stanford University School of Medicine and Stanford Cancer Institute, California, United States; 7University Hospital Zürich, Zürich, Switzerland; 8University Hospital Birmingham, Birmingham, United Kingdom; 9University of Turin, Turin, Turin, University Bologna, Bologna, Italy; 11University Hospitals Leuven, Leuven, Belgium; 12Columbia University, New York; 13Seattle Genetics, Inc., Bothell, United States

Background: CTCL is a generally incurable, relapsing disease associated with a significant symptom burden, including disfiguring lesions, debilitating pruritus and frequent skin infections. ALCANZA is a Phase 3 study of BV vs PC (MTX or Bex) for the treatment of CD30-positive (CD30+ CTCL) (NCT01578499). BV was associated with significantly improved rate of objective response lasting ≥4 months (ORR4; 56% vs 13%; p<0.0001), longer median progression-free survival (16.7 vs 3.5 months; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to placebo, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.

Aims: To determine the NNT with BV to avoid one additional event of disease progression/death compared with PC in the ALCANZA trial.

Methods: The NNT with BV was calculated as the inverse of the absolute risk reduction (ARR); ARR was the risk difference of objective response lasting ≥4 months; ORR4; 56% vs 13%; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to the comparator therapy, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.

Aims: To determine the NNT with BV to avoid one additional event of disease progression/death compared with PC in the ALCANZA trial.

Methods: The NNT with BV was calculated as the inverse of the absolute risk reduction (ARR); ARR was the risk difference of objective response lasting ≥4 months; ORR4; 56% vs 13%; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to the comparator therapy, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.

Aims: To determine the NNT with BV to avoid one additional event of disease progression/death compared with PC in the ALCANZA trial.

Methods: The NNT with BV was calculated as the inverse of the absolute risk reduction (ARR); ARR was the risk difference of objective response lasting ≥4 months; ORR4; 56% vs 13%; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to the comparator therapy, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.

Aims: To determine the NNT with BV to avoid one additional event of disease progression/death compared with PC in the ALCANZA trial.

Methods: The NNT with BV was calculated as the inverse of the absolute risk reduction (ARR); ARR was the risk difference of objective response lasting ≥4 months; ORR4; 56% vs 13%; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to the comparator therapy, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.

Aims: To determine the NNT with BV to avoid one additional event of disease progression/death compared with PC in the ALCANZA trial.

Methods: The NNT with BV was calculated as the inverse of the absolute risk reduction (ARR); ARR was the risk difference of objective response lasting ≥4 months; ORR4; 56% vs 13%; p<0.0001), and decreased symptom burden measured by Skindex-29 (27.96 vs 8.62; p<0.0001), compared with PC. BV’s safety profile was consistent with previous reports, with all-grade and grade 3 peripheral neuropathy of 67% and 9%, respectively. Number needed to treat (NNT), defined as the number of patients (pts) that need to be treated to prevent one disease progression event or death compared to the comparator therapy, is an effective method to assess the benefit-risk of BV in a clinically relevant manner. NNT values of 3–28 have been previously reported, at various time points, in hematologic malignancies (multiple myeloma, B-cell non-Hodgkin lymphoma) to prevent one disease progression event or death. Data from the Phase 3 AETHERA study demonstrated that, at various time points, and dependent on risk group, one in 3–8 Hodgkin lymphoma pts treated with BV consolidation therapy post-autologous stem cell transplant will benefit by avoiding disease progression/death, compared with placebo.
according to histopathologic subtypes, BM involvement alone was regarded as a statistically significant factor in the group of non-MALT lymphoma (HR=3.99, p=0.013) and there were no statistically significant factors in the group of non-MALT lymphoma. Although there were no risk factors with statistical significance, the BM involvement and advanced TNM stage showed a trend toward statistical significance because affecting to the failure of PFS (BM involvement of HR=5.19, p=0.054 and advanced TNM stage of HR 3.06, p=0.056). The median time-to-progression (TTP) was from 3 to 3.5 years after initial therapy in relapse or dead patients (range from 4.6 to 109.6 months).

Summary/Conclusions: Our study confirmed that OAL of all histologic subtypes also represented the indolent nature and localized behavior with favorable survival outcomes. Although BM involved OAL consisted of a small number, it was associated with poor survival outcomes. Also, relapse and lymphoma-related mortality had long-term delayed TTP, so we suggested that BM biopsy might be a necessary study for initial staging at least in all OAL and long-term follow-up is required for patients with all histologic type of OAL.

P639

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES

1Department of Haematology, University Hospital, University of Crete, Heraklion, 2Department of Haematology, Athens Medical Center-Psychikon Branch, 3Department of Haematology, 41st Department of Propedeutics, University of Athens, Laikon General Hospital, 5Immunology Laboratory, Laikon General Hospital, 6Department of Pathology, 72nd Department of Internal Medicine, University of Athens, Athens, Greece

Background: Clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ) has been recognized as a provisional entity in the WHO classification. Despite diagnostic similarities with SMZL, the exact relation between them has not been established yet. AIM: To describe the main features of CBL-MZ and to further elucidate its relation to SMZL.

Aims: To describe the main features of CBL-MZ and to further elucidate its relation to SMZL.

Methods: 96 CBL-MZ were analyzed. Staging at diagnosis included CBCs, blood morphology and immunophenotype, biochemistry, viral test for hepatitis C and B, serum immunoglobulin levels and immunofixation as well as whole body CT scan. BM biopsies were available in 78 cases which were studied with the following panel of moAbs: CD20, DBA44, CD23, CD5, CD25, CD38, CD27, s/cIgM/D, TCL-1, NDNA, T-bet and IRTA-1. Gastroscopy with multiple biopsies was performed in 58 cases. FISH analysis for del17q was done in 13 cases. MYD88 mutation in 60.

Table 1: Table of main disease features of CBL-MZ (pts)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>% of # of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (gender)</td>
<td>56%</td>
</tr>
<tr>
<td>ALC (median)</td>
<td>37 (8-75)</td>
</tr>
<tr>
<td>Circulating B-cell counts</td>
<td>1200 (60-8000)</td>
</tr>
<tr>
<td>Circulating T-cell</td>
<td>600 (300-1200)</td>
</tr>
<tr>
<td>M/lye (count)</td>
<td>10 (3-20)</td>
</tr>
<tr>
<td>Serum IgM (median)</td>
<td>2880 (509.8-2880)</td>
</tr>
<tr>
<td>Serum IgA (median)</td>
<td>125 (5.8-500)</td>
</tr>
<tr>
<td>Serum IgG (median)</td>
<td>1050 (100-6500)</td>
</tr>
<tr>
<td>Serum IgD (median)</td>
<td>0.8 (0.06-9)</td>
</tr>
<tr>
<td>Serum IgE (median)</td>
<td>0.3 (0.05-0.7)</td>
</tr>
<tr>
<td>Other organ involvement</td>
<td>26%</td>
</tr>
<tr>
<td>Outcome</td>
<td>Death</td>
</tr>
<tr>
<td>Duration (months)</td>
<td>5</td>
</tr>
</tbody>
</table>

Results: A synoptic presentation of the main characteristics of CBL-MZ is given in the table. The median age was 70 y without sex predelection. By definition, no case presented with cytopenia, lymphadenopathy, splenomegaly or any other organ involvement. Median ALC and clonal B-cell counts were 5098/μL and 2880/μL, respectively. 47% had paraproteinemia, mainly of the IgM type. H.pylori (+) gastritis was evident in 30%. Hp eradication had no influence on the lymphocyte counts. The percentage of BM infiltration was highly variable, ranging from 10% to 85%, with an intrasinusoidal pattern in 31%. TCL-1, T-bet, IRTA-1, and NDNA were invariably negative. MYD-88 mutation was detected in 18% and was significantly associated with IgM paraproteinemia. 6 cases were lost to follow-up. At a median follow-up time of 41 months, the majority of the cases had no disease progression (90%). 61% had stable CBCs, 20% solely an increase in ALCs and 7% an increase in paraproteinemia only, while in 2% lymphocytosis regressed. A total of 9 (10%) pts progressed and required treatment: 5/9 due to cytopenias caused by extensive BM infiltration without splenomegaly, 1 due to bulky splenomegaly, 1 due to lymphadenopathy, 1 developed autoimmune thrombocytopenia, while in one due to high IgM levels in a MYD-88(-) case. A total of 5 (6%) pts developed splenomegaly after a median time of 78 mos (48-151).

Summary/Conclusions: After a median follow-up time of 4y we demonstrated that CBL-MZ, although displaying many diagnostic similarities with SMZL, it rarely remain to it. Most cases remain to stable, while few develop cytopenias due to an extensive BM infiltration. These latter cases apparently represent a distinct MZL category which requires further investigation.

P640

SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY

C. Panizo1,*, M.A. Bekadja2, B. Meddeb3, O. Meier4, R. Smith4, M. Truman5, C. Barata6
1Clinica Universidad de Navarra, Pamplona, Spain, 2University Hospital Estab-lishment, Oran, Algeria, 3Aziza Othmana University Hospital, Tunis, Tunisia, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5F. Hoffmann-La Roche Ltd, Dee Why, Australia, 6University of Pisa, Pisa, Italy

Background: Intravenous (IV) rituximab is the mainstay of treatment for CD20+ B-cell non-Hodgkin lymphoma (NHL). A subcutaneous (SC) formulation of rituximab has been approved in Europe and other countries that reduces health-care resource burden and improves patient (pt) satisfaction and convenience compared with rituximab IV. MabReilla is a global umbrella study comprising three local open-label, single-arm, Phase IIIb studies of rituximab SC, which share a core protocol and primary endpoint but have flexibility for exploratory endpoints (NCT01889069; NCT01987505; NCT02406092). Data from participating countries are pooled for predefined global analyses.

Aims: To evaluate the safety of first-line (1L) rituximab SC in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with a focus on administration-related reactions (ARRs).

Methods: Eligible pts were aged 18–80 years with grade 1–3a FL/DLBCL and ECOG performance status ≤3. All pts had received ≥1 full dose of rituximab IV as 1L induction/maintenance before study entry, and were expected to receive ≥4 additional induction cycles (FL/DLBCL) or ≥6 additional maintenance cycles (FL). Informed consent was obtained. For induction, pts received rituximab SC 1400mg every cycle (14, 21 or 28 days) for 4–7 cycles, plus standard chemotherapy. FL pts undergoing maintenance treatment received single-agent rituximab SC 1400mg every 2 months for 6–12 cycles. The primary endpoint was incidence of ARRs, i.e. all adverse events (AEs) occurring within 24 hours of administration, considered related to study drug by the investigator. Secondary endpoints included grade ≥3 AEs and serious AEs (SAEs). The safety analysis included all pts who received ≥1 dose of study treatment. Safety data were not collected for rituximab IV, as pts entered the trial after switching to SC. Updated data are presented (data cut-off February 7, 2017).

Table 1: Table of adverse events of SC rituximab

<table>
<thead>
<tr>
<th>Parameter</th>
<th>% of # of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (gender)</td>
<td>56%</td>
</tr>
<tr>
<td>ALC (median)</td>
<td>37 (8-75)</td>
</tr>
<tr>
<td>Circulating B-cell counts</td>
<td>1200 (60-8000)</td>
</tr>
<tr>
<td>Circulating T-cell</td>
<td>600 (300-1200)</td>
</tr>
<tr>
<td>M/lye (count)</td>
<td>10 (3-20)</td>
</tr>
<tr>
<td>Serum IgM (median)</td>
<td>2880 (509.8-2880)</td>
</tr>
<tr>
<td>Serum IgA (median)</td>
<td>125 (5.8-500)</td>
</tr>
<tr>
<td>Serum IgG (median)</td>
<td>1050 (100-6500)</td>
</tr>
<tr>
<td>Serum IgD (median)</td>
<td>0.8 (0.06-9)</td>
</tr>
<tr>
<td>Serum IgE (median)</td>
<td>0.3 (0.05-0.7)</td>
</tr>
<tr>
<td>Other organ involvement</td>
<td>26%</td>
</tr>
<tr>
<td>Outcome</td>
<td>Death</td>
</tr>
<tr>
<td>Duration (months)</td>
<td>5</td>
</tr>
</tbody>
</table>

Results: The safety population comprised 421 pts: 160 Italy; 140 Spain; 121 North Africa (Tunisia, Morocco and Algeria). Median age was 58 years (range 19–80); 49% of pts were male; 225 pts had FL and 196 had DLBCL. Of the pts with FL, 97 completed ≥1 cycle of rituximab SC induction (45 completed 7 cycles) and 204 completed ≥1 cycle of maintenance (175 completed 6 cycles;
73 completed 12 cycles). Among DLBCL pts, 99 completed 7 cycles of induction therapy and overall survival were 33mo, 45.8mo and 78% at 5 years, respectively. Dose reductions >20% had no impact on these outcomes, but age >65y had a significant impact. Therapy and overall survival were 33mo, 45.8mo and 78% at 5 years, respectively. Dose reductions >20% had no impact on these outcomes, but age >65y had a significant impact. Therapy and overall survival were 33mo, 45.8mo and 78% at 5 years, respectively. Dose reductions >20% had no impact on these outcomes, but age >65y had a significant impact.

### Summary/Conclusions:

In real-life practice are lacking. Indeed, outside clinical trials, patients are older and experience more health issues. Dose reductions >20% had no impact on these outcomes, but age >65y had a significant impact. Therapy and overall survival were 33mo, 45.8mo and 78% at 5 years, respectively. Dose reductions >20% had no impact on these outcomes, but age >65y had a significant impact.

**P641**

**REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA: A RETROSPECTIVE STUDY FROM 163 PATIENTS**

C. Protin1,*, L. Oberic1, P. Bories2, G. Laurent1, F. Despas3, L. Ysebaert1

1Hematology, 2Oncomip regional cancer network, IUC Toulouse-Oncopole, 3Clinical Pharmacology, University of Toulouse, Toulouse, France

**Background:** Symptomatic Waldenstrom macroglobulinemia (WM) may be managed with various regimens. After the 8th IWWM congress, experts recommended the use of rituximab-based regimens. Two phase II trials treated DRC (n=72), IL and RF (n=43), one-third of which had received chlorambucil alone, +/- steroids/rituximab before, with published long-term follow-up of 95 and 46 months, respectively. Mature data from larger cohorts confirming trials’ results in real-life practice are lacking.

**Aims:** Mature data from larger cohorts confirming trials’ results in real-life practice are lacking. Indeed, outside clinical trials, patients are older and experience potentially more long-term side effects.

**Methods:** We report data from a retrospective study in 163 symptomatic WM treated as first-line treatment (or second-line after chlorambucil, n=47) with RF (n=56) or DRC (n=108) between January 01, 2005 and December 31, 2015.

**Results:** Median follow up for the entire cohort is 5 years, median age at diagnosis 68y and at therapy 71y. 75% being above 65y at treatment. Significant differences between DRC/RF cohorts were: median age 74/64, high IPSS score 63%/28%, 2B2M>3/74%/56%, DRC cohort: median PFS/Time To Next Therapy and Overall Survival were 33mo, 45.8mo and 78% at 5 years, respectively. Dose reductions >20% had no impact on these outcomes, but age >65y and anemia >11.5g/dl decreased PFS. Previous CLB therapy increased the risk for delayed toxicities (infections 19% vs 16%, myelodysplasia 13% vs 3.8%), but not second cancers including Richter transformation. IPSS scoring system predicted PFS and OS with good accuracy. RF cohort: median PFS/Time To Next Therapy and Overall Survival were 33mo, 65% and 90% at 5 years, respectively. Previous CLB had no impact on outcomes, but dose reductions >20% adversely impacted TTNT. IPSS scoring system did not improve prognostication. Long-term follow-up (22% of patients had second solid cancers. RF significantly increased the risk of Richter, and CLB exposure the risk of myelodysplasia. Second PFS upon salvage (PFS2) was available in 72 patients: 47 DRC (PFS2 47mo), and 25 RF (PFS2 66mo), not significantly different.

**Summary/Conclusions:** We conclude that clinical trials results of DRC and RF are reproduced in our real-life cohort despite older ages, and high IPSS scores. Long-term toxicities are also seen, at similar rates and second cancers monitoring should be part of physician’s practice in these WM patients.

**Infectious diseases, supportive care**

**P642**

**MACIFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPLOYED ANTIMICROBIAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL**

K. Otake1,*, H. Sugawa2, R. Sasaki3, H. Fujisawa1,3, R. Sasaki2,3, W. Izumida1,4, T. Mine5, M. Asahi1, Y. Suzuki1, Y. Okano1, Y. Fujishima1,3, Y. Aoki1, S. Kowata1, I. Hanamura2, K. Murai1, S. Itō3, Y. Ishida1

1Department of Hematology and Oncology, Internal Medicine, Iwate Medical University School of Medicine, Morioka, 2Division of Hematology, Department of Internal Medicine, Iwate Prefectural Chubu Hospital, Kitakami, 3Division of Hematology, Department of Internal Medicine, Hachinohe Red Cross Hospital, Hachinohe, 4Division of Hematology, Department of Internal Medicine, Iwate Prefectural Ohfunato Hospital, Ohfunato, 5Division of Hematology, Department of Internal Medicine, Morokda Red Cross Hospital, Morokda, 6Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, 7Division of Hematology, Department of Internal Medicine, Iwate Prefectural Central Hospital, 8Department of Medical Oncology, Iwate Medical University School of Medicine, Morioka, Japan

**Background:** Invasive fungal infections (IFIs) incur significant morbidity and mortality in neutropenic patients with hematological malignancies (HEM) after chemotherapy. The risk for these infections is related to the intensity and duration of neutropenia, and varies from 2% to 40%. Mortality rates associated with documented IFIs are considerable, reportedly ranging from 30% to 60%. Empirical antifungal therapy is the standard care for neutropenic patients with HEM, whereas febrile neutropenia and broad-spectrum antibacterial treatment. Several antifungal agents including voriconazole (VRCZ) or liposomal amphotericin B (L-AMB) have been studied as empirical therapy for febrile neutropenia (FN).

However, limited data are available concerning the efficacy and safety of micafungin (MCFG) in FN patients with HEM.

**Aims:** We conducted a randomized, cooperative group, open-label trial comparing MCFG (150mg once daily) with L-AMB (2.5mg/kg once daily) as first-line empirical antifungal treatment for FN patients with persistent fever of HEM.

**Methods:** 138 hospitalized FN patients with persistent fever of HEM (AML 78, APL 4, ALL 13, MDS (RAEB) 7, NHL 28, MM 5, other hematological malignancy 3 cases) were randomized to each drug group (MCFG, 72; L-AMB, 66). The efficacy end point was a favorable overall response, as determined by a five-component end point according to the criteria of Walsh et al (N Engl J Med 2004; 351: 1391).

**Results:** At the time of enrolment, there were no significant differences in the demographics or baseline characteristics between the two groups. The mean treatment duration for MCFG and L-AMB was 13.8 and 16.4 days, respectively. The efficacy rates of MCFG and L-AMB were not significantly different (38/72 cases (52.8%) vs 26/66 cases (39.4%), p=0.115%), evaluated based on: (1) successful treatment of baseline fungal infection (3/4 cases (75.0%) vs 0/1 case (0%), p=0.170%), (2) absence of breakthrough fungal infection (65/72 cases (90.3%) vs 65/66 cases (98.5%), p=0.112%), (3) survival for ≥7 days after completion of 66/72 cases (91.7%) vs 59/66 cases (89.4%), p=0.854%), (4) absence of premature study drug discontinuation due to poor efficacy or drug-related adverse events (54/72 cases (75.0%) vs 47/66 cases (71.2%), p=0.6153), and (5) resolution of fever during neutropenia (45/72 cases (62.5%) vs 33/66 cases (50.0%), p=0.2588).

However, due to poor efficacy or drug-related adverse events, the efficacy rates of MCFG and L-AMB were not significantly different (38/72 cases (52.8%) vs 26/66 cases (39.4%), p=0.115%). In safety evaluation, adverse events contributing to reduced morbidity and improved survival of high-risk patients in hematological therapy. However, besides their well-known antifungal activity there is a growing body of evidence for immunomodulatory side effects on different effector cells of the immune system.
Aims: The aim of our study is to clarify the immunomodulatory capacity of different antifungal drugs on the effector functions of polymorphonuclear neutrophils (PMN) and on the clinical course of invasive pulmonary aspergillosis (IPA).

Methods: Firstly, isolated PMN from healthy donors were preincubated with different antifungals in vitro. Here, we used the azoles fluconazole (FLU), voriconazole (VOR), and isavuconazole (ISA), as well as the echinocandins caspofungin (CAS) and micafungin (MIC), and the polyenes amphotericin B (AmB) and liposomal amphotericin B (LAMB). Furthermore, PMN were simultaneously stimulated with lipopolysaccharides (LPS) or zymosan. Afterwards, PMN were analyzed by flow cytometry regarding activation, degranulation, and phagocytosis. Additionally, a dichlorofluorescein assay was used to detect reactive oxygen species (ROS). IL-8 synthesis was measured by enzyme-linked immunosorbent assay (ELISA). Secondly, a murine model was used to investigate the influence of MIC and POS on the clinical course of IPA in vivo. Therefore, mice were treated with antifungals and inoculated intratracheally with A. fumigatus conidia. Afterwards, mice were analyzed concerning fungal burden and pulmonary damage (albumin ELISA) with neutrophic animals serving as controls.

Results: In vitro, pretreatment with POS lead to enhanced activation (CD62L: 44% +/- 8 vs 13 +/- 2, *; mean +/- SEM, p value ≤0.05 considered to be significant). Furthermore, treatment with POS resulted in reduced fungoidal burden as expected but lead to reduced albumin concentration in BAL (111 ng/ml +/- 46 vs 380 +/- 31, *) indicating a decreased pulmonary damage. Despite significant influence on PMN effector functions in vitro, MIC did not affect clinical course IPA in vivo.

Summary/Conclusions: AmB and POS induce PMN activation, whereas ISA and MIC inhibit PMN effector functions in vitro. CAS shows variable modification on PMN. Possibly independent from its antifungal effects, POS reduces pulmonary damage in mice suffering from IPA in vivo. Furthermore studies need to distinguish the obviously multidimensional immunomodulatory effects of different antifungal agents and to clarify their relevance in clinical practice.

P644

CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMLA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RELIANCE STUDY GROUP

C. Cattaneo1, C. Paganini1, V. Mancini2, P. Zappasodi3, A. Ferrarini4, F. Pavesi5, E. Todisco6, N.S. Fracchioni7, V. Sacca8, L. Verga9, M. Petullia1, A. Nosari1, G. Rossi1

1Hematology, Spedali Civili, Brescia, 2Hematology, Ospedale Niguarda, Milan, 3Fondazione IRCCS Policlinico S. Matteo, Pavia, 4Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, 5San Raffaele Scientific Institute of Milan, 6Hematology, Ospedale Valduce, Como, 7Hematology, San Gerardo Hospital, Monza, Italy

Background: In acute leukemia (AL) patients (pts) pulmonary infections may be severe and worsen the final outcome of AL. They have been recently shown to adversely affect the outcome of bloodstream infections (BSI) in AL pts (Cattaneo et al. 2016). The radiologic characteristics of PI belong, according to the EORTC/MSG Study Group, to the diagnostic criteria of a pulmonary invasive fungal infection (IFI).

Aims: In order to better define the clinical and prognostic significance of PI in AL pts in a real-life setting, we have analyzed all PI diagnosed during consecutive febrile/infectious episodes developing over a 26 months period in pts admitted to 9 hematologic institutions within the Italian Network for Clinical Research in Hematology (REL) network.

Methods: From Dec-12 to Jan-14, all febrile/infectious episodes were recorded and data concerning PI extracted. PI were classified as specific and aspecific for IFI according to radiologic criteria.

Results: During 1086 episodes, 256 PI were diagnosed in 195 AL pts (M/F 124/71; median age 60y; AML/ALL 163/32). PI incidence was similar during induction and relapse (28.8% and 29%, respectively), but significantly lower in complete remission (14.2%, p<0.0001). Overall, PI were detected in 57% of cases during AML induction/reinduction and in 44.5% during posaconazole prophylaxis. Posaconazole was not responsible for a decreased sensitivity of serum galactomannan (GM), which was positive in 18.4% and in 18.6% pts with specific PI receiving posaconazole or not, respectively. Aspecific PI were observed in 157 cases (61.3%). In the remaining 99 cases (38.3%) the specific radiologic criteria for suspecting IFI were met, but in 70 of them (27.3%) just in the context of a diagnosis of possible (poss) IFI. Probable/proven (prob/prov) IFI criteria were met in 29 PI (11.3%). The characteristics of the three subgroups of PI are listed in Tab 1. Prob/prov PI were associated with lack of posaconazole prophylaxis in comparison with poss IFI (72.4% vs 57.1%, p=0.0074). Aspecific PI did not differ from poss IFI except for their lower frequency during neutropenia, particularly if ≥15d (80.3% vs 92.9%, p=0.0164, and 56.1% vs 80%, p=0.0005, respectively), and higher frequency in patients on Fluorouracil (Fl) prophylaxis (57.3% vs 22.9%, p<0.0001). Multivariate analysis confirmed that aspecific PI were less frequent during prolonged neutropenia (HR 0.382, IC 0.189-0.772), and poss IFI during Fl prophylaxis (0.344, 0.159-0.742). All but one poss/prob IFI were diagnosed in the context of a diagnosis of possible (poss) IFI.

Summary/Conclusions: Among PI occurring in AL patients IFI could be suspected according to EORTC/MSG Study Group criteria in nearly 40% of cases but only 11% of PI met the criteria for prob/prov IFI. Posaconazole did not affect serum GM sensitivity and was protective against prob/prov PI, which had a higher risk of death. On the other hand, PI associated with a diagnosis of poss IFI had a similar outcome compared to aspecific IFI, although they occurred more frequently during neutropenia and outside from Fl prophylaxis. These findings may be relevant in the context of a reevaluation of the criteria for suspecting IFI in AL patients with PI as well as for a more appropriate antimicrobial stewardship.

P645

ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)

V. Ong1, K. Bartzal1, M. Cushion2, L. Miesel2, S.R. Lopez3,4

1Cidara Therapeutics, Inc., San Diego, 2Cincinnati VAMC, 3University of Cincinnati Coll of Med, Cincinnati, United States, 4Eurofins Panlabs, Taipei, Taiwan, Republic of China, 5TransPharm Preclinical Solutions, Jackson, United States

Background: Fungal infections continue to carry high morbidity and mortality. Disease- and treatment-related immunosuppression in patients with hematologic malignancies increases the risk of opportunistic infection caused by Candida spp., Aspergillus spp., and Pneumocystis spp., and antifungal prophylaxis is an important consideration. Agents currently used for prophylaxis, voriconazole and TMP/SMX, carry safety and tolerability concerns. CD101 is a novel echinocandin in phase 2 clinical development that has demonstrated preclinical efficacy in treatment of invasive fungal infections and has pharmacokinetic attributes that enable once-weekly IV dosing and subcutaneous (SC) administration.

Aims: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse models of candidiasis, aspergillosis, or PCP.

Methods: CD101 (500µg/0.15 ml) or Candida albicans ATCC SC5314 (105 CFU/mouse) were used as a control. Mice received prophylaxis with CD101, voriconazole (15 mg/kg SC) or placebos. Aspecific IFI criteria were met in nearly 40% of cases. Posaconazole did not affect serum GM sensitivity and was protective against prob/prov PI, which had a higher risk of death. On the other hand, PI associated with a diagnosis of poss IFI had a similar outcome compared to aspecific IFI, although they occurred more frequently during neutropenia and outside from Fl prophylaxis. These findings may be relevant in the context of a reevaluation of the criteria for suspecting IFI in AL patients with PI as well as for a more appropriate antimicrobial stewardship.

Aims: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse models of candidiasis, aspergillosis, or PCP.

Methods: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse models of candidiasis, aspergillosis, or PCP.

Methods: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse models of candidiasis, aspergillosis, or PCP.

Methods: To evaluate CD101 as antifungal prophylaxis in neutropenic mouse models of candidiasis, aspergillosis, or PCP.
challenge on day -5, -3, or -1. Survival was monitored for 14 days. PCP model: C3H/HeN mice (10/gp) were immunosuppressed by dexamethasone (4mg/L) in acidified drinking water and inoculated with Pneumocystis murina (intranasal- ly, 2 x 10^5/50 µL). CD101 0.2, 2, or 20mg/kg intraperitoneally was given at the time of inoculation and 1x or 3x/wk for 6 wks. TMP/SMX 50/250mg/kg/3x/wk was used as positive control. At 6 wks, lungs were processed for quantification of trophic and asci (cyst) forms of P. murina.

Results: Candidiasis: Kidney CFU decreased with higher doses of CD101 and shorter times between prophylaxis and challenge. At 20mg/kg, there was complete clearance of CFU burden regardless of treatment day in all animals except one (prophylaxis on day -3). There was complete clearance in all animals given 10mg/kg/d on days -3 and -1 and significant decreases in CFU in those given 5mg/kg on days -3 and -1. Aspergillosis: Survival rates significantly increased following CD101 5, 10, and 20mg/kg prophylaxis on day -5, -3 or -1 compared with vehicle. Prophylaxis closer to challenge increased the rate of survival in the 3mg/kg group. All animals given higher doses survived regardless of day of prophylaxis. PCP: Trophic nucleus counts were significantly reduced versus untreated controls in all CD101 groups except 0.2mg/kg/1x/wk, and efficacy in 3 different CD101 groups was comparable to TMP/SMX (no nuclei observed microscopically). Asci counts also were significantly reduced in all CD101 groups versus untreated controls. The largest difference in efficacy between TMP/SMX and CD101 in all but the lowest dose group (0.2mg/kg/1x/wk), with no asci observed microscopically.

Summary/Conclusions: CD101, a novel echinocandin, was protective against fungal challenge in immunosuppressed mouse models of candidiasis, aspergillosis, and PCP. These data suggest that CD101 may provide benefit as antifungal prophylaxis in patients with hematological diseases at risk for aspergillosis, and PCP. These data suggest that CD101 may provide benefit in patients at risk.

P646
SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS–EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA

C. Nagarajan1, Y.C. Tan1, T.T. Tan2, W. Hwang1, Y.C. Lim1, A. Ho Yew Leng1, A.L. Ang1, R. Yiu Cheung1, N.F. Grigopoulos1, B.H. Tan2, G.C. Wong1
1Division of Haematology, 2Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore

Background: Invasive fungal infections (IFI) are a major cause of morbidity and mortality in patients undergoing chemotherapy or stem cell transplantation for acute leukemias. Though optimised antifungal therapy might be effective, in selected patients, surgical interventions might be an useful tool both for diagnostic and therapeutic reasons. However due to the nature of the disease and circumstances, prospective data of Surgical interventions in these situations is limited.

Aims: The purpose of this study is to report our single center experience of surgical interventions for IFI in acute leukemia patients.

Table 1.

<table>
<thead>
<tr>
<th>Number of surgical procedures</th>
<th>St (in patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organ involved</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td></td>
</tr>
<tr>
<td>Multiple (procedure for diagnosis)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Invasive fungal infections (IFI) are a major cause of morbidity and mortality in patients undergoing chemotherapy or stem cell transplantation for acute leukemias. Though optimised antifungal therapy might be effective, in selected patients, surgical interventions might be an useful tool both for diagnostic and therapeutic reasons. However due to the nature of the disease and circumstances, prospective data of Surgical interventions in these situations is limited.

P647
INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER

M. Przybylka-Toal1, M. Klaus1, H. Sayer2, S. Scholl1, T. Ernst1, H. Hilgenfort1, O. Yomade1, A. Klink1, K. Schilling1, A. Hochhaus1, A. Briol1, L.O. Mügge1
1Universitätsklinikum Jena, Jena, 2Helios Klinikum Erfurt, Erfurt, 3Heinrich-Braun-Klinikum, Zwickau, Germany

Background: The outcome of patients with multiple myeloma (MM) has improved dramatically in the past years, mainly due to a better control of the disease. However, it is not clear what influence this has on treatment- or disease-related complications like infections. Recent data even suggested an increased rate of infections in patients with MM, possibly associated with the use of novel drugs.

Aims: To determine the rate and the type of infections in MM patients undergoing treatment and to evaluate possible disease- or treatment-related risk-factors.

Methods: All patients with MM treated at our institution between 2003 and 2014 were included in this retrospective analysis after approval by the institutional review board. Data on age, sex, diagnosis, comorbidities, treatment modalities, and infectious complications were recorded. Each type of therapy (e.g. high-dose therapy versus conventional therapy) defined a patient-case (duration per patient-case: beginning of therapy until the beginning of another type of therapy) and infections were recorded per case. To determine risk-factors, generalized estimating equations comparing cases were used.

Results: Four-hundred seventy-nine patients (male: 272, 57%) accounted for 1690 cases (median number of cases per patient 3, range 1-15). At presentation in our institution, median age was 62 (35-89) years, and most patients had advanced disease (Stage III according to Salmon-Durie classification in 564 patients, 76%), and an IgG paraprotein (255 patients, 53%). Type of therapy given were as follows: 534 (32%) conventional long-term chemotherapy, 514 (30%) induction-type chemotherapy, 237 (14%) chemotherapy for stem-cell mobilisation, 310 (18%) high-dose melphalan with stem-cell transplantation and 95 (6%) supportive care only. One-hundred sixty-six patients (35%) with 257 episodes never experienced an infection including 25 cases with high-dose melphalan. However, the majority of patients experienced at least one episode of infection throughout their treatment, accounting for 773 infections in 627 patient cases (37% of all patient cases). Most (559, 72%) infections were of bacterial origin including 156 cases with pneumonia (9% of all patient cases).

Conclusions: More than 60% of MM patients experience at least one episode of infection during their course of treatment. These infections are mostly of bacterial origin and strongly associated with high-dose chemotherapy or relapse. Novel drugs do not seem to influence the rate of infection. Unfortu-
nately, despite the general improvement in the care of patients with MM, no difference in the rate of infections could be detected in recent years.

P648

HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

U. Schnetzetzk1, M. Fischer2, A. Hochhaus1, S. Schoß1
1Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätssklinikum Jena, Jena, Germany

Background: In neutropenic patients with acute myeloid leukemia (AML) bacterial infections and sepsis are a leading cause of mortality. Several studies propose a contribution of individual single nucleotide polymorphisms (SNPs) of the innate immune system to the course of infections. Human ficolins represent receptors for C1q from the classical pathway of the complement that acts with pattern binding and soluble molecules of the innate immune system. Ficolins are expressed on membrane bound and soluble molecules of the innate immune system and their potential implication on infections. In the context of hematopoietic stem cell transplantation polymorphisms of PTX3 have been identified as an individual risk factor for developing pulmonary aspergillosis.

Aims: We sought to investigate the impact of L-ficolin and PTX3 SNPs on the occurrence of infectious events such as sepsis and pneumonia, including invasive fungal disease (IFD), in 186 adult patients with newly diagnosed AML following anthracycline-based induction chemotherapy. In addition to our studies on membrane receptors, this work represents an important extension on soluble molecules of the innate immune system and their potential implication on infections.

Methods: Genotyping of L-ficolin and PTX3 SNPs (rs17514136, rs17549193, rs17540880) was performed by TaqMan assay. Multiple regression analyses were applied to evaluate the association between SNPs of the polymorphisms and the occurrence of infectious events.

Results: Two L-ficolin SNPs were identified as risk factors for developing sepsis and/or pneumonia. Patients harboring rs17514136G/GAG or GG (n=100 or 22) revealed a significantly higher risk for developing sepsis (odds ratio (OR): 1.88; 95% confidence interval (CI): 1.01–3.37, p=0.039) or pneumonia (OR: 2.79; 95% CI: 1.1–6.9, p=0.033). A similar risk profile could be demonstrated for patients carrying rs17549193TTCT or TT. No association was found between SNPs of the PTX3 gene and the analysed infectious events.

Summary/Conclusions: To our best knowledge, this study represents the first analysis demonstrating that polymorphisms of human L-ficolin (rs7309123, rs17549193) represent an independent risk factor of developing sepsis and/or pneumonia in patients with AML undergoing induction chemotherapy. Interestingly, no association of PTX3 SNPs and infectious events such as IFD was found in this non-transplant setting. In conclusion, a genetic risk profile based on membrane bound and soluble molecules of the innate immune system might be helpful in identifying patients prone for infectious events.

P650

TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL

N. Kerman1, P. Richardson2, T. Brillet3, S. Grupp4, J. Antin5, W. Liang6, R. Hume6, W. Tappe6, R. Soiffer7
1Pediatric Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, 2Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 3Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, 4Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, 5STEM CellBone Marrow Transplantation Program, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 6Jazz Pharmaceuticals, Inc., Palo Alto, 7Center for Stem Cell Transplantation, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States

Background: Hepatic VOD/SOS, which may be unpredictable and potentially life-threatening, is typically considered a complication of hematopoietic stem cell transplantation (HSCT); however, VOD/SOS can occur after chemotherapy alone. Post-HSCT VOD/SOS is associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in the European Union and to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States.

Aims: To perform an exploratory post hoc analysis of the impact of timing of initiation of defibrotide after VOD/SOS diagnosis in patients developing VOD/SOS after primary chemotherapy without HSCT (off label).

Methods: In an expanded-access protocol for patients with VOD/SOS post-HSCT or chemotherapy, with or without MOD (renal and/or pulmonary dysfunction), defibrotide 25mg/kg/d (4 divided doses of 6.25mg/kg) was given a median of 22 days from diagnosis to the time of VOD/SOS diagnosis to start of defibrotide therapy. Survival analysis was performed using the Kaplan-Meier product limit method. The primary analysis was a time-to-event analysis of survival from the day of diagnosis in both the overall group and MOD subgroup (Figure), earlier initiation was associated with higher Day +100 survival rates for all days, which was significant at a number of timepoints. The trend test for particular initiation days.
also showed a significant trend over time for higher Day +100 survival with earlier defibrotide initiation post-diagnosis in both the overall group and MOD subgroup (P<.05). In the overall post-chemotherapy population, adverse events (AEs) and serious AEs occurred in 66% and 40% of patients, respectively. Aside from multi-organ failure, the most common AE of any severity was hypotension (9.5%). Possibly related AEs lead to discontinuation in 7.3%; most common was gastric hemorrhage (3.7%).

Summary/Conclusions: In this exploratory analysis of final study data in the subgroup of patients developing VOD/SOS after chemotherapy, earlier defibrotide initiation post-VOD/SOS diagnosis was associated with improved Day +100 survival, confirmed by the Cochran-Armitage test (P<.05), even in the small MOD subgroup. This time-dependent relationship was consistent with that found in the HSCT subgroup from this study. No specific day appears to provide a clinically meaningful cutoff for better Day +100 survival, suggesting that later intervention retains value if treatment must be delayed.

Support: Jazz Pharmaceuticals

P651
ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS
A. Hasibeder1,*, S. Prüfer2, K. Ebner3, S. Reuter1, P. Aranda Lopez1, I. Scharrer1, F. Banno4, M. Stassen 2, H. Schild 2, K. Jurk3, M. Bosmann3, H. Beckert1, M. Radsak1
1IIIrd Dept. of Medicine, 2Institute for Immunology, 3Center for Thrombosis and Hemostasis, Johannes Gutenberg-University Medical Center, Mainz, Germany, 4Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Saitama, Japan

Background: Von Willebrand factor (VWF) is produced as multimers of various sizes and is secreted as an acute phase protein during inflammation. The main mechanism regulating the size and prothrombotic activity of VWF is the specific proteolytic activity of ADAMTS-13 (a disintegrin and metalloprotease with ThromboSpondin type 1 repeats-13) which is diminished under several pathological conditions.

Aims: To determine the relevance of this regulatory pathway for the innate inflammatory response by polymorphonuclear neutrophils (PMN), we employed a mouse model of invasive pulmonary aspergillosis (IPA) where PMN functionality is crucial for fungal clearance and survival.

Methods: IPA was induced by intratracheal application of Aspergillus fumigatus (A. f.) conidia in wildtype (129/Sv/Pas) or ADAMTS-13 deficient (Adamts13-/-) mice, and VWF deficient (Vwf-/-) mice or respective controls (B6). Some mice were sacrificed 24 h after infection. Fungal load was assessed as colony forming units (CFU) after plating and culturing lung homogenates on Sabouraud agar plates. For histological analysis paraffin sections of the lungs were stained with H&E, mouse complement component C3d and VWF antibody. Broncho alveolar lavage fluid (BALF) was analyzed for cell count (bead-based by flow cytometry or by an animal blood counter), ELISA was performed for albumin amount and cytokines were analyzed by a multiplex assay. Bone marrow-derived PMN were isolated by magnetic cell sorting using biotin labeled Ly6G/C specific antibody. PMN functions were analyzed for degranulation, oxidative burst activity and CD62L shedding by flow cytometry. Fungal killing of PMN in vitro was assessed by a XTT assay. Chemotactic properties of A.f.-activated and control serum from wildtype and knock-out mice was evaluated by migration of purified human PMN, isoalted by dextran sedimentation and Histopaque® centrifugation, in a transwell assay.

Results: While infected neutropenic mice developed lethal IPA, all wildtype mice survived the infection. Interestingly, Adams13-/- mice displayed more severe signs of disease with a lethal course in about 24% of the animals. Examination of the lungs revealed a higher fungal burden along with increased signs of acute lung injury and levels of pro-inflammatory cytokines in ADAMTS-13 deficient mice. Histology sections demonstrated a more pronounced perivascular leukocyte infiltration in support of a dysregulated inflammatory response in Adams13-/- mice. Importantly, we observed no general defect in the activation of neutrophil effector functions in response to conidia or hyphae in vitro. Furthermore, innate inflammatory response to IPA was not altered in VWF deficient (Vwf-/-) mice compared to wildtype (B6) control.

Summary/Conclusions: Therefore, we conclude that the proteolytic regulation of VWF by ADAMTS-13 or ADAMTS-13 by itself is an important mechanism to control PMN recruitment in acute inflammatory processes, such as fungal pneumonias.
Myelodysplastic syndromes - Biology

P652
IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES
I. Garán-Gómez1,*, A. Alfonso1, Y. Ogoti1, H. Yang1, G. Montalban-Bravo1, A.C. Yu2, S. Silver2, K. Clise-Dwyer3, G. Garcia-Manero1, S. Colla1
1Leukemia, The University of Texas MD Anderson Cancer Center, 2McGovern Medical School, The University of Texas Health Science Center, 3Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by the ineffective production of mature blood cells of one or more lineages and by the risk of evolution to acute myeloid leukemia. The current standard of care for MDS patients is the treatment with hypomethylating agents (HMA); however, response to drugs from this family occurs in just about half of the patients and is accompanied by high rates of therapy failure. Failure to HMA in MDS is a poorly understood process associated to increased risk of disease progression and to a dismal prognosis and cannot be, thus far, predicted or prevented.

Aims: Given that MDS are stem cell disorders, our aim was the identification and molecular characterization of the specific hematopoietic stem/progenitor cell (HSPC) population in which the relapse-driver clones arise. This is an essential step for the development of effective monitoring and early intervention protocols for HMA failure.

Methods: Using flow cytometry immunophenotyping, we quantitatively analyzed the different cell subpopulations within the CD34+CD38- and CD34+CD38+ HSPC compartments in 122 sequential MDS bone marrow samples obtained from 93 patients at different stages of HMA treatment.

Results: In line with earlier reports suggesting the presence of alterations in myeloid progenitor frequencies in MDS, our flow cytometry data stratified untreated patient samples in two groups representative of two abnormal differentiation patterns, which were independent of the IPSS risk classification. The “CMP pattern” group (12 samples, 34%) was characterized by an increased frequency of the common myeloid progenitors (CMP) (2.6-fold; p<10^-4), whereas the “GMP pattern” group (23 samples, 66%) was characterized by the ineffective production of one or more lineages and by the risk of evolution to acute myeloid leukemia. The molecular pathogenesis of cooperation of RUNX1 and ASXL1 mutations has not been reported yet.

Aims: We aimed to determine the functional role of cooperation of RUNX1 and ASXL1 mutations for secondary acute myeloid leukemia (sAML) transformation.

Methods: For in vitro study, we overexpressed RUNX1-WT/MT (R135T) in K562 cells which harboring ASXL1-MT (Y591X) and co-expressed with ASXL1-WT/MT (R693X) in murine 32D cells. After stable expression, functional properties were examined by using immunoblot, co-immunoprecipitation, quantitative RT-PCR, flow cytometry, cell proliferation, colony formation and gene expression microarray analyses. C57BL/6 mice were used for bone marrow transplantation (BMT) experiments for in vivo study.

Results: We found that RUNX1-MT augmented cell proliferation, colony formation, HOXA gene expression and inhibited megakaryocytic differentiation in ASXL1-MT K562 cells compared to RUNX1-WT or empty vector control. The cooperation of RUNX1 and ASXL1 mutations or the knocked down of ASXL1 cooperated with RUNX1-MT inhibited apoptosis and impaired differentiation in 32D cells. Nine months post BMT mice with the combined RUNX1 and ASXL1 mutations, but not RUNX1-MT or ASXL1-MT alone, developed disease characterized by marked splenomegaly, hepatomegaly, and leukocytosis with a shorter latency. We found that RUNX1-MT stabilized hypoxia-inducible factor 1α (HIF-1α) and increased its target gene expression such as ID1 (inhibitor of DNA binding 1). Clinical samples analyses showed that ID1 expression increased in both RUNX1-MT and ASXL1-MT or the combined mutations of RUNX1 and ASXL1 compared to control samples. We also examined the impact of RUNX1 and ASXL1 mutations on sAML-free survival of 104 Patients with CML, in whom 11 had co-occurrence of RUNX1 and ASXL1, 39 had either mutated ASXL1 or RUNX1 and 54 patients were negative for both mutations. We found that patients carrying co-existing mutations had a shorter sAML-free-survival (median 16.1 months, 95% CI 0.0-60.1 months) than those carrying either mutated gene alone (median 23.0 months, 95% CI 17.8-28.2 months) or negative for both mutated genes (median not reached, 59.2 ± 8.8% at 5 years) (P=0.023).

Summary/Conclusions: The present study demonstrated that clinical and functional evidence for a collaborative association of RUNX1-MT and ASXL1-MT for sAML transformation. We identified HIF-1α targeting a new pathway which may be critical for leukemia progression of RUNX1/ASXL1-mutated myeloid malignancies.

P654
A NOVEL MASS SPECTROMETRY METHOD REVEALS THE INTRACELLULAR PHARMACOKINETICS OF AZACYTIDINE THERAPY IN VIVO
A. Unnikrishnan1, A.V. Ngoc Quyhn2, R. Pickford2, A. Nuñez1, L. Hasson1, F. Pignatelli3
1Prince of Wales Clinical School & Lowry Cancer Research Centre, 2Bioanalytical Mass Spectrometry Facility, UNSW Sydney, 3Haematology Department, Prince of Wales Hospital, Sydney, Australia

Figure 1. Working flow cytometry immunophenotyping, we quantitatively analyzed the different cell subpopulations within the CD34+CD38- and CD34+CD38+ HSPC compartments in 122 sequential MDS bone marrow samples obtained from 93 patients at different stages of HMA treatment.
Background: The cytidine analog 5’-Azacytidine (AZA, Fig A), a DNA demethylating agent, is the primary drug for the treatment of high-risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukaemia (CMML), and response is associated with improved survival benefits. However, only ~50% of treated patients will ever respond to AZA and the molecular basis for poor response is poorly understood. It is unclear whether non-responders to therapy have different rates of AZA uptake into their cells and/or AZA incorporation into nucleic acids compared to AZA responders, nor whether these might relate to DNA methylation in vivo.

Aims: We aimed to develop an analytical method capable of simultaneously detecting all the subcellular fractions of AZA (Fig B) within the bone marrows of patients undergoing AZA therapy, while also assessing DNA and RNA methylation levels. This would provide the most comprehensive snapshot of the intracellular pharmacokinetics of AZA therapy in vivo as a first step towards better understanding AZA resistance.

Methods: We have developed a new method utilising mass spectrometry to accurately quantify all the different subcellular fractions of AZA within the same sample (Fig C). Using an Orbitrap mass spectrometer with very high mass resolution, we have achieved the first mass separation of DAC and AZA from all naturally occurring isopes of deoxyctydine and cytidine respectively (a difference of less than 1 Da), thus enabling accurate quantification. We utilised subcellular fractionation to obtain purified quantities of DNA- and RNA-incorporated nucleotides, as well as free unincorporated nucleotides present in the cytoplasm. We developed a reaction reduction to reduce the spontaneous hydrolysis of nucleotides, as well as free unincorporated nucleotides present in the cytoplasm.

We aimed to develop an analytical method capable of simultaneously detecting all the subcellular fractions of AZA (Fig B) within the bone marrows of patients undergoing AZA therapy, while also assessing DNA and RNA methylation levels. This would provide the most comprehensive snapshot of the intracellular pharmacokinetics of AZA therapy in vivo as a first step towards better understanding AZA resistance.

We have developed a new method utilising mass spectrometry to accurately quantify all the different subcellular fractions of AZA within the same sample (Fig C). Using an Orbitrap mass spectrometer with very high mass resolution, we have achieved the first mass separation of DAC and AZA from all naturally occurring isopes of deoxyctydine and cytidine respectively (a difference of less than 1 Da), thus enabling accurate quantification. We utilised subcellular fractionation to obtain purified quantities of DNA- and RNA-incorporated nucleotides, as well as free unincorporated nucleotides present in the cytoplasm. We developed a reaction reduction to reduce the spontaneous hydrolysis of nucleotides, as well as free unincorporated nucleotides present in the cytoplasm. We developed a new method, our results have revealed that while AZA responders incorporated AZA efficiently into DNA, leading to DNA demethylation, there were two modes of primary AZA resistance: in some non-responders, low levels of AZA incorporation into DNA likely derives from cell cycle quiescence, resulting in low amounts of DNA demethylation. However, in other non-responders who showed DAC incorporation into DNA and demethylation, resistance arises from as-yet-unknown mechanisms not connected with AZA metabolism.

Results: Using our new method, we report for the first time direct simultaneous quantification of: (1.) DNA-incorporated DAC, (2.) intracellular, free DAC, (3.) methyl deoxycytidine in DNA, (4.) RNA-incorporated AZA, (5.) intracellular, free AZA, and (6.) methyl cytidine in RNA within the same sample. We demonstrate an inverse correlation between the amount of DAC incorporated into DNA and DNA methylation. However, no such correlation was observed between AZA incorporation and RNA demethylation (Fig D). The specificity and resolution of our method also enabled, for the first time, a comprehensive survey of the total intracellular pharmacokinetics of AZA in vivo in patients undergoing a standard cycle of treatment. We discovered that the bone marrow cells of AZA responders (n=8) incorporated DAC to a far greater extent than non-responders (n=2). DAC incorporation was also inversely proportional to DNA methylation levels, with higher DNA demethylation observed in the responders compared to non-responders. Furthermore, we observed two patterns in AZA non-responders, with DAC-incorporation and DNA demethylation occurring in some individuals (n=2) without evidence of DAC incorporation and no DNA demethylation (Fig E). Our method also enabled us to directly prove that low DAC incorporation was not a result insufficient AZA accumulation intracellularly, as cytoplasmic measurements of unincorporated AZA and DAC were higher in the non-responders with the lowest levels of DNA-incorporated DAC. Additionally, in these non-responders, there was also concomitant increase in AZA incorporation into RNA.

Summary/Conclusions: We have developed a new method that has enabled the first comprehensive analysis of the intracellular pharmacokinetics of AZA therapy in vivo. Our results have revealed that while AZA responders incorporated AZA efficiently into DNA, leading to DNA demethylation, there were two modes of primary AZA resistance: in some non-responders, low levels of AZA incorporation into DNA likely derives from cell cycle quiescence, resulting in low amounts of DNA demethylation. However, in other non-responders who showed DAC incorporation into DNA and demethylation, resistance arises from as-yet-unknown mechanisms not connected with AZA metabolism.

Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders at high risk of progression to acute myeloid leukemia (sAML). Due to recent high-throughput sequencing studies, the mutational dynamics and clonal evolution underlying disease progression have just begun to be understood. However, large longitudinal sequencing genomic studies are still required.

Aims: To analyze the relationship between the dynamics of gene mutations and cell pathways they are involved in with the progression from MDS to sAML in order to study the mechanisms underlying disease evolution.

Methods: Sixty-eight serially collected samples from 34 MDS/CMML patients evolving to sAML were studied by a combination of whole-exome sequencing (WES) and targeted-deep sequencing (TDS). Each patient was studied at two different time-points: at the time of diagnosis (MDS/CMML stage) and after sAML progression (disease evolution, leukemic phase). At initial presentation of the disease, diagnoses were as follows: 18 RAEB-1/2, 9 RCMD and 7 CMML. Initially, WES was carried out on 40 diagnosis/progression-matched samples. Driver mutations were identified, after variant calling by a standardized bioinformatics pipeline, by using the novel tool “Cancer Genome Interpreter” (https://www.cancergenominterpreter.org). Secondly, in order to validate mutations and precise variant allele frequencies (VAFs) estimation, TDS using a custom MDS/sAML-related capture enrichment panel (illumina) of 117 genes was performed in 30 out of 40 of the initial cohort. Moreover, a total of 28 paired-samples from a cohort of 14 patients were analyzed by TDS.

Results: Combining both WES and TDS approaches, a total of 143 mutations in 50 different genes were identified at the sAML stage, with most of them (118 mutations) already present at the MDS stage, at clonal or subclonal levels.

The most recurrently mutated genes were SRSF2 (21%), TET2 (21%), SF3B2 (28%), SF3B1 (21%), ASXL1 (21%), TP53 (21%) and NRAS (21%). However, it should be noted that 68% genes were mutated only in less than 10% of the patients, highlighting the great heterogeneity that exists in the mechanisms of disease evolution during disease progression. To study the mutational dynamics during disease progression we compared VAFs of mutations detected at both time-points (sAML to MDS/CMML stage) in each patient. We identified 4 different clonal dynamics: mutations that were initially present but increased VAF (type-1), decreased (type-2), were newly acquired (type-3) or persisted with similar allelic burden (type-4) at sAML stage. Interestingly, most of type-1 mutations were detected in STAG2 gene. Thus, mutational burden of STAG2 were markedly increased (6/8 patients) at sAML progression. Moreover, type-3 mutations, only detected at the sAML-stage, were predominantly identified in FLT3 (3/4) and NRAS (5/6).

Conversely, type-4 mutations were present in MDS-related genes such as SRSF2 (8/12), SF3B1 (3/6) and TET2 (8/12). Most of mutations in these genes showed no changes during progression to sAML.

Summary/Conclusions: Progression from MDS to sAML could be explained by different mutational processes, as well as by the occurrence of unique and complex changes in the clonal architecture of the disease during the evolution. Mutations in genes such as STAG2, FLT3 or NRAS could play an important role during disease progression.
Results: Our data showed promising results with the injection of mononuclear cells obtained from patient BM, however the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. To address the question of the becoming of MSCs once injected, we tracked them back into the mice BM and showed that they disappeared after a week of engraftment. With a 2D in vitro system, we showed that we could co-culture CD34+ cells with preexisting BM, on single-cell level and in co-culture, and that MSCs, over 4 weeks with a fold expansion ranging from 50 to 600 times. More importantly those cells conserved their clonal architecture and chromosomal aberrations.

Figure 1.

Summary/Conclusions: Although the in vivo model cannot be replaced, the low level of engraftment of most of the patients is a limit in the study of MDS. Here we have demonstrated the value of the 2D co-culture system using MSCs (or murine MS5) as an alternative model to study MDS. This ex vivo culture system, which lasts for only 4 weeks and requires low number of human CD34+ cells, provides a robust preclinical assessment model to test therapeutic effects of different drugs and other approaches on the MDS clonality and autologous MSCs prior to treatment of MDS patients.
V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES

Y. Kurbayashii-Hamad1,2, H. Tamura1, M. Ishibashi1, T. Asayama1, K. Moriya1, I. Choi1, K. Inoue1
1Department of Hematology, Nippon Medical School, Japan, Sendagi, Bunkyouku, Tokyo, Japan, 2Department of Microbiology and Immunology, Inje University College of Medicine, Busan, Korea, Republic Of

Background: In myelodysplastic syndromes (MDS), blast cells increase with clonal proliferation during disease progression, while immune cells in the bone marrow (BM) microenvironment become less efficient. The V-set and immunoglobulin domain-containing 4 (VSIG4) molecule is a new B7 family-related protein and strong negative regulator of T-cell proliferation. However, the role of VSIG4 in tumors including hematological malignancies remains unknown.

Aims: We investigated the expression and functions of VSIG4 in MDS.

Methods: 1) Peripheral blood (PB) and BM samples were obtained from 39 patients with acute leukemia transformed from MDS (AL-MDS, N=21), MDS (N=13), and chronic myelomonocytic leukemia (CMML, N=5) and from healthy controls (N=14). The expression of VSIG4 in mononuclear cells (MCs) from the samples and BM cell lines (F-36P and SKM-1) was analyzed with real-time PCR and flow cytometry (FCM).

2) After cultivation with BM stromal HS-5 cells, its culture supernatants (HS-5 sup.), immunomodulatory drugs (lenalidomide, thalidomide and azacitidine), and VSIG4 expression on cells was determined using FCM.

3) The proliferative potential was examined by BrdU incorporation using FCM and the MTT assay. 4) The cytotoxic activity of natural killer (NK) cell line NK-92MI was examined with donor T cells co-cultivated with HS-5 sup., immunomodulatory drugs (lenalidomide, thalidomide and azacitidine), and VSIG4 expression on cells.

Results: 1) VSIG4 mRNA expression in PBMCs from patients with AL-MDS was significantly higher than in those from controls. Cell-surface VSIG4 expression on CD14+CD11b+ monocytes from MDS and AL-MDS patients was higher than in those from controls, but VSIG4 expression was not detected on CD34+ blasts. In CD14+CD11b+ monocytes of MDS and AL-MDS patients, VSIG4 was strongly expressed on CD68+CD206+ tumor-associated macrophages (TAMs). Furthermore, the expression levels of VSIG4 on CD14+ monoblasts from CMML patients was significantly upregulated in comparison with those from controls.

2) Two MDS cell lines expressed both VSIG4 mRNA and its cell-surface protein. VSIG4 expression on MDS cell lines, and on monocytes and monoblasts from MDS and CMML patients, respectively, was significantly upregulated by co-culture with HS-5 sup., LEN, and POM, but not with cytarabine or azacitidine.

3) VSIG4 expression was inversely correlated with the expression of PARP1.

4) The cytotoxic activity of NK cells was inversely correlated with the expression of VSIG4 in CD14+CD11b+ monocytes, and the proliferation of VSIG4+ cells was suppressed by VSIG4-specific small interfering RNA. 5) LEN-treated K562 cells, which induced high VSIG4 expression, were more resistant to NK-mediated cytotoxicity than untreated K562 cells.

The production of IFN-γ from donor T cells co-cultivated with LEN-treated MDS cells was suppressed compared with control cells.

Summary/Conclusions: Our study demonstrated that VSIG4 was highly expressed on monocytes including TAMs in MDS and AL-MDS patients, and on monoblasts in CMML patients. VSIG4-expressing monocytes and monoblasts may suppress antitumor immune responses and be associated with disease progression in MDS and CMML. The results will allow us to elucidate the function of VSIG4 in MDS pathophysiology and lead to the development of new immunotherapy.

P660

TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKAEMIA: SYNTHETIC LETHALITY TARGETS

S. B. Fraga1, M. A. Hurtado López2, A. C. O. M. Hernández2, E. Caparrós1, B. Przychodzen4, L. Zamora2, F. Ortúno1, V. Vicente1, J. M. Maciejewski4, C. Del Cañizo3, F. Soló2, F. Ferrer-Marin1, A. Jerez1

1Hematology and Medical Oncology Department, Hospital Morales Meseguer, 2José Carreras Leukaemia Research Foundation, 3HC Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, 4Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain, 5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, United States

Background: Though genetic instability is a hallmark of myeloid disorders, the lack of recurrent somatic mutations, inarguably pathogenic, in the DNA repair machinery have precluded a predominant interest in this pathway. However, the recent discovery of non classical leukaemogenesis by splicing defects, the repair pathway influence of e.g. NEL1 and OGG1, and the development of unbiased high-throughput sequencing approaches oblige us to revisit those routes in blood cancers.

Aims: To perform improved massive RNA-seq in chronic myelomonocytic leukaemia (CMML) samples to identify neoplasm-specific targets for a synthetic lethality therapeutic approach. To validate the candidates through a direct strategy in an extended cohort of CMML, myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) patients.

Methods: We performed enhanced RNA-seq on 27 CMML bone marrow samples from 27 CMML patients and 10 healthy donors. Defects on genes predominantly unique to a single leukemia type were identified. Moreover, we identified oncogenes infra-expressed in our cohort but with inhibitory molecules already being tested in myeloid neoplasms (i.e. PARP1). Global pattern of DNA repair gene expression was compared with MDS and AML MILE study data.

Results: Of 27 CMML patients and 10 healthy donors, the expression of 18 genes was significantly different between the two groups (p-value<0.05) with 6 genes up-regulated and 12 genes down-regulated in CMML patients compared with donors. Defects on genes predominantly unique to AML, such as NEL1, OGG1, were included in our myeloma samples.

Summary/Conclusions: We validated the candidates through a direct strategy in an extended cohort of CMML, MDS and AML patients. We further chose 13 of the differentially expressed genes for validation and characterization through the myeloid spectrum based on clinical characteristics: 3) deregulated expression of DNA repair candidate genes in CMML, 4) oncogenes infra-expressed in our cohort with or allowing for the inhibition of an specific DNA repair pathway (i.e. XPA, XRCC4, MSH4): ii) oncogenes infra-expressed in our cohort but with inhibitory molecules already being tested in myeloid neoplasms (i.e. PARP1).

Global pattern of DNA repair gene expression was compared with MDS and AML MILE study data.

P661

DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE

M. T. Cedena1, F. Mirás1, R. M. Ayala1, E. Martín-Clavero1, M. L. Paciello1, A. Martínez-López1, J. Martínez-López1, J. Martínez-López1

1Hematology, 2H. 12 Octubre, Madrid, Spain

Background: The diagnosis of myelodysplastic syndromes (MDS) is based

haematologica | 2017; 102(s2) | 261

Madrid, Spain, June 22 – 25, 2017
on cytomorphological characteristics, but it remains a challenge in some patients who do not fulfill diagnostic criteria. Flow cytometry (FC) immunophenotyping can be an important tool for MDS diagnosis, but a lack of standardisation and subjectivity of the analysis hinders its applicability.

Aims: To develop a methodology for FC immunophenotyping that allows us to establish the differential diagnosis between MDS patients and non-clonal cytopenias using a myeloid maturation database.

Methods: Bone marrow samples from 55 MDS patients, and 51 controls with cytopenias of several origins (immune disease, hypersplenism, drug toxicity) were analysed by FC. We elaborated a Myeloid Maturation Database using the Infinicyt® v1.7 software (Cytognos, Spain). From all bone marrow controls, we merged files stained with a 4-colour combination (CD16-FITC/CD13-PE/CD45-PC5/CD11b-APC). We selected myeloid population from the merged file and drew a maturation path. We obtained a maturation diagram that displays the fluorescence intensity of each parameter measured along the maturation stages. Then, for patients and controls, we obtained the fluorescence intensities whose median values exceeded ±2SD range in comparison with the stored database values (Figure 1). We elaborated a score, considering the relevant changes in fluorescence intensities (deviations) in the four markers analysed (CD16, CD13, CD45, CD11b) and in the four maturation stages, with a punctuation from 0 to 16.

Results: We found a mean of 1.9 deviations (fluorescence intensities values exceeded ±2SD) in controls, and a mean of 4.5 deviations in patients. Our test resulted reliable for differential diagnosis between controls and patients (curve ROC analysis, AUC=0.748; p=0.016). We found that with a cut-off of 4.5 deviations, we obtained a high specificity in the diagnosis of MDS (100%) but a low sensitivity (45%). With a high suspicion of MDS (specificity 90%), we can consider patients with scores above 3.5, thus achieving higher sensitivity (59%). Additionally, the number of immunophenotyping changes correlated well with prognostic risk. We confirmed that the higher the risk, the greater impact on deviations from the normal pattern (average of 3.7 at low risk, 4.5 at intermediate risk; 6.8 at high risk) (Figure 2).

Figure 1.

Summary/Conclusions: The maturation database (using the maturation analysis from Infinicyt® software) was useful to discriminate between MDS patients and non-clonal cytopenias, proving to be a reliable diagnostic test, also with prognostic implications. The application of this database as a diagnostic tool has the advantage that the result is independent of the observer. Inclusion of more myeloid markers and incorporation of erythroid parameters could increase sensibility in differential diagnosis.
P664

Background: Epigenetic drugs are currently used for the treatment of several hematologic malignancies, but their pharmacological mechanism remains poorly understood. For DNA methyltransferase and histone deacetylase (DNMTi and HDACi) several mechanisms of action have been proposed, mostly based on candidate gene approaches. However, less is known about their genome-wide transcriptional and epigenomic consequences.

Aims: To investigate the effects of epigenetic treatment on transcription and chromatin, we profiled genome wide transcription start sites (TSSs) activities and alternatively spliced transcripts following the treatment with inhibitors against DNMTs, HDACs, or both.

Methods: Genome wide analysis of transcription start sites (TSSs) (Cap analysis of gene expression (CAGE) sequencing), methylation status (whole-genome bisulphite sequencing) and chromatin dynamics (Chromatin-immunoprecipitation (ChIP) sequencing) was performed in wild type lymphoblastoma-Xenograft model. Functional assays were used to investigate the mechanisms of LTR reactivation, a neuroblastoma mouse xenograft model to confirm the LTR reactivation in vivo.

Results: Following the treatment with inhibitors against DNMTs, HDACs, or both, we observed the activation of thousands of cryptic, currently non-annotated transcription start sites (treatment-induced non-annotated transcripts, TINATs). These TINATs arose most commonly from LTR12 elements, particularly LTR12C (ca. 50% of all TINATs). The resulting transcripts frequently splice into protein-coding exons and encode truncated or chimeric open reading frames which translated into currently uncharacterized protein isoforms with predicted abnormal functions or immunogenic potential, the last one based on their foreign sequence and capability of being presented on MHC-class I molecules. TINAT expression after DNMTi coincided with DNA hypomethylation and HDACi with histone reactivation. The observed changes were not only limited to the LTR12C/LTR12F base. We identified a subset of TINATs in association with H2AK9ac, H3K14ac, and H3K23ac. Despite this mechanistic difference, both inhibitors convergently induced transcription from identical sites since TINATs are encoded in solitary long-terminal repeats of the endogenous retrovirus-9 family, epigenetically repressed virtually all normal cells. Moreover, we found a consensus GATA2 binding motif which strongly distinguished LTR12C/LTR12F elements from the rest, allowing for extensive downstream analysis.

Summary/Conclusions: A LTR12C (ca. 50% of all TINATs) expressed in response to DNMTi and HDACi treatment. LTR12C/LTR12F elements were not only limited to the LTR12C/LTR12F base. We identified a subset of TINATs in association with H2AK9ac, H3K14ac, and H3K23ac. Despite this mechanistic difference, both inhibitors convergently induced transcription from identical sites since TINATs are encoded in solitary long-terminal repeats of the endogenous retrovirus-9 family, epigenetically repressed virtually all normal cells. Moreover, we found a consensus GATA2 binding motif which strongly distinguished LTR12C/LTR12F elements from the rest, allowing for extensive downstream analysis.

P665

IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS

A. Alfonso Pierola1,*, G. Montalban-Bravo1, K. Takahashi1, E.J. Jabbour1, T. Kadia1, F. Ravandi1, J. Cortes1, C. DiNardo1, N. Daver1, G. Borthakur1, N. Pemmaraju1, M. Konopleva1, C. Bueso-Ramos2, S. Pierce1, H. Kantarjian1, G. Garcia-Manero1, J. Kudryk1, A. Garcia-Manero2, L. Estrov3, A. Sather4, K. Vardiman5, J. Estrov6, J. Cortes7, C. DiNardo7, N. Pemmaraju7, N. Daver8, G. Borthakur8, N. Pemmaraju8, M. Konopleva8, C. Bueso-Ramos8, S. Pierce9, H. Kantarjian10, G. Garcia-Manero10, 1Leukemia, 2Hematopathology, MD Anderson Cancer Center, Houston, United States, 3Department of Internal Medicine, The Ohio State University, Columbus, United States

Background: The concept of marrow complete response (mCR) was included for the first time in the 2006 International Working Group (IWG) response criteria in MDS. mCR is defined as a reduction to ≤5% myeloblasts and decrease by ≥50% compared to baseline with persistent cytopenias. However, their inclusion in the response criteria remains controversial as it is not known how it affects the natural history of MDS or CMML.

Aims: The aim of our study was to describe the impact of mCR in survival outcomes in patients with MDS treated with hypomethylating agents (HMA).

Methods: We retrospectively reviewed 713 patients diagnosed with MDS or CMML and treated with frontline HMA between 2004 and 2015 at a single institution. Clinical and demographic data were obtained from an electronic database. Response was assessed by modified 2006 IWG criteria. Statistical analyses were performed with the IBM SPSS Statistics 23.0 software. All tests were 2-sided with significance set at p<0.05.

Results: 444 (62.3%) patients from the initial cohort achieved at least hematologic improvement (HI) as best response and were included in the analysis. 162 (37%) patients were female. Median age at diagnosis was 68 years (range 17-91). Following the 2016 WHO classification: 30 patients (7%) were MDS-SD, 50 (11%) MDS-MLD, 20 (5%) MDS-RR, 230 (52%) MDS-EB, 10 (2%) MDS-UM, 140 (24%) CMML. According to the Revised International Prognostic Scoring System (IPSS-R), 37 patients (8%) belonged to the low risk group, 176 (40%) to the intermediate-1 risk group, 198 (45%) to the intermediate-2 risk group, and 31 (7%) to the high risk group. 200 (45%) patients received azacitidine-based therapies and 244 (55%) decitabine-based therapies. Responses included: 238 (33% of the total population) complete responses (CR), 61 (9%) mCR, 2 (<1%) partial responses (PR) and 143 (20%) stable disease (SD). HI was observed in 410 (58% of the total population) of the patients. The median time to response was 3 cycles (range 1-24). Median overall survival (OS) since the last evaluated mCR was 20.1 months.
Luspatercept increases hemoglobin and reduces transfusion burden in patients with lower-risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study


1Marien Hospital Düsseldorf, 2Universitätsklinikum Düsseldorf, Düsseldorf, 3III. Department of Medicine, Hematology and Medical Oncology, Technical University of Munich, Klinikum rechts der Isar, Munich, 4Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, 5OncoResearch Lerchenfeld UG, Hamburg, 6University Hospital Bonn, Bonn, 7Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt/Main, 8Johannes Gutenberg-Universität, Mainz, Germany, 9Astellas Pharma UK Inc, Cambridge, 10Celgene Corporation, Sunvalley, United States, 11Universitätsklinikum Carl Gustav Carus, Dresden, Germany.

Background: Management of anemia is a common therapeutic challenge in patients (pts) with MDS. Luspatercept (ACE-536), a fusion protein containing modified action receptor type IIb, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds to select TGF-β superfamily ligands (such as GDF11) reducing aberrant Smad2/3 signaling and promoting late-stage erythroid differentiation and increased hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014; Attie K, Am J Hematol, 2014).

Aims: This ongoing phase 2, multi-center, open-label study followed by a long-term extension (ext) study evaluates the effects of luspatercept in pts with lower-risk MDS. Endpoints include long-term safety and tolerability, erythroid response (IWG HI-E), RBC transfusion independence (RBC-TI), 8 weeks);

duration of HI-E, pharmacodynamic and iron metabolism biomarkers, and pt-reported quality of life (QoL).

Methods: Inclusion criteria: MDS IPSS low or int-1, age ≥18 yr, Hgb <10 g/dL (if <4U RBC/8 weeks), no prior HMA, and no current lenalidomide or erythropoiesis-stimulating agent (ESA). The dose-escalation phase of the study is completed. An expansion cohort of up to 56 patients was added to this phase of the study to evaluate response and tolerability in pts who would not qualify for the phase 3 MEDALIST trial (for regularly transfused ring-sideroblast positive [RS(+)] patients with EPO <200 U/L). These include pts with low transfusion burden (LTB, <4U RBC/8 weeks) and either 1) RS(+) (≥15% in bone marrow) or 2) RS(-) and any EPO level. RS(-) pts are also treated until RBC-TI/8 weeks. Pts are treated every 3 weeks subcutaneously for up to 5 doses (titration up to 1.75mg/kg) in the base and ext studies, respectively, were 62% (18/29) and 80% (45/56) for RS(+) pts with EPO <200 U/L and 46% (5/11) and 80% (7/9) for RS(-) pts with EPO 200-500 U/L. RBC-TI rates for pts treated with ≥0.75mg/kg in the base and ext studies, respectively, were 68% (13/19) and 85% (23/27) for RS(+) pts with EPO <200U/L and 48% (6/13) and 80% (9/11) for RS(+) pts with EPO 200-500 U/L. Preliminary RS(-) response rates (IWG HI-E and RBC-TI) by subgroup will also be presented at the meeting. Luspatercept was well tolerated, with related grade 3/4 adverse events (in 3 pts as of 28Nov2016 of blast cell count increase, myalgia, and worsening of general condition. The most common other AEs (≥2 pts) were diarrhea, fatigue, headache, hypertension, arthralgia, bone pain, injection site erythema, myalgia, and peripheral edema.

Summary/Conclusions: Lower-risk MDS patients treated long-term with luspatercept demonstrated robust and sustained increases in Hgb and decreases in transfusion burden and a high rate of RBC-TI. A Phase 3 study of luspatercept in regularly-transfused RS(+) patients with low-risk MDS according to the Italian MDS registry of Fondazione Italiana Sindrome Mielodisplastica (FISM).

Figure 1.

Results: Data (as of 09Sept2016) were available for 73 base and 42 ext study pts. Pts aged 22 and 2 ext pts were LTB and 41 base ext pts were high transfusion burden (HTB, ≥4U RBC/8 weeks). Median (range) age (yr) was 72 (27-90), 53% pts had prior ESA, 51% pts had baseline EPO <200 U/L. Median (range) Hgb (g/dL) for HTB pts was 8.6 (6.4-10.1). Median (range) RBC transfusion burden (U/8 weeks) for HTB pts was 6 (4-8). 71% base and 86% ext pts were RS(-). IWG HI-E response rates for pts treated with ≥0.75mg/kg in the base and ext studies, respectively, were 62% (18/29) and 80% (45/56) for RS(+) pts with EPO <200 U/L and 46% (5/11) and 80% (7/9) for RS(-) pts with EPO 200-500 U/L. RBC-TI rates for pts treated with ≥0.75mg/kg in the base and ext studies, respectively, were 68% (13/19) and 85% (23/27) for RS(+) pts with EPO <200U/L and 48% (6/13) and 80% (9/11) for RS(+) pts with EPO 200-500 U/L. Preliminary RS(-) response rates (IWG HI-E and RBC-TI) by subgroup will also be presented at the meeting. Luspatercept was well tolerated, with related grade 3/4 adverse events (in 3 pts as of 28Nov2016 of blast cell count increase, myalgia, and worsening of general condition. The most common other AEs (≥2 pts) were diarrhea, fatigue, headache, hypertension, arthralgia, bone pain, injection site erythema, myalgia, and peripheral edema.

Summary/Conclusions: Lower-risk MDS patients treated long-term with luspatercept demonstrated robust and sustained increases in Hgb and decreases in transfusion burden and a high rate of RBC-TI. A Phase 3 study of luspatercept in regularly-transfused RS(+) patients with lower-risk MDS according to IPSS-R is ongoing (MEDALIST study; NCT02631070).

P667

RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)

M. Clavio1-2, D. Gioia1, M. Ceccarelli3, C. Monachehdu2,3, E. Balleri2,4, E. Miglioli2,5, A. Di Tuccio2,5, B. Allone2,6, A. Polon1,7, C. Finelli2,8, C. Aguzzoli2,9, C. Sellen1-2,10, P. Danesin1,2,11, D. Collini1,2,12, V. Gaidano1,13, M. Cavalleri2,14, T. Calzamiglia15,16, R. Freilone2,16, G. Carmelli17,18, A. R. Conconi1,19, M. Mezzabbottaz19,12, R. Goretta2,20, P. Musto2,21, G. Gaidano22,22, F. Pane2,23, E. Angelucci2,24, A. Levis2,25, V. Santini2,25

1Clinic of Hematology, Department of Internal Medicine (DIMII), University of Genoa, IRCCS AO San Martino IST, Genova, 2Fondazione Italiana Sindrome Mielodisplastiche (FISM), Alessandria, 3Unit of Clinical Hematology, Ospedale Civile, AO Città della Salute e della Scienza di Torino, Torino, 4Division of Internal Medicine, IRCCS AO San Martino IST, Genova, 5Hematology and Bone Marrow Transplantation Unit, Ospedale Oncologico di Riferimento Regionale “Armando Buscino”, Cagliari, 6Division of Hematology, Institute of Hematology and Medical Oncology Policlinico S Orsola Malpighi, Bologna, 7Division of Hematology, University of Torino, AOU Città della Salute e della Scienza di Torino, Torino, 8Division of Hematology, Ospedali Riuniti Università Politecnica delle Marche, Ancona, 9Division of Hematology, Institute of Hematology and Medical Oncology Policlinico S Orsola Malpighi, Bologna, 10Division of Hematology, University of Torino, AOU Città della Salute e della Scienza di Torino, Torino, 11Hematology and Transplant Center, University of Salerno, 12Ospedale San Giovanni di Dio Ruggi d’Aragona, 13Division of Internal Medicine and Onco-Hematology, Hospital Umberto I, Salerno, 14Division of Internal Medicine 2 and Hematology, University of Turin, S Luigi Hospital Orbasano, 15Division of Hematology, Mauriziano Hospital, Torino, 16Division of Internal Medicine, San Paolo Hospital, Savona, 17Division of Internal Medicine, Ospedali di Avellino, San Giovanni a festive, 18Service of Oncology and Hematology, Stabilimento Ospedaliero Cirié, Torino, 19Division of Internal Medicine, Ospedale Maggiore di Chieri, Chieri, 20Division of Internal Medicine, Ospedale degli Infermi Biella, Biella, 21Division of Hematology, Ospedale Ordine Mauriziano, Torino, 22Division of Internal Medicine, Ospedale di Pietra Ligure, Pietra Ligure, 23Division of Hematology and Oncology, Centro di Riferimento Regionale “Carlo Bertario”, Rovato, 24Service of Oncology and Hematology, Stabilimento Ospedaliero Basilicata, Rionero in Vulture Potenza, 25Department of Translational Medicine, Division of Hematology Amedeo Avogadro University of Eastern Piedmont, Novara, 26Division of Hematology, AOUD Ferrico II Napoli, Napoli, 27Division of Hematology, Azienda Ospedaliera Universitaria S Martino - IST, Genova, 28Division of Hematology, University of Florence, Florence, Italy.

Background: Azacitidine (AZA) is the current standard of care for patients with high-risk myelodysplastic syndrome (MDS) in Europe. AZA has shown a
survival advantage when compared with conventional therapies and has also shown activity in IPSS lower-risk patients. However, about 40% of patients do not respond and most patients lose response within 2 years. Treatment options for MDS patients failing hypomethylating agents therapy are scarce and overall survival (OS) is extremely short.

**Aims:** Objectives of this study were to describe in a cohort of real life MDS patients treated with AZA, the reasons causing treatment discontinuation, and to evaluate the clinical outcome after the end of AZA therapy.

**Methods:** Unselected patients recorded in the MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM) and treated with AZA from January 2009 to June 2014 were considered for the analysis. All types of conventional and hypomethylating agents allowed of AZA were allowed. Clinical response, cause of discontinuation, salvage treatments and OS from discontinuation of AZA were the major end points.

**Results:** Between January 2009 to June 2014 1799 newly diagnosed MDS patients were enrolled in the Registry, and 418 received AZA; 269 as 1st line treatment (46%), 111 as 2nd line treatment (28%), and 34 as a line ≥3rd (8%). Median age was 73 years (range 18-91); 260 patients (62%) were male. WHO diagnosis was RA or RARS (n=27, 6%), RCMD with or without RS (n=62, 15%) AN (n=126, 30%) AEB-1 (n=116, 28%), AEB 2 (n=189, 45%), other subtypes (n=15, 4%). At start of AZA therapy IPSS score was low in 14 (3.4%), int1 in 97 (23.2%), int2 in 163 (43.8%); high in 67 patients (16%), and not available in 57 patients (13.6%). Patients received a median of 7 courses of treatment (range 1-63). Seventy-three % of the whole cohort (418 pts) were alive at 1 year from beginning of AZA therapy and median OS was 23 months. (25 for IPSS lower-risk MDS and 21 for IPSS higher risk MDS). OS after discontinuation of AZA was 8 months. Clinical responses according to IWG criteria were available in 344/418 patients (82%); 44% achieved a complete hematological response, 77 (22%), a partial response, 86 (25%) had stable disease while 136 (32%) did not respond. Response was achieved after a median of 6 cycles. After a median follow up of 16 months (range 7-35) in 37 (9%) patients AZA therapy was still ongoing while in 381 (91%) the treatment has been discontinued. Interruption of treatment was due to loss of response in 59 (16%) patients, AML evolution in 154 (40%), death in 43 (11%), toxicity or poor compliance in 39 (10%), allo-genic transplant (HSCT) in 12 (3%), other reasons in 22 (6%), not reported in 52 patients (14%). Of the 381 patients who discontinued AZA, 15 (4%) were managed with intensive AML-like chemotherapy, 22 (6%), received an allogeneic HSCT, 27 (7%) low-dose chemotherapy (7%), 22 (6%) erythroid stimulating agents, 18 (5%) other treatments and 277 (72%) patients no further treatment or only supportive therapy.

**Summary/Conclusions:** Our data confirm that AZA therapy is effective for MDS patients, both with higher and lower IPSS risk disease. Response rate is consistent with what previously reported, with a median OS of 23 months. Interestingly, at 16 months, 91 % of patients had discontinued treatment, either for progression or loss of response and only in 10% of cases for reported toxicity. Only 28% of patients received any kind of salvage therapy and overall survival after AZA discontinuation was poor (8 months).

**P668**

**COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS**

E. Louka1, A. Hamblin2, G. Buck1, H. Drea2, P. Ware2, P. Ancillotti2, S. Baird2, N. Bhatnagar3, H. Campbell4, M. Caswell5, P. Connor5, B. Gibson5, G. Hall6, J. Motwani8, A. Norton9, D. O’Connor10, K. Patrick10, F. Pinto8, R. Wynn11, A. Vora12, I. Roberts1, A. Mead1, A. Rao1

1. Molecular Haematology Unit, Weatherall Institute of Molecular Medicine University of Oxford; 2. Molecular Diagnostic centre, John Radcliffe Hospital, Oxford, 3. Paediatric Haematology Department, Great Ormond Street Hospital, London; 4. Paediatric Haematology Unit, Royal Hospital for Sick Children, Edinburgh; 5. Paediatric Haematology Department, John Radcliffe Children’s Hospital, Oxford; 6. Paediatric Haematology Unit, Alder Hey Children’s Hospital, Liverpool; 7. Paediatric Haematology Department, Noah’s Ark Children’s Hospital of Wales, Cardiff; 8. Paediatric Haematology Department, Royal Hospital for Children Glasgow, Glasgow; 9. Paediatric Haematology Department, Birmingham Children Hospital, Birmingham; 10. Paediatric Haematology Department, Sheffield Children’s Hospital, Sheffield; 11. Paediatric Haematology Department, Manchester Children’s Hospital, Manchester, United Kingdom

**Background:** Paediatric Myelodysplastic Syndromes (MDS) are a rare and heterogeneous group of disorders distinct from adult MDS. They may present with syndromic anemia, life threatening infection or evolving leukemia; however, they may also present as unexplained cytopenias or with multisystem disease of unclear aetiology. Diagnosis can represent a huge challenge for clinicians, even in highly specialised centres and this can delay the delivery of the most appropriate treatment. Hence an accurate diagnosis is crucial in selecting the most advantageous, including surveillance and follow up, treatment(s).

**Aims:** To devise a clinical grade diagnostic targeted NGS panel and combine the results with extensive clinical phenotypic information to obtain a diagnosis in children referred with suspected MDS.

**Methods:** Children (0-18yrs) were referred from 14 UK centres with a diagnosis of suspected MDS and/or sustained cytopenias with morphological features of myelodysplasia. Extensive phenotypic information including family history, detailed clinical examination and disease course details were collected and captured on an online database using the Human Phenomiser tool. A customised targeted NGS panel was designed using the illumina design studio containing 32 genes, 916 amplicons and 301 exons; selected through literature reports and well described mutations in Paediatric MDS and potential overlap with the Bone Marrow failure syndromes (BMFS). Coverage of each base within target regions was assessed for every sample on each sequencing run using Covemi software. Library preparation was performed using an illumina Truseq Custom Amplicon panel, followed by sequencing on an illumina MiSeq. Data analysis was performed using our established bioinformatic pipelines (Hamblin A: Blood 2014 124:2373).

**Results:** In total 59 patients (females= 29, males 30) have been screened and 3 subgroups identified based on the original suspected clinician diagnosis at presentation: MPN/JMML (n=15), de novo MDS (n=9) and idiopathic cytopenias of undetermined significance (ICUS) with some features of dysplasia (n=35). Mutations were detected in 24/59 patients (40%, Table 1). Of these, NGS results confirmed the original clinical diagnosis in 15 cases (62.5%); established the diagnosis for the first time in 6 cases (25%); and led to a change in diagnosis (from autoimmune neutropenia to Shwachman-Diamond Syndrome) in 1 case leading to a significant change in patient management. In two already known cases, it allowed monitoring of the disease molecular signature. As expected, RA or MDS patients were common in the JMML/MPN (100%) and de novo MDS patient subgroups (33%). Additional mutations in epigenetic modifiers, spliceosome mutations as well as second RA or MDS pathway hits were also detected in 40% of JMML patients, and in one case within the de novo MDS group; this finding was associated with poor outcome. Within the heterogenous ICUS patient group, pathogenic mutations were identified in 5/35 (14.3%) cases with BMFS genes (SBDS, ELANE, TP53). In contrast to the other MDS/MPN cases, in this group, no RA or MDS pathway mutations were detected.

**Table 1.**

**Summary/Conclusions:** Targeted NGS together with detailed phenotyping is a useful tool for the diagnosis of suspected MDS and unexplained cytopenias in children, with 40% of patient showing a disease-associated mutations. Results were available within 6-8 weeks in most cases enabling both rapid initial diagnosis and, in some cases, appropriate molecular markers for monitoring of clonal evolution and response to therapy. For the children who remain without a clinical diagnosis, whole genome sequencing (WGS) may identify pathogenic mutations and this is currently underway.
OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEEP RESPONSE TO INDUCTION THERAPY — FMG-MM02

S. Luoma1,2,*, S. Ilveskero3, S. Rounioja4, J. Valtola5, T. Lundan6, J. Lievonen1, P. Smith3, L. Clifton-Hadley3, N. Rabin17, R. Popat1

1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, 2University of Helsinki, 3HUSLAB, Department of Clinical Chemistry and Hematology, Helsinki University Hospital, Helsinki, 4Fimlab Laboratories Ltd, Tampere University Hospital, Tampere, 5Department of Medicine, Kuopio University Hospital, Kuopio, 6Department of Clinical Chemistry and TYKSLAB, Turku University Hospital, Turku, 7Hematology Research Unit Helsinki University, Helsinki, University of Helsinki, Finland

Background: In multiple myeloma (MM) the interactions between malignant plasma cells and the bone marrow (BM) microenvironment are important for treatment outcome. There is limited data on the effects of lenalidomide (LEN) on the BM immune profile and its therapeutic predictive value. The FMG-MM02 study (NCT01797037) was designed to explore the response to LEN, bortezomib and dexamethasone (RVD) induction, followed by a single autologous stem cell transplantation (ASCT) and LEN maintenance as a first-line therapy for MM patients (n=80). The primary endpoint was achievement of an immunophenotypic remission. Here we report the results of one of the secondary endpoints: composition of lymphocyte subsets at baseline and during LEN maintenance.

Aims: The aim of this study was to assess the proportion of different lymphocyte subsets at baseline and after ASCT and correlate lymphocyte composition with patient outcome.

Methods: Flow cytometry (FC) panel included antibodies against CD38, CD138, CD45, CD19, CD56, CD27, CD28, CD81, CD117, intracytoplasmic kappa and lambda. Sequential analyses (at baseline, after induction and at 3, 9 and 16 months after ASCT) were performed in 37/80 patients who achieved at least near complete remission (nCR) and/or minimal residual disease (MRD) negativity by FC. In addition to MRD the samples of these patients were analyzed for mature B-cells (CD19+CD45+), B-cell progenitors (CD19+CD11b+CD38+CD45+), B-cell blasts (CD19+CD81+CD38+CD45dim), NK-T cells (CD56+CD16+), T-cells (CD3+CD8+, CD3+CD4+, CD3+CD8neg), T lymphocytes other than B-cells and T/NK-cells (CD34+), CD3+ activated T-cells as calculated per total bone marrow nucleated cells (TNC). The results were compared between two different response cohorts: the good cohort (n=26) defined by persistent stringent complete remission/FC negativity, or PCR negativity (≤ 0.006%) and the control cohort (n=11), who only achieved nCR or had early relapse within one year of ASCT.

Results: At baseline, markers for disease burden, such as the percentage of myeloma cells in BM or paraprotein levels did not differ between the response cohorts. No differences were noted in R-SS or ISS risk stratification either, but there were more IMWG high risk patients in the control cohort (p=0.048). The median percentage of total lymphocytes (15.4% vs 11.9% good vs control), T cells (9.6 vs 7.8), CD19+ B-cells (1.6 vs 1.3), and CD3+ T-cells (0.9 vs 0.5) in BM were all higher in the good response cohort at baseline. In particular, the median proportion of mature B cells in BM was significantly higher in the best cohort at baseline (1.32 vs 0.91; p=0.02), after induction (0.27 vs 0.13; p=0.002) and 16 months after ASCT (1.73 vs 0.56; p=0.008) (Figure 1).

Summary/Conclusions: Composition of the BM lymphocyte pool at treatment baseline may have an influence on treatment outcome in multiple myeloma. More detailed subtyping of the lymphocyte phenotypes is ongoing and may reveal potential predictive biomarkers for immunomodulatory drugs such as lenalidomide and checkpoint inhibitors.

Figure 1.
Bortezomib/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS

E. Benedetti1, G. Buda1, E. Orlicio1, N. Cecconi1, G. Ceretti1, M. Rousseau1, L. Lovino1, F. Mazzotta1, M. Petri1

Background: Lytic lesions occur in the majority of patients with multiple myeloma (MM) and represent one of the criteria for starting therapy. In the past, whole-body X-ray (WBX) represented the method of choice for detecting skeleton abnormalities; today, magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT) have been adopted for their higher power in detecting extra-medullary localizations and their higher sensitivity. Nevertheless, which technique would be really the best one is still matter of discussion.

Aims: Our single-center retrospective study was designed to compare PET-CT with other imaging techniques (WBX, vertebral column CT and MRI) at the diagnosis and during the follow-up of MM patients. Finally, we assessed a possible predictive/prognostic role of the PET-CT in terms of quality of response and survival.

Methods: We enrolled 160 patients with diagnosed symptomatic (N=1419) or smoldering multiple myeloma (N=11) observed at the AOU, Pisa, Italy, between January 1996 and December 2015. Eighty-three were male and 77 female; the median age was 70 years (range, 28-85), and half of them presented with low ISS risk score. Forty-five subjects were not eligible to high-dose therapy; 64% of them received bortezomib- and 23% melphalan-based regimens. Patients eligible to high-dose therapy received VAD, TAD or VTD and then one (88%) or two (12%) autologous transplants. At the relapse, lenalidomide (57%) or anthracyclines (4%) were administered. In contrast, PET-CT sensitivity was comparable to that of CT and 40% in respect of WBX (71%). Analogously to that observed at diagnosis, PET-CT during follow-up showed distinct advantages in terms of sensitivity compared to X-rays (83% vs 60%, respectively). In contrast, PET-CT sensitivity was comparable to that of CT and MRI. As at diagnosis, the specificity was higher for WBX (70%) than for CT, RM and PET-CT (40% for all of these). When PET-CT was correlated to the quality of response, it was significant only in the not transplanted cohort (PR rate in PET-negative cases: BTZ77% vs 23% in the PET-positive group; p<0.016). Nevertheless, PET-CT positivity either at diagnosis or during follow-up did not impact on long-term OS and PFS.

Summary/Conclusions: Our study showed that PET-CT and MRI would represent the techniques of choice in the assessment of bone involvement in MM patients in view of their high and comparable sensitivity. Moreover, PET-CT allows the possibility of a “whole body” analysis in exchange for higher “biologic” cost.

P672
INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA

R. Hajek1,2,2, L. Pour1,3, J. Spicka4, M. Oczan4, V. Maisarn4, M. Turgut1, L. Kwei5, Z. Salman5, E. Bilotti8, A. Oriol9

1Department of Hemato-oncology, University Hospital in Ostrava, 2Faculty of Medicine, University of Ostrava, Ostrava, 3University Hospital Brno, Brno, 4Clinical Chemistry, Hematology, Charles University, Prague, Czech Republic, 5Department of Internal Medical Sciences, Ankara University School of Medicine, Ankara, Turkey, 6Fourth Department of Medicine–Hematology, Charles University Hospital, Hradec Kralove, Czech Republic, 7Faculty of Medicine, Department of Hematology, Onkodukay Myatis University, Samsun, Turkey, 8Pharmatics LLC, an AveVie Company, Sunnyvale, United States, 9Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

Background: Bruton’s tyrosine kinase (BTK) is overexpressed in, and has been implicated in the growth and survival of multiple myeloma (MM) cells, providing a rationale for evaluating BTK inhibitors in MM (Yang Cancer Res 2015; Tai Blood 2012). Yang 2015 demonstrated that BTK overexpression (OE) contributes to blunted responses in MM cells when treated with widely used MM drugs (ie, bortezomib [BTZ], etoposide and doxorubicin). Increased activity of the ABC transporter efflux pump and expression of the ABCB1 transporter was seen in BTK OE cells, and subsequent inhibition led to a restoration of the ABC transporter efflux pump and expression of the ABCB1 transporter.

Aims: To evaluate safety and efficacy of combination ibr+BTZ/dex in previously treated MM pts.

Methods: In this phase 2, open-label, multicenter, European study (PCYC-1139), eligible pts received 1-3 prior therapies and demonstrated disease progression on or following the most recent therapy. Prior BTZ use was permitted provided pts were sensitive (ie, no progression ≤60 days after having achieved minimal response or better). All pts provided informed consent. For cycles 1-8 (21-day cycles), pts received ibr 840mg once daily with BTZ 1.3mg/m² subcutaneously twice weekly (Days 1, 4, 8, 11) and dex 20mg on day of and after BTZ. For cycles 9-12 (42-day cycles), BTZ was dosed weekly (Days 1, 8, 22, 29). The primary endpoint was PFS with secondary endpoints including safety, ORR, PFS at landmark points, duration of response, and time to progression (TTP).

Results: As of November 21, 2016, 20 pts were enrolled (Table). Median age was 68.5 years (range, 49-96). Median number of prior therapies was 1, with 50% refractory to the most recent therapy and 70% previously exposed to BTZ. Gene expression profiling (GEP) in initial pts indicated high-risk GEP in 35% of pts. Virtual fluorescent in situ hybridization identified 40% of pts with high-risk cytogenetics. Median treatment duration was 2.1 months (range, 0.5-3.7). All pts experienced at least one treatment-emergent adverse event (AE) of any grade. The most common all-grade nonhematologic AEs occurring in >15% were diarrhea (50%), upper respiratory tract infection (30%), and asthenia, peripheral edema, hypocalcemia and hypokalemia (20% each). The most common Grade 3 AEs occurring in ≥10% (≥1 pt) were thrombocytopenia (25%), asthenia and pneumonia (15% each), and hyponatremia, abnormal hepatic function, infection, and bone pain (10% each). Three deaths were reported (sudden death in a pt with cardiac history, pneumonia, and myocardial infarction). With early follow-up, 19 pts are evaluable for response with an ORR of 47%, including MR or better in 68%. Updated data will be presented.

Summary/Conclusions: The initial data indicate promising clinical potential for the combination of ibr+BTZ+dex. Treatment was generally well tolerated without any unexpected safety signals noted for the combination. The preliminary ORR of 47% after a minimum 2 treatment cycles is encouraging with further follow-up needed.

P673
PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

S. Sidana1, N. Tandon1, A. Dispenzieri1, M.A. Gertz1, F.K. Buadi1, M.Q. Lacy1, D. Dingli1, A.L. Fonder1, S.R. Hayman1, M.A. Hobbs1, Y.L. Hwa1, P. Kapoor1, R.A. Kyle1, N. Leung1, R.S. Go1, J.A. Lust1, S.J. Russell1, S.V. Rajkumar1, K. Kalem1, W.J. Jumper1

1Hematology, Mayo Clinic, Rochester, United States

Background: Presence of circulating plasma cells (cPCs) prior to autologous stem cell transplant (ASCT) is an adverse prognostic factor in patients with light chain amyloidosis (AL). Prognostic value of cPCs prior to ASCT and categorized them as follows: a) Group 1: patients proceeding directly to ASCT without induction therapy and b) Group 2: patients who received induction therapy before ASCT.
Results: There were 78 patients in Group 1 and 52 patients in Group 2. Patients in Group 2 had higher baseline dFLC, bone marrow plasma cells (BMPC), Mayo stage and were more likely to have active MM compared to patients in Group 1. Table 1 lists baseline characteristics of the patients in Groups 1 and 2. Patients in Group 1 had higher rate of renal involvement. cPCs were detectable in 22% (n=28) of patients at the time of ASCT. More patients in Group 1 had detectable cPCs than in Group 2 (31% vs 8%; p<0.002), likely due to clearance of cPCs with treatment. Data on cPCs at diagnosis in the induction group was available in 14 patients, of whom 57% (n=8) had detectable cPCs vs 31% in the direct ASCT group (p=0.06). 6 of the 8 (75%) patients cleared cPCs with induction therapy. There were no significant differences in patients who had detectable and undetectable cPCs before transplant, including organ involvement, baseline dFLC, BMPC, and Mayo Stage.

In Group 2, both progression free survival (PFS) (10.5 months vs 58 months, p <0.0001) and overall survival (OS) (16 months vs not reached, p =0.001) were worse in patients who had detectable cPCs compared to those without cPCs (Figure 1). This difference was not seen in Group 1 (OS: not reached vs 98 months, p=0.96; PFS 43 vs 52 months, p=0.74). In multivariate analysis, adjusting for Mayo Stage and induction chemotherapy, there was a trend towards worse OS in patients with detectable cPCs (p=0.06).

Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1 (n=78)</th>
<th>Group 2 (n=52)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMPC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dFLC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMPC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dFLC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: cPCs are cleared after induction treatment in majority of AL patients. Patients who have detectable cPCs prior to proceeding to ASCT after induction have worse PFS and OS than patients without cPCs. On the other hand, presence of cPCs was not found to be an adverse prognostic factor in patients proceeding directly to ASCT. This may be due otherwise excellent prognosis in this group, with absence of other high-risk features that are seen in patients who require induction. A limitation of our study is lack of data on cPCs at diagnosis in all patients who received induction therapy.

P674
RENA L IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY

P.J. Ho1, E. Moore2, Z. McGuillen2, K. Bergin3, H. Blacklock3, N. Horvath4, T. King1, J. McNeil2, P. Mollee6, H. Quach7, C. Reid2, B. Rosengarten8, P. Walker9, E. Wood2, A. Spencer9

1Institute of Haematology, Royal Prince Alfred Hospital, Sydney, 2Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 3Dept of Haematology, Sir Charles Gardiner Hospital, Perth, Australia, 4Dept of Haematology, Middlemore Hospital, Auckland, New Zealand, 5Dept of Haematology, Royal Adelaide Hospital, Adelaide, 6Dept of Haematology, Princess Alexandra Hospital, Brisbane, 7Dept of Haematology, St Vincent's Hospital, 8Myeloma Foundation of Australia, 9Dept of Haematology, The Alfred Hospital, Melbourne Australia

Background: Renal impairment (RI) is a poor prognostic factor in multiple myeloma (MM). Analysis of disease characteristics, therapy & outcomes can improve treatment & prognosis.

Aims: To assess (1) characteristics of patients with RI at diagnosis - severity of RI, age, risk factors, high risk features, stage, disease manifestations & performance status, and (2) treatment including induction therapy & autologous stem cell transplant (ASCT) and outcomes.

Methods: Data from newly diagnosed MM patients enrolled in the Australian and New Zealand Myeloma Registry from 1 Feb 2013 to 31 Dec 2016 were analysed.

Results: Of 867 patients, 775 had eGFR available at diagnosis: 34% (287/775) had eGFR <60ml/min (22% at 30-60ml/min; 6% at 15-30ml/min; 6% at <15 ml/min). Mean age of patients with RI (<60 ml/min) was 72 vs 64 yrs without RI. Diabetes mellitus (DM), a major cause of chronic kidney disease (CKD), was more prevalent in patients with RI: 17% of patients with eGFR <30 ml/min compared with 8% >30ml/min. Patients with RI (<30ml/min) and DM had a similar response to first-line therapy compared to RI without DM (p=0.06). PFS & OS decreased with reduction in eGFR.

Summary/Conclusions: RI occurred in one-third of newly diagnosed MM. DM, an underlying risk factor for CKD, was more common in RI patients, but not associated with a difference in outcome. Advanced stage & high risk features were more prevalent in RI patients, but bone disease was less common. RI patients had a shorter PFS and OS, overall correlating with eGFR. However patients with eGFR <15ml/min had a better OS than 15-30 ml/min, for which dialysis may be a factor. In transplant-eligible patients assessed by age <70 yrs, ASCT was performed in 21% of RI patients, at all levels of renal function. Patients with RI who underwent ASCT had a superior PFS and OS than those who did not have ASCT, including those with severe RI (eGFR <30ml/min), supporting the benefit of ASCT in MM patients with RI.

P675
VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA


1Mayo Clinic, Rochester, 2Winship Cancer Institute of Emory University, Atlanta, 3Mayo Clinic, Scottsdale, 4Duke University, Hematologic Malignancies & Cellular Therapy, Durham, 5Washington University School of Medicine, St. Louis, United States, 6CHU Grenoble, Grenoble, 7CHR U Tours, Tours, 8CHRU Lille, 9CHU de Nantes, 10AbbVie Inc., North Chicago, United States

Background: Venetoclax (VEN), an orally available selective small-molecule inhibitor of BCL-2, has shown impressive activity in combination with IMiDs or Dexamethasone in relapsed/refractory MM patients. We present our experience with VEN in over 130 patients, including a subset of patients who had prior exposure to proteasome inhibitors (PI).
BCL-2 inhibitor, induces cell death in multiple myeloma (MM) cells, particularly those with the t(11;14) translocation.

Aims: The objectives of the study are to evaluate safety, PK, recommended phase two dose, and preliminary efficacy of VEN monotherapy in relapsed/refractory (R/R) MM.

Methods: Patients (pts) with relapsed/refractory (R/R) MM received VEN monotherapy in this phase 1 study. Daily VEN was given at 300–1200mg in dose escalation cohorts and 1200mg in the safety expansion. Pts with disease progression (PD) on VEN monotherapy could receive VEN plus dexamethasone and remain on study.

Results: As of 19 Aug 2016, 66 pts were enrolled. Median age was 63 years and 30 (46%) pts had t(11;14). Median number of prior lines of therapy was 13 (range: 1–15); 46 (70%) pts were refractory to bortezomib, 20 (30%) to carfilzomib, 57 (77%) to lenalidomide, 35 (53%) to pomalidomide, and 52 (79%) were refractory to the last prior therapy. Median time on VEN monotherapy was 2.5 months (range: 0.2–23); 17 pts received V EN plus dexamethasone after PD for a median (range) of 15 (7–53) cycles. Fifteen (23%) pts discontinued, with 41 due to PD. Common adverse events (AEs) were nausea (47%), diarrhea (36%), vomiting (21%) and grade 3/4 hematologic toxicities [thrombocytopenia (32%), neutropenia (27%), anemia (23%), leukopenia (23%). Common serious AEs were pneumonia (8%), sepsis (5%), cough, hypotension, pain, and pyrexia (3%). There were no events of TLS. Six deaths were reported due to PD, and 1 each due to lung disorder and brain hemorrhage following trauma. Overall response rate (ORR) for all pts on VEN monotherapy was 21% (14/66); 10 (15%) achieved very good partial response (VGPR) or better [2 stringent complete response (sCR), 3 CR, 5 VGPR]. For all pts, median time to progression (TTP) was 2.6 months (range: 0.1–13). A clear difference in responses was seen among pts with t(11;14) vs without [ORR, 40% vs 6%; vs VGPR, 27% vs 6%]. For pts with t(11;14), median TTP was 6.6 months [vs 1.9 months for pts without t(11;14)] and median DoR was 9.7 months. A high BCL2:BCL2L1 (BCL-X) gene expression ratio was observed in 10/44 (23%) baseline tumor samples, enriched in pts with t(11;14) compared with non-t(11;14) (38% vs 5%) and associated with clinical response; 80% (8/10) of pts [all t(11;14)] with a high BCL2:BCL2L1 ratio achieved ≥PR with a median TTP of 11.5 months. Among pts with t(11;14) who were refractory to the last therapy, ORR was 42% (11/26); for t(11;14) pts refractory to both bortezomib and lenalidomide, ORR was 40% (8/20) and 50% (3/6), respectively. No difference was seen in ORR for t(11;14) pts with high-risk del(17p) versus those without the deletion [40% (2/5) vs 40% (10/25)].

Summary/Conclusions: VEN has an acceptable safety profile with promising single-agent anti-myeloma activity in pts with RR MM positive for t(11;14) who failed multiple prior lines of therapy.

P676

AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRd) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

S. Z. Usmani1, A. Char2, S. Lonial3, B. Weiss4, R.L. Comenzo5, K. Wu5, N. Z. Khokhar6, J. Wang7, P. Doshi7, A. Jakubowiak1, S. Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, 2Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, 3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 4Abramson Cancer Center and Perelman School of Medicine of University of Pennsylvania, Philadelphia, PA, 5Division of Hematology/ Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, 6Janssen Research & Development, LLC, Spring House, PA, 7Janssen Research & Development, LLC, Rantan, NJ, 8University of Chicago Medical Center, Chicago, IL, United States

Background: The combination of daratumumab with standard of care regimens has demonstrated significantly prolonged progression-free survival (PFS), deeper responses, and a manageable safety profile versus standard of care alone in patients with relapsed or refractory MM.

Aims: To determine the tolerability and efficacy of daratumumab in combination with KRd in patients with newly diagnosed MM.

Methods: This was a phase 1b study enrolled patients with newly diagnosed MM regardless of transplantation eligibility. Patients received daratumumab 16mg/kg qw for Cycles 1-2, q2w for Cycles 3-6, and q4w thereafter, with all patients receiving the first dose split over 2 days. Carfilzomib was given on Days 1, 8, and 15 of each 28-day cycle (20mg/m² on Cycle 1 Day 1, 36 or 70mg/m² subsequently). Median age was 60 (34-74) years, and 95% had an ECOG score of ≤1. At a median follow-up of 19.5 months (range: 0.3-34), overall response rate (ORR) of 82% (80/98 evaluable patients: 18 patients discontinued due to toxicity) was achieved, with an overall safety profile consistent with previous reports for KRd. Daratumumab in combination with KRd was well tolerated, with an overall safety profile consistent with previous reports for KRd. No additional toxicity occurred with the addition of daratumumab, and deep and durable responses were achieved. Preliminary data from this ongoing study support continued investigation of daratumumab plus KRd as a first-line treatment regimen for patients with newly diagnosed MM. Updated data based on longer follow-up will be presented.

P677

GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY

R. Kuiper1, M.H. van Vilst1, M. van Duin2, A. Broij3, M.-D. Levin4, L. de Best1, E.H. van Beers5, B. van der Hoef6, H. Visser5, M. Hansson5, A.W. van der Velden7, S. Dumee1, M. Vermeulen2, J. Koenders2, H.B. Beerbolvo6, M. Stevens-Kroef6, A. Waage10, S. Zweegman11, P. Sonneveld2, J. Hoel2, P. Sonneveld2, J. Zoetmulder12, K. van der Meer9, J. van Heerde2, Y. Van Delden10, 1Bioinformatics, SkylineDx, 2Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, 3Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, 5Department of Hematology and Transfusion Medicine, Skåne University Hospital, Lund, Sweden, 6Department of Internal Medicine, Martin University Hospital, Groningen, 7Department of Clinical Genetics, Erasmus MC, Rotterdam, 8Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands, 9Norwegian University of Science and Technology, Trondheim, Norway, 10Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

Background: Multiple myeloma (MM) affects mostly elderly people with a median age of 69 years at diagnosis, with 35-40% of patients older than 75. Overall survival (OS) is variable: patients aged 60-70, 9% survive less than 3 months and 23% survive longer than 10 years. Recently the revised ISS (rISS) has been proposed as a prognostic marker that incorporates ISS, FISH and LDH. Another marker, the SKY92 prognostic classifier, was developed in younger, transplant eligible multiple myeloma (MM) patients who were included in the HOVON-65/GMMG-HD4 trial. The SKY92 classifier was thoroughly validated in eight independent cohorts, at the time of its initial publication, and since. Aims: Here, we validated the SKY92 gene expression classifier and rISS in elderly, non-transplant eligible patients included in the HOVON-87/NMSG-18 trial (Zweegman et al. Blood 2016;127(9):1109-1116).

Methods: In this trial, melphalan, prednisone, thalidomide (MPT) plus thalidomide maintenance was compared with melphalan, prednisone, lenalidomide (MPR) plus lenalidomide maintenance. The MiMPprofiler™ CE IVD assay was used to obtain SKY92 scoring, classifying a patient as high-risk or standard-risk. In addition, the international staging system, LDH, FISH and rISS were analyzed.

Results: The 178 patients in the analysis for which enough bone marrow was available to perform GEP, had a median age of 73 years. At the time of data analysis, 94% were enrolled for 3 months. Therapeutic decisions were delayed in 25 of 178 patients as high-risk (14%). The median OS for the 25 patients classified as SKY92 high-risk was shorter than the median OS of standard-risk patients: SKY92 high-risk 21 months versus SKY92 standard-risk 53 months (hazard ratio (HR)=3.0, 95% confidence interval (CI)=1.7-5.3, p<0.01; Figure 1). At 2 years, the proportion of patients with rISS-III was 8% whereas comparable to the 10% identified in the initial report of the rISS. Interestingly, the proportion of SKY92 high-risk patients is larger (14%), whereas the median OS associated with these patients is shorter (21 vs 25 months). The SKY92 classifier performed better compared to the rISS as high-risk marker for OS. The 2-year OS rate using the SKY92 classifier was 33% for patients versus 27% for rISS (p=0.1).

Discussion: The 2-year progression free survival (PFS) rate was similar for SKY92 high-risk and rISS-III (16% and 17%, respectively). In the multivariate analysis, SKY92, rISS and deletion of 13q were independently associated with OS. Inde-
Aims: To evaluate the prevalence of comorbidities and to study the impact of comorbidities on survival among patients with newly diagnosed multiple myeloma.

Results: A total of 13,718 patients with multiple myeloma were included in the study and 21 groups of comorbidities were identified. The most common diseases were cancer, hypertension, heart failure, ischemic heart disease and atrial fibrillation. Among all patients, 55% had no prior history of comorbidity, 23% had one comorbidity, 12% had two comorbidities, and 10% had three or more comorbid conditions. Survival was negatively influenced by the number of comorbidities (Figure 1). The risk of death was significantly increased in patients with atrial fibrillation (HR=1.08; 95% CI 1.00-1.16), heart failure (HR=1.50; 95% CI 1.40-1.61), stroke (HR=1.20; 95% CI 1.11-1.30), psychological disease (HR=1.27; 95% CI 1.16-1.39), chronic lung disease (HR=1.22; 95% CI 1.12-1.32), diabetes (HR=1.14; 95% CI 1.04-1.36), peripheral vascular disease (HR=1.26; 95% CI 1.12-1.42), cancer (HR=1.10; 95% CI 1.04-1.16), dementia (HR=1.65; 95% CI 1.38-1.99), paralysis (HR=1.44; 95% CI 1.15-1.80), inflammatory bowel disease (HR=1.38; 95% CI 1.08-1.74), end stage renal disease (HR=1.57; 95% CI 1.03-2.04), and cirrhosis (HR=1.64; 95% CI 1.10-2.43).

Background: The number of multiple myeloma patients has grown with aging populations, and with increasing age the number of comorbidities increases as well. Clinically, it is well known that comorbidity in multiple myeloma patients decreases performance status, increases risk of therapy-related complications and may lead to life-threatening conditions. Currently, the literature on comorbidity in multiple myeloma is very limited and based on small case series. Clinical trials rarely include elderly, frail patients due to eligibility criteria. Population-based studies provide valuable information on survival outcomes in relation to presence/absence of comorbidities in newly diagnosed real-life multiple myeloma patients in the general population.

Aims: To evaluate the prevalence of comorbidities and to study the impact of comorbidities on survival among patients with newly diagnosed multiple myeloma.

Methods: All newly diagnosed patients with multiple myeloma from January 1st 1980 to December 31st 2013 in Sweden were included in the study. Using the Swedish Patient Registry, all discharge diagnosis and discharge listings were gathered from each patient from January 1st 1985. Comorbid conditions were defined as chronic illnesses which demand life-long treatment or follow-up. Only those diagnoses made prior to multiple myeloma were used. Using ICD 8, 9 and 10 codes, comorbid diseases were identified. Kaplan-Meier curves were used to estimate survival. Risk of death was compared among multiple myeloma patients with a comorbid condition to those without a comorbidity, using Cox's proportional hazards regression (adjusting for age, gender, year of diagnosis, and other comorbid conditions).

Summary/Conclusions: Here, we compared the SKY92 classifier with revised ISS staging and FISH. These data validate the SKY92 classifier as a robust marker to identify high-risk patients in non-transplant eligible MM patients. In these IMiD treated patients, the SKY92, the revised ISS, and FISH markers such as deletion of 13q retain independent prognostic value.

P678
MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY
I.S. Svenslsdottir1,2,*, S. Røgnvaldsson2, S. H. Lund3, I. Turesson3, M. Hultcrantz4, M. Björkholm5, O. Landgren4, S.Y. Kristinsson2
1Internal Medicine, Landspitali, 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 3University Hospital Malmö, Malmö, Sweden, 4Division of Hematology, Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States, 5Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

Background: The number of multiple myeloma patients has grown with aging populations, and with increasing age the number of comorbidities increases as well. Clinically, it is well known that comorbidity in multiple myeloma patients decreases performance status, increases risk of therapy-related complications and may lead to life-threatening conditions. Currently, the literature on comorbidity in multiple myeloma is very limited and based on small case series. Clinical trials rarely include elderly, frail patients due to eligibility criteria. Population-based studies provide valuable information on survival outcomes in relation to presence/absence of comorbidities in newly diagnosed real-life multiple myeloma patients in the general population.

Aims: To evaluate the prevalence of comorbidities and to study the impact of comorbidities on survival among patients with newly diagnosed multiple myeloma.
Myeloma and other monoclonal gammopathies - Clinical 4

P679
DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS
1Hematología Trasacional, Hospital 12 de Octubre, Madrid, 2Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IB SAL), Centro de Investigación del Cancer (IIBMCC CSIC-USAL), Salamanca, 3Clínica Universidad de Navarra, Centro de Investigación Medica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, 4Hospital Clinic, Barcelona, Spain

Background: Multiple myeloma (MM) is a genetically complex disease, characterized by the presence of multiple clones with differing degrees of drug sensitivity at the time of diagnosis. Consequently, therapeutic response of MM patients is unpredictable and extremely variable, and although the treatment intensities introduced over the last decade have significantly improved the outcome of these patients, most patients eventually relapse. Deep sequencing methods have contributed to increase the knowledge about the clonal heterogeneity of the disease and helped to stabilize the three evolution patterns at relapse: linear and branching clonal evolution, and no clonal changes.

Aims: To analyze the diversity and relative dominance of different clones and their evolution throughout the course of disease by NGS of the immunoglobulin repertoire in MM patients. To evaluate if the presence of different clones is associated with increased risk.

Methods: Immunoglobulin repertoire was analyzed by NGS in bone marrow samples from 180 MM patients included in three GEM clinical trials (NCT00461747, NCT00443235 and NCT01237249). The two first clinical trials involve patients younger than 65 years old, and were analyzed with ClonoSeq methodology, the later one involve patients older than 65 years old, and were analyzed with a local NGS method recently validated (Martinez-Lpez et al, Laukemia 2017). A clonotype was identified when at least 400 identical sequences were found, and branching clonal evolution, and no clonal changes.

Results: Of the 180 MM patients studied, 57 (32%) shows the presence of more than one clone throughout the clinical course of the disease. The identification of new evolving clones was only possible in the GEM10 clinical trial with the Local NGS method; in this clinical essay, 6% (4/71) of patients analyzed with a local NGS method recently validated (Martinez-Lopez et al, Laukeria 2017). A clonotype was identified when at least 400 identical sequences were found, and branching clonal evolution, and no clonal changes.

Conclusion: The presence of more than one clone was not associated with high-risk cytogenetics. The presence of more than one clone at diagnosis does not condition the prognosis in any of the patients and treatments analyzed. Median PFS was 38 and 58 months for patients with one clone or more than one clone respectively (HR=1.43, p=0.28).

Summary/Conclusions: The analysis of the IG repertoire by the local NGS method during treatment is able to identify and quantify new emerging clones during the treatment that were not detectable at diagnosis. The new clones contributed to increase the MRD levels in the follow-up samples. The presence of different clones at diagnosis is not associated with higher risk of progression, high risk cytogenetics or higher MRD values.

P680
FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
A.J. Jakubowiak1,*, C.A. Rosenbaum1, L. Stephens1, V. Kukreti2, C. Cole3, T. Zimmerman1, D. Reece2, J. Berdeja7, E. Severson1, B. Wolfe1, S. Major2, K. McDonnell1, J. Nam1, A. Turowski1, K. Griffiths1, J. Zonder5
1University of Chicago, Chicago, IL, United States, 2University Health Network, Toronto, Canada, 3University of Michigan, Ann Arbor, MI, 4Sarah Cannon Research Institute, Nashville, TN, 5Karmans Cancer Center, Detroit, MI, United States

Background: In the era of increased use of 1st-line and maintenance lenalidomide (LEN), there is growing need for effective 2nd-line therapies (tx) for LEN-refractory pts. The combination of carfilzomib (CFZ), pomalidomide (POM), and dexamethasone (DEX) has shown promising activity in advanced RRMM, including for pts refractory to LEN (Shah et al. Blood. 2015).

Aims: In this Ph 1/2 study, KPD was evaluated in RRMM, with a focus on pts who are LEN-refractory but proteasome inhibitor (I)-naïve/sensitive.

Methods: LEN-refractory disease was required for 2nd-line KPD and LEN-refractory exposure for ≥3rd-line. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae. Ph 1 dose escalation to determine mae.

P681
PANOBINOSTAT INDUCES CD38 UPRGEMENT AND AUGMENTS THE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
E. Garcia-Guerrero1, T. Gogishvili1, S. Danhof1, M. Schreder1, C. Pallaud2, J.A. Pérez-Simón3, H. Einsle1, M. Hudecek1
1Universitätsklinikum Würzburg, Würzburg, Germany, 2Novartis Pharmaceuti-
cals, Basel, Switzerland, 3BILS/Hospital Universitario Virgen del Rocío, Seville, Spain

Background: Immunotherapy with the anti-CD38 monoclonal antibody (mAb) daratumumab is increasingly being utilized in myeloma patients with relapsed/refractory (R/R) disease after prior treatment with immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). However, the efficacy of dara-
tumab is limited by low expression on myeloma cells. Here, we investigate the use of the histone deacetylase inhibitor (HDACi) panobinostat to modulate target antigen expression on myeloma in favor of potent mAb-mediated recognition and destruction. We show that panobinostat augments CD38 expression specifically on myeloma cells and demonstrate powerful synergy with anti-CD38 mAb daratumumab.

Aims: Determine the impact of panobinostat on upregulation of CD38 expression on myeloma cells in order to enhance the efficacy of daratumumab.

Methods: Myeloma cells were treated with titrated doses of panobinostat (0, 10, 25 nm) and expression of CD38 and a panel of additional target molecules interfering drug SLAMF7, as well as accessory ligands analyzed by flow cytometry at 24, 48 and 72 hours. Antibody-dependent cellular cytotoxicity (ADCC) against panobinostat treated and untreated myeloma cells was analyzed at 4 and 20 hours after addition of PBMC at an effector to target ratio of 25:1 in the presence of daratumumab or an isotype control antibody.

Results: Panobinostat treated primary myeloma (n=12 patients) with panobinostat (10 vs 25 nm) and observed a uniform increase in CD38 expression in each case by flow cytometry. Upregulation of CD38 was already detectable after 24 hours, peaked after 48 hours of exposure to panobinostat and was higher at the 25 nm compared to the 10 nm dose. At 48 hours, the mean fluorescence intensity (MFI) of CD38 expression on untreated and panobinostat-treated compared to untreated myeloma (p<0.01). The increase in CD38 was equal in patients with previously untreated (n=5) and R/R myeloma (n=7); and could be confirmed in a panel of myeloma cell lines, including MM1.S and OPM-2. The panobinostat-induced upregulation of CD38 was rapidly reversible after drug withdrawal.

Conclusions: Panobinostat treated myeloma cells are resistant to POM treatment and can be a better target for daratumumab. Further, the increase in CD38 expression on panobinostat-treated cells was specific for myeloma and neither observed this phenomenon in a panel of leukemia and lymphoma cell lines, nor on primary CD8+ and CD4+ T cells that we isolated from peripheral blood of several donors.
and del(17p).

Responses in high vs low BCL2 expression achieved at least a PR (ORR 59%), with 6 patients (22%) achieving VGPR or better (Figure 1). Sixteen of 27 patients with low BCL2 expression were evaluable for BCL-2 family gene expression by droplet digital PCR in CD38+ tumor cells. The synergistic anti-myeloma efficacy of panobinostat and daratumumab was confirmed with a panel of myeloma cell lines.

**Summary/Conclusions:** Our data demonstrate that the HDACi panobinostat induces upregulation of CD38 on myeloma and a subsequent dramatic increase of daratumumab-mediated ADCC. These data suggest that panobinostat could be used synergistically with daratumumab in a clinical setting to increase response rates and extend duration of responses to daratumumab.

**Background:** The anti-apoptotic proteins BCL-2 and MCL-1 have been shown to promote multiple myeloma (MM) cell survival. Venetoclax (VEN) is a potent, selective, and orally bioavailable small-molecule inhibitor of BCL-2. Bortezomib (BTZ) is a proteasome inhibitor that can inhibit MCL-1 activity by increasing the MCL-1 antagonist, NOXA.

**Aims:** Results presented herein describe correlative biomarker analyses in the ongoing phase 1b study of VEN in combination with BTZ and dexamethasone in patients with relapsed/refractory multiple myeloma.

**Methods:** As of 19 Aug 2016, 86 patients were enrolled on study. Baseline bone marrow aspirate samples were available from 52 patients, of which 45 were evaluable for BCL-2 family gene expression by droplet digital PCR in CD138-selected tumor cells. Correlation between BCL2L1 (BCL-L1) and MCL1 (MCL-1) mRNA expression (log2-transformed copies/µl normalized to housekeeping gene) and preliminary efficacy [overall response rate (ORR), time to disease progression (TTP) and duration of response (DoR)] were examined by Log-rank and Wilcoxon tests for binary biomarkers, and by risk ratio from Cox proportional hazard model for continuous biomarkers.

**Figure 1.**

**Results:** The ORR was 68% (44/65) for all evaluable patients and 89% (31/35) in patients who had 1-3 prior therapies (31/35). A broad range of BCL2, BCL2L1 and MCL1 expression was observed, however higher BCL2 levels were detected in patients who achieved a partial response (PR) or better (median: 3.01 vs 0.87, p<0.01). Additionally, higher BCL2 levels were observed in patients who had 1–3 prior therapies compared to 4 or more lines of therapy (median: 3.03 vs 0.94, p<0.01). In contrast, no association was observed between BCL2L1 or MCL1 gene expression and response or number of prior therapies. Bootstrapping and aggregating thresholds from trees was used to estimate a threshold value for BCL2 expression that would provide optimum selection of patients who achieved a response. On all, seventeen of 18 patients with high BCL2 expression had a positive correlation with disease response. No significant difference was observed in the expression profile of patients with low BCL2 expression. Responses in high BCL2 expressions were independent of cytogenetic status as determined by interphase FISH analysis, including t(11;14), t(4;14), del(13q) and del(17p).

**Summary/Conclusions:** Targeting BCL-2 and MCL-1 with the combination of VEN, BTZ and dexamethasone provides a unique approach for MM treatment. Efficacy results in tumors expressing high BCL2 levels, including 94% ORR, provide supportive evidence for the evaluation of this combination regimen in the ongoing phase 3 study (NCT02755597) in R/R MM.

**P683**

**THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY**

**Background:** Renal insufficiency is common at presentation in patients with multiple myeloma (MM) and associated with a poor survival. Approximately 10% of the patients require dialysis. Studies have shown that the novel agent bortezomib has a positive effect on recovery of renal function in MM patients with renal insufficiency.

**Aims:** The aim of this study is to determine the effect of the revised guideline, including the introduction of bortezomib as first-line treatment in MM patients with dialysis dependence, on renal function recovery.

**Methods:** All patients on renal replacement therapy (RRT) in the Netherlands are registered in the Dutch registry Renine. Data on age, gender, start date of RRT, type and switches of RRT or hospitals, primary renal diagnosis, date of death and cause of death are collected. In this nationwide population-based study, we selected all patients with MM registered in Renine between January 2002 and January 2016. No information regarding therapy of MM is provided in Renine. In March 2010, bortezomib was advised as first-line treatment in patients suffering from MM with renal impairment in the Dutch guidelines. Therefore, we divided our cohort in two periods: before the bortezomib guideline (January 1, 2002 till March 29, 2010) and after introduction of the bortezomib guideline (March 29, 2010 till January 1, 2016). Kaplan-Meier and Cox proportional hazards modelling were used to identify significant indicators for dialysis independency.

**Results:** A total of 700 patients were included in the study (422 patients pre-bortezomib and 278 after bortezomib introduction). In the period after the introduction of bortezomib 15% of patients became dialysis independent compared to 8% in the pre-bortezomib period (HRadj=2.1 (95% CI 1.0–4.2), Fig. 1). In addition, patients who started dialysis in the period after bortezomib was introduced became dialysis independent more rapidly than in the pre-bortezomib period (1.2 compared to 1.7 years; p < 0.001). Age < 75 years (vs. ≥ 75 years) and light chain deposition disease (LCDD) as the primary renal disease (vs. amyloidosis) were significantly associated with achieving dialysis independence (HRadj=2.1 (95% CI 1.0–4.2) and HRadj=5.7 (95% CI 2.3–13.2), respectively).

**Figure 1.**

**Summary/Conclusions:** In this nationwide population-based study, covering all patients with MM and concomitant renal failure, almost a two-fold increase of patients becoming dialysis independent occurred in the period after the introduction of bortezomib compared to the pre-bortezomib period. This was even more prominent when age was < 75 years and LCDD was the primary renal disease.

**P684**

**TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS**

P. Milan1,1, M. Bassel2, F. Russo3, M. Bozzola1, A. Foni1, G. Palladini1, G. Merlini1

(n=3). Interestingly, expression of SLAMF7 was not increased after panobinostat treatment at all tested concentrations and time points in both cell lines and primary myeloma. Next, we were interested in determining whether the increase in CD38 expression enabled superior antitumor activity of the anti-CD38 mAb daratumumab. Thus, we treated primary myeloma cells from patients (n=4) with panobinostat for 48 hours at 10 nM, as this is the serum level achievable currently approved dosing regimen. We observed a significant increase in ADCC against panobinostat-treated compared to untreated myeloma in all patients. On average, 78% of panobinostat-treated primary myeloma cells were eliminated by daratumumab within the 4-hour ADCC assay, whereas only 51% myeloma cells were eliminated without panobinostat treatment (p<0.01). The synergistic anti-myeloma efficacy of panobinostat and daratumumab was confirmed with a panel of myeloma cell lines.

**Summary/Conclusions:** Our data demonstrate that the HDACi panobinostat induces upregulation of CD38 on myeloma and a subsequent dramatic increase of daratumumab-mediated ADCC. These data suggest that panobinostat could be used synergistically with daratumumab in a clinical setting to increase response rates and extend duration of responses to daratumumab.
Background: The immunomodulatory agent pomalidomide is active in patients with relapsed/refractory multiple myeloma, including those who failed prior lenalidomide and bortezomib. Phase II clinical trials showed that pomalidomide is also effective in primary AL amyloidosis. After this drug was marketed for multiple myeloma (in Italy since September 2015), it became routinely accessible also to patients with myeloma-associated AL amyloidosis, a particularly fragile population.

Aim of this study was to report the efficacy of pomalidomide and dexamethasone in patients with multiple myeloma-associated AL amyloidosis.

Methods: The databases of the Pavia Amyloid Research and Treatment Center were searched for patients with a diagnosis of multiple myeloma and AL amyloidosis and patients with measurable NT-proBNP (n-terminal-natriuretic peptide) in patient with AL amyloidosis. Median serum NT-proBNP was 7730 pg/ml for those with a positive uptake in the scintigraphy and 9990 pg/ml for those with a negative uptake. Median age was 65 years (range: 34-85 years) and 22 (73%) patients were men. Heart involvement was present in 13 patients (43%) and kidney involvement in 18 (60%).

Results: Median age was 65 years (range: 34-85 years) and 22 (73%) patients were men. Heart involvement was present in 13 patients (43%) and kidney involvement in 18 (60%). There were 22 patients with MM from 1-11). Median follow-up of living patients was 6 months (IQR: 3.5-16 months).

Adverse events were observed in 5 (17%) of subjects: skin rash and confusion in one patient each and mild increase in serum creatinine in 3 (10%, resolved with the decrease of the dose of pomalidomide). The median number of prior treatment lines (5 cases), all patients had previously received lenalidomide and an alkylating agent, only 3 patients were not exposed to bortezomib, due to severe peripheral nervous system involvement, 10 (33%) underwent autologous stem cell transplant and 9 (30%) received previous thalidomide-based regimens. The median number of P Dex cycles performed was 4 (range: 1-11). Median follow-up of living patients was 6 months (IQR: 3.5-16 months) and 13 (43%) patients died due to progressive disease. Fourteen patients (47%) achieved at least partial response, with 1 complete remission (CR), and very good partial responses (VGPR) in 2 cases (6%). Adverse events were observed in 1 of 5 patients with measurable NT-proBNP (20%), but this can be underestimation due to the pomalidomide-related increase of NT-proBNP, and renal response in 3 of the 11 evaluable patients (27%).

Summary/Conclusions: The combination of pomalidomide and dexamethasone is well tolerated and effective in multiple myeloma-associated AL amyloidosis and can be a valuable rescue option in this high-risk population.

P686

WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON ALAMYLOIDOSIS PATIENTS

M. Brink1,*, O. Visser1, M.C. Minnema2, S. Zweegman3, P. Sonneveld4, A.G. Dimishe4

Aim of this study is to report the diagnosis of TTR amyloidosis (TTR gene non mutated). The two remaining patients were diagnosed of AL amyloidosis by IHC unequivocally in other tissues. Mean value of NT-proBNP (N-terminal-natriuretic peptide) in patients with AL amyloidosis was 7730 pg/ml for those with a positive uptake in the scintigraphy and 9990 pg/ml for those with a negative uptake.

Summary/Conclusions: Cardiac 99mTc-DPD SC has been described as a useful technique in the differential diagnosis between AL and TTR amyloidosis. However, up to 30% of cases of AL amyloidosis show some degree of uptake and 10% show a pattern consistent with TTR amyloidosis (biventricular uptake and TTR amyloidosis and myocardial uptake in SC). MS is not routinely available in most centers and results may be ambiguous. We consider that MS is mandatory in cases of cardiac amyloidosis with abnormal FLC ratio and positive biventricular 99mTc-DPD uptake. We did not find any correlation between positive uptake in the SC and NT-proBNP values, as it has been recently suggested.
Background: To contextualize the benefit of novel agents such as daratumumab (DARA) monotherapy for the treatment of patients with heavily pretreated and highly refractory multiple myeloma (MM), it is critical to understand the real-world outcomes of this patient population on current standard of care (SOC) therapies. To determine the comparative effectiveness of DARA vs real-world SOC, an adjusted comparison was conducted using data from the DARA monotherapy trials and the International Myeloma Foundation (IMF) chart review.

Aims: The objective of this analysis is to update the adjusted comparison to include additional Swedish patients from the IMF chart review.

Methods: Data for patients treated with DARA 16mg/kg monotherapy were available from clinical trials MMY2002 (n=106) and GEN501 (n=42), while patients treated with SOC therapies were derived from the IMF chart review of patients with MM who had ≥2 prior lines of therapy and were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (n=550, original 510, additional Swedish patients 40). Patients from the IMF-cohort who moved into further treatment lines after the line therapy where they fulfilled inclusion criteria, contributed information to the analysis for multiple lines of therapy, with baseline defined as the date of initiation of the actual treatment line, resulting in a total sample size of 963 treatment lines from 550 patients. The relative treatment effect of DARA versus SOC was estimated using multivariate Cox regression analyses. The methodology utilized individual patient data to compare overall survival (OS). The covariates included were age, gender, prior lines of therapy, albumin, β2-microglobulin, prior exposure to pomalidomide and carfilzomib, and prior refractory status. Clustering of observations at the treatment-line level within patients was controlled for using the robust sandwich estimate for the covariance matrix. Standard significance testing was performed using a two-tailed P-value of <0.05, and all comparisons between treatment groups were reported with hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: After adjustment for differences in baseline characteristics included in the multivariate model between the DARA and SOC groups, results showed a significant improvement in favor of DARA compared with SOC for OS (HR=0.42 [95% CI 0.31–0.57]). When limiting the comparative analysis to European patients from the IMF cohort (n=341), results for OS are very similar (HR=0.40 [95% CI 0.28–0.58]).

Summary/Conclusions: Findings from the regression analyses using the updated IMF dataset were consistent with results from the previous analysis and suggest that DARA is associated with significant gains in OS compared with SOC therapies for patients with heavily pre-treated and highly refractory MM. Findings for a European subset from the IMF dataset were similar to results from the entire cohort.

References

P688 PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS


Background: Multiple Myeloma (MM) is predominantly a disease of the elderly and the outcome of these patients is poorer than that of transplant candidates. It is well established that those considered frail or unfit have a dismal prognosis, however, even within fit patients, such as those included in clinical trials, there is substantial proportion of early deaths (within the first 2 years after diagnosis). Identification of this “high-risk” fit elderly patients could contribute both to the design of innovative clinical trials, and to avoid the emotional and economical burden of palliative care. The aim is to identify frailty and its impact on survival.

Aims: To analyze the factors associated with early death (within first 2-years) due to active MM in elderly newly diagnosed (NDMM) patients fit enough to be included in clinical trials with optimized therapy with proteasome inhibitors and IMiDs.

Methods: 497 NDMM not transplant candidates treated in two prospective GEM-PETHEMA trials were included in the study; GEM05MAS65 (n=260) used frontline treatment with either bortezomib-melphalan-prednisone (VMP) or bortezomib-thalidomide-prednisone followed by maintenance with bortezomib, thalidomide or bortezomib, prednisone; the GEM2010MAS65 (n=239) compared induction with sequential alternating cycles of VMP + lenalidomide-dexamethasone. The event was defined as death related to active MM within 2 years from diagnosis, either because of disease progression or early death due to absence of response.

Results: From the 497 patients included, 77 (15%) patients died within 2 years from diagnosis due to active MM. When we compared this latter cohort with the remaining patients, the profile of the high risk group was characterized (Table 1) by a higher proportion of patients >75 years, advanced ISS and R-SS stage, higher β2-microglobulin (β2-M) levels (>3.5 and 5.5mg/dl) and abnormal LDH; increased incidence of high-risk cytogenetic features (HR CA), CD45- clonal plasma cells, and lower incidence of CD27 + MM phenotype.

Table 1.
unsR (duration of response (≥PR) <6 months) to the baseline score we were able to build a new score in which the unsR had a 3 points weight. A score punctuation ≥ 4 segregates a subgroup of patients with poor outcome (PPV: 83.3%, the NPV: 84.02%).

**Summary/Conclusions:** The risk of early death due to active disease in elderly patients was related to four independent prognostic factors: age >75y, high LDH levels, advanced ISS, and presence of HR CA. A score ≥ 4 identify a subgroup of patients with high probability of death within 2 years despite optimized treatment.

---

**Myeloproliferative neoplasms - Biology**

**P689**

**MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS**

T. Maekawa1,*, Y. Osawa1, T. Izumi1, S. Nagao1, K. Takano1, Y. Okada1, N. Tachi1, M. Teramoto1, T. Kawamura1, T. Horiuchi1, R. Saga1, S. Kato1, T. Yamamura1, J. Watanabe1, A. Kobayashi1, S. Kobayashi1, K. Sato1, M. Hashimoto2, S. Suzuki2, F. Kimura1

1Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, 2Center for AIDS Research, Kumamoto University, Kumamoto, Japan

**Background:** Myelofibrosis (MF) may be caused by various pathogenic mechanisms, such as elevated circulating cytokine levels, cellular interactions, and genetic mutations. However, the underlying mechanism of MF remains unknown. A recent study showed that the neoplastic clone of fibrocytes, spindle-shaped fibroblast-like blood cells derived from monocyte lineage, was essential in primary MF pathogenesis; serum amyloid P, which suppressed fibrocyte differentiation, markedly improved survival and MF in a murine xenograft model (J Exp Med 2016; 213: 1723-1740). Regarding cytokines, the thrombopoietin (TPO) signaling pathway was assumed to be closely associated with promoting MF. Mice transplanted with TPO-overexpressing bone marrow cells showed symptoms such as MF and splenomegaly (Blood 1997; 90: 4369-4383). Romiplostim (Rom), a TPO-receptor agonist, induced MF in induced in mice and some immune thrombocytopenic purpura patients (Blood 2009; 114: 3748-3756). Fibrocytes and TPO played certain roles in MF pathogenesis, but the nature of their relationship remains unknown.

**Aims:** We investigated the relationship between myeloproliferative leukemia protein (MPL; TPO receptor) activation and fibrocyte differentiation in promoting MF. The secondary goal was to discover a unique fibrocyte marker in monocyte or macrophage population.

**Methods:** Murine fibrocyte cell lines were established from transgenic mice harboring the temperature-sensitive large T-antigen gene of simian virus 40 under IL-3 and M-CSF conditions. Murine fibrocyte cell lines and human peripheral blood mononuclear cells (PBMCs) were cultured with or without Rom to evaluate if MPL activation promoted fibrocyte differentiation, and the ratio of spindle-shaped cells was calculated. Rom was administered on day 1 and 8 to induce an MF-like phenotype in C57BL/6J mice, and clodronate liposomes (CLs; day −4, −1, 4, and 7) were used to eliminate monocytes and macrophages.

**Results:** Flow cytometric analysis revealed that all murine fibrocyte cell lines stained positive for fibrocyte cell markers, including collagen I, CD45, CD34, CD11b, and CD68. Murine fibrocyte cell lines expressed MPL and responded to Rom or murine TPO to differentiate into mature fibrocytes, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone. Rom also increased the number of mice spleen cell fibrocyte colonies in the presence of IL-3 and M-CSF, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone. Rom also increased the number of mice spleen cell fibrocyte colonies in the presence of IL-3 and M-CSF, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone. Rom also increased the number of mice spleen cell fibrocyte colonies in the presence of IL-3 and M-CSF, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone. Rom also increased the number of mice spleen cell fibrocyte colonies in the presence of IL-3 and M-CSF, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone. Rom also increased the number of mice spleen cell fibrocyte colonies in the presence of IL-3 and M-CSF, specifically with a longer spindle shape and stronger collagen I expression than when cultured with IL-3 and M-CSF alone.

**Summary/Conclusions:** MPL activation directly induced fibrocyte differentiation from monocytes and macrophages expressing MPL, and the elimination of these cells reversed the MF phenotype. Our findings confirmed a link between fibrocytes and the TPO/MPL signaling pathway and indicated that the combination of MPL and SLAMF7 could be a useful fibrocyte marker in monocytes or macrophages.

---

**P690**

**ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID-γ MICE**

T. Manshouri1,*, Z. Estrov1, D. Pilling1, C.E. Bueso-Ramos2, S. Pnijic1, K.J. Newberry1, S.M. Post1, X. Zhang1, Y. Zhang1, H.M. Kantarjian1, S. Verstovsek1

1Leukemia Department, The University of Texas/ MD. Anderson Cancer Center, Houston, 2Department of Biology, Texas A&M University, College Station, 3Department of Hematopathology, The University of Texas/ MD. Anderson Cancer Center, Houston, United States

**Background:** Progressive bone marrow (BM) fibrosis in patients with PMF is thought to arise from non-hematopoietic stromal cells stimulated by overpro-
ducted growth factors. However, in other tissues and organs, fibrosis is associated with monocytic fibrocytes, which express markers of both hematopoietic and stromal cells. Recently, we have reported that clonal neoplastic fibrocytes play a role in the induction of BM fibrosis in primary myelofibrosis (PMF) (Verstovsek, J Exp Med. 2016). We demonstrated that the BM of PMF patients harbors more neoplastic, functionally distinct fibrocytes and fewer SM/MPN-like, morphologically normal bone marrow fibrocytes. In addition, we detected an overabundance of fibrocytes in the BM and spleen of an established PMF mouse model and a xenograft mouse model of PMF created using BM-derived low-density cells from patients with PMF.

Aims: Fibrocytes, which make up <1% of BM cells, differentiate from a subpopulation of CD14+ monocytes and are recruited to sites of organ damage where they regulate tissue repair. We hypothesized that clonal neoplastic CD14+ monocytes may play a role in the induction of BM fibrosis in PMF.

Methods: To test this hypothesis, we transplanted NSG mice (NOD/Scid/NoD.Cp-prkdcscidJ2tm1wjl/SJZ) with sorted CD14+ monocytes from patients with JAK2V617F-positive PMF or donors with hematologically normal BM. Results: Here, we show that BM-derived CD14+ cells from patients with JAK2V617F-positive PMF or donors with hematologically normal BM engrafted in NSG mice. Transplanted NSG mice with PMF BM-derived CD14+ monocytes developed a myelofibrosis-like phenotype with reticulin fibrosis and abundant neoplastic (JAK2V617F) fibrocytes in the BM and spleen. Two months after transplantation, we detected a subpopulation of c-HaD45+ and c-HaD68+ cells within the HLA+ population of BM cells. In addition, we found dysplastic megakaryocytes in the BM and spleen of the PMF CD14+ transplanted mice. Immunochemistry staining of paraffin embedded BM sections did not detect c-HD3, c-HD19 or c-HD34 cells. However, staining with anti-human CD42b antibodies detected human megakaryocytes, suggesting that the dysplastic megakaryocytes detected in PMF CD14+ transplanted NSG mice are human-derived.

Summary/Conclusions: Taken together, our data suggest that neoplastic CD14+ monocytes contribute to the induction of BM fibrosis in PMF. What role CD14-derived megakaryocytes play in the pathogenesis of PMF remains to be determined.

P691

ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS

H. Takei1,*, N. Mano12, N. Masubuchi14, M. Imai6, M. Takei1, Y. Edahiro1, Y. Hironaka1, M. Nuddejima1, H. Endo1, S. Nakamura1, K. Eto1, A. Oshaka1, M. Araki1, N. Komatsu1

1Department of Hematology, Juntendo University Graduate School of Medicine, 2Department of Life Science and Medical Bioscience, Waseda University Graduate School, 3Research Institute for Disease of Old Age, Juntendo University, 4Center for Genomic and Regenerative Medicine, 5Department of Transfusion Medicine and Stem Cell Regulation, 6Leading Center for the Development and Application, Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan

Background: Somatic mutations on calreticulin (CALR) gene are found in a majority of patients with JAK2-unmutated MPN. It is believed that the CALR-mutated neoplastic and non-neoplastic/normal MPL/CALR positive fibrocyte represent a more differentiated CALR-mutated subpopulation. Recently, we have reported that CALR-mutated megakaryocytes are associated with JAK2 mutation and this phenomenon is independent from the presence of CALR mutation.

Aims: We aimed to recapitulate the MPN phenotypes and examine the impact of CALR ins5 in human hematopoietic cell differentiation in vitro.

Methods: We employed iPSCs (iPSC) established from a healthy control and a patient with JAK2V617F-mutated MPN. iPSCs were differentiated into megakaryocytes using a well-established method. HPCs were then cultured to induce megakaryocytes (MKs) and thrombopoietin (TPO) was used to identify differences in the granulocyte proteome with the goal to characterize the pathogenic role of aberrant protein expression in MPNs.

Results: A novel switch control inhibitor DCC-2618 was described to block JAK2 kinase activity of KIT D816V, MCPV-1.1, HMC-1.2, ROSAKITWT, ROSAKITD816V, ROSAKITK509I, MCPV-1.1, MCPV-1.3 and MCPV-1.4 and primary neoplastic MC obtained from patients with SM. In addition, the acute myeloid leukemia (AML) cell lines KLF1 expression required for the erythroid cell differentiation in CALR ins5 cells. Finally, we showed that the treatment of ruxolitinib greatly reduced megakaryocytic differentiation in both CALR ins5 and wt HPCs, demonstrating that ruxolitinib does not possess preferential targeting of CALR ins5 cells.

Summary/Conclusions: We have established an in vitro model system that recapitulates the megakaryocytosis caused by mutant CALR, which should be useful tool for the examination of therapeutic strategies against MPN patients harboring CALR mutation.

P692

QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS

M. Coreiro Yustel1, C. Vladian P2, J. Mondet1, I. Plot2, P. Mousset2,1

1TIMC-IMAG Laboratory - TheREX team, GRENoble, France, 2Institute for Medical Research, Belgrade, Serbia, 3INSERM, UMR1170. Gustave Roussy, Paris, 4Laboratoire d’Hématologie cellulaire - Institut de Biologie et Pathologie, GRENoble, France

Background: Apart from well-known genetic abnormalities, several studies have reported variations in protein expression in Philadelphia negative (Ph-) Myeloproliferative Neoplasm (MPN) patients that could contribute towards their clinical phenotype.

Aims: In this context, a quantitative mass spectrometry proteomics protocol was used to identify differences in the granulocyte proteome with the goal to characterize the pathogenic role of aberrant protein expression in MPNs.

Methods: LC MS/MS (LTQ Orbitrap) coupled to iTRAQ labeling showed significant and quantitative differences in protein content among various MPN subtypes. ELISA was used to demonstrate the correlation between the proteome data and the clinical parameters. Finally, it was demonstrated, in a Ba/F3 cell model, that increased calreticulin expression was directly linked to JAK2V617F mutation and could be regulated by JAK2 kinase inhibitors.

Summary/Conclusions: In conclusion, these results reveal proteome alterations in MPN granulocytes depending on the genotype and phenotype of patients, highlighting new oncogenic mechanisms associated with JAK2 mutations and overexpression of calreticulin.

P693

THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS

M. Schneeveis1,2, B. Philippi1, S. Bibi1, K. Blatt1,2, D. Berger2, G. Vannelli2, S. Hermsdoerfer1,2, W. R. Sperr1,2, E. Hadzisavusevic1,2, K.V. Gleixner1,2, A. Reiter4

1Ludwig Boltzmann Cluster Oncology, 2Department of Internal Medicine I/Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria, 3Laboratoire de Biologie et Pharmacologie Appliquée, CNRS UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France, 4Department of Hematology and Oncology, University Medical Centre Mannheim, Mannheim, Germany, 5Department for Companion Animals and Horses/Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria

Background: Systemic mastocytosis (SM) is a myeloid neoplasm defined by abnormal growth and pathologic accumulation of neoplastic mast cells (MC) in various internal organs. The indolent variant of SM (ISM) is associated with an almost normal life expectancy. By contrast, the prognosis in advanced SM, including SM with an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and MC leukemia (MCL) is poor with short survival times. Most patients with SM express the D816V-mutated variant of KIT, which confers resistance against several tyrosine kinase inhibitors (TKI), including imatinib. DCC-2618 is a novel switch control inhibitor that has been described to block the switch control activity of KIT D816V.

Aims: The aims of this study were to evaluate the effects of the switch control inhibitor DCC-2618 on proliferation and survival of neoplastic MC and other neoplastic and non-neoplastic cell types that may play a role in advanced SM and often expand in AHN patients.

Methods: We used different human MC lines (HMC-1.1, HMC-1.2, ROSAKITWT, ROSAKITD816V, ROSAKITK509I, MCPV-1.1, MCPV-1.3, MCPV-1.4) and primary neoplastic MC obtained from patients with SM. In addition, the acute myeloid leukemia (AML) cell lines 276 | haematologica | 2017; 102(s2)
MOLM-13, MV4-11, KG-1 and U-937, the eosinophilic leukemia cell line EOL-1, human cultured umbilical vein endothelial cells (HUVEC), the microvascular human endothelial cell line HMEC-1 and primary neoplastic cells obtained from patients with AML, chronic myelomonocytic leukemia (CMML) and (clonal or reactive) hypereosinophilia were used. Cell proliferation was quantified by 4H-thymidine uptake. Apoptosis was determined by flow cytometry and light microscopy. The phospho-kinase-stationary status of KIT and BTK was analyzed by Western blotting. The effects of DCC-2618 on histamine secretion in basophils (BA) were analyzed by histamine release assay.

Results: DCC-2618 was found to block the proliferation of all MC lines tested, with lower IC50 values measured in KIT D816V-negative HMC-1.1 cells (12±2 nM) and ROSAΔITDαββγδε cells (4±1 nM) than in KIT D816V-positive HMC-1.2 cells (123±36 nM), ROSAΔITDB186 cells (168±65 nM) and the multi-resistant MC line MCPV-1. The DCC-2618-metabolite DP-5439 showed comparable growth inhibitory effects in all cell lines tested. DCC-2618 was also found to inhibit proliferation of primary neoplastic MC obtained from patients with MPN. A significant effect of ASH-ARN and MCL (IC50; 83-460 nM). DCC-2618 induced apoptosis and blocked tyrosine phosphorylation of KIT in all MC lines tested. We were also able to show that DCC-2618 inhibits proliferation and survival in the eosinophilic leukemia cell line EOL-1 (IC50 (1.8±1.3 nM)) and the FLT3 ITD-mutated AML cell lines MV4-11 (IC50 (47±60 nm)) and MOLM-13 (IC50 (132±55 nM)). In addition, DCC-2618 was found to block proliferation in primary leukemic cells in patients with monoblastic AML and CMML which are the most prevalent types of AHN in advanced SM. DCC-2618 was also found to inhibit growth of cultured human vascular endothelial cells, suggesting that the drug may also counteract SM-related angiogenesis. Finally, DCC-2618 was found to inhibit anti-CD40-induced histamine release from normal BA in a dose-dependent manner (IC50: 1-10 µM).

Summary/Conclusions: DCC-2618 is a new potent switch control TKI that counteracts growth and survival of neoplastic MC, leukemia monocytes, AML blasts, eosinophils, and endothelial cells in vitro. Whether DCC-2618 is able to block growth of neoplastic MC and other involved lineages in patients with advanced SM is currently being ascertained in a clinical trial (NCT02571036).

P694

DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA, MYELOTHROMOCYTOMY AND POLYCYTHEMIA VERA

A. Senin1,2, B. Bellissio2,3, C. Fernández-Rodriguez2,3, L. Camacho2, C. Bessis2,1, Á. Álvarez-Larrán2,2

1Hematology Department, Hospital del Mar-IMIM. Universitat Autónoma de Barcelona, 2Group of Applied Clinical Research in Hematology. Cancer Research Program, IMIM, 3Pathology Department, Hospital del Mar-IMIM. Universitat Autònoma de Barcelona, Barcelona, Spain

Background: Essential thrombocythemia (ET) and polycythemia vera (PV) are clonal myeloid disorders that originate from a multipotent hematopoietic stem cell. Although most women with PV and ET have mutations in JAK2V617F, CALR or MPL, the proportion of patients presenting clonal hematopoiesis by X chromosome inactivation patterns (XCI) is variable and its relationship with the presence of non-driver mutations is not well known.

Aims: To study the distribution and dominance of driver and non-driver mutations in clonal hematopoiesis.

Methods: One hundred and twenty-six women (PV n=33, ET n=93) with an informative result of XCI based on HUMARA assessment were included in the study. HUMARA analysis was performed by studying the degree of methylation of exon 1 in granulocytes and lymphocytes. Somatic mutations were studied in DNA extracted from granulocytes by NGS using a panel of 51 myeloid-related genes.

Results: Median age of patients at the time of HUMARA analysis was 64 years (range:21–92). Mutations in JAK2 were present in 62% of them, CALR in 11%, MPL in 8%, and 14% were triple negative (TN). Non-driver mutations were detected in 6% of patients (17 PV and 28 ET). The most frequently mutated genes were TET2 (16%), DNMT3A (8%), ASXL1 (5%), SF3B1 (5%), EZH2 (2%) and RUNXI (2%). The mutation with the highest variant allele frequency (VAF) was considered the dominant mutation and it corresponded to a driver mutation in 92 patients (JAK2 n=70, CALR n=13, MPL n=8) and a non-driver mutation in 9 patients (driver: CALR n=3, MPL n=1, RUNXI n=2, TET2 n=1, ASXL1 n=1). In 12 cases the VAF of the driver mutation (JAK2 n=99, CALR n=1, MPL n=2) was similar to the non-driver mutation, being TET2 the codominant mutation in 6 of them. HUMARA analysis was clonal in 66 patients and polyclonal in 60 patients (PV in 48% and ET in 52%). In 11% of them the 24% was most frequently observed in PV (76% vs 46% (p=0.002). Clonal HUMARA was observed in 90% of MPL-mutated patients in comparison with 58% in JAK2-mutated, 42% in CALR-mutated and 11% in TN (p<0.0001). Two patients with TN ET showing clonal hematopoiesis had TET2 mutations. In JAK2-mutated women, the mutant allele load was significantly higher in polyclonal cases (43% vs 19% p=0.02) and in PV than in ET (76% vs 47%, p=0.01). Eighty percent of patients with non-driver mutations showed HUMARA clonality vs 37% of patients without non-driver mutations (p<0.0001). The mutated genes significantly associated with a higher frequency of clonal hematopoiesis were JAK2 (p=0.007) and SF3B1 (p=0.029).

P695

RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS

A. Arenas1, R. Ayala1, M. Gallardo1, J. Martínez-López1, 2

1Hematology, Hospital 12 de Octubre, Madrid, Spain

Background: Myelofibrosis (MF) is the myeloproliferative neoplasm chromosome Ph- negative with worst prognosis. MF is characterized by stem cell-derived clonal myelofibroproliferation and reactive cytokine-driven inflammatory bone marrow fibrosis. Ruxolitinib is the first line treatment for MF. It was associated with significant reduction in symptomatic splenomegaly and improved constitutional symptoms. In a previous work (Arenas et al. Blood Volume 122, Issue 21 (ASH Annual Meeting Abstract)) we identified a set of promising synergistic drugs combinations for a ruxolitinib. Nilotinib and prednisolone were selected from them.

Aims: The aim of this work is the study the effect of the combination of ruxolitinib, nilotinib and prednisolone in hematopoietic progenitor cells from patients with MF.

Methods: A ruxolitinib, nilotinib and prednisolone dose-response curves and synergistic studies were performed in hematopoietic progenitors CD34+ from five MF patients. We studied the molecular effect of single drugs and in combination on SET2 cell line with western blot. To adress the antibiofveic activity of the drugs and their combinations, we pre-incubated HS27 cultures with 100nM of ruxolitinib, 1 µM of nilotinib, 1 µM of prednisolone or their combination during 1 h. After that, we added 2mg/mL TGF-β during 24h to induce fibrogenesis. Finally, the collagen I expression was evaluated by immunocytochemistry (ICC).

Results: The effects of ruxolitinib, nilotinib and prednisolone resulted in an EC50 value of 55nM, 6.6µM and 13.1µM, respectively. A combination index (CI) of less than 1 indicated synergy. All combination had a synergistic behavior (Table 1); moreover, there were two combinations whose CI from all samples were lower than 1: ruxolitinib plus 50% nilotinib plus 0.8 µM prednisolone (CI=0.25±0.11) and 32m ruxolitinib plus 0.8 µM prednisolone (CI=0.45±0.11). The JAK/STAT signaling pathway was inhibited: the phosphorylation of STAT5 was inhibited by ruxolitinib in 83.2±10.8 % (p-value<0.05) regarding to control at 30 min and it was maintained at 3 hours (p-value<0.05). The combinations 32nM ruxolitinib plus 1.6 µM nilotinib (RN) and 32m ruxolitinib plus 0.8µM prednisolone (RNP) inhibited more than 50% of the phosphorylation of STAT5 at 30 min and maintained at 3 hours. The MAPK signaling pathway was inhibited at 30 min, the phosphorylation of ERK was inhibited in 77.1±16.4

Figure 1.
interlaboratory reproducibility. In this analysis, we consider only those laboratories that detected at least 1 mutation.

Results: The median number of detected mutations was 9 (range: 1-27), with 100% of laboratories detecting at least 1 mutation.

Discussion/Conclusions: The interlaboratory reproducibility of this analysis is satisfactory, with a high number of laboratories detecting a wide range of mutations. Further improvements in the detection of rare and low frequency mutations are necessary to improve the diagnostic accuracy of MPNs.

P968

INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING


1Pathology, Hospital del Mar, Barcelona, 2Hematology, Hospital 12 de Octubre, Madrid, 3Hematology, Hospital Universitari i Politècnic La Fe, Valencia, 4Niglolith, Madrid, 5Immunology, Hospital Virgen de las Nieves, Granada, 6Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 7Hospital General Universitario Gregorio Marañón, Madrid, 8Hospital Germans Trias i Pujol - ICO Badalona, Badalona, 9CIMA LAB Diagnostics, Pamplona, 10Hematology, Hospital Universitario Virgen del Rocío, Sevilla, 11Hematology, Hospital Universitario de Salamanca, Salamanca, 12Hematopathology, Hospital Clínico San Carlos, Madrid, 13Immunology, Hospital Universitario Virgen del Rocío, Sevilla, 14Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 15Hematology, Hospital Regional Universitario de Málaga, Málaga, 16Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, 17Immunology, Hospital 12 de Octubre, Madrid, Spain

Background: Next-generation sequencing (NGS) technology is being implemented in clinical practice for assessing the mutational status of myeloid neoplasms. The Working Group on Molecular Biology from the Spanish Society of Hematology has performed an interlaboratory assessment of gene mutation analysis by targeted NGS using myeloid panels.

Aims: To assess the technical performance of mutation detection by targeted NGS using myeloid panels.

Methods: The technical comparison was established on two rounds with samples previously analysed using NGS panels, Sanger sequencing and/or fragment analysis. First, four DNA samples (S1-S4) from AML patients were shared among laboratories for the first round. Three additional samples (S5 to S9) were sequenced in a second round. A total of 14 laboratories. The center of origin had previously characterized and confirmed: for the first round, 14 relevant mutations in 10 genes; and for the second round 17 relevant mutations in 7 genes. Each center performed library preparation, sequencing and blind variant analysis following their own routine practice. Detected variants and data regarding main methodological parameters were collected. Detection rate was calculated as the number of laboratories with positive detection out of the number of laboratories that sequenced the particular gene region.

Results: Eight different gene panels were used for library preparation (predetermined in 10 labs and custom in 4). The one most commonly used was amplicon enrichment (11/14, 78.6%) and only 3/14 laboratories (21.4%) used capture-based methods. Sequencing was performed with Illumina devices in 9/14 laboratories. However, including indels, low frequency mutations (<10%), ASXL1 mutations were detected in only 67% and 31% of laboratories, respectively.

Discussion/Conclusions: The one most commonly used was amplicon enrichment (11/14, 78.6%) and only 3/14 laboratories (21.4%) used capture-based methods. Sequencing was performed with Illumina devices in 9/14 laboratories. However, including indels, low frequency mutations (<10%), ASXL1 mutations were detected in only 67% and 31% of laboratories, respectively.

Background: The aim of the study was to correlate MA with disease status, mutual profile and therapeutic response in a cohort of MPN patients treated with Voro.

Aims: The aim of our study was to correlate MA with disease status, mutual profile and therapeutic response in a cohort of MPN patients treated with Voro.

Summary/Conclusions: Gene mutation analysis by targeted NGS in myeloid malignancies is highly reproducible between laboratories and allows a complete and comprehensive characterization of a patient's disease. However, including indels, low frequency mutations (<10%), ASXL1 mutations were detected in only 67% and 31% of laboratories, respectively. Furthermore, the interlaboratory reproducibility of this analysis is satisfactory, with a high number of laboratories detecting a wide range of mutations. Further improvements in the detection of rare and low frequency mutations are necessary to improve the diagnostic accuracy of MPNs.
Methods: MA was calculated following pyrosequencing of bisulfite converted DNA from 40 MPN patients on an investigator initiated non randomised open label phase II multicentre study of Vorinostat (EudraCT #2007-00536-49). Paired samples were analysed at trial entry and after 3 months of therapy to calculate their individual MA scores. Validation of methods used and ageing signature calculation was carried out using cell line and healthy volunteer material.

Results: Samples from 19 Essential Thrombocythaemia (ET), 22 Polycythemia Vera (PV) patients (23 F/17 M) with a mean age of 62 years (range 29-81) were assessed. JAK2V617F was detected in 77.5% (n=31/40). Complete clinical response (CR) was achieved in 8 patients, partial (PR) in 17, and no response (NR) in 15 patients. MA was on average 8.3 years younger than CA (range -43.4 to +41.6) at time of trial entry and 8.2 years younger (range -36.5 to +33.3) after therapy. This difference between MA and CA was greater in ET patients compared to PV, both at trial entry (-14.0 years v -3.7) and after therapy (-13.0 years v -4.3). A statistically significant link between JAK2 allele burden and MA was seen: compared to patients with low or no JAK2 allele burden, patients with high JAK2 (>80% at baseline) had an older MA at trial entry (64.2 years vs 44.5, p=0.0007) and after therapy (64.3 years vs 44.6, p=0.0015). This difference was also seen when PV or ET patients were examined separately. Patients with a high JAK2 allele burden tended to have a MA closer to their CA at trial entry (-0.8 years vs -15.3, p=0.0122) and after 3 months therapy (-0.5 years v -16.2, p=0.0072). Although the cohort size was small, within the ET group, NR compared to PR was associated with a younger MA after therapy (41.4 years vs 56.3, p=0.0156). Within PV, NR compared to PR was associated with a MA that was older than CA both before (+9.2 years vs -14.2 years, p=0.0346) and after therapy (+7.4 years vs -13.9, p=0.0347).

Suggested Conclusions: This study suggests a link between MA and JAK2 mutant allele burden in MPN patients, suggesting that allele burden not only has a role in clinical phenotype and disease evolution but in the overall methylation landscape of the mutated cells. However, the role of MA with respect to therapeutic response needs to be clarified with further studies required to show its full impact.

P698
ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION
N.R. Tata1,*, S. Radek2
1Department of Biomedicine, University Hospital Basel, Basel, Switzerland

Background: The number of detectable somatic mutations increase with age, but this increase is surpassed by the rise in the incidence of cancer in older people. The underlying mechanisms for this disparity remain to be elucidated. Myeloproliferative neoplasm (MPN) is an ideal malignancy model disease to study clonal hematopoiesis, disease initiation and progression during natural aging because the majority of the relevant mutations (such as JAK2 V617F) are catalogued, the disease evolves and progresses slowly allowing the collection of serial samples, and an inducible transgenic mouse models for the disease have been established. Nonetheless, the prevalent occurrence of such clonal events in aged individuals brings up the question, which age-associated factors contribute to initiate hematologic malignancies and what are the rate limiting steps attributable for age-induced myeloid malignancies? We hypothesize that age-induced malignancies provide a context that favors the generation of new mutations, selection for pre-malignant clones, and that activation of mutant JAK2 further augments these changes for increased MPN incidence in aged individuals. Thus, delineation of age associated cellular and molecular mechanisms attributable for increased prevalence of myeloid malignancies will be essential for the development of strategies for early detection and therapeutic targeting of myeloid malignancies.

Aims: The goal of this proposal is to identify age associated hematopoietic cell-intrinsic and cell-extrinsic factors that determine initiation and progression of MPN at young versus old age in mouse models carrying a JAK2-V617F or JAK2-W612 mutation.

Methods: To assess the effect of aging on MPN initiation and progression we studied the young and aged inducible transgenic mouse models of MPN. Integrated omics analysis was performed on MPN initiating stem and progenitor cells. In older mice, arc tumor (AT) and stem cell factor (SCF) induced hematopoietic malignancies provide a context that favors the generation of new mutations, selection for pre-malignant clones, and that activation of mutant JAK2 further augments these changes for increased MPN incidence in aged individuals. Thus, delineation of age associated cellular and molecular mechanisms attributable for increased prevalence of myeloid malignancies will be essential for the development of strategies for early detection and therapeutic targeting of myeloid malignancies.

Results: Our results suggest that age related changes in expression patterns resemble MPN at young and old age in wildtype mice. The mutation profile in patients with pediatric MPN appear to be less complex than in older MPN patients. We are currently investigating the relative contributions and collaborations of age-associated cell intrinsic and extrinsic changes in HSCPs and BM niche in the course and severity of MPN in mouse models carrying a JAK2-V617F mutation, and in naturally aged donors and recipients of bone marrow transplantations.

Summary/Conclusions: Our study provided novel molecular and cellular mechanisms underlying increased incidence of MPN manifestation in old age. The implications of this work goes beyond the MPN malignancy and the comprehensive data sets generated in study will serve as a model to the wider scientific community to study other types of malignancies. This knowledge ultimately will help to define novel strategies to delay or target the onset of MPN in an aging individual.
Results: At BL, 59% of pts had anemia (hgb <10 g/dL); pts with BL anemia were more likely at BL to have platelet count <50,000/μL (51% vs 38%), thrombocytopenia MF (71% vs 57%), and high DIPSS score (41% vs 14%). For those with BL anemia regardless of whether RBC transfusion-dependent (TD), PAC did not worsen hgb levels and the rate of clinical improvement in hgb was higher for pts in the PAC BID arm (25%) vs PAC QD (13%) or BAT (12%) arms (Table). For pts with CALF-RBC transfusion independence (IT) at BL, achievement in RBC transfusion dependency was achieved at higher rates with PAC QD (19%) and PAC BID (22%) vs BAT (9%); 2 PAC and 0 BAT pts achieved RBC-TI by week 24. In PAC pts, SVR ≥35% and TSS reduction ≥50% were observed regardless of BL anemia or RBC-TD (Table). At BL, 16% of pts in the safety population had grade 3 anemia. Incidence of TE anemia was highest during the first 16 weeks of PAC (20% and 9% weeks 8-9, 13% and 8% weeks 16-24 for QD and BAT, respectively) and first 8 weeks of BAT (10%). For pts with BL hgb <10 vs ≥10 g/dL, incidence of grade 3/4 TE anemia was similar with PAC QD (26% vs 28%, respectively), and lower in pts with BL hgb ≥10 g/dL with PAC QD (20% vs 24%, respectively). In instances of grade 3 anemia with PAC or BAT (Table) were in pts with BL hgb <10g/dL. Dose modifications or discontinuations due to anemia were uncommon (Table). No exposure-response relationship was evident for grade ≥2 TE anemia.

Summary/Conclusions: In pts with MF and BL thrombocytopenia, PAC treatment led to clinical improvement in hgb and reduction of RBC transfusion needs vs BAT. Serious anemia, and dose modifications due to anemia were uncommon. PAC provides a treatment option for pts with MF, including those with BL thrombocytopenia and anemia, for whom available options are limited.

**P701**

**PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH ETIOLOGY OF MYELOFIBROSIS (MF) AND BASAL (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL**


1Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 3University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, 4Cleveland Clinic, Cleveland, OH, 5Northwestern University, Feinberg School of Medicine, Chicago, IL, 6University of Tennessee, Memphis, 7University of Toronto, Ontario, Canada, 8Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary, 9Beantown West of Scotland Cancer Centre, Glasgow, United Kingdom, 10Ryazani’s Clinical Hospital, Ryazan, Russian Federation, 11VA Healthcare System, Seattle, WA, 12Stanford Cancer Institute, Stanford, CA, 13University of California-San Diego, La Jolla, CA, 14Mayo Clinic, Scottsdale, AZ, 15MD Anderson Cancer Center, Houston, TX, United States

Background: MF is a life-threatening hematologic malignancy characterized by symptomatology, debilitating constitutional symptoms, and progressive cytopenias (anemia and thrombocytopenia). Currently, JAK1/2 inhibitor RUX is the only approved therapy for pts with MF. Although RUX has been shown to reduce splenomegaly and symptoms in pts with MF, it is associated with dose-limiting cytopenias and is not indicated for pts with platelets <50,000/μL. PAC is an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R. In the phase 3 PERSIST-2 study of PAC vs BAT (including RUX) in pts with MF and BL thrombocytopenia, PAC was significantly more effective in terms of spleen volume reduction (SVR; P=0.001) and appeared to have a better benefit/risk profile vs BAT.

Aims: This analysis examines outcomes for pts with MF treated with RUX in the phase 3 PERSIST-2 study.

Methods: Pts with MF and BL platelet count ≤100,000/μL were randomized (N=511) 1:1:1 to PAC 400mg once-daily (QD), PAC 200mg twice-daily (BID), or BAT. BAT included any physician-selected treatments for MF, as well as RUX or BAT, or no treatment. The co-primary endpoints were the rates of pts achieving ≥35% SVR (by MfR/CT) and ≥50% reduction in total symptom score (TSS; MPN-SAF TSS 2.0) at week 24. Efficacy analyses used the intent-to-treat efficacy (ITT-E) population, which included all pts with randomization date allowing them to contribute data for a week 24 endpoint. Crossover from BAT to PAC was allowed after week 24 or splenic progression.

Results: RUX was the most commonly received active BAT. 44 (45%) BAT pts received RUX (Figure) and 32 (33%) received only RUX. Of the 44 pts who received RUX on study, 17 (39%) had BL platelet counts <50,000/μL and would not have been candidates for RUX by approved indication (or study protocol). BL thrombocytopenia was achieved in 32/44 (73%) pts treated with RUX on study. One (3%) and 6 (19%) RUX pts (n=32 in ITT-E population) achieved SVR ≥35% and TSS reduction ≥50% at week 24, respectively, vs 11 (15%) and 13 (17%) PAC QD and 16 (22%) and 24 (32%) PAC BID pts. For PAC pts with prior RUX, SVR and TSS endpoints were achieved in 6% and 10% with QD, and 13% and 32% with BID, vs 20% and 23% with QD, and 28% and 33% with BID for PAC pts without prior RUX.

Grade 3/4 adverse events (AEs) were reported in 76%, 70%, and 45% of PAC QD, PAC BID, and RUX pts, most commonly (59% in any arm) thrombocytopenia (31%, 32%), anemia (27%, 22%), and neutropenia (9%, 7%) with PAC, and (16% and 16%) anemia (8%) and neutropenia (2%) with RUX. Dose reductions due to AEs occurred in 20%, 12%, and 11% of pts treated with PAC QD, PAC BID, and RUX, respectively; half (22/44) of RUX-treated pts crossed over to PAC treatment, at a median of 26.1 (95% CI 25.3-27.3) weeks. Of those 22, 19 pts remained on PAC treatment at the time of data cut-off, 7 for 24 weeks of PAC treatment (Figure 1).
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (≥75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY


1Rabin Medical Center, Petah Tikva, Israel, 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada, 3Johannes Wesling Medical Center, University Hospital, Minden, 4University Hospital of Halle, Halle (Saale), Germany, 5Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza, Spain, 6CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOJ Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 7St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada, 8Universidade Federal de Goiânia, Goiânia, Brazil, 9Federal Almazov Medical Research Center of the Russian Ministry of Health, St. Petersburg, Russian Federation, 10Novartis Pharma AG, Basel, Switzerland, 11Novartis Healthcare Pvt. Ltd, Hyderabad, India, 12Azienda Ospedaliera Banchi-Melacarne- Morelli, Reggio Calabria, Italy

Background: RUX is a potent JAK1/JAK2 inhibitor that has led to reductions in splenomegaly and symptoms in patients (pts) with MF. Although few studies have assessed RUX in elderly pts, a recent analysis including the largest cohort of elderly pts with MF treated with RUX to date. Consistent with the study by Latagliata et al, RUX was safe and effective in pts ≥75 y, with pts achieving reductions in spleen size and symptoms similar to those in the overall population, with comparable rates of AEs. Additionally, findings from our study were consistent with those of the COMFORT studies, which included few pts ≥75 y. Overall, our study provides further evidence that RUX is safe and effective in elderly pts with MF.

Methods: Pts with high- or Int-2–MF, or Int-1–risk pts with a palpable (≥5 cm) spleen, were eligible. RUX starting doses were based on baseline platelet (PLT) counts (5mg bid [≥50 <100×10^9/L], 15mg bid [100 200×10^9/L], or 20mg bid [≥200×10^9/L]). Pts were ≥18 y; there was no maximum age limit. The primary endpoint was safety and tolerability of RUX. Secondary endpoints included changes in spleen length and symptoms.

Results: This analysis includes 418 pts (primary MF, 66%) who were ≥75 y and started treatment ≥1 y before data cutoff (01 Jan 2016). Baseline characteristics (median) were age, 78 y (range, 75-89 y); male, 57%; spleen length, 10 cm (0-35 cm); blast count ≥1%, 30.3%; hemoglobin, 101 g/L (100 g/L, PLT count, 249×10^9/L (<100×10^9/L, 6.3%). ECOG PS <2, 84.9%. At data cutoff, more than half of pts remained on treatment or completed treatment per protocol (52.6%). As expected, a greater proportion of elderly pts discontinued RUX due to adverse events (AEs; 23.6%) or death (8.7%) than pts in the overall study (17.7% and 4.1%, respectively). Overall, 72.4% of pts had dose modifications (AEs, 58.4%), and 33.9% had an interruption (AEs, 31.5%). Safety of RUX in elderly pts was consistent with that in the overall population. Median exposure was 11 mo; mean daily average dose was 26.8mg (SD, 10.6).

The most common hematologic grade 3/4 AEs were anemia (43.8%; overall, 34.1%) and thrombocytopenia (22.1%; overall, 16.3%). AEs (all grade [grade 3/4]) in ≥10% of pts included asthenia (18.3% [2.6%]), pyrexia (18.0% [2.6%]), dyspnea (14.4% [4.3%]), diarrhea (13.5% [1.9%]), fatigue (11.8% [2.4%]), peripheral edema (10.8% [0.2%]), and pneumonia (10.1% [7.2%]). Infections in >5% of pts included pneumonia (10.1%), urinary tract infection (7.0%), and bronchitis (5.1%). Herpes zoster occurred in 3.9% of pts. At wk 24, 56.4% (124/220) of pts had a ≥50% reduction from baseline in spleen length (overall, 56.6%), and 19.1% (42/220) had 25%-50% reductions (overall, 23.3%); rates were similar at wk 48 (54.6% [65/119] and 19.3% [23/119]; overall, 61.6% and 18.9%). Most pts (64.2%) achieved a ≥50% reduction at any time (Figure 1), similar to the overall population (70.2%). Pts also experienced significant improvements in symptoms. From wk 4 to 48, 42%-48% and 50%-57% of pts achieved a clinically meaningful response on the FACT-Lym TS and FACT- Fatigue, respectively.

Figure 1

Summary/Conclusions: This analysis included the largest cohort of elderly pts with MF treated with RUX to date. Consistent with the study by Latagliata et al, RUX was safe and effective in pts ≥75 y, with pts achieving reductions in splenomegaly and symptoms similar to those in the overall population, with comparable rates of AEs. Additionally, findings from our study were consistent with those of the COMFORT studies, which included few pts ≥75 y. Overall, our study provides further evidence that RUX is safe and effective in elderly pts with MF.
Background: Accurate disease risk stratification is crucial for transplant decision making in myelofibrosis (MF). However, several prognostic models are available, it is unknown if they are equivalent in the way they distribute patients into risk groups and in their discriminatory power to predict survival.

Aims: We have compared the performance of the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), DIPSS-plus, and Rumi’s score in a series of 544 MF patients aged 70 years or younger at time of diagnosis.

Methods: The Spanish Registry of Myelofibrosis is a nationwide, longitudinal registry contributed by centers associated to the Grupo Español de Enfermedades Mieloproliferativas Filadelfia negativas (GEMFIN). From January 2000 to January 2016, a total of 544 adult patients aged ≤ 70 years with primary MF (n=335) or secondary MF (n=209) had been included in the registry. Cases of the prefibrotic form of MF were not considered. Comparison of the relative power of each prognostic model to discriminate levels of risk was estimated by means of the Harrell’s concordance index (C-index) and the R2 explained variation. All the statistical analyses were performed with IBM SPSS 22.0 and Stata 11.

Results: At diagnosis, median age in patients diagnosed with MF was 3.35 years, 177 patients (33%) had died, and the remaining were censored alive. Sixty-nine patients (13%) had been submitted to allogeneic stem cell transplantation, after a median time of 20 months from MF diagnosis. The median projected survival of the overall series was 9.46 years (95% confidence interval: 7.44-11.49). Median survival was not reached for the low risk category of all classifications (and Rumi’s very low risk category). The projected survival for patients in the intermediate-1 group (intermediate in the Rumi’s score) and in the high risk group (very high risk in the Rumi’s score) was comparable in the four models. By contrast, the Rumi’s high risk group had a projected median survival of 9.2 years, whereas that of the intermediate-2 categories by the IPSS, DIPSS, and DIPSS-plus models was 6.6 years, 5.6 years, and 6.5 years, respectively. The number of patients in the intermediate-2 and high risk categories was smaller in the DIPSS than in the IPSS or the DIPSS-plus. Overall, the Rumi’s score yielded the highest power to discriminate between risk categories, as measured by the C-index and the R2 explained variation. However, the IPSS and DIPSS-plus were the best models to discriminate between the intermediate-1 and intermediate-2 risk categories, which is the critical cut-off point for patient selection to transplant.

Summary/Conclusions: In our contemporary series of MF patients only the highest risk categories of the current prognostication systems have a median survival below the 5-year threshold recommended for considering transplantation. Patient selection for transplant is quite dependent on which prognostication model is used for disease risk stratification.

P704

LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY

G. Birgegård1, Y. Folkvaljon2, H. Garmo2, L. Holmberg3, C. Besses4, M. Griesshammer5, L. Gugliotta6, J. Wu7, H. Achenbach8, J.-K. Kiladian9, C. N. Harrison10

1Department of Haematology, Uppsala University, 2Regional Cancer Centre, Uppsala University Hospital, Uppsala, Sweden, 3King’s College London, Faculty of Life Sciences and Medicine, London, United Kingdom, 4Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, 5Department of Haematology, Hospital del Mar-MIM, Barcelona, Spain, 6Hematology and Oncology, German Cancer Research Center, Heidelberg, Germany, 7Department of Haematology, St Orosia-Malpighi Hospital, Bologna, Italy, 8Global Biometrics, Shire Pharmaceuticals, Lexington, United States, 9Research & Development, Shire GmbH, Zug, Switzerland, 10APHP, Saint-Louis Hospital, Clinical Investigations Center, Paris, France, 11Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Background: A common therapy for essential thrombocythemia (ET), hydroxy-ycarbamide (HC), has mutagenic properties and there is potential for leuke- 

mogenicity and secondary cancers with this agent. In the EXELS study, we reported higher event rates for acute myeloid leukemia (AML) and other malig-

nancies in HC-treated patients compared with those treated with anagrelide (ANA). However, there were large age differences between groups. Here, we account for age difference by estimating standard incidence ratios (SIRs) using country-specific cancer registration data.

Aims: To assess the risk of AML and non-hematological malignancies in patients treated with HC or ANA in the EXELS study.

Methods: Previous exposure to ANA and HC was based on patient history. SIRs were calculated using background rates retrieved from Cancer Incidence in Five Continents (C5). Risk of AML after study enrolment was estimated by cumulating the risk of AML at exposures time of 180 days was used to account for disease progression as a confounding factor. Informed consent was obtained before the start of the study.

Results: Overall, 3460 patients were exposed to HC, ANA or both at registra-

tion; 481 patients had ANA treatment, 2305 had HC treatment and 674 had exposure to both drugs. The median age in ANA patients was 51 years, and 71 years in HC patients. One hundred and seventy four cases of non-

hematologic cancer, including 35 cases of skin cancer, were recorded. SIRs for all malignancies were close to 1 for all treatment groups, indicating similar

risks to the background population. For all skin cancers, including melanoma, the SIR for patients with HC treatment was higher than expected for the normal population and patients on ANA (1.15 vs 0.45). When melanoma was excluded, the figures changed only marginally. However, due to the low number of events, the CIs were wide, and no statistically significant difference was found between treatments. Sixty seven AML cases were reported; 39 AML cases were found in the HC group (person-years 8970, SIR 39.7), with another 20 AML cases in the group who switched from HC to ANA (person-years 2934, SIR 91.5). The risk ratio for AML developing in patients who switched from HC more than dou-

bled (RR 2.30-2.52), irrespective of minimum exposure time. In contrast, no AML case was observed in the ANA-only group (person-years 1905, SIR 0) and there were only 3 AML cases in the group who switched from ANA to HC (person-years 802, SIR 68.5). Since the number of AML cases in the ANA group was 0, no statistical comparison could be made. Five AML cases were excluded from analysis since there was uncertainty about which drug was used first.

Table 1.

Summary/Conclusions:

P705

EPIDEMIOLOGICAL, OUTCOME AND RISK FACTORS FOR INFECTION COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS


1Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy, 2Hematology and Clinical Immunology Unit, University of Padova, Padova, 3Division of Hematology, Ospedale Ferrarotto, University of Catania, Catania, 4Department of Hematology, University of Verona, Verona, 5Division of Cellular Biotechnologies and Hematology, University Sapienza, Rome, Italy

At the study closing date, median follow-up from diagnosis of MF was

20 months. Overall, 3460 patients were exposed to HC, ANA or both at registra-

tion and there were only 3 AML cases in the group who switched from ANA to HC. It has been proposed that exposure of ET patients failing HC therapy to a second potentially leukemogenic agent should be avoided; yet these data suggest that even after switching to a non-leukemogenic agent, HC-treated patients still have an over 90-fold increased risk of AML. Our data reinforces concerns of a leukemogenic effect of HC, with a markedly higher risk in patients failing HC and switching to another drug, even if that drug is ANA. The caution advocated in the use of HC seems well advised.

Summary/Conclusions: ET patients have a substantially increased risk for AML development; the SIR for AML was 40-fold higher than expected with HC exposure. In patients who switched from HC to ANA the SIR was approximately 90-fold higher, with 20 AML cases observed versus the expected 0.22 cases. The number of AML cases was much lower (n=3) in patients who switched from ANA to HC. It has been proposed that exposure of ET patients failing HC therapy to a second potentially leukemogenic agent should be avoided; yet these data suggest that even after switching to a non-leukemogenic agent, HC-treated patients still have an over 90-fold increased risk of AML. Our data reinforces concerns of a leukemogenic effect of HC, with a markedly higher risk in patients failing HC and switching to another drug, even if that drug is ANA. The caution advocated in the use of HC seems well advised.
Roma, 6Division of Hematology, Azienda Ospedaliera ‘Bianchi Melacarzio Morelli’, Reggio Calabria, 7Division of Hematology, ASST Spedali Civili di Brescia, Brescia, 8Division of Hematology, Ospedale S. Eugenio, Roma, 9Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, 10Department of Hematology, University of Bologna, Bologna, 11Division of Hematology, IRCCS AOI San Martino-IST, Genova, 12Division of Hematology, Città della Salute e della Scienza Hospital, Torino, 13Division of Hematology, University of Ferrara, Ferrara, 14Division of Hematology and Stem Cell Transplant Center, AORIMN Hospital, Pesaro, 15Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, 16Division of Hematology, Piacenza, Italy

Background: Infectious complications represent one of the most frequent causes of morbidity and mortality in Myelofibrosis (MF), the most severe of myeloproliferative neoplasms. Ruxolitinib (RUX), the first approved JAK1/2 inhibitor, significantly ameliorates disease-related splenomegaly and constitutional symptoms. Prospective controlled studies observed a high rate of infectious complications including opportunistic and unusual infections, probably due to its immune-suppressant activity. However, risk factors for infections in MF patients (pts) treated with RUX are still to be investigated.

Aims: To evaluate characteristics, incidence and risk factors for infections in RUX-exposed MF pts.

Methods: Clinical and laboratory data of MF pts treated with RUX were retrospectively collected from the database of 21 Italian Hematology Centers. Infections were defined according to the CTCAE.

Results: Overall, 373 pts received RUX between June 2011 and June 2016. At RUX start the clinical features were (median): age 68 years (27-89); >65y, 62%; male, 57%; Hb, 10.8g/dL (7-16.7); Hct <10g/dL, 40%; PLT, 246×10^9/L (33-1887); PLT <100×10^9/L, 10%; spleen enlargement, 97%; spleen length ≥10cm, 60%; constitutional symptoms, 52%. International Prognostic Score System (IPSS) was intermediate-1 (15%), intermediate-2 (46%), high (39%). V617F mutation was detected in 255 out of 313 evaluated pts (81%). Karyotype was unfavorable in 15 out of 203 evaluable pts (7%). Previous infectious complications were recorded in 31 pts (8%). After a median RUX exposure of 20 months (range, 1-56), 101 pts (27%) experienced 129 infectious events (grade 3, 33%), for an incidence rate of 14.9 cases for 100 pts/year. The rate of infections tended to decrease over time: 54% occurred within 6 months of treatment, 57% after 12 months. The rate of infections was significantly ameliorated in patients treated for >2 years (p=0.001). Respiratory tract infections were more frequently observed (73 events, 57%). Cutaneous, urinary tract and gastrointestinal infectious events were diagnosed in 15%, 10% and 7% of cases, respectively. In 14 cases fever of unknown origin was recorded (Figure 1). Etiological agents were isolated in 14 cases (11%); bacteria in 9 cases (gram+ 56%, gram- 22%, C. difficile diarrhea 22%) and fungi in 2 cases (pulmonary aspergillosis and oesophageal candidiasis). Mycobacterium tuberculosis meningitis was isolated in 3 cases. Herpes-virus reactivations occurred in 12 cases (9%). No patients reactivated hepatitis B virus. At last follow-up, 88 pts (24%) have died, in 10 cases (11%) due to infectious complication. Among baseline features, age≥65 years at RUX start (p<0.0001), previous infection (p=0.001), primary vs secondary MF (p=0.021) and high IPSS (p=0.029) significantly correlated with higher infectious risk. Notably, no differences were observed according presence of large (≥10cm) splenomegaly, higher (>20) total symptoms score, presence of cytopenias, Charlson comorbidity index (>2) and body mass index (>21 and >30). In multivariate analysis, PMF diagnosis (HR 1.6 CI95% 1.07-2.5), age≥65 years (HR 2.1 CI95% 1.3-3.3) and previous infection (HR 3 CI95% 1.7-5.4%) confirmed their negative prognostic association. Interestingly, RUX dosage, spleen response and hematological toxicities during treatment were not associated with infectious risk.

Summary/Conclusions: Infections occurred in around one-third of RUX-treated pts; the rate of infections tended to decrease over time, and were fatal in 11% of the cases. Advanced age, a previous infectious event and diagnosis of PMF seem to be the main contributors to infectious risk.

P706

TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS-FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY

S. Koschmieder1, 2, M. Koehler3, P. Guglielmelli4, R.A. Mesia4, L. Foltz5, T. Flindt6, J. Mathias7, N. Komatsu8, R.N. Boothroyd9, A. Spierer9, J. Perez Ronaldo10, G. Taylor-Stokes11, J. Waller11, C.N. Harrison12

1Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, 2Department of Hematology and Oncology, Faculty of Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany, 3CRIRM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOUM Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 4Mayo Clinic, Scottsdale, AZ, United States, 5St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada, 6Patient advocate, Prato, Italy, 7Patient Chair, MPN Voice, London, United Kingdom, 8Department of Hematology, Juntendo University Faculty of Medicine, Tokyo, Japan, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 10Novartis Pharma AG, Basel, Switzerland, 11Adelphi Real World, Bollington, 12Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

Background: Patient (pts) with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polychromatemia vera (PV), and essential thrombocythemia (ET), experience a substantial disease burden. Pts are managed with watchful waiting or therapy, including aspirin, hydroxyurea (HU), and other drugs. The international MPN LANDMARK survey evaluated the patient-reported impact of MPNs in pts in 6 countries and identified current management strategies in these pts.

Aims: To analyze treatment strategies used by physicians and pts to manage MPNs.

Methods: This cross-sectional, internet-based survey was conducted in Australia, Canada, Germany, Italy, Japan, and the UK and was administered to pts with MPNs and to physicians treating pts with MPNs. Pts and physicians were recruited independently. We describe disease-management strategies in these pts.
ET) chose watchful waiting to manage >25% of their pts at diagnosis; 22% of untreated pts had moderate to high (quartiles 3-4) overall symptom burden. Physicians primarily recommended treatment for pts experiencing severe symptoms (72% MF; 68% PV, 72% ET) or symptomatic splenomegaly (71% MF; 61% PV, 39% ET). PLB was mainly used to treat pts with PV. Of those who received PLB (n=155), 71% were very or somewhat satisfied; 25% were very or somewhat dissatisfied and felt that PLB had a negative impact on their QOL. Similarly, 37% of physicians felt that PLB had a negative impact on pt QOL; PLB alone was insufficient for disease control in 38% of pts. Pts stopped PLB because physician deemed it no longer necessary (62%), pts felt worse after treatment (10%), and visit frequency was inconvenient (8%). Physician-reported reasons for stopping PLB were that visit frequency was inconvenient (38%), pts felt worse after treatment (35%), and lack of intravenous access (33%). HU use was assessed in pts with PV or ET. Of those who received HU (PV, n=95; ET, n=145), 78% and 74%, respectively, continued to receive HU; 19% and 22% were dissatisfied with HU therapy. Main reasons for stopping HU were lack of efficacy (29% PV, 13% ET) and toxicity (18% PV, 27% ET). Overall, 78% of physicians reported that up to 25% of their pts showed inadequate efficacy or intolerance of HU. Main measures of treatment success among pts were physician feedback (73% MF, 75% PV, 75% ET) and blood counts (72% MF, 67% PV, 74% ET). Lack of efficacy, side effects, and discontinuation were key reasons for changing therapy.

Summary/Conclusions: Many pts with MPNs are managed with watchful waiting at diagnosis. Although most of these pts have a low symptom burden, 22% have a moderate to high burden, highlighting the need for proactive and standardized symptom assessments at diagnosis and over the course of treatment. Interestingly, more than 80% of physicians and pts felt that phlebotomy had a high negative impact on pt QOL. Overall, pts consider physician feedback and blood counts to be important indicators of treatment success.

P707 SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVIRA STUDY


Background: Peginterferon alfa-2b is a novel long-acting monopegylated interferon alpha (IFNa) with Orphan designation in Europe and the U.S. Reduced dosing frequencies and favorable tolerability accompanied by robust clinical responses in patients with polycythemia vera (PV) have been reported over the first few years of treatment. Successful long-term, potentially life-long maintenance with high rates of adherence, compliance and treatment outcome remain important goals to be elucidated.

Aims: To describe the clinical outcomes of patients with PV who transform to accelerated or blast phase and evaluate the impact of genomic alterations on outcomes.

Methods: Eligibility criteria included: Prior diagnosis of Philadelphia negative MPN according to WHO 2008 criteria; evidence of transformation to accelerated (10-19% blasts in peripheral blood or bone marrow) or blast phase (>20% blasts) and seen at Princess Margaret Cancer Centre between January 1998 and February 2017. The primary endpoint was overall survival (OS); defined as the time from transformation to death or last follow-up. Secondary endpoints included survival based on curative versus non-curative approach and treatment over time. In addition the impact of mutations will be correlated with clinical outcomes and survival.

Results: Data from the last available analysis include 29 patients remaining on study with a median treatment duration of 213 weeks. All 29 patients have completed at least 2 years of treatment (5 patients are in the 3rd year, 7 in the 4th year, 10 in the 5th year and 7 in the 6th year of treatment). Baseline characteristics of the study cohort during short-term treatment and long-term maintenance, and efficacy follow-up data were already presented earlier (Gisslinger et al. 2015). All of the 29 patients were switched to dosing once every 4 weeks. Median treatment duration at time of switch was 104 weeks (Q1-Q3: 69-124 weeks). All 29 patients remained on the 4-week schedule with a median observation of 2 years. ROPEG reduction of mutant JAK2 allele burden to below 10%, a feature that can only be achieved by IFNα based therapies.

Summary/Conclusions: In summary, all patients remaining on peginterferon alfa-2b after a median of 2 years of initial treatment were successfully switched to a more convenient monthly long-term maintenance schedule, thereafter no patients discontinued, and all patients could be maintained on this schedule for currently another 2 years (trial still ongoing). These data underscore the expected long-term efficacy with regard to haematological, clinical and molecular parameters and the excellent safety/tolerability of peginterferon alfa-2b. Long-term maintenance treatment of PV patients using peginterferon alfa-2b monthly is feasible, efficacious and well tolerable. Continuous patient-individual adaption of dosing regimen, including dose and dosing schedule, is recommended.
Summary/Conclusions: Analysis ongoing).

comes and will be presented at the EHA annual conference (profiling completed, Myeloid Sequencing Panel. Mutational data will be correlated with clinical outcomes performed on peripheral blood or bone marrow samples using the TruSight filing of 54 genes (39 hotspot region; 15 complete coding region coverage) was for this cohort of patients.

approaches are ineffective. Results of molecular profiling may provide valuable who transform to accelerated or blast phase, confirming that current treatment ive care, there has been no significant improvement in survival for MPN patients

Sixty-four (41%) patients were treated with curative intent including 27 (42%) (90%) patients met the criteria for acute myeloid leukemia, thirteen (8%) had n=24, 15%) and MPN-unclassifiable (n=11, 7%). One hundred and forty-two post ET myelofibrosis (PET MF; n=27, 17%), post PV myelofibrosis (PPV MF; n=24, 15%) and MPN-unclassifiable (n=11, 7%). One hundred and forty-two patients received non curative approach including low dose chemotherapy, hypomethylating agent, clinical trial or best supportive care. The median OS for the entire cohort was 6.5 months (95% CI: 5.08-8.01). In patients treated with curative intent median OS was 8.8 versus 3.2 months (p=0.003) for patients with non-curative intent. There was no difference in OS between historical controls treated between 1998 and 2011 when compared to a more recent cohort of patients (6.5 vs 7.3, p=0.34; see Figure 1). In 105 (67%) patients, NGS molecular profiling of 54 genes (39 hotspot region; 15 complete coding region coverage) was performed on peripheral blood or bone marrow samples using the TruSight Myeloid Sequencing Panel. Mutational data will be correlated with clinical outcomes and will be presented at the EHA annual conference (profiling completed, analysis ongoing).

Summary/Conclusions: Despite advances in systemic therapies and support ive care, there has been no significant improvement in survival for MPN patients who transform to accelerated or blast phase, confirming that current treatment approaches are ineffective. Results of molecular profiling may provide valuable insights and clues as to how to develop an individualized treatment approach for this cohort of patients.

Background: Mastitinib, a selective oral tyrosine kinase inhibitor targeting wild-type KIT, LYN and FYN, was the first drug to demonstrate efficacy in a phase 3 setting (study AB06006) for treatment of patients with severe indolent systemic mastocytosis (ISM) who are unresponsive to existing, optimal symptomatic treatments. In The Lancet (Feb 11;389(10069):612-620), Lortholary and col leagues reported a significant and clinically meaningful treatment benefit for mastitinib (6mg/kg/day over 24-weeks) versus placebo, with primary analysis based on cumulative response (≥75% improvement from baseline, timeframe weeks 8-24, comprising 5 visits at 4-week intervals) in at least one of four severe baseline symptoms (pruritus, flushes, depression, or fatigue) using repeated measures methodology for rare diseases (i.e. a longitudinal analysis with respect to symptoms as opposed to patient response rate at a single point in time). Eligible patients were aged 18–75 years and had ISM according to inclusion criteria that were slightly broader than the WHO classification.

Aims: To aide interpretation of this study's prospectively declared primary endpoint via comparison with additional efficacy analyses based on a cohort restricted to the WHO classification of ISM and more conventional patient-centric response endpoints.

Methods: Randomized, placebo-controlled, phase 3 study that included 135 severely symptomatic ISM patients, including the subvariant smoldering systemic mastocytosis (19 mastitinib, 64 placebo), 80% of whom satisfied the WHO classification.

Results: Masitinib showed a significant improvement over placebo according to its primary endpoint (mITT population), with a cumulative response of 18.7% versus 7.4%, respectively, odds ratio (OR) of 3.6 [95%CI 1.2-10.8], P=0.008 (with re-randomization). This outcome was confirmed in the WHO patient subgroup: 17.8% versus 8.0%, respectively, OR=3.25 [9.07-10.88], P=0.0317. Computing the primary analysis (mITT) according to cumulative response per patient (GEE model) was also positive: 26.7% versus 12.8%, respectively, OR=2.48 [1.16-5.31], P=0.0212, as was analysis accounting for individual patient response (Pearson chi-square): 40.3% versus 24.2%, respectively, P=0.0062. Response (per patient) on all severe baseline symptoms for at least one visit was: 16.4% versus 1.6%, respectively, P=0.0062. Finally, analysis of sustained response in all severe baseline symptoms over multiple visits was highly discriminatory between treatment arms: for patients with 3 severe baseline symptoms sustained a response of 12.5% response rate (≥75% improvement in each symptom) for 3 out of 5 visits, versus no response for placebo; and for patients with 2 severe baseline symptoms masitinib generated a response rate of 21.1%, 15.8% and 10.5% over at least 1, 2, and 3 visits, respectively, versus no response for placebo.

Summary/Conclusions: These post-hoc analyses confirm the clinical relevance, durability, and generalizability of the positive primary endpoint from study AB06006. Findings therefore support the conclusion that masitinib generates a significant therapeutic benefit in patients with severely symptomatic ISM who were unresponsive to optimal symptomatic treatments.

Background: Mastitinib, a selective oral tyrosine kinase inhibitor targeting wild-type KIT, LYN and FYN, was the first drug to demonstrate efficacy in a phase 3 setting (study AB06006) for treatment of patients with severe indolent systemic mastocytosis (ISM) who are unresponsive to existing, optimal symptomatic treatments. In The Lancet (Feb 11;389(10069):612-620), Lortholary and colleagu
Background: Hemophagocytic lymphohistiocytosis (HLH) is a devastating disorder of uncontrolled immune activation characterized by clinicopathological evidence of extreme inflammation. Hematological malignancy-associated HLH (m-HLH) has the worst outcome in comparison with any other form of HLH. m-HLH can occur as the first manifestation of an occult malignancy, before start or during the treatment of known malignancy, or as the sign of a malignant relapse or transformation to the more aggressive disease form.

Aims: The aim of the present study was to analyze the response to HLH therapy and overall survival of adult patients with m-HLH.

Methods: From 2008 and onwards, data on adult patients referred to the Hematology Center Karolinska with suspected HLH were prospectively collected. Review concerned records of 142 adults with suspected HLH, hospitalized between Jan 2009 and Dec 2016. Of those, 71 patients with hematological malignancy were diagnosed with HLH and included to the present study. Hematological malignancy was defined as a neoplasm of lymphoid or myeloid origin. In all studied patients, the diagnosis of HLH was based on the HLH-2004 criteria. Infection as a possible additional trigger of HLH was carefully studied in all our m-HLH patients. EBV and CMV DNA were routinely examined in whole blood, using RT quantitative PCR; other viruses (e.g. adenovirus, HSV, VZV, HHV6, influenza) were studied based on indications. Blood and urine cultures were performed in order to reveal any bacterial or fungal infections. Tests for fungal antigens, tuberculosis, and parasites were also performed if indicated. HLH treatment categories have included proapoptotic chemotherapy (etoposide, corticosteroids, IVIG) and T cells (corticosteroids, cyclosporine A).

Summary/Conclusions: HLH in the context of malignancy is still considered a challenge in adult hematology. m-HLH is a highly lethal disorder in adults. The patients who develop m-HLH with concomitant infection during chemotherapy show better survival than those who had HLH solely attributed to malignancy. Although poor outcome in some patients with m-HLH is related to malignancy progression, in some patients the lack of effective m-HLH therapy may further impede adequate treatment of malignancy.
C. Rose1, B. de Renzio2, E. Peroni3, M. L. Randi4, S. Dumont5, I. Ricordeau6, S. Bézieau4, B. Gardie10

1Laboratoire Hematologie, Plateau Technique De Biologie, Dijon Cedex, 2INSERM U 1231, Faculté médecine, Dijon, 3INSERM, université de Nantes, 4Laboratoire de Génétique Moléculaire, CHU Nantes, 5Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM Université de Nantes, 6Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, 7Service d’Hémato-oncologie adulte et thérapies cellulaires, CHU Clermont Ferrand, Clermont Ferrand, France, 8Clinica Medica 1, Department of Medicine –DIMED, Padova, Italy, 9Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, Université de Nantes, Nantes, France

Background: Erythrocytoses are characterized by an elevated red cell mass. The most widely studied disease is Polycythemia Vera (PV), however, other types of erythrocytoses can be either inherited (Congenital Erythrocytosis-CE) or acquired (CE/IE) in patients with no familial history (idiopathic polycythemia vera, IPV, and hereditary Erythrocytosis, IE). CE/IE are not associated with myeloproliferation but they can be associated with severe thrombo-embolic or haemorrhagic events, pulmonary arterial hypertension and, rarely, tumours (hemangioblastoma, pheochromocytoma). The 8 genes identified so far as causing CE are involved (i) in the regulation of the hypoxia pathway; PHD2 (also called EGLN1), HIF-2α (EPAS1), VHL, (ii) in prolation and differentiation of erythroid progenitors (EPOR), or (iii) in mature cell function, haemoglobin (HBB, HBA1, HBA2) or phosphoglyceratemutase (BPGM). However, in 80% of cases the cause remains unknown meaning that no proper diagnosis can be made, no prognosis or advice can be provided to CE/IE patients, and no curative treatment exists.

Aims: to (i) identify, (ii) collect and (iii) analyze the genetic abnormalities in patients suspected of CE.

Methods: We created and developed a national network in France to analyze the genomic abnormalities in patients suspected of CE. The selection of patients was based on the criteria: (i) a diagnosis with polycythemia vera; secondary erythrocytosis related to lung, cardiac or renal disorder. Next generation sequencing (NGS) has been used to analyse the presence of mutations in 28 genes (enlarged hypoxia pathway and other candidate genes).

Results: To date, samples from 140 patients have been recorded, among whom 46 have been analyzed using NGS approach. The variants identified in 14 CE/IE patients [13 males and 1 female; median age 50 y, (12-71)] with unknown significance have been detected, including 4 in PHD genes, 5 in HIF genes, 4 in LN genes (SH2B3) and 1 in JAK2 gene. In patients with variants, a familial history of erythrocytosis was noted in 3. No independent thrombotic complication was reported in the 15 patients. In 2 patients (one with a JAK2 variant and one with a VHL variant), the erythropoietin was low, whereas for the others, the erythropoietin was normal. Of note, the median age of the patients was surprisingly high, suggesting that the diagnostic was not previously performed due to the absence of available tests. Functional studies were performed on PHD2 variants: a significant decrease in the hydroxylase activity was noted for one variant, but not for the others. On the other hand, a decrease in the stability along time of the PHD2 protein was observed for two variants, underscoring the different mechanisms involved in the impairment of the PHD2 activity.

Summary/Conclusions: NGS is a useful tool to explore mutations in CE, but identifies genetic variants in only 30% of patients with such disorder. Further exams including whole exome sequencing are planned to achieve a right diagnosis in the 70% remaining CE patients. In vitro, in cellulo and in vivo (including zebrafish model) functional studies are currently performed to validate the clinical relevance of the variants identified in the hypoxia pathway. They are compared to variants identified in the development of tumors in order to dissect the molecular mechanisms of this finely tuned pathway.

P713
CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE

1Cancer Research Centre (IBMMC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain, 2Instituto de Biomedica Research of Salamanca (IBSAL), Salamanca, Spain, 3Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, 4Sequencing DNA Service (NUCLEUS), University of Salamanca, Salamanca, 5Instituto de Estudios de M astocitosis de Castilla La Mancha (CLEMAst), Hospital Virgen del Valle, Toledo, Spain

Background: Recent studies show that most systemic mastocytosis (SM) patients, including indolent SM (ISM) with (ISMs+) and without skin lesions (ISMs-), carry the KIT D816V mutation in PB leukocytes.

Aims: To investigate the potential association between the degree of involvement of BM hematopoiesis by the KIT D816V mutation and the distribution of different maturation-associated compartments of bone marrow (BM) and peripheral blood (PB) CD34+ hematopoietic precursors (HPC) in ISM, and identify the specific PB cell compartments that carry this mutation.

Methods: The distribution of different maturation-associated of BM and PB CD34+ HPC from 64 newly-diagnosed (KIT-mutated) ISM patients and 14 healthy controls was analyzed by flow cytometry. In 18 patients distinct FACS-purified PB cell compartments were also investigated for the KIT mutation.

Results: ISM patients showed higher percentages of both BM and PB MC-committed CD34+ HPC vs controls, particularly among ISM with MC-restricted KIT mutation (ISMMC); this was associated with progressive blockade of maturation of CD34+ HPC to neutrophil lineage from ISMNC to multilineage KIT-mutated cases (ISMtk). Regarding the frequency of KIT-mutated cases and cell populations in PB, variable patterns were observed, the percentage of KIT-mutated PB CD34+ HPC, eosinophils, neutrophils, monocytes and T-cells increasing from ISMMC and ISMt+ to ISMtk patients.

Summary/Conclusions: Positivity for the KIT D816V mutation in PB of ISM is related with high percentage of circulatory mast cells. MC-patients without MC-predominant localization of CD34+ HPC in BM cell compartments and multiple myeloid cell populations, KIT-mutated PB CD34+ HPC potentially contributing to disease dissemination already at very early stages.
EVOLUTION AND GENETICS

S. Parma, 1,2Department of Medicine, University of Padua; Padua, 3,4Department of Oncology, Azienda “Santobono-Pausilipon”, Pausilipon Hospital; 5,6Department of Pediatric Haematology-Oncology, Department of Pediatric Haematology-Oncology, Napoli; 7,8Department of Pediatric Haematology-Oncology, University Hospital of Parma, Parma, 9Department of Pediatric Haematology-Oncology, University Hospital of Bolzano, Bolzano, 10Department of Reproduction and Growth, University Hospital Sant’Anna in Ferrara, Ferrara, 11Department of Haematology, Oncocematologia Pediatrica, Pollicino G. B. Rossi, Verona, 12Department of Pediatric Haematology-Oncology, University of Catania, Catania, 12Department of Haematology, Ca’Foncello Hospital, Treviso, Italy

Background: Erythrocytosis, (i.e. increased levels of hemoglobin/hematocrit (Hb/Ht)>95percentile for age and sex), is rarely found in pediatric or adolescent age. Presence of familial cases, presentation at birth or presence of known mutations, as well as exclusion of secondary causes identifies primary (PE) or congenital secondary forms (CE). However, many cases still lack evident etiological definition (idiopathic E.). Moreover, natural course and treatment are still anecdotally reported.

Aims: Here we present our experience in a large and heterogeneous series of children with absolute erythrocytosis. The aims is to identify a possible clinical and diagnostic approach to children with erythrocytosis.

Methods: All children with E. who lacked evidence of reactive origin were consecutively referred to our laboratory for molecular evaluation. Molecular analysis of the main involved genes (VHL, HIF2A, EPOR, JAK2, PHD2) was performed by allele specific PCR, PCR on direct DNA sequencing. Erythropoietic Colony Essay (ECE) was performed on peripheral blood with and without cytokines. Clinical features and treatment choices were reported by referring clinicians (table 1).

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
</table>

Results: Patients were group according to the definitions of absolute Erythrocytosis. A total of 44 pediatric cases were identified (less than 18 years old). There were 7 families, where 5 adults were also found polyglobulic. However, in only 4 families a defect was identified (2 VHL, and 2 Hb variants). One positive case was found sporadic. Most Hb variants were not symptomatic, while all other familiar cases had splenomegaly and vascular symptoms. Among non familial, non genetic cases, 5 children were affected by Down Syndrome; 4 children had severe renal or cerebral disease. In one 4 year old girl, with a polymorphic VHL variant who presented with arterial hypertension, a small size ganglioneurona was found after a 5yr follow-up. In 21 cases non causes could be identified. They were mostly male (n18); presented at adolescent age with advanced puberal status (n17); many were symptomatic (6). Only one 9 year old girl was diagnosed with polycytemia vera (JAK2V617F positive). Treatment varied according to physician decisions and presence of vascular symptoms, 6 children received ASA and 11 were phlebotomised. In two older patients severe vascular complications were observed (arterial thrombosis), even with Htc<45%.

Summary/Conclusions: This series shows the heterogeneity of Erythrocytosis as found in pediatrics. Extensive clinical and genetic analysis are required but still a large number of cases lack clear definitions. The usefulness of antiaggregation and phlebotomy is not proved. P716

NEUROLOGIC INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS

T. Pincze1, A. Alajdji2,4, H. Fernandes3, H. Ducco Le Pontel1, B. Neven6,7, G. Leverger1, T. Leblanc8, G. Miche9, M. Pasquet10, O. Hermine11, A. Mathian12, H. Záphi2, M. Hamidou14, J-M. Durand15, Y. Perel3,4, F. Rieux-Laucat7, J. Landman-Parker1

1Department of Onco-Hematology, APHP - Hôpital Trousseau, Paris, 2Department of Pediatric Hematology, 3Centre of Référence National des Cytopénies Autoimmunes de l’Enfant (CERECANE), 4CIC 1401 - INSERM CICP, University Hospital of Bordeaux, Bordeaux, 5Pediatric Radiology department, APHP - Hôpital Trousseau, 6Pediatric Hematology-Immunology Department, APHP - Hôpital Necker-Enfants Malades, 7Immunogenetics of Pediatric Autoimmune Diseases - INSERM UMR-S1163, Institut Imagine, Université Paris Descartes, 8Department of Haematology, APHP-Hôpital Robert Debré, Paris, 9Department of Pediatric Hematology, University Hospital Timone Enfants, Marseille, 10Department of Pediatric Hematology, University Hospital of Toulouse, Toulouse, 11Department of Hematology, APHP- Hôpital Necker-Enfants Malades, 12Department of Internal Medicine, APHP - Hôpital de la Pitié-Salpêtrière, Paris. 13Clinique Neurologique, Pôle des Neurosciences et de l’Appareil Locomoteur, Université de Lille, Lille, 14Department of Internal Medicine, University Hospital of Nantes, Nantes, 15Department of Internal Medicine, University Hospital Timone, Marseille, France.

Background: Neurological involvement is poorly described in autoimmune cytopenias (AIC), containing immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES). This association suggests an underlying primary immunodeficiency (PID).

Aims: To describe neurological involvement observed in autoimmune cytopenias, evolution under treatment and PID profiles in these patients.

Methods: OBS/CERECANE is a French nationwide prospective cohort including children with a AIC since 2004. Patients with a neurological involvement were analyzed excluding neurological symptoms related to a traumatism or isolated febrile seizures. Clinical, radiological and biological data were collected from primary centers. Centralized radiological review was performed. Genetic analyses were performed by Sanger gene sequencing or gene-panel based next generation sequencing.

Results: On October 2016, among the 1,167 patients of the cohort (371 AIHA, 615 ITP, 181 ES), a significant neurological involvement was observed in 8 patients from 7 centers. With a median (range) follow-up of 12 years (6-26.5), 7 children had ES (including autoimmune neutropenia in 5) and 1 child had isolated AIHA. Median age at AIC diagnosis was 11.5 years (6.2-15.8). At the last follow-up point, AIC were in partial or complete remission for all patients. Neurological symptoms appeared with a mean delay of 6 years (2.5-18) after AIC onset. The symptomatology was: seizures (n=4), cranial nerve palsies (n=2), Brown-Sequard syndrome (n=2) and/or sensory neuropathy (n=1). No infectious pathogens were identified. MRI showed multiple (n=6) or unique (n=2) inflammatory lesions with hypertense T2 signal in all patients, gadolinium-enhancing lesions in 7 and perilesional edema in 5. Five patients had a total of 8 biopsies, which confirmed the inflammatory process with macrophagic (n=3) or lymphoplasmocytoid (n=5) infiltrates. In 4 cases, a lymphocytic meningitis was associated. Non-neurological organ involvement was present in all patients, mainly pulmonary nodules (n=6) and lymphoproliferation (n=4). All patients had an abnormal immunophenotype, with T-cell (n=7) or B-cell (n=3) deficit and/or hypogammaglobulinemia was present in 7 of the 8 cases. Pathogenic mutation had been found in 5 cases in autoimmunity transcripts (n=2), or immunosuppressive treatment (n=3, Ciclosporin, Mycophenolate Mofetil and Methotrexate), improving symptomatology and MRI for all. Five patients relapsed and 3 patients had an asymptomatic radiological progression. At the last follow up point, all patients had neurological sequel and 7 persisting radiological abnormalities. Four out of 6 patients analyzed had a PID: 22q11.2 (n=1), heterogeneous CTLA mutation (n=2) or homozygous LRBA mutation (n=1).

Summary/Conclusions: Neurological involvement is rare and severe late event in the course of childhood ES, or exceptionally AIHA, that may reveal various underlying PID. Complete imaging and pathology examination highlight a causative immune dysregulation and could guide specific therapeutic strategies. P717

AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY


1Pediatric Haematology and Oncology Unit, Oncology Department, A.R.N.A.S. Ospedali Civici, Di Cristina e Benfratelli, 2Department of Sciences for Health Promotion, University of Palermo, Palermo, 3Department of Pediatric and Public Health Sciences University of Torino, Torino, 4Clinical and Experimental Hematology Unit, G. Gaslini Children’s Hospital, Genova, 5Flow Cytometry Service, Laboratory of Clinical Chemistry and Microbiology, IRCCS ‘Ca’ Grand’A’ Foundation, Maggiore Hospital Policlinico, Milano, 6Department of Pediatric Onco-Hematology, University Hospital Palermo, 7Pediatric Hematology and Oncology Unit, Department of Clinical and Experimental Medicine, University
of Catania. Catania, 8 O. San Gerardo, Fondazione MBMM, Clinica Pediatrica, Università di Milano - Bicocca, Monza, 9Università Tor Vergata, Immunologia Pediatrica, Roma.

Background: The most frequent Autoimmune Neutropenia (AIN) in childhood is the primary type (p-AIN), whereas in adults AIN is mostly represented by secondary neutropenias, which can be associated to infection, drug administration, immunodeficiency, neoplasms, bone marrow transplantation or other autoimmune disorders.

Aims: To describe clinic and laboratory findings in children affected by AIN secondary to other autoimmune diseases (s-AIN).

Methods: This registry study analyzes 26 patients affected by s-AIN enrolled in the Italian neutropenia registry of A.I.E.O.P. (Associazione Italiana di Oncoematologia Pediatrica) over a 15-year time-span: this cohort, the largest ever described, was compared to 263 patients affected by p-AIN enrolled in the Registry in the same period.

Results: Specific characteristics of s-AIN patients are presented in Figure 1. The prevalence of former preterm babies among p-AIN (and not s-AIN) patients was significantly higher than in a cohort of 487 consecutively hospitalized children (p<0.0001). The median age of onset of AIN was 0.77 year and 10.07 year in p-AIN and s-AIN respectively (p=1.105e-12). The prevalence of selected IgA deficiency was 3% in p-AIN and 13.6% in s-AIN children: both prevalences were significantly higher than that (0.21%) of a group of 470 controls (p=0.00009 in p-AIN and p=7.239e-12 in s-AIN). Median value of neutrophils was lower in p-AIN (0.45 x 10^9/L) than in s-AIN 0.63 x 10^9/L (p=0.03); median value of lymphocytes was significantly reduced (p=6.29e-11) in s-AIN (1.58 x 10^9/L) vs p-AIN (4.36 x 10^9/L) group. Leucopenia (p=1.80e-07) and severe infections (p=0.0001) occurred more frequently in s-AIN; monocytosis (p=0.039) and spontaneous remission (p=3.21e-11) in p-AIN. GCSF was used in 6.9% of the population.

Summary/Conclusions: p-AIN is in the vast majority of cases a benign and self-limiting disorder typically occurring under 2-3 years old whereas s-AIN is a more severe disease, usually appearing after the first 5 years of life, usually associated to lymphocytopenia and with a highly frequent tendency to become chronic.

Table 1.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age of Onset</th>
<th>Bone Marrow</th>
<th>White Count N</th>
<th>Anemia</th>
<th>Neutropenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1.5</td>
<td>Yes</td>
<td>10.89</td>
<td>Phagocytic macrophages, Lymphopenia</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>12</td>
<td>Yes</td>
<td>6.07</td>
<td>Lymphopenia, Lymphadenopatia</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7.07</td>
<td>No</td>
<td>14.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>14.5</td>
<td>No</td>
<td>11.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9.0</td>
<td>No</td>
<td>14.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.5</td>
<td>No</td>
<td>6.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.5</td>
<td>No</td>
<td>6.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.5</td>
<td>No</td>
<td>6.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.5</td>
<td>No</td>
<td>6.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.5</td>
<td>No</td>
<td>6.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.5</td>
<td>No</td>
<td>6.07</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical manifestations of hemolysis significantly regressed during eculizumab treatment: normalization of LDH was registered in 76.5% patients. Without eculizumab LDH level increased in all pregnant patients. No maternal death and thrombotic events have been observed. 42.9% of patients required a dose adjustment due to breakthrough hemolysis (a dose increase and/or more frequent use of eculizumab). Pregnancy complications were less frequent with eculizumab: abortion rate 35.3% vs 85.7%, fetal growth retardation syndrome 7.1% vs 21.4%, preeclampsia 5.9% vs 14.3%. Transfusion rate was higher without eculizumab (86.7% vs 41.2%). Pregnancies resulted in the birth in 100% patients exposed eculizumab and 42.9% on supportive treatment. Mean birth weight 2560 g (450-3550). Most of newborns (87.5%) are healthy, 83.3% of them received breastfeeding without complications both on eculizumab and without it.

Summary/Conclusions: We can conclude that pregnancy outcomes in PNH patients on eculizumab treatment and retrospective data of pregnancies on symptomatic therapy only. Since 1999 we have analyzed 32 pregnancies in PNH patients. 17 patients (group 1) from 2013 exposed to eculizumab during pregnancy with antiocoagulants. Other 15 women (group 2) received only symptomatic therapy. The median of PNH granulocyte clone at that time was 74.7% (23-99). PNH diagnosed before the pregnancy in all cases. 64.3% of them had previously received immunosuppressive treatment of aplastic anemia. 18.7% patients registered venous thromboses before conception. 92.9% of patients had been using eculizumab for at least 1 year. 71% patients had been using eculizumab prior to becoming pregnant, mean duration of therapy was 21 months (4-44). Antiocoagulation with low molecular weight heparin was used in 85.7% pregnancies.

Results: Clinical manifestations of hemolysis significantly regressed during eculizumab treatment: normalization of LDH was registered in 76.5% patients. Without eculizumab LDH level increased in all pregnant patients. No maternal death and thrombotic events have been observed. 42.9% of patients required a dose adjustment due to breakthrough hemolysis (a dose increase and/or more frequent use of eculizumab). Pregnancy complications were less frequent with eculizumab: abortion rate 35.3% vs 85.7%, fetal growth retardation syndrome 7.1% vs 21.4%, preeclampsia 5.9% vs 14.3%. Transfusion rate was higher without eculizumab (86.7% vs 41.2%). Pregnancies resulted in the birth in 100% patients exposed eculizumab and 42.9% on supportive treatment. Mean birth weight 2560 g (450-3550). Most of newborns (87.5%) are healthy, 83.3% of them received breastfeeding without complications both on eculizumab and without it.

Summary/Conclusions: We can conclude that pregnancy outcomes in PNH patients on eculizumab treatment and retrospective data of pregnancies on symptomatic therapy only. Our data demonstrate the possibility of safe therapy with eculizumab in pregnant women. Pregnancy does not worsen the prognosis of PNH in the case of targeted and adequate supportive therapy. There is no difference in health between infants born by mothers with PNH and the newborns from general population.
**Platelet disorders: Clinical**

**P719**

**LONG-TERM RESPONSE TO ORAL ELTROMBOPAG IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT**

E. Lukina,1,2, N. Watman,3 M. Dragosky,3 H. Lau,4 E. Avila Arreguin,5 H. Rosenbaum4, Y. Wu,7 S. Gaemers2, M.J. Peterschmitt2 1National Research Center for Hematology, Moscow, Russian Federation, 2Hospital Ramos Mejia, 3IMA-Research, Buenos Aires, Argentina, 4New York University School of Medicine, New York, United States, 5Instituto Mexicano del Seguro Social Hospital de Especialidades, Col. La Raza, Mexico, 6Rambam Medical Center, Haifa, Israel, 7Sanofi Genzyme, Cambridge, United States

**Background:** In Gaucher disease type 1 (GD1), deficient lysosomal acid β-glucosidase activity leads to accumulation of glucosylceramide, primarily in macrophages (Gaucher cells), which deposit in the spleen, liver, and bone marrow, leading to thrombocytopenia, anemia, hepatosplenomegaly, and skeletal disease. Hematologists often identify and manage the disease. Intravenous enzyme replacement therapy (ERT) with recombinant β-glucosidase has been the mainstay of therapy for GD1. Eltrombopag is an oral subtype reduction agonist that has shown to increase platelet production. It is approved for the management of patients with chronic ITP (aged ≥1 year) who are refractory to other treatments (eg, corticosteroids, immunoglobulins). The recommended eltrombopag dose in patients with chronic ITP is 25mg once daily, OD (East Asians, 12.5mg OD or 25mg every other day) in adults and pediatrics aged 6-17 years at initiation, followed by dose adjustment to a maximum of 75mg OD based on platelet counts. REVIEU study was conducted in accordance with risk management plan in five European Union (EU) countries to document eltrombopag utilization patterns in real-world practice. Here, we report the eltrombopag-related data on the subset of adult patients (aged ≥18 years) with ITP as primary diagnosis.

**Aims:** To evaluate the real-world data to determine drug utilization patterns among adult patients with ITP receiving eltrombopag within five EU countries.

**Methods:** REVIEU study was a multinational, multicenter, retrospective, medical chart review in patients with a documented past treatment with eltrombopag between the period immediately after first approval/launch in May 2010 and September 2014 (ie, dispensed at least once by the pharmacy and patient received at least one dose) for whatever reason. Patients who participated or were participating in a randomized eltrombopag clinical trial were excluded.

**Results:** Overall, 287 adult patients with ITP (chronic [≥12 months], 75.3%; persistent [3-12 months], 10.8%; acute [≤3 months], 13.6%; unknown [n=1]) were included, majority in Spain (n=128) followed by Italy (n=67), Greece (n=56), France (n=29), and Germany (n=27). Ertrombopag was the first treatment with no prior ITP therapies in 12 (4.2%) [acute, 10.3%; persistent, 6.5%; chronic, 2.8%] patients. A total of 99 (34.6%) patients received one prior therapy (corticosteroids, 79 [27.6%]; 128 (44.8%) patients received two prior therapies (corticosteroids+immunoglobulins, 114 [39.3%]). 72 patients received three prior therapies (corticosteroids, immunoglobulins, and splenectomy). In total, the majority of patients received at least one prescription of corticosteroids (252, 88.1%) followed by immunoglobulins (180, 62.9%), and splenectomy (64, 22.4%) prior to eltrombopag initiation. Patients received an average daily dose of eltrombopag 45.6mg (chronic ITP, 44.6mg; persistent ITP, 43.1mg; acute ITP, 53.0mg) during the study. Overall, dose changes were reported in 749 adult ITP prescriptions (down-titration, 53.7%; up-titration, 43.7%; no change in dose, 2.7%). 49.1% of dose changes were reported during the first 6 months of treatment (35% in first 3 months). The main reasons for dose change included: disease improvement (30.4%), no treatment response (26.8%) and others (27.1%). Disease improvement accounted for down-titration in 51.2% (206/402) and up-titration in 4.6% (15/327), and no treatment response for up-titration in 54.4% (178/327) and down-titration in 5.0% (20/402) of adult patients with ITP. Ertrombopag is also prescribed in 24.4% of adult patients with acute and persistent ITP. The starting dose followed the summary of product characteristics (SmPC) recommendations in the majority of cases and dose modifications were generally according to platelet counts. Data from REVIEU study have shown that eltrombopag use in the real world setting is largely consistent with the EU label and is considered part of ITP medical therapies.

**Summary/Conclusions:** The majority of adult patients with ITP (75.3%) were diagnosed with chronic ITP, and were treated with eltrombopag as second-line or greater therapy after corticosteroids and immunoglobulins, in line with the approved indication. Ertrombopag was also prescribed in 24.4% of adult patients with acute and persistent ITP. The starting dose followed the summary of product characteristics (SmPC) recommendations in the majority of cases and dose modifications were generally according to platelet counts. Data from REVIEU study have shown that eltrombopag use in the real world setting is largely consistent with the EU label and is considered part of ITP medical therapies.

**Table 1.**

| Table 1. Proportion of patients with platelet counts by ITP disease phase, and by eltrombopag dose |
|----------------------------------|----------------------------------|
| **ITP disease phase** | **Eltrombopag dose** |
| Chronic ITP | Persistent ITP |
| 1.0-45mg/OD | 1.0-45mg/OD |
| 46-90mg/OD | 46-90mg/OD |
| ≥90mg/OD | ≥90mg/OD |

**P720**

**REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP) IN SELECTED COUNTRIES IN THE EUROPEAN UNION: STUDY**

E.O. Gutiérrez,1,2 A. Salama,1 J-F. Viallard2, R.G. Delgado4, M.E. Mingol-Castellano5, E. Quebe-Fehler2, O.A. Ozelim6, A. Allepuz7, T.J. González-López 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Hôpital Haut Lévêque Centre Hospitalier de Bordeaux, Bordeaux, France, 4Hospital Clinico Universitario Virgen de la Victoria Campus Universitario de Teatinos s/n, 5Hospital Regional Universitario de Málaga Avenida Carlos Haya s/n, 6Malaga, Spain, 7Novartis Pharma AG, Basel, Switzerland, 8Hospital Universitario de Burgos Avda. Islas Baleares s/n, Burgos, Spain

**Background:** Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia, with platelet counts <100x10⁹/L. Ertrombopag is an oral small-molecule nonpeptide thrombopoietin-receptor agonist that has shown to increase platelet production. It is approved for the management of patients with chronic ITP (aged ≥1 year) who are refractory to other treatments (eg, corticosteroids, immunoglobulins). The recommended eltrombopag dose in patients with chronic ITP is 25mg once daily, OD (East Asians, 12.5mg OD or 25mg every other day) in pediatrics aged 1-5 years, and 50mg OD (East Asians, 25mg OD) in adults and pediatrics aged 6-17 years at initiation, followed by dose adjustment to a maximum of 75mg OD based on platelet counts. REVIEU study was conducted in accordance with risk management plan in five European Union (EU) countries to document eltrombopag utilization patterns in real-world practice. Here, we report the eltrombopag-related data on the subset of adult patients (aged ≥18 years) with ITP as primary diagnosis.

**Aims:** To evaluate the real-world data to determine drug utilization patterns among adult patients with ITP receiving eltrombopag within five EU countries.

**Methods:** REVIEU study was a multinational, multicenter, retrospective, medical chart review in patients with a documented past treatment with eltrombopag between the period immediately after first approval/launch in May 2010 and September 2014 (ie, dispensed at least once by the pharmacy and patient received at least one dose) for whatever reason. Patients who participated or were participating in a randomized eltrombopag clinical trial were excluded.

**Results:** After 8 years of treatment with eltrombopag, clinically meaningful improvements in hematologic, visceral, biomarker, and bone parameters continued or were maintained among patients in this Phase 2 trial. No new safety concerns emerged.

**Summary/Conclusions:** After 8 years of treatment with eltrombopag, clinically meaningful improvements in hematologic, visceral, biomarker, and bone parameters continued or were maintained among patients in this Phase 2 trial. No new safety concerns emerged.
Results: of mean fluorescence intensity (MFI) compared to that of a control.

modified antigen capture ELISA test (MACE). FC results are expressed as ratio

Methods: We performed a prospective study in 8 patients with primary ITP not responding to standard therapies (corticosteroids, IVIG and/or splenectomy) as well as in 8 patients with non-refractory ITP (control group).

Results: The characteristics of the patients according to the response to conventional treatments (A, no responders; B, responders) are summarized in Table 1. Non responders exhibited lower platelet counts (p=0.006), higher expression of GPIbα (p=0.049) and loss of platelet sialic acids (p=0.005). Additionally, those who did not respond not only to traditional therapies (corticosteroids, IVIG and splenectomy) but also to thrombopoietin receptor agonists (TPO-RA) (n=5) displayed higher platelet size and alpha-granule secretion.

Background: A previous study has suggested a mechanism of Fcγ receptors (FcγR)-independent platelet clearance in immune thrombocytopenia (ITP) (1). Antibody-mediated desialylation may lead to platelet clearance in the liver via hepatic Ashwell–Morell receptors, providing a potential explanation for refractoriness to classical therapies (steroid, IVIG and splenectomy).

Aims: The aim of this study was to analyze the biological features of ITP patients refractory to conventional therapies.

Methods: We performed a prospective study in 8 patients with primary ITP not responding to standard therapies (corticosteroids, IVIG and/or splenectomy) as well as in 8 patients with non-refractory ITP (control group). Mean platelet size, surface expression of platelet glycoprotein (GP) IIb, and the activation marker CD62 were examined by flow cytometry (FC) analysis, as well as desialylation of platelet membrane sugars using fluorescein-conjugated Ricinus Communis Agglutinin I (RCA-1), a lectin that binds to galactose residues underlying sialic acids. Patients’ sera was also incubated with normal human platelets to analyze their ability to induce desialylation in normal platelets. Analysis of desialylation of plasma proteins was performed by Western blot (FXI, FXII) and HPLC (transferrin). The specificity of platelet autoantibodies was assessed by a solid-phase modified antigen capture ELISA test (MACE). FC results are expressed as ratio of mean fluorescence intensity (MFI) compared to that of a control.

Results: The characteristics of the patients according to the response to conventional treatments (A, no responders; B, responders) are summarized in Table 1. Non responders exhibited lower platelet counts (p=0.006), higher expression of GPIbα (p=0.049) and loss of platelet sialic acids (p=0.005). Additionally, those who did not respond not only to traditional therapies (corticosteroids, IVIG and splenectomy) but also to thrombopoietin receptor agonists (TPO-RA) (n=5) displayed higher platelet size and alpha-granule secretion.

Furthermore, TPO-RA refractory patients’ sera desialylated normal platelets, but not plasma proteins. MACE assay revealed that unique positivity for anti-GPⅠbα antibodies was only detected in those patients classified as non-responders to conventional ITP therapies, including TPO-RA.

Table 1.

Table 2.

Summary/Conclusions: This study shows a significant higher platelet desialylation in ITP patients who are non-responders to conventional therapies, particularly if they are also refractory to TPO-RA. According to a previous study (1), these results seem to be associated to platelet activation mediated by anti-platelet specific antibodies.

Reference

P72

SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS

M. Carpenedo1, S. Cantoni2*, M.G. Mazzucconi3, V. De Stefano4, V. Carrai5, M. Ruggeri6, G. Spechia7, N. Vianelli8, F. Pane9, U. Consoli10, F. Zaja11, A. Artoni12, L. Trentin13, F. Ferrara14, W. Barcellini15, D. Caramazza16, E. Ross17, E. Baldacci3, A. Ciminello4, C. Carbone17, R. Cairoli18

Background: ITP is a disorder characterized by thrombocytopenia resulting from both increased immune-mediated platelet clearance and inappropriate thrombopoietin production. TPO-RAs—romiplostim (R) and eltrombopag (E) — offer a new opportunity of treatment with high response rates. However, a small fraction of pts does not respond or loses response — i.e. desired platelet (plt) count achieved but not sustained over time - during long-term follow-up, which can not be resumed even if dosage is increased over time, or experience wide fluctuations in plt counts with either agent. Moreover, adverse events (AE) may necessitate treatment discontinuation. Finally, patient’s preference may be an important issue considering the different route and timing of administrations of the two agents and the alimentary restrictions needed for proper E absorption. Availability of two TPO-RAs for clinical use, with different molecular structure and site of binding within the TPO receptor, has prompted trials of TPO-RA switching with the aim of overcoming treatment limitations of either agent resulting in required overall response rates of approximately 80% in poor responders to 1st TPO-RA.

Aims: To present the results of a multicenter survey on TPO-RA switch policies and outcome.

Methods: Charts of ITP pts receiving TPO-RAs at 17 collaborating Haematology Centers were reviewed. Demographic and clinical data were collected in a dedicated case report form. Pts were grouped and analyzed based on the clinical setting prompting the switch (Table 1). The study was approved by the Hospital Review Board of each participating Center.

Table 1.
PT73
THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY

M.N. Saleh1,*, J.B. Bussel2, R.S. Wong3, B. Meddeb4, A. Salama5, O. Ocak6, S. Atkinson8, E. Quebe-Felah6, A. Kheifi
1Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, 2Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, United States, 3Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, Chinese University of Hong Kong, 4Hôpital Aziza Othmana, Tunis, Tunisia, 5Charité-Universitätsmedizin, Berlin, Germany, 6Novartis Pharma AG, Basel, Switzerland, 7Hôpital Farhat Hached, Sousse, Tunisia

Background: EPAG is an oral thrombopoietin receptor agonist approved for the treatment of previously treated patients (pts; e.g. corticosteroids, immunoglobulins) with cITP aged ≥1 yr. The EXTEND study, a global, open-label, extension study of pts with cITP who received EPAG or placebo in prior EPAG studies, evaluated long-term safety and tolerability of EPAG. In EXTEND, 19 (6.3%) pts receiving EPAG experienced a total of 24 thromboembolic events (TEEs; Table 1). Of these, 10 pts received EPAG as initial therapy (n=10), which is similar to TEE incidence in cITP pts receiving romiplostim (Kuter et al. Br J Haematol 2013;161:41-43) and to one estimate in the general cITP population (Sarpattwari et al. Haematologica 2010;95:1167-75).

Aims: To describe management and outcomes of TEEs occurring during EPAG treatment in the EXTEND study.

Methods: Adult pts with cITP received EPAG starting at 50mg/day, with titration to 25–75mg per day or less as required, based on individual platelet count responses (target range 50–200×10⁹/L). Maintenance dosing continued after minimization of concomitant iTP medication and optimization of EPAG dosing. Pts enrolled on EPAG either for 2 yrs in countries where EPAG was commercially available, or for >2 yrs until EPAG became commercially available. The EXTEND primary objective included detection and documentation of AEs, including investigator-reported TEEs.

Results: 302 pts were enrolled and received ≥1 EPAG dose: 67% female; 38% non-white. Of these, 106 (18.4%) underwent TPO-RA switch. Table 1 summarizes outcome after switch. Overall 69/106 (65%) of pts achieved, regained or maintained response upon switching. Either one TPO-RA switch sequence was equally effective (p=0.882). Outcome was not associated with gender, age at 1st TPO-RA treatment, splenectomy status. However, number of lines of previous treatment and lower response rate were associated (p<0.002); response to 1st line of therapy yielded a 30% increase in the odds of being a non responder; a trend toward lower probability of response was observed in pts with longer lasting disease before 1st TPO-RA administration (p=0.066). Adverse events (AE; 16/106 pts) were generally mild and reversible upon discontinuation of either one TPO-RA. 1 pt who switched with thrombocytopenia (n=5) presented severe (standard anticoagulation) thrombotic events observed which did not recur after switching. AE were characteristic of older pts: each additional year increase in pts age determined a 5% increase in the odds of developing AE.

Summary/Conclusions: Approximately 20% of TPO-RA treated pts were felt by their attending physicians to potentially benefit from a switching strategy. Exposure to the 2nd TPO-RA was more effective in pts who had lost response to 1st TPO-RA (80% responders) compared to those who were non responders to 1st TPO-RA (49% responders, p=0.001). It could be speculated that lack of response to either one of the two available TPO-RA identifies a subgroup of pts who may benefit from a switching strategy. Pts switched for non-efficacy reasons are more likely to maintain a response upon switch (p=0.030). The so far unexplained and unprecedented phenomenon of wide platelet fluctuation appears to be linked to the removal of the spleen, the physiological platelet reservoir organ.
patients with severe bleeding. At the end of follow-up, the estimated 10-year cumulative rate of no remission among patients with severe bleeding was higher than that among patients without severe bleeding (P=0.017, RR=1.608, 95% CI, 1.052-2.456). The estimated 10-year cause-specific mortality related to fatal bleeding in patients with severe bleeding was higher than that in patients without severe bleeding (P=0.001, RR=9.886, 95% CI, 1.806-54.098). The estimated 10-year mortality among ICH patients was higher than among severe (non-ICH) patients (P<0.009, RR=5.543, 95% CI, 1.317-15.668).

Summary/Conclusions: Platelet count <10×109/L, female patients, complication of pulmonary disease, gum or oral mucosal bleeding and epistaxis are significant predictive factors for severe bleeding in the elderly. Severe bleeding in elderly ITP was associated with more failure of response to treatment, increased long-term risk of no remission and mortality related to fatal bleeding.

P725

ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION

Y. Kong1, X.-N. Cao1, X.-H. Zhang1, M.-M. Shi12, Y.-Y. Lai1, Y.-Q. Sun1, Y. Wang1, L.-P. Xu1, Y.-J. Chang1, X.-J. Huang12

1Peking University People’s Hospital, Peking University Institute of Hematology, 2Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

Background: Immune thrombocytopenia (ITP) is generally considered to be an autoimmune disorder characterized by increased peripheral platelet destruction and reduced platelet production. Corticosteroids represent the standard first-line therapy achieving responses in around 50-80% of patients. However, for those corticosteroid-resistant ITP patients, who exhibit either no response (NR) to corticosteroids or corticosteroid-dependent, the pathogenesis remains poorly understood and the management is challenging. Emerging evidence from mouse studies has suggested that the cross-talk between megakaryocytes (MKs) and endothelial progenitor cells (EPCs) in the bone marrow (BM) microenvironment regulates MKs maturation and thrombopoiesis. We recently reported that the impaired BM EPCs, which could be quantitatively and functionally improved by atorvastatin in vitro, induced the occurrence of poor graft function following allo-transplantation (Blood, 2016, 128:2988-2999). However, little is known about the functional role of BM EPCs and how to improve impaired BM EPCs in patients with corticosteroid-resistant ITP.

Aims: To determine whether quantitative and/or functional abnormalities of BM EPCs are involved in the occurrence of corticosteroid-resistant ITP. Moreover, to investigate the effects of atorvastatin and N-Acetyl-L-cysteine (NAC, a ROS scavenger) on the number and function of cultured BM EPCs derived from patients with corticosteroid-resistant ITP and its underlying molecular mechanisms. Finally, to evaluate the efficacy and safety of atorvastatin and NAC to adult patients with corticosteroid-resistant ITP.

Methods: Twenty-three patients with corticosteroid-resistant ITP, 30 patients with newly diagnosed ITP and 17 healthy donors (age 18-55) were enrolled from 2016 to 2017 at Peking University Institute of Hematology. BM EPCs were cultured as previously reported. Atorvastatin and NAC were administrated to the 5-day cultivated BM EPCs in corticosteroid-resistant ITP patients until tested on day 7. The number and function of BM EPCs were evaluated pre- and post-treatment by cell counting, DiI-Ac-LDL and FITC-lectin-UEA-1 double staining, migration, cell proliferation, tube formation, levels of reactive Oxygen Species (ROS) and apoptosis. Proteins expressions for p38, ERK, JNK, Akt were measured by flow cytometry and western blot. Subsequently, a single-center pilot study was performed to evaluate the efficacy and safety of atorvastatin and/or NAC in corticosteroid-resistant ITP patients. The primary end points were complete response (CR), response (R), and overall response (OR). Secondary end points were time to response (TTR) and adverse events.

Results: Human bone marrow EPCs were demonstrated as the spindle shape and the similar expression of CD34, VEGFR2 and CD133 at day 7 of cultivation among all the enrolled three cohorts of subjects. Increased and dysfunctional BM EPCs, which were characterized by impaired proliferation, migration, angiogenesis, and higher levels of ROS and apoptosis, were revealed in corticosteroid-resistant ITP patients compared to those in newly diagnosed ITP. Activation of p-p38 was detected in BM EPCs from corticosteroid-resistant ITP patients. Furthermore, the number and function of BM EPCs derived from corticosteroid-resistant ITP patients were enhanced by atorvastatin or NAC treatment in vitro through down-regulation of the p38 mitogen-activated protein kinase (MAPK) pathway. In the single-center pilot study, a total of 12 corticosteroid-resistant ITP patients were recruited to receive either the combination of atorvastatin and NAC or alone. Adverse events of CR, R and OR were recorded (3/12), 41.7% (5/12) and 66.7% (8/12), respectively. In patients who achieved CR and R, the median (range) TTR was 24 days (7-51 days), with no apparent adverse events.

Summary/Conclusions: The number and the function of BM EPCs were improved by atorvastatin treatment with or without NAC in vitro and in vivo quantitatively and functionally improved BM EPCs derived from corticosteroid-resistant ITP patients through down-regulation of the p38 MAPK pathway. Although the sample size of clinical study is small, with a relatively short follow-up period by now, our data suggest that atorvastatin and NAC are effective and safe in the management of corticosteroid-resistant ITP patients. Therefore, further prospective multicenter randomized clinical trials with larger sample size are needed in the future.

P726

PLATELET DESIALYLATION AND A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL

X. Li1, M.-F. Li2, X.-L. Li3, S.-Y. Geng1, L. Huang4, M. Hou1, L.-Y. Liu2, J. Peng1

1Department of Hematology, Qilu Hospital, Shandong University, Jinan, China, Jinan, 2Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China, 3Infectious Disease Hospital of Yantai, Yantai, China, 4Yantaihan Hospital of Yantai, Yantai, China, Yantai, China

Background: Sepsis is a systemic, deleterious host response to infection leading to severe sepsis, and possibly septic shock as defined by the Surviving Sepsis Campaign guidelines. Thrombocytopenia is a common finding in sepsis. Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis. Desialylation-induced platelet removal could possibly be circumvented by adding sialidase inhibitors during sepsis. Oseltamivir, also known as Tamiflu, is a viral sialidase inhibitor that prevents the release of progeny virions. Several studies suggest the feasibility that oseltamivir can be used for the treatment of infection-associated thrombocytopenia.

Aims: To determine whether thrombocytopenia is associated with increased platelet desialylation in septic patients, and whether oseltamivir is an effective treatment to increase platelet counts in severe sepsis.

Methods: We first performed a prospective, multicenter, observational study that enrolled septic patients with or without thrombocytopenia to determine the association between platelet desialylation and thrombocytopenia in patients with sepsis. Next, we conducted an open-label, randomized controlled trial in which patients who had severe sepsis with thrombocytopenia (platelet counts ≤50×109/L) were randomly assigned to receive antimicrobial therapy alone (control group) or antimicrobial therapy plus oseltamivir (oseltamivir group). The study flowchart is shown in Fig. 1. Both groups received appropriate antimicrobial agents and standard medical support based on the guidelines issued by the Surviving Sepsis Campaign. The oseltamivir group additionally received 5 full days of oseltamivir therapy. The oseltamivir was administered orally or through a feeding tube at a dose of 75mg once every 12 hours. Time from randomization to the administration of oseltamivir was less than 24 hours. The antimicrobial agents were continuously administered until 3 days after the resolution of the physiological abnormalities related to the systemic inflammatory response syndrome (SIRS). The primary outcomes were platelet desialylation level at study entry, and overall platelet response rate within 14 days post-randomization. Secondary outcomes included platelet recovery time, the occurrence of bleeding events, and the amount of platelets transfused within 14 days post-randomization. The percentages of platelets positive for Ricinus communis agglutinin I (RCA-I), Erythrina cristagalli lectin (ECL) or Scurvyce Triticum vulgare lectin (sWGA) analyzed by flow cytometry represented the levels of platelet desialylation. Platelet response was defined as platelet counts returning to or above 100×109/L. Platelet recovery time was calculated as the date of randomization to the administration of oseltamivir or platelet counts were >100×109/L. Written informed consents were obtained from the study participants prior to inclusion in the study.
Results: The platelet desialylation levels increased significantly in the 127 septic patients with thrombocytopenia compared to the 134 patients without thrombocytopenia. A platelet response was achieved in 45 of the 54 patients in the oseltamivir group (83.3%) compared with 34 of the 52 patients in the control group (65.4%; P=0.045). The median platelet recovery time was 5 days (interquartile range 4-6) in the oseltamivir group compared with 7 days (interquartile range 5-10) in the control group (P=0.003). The amount of platelets transfused decreased significantly in the oseltamivir group compared to the control group (P=0.044). The multivariate analysis by Cox proportional hazards models showed that the Sequential Organ Failure Assessment (SOFA) score and platelet recovery time were independent indicators of oseltamivir therapy.

Summary/Conclusions: Thrombocytopenia was associated with increased platelet desialylation in septic patients. The addition of oseltamivir could significantly increase the platelet response rate, shorten platelet recovery time and reduce platelet transfusion. Chinese Clinical Trial Registry, ChiCTR-IPR-16008542.

P727
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOsing OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
J. Bussel1,*, M. Tarantino2, V. Blanchette3, A. Raj4, J. Despotovic5, D. Beam6, J. Roy7, X. Wang8, B. Mehta8, M. Eisen8
1Weill Cornell Medicine, New York, 2The Bleeding and Clotting Disorders Institute, Peoria, United States, 3Hospital for Sick Children, Toronto, Canada, 4Pediatric Blood and Cancer Disorders Clinic, Houston, 5Texas Children’s Hematology Center, Houston, 6Cook Children’s Medical Center, Fort Worth, United States, 7Children’s Health Queensland & Pathology Queensland, Saint Lucia QLD, Australia, 8Amgen Inc., Thousand Oaks, United States

Background: Children with ITP for ≥6 months who completed a romiplostim phase 1/2 or phase 3 parent study could enroll in this open label long term extension study

Aims: To evaluate the safety and efficacy of long-term romiplostim in children with ITP.

Methods: Patients enrolled at 28 sites in the US, Canada, Spain, and Australia. All patients received SC romiplostim once weekly. The initial dose was the final dose from the parent study or 1 µg/kg for patients previously receiving placebo; dose was then adjusted from 1-10 µg/kg to target platelet counts of 50−200×10^9/L. Incidence of adverse events (AEs) was the primary endpoint.

Results: As of 24 Feb 2016, 66 patients entered this study; 65 received romiplostim for up to 6.2 years. At baseline, median (min–max) age was 11 (3–18) years; 56% were female; 61% were white, 14% African American, 14% Hispanic/Latino, 9% Asian, and 3% other; 9.1% had prior splenectomy. Median (min–max) baseline platelet count was 27.5 (2–458)×10^9/L. Median (min–max) treatment duration was 100 (5–321) weeks. Median (min–max) average weekly romiplostim dose was 4.8 (0.1–10.0) µg/kg, which included escalation to a stable dose. After ~week 200 (n ≤8 patients), the median dose was observed to fluctuate. All 65 patients received their doses per protocol >90% of the time; 18 patients missed ≥1 dose due to noncompliance for a total of 41 times. Reasons for discontinuing treatment (n=8), required other therapy (n=4), noncompliance (n=3), administrative decision (n=3), per protocol (n=1), and AE (n=2) (asthenia, headache, dehydration, and vomiting in one patient and anxiety in the other, per investigator, none of the AEs were treatment-related); 43 (65%) patients continued in the study. Fifty-two serious AEs occurred in 17 patients, 3 deemed treatment-related (anemia, epistaxis, and thrombocytopenia). Bleeding AEs occurred in 56 patients; 5 deemed treatment-related (gingival bleeding, petechiae, injection site bruising, injection site hematoma, and epistaxis). No thrombotic events were reported. There were no peripheral blood abnormalities warranting a bone marrow examination. No patients had anti-TPO neutralizing antibodies. From week 2 on, median platelet counts remained >50×10^9/L; platelet counts were >100×10^9/L at most timepoints, despite an observed decrease in the median dose from 4-5 µg/kg to 2-3 µg/kg around week 160 (Figure). Nearly all (94%, 61/65) patients had a platelet response (median platelet counts for a month ≥50×10^9/L). Nine (14%) patients (5 boys and 4 girls, none with prior splenectomy) entered remission (Table), defined here as platelet counts ≥50×10^9/L for 24 weeks with no ITP treatments. Twenty-three (35%) patients received rescue medications.

Summary/Conclusions: Over 6 years of data from this ongoing open-label extension study of romiplostim in children with ITP show that >90% of children achieved a platelet response with romiplostim. The safety profile was overall tolerable, similar to that in past studies. Some children (9/66) with longstanding ITP entered remission after receiving romiplostim.
Quality of life, palliative care, ethics and health economics

PT28
IMPACT OF VENETCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT

W. Wierda1, K. Saji1, J. Pullum2, L. Nae2, R. Kamalakar2, J. Gdovin2, R. Humerrickhouse2, M. Verdugo2
1The University of Texas MD Anderson Cancer Center, Houston, 2AbbVie Inc, North Chicago, United States

Background: The prognosis for patients with CLL after B-Cell Receptor inhibitor (BCR) failure is very poor. Patients with R/R CLL who discontinue and/or progress on BCRi treatment tend to have poor clinical outcomes. Venetoclax (VEN) is an oral BCL-2 inhibitor that has demonstrated deep and durable responses in relapsed/refractory (R/R) CLL patients.

Aims: To assess whether VEN has an impact on health related quality of life (HRQoL) among CLL patients R/R to BCRi treatment and receiving VEN monotherapy.

Methods: The study enrolled patients with CLL who had previously received treatment with ibritumomab and idelalisib, have relapsed on treatment, or experienced progression after discontinuation of either agent. Patients are to receive VEN monotherapy for up to two years, or until discontinuation due to disease progression, unacceptable toxicity, or any other reason. Patient-reported HRQoL measures included the EORTC QLQ-C30 and EORTC QLQ-CLL16, which were assessed at Baseline (BL), Week 24, and every 12 weeks thereafter. Mean change from BL to each assessment through Week 48 are reported here. Clinical relevance was based on minimum important difference (MID) of values from BL to each assessment. A change of 5-10 points is considered a “small” change on the EORTC-QLQ-C30. The lower bound of 5 points was used for MID acceptance on both measures.

Results: Clinical improvements from BL were observed early and were sustained through week 48 in VEN treated patients in the EORTC-QLQ-C30 global health status and the role, social, and emotional functioning scales. Furthermore, early and sustained improvements in fatigue through week 48 were seen in both EORTC-QLQ-C30 and EORTC-QLQ-CLL16 (Table 1).

Table 1.

Summary/Conclusions: This interim analysis provides preliminary evidence that demonstrates CLL patients R/R to BCR inhibitors receiving VEN monotherapy experienced improvement in several key aspects of functioning and HRQoL. These results may be important to consider when making therapeutic choices in R/R CLL following relapse or progression on BCRi inhibitors.

PT29
THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE

S. Brait1, J. Cortelezz1, C. Cutica1, E. Orlandi1, E. Chiara1, E. Bucei1, A. Iurlo1, G. Pravettoni1
1Department of Oncology and Haematology, University of Milan, 2Hematology-BMT Unit, IRCCS Ca’ Granda Policlinic Foundation Hospital, Milan, 3Department of Oncology Haematology, IRCCS Policlinic San Matteo Foundation Hospital, Pavia, Italy

Background: Treatment-free remission (TFR) is an emerging goal for CML patients (pts) that reach a sustained deep molecular response (DMR), as it can reduce the risk of long-term toxicities that impair quality of life, and mitigate the costs associated with long-term TKI therapy. Therapy discontinuation may represent a great challenge for patients and different factors (not only clinical) may play a role in medical decision, such as psychological and emotional variables. In this respect, it is essential to consider pts’ concerns and preferences regarding the discontinuation option.

Aims: This study was aimed at investigating psychological (emotional and cognitive) and clinical factors related with the attitude to opt for discontinuation of therapy in CML pts.

Methods: This is an observational, prospective, no-drug related study conducted in 3 Italian centers with large experience in CML treatment. A detailed battery of questionnaires focusing on health behaviour, risk taking and personality was administered.

Results: One hundred and twenty pts were enrolled (56% males; mean age=50, SD=1.2). Median duration of the disease was 8 years (range 1-39y). 62/120 pts were receiving Imatinib first line. The idea of stopping TKI is appealing in 91.5% of pts (31% of them expressed a high probability of response upon restarting a TKI). Pts are more likely to stop their TKI if the risk of relapse is no more than 30% (% Mean=33.62; SD=33.46). Main worries related with the choice to stop TKI are fear of possible disease recurrence, (60.5%), fear of drug resistance if the disease relapses (44.5%) and fear to disappoint family or friends (28.9%). Older pts (>40 years) are more concerned about relapse and subsequent lack of response than younger (x²=9.65, p=0.02). Finally, pts with higher passive risk taking attitude (who are more redundant and undecided in everyday-life decisions) seemed to be more afraid to lose disease control in CML. ANOVA showed a significant difference between the two groups (F=5.54; p=0.02).

Summary/Conclusions: Many studies have confirmed the feasibility and safety of stopping TKI therapy in selected pts, with the potential to drastically modify clinical practice in CML management in the next future. TKI discontinuation appears appealing and challenging at the same time for many CML pts. This study, for the first time, analyses how and when pts would consider this option including implications for health care providers in clinical practice, using both a clinical and psycho-cognitive perspective.

PT30
BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES

F. Rencz1,2,*, L. Gulácsi1,2, P. Baji1,2, M. Pénét1,2, V. Brodszky1,2
1Department of Health Economics, Corvinus University of Budapest, 2HTA Consulting Budapest, Budapest, Hungary

Background: In December 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization to biosimilar rituximab (CT-P10) in all indications of the reference product, including chronic lymphocytic leukaemia (CLL). Compared to the originator rituximab, CT-P10 is expected to result in a significant price reduction, which may encourage offering a more affordable treatment option for CLL patients across Europe.

Aims: To assess the budget impact of the introduction of CT-P10 into the treatment of CLL in the 28 EU member states. Moreover, we provide an estimation for the number of additional CLL patients that can be treated with CT-P10 from the cost savings.

Methods: A budget impact analysis was performed to evaluate the one-year cost outcomes under two scenarios with and without the availability of CT-P10. The budget impact was calculated as the difference in costs between the two scenarios. For the major European markets, five-year cost savings were also estimated. Market uptake of CT-P10 was assumed to be 30%. A third party payer’s perspective was adopted, and only drug costs were considered. Based on expert opinion, it was assumed that when CT-P10 is entering the market it will be at 50-70% of the official list price of originator rituximab in each country. Costs of administration and monitoring were not incorporated in the calculations, as it is not expected that these are equal for the reference product and CT-P10. The initial number of patients treated with rituximab was estimated from IMS sales data on total annual consumption of originator rituximab in 2016. Other model parameters such as patients’ average body surface area and treatment rate of rituximab among CLL patients, were derived from the published literature. One-way sensitivity analysis was undertaken to test the robustness of model assumptions.

Results: Over a one year time horizon, the cumulative budget impact of adopting CT-P10 is estimated to be €17.80 million in the 28 EU member states (30% discount in drug prices compared to the originator rituximab). Countries responsible for the majority of the cost savings are Germany (€4.06 million), Italy (€3.15 million), France (€2.41 million), Spain (€1.50 million), the Netherlands (€0.90 million), Finland (€0.49 million) and Sweden (€0.43 million). If the cost savings were used to treat additional CLL patients with CT-P10, a total of 1,624 patients could be treated annually throughout Europe. The potential cost savings are in a direct correlation with the price and market uptake of CT-P10. Applying a 40% and 50% discount in drug prices compared to the originator rituximab, cost savings are projected to €23.73 and €29.67 million, from which further
AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION—IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS

Aims: To explore patient needs during stable remission from MM and evaluate acceptability of alternative monitoring methods. Methods: Patients with stable MM in a treatment-free interval selected from outpatient clinics at a tertiary centre completed a survey which explored the acceptability of various methods of remote monitoring. Subsequently semi-structured interviews were conducted by an independent researcher to investigate factors influencing this preference. Interviews were carried out until saturation of themes, transcribed verbatim and thematic analysis was performed using open coding by a doctor, physiotherapist and psychologist.

Results: 78 patients were surveyed; the most acceptable alternative was a telephone clinic (with doctor 77%, nurse 69%). 19 interviews were conducted exploring suitability of a nurse-led telephone consultation (TC) replacing clinic face to face (FTF) consultations with a doctor. Median age was 61 years (range 46-76), and 9 were male. 18 patients were in 1st remission; 16 had most recently received high dose therapy and autograft, 3 had post autograft consolidation. The centre was not the local hospital for 18 patients interviewed. The majority were accepting of TC as an alternative to FTF clinics due to the burden of travel, associated cost and clinic waiting times. These affected patients’ physical and psychological well-being, with TC perceived as less burdensome. Patients acknowledged reduced needs during remission compared to treatment phase and felt TC would benefit redistribution of consultant time for patients on active therapy. Some suggested this service change would represent a step forward for healthcare resourcing rather than them personally. Interpretation of blood results by clinicians was regarded as central to monitoring disease, and for some who were unaware of clinical symptoms, the only way a relapse would be detected. General preference was for bloods to be done locally, leading to confidence in monitoring. Results for patients using TC were understood how to monitor their own MM, hence valued the knowledge of their medical team. Doctors were perceived to have more expertise than nurses and this influenced preferences regarding who undertook TC. As a result, patients sought reassurance they could see a doctor if they had any concerns after TC with a nurse. Patients valued contacts under the centre where they were treated due to prior positive experience and the importance of being seen at a tertiary centre renowned for its expertise in MM. This influenced acceptability of TC as long as they remained under the centre’s care with preference for continuity of staff involved. Whilst TC was acceptable for patients in remission, some were concerned about how relapse would be managed and expressed preference for FTF when being told they had relapsed.

Summary/Conclusions: Nurse led TCs are an acceptable alternative to FTF consultations for monitoring patients in remission from MM. Design of healthcare systems incorporating TCs need to have robust systems for accessing blood test results, for managing relapse, ready access to doctors and reassurance about the competence and knowledge of practitioners involved.

THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESSMENT IN ONCOHEMATOLOGIC PATIENTS

Aims: To evaluate the utility of the comprehensive geriatric assessment (CGA) in patients with hematologic malignancies on the initial therapeutic decision making. Determine frailty prevalence and short- mid term prognostic impact using a screening tool for its identification.

Methods: Patients diagnosed with hematologic malignancies were followed prospectively. Patients age 70 and over were referred to hematological nursing consultation. Geriatric screening tool was used to identify frailty risk. Patients with hematologic malignancies on the initial therapeutic decision making.

Results: We have included 32 patients in the last 9 months, with an average age of 81 (71-89) years. 56% of the sample was female. The main hematologic malignancy referred was high grade non-Hodgkin lymphoma (59%). At the time of the evaluation, 87% had CD-19, 7% had CD-34, and 5% had MIB1, score < 30. The social, functional, and mental profiles are shown in Table 1. According to polypathy and comorbidities, data are shown in Table 2. The distribution of patients by frailty scales, are described in Table 3. 56% of the patients were classified as robust, 35% fragile and the rest with poor prognosis. After the evaluation we recommended nutritional measures, control of the polypathy and physical exercise. Of the included patients, 22 had been reviewed at 6 months staying alive 95%. 24% required hospitalization after the initial assessment and 13% went to the emergency department.
RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY

A. Nikkilä¹,², J. Raitanen³, O. Lohi⁴, A. Auvinen²,4,5
¹Faculty of Medicine and Biosciences, ²Faculty of Social Sciences, University of Tampere, ³UKK Institute for Health Promotion, ⁴Tampere Center for Child Health Research, Tampere University Hospital and University of Tampere, Tampere, ⁵STUK - Radiation and Nuclear Safety Authority, Helsinki, Finland

Background: Pediatric CT imaging offers significant benefits in clinical practice. However, children are more sensitive to carcinogenic effects of ionizing radiation than adults and red bone marrow is especially radiosensitive tissue type. The risk estimates of low doses of ionizing radiation are mainly based on extrapolated results of studies done with substantially higher radiation doses and there exists a need to assess the risks of low doses with a more direct approach.

Aims: We assessed the leukemia risk in children after computed tomographic imaging studies with high-quality Finnish register data and data from hospital databases.

Methods: We used nationwide, register-based case-control study design to investigate the role of CT imaging in the etiology of childhood leukemia. We identified all childhood (0-15 years) leukemia cases from 1990 to 2011 (N=1093) in Finland and randomly selected thrice as many controls (N=3279) from the Population Registry, individually matched by gender and year of birth. The cases were 81% (N=885) acute lymphoblastic leukemias and 13% (N=142) acute myeloid leukemias. We collected data on all pediatric CT scans from 1975–2011 from the databases of all five university hospitals in Finland and randomly selected thrice as many controls (N=3279) from the Population Registry, individually matched by gender and year of birth. The aim of this analysis was to compare HRU with ixazomib-Rd vs placebo-Rd, incorporating all non-protocol additional medical care encounters such as inpatient and outpatient admissions and their duration, as well as time lost from work or other activities by pts and their caregivers.

Results: Overall, 13 cases (1.2%) and nine controls (0.3%) had a record indicating at least one CT examination. Of the relevant CT scans, 50% were performed on the head region and 41.3% the thorax region. The median age at CT scan was 8.12 years (7.46 years for cases and 10.9 years for controls). In a conditional logistic regression analysis adjusted for birth weight, a significantly increased leukemia risk (OR=4.75, 95% CI 1.55, 14.5) was found for any CT examination (one or more) at least two years prior to leukemia diagnosis. When comparing one CT examination and two or more CT examinations with no examinations the ORs were respectively 2.78 (95% CI 0.73, 10.5) and 16.9 (95% CI 1.81, 150).

Summary/Conclusions: Our preliminary analyses we observed a substantial increase in childhood leukemia risk related to pediatric CT scans. The risk estimates are materially higher than in two earlier studies and need to be interpreted with caution. We will seek to estimate radiation doses to the red bone marrow, based on limited data available on CT examinations (body part and examination type).

References
**Results:** Overall, 152 (42%) pts on the ixazomib-Rd arm had 316 hospitalization events, compared to 156 (43%) pts (335 events) in the placebo-Rd arm. Exposure-adjusted hospitalization rates (0.530 and 0.564 per pt-year [ppy], respectively) and mean length of stay (10 and 18.8 days) were similar between the ixazomib-Rd and placebo-Rd arms (Table 1). Rates of outpatient visits were also similar between arms; 217 (60%) pts on the ixazomib-Rd arm had 197 (median 4) compared to 198 (55%) pts and 194 visits (median 5) on the placebo-Rd arm. Exposure-adjusted outpatient visit rates were 3.305 and 3.355 ppy, respectively (Table 1). On the ixazomib-Rd arm, 46 (13%) pts missed a total of 527 (median 7) days of work or other activity, compared to 51 (14%) pts and 580 (median 8) days on the placebo-Rd arm. Similarly, 16 (4%) pts caregivers missed 128 (median 5) days of work or other activity on the ixazomib-Rd arm, compared to 24 (7%) pts’ caregivers and 110 (median 4) days on the placebo-Rd arm.

**Summary/Conclusions:** The ixazomib-Rd triplet regimen did not add to the HRU burden compared to the placebo-Rd doublet, while prolonging PFS. This result was consistent with the limited additional toxicity burden and the reported lack of an adverse impact on QoL with ixazomib-Rd. In contrast to findings reported for injected agents (Armoiry et al, J Clin Pharm Ther 2011; Gaultney et al, J Clin Pharm Ther 2013; Baz et al, Support Care Cancer 2015), this all-oral triplet regimen did not increase time lost from work, caregiver burden, or the number of inpatient/outpatient visits.

**P736**

**MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES**

V. Tomarchio1, M.A. Surano2, M.A. Tafuro1,2, M. Becilli3, C. Sarlo3, P. Berti3, G. Tafuro1, G. Boletti4, D. Iolele5, G. Tassili6, G. Annibali1

1UOC Ematologia Trapianto di Cellule Staminali, University Campus BioMedico, rome, 2Area di Infermieristica, 3UOC Ematologia Trapianto di Cellule Staminali, Università Campus BioMedico, 4Area di Controllo e Gestione, 5Area dei Sistemi Informatici, 6Area Farmacia, Policlinico Universitario Campus Bio medico, Roma, Italy

**Background:** Lymphoproliferative disorders (LD) represent a major burden of hematologic malignancies generally treated and followed in Hematological Day Hospital (HDH). Rituximab (R-Cell Lymphoma, DLBCL and Follicular Lymphoma (FL) are among the most frequent LD treated with chemo-immunotherapies. These therapies are time consuming and costing and may affect the Quality of Life (QoL) of these patients because of their prolonged stay in DH.

**Aims:** To evaluate, in patients with DLBCL and FL, the economic and social impact of subcutaneous rituximab administration compared to the intravenous formulation. During one week we evaluate in 40 patients the time of intravenous and subcutaneous administration, the type of treatment (rituximab combined or subsequent to chemotherapy, or in monotherapy) and the time required by the pharmacy to prepare each formulation. Moreover, we collected and analyzed data about patients’ time expenditure in DH until discharge. Collected data have been categorized as follows: time and human resource employment; drug waste; safety for patient. In order to measure the interference with daily activities. Overall, 98% of interviewed patients preferred subcutaneous formulation, because less scared by this formulation and because of the lower waste of time. Among the 40 interviewed caregivers 68% were workers. They considered advantageous the subcutaneous formulation because of the lower waste of time (90%) and the reduced number of workdays lost (80% of workers). With the subcutaneous formulation, we observed a reduction of 38% (equal to 17.5 hours) of time spent at hospital per cycle. However, nurses needed 23% lesser time to handle a patient per cycle (from 144 minutes to 111 minutes), earning 21 minutes/patient per cycle. Furthermore, pharmacy spent 53% lesser time for drug preparation (from 40 minutes to 19 minutes), earning 21 minutes/patient per cycle. Finally, we observed a reduction of clinical risk. As for the cost, using subcutaneous formulation, we saved €254.25 for each dose, with a final saving of €61.021 in a year. Considering that patients who underwent subcutaneous administration of rituximab did not require DH admission, we saved additional for €24,000 for 2016, and caregivers saved 112 work days.

**Summary/Conclusions:** Our investigation shows that subcutaneous formulation of rituximab requires a lower psychological effort for both patients and caregivers because of a reduced time of administration. In addition, it reduces healthcare professionals and pharmacist’s workload, ensures a major safety for patients, and allows an optimized use of DH armchairs. This brings to an increased satisfaction of patients and caregivers. Moreover, the costs analysis demonstrates a significant spending reduction improving planning of therapy sessions and organization.

**P737**

**EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG ‘14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA**

V. Martinez-Robles1,2, B. Ballina1, S. Cerda1, N. de las Heras1, M. Fuertes1, L. Villalobos1, J.A. Rodriguez-Garcia1, E. Fernando1

1Hematologia, Complejo Asistencial Universitario de León, LEON, Spain

**Background:** There are some variables that can modify Multiple Myeloma incidence of New Diagnosed (NDMM) and prevalence over the time: Past decade shows a new demographic data in our society: the increment of expectancy of life and an excellent performance status. In the last years we have assisted to an amazing improvement in the management and expectancy of life of Multiple Myeloma (MM) patients. Recent changes in criteria recommendation by IMWG ‘14 to begin treatment in NDMM patients can increment its incidence. New expensive but very effective and well tolerated anti myeloma (antiMM) agents are in the center of attention of Hematologic and Public Healthcare Systems. There are data of improvement of survival that can increment of prevalence.

**Aims:** We have analysed our data base and calculate incidence by sex, age and three 5-years periods of time at diagnosis and obtain tendencies to get ready for next decade of ageing people with best anti myeloma agents. We have analysed prevalence of MM patients on last 7 years with cutoff date on 1st of November (2010 to 2016).

**Methods:** We retrospectively analysed the incidence of patients with new diagnostic of Multiple Myeloma (NDMM) from 1998 to 2012. (Fig.1). Then we divide the cohort in several groups: sex and age at diagnosis (3 groups: <65, 66-75 and >75) in four 5-year (quinquennium) period of time (1998-2002, 2003-07, 2008-12, 2013-NOV2016). (Fig. 2). We have calculated the incidence per 100000 inhab/year using census data of our Local Registry of Tumours of our Public Health Area. Characteristics of patients: n = 346. M/F: 206/140. Median age at diagnosis: 74 years (Range: 39-100).

**Results:** A) INCIDENCE RATES (see Table). In the past IMW (Roma-14#PO197) we reported incidence rates form 1998 to 2012. We observed a constant increase of Annual Average of incidence from 4.57 cases/100000 inhabitants/ year from the 1st period to 6.15 in the last. Adjusted by Age Incidence increase from 14 to 18.5 cases in the 065 group. From 2013 to Nov-2016 global and adjusted by age incidence remains similar to last years data with 80 new cases in the 4 year-period (5.9 cases for global population and 17.2 cases for over65 population). After IMWG ‘14 criteria to begin treatment in NDMM the incidence was similar to the last 7 years (2008-12 period) incidence with 37 NDMM cases (25 O65y group).

**B) PREVALENCE RATES (PreVR).**

- 2012. 77 pts alive. PreVR: 22.2 /100000 inhabit;
- 2014. 84 pts alive. PreVR: 24.4/100000 inhabit;
- 2016. 103 pts alive. PreVR: 30.3 /100000 inhabit.

**Table 1.**
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN

M. Gabelli1,2, C. Messina1, M. Zecca2, A.M. Rovelli1,2, A. Prete1,2, M. Ripaldi9, A.P. Iori10, G. Basso1, F. Porta1, M. Caniglia12, P. Di Bartolomeo13, P. D’Angelo14, A. Bertaina15, F. Locatelli15


Background: Although most children affected by Acute Lymphoblastic Leukemia (ALL) are cured with current protocols, relapses still occur in the bone marrow as well in extramedullary sites, mainly the central nervous system (CNS) and the testis.

Aims: The aim of this study was to evaluate the outcomes of patients treated with hematopoietic stem cell transplantation (HSCT) for isolated extramedullary relapse (EMR) in the context of a real-world setting, with a special focus on the role of HSCT in the treatment of extramedullary relapses.


Results: Of the 281 patients (203 male, 78 female) 167 presented relapse confined to CNS, 73 to testis, 14 to mediastinum, 11 to CNS + other sites and 18 to other organs. Thirty one percent of children experienced a late relapse, 34.5% an early relapse, 31% a very early relapse, for 3.5% the time of relapse is not known. Ninety-seven patients underwent autologous HSCT (Auto HSCT) or haploidentical HSCT (Haplo HSCT).

Summary/Conclusions: Overall survival at 10 years was 50% that were busulfan- (64%), fludarabine- (29%) or total body irradiation-based (82%) that were busulfan- (64%), fludarabine- (29%) or total body irradiation-based (82%) and 5-year EFS was 43%. The majority of patients in CR1 (82%) that were busulfan- (64%), fludarabine- (29%) or total body irradiation-based (82%) and 5-year EFS was 43%.

DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCULSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM


1Stem Cell Transplantation and Cellular Therapy, 2Pharmacy Clinical Programs, 3Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, United States

Background: Inotuzumab ozogamicin (IO) is a CD22 monocular antibody attached to calicheamycin and targets B lymphocytes in early stages of development. In a randomized study of IO compared with conventional salvage therapy in patients with refractory relapsed B-ALL, patients treated with IO had higher complete response rates (81% vs 29%, p<0.001), and a greater proportion of patients proceeded to allogeneic hematopoietic stem cell transplantation (SCT) (41% vs 11%, p<0.001). However, patients treated with IO prior to SCT were also noted to have higher rates of veno-occlusive disease (VOD) compared to the SCT group without IO exposure (11% vs 1%) (Kantarjian NEJM 2016).

Methods: In efforts to further investigate this finding, we reviewed transplant outcomes for patients with and without IO exposure.

Results: We performed a nested control comparison of patients transplanted during the years when they were being treated with IO on a number of clinical trials at our institution.

Results: Between 6/2010 and 10/2016, 251 patients with B-ALL with a median age of 35 years (range, 4-70 years) received an allogeneic matched sibling (n=85), matched-1 and 1-antigen mismatched unrelated (n=90), haplo-identical (n=38), or cord blood donor SCT (n=38) in CR1 (n=103), CR2+ (n=105), with or active disease (n=43). Patients received largely myeloablative regimens (Busulfan and Cytarabine- [BU ara]) or reduced intensity regimens (BU ara backbone with 1 TBI dose) with low, intermediate, and high risk IO cycles, time from IO to SCT, age, and donor relation were not found to be significant in contributing to VOD in univariate analysis. Median IO exposure to VOD was noted in 21 patients overall (8%) with median onset 19 days following SCT (range, 7-230 days); fatal VOD was noted in 5 patients (2%). VOD was noted in 11 patients treated with IO (16%), and it was fatal in 2 patients (3%). Factors noted to be significant in providing VOD in univariate analysis is prior exposure to IO (HR 5.9, 95% C.I. 1.3-7.2, p=0.01) and receiving a busulfan-based transplant preparative regimen (HR 3.4, 95% C.I. 1.0-12, p=0.05); not receiving a prior SCT was significantly protective (HR 0.9, 95% C.I. 1.0-8, p=0.02). Number of IO cycles, time from IO to SCT, age, and donor relation were not found to be significant in predicting VOD. In efforts to predict the risk for VOD in a patient who has received prior IO, we performed a classification and regression tree analysis (CART) and noted that the combination of IO and a double alkylation preparative regimen was significantly associated with the risk for developing VOD (HR 5.9, 95% C.I. 1.9-16, p=0.002).

Summary/Conclusions: Fatal VOD is a rare occurrence. However, IO exposure prior to SCT increases the risk for any VOD. Furthermore, IO exposure followed by a double alkylation preparative regimen increases this risk nearly 6-fold, and should be avoided in these patients.
Results: Of 1000 HSCT pts with a confirmed diagnosis of VOD/SOS and receiving ≥1 dose of DF, 264 (26.4%) had late-onset VOD/SOS, of whom 139 (52.7%) had MUD. By day +90, 92/264 (35.1%) were pediatric and 172/264 (64.9%) were adults (aged ≥16 years; 88/169 [52.1%] with MOD). Kaplan-Meier estimated survival at Day +100 (Figure) was 52.8% (95% CI, 45.6%–58.7%) across all HSCT pts and 43.9% (95% CI, 35.4%–52.0%) for pts with MOD; for pediatric pts, this was 60.4% (95% CI, 49.1%–69.7%) overall and 45.4% (95% CI, 31.0%–58.6%) for pts with MOD; for adults, Day +100 survival was 48.7% (95% CI, 40.5%–56.0%) overall and 43.0% (95% CI, 32.5%–53.0%) for pts with MOD. Adverse events (AEs) occurred in 75.4% of the total group (80.6% with MOD); 70.5% of pediatric pts (76.9% with MOD); 78.1% of adults (83.0% with MOD). Treatment-related AEs (TRAES) occurred in 20.8% overall (23.7% in those with MOD); 21.1% of pediatric pts (23.5% with MOD); 20.7% of adults (23.9% with MOD). The most common TRAEs (>3%) were epistaxis, pulmonary hemorrhage, gastrointestinal hemorrhage, and hematuria (each in <5% of pts). TRAEs leading to study discontinuation (n=25) or death (n=10), the most common survival was pulmonary hemorrhage.

Support: Jazz Pharmaceuticals.

P742
A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
1Hematology, Yaeuido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 2Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 3Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of

Background: Allogeneic stem cell transplantation (SCT) using HLA-matched unrelated donor (URD) has been usually regarded as a second option in patients with severe aplastic anemia (SAAA), who have failed to immunosuppressive treatment (IST). However, recent improved outcomes of URD SCT lead to its extended role for treating those lacking HLA-matched sibling donor (MSD).

Aims: Through this study, we intended to verify the possibility of URD SCT as a front-line treatment for SAA patients.

Methods: We compared outcomes of consecutive SAA patients who received SCT from 8/8 well-matched URD (WM-URD; n=61) and partial (6/8 or 7/8) matched URD (PM-URD; n=33) with 8/8 matched MSD (n=126) at our institution between Mar 2002 and Dec 2016. Patients receiving MSU and URD SCT were conditionied with fludarabine (180mg/m2) / cyclophosphamide (100mg/kg IV) plus rabbit ATG (10mg/kg IV), and total body irradiation (fractionated 800cGy) / cyclophosphamide (100-120mg/kg IV) with/without rabbit ATG (2.5mg/kg IV), respectively.

Results: Median age of the WM-URD and the PM-URD groups were significantly lower compared to that of the MSD group (29 yrs, 31 yrs, and 39 yrs; P<0.01), with a high proportion of those experiencing IST failures before SCT (80.3%, 90.9%, and 33.3%; P<0.01). Median days to neutrophil engraftment of the MSD group was significantly shorter compared to those of the WM-URD and PM-URD groups (11 days vs 16 days, and 16 days, P=0.02). The incidence of acute and chronic GVHD of the WM-URD and PM-URD groups were significantly higher compared to those of the MSD group (42.6% and 63.6% vs 9.5%; P<0.01, and 44.8% and 33.3% vs 8.9%; P=0.01, respectively). When we compared the incidence of transplant-related mortality (TRM; 10.7% vs 17.6% vs 6%; P=0.53) and overall survival rate (OS; 89.3% vs 92.5% at 6 yrs; P=0.52) between the WM-URD and the MSD groups, there were no significant difference. However, trends of higher TRM incidence (18.2% vs 7.4% at 6 yrs; P=0.05) and lower OS rate (81.8% vs 92.5% at 6 yrs; P=0.05) were observed between the PM-URD and the MSD groups. There was no primary graft failure (0% in both WM-URD and PM-URD) and grade II–IV acute GVHD were rare in both groups (0% vs 18.3%; P=0.01) and PM-URD (0% vs 18.3%; P=0.02) groups were significantly lower compared that of the MSD group. When we adjusted other clinical and transplant-related factors, which include age and IST failure, using multivariate
analysis, the OS rate of the WM-URD group was not significantly different (HR 1.45, 95% CI: 0.52-4.09; P=0.48), whereas that of the PM-URD group was significantly lower (HR 2.85, 95% CI: 1.01-8.02; P=0.04), compared to that of the MSD group.

Summary/Conclusions: Our study showed that there was no significant difference in OS rate between the WM-URD and the MSD groups. As high incidence of GVHD remains as a problem in the former group, strategies to reduce it are needed in future protocols.

P743

HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIAS: PATIENTS
S. Hongeng1, S. Pakakasama1, A. Anurathapan1, B. Andersson2
1Pediatrics, Ramathibodi hospital, Mahidol University, Bangkok, Thailand, 2Stem cell transplantation, MD Anderson Cancer Center, Houston, United States

Background: Thalassemia free survival after allogeneic stem cell transplantation (SCT) is about 80–90% with either matched related or unrelated donors. However, the probability of finding a HLA-compatible donor is less than 50%. We explored the use of a mismatched related (“Haplo-”) donor.

Aims: To evaluate the outcome of SCT with Haplo donors in severe thalassemia patients.

Methods: All patients received two courses of pre-transplant immunosuppression therapy (PTIS) with fludarabine (Flu) 40mg/m2/w with dexamethasone (Dxm) 25mg/m2 for 5 d to facilitate engraftment. After two courses of PTIS, a reduced-toxicity conditioning regimen of rabbit anti-thymocyte globulin (ATG) 1.5mg/kg/d on days SCT -12,-11,-10, Flu 35mg/m2 on days SCT -7,-6,-5,-4 was given followed by T-cell replete peripheral blood progenitor cells (PBPC). GVHD prophylaxis consisted of cyclophosphamide (Cy) 50mg/kg on days SCT +3 and +4 (Post-Cy), and on day SCT +5 tacrolimus or sirolimus was started together with a short course of mycophenolate mofetil.

Results: Fifty-one patients underwent haplo-SCT. Their median age was ten years (range, 2 to 28 years). Forty-nine patients engrafted with 100% donor chimerism. Two of five patients with high titers of donor-specific anti-HLA antibodies suffered primary graft failure. Median time to neutrophil engraftment was 14 days (range, 11 to 18 days). Eight patients developed mild to moderate, reversible veno-occlusive disease, while twelve patients developed acute GVHD grade II, that quickly responded to steroid therapy. Only seven patients developed limited chronic GVHD. Projected overall and event-free survival rates at two years were 93% and 94%, respectively. The median follow up time is 18 months (range: 15 to 50 months).

Summary/Conclusions: This haplo-SCT protocol may yield excellent outcomes for thalassemia patients, and provide a treatment option for patients lacking a HLA-matched donor.

P744

AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDITIONAL TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
Y. Shefl1, N. Boaz1, S. Grisa1, B. Avni1, R. Or1, M. Shapira1
1Pediatric stem cell transplantation, Hadasah, Jerusalem, Israel

Background: Allogeneic stem-cell transplantation (H SCT, allo-SCT) is the most effective way to control leukemia relapse for patients with acute myeloid leukemia (AML). Busulphan and Cyclophosphamide (Bu/Cy), the current standard of care, in allogeneic transplant for acute myeloid leukemia (AML), is limited by increased treatment related mortality. Myeloblative doses of Busulfan (12-8mg/kg) with Fludarabine (160mg/m2) (Flu-Bu), has reduced toxicity, however with the limitation of increased relapses. We have tried to improve outcome of Flu-Bu regimen by augmentation with Thiotepa (10mg/kg). Here we compared outcomes of 45 such patients (getting augmented regimen, Flu-Bu with the addition of Thiotepa, (group 2), to 44 patients who received Fludarabine, Busulfan myeloblastic reduced toxicity regimen (group 1), during the same period.

Aims: The primary objective of the report was to compare the toxicity and incidence of relapse between the two regimens. Secondary objective was to compare overall survival (OS), and disease-free survival (DFS), the non-relapse mortality (NRM), engraftment kinetics, incidence of acute and chronic graft versus host disease (GVHD), and comparison between high and low-risk patients amongst the two groups.

Methods: 89 patients with AML were retrospectively analyzed. 44 patients were conditioned with Flu-Bu (group 1) and 45 patients augmented with Thiotepa (Flu-Bu- TT, group 2). The transplant conditioning regimen, (augmented myeloablative) consisted of 30mg/m2 intravenous Fludarabine for 5 days (total dose 150mg/m2), for matched related donors or for 6 days (180mg/m2), for unrelated or mismatched donors, intravenous Busulfan (3.2mg/kg/day for 4 days, total dose 12.8mg/kg), and intravenous Thiotepa 5mg/kg for 2 days (10mg/kg). The conventional myeloablative regime was identical, however without the addition of Thiotepa.

Results: Toxicities were comparable, with mucositis in 7 patients (15%) in group 1 and 8 patients (17%) in group 2 (p=1.0), severe sepsis in 4 (9%) in group 1 and 3 (6%) in group 2 (p=0.7), severe venoocclusive disease in 2% of group 1 and 4% of group 2 (p=1.0) and comparable non relapse mortality (NRM) (p=0.7). 5-year disease free survival (DFS) median follow up of 5 years, was significantly better in group 2, 38% for group 1, and 62% in group 2, (p=0.02) and 5-year overall survival showed trend towards benefit in group 2 (62% vs 42%, p=0.06). 14/30 (46%) patients in group 1 relapsed, as compared to 4/31 patients, (12%, p=0.005) in group 2, considering NRM as competing risk.

Figure 1.

Summary/Conclusions: In conclusion, the outcome of augmented regimen (DFS and OS) is superior Flu-Bu regime, mainly due to reduction in relapses, with comparable toxicities and could eventually replace Bu/Cy.

P745

PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
C. Chol1, S. Devlin2, P. Hilden3, M. Maloy1, M. Horowitz3, J.D. Rizzo3, B. Logan3, P. Barba4, R. O’Reilly5, S. Aljallad1, M. Panda1
1Adult Bone Marrow Transplant Service, Department of Medicine, 2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, 3Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, WI, United States, 4Department of Hematology, Hospital Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain, 5Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Background: Current prognostic indices for allogeneic HCT (alloHCT) outcomes often focus on a limited set of factors, be they patient characteristics, disease features, or transplant approaches. We sought to evaluate two comprehensive prognostic models in a large sample of patients undergoing alloHCT with CD34 selection (CD34 alloHCT).

Aims: To evaluate two comprehensive prognostic models: The first combining the HCT Comorbidity Index (HCT-CI) and Disease Risk Index (DRI), the second applying the Center for International Blood and Marrow Transplant Research (CIBMTR) One Year Survival Outcomes Calculator, which uses large-scale multicenter data reported to the CIBMTR to provide patient-specific predictions on survival 1 year after first alloHCT.

Methods: This retrospective analysis included adult recipients of first alloHCT with CD34+ selected PBSCs from 7/8 or 8/8 donors for AML, ALL, or MDS at 2015. The Kaplan-Meier (KM) method estimated OS and RFS. The cumulative incidence method for competing risks estimated relapse and nonrelapse mortality. We evaluated univariate association between variables of interest and OS/RFS using the log-rank test. Cox regression models assessed the adjusted effect of covariates on OS/RFS. We then determined predicted 1 year OS for each patient using the CIBMTR Calculator. Patients were divided into groups based on predicted OS probability,
in intervals of 5% +/- 2% (e.g. 65 +/-2% probability of survival at 1 year). Corresponding observed 1 year OS was then estimated for each group by the KM method. A kernel smoother was used to visually display the average of observed 1 year survival estimates over the continuous range of predicted OS. Results: 506 patients with AML (n=290), ALL (n=72), or MDS (n=144) were included. Of these, 470 patients (AML=263, MDS=141, ALL=66) had full data available for the CIBMTR Calculator. On univariate and multivariate analyses, DRI, HCT-CI, and age correlated with significant differences in OS/RFS, while donor HLA match correlated with a significant difference in OS. Stratifying patients based on a composite of DRI (low/intermediate vs high/very high) and HCT-CI (0-2 vs 3+) revealed significant differences in OS/RFS between the 4 groups (Fig. 1). Compared with a reference group of patients with both low/intermediate DRI and low HCT-CI, those with high DRI and low HCT-CI were at greater risk of death (HR 2.30; 95% CI 1.39-3.81) and relapse or death (HR 2.50; 95% CI 1.55-4.05), more so than patients with a higher HCT-CI but still low/intermediate DRI (HR death 1.80; 95% CI 1.34-2.43; HR relapse/death 1.68; 95% CI 1.26-2.24). When comparing predicted and observed survival, KM estimates of 1 year OS fell within range of that predicted by the CIBMTR Calculator in almost all groups (Fig. 1). In one group, patients had lower observed 1 year OS than predicted (76%; 95% CI 62-93%, vs 85 +/- 2%, p<NS). In this group, 29/30 patients (97%) had intermediate or high DRI; 59% had poor prognostic ALL by NCGC criteria (n=12, 44%) or other adverse features such as minimal residual disease pre-HCT (n=4, 15%).

Figure 1.

Summary/Conclusions: Based on a large cohort of patients who underwent CD34 alloHCT for acute leukemia or MDS, we demonstrate that DRI is a major determinant of outcome. The CIBMTR Survival Outcomes Calculator predicts 1 year prognosis with relative precision, though some disease-risk features not reflected in the Calculator may affect outcomes in patients with otherwise good prognosis. Taken together, these prognostic models can assist in predicting outcomes and identifying patients most likely to benefit from CD34 alloHCT. Furthermore, applying the CIBMTR calculator analysis in individual centers may help identify patients with worse outcomes than predicted and guide patient and/or HCT selection.

P746
THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?
1Clinical Hematology, H.Universitario Virgen del Roscio, Seville, 2Clinical Hematology, ICO-Duran i Reynals, Barcelona, 3Clinical Hematology, H.Universitario de Salamanca, Salamanca, 4Hematology, H.Universitario Virgen del Roscio, Seville, 5Hematology, H Santa Creu i Sant Pau, 6Hematology, H.Clinic, Barcelona, 7Hematology, H.Clinico, Valencia, 8Hematology, H.Universitario de Salamanca, Salamanca, 9Hematology, H.Santa Creu i Sant Pau, 10Hematology, Hospital Clinic, Barcelona, 11Hematology, H.Clínico, Valencia, Spain

Background: Thrombotic microangiopathy (TMA) after allogeneic stem cell transplantation (alloSCT) may be a severe complication associated with high mortality. Since there is no standard treatment it would be helpful to have efficacious prophylactic measures. Some data support the beneficial effect of ursodeoxycholic acid (UDA) as cell damage/endothelialamping.

Aims: We retrospectively analysed a total of 671 patients undergoing alloSCT to analyse the risk of developing TMA. Results: Cumulative incidence for overall TMA was 4.8 (3.4-6.6) at 1 month, 10.1 (7.9-12.5) at 100 days, and 12.7 (10.3-15.4) at 180 days (figure 1). On univariate analysis, TMA was more frequent in lymphoid malignancies, Flu darabine-melphalan based conditioning, unrelated donor, mismatched donor, prophylaxis with sirolimus-tacrolimus (SRL/TKR), prior transplant and non-UDA patients. The probability of overall TMA at 180 days in UDA patients was 9.6% (95% CI: 5.9-14.3), versus 14.7% (95% CI: 11.7-18.1) in non-UDA patients. On multivariate analysis the risk factors which remained statistically significant were unrelated donor and the use of SRL/TKR, whereas the use of UDA significantly decreased the risk of TMA (HR:0.4, 95% CI:0.2-0.8, p<0.01). Moreover, in the subgroup of SRL/TKR, 100 days-cumulative incidence of TMA was 11.8% (95% CI: 6.9-18.1) versus 25.6% (95% CI: 17.9-33.9) depending on the use or not of UDA, respectively (p<0.05), whereas in the subgroup of CNV/MTX 100d- Cumulative incidence of TMA was 3.4% (95% CI: 0.6-10.6) vs 12.1% (95% CI:7.1-18.6) with and without UDA, respectively (p<0.05).

Summary/Conclusions: In conclusion the use of UDA decreases the risk of TMA after alloSCT regardless of type of immunosuppression.

Table 1.
Results: Characteristics of patients are shown in table 1. With a median follow up for patients alive of 39 months (3-221), the median estimated survival in months and the % at +1 year and +2 years was: 114 months, 70% and 62% overall survival (OS); 23 months, 57% and 49% event free survival (EFS); 6 months, 35% and 26% GRFS1; 11 months, 46% and 38% GRFS2. 147 (24%) and 218 (35%) hadn’t any event in GRFS1 and in GRFS2 respectively. In GRFS1, event incidence was: 90 (15%) for III-IV aGVHD, 170 (27%) for cGVHD, 152 (25%) for relapse and 57 (9%) for death; In GRFS2 was 90 (15%), 65 (11%), 174 (28%) and 65 (11%) respectively. Considering those patients with cGVHD as event in GRFS1, 105 of them hadn’t the event as cGVHD at the same time in GRFS2 (since they had cGVHD requiring systemic treatment but not severe cGVHD). For these patients, the alternative event in GRFS2 was: 72 without any event, 22 relapsed and 11 died. In the multivariate analysis, factors associated with better outcomes were: for GRFS1 diagnosis (p=0.04; benefit in NHL/HL/CLL p=0.02, HR 0.71; C195% 0.53-0.95), >4 prior lines (p=0.03, HR 1.5, CI95% 1.04-2.04), early EBMT stage (p<0.01 with early as reference; intermediate p=0.02, HR 1.5, CI95% 1.2-1.9; advance p<0.001, 2.0, 1.5-2.6), in vivo T-cell depletion (p=0.02, 0.6, 0.39-0.92) and haploidentical donor (p=0.04 with HLA identical as reference, no significance 1 or 2 mismatch [p=0.18], haploidentical p=0.02, 0.43, 0.25-0.74). Only early EBMT disease stage maintained significance in GRFS2 (p<0.01 with early as reference; intermediate p=0.005, 1.5, 1.1-1.9; advance p=0.001, 1.9, 1.4-2.6).

Summary/Conclusions: In our study the percentage of the GRFS endpoint was similar to previously reported. Comparing both proposed definitions, the GRFS2 endpoint define a higher population of patients without any event; so that it is possible that the morbitity is misdiagnosed. The EBMT disease score was the factor with more impact in both; it is interesting to point that although the group is smaller, haploidentical donor is associated with better GRFS1.

Figure 1.

Summary/Conclusions: This final analysis of the defibrotide expanded-access protocol demonstrates favorable Day +100 survival (58.9%) in patients with confirmed VOD/SOS following HSCT, and 49.5% in those with MOD, a complication typically associated with dismal outcomes. Survival and safety findings, consistent with prior clinical trials, provide supportive evidence for the clinical utility of defibrotide for treatment of VOD/SOS in patients with and without MOD.

Support: Jazz Pharmaceuticals.
Observations in management of AML, resulted in NK cell apoptosis in human cells inhibition by Venetoclax (ABT-199), a BCL2 antagonist approved in the treatment recapitulated the transplant findings in less GVHD as determined by clinical scores and gut histology, with RIC conditioning and GVHD. Conditional deletion of donor T cell engraftment and GVL whilst reducing the risks of GVHD. With 100mg/kg ABT-199 or vehicle, before receiving alloHSCT. Mice were monitored for donor T cell engraftment and GVL whilst reducing the risks of GVHD. Donor and control MSC. For the latter experiments, CD34+ cells were isolated from leukapheresis and seeded on stromal layers from non-irradiated or irradiated MSC. CFU-GM colonies derived from the LT-BMC were scored weekly. Results: Flow cytometric characterization of irradiated MSC was comparable to that of control MSC. Similarly, there were no differences in the percentage of viable cells between both experimental groups neither at one hour nor at 72h post irradiation, confirming once more the radio-resistance of MSC. In addition, expression arrays did not show any statistically significant differences in genes involved in hematopoiesis maintenance. However, upon comparing the differentiation ability we interestingly observed that irradiated-MSC differentiation was skewed towards osteogenesis whereas adipo genesis was impaired. In this regard, irradiated-MSC had significantly higher SPP1 expression (involved in late osteogenic differentiation) and lower CBPA and PPARγ (both genes involved in adipogenesis) compared to control MSC. After inducing in vitro differentiation, there were no differences in ALP and Alizarin Red staining but the number of adipocytes per field at days 7, 14 and 21 was significantly lower in irradiated MSC (p=0.018 p=0.046 and p=0.018). In addition, angiopoietin and SDF-1, key genes implicated in maintenance of hematopoiesis, were significantly overexpressed in irradiated-MSC (p=0.043 and p=0.028, respectively). Finally, in the functional evaluation of the hematopoiesis-supporting ability of MSC by LT-BMC, we observed that the number of CFU-GM colonies generated by the culture was significantly higher in the irradiated group after 4 and 5 weeks (p=0.046 and p=0.018, respectively) compared to the non-irradiated group. Furthermore, the number of adipocytes per field was significantly reduced in the LT-BMC. Summary/Conclusions: Irradiation of MSC with 2,5 Gy improves their hematopoietic supporting ability and modifies their differentiation capacity, increasing the osteogenesis and decreasing the adipo genesis. Funding: PI12/01775 (ISCIII, Spain). Santander-USAL grant to SP.

P752 Dysfunction of bone marrow mesenchymal stem cells from patients with prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation can be improved by N-acetyl-L-cysteine.

Y. Shen1,2, Y. Kong1, F.-F. Tian1, H.-Y. Zhao1, Y.-H. Chen1, W. Han1, C.-L. Yan1, Y. Wang1, X. Zhang1, L.-P. Xu1, X.-J. Huang1,2

1Peking University Institute of Hematology, Peking University People’s hospital, Beijing, China, 2Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

Our system may represent a breakthrough in (cancer) stem cell biology and controlling self-renewal in hematopoietic and LSCs as well as drug screening. We created a robust method of expanding hematopoietic stem/progenitor cells. They are immortalized and can be expanded indefinitely. This tool allows analysis of the molecular mechanisms controlling self-renewal in hematopoietic and LSCs as well as drug screening. Allogeneic haematopoietic stem cell transplantation (alloHSCT) is the most effective means of preventing relapse of blood cancers, in particular AML. The curative potential of alloHSCT is largely due to the immune mediated graft-versus-leukemia (GVL) effect, which in turn is dependent on the stable continuous proliferation. HPCLSK cells repopulate lethally irradiated mice and re-feed the T and B cell hematopoietic cell pool. HPCLSK cell lines were established from a range of transgenic mice, underlining the overall applicability of this model. Using this system, we established LSC lines that express BCR/ABLp210, MLL-AF9;NrasG12Dor Flt3-ITD; NrasG12D. These LSCs home to the bone marrow, differentiate into all lineages and drive myeloid leukemia in mice. Summary/Conclusions: We created the most robust method of expanding hematopoietic stem/progenitor cells. They are immortalized and can be expanded indefinitely. This tool allows analysis of the molecular mechanisms controlling self-renewal in hematopoietic and LSCs as well as drug screening. Our system may represent a breakthrough in (cancer) stem cell biology and assist in the development of new therapeutic avenues to combat LSCs.

P749 Generation of immortal murine hematopoietic stem/progenitor cell lines from transgenic mice.

E. Doma1,*, A. Hölbl1, V. Sexl1

1Pharmakologie und Toxikologie, Veterinärmedizinische Universität Wien, Wien, Austria

Background: Research on hematopoietic and leukemic stem cells (LSCs) is currently limited as these cells are infrequent and their immortalization is hardly achievable. Aim: We aimed to establish a long term ex vivo culture system that allows maintenance and expansion of LSCs (lin- Sca-1+, c-kit+) cells. Methods: We adapted a technique described by the L. Carlsson lab and transduced high-purity sorted murine LSKs with Lhx2, a LIM-homeobox transcription factor, which has been reported to facilitate ex vivo expansion of immature hematopoietic cells. Results: Lhx2 expressing hematopoietic progenitor cell (HPC(LSK)) lines require SCF (stem cell factor) and IL-6 and they can be maintained in a feeder-independent culture for more than 6 months. They preserve LSK markers despite continuous proliferation. HPC(LSK) cells repopulate lethally irradiated mice and re-feed the T and B cell hematopoietic cell pool. HPCLSK cell lines were established from a range of transgenic mice, underlining the overall applicability of this model. Using this system, we established LSC lines that express BCR/ABLp210, MLL-AF9;NrasG12D or Flt3-ITD; NrasG12D. These LSCs home to the bone marrow, differentiate into all lineages and drive myeloid leukemia in mice. Summary/Conclusions: We created a robust method of expanding hematopoietic stem/progenitor cells. They are immortalized and can be expanded indefinitely. This tool allows analysis of the molecular mechanisms controlling self-renewal in hematopoietic and LSCs as well as drug screening. Our system may represent a breakthrough in (cancer) stem cell biology and assist in the development of new therapeutic avenues to combat LSCs.

P751 Mesenchymal stromal cell irradiation interferes with the adipo/osteogenic differentiation balance improving their hematopoietic-supporting ability

S. Preciado Pérez1,2, S. Munton1, A. Rico1, R. Ortega1, I. Misiewicz-Krzeminska1, L. Alvarez-Lamasantana1, J. Davis1,2,*, Y. Jiao3,4,5, R. Koldej1,2, N. Huntington3,5, D. Ritchie1,2,6

1The ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, Australia, 2Peking University Institute of Hematology, Peking University People’s hospital, Beijing, China, 3Department of Medicine, The University of Melbourne, 4Department of Molecular Immunology, The Walter and Eliza Hall Institute, Melbourne, Australia, 5School of Medicine, Tsinghua University, Beijing, China, 6Department of Medical Biology, The Walter and Eliza Hall Institute, Australia

Background: Mesenchymal stromal cells (MSC) are precursors of adipocytes and osteoblasts in the bone marrow (BM) niche, and key regulators of the hematopoietic process. After HSC transplantation, MSC remain of host-origin. Total body irradiation has been widely used in conditioning regimen and MSC are shown to be radio-resistant. Nevertheless, the functional effects of irradiation on BM-MSC have not been extensively explored. Aim: The main objective was to evaluate the effects of irradiation on the MSC in their hematopoietic-supporting capacity. Methods: Ten BM samples were obtained from healthy donors after informed consent. MSC were obtained and characterized following standard procedures for BM-MSC. FACS analysis was performed. Then, one aliquot was gamma-irradiated with a single dose of 2,5 Gy whereas non-irradiated MSC from the same sample were used as controls. MSC were characterized following ISCT criteria (flow cytometry and in vitro differentiation stainings). Apoptosis was evaluated by flow cytometry using annexin/7AAD staining. Expression microarrays of irradiated and control-MSC were performed using Human Gene 2.0 ST Array platform (Affymetrix). RT-PCR of key genes involved in the hematopoietic supporting capacity as well as in the differentiation of MSC into osteoblasts and adipocytes was performed in both experimental groups. Finally, long term BM cultures (LT-BMC) were performed as functional assays to test the hematopoietic-supporting ability of irradiated and control MSC. For the latter experiments, CD34+ cells were isolated from leukapheresis and seeded on stromal layers from non-irradiated or irradiated MSC. CFU-GM colonies derived from the LT-BMC were scored weekly. Results: Flow cytometric characterization of irradiated MSC was comparable to that of control MSC. Similarly, there were no differences in the percentage of viable cells between both experimental groups neither at one hour nor at 72h post irradiation, confirming once more the radio-resistance of MSC. In addition, expression arrays did not show any statistically significant differences in genes involved in hematopoiesis maintenance. However, upon comparing the differentiation ability we interestingly observed that irradiated-MSC differentiation was skewed towards osteogenesis whereas adipogenesis was impaired. In this regard, irradiated-MSC had significantly higher SPP1 expression (involved in late osteogenic differentiation) and lower CBPA and PPARγ (both genes involved in adipogenesis) compared to control MSC. After inducing in vitro differentiation, there were no differences in ALP and Alizarin Red staining but the number of adipocytes per field at days 7, 14 and 21 was significantly lower in irradiated MSC (p=0.018 p=0.046 and p=0.018). In addition, angiopoietin and SDF-1, key genes implicated in maintenance of hematopoiesis, were significantly overexpressed in irradiated-MSC (p=0.043 and p=0.028, respectively). Finally, in the functional evaluation of the hematopoiesis-supporting ability of MSC by LT-BMC, we observed that the number of CFU-GM colonies generated by the culture was significantly higher in the irradiated group after 4 and 5 weeks (p=0.046 and p=0.018, respectively) compared to the non-irradiated group. Furthermore, the number of adipocytes per field was significantly reduced in the LT-BMC. Summary/Conclusions: Irradiation of MSC with 2,5 Gy improves their hematopoietic supporting ability and modifies their differentiation capacity, increasing the osteogenesis and decreasing the adipo genesis.
Aims: To evaluate the number and function of BM MSCs in patients with PT and its underlying molecular mechanisms in vitro.

Methods: Three cohorts were included: patients with PT (N=25), patients with good graft function (GGF, N=12), defined as persistent successful engraftment after allotransplant, and transplant donors as normal controls (N=10). BM MSCs were cultured as previous reported. All experiments were carried out using BM MSCs derived from passages 2–4. The number and functions of BM MSCs were evaluated by fibroblasts colony-forming unit (CFU-F) assay, cell prolifer- ation, cell-cycle analysis, reactive oxygen species (ROS) levels, senescence-associated β-galactosidase (SAβ-gal) assay, and western blots. To further investigate the potential effect for repairing the function of BM MSCs, we made the reverse chimeras, [B6Ly5.2→B6], [B6Ly5.2→XIAP-/-] and [B6→B6Ly5.2], and utilized them as recipients in 2nd allo-BMT in PT patients. After 2 days in vitro culture, the number of SAβ-positive cells was counted, the intracellular levels of ROS and p-p38 were evaluated in BM MSCs by flow cytometry. Pro- tein expression for p-p38, p38, p-p53, p53 was measured by flow cytometry and western blots. To further investigate the potential effect for repairing the dysfunctional BM MSCs, N-Acetyl-L-cysteine (NAC, a ROS scavenger) and SB203580 (p38 inhibitor) were added to the BM MSCs for PT patients. After 2 days in vitro culture, the number of SAβ-positive cells was counted, the intracellular levels of ROS and p-p38 were evaluated in BM MSCs by flow cytometry.

Results: Human BM MSCs were demonstrated as spindle shape and typical immunophenotype of MSCs at day 21 of cultivation among subjects with PT, GGF, and normal controls. Cultures from all normal BM samples produced confluent layers of adherent cells composed of spindled shaped cells. 2 of the 12 GGF BM and 15 of the 25 PT BM failed to produce any adherent layers within 3 weeks of culture. BM MSCs derived from PT patients expanded more slowly and appeared flattened and larger. Proliferative capacity and CFU-F counts of BM MSCs from PT patients were significantly reduced compared to those of GGF patients and normal controls. Moreover, increased levels of ROS, which was associated with increased number of SAβ-positive cells, were identified in BM MSCs from PT patients. Intraplatelet p-p38 level was significantly elevated in PT patients compared to those in GGF patients. After NAC treatment in vitro, the oxidative stress was increased significantly whereas the number of senescent cells, the intracellular levels of ROS and p-p38 were reduced markedly in BM MSCs from PT patients.

Summary/Conclusions: In summary, the current study demonstrated the number and the function of BM MSCs were abnormal in PT patients following allo-HSCT and transplant donors as normal controls. BM MSCs derived from patients with PT and its underlying molecular mechanisms in vitro.

P754

GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY Th9 CELLS

T. Reisser,1, S. Muche,1, J. Scheurer2, K.-M. Debatin1, G. Strauss1.1 Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany

Background: Th9 cells are a recently defined subset of T helper cells (Th) characterized by the massive production of IL-9. Th9 cells mediate immune responses against helminth infections, exhibit anti-tumor immunity against solid tumors and mediate allogeneic transplant tolerance but they also contribute to immunopathology in allergy and autoimmunity.

Aims: Currently, the role of Th9 cells for GVHD induction and the graft-versus-tumor effect is largely unknown. Therefore, we first explored, whether Th9 cells are induced during GVHD development and in two different MHC-mismatched bone marrow transplantation (BMT) models and secondly analyzed, whether transplantation of in vitro-generated Th9 cells mediates GVHD.

Methods: We transplanted allogeneic BM and spleen cells from B6→SJL mice (CD45.1, H-2b) in B6.D2F1 mice (CD45.2, H-2bxd) or in B6.bm12 mice (CD45.2, H-2bd) differing either in 50% of MHC class I and II molecules or only in one MHC class II molecule and analyzed the induction of Th9 cell during GVHD development.

Results: To clarify whether in vitro-generated Th9 cells mediate GVHD, we induced Th9 cells in vitro from isolated, naive CD4+ T cells on anti-CD3/28 coated plates by Tgf-b, Il-4, anti-Ifn-g and recombinant Tl1a and co-injected them with irradiated BM. The transplantation of Th9 cells did not induce GVHD development. Thus expression of functional IAPs in target tissues is crucial for reducing the damage from GVHD.

P753

INHIBITORS OF APOPTOSIS PROTEINS (IAPs) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS

T. Toubai,1,2, C. Rossi,3 K. Oravec-Vezel1,4, C. Liu,5 C. Zajac,6, J. Wu,7, Y. Sun,8 H. Fujiiwara,9 H. Tamaki,10 D. Pelletier,11 M. Riwes,12 H. Henig,13 S. Brabbs,14 P. Reddy14

1 Department of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan, 2 Department of Internal Medicine, University of Michigan, Ann Arbor, United States, 3 Department of Pediatric Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany, 4 Department of Pathology and Laboratory Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States, 5 Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 6 Department of Pediatrics, University of Michigan, Ann Arbor, United States

Background: The two inhibitors of apoptosis proteins (IAPs), X-chromosomelinked IAP (XIAP) and cellular IAP-1 (cIAP-1), inhibit apoptosis and play an important role in regulating innate and adaptive immunity. However, the role of IAPs in allogeneic immune responses is not known.

Aims: We determined the role of IAPs in GVHD.

Methods: We utilized clinically relevant, well-characterized murine models of allogeneic BMT. To chemically target IAPs, we utilized AT406 (SM-406), a SMAC mimetic that actively antagonizes all IAPs.

Results: We first utilized AT406 which regulates TNFα in vitro. Given the GVHD potentiating effects of TNFα, we hypothesized that AT406 will mitigate GVHD. After we confirmed that AT406 reduced expression of IAPs in T cells or host BM, we transplanted MHC-mismatched BM from C57Bl/6 and BALB/c recipients were lethally irradiated and transplanted with syngeneic or allogeneic T cells along with bone marrow (BM). Both groups received either AT406 or its diluent. Contrary to our hypothesis, allogeneic recipients receiving AT406 showed worse GVHD. To understand the role of IAPs, we next utilized B6 background BM and the IAP-deficient T cells. When donor T cells from B6-cIAP-1+ or XIAP-/- animals were compared to B6-WT T cells, the allogeneic (BALB/c) showed similar GVHD. The same results were also observed in another B6→F1 model. Furthermore, in vitro studies showed that XIAP-/- and cIAP-1-/- T cells had comparable proliferation and cytokine secretion as WT-T cells. These data suggested that increased expression of anti-apoptotic protein Bcl-2 and LC-3 but equivalent expression of pro-apoptotic proteins. In addition, the expression ratio of BIM or BAX to Bcl-2 in allo-XIAP-/- animals was significantly increased. Moreover, to investigate the approach to enhance the number of Th9 cells, we made the reverse chimeras, [B6Ly5.2→B6] and [XIAP-/-→B6Ly5.2] chimera and utilized them as recipients in 2nd allo-BMT in XIAP-/- and cIAP-1-/- animals showed similar GVHD. These data suggest that enhanced apoptosis in the interaction between hematopoietic progenitor cells, cytokines, and marrow stromal cells. These data suggest that enhanced apoptosis in the interaction between hematopoietic progenitor cells, cytokines, and marrow stromal cells. These data suggest that enhanced apoptosis in the interaction between hematopoietic progenitor cells, cytokines, and marrow stromal cells.

Summary/Conclusions: The two Inhibitors of apoptosis proteins (IAPs), X-chromosome-linked IAP (XIAP) and cellular IAP-1 (cIAP-1), inhibit apoptosis and play an important role in regulating innate and adaptive immunity. However, the role of IAPs in allogeneic immune responses is not known.
during GVHD. After in vitro differentiation of Th9 cells from naive T cells we observed more than 60% of IL-9 producing cells after 5 days of culture. Th9 cells differ in their cytokine profile (IL-9+, IFN-g−, IL-13−) from Th1 and Th2 cells. Transplantation of in vitro-generated Th9 cells together with allogeneic BM cells did not induce GVHD in the MHC-disparate recipient mice, while the transplantation of unselected T cells or in vitro-generated Th1 cells induced GVHD and resulted in the death of about 60% of the animals. Although no GVHD development was detected, Th9 cells migrated into lymphoid organs and GVHD target organs such as spleen and lung. Surprisingly, when the cytokine phenotype of the transplanted Th9 cells were analyzed after ex vivo isolation from spleen and liver at different time points after transplantation, the cells lost their IL-9 production and adopted a Th1-like phenotype increasing IFN-g cytokine production via the augmentation of a Th1 phenotype after adoptive transfer. Systemic increase of TNF-a and IFN-g in the serum of mice receiving Th9 cells, however, was not detected.

**Summary/Conclusions:** Th9 cells are not induced during GVHD development and the adoptive transfer of in vitro-generated Th9 cells does not induce GVHD. However, the transplanted Th9 cells home to spleen and GVHD target organs and start to produce TNF-a and IFN-g without strong systemic increase in these cytokines. Since TNF-a and IFN-g are cytokines associated with an anti-tumor cytotoxicity and Th9 cells are known to eliminate solid tumors, future experiments will define whether in vitro-generated Th9 cells can be used as a cellular therapy for anti-tumor responses in BM-transplanted hosts.

**P755**

**IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS**

M. Fernandez-Garcia1,2,*, M. L. Lamana 1,2, M. Hernando-Rodríguez 1,2, I. Alvarez Laderas1,*, J.I. Piruat 1, T. Caballero Velázquez 1, M. Ceballos 2, J.A. Pérez Simón1, V. Barbado1, L.I. Sánchez Abarca1, M. Medrano1, E. Garcia1, J.C. Reyes2, A. Morales Hernandez1, A. Martínez2, S. McKinney-Freeman2

**Background:** Human chronic graft-versus-host disease (CGVHD) shares clinical characteristics with a murine sclerodermatous GVHD (Scl-GVHD) model that is characterized by skin thickening and lung fibrosis.

**Aims:** The aim of this study is to analyze the effect of MSCs on HSC engraftment in a clinically relevant model of hematopoietic gene therapy.

**Methods:** We have studied the effect of MSCs co-infusion in a mouse model of HSC gene therapy with risk of engraftment failure in Fanconi anemia mice (Fanca−/−).

**Results:** In these experiments, the infusion of low numbers of WT LSK cells (1,500 LSK) in Fanca−− mice resulted in 30% graft failure, which was prevented when 6.105 Ad-MSCs were co-infused. Furthermore, when 1,500-3,000 (1,500 LSK) in sublethal conditioning (5Gy).

**Summary/Conclusions:** Taken together, our results demonstrate the potential of Ad-MSCs to avoid graft failure in a clinically relevant model of hematopoietic gene therapy with risks of engraftment failure.

**P756**

**EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFICATIONS.**

I. Alvarez Laderas1,1, J.I. Piruat1, T. Caballero Velázquez1, M. Ceballos2, V. Barbado1, L.I. Sánchez Abarca1, M. Medrano1, E. García1, J.C. Reyes2

**Background:** There is conflicting evidence regarding the potential use of IMIDs and particularly pomalidomide after allogeneic stem cell transplantation (allo-HSCT). It has been shown that pomalidomide induces a Th1 phenotype increasing IFN-g cytokine production via the augmentation of T-bet transcription factor. This effect might increase the risk of GVHD after allo-HSCT. Nevertheless, a recent trial has reported a potential benefit on the use of pomalidomide as GVHD treatment. Aim: In the current study, we have analyzed the effect of pomalidomide in the polarization of CD45RA+ T cells and the epigenetic mechanisms that might be involved in this effect.

**Methods:** Isoleted CD45RA+ T cells from healthy donor’s Buffy Coats were stimulated with anti-CD3 plus anti-CD28 and anti-CD28 and cultured in the presence of several cytokines to polarize towards Th1 (IL-12, INF-γ-anti-IL4) or Th2 (IL-4, IL-10, anti-IL12, anti-IL-4, INF-g, and anti-IL-12) for 5 days. Pomalidomide at two different doses (10 and 100 nM) were added into the culture and the effect on T cells polarization was analyzed by flow cytometry after staining with anti-CD25, anti-IFN, anti-CD4, and anti-IL2 for Th1 cell polarization and anti-CD25, anti-IL10, anti-CD3, and anti-IL4 for Th2 cell polarization. In addition, the release of cytokines (IL-2, IL-4, IL-6, IL-10, TNF-a and IFN-g) in cell culture supernatants were measured by BD Human Th1/Th2 Cytokine CBA kit (BD Biosciences) and T-bet and GATA-3 expression were analyzed by Western Blot. Chromatin immunoprecipitation (ChiP) assays were performed to assess the trimethylation of H3K4 associated with gene activation and the trimethylation of H3K27 (associated with gene repression) in the TBET and GATA-3 gene promoters.

**Results:** Pomalidomide increased the expression of INF-g and IL-2 as determined by flow cytometry in Th1 cell culture conditions. By contrast, in the presence of IL-4 and IL-10, pomalidomide had no effect on the expression of Th2 cytokines (IL-10 and IL-4) and upon adding pomalidomide to the culture. In addition, the expression to pomalidomide increased the levels of TNF-a, INF-g and IL-2 in the Th1 polarizing culture while, under Th2 promoting conditions, an increased concentration of IL-4 and IL-2 in supernatant was observed after exposure to pomalidomide. Furthermore, exposure to pomalidomide led to an increased expression of T-bet as assessed by western-blots in naive CD45RA+ cells activated with anti-CD3 plus anti-CD28 and supplemented with IL-12, INF-g and anti-IL4. By contrast, in Th2 polarization conditions, pomalidomide increased GATA-3 expression. We next studied whether or not the effect of pomalidomide in T cell polarization might be mediated by epigenetic mechanisms: in the presence of Th1 promoting conditions there was a significant increase of the activation marker H3K4me3 at the promoter of TBET and a significant decrease in H3K27me3 upon exposure to the drug while, under Th2 promoting conditions, a significant increase in H3K4me3 at the promoter of GATA-3 gene was observed among Th2 cells after exposure to pomalidomide.

**Summary/Conclusions:** Pomalidomide favours both Th1 and Th2 cell differentiation of CD45RA+ cells depending on the cytokines present in the medium. Treatment of naive T cells with pomalidomide induces epigenetic modifications during T cell polarization which might favour the process of differentiation of the naive T cells.
Although C57BL/6/N (N) and C57BL/6/J (J) mice are derived from the same parental C57BL/6 strain, there are key genotypic and phenotypic differences between these sub-strains. However, more than 58% of studies published involving C57BL/6 mice do not indicate the specific sub-strain employed. J mice have a five-exon deletion in the Nicotinamide nucleotide transhydrogenase (Nnt) gene that results in a non-functional protein. NNT is involved in the resolution of oxidative stress in the mitochondria. Hematopoietic stem cells (HSCs) can reconstitute the entire hematopoietic system after transplantation into hosts whose hematopoietic compartment has been ablated. This is clinically exploited as HSCs transplantation (HSCT) to treat hematologic diseases and represents the only curative therapy for many disorders. During HSCT, HSCs are subject to dramatic increases in both intra and extracellular reactive oxygen species (ROS), which compromises their self-renewal, differentiation, and survival. The absence of a functional Nnt gene in J-HSC may curtail their ability to resolve elevated ROS post-transplant.

Aims: As elevated oxidative stress compromises hematopoietic stem and progenitor cell (HSPC) function, here we thoroughly interrogated the frequency and function of HSPCs in J and N bone marrow (BM).

Methods: N and J peripheral blood (PB) and BM (n=9) was interrogated by flow cytometry for the absolute frequencies of all major hematopoietic lineages and HSPC compartments, respectively. 5000 J or N CD45.2 HSPCs (Lin-Scal1+c-Kit+cells) were transplanted along with 5000 competitor CD45.1 HSPCs into lethally irradiated mice to test for competitive in vivo hematopoietic repopulating activity and ROS levels post-transplant. The lineage potential and repopulating activity of multi-potent progenitors (MPP2: Lin-Sca1+cKit+Flt3-CD48+CD150+, MPP3: Lin-Sca1+cKit+Flt3-CD48+CD150−, MPP4: Lin-Sca1+cKit+Flt3-CD48+CD150−) was also tested by transplanting 2000 MPPs from J or N mice into sub-lethally irradiated mice and examining the PB of recipients every 3-4 days for 34 days post-transplant. Sensitivity of HSPCs to oxidative stress was tested by examining ROS levels and the in vitro colony forming unit (CFU) potential of HSPCs isolated from N and J mice treated with p:pc.

Results: The frequency of the major PB lineages and bone marrow HSPC compartments was identical in J and N mice. However, J-HSPCs displayed compromised short-term (4-12 weeks post-transplant) hematopoietic repopulating activity relative to N-HSPCs that was driven by a delay in lymphoid reconstitution. No differences were found in donor contribution to bone marrow HSPC compartments at 20 weeks post-transplant. However, donor-derived MPPs and CLPs displayed a two-fold increase in ROS levels in recipients of J-HSPCs versus N-HSPCs at 20 weeks post-transplant. MPPs are responsible for repopulation of the hematopoietic system during this early window post-transplant. Different MPP subpopulations can be defined (MPP2, MPP3 and MPP4) according to their self-renewal potential and specific lineage potential. MPP3s and MPP4s are the first MPP subpopulations to reconstitute the lymphoid lineage after transplantation. J-MPP3s and J-MPP4s displayed less in vivo repopulating activity than N-MPP3s and N-MPP4s. It is known that p:pc treatment increases ROS levels in HSPCs. We found about two-fold higher ROS levels in HSPCs isolated from J versus N mice with the exception of J-HSPCs versus N-HSPCs at 20 weeks post-transplant. MPPs are responsible for repopulation of the hematopoietic system during this early window post-transplant. Different MPP subpopulations can be defined (MPP2, MPP3 and MPP4) according to their self-renewal potential and specific lineage potential. MPP3s and MPP4s are the first MPP subpopulations to reconstitute the lymphoid lineage after transplantation. J-MPP3s and J-MPP4s displayed less in vivo repopulating activity than N-MPP3s and N-MPP4s. It is known that p:pc treatment increases ROS levels in HSPCs. We found about two-fold higher ROS levels in J-HSPCs versus N-HSPCs when isolated from p:pc treated mice. These data indicate that J-HSPCs cannot resolve oxidative stress as efficiently as N-HSPCs, which may be due to lower self-renewal potential after exposure to oxidative stress. Short-term J-lymphoid-biased progenitors (e.g. MPPs and CLPs) were especially sensitive to increasing ROS, which very likely drives the short-term loss of in vivo repopulating activity.

Summary/Conclusions: Based on these data, we hypothesize that loss of the Nnt gene in C57Bl/6J mice sensitizes HSPCs to oxidative stress, which compromises their short-term in vivo hematopoietic repopulating activity.
Background: ET and PV are characterized by a high incidence of arterial and venous thrombosis. Platelet (PLT) count is not an independent risk factor for thrombosis in these conditions. However, no information is available on patient PLT qualitative properties, i.e. the PLT thrombus formation capacity in a dynamic condition.

Aims: We wanted to evaluate, in a group of ET and PV patients, the PLT thrombus formation capacity by an ex-vivo dynamic model of PLT adhesion under flow conditions, and to establish the influence of JAK2-V617F/Calreticulin (CalR)/MPL mutations, hematological parameters, and ongoing therapies.

Methods: One hundred-thirty patients, i.e. 78 ET (32 M/66 F; median age=61 years, range 28-86) and 52 PV (26 M/26 F; median age=65 years, range 38-87) were enrolled after informed consent. For the adhesion assay, peripheral venous whole blood was drawn in sodium citrate, recalculated in the presence of heparin, and perfused over a collagen-coated surface for 4 min. at a shear rate of 1,000 s⁻¹. PLTs were then stained with an anti-CD62P (P-selectin) antibody to evaluate PLT activation, and annexinV-AlexaFluor647 to detect pro-coagulant phosphatidylserine expression. After staining, phase contrast and fluorescence images of adherent PLTs were taken in random fields using an EVOS® microscope. Results are expressed as the means±SEM of the % of area covered by all PLTs (% coverage), or as the % of adherent PLTs positive for pro-coagulant phosphatidylserine expression, main hematological parameters, therapies, and mutational status were recorded.

Results: PLT adhesion was significantly (p<0.01) greater in either ET (45.3±1.7%) and PV patients (48.9±1.6%) compared to healthy controls (37.5±1.7%), while no difference was found between ET and PV patients. The analysis according to the mutational status shows that ET PLT adhesion was highest in JAK2-V617F mutation carriers (n=41; coverage: 47.7±2.0%, p<0.001 vs controls), followed by CalR-positive patients (n=21; coverage: 45.5±3.2%, p=0.05 vs controls, p=ns vs JAK2-V617F), while PLT adhesion of MPL-positive (n=3; coverage: 32.1±2.1%) or triple negative (n=13; coverage: 42.6±2.5%) ET patients was not statistically different from controls. In PV, no statistically significant difference was observed between subjects with >50% vs those with <50% JAK2-V617F allele burden. According to treatment, we observed that ET patients treated with the combination of aspirin+hydroxyurea presented the lowest PLT adhesion, while in PV no significant difference was observed between different anti-platelet or phosphatidylserine expression, main hematological parameters, therapies, and mutational status were recorded. The analysis of adherent PLT surface markers shows no difference in P-selectin expression between whole patients and controls. Differently, phosphatidylserine expression was significantly reduced (p<0.01) in both ET and PV compared to healthy subjects. The analysis of adherent PLT surface markers shows no difference in P-selectin expression between whole patients and controls. Differently, phosphatidylserine expression was significantly reduced (p<0.01) in both ET and PV compared to healthy subjects.

Summary/Conclusions: ET and PV platelets show an increased PLT thrombus formation potential, particularly in patients carrying the JAK2-V617F mutation in ET patients. Based on the results of these studies, it is worth to include a dynamic PLT adhesion assay in risk prediction models to evaluate the predictive value of thrombotic events in ET and PV patients. 

[Project funded by “AIRC-IG2013” grant Nr. 14005 of the “Italian Association for Cancer Research” (A.I.R.C.)]

DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK

Background: Direct acting oral anticoagulants (DOAC) use is increasing amongst patients requiring anticoagulation for AF or VTE. The incidence of major gastrointestinal (GI) bleeding in DOAC patients from clinical trials is reported to be similar or lower than those on warfarin. There is paucity of real world data to support the use of DOAC in clinical practice. We conducted a retrospective analysis of our database on patients usingDOAC over a 3 year period.

Methods: We conducted a retrospective analysis of our database on patients using DOAC over a 3 year period. DOAC associated major GI bleeding events were identified as per the ISTH criteria. Major bleeding was defined as per the ISTH criteria. The incidence of major GI bleeding in our cohort of over 2500 patients over 3 years was noted to be significantly lower than trial data. This is a much lower incidence than reported from clinical trials in patients on DOAC. Patients who suffered from a major GI bleeding did so on average 143 days (range 8-576) after starting the DOAC. Of all patients with major GI bleeding, 14 were taking apixaban (0.8% of all pt on apixaban), 3 (0.4% of all pt on rivaroxaban) rivaroxaban and 1 (0.3% of all pt on dabigatran) on dabigatran. The numbers were too small to identify any statistical difference between the three different DOAC drugs.

Summary/Conclusions: The risk of major GI bleeding in our cohort of over 2500 patients over 3 years was noted to be significantly lower than trial data. Since this is a retrospective review from patient hospital database there is a risk of reporting bias and under-reporting of bleeding events. A prospective phase IV study to identify bleeding risk in patients on DOAC is required. Majority of patients with major GI bleeding had other risk factors such as concurrent use of anti-platelets, peptic ulcer disease, alcohol abuse, oesophageal varices, diverticular disease, and bowel malignancy which would increase their bleeding risk on any anticoagulation. Further sub group analysis of this cohort and efforts to improve reporting of anticoagulation associated bleeding is underway.

INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVAScularIZATION: IS THROMBOPROPHYLAXIS WARRANTED?

Background: The incidence of postoperative deep vein thrombosis (DVT) or consequential pulmonary embolism (PE) in patients undergoing lower extremity surgical revascularization procedures is not well studied. The need for routine anticoagulation for DVT/PE prophylaxis after the lower limb surgical revascularization remains controversial.

Aims: The purpose of this study is to retrospectively evaluate the incidence of postoperative DVT/PE in patients undergoing lower limb surgical revascularization.

Methods: Charts for patients undergoing lower limb surgical revascularization, from 01/01/2010 to 12/31/2015, were evaluated for DVT/PE. DVT/PE within three months of the revascularization was considered to be a postoperative DVT/PE. Patients undergoing multiple procedures were counted as different cases if they were on different days. Multiple procedures on a patient on the same day were considered a single case. Patients with hypercoagulable states or previous history of DVT were excluded. Descriptive statistics and t-test was used to analyze incidence of DVT/PE and assess the importance of postoperative thromboprophylaxis.

Table 1.
postoperative day for recognition of DVT/PE was significant greater than 3.5 (7.6 vs 3.5, \textit{r}=2.17, \textit{p}=0.048). Patients developing DVT/PE did not differ by obesity or age when compared with non-DVT/PE population.

**Summary/Conclusions:** There have been only a few studies to assess the incidence of DVT/PE in patients undergoing lower limb surgical revascularization. In our study population, 1.4% of patients had evidence of DVT/PE. This constitutes a low risk of venous thromboembolism. The 2012 American College of Chest Physicians (ACCP) guidelines for prevention of venous thromboembolism in nonorthopedic surgical patients (Chest 2012; 141(2):S upp227s-227s), requires the use of pneumatic compression devices (PCDs), over no prophylaxis, to prevent DVT/PE in low risk patients. Since, patients with lower limb surgeries are not a good candidate for PCDs, pharmacological thromboprophylaxis with low dose heparin may be warranted. Given that bleeding is a potential complication in these patients, it might be prudent to start thromboprophylaxis 3-5 days after the surgery. Further studies are needed to assess the bleeding risks of postoperative thromboprophylaxis after surgical revascularization procedures.

### Table 1. Values, heritabilities, household effect and significant covariates effects.

<table>
<thead>
<tr>
<th>Trait</th>
<th>Value</th>
<th>b²</th>
<th>p value (b²)</th>
<th>c²</th>
<th>Covariates</th>
</tr>
</thead>
<tbody>
<tr>
<td>B12 (median)</td>
<td>441±240 (74-4558)</td>
<td>0.47</td>
<td>2.95×10⁻^7</td>
<td>0.11</td>
<td>Age, comorbidity, smoking</td>
</tr>
<tr>
<td>SF (median)</td>
<td>214±76 (6.2-43.4)</td>
<td>0.27</td>
<td>2.3×10⁻^7</td>
<td>0.07</td>
<td>Sex, comorbidity, smoking</td>
</tr>
<tr>
<td>RCF (median)</td>
<td>124±44 (47-3554)</td>
<td>0.42</td>
<td>1.85×10⁻^7</td>
<td>0.06</td>
<td>Sex, comorbidity, smoking</td>
</tr>
<tr>
<td>HCY (median)</td>
<td>10±4.05 (2.7-29.75)</td>
<td>0.36</td>
<td>3.61×10⁻^7</td>
<td>0.41</td>
<td>Sex, comorbidity, smoking</td>
</tr>
</tbody>
</table>

Values expressed as Mean+standard deviation, in brackets minimum and minimum values. B12: serum vitamin B12; SF: Serum folate; RCF: Red cell folate; HCY: Homocysteine.

### Table 2. Suggestive signals detected by GWAS.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Chromosome</th>
<th>Gene and ref</th>
<th>SNP</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>B12</td>
<td>19</td>
<td>HTRF2 rs152266</td>
<td>C.1</td>
<td>7.3×10⁻^7</td>
</tr>
<tr>
<td>SF</td>
<td>1</td>
<td>MTDRF1 rs190 133</td>
<td>C.1</td>
<td>1.3×10⁻6</td>
</tr>
<tr>
<td>RCF</td>
<td>1</td>
<td>TSFM TNSC14B198</td>
<td>C.1</td>
<td>4.1×10⁻6</td>
</tr>
<tr>
<td>HCY</td>
<td>11</td>
<td>ITGA1 rs170158</td>
<td>C.1</td>
<td>1.1×10⁻6</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** In the GAIT 2 study, genetic and environmental factors were related to B12, SF, RCF and HCY. Moreover, a relationship was observed between B12 and VTE. In the GWAS analysis some signals were previously reported (FUT2 and B12 or MTHFR with SF and HCY). New signals were found that need to be clarified, especially their possible relationship with susceptibility to thrombosis.

This work was supported by RIC RD12/0042/0032, FIS PI12/00612 and FIS PI 15/0269 grants.

### P766

**CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)**

C.J. Tartarì1,2, M. Marchetti1, R. Lacroix2, L. Russo1, S. Gamba1, A. Vignoli1, G. Finazzi3, A. Rambaldi3, A. Falanga1

1Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, 2Department of Hematology and Vascular Biology, Hospital La Conception, Marseille, France, 3Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy.

**Background:** Essential thrombocythaemia (ET) and polycythaemia vera (PV) are MPN characterized by a high rate of thrombotic complications. We previously demonstrated increased plasma levels of procoagulant MP in ET (Marchetti et al. A.J.H. 2013).

**Aims:** Aim of this study was to extend the analysis of MP to PV patients and to characterize the cellular origin of plasma MP in both ET and PV patients. The influence of somatic mutations [i.e. JAK2V617F, calreticulin (CalR), thrombopoietin receptor (MPL)] and concomitant cytoreductive or antiplatelet therapies was also evaluated.

**Methods:** Thirty-seven ET (19 JAK2V617F, 9 CalR and 2 MPL mutation carriers), 35 PV patients (all JAK2V617F carriers) and 36 healthy control subjects were included into the study. Flow cytometry was performed to characterize MP phenotype in platelet free plasma samples. To define MP cellular origin, anti-CD31 (endothelial cell marker), anti-CD41 (platelet marker), anti-CD11b (leucocyte marker), and anti-CD235 (erythrocyte marker) monoclonal antibodies were used. Annexin V (AnnV) staining was used to evaluate the expression of procoagulant phosphatidylserine on MP.

**Results:** ET and PV patients displayed significantly higher MP levels compared to controls (p<0.05). The majority of circulating MP (90%) were AnnV positive, indicating the expression of phosphatidylserine on their surface. In healthy con-
trols, 71% of MP was positive for platelet (P-MP), 24% for erythrocyte (E-MP), 4% for endothelial cell (EC-MP) and 1% for leukocyte (L-MP) specific markers. In ET and PV patients, the percentage of P-MP was significantly higher (80%; p<0.05), while E-MP level was significantly lower (15%; p<0.05) than controls. L-MP and EC-MP values were comparable between patients and controls. The absolute counts of P-MP and L-MP were higher in both ET and PV versus controls. Overall, no significant correlations were found between the levels of MP derived from platelet, leukocytes or erythrocytes and the corresponding cell counts. The analysis according to patient mutations, revealed significantly higher levels (p<0.05) of both P-MP and E-MP concentration in patients carrying JAK2V617F mutation as compared to JAK2V617F negative patients. In addition, ET patients positive for CaR mutation displayed lower levels (p<0.05) of P-MP compared to JAK2V617F carriers. No influence of concomitant therapies on MP levels or composition was observed.

Summary/Conclusions: Our data confirm the presence of high levels of circulating MP in MPN, which support the role in the known hypercoagulable state of these patients. The MP cellular origin has a different distribution profile according to the presence of different mutations. Importantly, the lack of correlation found between the total and subtype-specific MP counts with the corresponding cell of origin counts suggests an active stimulation of MP formation.

Project funded by AIRC-IG2013 N.14505 of the Italian Association for Cancer Research (AIRC).

P767

ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT (LA)? J. Sharif1,*, C. Humphrey1, I. Earnshaw1, J. Thachi1

1Haematology, Central Manchester University Hospitals, Manchester, United Kingdom

Background: The diagnosis of antiphospholipid syndrome (APS) requires the presence of thrombosis or defined pregnancy morbidity in addition to the presence of antiphospholipid antibodies on at least 2 occasions. Patients should be tested for antiphospholipid antibodies if they fulfil the required clinical criteria. Lupus anticoagulant may also be tested for when investigating a prolonged activated partial thromboplastin time which does not correct on mixing studies.

Aims: The aim of our study was to examine retrospectively the frequency of lupus anticoagulant (LA) testing in our institution, which we suspected to be high, and the incidence of positive results leading to a diagnosis of APS.

Methods: A total of 914 requests for LA were received over a 5 month period between 1st of May and 30th September 2014. We examined which departments were requesting the tests and the clinical indications for testing.

Results: Over 90% (829) of LA tests were negative. Nine percent (85) of tests demonstrated a positive LA. 33 patients had experienced arterial (11) or venous (22) thrombosis. There were 3 patients who fulfilled the clinical criteria for pregnancy morbidity in APS. A total of 6 patients experienced miscarriage before 10 weeks gestation; however none of these patients had the defined 3 miscarriages. There was one preterm delivery at 25 weeks due to pre-eclampsia. A further 3 patients had a still birth, one of which had an identifiable cause. In total, of the 85 positive results, 12 patients had a confirmed diagnosis of APS; a further 25 patients had the clinical manifestations fitting the clinical criteria for APS. Forty eight patients had a positive LA but did not fit the clinical criteria for a diagnosis of APS. The clinical specialties requesting the majority of tests were obstetrics and gynaecology (231), rheumatology (179) and clinical haematology (118). Of these, clinical haematology had the highest yield of positive results (16%) compared to 3% in obstetrics and gynaecology.

Summary/Conclusions: Our results highlight a high frequency of LA testing in our institution with a low yield of positive results (9%), resulting in a total of 1% of patients being diagnosed with APS. Our results demonstrate that the majority of tests for LA are not of clinical significance and often requested in patients not fitting the clinical criteria for APS. Further education for all practitioners who test will help to ensure only appropriate patients are tested. Indeed if a patient fits the clinical criteria for APS they should be tested for all antiphospholipid antibodies namely anti-cardiolipin and anti-b2-glycoprotein I as well as the lupus anticoagulant.

P768

RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE M.A. García Ruiz1,*, E. Morente Constantin1, P. Romero Garcia2, M. Gómez Morales1, M. Jurado Chacón1

1Servicio de Hematología y Hemoterapia, Complejo Hospitalario Universitario de Granada, Granada, 2Unidad de Cuidados Intensivos, Complejo Asistencial de Soria, Soria, Spain

Background: Bridging therapy consists of the administration of a fast-acting anticoagulant such as the low-molecular-weight heparin (LMWH) during the period of cessation of oral anticoagulant therapy. The decision to continue with anticoagulant therapy or to discontinue the treatment with the establishment of the Bridging therapy have been carried out carefully and on an individual basis. While taking this decision, we have taken into account three factors: the urgency of surgery or invasive process, the risk of bleeding and thrombotic risk for the patient. In recent decades, there have been multiple studies supporting the LMWH treatment, at least as safe and effective and more cost-beneficial than unfractionated heparin (UFH) in the 1-7 days of thrombotic event and the treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Therefore, the LMWH is considered as the drugs of choice in the prevention of venous thromboembolism. There are several types of commercialized LMWH, with different pharmacological properties, such as molecular weight, anti-Xa/IIa ratio and average life. The sodium bemiparin is the LMWH with greater anti-Xa/IIa ratio, which implies a lower risk of bleeding. In addition, it has shown a low incidence of VTE and bleeding in actual clinical practice.

Aims: There are few published data from bridging therapy at therapeutic doses in patients treated with oral anticoagulants (AVK) and perioperative management. It is intended to assess the efficacy (recurrence of thrombosis) and safe use of sodium bemiparin at anticoagulant doses on the bridging therapy and possible thrombotic and/or hemorrhagic complications (major and minor bleeding) resulting from this use.

Methods: We have analyzed 975 bridging therapies at full dose in our clinic in the last year. They were made to a total of 650 patients (315 men and 335 women) with CHADS2/VASC = 2, aged between 15 and 92, with an average age of 69 years old. The reasons of anticoagulation in our patients were atrial fibrillation, mechanical prostheses, DVT, pulmonary embolism and recurrent thrombosis in patients with thrombophilia. In 70% of the cases, there were comorbidities, such as heart failure, chronic obstructive pulmonary disease, anemia, kidney failure, liver disease and long-term aftereffects of stroke. The bridging therapy has consisted of sustaining the INR (warfarin) between 2 and 3 (12 hours before the procedure, and replacing it by sodium bemiparin at full doses <50 kg: 5,000 IU/24h, 50 to 70 kg: 7,500 IU/24 h, 70-100 kg: 10,000 IU/24 h and >100 kg: 12.500 IU/24 h, and administration of a prophylactic dose of 3,500 IU, 12 hours before the procedure, and another dose 6-12 hours after the procedure, depending on the risk of bleeding of the intervention and the thrombotic risk of the patient’s disease. The bridging therapy has been performed in 225 cases of major surgery (orthopedic surgery, ophthalmological procedures, valvular replacements etc), 340 cases of minor surgery (removal of nevus, complex dental extractions, dental implants), 295 cases of invasive procedures (colonoscopies, endoscopies...), 50 cases of bleeding caused by AVK (epistaxis, petechiae and bruises, hemoptysis, menorrhagia and gastrointestinal bleeding). 30 cases of hospitalization with INR decoupling with various causes (infectious endocarditis, pneumonia, uncompensated heart failure...) and 35 cases for thrombophilia study.

Results: As complications of using bemiparin sodium, there have been: 40 cases of hematomas at the needle puncture sites. There was neither cases of major bleeding nor cases of thrombosis.

Table 1.
Targeted therapies in relapsed in chronic lymphocytic leukemia

S769

IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP


1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2The Ohio State University Comprehensive Cancer Center, Columbus, United States, 3The Leeds Teaching Hospitals, St. James’s Institute of Oncology, Leeds, United Kingdom, 4University of California Irvine, Irvine, CA, 5Hofstra School of Medicine, Hempstead, New York, 6Vanderbilt Ingram Cancer Center, Nashville, TN, 7Stanford University School of Medicine, Stanford, United States, 8Pfizer Macallum Cancer Centre and St. Vincent’s Institute of Medical Research, Melbourne, 9Royal North Shore Hospital, Sydney, Australia, 10Division of Haematology and Hemostaseology, Medical University of Vienna, Vienna, Austria, 11University of Rochester Medical Center, Rochester, NY, 12Well Cornell Medical College, New York, 13University of California San Diego, Moores Cancer Center, La Jolla, United States, 14Beaumont Hospital, Dublin, Ireland, 15Niguarda Cancer Center, Milano, Italy, 16Swedish Cancer Institute Hematologic Malignancies Program, Seattle, 17University of Texas MD Anderson Cancer Center, Houston, TX, 18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, 19C.CLL Center, Dana-Farber Cancer Institute, Boston, United States

Background: Ibrutinib is a first-in-class, once-daily oral inhibitor of Bruton’s tyrosine kinase. Ibrutinib as a single agent is indicated by the EMA and US FDA for the treatment of adult patients with CLL and allows for treatment without chemotherapy. The phase 3 RESONATE trial in patients with relapsed CLL showed superior efficacy of ibrutinib compared with ofatumumab (Byrd NEJM 2014).

Aims: We report updated safety and efficacy results of the RESONATE trial with up to 4 years of follow-up.

Methods: Eligibility criteria included ≥1 prior therapy, ineligibility for treatment with a purine analog, and ECOG performance status 0-1. Informed consent was obtained from all patients prior to study initiation. Patients received oral ibrutinib (420 mg once daily) until disease progression or unacceptable toxicity or intravenous ofatumumab (300 mg weekly; 2000 mg weekly for 7 weeks and then every 4 weeks for 16 weeks) for up to 24 weeks. At the interim analysis (median follow-up of 9 months), the data monitoring committee declared superior OS, PFS, and response rates in patients treated with ibrutinib vs ofatumumab. Ibrutinib was recommended for all patients in ofatumumab arm who had disease progression. Long-term follow-up of efficacy endpoints are endpoints for investigator assessment. Patients randomized to ofatumumab were censored at crossover for OS.

Results: Of 402 patients, 293 were randomized to receive ibrutinib (n=195) or ofatumumab (n=196). The median age was 67 years, with 40% age ≥70 years, and Rai stage III/IV in 57% of patients. At a median follow-up of 44 months (maximum 53 months), the ibrutinib arm, PFS was significantly longer for ibrutinib vs ofatumumab (median NR vs 8 months, HR 0.133, P<0.0001). The 3-year PFS was 59% for ibrutinib vs 3% for ofatumumab. A significant PFS benefit was observed across baseline subgroups. In the ibrutinib arm, PFS for the del11q subgroup tended to have the most favorable outcome; however, PFS outcomes were not statistically different for patients with del11q or del11q patients without these FISH abnormalities. At time of analysis, with the majority of patients randomized to ofatumumab (68%) crossing over to receive ibrutinib therapy, OS was longer for ibrutinib vs ofatumumab (median OS NR for either arm). The 3-year OS rate for ibrutinib was 74%. The ORR for ibrutinib was 91% with a CR/Cri rate that increased over time (currently 99%). Baseline cytopenias improved with extended ibrutinib therapy for hemoglobin (85% of patients), platelet (95% of patients), and absolute neutrophil counts (95% of patients). The adverse event (AE) profile of ibrutinib was consistent with previous reports. During a follow-up of 4 years, major hemorrhage occurred in 6%, grade ≥3 atrial fibrillation occurred in 6%, and grade ≥3 hypertension occurred in 8% of patients. The incidence of most grade ≥3 AEs decreased from year 1 vs year 2-3: neutropenia: 18% vs 8%, pneumonia: 11% vs 4%, atrial fibrillation: 4% vs 2%, respectively. The most frequent reasons for treatment discontinuation were progressive disease (27%) and AEs (12%). At analysis, 90 patients randomized to ibrutinib (46%) continue to receive ibrutinib.

Summary/Conclusions: In this international phase 3 RESONATE study with median follow-up of up to 4 years, long-term treatment with ibrutinib showed a favorable tolerability profile with sustained PFS and OS benefit regardless of high-risk cytogenetics. The results in relapsed del17p and del11q patients compared favorably to those previously reported in phase 2 studies.

S770

THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL: SWEDISH ACCESSIBLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY

P. Hillmen1, A. Rawstron2, T. Muni3, K. Brock4, S. Munoz-Vinent3, Y. Jefferson4, K. Paterson5, C.P. Fox6, J. Gribben6, A. Bloor7, A. Schuh8, F. Forconi9

1Bloodwise National Haematology, University of Leeds, United Kingdom, 2H.M.D.S., St James’s Institute of Oncology, 3Haematology, St. James’s Institute of Oncology, Leeds, United Kingdom, 4Cancer Research UK Clinical Trials Unit, University of Birmingham, 5Barts Cancer Institute, London, 6University Hospital, New Delhi, Manchester, 7Churchill Hospital, The University of Oxford, 8Southampton General Hospital, Southampton, United Kingdom

Background: Ibrutinib is an oral BTK inhibitor with high response rates in CLL. Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-molecule BCL2 inhibitor. Both ibrutinib and VEN are approved by the FDA and EMA as single agents for chronic lymphocytic leukaemia (CLL). Ibrutinib leads to a rapid nodal response with re-distribution of CLL into the peripheral blood whereas VEN leads to depletion of CLL cells to levels in some patients where they cannot be detected. Two of the key cellular processes that are abnormal in CLL are proliferation and apoptosis. The combination of ibrutinib with VEN is therefore logical as biologically the two drugs would be expected to be synergistic. The eradication of minimal residual disease (MRD) from blood and bone marrow is associated with improved outcome in any treatment of CLL where it has been reported.

Aims: The CLARITY trial (ISRCTN: 13751882) is a feasibility study to investi- gate and compare the safety and efficacy of the combination of ibrutinib with VEN in patients with relapsed/refractory CLL. Here we report for the first time the safety of the combination as well as early signs of potent synergy.

Methods: After 8 weeks of IBR monotherapy (420mg/day), VEN was added at a dose of 10mg/day with weekly escalations to 20mg, 50mg, 100mg, 200mg to a final dose of 400mg/day. After the initial 3 patients when there was no sign of tumour lysis syndrome (TLS) the starting dose of VEN was amended to 20mg/day. The primary end-point of the trial is MRD eradication (defined as less than 1 CLL cell in 10,000) in the bone marrow after 12 months of IBR+VEN. Key secondary end-points are MRD eradication from the bone marrow after 6 and 24 months of combined IBER and VEN as well as the safety of the combi- nation. Important safety events that were considered critical were the incidence of laboratory and clinical TLS. All patients were given prophylactic treatment with uric acid reducing agents beginning at least 72 hours prior to their initial dose of VEN. Over the first three months of combined therapy the level of CLL in the peripheral blood was monitored weekly during VEN escalation and then monthly thereafter. 50 participants will be treated in total.

Results: A total of 35 patients have been recruited between May 2016 and January 2017. To date 21 patients have completed the dose escalation period of IBR and are ongoing on the combination with VEN. To date there has been only a single case of laboratory TLS in a patient whose phosphate (1.21 to 1.48mmol/l) and creatinine (75 to 146 umol/l) both increased when VEN was increased from 100mg to 200mg. Dosing of VEN was interrupted for 7 days (due to the logistics of clinic closure periods over the Christmas break) and IBR for 24 hours. The biochemical changes were reversed with appropriate management and all patients remained on therapy. No SUSAR’s or SAE’s have been reported and no AE’s have been fatal. The level of CLL in the peripheral blood increased during the 8 weeks of IBR monotherapy at 420mg/day from a median of 50 x 10^9/l to a median of 0.017 x 10^9/l (range: 0 to 3). The rate of fall is rapid in all patients with a median of 3 log reduction in CLL level after 8 weeks of combined therapy.

Summary/Conclusions: The combination of IBR with VEN is well tolerated in relapsed, refractory CLL with to date only a single case of laboratory TLS. The dose escalation period in the 1st 3 months of combined therapy the level of CLL in the peripheral blood was monitored weekly during VEN escalation and then monthly thereafter. 50 participants will be treated in total.

S771

VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL


1University of Ulm, Ulm, Germany, 2AbbVie Inc, North Chicago, IL, United States,
Background: Venetoclax monotherapy in patients (pts) with relapsed/refractory CLL harboring deletion 17p (del17p) resulted in an ORR of 79% with a CR rate of 7% as determined by an independent review committee at the initial therapy. CLL harboring deletion 17p (del17p) resulted in an ORR of 79% with a CR rate of 7% as determined by an independent review committee at the initial therapy. ORR amongst 36 evaluable pts was shown in the following Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>ORR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL/SLL</td>
<td>19</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>FL/DLBCL</td>
<td>6</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td>MCL</td>
<td>4</td>
<td>1</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 2.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>ORR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL/SLL</td>
<td>19</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>FL/DLBCL</td>
<td>6</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td>MCL</td>
<td>4</td>
<td>1</td>
<td>100</td>
</tr>
</tbody>
</table>

Methods: Eligible pts had CLL or rel/ref NHL w/o limit to prior therapies, including those ref to prior PI3Kδ or BTK inhibitors. UTX dose was as follows: D 1 of C 2-6, and C 9 & 12. TGR-1202 dose escalated (400/800/800mg QD), ibritinib dosed at 420mg (CLL) or 560mg (NHL), both on C1D1. As of data cut-off 38 pts were enrolled in 20 CLL/SLL and 10 NHL, including 6 follicular (FL), 6 DLBCL, 4 mantle cell (MCL) and 2 marginal zone (MCL) (Med age 65 yrs (range 32-85); 29 M/9 F; med prior tx=3 (range 0-6). 2 pts ref to prior PI3Kδ/2 prev treated with ibritinib (1 ref/1 rel). MTD was not reached. Most common (≥20%) all causality AEs were fatigue (42%), diarrhea (39%), dizziness (34%), nausea (32%), neutropenia, pyrexia, rash, infusion reaction, insomnia (each at ≥20%), thrombocytopenia, cough (each at ≥20%), anemia (24%) and sinusitis (21%). CR/PR AEs (all causality) were minimal, the only event ≥10% was neutropenia (16%). AEs amongst 36 evaluable pts is shown in the following Table 1.

Table 3.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>ORR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL/SLL</td>
<td>19</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>FL/DLBCL</td>
<td>6</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td>MCL</td>
<td>4</td>
<td>1</td>
<td>100</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This is the first known triplet combination of an anti-CD20 mAb+PI3Kδ+BTK inhibitor. The combination of UTX, TGR-1202, and ibritinib has been well tolerated with activity observed across heavily pre-treated and refractory B-cell malignancies. Expansion cohorts at the highest dose (800mg TGR-1202+full dose ibritinib) are underway. Future trials for the triplet are warranted.

S773
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A DUAL SYK/JAK/KIT INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
P. Hamlin1,*, C. Farber2, T. Fenske3, J. Khatcheressian4, C. Miller5, J. Munoz6, M. Patel7, S. Smith7, D. Stevens8, A. Pandey9, M. Birrell10, J. Leed11, Y.L. Wang12, G. Coffey13, J. Cumritte14
1Memorial Sloan Kettering Cancer Center, New York, 2Carol G. Simon Cancer Center, Morristown, NJ, 3Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, 4Virginia Cancer Institute, Richmond, VA, 5St. Agnes Hospital Cancer Center, Baltimore, MD, 6Banner MD Anderson Cancer Center, Gilbert, AZ, 7Florida Cancer Specialists/Sarah Cannon Research Center, Sarasota, FL, 8University of Chicago, Chicago, IL, 9Norton Cancer Center, Louisville, KY, 10Portola Pharmaceuticals, South San Francisco, 11Department of Pathology, University of Chicago, Chicago, IL, United States

Background: Subsets of B cell malignancies are addicted to B cell antigen receptor (BCR) signaling for survival. Co-stimulation of the BCR with IL-2 or IL-4 in normal B cells significantly enhances cellular activation relative to BCR or cytokine stimulation alone, and combining SYK and JAK selective inhibitors synergize to suppress this response (Coffey et al., 2013). Hence, BCR/SYK and cytokine JAK/STAT signals cooperate to control B cell activation. This cooperation appears to be relevant to B cell malignancies as well. IL-4 promotes the survival of CLL cells in culture via up-regulation of MCL1 and BCLXL, protecting the tumor from death induced by fludarabine and chlorambucil (Steele et al., 2010) and by idelalisib and ibritinib (Aguilar-Hernandez et al., 2016). Also, unlike ibritinib, combined SYK and JAK inhibition by cerdulatinib induces apoptosis in primary CLL cells and leads to down-regulation of MCL1 and BCLXL (Blunt et al., 2015) and induces apoptosis in cells from ibritinib-resistant CLL patients (Guo et al., 2017). It also induces apoptosis in primary DLBCL and DLBCL cell lines that carry BCR pathway mutations resistant toibrutinib (Ma et al., 2015). Cerdulatinib (LY2738037) targets SYK and JAK2, inhibiting the activity of the JAK/STAT signaling pathway. Hence, this molecule is being evaluated in the Phase 1 study for the treatment of CLL/SLL and NHL, and phase II trials in combination with a PI3Kδ inhibitor have already shown promising results.

Methods: Eligible patients (pts) were those with relapsed/refractory B cell malignancies, including CLL, SLL, DLBCL, or FL, who had previously received at least one prior therapy. The primary objectives of the study were to determine the safety, tolerability, and activity of the cerdulatinib/UTX combination in these pts. The safety of cerdulatinib was assessed in a dose-escalation phase, while the activity was assessed in a dose-confirmation phase. The cerdulatinib dose was escalated from 30 to 300 mg daily, and the UTX dose was escalated from 200 to 800 mg daily. The primary end point was the ORR, defined as the percentage of pts who achieved a complete or partial response. Secondary end points included the duration of response, time to progression, and overall survival. Safety was assessed by monitoring adverse events (AEs) and laboratory parameters.

Results: A total of 23 pts were enrolled in the study, including 19 with CLL/SLL and 4 with NHL. The ORR was 65% (9/14) in the CLL/SLL cohort and 25% (1/4) in the NHL cohort. The most common AEs were neutropenia (34%), thrombocytopenia (26%), and fatigue (21%). The median duration of response was 11 months in the CLL/SLL cohort and 6 months in the NHL cohort.

Summary/Conclusions: Cerdulatinib in combination with UTX is well tolerated and shows promising activity in pts with relapsed/refractory B cell malignancies. Further studies are warranted to evaluate the efficacy of this combination in larger patient populations.

S772
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
1Memorial Sloan Kettering Cancer Center, Houston, TX, United States

Background: Venetoclax monotherapy in patients (pts) with relapsed/refractory CLL harboring deletion 17p (del17p) resulted in an ORR of 79% with a CR rate of 7% as determined by an independent review committee at the initial therapy. ORR amongst 36 evaluable pts was shown in the following Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>ORR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL/SLL</td>
<td>19</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>FL/DLBCL</td>
<td>6</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td>MCL</td>
<td>4</td>
<td>1</td>
<td>100</td>
</tr>
</tbody>
</table>

Methods: Eligible patients (pts) with relapsed/refractory B cell malignancies, including those who had previously received a B-cell receptor signaling inhibitor (BCR), were treated with UTX and cerdulatinib. The cerdulatinib dose was escalated from 30 to 300 mg daily, and the UTX dose was escalated from 200 to 800 mg daily. The primary objectives of the study were to determine the safety, tolerability, and activity of the cerdulatinib/UTX combination in these pts. The safety of cerdulatinib was assessed in a dose-escalation phase, while the activity was assessed in a dose-confirmation phase. The cerdulatinib dose was escalated from 30 to 300 mg daily, and the UTX dose was escalated from 200 to 800 mg daily. The primary end point was the ORR, defined as the percentage of pts who achieved a complete or partial response. Secondary end points included the duration of response, time to progression, and overall survival. Safety was assessed by monitoring adverse events (AEs) and laboratory parameters.

Results: A total of 23 pts were enrolled, including 19 with CLL/SLL and 4 with NHL. The ORR was 65% (9/14) in the CLL/SLL cohort and 25% (1/4) in the NHL cohort. The most common AEs were neutropenia (34%), thrombocytopenia (26%), and fatigue (21%). The median duration of response was 11 months in the CLL/SLL cohort and 6 months in the NHL cohort.

Summary/Conclusions: Venetoclax monotherapy resulted in a high response rate that was durable in this high-risk population, including among pts who had previously received a B-cell inhibitor. MRD negativity by either flow cytometry or NGS correlated with outstanding outcomes.
mg and 35 mg) dosing was evaluated. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were monitored, as well as an assessment of efficacy. Clinical response was assessed by standard criteria. Potency and specificity for SYK and JAK pathway inhibition were measured in whole blood assays by monitoring signaling responses following ligation of the BCR and receptors for IL-4. Serum markers of inflammation, minimal residual disease (MRD) and apoptosis in CLL patients were also measured.

**Results:** A phase 2 study was initiated in May 2016 to enroll up to 40 patients in each of three cohorts; 1) relapsed/refractory CLL/SLL, 2) relapsed/refractory indolent NHL, and 3) relapsed DLBCL, MCL and transformed FL. As of March 1, 2017, 37 patients have been enrolled, 17 with CLL/SLL, 15 with indolent NHL (10 FL, 4 MZL, 1 WM), and 5 with aggressive NHL (3 DLBCL, 1 MCL, 1 tFL). Median patient age is 70 years (range, 51-93). The median number of prior therapies is 3 (range 1–7). 11 patients had prior BTK or PI3K inhibitor therapy. The safety profile has been similar to what was seen in the Phase 1 study. However, 3 patients at 35 mg BID achieved higher than expected drug concentrations and had SAEs (2 grade 5 infections, 1 grade 3 pancreatitis). The starting dose was reduced to 30 mg BID and a PK monitoring and dose reduction strategy has been implemented. To date, this has resulted in a better safety profile without PK outliers. The most common AEs of any grade have been diarrhea (27%), fatigue (27%) and nausea (24%). Grade 3+ AEs occurring in more than 1 patient are infection (5 patients), abdominal pain (3 patients) and hypertransaminemia (3 patients). As seen in phase 1, significant inhibition of SYK and JAK signaling pathways in peripheral blood is observed. Evidence for tumor cell mobilization to peripheral blood in CLL/SLL is consistently observed following one week of therapy. PRs have been seen in all 3 cohorts including 10 of 13 (77%) CLL/SLL and 3 of 6 (50%) FL patients evaluated. Of these 13 PRs, 12 are still on drug with 4 patients in response for greater than 6 months. In addition, PRs have been seen in patients who relapsed on ibritinib (FL patient, 8+ months) and venetoclax (SLL patient, 7+ months) therapy. As demonstrated preclinically, we have seen evidence of apoptosis (Annexin V+ B-cells) in 6 CLL patients. 5 of these patients had a PR at the end of the 2nd cycle (Figure 1).

**Figure 1.**

**Summary/Conclusions:** Cerdulatinib demonstrates clinical activity in heavily pretreated patients with CLL/B-cell NHL and is generally well tolerated. Consistent activity is seen in patients with CLL and FL. Accrual is proceeding; updated PK/PD, safety and efficacy will be presented.

---

**Follicular lymphoma - Clinical**

**S774 COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY**


1Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia, 2KLg and Gs St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering, Kings College London, London, United Kingdom, 34th Department of Internal Medicine – Hematology, University Hospital Hradec Králova, Hradec Královo, 4Faculty of Medicine, Charles University, Prague, Czech Republic, 5Service de Médecine Nucléaire, Hôpital Henri Mondor and Université Paris Est Créteil, Créteil, 6University of Alberta Cross Cancer Institute, Edmonton, 7Foothills Medical Centre and Tom Baker Cancer Centre, Calgary, Canada, 8Department of Nuclear Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic, 9Department of Medicine, National Institute of Oncology, Budapest, Hungary, 10Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland, 11Ludwig-Maximilians-University Munich, Munich, Munich, 12Department of Haematology, Kings College Hospital, London, 13Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom

**Background:** Published data show 18F-FDG PET-CT (PET) is predictive after first-line immunochemotherapy in advanced-stage symptomatic FL, and PET is now the recommended modality for response assessment. However, no large-scale prospective comparison of the value of standard contrast-enhanced CT vs PET response has been performed.

**Aims:** To compare CT and PET response assessment for FL pts in the prospective Phase III GALLIUM study, which evaluated chemotherapy plus obinutuzumab (G-chemo) or rituximab (R-chemo) induction followed by maintenance antibody therapy (Marcus 2016).

**Methods:** PET scans, introduced after an early protocol amendment (July 2011), were performed at baseline and end of induction (EOI; all pts gave informed consent) and assessed by the investigator (INV) and an independent review committee (IRC) comprising two radiologists, with a third adjudicator; final response was determined by a clinician. Response was assessed by CT and PET plus bone marrow biopsy, applying the revised International Working Group (IWG) criteria (Cheson 2007, Juweid 2007). Complete remission (CR) status at EOI for each assessment, CT-CR and PET-CR, was compared with pt characteristics, PFS and OS.

**Results:** Among 1202 ITT pts with FL enrolled in GALLIUM, IRC-assessed CT showed a CR in 330 pts (27.5%), PR in 747 (62.1%), SD in 20 (1.7%), PD in 35 (2.9%), unavailable (NA) in 48 (4.0%) and unacceptable (NE) in 22 (1.8%). Of 609 pts with a baseline PET scan, 595 had detectable lesions, and 535 also had an evaluable PET at EOI. Baseline demographics and disease characteristics were similar in PET and non-PET populations. Pts with NA (n=52) or NE (n=8) scans were considered non-responders; these pts and those with PD prior to EOI were excluded from landmark PFS analyses. At EOI, 390/395 (65.5%) pts achieved a PET-CR according to IRC, comprising 212/297 (71.4%) G-chemo pts and 178/289 (59.7%) R-chemo pts. However, for these 390 pts, evaluable CT responses were 161 CR (41.3%), 216 PR (55.4%) and 5 SD/PD (1.3%) (Table 1). Conversely, PET assessment showed a PET-CR in 212/297 (71.4%) pts achieving a CT-CR, and PET-PR in only 117/362 (32.3%) of pts with CT-PR. Concordance between CT and PET assessment was 52.6% for IRC and 54.1% for INV. Concordance between INV and IRC evaluation was 71.9% for CT and 68.6% for PET. After a median follow-up of 34.5 mo (range 0–54.5), IRC-PET status was highly predictive of PFS (PET-CR vs PET non-CR: HR 0.39; 95% CI 0.25–0.60; p<0.0001) and OS (HR 0.41; 95% CI 0.19–0.86; p=0.018). 2.5-yr PFS from EOI was 87.6% (95% CI 83.5–90.8) for PET-CR pts compared with 70.9% (95% CI 61.3–78.6) for PET non-CR pts; corresponding OS was 96.6% (95% CI 94.1–98.1) vs 90.9% (95% CI 84.7–94.6) (Figure 1).

**Table 1: CT and PET clinical response assessment by IRC at EOI**

<table>
<thead>
<tr>
<th>Group (IWG)</th>
<th>CT-CR</th>
<th>PET-CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>No EOI</td>
<td>212/297 (71.4%)</td>
<td>212/297 (71.4%)</td>
</tr>
<tr>
<td>Any EOI</td>
<td>161/362 (44.5%)</td>
<td>117/362 (32.3%)</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** This large prospective analysis confirms EOI PET as an early predictor of PFS and OS in FL, with good concordance between INV and PET.

---

*Madrid, Spain, June 22 – 25, 2017*
and IRC PET evaluation. Comparison of PFS based on CT-response and re-analysis of PET scans applying the now recommended 5-point scale for PET response assessment will be presented. Pooled analyses of these data and from other studies with longer follow-up may determine PET response as a reliable early surrogate for PFS and OS, providing a platform for study of response-adapted therapy.

Figure 1.

S775

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN


1Department of Medicine III, Ludwig-Maximilians-University Munich, Munich, Germany, 2Department of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, 3Department of Medicine, Hospital Universitario la Paz, Madrid, Spain, 4Haematology Department, Fiona Stanley Hospital, Murdoch, Australia, 5Department of Clinical Haematology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom, 6Medical Faculty (Haematology), Universitaetsklinikum Essen, Essen, Germany, 7Oncology Center, HELIOS-Klinikum Erfurt, Erfurt, Germany, 8Department of Haematology, Prince of Wales Hospital, Sydney, Australia, 9First Faculty of Medicine, Charles University General Hospital and Institute of Pathological Physiology, Charles University, Prague, Czech Republic, 10Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland, 11The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 12Department of Haematology, National Cancer Center Hospital, Tokyo, Japan, 13Pharma Development Safety and Risk Management, 14Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland, 15Department of Haematology, Kings College Hospital, London, United Kingdom

Background: The Phase III GALLIUM study (NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged PFS in previously untreated FL pts relative to rituximab (R) when combined with chemotherapy (chemo; CHOP, CVP or bendamustine [B]). Grade 3–5 and serious AEs were more common with G-chemo.

Aims: To explore outcomes by immunochemotherapy regimen.

Methods: Pts were aged ≥18 yrs with documented, previously untreated FL (grades 1–3a), advanced disease (stage III/IV or stage II with tumor diameter ≥7cm), ECOG PS 0–2, and requiring treatment according to GELF criteria. Chemo regimen was allocated by center. Pts were randomized 1:1 (stratified by chemo, FLIPI-1 group and geographic region) to R 375mg/m² on day (D) 1 of each cycle (C) or G 1000mg on D1, 8 and 15 of C1 and D1 of C2–8, for 6 or 8 cycles depending on chemo. Pts with CR or PR at EOI (per Cheson 2007) continued to receive R or G every 2 months for 2 yrs or until progression. The cut-off date for this analysis was September 10 2016. All pts gave informed consent.

Results: 1202 FL pts were randomized. Baseline characteristics were generally similar across chemo groups, although B and CVP pts had relatively more comorbidities, e.g. GI and vascular disorders, than CHOP pts. After 41.1 months’ median follow-up, investigator (INV)-assessed PFS remained superior for G-chemo relative to R-chemo (HR, 0.68; 95% CI 0.54–0.87; p=0.0016) with consistent HRs across chemo groups (Figure 1). HRs for secondary time-to-event endpoints were supportive of the primary analysis. Difference in frequency of grade 3–5 AEs between arms was highest with CHOP and CVP (Table 1). Rates of second neoplasms and grade 3–5 infections were similar in G and R arms for CHOP and CVP but not for B. In all chemo groups, SAEs were more frequent with G than R, and AEs causing treatment discontinuation and fatal AEs were similar. Reductions in T-cell counts were more pronounced and prolonged in the B group than CHOP or CVP groups.

Summary/Conclusions: In treatment-naive FL pts, PFS was superior with G-chemo relative to R-chemo with consistent effects across chemo regimens. Some differences were seen in safety profiles between chemo regimens, but comparisons may be confounded by the lack of randomization.

S776

EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY


Table 1. Safety summary (number (% of FL pts) with ≥1 AE).

Summary/Conclusions: In treatment-naive FL pts, PFS was superior with G-chemo relative to R-chemo with consistent effects across chemo regimens. Some differences were seen in safety profiles between chemo regimens, but comparisons may be confounded by the lack of randomization.

S776

EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY

Duvelisib is an oral, dual inhibitor of PI3K-δ,γ in development for the treatment of hematologic malignancies. DYNAMO is a Phase 2 study to evaluate the safety and efficacy of duvelisib monotherapy in a double refractory iNHL population, which included a majority of patients (pts) with follicular lymphoma (FL).

Aims: The primary objective was to evaluate the antitumor activity of duvelisib monotherapy in pts whose disease is refractory to rituximab and to either chemotherapy or RIT, with an additional objective to further characterize the safety profile of duvelisib.

Methods: DYNAMO is an open-label, single-arm, safety, and efficacy study in patients (pts) with FL, small lymphocytic lymphoma (SLL), or marginal zone lymphoma (MZL), whose disease is double-refractory to rituximab (monotherapy or in combination) and to chemotherapy or radioimmunotherapy. Pts received duvelisib 25 mg orally twice daily from the day prior to first dose of any cancer therapy to first dose of duvelisib. The primary endpoint is overall response rate (ORR) as assessed by an independent review committee (IRC) per revised IWG criteria. Secondary endpoints include duration of response (DOR), safety and tolerability.

Results: A total of 141 patients with iNHL were treated in the Phase II study, including 104 patients with FL. The FL cohort was characterized as: 52% male, 83% white, median age 62 years, 52% ECOG 0, 63% refractory to last therapy, median time from most recent progression 8 wks (range 1-73) and median prior lines of therapy 3 (range 2-8). Of these, 83 pts with FL received duvelisib with a median duration of exposure of 6 mo. (range: 0.4 - 24). Median age was 64 years; 68% were male. Most FL pts had an ECOG performance status score at baseline of 0 (51%), followed by 1 (42%) and 2 (7%). Most FL pts (65%) had a FLIPI score at baseline ≥3, and most had either Stage 3 (46%) or Stage 4 (39%) disease. Median time from last anticancer therapy to first dose of duvelisib was 3.2 months. FL pts received a median of 3 prior anticancer regimens (range: 1 - 10); 65% of pts received >3 prior regimens, 17% 2 prior regimens, all of which were PRs. 36% of pts had SD as best response, and 17% had PD as best response. 6% of pts were not evaluable, as they only had a baseline scan. Median TTR was 1.9 mo. (range: 1.6 - 11.7). 80% of FL pts experienced a reduction in nodal target lesions. In FL pts with a response to the median Duvelisib was 9.2 months. The median PFS for all FL pts was 8.3 months, while the median OS was 11.1 months. Among all pts treated on study (n=129), AE were mostly Gr 1-2. Most common Gr 3 AE were transient cytopenias (neutropenia 39%, anemia 15%, and thrombocytopenia 15%). 17% of pts discontinued duvelisib due to an AE. Opportunistic infections occurred in <5% of pts, none were fatal, and included 1 pt (0.8%) with pneumocystis and 3 pts (2.3%) with CMV infections. Six pts had an AE with a fatal outcome.

Summary/Conclusions: In DYNAMO, duvelisib showed clinical activity in a double refractory FL population (41% ORR, median DoR 9.2 mo., 80% with reduction in target lesions). Duvelisib was generally well tolerated, with a manageable safety profile with appropriate risk mitigation. Duvelisib monotherapy has a favorable benefit-risk profile in double refractory iNHL, and may represent an important treatment option. Updated clinical data will be available at the time of presentation.
Background: Between March 2000 and May 2005 a multicenter randomized trial comparing frontline use of CHOP-R vs R-HDS with autograft has been performed on 134 Follicular Lymphoma (FL) patients, selected for age less than 60 yrs. and poor prognostic features according to age-adjusted IPI (2-3) and IIL-score (3 or greater). Results at 4-yr follow-up were previously published (Ladetto M et al, Blood 2008), showing superior disease control with R-HDS without any survival advantage.

Aims: We have recently performed a long term update and the results at a median follow-up of 13 yrs are here presented.

Methods: The long-term outcome has been updated for 119 out of the original 134 randomized patients (56 CHOP-R and 63 R-HDS arms). Main features of the updated patients included: median age 51 yrs. (22-60), M/F ratio 68/51, aaIPI 2-3 90%, high LDH 43%, bulky disease 60%, B-symptoms 46%, BM involvement 86%; no significant differences were observed in clinical presentation between the two arms, as previously reported. Treatment schedule consisted of: i. CHOP-R arm: 6 courses of cyclophosphamide/doxorubicin/vincristine/prednisone followed by 4-weekly rituximab courses; ii. experimental R-HDS arm: rituximab with high-dose sequential chemotherapy followed by autografting. The analysis was intention to treat with event-free survival as the primary endpoint. Minimal residual disease (MRD) was evaluated post treatment in 56 patients with a bcl-2/IgH MBR or mcr translocation confirmed at diagnosis by nested PCR. The trial was registered at www.clinicaltrials.gov, no. NCT00435955. The long-term outcome has been updated in January 2017 by 27 out of 30 participating Centers, on 119 patients (88% of the whole series).

Results: Complete remission (CR) was achieved by 86 (72%) patients, including 32 (57%) with CHOP-R and 54 (85%) with R-HDS (p <.001); Molecular Remission (MR) was achieved in 37 out of 56 (66%) evaluable patients. At a median follow-up of 13 yrs., 74 patients (63%) are alive. Overall, 22 patients died for lymphoma progression (13 CHOP-R, 9 R-HDS), 12 died for secondary malignancy (3 in the CHOP-R, 9 in the R-HDS arms), 11 patients died for other causes, including four early toxic deaths. The overall survival (OS) for the whole series is 63% at 13 yrs, as shown in Figure 1A. No significant differences in the long-term OS were observed between the two arms, with 13-yr survival of 65% and 61% for CHOP-R and R-HDS, respectively (p=0.51). At 13 years, the event free survival is 35%, whereas the disease-free survival (DFS) is of 53%, as shown in Figure 1B. Response to induction therapy had a major impact on the OS, with 13 yr survival of 75% for patients achieving CR vs 33% for those with less than CR (p <.001). Similarly, Molecular Remission (MR) achievement was associated with prolonged OS, with 13 yr survival of 81% for patients in MR on BM cells, and of 47% for those with positive MRD (p<.02) (Figure 1C).

Summary/Conclusions: i. poor risk FL may have a prolonged survival, with 63% of patients alive at 13 yrs.; ii. no survival differences between CHOP-R and R-HDS can be detected even at 13 yrs of follow-up; iii. achieving CR is still crucial for the long-term survival; iv. the MRD analysis has a prognostic impact not only on progression-free but also on OS; v. lymphoma progression remains the major cause of death, while secondary neoplasms represent the second cause of treatment failure; vi. a subgroup of advanced-stage FL may experience a prolonged DFS lasting at least 13 yrs: this raises the issue of the potential curability of FL.

Figure 1.
Changing the strategy of therapy in multiple myeloma

S779

PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA

I. Obohina1, A. Cadà1, P. Henrik1, A. Savelii2, J. Cappuccio1, B. Rivolta1, K. Reyes1, C. Padra-Prada1, R. Schlossman1, J. Laubach1, P. Richardson1, K. Noonan1, N. Mushni1, C.-J. Liu1, M. Bustoros1, A. Badros3, J. Matous4, K. Noonan1, N. Munshi1, C.-J. Liu1, M. Bustoros1, K. Salem1, S. Manier1, J. Park1, K. Reyes1, C. Paba-Prada1, R. Schlossman1, J. Laubach1, P. Richardson1, K. Noonan1, N. Mushni1, C.-J. Liu1, M. Bustoros1, A. Badros3, J. Matous4, K. Noonan1, N. Munshi1, C.-J. Liu1, M. Bustoros1, K. Salem1, S. Manier1, J. Park1.

1Multiple Myeloma, Dana-Farber Cancer Institute, 2Blood Cancer Research Partnership, Boston, 3Multiple Myeloma, University of Maryland Greenebaum Cancer Center, Baltimore, 4Multiple Myeloma, Colorado Blood Cancer Institute, Denver, 5Multiple Myeloma, Beth Israel Deaconess Medical Center, 6Multiple Myeloma, Massachusetts General Hospital, Boston, 7Multiple Myeloma, Eastern Maine Medical Center, Bangor, 8Multiple Myeloma, Levine Cancer Institute, Charlotte, 9Multiple Myeloma, Newton-Wellesley Hospital, Newton, 10Multiple Myeloma, Barbara Ann Karmanos Cancer Institute, Detroit, 11Multiple Myeloma, University of Chicago Medical Center, Chicago, United States

Background: This study aimed to determine the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma (SMM). The study hypothesis was that the combination of elotuzumab, lenalidomide, and dexamethasone could induce response and delay progression to overt MM in high-risk SMM. The primary endpoint was time to progression (TTP) following induction therapy with the combination of elotuzumab, lenalidomide, and dexamethasone.

Methods: Patients were enrolled if they met the criteria for high-risk SMM, as defined by cytogenetics, FISH, or both. Patients were randomly assigned to receive either elotuzumab, lenalidomide, and dexamethasone for 28 days, followed by a 14-day washout period, and then 4 cycles of elotuzumab, lenalidomide, and dexamethasone every 28 days. The primary endpoint was TTP following induction therapy, measured from the first day of the first cycle of induction therapy to the date of progression to overt MM or the date of last contact.

Results: A total of 66 patients were enrolled in the study. The median age of patients was 66 years (range 42–82). At the time of data cutoff, 24 patients (36%) had progressed to overt MM, and 42 patients (64%) were still in protocol. The median TTP for the entire cohort was 23.2 months (95% CI: 13.3–31.6). The median TTP for patients with high-risk cytogenetics in 2 or more chromosome arms was 12.5 months (95% CI: 6.9–19.7), and for patients with high-risk FISH abnormalities, it was 24.6 months (95% CI: 16.0–33.3). The 2-year overall survival rate was 92%.

Conclusion: The combination of elotuzumab, lenalidomide, and dexamethasone shows promise in high-risk smoldering multiple myeloma and may delay progression to overt MM.

S780

TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION


1Dana-Farber Cancer Institute, Boston, 2Ohio State University, Columbus, 3University of Chicago Medicine, Chicago, 4Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, 5John Theurer Cancer Center, Hackensack, 6Sarah Cannon Research Institute, Nashville, 7Stanford Comprehensive Cancer Center, Stanford, 8Mount Sinai School of Medicine Ruttenberg Treatment Center, New York, 9Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 10University of Michigan Cancer Center, Ann Arbor, 11Massachusetts General Hospital, Boston, 12Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, 13H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States

Background: This phase 1/2 study (NCT01383928) evaluated twice-weekly ixazomib plus Rd as induction therapy, followed by maintenance therapy with single-agent ixazomib. We report long-term efficacy and safety data in patients who did not withdraw from the study in order to receive SCT.

Methods: Patients with newly diagnosed NDMM (SCT-eligible or ineligible) received twice-weekly oral ixazomib (3.0 or 3.7 mg on days 1, 4, 8, 11) plus lenalidomide on days 1-21 of a 28-day cycle. Patients who went on to maintenance received a median (range) of 7 (1–16) cycles of single-agent twice-weekly ixazomib. Response/progression was assessed per IMWG criteria after cycles 1, 2, 3, 4, and then every 2 cycles during induction and maintenance.

Results: Of the 64 enrolled patients, 40 continued on study treatment without early withdrawal for SCT. Of these 40 patients, 18 went on to SCT. The median age of patients was 66 years (range 34–82), and 45% (18/40) had ISS disease stage III. The overall response rate (ORR), partial response (PR), and complete response (CR) rates were 92%, 85%, and 28%, respectively.

Conclusion: Twice-weekly ixazomib plus Rd was well tolerated and demonstrated a high response rate in patients with newly diagnosed NDMM. The study results support the use of twice-weekly ixazomib plus Rd as an induction therapy, followed by maintenance therapy with single-agent ixazomib in patients with newly diagnosed NDMM who did not undergo SCT.
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY


Summary/Conclusions: Multiple myeloma is characterized by osteolytic bone disease, with up to 80% of pts presenting with detectable lesions. Myeloma bone disease is mediated by osteoclast activating factors such as RANKL, increasing the risk of skeletal-related events (SREs) and impacting morbidity and mortality. DMB, a human monoclonal antibody that targets and binds to RANKL, can be administered subcutaneously (SC) to pts regardless of renal function.

Aims: This study evaluates the efficacy and safety of DMB compared with ZA in newly diagnosed myeloma pts.

Methods: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.

Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.

Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.

Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.

Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.

Results: A total of 1718 pts were randomized, 859 to each arm. Baseline demographic and disease characteristics were balanced, with 66.0% of DMB and 67.2% of ZA pts reporting prior SRE history. CrCl≥60mL/min was reported in 67.2% of ZA pts reporting prior SRE history; CrCl≤60mL/min was reported in 23.98 m close to first on-study SRE (HR[95%CI]=0.98[0.85,1.14]). Superiority was not demonstrated for time to first on-study SRE (P=0.82) and time to first and subsequent on-study SRE, and overall survival (OS). Progression-free survival (PFS) was an exploratory endpoint. Safety was also assessed.
Background: Pembrolizumab (pembro) is a humanized, highly selective, high-affinity IgG4/k antibody that blocks the interaction between programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2, activating antitumor immunity. Pembro plus lenalidomide (len) and low-dose dexamethasone (dex) may provide synergistic antitumor activity in relapsed/refractory multiple myeloma (RRMM). Biomarkers indicative of response, pharmacodynamic activity, and/or mechanism of action to combination therapies are also needed.

Aims: To determine the maximum tolerated dose (MTD) and safety and tolerability of pembro plus len and low-dose dex in patients with RRMM. Additionally PD-L1 and PD-L2 expression in bone marrow (BM), immune profiles in circulating lymphocytes, and gene expression in blood were evaluated.

Methods: This open-label, phase 1 KEYNOTE-023 (NCT02038502) study of pembro plus len and low-dose dex enrolled patients with RRMM previously treated with ≥2 prior therapies, including both a proteasome inhibitor and an immunomodulatory drug. Patients received pembro 200 mg IV every 2 weeks (Q2W), len 25 mg orally on days 1-21, and dex 40 mg orally weekly on each 28-day cycle. Primary end points were safety and determination of the MTD. ORR was assessed by IMWG 2006. Exploratory biomarker analyses included analysis of PD-L1 and PD-L2 on CD38+CD138+ cells in BM aspirate samples obtained at screening, or before the first dose of study drug. Absolute and/or relative numbers of circulating lymphocytes (by flow cytometry [FC]) and gene expression profile (GEP) (by NanoString) were evaluated in predose; cycle 1, day 1 (C1D1); and cycle 2, day 1 (C2D1) blood samples.

Results: MTD was determined as pembro 200 mg IV Q2W plus len 25 mg and dex 40 mg. Median (range) age was 61 years (46-77); median (range) number of prior lines of therapy was 4 (1-10); 38 (75%) patients were len-refractory, and 27 (53%) were double refractory. Most common grade ≥3 treatment-related AEs (TRAEs) were neutropenia (33%), thrombocytopenia (18%), and anemia (12%). 2 patients (4%) died because of TRAEs (hepatic failure, ischemic stroke). Immune-related AEs occurred in 5 (10%) patients. No pneumonitis was reported. ORR in the efficacy population was 39/40 (98%) in the efficacy population and 38/39 (97%) in the intent-to-treat population. The disease control rate reported. ORR in the efficacy population was 20/40 (50%) (1 sCR, 5 VGPR, 14 PR, 0 SD) in the efficacy population and 19/39 (49%) in the intent-to-treat population.

Conclusion: Pembrolizumab plus lenalidomide and low-dose dexamethasone is well tolerated with >90% of pts still receiving Tx at wk 80. Pembrolizumab plus lenalidomide and low-dose dexamethasone is well tolerated with >90% of pts still receiving Tx at wk 80.
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY


1Stanford University Medical Center, Stanford, United States, 2Saint-Louis Hospital (APHP) and Paris Diderot University, Paris, France, 3Monash University, Melbourne, Australia, 4University Hospitals Leuven, Leuven, Belgium, 5Kaposi Mar Swimming Hospital, Kapoever, Hungary, 6Medical University of Warsaw, Gdansk, Gdansk, Poland, 7Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom, 8University of Miyazaki, Miyazaki, Japan, 9Emory University School of Medicine, Atlanta, 10Gilead Sciences, Inc., Foster City, United States, 11Hospital Clinic, University of Barcelona, Barcelona, Spain, 12Mayo Clinic Cancer Center, Scottsdale, United States

Background: Momecotinib (MMB), an investigational oral JAK inhibitor (JAKI), has been shown in early trials to reduce spleen volume, improve disease associated symptoms and improve red blood cell (RBC) transfusion requirements in patients with myelofibrosis (MF).

Aims: To test the non-inferiority of MMB vs ruxolitinib (RUX) in spleen volume reduction and symptom amelioration, and superiority in transfusion requirement, in JAKI naive patients with primary myelofibrosis, and post-polycthenia vera or post-essential thrombocytophenia myelofibrosis.

Methods: Eligibility included primary myelofibrosis or post-polycthenia vera/essential thrombocytophenia myelofibrosis; International Prognostic Scoring System (IPSS) high risk, intermediate-2 risk, or intermediate-1 risk associated with symptomatic splenomegaly; palpable spleen ≥5cm; and no Grade ≥2 peripheral neuropathy. Informed consent was obtained. Stratification was by transfusion dependency and platelets (<100K, 100K-200K, and >200K/μl). Patients were randomized 1:1 to 24 weeks of open-label MMB 200 mg QD or BAT. Assessments included spleen volume by MRI, and patient-reported symptoms using a daily eDiary for modified MPN-SAF Total Symptom Score (TSS). The primary endpoint was spleen response rate (SRR; ≥35% reduction in volume from baseline) at 24 weeks. Secondary endpoints, evaluated sequentially, were rates of TSS response (TSS RR; ≥50% reduction from baseline), RBC transfusion independence and RBC transfusion dependence, and rate of RBC transfusion.

Results: 175 of 215 (81%) and 201 of 217 (93%) patients randomized to MMB and RUX, respectively, completed the 24 week double blind phase. Efficacy results are shown in the Table 1. The most common Grade ≥2 adverse events led to study drug discontinuation in 7% of MMB and 3% of RUX patients. Treatment emergent peripheral neuropathy occurred in 22 (10%) of MMB (all Grade ≤2) and 10 (5%) of RUX (9 Grade ≤2, 1 Grade 3) patients in the double blind phase, none discontinuing study drug for this problem. Overall, adverse events led to study drug discontinuation in 13% of MMB and 8% of RUX patients in double blind phase.

Table 1.

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>MMB</th>
<th>RUX</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen response rate, %</td>
<td>26.5</td>
<td>29.0</td>
<td>0.01*</td>
</tr>
<tr>
<td>TSS response rate, %</td>
<td>28.4</td>
<td>42.2</td>
<td>0.001*</td>
</tr>
<tr>
<td>Transfusion independence rate, %</td>
<td>66.5</td>
<td>49.3</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Transfusion dependence rate, %</td>
<td>30.2</td>
<td>40.1</td>
<td>0.019</td>
</tr>
<tr>
<td>Transfusion rate (units/month), median</td>
<td>0.0</td>
<td>0.4</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Table S786

PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

S. Verstovsek1, A.M. Vannucchi2, U. Platzbecker3, F. Cervantes4, V. Gupta5, D. Lavori6, F. Passamonti7, Y. Dong8, J. Kawashima9, J.D. Maltzman10, J.-J. Kiladjian10, C.N. Harrison11

1University of Texas MD Anderson Cancer Center, Houston, United States, 2University of Florence, Florence, Italy, 3Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany, 4Hospital Clin, University of Barcelona, Barcelona, Spain, 5Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, 6Hadasah-Hebrew University Medical Center, Jerusalem, Israel, 7University of Insubria, Varese, Italy, 8Emory University School of Medicine, Atlanta, 9Gilead Sciences, Inc., Foster City, United States, 10Saint-Louis Hospital (APHP) and Paris Diderot University, Paris, France, 11Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

Background: Momecotinib (MMB), an investigational oral JAK inhibitor, has been shown in early trials to reduce spleen volume, improve disease associated symptoms and improve red blood cell (RBC) transfusion requirements in patients with myelofibrosis.

Aims: Test the superiority of MMB versus best available therapy (BAT) in splenic volume reduction, symptom amelioration, and transfusion requirement at 24 weeks in patients with primary myelofibrosis (PMF), post-polycthenia vera or post-essential thrombocytophenia myelofibrosis (Post-PV/ET MF) who were previously treated with ruxolitinib.

Methods: Eligibility included PMF or post-PV/ET MF; Dynamic International Prognostic Scoring System (DIPSS) high risk or intermediate-2 risk, or intermediate-1 risk associated with symptomatic splenomegaly; currently or previously treated with ruxolitinib for at least 28 days who either required transfusions or dose reduction to <20 mg BID with at least one of Grade ≥3 thrombocytophenia, anemia, or bleed; palpable spleen ≥5cm; and no Grade ≥2 peripheral neuropathy. Informed consent was obtained. Stratification was by transfusion dependency and baseline TSS (modified MPN-SAF Total Symptom Score) ≥18 or ≥20. Patients were randomized 2:1 to 24 weeks of open-label MMB 200 mg QD or BAT. Assessments included spleen volume by MRI, and patient-reported symptoms using a daily eDiary for TSS. Primary endpoint was spleen response rate at 24 weeks (SRR24; ≥35% reduction in volume from baseline). Secondary endpoints, evaluated sequentially, were rates of TSS response (TSS RR; ≥50% reduction from baseline), RBC transfusion independence, RBC transfusion dependence (TD) and RBC transfusion dependence (TD).

Results: 73 of 104 (70%) and 40 of 52 (77%) patients receiving MMB or BAT, respectively, completed the 24 week randomized treatment phase. BAT for 88% of patients included ruxolitinib, and 27% of patients were on ruxolitinib in combination with other drugs. Efficacy results are in Table 1. The most common treatment-emergent adverse events in MMB patients were diarrhea (33%), anemia (19%), nausea (19%), and cough (17%), and in BAT patients, anemia (21%), fatigue (19%), anemia (15%), diarrhea (15%), and abdominal pain (15%); the most common Grade ≥3 adverse events in MMB patients were anemia (13%) and thrombocytopenia (7%), and in BAT patients, anemia (13%), thrombocytopenia (6%) and abdominal pain (6%). Treatment emergent peripheral neuropathy occurred in 11 (11%) of MMB (1 Grade 3) and in no BAT patients; MMB was discontinued in 3 patients due to neuropathy.

Table 1.

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>MMB</th>
<th>BAT</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRR, %</td>
<td>6.7</td>
<td>5.8</td>
<td>0.90</td>
</tr>
<tr>
<td>TSS RR, %</td>
<td>26.2</td>
<td>5.9</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Transfusion rate (units/month), median</td>
<td>0.3</td>
<td>2.7</td>
<td>0.39</td>
</tr>
<tr>
<td>TI rate, %</td>
<td>43.3</td>
<td>21.2</td>
<td>0.001*</td>
</tr>
<tr>
<td>TD rate, %</td>
<td>50.0</td>
<td>63.5</td>
<td>0.10</td>
</tr>
</tbody>
</table>

*p-values nominally significant.
Summary/Conclusions: In previously ruxolitinib-treated patients with myelofibrosis, 24 weeks of momelotinib was not superior to best available therapy for splenic response, but significantly better in improving disease related symptoms and transfusion independence. NCT02101268.

Molecular Response to Hydroxyurea and Rogepegingiferon ALFA-2B in the PROUD-PV Randomized Phase 3 Trial

J.-J. Kiladjian1,2,3,*, B. Cassinat2,4, J. Soret-Dulphy1, E. Verger1, L. Roy2, J. Rey4, N. Masliah4, B. Grobmann-Iszay2, C. Klade7, H. Gisslinger6
1Clinical Investigations Center, Hopital Saint-Louis, 2INSERM UMRs-1113, 3Paris Diderot University, 4Hopital Saint-Louis, Paris, 5Hopital Henri Mondor, Creteil, 6Institut Curie, Paris, 7AOP Orphan Pharmaceuticals AG, 8Medical University of Vienna, Vienna, France

Background: Interferon alpha (IFNa) has been successfully used to treat myeloproliferative neoplasms (MPN) for many years and several phase 2 studies have independently shown high rates of hematological and molecular responses assessed by the quantification of mutant JAK2 allele burden (%JAK2V617F) in peripheral blood. However, direct in vivostudies investigating the impact of IFNa treatment on proliferation of bone marrow (BM) normal and malignant hematopoietic progenitors are lacking.

Aims: To look at the randomized controlled phase III trial (PROUD-PV) comparing the novel, long-acting Rogepegingiferon alfa-2b (AOP2014) with hydroxyurea (HU) in polycythemia vera (PV) patients (pts) to assess correlation between evolution of %JAK2V617F in peripheral blood and the impact of therapy on malignant clones by functional assays testing mutant BM hematopoietic progenitors in the French study population.

Methods: Randomized, controlled, multicenter phase 3 trial comparing efficacy, safety and tolerability of hydroxyurea and Rogepegingiferon Alfa-2b in PV pts (NCT01949805). The primary endpoint was non-inferiority of AOP2014 vs HU at 12 months (mos) of therapy in terms of complete hematological response (CHR) according to ELN criteria and normal spleen size. As an important secondary endpoint the effect of treatment on %JAK2V617F was assessed as rate of complete and partial molecular response (CPMR) according to modified ELN criteria. In the group of pts enrolled in France, we could study BM progenitor clonal architecture by culture with or without Erythropoietin (EPO) at baseline and after 12 months of therapy. The presence of colonies without EPO, namely Endogenous Erythroid Colonies (EECs) is a hallmark of PV. After 14 days, erythroid colonies were enumerated and picked for molecular analyses.

Results: A total of 257 pts were randomized in 13 European countries including 13 pts in France. Non-inferiority of AOP2014 versus HU regarding CHR could be demonstrated in the whole study population (43.1% vs 45.6%). In the subgroup of French pts (54% males, mean age 55 years) CHR at 12 mos was 40% in pts receiving AOP2014 (n=5) and 50%, in those receiving HU (n=8). %JAK2V617F at baseline in the AOP2014 and HU arms were 39.4% and 46% after 12 mos of therapy in terms of CHR. BM progenitors could be studied in 10/13 French pts, 3 treated with AOP2014 and 7 with HU. AOP2014 treatment induced an important decrease of the proportion of EECs at baseline and after 12 months of therapy compared to HU (median decrease 25%). In addition, clonal architecture studies showed that the % of JAK2V617F mutant colonies before and after treatment profoundly decreased in all AOP2014-treated pts (median decrease 96% at baseline to 46% at 12 mos). Among HU-treated pts, only 1 experienced a decrease in the % of mutated colonies while mean ratio of mutant vs wild type JAK2 colonies did not significantly decrease (from 87% at baseline to 79% after 12 mos).

Summary/Conclusions: In this phase 3 trial comparing Rogepegingiferon alfa-2b versus HU, we found a different impact of both drugs on hematopoietic cells. Although both treatment induced a decrease of JAK2 mutant allele burden at 12 mos in peripheral blood, BM clonogenic assays suggest that AOP2014 is able to specifically target JAK2 mutant progenitors, an effect not seen in HU treated pts. Such targeted impact of AOP2014 may account for the strikingly different kinetics in allele burden reduction and suggests that sustained long-term molecular response may only be achieved with IFNa based treatment.

POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201+ A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS COMPARED WITH HISTORICAL CONTROLS

1University Medical Centre Mannheim, Mannheim, Germany, 2University Medical Center Groningen, Groningen, Netherlands, 3University of New Mexico, Albuquerque, 4Brigham and Women’s Hospital, 5Dana-Farber Cancer Institute, Boston, United States, 6University of Paris Descartes, Institute of Science, Paris, France, 7The Ohio State University Comprehensive Cancer Center, Columbus, 8University of Pennsylvania, Philadelphia, 9Memorial Sloan Kettering Cancer Center, New York, 10Novartis Pharmaceuticals Corporation, East Hanover, United States, 11Novartis Pharma SAS, Rueil-Malmaison, France, 12Novartis Pharma AG, Basle, Switzerland, 13University of Cologne, University of Heidelberg, Cologne, 14Ludwig Maximilians University Munich, Munich, Germany, 15Medical University of Vienna, Vienna, Austria, 16Stanford University School of Medicine, Stanford, United States

Background: AdvSM (ie, aggressive SM [ASM]), SM with an associated hematologic neoplasm [SM-AHN], and mast cell leukemia [MCL] comprises rare hematologic neoplasms with a poor prognosis. KIT D816V mutations occur in a majority of patients with advSM. Midostaurin is a multitargeted kinase inhibitor that blocks wild-type and D816V-mutated KIT. Two single-arm phase 2 studies (D2201+A2213) evaluated the safety and efficacy of midostaurin in advance SM. Overall, 60% and 69% of patients in D2201 and A2213, respectively, achieved the primary endpoint of partial or complete normalization of SM-related organ damage.

Aims: We compared pooled data from these studies with data from a patient registry to determine the effects of midostaurin on overall survival (OS).

Methods: Data from the midostaurin studies, in which patients received midostaurin 100 mg twice daily until progression or toxicity, were pooled. Historical control data were obtained from a contemporary patient registry based at University Medical Centre Mannheim, Germany. Although the primary analysis did not include matching for patient selection, subgroup analyses, and multivariate analyses were performed to assess potential baseline characteristics affected OS and estimated HR. Propensity scoring was used for supportive analyses to match the patients in the registry. Patients were evaluated for OS based on time from diagnosis to death; patients in the pooled analysis with known dates of diagnosis were included in the primary analysis. A sensitivity analysis to compensate for potential bias in patient selection was conducted using the start date of last treatment to death.

Results: The primary analysis of OS in patients with advSM included 89 patients from the midostaurin pooled analysis for whom the date of diagnosis was available (77% of the entire pooled cohort) and all 46 patients from the German registry who had not been treated with midostaurin. OS rates among patients from the pooled analysis and registry were similar; 66% of patients in the pooled cohort and 63% in the registry had an AHN (Table 1).KIT D816V mutations were present in 82% of patients in the pooled analysis and 96% in the registry. More patients in the registry (67%) vs the pooled analysis (42%) were aged >65 y. Median follow-up (time from diagnosis to data cutoff for the analyses) was similar for the 2 patient groups: registry, 54.9 (range, 1.9-150.4) mo and midostaurin, 53.6 (range, 31.6-215) mo. Patients in the midostaurin pooled analysis had a clinically relevant improvement in OS vs historical controls (HR=0.62 [95% CI, 0.39-0.98]; P=.0204; Figure 1). Median OS was 42.8 (95% CI, 31.0-53.9) mo in the pooled analysis vs 24.0 (95% CI, 13.0-39.5) mo in the registry. Multivariate Cox regression analysis after adjusting for covariates was consistent with the primary analysis: HR=0.51 (95% CI, 0.30-0.88); P=.0147. Data using propensity score for matched pairs (n=44) were also consistent (HR=0.381 [95% CI, 0.169-0.98]; P=.021). All subgroup analyses of OS showed HR in favor of midostaurin for all subgroups analyzed (median follow-up >65 y; KIT D816V status, number of prior therapies [≥1 vs ≤1; and SM subtype] except MCL). Subgroup analysis data should be interpreted with caution due to the small patient numbers in the German registry. Sensitivity analysis of OS from date last treatment received (pooled analysis, n=115; registry, n=42) was consistent with the main analyses (HR from the multivariate analysis=0.38 [95% CI, 0.22-0.65]; P=.0004).

Table 1.
Summary/Conclusions: Midostaurin was associated with a 38% lower risk of death vs historical controls. Benefit was generally consistent across key subgroups.

Background: Approximately 10% of the children with Down syndrome are diagnosed with transient myeloproliferative disorder (TMD) within the first days of life. Previous studies have shown that TMD patients face an around 20% risk of early death and a 20% to 30% risk to develop myeloid leukemia during the first 4 years of life (ML-DS).

Aims: The aim of the AML-BFM TMD Prevention 2007 trial was to analyze the outcome of patients diagnosed with TMD and to evaluate whether the application of a low-dose cytarabine treatment can prevent the progression to ML-DS.

Methods: The AML-BFM TMD Prevention 2007 trial is a multi-center, non-randomized, historically controlled study. Patients with TMD were prospectively enrolled. They received a low-dose cytarabine treatment (1.5 mg/kg i.v./s.c. daily for one week respectively if they met the following criteria: TMD-related symptoms (e.g. hyperleucocytosis, hepatopathy) at diagnosis, MRD-positivity (FACS≥10⁻³ or qPCR≥10⁻⁴) eight weeks after diagnosis. Patients could receive cytarabine treatment up to three weeks in case of failure to respond to the cytarabine-treatment (morphologic detection of blasts between week four and eight after diagnosis and/or MRD-positivity after treatment in week ten after diagnosis).

Results: Here we report a cohort of 108 patients (male: 60, female: 48) diagnosed with TMD. The median age at diagnosis was 4 days. As common in children with Down syndrome, many of the patients presented with comorbidities (cardiac defects: 68%, other malformations: 15%); 36% were delivered preterm. 45 patients received low-dose cytarabine treatment, 57 patients did not receive this treatment. Overall, patients in this trial do not show a significantly better event-free survival (EFS; 72±4% vs 63±4%, p=0.15) and overall survival (OS; 91±3% vs 85±3%, p=0.15) than the historic control group (n=146). The cumulative incidence (CI) of death was lower, (8±5% vs 15±3%) albeit not significantly (p=0.09). The CI of ML-DS was also similar (19±4% vs 22±4%, p=0.88).

Patients that presented with TMD-related clinical symptoms (n=43; symptoms: hyperleucocytosis [WBC>100,000], hepatopathy, ascites, hydrops fetalis) had a tendency for a better EFS (59±8% vs 44±8%, p=0.097), OS (80±6% vs 67±7%, p=0.15) and CI of death (20±7% vs 33±7%, p=0.10) than patients with those symptoms in the historic control group (n=45). For the progression to ML-DS there is no significant difference between the two groups (21±7% vs 23±7%, p=0.91). For patients that do not show any of the TMD-related symptoms (n=59), no significant differences were observed regarding EFS (81±5% vs 71±5%, p=0.27), OS (98% vs 93±3%, p=0.16) and CI of ML-DS (19±8% vs 22±4%, p=0.95) compared to patients without these symptoms in the historic control (n=101).

Summary/Conclusions: The consequent treatment with low-dose cytarabine of symptomatic patients results in a trend towards reduced CI of death as compared to the historic control. However, progression to ML-DS remains unchanged, suggesting that the treatment with low-dose chemotherapy does not seem to prevent the development of subsequent leukemia in TMD-patients. Therefore, a general preventive chemotherapeutic treatment of children diagnosed with TMD cannot be recommended. However, children with TMD-related symptoms should receive low-dose cytarabine to reduce disease-related mortality.

S790

FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70


1Department of Paediatric Haematology and Oncology, Hannover Medical School, Hannover. 2Pediatric Oncology and Hematology, Pediatrics III, University Hospital of Essen, Essen, Germany

Background: The consequent treatment with low-dose cytarabine of symptomatic patients results in a trend towards reduced CI of death as compared to the historic control. However, progression to ML-DS remains unchanged, suggesting that the treatment with low-dose chemotherapy does not seem to prevent the development of subsequent leukemia in TMD-patients. Therefore, a general preventive chemotherapeutic treatment of children diagnosed with TMD cannot be recommended. However, children with TMD-related symptoms should receive low-dose cytarabine to reduce disease-related mortality.
Background: AML is a heterogeneous disease based on genetic characteristics with impact on prognosis. So, it becomes necessary to treat patients according to risk-adapted therapies.

Aims: To analyze the results of intensive induction and post-remission treatment in 868 patients with the novo AML enrolled into the CETLAM-03 trial between 2003 and 2012 with a prolonged follow-up (results reported at 10 years).

Methods: Patients received 1 or 2 induction chemotherapy courses of IDICE-G (idarubicin, intermediate cytarabine (IDC), VP-16 and priming with G-CSF) followed by mitoxantrone and IDC as consolidation therapy. Further treatment was assigned according to the CETLAM risk groups as follows: Favorable risk (FR) defined as favorable cytogenetics according to MRC, autologous stem cell transplantation (ASCT) for leukocyte index [1 leukocytes (BM blasts/1000) ≥0 or high dose cytarabine (HDAC) (one course) if LI >20. Intermediate risk (IR), defined as patients in CR after a single induction course, <50x10^9/l white blood cells at diagnosis, normal karyotype and absence of FLT3-ITD internal tandem duplication (FLT3-ITDwt) and no MLL rearrangement: ASCT. Adverse risk (AR), patients classified in FP or IR: IP or ASCT or allo-SCT (allo-SCT) depending on donor availability (HLA-identical sibling or unrelated donor if high risk of relapse).

Results: There were enrolled 868 patients. Median age was 53 years-old (16-70). According to MRC cytogenetics, available in 802 patients, 99 belonged to the favorable (12%), 581 (73%) to the intermediate and 122 (15%) to the adverse groups. 66 patients with no metaphases, FLT3-ITD was present in 128 patients with normal karyotype (36%). Four patients died before treatment and 864 patients received induction therapy. 77% of patients achieved a CR (88% with a single course), 11% were refractory and 12% died during induction. CR rate was 92% for patients with FLT3-ITD mutation in intermediate cytogenetic and no mutations, 77% if FLT3-ITD, 70% in adverse cytogenetics and 62% if monosomal karyotype was present (p<0.001). The multivariate analysis showed that mutational status (adverse cytogenetics, FLT3-ITD and absence of NPM1 mutation) had an adverse impact on CR achievement, but was associated with a high rate of patients not achieving CR and post-remission results of OS, EFS and CIR according to the different CETLAM risk groups at 10 years follow up were: FR (n=95, 14%); IR 85±4%, 70±6% and 22±1%; IR (n=99, 17%): 64±6%, 51±5% and 47±2%; AR (n=417, 64±1%, 51±3% and 52±16% respectively. In IR there were no differences in OS, EFS and CIR depending if treatment was HDAC or ASCT. In AR statistical differences were observed at 10 years in EFS and CIR when comparing AS vs allo-SCT (27±4% vs 89±4%, p=0.026 and 86±6% vs 89±1%, p<0.001). In IR intention to treat was ASCT, but in 21% mobilization failed and most of them received HDAC. Forty-nine patients received an ASCT and 21 relapsed, 9 of them were rescued with an allo-SCT.

Summary/Conclusions: In this, the largest such study reported to date, the demonstration that mutations in CDKN2A, IDH1 and TP53 are associated with reduced OS and EFS in AML suggests that new strategies are required to improve outcomes. Furthermore our data identify serial quantitation of LSC populations as a potentially important biomarker of response to Aza based therapies which may assist in the evaluation of novel treatment combinations.

S792
SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT
S. Ahmed1, R. Saliba1, G. Rondon1, A. Alousi1, Q. Bashir2, S. Ciurea3, G. Al-Atrash1, K. Patel2, A. Olson1, D. Marin1, K. Rezvani1, P. Kebriaei1, U. Popat1, E. Shpall1, R. Champlin1, B. Oran1,
1Stem cell transplant and cellular therapy, 2Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, United States
2Hematology, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, 3Haematology, Centre for Clinical Haematology, University of Birmingham, University of Birmingham, 4Haematology, Centre for Clinical Haematology, University of Birmingham, University of Birmingham, 5Haematology, Centre for Clinical Haematology, University of Birmingham, University of Birmingham, 6CRCTU, University of Birmingham, 7Cancer Research UK Clinical Trials Unit, University of Birmingham, 8Haematology, Centre for Clinical Haematology, University of Birmingham, University of Birmingham, 9Department of Haemato-Oncology, St Bartholomews Hospital, London, 10MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford, Oxford, United Kingdom

Background: The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is a genetic alteration found in approximately 30% of patients with acute myeloid leukemia. Although several studies have shown that FLT3-ITD AML achieve remission rates similar to those with FLT3 wildtype status with induction chemotherapy regimens; patients with FLT3-ITD have significantly shorter remission durations and increased rates of relapse. Even though allogeneic SCT improves outcomes, patients still have higher rates of relapse compared to those with FLT3 wildtype status. Sorafenib (SFB) is a TKI with activity against RAF, VEGF and FLT3-ITD and its use as maintenance therapy after allogeneic SCT has been shown as a promising approach to decrease relapse. Several studies report that SFB maintenance post SCT provides durable complete responses; however, there are also descriptions of sorafenib post SCT triggering acute GVHD, cytopenias, rash and diarrhea.

Aims: To assess the outcomes, including progression free survival (PFS) and overall survival (OS), in patients with FLT3-ITD mutated AML who receive SFB maintenance after allogeneic SCT.

Methods: We analyzed adult patients (age 18-60) with a diagnosis of FLT3-ITD mutated AML leukemia in the first 2010-2016 cohort who received an autologous transplantation at our institution. Patients who received maintenance SFB (maintenance group) with control patients, FLT3-ITD mutated AML who did not receive maintenance post SCT (control group); we matched each case to two control patients accounting for disease status, type of conditioning, donor type, age and cytogenetics. To be considered as maintenance, SFB had to be started within 101 days of the SCT. To reduce bias from disease risks and transplant-related mortality (TRM), all patients were required to be in complete remission (CR) at study entry - defined as the date of SFB initiation for cases and the same time point after SCT for their matched controls. Sorafenib (SFB) is a TKI with activity against RAFLVEGF and FLT3-ITD and its use as maintenance therapy after allogeneic SCT has been shown as a promising approach to decrease relapse.

Results: No statistically significant differences were observed between cases and controls using Kaplan-Meier method. OS and PFS were compared between cases and controls using log rank test and cox proportional hazards regression analysis. Patient-, transplant- and disease characteristics were compared between cases and controls using chi square and Fisher exact tests.
characteristics were comparable between groups as presented in Figure 1. Patients were classified by the European Leukemia Net (ELN) classification and 23% in both groups were categorized as adverse risk while 77% were intermediate risk. All patients received myeloablative conditioning and diseases status at SCT was first/second complete remission (CR1/2) with or without count recovery (CnN) in 69% while it was active disease in 31%. PFS at 24 months post SCT was 82% in the maintenance and 45% in control group HR 0.3; 95% CI (0.1-1.3) p=0.1. Overall survival at 24 months was also higher in SFB cases as 100% compared with 60% in control group p=0.035. Only 2 patients relapsed post SCT on SFB maintenance, one with new TP53 mutation at relapse, and other received only <30 days of SFB. However, more than half the patients had disease progression within the control period. The most commonly administered dose was 400 mg daily (5 patients) for 28 days cycle; only 2 patients tolerated higher doses and 6 patients received SFB as 300mg daily or less. There were delays in subsequent cycles in 10 of 12 patients, and the most common reasons for delays included cytopenias, liver function test abnormalities, and fatigue.

Figure 1

Summary/Conclusions: Sorafenib maintenance is safe and can produce long term durable remissions after allogeneic stem cell transplant in a high risk population with FLT3-ITD mutated AML.

S793

A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA


1Baylor University Medical Center, Dallas, TX, 2Gehr Family Center for Leukemia Research - City of Hope, Duarte, CA, 3Ohio State University Comprehensive Cancer Center, Columbus, OH, 4Colorado Blood Cancer Institute, Denver, CO, 5Cleveland Clinic, Cleveland, OH, 6Massachusetts General Hospital, Boston, MA, 7John Theurer Cancer Center, Hackensack, NJ, 8Fred Hutchinson Cancer Research Center, Seattle, WA, 9Loyola University Medical Center, Maywood, IL, 10Karmanos Cancer Institute, Detroit, MI, 11Sarah Cannon Research Institute, Nashville, TN, 12University of Washington Medical Center, Seattle, WA, 13MD Anderson Cancer Center, Houston, TX, 14Seattle Genetics, Inc., Bothell, WA, 15University of Alabama-Birmingham, Birmingham, AL, United States

Background: For patients <65 yrs with newly diagnosed AML, standard induction treatment is continuous infusion of cytarabine for 7 days and an anthracycline for 3 days (7+3). Although a high percentage of patients achieve a CR by morphologic criteria, some requiring a 2nd induction, many are resistant to treatment or achieve a morphologic CR with evidence of minimal residual disease (MRD). Vadastuximab talirine (SGN-CD33A; 33A) is a CD33-directed antibody conjugated to 2 molecules of a pyrrolobenzodiazepine dimer. Combining 33A with 7+3 could result in enhanced and deeper (MRD negative) remissions, resulting in reduced relapse rates and improved OS.

Aims: This phase 1b study (NCT02326584) evaluated the safety and antileukemic activity of escalating doses of 33A on 2 schedules: split dose (D1 and 4) or single dose (D1) with 7+3 induction therapy (cytarabine 100 mg/m2 and daunorubicin 60 mg/m2). Method: patients must be eligible for induction therapy. Response assessments occur on D15 and 28. Second induction and post-remission therapies were per investigator choice and did not include additional 33A. MRD was assessed centrally by bone marrow exam by a multiparametric flow at D15 and D28.

Results: Split-dose cohort: 42 patients (median age 45.5 yrs [range, 18-65]) were treated with 33A on D1 and 4 (10+10 [n=4] or 20+10 [n=38] mcg/kg) with 7+3. Most patients had intermediate (50%) or adverse (36%) cytogenetic risk. 19% had secondary AML. 2 patients had hematologic DLTs (lack of recovery of platelets [25K] and/or ANC [500] by D42) and 20+10 mcg/kg was determined to be MTD. The median time to count recovery from D1 of therapy in patients who achieved CR/CRi was 4.9 wks for ANC (≥1K) and 5.1 wks for platelets (≥100K). No non-hematologic TEAEs ≥G3 were reported in >10% of patients; non-hematologic TEAEs of any grade occurring in ≥25% of patients were nausea (62%), diarrhea, and constipation (38% each). Of the 42 efficacy evaluable (EE) patients, best responses included 25 CR (60%), 7 CRi (17%), and 5 morphologic leukemia-free state (mLFS; 12%) with a CR+CRi (CRc) rate of 76%; 23 of 25 (94%) responses were achieved in the 1st cycle. Of the patients with blast clearance (CR+CRi+mLFS), 73% (7/37) achieved MRD negative status. Single-dose cohort: To date, 25 patients (median age 58 yrs [range, 38-65]) were treated with 33A on D1 only (30 [n=14] or 40 [n=11] mcg/kg) with 7+3. Patients had intermediate (48%) or adverse (36%) cytogenetic risk. 16% had secondary AML. The median time to count recovery from D1 of therapy was 4.1 wks for ANC (≥1K) and 5.9 wks for platelets (≥100K) in patients who achieved CR/CRi. Four patients had hematologic DLTs, 1 at 30 and 3 at 40 mcg/kg. Non-hematologic TEAEs were consistent with those seen in the D1 and 4 schedule. Of the 24 EE patients, best responses included 12 CR (50%), 6 CRi (25%), and 3 mLFS (13%) with a CRc rate of 75%, achieved in 1st cycle. Of the evaluable patients with blast clearance, 89% (17/19) achieved MRD negative status. The CRc rate at the 40 mcg/kg dose level was 91% (10/11); all 11 patients had blast clearance and 90% (9/10) of evaluable patients achieved MRD negative status. Across schedules (N=67), the CRc rate was 76%; 79% (44/56) of evaluable patients with blast clearance achieved MRD negativity. The 30- and 60-day mortality rates were 1% and 7%, respectively. Median OS is not reached for either schedule and 52 patients (78%) were alive at the time of analysis.

Summary/Conclusions: 33A can be safely combined with 7+3 with acceptable count recovery in this population at the doses and schedules studied. Extramedullary AEs, including hepatotoxicity, and induction mortality rates were similar to reported rates for 7+3 alone in this AML population. A high remission rate with the 1st induction cycle was observed, the majority of which were MRD negative.
S794

21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE PATIENTS TREATED WITH THE JANUS KINASE INHIBITOR INCB039110

K. Staser1,2, J. Choi1, J. Khoury2, M. Jagasia3, H. Alf4, G. Schiller5, M. Arbushites6, P. Delaite6, Y. Yan7, K. Rhein6, Y.-B. Chen7, M.-A. Perales8, L. Gehrs1, J. Ritchey1, J. DiPersio1, M. Schroeder1

1Washington University in Saint Louis, Saint Louis, 2Emory University School of Medicine, Atlanta, 3Vanderbilt-Ingram Cancer Center, Nashville, 4City of Hope, Duarte, 5David Geffen School of Medicine at UCLA, Los Angeles, 6Incite Corporation, Wilmington, 7Massachusetts General Hospital, Boston, 8Memorial Sloan Kettering Cancer Center, New York City, United States

Background: Although ~50% aGVHD patients respond to steroids, no consensus second-line treatment exists. Recent preclinical models, retrospective studies, and this prospective trial have demonstrated safety and efficacy of JAK inhibitors (e.g. ruxolitinib, INCB039110) in steroid-refractory aGVHD.

Aims: Here, we present 21-marker FACS analysis of blood from patients enrolled in a prospective, randomized, parallel-cohort, open-label phase 1 trial of the potent and selective JAK1 inhibitor INCB039110 for aGVHD (NCT02614612). Preliminary results were previously presented at ASH 2016 (Schroeder et al).

Methods: Patients (n=30) were >18 years old undergoing first allo-HCT from any source with steroid-refractory or treatment-naive grades II/IV aGVHD randomized 1:1 to 200 or 300 mg oral daily INCB039110 combined with corticosteroids. Peripheral blood, obtained at treatment days 7, 14, 28, 56, 100, and 180, was analyzed by 21-color FACS quantifying >30 cell types, including B, CD4+ and CD8+ T cells, memory T, regulatory (Treg), Th1, Th2, Th17, T follicular helper (Tfh), Th9, Th22, ThGM-CSF cells, granulocytes, monocytes, myeloid-derived suppressor cells (MDSCs), natural killer cells (NKS), and monocytes and plasmacytoid dendritic cells (DCs). Patients were stratified by treatment response (e.g. complete response (CR), partial response (PR), mixed response (MR)).

Results: During INCB039110 treatment, overall B, T, and myeloid proportions did not correlate with response. However, the CR group increased showed increased naive T cells (CD45RA+CD27+CD4+), mDCs (CD3-CD20-CD14+HLADR+), memory CD4+ T cells (CD3+CD4+CD45RA-). Among CD4+ memory cells, the CR group showed significant trend toward significant increases in Tfh (CCR10-CXCR5+), Th1 (CXCR5-CXCR6-CXCL10-CXCR3+), Th2, Th17 (CXCX5-CXCR6+CXCR4+CXCR3+CXCL10-), ThGM-CSF (CXCX5-CXCR6-CXCL10-CXCR3), and Th22 (CXCX5-CXCR6+CXCR4+CXCR3-CXCL10+). Tregs (CD4+CD25+) were significantly increased in the CR group. Within the monocyte subgroup (CD3-CD20-CD14+), the CR group skewed toward classical monocytes (HLADR+CD16+) (64.7% vs 36.0%, CR vs PR/MR, p=0.0078) and away from MDSCs (HLADR-CD16-) (30.0% vs 58.4%, CR vs PR/MR, p=0.0139) during treatment. Interestingly, the NK-to-MDSC ratio was a sensitive and specific predictor of CR vs all other responses, a finding consistent for both CD16+ and CD16- NK cells (Figure 1a, b). Below is a summary of pre-treatment, decreased naive CD8+ T cells (CD45RA+CD27+) predicted CR versus PR/MR (12.6% vs 32.3% of CD8+ cells, CR vs PR/MR, p=0.0047) with a similar trend toward decreased naive CD4+ T cells (13% vs 24.4% of CD4+ cells, CR vs PR/MR, p=0.0749). While naive T cells did not correlate with pre-treatment aGVHD grade, grades III-IV aGVHD demonstrated increased Th2 (CD45RA-CXCR5-CXCR6-CXCL10-CXCR3+) and activated CD8+ cells (CD38+HLADR+) as compared to grade II aGVHD. Further correlation with serum cytokines, JAK-STAT signaling, and pharmacology will be available at time of presentation.

Summary/Conclusions: Decreased pre-treatment naive T cells may predict better outcomes in INCB039110-treated aGVHD. During treatment, increased DCs, NKs, and memory T cells subsets correlated with better response. Surprisingly, increased MDSCs associated with poorer response, suggesting MDSC expansion during persistent inflammation. The NK-to-MDSC ratio may be an important clinical marker to track treatment progress. Finally, this study establishes a novel FACS-based 21-marker immunophenotyping method with superior throughput, sample preservation, and flexibility as compared to cytometry time of flight (CyTOF) methods.
gens with recipients. However, causal phenotypical homozygosity in the non-shared haplotype matched the real degree of disparity less than 4/8 in a few donor/recipient pairs.

Aims: Since 2010, patients who lacked a HLA-identical donor have been transplanted from a haplo-identical donor in our two Italian institutions. In this large series of patients we aim to verify the real degree of antigen disparity between donor and recipient and whether it impacts on transplantation (SOTI) and whether it impacts on transplant outcomes.

Methods: All haplo transplants performed in two Italian institutions from August 2010 to July 2016 (n=318) were included. All patients received a myeloablative regimen (MA) followed by unmanipulated bone marrow and high dose post-transplant cyclophosphamide (PT-CY), combined with cyclosporine and mycophenolate. Donors and recipients were typed until 2015, using DNA method (SSO and SBT) for HLA A, B, C, DRB1, DQ and DP at a high resolution level, as defined by EHI standards and by NGS at allelic level in 2016 for the same loci. When applicable (72,3% of patients) members of the immediate family where typed to definitively establish HLA genotype and haplotype identity. Differences in haplotype were represented in HVG direction.

We evaluated overall survival (OS) and non-relapse mortality (NRM) according to the amount of overall mismatches; also, we analyzed cumulative incidence of grade II – IV aGVHD, moderate-severe chronic GvHD and relapse according to the degree of HLA mismatches in the GVH direction and grade of GvHD direction to the degree of HLA mismatches in the HVG direction. For analysis purpose, the whole patient population was divided into 2 groups: 0-1-2 antigen mismatches versus 3-4 antigen mismatches. The same distinction was maintained when analyzing only GVH or HVG directed mismatches. Acute GvHD was calculated at day 100, the other parameters were calculated in second year of follow up. OS was estimated using the Kaplan-Meier approach while cumulative incidence was calculated for aGvHD, cGvHD, relapse and NRM.

Results: Median age of patients was 48 years (17-74). Diagnoses included acute myeloid leukemia (130), acute lymphoblastic leukemia (64), lymphoma and plasma cell malignancies (43), myelodysplastic syndrome (33). 144 patients (45%) were transplanted in advanced phase of disease. With a median follow up of 562 days (range 6-2241 days), 2-year OS was 55.7%. Concerning the proportion of “true” haplo-identical D/R pairs, 231 out of 318 (72%) couples showed 4/8 mismatches at HLA A, B, C, DRB1 and HLA DRB1 loci. Neither OS nor NRM showed significant correlation with the degree of overall mismatches at 2 years (0-2mm: 54.2%-vs 3-4mm:58.8%, p=0.58 and 0-2mm:18.2%-vs 3-4mm:19.1%, p=0.93, respectively). Considering only GVH directed mismatches, no difference was highlighted between low or high HLA mismatch burden in cumulative incidence of aGVHD (12.6% vs 23.9%, p=0.13), cGVHD at 1 year (12.2% vs 14.8%, p=0.84) and relapse (33.3% vs 24%, p=0.26). In this series graft rejection rate was 6.6%; no correlation was observed with the amount of HLA mismatch in the HVG direction.

Summary/Conclusions: In this series, about one third of haploidentical donor/recipient pairs differ for less than 4/8 HLA antigens. Furthermore, in the setting of a MA conditioning with PT-CY the real degree of HLA disparity observed had no impact on OS, NRM, CI of Relapse and acute and chronic GvHD.

S797 CYCLOPHOSPHAMIDE VERSUSETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING REGIMENTS FOR PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

S. Giebel1,*, M. Labopin2,3,4,5, E. Polge2,3,4,5, E. Forcade6, A. Ganser7, L. Volin8,9, I. Yakoub-Agha8, K. Orchard9, M. Michallet10, G. Stuhler11, S. Chaganti12, A. Nagler3,18

Aims: The choice of pre transplantation conditioning has never been a subject of a randomized trial. The benefit of TBI over chemotherapy-based regimens. TBI is most frequently administered in combination with either cyclophosphamide (CyTBI) or etopoide (VpTBI).

Methods: Adult patients with Ph-negative ALL (n=1498) treated with alloHCT from either HLA-identical sibling (n=696) or unrelated donor (n=802), in CR1 (n=1186) or CR2 (n=312), between year 2000 – 2015, were included in the analysis. Peripheral blood was used as a source of stem cells in 62% of the patients. Conditioning for adult patients was myeloablative in all cases (the median TBI dose was 12y): 1346 patients were treated with CyTBI while 152 patients with VpTBI. Patients in the VpTBI group were younger (median 28 vs 30y, p=0.04), treated in more recent median year of HCT (2009 vs 2007, p=0.009) and treated more frequently with second CR1 (87% vs 78%, p=0.012).

Results: In a univariate analysis, as compared to CyTBI, the use of VpTBI was associated with significantly reduced incidence of relapse (17% vs 30% at 5 years, p=0.007), increased crude survival-free relapse (DFS, 60% vs 50%, p=0.04) as well as improved “GVHD and relapse-free survival” (GRFS, 43% vs 33%, p=0.04). No significant effect could be observed in terms of the incidence of non-relapse mortality, acute or chronic GvHD. In a multivariate model the use of VpTBI was associated with reduced risk of relapse (HR=0.62, p=0.04) while the effect on other study end-points was no longer significant. Among other factors, recipient age (HR=1.17 per every 10 years, p<0.00001), year of alloHCT (HR=0.97 per every year, p=0.001) and disease stage (HR=2.14 for CR2, p<0.0001) had significant influence on the risk of treatment failure, either relapse or non-relapse mortality. The risk of relapse was additionally increased for sibling vs unrelated donor transplants (HR=1.47, p=0.01) and donor/recipient gender combination other than female/male (HR=1.22, p=0.04).

Summary/Conclusions: Conditioning regimen based on etoposide combined with TBI appears more effective than the cyclophosphamide TBI combination for adult patients with Ph-negative ALL treated with alloHCT. Further, prospective studies are needed to confirm our observation and potentially discriminate subgroup of patients who are most likely to benefit from the use of etoposide.
27%. The main cause of death was disease-related. In multivariate analysis, active disease correlated strongly with worse OS, LFS and NRM. The other factors influencing outcomes were UD with increased NRM, and age with decreased OS and LFS.

Based on the frequencies of the different additional cytogenetic abnormalities, we identified 4 groups within our cohort. Group 1 (None) included 47 pts with -5/5q- but without CK, MK or abn(17p). Group 2 (CK) included pts with -5/5q- and CK but no MK or abn(17p) (N=90). Group 3 (MK) included 169 pts with -5/5q- and MK but no abn(17p). Finally, group 4 (17p) included pts with -5/5q- and abn(17p) (N=193). The 4 groups were quite similar in term of characteristics. The 2-year probability of LFS was 39% for group 1, 25% for group 2, 20% for group 3 and only 13% for group 4 (p<0.001). OS decreased also significantly from group 1 to group 4 (p=0.001). NRM was similar across the groups. In multivariate analysis, factors associated with worse OS and LFS were active disease, age, MK and abn(17p). The corresponding 2-year probability of GVHD and relapse-free survival was 27% for group 1, 17% for group 2, 14% for group 3 and 7% for group 4 (Figure 1).

Figure 1.

Summary/Conclusions: SCT in -5/5q- AML provides a durable response for approximately 20% of pts. Active disease at time of transplantation was the most powerful predictor of an inferior outcome. The presence of -5/5q- without CK, MK or abn(17p) was associated with a significant better survival and the addition of MK or abn(17p) translated into worse outcomes. We confirmed the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcomes.

Future efforts should be focused on this subgroup in order to improve the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcome. Future efforts should be focused on this subgroup in order to improve the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcomes. Future efforts should be focused on this subgroup in order to improve the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcomes. Future efforts should be focused on this subgroup in order to improve the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcomes. Future efforts should be focused on this subgroup in order to improve the deleterious effect of the combination of -5/5q- and abn(17p) on SCT outcomes.
high PU.1 expression without fusions showed extremely poor prognosis, suggesting the prognostic value of aberrant PU.1 expression in pediatric T-ALL. Although it remains unclear, why cases with PU.1 fusions/high PU.1 expression have a poor prognosis, our results indicate that these cases are genetically distinct subgroup from other pediatric T-ALL.

S801
MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR RERRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBlastic LEUKAEMIA – A REPORT OF THE EUROCLONALITY-NGS CONSORT IUM


1Medical Department II, Unit for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany, 2CLIP - Childhood Hematology, investigated the diagnostic and treatment of childhood acute leukemia, 3Department of Pediatric Hematology, Great Ormond Street Hospital For Children, and UCL Institute of Child Health, London, United Kingdom, 4Central European Institute of Technology, Masaryk University, Brno, Czech Republic, 5Centre de génétique moléculaire et chromosomique, Hôpital Pitié - Salpêtrière, Paris, France, 6Centro Ricerca Tettamanti, Clinic Pediatrica, Università di Milano-Bicocca, Monza, Italy, 7Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain, 8CRISIAL (Centre de Recherche en Informatique, Signal et Automatique de Lille), Unité Mixte de Recherche (UMR CNRS 9189), Université de Lille and Inria Lille, Lille, France, 9Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands, 10Bristol Children’s Hospital, Southmead Hospital, Bristol, United Kingdom, 11Institut für Pathologie, Universitätmedizin Berlin, Berlin, Germany, 12Laboratoire d’hématologie, Hôpital Necker, Paris, France, 13Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, 14Department of Pediatric Haematology, Royal Children’s Hospital, Melbourne, Australia, 15Department of Immunology, Erasmus MC, Rotterdam, Netherlands

Background: The outcome of Ph+ acute lymphoblastic leukemia (Ph+ ALL) has drastically improved since the introduction of tyrosine kinase inhibitors (TKI). At present however, well-defined prognostic markers, beyond the monitoring of minimal residual disease (MRD) during follow-up and to a lesser extent IKZF1 deletions, are lacking.

Aims: To identify genomic lesions of prognostic value, we evaluated copy number aberrations (CNA) by SNP arrays, confirmed them by multiplex ligation-dependent probe amplification (MLPA) and we set up a droplet digital PCR (ddPCR) assays for additional lesions. Furthermore, we correlated the lesions identified with MRD monitoring, outcome and biological features, such as expression of the transcription factor PU.1, as type of fusion protein (p190 or p210). Finally, in a subset of patients gene expression profiling (GEP) was carried out.

Methods: Genomic DNA of 116 newly diagnosed adult Ph+ ALL patients enrolled in 4 consecutive GIMEMA trials, namely 0218B, 0914, 1205 and 1508, was evaluated. All the trials were based on an induction with steroids and TKI, the first 2 with imatinib and the remaining with dasatinib. For CNA, the Cytoscan HD Arrays (Affymetrix, Santa Clara, CA) were used. The lesions were confirmed by MLPA on all samples using the Salsa MLPA P335-43 ALL- IKZF1 kit (MRC-Holland, Amsterdam, The Netherlands). ddPCR was used to validate lesions targeting MEFF2C. In 42 cases, GEP experiments were performed using the HGU133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA).

Results: We found a similar load and type of lesions across the 4 trials, one of which included elderly. The majority of lesions targeted IKZF1 (84%), PAX5 (36%) and CDKN2A/B (32%). In our cohort, IKZF1 deletions alone did not affect complete molecular response (CMR), the second one patients who had IKZF1 deletions and TRG5/6 deletions had a significant inferior outcome (p=0.004, p=0.003 respectively). In line with this, a worse DFS was observed for the so-called “IKZF1 plus” cases, i.e. concomitant deletions of IKZF1 and CDKN2A/B and/or PAX5 (46% vs 24% at 36 months, p=0.005). MLPA confirmed the incidence of these deletions and allowed the study of IKZF1 isoforms. Among IKZF1 deleted cases, patients carrying the Δ4-7 isoform (25%) had a worse DFS (p=0.02) than patients harboring other IKZF1 isoforms. Importantly, SNP arrays highlighted novel genomic lesions targeting MEFF2C in 13% of cases, which were associated to the achievement of a CMR (p=0.05) and had a significant impact on DFS (62% vs 32% at 36 months, p=0.02). The association with CMR was not affected by the trial (p=0.76) or the TKI used (p=0.57). This result was confirmed by ddPCR. Unsupervised hierarchical clustering of GEP experiments identified 3 subgroups: the first comprised mainly patients who reached a CMR, the second one the patients who had IKZF1 alone, and the last one comprised “other” cases. This analysis allowed an overview of genes involved in cell communication and protein modification process in PAX5 deleted cases, suggesting that these genes could be contributing factors in BCR/ABL1 driven leukemogenesis.

Summary/Conclusions: In adult Ph+ ALL, IKZF1 deletions have a prognostic impact as well as other lesions. Among IKZF1 deletions, only the Δ4-7 deletion has a deleterious effect. MEFF2C lesions carry prognostic implications, being significantly associated with a better prognosis. This study paves the way to design a prognostic model for adult Ph+ ALL that includes these findings and more conventional features, in order to better stratify patients at diagnosis and to further optimize treatment.

S802
POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14, ISRCTN 66541317)


1Cancer Institute, UCL, London, United Kingdom, 2Faculty of Medicine, Alexandria University, Egypt, 3Cancer Trial Centre, Royal Cancer Institute, QMUL, London, United Kingdom, 4Royal Hallamshire Hospital, Sheffield, United Kingdom, 5University Hospitals Bristol NHS Trust, Bristol, 6Department of Haematology, Cancer Institute, UCL, London, United Kingdom

Background: Risk assessment after autologous and syngeneic stem cell transplantation for acute lymphoblastic leukemia (ALL) using flow cytometry MRD is limited. Notably, the use of monoclonal antibodies (mAbs) for MRD assessment is hampered by the emergence of MRD clones that are not detectable by mAbs. In contrast, real-time polymerase chain reaction (PCR) systems can detect novel MRD clones. In the current study, we investigated the clinical utility of real-time QPCR for MRD quantification. MAR-Predicting High Relapse Risk following RIC-ALL (UKALL14, ISRCTN 66541317)

Methods: Patients who underwent autologous or syngeneic stem cell transplantation for ALL were enrolled. All families were tested for t(4;11) in case of bi-allelic rearrangements or background are avoided. MRD in case of bi-allelic rearrangements or background are avoided. ing time is reduced and labour intensive conventional methods to resolve mixed sequences in case of bi-allelic rearrangements or background are avoided. medical therapy of the patient.

Results: Predictive values of real-time QPCR were assessed in a large cohort of patients. The results indicated that real-time QPCR is a sensitive and specific tool for predicting MRD relapse risk. The predictive values of real-time QPCR were significantly higher than those of flow cytometry. The results also showed that the predictive values of real-time QPCR were independent of other clinical variables such as age, sex, and disease stage. The results also showed that the predictive values of real-time QPCR were independent of other clinical variables such as age, sex, and disease stage. The results also showed that the predictive values of real-time QPCR were independent of other clinical variables such as age, sex, and disease stage.

Summary/Conclusions: The predictive values of real-time QPCR were significantly higher than those of flow cytometry. The predictive values of real-time QPCR were independent of other clinical variables such as age, sex, and disease stage.
Background: Reduced intensity conditioned allogeneic haematopoietic stem cell transplant (RICalloHCT) enables HCT to be performed in older patients. The UK NCI UKALL14 study of adult acute lymphoblastic leukaemia (ALL) considers patients ≥41 years “high risk” and recommends a RICalloHCT where there are high quality donors. Other “high risk” factors are high WBC at presentation, t(9;22), t(4,11), hypodiploid/near triploidy, complex karyotype and positive minimal residual disease (MRD) after completing induction therapy. The presence of MRD at this time-point predicts poor outcome after conventional chemotherapy. There is evidence that myeloablative alloHCT can overcome this risk, but the benefit of RICalloHCT is uncertain.

Aims: To determine whether RICalloHCT mitigates the high relapse risk predicted by MRD positivity after induction therapy.

Methods: Protocol treatment: patients receive a steroid pre-phase before 2 cycles of induction chemotherapy. At the end of induction, patients are assigned subsequent therapy on the basis of risk. All patients over 41 years are allocated RICalloHCT, conditioned with fludarabine, melphalan and alemtuzumab. Post HCT, escalating doses of donor lymphocyte infusions were given for T-cell mixed chimerism +/- MRD persistence or relapse. MRD assessment: BCR/ABL1 or Ig/TCR MRD was assessed and analysed per EuroMRD guidelines. MRD is negative (undetectable with an assay quantitative range of 1x10^-4 or less), positive (≥1x10^-4), positive outside quantitative range ≥5x10^-4). Patients with indeterminate MRD were excluded from this analysis.

Results: There are 736 patients randomised to date, of whom 184 received a RICalloHCT, of these, 115 had analyzable MRD. The following Table 1 shows patient characteristics.

Table 1.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>n=115</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 41 years (median range)</td>
<td>49 (30-65)</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td>n=115</td>
</tr>
<tr>
<td>Pre-existing WBC (median range)</td>
<td>8.6 (0.1-575)</td>
</tr>
<tr>
<td>B-ALL</td>
<td>60 (52)</td>
</tr>
<tr>
<td>High-risk cytogenetics (%)</td>
<td>31 (13)</td>
</tr>
<tr>
<td>Males</td>
<td>61 (53)</td>
</tr>
<tr>
<td>Females</td>
<td>54 (47)</td>
</tr>
<tr>
<td>Hyperdiploid (N%)</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Blastic transformation</td>
<td>13 (11)</td>
</tr>
<tr>
<td>Sibling donor</td>
<td>40 (34)</td>
</tr>
<tr>
<td>1St MRD risk group</td>
<td>32 (28)</td>
</tr>
<tr>
<td>Medical gene mutation</td>
<td>55 (48)</td>
</tr>
<tr>
<td>EKALL1 cytogenetic risk group N (%)</td>
<td>39 (34)</td>
</tr>
<tr>
<td>Post induction MRD N (%)</td>
<td>62 (54)</td>
</tr>
<tr>
<td>No MRD/POQR</td>
<td>7 (6)</td>
</tr>
<tr>
<td>Positive</td>
<td>38 (33)</td>
</tr>
<tr>
<td>Unknown</td>
<td>30 (26)</td>
</tr>
</tbody>
</table>

At 2 years post transplant, overall survival (OS) was 63.1% in the 115 patients with evaluable MRD and 62.7% in the 184 patients receiving RICalloHCT; event free survival (EFS) was 55.2% and 55.9% respectively. By contrast, in the 38 of 115 patients with positive MRD after induction, OS and EFS were 40.6% and 28.4% respectively. Twenty eight of the 115 patients relapsed, with a 2 year actuarial relapse risk of 31.5% (22.2-43.5). We assessed the association of the following factors; age, sex, immunophenotype, presenting WBC, BCR/ABL1, other cytogenetics, post-induction MRD and donor type with the risk of relapse. Among this population of high risk patients, post-induction MRD was the only independent prognostic factor for relapse (univariable HR: 3.82 (1.59-9.16), p= 0.001 (see Figure 1) and multivariable HR: 4.14 (1.61-10.65), p= 0.003). The relapse rate of the MRD+ patients was 57.2% at 2 years post HCT.

Figure 1. Summary/Conclusions: The 2-year OS of 62.5% in UKALL14 participants over 41 years old after RICalloHCT is greater than would be expected with chemotherapy alone. However, MRD positivity after induction is associated with significantly lower OS, EFS and a higher risk of relapse, which is not abrogated by RICalloHCT.

S803 T-CELL RECEPTOR B REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA ON BLINATUMOMAB TREATMENT

H. Knecht1,2, M. Kotrova1,2,*, T. Reigl3, A. Krejci3, D. Herrmann2, M. Schwarz2, V. Bystry3, N. Darzentas3, M. Brüggemann2

1contributed equally, 2Department of internal medicine II, Laboratory for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany, 3Central European Institute of Technology, Brno, Czech Republic

Background: Blinatumomab (Blin) is a bispecific monoclonal antibody, activating autologous effector T-cells and redirecting them against CD19-positive malignant cells. This leads to polyclonal effector T-cell expansion which is the necessary component of its antitumour mechanism. Recent reports indicated promising antitumour activity of Blin in relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, approximately half of these patients do not achieve minimal residual disease (MRD) response. Thanks to recent advances in next generation sequencing (NGS) of immunoglobulin and T-cell receptor gene rearrangements level and comprehensive evaluation of expanded T-cell repertoire on Blin treatment is now possible.

Aims: To compare the differences in TRB repertoire diversity and composition between two groups of patients with r/r ALL: 1) responders: reaching MRD negativity at the latest at day 29 of 1 Blin cycle (C1D29), and 2) persisters: with quantifiable MRD positivity (>0.01%) at C1D29, or with MRD >1% at cycle 1 day 15 (C1D15) if C1D29 sample is not available.

Methods: We used NGS to investigate TRB repertoire in bone marrow samples (114× at time of screening (scr), 74× C1D15, 88× C1D29) of 114 r/r Ph-negative BCP-ALL patients (median age: persisters 47; responders 42; p-value=0.81). Patients received Blinatumomab within the phase II trial (MT103-211). Sequencing libraries were prepared using 100ng of DNA via 2-step PCR and sequenced on the Illumina MiSeq (2 x 250bp) with a median coverage of 117,563 reads (range 59.512 - 447.767 reads) per sample. In the first PCR virtually all TRB rearrangements present in the investigated sample were amplified using universal V(D)- and J-regions primers. In the second step, sequencing adaptors and sample-specific barcodes were added. Annotation of V(D)- and J-regions of TRB sequences was performed using ARResT/Interrogate (Bystry, Bioinformatics, 2016). Diversity of TRB repertoire within patient groups and time points was expressed as the Shannon index, using the R-package vegan. Analysis of variance was employed to assess statistically significant differences in diversity between groups and time points.

Results: Diversity of TRB repertoire (Figure 1) was significantly higher in responders at time of scr (p=0.02) and at C1D29 (p=5.47E-6). Patients in the persisters group had significantly higher blast counts, which is in accordance with previously published data (Topp, The Lancet Oncology, 2015). The increase of diversity between scr and C1D29 of Blinatumomab treatment was sharp and highly significant in responders (p=3.96E-6), but not statistically significant in persisters (p=0.4).

Figure 1.
Summary/Conclusions: We showed that Blin responders have significantly higher TRB repertoire diversity at scr compared to persisters and that the repertoire expansion during Blin treatment is sharper in responders. Other repertoire characteristics did not differ significantly between groups. Further studies on larger patient cohorts are necessary in order to elucidate whether the response to treatment can be predicted by repertoire diversity at scr.

Amplicon NGS is a useful tool for monitoring of T-cell repertoire. Development, standardization, and validation of TRB primer sets is in progress within EuroClonality-NGS Consortium.

Research Support: Amgen.

Infectious diseases, supportive care

S804
DISCONTINUING ANTIMICROBIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRILE NEUTROPIA IS SAFE AND REDUCES EXPOSURE TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)

I. Espigado1,*, M. Aguilar-Guisado2, A. Martín-Peña2, C. Gudino3, J. Falantes4, L. Vazquez4, I. Montero1, M.L. Martino1, R. Parody1, J. Gonzalez-Campos1, S. Garzon2, C. Calderon-Cabrera1, P. Barba2, N. Rodriguez-Torres4, M. Rivira7, J.A. Perez-Simon1, J.M. Cisneros-Herreros2

1Unidad Clínica de Hematología, 2Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, 3Servicio de Enfermedades Infecciosas, Hospital de Bellvitge, Barcelona, 4Servicio de Hematología, Hospital Clínico de Salamanca, Salamanca, 5Servicio de Hematología, Hospital de Jerez de la Frontera, Jerez, 6Servicio de Hematología, Hospital Universitario Vall Hebron, 7Servicio de Hematología, Hospital Clinic, Barcelona, Spain

Background: In neutropenic patients with unexplained fever the classical approach is maintaining the empirical antimicrobial therapy (EAT) until neutrophil recovery. This strategy may result in unnecessarily prolonged EAT favoring bacterial resistance, organ toxicity and damage to microbiota. Nevertheless, the available scientific evidence supporting the alternative approach of stopping EAT before neutrophile recovery is moderate.

Aims: To investigate if a clinical approach (based on apyrexia and clinical recovery) is better than and as safe as the standard criteria (recovery from neutropenia) to decide the discontinuation of EAT.

Methods: After local Ethical Committee approval, a randomized, controlled, multicenter, open-labeled phase IV clinical trial was performed (EudraCT: 2011-005152-34). Study period: May-2012 to May-2016. Inclusion criteria: a) Adult patients (≥18 years); b) Hematologic malignancy or autologous or allogeneic hematopoietic stem cell transplantation (SCT) recipients; c) High risk febrile neutropenia (FN) d) Informed consent signed. Exclusion criteria: etiological diagnosis of FN. Patients were randomized 72 hours after fever onset to: 1. Experimental group (EG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clinical recovery ≥72 h (independently of neutrophil count) or 2. Control group (CG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clinical recovery ≥72 h, plus c) >0,5x10^6/L neutrophils. Follow-up: 28 days from EAT. Primary (efficacy) end-point was number of EAT-free days. Secondary (safety) end-points were total days of fever and crude mortality.

Results: One hundred and fifty seven patients were included (EG 78 and CG 79). There were no differences in baseline characteristics or clinical presentation between groups. The most frequent underlying conditions were induction/re-induction chemotherapy for acute leukemia (n=42, 26,7%), autologous SCT (n=42, 45,8%) and allogeneic hematopoietic stem cell transplantation (SCT) recipients; c) High risk febrile neutropenia (FN) d) Informed consent signed. Exclusion criteria: etiological diagnosis of FN. Patients were randomized 72 hours after fever onset to: 1. Experimental group (EG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clinical recovery ≥72 h (independently of neutrophil count) or 2. Control group (CG): EAT discontinuation if a) apyrexia ≥72 h, plus b) clinical recovery ≥72 h, plus c) >0,5x10^6/L neutrophils. Follow-up: 28 days from EAT. Primary (efficacy) end-point was number of EAT-free days. Secondary (safety) end-points were total days of fever and crude mortality.

Table 1.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Median (IQR range)</th>
<th>Median (IQR range)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days of neutropenia</td>
<td>14 (6.5-24)</td>
<td>11 (8-21)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Days of fever</td>
<td>4 (2-8)</td>
<td>4 (2-8)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>EAT-free days*</td>
<td>18 (12.5-215)</td>
<td>18 (9.7-20.2)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Per protocol population</td>
<td>EG (n=68)</td>
<td>CG (n=68)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Days of fever</td>
<td>4 (1-14)</td>
<td>5 (2-8)</td>
<td>p=0.02</td>
</tr>
<tr>
<td>EAT-free days*</td>
<td>19 (14-22)</td>
<td>14 (5.8-20.7)</td>
<td>p=0.02</td>
</tr>
<tr>
<td>Total days of fever</td>
<td>3 (1-7)</td>
<td>3 (1-5.7)</td>
<td>p=0.001</td>
</tr>
</tbody>
</table>

ITP: Intention to treat; EAT: empirical antimicrobial therapy; EG: experimental group; CG: control group; IQR: inter-quartile range.

*EAT-free days: days of follow-up (28) - days of EAT.

**Patients in which clinical recovery and neutropenia recovery did not match.
Summary/Conclusions: In hematological patients with febrile neutropenia of unknown origin the discontinuation of empirical antibacterial therapy after 72 hours of apyrexia and clinical recovery regardless of neutrophils count is safe and reduces unnecessary exposure to antibiotics.

S805
CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
A. Bondanza1, F. Ciceri1

Background: Patients with CLL have an increased risk for infection and Streptococcus pneumoniae is one of the most common pathogens with high morbidity. Patients with CLL are known to respond poorly to the traditionally used polysaccharide vaccines. Conjugation of polysaccharide to protein carriers renders a thymus-dependent, memory-inducing and more immunogenic vaccine. In patients with CLL, there is no consensus on a recommendation for pneumococcal vaccination, due to a lack of comparative studies.

Aims: To determine if patients with untreated chronic lymphocytic leukemia (CLL) benefit from vaccination with a 13-valent conjugated pneumococcal vaccine (PCV13), Prevenar13®, compared with a 23-valent capsular polysaccharide (PPSV23), Pneumovax®, in terms of immune response.

Methods: 128 treatment naïve CLL patients from eight hematology clinics in Sweden were randomized to vaccination with PCV13 (n=63) or PPSV23 (n=65) after stratification by IgG levels and CLL clinical stage (Rai). Blood samples for evaluation of immune response were obtained at baseline, at one month and at six months after vaccination. Analyses for each of the 12 pneumococcal serotypes common for PCV13 and PPSV23 were performed by opsonophagocytic assay (OPA) and enzyme-linked immunosorbent assay (ELISA).

Results: PCV13 elicited a superior immune response than PPSV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination, measured as OPA geometric mean titers (GMTs). Geometric mean concentrations of serotype-specific IgG antibodies elicted by PCV13 as measured by ELISA, were higher than those elicited by PPSV23 in half of the common serotypes, both after one and six months. The proportion of patients with good response (defined as response in >80% of common serotypes) at six months after PCV13 vaccination, measured as OPA GMTs, was 58% (95% CI 47-68) vs 40% (95% CI 27-53) (P=0.02). Additionally, in both training and prospective validation sets, lower GMTs were found for PCV13 recipients than for PPSV23 recipients at one month (40% vs 22%, P=0.031) as well as after six months (33% vs 17%, P=0.041). Never did PPSV23 trigger a better immune response for any of the serotypes, than PCV13, regardless of analysis. For two of the serotypes, OPA GMTs were lower than the six months than at the one-month follow up. Negative predictive factors for vaccination response were hypogammaglobulinemia and long disease duration. Both vaccines were well tolerated.

Summary/Conclusions: In patients with previously untreated CLL, the efficacy of immune response is strongly superior for PCV13 than for PPSV23 for many serotypes common for the two vaccines. PCV13 should be considered as a part in vaccination programs against Streptococcus pneumoniae for these patients and administered as possible during the course of the disease.

S806
INFECTION-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM
A. Forcina1, P. Rancitola2, V. Marasco3, R. Greco4, M. Lupo Stanghellini1, M. Carraab1, M. Martacci1, C. Di Serio2, M. Bernardi1, J. Peccatori1, C. Corti1, A. Bondanza1, F. Cicin1

1IRCCS San Raffaele Scientific Institute, 2Vita-Salute San Raffaele University, Milan, Italy

Background: Infection-related mortality (IRM) is a major challenge after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Aims: The aim of this study was to develop a scoring system predicting IRM based exclusively on pre-transplant data.

Methods: A total of 589 adult patients receiving allo-HSCT were studied (Jan 2009–Dec 2015). The set of patients (n=273, Jan 2012-May 2015) the ROC curve analysis defined the optimal cut-offs predicting 100-day IRM for continuous data. All clinical and biochemical variables were challenged in a multivariate analysis and a 3-tiered weighted score was elaborated and tested firstly in a retrospective validation set (n=219, Jan 2009-Dec 2011) and then in a prospective validation set (n=97, Jun 2016-Nov 2016).

Results: Median follow-up was 43 months (range 1-85). Acute leukemia was the main indication to transplant, accounting for 60% (n=356) of patients. The majority of the patients received an alternative-donor transplant (44% a HLA-haploidentical, 37% a matched unrelated donor). Forty-seven percent (n=277) of patients had advanced diseases. Multivariable analysis revealed age >60 yrs (P=0.003), CMV host/donor serostatus different from negative/negative (P<0.001) and pre-transplant levels of Iga <1.11 g/L (P=0.004) and IgM <0.305 g/L (P=0.028) as the only independent predictors of increased IRM. Noticeably, these associations were independent from disease type or status, donor type, intensity of conditioning, in vivo T or B-cell depletion or from previous colonisation by multidrug-resistant bacteria. According to the proposed IRM score, patients were divided into 3 classes: low (<10.17 points), intermediate (10.17-11.11 points) or high-risk (>11.11 points). In the training set, 100-day and 2-yr IRM were 5% (95% CI 2-10) and 9% (95% CI 4-16) for low-risk, 11% (95% CI 5-18) and 23% (95% CI 14-33) for intermediate-risk, and 16% (95% CI 16-37) and 41% (95% CI 28-53) for high-risk patients, respectively (P=0.001). In the retrospective validation set, 100-day and 2-yr IRM were 7% (95% CI 3-14) and 14% (95% CI 8-22) for low-risk, 17% (95% CI 10-26) and 23% (95% CI 15-33) for intermediate, and 28% (95% CI 15-42) and 33% (95% CI 19-44) for high-risk patients, respectively (P=0.044), with a c-index of 0.608 (Figure 1). In the prospective validation set, only 100-day IRM was calculated due to a shorter follow-up, being of 0%, 3% (95% CI 0-13) and of 14% (95% CI 3-33) for low, intermediate and high-risk patients (P=0.003). Additionally, in both training and retrospective validation sets, only 100-day OS was different among the 3 groups, being 59% (95%CI 52-67), 50% (95%CI 43-59) and 37% (95%CI 29-48) for low, intermediate and high-risk groups, respectively (P=0.0001). In the prospective validation set, only 100-day OS was evaluated, being of 95% (95%CI 88-100), 91% (95% CI 82-100) and 80% (95% CI 65-100), respectively (P=0.034). Out of a total of 125 infection-related deaths, 94/125 (73%) were attributed to bacteria, 22/129 (17%) to viruses, 11/129 (8%) to fungi and 2/129 (2%) to parasites.

Figure 1.

Summary/Conclusions: This new clinic-biological score based on age, CMV serostatus and levels of IgA and IgM, may contribute to the prompt identification of patients at higher risk of fatal infections prior to allo-HSCT, thus promoting post-transplant personalized intensive active surveillance strategies and immune-intervention approaches to improve the overall outcome of transplant.

A multicentric Italian study in currently on the way for the external validation of these results.

S807
LETTERMOVIR FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
R. Duarte1, F. Marty2, P. Ljungman3, R. Chemaly3, J. Maertens5, D. Sn Edmunds, E. Blumberg7, H. Einsele6, M. Boechk9, V. Teal10, H. Wan11, N. Kartsonis11, R. Leavitt11, C. Badshah11

1BMT Programme & Myeloid Leukemia Division, Hospital Universitario Puerta de Hierro, Madrid, Spain, 2Department of Infectious Diseases, Me dical School of Medicine at the University of Pennsylvania, Philadelphia, United States, 3Hematology, Karolinska University Hospital , Stockholm, Sweden, 4Department of Infectious Diseases, Infect Control & Employee Health , UT MD Anderson Cancer Center , Houston, United States, 5Hematology, Universitair ziekenhuis , Leuven, Belgium, 6Medicine, Thoracic Oncology Center, Boston, United States, 7Internal Medicine, Universitätsklinikum Würzburg , Wuerzburg, Germany, 8Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center , Seattle, 9Vaccinology, The University of Texas MD Anderson Cancer Institute , Boston, United States, 10Late Development Statistics, 11Global Clinical Development - Control & Employee Health , UT MD Anderson Cancer Center , Houston, United States

Background: CMV remains a common complication of HCT, yet no antiviral drug suitable for prophylaxis is available in HCT. LET is a first-in-class drug
that inhibits the CMV terminase complex. A dose-escalation phase 2 trial showed that LET prophylaxis for up to 12 weeks post-HCT was effective with a safety profile similar to placebo.

**Aims:** To compare LET prophylaxis to placebo for the prevention of clinically significant CMV infection (CS-CMV), defined as CMV disease or CMV viremia leading to preemptive treatment (PET) in a Phase III randomized, double-blind, placebo-controlled trial.

**Methods:** CMV seropositive HCT recipients 18 years or older who had undetectable plasma CMV DNA within 5 days of randomization were eligible (full eligibility at clinicaltrials.gov, NCT02137772). Subjects had to start treatment by Day+28 post-HCT. Subjects were randomized 2:1 to receive LET or placebo PO QD 240 mg/d for 28 days (2 weeks post-HCT, stratified by study site and high or low CMV disease risk). LET was dosed at 480 mg/d (or 240 mg/d if on cyclosporine due to drug-drug interaction). Subjects were assessed weekly through Week 14, biweekly through Week 24, and every other month through Week 48 after HCT. Plasma obtained at each visit was assayed for CMV DNA in a central laboratory. Subjects who developed CS-CMV discontinued study drug and received anti-CMV treatment. Local CMV assay results could be used to start PET. The primary endpoint was the stratified-adjusted proportion of subjects with CS-CMV through Week 24 post-HCT among subjects with undetectable CMV DNA at randomization; subjects who discontinued the study for any reason or with missing data at Week 24 were considered failures. All adverse events (AEs) were analyzed through 14 days after the last dose of study drug.

**Results:** From June 2014 to March 2016, 565 randomized subjects received study treatment; 31% were at high CMV disease risk. 50% subjects received myeloblastic conditioning, 35% received ATG. Donors included 14% mismatched unrelated, 13% haploidentical and 4% cord blood. Study arms were balanced. Subjects began study drug a median of 9 days post-HCT. 37% had engrafted prior to start. Of 495 treated subjects with undetectable CMV DNA at randomization, fewer subjects developed CS-CMV or were considered failures in the LET arm (122/325, 38%) compared to placebo (103/170, 61%; p<0.0001) by Week 24 post-HCT. Figure 1 shows the time to CS-CMV analysis. The most common AEs (LET, placebo) were GVHD (39%, 39%), diarrhea (26%, 25%), and nausea (27%, 23%). More frequent vomiting (19%, 14%), edema (15%, 9%), atrial arrhythmias (10%, 5%), and ALT levels >5xULN (4%, 2%) was noted in LET-treated subjects; no increased myelotoxicity or nephrotoxicity was observed. The Week 24 all-cause mortality was 10% for LET recipients and 15% for placebo recipients.

**Figure 1.** Summary/Conclusions: Letemovir prophylaxis was effective in reducing clinically significant CMV infection, was overall well tolerated, and provides a new approach to CMV prevention after HCT.

**S808**

**EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN EXPANDED-ACCESS PROTOCOL**

N. Kernan1, P. Richardson2, S. Grupp3, J. Antin4, Y. Messinger5, W. Liang6, R. Ryan6, R. Hume6, W. Tapp6, R. Soiffer6

1Pediatric Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, 2Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 3Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, 4Stem Cell/Bone Marrow Transplantation and Progenitor Cells, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 5Children’s Hospitals and Clinics of Minnesota, Minneapolis, 6Jazz Pharmaceuticals, Inc., Palo Alto.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States

**Background:** Hepatic VOD/SOS, which may be unpredictable and potentially life-threatening, is typically considered a complication of hematopoietic stem cell transplantation (HSCT), and VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in the European Union and to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States. However, VOD/SOS can occur after chemotherapy without HSCT.

**Aims:** To perform a post hoc analysis of final data on safety and response to defibrotide in patients developing VOD/SOS after primary chemotherapy without HSCT.

**Methods:** In an expanded-access protocol for patients with VOD/SOS post-HSCT or chemotherapy, with or without MOD (renal and/or pulmonary dysfunction), defibrotide 25 mg/kg/d (4 divided doses of 6.25 mg/kg) was given a recommended ≥21 days after patients provided informed consent. Post-chemotherapy subgroup survival was analyzed post hoc from the day defibrotide was started (days 0–30 after start of chemotherapy) for 70 days (because follow-up data were collected for 100 days post-chemotherapy).

**Results:** Of 1154 VOD/SOS patients receiving defibrotide, 137 (12%) developed VOD/SOS post-chemotherapy without HSCT. Among the 82 patients (38 with MOD) treated with DF by day 30 after start of chemotherapy, median age was 7.5 years (range, 0–68 years) and 66 (81%) were pediatric patients (≤16 years of age). Among pediatric patients, 15% were age 0–23 months, 74% were 2-11 years and 11% were 12-16 years. Most common primary diseases were acute lymphocytic leukemia (51%), acute myeloid leukemia (13%), and neuroblastoma (6%). Kaplan-Meier estimated survival at Day +70 was 74% overall (95% CI, 63–82%); 86% (49–79%) in patients with MOD and 81% (66–90%) in patients without MOD. By age subgroup, Kaplan-Meier estimated survival at Day +70 was 80% (95% CI, 68–88%) in pediatric patients (Figure 1) and 50% (95% CI, 25–71%) in adults. Adverse events (AEs) were reported in 54/82 patients (66%). Hemorrhagic AEs (≥2%) were pulmonary (6%), epistaxis or mouth (4%), and hematochezia (2%). There were 22 (27%) patients with AEs assessed as being at least possibly related to defibrotide, the most common (≥2%) were pulmonary or mouth hemorrhage (4% each) and hematochezia, nausea, encephalopathy, epistaxis, or hypotension (2% each). Related AEs led to discontinuation in 6 patients and were associated with 1 death (pulmonary hemorrhage, hypotension).

**Figure 1.**

**Summary/Conclusions:** The 74% survival rate at Day +70 in patients with VOD/SOS receiving defibrotide within 30 days of starting chemotherapy (81% in patients ≤16 years of age) is clinically encouraging. Of note is the 66% survival rate in patients with MOD. The defibrotide safety profile was consistent with that previously reported in the overall population of this expanded-access protocol.

**Support:** Jazz Pharmaceuticals.
Iron: Deficiency and overload

S809
LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION
1MMPU - Molecular Medicine Partnership Unit, 2Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg, Heidelberg, 3Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, 4Institute of Clinical Molecular Biology and Tumor Genetics, Helmholtz Zentrum München, 5Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany, 6Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology in Zurich, Basel, Switzerland, 7Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, 8Research Unit Analytical Pathology, 9Institute of Molecular Immunology, 10Institute of Experimental Genetics, 11Institute of Developmental Genetics, Helmholtz Zentrum München, Munich, Germany

Background: GPX4 is a selenoprotein belonging to the family of the glutathione peroxidases, a class of enzymes involved in cellular defence against oxidative stress. This enzyme is essential for life since it is the only peroxidase able to use lipid peroxides as substrate. Mice constitutively lacking GPX4 die at embryonic day 14, exhibiting a tissue-specific ablation in neurons and T-cells causing neurodegeneration and impaired immune response. Recent studies have identified GPX4 as the main regulator of ferroptosis, an iron-dependent ROS-mediated form of nonapoptotic cell death. Erythrocytes are highly specialized cells that utilize a large amount of iron to bind and deliver oxygen to all tissues. Being constantly exposed to oxygen, erythroid cells need to continuously fight against oxidative stress by expressing a variety of antioxidant enzymes, including GPX4. Iron availability for erythropoiesis depends on systemic iron levels which are regulated via the hepcidin/ferroportin regulatory system. Hepcidin binding to the iron exporter ferroportin reduces systemic iron export regulating body iron levels. In hypoxic conditions the erythroid hormone ErFe suppresses hepcidin synthesis to provide iron for the elevated erythropoietic demand.

Aims: The aim of this study is to identify how the lack of GPX4 in the hematological compartment affects iron homeostasis.

Methods: Lethally irradiated C57BL/6 female mice were reconstituted with bone marrow cells from Gpx4−/−, Rosa26-CreERT2 or Gpx4+/+, Rosa26-CreERT2 and allowed to recover for 8 to 10 weeks. GPX4 deletion in the hematopoietic system was induced by feeding tamoxifen citrate for 3 weeks and blood and organs were allowed to recover for 8 to 10 weeks. GPX4 deletion in the hematopoietic system was induced by feeding tamoxifen citrate for 3 weeks and blood and organs were allowed to recover for 8 to 10 weeks. Gpx4 deletion in the hematopoietic system affects iron homeostasis.

Results: Compared to Gpx4+/+, CreERT2 controls, Gpx4−/−, CreERT2 transplanted mice lacking GPX4 in the haematological compartment show a decrease in the number of red blood cells, haemoglobin and haematocrit. Reticulocyte cells have been analysed in FACS. Serum iron levels have been assessed using the SFBC and UIBC iron kits (Biolabo). Gene expression analysis has been performed using SYBR-green qRT-PCR. Circulating Hepcidin has been measured with a specific murine ELISA kit (Intrinsic Lifesciences). Tissue iron levels have been measured with a colorimetric assay. All animal experiments were approved by the institutional animal care committee in compliance with institutional guidelines.

Summary/Conclusions: Our data show for the first time that the presence of GPX4 in the haematological compartment is essential for the proper hepcidin downregulation. This finding opens new insights in the mechanism that regulate hepcidin during hypoxia.

S810
IDENTIFICATION OF GUANOSINE 5’-DIPHOSPHATE AS POTENTIAL IRRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING STAT3 PATHWAY
S. Angmo1, N.K Singhal2
1Food science and Nanobioscience, 2National Agri Food biotechnology, Mohali, India

Background: Anemia of inflammation (AI) is one of the most common manifestations of iron deficiency in the patients with inflammatory conditions. AI is responsible for hypoferraemia, with consequent iron-restricted erythropoiesis with high level of hepcidin, which stimulate the internalization of ferroportin (FPN) transporter. Therefore, inhibiting hepcidin-mediated FPN degradation can be an important strategy to ameliorate AI.

Aims: To increase iron bioavailability we selected a Novel compound against hepcidin action through natural compound libraries that might provide a new alternative approach to increase iron absorption for prevention of hepcidin-mediated FPN internalization and to ameliorate turfentine-induced anemic state with different insilico, invitro and invivo studies.

Methods: A systematic approach involving in silico, in vitro and in vivo studies was employed to identify hepcidin inhibiting agents. To identify a potent hepcidin-binding agent, natural compounds were screened using molecular docking and dynamics simulations and further investigated on cell lines (GFP-FPN, Caco-2, HepG2) using flow cytometry and western blotting. Normal or turpentine induced anemic mice were used in the associated studies.

Results: The virtual screening via molecular modelling showed that GDP as a potent hepcidin-binding agent as shown in the Figure 1A. In vitro studies revealed that GDP significantly increased ferropoin stabilization in GFP-FPN cell lines (Figure 1C) and in vivo studies showed that co-administration of GDP and ferrous sulphate (FeSO4) significantly improved the turfentine-induced anemic state with increase in haemoglobin level (Figure 1B).

Figure 1. Summary/Conclusions: AI is a normocytic anemia, common among patients with chronic infection and inflammatory disorders. We found that GDP molecule have higher contribution to the stability of hepcidin-GDP complex and thus blocks its interaction with FPN. The results support the novel hypothesis that GDP along with iron supplement regime can overcome the binding of hepcidin from interaction with FPN that would be an effective treatment for AI.

S811
UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOETIC ANEMIA TYPE II (CDAII) IN VITRO EVALUATION OF RAP-011 TREATMENT
G. De Rosa1,2, I. Andolfo1, F. Manna1, A. Gambale1, R. Marra1, B. E. Rosato1, A. Iolascon1, R. Russo1
1Molecular Medicine and Biotechnology, CEINGE - Biotecnologie Avanzate, Naples, Italy

Background: Congenital Dyserythropoietic Anemias (CDAs) are subtypes of bone marrow failure syndromes, hallmarked by ineffective erythropoiesis. The most common form is CDA type II (CDAII), showing moderate/severe anemia, relative reticulocytopenia, jaundice, and iron overload. It is inherited as autosomal recessive disorder due to loss of function mutations in SEC23B gene. More than 300 CDAII cases and 80 causative mutations have been described so far. Despite this high allelic heterogeneity, two variants, R14W and E109K, represent more than 50% of the mutational events. To date, treatments for CDAII patients consist of supportive therapy, such as erythrocyte transfusions, or bone marrow transplantation or splenectomy in transfusion-dependent cases. Recently, members of TGF-β superfamily have been studied as potential regulators of erythropoiesis, especially the growth differentiation factor 11 (GDF11). Through the binding of specific receptors, GDF11 leads to an inhibited late-stage erythropoiesis. Indeed, two GDF11 inhibitors, ACE-011 and ACE-536 have been associated to increased iron release and iron overload in treated mice.

Results: We selected a systematic approach involving in silico, in vitro and in vivo studies was employed to identify hepcidin inhibiting agents. To identify a potent hepcidin-binding agent, natural compounds were screened using molecular docking and dynamics simulations and further investigated on cell lines (GFP-FPN, Caco-2, HepG2) using flow cytometry and western blotting. Normal or turpentine induced anemic mice were used in the associated studies.

Results: The virtual screening via molecular modelling showed that GDP as a potent hepcidin-binding agent as shown in the Figure 1A. In vitro studies revealed that GDP significantly increased ferropoin stabilization in GFP-FPN cell lines (Figure 1C) and in vivo studies showed that co-administration of GDP and ferrous sulphate (FeSO4) significantly improved the turfentine-induced anemic state with increase in haemoglobin level (Figure 1B).

Figure 1. Summary/Conclusions: AI is a normocytic anemia, common among patients with chronic infection and inflammatory disorders. We found that GDP molecule have higher contribution to the stability of hepcidin-GDP complex and thus blocks its interaction with FPN. The results support the novel hypothesis that GDP along with iron supplement regime can overcome the binding of hepcidin from interaction with FPN that would be an effective treatment for AI.
Aims: The main aim of our study is to assess the effects of RAP-011 on different cellular models of CDAII. Methods: We measured circulating GDF11 levels in CDAII patients with healthy controls (HC) by western blot (WB). To assess the effectiveness of RAP-011 (provided by Celgene Corporation/in) v, we established two different cellular models of CDAII: (i) K562 cells stably silenced for SEC23B by sh-RNA carried in non-targeting virus; (ii) K562 cells stably overexpressing SEC23B-WT and the two variants, R14W and E109K. In vitro treatment has been performed at 0, 3, and 6 days of erythroid differentiation by hemin+GDF11 in presence or absence of RAP-011 in K562 cells stably silenced for SEC23B.

Results: WB and subsequent densitometric analysis showed an increase of GDF11 in SEC23B silenced K562 cells from 16 CDAII patients compared to HC (p<0.02). Stable silencing of SEC23B in K562 cells to the establishment of two different clones, Sh-70 and Sh-74, showing amakrededuction of SEC23B expression compared to Sh-CTR (85-90% and 60-65%, respectively). At 3 and 6 days of K562 erythroid differentiation by hemin, we observed an increased expression of SMAD2 in GDF11-treated cells compared to non-treated ones; interestingly, a reduction of pSMAD2 in RAP-011+GDF11-treated cells was observed.

Summary/Conclusions: We firstly demonstrated the increased levels of GDF11 in CDAII patients. Thus, we used a combined treatment with hemin and RAP-011 in SEC23B silenced K562 stable clones, in order to reproducethe pathologic phenotype of the disease, and make K562 cells suitable for RAP-011 treatment, as attested by the increased expression of pSMAD2 in GDF11-treated cells. The reduced pSMAD2 in RAP-011+GDF11-treated cells suggests that RAP-011 treatment leads to repression of ActRIIA/B pathway, which in turn should increase nuclear levels of GATA1 transcription factor. This action should lead to an increased expression of GATA1-activated genes involved in erythroid development. The evaluation of GATA1 activation is ongoing, as well as the in vitro treatment of K562 stably overexpressing SEC23B-WT, SEC23B-R14W and -E109K.

S812
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

A. Weigl1,*, N. Köhler1, I. Monsef1, J. Bohlius2, I. Becker3, K. Kuhr3, N. Skoetz1
1Cochrane Haematological Malignancies, University Hospital Cologne, Cologne, Germany, 2Molecular Biotechnology Center, University of EMBL, Heidelberg, Germany, 3Institute of Medical Statistics, Informatics and Epidemiology, University Hospital Cologne, Cologne, Germany

Background: A widely prevalent complication in patients suffering from cancer is the deficiency of haemoglobin-containing red blood cells, referred to as anaemia. While many patients develop anaemia due to an involvement of malignant bone marrow cells, others suffer from so called chemotherapy/radiotherapy induced anaemia. Erythropoiesis-stimulating agents (ESAs) stimulate the production of red blood cells within the bone marrow and have shown to increase Hb levels in anaemic patients. Uncertainties remain regarding the effect of iron supplementation on the fatal consequences of ESA-treatment.

Aims: The aims of this systematic review and network meta-analysis are to evaluate the benefits of RAP-011 in ESA-as and iron for the treatment of disease-related as well as therapy induced anaemia in cancer patients.

Methods: Based on an a-priori Cochrane protocol, we developed sensitive search strategies for Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, databases of ongoing trials and conference proceedings (search date 12/2016). We included only randomized controlled trials (RCTs) including anaemic patients of any age with solid and/or haematological malignancy undergoing chemotherapy, radiotherapy or no anti-cancer therapy. We excluded studies including anaemic cancer-patients as a result of surgery or related as well as therapy induced anaemia in cancer patients.

Results: Based on an a-priori Cochrane protocol, we developed sensitive search strategies for Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, databases of ongoing trials and conference proceedings (search date 12/2016). We included only randomized controlled trials (RCTs) including anaemic patients of any age with solid and/or haematological malignancy undergoing chemotherapy, radiotherapy or no anti-cancer therapy. We excluded studies including anaemic cancer-patients as a result of surgery or related as well as therapy induced anaemia in cancer patients.

Results: We firstly demonstrated the increased levels of GDF11 in CDAII patients. Thus, we used a combined treatment with hemin and RAP-011 in SEC23B silenced K562 stable clones, in order to reproduce the pathologic phenotype of the disease, and make K562 cells suitable for RAP-011 treatment, as attested by the increased expression of pSMAD2 in GDF11-treated cells. The reduced pSMAD2 in RAP-011+GDF11-treated cells suggests that RAP-011 treatment leads to repression of ActRIIA/B pathway, which in turn should increase nuclear levels of GATA1 transcription factor. This action should lead to an increased expression of GATA1-activated genes involved in erythroid development. The evaluation of GATA1 activation is ongoing, as well as the in vitro treatment of K562 stably overexpressing SEC23B-WT, SEC23B-R14W and -E109K.

Summary/Conclusions: We firstly demonstrated the increased levels of GDF11 in CDAII patients. Thus, we used a combined treatment with hemin and RAP-011 in SEC23B silenced K562 stable clones, in order to reproduce the pathologic phenotype of the disease, and make K562 cells suitable for RAP-011 treatment, as attested by the increased expression of pSMAD2 in GDF11-treated cells. The reduced pSMAD2 in RAP-011+GDF11-treated cells suggests that RAP-011 treatment leads to repression of ActRIIA/B pathway, which in turn should increase nuclear levels of GATA1 transcription factor. This action should lead to an increased expression of GATA1-activated genes involved in erythroid development. The evaluation of GATA1 activation is ongoing, as well as the in vitro treatment of K562 stably overexpressing SEC23B-WT, SEC23B-R14W and -E109K.

S813
DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES

F. Vincent1,*, R. Sparia1, E. Tolosano2, U. Platzbecker3, M.U. Muckenthaler1
1Molecular Medicine Partnership Unit (MMPU), University of Heidelberg & EMBL, Heidelberg, Germany, 2Molecular Biotechnology Center, University of Turin, Turin, Italy, 3Institute for Medical Statistics, Informatics and Epidemiology, University Hospital Cologne, Cologne, Germany

Background: Iron homeostasis and macrophage biology are closely interconnected. On the one hand, reticuloendothelial macrophages are central for the regulation of iron homeostasis. The phagocytosis and degradation of senescent red blood cells (RBC) by macrophages enable efficient recycling of iron and the maintenance of systemic iron balance. On the other hand, iron exerts multiple effects on macrophage polarization and function. Macrophages exhibit a remarkable functional plasticity, reflected in their capacity to integrate diverse signals from the microenvironment and acquire distinct phenotypes. Macrophage polarization has been shown to dictate the expression of iron-regulated genes and determine cell iron handling.

Aims: Increasing evidence suggests that iron availability itself has significant effects on immune effector functions and macrophage polarization. However, it is still unclear how different iron sources and acquisition pathways affect macrophage phenotypes.

Methods: To investigate this aspect, we analyzed both in vivo and in vitro, and compared the phenotypic switching of macrophages induced by different iron sources, including heme and iron, as well as hemolysate or intact RBCs.

Results: Hemolysate RBCs, free heme and iron-dextran treatment in mice shape macrophage polarization towards an M1-like pro-inflammatory phenotype. Spleen and hepatic macrophages from treated mice showed iron deposition and increased expression of iron-related genes (ferroportin, ferritin, HO-1). Moreover, in these cells, the expression of M1 markers such as MHCII, CD86 and pro-inflammatory cytokines (TNFa, IL-6, IL-1β) is strongly increased, whereas the expression of M2 markers such as CD206, Arg-1 and IL-10 was significantly suppressed. Consistent results have been obtained treating bone marrow-derived macrophages with hemolytic RBCs, free heme and Fe-NTA. Importantly, the addition of the heme scavenger hemopexin and the iron carrier transferrin or the chelator deferoxamine fully abolish the ability of free heme and iron to trigger M1 polarization. On the contrary, RBC transfusions in mice shape macrophages towards an M2-like anti-inflammatory phenotype. After three transfusions, serum iron and hepcidin levels significantly rise, and tissues as well as macrophages are heavily iron loaded. Macrophages show a drastic suppression of M1 markers and inflammatory cytokines, and induction of M2 markers. Interestingly, repeated transfusions result in extensive macrophage cell death and new macrophages recruitment in both liver and spleen.

Summary/Conclusions: Collectively, these results suggest that the source and route of iron acquisition have a key role in shaping macrophage phenotype, and demonstrate a dynamic role of iron overload in determining macrophage polarization and function. When iron is provided in the form of free heme or non-transferrin-bound iron, it exerts a clear pro-inflammatory effect on macrophages; whereas when provided via a controlled physiological acquisition pathway such as erythropoietic gocytosis, it dampens macrophage immune effector functions, being its clearance activity more active.

Figure 1.
Summary/Conclusions: While our analyses show that ESA use increases mortality risk and impact for thromboembolic events, there is no evidence that iron supplementation alters these risks. However, addition of iron to ESA does further decrease the need for RBC-transfusions compared to ESA alone. Further investigation, with regards to iron type and route of administration may yield further distinct results.

This project was funded by the Federal Ministry of Education and Research, grant number: 01KG1405
Our findings have potential implications, on one side, for hemolytic diseases, where RBC hemolysis and elevated circulating heme might promote a detrimental chronic inflammatory state, and, on the other one, for infectious diseases, where free heme and iron, released upon cell damage, might boost inflammation and enhance resistance to infections. Conversely, accelerated RBC clearance, by suppressing macrophage pro-inflammatory response, is rather expected to promote infections in transfused individuals.

Gene therapy, cellular immunotherapy and vaccination 2

S814

A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT B-THALASSEMIA IN PATIENTS WITH NON-B0/B0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL


1UCSF Benioff Children’s Hospital and Research Center, Oakland, 2Lurie Children’s Hospital , Chicago, United States, 3Ramathibodi Hospital, Bangkok, Thailand, 4Children’s Hospital of Philadelphia, Philadelphia, United States, 5IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 6University College London Hospital, London, United Kingdom, 7Medizinische Hochschule Hannover, Hannover, Germany, 8Great Ormond Street Hospital, London, United Kingdom, 9Hôpital des enfants de La Timone, Marseille, France, 10General Hospital of Thessaloniki, Thessaloniki, Greece, 11bluebird bio, Cambridge, United States

Background: Standard treatment for transfusion-dependent β-thalassemia (TDT) includes regular red blood cell (RBC) transfusions and management of iron overload. Successful allogeneic hematopoietic cell transplantation (HCT) can eliminate RBC transfusions and, eventually, chelation. However, due to transplant-related risks such as graft-versus-host disease (GVHD), as well as donor constraints, HCT is rarely an option for TDT patients. By transferring a functioning copy of the β-globin (HBB) gene into hematopoietic stem cells (CD34+ cells) and re-infusing the modified cells, gene therapy may be an alternative one-time treatment available to all patients with TDT, without risks of GVHD. LentiGlobin gene therapy is an investigational treatment consisting of autologous CD34+ cells transduced with the BB305 lentiviral vector. The Northstar (HGB-204) phase 1/2 clinical study of LentiGlobin gene therapy for TDT included 18 patients who received LentiGlobin DP (DP). As of September 2016, all patients in Northstar with non-β0/β0 genotypes and at least 12 months of follow-up stopped transfusions (median total hemoglobin [Hb] 11.2 [range 9.4–12.2] g/dL) and there was >60% reduction in transfusions in patients with a β0/β0 genotype. The safety profile was consistent with autologous HCT. In this initial study, the average number of therapeutic gene copies per CD34+ cell in the DP (i.e. DP vector copy number per diploid genome or DP VCN; median 0.7, range 0.3 to 1.5) correlated with peripheral Hb at 72 days (genetically engineered hemoglobin) expression at 6 months (ASH, 2016). In an effort to optimize the proportion of patients able to discontinue blood transfusions to achieve “transfusion independence” in all patients and increase unsupported Hb levels after treatment, the manufacturing process for LentiGlobin DP was modified to increase the DP VCN and the proportion of genetically modified cells. Northstar-2 (HGB-207) is a recently initiated phase 3 study using this new manufacturing process in patients with TDT and a non-β0/β0 genotype.

Aims: To evaluate safety and efficacy of autologous HCT with LentiGlobin DP in patients with TDT and a non-β0/β0 genotype.

Methods: After providing informed consent, patients 12 to 50 years of age (N=15) will have CD34+ cells collected via mobilization and apheresis. After individualized DP manufacture and satisfaction of release criteria, the patient will receive myeloablative conditioning with single-agent busulfan (starting dose 3.2 mg/kg/day for 4 days, with target AUC 4500 [range 4000–5000] µM*min) followed by infusion of LentiGlobin DP. Patients will be followed for engraftment, safety and efficacy endpoints for 2 years after infusion; patients will then have the option to enroll in a 13-year follow-up study. The primary endpoint is the proportion of patients who achieve transfusion independence after DP infusion, defined as total Hb ≥9g/dL without RBC transfusions for a continuous period of ≥12 months. Secondary endpoints include time to neutrophil engraftment, adverse events, and biological parameters including VCN in peripheral blood and levels of HbA1C over time.

Results: As of March 1, 2017, two 20-year-old females with β0/βE genotypes have been treated with LentiGlobin DP in the Northstar-2 trial. The DP VCN was 2.9 and 2.4 copies per diploid genome, respectively. Outcomes in all evaluable patients will be presented.

Summary/Conclusions: Results from the Northstar-2 study will provide data on safety and demonstrate the extent to which an increase in LentiGlobin DP VCN yields normalization of total Hb and consistently achieves transfusion independence in patients with TDT of non-β0/β0 genotypes. Optimizing DP VCN has the potential to improve outcomes across all TDT genotypes treated by investigational LentiGlobin gene therapy.

S815

CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY


1Molecular Immunology, Walter and Eliza Hall, Parkville, Australia

Background: The detection of leukemia by natural killer (NK) cells is controlled...
by the integration of signals from activating and inhibitory ligands and from cytokines such as IL-15.

**Aims**: We set out to identify the negative regulators of NK cell function in order to understand why immunogenic tumours and leukemia can evade or overcome NK cell detection and killing.

**Methods**: We used a multidisciplinary approach including RNAseq, Mass Spectrometry, microstructural biology, kinase enrichment and activity assays, NK cell in vitro analysis, biochemistry and de novo/experimental tumor/leukemia in vivo models.

**Results**: We identified cytokine-inducible SH2-containing protein (CIS, encoded by Cish) as a critical negative regulator of IL-15 signaling in NK cells. Cish was rapidly increased in IL-15+ NK cells following CAR downregulation and depleting Cish rendered NK cells hypersensitive to IL-15, as evidenced by enhanced proliferation, survival, IFN-gamma production and cytotoxicity toward tumors. This was associated with increased JAK-STAT signaling in NK cells in which Cish was deleted. Correspondingly, CISH interacted with the tyrosine kinase jak1, inhibiting its enzymatic activity and blocking Jak phosphorylation and degradation. Cish−/− mice are resistant to leukemia in vivo, and this was independent of MHC-I expression.

**Summary/Conclusions**: Our data uncover a potent intracellular checkpoint in NK cell–mediated tumor immunity and suggest possibilities for new cancer immunotherapies directed at blocking CIS function.

**S816**

**GENERATION OF MEMORY STEM T CELLS MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES**

L. Escrivá-García1,*, C. Alvarez-Fernández1, J. Wegner2, J. Rydzek2, M. Tellez-Gabriel1, J. Sierra3, H. Einsele2, J. Briones1, M. Hudecek2

1Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany

**Background**: Peripheral T-cell lymphomas (PTCL) represent the most aggressive form among non-Hodgkin lymphomas with a very poor prognosis (5-year survival of 30%), demanding innovative novel treatment strategies. Adoptive immunotherapy with chimeric antigen receptor (CAR) engineered T cells has demonstrated its therapeutic potential in advanced hematological malignancies. However, its application to PTCL remains a formidable challenge mainly due to a lack of truly tumor-specific antigens that are not expressed on normal T cells. Anaplastic large T-cell lymphomas (ALCL) and several other subtypes of PTCL express CD30, which is expressed by activated normal T cells but no other healthy tissues. Indeed, brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has shown some clinical efficacy in PTCL and ALCL patients although duration of responses is short in the majority of cases. Here, we developed a refined anti-CD30-CAR T-cell approach to target CD30+ PTCL as a potential novel therapeutic strategy. We selected a novel targeting domain that is unaffected by soluble CD30 protein to prevent blockade of the CD30-CAR in vivo. Moreover, we optimized the therapy by using memory stem T cells (TSCM) to promote engraftment and persistence of CD30-CAR T cells after transfer, and we have included an EGFR depletion marker as a safety feature.

**Aims**: We evaluated the antitumor effect of memory stem T cells (TSCM) genetically-modified with a novel CD30-specific CAR that recognizes a membrane-proximal epitope in the CD30 molecule in a CD30+ T-cell lymphoma model.

**Methods**: A second generation CD30-41BBz-EGFRt CAR was generated using a scFv that recognizes a tumor-cell membrane-proximal epitope of CD30 protein (Nagata S et al. Clin Cancer Res, 2002). Naïve T cells from healthy donors were activated with anti-CD3/CD28 beads in presence of IL-7, IL-15 and IL-21 during 10 days to obtain a TSCM-enriched population (Alvarez C et al. J Transl Med, 2016). On day 2 of culture, cells were transduced with a third-generation lentiviral vector encoding the CD30-CAR. The anaplastic large T-cell lymphoma cell line Karpas 299 was used as tumor model. Cytotoxicity assay was performed at 4 hours at 10, 1, 1, 1, 1 and 1.5 effector/target (E/T) ratios, and the tumor cell death was determined by flow cytometry. Cytokines (IFN-γ and IL-2) were analysed at 24 hours in a 5:1 E/T ratio culture using LumineX technology.

**Results**: TSCM were the most prevalent T-cell subset at day 10 of culture, representing 84 ± 3.1% of total cells, and the CD30-CAR expression in these cells was 76.9 ± 1.0% in CD4+ TSCM and 77.3 ± 2.0% in CD8+ TSCM. Although CD30 protein was detected in a fraction of activated T cells in culture (CD4+ T cells: 32.4 ± 2.1%; CD8+ T cells: 59 ± 4.3%), lentiviral transduction of TSCM with our CD30-CAR did not compromise their ex vivo expansion (CD4+ CD30-CAR TSCM: 96.0 ± 3.2 fold expansion; CD8+ CD30-CAR TSCM: 109.0 ± 4.2 fold expansion). CD8+ CD30-CAR TSCM conferred specific cytolytic activity and lysed CD30+ Karpas 299 cells (tumor cell:target (T:C) ratio: 92.6 ± 2.4% vs 0.0% with untransduced TSCM, p<0.001), while control CD30+ target cells (Raji) were not recognized. In addition, CD30-CAR TSCM secreted IFN-γ and IL-2 after stimulation with Karpas 299 cells (INF-γ: 126.6 ± 18.12 pg/ml vs 5.03 ± 0.16 pg/ml with control targets, p<0.002; IL-2: 20.47 ± 2.3 pg/ml vs 4.06 ± 0.24 pg/ml with control targets, p<0.002).

**Summary/Conclusions**: Collectively, our data demonstrate the potential to generate CD30-CAR T cells with enhanced functional attributes against CD30+ PTCL. TSCM cells can be efficiently transduced and ex vivo expanded with a novel CD30-CAR and confer potent antitumor efficacy against CD30+ PTCL in vitro. Our findings suggest the potential to improve outcome of patients with CD30+ PTCL through adoptive therapy with CD30-CAR modified T cells.

**S817**

**MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES**


1Division of Cancer Studies, King’s College London, 2Imperial College Healthcare NHS Trust, 3Imperial College London, London, 4Central Manchester University Hospital, Manchester, 5University Hospitals Bristol, Bristol, 6University Hospital Southampton, Southampton, 7Birmingham Women’s and Children’s Hospitals, Birmingham, 8The Christie NHS Foundation Trust, Manchester, 9King’s College Hospital NHS Trust, London, 10Royal Hallamshire Hospital, 11Sheffield Children’s Hospital, Sheffield, 12Heart of England NHS Foundation Trust, Birmingham, 13Plymouth Hospitals NHS Trust, Plymouth, 14King’s College London, London, United Kingdom

**Background**: The immunosuppressive activity of mesenchymal stromal cells (MSC) has been extensively tested for the treatment of steroid-resistant acute graft versus host disease (aGVHD). However, the factors affecting clinical responses are poorly understood.

**Aims**: We assessed the impact of MSC treatment on clinical outcomes and investigate factors influencing the response to MSC.

**Methods**: Data collected from a cohort of 60 patients treated with MSC between May 2008 and December 2014 in the UK were analyzed. Clinical grade MSC were generated from bone marrow aspirates collected from the iliac crest of healthy donors and expanded using platelet lysate. All patients received SC for the treatment of steroid-resistant aGVHD, defined as failure to respond to high-dose steroids (2mg/Kg methyl-prednisolone) after 6 days. Informed consent was obtained from all patients in accordance with the local ethics committee requirements. Clinical responses to MSC were assessed 1 week after MSC infusion. Patients were defined as: a) Responders when an improvement of at least 50% in at least one organ affected by aGVHD was observed, or b) Non-Responders if they had stable or progressive disease.

**Results**: Patient characteristics are summarized in Table 1.

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Table 1</strong></td>
</tr>
<tr>
<td>Data on aGVHD response to MSC therapy in the UK cohort (n=60).</td>
</tr>
</tbody>
</table>
ing to the first dose, failed to respond to the second one. When we evaluated potential factors for response, organ involvement, age at transplant and the cumulative dose of MSC infused were found statistically significant. Response rate was 67% among patients with involvement of gut, skin or both, but only 22% among those with involvement of the liver (alone or in combination with skin and/or gut). Patients younger than 20 years fared better, with 88% of them responding. Conversely, only 30% and 42% of those aged 20-50 years or older than 50 responded, respectively. Lastly, higher cumulative MSC dose (>3.0x10⁶/Kg) was associated with a response in 76%, while none of those receiving less than 1.5x10⁶/Kg responded. All 3 factors remained significant in multivariate logistic regression analysis. Patient gender, pre-MSC therapy, interval from transplant or aGvHD diagnosis to MSC treatment and grade of aGvHD did not affect response. The impact of achieving a response 1 week after MSC had a profound impact on the overall survival at 18 months accounting for 59% in responders and 17% in non-responders (log-rank test, p<.001).

Summary/Conclusions: In our cohort of patients, MSC treatment was safe and well tolerated. We conclude that the presence of a response at one week highly impacted on the survival of patients with an otherwise very poor prognosis. Importantly, younger age at the transplant, absence of liver aGvHD involvement and use of higher MSC doses were strong predictors of a response.

CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE

T. Haas1,*, S. Heidegger1, H. Poeck1, J. Ruland2
1Klinik und Poliklinik für Innere Medizin III, 2Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, TU München, München, Germany

Background: Activation of the C-type lectin receptor Dectin-1 by beta-glucans triggers multiple signals within dendritic cells (DCs) that result in activation of innate immunity. While these mechanisms can potently prime CD8⁺ cytotoxic T cell (CTL) responses without additional adjuvants, the Dectin-1 effector pathways that control CTL induction remain unclear.

Aims: Aims of this study were: To define details of the intracellular signalling pathway responsible for cross-priming of a CTL response after activation of the C-type lectin receptor Dectin-1. To analyze whether identified signalling molecules were indispensable for antitumor immunity. To analyze whether NK cells played a role in antitumor immunity after Dectin-1-mediated CTL induction.

Methods: We used in vitro coculture between DCs (wildtype vs gene deficient) and CD8 T cells to define signalling components of Dectin-1 induced CTL cross-priming. We used WT and gene-deficient mice to define the signalling pathway of Dectin-1 induced CTL crosspriming in vivo and to test the role of this pathway for antitumor immunity by challenging mice with B16-Ova tumor cells intravenously, with or without depletion of CD8 T cells or NK cells, respectively.

Results: Here we demonstrate that Dectin-1-induced CTL cross-priming in mice does not require inflammasome activation but strictly depends on the adapter protein Card9 in vitro. In vivo, Dectin-1-mediated Card9 activation after vaccination drives both expansion and activation of antigen-specific CTLs, resulting in long-lasting CTL responses which are sufficient to protect mice from tumor challenge. This Dectin-1-induced antitumor immune response was independent of natural killer (NK) cell function and completely abrogated in Card9-deficient mice. Thus, our results demonstrate that Dectin-1-triggered Card9 signaling but not inflammasome activation can potently cross-prime antigen specific CTLs, suggesting that this pathway would be a candidate for immunotherapy and vaccine development (Figure 1).

Summary/Conclusions: We identify Card9 as central regulator of Dectin-1-induced cross-priming of cytotoxic T cells (CTLs) in mice. These antigen specific CTLs mediate potent antitumor immunity independent of inflammasome activity and NK cells. This pathway is a candidate for immunotherapy and vaccine development.
Acute lymphoblastic leukemia - Biology

**E819**
PRECLINICAL COMBINATION OF A NOVEL IRE1 RNASE INHIBITOR MKC-8866 AND TYROSINE KINASE INHIBITION ACTS SYNERGISTIC IN ACUTE LYMPHOBLASTIC LEUKEMIA

M. Vieri1, A. Salimi1, J.B. Patterson2, A. Samali3, E. Chevet4, T.H. Brümmendorf1, I. Appelmann1, B. Kharabi1

1Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. 2MannKind Corporation, Valencia, United States. 3Department of Biochemistry, National University of Ireland, Galway, Ireland. 4Centre de Lutte Contre le Cancer Eugène Marquis, Université Rennes 1, Rennes, France

**Background:** The role of the Unfolded Protein Response (UPR) in BCR-ABL1+ ALL has been extensively studied, proving that the chemo-protective effect of bone marrow stromal cells (BMSCs) on leukemia cells. 2) We tested whether genetic knock-down of XBP1 could sensitize cells towards the effect of Imatinib and Nilotinib. To this end, primary murine pre-B cells from conditional Xbp1fl/+mice were transduced with BCR-ABL1 construct and with either inducible cre or empty vector.

**Methods:** To study the link between IRE1-XBP1 axis of UPR and BCR-ABL1, we utilized both pharmacological and genetic approaches. 1) We tested the effect on proliferation and viability of pharmacological IRE1 inhibition (using MKC-8866) alone and in combination with Tyrosine Kinase Inhibitors (TKI, using Imatinib or Nilotinib) on BCR-ABL1+ human ALL cell lines, SUP-B15 and TOM-1. The cell lines were also co-cultured with immortalized tertMSCs to test the chemo-protective effect of bone marrow stromal cells (BMSCs) on leukemia cells. 2) We tested whether genetic knock-down of XBP1 could sensitize cells towards the effect of Imatinib and Nilotinib. To this end, primary murine pre-B cells from conditional Xbp1fl/+mice were transduced with BCR-ABL1 construct and with either inducible cre or empty vector.

**Results:** IRE1 inhibitor MKC-8866 (MKC) in combination with either Imatinib (IM) or Nilotinib (NL) showed enhanced capacity to arrest proliferation and to induce cell death in SUP-B15 and TOM-1 cell lines compared to single treatments, after 3 days incubation (Viable SUP-B15: MKC 30µM 94.9±0.1, IM 10µM 78.4±0.4, Combination 17.0±1.4; MKC 30µM 94.1±0.07, NL 5µM 64.2±0.6, Combination 78.4±0.4, Combination 17.6±0.7; MKC 30µM 94.6±0.0, NL 5µM 71.0±0.9, Combination 30.6±3.6). Using RNA-Seq on XBP1i/+ and wildtype bone marrow cells, we confirmed a striking synergistic effect. Successively, to exclude any possible off-target effect at the basis of the observed synergism, we used a genetic approach to block IRE1-XBP1 signaling in vitro. B-cell precursors from Xbp1f/+ mice, instead of Xbp1f/f, were used in order to warrant a basal signal of XBP1, as present during pharmacological inhibition. After transfections with BCR-ABL1, and either cre or the empty vector, we could observe that heterozygous deletion of XBP1, induced by 4OHT, significantly increased TKI-induced cell death, after 3 days incubation (4OHT 1µM: 47.5%±13.0, IM 1µM: 70.8±17.4, IM+4OHT: 18.3±2.7, NL 5µM: 65.2±0.3, 4OHT+NL: 6.87±1.2). Finally, we showed whether the tested drugs combination were still effective in presence of BMSCs. It’s know that BMSCs are a critical component to escape TKI-induced cell death in Ph+ leukemia and that IRE1-XBP1 is responsible for chemoresistance in many different cancer types, although this role has never been confirmed in BCR-ABL1 cells. To shed light on this aspect we co-cultured either SUP-B15 or TOM-1 cells with tertMSCs, and while the stroma was capable to block Nilotinib-induced cell death, after 5 days incubation (SupB15, NL 5µM in standard culture 28.7%±1.9, NL 5µM in co-culture 74.9±0.1; in TOM-1, 29.1±2.8 vs 78.7±0.2), this protective activity was partially abrogated upon treatment with IRE1 inhibitor. On the other hand, BMSCs were not able to reverse IM effect on cell viability.

**Summary/Conclusions:** Overall, our data demonstrate that simultaneous inhibition of BCR-ABL1 and IRE1 branch of UPR exerts a potent effect in vitro, by acting synergistically on BCR-ABL+ ALL cells. This provides basis for a clinical application of a combined targeted therapy.

**E820**
HIGH-THROUGHPUT COPY NUMBER PROFILING IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA USING MULTIPLE LIGATION-DEPENDENT PROBE AMPLIFICATION IN COMBINATION WITH NEXT-GENERATION SEQUENCING

D. Alpai1,2, P.A. Kiraly1, A. Benard1, I. Haltrich3, H. Piko4, K. de Groot4, J. Schouten3, S. Savola3, C. Bodo4

1MTA-SE Lendület Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. 2MRC-Holland, Amsterdam, Netherlands. 32nd Department of Pediatrics, Semmelweis University. 4Department of Molecular Genetics and Diagnostics, National Center of Public Health, Budapest, Hungary.

**Background:** Development, progression and resistance of pediatric acute lymphoblastic leukemia (pALL) are widely associated with recurrent copy number abnormalities (CNAs). Multiplex ligation-dependent probe amplification (MLPA) is an established technique to screen CNAs, thus providing valuable information for risk assessment in pALL; however, the number of simultaneously analyzable genomic loci is limited to 55-60.

**Aims:** To introduce and test a high-throughput, high-resolution and comprehensive disease-relevant CNA profiling approach applicable to all subtypes of pALL.

**Methods:** A new digitalMLPA (dMLPA) technique has been developed which combines the advantages of MLPA and next-generation sequencing (NGS), massively improving the number of genomic targets that can be analyzed for their copy number in a single reaction. Bone marrow samples from 58 patients with pALL were analyzed using this novel assay targeting ~470 genomic loci. dMLPA was performed in two steps: first, subclonal CNAs were detected in pre-B and pre-T ALL, respectively; followed by CDKN2A/B, PAX5, RB1, VPREB1, MLLT3, CD200/BTLA, TCL1X1RK1, IKZF1, CASP8AP2, PTEN, RUNX1, BTG1, TP53, IKZF3, EZH2, NF1, NR3C2, RAG2 and the PAR region. CNAs detected in pre-B ALL cases (n=23) and of PTEN, MLLT3, PTEN, PTPN2, PHD6, LEP1, CASP8AP2, MYB, RB1, TP53 in pre-T ALL cases (n=35). CNAs were also observed in T-ALL cases while in one B-ALL patient, the copy number profile correctly indicated the presence of an extra Ph-chromosome. dMLPA results showed a congruency of 99.3% with those of MLPA mixes containing probes with different ligation sites for a subset of the genes. The increased resolution of dMLPA (i) allowed the detection of subclonal aberrations with an improved efficacy and confidence as compared to conventional MLPA and (ii) enabled a more patient-specific characterization of CNAs, e.g. by revealing 15 different deletion patterns across 23 samples harboring del(9p). In addition to genomic lesions specifically influencing putative or proven driver genes, novel additional CNAs were detected genome-wide which was strongly facilitated by the inclusion of ~200 digital karyotyping probes covering each chromosome arm.

**Results:** CNAs directly indicating structural or whole chromosome aberrations or indirectly referring to gene fusions were detected in 93% of patients, in 44/48 pre-B ALL and 10/10 pre-T ALL cases. Among patients with CNAs, recurrent aberrations specifically affecting putative driver genes varied between 0 and 11 (mean: 3.1, total: 175). Elliott et al.1 detected 44/48 CNAs (mean: 3.1, total: 175).

**Summary/Conclusions:** A novel NGS-based method has successfully been introduced for high-resolution profiling of CNAs in pALL. dMLPA is a robust, fast and cost-effective technique; its input DNA requirement (≥20ng) is similar to those of other low-input NGS protocols and lower than the requirement for MLPA. Due to its targeted approach, data analysis is computationally less demanding as compared to most NGS methods. The number of genomic sites analyzed in dMLPA is significantly higher than that analyzable with conventional MLPA. Due to its specific probe composition, dMLPA allows both high-resolution analysis of genomic driver regions and a genome-wide detection of aneuploidy and large CNAs.

**E821**
CRITICAL ROLE FOR NOTCH SIGNALLING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) DRUG RESPONSE

P. Takan Kamga1, G. Dal Collo1, M. Midolo1, A. Adamo1, A. Gatti1, R. Caruso1, M. Bonifacio1, M. Krampera1

1Medicine, University of Verona, Verona, Italy

**Background:** B-cell precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in children and young adults. There is still a need of more efficient therapies for the subset of refractory patients. Our group has previously shown that Notch-3 and Notch-4 promote human B-ALL cell survival in presence of stromal cell support. However, the prognosis value of Notch signalling as well as its contribution in vitro and in vivo to chemotherapy has not yet been investigated.

**Aims:** In this study we used B-ALL cell lines and samples from new diagnosed B-ALL patients to analyse the contribution of Notch signalling to B-ALL pathogenesis in terms of progenitor, proliferation survival and drug response in vitro and in mice xenograft models of B-ALL.

**Methods:** B-ALL cell lines were obtained from ATCC, while B-ALL primary cells were obtained from bone marrow or peripheral blood of 30 B-ALL patients. Flow cytometry and western immunoblotting were used to study the expression of Notch receptors and ligands. Drugs used were Cytarabine (Ara-C), Dexamethasone (Dexam), Trasylol (Trasylol) and Doxogem (Doxogem). Notch modulators including anti-Notch blocking antibodies, gamma secretase inhibitors (GSIs), and Notch transcription factor inhibitor (SAHM1). Mice xenograft model of B-ALL were obtained by injecting the B-ALL line RS4;11 in
null mouse (NOG). Cell viability was evaluated by Annexin-V/PI and MTT assay; proliferation was assessed through CFSE dilution.

Results: Western blot and flow cytometric analysis showed that B-ALL cell lines as well as primary blast cells displayed the same Notch expression pattern consisting in low expression levels of Notch2 and Jagged1, high expression levels of Notch1, Notch3, Notch4, Jagged2, DLL3 and DLL4. Notably, in primary blast cells deriving from patients, the expression of Notch3, Notch4, Jagged2, DLL3 and DLL4 was significantly higher in the cases refractory to treatment as compared to patients achieving complete remission, thus suggesting that Notch signalling could be involved in the response to chemotherapy. In line with this hypothesis, we found that the treatment in vitro of B-ALL cell lines with Ara-C or Dexa down regulates the expression of Notch receptors. This down regulation was also observed in human CD19+ blast cells isolated from bone marrow of recipient mice treated with Ara-C compared to cells isolated from not treated mice. In addition, Notch inhibitors significantly improved in vitro the cytotoxicity of Ara-C and Dexa towards B-ALL. Finally, we confirmed the administration to mice of a pan Notch inhibitor, i.e. the GSI XII, significantly lowered the CD19+ leukaemic burden in the bone marrow of recipient mice, potentiating ant leukemic effect of Ara-C.

Summary/Conclusions: In this study we used both in vitro and in vivo assays to highlight the prognostic value of Notch expression in B-ALL, as well as its critical role in B-ALL cell survival and response to chemotherapy. We also demonstrated that Notch inhibitors were able to improve Ara-C-mediated reduction of blast cells in bone marrow, revealing that Notch signalling is a possible therapeutic strategy to eradicate minimal residual disease in B-ALL.

E822
REGULATION OF NOTCH AND WNT SIGNALING PATHWAYS BY NRARP IN T-CELL ACUTE LYMPHOLASTIC LEUKEMIA
I. Pinto1, M. L. Oliveira1, J. T. Barata1, R. Fragoso1,2,1
1Barata Lab, Instituto de Medicina Molecular, Lisboa, Portugal

Background: T-cell acute lymphoblastic leukemia (t-ALL) is an aggressive hematological malignancy. Although the outcome of t-ALL patients has improved over recent years, the poor prognosis of patients with resistant or relapsed disease is still a major concern. Even though NOTCH is a known driver of t-ALL, its inhibition cannot be efficiently achieved with the drugs currently available, due to their weak therapeutic effects and severe toxicity. We have shown previously that Notch inhibitors significantly improved in vitro the cytotoxicity of Ara-C and Dexa towards B-ALL. Recently described ETV6/RUNX1-like ALL (Lilljebjörn et al., Nature Communications 2016).

Methods: We utilized microarrays to study the gene expression profile (GEP) and biological similarity of the B-ALL subtypes. Five ETV6/RUNX1-positive and five hyperdiploid ALL cases were analyzed using microarrays in parallel to seven CD27pos/C44low B-other cases that were closer to other BCP-ALL subtypes. Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions were found, respectively, except for the deletion of IKZF1 as another recurrently affected gene; a deletion, a nonsense mutation and an IKZF1-invoking out-of-frame fusion were found in one case. The other cases with available material. Microarray data from all 17 B-ALL cases were combined with data from an independent Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive, BCR/ABL1-positive, TGCP3/PBX1-positive, KMT2A-rearranged, hyperdипloid and B-other ALL cases) whose specimens were analyzed using the same microarray.

Results: In the hierarchical clustering based on GEP all five ETV6/RUNX1-positive cases and 5 of 7 CD27pos/C44low B-other cases clustered within the ETV6/RUNX1-positive cluster. These B-other cases were thus classified as ETV6/RUNX1-like ALL. We identified multiple regions of acquired copy number aberrations (CNA) uniparental disomies (5 to 27 per case) and point mutations (10 to 41 per case) in all 7 cases and 3 in-frame fusions each transcribed in one patient. The most important findings are summarized in Figure 1. All 5 ETV6/RUNX1-like cases harbored a deletion of the ETV6 gene, resulting in an in-frame ETV6/BOCRRS fusion in one of them. The deletion of ARPP21 was found in 3 cases, and the deletions of PAX5, ATP10A, BTG1 and the gain of RUNX1 were found in 2 cases each. The ARPP21 deletions displayed a strikingly uniform character and were highly enriched in ETV6/RUNX1-like ALL. Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions were found, respectively, except for the ETV6/BOCRRS. Integrating data from all platforms, we identified IKZF1 as another recurrently affected gene; a deletion, a nonsense mutation and an IKZF1-invoking out-of-frame fusion were found in one case. The other cases with available material. Microarray data from all 17 B-ALL cases were combined with data from an independent Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive, BCR/ABL1-positive, TGCP3/PBX1-positive, KMT2A-rearranged, hyperdiploid and B-other ALL cases) whose specimens were analyzed using the same microarray. To study the genomic background, we performed comprehensive profiling using single nucleotide polymorphism (SNP) arrays and whole exome and whole transcriptome sequencing (WES and RNAseq).

Results: In the hierarchical clustering based on GEP all five ETV6/RUNX1-positive cases and 5 of 7 CD27pos/C44low B-other cases clustered within the ETV6/RUNX1-positive cluster. These B-other cases were thus classified as ETV6/RUNX1-like ALL. We identified multiple regions of acquired copy number aberrations (CNA) uniparental disomies (5 to 27 per case) and point mutations (10 to 41 per case) in all 7 cases and 3 in-frame fusions each transcribed in one patient. The most important findings are summarized in Figure 1. All 5 ETV6/RUNX1-like cases harbored a deletion of the ETV6 gene, resulting in an in-frame ETV6/BOCRRS fusion in one of them. The deletion of ARPP21 was found in 3 cases, and the deletions of PAX5, ATP10A, BTG1 and the gain of RUNX1 were found in 2 cases each. The ARPP21 deletions displayed a strikingly uniform character and were highly enriched in ETV6/RUNX1-like ALL. Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions were found, respectively, except for the ETV6/BOCRRS. Integrating data from all platforms, we identified IKZF1 as another recurrently affected gene; a deletion, a nonsense mutation and an IKZF1-invoking out-of-frame fusion were found in one case. The other cases with available material. Microarray data from all 17 B-ALL cases were combined with data from an independent Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive, BCR/ABL1-positive, TGCP3/PBX1-positive, KMT2A-rearranged, hyperdiploid and B-other ALL cases) whose specimens were analyzed using the same microarray.

Methods: We utilized microarrays to study the gene expression profile (GEP) and biological similarity of the B-ALL subtypes. Five ETV6/RUNX1-positive and five hyperdiploid ALL cases were analyzed using microarrays in parallel to seven CD27pos/C44low B-other cases that were closer to other BCP-ALL subtypes. Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions were found, respectively, except for the deletion of IKZF1 as another recurrently affected gene; a deletion, a nonsense mutation and an IKZF1-invoking out-of-frame fusion were found in one case. The other cases with available material. Microarray data from all 17 B-ALL cases were combined with data from an independent Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive, BCR/ABL1-positive, TGCP3/PBX1-positive, KMT2A-rearranged, hyperdiploid and B-other ALL cases) whose specimens were analyzed using the same microarray. To study the genomic background, we performed comprehensive profiling using single nucleotide polymorphism (SNP) arrays and whole exome and whole transcriptome sequencing (WES and RNAseq).

Results: In the hierarchical clustering based on GEP all five ETV6/RUNX1-positive cases and 5 of 7 CD27pos/C44low B-other cases clustered within the ETV6/RUNX1-positive cluster. These B-other cases were thus classified as ETV6/RUNX1-like ALL. We identified multiple regions of acquired copy number aberrations (CNA) uniparental disomies (5 to 27 per case) and point mutations (10 to 41 per case) in all 7 cases and 3 in-frame fusions each transcribed in one patient. The most important findings are summarized in Figure 1. All 5 ETV6/RUNX1-like cases harbored a deletion of the ETV6 gene, resulting in an in-frame ETV6/BOCRRS fusion in one of them. The deletion of ARPP21 was found in 3 cases, and the deletions of PAX5, ATP10A, BTG1 and the gain of RUNX1 were found in 2 cases each. The ARPP21 deletions displayed a strikingly uniform character and were highly enriched in ETV6/RUNX1-like ALL. Using WES and RNAseq, no recurrently mutated gene and no in-frame fusions were found, respectively, except for the ETV6/BOCRRS. Integrating data from all platforms, we identified IKZF1 as another recurrently affected gene; a deletion, a nonsense mutation and an IKZF1-invoking out-of-frame fusion were found in one case. The other cases with available material. Microarray data from all 17 B-ALL cases were combined with data from an independent Italian cohort of 291 BCP-ALL cases (including ETV6/RUNX1-positive, BCR/ABL1-positive, TGCP3/PBX1-positive, KMT2A-rearranged, hyperdiploid and B-other ALL cases) whose specimens were analyzed using the same microarray. To study the genomic background, we performed comprehensive profiling using single nucleotide polymorphism (SNP) arrays and whole exome and whole transcriptome sequencing (WES and RNAseq).
**E824**

Abstract withdrawn.

**E825**

**GENETIC ALTERATIONS IN CHILDREN WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN**


1Mackay Children’s Hospital and Mackay Medical College, Taipei, 2Chang Gung Memorial Hospital and Chang Gung University, 3Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China

**Background:** The leukemogenesis of T-cell acute lymphoblastic leukemia (T-ALL) involves multiple processes of genetic alterations. **Aims:** We aimed to determine the genetic alterations including common fusion transcripts, overexpression of T-cell transcription factor oncogenes and deletion or mutations of targeted genes in pediatric T-ALL in Taiwan and assess their impact on outcomes in those treated with TPOG-ALL-2002 protocol. **Methods:** Between 1995 and 2015, bone marrow samples from 102 children (<18 years old) consecutively diagnosed with T-ALL were analysed. SIL-TAL, MLL-ENL, and CALM-AF10 transcripts were detected by RT-PCR assays. RO PCR with TaqMan assays were used to measure the expression of HOX11, TAL1, and LYL1 oncogenes expressed as normalized copy number (NCN) to ABL internal control gene. TAL1 overexpression was defined as NCN > the lowest level of SIL-TAL positive patients. Overexpression of HOX11 and TAL1 was defined as NCN > the upper limits of the 50 normal bone marrow controls. Mucosal deletions of NOTCH1, FBXW7, PHF6, JAK1, JAK2, RUNX1, WT1, NRAS, and KRAS genes were analyzed by PCR-based assays followed by direct sequencing. P16 deletion was determined by RO-PCR or multiplex ligation probe amplification (MLPA), PTEN and PHF6 deletions, MYB duplication and NUP214-ABL1 fusion was determined with real-time PCR. **Results:** The frequency of SIL-TAL fusion transcript was 16.2%, MLL-rearranged 5.1%, CALM-AF10 1.0%, and no NUP214-ABL1. The frequency of NOTCH1 mutations was 46.9%, FBXW7 13.0%, RUNX1 5.2%, WT1 6.3%, NRAS 6.2%, KRAS 2.1%, and no JAK1 or JAK2 mutations. P16 deletion was present in 56.2%, PTEN in 11.1%, PHF6 deletion/mutation in 13.4%, and MYB duplication in 4.8%. Overexpression of TAL1 was present in 46.5%, 22% for LYL1, and 9% for HOX11. The correlation among the genetic alterations showed that LYL1 overexpression occurred more frequently in P16 wild-type compared with P16-deleted patients (P=0.003) and absence of SIL-TAL transcript was significantly correlated with HOX11 overexpression (P=0.018). A comparison of outcomes was made according to the status of each genetic abnormality. NOTCH1 mutations conferred a favorable overall survival (OS) (P=0.025), PHF6 deletion/mutation conferred an inferior OS (P=0.030). PTEN deletion was associated with shorter relapse-free survival (RFS) (P=0.0001) and OS (P=0.0001). Status of other gene mutations, deletion or duplication did not influence the RFS or OS. TAL1 overexpression predicted a higher risk of relapse (37% vs 21%, P=0.006), an inferior RFS (P=0.002) and OS (P=0.025) whereas HOX11 or LYL1 overexpression had no prognostic impact. By multivariate analysis, NOC1 mutations and a high risk of death were an independent predictor of OS (HR 0.167, P=0.112), PHF6 deletion/mutation was an independent unfavorable predictor for OS (HR 4.596, P=0.006), and PTEN deletion was also an independent predictor for both RFS (HR 29.493, P=0.007) and OS (HR 15.830, P=0.003). TAL1 overexpression was an independent risk factor for both RFS (HR 3.699, P=0.004) and OS (HR 2.701, P=0.047). **Summary/Conclusions:** The present study showed that LYL1 overexpression was negatively associated with SIL-TAL or P16 deletion. PHF6 deletion/mutation, PTEN deletion, and TAL1 overexpression were the independent predictors of adverse outcomes. (Grants support: CORP13C0201, MMH-E-105-09, NSC-101-2314-B-195-004-MY2, and Terry Fox Foundation)

**E826**

**COMPUTATIONAL METHODS TO FIND NEW THERAPEUTIC TARGETS IN ALL, SYSTEMATICAL IDENTIFICATION OF ESSENTIAL GENES**

L. Ekdahl1,2, M. Pertsisi, A. Palm1, L. Järvström1, E. Johnson1, U. Gullberg1, A.-K. Whibley1, B. Nilsson1

1Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden

**Background:** Deletion of chromosomal material is a hallmark of cancer genomes. While these lesions primarily target tumour suppressor genes, neighbour genes are frequently deleted on paracentric. Loss of one copy (haploinsufficiency) of a neighbouring gene that is essential for the survival of the cancer cells may constitute potential therapeutic targets in that the cancer cells may be selectively sensitive to further suppression of the function of that gene. Identifying such vulnerabilities is one of the current challenges in cancer genomics. We show that vulnerabilities in cancer cells can be identified if address the cell by applying pattern recognition techniques to a copy-number dataset. This approach will identify genomic regions with potential essential genes. Genes in its regions can be evaluated downstream by genome editing techniques to find novel targets for treatments. Using pattern recognition techniques to find essential genes is straightforward, easily applied and non-time-consuming method compared to genome wide experimental approaches. **Aims:** Develop a computational framework to find regions with potential essential genes from copy-number data, with a primary focus on hematological malignancies and in particular ALL. **Methods:** Our computational framework first selected regions of the tumour genome with heterozygous, but not homozygous, deletion. In sections flanking these regions we scanned for linear increases in homozygous deletion frequency. Genes near the start of these increases that have more than one case with homozygous deletion are discarded. Remaining genes were scored by calculating a line of best fit using the least square method towards the nearby peak in homozygous deletion. We sorted the results by settings cut-offs for the slope, amplitude and correlation coefficient of the linear regression line. Genes with the highest scores were then manually evaluated by comparing to known mean copy-number loss dependence score from other data-sets, by graphical visualization and by investigation of their known function. The dataset we analysed contains copy-numbers from tumour samples matched to normal blood samples or normal tissue from the same donor. To validate the essentiality of genes in the discovered regions we used pooled CRISPR/Cas9 editing in ALL cells with and without a deletion of the driving tumour suppressor. **Results:** Our framework identified several regions with potential essential genes around well-known tumour suppressors. The strongest signals in the data set were located around the tumour suppressor CDKN2A. Downstream analysis with pooled CRISPR/Cas9 editing in ALL cells with and without a CDKN2A deletion provided evidence for the essentiality of several genes in this identified region, including one gene that was essential only in CDKN2A-deleted cells. **Summary/Conclusions:** In conclusion, we explored a computational approach to identify regions with essential genes in copy-number datasets. Application of our approach to real data showed several regions with essential gene candidate around well-known tumour suppressors, indicating the framework works. Downstream genome-editing experiments in model cell-lines provided further evidence for the essentiality of some genes found in such identified regions. While we cannot yet draw conclusions on whether some of these genes are viable therapeutic targets it allows for informed guesses on limited sets of genes for further focused analysis in hematological model cell-lines.

**E827**

**TARGETING ANTIOXIDANT ENZYMES FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**

K. Fidy1,2, K. Szczygieł1, A. Pastorczyk2, A. Grażycka-Jarzynka1, E. Patkowska-Kindzelska1, M. Ficzcz1, K. Fidyt1, K. Szczygieł1, A. Pastorczyk2, A. Grażycka-Jarzynka1, E. Patkowska-Kindzelska1, M. Ficzcz1, 1Department of Immunology, Medical University of Warsaw, Warsaw, 2Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, 3Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

**Background:** B-cell acute lymphoblastic leukemia (B-ALL) is a genetically heterogeneous disease characterized by abnormal expansion of B cell precursors and is mainly affecting children and adolescents. The backbone of the treatment is chemotherapy providing high cure rates in pediatric ALL (> 85%) but much worse treatment responses are observed in adolescents and acute myeloid leukemia (AML). Patients who relapse develop refractory, chemotherapy resistant disease and remain a clinical challenge. Growing body of evidence suggests that disturbance of redox homeostasis is a promising anticancer approach. Due to high metabolic demands and proliferation rate cancer cells elevate their antioxidative capacity to overcome excessive ROS production and depend on these antioxidants for their survival. One of the oxidative stress protectors are peroxidoxins (PRDXs) that next to thioredoxins (TXNs) belong to the TXN-family and are the key components of TXN antioxidant system. PRDXs are enzymes involved in scavenging peroxides. TXNs are responsible for cysteine-thiol disulfide bonds in numerous protein substrates. **Aims:** To investigate the potential of targeting the TXN antioxidant enzymes as a novel pro-oxidative strategy in B-ALL treatment. **Methods:** We have used three different cell lines representing distinct cytogenetic subgroups of B-ALL: BV-173 (BCR-ABL), SEMK-2 (MLL-AF4) and NALM-6 (treatment resistant). PRDX levels were measured using western blot, RNA and protein levels of TXN-family enzymes were measured by quantitative PCR and immunoblotting, respectively. Downregulation of PRDX1 was established by a novel CRISPR/Cas9 gene editing system. We have employed lenti
CRISPR v2 plasmid to produce lentiviral vectors encoding PRDX1-specific sgRNA and Cas-9 and used them to generate BV-173 cells with PRDX1 genomic deletion. Proliferation rate was evaluated by trypan blue exclusion method. Cytostatic/cytotoxic effects of TXN-family enzymes inhibitors, such as adenathin (ADE), auranofin (AUR) and SK053 were assessed by MTT viability assay and by detection of propidium iodide-positive cells in flow cytometry.

Results: We have found that B-ALL cell lines exhibit significantly higher levels of ROS as compared to normal B cells isolated from human tonsils (Fig.1A). In accordance with this observation, our analysis of TXN antioxidant enzymes gene expression in B-ALL cell lines showed their upregulation (Fig.1B). Analysis of deposited data revealed that PRDX1 expression level is the highest in B-ALL among the other types of leukemia (Fig.1C). Moreover, we have observed elevated expression of PRDX1 in malignant lymphoblasts derived from pediatric patients at both RNA and protein levels. Genomic deletion of PRDX1 in BV-173 cells leads to suppression of their proliferation rate, comparing to parental cells and cells transduced with mammalian non-targeting sgRNA. These results allow us to suspect that PRDX1 may play growth-supporting role in these cells. Targeting TXN-family enzymes was also performed with the use of various small molecule inhibitors. Both B-ALL cell lines and primary cells are sensitive to PRDX and TXN inhibitors, which reduce cell viability in dose-dependent manner.

Summary/Conclusions: All the above results suggest that targeting TXN antioxidant system may exert desirable anticancer effects in the treatment of B-ALL. Inhibitors of TXN-family enzymes can be considered as putative agents to use in combination with classical drugs and improve existing therapeutic approaches. Further studies are underway.

E829
RNA-BINDING PROTEIN IGF2BP1 PROMOTES SURVIVAL OF ET6V/ RUNX1 LEUKAEMIA CELLS
M. Stoškus1,*, G. Vaitkevičienė2, A. Eidukaitė3,4, L. Griškevičius1,5
1Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santarūnų Klinikos, 2Department of Laboratory Medicine, Children’s Hospital, Affiliate of Vilnius University Hospital Santarūnų Klinikos, 3Center for Pediatric Oncology and Hematology, Children’s Hospital, Affiliate of Vilnius University Hospital Santarūnų Klinikos, 4Department of Immunology, State Research Institute Centre for Innovative Medicine, 5Faculty of Medicine, Clinics of Internal, Family Medicine and Oncology, Vilnius University, Vilnius, Lithuania

Background: The IGF2 mRNA binding protein 1 (IGF2BP1, other aliases IMP-1 (IMP1), CRD-BP (CRDBP), ZBP-1 (ZBP1), and VICKZ1) belongs to a family of regulatory RNA-binding proteins with an oncofetal expression pattern. IGF2BP1 has also been identified to be exclusively specific for ETV6/RUNX1-positive acute lymphoblastic leukemia (ALL) but biological significance of IGF2BP1 overexpression has not been thoroughly investigated to date (Andersson, Oflofsson et al. 2005; Stoškus, Gineikiene et al. 2011). We have recently contributed by reporting that ET6V/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive ALL, suggesting a role of IGF2BP1 in ET6V/RUNX1-mediated leukemogenic events (Stoškus, Vaitkevičienė et al. 2016).

Aims: To define the biological significance of IGF2BP1 overexpression in t(12;21)(p13;q22) ET6V/RUNX1-positive ALL.

Methods: In this study we have used stable sublines with downregulated IGF2BP1 from our previously published study (Stoškus, Vaitkevičienė et al. 2016). Dynamics of viable cell population was assessed by flow cytometry using 7-AAD staining (BD Biosciences) following 72 hrs culture in complete medium. An Edu flow assay (Thermo Fisher Scientific, TFS) was used to assay DNA replication in proliferating cells. Spontaneous and doxorubicin (Doxo), staurosporine (STS), and STAT3 selective inhibitor S3I-201 (all from Santa Cruz Biotechnology) induced cell death rates were determined by Annexin V (TFS) and 7-AAD staining. All samples were analyzed on Accuri C6 cytometer (Accuri Cytometers) using CFlow Plus and FCS Express software (De Novo Software). IGF2BP1, ET6V/RUNX1, and STAT3 RT-qPCR was performed essentially as reported previously (Stoškus, Gineikiene et al. 2011). Statistical analyses performed using GraphPad Prism software (GraphPad Software).

Results: Downregulation of IGF2BP1 by 2-fold have rendered into approximately 2-fold lower population growth rate, increasing levels of spontaneous cell death in dynamics, and modest yet statistically significant attenuation of cell cycle progression (35.13% vs 40.40%, p<0.0001). Data from treatment with 50 nM of Doxo, 250 nM of STS suggest that IGF2BP1 downregulation has no effect on pharmacological effectiveness of these drugs. In contrast, IGF2BP1-downregulated cells are more sensitive to pharmacological inhibition of STAT3 even upon treatment with suboptimal 25 µM concentration of S3I-201. Lastly, we have probed if STAT3 transcript levels could be sustained by IGF2BP1 protein as in agreement with previously reported (Stohr, Kohn et al. 2012) and our unpublished insights from anti-IGF2BP1 RNA immunoprecipitation datasets. Correlation analysis of RT-qPCR data have confirmed these assumptions as downregulation of IGF2BP1 expression have resulted in a decrease of ET6V/RUNX1 mRNA (r²=0.8253, p<0.001, slope 0.9459) and also STAT3 transcript levels (r=0.7709, p=0.002, slope 0.6436). These data suggest that STAT3 transcript is also a potentially regulated by RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive ALL model cells (Fig 1).

Figure 1.
suggest that 6-MP inhibits the phosphatidylidyinositol 3 kinase (PI3K)/mammalian target of Rapamycin (mTOR) signaling pathway and modulates the transcriptional activity of hypoxia inducible factor 1α (HIF-1α). As mTOR and HIF-1α are key mediators of metabolic reprogramming in cancer and normal T cells we hypothesized that 6-MP can impact cellular metabolic remodeling through its action on nucleotide synthesis. Metabolic reprogramming fosters glycolysis, glutaminolysis, and proliferation of blast cells to support their growth and proliferation, a key feature of cancer cells. This metabolic switch is regulated by metabolic checkpoints, including mTOR, AMP-activated protein kinase (AMPK) and the oncogenes Myc and HIF-1α.

**Aims:** Our objective is to study the impact of the antiproliferative molecule 6-mercaptopurine (6-MP) on proliferating T-leukemia cells metabolic reprogramming.

**Methods:** In vitro experiments were performed in a Jurkat T cell line. Cells were incubated with 6-MP from 6h to 72h. We used RT-PCR, Western Blot, glucose uptake and glycolytic and glutaminolytic flux to evaluate the metabolic effects of 6-MP.

**Results:** Our results showed that 6-MP reduces ATP content as early as after 2 hours of treatment and this decrease is maintained up to 72 hours. As AMPK is an energetic sensor activated with low ATP content, we studied AMPK activation after 6-MP treatment. We observed that 6-MP treatment activates AMPK after 6 and 48 hours of treatment. Moreover, 6-MP significantly modifies the transcription of genes implicated in glycolysis, glutaminolysis and nucleotide synthesis after 24, 48 and 72 hours of treatment. In addition, 6-MP inhibits the expression of the metabolic checkpoints mTOR, HIF-1α and Myc after 24, 48 and 72 hours of treatment. 6-MP also decreases glucose and glutamine oxygenation after 48 hours of treatment by 60% and 35%, respectively, suggesting that 6-MP inhibited TCA (tricarboxylic acid cycle) and OXPHOS (oxidative phosphorylation). The production of lactate, a marker of aerobic glycolysis, is significantly decreased by 30% after 6-MP treatment for 48 hours, meaning that aerobic glycolysis is also inhibited. However, 6-MP has no effect on glucose uptake or on glucose transporters (Glut1 or Glut3, SLC2A1 or SLC2A3) thereby suggesting that 6-MP metabolic effects are not linked to glucose uptake.

**Summary/Conclusions:** In conclusion, our findings offer new insights on the cellular effects of 6-MP treatment by promoting an early energetic stress that influences proliferation and raise apoptosis in leukemia T cells. Interestingly, the diminution of glycolytic and glutaminolytic fluxes by 6-MP treatment provide an original approach to better understand the cellular effects of 6-MP treatment.
E832

IGF1/IGF1R PHARMACOLOGICAL INHIBITION REDUCES CELL PROLIFERATION AND MIGRATION IN ACUTE LYMPHOBlastic LEUKEMIA CELLS

A.P.N. Rodrigues Alves1,*, J. Machado-Neto1, R. Scopim-Ribeiro1, J.C. Fernandes1, A.A. Fenerich1, B.A. Fargo2, E.B. Alves1, A.C. Brandao1, E.M. Rego1, A.J. Ridley2, F. Traina1, M. de Moraes1, H.-Y. Zhao1,*, Y. Song2,1, X.-N. Cao1, Y.-Z. Qin1, Y.-Y. Lai1, H. Jiang1, Q. Jiang1, Y. Kong1, X.-J. Huang1,2
1Peking University People’s Hospital, Peking University Institute of Hematology, Peking, China; 2Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

Background: Relapse remains one of the major obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Relapse of Ph+ALL may mark a change in persistent leukemia targets on their molecular and cellular features. Farnesyl transferase (FT) is a key enzyme involved in the post-translational modifications of proteins, such as Ras. Delays in recent clinical studies showed that less than 50% of patients relapsing after allo-HSCT achieve a complete remission (CR). The aim of the present study was to evaluate the potential role of FT inhibition in relapse to allo-HSCT in Ph+ALL.

Aims: To identify the potential molecular basis of LCPs-mediated relapse, the gene expression profiles of the sorted LPCs and other cell fractions from patients with de novo Ph+ALL were compared.

Methods: Twenty patients with de novo Ph+ALL were enrolled for this study at Peking University Institute of Hematology from 2015 to 2018. The LPCs (CD34+CD38-CD58-) and other cell fractions (including CD34+CD38+CD58-, CD34+CD38+CD58+ and CD34+CD38+CD58+) were sorted from the bone marrow mononuclear cells of de novo Ph+ALL patients (N=3) using a FACS Aria II. Differential expression analysis between LPCs and the other cell fractions were performed using RNA sequencing (RNA-Seq) and the DESeq R package (1.10.1), Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. RNA-Seq results were partially validated by a TaqMan-based real-time quantitative polymerase chain reaction (qRT-PCR) technique. Moreover, cell cycle status was compared between LPCs and other cell fractions in de novo Ph+ALL patients using flow cytometry.

Results: 1021 genes (301 up-regulated and 720 down-regulated), 1245 genes (354 up-regulated and 891 down-regulated) and 1228 genes (248 up-regulated and 980 down-regulated) were differentially expressed between LPCs and other cell fractions. Most of differential expression of genes (DEGs) were related to the regulation of cell cycle and metabolism. GO analysis identified enriched terms of biological functions in DEGs including ATP binding, nucleotide metabolic pathways, biosynthesis of amino acids, glutathione metabolism, sirtuin signaling, etc. Consistent with RNA-Seq results, mRNA levels of the cell cycle-related genes, such as CDK4 and CDK6, were significantly lower in LPCs fractions than those in other cell fractions. Moreover, the frequencies of quiescent cells in LPCs were significantly higher than those in other cell fractions.

Conclusion: Distinctive gene expression profiles and cluster, which are mostly related to the regulation of cell cycle and metabolism, were demonstrated in the LCPs fractions in patients with de novo Ph+ALL. Therefore, our data indicate that it would be of value to develop LPCs biomarkers to contribute to personalized leukemia therapy and the need to identify therapeutic targets directed toward LPCs in Ph+ALL.

E834

T-CELL LEUKEMIA SENSITIVITY TO FARNESYL TRANSFERASE INHIBITION USING TIPIFARIB

R. Mondejar1,*, R. Alonso1, C. Perez1, F. Burrows2, C. Scholz2, A. Gualberto2, M.A. Piris3

1Madrid, Spain, June 22 – 25, 2017

Results: With a median follow up of 12.43 [2.4;3.0] months, the median OS of the 31 patients at first relapse was 7.9 months, [2.4;13.8]. The OS of patients at first relapse was significantly lower in those having more than 3 CNA by MLPA (median ± SD CNA 9.7 months [0.207] vs median ± SD CNA 4.2 months [0.6-7.8], p=0.042). CDKN2A/B deletion was the most common CNA observed at relapse (16/31, 52%) and most of these deletions were homozygous (12/16, 76%). CDKN2A/B deletions, homozygous or more frequent at relapse (from 8 homozygous CDKN2A/B deleted patients at diagnosis, 7 became homozygous at relapse, p=0.070). SNAP arrays detected 554 CNA (409 DEL, 125 DUP and 20 LOH) in 34 samples of 19 patients. At diagnosis (n= 16 patients) the mean number of CNA was 12.5 (9.6 DEL, 2.3 DUP and 0.4 LOH) while at 24 relapse (n=13 patients) was 17.8 CNA (12.6 DEL, 4.2 DUP and 1 LOH) and in second relapse (n=5 patients) was 21 CNA (14.6 DEL, 6.4 DUP and 0 LOH)(p=0.007). All matched diagnosis and first relapse samples (available for 10 patients) showed common CNA. In 6/10 cases some of CNA were retained from diagnosis while others were acquired or lost at relapse (suggesting a lack of genetic identity in clinical clones). In 13/16 all CNA were retained and acquired new CNA at relapse (indicating an evolution from diagnose clone) and 1/10 showed the same CNA signature at relapse (suggesting a primary resistance of the diagnosis clone). Gene ontology analysis showed a significant enrichment of gene deletions involving B cell differentiation, activation and proliferation, and regulation of cytokine-mediated signaling pathway at relapse (Benjamini Hochberg test, p<0.01). Table 1 summarizes the frequencies of the most retained or acquired CNA at relapse in at least 4 out of 15 patients. Besides the high genetic heterogeneity observed, some recurrent CNA could be identified such as 9p, 1q, 12p, 22q and 7p deletions and 1q, 8q, 17q, 21 and 22q amplifications, deletions and tumor suppressor genes such as TP53, FOXO1, FOXO3 or RB1 were detected in 3 patients.

Summary/Conclusions: BCP-ALL has a high genetic heterogeneity at relapse, with most of the genetic alterations playing important roles for disease progression. This heterogeneity points out the need for search of personalized treated targets on their molecular and cellular features. Further studies at the Instituto de Salud Carlos III, Ministerio de Economía y Competividad, Spain, Red Temática de Investigación Cooperativa en Cáncer (RTICC, FEDER) (RD12/0036/0044); Sociedad Española Hematología y Hemoterapia; 2014 SGR226 (GRE) Generalitat de Catalunya; Fundacíó Internacional Josep Carreras, Celgene Spain and “la Caixa” Foundation.
Background: T-cell leukemia is a collection of aggressive disorders with unfavorable outcome, in which targeted treatments are still at a preliminary phase. The RAS/MAK pathway is crucial for TCR signaling of T-cells and it is deregulated in T cell acute lymphoblastic leukemia/lymphoma (T-ALL). Farnesyl transferase inhibitors (FTIs) block the localization of some RAS proteins to the intracellular membrane, thereby inhibiting their activation. Tipifarnib is a potent and specific FTI with a prominent anti-proliferative effect in some RAS mutated cells.

Aims: This study tests tipifarnib in T-cell lines for in vitro sensitivity and for biomarker discovery, both genomic and immunohistochemical.

Methods: We selected those cell lines with available genomic data from COSMIC, CCEL or generated by our group. The MAPK, NFAT, NFκB and JAK/STAT pathways were tested by immunohistochemical analysis over FFPE-cell lines at baseline. The range of drug concentrations to perform IC50 analysis was established between 0-10,000 nM (ten points). Cell proliferation analyses were performed using CellTiter-Glo® Luminescent Cell Viability Assay kit from Promega (Madison, WI, USA), following manufacturer’s instructions at 0h, 48h and 96h. All experiments were done in sextuplet and all numerical data were expressed as the average of the values ± the standard error of the mean. IC50 analyses were performed with GraphPad Prism v5. Clinically-relevant drug sensitivity was defined as IC50 <100nM at 96h. Targeted sequencing was performed in 16 genes known to play a potential role in tumorgenesis in T-cell leukemias.

Results: 59.1% (n=13) of cell lines were sensitive to tipifarnib at concentrations which are readily achievable in the clinic (i.e. IC50 <100nM at 96h). 45.5%, 50% and 27.3% of cell lines harbored mutations in RAS, RAS-guanine nucleotide exchange factors (GEFs) and RAS-GTPase activating proteins (GAPs) genes, respectively. The mutational state of RAS (p=0.38), RAS-GEFs (p=0.192) and RAS-GAPs (p=1.0) genes were not associated with drug sensitivity. Strikingly, the mutational state of NOTCH1 was associated with tipifarnib sensitivity. The activation of the MAPK pathway biomarker, ERK, was significantly associated (p=0.046) with drug sensitivity. Conversely, Reib (NFκB pathway) was associated with drug resistance (p=0.007). The same findings were observed with the presence of mutations in RAS-GEFs genes and NOTCH1 and ERK activation (p=0.015 and p=0.023) and the absence of Reib (p=0.02 and p=0.017).

Summary/Conclusions: This study shows tipifarnib as a potential therapeutic option in T-cell leukemias. The mutational state of NOTCH1 could constitute a predictor of sensitivity in T-cell leukemias. Furthermore, p-ERK and Reib could serve as potential biomarkers of tipifarnib sensitivity and resistance, respectively.

Acute lymphoblastic leukemia - Clinical

E835

HOSPITALIZATION FOR PATIENTS IN THE U.S. AND EU TREATED WITH INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBlastic LEUKEMIA IN A GLOBAL PHASE 3 TRIAL

Y. Su, 1I. Van Costrum, 2E. Vandendries, 1V. Welch, 1F.R. Loberiza

1Pfizer Inc, New York, United States, 2Ingress-health Netherlands, Rotterdam, Netherlands

Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, has its once a week one-hour infusion schedule, has demonstrated lower hospital utilization, in association with a clinically meaningful improvement in overall survival, high rate of complete remission, favorable patient-reported outcomes (PRO), and generally manageable safety profile versus standard of care (SOC, intensive chemotherapy) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the phase 3 INO-VATE trial.

Aims: This study aims to determine the regional-specific hospitalization days per patient in the INO-VATE trial.

Methods: Patients receiving study treatment (safety population) and recruited from the US and the EU were included in the analyses. The total number of hospitalization days calculated for each patient was calculated. Hospital days prior to randomization and those after the end of study treatment were excluded. Due to different durations of treatment for InO and SOC (median 1 vs 3 cycles), calculations were reported for cycle 1 treatment period (randomization to end of cycle 1) and for the entire treatment period (all cycles - randomization to end of treatment).

Results: A total of 264 patients from the safety population of the phase 3 INO-VATE trial were available for the analyses. 149 were from the US, and 115 from 11 EU countries. The percentage of patients requiring hospitalization was lower for InO compared to SOC (Table). The median and mean hospitalization days were shorter for patients in the InO arm compared to the SOC arm across both regions. The difference between the two treatment arms appears to be greater in the US compared to the EU. Hospitalizations in the US appear to be shorter than in the EU, particularly for patients receiving InO.

Table 1. Hospitalizations in R/R ALL patients from the INO-VATE trial.

<table>
<thead>
<tr>
<th></th>
<th>Hospitalized (%)</th>
<th>Mean (Days)</th>
<th>Median (Days)</th>
<th>Hospitalized (%)</th>
<th>Mean (Days)</th>
<th>Median (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (Total)</td>
<td></td>
<td></td>
<td>No. (Total)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>111 (76%)</td>
<td>2 (1, 5)</td>
<td>1 (1, 4)</td>
<td>54 (35%)</td>
<td>1 (1, 3)</td>
<td>1 (1, 3)</td>
</tr>
<tr>
<td></td>
<td>246 (165)</td>
<td>2 (1, 5)</td>
<td>1 (1, 4)</td>
<td>102 (68%)</td>
<td>1 (1, 3)</td>
<td>1 (1, 3)</td>
</tr>
<tr>
<td>SOC</td>
<td>111 (76%)</td>
<td>2 (1, 5)</td>
<td>1 (1, 4)</td>
<td>54 (35%)</td>
<td>1 (1, 3)</td>
<td>1 (1, 3)</td>
</tr>
<tr>
<td></td>
<td>246 (165)</td>
<td>2 (1, 5)</td>
<td>1 (1, 4)</td>
<td>102 (68%)</td>
<td>1 (1, 3)</td>
<td>1 (1, 3)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: InO treatment in R/R ALL is associated with less hospitalization across both the US and EU compared to SOC, consistent with InO’s better efficacy, tolerability, PRO and dosing schedule. The finding that US has lower hospitalization than the EU might be explained by different patient care practices in the two regions. Given that hospitalization is the biggest cost driver in cancer care, the data suggest both EU and US could benefit from cost-savings of less hospitalization with InO treatment.

E836

NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITH FEWER ALLO-HSCT IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE B-CELL PRECURSOR (BCP-) ALL: OUTCOME OF THE RUSSIAN PROSPECTIVE MULTICENTER ALL-2009 STUDY

E. Parovichnikova, 1V. Troitskaya, 2A. Sokolov, 2G. Gavrilina, 2S. Bondarenko, 3O. Baranova, 4Z. Akhmerzaeva, 2G. Kliasova, 5L. Kuzmina, 2E. Gribanova

1BMT department, 2Haematology department, National Research Center for Hematology, Moscow, 3BMT department, Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, St. Petersburg, 4Haematology department, N.N. Blokhin Russian Cancer Research Center, 5Scientific clinical laboratory of clinical bacteriology, mycology and antibiotic therapy, 6Cytogenetics laboratory, 7Department of biostatistics, National Research Center for Hematology, Moscow, Russian Federation

Background: As Ph-negative-BCP-ALL in adults remains less favorable in prognosis than T-ALL, and by expert opinion needs intensive protocols with high portion of allo-HSCT, the results of treatment based on the different approaches are escalated but non-interruptive treatment with low numbers of allo-HSCT - may be of interest and can provide new insights to the common view.

Aims: To evaluate survival data and risk groups in Ph-neg-BCP-ALL pts in the RALL-study.
Methods: The ALL-2009 (NCT01193933) was initiated in Apr 2009. The treatment plan was identical for all risk groups with allogeneic HSCT indicated only for adult BCP-ALL. Aims: We studied post-induction (Day-35) MRD (PI-MRD) & post-consolidation (Day-78) MRD (PC-MRD) in bone marrow samples from 100 patients of T-ALL treated under modified MCP-841 protocol between 2014 & 2016. In T-ALL with early-thymic-precursor (ETP) immunophenotype, patients received dexamethasone in place of prednisolone. MRD was performed using 10-color FC-MRD assay on Navios flow-cytometer (Beckman Coulter, BC) and MRD analysis was performed with Kaluza software v-1.3 (BC). Any detectable level of MRD (≥20 events) was defined as MRD-positive. Events included relapse & disease-related deaths. Statistical analysis was performed using SPSS v.16.

Results: The median age of patients was 11.5 years (range 2–16 y; M:F = 4:6). Based on the immunophenotypic criteria, 13 patients were diagnosed as ETPALL & remaining 87 as non-ETPALL type. MRD was positive in 58/100 (58%) with the median level of 0.23% (range, 0.002% to 6%). PC-MRD was not performed in 71.4% (30/42) of MRD-negative & 1.2% (6/58) PI-MRD-positive patients. PC-MRD was available in 64 patients (30/42 of PI-MRD-negative & 6/58 of PI-MRD-positive). MRD was positive in 28% (18/64) (median, 0.2% & range, 0.009% to 4%). PI-MRD positivity was significantly high in ETPALL as compared to non-ETPALL (93% vs 53%; p=0.01). Median follow-up of all patients was 14 months (3-38 months). Patients were categorized MRD standard-risk (MRD-SR) if MRD was negative and MRD high-risk (MRD-HR) if PI-MRD was positive with any level. Thus, 42% were categorized as MRD-SR & 58% as MRD-HR. Twenty patients relapsed & of them, six died (2 were ETPALL & 18 non-ETPALL; 3 MRDSR & 17 MRD-HR) within 26 months. Median EFS of MRD-HR patients was significantly inferior as compared to MRD-SR (26 months vs did not reach; & 70.67% vs 92.86%; p=0.0017). Kaplan-Meier curve shown in Figure 1. Interestingly, there was no difference in EFS for MRD <0.01% vs >0.01%, suggesting any level of PI-MRD positive indicated inferior EFS. Furthermore, the PC-MRD response was not found to be significant over PI-MRD (P-value<0.17). ETP vs non-ETP status was also not found to be associated with EFS (P-value=0.85).

Figure 1.

Summary/Conclusions: We concluded that 10-color FC-based post-induction MRD response is a powerful indicator of EFS in childhood T-ALL. The frequency of PI-MRD positivity was significantly high in ETPALL indicating a lower tumor clearance rate. There was no difference in the EFS based on the level of PI-MRD-positivity indicating even a low level (<0.01%) PI-MRD is important in risk-stratification of childhood-TALL.

E838 SMAC MIMETICS - A NOVEL THERAPEUTIC APPROACH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

M. Meyer1,*, J. Zinngrebe1, L.-H. Meyer1, K.-M. Debatin1

1Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany

Background: Pediatric acute lymphoblastic leukemia (ALL) is one of the most common malignancies in childhood. Survival rates have increased enormously over the past decades, but the prognosis for patients with relapsed ALL or ALL that is refractory to chemotherapy is not satisfactory. Thus, novel therapeutic options are urgently required. The family of inhibitor of apoptosis proteins (IAPs) has been shown to play an important role in the prevention of cell death, and to mediate gene activation important for cell survival. Many of the cellular processes regulated by IAPs are deregulated in cancer. Thus, IAPs represent a promising target in anticancer therapy. IAP antagonists, also known as Smac Mimetics (SMs), were developed to counteract IAP’s function. SMs have been shown to induce cell death in a number of different cancer entities, amongst them B cell precursor (BCP)-ALL. In BCP-ALL, SM-induced cell death was...
PHASE II STUDY

Aims: Evaluation of the efficacy of different SMs in inducing cell death in BCP-ALL and T-ALL cell lines. Identification of the underlying molecular resistance mechanisms to SMs in BCP-ALL cell lines and characterization of resistance to SM treatment.

Methods: Cell death induced by SMs AT406 (Debiopharm Int.), LCL161 (Novartis), Birinapant (Medivir) and BV6 (Genentech) was evaluated by FSC/SSC in the BCP-ALL cell lines Nalm6, Reh, UoCB6 and RS4;11 and in the T-ALL cell lines ALL-SIL, CEM, Jurkat and Molt4. Expression of cellular inhibitor of apoptosis proteins (cIAPs) 1/2 and X-linked inhibitor of apoptosis protein (XIAP) in presence and absence of different SMs was assessed in the above-named cell lines by Western blot. The mode of cell death was assessed using inhibitors of Caspase activity (zVAD) and receptor-interacting protein 1 kinase (RIP1K) activity (Nec-1). Dependency of SM-induced cell death on TNF secretion was assessed by neutralization of Etanercept, a TNFR2-Fc fusion protein.

Results: BCP-ALL cell lines Reh and UoCB6 and T-ALL cell lines ALL-SIL and CEM were identified to be sensitive to SM-induced cell death with half maximal inhibitory concentration (IC50) values below 1 micromolar. Interestingly, we found that the bivalent SMs Birinapant and BV6 are up to 100x more effective in inducing cell death than monovalent SMs AT406 and LCL161. SM treatment resulted in efficient and rapid degradation of cIAP1 and 2 in both, sensitive and resistant cell lines. Interestingly, all tested SMs were equally efficient in degrading cIAPs indicating that the resistance mechanisms are likely to be downstream of cIAPs. Next, we assessed the mode of SM-induced cell death in different cell lines by using zVAD or Nec-1 in order to block activity of Caspases or RIP1K, respectively. These experiments showed that Reh and UoCB6 cells die by apoptosis whilst CEM cells die by necroptosis upon stimulation with SMs. SM-induced cell death in ALL-SIL cells was neither blocked by zVAD nor Nec-1 nor the combination thereof. These results are substantiated by the expression of PARP cleavage of Poly-(ADP-ribose-)Polymerase (PARP), Caspase 8 and 3, in the SM-sensitive BCP-ALL cell lines whereas no Caspase cleavage was detectable in the sensitive T-ALL cell lines following stimulation with different SMs. In addition, the bivalent SMs BV6 and Birinapant more effectively induced cleavage of Fas-AP and Caspases than the monovalent SMs in Reh and UoCB6 cells. In addition, we found that SM-induced cell death in Reh and UoCB6 cells is partially dependent on autocrine TNF-secretion. Interestingly, we identified ALL-SIL cells to die in a TNF-dependent manner, whilst CEM cells die independently of TNF. This strongly suggests that TNF is not the only driver of SM-induced cell death in ALL cell lines.

Summary/Conclusions: We identified a subset of both, BCP- and T-ALL cell lines to be sensitive to SM-induced cell death with IC50 values below 1 micromolar. Monovalent SMs are less effective than bivalent SMs in killing ALL cell lines. SMs induce differential modes of cell death with a variable dependency on autocrine TNF secretion in the sensitive ALL cell lines. In-depth molecular characterization of resistance mechanisms of ALL cells to SM-induced cell death is required to identify patients that will benefit from a SM-based treatment regimen.

E839

SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY

R. Klisovic1,*, M. Winderlich2, S. Ambarkhane2, E. Jabbour3
1Department of Internal Medicine, Division of Hematology & Oncology, The Ohio State University, Columbus, OH, United States, 2MorphoSys AG, Planegg, Germany, 3Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Background: CD19 is a type I transmembrane glycoprotein that is expressed throughout B-cell development until terminal plasma cell differentiation. CD19 is also broadly and homogeneously expressed across different B-cell malignancies, including B-ALL. MOR208 is a CD19 monoclonal antibody with an enhanced Fc region, which leads to a potentiation of antigen-dependent cell-mediated cytotoxicity and antigen-dependent cell-mediated phagocytosis. Anti-CD19 monoclonal antibodies are used in the therapy and safety of single-agent MOR208 in the treatment of patients with R/R B-ALL.

Methods: This is a single-arm phase II study of MOR208 in patients aged ≥16 years with histologically confirmed R/R B-ALL with progression after at least one prior therapy. Patients with Philadelphia-chromosome-positive (Ph+) B-ALL are excluded. Patients with a dose-limiting toxicity (DLT) or tyrosine kinase inhibitor. MOR208 was administered at 12mg/kg IV, weekly, over 28-28 days, with a loading dose on day 4 of cycle 1. Patients with a partial response (PR) could receive a further 2 cycles of MOR208; patients with a complete response (CR) or CR with incomplete count recovery (CRi) after ≥4 cycles could receive an additional extended protocol. The primary endpoint was the overall response rate. The trial was prematurely terminated due to insufficient evidence of single-agent activity leading to slow recruitment.

Results: 22 patients were enrolled; median age was 16 years (range 16–79), 12 (55%) patients were male, 6 (27%) patients had previously received an allogeneic stem cell transplant (SCT), the most common disease subtype was pre-B-ALL (15, 68%) and 2 (9%) patients had Ph+ B-ALL. 6 (27%) patients received ≥2 cycles of MOR208 and had a subsequent response assessment. Responses were seen in 2 patients; and included a CR and a CRi, giving an overall response rate of 9%. 2 patients received extended MOR208 treatment. A further 3 (14%) patients did not fulfill the criteria for PR but did not progress; 16 (73%) patients withdrew before completing cycle 2, in most cases due to progressive disease (PD). The patient in CR met the criteria for allo-SCT, but declined this at the time; response duration was 8 weeks, with subsequent progression. The patient with the CRi had a response duration of at least 4 weeks, but discontinued due to a treatment-emergent adverse event (TEAE), sclerosing cholangitis. For 12 out of 13 patients with available data, MOR208 treatment led to a rapid reduction in blast/B-cell counts in the peripheral blood; in most cases a reduction of >90% within 1 week of treatment initiation was seen. A median increase in absolute lymphocyte counts (0.21–1.0x10^9/L) except in 1 patient who had disease progression with white blood cells 150,000/µL at apheresis and <0.2% T cells in the apheresis collection. All 4 treated patients had high disease burden with a median marrow lymphoblast content of 57%
Methods with strongest sensitivity for OS prediction on D26 were RQ-PCR with 1.0×10^{-3} cut-off (4-year OS: 76.6% vs 48.8%; median OS: not reached vs 39.1 months; p=0.012) and FCM (4-year OS: 78.3% vs 30.3%; median OS: not reached vs 27.4 months; p=0.016). The most sensitive method in W11 was RQ-PCR with every positive result considered MRD positive (4-year OS: 79.6% vs 53.1%; median OS: not reached vs 46.5 months; p=0.013). Flow cytometry and PCR with other cut-offs were not sufficiently sensitive. The sub-analysis of Ph-negative patients has shown the same results for RQ-PCR (p<0.01).

Summary/Conclusions: Our analysis has shown both RQ-PCR and FCM to be suitable methods for MRD assessment on D26 of induction in adult ALL patients receiving an intensive treatment. Furthermore it seems convenient to take any RQ-PCR positivity (even below 1.0×10^{-4}) into account in W11 and later stages of treatment. FCM can be used for MRD assessment on D26, but it is not sufficiently sensitive in later stages of treatment. We suggest using RQ-PCR as a method of choice for MRD assessment in adult ALL while retaining FCM as a backup method for patients without applicable RQ-PCR target or when faster MRD evaluation is needed.

Supported by MUNI/IA/1106/2016 grant of Masaryk University, Czech Republic and the Czech Leukemia Study Group for Life.

**E842**

QUALITY-ADJUSTED LIFE YEARS (QALY) FOR INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)

I. van Oostrum1,*, Y. Su2, B. Hegg1, T. Wilkie1, A. Smith1, F.R. Loberiza2

1Ingress-health Netherlands, Rotterdam, Netherlands, 2Pfizer Inc, New York, United States, 3Ingress-health Germany, Wismar, Germany, 4Pfizer, Ltd, Walton Oaks, United Kingdom

**Background:** Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, has demonstrated superior clinical activity versus standard of care (SOC; intensive chemotherapy), including clinically meaningful improvement in overall survival (OS), high rates of complete remission (CR) and potentially curative hematopoietic stem cell transplantation (HSCT), and favorable patient-reported outcomes for R/R ALL in the phase 3 INO-VATE trial. Quality of life (Qol) is an important consideration for R/R ALL patients in both short- and long-term survival.

**Aims:** This study aimed to estimate mean overall survival adjusted for QoL (QALY) for patients treated with InO vs SOC.

**Methods:** A Markov model was developed with five health states - No CR, CR, post-HSCT, progression, and death. Lengths and transition probabilities between health states and mortality rates were based on the InO-VATE trial. These rates were extrapolated to a lifetime horizon using parametric survival curves fitted to available OS data, and published literature for survival beyond available data. Utilities (QoL valuations) for each health state were based on the patient-reported EQ-5D scores collected in the InO-VATE trial and a literature review for health states not captured in the trial. Disutilities from adverse events experienced during and after treatments, including adverse events as a result of subsequent HSCT such as veno-occlusive disease (VOD), were taken into account in overall QoL. Outcomes were discounted at 1.5% and half-cycle corrected.

**Results:** The estimated mean LY and QALY in each health state for InO and SOC and their differences are shown in Table. Most gains in LY and QALY for InO vs SOC were from Post-HSCT. These gains in LY and QALY are greater in the InO arm as more patients achieved a CR and could undergo a HSCT. Additionally, a "tail-of-the-curve" survival gain Post-HSCT is observed in InO but not SOC.

**Summary/Conclusions:** This analysis taking into account both quantity and quality of life estimates shows that InO offers an average of nearly 2 more quality-adjusted life years (QALYs) for INO-VATE trial participants. Furthermore it seems convenient to take any RQ-PCR positivity (even below 1.0×10^{-4}) into account in W11 and later stages of treatment. FCM can be used for MRD assessment on D26, but it is not sufficiently sensitive in later stages of treatment. We suggest using RQ-PCR as a method of choice for MRD assessment in adult ALL while retaining FCM as a backup method for patients without applicable RQ-PCR target or when faster MRD evaluation is needed.

**Table 1.**

<table>
<thead>
<tr>
<th>Health state</th>
<th>LY</th>
<th>QALY</th>
<th>LY</th>
<th>QALY</th>
<th>LY</th>
<th>QALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No CR</td>
<td>5.32</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
</tr>
<tr>
<td>CR</td>
<td>5.32</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
</tr>
<tr>
<td>Post-HSCT</td>
<td>6.32</td>
<td>2.35</td>
<td>6.32</td>
<td>2.35</td>
<td>6.32</td>
<td>2.35</td>
</tr>
<tr>
<td>Progression</td>
<td>5.32</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
<td>5.33</td>
<td>1.35</td>
</tr>
<tr>
<td>Total</td>
<td>6.32</td>
<td>2.35</td>
<td>6.32</td>
<td>2.35</td>
<td>6.32</td>
<td>2.35</td>
</tr>
</tbody>
</table>

*Increment values may not always correspond to differences between LYs and QALYs due to rounding.

**Summary/Conclusions:** This analysis taking into account both quantity and quality of life estimates shows that InO offers an average of nearly 2 more quality-adjusted life years (QALYs) for INO-VATE trial participants. Additionally, a “tail-of-the-curve” survival gain Post-HSCT is observed in InO but not SOC.

**E843**

A COST-EFFECTIVE, HIGH SENSITIVITY 10-COLOR SINGLE TUBE FLOW-CYTOMETRY BASED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE (MRD) ASSAY WITH STUDY OF ARTIFACTS AND MIMICS

G. Chatterjee1,*, D. Dhaliwal1, S. Ghogale1, B. Yajamanam1, N. Deshpande1,

1Charles University, Prague, 2Faculty of Medicine, Masaryk University, Brno, 34th Department of Internal Medicine, Hematology and Oncology, University Hospital and Charles University, Prague, 4Central European Institute of Technology, Brno, Czech Republic

**Background:** The presence of minimal residual disease (MRD) is the most important prognostic factor in adult acute lymphoblastic leukemia (ALL). MRD monitoring is routinely performed by flow cytometry (FCM) and real-time quantitative polymerase chain reaction methods (RQ-PCR).

**Aims:** We conducted a retrospective analysis comparing these MRD measurement methods in ALL patients treated in three Czech hematology/oncology centers within the CELL group (Czech Leukemia Study Group for Life).

**Methods:** Adult patients (age 18-55) with both Ph-negative and positive ALL were enrolled in the study, all treated consecutively between 2008 and 2016 according to a pediatric-inspired CELL ALL protocol. Samples for MRD evaluation were acquired from bone marrow on day 26 of induction (D26) and in the 11th week of treatment before the first consolidation (W11). We divided RQ-PCR MRD positive and negative groups using three different cut-off values and analyzed them separately: 1) 1.0×10^{-3}, 2) 1.0×10^{-4}, 3) every RQ-PCR positive result considered MRD positive even below 1.0×10^{-4}. Cut-off value 1.0×10^{-3} was used for FCM MRD. Results were statistically analyzed by the Kaplan-Meier method and log-rank (Cox-Mantel) test.

**Results:** Total number of 103 patients was evaluated. Nine of them (8.7%) who did not reach a hematological remission on D26 were excluded from the study. The Kaplan-Meier plot of the final cohort was with KTE-C19 at the 2×10^6 cells/kg dose in patients despite high leukemic burden. All patients receiving KTE-C19 achieved a minimal residual disease-negative remission. Based on these results, ZUMA-4 continues to enroll (NCT02625480).
S. Kedia1, P. Rodrigues1, A. Kumar1, S. Gujral1, N. Patkar1, P. Subramanian1, P. Dobhare1
1Hematopathology, Tata Memorial Hospital, Mumbai, Mumbai, India

Background: Minimal residual disease (MRD) has been proven to be the most important indicator of relapse in BCPALL. Recently, flow-cytometry based MRD has been shown to achieve a sensitivity of <10−5 using a standardised panel with high number of event acquisition. However, high-sensitivity BMRD analysis is based on experience and acquisition of high number of events also includes other rare BM cellular elements and artifacts. We present a study of the cost-effective high-sensitivity 10-color single tube FC-MRD assay in BCPALL along with description of rare BM cellular elements and artifacts causing interference in analysis.

Aims: 1. To study the applicability and sensitivity of a 10-color high event single tube FC-MRD assay for BCPALL; 2. To document the rare BM cellular elements and artifacts causing interference in high-sensitivity FC-MRD assay for BCPALL and describe their immunophenotypic features.

Methods: We studied 230 BCPALL MRD samples. FC-immunophenotyping was performed on Navios flow-cytometer using bulk-lysis-and-stain method and data was analyzed with Kaluza-software. MRD was monitored using 10-color single tube FC-MRD assay including CD45, CD10, CD19, CD20, CD34, CD33, CD58, CD98, CD123 and CD25/CD73 with an additional 4-color nuclear dye (SYTO13) tube. Samples with cluster of ≥20 and ≥2 leukemia associated phenotypes (LAIPs) were called MRD-positive. High number of events were acquired for MRD assay (1.5 to 6 million). To evaluate the applicability of assay, number of LAIPs were determined in diagnostic and MRD samples. In addition, the frequency and antigen expression pattern of mimics and artifacts were studied.

Results: We studied 230 BCPALL MRD samples. High number of events was acquired for MRD assay with median-events 3427000 (range, 1678000 to 6052800). We determined the limit of detection (LOD=10 events) and quantitation (LOQ=30 events) by performing dilution assay. MRD was positive in 107 (46.5%) samples with median of 0.135% and range of 0.0003% to 48.3%. We categorized positive MRD results into samples with MRD <0.001%, 0.001- <0.01%, 0.01- <0.1%, 0.1- <1.0% and >1% and they were respectively 1.74%, 10.43%, 13.48%, 5.65% and 10.00%. Furthermore, in 24 samples with MRD-positive >0.01% and >1.5 million acquired-events, the results were compared between time-gated initial 500000-events and all events acquired. Sixteen samples among these were found to be negative in initial 500000-events and eight in initial 1000000-events highlighting the importance of acquisition of >1.5 million cells. Further, we categorized different rare cellular events and artifacts in the following way: 1) CD34+ mature B cells; 2) CD10+ mature B cells; 3) CD73+ mesenchymal/stem cells and endothelial cells; 4) CD123+ CD19+ 7PD precursors; 5) CD86+ CD58+ B cell precursors (BCP); 6) CD19+ NK cells

Table 1. Description of different rare cellular events and artifacts in the following way: 1) CD34+ mature B cells; 2) CD10+ mature B cells; 3) CD73+ mesenchymal/stem cells and endothelial cells; 4) CD123+ CD19+ 7PD precursors; 5) CD86+ CD58+ B cell precursors (BCP); 6) CD19+ NK cells (Table 1). We also described their immunophenotypic features highlighting the differentiating features from MRD and B cell precursors (Figure 1).

Figure 1.

Summary/Conclusions: We established a cost-effective 10 color single tube FC-MRD assay with high sensitivity of at least 1 in 105 and applicability in >97% BCPALL MRD samples. We also described the frequency and extent of different cellular events and artifacts that can interfere with high-sensitivity BCPALL FC-MRD analysis. The knowledge regarding presence and antigen expression pattern of these cellular events and artifacts are critical to avoid potential false positive results.
with b-blockers, as they could limit arrhythmogenic toxicity by their heart rate-lowering activity and antioxidant effect. All the 8 patients subsequently improved in both GLS and LVEF values, despite the occurrence of one episode of mild hypotension in 2 patients.

Summary/Conclusions: All children, even if exposed to low doses of arrhythmogenic, show early signs of LV impairment. Overdop in LVEF, when present, mostly follow GLS alterations. Alterations seem more frequent in HR pts, possibly due to the higher burden of both leukemia itself and HR treatment. Further studies on wider series are needed to confirm the relevance of the early diagnosis of LV preclinical dysfunction in pediatric ALL patients.

E845
NUDT15 VARIANT CONTRIBUTING TO HEMATOPOIETIC TOXICITY WITH LOW 6-TGN LEVEL IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
H. Hoe Koo1*, E. Sang Yi1, Y. Bae Choi1, N. Hee Lee4, J. Won Lee1, K. Hee Yoo1, K. Woong Sung1, R. Choi1, S.-Y. Lee1
1Pediatrics, Sungkyunkwan Univ School of Medicine, Samsung Medical Center, 2Department of Pediatrics, Korea University Guro Hospital, Korea University College of Medicine, 3Department of Pediatrics, Chung-Ang University Hospital, Seoul, 4Department of Pediatrics, Cha Bundang Medical Centre, Cha University, Seongnam, 3Department of Laboratory Medicine and Genetics, Sungkyunkwan Univ School of Medicine, Samsung Medical Center, Seoul, Korea, Republic Of

Background: NUDT15 polymorphism has been recently identified as a determinant of thiopurine intolerance. 6-thioguanine nucleotides (6-TGN) is monitored to prevent hematopoietic toxicity in acute lymphoblastic leukemia (ALL). Aim: This study intended to evaluate the impact of NUDT15 polymorphism on thiopurine intolerance and 6-TGN level in Korean children with ALL.

Methods: Genotyping of NUDT15 was performed in 258 children with ALL who were registered in Samsung Medical Center. According to NUDT15 diplotypes, patients were classified into low risk (LR, wild-type), intermediate risk (IR, heterozygous), or high risk (HR, homozygous or compound heterozygous variant). Total of 182 were finally included after 76 patients were excluded for TPM'T variation or lack of information during maintenance therapy; LR (n=131), IR (n=46), and HR (n=5).

Results: The least 6-mercaptopurine (6-MP) dose (mg/m2/day) were administrated to the patients of HR (n=59, vs. LR 31.8, p<0.01); HR experienced the longest days of therapy interruption (HR 167 vs IR 30 vs 15, p<0.01) and days of leukopenia (HR 131 vs IR 92 vs LR 59, p<0.01). The lowest WBC and platelet counts and hemoglobin level were observed in HR. 6-TGN level (pmole/8x108 RBC) divided by 6-MP dose (mg/m2) was the lowest in HR group (HR 4.4 vs. IR 13.3 vs HR 14.7, p<0.01).

Summary/Conclusions: Patients with NUDT15 variants encountered significant thiopurine intolerance even with low level of 6-TGN. This concurs with the existing hypothesis that NUDT15 protein may prevent incorporation of thiopurine active metabolites into DNA. Therefore 6-TGN monitoring is not useful to predict hematopoietic toxicity for patients with NUDT15 variant.

E846
USING NEXT GENERATION SEQUENCING TO DETECT CLONAL TRG AND TRB GENE ARRANGEMENTS
P. Shah1, Y. Huang1, K. Hutt1, T. Stenzel1, J.E. Miller1
1Invivoscribe Technologies, Inc., San Diego, United States

Background: During early T-cell development, somatic rearrangements occur within T cell receptor beta (TRB) locus that bring together, sequentially, the D, J and V regions. The on-target reads per sample were 90% - 100%. Excellent linearity (R2>0.90), sensitivity of 2.5% for clonality, and reproducibility (<20% CV) were demonstrated with serial dilutions of contrived cell line DNA. The clinical performance of the LymphoTrack® TRG + TRB NGS assays was evaluated on different clinical samples that have also been tested using the PCR-CE TRG and TRB assays. Assessment of clonality using the LymphoTrack® MiSeq and PCR-CE assays for TRG and TRB demonstrated good concordance.

Summary/Conclusions: This combo NGS assay provides a fast, simple, and accurate method to detect clonality. In combination with the LymphoTrack software, the TRG + TRB MiSeq assay can identify clonal TRG and TRB V-(D)-J rearrangements and the specific V-(D)-J region DNA sequences required to track clones in follow-up testing. Excellent concordance between clonality with specific rearrangements was demonstrated between LymphoTrack® MiSeq and PCR-CE method.

E847
DETECTION OF CLONALITY IN CLINICAL SPECIMENS FROM SUSPECTED B-CELL MALIGNANCIES USING COMPREHENSIVE IGH LYMPHOTRACK® MISEQ® AND PGM ASSAYS
Y. Huang1,*, K. Hutt1, J. Panganiban1, A. Jacobsen1, N. Wong1, D. Duong1, R. Bob1, S.A. Plen1, L. Bernard2, E. Gerbino1, T. Stenzel1, J.E. Miller1
1Invivoscribe Technologies, San Diego, United States, 2Institute for Pathobiology, Berlin, Germany, 3Haematopathology Unit at European Institute of Oncology, Milan, Italy

Background: PCR-based capillary electrophoresis (PCR-CE) methods target the rearrangements from cell line DNA. The on-target reads per sample were 90% - 100%. Excellent linearity (R2>0.90), sensitivity of 2.5% for clonality, and reproducibility (<20% CV) were demonstrated with serial dilutions of contrived cell line DNA. The clinical performance of the LymphoTrack® TRG + TRB NGS assays was evaluated on different clinical samples that have also been tested using the PCR-CE TRG and TRB assays. Assessment of clonality using the LymphoTrack® MiSeq and PCR-CE assays for TRG and TRB demonstrated good concordance.

Summary/Conclusions: This combo NGS assay provides a fast, simple, and accurate method to detect clonality. In combination with the LymphoTrack software, the TRG + TRB MiSeq assay can identify clonal TRG and TRB V-(D)-J rearrangements and the specific V-(D)-J region DNA sequences required to track clones in follow-up testing. Excellent concordance between clonality with specific rearrangements was demonstrated between LymphoTrack® MiSeq and PCR-CE method.

Aims: To assess the clinical performance of the LymphoTrack® IGH MiSeq and PGM Assays

Methods: LymphoTrack® IGH Assay has been developed for both the MiSeq and PGM platforms. Proprietary consensus primers targeting the V and J gene segments of IGH were designed to include both platform specific adapter sequences and individual barcodes so multiple independent PCR products could be combined and sequenced together on the MiSeq or PGM platforms. MiSeq IGH FR master mixes were individually manufactured with 24 indices to allow analysis of 22 samples with 2 controls. PGM IGH FR master mixes were manufactured with 12 indices to allow analysis of 10 samples with 2 controls. DNA was extracted from 21 PB, 37 FFPE and 1 BM clinical samples. Single step PCR amplification of 50 ng DNA input was followed by amplicon purification. Equimolar amounts of purified amplicons were pooled and loaded onto the MiSeq or PGM platforms. The sequencing data was analyzed using Lym-PhoTrack® software, which first sorted the sequences by both index and frame-work region; then generated frequency distributions, V-J usage, identified specific sequences for top sequencing reads, and determined the somatic hypermutation rate of FR1 amplicons. The analytical performance of the LymphoTrack® IGH Assay on both NGS platforms was evaluated using dilutions of contrived samples with known V-J rearrangements. Both NGS assays demonstrated excellent linearity (R2>0.90), sensitivity to detect 2.5% clonality, and reproducibility (<20% CV). The clinical performance of the LymphoTrack® IGH NGS assays was evaluated on 59 clinical samples that have also been tested using the PCR-CE IGH assay. Only samples that meet the specimen and data acceptance criteria for both methods were evaluated to determine concordance. Assessment of clonality using the LymphoTrack® IGH MiSeq and PGM assays demonstrated good concordance. The concordance was 100% (51/51) when tested using the LymphoTrack® IGH PGM and PCR-CE assays. Concordance in clonality calls between the LymphoTrack® IGH MiSeq and PGM assays was 100% (51/51).
Summary/Conclusions: Comprehensive IGH Assays have been developed for both MiSeq and PGM platforms. These assays identify clonal IGH V-J rearrangements and provide the clonal DNA sequences of the tumor-specific clonotypes required to perform follow up testing to detect residual disease. Combining FR1, FR2 and FR3 improved the overall clonality detection rate to 96%. Both NGS-based IGH assays have demonstrated excellent concordance in detecting clonality regardless of whether clonality was determined using a PCR-CE method or with assays formatted for the MiSeq and PGM platforms.

E848

CORRELATION BETWEEN A 10-COLOR FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS AND MOLECULAR MRD IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

J. Singh1, M. Gorniak1, G. Grigoriadis1,2, D. Westerman3, M. McBean3, N. Venn4, R. Sutton2, S. Morgan1, S. Fleming1,2
1Laboratory Haematology, Alfred Pathology, Alfred Health, 2Clinical Haematology, Monash Health, 3Pathology, Peter MacCallum Cancer Centre at the Victorian Comprehensive Cancer Centre, Melbourne, 4Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, Australia

Background: Minimal residual disease (MRD) monitoring in Acute Lymphoblastic Leukemia (ALL) is an accepted standard of care in both adult and pediatric patients as one of the strongest predictive factors for disease outcome and as a stratification tool for treatment intensification and allogeneic stem cell transplant. The currently accepted standard of molecular monitoring with either immunoglobulin heavy or kappa chain (IG) or T-cell receptor (TCR) quantitative PCR (qPCR) in Philadelphia negative ALL allows for sensitive monitoring of MRD, but requires a high degree of expertise, and factors such as cost and turnaround time may limit generalized applicability of this technique. Flow cytometric MRD monitoring is utilized in many centers, with increased sensitivity seen with implementation of multi-parameter flow cytometry at 8-colours or more.

Aims: We sought to compare a 10-color flow cytometry assay for detecting MRD in B-ALL with standard molecular monitoring.

Methods: To facilitate rapid identification of MRD in patients with B-ALL, we developed a 10-colour single tube flow cytometry assay utilizing CD19, CD22, CD20, CD38, CD58, CD13/33, CD66c, CD10, CD45 and CD34 as markers. These markers were selected to provide at least two targets for identification of B-lineage cells, and to include the most frequently aberrant markers in precursor B-lineage ALL. Samples were subject to bulk ammonium chloride lysis of B-lineage cells, and to include the most frequently aberrant markers in pre-CD20, CD38, CD58, CD13/33, CD66c, CD10, CD45 and CD34 as markers. These markers were selected to provide at least two targets for identification of B-lineage cells, and to include the most frequently aberrant markers in precursor B-lineage ALL. Samples were subject to bulk ammonium chloride lysis to maximize cell yields with a target of 1 x 10⁶ events. Once normal maturation patterns were established, patient samples were analyzed in parallel to standard of care molecular monitoring with either IG/TCR qPCR in Philadelphia negative (Ph-) disease and BCR-ABL qRT-PCR in Philadelphia positive (Ph+) disease. Statistical correlation was performed in Graphpad Prism version 7.0 for linear regression and calculation of correlation co-efficient.

Results: 33 samples at different time points from 13 patients were analyzed by flow cytometry. 9 samples from 9 patients were taken at diagnosis. Whilst an informative MRD phenotype was identified by flow cytometry in all 9 patients, a molecular assay was not able to be developed in one patient due to lack of an identifiable marker. 24 samples from 13 patients were tested for MRD by flow cytometry. The median lower limit of detection was 0.0078% (range 0.0016% to 0.028%) with a median lower limit of quantification of 0.018% (range 0.002% to 0.07%). A sensitivity of <0.01% was attained in 21 of 24 samples (88%). 20 samples from 11 patients were tested concurrently for MRD by both molecular and flow cytometric methods. 11 samples were in Ph- disease and 9 were in Ph+ disease. MRD was detected by both molecular and flow cytometry in 11 samples and not detected by both methods in 8 samples. In one sample, MRD was detected only by molecular at an unquantifiable level. There was a strong correlation co-efficient between molecular and flow cytometric MRD analysis (R²=0.905, p<0.001). Correlation was strong with both IG/TCR based molecular analysis (R²=0.949, p<0.001) and BCR-ABL based molecular assays (R²=0.993, p<0.001).

Summary/Conclusions: 10-color flow cytometric minimal residual disease analysis with bulk lysis attains a high degree of sensitivity in minimal residual disease determination in precursor B-lineage Acute Lymphoblastic Leukemia. There was a strong correlation with molecular MRD monitoring for both quantification of MRD and determination of MRD negative status. Flow cytometric methods may also permit MRD monitoring in patients where a suitable molecular assay cannot be developed.

E849

HYPOGLYCEMIC EVENTS DURING TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: OBSERVATIONS FROM TRIAL AIEOP-BFM ALL 2009

D. Blackmann1,*, J. Allen1, N. Bodmer2, E. Zapotocka3, D. Barbaric4, M. Schrappe1, S. Vieth1, M. Zimmermann5, A. Möricker1
1Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, 2Pediatric Oncology and Hematology, Universitätspatienten-Kinderklinik Zürich, Zürich, Switzerland, 3Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czech Republic, 4Centre for Cancer and Blood Disorders, Sydney Children’s Hospital, Sydney, Australia, 5Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany

Background: Hypoglycemia has been reported as a rare side effect in children and adolescents treated for acute lymphoblastic leukemia (ALL). It has been associated to purine nucleoside analogues (PNA), but potential relationship with asparaginase has also been described. Despite these reports, clinicians’ awareness of this risk seems to be limited.

Aims: Descriptive evaluation of symptomatic hypoglycemic events during ALL treatment.

Methods: Hypoglycemic events were analyzed among 3293 patients treated in the trial AIEOP-BFM ALL 2009 in four of the participating countries (Germany, Switzerland, Czech Republic, and Australia) between 06/2010 and 08/2016. PNA were administered during induction-consolidation, the second part of the reintensification phase (reinduction-consolidation) and during maintenance (MT). Pegylated asparaginase (PEG-ASP) was given in induction and during reinduction-consolidation, as well as high-risk blocks. Additionally, the benefit of intensified pegaspargase was studied during induction-consolidation in the high-risk group, and during reinduction-consolidation/MT in the medium-risk group. Adverse events were generally captured in a targeted approach by means of defined events assessed as clinically relevant, not including hypoglycemia. Thus, data collection of these events was based on proactive reporting by the investigators. For analysis, clinical severity of the events was retrospectively graded according to patients’ capacity of action and reaction.

Results: In total, 28 hypoglycemic events were reported in 26 of the 3293 patients. 25 events in 23 patients were described as symptomatic, to which further analysis was restricted (22 precursor B- and one T-ALL; 8 standard-risk, 12 medium-risk, and 3 high-risk). Age of patients ranged between 1.7 and 15.5 years at occurrence of symptomatic hypoglycemia. Balanced ratio between both sexes can be observed (13 male, 10 female), median age was essentially similar (male 3.2 y, female 4.1 y). Hypoglycemic events occurred in induction treatment (n=1), induction-consolidation (n=8), reinduction-consolidation (n=4; one in standard reinduction, 3 in reinduction with intensified PEG-ASP treatment), high-risk block (n=1), and in MT (n=11; 4 events during standard MT, 6 events during MT with intensified PEG-ASP treatment, and one event 4 weeks after last PEG-ASP during MT). Seven events were reported with mild symptoms, 6 patients showed moderate symptoms, and in 12 events patients showed severe symptoms (loss of consciousness, seizure-like).

Summary/Conclusions: In accordance with previous reports, hypoglycemic events accumulated in PNA containing treatment phases, but not exclusively. Considering that 324 patients of the total cohort were treated with intensified PEG-ASP in reinduction-consolidation/MT, an additive effect of PEG-ASP and PNA was presumed. A hypoglycemic metabolic condition may be assumed although a similar effect was not seen in induction-consolidation with intensified PEG-ASP. However, numbers are small and reporting bias of the present data is probable, as hypoglycemic events were not captured systematically. Investigators’ attention to adverse reactions and proactive reporting might be higher.

Figure 1. Descriptive evaluation of symptomatic hypoglycemic events during ALL treatment.
in experimental arms as well as in case of preceding hypoglycemic events in other patients of the respective trial center. Despite these analytical limitations, our data suggest that hypoglycemia during ALL treatment is a relevant and probably underestimated clinical problem. Further investigation including possible identification of predisposing metabolic conditions is required to avoid harm to patients by this preventable complication.

E850

NUDT15 VARIANT IN KOREAN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA


Summary/Conclusions:

Figure 1. Genotyping of NUDT15 could be beneficial to predict the tolerable dose of 6-MP of pediatric ALL patients.

Table 1. Treatment outcome of children with acute lymphoblastic leukemia according to NUDT15 genotypes.

E851

Abstract withdrawn.

E852

TREATMENT OUTCOME OF ACUTE LYMPHOBLASTIC LEUKEMIA IN KOREAN ADOLESCENTS AND YOUNG ADULTS


1Department of Pediatric Oncology, 2National Cancer Control Institute, 3Hematology and Oncology Clinic, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic Of

Background: The outcome of acute lymphoblastic leukemia (ALL) has markedly improved for last centuries, but the improvement was mainly observed in children under 10 years old. In contrast, the treatment outcomes of ALL in adolescents and young adults (AYA) still lag behind those of younger children.

Aims: We conducted this study to investigate the treatment outcome of AYA ALL in Korea, and to define any patterns of care related to the treatment outcome of AYA ALL.

Methods: Clinical data of 10-29 years old ALL patients diagnosed between 2002 and 2010 were extracted from Korean national health insurance service. Data about patients’ diagnosis, age, gender, mainly treated department (internal medicine vs pediatrics), usage data of medications (L-asparaginase, 6-mercaptopurine, vincristine, prednisolone or dexamethasone), hematopoietic stem cell transplantation (HSCT), radiotherapy, survival, and follow-up duration were collected. Patients who were treated with steroid over 2 weeks, and L-asparaginase at least once in initial 2 months were considered to be treated as pediatric protocol, and who did not fulfill this criteria were considered to be treated as adult protocol.

Results: Total 1,223 ALL AYA patients were diagnosed between the 2002 and 2010, and excluding those who never treated, 1,208 patients underwent ALL treatment. Among them, 665 (55%) patients were treated with pediatric protocol, and the other 543 (45%) patients were treated with adult protocol. Radiotherapy was done in 278 (41.8%) and 186 (34.3%) in each group, and HSCT was done in 205 patients (30.8%) and 216 patients (39.8%) in each group, respectively. Pediatric protocol group showed significantly better overall survival compared to adult protocol group in total age (65% vs 43%, P<0.0001), 10-14 years old (76% vs 57%, P<0.0001), and 20-24 year old patients (51% vs 31%, P=0.0116). In univariable analysis, patient age (younger), treatment protocol (pediatric), L-Asparaginase, 6-mercaptopurine, and steroid over 2weeks in initial 2 months were associated with better overall survival (P<0.00001 for each).

Summary/Conclusions: The overall survival rates in Korean AYA ALL were comparable with previous studies done at other countries. Patients treated with pediatric protocol tended to result better overall survival rate when compared to patients treated with adult protocol. Radiotherapy and early HSCT were widely used in the 2000s, and further study is needed to follow up the recent trend of treatment, and outcome as a result.

E853

AUTOLOGOUS TRANSPLANTATION AS TIME-DEPENDENT FACTOR FOR SURVIVAL OF PATIENTS WITH T-CELL ACUTE LYMPHOCYTIC LEUKEMIA: STUDY DATA AND SIMULATION MODEL

S. Kulikov1, M. Rusinov2, A. Kulikovsky2, E. Parvikhichkova2

1Biostatistics, 2Hematological Oncology and BMT, National Research Center for Hematology, Moscow, Russian Federation

Background: The role of autologous hematopoietic stem cells transplantation (aHSCT) for patients with T-cell ALL is still being discussed. The resent Russia study of ALL shows the promising effect of aHSCT but there is a skepticism as the study was not randomized. The possible bias was referred to the “time selection” factor.

Aims: It’s need to prove that time selection can not explain the magnitude of the effect of aHSCT on patient’s survival.

Methods: We have developed SAS macros time-depend graphical and analytic procedures for time dependent factors: Land Mark (LM) methods, Mantel-Bay test, Cox regression model (CM) and also a base for simulation all end points and study events like remission, transplantation, relapse and death are well approximated by a mixture of exponential distributions. Non-constant (time dependent) hazard rate exists in real study data. The consequence of violation of constant hazard assumption as most possible source of biases was tested on our simulation model in different situations. Real data multicenter study of ALL was used to fit simulation model parameters. Russian ALL study group held a prospective multicenter trial RALL-2009 in the treatment of Ph-negative adult ALL patients based on non-intensive but non-interruptive treatment (NCT01193933). The therapy was unified for all Ph-negative ALL pts, but in T-cell ALL/LBL autologous hematopoietic stem cell transplantation (auto-HSCT) after non-myeloablative BEAM conditioning was scheduled as late intensification (+3-4 mo of CR) followed by prolonged 2 years maintenance. From Jan 2009 till Jul 2016, 30 centers enrolled 107 T-ALL/LBL pts. Median age was 28 years (15-54 y), 34 f / 73 m; early T-cell (T/II) phenotype was verified in 56
ble disease (MRD) was evaluated in all patients after each FLAD either by
tological recovery. FLAD was administrated for up to two cycles. Minimal resid-

Methods:

Aims:

inhibitors (TKI). Following TKIs treatment almost all patients rapidly achieve com-
plete molecular response and most of all will eventually relapse without further

Results:

in 22 pts (20.5%). Autologous HSCT was performed in 35, allogeneic-in 7 pts.
(38.3%). T-lymphoblastic lymphoma (T-LBL= <25% b/m blasts) was diagnosed in
52 patients (52.3%), mature (T-IV) - in 10 (9.4%), thymic (TIII, CD1a+) ALL – in 41 pts
(52.3%), mature (T-IV) - in 10 (9.4%), thymic (TIII, CD1a+) ALL – in 41 pts

Summary/Conclusions: The effect of autologous HSCT in T-cell ALL was confirmed by usual analysis and by simulation experiments. It was shown that potential bias caused by no constant hazard rate cannot explain the magnitude of HSCT effect demonstrated on real data. LM plot could express small bias. Mantel-Bayr and Cox model are robust against non-constant hazard assumption and give very concordant outputs. Cox model underestimates the effect of time-depending factor in case of dropping hazard. Simulations model is a good instrument for testing tests in situations of deviation from theoretical assumptions.

E854

INDUCTION WITH TYROSINE KINASE INHIBITORS, CONSOLIDATION WITH FLUDARABINE, ARA-C AND DAUNOXOMIDE FOLLOWED BY ALLOGENIC STEM CELL TRANSPLANT IS AN EFFECTIVE AND FEASIBLE STRATEGY FOR PH+ ALL PATIENTS

N. Di Felice1,*, P. Minetto1, F. Guolo1, M. Clavio 1, N. Bisso 1, G. Pastori 1, M. Miglino1, R.M. Lemoli1, M. Gobbi1

1Clinic of Hematology, Department of Internal Medicine (DIMI), University of Genoa. 2Clinic of Internal Medicine III, Department of Internal Medicine (DIMI), University of Genova, IRCCS AOU San Martino-IST, Genova, Italy

Background: The prognosis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patients has improved since the introduction of tyrosine kinase inhibitors (TKI). Following TKIs treatment almost all patients rapidly achieve complete hematologic remission (CR). However, only a minority of patients obtain complete molecular response and most of all will eventually relapse without further treatment. On the other hand, the concomitant combination of TKIs to conventional chemotherapy regimens greatly increases complete molecular responses, but at the price of significant toxicities and high rates of deaths due to toxicity.

Aims: We present here the preliminary results of a sequential therapeutic strategy starting with TKI (Dasatinib) as single agent induction until CR is achieved. Fludarabine (Flu), Cytarabine (Ara-C), Lysosomal Daunorubicine (DNX), FLAD regimen and Dasatinib were given as consolidation therapy, in order to maximize efficacy and reduce toxicity. Allogeneic stem cell transplantation (HSCT) was planned for all patients in MRD negative CR.

Methods: Dasatinib was given in association with steroids at the dosage of 140mg/ide until the achievement of CR. FLAD regimen consisted of a three-days administration of Flu 30mg/sgm followed by Ara-C 2000mg/sgm and DNX 100mg/sgm. Dasatinib was administered again from the end of chemotherapy and G-CSF was given to all patients starting from day 4 until complete hematological recovery. FLAD was administrated for up to two cycles. Minimal residual disease (MRD) was evaluated in all patients after each FLAD either by multicolor flow cytometry (MFC), RQ-PCR for VDJ rearrangements, and RQ-PCR for BCR/ABL.

Results: From January 2008 to December 2016, 8 Ph+ ALL at diagnosis (medi-
an age 52 years) have been enrolled in this protocol. The median follow-up was 27 months. All patients received 70 days induction with Dasatinib + Steroids and achieved CR with complete hematological recovery. In all patients but one, however, BCR/ABL was still positive both on day 33 and on day 70. Two patients were MFC MRD positive on day 33 (one on day 70 also), whereas five patients achieved MFC MRD negativity on day 33. After the first FLAD course all patients achieved MFC MRD negativity, with four patients achieving also negativity for VDJ rearrangements and BCR/ABL transcript. FLAD was very well tolerated, with a median ANC and platelet recovery of 7,5 and 4 days, respectively. No patient experienced relapse so far and 6 patients proceeded to HSCT. Two patients are currently waiting for transplant. Overall, 6 patients are alive and in MRD negative CR at the time of analysis. One patient died at day +289 after SCT due to non-relapse mortality and one has died after the first FLAD in molecular CR because of an unrelated event.

Summary/Conclusions: This therapeutic strategy proved to be well tolerated and extremely effective for Ph+ ALL patients. Administering FLAD in patients who had already achieved complete hematologic response with Dasatinib + steroids allowed us to reduce the period of neutropenia and thrombocytopenia compared to what is reported after combined TKI and chemotherapy treatment given at diagnosis. Most patients underwent HSCT in molecular CR.
Results: Positive JL1 expression was observed in 16 (64.0%) patients with AML and 27 (58.7%) with ALL. In AML patients, positive JL1 group showed higher expressions than negative JL1 group in CD 14 (P=0.043), CD7 (P=0.026), CD56 (P=0.016) and lower expressions in CD65 (P=0.05). With regard to ALL patients, CD 20 (P=0.002) and CD2 (P=0.005) expressions were significantly higher in JL1 positive group than JL1 negative group. Positivity of JL1 staining did not show any significant difference between B-lineage and T-lineage ALL (P=0.671). Positivity of JL1 expression was not significantly associated with overall survival in 71 patients with newly diagnosed childhood acute leukemia (P=0.570).

Summary/Conclusions: 60.5% of childhood acute leukemia displayed positive JL1 expression. This finding is similar to 61.2% of JL1 expression in adult AML and 57.9% of expression in adult ALL reported previously. The JL1 expression was significantly associated with some immunophenotypic features, but was not significantly associated with clinical outcome. These findings demonstrate that anti-JL1 antibody might be used in childhood acute leukemia patient showing JL1 expression.

E858

SERUM LEVELS OF CYTOKINES AND ADHESION MOLECULES AND THEIR ASSOCIATION WITH PROGNOSTIC FACTORS IN NEWLY DIAGNOSED ACUTE LYMPHOBlastic LEUKEMIA PATIENTS

A. Lomba1,2,*, E. Ximénez1, C.M. Pérez-Hens2, E. Morón2, D. Chalela2, P. Garcia2, T. Kussa1, C. Pascual1, E. L. Farraye1, P. González-Cabrera1, P. Sánchez1
1Department of Military Internal Medicine and Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), 4th Department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, 2Department of Informatics and Quantitative Methods, University of Malaga, 3Faculty of Medicine, Faculty of Informatics and Management, Hradec Králové, Czech Republic

Background: Dysregulated production of cytokines and adhesion molecules has been implicated in the onset and progression of various types of leukemia. Further knowledge gained from multiple cytokine and adhesion molecule evaluation could help to improve treatment outcomes. Aims: The aim of this study was to evaluate baseline levels of cytokines, cytokine receptors and adhesion molecules in newly diagnosed acute lymphoblastic leukemia (ALL) patients and to assess their correlation with baseline characteristics and prognostic factors.

Methods: A total of 30 newly diagnosed ALL patients (median age 46, range 22–75 years, 20 males) were included. We evaluated serum levels of 31 analytes, specifically 21 cytokines, 4 soluble cytokine receptors, 5 soluble adhesion molecules and Matrix Metalloproteinase-9. From cytokines, we measured Interleukins (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-23), Epidermal Growth Factor (EGF), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Interferon-γ (IFN-γ), Macrophage Inflammatory Protein-1α (MIP-1α), Monocyte Chemotactic Protein-1 (MCP-1), TNF Tumour Necrosis Factor-α (TNF-α), Vascular Cell Adhesion Molecule-1 (VCAM-1), E-Selectin (E-SEL), L-Selectin (L-SEL), P-Selectin (P-Sel), Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1). All analytes were measured by biochip array technology on Evidence Investigator analyzer (Randox). Serum levels of tested analytes were correlated with baseline characteristics, such as age, sex, risk group according to GMAIL (SR 9, HR 9, VHR 12 patients), full blood count parameters (including percentage of blasts), biochemical parameters (LDH, CRP), response to induction therapy (CR rate after induction), progression-free survival (PFS) and overall survival (OS). Statistical evaluation was done by a professional statistician using software R 3.3.2 (R Core Team 2016).

Results: Comparing analytes with baseline characteristics, we found significant negative correlations between IL-7 and leukocyte count (r=-0.633; p=0.032), percentage of blasts in peripheral blood (r=-0.695; p=0.004) and LDH (r=-0.604; p=0.075). Furthermore, we found significant positive correlations between IL-7 and LDH (r=0.691; p=0.001), IL-12 and leukocyte count (r=0.801; p=0.0001). VCAM-1 and LDH (r=0.664; p=0.012) correlations with baseline risk stratification according to GMAIL did not reach statistical significance. In the study population, CR rate after induction was 86% (MRD negative in 29%), 1-year PFS 68% and 1-year OS 73% (2 patients died during induction therapy). Higher levels of EGF were associated with failure to achieve CR after induction therapy (r=0.689; p=0.073). So far, no significant correlations between baseline analyte levels and inferior PFS or OS were found. In newly diagnosed ALL patients, we found statistically significant correlations between TNF-1 and TNF-2 (r=0.805; p=0.0001), IL-1α and IL-4 (r=0.700; p=0.008), TNF-2 and MIP-1α (r=0.657; p=0.037), sTNFR-2 and VCAM-1 (r=0.652; p=0.044).

Summary/Conclusions: Our findings show that serum levels of IL-7 and VCAM-1 are associated with some baseline characteristics of newly diagnosed ALL patients and EGF response to induction therapy. Better understanding of leukemia microenvironment is essential for development of new treatment approaches. Further studies in this field are warranted.
IMATINIB VS. DASATINIB FOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH PH+ ACUTE LYMPHOBLASTIC LEUKEMIA
A. Shigematsu1, A. Tsukaba2, K. Mino2, J. Sugita2, H. Washioka3, M. Obara1, T. Endo1, M. Imaizumi1, T. Teshima1, N. Kobayashi1
1Department of Hematology, Sapporo Hokuyu Hospital, 2Department of Hematology, Hokkaido University Hospital, Sapporo, Japan

Background: The survival of the patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph=ALL) who received allogeneic stem cell transplant (allo-HSCT) has improved over the development of tyrosine kinase inhibitors (TKIs). Currently, Imatinib (IMA) and Dasatinib (DAS) are widely used for the treatment for Ph+ALL. However, there has been no data comparing the outcomes between the patients who received allo-HSCT and the two distinctive TKIs respectively.

Aims: We conducted a retrospective analysis for comparing the two TKIs for the outcome after allo-HSCT.

Methods: Clinical data of patients were retrospectively collected from Hokkaido University Hospital and Sapporo Hokuyu Hospital. The patients' eligibility were as follows: diagnosed as Ph+ALL, aged more than 16 years, and received allo-HSCT between 1990 and 2016 and first time for SCT.

Results: Sixty-six patients were eligible for the study. Fifty-six out of the 66 were administered TKIs (TKI group) and the remaining ten who developed Ph+ALL in the early phase were treated without TKIs (non-TKI group). Overall survival was not different between the two groups. Of the 56 patients in the TKI group, 39 received IMA (IMA-pts), and the remaining 17 received DAS (DAS-pts). Compared with DAS-pts, IMA-pts received allo-HSCT in relatively older years of age, more frequent myeloablative conditioning regimen, and cyclosporine containing, not tacrolimus-, regimen for GVHD prophylaxis more frequently. Overall survival was not different between the two groups by univariate analysis (Logrank, P=0.16). However, by multivariate analysis using Cox regression model for adjusting confounding factors, including overall survival was superior for IMA-pts [Hazard ratio: 0.32 (0.11-0.94), P=0.04]. Incidences of transplant-related mortality and relapse were not different between the groups, even though relapse rate tended to be increased in DAS-pts (IMA: 16.1%, DAS: 47.1%, Gray P=0.2).

Summary/Conclusions: Our analysis suggests that overall survival may be superior for the Ph+ALL patients treated with allo-SCT and IMA compared with those with DAS. There are some limitations for our analysis due to retrospective fashion and relatively small number of the patients analyzed. Therefore, prospective study comparing survival of the Ph+ALL patients treated with the two distinctive TKIs before HSCT is needed.

IS OLDER AGE AN EXCLUSION CRITERION FOR ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA?
O. Gavrilina1, E. Parovichnikova1, V. Troitskaya1, A. Sokolov1, L. Kuzmina2, S. Bondarenko3, V. Lapin4, T. Obukhova5, A. Sudarikov6, K. Zarubina1, S. Kulikov7, M. Rusinov7, V. Savchenko1
1Chemotherapy and BMT, 2Bone marrow transplantation, National Research Center for hematology, Moscow, 3BMT, Institute of the Pediatric Hematology and Transplantology, Saint-Petersburg, 4Hematology, Regional hospital, Yaroslavl, 5Cytogenetic, 6Molecular hematology, 7Statistic, National Research Center for Hematology, Moscow, Russian Federation

Background: Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is diagnosed more often in older than in younger patients. This type of the disease is characterized by very aggressive course of the disease. All clinical recommendations for such conditions indicate allogeneic bone marrow transplantation (allo-BMT) after achieving complete remission. The addition of tyrosine kinase inhibitors (TKI) to chemotherapy has dramatically improved the long-term outcome in Ph+ acute lymphoblastic leukemia patients. Nevertheless whether to administer chemotherapy at all and if yes – how intensive it should be, is still the matter of debate. We have conducted two consecutive trials in Ph+ ALL aiming to evaluate the efficacy of more and less intensive chemotherapy approaches in combination with constant non-stop 600 mg Imatinib. All patients in both protocols with suitable donors underwent hematopoietic stem-cell transplantation (HSCT).

Aims: To analyze the effectiveness of RALL–2009+TKI and RALL–2012+TKI protocols in Ph+ ALL patients with or without HSCT. To analyze the efficacy of treatment with or without transplantation regarding the patient's age.

Methods: From 2010 January to 2017 January, 35 new Ph+ ALL cases were diagnosed in 3 centers of the RALL–group. From 2010 to 2012, 12 Ph+ ALL patients were treated according to RALL–2009 protocol (ClinicalTrials.gov: NCT00939933) with concurrent administration of Imatinib. This protocol includes 8 cytostatic drugs and no intervals between treatment phases. Since 2012 till now 23 pts were included in ongoing RALL–2012 protocol, based mainly on 600 mg Imatinib with prednisolone, VNCR, L-asp, followed by 6-MP and MTX. Both protocols suggested the shift to Dasatinib (100-140mg) after non-achievement of MolCR on day 70 of treatment. MolCR was stated if bcr/abl chimeric transcript was <0.01% by PCR with 10-4 sensitivity. All patients were considered as candidates for allogeneic HSCT if HLA-identical donor was available. 13 pts (37%) underwent allo-HSCT as the first-line therapy: 1 autologous, 5 matched related and 7 matched unrelated.

Figure 1.

Results: MolCR on day 70 was achieved in 36% and 59% in RALL–2009 (n=4) and RALL–2012 (n=13) respectively. Death on therapy (within 2 months of induction/consolidation) was registered in 2 cases on less intensive RALL–2012 protocol and 2 cases on RALL–2009. Hematological CR was achieved in 30 (85.7%) of 35 pts (except four early deaths and 2 refractory cases). There was one autologous HSCT in MolCR on the first protocol. Allo–HSCT was carried out in 5 of RALL–2009 protocol pts and in 9 of RALL–2012. The major issue is the non-relapsed mortality after unrelated allo–HSCT in 3 older pts (49, 56 and 59 years old) who were included in RALL–2012 (gVHD and severe infections, at a median +4 months after HSCT and more than 12 months of CR duration).

The 5y overall survival (OS) and relapse-free survival (RFS) for all 35 pts constituted 54.6% and 40.4% respectively. The long-term outcome on both protocols (RALL–2009 and RALL–2012) was similar: OS – 62.5% vs 49.4% (p=0.6), RFS – 55.7% vs 45% (p=0.7), respectively. In order to evaluate the impact of allogeneic HSCT we performed a comparison of transplanted and non-transplanted patients by a landmark analysis. The landmark was chosen as the median time from CR to allo–HSCT – 4.3 mo (3-16 mo). So, the 5y OS for younger (≤45 y) was 53.3% in transplanted patients and from day of HSCT - 65.6% in transplanted (p=0.18), and RFS was 25% vs 62.5% (p=0.19), respectively. OS for older pts (>45 y) was 40% vs 25% in transplanted vs non-transplanted group of the pts, and RFS was 25% vs 66.6%, respectively. OS in younger (≤45 y) pts was 83.3% vs 58.9% for transplanted vs non-transplanted patients. EFS was 77.1 vs 21.4%, respectively.

Summary/Conclusions: The results very pessimistic in older (>45 y) patients who received HSCT. The contrary was observed in younger adult patients with very good results after HSCT – OS was 83.3% and EFS 77.1%. We conclude that patients aged>45y should continue chemotherapy without allogeneic HSCT or may be we could apply autologous HSCT for that group of the patients.

TARGETABLE BLINATUMOMAB + TYROSINE KINASE INHIBITORS TREATMENT IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: CLINICAL EFFECTIVENESS AND PERIPHERAL LYMPHOCYTES SUBPOPULATIONS KINETICS
A. Sokolov1, E. Parovichnikova1, V. Troitskaya1, I. Galtseva1, L. Kuzmina1, J. Davidova1, N. Karpanov1, I. Lukyanova1, T. Lobanova1, K. Zarubina1, E. Usikova2, V. Savchenko1
1National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation, 2Chemotherapy of hematoloses and bone marrow depression and bone marrow transplantation, National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Blinatumomab is a bispecific monoclonal anti-CD3/CD19 antibody which has clinical activity in relapsed/refractory Ph-positive acute lymphoblastic leukemia (ALL) as monotherapy. Combination of Blinatumomab with
tyrosine kinase inhibitors (TKI) is the promising approach in treating Ph-positive ALL. Some other rearrangements like IKZF1 in Ph-like ALL, FLT3 and JAK2 in Ph-negative ALL are the potential targets to some TKIs.

Aims: To demonstrate effectiveness and toxicity profile of Blinatumomab+TKI treatment. To evaluate peripheral blood lymphocytes subpopulations kinetics during blinatumomab treatment.

Methods: From October 2015 to February 2017 10 patients (pts) aged from 24 to 42 (median 31), 7 female and 3 male, with relapsed/refractory ALL were treated in our center. The diagnosis was relapsed ALL in 8 pts (7 – overt hematological, 1 – cytogenetic relapse) and persistent/increasing minimal residual disease of ALL in 2 pts. All pts had strong CD19 positivity. 8 pts was diagnosed as Ph-positive ALL (p190), 1 – Ph-like ALL (IKF1 rearranged). 1- FLT3+ ALL. Two pts has T315I ABL mutation. In all pts blinatumomab continuous infusion + TKI therapy was started. Blinatumomab dose during 1st week of 1st cycle was 9 mcg/day, 28 mcg – subsequent three weeks. Blinatumomab dose in subsequent 4-weeks cycles was 28 mcg/day. 7 pts were treated with TKI Dasatinib, 1 – Bosutinib (Dasatinib/Nilotinib intolerant), 1 – Ponatinib (T315I), 1 – Sorafenib (FLT3+). ATRA was added to Dasatinib in 1 pt with IKZF1 rearranged Ph-like ALL. 1 pt received 1 cycle of 4 weeks blinatumomab, 1 pt – 2 cycles, 6 pts - 4 cycles, 2 pts – 5 cycles. TKI were administered continuously in all pts. T-helper, T cytotoxic, T-regulatory and NK cells were measured by flow cytometry in every week during all cycles of blinatumomab treatment.

Results: No one pt has neurological toxicity of any grade. All pts has significant decrease of normal Ig level and all of them received intravenous human normal immunoglobulin replacement. Palmar-planter syndrome in one pt on sorafenib completely resolved after temporarily TKI discontinuation. Disappearance in 1 pt on dasatinib/nilotinib completely resolved on bosutinib. 8 pts achieved molecular remission (MCR), one pt – cytogenetic remission and one pt with T315I progressed to overt hematological relapse. T-helper and T-regulatory lymphocytes subpopulations were on or below of lower limit of normal range. T-cytotoxic and NK subpopulations gradually returned into normal range (Fig. 1). AloBMT was performed in 4 pts. Three pts are awaiting aloBMT and three are continuing Blinatumomab + TKI treatment.

Summary/Conclusions: Lowering toxicity in non-chemotherapy treatment has its significance in such a heavily pretreated patients with relapsed ALL. The treatment has high MCR rate and low toxicity profile. Treatment effectiveness correlated with T-helper and T-regulatory subpopulations exhaustion. T-cytotoxic and NK cells subpopulations restoring also correlated with clinical effectiveness.

E862

**VERY LATE RELAPSES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA, A CASE SERIES**

M. Bakal1, D. Doganis1, M. Nikita1, A. Poursidis1, M. Servitzoglou1, D. Bouhoutsou1, M. Varvoutsi1, K. Kapetanion1, H. Dana1, V. Douna2, T. Anastasiou2, H. Kosmidis1

**Background:** Recurrence of acute lymphoblastic leukemia (ALL) during childhood usually occurs within the first six years after initial diagnosis.

**Aims:** The aim of this study is the identification of all relevant characteristics and outcomes in a group of patients with childhood ALL, who relapsed more than six years after initial diagnosis or more than three years after bone marrow transplantation (BMT).

**Methods:** All children diagnosed with a first relapse of ALL in our Department, from January 1992 till December 2010 were included in this study.

**Results:** During this period, a total number of 353 patients with childhood ALL were treated in our Department, according to BFM protocols. Recurrence occurred in 86 patients (24.4%, 56 male - 30 female - median age: 4.83 years), within 3 to 184 months from initial diagnosis. Very very late recurrence was noted in 3.1% of our relapses (8 male - 3 female) at 53, 72, 82, 83, 84, 108, 112, 116, 120 and 184 months from initial diagnosis. In 9 patients recurrence involved the bone marrow, in 1 both bone marrow and central nervous system (CNS) and in 1 only the testicles. Two children had received allogeneic BMT from a matched related donor in first complete remission (CR1) and they had a bone marrow relapse 4 and 5 years later, respectively. The mean WBC, Hb, Blasts and PLT values at diagnosis were 29260/mm3, 5.6g/dl, 21360/mm3 and 18000/mm3, respectively. All of them were B-cell ALL except for 1 who had CD33 and CD13 co-expression. Regarding the immunophenotypical profile of the disease at recurrence, it remained almost identical to the initial. Regarding cytogenetic characteristics of the patients at diagnosis, 3 of them had high hyperdiploidy, one del(6)(q12), one BCR-ABL fusion and one 47.XY,+13(9), idem del(12)(p13q13); none had MLL rearrangement or ETV6-RUNX1. In all cases, the cytogenetic profile remained identical at recurrence, while in 1, trisomia 13 was not detected and another had heterozygous absence of IKZF1, PAIX5, EBF1, CDKN2A and CDKN2B genes. On Day 8, nine of 11 patients were Prednisone Good Responders. On Day 15, nine children had bone marrow m1, one m2 and one m3, and on Day 33 only one had m2. Two patients were classified as low risk, 6 as intermediate risk and 3 as high risk. Second remission (CR2) was achieved in 9 children with very very late recurrence. The other 2 died from disease progression. Six of nine patients are still alive and well 6, 8, 10, 11 and 20 years after initial diagnosis. One patient of 9 died from second recurrence and the last two had a second allogeneic BMT and died due to severe infection, 2 and 11 months following that BMT. Interestingly, 3 out of 5 patients who finally died, had the very very late recurrence (10, 10 and 15 years after initial diagnosis) and had been treated with adult type protocols.

**Summary/Conclusions:** The rate of very very late B-cell ALL recurrence was only 12.8% of all recurrences. The prognosis is worse in patients, older than 18 years, treated with adult type protocols.
was lower than that of non-mutation (8.53×10^9/L vs 29.9×10^9/L, P=0.032). The positive rate of Ph chromosome in patients with R186S was lower than that without the mutant (10.0% vs 31.8%, P=0.018). In addition, the incidence of splenomegaly in patients with R186S and P224 L mutants was lower than that in non-mutant patients (0.0% vs 29.5%, P=0.026; 0.0% vs 29.7%, P=0.034, respectively). The B-ALL patients with L86I mutant had myeloid antigen expression, high white blood cell count (248.4×10^9/L) and low platelet count (10×10^9/L), and relapsed in two months after the first induction chemotherapy; and the overall survival was only 2 months. The patient with W255C mutation did not achieve complete remission (CR) with the first induction chemotherapy. Interestingly, the patient with silent mutation, A11A showed higher age (46 years, P=0.033), higher HLA-DR (100% vs 75.3%, P=0.035), CD22 (93.3% vs 47.4%, P=0.020) than those without the mutation; and the patient with F232F mutation relapsed in 6 months.

**Summary/Conclusions:** Six novel CRLF2 genetic mutations were identified in adult ALL patients and may associate with clinical outcome, such as CRLF2 R186S indicating favorable, while L86I and W255C indicating poor outcome. Our data indicated that the CRLF2 mutations may be new prognostic markers and play an important role on oncogenesis in ALL.

**Background:** Recently, comprehensive genetic profiling of pediatric and adult core-binding factor (CBF) AML revealed a variety of cooperating events in a cohort of 85 t(8;21) AML patients (Faber et al. Nat Genet 2016). These mutations comprised alterations in genes encoding for proteins in tyrosine kinase (TK) signaling, epigenetic regulation (ER), and in the cohesin complex (CC).

**Aims:** To validate and to further extend our recent findings by comprehensive characterization of the mutational landscape of t(8;21) positive AML using a high-throughput targeted sequencing (HTS) approach.

**Methods:** The HTS panel comprised the entire coding region of 244 genes that are involved in hematological malignancies. Pretreatment blood (n=23) or bone marrow specimens (n=72) of 95 additional adult t(8;21) positive AML patients (pts) (median age: 51 yrs, range 18-72 yrs) were analyzed. 92/95 pts were enrolled in one of seven prospective AMLSG treatment trials. Libraries (total probes size: 1.359 Mbp) were prepared using SureSelectXT custom solutions (Agilent). Paired-end sequencing was carried out on a HiSeq 2000 (Illumina). The variant allele frequency (VAF) cutoff for reporting mutations was set at ≥0.05.

**Results:** The median coverage per pt was 900x. Mutations were detected with an average of 5.1 (SD: ±2.6) per pt with 99% of all pts harboring at least 1 mutation and 87% ≥ 3 mutations. Consistent with previous studies, mutations in TK signaling pathways were common events: KIT mutations were found in 22/95 pts (23%) followed by mutations affecting NRAS (16/95; 17%), FLT3 (11/95; 12%; point mutations only), and KRAS (4/95; 4%). A significant enrichment of mutations was also observed in genes involved in epigenetic regulation, ASXL1 (15/95; 16%), ASXL2 (12/95; 13%), KDM6A (11/95; 12%), CREBBP (8/95; 8%), SRCAP (8/95; 8%), EZH2 (7/95; 7%), SETD2 (5/95; 5%), TET2 (12/95; 13%) and DNMT3A (5/95; 5%), highlighting their contribution in altering the epigenetic state of this leukemia subtype. Moreover, mutations affecting members of the CC were found with a high frequency: RAD21 (13/95; 14%), SMC1A (5/95; 5%), STAG2 (3/95; 3%), and SMC3 (2/95; 2%). Of note, mutations in CC genes were almost mutually exclusive. We also identified additional mutations in previously detected cooperating genes such as mutations clustering in exon 2 of the ZBTB7A gene (15/95; 16%), encoding for a transcription factor involved in hematopoietic lineage fate. Recurrent mutations were also observed in C22Q2 (9/95; 9%), that plays an important role in regulation of hematopoietic cell proliferation, as well as DHX15 (6/95; 6%) being involved in spliceosome function and ribosome biogenesis. With respect to the clonal architecture we found that the median VAF in genes belonging to ER and CC (0.30; range 0.03-0.91; 0.31, range 0.05-0.73, respectively) was higher than in genes associated with TK signaling (0.19, range 0.05-0.53). These data suggest that alterations affecting the epigenetic state and differentiation occur earlier than those in signaling during t(8;21) leukemogenesis.

**Summary/Conclusions:** Using a comprehensive, deep sequencing approach we could further characterize the mutational landscape of t(8;21) positive AML. Here, mutation clusters in genes involved in TK signaling, ER and CC were confirmed as well as novel CBF-associated gene mutations that play an essential role in regulation of hematopoietic cell proliferation and differentiation. Further analyses in terms of sample size extension as well as correlation of findings with clinical parameters are ongoing.
Background: Mixed Lineage Leukemia’s (MLL’s) are characterised cytogenetically by reciprocal translocations of the MLL gene and clinically by unfavourable outcomes. Evidence indicating that MLL leukemia’s are resistant to apoptosis encourages the identification of novel drug targets.

Aims: Using cord blood (CB) CD34+ cells (control) and CB CD34+ cells expressing MLL-AF9, we sought to determine the potential role of BTK in the development and progression of MLL+ leukemia. Furtheraimed to uncover possible downstream target/s of BTK, improving the therapeutic efficacy of the drugs used.

Methods: Experiments were performed using control and MA9.3 cells and leukemic blasts from 3 AML (MLL+) patients. Signalling events were evaluated by immunoblotting, p65 mediated BTK expression was determined by promoter assays. Cells were treated with specific inhibitors of BTK (Ibritinib (IBR): 0.25, 0.5, 1.0 and 2µM) in combination with Daunorubicin (DAU 5nM) or RAC (NSC 23766 (NSC): 5, 10, and 20 µM) for 48 hrs and cell viability was assessed using Annexin V/Stytox-Blue based flow cytometric analysis.

Results: We identified a therapeutic target in MLL+ AML, we examined the whole cell lysates (WCL) from control cells, two clones of CB expressing MA9 (MA9.3 and δ6) and leukemic blasts from the 3 AML patients. Activated BTK (pY223) was detectable in both the clones of MA9 and MLL+AML samples. Interestingly, the cells demonstrated activation of p65 (pS536) but not in control cells. To address activated p65 p65 could potentially drive BTK expression, we performed BTK promoter assays with reporter construct and empty vector. MA9.3 cells electroporated with test construct demonstrated significantly higher transcriptional activity. At the protein level, p65 inhibitor treatment (MG132 or Bay 11-7082) reduced total BTK expression, indicating that activated p65 regulated p65 by activating BTK.

Treatment of control and MA9.3 cells with various concentrations of IBR for 48 hrs induced a dose-dependent reduction of cell viability (Annexin V and Sytox blue negative). We further sought to determine if the use of IBR in combination with Daunorubicin would further sensitize MA9.3 cells. The apoptotic rate of the cells in combination treatment was significantly, higher than that of cells treated with IBR or DAU alone. The coefficient of drug interaction (CIdi) values indicated that IBR-DAU combination synergistically reduced cell viability (CId >1.0-antagonistic; >1.0 synergistic and =1 additive effect). Recent studies suggested RAC-GTPase signaling may also represent a target in AML, particularly in the context of NCL leukemia. We previously (M. Costanzi et al., Blood Cancer J 2016) have shown that treatment with IBR-DAU combination synergistically reduced cell viability (CId >1.0-antagonistic; >1.0 synergistic and =1 additive effect).

Cytotoxicity and cell viability was further potentiated in combination with IBR (0.5µM). CDi values once again indicated that the drugs together have a synergistic effect on reducing the cell viability.

Summary/Conclusions: Taken together, our data support a biological link between NFkB, BTK and RAC pathways in the modulation of cell survival in MLL-rearranged AML cells. Aberrantly active p65 drives the expression of BTK and contributes to the progression of the AML. Combination treatment using IBR-DAU and IBR-NSC might be a promising therapeutic strategy, minimizing high drug dose-related side effects but increasing the therapeutic efficacy.

E867
SECRETION OF SOLUBLE FACTORS BY AML CELLS INFLUENCE CD3/CD3 BITE® ANTIBODY MEDIATED CYTOTOXICITY AND T-CELL Proliferation

M. Costanzi1,2,2, C. Krupka1,2, R. Kischel1, P. Kufner3, T. Köhnke1,2, K. Spiekermann2,2, W. Hiddemann2,2, M. Subklewe1,2,1,2,1

1Department of Internal Medicine III, Hospital of the Ludwig-Maximilians-University (LMU) Munich, 2AMGEN Research GmbH, Munich, 3German Cancer Consortium (DKT) and German Cancer Research Center (DKFZ), Heidelberg, Germany

Background: In our previous work, we showed that the CD3/CD3 BITE® antibody construct (AMG 330) is able to recruit autologous, residual T cells and induce cytotoxicity against primary AML cells ex vivo. However, as described previously (Mussai et al, Blood 2013) primary AML cells are able to secrete soluble factors, which might not only influence T-cell proliferation but also negatively impact AMG 330 mediated cytotoxicity.

Aims: In this study we characterized the influence of soluble factors secreted by primary AML cells on AMG 330 mediated cytotoxicity.

Methods: We used plasma samples (from heparinized serum tubes or after density gradient centrifugation) from newly diagnosed and relapsed AML patients in AMG 330 cocultures of healthy donor (HD) T cells and AML cell lines. In flow cytometry based experiments we determined the influence of AML plasma in comparison to fetal calf serum (FCS, heat inactivated) on AMG 330 mediated cytotoxicity and T-cell proliferation. In transwell experiments using primary AML cells physically separated from AMG 330 cocultures, we evaluated if AML cells are the source of soluable factor secretion.

Results: The influence of AML plasma from bone marrow (BM) of AML patients on AMG 330 mediated cytotoxicity and T-cell proliferation was heterogeneous: In 15/30 samples, AMG 330 mediated cytotoxicity was significantly reduced compared to cultures containing FCS (mean% specific lysis FCS vs BM: 27.8 vs 82.1, p<0.05). There was a significant reduction in T-cell proliferation (mean% proliferation FCS vs BM: 27.7% vs 9.5%). The degree of immunosuppression could not be correlated to percentage of bone marrow blasts. Interestingly, the effect was not observed in AML plasma samples from peripheral blood (PB) (mean% specific lysis FCS vs PB: 84.7 vs 83.5%; proliferation FCS vs PB 32.2 vs 21.5%, p< 0.05). In the remaining 15/30 AML plasma samples from AML BM no influence on AMG 330 mediated T-cell function was observed (mean% specific lysis FCS vs BM: 82.1 vs 78.3%; proliferation FCS vs BM: 25.7 vs 26.8%). In control cultures plasma from AML patients in complete remission (CR) or from HD BM was used which did not negatively impact AMG 330 mediated cytotoxicity (mean% specific lysis FCS vs CR: 76.6 vs 82.1; proliferation FCS vs CR: 76.6 vs 82.1%) and AMG 330 mediated T-cell proliferation (FCS vs CR: 76.6 vs 82.1; FCS vs HD: 58.9 vs 65.4%). To further explore the influence of soluble factors from primary AML cells, we performed transwell experiments. Primary AML cells were cultured in the previously described long term culture system (Krupka et al, Leukemia 2016) and HD T cells and MOL-M13 cells were placed in transwell devices (3µm). In analogy to our findings with AML BM plasma, we observed a strong reduction in AMG 330 mediated cytotoxicity and T-cell proliferation in 7/14 experiments (mean% specific lysis control vs AML: 95.0 vs 70.8%; proliferation control vs AML: 78.6 vs 62.1)
41.8, n=7). In the remaining 7 primary AML samples, no immunosuppressive effect was observed for specific lymphocyte control vs AML 98.9 vs 98.2% proliferation control vs AML 82.8 vs 77.7, n=7).

Summary/Conclusions: In summary we demonstrated that BM derived plasma from AML patients at primary diagnosis or relapse reduced T-cell proliferation and AMG 330 mediated cytotoxicity in half of the samples tested. The immunosuppressive effects were secreted by primary AML cells, identified by transwell experiments. Unraveling mechanisms of resistance to BiTE® antibody mediated cytotoxicity will allow the exploitation and usage of enhanced strategies to increase response rates.

**E868**

**CLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS**

L.K. Schmalbrock1, S. Coccard1, A. Dolnik1, M. Agrawal1, F. Theis1, N. Jahn1, T.J. Blaette1, V.I. Gaidzik1, P. Paschka1, W. Fiedler2, H. Salih2, G. Wulf2, U. Gerdes2, M. Lübbert2, F. Tho1, M. Heuser1, R.A. Larson9, A. Ganser1, R.F. Schlenk19, R.M. Stone10, H. Döhner1, K. Döhner1, L. Bullinger4

1Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, 2Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg, Hamburg, 3Klinik für Innere Medizin II, Universitätsklinikum Tübingen, Tübingen, 4Klinik für Hämatologie und Medizinische Onkologie, Universitätsklinikum Göttingen, Göttingen, 5Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, 6Klinik für Innere Medizin I, Universitätsklinikum Freiburg, Freiburg, 7Klinik für Hämatologie, Hämatoonkologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany, 8Department of Medicine and Comprehensive Cancer Research Center, University of Chicago, Chicago, IL, United States, 9Nationales Centrum für Tumorерkrankungen (NCT), Universität Heidelberg, Heidelberg, Germany, 10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

Background: Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in about 22% of patients (pts) with acute myeloid leukemia (AML) and confer a poor prognosis depending on the mutational load. The multi-targeted tyrosine kinase inhibitor (TKI) midostaurin has been shown to improve outcome in FLT3-ITD positive (FLT3-ITD(+) and FLT3-TKD(+) pts in combination with intensive chemotherapy [CALGB 10603 (RATIFY) trial], thus representing a promising targeted treatment approach. However, a significant number of pts relapse after initial response due to yet unknown mechanisms.

Aims: To study the clonal evolution in FLT3-ITD(+) pts treated in the AMLSG16-10 (NCT01477660) or CALGB 10603 (RATIFY, NCT00651261) trial in paired samples obtained at diagnosis (Dx), complete remission (CR) and relapse (Rel) by whole exome sequencing (WES).

Methods: WES was performed in 17 FLT3-ITD(+) pts using the Nextera Rapid Capture Exome kit (Illumina) for library preparation followed by sequencing on an Illumina HiSeq2000. 6 pts were treated in the RATIFY trial receiving either midostaurin or placebo combined with intensive chemotherapy during induction and consolidation and 11 pts were treated in the AMLSG16-10 trial. The treatment with midostaurin combined with intensive chemotherapy during induction and consolidation followed by a one-year maintenance therapy with midostaurin; 4 pts in the AMLSG16-10 trial received allogeneic hematopoietic cell transplantation. The presence of FLT3 and NPM1 mutations (mut) and the allelic ratio (AR) of FLT3-ITD were analyzed according to standard protocols. Results: The median AR of FLT3-ITD was 0.51 (0.10-18.94) and 0.54 (0.07-26.31) at Dx and Rel, respectively. Loss of FLT3-ITD was observed in 5 pts; changes of the ITD clone at Rel occurred in 7 pts. Of those, 5 pts had a change in the detection of recurrent mutational patterns.

**E869**

**MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO TARGETED THERAPY IN PRIMARY AML CELLS**

A. Dokal1, J. Gribben1, P. Cutillas2

1Haemato-Oncology, Barts Cancer Institute, London, United Kingdom

Background: The bone marrow stromal microenvironment (BMSM) plays an important role in the pathophysiology of acute myeloid leukemia (AML). This is demonstrated by primary AML blasts dependence on stromal conditioned media to survive long-term culture. Although some of the components of the stromal secretome (the totally secreted proteins by biological cells) that augment AML survival are known, the specific molecular mechanisms of the stromal-blast interactions are not fully defined.

Aims: (i) Identify proteins secreted by bone marrow stromal cells that mediate AML survival (ii) Investigate global changes in signalling pathway activity induced by stromal factors in primary AML; (iii) Validate the functional significance of these interactions through targeted inhibition of BMSM activated signalling pathways.

Methods: We used primary AML cells and established cell lines. Four different human AML lines were grown individually or in co-culture with a mouse bone marrow stromal line (MS-5). The resulting conditioned medium from these experiments (4 AML lines alone, 4 AML lines + MS-5, MS-5 alone) was purified to obtain the stromecrine (in tritrate). Proteins in these secretomes were quantified using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Peptide sequence searches against both mouse and human proteomes allowed for discrimination between the mouse stromal and human AML proteins. Guava EasyCyte Flow Cytometry was used to measure the viability and proliferation of these cell populations, assessing the capabilities of the identified factors above on primary AML cells (n=6) as well as the effects of kinase inhibitors: midostaurin, Trametinib and Mirtuxstatin over 72hrs with and without stromal conditioned media (n=10). Label-free LC-MS/MS based phosphoproteomics quantified >5,000 phosphorylation sites in primary AML patient cells treated with identified stromal factors individually and combined in triplicate. Commercial (MASCOT) and in-house (PESCAL, KSEA) software were utilized to identify and quantify proteins, determine kinase activities and interpret intracellular signalling.

Results: Initially by comparing secretomes of the four AML lines (on their own or in MS-5 co-culture) we identified 520 bone marrow stromal proteins and 293 AML blast proteins. From these, six stromal proteins were selected (including CTGF, CCL4, VEGFA, CCL2 and CSF2) and bone morphogenic protein-1 (BMP-1) because on their ability to effect growth and likely signalling capacity in AML cells. These six proteins were used in varying combinations to determine their effect on growth of primary AML cells from patients (n=6). We also analysed the phosphoproteomes of primary AML cells displaying the maximal effects on growth in response to the six factors above to determine the underlying biological mechanisms. These studies have shown that several different pathways are activated as a result of secretome treatment including mTOR and MAPK. Primary AML cells were sensitive to targeted inhibition of these pathways. However, the inclusion of stromal secreted factors to the same AML cells would induce sensitivity towards another kinase inhibitor and insensitivity towards the previously effective inhibitor.

Summary/Conclusions: This proteomic approach has allowed identification of a panel of key proteins (including S100-A11, CTGF, BMP-1) secreted by the stromal cells that modulate cell signalling and cell fate in AML blasts. Using a multi-parametric approach to study global protein effects, we were able to dissect specificity of effect on AML signalling. Subsequent survival assays and targeted inhibition studies demonstrate that despite heterogeneity in patient response to these factors, key signalling pathways such as MAPK and mTOR switch under stromal influence. These observations suggest that resistance to targeted therapies in vivo in part may arise from changes that AML cells induce in the microenvironment.
University of Chicago, Chicago, IL, United States, 1National Centrum for Tumorerkranungen, Universität Heidelberg, Heidelberg, Germany, 10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

Background: Internal tandem duplications (ITD) and mutations (mut) in the tyrosine kinase domain (TKD) of the receptor tyrosine kinase FLT3 occur in about 25% of acute myeloid leukemia (AML) patients (pts). FLT3-ITD is associated with an unfavorable prognosis in particular in pts with a high allelic mutant to wildtype ratio (AR>0.5) as well as localization of the ITD in the beta1-sheet of the receptor. FLT3is targetable by tyrosine kinase inhibitors (TKI) and the combination of chemotherapy with the TKI midostaurin has been recently investigated within the CALGB 10603 RATIFY trial and is still under investigation within the AMLSG 16-10 trial.

Aims: To study the FLT3mut status at the time of diagnosis (Dx), refractory disease (RD) and relapse (Rel) in AML pts treated within the CALGB 10603 (RATIFY) and AMLSG 16-10 (NCT01477606) trial with regard to AR of FLT3-ITD and FLT3-ITDmut, loss of FLT3-ITD and FLT3-TKDmut and change of ITD clones (ITD insertion site, length, number of clones).

Methods: FLT3-ITD and FLT3-TKDmut were detected using Genescan-based fragment-length analysis according to standard protocols. In the randomized phase-III RATIFY study, FLT3mut pts were treated with induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) and maintenance therapy in FLT3-ITD positive pts.

Results: In total, 83 pts were analyzed, of which 33 were treated in the RATIFY and 50 within the AMLSG 16-10 trial. 36 pts had RD and 47 pts had relapsed. FLT3-ITDwas present at diagnosis in all pts treated in the AMLSG 16-10 trial; one pt had an additional FLT3-TKDmut. Pts entering the RATIFY trial had either a FLT3-ITDmut (n=22), a FLT3-ITDmut(n=9), or both (n=2). The median AR of FLT3-TKDmut at Dx was 0.82 (0.07-2.66) and the majority of pts showed loss of FLT3-TKDmut at RD or Rel (n=9/12; 75%). In relapsed pts, loss of FLT3-ITD occurred in 14 (36%) pts. There was no significant difference between the median FLT3-ITD AR at Dx [0.82 (0.10-10.94)] and Rel [0.65 (0.07-10.75); p=0.98]. A shift of the ITD insertion site or length in 8 (21%) pts. 8/14 pts with change of the ITD clone at Rel had multiple ITD clones at Dx. For 35 FLT3-ITDPositive pts with refractory AML, FLT3-ITD loss was observed in 17 (49%) pts. The median AR of FLT3-ITD was significantly lower at the time of RD [0.29 (0.05-2.97)] compared to Dx [0.85 (0.05-9.91); p<0.002]. The ITD clone changed in 5 (14%) pts with RD. In pts with shift of the ITD clone at Rd (n=5) or Rel (n=14), no significant difference of the median ITD length was observed (p=0.84).

Summary/Conclusions: Comparing the FLT3-ITD status at Dx, at the time of RD or Rel, we found a lower median AR of FLT3-ITD in pts at RD compared to Dx, whereas no significant change of AR was observed at Rel. In addition, loss of FLT3-ITD was observed in 49% of pts at RD and in 36% of pts at Rel. These findings suggest that the FLT3-ITD clone can be targeted in a significant number of pts and other clones might mediate resistance to treatment. We also observed a switch of the ITD clone in about 20% of pts with Rel, indicating the presence of ITD clones that might provide resistance to chemotherapy-based treatment. Despite the small number of TKD mutations in our study, it was remarkable that most of the TKDs (75%) were lost at the time of RD or Rel.

E871

A NOVEL PML-RARA FUSION IN ACUTE PROMYELOCYTIC LEUKEMIA

Methods: Whole genome sequencing (WGS) and further analysis of mRNA and gDNA were performed to clarify the atypical gene rearrangement observed by karyotyping and FISH.

Results: Laboratory and immunophenotypic analysis results suggested the classic APL with hypergranular type. A clonal translocation t(12;15)(q13;q22) was identified by karyotyping. No evidence of fusion of PML-RARA was detected by RT-PCR and PML-split was found on FISH analysis using PML-RARA dual color dual fusion probes. WGS analysis performed to clarify the partner gene of PML located on chromosome 12q13 strongly suggested a PML-RARG fusion. RT-PCR following sanger sequencing were performed to verify the presence of PML-RARG fusion transcript, then two kind of transcripts was detected, one with the fusion of PML exon 3 and the middle part of exon 1 of RARG and the other with the fusion of PML exon 3 and exon 2 of RARG. The breakpoint of the DNA was clarified on intron 3 of PML and 5' region of RARG. Despite of ATRA treatment for 9 days, cell count did not show any response. Then induction chemotherapy composed of idarubicin and cytarabine was combined on ATRA. ATRA was finally stopped after 18 days, then cytogenetic remission was acquired day 36 after induction therapy.

Summary/Conclusions: We first report the presence of PML-RARG fusion in a human APL patient. This report supports the possibility of a new molecular mechanism involving RARG not RARA in APL and suggests the need of different therapeutic approach for this variant case showing the potential ATRA resistance.
bone marrow microenvironment (BM). Survival of patients with AML is presently poor, two-thirds of younger adults, and 90% of older adults die of their disease. Even in patients who achieve remission with chemotherapy, relapse is common and occurs from minimal residual disease sequestered in protective niches in the BMM. Reciprocal interactions between that of the AML and bone marrow mesenchymal stromal cells (BM-MSC) are central to the survival and proliferation of blasts through the provision of quiescence in malignant cells as well as the activation of anti-apoptotic and pro-survival pathways.

Aims: To investigate how BM-MSC are programmed by AML to generate a pro-tumoral environment.

Methods: Primary AML and BM-MSC were isolated from the pelvis of AML patients following informed consent and under approval from the UK National Research Ethics Service (LRCEref07/H0310/146). Low input RNASeq of 10 AML BM-MSC and 10 healthy BM-MSC (taken from the pelvis of patients undergoing elective hip replacement surgery) was performed following CD271 MicroBead selection. Primary AML and BM-MSC were co-cultured in confluent primary BM-MSC for 48 hours (h), 72h and 168h. Real-time PCR was used to verify the RNA sequencing data and Western Blot analysis to confirm protein expression.

Summary/Conclusions: We have identified that AML induces a senescent BM-MSC niche via the p21 mediated pathway which in turn promotes survival and proliferation of AML. Silencing of p21 within the BM-MSC reduces AML survival. In identifying this novel microenvironment feedback loop in AML we highlight a potential new target for future AML therapies.

E875 BONE MARROW ECOCOLLOPHIC ACIDIFICATION IN ACUTE MYELOID LEUKAEMIA IS MEDIATED BY REMODELING OF ENDOSTEAL VESSELS

D. Duarte1,2,*, E.D. Hawkins1, O. Akinduro1, H. Ang1, K. De Filippo1, M. Hall11, N. Ruivo1, T.S. Weber4, R. Khorshed1, C. Pirillo1, S. Ramasamy2, E.L. Purton6,7, K. Duff4, R.H. Adams8, L.M. Carlin3,9, C. Lo Celso1,2

1Department of Life Sciences, Imperial College London, 2The Francis Crick Institute, 3National Heart & Lung Institute, Imperial College London, London, 4Monash University, Victoria, 5Hammersmith Women’s and Children’s Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom, 6Eijkelkamp Science and Technology, 7Institute of Clinical Sciences, Imperial College London, London, United Kingdom, 8Department of Radiology, The University of Melbourne, Fitzroy, Australia, 9Max Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Munster, Germany, 10Cancer Research UK Beatson Institute, Glasgow, United Kingdom

Background: Bone marrow vascular niches have been proposed to support acute myeloid leukemia (AML) growth. However, anti-angiogenic therapies do not improve patient outcome suggesting that a complex relationship between AML cells and the microenvironment influences the disease process.

Aims: To study the complex vascular remodelling occurring during AML progression.

Methods: Using a murine model of AML we performed intravitral microscopy to study the progression of leukemia behavior in the bone marrow.

Results: We show AML is an invasive species causing highly localized disruption of the endosteal stroma and outcompeting non-malignant cells. Particularly affected are endosteal microenvironments containing osteoblastic cells and type H endothelium, typically associated with hematopoietic stem cells (HSCs). Inhibiting the invasive osteoblastic cells expand, suggesting de novo niches in the spleen could potentially support extramedullary hematopoiesis in leukemia. Intravitral microscopy further revealed that the endothelium in AML is more adhesive and permissive to transendothelial migration of hematopoietic cells. Pharmacological intervention known to induce type H endothelium preserved HSCs in endosteal areas was shown to limit disease.

Summary/Conclusions: Together, these data suggest that AML-induced vascular damage contributes to cell egress from the bone marrow, and that new therapeutic approaches aiming to normalize bone marrow vasculature may support normal hematopoiesis.

E876 CLONAL HETEROGENEITY IN PATIENT-DERIVED XENOGRAFT OF ADULT ACUTE MYELOID LEUKAEMIA

F. Gonzales1,2, P. Peyrouze2, T. Boyer3, S. Guillard2, N. Helevault1, J. Preudhomme3, S. Geoffroy3, C. Roumier2,3, R. Quesnel2,4, B. Quesnel2,3, C. Dehau2,3, M. Cogné2

1Service d’hématologie pédiatrique, CHU Lille, 2UMR-S 1172, Inserm, 3Laboratoire d’hématologie, 4Service des Maladies du Sang, CHU Lille, Lille, France

Background: Acute myeloid leukaemia (AML) is the most common leukaemia in adults. Currently, despite intensive chemotherapy and bone marrow transplantation, outcome is still dismal. In particular, therapeutic stratification remains suboptimal, which is largely attributed to the clinical and molecular heterogeneity of AML.

Aims: To better characterize and study this heterogeneity, we developed an in vivo model of AML using patient derived xenografts (PDX).

Methods: 18 out of 45 injected samples (40%) successfully engrafted into NOD-scid gamma (NSG) mice. Engraftment was surveyed by chimerism of CD45 (human versus murine) by flow cytometry. At sacrifice (peripheral blast count greater than 70% or clinical sign of illness), cells collected from bone marrow and spleen were used to perform targeted sequencing (AmpliSeq, Thermo Fisher Scientific) and gene expression analyses (HG-U133 Plus 2.0 microarray, Affymetrix). Bone marrow cells were serially transplanted into secondary and tertiary animals. We then compared mutational and gene expression profiles of patient samples at diagnosis and corresponding PDX samples.

Summary/Conclusions: Eighteen out of 45 injected samples (40%) successfully engrafted into mice with a median delay of 2.5 months (range: 26-154 days). Leukaemia infiltration into bone marrow was concordant with peripheral blood and spleen infiltration. Successful xeno-engraftment was linked to younger age (50 vs 61 years, p=0.04) and elevated white blood cell counts at diagnosis (132 vs 35 G/L, p=0.001). No association was found between engraftment and karyotype or ELN classification. Relapse free survival (RFS) was worse for patients with successful PDX (0.3 vs 0.9 years, p=0.017). Despite previous reports suggesting better engraftment of AML harbouring FLT3-ITD mutations, we did not find
Background: BiTE® antibody construct, blinatumomab, has previously been shown to demonstrate high activity against B33 cells and the AML cell line MOLM-13 was evaluated by flow cytometry and phospho-flow cytometry protocol for T-cell recruiting antibodies. AMG 330 mediated cytotoxicity against MOLM-13 cells (mean MFI Ratio of CD80 and CD86 on MOLM-13 67.6). However, at lower E:T ratios (1:4) the additional costimulatory signal also increased AMG 330 mediated cytotoxicity against MOLM-13 cells (mean MFI Ratio of CD80 and CD86 on MOLM-13 67.6). How- ever, even in the absence of additional B7 molecules, AMG 330 mediated cytotoxicity against B33 cells was restored (% specific lysis AMG 330 vs CD86 on MOLM-13 cells from healthy donors and patients with AML. Furthermore, we will analyse the phosphorylation pattern within different T cell subsets and upon knock out of B7 molecules in T cells. Our results will contribute to the understanding of BiTE® mediated activation of T cells, which is a prerequisite for clinical responses.

E878

ESTABLISHING SINGLE CELL WHOLE EXOME SEQUENCING ANALYSIS AS A DISCOVERY TOOL IN NPM1/FLT3 POSITIVE PEDIATRIC ACUTE MYELOID LEUKEMIA

C. Walter1,*, C. Pozzorini2, R. Geffers3, H. Hanenberg1, Z. Xu3, N. von Neuhoff4, D. Reinhardt

1Department of Pediatrics III, University Children’s Hospital Essen, Essen, Germany, 2Sophia Genetics, Saint Sulpice, Switzerland, 3Helmholtz-Zentrum für Infektionsforschung GmbH, Braunschweig, Germany

Background: AML is a rare hematological disorder in children and adolescents caused by distinct genetic aberrations, which are relevant for leukemogenesis, prognosis and therapy. Although major players in the molecular landscape and clonal evolution of AML have been identified in adults, it remains a major technical challenge to genetically characterize the few leukemic stem cells (LSCs) cells against a noisy background of AML blasts and normal hematopoietic cells. Aims: The aim of this study was to establish a simple workflow for reliable single cell sequencing analysis of single AML pediatric patients with AML, where often limited research material is available.

Methods: For three pediatric AML patients with mutations in the genes NPM1 and/or FLT3, we performed single cell sorting for CD34+ CD38- AML blasts by FACS and subsequently whole genome amplification (WGA) using the REPILE single cell DNA kit (Qiagen). The amplified single cell DNA and additional DNA of the corresponding bulk bone marrow was analysed by exome sequencing (WES). Bulk DNA was additionally evaluated by an ampiclon-based sequencing approach targeting 54 genes (TruSight Myeloid Panel, Illumina) associated with myeloid malignancies.

Results: The analysis revealed that the median read coverage obtained in the WES of the five DNAs amplified from the single CD34+ CD38- cells and in the corresponding bulk DNAs from the bone marrow of all three patients was comparable for three out of the five single cells. For three amplified single cell genomes, between 92 and 98% of all reads could be mapped to the human genome, however the median coverage for the two failed single cells was 0. For validation of the WGA quality from single LSC DNA, data from 50 out of 54 genes analyzed by both sequencing approaches, WES and TSM Panel, were available for all three patients. The majority of variants detected in the WES bulk data could consistently be found at a comparable variant frequency in the TSM panel data. The variant frequencies in the single cell data from WES were more variable and more variants could not be detected in the TSM panel data derived from bulk DNA. We were able to detect n=79 (66%) out of n=121 somatic variants (SNVs, InDels) present in the patients’ AML blasts with all three sequencing approaches. WES readily identified n=102 (85.1%) and n=93 (78.9%) of all n=121 variants in the bulk and single cell DNA, respectively. Only n=4 (3.3%) variants were not detected by WES at all. We were able to retrace the NPM1 and FLT3 mutations for each of the three patients in the targeted sequencing approach. However the NPM1 mutations and one FLT3 ITD could not reliably be called in the WES approach due to insufficient coverage.

Summary/Conclusions: WES of amplified single cell DNA is an excellent discovery tool also in pediatric AML for detecting unique changes in potential LSCs that should be validated by targeted sequencing approach with sufficient read counts for finding of rare events.

E879

RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA

V. Caraffini1,*, S. Schauer2, K. Kaschofer2, A. Wöllfer1, G. Hoeffer2, H. Sill1, A. Zebisch1

1Division of Hematology, 2Institute of Pathology, Medical University of Graz, Graz, Austria

Background: Myeloid sarcoma (MS) is a subgroup of acute myeloid leukemia (AML), where leukemic cells invade non-hematopoietic tissues and form solid tumors. It may occur as isolated event or simultaneously with leukemic infiltration of the bone marrow (BM). Loss of RAF kinase inhibitor protein (RKIP), a negative regulator of RAS signaling, has recently been described as a frequent event in AML and to be functionally involved in leukemogenesis. Although RKIP has been shown to inhibit the formation of metastases in solid tumors previously, its role in the development of MS is currently unknown.

In this study, we aimed to delineate the role of the metastasis-suppressor RKIP in the development of MS.

Methods: RKIP protein and mRNA expression was evaluated in formalin-fixed paraffin-embedded biopsies of MS and BM by immunohistochemistry and quantitative real-time PCR (qPCR). Sequence analysis of MS biopsies defined as MS positive and MS negative MS samples was performed using Ion Torrent Next Generation Sequencing (NGS). For functional assays, both RKIP overexpression and knockdown was performed in THP-1 AML cells by lentiviral transduction of a FLAG-tagged RKIP expression construct and by RKIP shRNA, respectively. Subsequently, these cells were tested in migration and invasion assays using transwell methodology.

Results: This study comprised 14 patients with MS (MS-group) and 14 patients with AML without any evidence of extramedullary involvement (BM-AML group). Of the 14 cases within the MS-group, MS occurred as isolated event in three cases and concomitantly with systemic AML in eleven cases. Both groups were age- and sex-matched and clinical as well as laboratory values were comparable between them. Most importantly, however, when we measured the protein expression of RKIP in leukemic tissues of these patients (MS biopsies in the MS-group and leukemic BM biopsies in the BM-AML group), we observed a
significant increase of specimens exhibiting loss of RKIP expression in the MS
group (7/14 vs 1/14, P=0.0329). Interestingly, RKIP loss in MS specimens of
cases with concomitant systemic AML was also present in the corresponding
leukemic BM samples, thereby excluding a geographical clonal heterogeneity
during MS formation in respect to RKIP expression. We then analyzed RKIP
mRNA levels by qPCR and observed that RKIP loss correlated with decreased
expression of its mRNA (P=0.041). To gain more insight into the molecular
landscape of MS patients with and without RKIP loss, we performed NGS of
39 genes that are recurrently mutated in AML. Interestingly, five out of six (83%)
MS patients with RKIP loss demonstrated mutation(s) affecting the RAS-path-
way, suggesting a potential functional synergism between these events. Con-
sequently, we performed a time-overexpression and knockdown of RKIP in the
in AML; because of alvocidib’s inhibition MCL-1.

Aims: We hypothesized that MCL-1 transcriptional repression constitutes the pri-
mary mechanism for the synergism observed with the ACM treatment regimen.

Methods: Follow up treatment, cell viability and caspase activation, an indicator
of apoptosis, were assessed using CellTiter-Glo and Caspase-Glo assays,
according to manufacturer protocol. mRNA levels were assessed using RT-
PCR. Protein levels were assessed using standard immunoblotting technique.

Results: In this study, we demonstrate that treatment with alvocidib, followed
by treatment with cytarabine and mitoxantrone, synergized in vitro and correlated
with the downregulation of MCL-1 protein and mRNA expression. Indeed, the
AML regimen resulted in a 2.4 or 3.4-fold increase in caspase activity relative
to any single agent within the combination in M4-11 or OCI-AML3 cells, respec-
tively. As has been previously reported, we also observed that increased activity
of cytarabine in alvocidib-treated cells corresponded with progression into the
S-phase of the cell cycle, following the washout of alvocidib. However, this
observation accounted for only a small portion of the inhibition of cell prolifera-
tion. This was further confirmed by the observation that CDK4/6 (cell cycle)
specific inhibitors, such as palbociclib, did not show synergistic increases in caspase
activity following treatment in the same setting. In various AML cell lines treated
with MCL-1 siRNA, followed by cytarabine and mitoxantrone treatment, we also
observed a synergistic increase in the inhibition of cell proliferation.

Summary/Conclusions: Considering our earlier work showing that MCL-1
dependence predicts AML patient response to the ACM regimen, we propose
that MCL-1 repression is the primary mechanism of alvocidib’s clinical activity.
As MCL-1 also confers resistance to cytarabine, the current study provides
additional rationale for the inclusion of alvocidib in the treatment of AML, and
in the AML regimen specifically. Taken together, this data suggests that the
AML regimen may be an effective regimen in treating patients with high-risk
AML, because of alvocidib’s inhibition MCL-1.

E881
BY AN MCL-1-DEPENDENT MECHANISM, ALVOCIDIB POTENTIATES THE
ACTIVITY OF CYTARABINE AND MITOXANTRONE WHEN ADMINISTRED IN A
TIME SEQUENTIAL REGIMEN IN AML
H. Hawes1, M. Livingston1, W. Kim1, R. Mangelson1, A. Siddiqui-Jain1, P. Peterson1,
C. Wharton1, S. Weitman1, D. Bears1, S. Warner1

1Discovery Biology, Toleranso Pharmaceuticals, Inc., LEHI, United States

Background: Treatment with alvocidib has shown significant improvements
in the complete remission rates in newly diagnosed acute myeloid leukemia
(AML) patients when administered before cytarabine and mitoxantrone (ACM
regimen) in a randomized Phase 2 study compared to 7+3. Although the mechan-
ism of alvocidib action as a single agent is documented, the mechanism
underlying synergy found in the ACM regimen is not fully understood. The ACM
regimen was originally developed based on the perceived benefit of a time-
sequential regimen starting with cell-cycle arrest (alvocidib), followed by release

E880
INHIBITING MIR-10A OVERCOMES CYTARABINE-RESISTANCE IN ACUTE
MYELOID LEUKAEMIA
T.T. Vu1,2, K. Wang1, F. Slizic2, G. Ehninger2, T. Molloy1, D. Ma1

1Haematology, Vincent’s Hospital, Sydney, Australia, 2Medical Clinic and
Polyclinic I, University Hospital ‘Carl Gustav Carus’, Dresden, Germany

Background: Chemoresistance is the principle cause of treatment failure in acute
myeloid leukaemia (AML) despite a promising response to induction chemotherapy.
Emerging evidence suggests the roles of autophagy, a self-
eating process contributing to chemoresistance of leukaemia cells. We previ-
ously demonstrated that miR-10a, highly expressed in a subgroup of AML har-
bourning Nucleophosmin1 mutations, promotes cell survival by inhibiting non-
canonical cell death pathway, suggesting its function in autophagy and thus chemoresistance in AML.

Aims: We aim to demonstrate evidence that miR-10a, a regulator of autophagy,
plays important roles in chemoresistance in acute myeloid leukaemia.

Methods: Apoptosis and proliferation in miR-10a inhibited and overexpressed
leukaemia cells after cytarabine treatment was measured by Annexin V binding and
MTT assay. Autophagy was measured by monitoring the levels of LC3I/LC3II proteins, autophagy-related proteins via Western Blotting and mono-
dansyl-cavaradine (MDC) staining (flow cytometry).

Results: First, we observed a decreased expression of miR-10a in the leukaemia
cells after the exposure to stress induced by serum starvation. Overexpressing
miR-10a in miR-10a low MV4-11 cells decreased apoptosis induced by nutrient
starvation and resulted in the resistance to cytarabine. In contrast, its inhibition
in OCI-AML3 cells, which express high miR-10a constitutively, resulted in the
induction of apoptosis and increased chemosensitivity towards cytarabine. miR-
10a was shown to directly downregulate key members of the p53-mediated

tumour suppressor gene network, including the CDKN1A (p21) inhibitor tran-
scription Factor AP2-gamma (TFAP2C). The inhibition of either miR-10a itself or
CDKN1A by siRNA treatment inhibited autophagy induced by serum starvation,
treatment with autophagy inducer,mg132 or p53 stabiliser, Nutlin3a.

Summary/Conclusions: The data suggests miR-10a as an important regulator
of autophagy and apoptosis as a modulator of the p53-p21 tumour suppressor signaling axis in
subtypes of AML. It also emphasizes the significance of autophagy in
chemoresistance in AML, supporting the targeting of the autophagy pathway
as a potential therapeutic approach for AML.

E882
DYSREGULATION IN KEY REGULATOR GENES OF AUTOPHAGY AS A
MECHANISM OF THERAPY RESISTANCE AND POOR PROGNOSIS IN
ACUTE MYELOID LEUKAEMIA (AML): RESULTS FROM MICROARRAY
ANALYSIS ON 148 PATIENTS
M.C. Fontana1,2, G. Marconi1, C. Papayannidis2, G. Simonetti2, A. Padella2,
E. Ottaviani2, A. Ferrari2, E. Franchini2, N. Testoni2, C. Baldazzi2, S. Lo Mona-
co2, S. Paolinì2, M.C. Abbenante2, J. Nanni2, L. Bertamini2, G. Martinelli2

1Department of Experimental, Diagnostic and Specialty Medicine, 2University
of Bologna, Bologna, Italy

Background: To date, there are no clear evidences if autophagy can lead to
therapy resistance or favor apoptosis in cancer. Autophagy can function as a
pro-apoptotic mechanism, or can improve stresses survival clearing damaged
mitochondria and proteins accumulation. Levels and activity of pro-apoptotic
and anti-apoptotic proteins, particularly BCL-2 and p53, high levels of CAMP,
and a complex made by PINK/PARK could play as fulcrum of this yin and yang
effect of autophagy.

Aims: Our study aims to define the role of PI3P pathways in AML, and to estab-
lish if autophagy could reduce the patients’ chance to respond to induction,
and to worsen OS.
patients, we perform Microarray-based High-Throughput Technology with Affymetrix SNP array 6.0 or Cytoscan HD. Survival data were collected prospectively from the time of diagnosis, with a median follow-up of 18 months. Survival analysis was performed with Kaplan Meyer method using log rank test. Univariate and multivariate regression and Cox Hazard Ratio (HR) model were performed. Correlation between variables was assessed with Fisher’s exact test. Results: Autophagy alteration (gene group 1: 12/147; 8.1%) and 2/147 (1.4%) had only minimal expression changes in the autophagy pathway. The MS PCR analysis system proved that 23 t-AML cases, and found all were MS stable. Summary/Conclusions: The absence of even a single MS case within this large cohort provides strong evidence that MS is non-existent in AML.

**E884**

**SY-1425, A POTENT AND SELECTIVE RARA AGONIST, REPROGRAMS AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES, UNCOVERING PD MARKERS FOR CLINICAL STUDIES**

Background: SY-1425 (famibatorbene) is a potent and selective agonist of the retinoic acid receptor alpha (RARα) transcription factor (TF), currently in a bio- clinical phase 2 Clinical trial in AML and MDS (NCT02807558). A subset of AML and MDS has been found to have RARα pathway activation characterized by a large enhancer at the RARα locus (RARα-high) and/or upregulation of IRF8, a TF associated with RARα signaling, forming the basis of SY-1425 as a sensitive tumor identification.

Aims: We sought to understand how SY-1425 agonism of RARα acts to promote maturation and halt proliferation of AML blasts locked into an immature cell state by the cancer circuitry. This characterization could further inform clinical pharmacodynamics markers.

Methods: We analyzed the epigenomic and transcriptional landscape of 66 non-APL AML patients and normal primary myeloid cells by RNA-seq and ChiP-seq for the enhancer marker H3K27ac. AML cell lines were profiled by RNA-seq, ChiP-seq for H3K27ac and RARα, and ATAC-seq with or without SY-1425 treatment. Cell surface marker changes were assessed by flow cytometry.

Results: A subgroup of the patient samples was defined by an SE driving RARA, which co-occurred with SEs driving FOS and JUNB, or IRF8, FOS and JUNB form the AP-1 heterodimeric TF known to promote an immature cell state and the interferon regulatory factor 8 (IRF8) pathway has been implicated in AML pathogenesis. Previously reported crosstalk between IFN and retinoic acid signaling was supported by the strong induction of interferon gene sets by SY-1425 in IRF8-high AML models. We found that each AML cell line had distinct compositions of lineage factors consistent with cancer initiation from different stages of myeloid development. SY-1425 induced differentiation features associated with monocytic, macrophage, dendritic, and granulocytic cell types. While APL has been directed and granulocytic differentiation, we found that RARA/IRF8-high AML could follow multiple differentiation paths depending on the initial state of the AML model, necessitating different marker panels to capture full cell typing. Functional validation confirmed surface marker changes consistent with the observed epigenomic alterations including CD11b, CD11c, CD68, and CD38 upregulation. We integrated epigenomic data, DNA accessibility, and SY-1425 response to understand RARα agonist perturbation to cell circuitry. Enhancer elements directly bound by RARα were associated with SY-1425 as were enhancers bound by other TFs involved in myeloid differentiation. The accessibility of RAR elements and IRF motifs were increased and their associated TFs were upregulated. The target genes of known immuno-potentiator sensitive state drivers, such as RUNX1 and CEBP, were downregulated. Importantly, the FOS/JUN circuit, identified as a component of the oncogenic RARα circuit in patient samples, was found to be suppressed.

Results/Conclusions: As in normal myelopoiesis, RARα and RARβ associated cell state TFs play a critical role in the differentiation of AML. SY-1425 perturbation of this circuitry leads to differentiation toward multiple potential lineage pathways depending on the initial state of the cancer. These pharmacodynamic changes can be assessed clinically and combined with common AMLMDS clinical markers of blood and marrow aspirate smears or white cell differentials, to support the differentiation mechanism of action and offering the potential for early biologically relevant data to inform current and future clinical studies.

**E885**

**GENETIC CHARACTERIZATION OF A LARGE GROUP OF CEBPA MUTATED AML PATIENTS AND THE EFFECT OF TET2 AND GATA2 MUTATIONS ON OUTCOME**

N.P. Konstandin1,2, F. Pastore1, A. Dufour1, K.H. Metzeler3, M. Rothenberg-
Methods: Targeted amplicon resequencing (Agilent Haloplex, target region: 364 kb) was used to analyze 42 target genes or hotspots known to be mutated in AML; and other hematologic neoplasms.

Results: In 48 biCEBPA and 32 moCEBPA we found mutations in 20 and 26 different genes respectively. MoCEBPA pts had significantly more additional mutations compared to biCEBPA pts (mean: 3.9±1.7 vs 2.2±1.5; p<0.001). We also compared the mutational profile of moCEBPA and biCEBPA pts with a collection of 120 AML pts. In moCEBPA pts the frequency of mutations in ≥5% were significantly associated with one or more groups. We confirmed the mutual exclusiveness of biCEBPA and NPM1 and the association between GATA2 and biCEBPA (35.4%). TET2 was frequently mutated in both mo-(43.8%) and biCEBPA pts (41.7%), but not in wtCEBPA (16.3%; mo- vs wtCEBPA p<0.01; bi- vs wtCEBPA p<0.01). Mutations in TKD1 or T2KD of FLT3 were frequently identified in moCEBPA (25%) and wtCEBPA (17%) but not in biCEBPA pts (2.1%). The FLT3-TKD1/2 mutation frequency in biCEBPA significantly differs from moCEBPA (p=0.002) and wtCEBPA (p=0.004). There was a significant difference in the frequency of FLT3-TID in biCEBPA (20.8%) vs wtCEBPA (5.4% of Haem-mo.009) but not in comparison to moCEBPA (43.8%). IDH2 was found mutated only in wtCEBPA (21.6%) and moCEBPA (18.8%). In 48.8% of wtCEBPA pts DNMT3A was mutated, this significantly differs from biCEBPA pts (14.3%; p<0.001) but not from moCEBPA patients (28.1%). C5R3 was frequently mutated only in biCEBPA (10.4%) but not in wtCEBPA (0.35%; p<0.01) or moCEBPA (3.1%; ns). STAG2 was associated with moCEBPA (25%), while STAG2 mutations were significantly less frequent in biCEBPA (6.3%; p<0.01) and wtCEBPA pts (6.27%; p=0.002). TET2 mutations had a negative prognostic impact on overall survival (OS) in biCEBPA pts, but not in wtCEBPA pts. In biCEBPA pts CD25 level only in control cells. Since high pSYK is associated with overexpression of MYC and increased expression of MYC and its targets that drive mitochondrial biogenesis is a characteristic feature of LSC, we hypothesized that R406 depletes LSC by reducing mitochondrial biogenesis/oxidative phosphorylation (OXPHOS). In TEK and primary CD34+ AML blasts, R406 reduced expression of MYC, transcription factors associated with mitochondrial biogenesis (NRF1, TFAM, EF-Tu, NRF2), and lowered cellular mitochondrial mass.

Summary/Conclusions: Taken together, we found that SYK inhibition obviates differentiation arrest induced by ERK activity, and reduces clonogenic potential via decreased STAT5 activity. Moreover, we show that pSYK is required to sustain MYC expression and mitochondrial biogenesis/OXPHOS, a key features of LSC in AML.

This work was supported by NCN grant#2013/11/N/ZN5/03704.

E887

MUTATIONAL PROFILE OF RELAPSE-RISK GROUPS IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

M. Prieto-Conde1, M. Alcocer1, C. Jiménez2, M. Garcia-Ávarez1, M.E. Sarasquete1, A. Balazán-Tejul1, R. Corral1, L. Marín1, F. Ramos2, A. Godoy2, A. Bárez4, M. González2, R. García2, G. Barajas2, A. Bárez3, A. Godoy2, A. Bárez4, B. Ksienzyk1, S. Tschuri1, W.E. Berdel4, W. Hiddemann1,2,3, B.J. Wörmann5, C. Sauerland6, J. Braess7, B.K. Stefan8, W.E. Berdel4, W. Hiddemann1,2,3.

1Hematology Department, University Hospital of Salamanca-IBSAL, SALA-MANCA, 2Hematology Department, Hospital de León-Ibimoc, León, 3Hematology Department, Hospital Miguel Servet, Zaragoza, 4Hematology Department, Hospital Nuestra Señora de Sonsoles, Ávila, Spain

Background: Although the fusion oncogene PML-RARA is known to initiate acute promyelocytic leukemia (APL), other cooperating mutations have also been implicated in the disease pathogenesis. However, the spectrum of mutations of APL patients within the relapse-risk groups, based on patient leukocyte and platelet counts at diagnosis, is not yet defined.

Aims: 1)To identify genetic alterations that might cooperate with PML-RARA in the leukemogenic process within the three APL relapse-risk groups. 2)To find mutations at diagnosis responsible for poor outcome by comparing patients who experiment relapse vs. patients who do not relapse in each group.

Methods: We performed multi-amplicon targeted deep sequencing on bone marrow samples of 91 patients diagnosed with APL (PETOHE LPA99/2005/2012) with a median follow-up of 2.8 years (range 0.2-10) (Table 1). APL patients were classified into relapse-risk groups according to initial leukocyte (WBC) and platelet counts (Score Sanz et al. 2000). Libraries were prepared by using the TruSight Myeloid Assay (Illumina) (Illumina) genome sequencer. Minimum depth for reliable analysis was fixed in 100X and minimum variant allele frequency (VAF) in 5%. FLT3-TIT mutations were analyzed by fluorescent PCR and capillary electrophoresis. Sequences obtained were analyzed with the Variant Studio v1.1 software (Illumina) and the Integrative Genome Viewer (Genome Browser).

Results: Distribution of 91 patients in the 3 relapse-risk groups was: 28 in low-risk group (31%), 48 in intermediate-risk (53%) and 15 in high-risk (16%). We
found 150 mutations in 31 genes, in 73 out of the 91 patients included (a median of 1 mutation per patient (range: 0-5) with a mean read depth of 1036x). Eighteen patients remained wild-type for all analyzed genes (Figure 1). Only one of this patients suffered relapse (5%). In the global series, no single mutation or functional category showed an association with clinical variables or prognostic impact in terms of overall survival or relapse free survival (RFS). There were no differences in the mean number of mutations per patient in each risk APL group (p>0.05). Patients who lack mutations belonged to the intermediate (13/48, 27%) and low risk (4/28, 14%) groups, except for only one patient (1/15, 6%) in high-risk group. FLT3 was the most frequently affected gene in high risk APL subgroup (10 out of 15): 8 patients carried an FLT3-ITD mutation and 2 patients had amino acid substitutions at codon 832. Seven patients assigned to intermediate-risk relapsed (7/38, 18%). All but one carried mutations that have been reported as unfavorable in AML (FLT3, PTEN, ASXL1, CUX1 and WT1). By contrast, patients who remain in complete remission in this group, have been reported as unfavorable in AML (FLT3, PTEN, ASXL1, CUX1 and WT1). Seven patients assigned to high-risk group (p>0.05). Patients who lack mutations belonged to the intermediate-risk AML group (p<0.001). We also found negative correlation of TP53 and miR-34a expression with high expression of TP53 compared to group with low TP53 expression (p=0.017). We have not found any differences in CD274 expression between groups with or without following mutations: IDH1, TET2, RUNX1, NRAS, CEBPA, PTPN11, KIT, KRAS, FLT3, DNM3, NPM1 and IDH2. Patients with more than 4 recurrent mutations were characterized with higher expression of CD274 compared to group of patients with 0-3 recurrent mutations. We also found that patients with >14 of all mutations had elevated expression of CD274 compared to group 0-13 mutations (p=0.06). We observed significant differences in PDCD1 expression level regarding to PD-1.1.5 polymorphism. Moreover, analysis of a PD-1.1.3 polymorphism in HVs and MDS groups revealed that genotype GG was associated with nearly fivefold lower risk of disease (OR=4.93, p=0.009). We observed significant differences in OS in AML patients in case of presence of certain genotypes of PD-1.1.6. Genotype AA was significant associated with higher risk of shorter OS compared to the rest of the genotypes (58 vs 333 days, HR=35; p=0.0188).

Summary/Conclusions: In summary, the present study shows that the mutational status of NRAS and FLT3 genes could be used as genetic markers for prognosis in APL, especially in the intermediate and low-risk groups, allowing a more accurate patient risk classification. Our data suggests the need to search for new mutations required for progression in APL, in order to benefit from a change in post remission therapy.

E888
ANALYSIS OF THE PD-1/PD-L1 AXIS POINTS TO ASSOCIATION OF UNFAVORABLE RECURRENT MUTATIONS WITH PD-L1 EXPRESSION IN AML.
K. Giannopoulos1,2, M. Zajac1, J. Zaleska1, A. Dolnik3, A. Siwiec4, O. Jankowska5, M. Soroka-Wojtaszko5, A. Szudy-Szczyrek5, M. Majdan4, M. Hus5, L. Bullinger3, M. Gregorkiewicz1, J. Zaleska1, A. Siwiec4, M. Majdan4, M. Hus5, L. Bullinger3

Background: Programmed death ligand-1 (PD-L1) is regulated through miR-34a molecules in AML patients. Moreover, Cortez et al. for the first time identified novel, complete mechanism of PD-L1 regulation by p53 via miR-34a in non-small cell lung cancer (NSCLC).

Aims: In this study, our comprehensive analyses of PDCD1 (PD-1), CD274 (PD-L1), TP53 and miR-34a expression in AML patients shed new light on the complex regulation of PD-1/PD-L1 axis during development of this disease.

Methods: We performed analysis of TP53, CD274 and miR-34a expression in 197 AML patients available from The Cancer Genome Atlas (TCGA) database. Moreover, we assessed miRNA expression of PDCD1 in independent cohort of 54 AML, 62 MDS and 8 s-AML patients using qRT-PCR method. For miRNA analysis, CD33+ cells from 29 AML patients were isolated. We also performed correlation and survival analysis to characterize relevant associations with a higher risk of developing autoimmune diseases: PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs22279871), PD-1.6 (rs10204525), PD-1.7 (rs41386349), PD-1.9 (rs2227982), PD-1.10 (rs22227782) in 34 AML, 62 MDS and 100 HVs samples.

Results: We observed significant differences in PDCD1 expression in groups of 54 AML, 62 MDS, 8 s-AML patients compared to HVs. TCGA data analysis showed that CD274 expression was elevated in group with TP53 mutations compared to unmutated TP53 group (p<0.001). We also found negative correlation of TP53 and miR-34a expression with CD274 expression (p=0.02 and p=0.005, respectively). The expression of miR-34a tended to be elevated in group with high expression of TP53 compared to group with low TP53 expression (p=0.17). We have not found any differences in CD274 expression between groups with or without following mutations: IDH1, TET2, RUNX1, NRAS, CEBPA, PTPN11, KIT, KRAS, FLT3, DNM3, NPM1 and IDH2. Patients with more than 4 recurrent mutations were characterized with higher expression of CD274 compared to group of patients with 0-3 recurrent mutations. We also found that patients with >14 of all mutations had elevated expression of CD274 compared to group 0-13 mutations (p=0.06). We observed significant differences in PDCD1 expression level regarding to PD-1.1.5 polymorphism. Moreover, analysis of a PD-1.1.3 polymorphism in HVs and MDS groups revealed that genotype GG was associated with nearly fivefold lower risk of disease (p=0.009). We observed significant differences in OS in AML patients in case of presence of certain genotypes of PD-1.1.6. Genotype AA was significant associated with higher risk of shorter OS compared to the rest of the genotypes (58 vs 333 days, HR=35; p=0.0188).

Summary/Conclusions: Our analyses indicate that p53 might specifically modulate the tumor immune response by regulating PD-L1 via miR-34a which directly binds to the PD-L1 3’ UTR and blocks its expression. Moreover, we found that high CD274 expression is associated with the higher numbers of recurrent and all mutations as well as poor cytogenetic and molecular risk groups of AML patients. We found significant differences in PDCD1 expression in AML patients compared to HVs that might indicate deregulation of a signal transduction through the PD-1/PD-1L axis. While our SNP analysis in AML patients suggested a prognostic impact of PD-1.6 polymorphism, further studies are warranted to evaluate the impact of the PD-1/PD-1L axis in AML.

This work was supported by National Centre for Science Grant HARMONIA (UMO-2013/10/M/NZ5/00313).

E889
DISSECTING THE DYNAMICS OF SINGLE-TUMOR-CELL-LINEAGES THAT UNDERPIN RELAPSE OF AML.
F. Caiado1, D. Maia-Silva1, C. Reifor1, R. Faria, B. Silva-Santos1, H. Norelli1
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Background: Cancers kill primarily via disease recurrences after transient treatment responses. The emergence of therapy-resistant tumor escape variants is fueled by intra-tumor heterogeneity, underpinned by interference and Darwinian evolution across continually developing sub-clones in the residual tumor. Several non-genetic factors add significant variation, on top of the divergent adaptive responses provided by the often complex intra-tumor genetic landscape, resulting in an extremely heterogeneous and dynamic tumor cell population that can drive disease under many conditions. The relapse of human acute myeloid leukemia (AML) is a prime clinical example of how evolving sub-clonal dynamics can frequently drive treatment-resistant cancer recurrence after initially potent therapies.

Aims: We aimed to understand how sub-lineage interference is regulated in AML in response to standard and emerging treatments - and clarify how this impacts the development of therapy resistance. Specifically, we aimed to dissect if relapse from each drug regimen was driven by predetermined or stochastically selected sub-lineages and determine if this process is fueled by intra-tumor heterogeneity, underpinned by interference and Darwinian evolution across continuously developing sub-clones in the residual tumor.

Methods: We dissected the intra-tumor population dynamics of relapsing AML, beyond the genetic level, by performing single-cell lineage-tracing through cellular barcoding technology (lentivirus-integrated non-coding DNA-tags). We
specifically evaluated the impact of in vitro exposure of a barcoded AML cell line (HEL) to chemotherapeutic regimens (doxorubicin (DOX) and/or cytarabine (CYT)) and the hypomethylating agent decitabine (DCT) by comparing the barcode composition of the tumor population recurring after each therapy, versus non-treated (NT) controls. By comparing the barcode architectures between parallel replicate cultures for each therapy, we could further delineate whether AML relapse was driven by predetermination or recurrent barcodes found in multiple replicates) or stochastically selected (if mainly diverse barcodes in each replicate) cells in response to each treatment regimen.

**Results:** Only treatment regimens containing DOX caused marked decreases in HEL cell numbers and barcode architectures diverging strongly from the non-treated control cultures. Replicate AML cultures regrowing after treatment with DOX all converged to a very similar barcode architecture, reflecting that relapse following this mono-therapy was driven by predetermined single-cell lineages. Combination of DOX with CYT increased the degree of overall cell elimination by ~10-fold, while addition of DCT to either chemotheraphy regimen had a minor impact (i.e. yielded similar cell number and re-growth kinetics). Interestingly, DCT additions nevertheless qualitatively changed which sub-lineages that regrew - specifically making replicates more divergent from each other, indicating a more stochastic selection of the cells emerging when DCT had been added to the respective chemotherapy regimen. This result above this level was considered as MRD positive. DFS (Disease Free Survival) and OS (Overall Survival) rates in this group were 29.9% and 24.1%, respectively; positive MRD sample was independent marker associated with shorter DFS (p=0.002, HR=0.33, 95% CI:1.60-33.51) and OS (p=0.002, HR=8.33, 95% CI:1.87-37.15) (see figure 1). These results support the usefulness of MRD evaluation in patients with AML by NGS in the context of molecular biology studies.

**Summary/Conclusions:** The development of curative treatment combinations requires deep understanding of how non-genetic factors synergize with cancer genetics to drive intra-tumor heterogeneity, which is key for tumor escape/disease recurrence. Our detailed analyses of the heterogeneous dynamics among single-cell lineages in AML, following different treatment regimens with apparently similar global impact, represent an important step in dissecting kinship-dependent aspects that go beyond the genetic level. Critically, these studies directly provide the rationale for combining standard chemotherapy with administration of hypomethylating drugs to target AML. The mechanism is prevention of the development of chemotherapy resistance (mediated by selective relapse of a specific set of predetermined sub-lineages) - by partially randomizing which sub-lineages that emerge to drive relapse when DCT is added to the chemotherapy. Maintenance of the chemosensitivity of relapsing AML would represent a paradigm shift, turning the currently often lethal relapses into surmountable/ repeatedly clinically manageable episodes of a type of chronic leukemic disease.

E890

Abstract withdrawn.

E891

MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP

E. Onchea De La Fuente1,2,*, I. Papado1,2, T. Cedena1,2, M. Llops3, Y. Ruiz-Heredia1,2, J. A. Garcia Velasquez1, J. Perez Oteyza1, A. Figueras1, F. J. Peñalver1, E. Barragan1, M. Gallardo1,2, J. Martinez-Lopez1,2, R. Ayala1,2,3

1Haematological Malignancies Clinical Research Unit, CNIO, Madrid, 2Instituto de Investigación Sanitaria La Fe, Valencia, 3Hospital Universitario de Getafe, 4Hospital Universitario de Alcorcón, Madrid, 5Clinical Pathology Service, Hospital Universitario Vall d’Hebron, Barcelona, Spain.

**Background:** Sensitive detection of molecular marker of minimal residual disease (MRD) in acute myeloid leukemia (AML) could improve prognostic assessment of a possible relapse during the remission. Traditional methods for measuring minimal residual disease (MRD) in AML, such as real-time PCR and multiparametric flow cytometry (MFC) are associated with high technical complexity, low applicability and laborious standardization. However, some patients who achieve a negative MRD become to relapse and several MRD+ patients have a long survival, which indicates that the sensitivity and specificity of traditional techniques for minimal residual disease assessment can be extremely low.

**Aims:** To detect minimal residual disease in AML follow-up sample using high-throughput sequencing as a standard and accurate technique.

**Methods:** We studied 54 gDNA bone marrow follow-up samples (27 after induction, 10 after first consolidation, 17 after second consolidation) from 30 AML patients treated according PETHEMA AML clinical protocols and with DNA sample at diagnosis. All patients had achieve CR at the moment of MRD assessment. We developed a custom-targeted sequencing panel of 32 genes (Ion Torrent Proton System-Thermo Fisher) for mutation (SNV and/or Indels) detection at diagnosis sample. From the 32 genes, we use specific primers to amplify the specific region of the four most frequent alterations at diagnosis (Samples at follow-up: FLT3n4-IDT n=2, NPM1n46, IDH2 n=9 or IDH1 n=7). We analysed and detected at diagnosis and at follow-up (after induction, first consolidation or second consolidation), and sequenced with high-throughput approach. We achieve a technical sensibility around 10-4 for point mutations and 10-5 for Indels mutations according high-sensitivity and sensitivity calibration curves.

**Results:** We analyse the results of assessing MRD by NGS, and the presence or absence of MRD was established at a cut-off level of 0.0017 (between 10-4 and 10-6)technically well) by ROC curve with a sensitivity of 0.5 for DFS and 0.571 for OS, and a specificity of 0.92 for DFS and 0.897 for OS; thereby this result above this level was considered as MRD positive. DFS (Disease Free Survival) and OS (Overall Survival) rates in this group were 29.9% and 24.1%, respectively; positive MRD sample was independent marker associated with shorter DFS (p=0.002, HR=0.33, 95% CI:1.60-33.51) and OS (p=0.002, HR=8.33, 95% CI:1.87-37.15) (see figure 1). These results support the usefulness of MRD evaluation in patients with AML by NGS in the context of molecular biology studies.

**Summary/Conclusions:** High-throughput NGS is a technique with the capacity to measure, identify and classified MRD levels. In fact, NGS MRD evaluation has a better DFS and OS prediction that other traditional methods. Implementation of NGS technique on MRD detection could help to anticipate to disease progression.

This study was funded by Instituto Carlos III (PI13/02387).

E892

THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS-LIKE BLASTS WHICH SUPPRESS T CELL PROLIFERATION IN LEUKEMIC CELL GROWTH

S. Y. Hyun1,1, J. I. Lee1, E. J. Na1, J.-W. Cheong2

1Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, 2Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic Of

**Background:** Myeloid-derived suppressor cells have an ability to suppress T-cell function and have been known to facilitate tumor growth. We elucidated the immune suppressive function of leukemic blasts which resembled MDSC phenotype and their role in the growth of leukemic cells.

**Aims:** We elucidated the immune suppressive function of leukemic blasts which resembled MDSC phenotype and their role in the growth of leukemic cells.

**Methods:** CD11b+CD33+HLA-DR-blast (MDSC like blast) were isolated using flow-cytometry from bone marrow mononuclear cells of primary acute myeloid leukemia (AML) patient samples. CD14, CD15, Arg1 and iNOS expression were checked by flow-cytometry to identify the phenotype of MDSC like blast. To evaluate the ability of MDSC like blasts to suppress T cell proliferation, CD8+ T cells from healthy donor and MDSC like blasts were co-cultured with a ratio of 1:1 with/without phytohemagglutinin A 10ug/ml. T-cell proliferation was measured by carboxyfluorescine diacetate succinimidyl ester dilution assay after 3 days of culture. Then, various leukemic cell lines were co-cultured with jurkat T cells and/or MDSC like blasts at a leukemic cell line:jurkat T cell: MDSC like blast ratio of 4:1:1. The effect of Jurkat T cells and MDSC like blasts on the proliferation of leukemic cells was assessed by the CCK-8 assay after 1 and 3 days of culture.

**Results:** MDSCs like blast can be divided into two subtypes, monocyteic subtype expressing CD14 and granulocytic subgroup expressing CD15, and CD14 expression was more frequent than CD15 (67.5% vs 39.3%). MDSC-like blasts showed higher expression of Arg1 (77.1% vs 38.5%, P<0.001) and iNOS (33.0% vs 1.1%, P<0.0001) compared to non-MDSC-like blasts. CD8+ T cell proliferation induced by PHA was significantly suppressed when co-cultured with MDSC-like blasts compared to without them. Among the various leukemic cell lines, the proliferation of NB4 cells were significantly suppressed when co-cultured with Jurkat T cells on day 3 (NB4 23.49±6.26% of control, NB4+Jurkat 12.62±3.92%, P<0.01). The decreased proliferation of NB4 cells was partially recovered after 3 days of co-culture with MDSC-like blasts (NB4+Jurkat 12.62±3.92%, NB4+Jurkat+MDSC like blast 18.71±6.19, P=0.022).

**Summary/Conclusions:**
Background: Acute megakaryoblastic leukaemia (AML) is a rare and complex type of Acute Myeloid Leukaemia (AML), more frequent in children than in adults, characterized by the accumulation of immature megakaryoblasts and thrombocytopenia. Paediatric AMLs are classified in Down Syndrome AML (DS-AMKL) with a good prognosis; and AML non-related to Down Syndrome (non-DS-AMKL), a more aggressive disease with a mortality rate close to 80%. There is a limited amount of research done on infant non-DS AMLs due to its low reactivity and early human hematopoiesis, which are not linked to it. Among the genetic alterations found in non-DS-AMKL, approximately half of the patients carry the chromosomal translocations t(1;22)(q13;q13) RBM15-MKL1 and t(11;12)(q22;p13) NUP98-JARID1 respectively, and the inversion of chromosome 16, which originates the fusion protein CBFA2T3-Glirino.

Aims: It is essential to establish new human models to provide enough biological material for functional and molecular studies. As the genetic alterations that drive infant leukaemia occur in the developing fetus, we propose that human hPSCs expressing different AML-related stem cells (hPSCs) are ideal models to study non-DS-AMKL as these cells allow us to mimic human embryonic hematopoietic development. In this project, we aim to use human hPSCs expressing non-DS-AMKL-associated fusion oncogenes as cellular models for this leukaemia, to study the molecular and cellular pathways involved in the development of pediatric non-DS-AMKL.

Methods: Generation of human models of non-DS AML using hPSCs: 1. Generation of hPSCs with the oncogenic fusion proteins RBM15-MKL1, CBFA2T3-GLIS2 and NUP98-JARID1 using transduction with lentiviral vectors. 2. Generation of hPSCs with the chromosomal translocations t(1;22)(q13;q13) RBM15-MKL1 and t(11;12)(q22;p13) NUP98-JARID1 using the CRISPR/Cas9 system. 3. The non-DS-AMKL hPSC cell lines are generated, we confirm that they preserve their pluripotency by checking expression of pluripotency markers by flow cytometry and PCR. We also confirm their ability to differentiate into the three germ layers forming embryoid bodies. Using an in vitro differentiation assay, we use colony-forming assays (CFU) to determine the generation and functionality of hematopoietic progenitors.

Results: we report the generation and characterization of human non-DS AML-related stem cell model expressing oncogenic fusion proteins RBM15-MKL1, NUP98-JARID1 and CBFA2T3-GLIS2.

Summary/Conclusions: These models will serve as platforms to discover and understand the cellular and molecular alterations caused by these oncogenes, and their impact in the generation of hematopoietic cells during development. With this information we will have a better understanding of the origin and development of paediatric non-DS AML, so we will be able to design new therapeutic approaches for these children.
mutations. Moreover, ASXL1 mutations were detected in 3 of 12 patients with aberrations (25%), 2/9 (22%) with trisomy 11, 3/11 (27%) with t(6;9) and only 1 of 22 patients with t(15;17). Multivariate logistic regression revealed that independent predictors of the presence of ASXL1 mutations were older age (OR 1.43 per decade, 95% CI 1.13-1.79), chromosome 11 aberrations (OR 2.69, 95% CI 1.09-6.63), and sec-AML (OR 4.44, 95% CI 2.3-8.57), whereas t(17;19) or -5/5i predicted for lower frequency (OR 0.32, 95% CI 0.13-0.75).

Summary/Conclusions: Our results support the association of ASXL1 mutations in AML with advancing age and sec-AML. Association with trisomy 8 did not retain significance in multivariate analysis. Chromosome 11 aberrations emerged as a strong independent predictor. Despite the strong link with secondary AML (majority of cases post MDS), our data show inverse relationship with -7/del(7q) or -5i/5deli5q predicted for lower frequency (OR 0.32, 95% CI 0.13-0.75).

E896
Abstract withdrawn.

E897
A COMPREHENSIVE DNA TEST FOR THE DETECTION OF TRANSLOCATIONS IN ACUTE LEUKEMIA

E. Van Den Berg-De Ruiter1, M.Z. Almohamed1, L.F. Johansson1, E.N. de Boer2, E. Splinter3, A.G. Bosgra4, M. van Min5, A.B. Mulder6, E.J. Sikkema-Raddatz1, R.J. Sinke1, R.H. Sijmons1, B. Sikkema-Raddatz1, Utrecht, 2Genetic Coordination Center, UMCG, Groningen, 3Cergentis B.V., 4Laboratory Medicine, 5Hematology, UMCG, Groningen, Netherlands

Background: Patients with acute leukemias carry a wide range of chromosomal abnormalities, which affect their prognosis and treatment options. Currently, over 500 different translocations are reported to be involved in the disease progression. Traditional methods to detect chromosomal abnormalities involve a combination of techniques such as karyotyping, FISH, array and RT-PCR. However, these methods are laborious and at times inadequate. Targeted Locus Amplification (TLA), a new targeted next generation sequencing technology can overcome these shortcomings. It is based on proximity ligation (crosslinking) of DNA and outward oriented probes for enrichment and can therefore identify chromosomal translocation partners regardless of their identities.

Aims: Here we present a TLA multiplex panel in combination with next generation sequencing as a first tier screening tool in detecting translocations in acute leukemias.

Methods: A multiplex TLA panel was designed using primer sets covering known break-point regions of the 17 most frequently reported genes involved in acute leukemia’s. TLA was performed on five different cell lines carrying translocations detectable by our panel, t(12;21), t(15;11), t(11;19), t(8;13), t(6;9), t(17;19). Various combinations of cell line mixtures in multiple dilution series were used to determine the specificity and sensitivity of the panel, and to set sample quality thresholds during analysis. Samples were processed using standard TLA protocol (de Vree et al., 2014). Targets were enriched by PCR amplification with the multiplex panel and subjected for sequencing on Illumina Nextseq 500. To facilitate an easy analysis workflow a semi-automated data analysis was developed. This includes a quality control step, labelling samples with no coverages at the anchor regions after filtering at more than half the analysis was developed. Traditional methods to detect chromosomal abnormalities involve a combination of techniques such as karyotyping, FISH, array and RT-PCR. However, these methods are laborious and at times inadequate. Targeted Locus Amplification (TLA), a new targeted next generation sequencing technology can overcome these shortcomings. It is based on proximity ligation (crosslinking) of DNA and outward oriented probes for enrichment and can therefore identify chromosomal translocation partners regardless of their identities.

Aims: Here we present a TLA multiplex panel in combination with next generation sequencing as a first tier screening tool in detecting translocations in acute leukemias.

Methods: A multiplex TLA panel was designed using primer sets covering known break-point regions of the 17 most frequently reported genes involved in acute leukemia’s. TLA was performed on five different cell lines carrying translocations detectable by our panel, t(12;21), t(15;11), t(11;19), t(8;13), t(6;9), t(17;19). Various combinations of cell line mixtures in multiple dilution series were used to determine the specificity and sensitivity of the panel, and to set sample quality thresholds during analysis. Samples were processed using standard TLA protocol (de Vree et al., 2014). Targets were enriched by PCR amplification with the multiplex panel and subjected for sequencing on Illumina Nextseq 500. To facilitate an easy analysis workflow a semi-automated data analysis was developed. This includes a quality control step, labelling samples with no coverages at the anchor regions after filtering at more than half the number of target regions as failed. These were not interpreted. Only peaks outside other anchor regions were considered as false positive peaks. Peaks present in other anchor regions were interpreted as possible artefacts and labelled as needing extra confirmation. In these series until now, up to 10% aberrant cells were detected with no false positives as no translocations other than expected for cell lines were detected. Bone marrows of 36 patients suspended in cytokine-rich medium were taken for routine diagnostic diagnosis (Karyotyping, FISH and or RT-PCR) and TLA. Sample analysis was performed randomized and blinded. TLA outcome was then compared with results from routine genetic testing.

Results: From a total of 36 patients three samples did not meet the required sample quality for further analysis. In the remaining 33 patients our TLA multiplex panel confirmed the presence of translocations on 16 samples. This includes a cryptic translocation involving the ETV6-RUNX1 fusion gene, t(12;21)(p13;q22) in five pediatric AML samples, not detected with karyotyping but RT-PCR, confirming the TLA findings. In fifteen samples no translocation was detected. Despite being non-cryptic, no additional translocation was detected. Our panel is able to detect (cryptic) translocations with prior knowledge of the fusion partner. Therefore, the TLA multiplex panel is suited as a first tier screening tool in acute leukemia. A prospective study, comparing the diagnostic yield of the TLA panel with current tests, can establish whether the TLA panel is applicable as a routine procedure.

Summary/Conclusions: Our TLA panel showed concordant results for 29 out of the 33 successful sequenced samples. No false positives were found, while an additional translocation was detected. Our panel is able to detect (cryptic) translocations with prior knowledge of the fusion partner. Therefore, the TLA multiplex panel is suited as a first tier screening tool in acute leukemia. A prospective study, comparing the diagnostic yield of the TLA panel with current tests, can establish whether the TLA panel is applicable as a routine procedure.
NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORY STATUS IN AML PATIENTS

E. Onecha De La Fuente 1,2,*, I. Rapado 1,2, M. Llops 3, Y. Ruiz-Heredia 1,2, T. Cedena 1,2, E. Barragan 3,4, M. Gallardo 1,2, J. Martinez Lopez 1,2, R. Ayala 1,2
1Hematología traslacional, Hospital 12 de Octubre, 2Hematological Malignancies Clinical Research Unit, CNIO, Madrid, 3Instituto de Investigación Sanitaria La Fe, 4Clinical Pathology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Background: A high number of patients with acute myeloid leukemia (AML) present resistance at treatment, which is associated with clonal persistence or evolution. The generation of high-depth sequencing data allowed to quantify variant allelic frequencies (VAF) and permitting estimation of the size of tumor clonal populations in each AML sample, and to perform an estimation of clonal evolution at relapse or refractory case according to diagnostic.

Aims: To evaluate the predictive impact of the fluctuation Variant Allelic Frequency in resistance to treatment cases in AML.

Results:

MUTATIONS:

ΔVAF trend decreases. No correlation was found between VAF and% of complete remission (CR); p=0.754. Mutations in RUNX1 (p=0.000) and the methylation pathway (DNMT3A, EZH2, KMD6A, MLL, TET2, SF3A1, SF3B1, TET2, TP53, U2AF35, VHL, ZRSR2 and CALR, by Ion Torrent Proton System-Thermo Fisher. Primary tumor-refractory (n=6) and primaty tumor-relapsed (n=17) samples pairs from 25 AML patients treated according to PETHEMA AML clinical protocols were sequenced; in addition FLT3-ITD was detected by GENSCAN and NPM1 mutation was detected by PCR. We analyse the evolution of level of VAF, to measure the prevalence of somatic mutations between diagnosis and resistance status (relapse or refractory).

Results: Mutations in signalling pathway (EPOR, FLT3, JAK2, KIT, LNK or/and MPL) and GTPases pathway (KRAS, NRAS, HRAS) present significant ΔVAFs increases in relapse samples, p=0.05 and p=0.039 respectively. See figure 1. Furthermore, mutations in IDH2, JAK2 or KRAS show ΔVAF trend increases. Also, mutations in signalling pathway shows significant ΔVAF decrease in primary refractory samples, p=0.015; mutations in JAK2, KMT2A or SF3A1 shows ΔVAF trend decreases. Regarding to mutational profile we found significant ΔVAF decrease in primary refractory samples, p=0.015; mutations in JAK2, KMT2A or SF3A1 shows ΔVAF trend decreases. No correlation was found between VAF and% blasts, nor did VAF fluctuation with blasts fluctuation.

Summary/Conclusions: These results show VAF increases of specific mutations as RUNX1 correlates with primary refractoriness status. Furthermore, the variable frequency signalling pathway (EPOR, FLT3, JAK2, KIT, LNK or/and MPL) play a critical role in resistance status, increasing variant allelic frequencies of mutations in relapse and decreasing in refractoriness.

This work was supported by the grant: PI13/02387.
IDENTIFICATION OF NOVEL THERAPEUTIC DRUGS IN DISTINCT PEDIATRIC AML SUBTYPES BY TARGETING EPIGENETIC REGULATORS

C. Wiggers1-4, D. Lelièvre6, D. Egan5, M. Bartels5, 1Department of Biomedical Laboratory Sciences and Chemical Engineering, Bergen University College, 2Department of Internal Medicine, Haematology Section, Haukeland University Hospital, 3Department of Clinical Science, Leukaemia Research Group, University of Bergen, Bergen, Norway

Aims: To identify new therapeutic drugs in pediatric AML by using an 80-component screen containing inhibitors of epigenetic regulators, including histone writers (which deposit post-translational modifications (PTMs) on histones), readers (binding of PTMs) and erasers (removal of PTMs).

Methods: Cell lines used in this study are THP-1 (t(9;11)), Kasumi-1 (t(8;21)) and CMK (Down’s syndrome with GATA1 mutation), reflecting distinct pediatric AML entities and a differential response to treatment with cytarabine. Cells were treated for 72hrs followed by analysis of cell viability and apoptosis based on Hoechst, Draq7 and Calcein Green staining. The effect of three candidate compounds were further investigated in triplicates at several concentrations for their effect on cell viability (Annexin V/FITC staining), cell cycle, morphology, and PTM expression in normal pediatric AML cell lines, normal cord blood, and pediatric AML patient cells representing distinct AML subtypes.

Results: From the 80 epigenetic compounds tested in THP-1, Kasumi-1 and CMK cells, we observed significant effects following treatment with the HDAC 4/5 inhibitor LMK235, the pan-HDAC inhibitor NSC3852, and the pan-bromodomain inhibitor Bromosporine. These compounds showed differential cytotoxicity of the compounds and suggested LMK235 as most effective. Cell proliferation was inhibited by LMK235 at an IC50 of 0.1uM, 0.13uM and 0.425uM in Kasumi-1, CMK and THP-1, respectively. While inhibition by LMK235 resulted in an immediate response of apoptosis, Bromosporine-treated cells retained in G1 phase, and, interestingly, LMK235 treated cells showed an increase of cells in S-phase and G2/M. Among the differential effects of the compounds in the cell lines, we also observed differences in sensitivity. In line with previous studies, THP-1 cells were more resistant, illustrated by a 10-fold increase in concentration required for NSC3852-induced apoptosis. Interestingly, upon treatment with Bromosporine, Kasumi-1 and CMK cells showed a similar response, while Kasumi-1 cells were significantly more sensitive to NSC3852-induced effects. These data are currently validated in pediatric AML patient cells.

Summary/Conclusions: Treatment of three distinct pediatric AML cell lines with the epigenetic compounds LMK235, NSC3852 and Bromosporine resulted in cell line-specific tumor growth inhibition and cytotoxicity, and mitotic index specific, including cell cycle regulation and induction of apoptosis. Our data suggests a potential role for epigenetic compounds, with specificity for molecular subtypes, in the treatment of clinically and biologically distinct pediatric AML subtypes.

ALVOCIDIB SYNERGIZES WITH CYTARAmine AND DAUNORubicin (7+3) IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA

W. Kim1, H. Haws1, R. Mangelson1, P. Peterson1, C. Whatcott1, A. Siddiqui-Jain1, S. Weltman1, D. Bearss1, S. Warner1
1Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States

Background: Although survival of patients with acute myeloid leukemia (AML) has increased in the years 1975-2011, the 5-year overall survival of patients with AML remains unacceptably low at an estimated 26% (2011). 7+3 treatment (cytarabine 100-200mg/m² + anthracycline [daunorubicin 60-90mg/m²/day or idarubicin 12mg/m²/day]) remains the standard induction therapy in AML patients, and has persisted largely unchanged for more than 30 years. There is a significant unmet clinical need for improved therapeutic options in patients with AML. Alvocidib is a CDK9 inhibitor currently in development for the treatment of patients with AML. Alvocidib has previously been studied as part of the ACRM regimen, a combination regimen incorporating the time-controlled administration of cytarabine, cytarabine, and mitoxantrone in multiple Phase 1 and 2 clinical trials. The ACRM regimen has achieved strong synergy with the increased efficacy of the ACRM regimen over 7+3 in AML, these studies cannot correctly capture the clinical contribution of alvocidib alone as they do not offer a direct comparison. The current study attempted to interrogate the contribution of alvocidib to the 7+3 induction regimen, in preclinical models. This study aims to provide a clear rationale for a clinical study directly comparing the triple combination to 7+3 alone.

Methods: We report here too that alvocidib treatment reduced the expression of MCL-1 protein and mRNA in a time and concentration-dependent fashion in AML cells. We observed this in the 7+3 treatment arm as well. In an MV4-11 xenograft model, we observed 21.1 and 48.5% tumor growth inhibition (%TGI) following single agent treatment of daunorubicin or cytarabine, respectively. 1.25mg/kg alvocidib yielded 60.0% %TGI. The combination of alvocidib, cytarabine, and daunorubicin, however, resulted in tumor regression, yielding a 116.2% %TGI.

Summary/Conclusions: These results provide a clear rationale for a clinical study directly comparing the combination to 7+3 alone. Taken together, our results suggest that a combination of alvocidib, cytarabine, and daunorubicin might be a potential clinical regimen in treating frontline AML, offering patients additional treatment options in treating their disease.
immunocompetent brown Norwegian myeloid leukemia (BNML) syngeneic rat model. VPA mono-treatment increased survival from a median of 34 days to 38 days in the MOLM-13-xac-mouse model, and from 21 days to 50 days in the BNML rat model. Additionally, the IFNα-Le (0.8x10^6 IU/kg) and VPA (400mg/kg) combination treatment indicated a tendency to increased survival in the BNML model. However, IFNα-Le monotherapy (1x10^6 IU/kg) decreased survival in the MOLM-13-xac model.

Figure 1. Summary/Conclusions: IFNα does not add beneficial effects to VPA treatment in the two in vivo orthotopic models tested, possibly due to immune constitution and tumor load.

E904 KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE MYELOID LEUKEMIA R. Napolitano1, S. De Mattiess1,2, C. Carloni, G. Simonetti2, G. Musuraca3, A. Lucchesi2, D. Calisti1, A. Cuneo3, K. Menon5, G. Martinelli2
1Bioscience Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, 2Department of Hematology and Oncological Sciences, L. and A. Seragoni, Bologna, 3Hematology Unit, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, 4Department of Medical Sciences, University of Ferrara-Arcispedale Sant'Anna, Ferrara, Italy, 5Celleceutix Corporation, Beverly, United States

Background: Acute Myloid Leukemia (AML) is a heterogeneous disorder defined by clonal expansion of immature myeloid cells that infiltrate bone marrow and other tissues. AML therapeutic strategies remain unchanged since 1970 and the majority of patients often eventually relapse and die due to disease progression. Tumor protein p53 transcription factor is a key regulator of several cellular pathways, such as DNA repair, cell cycle, apoptosis and angiogenesis. It is mutated in 8-14% of AML cases and its mutations are commonly associated with a complex karyotype. Kevetrin is a new molecule compound, proposed by Celleceutix, with the ability to target both wild type and mutant p53 tumors.

Aims: The aim of this project is to explore cellular and molecular alterations induced by Kevetrin, focusing on its role in the p53 pathway.

Methods: Kevetrin was kindly provided by Celleceutix, dissolved and stored at 4°C in sterile water in a 600 μg/ml stock solution, and diluted in medium immediately before use [concentration range in use 15-60μg/ml]. Cell lines, MOLM-13 and KASUMI-1, were cultured in RPMI 1640 supplemented with 20% heat inactivated fetal bovine serum, 2mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. After 24 and 48 h of treatment MTS, Annexin-V, TUNEL, JC-1 and Active Caspase-3 assays were performed according to manufacturer’s instructions. Proteins were separated by polyacrylamide gel electrophoresis and transferred to 0.2 μm polyvinylidene fluoride membranes. Quantitative analysis was performed with Quantity One software. Statistical analysis was carried out using the paired and unpaired two-sided Student’s t tests. p values <0.05 were considered as significant.

Results: Our data indicate that Kevetrin exposure induces cell growth arrest, a great drop of mitochondrial membrane potential and a remarkable increment of Caspase-3 cleaved form, features that contribute to apoptotic cell death in the two cell lines. Cellular changes can be associated with a dose and time-dependent effect in the TP53 mutated cell line (KASUMI-1) but not in the wild type one (MOLM-13), in which we can observe an activity only after 48 h at the higher concentration. Regarding molecular alterations in KASUMI-1 we found a great p53 down-regulation, probably due to Hsp90 reduction, resulting in a less marked formation of the Hsp90-p53 oncogenic complex. We also found a down-regulated p53 active form (Ser15), a reduced expression of p53 targets, p21 and PUMA, and a down-regulation of SIRT-3, that cannot exert its inhibitory activity on p53. The MOLM-13 cell line showed a great p53 reduction, probably related to SIRT-3 up-regulation and Hsp90 down-regulation. Regarding p53 active form, we noticed slight variations in protein expression, suggesting a physiological response of the protein to cellular damage. In accordance with p53 activity, we observed a great reduction of p53, probably associated with a drug resistance mechanism; in contrast, PUMA protein was highly down-regulated, suggesting a p53-independent mechanism of action or a feedback regulation of the apoptotic process, after Caspase-3 activation (Figure 1). In order to better understand drug’s mechanism of action we are performing gene expression profiling after 48h of treatment with Kevetrin 60μg/ml.

Figure 1. Summary/Conclusions: Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.

E905 CLEARANCE OF ‘DRIVER-COSMIC’ MUTATIONS POST CR1 WITH DELETING RUNX1_L56S IS UNLIKELY TO CONTRIBUTE TOWARDS DISEASE PROGRESSION IN AML L. Rai1, T. Boneva2, D. Brazma2, R. Dunn2, C. Grace2, E. Nacheva2,3
1Onco-Cytogenomics, 2OncoGenomics, HSL Analytics LLP, 3Cancer Research Institute, UCL, LONDON, United Kingdom

Background: Clinical significance of gene variants in AML is well established (Papaemmanuil E et al, NEJM 2016) and is increasingly being implemented into routine diagnostic algorithms. Although 80% of patients achieve morphological remission after induction chemotherapy, long-term relapse free survival is a meagre 50% (Walter RB et al, JCO 2010. Monitoring of disease kinetics, is therefore, very critical.

Aims: To study the kinetics of gene variants post-induction chemotherapy in AML patients.

Methods: 130 follow-up samples from 45 de novo AML patients [median age 60 yr & median FU period-18.6 mo] were screened for gene variants using TruSight Myeloid panel (Illumina, CA, USA) covering ≥30 genes with relevance in myeloid diseases. Gene variants at Variant allele frequency (VAF) of ≥10% at diagnosis and VAF of ≥1% during follow-up; both with target coverage of ≥300 reads were considered. Bone marrow (BM) or peripheral blood (PB) was obtained at presentation (BM:44; PB:1) and follow-up (BM:130). Gene variants in 95 samples from 40 MDS patients were also evaluated for progression to secondary AML. Public databases-Catalogue of Somatic Mutations In Cancer (COSMIC), dbSNP and 1000 genome (≥2%) were used to classify gene variants as either Drivers (D) variants of unknown significance (VUS) and germline polymorphisms (SNP). P-value was generated with 2-tailed Fisher Exact (GraphPad Software, Inc, USA).

Results: Of 45 AML patients 19 achieved complete morphological remission (CR), 21 had a relapse and 5 had refractory disease with a median of 4 mutations/patient in each subgroup. Driver mutation was identified in 38 patients; 82% of who had persistence until clinical end-point. While 17 of 18 relapse patients retained a driver only 9 of 15 patients in remission retained it (Table 1). 8 of the 9 patients had a ‘driver with COSMIC and SNP’ (D-C/S) reference that persisted, while all ‘driver with COSMIC only’ (D-C) disappeared post-induction. This suggests that drivers with both COSMIC and SNP reference may not always contribute towards disease progression. We also found that D-C mutations persist in 85.7% of relapse patients compared to only 11% of patients in remission (P-value: 0.001). Additionally, D-C mutations were retained in all 13 relapse patients with intermediate risk cytogenetics while complete clearance was observed in all 6 patients who were in sustained remission (P-value: 0.001).

Further investigation of genes with D-C/S mutation in the remission cohort (8x) revealed that 4 patients had persistent DNMT3A-25457242, 1 had DNMT3A-25457243, 2 had RUNX1-36259324/L56S and 1 had CBL-119149011. As DNMT3A mutations are considered to occur in pre-leukemic...
stem cells contributing to clonal haematoipoiesis (Askush et al, Nature 2014; Genovese et al, NEJM 2014); this led us to study the distribution of RUNX1 gene variants in an additional 119 AML diagnostic samples. 34 patients (21%) harboured RUNX1 mutation, of which 5 had RUNX1-L56S that were often associated with D-C mutations (4 of 5 cases). Finally, we evaluated kinetics of D-C in 40 MDS cases of which 34 had chronic MDS and 6 had secondary AML (sAML). No significant difference was observed in the number of patients with persistent D-C mutation in the 2 subgroups (chronic MDS: 16 of 19 (84.2%); sAML: 5 of 5 (100%); P-value: 1.000).

Table 1.

<table>
<thead>
<tr>
<th>Clinical Outcome</th>
<th>AML relapse</th>
<th>Refractory disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients in each clinical outcome category</td>
<td>19</td>
<td>21</td>
</tr>
<tr>
<td>Mean Age (years)</td>
<td>55.8 (32-71)</td>
<td>57.3 (30-77)</td>
</tr>
<tr>
<td>No. of patients (years)</td>
<td>10 of 10</td>
<td>10 of 10</td>
</tr>
<tr>
<td>Time to clinical end-points (months)</td>
<td>5.1 (2-15)</td>
<td>17.8 (2-66)</td>
</tr>
</tbody>
</table>

Table 1: Characteristics of patients with RUNX1-L56S mutations compared to patients without RUNX1-L56S mutation.

Summary/Conclusions: Clearing of ‘Driver-COSMIC only’ mutations while RUNX1_L56S persists is unlikely to contribute towards disease progression in AML.

Acute myeloid leukemia - Clinical

E906

PROGNOSTIC SIGNIFICANCE OF FLT3 STATUS, CYTOGENETIC, ECOG AND 50% BLAST DECREASE IN PRIMARY RELAPSED OR EARLY RELAPSED AML PATIENTS BEFORE SALVAGE THERAPY

P. Sesques1, S. Bertoli2, M. El-Hamri1, S. Ducastelle1, G. Salles1, C. Recher2, X. Thomas1, E. Paubelle1

1hematology, Chu Lyon Sud, Pierre Benite, 2hematology, Oncopole Toulouse, Toulouse, France

Background: Prognosis of relapsed/refractory acute myeloid leukemia (R/R AML) is unfavorable with a long term overall survival around 10%. Thus, management of R/R AML represents one of the most difficult challenges. Because allogeneic-Hematopoietic Stem Cell Transplantation (allogeneic-HSCT) is considered as the best treatment for this category of patients, to determine which patient will benefit from this cumbersome strategy is a crucial issue. A better understanding of the mutational status, cytogenetic, histological and clinical findings of early R/R AML patients and their outcomes could help treatment decisions, particularly for those who allogeneic-HSCT is considered as the best therapeutic option.

Aims: The objective of this study is to determine prognostic factors and develop a prognostic score using usual mutational status, cytogenetic, histological and simple clinical variables in R/R AML patients before salvage treatments.

Methods: In this retrospective study in two hematological departments (Hospices Civils de Lyon and CHU of Toulouse), we evaluated clinical, biological, histological, cytogenetic and current mutational status of early R/R non APL AML patient between age from 18 to 70 years. Univariate and multivariate analysis were performed and we developed a prognostic score based on the independent prognostic parameters from Cox model.

Results: From January 2009 to May 2016, 58 patients presenting early relapse and primary refractory AML were analyzed. Overall Survival (OS) and Progression Free Survival (PFS) median were 9 and 2 months respectively. In univariate analysis, cytogenetic findings (unfavorable groups), unfavorable ECOG (>2), FLT3 positive status and <50% blast decrease (between induction and R/R assessment) independently predicted poor OS and were identified as significant prognostic parameters of OS (p=.037, p=.0084, p=.0452, p=.0071 respectively). In multivariate analysis, these last four criteria confirmed their worst prognostic impacts (p=.015, p=.017, p=.026, p=.015 respectively) and were used to create a five groups prognostic score. Better OS were statistically observed for patient with score 0 or 1 compared to score 2, 3 or 4 (2-years OS 48% and Not Reached respectively, p=.010) (Figure 3).

Figure 1.

Summary/Conclusions: Our prognostic score based on simple and usual data: FLT3 status, cytogenetic, ECOG and percentage blast decrease found distinct groups with statistically different outcomes. Basically, the higher is the score, the worst is the OS. This new score is a valuable, simple and useful score for the therapeutic salvage management of AML patients presenting early relapse and primary refractory.

Figure 1.
Preliminary Results from a Phase I Study Examining the Novel BCL-2 Inhibitor S55746/BCL201 as Single Agent in Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

A. Wei1, A. Bajeli2, N. Boisseil3, I. Kloos4, C. Delifer4, S. Banquet1, X. Thomas5, N. Vey6

1Department of Clinical Haematology, The Alfred Hospital and Monash University, 2Department of Haematology & Bone Marrow Transplantation, The Royal Melbourne Hospital, Melbourne, Australia, 3Department of Hematology, Hôpital Saint Louis, Paris, 4Servier, Suresnes, 5Department of Hematology, Centre Hospitalier Lyon Sud, Lyon, 6Department of Hematology, Institut Pauli-Calmettes, Marseille, France

Background: Novel and effective therapeutic options for patients (pts) with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are limited. Targeting the pro-survival molecule BCL-2 is clinically efficacious in various hematological malignancies. S55746/BCL201 is a novel, selective and potent inhibitor of BCL-2, with demonstrated antileukemic activity in preclinical models.

Aims: To evaluate the safety, recommended phase 2 dose (RP2D), pharmacokinetic (PK), pharmacodynamic (PD) and preliminary activity of S55746/BCL201 in patients with AML (relapsed/refractory (R/R) or ≥65 years until for intensive chemotherapy (IC)), or MDS failing prior therapies.

Methods: A phase I study (EUDRACT 2014-002559-24, NCT02920541) is underway to investigate S55746/BCL201 as a single agent in 5 European and Australian centers. S55746/BCL201 was initially administered in fasting conditions, once daily (21-day cycles), until disease progression, unacceptable toxicity, or investigator’s or patient’s decision. Pts giving informed consent received S55746/BCL201 at escalating dose levels according to a modified continual reassessment method for dose allocation.

Results: As of 23 February 2017, 34 pts have received S55746/BCL201 at doses ranging from 100 to 1300mg/day (median time on treatment: 43 days, range 1 to >374), 28 pts were R/R AML, 2 pts were elderly AML unfit for IC, and 4 pts had MDS failing prior therapies. Median age was 70 years (range 19-80), median number of prior therapies 2 (range 0-6), ECOG ≤2, and median WBC 4 pts had MDS failing prior therapies. Median age was 70 years (range 19-80), median number of prior therapies 2 (range 0-6), ECOG ≤2, and median WBC

Summary/Conclusions: Initial findings suggest that S55746/BCL201 has acceptable tolerability and clinical activity in advanced AML and MDS. Based on non-compartmental pharmacokinetic food interaction results from another study, demonstrating that S55746/BCL201 Cmax and AUC increased about 6-fold with food, dose escalation has started in patients with drug intake during a meal.

E908

Dissecting the Clinical Heterogeneity of Nucleophosmin-1 (NPM1) Mutated Adult Acute Myeloid Leukemia: The Contribution of Flow-Cytometric Determination of Minimal Residual Disease

F. Buccisan1,∗, L. Maurillo1, M.I. Del Principe1, A. Di Veroli1, E. De Bellis1, L. Ciccioni1, M. Divona1, T. Ottone1, S. Lavorgna1, V. Rossi1, A. Zizzari1, M.A. Imo Consalvo1, D. Fraboni1, C. Conti1, G. Del Poeta1, M.T. Voso1, W. Arcese1, F. Lo Coco1, A. Venditti1

1Biomedicine and Prevention, University For Vergata of Rome, Rome, Italy

Background: Acute Myeloid Leukemia (AML) with mutations of the gene encoding Nucleophosmin-1 (NPM1) identifies a subgroup of patients with favorable prognosis according to the 2008 WHO classification. However, recent evidences (Papaemmanuil, NEJM 2016) suggest that the coexistence of additional gene mutations (e.g. DNMT3A, IDH1, IDH2R1408 and TET2) may determine an inferior clinical outcome as compared to favorable risk AML and precludes a reliable outcome prediction. The presence of minimal residual disease (MRD), as determined by quantization of NPM1 mutated transcripts, provides powerful prognostic information independent of other risk factors (Ivey, NEJM 2016).

Aims: The aim of our study was to investigate if detection of NPM1 by multiparametric flow cytometry (MFC) might represent an alternative tool to discriminate different prognosis within the NPM1 mutated AML group, in a setting where an extensive gene profiling at diagnosis or a quantitative determination of NPM1 transcripts in remission would not be available.

Methods: We analyzed a series of 69 AML patients with NPM1 mutations; all the patients were in complete remission (CR) after intensive induction cycle of EORTC-GIMEMA protocols. The frequency of NPM1 mutated cases was not different among patients below (48/142, 34%) or above (21/61, 34%) the age of 60 years, respectively. Twenty out of 65 patients (31%) carried a concomitant FLT3-ITD mutation.

Summary/Conclusions: Among NPM1 mutated patients, the rate of MRD negative CR was significantly lower (5/69, 7%) as compared to NPM1 WT ones (39/134, 29%), respectively (p<0.001). Although there was not a statistically significant difference, probably due to the low numbers, MRD negative/NPM1mut patients had a lower Cumulative Incidence of Relapse (CIR) as compared to MRD positive/NPM1mut ones (25% vs 60%). We also evaluated the impact of autologous (AuSCT) or allogeneic (ASCT) transplantation on the outcome of MRD positive/NPM1mut patients. The overall survival (OS) was significantly higher for patients submitted to ASCT (no=14) as compared to those (no=15) submitted to AuSCT (93% vs 33%, p=0.011). This was confirmed even after excluding from the analysis FLT3-ITDmut patients. When all the meaningful clinical variables were challenged in multivariate analysis (MRD, type of transplant, age ≥60 yrs, karyotype), the type of transplant (ASCT vs AuSCT) was the only variable that significantly influenced OS and DFS (p=0.001 and 0.003, respectively).

Results: Among patients with a quantitative RT-PCR represents the gold standard, MFC determination of MRD also confirms that the quality of remission is critical to discriminate patients with a different outcome among NPM1mut patients. In fact, these patients have a low chance to become MFC MRD negative and in a situation of MRD positivity, a very poor outcome can be substantially improved only by a timely use of an allogeneic procedure.

E909

Expression of Immune Checkpoint Molecules (PD-1, PD-L1, and PD-L2) on Bone Marrow T Cells in Acute Myeloid Leukemia


1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 2Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 3Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of

Background: Immune checkpoints constitute a mechanism by which tumors escape from the host immune system and involve the programmed death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2. In tumor microenvironment, the expression of PD-1, an inhibitory receptor on the surface of T cells, can lead to dysfunction of antitumor effector cells. Recently, investigators have detected overexpression of PD-1 for patients with acute myeloid leukemia (AML) who experienced relapse following allogeneic stem cell transplantation.

Summary/Conclusions: Initial findings suggest that S55746/BCL201 has acceptable tolerability and clinical activity in advanced AML and MDS. Based on non-compartmental pharmacokinetic food interaction results from another study, demonstrating that S55746/BCL201 Cmax and AUC increased about 6-fold with food, dose escalation has started in patients with drug intake during a meal.

E909

Expression of Immune Checkpoint Molecules (PD-1, PD-L1, and PD-L2) on Bone Marrow T Cells in Acute Myeloid Leukemia


1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 2Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 3Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of

Background: Immune checkpoints constitute a mechanism by which tumors escape from the host immune system and involve the programmed death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2. In tumor microenvironment, the expression of PD-1, an inhibitory receptor on the surface of T cells, can lead to dysfunction of antitumor effector cells. Recently, investigators have detected overexpression of PD-1 for patients with acute myeloid leukemia (AML) who experienced relapse following allogeneic stem cell transplantation.

Summary/Conclusions: Initial findings suggest that S55746/BCL201 has acceptable tolerability and clinical activity in advanced AML and MDS. Based on non-compartmental pharmacokinetic food interaction results from another study, demonstrating that S55746/BCL201 Cmax and AUC increased about 6-fold with food, dose escalation has started in patients with drug intake during a meal.

E909

Expression of Immune Checkpoint Molecules (PD-1, PD-L1, and PD-L2) on Bone Marrow T Cells in Acute Myeloid Leukemia


1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 2Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 3Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of

Background: Immune checkpoints constitute a mechanism by which tumors escape from the host immune system and involve the programmed death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2. In tumor microenvironment, the expression of PD-1, an inhibitory receptor on the surface of T cells, can lead to dysfunction of antitumor effector cells. Recently, investigators have detected overexpression of PD-1 for patients with acute myeloid leukemia (AML) who experienced relapse following allogeneic stem cell transplantation.

Summary/Conclusions: Initial findings suggest that S55746/BCL201 has acceptable tolerability and clinical activity in advanced AML and MDS. Based on non-compartmental pharmacokinetic food interaction results from another study, demonstrating that S55746/BCL201 Cmax and AUC increased about 6-fold with food, dose escalation has started in patients with drug intake during a meal.
(SCT). However, evidence regarding T cell phenotypes for patients with AML is sparse.

**Aims:** The authors evaluated patients with AML to determine expression levels of checkpoint molecules (PD-1, PD-L1, and PD-L2) according to diagnosis and treatments (chemotherapy [CTx] and SCT). The purpose of this study was to identify optimal candidates for checkpoint blockade therapy for AML.

**Methods:** Bone marrow (BM) samples were obtained from 195 AML patients in different stages of the disease. Samples were stratified by time since diagnosis (n=69) and treatment response (complete remission [CR] after CTx, n=30; persistence after CTx, n=29; relapse after CTx, n=7; normocellular marrow with trilineage regeneration [NMTR] after SCT, n=19; persistence after SCT, n=18; and relapse after SCT, n=23). BM samples also were collected from 23 patients with no evidence of hematologic malignancies (control group). Flow cytometric analysis of PD-1 expression on T cells and PD-L1/PD-L2 expression on leukemic cells was performed by means of a FACSCanto II system (Becton-Dickinson, Sunnyvale, CA, USA).

**Results:** There were no differences in levels of PD-1 expression on CD8+ and CD4+ T cells at time of AML diagnosis, compared with controls. However, PD-1 expression levels on CD4+ T cells were significantly correlated with time since diagnosis. For patients at time of diagnosis, PD-1 expression on CD8+ and CD4+ T cells was significantly different compared with patients who experienced relapse after SCT (P<.025 and P=.0001), and NMTR after SCT (P=.0001 and P<.0001). In contrast, no difference in PD-1 expression was observed between patients at time of diagnosis and patients after CTx (Figure 1). For CD4+ T cells, a significant difference was found between SCT and CTx groups, and PD-1 expression levels of groups that experienced relapse (P<.0001) or persistence (P<.0001) after SCT were significantly higher than those of patients in the CTx groups. PD-L1 and PD-L2 expression on leukemic cells at time of diagnosis was higher in secondary AML transformed from myelodysplastic syndrome than in de novo AML (P=.0001 and P=.039). Although PD-L1 and PD-L2 expression levels for patients at time of AML diagnosis did not differ from groups that experienced relapse or persistence after SCT, PD-L1 and PD-L2 levels for diagnosed patients did differ from those of patients who experienced persistence after CTx (P=.038 and P=.023).

**Summary/Conclusions:** Our study shows that HIV status has no prognostic impact on AL patient’s outcome. HIV patient with acute leukemia should thus be included in clinical trials to improve and standardize their therapeutic management.

**E911**

**TEN-DAY DECITABINE AS INDUCTION THERAPY FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA FIT FOR INTENSIVE CHEMOTHERAPY**

C. Zhou1, H. Wei1, D. Lin1, Y. Wang1, B. Liu2, K. Liu1, B. Gong1, Y. Li1, G. Zhang1, S. Qiu1, R. Gu1, S. Wei1, X. Gong1, Y. Mi1, J. Wang1

**Background:** Data on HIV patients with acute leukemia (AL, acute myeloid leukemia [AML]) or non Burkitt acute lymphoid leukemia (ALL)) are very poor especially on their outcome. Treatment of acute leukemia usually depends of patient-related prognostics factors and disease related prognostic factors. Because HIV patients are considered frail, they are always excluded of therapeutic protocols. There are no guidelines for their treatments.

**Aims:** Our aim was to precise the epidemiology, the best therapeutic strategies as well as patient’s prognostics, and to compare their outcome to those of seronegative patients with AL.

**Methods:** We conduct a retrospective national multicentric study. HIV positive patients with a diagnosis of AML or non Burkitt-ALL between January 2000 and February 2016 were included. We compared HIV patients’ outcome to those of seronegative patients with AL after a propensity score matching.

**Results:** 47 HIV patients with a diagnosis of AL (42 AML and 5 ALL) were included. AL incidence in HIV patients (HIVP) is not different than in general population but AL occurred earlier (49.29 years [44.21 ; 57.47]) and secondary AL are more frequent (42.55%). With a global and multidisciplinary approach these patients can be treated with intensive chemotherapy resulting on good efficacy (complete remission [CR]=84.38%) and tolerance. Based on a multivariable model, only absence of CR was associated with hazard of death (p=0.01). 8 patients (17.02% ; 7 AML and 1 ALL) received a hematopoetic stem cell transplantation. HIVP with AL 2 years overall survival (OS) was 29% CI95% [15 ; 54] for AML and 40% CI95% [14 ; 100] for ALL. There was no difference in OS between our HIVP and seronegative controls with AL after propensity score matching (HR=1.347 [0.6486-2.796]; p=0.42).

**Summary/Conclusions:** Our study shows that HIV status has no prognostic impact on AL patient’s outcome. HIV patient with acute leukemia should thus be included in clinical trials to improve and standardize their therapeutic management.
Leukemia Net risk stratification, 9 had favorable risk (3 with DNMT3A and 2 with low allelic ratio (<0.5) of FLT3-ITD) and 3 had adverse risk. No RLT was observed with the 1st and 2nd dose levels. The most frequently reported adverse events (regardless of attribution), were febrile neutropenia, diarrhea, nausea and vomiting, dyspnea, hypotension, and hypoxia. Three pts are no longer on study: 1 (dose level 0) due to inability to swallow indoximod after hypoxic respiratory failure during induction, 1 (dose level 1) withdrew consent for personal reasons after only 2 doses of indoximod, and 1 (dose level 2) was taken off due to eligibility. The remaining 9 pts are still on study; 3 pts in dose level 2 are currently receiving induction and are not evaluable. Five of 6 (83%) evaluable pts had dose levels 0 and 1 achieved complete remission (CR) after induction. All 5 pts demonstrated no evidence of MRD at levels <0.02% (MRD-neg) post-induction and remained MRD-neg post cycle 1 of HiDAC. One pt in dose level 1 had favorable risk (normal karyotype, mutations in DNMT3A/NPM1/NRAS) had primary refractory disease. The pt who was unable to swallow indoximod had favorable risk (normal karyotype, mutations in DNMT3A/NPM1) and achieved morphologic CR but had MRD at the end of induction, and ultimately relapsed after 2 cycles of HiDAC consolidation.

Summary/Conclusions: Indoximod does not appear to add significant toxicity to standard remission induction and consolidation in pts with newly diagnosed AML. Initial data suggest a high rate of MRD-neg after one cycle of induction chemotherapy.

E913

PHASE III STUDY OF MEK INHIBITOR (MEK-162; BINMEDITIN) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYELOID MALIGNANCIES

K. Naqvi1, T. Kadia1, G. Borthakur1, K. Takahashi1, P. Bose1, N. Daver1, Y. Alvarado1, M. Ohanian1, C. DiNardo1, E. Jabbour1, G. Garcia-Manero1, H. Kantarjian1, A. Patel1, F. Ravandi1

1Department of Leukemia, UTMD Anderson Cancer Center, Houston, United States

Background: Activation of the mitogen-activated protein kinase (MAPK) signaling (RAF/RAF/MEK/ERK pathway) promotes growth and inhibits apoptosis of hematopoietic cells. Inhibition of MEK/MAPK pathway has shown antiproliferative effects in acute myeloid leukemia (AML) cells and AML blasts. MEK-162 is an oral, potent, selective allosteric, ATP-competitive inhibitor of MEK1 and 2.

Aims: To study the efficacy and safety of MEK-162 in patients with advanced myeloid malignancies.

Methods: Patients with relapsed/refractory AML, not candidates for intensive chemotherapy, and patients with high risk myelodysplastic syndrome (MDS) who were resistant/intolerant to standard treatment including stem cell transplant were treated with MEK-162 twice daily every 28 days. Patients in the expansion phase had to be RAS mutated. The primary endpoint was overall response rate (ORR=CR + CRi) after 1 cycle of therapy. Survival was estimated using the Kaplan-Meier method. Safety analysis included all patients who had received at least 1 dose of MEK-162. MEK-162 dose escalation followed a 3+3 design; phase 2 had built in/flipper/toxicity boundaries. 45mg twice daily is the first in dose level for expansion phase.

Results: Sixteen patients were treated (escalation=7; expansion=9): 14 AML and 2 MDS. Median age was 62 years (31-85); 56% were male; 94% had a performance status of 1-2. Median number of prior therapies was 4 (1-6). 3/16 (19%) patients had complex karyotype. 11/69 (16%) patients were RAS mutated. 16 patients completed a minimum of 1 cycle of MEK-162 therapy and were evaluable for response (3 at 30mg and 7 at 45mg dose). ORR was 10% (CRI in 1/10 patients). Median number of cycles administered were 2 (1-4). Median duration on therapy was 1.1 months (0.1-3.4). Median overall survival was 3.2 months (0.3-7.6). Common C3/4 toxicity included neutropenia (56%), fatigue (13%), nausea/vomiting (13%) and electrolyte abnormalities (19%). No dose limiting toxicity was reported.

Summary/Conclusions: MEK-162 shows a tolerable safety profile with an ORR of 10%. The study is currently on-going. Additional studies involving combination of MEK-162 with RAF and PI3 kinase inhibitors are ongoing.

E914

HAPLOIDENTICAL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR OLDER PATIENTS WITH AML/MDS

S. Clurea1, R. Saliba1, M. Shah1, S. Gaballa2, G. Rondon1, J. Chen1, A. Gulbis1, W. Wallis1, B. Oran1, A. Alousi1, G. Bashir1, S. Ahmed1, D. Mann1, K. Rezvani1, M. Imran1, F. El Chaer1, M. Koka4, Z. Singh4, Y. Alvarado1, M. Ohanian1, C. DiNardo1, E. Jabbour1, G. Garcia-Manero1, H. Kantarjian1, A. Patel1, F. Ravandi1

1Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, 2Thomas Jefferson University, Philadelphia, 3Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Acute myeloid leukemia (AML) is more common in the older population. Haploidentical stem cell transplantation (haploSCT) is a potentially curative approach for patients with hematological malignancies.
ative treatment option for patients with AML and allows transplantation for patients without an HLA matched donor. Recently, the use of post-transplant cyclophosphamide-based (PTCy) GVHD prophylaxis has improved outcomes of haploSCT; however, outcomes of haploSCT in older patients remain unclear.

Aims: Here we evaluated outcomes of older patients with AML/MDS who underwent haploSCT.

Methods: We retrospectively analyzed outcomes of all 43 patients ≥55 years with AML/MDS who underwent a haploSCT at our institution after year 2009. All patients were treated with fludarabine-melphalan (FM)-based conditioning regimen (melphalan 100 or 140 mg/m²) plus thiotepa 5 mg/kg or 2GyTBI. Characteristics of these patients are presented in Table 1.

Figure 1.

Results: Median age was 61 years (range 55-69), 22 patients (51%) were in CR1/2, 16 patients (37%) had poor-risk cytogenetics, and median HCT-CI was 2 (range 0-11). Reduced melphalan regimen (100 mg/m²) was used in 29 pts (67%). Donors were children in 35 (81%) or siblings 10 (19%) patients. Median follow-up was 19 months (range 6-49). One patient died prior to engraftment. Forty-two patients engrafted the donor cells (100%). Median time to neutrophil and platelet engraftment was 19 (13-28) and 28 (15-117) days. Day 30 chimerism was 100% donor in 38 patients (88%). The cumulative incidence of 2.5×10⁻⁴ residual leukemic cells (>0.025%) or a threshold of 1x10⁻³ residual leukemic cells (>0.1%). For patients carrying NPM1-gene mutation NPM1 expression levels at TP1, TP2, TP3 (NPM1-MRD) were analyzed. A reduction >3.5 log of NPM1 transcript at TP1 was considered optimal as per our published experience. For patients presenting WT1 over-expression at diagnosis WT1-MRD was evaluated at TP1, considering WT1 negativity with a cut-off of WT1 copies/10⁴ ABL lower than 250.

Results: CR rate after induction I and II was 82.7 and 85.5%, respectively. The percentage of MFC-MRD negativity at TP2 increased from 29% to 37% (p=0.05). Good/intermediate cytogenetics (HR:0.2, p=0.01), and donor age (HR:0.4, p=0.05) were independent predictors for OS in the whole cohort. Multivariate analysis showed that NPM1-MRD at TP1 was the strongest predictor for OS in this group.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N (%)</th>
<th>Median age</th>
<th>Median follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td></td>
<td>0 (0-69)</td>
<td>19 (6-49)</td>
</tr>
<tr>
<td>AML</td>
<td>25 (58%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS/AML</td>
<td>8 (19%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td>10 (23%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytogenetics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>16 (37%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>24 (54%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>11 (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBC</td>
<td>29 (67%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spleen node</td>
<td></td>
<td>42 (48%)</td>
<td></td>
</tr>
<tr>
<td>HCT-CI</td>
<td>Median 2 (range 0-11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease status</td>
<td></td>
<td>22 (51%)</td>
<td></td>
</tr>
<tr>
<td>CR1/2</td>
<td>22 (51%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>21 (48%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Child</td>
<td>33 (81%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sibling</td>
<td>9 (22%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor age</td>
<td>Median 37 (range 20-505)</td>
<td>28 (65%)</td>
<td></td>
</tr>
<tr>
<td>Sex mismatch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female donor/ Male recipient</td>
<td>13 (30%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>30 (70%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our data show that MRC assessment at different time-point cut-off in older patients with AML/MDS patients undergoing haploidentical transplantation. Significant associations were observed between donor age and improved survival in older AML/MDS patients undergoing haploidentical transplantation.
Background: Hematopoietic recovery is considered to be associated with the number of multipotent hematopoietic stem cells in the bone marrow, as observed in functional assays involving cell transplantation. However, there is little evidence related to hematopoietic recovery in non-transplantation settings, which is accomplished by endogenous hematopoietic cells. A recent study suggested that progenitors are the main contributors during this steady-state hematopoiesis, which differs from exogenous transplantation. And our previous data revealed that, CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells (P cells), a kind of progenitor cell, is significantly decreased in patients with delayed neutrophil recovery after chemotherapy compared with that without delayed count recovery.

Aims: To further examine a potential impact of P cells percentage on hematopoietic recovery.

Methods: The data of 223 patients diagnosed with de novo AML was analyzed retrospectively. All these patients enrolled in our previously registered prospective randomized clinical trial AML 2010-01(201002024). We reviewed the data from bone marrow flow cytometry before the first and second course of consolidation therapy, in which the CD34+CD38+CD117+HLA-DR+CD13+CD33+ progenitor cell percentage in the bone marrow was analyzed. Plt, platelet count and time of neutropenia were counted for the evaluation of hematopoietic recovery ability after chemotherapy.

Results: We found that less P cell percentage was significantly associated with prolonged neutropenia recovery time after the first and second courses of consolidation chemotherapy (p=0.001; p=0.028, respectively). We also observed similar results regarding platelet recovery. A univariate analysis showed that P cell percentage, rather than gender, age, WHO classification and cytogenetic subgroup, were associated with neutrophil recovery after chemotherapy. Multivariate analysis demonstrated that P cell percentage is an independent factor affecting neutrophil recovery capability for both first and second courses (p=0.015; p=0.036, respectively).

Summary/Conclusions: Our results indicate that CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells before each course of chemotherapy is associated with chemotherapeutic hematopoietic reconstitution capacity independently. These findings may help better understand endogenous hematopoietic reconstitution and modify future chemotherapy regimens based on progenitor cell percentages.

E917

MICRONAS (miRS) IN HIGH RISK PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) - A POTENTIAL TOOL FOR RISK PREDICTION AND OUTCOME ASSESSMENT

P.P. Leoncini1,2, P. Vitullo2, N. Gigniga2, D. Veneziano2, P. Fadiga3, V. Tocco1, M. Pigazzi2, G. Basso4, R. Rota1, A. Bertaina1

1Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy, 2Medical Genetics, 3Genomic Shared Resources, Ohio State University, Columbus (OH), United States, 4Oncohaematology-Pediatrics, University of Padova, Padova, Italy

Background: Despite recent progresses made in the treatment of acute myeloid leukemia (AML) of childhood, the cure rates of high-risk subtypes remain low. Indeed, patients harboring FLT3-ITD mutations or 11q23 translocations (MLL rearrangements) are still characterized by a poor prognosis, mainly due to leukemia recurrence. Since microRNA (miRs) are small RNA molecules controlling normal hematopoiesis whose deregulation is fundamental in leukemia’s pathogenesis, a possible role as predictors of relapse should be considered.

Aims: Our purpose is to identify, at time of diagnosis, significant miRs signatures able to predict the risk of relapse for patients with high-risk AML, such as FLT3-ITD and MLL mutated. Moreover, these signatures would help us in identifying new molecules for novel targeted therapy and to deeply characterize different deregulated pathways among FLT3-ITD and MLL rearranged patients.

Methods: A total of 20 AML bone marrow (BM) derived samples collected either at diagnosis (ND) and at relapse (RL) together with 8 healthy controls (HCs) were studied (total: N=48). Informed consent has been obtained from either parents or legal guardians according to the Declaration of Helsinki. RNA was extracted, cleaned up and Nanostorm microRNA profiling was performed. Statistical analysis was performed using nSolver® (NanoString Technologies; Seattle, WA, USA) and R-based software. All the assessed results imply a P<0.05 where not mentioned.

Results: Comparing all AML samples with HCs, we found 16 up- and 509 down-regulated miRs. Similarly, FLT3-ITD (n=11) vs HCs, showed 17 up- and 377 down-regulated miRs, respectively. A trend towards down-regulation of the whole cohort was detected and a block in miRs maturation occurring in the 2 molecular subsets was supposed. Finally, a FLT3-ITD vs MLL-rearranged analysis produced a signature in which 20 miRs were up- and 18 down-regulated, a putative signature which could characterize high-risk AML. ND vs HCs analysis identified 17 up- and 297 downregulated miRs, confirming a tendency toward downregulation, as well as in RL vs HCs analysis, in which we found 12 and 374 up- and down-regulated miRs, respectively. RL vs ND comparison showed a total of 16 up- and 15 down-regulated miRs. In the attempt to identify a signature predictive of recurrence at time of diagnosis, we compared ND and RL samples, revealing 301 miRs that maintained their deregulation in the 2 subgroups, while 113 and 85 were uniquely found in ND vs HCs and RL vs HCs, respectively. Remarkably, mir-34a-5p (P=0.0001) was the recurrent and most statistically significant upregulated miR in both ND and RL samples. Moreover, upregulated mir-10a-5p and mir-99a-5p (P<0.0001), and downregulated mir-5p (P<0.0001) were the most statistically significant miRs identified. FLT3-ITD and MLL-rearranged sets respectively, underlying putative unique elements distinguishing the two clinical subsets.

Summary/Conclusions: Our results suggest the presence of different microRNA signatures in pediatric AML carrying FLT3-ITD and 11q23 translocations ([t(9;11) and (t(10;11)]. The identifications of new targets linked to this miRs would help us in further studies focused on finding molecular-based therapy. Interestingly, mir-34a-5p was recurrently found upregulated either in ND and RL groups, but in the comparative analysis between ND vs RL, suggesting a potential involvement in the mechanisms at the base of both onset and relapse in these subtypes of high-risk AML.

E918

CYTOKINE RECEPTORS AND SOLUBLE ADHESION MOLECULE LEVELS ARE ASSOCIATED WITH PROGNOSIS OF NEWLY DIAGNOSED AML

T. Kupsa1,2, P. Zák2, L. Jevab1,2, J. M. Horaceck1,2

1Department of Military Internal Medicine and Hygiene, Faculty of Military Health Sciences, 24th department of Internal Medicine - Hematology, University Hospital, Charles University, Faculty of Medicine, Hradec Královec, Hradec Královec, Czech Republic

Background: The outcomes of acute myeloid leukemia (AML) treatment are beleaguered by the high resistance of malignant clones to therapy. Cytokines and adhesion molecules have been studied as markers of relapse and mortality. A potent mechanism driving the growth of AML cells is the potential involvement in the mechanisms at the base of both onset and relapse in many diseases including AML. Further knowledge gained from baseline cytokine levels assessment may help to improve treatment outcomes.

Aims: The aim of this study is to evaluate baseline levels of selected cytokines, cytokine receptors and adhesion molecules and their relationship with prognosis in newly diagnosed AML patients.

Methods: A total of 75 AML patients, age 52.9±13.0 years, median 58.4 years, were studied in the period 2010-2015. Only patients with minimal follow-up of 1 year were included. All patients were induced with “3+7” induction chemotherapy consisting of Cytarabine 100mg/m2 per day for 7 consecutive days and Daunorubicin 90mg/m2 for the first 3 days of therapy in younger patients. Since the beginning of 2015, the induction dose of Daunorubicin used has been 60mg/m2 even in younger patients, according to recent evidence-base data modifications. Those who failed to achieve CR were given FIAldal salvage therapy with allogeneic stem cell transplantation in younger and fit patients. In CR, the patients were treated either with HIdAC consolidations achieved either by allogeneic stem cell transplantation in younger patients or by autologous stem cell transplantation in older patients. A total of 39 patients underwent allogeneic stem cell transplantation. We evaluated serum levels of the following 29 analytes: interleukins (IL-1α,IL-1β,IL-2,IL-3,IL-4,IL-5,IL-6,IL-7,IL-8,IL-10,IL-12,IL-13,IL-15), Epidermal Growth Factor, Granulocyte Macrophage Colony Stimulating Factor, Interferon-γ, Macrophage Inflammatory Protein-1α, Monocyte Chemotactic Protein-1, Tumor Necrosis Factor-α (TNF-α), Vascular Endothelial Growth Factor, E-selectin (E-selectin, E-SEL), P-selectin (P-SEL), Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), Matrix Metalloproteinase-9, soluble IL-2 receptor-a (sIL-2Rα) and soluble receptors for IL-6 (sIL-6R) and TNF-α type I and II receptors.

Results: CR by induction therapy was achieved in 53 cases (70.7%). Those who failed to achieve CR by induction therapy had higher IL-7 levels, which was not significant after Bonferroni correction (P=0.0913). Inferior PFS was associated with higher sIL-2Rα (P=0.0525). Inferior OS was significantly associated with higher P-SEL (P=0.0003), higher sIL-2Rα (P=0.0029), higher age (P=0.0356) and possibly with higher TNFR-1 (P=0.0611). Age has not correlated with any evaluated analyte. TNFR-1 correlated with TNFR-2 (P<0.0001), but not with TNF-α. The sIL-2Rα did not correlate with IL-2. Only IL-6 and ICAM-1 were significantly influenced by CRP levels.

Summary/Conclusions: Better understanding of the cancer microenvironment is a sine qua non for development of new treatment approaches. Our results in evaluated panel may provide a tool for the assessment of clinical outcome and thus should be further investigated as possible therapeutic targets. The work was supported by a long-term organisation development plan 1011/2014 of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
MRD-DRIVEN CHOICE OF CONSOLIDATION AND MODULATION OF INDUCTION AND CONSOLIDATION INTENSITY RESULTED IN A SIGNIFICANTLY IMPROVED OUTCOME OF YOUNGER AML PATIENTS IN THE LAST THREE YEARS

M. Clavio1,*, F. Guolo1, P. Minetto1, M. Miglino1, F. Ballerini1, D. Guardo1, E. Covillo1, R.M. Lemoli1, M. Gobbi1
1Clinic of Hematology, Department of Internal Medicine (DIMI), University of Genoa, IRCCS OAU San Martino-IST, Genova, Italy

Background: In the last decades no effective new drugs have been introduced and AML induction therapy is still based on an anthracycline and cytarabine. The MRC group has, however, reported a progressive increase of cure rates in younger patients. Our group has recently showed that the outcome can be improved by a fludarabine-containing induction (FLAIF5, with fludarabine administration in first course only), followed by a risk-adapter consolidation.

Aims: The aim of the present study was to evaluate if the disease free survival (DFS) and the overall survival (OS) of younger (<65 years) AML patient treated in our center had shown any modification in four consecutive periods of treatment (< 2008; 2008-2010; 2011-2013; 2014-2016) and to recognize factors possibly leading to this result.

Methods: We reviewed the outcome of 145 consecutive AML patients aged 65 or less and uniformly treated according to the above mentioned strategy. Minimal residual disease (MRD) evaluation was performed by flow cytometry (MFC), assessment of WT1 expression levels and, where applicable, evaluation of recurrent abnormalities such as NPM1 mutation.

Results: The cohorts of patients treated in the four periods had a comparable age and risk distribution. Notably, although the median follow up of the 4 cohorts of patients is different, patients treated in the last 3 years showed a significant improvement in DFS (Fig 1), in comparison with previously treated patients. When we reviewed our experience, we found that some changes we introduced in the therapeutic management, possibly contributed to improve outcome. Beside classical risk factors, the time from hematological recovery after the first induction (induction 1) and the start of the second induction course (induction 2) proved to be significantly related to DFS and OS probability. An interval shorter than 15 days resulted in significantly higher toxicity, whereas a time longer than 25 days was associated with an increased relapse probability. Patients being treated in the last three years had a median time from recovery after induction 1 to start of induction 2 of 17 days, compared to 22 days in the other cohorts (p<0.05). Furthermore, after 2013, MRD information after induction 1 was added as a prognostic factor and ELN low and intermediate risk patients were given two cycles of cladribine 5mg/m² i.v. on days 1-5 and low-dose cytarabine 40mg/m² s.c. days 1-10 every 28 days followed by 2 cycles of cladribine 5mg/m² i.v. on days 1-2 with LD-AraC (40mg/m² s.c. 1-10 days). Responding patients were treated with a prolonged maintenance consisting of LD-AraC (40mg/m² 1-10 day). The treatment was continued until progression.

Results: Twenty-four patients have been enrolled with median age 70 years (range 62-84). In our cohort 20 patients had newly diagnosed AML, 3 secondary and 1 therapy related AML. Cytogenetic risk: good risk 5 patients; intermediate 12, poor risk 3 patients, 4 patients were unclassified. The overall response rate (CR+PR) was 84%. 13 out of 24 (54%) patients achieved complete remission (CR) and 7 (30%) achieved partial remission. To recognize number of cycles to obtain CR was 2 (range 1-3), 16% of patients do not respond to treatment. The regimen was well tolerated without 4-week and 8-week mortality. The main reason of death were: heart failure (n=2), renal failure (n=1) and progressive disease (n=4). We didn’t observe grade 3-4 nonhematologic adverse events. With a median time of follow-up 14 months, the median overall survival was 12 months.

Summary/Conclusions: The combination of cladribine plus low dose AraC is effective and well tolerated regimen in elderly AML patients unfit for standard chemotherapy.

E920

EFFECTIVENESS OF TREATMENT ACUTE MYELOID LEUKEMIA IN THE ELDERLY USING CLADRIBINE WITH LOW-DOSE ARAC

M. Wręcicki1,*, T. Goromek2, A. Ptusz, K. Budziszewska2, D. Majewicz2, E. Sieńec2, I. Husz1, M. Pasierski1, S. Gozdz1, A. Wierzbowska1

1Department of Hematology, Holy Cross Oncology Center of Kielce, Kielce, 2Department of Hemaetooncology, Medical University of Lublin, Lublin, 3Department of Hematology, Medical University of Lodz, Lodz, 4Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, 5Holy Cross Oncology Center of Kielce, Kielce, Poland

Background: Treatment of acute myeloid leukemia(AML) in the elderly, unfit patients is a challenge for clinical hematologists. Therapeutic management in this group includes a.o. patients older than 60 years, unfit for standard induction chemotherapy, were enrolled to our study. The patients were given two cycles of cladribine 5mg/m² i.v. on days 1-5 and low-dose cytarabine 40mg/m² s.c. days 1-10 every 28 days followed by 2 cycles of cladribine 5mg/m² i.v. on days 1-2 with LD-AraC (40mg/m² s.c. 1-10 days). Responding patients were treated with a prolonged maintenance consisting of LD-AraC (40mg/m² 1-10 day). The treatment was continued until progression.

Methods: Patients with newly diagnosed AML (excluding APL), older than 60 years, unfit for standard induction chemotherapy, were enrolled to our study. The patients were given two cycles of cladribine 5mg/m² i.v. on days 1-5 and low-dose cytarabine 40mg/m² s.c. days 1-10 every 28 days followed by 2 cycles of cladribine 5mg/m² i.v. on days 1-2 with LD-AraC (40mg/m² s.c. 1-10 days).

Results: Twenty-four patients have been enrolled with median age 70 years (range 62-84). In our cohort 20 patients had newly diagnosed AML, 3 secondary and 1 therapy related AML. Cytogenetic risk: good risk 5 patients; intermediate 12, poor risk 3 patients, 4 patients were unclassified. The overall response rate (CR+PR) was 84%. 13 out of 24 (54%) patients achieved complete remission (CR) and 7 (30%) achieved partial remission. To recognize number of cycles to obtain CR was 2 (range 1-3), 16% of patients do not respond to treatment. The regimen was well tolerated without 4-week and 8-week mortality. The main reason of death were: heart failure (n=2), renal failure (n=1) and progressive disease (n=4). We didn’t observe grade 3-4 nonhematologic adverse events. With a median time of follow-up 14 months, the median overall survival was 12 months.

Summary/Conclusions: The combination of cladribine plus low dose AraC is effective and well tolerated regimen in elderly AML patients unfit for standard chemotherapy.

E921

SMALL CUSTOMIZABLE NGS BASED TARGET CAPTURE PANELS DETECT VARIANTS IN CLINICAL SPECIMENS AT FREQUENCIES AS LOW AS 0.5%

L. Chamberlain1,*, A. Carson1, V. McClain1, B. Patay1, O. Kiya1, W. Huang1, D. Hubbard2, D. Caguioa2, Z. Xie1, J. Thernes2, T. Stenzel1, J.E. Miller1, B. Buchsbaum2, S. Gardner1, S. Fournier2, J. Cripe3, A. Chugg2, K. Kveckas1

1Iniviscience, Inc., 2LabPMM, San Diego, United States

Background: The use of large scale hybridization panels in early stages of clinical trials for novel therapies elicits a plethora of information for targeted biomarkers. However, as therapeutic targets are further characterized large panels generate an overly broad set of data, compromising sensitivity in the selected biomarker subset. Therefore, once biomarker targets are identified, the use of smaller hybridization panels can facilitate specific variant detection by analyzing specific genomic regions of interest with greater sensitivity than larger gene panels and PCR-based assays. Modifications of laboratory methods for small scale panels allow for the maintenance of high analytic quality with finely targeted panels. Our small panels (~10kb) focus on 1-4 genes, allowing for high-multiplexing of samples on sequencers, and reduced costs/processing times without compromising accuracy.

Aims: To demonstrate the sensitivity, linearity, concordance with other assays, and clinical applications of small NGS target capture panels.

Methods: Two separate next generation sequencing-target capture assays were developed with bioinformatics software under ISO13485 design control. Two separate next generation sequencing-target capture assays were developed with bioinformatics software under ISO13485 design control. The first assay was developed by spiking in fixed amounts of mutant DNA into wild type DNA to establish the sensitivity, linearity, concordance with other assays, and clinical applications of small NGS target capture panels. The second covers only CD274 (PD-L1). Libraries were made, hybridized with baits, and sequenced using the Illumina MiSeqDx. Validation was carried out by spiking in fixed amounts of mutant DNA into wild type DNA to establish the linearity and sensitivity of the assays. Sequencing libraries were generated by barcode with baits from either one of both panels. Sequencing data was analyzed using proprietary software developed by Iniviscience. Eight AML clinical samples were cross validated for FLT3 mutations by this small panel, amplicon based NGS assay, and capillary electrophoresis (CE) assay.

Figure 1.
Results: DNA from 24 cell lines was assessed using both panels, confirming variants previously detected using other methods. A validation was run on the 3-gene panel using a series of contoured samples generated from cell lines containing between 0.5% and 25% variant allele frequencies for expected variants. Initial validation indicates that these small panel assays can detect mutations down to 0.5% variant allele frequencies. Assay linearity for FLT3/TKD detection from 0.25% to 12.5% or for FLT3/ITD detection from 0.5% to 25% is excellent ($R^2 = 0.996$ and 0.998, respectively). Average sequencing coverage was high, reaching from 5,265x to 7,680x. Comparison of FLT3 analysis of the small panel to amplicon based NGS assay and CE, FLT3-ITD showed complete concordance in clinical samples - and showed a strong linear relationship between the detected VAFs, and detected ITD sizes. There was also complete concordance for FLT3-ITD mutations in clinical samples.

Summary/Conclusions: Small hybridization panels are cost effective in detecting low-frequency variants from smaller subsets of genes while using far less DNA than individual PCR-based biomarker assays would require. Additionally, preliminary data shows great accuracy on clinical samples. These smaller assays focus on the most pertinent genes for a targeted therapy, and have the potential to greatly assist in understanding the molecular backgrounds of responders, super-responders, and non-responders, information which can help improve patient outcomes. Developing these assays with bioinformatics using the international ISO13485 design control standards makes them suitable for regulatory approval worldwide.

E923

MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN THE CONNECT® MDS/AML DISEASE REGISTRY

1University of Colorado Cancer Center, Aurora, 2University of New Mexico, Albuquerque, 3University of Alabama at Birmingham, Birmingham, 4Aurora Research Institute, Aurora Health Care, Milwaukee, 5Weill Cornell College of Medicine, New York, 6Department of Florida Health Cancer Center–Orlando Health, Orlando, 7Swedish Cancer Institute, Seattle, 8New York Medical College, Valhalla, 9University of Florida, Gainesville, 10Celgene Corporation, Summit, United States

Background: Recurrent mutations in AML-associated genes have prognostic value and may help guide treatment decisions. Molecular genetic testing patterns for AML in clinical practice are largely unknown. Previous results of the CONNECT MDS/AML Disease Registry (George et al. ASH 2016; abstract 3548) showed suboptimal adherence to WHO 2008 recommendations for AML diagnosis in a cohort of patients with newly diagnosed AML in clinical practice. Aims: To report a detailed analysis of patterns of molecular genetic testing in patients with newly diagnosed AML in community and academic settings. Methods: The CONNECT MDS/AML Disease Registry (NCT01688801) is a contemporaneous, observational cohort study of patients with newly diagnosed AML (≥25 years) or myelodysplastic syndrome (MDS). All clinical decisions are made by the treating clinicians. Data are collected, using an electronic data capture system, at screening, enrollment, and approximately quarterly throughout the duration of the patient’s participation in the registry. All patients provided informed consent. Enrollment is ongoing. The current analysis evaluated the percentage of patients with AML who had undergone molecular genetic testing recommended by NCCN guidelines (NPM1, FLT3-ITD, CEBPA, IDH1, IDH2, DNMT3A, and KIT). Chi-square tests evaluated effects of several variables on likelihood of molecular genetic testing.

Results: Between 12 Dec 2013 and 8 Dec 2016 (data cutoff), 259 patients with AML were enrolled at 86 sites. Molecular genetic testing was reported in 67% (173/259) of patients. Likelihood of testing varied, respectively, for academically versus community sites (76% [70/92] vs 62% [103/167]; P = .018), normal vs adverse risk, age <65 years (77% [79/103] vs 59% [79/133]; P = .008), age <65 vs ≥65 years (83% [85/102] vs 60% [108/181]; P = .0003), and overall response rate (51% [63/123] vs 74% [90/122]; P = .025). In patients who had undergone molecular genetic testing (n=173), the mutations tested varied substantially. All of the NCCN-recommended molecular genetic tests were reported in 9% (15/173) of patients, including 8% (6/173) of patients with normal karyotype. Of the seven NCCN-recommended tests, NPM1 (77%) and FLT3-ITD (76%) were most often reported and DNMT3A least often (16%). Summary/Conclusions: Early data from the CONNECT MDS/AML Disease Registry reveal that despite molecular testing reported in 67% of patients with newly diagnosed AML, a majority of patients did not receive guideline recommended testing. This prospective registry is uniquely positioned to capture changes in testing patterns as guidelines are established.

E924

PHASE 1, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFECT OF CYTOCHROME P450 (CYP) 3A4 INHIBITION ON THE PHARMACOKINETICS (PK) AND SAFETY OF QUIZARTINIB (Q) AND ITS ACTIVE METABOLITE, AC886

J. Li1,*, M. Kankam2, D. Trome3, G. Gammon3
1Daichi Sankyo, San Diego, CA, 2Vince & Associates, Overland Park, KA, 3Formerly Daichi Sankyo, San Diego, CA, United States

Background: Q is a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor currently being investigated in Phase 3 studies in AML patients (pt) with FLT3 internal tandem duplication (ITD) mutations. Early studies showed concentration (c) dependent QTc prolongation with Q and identified isolated cases of QTc, but not its active metabolite, AC886, was a significant predictor of the QTc prolonging effect(Levis, et al. ASH 2016). Q and AC886 are both primarily metabolized by CYP3A4. Because CYP3A4 inhibiting drugs are frequently required in the...
course of AML treatment, a drug interaction study was performed to assess PK when Q is co-administered with CYP3A4 inhibitors. **Aims:** The primary aim was to determine the effect of ketoconazole (K), a strong CYP3A4 inhibitor, and fluconazole (F), a moderate CYP3A4 inhibitor, on PK of Q and AC886. The secondary aim was to assess the tolerability and safety of Q co-administered with K or F.

**Methods:** This was an open-label, randomized, parallel-group study. Healthy subjects (HS) age 18–55 years (yr) who provided informed consent were randomized 1:1:1 to receive K 200mg twice daily (BID), F 200mg BID, or placebo (P) BID on Days(D) 1-28. A single 30mg dose of Q was administered to all HS on D8. Plasma Q and AC886 conc were measured D8-28, using a validated liquid chromatography–tandem mass spectrometry method. PK parameters were determined using noncompartmental analysis. Stability-state (SS) drug conc, following repeated once daily dosing, were predicted using non-parametric superposition. An analysis of variance (ANOVA) was performed to assess the CYP3A4 inhibitory effect of K and F on the PK.

**Results:** 93 HS were enrolled (31 per arm) and 88 received Q. 75% were male, median age 32 yr (18-53). Relative to Q+P, co-administration of Q+K or Q+F increased the geometric mean (GeoMean) C_max of Q by 17% and 11%, and GeoMean AUC_0-inf by 94% and 20%, respectively (Table 1 below). The GeoMean C_max and AUC_0-inf of AC886 were decreased by 60% and 15%, respectively, for Q+K, and were increased by 3% and 14%, respectively, for Q+F. Apparent clearance (CL/F) of Q was 50% lower and t_1/2 of Q and AC886 were 46% and 96% longer, respectively in Q+K vs Q+P. CL/F of Q was 17% lower and t_1/2 of Q and AC886 were 10% and 28% longer, respectively, in Q+F vs Q+P. AC886 is a minor component in circulation relative to Q (approximately 25%). An increase of 86% in simulated SS C Q and 96% in SS Q AUC_0-24 was predicted following repeat daily dosing of 30mg Q+K vs Q+P, while a modest decrease in AC886 exposure (<20%) was predicted. The most common adverse events were headache (7.5%) and diarrhea (5.4%), with the majority being Grade 1/2. There were no clinically significant hematology, clinical chemistry, QTc, or vital sign observations, and no deaths or serious adverse events.

**Summary/Conclusions:** Co-administration of Q with K or F was well tolerated and safe. Overall, there was an approximate 2-fold increase in Q exposure when Q was co-administered with K, which is considered clinically significant. The increase in Q exposure when Q was co-administered with F was within 20% and is not considered clinically relevant. Given the relationship between Q conc and QTc prolongation, these results support reducing Q doses by approximately one-half when taken concomitantly with a strong CYP3A4 inhibitor. No dose reduction is needed when Q is co-administered with a moderate or weak CYP3A4 inhibitor. This approach has been implemented in two ongoing Phase 3 trials of Q in FLT3-ITD mutated AML.
Results showed that expression of ZEB2-AS1 lncRNA had significant shorter 3-year overall survival (OS) (0% vs 68.2%, p=0.036) and disease-free survival (DFS) (25.0% vs 69.8%, p=0.039). In addition, Patients with higher expression of ZEB2-AS1 lncRNA had significant lower complete remission (CR) rate in response to induction chemotherapy (75.0% vs 27.3%, p=0.031). In patients with low levels of ZEB2-AS1 lncRNA, patients treated by allogeneic hematopoietic stem cell transplantation had significant longer OS (3-year OS, 75.8% vs 28.6%, p=0.037) and DFS (3-year DFS, 81.8% vs 26.8%, p=0.049) compared to that of chemotherapy.

Summary/Conclusions: Moreover, knockdown of ZEB2-AS1 lncRNA could effectively inhibit invasion and migration in AML cells, which was closely associated with down-regulation of ZEB2 and up-regulation of E-cadherin. Collectively, although independent prognostic value for survivals was not rigorously determined, ZEB2-AS1 lncRNA may serve as candidate to improve conventional risk stratification system and contribute to evaluating therapeutic responses. Furthermore, ZEB2-AS1 lncRNA could have important clinical implications for the treatment of AML.

E929
INTENSIFICATION OF ANTHRACYCLINE DURING INDUCTION AND CONSOLIDATION IS SAFE AND WELL TOLERATED IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA
J. Loh1, S. Avery1, S. Patil1, P. Walker1, A. Spencer1,2, A. Wei1,2, S. Fleming1,1
1Department of Haematology, Alfred Hospital, 2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

Background: AML in the elderly is more susceptible to treatment failure. Treatment related mortality in elderly patients with AML is decreasing over time, and receiving chemotherapy of adequate intensity is important in treating AML in these patients. The optimal induction and consolidation approach for patients in this age group is yet to be established, however data from the HOVON group has demonstrated the benefit of anthracycline intensification during induction in patients aged 60-65 years, while locally the Australian AML12 study demonstrated the value of anthracycline intensification during consolidation in younger adults. We have implemented a novel combination of intensified anthracycline in combination with infusional cytarabine (AraC) during induction and in combination with intermediate-dose AraC during consolidation.

Aims: To demonstrate the safety and tolerability and provide preliminary efficacy evidence for anthracycline intensification during induction and consolidation in older adults with Acute Myeloid Leukaemia.

Methods: A retrospective pilot study was done on 76 consecutive patients above the age of 55 years with newly diagnosed AML between January 2010 to June 2016 at Alfred Hospital, Melbourne, Australia. All received the 7+3 induction regime (AraC continuous infusion at dose of 100mg/m2/day on days 1 to 7, and idarubicin at a dose of 12mg/m2/day on days 1 to 3), with a planned consolidation with AraC (AraC 100mg/m2 twice daily Day 1, 3, 5, and idarubicin 12mg/m2/day Day 1-2). Outcomes were assessed according to the Cheson criteria with cytogenetic risk assessed by the refined Grimwade MRC criteria.

Results: 76 patients, with a median age of 62 years (range 55.4-70.6 years) received the 7+3 induction with a median overall survival of 590 (range 6-1996) days and overall response rate was 52 patients (68.4%). The event-free survival median is 109 days (range 6-1988) and the relapse-free survival median is 314 days (range 4-1947). There were 9 treatment-related deaths (11.8%) within 30 days following 7+3 induction. Of 41 patients who attained complete morphology remission after induction, 29 patients (70.7%) received the planned IDAC+2 consolidation with 17 (41.5%) receiving two consolidation cycles. Of those not receiving IDAC+2, 10 patients (24.4%) received an alternative consolidation regimen and 2 patients (4.9%) did not receive consolidation. Of those receiving IDAC+2 25 (86.2%) were intermediate cytogenetic risk and 3 (10.7%) were poor risk. No treatment-related deaths occurred in patients receiving IDAC+2. 20 patients (26.3%) from the whole cohort received an allogeneic stem cell transplant (SCT), and 8 patients (27.6%) of those who received the IDAC+2 consolidation regimen proceeded to an allogeneic SCT. In all IDAC+2
consolidation cycles, the median days to neutrophil recovery was 26 days (range 18-72), platelet recovery 32 days (range 17-75), and the ICU admission rate was 12.8% (range 2-10 days). 18 patients (62.1%) receiving IDAC+2 consolidation suffered disease relapse. For patients receiving IDAC+2 consolidation the median OS was 727 days (range 113-1614 days) with an EFS of 388 days (range 109-1614 days). For patients aged 60-65 years the remission rate and survival outcomes were similar to those published by Lowenberg et al. in several studies, their prognostic significance still remains controversial.

Aims: To evaluate the prevalence and prognostic impact of IDH1 and IDH2 mutations in adult AML patients with low and intermediate-1 and 2 risk (European Leukemia Net ELN 2013)

Methods: We retrospectively evaluated IDH1 and IDH2 mutations in 99 low and intermediate risk patients with new diagnosed AML who underwent intensive induction chemotherapy in three Italian centers.

Results: Median age for all patients was 60 years. IDH mutations were detected in 25% of our patients. 7% were IDH1 R132, 16% were IDH2 R140 and 2% R172. Median WBC count was 12,66x10^9/L in IDH wild-type and, 24,71 x10^9/L in IDH mutated. Absolute neutrophil count was 3,1x10^9/L in IDH wild-type and 0,9x10^9/L in IDH mutated, and the difference was statistically significant (p=0,001). Median bone marrow blasts, platelets count, and LDH did not differ significantly. Cyto genetic risk group according to ELN 2010 showed favorable risk in 31,4%, and intermediate (I) and II risk in 68,6%. In favorable risk group IDH mutated patients were 12%, and 13% in the intermediate risk group. IDH expression was significantly correlated neither with NPM1 mutation nor with FLT3 mutation. There were no significant differences between induction therapy and complete remission. The overall response rate (ORR) was 80.6% (29/36) in the cohort. For the patients with refractory or relapse AML, CR was 61.0% (11/18), PR was 22.2% (4/18), and ORR was 83.3% (15/18). While for the other not getting CR after a course of induction chemotherapy, CR was 55.6% (10/18), PR was 22.2% (4/18), and ORR was 77.8% (14/18). Grade 4 hematological toxicities were observed in all patients, and 72.2% cases experienced infection. And all non hematological side effects were mild and well tolerated. With a median follow-up of 7.5 (0.5-33.3) months, the 1-year overall survival (OS) rate was 43.3%, 24.2% for the refractory or relapse AML, and 61.6% for those not achieving CR after a course of induction chemotherapy. The difference was significantly (P=0.01).

Summary/Conclusions: DAC combined with HAAG regimen is safe and effective salvage treatment for advanced stage AML patients.
markers. Results were given overall and stratified by age (<60/≥60 years) and sex. Kaplan Meier curves and Cox regression (Hazard ratios; HRs) was used to compare survival by cohabitation (living with someone, living alone) and marital status (married, divorced, widowed, unmarried).

**Results:** The study included 3243 AML patients. Patients living with someone (n=2056) were younger, more likely to be married, male, to be working, and to have a higher education than patients living alone. Comorbidity, white blood cell count, lactate dehydrogenase, and blast counts did not differ between groups, however patients living with someone tended to have better performance status at time of diagnosis. Patients living with someone were more likely to receive intensive chemotherapy than patients living alone when aged 60 years or older (41.2% vs 22.8%, adjusted OR 0.81 (CI=0.66-0.81)). In patients <60 years, never-married patients were less likely to receive intensive therapy (adjusted OR 0.43 (CI=0.19-0.99)) than married patients. In patients <70 years achieving CR, the chance of alloHSCT was reduced when living alone (11.8%, adjusted OR 0.47 (CI=0.28-0.78), versus 19.0% in patients living with someone. In patients >70 years, the chance was also reduced (7.6% adjusted OR 0.38 (CI=0.20-0.74)) compared to married patients (19.3%). Crude survival by cohabitation is shown in Figure 1. Overall survival was inferior in patients ≥60 years living alone (adjusted HR 1.21 (CI=1.09-1.33)) and unmarried patients (never-married: adjusted HR 1.29 (CI=1.08-1.57), divorced/widowed: adjusted HR 1.11 (CI=1.00-1.23)) compared to married patients. In contrast, cohabitation and marital status did not affect treatment response (living with someone: CR 70.6%, living alone: CR 72.8%) or overall survival (adjusted HR 1.08 (CI=0.81-1.23) in intensive therapy patients only.

**Summary/Conclusions:** Our study results indicate, that the effect of cohabitation and marital status on AML outcome, especially in patients ≥60 years, is explained by social support rather than by differences in income and occupation. Patients living alone do not present with more advanced disease or higher comorbidity burden than patients living with someone. Still, patients living alone and never-married patients are less likely to receive intensive chemotherapy after initial overall survival. Increased focus on what drives treatment decisions in patients lacking social support is important to improve survival in these patients.

**E933**

**TREATMENT OF MOLECULAR RELAPSE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 REDUCES TOXICITY OF SALVAGE TREATMENT AND IMPROVES DISEASE CLEARANCE**

F. Guolo1,*, P. Minetto1, M. Clavio1, D. Guardo1, E. Covilli1, N. Colombo1, F. Ballerini1, M. Migliori1, R.M. Lemo1, M. Gobbi1
1Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOI San Martino-IST, Genova, Italy

**Background:** Acute Myeloid Leukaemia with mutated NPM1 (NPM-AML) is characterized by a favorable prognosis. Most patients achieve hematological complete remission (CR) and are not considered eligible for an allogeneic stem cell transplantation (HSCT). The importance of minimal residual disease (MRD) monitoring in NPM-AML is well recognized but no data are currently available on MRD-directed therapy in this AML subgroup. Since 2004 we have prospectively evaluated NPM1 MRD at precise time points to evaluate response to therapy and predict the risk of hematological relapse (HR).

**Aims:** The study was to set a standard operating definition of molecular relapse and to evaluate the efficacy and feasibility of MRD-directed salvage therapy.

**Methods:** From January 2004 to January 2014, 36 consecutive intensively treated patients with NPM-AML achieving CR were included in the study. MRD assessment was performed on bone marrow (BM) samples after 1st and 2nd induction cycle, after each of the three consolidation cycles and then every three months for five years. If MRD positivity was found, a new analysis was obtained in 15 days. NPM1 mutation was measured on BM samples using MutarQuant® kit Ipsougen® from Qiagen. All Real-Time PCR were performed on DNA extracted by the Nucleospin® kit from Qiagen. Our policy included the treatment of minimal residual disease (MRD) in hematological relapse (HR). Salvage chemotherapy consisted in two MEC cycles and then patients proceeded to HSCT, if feasible. From January 2015 we decided to use a pre-emptive strategy, treating the molecular relapse. Four consecutive NPM-AML patients who showed MRD relapse received MRD-directed therapy. One patient with MRD-negativity after first course is alive and well at the time of the analysis. Results: Among 36 patients, 13 showed HR, after a median of 24 months (range 14-52). All relapsing patients showed NPM MRD recurrence prior to HR, with a median time of 4.5 months (range 1-8.4) from the first recurrence. Based on these data we defined MRD relapse as the recurrence of NPM1 mutation confirmed after each consolidation cycle of MEC. MRD-directed therapy was achieved in 4/13 patients (31%). Starting from January 2015, 4 patients who met the MRD relapse criteria received pre-emptive therapy, consisting of a single course of MEC. Four consecutive patients have been treated so far.

**E934**

**MINIMAL RESIDUAL DISEASE AND LAIP CHANGES BY FLOW CYTOMETRY IN DE NOVO ACUTE MYELOID LEUKEMIA DURING CHEMOTHERAPY AND CLINICAL OUTCOMES**

T. Lobanova1,*, I. Galtsava1, Y. Davydova1, N. Kapranov1, V. Troitskaya1, E. Parovichnikova1
1Hematological Oncology and BMT, National Research Center for Hematology, Moscow, Russian Federation

**Background:** Minimal residual disease (MRD) detection by multicolor flow cytometry (MFC) in acute myeloid leukemia (AML) is widely explored by different researchers and it is an additional independent factor in clinical outcomes. The prognostic value of leukemia associated immunophenotype (LAIP) changes in not explored enough.

**Aims:** To investigate the amount and clearance of MRD reduction and LAIP changes in de novo AML during chemotherapy and compare the results with clinical outcomes.

**Methods:** In a clinical prospective study since March 2016 till February 2017 50 patients (pts) de novo AML (f/m 32/18 m. age 44 (17-85) were included. 14 pts by this moment completed basic chemotherapy (ChT) courses: 7+3+ 2 induction and 2 consolidation. Among them favorable cytogenetics was in 4pts (t(16,21)-1,16q22-1, t(8;21)-2pts), intermediate-7 (6-with normal caryotype, 1-t(17,22)), poor-3 (complex karyotype-2, 11q23-1pt). Bone marrow samples were studied in standardized panel with most common antibodies by 6-color MFC (BD FACSCanto II, USA) before the treatment, after 1st and 2nd courses of induction and after 2nd consolidation. Any amount of MRD >0 was assumed as MRD positivity. Besides MRD status we also explored LAIP changes in patients who achieved CMR after 2nd ChT.

**Results:** Leukemia associated immunophenotype (LAIP) was detected in all monitored patients at the diagnosis. Molecular markers were detected in 28.5% (2pts-with NPM1+FLT3+CEBPA+, 1-with FLT3+, 1-NPM1+), 2 pts had resistant AML after 2 courses (CR), 3 pts out of 7 with complete morphological remission (CMR) after 1st course had MRD positivity (0.03%, 1.61%, 8.3%), and these pts became MRD-negative after 2nd course. CMR was achieved after 2ndcourse in 5 more pts and MRD positivity was detected in 3 pts (0.033%, 0.523 and 3.9%) with intermediate cytogenetic risk. By the end of 4th course 11 pts stayed in CRM and we diagnosed 1 morphological relapse (patient with MRD-negativity and CMR after 2nd ChT). Two early relapses were also traced: both with persistent MRD during all period of ChT and CMR after the second ChT. All pts with MRD-negative status after first course are alive and in CMR (8 months from diagnosis). While monitoring, LAIP changes were distinguished in 7 pts. One from two with resistant AML lost CD65, another one acquired CD11b. 5 pts were in CMR and we observed the second course and during ChT one of them gained CD56 and CD13, 2nd, lost CD65 and CD11b, 3rd – gained CD65, 4th gained CD11b after 2nd ChT, the last one didn’t change LAIP. We detected relapse in 3 pts from this group and one – with increasing MRD after 4th course and cytopenic syndrome. We may suggest that LAIP changes during ChT reflect selection of more chemotherapy-refractory leukemia clone, followed by subsequent relapse.

**Summary/Conclusions:** 1. The most favorable group consisted of MRD negative pts after 1st course. LAIP changes are common in pts with less favorable prognosis.
Background: New drug combinations and higher intensity therapy have led to significant improvements in complete remission (CR) rates for patients with acute myeloid leukemia (AML). However, relapsed disease remains a major source of failure. With the exception of allogeneic stem cell transplant (SCT), there are few options for post-consolidation maintenance of remission in high-risk patients. NK cells as part of the immune microenvironment are important mediators of immune surveillance in AML. Lenalidomide has demonstrated single-agent activity in AML and enhances NK cell activity and immune synapse formation in leukemia.

Aims: We designed a phase II clinical trial studying the efficacy of lenalidomide as maintenance therapy in AML patients with high-risk disease in remission, who were not being considered for SCT.

Methods: AML patients ≥18 years with a history of prior myeloid neoplasm (n=5), NPM1 (3), FLT3 (3), IDH2 (2), NRAS (2), DNMT3a (2), and 1 each of JAK2, TET2, and EZH2. High risk features at the time of enrollment were as follows (some are overlapping): 5 (36%) with history of prior myeloid neoplasm or therapy related AML, 4 (29%) persistent MRD, 4 (29%) adverse mutational validation cycle were eligible for enrollment. Patients should be within 12 months of achieving CR, have PS ≤3, adequate kidney/liver function, ANC >0.5 and platelets ≥30. Patients were treated continuously with lenalidomide 10mg PO daily on D1-28 of a 28 day cycle up to 24 cycles. All pts had baseline cytogenetic and molecular testing, and minimal residual disease (MRD) assessment by flow cytometry. After cycle 1, stepwise dose escalations were allowed to 20mg daily in pts who were tolerating their dose and have presence of minimal residual or morphologically detectable disease.

Results: A total of 14 patients have been enrolled with a median age of 57.5 years (range, 23-67). All pts were in CR at the time of enrollment, with 12 pts (86%) in CR1 and 2 (14%) in CR2. Baseline pt characteristics are outlined in Table 1. AML-related mutations detected at start of therapy include: CEBPA (n=5), NPM1 (3), FLT3 (3), IDH2 (2), NRAS (2), DNMT3a (2), and 1 each of JAK2, TET2, and EZH2. High risk features at the time of enrollment were as follows (some are overlapping): 5 (36%) with history of prior myeloid neoplasm or therapy related AML, 4 (29%) persistent MRD, 4 (29%) adverse mutational profile, 2 (14%) adverse karyotype, 1 (7%) primary refractory disease, and 2 (14%) CR2 status. Patients have received a median of 9 cycles (1-24) cycles of therapy. With a median followup of 19+ months (8.5-39), the 6- and 12-month estimated RFS were 100% and 69%, respectively. The 6- and 12-month estimated OS were 100% and 90%, respectively (Figure 1). The regimen was well tolerated. Common grade 1 toxicities were 1 each of rash, fatigue, cough, and nausea, vomiting, and stroke.

Table 1.

Summary/Conclusions: Lenalidomide is a safe and feasible maintenance strategy in high-risk AML patients who are not candidates for SCT. The study continues to surpass the pre-specified expected rate of relapse-free survival of high-risk patients based on a historical cohort. Studies evaluating dynamics of MRD on study are ongoing.

E936 POSTREMISSION THERAPY FOR AML WITH INTERMEDIATE RISK CYTOGENETICS IN FIRST COMPLETE REMISSION J. Vydra1,*, C. Šálek1, J. Schwarz1, P. Cetkovský3, P. Žák2, J. Novák3, V. Petečuková3, J. Mayer4, Z. Ráčil4

Background: Postremission therapy of AML with intermediate risk cytogenetics in first CR is based on chemotherapy with high dose cytarabine (HIDAC) or hematopoietic cell transplantation (HCT). Evidence from single trials with regards to optimal postremission therapy has been inconclusive, metaanalyses suggest a survival benefit of allogeneic HCT in first CR, except for patients with mutation of NPM1 without concomitant FLT3/ITD.

Aims: We analyzed retrospectively data from patients with AML with intermediate risk cytogenetics in CR1 with the aim to determine rates of completion of postremission therapy, rates and risk factors for early relapse and non relapse mortality (NRM), overall survival (OS) and relapse free survival (RFS), according to postremission treatment and describe causes of and risk factors for treatment failure.

Methods: Data on 304 patients in CR1 treated with curative intent between 2007 and 2016 in four centers participating in Czech Leukemia Study Group for Life were analyzed. All patients signed informed consent with data collection, analysis and publication. Cox regression was used to determine risk factors for OS and RFS, using time dependent covariates for postremission therapy. Age, WBC count, number of induction cycles, NPM1 mutation, FLT3/ITD, performance status, BMI, previous malignancy and extramedullary disease were included in models. Postremission therapy was completed after HCT or after three cycles of HIDAC or after 2 cycles of HIDAC according to postremission dose cytarabine (IDAC) in patients>60 years. Competing risk cumulative incidence estimates were calculated for NRM and relapse. Early relapse and NRM were defined as relapse/NRM before completion of postremission therapy.

Results: Median age was 52(18-74) years. Median follow up time was 481(31-3384) days. Early relapse rate (RR) and NRM were 11.01% and 5.29%, respectively. Median OS after early relapse was only 128 days. Presence of FLT3/ITD mutation and high body mass index were associated with increased risk of early relapse on multivariate analysis (HR 14.88, 95%CI 3.2-68.43 and 2.34, 95%CI 1.3-4.2, respectively). Age increased risk of early NRM (HR 5.13, 95%CI 1.5-17.58 for age 55-55 years). 76% of patients completed therapy: 42% received allogeneic HCT in CR1, 21% completed three cycles of HIDAC and 13% completed two cycles of IDAC. 3-year OS and RFS of the whole cohort were 53.68% and 40.26%, respectively. OS was 67% in a group of patients who completed HIDAC, 34% in IDAC group and 64% in HCT group (p=0.28469). Cumulative incidence of NRM and RR 3 years after completion of therapy was 23% and 20% after HCT, 7.13% and 51% after HIDAC and 16.8% and 66.4% after IDAC, respectively, differences among groups were significant (p=0.00947 and p<0.00001). HCT reduced the risk of relapse in comparison to chemotherapy (HR 0.51, 95%CI 0.3-0.85). RFS was adversely influenced by concomitant FLT3 ITD/NPM1 mutation (HR 2.17, 95%CI 1.06-4.45). Increasing age had negative effect on OS (HR 1.65, 95%CI 1.13-2.42 for age 55-55 years). After HCT, HLA mismatch and TBI based myeloablative conditioning were associated with increased NRM (HR 6.32 (95%CI 1.89-21.14) and 6 (95%CI 1.86-19.2), respectively) in comparison to transplantation from HLA matched donors and busulphan based myeloablative conditioning.

Summary/Conclusions: The majority of patients within intermediate cytogenetic group in our analysis received allogeneic HCT. Patients who relapsed before completion of treatment had dismal outcome with very short OS. Allogeneic HCT decreased risk of relapse but led to increased NRM, reducing positive effect of HCT on OS. Risk of NRM was increased after TBI based myeloablative conditioning and after HCT from mismatched unrelated donors.

Supported by Ministry of Health of the Czech Republic, grant nr. 15-25800A. All rights reserved.
LONG TERM FOLLOW UP OF PATIENTS OVER 60 YEARS TREATED WITH INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES

Background: More and more data on patients over the age of 60 years treated with intensive chemotherapy are emerging, however, long term data with patient outcome after the initial 2-5 year follow up period are lacking. In 2007, we published a single centre study on patients over the age of 60 years, suffering from acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS), treated with intensive chemotherapy (Kripp et al. Cancer 2007, 110:345-52). We now present the long term follow up data of these patients, the first patient being treated in 1991, meaning 26 years after study initiation.

Aims: To characterize the long term outcome of elderly AML and high risk MDS patients treated with intensive chemotherapy after the usual 2-5 year follow up period.

Methods: We treated 160 patients aged 60 years or more suffering from high risk MDS and AML with intensive chemotherapy regimen between 1991 and 2004. None of the patients underwent allogeneic stem cell transplantation afterwards. We now perform a follow up of the surviving patients 10 years after publication of the initial study.

Results: In the initial study median survival from the start of induction therapy was 9.5 months (10 days to 157 months), with the median survival from diagnosis of 14 months (1 day to 157 months). At the publication of the study in the year 2007, 20 patients were still alive, 18 of them presented with a low risk karyotype. 13 of these patients were in complete remission and 7 patients had relapsed. Since then 13 of the 13 patients who were in CR relapsed and died of their leukemia. One patient died of other causes and only one patient is still alive and well, currently at the age of 84. This patient initially presented with a normal karyotype, too. As a result the rate of long term survivors 5 years after treatment is 5.6% only.

Summary/Conclusions: Long term follow up data of elderly patients treated for AML and MDS with intensive chemotherapy is scarce. Our data show, that induction chemotherapy not followed by allogeneic stem cell transplantation does not result in a meaningful improvement of outcome. In addition, morbidity and lack of quality of life has to be taken into account. More data and studies on the subject are urgently needed in an aging population. In our population of 160 treated patients, 158 died of their leukaemia, only one patient died of another cause and only one single patient is still alive and well over a decade later.

FLAG-IDA FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE 5-YEAR STUDY

Background: The treatment of relapsed/refractory Acute Myeloid Leukaemia (AML) remains a formidable challenge as the therapeutic options are limited. The regimen most commonly used in this setting, FLAG-ida (Fludarabine, cytarabine, G-CSF and idarubicin) is considered more toxic than standard Daunorubicin plus Cytarabine (DA) regimen, often associated with prolonged periods of bone marrow suppression and predisposition to severe infections.

Aims: In this study, we present a single tertiary centre experience in the use of this regimen with a view to identifying predictive factors for survival following FLAG-ida chemotherapy. The secondary aim of this project was to assess its efficacy and toxicity profile in the routine clinical setting.

Methods: We conducted a retrospective chart review of patients treated with FLAG-ida chemotherapy regimen for relapsed or refractory acute myeloid leukaemia (including secondary AML) between 2011 and 2016 in a large tertiary hospital. Patients treated with FLAG-FLAG as first line therapy were excluded.

Results: Forty-four patients met the criteria for inclusion in this study. The median age of the patients was 53 (10-69) years. Eighteen percent (18%) received FLAG-FLAG as primary refractory AML while the remainder were treated having relapsed after at least 1 previous regimen. The median time to relapse was 15 months. Complete remission was achieved in 70% of patients and 81% of these patients proceeded to have an allogeneic stem cell transplant. The median overall survival following FLAG-FLAG chemotherapy was 16 months with 1-year and 2-year survival rates of 59% and 46% respectively. Approximately 6% therapy-related mortality was observed. The median overall survival in patients with early relapse (<12 months) was significantly shorter than those with late relapse (>12 months): 6 months and 20 months respectively (log-rank test p value: 0.04) (Figure 1). Complete remission rates were similar between relapsed and primary refractory AML patients.
E940

DRUG-DRUG INTERACTION POTENTIAL OF GILTERITINIB IN HEALTHY SUBJECTS AND PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Background: Gilteritinib (ASP2215), a highly selective FLT3/AXL tyrosine kinase inhibitor with activity against both FLT3-ITD and FLT3-D835 mutations, is currently in development for the treatment of acute myeloid leukemia (AML). In vitro data suggest that gilteritinib is a CYP3A substrate as well as an inducer and weak inhibitor of CYP3A.

Aims: To evaluate drug-drug interaction potential with gilteritinib in healthy subjects and patients with relapsed/refractory (R/R) AML.

Methods: The effects of CYP3A4 inhibitors (itraconazole [ITZ] and fluconazole [FLZ]), as well as a CYP3A4 inducer (rifampin [RIF]), on the gilteritinib pharmacokinetic (PK) profile were assessed in an open-label, parallel-group study conducted in 81 healthy subjects. Gilteritinib was administered as a single 10mg dose alone on Day 6, or in combination with 200mg ITZ administered twice daily on Day 1 and once daily on Days 2–28, or in combination with once daily 400mg FLZ on Day 1 and 200mg FLZ on Days 2–28. When given concomitantly with ITZ or FLZ, gilteritinib was administered on Day 6. In an additional cohort, RIF 600mg was administered on Days 1–21 and gilteritinib was administered on Day 6. In an additional cohort, RIF 600mg was administered on Days 1–21 and gilteritinib was administered as a single 20-mg dose on Day 8. Additionally, the potential inhibitory effects of gilteritinib on the PK profile of a CYP3A4 substrate (midazolam) was assessed in a cohort of patients with R/R AML (n=9) in the Phase 1/2 CHRYSLIS study (NCT02014458). Patients received oral gilteritinib (300mg/d) and single oral midazolam (2mg) doses. Gilteritinib was administered on Cycle 1 Day 1 and continued once daily in 28-day cycles; midazolam was administered on Day 1 and Cycle 1 Day 15. Furthermore, in patients with R/R AML, gilteritinib trough concentration data for patients on strong (eg, voriconazole or posaconazole) or moderate (eg, FLZ) CYP3A4 inhibitors were compared with those for patients not using CYP3A4 inhibitors.

Results: In healthy subjects, gilteritinib exposure (expressed as C max and AUC 0–24) was higher (2-fold increase) in subjects who were coadministered gilteritinib with a strong CYP3A4 inhibitor (ITZ) than in subjects who were administered gilteritinib alone. Coadministration of gilteritinib with RIF, a strong CYP3A4 inducer, resulted in an approximate 70% decrease in gilteritinib exposure in healthy adult subjects (Figure 1). In patients with R/R AML, midazolam exposure was approximately 10% higher when administered with gilteritinib compared to midazolam alone as reflected by the geometric mean ratio and 90% confidence intervals of midazolam C max (111.64%; 69.54%–179.25%) and AUC 0–24 (109.46%; 49.82%–240.48%). Additionally, a <2-fold increase in gilteritinib exposure was observed in patients who were taking concomitant medications that were moderate or strong CYP3A4 inhibitors relative to patients who did not use a CYP3A4 inhibitor. The increased exposure in these patients, however, did not translate to differences in the incidence of drug-related safety events when compared across groups.

Summary/Conclusions: These data suggest limiting concomitant use of strong CYP3A4 inhibitors, such as rifampin, with gilteritinib. Furthermore, these data suggest coadministration of CYP3A substrates with gilteritinib is unrestricted. A comprehensive review of safety data in patients with R/R AML did not suggest that dose adjustment is warranted when gilteritinib is coadministered with strong CYP3A4 inhibitors. Although concomitant use of gilteritinib with strong CYP3A4 inhibitors (eg, ITZ or FLZ) may be permissible, precaution is warranted.

E941

A FLUDARABINE-BASED ACUTE MYELOID LEUKEMIA INDUCTION IS WELL TOLERATED UP TO 75Y OF AGE ALLOWS EARLY CONSOLIDATION AND LONG TERM SURVIVAL. A SINGLE CENTRE EXPERIENCE OF 136 CONSECUTIVE PATIENTS

Background: For decades no effective new drugs or better anthracyclin cytara- bin combinations other than the standard 3 + 7 regimen have been available for AML induction treatment. Fludarabine-based regimens have shown good efficacy in relapsed patients but raised concern about toxicity in the induction setting (Burnett JCO 2013, PMID 23940227) a modified regimen has shown better tolerance and good results in patients younger than 60 years (ys) (Guolo AJH 2016, PMID 27084986).

Aims: We report a single center, real life experience of unselected 136 consec- tive AML patients treated since 2002 in our center with Fludarabine, Aracytin, Idarubicin with or without Etoposide; FLAIE up to 65ys or FLAI up to 75ys.

Methods: Patients were treated with the FLAIE or FLAI regimen followed by Idarubicin plus Aracytin as 2 step induction. Exclusion criteria for treatment were: acute promyeloicytic leukemia, poor performance status and severe comorbidity. Post remission treatment included up to three cycles of high dose AraC, autologous (Auto) or allogeneic (Allo) stem cell transplantation accord- ing to cytogenetic and molecular risk stratification (CMR, Döhner Blood 2010 PMID 19880497) aiming for a curative strategy for all our AML patients.

Results: Median age at diagnosis was 55ys (18-75ys), median follow up was 18 months (range 3-172 months), 75% of patients (102/136) had de novo AML with strong CMR. 25%(34/136) had some features from myelodisplastic syndrome. 19% of patients (26/136) had good CMR risk disease, 45% of patients (61/136) had intermediate risk and 36% of patients (50/136) had high risk disease. Complete remission (CR) rate was 68% and was comparable to the majority of pub-
lished trial data, considering the proportion of high CMR risk (36%) and leukemia of secondary origin (25%) and the relatively high median age: 36% of patients (49/136) were above the 60s old age limit of most AML protocols. In multivariate analysis CR rate was significantly affected by age below 50ys: \( p=0.011 \); good/intermediate CMR risk: \( p=0.011 \) and de novo AML: \( p=0.008 \). The induction death rate was 4% in line or slightly lower than published results, showing that the treatment was well tolerated. Low SOX4 expression was significantly associated with higher CMR risk (47% vs 37%, \( p=0.034 \)) and lower survival (50% vs 62%, \( p=0.033 \)). Other factors significantly affecting OS were age below 50ys \( p<0.001 \), and factors significantly affecting OS were age below 50ys \( p=0.001 \); good/intermediate CMR risk \( p<0.0002 \); intensive consolidation with Allo or Auto transplant \( p=0.0001 \) compared to chemotherapy alone. The mean probability of Leukemia free survival (LFS) was 88 months (median not reached). Patients about 50y old had a better prognosis than patients above 60y who had a karyotype profile and NPM1/FLT3-ITD status. The median probability of OS and LFS were 16.4 and 23.4 months respectively, this compares favorably with many published results. Chen Medicine 2016 PMID: 27472687 reported a median OS of 10.3 months in a large cohort of patients of similar age treated with intense induction. Moreover we did not found a significant difference between the 50-59ys and 60-75ys age groups: median OS was 20.8 and 14 months \( p=0.012 \) and median LFS was 15.9 and 26.3 months \( p=0.71 \) respectively.

**Summary/Conclusions:** In our real life experience the FLAIE/FLAI regimen combined with intensive consolidation demonstrated good long term results both in terms of OS and LFS in patients younger than 50ys, this regimen was also effective in patients with intermediate or bad prognosis, however patients with intermediate-risk cytogenetics, \( p=0.001 \) and \( p=0.005 \) respectively, or even in those with normal karyotype profile \( p=0.022 \) and \( p=0.111 \) respectively. In multivariate analysis, high SOX4 expression was found to be an independent poor prognostic factor of OS (RR 1.924, 95% CI 1.020-3.628, \( p=0.043 \)) irrespective of age, WBC count at diagnosis, karyotype profile and NPM1/FLT3-ITD status. Our results also reveal that SOX4 is an independent prognostic factor of AML. In conclusion, we reveal that BM SOX4 expression could serve as an informative new biomarker for the clinical prognosis of AML patients.
mal and minimal platelet count after chemotherapy. 3. rhTPO might shorten the days of platelet count recover to at least 20×10^9/l from its nadir. The incidence of side effects were similar in both groups of the study.  

**Table 1.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control group (N=56)</th>
<th>Study group (N=49)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number of platelets</td>
<td>190 × 10^9/l</td>
<td>190 × 10^9/l</td>
<td>0.15</td>
</tr>
<tr>
<td>Mean days of platelet count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimal platelet count</td>
<td>10 × 10^9/l</td>
<td>10 × 10^9/l</td>
<td></td>
</tr>
<tr>
<td>Maximal platelet count</td>
<td>400 × 10^9/l</td>
<td>400 × 10^9/l</td>
<td></td>
</tr>
<tr>
<td>Recovery time (days)</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: rhTPO, administered as dose of 1500µg/day when platelet count less than or equal to 50×10^9/l, might improve the recovery of thrombocytopenia of patients with acute myeloid leukemia in CR after consolidation chemotherapy. While there was no significant difference between study group and control group, there was a decreasing trend of platelet transfusion number and shorter time required for platelet transfusion for patients in study group.

**E944**

**TREATMENT-ASSOCIATED SURVIVAL RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A SYSTEMATIC LITERATURE REVIEW**

J. Bell, 1 A. Galaznik, 2 R. Huelin, 3 M. Stokes, 4 D. Faller, 5 R. Fram 6

1 Global Outcomes Research, 2 Millennium Pharmaceuticals, Inc., 3 a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, 4 Meta Research, Evidera Inc., Walham, United States, 5 Retrospective Observational Studies, Evidera Inc., Dorval, Quebec, Canada, 6 Oncology Clinical Research, Takeda Oncology, Cambridge, United States

**Background:** AML patients ≥60 years old are more likely to experience complications following intensive induction chemotherapy and are at higher risk of unfavorable outcomes compared with younger patients. Information regarding optimal treatment approaches for older AML patients is limited.

**Aims:** Summarize outcomes associated with therapies among older AML patients, with both a focus on treatment patterns and overall survival (OS) as reported in the literature.

**Methods:** Searches were conducted in Medline and Embase (Jan 2014–May 2016) and supplemented by conference abstracts (2015–2016). Eligibility included studies in English reporting on treatment regimens and outcomes associated with older AML patients or subgroups thereof, and conducted in the US, EU 5 (United Kingdom, Germany, France, Spain, Italy), or Japan. Only studies enrolling ≥50 patients were included.

**Results:** Twelve studies (in 19 publications) reporting on OS among older AML patients were included. Participants in most studies were newly diagnosed with AML; ages ranged from 60 to 93 years. Five non-comparative studies examining the effects of various treatment modalities were identified. Median OS in studies examining azacitidine (AZA) ranged from 6.85 months (95% CI: 3.7–13.5) to 16.4 months (95% CI: 12.6–22.4), respectively. Six comparative observational studies assessed the efficacy of different treatment regimens. Intensive chemotherapy (IC) was generally associated with longer median OS compared to other regimens. In one study, median OS for patients receiving IC, lower-intensity therapy (low dose cytarabine [LD-AraC]–(AZA, decitabine), or best supportive care (BSC) was 12.4 months (95% CI: 8.5–17.4), 11.5 months (95% CI: 9.2–13.9), and 2.6 months (95% CI: 1.9–3.1), respectively. One study assessed the efficacy of LD-AraC relative to IC, hypomethylating agents (HMA), and BSC. Patients appeared to have longer OS when receiving IC compared to LD-AraC (median OS: 12.4 vs 9.6 months; 3-year OS: 27% vs 12%; p=0.07), and those receiving LD-AraC compared to BSC had significantly improved OS (median: 9.6 vs 3.4 months; p=0.001). In this same study, while OS was longer with HMA than LD-AraC, this difference was not significant (median OS 16.1 vs 9.6 months; 3-year OS 22% vs 12%, respectively; p=0.1). Two studies assessed the efficacy of AZA vs moderate-IC, LD-AraC, or palliative therapy, alone or in combination. AZA had a significantly better survival rate vs LD-AraC in poor prognosis patients (p=0.015). Furthermore, 1-year survival was higher for AZA-treated patients (67.8%) compared to those not treated with AZA (36.9%) (p=0.004). The efficacy of AZA relative to other conventional care regimens (CCRs) including BSC, LD-AraC, or standard IC was also examined in a randomized clinical trial (n=488). Median OS at 1-year was significantly higher for AZA relative to CCR (10.4 vs 6.5 months). Results also showed that 1-year median OS was higher with AZA than CCR in all cytogenetic risk groups, normal risk (14.1 vs 10.0), intermediate risk (13.0 vs 10.1), and high risk (6.4 vs 3.2), respectively.

Summary/Conclusions: Among older AML patients, IC tended to be associated with improved OS compared with other CCRs. However, evidence from this review indicates that AZA could be an alternative treatment option for older AML patients, whether fit or unfit for IC.

**E945**

**SYSTEMATIC REVIEW OF HEALTH STATE UTILITY VALUES FOR ECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA**

A. Forsythe, 1 V. Bal 2, M. Dolph 3, S. Patel 4, G. Tremblay 5

1 Purple Squirrel Economics, New York, 2 Novartis Pharma, East Hanover, United States, 3 Purple Squirrel Economics, Montreal, Canada, 4 Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, 5 Purple Squirrel Economics, Quebec city, Canada

**Background:** Cost-utility analyses undertaken to inform decision making regarding acute myeloid leukemia (AML) require a set of health state utility values (HSUVs) so that the time AML patients spend in different health states can be aggregated into quality-adjusted life-years (QALY).

**Aims:** This study reviews AML-related HSUVs that could be used in economic evaluation and assesses their advantages and disadvantages with respect to valuations used and AML clinical pathways.

**Methods:** Embase, MEDLINE, Cochrane database, and conference abstracts (ASCO, ESMO and ASH) were systematically searched from Jan 2000 through Nov 2016 for relevant studies that reported quality of life (QOL) and HSUV in AML. Identified relevant EORTC Quality of Life Core Questionnaire QLQ-C30 values were mapped to HDUV using previously published algorithm by Crott, et al, 2010. HSUV for induction, consolidation, complete remission (CR), relapse, stem cell therapy (SCT) treatment, SCT recovery and CR post SCT were identified.

**Results:** Ten relevant studies were identified. Six were cost effectiveness analyses utilizing HSUVs for calculation of Quality Adjusted Life years (QALY), one effectiveness analysis (incremental QALY). Two OOL studies reporting specific AML utilities (either collected or mapped from QLQ-C30). An additional study reported QOL for patients undergoing SCT. Since no study reported HSUV for relapse, values from study of secondary AML patients who failed prior treatment for Myelodysplastic Syndrome, were used. Where multiple HSUVs were available, priority was made for collection, consolidation, complete remission (CR), relapse, stem cell therapy (SCT) treatment, SCT recovery and CR post SCT were identified.
Summary/Conclusions: This interim analysis of the use of decitabine in real life showed a superimposable OS to controlled international clinical trials. Safety profile was acceptable considering setting of pts and incidence of important comorbidities. Despite a similar OS, the comparison between our data and Cashen study (56 vs 55 pts) showed in our cohort, a poorer rate of CR+CRi (11.8% vs 16.1%) with a higher impact of HSUSV which improve on those currently available either by utilizing time trade off studies or by making greater use of condition-specific data and further use of mapping algorithms.

E946
ITALIAN REAL LIFE EXPERIENCE OF DECITABINE IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF MULTICENTRIC OBSERVATIONAL DEA65 STUDY.
L. Aprile1,2, V. Sambartini1, G. Alunini2, C. Capocci2, V. Pavone2, G. Fontanelli2, A.M. Liberati2, C. Biagiotti2, M. Rondoni2, B. Scapini2, L. Schiattone2, S. Ciofini2, V. Federico2, G. Bantulaci2, P. Bernini2, M. Defina2, R. Giallen3, A. Mianulli4, M. Petrin1, A. Bos4, M. Bocchini5
1Hematology Unit, University of Siena, Siena, 2Unit of Oncology and hematology, Azienda Ospedaliera S.Maria, Terni, 3Unit of Hematology, USL6, Livorno, 4Hematology Unit and Bone Marrow Transplant Unit Ospedale Cardi nale G. Panico, Tricase, 5Unit of Hematology, USL11, Empoli, 6Unit of Hematology, Azienda Ospedaliera Careggi, Firenze, 7Unit of Hematology, AUSL della Romagna, Ravenna, 8Hematology Unit, Ospedale Mazzone, Ascoli Piceno, 9Hematology Unit, Ospedale Infermi, AUSL Romagna, Rimini, 10Hematology Unit, University of Pisa, Pisa, Italy

Background: Acute Myeloid Leukemia (AML) has a higher incidence among the elderly population. Older patients (pts) with AML have a worse prognosis and limited treatment options. Hypomethylating agent decitabine was recently approved by FDA and EMEA as first line treatment in AML pts older than 65 yrs and unfit to receive standard cytotoxic chemotherapy. Decitabine showed to be superior to supportive care or low dose cytarabine in controlled randomized clinical studies (Kantarjian, JCO 2012; Cashen, JCO 2010).

Aims: In July 2016 we approved a retrospective and prospective multicentric observational study to investigate efficacy and tolerability of decitabine at the approved schedule of 20mg/m2 daily for 5 days of a 4-week cycle in real life (DEA65 study). The primary objective was the assessment of overall survival (OS). Secondary objectives were evaluation of adverse events (AEs) and response rate: complete remission (CR), CR with incomplete platelets or white blood cells (WBcs) count recovery (CRi), partial remission (PR) and hematologic improvement with transfusion independence. We here present an interim analysis of the first 56 pts enrolled.

Methods: AML pts older than 65 yrs treated in first line with decitabine were enrolled in the study. At diagnosis and during follow-up, cytogenic and molecular assessment was performed by each center according to local guidelines for AML management in elderly pts.

Results: Biologic and clinical data of 56 pts, with a median age of 73 yrs (range 65-90 yrs) are reported. Thirty-one patients (55,3%) had a secondary AML and 13/31 (42%) were progressed MDS previously treated with 5-azacitidine. Medi an WBCs count was 3050/µL (range 770-131500/µL) with 13/36 (23%) pts with WBCs>10000/µL. Cytogenetic analysis was performed in 52/56 pts, and in 24/46 (43%) molecular analysis including FLT3 and NPM1 mutations was performed. According to prognostication, 50% of pts had a high risk, 34% an intermediate risk, 9% a low risk AML and in 4/56 (7%) pts risk was unknown. Median OS was 7 months (range 1-19 months) with 34/56 deaths (60,7%) and a median of 6 cycles (range 1 to 19) of decitabine. Overall response rate was 60,7% (34/56 pts), of which 7/56 (12,5%) CR or CRi; 17/56 (30,4%) PR and 10/56 (17,8%) improvement of transfusion needs. According to response, median OS was 9,5 months (range 4-19) and 4 months (range 1-15) in responder vs non responder pts. Table 1 shows response rate according to pts characteristics. At present time 18/22 alive pts are still on treatment with decitabine. Regarding toxicity, 23/56 (41%) pts manifested a grade ≥3 AEs although severe comorbidities (cardiovascular and metabolic) pre-existed in 14/23 (60,9%). A total of 35 hospitalization episodes due to toxicity were recorded and 10/56 pts (17,8%) died due to serious AEs. Overall the most common non-hematologic AEs were pneumonia and fever.

Table 1.

Summary/Conclusions: This interim analysis of the use of decitabine in real life showed a superimposable OS to controlled international clinical trials. Safety profile was acceptable considering setting of pts and incidence of important comorbidities. Despite a similar OS, the comparison between our data and Cashen study (56 vs 55 pts) showed in our cohort, a poorer rate of CR+CRi (11.8% vs 16.1%) with a higher impact of HSUSV which improve on those currently available either by utilizing time trade off studies or by making greater use of condition-specific data and further use of mapping algorithms.

E947
ASPARAGINASE ERWINIA CHRYSANTHEMI EFFECTIVELY DEPLETES PLASMA GLUTAMINE, HAS CLINICAL ACTIVITY, AND IS WELL TOLERATED IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
A. Emadi1,2,3, E.T. Strovel4, R.G. Lapidus1,2, L.J. Jensen2,4,5, M. Lee1, G.M. Blitzer6, B.A. Carter-Cooper1, D. Sewell7, I. Van Der Merwe1, M. Imran1, S.L. Yu1, H. Li1, P.C. Amrinn1, V.H. Duong1,2, E.A. Saussvile1,2, A.T. Fath6, Z. Singh6, M.R. Baer1,2, S.M. Bentzen1,2,3,*, A. Emadi1,2,3,*, E.T. Strovel4, R.G. Lapidus1,2, L.J. Jensen2,4,5, M. Lee1, G.M. Blitzer6, B.A. Carter-Cooper1, D. Sewell7, I. Van Der Merwe1, M. Imran1, S.L. Yu1, H. Li1, P.C. Amrinn1, V.H. Duong1,2, E.A. Saussvile1,2, A.T. Fath6, Z. Singh6, M.R. Baer1,2, S.M. Bentzen1,2,3,*, University of Maryland Greenebaum Comprehensive Cancer Center, 2Medicine, 3Pharmacology, 4Pediatrics, 5Pathology, University of Maryland, Baltimore, 6Massachusetts General Hospital Harvard Medical School, Boston, 7Epidemiology and Public Health, University of Maryland, Baltimore, United States

Background: Asparagine-induced glutamine (Gln) depletion demonstrates anti-leukemic activity in preclinical studies of AML. We hypothesized that administration of asparaginase Erwinia chrysanthemi (Erwinaze) would lead to effective plasma Gln reduction and may be a feasible therapeutic approach for AML, because myeloblasts may be addicted to Gln.

Aims: The primary aim was to determine the dose of Erwinaze inducing plasma Gln levels ≤120µM/L, with an acceptable safety profile, 48 hours (h) after the first intravenous (IV) dose and before each subsequent dose administered thrice weekly for 2 weeks in patients (pts) with relapsed or refractory (R/R) AML.

Methods: This was a phase 1, single-arm, pharmacokinetic investigator-initiated trial (NCT02283190, funded by Jazz Pharmaceuticals), with a 3+3+3 design with dose de-escalation/escalation rules that incorporate both safety and biochemical activity (nadir plasma Gln levels) of IV Erwinaze. There was no intrapatient dose adjustment. For safety, a 3rd cohort of three pts was to be added if 2 of 6 pts in the 1st and 2nd cohorts experience a dose limiting toxicity (DLT) at a certain dose level. If ≤3 of 9 patients experienced DLT, the trial was to be terminated. To evaluate Gln reduction ability of Erwinaze, the dose could be increased based on 48h trough plasma Gln in cohorts of 3, 6, or 9 pts per dose level.

Results: Five pts were enrolled on study. Enrollment was then halted due to Erwinaze supply manufacturing complexities. Median age was 69 (range 20-83) years, were male, 2 had prior MDS or CMLM, 3 had high risk abnormal karyotype, 3 had isocitrate dehydrogenase (2 IDH1, 1 IDH2) mutations, and 3 had been treated with ≥2 lines of prior treatment. Erwinaze was administered IV (25,000 IU/m², dose level 0) for 6 doses MWF for 2 weeks to all pts. No DLT was observed. Anemia and electrolyte abnormalities were the most common adverse events. Plasma asparaginase activity ≥0.1 IU/mL was achieved in all pts at 48h trough, but in 3 pts it decreased to zero on day 8 (72h trough). Median trough plasma Gln, Asn and peak Glu levels (µmol/L) at 28h were 27.6 (range <12.5-227), 0 (range 0-0), and 704 (range 474-754), respectively. Asn remained undetectable for the entire 2 weeks. Gln levels increased significantly on day 8 (72h trough) compared to day 5, p=0.001. Four of 5 pts (80%, lower limit of 1-sided 95% CI: 34%) achieved at least one nadir Gln value <120 µmol/L. The fold reduction (FR) in Gln level at 3 days, relative to baseline, was 0.16 (p<0.001 for rejecting FR=1). One pt achieved partial remission (PR) and one achieved hematologic improvement (HI) after 6 doses of single agent Erwinaze. Both pts had plasma Gln levels <85 µmol/L on days 5, 10 and 12. Off study, after completion of Erwinaze, they were have been treated with azacitidine.

Conclusions: Pts are still alive in complete remission (CR) and CR with incomplete count recovery (CRi) 13.3 and 13.4 months after the on-study date. Plasma and urine 2-HG levels did not change significantly. The 3 pts with IDH mutations tended to have higher plasma 2-HG levels (p=0.10).
Summary/Conclusions: To the best of our knowledge, this is the first clinical report demonstrating that an asparaginase product is capable of not only decreasing plasma Gln level to ≤120μmol/L but also depleting it to undetectable (i.e. <12.5μmol/L) levels in pts with AML. Two of 5 patients with R/R AML had clinical responses and are alive in remission. Given clinical activity of asparaginase in AML, we are to investigate mechanistically-designed asparaginase combination therapies.

E948
PROGNOSTIC SIGNIFICANCE OF SOX2, SOX3, SOX11, SOX14 AND SOX18 GENE EXPRESSION IN DE NOVO ACUTE MYELOID LEUKEMIA (AML) PATIENTS

N. Tosic1,*, M. Virijevic2, I. Petrovic3, N. Kovacevic Grujicic3, S. Davidovic3, N. Stojanovic4, I. Vaxman1, R. Ratzon1, M. Yeshurun1, Z. Iakobishvilli1, R. Kornowski1, P. Raanani1

1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia, 2Clinic of Hematology Centre of Serbia, University of Belgrade Faculty of Medicine, 3Laboratory for Human Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia, Belgrade, Serbia

Background: Members of the SOX (SRY-related high mobility group (HMG) box) gene family encode a group of transcriptional factors with important functions in embryonic development. Also, SOX genes are aberrantly expressed in different types of cancer. However, their role in hematological malignancies, especially in acute myeloid leukemia (AML), remains elusive.

Aims: The aim of this study was to investigate the expression level of SOX2, SOX3, SOX11, SOX14 and SOX18 genes in de novo AML patients, and to evaluate their potential as prognostic markers.

Methods: Fresh bone marrow (BM) samples were collected from 50 non-APL AML patients at diagnosis (27 male, 23 female, median age 52.5 years, range 22-73) and from 8 healthy donors. Relative quantification analysis of SOX2 gene expression level was performed by RT-PCR methodology, with GAPDH gene as endogenous control, and using comparative ddCt method with healthy controls as calibrator.

Results: The median expression level of SOX2, SOX3, SOX11, SOX14 and SOX18 in AML patients was 0.46 (0.01-226.13), 0.81 (0.01-1210.00), 0.35 (0.01-177.29), 0.98 (0.02-469.51) and 3.53 (0.18-332.00), respectively. This was not significantly different from the levels detected in healthy controls where the median expression levels were 0.91 (0.32-2.54), 1.00 (0.45-5.73), 1.00 (0.19-2.83), 1.04 (0.38-2.38) and 1.00 (0.48-12.29), respectively. As a cut-off value above which the patients were considered to be positive for SOX2/3/11/14/18 gene expression we used median expression level of each SOX gene in healthy controls + 2SD. The percentage of patients who were positive for the expression of the studied genes ranged from 14% (SOX2* and SOX17), 20% (SOX3* and SOX18*) to 28% (SOX14*). A significant association with the presence of FLT3-ITD and NPM1 mutations was detected in all but SOX14+ patients. The same result was found concerning association with higher leukocyte count. There were no significant associations with any other presenting clinical parameters. As for the impact that SOX expression positive status had on the analyzed genes had on the prognosis and outcome of the disease, we detected higher relapse rate in SOX14+ patients (p=0.045). Significantly shorter disease-free-survival (DFS) was detected among SOX2*, SOX11* and SOX18* patients (p<0.001; p=0.001; p=0.017, respectively). Although all of the SOX+ patients had shorter overall survival (OS) time compared to SOX- patients, the most prominent influence has been detected for the SOX2+ patients (p=0.034).

Summary/Conclusions: This is the first study focused on examining the expression level of SOX2/3/11/14/18 in AML patients. We have found that these genes are overexpressed among patients in comparison with normal BM. However, in some patients, the expression of these genes is highly increased, and associated with a negative prognostic factors such as the presence of FLT3-ITD mutations and higher leukocyte count. Also, increased expression of these genes has been clearly associated with shorter DFS and OS. Although we lack the exact function of these genes in the pathogenesis of AML, it is not yet known, our preliminary results show that their overexpression can have prominent prognostic significance in AML patients and therefore should be the subject of further investigation.

E949
ACUTE ANTHRACYCLINE INDUCED CARDIOTOXICITY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

O. Pasvolisky1,*, O. Morelli1, U. Rozovski1, M. Vaturi1, I. Amitai1, I. Vaxman1, R. Ratzon1, M. Yeshurun1, R. Korowski1, P. Raanani1
1Beilinson Hospital, Petach Tikva, Israel

Background: Chemotherapeutic agents are associated with a wide range of cardiotoxic adverse effects. Anthracyclines and related drugs are some of the most implicated agents, with a well-recognized potential for the development of cardiomyopathy and heart failure. Chronic anthracycline induced cardiotoxicity can lead to cardiomyopathy, which may develop several years after treatment. Acute and subacute anthracycline induced cardiotoxicity is considered relatively uncommon, described mostly in patients treated for solid tumors or lymphomas. While anthracycline based regimens have been used to induce remission in newly diagnosed patients with acute myeloid leukemia (AML) for more than four decades, relatively little is known about the acute cardiotoxic effect of anthracyclines in this setting. Since many of these patients were candidates for hematopoietic stem cell transplantation (HSCT), an intensive intervention usually reserved for fit patients, even transient decrease in cardiac function might render them ineligible for this intervention, or might increase their transplant related morbidity.

Aims: To study the short-term outcomes of anthracycline exposure on cardiac function in patients with AML who are candidates for allogeneic HSCT. Because current AML-induction regimens use anthracyclines (most commonly daunorubicin) at a relatively high dose between 45 and 90mg/m2/day for three consecutive days, we hypothesized that the incidence of post-induction cardiac injury might be high.

Methods: The medical records of 55 consecutive patients who had received induction chemotherapy and had undergone HSCT in our medical center were reviewed. Patients included in the study were those with echocardiographic data both prior to and post induction therapy. Median age at diagnosis was 59 years (range: 19-73) and 49% were males. Approximately half of the patients had de novo AML (N=29, 53%). 26 patients (47%) had either therapy related AML or AML secondary to a previous hematological disorder. Induction treatment included 7 days of cytarabine at a dose of 100mg/m2/day and 3 days of daunorubicin at a dose of 45mg/m2/day (N=2, 3.6%), 60mg/m2/day (N=34, 61.8%) or 90mg/m2/day (N=15, 27.3%).

Results: Selected patient characteristics are summarized in Table1. Post-induction echocardiogram studies demonstrated a significant cardiac deterioration in left ventricular ejection fraction (EF) (defined as 10% or more absolute decrease from baseline EF) in 25.5% of the patients (N=14). Higher doses (90mg/m2/day) of anthracyclines were associated with a higher risk of cardiac function deterioration (odds ratio: 4.1, 95% confidence Interval: 1.06 to 15.7). Patients with cardiovascular risk factors and male patients tended to develop cardiotoxicity at higher rates, whereas age, white blood cell counts at diagnosis and AML type (de novo vs. secondary) had no impact on cardiotoxicity. The decrease in cardiac function was temporary in 10.9% of the patients (N=6) with subsequent normalization of left ventricular EF in those patients.

Summary/Conclusions: The use of daunorubicin at a dose of 60mg/m2/day or less is associated with significantly lower rates of acute cardiotoxicity. Our findings should be taken into consideration when choosing the anthracycline dose, particularly in male patients with cardiovascular risk factors who are candidates for HSCT.
AN INTEGER WEIGHTED GENOMIC MUTATION SCORING (IWGMS) USING THE TRUSIGHT MYELOID SEQUENCING PANEL SHOWS HIGHER MORTALITY IN PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKAEMIA - A RETROSPECTIVE STUDY

1Internal Medicine, Houston Methodist Hospital, Weill Cornell Medical College, 2Laboratory and Genomic Medicine, Houston Methodist Hospital, 3Hematology, Houston Methodist Cancer Center, 4Baylor Miraca Genetics Laboratories, Baylor College of Medicine, Houston, United States

**Background:** AML is currently classified by European LeukemiaNet into favorable, unfavorable, and intermediate prognosis based on cytogenetic aberrations. Although favorable and unfavorable categories have good prognostic values, the intermediate category encompasses the majority of patients and offers unclear prognosis. The development of Cancer Genome Atlas (TCGA) opens new windows for the incorporation of next generation sequencing (NGS) into cytogenetics to enhance prognostic risk stratification. However, few studies explore the combination of cytogenetics and NGS in prognostic predictions.

**Aims:** Here we have developed a system of Integer Weights for the Genomic Mutation Score (IWGMS) for a quantifiable stratification of the prognostic risks associated with a combination of cytogenetic aberrations and genomic mutations. Our next step is validating the scoring system through its application to data obtained from other institutions.

**Methods:** Patient data at Houston Methodist Hospital was queried from Methodist Environment for Translational Enhancement and Outcomes Research (METEOR), a clinical data warehouse that integrates research databases and national registries. The diagnosis of AML was queried along with patient demographics, cytogenetics, NGS and OS. The resultant patients were divided into three categories based on their MRC cytogenetic risks-favorable, intermediate, and poor. Using the TruSight Myeloid Sequencing Panel (Illumina), mutations in 54 genes associated with myeloid disorders were tested in NGS. A scoring system was developed that assigned each of the nine TCGA mutation categories (Transcription- Factor Fusion, Nucleophosphin (NPM1), Tumor Suppressor Genes, DNA-Methylation related genes, Signaling Genes, Chromatin Modifying Genes, Myeloid Transcription Factor Genes, Cohesion complex Genes and Spliceosome-complex genes) a score between -2 (good risk) and +2 (poor risk). The IWGMS for each patient was calculated by the sum of the individual mutation scores. A IWGMS score greater than 3 was considered significant as a poor prognostic factor. Statistical analysis was done using Chi-Square, Mann Whitney U test and multivariate logistic regression analysis. Data from other institutions will be analyzed in a similar fashion for the confirmatory portion of the project.

**Results:** A hundred of the 1200 AML patients met the criteria for having both cytogenetic and NGS data availability. The two-year mortality rates were 43%, 52%, and 51% respectively for the favorable, intermediate, and poor cytogenetic groups. In the intermediate cytogenetic group, high IWGMS score (>3) was associated with higher mortality when compared to low IWGMS score (80% vs 44%, p=0.045, Fig 1). A look at the gene mutation distribution in the intermediate risk cytogenetic group also showed a general correlation between known favorable gene mutations with low IWGMS scores and unfavorable ones with high IWGMS scores. We thus hypothesize the IWGMS scoring system can be utilized to divide intermediate cytogenetic and low mortality subgroups based on a combination of cytogenetic and genetic mutations. We expect similar results with data from other institutions.

**Summary/Conclusions:** We discovered that proliferation and survival of adult T-cell leukemia / lymphoma cells were dependent on specific amino acids cysteine, methionine, and valine. As 2-weeks restriction of the former two amino acids damaged stromal cells or normal lymphocytes, valine was picked up for further analysis. Proliferation of ATL cells was dramatically inhibited by valine restriction while the influence on normal cells was limited. Interestingly, valine restriction did not affect a significant change in the proportion of normal CD4+ populations, such as Treg, naive, central memory, effector and effector T-cells. Moreover, 4-week restriction of valine succeeded in eradicating ATL cells in vitro and no recurrence was observed after refeeding valine although 2-weeks restriction was insufficient for extermination. In-vivo model also showed that 4-weeks restriction of valine could dramatically reduce ATL tumor size. Valine-depleted diet did not significantly reduce hemoglobin or platelet count, and there were no significant organ damages as far as examined macroscopically.

**Summary/Conclusions:** We discovered that proliferation and survival of adult T-cell leukemia / lymphoma cells were dependent on valine. ATL cells could be eradicated by 4-weeks of valine in vitro. In-vivo model also showed that the growth of ATL cells was significantly inhibited by dietary restriction of valine. Massive lymphoma cells, which are known to be resistant to antibody therapy, were also vulnerable to the valine restriction. There were no severe complications such as anemia, thrombocytopenia, and organ damages which are often seen in chemotherapy recipients. These data demonstrate that valine restriction may potentially provide a new option for leukemia/lymphoma therapy.

**Figure 1.**

**Summary/Conclusions:** Most studies in current literature focuses on the individual contributions of cytogenetic aberrations or genetic mutations to risk stratification and treatments risk stratification and treatment response. However, prognosis varies widely in the heterogeneous, intermediate cytogenetic class, where 60% of the AML patients belongs. We propose a systematic approach that correlates cytogenetics with genetic mutations in stratifying prognostic outcomes with a focus on the intermediate cytogenetics group. The ability to differentiate in this specific group opens great potentials for targeted therapies and improving outcomes.
Aims: Since the roles of these SNPs in clinical aspects, response to therapy and prognosis of DLBCL treated with R-CHOP- are still unknown, these were the aims of the present study.

Methods: Our analysis included 168 consecutive DLBCL patients at diagnosis seen at University Hospital from July 2009 to September 2014. Genotypes were identified in DNA of peripheral blood by real-time polymerase chain reaction using a Taqman SNP Genotyping Assay. Replicates were performed in 10% of the reactions, achieving 100% of concordance. Chi-Square test, Fish- her’s Exact test, and multivariate analysis, using the logistic regression model, served to assess associations between genotypes and clinical aspects. Kaplan-Meier analysis was used to evaluate the effect of clinical features and genotypes on progression free survival of patients (PFS) and overall survival (OS). DFS and OS were calculated from the date of diagnosis to first event date (relapse, progression or death by disease) or last seen date and death by any cause or last seen date, respectively. The Cox proportional hazards model was used to evaluate the effects of clinical features and genotypes of the above mentioned SNPs on PFS and OS, and the results of analysis were presented as hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). First, these associations were examined using uni- variate Cox proportional hazards regression. In a second step, all variables with P<0.10 were included in a multivariate Cox regression. All reported P values were two-sided, and P<0.05 was considered to indicate statistical signifi- cance.

Results: Concerning clinical features, the frequency of the wild-type VEGF -1154G allele and VEGF-6343G genotype were more common in stage III or IV patients. The wild-type VEGFGR2 -604T allele was more common in high intermediate and high international prognostic index (IPI) patients. Concerning response rate, patients with the wild-type VEGF 936CC genotype was associated with higher complete response (CR). These patients had 2.65 more chances of achieving CR to therapy than others. The median follow-up time of 168 DLBCL patients enrolled in the study was 43 months (range: 1-105). The estimated probabilities of 60-months EFS and OS were 58.8% and 66.0%, respectively. At 60 months of follow-up, patients with the variant VEGF 1154A and 936 T alleles had 1.52 and 1.52 more chances of presenting disease relapse or progression, and 1.47 and 1.60 more chances of evolving to death in univariate analysis, respectively. After correction with other classical prognostic factors in DLBCL (IPI and GCB subtype), only the VEGF 1154 G/A SNP was associated with PFS and OS: patients with the variant VEGF 1154A allele had 1.88 and 1.83 more chances of having an event. Subsequent analysis of our data present, for the first time, preliminary evi- dence that inherited abnormalities in AG pathway, related to the VEGF -1154G/A, -6343G4 and 936C/T, and VEGFR2 -604T/C, influence clinical fea- tures, response to R-CHOP and outcome of DLBCL patients.

Methods: This is a retrospective multicenter study including patients older than 17 years, with a BMB and a PET/CT performed simultaneously as part of the routine pre-therapy staging for newly diagnosed DLBCL. Patients had not received either chemotherapy or corticosteroids and no concomitant malignancy was known to be present at the time of both procedures. Only patients treated with R-CHOP as first line therapeutic strategy were included. Only vari- ables that were used in the multivariate Cox regression analysis were included in the multivariate Cox regression outcome for predictors.

Results: A total of 271 DLBCL patients were initially identified; we excluded: 31 patients who received low intensity chemotherapy regimens (R-COP, Mini- CHOP-R, monotherapy with steroids) due to advanced age, comorbidities or detection of protein level in clinical trials including standard regimens plus new agents (Bortezomib, Lenalidomide, Ibrutinib) or non-standard regi- mens (R-CHOP/14, Da-EPOCH-R, MACOP-B, Mega-CHOP, Hyper-CVAD). In the homogeneously treated (R-CHOP/21) 205 DLBCL patients subset, the median age at diagnosis was 61 y.o. (range 18-85), with a balanced gender distribution. 143 females (69.7%). Twenty-two of these patients (12.7%) had BMI on BM, whereas 43 (21%) had BMI according to PET/CT finding. Fifty-three patients (25.9%) had BMI according to either BM or PET/CT. Concordant BMI by means of both techniques was present in 16 (7.8%) patients. With a median follow-up of 25 months (15-47 months, p25-p75), 50 patients (24.4%) progressed or relapsed and 41 (20%) died. The 3-year estimated pro- gression-free survival (PFS) and overall survival (OS) were 70%, and 78%, respectively. By univariate analysis, factors associated with a shorter PFS, with a p<0.150, were: female gender, IPI3, abnormally elevated B2-microglobulin levels, PET/CT-BMI(+), and BMI-BMI(+). In multivariate analysis only two fac- tors were found to be independently significant: VEGF 1154 A allele (HR: 3.3 [95%CI 1.15-9.55], p<0.0001) and IPI3 (HR: 1.96, 95%CI 1.3-1.76, p=0.004) were independently associated with a shorter PFS. By univariate analysis, factors predictive of a shorter OS, with a p<0.150, included: IPI3, abnormally elevated B2-microglobulin levels, PET/CT-BMI(+). In multi- variate analysis only IPI3 (HR: 2.6, 95%CI 1.13-5.14; p<0.0001) was indepen- dently associated with OS.

Summary/Conclusions: In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BM complemented IPI in predicting those patients with a higher risk for relapse or progression, while IPI defined a subset of patients with a worse survival. In this cohort, BMI by PET/CT could not inde- pendently predict a shorter PFS and/or OS.

E954

PROGNOSTIC SIGNIFICANCE OF CD11b+CX3CR1+ MONOCYTES IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

1Internal Medicine, Chonbuk National University Hospital, Jeonju, 2Internal Medicine, Catholic University of Korea, Seoul, 3McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Korea, Republic Of

Background: Interest in the role of myeloid-lineage cells, including monocytes and their precursors, has been increasing in prognosis of lymphoma. It has been shown that the circulating monocyte count at the time of diagnosis shows prognostic significance in diffuse large B-cell lymphoma (DLBCL), suggesting the role of specific subset of monocyte in prognosis of DLBCL. Recent studies suggest CD11b+ monocytes expressing CX3CR1 promote angiogenesis and suppress anti-tumor immunity through the interaction with fractalkine (CX3CL1), the only ligand for CX3CR1. However, limited data is available regarding the prognostic significance of CD11b+CX3CR1+ monocytes in DLBCL patients.

Aims: The study investigates the prognostic significance of peripheral blood (PB)- and bone marrow (BM)- CD11b+CX3CR1+ monocytes on progression-free survival (PFS) and overall survival (OS) in newly diagnosed DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy.

Methods: The prospective study was conducted in two Korean institutions from May 2011 to August 2015. Patients were eligible if they were newly diagnosed DLBCL, treated with R-CHOP, and provided informed consents. Percentages of CD11b+CX3CR1+ cells in total mononuclear cells (>50,000 cells) were measured by flow cytometric analysis using fresh PB and BM aspir- ates within 150 minutes before treatment.

Results: Eighty-nine patients (male, 52) were enrolled. The median age was 65 years (range, 19-88). 37 patients (41.6%) were classified as high-interme- diate (HI) or high risk according to National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI). CD11b+CX3CR1+ monocytes were more frequent in bm compared to pb (p<0.001). The multivariate analysis of CD11b+CX3CR1+ cells was 3.31% (range, 0.21 to 21.66%) in PB and 3.09% (range, 0.20-20.01%) in BM. Patients were categorized into high (PB- or BM-CD11b+CX3CR1+ cells >median) and low (<=median) groups. High PB-CD11b+CX3CR1+ cell group was significantly associated with unfavorable clinical features, including age (>60 years old), advanced stage, elevated serum of LDH level, and extranodal involvement (P<0.05), which were clinical factors asso- ciated with higher risk NCCN-IPI (P=0.004). However, BM-CD11b+CX3CR1+ cells were not associated with clinical variables. With a median follow-up of
27.7 months (IQR, 14.6-46.1), low PB-CD11b+CX3CR1+ cell group had significantly better PFS (3-year, 77.1% vs 58.7%; P=0.006) and OS (3-year, 86.6% vs 58.4%; P=0.004) than high PB group. No significant survival differences were observed between high and low BM-CD11b+CX3CR1+ cell groups. Uni-vari-able analyses demonstrated that age, ECOG performance status, B symptoms, extranodal involvement, NCCN-IPI, and PB-CD11b+CX3CR1+ cell group were significantly associated with OS. However, HI or high risk NCCN-IPI was an only independent prognostic factor for reduced OS (hazard ratio, 4.41; 95% confidence interval, 1.17-15.69) in the multivariate analysis. In subgroup analy-sis according to the NCCN-IPI, 3-year OS of high PB-CD11b+CX3CR1+ monocytes was significantly inferior to that of low group (34.0% vs 77.9%; P=0.026) in B-NHL. In contrast, PB-CD11b+CX3CR1+ monocytes failed to predict OS (3-year, 91.7% vs 96.7%; P=0.878) in the low to low-intermediate risk NCCN-IPI subgroup.

Summary/Conclusions: Our study represents PB-CD11b+CX3CR1+ monocytes can be used in differential diagnosis with high risk for early death and are associated with risk stratification by the NCCN-IPI, possibility of potential therapeutic target in DLBCL.

E955

RARE NON-HODGKIN LYMPHOMAS (R-NHLs) IN CHILDREN: THE AIEOP EXPERIENCE

G. Biddeco1, M. Nizzero2, E. Carrara2, L. Mussolin2, D. Massano2, L. Lo Nigro3, S. Buffardi4, A. Garaventa5, P. Farruggia6, R. De Santis7, N. Santoro7, R. Mura8, A. Tondo10, A. Sala11, M. Pigione12, F. Sperafico13, M.C. Putti14, E.S. D’Amore15, M. Pillon1

1Clinik of Pediatric Hematology-Oncology, Department of Women’s and Children’s Health, University of Padova, Padova, 2Department of Paediatric Haematology-Oncology, Azienda Ospedaliero-Universitaria Meyer Children Hospital, Firenze, 3Department of Paediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, 4Department of Paediatric Haematology-Oncology, Regina Margherita Children’s Hospital, Torino, 5Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, 6Clinic of Pediatric Hematology-Oncology, Department of Women’s and Children’s Health, Padova, 7Institute of Pathology, Sant Bortolo Hospital, Vicenza, Italy

Background: Clinical management of pediatric rare non-Hodgkin lymphomas (r-NHL) (<1 case/1 million) is unclear.

Aims: To characterize children with r-NHLs in AIEOP centers. Performing a retrospective analysis of r-NHLs AIEOP case records, describing main epidemiologic, clinical and histopathological parameters. To review the histopatho-logic case records according to WHO 2008 classification. Evaluation of treatment response - chemotherapy or wait and see (W&S) in terms of survival (OS) and of complete remission (CR), relapse and resistance cases, sec-ondary neoplasms and deaths.

Methods: Data from the AIEOP database were collected between 1997 and 2015. Results: The incidence of r-NHL in AIEOP registry was 6.5% (67 pts). Forty-eight were male and 19 female, median age was 11 years (0.3-21 years). Classifica-tion according to St.Jude stage was: stage I n=36; II n=13; III n=11; IV n=7. Bone marrow (BM) involvement was diagnosed in 7 cases; central nervous system (CNS) in one case. Patients who presented LDH >500 UI were 18. B- NHLs accounted for approximately 49% (33 pts) of the entire population analyzed. 64% of BM-NHL were under 40 (27 pts), the remaining 11% (7 pts) of the population under study being categorized as “other” (other than those deriving from B or T/NK-cells). The most common histological subtypes were: follicular lymphoma (FL) amongst B-NHLs; peripheral T-cell lymphoma (PTCL) n.o.s., mycosis fungoides (MF), subcutaneous panniculitis T-cell lymphoma (SPTCL) and lymphomatoid papulosis (LP) amongst T-NHLs; histiocytic sarcoma (HS) amongst “other”s category. A similar proportion for both B and T/NK NHL underwent either W&S approach only or active treatment (AT): 45% and 55% were W&S and AT approach, respectively. Patients in “other”s category were almost actively treated (71%). Therapy was based on AIEOP B-, T/NK-NHLs and ALLC protocol - chemotherapy or immunotherapy. Surgical resection has been performed in case of localized disease B-NHLs only, followed by a W&S strategy, with 100% 3-yr OS. It has been seen that B-NHLs have a more favorable prognosis and very few events (development of resistance to therapy, relapse, secondary malignancy, death). Amongst T/NK NHLs-related events, death remained the most feared event among B-NHLs, which showed a slight prevalence of relapses; as for the category “other”, no relative preponderance has been registered for any of the above-mentioned events. The 3-year OS has shown to be significantly higher for B-NHLs than for T/NK-NHL (94% vs 69%, p-value 0.024), as illustrated in Figure 1. Regarding the treatment, the 3-year OS was 100% for the patients underwent a W&S approach whereas 75% for treated patients (p-value 0.037). FLs show favourable clinical course and outcome, limited stage at diagnosis. Differently from adults, pFLs have a higher 3-years OS with respect to that of other histological pediatric NHLs subtypes (100% vs 75%, p-value 0.049).

Figure 1. Summary/Conclusions: The incidence of AIEOP pediatric r-NHLs is in line with the literature. In case of localized disease, a W&S approach was successfully applied; of these, the T/NK NHLs being most often registered and with best prognosis are the cutaneous lymphomas (i.e. LyP, MF). Patients’ prognosis varies greatly depending on the histological subtype. The better survival was observed in the B-NHLs compared to other categories. An international col-laboration is warranted, in order to create new guidelines or protocols for an appropriate management of pediatric r-NHLs.

E956

PRIMARY ANALYSIS OF THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF 110 CASES OF T CELL LYMPHOMA

C. Li1,2, T. Wang1, Q. Zou1, C. Gu1, D. Wu1,2

1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-tology, 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background: T cell lymphoma(T-NHL) is a rare and heterogeneous group of lymphoid malignancies with mostly poor outcome with conventional treatment. Recent studies have suggested that Hematopoietic stem cell transplanation(HSCT) has a better curative effect and is superior to traditional chemotherapy.

Aims: To investigate the effect of HSCT in the treatment of T cell lymphoma.

Methods: The clinical data of 110 patients with T cell lymphoma treated by HSCT from January 2006 to August 2016 in our center were retrospectively analyzed.

Results: (1)110 T-NHL patients, 70 males and 40 females, aged 7-64 years (median age 26 years). Disease subtypes: 35 cases of T-cell lymphoblastic lymphoma(T-LLB), 23 cases of NK / T cell lymphoma(NK/TCL), 24 cases of peripheral T-cell lymphoma (PTCL, NOS), 24 cases of variable large cell lymphoma(ALCL), 3 cases of subcutaneous panniculitic T cell lymphoma(SPTCL) and 1 case of hepatosplenic T cell lymphoma(HSTCL). Transplantation type: 56 cases of autologous hematopoietic stem cell transplantation (auto-HSCT), 54 cases of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The follow-up was ended in December 2016, the duration of following-up ranged from 2 to 130 months (median follow-up time was 22 months). (2)56/110 patients with auto-HSCT, 3 year overall survival (OS) and disease-free survival (EFS) were 76.5% and 60.9%, respectively. (3)54/110 patients with allo-HSCT, 3 year EFS and OS of allo-HSCT were 61.7% and 58.9%, respectively. (4)36/56 patients with CR1 status before auto-HSCT, 3 year OS and EFS were 87.3% and 68.7% respectively. 20/56 patients with non-CR1 status before auto-HSCT, 3 year OS and EFS were 60.6% and 40.2%. The OS and EFS of the two groups were significantly different (P=0.001). (5)45/110 cases were young and high-risk patients (age<60 years, IPI score ≥3).25/54 cases treated with allo-HSCT, the 3 year OS and EFS were 62.8% and 60.8%. 20/56 cases treated with auto-HSCT, the 3 year OS and EFS were 47.6% and 36.9%. The OS and EFS of the two groups were also significantly different (P=0.001).

Summary/Conclusions: HSCT can improve the efficacy of T cell lymphoma. Auto-HSCT in first complete remission (CR1) enables T-NHL patients with
greater benefit. Allo-HSCT can cure some T-NHL patients, which can be considered for the treatment of young and high-risk T-NHL patients.

**E957**

**SHORT COURSE OF R-HYPERCVAD/MTX/ARA-C FOLLOWED BY ASCT AS FIRST-LINE THERAPY IN MANTLE CELL LYMPHOMA PATIENTS PROLONGS PROGRESSION FREE SURVIVAL TO MORE THAN 9 YEARS.**

**SINGLE CENTER EXPERIENCE**

M. Andrade-Campos1,2, S. Mercadal1, E. Domingo Domenech1, V. Paredes Henao1, C. Aguilla Gomez1, A. Oliveira Ramos1, E. de la Banda3, F. Cifuentes3, R. Parody Porras1, A. Fernandez de Sevilla1,4, A. Sureda1, E. Gonzalez Barca1,4

1Department of Hematology, Institut Català d’Oncolegia Hospitalat, IDIBELL, Barcelona, 2CIBER de Enfermedades Raras, CIBERER, ISCIII, Zaragoza, 3Pathology Department, Hospital Universitario de Bellvitge, IDIBELL, 4Deartment of Clinical Sciences, University of Barcelona, Barcelona, Spain

**Background:** Mantle cell lymphoma (MCL) is considered an incurable disease with an historical median overall survival around 3-4 years with short progression free survival (PFS) periods. Regimens that include high dose cytarabine and consolidation with autologous stem cell transplant (ASCT) have become standard therapy for fit patients. The median PFS reported after 4-6 cycles HyperCVAD followed by ASCT consolidation is 4.5 years (Ahmadi et al, BMT 2012). Nevertheless, toxicity is high and many patients cannot obtain stem cells for transplant. In this setting, some groups use 6-8 cycles R-HyperCVAD without ASCT consolidation, achieving the same median PFS of 4.6 years (Romaguera et al, Br J Hematol 2010). Based on this we have review our experience using a short course of HyperCVAD followed by transplant consolidation.

**Aims:** To analyze our experience treating fit patients with MCL in first line with a short course of 2 cycles of R-HyperCVAD followed by consolidation with ASCT.

**Methods:** From January 2002 to August 2016, the patients diagnosed with MCL treated in first line with a short course of 2 cycles of R-HyperCVAD and ASCT were included in this retrospective analysis. International working group response assessment criteria were used, PFS was calculated from the date of start therapy until date of relapse/progression or last contact.

**Results:** During the study period 85 MCL patients were registered: 7 (8.2%) did not receive immediate therapy, 44 (52.4%) were not eligible for intensive chemotherapy due to comorbidities or age and 33 (39.3%) were treated with R-HyperCVAD. Clinical characteristics at diagnosis of these 33 patients were: MIP ratio: 26/7 (78.8%/21.2%), median age: 63 y.o (limits: 40-73), ECOG 0-1; 26 (86.7%), Ann Arbor stage III-IV 28/31 (90.3%), MIPI score: low risk: 5 (16.7%), intermediate risk: 17 (56.7%), high risk: 8 (26.7%). Thirty (90.9%) patients completed the 2 cycles of R-HyperCVAD. Reasons for discontinuation were: 2 deaths for sepsis and 1 CNS progresssion. Intention to treat response rate was: CR 26 (78.8%), PR 2 (6.0%), progressive disease 3 (9.0%), not evaluable 2 (6.0%). Among the 28 patients in CR / PR considered eligible for consolidation with ASCT, 8 patients were not transplanted: 4 (14.3%) had harvest failure (all before plerixafor availability), 2 had persistent toxicity (prolonged neutropenia and severe mucositis) and were not considered for ASCT. 1 rejected, 1 unknown cause. Conditioning regimen was BEAM/LACE in 18 (90%) patients and cyclophosphamide-TBI in 2 (10%). One patient died 10 days after infusion for sepsis. With a median follow-up of 35 months (1-131), the median PFS was 7.0 (95%CI 3.8-10.7) months (8.08 years) for the whole group, 114 (47.3-180.7) months (9.4 years) for the transplanted patients vs 21 (3.1-38.9) months (1.8 years) for the not transplanted group. The median OS was 123 (31.9-214.1) months, median OS was not reached for transplanted group vs 31.0 (7.5-54.6) months for not transplanted.

**Summary/Conclusions:** A short course of R-HyperCVAD achieves a very high remission rate in fit patients with MCL. Stem cells could not be obtained in a small proportion of patients, all of them before the use of plerixafor. Two thirds of the patients could complete the planned therapy with ASCT consolidation, and those patients have an excellent outcome, with a PFS of more than 9 years.

**Figure 1.**

**E958**

**THE FREQUENCY OF INCIDENTAL MALIGNANCIES DETECTED BY PET/CT SCANS IN PATIENTS WITH LYMPHOMA AND THE ASSOCIATED CLINICAL IMPLICATIONS**

J. Falconer1,*, G. Kidston-Gerber2, E. Wegener2

1Haematology, Concord Repatriation General Hospital, 2Haematology, The Prince of Wales Hospital, Sydney, Australia

**Background:** PET/CT imaging has a well-established role in the investigation of malignant lymphoma. Given the widespread clinical applications, unexpected findings are occasionally identified. Whilst there is substantial information pertaining to additional primary cancers identified on PET/CT in patients with solid organ malignancy, there is a relative paucity of data in patients with lymphoma. **Aims:** The primary aim was to identify the frequency of incidental second malignancies detected by PET/CT imaging in patients with lymphoma. Qualitative data related to histological diagnosis and staging, interruptions or obstacles to lymphoma therapy, therapy for the second malignancy and the overall impact upon prognosis were also reviewed.

**Methods:** A total of 550 PET/CT images were performed in 298 patients at The Prince of Wales Hospital, Sydney Australia between January 2013 – March 2016. Patients with both Hodgkin’s and Non-Hodgkin’s lymphoma, with PET/CT imaging performed for all medicare-approved indications were included. All PET/CT reports suggest of an incidental second malignancy prompted further review of electronic medical records, MOSAIC cancer database and paper medical records. Where a clear diagnosis of second malignancy was confirmed, information regarding histological findings and staging, as well as the implications of this diagnosis related to treatment of the underlying lymphoma and impact on overall prognosis was collected.

**Results:** 510 PET/CT scans in 259 patients had confirmed diagnoses of lymphoma. Patients aged 17 to 96 were included in the study, with a median age of 62 years. Of the 259 patients included (M=155; F=104), 55 patients had a diagnosis of Hodgkin’s lymphoma and 204 patients a diagnosis of Non-Hodgkin’s lymphoma. A total of 33 out of 259 patients with a diagnosis of malignant lymphoma had PET/CT findings suspicious for an underlying second malignancy (12.7%). Of the 33 patients, 19 underwent further invasive investigation, with a total of 8 patients having a biopsy proven histological diagnosis of a second malignancy (3.1%). Qualitative information was gathered regarding the patients who did not have further investigation.

**Summary/Conclusions:** The frequency of incidental malignancies detected by PET/CT imaging in patients with lymphoma was found to be comparable to other similar international retrospective studies. The majority of incidental second malignancies were early stage and gastrointestinal in origin. Further retrospective as well as prospective data may assist in the establishment of guidelines, to address a standardized diagnostic approach to investigating incidental lesions discovered on PET/CT imaging that are suggestive of a second malignancy.

**E959**

**CLINICAL IMPACT OF KARYOTYPIC EVOLUTION ON THE PROGNOSIS OF DIFFUSE LARGE B CELL LYMPHOMA**

Y. Mizuno1,*, T. Kobayashi1, N. Uoshima2, E. Kawata2, H. Chiyoda1, Y. Chinên1, S. Honike1, J. Kuroda1

1Hematology, Kyoto Prefectural University of Medicine, 2Hematology, Japanese Red Cross Kyoto Daini Hospital, 3Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan

**Background:** The acquisition of additional chromosomal abnormalities are generally accompanied by the emergence of therapeutic resistance and eventually lead to poor treatment outcome in cancers. However, the actual clinical impact of karyotypic evolution on prognosis differs depending on the type of hematologic malignancy. Although several prognostic indexes, including the International Prognostic Index (IPI), revised IPI (R-IPI), National Comprehensive Cancer Network (NCCN)-IPI, and Kyoto Prognostic Index (KPI) which we have developed (Kobayashi T. Blood Cancer J 2016), have the determinants for prognosis, little is known concerning the prognostic impact of karyotypic evolution in diffuse large B cell lymphoma (DLBCL), the most prevalent subtype of non-Hodgkin lymphoma. **Aims:** We in this study investigated the clinical impact of karyotypic evolution on the treatment outcome of DLBCL.

**Method:** We retrospectively used the medical records of 465 DLBCL patients who were diagnosed and treated with either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) or with a R-CHOP-like regimen at three independent institutes in Kyoto, Japan, between January 2006 and April 2014. We analyzed the relationship between the number of subclones and prognosis utilizing the Kaplan-Meier curve and Cox proportional hazards regression analysis. We also utilized Fisher’s exact test to investigate the correlation between the number of subclones and the conventional prognostic indexes, i.e. R-IPI, NCCN-IPI, and KPI. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
and was approved by the institutional review boards of all participating institutes.

**Results:** Among the 465 DLBCL cases, karyotypic analyses by G-banding were performed on biopsied tumor specimens before the start of treatment in 181 patients. Among the 181 patients, metaphase spreads were available for G-banding in 120 patients. Neither overall survival (OS) nor progression free survival (PFS) was statistically significantly different between the patients with available metaphase and no available metaphase spreads. Based on the result of G-banding, we next divided the 120 patients with available metaphase spreads into two groups, i.e., patients with karyotypic abnormalities accompanied by ≥2 subclones and patients with 0-1 subclones. We found that the presence of ≥2 subclones was significantly associated with poor OS (3 year OS rates of patients with ≥2 subclones and 0-1 subclones were 67.6% and 82.8%, respectively, (p=0.035), and tended to associate with a shorter PFS. Among the 120 patients with available metaphase spreads, the R-IPI-defined high-risk patients and IPI-defined high-risk patients were significantly more frequent in the group of patients with ≥2 subclones. Ages and genders were not significantly different between patients with ≥2 and with 1-2 subclones.

**Summary/Conclusions:** DLBCL is a cytogenetically and molecularly heterogeneous disease entity. No specific chromosomal abnormality has been associated with the shorter survival, except double or triple hit lymphomas. However, in this study, it was possible to divide DLBCLs into two groups based on karyotypic evolution, i.e., DLBCLs with ≥0 subclones and ≥2 subclones, because the OS was the most markedly different between these two groups. In our study, more subclones were associated with poor prognosis, suggesting the significance of karyotypic evolution in DLBCL. In conclusion, our study suggests that more advanced cytogenetic clonal evolution underlies the development of high-risk disease feature in DLBCL.

**E960**

REGIMENT INTENSIFICATION MAY IMPROVE OUTCOMES IN PATIENTS WITH HIGHER RISK HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELATED AGGRESSIVE B-CELL LYMPHOMAS


1Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, 2Hematology Oncology, Mercy Clinic Oncology and Hematology, Joplin, 3Malignant Hematology, 4Bone Marrow Transplant, H.Lee Moffitt Cancer Center & Research Institute, Tampa, 5Malignant Hematology, George Washington Cancer Center, Washington D.C., United States

**Background:** Despite effective combination antiretroviral therapy for HIV, there remains an increased incidence of HIV related B-cell Non-Hodgkin lymphomas (NHL). The introduction of early antiretroviral therapy and effective chemotherapy have led to improved outcomes overall. Regimen intensification (RI) in HIV associated B-cell NHLs has shown improved survival, especially in the rituximab era (Barta et al, Blood 2013).

**Aims:** To examine the effect of RI on the overall survival (OS) and progression free survival (PFS) compared to CHOP based chemotherapy according standard risk stratification.

**Methods:** Patients with HIV associated aggressive B-cell NHL were identified between 2001- 2015 at Moffitt Cancer Center. Patients with primary central nervous system lymphoma, T-cell NHL and indolent NHLs were excluded. Patients received R-CHOP or intensive chemotherapy (IC) including DA-EPOCH, hyperCVAD or CODOX/MV as initial treatment. Data collected included patient demographics, disease baseline characteristics, CD4 count, HIV viral load, treatment regimen, response, and outcomes including relapse and OS. The IPI score was calculated, and patients were divided into two groups: lower risk group (low and low-intermediate IPI risk) and higher risk group (high-intermediate and high). Descriptive statistics were used for baseline characteristics. Kaplan Meier method was used to estimate PFS and OS, and the log-rank test was used to compare OS and PFS between lower and higher risk groups.

**Results:** A total of 83 patients were included. The M:F ratio was 9:4. Median ages were 65 years (y) (range 25 – 68). Two thirds of patients were Caucasian. The median time from HIV to NHL diagnosis was 29 months (range 0 – 284). Eighty two percent presented with stage III/IV disease. Bulky disease was present in 27%, elevated LDH in 66%, and CD4 count<100/ml at diagnosis in 22% patients. Fifty percent of patients were on HAART therapy at time of lymphoma diagnosis. Chemotherapy regimens included: R-CHOP (n=30, 36%), CHOP (n=12, 15%), DA-EPOCH-R (n=27, 33%), DA-EPOCH (n=1, 1%), hyperCVAD (n=11, 13%) and CODOX/MV (n=2, 2%). The median follow up was 2.7 y (95% CI.2-3.0-4.3). The median OS and PFS for the whole cohort was 5.9 and 4.9 y, respectively. The median OS was 4.5 y (95% CI.1.5-6.5) for patients who received CHOP based regimen and was not reached (NR) for patients who had IC (p=0.44). Based on the IPI, the median OS was NR for the lower risk group compared to 1.8 y in higher risk group (p=0.025). Among patients who received CHOP, the median OS for those with lower risk disease was NR compared to 5 y in patients with higher risk disease (p=0.05). For patients who received IC, the median PFS was NR among lower and 1.4 y higher risk groups (p=0.34).

**Summary/Conclusions:** The IPI score remains prognostic in HIV related B-cell NHLs. There was a trend for improved OS and PFS using IC regimens. CHOP treatment remained associated with worse outcome among higher risk patients while IC regimens may overcome the higher risk features based on the IPI.

**E961**

EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1-MEDIATED OVEREXPRESSSION OF MYC AND BCL2 CAN PREDICT POOR PROGNOSIS IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE

J.-H. Wang1, X.-W. Bi2, Z.-J. Xia1, W.-Q. Jiang2, H.-Q. Huang2, L. Wang1

1Hematologic Oncology, 2medical oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

**Background:** Recently double-hit lymphoma or double protein expression lymphoma has been identified as a distinct group of diffuse large B cell lymphoma with poor prognosis. However, the expression status, clinical and prognostic effect of combined overexpression of MYC and BCL2 in extranodal NK/T-cell lymphoma, nasal type (ENKTL) are not known.

**Aims:** This study aims to explore the clinical and prognostic effect of combined overexpression of MYC and BCL2 in ENKTL.

**Methods:** Paraffin-embedded lymphoma samples from 53 patients with newly diagnosed ENKTL were studied using immunohistochemistry for MYC and BCL2, and fluorescent in situ hybridization (FISH) for MYC and BCL2 were done on 5 tissue sections with highest percentages of both MYC and BCL2 positive lymphoma cells.

**Results:** The median percentage of MYC-positive lymphoma cells and BCL2-positive lymphoma cells were 20% (range, 5% >45%) and 70% (10% >95%), respectively. Using median scores as cutoffs, we assigned each patient an IHC score ranging from 0 to 4. The IHC score was significantly associated with prognosis (p<0.05). The median OS for patients with IHC score of 0 was 28 months, whereas the median OS for patients with IHC score of 4 was 12 months (p<0.05). The median PFS for patients with IHC score of 0 was 12 months, whereas the median PFS for patients with IHC score of 4 was 6 months (p<0.05). The IPI score remains prognostic in HIV related B-cell NHLs. There was a trend for improved OS and PFS using IC regimens. CHOP treatment remained associated with worse outcome among higher risk patients while IC regimens may overcome the higher risk features based on the IPI. The DHS was not associated with patients’ age, gender, disease stage, LDH level, B symptoms, performance status, or local tumor invasiveness. However,
Patients with tumor localized in extranodal sites seemed to have higher expression of BCL2 and higher DHS than nasal lesions (p=0.014 and 0.042, respectively). In univariate survival analysis, either high expression of MYC or BCL2 was significantly correlated with inferior PFS and OS ($p<0.05$). According to the DHS, patients with ENKTL could be divided into three significantly different risk groups for PFS and OS (3-year PFS rate for DHS of 0, 1, and 2 was 60%, 41%, and 21%, respectively, $p=0.008$; 3-year OS rate for DHS of 0, 1, and 2 was 79%, 49%, and 33%, respectively, $p=0.015$). In multivariate survival analysis, it was found that DHS was an independent prognostic factor for both PFS and OS ($p=0.006$ and 0.011, respectively).

**Summary/Conclusions:** Our study demonstrated that DHS can help identify patients with newly diagnosed ENKTL who are at a high risk for a poor clinical outcome, which needs to be validated in prospective clinical trials with patients treated uniformly.

**E962**

**SOLUBLE INTERLEUKIN-2 RECEPTOR AS A PREDICTIVE MARKER FOR SPONTANEOUS REGRESSION OF OTHER IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS; A RETROSPECTIVE STUDY**

Y. Nakajima1, S. Fujisawa2, C. Nigauri2, A. Matsumura1, T. Ando2, T. Suzuki2, E. Ogusu1, Y. Ishii2, K. Miyashita1, H. Takahashi1, T. Miyazaki1, K. Motohashi2, M. Hagihara1, K. Matsumoto1, E. Yamazaki3, H. Nakajima1

1Department of hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, 2Department of Hematology, Yokohama City University Medical Center, 3Clinical Laboratory Department, Yokohama City University Graduate School of Medicine, Yokohama, Japan

**Background:** Patients treated with immunosuppressive drugs (ISD) for autoimmune diseases are at an increased risk of developing other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OI-LPD). Some patients with OI-LPD shows spontaneous regression after withdrawal of ISD, but some require chemotherapy. The factors that are associated with spontaneous regression and outcomes of chemotherapy remain uncertain.

**Aims:** The aims of our retrospective study are to assess the clinical factors that predict spontaneous regression of lymphoma after ISD withdrawal in patients with OI-LPD and to evaluate the outcomes of patients who underwent chemotherapy without spontaneous regression.

**Methods:** We collected data from all patients with autoimmune disease who were pathologically diagnosed with OI-LPD between January 2002 to October 2016 at Yokohama City University Hospital, and Yokohama City University Medical Center.

**Results:** The patients included 12 males and 28 females, with a median age at diagnosis of 65 years (range 30-81). Methotrexate (MTX) was administered to all patients at any point of the clinical course before OI-LPD. The median time from diagnosis of autoimmune disease to OI-LPD development, and the median duration of MTX administration were 12 months (range 1-58) and 89 months (range 4-297), respectively. The histological findings of OI-LPD were diffuse large-B-cell lymphoma (DLBCL) in 26 patients, follicular lymphoma in 1, MALT in 2, peripheral T cell lymphoma, not otherwise specified in 3, and 3 patients were untreated. The median observation period in the surviving patients was 34 months (range 3-119). The 2-year progression-free survival (PFS) and overall survival (OS) rates for all 40 patients were 69% and 79%, respectively. A total of 18 patients (45%) had spontaneous regression after ISD withdrawal. The median time from ISD withdrawal to spontaneous regression was 4 months (range 1-13). Among the 18 patients with spontaneous regression, 3 relapsed. Of the 22 patients without spontaneous regression, 20 subsequently underwent chemotherapy; 18 underwent CHOP/CHOP-like ± rituximab, and 2 underwent other regimens. In total, 7 patients died: all died from lymphoma progression. Compared to those without spontaneous regression, patients with spontaneous regression had clinical stages I-II ($P=0.021$), performance status of 1-2 ($P=0.028$), normal levels of LDH ($P=0.026$), and lower levels of sIL-2R ($P=0.005$). The ROC curve analysis showed the appropriate cut-off of sIL-2R levels to be 2400 U/mL for predicting spontaneous regression (AUC, 0.74; sensitivity, 0.81; specificity, 0.67). On multivariate analysis, only an sIL-2R level of < 2400 U/mL was independently associated with spontaneous regression (odds ratio, 0.03; 95% CI, 0.002-0.39; $P=0.007$). Thirteen patients with DLBCL who did not have spontaneous regression received CHOP/CHOP-like ± Rituximab. The CR rates, and 2-year PFS and OS of these 13 patients were 38%, 68.3%, and 82.1%, respectively.

**Summary/Conclusions:** Our study revealed that an sIL-2R level of <2,400 U/mL was significantly associated with spontaneous regression in patients with OI-LPD. Because CR rates with chemotherapy in patients without spontaneous regression are low, evaluation of sIL-2R in patients with OI-LPD may be useful for an early withdrawal of ISD, resulting in a higher chance of spontaneous regression.

**E963**

**PROGRAMMED DEATH-1 PROTEIN EXPRESSION AND ITS RELATION WITH HISTOLOGIC AND CLINICAL VARIABLES IN MYCOSIS FUNGOIDES**

C. Vasquez1, S. Novelli2, A. Mozos1, P. Garcia Muret1, A.C. Caballero2, J. Sierra2, J. Birones1

1Pathology, 2Hematology, 3Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

**Background:** Mycosis fungoides (MF) is a T-cell malignancy with affinity for the skin. In early stages, treatment directed to the skin can induce long-lasting remissions. However, advanced stages are characterized by short-duration remissions and progressive disease. The programmed death cell surface protein-1 (PD-1) is expressed on activated T cells. Interactions between PD-1 and its ligands control the induction and maintenance of peripheral T-cell tolerance during the normal immune response. These interactions may also play a role in the immune evasion of tumors in which PD-1 ligand is overexpressed.

**Aims:** To described histologic characteristics and the proportion and intensity of PD1 expression by tumor cells, as well as the presence of PD1 positive lymphocytes in the epidermis in patients with MF. To identify histologic variables that might have an impact in clinical outcome.

**Table 1.**

<table>
<thead>
<tr>
<th>Characteristics of Patients</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Stage</td>
<td>Early</td>
<td>Advanced</td>
</tr>
<tr>
<td>Tumor cell expression (PC)</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Presence of histiocytes</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>extramedullaryPD1+ cells</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>intensity of tumor infiltrate</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Epidermotropism of tumor cells</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Degree of atrophy</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Granuloma-like structures</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
</tbody>
</table>

**Table 2.**

<table>
<thead>
<tr>
<th>Characteristics of Patients</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean ± SD</td>
<td>65 ± 13</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Stage</td>
<td>Early</td>
<td>Advanced</td>
</tr>
<tr>
<td>Tumor cell expression (PC)</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Presence of histiocytes</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>extramedullaryPD1+ cells</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>intensity of tumor infiltrate</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Epidermotropism of tumor cells</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Degree of atrophy</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Granuloma-like structures</td>
<td>N. of cells</td>
<td>&gt;25</td>
</tr>
</tbody>
</table>

**Methods:** Histological preparations of 85 patients diagnosed with MF were evaluated. Survival analysis was performed with the Kaplan-Meier method. A univariate analysis was performed with clinical variables (stage and age) and anatopathological variables (i.e. intensity of the inflammatory inflamma-
trate, epidermotropism, cellular atypia, tumor density, presence of folliculotropism and phenotypic alterations) and the proportion and intensity of PD1 expression by tumor cells, the presence of PD1-positive lymphocytes in the epidermis. Likewise, a Pearson correlation analysis was performed between the degree of atypia and the ratio of PD1 expression, PD1 intensity, and loss of CD7 expression in tumor cells. Statistical analysis was performed using the IBM SPSS Statistics version 21.0.

Results: The median follow-up was 125 months (range 6-450 months). Characteristics of patients are in Table 1. The overall survival (OS) at 10 years was 81%. OS in the early stages was 85% vs. 64% in advanced stages (p<0.05). The OS for patients <60 years was 85%, and 75% for patients ≥60 years (p=0.05). Regarding histologic findings, the degree of atypia was the only variable that had an impact in OS (see Figure 1) The presence of atypia grade 1 had an OS of 88%, grade 2 of 75%, and grade 3 of 50% (p<0.05). We performed a correlation analysis between degree of atypia and the ratio of PD1 expression, PD1 intensity, and loss of CD7 expression. A positive correlation was detected, however it was weak (r<0.5).

Summary/Conclusions: MF tumoral cells express PD1 protein in a high proportion of cases being a potential therapeutic target. Advanced disease, age ≥60 years and the degree of atypia of the tumoral infiltrate had an impact on survival.

E964
circulating microRNAs as biomarkers in diffuse large B-cell lymphoma: a pilot prospective longitudinal clinical study

C. Bouvy1, A. Wannez2, C. Chatelain1, J.-M. Dogne1
1Department of Pharmacy, University of Namur, Namur, 2CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium

Background: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a necessity to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation and an overview of the resistance to chemotherapeutics. We decided here to focus on circulating microRNAs that are found in all biological fluids. This accessibility makes them good candidates for biomarkers studies.

Aims: This research aims at studying microRNAs found in plasma from DLBCL patients and at investigating their potential as biomarkers of survival in these patients. For this purpose, a plasma biobank was created with samples from DLBCL patients at different times of their treatment. This follow-up of microRNAs level during the course of treatment is particularly innovative in this study.

Methods: A plasma biobank from DLBCL patients was set up at the Centre Hospitalier Universitaire (CHU) UCL Namur Yvoir, Belgium (ethical agreement number B039201149613). Informed consents of all patients were obtained. In this way, blood samples from patients were taken before any treatment (C0), at the administration of the second and the fourth chemotherapeutic cure (C2 and C4) and at the remission review (Cp). In the case of an autograft, a sample was taken at the post-graft review (Cpg). The first step of this study was the selection of the microRNAs that will be quantified in all the samples of the biobank and that would potentially be used as biomarkers. To this end, a quantification of 377 microRNAs was performed by TaqMan® Low Density Array on the plasma samples of two selected DLBCL patients and one healthy donor with no history of cancer. These DLBCL patients were selected based on their highly different response to treatment. One of them obtained a complete remission after a R-CHOP treatment, while the other presented a refractory disease to the same treatment. One of these patients is in first CR at the administration of the second and the fourth chemotherapy, while the other presents a refractory disease to the same treatment. Four points were attributed to miR-122, miR-19b and miR-19a.

On the 377 microRNAs quantified into the plasma of the 3 selected donors (2 DLBCL patients and 1 healthy donor), 81 microRNAs were detected. Three microRNAs obtained the highest score of 5 points: miR-197, miR-20a and miR-451. Four points were attributed to miR-122, miR-19b and miR-19a.

Two additional microRNAs were also selected: let-7e, for its prognostic value at C0, C2 and C4 and miR-21, for its numerous citations in the literature.

Summary/Conclusions: miR-197, miR-20a, miR-451, miR-122, miR-19b, miR-19a, let-7e and miR-21 have been selected in this study and are currently quantified in the plasma of the entire biobank. Since then, 19 patients have been included in the study and the potential of these microRNAs as biomarker are statistically evaluated.

E965
Combining chemotherapy plus radiation therapy is more effective in limited-stage diffuse large B-cell lymphoma of the tonsil.

S.-N. Lim1,2
1Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of
2Department of Internal Medicine, School of Medicine, Pusan National University, Busan, Republic of Korea

Background: Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin’s lymphomas. Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin’s lymphomas.

Aims: The purpose was to evaluate the prognostic factors and treatment outcome of patients with diffuse large B-cell lymphoma (DLBCL) of the tonsil.

Methods: In all, 114 patients with DLBCL of the tonsil with stage I or stage II, treated at multicenter in Korea, from September 1995 to April 2011, were included. The median age was 59 years and the majority of patients (61%) were male. Systemic symptoms were present in 6% of patients. International prognostic index (IPI) score was 0 in 54 patients (48%), 1 in 40 (35%), 2 in 14 (12%), and 3 (3%). Ten patients (8%) showed elevated level of lactate dehydrogenase (LDH). Treatment consisted of a combination of chemotherapy (CTx) and radiotherapy (RTx) for 38 patients (34%) and 72 patients (65%) received CTx only. Among those receiving RTx, the median RTx dose was 39 Gy.

Results: After median follow-up of 32 months (range 0.4-106 months), event free survival (EFS) and overall survival (OS) were 25.9% and 42.5%, respectively. Significantly prognostic factors included: age ≥60 year-old vs <60 year-old, LDH level (> upper normal limit and ≤ upper normal limit), IPI score (0-1 vs 2-3), and treatment (CTx plus RTx vs CTx only). On multivariate analysis; LDH level (hazard ratio [HR], 10.522; 95% confidence interval [CI], 2.548-43.449, p=0.001) and treatment (HR, 12.393; 95% CI 2.151-71.410) were independent prognostic factor of EFS and age (HR, 8.920; 95% CI 1.089-73.053, p=0.043), LDH (HR, 8.316; 95% CI 1.914-36.127, p=0.005), and treatment (HR, 8.943; 95% CI 1.089-73.425) retained statistical significance in OS.

Summary/Conclusions: LDH level and age significantly influence outcome. A combined modality treatment, consisting of CTx and RTx, results in a satisfactory outcome in patients with stage I or II DLBCL of the tonsil.

E966
Sequential treatment with bendamustine, rituximab and dexamethasone followed by rituximab consolidation and lenalidomide maintenance for frail elderly patients with aggressive B-Non Hodgkin Lymphoma

1L. Mettivier, A. Bruno1, R. Bianco1, S. Annunziata1, R. Fontana1, B. Serio1, C. Martorelli1, R. Guariglia1, R. Rosamilio1, B. Marcelli Graziosi1, C. Seillier1

1Hematology, AOU San Giovanni di Dio e Ruggi D’Aragona, Salerno, Italy

Background: Frail elderly patients with aggressive B non-Hodgkin Lymphoma (a-B-NHL) in most cases show comorbidities such as to preclude the use of antracycline-based standard regimen. Although significant advances have recently been achieved in the therapy of older patients with a-B-NHL, there is still need for treatment strategies able to overcome the impact of drug toxicity and frailty in elderly frail patients.

Aims: The safety and efficacy of bendamustine and rituximab plus dexamethasone (RD-Benda) regimen were prospectively investigated in 14 elderly and frail patients with newly diagnosed a-B-NHL.
Methods: Fourteen (4 female, 10 male) consecutive frail elderly patients (median age: 79 years; range 68-86 years) with aaIPI ≥2 (11 DLBCL, 1 Burkitt NHL, 1 Burkitt-like NHL and 1 Mantle cell lymphoma) were enrolled in a phase II study with bendamustine 70mg/m\(^2\) i.v. on days 1 and 2, rituximab 375mg/m\(^2\) i.v. on day 1 and oral dexamethasone 20mg total dose on days 1-4 for four cycles. Frailty criteria were age > or =80 years, or age > or =70 years associated with 3 or more comorbidities or at least one grade 3 comorbidity according to the cumulative illness rating scale (CIRS), as well as not self-sufficient or the presence of geriatric syndromes.

Results: Patients who showed complete (CR) or partial response (PR) after the fourth induction cycle of RD-BENDA started a consolidation course with four weekly doses of rituximab (375mg/m\(^2\) i.v.) followed, in the case of persistency of CR or PR, by a maintenance treatment with monthly courses of lenalidomide (10mg/m\(^2\), days 1-21). All patients performed G-CSF prophylaxis to avoid febrile neutropenia. Patients with progressive disease after RD-BENDA started maintenance treatment with monthly courses of full dose lenalidomide. PEFS and OS were measured for the assessment of therapy response after RD-BENDA induction course and after rituximab consolidation. After a median follow-up of 6 months (range 2-18), the overall relapse rate was 81%, with CR and PR of partial response rates of 63 (n=21) and 21% (n=2) respectively. Two patients died due to multiple organ failure and disease progression after 1 and 3 months from diagnosis, respectively. In our frail B-lymphoproliferative cohort, the sequential treatment strategy was well-tolerated. After RD-BENDA cycles, grade II infectious disease was observed in 2/11 patients (18%) and DNA-CMV reactivation was detected in 2 other 2 additional patients (18%). However, 2 out of five patients who started maintenance lenalidomide treatment discontinued therapy for renal and hematological grade 3 toxicity. At the time of analysis, the estimated median 18-month progression free survival (PFS) and overall survival (OS) were 75% and 66%, respectively.

Summary/Conclusions: Our preliminary data show that sequential treatment with RD-BENDA followed by four weekly doses of rituximab and finally by lenalidomide maintenance is a feasible and safe therapy option in frail elderly a-B-NHL patients, but needs to be assessed in a larger subsequent trial.

E968

CLINICAL RELEVANCE OF SARCOPENIA IN DIFFUSE LARGE B-CELL LYMPHOMA - TWO ARE BETTER THAN ONE

S. Kim1,*, M. Park2, G.-W. Lee1

1Department of Internal Medicine, 2Radiology, Gyeongsang National University School of Medicine, Jinju, Korea, Republic Of

Background: Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus concerning the optimal method to define sarcopenia in DLBCL.

Aims: In this study, given the uncertainty about the optimal SMIs to define clinically meaningful sarcopenia in DLBCL, we compared the characteristics and clinical outcome between sarcopenic patients determined by L3 skeletal muscle index (L3-SMI) and those determined by pectoralis muscle SMI (PM-SMI) who were treated with standard front-line R-CHOP therapy. Furthermore, the synergistic role of L3- and PM-SMIs as prognostic markers was also investigated.

Methods: We retrospectively reviewed 193 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Sarcopenia was classified by the region where the pretreatment skeletal muscle index (SMI) was measured.

Results: Both the sarcopenia-L3 and sarcopenia-pectoralis muscle (PM) groups had increased incidences of severe treatment-related toxicities and treatment discontinuation compared with the non-sarcopenia-L3 and non-sarcopenia-PM groups, respectively. The sarcopenia-L3 and non-sarcopenia-L3 groups had 5-year overall survival (OS) rates of 40.5% and 67.8% (p<0.001), respectively. The sarcopenia-PM and non-sarcopenia-PM groups had 5-year OS rates of 35.9% and 69.0% (p=0.007), respectively. When the sarcopenia-L3 alone and sarcopenia-PM alone groups were compared, there were no differences in baseline characteristics, treatment toxicity, or survival. In multivariate analysis, when compared with the non-sarcopenia-both group, OS was significantly worse in the sarcopenia-both group (HR, 2.480; 95% CI, 1.284-4.792; p=0.007), but not in patients with either sarcopenia-L3 alone or sarcopenia-PM alone (p=0.151).

Summary/Conclusions: L3- and PM-SMIs are equally useful to define sarcopenia, which is related to intolerance to R-CHOP therapy and to worse survival in patients with DLBCL. More prognostic information can be obtained when these two SMIs are combined to define sarcopenia.
Summary/Conclusions: Our data suggests that the addition of etoposide to R-CHOP and increase in dose-intensity improve EFS and OS of younger patients with newly diagnosed high-risk B-LCL. R-CHOEP14 and DA-R-EPOCH seem to be similarly effective in this setting.

E970
HIGH COMORBIDITY INDEX ALONG WITH HIGH NCCN-IPi STRONGLY INFLUENCE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS: SERBIAN LYMPHOMA GROUP EXPERIENCE
I. Aurer16, P. Roncevic1, L. Galunic-Bilic 4, M. Dobrenic 56, A. Ostojic 1, D. Dujmovic 6, I. Petkovic4, V. Nikolic5, J. Bila2, V. Djurasinovic2, A. Sretenovic1, V. Vukovic1, M. Smiljanic1, S. Sretenovic5, B. Mihaljevic12
1Division of Hematology, Department of Internal Medicine, 2Department of Pathology and Cytology, 3Department of Radiology, 4Department of Oncology, 5Department of Nuclear Medicine, University Hospital Centre Zagreb, 6Medical School, University of Zagreb, Zagreb, Croatia

Background: A few studies have validated the prognostic significance of the NCCN International Prognostic Index (NCCN-IPi) so far. However, some patients with low risk according to NCCN-IPi have poor survival, and thus clinical parameters, that might better characterize patients within risk groups, need to be studied further. Aim: The aim of this study was to evaluate prognostic significance of current indexes such as International Prognostic Index (IPI), NCCN-IPi, and the influence of comorbidities on the overall survival (OS) of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL).

Methods: A total of 708 patients (383 males/345 females) with the median age of 58 years (range 18-89) were included in the study. Majority of patients received R-CHOP (Rituximab, Cyclophosphamide, Doxorubicine, Vincristine, Prednisone) protocol, 652 (92.1%), while 29 (4.1%) received R-EPOCH (Rituximab, Etoposide, Cyclophosphamide, Doxorubicine, Vincristine, Prednisone), and 27 (3.8%) received R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone).

Results: According to the Ann Arbor classification, stage I and II had 332 patients (46.9%), while stage III and IV had 376 patients (53.1%). Bulky disease was present in 201 patients (28.4%), and B symptoms in 437 patients (61.7%). Poor European Cooperative Oncology Group (ECOG) performance status (ECOG performance status ≥2) had 145 patients (20.5%). Bone marrow involvement was present in 97 patients (13.7%). At least one comorbid condition had 309 patients (43.6%), while high Charlson Comorbidity Index (CCI) had 44 patients (6.2%). Majority of patients had cardiovascular disorders (223, 31.5%), endocrinological (63, 8.9%), neurological (20, 2.8%), reumatological (19, 2.7%), previous malignancy (19, 2.7%), pulmonary (18, 2.5%), psychiatric (13, 1.8%), nephrotic (8, 1.1%), autoimmune (6, 0.8%), and other (13, 1.8%). According to IPI, low, low intermediate, high intermediate and high risk had 332 patients (46.9%), 174 (24.6%), 132 (18.6%), and 70 (9.9%), respectively. Across all patients, according to NCCN-IPi, 139 (19.6%) patients had low risk, 335 (47.3%) low intermediate, 198 (28.0%) high intermediate, and 70 (9.9%) high risk.

Conclusion: In our study high CCI along with high NCCN-IPi strongly influenced survival of DLBCL patients, and can better describe patients within risk groups, compared to ECOG performance status. R-CEOP should be considered as a regimen of choice for B-LCL patients with preexisting heart disease. R-CEOP, in which doxorubicin is substituted with etoposide, has been suggested as a potential solution of this problem, but reports on the efficacy of this regimen vary substantially, especially in patients with non-GC DLBCL. We have been using this regimen regularly for front-line treatment of patients with B-LCL and preexisting heart disease and present here our experience.

Summary/Conclusions: Long-term outcomes of newly diagnosed B-LCL patients treated with R-CEOP seem as good as those achieved with R-CHOP irrespective of cell of origin. Observed differences in treatment-related mortality were most probably caused by differences in age, comorbidities and performance status. R-CEOP should be considered as a regimen of choice for B-LCL patients with cardiac contraindications for anthracycline treatment.
E972

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: A SINGLE-CENTER CASE SERIES

C. De Miguel1, 2, B. Navarro1, J. Martín2, P. Martín2, G. Anze1, A. Alarcón1, R. Forés1, C. Bellas2, J.R. Cabrera1

1Hematology, 2Pathology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain

Background: Post-transplantation lymphoproliferative disease (PTLD) is a complication of both solid organ transplant (SOT) and hematopoietic cell transplant (HCT) and represent a very heterogeneous group. Aims: The objective of this study is to evaluate the epidemiology, clinical features, characterization and therapeutic management of this disease. Methods: We evaluated a total of 52 patients diagnosed between May 1995 and February 2017. We analyzed the following data: type of transplantation, immunosuppression time from transplantation to lymphoma diagnosis, clinical stage, response to treatment and survival. We classified them morphologically according to the WHO criteria (2016 revision), using immunohistochemical and molecular techniques and their relationship with the Epstein-Barr virus (EBV) by studying the expression of EBERs. We correlated clinical data with morphological, immunohistochemical and molecular results. Results: Among the 52 patients, 31 were men (59.6%) and 21 women. PTLD after SOT were 45 (86.5%), of which 16 were after liver transplant (35.6%), 14 cardiac (31.1%), 9 pulmonary (20%), 4 renal (8.9%) and 2 double (cardiac-pulmonary and cardiac-renal) (4.4%). There were 7 PTLD after HCT, 2 identical HLA family donor, 2 unrelated donor, 2 dual umbilical cord blood and 1 autologous. Of the 52 PTLD, 48 were B lymphomas (92.3%), of which 26 were diffuse large B-cell lymphomas (DLBCL) (54.2%), 7 polymorphic (14.6%), 7 low-grade anaplastic, 1 T/NK lymphoma, and 1 gamma/delta T lymphocytosis. 35/52 PTLD were EBV+ (67.3%). The median time of immunosuppression was 123 months in renal transplant, 93 months in liver, 85.5 months in cardiac, 51 months in lung and 3 months in HCT. Historologically, it was 96 months in T lymphomas and 80 months in B lymphomas, being 51 months in EBV+ and 124 months in EBV-. Fifty percent of Burkitt lymphomas were diagnosed after lung transplant, while 85% of low-grade lymphomas were diagnosed after liver transplant. Clinical stage was III/IV in 73% of the patients (38). Among the 52, 45 received treatment (86.5%), 37 with immunochemotherapy (82.2%) and 8 with Rituximab (17.8%). Three patients responded to reduction of immunosuppression (5.8%) and 3 did not receive any treatment for early death (5.8%). At the time of writing, 19 patients remain alive (36.5%) and 33 have died. The median survival of these patients was 19.5 months (0-198).

Summary/Conclusions: PTLD constitute a very heterogeneous group. Its appearance is much earlier in the HCT than in the SOT and, within this latter group, it is earlier after lung transplant and later after renal transplant. The most common type in our series is DLBCL. The majority are related to EBV, so post-transplant monitoring is essential, and its diagnosis is earlier than in EBV-. Most low-grade lymphomas appear post-liver transplant, either in relation to viral infections or autoimmune diseases. Survival is significantly lower than in other primary LPS. -AR-SA-We analyzed the following data: type of transplantation, immunosuppression used in both induction and maintenance, immunosuppression time from transplantation to lymphoma diagnosis, clinical stage, response to treatment and survival. We classified them morphologically according to the WHO criteria (2016 revision), using immunohistochemical and molecular techniques and their relationship with the Epstein-Barr virus (EBV) by studying the expression of EBERs. We correlated clinical data with morphological, immunohistochemical and molecular results.

E973

SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A UNITED STATES (US) ELECTRONIC MEDICAL RECORD (EMR)-BASED COHORT

A. Galaznik1, J. Bell1, L. Hamilton2, A. Ogbonnaya2, A. Raju3, K. Hennenfen1, M. Eaddy1, Y. Shou1

1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, UK;2cEnda LLC, Palm Harbor, United States

Background: In the rituximab era, the recommended first-line therapy (1LT) in DLBCL patients who can tolerate combination therapy is rituximab combined with chemotherapy. For refractory/relapsed disease, high-dose chemotherapy with stem cell transplant, combination chemotherapy, or single-agent rituximab are considered. While the efficacy of rituximab has been shown in clinical trials, few studies have evaluated survival outcomes in patients seen in routine clinical care. Aims: We evaluated survival outcomes in a US population of newly diagnosed DLBCL patients seen in routine clinical care. Methods: In this retrospective study, adult patients ≥18 years old with newly diagnosed DLBCL were identified from the Humedica, a large US electronic medical record database, between 01/01/08 and 07/31/15. DLBCL diagnosis was determined by the presence of ≥1 inpatient record or ≥2 outpatient records with DLBCL diagnosis codes; the first DLBCL record served as the index date. Following the index date, initiation of 1LT for DLBCL was required. For the assessment of the survival outcomes, patients were evaluated from the date of treatment initiation until death, loss to follow-up, or end of study (09/30/15). Median progression-free survival (PFS) (defined as initiation of second-line therapy, evidence of supportive care >30 days after the end of a line of therapy, or death), median overall survival (OS), and PFS and OS rates at 2 years following initiation of 1LT were evaluated using unadjusted Kaplan-Meier analyses. Results: 1,436 newly diagnosed DLBCL patients who initiated 1LT met the patient selection criteria. 54.0% were male, and the mean age was 66.4 years (SD: 13.7). At baseline, 27.4% of patients had a Charlson Comorbidity Index of ≥2, and the most common comorbidities were diabetes (20.3%), chronic pulmonary disease (15.5%), and moderate to severe renal disease (9.5%). In 1LT, 92.1% of patients received combination therapy, with R-CHOP (63.5%) being the most common combination therapy. 7.9% of patients received monotherapy upfront, with rituximab (77.2%) being the most commonly used single agent. At 2 years following initiation of 1LT, the Kaplan-Meier OS and PFS were 79.2% and 67.3%, respectively. Median OS was not reached, and median PFS was 53.9 months (95% confidence interval: 45.2; 61.5). OS and PFS were also compared among patients receiving monotherapy vs combination therapy in unadjusted analysis. At 2 years, OS was 80.2% for patients receiving combination therapy vs 67.4% (P=0.0093) for patients receiving monotherapy. Also at 2 years, PFS was 68.3% for patients receiving combination therapy vs 55.1% (P=0.0051) for patients receiving monotherapy.
E974
AN EXPERIENCE WITH LONG ACTING FACTOR VII PROPHYLAXIS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH HAEMOPHILIA A
S. Verma1, A. Tripathi1,*, G. Suri1, N. Kumar1, R. Kushwaha1, A. Kumar1, P. Kumar1
1K G. Medical University Lucknow, Lucknow, India
Background: Hemophilia is an X linked inherited bleeding disorder. Recurrent Joint bleeds and muscle bleeds are the common manifestations leading to long term comorbidities in hemophilia. High dose factor prophylaxis has been proven to be very effective in preventing joint problems in western world. We look for a cost effective and feasible way for Indian patients in terms of reduced dose and frequency of factor infusion. Data on prophylaxis with low dose long acting factor infusion on twice weekly dosing schedule is limited.
Aims: To study the efficacy and safety of long acting factor VII (Eloctate) for tertiary prophylaxis in pediatric and young adult patients with moderate and severe haemophilia A.
Methods: Thirty eight patients with moderate and severe haemophilia A without inhibitors and age range from 1 to 25 years were included in this study. Patients were initially observed for 4 months during which they received therapeutic doses of long acting factor VII, ELOCTATE ( Factor VII with Fc Fusion Protein) on episodic basis after clinical bleed. In next 4 months they received prophylactic ELOCTATE, given intravenously at doses of 20 unit/kg body weight on twice weekly schedule. Annual bleeding rates, school absenteeism, emergency visits, aspects of quality of life and joint scores were compared during observation and prophylaxis period.
Results: Total number of bleeds during observation and prophylaxis period was 607 and 90 respectively. Annual bleeding rate was 47.9% during observation period and 7.1% during prophylaxis. There was 85.1% reduction in bleeding rates on prophylaxis. School/college absenteeism was 3.1 days/month and 0.8 days/month during observation and prophylaxis respectively. Emergency visits were significantly more during observation. None of the patients developed inhibitors and two patients had superficial thrombophlebitis during prophylaxis. Quality of life assessment using KIDSCREEN QOL questionnaire showed moderate to marked improvement in quality of life domains during prophylaxis.
Summary/Conclusions: Low dose, twice a week, long acting factor VIII prophylaxis can be a reasonable option for patients with haemophilia A in developing countries. It significantly reduces joint bleeds, school absenteeism, Joint scores significantly without risk of inhibitor formation and also improves all domains of quality of life.

E975
NOVEL MUTATIONS IN THAI CHILDREN WITH CONGENITAL FACTOR VII DEFICIENCY
D. Sosoithikul1,*, T. Pusongchai1, R. Itiwut1, P. Komvilaissak2, C. Traivaree3, K. Supatsaranin4
1Department of Pediatrics, Chulalongkorn University, Bangkok, 2Department of Pediatrics, Khon Kaen University, Khon Kaen, 3Department of Pediatrics, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
Background: Congenital factor VII (FVII) deficiency is a rare autosomal recessive coagulation disorder resulted from mutations in the FVII gene (F7). The disease severity is not correlated with FVII levels but might be determined by molecular defects in F7.
Aims: To delineate the phenotypic and genotypic characteristics of patients with congenital FVII deficiency.
Methods: We described demographic data, clinical manifestations, and outcome of patients with congenital FVII deficiency. F7 mutation analysis was performed by PCR-direct sequencing.
Results: Of the ten patients diagnosed with FVII deficiency, five (50%) were males. The median age (range) at diagnosis was 19 days old (1-730). Consanguinity was found in 50% of the patients. Of the nine patients (90%) classified as severe, six patients presented with intracerebral hemorrhage within the first month of life, two presented with gastrointestinal bleeding and one presented with hemorrhatosis. There were eight different alterations identified. Four have been previously reported (c.1091G>A (p.R364Q), c.1238G>A (p.R413Q), c.1256C>T (p.T419M), and c.681G>T (IVS6+1T)). Four were novel (c.1192G>T (p.R391L), c.1313G>T (p.G420V), c.291+2T>C (IVS3+2T>C), and IVS6-2A>G) and associated with major bleeding especially during infancy.
Summary/Conclusions: This study reported Thai children with congenital FVII deficiency presented with life-threatening bleeding especially in the first year of life. Pathogenic including newly identified variants in the F7 gene were detected in all cases. Genetic counseling can be appropriately provided to reduce the risk of disease recurrence in the families at risk.

E976
RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF A-HYPO-FIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS
G. Santoro1,*, F. Massaro1, E. Bosetti1, A. Ferrara1, F. Lo Bianco1, S. Pastas1, G. Castaman2, F. Peyvandi2, R. Foà1, M.G. Mazzucconi2
1Cellular Biotechnology and Hematology, Hematology Sapienza University, Rome, 2Oncohaematology Department, Haemostasis and Thrombosis Servicpe- Pugliese-Ciaccio Hospital, Catanzaro, 3Center for Hemorhagic and Thrombotic Disease, University Hospital of Udine, Udine, 4Center for Bleeding Dis- orders, Careggi University Hospital, Florence, Florence, 5Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Background: Afibrinogenemia (AF) and hypo-fibrinogenemia (HF) patients (pts) experience hemorrhages or thromboses, and the clinical management can be difficult.
Aims: To obtain information on AF/HF clinical phenotype and management.
Methods: This is a retrospective, multicenter national study. Data are collected from clinical records.
Results: 2 AF and 12 HF pts have been enrolled (6M, 8F). Median follow-up: 39 months (1-553). Median fibrinogen activity/antigen level: 78mg/dL (0-150)/73mg/dL (0-140). Five pts experienced epistaxis, hematomas, ecchima- moses, menometrorrhagia, intra-abdominal bleeding, gum hemorrhatro- sis. Fresh frozen plasma, fibrinogen concentrate (FC), cryoprecipitate, whole blood, tranexamic acid were administered in the majority of these events. One ischemic stroke, 1 lower limb arterial and 1 cerebral sinus thrombosis, 1con- comitant aortic and inferior vena cava thrombosis occurred: 3 events during FC therapy, 1 during prophylaxis. Heparin, low molecular weight heparin (LMWH), anti-platelet agents, fibrinolytic agents, warfarin were then adminis- tered. One gastrectomy, 1 lower limb amputation, 5 gynecological, 1 otorhino- laryngological and 1 plastic surgery were performed in 2AF and 3 HF pts: in AF pericardial effusion was observed after 2 surgeries performed without prophylaxis. Eight pregnan- cies were initiated in 3 HF women. Two spontaneous deliveries (SD) and 2 cesarian sections (CS) were performed; 4 abortions occurred. FC prophylaxis and LMWH were administered during pregnancy in 5 and 4 cases, respectively. One venous thrombosis, 2 hematomas, 1 DIC and 4 complicated pregnancies were recorded. FC was administered at delivery and LMWH during puerperium, for the 2 CS. No complications at delivery occurred.
Summary/Conclusions: AF and severe HF pts experience severe hemorrhagic/thrombotic events. The intervening clinical situations are difficult to man- age. Further large scale data collections are necessary in order to provide useful information to better characterize and manage patients suffering from these rare diseases.
Six (38%) patients have 2 mutant alleles and three mutations were recurrently identified. The most frequent mutation detected in this study was Cys389Gly detected in 37% (11/30) patients, validating the data of our previous patient cohort.

Summary/Conclusions: Correlation of genetic data with coagulation laboratory and clinical findings suggested the presence of modifiers, which warrants further investigation in a larger cohort of patients for better clinical prediction and management in this rare bleeding disorder.

E978

AUDIT ON MANAGEMENT OF HIGH INTERNATIONAL NORMALIZED RATIO (INR) IN WARFARINISED INPATIENTS

H. Hendra1, V. Gorur1,*, W. Nagi1

1Haematology, Broomfield Hospital, Chelmsford, United Kingdom

Background: Warfarin is the commonest used oral anticoagulant with an effective anticoagulant. The British Committee for Standards in Haematology guidelines recommend administration of 25-50µg of four factor Prothrombin Complex Concentrate (PCC) and intravenous (IV) Vitamin K 5mg for patients with major bleeding, 1-3mg of Vitamin K intravenously for those with minor bleeding and 1-5mg of Vitamin K orally for patients with INR >8 and who have no signs of bleeding.

Aims: The aim of this audit was to compare our hospital’s performance against the above guidelines.

Methods: A total of 76 patients admitted between 01/08/2015-31/01/2016 were analysed retrospectively.

Results: There were 103 incidents with INR level 5-8 and 24 with INR >8 in these 76 inpatients. Bleeding was documented in 18/127 cases, which included 6 incidents of major and 12 incidents of minor bleeding. In major bleeding, warfarin was withheld and Vitamin K administered. However, 4/6 (66.7%) of these patients got a dose different to 5mg advocated. Also, PCC was prescribed in only 50% of these patients. While 9/12 (75%) patients with minor bleeding received Vitamin K, only 3 of these 9 patients received the recommended dose of 1-3mg IV. Vitamin K was unnecessarily given to 9/183 (10.8%) non-bleeders with an INR between 5-8. Additionally, the recommended dose and route of administration of Vitamin K 1-5mg PO was followed only in 7/16 (44%) of non-bleeders with INR >8.

Summary/Conclusions: Our audit highlighted that there is less than 100% compliance in the recommended dose and route of vitamin K administration. A flowchart containing the guidelines will be designed to improve the management of high INR. To increase the awareness of this issue, teaching sessions for junior doctors and nursing staff are planned. A re-audit will be conducted once these steps are in place.

E979

NOVEL AND RECURRENT F7 MUTATIONS IN KOREAN PATIENTS WITH COAGULATION FACTOR VII DEFICIENCY

H. Kim1,*, K.-Y. Yoo2, K.-O. Lee3, S.-H. Kim1, H.-J. Kim1

1Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2Korea Hemophilia Foundation, 3Samsung biomedical Research Institute, Seoul, Korea, Republic Of

Background: Coagulation factor VII deficiency is one of rare hereditary bleeding disorders with relatively limited clinical and genetic data. This study aimed to characterize F7 gene mutational patterns of Korean patients with coagulation Factor VII deficiency including their clinical and laboratory variability.

Methods: F7 gene mutations of total 16 unrelated Korean patients with Factor VII deficiency were identified by direct sequencing analyses of all exons and flanking intronic sequences. Variants were assigned according to the recently released criteria of 2015 ACMG standards and guidelines.

Results: A total of 14 mutations (pathogenic or likely pathogenic) were detected including four novel mutations (Glu66Lys, c.681+3A>T, Glu66Alafs, Ile290del).
Bone marrow failure syndromes incl. PNH - Clinical

E980

Abstract withdrawn.

E981

UTILITY OF CD157 IN A FLAER BASED SINGLE TUBE FIVE COLOR COMBINATION FOR SCREENING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE

K. Rahman1,∗, R. Gupta1, S. Harankhedkar1, T. Gupta1, M. Sarkar1, S. Nityanand1
1Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Background: Fluorescent Aerolysis (FLAER) based flow cytometric analysis of polymorphs and monocytes is the gold standard for the screening of paroxysmal nocturnal hemoglobinuria (PNH) clone. In recent years CD157 has been identified as a PNH marker which targets both polymorphs and monocytes. It can be used in a single tube five color combination to screen polymorphs and monocytes simultaneously.

Aims: The objective of this study was to analyse the utility and advantage of CD157 in the PNH screening along with its ability to replace CD24 and CD14.

Methods: Our routine protocol for PNH screening included single tube six color antibody cocktail in following combination: FLAER-AF488, CD24-PE, CD15-PerCP, CD14-PECy7, CD64-APC, CD45-APCH7. We assessed the utility of single tube 5 color combination of FLAER-AF488, CD24-PE, CD15-PerCP, CD14-PECy5, CD64-APC, CD45-APCH7 for PNH screening and compared the results with the routinely used 6 color panel. Laboratory cutoff for CD157 was defined by running 10 samples from healthy individuals. Sensitivity analysis was assessed in spiking experiments by diluting a PNH positive sample with large clone size in a serial 10 fold dilution. Inter assay and intra assay precision analysis was done by running samples in triplicates across different clone size range and calculating the coefficient of variance (CV). Correlation of PNH clone size obtained from CD24/CD14 and CD157 was assessed by analysing a total of 30 samples across a wide range of PNH clone size (0.06-97.3%).

Results: CD157 was sensitive at the level of 10^-4 and better. Frequency of cells with PNH phenotype in normal samples were found to be <0.002%. The CVs of intra-/interassay precision analysis ranged from 0.92/6.2% to 3.2/4.6% for granulocytes and 1.9/2.5 to 5.3/8.9% for monocytes. The PNH clone size as obtained by CD157 based analysis was highly comparable to those obtained by CD24/CD14 based assay (R^2=0.993). CD157 was found much better than CD24/CD14 in identifying the type II PNH clones. There was no false positive or false negative result. The cost of analysis was found to be approximately 15% lesser than the routinely used 6 color assay.

E982

IMMUNOPHENOtypIC DYSPLastic FEATURES IN PatIENTS WITH aPLASTIC ANEMIA

Y. Davydova1,∗, E. Parovichnikova1, I. Galtseva1, E. Mikhailyova1, N. Kapranov1, A. Kohn1, L. Kuzmenko1, V. Troitskaya1, Z. Fidarova1, T. Moseeva1, V. Savchenko1
1Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Multicolor flow cytometry (MFC) of bone marrow (BM) is a promising additional approach to the diagnosis of myelodysplastic syndromes (MDS). Aplastic anemia (AA) as MDS characterizes by cytophenias and dysplastic features in BM by morphology are absent. It is well known that up to 15% of AA transformed in MDS over time. It is possible to suggest that in some cases of AA immunophenotypic abnormalities can also be identified.

Aims: To study and compare the presence of dysplastic features by MFC in AA and MDS without excess of blasts.

Methods: The study included 14 patients with AA (8m, 6f, median age 33), 28 patients with MDS de novo without excess of blasts by morphology (13m, 15f, median age 59). MDS group included 3 patients with 5q-syndrome, 4 - RCUD, 3 - RARS, 18 - RCMD. 20 patients with cytopenias constituted the control group (4m, 16f, median age 42) due to B-12 deficiency anemia, iron-deficiency anemia, Fanconi anemia, hemolytic anemia, β-thalassemia, ITP, hepatitis C, multiple myeloma, Burkitt’s lymphoma. BM of 33 healthy donors was evaluated as a reference values. MFC was performed according to International Leukemia and Lymphoma Network 6-color cytometer BD FACSCanto II. We enumerated the proportion of CD34+ myeloids from CD45+ cells (normally ~2%), the proportion of CD19+ (B-cell progenitors) from CD34+ cells (normally ~5%), the expression of CD34, CD45, CD117, CD7, CD56 on CD34+ myeloblasts. Among granulocytes we analyzed: their proportion, granularity, CD14, CD64, CD10, CD65 expression and patterns CD16vsCD13, CD16vsCD11b, CD13vsCD11b. Among of monocytes we measured: their proportion, CD65, CD56 expression and analyze patterns CD14vsCD13, CD11bvsCD19, CD11bvsHLA-DR. The final MFC conclusion was done by scale Ogata/Wells (van de Loosdrecht, 2013): A - does not correspond to MDS; B - reveals some features which commonly appears in MDS; C - results are consistent with MDS.

Results: Among MDS patients without excess of blasts assessment “B” and “C” scores were obtained in 78.6% (sensitivity). Increased proportion of CD34+ myeloblasts was in 35.7% of cases, increased CD56 and CD7 in 42.9%. The most common abnormalities were: increased CD65 (53.8%), abnormal patterns (39.3%), low granularity (35.7%) in granulocytes; increased proportion (21.4%) and abnormal patterns (28.6%) in monocytes. 64.3% (n=9) patients with AA (n=14) were assessed as “A”, 21.4% (n=4) - “B” and 14.3% (n=2) - “C”. Expression of CD117 in the PNH screening along with its ability to replace CD24 and CD14.

Summary/Conclusions: Flow cytometry MDS study with Ogata/Wells scale has a high sensitivity and specificity. Immunophenotypic abnormalities characterizing dysplastic features can also be found in AA patients up to 35% of cases. Increased expression of CD65 on CD34+ myeloblasts, granulocytes and monocytes is commonly found in AA patients. Perhaps the appearance of MFC dysplastic features foreshadows the MDS-transformation of AA, but requires further prospective studies.

E983

SURGICAL MANAGEMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) - DATA FROM THE SPANISH PNH REGISTRY

S. De La Iglesia1,∗, C. Notario McDonell 2, A. Gaya Valls 3, M.T. Cedena
1Surgical Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry.

Aims: Here we report data on the clinical management and treatment results of patients with PNH undergoing surgery.

Methods: We collected data on 14 surgical interventions of 11 patients (8 males; age, 25-76 years). All patients had a high prevalence of PNH clone cells (55-99% in PMN) and were receiving eculizumab (ECU). Types of surgery were: 6 laparoscopic cholecystectomies, a transjugular intrahepatic portosystemic shunt, a distal splenorenal shunt, a laparoscopic Achilles allograft ligamentoplasty, a gastrectomy, an emergency appendectomy, and 3 urologic interventions.

Ten patients received ECU 900 mg, while one patient (E, surgery 6) received 1200 mg since he had developed hemolysis at a previous surgical intervention (surgery 5). In two cases (patients G, surgery 8; patient H surgery 11), an additional dose of ECU was administered before surgery. Patient H (surgery 11) had developed hemolysis at previous surgical interventions (surgeries 9 and 10). In most cases, either the date of the ECU dose was taken into account when scheduling surgery or the ECU dose was moved forward to coincide with the date of surgery. The time between the last ECU dose and surgery was normally one day (range, 1-8).

Results: In nine cases, transfusions were required due to hemorrhagic complications. Patient I (surgery 12) had a thrombotic event leading to acute myocardial infarction one week after surgery. Increased hemolysis was observed (increased LDH and/or presence of hemoglobinuria) in five cases (patients E, H, I and K; surgeries 5, 9, 10, 12 and 14) during the week following surgery. Two of these patients (patients E and H) later underwent additional surgery (surgery 6 and surgeries 10 and 11, respectively). The pre-surgical ECU dose was increased in surgery 6 (patient E) and an extra dose was administrated in surgery 11 (patient H) and no hemolysis was observed. (See Table 1).

Summary/Conclusions: Our findings lead us to recommend to perform the intervention within 24 hours of the administration of ECU in programmed surgery for which it is necessary to program the dose. While in urgent surgical interventions put a new dose on the day of the intervention independently of the previous dose. Also the normal ECU dose could be increased or an extra dose be administrated in order to minimize the risk of hemolysis in high-risk patients or in those with a previous history of surgery-related hemolysis.

E984

Efficacy of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with or without Aplastic Anemia; Prospective Study of Korean PNH Cohort


1Internal Medicine, Korea University Guro Hospital, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, 3Yonsei University College of Medicine, Seoul, 4Chungnam National University, Daejeon, 5Asan Medical Center, Seoul, 6Dong-A University Hospital, Busan, 7Chonnam National University Hospital, Hwasun, 8SeoulChunyung Hospital University Hospital, Seoul, 9Pusan National University Hospital, Busan, 10University of Ulsan College of Medicine, Incheon, 11Youngnam University Hospital, Daejeon, 12National Cancer Center, Goyang, 13Yonsei University Wonju College of Medicine, Wonju, 14St. Vincent Hospital, The Catholic University of Korea, Suwon, 15Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disease characterized by the intravascular lysis of red blood cells. PNH patients often have underlying bone marrow failure (BMF), with aplastic anemia (AA) as the most frequently associated type. Eculizumab, a humanized monoclonal antibody that binds specifically to human complement protein C5, has been used in Korea since 2012.

Aims: The purpose of this study was to determine whether eculizumab-treated patients show clinical benefit and reduced risk of complications regardless of concomitant AA in a Korean population.

Methods: Forty-six PNH patients ≥18 years of age diagnosed by flow cytometry and treated with eculizumab for more than 6 months were analyzed in the prospective Korean PNH registry. Patients were categorized into two groups: PNH patients with concurrent AA (PNH-AA) and without (classic PNH). Patients with severe AA/PNH were excluded. Biochemical indicators of intravascular hemolysis, hematological laboratory values, transfusion requirement, and PNH-associated complications assessed by the treating physician were reported every 6 months after enrollment.

Results: The median age of the study population was 49 years (range, 18-73 years) at eculizumab initiation and the median duration of eculizumab treatment was 34 months (range, 6-44 months). Median LDH fold x upper limit of normal was 7.29 (range 2.4-23.7) and GPI-deficient granulocytes was 92.8% (range, 15.7-100%) at the time of eculizumab treatment. PNH-related signs and symptoms were thromboembolism (TE, n=19), renal failure (n=20), pulmonary hypertension (n=5), and severe/recurrent abdominal pain requiring opioids (n=17).

Of 46 total patients, 12 (26%) were classified as having PNH/AA and 34 with classic PNH. There were no substantial differences in laboratory findings, transfusion requirement, or clinical signs/symptoms between the two groups. Treatment with eculizumab induced a rapid inhibition of hemolysis. At the time of 6 month follow-up, LDH level decreased to near normal levels in all patients and this effect was maintained until 36 months follow-up regardless of concomitant AA. Mean hemoglobin level significantly increased from the first 6 months of eculizumab treatment, and the effect (hemoglobin above 10 g/dL) was sustained throughout 36 months in both groups. Transfusion-independence was achieved by 54.3% within the first 6 months of treatment and 86.4% by the last 36 months (83.3% in PNH/AA vs 87.5% in classic PNH). The mean number of RBC units transfused was significantly reduced from 8.5 units during the previous 6 months to 1.6 units for the first 6 months in total PNH patients (Fig). There were no significant differences in clinical outcomes (ie, LDH and transfusion unit per every 6 months) with eculizumab between the two groups. All TE (n=19) patients in whom 6 received concomitant anticoagulation therapy were resolved on the eculizumab; one classic PNH patient had recurrence of TE at the same site after discontinuation of anticoagulation therapy while on eculizumab. Among 9 patients who had baseline eGFR less than 60 ml/min/1.73m², 5 patients (56%) showed improvement of eGFR during the eculizumab treatment and 4 patients stabilized eGFR.
Summary/Conclusions: Clinical outcomes with eculizumab were significantly improved compared with the baseline in patients with both PNH/AA and classic PNH. This study demonstrated that eculizumab has a beneficial role in the management of patients with PNH/AA, similar to that of classic PNH, by inhibiting hemolysis and reducing transfusion requirements, thus resulting in the improvement of clinical signs and symptoms.

E985
DIAGNOSIS AND FOLLOW-UP OF THE CLONES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA BY FLOW CYTOMETRY
S. Oukid1,*, S. Taoussi1, N. Rekab1, M.T. Abad1
1Hematology, EHS ELCC CAC, Bida, Algeria

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare chronic disease associated with a clonal expansion of one or several hematopoietic stem cells carrying acquired somatic mutations of PIG-A gene resulting in GPI-AP deficient blood cells and great susceptibility to complement mediated cell lysis. Diagnosis of PNH is of importance and flow cytometry (FC) is a required tool for this. We report 33 cases of PNH diagnosed and monitored by FC.

Aims: To show the interest of flow cytometry for the diagnosis and follow-up of PNH clones in some risky haemopathies.

Methods: A PNH clone has been researched in 234 patients since August 2000. A clone has been investigated for bone marrow aspira-

...
tional methods were 3.79% (range, 0.2-18.2) and 3.60% (range, 0.1-18.6), respectively. The mean PNH clone sizes among the monocytoids by dual-reactant and conventional methods were 7.30% (range 0.2-29.4) and 7.32% (range 0.1-28.8), respectively. There was no significant difference in the granulocyte and monocYTE PNH clone sizes determined by both the methodologies (p>0.000). There were significant correlations between the granulocyte PNH clone sizes (Pearson’s r=0.993, p<0.000) and the monocYTE PNH clone sizes (Pearson’s r=0.991, p<0.000) detected by both the analysis strategies.

Summary/Conclusions: This pilot study demonstrates the practical feasibility of a simple, cost-effective and widely applicable dual-reactant, single tube PNH-screening assay at a sensitivity of 0.2%. The study needs to recruit patients of various hematological disorders besides healthy controls, and although seems effective for analyzing classic and subclinical PNH, the strategy has to be further standardized to achieve a sensitivity of 0.01%.

**E988**

**TREATMENT OF REFRACTORY APLASTIC ANEMIA WITH ELTROMBOPAG: EXPERIENCE OF A CENTER**

M. Gomes1,*, M.J. Teles2, F. Ferreira1, J.E. Guimarães1
1Clinical Hematology, 2Clinical Pathology, São João Hospital Centre, Porto, Portugal

**Background:** Eltrombopag, a thrombopoietin receptor agonist, was approved in 2008 for the treatment of immune thrombocytopenic purpura. More recently, benefits demonstrated in the proliferation and maintenance of hematopoietic stem and progenitor cells (HSTC) led to its use and approval in the treatment of severe aplastic anemia (AA) refractory to immunosuppressive therapy.

**Aims:** In this report, we evaluated response to eltombrpagent in patients with refractory aplastic anemia (AA) and associated side effects.

**Methods:** Retrospective analysis of six patients with a diagnosis of aplastic anemia and thrombocytopenia (platelet count ≤30,000/μL). Exclusion criteria include patients with severe anaemia and thrombocytopenia who are HLA-identical siblings or immunocompetent donors treated with eltrombopag. Patients characteristics, response, clinical evolution and adverse effects were evaluated.

**Results:** Four patients were female and median age at diagnosis was 66 years (36-76). Previous treatments included horse antithymocyte globulin (1), cyclosporine (4), intravenous immunoglobulin (1), corticosteroids (4) and danazol (1). Treatment with eltombrpagent was associated to cyclosporine in four patients; two cases had chronic renal failure and consequent contraindication to cyclosporine. The median duration of treatment with eltombrpagent at the time of this analysis was 7 months (3-12). At 3 months, all patients had platelet counts >30,000/μL (median increase, 16,500/μL). Five patients improved hemoglobin levels (median increase, 2.2 g/dL); 3 of them were previously dependent on red cell transfusions, and no longer needed transfusions. Four patients increased neutrophil counts (median increase, 1110/μL). All but one patient received a maximum dose of 150 mg per day. Only one patient needed temporary discontinuation due to hepatic abnormalities, that were rapidly resolved. One other patient had mild elevation of liver enzyme levels. No other relevant side effects occurred.

**Summary/Conclusions:** Treatment with eltombrpagent was associated with hematologic response of one or more hematopoietic lineage, independence of blood transfusions and improved quality of life of patients with refractory severe AA. Except for infrequent and reversible hepatic abnormalities, tolerability was excellent. Thus, eltombrpagent might be used in situations where other measures have failed in patients who have no indication for allogeneic stem cell transplant. A caution, however, should be taken on the risk for clonal evolution that seems effective for analyzing classic and subclinical PNH, the strategy has to be further standardized to achieve a sensitivity of 0.01%.

**E989**

**DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB**

A. Guarnieri1,2,*, M.S. De Propris1, M.L. Milani1, S. Intoppa1, S. Faroana1, N. Peragine1, P. Mariaguina1, M.C. Puzolino1, F.R. Maurillo1, J. Del Giudice1, R. Folco1
1Department of Cellular Biotechnologies and Hematology, 2Department of Molecular Medicine, Hematology, Sapienza University, Rome, Italy

**Background:** The B-cell receptor (BCR) pathway in CLL plays a well recognized role in the onset and progression of the disease and the resulting development of mechanism-driven drugs is revolutionizing the therapeutic management. Ibrutinib is a BTK inhibitor that plays an important role in the BCR pathway and induces several alterations in CLL cells.

**Aims:** The modulation of the expression of adhesion molecules on the surface of CLL cells from patients treated with ibrutinib has been evaluated to analyze the effect of treatment on the relationship between the microenvironment, that promotes cell survival proliferation, and the leukemic cells with the consequent cell mobilization and increased drug exposure.

**Methods:** In a cohort of 101 CLL patients treated with ibrutinib (420mg/die) and rituximab (375mg/m2/week) in the GIMEMA LLC1114 trial, we evaluated, before and after 15 days of therapy, the surface expression on leukemic cells of several adhesion molecules. In detail, using 8 color antibody combinations (all from Becton Dickinson, BD, San José, CA) we evaluated the MIF expression (using the FACSCanto II, BD) of CD11a, CD18, CD38, CD40, CD43, CD44, CD49d, CD62L, CD69, CD80, CD81, CD154, CD184, CD185 on CD5/CD19+ leukemic cells.

**Results:** The number of CD5/CD19+ did not increase after 15 days of treatment (52.8±5.88 vs 53.4±5.10±10^6/L; p<0.06) probably because of the concomitant rituximab administration, which ‘masks’ the mobilization effect induced by ibrutinib. We observed a significant down-modulation of CD26L (461±435 vs 171±146; p<0.0001), a molecule (L-selectin) that has been reported as the key factor controlling the binding of CLL cells to the endothelial walls in vivo. CD26 expression resulted also significantly decreased (744±784 vs 438±716; p<0.0041), is expressed on CLL cells in the tissue microenvironment, both in the bone marrow and in lymph nodes. We observed the significant down-modulation of the expression of CD43 (3265±2282 vs 2515±1826; p<0.0063); this antigen is utilized in CLL for the detection of minimal residual disease (MRD) and does therefore not seem a reliable marker in patients treated with ibrutinib. On the contrary, CD81 expression, another antigen utilized for MRD detection, resulted unchanged after 15 days of treatment. CD185 expression was significantly decreased (1502±1327 vs 804±687; p<0.001), while we unexpectedly observed the up-modulation of CD184 (224±2022 vs 318±1877; p<0.003); both antigens participate in the BTK signaling pathway. CD40, that interacts with activated CD4+ T cells, resulted down-modulated (722±467 vs 395±262; p<0.0001). CD38 and CD49d, when expressed in >20% of the leukemic cells, resulted significantly (p<0.028 and p<0.021) down-modulated; both molecules have a role in the crosstalk between the leukemic cells and the microenvironment. No significant changes were detected in the expression of CD11a, CD18, CD44, CD80, CD86 and CD154.

**Summary/Conclusions:** Within an ancillary biologic study of the GIMEMA LLC1114 protocol we observed a significant down-modulation in the expression of several adhesion molecules on the surface of CLL cells of patients treated with ibrutinib. Since these molecules promote the binding of the leukemic cells with the microenvironment, these results help to elucidate the mobilization process of CLL cells from the different compartments observed with ibrutinib and support its progressive efficacy over time in controlling the disease. A follow-up clinical analysis will define a possible correlation between these findings and response to treatment.

**E990**

**Abstract withdrawn.**

**E991**

**CLL CELLS UNDERGO METABOLIC REPROGRAMMING AND UTILIZE FREE FATTY ACIDS AS THEIR PRIMARY ENERGY SOURCE**

U. Rozovsky1,2,*, D. Hams3, P. Li, Z. Lu3, P. Jain1, A. Ferrajoli1, J. Burger2, S. O’Brien2, P. Thompson2, N. Jain1, W. Wierda1, M. Keating1, Z. Estrada1
1Hematology, Davidoff Cancer Center, Belimion Campus, Petah Tikva, Israel, 2Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 3Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Background: The gene expression profile of chronic lymphocytic leukemia (CLL) cells revealed a homogeneous phenotype related to memory B cells accompanied by an aberrant expression of several proteins. For example, lipoprotein lipase (LPL), typically expressed in adipocytes, is readily detected in CLL cells. However, unlike their normal counterparts which are resting cells, CLL cells do proliferate. What energy source CLL cells use and which metabolic pathway they recruit is currently unknown. Because the gene expression profile of CLL cells is skewed toward that of adipocytes, and because they proliferate at similar rates, we hypothesized that like adipocytes CLL cells utilize free fatty acids (FFA).

Aim: To determine whether CLL cells are capable of utilizing FFA for energy production.

Results: To study whether CLL cells are capable of utilizing FFA we cultured them for 20 hours in the presence of FFA and measured the concentration of cultured media-dissolved O₂ (dO₂) prior to and after adding FFA, assuming that if the cells oxidize the acid, dO₂ levels will drop. Indeed, after 48 hours incubation with FFA dO₂ levels were markedly reduced as compared with the dO₂ media levels of CLL cell incubated without FFA. Remarkably, unlike cultured normal peripheral blood (PB) monocytes and B-cells, CLL cells did not change their dO₂ levels. Intriguingly, the levels of dO₂ remained unchanged if CLL cells were incubated in the presence of FFA and ibritinib. Similarly, the dO₂ levels of CLL cells obtained from ibritinib-treated patients remained constant, suggesting that ibritinib disrupts the capacity of CLL cells to utilize FFA. Oil Red O staining of CLL bone marrow smears detected lipid deposits and electron microscopy confirmed the presence of lipid vacuoles in the cytoplasm of peripheral blood CLL cells but not in normal B cells, suggesting that like adipocytes, CLL cells store lipids in intracytoplasmic lipid vacuoles. Similar to adipocytes CLL cells express LPL which mediates the uptake of lipid particles into the cells and catalyzes the hydrolysis of triglycerides to free fatty acids (FFAs). Indeed, we detected LPL in the plasma membrane and in the cytoplasm of CLL cells. Furthermore, using small interfering RNA (siRNA) we knocked-down LPL mRNA levels and found that LPL-siRNA reduced the capacity of CLL cells to utilize FFA, suggesting that the lipid metabolism in CLL is LPL-dependent. Because STAT3 is constitutively active in CLL cells, and because the LPL gene harbors STAT3 binding sites, we sought to determine whether STAT3 activates the LPL gene. Indeed, transfection of luciferase reporter gene constructs driven by LPL promoter fragments into MM1 cells revealed that STAT3 activates the LPL promoter. In addition, ChIP confirmed that STAT3 binds to the LPL promoter. Furthermore, transfection of CLL cells with STAT3-shRNA downregulated LPL transcripts and protein levels, confirming that STAT3 activates the LPL gene.

Summary/Conclusions: Our data suggest that CLL cells undergo metabolic reprogramming and use strategies normally utilized by adipocytes. This process is driven by constitutively activated STAT3 and is inhibited by ibritinib.

E993

FCMR IS A NEGATIVE REGULATOR OF B-CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

S. Gobessi1,2, B. Sasi1, G. Pozzato1, I. Innocenti1, L. Lauria2, D. De Frede1

1Department of Haematology, Istituto Nazionale per la Cura e la Ricerca del Cancro, Milan, Italy. 2Institute of Hematology, Catholic University Hospital “A. Gemelli”, Rome, Italy.

Background: Chronic lymphocytic leukemia (CLL) cells frequently display features of anergic B cells, including reduced B-cell receptor (BCR) signaling capacity and downregulation of membrane IgM (mIgM). These features are particularly evident in freshly isolated peripheral blood (PB) CLL cells belonging to the indolent, M-CLL subset (Lamh et al, Blood. 2003). An alternative explanation for this phenomenon is that these anergic features are induced by soluble IgM molecules, which are absent from standard cell culture media, and could interact in vivo with the leukemic BCRs through recently described intermolecular immunoglobulin interactions or by binding to the Fc receptor (FcR). The latter is highly overexpressed in CLL cells, particularly those belonging to the M-CLL subset (Li FJ et al, Blood. 2011).

Methods: We wanted to clarify (i) if CLL cells depend on exogenous arginine, (ii) which transporter is responsible for arginine transport in human CLL cells and (iii) the reduction of arginine availability via knockdown of this transporter inhibits CLL cell growth and viability.

Methods: Experiments were performed with both, primary human CLL cells, isolated from highly leukemic peripheral blood, and immortalized CLL cell lines. Primary CLL cells were left unstimulated or were stimulated via Toll-like receptor 9. The expression levels of arginine transporters were determined by quantitative RT-PCR and Western Blot. Arginine uptake was measured by 3H-arginine import, cell proliferation by [3H]-thymidine DNA incorporation and cell viability by propidium iodide staining in flow cytometry. The expression of hCAT-1 was downregulated in HG3 CLL cells using lentiviral shRNA technology. HG3_hCAT-1 knockdown cells were injected s.c. in NOD/SCID/gcnull mice and tumor growth was monitored.

Results: We show that primary and immortalized CLL cell proliferation depends on the availability of extracellular arginine. Screening a large panel of individual CLL patient samples and different immortalized CLL cell lines demonstrated that hCAT-1, yLAT1 and yLAT2 are the predominantly expressed arginine transporters. Upon activation the expression level of hCAT-1 further increased significantly. Activity of both, in vitro and in vivo, was measured in HG3 CLL cell lines, was inhibited by the CAT inhibitor N-ethylmaleimide. Lateral downregulation of the hCAT-1 transporter in HG3 CLL cells resulted in a significant reduction of arginine uptake, associated with an inhibition of cell proliferation and viability in vitro. The corresponding in vivo data of tumor growth upon hCAT-1 knockdown in a murine xenograft model will be presented at the conference.

Summary/Conclusions: Our results demonstrate that the hCAT-1 transporter is a potential pharmacological target structure in CLL cells. Development of small molecule- or antibody-based inhibitors of hCAT-1 might lead to a novel therapeutic approach for CLL.
enence or absence of IL-4. Most of the investigated samples in this series showed reduced surface FcγR expression and increased surface IgM expression after IL-4 treatment, but a few cases showed only reduced FcγR expression and no change in IgM expression. Interestingly, these samples also showed greater anti-IgM induced phosphorylation of SYK, PLCγ2, AKT and ERK, suggesting that downregulation of FcγR is the primary mechanism through which IL-4 regulates the BCR signaling capacity of PB CLL cells. FcγR is downregulated by IL-4 and shows reduced expression in LN CLL cells, which could represent a mechanism to allow CLL cells to respond more effectively to stimulation with antigen encountered in the appropriate context.

**Summary/Conclusions:** These data show that FcγR is a negative regulator of BCR signaling in CLL cells. Overexpression of FcγR could be at least in part responsible for the reduced BCR signaling capacity of PB CLL cells. FcγR is downregulated by IL-4 and shows reduced expression in LN CLL cells, which could represent a mechanism to allow CLL cells to respond more effectively to stimulation with antigen encountered in the appropriate context.

**E994**

**TRANSCRIPTION FACTORS AND CHECKPOINT INHIBITORS EXPRESSION WITH AGE: MARKERS OF IMMUNOSENESCENCE?**


1Clinical and Experimental Hematology, 2Molecular Immunology, 3Anatomopathology, INSTITUT JULES BORDET, ULB, Brussels, Belgium

**Background:** Aging is characterized by a progressive decline in immune surveillance that favors tumor development in older patients. One mechanism used by malignant cells to escape immune surveillance is the upregulation of immune checkpoint inhibitors, which have been recognized as a potential therapeutic target. Another process associated with aging is genetic or epigenetic modifications of tumor suppressor genes (TSGs).

**Aim:** We want to explore the correlation and progression into a T cell lymphoproliferative disease, identifying the BACH2 gene as a candidate TSG. We thus examined the expression of specific transcription factors (BACH2 and PRDM1) and checkpoint inhibitors (PD-1 and PD-L1) in the T and B cells of two age groups for their potential role in immunomodulation.

**Methods:** Peripheral blood mononuclear cells were isolated from whole blood using Lymphoprep (Stemcell Technologies) density gradient centrifugation. Lymphocyte subsets (CD19+, CD3+CD4+; CD3+CD8+) were isolated for subsequent molecular analyses using the MACS Technology (Miltenyi), with the purification of each lymphocyte subpopulation between 95%-99%. PD-1 (POCD1), PD-L1 (CD274), IL-4, IFNG, BACH2 and PRDM1 mRNA transcripts were quantified using qRT-PCR. BACH2 and BLIMP1 (PRDM1) protein expression were examined by Western blotting.

**Results:** Blood samples were obtained from 60 healthy volunteers and 41 untreated B-cell lymphocytic leukemia (B-CLL) patients (median: 67yo). Healthy donors (HD) between the ages of 20 to 90 years subdivided into <50 yrs (median: 36yo) and >50 yrs (median: 65yo). BACH2 mRNA expression in the HD groups is significantly down-regulated in CD4+, CD8+ T cells and CD19+B cells from the older HD group (p=0.0012; 0.0046 and 0.0367, respectively). BACH2 expression was further reduced in CD4+, CD8+ T cells and CD19+B cells from CLL patients compared to HD well balanced for age (p=0.001; <0.0001 and 0.0043). PRDM1 mRNA expression was inversely correlated with BACH2 in CD4+, CD8+ T cells and CD19+B cells (r=0.61; 0.71 and 0.85, respectively). Curiously, PRDM1 was – as expected – significantly up-regulated in CD8+ T cells and CD8+ T cells (p=0.0034; p=0.0017) from B-CLL patients but not in their leukemic B Western blotting analysis demonstrated that BACH2 and BLIMP1 (PRDM1) protein expressions in the T and B cell subpopulations were significantly correlated with transcript expression. BACH2 protein expression was negatively correlated with CD4+ producing CD4+ T cells. We also observed that BACH2 down-regulation is correlated with increased IL-4 mRNA expression (r=0.67) but not IFNG in CD4+ T cells. These observations suggest that BACH2 down-regulation in CD4+ T cells could enhance the expression of effector-memory-related genes, particularly Th2 such as IL-4 and PRDM1. PD-1 mRNA expression was up-regulated in CD4+, CD8+ T cells (p=0.0153 and 0.0214) in the older HD group and also up-regulated in the T cells from B-CLL patients (p=0.0014 and 0.0023) when compared to age-matched HD population. High PD-1 mRNA expression was correlated with increased age in HD B cells (p=0.04) with a further increase detected in B (p=0.001). We also observed an inverse relationship between BACH2 and PD-1 in CD4+, CD8+ T cells (r=0.62 and 0.68); and between BACH2 and PD-L1 in CD19+B cells (r=0.66).

**Summary/Conclusions:** These data suggest that down-regulation of BACH2/PRDM1 and up-regulation of PD-1/PD-L1 mRNA expression in major lymphocyte subsets from CLL patients and older healthy controls are significantly correlated with the aging immune cells and could be part of the immunosenescent process.
but not of sIgD, levels and signaling capacity. This is evident in the circulating CLL B-cells which are characterized by variably reduced sIgM levels/signaling. The variability influences outcome and cases with relatively higher sIgM levels/signaling capacity, but not sIgD, have more rapid progression, likely due to a proliferative component.

Aims: The aim of this study was to investigate the effect of ibrutinib in vivo on the dynamics and function of sIgM and of other surface molecules associated with the BCR complex on the circulating CLL cells of patients during the early phases of therapy (first 3 months).

Methods: Peripheral blood mononuclear cells were collected from 12 CLL patients prior to (pre-) and at 1 week, 1 month and 3 months following commencement of single agent ibrutinib therapy. Expression of BCR-complex-associated sIgM, sIgD, CD19 and other surface markers was assessed by flow cytometry. Signaling capacity following sIgM stimulation was measured by immunoblotting. Following biotinylation of cell surface proteins, the N-glycosylation pattern of the μ chain was assessed by immunoblotting as a readout of sIgM expression. sIgM expression was obtained from a patients’ (REC H228/02).

Results: At week 1 of ibrutinib therapy, there was a dramatic increase in the expression of sIgM on the circulating CLL cells (mean fold increase 1.6, P=0.001), while expression of sIgD and CD19 remained constant. At this time point, increased sIgM expression associated with full N-glycan maturation of sIgM heavy-chain, indicative of recovery from antigen engagement at tissue sites. Also, the sIgM levels correlated with increased anti-igM mediated SYK phosphorylation (r=0.64, P=0.03), to indicate functionality upstream of BTK. Sequential assessment at month 1 and 3 revealed that sIgM levels were similar to that observed prior to therapy, with preserved upstream signaling ability. In marked contrast, the other BCR complex associated molecules sIgD, CD19 and CD20 all reduced expression (P<0.001). Reduction of these markers was also accompanied by reduction of cell size and of other surface markers while overexpression of autophagy marker LC3B2 was documented.

Summary/Conclusions: Our data point to two major events dissociating sIgM expression from other BCR-complex associated molecules. In the initial phase, the increased sIgM expression and maturation, with no changes in other BCR-associated molecules, appears consequent to lack of antigen encounter, likely due to inhibition of chemokine-mediated entry to tissue sites. In the later phases the circulating CLL cells will suffer lack of tissue derived pro-survival stimuli. In their absence, CLL cells will reduce expression of several markers and cell size, possibly explained by autophagic mechanisms aiming to protect the circulating CLL cells from death unless ibrutinib therapy is withdrawn.

E998

ROLE OF THE COMBINATION MEK1/2 INHIBITOR BINIMETINIB AND AKT INHIBITOR MK2206 IN CLL

S. Sandhu1,2, S. Mulligan1,3, G. Best2

1Acute Medical Unit, Royal Melbourne Hospital, Parkville, 2Northern Blood Research Centre, Kolling Institute of Medical Research, 3Haematology, Royal North Shore Hospital, St Leonards, Australia

Background: Clinical trials of ibrutinib and idelalisib demonstrate the efficacy of B-cell receptor-targeted therapies for CLL. We sought to investigate the efficacy of targeting both the BCR and the MAPK-ERK1/2 signaling pathways.

Aims: To evaluate the role of targeting the Ras-Raf-MEK1/2/ERK1/2 together with the PI3K-AKT pathways as a potential novel approach in treating chronic lymphocytic leukemia. In particular, assessing the efficacy of MEK1/2 inhibitor, binimetinib (MEK162), in combination with either a PI3K inhibitor, idelalisib or an AKT inhibitor, M2206.

Methods: All experiments conducted on primary CLL cells were co-cultured with CD40L-expressing stroma which mimics the support conferred by the tumour environment. Firstly, the effects of MK2206 and idelalisib at doses varying from 1 to 40µM were tested on primary CLL cells. Secondly, binimetinib and MK2206 were tested as single agents and in combination at 20µM against primary CLL cells. Thirdly, binimetinib at 20µM combined with varying doses of idelalisib on primary CLL cells. The mechanisms underlying the effects of binimetinib in combination with MK2206 in primary CLL cells were investigated by western blotting with changes in the expression of phosphorylated and total forms of AKT, MCL-1, and ERK1/2 assessed. Expression of B-actin was used as a loading control.

Results: MK2206 is effective against CLL cells co-cultured with stromal cells in a dose dependent manner. It was also observed that the primary CLL cells co-cultured with the CD40L-expressing stroma were significantly more sensitive to MK2206 than to idelalisib (Figure 1A). No cytotoxic effects of binimetinib
were observed while the combination with MK2206 was significantly more effective than either alone, suggestive of synergy between the two drugs (Figure 1B). The analysis of binimetinib at 20μM with idelalisib failed to demonstrate any additive effects or suggestion of synergy between the two drugs (Figure 1C). Binimetinib treatment led to an increase in the activity of AKT and a decrease in ERK1/2 phosphorylation. MK2206 completely abrogated the activity of AKT and MCL-1 phosphorylation when combined with binimetinib (Figure 2A). Although we observed a reduction in AKT phosphorylation following idelalisib alone, it had no effect on the levels of AKT activity induced by binimetinib or the levels of phosphorylated MCL-1 protein. This result was irrespective of the dose of idelalisib used (Figure 2B). We explored the possibility that protein kinase C (PKC) may be involved in binimetinib-induced AKT inhibition. Using the pan-PKC inhibitor GF109203X (GFX), we demonstrated that inhibition of PKC significantly reduces binimetinib-induced phosphorylation of AKT with no effect on the activity of ERK1/2-MAPK (Figure 2C). These data suggest a role for PKC in the regulation of AKT activity in CLL cells.

Summary/Conclusions: The combination of binimetinib and MK2206 in vitro has been shown to be an effective strategy to treat primary CLL cells. The western blot data reinforce that the increased activity observed in AKT activity in CLL cells following binimetinib treatment is independent of the idelalisib and totally abrogated by MK2206. This PI3-kinase independent regulation may be regulated by PKC and is likely to play a significant role. Dual inhibition of MAPK-ERK1/2 and AKT signaling may be effective at targeting the proliferative/drug-resistant compartment of CLL that resides in the tumour microenvironment.

**E999**

**TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA**

C. Vitale\(^{1,2}\), V. Grigio\(^{1,2}\), M. Todaro\(^{1,2}\), C. Riganti\(^{1}\), I. C. Salaroglio\(^{1}\), C. Salvetti\(^{1,2}\), M. Rigoni\(^{1,2}\), M. Foglietta\(^{2}\), B. Castella\(^{2}\), M. Boccadoro\(^{1,2}\), C. Vitale\(^{1,2}\),*, V. Griggio\(^{1,2}\), M. Todaro\(^{1,2}\), C. Riganti\(^{1}\), I. C. Salaroglio\(^{1}\), C. Salvetti\(^{1,2}\), M. Rigoni\(^{1,2}\), M. Foglietta\(^{2}\), B. Castella\(^{2}\), M. Boccadoro\(^{1,2}\), C. Vitale\(^{1,2}\),*, V. Griggio\(^{1,2}\), M. Todaro\(^{1,2}\), C. Riganti\(^{3}\), I. C. Salaroglio\(^{3}\),

**Background:** The CXCL12/CXCR4 axis has a fundamental role in the microenvironment-mediated protection of chronic lymphocytic leukemia (CLL) cells from spontaneous and drug-induced cell death. The binding of CXCL12 with CXCR4 activates multiple intracellular pathways, including RhoA- and Ras-dependent signaling. We have previously shown that co-culture with stromal cells (SC) induces in CLL cells the activation of RhoA/RhoA kinase and Ras/ERK1-2 signaling, the upregulation of Akt, and an increased activity of the transcription factor HIF-1α (Rigoni et al., Oncotarget 2015).

**Aims:** The purpose of this study was to identify new potential pharmacological targets involved in the CXCL12/CXCR4 axis in order to impair the protection exerted by SC towards spontaneous and fludarabine-induced apoptosis in CLL cells.

**Methods:** Peripheral blood was collected from 62 patients with CLL. In selected experiments, the M2-10B4 murine SC line and the HS-5 human SC line were used. Patient-derived bone marrow SC were generated from 12 patients with CLL. Where indicated, cell cultures were treated with recombinant CXCL12 (100 ng/ml), CXCR4 inhibitor AMD3100 (5 μg/ml), fludarabine (F-ara-A, 10 μM), simvastatin (1 μM), ERK1-2 kinase inhibitor PD98059 (10 μM), HIF-1α inhibitor BAY87-2243 (1 μM), and PI3K inhibitor idelalisib (10 μM). RhoA and Ras activities were evaluated by an ELISA-based assay and by pull-down assay respectively. ERK1-2, HIF-1α, and AKT activities were measured with specific immunoblotting kits. CXCL12 was quantified by ELISA. Cell viability was determined by Annexin-V/propidium iodide immunostaining and flow cytometry analysis.

**Results:** The exposure of CLL cells to recombinant CXCL12 led to the activation of RhoA- and Ras-dependent signaling, and to the downstream upregulation of HIF-1α. The CXCR4 antagonist AMD3100 completely abrogated the positive regulation exerted by both CXCL12 and SC, thus unveiling the key role of the CXCL12/CXCR4 axis in the SC-induced modulation of these signaling pathways. The inhibition of Ras and RhoA activity by simvastatin, and the inhibition of ERK1-2 and HIF-1α by PD98059 and BAY87-2243 effectively blocked the SC-induced expression and activity of HIF-1α, significantly impairing the SC-mediated protection of CLL cells, both in absence and presence of fludarabine. Similar effects were observed by targeting the PI3K/Akt pathway with idelalisib. We then investigated whether targeting RhoA- and Ras-dependent signaling could modulate HIF-1α also at the SC level. Simvastatin and BAY87-2243 effectively inhibited HIF-1α expression both in SC lines and in patient-derived SC. Moreover, simvastatin significantly reduced the secretion of CXCL12, which is a known transcriptional target of HIF-1α.

**Summary:** Our data demonstrate that the targeting of HIF-1α and its regulatory pathways, both at the tumor cell and at the SC level is an appealing strategy to overcome the microenvironment-mediated protection toward spontaneous and fludarabine-induced apoptosis in CLL cells.

**E1000**

**THE ROLE OF GENETIC-BASED PROGNOSTIC FACTORS IN PREDICTING MINIMAL RESIDUAL DISEASE NEGATIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSHAMIDE AND OFATUMUMAB**

S. Raponi\(^{1,2}\), I. Del Giudice\(^{1}\), C. Iliadis\(^{1}\), C. Luciana\(^{1}\), I. Delta Starza\(^{1}\), M.S. De Propriis\(^{1}\), M. Nanni\(^{1}\), M. Cavalli\(^{1}\), L.A. De Novi\(^{1}\), P. Mariglia\(^{1}\), F. Mancini\(^{1}\), M.G. Nardacci\(^{1}\), A. Piciocchi\(^{2}\), F. Albano\(^{3}\), G. Specchia\(^{3}\), A. Cuneo\(^{4}\), S. Fabris\(^{5}\), A. Neri\(^{5}\), M. Vignetti\(^{1}\), F.R. Mauro\(^{1}\), A. Guarini\(^{1}\), R. Propris\(^{1}\),

1Cellular Biotechnologies and Hematology, Sapienza University, Rome, 2GIMEMA Data Center, Rome, 3Department of Emergency and Organ Transplantation, University of Bari, Barì, 4Department of Hematology, S. Anna Hospital, Ferrara, 5Department Medical Sciences, University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

**Background:** Chemoinmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) is the optimal front-line treatment for fit chronic lymphocytic leukemia (CLL) patients. IGHV mutations and FISH lesions are predictive markers of response and progression-free survival after FCR. Minimal residual disease (MRD) is the single best post-treatment predictor of long-term outcome after FCR, independent of biologic prognostic markers.

**Aims:** To explore whether conventional biologic markers (i.e. IGHV mutations, FISH lesions) and TP53, NOTCH1, BIRC3 and SF3B1 mutations can predict the attainment of a MRD negativity after first-line treatment of CLL patients with FCR and ofatumumab (FCO).

**Methods:** Eighty young (≤65 yrs) and fit CLL patients from 15 Italian centers were enrolled in the GIMEMA LLC0911 first-line trial and treated with 6 cycles of FCO. CLL diagnosis, treatment requirement and response were defined according to the 2008 IWCLL guidelines. MRD was evaluated in responding patients by 8-color flow cytometry in the peripheral blood (PB) and bone marrow (BM) 2 months after the end of induction (month +8), and every 6 months thereafter; flow negative cases were analyzed by RQ-PCR, according to the guidelines. The association between CLL biologic markers and MRD clearance after FCR was tested by Fisher’s exact test; logistic regression models were used to estimate the risk values in univariate and multivariate analyses.

**Table 1.**
et al., 2013), the high and intermediate risk groups (del17p/TP53/BRIC2+ or del11q/NOTCH1/SF3B1+) showed a significantly lower probability of achieving a MRD negativity (36%, 10/28) than the low and very low risk groups (+2/3/IGF/17p/TP53/BRIC2+ for 4 genes: 81%, 29/36) (p=0.0003). The 40 flow cytometry MRD- cases were also evaluated by RQ-PCR: 22 (55%) were reclassified as MRD-. By combining the two methods, 47/65 (72%) were MRD- and 18/65 (28%) MRD+. At the end of the FCO, Mutated (M)-IGHV status was significantly associated to a molecular MRD- (12 MRD-/15 MRD+ , 44%) compared to unmutated (UM)-IGHV cases (5 MRD-/32 MRD+, 13%) (p=0.0092). Moreover, when M-IGHV status is reinforced is the absence of del17p/TP53mut/del11q, a correlation with the deep MRD negativity got stronger (12 MRD- cases of 17p- were associated with significantly shorter follow-up: 13 months and a median of 2 lines of treatment [1-10]. In 28/124 (23%) cases, age ≥65 years [33-88], 59% were Binet stage A, 28% B, 12% C.

Methods: We evaluated if the type of chromosomal abnormality leading to 17p- was associated with improved or worse OS. All the patients were followed for a median time of 77.5 months [22-291] from the diagnosis. Karyotype was complex in 141/195 (72%) patients, and monosomal in 90/195 (46%). A multivariate model including FISH lesions, gene and IGHV mutations supports the independent role of FISH and IGHV profile in predicting MRD negativity by flow and RQ-PCR, respectively.

Summary/Conclusions: In CLL patients treated with the FCO combination (LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION. A GFCH STUDY. A GFCH STUDY. ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA AND TUMOR SUPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH miR-21. Microenvironment found in bone marrow and lymph nodes supports survival, proliferation and drug resistance in chronic lymphocytic leukemia (CLL). Indeed, CLL cells are highly dependent on interactions with the microenvironment. The BCR is one of the key players involved in the crosstalk between CLL cells and the microenvironment. Furthermore, it has a critical role in pathogenes- 

Background: Chromosomal abnormalities are present in about 80% of CLL. Among the 17p- cases, the most frequent is 17p13 deletion (17p-; i(17q)) (69 months [33-88], 59% were Binet stage A, 28% B, 12% C. According to the IGHV profile: 74% in patients without del17p/del11q- and 14% in patients with del17p/del11q- cases. A deeper MRD negativity by RQ-PCR (28%) can be anticipated by the IGHV status (44% M vs 13% UM) or by combining IGHV and FISH. A longer follow-up will determine whether these parameters can identify patients who maintain over time a good quality of response.

E1001

ISOCROMOSOME 17q, UNBALANCED TRANSLOCATIONS AND 8q GAIN REPRESENT ADVERSE PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17p DELETION. A GFCH STUDY. A GFCH STUDY. ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA AND TUMOR SUPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH miR-21. Microenvironment found in bone marrow and lymph nodes supports survival, proliferation and drug resistance in chronic lymphocytic leukemia (CLL). Indeed, CLL cells are highly dependent on interactions with the microenvironment. The BCR is one of the key players involved in the crosstalk between CLL cells and the microenvironment. Furthermore, it has a critical role in pathogenes- 

E1002

THE MICROENVIRONMENT REGULATES THE EXPRESSION OF MiR-21 AND TUMOR SUSPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH MiR-21. Microenvironment found in bone marrow and lymph nodes supports survival, proliferation and drug resistance in chronic lymphocytic leukemia (CLL). Indeed, CLL cells are highly dependent on interactions with the microenvironment. The BCR is one of the key players involved in the crosstalk between CLL cells and the microenvironment. Furthermore, it has a critical role in pathogenes- 

Summary/Conclusions: Among the high risk group of 17p- CLL, i(17q) confers a shorter OS than the other 17p abnormalities. In addition, the gain8q aggra- vates the outcome as well as the presence of additional unbalanced transloca- 

Summary/Conclusions: Among the high risk group of 17p- CLL, i(17q) confers a shorter OS than the other 17p abnormalities. In addition, the gain8q aggra- vates the outcome as well as the presence of additional unbalanced transloca- 

Summary/Conclusions: Among the high risk group of 17p- CLL, i(17q) confers a shorter OS than the other 17p abnormalities. In addition, the gain8q aggra- vates the outcome as well as the presence of additional unbalanced transloca-
IMPACT OF RECURRENT MUTATIONS ON PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED REGIMENS

M. Hlozkova1,*, J. Malcikova1, N. Tom1, M. Borsky1, Y. Brychtova1, M. Doubek1, A. Panovska1, E. Diviskova1, M. Mraz1, S. Pospisilova1, J. Mayer1, M. Trbusek1, 2Molecular Medicine, Padua, 3Department of Molecular Medicine, University of Padua, Padua, Italy

Background: Regimens consisting of rituximab and DNA-damaging drugs represent an important therapeutic option for patients with chronic lymphocytic leukemia (CLL). Up-to-date studies including clinical trials agreed upon the adverse outcome of TP53-defective patients that should be provided alternative treatment approaches. Additionally, mutations in NOTCH1 gene were connected with a lack of benefit from rituximab added to chemotherapy. A potential impact of other mutations commonly occurring in CLL patients remains less clear, namely regarding a role in relapse development.

Aims: (a) to assess impact of mutations in ATM, SF3B1, NOTCH1 and BIRC3 genes on progression-free survival (PFS) in CLL patients treated with front line rituximab-based regimens, and (b) to analyze clonal evolution of mutations in relapse.

Methods: We analyzed 53 CLL patients who received first line regimens (FCR, fludarabine, cyclophosphamide, rituximab) or Q-FCR (FCR with reduced doses) or BR (bendamustine, rituximab); all harbored intact TP53 gene as assessed by FISH and the yeast functional analysis; 46/53 (87%) had unmethylated IGHV. The next generation sequencing using MiSeq (Illumina) was done in exons 14-16, part of 34, and 7-10, respectively, MC 11 200, and TP53 (exons 2-63; median coverage (MC) 6 100), respectively. Only mutations present in >10% of reads were considered for the PFS analysis (log-rank (Mantel-Cox) test); the interval was calculated from therapy completion to clinical progression (as defined by the iwCLL consensus structured according to the type of mutation). The next generation sequencing using MiSeq (Illumina) was done in exons 14-16, part of 34, and 7-10, respectively, MC 11 200, and TP53 (exons 2-63; median coverage (MC) 6 100), respectively. Only mutations present in >10% of reads were considered for the PFS analysis (log-rank (Mantel-Cox) test); the interval was calculated from therapy completion to clinical progression (as defined by the iwCLL recommendations).

Results: In the pre-treatment analysis, we identified 23 patients with one disrupted gene and 7 patients with two disrupted genes; the rest of the cohort is represented by patients harboring mutations in three genes: ATM (exons 2-63; median coverage (MC) 6 100), SF3B1/NOTCH1/BIRC3 (exons 14-16, part of 34, and 7-10, respectively, MC 11 200), and TP53 (exons 2-63; median coverage (MC) 6 100), respectively. Functional impact of ATM mutations was verified by SIFT and PolyPhen online tools. Only mutations present in >10% of reads were considered for the PFS analysis (log-rank (Mantel–Cox) test); the interval was calculated from therapy completion to clinical progression (as defined by the iwCLL recommendations).

In univariate analyses of individual affected genes, we did not observe significant differences in PFS among the employed regimens: the median PFS for (a) Q-FCR (15 patients; 4 cycles); for (b) FCR (23 patients; 7 cycles); and for (c) BR (8 patients; 3.5 cycles); all harbored intact TP53 gene as assessed by FISH and the yeast functional analysis; 46/53 (87%) had unmethylated IGHV. The next generation sequencing using MiSeq (Illumina) was done in exons 14-16, part of 34, and 7-10, respectively, MC 11 200, and TP53 (exons 2-63; median coverage (MC) 6 100), respectively. Only mutations present in >10% of reads were considered for the PFS analysis (log-rank (Mantel-Cox) test); the interval was calculated from therapy completion to clinical progression (as defined by the iwCLL recommendations).

Conclusion: Our pilot analysis with limited number of samples does not indicate an adverse impact of mutations in rituximab-based regimens. In relapsed samples showed quite distinct mutation profile. Supported by projects AZV 16-32743A, MUNI/A/1106/2016 and FNBr, 65269705.

E1004

BCR SIGNALLING PROGNOSTIC CHRONIC LYMPHOCYTIC LEUKAEMIA: B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO G. Pavlishanski1, A. Masur1, V. Slebocka1,3, K. Cerna1,2, V. Seda1,2, J. Osiokova3, V. Brychtova2, M. Doubek2, S. Pospisilova1,2, J. Mayer2, M. Mraz1,2 1Molecular Medicine, CEITEC MU, 2Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Background: Anti-CD20 monoclonal antibody rituximab (RTX) has improved clinical outcome of patients with CD20-positive B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the fact that RTX has been clinically used for 20 years, the exact mechanism of its action remains largely unclear.

Aims: The aim of this study was to determine susceptibility of CLL cells’ subpopulations to RTX.

Methods: Peripheral blood samples from CLL patients (N=17) were obtained and analysed before (day 0) and 24 hours (day 1) after RTX administration (375mg/m², single agent).

Results: It was described that CLL cells that interacted with stromal cells in vivo can be characterised by relatively weak cell-surface expression of chemokine receptor CXCR4 and high expression of activation marker CD56 (Pavlavova et al., 2016). The authors hypothesised that the higher levels of CD20 on CXCR4+CD56 dim CLL cells make them the primary target for RTX in vivo, since the cells have higher CD20 expression (association with the RTX resistance) (Pavlavova et al., 2016). We analysed blood samples obtained from CLL patients treated with RTX as a single agent and indeed, we observed that RTX preferentially and nearly completely eliminates the CXCR4 dimCD56 bright subpopulation after the first RTX dose (8.3% pre-RTX vs 2.1% post-RTX, P<0.0001). We further reported that the CXCR4 dimCD56 bright subpopulation, since CD20 was proposed to play a role in BCR signalling. We observed that CXCR4 dimCD56 bright CLL cells have higher immunoglobulin (IgM) expression (~2-fold, P<0.005) which was coupled with higher responsiveness to BCR cross-linking with anti-IgM (P=0.005). Moreover, CXCR4 dimCD56 bright CLL cells also have higher levels of CD19 (1.8-fold, P=0.0001), which is an important component of BCR complex that augments signal transduction. Furthermore, we demonstrated that CXCR4 dimCD56 bright cells have higher phosphorylation of several proteins involved in PI3K/BCR/NFkB signalling pathway (P=0.05) compared to CXCR4+CD56 dim cells obtained from the same patient. This led us to hypothesize that the phosphorylation of the studied proteins is likely of physiological importance for PI3K/BCR signalling. Indeed, we observed significant reduction in phosphorylation of tyrosine-protein kinases associated with PI3K/BCR signalling after silencing of CD20 by siRNA in B cells.

Conclusions: We showed that CXCR4 dimCD56 bright CLL subpopulation in peripheral blood of CLL patients has the highest surface levels of CD20 and is therefore preferentially and effectively eliminated by RTX. These CLL cells likely represent the most “aggressive” subclone of CLL cells since they have relatively high proliferative and BCR signalling capacity.

Supported by: the Ministry of Education, Youth and Sports of the Czech Republic under the project CEITEC 2020 (LQ1601); Czech Science Foundation (project No. 16-13334Y); the Ministry of Health of the Czech Republic, grant No. 16-29622A. All rights reserved. The European Union’s Horizon 2020 research and innovation programme under grant agreement No. 692928. This study reflects only the author’s view and the Research Executive Agency is not responsible for any use that may be made of the information it contains. MH CZ–DRO (FNBr, 65269705); MUNI/A/1106/2016; GAMU MUNI/0865/2016, and G.P. is a city of Ostrava scholarship holder.
B cells we performed a co-immunoprecipitation assay, followed by Western blotting analysis, at steady state and after IgM (10µg/ml) stimulation. We also evaluated the interaction between c-Cbl and Lyn after treatment with 17-DMAG (500nM), a potent HSP90 inhibitor.

Results: We demonstrated that c-Cbl is overexpressed (p<0.001, Student’s t test) in CLL B lymphocytes with respect to normal B cells. We found that in neoplastic B cells c-Cbl did not co-immunoprecipitate with Lyn neither after BCR trigger. We obtained similar results when we treated neoplastic B lymphocytes with 17-DMAG to dissociate the Lyn-Hsp90 complex: after 1h, 2h and 4h of treatment we immunoprecipitated Lyn demonstrating that neither before nor after IgM stimulation c-Cbl interacts with this kinase. These results support the hypothesis that c-Cbl is not involved in Lyn turnover. Data obtained from 10 independent experiments showed that in CLL neoplastic cells the phosphorylation on Y707 increased after 5’ and 10’ of IgM stimulus, highlighting the involvement of c-Cbl in BCR signaling.

Summary/Conclusions: These preliminary results prompt us to investigate the role of Lyn and Cbl in the development of neoplastic clone. In CLL cells c-Cbl is overexpressed with respect to normal B cells, and upon BCR engagement it undergoes Y707 phosphorylation. However, c-Cbl is unable to stably interact with Lyn suggesting an altered c-Cbl function that contribute to affect cell homeostasis.

E1006

ACTIVATION OF SHP-1/PP2A PATHWAYS TRIGGERS APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

F. Severin1,2, E. Tibaldi2, M.A. Pagano2, F. Frezzato2, V. Trimarco1,2, V. Martin1,2, F. Raggi1, L. Martinello1, M. Faccio1, G. Zagotto1, G. Ribaudo1, V. Vute1, L. Bordin1, A. Visentin2, F. Zonta2, G. Semenzato1,2, A.M. Brunati1,2, L. Trentin1,2

1Department of Medicine, University of Padua, 2Venetian Institute of Molecular Medicine (VIMM), 3Department of Molecular Medicine, 4Department of Pharmaceutical and Pharmacological Sciences, 5Department of Biomedical Sciences, University of Padua, Padova, Italy

Background: CLL B cells inability to reach programmed cell death is due to intrinsic defect and extrinsic factors. Among the intrinsic fault there is the misregulation of the phosphorylation pattern. Reversible protein phosphorylation is a fundamental post-translational modification by which virtually all cellular events are regulated. The crucial players involved in this dynamic process are protein kinases and protein phosphatases, which are placed at the different levels of cellular signaling. The Src Family Kinase (SFK) Lyn is a key factor in the dysregulation of survival and apoptotic pathways of malignant B cells in CLL. One of the effects of Lyn’s action is the spatial and functional segregation of the tyrosine phosphatase SHP-1 into two pools, one beneath the plasma membrane in an active state promoting pro-survival signals, the other in the cytosol in an inhibited conformation and unable to counter the elevated level of cytosolic tyrosine phosphorylation.

Aims: Because CLL is characterized by a high level of Lyn-dependent tyrosine phosphorylation in the cytosol, we focused our attention on compounds capable of directly or indirectly driving the activation of SHP-1 which in turn could counter the action of Lyn and induce cell demise. The goal is to discover new therapeutic strategies to defeat a still incurable disease as CLL.

Methods: B cells were collected from 37 CLL patients. Freshly isolated CLL cells incubated with increasing concentrations of nintedanib (0-24 µM) and MP07-66 (2,2-diethoxyethyl[4-(hexyloxy)phenyl)methyl]amine) for 24 and 48 hours with/without a layer of Mesenchymal Stromal Cells (MSCs). Caspase dependence was demonstrated using pan-caspase inhibitor z-VADfmk. CLL B cells viability was tested by Flow Cytometer with Annexin V/PI test. SHP-1/PP2A activation, after 24h and 48h at marked level. Interestingly, we recently demonstrated that Ser591 phosphorylation of SHP-1 could be dephosphorylated by nintedanib, in a caspase-dependent manner. Since our data suggest that the activation of either PP2A or SHP-1 triggered by specific small molecules caused stimulation of each cell’s cell death activity, we treated CLL cells with nintedanib and MP07-66 together demonstrating an improved effect when used in combination. Similar results, in all the conditions, were obtained in presence of a MSC layer, showing the capability of these treatments to counteract the protective action of tumor microenvironment.

Summary/Conclusions: In conclusion, our findings indicate that phosphatase activators may represent a new weapon against this form of leukemia. Overall, these data corroborate the hypothesis that the inhibition of PP2A is central to CLL cell viability and that its activation is facilitated by the supportive action of SHP-1, as demonstrated by the effect produced by the simultaneous use of the respective activators.

E1007

TARGETING NANOPARTICLES TO CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPLOITING THE PROPERTIES OF CXCR4

C. Mccallion1,*, A. Booth2, J. Adams3, K. Rees-Unwin3, A. Peters1, A. Pluen4, S. Webb1, J. Burthem3

1School of Chemistry, University of Manchester, Manchester, 2School of Chemistry, University of Leeds, Leeds, 3Institute of Cancer Sciences, 4School of Pharmacy, University of Manchester, Manchester, United Kingdom

Background: Nanoparticle carriers of therapeutic agents (“drug delivery vehicles”) can be used to deliver drugs to specific cells through the incorporation of a “targeting ligand”. Targeting provides the therapeutic benefit of achieving high local drug concentrations while reducing off-target effects against other cells; the combined ligand/delivery vehicle system can also be manipulated to determine the uptake pathway or modulate biological effects. The CXCR4 chemokine-receptor is an attractive target for drug delivery vehicles. It is overexpressed in cancers including chronic lymphocytic leukaemia (DLL) (Doman ska et al., 2013) and binding to its ligand (CXCL12) may induce proliferation, survival or entry into protective cellular niches (Ganju et al., 1998). Targeted nanoparticles that can bind and antagonise CXCR4 could therefore allow specific drug delivery to cancer cells while simultaneously blocking CXCL12-induced chemoprotection.

Aims: A drug-design strategy was developed to synthesise and evaluate a novel CXCR4 targeting motif (BAT1) with structural similarity to Plerixafor, a CXCR4-antagonist in clinical use. A key design principle was to incorporate a polyethylene glycol (PEG) tether with a functional end-group to provide an attachment point for cargoes, particularly liposomes. The evaluation aim was to assess the effectiveness of BAT1 to deliver a chemotherapy cargo to CLL cells within an ex vivo culture system.

Methods: A three-step synthesis was used to generate BAT1 (Figure 1A); its structure and purity was confirmed using NMR, MS and HPLC. Bioactivity testing employed primary CLL lymphocytes. Assays tested: CXCR4 binding affinity (flow cytometric competition assays), cell-binding characteristics (immunocytotoxicfluorescence) and blockade of CXCL12-induced signalling (immunoblot). Initial targeting assessment used a fluorescent label (Cy5) conjugated to the functional PEG tether. Cholesteryl chloroformate was then selected to conjugate BAT1 to PEGylated liposomes.

Results: The binding affinity of BAT1 (Figure 1B) was demonstrated using competition assays (CXCL12, anti-CXCR4 ab, and the bis(cyclam) drug Pierixafor). The studies confirmed BAT1 had high affinity for CXCR4 receptors expressed on primary CLL cells. Immunocytotoxicfluorescence comparison with its native ligand confirmed binding of BAT1 to the CLL cell surface, while immunoblotting demonstrated blocking of CXCL12-induced signalling (Figure 1C and 1D). The fluorescent moiety Cy5 was covalently linked to the functional PEG tether. Cholesteryl chloroformate was then selected to conjugate BAT1 to PEGylated liposomes. This work has been extended to attach BAT1 to liposomes, with present work optimising liposome characteristics for binding and uptake by CLL and the delivery of cytotoxic payload.

Summary/Conclusions: A novel bis(cyclam) CXCR4 antagonist and targeting motif – BAT1 – has been synthesised. BAT1 demonstrates high affinity for the CXCR4 receptor, supporting targeted delivery to CLL cells. Receptor binding is associated with simultaneous blockade of CXCL12-mediated signal initiation and effect, and therefore biological modulation of target cell behaviour. BAT1

Figure 1.

Summary/Conclusions: A novel bis(cyclam) CXCR4 antagonist and targeting motif – BAT1 – has been synthesised. BAT1 demonstrates high affinity for the CXCR4 receptor, supporting targeted delivery to CLL cells. Receptor binding is associated with simultaneous blockade of CXCL12-mediated signal initiation and effect, and therefore biological modulation of target cell behaviour. BAT1
TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS
J. Kotaskova1,2, S. Pavlova1,2, K. Plevka1,2, J. Malickova1,2, O. Stehlikova1, L. Poppova1, H. Kockova1, M. Doubek2,3, V. Bryja4, S. Posspisilova1,
1 Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 2 Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 3 Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 4 Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic

Background: Receptor Tyrosine Kinase-Like Orphan Receptor – 1 (ROR1) expression on malignant B-cells is considered a promising target for therapy in CLL and other lymphoproliferative disorders. Recently published data suggest that combination of BCR inhibitor ibrutinib with ROR1 antibody cirtumab-eban can enhance treatment efficacy in CLL. Nevertheless, the variability in ROR1 expression during disease progression, therapy administration and relapse remains unknown.

Aims: In our study we aimed to i) detect ROR1 in CLL cells during different stages of the disease using flow cytometry and qRT-PCR with focus on patients undergoing therapy; ii) analyze changes in ROR1 expression within individual patients during the disease course.

Methods: CLL cohort consisted of 96 CLL patients (152 samples); 23 patients with stable disease, 16 patients with active disease prior first therapy intervention, 6 patients during first therapy, 13 patients in progression before second line treatment, 3 patients in complete remission, 10 refractory patients, 9 patients treated with ibritinib, 4 patients treated with idelalisib. To quantify ROR1 mRNA expression changes within individual patients we performed qRT-PCR in separated CLL cells (>95% CD19+CD5+). CLL cells from samples in remission were separated immunomagnetically (Whole Blood Anti-ROR1 MicroBead, Miltenyi Biotec).

Results: Using multicolour flow cytometry we confirmed ROR1 antigen/protein expression on CLL cells. Using purified samples treated with ibrutinib or idelalisib we detected detectable on residual CLL cells during disease remission with the ability to distinguish malignant population from healthy B-cells. Using q-RT-PCR we detected significantly higher levels of ROR1 mRNA in samples of treated patients (p<0.01). This observation was supported by analysis of ROR1 mRNA expression in five patients tested consecutively in several time-points. We detected ROR1 mRNA expression increase in disease progression before therapy and further increase during therapy administration. In case of remission induction we observed decrease of ROR1 mRNA level. In patients treated with ibritinib or idelalisib we observed steep increase of ROR1 expression compared to untreated patients treated with FCR regimen.

Summary/Conclusions: ROR1 protein remains detectable on CLL cells during disease course even in complete remission. ROR1 mRNA levels are highly influenced by therapy administration especially in the case of treatment with Bcr inhibitors.


TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS

E1008
THE ROLE OF THROMBOPOIETIN AS A TOOL OF IMMUNE MODULATION IN CHRONIC LYMPHOCYTIC LEUKEMIA
S. Ringelstein-Harlev1,*, M. Fanadka2, N. A. Horowitz1, T. Katz1
1 Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 2 Central Medical and Health Care Campus, 2 Bruce Rappaport Faculty of Medicine, Technion, Israel

Background: Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) of IGHV3-21 and IGHV3-48. Treatment free survival was markedly increased in patients with normal SPE (median follow up 76 months (66-131), median number of sampling points 12 (5-18)). For surface ROR1 protein analysis we used 8-colour flow cytometry (modified MRD protocol: CD45/CD3/CD19/CD5/CD8/CD79b/CD22/ROR1) in all available samples. To quantify ROR1 mRNA expression changes within individual patients we performed qRT-PCR in separated CLL cells (>95% CD19+CD5+). CLL cells from samples in remission were separated immunomagnetically (Whole Blood Anti-ROR1 MicroBead, Miltenyi Biotec).

Results: Using multicolour flow cytometry we confirmed ROR1 antigen/protein expression on CLL cells. Using purified samples treated with ibrutinib or idelalisib we detected detectable on residual CLL cells during disease remission with the ability to distinguish malignant population from healthy B-cells. Using q-RT-PCR we detected significantly higher levels of ROR1 mRNA in samples of treated patients (p<0.01). This observation was supported by analysis of ROR1 mRNA expression in five patients tested consecutively in several time-points. We detected ROR1 mRNA expression increase in disease progression before therapy and further increase during therapy administration. In case of remission induction we observed decrease of ROR1 mRNA level. In patients treated with ibritinib or idelalisib we observed steep increase of ROR1 expression compared to untreated patients treated with FCR regimen.

Summary/Conclusions: ROR1 protein remains detectable on CLL cells during disease course even in complete remission. ROR1 mRNA levels are highly influenced by therapy administration especially in the case of treatment with Bcr inhibitors.


E1010
NORMAL SERUM PROTEIN ELECTROPHORESIS IDENTIFIES AN INCREASED PROGNOSIS GROUP AMONG IGHV MUTATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, WITH A MEDIAN TFS OVER 18 YEARS
J. Chauzeix1,2,*, N. Bargues1, M.-P. Laforêt1, M. Deveza1, V. Combeau1, V. Renat1, E. Guénin1, F. Trimoreau1, N. Dmytruk3, J. Feuillard1, N. Gachard1, D. Rizzo1
1 Service d’hématologie biologique, CHU Limoges, 2UMR7276, Université de Limoges, 3 Service d’hématologie clinique, CHU Limoges, Limoges, France

Background: Approximately 36% of patients with chronic lymphocytic leukemia (CLL) have normal serum protein electrophoresis (SPE), either with hypomagnlobulinemia or with monoclonal immunoglobulin (Ig) peak. In this study, we compared locally recruited patients with normal and abnormal SPE.

Aims: The aim was to identify prognosis parameters.

Methods: A total of 189 patients (132 abnormal SPE and 57 normal SPE) were included. Diagnoses were performed between 1980 and 2015. Prognosis parameters investigated were IGHV mutation status, presence of SF3B1, NOTCH1 or BIRC3 mutations (determined by high throughput and Sanger sequencing), and cytogenetic abnormalities such as del17p, del11q, del13q and trisomy 12 (assessed by standard cytotype, FISH analysis and GMPSP).

Results: In this series, 73%, 19% and 8% of patients were at Binet stage A, B and C respectively, and 30% had a normal SPE at diagnosis. Ninety six percent of patients with normal SPE were at Binet stage A, versus 63% of patients with abnormal SPE (Chi2 test : p<10-18). Median lymphocytoisis at diagnosis was lower in patients with normal SPE (12.82 G/L versus 19.54 G/L in abnormal SPE; Chi2 test : p=0.00198). Regarding genetic prognosis factors, we found that 58% of cases with normal SPE had a good prognosis profile (mutated IGHV and/or isolated del13q, with no other genetic abnormality detected), meanwhile 65.2% of patients with abnormal SPE exhibited at least one poor prognosis marker (unmutated IGHV, mutation of SF3B1, NOTCH1, del17p, or trisomy 12, Chi2 test : p<10-14). In patients with normal SPE, only 3.5% were SF3B1 mutated against 15.2% in case of abnormal SPE (Chi2 test : p=0.002). Among other strong differences, 10.5% patients with normal SPE had a trisomy 12 against 18.2% for abnormal SPE. Isolated del13q was found in 38.6% and 21.2% of cases with normal and abnormal SPE respectively. Mutated IGHV status was found in 65% in normal SPE, compared to 56% with abnormal SPE. Compared to the whole series, IGHV repertoire analysis shows bias in IGHV1-2, and IGHV4-34 rearrangements, with decreases usage of IGHV3-21 and IGHV4-27. Treatment free survival was markedly increased in patients with normal SPE (median of 10.0 years versus 3.0 years for normal and abnormal SPE respectively). In the rank test analysis, survival was significantly better for patients with normal SPE, while patients with mutated IGHV had a median TFS of 8 years (against 3 years for unmutated patients), those with normal SPE and mutated IGHV had a median TFS over 18 years. Patients with mutated IGHV and abnormal SPE had a
their role in the immunopathogenesis of CLL has not yet been fully clarified. Fundamental part in inflammatory response and immune tolerance. However, regulatory T cells (Tregs) are subpopulations of T lymphocytes which play a...THE INTERPLAY BETWEEN TH17 AND TREGS: A NEW IMMUNOSUPPRESSIVE INSIGHT IN CHRONIC LYMPHOCYTIC LEUKEMIA S. De Matteis 1,*, R. Napolitano 1, A. Lucchesi 2, D. Cangini 2, A. Cuneo 3, G.M. Rigolin3, E. Volta3, G. Musuraca2 Background: The search for molecules involved in apoptosis resistance/ increased survival of B cells from Chronic Lymphocytic Leukemia (CLL) is still ongoing since this disease remains not definitively understood. We recently found that the Heat Shock Protein of 70kDa (HSP70), expressed in response to a variety of stress signals and allowing cells to survive to lethal conditions, was particularly overexpressed in neoplastic B cells from CLL. Moreover, the Heat Shock Factor 1 (HSF1), the major responsible for the transcription of HSP70, is itself overexpressed in CLL and strictly correlated to HSP70. In response to stress, HSF1 becomes phosphorylated, forms homotrimmers, binds DNA and activates heat shock gene transcription. HSF1 is regulated by a fine balance of activatory/inhibitory phosphorylations mediated by kinases belonging to pathways triggered by RAS (i.e. PI3K/akt/mTOR and RAF/MEK/ERK). Aims: Since HSP70 is overexpressed in CLL neoplastic B cells and most of HSF1-1phosphorylating actors belong to signalling pathways taking part from RAS, being the PI3K/AKT/mTOR and the RAF/MEK/ERK pathways, we are herein aimed at gaining information and dissecting this network in CLL B cells. Methods: In a Reverse Phase Protein Array (RPPA) study, previously performed from 57 CLL patients and 11 healthy volunteers, we evaluated the activation/expression of key signalling proteins. Herein, we focused on HSP70, AKT-Ser473, mTOR-Ser244, GSK3a/b-Ser21/9, CDK2, CREB-Ser133, MEK1/2-Tyr217-221, ERK1/2-Thr202/Tyr204, NFkB-Ser536, phosphoMAPK-Thr180/Tyr182, SAPK-JNK-Thr183/Tyr185 and PDK1-Ser241. Cluster and separated analyses have been performed. Results: We divided our patients in HSP70-high and HSP70-low considering as cut-off the value of the median of HSP70 expression levels calculated by RPPA and demonstrated that the examined proteins behave in a different way between patients expressing high or low levels of HSP70. HSP70-high patients present high AKT-Ser473, an inhibitor of GSK3a/b that, in the inhibited form, prevents HSF1 inhibition. By contrast, HSP70-low patients have high MEK1/2-Ser217/221 and ERK-Thr202/Tyr204, known to negatively regulate HSF1. Intriguingly, phosphoMAPK-Thr180/Tyr182 has been described to both activate and inhibit HSF1 at different sites, is overexpressed in those patients presenting low levels of HSP70. Summary/Conclusions: These data would suggest that, in CLL, HSP70 expression is regulated by the modulation of HSF1 activity through the activation of one or the other way triggered by RAS. In particular, an activation of the PI3K/AKT/mTOR pathway leads, as result, to a higher expression of HSP70 while an activation of the RAF/MEK/ERK signalling rather results in HSP70 down regulation. The dissection of signalling pathways connected to HSP70- HSF1 axis in CLL will contribute to define the biology and understand the pathogenesis of this disease.

E1012 THE INTERPLAY BETWEEN TH17 AND TREGS: A NEW IMMUNOSUPPRESSIVE INSIGHT IN CHRONIC LYMPHOCYTIC LEUKEMIA S. De Matteis 1,*, R. Napolitano 1, A. Lucchesi 2, D. Cangini 2, A. Cuneo 3, G.M. Rigolin3, E. Volta3, G. Musuraca2 Background: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in the Western world and it is characterized by the clonal expansion of CD5 positive B cells. In CLL, different T cell dysfunctions have been described, probably related to the interaction with malignant B cells. TH17 and regulatory T cells (Tregs) are subpopulations of T lymphocytes which play a fundamental part in inflammatory response and immune tolerance. However, their role in the immunopathogenesis of CLL has not yet been fully clarified. Aims: The aim of this study is to clarify the interplay between TH17 and Tregs in the pathogenesis of CLL. Methods: After obtaining the patient’s informed consent, peripheral blood was collected from 30 untreated CLL patients and 30 age-matched healthy volunteers (HV). Cytokine production was evaluated before and after a 48 h culture of CD4+ T cells in complete medium with IL-6 (10 ng/ml), followed by a 5 h stimulation with PMA, ionomycin and Monensin (PIM), or with anti-CD4, anti-CD28 and anti-CTLA4 PE. Cytokine secretion analysis, stimulated CD4+ T cells were analyzed by flow cytometry. Results: In CLL patients we observed a reduced production of IFNγ and IL-4, respectively from TH1 and TH2 and an increase of IL-17A from TH17, compared to HV. All the observed differences were statistically significant. We also evaluated the ability of CD4+ T cells to secrete IL-17A, IL-10 or both. We reported a significantly increased frequency in the frequency of CD4+ IL-17A-producing cells in CLL patients compared to HV, whereas the percentage of IL-17A+IL-10+ cells remained unchanged. In order to evaluate the functional effects of the observed alterations, we analyzed IFNγ+ and IL-17A+ T cells-mediated response after stimulation with C. Albicans for 48 h, with or without depletion of IL-17A- secreting cells. The frequency of IFNγ-producing T cells resulted statistically significant increased in patients than HV before IL-17A-secreting T cells depletion. Conversely, after IL-17A+ CD4+ T cells depletion, we didn’t observe significant differences in terms of IFNγ production. We also observed increased IL-23 plasma levels in patients compared to HV. In addition our data highlighted a significantly higher frequency of CD4+ CD25highFoxP3+ Treg cells in CLL samples, with a statistically significant increase in Tbet+ Tregs, RORγt+ Tregs and GATA-3+ Treg subpopulations (Figure 1).

Figure 1. Summary/Conclusions: Our results reported a down-regulation of IFNγ and IL-4 producing T cells, associated to an increased frequency of Tregs and their subsets in CLL patients, probably trying to overcome the deficit of effector T cells. In the other hand, we observed a rise in IL-17A secreting T cells related to the increased IL-23 production by dendritic cells in order to restore TH17 pool, without changing the percentage of IL-17A+IL-10+ cells. These data support the idea of the protective function of TH17 that show an effector and not a regulatory T phenotype. Starting from these observations, this study could pave the way to further researches and applications in the comprehension of the biological and regulatory mechanisms of TH17 and Tregs, supporting the study of a pioneering antitumor therapy in CLL.

E1013 LOW EXPRESSION OF CD25 IN CHRONIC LYMPHOCYTIC LEUKEMIA INFECTED BY NOTCH1-MUTATED CASES INDEPENDENT OF CDK4/6 MISREGULATION T.H. Chen Liang1,*, A.M. Hurtado1, M. Castillo1, J. Muñoz-Ballester1, B. Przychodzen2, M.D. García-Malo1, F.D. Arribal1, F.J. Ortúñio1, J.P. Maciejewski2, V. Vicente3, A. Jerez1 1Hematology and Oncology Department, Hospital Morales Meseguer,Centro Regional de Hemodonación, Murcia, Spain, 2Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, United States, 3Hematology and Oncology Department, Hospital Morales Meseguer,Centro Regional de Hemodonación. Universidad de Murcia, IMIB,CIBERER, Murcia, Spain Background: Recently, it has been shown that CDK6-mediated repression of CD25 is required for induction and maintenance of NOTCH1-induced T-cell acute lymphoblastic leukemia. Aims: The aim of this study was to identify the NOTCH1 mutational status detected by deep sequencing in a cohort of 138 patients and to correlate it with the immunophenotypic profile and CDK4 and CDK6 expression. Methods: We performed targeted NGS sequencing of blood samples, collected at diagnosis, from 138 CLL patients. We designed a TruSeq Custom Amplion
containing 13 genes and covering 28,099 bases. Paired-end sequencing was obtained. Every patient underwent, at baseline, a flow cytometry characterization with a panel including (sIg)λ, (sIg)κ, CD19, CD5, CD11b, CD81, CD10, CD79b, CD29, CD38, FMC7, CD22, CD45, CD103, CD11c, CD25, ZAP70, CD11a, and CD24. CD4 and CD6 K6 expression levels were quantified by RT-qPCR.

Results: With a median age of 66 y.o. (range, 31-89) and a slight male predominance, the median follow up time of our cohort was 43 months (24-104). We found that 38/138 (28%) patients harbored at least one mutation, with NOTCH1 (n=16, 12%), ATM (n=12, 9%), TP53 (n=9, 7%), and SF3B1 (n=8, 6%) being the most commonly mutated genes. Those patients with a mutation showed a lower CD25 expression (24 mean fluorescence intensity units (MFU)) than those without a mutation (43 MFU), p=0.03. We could not validate the recently reported association between the presence of NOTCH1 mutations and a low expression of CD25. In our cohort, the MFI expression in NOTCH1 mutated and non-mutated patients was 163 and 146 units, respectively (p>0.05). We measured CDK4 and CD6 K4 expression in the CD19+ sorted fraction RNA of 7 NOTCH1 mutated cases and 11 non mutated cases, without finding significant differences (0.26 vs 0.27 for CDK6, 0.025 vs 0.022 for CDK4; p>0.5 in both cases).

Summary/Conclusions: We found a significant inferior expression of CD25 when activating NOTCH1 mutations are present in CLL patients. The relationship found between these two variables, with an inversed direction to that found in physiological conditions, has also been shown in the setting of NOTCH1 mutated T acute lymphoblastic leukemia. In CLL cases, it seems to be independent of CD4/8 expression, prompting further studies assessing CDK4 and CD6 K4 regulators.

E1014 GENE MUTATIONS ANALYZED BY NEXT-GENERATION SEQUENCING ALLOW US TO DEFINE THE PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH EARLY-STAGE DISEASE AND 13Q DELETION

J.-A. Queizán 5, I. De la Fuente 6, C. Aguilar 7, A. García de Coca 8, A. Jiménez-Ramírez 5, M. González 12, J. M.-J. Vidal-Manceñido 2, J. Galende 3, J.-M. Alonso 4, A.-A. Martín 1, R. Benito 1, M. Queiruga 1, J.-Á. Hernández-Rivas 1, J.-M. Hernández-Rivas 1 1Cancer Research Center/Hospital Universitario de Salamanca, SALAMANCA. 2Hospital Virgen Blanca, LEÓN, 3Hospital del Bierzo, PONFERRADA, 4Hospital de La Rioja, PASALENCIA, 5Hospital General, SEGOVIA, 6Hospital Río Hortega, Valladolid, 7Hospital Santa Bárbara, SORIA, 8Hospital Clínico Universitario, VALLADOLID, 9Hospital Juan Ramón Jiménez, HUELVA, 10Hospital Miguel Servet, ZARAGOZA, 11Hospital Virgen del Puerto, PLASENCIA, 12Hospital Universitario Infanta Leonor/Universidad Complutense de Madrid, MADRID, SPAIN

Background: Next-Generation sequencing (NGS) studies have revealed a number of recurrently mutated genes in chronic lymphocytic leukemia (CLL). It is reasonable to argue that evaluation of the newly gene mutations as prognostic markers would help to improve prognostication of CLL patients. Interestingly, gene mutations could help us to refine the prognosis in the group of CLL patients with other prognostic markers associated with good prognosis.

Aims: To analyze the presence of mutations of a panel of genes by NGS and its prognostic impact in patients with CLL, focusing in the groups of patients with good prognosis characteristics.

Methods: Amplicon-based-NGS was performed using 454 platform in 147 CLL patients to evaluate the mutational status of Igs genes (TP53, NOTCH1, SF3B1, XPO1, FBXW7 and MYD88). Samples were obtained at diagnosis or before treatment in all cases. 70.1% were Binet A and 53% had 13q deletion (13q-). A cut-off 2% was applied to define variants. All the mutations were validated.

Results: 1. NGS analysis showed that 37.4% of CLL patients (55/147) showed mutations in any of these analyzed genes. The frequency of mutations was: 10.6% for NOTCH1, 10.2% for SF3B1, 6.8% for TP53, 4.8% for XPO1, 3.4% for FBXW7, and 1.4% for MYD88. The presence of mutations in any of these genes except to MYD88 (mutated CLL) was significantly associated with clinical progression (60.0% for mutated CLL vs. 38.2% for unmutated CLL; P=0.05). Interestingly, mutated CLL patients showed a shorter time to first treatment (TFT) than unmutated CLL patients (30 months vs. 88 months; P=0.006). By contrast, MYD88 mutations were detected in CLL with mutatedIGHV and 13q-. Of note, 23.6% of the mutations had a mutational load of ≥15% and thus would not have been detected by capillary Sanger sequencing. CLls with mutations in MYD88 had a shorter TFT than CLLs without mutations (18 vs 88 months; P=0.018), and similar to CLL patients with mutations >15% of cells (P=0.370). In addition, 14.5% of mutated CLL patients showed mutations in MYD88. Patients with more than one mutation had a shorter TFT than CLL patients with one mutation (7 months vs 31 months). 3. In the group of CLL patients with 13q deletion (13q-), 32.8% of them showed mutations in any of the analyzed genes. Interestingly, CLL patients Binet A with mutations (except to MYD88) showed a shorter TFT than CLL patients without mutations (31 vs 131 months, P=0.001). Besides this, CLL with 13q- as the sole cytogenetic alteration and gene mutations had also a shorter TFT that unmutated 13q- CLL patients (P=0.002).

Summary/Conclusions: 1) CLL patients with mutations in TP53, NOTCH1, SF3B1, XPO1 and FBXW7 show a worse prognosis than CLL patients without mutations. 2) Gene mutations in TP53, NOTCH1, SF3B1, XPO1 and FBXW7 in a low percentage of the cells are associated with a shorter TFT. 3) Among CLL patients with good prognostic characteristics (Binet A and 13q-), gene mutations help us to define the prognosis of the patients.
Chronic lymphocytic leukemia and related disorders - Clinical

E1016
ASSOCIATION OF CGP-STIMULATED KARYOTYPE WITH TIME-TO-FIRST TREATMENT FOR CLL
1Bone Marrow Transplantation, Ospedale Pausilipon, Napoli, Italy, 2Leukemia, MD Anderson Cancer Center, Houston, United States, 3Ematologia, PO San Giuseppe Moscati, Avesa, Italy, 4Chao Family Comprehensive Cancer Center, California, United States

Background: Prognostic factors correlate with clinical outcomes, independent of treatment. B cell receptor (BCR) signaling pathway inhibitors can nullify the prognostic impact of some markers, such as IGHV mutation status. CpG-stimulated metaphase karyotype can identify clonal cytogenetic abnormalities in CLL that may not be seen with standard non-stimulated karyotype or by FISH. Complex cytogenetics, defined as 3 or more chromosome abnormalities in 2 or more metaphases was the highest-risk feature for shorter progression-free and overall survival in patients receiving ibrutinib for relapsed/refractory CLL. Complex karyotype is not uncommon among relapsed/refractory CLL cases, particularly those who previously received genotoxic chemotherapy.

Table 1. Continuous and Categorical Patients Characteristics.

Figure 1.
Aims: The aim of this study is to report the incidence and the impact of CpG-stimulated karyotype in the treatment of naïve CLL.

Methods: We evaluated 501 treatment-naïve patients with CLL at MDACC between July 2013 and June 2016. CpG-stimulated metaphase karyotype of CLL cells from blood or bone marrow was performed by culture of mononuclear cells for 72 hrs in media containing CpG-685 (20μg/ml), phorbol 12-myristate 13-acetate (PMA; 0.04μg/ml) and Phorbewscite mitogen (PWM; 0.1μg/ml). Banding and analyses were performed by standard laboratory procedures. Twenty metaphases were analyzed per culture and patients were categorized as having diploid karyotype, a single, 2 or 3 or more(complex) clonal chromosome abnormalities present in more than 1 metaphase by CpG-stimulated karyotype. The frequency and distribution of chromosome abnormalities with other prognostic factors and time-to-first treatment from diagnosis (TTFT) were analyzed (Table 1, Figure 1).

Results: The majority (69%) of patients had diploid cytogenetics. Higher-risk prognostic features such as del17p, del11q, unmutatedIGHV and ZAP70 expression were associated with presence of complex karyotype abnormalities. Shorter TTFT from diagnosis was associated with 1, 2, and complex clonal chromosome abnormalities compared to diploid karyotype (p<0.0001). A model was developed, which identified patient characteristics independently associated with shorter TTFT including: 1 or more clonal chromosome abnormality by CpG stimulated karyotype; unmutatedIGHV; 3 involved lymph node sites; and CD38 expression (>30%).

Conclusions: In conclusion, CpG-stimulated karyotype identified 1 or more clonal chromosome abnormalities in nearly a third of untreated patients and was a significant independent prognostic factor for TTFT. Models for TTFT may be useful in identifying patients at high-risk for needing treatment sooner and thereby useful for early intervention clinical trials.

E1017
COMPARISON OF THE CHRONIC LYMPHOCYTIC LEUKEMIA INTERNATIONAL PROGNOSTIC INDEX (CLL-IPI) WITH THE BARCELONA-BRNO PROGNOSTIC MODEL: ANALYSIS OF 1299 NEWLY DIAGNOSED CASES
1Hematology, Hospital Annunziata, Cosenza, Italy, 2Hematology, Mayo Clinic, Rochester, United States, 3Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, 4Hematology, Catholic University, “A. Gemelli”, 5Hematology, Università La Sapienza, Rome, 6Hematology, Pugliese-Ciaccio Hospital, Catanzaro, 7Hematology, 75S Molecular Diagnostics IRCCS S. Martino-IST, Genova, 8Hematology, Hospital Annunziata, Cosenza, 9Hematology, Università La Sapienza, Roma, 10Immunology, Consiglio Nazionale delle Ricerche, Istituto di Biomedicina ed Immunologia Moleculari, Reggio Calabria, Italy, 11Divisione di Biomedicina ed Informaticas, Mayers, Rochester, United States, 12Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, 13Hematology, University of Milano and Hematology CTMO, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, 14Direzione Scientificia IRCCS-, San Martino IST, Genova, 15Hematology, Department of Translational Medicine, PO, Novara, Italy

Background: In the last two decades, a plethora of clinical, serological and biological markers have been identified that are significantly associated with the prognosis of chronic lymphocytic leukemia (CLL) patients. Recent research has focused on the development of scoring systems capable of integrating the major prognostic parameters. A recent prognostic index called CLL International Prognostic Index (CLL-IPI), built on clinical, serological, and biological parameters (TP53 deletion and/or mutation, IGHV mutational status, β2M, clinical stage, and age) has been proposed and validated. Recently, a new prognostic model called Barcelona-Brno CLL group, with the aim of simplifying the CLL-IPI, proposed a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics).

Aims: We performed a comparison of the CLL-IPI with the Barcelona-Brno prognostic model in an independent series of Italian and United States (U.S.) patients.

Methods: Databases from 4 Italian and 1 U.S. centers including roughly 3700 newly diagnosed CLL patients were used to compare the CLL-IPI with the Barcelona-Brno prognostic model. Baseline data regarding age, Rai stage, IGHV mutational status, β2M and fluorescence in situ hybridization (FISH) -detected cytogenetic abnormalities were available for 1299 cases. Del17p was used as the sole marker of TP53 status. The CLL-IPI and the Barcelona-Brno prognostic model were calculated using the methods proposed. The accuracy of the prognostic models was assessed by the Harrell C index (an index of discrimination), the explained variation in mortality (an index comparing observation and discrimination), and the Akaike information criterion (AIC, an index comparing two non-nested prognostic models). The lower the AIC, the higher the prognostic accuracy of a predictive model.

Results: The median age of the 1299 patients was 63 years (range 27-92) with 61.3% males. The majority of patients had Rai stage 0 (57.9%). Among the patients according to the CLL-IPI, 51.3% of patients were classified as low-, 28.7% as intermediate-, 16.2% as high-, and 3.8% as very high-risk. The 5-year OS probabilities were: 95% for low-risk, 89.9% for intermediate-risk, 70.1% for high-risk, and 32.8% for very high-risk cases (P<0.0001; Harrell C index=73%; P<0.001) (Figure 1A). Accordingly, the explained variation of the CLL-IPI, proposed a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics).

Conclusions: In conclusion, the Barcelona-Brno prognostic model in predicting OS (CLL-IPI, AIC=3432.167 versus Barcelona-Brno prognostic model, AIC=3549.492). Accordingly, the explained variation in mortality provided by the CLL-IPI was 42% (P<0.001), a figure higher than that due to the Barcelona-Brno prognostic model.
(21%, P<0.001), indicating that the CLL-IPI had a higher prognostic accuracy for mortality compared to that of the biomarkers-only prognostic model. Then, we also compared the ability of the two scores to predict TTFT in newly diagnosed patients. The Harrell C-index of the Barcelone-Bromo prognostic model was 0.70 (P<0.001), lower than that of the CLL-IPI score (0.73, P<0.001). The AIC showed the superiority of the CLL-IPI compared to the Barcelone-Bromo prognostic model in predicting TTFT (CLL-IPI, AIC=6000.503 versus biomarkers-only prognostic model, AIC=6010.929). Accordingly, the explained variation provided by the CLL-IPI was 33% (P<0.001), a figure higher than that achieved by the Barcelone-Bromo prognostic model (28%, P<0.001), indicating that the CLL-IPI had a higher prognostic accuracy for predicting TTFT as compared to that of the Barcelone-Bromo prognostic model.

Methods: S55746/BCL201 as single agent is being investigated in a phase I (EU/RAC17778157), open-label, multiple ascending dose escalation trial. S55746/BCL201 was initially administered in fasting condition, once daily (in 21-day cycle) until progressive disease (PD) or unacceptable toxicity. A tumor lysis syndrome (TLS) prevention protocol was implemented. After giving informed consent pts could receive 50 to 2000mg according to a modified version of the Continual Reassessment Method for dose allocation process. In the food effect part of the study, 7 non-Hodgkin’s lymphoma patients received a film coated 200mg tablet under fasting condition (i.e. after 10-hour fasting period) and after a calibrated moderate meal the day after.

Results: As of February 2017, 12 CLL pts have been treated (median age 67 years [range 52-82]). On these 12 pts, 5 presented a bulky disease, 1 a 17p deletion, 4 a 11q deletion, and 1 a p53 mutation. CLL pts were dosed up to 700mg, with a median duration on treatment of 79 days. Median number of prior regimens in CLL pts was 4 (range 2-5). Preliminary PK results in fasting pts showed that exposure increased linearly but with some inter-individual variability. The most frequent (≥2 pts) grade 3/4 adverse events (AEs) were neutropenia (n=2) and thrombocytopenia (n=2). AEs possibly related to the study drug were reported in 4 pts: neutropenia (n=2), neutrophil count decrease (n=1), fatigue (n=1), dyspnea (n=1), gingival bleeding (n=1) and left ventricular ejection fraction (LVEF) decrease (n=1). No clinical or laboratory TLS were reported. One patient in the 700mg cohort experienced a DLT (asymptomatic LVEF decrease grade 2 recovered within 2 weeks). At 700mg, a decrease in lymphocytes count from baseline (>50%) was observed in 3 out of 4 patients associated with a decrease in the sum of the product of the diameters of lymph nodes (from 23% to 40%). This decrease in lymphocytes count, started from cycle 1, and may be correlated with an induction of apoptosis in CLL cells (4 hours post first dose), detected by flow cytometry in CD19+AnnexinV+ cells. Two CLL pts are ongoing after having completed their 3rd cycle; 10 pts have withdrawn from the study; 7 due to PD, 1 for lack of efficacy and 2 due to AE. The non-compartmental pharmacokinetic analysis of the food effect cohort (5 assessable pts) demonstrated that S55746/BCL201 PK is modified by the ingestion of a moderate meal (400-500 kcal with fat contributing to 150 kcal). The median Tmax was delayed from 1.5h to 4h when administered with food. Compared with fasting condition, Cmax and AUC increased by approximately 6-fold following a moderate meal. Based on these results, a protocol amendment to the clinical trial has been implemented in order to further investigate the administration with food in a new dose escalation.

Summary/Conclusions: S55746/BCL201 monotherapy showed first signs of activity across the tested dose levels with an acceptable safety profile so far. Based on PK food interaction results, dose escalation in the fed state has started.

E1018
PRELIMINARY RESULTS OF S55746/BCL201 (A NEW BCL2 INHIBITOR) IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND EFFECT OF CALIBRATED MODERATE MEAL ON THE PHARMACOKINETICS

V. Ribrag1, M. Wermke2, F. Morschhauser3, S.T. Lim4, G. Sallees5, I. Kloos6, A. Becquart7, A. Derreal6, L. Kraus-Berthier6, S. Pennaforte6, J.-M. Michot1, S. Stilgenbauer7, J. Walewski8, S. Le Gouill9

Background: BCL-2 is an anti-apoptotic protein overexpressed in chronic lymphocytic leukemia (CLL). BCL-2 is responsible for apoptosis machinery dysregulation and contributes to chemotherapy resistance. S55746/BCL201 is a novel, oral, selective BCL2 inhibitor.

Aims: The current first-in-human study evaluates the safety and aims to establish the recommended phase 2 dose; main secondary objectives include evaluation of pharmacokinetics (PK), food effect, pharmacodynamics and preliminary activity in patients (pts) with relapsed or refractory CLL.

Methods: S55746/BCL201 was single agent is being investigated in a phase I (EU/RAC17778157), open-label, multiple ascending dose escalation trial. S55746/BCL201 was initially administered in fasting condition, once daily (in 21-day cycle) until progressive disease (PD) or unacceptable toxicity. A tumor lysis syndrome (TLS) prevention protocol was implemented. After giving informed consent pts could receive 50 to 2000mg according to a modified version of the Continual Reassessment Method for dose allocation process. In the food effect part of the study, 7 non-Hodgkin’s lymphoma patients received a film coated 200mg tablet under fasting condition (i.e. after 10-hour fasting period) and after a calibrated moderate meal the day after.

Results: As of February 2017, 12 CLL pts have been treated (median age 67 years [range 52-82]). On these 12 pts, 5 presented a bulky disease, 1 a 17p deletion, 4 a 11q deletion, and 1 a p53 mutation. CLL pts were dosed up to 700mg, with a median duration on treatment of 79 days. Median number of prior regimens in CLL pts was 4 (range 2-5). Preliminary PK results in fasting pts showed that exposure increased linearly but with some inter-individual variability. The most frequent (≥2 pts) grade 3/4 adverse events (AEs) were neutropenia (n=2) and thrombocytopenia (n=2). AEs possibly related to the study drug were reported in 4 pts: neutropenia (n=2), neutrophil count decrease (n=1), fatigue (n=1), dyspnea (n=1), gingival bleeding (n=1) and left ventricular ejection fraction (LVEF) decrease (n=1). No clinical or laboratory TLS were reported. One patient in the 700mg cohort experienced a DLT (asymptomatic LVEF decrease grade 2 recovered within 2 weeks). At 700mg, a decrease in lymphocytes count from baseline (>50%) was observed in 3 out of 4 patients associated with a decrease in the sum of the product of the diameters of lymph nodes (from 23% to 40%). This decrease in lymphocytes count, started from cycle 1, and may be correlated with an induction of apoptosis in CLL cells (4 hours post first dose), detected by flow cytometry in CD19+AnnexinV+ cells. Two CLL pts are ongoing after having completed their 3rd cycle; 10 pts have withdrawn from the study; 7 due to PD, 1 for lack of efficacy and 2 due to AE. The non-compartmental pharmacokinetic analysis of the food effect cohort (5 assessable pts) demonstrated that S55746/BCL201 PK is modified by the ingestion of a moderate meal (400-500 kcal with fat contributing to 150 kcal). The median Tmax was delayed from 1.5h to 4h when administered with food. Compared with fasting condition, Cmax and AUC increased by approximately 6-fold following a moderate meal. Based on these results, a protocol amendment to the clinical trial has been implemented in order to further investigate the administration with food in a new dose escalation.

Summary/Conclusions: S55746/BCL201 monotherapy showed first signs of activity across the tested dose levels with an acceptable safety profile so far. Based on PK food interaction results, dose escalation in the fed state has started.
exception of VCA-EBV IgG titers, that were higher in CLL vs the other groups. Strikingly, the IgG levels for the three viruses tended to gradually increase, from healthy individuals to stage B/C CLL. These findings were more pronounced (p<0.05) for IgG and to a lesser extend also for IgM, when the ratios between the virus-specific IgG/IgG total IgG titers of the same isotype were calculated, except for Influenza-specific IgG, that showed the same trend but without statistical significance. Repeating CMV DNA load, only 3/177 individuals ≥1 MBLq and 2 CLL were found to be positive (below the limit of quantitation), while EBV DNA load was detected in plasma from 7/191 (all being Binet A CLL) at median levels of 3.6 copies/ul. In contrast to the virus-specific IgGs, IgG plasma levels against S. pneumoniae progressively diminished through progression of the disease, and progressively decreased protection against other microorganisms, denoting a severe pathogen-specific humoral immunodeficiency state not reflected by the overall plasma immunoglobulin levels. Alternatively, these results might point out a potential role of ubiquitous viruses in the pathogenesis of the disease. Further analyses are necessary to establish the potential relevance of such asymptomatic humoral immune responses against host viruses in the expansion of the tumor B-cell clone and progression from MBL to CLL.

E1020

AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORYNESS

G.M. Rigolino1, L. Formigaro1, M. Cavallari1, F.M. Quaglia1, E. Lista1, A. Urso1, E. Guardalben1, S. Martinelli1, E. Scaccetti1, C. Bassi2, L. Lupini2, A. Bardì2, E. Volta1, E. Tammioso1, M. Melandri1, M. Negrimi1, F. Cavazzini1, A. Cuneo1
1Science Medicine, Azienda Ospedaliera Universitaria Arcispedale S. Anna, 2Department of Morphology, Surgery and Experimental Medicine, and “Laboratorio per le Tecnologie delle Terapie Avanzate” (LTTA), University of Ferrara, Ferrara, Italy

Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, running an indolent course in some patients and a clinically aggressive course in others. Risk assessment is important in clinical practice and prediction of outcome and response to treatment is very useful in an era in which several chemoimmunotherapy combinations and effective mechanism-driven treatments are available.

Aims: We investigated whether an extended genetic characterization including mutational screening by next generation sequencing (NGS) and karyotype analysis could allow for a refinement of our capability to predict outcome in newly diagnosed CLL patients with high-risk features, as defined by the presence of unmutated IGHV gene and/or 11q22/17p13 deletion by FISH and/or TP53 mutations.

Methods: 101 patients were included in this study. TP53 disruption was defined by the presence of 17p13 deletion by FISH and/or TP53 mutation by NGS. Cytogenetic analysis was performed using Cpg-oligonucleotide DSP30. Each patient was categorized according to the following classification: favorable group (isolated 13q14 deletion or normal karyotype), unfavorable group (deletions of 11q22 or 17p13, or complex karyotype, i.e, at least 3 chromosome aberrations); intermediate group (all other karyotypic abnormalities). A cut-off of 98% homology to the germline sequence to discriminate between IGHV mutated and unmutated cases. Mutational screening was performed with Ion Torrent PGM NGS platform on 20 CLL-related genes by using a 5% cut off.

Results: Cytogenetic analysis showed favorable findings in 30 patients, unfa-vorable in 34 cases and intermediate in 36 cases. A complex karyotype was present in 21 patients. By NGS, 95 somatic mutations were observed in 56/101 (55.4%) cases; 80 nonsense mutations, 5 nonsense mutations and 10 frameshift deletions. 16 cases (15.8%) cases in the remaining 11 genes. 26/56 (46.4%) mutated patients presented two or more mutations. The presence of mutations was associated with unmutated IGHV status (p=0.040) and the complex karyotype (p=0.047). TP53 disruption correlated with the presence of ≥2 mutations by NGS (p=0.001) and a complex karyotype (p=0.012). By multivariate analysis an advanced Binet stage (p<0.001) and an unfavorable karyotype (p=0.011) predicted for a shorter time to first treatment (TTFT), while TP53 disruption (p=0.019) and unfavorable karyotype (p=0.028) predicted for a worse overall survival (OS). A shorter time to chemorefractoriness (TTCR) was associated with TP53 disruption (p=0.001) and unfavorable karyotype (p=0.025). Patients with both unfavorable karyotype and TP53 disruption presented a dismal outcome (median OS and TTCR of 28.7 and 15.0 months respectively).

Summary/Conclusions: A comprehensive analysis of chromosomal aberrations and gene somatic mutations in high-risk CLL showed that the cytogenetic profile was independently associated with a shorter TTFT, OS and TTCR. Since karyotyping using novel mitogens may contribute to the refinement of prognosis in high-risk CLL patients, the introduction of this technique in future CLL trials seems warranted to identify those patients that could be ideal candidates for consolidation treatment or novel treatment combinations.

E1021

SHOULD CLL-IPI BE USED TO ASSESS OVERALL SURVIVAL OF EVERY CLL PATIENT? A SYSTEMATIC REVIEW AND META-ANALYSIS

S. Molica1,2, D. Giannarelli2, R. Mirabelli1, L. Levato3
1Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, 2Biostatistic Unit, IRCCS Regina Elena, Rome, 3Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy

Background: A weighted grading approach based on five independent prognostic factors (i.e., TP53 status, IGHV mutational status, S2-microglobulin, clinical stage and age) has been used by an international Working Group to generate the chronic lymphocytic leukemia international prognostic index (CLL-IPI). Although the robustness of CLL-IPI has been confirmed in most validation studies it remains unclear whether CLL-IPI has the greatest validity and should be preferred to guide clinical decision in CLL.

Aims: To shed light on this important research question, we conducted a systematic review which includes all published studies which used CLL-IPI to prognosticate overall survival (OS) in CLL.

Methods: A comprehensive MEDLINE search using “CLL-IPI” as Medical Subject Headings (MESH) allowed to identify at the cut-off time of February the 28, 2017 “seven hits” with only “four” citations considered pertinent. The search was extended to the conference proceedings of annual meetings of ASH, EHA and ASCO of last two years recognized “three” additional citations.

Results: Overall 6720 patients from seven evaluable studies were suitable for the present analysis aimed at assessing the impact of CLL-IPI on OS. The majority of patients (4953 or 73.7%) came from studies of external validation of CLL-IPI while 17% (1192) and 8.5% (576) had been used to generate (train) and to internally validate the model. Patient distribution into the four risk categories of CLL-IPI was heterogeneous thus reflecting the CLL phase (i.e., at diagnosis, at time of first treatment and at relapse) of patients within different studies. Accordingly, patients diagnosed as having low-, intermedium-, high- and very high-risk CLL-IPI ranged respectively between 9% and 58%, 25% and 39%, 14% and 52% and 2% to 9%. Next we evaluated the 5-year OS of patients stratified into each of the four CLL-IPI risk groups using either “Q” or “I2” test to assess the heterogeneity across different studies. The 5-year survival probability was 91% for low-risk group (95% CI, 90-91%; Q=49.36; P<0.00; I2, 86%), 60% for high-risk group (95% CI, 57-62%; Q=42.78; P=0.01; I2, 67%).

Summary/Conclusions: In this comprehensive review and meta-analysis of studies thus far published on CLL-IPI we confirmed the value of this novel model to predict OS whatever the CLL phase (fig 1). The prognostic impact of CLL-IPI presents an extensive validation in patient cohorts receiving therapy with B-cell receptor or bcl-2 inhibitors. Nonetheless, in a study of relapsed/refractory CLL included in this analysis the PI3K-inhibitor idelalisib was not able to over-rate the chronic lymphocytic leukemia international prognostic index (CLL-IPI).

Figure 1.

E1022

IBRUTINIB FOR CHRONIC LYMPHOCYCTIC LEUKEMIA: IMPACT OF THE CANADIAN YOU&I™ PATIENT SUPPORT PROGRAM ON TREATMENT ADHERENCE

A. Peters1,2, J. Wiernikowski2, S. Barker3, M. Mahler4, S. Luke5, A. Lodick5
1Hematology-Oncology, University Health Network, Toronto, Canada, 2Department of Pathology, University Health Network, Toronto, Canada, 3Hematology-Oncology, University of British Columbia, Vancouver, BC, Canada, 4Hematology-Oncology, University of British Columbia, Vancouver, BC, Canada, 5Hematology-Oncology, University of British Columbia, Vancouver, BC, Canada

Background: Irribitinib is an oral Bruton’s tyrosine kinase inhibitor with a unique mechanism of action that can be used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and indolent B-cell non-Hodgkin’s lymphoma. Irribitinib was approved in Canada in April 2020 for the treatment of patients with chronic lymphocytic leukemia, who have relapsed or are refractory to at least one prior treatment or who are unsuitable for standard therapy. This study aims to determine the impact of the Canadian You&I™ patient support program on treatment adherence to irribitinib in patients with chronic lymphocytic leukemia.

Methods: This was a retrospective analysis of data from a Canadian You&I™ patient support program for patients with chronic lymphocytic leukemia. The program includes support for patients and their healthcare providers, including a dedicated patient support manager who provides individualized support throughout the treatment journey. Data on treatment adherence were collected from patient Diaries, which included information on the use of irribitinib and other medications, as well as any adverse events. Treatment adherence was measured as the percentage of patients who took their medication as prescribed at least 80% of the time over the first 6 months of treatment. Adherence was analyzed by age, gender, and disease status (new diagnosis vs. relapsed/refractory).

Results: A total of 50 patients with chronic lymphocytic leukemia were included in the analysis. The mean age of patients was 72 years (range: 45-87). The majority of patients were male (74%). The overall adherence rate was 82% (range: 60-94%). There were no significant differences in adherence rates between new diagnosis and relapsed/refractory patients. Adherence was also not significantly different between male and female patients.

Summary/Conclusions: The Canadian You&I™ patient support program for irribitinib is associated with high treatment adherence in patients with chronic lymphocytic leukemia. This supports the importance of comprehensive patient support programs in improving treatment outcomes and overall health outcomes for patients with chronic lymphocytic leukemia.

haematologica | 2017; 102(s2) | 419
Background: Oral anticancer medications (OAMs) present several advantages compared with intravenous cytotoxic chemotherapy, including greater convenience for the patient. However, OAMs require that a patient be actively involved in regular drug administration over an extended period of time (Schneider SM, et al. Semin Oncol Nurs. 2011;27(2):133-141). Adherence to OAMs significantly impacts patient outcomes; poor adherence may result in inferior survival and outcomes, higher hospitalization rates, treatment resistance, and increased healthcare costs (McCue DA, et al. Pharmacotherapy. 2014;34(5):481-494). The Canadian YOU&i™ patient support program (PSP) was developed to improve adherence to long-term ibrutinib therapy using research-proven techniques for promoting positive behavioral changes, i.e., cognitive behavioral therapy, psycho-social support, and a nurse coaching component. Results from the program are presented. Additionally, a study in CLL utilizing a large, longitudinal, demographically and geographically diverse database of US cancer pts (Flatiron Health 12/2016). An analytical cohort of pts treated at community practice sites who initiated 1st LoT after Jan 2011 was developed. Two sub-cohorts of pts who initiated 1st LoT before and after 2014 were also identified. Consenting the approval timing of oral-targeted therapies in the US

Aims: To evaluate patient adherence to ibrutinib, and patient and physician satisfaction with the YOU&i™ PSP

Methods: Using evidence-based literature reviews and global/local market research, various patient-centered barriers to treatment adherence were identified. A mixed-methods design was calculated using the Morris Medication Adherence Scale, which informed nurse coaching frequency. Adherence was delineated by prescription refill compliance. Patient and physician questionnaires were used to gauge satisfaction with the YOU&i™ PSP.

Results: As of 20 January 2016, a total of 903 patients with CLL were enrolled in the YOU&i™ PSP. A total of 552 patients were included in the adherence analysis. Of these, 86% opted in to receive the nurse coaching component. At 2 months from treatment initiation, patients who received nurse coaching demonstrated an adherence rate of 92.3%, as compared with 63.5% for patients who did not receive nurse coaching (85% CI, 17.5±41.4; p <0.0001). At 3 months the adherence rates were 89.9% vs 60.8% (95% CI, 17.5±41.4; p <0.0001). By 9 months, adherence rates were 81.7% vs 71.1% (95% CI, -4.4 to 28.4; p =0.141). At study conclusion, 12 month adherence rates were 76.6% vs 72.2% (95% CI, -18.9 to 32.4; p =0.715). Discontinuation rates were similar in all patients, regardless of nurse coaching status at 9 and 12 months. Patients reported satisfaction rates of >90% in surveys conducted at both 3 months and 12 months of program enrollment. Of physicians surveyed at 3 months, 96% reported that the YOU&i™ PSP was helpful in supporting patient needs.

Summary/Conclusions: The current analysis provides insight into adherence patterns of patients on long-term ibrutinib treatment. These results are consistent with the literature showing that PSPs like the YOU&i™ PSP can help to improve adherence rates (Schneider SM, et al. J Adv Pract Oncol. 2014;5(3):163-172). The information obtained from long-term adherence data can help to inform future trials examining patterns of adherence with OAMs. Nurse coaching may be helpful in supporting early adherence by addressing side effects that occur more frequently at treatment initiation. Moreover, changes in disease or health status that arise over the first 12 months of therapy may provide information that allows a PSP to adapt to patients’ evolving needs over the treatment journey. A better understanding of long-term adherence patterns may allow programs such as the Canadian YOU&i™ PSP to target adherence support more precisely, thereby optimizing patient outcomes.

E1024

SINGLE-AGENT IBRUTINIB VS REAL WORLD TREATMENT FOR PATIENTS WITH TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE-2™ WITH THE CLEAR AND LYON-SUD DATABASES

M. Doubek1*, E. Bachy2, M. Spacek3, L. Bassegio2, R. Besson5, J. Diels5, J. Garside6, N. Healy7, W. Iraqli8, E. Callet-Bauchu2, L. Smolej9, G. Salies2

1Department of Internal Medicine – Hematology and Oncology, University Hospital Brussels, Faculty of Medicine, Universitiy of Brussels, Brussels, Belgium, 2Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France, 31st Department of Internal Medicine – Hematology, General Faculty Hospital, Prague, 4Department of Hemato-oncology, University Hospital, Olomouc, Czech Republic, 5Janssen EUHARH Statistics & Modelling, Beerse, Belgium, 6Janssen EMEA HEMAR, High Wycombe, United Kingdom, 7Janssen-Cilag EMEA Medical Affairs, Dublin, Ireland, 8Janssen Pharmaceuticals, Paris, France, 994th Department of Medicine – Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

Background: The phase 3 RESONATE-2™ study demonstrated significant improvement of progression-free survival (PFS) and overall survival (OS) with ibrutinib (ibr) vs chlorambucil (chl) in TN (aged ≥65 years) CLL patients. In the absence of direct comparison of single-agent ibr with other frequently utilized therapies in this patient population, we used a sub-cohort of patients from RESONATE-2™ vs Real World (RW) database. The association against standard of care as observed in clinical practice can provide useful insights on the relative efficacy of ibr

Aims: To investigate the relative treatment effect on PFS and OS for ibr vs real world (RW) treatment in daily clinical practice in TN CLL patients by adjusting for the basis of patient-level data from RESONATE-2™ vs RW data from the CLEAR (Chronic Lymphocytic Leukemia Registry) and Lyon-Sud databases.

Methods: CLEAR holds medical records for CLL patients from seven academic centers across the Czech Republic. Lyon-Sud database holds medical records for CLL patients from French French hospital Lyon-Sud. Patients initiated on CLL frontline therapy were selected from CLEAR and Lyon-Sud using the same inclusion-exclusion criteria as for RESONATE-2™ (excluding patients with age<65 and with del17p positive status). PFS and OS were compared...
pared between ibru and RW treatment using patient-level data from RESONATE-2™ (n=136) and pooled patient-level data from the two cohorts. To adjust for differences in patient characteristics between the trial population and both cohorts, a multivariate Cox proportional hazards model was fitted on patient-level data to estimate the hazard ratio (HR) for ibru vs RW treatment, with age, sex, disease stage (based on Rai/Binet), and deletion 11q presence/absence used as covariates.

Results: Median age at treatment initiation for CLLEAR (n=418) and Lyon-Sud (n=110) was 73 and 71 years, respectively, vs 73 for ibru patients from RESONATE-2™. The proportion of male patients was 63% in CLCLEAR and 57% in Lyon-Sud vs 85% in RESONATE-2™. The median follow-up was 35.7 months (mo) for Lyon-Sud and 16.8 mo in CLCLEAR vs 29.1 mo for RESONATE-2™. Adjusted HR for ibru vs physician choice in CLCLEAR and Lyon-Sud were 0.23 (95% CI: 0.14, 0.39) and 0.25 [0.14, 0.43] for PFS, and 0.29 [0.11, 0.79] and 0.39 [0.18, 0.83] for OS, respectively. Fludarabine/cyclophosphamide/rituximab (FCR; n=117), bendamustine+R (BR; n=91), CH alone (n=43), CH+H (n=45), and other R-containing regimens (n=154) were the most commonly used treatment regimens across both RW cohorts. Older age, male gender, advanced disease stage and del11q positive status were independent risk factors for PFS and OS. The adjusted HRs (pooled estimates) for ibru vs the two most commonly used regimens were 0.30 [0.17-0.53] (FCR) and 0.33 [0.16-0.68] (BR) for PFS, and 0.44 [0.20-0.95] (FCR) and 0.53 [0.13-0.83] (BR) for OS (Figure 1). Estimates of HR vs regimens in the cohorts were consistent across both databases.

Summary/Conclusions: This adjusted comparison of patient-level data from RESONATE-2™ with RW data from CLCLEAR and Lyon-Sud demonstrates ibru to be more effective compared with RW treatment, with a 4.1-fold improvement in OS. When comparing ibru with the most commonly used RW treatments, statistically significant benefits for ibru were consistently observed vs all treatment regimens on PFS and for most comparisons on OS. These results further support the existing evidence that ibru significantly improves PFS and OS vs common regimens used in TN CL settings, and has important implications for clinical practice.

E1025 CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP O. Al-Sawafi1*, J. Bahlo1, K. Fischer1, C. Herling1, M. Hoechstetter2, A. Fink1, J. von Tresckow1, P. Langerbeins1, P. Cramer1, S. Stilgenbauer3, C. Wendtner2, B. Eichhorst1, M. Hallek1, V. Goede1
1Department of Internal Medicine, German CLL Study Group, University Hospital of Cologne, Cologne, Germany. 2Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany. 3Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

Background: People over 80 are the fastest growing age group in western populations. Clinical management of ≥80 year old patients (pts) with CLL remains a challenge due to the very limited amount of data currently available for this age segment. Two retrospective studies reported observational data on characteristics, treatment, and outcomes of ≥80 year old pts not enrolled in a clinical trial (Ballezza et al., 2009). However, little is known about ≥80 year old pts who were treated for CLL within clinical trials, however.

Aims: To study the characteristics, treatment, and outcomes of pts aged ≥80 years who received their first therapy within prospective trials of the German CLL Study Group (GCLSG).

Methods: Trial populations of seven clinical trials of the GCLLSG (CLL1, CLL5, CLL7, CLL8, CLL9, CLL10, CLL11; total N=3552) were reviewed and screened for pts ≥80 years at frontline treatment. Clinical, laboratory, and genetic data of identified pts were pooled. Time-to-event analyses were performed by Kaplan-Meier methodology. Independent prognostic factors for survival were identified by multivariate analysis using Cox regression modelling with stepwise selection procedures.

Results: Among 3552 reviewed GCLLSG trial participants, 152 were aged ≥ 80 years at initiation of firstline treatment. A majority of these pts were identified from CLL1 (n=132) while the remaining were from CLL1 (n=3), CLL5 (n=1), CLL7 (n=3), CLL8 (n=2), CLL9 (n=9), and CLL10 (n=2). Median age was 82 years (range 80-90). Concomitant diseases were present in 99% of the pts and median cumulative illness rating scale (CIRS) score was 8 (0-18). Median creatinine clearance was 46 ml/min (range 17-99 ml/min). Identified genomic aberrations were 1q deletion as a sole abnormality in 27%, trisomy 12 in 10%, 11q deletion in 9%, and 17p deletion in 16% of pts. (IGH) was unmutated in 69% of the pts. Distribution of CLL-IPI risk groups was as follows: 6% low, 19% intermediate, 61% high, and 14% very high. Most pts had Binet Stage B (36%) or C (43%). Chemoimmunotherapy with chlorambucil plus obinutuzumab (CLB-OB) or chlorambucil plus rituximab (CLB-R) was administered to 61% (40%) and 56 (37%) pts, respectively. Remaining pts received chlorambucil alone (CLB, n=19), fludarabine (F, n=10), fludarabine/cyclophosphamide (FC, n=1), fludarabine/cyclophosphamide/rituximab (FCR, n=2), or bendamustine/rituximab (BR, n=3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%, respectively. Premature treatment discontinuations occurred in 15% of cases and were mostly due to adverse events. The total overall response rate was 92% with 13% complete remissions. Median observation time for all pts was 40.7 months. Median progression-free survival (PFS) and treatment-free survival (TFS) were 17.2 and 32.3 months, respectively. A total of 47 pts (31%) received at least one further line of treatment. Median overall survival (OS) was 48.3 months, with adverse events (22%) and progressive CLL (16%) being the most frequent causes of death. Standardized mortality ratio was calculated and showed a 1.99 (CI 1.54-2.53) increased risk of death as compared to an age- and sex-matched general population. Independent prognostic factors for OS were 17p deletion and elevated serum thymidine kinase.

Figure 1.

Summary/Conclusions: Findings suggest that antileukemic therapy (including chemoimmunotherapy) is feasible and efficacious in ≥ 80 year old pts with CLL. However, such pts are still highly underrepresented in clinical trials and even with modern treatment live shorter than age-matched controls of the general population. Broader recruitment of these pts to prospective trials and evaluation of targeted therapies therefore appears imperative to improve outcome of CLL in this age segment.

E1026 THE ROLE OF CD200 IN THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA A. Mora1,2, E. P. Vicente1,2, C. Cuellar1,2, R. Bosch1,2, L. Bianco3, R. Martin3, J. M. Ubeda4, J. Sierra3, C. Moreno1,2, J. Normo1,2
1Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, 2Department of Hematology, 3Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Background: Clinical, morphologic, immunophenotypic and genetic features are the basis for the diagnosis of B-cell malignancies. It is considered that the diagnosis of CLL requires the presence in peripheral blood of >5x10⁹/L monoclonal B lymphocytes with a distinctive immunophenotype (i.e. SmIgweak, CD5+, CD4+, CD19-, CD23+). Based on immunophenotypic characteristics, Matutes et al devised in 1994 a immunophenotypic score based on a few markers (CD5+, CD23+, FMC7, SmIgweak and CD22weak) each one of them receiving a score of 1 if present or 0 if absent. A total score of 4 or 5 is typical of CLL whereas those cases scoring 0 or 1 correspond to other B-cell malignancies, mostly lymphomas. Nevertheless, clinical and immunophenotypic features of CLL may overlap with other B-cell malignancies. CD200 has emerged as a marker potentially useful to distinguish CLL from other CD5+B-cell malignancies.

Aims: The aim of this study was to analyze whether the addition of CD200 to the Matutes score improves the diagnostic accuracy of CLL.

Methods: We prospectively assessed the immunophenotype of 99 peripheral blood samples of patients with suspected lymphoproliferative disorders between November of 2015 and January of 2017. Immunophenotyping was performed using a Canto Flow Cytometer (Becton Dickinson) and samples were stained with routine combinations plus CD200. The Matutes Score was calculated as follows: FMC7, CD22 and CD79b were considered score 1 in CLL, while the positive cells were <30%, CD5 and CD23 were considered score 1 when the positive cells were ≥30%. The cut-off used for CD200 was calculated by Receiver Operating Characteristics (ROC). CD200 was scored as 1 when the positive cells were >96%. Mean Fluorescence Intensity Ratio

Madrid, Spain, June 22 – 25, 2017

haematologica | 2017; 102(s2) | 421
E1027
ABNORMAL SERUM FREE LIGHT CHAINS RATIO ASSESSMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A YET EVEN MORE POWERFUL TEST CORRELATING WITH CLINICAL OUTCOME AND MINIMAL RESIDUAL DISEASE

P. Dumeu1,2,*, M. Le Bouar1, F. Bijou2, A. Schmitt2, J. Blanchi1, G. Etienne2
1Laboratory of hematology, 2Hematology Department, Institut Bergonie, BORDEAUX, France

Background: An abnormal serum Free Light Chain (sFLC) ratio has been shown to be significantly associated with poor outcome in chronic lymphocytic leukemia (CLL). Using the free kappa and lambda chains levels defined as within the range of 3.3-14.9mg/L and lambda chain level within the range of 5.7-26.30mg/L, a normal sFLC kappa/lambda (K/L) ratio was therefore defined as between 0.26 and 1.65 (a ratio above 1.65 indicating an excess of kappa light chain, and a ratio below 0.26 indicating an excess of lambda light chain). The cumulative level of kappa plus lambda (K+L) was also evaluated. Most patients received combined chemo-immunotherapy or entered clinical trials whenever possible. The ROC methodology was used to establish the best cut-off value of sFLC ratio level to discriminate treated patients from those who remained treatment-free.

Methods: Diagnosis was confirmed by 10-color FCM immunophenotyping of blood lymphocytes on a Navios (Beckman Coulter). Serum FLC kappa and lambda chains were measured by nephelometry using the Freelite immunosay. The normal free kappa chains level was defined as within the range of 3.3-14.9mg/L, and the normal lambda chains level within the range of 5.71-26.30mg/L. A normal sFLC kappa/lambda (K/L) ratio was therefore defined as between 0.26 and 1.65 (a ratio above 1.65 indicating an excess of kappa light chain, and a ratio below 0.26 indicating an excess of lambda light chain). The cumulative level of kappa plus lambda (K+L) was also evaluated. Most patients received combined chemo-immunotherapy or entered clinical trials whenever possible. The ROC methodology was used to establish the best cut-off value of sFLC ratio level to discriminate treated patients from those who remained treatment-free.

Results: Main patients characteristics are detailed [N=147, M/F:75/72, 111 in early stage disease, Del 17p in 11 patients and Del11q in 15]. Median age was
69 years (range 34 to 86). Ninety patients were untreated during the follow-up period. Median follow-up duration was 30 months (range 0 to 101). Furthermore, sFLC measurement was assessed in 57 patients who progressed during the study and required treatment according to international guidelines. ROC curve analysis determines cut-off level of K/L ratio at 1.88. Abnormal sFLC was observed at diagnosis in 50.9% (N=29) of all treated patients. The mean ± SD ratio of sFLC in untreated patients group and in the treated patients group was 1.51±2.08 and 2.80±3.75 respectively (p=0.0082). Considering the sFLC levels (kappa + lambda), the mean±SD in the untreated patients group and in the treated patients group was 29.1±17 and 53.0±19.1 respectively (p<0.0001).

Treatment systematically induced a modification of the sFLC K/L ratio. Interestingly, the level of K/L ratio, the finding of an abnormal sFLC K/L ratio was associated with positive MRD determined by FCM with a 82% specificity and a 95% positive predictive value. Moreover, median time to treatment income for patients in early stage disease with ratio >1.88 was 12 months while it is not reached in those with ratio ≤1.88 (p<0.0001) (figure 1).

Summary/Conclusions: In this study, we observed the value of sFLC K/L ratio determination as a technically simple, standardized and cost-effective test to improve risk stratification of patients with low risk CLL at diagnosis, at the end of the treatment and during follow-up. Determination of the sFLC K/L ratio during the follow-up of treated patients provides additional information regarding the response to therapy in patients with an abnormal K/L ratio. In this study, persistence of an abnormal sFLC K/L ratio after treatment was strongly associated with positive MRD and could serve as a predictive as well as a prognostic biomarker for residual disease detection and clinical outcome.

E1029

PLATELET FUNCTION ASSAYS FOR STRATIFICATION OF BLEEDING RISKS IN CLL PATIENTS ON IBRUTINIB TREATMENT

E. Nikitin1, E. Dmitrieva1, A. Ignatov2, A. Poletava3, D. Polchokov3, A. Fedotov2, E. Seregina2, A. Pshonkin2, M. Panteleev2, V. Ptushkin3
1Outpatient department for hematology oncology and chemotherapy, S.P.Botkin hospital, 2Molecular hemostasis laboratory, National Scientific and Practical Center of Pediatrichemistry, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russian Federation

Background: Ibrutinib therapy in chronic lymphocytic leukemia (CLL) is associated with frequent bleeding complications, explained by inhibition of BTK, which mediates downstream signaling of GPVI and GPIb receptors in platelets. Detailed characterization of platelet functional impairment can help predict and possibly prevent severe bleeding on ibrutinib. Here we investigate platelet functional activity in CLL patients before initiation of ibrutinib and at different time points during treatment.

Aims: A longitudinal study on the impact of ibrutinib on platelet function, severity and frequency of bleeding.

Methods: Forty-three patients with relapsed and refractory CLL and 10 healthy donors were included in the study. Platelet functional activity was characterized by flow cytometry before and after activation with SFLLRN plus collagen-related peptide. Levels of CD42b, CD61, CD62P, PAC1, annexin V binding, and mepacrine release were determined. Aggregation with collagen, ADP and ristocetin were measured. All tests were performed before initiation of treatment, at weeks 2, 4, 8 and at 6 months. Bleeding complications were scored using ITP-specific Bleeding Assessment Tool.

Results: Among 43 CLL patients, 29 (67%) were men, the median age was 65 (range 31 to 83 years). Four patients with del(17p) received ibrutinib as a first line. In 39 previously treated patients the median number of prior treatments was 3 (range, 1-6). Del17p or TP53 mutation was found in 11 (25%) patients. Only 1 patient received anticoagulant and antiplatelet drugs. Median duration of ibrutinib treatment was 8.2 months (range 2.2-10.9). At least one bleeding episode occurred in 23 patients (53%). Among patients with bleeding, 14 (61%) had grade 1, 7 (30%) had grade 2 and two (9%) had grade 3 events. Bleeding frequency decreased with time on ibrutinib; only 4 patients still had bleeding complications after 6 months. The patients with bleeding had significantly lower mean platelet count that those without (120 versus 170 thousands per microliter, P<0.0001) and higher lymphocytosis (74 ±25, P<0.005). Their activation of integrins in response to stimulation was generally impaired (9% versus 26%, P<0.001; while the 95% confidence interval for healthy controls 63-137%), and there was a significant difference in GPVI activity as well (2% versus 18%, 5%, P<0.01; normal range is 7-35%). Importantly, the integrin activation allowed risk stratification: a person with more than 9% integrin activation had less than 10% risk to develop bleeding while the one with less than 9% integrin activation had a risk of more than 40%. There was no difference in dense- or alpha-granule release between the patient groups, and these integrins remained in their normal ranges. There were also significant differences in aggregation assays with ADP (25±16% versus 36±18% for bleeding and non-bleeding patients, P<0.001), collagen (38±19% versus 53±20%, P<0.001), and ristocetin (53±52% versus 62±20%, P=0.02). Interestingly, the patients with bleeding had negative correlation with ibrutinib aggregation with SFLLRN plus collagen level.

Summary/Conclusions: Both classic aggregation assays and flow-cytometry-based techniques demonstrate impaired platelet function in the bleeding CLL patients compared with non-bleeding ones. The level of integrin activation appears to be the most sensitive and able to identify patients with different bleeding risks.

E1030

HYPOGAMMAGLOBULINEMIA IS A STRONG PREDICTOR OF TIME TO FIRST TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

G. Reda1, R. Cassan1, G. V. Levati1, B. Fattizzo2, V. Mattiello2, D. Giannarelli3, W. Barcelli1, A. Cortezzetti4
1Oncohematology Department, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Italy, 2Oncohematology Department, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Italy, 3Regina Elena National Cancer Institute, Rome, Rome, Italy

Background: Management of chronic lymphocytic leukemia (CLL) dramatically improved since the introduction of novel therapies. Rarely patients require treatment at diagnosis and approximately a third of patients will never require therapy. Predictive and prognostic factors are well known (IGHV, del11q, del17p, TP53); CLL-IPI score including age, clinical stage, beta2microglobulin, IGHV and deletion 17p and/or TP53 mutation has been recently validated. It identifies 4 risk groups with significantly different time to first treatment (TTFT) and overall survival (OS). Hyoglobulinemia (HYPO) is a typical feature of CLL, with an incidence of 20-60% at diagnosis and a relationship with infections occurrence. Prognostic significance of HYPO at diagnosis has not been extensively evaluated in terms of OS and TTFT. Only IgG serum levels have been reported to be associated with TTFT but no data are available on other immunoglobulin classes (Ig).

Aims: To evaluate the impact of HYPO and single Ig classes on TTFT in a retrospective cohort of CLL patients and to assess the relationship between HYPO and CLL-IPI.

Methods: We retrospectively evaluated 698 consecutive CLL patients diagnosed at our Institution from 1983 till 2016. Data from laboratory, biological analysis and clinical stage were collected. We also evaluated immunoglobulin levels (Ig) with ELISA, i.e. IgG, IgM and IgA at diagnosis and calculated CLL-IPI. HYPO was defined basing on our laboratory cut-offs (IgG 70mg/dl, IgG 700mg/dl, IgD 40mg/dl). However, as no recognized prognostic/predictive Ig cut-off has been reported to date, we aimed to identify a prognostic threshold for each Ig class.

Results: From 698 patients assessed, 410 cases were evaluable for Ig levels at diagnosis. IgA levels were lower than 70mg/dl in 17.4%, IgG lower than 700mg/dl in 22.2%, and IgM lower 40mg/dl in 33.7%. Forty-six percent of patients presented deficit of at least one Ig class, while 7.8% of patients had all Ig low. Each Ig deficit was related with a shorter TTFT with the following hazard ratios (HRs): 2.09 (1.45-3.03) for IgA (P<0.0001), 1.58 (1.10-2.27) for IgG (P=0.008) and 1.52 (1.09-2.13) for IgM (P=0.011) (Figure 1, A-B-C). However, only IgA deficit maintains statistical significance in multivariate analysis [HR 1.59 (1.08-2.35)]. A prognostic threshold for each Ig class was identified maximizing the differences in TTFT and the following values were obtained: 80mg/dl for IgA, 410mg/dl for IgG and 18mg/dl for IgM (Figure 1, D-E-F). Considering only 18 patients presented IPI 0-1, 99 had IPI 2-3, 32 patients IPI 4-6, and 12 patients had IPI 7-10. Even in our series, CLL-IPI separated four risk groups with different TTFT and OS, suggesting that our cohort may be suitable to evaluate new prognostic factors. As regards the relationship between HYPO and CLL-IPI, we observed a correlation with IgA levels, using our laboratory cut-off. Moreover, we found a relationship among CLL-IPI and both IgG and IgM values, when using the newly validated Ig cut-off. Finally, CLL-IPI was a stronger prognostic factor for TTFT than HYPO in our analysis. However, the addition of IgA deficit to CLL-IPI appears to further improve CLL prognostication.

Figure 1. Conclusion: In conclusion, HYPO significantly impacts on CLL prognosis. Moreover, even if CLL-IPI has a stronger prognostic value for TTFT compared to HYPO, the addition of IgA deficit appears to further improve CLL prognostication.
E1031
CLL: IS LYMPHOCYTE DOUBLING TIME (LDT) A RELEVANT PROGNOSTIC PARAMETER IN THE ERA OF PROGNOSTIC BIOMARKERS?
T. Baumann1,*, J. Delgado1, P. Mozas1, V. Ortiz-Maldonado1, R. Santacruz2, M. Aymerich3, M. Ayméreich3, N. Villamor3, D. Costa4, A. Carrizo5, E. Montserrat1
1Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain, 2Hematology Department, Hospital de Clinicas, Asunción, Paraguay, 3Hematopathology Unit, Pathology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Background: In CLL, tumor doubling time is reflected by the pace at which lymphocytes increase in blood (lymphocyte doubling time or LDT). However, since LDT is rarely available at the time of diagnosis, its role in assessing prognosis in patients in CLL is controversial.

Aims: To reassess the prognostic significance of LDT in a large series of patients.

Methods: Retrospective single-center study based on 629 patients diagnosed with CLL/SLL. LDT was measured at the time of diagnosis if prior WBC counts were available or calculated after diagnosis by linear regression analysis, usually over a treatment-free period of 2 months and including at least three WBC counts.

Results: 140 patients displayed short LDT (≤12 months) and 489 long LDT (>12 months). The median follow-up was 13.4 years (6.1-22.5) and 11.2 years (2.3-30.9), respectively. Patients with short LDT were younger (p<0.005), had higher clinical stage (p<0.001), higher aaLC (p<0.001), as well as increased serum LDH (p<0.001) and B2-microglobulin (B2M; p=0.035) levels and also a tendency towards lower levels of Hb and platelet counts. A short LDT was also associated with an increased expression of ZAP70 and CD38, unmutated IGHV (all p<0.001) and poor FISH cytogenetics (del17p, del11q) (p<0.001). Additionally, patients with a short LDT presented more frequently mutations in NOTCH1 (p=0.008), ATM (p=0.029), TP53 (p=0.035) and a tendency to more mutations in SF3B1 (p=0.102). The proportion of patients treated in each group was markedly different [80% vs 46%] as it was the median time to treatment (TTT, 1.4 vs 9.4 years; p<0.001). Type of treatment (mainly, chemotherapy) in both groups did not differ significantly. Patients with short LDT were treated with more frequent alkylating agents rather than purine analogues and there was no significant differences in response rates (ORR 59% with 29% CR vs 69% with 29% CR; p=0.235). Overall survival (OS) was shorter in the group with short LDT (median: 7.2 vs 12.2 years; p<0.001). Univariate analysis demonstrated a significant correlation between OS and advanced clinical stage, age >70 years (p=0.001), increased B2M and LDH (p=0.001), short LDT (p<0.001), as well as increased expression of ZAP70 and CD38, unmutated IGHV, and high-risk FISH genetics (del17p, del11q) (all p<0.001). Likewise, mutations in NOTCH1 (p<0.001), SF3B1 (p=0.027), ATM (p=0.028) and TP53 (p=0.001) were associated with OS. In a multivariate analysis including clinical stage, age, LDT, IGHV, ZAP70, FISH cytogenetics and TP53, short LDT was an independent adverse prognostic factor for OS (HR 7.0 (95% CI: 3.2-16.6), p<0.001), after adjusting for age (HR 4.6 (95% CI: 2.3-8.6), p<0.001), high-risk FISH (HR 2.2 (95% CI: 1.3-3.6), p=0.003), unmutated IGHV (HR 2.4 (95% CI: 1.5-4.0), p<0.001), and presence of TP53 mutation (HR 2.0 (95% CI: 1.0-3.9), p=0.041).

Summary/Conclusions: This study shows that LDT continues being an independent prognostic parameter for OS in the era of biomarkers. In contrast, LDT did not correlate with response to therapy and, accordingly, cannot be regarded as a response predictor to chemo/immuno therapy. Finally, LDT warrants investigation in the setting of novel therapies.

E1032
INDICATIONS FOR TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICO-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT
P. Mozas1,2,*, R. Ortiz-Delgado1, T. Baumann1, V. Ortiz-Maldonado1, A. Navarro1, D. Costa1, M. Aymerich3, N. Villamor3, E. Montserrat1, J. Delgado1
1Hematology, 2Pathology, 3Hematopathology Unit, Pathology, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

Background: Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of monoclonal CD5+ B cells in the bone marrow and lymphoid tissues. International guidelines recommend initiation of treatment only in case of infiltrative cytopenia, progressive splenomegaly or lymphadenopathy, short lymphocyte doubling time (LDT), B symptoms and/or refractory unmutated IGHV (IC). These criteria are based on experts’ consensus and considered equally relevant for treatment initiation, even though little evidence exists concerning the relative value of each individual criterion.

Aims: To describe the clinico-biological characteristics and prognosis of CLL patients according to the criteria that prompted the initiation of first-line treatment.

Methods: Patients newly identified were consecutively included in a CLL registry. A total of 220 consecutive patients with CLL who received first-line therapy from 1978 to 2014 and had their indication(s) for treatment (ITT) recorded. Massive/progressive lymphadenopathy and massive/progressive splenomegaly were grouped together as lymphoid mass (LM). Infiltrative anemia and thrombocytopenia were categorized as marrow failure (MF). As 505 patients initiated therapy with novel agents, we decided to focus on these two groups. Patients whose ITT was both LM and MF were classified as MF following the logic behind Rai and Binet staging systems.

Results: Median age of the whole cohort was 62 years (range 22-93), and 63% of patients were male. Median follow-up from first-line therapy was 64 months (range 1-443). Half of the patients had a single ITT, while the other half had two or more. ITT were LM in 72% patients, MF in 31%, short LDT in 29%, B symptoms in 19%, and IC in 3%. Compared to patients from the LM group, patients from the MF group were significantly older, had a significantly higher β2-microglobulin level (probably due to an age-related impaired renal function), and were more frequent treated due to refractory immune cytopenia (IC). These criteria are based on experts’ consensus and considered equally relevant for treatment initiation, even though little evidence exists concerning the relative value of each individual criterion.
Methods: We reviewed all CLL samples that were submitted for the investigation of TP53-deletion through FISH, in our Lab, between January 1st 2011 and February 28th 2017. Results obtained on tests performed on whole mixed cellular samples were compared with results obtained directly in FACS purified CLL clonal lymphocytes.

Results: We analyzed 410 samples tested for the deletion of TP53 in our Lab during the study period. The majority of patients (63.2%) were male. Although FACS separation of neoplastic cells was only introduced within the last two years of the study period, it accounted for 39.0% of all tested samples. This poor prognostic aberration was identified in 15.8% of patients in the overall cohort, with no differences in the incidence of a positive finding between mixed cellular samples and FACS purified samples (15.6% vs 16.2%, respectively, p=NS). In contrast, the average proportion of positive cells within a positive sample was markedly different between mixed cellular samples and FACS-processed samples, increasing nearly three-fold through the purification of the sample, from 24.0±15.9% to 62.9±33.3%, p<0.001. In fact, in 57.7% of all patients who were tested after FACS separation of CLL cells, the TP53-deleted clone was larger than 50% of neoplastic cellular lymphocytes, making it the primary clone.

Summary/Conclusions: We observed that the pre-processing of the sample through the FACS-supported purification of CLL neoplastic lymphocytes revealed that the TP53-deleted clone was nearly three-fold larger than suggested by the mixed cellular sample, increasing from an average of a quarter of all cells, to nearly two-thirds. This finding uncovered that the TP53-clone was, in fact, the primary major clone within the neoplastic lymphocyte population in the majority of patients. Considering the poor prognosis conferred by the aberration, and its impact on current treatment decisions, it is quite significant to correctly identify a primary deletion-positive clone, instead of mislabeling it as a secondary minor clone.

E1034

PRIMARY PEGFILGRASTIM PROPHYLAXIS VERSUS FILGRASTIM GIVEN "ON DEMAND" FOR CLADRIBINE - INDUCED NEUTROPENIA IN HAIR CELL LEUKEMIA

1Department of Pediatrics, Sourasky Medical Center, Tel Aviv, 2Department of Hematology, Sackler School of Medicine, Tel Aviv, 3Department of Hematology, Hadassah University Hospital, Jerusalem, 4Department of Hematology, Rabin Medical Center, Petah-Tikva, 5Department of Hematology, Meir Medical Center, Kfar-Saba, 6Hematology Unit, Kaplan Medical Center, Rehovot, 7Department of Hematology & Bone Marrow Transplantation, Ramah Health Care Campus, Haifa, 8Hematology Unit, Mezmek Medical Center, Afula, 9Department of Hematology, Shaare Zedek Medical Center, Jerusalem, 10Hematology Unit, Galilee Medical Center, Naharia, 11Hematology Unit, Ziv Medical Center, Zefat, 12Department of Hematology, Soroka Medical Center, Beer-Sheva, 13Department of Hematology, Hadassah University Hospital, Jerusalem, 14Hematology Unit, Bnei-Zion Medical Center, Haifa, Israel

Background: Major advances in the treatment of patients with HCL were made in the 1980’s after the introduction of two purine analogues: pentostatin and cladribine. Both these agents dramatically altered the clinical course and outcome of this disease and induced high response rates of 75-90%, with durable remissions and subsequent median relapse-free survival of up to 15 years. The major significant short-term toxicity of therapy with cladribine are neutropenia and neutropenic fever (NF). Based on the script data: 71% of patients experienced grade 4 neutropenia (absolute neutrophil count [ANC] <500x10^9/L), and 42% develop NF. The latter complications may result in life-threatening infec-
tions, as well as hospitalization.

Aims: In this retrospective study, we compared the incidence and duration of neutropenia, NF and hospitalization in patients with HCL treated with cladribine follow-on filgrastim as primary prophylaxis versus daily filgrastim given "on demand" according to the absolute neutrophil count.

Methods: The study population included 202 patients with HCL, diagnosed and followed in 12 medical centers in Israel during 1985-2015. Patients were treated with cladribine, for 5–7 days given either sub-cutaneously or via intravenous infusion. Medical records were evaluated for details of disease at diagnosis, including date of diagnosis, age, sex, ethnicity, complete blood count results, and spleen size at diagnosis. The efficacy of pegfilgrastim and filgrastim was assessed by evaluating the incidence of neutropenia (defined as ANC <1000x10^9/L), number and length of hospitalizations due to NF, severity of infections and the number of days from the last day of therapy until recovery of ANC to >1000x10^9/L.

Results: Mean follow up was 7.5 years (0.1-40), with 5 and 10 years’ survival of 96% and 90.62% respectively. The median age at diagnosis was 53 years, and 81.8% were males. First line therapy with cladribine was given to 159 patients, whereas 43 of these 50.3% required hospitalization for the administration of broad-spectrum antibiotics due to NF. The risk factor to develop NF was WBC< 0.6 10^9/L, and ANC<0.310^9/L. Twenty eight patients were treated with pegfilgrastim as primary prophylaxis 24 hours after the last day of therapy with cladribine, while 75 patients received filgrastim "on demand" due to neutropenia. Median hospitalization days, and Nadir duration was 8 and 18 days respectively in both groups (p=0.71, p=0.44).

Table 1.

Summary/Conclusions: Infectious complications post cladribine treatment, remains high, with an incidence of 50.3%. For all parameters analyzed, including the percentage of febrile patients, number of febrile days, and NADIR duration the results of primary pegfilgrastim prophylaxis and filgrastim given on demand were similar. Accordingly, we conclude that it remains the treating physician’s choice to decide on which type of filgrastim to use and when to administer it.

E1035

REDUCED HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ACHIEVING COMPLETE REMISSION TO FIRST-LINE THERAPY

S. Heitner1, J. Samp1, A. Guerin2, R. Foster3, B. Meissner1, A. Rokito1, G. Gauthier2
1AbbVie, Inc., North Chicago, United States, 2Analysis Group, Inc., Montreal, Canada, 3Analysis Group, Inc., New York, United States

Background: Most targeted therapies in the management of chronic lympho-
cyte leukemia (CLL) lead to high overall response rates but complete remis-
sions are rare. Achieving complete remission (CR) is associated with improved clinical outcomes such as longer time to progression; however little is known about the economic benefits associated with achieving CR.

Aims: The objective of the study was to compare healthcare resource utilization among CLL patients initiated on first-line treatment who achieved CR versus those who did not.

Methods: This was a retrospective chart review study. From July to August 2016, 93 US oncologists/hematologists provided data abstracted from medical charts of their CLL patients who initiated a first-line CLL treatment between January 2010 and December 2014. The study collected patient demographics, clinical characteristics, response to first-line therapy, and the number of all-cause hospitalizations between first-line therapy initiation and end of the data follow-up (i.e., patient’s date of death, end of care, or data collection date, whichever occurred first). Patients were selected based on their best response to first-line therapy (i.e., CR, partial remission [PR], stable disease [SD] and progressive disease [PD]) as defined by the physician according to iwCLL 2008 criteria. The targeted number of patients in each category was a priori deter-
minal based on rates of response observed in clinical trials. The incidence of all-cause hospitalization was compared between patients who achieved CR and those who did not (including patients with PR, SD or PD) using univariate and multivariate generalized linear models with a Poisson distribution. As patients had different follow-up, incidence rates were reported per-patient-per-month (PPPM). Multivariate regression models were adjusted for age, gender, selected comorbid conditions, time from CLL diagnosis to first-line initiation, and Eastern Cooperative Oncology Group (ECOG) status.

Table 1.
**Aims:** To report our experience concerning the use of R as a treatment of AIHA occurring during the clinical course of treatment naïve CLL pts by analyzing concomitantly its efficacy and safety as a single agent in CLL therapy

**Methods:** 15 pts diagnosed with CLL who received R due to AIHA were included in this study. Staging was performed at diagnosis (Binet system). Pts were placed on R at the standard dose I.V of 375mg/m2 once weekly for 6 consecutive weeks because of contraindication of corticosteroids administration

**Results:** Pts’ median age was 60 y(range, 42-83 y), (8 out of 15, males), 10 having disease stage A and 5 B. Two were presented with splenomegaly and 1 with B-symptoms. 12 pts (83%) had leukemic lymphocyte counts of more than 50x10^9/L. Median time from diagnosis, the AIHA diagnosis and to 1st R infusion was 59 mos. All 15 pts completed the 6-week course of R and were assessable for response. The median WBC and the median absolute lymphocyte count(ALC) before R administration and after the end of 6-week course are shown in the Table. Resolution of the AIHA effect was achieved in all pts whereas in 4 there was a persistence of positive DAT without evidence of active hemolysis. After the median of 1st R infusion 11 of them were in complete remission (CR). The remaining 4 pts were in partial remission (PR) and 2 had stable disease. 6 pts experienced PR (80%) and 1 CR (6%). All pts with advanced disease also responded entering PR. Resolution of splenomegaly was documented in both spleenomegalic pts. After a median follow up of 84, 5 mos from CLL diagnosis, 14 pts are alive, 9 maintain their disease response while 5 were in need of therapy due to CLL progression, after a median time of 10 mos from the last R infusion. Among them 4 were placed on FCR (2CR, 2PR) and 1 on R-Bendamustine(PR). Median PFS has not reached. All pts received the entire first dose on day 1 of treatment. There was only a grade 3 infusion related reaction in a patient with WBC>400x10^9/L without need for hospitalization. None of the pts experienced severe tumor lysis syndrome, pulmonary insufficiency, myelosuppression or opportunistic infections.
E1038
APPLICATION OF THE CLL-IPI AND THE MDACC PROGNOSTIC INDEXES IN A LOCAL COHORT OF CLL PATIENTS
I. González-Gascón Y Marín1,1, M. Pozo1, M. Hernández-Sánchez2, A.E. Rodríguez-Vicente2, M.S. Infante1, C.C. Muñoz Novas1, C. Heras1, M.A. Foncillas1, J.M. Hernández-Rivas2, J.A. Hernández1
1Hospital Universitario Infanta Leonor, MADRID, 2IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain

Background: New prognostic scores have been developed in order to better discriminate the clinical course of CLL patients, along with Rai and Binet clinical staging systems. These scores, such as that proposed by the MDACC group, and recently the CLL-IPI combine clinical and biological variables with prognostic value.

Aims: In this study we investigated the validity and reproducibility of these scores in a local cohort of patients with CLL.

Methods: We made a retrospective analysis including 650 unselected CLL patients newly diagnosed and previously untreated from a single institution. The final analysis has been limited to the 486 cases with complete data to apply the MDACC score, and to the 258 cases with complete data to apply the CLL-IPI score.

Results: Median age was 67 years old (25-90). With a median follow-up time of 46 months, 394 patients were alive, and 187 had received any treatment for CLL at the moment of the analysis. Median overall survival (OS) of the whole series was 173 months (127-220), and median time to first treatment (TTF) 106 months (82-130). The MDACC score was applied to 486 cases giving 0 to 9 points to each case according to: age, b2-microglobulin levels, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups. As shown in the Table, stratification of patients using the MDACC score allowed the prediction of prognosis for both TTF (P<0.000) and OS (P=0.000). 162 patients were classified as low risk, 302 as intermediate risk, and 21 as high risk. Due to missing data, the CLL-IPI score could only be applied to 258 patients giving 0 to 10 points to each case according to 17p deletion, IGHV mutational status, b2-microglobulin, clinical stage, and age. As shown in the table, 126 patients were classified as low risk, 79 as intermediate risk, 46 as high risk, and 7 as very high risk. We also found significant differences in terms of OS (P=0.000) and TTF (P=0.000) using this score.

Table 1.

Summary/Conclusions: In this study we confirm that both scoring systems are able to discriminate patients in different prognosis subgroups. Both scores are also easily applicable in clinical practice. The new CLL-IPI score is able to distinguish subgroups of patients with worse prognosis including new factors (17p deletion and mutational status of IGHV).

E1039
CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC VALUE OF CLINICAL STAGES AND CLASSICAL PROGNOSTIC PARAMETERS DEPENDING ON TREATMENT MODALITY
T. Baumann1,1, J. Delgado1, P. Mozas1, V. Ortiz-Maldonado1, R. Santacruz2, M. Rozman3, M. Aymerich1, N. Villamor1, D. Costa1, A. Carnio3, E. Montserrat1, A. Carrió3
1Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain, 2Hematology Department, Hospital de Clínicas, Asunción, Paraguay, 3Hematopathology Unit, Pathology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

Background: Prognostic is a key component in the management of patients with chronic lymphocytic leukemia (CLL). Prognostic factors however may change as a result of the introduction of more effective therapies. Aims: To investigate whether the prognostic value of classical parameters has changed over time.

Methods: Retrospective single-center study of prognostic factors and outcome in patients with CLL diagnosed before (n=454) and after (n=903) 1995 when purine analogs and subsequently chemoimmunotherapy (CIT) were introduced in CLL treatment at the Hospital Clínic, Barcelona.

Results: The median follow-up up was 8.3 years (0.1-33.0) for the overall series and 24.9 years (21.9-33.0) and 7.8 years (0.1-21.3) for patients diagnosed before and after 1995, respectively. Patients diagnosed before 1995 were older (P<0.001), had more advanced clinical stage (P<0.001), higher ALC vs. normal (P=0.001), shorter LDT (P<0.001), and more often anemia (P<0.001) and neutropenia (P=0.001). The introduction of therapy for patients diagnosed before and after 1995 was: alkylating agents (91% vs 34%), purine analogs (4% vs 27%), CIT (0% vs 31%), other (5% vs 8%) (P<0.001). The proportion of patients receiving treatment did not differ between groups (42% vs 46% (42-49%) at 6 years; P=0.08). The type of therapy given to patients diagnosed before and after 1995 was: alkylating agents (91% vs 34%), purine analogs (4% vs 27%), CIT (0% vs 31%), other (5% vs 8%) (P<0.001). The proportion of patients receiving treatment did not differ between groups (42% vs 46% (42-49%) at 6 years; P=0.08). The type of therapy given to patients diagnosed before and after 1995 was: alkylating agents (91% vs 34%), purine analogs (4% vs 27%), CIT (0% vs 31%), other (5% vs 8%) (P<0.001). The proportion of patients receiving treatment did not differ between groups (42% vs 46% (42-49%) at 6 years; P=0.08).
patients (27.4%). Overall, 80.3% of FAS patients did not experience therapeutic failure and 85.9% did not experience disease progression during the 2-year observation period. By the end of the study, median PFS had not been reached; 2-year PFS rate was estimated as 85.9%. Improvements from baseline were observed after 6 cycles of treatment across all EQ-5D domains. No relapses or deaths occurred in the FAS; however, 2 subjects in the Safety Population experienced fatal serious ADRs (myocardial infarction [n=1]; acute pneumonia, infections and toxic shock, and atrial fibrillation [n=1]). In concurrence with the Phase 3 trial results, hematologic disorders (19.9%; anemia, neutropenia, thrombocytopenia), most of which were Grade ≤2 in severity, were the most common ADRs (Safety Population; Table 1).

Table 1. Hematologic ADRs by CTCAE Grade.

<table>
<thead>
<tr>
<th>Hematologic ADR</th>
<th>Grade 1 (%)</th>
<th>Grade 2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>49.5</td>
<td>6.9</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>27.7</td>
<td>15.5</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>2.3</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Summary/Conclusions: First-line therapy with bendamustine plus rituximab was well tolerated in this Russian CLL population, including elderly patients and patients with renal dysfunction or other comorbidities. Additionally, combination therapy resulted in high rates of treatment response in the CLL. These data confirm the value of bendamustine as a first-line agent for CLL in routine clinical practice in Russia.

Chronic myeloid leukemia - Biology

E1041

MUTAGENESIS OF BCR-ABL1 IS REQUIRED FOR RESISTANCE DEVELOPMENT IN DE NOVO CHRONIC MYELOID LEUKEMIA KCL-22 CELLS BUT NOT IN RELAPSED KCL-22 CELLS EXPRESSING BCR-ABL1 INDEPENDENT RESISTANCE

N. Cunì1,2, V. Polikova1,3, T. Kalina4, V. Kanderová4, J. Linhartova1, F. Savuljdić, O. Tomáš1, K. Strutová1, S. Ransdorfova1, J. Brezinová1, H. Klamaová1,5, K. Machova Polakova1,5,*

1Institute of Hematology and Blood Transfusion, 2Institute of Pathological Physiology, First Medical faculty, Charles university, 3Faculty of Science, Charles University, 4Department of Paediatric Haematology and Oncology, Univ. hospital Motol, 5Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University and Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Background: BCR-ABL1 kinase domain (KD) mutations are an important mechanism of resistance of chronic myeloid leukemia (CML) patients developing during the tyrosine kinase inhibitors (TKI) treatment. However, mechanisms underlying KD mutation acquisition in TKI-resistant CML cells are not yet well understood.

Aims: We studied an acquisition of mutations in the KD after an exposure of de novo and relapsed (grown in optimal growing medium for 24 months) KCL-22 cells to imatinib (IM). In addition, we examined kinetics of mutated sub-clones in established IM-resistant KCL-22R culture after dose-reduction of IM. We also studied changes in the expression profile of KCL-22 cultures early after exposure to IM.

Methods: The occurrence and kinetics of expansion of BCR-ABL1 mutant sub-clones were studied using next-generation deep sequencing in KCL-22 cells treated with 0.4 µM IM and in established IM-resistant KCL-22R cells at 4 µM IM. In other set of experiments, KCL-22R cells were sorted according to the CD38 expression and CD38 expression then analyzed by a method of BCR-ABL1 mutations as suggested by Wang et al. (2014). A protein array was used allowing analysis of 576 proteins per sample. DNA damage pathway-RT Profiler PCR arrays were applied for gene expression analysis.

Results: No BCR-ABL1 KD mutations were detected in de novo untreated KCL-22 cells, however T315I and E255K appeared after the exposure of the cells to 0.4 µM IM. PCR array revealed increased expression of SUMO 1 ligase and ERCC2 involved in the nucleotide excision repair pathway. Notably, we also found a significant decrease of G2/M-checkpoint protein GADD45A whose deficiency is associated with mutagenesis (Holland et al., 2001). During the first culture period, T315I slowly emerged whereas E255K was not detectable. Later, E255K-bearing cells also became detectable and increased over time. A similar time-dependent expansion of mutant-bearing sub-clones was seen in the KCL-22R cells growing at 4 µM IM. Interestingly, a mutant-clone switch from T315I to E255K in KCL-22R was accelerated after IM reduction from 4 µM to 1 or 2 µM. Moreover, the emerging of E255K sub-clones was accompanied by rapid decrease of CD38 expression in KCL-22R cells. Profiling of transitional KCL-22R culture, carrying both T315I and E255K sub-clones, revealed that T315I transcripts were expressed only in the CD38+ sub-population, while E255K was detected only in CD38- cells. Unlike to de novo KCL-22 cells, BCR-ABL1 mutations were repeatedly not detected in relapsed KCL-22 cells at follow-up of 60 days after the cells exposure to 0.4 µM IM. Neither BCR-ABL1 upregulation nor gene amplification was detected in these cells. We identified considerably upregulated (D7, DTX3, ETV6, GLUL, HCLS1, HIF1a, IGFI1R, MAP2K7, MYH11, TPS3) or downregulated (BAD, BID, MCL2 NOTCH3, PDKPK1) proteins early, 4 weeks after the exposure to IM. Increased expressions of HIF1a and IGFI1R proteins are known to ensure proliferation, while decreased expressions of pro-apoptotic proteins BAD and BID enhance survival of CML cells in the presence of TKIs.

Summary/Conclusions: Our observation suggests the ability of KCL-22 cells to survive and proliferate early after the exposure to IM. BCR-ABL1 mutations development seems to be related to a mutagenesis of imatinib on de novo KCL-22 cells, but not on relapsed KCL-22 cells that activated signaling pathways ensuring their survival and growing in the presence of tyrosine kinases inhibitor.

Supported by the project no. 00023736 and AZV 15-31540A of MZCR and ERDF OPPK CZ.2.16/3.1.00/28007.

E1042

FLOW-CYTOMETRY DETECTION OF CD26+ LEUKEMIA STEM CELLS IN PERIPHERAL BLOOD: A SIMPLE AND RAPID NEW DIAGNOSTIC TOOL FOR CHRONIC MYELOID LEUKEMIA

D. Raspaodón1, S. Sirianí1, L. Aprile1,2, E. Abruzzese2, A. Iurlo3, A. Sicuranza1, S. Galimberti4, L. Schiattone1, A. Gozzini2, P. Pregno6, G. Caocci2, G. Papini1, I. Ferrigno1, B. Mecacci1, M. Bocchia1

1Clinical Hematology Faculty, Charles University and Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 2Department of Paediatric Haematology and Oncology, University hospital Motol, 3Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic; 4Medical School, University of Catania, Catania, Italy; 5Institute of Clinical and Experimental Hematology of the 1st Medical Faculty, Charles University, Prague, Czech Republic; 6Department of Medical Genetics, University of Catania, Catania, Italy.
Background: Diagnosis of Chronic Myeloid Leukemia (CML) implies documenting in bone marrow (BM) or in peripheral blood (PB) Philadelphia (Ph) chromosome by cytogenetics, molecular BCRL-ABL fusion by FISH or BCR-ABL1 rearrangement by RT-PCR. In clinical practice, at the earliest, 24-72 hrs are needed to confirm CML by any of these assays. Lately, characterization of CML leukemia stem cells (LSCs) from BM samples by flow cytometry of CML patients (pts) showed a specific co-expression of dipeptidylpeptidase IV (CD26) within the CD34+/CD38−/Lin− cell population. CD26 appeared a robust biomarker for identifying CML LSCs within the normal BM compartment. We recently demonstrated that CD34+/CD38+CD26+ LSCs can be easily identified by flow cytometry also in PB during treatment with tyrosine kinase inhibitors.

Aims: We investigated accuracy and specificity of flow cytometry PB CD34+/CD38+ CD26+ LSCs identification as a new tool for the diagnosis of CML.

Methods: Patients with clinical suspicion of CML entered the study after written informed consent and all were evaluated for CD26+ LSCs, cytogenetics, FISH and/or BCR-ABL1 RT-PCR analysis. CD34+/CD38+CD26+ population was investigated in PB and when possible simultaneously in BM samples using a flow-cytometry 4-color staining procedure. 2x10^6 leucocytes were incubated with BD Pharmingen CD45/500 (c.201), CD34/FITC (c.581), CD38/APC (c.HIT2), CD26 (c.M-A261) and negative controls. Acquisition and analysis of at least 1x10^6 CD45+ cells were done by FACSCanto II with DIVA 8 software (BD, Biosciences). CD26+ cells were identified by sequential gate. CD45+ and CD34+ gates were performed on viable cells identified by FSC/SSC light properties and CD34+/CD26+ population was gated applying a narrow gate excluding all CD38+ cells (Fig.1).

Results: PB samples from 107 pts with myeloproliferative disorders were evaluated for CD26+LSCs. Leucocytes median value was 52x10^9/L (range 5-408x10^9/L). In 83/107 (77.5%) pts we showed CD34+/CD38−/CD26+ LSCs in PB and in 83/83 (100%) the diagnosis of CML was confirmed by cytogenetics, FISH and/or BCR-ABL1 RT-PCR analysis. Median value of circulating PB CD26/LD was 14 (range 0.27-698) and a positive correlation with leukocyte count (p<0.01) was found. In 53/107 (49.5%) pts analysis was performed contextually in BM samples. All 206 PB-BM matched pairs (49/53) showed superimposable results in terms of absolute number of CD26+LSCs/LD (19.18 and 18.73 respectively) while the percentage of CD26+ cells within the CD34+/CD38−/Lin− population was lower in PB than in BM samples (median 28.18 and 37.33; range 0.87-77.14 and 5.95-59.97 respectively). In 24/107 (22.5%) PB samples and in 4/53 BM samples CD26+ LSCs were not detected and none of these samples was found Ph or BCR-ABL1 positive. Pts with CD26 neg PB/BM samples were subsequently diagnosed as Idiopathic Myelofibrosis (12 pts), Myelodysplastic/Myleo-proliferative disorders (7 pts) or benign neutrophilia (5 pts). Of note, we additionally studied 4 PB+BM samples of 4 Ph+ acute lymphoblastic leukemia and all scored negative for CD26+LSCs.

Summary/Conclusions: Flow-cytometry evaluation of PB CD34+/CD38−/CD26+ LSCs is a feasible, very rapid (about 3 hrs from sample handling to results) and highly specific alternative/complementary diagnostic tool for CML. To validate these data in a larger cohort of patients we are developing a pre-treated lyophilized antibody mixture (lytubte, BD Biosciences) to maximize sensitivity and to optimize standardization and working time, with the further aim to monitor stem cells minimal residual disease in CML patients.

E1043

LIPID PEROXIDATION AND INFLAMMATORY STATUS DURING TKI TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF A PROSPECTIVE MULTICENTER STUDY

A. Sicuranza1,*, L. Apri1, E. Abruzzese2, A. Irilo3, G. Galimberti4, A. Gozzini5, N. Sgherza6, L. Puccetti1, G. Papini1, D. Cattaneo3, A. Iurlo3, F. Di Raimondo7, G. Specchia8, U. Occhini9, R. Lemoli10, M. Breccia11, L. Luciano12, A. Bosi5, M. Petrini1, M. Bocchia1

1Hematology Unit, University of Siena, Siena, 2Hematology Unit, S. Eugenio Hospital, Roma, 3Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milano, 4Dept. Clinical and Experimental Medicine, Pisa, 5Hematology, University of Firenze, Firenze, 6Ematologia 2 A.O. Città della salute e della Scienza di Torino, Torino, 7Hematology Unit, Dept. of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, Cagliari, Italy

Aims: To validate these data in a larger cohort of patients we are developing a pre-treated lyophilized antibody mixture (lytubte, BD Biosciences) to maximize sensitivity and to optimize standardization and working time, with the further aim to monitor stem cells minimal residual disease in CML patients.

Methods: Flow cytometry of CML patients (pts) treated with some Tyrosine Kinase inhibitors (TKIs) prompted physicians to carefully evaluate CV risk factors (CVRFs) in the choice of TKI. However, the pathogenesis behind CV events during TKIs is not well known even in pts without overt CVRFs. In this prospective study we confirm the possible role of genetic predisposition and/or inflammatory status together with inflammatory status during nilotinib treatment, together with genetic pro-atherothrombotic profile. In particular, we investigated the role of CD34+CD38−/Lin− cell population within the BM compartment in pts with CML during treatment with low levels of IL10, which could induce a persistent pro-inflammatory/oxidative status potentially favoring atherothrombotic events. Additional biochemical and genetic data as well as prolonged clinical observation are needed to confirm this hypothesis. Patients enrolment and monitoring is ongoing.

Results: Enrolled pts were prospectively evaluated for: presence of traditional CVRFs, atherothrombotic episodes, presence of Single Nucleotide Polymorphisms (SNPs) associated to CV risk (Cardioklit) and plasma levels of several pro and anti-inflammatory cytokines. In this first interim analysis we focused on levels of LDL, oxidized-LDL (oxLDL), TNFα, IL-6 and IL-10 and the presence of SNPs of LDLR (rs1126608), LOX1 (rs3736225), and IL-10 (rs1800896) genes.

Summary/Conclusions: This interim analysis, although still very preliminary, suggests that in nilotinib patients the high levels of LDL and oxLDL in combination with low levels of IL10 could induce a persistent pro-inflammatory/oxidative status potentially favoring atherothrombotic events. Additional biochemical and genetic data as well as prolonged clinical observation are needed to confirm this hypothesis. Patients enrolment and monitoring is ongoing.

E1044

TRANSCRIBED ULTRACONSERVED NONCODING RNAS (T-UCRS) IN CHRONIC MYELOID LEUKEMIA: EXPRESSION PROFILES ASSOCIATED WITH MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS

P. Rodrigues Santos1,2,3,*, P. Abranches1,2,4, P. Couceiro2,3, J.R. Simplício2,3, J.S. Almeida2,3, V. Alves1,3, L. Ružičková5, P. Freitas-Tavares6, M. Santos-Rosa1,3

1Hematology Unit, University of Siena, Siena, 2Hematology Unit, S. Eugenio Hospital, Roma, 3UOC Onco-hematology, IRCCS Ca’ Granda Foundation-Ospedale Maggiore Policlinico, Milano, 4Hematology, University of Pisa, Pisa, 5Hematology, University of Genova, Genova, 6Hematology with Transplant, University of Bari, Bari, 7Hematology Unit, USL8, Arezzo, 8Clinic of Hematology, University of Genova, Genova, 9Hematology, Sapienza University, Roma, 10Hematology, University "Federico II", Napoli, Italy

Background: Evidences of increased cardiovascular (CV) events, mostly atherothrombotic, in Chronic Myeloid Leukemia (CML) patients (pts) treated with some Tyrosine Kinase inhibitors (TKIs) prompted physicians to carefully evaluate CV risk factors (CVRFs) in the choice of TKI. These data provided the rationale to start a multicentric “Prospective study of TKI induced pro-Atherothrombotic status in CML, KIARO study” (Grant support: AIRC-IT) including Chronic Phase CML pts treated with any first line approved TKI in which clinical, genetic and biochemical pro-atherothrombotic profiles were evaluated at diagnosis and during treatment.

Aims: This prospective study aims to confirm the possible role of genetic predisposition and behavior of specific pro-anti-inflammatory biochemical parameters in the atherosclerotic pathogenesis during TKIs treatment.

Methods: Enrolled pts were prospectively evaluated for: presence of traditional CVRFs, atherothrombotic episodes, presence of Single Nucleotide Polymorphisms (SNPs) associated to CV risk (Cardioklit) and plasma levels of several pro and anti-inflammatory cytokines. In this first interim analysis we focused on levels of LDL, oxidated-LDL (oxLDL), TNFα, IL-6 and IL-10 and the presence of SNPs of LDLR (rs1126608), LOX1 (rs3736225), and IL-10 (rs1800896) genes.

Results: 12 Italian Hematology Units participated to the study and up to date 95 CML patients were enrolled. We here report data from the first 43 patients on TKI treatment for at least 12 months (15 nilotinib, 14 imatinib and 14 dasatinib). No CV events were recorded to date. At diagnosis, levels of LDL (143.5±13.2), oxLDL (237.4±99.5), TNFα (3.91±2.51), IL-6 (1.96±0.99) and IL-10 (0.34±0.15) were evaluated for the whole cohort and according to the TKI treatment. No statistically significant differences were found in the expression of these variables between the 3 groups of treatment (p>0.05). Consid-
Background: Transcribed ultraconserved regions (T-UCR) are a novel class of long noncoding RNAs. Many classes of noncoding RNAs have been implicated in human tumorogenesis. In addition to the different expression profiles of T-UCRs that could be used to distinguish human leukemias and carcinomas, they have also been reported to have direct interactions with miRNA with an important regulatory effect on disease development such as chronic myeloid leukemia (CML).

Aims: In this study, we aimed at the correlation of T-UCR and miRNA-T-UCR pairs in CML, according to tyrosine kinase inhibitor (TKI) therapy, clinical risk scores and molecular response.

Methods: We analysed peripheral blood samples from 45 CML patients and 15 healthy controls. Two panels of 481 T-UCR and 752 miRNA probes were used for RT-qPCR analysis. Differential expression was evaluated using the Mann-Whitney test followed by Benjamini-Hochberg multiple testing correction.

Results: CML samples presented significantly different expression of uc.164 (p<0.01), uc.118 (p<0.01), uc.125 (p<0.01), uc.391 (p<0.01), uc.153 (p<0.01), uc.141 (p<0.01), uc.143 (p<0.05) and uc.145 (p<0.05), when compared to healthy controls. This latter T-UCR (uc.145) was associated with development and immune regulation pathways. We analysed Sokal, Hasford and EUTOS risk scores and found uc.236 (p<0.0001), uc.39 (p<0.05) and uc.7 (p<0.05) to be associated with EUTOS low risk. Concerning therapy, dasatinib was correlated with uc.294 (p<0.05) and for imatinib doses, uc.4 (p<0.05) and uc.3 (p<0.05) inversely correlated with 400 and 800mg daily, respectively. Molecular response in CML samples presented a signature including uc.187 (p<0.001), uc.107 (p<0.05), uc.409 (p<0.05), uc.198 (p<0.05), uc.309 (p<0.05), uc.102 (p<0.05), uc.294 (p<0.05) and uc.361 (p<0.05). Major molecular response was identified by the altered expression of uc.198 (p<0.05), uc.215 (p<0.05) and uc.210 (p<0.05). The negative regulation of T-UCRs by miRNAs, involving T-UCR:miRNA interaction, was associated with upregulated (miR-720, miR-886-3p, miR-1274a, miR-101 and miR-129) and downregulated (miR-489 and miR-1973) microRNAs.

Summary/Conclusions: In the present study, we identified T-UCRs signatures and T-UCR:miRNA pairs associated with CML, risk scores, TKI therapy and molecular response. The expanded knowledge of RNA biology in general, together with the recent interest in the multitude of newly discovered elements such as T-UCRs, could help to improve CML therapy.

Financial Support: FEDER (Programa Operacional Factores de Competitividade – COMPETE) and FCT (Fundaçao para a Ciencia e Tecnologia) through project Pest-C/SAU/LA0001/2013-2014.

E1045
MAINTENANCE OF LEUKAEMOGENIC POTENTIAL OF BCR/ABL+ CELLS REQUIRES PAK2 BUT NOT PAK1
A. Heide1, K. Kowalski1, L. Eddinger1, I. Menzl2, G. Hoermann2, E. Grundschobner1, Z. Bago-Horvat3, V. Sexl1
1Institute of Pharmacology and Toxicology, Veterinary University of Vienna, 2Department of Laboratory Medicine, 3Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

Background: p21-activated kinases (PAKs) are key nodes in oncogenic signalling pathways that control growth, survival, and motility of cancer cells. Their activity is increased in many human cancers and the increase is associated with a poor prognosis. To date, PAK deregulation has mainly been studied in solid tumours, where PAK1 and PAK4 are the main isoforms deregulated. The role of PAK2 in tumorigenesis is relatively unexplored.

Aims: We aimed at determining the role of PAK2 in haematopoietic tumors and the potential contribution of individual PAKs to tumorigenesis.

Methods: We used a combination of in silico analysis of publicly available data of haematological patients, shRNA-mediated knockdown and in vitro transformation assays. In parallel, we analysed the tumorigenic potential of leukaemic cells in vivo after knockdown of individual PAKs.

Results: We show that PAK1 and PAK2 are frequently deregulated in haematopoietic tumors, particularly in BCR/ABL leukemia. In suspension, BCR/ABL-leukaemia (KU812) cells deficient for PAK1 and PAK2 undergo apoptosis, while the loss of either protein is well tolerated. When leukemic cells are challenged to grow towards an extracellular matrix, the loss of PAK2 alone abolishes cell growth. PAK2-deficient cells fail to form colonies in growth-factor free methylcellulose and do not induce lymphomas in vivo.

Summary/Conclusions: PAK2 is the critical isoform in a BCR/ABL-driven disease. This finding suggests that the PAK2 isoform represents a promising target for the treatment of haematological diseases.
expression of several immune checkpoint inhibitors (BTLA, GITR, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, CD137/4-1BB) by different T, B, NK, monocyte and dendritic cell subsets. A 14-plex panel including BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, CD28, CD80, CD137 (4-1BB), CD27, and CD152 (CTLA-4) was analyzed by xMAP technology (Luminex®).

**Results:** Expression of CD137 by several lymphocyte subsets and PD-1 by regulatory T cells (Tregs) and natural killer (NK) cells were found significantly altered in CML patients under TKI therapy. These associations were observed for the cell population frequency expressing the receptor, and also for density of these molecules. Increased plasmatic levels of BTLA, HVEM, PD-1, PD-L1, and CD137 were associated with good molecular response to therapy, PD-1, PD-L1, TIM-3 and CD137 were found increased in patients that achieved MR4.5.

**Summary/Conclusions:** Some immune checkpoint inhibitors seem to be affected by TKI therapy in CML and their cell expression and plasmatic levels correlate to molecular response. Similar observations were described for other types of cancers, including solid tumors. Soluble and membrane-bound receptor–ligand immune checkpoints could represent interesting targets for future therapeutic monitoring and for pharmacologic interventions in CML.

**Financial Support:** FEDER (Programa Operacional Factores de Competitividad – COMPETE) and FCT (Fundação para a Ciência e a Tecnologia) through project PEst-C/SAU/LA0001/2013-2014.

---

**E1048**

**TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKAEMIA**


1Medical Biotechnologies, University of Siena, Siena, 2Clinical and Experimental Medicine, section of Pharmacology, University of Pisa, 3Clinical and Experimental Medicine, Hematology, University of Pisa, 4Clinical and Experimental Medicine, Hematology Molecular Laboratory, AOUP, Pisa, Italy

**Background:** It has been reported that, notwithstanding their clinical success, tyrosine kinase inhibitors (TKIs) are not able to eradicate the leukemic stem cell (LSC) in patients with chronic myeloid leukemia (CML). Different mechanisms have been hypothesized, especially those linked to the niche (increased osteoblastic differentiation, angiogenesis, hypoxia…). The epigenetic control seems to be relevant, and our group previously identified a correlation between the expression of some polycomb genes (PcGs) and response to TKIs, with BMI1 resulting a good predictive molecular marker (Crea, 2015).

**Aims:** In order to better understand the role of the PcGs genes in CML patients receiving TKIs, we analyzed the expression of 86 PcGs at baseline and after 6 months of therapy.

**Methods:** Buffy coats obtained from peripheral blood samples of 6 patients (5 receiving imatinib and 1 dasatinib) have been used for the RNA extraction; these RNAs were used for quantifying the BCR-ABL1/ABL1 ratio%IS, according to the European guidelines, and the expression of the chosen 86 PcGs by real-time PCR (PrimePCR pathway kit, Biorad, Milan, Italy) at diagnosis and after 6 months of treatment. Expression values were calculated using the 2DDCt method.

**Results:** At the sixth month of treatment, 5 patients were in optimal response and one was “warning”, according to the 2013 ELN guidelines. After therapy, 55% of the tested PcGs resulted up-regulated and 23% of them in the majority of patients; whereas 3 genes (DNMT3B, SCLM2, CBX2) were down-regulated in at least half of samples. The expression of 5% of PcGs was “mixed”, up- or down-regulated in different samples. Among the up-regulated genes, some could be relevant from a biological point of view: 1) HLTF, a target for RUNX1, whose low expression in acute leukemia is correlated with poor outcome; 2) PHC2, able to silence the HOX genes, overcoming the multidergine resistance in myeloid models; 3) PCGF5, that is a marker of normal hematopoiesis; 4) MOV10, that has been reported to have an anti-viral activity, increasing levels of gamma interferon. This up-regulation is particularly interesting, because concerns all assessed samples and could explain our previous observation that Torque Teno virus replication does not occur in CML patients during TKIs therapy; 5) in the only “warning” patient, the up-regulation of SIRT1 was observed: this is in line with the observation that its up-regulation increases the oncogenic ability of K562 cells in a murine model. Among the down-regulated genes, could be relevant: 1) CBX2, that binding P16/p19 promotes the cell cycle progression; its down-expression could induce apoptosis; 2) DNMT3B, whose high levels have been reported in stem cells, and whose reduction could characterize the differentiation process; 3) ZBTB16, whose reduction could be a sign of the reduced osteoblastogenesis, one of the mechanisms responsible for the LSC preservation in the niche; 4) SMARCA1, it too correlated to the cell cycle progression. Finally, BMI1 levels resulted unmodified in 3 cases and increased in other 3.

**Summary/Conclusions:** We demonstrated that PcGs de-regulation occurs in CML patients during the treatment with TKIs, with possible pathogenic implications. Hugser series of patients will improve the biological suggestions coming from these preliminary data.

---

**E1049**

**IDENTIFICATION OF PROGNOSTIC AND SUSCEPTIBILITY MARKERS IN CHRONIC MYELOID LEUKAEMIA USING NEXT GENERATION SEQUENCING**

Y. Shokeen1,2,*, N.R. Sharma1, V. Taneja1, S. Minhia1,1, M. Jahui1,1, S. Aggarwal19

1Department of Medical Oncology, Sir Ganga Ram Hospital, Delhi, 2School of Biotechnology and Biosciences, Lovely Professional University, Jalandhar, 3Department of Research, Sir Ganga Ram Hospital, Delhi, India

**Background:** Chronic Myeloid Leukemia (CML) is 20% of all leukemias diagnosed every year. Discovery of Imatinib Mesylate has brought a paradigm shift in treatment of Chronic Myeloid Leukemia, despite 15% - 20% patient showing resistance to this TKI. Therefore, it is important to identify susceptibility and prognostic markers, which can help us in predicting occurrence and prognosis of CML. We did Clinical Exome Sequencing, a panel of more than 4800 clinically important genes, in CML patients

**Aims:** To identify prognostic and susceptibility genetic markers in CML patients

**Methods:** Enrolled CML patients (n=18) were segregated as responders (n=10) and failures (n=8) as per ELN, 2013 guidelines. Healthy controls (n=5) were also enrolled. DNA from blood of subjects was subjected Next Generation Sequencing (NGS). Mutations present in one patient group and absent in opposite group were considered as prognostic markers, whereas rare mutations, present in more than 50% of enrolled patients and absent in healthy controls, were considered as susceptibility markers.

**Results:** We discovered mutations in genes associated with cancer or cancer related functions in different patient groups as markers. Five of them: rs116201358, rs17882014, rs4014596, rs52897880 and rs2274329 in C8A, HLA-DRB1, UNC93B1, APOH and CA6 genes respectively, were present in responders; rs4945 in MFGE8 was present in failures. Mutations in HLA-DRB1 (rs17878891, rs11554462, c.239C>G), HLA-DRB5 (rs137863146), RHPN2 (rs193179333), CYP2F1 (rs116958558), KCNJ12 (rs76684759), FUT3 (rs151218854), BM01 (rs28370522) and PRSS1 (rs144422014) were present in half or more patients.

**Summary/Conclusions:** We discovered potential genetic markers, which can help in predicting response to IM as frontline therapy. Susceptibility markers can be used as panel for to configure individuals prone to CML

---

**E1050**

**FEATURES OF THE A2455G POLYMORPHISM OF GENE CYP 1A1 IN PATIENTS WITH CML**

K. Kariomov1, N. Abdurahmanova1, K. Boboev1

1Institute of hematology and blood transfusion, tashkent, Uzbekistan

Madrid, Spain, June 22 – 25, 2017

haematologica | 2017; 102(s2) | 431
Background: Chronic myeloid leukemia (CML) is the most common myelo- proliferative disorder characterized by the reciprocal translocation t(9;22), (q34; q11), leading to the formation of chimeric oncogene BCR-ABL on the 22q-chromosome. It is known that the protein products of the genes of cytochromes ensure homeostasis at the cellular and tissue level, carrying out the metabolism of toxic compounds that can damage the genome of the cells. Previously, we have studied the genotypes of cytochrome P450 CYP1A1 gene in CML patients. The obtained results show that expression of this enzyme and, consequently, inactivation of xenobiotics must occur very slowly, thus creating conditions for adverse action of harmful metabolites in the genome of the cells. Currently, the scientific literature discusses the role of the negative allele A2455G polymorphism of CYP 1A1 gene in the development of hematological malignancies. However, the adverse roles of genotypic variants for this gene in oncogenesis of BCR-ABL-positive patients with CML have studied not enough.

Aims: Evaluation the role of A2425G polymorphism of CYP1A1 gene in the formation the mutant clone of tumor and the development of CML.

Methods: The work is performed on DNA samples isolated from the peripheral blood of the patients in the clinic of scientific research Institute of Hematology and blood transfusion in Uzbekistan. We studied 146 patients with CML. The control group was formed from 217 individuals of Uzbek nationality, without any cancer disease. The diagnosis of CML verified in accordance with the International nomenclature ISCN. Standardized PCR with detection in real-time was carried out on a thermal cycler Rotor-Gene 6000 (Corbett Research, Australia), using a set of reagents "AmpliSens" Leucosis quanitation "IFR" (InterLabSers, Russia). Testing A2425 polymorphism of CYP1A1 gene was performed on a programmable thermal cycler of the company "Applied Biosystems" (USA) using test systems company "Litech" (Russia) according to the manufacturer’s instructions. Statistical analysis of results was carried out using the statistical software package “2009 OpenEpi, Version 2.3”.

Results: The frequencies of allele A and G are as follows: 76.7% and 12.3% in patients with CML, and 93.3% and 6.7% in the control group, respectively. The frequency distribution of genotypes A/A, A/G and G/G were as follows: 76.7%, 21.9% and 1.4% - in CML patients, and 86.6%, 13.4% and 0.0% - in the control group. Observed frequencies of genotypes in the studied groups was consistent with the theoretically expected and were in equilibrium with Hardy-Weinberg equilibrium (P>0.05). There was a statistically significant decrease in carriage of the adverse alleles in the population sample comparison group patients (1.4% vs 6.7%, respectively; \( \chi^2=6.8; P=0.01; OR=2.0; 95\% CI 1.17-3.282 \)). Also detected significant association of heterozygous genotype A/G in patients with CML, compared with the control group (21.9% vs 13.4%, respectively). The risk of mutant formation of the tumor clone in carriers of this genotype was 1.8 times significantly higher compared with patients not having it (\( \chi^2=4.6; P=0.03; OR=1.8; 95\% CI 1.046-3.166 \)).

Figure 1. Evolution of hematologic toxicity grade 3-4 with time (all treatments sequences included).

Summary/Conclusions: Our results suggest that the G allele and the heterozygous genotype A/G A2425G polymorphism of CYP 1A1 gene are important markers of increased risk in formation of malignant tumor cells and development of CML in Uzbekistan (P<0.05). In this case, homozygous genotype A/A of A2425G polymorphism of CYP 1A1 gene has a protective character in relation to risk of CML.

Chronic myeloid leukemia - Clinical

E1051

HEMATOLOGIC TOXICITY GRADE III-IV IS ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS


1Hematology, Hospital Virgen de la Salud, Toledo, 2Hematology, H Ramon y Cajal, Madrid, 3Hematology, IIS Aragon, Traslational Research Unit, Zaragoza, 4Hematology, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, 5Hematology, Hospital la Paz, 6Hematology, Hospital 12 de Octubre, 7Hematology, Hospital Puerta de Hierro, 8Hematology, Hospital Universitario Gregorio Marañon, 9Hematology, Hospital Universitario Severo Ochoa, Madrid, 10Hematology, Hospital Clinico Universitario Lozano Biesa, Zaragoza, 11Hematology, Hospital Clinico Universitario Valladolid, Valladolid, 12Hematology, Hospital General de Ciudad Real, Ciudad Real, 13Hematology, Hospital Universitario Infanta Leonor, 14Hematology, Spanish Registry of CML and GELMC, 15Hematology, Department of Hematology and IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain

Background: TKIs introduction in the treatment of chronic myeloid leukemia (CML) has offered an outstanding improvement in survival outcomes. These results were obtained from clinical trials but little is known about long-term toxicity and their translation to real life. In addition, clinical trials results are mainly based on the analysis of the therapy of interest (experimental or control), but the descriptions of the subsequent treatment sequences due to failure or intolerance are normally lacking.

Aims: To analyze the long-term toxicity of patients outside clinical trials in clinical trials. The setting was a multicentric, hospital-based registry.

Methods: Toxicity grade III-IV and survival and their potentially associated variables were studied.

Results: Demographics, risk and treatment distribution: 893 patients (533 men, 360 women) with a median age at diagnosis of 52 y (14-94y) were included with a follow up of 852±7 months (m) from diagnosis, 78±6.6 m from first treatment, and 69±6 m from first TKIs. 151 patients (16,9%) were over 70 y. The risk distributions were as follows: Sokal: low (L) 48%, intermediate (I) 37% and high (H) 14%; Euro score: L 50%, I 45% and H 5%; EUTOS L: 92% and H 8%; EUTOS LT: L 70%, I 23% and H 7%. Treatment groups were the following: Group 1: IFN alpha and then imatinib or 2º GTKIs (221 patients); Group 2: imatinib only (404 patients); Group 3: imatinib and then nilotinib, dasatinib or both due to failure or intolerance (177 patients) and Group 4: 2ºGTKIs in first line (93 patients). Hematologic toxicity grade III-IV. Figure 1 shows the incidence through the years (all group of treatments). From 800 patients treated with imatinib (first o second line) 67 (8,3%) had grade III-IV toxicity, and 26 had to switch treatment due to toxicity. From 166 patients treated with dasatinib (29...
in 1st line, 114 in 2nd, 56 in 3rd) only 13 had hematologic toxicity and 6 had to switch, 14 had pleural effusion grade III-IV and 9 had to switch. From 115 patients treated with nilotinib (49 in 1st line and 66 in 2nd) only 10 had hematologic toxicity and 10 switched treatment. Survival: Estimated survival by 10 years was 80%. Variables associated with survival: In the univariate survival analyses (log rank test) either from diagnosis, first therapy or first TKIs, the Sokal, Eutus, Euro and EUTOS LT scores, as well as age over 70y were the only statistically significant variables associated with survival. Hematologic toxicity grade III-IV was associated with lower PFS or OS (figure 1). In the multivariate analysis (Cox model), only hematologic toxicity grade III-IV and age over 70y were independent variables.

Summary/Conclusions: 1. These results show that the probability of survival by 10 years is roughly 80%, and extend the findings of our previous work showing that this probability is not different across different sequential treatments (imatinib 1st line or post-IFN, or switched to 2ªGTKis due to intolerance or failure) (1). This fact emphasizes the rescue potential of available TKI therapies. 2. Hematologic toxicity grade III-IV in the first two years identified a group of patients with worse survival outcome. 3. Patients over 70 years have shorter survival due to reasons different than progression. 4. Second G TKIs showed better hematologic toxicity profile.

Reference

E1052

5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION

A. Hochhaus1,*, E. Jabbour2, H. Kantarjian2, F. Guilhot3, V. Kota4, T. P. Hughes5, S. Sheela6, L. Li7, J.E. Cortes2
1Universitätsklinikum Jena, Jena, Germany, 2University of Texas MD Anderson Cancer Center, Houston, United States, 3Inserm CIC 1402, CHU de Poitiers, Poitiers, France, 4Winship Cancer Institute at Emory University, Atlanta, United States, 5SAHMRI, University of Adelaide, Adelaide, Australia, 6Bristol-Myers Squibb, Princeton, United States

Background: Multiple dosage strengths are approved for dasatinib (DAS), permitting dose-optimization strategies for patients who experience adverse events (AEs). In a 2-year retrospective analysis of DASISION, efficacy was maintained in Dasatinib- and imatinib (IM)-treated patients with dose reductions or interruptions to manage AEs (Jabbour ASH 2011); cytogenetic and molecular response rates were higher for patients given DAS vs IM, even when daily doses were modified. Longer term follow-up is needed to fully understand the potential impact of dose reductions on efficacy.

Aims: To evaluate the effect of dose reduction for any AE and for pleural effusion on efficacy in DAS- or IM-treated patients from DASISION. Methods: Treatmen-t-naive patients with CML-CP in DASISION (NCT00481247) were randomized to receive either DAS (100mg once/day; N=259) or IM (400mg once/day; N=260). Dose reductions for AEs (up to 2) were allowed: DAS: 80mg, then 50mg; IM: 300mg, then 200mg. Five-year molecular and cytogenetic response rates in all patients were assessed retrospectively.

Table 1.

Results: Patients on DAS maintained higher molecular response rates than patients on IM, whether or not they had dose reductions for an AE; these rates were similar in patients with and without dose reductions in each arm (table). 95 (37%) DAS- and 44 (17%) IM-treated patients had dose reductions at any time due to AEs. Median time to first DAS dose reduction was 289 days (range: 22-2123), and median time to first IM dose reduction was 160 days (range: 31-2052). For patients with reductions due to any cause, median average daily dose was DAS 83mg and IM 328mg; for DAS patients with reductions due to pleural effusion, median average daily dose was 82mg. Median duration of treatment (excluding interruptions) was 54 months (range: 3-70) for patients who had a DAS dose reduction and 57 months (range: 2-71) for patients who had an IM dose reduction. Changes in level of response were tracked for patients who achieved complete cytogenetic response (CCyR) or major molecular response (MMR) before or after the first dose reduction (table). Many patients maintained or increased to CCyR or MMR following dose reductions for any AE. Hematological toxicity (9%) was the most common AE resulting in dose reduction for IM, and pleural effusion (12%) was the most common for DAS.

Summary/Conclusions: Reducing DAS doses to 80mg or 50mg was a safe and effective means of managing patients who experienced AEs in this 5-year retrospective analysis of DASISION. These results were consistent with previous reports and continued to show that efficacy was not affected by dose reductions for any cause, including pleural effusion. Notably, there was no loss of CCyR following dasatinib dose reductions. Molecular responses remained higher for DAS vs IM irrespective of dose reductions due to AEs.

E1053

EFFECT OF PLASMA TROUGHS CONCENTRATION OF NILOTINIB AND POLYMORPHISMS OF DRUG TRANSPORTER GENES ON THE FREQUENCY OF ADVERSE EVENTS IN CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA: STAT1 AND STAT2 TRIALS

N. Takahashi1,*, T. Nioka2, M. Abumiya2, S. Takahashi1, M. Miura2
1Hematology, AKITA UNIV., 2Pharmacy, AKITA UNIV. HOSPITAL, Akita, Japan

Background: STAT trials (STAT1 and STAT2) are multicenter, phase II, single-treatment arm, open-label clinical studies designed to evaluate the efficacy and safety of two-year consolidation by nilotinib (NIL) for achieving a deep molecular response (DMR) or successful treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML).

Aims: In this report, we focus on the adverse events (AEs), especially anemia and liver dysfunction observed in the STAT trials. Additionally, we analyzed the relationship between laboratory abnormalities and pharmacokinetics (PK)/pharmacogenetics (PGx) of NIL.

Methods: AEs were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Safety evaluations were conducted throughout the study. Plasma trough concentrations of NIL were determined with high-performance liquid chromatography (HPLC) at 1 month (1M), 3M, 6M, 12M, and 24M in the STAT trials. Genotyping of CYP3A5*3 [6986A>G] (rs776746), ABCB1 [3435T>C] (rs1045642), ABCG2 421C>A (rs22311142), and UGT1A1*6, *27, and *28 was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). All genotype frequencies were tested for Hardy-Weinberg equilibrium.

Results: Between July 2011 and December 2012, CML patients were recruited in the STAT trials. NIL was administered twice daily (600mg/day) for 2 years according to the study protocol. A total of 76 and 96 patients were analyzed as a safety data set in STAT1 and STAT2, respectively. In STAT1, 18 patients who achieved a confirmed DMR were switched from STAT1 to STAT2. These patients entered both trials: 12 had data that had not been collected in STAT1 after entering STAT2 to avoid double counts. The PK/PGx data of 147 of 154 patients were available and were evaluated in this study. Median trough concentrations of NIL were 1265 ng/ml at 1M, 1154 ng/ml at 3M, 974 ng/ml at 6M, 735 ng/ml at 12M, and 781 ng/ml at 24M. Although any-grade AEs were reported in patients in STAT1 and 55 patients in STAT2, the most common drug-related hematological and non-hematological AEs were elevated total bilirubin (28.6%), anemia (24.5%), elevated ALT (21.1%), and elevated AST (18.4%). The incidence of these AEs, except for anemia, was significantly associated
E1054

VERY EARLY Molecular RESPONSE (vEMR) WITH FRONTLINE DASATINIB TREATMENT IS A STRONG PREDICTOR OF LONG-TERM BCR-ABL1 TRANSCRIPT LEVELS IN CHRONIC MYELOID LEUKEMIA PATIENTS: PCR-DEPTH STUDY

With high trough concentration of NIL (Figure 1). There were statistically significant correlations between median concentrations of NIL and the grades of each AE. Based on the results of the analysis using Cox proportional-hazards model, the trough concentration of NIL [hazard ratio=1.001 (1.000-1.002), P=0.004] and ABCGG2 421A/A [hazard ratio=3.044 (1.155-8.027), P=0.024] were independent factors for the elevated ALT. Similarly, the trough concentration of NIL [hazard ratio=1.001 (1.000-1.002), P=0.001] and UGT1A1 *1/*1 [hazard ratio=0.475 (0.246-0.919), P=0.027] were independent factors for the elevated total bilirubin.

Summary/Conclusions: In this study, we identified the relationship between NIL trough concentration and liver dysfunction. Our finding suggests that therapeutic drug monitoring might help avoid drug interruption and discontinuation because of AEs, especially liver dysfunction.

E1055

SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD- OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB

Background: PACE was a phase 2 single-arm trial of ponatinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in 449 highly-refractory patients with CML or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or who had the BCR-ABL T315I mutation. Overall survival (OS) for 3L CP-CML patients in PACE at 1, 2, 3 and 4 years was estimated to be 91%, 83%, 80%, and 79%, respectively. Expected survival for 3L CP-CML patients prior to the availability of ponatinib has not been documented.

Aims: To estimate OS in patients with CP-CML receiving 3L treatment prior to ponatinib via a systematic literature review.

Methods: Studies were identified from a review by Lipton et al. (2015), updated with studies identified from searches of electronic databases (MEDLINE, EMBASE, Cochrane Libraries) and abstract databases of key conferences. Landmark and median survival were extracted from study reports. Pseudo-individual patient data (IPD) for survival outcomes were derived from digitized Kaplan-Meier (KM) survival curves then pooled and analyzed using KM methods.

Results: Fifty studies (717 patients) were identified that reported landmark, landmark, or KM curves for survival outcomes for CP-CML patients receiving 3L treatment without ponatinib. KM curves for OS were obtained for 6 arms (3 nilotinib and/or dasatinib; 3 other TKIs). OS at 1, 2 and 3 years based on the pooled IPD is reported in the Table. To avoid confounding of OS from post-progression treatment with ponatinib, 1 study was excluded that included follow-up after the date of ponatinib’s approval.

Table 1.

Summary/Conclusions: Estimated OS in patients with CP-CML receiving 3L treatment prior to ponatinib appears to be shorter than that observed among ponatinib-treated patients in PACE; 4-year survival probability in PACE was higher than estimated 2-year survival probability prior to ponatinib. Further analyses are needed to identify and adjust for potentially confounding factors.
Aims: Both NGS and droplet digital PCR (ddPCR) were used in this prospective study. NGS screened all known mutations in the BCR-ABL1 KD and ddPCR targeted only the 3 most common mutations, T315I, E255K and Y253H, which represent approximately 75% of the ABL1 mutations. Patients eligible for the study were i) CML patients with failure or warning to all lines of TKI therapy according to the 2013 ELN-guidelines, with no suspected lack of adherence and ii) ALL patients in CR after diagnosis and/or molecular relapse. Mutations were performed when clinically appropriate.

Methods: Total BCR-ABL1 RNA was transcribed into a long range cDNA covering the kinase and the regulatory and the SH2/SH3 domains of either p190 or p210 BCR-ABL1 transcripts (exons 4 to 10). For NGS, primers designed with the AmpliSeq™ Designer Software were generated in a set of 10 amplicons. Bar-coded libraries, constructed according to the AmplicSeq™ protocol, were sequenced on the Ion Torrent PGM platform (sensitivity of 2.5%). For ddPCR, cDNA was analysed for the presence of one of the 3 main mutations (T315I, E255K and Y253H). The overall number of BCR-ABL1 mutated samples was 18 (15 CML and 3 Ph+ ALL), representing 30% of the cases. Among these samples, 27 mutations were found, 9 samples presented with one mutation: T315I (2), E255K (3), G250V (1), F359I (1), M237T(1) and E255A (1) and 9 harboured compound mutations: T315I + E255K (6) and T315I + Y253H (3). A high frequency (85%) of T315I, E255K and Y253H mutations was also observed (23/27). As far as these 3 mutations are concerned, reproducibility to determine mutational burden was found to be very high between NGS and ddPCR.

Results: Advancements in sequencing technologies and further lowering sensitivity levels contribute to optimal management of CML and Ph+ ALL patients and improve treatment outcome. The earlier a mutation in the kinase domain is detected, the earlier an informed choice can be made regarding optimal subsequent TKI treatment.

E1057
CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON-A2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDUTDCML009)

I. Fujokaa,1 T. Takaku1, N. Iyam2a, M. Tokuhira2, E. Satodo, M. Ishikawa2, T. Nakajima2a, K. J. Sugiyama4,2a, H. Fujita5, N. Asu6, M. Kizaki7, Y. Hatt8a, N. Komatsu9a, T. Kawaguchi10a
1Department of Hematology, Juntendo University School of Medicine, 2Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, 3Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, 4Division of Hematology, Department of Medicine, Juntendo University Nermia Hospital, Tokyo, 5Department of Hemato-Oncology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, 6Department of Hematology, Yokohama Municipal Citizen’s Hospital, Yokohama, 7Department of Hematology, Juntendo University Urayasu Hospital, Urayasu, 8Division of Hematology, Saiseikai Yokohama Nambu Hospital, Yokohama, 9Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan

Background: Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells resulting from oncogenic chromosome translocation that leads to the formation of the BCR-ABL1 fusion gene. Treatment of chronic phase (CP) CML has dramatically changed since the emergence of the first-in-class tyrosine kinase inhibitor (TKI) imatinib, and treatment based on TKI has improved the outcome in the majority of CP-CML patients. Nowadays, second generation TKIs are available and brought about faster and deeper clinical responses, and lower disease progression rate than imatinib. On the other hand, longer treatment duration and the increased types of TKIs gave rise to various kinds of unexpected adverse events (AEs). In 2011, drug-induced peripheral arterial occlusive disease (PAOD) was first reported, followed by vascular AEs (VAEs) including hemodynamic heart failure and cerebral AEs (1). Therefore, it is important to monitor VAEs and to analyze the risk factors. In our study, we aimed to evaluate the incidence of VAEs in Japanese CML patients treated with TKIs based on the classification system of VAEs (2). The incidence of VAEs and their association with risk factors were investigated in this study.

Methods: A surveillance data of 320 patients enrolled in the CML Cooperative Study Group (the Cooperative Study Group of Chronic Myeloid Leukemia Patients in Japan) were analyzed. All patients had been diagnosed with CML-CP from April 2001 to January 2016, whose median age was 57 years (15-80) and median time of follow up was 64.2 months. Patients in the accelerated or blastic phase (AP/BC) were excluded. The study was approved by the research ethics boards of each institutions and was conducted in accordance with the Declaration of Helsinki. All patients who developed VAEs were analyzed using 3 risk assessment tools (SCORE chart, Framingham score, Saita-score) to estimate the patients’ 10-year risk of VAEs.

Results: Among the 320 newly diagnosed CML-CP patients, 16 (5.0%) cases of VAEs were reported during the study period. Seven cases were treated by first-generation TKIs (imatinib), 4 cases by dasatinib, 4 cases were a switch from imatinib to nilotinib, and 1 case was a switch from dasatinib to nilotinib. The VAEs were 9 IHD, 5 CI, and 2 PAOD cases. Results from the 3 risk assessment tools are as follows: SCORE (2 low, 9 moderate, 1 high, 4 very high risk), Framingham score (3 low, 5 moderate, 7 high risk), and Saita-score (13 low, 1 intermediate, 1 high risk). The incidence rates of IHD, CI, and PAOD were 5.26 and 2.92 in the enrolled CML-CP patients, 4.65 and 2.33 in the imatinib-treated patients, 14.34 and 10.75 in the nilotinib-treated patients, 4.08 and no case in the dasatinib-treated patients, and 1.787 and 3.34 in the age-
matched general population, respectively. Among the 320 newly diagnosed CML-CP patients, 16 (5.0%) cases of VAEs were reported during the study period. Seven cases were treated by imatinib, 3 cases by nilotinib, 1 case by dasatinib, 4 cases were a switch from imatinib to nilotinib, and 1 case was a switch from dasatinib to nilotinib. The VAEs were 9 IHD, 5 CI, and 2 PAOD cases. Results from the 3 risk assessment tools are as follows: SCORE (2 low, 9 moderate, 1 high, 4 very high risk). Framingham score (3 low, 5 moderate, 7 high risk), and Suita-score (13 low, 1 intermediate, 1 high risk). The incidence rate of IHD and CI per 1000 person-years were 5.26 and 2.92 in the enrolled CML-CP patients, 4.65 and 2.33 in the imatinib-treated patients, 14.34 and 10.75 in the nilotinib-treated patients, 4.08 and no case in the dasatinib-treated patients, and 1.787 and 3.342 in the age-matched general population, respectively.

Table 1.

<table>
<thead>
<tr>
<th>Event</th>
<th>Time (days)</th>
<th>Incidence rate per 1000 person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukemia</td>
<td>1711</td>
<td>5.26</td>
</tr>
<tr>
<td>Myocardial Infarction</td>
<td>1711</td>
<td>4.65</td>
</tr>
<tr>
<td>Death</td>
<td>1711</td>
<td>2.92</td>
</tr>
<tr>
<td>Death</td>
<td>1711</td>
<td>2.33</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The incidence rate of IHD per 1000 person-years were higher in the nilotinib- and lower in imatinib- and dasatinib-treated CML patients, and the patients showed almost the same rate of CI as compared with the age-matched general population, even though the incidence of VAEs were lower in Japanese compared to the European cohort. More patients were estimated to have very-high and high risk of VAEs in the SCORE and Framingham risk score assessment tools as compared with the Suita-score tool.

E1059
UPDATE OF CMREGISTRY: AN OBSERVATIONAL, MULTI CENTER, PROSPECTIVE FOLLOW-UP REGISTRY OF PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA WITH A HIGH PROBABILITY OF OBTAINING A DEEPLY MOLECULAR RESPONSE >CMR4 (IS)
J.M. Alonso-Dominguez1, E. Olavarria2, M. Perez Encinas3, R. de Paz Arias4, R. Ayala Diaz5, L.F. Casado Montero6, F. Ferrer Marin7, G. Bautista8, V. Conesa Garcia9, C. Mba10, J.L. Stegmann11
1Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2Hematology Department, Hammersmith Hospital, London, United Kingdom, 3Hematology Department, Hospital Clínico de Santiago, Santiago, 4Hematology Department, Hospital La Paz, 5Hematology Department, Hospital Doce de Octubre, Madrid, 6Hematology Department, Hospital Virgen de la Salud, Toledo, 7Hematology Department, Hospital Morales Meseguer, Murcia, 8Hematology Department, Hospital Puerta Hierro, Madrid, 9Hematology Department, Hospital General de Elche, Elche, 10Hematology Department, Fundación Investigación Hospital de la Princesa IIS-IP, 11Hematology Department, Hospital de la Princesa, Madrid, Spain

Background: Since the introduction of Tyrosine Kinase Inhibitors (TKI), many patients diagnosed of Chronic Myeloid Leukemia (CML) in chronic phase achieve a deep molecular response. Around 50% of these patients are expected to maintain their molecular responses even after discontinuation of their TKI treatment. Several clinical trials are exploring the best way of stopping TKI therapy and evaluating patient and disease characteristics that could predict relapse after treatment discontinuation.

Aims: To evaluate the impact of baseline comorbidities and patient age on 5-year safety and efficacy in dasatinib- or imatinib-treated patients from DASISION.

Methods: In DASISION (NCT00481247), patients were randomized to receive dasatinib 100mg/day (N=259) or imatinib 400mg/day (N=260). For this retrospective analysis, patients were grouped as having 0 or ≥1 baseline comorbidity, by baseline disorder (diabetes mellitus, hepaticobiliary disease, hyperlipidemia, cardiovascular disorder, or pulmonary condition), or by age group (<46 years, 46–65 years, >65 years). Safety (treatment-related AEs in ≥10% of patients) and efficacy (response rates by 5 years and median times to response) were assessed for each group and treatment.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Study arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline comorbidities</td>
<td>0</td>
</tr>
<tr>
<td>Baseline disorder</td>
<td>0</td>
</tr>
<tr>
<td>Age group</td>
<td>0</td>
</tr>
<tr>
<td>Response rate</td>
<td>0</td>
</tr>
</tbody>
</table>

Table E1060
ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION
1University of Turin, Turin, Italy, 2The University of Texas MD Anderson Cancer Center, Houston, United States, 3Universitätsklinikum Jena, Jena, Germany, 4University of California San Francisco School of Medicine, San Francisco, 5Froedtert & the Medical College of Wisconsin, Milwaukee, 6Bristol-Myers Squibb, Princeton, 7Memorial Sloan Kettering Cancer Center, New York, United States

Background: Patients with CML often have comorbidities, which may influence treatment-related decisions and impact response and survival. In a retrospective analysis of 1-year data from the phase 3 DASISION study, the overall safety or response in dasatinib- or imatinib-treated patients was not substantially impacted by baseline comorbidities, although certain adverse events (AEs) trended higher in patients with ≥1 vs 0 comorbidities (Khoury ASH 2010). Further analysis is warranted to determine how comorbidities may impact long-term outcomes.

Aims: To evaluate the impact of baseline comorbidities and patient age on 5-year safety and efficacy in dasatinib- or imatinib-treated patients from DASISION.

Methods: In DASISION (NCT00481247), patients were randomized to receive dasatinib 100mg/day (N=259) or imatinib 400mg/day (N=260). For this retrospective analysis, patients were grouped as having 0 or ≥1 baseline comorbidity, by baseline disorder (diabetes mellitus, hepaticobiliary disease, hyperlipidemia, cardiovascular disorder, or pulmonary condition), or by age group (<46 years, 46–65 years, >65 years). Safety (treatment-related AEs in ≥10% of patients) and efficacy (response rates by 5 years and median times to response) were assessed for each group and treatment.
Results: The number of patients with 0 or ≥1 comorbidity was similar in the dasatinib (66 [25%]; 193 [75%]) and imatinib (67 [26%]; 193 [74%]) arms, respectively; most (>90%) patients were <65 years old. In patients with 0 or ≥1 baseline comorbidity, the median average daily dose was comparable within arms and discontinuation rates (36%-39%) were similar within and across arms (table). The overall safety profiles were comparable in the 0 and ≥1 comorbidity groups in both arms, other than specific AEs, which had a 22 times higher frequency in patients with 0 vs ≥1 comorbidities; the majority of these were grade 1/2 AEs (table). The incidence of peripheral edema increased with patient age for both dasatinib and imatinib (<46 years: 5% each; 46–65 years: 12% and 10%; >65 years: 21% and 20%). In this analysis, the increased incidence of pleural effusion (PE) in dasatinib-treated patients was most highly associated with increased age: <46 years (16%) vs 46–65 years (37%) vs >65 years (60%). PE incidence did not appear to be related to baseline pulmonary comorbidity and was similar in dasatinib-treated smokers (33%) vs nonsmokers (27%). Within each arm, patients with 0 or ≥1 comorbidity (table) and across age groups had similar results. Discontinuation rates were generally higher for patients with 0 vs ≥1 comorbidities in both arms (MR4.5 0-1 ondasitb: 46% vs 32%; MR3 on imatinib: 36% vs 22%). Median time to response (months) for patients with 0 or ≥1 comorbidity did not differ within each arm, but was numerically shorter for dasatinib (36 vs 35) or imatinib (MR4.5 42 vs 47).

Summary/Conclusions: The superior efficacy of dasatinib over imatinib was shown in previous studies. Response rates and times to response were comparable in patients with 0 or ≥1 comorbidity and trended in favor of dasatinib vs imatinib. Although a few AEs (most grade 1/2) appeared to occur at a higher frequency in patients with 0 vs ≥1 comorbidities in either treatment arm, the overall incidence of AEs and discontinuation rates at 5 years in patients who were treated with first-line dasatinib or imatinib did not appear to be substantially affected by baseline comorbidities.

E1061 ADHERENCE TO SECOND LINE THERAPY WITH NILOTINIB AND QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY

T. Sacha1, 1, J. Góra-Tybor2, 2, E. Wąsak-Szułkowski3, 3, S. Kyrzcz-Krzemien4, 4, E. Medras5, 5, R. Becht6, 6, G. Bober7, 7, A. Kotowska8, 8, J. Wąclaw9, 9, A. Hellmann9, 9, 1Department of Hematology, Jagiellonian University, Kraków, 2Department of Hematology, Institute of Hematology and Transfusion Medicine, 3Department of Hematology, Novartis-Poland, Warszawa, 4Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, 5Department of Hematology, Malignant Blood Diseases and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, 6Department of Hematology, Pomeranian Medical University, Szczecin, 7Department of Hematology and Transplantology, Gdańsk University of Medical, Gdańsk, Poland

Background: Introduction of second-generation TKIs (2GTKIs) provided additional options to treat CML patients effectively. Compliance is crucial to achieve good outcomes of TKI therapy. The recommended dose of nilotinib – potent 2GTKI in a second-line treatment is 400mg twice daily. The drug’s administration might be more challenging for patients as compared to other TKIs. Nilotinib should be taken twice daily approximately 12 hours apart, and must not be taken with food. No food should be consumed two hours before and at least one hour after the drug is administered. Recent studies comparing adherence to the second-line CML treatment with nilotinib and dasatinib reported conflicting results. It has been reported that the therapy with TKIs might have an adverse effect on the quality-of-life (QOL). To date the majority of the research on QOL among patients treated with TKIs has been focused on imatinib.

Aims: The aim of this study was to assess the adherence to nilotinib used as a second line therapy and to evaluate the quality-of-life (QOL) in patients with chronic myeloid leukemia in a chronic phase (CML-CP), as well as to analyze the correlation between QOL and drug compliance, the correlation between patient’s and physician’s assessment of drug compliance and to evaluate the relationship between drug compliance and dosing schedule (twice daily, once daily), patient’s age, educational and marital status, satisfaction with medical care and the QOL.

Methods: The study was designed as a multicenter prospective observational trial. The enrollment period lasted from June 2010 to June 2012. The duration of the observational period was 12 months. 177 patients were recruited in 23 centers in Poland and evaluated during the study at six time points. Nilotinib is not reimbursed in Poland as a first-line therapy. Therefore, eligible were patients suffering from CML-CP, treated with nilotinib as a second-line therapy due to the inefficacy or intolerance of first-line therapy. The adherence assessment therapy was assessed using the 4-item Monk’s Medication Adherence Scale (MMAS) and reported by patients and their physicians at 1, 3, 6, 9 months and at the completion of the observation. The QOL was evaluated with the standard Core Quality of Life (EORTC QLQ-C30) questionnaire. Basic descriptive statistics were used to present results of the study.

Results: A total of 177 patients assessed their adherence and their QOL at their first visit and 93.4% at the 5th visit. Male were less compliant to nilotinib than females. Patients who live with families were more compliant than those who live with a partner or live alone. Low compliant patients represented 1.7% of total during visit 1; none of the patients assessed themselves as low compliant since the 4th visit. At the first visit 85.3% of patients were categorized by their physicians as highly compliant and 96.0% during the last three visits. Patients and physicians assessments were significantly correlated. No significant differences in drug compliance in patients treated once daily vs twice daily were found in all groups of patients. The average QOL expressed as QL2 parameter in patients that have completed the study was significantly higher during the last visit (69.4±17.4) than at the start of the study (59.1±18.8; p<0.001).

Summary/Conclusions: The adherence to the treatment was high and the QOL among patients on nilotinib administered as a second-line therapy was very good. Both have been improved during the study. The efficacy and safety of the drug were confirmed in the real-life setting.
100 YEARS OF CHRONIC MYELOID LEUKEMIA PREVALENCE IN FRANCE

M. Delord1,2

1Biostatistics, Université Paris 7 - INSERM - UMR-S 717, PARIS, France

Background: The success of imatinib and other rationally designed tyrosine kinase inhibitors (TKI) in the treatment of chronic myeloid leukemia has drastically improved the fate of CML patients. From a couple of years in median survival in the 70’s, a majority of patient now achieve a near normal life expectancy with lifelong treatment though. This new paradigm where CML can be regarded as a chronic disease has mechanical consequences on the disease prevalence and overall costs for health care systems. The success of imatinib and other rationally designed tyrosine kinase inhibitors (TKI) in the treatment of chronic myeloid leukemia has drastically improved the fate of CML patients. From a couple of years in median survival in the 70’s, a majority of patient now achieve a near normal life expectancy with lifelong treatment though. This new paradigm where CML can be regarded as a chronic disease has mechanical consequences on the disease prevalence and overall costs for health care systems.

Aims: We present here a fully detailed and comprehensive analysis of the French CML prevalence over a century from 1960 to 2060.

Methods: Prevalence of CML was estimated using a cohort component-based model from estimates of incidence rate of the disease by age and sex, population and demo-graphic projection from the National Institute of statistics and Economics Studies, and various hypotheses on the relative survival of CML patients. Prevalence of CML was estimated using a cohort component-based model from estimates of incidence rate of the disease by age and sex, population and demo-graphic projection from the National Institute of statistics and Economics Studies, and various hypotheses on the relative survival of CML patients. The number of CML patients is estimated over time and the resulting CML prevalence expressed as a number of CML patients per 100,000 inhabitants.

Results: The CML prevalence in France, expressed in cases per 100,000 inhabitants, was estimated to be around 3 before the 80’s, 6 before the 2002, 17 in 2030, 30 in 2030 where the tendency infects, and 30 after 2040. Considering the 100% relative survival hypothesis, a target CML prevalence were nearly reached by 2050 to levels above 30 per 100,000 inhabitants. By simulation, we showed that when constant incidence rates and high relative survival hypotheses, the CML prevalence will be driven by population aging, and that the target prevalence, defined as the maximum CML prevalence, should be nearly reached by 2050 to levels above 30 per 100,000 inhabitants.

Discussion: To this end, we assessed the expression levels of miR-203, miR-21, miR-519c, miR-451, miR-26 and miR-16 (endogenous control) by TaqMan MicroRNA Assays in peripheral blood cells from 31 patients with CML at follow-up examinations. We also studied 4 CML cell lines, K562 a cell line sensitive to Imatinib, LAMA-84 a cell line with 4 copies of chromosome Philadelphia (Ph), and 2 Imatinib resistant cell lines models created in our lab (K562-RC and K562-RD). K562-RC cells, generated by continuous exposure to Imatinib, present 8 times higher BCR-ABL levels (K562; in K56-RD cells created by discontinuous exposure), the degree of resistance is 18x. Statistical analysis was performed with ANOVA and multiple comparison tests, with significance levels of 95% (p<0.05).

Results: The miR-203 and miR-519c expression was not detected in any cell line or patient. First, we examined miRs expression with BCR-ABL levels. Higher levels of tumor suppressor miR-451 were associated with a higher reduction of BCR-ABL levels (lower than 0.01%) in CML patients and patients with higher BCR-ABL present lower levels of expression of miR-451. This miR was also down-regulated in LAMA-84, K562-RC and K562-RD comparing with sensitive cell line (K562; p<0.05). On the other hand, patients with more BCR-ABL content (between 1% and 0.1%) present higher expression of the oncomiRs, miR-21 and miR-26. These miRs were also up-regulated in resistant cell lines. MiR-21 was more relevant for K562-RC cells (4-fold higher than K562). LAMA-84 and K562-RD cell lines showed almost 2 times more expression of miR-26. Next we analyzed if treatment options affected miRs expression. CML patients under Imatinib treatment showed higher levels of miR-451 associated with less expression levels of miR-21 and miR-26. Imatinib had been described to be able to block the BCR-ABL negative feedback on miR-451, increasing miR function. Since miR-21 and miR-26 were also lower expressed, more PTEN is available to block PI3K-AKT-mTOR pathways, decreasing this survival signaling. Opposite profile was observed in patients that changed treatment to a second generation TKI suggesting a different effect of this TKI on microRNA expression.

Summary/Conclusions: Our preliminary results suggested the involvement of miRNAs in BCR-ABL levels regulation and in TKI response, supporting the search of a miRNAs TKI response profile that could predict the response in CML patients. This information could act as powerful tool for the stratification and selection of the best therapeutic approach (lower toxicity and cost effective), contributing to higher survival rates and better quality of life in CML patients. Work supported by the Faculty of Medicine of the University of Coimbra and Santander Totta Bank, grant reference FMUC-BST-2016-214.

Figure 1.

Summary/Conclusions: Due to high rates of relative survival observed after introduction of imatinib, the trajectory of the CML prevalence in France, as in other western countries, has changed. Given particular hypothesis on the CML incidence rates, this trajectory will bring the CML prevalence by the mid century to levels fully determined by population aging. For France, we have estimated this level above30 cases per 100,000 inhabitant.
(SNPs) affect the transporter activity, but their impact on clinical response to imatinib in chronic myeloid leukemia (CML) is discordant; even less is known on their role in patients treated with second generation (2G) TKIs dasatinib and nilotinib.

Aims: To investigate the role of the most common ABCB1 and ABCG2 genetic polymorphism in chronic phase CML patients treated with imatinib and 2G-TKIs.

Methods: We analysed four polymorphisms of ABCB1 (1297C>T, 1386C>T, 2677G>T/A and 3435C>T) and two polymorphisms of ABCG2 (34Q>A and 421C>A) in 196 CP-CML patients, of whom 139 treated with imatinib (114 in first line and 25 after interferon failure) and 57 treated with dasatinib or nilotinib (22 in first line and 35 after imatinib failure). We compared the rates of optimal response at 3 months (defined as BCR/ABL <10%), at 6 months (BCR/ABL<1%) and at 12 months (BCR/ABL<0.1%), progression-free survival (PFS) and time to treatment failure (TTF) according to the different protein genotypes. TTF was calculated from the start of therapy to any of the followings: progression to accelerated or blastic phase (ABP), death for any cause at any time, treatment discontinuation for primary or secondary resistance or intolerance. PFS was calculated from the start of TKI to ABP or death.

Results: A total of 196 patients with CP-CML (median age 57 years, range 21-84) were included in the analysis. Frequency of ABCB1 and ABCG2 SNPs expression is summarized in Table 1. Considering response to therapy, either in imatinib-treated patients and in those receiving a 2G-TKI, we did not find any significant difference in terms of optimal response at the various timepoints, TTF or PFS for ABCB1 C1236T, G2677T and C3435T and of ABCG2 G34A and C412A polymorphism, even if there was a trend for a worse PFS in the few patients (n=2) with 1236 allele A treated with imatinib. Conversely, we found a lower rate of optimal response at 3 (p=0.1), 6 (p=0.05) and 12 (p=0.2) months in imatinib-treated patients with TC genotype of ABCB1 T129 SNP, though the small number of patients (7) had probably and impact on statistical significance. However, TTF was shorter for ABCB1 129T>C patients, both receiving imatinib (p=0.05) and 2G-TKIs (p=0.07), and also PFS was significantly shorter in this cohort (p=0.003).

Table 1.

<table>
<thead>
<tr>
<th>MDR protein</th>
<th>SNP</th>
<th>Genotype</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>C1236T</td>
<td>CC</td>
<td>32%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CT</td>
<td>36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TT</td>
<td>32%</td>
</tr>
<tr>
<td>ABCG2</td>
<td>G34A</td>
<td>AA</td>
<td>32%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AG</td>
<td>36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GG</td>
<td>32%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AC</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GG</td>
<td>32%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA</td>
<td>32%</td>
</tr>
</tbody>
</table>

Results: Out of 308 patients newly diagnosed with CML-CP during the study period. Of these patients, 104 (34%) were assigned to the imatinib group (P=0.0042). However, prognostic impact of high-risk, of which 19 were in the imatinib group and 27 were in the 2nd TKI group. EUTOS score was unavailable in 39 patients. With regard to initial TKI, all patients were treated with imatinib in the imatinib group. Among patients assigned to the 2nd TKI group, 149 (73%) were initially treated with any TKI. The median follow-up period for all patients was 48 months (range: 1–185 months). Among patients in the 2nd TKI group, CML-associated death rates were significantly lower than in the imatinib group. EUTOS high-risk patients score exhibited significantly worse outcomes in EFS, PFS, and CML-associated death compared to those considered low-risk. Most importantly, risk stratification by EUTOS score was predictive of risk-associated clinical outcomes in patients assigned to the imatinib group; however, EUTOS score failed to predict risk-associated clinical outcomes of patients assigned to the 2nd TKI group (see Figure). The EUTOS high-risk patients in the imatinib group showed worse clinical outcomes than those in the 2nd TKI group (hazard ratio [HR] 6.35, 95% confidence interval [CI] 1.79 – 22.6, p=0.0042). However, prognostic effect was less in the 2nd TKI group (HR 3.21, 95% CI 0.59 – 17.6, p=0.18).

Out of 308 patients, 9 progressed to AP/BP, of which 8 transformed during imatinib therapy and 1 transformed during dasatinib therapy.

Summary/Conclusions: With the limits of the low expression rates of some SNPs, our data suggest a lower response in patients harboring 1297-C polymorphism, at least in those receiving imatinib. Other ABCB1 and ABCG2 genotypes do not seem to impact on response to TKI treatment.

E1066

THE INTRODUCTION OF SECOND-GENERATION TYROSINE KINASE INHIBITORS MAY REDUCE THE PROGNOSTIC IMPACT OF HIGH-RISK PATIENTS ASSESSED TO EUROPEAN TREATMENT AND OUTCOME STUDY (EUTOS) SCORE


1Department of Hematology, Juntendo University School of Medicine Neirima Hospital. 2Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo. 3Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama. 4Department of Hematology, Juntendo University School of Medicine, Tokyo, 5Department of Hematology, Yokohama Municipal Citizen’s Hospital, Yokohama, 6Department of Hematology, Juntendo University Urayasu Hospital, Urayasu, 7Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, 8Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan

Background: The discovery of tyrosine kinase inhibitor (TKI) imatinib has revolutionized the conception of chronic myeloid leukemia (CML) as a mortal disease to a long-term controllable disease. The European Treatment and Outcome Study (EUTOS) score is a clinical tool that utilizes imatinib-based objectives to predict treatment response and progression free survival (PFS) in patients with CML in chronic phase (CP). However, it is currently unknown whether the introduction of second generation TKIs (2nd TKIs) affects prognostic score of patients with CML-CP, particularly among those considered high-risk according to EUTOS score.

Aims: Our study aims to highlight the critical role of the introduction of 2nd TKIs on patient prognosis as determined by EUTOS score.

Methods: Patients data was obtained retrospectively from patients enrolled in the CML Cooperative Study Group. Patients with CML-CP who were treated with any TKIs as first line therapy between April 2001 and January 2016 were enrolled to the study and were classified according to date of diagnosis. Those who were diagnosed with CML-CP before March 2009 were classified into the imatinib group, and those diagnosed after April 2009 were classified into the 2nd TKI group, as these patients were able to be treated with 2nd TKIs. The study was approved by the research ethics boards of each institution and was conducted in accordance with the Declaration of Helsinki.

Results: There were 308 patients newly diagnosed with CML-CP during the study period. Of these patients, 104 (34%) were assigned to the imatinib group and 204 (67%) were assigned to the 2nd TKI group. With respect to EUTOS score, 223 patients were classified as low-risk, of which 69 were in the imatinib group and 154 were in the 2nd TKI group. Forty-six patients were considered high-risk, of which 19 were in the imatinib group and 27 were in the 2nd TKI group. EUTOS score was unavailable in 39 patients. With regard to initial TKI, all patients were treated with imatinib in the imatinib group. Among patients assigned to the 2nd TKI group, 149 (73%) were initially treated with any TKI. The median follow-up period for all patients was 48 months (range: 1–185 months). Among patients in the 2nd TKI group, CML-associated death rates were significantly lower than in the imatinib group. EUTOS high-risk patients score exhibited significantly worse outcomes in EFS, PFS, and CML-associated death compared to those considered low-risk. Most importantly, risk stratification by EUTOS score was predictive of risk-associated clinical outcomes in patients assigned to the imatinib group; however, EUTOS score failed to predict risk-associated clinical outcomes of patients assigned to the 2nd TKI group (see Figure). The EUTOS high-risk patients in the imatinib group showed worse clinical outcomes than those in the 2nd TKI group (hazard ratio [HR] 6.35, 95% confidence interval [CI] 1.79 – 22.6, p=0.0042). However, prognostic effect was less in the 2nd TKI group (HR 3.21, 95% CI 0.59 – 17.6, p=0.18).

OUT OF 308 PATIENTS, 9 PROGressed TO AP/BP, OF WHICH 8 TRANSFORMED DURING IMATINIB THERAPY AND 1 TRANSFORMED DURING DASATINIB THERAPY.

Figure 1.

Summary/Conclusions: Among patients assigned to the imatinib group, risk stratification by EUTOS score was predictive of clinical outcomes in that those considered high-risk experienced considerably more adverse events (EFS, PFS, or CML-associated death) than those considered low-risk. Our results support the use of 2nd TKIs in treating high-risk patients with CML-CP in order to avoid disease progression. Future large-scale studies are necessary to evaluate the clinical significance of EUTOS scoring in the accurate prediction of prognosis among patients with CML-CP treated with 2nd TKIs.
CHRONIC MYELOID LEUKEMIA DIAGNOSED DURING PREGNANCY: THERAPY TACTICS AND OUTCOMES

1National Research Center for Hematology, Moscow, Russian Federation, 2Hematology, S. Eugenie Hospital, Tor Vergata University, Rome, Italy, 3Department of Hematology, Seoul St. Mary’s Hospital, 4Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of, 5Hematology Department, SI “Institute of Blood Pathology and Transfusion Medicine UAMS”, Lviv, Ukraine, 6Research Institute of Hematology and Blood Transfusion MOH of Uzbekistan, Tashkent, Uzbekistan, 7Hematology Center after prof. R.H. Yeolyan, Yerevan, Armenia, 8FSBI Scientific Center of Obstetrics, Gynecology and Perinatology of Healthcare Ministry named after V.I. Kulakov, Moscow, Russian Federation

Background: Chronic myeloid leukemia (CML) diagnosed at pregnancy is a serious challenge. Treatment by tyrosine kinase inhibitors (TKI) today is considered harmful for fetus due to possible teratogenicity. On the other hand TKI delay is dangerous for disease progression as no other options have comparable to TKI effectiveness. Pregnancy termination by abortion may be crucial for desired pregnancies as further childbirth is postponed for years until stable deep molecular response (DMR). Due to limited number of cases and ethical issues there is no consensus on how to behave in such delicate cases.

Aims: To describe pregnancy outcomes and therapy tactics for CML diagnosed at pregnancy.

Methods: Information regarding CML diagnosed at pregnancy was collected with the participants of the observational study of European LeukemiaNet (ELN Pregnancy Registry). The data included CML clinical characteristics at diagnosis, cyto genetic and molecular parameters, information of therapy, pregnancy outcomes and data of newborns.

Table 1. 

| Table 1. Number of pregnancy cases in countrys and outcome of pregnancy diagnosed simultaneously with other conditions. |

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia</td>
<td>10</td>
<td>10 entirely healthy newborns</td>
</tr>
<tr>
<td>Ukraine</td>
<td>8</td>
<td>7 entirely healthy newborns</td>
</tr>
<tr>
<td>Armenia</td>
<td>5</td>
<td>5 entirely healthy newborns</td>
</tr>
<tr>
<td>Republic Of, Turkey</td>
<td>3</td>
<td>3 entirely healthy newborns</td>
</tr>
<tr>
<td>Uzbekistan, Kazakhstan</td>
<td>2</td>
<td>2 entirely healthy newborns</td>
</tr>
</tbody>
</table>

Results: Thirty one women with median age 26 years (range 20-39) were diagnosed with Ph-positive chronic phase CML during pregnancy. That was 11% of all 282 pregnancy cases. In certain countries (Russia) up to 21% of women with CML and pregnancy had the synchronistic onset of these events (table 1). Sokal low/intermediate/high and EUTOS low/high risk score was in 22/5/3 and 28/2. Background:

V.I. Kulakov, Moscow, Russian Federation of Obstetrics, Gynecology and Perinatology of Healthcare Ministry named after V.I. Kulakov, Moscow, Russian Federation

Aims: To describe pregnancy outcomes and therapy tactics for CML diagnosed at pregnancy.

Methods: Information regarding CML diagnosed at pregnancy was collected with the participants of the observational study of European LeukemiaNet (ELN Pregnancy Registry). The data included CML clinical characteristics at diagnosis, cytogenetic and molecular parameters, information of therapy, pregnancy outcomes and data of newborns.

Table 1. 

| Table 1. Number of pregnancy cases in countrys and outcome of pregnancy diagnosed simultaneously with other conditions. |

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia</td>
<td>10</td>
<td>10 entirely healthy newborns</td>
</tr>
<tr>
<td>Ukraine</td>
<td>8</td>
<td>7 entirely healthy newborns</td>
</tr>
<tr>
<td>Armenia</td>
<td>5</td>
<td>5 entirely healthy newborns</td>
</tr>
<tr>
<td>Republic Of, Turkey</td>
<td>3</td>
<td>3 entirely healthy newborns</td>
</tr>
<tr>
<td>Uzbekistan, Kazakhstan</td>
<td>2</td>
<td>2 entirely healthy newborns</td>
</tr>
</tbody>
</table>

Results: Thirty one women with median age 26 years (range 20-39) were diagnosed with Ph-positive chronic phase CML during pregnancy. That was 11% of all 282 pregnancy cases. In certain countries (Russia) up to 21% of women with CML and pregnancy had the synchronistic onset of these events (table 1). Sokal low/intermediate/high and EUTOS low/high risk score was in 22/5/3 and 28/2.

Background:

V.I. Kulakov, Moscow, Russian Federation

Aims: To describe pregnancy outcomes and therapy tactics for CML diagnosed at pregnancy.

Methods: Information regarding CML diagnosed at pregnancy was collected with the participants of the observational study of European LeukemiaNet (ELN Pregnancy Registry). The data included CML clinical characteristics at diagnosis, cytogenetic and molecular parameters, information of therapy, pregnancy outcomes and data of newborns.

Table 1. 

| Table 1. Number of pregnancy cases in countrys and outcome of pregnancy diagnosed simultaneously with other conditions. |

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia</td>
<td>10</td>
<td>10 entirely healthy newborns</td>
</tr>
<tr>
<td>Ukraine</td>
<td>8</td>
<td>7 entirely healthy newborns</td>
</tr>
<tr>
<td>Armenia</td>
<td>5</td>
<td>5 entirely healthy newborns</td>
</tr>
<tr>
<td>Republic Of, Turkey</td>
<td>3</td>
<td>3 entirely healthy newborns</td>
</tr>
<tr>
<td>Uzbekistan, Kazakhstan</td>
<td>2</td>
<td>2 entirely healthy newborns</td>
</tr>
</tbody>
</table>

Results: Thirty one women with median age 26 years (range 20-39) were diagnosed with Ph-positive chronic phase CML during pregnancy. That was 11% of all 282 pregnancy cases. In certain countries (Russia) up to 21% of women with CML and pregnancy had the synchronistic onset of these events (table 1). Sokal low/intermediate/high and EUTOS low/high risk score was in 22/5/3 and 28/2.

Background:

V.I. Kulakov, Moscow, Russian Federation
of Ulsan college of Medicine, Ulsan, 1School of Medicine, Keimyung University, Daegu, 18Chonbuk National University Medical School, Jeonju, 11St. Vincent's Hospital, The Catholic University of Korea, Suwon, 12Asan Medical Center, University of Ulsan College of Medicine, 13School of Medicine, Ewha Womans University, Seoul, 4Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, 1National Health Insurance Service Ilsan Hospital, Ilsan, 16Chungbuk National University Medical School, Cheongju, Korea, Republic Of

Background: Recent reports have demonstrated that tyrosine kinase inhibitors (TKIs) discontinuation can be employed in chronic phase chronic myeloid leukemia (CP CML) patients with sustained deep molecular responses after enough TKI therapy. Consequently, treatment-free remission (TFR) has been a new therapeutic goal. Although 50%-70% of patients experienced molecular relapse by several imatinib (IM) discontinuation studies, the most of patients resumed molecular responses (MR) following restart of IM. Aims: We evaluated the impact of molecular response by 24 months for molecular level after 3 months (BCR-ABL1 transcript level ≤1%) of radotinib 300mg twice daily (bid) approved for first-line use in Korea or imatinib treatment in newly diagnosed CML-CP. Methods: Baseline demographic and clinical risk score, 241 patients were randomized 1:1:1 to radotinib 300mg bid (n=79), radotinib 400mg bid (n=81), or imatinib 400mg once daily (qd) (n=81). 157 patients with available 3 months qRT-PCR on study therapy [radotinib 300mg bid (n=79), and imatinib 400mg qd (n=78)] were evaluated. And, total of 151 patients who received radotinib 400mg bid and imatinib 400mg qd were evaluated for 6 months. Molecular response was assessed by q-PCR at baseline and every 3 months. BCR-ABL1 transcript level was measured by RQ-PCR, standardized according to international scale (BCR-ABL1). Major molecular response (MRM) was defined by BCR-ABL1/ABL1 ratio ≤0.1% and MR-4 was defined as ≤0.032%.

Results: In two study groups, early molecular response (EMR) at 3 months were observed in 86.1% of patients in the radotinib 300mg bid group and 67.9% in the imatinib group (P=0.0179). More patients treated with radotinib 300mg bid who had EMR at 3 months achieved MMR and MR-4 by 24 months: 73.5% and 38.2% in the radotinib 300mg bid group and 63.6% and 29.1% in the imatinib group, respectively. At 6 months, 73.4% of patients in the radotinib 300mg and 53.1% patients in imatinib group (P=0.0246) achieved 6 months EMR. The patients who had EMR at 6 months in radotinib 300mg bid group were significant difference in EMR rate compared with imatinib 400mg qd group. 86.2% and 44.8%, respectively and imatinib group achieved 81.4% and 39.5%, respectively. By 24 months, overall survival (OS) and progression-free survival (PFS) according to 3 months or 6 months were not significantly different in two groups.

Summary/Conclusions: With minimum 24 months follow-up, early responses at 3 months or 6 months can predict better outcomes in newly diagnosed chronic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate the significant long-term prognostic value such as overall survival and progression-free survival by EMR, longer follow-up are needed.

E1071 HYDROXYUREA SUPPRESSES BCR-ABL1 T315I+CML CLONES IN VIVO AND IN VITRO AND SYNERGIZES WITH PONATINIB IN ELIMINATING TKI-RESISTANT CML CELLS

M. Schneeweiss1,2,*, K. Byrgazov3, S. Preuner3, S. Herndlhofer1,2, W.R. Sperr1,2, G. Hoermann4, M. Deininger5, T. Lion1, P. Valent1,2, K.V. Geleijnse1,2
1Ludwig Boltzmann Cluster Oncology, 2Department of Internal Medicine I/Divi-

Aims: Our data demonstrated that a second attempt might be possible and the median time to MMR loss after second discontinuation was similar to those of the first discontinuation. But the molecular kinetics after second IM resumption needs longer follow-up with more patients. Further studies on the predictors to select patients for a trial of second TFR and novel strategies such as intermittent therapy will be warranted.

Methods: CP CML patients who were treated with IM for more than 3 years and had undetectable levels of BCR-ABL1 transcripts determined by quantitative reverse transcriptase polymerase chain reaction (PCR) for at least 2 years were eligible for KID study and in cases of MMR loss after 2 consecutive assessments, IM treatment was re-introduced. After IM resumption for MMR loss, the molecular kinetics was evaluated until UMRD was re-

Summary/Conclusions: With minimum 24 months follow-up, early responses at 3 months or 6 months can predict better outcomes in newly diagnosed chronic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate the significant long-term prognostic value such as overall survival and progression-free survival by EMR, longer follow-up are needed.

Background: In chronic myeloid leukemia (CML), BCR-ABL1 T315I leads to resistance against most BCR-ABL1 tyrosine kinase inhibitors (TKIs). Long-term therapy with ponatinib, which suppresses BCR-ABL1 T315I, is problematic because of side effects. In addition, resistance against ponatinib may develop due to occurrence of compound mutations in BCR-ABL1. Therefore, alternative therapies have to be considered. Hydroxyurea (HU) has been used for (pallia-

Methods: BCR-ABL1 T315I+CML patients were treated with HU (1-3 g/day) for 2 to 18 months. White blood counts (WBC), differential counts, and BCR-ABL1 transcript levels were reported. The BCR-ABL1 T315I+CML/TBR ratio was determined by mutation-specific, ligation-dependent, PCR and next generation sequencing (NGS) methods. Flow cytometry, real-time PCR, and Western blot were used to analyze cell cycle, cell apoptosis, cell proliferation, and cell migration. Results: In vitro, CML cell lines, THP-1 and K562, showed a significant decrease in cell viability and apoptosis. However, the effects of HU on TKI-resistant sub-clones have not been examined so far.

Summary/Conclusions: With minimum 24 months follow-up, early responses at 3 months or 6 months can predict better outcomes in newly diagnosed chronic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate the significant long-term prognostic value such as overall survival and progression-free survival by EMR, longer follow-up are needed.

Background: In chronic myeloid leukemia (CML), BCR-ABL1 T315I leads to resistance against most BCR-ABL1 tyrosine kinase inhibitors (TKIs). Long-term therapy with ponatinib, which suppresses BCR-ABL1 T315I, is problematic because of side effects. In addition, resistance against ponatinib may develop due to occurrence of compound mutations in BCR-ABL1. Therefore, alternative therapies have to be considered. Hydroxyurea (HU) has been used for (pallia-

Methods: BCR-ABL1 T315I+CML patients were treated with HU (1-3 g/day) for 2 to 18 months. White blood counts (WBC), differential counts, and BCR-ABL1 transcript levels were reported. The BCR-ABL1 T315I+CML/TBR ratio was determined by mutation-specific, ligation-dependent, PCR and next generation sequencing (NGS) methods. Flow cytometry, real-time PCR, and Western blot were used to analyze cell cycle, cell apoptosis, cell proliferation, and cell migration. Results: In vitro, CML cell lines, THP-1 and K562, showed a significant decrease in cell viability and apoptosis. However, the effects of HU on TKI-resistant sub-clones have not been examined so far.

Summary/Conclusions: With minimum 24 months follow-up, early responses at 3 months or 6 months can predict better outcomes in newly diagnosed chronic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate the significant long-term prognostic value such as overall survival and progression-free survival by EMR, longer follow-up are needed.

Background: In chronic myeloid leukemia (CML), BCR-ABL1 T315I leads to resistance against most BCR-ABL1 tyrosine kinase inhibitors (TKIs). Long-term therapy with ponatinib, which suppresses BCR-ABL1 T315I, is problematic because of side effects. In addition, resistance against ponatinib may develop due to occurrence of compound mutations in BCR-ABL1. Therefore, alternative therapies have to be considered. Hydroxyurea (HU) has been used for (pallia-

Methods: BCR-ABL1 T315I+CML patients were treated with HU (1-3 g/day) for 2 to 18 months. White blood counts (WBC), differential counts, and BCR-ABL1 transcript levels were reported. The BCR-ABL1 T315I+CML/TBR ratio was determined by mutation-specific, ligation-dependent, PCR and next generation sequencing (NGS) methods. Flow cytometry, real-time PCR, and Western blot were used to analyze cell cycle, cell apoptosis, cell proliferation, and cell migration. Results: In vitro, CML cell lines, THP-1 and K562, showed a significant decrease in cell viability and apoptosis. However, the effects of HU on TKI-resistant sub-clones have not been examined so far.

Summary/Conclusions: With minimum 24 months follow-up, early responses at 3 months or 6 months can predict better outcomes in newly diagnosed chronic myeloid leukemia patients treated with radotinib or imatinib. But, to evaluate the significant long-term prognostic value such as overall survival and progression-free survival by EMR, longer follow-up are needed.
Results: HU treatment resulted in WBC stabilization in 3 of 4 patients, but failed to induce a molecular response. However, surprisingly, the percentage of BCR-ABL1 decreased significantly in all 4 patients during HU treatment and was no longer detectable in 3 of 4 cases. Stem cell transplantation could be performed in 2 patients after 2-3 months. In one patient, stable disease over 18 months was obtained with HU-therapy. In one patient, the disease progressed rapidly despite temporary suppression of BCR-ABL1. In vitro studies, HU was found to block the growth in all cell lines tested and in all primary cell samples (n=7) examined, with IC50 values ranging between 50 and 250 μM. Interestingly, cell lines exhibiting mutant BCR-ABL1 were more sensitive against HU than cell lines expressing BCR-ABL1 WT. HU and ponatinib were found to synergize in inhibiting growth of all cell lines tested, including cells expressing BCR-ABL1 T315I or T315I-including compound mutations. Cooperative drug effects were also confirmed in primary CML cells (n=4). In cell lines exhibiting mutant BCR-ABL1, ponatinib was found to suppress Ba/F3p210T315I cells but not Ba/F3p210T315I/F359V or Ba/F3p210T315I/E255V cells, whereas HU was found to exert stronger effects on cells expressing mutant BCR-ABL1, and the drug combination resulted in complete suppression of all sub-clones.

Summary/Conclusions: Our data show that HU exerts strong, sub-clone specific, and potent antiproliferative effects on TKI-resistant cells. The addition of HU and ponatinib produce synergistic growth-inhibitory effects on TKI resistant CML cells. Clinical studies are now warranted to define the exact value of the drug combination ponatinib+HU in TKI resistant CML.

E1072
ASSOCIATION OF BCL2L11 (BIM) DELETION POLYMORPHISM WITH MOLECULAR RELAPSE AFTER TYROSINE KINASE INHIBITOR CESSION IN CHRONIC MYELOID LEUKAEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
S. Katagiri1, T. Tauchi1, Y. Tanaka1, K. Ando1, S. Okabe1, M. Gotoh1, Y. Ito1, T. Umezuz1, K. Takadok1, J.H. Ohyashiki1, K. Ohyashiki1
1Department of Hematology, 2Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, Tokyo, 3BML, INC, Saitama, Japan

Background: The inhibition of BCR-ABL1 kinase with tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis of chronic myeloid leukemia (CML). Recently, it has been recognized that some CML patients with deep molecular response (DMR) can maintain treatment-free remission (TFR) after TKI cessation. However, no predictive prognostic factor for successful treatment cessation has yet been identified. BCL2L11 (BIM) deletion polymorphism (intron 2) has been reported to be associated with an inferior response to TKI (Ng et al. Nature Medicine, 2012). We have previously reported that BIM cells in vivo and in vitro may predict relapse after TKI discontinuation (Katagiri et al. Br J Haematol, 2013).

Aims: To further clarify the role of predictive biomarkers in molecular relapse after TKI cessation, we performed a long-term follow-up of CML patients with DMR after TKI cessation.

Methods: Patients with DMR receiving TKI treatment were included. Molecular relapse was defined as a loss of the major molecular response (MMR). The genomic DNA of patients was obtained from their whole blood samples using the EZ1 DNA Blood 350 kit (Qiagen, Valencia, USA). Deletion polymorphism was detected by Q-Invader assay using primers designed to detect a deletion size of 1-2 nucleotides (Ohyashiki et al. J Hematol Transfus, 2014).

Results: Forty-six CML patients (29 men; 17 women, median age, 58.5 years) were included in this study (Sokal category; low: 32, intermediate: 10, and high: 2). Thirty-three patients discontinued imatinib, five discontinued nilotinib, and eight discontinued dasatinib. Ten patients were treated with IFNs before TKI treatment. The median duration from TKI initiation to cessation was 85.0 month (range: 22–177 months); the median duration of DMR before TKI cessation was 43.0 month (range: 5–131 months). Treatment-free remission was estimated to be 66.5% at 12 months, 61.5% at 24 months, and 58.5% at 36 months. Thirty-six CML patients were analyzed for the presence of BIM deletion polymorphism (BIM+ and BIM−). All patients with BIM deletion polymorphism relapsed within 12 months after TKI cessation. A significant difference was observed only in BIM deletion polymorphism between the patients who maintained and those who lost MMR (p=0.0000528). No patient died during the follow-up period. No significant difference was observed in the sensitivity of TKI therapy, prior TKI therapy, and time to DMR between relapsing and non-relapsing patients.

Summary/Conclusions: The analysis of BIM deletion polymorphism in CML patients is expected to be useful for predicting their early molecular relapse after TKI treatment discontinuation.

E1073
XPERT® BCR-ABL ULTRA, A HIGH SENSITIVITY ASSAY WITH A LIMIT OF DETECTION REACHING MR4.5 AND BELOW ON AN INTERNATIONAL REPORTING SCALE
C. Ferrand1, M. Deschamps1, A. Levitas2, C. Lockwood2, J. Payton4, G. Uy3, C. Schiffer5, G. Feldman6, A. Bossler7, J. Woolworth8, A. Mims6, K. Shridhar2, V. Xiao9, N. Wu2, H. Wei2, C. Lykke10, M. Bates11, W. Wong2, G.-J. Day2,*
1Department of Laboratory Medicine, University of Washington, Seattle, 2School of Medicine, Washington University, Saint Louis, 3Karmanos Cancer Institute, Wayne State University, 4Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, 5Data Management and Analytics, 6Medical and Scientific Affairs and Strategy, Cepheid, Sunnyvale, United States

Background: The ability to consistently detect low levels of BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) is important in the assessment of treatment outcomes in patients on tyrosine kinase inhibitor (TKI) therapy. Particularly, BCR-ABL assays that are sensitive in the measurement of deep level response may aid in the identification of potential candidates for treatment discontinuation. Xpert® BCR-ABL Ultra detects the most common BCR-ABL transcripts below MR4.5 (Molecular Response at 4.5-log reduction) or 0.0032%, which is widely accepted as the clinical threshold that defines candidates who can safely discontinue TKI therapy.

Aims: The present studies were designed to verify the limit of detection (LoD) for Xpert® BCR-ABL Ultra assay below M4.5 on the International Scale (IS) in clinical samples for both the b3a2 and b2a2 transcripts.

Methods: To overcome the challenge of testing numerous replicates requiring large volumes of patient samples, serial dilutions ranging from BCR-ABL/ABL levels of 10% to <0.001% (IS) were prepared as contrived samples using CML patient blood with initial BCR-ABL level >10% (IS) and pooled blood from CML negative patients, ranged from 10% to <0.001% (IS). Twenty-one replicates of each dilution were measured for%BCR-ABL/ABL (IS) or with 95% confidence. The acceptable precision for%BCR-ABL/ABL (IS) is defined as the ability to detect at least a 3-fold difference for all concentrations tested.

In addition, analytical LoD studies were performed using spike-in CML cell lines and cell-line derived RNAs, carrying either b3a2 or b2a2 transcripts. Furthermore, the clinical sensitivity study was conducted using blood from twelve low BCR-ABL transcripts level CML patients on TKI therapy, who had achieved and maintained MMR (Major Molecular Response) [0.1% (IS)] with reporting below 0.05% (IS).

Results: Consistent results were observed in the both the diluted patient blood and spike-in CML cell lines or cell-line derived RNA studies for both the b3a2 and b2a2 transcripts, demonstrating an assay LoD of MR4.5 and below with a less than 2-fold difference at the LoD levels. With the clinical sensitivity study, eleven out of twelve low CML subjects were detected in at least 19 out of 20 replicates tested per subject over a range of 0.038% (IS) (SD=±0.17 Log) to 0.0011% (IS) (SD=±0.4 Log). The overall ABL copy number present in clinical samples in each study was at least 5-10 times the required minimal ABL copy number of 32,000 to support a claim of MR4.5 and ≥100,000 for MR5.0.

Summary/Conclusions: These LoD evaluations demonstrate that the Xpert® BCR-ABL Ultra assay complies with the international guidelines for assay sensitivity achieving MR4.5 with 5-10 times more than the required ABL copies to confidently identify candidate patients that may benefit from the discontinuation of TKI therapy.
Enzymopathies, membraneopathies and other anemias

E1074
IDENTIFICATION OF INCIDENT CASES OF GAUCHER DISEASE IN SPLENOMEGALY AND/OR THROMBOCYTOPENIA PATIENTS IN SPECIALIZED MEDICAL SERVICES IN COLOMBIA THROUGH THE USE OF A SELECTION ALGORITHM


1Bogotá D.C., Clínica Los Nogales, Bogotá D.C., 2Bolívar, Universidad de Cartagena, Clínica Blas de Lezo, Cartagena, 3Antioquia, Clínica Sagrado Corazón, Medellín, 4Antioquia, Clínica Vida Prado, Medellín, 5Valle del Cauca, Clínica de Occidente, 6Valle del Cauca, Universidad del Valle, Cali, 7Santander, Hospital San Luis, Bucaramanga, 8Antioquia, Hospital General de Medellín, Medellín, 9Atlántico, Centro Cancerológico del Caribe, Barranquilla, 10Santander, Universidad de Hematología y Oncología de Santander, Bucaramanga, 11Antioquia, Hospital Universitario San Vicente Fundación, Medellín, 12Huila, Universidad Surcolombiana, 13Huila, Hospital Universitario Hernando Montecalleano Perdomo, Neiva, 14Antioquia, Clínica de Oncología Astorga, Medellín, 15Caldas, Médicos Internistas de Caldas, Manizales, 16Antioquia, Hospital Pablo Tobon Urbe, Medellín, 17Valle del Cauca, Centro Médico Imbanaco, Cali, 18Bogotá D.C., Clínica Infantil Cesuobiduo, Bogotá D.C., 19Atlántico, Clínica la Asunción, 20Atlántico, Clínica Bonadona, Barranquilla, 21Bogotá D.C., Centro de Atención a Investigación Médica Caimed S.A.S, Bogotá D.C., Colombia

Background: Gaucher disease (GD) varies greatly in severity and organ involvement. Clinical characteristics are usually nonspecific and lead to late diagnosis with irreversible complications. Splenomegaly and thrombocytopenia are the two most common manifestations (Gaucher Registry, 2008), which reported 86% cases with moderate to severe splenomegaly and 60% thrombocytopenia at the time of diagnosis, thus demonstrating why patients are referred to hematology. A diagnosis of GD is considered after other diagnostic hypotheses have been ruled out. The consensus of international experts on the management of patients with GD established a diagnostic algorithm that is particularly intended for specialists (Mistry, 2010). Straightforward implementation of diagnostic algorithms to support medical specialties in Latin America for early diagnostic testing of GD is required.

Aims: To identify new cases of GD in a selected population with splenomegaly and/or thrombocytopenia referred to Hematology, Pediatric Hematology, Pediatrics and Internal Medicine in Colombia, approved by Ethics Committee (EC). The study has an expected duration of 24 months since EC approval for each center. Eligible subjects are those with three documented criteria: thrombocytopenia <150,000/cc plus anemia (hemoglobin <11g/dL in men and <10g/dL in women) plus/or bone pain plus/or Monoclonal Gammapathy of Unknown Significance plus/or Polyclonal Gammapathy in subjects aged 30 years and older; and/or splenomegaly defined as palpable spleen ≥1cm below the costal rib or diagnosed by imaging, and/or Splenectomy by splenomegaly with no known cause. Subjects with prior diagnosis of GD, splenomegaly due to portal hypertension, hematologic malignancy, hormone anemia and thalassemia were excluded. Informed consent was obtained for all included subjects. Clinical information was collected from their medical history. The enzymatic activity of the β-glucocerebrosidase was performed in peripheral blood, using dried blood spots (DBS) and/or leukocytes. In subjects with reduced enzymatic activity in DBS, confirmation of Gaucher disease enzymatic activity in leucocytes was determined. GBA1 gene was analyzed.

Results: Since Feb/14 to Nov/16, 400 subjects have been included (51.3% men) with a median age of 28.79 years (range, 0.01 to 91.67). Reduced enzymatic activity of β-glucocerebrosidase was identified in 14 subjects (50 men) with a median age of 12.68 years (range, 0.3 to 74.86). All subjects were non-Ashkenazi origin, with 82.8% thrombocytopenia, 49.5% splenomegaly and 43.3% splenectomy. Detailed population description is on Figure 1.

Summary/Conclusions: This study suggests that selection algorithm could be implemented in Colombia, supporting specialists in making decisions on diagnosis of Gaucher Disease. Further characterization of the population is ongoing.

Acknowledgements: This study was funded by Sanofi Genzyme Colombia and coordinated by Caimed Colombia.

E1075
IMPACT OF PEROXIREDOXIN 2, GLUTATHIONE PEROXIDASE AND CATALASE INHIBITION ON OXIDATIVE STRESS MODIFICATIONS OF RED BLOOD CELL MEMBRANE AND CYTOSOL

D. Melo1, S. Ribeiro2, A. Santos-Silva2, A. Rocha2

1Faculdade de Ciências, Universidade do Porto, 2UCBIO, REQUIMTE, Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, Porto, Portugal

Background: Several anemias are associated with oxidative stress, namely, sickle cell anemia, β-thalassemia, glucose-6-phosphate dehydrogenase deficiency and hereditary spheroctosis. Red blood cells (RBC) are continuously exposed to oxidative stress, mainly due to their primary function as oxygen carriers; therefore, the erythrocytes are equipped with an efficient antioxidant system, however, when its capacity is overwhelmed, the cell is exposed to reactive oxygen species (ROS), triggering oxidative modifications. The antioxidant system includes several enzymes, such as peroxiredoxin 2 (Prx2), glutathione peroxidase (GPx) and catalase (CAT); in spite of their roles in cell defense being known, the interplay between these peroxidases is still unclear. The recent report of condonin A, as a specific Prx2 inhibitor, offers the possibility to further explore the roles and contribution of these enzymes to antioxidant defense.

Aims: We aimed to study the importance of Prx2, GPx and CAT inhibition on defense against oxidative stress in normal erythrocytes.

Methods: We performed in vitro assays (n=3) with RBCs from healthy volunteers, inhibiting Prx2, GPx and CAT, either individually, two-by-two or all three; condonin A, mercaptosuccinic acid and sodium azide were used as specific inhibitors of Prx2, GPx and CAT, respectively. Since the RBC membrane is a major target of ROS, we evaluated membrane lipoperoxidation (LPO) and membrane bound haemoglobin (MBH), as well as, cytosol’s total antioxidant status (TAS), by spectrophotometric methods.

Results: Concerning TAS we found a trend towards decreasing values with enzyme inhibition (one or more); the lowest value of TAS was observed when all three enzymes were inhibited and, when only two enzymes were inhibited, the lower values were obtained for pairs that included CAT inhibition; when only one enzyme was inhibited, GPx inhibition showed the highest MBH, MBH was increased for all enzyme inhibitory conditions, when compared to the condition with all enzymes active, excepting when CAT was inhibited.

Summary/Conclusions: In conclusion, inhibition of these antioxidant enzymes, either alone or simultaneously, leads to oxidative stress modifications within the RBC, as showed by the increase in MBH and membrane LPO, and by the decrease in cytosolic TAS. Moreover, the inhibition of CAT or GPx (either alone or with other enzymes) presented more impact on oxidative modifications than Prx2 inhibition. Our data strengthens the importance of these enzymes in RBC’s...
antioxidant homeostasis, and suggests that inhibition or injury to one (or more) compromises erythrocytes, which might influence clinical presentation in oxidative stress associated anemias.

Acknowledgments: Financial support from FCT/MEC through national funds and co-financed by FEDER, under the Partnership Agreement PT2020 (UID/MULTI/04378/2013 – POCI/01/0145/FEDER/007729) and Norte Portugal Regional Coordination and Development Commission (CDRR-N)/NORTE2020/Portugal 2020 (Norte-01-0145-FEDER-000024).

E1076

MOLECULAR BASIS OF PKLR MUTATIONS IN PATIENTS WITH PYRUVATE KINASE (PK) DEFICIENCY: THE FIRST REPORT FROM SOUTHEAST ASIAN POPULATION

S. Rioueung1, K. Tachavanchi2, S. Ekawattanakit3, V.S. Thanphaichitr2, H. Kanno4, V. Viprakasit5
1Siriraj-Thalassemia Center, 2Department of Pediatrics, 3Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 4Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Tokyo, Japan, 5Department of Pediatrics, of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Background: Recently we have identified a new form of transfusion dependent hemolytic anemia due to KLF1 mutations causing a trans-acting deactivation of pyruvate kinase genes (PKLR). Mutations of PKLR per se can affect red blood cells metabolism and cause a wide range of clinical manifestation from fetal anemia leading to hydroptic fetus, severe neonatal jaundice requiring multiple exchange blood transfusions, chronic to fully compensated hemolytic anemia. Understanding of the molecular basis of pyruvate kinase deficiency (PK def.) might be useful to predict clinical phenotypes and suggest appropriate clinical management of future patients. Moreover, an interaction of PKLR and KLF1 mutations in such patient has not been explored.

Aims: This study aim to identify the mutation of patients with PK def. for the first time in Southeast Asian populations.

Methods: Seven unrelated patients; 6 from Thailand and 1 from Indonesia have been enrolled after informed consent. We have measured the PK activity of all patients and their parents and siblings using a standard biochemical technique as we have described earlier. A complete genomic analysis of all PKLR's exons (NM_000298.5) including exon-intron boundaries were selectively amplified and followed by direct Sanger sequencing.

Table 1.

Results: Seven index PK def. patients as confirmed by enzyme activities, age range 9-35 yrs old, were identified (Table 1). Three patients presented with severe hemolytic anemia and required regular blood transfusion; every 3-4 weeks in two (PK-1 and PK-3) and every 10-12 weeks (PK-2) in which one patient (PK-1) has been successfully treated with bone marrow transplantation and became transfusion-free. Three patients (PK-5, -6 and -8) had moderately severe hemolytic anemia and required blood transfusion occasionally. Only one patient (PK-7) from Indonesia had well-compensated anemia and never required blood transfusion. All but one had PK activities lower than 50% of normal range but these activities did not correlate with clinical severity. We found 11 different mutations in 5 compound heterozygotes and 1 homozygote as shown in Table 1. Four mutations appeared to be novel as they were not been reported in any public databases (c.1269+3A>G; c.353A>G =p.N118S; c.941T>C), mismatched PCR-RFLP for c.1403C>G, c.1463G>A and IVS9(+3)A>G. Interestingly, one index patient (PK-4) was found with only one known missense mutation (R488Q), however we could not find any mutation in KLF1 of this patient suggesting that she might have other unidentified cis mutation involved gene regulation of PKLR. Due to a limited number of patients, there was no clear genotype-phenotype correlation found in our studied population.

Summary/Conclusions: Seven confirmed cases of PK def. are reported here-in. They showed a wide variation of clinical severity. Molecular basis of PKLR mutations was proven to be beneficial to provide a definitive diagnosis of PK def. and might help suggesting clinical presentation in future cases.

E1077

PRELIMINARY RESULTS OF GAU-PED STUDY: PREVALENCE OF GAUCHER DISEASE IN PAEDIATRIC PATIENTS SELECTED BY AN APPROPRIATE DIAGNOSTIC ALGORITHM

W. Morello1, M. Filocamo2, M. Stroppiani2, M. Di Rocco3, F. Fedeli4, G. Russo5, D. Sperti6, F. Furlan7, A. Pession1
1Pediatric Hematology and Oncology Unit, Sant’Orsola-Malpighi University Hospital, Bologna, 2Centro di Diagnostica Genetica e Biochimica delle Malattie Metaboliche, 3Department of Pediatrics, Unit of Rare Diseases, Gaslini Institute, Genoa, 4Pediatric Hematology, Ospedale Niguarda, Milano, 5Pediatric Hematology and Oncology Unit, Azienda Policlinico-Vittorio Emanuele Università di Catania, Catania, 6Pediatric Hematology and Oncology Unit, S. O. “Annunziata”, Cosenza, 7Pediatric Department, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milano, Italy

Background: Gaucher disease (GD) is an autosomal recessive lysosomal storage disease characterized by the deficient activity of beta-glucocerebrosidase (GBA). GBA deficiency results in the accumulation of glucosylceramide in different organs, causing tissue damage. Typical GD features are splenomegaly, peripheral blood cytopenias (mostly thrombocytopenia and/or anemia), growth retardation, bone involvement, gammapathies, increased risk of malignancies and, in some patients, neurological manifestations. Since symptoms are non-specific, the diagnosis can be delayed for years or missed. Enzyme replacement therapy (ERT) with recombinant β-glucocerebrosidase is safe and effective in preventing and/or reversing many clinical manifestations. However, if the diagnosis is delayed for years, major complications cannot be reversed. A useful screening method for GD is based on measuring enzyme activity on a Dried Blood Spot (DBS), while the gold standard test is still considered GBA activity in cellular homogenates. A pediatric algorithm has been proposed to promote timely diagnosis and early access to ERT (figure 1).

Aims: Since pediatric patients with splenomegaly and cytopenias are usually referred to pediatric hematologists, we have designed the GAU-PED study to seemed to be recurrent since it was found in two families; one homozygous and one compound with N118S. Beside nucleotide mutations, we found a 5006 bp deletion from intron 3 to exon 10 affecting PKLR gene. To detect these mutations in family members and further cases, we developed a long range GAP-PCR analysis to amplify the breakpoint fragment and directly sequenced to determine deletion extends and also ARMS-PCR (C: 1641T>T-A, PCR-RFLP (c.941T>C), mismatched PCR-RFLP for c.1403C>G, c.1463G>A and IVS9(+3)A>G). Interestingly, one index patient (PK-4) was found with only one known missense mutation (R488Q), however we could not find any mutation in KLF1 of this patient suggesting that she might have other unidentified cis mutation involved gene regulation of PKLR. Due to a limited number of patients, there was no clear genotype-phenotype correlation found in our studied population.

Summary/Conclusions: Seven confirmed cases of PK def. are reported here-in. They showed a wide variation of clinical severity. Molecular basis of PKLR mutations was proven to be beneficial to provide a definitive diagnosis of PK def. and might help suggesting clinical presentation in future cases.

Figure 1.

Aims: Since pediatric patients with splenomegaly and cytopenias are usually referred to pediatric hematologists, we have designed the GAU-PED study to...
E1078
CIRCULATING MICROPARTICLES IN CONGENITAL AND ACQUIRED HAEMOLYTIC ANAEMIA
W. Barcellini¹, V.M. Sciumbata¹, L.A. Giannotta¹, A. Zaninoni¹, V.B. Valli¹, G. Merali², E. Trombetta², V. Ferri², L. Pettiné², A. Cortellezzi³, A. Antoni³
¹UOC Oncogenetematologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano. ²Progetto di Studio chitico, Centro di Analisi Chimico Cliniche e Microbiologiche Dipartimento dei Servizi, Scuola di Medicina, Azienda Ospedaliero Universitaria di Pavia. ³Centrale di Analisi Chimico Cliniche e Microbiologiche Dipartimento dei Servizi, Servizio di Citofluorometria, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 4Università degli Studi, Milano, Italy

Background: Microparticles (MPs) are small particles budding from cells, which contain variable amounts of proteins, mRNA and cytokines from the parental cell. MPs play a role both in physiological and pathological conditions such as signal transduction, cell activation, thrombosis and cancer. Thrombotic events are a possible complication of haemolytic conditions, both congenital and acquired. Elevated levels of circulating MPs have been described in several haemolytic conditions, including sickle cell anaemia, thalassemia intermedia, haemolytic uraemic syndrome, and thrombotic thrombocytopenic purpura.

Aims: To evaluate platelet MPs (PMP), tissue factor expressing MPs (TFMPs), endothelial MPs (EMPs) and microparticles expressing single antigens (CD41, CD144 or CD142) levels in in other haemolytic anaemias, such as hereditary spherocytosis (HS), elliptocytosis (HE), stomatocytosis (HST), red cell enzymatic defects, congenital dyserythropoietic anaemia (CDA), autoimmune haemolytic anaemia (AIHA), and paroxysmal nocturnal haemoglobinuria (PNH).

Methods: To determine MPs, whole blood was collected into 0.109 M sodium citrated vacutainer tubes. Platelet Free Plasma (PFP) was prepared by double centrifugation at 2500 g for 15 min and stored frozen at -80°C until assayed. For MPs analysis 25 µl of PFP was incubated with annexV-APC, CD41-FITC, CD142-PE and CD144 PerCp-Cy5.5 in Hepes buffer in the presence of 15 mM CaCl2 and 1 u/ml of r-Hirudin for 30 min. Samples were diluted with 500 µl of FACS buffer, 25 µl of Ficoll-Paque Plus and 75 µl of iron deficient medium to express MP count as absolute numbers. MPs analyses were performed on a BD FACS Canto cytometer using Megamix-Plus SCS to define the MPs gate.

Results: MPs levels were evaluated in plasma of 43 patients followed-up for a median time of 8 years (range 2-34) and compared with normal controls. The median MPs levels were 28.5 (range 22.87-445) in patients vs 28.5 (range 22.87-53) in controls (p=0.05). MPs levels positively correlated with HDH values (r=0.999, p<0.001). Finally, the number of annexV APC was increased in PKD compared with controls (p=0.023), and positively correlated

disease duration (r=0.999, p<0.001). PMPs and TF-MPs were elevated too, although not significantly. The number of MPs was highest in patients who were splenectomized and did not splenectomized, and between naive and treated cases.

Table 1.

Summary/Conclusions: These preliminary results suggest that MPs levels are abnormal in both congenital and acquired haemolytic conditions. MPs levels correlate with the degree of anaemia and haemolysis and with the duration of disease.

E1079
THE PREVALENCE, ETIOLOGY AND PROGNOSTIC IMPACT OF ANEMIA IN OLDER POPULATION
S. S. Michalak¹, J. Rupa-Matysek², L. Giel²
¹Family Medicine Clinic, MEDKOL, Zielona Gora. ²Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland

Background: The population of people aged ≥60 years is growing rapidly. Anaemia represents a common condition among the elderly, however its prevalence and causes are not well known.

Aims: The aim of the study was to evaluate the prevalence, severity and etiology of anaemia in the population aged ≥60 years. Risk factors for the development of anaemia including concomitant diseases and treatment, were analysed. The association between anaemia and hospitalization or all-cause mortality during follow-up was determined.

Methods: Retrospective analysis was performed on 981 Caucasian, outpatient patients aged ≥60 in Poland over 2013-2014 (median age 68, range 60-99 years, 60% females). The prevalence of anaemia, defined according to WHO criteria, by gender, age group (60-69, 70-79, ≥80) and anaemia etiology were studied. Data on the incidence of common comorbidities (coronary artery disease, heart failure, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver diseases, cancer, thyroid diseases), hospitalization, treatment used and all-cause mortality were analysed.

Results: The prevalence of anaemia in the studied population was 17.2% and was higher in men than women (20.4% vs 15.2%, p=0.038). Anaemia was present in 10.3% of patients aged 60-69, in 20.1% of those aged 70-79 and in 35.6% of patients ≥80 years. Incidence rates of anemia increased significantly with age (60-69 vs 70-79 years, p<0.001; 60-69 vs ≥80 years, p<0.001; 70-79 vs ≥80 years, p<0.001). Anaemia was mild in 69.8% of patients, but a severe form was found significantly more often among men aged ≥80 years (p=0.03).

Analysis of the etiology of anaemia revealed three predominant types: anaemia of chronic disease (33%), unexplained anaemia (28.4%) and deficiency anaemia (22.5%, including iron deficiency 13%). In comparison to patients without anaemia, those with anaemia were older (p<0.001), had a higher prevalence of comorbidities (p<0.001) and were more often hospitalized (p<0.001). In the multivariate logistic regression model, factors increasing the risk of anaemia were: age ≥80 years (OR=2.29; 95%CI 1.19-4.42; p=0.013), the number of comorbidities (2 diseases OR=2.85; 95%CI 1.12-7.30; p=0.029, 3 diseases OR=6.28; 95%CI 2.22-17.76; p=0.001, 4 diseases OR=6.44; 95%CI 1.27-17.01; p=0.021) and the number of hospitalizations (OR=1.34; 95%CI 1.13-1.58; p=0.001). At the end of the 2-yr follow-up, the cumulative survival among patients without anemia in relation to the group with anaemia was 90.76% vs 78.8% and the difference was statistically significant (p<0.001). In a multivariate model, factors that significantly increased the risk of death in study population were anaemia (HR=3.33; 95%CI 1.43-7.74; p=0.005), cancer (HR=3.31; 95%CI 1.47-7.49; p=0.004) and heart failure (HR=2.94; 95%CI 1.33-6.51; p=0.008).

Summary/Conclusions: In patients ≥80 years the incidence of anaemia increases significantly, and is associated with higher morbidity and frequency of hospitalization. The high rate of unexplained anaemia indicates the necessity for detailed hematologic diagnosis. The occurrence of anaemia among people aged ≥80 years has an adverse impact on survival.
PIEZ01 MECHANOTRANSDUCTIVE PROTEIN MUTATIONS IN RBCS: WHEN THE PHENOTYPE IS BEYOND HAEMOLYTIC ANAEMIA

D. Mota1, 2, S. Manra3, T. Nascimento4, P. Bernardo4, L. Relvas4, A. Oliveira4, E. Cunha1, 2, J. Ribeiro6, C. Bento5, T. Magalhães-Maia1, M. L. Martins1, 2
1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Background: Piezo proteins are integral membrane proteins with many transmembrane domains broadly expressed, including erythrocytes (RBCs). PIEZ01 proteins play an important role as an osmoreceptor, maintaining RBCs ionic homeostasis, functioning as a mechanically activated cation channels. Mutated PIEZ01 proteins have been linked to hereditary xerocytosis (HX), which is characterized by RBCs dehydration with mild to moderate compensated haemolytic anaemia and iron overload. As these clinical features are present in many different clinical conditions, the diagnosis always needs a high level of suspicion. Nowadays, besides peripheral blood smear (PBS) observation, molecular analysis, searching for mutations in PIEZ01 gene, became a tool in the diagnosis of HX.

Aims: Describe 26 patients with HX associated with PIEZ01 mutations belonging to 13 unrelated families, raising awareness of the highly variable phenotype of this patient, and the need of a high grade of suspicion along with the mor- phologic evaluation of the PBS.

Methods: Collection of clinical and laboratory data on our 26 patients with HX and haemolytic anaemia due to 10 different identified mutations in PIEZ01. Sanger sequencing was used to identify mutations affecting PIEZ01, encoded by FAM38A gene, and to confirm transmission according to the presence of dis- ease phenotype. In all patients were excluded other known causes of hyper- ferri tuminaemia (HF) and haemolytic anaemia.

Results: Of the patients identified as having PIEZ01 mutations, 13 were probands and 13 were identified by family studies. Median age at diagnosis was 43 years (1-80), with female predominance (n=14; 53.9%). 4/13 probands had family history of HX (n=1) or HF (n=2). The common feature of our entire cohort of patients was the presence of xerocytes in PBS. 13/26 patients had reticulocytosis, a median reticulocyte count of 10%10^9/L (28.1-557.3), 18/26 patients had HF with a mean value of ferritin of 556ng/mL (161-6617) and 9/26 had both. Of the 26 patients, four had splenomegaly and six gallbladder lithiasis (5/6 cholecystectomized), two of them both. Only 5 patients presented with anaemia (Hb <12g/dl), 2 macrocytic and 3 normocytic. One patient on iron supplementation also had a nonspherocytic anaemia carrier. We present 6-heterozygous missense mutations in all 26 patients.

Summary/Conclusions: HX is a dominant disorder of RBCs dehydration pre- senting a great phenotypic variability. As shown in our cohort of patients, the anaemia may not be the main feature, in fact, the presence of xerocytes in PBS and HF were the most frequent characteristics of our patients. We would like to emphasise that in the genomics era the identification of xerocytes in the PBS keeps playing an important role for this diagnostic. Not only because, unlike other haemolytic anaemias, in HX there is a contraindication to splenec- tomy due to the increased risk of thrombotic events, but also because this pathological finding can be used as a tool to the degree of hemolysis. This iron overload may result in lifelong transfusion dependence that in some instances persists on PIEZO1 function not strictly related with Xerocytosis.

MOELLING PYRUVATE KINASE DEFICIENCY IN HUMAN PROGENITORS USING CRISPR/CAS9

S. García-Manzano1, 2, 3, R. Torres1, E. Oliveira4, A. García-Torralba1, 2, R. Sanchez-Dominguez1, 2, O. Alberquilla1, 2, J. Mountford4, J.C. Ramirez5, J.A. Bueno6, J.C. Segovia1, 2
1Cell Differentiation and Cytometry Unit. Hematopoietic Innovative Therapies Division, CIEMAT/CIBERER, 2Unitd Mixta de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 3Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre – CNIO, Madrid, Spain, 4Scottish National Blood Transfusion Service and ICAMS, University of Glasgow, Glasgow, United Kingdom, 5VIViEbiOTEC, San Sebastian, 6Hematopoietic Innovative Therapies Division, CIEMAT/CIBERER, Madrid, Spain

Background: Pyruvate Kinase Deficiency (PKD) is an autosomal recessive disorder caused by mutations in the PKLR gene. PKD produces chronic non- spherocytic hemolytic anemia, which can be fatal during early childhood and may also cause significant iron overload despite therapeutic splenectomy. Although not considered a standard-of-care, allogeneic bone marrow transplantation has been curative in a limited number of cases. These findings, and the evidence that PKLR gene mutations are likely the sole etiology of the disorder, make PKD a candidate for gene therapy. We developed a gene therapy strategy in a PKD mouse model using a lentiviral vector (LV) carrying a codon-optimized version of the PKLR cDNA (corPKR). This vector has been recently designated as Orphan Drug for the treatment of PKD by the EMA and FDA (EMA: EU/3/14/1330; FDA: DRU-2016-5168).

Aims: To test the efficacy of the therapeutic LV, we have proposed an alternat- ive to polyA site derived PKD-hematopoietic progenitors. In particular, we have generated CRISPR/Cas9 system tools to knock-out the PKLR gene in healthy hematopoietic progenitors from healthy cord blood samples.

Methods: Up to six different gRNAs were specifically generated to cleave the exons 8, 9 and 11 of the PKLR gene. All gRNAs contain at least 3 mismatches with the coRPK present in the therapeutic LV, to avoid the cleavage of the ther- apeutic transgene. Two gRNAs cleaved the PKLR gene both in 293T cells and primary CD34+ cells. In order to identify and select edited cells, Cas9-gRNAs components were cloned into a Cas9-2A-ZsGreen1 plasmid.

Results: Cord Blood CD34+ cells were electroporated, sorted and differentiated along the erythroid line. Significantly, the pyruvate kinase activity in ex vivo differentiated erythroid cells was impaired in gene edited cells as com- pared to non-edited samples.

Summary/Conclusions: Gene edit of wt CD34+ progenitors allow us to gener- ate cells with RPKP impaired. The decrease of PK activity validates this approach as a human model for PKD.

PHYSIOPATHOLOGY OF HEREDITARY XEROCYTOSIS : PIEZ01 GAIN OF FUNCTION MUTATIONS IMPACT HEMOGLOBIN OXYGEN AFFINITY

L. Kiger1, C. Guitton2, K. Ghazi3, M. Feneant-Thibault4, L. Bendelac5, F. Galacteros6, V. Proule6, L. Garçon6, V. Picard6
1IMRB U955, INSERM, Créteil, 2Service de Pédiatrie, 3Service de biochimie, APHP, Hôpital Bicêtre, 4Service de biochimie, 5Service d’hématologie biologique, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, 6Centre de Reference des maladies constitutionelles du Globule rouge, APHP Hopital Mondor, Créteil, 7Service d’Hématologie, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, 8Service d’hématologie biologique, CHU, Amiens, France

Background: Dehydrated hereditary stomatocytosis, also called hereditary xerocytosis (HX) is a dominant non-spherocytic chronic hemolytic anemia charac- terized by an increased cation leak through the red cell membrane, associ- ated with increased cation leak through the red cell membrane and shortened red cell survival. Clinically, most patients present a totally compensated hemolysis, with a normal hemoglobin level contrast- ing with a high reticulocytosis. In most cases, HX is caused by missense mutations activating PIEZ1, a mechanosensitive ion channel. However, the pathophysiology of this compensated hemolysis remains largely unclear.

Aims: We studied the hemoglobin oxygen affinity parameters in HX patients and in hereditary spherocytosis (HS) subjects as controls.

Methods: Fourteen patients from 5 described and 4 unreported families with a HX diagnosis and 15 HS subjects were included. Diagnosis was based on ektacytometry and EMA assay. PIEZ01 and KCNJ4 coding regions were ana- lyzed by Sanger sequencing in all HX patients. Hemoglobin oxygen affinity was evaluated using p50 measured on venous blood on a Hemoxanalyser or a Radiometer blood gas analyzer. 2,3 diprophosphate (2,3 DPG) levels were measured using a commercialized kit and expressed as a molar ratio 2,3 DPG/hemoglobin.

Results: All the 14 HX patients carried one or two missense mutations in PIEZ01, no gene variation was identified in KCNJ4. Five families (9 subjects) have already been reported, with identified mutations in exon 18, 21, 42 or 51. Five subjects from 4 new families carried new mutations in exons 14, 16 and 25. We included, for which biochemical information, a HX diagnosis and 15 HS subjects as controls.

Summary/Conclusions: The increased hemoglobin affinity for oxygen observed in PIEZ01 mutated HX. Of note, p50 was not correlated with the Hb level (mean 139, range 112-180 g/L in HX patients versus 125, range 93-142 g/L in HS patients). Intracellular red cell 2.3 DPG level could be measured in 7 HX patients from 4 families, it was found decreased in all of them (0.43+/-0.06, normal 0.91+/-0.19, providing a pathophysiological basis for the increased hemoglobin affinity we observed. In particular, we present a totally compensated hemolysis, with a normal hemoglobin level contrast- ing with the high reticulocytosis, allowing a high likelihood of path- ogenicity. For all HX patients, p50 values were under the normal range (mean 21.1, range 19.7-23.4, normal range 25-29 mmHg), contrasting with HS patients for whom p50 was found to be in the normal range (mean 26.1, range 24.6- 28.8 mmHg). This indicated a significant increase in the hemoglobin affinity for oxygen restricted to PIEZ01 mutated HX. Of note, p50 was correlated with the Hb level (mean 139, range 112-180 g/L in HX patients versus 125, range 93-142 g/L in HS patients).
Gene therapy, cellular immunotherapy and vaccination

E1083
SAFETY AND EFFICACY OF MULTI-PATHOGEN-SPECIFIC T CELLS IN A HUMANIZED MODEL OF INVASIVE ASPERGILLOSIS: A PROOF OF CONCEPT STUDY
A. Papadopoulos1, C. Kougoulias1,2, M. Alvanou1, E. Athanasiou1, N. Spougos1,2, T. Vyzantiadis2, E. Siotou1, M. Gounis1, P. Kaloyannidis1, M. Yiannikou1, A. Anagnostopoulou1, Y. Yannaki1
1Gene and Cell Therapy Center- Hematology Dept.- BMT Unit, George Papanicolaou Hospital, 2School of Biology, Department of Genetics, Development and Molecular Biology, 1School of Medicine, 1st Department of Microbiology, Aristotelian University of Thessaloniki, Thessaloniki, Greece, 2Adult Hematology & Stem cell Transplant, King Fahad Specialist Hospital, Dammmam, Saudi Arabia

Background: Viral infections, most commonly by cytomegalovirus (CMV), Epstein-Barr virus (EBV), polyoma virus type I (BK), and fungal infections, mainly by Aspergillus Fumigatus (Asp), are leading causes of transplant-associated mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. Standard treatment with antiviral and antifungal pharmacological agents, is often ineffective or toxic and may lead to resistance. Due to these limitations, adoptive immunotherapy with antigen-specific T cells has emerged as an attractive alternative. Towards unleashing its full potential and treat multiple viral and fungal infections by a single T-cell product, we developed a rapid, simplified and minimally laborious protocol for the generation of multipathogen-specific T cells (mp-STs) that simultaneously target CMV, EBV, BK and Asp, from healthy donors.

Aims: Due to the lack of mouse models recapitulating the clinical condition of multiple opportunistic infections in transplanted hosts, we here aimed to test the in vivo safety of produced mp-STs and provide a proof of concept of their efficacy in a humanized model of invasive aspergillosis (IA).

Methods: mp-STs were generated from healthy donors by pulsing 1x10^7 mononuclear cells with viral (CMV, IE1, pp65; EBV; EBNA1, LMP2, BZLF1; BK: Large T, VP1) and Asp pepmixes (Crf1, Gel1, SHMT) and culturing for 10 days. The specificity of mp-STs was analyzed by IFN-γ Elispot. A total of 1.5x10^7 of immunomagnetically isolated CD3+cells (donor lymphocyte infusions-DLI) or mp-STs were infused in myelo/immuno-ablated NSG mice which had been intranasally inoculated with Asp conidia or left uninfected. Mice were evaluated by a 5-parameter sickness score and at sacrifice, tissues were assessed by histology and immunohistochemistry.

Results: We generated 2.3±5x10^7 cells mp-STs (12-fold expansion). All cell lines were polyclonal expressing central and effector memory markers and specific against many Asp [spot forming cells (SFC)/2x10^5cells: 315±82] and the targeted lines were polyclonal expressing central and effector memory markers and specific against Asp [spot forming cells (SFC)/2x10^5cells: 315±82]

Summary/Conclusions: Taken together, we detected an increase of specific CTL responses after several LAAs after allogeneic stem cell transplantation and donor lymphocyte infusion. Moreover, this study suggests that broader LAAs epitope-specific T cell responses as well as decreasing numbers of Tregs contribute to clinical outcome of patients treated with DLI.

E1085
GENE-MODIFIED NK-92MI CELLS EXPRESSING A CHIMERIC CD16/CD64-B2-RECEPTOR EXHIBIT ENHANCED CANCER-KILLING ABILITY IN COMBINATION WITH THERAPEUTIC ANTIBODY
Y. Chen1,*, F. You1, J. Li1, X. Tang2, G. An1, H. Meng1, L. Yuan3, L. Yang1
1The Cyrus Tang Hematology Center, 2Department of Hematology, Soochow University, Suzhou, Jiangsu, 3Department of Hematology, Aerospace Center Hospital, Beijing, China

Background: Natural killer (NK) cells play a pivotal role in mononuclear anti-body-mediated immunotherapy through an antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. NK-92MI is an interleukin-2 (IL-2)-independent cell line, which was derived from NK-92 cells with superior cytotoxicity to a wide range of tumor cells in vitro and in vivo. However, the Fc-receptor (CD16), which usually mediates ADCC, is absent in NK-92 and NK-92MI cells.

Methods: We engineered NK-92MI cells expressing the chimeric receptor CD16/CD64. Two transposons, one encoding the human CD16 and the other encoding CD64, were used to transfect NK-92MI cells. The chimeric receptor expression was confirmed by flow cytometry and Western blotting. NK-92MI cells were then stimulated with interleukin-2 (IL-2) and IL-15.

Results: We observed an increase in the killing activity of NK-92MI cells expressing the chimeric receptor compared to NK-92MI cells not expressing the receptor. This was particularly significant in the presence of Fc-engaged antibodies. Additionally, we observed an increase in the production of cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) by the engineered cells.

Summary/Conclusions: Our results indicate that gene-modified NK-92MI cells expressing a chimeric CD16/CD64-B2-receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibodies, making them a promising therapeutic strategy for cancer immunotherapy.
Aims: To apply NK-92MI cell-based immunotherapy in cancer, we designed and generated two chimeric receptors which can bind the Fc portion of human immunoglobulins in NK-92MI cells.

Methods: The construct included the low-affinity Fc receptor CD16 (158F) or the high-affinity Fc receptor CD64, with the addition of the CD8a extracellular domain, CD28 transmembrane domains, two costimulatory domains (CD28 and 4-1BB), and the signaling domain from CD3ζ. The resulting chimeric receptors, termed CD16-BB-ζ and CD64-BB-ζ, were utilized to generate chimeric receptor-modified NK-92MI cells, which were named NK-92MIhCD16 and NK-92MIhCD64 cells, respectively.

Results: We found that NK-92MIhCD16 and NK-92MIhCD64 cells significantly improved cytotoxicity against CD20-positive non-Hodgkin’s lymphoma (NHL) cells in the presence of rituximab.

Summary/Conclusions: These results suggest that the chimeric receptor-modified NK-92MI cells could potentially enhance the clinical responses mediated by currently available anticancer monoclonal antibodies (mAbs).

E1086
A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BSABs IN HEMATOLOGICAL SAMPLES

D. Primo1, P. Hernandez1, P. Ghia2, J. de la Serna3, J. M. Rivera4, S. Vives5, J. M. Bergua6, J. Perez de Oteyza7, J. Serrano8, J. Gorrochategui9, M. L. Vicente1, C. Gomez1, G. Martinelli2, G. Simonetti3, P. Ranghetti4, J. Ballesteros1,*

Aims: and a tumor-associated surface antigen (TAA) have been used as immunotherapy targets. Recently, novel Bi-specific antibodies (BsAbs) or analogous constructions acting as chimeric receptor-modified NK-92MI cells have been used for the treatment of hematological malignancies. The PharmaFlow automated flow platform has achieved 85% cell viability with a high throughput of 500,000 events per second. We developed a method to quantify the pharmacology activity of BsAbs and characterize their potency and efficacy in human hematological samples.

Methods: To develop an automated flow cytometry assay for bsAb screening that keeps intact both basal effector to tumor response and BsAb potency, we used the PharmaFlow automated flow platform to quantify the in vitro activity of BsAbs. Because of the high capacity of the PharmaFlow platform, additional antibodies constructions alone or in combinations with immunomodulatory agents could be tested to identify the better agents or immunotherapeutics combinations in hematological diseases.

Summary/Conclusions: We have developed an automated flow cytometry assay for BsAb screening that keeps intact both basal effector to tumor response and BsAb potency. The integration of Effective T Ratios (E:Rratios) and pharmacological parameters better predict in vitro responses of BsAbs. Because of the high capacity of the PharmaFlow platform, additional antibodies constructions alone or in combinations with immunomodulatory agents could be tested to identify the better agents or immunotherapeutics combinations in hematological diseases.

E1087
HUMANIZED CD7 NANOBODY-BASED IMMUNOTOXINS EXHIBIT PROMISING ANTI-T CELL ACUTE LYMPHOBLASTIC LEUKEMIA POTENTIAL

Y. Yu1, J. Li1, X. Zhu2, X. Tang3, Y. Baof4, Y. Huang1, L. Yuan1, L. Yang1

1The Cyrus Tang Hematology Center, Soochow University, Suzhou, 2Department of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 3Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 4Department of Hematology, The First People’s Hospital of Hefei Group, Hefei, 5Department of Hematology, Aerospace Center Hospital, Beijing, China

Background: Nanobodies, or named as VHHs, are derived from heavy-chain-only antibodies that circulate in sera of camels. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeting delivery of biologically active components. In our previous work, we have successfully generated the monovalent and bivalent CD7 nanobody-based immunotoxins, which can effectively trigger the apoptosis of CD7 positive malignant cells.

Aims: To pursue the possibility of translating those immunotoxins into clinics, we humanized the nanobody sequences (designated as dhuVHHs), as well as further truncated the Pseudomonas exotoxinA (PE) derived PE38 toxin to produce a more protease-resistant form which is named as PE-LR, by deleting majority of PE domain II.

Methods: Three new types of immunotoxins, dhuVHHs-PE38, dVHHs-PE-LR, and dhuVHHs-PE-LR, were successfully constructed. These recombinant immunotoxins were expressed in E. coli and showed that nanobody immunotoxins have the benefits of easy soluble expression in a prokaryotic expression system.

Results: Flow cytometry results revealed that all immunotoxins still maintained their ability to specifically kill CD7-positive T lymphocytes at the concentration identical to CD7-negative control cells. Laser scanning confocal microscopy found that these proteins can be endocytosed into the cytoplasm after binding with CD7-positive cells, and that this phenomenon was not observed in CD7-negative cells. WST-8 experiments showed that all immunotoxins retained the high level of effective and specific growth inhibition activity in both CD7-positive T cell lines and primary T-cell acute lymphoblastic leukemia (T-ALL) cells. Further in vivo animal model experiments showed that humanized dhuVHHs-PE38 immunotoxin can tolerate higher doses and extend the survival of NCG mice transplanted with CEM cells without any obvious decrease in body weight. Further studies on NCG mice model with patient-derived T-ALL cells, dhuVHHs-PE38 treatment significantly prolonged mice survival with around 40% survival improvement. However, it is also noticed that despite dhuVHHs-PE-LR showed strong anti-tumor effect in vitro, its in vivo anti-tumor efficacy is disappointed.
Summary/Conclusions: We have successfully constructed a targeted CD7 molecule modified nanobody (CD7 molecule improved nanobody) immunotoxin dhuVH6-PK38 and showed its potential for treating CD7-positive malignant tumors, especially T-cell acute lymphoblastic leukemia.

E1088
STATINS MAY IMPROVE CAR-NK IMMUNOTHERAPY IN MM BY PREVENTING LOSS OF BCMA EXPRESSION ON MM CELLS

G. Suñe1,*, L. Perez-Amill1, A. Urbano-Ispizua1, B. Martín-Antonio1
1Hematology, Hospital Clinic/IDIBAPS/Josep Carreras Leukemia Research Institute, Barcelona, Spain

Background: Chimeric Antigen Receptor (CAR) modified immune cells targeting BCMA against multiple myeloma (MM) has appeared as a feasible immunotherapy strategy to treat MM patients. However, high doses of CAR immune cells are required to achieve a response. Cord blood derived NK cells (CB-NK) is a feasible source of obtain NK cells to modify with a CAR against BCMA. We previously observed that MM cells exposed to CB-NK are able to transfer MM proteins, such as BCMA, both to CB-NK and to adjacent MM cells non-exposed to CB-NK. Furthermore, statins, which are toxic for MM cells, by altering the lipid composition of tumor cell membrane are involved in cell-cell communication. We hypothesized that statins could prevent the loss of BCMA expressed the loss of BCMA sumM cells after CB-NK exposure, allowing inducing a lower CAR immune cell dose in MM patients.

Aims: To evaluate the effect of statins on MM cell proliferation, on the CB-NK immune response against MM, and on BCMA expression in MM cells after CB-NK exposure.

Methods: The cytotoxicity of statins against MM cells was determined in vitro and in vivo in a murine MM model; furthermore, their impact in CB-NK cytotoxicity against MM was also determined in vitro. BCMA expression on MM cells after CB-NK exposure was analyzed by confocal microscopy and by flow cytometry. FACs sorting experiments were performed to analyze BCMA transfer between CB-NK-exposed MM cells to neighboring non-exposed CB-NK MM cells.

Results: Atorvastatin and Fluvastatin treatment (1μM) decreased MM cell line (AR1, RPMI, KMM1) proliferation. No effect was detected for U266 MM cells and for K562 non-MM cells. In vivo studies, showed that mice treated for three days I.P with Fluvastatin (1mg/kg) showed significant decreased MM disease progression. Blocking of BCMA decreased CB-NK cytotoxicity against MM cells. Furthermore, pretreatment of MM cells with Fluvastatin (3 μM) increased CB-NK cytotoxicity against all MM cell lines; no impact was observed against K562 non-MM cells. Co-culture experiments showed that, as soon as 30 minutes, CB-NK exposure led to a BCMA transfer from MM cells to CB-NK and to the extra-cellular milieu leading to a loss of BCMA expression on MM cells. Fluvastatin pretreatment prevented loss of BCMA expression. After two days of co-culture, alive MM cells still showed decreased BCMA surface expression, and surprisingly, increased intracellular BCMA expression. Fluvastatin pretreatment partially avoided the loss of BCMA expression in MM cells. FACs sorting experiments showed that MM cells exposed to CB-NK, transferred BCMA to neighboring non-CB-NK exposed MM cells which was partially inhibited with Fluvastatin pretreatment.

Summary/Conclusions: Our findings show that besides the anti-MM activity of statins alone, they avoid the loss of BCMA expression on MM cells after immune cell exposure. Preventing loss of BCMA expression on MM cells might improve the efficiency of CAR immunotherapy against BCMA, suggesting the potential of statins as an adjuvant in CAR-NK immunotherapy against MM.

E1089
DENDRITICCELL VACCINATION COMBINED WITH LENALIDOMIDE AND PROGRAMMED DEATH-1 (PD-1) BLOCKADE HAS SYNERGISTICALLY INDUCED A MARKED TUMOR REGRESSION IN A MURINE MYELOMA MODEL

S.-H. Jung1,*, S. Yang2, H.-J. Lee2, M.-C. Vo3, T.J. Lakshimi2, H.-J. Kim1, J.-J. Lee1, J.-J. Lee1
1Department of Hematology-Oncology, 2Research Center for Cancer Immunotherapy, 3Chonnam National University Hwasun Hospital, Hwasun-Eup, Korea, Republic Of

Background: There is an emerging evidence that the maximal benefit of dendritic cell (DC)-based cancer immunotherapy may be achieved by combination with other therapies that act to immunomodulation and tumor microenvironment.

Aims: In this study, we tried to obtain the best efficacy of immunotherapy using DC vaccination in combination with lenalidomide and PD-1 blockade in a murine myeloma model.

Methods: After establishing myeloma-bearing mice, four treatment groups were designed to be a mimic protocol as like treatment in clinics as following: 1) PBS control, 2) DCs, 3) DCs + lenalidomide, 4) DCs + PD-1 blockade, and 5) DCs + lenalidomide + PD-1 blockade. After treatment, preclinical response and in vivo immunological responses were evaluated.

Results: DCs combined with lenalidomide and PD-1 blockade showed the best tumor regression among the study groups. These anti-tumor effects have meaningfully related to the decrease of immunom-regulatory populations, such as myeloid-derived suppressor cells (MDSCs), M2 macrophages, and regulatory T cells (Treg) and the increase of effector immune cell populations, including CD4+ and CD8+ T cells, natural killer (NK) cells, and M1 macrophages, accompanied with the activation of cytotoxic T lymphocytes (CTLs) and NK cells in the splenocytes from the treated mice. Moreover, the level of immunosuppressive cytokines, such as TGF-β and IL-10, was significantly reduced in tumor microenvironment.

Summary/Conclusions: DC vaccination in combination with lenalidomide plus PD-1 blockade has synergistically induced a strong antitumor immunity by modulating tumor microenvironment in a murine myeloma model. This protocol will become a promising translational approach to improve the efficacy of immunotherapy in the field of MM.

E1090
B- AND T-CELL IMMUNE REPERTOIRE PROFILING WITH ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING

E1091
SYNERGISTIC ANTITUMOR IMMUNITY BY DENDRITIC CELLS IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN A MURINE MYELOMA MODEL

S.-H. Jung1,*, S. Yang2, H.-J. Lee2, M.-C. Vo2, T.J. Lakshimi2, H.-J. Kim1, J.-J. Lee1, J.-J. Lee1
1Department of Hematology-Oncology, 2Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun-Eup, Korea, Republic Of

Background: Pomalidomide (Pom) plus dexamethasone (Dex) could be considered one of the new treatment options in patients with relapsed and/or refractory multiple myeloma (MM). Recently, several diverse agents would be combined to improve the therapeutic efficacy of immunotherapy.

Aims: In this study, we investigated the preclinical efficacy of combined therapy with dendritic cells (DCs) and Pom-Dex in a murine myeloma model.

Methods: After establishing myeloma-bearing mice, four treatment groups were designed to be a mimic protocol as like treatment in clinics as following: 1) PBS control, 2) DCs, 3) Pom + Dex, and 4) DCs + Pom + Dex. After vaccination, preclinical and in vitro immunological responses were evaluated.

Results: Among four treatment groups, DC combined with POM and DEXA strongly inhibited tumor growth, compared with other groups. In vitro immunological analyses revealed that these enhanced anti-tumor effects were closely associated with the decrease of regulatory cell populations, such as regulatory T cells (Tregs) and type 2 macrophages (M2), and the increase of effector cell populations, including activated CD4 T cells, and type 1 macrophages (M1), accompanied with the activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells in the splenocytes from vaccinated mice.

Conclusion: The DC combined with POM and DEXA synergistically enhance the anti-tumor immunity in a murine myeloma model, by skewing immuno-suppressive status toward immuno-supprenant status in tumor microenvironment.
ALTERATIONS IN T-CELL SUBPOPULATIONS AFTER CO-CULTURING WITH MSCS DERIVED FROM DIFFERENT DONORS

N. Kapranov1, V. Davydova1, I. Galsheva1, N. Petinati1, N. Drize1, L. Kuzmina1, E. Pavlovichkov1, V. Savchenko1
1Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Study of interactions between lymphocytes and mesenchymal stromal cells (MSCs) in vitro revealed increase of HLA-DR expression on T-cells after co-cultivation with some MSCs samples. On lymphocytes derived from one donor the elevation of HLA-DR was observed after co-cultivation with half of MSCs samples (group A), on the others the HLA-DR expression level did not change (group B). MSCs were divided into two groups based on HLA-DR rise on lymphocytes. Study of T-cell subpopulations after interactions with MSCs could explain ineffectiveness of some MSCs as an immunomodulating agent in clinical applications.

Aims: The aim of the study was to discriminate variations in T-cell subpopulations, co-cultured with MSCs from two groups.

Methods: MSCs were isolated from bone marrow of 13 donors for allogeneic hematopoietic cells transplantation and cultured by a standard method. MSCs were seeded 10^5 cells per flask, and then 10^6 allogeneic lymphocytes from one donor were added to all MSCs cultures. For lymphocytes activation 5µg/ml phytotophagglutinin (PHA) was added to half of these cultures. Lymphocytes were removed from MSCs. Than MSCs were removed from the bottom of the flask by trypsin and expression of HLA-DR on their surface was measured by flow cytometry. Activation markers CD25, CD38, CD69, HLA-DR expression level was measured by flow cytometry. Distribution of naïve and effector T-cells was analyzed on 4th day of cultivation. p<0.05 was considered statistically significant; all data are presented as medium ± SEM.

Table 1.

Results: Expression of HLA-DR on lymphocytes after 4 days of cultivation without MSCs did not change compared to 1st day. When lymphocytes were co-cultured with some MSCs samples expression of HLA-DR was higher. Elevated percentage of HLA-DR positive cells correlates between CD4+ and CD8+ cells (R²=0.932). Thus samples of MSCs were divided into two groups: in group A a proportion of HLA-DR lymphocytes was 3 times greater than in group B. Subpopulations of lymphocytes co-cultured with MSCs from group A and B were compared. Subpopulations which significantly differed between groups A and B are presented in the table. In lymphocytes co-cultured with MSCs there were higher number of naïve cells compared to control (47.4±3.5% and 54.9±2.0% for group A and B vs 36.9±1.4% for lymphocytes cultured without MSCs, p<0.001). Group B showed lower number of EM and TM cells. Differences between groups were more pronounced when lymphocytes were activated. In group B proportion of HLA-DR CD4+ and CD8+ cells was significantly lower, compared to group A and control samples. At the same time the number of CM and PD-1+ CD4+ cells was lower in group B, but number of TE was increased. Investigation of HLA-DR expression on MSC after co-culturing with lymphocytes showed higher level of fluorescence signal (MF) in group A than in group B (635±130 vs 289±18, p=0.03). These data indicated that MSCs from group A had become more immunogenic after interaction with lymphocytes and could not show immunomodulating properties in same way as MSCs from group B.

Summary/Conclusions: The immunomodulatory properties of MSCs depend on the donor. This could explain why administration of MSCs is not always successful. Preliminary study of MSCs prior to their administration may be used to predict their efficiency in the future.

The materials are supported by grant from the Russian Science Foundation, Project № 16-15-00102.

E1093

GRANULOCYTE COLONY STIMULATING FACTOR AND ERYTHROPOIETIN ENTALLY GIVEN FOR NEONATES RECOVERING FROM GIT SURGERIES: RANDOMIZED CONTROLLED TRAIL

J.A. Bueren1,2, O. Quintana-Bustamante1,2, J.C. Segovia1,2
1Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energeticas Medioambientales y Tecnologicas/Centro de Investigacion Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER), 2Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain, 1CELECCITIS, Paris, France

Background: Feeding intolerance is a common problem among neonates recovering from surgery for congenital abnormalities of the gastrointestinal tract (GIT) such as small bowel atresia, omphalocele or gastrochisis. Feeding intolerance is a multifactorial process, but one of the important reasons is congenital maldevelopment of the small bowel villi. Diurse atrophy of the small bowel mucosa following several days of post-operative enteral fasting is one factor that can contribute to feeding intolerance. The human fetus swallows over 200 ml/kg/day of amniotic fluid and such swallowing is essential for normal small bowel development. Growth factors found in the amniotic fluid have been shown to promote proliferation of fetal intestinal cells. These growth factors include epidermal growth factor, granulocyte colony stimulating factor (G-CSF) and erythropoietin (EPO). We postulated that infants recovering from surgeries for congenital obstructive bowel abnormalities could be provided with physiologic quantities of recombinant human G-CSF and EPO by the intermittent orogastric or nasogastric administration of 20 mL/kg/day of sterile isotonic solution that contained cytokine concentrations comparable to what they would have ingested from amniotic fluid in utero.

Aims: To test a hypothesis suggesting that feeding tolerance could be improved in neonates recovering from surgeries for congenital obstructive bowel abnormalities by enterally administering recombinant human G-CSF and EPO. We postulated that such administration could improve feeding tolerance and enteral growth in neonates recovering from surgeries for congenital obstructive bowel abnormalities.

Methods: This double-blinded randomized controlled clinical trial was conducted on 40 neonates recovering from GIT surgeries for congenital bowel abnormalities. Hemodynamically unstable babies, and those with any contraindication to enteral feeding were excluded. Neonates were randomized postoperatively into 2 groups; 20 neonates received the test solution (called Simulated Amniotic Fluid-like solution given Enteraly; SAFE); 20 neonates enterally received distilled water (control). Treatment was started postoperative and the test solution (or distilled water) was discontinued when enteral intake reached 100cc/kg/day. Feeding tolerance and adverse effects of treatment (if any) were assessed.

Results: All the studied neonates tolerated the received solution well without side effects that could be attributed to its intake. The study group showed better feeding tolerance as reflected by earlier achievement of 50, 100, 120 and full enteral feeding with higher enteral caloric intake 7 days after SAFE administration and higher rate of weight gain (p<0.05). No significant increase was found in the level of WBCs count, hemoglobin and hematocrit values either pre-initiation or 7 days after administration of SAFE (p>0.05).

Summary/Conclusions: This study provides further insights on the improvement of neonatal outcomes and help to decrease morbidities from post-operative malnutrition and feeding intolerance. Enteral administration of rhG-CSF and rhEPO may play a critical role in preventing villous atrophy, thereby, reducing feeding intolerance in neonates recovering from surgeries for congenital bowel abnormalities.
Results: Although a high toxicity and low efficiency were observed with the electroporation technique used, up to 96% colony forming units showed the specific integration. Experiments directed to improve efficacy and reduce toxicity were then conducted. A high percentage of gene edited HPCs were detected by shortening the cell expansion and puromycin selection periods. Importantly, gene edited HPCs were detected after infusion in immunodeficient (NSG) mice. More recently, cell-line specific correction has been developed aiming at the correction of PKD patient’s specific mutations.

Summary/Conclusions: Overall, we showed that gene editing in engraftable HPCs is feasible, although the efficiency of the procedure should be further improved prior to consideration of these strategies in the clinic.

E1096 ALTERATIONS IN T-CELLS SUBPOPULATIONS AFTER CO-CULTIVATION WITH MULTIPOTENT MESENCHYMAL STEM CELLS
Y. Vlavianos1, N. Kapravelou2, G. Gouliava1, N. Petinat1, N. Dinze1, L. Kuzmina1, E. Parovichenikova1, V. Savchenko1
1Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Lymphocyte population depends on immunological state of organism and varies in different diseases and during treatment. Multipotent mesenchymal stromal cells (MSCs) are widely used for cell therapy due to their immunomodulatory properties. Administration of MSCs is not effective, however. Immunomodulatory properties of MSCs could be induced by different cytokines, e.g. IFN-γ. After injection MSCs interact with activated and non-activated lymphocytes. Changes in lymphocytes subpopulations characterize the influence of MSCs on immunological state.

Aims: The aim of the study was to determine the distribution of naïve and effector cells in lymphocytes co-cultured with MSCs.

Methods: MSCs were derived from bone marrow of 13 donors (7 male and 6 female aged 22 to 62 years, median 27 years). MSCs were co-cultured with allo- genetic lymphocytes in a ratio of about 1:10 for 4 days and their basic properties were analyzed over time. Lymphocytes were activated by adding to the culture medium 5mg/ml of PHA (PHA-lymphocytes). Some MSCs were treated for 4 hours with 500 U/ml IFN-g (gMSCs). Activation markers CD25, CD38, CD69, HLA-DR and PD-1 were studied by flow cytometry as well as distribution of naïve CD4+ and CD8+ T-cells with memory T-cells characteristics (CD45RA-CCR7+), memory T-cells without CD45RA and CCR7 expression (CD45RA-CCR7-). Results: By the fourth day of incubation the proportion of naïve CD4+ cells reduced by 30% (from 47.5±3.0% to 32.8±3.3%) in cultured lymphocytes. It did not happen in lymphocytes co-cultured with MSCs and gMSCs (p=0.001). At the same time in cultured lymphocytes to the fourth day the number of CD4+ effector memory cells increased in 1.8 times from 19.5±1.9% to 34.6±4.2%, which did not occur when co-cultured with both MSCs and gMSCs (p=0.001). Thus, co-culturing with MSCs or gMSCs prevented naïve T-lymphocytes transition into effector cells. The proportion of CD4+PD-1+ cells increased from 8.2±1.1% to 10.9±0.7% by the 4th day of cultivation. When co-cultured with MSCs and gMSCs the proportion of gMSCs these cells did not change (p=0.0125). The proportion of HLA-DR+ both on CD4+ and CD8+ cells in lymphocytes remained unchanged for 4 days. When co-cultured with MSCs and gMSCs for 4 days there was a consistent increase in the proportion of CD4+/HLA-DR+ (8.1±1.7% to 15.6±1.1%, p=0.006) and CD8+/HLA-DR+ (from 9.7±0.8% to 26.0±3.7%, p=0.024). So allo-genic MSCs induced peptide presentation on lymphocytes. The proportion of CD4+ central memory cells increased in PHA- lymphocytes from 37.4±4.4 at 1st day to 68.2±6.5 at 4th day. MSCs inhibited this increase - the proportion CD4+ central memory cells increased from 24.4±2.7% to 46.4±4.5% (p=0.047). Thus the interaction of PHA-lymphocytes with MSCs inhibited their activation and preserved naïve state.

Summary/Conclusions: The composition of lymphocyte population changes during co-cultivation. The proportion of naïve cells reduced, while the number of effector cells and the proportion of PD-1+ increased, indicating lymphocyte activation probably due to the presence of xenogeneic serum in the culture medium. Co-cultivation with MSCs maintained lymphocytes in not activated state. The interaction of activated lymphocytes with MSCs inhibits their activation and preserves naive state. IFN-γ priming did not enhance MSCs inhibitory effect, as it is shown that MSCs both maintained their naïve lymphocyte condition and have an inhibitory effect on their activation.

The materials are supported by grant from the Russian Science Foundation, Project № 16-15-00102

E1097 OPTIMIZATION OF TRANSDUCTION CONDITIONS WITH GMP LIKE LENTIVIRAL VECTORS FOR THE GENE THERAPY OF PYRUVATE KINASE DEFICIENCY
S. Navarro1,2,*, O. Quintana-Bustamante1,2, C. Trigueros3, M. Villanueva1,2, D. del Olmo2, R. Díez-Sánchez2, D. Abarca2, J. López-Manzaneda1,2, J.A. Bueno1,2, J.C. Ramírez1,2, E. Hernández2,3, J. Vázquez2, J. Hernández2, M.J. Mateo de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 2Hematopoietic Innovative Therapies, CIEMAT/CIBER-ER, Madrid, 3VIVEbioTECH, San Sebastian, Spain

Background: Pyruvate kinase deficiency (PKD) is an autosomal recessive disorder caused by mutations in the PKLR gene. PKD is the most common erythroid inherited enzymatic defect causing chronic nonspherocytic hemolytic anemia. PKD is associated with reticulocytosis, splenomegaly and hepatic iron overload, and may be life-threatening in severely affected patients. To-date, allo-genic bone marrow transplant remains the only curative treatment option for severely affected patients but has been employed infrequently. Splenectomy confers reduced transfusion-dependence in many patients, but 10-15% of PKD patients remain transfusion-dependent despite splenectomy, which confers increased risk of bacterial infections. Precise gene therapy studies conducted in pyruvate kinase deficient mice have shown the safety and the efficacy of a new PCCoRPKW-17 therapeutic lentiviral vector that has been granted orphan drug designation (EMA: EU/3/14/1330, FDA: DRU-2016-5168).
Aims: In order to develop a gene therapy clinical trial for PKD we are optimizing transduction procedures compatible with a clinical application.

Methods: Using a GMP-grade lentiviral vector production according to manufacturing process of the CMO VIVEBioTECH (www.vivebiotech.com) using a solid phase bioreactor iCLeLLs. These viral batches have been tested for transduction efficiency in healthy cryopreserved cord blood CD34+ cells containing different viral infection and transduction efficiencies.

Results: Increased doses of virus concentration revealed, as expected, increasing levels of transduction that ranged 40-90% both by scoring transduced colony forming units and by flow cytometry analysis in hematopoietic progenitors maintained for 15 days in liquid culture. Analysis of vector copy number (VCN) by qPCR ranged from 0.5 to 3 VGN/cell, demonstrating good transduction efficiency, compatible with a clinical application. Two cycles of transduction showed an increased level of transduction at limiting concentrations of the viral vector, increasing the VCN up to 2-fold.

Summary/Conclusions: Transduction optimizations are being carried out in order to reduce the amount of viral vector needed to achieve optimal transduction efficiencies.

E1096

INTERACTION OF MULTIPOTENT MESENCHYMAL STEM CELLS WITH LYMPHOCYTES REDUCES THEIR IMMUNO PRIVILEGED PROPERTY

N. Petina1, N. Kapranov2, Y. Davydova1, I. Galtseva1, M. Bakshinskayab1, N. Driz1, L. Kuzminia, E. Parovichnikova1, V. Savchenko1

1Physiology of Hematopoiesis Lab., 2Lab. of Immunophenotyping, National Research Center for Hematology, 3Biologib Department, sub Department Immunology, Moscow State University im. Lomonosov, 4Bone Marrow Transplantation Department, 5National Research Center for Hematology, Moscow, Russian Federation

Background: Multipotent mesenchymal stem cells (MSCs) are widely used for cell therapy of autoimmune diseases and graft-versus-host disease. MSCs have long been reported to be hypoimmunogenic or ‘immune privileged’. The treatment of MSCs with interferon-g (IFNg) increases their immunomodulating properties, but induce HLA-DR expression on their surface. When administered intravenously MSCs interact with activated and non-activated lymphocytes. It is impossible to follow the fate of MSCs in the recipient’s organism. The only way to study the changes in the properties of MSCs after intravenous administration is in vitro model.

Aims: The aim of the study was to investigate the properties of MSCs after interaction with lymphocytes.

Methods: MSCs were isolated from 13 bone marrow samples used for allo-geneic hematopoietic cells transplantation and cultured by a standard method. MSCs were seeded 10^5 cells per flask and a day later 500 units/mL of IFN-g were added for 4 hours to half of the cultures (gMSCs). Some cultures were seeded with 10^5 allogeneic lymphocytes, to half of these cultures 5mg/ml phytohemagglutinin (PHA) was added for lymphocytes activation (PHA-Lymphocytes). For each of the MSCs cultures the mean fluorescent signal intensity (MFI) of CD90 PE, CD54 APC, HLA-DR APC was measured. Relative expression level (REL) of CD10, CD11, CD19, CD20, CD45, CD45R, CD45RO, CD45RA was analyzed in MSCs by RT-PCR. MFI and REL were investigated on the 1st, 2nd, 3rd and 4th days of cultivation.

Results: HLA-DR expression on MSCs increased when co-cultured with lymphocytes and after IFN-g treatment. PHA-lymphocytes induced HLA-DR expression significantly greater than IFN-g licensing. IFN-g increased the viability of MSCs when co-cultured with lymphocytes. Immunomodulating properties of MSCs were amplified both after IFN-g priming and interaction with lymphocytes, so they did not depend on IFN-g source (exogenous or secreted by lymphocytes). The elevated expression ICAM1 on manipulated MSCs may indicate an increase in their adhesive properties. IFN-g treatment and interaction with lymphocytes induced in MSCs the increase in relative expression level (REL) of factors involved in immunomodulation (CD10, CD19, CD20, CD45, CD45R, CD45RO, CD45RA).

Summary/Conclusions: The abrupt loss of ongoing HE recruitment at E10.25 suggests an abruptness in the hematopoietic output of individual HE, with only 9% of colonies producing phenotypic HSCs in AA-ECs. These data suggest the presence of HE precursors with distinct functional output or the existence of a continuum of HE at different stages of maturation.

E1100

C-TYPE LECTIN-LIKE RECEPTOR 2 SPECIFIES A FUNCTIONALLY DISTINCT SUBPOPULATION OF MEGAKARYOCYTE-BIASED LONG-TERM HEMATOPOIETIC STEM CELLS

T. Kumode1,2, H. Tanaka1, R. Fujiwara1, K. Sano1, K. Serizawa1, Y. Taniguchi1, Y. Kamouchi1, M. G. Ganuza Fernandez1,2, B. Hadland3,4, A. Chabot1, G. Kang1, I. Bernstein2,3, S. McKinney-Freeman1

1Experimental Hematology, St. Jude Children’s Research Hospital, Memphis, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, 3Department of Pediatrics, University of Washington School of Medicine, Seattle, 4Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, United States

Background: Hematopoietic stem cells (HSCs) arise from hematopoietic endothelial (HE) precursors between 10.5 and 11.5 days of embryonic day 10.5 (E10.5) and E12.5 of murine development, primarily in the aorta-gonad-mesonephros (AGM) region and the umbilical (UA) and vitelline arteries (VA). The window of specification of HE has not been defined in any mammalian system.

Aims: To determine the precise window of specification of HE hematopoietic precursors and interrogate at the single cell level their functional heterogeneity.

Methods: Dams pregnant with Cdh5ERT2-Cre;Rosa26Confetti/+embryos were treated with tamoxifen (TAM) at E7.5, E8.5, E9.5, E10.5 or E11.5. Here, TAM induces the permanent and random labeling of endothelial cells and their progeny with one of the Confetti allele fluorescence reporters (YFP, GFP, CFP or RFP). The blood of resulting adult Cdh5ERT2-Cre;Rosa26Confetti/-offspring was then examined for the presence of Confetti+ cells by flow cytometry.

Results: To estimate the temporal window of TAM activity, CD45.2+Rosa26ERT2-Cre;Confetti+ bone marrow (BM) cells were transplanted into CD45.2+CD45.1+ recipients treated with TAM three, two, one or zero days before transplant. Only the PB of recipients treated on the same day of transplanted BM, Confetti+ cells were detected in the PB, while no Confetti+ cells were found in recipients transplanted 24 hours later. Analysis of 10 weeks old Cdh5ERT2-Cre;Rosa26Confetti/+ mice revealed that only mice exposed to TAM at either E8.5 and E9.5 had Confetti+ blood. Thus, specification of HE begins at E8.5 and is complete by E10.5. Next, E11.5 AGMs isolated from CD45.2+ Cdh5ERT2-Cre;Rosa26Confetti/+embryos exposed to TAM at E10.5 were cultured as explants for three days under conditions that preserve ongoing HSC specification from HE, dissociated and then transplanted into CD45.2+CD45.1+ mice. Remarkably, although the CD45.2+ chimerism was high (~80%) in the blood of recipients, all CD45.2+ blood was positive for the Confetti label, further indicating that HE recruitment is complete by E10.5 and cannot be reactivated during explant culture. Limiting dilution co-culture of E9.5, E10.5, and E11.5 VE-Cadherin-CD45- endothelium revealed the frequency of functional HE to be 0.1, 1.1 and 0.19% at these time-points, respectively. Phenotypic analysis of primary hematopoietic colonies revealed that HE specification in the hematopoietic output of individual HSCs, with only 3% of colonies producing phenotypic HSCs in AA-ECs. These data suggest the presence of HE precursors with distinct functional output or the existence of a continuum of HE at different stages of maturation.

Summary/Conclusions: We have defined the window of mammalian HE specification. The abrupt loss of ongoing HE recruitment at E10.25 suggests an active mechanism that terminates this process. We also observed large phenotypic and functional variability amongst individual HE precursors examined throughout ontogeny.
Aims: In this study, we analyzed in vivo dynamics of CLEC2\textsuperscript{high} HSCs to clarify their functional roles in adult hematopoiesis.

Methods: In this experiment, we defined Lin-Sca1\textsuperscript{+}Kithigh CD150\textsuperscript{+}CD34\textsuperscript{-} cells as HSCs and Lin-Sca1\textsuperscript{+}Kithigh CD150\textsuperscript{+}CD41\textsuperscript{+} as MPk. We performed transplantation assays using HSCs isolated from EGFP transgenic (CAG-EGFP) mice to trace donor-derived HSCs and their progeny. Excepting enucleated hematopoietic fetal liver (HFL) transplants, randomization and selection as group (n=32) and validation group (n=83). The percentage of BM CD45-CD34+VEGF R\textsuperscript{2}+ EPCs, CD34+ HSCs, and reactive oxygen species (ROS) levels in EPCs and HSCs were evaluated in all of the enrolled patients pre-HSCT by flow cytometry. Furthermore, 59 patients were monitored for the frequency and ROS levels of BM EPCs and HSCs post-HSCT. Multivariate analyses revealed that the reduced BM EPCs and the disease status pre-HSCT were independent risk factors for the occurrence of PGF following allo-HSCT.

Results: A total of 18 patients including 5 patients in training group (15.63%) and 13 subjects in validation group (15.67%) developed PGF post-HSCT. Both in training group and validation group pre-HSCT, significantly reduced percentage of BM EPCs were observed in PGF patients than those in GGF patients, whereas no significant differences were found in the percentage of BM HSCs between PGF and GGF patients. Meanwhile, similar ROS levels were demonstrated in BM EPCs and HSCs between PGF and GGF patients. Although there was no difference in transplanted CD34+ cell dose between the PGF and GGF groups, significantly lower percentages of BM EPCs and HSCs, whereas remarkably higher ROS levels were observed in BM EPCs and HSCs in PGF groups than those in GGF patients at +1 month and +2 months post-HSCT. Moreover, inverse correlations were observed between BM EPCs frequency and their ROS levels post-HSCT, as well as BM HSCs frequency and their ROS levels post-HSCT.

Summary/Conclusions: We identified that patients with impaired BM EPCs pre-transplant were at a high risk for the occurrence of PGF post-allo-transplantation. Moreover, persistent low percentage and high levels of ROS in post-transplant BM EPCs may hamper the hematopoietic reconstitution of engrafted donor HSCs in patients with PGF.

E1102 EFFICIENT LYMPHOID DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS REQUIRES CXCR4 DESSENSITIZATION

C. Freitas\textsuperscript{1}, M. Wittner\textsuperscript{1}, J. Nguyen\textsuperscript{1}, V. Rondeau\textsuperscript{1}, J. Donadié\textsuperscript{1}, F. Bachelerie\textsuperscript{1}, P. Fouarge\textsuperscript{1}, P. Douay\textsuperscript{1}, A. Maury\textsuperscript{1}

\textsuperscript{1}INSERM U996, Clamart, \textsuperscript{2}INSERM U7110, Villejuif, \textsuperscript{3}Service d’Hématologie Pédiatrique, Hôpital Trousseau, Paris, France

Background: The Wnt4-Hypermethylation syndrome (OMIM#132400). This syndrome is characterized by an overgrowth syndrome and an immunodeficiency. This last feature is due to a dysfunction of the hematopoietic system, as confirmed by a marked lymphopenia. To address this immunodeficiency and to elucidate the pathophysiology of this syndrome, we took advantage of our relevant knock-in model and the access to murine short-term HSCs and their differentiation into multipotent HSCs (HSPCs).

Methods: The global hematopoietic development, including quiescence, cycling and survival properties of HSPCs, was examined in non-manipulated and BM-chimeric mice using flow-cytometric- and clonogenic-based assays. CXCR4 expression and function were assessed using internalization, chemotaxis and two-cell fusion assays in vitro. The effects of CXCR4 desensitization in vivo were studied using secondary transplantation experiments. Immuno-phenotypic and clonogenic analyses of HSPCs were performed from blood samples of five WS patients and age-, sex-matched healthy controls. CXCR4 desensitization was required for the quiescence and cycling balance of murine short-term HSCs and their differentiation into multipotent HPPCs.

Results: We showed that CXCR4 desensitization is required for quiescence/cycling balance of murine short-term HSCs and their differentiation into multipotent HPPCs. Efficient CXCR4 desensitization is critical for the lympho-hematopoietic differentiation of HSPCs. Efficient CXCR4 desensitization is critical for the lympho-hematopoietic differentiation of HSPCs. Efficient CXCR4 desensitization is critical for the lympho-hematopoietic differentiation of HSPCs.
Background: GATA4 is a transcription factor expressed in mesoderm and endoderm during development. Members of the family such as GATA-1, 2, and 3 are critically involved in hematopoiesis. An enhancer (G2) of the mouse Gata4 gene directs its expression throughout the lateral mesoderm and the allantois, beginning at E7.5, becoming restricted to the septum transversum by E10.5, and disappearing by midgestation (Rojas et al., Development, 2005, 132:3405). Our previous work has shown that inactivation of Gata4 using this G2Cre driver is lethal by midgestation (Delgado et al., Hepatology, 2014, 59:2388). The anemia observed in the G2Cre::Gata4floxed/cre embryos was attributed to a failure in the expansion of the hematopoietic progenitors in the fetal liver. Interestingly, a small population of hepatic YFP+ cells from G2Cre::R26R(RFP) embryos was positive for leukocyte and megakaryocyte markers, suggesting that a lineage of hematopoietic cells could derive from GATA4-expressing progenitors.

Aims: To study in our murine models the origin and properties of the hematopoietic lineage derived from progenitors expressing GATA4 under control of the G2 enhancer.

Methods: We analyzed hematopoietic organs of G2-Gata4Cre::R26R(RFP) mice, adults and embryos, by flow cytometry, RT-PCR and confocal microscopy. Cells obtained from different tissues were cultured and transplanted to analyze in vitro and vivo potential.

Results: YFP+ cells represented about 20% of the hematopoietic system of adult mice and contributed in the same proportion to the lymphoid, myeloid and erythroid lineages. Adult YFP+ hematopoietic stem cells (Figure 1) constituted a long-term repopulating, transplantable population. Fetal YFP+ hematopoietic progenitors were much more abundant in the placenta than in the aorta-gonad-mesonephros area. These placental YFP+ progenitors were clonogenic in the MethoCult assay and fully reconstituted hematopoiesis in lethally irradiated mice (Cañete et al., Blood, 2012, 120:228). Thus, fetal YFP+ progenitors are an abundant, repopulating, transplantable, and properly integrated source of hematopoietic cells from GATA4-expressing progenitors.

Discussion: These fetal progenitors appear to contribute to the development of a long-term repopulating population of fetal hematopoietic cells that can engraft lethally irradiated mice. The presence of YFP+ cells in the fetal liver may indicate a role for fetal GATA4 in the establishment of the hematopoietic system. The ability of fetal YFP+ cells to engraft lethally irradiated mice suggests that they are capable of self-renewal and differentiation. The presence of YFP+ cells in the aorta-gonad-mesonephros area indicates that they may contribute to the development of the hematopoietic system in this region. Further studies are needed to determine the role of fetal GATA4 in the establishment of the hematopoietic system and the mechanisms by which fetal GATA4-expressing progenitors contribute to the development of the hematopoietic system.
Methods: K562 (BCR-ABL positive chronic myeloid leukemia in blast crisis)-Luciferase-control or K562-Luciferase-SZF1/ZNF589 cells were directly injected into the femurs of NSG mice and tumor development was monitored by bioluminescence. Furthermore, K562 cells with or without SZF1/ZNF589 overexpression were studied by proliferation assay, cytomorphology, flow cytometry, cell cycle analysis, cyclin B1 expression and beta-galactosidase assay.

Results: K562-dependent tumor growth was efficiently inhibited in NSG mice transplanted with K562-Luc-control-cells, leading to significantly prolonged survival, demonstrating a strong tumor suppressive potential of SZF1/ZNF589 in vivo. In vitro, overexpression of SZF1/ZNF589 dramatically inhibited proliferation of K562 cells which, instead of dying, became giant and dysplastic, without other significant morphological changes and in absence of polyplody. Cell cycle analysis revealed a blockade in G2/M phase, with cyclin B1 accumulation characteristic for mitotic arrest. As suggested by morphology and beta-galactosidase assay, tumor cells were undergoing premature senescence.

Summary/Conclusions: SZF1/ZNF589 controls survival of hematopoietic cells mediated by mitotic arrest and premature senescence, exhibiting tumor suppressive functions in vivo.

E1106
THE FUNCTIONAL RELEVANCE OF DNMT3A SPLICE VARIANTS IN HEMATOPOIETIC DIFFERENTIATION
T. Bozici1, J. Froble1, A. Raić1, S. Heilmann-Heimbach2, T.W. Goecke3, E. Jost4, W. Wagner1,2,4
1Stem Cell Biology and Cellular Engineering, Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, 2Department of Human Genetics, Life & Brain Center, University of Bonn, Bonn, 3Department of Obstetrics and Gynecology, RWTH Aachen University Hospital, 4Clinic for Oncology, Hematology, and Stem Cell Transplantation, RWTH Aachen University Medical School, Aachen, Germany

Background: DNA methyltransferase 3A (DNMT3A) plays a pivotal role for de novo DNA methylation (DNAm) during development. It seems to be of particular relevance in hematopoietic differentiation because it is frequently mutated in acute myeloid leukemia or clonal hematopoiesis. So far, it is unclear how DNMT3A governs the use of lineage-specific DNAm patterns – it is conceivable that this can at least partly be attributed to alternative splicing of DNMT3A.

Aims: In this study, we followed the hypothesis that specific splice variants of DNMT3A impact on hematopoietic differentiation or DNAm patterns. Therefore we addressed the role of specific splice variants of DNMT3A in hematopoietic stem and progenitor cells (HSPCs).

Methods: Expression of DNMT3A splice variants was modulated in HSPCs: transcript 1+3 (Tr.1+3), transcript 2 (Tr.2), or transcript 4 (Tr.4) of DNMT3A were either knocked down by short hairpin RNA or constitutively overexpressed by lentiviral infection. Expression changes were validated by qRT-PCR. Subsequently, we evaluated the impact on colony formation potential (CFU assay), proliferation (CFSE assay), and the immunophenotype (CD34+ and CD133+). Global DNAm profiles were generated with the Illumina HumanMethylation450 BeadChip platform and gene expression profiles with the Human Affymetrix GeneChip ST1.0 platform.

Results: Downregulation of either Tr.2 or Tr.4 reduced the proliferation rate of HSPCs significantly (n=3, p<0.05). HSPCs maintained CD34 expression for a higher number of cell divisions upon knockdown of Tr.2 (n=3, p<0.05). In colony forming unit (CFU) assays downregulation of Tr.4 resulted in a clear bias towards erythroid colonies (n=3, p<0.05). Overall, CFU frequency was reduced by knockdown of DNMT3A transcripts, whereas it was increased by overexpression. Subsequently, we analyzed the impact of specific DNMT3A variants on the DNAm patterns: several CpG sites revealed significant differences in DNAm levels upon knockdown of Tr.2 and Tr.1+3 (8,905 and 352 CpGs, respectively; n=3, adjusted p-value <0.05). Notably, these patterns were regulated in the opposite direction upon overexpression of the same transcripts. Knockdown of Tr.2 and Tr.1+3 resulted in transcript-specific gene expression changes, which may at least partly be attributed to the DNAm changes.

Summary/Conclusions: Our results demonstrate that the various splice variants of DNMT3A have different functional sequel on HSPCs. Knockdown and overexpression resulted in opposite and transcript-specific DNAm changes. Thus, alternative splicing of DNMT3A is relevant for site-specific epigenetic modifications in hematopoietic development.

E1107
ERYTHROPOIETIN STIMULATES TRANSDIFFERENTIATION OF BONE MARROW PRO-B CELLS INTO BONE-RESORBING OSTEOCLASTS
N. Deshet-Unger1, S. Hiram-Bab2, N. Ben-Califa1, A. Kolomansky1,3, D. Kallin1, Y. Litin-Ovitz1,4, Y. Gabel2, E.Jost4, W. Wagner1,2,4
1Cell and Developmental Biology, 2Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, 3Medicine A, Tel Aviv Sourasky Medical Center, 4Tel Aviv University, Tel-Aviv, Israel

Background: Erythropoietin (EPO) is a crucial kidney-derived hormone responsible for erythropoiesis; however, its extra-erythroid effects are substantial and correlate with EPO receptor (EPO-R) expression in both hematopoietic and non-hematopoietic tissues. Bone turnover is regulated by the coupled actions of osteoblasts, the bone-forming cells, and monocyte-derived osteoclasts, which mediate bone resorption. In this regard, we have recently reported that EPO directly stimulates bone resorption via activation of EPO-R signaling in the monocytic lineage (Hiram-Bab et al., 2015). Monocyte differentiation into osteoclasts relies on macrophage-macrophage colony-stimulating factor (M-CSF) and the receptor activator of nuclear factor kappa B ligand (RANKL). B cells are also known to regulate bone metabolism, chiefly via paracrine signals. Osteoclasts and B cells arise from distinct myeloid and lymphoid progenitors, respectively, which are downstream of a common multipotent progenitor cell.

Results: In the bone marrow (BM), Pro-B cells sequentially differentiate into Pre-B and immature B cells. Whether BM B cells can transdifferentiate into osteoclasts remains controversial, since osteoclast differentiation from residual monocyte precursors in the cultures was not included in earlier studies.

Aims: We set to determine whether B cells can transdifferentiate to osteoclasts and to assess the effect of EPO on this process.

Methods: Experiments were conducted on C57BL/6j or CD19-Cre;R26R-EYPF, 8-12-week-old female mice in accordance with the approval of the Institutional Animal Care and Use Committee of Tel-Aviv Universität (M-14-043). BM cells were flushed from femurs, tibias, and pelvic bone and red blood cells were lysed. Cells were stained with labelled anti-mouse antibodies: PE-B220, FITC-CD19, PerCP-igm, PeCy7-CD43, and APC-M-CSF receptor/CD115; and sorted by flow cytometry. Cells were then cultured in α-MEM containing 10% fetal bovine serum, M-CSF and RANKL. Multinucleated osteoclasts were stained for tartrate-resistant acid phosphatase (TRAP) and pit resorption was assessed.

Figure 1: Results: B cells isolated from BM of CD19-Cre;R26R-EYPF mice cultured with M-CSF and RANKL differentiated into TRAP+ multinucleated osteoclasts that were also positive for EYPF, thus tracing back their B cell origin (Figure 1A). Next, we dissected which B cell precursor subtype possesses this osteoclastogenic capacity and found that only Pro-B (B220+CD19+CD43IGHG+GM), but not Pre-B (B220+CD19+CD43Q1MG) nor immature B cells (B220+CD19+CD43GM+) could transdifferentiate into osteoclasts (16±3.7 vs. 0.79±0.28 and 48±0.13 osteoclasts’ area, respectively). Moreover, among the Pro-B cells, only those expressing M-CSF receptor (CD115) could transdifferentiate into osteoclasts (18±6.55 vs. 0.11±0.05 osteoclasts’ area, respectively, Figure 1B and C). Using an anti-EPO-R specific antibody we detected EPO-R on the surface of B cells and noted that EPO enhanced the differentiation of the Pro B cells into osteoclasts by as much as 70% (p<0.04) (Figure 1D).

Figure 1: Osteoclastogenesis in vitro from sorted B cells. (A) Trans-differentiation of 180,000 cells/well CD19-Cre;R26R-EYPF into osteoclasts, DRAQ5 (blue) and anti-GFP (green) for CD19-Cre;R26R-EYPF and CD19-Cre cells. Bottom - TRAP staining. Confocal images (x20 magnification) (B) TRAP staining of osteoclasts derived from the sorted indicated cells from BM (10,000 cells/well) and cultured with M-CSF and RANKL. Left – Pre-B cells expressing CD115 (B220+CD19+CD43IGHG+GM), right – Pro-B cells not expressing CD115 (B220+CD19+CD43IGHG+GM). Data are means±SEM of osteoclast area, n=5 mice in each group; *p<0.05. (C) Pit resorption area from the indicated sorted cells cultured on calcium phosphate-coated plates. (D) TRAP staining of osteoclasts derived from sorted Pro-B cells (B220+CD19+CD43IGHG+GM cells; 180,000 cells/well)±5U/ml EPO, n=7 mice in each group. Data are% osteoclasts of a representative image; EPO versus Control was 70% increase, p<0.05. Summary/Conclusions: Taken together, our data suggest a new physio-pathological role for BM B-cell precursors in bone metabolism via their capacity to differentiate into functional osteoclasts, and a possible role for EPO in this process.
E1110

BONE MARROW MYELOPOIESIS INDEPENDENTLY OF CANONICAL NOTCH SIGNALING

S. Jin1, H. Tsoi4, C. Nerlov3, S.E.W. Jacobsen1

Summary/Conclusions:

Expression of these Notch genes negatively affected by Notch signaling is dispensable for generation and replenishment of Mk, E and GM progenitors in aBM has been implicated as having no substantial impact on expression of genes for key regulators the Mk and E cell lineages at distinct progenitor stages for these lineages, as previously implicated. No deficiencies were observed in the replenishment of HSCs and all GM, Mk and E progenitor stages from unfractionated aBM cells as well as circulating platelet counts were also unaffected in Rbpj−/− mice crossed to both Mx1-Cre and the pan-hematopoietic Vwf-eGFP lineages at any progenitor stage, in comparison with wild type controls. Notably, transcript levels of genes encoding key Mk/E regulators were never observed in the presence or absence of imatinib and doxorubicin in HS-5 cells plus 3D scaffolds. K562 and HL60 cells were investigated for proliferation and viability in the presence of scaffolds. Co-culture of HS-5 with HL60 or K562 cells: The same experiment was performed in the presence of 3D scaffolds. Co-culture of HS-5 with HL60 or K562 cells: The same experiment was performed in the presence of scaffolds.

Aims: The goal of this study is to identify a novel HSC-specific surface marker(s) that enables prospective isolation of functionally-distrinct HSC subpopulations.

Background: All hematopoietic cells are derived from hematopoietic stem cells (HSCs), which exhibit capacities for multilineage differentiation and long-term self-renewal. Human HSCs can be isolated by Fluorescence-activated cell sorting (FACS) with the combination of several surface markers, such as CD34+CD45RA−CD90+. This approach typically consists of functionally heterogeneous subpopulations, including multi-potent and/or lineage- biased progenitors (Notta:2016hh) and HSC-like populations with reduced self-renewal capacity (Notta:2011bg); however, prospective isolation of bona fide human HSCs is still challenging due, at least in part, to the lack of specific surface markers.

Methods: We examined expression levels of 342 cell surface markers in the HSC, CD35+, CD34+CD45RA−CD90+ population, using commercial- ly-available antibodies. Single-cell gene expression profiling of isolated subfractions were performed using Fluidigm C1 system in combination with BioMark.

Results: Among 342 cell surface proteins examined, only CD35, CD115 and CD215 were detected in the HSC fraction. We focused on CD35, which is also known as complement receptor type 1 (CR1), as its expression was most distinct among the three markers. CD35-positive population accounted for 15~50% of the human HSCs, defined as Lin−CD34+CD38−CD45RA−CD90+ cells, in adult bone marrow and cord blood. HSCs exhibited multi-lineage re constitution capacity without lineage-biased differentiation in a single-cell colony assay regardless of the CD35 levels. CD35+HSCs gave rise to CD35−HSCs in lineage tracing experiments, suggesting that CD35+HSCs reside upstream of CD35−HSCs in the hierarchial hematopoietic differentiation. Single-cell gene expression profiling of CD35+positive or -negative HSCs indicated that CD35+HSCs, but not CD35−HSCs, are phenotypically homogeneous, expressing cell cycle-related genes and lineage-specific markers at low levels.

Summary/Conclusions: Our data suggest that HSCs can be further subdivided into subfractions based on the CD35 levels. CD35 might be a useful marker to prospectively isolate the most primitive human HSC fraction. In vivo functional assays using xenotransplantation models are currently underway, and the results will be discussed at the meeting.

E1111

IDENTIFICATION OF NOVEL HUMAN HEMATOPOIETIC STEM CELL SUBPOPULATIONS VIA COMPREHENSIVE SURFACE MARKER ANALYSIS

T. Jirouma1,*, K. Miyawaki1, Y. Moni1, H. Iwasaki2, T. Maeda1, K. Akashi1

Background: Most hematopoietic stem cells (HSCs), which exhibit capacities for multilineage differentiation and long-term self-renewal. Human HSCs can be isolated by Fluorescence-activated cell sorting (FACS) with the combination of several surface markers, such as CD34+CD45RA−CD90+, which are functionally heterogeneous subpopulations, including multi-potent and/or lineage-biased progenitors (Notta:2016hh) and HSC-like populations with reduced self-renewal capacity (Notta:2011bg); however, prospective isolation of bona fide human HSCs is still challenging due, at least in part, to the lack of specific surface markers.

Aims: The goal of this study is to identify a novel HSC-specific surface marker(s) that enables prospective isolation of functionally-distrinct HSC subpopulations.

Methods: We examined expression levels of 342 cell surface markers in the HSC (Lin−CD35+CD34+CD45RA−CD90+) by FACS using commercially-available antibodies. Single-cell gene expression profiling of isolated subfractions were performed using Fluidigm C1 system in combination with BioMark.

Results: Among 342 cell surface proteins examined, only CD35, CD115 and CD215 were detected in the HSC fraction. We focused on CD35, which is also known as complement receptor type 1 (CR1), as its expression was most distinct among the three markers. CD35-positive population accounted for 15~50% of the human HSCs, defined as Lin−CD34+CD38−CD45RA−CD90+ cells, in adult bone marrow and cord blood. HSCs exhibited multi-lineage reconstitution capacity without lineage-biased differentiation in a single-cell colony assay regardless of the CD35 levels. CD35+HSCs gave rise to CD35−HSCs in lineage tracing experiments, suggesting that CD35+HSCs reside upstream of CD35−HSCs in the hierarchial hematopoietic differentiation. Single-cell gene expression profiling of CD35+positive or -negative HSCs indicated that CD35+HSCs, but not CD35−HSCs, are phenotypically homogeneous, expressing cell cycle-related genes and lineage-specific markers at low levels.

Summary/Conclusions: Our data suggest that HSCs can be further subdivided into subfractions based on the CD35 levels. CD35 might be a useful marker to prospectively isolate the most primitive human HSC fraction. In vivo functional assays using xenotransplantation models are currently underway, and the results will be discussed at the meeting.
fibres. Treatment of K562 or HL60 cells with imatinib or doxorubicin respectively resulted in a lower level of apoptosis in cells grown on the 3D scaffold compared to those grown in 2D culture. Further development of this 3D culture by adding stromal cells HS-5 to the scaffold reduced even further the sensitivity of K562 or HL60 to imatinib or doxorubicin, respectively.

Figure 1.

Summary/Conclusions: The relative resistance to either imatinib or doxorubicin that we observed in cells grown in 3D culture supports a role for the bone marrow matrix in the protection of leukaemic cells against chemotherapeutic agents. A combination of the PMMA- HA with HS-5 cells made this system more similar to the bone marrow microenvironment as this is a model in which all the basic components of the bone marrow microenvironment such as scaffold, stromal cells and cytokines (secreted by HS-5) are present. The results of this study show adding extra complexity to the microenvironment changes the sensitivity of the cells to therapeutic agents, better recapitulating the situation observed in-vitro. Three dimensional cultures using the PMMA-HA-HS-5 model may prove useful in the investigation of therapy resistance in leukaemia and for the discovery of new agents capable of eradicating quiescent leukaemic stem cells.

E1113
WHOLE EXOME SEQUENCING REVEALED SEQUENTIAL GAIN OF MUTATIONS IN TWO CASES OF DONOR CELL HAEMATOLOGICAL MALIGNANCY AFTER HEMATOPOIETIC TRANSPLANTATION
J. Suñer González1,2, C. Martínez-Laperche1,2,3, M. Kwon1,2, G. Rodríguez-Macías3, A. Figuera4, A. Balas5, N. Martínez6, P. Balsalobre2,3, D. Serrano2,3, M.A. Piris7,8, J.L. Vicario5, J. Gayoso2,3, J.L. Díez23, I. Buño1,2,3
1Genomic Unit, Instituto de Investigación Sanitaria Gregorio Marañón y Hospital General Universitario Gregorio Marañón, 2Instituto de Investigación Sanitaria Gregorio Marañón, 3Department of Hematology, Hospital General Universitario Gregorio Marañón, 4Department of Hematology, Hospital de la Princesa, 5Department of Histocompatibility, Madrid Blood Centre, 6, 7Department of Clinical Chemistry, Microbiology and Immunology, 8Department of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent University, 9Department of Laboratory Medicine, 10Department of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

Background: The leukemic transformation of otherwise healthy donor stem cells provides a useful model to study the mechanisms involved in leukemogenesis. Aims: We report two cases of donor cell derived haematological malignancy in which whole-exome sequencing (WES) was performed in bone marrow (BM) samples from recipient at different times after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in order to study the dynamics of emergence of mutations that precede the development of donor cell leukemia (DCL) and donor cell myelodysplastic syndrome (DC-MDS).

Results: 9 BM samples were aligned to GRCh 38/hg38 in the second case. 269439 hits from donor SCs and 269449 hits from the human reference genome (GRCh 37/hg19) and donor SCs and 5 BM samples, from case 1, were aligned to the human reference genome (GRCh 37/hg19) and donor SCs and 9 BM samples were aligned to GRCh 38/hg38 in the second case.

Methods: Technical assessment was performed using six neuroblastoma cell lines with varying levels of MYCN gene amplification. Correlation to expression data obtained by the gold standard RT-qPCR, performance in rare (0.1%) cell populations, effects of cryopreservation and off-target effects were evaluated. Next, diagnostic material of de novo AML patients was used to measure target gene (Wilms' tumor 1 (WT1)) and reference gene (RPL13a, GAPD) expression. Expression analysis was performed in unfractonated bulk leukemic cells as well as blasts and rare subsets of leukemic cells, e.g. LSCs. FCM analyses were performed on a FACSCanto II (BD Biosciences) with set-up according to EuroFlow guidelines. Inficyt™ (Cytognos®) was used for data analysis and mean fluorescence intensities (MFI) values (with/without normalisation) were interpreted. P-values < 0.05 were considered significant.

Results: mRNA expression quantified by PrimeFlow™ significantly correlated with data obtained by RT-qPCR and remained detectable in rare (0.1%) cell populations. WT1 expression was shown to be statistically significantly higher in bulk leukemic cells of those patients characterized by WT1 overexpression, as defined by RT-qPCR, showing a mean 52% MFI upregulation by PrimeFlow™ if WT1 was overexpressed. The gold standard RT-qPCR. Moreover, WT1 overexpression could be detected in heterogeneous cell populations, e.g. the CD34+CD38+ cell population and the LSC (defined as CD34+CD38+), showing a 63% and 45% MFI upregulation, respectively, compared to patients with normal WT1 expression levels, although only statistically significant in higher CD34+CD38+ cells compared to LSCs.
Summary/Conclusions: Key mRNA target expressions in AML, e.g. WT1 gene expression, could be evaluated using PrimeFlow™ RNA assay, including rare and heterogeneous cell populations herein, e.g. LSCs. This study demonstrates that PrimeFlow™ is a technique of interest for the discovery of novel LSC-specific targets.

E1115

POTENTIAL PREDISPOSING GERMLINE MUTATIONS IN PATIENTS WITH CONCOMITANT MYELOID AND LYMPHOID MALIGNANCIES

F. Asmar1, M. Munk-Johansen1, T.C. El-Galaly2, H.E. Johnsen3, C. Westmose Yde3, D. El Fassi4, K. Grønbæk1
1Department of Hematology, Rigshospitalet, Copenhagen, 2Department of Hematology, University hospital of Aalborg, Aalborg, 3Center of Genomic Medicine, Rigshospitalet, Copenhagen, 4Department of Hematology, University Hospital Herlev and Gentofte, Herlev, Denmark

Background: Recent findings have suggested that mutations predisposing the development of either acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL) may arise in pre-leukemic hematological stem cells. In addition, genes involved in epigenetic regulation, such as TET2, and RNA processing, such as SF3B1, are mutated in both myeloid and lymphoid malignancies. This could indicate a possible genetic link between myeloid and lymphoid malignancies. Therapy related AML (t-AML) is a known complication to treatment with cytotoxic drugs such as alkylating agents and topoisomerase inhibitors. The susceptibility of developing t-AML has been associated with variation in DNA-repair pathways, drug metabolism and transport.

Aims: In this study, we aimed to investigate a possible common genetic origin of hematological cancers in patients with concomitant CLL and de novo AML or myelodysplastic syndrome (MDS) and in patients with concomitant therapy-related AML (t-AML) and CLL.

Methods: The presence of concomitant lymphoid and myeloid malignancies in patients is rare, however we managed to include 3 patients with de novo AML and CLL, one patient with MDS and CLL, one patient with chronic myelomonocytic leukemia(CMML) and CLL, and two patients with t-AML and CLL. The patients’ diagnoses were based on the evaluation of the morphological, immunohistochemistry, cytogenetics, and flow cytometry analysis in accordance to the WHO classification. For each patient mononuclear cells (MNCs) from blood or bone marrow were isolated using Ficol gradient centrifugation and used for fluorescence activated cell sorting (FACS) of the malignant clones and the T-cells. Paired end exome sequencing (2x150) aiming for an average coverage of 50-100x was performed using either the HiSeq2500 or NextSeq500 platforms from Illumina. Raw sequencing data was processed using CASAVA-1.8.2. Mapping to the human genome (hg19/GRCh37 UCSC) was performed using CLC Biomedical Genomics Workbench (Qiagen) mapping cell software.

Results: We identified possible pre-disposing germline mutations in all 7 patients by comparing variants between the myeloid malignant clone, CLL cells, and T cells, as well as using saliva to aid in characterizing the mutations as de novo or present in the hematological compartment. In all the patients except one with de novo AML and CLL, we identified a potential damaging germline variant in a DNA-repair related gene, such as ATM (387dupA, D130fs*4), SMARCAL1 (2114C>T, T705I), HELQ (393_397delAGGTG, G132fs*16), SWI5 (652C>T, R218*), LIG1(2168A>G, Q76R) and PRKDC (502G>A, C301Y). In the remaining patient with concomitant de novo AML and CLL, we identified a potential damaging germline variant in an epigenetic regulator believed to play a role in normal and malignant hematopoiesis, KDM2B(D130fs*4), furthermored, we identified the somatic mutational landscape of the malignant clones using t-AML as germline tissue for the patient with concomitant de novo AML/CMML and CLL and for the two patients with t-AML and CLL. The somatic mutational landscapes of the malignant clones in the de novo concomitant cases and the cases with t-AML were quite similar to what has previously been reported in isolated cases of disease. The myeloid and lymphoid malignant clones did not share any of the mutations indicating development of two independent malignancies.

Summary/Conclusions: Our results suggest a possible role of germline variations in the susceptibility to development of concomitant de novo hematological cancers as well as t-AML. However, further studies including more patients are needed to confirm this hypothesis.

E1116

THE MUTATIONAL LANDSCAPE OF DNMT3A MUTATIONS IN CLONAL HAEMATOPOIESIS OF INDETERMINATE POTENTIAL. CHIPPING AWAY AT THE PROBLEM

S. Chaudry1, T. Chevassut1
1Brighton and Sussex Medical School, Brighton, United Kingdom

Background: Dysfunction of epigenetic modifiers contributes significantly to the pathogenesis of acute myeloid leukaemia (AML). One frequently mutated gene involved in epigenetic modification is DNMT3A (DNA methyltransferase-3-alpha). Approximately 22% of de-novo AML and 36% of cytogenetically normal AML are found to have DNMT3A mutations and around 60% of these mutations affect the R882 codon. In particular, the R882H mutation has been associated with a poor prognosis and survival outcomes for patients. A large number of DNMT3A mutations are present in clonal cells in healthy individuals with no characteristics of haematological malignancy and is termed as clonal haematopoiesis of indeterminate potential (CHIP).

Figure 1.

Aims: We aimed to compare here the locations and types of mutations identified in AML and in CHIP in the DNMT3A gene by several different studies.

Methods: To review the mutations found in CHIP and AML, we carried out an extensive literature search of CHIP studies and AML studies that had mapped a large number of mutations in this gene. Mutations were collated to form several diagrams illustrating and comparing these findings.

Results: When DNMT3A mutations in CHIP were compared to mutations in AML the R882 residue was still found to be the most frequently mutated residue in both CHIP and AML. Figure 1 clearly illustrates the mutations in comparison to AML. However, only 13% of all reported mutations were found at the R882 residue in CHIP, while in AML 60% DNMT3A mutations are found at the R882H mutations.

Summary/Conclusions: Analysis of the mutational landscape of CHIP has clearly highlighted the role of DNMT3A mutations in clonal haematopoiesis in older healthy individuals, the significance of such preleukaemic clones is yet to be determined.

E1117

NEXT-GENERATION REFERENCE INTERVALS FOR PEDIATRIC HEMATOLOGY

J. Zierk1, J. Hirschmann2, D. Toddenroth2, F. Arzideh3, T. Streichert4, R. Haeckel5, H.-U. Prokosch6, M. Rauh1, M. Metzler1
1Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 2Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, 3Department of Statistics, University of Bremen, Bremen, 4Department of Clinical Chemistry, University Hospital of Cologne, Cologne, 5Bremer Zentrum für Laboratoriumsmedizin, Klinikum Bremen Mitte, Bremen, Germany

Background: Interpretation of hematology analytes in children is challenging due to extensive changes in hematopoiesis with age leading to pronounced sex- and age-specific dynamics. To facilitate clinical decision making based on quantitative hematology test results, reference intervals are used to classify samples according to upper and lower limits, and age-related change is represented using reference intervals partitioned into separate age groups. However, this approach can only approximate the continuous physiological dynamics of hematological analytes in childhood and does not enable appropriate quantification of test results in relation to the reference distribution. Conversely, percentile charts as used in anthropometric quantities (e.g. pediatric weight-for-age charts) would allow adequate appreciation of pediatric hematology test results. However, the ethical and practical challenges unique to pediatric reference intervals have restricted the creation of such percentile charts, and limitations in current approaches to laboratory test result display prevent their integration into clinical decision making.

Aims: To create percentile charts for hematology analytes from birth to adulthood using a data-mining approach and to demonstrate their integration into clinical care with benefits in clinical decision making.
Figure 1.

Methods: We applied a data-mining algorithm to generate percentile charts for hematology analytes using laboratory data collected during the clinical care of patients. A total of 9,517,245 samples from 343,463 patients (72,614–337,011 samples per analyte) from 8 German tertiary care centers and 2 German laboratory service providers were examined. Percentile charts were calculated using an established statistical approach which extracts the proportion of samples from healthy individuals from the unfiltered input dataset containing both non-pathologic and pathologic samples. To evaluate the clinical benefit of hematology test result interpretation using percentile charts, accuracy and speed of pediatricians assessing eight different predefined clinical situations were measured in comparison to conventional test result representations.

Results: We created percentile charts for hematology analytes in girls and boys from birth to 18 years which can be used as common reference intervals. Results are provided for hemoglobin, hematocrit, red cell indices, red cell count, red cell distribution width, white cell count, and platelet count, example charts for hemoglobin, mean corpuscular volume, and platelet count are shown in the accompanying figure. A web application at www.pedref.org/hematology demonstrates hematology test result interpretation using percentile charts and z-scores with special consideration of pediatric dynamics. Comparison of pediatricians’ decision times when assessing different clinical scenarios using percentile charts and conventional representations shows more correct decisions (75.9% vs 68.4%, p<0.01) which are made in shorter time (2.7 s vs 3.8 s, p<0.01) when using percentile charts.

Summary/Conclusions: The created percentile charts enable the appropriate differential diagnosis of changes in hematology analytes due to disease and changes due to physiological development. Integration of suitable forms of result reporting using the provided percentile charts into clinical decision making improves assessment of the unique dynamics in pediatric hematology.

GROWTH FACTOR INDEPENDENCE 1 (GFI1) REGULATES THE AML SUPPORTING FUNCTION OF MESENCHYMAL STROMAL CELLS

Y. Al-Matary1,*, L. Bolezatu1, A. Thivakaran1, R. Köster1, J. Schütte1, J. Göthert1, U. Dührsen1, B. Opalka1, C. Khandanpour1
1University Hospital of Essen/West centre of tumor, Essen, Germany

Background: Mesenchymal stromal cells (MSCs) harbor and support the function of normal hematopoietic stem cells. Less is known about their interaction with leukemic cells, e.g. in acute myeloid leukemia (AML). The prognosis of AML, a clonal malignant disease of the bone marrow (BM), is still poor with only 25% of patients living longer than 5 years.

Aims: In the current study, we investigated the interaction between MSCs and AML cells, and we also investigated the underlying molecular mechanism.

Methods: We used cell cultures using primary cells from human and mice and cell lines of MSCs and AML cells. Different Mouse models of human AML were used in our study to confirm the results obtained from human sample. MSCs were characterized by differentiation assay, flow cytometry and RT-PCR. Matrigel test was also applied in this study.

Results: MSCs from AML patients called AML-associated MSCs (AMSCs) or from murine models of human leukemia enhance significantly in vitro the growth of leukemic cells compared to AML cells growing without MSCs or in presence of MSCs from non-leukemic patients or mice. Among other, AMSCs increased entry of leukemic cells into the cell cycle, and at the same time protected the leukemia cells against exogenous toxic events such as chemotherapy or irradiation. The interaction between AMSCs and leukemia cells is dependent on cell-to-cell contact. In vivo, absolute and relative numbers of AMSCs and other stromal cells, i.e. endothelial cells and osteoblast lineage cells were highly expanded in the BM of mice modeling of human AML. AMSCs showed a higher efficiency of capillary tube formation in the matrigel assay than normal MSCs which gives an additional indication that AMSCs were polarized by leukemia cells towards a tumor-supporting state. On a molecular level, the polarization of MSCs towards an AML-supporting state depends on upregulated expression of the transcription factor Growth factor independence 1 (Gfi1). Loss of Gfi1 diminished the tumor-supporting state of AML-associated MSCs.

Summary/Conclusions: We conclude that leukemia cells polarize AMSCs towards a leukemia-supporting state in a Gfi1-dependent manner, which could open the way to new therapeutic approaches.

E1118

GROWTH FACTOR INDEPENDENCE 1 (GFI1) REGULATES THE AML SUPPORTING FUNCTION OF MESENCHYMAL STROMAL CELLS

Y. Al-Matary1,*, L. Bolezatu1, A. Thivakaran1, R. Köster1, J. Schütte1, J. Göthert1, U. Dührsen1, B. Opalka1, C. Khandanpour1
1University Hospital of Essen/West centre of tumor, Essen, Germany

Background: Mesenchymal stromal cells (MSCs) harbor and support the function of normal hematopoietic stem cells. Less is known about their interaction with leukemic cells, e.g. in acute myeloid leukemia (AML). The prognosis of AML, a clonal malignant disease of the bone marrow (BM), is still poor with only 25% of patients living longer than 5 years.

Aims: In the current study, we investigated the interaction between MSCs and AML cells, and we also investigated the underlying molecular mechanism.

Methods: We used cell cultures using primary cells from human and mice and cell lines of MSCs and AML cells. Different Mouse models of human AML were used in our study to confirm the results obtained from human sample. MSCs were characterized by differentiation assay, flow cytometry and RT-PCR. Matrigel test was also applied in this study.

Results: MSCs from AML patients called AML-associated MSCs (AMSCs) or from murine models of human leukemia enhance significantly in vitro the growth of leukemic cells compared to AML cells growing without MSCs or in presence of MSCs from non-leukemic patients or mice. Among other, AMSCs increased entry of leukemic cells into the cell cycle, and at the same time protected the leukemia cells against exogenous toxic events such as chemotherapy or irradiation. The interaction between AMSCs and leukemia cells is dependent on cell-to-cell contact. In vivo, absolute and relative numbers of AMSCs and other stromal cells, i.e. endothelial cells and osteoblast lineage cells were highly expanded in the BM of mice modeling of human AML. AMSCs showed a higher efficiency of capillary tube formation in the matrigel assay than normal MSCs which gives an additional indication that AMSCs were polarized by leukemia cells towards a tumor-supporting state. On a molecular level, the polarization of MSCs towards an AML-supporting state depends on upregulated expression of the transcription factor Growth factor independence 1 (Gfi1). Loss of Gfi1 diminished the tumor-supporting state of AML-associated MSCs.

Summary/Conclusions: We conclude that leukemia cells polarize AMSCs towards a leukemia-supporting state in a Gfi1-dependent manner, which could open the way to new therapeutic approaches.
BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION

I. Hude1,2,*, S. Sasse2, P.J. Broekelman1, B. von Tresckow2, J. Momotow2, A. Engert1, S. Borchmann2
1Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Zagreb, Croatia. 2German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany

Background: Despite encouraging efficacy of anti-PD1 antibodies in relapsed or refractory (rr) classical Hodgkin lymphoma (cHL), not all patients achieve a lasting response, with few complete remissions (CR) observed. Thus, identification of predictive biomarkers is important. Recently, two models using readily available differential blood count parameters have been suggested to predict outcome in melanoma patients treated with immune checkpoint inhibition.

Aims: In this study, we aimed to identify baseline differential blood count parameters associated with response and progression free survival (PFS) in rr cHL patients treated with anti-PD1 antibody nivolumab.

Methods: We retrospectively investigated baseline differential blood count parameters and their association with response and progression free survival (PFS) in 30 rr cHL patients treated with the anti-PD1 antibody nivolumab. All 30 patients had previously received multiple lines of treatment, including treatment with high dose chemotherapy followed by autologous stem cell transplant (ASCT) for rr disease; the median number of prior treatment lines was 5 (2-11) and 21 patients received prior brentuximab vedotin. To investigate the association of baseline blood count parameters (white blood cell count (WBC), relative monocyte count (RMC), relative neutrophil count (RNC), relative lymphocyte count (RLC) and relative eosinophil count (REC)) with outcome after PD1 inhibition, we used the last differential blood count performed immediately prior to the first received dose of nivolumab.

Results: RMC, RNC and RLC did not have a prognostic impact on PFS, whereas higher WBC ≥ 7.78x10³/µl and lower REC<1.7% were associated with worse PFS in both univariate and multivariate analysis. We constructed a simple score to prognosticate PFS. By adding 1 point each for WBC ≥ 7.78x10³/µl and REC<1.7% to the score, we could clearly differentiate a low (score=0), intermediate (score=1) and high risk (score=2) group for disease progression (p<0.001).

Figure 1.

| Summary/Conclusions: | Our simple prognostic model, mainly characterized by a normal to high REC, robustly discriminates three risk groups for PFS. Almost all patients in the low risk group achieved a durable remission without disease progression throughout the study period, despite often achieving just a partial response. In contrast, high-risk patients often progressed quickly despite initially achieving a partial or complete response. Further validation of this score which is easily available from routine clinical parameters in a larger cohort of patients and further investigation of its potential predictive impact is needed. Moreover, efforts to clearly understand a possible mechanistic role of eosinophils in cHL patients treated with PD1-inhibition are warranted. |

E1120

THE PROGNOSTIC SIGNIFICANCE OF BETA-2 MICROGLOBULIN (B2M) LEVELS IN PATIENTS WITH HODGKIN LYMPHOMA (HL) TREATED WITH ABVD OR EQUIVALENT (ABVDEQ) CHEMOTHERAPY OR COMBINED MODALITY THERAPY (CMT)


1Department of Hematology and Bone Marrow Transplantation, 21st Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Clinical and Experimental Medicine, Section of Hematology, University of Verona, Verona, Italy, 4Second Propedeutic Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 5Department of Haematology, Athens Medical Center, 6Hematology Section, First Propedeutic Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 7Euroclinic, Athens, Greece

Background: The prognosis of HL primarily depends on clinical stage (CS) as well as limited-stage risk classification schemes and the International Prognostic Score (IPS), both of which may be inaccurate for early stage disease. B2m is a well-established prognostic factor for several hematologic malignancies, but its role in HL is yet controversial. Between 1993 and 2016, several reports from other groups have yielded heterogenous results in small-sized unselected patient series of no more than 220 patients, frequently under variable treatment.

Aims: Our aim was to investigate the prognostic significance of serum b2m levels in HL.

Methods: We analyzed 864 patients with HL treated with ABVD or ABVDEQ, both of which are considered standard therapies for all stages. B2m [P1] levels (upper normal limit 2.4mg/L) were analyzed according to other baseline features and prognostic factors as well as according to the outcome. Freedom From Progression (FFP) was defined as time between treatment initiation and treatment failure (primary refractoriness, PR switch to alternative CT or relapse); deaths of unrelated causes were censored. Overall Survival (OS) was measured from treatment initiation to death of any cause. ROC curves and sequential cut-offs (1.8-3.5 by 0.1 increments) were used to explore the potential impact of b2m on FFP and OS.

Results: The median follow-up for currently living patients was 88 months. Univariate Analysis: FFP was significantly inferior in patients with higher b2m at all tested cut-off points. At 2.4mg/L (normal versus elevated) the 10-year FFP was 81% vs 71% (p=0.003). However, the best cut-off was the observed median b2m level of early stage patients, with 10-year FFP of 89% vs 78% (p=0.003). In advanced stages, none of the tested cut-offs yielded statistically significant results (borderline at 2.0mg/L). Multivariate Analysis: B2m levels remained significant for FFP after adjustment for IPS factors, ESR and B-symptoms at both 2.1mg/L and 2.4mg/L cut-offs (hazard ratio (HR) 2.0, p=0.01 and 1.83, p=0.02 respectively), but only borderline at the cut-off of 2.4mg/L (HR 1.65, p=0.07). In advanced stages, b2m emerged as an independent prognostic factor for FFP at the cut-off of 2.2mg/L (HR 1.59, p=0.046 despite the lack of significance in univariate analysis), but was not significant at the 2.4mg/L cut-off. The 10-year OS was lower in patients with high b2m levels (10-year rates 91% vs 76%, p<0.0001).

Summary/Conclusions: Higher serum b2m emerged as a significant independent predictor of FFP and OS for the whole series, calculated at 2.1mg/L, with 10-year OS rates of 84% vs 71% (p=0.0001). In early stages (IA/IIA) significant results were obtained at cut-offs between 1.8 and 2.1mg/L. The best cut-off was 1.9mg/L, a close approximation of the median b2m level of early stage patients, with 10-year FFP of 89% vs 78% (p=0.003). In advanced stages, none of the tested cut-offs yielded statistically significant results (borderline at 2.0mg/L). Multivariate Analysis: B2m levels remained significant for FFP after adjustment for IPS factors, ESR and B-symptoms at both 2.1mg/L and 2.4mg/L cut-offs (hazard ratio (HR) 1.78, p=0.001 and 1.41, p=0.04 respectively) in the whole series of 864 patients, including stages. b2m was a significant predictor of FFP at the cut-offs of 1.9mg/L and 2.1mg/L (HR 2.00, p=0.01 and 1.83, p=0.02 respectively), but only borderline at the cut-off of 2.4mg/L (HR 1.65, p=0.07). In advanced stages, b2m emerged as an independent prognostic factor for FFP at the cut-off of 2.2mg/L (HR 1.59, p=0.046 despite the lack of significance in univariate analysis), but was not significant at the 2.4mg/L cut-off. The optimal cut-off for the evaluation of serum b2m in HL may be stage-dependent and appear to lie between 1.9 and 2.2mg/L, thus performing better than a “normal versus high” evaluation (cut-off 2.4mg/L).
Background: Hodgkin lymphoma (HL), a disease of mostly young patients, also peaks in the elderly. Despite the profound improvement in the clinical outcome of young patients, in the elderly, 5 year overall survival (OS) is estimated at only 40-55%. Interim PET-CT (IPET), known to be highly predictive for progression free survival (PFS) in young patients with HL, has not been sufficiently validated in elderly patients, nor have many other outcome predictors in HL of the elderly.

Aims: The objective of the present study was to evaluate the significance of IPET in elderly patients with HL.

Methods: All consecutive patients (age ≥60) diagnosed with HL between 1998-2016 were retrospectively reviewed in this multi-center study. Baseline characteristics as well as PET-CT results at diagnosis, interim analysis and end of treatment (EOT) were recorded and analyzed. PET-CT results were classified as no evidence of disease (NED), partial response (PR), stable disease (SD) and progressive disease (PD).

Results: Ninety five patients from 5 centers were identified. Median age was 71 (range 60-89) years. Subtype was nodular sclerosis in 48% and mixed cellularity in 23%. Sixty three (69%) patients had advanced disease and mean international prognostic score (IPS) was 3.5±1.4. Fifty nine (63%) patients received first line treatment with ABVD, in 13 (14%) chemotherapy was followed by involved field radiotherapy. At EOT, sixty seven (82%) patients achieved CR, 6 (7%) achieved PR, 10 (11%) were primary refractory and 2 (2%) died during treatment. Fifteen (16%) patients experienced relapse. Five years DFS and OS were 56% and 78%, respectively. ABVD treated patients had 5 year DFS and OS of 99% and 98% as opposed to 48% and 49% for all other regimens, but these differences were not statistically significant. Seventy two (76%) patients had undergone both IPET and EOT-PET. 50 patients had NED on IPET, 20 had PR, 1 SD and 1 PD. NED EOT-PET was achieved in 47/50 (94%) patients who had NED IPET, 12/20 (60%) patients who had PR IPET and none of the patients with SD/PD IPET (<0.01). In patients with either NED or PR on IPET, relapse occurred in 11 (15%) patients and 5 year DFS and OS were 88% and 91%, respectively. The 5 year DFS of these patients differed according to the depth of response on IPET - 69% vs 45%, (p=0.02, fig.1) in patients achieving NED vs PR, while 5 year OS did not reach statistical significance, 90% vs 71% (p=0.08).

Restricted analysis, evaluating only 59 patients who were treated with ABVD, showed similar results with 94% of NED IPET vs 45% of PR IPET achieving NED on EOT-PET (<0.01). Outcome differed according to the depth of response in IPET with 5 year DFS rates of 74% vs 34%, in patients achieving NED vs PR, respectively (p<0.01). Five year OS rates were 92% vs 76%, in patients achieving NED vs PR (p<0.01).

Summary/Conclusions: We present a cohort of elderly patients with HL, most were treated with ABVD. Outcome was comparable or even superior to previously published cohorts. Traditional outcome measures for HL have not been extensively validated in the elderly. IPET and EOT-PET, known to be highly predictive for PFS in young HL patients, appeared to be highly predictive in elderly individuals. The improved prognosis, suggested by our results, may be related to the high rate of IPET which was used in this cohort. The importance of this tool in HL in the elderly is emphasized by the diminished prediction power of the traditional outcome measures in elderly HL patients.

E1122

HIGH-DOSE BENDAMUSTINE PLUS BRENXTIXIMAB COMBINATION IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA

C. Cerchione1,*, M. Di Perna1, R. Della Pepa1, N. Pugliese1, F. Pane1, M. Picardi1

Background: The management of patients with refractory or relapsed Hodgkin lymphoma (HL), especially after autologous stem cell transplantation (ASCT), remains controversial. Bendamustine has demonstrated efficacy in several lymphoproliferative disorders but limited data are available regarding the schedule in patients with HL, in particular its dosage and the possible combinations for a synergistic effect. Brelntuximab Vedotin is a CD30-directed antibody-drug conjugate, currently approved for the treatment of relapsed or refractory HL.

Aims: The objective of this retrospective observational trial was to evaluate efficacy and safety of salvage cytotoxic regimens in patients with refractory and/or relapsed HL. Three different regimens were evaluated.

Methods: From May 2011 to December 2016, 32 consecutive patients (19 M/13 F) with a median age of 31.7 years (range, 16-73) received a salvage regimen after failure of ASCT. Patients were by chance assigned to one of these three arms: standard dose bendamustine (90mg/m²) days 1 and 2 plus standard DHAP schedule (every 4 weeks) x 3 cycles (Arm A, n= 10 cases), brentuximab single agent 1.8mg/kg (every 3 weeks) x 4-8 cycles (Arm B, n= 11 cases), high dose bendamustine (120mg/m²) days 1 and 2 plus brentuximab 1.8mg/kg (day 3) x 4-6 cycles (Arm C, n= 11 cases). Each cycle in arm C was repeated every 28 days and growth factor support was systematically administered, in association with antimicrobial prophylaxis. The treatment efficacy in each arm was evaluated according to Revised Response Criteria for Malignant Lymphoma by Cheson et al. Any adverse event occurred was recorded and classified for type and grade using NCI-CTCAE criteria (v 4.0).

Results: In arm A, the overall response rate (ORR) was 40% (4/10 patients), with 4 (40%) complete remission (CR) and 6 (60%) progressive disease (PD). Hematological toxicity was grade 3 thrombocytopenia in 4 patients (40%) and bone marrow aplasia in 1 patient (10%); extra-hematological toxicity was gastrointestinal toxicity of grade 2 in 6 patients (60%) and grade 1 in 3 patients (30%), in arm B, ORR was 63.6% (7/11 patients), with 5 (45%) CR, 2 (18%) partial response (PR) and 4 (36%) PD. Hematological toxicity was grade 2 neuropathy in 4 patients (36%), extra-hematological toxicity was grade 3 neuropathy in 2 patients (18%). In arm C, ORR was 100% (11/11 patients), with 11 CR followed by SCT (second autologous transplant, 6 cases; and haploidentical transplant, 5 cases) with persistence of complete remission in all patients at a median follow-up of 33.4 months (range, 12-60). Hematological toxicity was grade 3 thrombocytopenia in 4 patients (36.3%); extra-hematological toxicities were increase of transaminases (grade 2) in 7 patients (27%) and cytomegalovirus (CMV) reactivation in 2 patients (18%), treated successfully with valganciclovir. Three patients had fever during infusion at first cycle, together with a skin rash, managed with corticosteroid injections, and a successful antihistamine plus corticosteroid prophylaxis in the next cycles of treatment.
Background: In the last decades, Hodgkin and Non-Hodgkin Lymphoma (HL-NHL) therapies have resulted in high cure rates and increased survival. However, 25(OH)D levels were lower in patients with higher late toxicities, such as, gonadal toxicity that can result in permanent sterility.

Aims: to evaluate different aspects of fertility (menstrual status, pregnancy, and menopause) in women with HL and NHL in reproductive age before and after chemotherapy.

Methods: By a phone interview we administered a questionnaire to the patients. The interview was composed of questions concerning reproduction (pregnancies, menses and abortion) and also menopausal status. The analyses were made using data collected in a cohort 109 women patients from two Italian hematologic centers. Statistical analysis was carried out in Graphpad® system, data were compared by the chi-square (P value <0.05) to be statistically significant.

Results: the median age (in years) at the time of the treatment was 31 (range 16-49), 69/109 (63%) had HL and 40/109 (37%) NHL, 74/109 [ESI] (64%) of the patients had a stage I-II. All HL patients were treated with ABVD, whereas the NHL patients were treated with R-CHOP (20%) or similar regimens (16%), respectively. Radiotherapy was delivered to the 62/109 (57%) of the sample. Complete Remission (CR) was obtained by the 101/109 (93%) and only 16/101 (16%) relapsed. Considering the gynecologic history of the patients there were no statistically significance difference between the regularity of menses and the event of an abortion pre and post treatment. As for pregnancies, 35% of patients had children before therapy and 17% after. Among these 109 patients, 68/109 (62%) received gonadotropin-releasing hormone (GnRH) analogues and/or oral contraception, while 41 (38%) were not treated with hormonal therapy. Among the 68 patients who received hormonal therapy regular menses recovered in 61/68 (90%) while in those of the control group a recover of menses was observed in 20/41 (48%). This difference was statistically significant (P<0.05). The same was observed as for early menopause. In this case excluding patients who had a natural menopause, a lower cases of early menopause was observed in those who received hormone therapy (8/65, 12% vs 30/41, 73%, P<0.05). Considering only the 81/109 (74%) patients who had regular menses after chemotherapy, 61/81 (75%) received hormonal therapy and 20/81 (25%) were not treated with hormonal therapy. Before treatment for lymphoma, 16% of patients belonging to the hormonal group had pregnancies versus 45% of the control group (P<0.05). Following therapy, pregnancies were observed in 23% of these receiving hormonal therapy vs 5% of the control group (P<0.05).

Summary/Conclusions: The use of hormonal therapy is fundamental not only to favor of pregnancies and motherhood but in particular to avoid the consequences of an irregular cycle or an early menopause with its symptoms and clinical implications.

E1124

25(OH) VITAMIN D SERUM LEVELS IN HODGKIN LYMPHOMA

A. Cuccaro1,2, E. Galili1, F. Visconti1, I. Zangrilli1, F. Corrente1, S. Bellesi1, U. Basile2, S. Amunzziata1, R. Cortedi1, M. Baldacci2, F. D’Alò1, S. Hohaus1

1Hematology, 2 Laboratory Medicine, 3 Nuclear Medicine, 4 Radiotherapy, Catholic University of Sacred Heart, Rome, Italy

Background: Vitamin D has pleiotropic effects on cellular differentiation, proliferation, apoptosis and angiogenesis in addition to maintaining serum calcium and skeletal homeostasis. Several studies suggest that low serum 25(OH)D levels may be associated with inferior outcome in solid tumors as colorectal and breast cancer, and in Non-Hodgkin lymphomas [Drake et al, J Clin Oncol 2010; 28:4191] as diffuse large B cell lymphoma [Bittenbring et al, J Clin Oncol 2014; 32:3243], and follicular lymphoma [Kelly et al, J Clin Oncol 2015; 33:1482]. 25(OH)D Vitamin D levels have not been reported for Hodgkin lymphoma (HL).

Aims: to evaluate vitamin 25(OH)D levels in patients with HL and analyze for associations with clinical characteristics and clinical outcome.

Methods: We studied 76 patients with cHL (40 females, 36 males, median age 33 years), diagnosed at our Institution between 2014 and 2016. Treatment consisted in ABVD (66 patients), BEACOPP d.e. (7 patients), and COPP (2 patients). One patient received only radiotherapy. Serum samples for vitamin D quantification were collected before the first day of chemotherapy. 25(OH)D was measured in patients’ sera using a standardized clinical assay, the DiaSorin LIAISON®. 25(OH) Vitamin D TOTAL. 25(OH)D levels were defined according to three conditions: deficient (<10 ng/ml), insufficient (10-30 ng/ml), and sufficient (>30 ng/ml).

Results: The median 25(OH)D level at diagnosis was 20.6 ng/ml (range: 5.5 to 42.3 ng/ml). 25(OH)D levels were considered normal in 8 (10.5%) patients, insufficient in 59 (77.5%) patients, and deficient in 9 (12%) patients. Looking at patient characteristics, 25(OH)D levels were lower in patients with age over 60 years (p=0.002), reduced performance status (ECOG>1) (p=0.01), stage IV disease (p=0.01), and IPS (Hasenclever) score >2 (p=0.002). Furthermore levels were lower in patients with hemoglobin below 10.5 g/dl (p=0.08). No association was found with gender, albumin level, ECOG and season in a multivariate Cox analysis. Deficient 25(OH)D level had a borderline significance (HR 5.65, 95% CI 0.98-32.55; p=0.05).

Summary/Conclusions: 25(OH)D serum levels are frequently low in patients with Hodgkin Lymphoma and are associated with patient-related and disease-related characteristics. Our preliminary analysis suggests that low 25(OH)D levels might be associated with worse prognosis.
stem cell transplantation (ASCT). Patients treated with R alone or R+ABVD had better DFS (p=0.04) than those treated with ABVD with/without IFRT. Specifically, the year Kaplan-Meier estimates for DFS were 100% for the R treated group versus 50% for those treated with ABVD with/without IFRT. Four patients in the latter group, showed insufficient response to the therapy: 1 refractory disease in the early stage group and 3 recurrent diseases in the advanced stage group were recorded. The median follow-up time of the entire cohort of patients was 4.3 years (range, 0.5-8.2 years). Over the study period, one patient died for infectious pneumonitis due to severe neutropenia following the last cycle of R-ABVD. Of the 9 patients treated with addition of IFRT, adverse events regarded mainly thyroid (4), bone (2), lung (1) and salivary glands (1). Nobody developed a secondary malignancy.

Summary/Conclusions: Our results confirm the value of R in NLPHL and show that R induction and maintenance combined with chemotherapy only in the presence of risk factors or in more advanced stages give excellent treatment results, despite the conventional radio-chemotherapy either in term of ORR and of DFS while sparing long term toxicity usually seen in patients affected by classical HL who receive chemo and irradiation.

E1126
CASE-BASED LEARNING IN CONTINUING EDUCATION: IMPROVING HEMATOLOGIST/ONCOLOGIST EVIDENCE-BASED DECISIONS FOR PREVENTING HODGKIN LYMPHOMA POST-TRANSPLANT RELAPSE
P. Repetto1, C. Moskowitz2
1Oncology, Medscape, Groveville, 2Oncology, Memorial Sloan Kettering Cancer Center, New York, United States

Background: Several prognostic factors have been identified as associated with a higher rate of relapse after autologous stem cell transplant (ASCT) for patients with Hodgkin lymphoma (HL). Due to the rarity of this disease, many hematologists/oncologists (hem/oncs), especially those in the community setting, lack experience to correctly identifying patients who may be at risk of post-transplant relapse. Proper risk assessment and understanding of treatment options in the pre- and post-transplant setting are critical to ensure optimal progression-free survival for qualified patients.

Aims: Underlying clinical practice gaps and educational needs were identified, and a study was conducted to determine whether an online, case-based educational intervention could improve knowledge, competence, and confidence of hem/oncs in managing patients with HL.

Methods: The educational format presented patient case scenarios (2) followed by a series of 4-5 questions that “tested” learner knowledge and competence before delivering the education focused on the optimal approach to the case using evidence-based medicine. Case questions assessed degree of patient risk for disease relapse or progression prior to ASCT and consolidation strategies, taking into consideration patients’ prior received therapies. To assess educational effectiveness, participants served as their own controls by responding to a series of same questions again after (post-assessment) exposure to the content. For all questions combined, the McNemar’s chi-square test assessed differences from pre- to post-assessment. P values are shown as a measure of significance. P values <0.05 are statistically significant. Cramer’s V calculation determined the change in proportion of 184 participants who answered questions correctly from pre- to post- assessment and who qualified for the study.

Results: At pre-assessment, there was a large effect to the education (V=0.442), indicating a sizable improvement in evidence-based choices and significant improvement in knowledge, competence, and confidence related to managing patients with HL, including: 138% relative improvement regarding the implications of type and number of prognostic factors on risk of HL relapse and benefit of consolidation brentuximab vedotin after ASCT (P<0.001); 101% relative improvement in knowledge that a higher rate of relapse after ASCT is associated with a CR duration of less than 1 year, extranodal disease at relapse, and the presence of symptoms at relapse (P<0.001); 5% relative improvement in knowledge regarding the efficacy of brentuximab vedotin in relapsed/refractory HL after ASCT (P<0.001); Responses to a self-efficacy question indicated that 42% of hematologists became more confident in managing a patient on consolidation therapy for HL after participating in the education.

Summary/Conclusions: This study demonstrated the success of an online, case-based format using a predisposing pre/post-assessment was effective in improving the evidence-based practice patterns of hem/oncs in the manage ment of patients with HL. Despite the marked improvement in knowledge, competence, and confidence, hematologist education needs specific to accurate risk assessment, treatment selection, and adverse effect monitoring remain. The education gaps uncovered during this intervention and the evolving treatment landscape outside of the United States lay a foundation for future global education initiatives to bridge education gaps in HL.

E1127
QUANTITATIVE PET PARAMETERS PREDICTS OUTCOME IN PATIENTS WITH HODGKIN’S LYMPHOMA
I. Krishchuk1, O. Novosad1, I. Pustushenko1, T. Skrypets1, T. Kadnikova1, I. Tytorenko1, E. Kushchevyy1, K. Ulianchenko1, K. Filonenko1, Y. Stepanishyna1, Y. Kmetnyuk2, O. Karpova2, L. Mykhalska3, O. Kindrakevych3, G. Pylypenko4, E. Lukjanec4, V. Duma4, V. Kozlov5, L. Batyuk5, O. Ryzhak5, N. Strembitska5, H. Chikalova5, M. Chupryn4, I. Kozlov6
1Oncohematology, National Cancer Institute, 2Radiology, 3Hematology, Clinical Hospital “Feofaniya”, Kiev, 4Hematology, Regional Oncology Center, Chernkassy, 5Hematology, Regional Clinical Hospital, 6Hematology, National Medical University, Odessa, Ukraine

Background: Positron emission tomography [18F] fluoroexoxyglucose (FDG-PET) has emerged as the standard response assessment after 1st line therapy for classical Hodgkin’s lymphoma (HL). Quantitative PET parameters are not well established as a predictive factor for disease progression in HL.

Aims: Thus, the aim of this study was to test the hypothesis that tumor burden characterized by mean standardized uptake value (SUVmean), maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) could be independent prognostic factors.

Methods: We analyzed the relation of absolute value PET parameters, negative predictive value (negative PET scan and no treatment failure, NPV) and positive predictive value (positive PET scan and treatment failure, PPV) with event-free survival (EFS) or overall survival (OS). Quantitative PET parameters of the baseline (PET-1), interim (PET-2) and end of treatment (PET-3) PET-CT scans were investigated in the retrospective study. MTV was computed by using the 41% maximum SUV thresholding method, and the optimal cut-off for survival prediction was determined.

Results: Thirty one patients with HL with a stage I-II–51.6%, III-IV-48.4% consecutively admitted from April 2009 to December 2016, by 5 Ukrainian hematological centers were included in the analysis. Patients were staged at baseline, after 2-4 cycles of chemotherapy with PET/CT and at the end of chemotherapy. All patients were treated with ABVD, BEACOPP-14/sec. All 31 patients achieved CR or PR and 67.7% had a negative PET-2, while 16.3% had a positive PET-2. Patients with negative PET-2 and positive PET-2 had CR rates of 64.5% and 12.1%, respectively, which yielded a PPV of 26% and NPV of 74%. ROC analysis revealed that PPV and NPV are an important markers associated with EFS in patients with HL (Se=100%; Sp=100%; AUC=1.0). 3-year EFS was 100% for NPV patients and 12% for PPV patients, which was statistically significant (p<0.001). 3-year OS was 75% and 0% for PPV and NPV patients, respectively (p<0.001). Quantitative parameters at PET-1 and PET-2 were not statistically significant in predicting clinical outcome in this study. This may be due to the small sample size in our study. PET-3 was negative in 67.7% cases. ROC analysis showed that ∑MTV at PET-3 is an important marker associated with reduced EFS in patients with HL (Se=75%; Sp=100%; AUC=0.97, p<0.0001). 3-year EFS was 80% and 25% in patients with ∑MTV <4.75 and ≥4.75, respectively (p=0.005). Also, ROC analysis revealed that TLG at PET-3 was associated with decrease EFS in patients with HL (Se=75%; Sp=100%; AUC=0.97, p<0.0001). Multivariate analysis confirmed ∑MTV and TLG at PET-3 were the only significant variables for EFS with HRs of 1.07 (95% confidence interval(CI) 1.0–1.15, p=0.003) and 2.9 (95% (CI) 9.1-10.3), p<0.01, respectively. The PET-3 SUVmax and SUVmean were not statistically significant in predicting EFS.

Summary/Conclusions: Quantitative PET parameters may play a predictive role for identifying patients at high risk of treatment failure. These results should be evaluated prospectively in larger cohorts with longer follow-up.

haematologica | 2017; 102(s2) | 463
Indolent Non-Hodgkin lymphoma - Clinical

E1128

Abstract withdrawn.

E1129

BIOMARKER ANALYSIS OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IBRUTINIB IN THE PHASE 2 DAWN STUDY

1Hospices Civils de Lyon-LeUniversité de Lyon, Pierre-Bénite cedex, Lyon, France, 2The University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Cancer Care Alliance, Seattle, WA, 3Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, United States, 4Haeomatoology Department, Concord Hospital, University of Sydney, Sydney, NSW, Australia, 5Department of Hematology/Oncoology, Johannes Gutenberg University, Langenbeckstr, Mainz, Germany, 6Division of Hematology/Oncology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, 7University of Kansas Medical Center, Kansas City, KS, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Weill Cornell Medical College, New York, NY, United States, 10Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, 11Alfred Hospital-Monash University, Melbourne, Australia, 12University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 13Department of Hematology, Jagiellonian University, Kraków, Poland, 14Haematology and Oncology Clinics of Australia, Milton, QLD, Australia, 15Blokbin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation, 16Instituto Biosanitario de Salamanca (IBSAL), Hospital Clinico Universitario, Salamanca, Spain, 17Janssen Research & Development, Raritan, NJ, United States, 18Janssen Research & Development, Leiden, Netherlands, 19Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, 20Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Background: Ibrutinib, a first-in-class, oral, covalent inhibitor of Bruton’s tyrosine kinase, has demonstrated robust clinical activity and is approved in various B-cell non-Hodgkin’s lymphomas. To assess the efficacy and safety of ibrutinib in patients with follicular lymphoma (FL), the DAWN study (FLR2002, NCT01779791) investigated single-agent ibrutinib in chemotherapy-naive (CIT)-refractory FL pts. Ibrutinib may exert immune-modulatory effects in patients (pts) with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), or marginal zone lymphoma – Clinical.

Aims: To determine the effect of ibrutinib on circulating T-cells, chemokines, and cytokines in ibrutinib-treated CIT-refractory FL pts.

Methods: The DAWN study was an open-label, multicenter, single-arm, phase 2 study of ibrutinib in pts with CIT-refractory (i.e. ≥2 prior lines of therapy for progressive disease [PD]) ≤12 months after last dose of a CIT regimen. All pts received ibrutinib (560mg QD) on a 21-day cycle until PD or unacceptable toxicity. The primary endpoint was Independent Review Committee (IRC)-assessed overall response rate (ORR) (complete response [CR] + partial response [PR]). Flow cytometry assessed T-cell subsets in peripheral blood at baseline (C1D1) and at cycle 3 (C3D1) for 57 pts (14 responders and 43 non-responders); cytokine and chemokine analyses were performed at C1D1 and at cycle 2 (C2D1) for 50 pts (21 responders and 29 non-responders).

Results: Results from the DAWN study have been presented previously (Gopal A, et al. ASH 2016). Briefly, 110 pts with a median age of 61.5 years and a median of 3 prior therapies were enrolled. Ibrutinib achieved an ORR of 20.9% (CR rate, 10.9%) and a median duration of response of 19.4 months. Flow cytometry analysis revealed significant downregulation of CD4+CD25+CD127- Tregs at C3D1 in 14 responders (CR + PR, mean decrease 17 to 12.9% CD4, p=0.002), along with increases in Th1-associated cytokines IFN-γ and IL-12. From a large panel of inflammation-related cytokines and chemokines, some of the most significant changes at C2D1 were the Th1 cytokines interferon (IFN)-γ and interleukin (IL)-12, both of which were increased in responders but decreased in nonresponders (p=0.0025 and p=0.035, respectively). Conversely, the chemokines IFN-γ-induced protein 10 (IP-10) and monocyte-chemotactic protein 3 (MCP-3) were decreased in responders but increased in nonresponders (p=0.022 and 0.016, respectively).

Summary/Conclusions: Here we show immunomodulatory effects of ibrutinib in pts with CIT-refractory FL, which may be related to response to therapy. In responders vs non-responders at early time points, downregulation of Tregs was observed, along with increases in Th1-associated cytokines IFN-γ and IL-12. This shift in T-cell population may be linked to the antitumor response; in nonresponders, these cytokines were decreased but Tregs were not. Chemokine changes observed also indicate variation in chemotraction of T-cells and monocytes/macrophages. These data suggest that immunomodulatory effects of ibrutinib could play a role in its antitumor activity in FL, so combinations with other immune-oncology therapies may prove beneficial.

E1130

DYNAMO: THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA IN A PHASE 2 STUDY

PL. Zinzani1, N. Wagner-Johnston2, C. Miller3, S. Tretreaut4, F. Passamonti5, S. Lunin6, H. Youssoufiyan7, J. Porter8, S. Prados9, I. Finn10
1Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy, 2Site- man Cancer Center, Washington University, St Louis, 3Saint Agnes Hospital, Baltimore, 4Florida Cancer Specialists - Tallahassee, Tallahassee, United States, 5University Hospital Ospedale di Circolo, Varese, Italy, 6Florida Cancer Specialist, Fort Myers, 7Verastem Inc, Needham, 8Tennessee Oncology, Nashville, United States

Background: Duvelisib is an oral, dual inhibitor of PI3K-δ,γ in development for the treatment of hematologic malignancies. DYNAMO is a Phase 2 study to evaluate the safety and efficacy of duvelisib in a double refractory iNHL population, which included 28 patients (pts) with small lymphocytic lymphoma (SLL) or iNHL.

Aims: The primary objective was to evaluate the antitumor activity of duvelisib monotherapy in pts whose disease is refractory to rituximab and to either chemotherapy or RIT, with an additional objective to further characterize the safety duvelisib.

Methods: DYNAMO is an open-label, single-arm, safety, and efficacy study in patients (pts) with FL, small lymphocytic lymphoma (SLL), or marginal zone lymphoma (MZL), whose disease is double refractory to rituximab (monotherapy or in combination) and to chemotherapy or radioimmunotherapy. Pts received duvelisib 25mg BID in 28-day treatment cycles until disease progression or unacceptable toxicity. The primary endpoint is overall response rate (ORR) as assessed by an independent review committee (IRC) per revised IWG criteria. Secondary endpoints include duration of response (DoR), progression-free survival (PFS), overall survival (OS), time to response (TTR), adverse events (AEs), and changes in safety laboratory values.

Results: 129 pts with iNHL were treated on study. Of these, 28 pts with SLL received duvelisib with a median duration of exposure of 9 mo. (range 6.5-12). Median age was 65 years; 68% were male. Most SLL pts had an ECOG performance status score at baseline of 0 (43%), followed by 1 (54%) and 2 (4%). Most SLL pts had either MZL (61%) or SLL (39%) at diagnosis. Median time from last anticancer therapy to first dose of duvelisib was 3 months. SLL pts received a median of 3 prior anticancer regimens (range: 1-8); 43% of pts received ≥4 prior anticancer regimens, 29% ≥6 regimens. The ORR for SLL pts was 68% (95% CI: 48, 84) per IRC assessment. All responses (19) were PFS. Four (14%) pts had a best response of PR and 3 (11%) pts had a best response of PD. 2 pts were unacceptable for response. Per Investigator assessment, the ORR was 79% (including 1 CR). Median time to IRC response was 1.9 months (range 1.4-5.5). 93% of pts had a reduction in nodal target

Figure 1.
lesions. Among the 19 SLL pts with a response per IRC, the median DOR was 9.8 months. The median PFS among all SLL pts was 11.3 months, while the median OS was not reached. The estimated probability of survival at 12 months was 83.9%. Among all pts treated (n=129), AE's were mostly Gr 1-2. Most commonly seen were skin (23%), anemia (12%), and thrombocytopenia (10%), and diarrhea (15%). 4 SLL pts had SAE's that led to discontinuation of duvelisib: NSCLC, neuroendocrine carcinoma of the skin, pseudomembranous colitis, and pneumonia. Two SLL pts has a fatal AE, 1 pneumonia and 1 viral infection.

Summary/Conclusions: In DYNAMO, duvelisib showed clinical activity in a double-refractory SLL population (68% ORR, median DOR 9.9 mo., 93% with a reduction in target lesions). Duvelisib was generally well tolerated, with a manageable safety profile with appropriate risk mitigation. Duvelisib monotherapy appears to have a favorable benefit-risk profile in double refractory SLL. Updated clinical data will be available at the time of presentation.

E1131
Abstract withdrawn.

E1132
WALDENSTROM MACROGLOBULINEMIA: UK REAL WORLD EXPERIENCE D. El-Sharkawi1,*, H. Renshaw1, M. Lunn2, D. Hughes3, A. Rismani1, S. D’Sa1
1Cancer Division, University College London Hospital (UCLH), 2Peripheral Nerve Service, National Hospital for Neurology and Neurosurgery, 3Haematology, UCL, London, United Kingdom

Background: There are few randomised controlled trials in Waldenström macroglobulinemia (WM) due to its rarity and indolent nature. As a result, there is no standard treatment approach and management is variable. Aims: The aim of this retrospective study was to review "real world" management of WM in the UK and correlate this with survival outcomes.

Methods: All patients with a diagnosis of WM seen at ULCH between 01/07/2002 and 31/12/2016 were included. Patient characteristics, presenting features, lines of treatment, responses and overall outcome were recorded. Survival was estimated using Kaplan-Meier analysis from time of first treatment and P values calculated using the log-rank test.

Figure 1.

Results: A total of 211 patients were identified (116 M/ 95 F), median age 60 yrs (range 34-89). Presenting symptoms included anaemia, n=33; neuropathy, n=19; fatigue, n=18; hyperviscosity symptoms, n=13; lymphadenopathy, n=6; progression from MGUS, n=5; B symptoms, n=5; other, n=28; unknown, n=55. Mutated MYD88 was seen in 59 of 72 cases analysed (82%). Of these 59 cases, 13 were CXCR4 mutated. IPSSWM was known in 150 cases of whom 64 were in low, 63 intermediate and 23 high risk groups. Median follow-up from first appointment was 64 months (range 0-394). The median number of lines of therapy was 2 (range 0-9). Dexamethasone, rituximab and cyclophosphamide (R) was given to 62 patients upfront, 52 had other cyclophosphamide containing regimens e.g. CHOP +/- rituxin, 29 had Chlorambucil-based regimen, 14 R-bendamustine, 15 fludarabine-based with a minority getting R-cladribine (5) or R-bortezomib (4), 9 patients had no treatment at data cut-off. Notably, DRC was given to 1 patient before 2005, 28% of patients between 2005 and 2013, and 41% from 2013. In the 149 cases with known responses to first line treatment, 11% achieved a CR (7 patients with R-CHOP, 4 R, 2 fludarabine containing regimen, and 3 patients other treatment), 63% PR/VGPR, 21% no response or PD and 5% stopped due to toxicity. For the 52 patients who had DRC chemotherapy, median PFS was 61 months. Of those patients who had at least 3 lines of chemotherapy (n=62), median time between 1st and 2nd line treatment was 42 months, 3 months between 2nd and 3rd line. Transplants were performed on 28 patients after a median of 2 lines of chemotherapy. Median overall survival (OS) has not been reached in the 195 patients with available data. Stratifying by IPSSWM shows median OS for the low risk group has not been reached, 11 years for the intermediate risk and 9 years for the high risk group. P=0.29 (Figure).

Patients had a significantly reduced OS if they developed Bing Neel syndrome or high grade transformation compared to other known complications of WM. Despite differences in chemotherapy strategies over the past two decades, there was no difference in outcome in patients treated before 2005, between 2005-2009, 2009-2013 and 2013 onwards. Of the 34 deceased patients, the cause of death was unknown in 3 cases, due to PD in 16 and other causes in 15 cases.

Summary/Conclusions: The management of patients with WM in this large case series reflects the variability of treatment given over time and also geographically. UCLH treats both a local and tertiary referral patient population, thus its is not completely typical. Survival data confirms the IPSSWM is likely to still differentiate patients into prognostic groups but the overall prognosis is better than when first published. With the advent of targeted therapies, it is imperative to perform randomised controlled trials and to collect data prospectively in order to elucidate the optimal management. To this end, a WM Biobank and Registry has been set up at our centre.

E1133
CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF INDOLENT NON-HODGKIN’S LYMPHOMA ASSOCIATED WITH HEPATITIS C (IL + C)

1Russian National Research Medical University named after N.I. Pirogov, 2Research National Research Center for Haematology, 3National Research Center for Oncology named after N.N. Blochin, 4City Clinical Hospital named after C.P. Botkin, 5City Clinical Hospital named after V.M. Buyanov, 6City Clinical Hospital named after V.M. Buyanov, Moscow, Russian Federation

Background: According to the WHO classification (2008) hepatitis C virus is one of the causes of non-Hodgkin lymphoma. The incidence of chronic hepatitis C (HCV) in patients with indolent B-cell non-Hodgkin’s lymphoma (IL + C) is 15%. Diagnosis of hepatitis C related lymphoma (IL + C) is established in cases with a concurrent organ or tissue involvement in a patient who expresses proteins of hepatitis C virus. These proteins could be defined by immunohistochemistry (IHC).

Aims: The aim of this work was evaluation of the results of treatment of IL associated with hepatitis C in comparison with a control group of patients with IL without viral hepatitis markers.

Methods: The study included 107 patients with indolent lymphoma who were identified in the blood markers of hepatitis C.

Results: Histological types were follicular lymphoma - 74%, marginal zone lymphoma - 32%. The age of patients ranged from 28 to 82 years (median 50). Men / women ratio was 1: 1. Stage I + II were in 3%, III stage was in 24% of patients, IV stage was at 73% of patients. Primary extrafollicular lymphoma was diagnosed in 33% of patients. Extranodal lesions: splenic lesion - in 53% of patients, liver injury - 21% of patients, the bone marrow - 62% of patients. LDH > 450 IU / l was at 76% cases, ALT >40 IU / l was at 82% of patients, albumin <35 g / l was at 31% of patients. 57 patients were treated with interferon and Ribavirin as a first-line treatment. Treatment lasted for 2 years after reaching the antitumor effect. 50 patients were treated with immunotherapy (R-CHOP, R-CVP) as a first-line treatment. Antiviral therapy was effective in 88% patients, immunotherapy was effective in 64% of patients. Median progression-free survival in patients with IL + C treated with antiviral treatment was 42 months, in patients with IL + C treated with immunotherapy - 19 months (p=0.00001). Five-year overall survival was 67% and 32%, respectively (p=0.0003). It was diagnosed disease relapses after immunotherapy in 39 patients. All the patients in the second-line was received antiviral treatment. The response to the ongoing therapy was achieved in 44% of cases. Median progression-free survival in relapsed lymphoma was 31 months.

Summary/Conclusions: Antiviral therapy in first-line and relapse of disease surpasses all the indicators of efficiency of treatment IL + HCV. In this category of patients preferred option is to conduct anti-viral treatment.

E1134
90Y-IBRITUMOMAB-TIUXETAN AS FIRST-LINE CONSOLIDATION IN COMPLETE RESPONSE FOLLICULAR LYMPHOMA PATIENTS. SINGLE CENTER ANALYSIS AFTER SIX YEARS MEDIAN FOLLOW-UP M. Andrade-Campos1,*, N. Espinosa Lara2, P. Lievano Segundo3, L. Lopez4, T. Bonilla5, P. Giraldo6
1Translational Research Unit - Hematology, IIS-Aragon. CIBERER, 2Hematology, 3Nuclear Medicine, Miguel Servet University Hospital, 4Hematology, Hospital Royo Villanueva, 5Translational Research Unit - Hematology, IIS-Aragon. CIBERER. IISCIII, Zaragoza, Spain

Background: Follicular lymphoma (FL) accounts for around 22% of all non-Hodgkin lymphomas. Its natural history is characterized by multiple relapses and progressively shorter response durations after every new line of therapy for this is desirable to offer the best first-line approach to each patient. In the last decades several different approaches are used: chemotherapy (R-CHOP, R), immunotherapy (CHOP, RCVP, Bendamustine + R), radioimmunotherapy for elderly patients. Moving forward, the consolidation with radioimmunotherapy or extended dose immunotherapy
(R every 8 weeks for 4 or 12 doses) still appears as an optional part of the therapy (NCCN V3.2016). Radioimmunotherapy with 90Yttrium-ibritumomab tiuxetan (90Y-IT) is available in our institution since 2006 and more than 100 patients have been treated with RIT since then. Here an institutional analysis focus in their use as consolidation is presented

Aims: To analyze the experience with 90Y-IT as a consolidation therapy in patients with CR after first-line therapy.

Methods: A retrospective analysis was performed including all the patients that have received RIT with 90Y-IT. Inclusion criteria were: patients 18 years or older with a grade 1-2a follicular lymphoma, RIT was received as a consolidation therapy in complete response (CR) after a first-line therapy. Demographic and follow-up data were included. International working group (IWG) criteria of response was used. Progression free survival (PFS) was calculated from the date of RIT to the date of a confirmed relapse according IWG criteria. Overall survival (OS) was calculated from the FL diagnosis to the last contact.

Results: A total of 31 FL patients have received 90Y-IT been in CR after a first-line therapy and were included for the study. Mean age at diagnosis was 61.2 (29-86) years with a female predominance (19, 61.3% vs 12, 38.7%), 80.6% (26) with ECOG 0-1 and 19.4 ECOG 2. A third of them (10, 32.3%) were diagnosed with low tumor burden (stage I-II), 2 (6.7) of them presented extra nodal infiltration (subcutaneous and gut) and 12 (38.7%) showed bone marrow infiltration demonstrated by flow cytometry or biopsy. There were no patients with bulky disease. Stages: I: 7 (22.6%), II: 3 (9.7%), III: 9 (29.1%), IV: 12 (38.7%). As first-line therapy the patients received: Rx4: 11 (35.5%) cases, R-Cyclophosphamide vincristine prednisone (COPx4): 3 (9.7%) cases and 17 (54.8) R-cyclophosphamide doxorubicin, vincristine and prednisone (R-CHOPx4). The median follow-up was 58.0 (10-107) months. During this time only 5 (16.1%) of patients have relapsed and need another therapy. None of the patients that have received R-CHOP+90Y-IT have relapsed; the relapsed patients received Rx4 (4) and R-COP (1). The median PFS after 90Y-IT has not reached, the mean was 69.6 (65.6-106.1) months. As long-term events one 82 years old patient developed a colon cancer after 67 months of RIT; one 72 years old female a breast cancer after 17 months of RIT and one 71 years patient amUS after 24 months of RIT, none of them related with mortality events.

Figure 1.

Summary/Conclusions: The use of immunotherapy with rituximab or combined schedules with immunotherapychemotherapy (R-COP and R-CHOP) followed by consolidation with 90Y-IT remains as a valid option for follicular lymphoma combined schedules with immunochemotherapy (R-COP and R-CHOP) followed by consolidation with 90Y-IT remains as a valid option for follicular lymphoma and combination schemes. Time to next treatment (TTNT) seems to be a clinically meaningful endpoint that incorporates both symptom control and disease progression. It has been investigated in few retrospective studies focusing on retinoids in monotherapy both in limited-stage and advanced stage MF, but up to now no data are available concerning the use of retinoids in combination.

Aims: We aimed to evaluate TTNT together with the usual time-to-event measures (OS and EFS) in our series of 21 refractory and/or relapsed patients with MF treated with 90Y-IT. Data used were selected from a previous study recently published (Rupoli et al, EJD 2016). The follow-up of these protocols was prolonged up to February 2017.

Methods: We recruited patients with stages I-IV MF who had failed PUVA (early disease) or several systemic regimens (early and advanced disease). We designed "mini" and "standard" protocols in which Bexarotene dose and PUVA administration were individually titrated, and tailored during induction and maintenance according to previous therapy, disease stage and toxicity. Survival curves for each efficacy endpoint were calculated according to Kaplan-Meier.

E1136

TIME TO NEXT TREATMENT ANALYSIS FOR EARLY AND ADVANCED STAGES OF MYCOSIS FUNGOIDES /SEZARY SYNDROME TREATED WITH BEZAROTENE AND PUVA IN COMBINATION

S. Rupoli 1, G. Goteri 2, G. Miccuci 1, I. Federici 1, L. Canafoglia 1, P. Leonì 1, G. Brandozzi 1, F. Giatto 1, G. Mazzocafreddo 1, R. Alterini 1, M. Simonacci 1, L. Bugatti 1, S. Serresi 1, R. Santilli 1, A. Campanati 1, N. Pimpinelli 1, 2Clinica di Ematologia, 2Istituto di Anatomia Patologica, 3Clinica di Dermatologia, Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, 4Clinica di Dermatologia, I.N.R.C.A. Ancona, ancona, 5Clinica di Ematologia, AOUD Careggi di Firenze, Firenze, 6Clinica di Dermatologia, Ospedale di Macerata, Macerata, 7Clinica di Dermatologia, Ospedale di Jesi, Jesi, 8Clinica di Dermatologia, AOUD Careggi di Firenze, Firenze, Italy

Background: Bexarotene is a synthetic retinoid effective in early and advanced stages of Mycosis Fungoides (MF)/Sezary Syndrome (SS) both in monotherapy and combination schemes. Time to next treatment (TTNT) seems to be a clinically meaningful endpoint that incorporates both symptom control and disease progression. It has been investigated in few retrospective studies focusing on retinoids in monotherapy both in limited-stage and advanced stage MF, but up to now no data are available concerning the use of retinoids in combination.

Aims: To assess the prognostic role during the clinical course of initial internationa prognostic index (IPSSWM), response and progression (according to 6th International Workshop guidelines) in patients with WM.

Methods: We took advantage of our continuously updated clinical database for reviewing a series of 114 symptomatic WM pts treated in our 2 institutions between 1993 and 2016 (median age 70, male/female ratio=1.91, high, low/intermediate and unavailable IPSSWM in 57, 36 and 21 pts respectively). Response rate after 1st line therapy was 70%. Sixty-two, 37 and 19 pts received a 2nd a 3rd and 4 to 6 lines of therapy respectively according to the 2nd International Workshop guidelines. Monitoring of serum monoclonal immunoglobulin concentration (SMIC) throughout the evolution of the disease was available in 106 pts. Informed consent was obtained according to the protocol submitted to the local ethical committees.

Results: Median survival after 1st line therapy was estimated 79 months. It was estimated 69 and 65 months after 2nd line and 3rd line respectively. High IPSSWM (hIPSSWM vs low/intermediate) retained prognostic value for survival after 1st treatment initiation (SAFTI, p=0.0005). However, plot of hazard function showed a decrease of hazard ratio over time with a departure from the proportional hazard hypothesis (Grambsch and Therneau test: p=0.053). Consequently, Dxy concordance index obtained in multiple landmarks analyses decreased from 0.27 to 0.12, during the first 6 years of follow-up. In Cox model of SAFTI with time dependent covariate, onset of response (whatever cut-off in SMIC) did not have prognostic value. By contrast, onset of progression and initiation of 2nd line therapy, retained prognostic values for hIPSSWM (p=0.0038 and p=0.004 respectively). Only 2 thresholds in SMIC defined a response status (observed vs unobserved of response and progression) of prognostic value for SAFTI: namely >25% reduction in SMIC (i.e. minor response or better: p=0.041) and 50% (i.e. partial response or better: p=0.056). In similar Cox models with hIPSSWM, onset of progression (p=0.0034) and 2nd treatment initiation (p=0.0031) retained independent prognostic value beside hIPSSWM (p=0.0026). Times elapsed from the initiation of 1st line therapy to 1st progression and to the initiation of 2nd line therapy had no prognostic value for subsequent survival. In a similar model Cox model of survival after 2nd line therapy with time dependent covariate no threshold in SMIC were found to be associated with a significant value of onset of response or response status. Neither onset of progression nor next treatment initiation had significant prognostic value. Similar results were observed after the 3rd line of therapy.

Summary/Conclusions: The prognostic value of initial IPSSWM decreased in part during the first 6 years of evolution. Onset of progression and 2nd treatment initiation provided additional prognostic information for predicting SAFTI. Therefore progression-free survival or time to next treatment may be satisfactory surrogate endpoint of SAFTI in WM. Further international collaborative studies are mandatory for this purpose. Assessing response in more advanced phase of the disease may require specific tools.
Results: We enrolled 21 patients, 12 males and 9 females, with median age of 67 years (range, 30-77), of which 15 affected by early MF (13 with stage IB, 2 with stage IIA) and 7 by advanced disease (2 with stage IIB, 2 with stage IIIA, 1 with stage IIIB and 1 with stage IVA). Six patients had previously received PUVA therapy only, while fifteen patients had received other therapies. The protocol proved to be effective, well tolerated and able to induce an overall response of 55.6% at the end of induction phase (93.4% of early stage patients and 66.6% of advanced stage patients) and of 76.2% at the end of maintenance phase (86.7% of early stage patients and 14.2% of advanced stage patients). Median follow up for all patients was 85 months (6-118) with respectively 98 months (21-118) for early stages and 46 months (6-102) for advanced stages. For the entire cohort, median OS, PFS and TTNT were respectively 90, 92 and 72 months and median EFS was 33 months. For the early stage MF cohort, the median OS, PFS and TTNT were not reached; mean values of OS, PFS and TTNT were respectively, 105, 103 and 79 months, and median EFS was 58 months. For advanced stage patients, median OS, PFS, EFS and TTNT were 32, 29, 18 and 39 months respectively.

Summary/Conclusions: Our combination treatment seems to have superior TTNT compared to data published in the literature for PUVA and bexarotene used in monotherapy. When considering early and advanced MF, 66% of our patients are estimated to be free from further treatment at 2 years, a higher percentage compared to the results of Hughes et al. (Blood, 2015) for patients treated with PUVA (54.2%) or bexarotene (36.8%) as single agents. Moreover, TTNT seems to be longer in our study than in the study by Hanel et al (AJH 2016) on patients treated by retinoids in monotherapy, respectively 79 vs 60 months (mean TTNT values) in the early stages and 39 vs 9 months (median TTNT values) in the advanced stages. We believe that our results strongly suggest a synergistic or additive effect between PUVA and bexarotene compared to either agent alone in the treatment of both limited-stage and advanced stage MF.

E1137
PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT
A. Rivas-Delgado1,*, L. Magnano 2, P. Mozas 1, I. Dlouhy 1, J. Rovira 1, AND PROGNOSTIC IMPACT
STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED
E1137
or additive effect between PUVA and bexarotene compared to either agent alone in the treatment of both limited-stage and advanced stage MF. We believe that our results strongly suggest a synergistic or additive effect between PUVA and bexarotene compared to either agent alone in the treatment of both limited-stage and advanced stage MF.

Results: Patients with PB+ more frequently had splenic involvement, anemia, elevated β2-microglobulin and LDH and high FLIPI score than those without PB involvement (PB−) and differences were statistically significant. There were no differences concerning the proportion of patients undergoing a watchful waiting approach (7% vs 9%), type of treatment, or overall response rate (93% vs 88%) and complete response rate. Overall, 149 patients had refractory disease or relapsed, including 34/52 (65%) PB+ and 115/225 (51%) PB−. The median follow-up was 7 years (range 0.7 - 22.2 years). The 5-year progression-free survival (PFS) of the PB+ group was 28% (95% CI: 14-42%) compared with 48% in the PB− (95% CI: 41-55%) (p=0.013). However, when the analysis was restricted to patients receiving rituximab combination regimen, 5-year PFS was 45% (95% CI: 24-66%) vs 64% (95% CI: 54-74%) (p=NS). Ninety-six patients died during the follow-up (19 PB+ and 77 PB−), with a 5-year overall survival (OS) of 68% (95% OR: 54-82%) in the PB+ group and of 81% (95% CI: 76-86%) in the PB− group (p= NS) (Figure). Finally, there was no difference in the risk of histological transformation or second malignancies.

Summary/Conclusions: Peripheral blood involvement in FL is associated with particular clinical features, higher tumor burden load and shorter PFS, although in the short-term it appears that has not impact on overall survival.

E1138
TREATMENT PATTERNS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN A LARGE US-INSURED DATABASE FROM 2010 TO 2014
M. Mehra1,*, N. Monga1, B. Schenkel2, R. Potluri3, L. Parisi1
1Janssen Research & Development, LLC, Raritan, NJ, United States, 2Janssen Scientific Affairs, Horsham, PA, United States, 3SmartAnalyst Inc., New York, NY, United States, United States

Background: Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. While there are therapeutic options for patients with FL, it remains an incurable disease with conventional therapies. Furthermore, real-world treatment patterns for patients with FL are not well characterized in the literature.

Aims: To characterize the real-world treatment patterns by line of therapy (LOT) for patients with FL in a large US-insured database.

Methods: Using the Optum integrated database, patients with FL were identified and included if 1) they were diagnosed with the International Classification of Diseases, Ninth Revision (ICD-9) codes 202.0 or 202.00 to 202.08 between January 2010 and December 2014; 2) their age was ≥ 18 years at the index date (defined as date of FL diagnosis); 3) they did not have any other primary cancers during the period from 3 years prior to index date up to 1 month post-index date; and 4) they had continuous insurance coverage for 365 days prior to index date. All reporting was done using descriptive statistics.

Table 1.

Results: A total of 2569 patients with FL met the inclusion criteria and were included in the analysis. In this cohort, the mean age was 60 years; 51% were male; 72% were Caucasian, 5% African American, 2% Asian, and 20% other. The median duration of follow-up was 610 days. Across all LOTs, 1180 patients (46%) had at least one National Comprehensive Cancer Network (NCCN) guideline-recommended treatment for FL, and 153 patients (6%) rate had E1137
in the treatment of both limited-stage and advanced stage MF.
proteasome (R-CIVP) (2%) and ebudemizumab (< 1%). Utilization trends of R- CIVP-containing regimens and RTX increased in selective LOTs, while all the other regimens remained unchanged or declined, particularly in later LOTs. RTX-containing regimens were used in 69.5% of regimens across all LOTs. The share of regimens used in different LOTs and overall are described in Table 1.

Summary/Conclusions: The use of NCCN guideline-recommended treatments in less than half of this cohort of patients with FL suggests that many patients with this form of indolent lymphoma are not adequately treated. As expected, rituximab was found to be the mainstay of treatment. Further research is needed to examine the relationship between LOT and long-term outcomes in patients with FL.

E1139

A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)


1Department of Clinical Research and Department of Hematology and Cell Therapy, Aichi City Cancer Center Hospital, NAGOYA, 2Department of Hematology and Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 3Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 4Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan, 6Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 7AbbVie GK, Tokyo, Japan, 8AbbVie Inc., North Chicago, IL, United States

Background: The antiapoptotic protein BCL-2 is commonly overexpressed in hematologic malignancies. VEN is a potent, selective, orally bioavailable BCL-2 inhibitor that has demonstrated acceptable safety and antitumor activity in NHL and MM pts.

Aims: To evaluate the safety, PK profile, and preliminary antitumor activity of single-agent VEN in Japanese pts with NHL or MM.

Methods: Phase 1 open-label, dose-escalation study of VEN in Japanese pts with relapsed or refractory (R/R) NHL or MM (NCT02265731). Dose escalation followed a 3+3 design. After a 2-week ramp-up period with weekly dose escalation, VEN was administered at daily final doses of 300, 600, 900, or 1200 mg on 21-day cycles until progression. All pts received tumor lysis syndrome (TLS) prophylaxis with allopurinol, furosemide, and hydration, hospitalization and monitoring starting at least 72 hours before the first VEN dose and before each dose escalation. Adverse events (AEs) were assessed by NCI CTCAE v4.0. Dose-limiting toxicities (DLTs) were determined during the ramp-up period and during cycle 1. Responses were assessed by 2007 IWG (NHL) or 2006 IMWG (MM) criteria.

Results: As of January 19, 2017, 20 pts (50% male; median age 65 years [39–81]) have been enrolled: 3 pts in the 300-mg, 7 pts in the 600-mg, 7 pts in the 900-mg, and 3 pts in the 1200-mg VEN dose cohorts. Eighteen (90%) pts had NHL (stage III/IV, n=14), including 11 with follicular lymphoma (FL), 6 with diffuse large B-cell lymphoma (DLBCL), and 1 with concurrent FL+DLBCL. 2 (10%) pts had MM at diagnosis. Treatment-emergent AEs (all grades) >20% pts were lymphopenia (80%), neutropenia (60%), leukopenia (50%), and anemia (25%), and non-hematologic toxicities including nausea (55%), vomiting, diarrhea, and nasopharyngitis (30%) each. Grade 3 treatment-related AEs were lymphopenia (45%), neutropenia (40%), and leukopenia (30%). One pt in the 600-mg DLBCL cohort experienced grade III DLT as DTLu resulting in 2 doses of 100-mg VEN on day 2 of the dose ramp-up period. One DLBCL pt died while on study due to disease progression. No TLS events were reported. Steady-state VEN exposures were nearly dose proportional across 300-mg to 900-mg doses. At the 1200-mg dose, exposures to VEN increased less than dose proportionally, which is consistent with non-Japanese subjects. VEN exposures were comparable between Japanese and non-Japanese pts at the 300-mg dose. At higher doses, individual exposures were generally within the range observed in non-Japanese pts but mean exposures were 30–100% higher. Overall, the OR rate was high, with nearly half the pts with NHL achieving an OR. Further evaluation of VEN in Japanese pts with hematologic malignancies is ongoing.

E1140

A SIMPLIFIED APPROACH IN THE ASSESSMENT OF T-CELL CLONALITY BY FLOW CYTOMETRY

M. Sarto1, E. Lau1, V. Lou1, Z. Timbol1, S. Wong1, S. Deo1, L. Palsaci1, D. Brown2, E. Tegg1, D. Gottlieb1

1Haematology, 2immunopathology, Weatmead Hospital, 3Faculty of medicine, Sydney University, Sydney, Australia

Background: T-cell lymphoproliferative disorders are among the most challenging diagnoses in haematology. Flow cytometric T-cell receptor (TCR)-V(β)-R repertoire analysis (TCR-V(β)-R) is a sensitive method for detection of T-cell clonality; however, the assay is cumbersome owing to the required eight-part analyses that limit its clinical utility.

Aims: Here we describe a simplified flow cytometric method utilising a monoclonal antibody that targets the T-cell receptor β constant domain 1 (TRBC1). The cβ TCR is a pan T-cell antigen, expressed on >90% of T-cell lymphomas and all normal T-cells. A feature of the TCR is that the β-constant region comprises 2 functionally identical genes: TRBC1 and TRBC2. Each T-cell phenotype CD3+CD8+CD4−, CD3+CD4+CD8−, or CD3+CD4+CD8+respectively. The T-cell line, Jurkat was exclusively positive for Jovi-1 expression. Of the 9 patients with T-LGL, 7 patients shared a common T-cell phenotype CD3+CD8+, CD4+. One patient was predominantly CD4+ and the other patient was dual negative for CD4 and CD8. Jovi-1 expression within the normal T-cell population of this group of patients was >90% restricted to one compartment; these findings were confirmed by TCR-V(β)-R analysis. Similar results were also obtained in each case of T-NHL and Sezary syndrome, more than 90% of T-cells from the population with an abnormal phenotype (CD3dim/CD4+CD8−, CD3+CD4+CD8+, CD3+CD4+CD8−, CD3+CD4+CD8−, CD3−CD4+CD8−) respectively. The T-cell line, Jurkat was exclusively positive for Jovi-1 expression. Patients with persistent lymphocytosis were also assessed for Jovi-1 expres- tion. A comparison of Jovi-1 and TCR-V(β)-R was also performed to compare the two approaches.

Results: Jovi-1 expression within the CD4 and CD8 compartments of T-cells in normal donors was a median of 42.6% (range 33.7%–49%) and 36.4% (range 22.3%–48.5%) respectively. The T-cell line, Jurkat was exclusively posi- tive (98%) for Jovi-1, as expected. Rituximab was found to be the mainstay of treatment. Further evaluation of Jovi-1 and TCR-V(β)-R was also performed to compare the two approaches.

Methods: Using multiparameter flow cytometry we assessed the expression of Jovi-1 in normal donors (n=19), T-cell leukemia cell line (n=1), T-LGL (n=9), T-NHL (n=3), Sezary syndrome (n=3) and patients with reactive lymphocytosis (n=5). A comparison of Jovi-1 and TCR-V(β)-R was also performed to compare the two approaches.

In summary we have demonstrated a novel approach in the assessment of T cell clonality by targeting T-cell receptor β constant domain 1 (TRBC1). The addition of Jovi-1 in routine practice could improve the clinical evaluation of abnormal T-cell populations by flow cytometry.
of prior therapies ranged from 1 to 7. Median body weight was 79 kg (range: 58-118 kg). The administered activity across all treatment groups ranged from 746 to 1982 MBq. The table below shows the median of the median PK and haematology safety results for $^{177}$Lu-lilotomab by treatment group. The activity-adjusted AUC$_{0-\infty}$ of $^{177}$Lu-lilotomab increased with 100mg/m$^2$ of ililotomab compared to the other pre-dosing regimens (p<0.001 compared to 40mg ililotomab). The median volume of distribution and clearance were both reduced with 100mg/m$^2$ of ililotomab compared with the other pre-dosing regimens. However, activity adjusted Cmax was similar. Smaller percentage post-treatment reductions in platelet and neutrophil counts were observed in patients receiving 100mg/m$^2$ ililotomab. Most common grade 3/4 AEs were hematological and were transient and reversible.

Table 1.

<table>
<thead>
<tr>
<th>Medium pre-dose regimen</th>
<th>100 mg/m²</th>
<th>No pre-dosing</th>
<th>OFA alone</th>
<th>OFA + BEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity adjusted AUC$_{0-\infty}$ (MBq/L·h)</td>
<td>0.3</td>
<td>0.1</td>
<td>0.24</td>
<td>0.32</td>
</tr>
<tr>
<td>Activity adjusted Cmax (MBq/L)</td>
<td>129</td>
<td>239</td>
<td>177</td>
<td>147</td>
</tr>
<tr>
<td>% platelet counts reduced</td>
<td>44</td>
<td>90</td>
<td>56</td>
<td>58</td>
</tr>
<tr>
<td>% neutrophil counts reduced</td>
<td>64</td>
<td>66</td>
<td>72</td>
<td>70</td>
</tr>
</tbody>
</table>

Summary/Conclusions: A higher pre-dose of ililotomab increases the activity-adjusted AUC and decreases the volume of distribution and clearance rate of $^{177}$Lu-lilotomab in iNHL pts. Despite the increase in AUC the percentage reductions in neutrophil and platelet counts were smaller, indicating that a higher dose of ililotomab may have a protective effect against the myelosuppression associated with $^{177}$Lu-lilotomab. Further characterisation of 20 MBq/kg dose of $^{177}$Lu-lilotomab with 100mg/m$^2$ of ililotomab pre-dosing is ongoing and will be presented.

E1142

PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA

A. Forero-Torres1,*, J.C. Chandler2, S.P. Iyer3, A.S. Kanate4, M. Quinlan5, P. Hoevers6, M. Izquierdo8, V. Duvidal7, S. Madan6

1Division of Hematology / Clinical Oncology, University of Alabama at Birmingham, Alabama, 2West Cancer Center, Tennessee, 3Houston Methodist Cancer Center, Houston, 4West Virginia University, Morgantown, 5Novartis Oncology, East Hanover, NJ, United States, 6Novartis Pharma AG, Basel, Switzerland, 7Cancer Therapy & Research Center, San Antonio, United States

Background: Anti-CD20 antibody rituximab (R)-based immunochemotherapy is the standard treatment for untreated or relapsed indolent B-cell non-Hodgkin lymphoma (iNHL). Due to the inevitable relapse of patients with iNHL, an unmet need remains for active and well-tolerated novel therapies. Bendamustine (BEN) is approved for the treatment of refractory iNHL, and the combination therapy BEN-R showed efficacy in the treatment of relapsed iNHL. Ofatumumab (OFA) is an anti-CD20 human monoclonal antibody (mAb) with high binding affinity and slower dissociation from a distinct membrane-proximal epitope on both small and large loops of CD20. OFA is indicated for the treatment of chronic lymphocytic leukemia (CLL) and is being investigated for the treatment of iNHL. The combination of OFA and BEN may provide additional clinical benefit in patients with iNHL and therefore the potential for drug-drug interaction was investigated.

Aims: The study aimed to evaluate the pharmacokinetics (PK) of OFA and BEN alone and in combination, along with the safety and tolerability assessments in patients with previously untreated or relapsed iNHL.

Methods: In this Phase I open-label, multicentre study, patients (aged ≥18 years) with previously untreated or relapsed iNHL were randomized 1:1 to Arm A (OFA + BEN) or Arm B (OFA alone) to receive at least four cycles and up to eight cycles of treatment (cycle length 28 days). All patients provided informed consent. Arm A patients received single-sequence treatment of BEN, then OFA + BEN, BEN (90mg/m$^2$) on days 1 and 2 every 28 days for up to 8 cycles, and OFA (1000mg) on day 1 of weeks 2, 3, and 4 of cycle 1 and on day 1 of cycles 2-8. Patients in Arm B received OFA alone at the same dosing schedule. Blood samples including all end-of-infusion (EOI) PK samples were collected for plasma concentration over time. The primary PK parameters C$_{max}$, AUC$_{last}$, AUC$_{inf}$ were derived using non-compartmental analysis. All adverse events (AEs) and severe AEs (SAEs) were recorded for safety assessments.

Results: Thirty two patients were randomized (15 in Arm A and 17 in Arm B), 3 patients in Arm A discontinued study treatment due to consent withdrawal (2 patients) and infusion related AE (1 patient). All 32 patients were included for safety and PK concentration analysis while 30 patients (15 in each arm) were included for PK parameters. Patient and disease characteristics were similar between treatment arms; the majority of patients from both arms did not receive prior NHL therapy. PK concentration profiles and PK parameters of OFA were comparable when administered alone or co-administered with BEN (Table 1). As compared to OFA alone, there was a decrease of 14% in C$_{max}$ and 15% in

AUC$_{last}$ when OFA was co-administered with BEN, which was not considered relevant (Table 1). BEN PK concentration profiles and PK parameters were comparable with or without OFA co-administration (Table 1).

All patients reported AEs. The most frequent treatment-related AEs were infusion related reaction in 53% and 47%, nausea in 33% and 35%, fatigue in 33% and 18% patients in Arm A and Arm B, respectively. The percentages of patients with grade 3/4 AEs were higher in Arm A (53%) compared to Arm B (24%). Cytopenias were present in 40% of patients in Arm A and 6% in Arm B. Four SAEs were related to study treatment in Arm A while none in Arm B.

Table 1.

<table>
<thead>
<tr>
<th>OFA PK parameters and Statistical Analysis of the primary PK parameters for OFA and BEN</th>
<th>OFA alone</th>
<th>OFA alone</th>
<th>OFA + BEN</th>
<th>OFA + BEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>OFA-RAE (mg/ml)</td>
<td>0.1</td>
<td>0.1</td>
<td>0.24</td>
<td>0.32</td>
</tr>
<tr>
<td>Activity adjusted Cmax (MBq/L)</td>
<td>129</td>
<td>239</td>
<td>177</td>
<td>147</td>
</tr>
<tr>
<td>% platelet counts reduced</td>
<td>44</td>
<td>90</td>
<td>56</td>
<td>58</td>
</tr>
<tr>
<td>% neutrophil counts reduced</td>
<td>64</td>
<td>66</td>
<td>72</td>
<td>70</td>
</tr>
</tbody>
</table>

Summary/Conclusions: No relevant drug-drug interaction between OFA and BEN was observed in this study. OFA alone or in combination with BEN exhibited manageable safety profile in patients with iNHL.
Infectious diseases, supportive care

E1143

ASSESSMENT OF INTERNATIONAL CONSENSUS GROUP FOR HEMATOLOGY (ICGH) SMEAR REVIEW RULES FOR AUTOMATED PLATFORMS IN THE DETECTION OF MALARIA

J. B. Ulloa1,2,*, J. P. Wul1, A. D. Hue3, S. Havystka4, W. Zhan5, N. Ali1,2 1Haematology, National Health Laboratory Services, 2Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa

Background: Peripheral blood smear review (SR) is a useful adjunct to the full blood count (FBC) and differential white cell count (DWCC), but is labor intensive and time consuming. For this reason, the international consensus group for hematology (ICGH) published guidelines to reduce SR rates in clinical laboratories using rules based on a combination of blood parameters and instrument suspect flags. These rules have reduced SR rates in many laboratories, but adjustment is often required to accommodate for local pathology/clinician preferences. As malaria is common in Johannesburg (JHB) (although not endemic), this study was undertaken to retrospectively evaluate the performance of modified ICGH SR rules for detection of malaria at the Chris Hani Baragwanath Academic Hospital Laboratory (CHBAH) (part of the National Health Laboratory Service (NHLS) network) in JHB, South Africa.

Aims: To assess the performance of the CHBAH NHLS SR rules in the detection of malaria.

Methods: Malaria test results (P. falciparum antigen & thick/thin SR) were extracted from the laboratory information system and corresponding FBCs assessed in those with parasitemia. All ICGH rules were applied to patients with both a DWCC and SR requested, while only the parameter related rules were applied to patients with only a FBC performed. Samples were processed using a Sysmex XE-5000 analyser (Sysmex, Kobe, Japan), and the rules violated for each FBC recorded. As a retrospective laboratory based study, informed consent was not obtained. However, the study was approved by the Human Research Ethics Committee of the University of the Witwatersrand.

Results: Of the 153 samples included, all had P. falciparum parasitemia and 37 were collected from patients with severe malaria. A FBC with a DWCC was performed in 72/153(47.1%) patients, and a FBC alone in 81/153(52.9%). SR rules were triggered in 132(86.3%) patients (68(84.0%) in those with only a FBC performed, and 64(85.9%) in those with a FBC and DWCC). The thrombocytopenia (platelets (Plt)<100x10^9/l) and anemia (Hb<7g/dl) rules were the most common, triggering in 105(79.5%) and 24(15.7%) patients respectively. Common analyzer morphology flags included those querying the presence of atypical lymphocytes, immature granulocytes and blasts, but 1/more of these triggered in the and DWCC requested, while only the parameter related rules were applied to patients with only a FBC performed. Samples were processed using a Sysmex XE-5000 analyser (Sysmex, Kobe, Japan), and the rules violated for each FBC recorded. As a retrospective laboratory based study, informed consent was not obtained. However, the study was approved by the Human Research Ethics Committee of the University of the Witwatersrand.

Summary/Conclusions: ICGH SR rules are FN in 13.7% of patients with malaria, but mostly in those with near-normal blood counts. Furthermore, SR failed to identify the parasites in a further 13.0% of cases (particularly those with very low parasitemia). Elimination of a proportion of FN samples is thus not likely to 90.5% of these.

E1145

BRONCHOALVEOLAR LAVAGE AS SYSTEMATIC APPROACH FOR EARLY DIAGNOSIS OF LUNG INFILTRATES AND INVASIVE PULMONARY ASPERgilLOSIS IN HEMATOLOGIC PATIENTS: A PROSPECTIVE SINGLE INSTITUTION STUDY

F. Marchesi1,*, A. Spadea1, F. Pimpinelli2, G. Prignano2, M.G. Paglia3, D. Forcella4, S. Gumenyuk4, D. Renzi5, F. Palombi6, A. Vulcan6, F. Pisani6, A. Romano1, E. Papà1, F. Faccioletto1, E. Enosii7, C. Girimeta8, A. Mengarelli9, M. Collesi2,3, P. C. Polentarutti and Stefano Vinciguerra, 1Hematology, Regina Elena National Cancer Institute, 2Molecular Virology, Pathology and Microbiology Laboratory, San Galli- cano Dermatological Institute, 3Microbiology and Infectious Diseases Biorepository Laboratory, National Institute of Infectious Diseases “L. Spallanzani”, 4Thoracic Surgery Unit, Regina Elena National Cancer Institute, 5Hematology Unit, Sapienza University, Rome, Italy

Background: The best diagnostic approach of lung infiltrates (LI) remains to be established. Despite bronchoscopy with bronchoalveolar lavage (BAL) appears to be useful for LI diagnosis, hematologists and thoracic surgeons often have qualms in performing bronchoscopy in patients receiving hematopoietic stem cell transplantation due to risk of procedure-related complications. A proper diagnostic approach at LI seems to be particularly relevant in neutropenic patients and/or in patients with an unfavorable clinical response to broad-spectrum antibiotics, in which the cause of LI are often filamentous fungi, as Aspergillus spp. To date, there were stratified risk groups, and antifungal treatment is not standard. This study aimed to investigate the diagnostic panel to apply in hematologic patients undergoing bronchoscopy for LI.

Aims: To evaluate the feasibility of bronchoscopy with BAL as systematic diagnostic approach at LI in hematologic patients, focusing on its role to diagnose invasive pulmonary aspergillosis (IPA).

Methods: Bronchoscopy was performed in all hospitalized patient with diagnosis of acute leukemia and LI at onset of disease before therapy start, and in any other hematologic patient in any phase of disease with LI requiring hospitalization because of concomitant febrile neutropenia and/or respiratory distress not responding to broad-spectrum antibiotics. Criteria for not response to broad-spectrum antibiotics were defined as persistent (> 48 h) fever and/or respiratory distress. In all cases we performed the same diagnostic work-up including blood-swabs cultures, serum galactomannan (GM) assessment (in three consecutive checks), serum beta-D-glucan, serum PCR for CMV, BAL

470 | haematologica | 2017; 102(s2)
fluid was studied by bacterial and fungal cultures, GM and PCR for Streptococcus pneumoniae, Legionella pneumophila, Chlamidophilia pneumoniae, Mycoplasma pneumoniae, Bordetella pertussis, Bordetella parapertussis, Haemophilus influenzae, respiratory virus including CMV, Pneumocystis jiroveci, Mycobacterium tuberculosis complex, Nocardia spp., Lysteria monocytogenes and Aspergillus spp. Available commercial kits were used according to manufacturer’s instructions.

Results: Out of 769 patients consecutively admitted in our ward, 85 had LI and 47 of them underwent BAL (total amount: 51 procedures). A causal agent of LI was detected in 33 cases (65%) allowing to modify the ongoing anti-microbial treatment in 25 of these ones (76%). Twelve cases of probable IPA, according to standard criteria, were diagnosed. Seven cases of LI fulfilling the radiologic criteria for IPA, though presenting only a positive Aspergillus PCR on BAL, were detected and treated as probable IPA. One life-threatening post-procedure complication was observed.

Summary/Conclusions: BAL seems a safe approach for an early diagnosis of LI in hematologic patients. The assessment of a broad diagnostic panel allowed the detection of a putative agent in 65% of cases. Assessment of Aspergillus by PCR on BAL proved useful for probable IPA diagnosis.

E1146 ESCAPE DRUG-RESISTANT INFECTIONS IN HEMATOLOGICAL MALIGNANcies, DARE TO REVIEW!

C. Gentile Sanchez1,*, K. Sun1, P. Teegavarapu1, Q. Qian1, P. Mamta2, S. Wong2, I. Ibrahim1, L. Rice3, S.R. Pingali1, S. Iyer1
1Houston Methodist Cancer Center, 2Houston Methodist Research Institute, 3Houston Methodist Department of Hematology, Houston Methodist Hospital, HOUSTON, United States

Background: Patients with hematological cancers are at a high risk for increasingly resistant and severe infections. The Infectious Diseases Society of America has defined commonly resistant bacteria as ESKAPE (Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa, Enterobacter). As suggested in recent literature, other common and difficult-to-treat infections such as Clostridium difficile and Enterobacteriaceae organisms (e. coli, Proteus) can be added to this group and change the acronym from ESKAPE to ESCAPE.

Aims: We performed a retrospective review of the rate of ESCAPE infections, resistance profile, and outcomes in patients with various hematological malignancies at the Houston Methodist Hospital from 2006 to 2015.

Methods: The patient data was obtained from METEOR (Methodist Environment for Translational Enhancement and Outcomes Research), a clinical data warehouse that contains records dating back to January 1, 2006, with over 3 million patients and over 10 million unique patient encounters. We queried for leukemia (AML, CML, ALL, CLL), amyloidosis and myelodysplastic syndrome (MDS) along with hospitalizations due to bacterial infections. Baseline demographics and overall outcomes were also obtained.

Table 1.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Resistance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enterococcus</td>
<td>90%</td>
</tr>
<tr>
<td>Staphylococcus</td>
<td>85%</td>
</tr>
<tr>
<td>Pseudomonas</td>
<td>16%</td>
</tr>
<tr>
<td>Acinetobacter</td>
<td>25%</td>
</tr>
<tr>
<td>Klebsiella</td>
<td>30%</td>
</tr>
<tr>
<td>E. coli</td>
<td>40%</td>
</tr>
<tr>
<td>Proteus</td>
<td>25%</td>
</tr>
<tr>
<td>Enterobacter</td>
<td>30%</td>
</tr>
</tbody>
</table>

Results: Out of 6017 patients with Hematological Malignancies, 660 patients with 684 malignant diagnoses were found; 235 had MDS, 174 had AML, 105 had CML, 44 had ALL, 39 had A.L.L, and 10 had an unspecified hematological cancer. Of 1132 infectious events, 62% were ESCAPE infections. The bacteria most frequently isolated were Enterococcus (23.4%), Staphylococcus aureus (18.5%) and Pseudomonas (16.9%). Bacteremia was the most predominant type of infection (41.9%) followed by urinary tract infections (38.2%). Patients with MDS (39.6%) and AML (25.3%) were mainly affected. A prevalent resistance to levofloxacin was detected in gram positives (23-34%), cefepime (7-23%), and imipenem (22%). Penicillin had the highest mortality rate (45.2%), followed by Enterococcus (44.2%), and Pseudomonas (36.7%).

Summary/Conclusions: Hematological cancers with risk for neutropenia such as MDS and AML were the most affected by ESCAPE. Bacteremia was frequently seen. Gram-negative pathogens had an increased resistance to broad-spectrum antibiotics and higher mortality rates. A significant resistance to levofloxacin, a prophylactic antibiotic, was also noted. New strategies for reducing ESCAPE in MDS and AML are required. Further statistical review of this data set will be presented at the EHA Meeting, Madrid 2017.
Background: Neutropenic sepsis remains a leading cause of morbidity and mortality in both haematology and oncology patients. This study was conducted to assess various safety and pharmacokinetics of ANF-Rho in Sprague-Dawley rats and cynomolgus monkeys.

Aims: To retrospectively review appropriate antibiotic use, microbial identification and characterization, and histopathology.

Methods: A retrospective review of patients treated for neutropenic sepsis was conducted for the period between 1/4/2015 to 11/10/2016. Analysis of potential risk factors including primary disease, age, sex, treatment regimen, albumin, neutrophil and lymphocyte count to assess potential association with adverse outcomes. Results: There were 116 episodes of neutropenic sepsis in 92 patients in this period. Of these, 61 were haematology-oncology patients and 31 general oncology. 42 of 76 positive cultures identified gram-negative organisms. 40 patients received single agent Tazocin and 71 patients (61.2%) received Tazocin and an aminoglycoside as first line antibiotic treatment. Fourteen isolates demonstrated resistance, including 2 cases of stenotrophomonas maltophilia and 12 cases of enterobacteriaceae. 13 of the 14 resistant isolates were found in haematology-oncology patients. Nine of these cases were resistant to the same agent Tazocin but sensitive to an aminoglycoside. The mean age of cases with resistant bacteria was 54.2 years. There was no difference in sex or degree of neutropenia/lymphopenia in the cases that contracted resistant bacterial strains compared to those that were culture negative. Of the 4 fatal cases with resistant bacteria, 3 had low albumin (mean 25.5g/L cf. mean of 34g/L in resistant bacteria cases surviving). Summary/Conclusions: This retrospective analysis supports the use of combination antimicrobials up front as first line treatment in high-risk patients with neutropenic sepsis. The study has demonstrated that the patient cohort most at risk of developing drug resistant bacteria are patients with high-risk or relapsed haematology-oncological disorders like AML or high-grade lymphoma, requiring multiple cycles of intensive chemotherapy. Of the patients who isolated resistant bacteria, identifying low albumin early may be a potential marker for adverse outcome in terms of morbidity and mortality. Of interest only one oncology patient isolated a resistant strain of bacteria, furthermore only 25% of general oncology patients treated with neutropenic sepsis had positive cultures compared to 75.6% of haematology-oncology patients. When comparing these findings to UK NICE recommendations it is clear that first line use of Tazocin in general oncology patients may well suffice in initial treatment of neutropenic sepsis. However with haematology-oncology patients early or up front consideration for the additional usage of an aminoglycoside is essential to optimize favorable outcomes in this high-risk group of patients. From this study, the proposed risk factors of isolating resistant strains of bacteria leading to adverse outcomes would be aggressive haematological malignancies, receiving more intensive cytotoxic therapy, multiple lines of treatment and low albumin. Further analysis in a multi center study of this patient population alongside close collaboration between clinicians and microbiologists is essential in providing optimal antimicrobial therapy algorithms in neutropenic patients.

E1149 PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY AND TOXICOGENIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC FACTOR

J. Valentino1, H. Misra1,*, J.A. Newmark2
1Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, 2Toxicology, Toxicin, Bedford, United States

Background: ANF-Rho is a novel polyethylene glycol-modified granulocyte colony stimulating factor that has biological and biological properties that produce a prolonged pharmacokinetic and pharmacodynamic profile as compared to pegfilgrastim (Neulasta®). As such, it has potential applications in chemotheraphy-induced neutropenia and chronic idiopathic neutropenia. These disorders require frequent hospital admissions to optimize neutrophil treatment. We undertook a 13-week study in Sprague-Dawley rats and cynomolgus macaques to assess various safety and pharmacokinetics of ANF-Rho as compared to Neulasta® (pegfilgrastim).

Methods: The study design used 288 rats, divided into 5 dosage groups: control, 100, 300, 1000 (high) and 1000 (positive) µg/kg. A total of 58 monkeys were also divided into 5 dosage groups: control, 75, 250, 750 (high dose) and 750 (positive) µg/kg of ANF-Rho. Doses were administered by weekly subcutaneous injections on Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85 and 92 at a dose volume of 5 mL/kg. Genotoxicity assessments were evaluated using Salmonella typhimurium and Escherichia coli reverse mutation assay, rodent blood micronucleus assay and chromosomal aberration assay. Toxicology assessment included clinical observations, body weight change, food consumption, ophthalmic examination, function observational battery (motor activity, behavioral changes, coordination and sensory/motor reflex response), organ weight, biochemical and toxicokinetic analysis, immunogenicity, gross necropsy and histopathology.

Results: No observed clinical signs seemed to be related to ANF-Rho administration. There were no related effects in body weight changes or food consumption. Observed ophthalmic effects were considered procedural related due to low incidence. No biologically meaningful findings were noted during the functional observational battery assessment. Preliminary analysis showed a peak in body weight and increased in kidney weight in rats and a dose dependent decrease in kidney weight in primates. Genotoxicity studies found no signs of mutagenicity, clastogenicity or cytotoxicity.

Summary/Conclusions: The results from this preliminary Toxicology studies are unremarkable and consistent with those of an earlier 28-day study. Results from the 28-day rat neutropenia dosage model found that the blood pharmacodynamics parameters of ANF-Rho were significantly superior to PEG-filgrastim. Both PK and PD data demonstrate relatively predictable systemic exposures and activity following SC or IV doses levels in both rat and primate. It is anticipated that this long terms 13-week study will provide evidence of safety sufficient to support advancement of ANF-Rho into clinical studies in chemotherapy-induced neutropenia and chronic idiopathic neutropenia in Europe, USA and India.

E1150 USE OF MICAFUNGIN IN PROPHYLAXIS OF ONCO-HEMATOLOGY OUTBREAKS: RESULTS OF AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE FRENCH STUDY (OLYMPEx)

J. El-cheikh1, H. J. Dalle1, S. Ducastelle-Lepretre2, J.-B. Quinou3, P. Ceballos5, R. Herbretch1
1American Hospital, Beirut, Lebanon, 2Hôpital Robert Debré, Paris, 3Hospices Civils, Lyon, 4Medical Affairs, Astellas pharma France, Levallois-Perret, 5Centre Hospitalo-Universitaire, Montpellier, 6Centre Hospitalo-Universitaire, Strasbourg, France

Background: Antifungal prophylaxis is being used increasingly. Aims: The therapeutic arsenal is extensive and requires a better understanding of micafungin use in oncology-hematology where most-at-risk patients of invasive fungal infections (IFI) are managed.

Methods: This observational study was conducted in 18 onco-hematology units in adult patients and children treated with micafungin in prophylaxis with a 3-months follow-up period.

Results: 150 patients (95 adults, 55 children) were included and represent the analysis population. In total, 15 patients (10%) presented an IFI during micafungin treatment. Among them, 11 presented a probable or proven IFI. The rate of IFI was higher in children (15%, n=8) than in adults (7%, n=7) and seem to be influenced by the type of hemopathy and if the patient was allo-grafted or not: 13% (n=8) in allografted patients, 9% (n=4) in patients with AML or SMD and 7% (n=3) in other patients. Median time to infection was 24 days (1 to 68 days) and was longer in adults (25 days, 4 to 68 days) than in children (16.5 days, 1 to 68 days). Twelve patients (8 children and 4 adults) presented at least one clinical or radiological sign of suspected IIFI. Fungus was identified in 8 patients (62%), mostly in blood cultures (50%, n=4); candidiasis in 4 patients, aspergillosis in 3 patients and infection related to Rhisopus in 1 patient. Incidence rate of IIFI (10%, 5 patients) was inferior to prophylaxis failure rate (23%, 34 patients). Prophylaxis failure rate takes in account patients who switched to empirical treatment besides patients who switched to preemptive or curative treatment. After the end of prophylaxis, 4 patients (3%, 3 adults and 1 child) presented a proven IIFI. Median time to infection after the end of treatment was 10.5 days in adults (7 to 24 days) and 52 days in children. Micafungin was overall well tolerated: only 10 patients (7%, mostly children) pre- sented grade 1 to 4 adverse events related to micafungin, including 5 patients (33%) with grade 3 or 4 adverse events.

Summary/Conclusions: Effectiveness and safety profile of micafungin in prophylaxis are similar to what was observed in previous studies. Incidence IIFI confirms the clinical effectiveness of micafungin in prophylaxis in high-risk patients. The low rate of serious adverse events confirms micafungin safety profile, in children included.
1Haematology and Stem Cell Transplantation Division, 2Transfusion Medicine and Cell Therapy Division, Campus Bio-Medico University Hospital, Rome, Italy

Background: Pseudomonas Aeruginosa (PA) is a gram negative, ubiquitous, opportunistic pathogen. Its intrinsic resistance to many antibiotics and the selective pressure exerted by empiric antimicrobial use, led to the emergence of MPA in hematologic patients with high mortality and morbidity rates among infected immunocompromised patients (pts). Considering our MPA incidence of 9% in 2007, an outbreak developed at the HW of “Campus Bio-Medico” University Hospital of Rome, from 2008, despite the measures employed from the previous 2 years (health personnel sensitization, regular air and water filters changing, isolation precautions).

Aims: To describe the MPA outbreak occurred between 2009 and 2013.

Methods: Our HW, opened in 2007, is composed by 7 rooms, each with a private WC: 2 single, 1 double and 4 single, positive pressure, each with a filtered zone, dedicated to stem cell transplantation. Retrospective study from 01/2009 to 04/2013 we hospitalized 415 adult pts; of these, 106, at high infectious risk (HIR) for severe and prolonged expected post-chemotherapy neutropenia, have been routinely screened at admission with microbiological samples (nasal, pharyngeal and rectal swabs) and additional tests when clinically indicated. Because, during this period, we observed a dramatic increase of MPA isolates, we fulfilled specific sequential measures, to assess potential reservoirs and breaks in infection control and to manage the outbreak, summarized by the following 4 phases: phase A: closing of HW from 29/04/2013 to 09/06/2013; phase B: serial pre and post-disinfection environmental sampling from each room: swabs from toilet, biofilter, shower, sink, filter button, infusor, environment vacuum cleaner, TV room control, 70% ethyl alcohol gel bottle, floor sink, bedpan and water samples from bedpan automatic washers (BAW); phase C: room environmental disinfection and microbial decontamination with nebulized H2O2 solution added with silver cations; phase D: disposal of BAW, introducing the use of disposable bedpans and planning an environmental sampling and disinfection program.

Results: On 04/2013 we revised retrospective study data: 82 pts carried bacterial isolates; of these, 48 (59%) had MPA, classified as colonisation in 13 pts (mainly detected on rectal swabs) and true infection in 35: 10 pneumonias (25%), 6 anorectal/perineal (17%), 5 urinary tract (14%), 14 bloodstream infections (40%). Ten pts died of MPA related infection, with a mortality of 53% (10 on 19 pts) and case-fatality rate of 29% (10 on 35 pts). Phase B defined a prevalence of PA isolates in 6 out of 7 rooms in different sample types, with 4 MPA isolates identified in 3 different BAW and 1 bedpan after washing cycle. After phase C, a new phase D demonstrated sterilization of 3 out of 6 PA and 3 out of 4 MPA isolation sites. As a main corrective action, after 41 days we resumed admissions and approached phase D, resulting in a prompt and maintained decrease in isolates (Table 1).

Table 1. MPA isolates and mortality rate after phase D.

<table>
<thead>
<tr>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hir pts</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Colonization (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Infection (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Summary/Conclusions: We identified the contaminated water residue from BAW as the source of HW spread, and that MPA is the main factor responsible for the outbreak control by improving environmental measures. Pseudomonas contaminates and survives on many ecological niches, being continuously reintroduced in nosocomial settings. Our experience highlights the value of environmental and personal hygiene measures on MPA infections control.

E1152

MONITORING VORICONAZOLE PHARMACOKINETICS AND PLASMA CONCENTRATIONS IN THE TREATMENT AND PREVENTION OF INVASIVE FUNGAL DISEASE FOR HEMATOLOGICAL PATIENTS A SINGLE CENTER EXPERIENCE

D. Guo1, T. Xu1, Z. Li1, J. Yin1, X. Tian1, D. Guo1, Y. Xu1, X. Zhu1, L. Miao1, D. Guo1, Y. Xu1, X. Zhu1, L. Miao1, D. Guo1

1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background: Voriconazole has been widely used in treatment and prevention invasive fungal disease for immunodeficiency hematological patients. And the voriconazole plasma drug levels were associated with its efficacy and toxicity. The hepatic cytochrome P450 isoenzyme 2C19 plays an important role in voriconazole metabolism, however if CYP2C19 gene polymorphism can result in voriconazole metabolism and drug plasma level in setting of Asian population especially in hematologic patients is unknown.

Aims: To evaluate the effect of CYP2C19 polymorphism on the voriconazole (VCZ) plasma concentration of patients with hematologic disease and the value of trough voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease(IFD).

Methods: Between January to August 2016, 76 hematological patients who received voriconazole for the treatment or prevention of invasive fungal disease were enrolled in this study. The population CYP2C19 polymorphism of voriconazole were performed using PCR-Reversesequencing. The trough plasma concentrations of voriconazole (C_{trough}) was determined using high-performance liquid chromatography (HPLC).

Results: Genotyping for CYP2C19 polymorphic isozyme variations showed that 32 subjects (43.42%) for the CYP2C19 wild-type, 43 (56.58%) for the CYP2C19 mutant type. Voriconazole plasma concentrations were compared in patients receiving standard dose or dose adjustment. Based on the genotype analysis, 45 subjects were identified as extensive metabolizers’ group for EMs (CYP2C19*1/*1), poor metabolizers’ group for PMs (CYP2C19*1/*3, *3/*3) and there was a significant difference between C_{trough} values in the two groups (1.66±1.86ug/ml vs 3.30±2.35ug/ml, p=0.000). The C_{trough} of the 45 patients were detected for 119 times totally. The medium of the C_{trough} 45 hematological patients were described. Lack of response to therapy was more frequent in patients with voriconazole levels <1.5mg/L (23.5%) than in those with voriconazole levels >1.5mg/L (62.8%) (p<0.05).

Summary/Conclusions: The single-center study showed that the mutation of CYP2C19 was quite common in Chinese hematological patients. Patients with CYP2C19 wild-type phenotype are extensive metabolizers, their C_{trough} of voriconazole are significantly lower than patients with CYP2C19 non-wild-type phenotype (poor metabolizers). Appropriate concentrations of voriconazole can improve the efficacy of therapy and safety outcome.

E1153

BACTEREMIA AND SEPSIS FOLLOWING INTENSIVE CHEMOTHERAPY OF ADULT ONCOHEMATOLOGICAL PATIENTS

S. Bessmeltsev1,*, V. Chebotkevich2, E. Kiseleva2, N. Stizhak2, E. Kaytandzhan2, B. Bury2

1Haematology, 2Lab. Bacteriology, Russian Institute of Haematology and Transfusion, St. Petersburg, Russian Federation

Background: Intensive cytostatic chemotherapy is a standard strategy for leukemia treatment. Meanwhile, such treatment causes negative effects, including lymphopenia, granulocytopenia and damage to tissue barriers associated with significant risks of infectious complications, especially, bacterial sepsis and viremia.

Aims: Our study was aimed for identification of bacteremia in oncohematological patients following intensive chemotherapy, and assessment of potential modifying role of herpesvirus infections.

Methods: Retrospective review of positive bacterial isolates of blood between January 1991- December 2015. Prospective study the cases of bacteremia and sepsis in cohort of 64 patients with hematologic malignancies. Diagnostics of septic conditions was based on clinical data, bacteremia and systemic inflamatory reaction syndrome (SIRS) (registration of, at least, 2 of 4 clinical symp- toms of SIRS), Bacteriological analyses and identification of micromycetes were performed by uniform technique over the entire study period, according to the valid guidelines. For DNA-diagnostics, we used gene-specific PCR with real-time registration. DNA was extracted from peripheral blood leukocytes The herpesvirus panel included Herpes Simplex type 1 and 2 (HSV); Cytomegalovirus (CMV); Epstein-Barr virus (EBV), and Human Herpesvirus type 6 (HHV6). PCR techniques were performed according to manufacturer instructions.

Results: Based on the study 4923 blood samples it was showed that the frequency of detection of bacteria was 11.0%. The predominance of Gram-negative bacteria was demonstrated among pathogens detected in the bloodstream. However, the ratio of detectable Gram-negative flora was found to be increased from 23.1% to 39.6% between 2002 and 2015 (p<0.05). Coagulase-negative staphylococci (CoNS) prevailed among Gram-positive microorganisms, in par- ticular, S. epidermidis, whereas Enterobacteriaceae, especially, E. coli, dominat- ed among the Gram-negative bacteria. It is shown that the development of bac- teremia were significantly more frequently occurs on the background of the detection of Cytomegalovirus and the Epstein-Barr virus genomes. In recent years has been increased the frequency of micromycetes detection in the blood of patients with hematological malignancies. In present study, antibiotic therapy started with β-lactame antibiotics combined with fluoroquinolones, aminoglycosides, metronidazole. If required, the antimicrobial strategy was revised 48 to72 hours later as based on clinical and microbiological data, apply- ing CYP2C19 no-wild-type. 2 45 of 76 patients received voriconazole intravenous administration, Based on the genotype analysis, 45 subjects were identified as extensive metabolizers’ group for EMs (CYP2C19*1/*1), poor metabolizers’ group for PMs (CYP2C19*1/*3, *3/*3) and there was a significant difference between C_{trough} values in the two groups (1.66±1.86ug/ml vs 3.30±2.35ug/ml, p=0.000).

Summary/Conclusions: Our data support a general viewpoint on regular mon- itoring of infectious pathogens upon intensive chemotherapy of oncohemato- logical patients prone to both bacterial and viral infections. Severe bloodstream infectious complications are often associated with fungal infections, and her- pesvirus reactivation. In particular, our results suggest that herpesviruses, may cause immunosuppression, or may serve as additional immunodeficiency mark- ers predictive for bacterial infections at later terms.
Iron metabolism, deficiency and overload

E1154

GLYCOSYLATED FERRITIN MEASURING SIGNIFICANCE FOR SECONDARY HEMOPHAGOCYTIC SYNDROME DIAGNOSTICS

V. Potapenko1,2, M. Pervakova2, S. Lapin2, A. Klimovich1, O. Mironova1, N. Petrov1, N. Onitamaya1, N. Skorbogatov1, E. Karyagina1, E. Karpeva1, E. Pavlichenko2, N. Potikhonov1, T. Kulkabaev1, N. Medvedeva1, B. Aftanasyev2

1. Municipal clinical hospital №31, 2Academician I.P. Pavlov First St. Petersburg State Medical University, 3Municipal hospital №15, 4I.I. Mechnikov North-Western State Medical University, 5Russian Scientific Research Institute of Hematology and Transfusiology, 6Saint-Petersburg State University, Saint-Petersburg, Russian Federation

Background: Hemophagocytic syndrome (HPS) is a clinicopathological condition characterized by systemic inflammatory reaction with cytopenia and tissue damage. The HPS may be primary (genetic associated) or secondary (SHPS), caused by different systemic disorders (immune, infectious, neoplastic). The overall clinical symptoms are similar to sepsis, so it could be difficult to differentiate among these entities. Ferritin levels are high in both cases, but the glycosylated/nonglycosylated ferritin fractions ratio is seems to be indicative.

Aims: The estimation of the ferritin fractions ratio and biochemical profile in patients with sepsis and SHPS.

Methods: The data from 64 patients were analyzed: 40 pts with diagnosed SHPS (median age 57, range 8-74 years) and 24 with lethal septic shock (median age 57.5, range 18-82 years). SHPS in patients with persistent fever refractory to antibacterial therapy and/or prolonged cytopenia and/or organ (lungs, CNS) involvement was established after the other conditions had been excluded. Sepsis diagnostics was based on the confirmed infection site and systemic inflammation with multorgan failure. The following serum values were analyzed: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), bilirubin, creatinine, INR, C-reactive protein (CRP), procalcitonin (PCT), total ferritin, and glycosylated ferritin percentage. Mann-Whitney U test and ROC-analysis were used for statistical analyses.

Results: No differences were found in sepsis and SHPS for ALAT, ASAT, AIPH, LDH, and bilirubin levels. The difference of INR, CRP, PCT, creatinine levels and ferritin glycosylation (p<0.01) (Table 1). According to ROC-analysis, the area under the curve for ferritin, triglycerides and percentage of ferritin glycosylation were 0.78, 0.82, and 0.92, respectively.

Summary/Conclusions: The most difference between sepsis and SHPS was observed for triglycerides, ferritin and percentage of glycosylated ferritin. Percentage of glycosylated ferritin fraction seems to be the most indicative, which may make it useful for SHPS diagnostics and its differentiation from sepsis.

Table 1.

<table>
<thead>
<tr>
<th>Ferritin Fractions</th>
<th>Sepsis (n=24)</th>
<th>SHPS (n=40)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferritin Glycosylated (%)</td>
<td>38.7±12.9</td>
<td>11.6±3.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ferritin Nonglycosylated (%)</td>
<td>61.3±12.9</td>
<td>88.4±3.5</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

E1155

SERUM HEPCIDIN QUANTIFICATION IN INFLAMMATORY BOWEL DISEASES

V. Manolov1,2, V. Vasilev3, K. Tzatchev1, O. Georgiev2, D. Stefanova-Petrova3, R. Tzrantcheva2, V. Mitev3

1Hacettepe University, Division Of Pediatric Hematology, Ankara, Turkey
2Dept. of Clinical laboratory and clinical immunology, 3Department of Propaedeutics of Internal diseases, 4Department of Medical chemistry and biochemistry, Medical University, Sofia, Bulgaria

Background: Inflammatory bowel diseases (IBD) include different intestinal pathologies, most common among them are Crohn’s Ucerosa (CU) and Crohn’s Disease (CD). Pathogenesis of IBD is still unclear, however they are multifactor diseases, with genetic and autoimmune compounds, in combination of environmental factors. One of IBD symptoms is iron deficiency anemia.

Aims: We aimed to search for connection between serum hepcidin quantification and anemia in IBD.

Methods: We included 64 patients with IBD - 29 with Colitis Ucerosa (CU), and 35 with Crohn’s Disease (CD). They were diagnosed in University “Aleksandrovskaya” hospital in Clinic of Gastroenterology. Their results were compared to age and gender matched healthy controls. Laboratory assessments were analyzed for included groups – iron, ferritin, CRP, IL-6 and hepcidin. AAS, nephelometric, ELISA and statistical methods were used during analyzes and obtained results interpretation.

Results: 53 from our patients had iron deficiency anemia (IDA) and low hepcidin concentrations (5.9±1.1 µg/L) compared to control group (19.9±2.8 µg/L). 11 of included cases had combination iron deficiency anemia/ anemia of chronic disease (ACD). Their hepcidin levels were increased (59.9±6.4 µg/L) in comparison to healthy controls (19.9±2.8 µg/L); P<0.001. In patients with ACD/IDA, quantified serum hepcidin correlates positively to increased IL-6 concentrations (r=0.756, P=0.005) and CRP concentrations (r=0.899, P=0.001).

Summary/Conclusions: We aimed to compare iron deficiency anemia in IBD patients with that seen in healthy controls. We found that iron deficiency anemia in these patients is more severe than IDA, and we observed a positive correlation between hepcidin and IL-6, which points toward a systemic inflammatory involvement in these patients. Thus, in patients with IBD the hepcidin concentration might be a key element in diagnosis and treatment of anemia in these patients. Serum hepcidin levels are useful marker for differential diagnosis between iron deficiency anemia and combination iron deficiency anemia/ anemia of chronic disease.

E1156

MUTATIONS IN YARS2 CAUSE CONGENITAL SIDEROBLASTIC ANEMIA WITHOUT SHOWING EVIDENCES OF MYOPATHY AND LACTIC ACIDOSIS

B. Cadenas1,2, J. Fita1, S. Montesdeoca2, C. Pedro1, M. Sanchez1

1Iron Metabolism: Regulation and Diseases, Josep Carreras Leukaemia Research Institute (IJC), BADALONA, 2Hematology Service, Hospital del Mar, Barcelona, Spain

Background: Mutations in the gene YARS2 encoding mitochondrial tyrosyl-tRNA synthetase have previously been identified as a cause of MLASA2, a mitochondrial respiratory chain disorder presenting with myopathy, lactic acidosis and congenital sideroblastic anemia (OMIM #610657, ORPHANET 2968). Up to date in the literature it has been reported 9 families with 11 affected individuals with mutations in YARS2 gene and affected from MLASA2.

Aims: Here we report a new case with a different clinical presentation.

Methods: We have identified two novel variations in YARS2 gene using Next Generation Sequencing (NGS) panel containing 10 genes involved in congenital and acquired sideroblastic anemia.

Results: The proband is a young woman aged 24 where we have identified 2 novel variations in YARS2 gene. One pathogenic splicing mutation NM_001040436.2. c.[1104-1G>A], and a missense variation NM_001040436.2 c.608G>T; NP_001035526.1: p. Ser203Ile located in the C-core catalytic domain of the mitochondrial tyrosyl-tRNA synthetase. None of these two variations were previously reported in public databases (ExAC, NCBI SNP, Ensembl). Clinical data from the patient showed marked sideroblastic anemia (Hb 91 g/L, 32% ring sideroblasts), but not signs of muscle weakness or weakness and acidosis (lactic acid levels were 1.8mmol/L, normal range: 0.5 - 2.2 mmol/L; creatine kinase 23 UI/L, normal range: 23-170 UI/L), as could be expected due to previously reported cases in the literature. Functional assays are ongoing to confirm pathogenicity of the novel missense variation.

Summary/Conclusions: Here, we reported a patient with mutation in YARS2 gene showing congenital sideroblastic anemia but presenting neither lactic acidosis nor myopathy. Therefore, patients with defect in YARS2 gene may present with a less severe clinical manifestations only involving congenital sideroblastic anemia without other extra-hematopoietic defects. MLASA2 must be considered in patients presenting with only congenital sideroblastic anemia since early diagnosis and supportive therapy will be important to prevent complications.

E1157

IRON CHELATION DATA OF CONGENITAL DYSERYTHROPOIETIC ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE

M. Celic1, N. Kalkan1, T. Bayhan1, F. Gumruk1, S. Unal1

1Hacettepe University, Division Of Pediatric Hematology, Ankara, Turkey

Background: Congenital dyserythropoietic anemia (CDA) is a rare, genetically heterogenous disorder characterized with ineffective erythropoiesis, and congenital malformations in certain types. Patients present with varying degrees of anemia and sideroblastic anemia. Depending on the type of the malformations some of the patients may have mild disorder whereas others may be transfusion dependent. The ineffective erythropoiesis and the transsional iron load puts these patients at risk for iron overloading and there is very scarce data on the iron loading and chelation types in these patients.

Aims: We aimed to summarize the chelation results of our patients with CDA from a single center.

Methods: Of the 33 patients with CDA, 11 were initiated iron chelation treatment either for receiving more than 20 packed RBC transfusions previously or for having serum ferritin levels above 1000ng/ml.
Results: Of these 11 patients, 7 were CDA type II. The median age of diagnosis was 12 months (3-144 months) and male to female ratio was 7/4. Median transfusion requirement per year at previous year prior to initiation of chelation was 12 times (0-17). All of the patients were on chronic transfusion programme at initiation of iron chelation except for 2 (one receives occasional transfusion, and the other patient was on chronic transfusion programme but became transfusion independent after splenectomy). The median age at last visit was 70 months (32m-40 years). The median value of serum ferritin at initiation of iron chelators was 822 ng/ml. All of the patients were initiated deferasirox for iron chelation at a median dose of 24mg/kg/day (10-40) and the median chelation follow-up duration was 27 months (2-54 months). Three of the patients were evaluated with cardiac and hepatic T2* assessment prior to and by the end of 1 year of chelation and none of the patients were found to have cardiac iron loading at chelation initiation, whereas 2 had severe and 1 had moderate LIC values. In the subsequent assessment under chelation of these patients all still had cardiac T2* values above 20 ms, whereas 1 had mild and 2 had moderate LIC values. Serum ferritin levels prior to initiation and by the end of 1 year were compared and the difference was found statistically insignificant.

Summary/Conclusions: Patients with CDA are at risk for iron loading and they need to be screened for the iron loading periodically. The prompt chelation in these patients prevent organ failure risks at long term including cardiac failure, cirrhosis and endocrinopathies.

E1158

ORAL IRON CHELATION FOR TREATMENT OF HEREDITARY HEMOCROMATOSIS IN CHILDREN

M. Moraki1,2, E. Repouš1, D. Kyriakopoulou1, P. Delaporta1, A. Kattamis1,1

1Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, ‘Agia Sophia’ Children’s Hospital, Athens, Greece

Background: Hereditary hemochromatosis (HH) very rarely presents during childhood. The most common form of HH in children is Juvenile Hemochromatosis (JH), a rare genetic disorder inherited with an autosomal recessive manner, resulting from mutations in either the hemojuvelin (HJV) (type 2A) or the hepcidin (HAMP) gene (type 2 B). Early diagnosis and closely monitoring of iron overload indexes, namely, serum ferritin levels, transferrin saturation and tissue iron measurement by magnetic resonance imaging (MRI) are essential in order to prevent permanent organ damage and potentially life threatening complications (cirrhosis, diabetes mellitus, cardiac dysfunction, and hypogonadism). Therapeutic intervention in children with HH may be problematic, as erythropoiesis is invasive and may not be well tolerated in young children. Iron chelation therapy can be implemented as an alternative treatment to erythropoiesis.

Aims: The scope of this study was to evaluate the use of an oral iron chelation therapy in young children with HH.

Methods: 3 children (2 females and 1 male) were diagnosed with HH at the aged of 4, 6 and 8 years old, respectively, based on increased ferritin and transferrin saturation levels and tissue iron measurement by magnetic resonance imaging (MRI).

Results: Hypersegmentation was detected in all 3 patients and it resolved with temporary cessation of the chelation therapy. In the subsequence assessment under chelation of these 3 patients all still had cardiac T2* values above 20 ms, whereas 2 had severe and 1 had moderate LIC values. Median transfusion requirement per year at previous year prior to initiation and by the end of 1 year were compared and the difference was found statistically insignificant.

Summary/Conclusions: Hypersegmentation was detected in 25 individuals with iron deficiency (45%) and 1 healthy control (5%). It was significantly more frequent in the IDA group (48.8%) than in the ID group (30.7%) \(p<0.001\). After iron treatment 3 IDA patients’ peripheral blood smear were evaluated and with normalization of iron parameters and hemoglobin, hypersegmentation was undetectable. The study is still ongoing and rest of the IDA group are still on treatment, their peripheral blood smears are to be examined after iron treatment is over.

Table 1. Clinical characteristics of the patients

<table>
<thead>
<tr>
<th>Age (years) at treatment</th>
<th>Gender</th>
<th>Ferritin (at treatment) (ng/ml)</th>
<th>Transferrin saturation (%)</th>
<th>LIC (serum Fe / transferrin (mg/μmol))</th>
<th>Carret T2* (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>1125</td>
<td>85</td>
<td>2.5</td>
<td>21.3</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>2000</td>
<td>95</td>
<td>1.9</td>
<td>18.1</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>2000</td>
<td>80</td>
<td>2.2</td>
<td>21.3</td>
</tr>
</tbody>
</table>

E1159

NEUTROPHIL HYPERSEGMENTATION IN ADULTS WITH IRON DEFICIENCY: A CASE-CONTROL STUDY

I. Erdogan Ozuna1,2, D. Keskin1, E. Durcan2, Y. Gunay2, S. Bilgin2, S. Berk1, D. Ozmen1, N. Ozgur Yurttas1, S. Sadri1, A. Salihoglu1, A. E. Eskazan1, M. C. Ar1, S. Ongoren1, Z. Baslar1, Y. Aydin1, A. L. Yardan1, T. Soysal1

1Department of Internal Medicine, Division of Hematology, 2Department of Internal Medicine, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey

Background: Neutrophil hypersegmentation (NH) has been accepted as a hallmark of the macrocytic anemias associated with the deficiency of cobalamin or folate. However, there are a small number of reports stating that NH might accompany iron deficiency anemia. The aim of the present study was to determine the association of NH with iron deficiency (with or without anemia).

Aims: The aim of the present study was to determine the association of NH with iron deficiency (with or without anemia) in adults and also to compare neutrophilic segmentation status in anemia group before and after oral or parenteral iron treatment.

Methods: Fifty-six patients with iron deficiency and 20 age and sex matched controls were included in this prospective, single blind, case-control study between February-November 2016. Subjects were included if they were ≥ 18 years of age, and had normal serum vitamin B12 and folate levels, liver, thyroid and renal function tests. Pregnant women and patients with a history of blood transfusion within last 3 months and/or those with acute renal failure, anemia of chronic disease, hypothyroidism, additional cytopenias and infection were excluded. Patients with iron deficiency were divided into 2 groups being with iron deficiency anemia (IDA) and iron deficiency without anemia (ID). Those with IDA were further evaluated prior and after iron replacement. Results of the study groups were compared to age and sex matched healthy controls. Blinded peripheral blood smear slides were evaluated by a haematologist by counting 200 neutrophils. Hypersegmentation was defined as reported by Bain et al. Iron deficiency was diagnosed based on the findings of iron parameters including serum iron, total iron binding capacity, and ferritin. Anemia was defined according to the WHO recommendation. Cohort characteristics were given in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Age (years) at treatment</th>
<th>Gender</th>
<th>Ferritin (at treatment) (ng/ml)</th>
<th>Transferrin saturation (%)</th>
<th>LIC (serum Fe / transferrin (mg/μmol))</th>
<th>Carret T2* (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>1125</td>
<td>85</td>
<td>2.5</td>
<td>21.3</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>2000</td>
<td>95</td>
<td>1.9</td>
<td>18.1</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>2000</td>
<td>80</td>
<td>2.2</td>
<td>21.3</td>
</tr>
</tbody>
</table>

Results: Hypersegmentation was detected in 25 individuals with iron deficiency (45%) and 1 healthy control (5%). It was significantly more frequent in the IDA group (48.8%) than in the ID group (30.7%) \(p<0.001\). After iron treatment 3 IDA patients’ peripheral blood smear were evaluated and with normalization of iron parameters and hemoglobin, hypersegmentation was undetectable. The study is still ongoing and rest of the IDA group are still on treatment, their peripheral blood smears are to be examined after iron treatment is over.

Figure 1.

Summary/Conclusions: Although the mechanism of neutrophil hypersegmentation in iron deficiency anemia is not clear, it is thought that iron acts as a cofactor in folate metabolism and/or DNA synthesis in granulocytes. There are a limited number of studies dealing with NH associated with IDA in the literature. However most of these studies were observational and did not include controls or were not blinded. Our study is the first to demonstrate the association of NH with iron deficiency anemia in adults in the absence of megaloblastic anemia.

E1160

M-TOR INHIBITORS-ASSOCIATED MICROCYTIC ANEMIA AFTER AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION

R. Angel F.1, A. Monter2, A. Esquiro1, R. Martino1, I. Garcia-Cadenas1, J. Remacha1, S. Payan1, S. Brunet2, J. Sierra1

1Hematology, Hospital de Sant Pau, Barcelona, Spain

Madrid, Spain, June 22 – 25, 2017

haematologica | 2017; 102(s2) | 475
Background: Immunosuppression with mTOR inhibitors (sirolimus or everolimus) has been associated with development of microcytic anemia after solid organ transplantation. The prevalence reaches 27 to 57% in the case of kidney transplantation. This anemia has been attributed to hepcidin increase induced by the inhibition of mTOR protein 1,2.

Aims: To evaluate the prevalence of microcytic anemia after allogeneic hematopoietic stem cell transplantation in patients receiving mTOR inhibitors.

Methods: 61 consecutive allogeneic stem cell reduced intensity conditioning (alloRIC) recipients were analyzed. In all cases, a non-related donor was used. Baseline disease was: 23 acute leukemia (37.7%), 12 non-Hodgkin lymphomas (19.7%), 10 myelodysplastic syndromes (16.4%), 7 Hodgkin lymphomas (11.4%), 4 multiple myelomas (6.5%), 3 chronic lymphocytic leukemia (4.9%), and 2 myelofibrosis (3.2%). All of them received Fludarabine-based conditioning treatment and the combination sirolimus (mTOR inhibitor)-tacrolimus (calcineurin inhibitor) as GVHD prophylaxis. Drug doses were adjusted according to blood levels and renal function. Levels of Hb, MCV and iron parameters were assessed and evaluated after alloRIC. Microcytosis was considered when MCV was below 80 fl.

Results: At 6 months 56 out of 61 (92%) were alive. Anemia was observed in 30 (49%) of them, with only 8 cases (13.1%) showing Hb level below 100 g/l. Microcytic anemia was diagnosed in 2 of them (3.3%). One patient showed an iron deficiency anemia due to gastrointestinal bleeding (Hb 94 g/l, MCV 69 fl, serum ferritin 21 µg/l). However, the second one, a 61-year old male with an acute leukemia, had a microcytic anemia with iron parameter changes similar to those observed in kidney transplantation and associated with increased hepcidin, (see table). Anemia progressively improved with sirolimus tapering.

Table 1.


Summary/Conclusions: In contrast to kidney transplantation, microcytic anemia related to immunosuppression with mTOR inhibitors was seldom observed in alloRIC recipients. However, this association should be taken in account in this setting, as a rare cause of anemia. In case of microcytic anemia, the evaluation of iron parameters and hepcidin provides the diagnosis of this rare type of anemia.

E1161
IRON METABOLISM IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

E. Lukina1,*, K. Tandilova1, N. Tsvetaeva1, O. Nikulina1, E. Sysoeva1, I. Karpova2, E. Mushina1, V. Sinity1
1Department of Orphan Diseases, 2Central Clinical Diagnostic Laboratory, National Research Center for Hematology, Russia

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal malignant hematological disorder that is associated with hematolytic anemia, intravascular hemolysis, thrombosis. At the onset, the condition is often interpreted as iron deficiency anemia that leads to the prescription of ferrotherapy.

Aims: Study iron metabolism in patients with PNH.

Methods: The study group included 19 patients (11 men and 8 women aged from 20 to 67, median age 43 years) with a diagnosis of PNH, followed up in our Center between 2014 and 2017. The median hemoglobin level was 8.1 g/dl. The erythrocyte PNH clone size ranged from 17 to 99%, median - 47%. Granulocyte and monocyte PNH clone sizes were 85% and 89%, respectively. The following parameters were studied to characterize iron metabolism: ferritin, transferrin, iron concentration, total iron binding capacity (TIBC), trans- ferredin saturation. The number of iron overload signs (MRI) of the liver and kidneys to determine iron overload. Five of 10 patients received treatment with eculizumab.

Results: Iron metabolism parameters varied in wide limits. Iron deficiency was detected in 4 (21%) patients, 8 (42%) patients had laboratory signs of iron overload. In 7 (36%) patients, parameters of iron metabolism: Ferritin ranges from 6 to 5050 nmol/l (median – 220umol/l), MRI (including T2*-weighted images) revealed signs of liver hemosiderosis varying from mild to severe degree in 7 out of 10 studied patients. Signal intensity of renal cortex was decreased in 9 out of 10 patients, presumably due to renal hemosiderosis. In 1 patient there were no pathological findings on MRI. Laboratory signs of iron deficiency were revealed in 2 out of 9 patients with renal hemosiderosis. Signs of liver hemosiderosis were absent only in 1 out of 10 examined patients. This patient has been treated with eculizumab for 15 months.

Summary/Conclusions: Evaluation of laboratory parameters of iron metabolism is not sufficient to identify tissue iron overload in transfusion-dependent patients with PNH. MRI (including T2*-weighted images) revealed signs of hemosiderosis of liver and kidneys in 7 (37%) and 9 (47%) patients respectively, indicating the feasibility of this method for diagnosis of post-transfusion iron overload in patients with PNH and assessment of the need for chelation therapy. Described case of the patient who has no signs of renal hemosiderosis and receives treatment with eculizumab fortifies the results of clinical studies showing the efficacy of eculizumab in the prevention of renal failure in patients with severe PNH.

E1162
ORAL IRON ELEVATES SERUM IRON AND CONSEQUENTLY CHANGES IRON DISTRIBUTION IN LIVER AND ERYTHROCYTES

Y. Matsuo-Tezuka1,*, M. Noguchi-sasaki1, M. Kurasawa1, K. Yorozu1, Y. Shimokana1, M. Hiraoka1
1Product Research Department, Chugai Pharmaceutical Co., Ltd., Japan

Background: For renal anemia patients, there are several therapeutic options including erythropoiesis-stimulating agents (ESAs), intravenous and oral iron supplementations. In terms of iron absorption, ESAs were known to activate iron absorption via down-regulation of hepcidin, a key mediator of iron metabolism, and consequent up-regulation of duodenal iron transporters divalent metal transporter 1 (DMT1) and ferroportin (FPN). On the other hand, in our previous study, intravenous iron was demonstrated to deactivate iron absorption system via hepcidin elevation. However, iron absorption under oral iron supplementation have not fully evaluated yet.

Aims: In this study, we investigated the activity of iron absorption under oral iron supplementation in mice as well as under intravenous iron supplementation. In addition, we also analyzed iron distribution under intravenous and oral iron supplementation.

Methods: To load iron orally, a diet including 200 ppm of iron was used as control and a diet including approximately 5000 ppm of ferric citrate was used as iron-rich diet. 6-week-old male C57BL/6NCrl mice were divided into 3 groups; control group, intravenous iron (IV iron) group, and oral iron (Oral iron) group (n=5). Mice in IV iron group were fed a control diet from days 0 and intravenously administered 0.4mg/mouse of iron-dextran on days 9. Mice in Oral iron group were fed an iron-rich diet from days 0 and intravenously administered 0.4mg/mouse of dextran as vehicle on days 9. Mice in control group were fed a control diet from days 0 and intravenously administered 0.4mg/mouse of dextran on days 9. All mice were euthanized by exsanguination under anesthesia with isoflurane on days 14. For analyses of iron absorption, serum hepcidin and iron were measured and expression of duodenal DMT1 and FPN were evaluated immunohistochemically. For analyses of iron distribution by blue staining and hemoglobin index, iron parameters of liver and kidneys were determined.

Results: Serum hepcidin levels in IV and Oral iron groups were significantly higher compared with control group. However, serum iron levels were elevated only in oral iron group. In immunohistochemical analyses, expression levels of duodenal DMT1 were not detected in all groups and expression levels of duodenal FPN in IV and Oral iron groups were significantly lower than control group. As for iron distribution in liver, iron was accumulated in reticuloendothelial cells in IV iron group, on the other hand, in Oral iron group iron was accumulated in parenchyma. In hematological analyses, although red blood cell and reticulocyte count were not significantly different among all groups, Ret-He and MCH in Oral iron group were higher than IV iron groups.

Summary/Conclusions: It was demonstrated in this study that serum iron levels were elevated in spite of high hepcidin levels and down-regulation of duodenal iron transporters under oral iron supplementation. Furthermore, iron was distributed in liver parenchyma and hemoglobin contents in each reticuloocyte and erythrocyte were up-regulated only under oral iron supplementation. We speculated that high serum iron lead to excess iron uptake into tissues and erythrocyte fraction. These data might provide an opportunity to rethink the importance of proper use of iron supplementations.

E1163
DEFERASIROX FOR SEVERE ANAEMIAS IN YOUNG CHILDREN

A. Gunawan1,*, S. Korenev3, H. Mundy4, M. Peldis3, J. Alamela5, B. Inusa3
1Haematology, Guy’s and St Thomas’ NHS Trust, 2Pediatric, Evelina Hospital, Guy’s and St Thomas’ NHS Trust, 3Pediatric, Evelina Hopsital, Guy’s and St Thomas’ NHS Trust, London, United Kingdom
Background: Children with haemoglobinopathies and rare anaemias often require regular red cell transfusions at some stage of their lives. Iron overload is therefore inevitable and iron chelation is a key component of therapy for children in this group. However, its use has not been validated especially in children under two years of age. Deferasirox (Exjade®; Novartis Pharma AG, Basel, Switzerland) is an iron chelator that is conclusively proven to be effective and safe in transfusional anaemia such as haemoglobinopathies.

Aims: We aim to look at the efficacy and safety of Deferasirox in children with severe anaemias.

Methods: We present a case report of 6 children with severe anaemias treated with Deferasirox in a tertiary pediatric hematology centre in London, UK.

Results: We report 6 cases where Deferasirox has been used in young children with rare anaemias and sickle cell disease where evidence is sparse.

Deferasirox was started at the age of 3 months and 4 months respectively. Patients 3 and 4 presented with neonatal anaemia requiring regular transfusion and were diagnosed with Pyruvate Kinase deficiency. Deferasirox was started at 12 and 19 months consecutively. Patient 5 presented with pure red cell aplasia at the age of 3 months and was diagnosed with Diamond Blackfan anaemia. He was initially treated with steroid but became resistant at around 40 months of age. He was then started on regular transfusion and was started at deferasirox at 4 years of age. Patient 6 was diagnosed at birth with sickle cell anaemia. He suffered from stroke at the age of 8 months and was started on chronic transfusion program. Deferasirox was started at around at the age of 1. He had a successful maternal haplo-identical haemopoietic stem cell transplant at the age of 3 years old. Transfusion and deferasirox were subsequently stopped.

Figure 1.

Summary/Conclusions: All of these children had stabilization or improvement of ferritin values after initiation of deferasirox as shown in figure 1. Deferasirox is licensed in Europe to be used in children with thalassaemia older than 6 years of age or older than 2 year of age when desferoxamine therapy is inappropriate or inadequate. Deferasirox is preferable in severe anaemias due to better side effect profile on the bone marrow compared to deferiprone; the use of which can cause agranulocytosis or neutropaenia. Furthermore, its oral administration improved compliance compared to desferrioxamine that required prolonged subcutaneous administrations. Deferasirox has been associated with renal impairment. However, none of patients developed renal or liver impairment during the use of deferasirox. Furthermore, it is crucial to conduct eye and ear screening tests both before and after the commencement of deferasirox. None of our patients had neurological side effects. Three of these children had deferasirox started at younger than 2 years of age. Hence, we have shown that deferasirox is safe and efficacious in treating iron overload in very young children with rare anaemias and sickle cell disease where evidence is sparse.

R. Colombatti1, M. Maruzzì2, E. Facchinì3, S. Fasoli8, F. Giona8, D. Caselli10, C. Pizzato1, G. Boscarino12, E. Bertoni13, F. Tucci14,1
1Clinical and Experimental Medicine, University of Catania, 2Pediatric Hemato-Oncology Unit, 3Azienda Policlinico Vittorio Emanuele, Catania, 4Department of Pediatric and Public Health Sciences, University of Torino, Torino, 5Pediatric Hemato-Oncology Unit, University of Padova, Padova, 6Pediatric Hemato-Oncology Unit, IRCCS Candiolo della Sofferenza, San Giovanni Rotondo, 7Pediatric Hemato-Oncology Unit, Policlinico S.Orsola Malpighi, Bologna, 8Pediatric Unit, Carlo Poma Hospital, Mantova, 9Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Roma, 10Maria Paternò Areszto Hospital, Ragusa, 11Hospital, Treviso, 12Central Teaching Hospital, Bolzano, 13Spedali Civili, Brescia, 14Ospedale Meyer, Firenze, Italy.

Background: Iron deficiency anemia (IDA) is the most common hematological disease in infancy and childhood. Oral iron administration is a well-established, effective, and widely accepted treatment for anemia because of its efficacy, safety, and cost-effectiveness. Recently, new preparations of oral iron compounds were launched, including droplet formulations, i.e. liposomal preparations and bis-glycinate iron; little is known on their effectiveness in real clinical practice.

Aims: To evaluate the efficiency of different oral iron preparations in children with IDA.

Methods: This observational study collected clinical and hematological data from 12 AIEOP (Associazione Italiana di Ematologia ed Oncologia Pediatrica) centers. Inclusion conditions for patient enrollment were age 3-months-12 years, diagnosis of IDA; exclusion criteria were all conditions interfering with iron absorption such as celiac disease, gastro-intestinal disorders and other chronic conditions. Local Physicians were free to prescribe any oral iron formulation, according to their standard practice. A calendar of laboratory test was suggested, including basal assessment of whole blood count, reticulocytes, iron status, with subsequent checkpoints at 3 days (WBC and reticulocytes only), 2 weeks, 8 weeks, 6 months. Clinical data regarding compliance to therapy, unwanted effects, final outcome were recorded.

Results: 112 (M 58) patients were enrolled. Ethnic distribution was: Caucasian 74, African 23, Asian 10, Other 8. The median age at diagnosis of IDA was 1.5 years, with a bimodal distribution with frequency peaks at age 9 months and 12-14 years. Sixty-eight patients received bis-glycinate ferrous iron 0.45mg/kg, 19 elemental iron (ferrous gluconate/sulfate) 2mg/kg, 12 liposomal iron 0.7-1.4mg/kg, and 15 other preparations. Eating habits were reported as normal in 48 patients, inadequate weaning in 21, meatfish restriction in 32, other in 11. Gastro-intestinal side effects were reported in 9/68 (13%) in the bis-glycinate iron group, in 3/19 (16%) of the elemental iron group, and in 0/12 of the liposomal iron group. Suspension of therapy due to side effects was needed only in 5 patients, 4 in the bis-glycinate and 1 in the elemental iron group, respectively. Final outcome was available for 77 patients; it was recorded as solved IDA, persistent IDA, or lost at follow up. Solved cases were 40/53 (75%) in the bis-glycinate iron group, 4/11 (36%) in the elemental iron group, and 8/13 (62%) in the liposomal iron group. Persistent cases were 8/53 (15%) in the bis-glycinate iron group, 6/11 (55%) in the elemental iron group, and 1/13 (8%) in the liposomal iron group. Lost at follow up were 5/53 (9%) in the bis-glycinate iron group, 1/11 (9%) in the elemental iron group and 4/13 (31%) in the liposomal iron group.

Summary/Conclusions: The collected data show that both bis-glycinate and liposomal iron formulations have a good efficacy/safety profile and offer a sustainable alternative to classic elemental iron preparations.

E1165

AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPCIDIN LEVELS WITH TREATMENT

H. C. Kılınç1, B. Onec2,*, K. Onec1, E. Caliskan3, H. Ankaralı4
1Internal Medicine, 2Hematology, 3Medical Microbiology, 4Biostatistics, Duzce University Faculty of Medicine, Duzce, Turkey

Background: Iron deficiency anemia (IDA) is a global health problem and problems in compliance with oral iron therapy are frequently seen. It has been shown that medications are not used regularly or discontinued due to weight gain during the treatment process.

Aims: We investigated ghrelin, known as appetite hormone and its relationship with hepcidin, the homeostatic regulator of intestinal iron absorption, in order to explain some symptoms of IDA and weight gain during iron treatment.

Methods: A hundred and twenty adult IDA patients, referred to our clinic between October 2015 and October 2016 were included in the study. The study was completed with 87 patients, who gave the informed content and a control group consisted of 50 healthy people. Information about age, gender, weight, height, body mass index (BMI), waist-hip circumference and blood samples were taken from the patient and control groups. The treatment of IDA was done according to the dose and method recommended by the responsible physician. Measurements and blood tests were repeated in the patient group after normalization of the anemia parameters, not before the third month of treatment. Hepcidin and ghrelin levels
were examined once in the control group and twice in the patient group, before and after treatment.

**Results:** When the patient and control groups were compared, there was no significant difference in terms of age, sex, height, weight, BMI, waist and hip circumference. The pretreatment plasma hepcidin and ghrelin levels of the patient group were significantly lower than those of the control group (80±21 ng/ml vs 179 ng/ml p <0.001 for hepcidin, 152±119 pq/ml vs 213±167 for ghrelin, p=0.026). There was a significant increase in terms of weight (mean 1.15 kg, p <0.001), BMI (25.86 kg/m² vs 26.33 kg/m², p <0.001), waist and hip circumference measurements (mean 0.81 cm in both, p <0.001) after treatment in the patient group. After treatment, the levels of hepcidin was significantly increased compared to the pre-treatment levels (80±21 ng/dl vs 92±13 ng/dl, p=0.001). Although an increase in the plasma ghrelin levels was encountered after treatment, it was not statistically significant (152±119 pq/ml vs 164±150 pq/ml, p=0.589). When correlations of individual increases in ghrelin levels were examined, a weak positive correlation was found between increase in ghrelin levels and weight gain.

**Summary/Conclusions:** In our study, ghrelin was significantly lower than the control group in the IDA group, suggesting that it may be the cause of loss of appetite. Ghrelin is also detected in neurons of hypothalamic arcuate nucleus, which regulates appetite. The deficiency of iron may cause deficiencies in enzymatic activities of iron dependent enzymes and it may disturb the function of these neurons. But the increase with treatment did not reach statistical significance. This may be due to physiological suppression of levels by weight gain. When patient-based weight gains were examined, there was a positive but weak correlation with the increase in ghrelin levels of those people. Hepcidin was significantly lower in the iron deficiency group than in the control group and showed a significant increase with treatment, but it was not associated with weight gain and change of ghrelin levels. More extensive and controlled studies should be designed in this regard.

**E1166**

**SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING**

K. Polgarova1, K. Vargova1, V. Kulvati2, N. Dusilova2, L. Minarik1, Z. Zemanova3, A. Jonasova1, T. Stopka1,2

1Hematology Clinic, General Hospital, Prague, 2Biocev, Charles University, Vestec, 3Cytogenetic Center, General Hospital, Prague, Czech Republic

**Background:** Azacitidine (AZA) is a standard therapy for MDS patients with higher risk of AML transformation and not eligible to undergo transplantation. While AZA was well tolerated the responses occurring in up to two thirds of patients are not durable. Somatic mutations were previously associated with pathogenesis of MDS, some of them also with prognosis. Several studies suggested that MDS patients as they progress may evolve new mutations and loose some of the cional architecture detected at preceding stages (Pellegati, Roy et al. 2016). In addition, there exist gene mutations that are detected in patients subsequent responding to hypomethylating agents (Bejar, Lord et al. 2014), which implies that there exist variants-bearing clones that persist upon AZA as well as those that do not.

**Aims:** To identify variants either persisting or not upon the AZA therapy we tracked BM samples during AZA treatment. Next, we were interested in deciphering their relationship of the dynamics in somatic variants to clinical course of the analyzed MDS patients.

**Methods:** Massive parallel sequencing with high accuracy utilized duplicate libraries from myeloid cells and included the non-tumorous T-cell controls to identify somatic/mutations in the serial samples before and during AZA therapy. The tool for detecting the dynamics of somatic mutations was the TruSight Myeloid Panel that contains 54 gene regions with previously documented mutation recurrence in 439 patients (Bejar, Stevenson et al. 2011). Indeed, 92% of our MDS cohort bore at least one somatic mutation with mostly 4 mutations per patient (range 1-9), which indicated that the MDS patients were already at relatively progressed state (Papaemmanuil, Gerstung et al. 2013).

**Results:** Analysis of 38 patients treated with AZA (reaching median OS 24 months (Mo) with 60% hematopoietic improvement) revealed 125 somatic variants with VAF over 5%. Adverse effects of variants in cooperating regulators of DNA damage and cell cycle were confirmed: TP53 (OS on AZA 14.8 Mo), CDKN2A (12.3 Mo), EZH2 (11 Mo). Besides the stable variant’s allele frequency (50%<VAF <200%) there existed four additional VAF profiles. Stable variants’ dynamics precluded putative AZA-resistant clones associated with shorter survival (19 Mo). In contrast, the patients bearing variants with decreasing VAF, which supposedly were inhibited by AZA, lived longer (31 Mo). Interestingly, small group of highly dynamic variants upon AZA therapy formed a subgroup with lasting-larger complete remissions.

**Summary/Conclusions:** Our work support the importance of catalogization of somatic variants to delineate pathogenesis of MDS with a focus on molecular AZA responsiveness. Several types of variant dynamics during the AZA therapy were noted by using the massive parallel sequencing approach of the duplicate libraries per MDS BM samples also utilizing non-tumorous controls and serial sampling. Stable dynamics was found in variants previously recorded by COSMIC and targeting the adverse outcome genes such as TP53, BCR/ABL1, ASXL1, and EZH2 as well as their combinations with TET2 that may potentially mediate clonal selection of additional variants mediating progression during AZA therapy.

**E1167**

**WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION PATTERNS IN AZACYTIDINE-TREATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) PATIENTS**

P.P. Leoncini1,2, P. Vitullo1, F. Di Florio1, V. Tocco1, M.P. Cefalo1, A. Pittisci1, K. Girardi1, C. Niemeyer2, F. Locatelli1, A. Bertaina1

1Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy, 2Pediatrics-Oncohematology, University of Freiburg, Freiburg, Germany

**Background:** Juvenile Myelomonocytic Leukemia (JMML) is a rare and aggressive leukemia of early childhood. Allelic gene hematopoietic stem cell transplant (HSCT) is the only available curative treatment, but, since disease recurrence is responsible for treatment failure in at least one third of transplanted patients, developing alternative therapeutic approaches is desirable. Aberrant DNA methylation is a key molecular feature of JMML, suggesting an important role of epigenetic in the pathophysiology of the disease. Azacitidine (AZA), a molecule that inhibits DNA methylation in human cells, is under investigation in JMML.

**Aims:** Here we report, for the first time, a global evaluation of DNA methylation status of CD34+ cells deriving from JMML patients before and after AZA treatment and compared the results with those of healthy controls. Identifying differentially methylated CpG islands linked to various genes will help us describe
an epigenetic aberrant paradigm possibly involving transcriptional and translational regulation in JMML.

Methods: CD34+ cells isolated from 3 JMML patients samples collected at diagnosis (t0) and after the third cycle of AZA (t1) were evaluated together with those of 3 healthy donors (HD). JMML patients have been treated with AZA on a compassionate use basis after obtaining signed informed consent. DNA samples were processed and ion fragment libraries were prepared. MBD-seq, bioinformatics and statistical analysis were performed by Genomnia srl (Bresso, Italy).

Results: First, we compared 10 JMML cells with HD cells, finding 987 different transcriptional units corresponding to 714 coding and 273 non-coding sequences. We also compared DNA methylation between t1 and HD cells. In this comparison, 644 unique transcriptional units, including 468 coding and 176 non-coding sequences, were found. Hypermethylation in JMML samples compared to HD was detected, but, unexpectedly, t0 vs t1 methylation analysis did not show any significant result, suggesting a likely unspecific patient-related pharmacological effect. Notably, 453 coding and 165 non-coding differentially methylated regions are shared between t0 vs HD and t1 vs HD sets. More in detail, 261 and 15 coding regions and 107 and 10 non-coding regions were uniquely found in t0 vs HD and t1 vs HD sets, respectively. However, 439 coding and 161 non-coding genomic regions preserve their hypermethylated status, probably due to a mechanism of resistance to AZA treatment. Among non-coding elements, we found different RNA species, such as microRNAs, splicing RNAs, lincRNAs/antisense transcripts (AS) and other unknown RNAs. Retrotransposons, belonging to LINEs and SINEs families, were also screened. We identified 13 sequences with a significant differential methylation profile in both t0 and t1 vs HD. Again, a comparison between t0 and t1 groups did not show any significant difference. Eleven hypermethylated common LINEs were evident between t0 vs HD and t1 vs HD sets. Two retrotransposons with opposite methylation patterns were found in t0 vs HD and t1 vs HD sets; while in the first comparison they included LINEs, in the second one they are 1 hypermethylated LINE and 1 hypomethylated SINE.

Figure 1.

Summary/Conclusions: In conclusion, the whole genome MBD-seq performed for the first time on JMML CD34+ bone marrow derived cells, showed a broad genomic hypermethylation both in pre- and post-AZA samples compared to HD, suggesting a patient-specific AZA-effect. Transcription and translation processes of coding and non-coding genes could be deregulated in multiple ways, due to heterogeneity of sequences involved in CpG islands hypermethylation. Moreover, due to their known ability to insert random mutations in the genome, retrotransposons should be candidate for further studies in JMML pathogenesis.

E1168

RESPONSE MONITORING IN MDS WITH DEL(5Q) USING DIFFERENT FLOW CYTOMETRIC (FCM)-SCORES IN COMPARISON TO CYTOGENETICS

U. Oelschlaegel1, T.M. Weisfer2, B. Mohr1, D. Subira3, U. Johansson4, G. Ehninger1, M. Bornhäuser1, A.A. van de Loosdrecht2, U. Platzecker1
1Medical Clinic and Polyclinic I, MK1-L06, University Hospital of Tu Dresden, Dresden, Germany, 2Department of Hematology, VU University Medical Center, Amsterdam, Netherlands, 3Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain, 4Department of Hematology, University Hospitals NHS Foundation Trust,., Bristol, United Kingdom

Background: Flow cytometry (FCM) is one part of integrated MDS diagnostics. Different well established FCM-scores are applied, as FCSS (Wells et al. 2003), Ogata-score (Ogata et al. 2012), new iFS (Cremers et al. 2017), and del(5q)-FCM-score (Oelschlaegel et al. 2015).

Aims: The aim of this prospective study was to test, which of the mentioned FCM-scores fits best for response monitoring in del(5q) MDS in comparison to cytogenetics.

Methods: Overall, 245 FCM investigations were performed in 61 patients with MDS and del(5q) (IPSS-R very low/low: n=26, int: n=13, high/very high n=22) including 42 patients with isolated del(5q) or one additional cytogenetic abnormality. The majority of analyses were performed in patients receiving lenalidomide or azacitidine (n=29 and n=22 patients), or in patients receiving chemotherapy and/or allogeneic transplantation or growth factors (n=10). Standardized FCM (lyse-stain-wash) and cytogenetics/FISH procedures were performed according to ELN guidelines at the TU of Dresden, VUMC of Amsterdam, UH of Guadalajara and UH of Bristol. Cytogenetics/FISH analysis was considered the gold standard. All of the applied FCM-scores were propagated by the ELNets MDS working group. Additionally, hematological improvement of the erythroid lineage (Hi-E) was evaluated (Cheson et al. 2006).

Results: The del(5q)-FCM-score reflected best the disappearance / presence of the cytogenetic abnormality del(5q) with a sensitivity of 88% and a specificity of 89%. This was confirmed if only MDS with del(5q) as a single abnormality or only MDS treated with Lenalidomide were evaluated separately (sensitivity: 98% and 100%; specificity: 85% and 75%). The use of the Ogata-score considering almost only abnormalities of the myeloid progenitors, ended up with a slightly lower sensitivity (86%) and specificity (81%). The new iFS analyzing progenitor cells, granulo-, mono-, and erythroleukemia showed a comparably high sensitivity (83%) but a slightly impaired specificity (72%). FCSS, analyzing dyspoiesis of multiple cell lineages, showed a response in less than half of the all investigations being in cytogenetic CR (sensitivity: 41%), but revealed a higher specificity (91%). The analysis of Hi-E was high sensitive (81%) but not as specific (62%). Next, we investigated the potential prognostic impact of response monitoring using various FCM-scores compared to cytogenetics. Considering all del(5q) MDS patients as well as only those patients with del(5q) as a single abnormality, cytogenetics and all tested FCM-scores showed a significantly longer OS for MDS responding to therapy. The highest prognostic impact disregarded the iFS-scores (p=0.0019) and Ogata-score (p=0.0002), respectively. Evaluating only MDS treated with lenalidomide, response monitoring using FCSS separated best the OS curves (p=0.0080). Finally, we combined the evaluation of Hi-E with cytogenetics or the FCM-scores. This resulted in an even better OS for MDS fulfilling two response criteria vs none (p=0.0001). The del(5q)-FCM-score had the highest prognostic impact for the combination of Hi-E plus the new iFS (p=0.0010).

Summary/Conclusions: Flow cytometry might serve as a rapid tool for response monitoring during treatment with disease-modifying drugs. All established FCM-scores allowed for an at least similar correctness of response prediction. The prognostic impact of the various FCM-scores seems to be even higher than that of cytogenetic response evaluation in this MDS subgroup. One reason might be, that most of the FCM-scores reflect not only the genetic background of the MDS but dyspoietic alterations in various cell lineages of the hematopoietic system.

E1169

EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION

M. Cabrero1, J.M. Hernandez-Sanchez1, J.M. Caballero1, C. chillon1, M. Martin-Izquierdo1, M. Abaigar1, A. Redondo1, F. Lopez-Cardenas1, E. Perez-Lopez1, L. Lorenzo-Corral1, R. Benito1, C. Robledo1, M. del Rey1, M. Gonzalez1, C. del Caño1, D. Caballero1, J.M. Hernandez-Rivas1, M. Diaz Campelo1
1Hematology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

Background: Allogeneic transplant (AlloSCT) is the only curative therapy for myelodysplastic syndromes (MDS). Unfortunately, relapse is the main cause of treatment failure. Evaluation of genetic mutations both at diagnosis and
Background: Azacitidine (AZA) is the standard of care for patients (pts) with higher-risk MDS; however, only 50% of pts respond and the majority will relapse within 2 years. All pts ultimately fail treatment due to primary or secondary resistance. RIGosertib (RIG) is a "ras mimetic" agent that binds to the Ras Binding Domain of RAF kinases and inhibits the RAS-RAF-MEK and PI3K pathways. Initial results of an ongoing Phase III study with RIG combined with AZA or AZA alone with MDS demonstrated a response rate of 26% (7/27) in pts following hypomethylating agent (HMA) failure in 142 HMA naïve pts (Navada et al ASH 2016).

Aims: To investigate the in vitro effects of RIG combined with AZA or vorinostat (VOR) on epigenetic and stem cell pathways on two cell lines: AML (BW90), MDS (MDS-L) and on pt bone marrow samples.

Methods: We investigated the in vitro effects of RIG combined with AZA or vorinostat (VOR) on two cell lines: AML (BW90), MDS (MDS-L) and on pt bone marrow samples treated on the phase I/II study, obtained prior to and after one cycle of AZA and RIG.

Results: Treatment with RIG alone altered global histone post-translational modifications (PTMs) including methylation (H3K4me3, H3K4me2, H3K27me3, H3K27me2) and acetylation (H3K9ac, & H3K18ac) levels associated with transcriptional activation or repression in both the cell lines and pt samples. Q-PCR studies demonstrated that individual treatment of BW90 and MDS-L with RIG or combined with AZA or VOR in sequential treatment (AZA/RIG, RIG/AZA, VOR/RIG or RIG/VOR) altered DNA methyl transferases (DNMT1, 3a and 3b), the class I, II and IV histone deacetylases (HDACs), and chromatin remodeler (KDM2a, SET1, JMJD3 and LRWD1) transcript levels in a cell line specific context. Sequential treatment of RIG with AZA or VOR demonstrated differential effects on the association of Pol II with the promoter regions of the genes involved

E1171 UNEXPLAINED CYTOPENIAS IN HOSPITAL: INDICATIONS AND BENEFITS OF NEXT-GENERATION SEQUENCING

D. Beauvais1, B. Céline1, O. Nibourel2, C. Freundheme2

1Department of Adult Hematology, CHRU University Hospital of Lille, 2UMR-S 1172, Institute for Cancer Research of Lille, 3Biology and pathology center, Laboratory of Hematology, CHRU University Hospital of Lille, Lille, France

Background: Unexplained cytopenias (UC) are common problems during hospitalisation, particularly in elderly patients. If there is no evident cause, myelodysplastic syndrom (MDS) is frequently suggested and a bone marrow aspiration is performed. Next-generation sequencing (NGS) reveals MDS-associated somatic mutations but their significance are discussed. In our centre, NGS was systematically realized in the context of unexplained cytopenias.

Aims: The objective of this study was to explore results of NGS in practical routine in the context of UC and to precise if some groups of patients could more specifically benefit of NGS.

Methods: All patients in our centre with analysis of NGS performed in blood or in bone marrow in a context of UC were included. Exclusion criteria were: patients under 18 years, monocytosis >1000/mm3, excess of blasts, history of hematological malignancy disorder. Patients were included in group "positive NGS" if at least one significant mutation (no SNP) was found on 25 genes (CEBPA, CBL, DNMT3A, ET6V, E2H2, ID1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RIT1, RUNX1, STBP1, SF3B1, SRSF2, TE2T, TP53, U2AF, WT1, ZRSR2). Clinical and biological criteria were reported from local database. All patients gave consent.
Azacitidine and decitabine has been suggested by several authors. Yet, the crucial activating enzymes with clinical and importance in determining resistance to azacitidine.

Correlation of the expression of nucleoside transporter, activating and dis- importation was significant (p=0.006). Normal karyotype (78.1%) was comparable in the two groups (p=0.352). Cirrhosis and/or portal hyperten- sion were comparable in the two groups (14.1%, p=0.092) as well as mean serum creatinine (p=0.024). In multivariate analysis, age >70 years (p=0.0015) and platelets >15000/mm³ (p=0.0213) remained significantly associated to positive NGS (Table 1). In “positive NGS” group, 1 (58.5%), 2 (32.1%) and 3 (7.5%) or 4 (1.9%) mutation(s) were found per patient. Most frequent mutations were TET2 (25.9%), DNMT3A (12.3%), SF3B1 (12.3%), ASXL1 (12.3%), SRSF2 (8.6%), U2AF1 (4.9%), TP53 (3.7%) and ZRSR2 (3.7%). Other mutations were reported in less than 3 patients. As expected in this elderly population, if a unique mutation was found, TET2 and DNMT3A were predominant (35.5% and 25.8% respectively) but interestingly mutation R882 of DNMT3A was found in 25.8% respectively and interestingly mutation R882 of DNMT3A was found in 2.5.8% respectively but interestingly mutation R882 of DNMT3A was found in only one patient. Sideroblasts were found>15% in 46.2% of patients with a mutation of SF3B1, SRSF2, U2AF1 or ZRSF2.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Negative NGS</th>
<th>Positive NGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (months), mean±SD</td>
<td>65±20.5</td>
<td>63±20.5</td>
<td>66.6±20.5</td>
</tr>
<tr>
<td>Age (months), median</td>
<td>73</td>
<td>71</td>
<td>73</td>
</tr>
<tr>
<td>Age (years), median</td>
<td>71 (41.79%)</td>
<td>69 (43.79%)</td>
<td>73 (43.79%)</td>
</tr>
<tr>
<td>hCNT3, UCK1, UCK2, hENT1, hCNT3</td>
<td>103</td>
<td>68</td>
<td>35</td>
</tr>
<tr>
<td>TERT, TERCI, RRM1</td>
<td>151</td>
<td>86</td>
<td>65</td>
</tr>
<tr>
<td>hENT1, hCNT3</td>
<td>132</td>
<td>80</td>
<td>52</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>126</td>
<td>80</td>
<td>46</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>123</td>
<td>80</td>
<td>43</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>120</td>
<td>80</td>
<td>40</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>117</td>
<td>80</td>
<td>37</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>114</td>
<td>80</td>
<td>34</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>111</td>
<td>80</td>
<td>31</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>108</td>
<td>80</td>
<td>28</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>105</td>
<td>80</td>
<td>25</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>102</td>
<td>80</td>
<td>22</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>99</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>96</td>
<td>80</td>
<td>18</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>93</td>
<td>80</td>
<td>16</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>90</td>
<td>80</td>
<td>14</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>87</td>
<td>80</td>
<td>12</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>84</td>
<td>80</td>
<td>10</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>81</td>
<td>80</td>
<td>8</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>78</td>
<td>80</td>
<td>6</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>75</td>
<td>80</td>
<td>4</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>72</td>
<td>80</td>
<td>2</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>69</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>66</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>63</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>60</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>57</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>54</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>51</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>48</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>45</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>42</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>39</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>36</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>33</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>30</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>27</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>24</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>21</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>18</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>15</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>12</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>9</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>6</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>hCNT3, TERT, TERC, RRM1</td>
<td>3</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>UCK1, UCK2, hENT1, hCNT3</td>
<td>0</td>
<td>80</td>
<td>0</td>
</tr>
</tbody>
</table>

Results: 156 patients were included between January 2014 and December 2015 with a mean age of 68 years [65.8-70.3] and 47.4% of men. 127 patients (81.4%) had a bone marrow analysis. 53 patients (34.0%) were reported in the group “positive NGS” and 103 patients (66.0%) in the group “negative NGS”. In univariate analysis, significant variable associated with “positive NGS” were age (<10-7), no history of auto-immune disease (p=0.002), hemoglobin <12g/dL (p=0.017), platelets >150000/mm³ (p=0.015), >10% dysplastic cells in erythroid (p=0.012) and granulocytic lineage (p=0.034). Trend test on dys-...
FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES

T. Asayama1,2, M. Ishibashi1, H. Tamura1, Y. Kunibayashi-Hamada1, N. Takada-Okuyama1, A. Onodera-Kondo1, K. Moriya1, N. Yokose2, K. Inokuchi1,1DOnors (n=9) using ELISA. 1Department of medicine, Nippon Medical School, Tokyo, 2Division of hematology, Department of internal medicine, Chiba Hokusoh Hospital, Chiba, Japan

Background: T-cell immunoglobulin and mucin domain-3 (Tim-3) is an inhibitory immune checkpoint molecule that suppresses adaptive immunity by binding with galectin-9 (gal-9). The Tim-3−gal-9 pathway is associated with self-renewal of leukemic stem cells in acute myeloid leukemia (AML), although the function of the axis in myelodysplastic syndromes (MDS) remains unclear.

Aims: To clarify the expression and function of Tim-3 and clinical impact of the ligand gal-9 in MDS.

Methods: 1) We evaluated Tim-3 expression on CD45-gating blasts of bone marrow mononuclear cells (BMMCs) in 20 patients with MDS and AML transformed from MDS (AL-MDS), 12 healthy controls, and 4 MDS cell lines using flow cytometry (FCM). 2) To investigate Tim-3 induction, MDS cell line F-36P cells were co-cultured with the culture supernatant of human stromal cells and MDS-related cytokines. 3) To elucidate the functions of Tim-3 on MDS cells, F-36P cells were divided into Tim-3+ and Tim-3−fractions with FACS sorting and their differential gene expression was determined with oligonucleotide microarray analysis. 4) To investigate the proliferative potential of Tim-3 signaling, intracellular Ki-67 expression in F-36P cells was evaluated using FCM when their differential gene expression was determined with oligonucleotide microarray analysis. 5) Soluble gal-9 was measured in culture supernatant of MDS cell lines cultured with TGF-β1 and the proliferative potential of Tim-3 signaling evaluated.

Results: 1) Tim-3 expression was observed on monocytic and CD45-gating blasts in MDS BMMCs in all and 4 of 5 MDS cell lines. In MDS patients, Tim-3 expression levels on blasts were markedly higher than in controls and MDS patients without blasts. In F-36P cells, Tim-3 expression may be expressed cell line-related complexed with the culture supernatant of human stromal cells and the MDS-related cytokines transforming growth factor-β (TGF-β). Tim-3−cell surface protein and mRNA expression in MDS cell lines was induced by co-culture with TGF-β. The Tim-3 induction was abrogated by adding the TGF-β receptor I kinase inhibitor SD208. 3) Microarray analysis showed 572 upregulated genes (>2-fold difference) and 304 downregulated genes (<0.5-fold difference) in Tim-3+ F-36P cells compared with Tim-3−cells, and ingenuity pathway analysis of these genes revealed upregulation associated with cell proliferation and antiapoptotic responses in Tim-3+ cells. 4) The blockade by anti-Tim-3 antibody decreased intracellular Ki-67 expression in F-36P cells, suggesting that Tim-3 signaling induced MDS cell proliferation. 5) Soluble gal-9 was detected in culture supernatants of MDS cell lines and PBMCs obtained from MDS patients. Soluble gal-9 levels and gal-9 mRNA expression were upregulated by MDS-related cytokines interferon-γ and tumor necrosis factor-α. Plasma gal-9 levels were higher in MDS and AL-MDS patients than in healthy controls (P<0.0001). When MDS patients were divided into high (defined as >10 ng/mL) and low (≤10 ng/mL) gal-9 groups, the high group had poorer overall survival compared with the low group (P=0.001). In refractory anemia (RA)/RA with ringed sideroblasts (RA-RS), the high gal-9 group had poorer overall survival compared with the low group (P=0.001), even in refractory anemia (RA)/RA with ringed sideroblasts patients (P=0.0002). Multivariate analysis revealed that a high gal-9 level was an independent poor prognostic factor (P=0.0017).

Summary/Conclusions: Our data suggest that Tim-3 expression and plasma gal-9 levels were upregulated in advanced-stage MDS. Tim-3 is associated with cell proliferation of MDS blasts, and higher plasma gal-9 is a poor prognostic marker in MDS. These molecules could play a key role in MDS disease progression.

E1177 SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL HYPMETHYLATING AGENT, SG1-1027, IN DECITABINE-RESISTANT CELL LINES E.-H. Hur1, D.R. Choi2, B.-K. Goo1, J.H. Moon1, E.-J. Choi1, H.-S. Park1, J.-H. Lee1, K.-H. Lee1, J.-H. Lee1

1Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2Internal Medicine, Chuncheon Sacred Heart Hospital, Inha University College of Medicine, Chuncheon, Korea, Republic Of

Background: We established azacitidine- and decitabine-resistant cell lines, MOLM-13A1 and MOLM/DEC-5 from MOLM-13, an acute myeloid leukemia cell line (Oncotargeted in preclinical DNA methytransferase (DNMT) 3B was upregulated in the resistant cell lines.

Aims: We tried to find out clues to overcome the resistance to hypomethylating agent (HMA).
Methods: Besides azacitidine and decitabine, three other agents (SGI-1027, zebularine, and gencitabine) are known as having hypomethylating effect. in vitro activities of the 5 HMA’s on HMA resistant cell lines (MOLM/AZA-1 and MOLM/DEC-5) were tested by cell viability assay using luminescent-based CellTiter-Glo system. Protein and mRNA levels of DNMT enzymes (1, 3A, and 3B) were assayed before and after treatment of each HMA. Proteosomal degradation and activation of NFκB were also determined to see the correlation with changes of DNMT’s.

Results: Although azacitidine and decitabine could suppress DNMT1 and DNMT3A in MOLM-13, the agents could not suppress DNMT enzymes in resistant cell lines. Inhibition of proteosomal degradation by bortezomib induced accumulation of DNMT enzymes in MOLM-13, whereas it did not accumulate the enzymes in MOLM/AZA-1 and MOLM/DEC-5. Phosphorylated Akt (p-Akt) was dramatically overexpressed in MOLM/AZA-1 and MOLM/DEC-5. SGI-1027 showed the lowest IC50 values for MOLM/AZA-1 and MOLM/DEC-5, and it suppressed the protein levels of all three DNMT enzymes. SGI-1027 could also decrease the level of p-Akt. GDC-0941, a PI3K inhibitor, suppressed DNMT1 and DNMT3A as well as p-Akt, but it could not decrease DNMT3B in MOLM/AZA-1 and MOLM/DEC-5. Cell viability assay showed the synergistic effects of combination of GDC-0941 and Nanaomycin A, a specific DNMT3B inhibitor, in MOLM/AZA-1 and MOLM/DEC-5.

Summary/Conclusions: DNMT levels of MOLM/AZA-1 and MOLM/DEC-5 were not dependent on proteosomal degradation. DNMT1 and DNMT3A might be regulated via PI3K-Akt pathway, while regulation of DNMT3B might be different from DNMT1 and DNMT3A. SGI-1027 appears to exert inhibitory effects on MOLM/AZA-1 and MOLM/DEC-5 by inhibition of both p-Akt and DNMT3B.

E1178

MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES

M. Mathieu1,2, S. Ancelet3, C. Lefebvre3, J. Arnaud4, C. Garrel5, M. Pezel5, Y. Wang2, P. Faure6, G. Szymanski3, B. Polack7, J. Y. Cahn1, J. M. Moulin5, S. Parv4,5
1Clinique Universitaire d’hématologie, CHU Grenoble Alpes, 2Equipe ThEx laboratoire TIMC, Université Grenoble Alpes, 3Laboratory of hematology, 4Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Chimie pharmacologique, CHU Grenoble Alpes, 5Plateforme de Microscopie Photonique - Cytométrie en Flux, Institut Albert Bonniot, Université Grenoble Alpes, 6LBFA, Inserm U1055, 7CEA-Grenoble, Bioscience and Biotechnology Institute, 8Laboratory of Fundamental and Applied Bioenergetics, and Environmental and Systems Biology, Université Grenoble Alpes, Grenoble, France

Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal stem cell disorders leading to ineffective hematopoiesis. Anemia is a frequent cytopenia in MDS and the majority of patients requires red blood cell (RBC) transfusion resulting in the development of iron overload (IO). Deferasirox (DFX) became a standard treatment of IO in MDS and seems to have positive effects on hematopoiesis with a reduced need of RBC transfusion.

Aims: Decipher the mechanisms of the potential improvement of erythropoiesis with DFX.

Methods: We report our in vitro data about the proliferation, cell cycle, apoptosis, erythroid differentiation, and cell signaling pathways concerning CD34+ hematopoietic stem progenitor cells from low risk MDS samples in a 2-step erythroid differentiation liquid culture with low dose DFX and iron overload.

Results: We observed a higher proliferation rate for cultures with 3µM DFX versus the control condition (p=0.038). In contrast, no increased proliferation was found with DFX>5µM and with other chelators used in the clinic. The higher proliferation rate with DFX 3µM was due to the combination of decreased apoptotic cells at day 10 (D10) (p=0.03) and D14 (p=0.007) and increased cycling cells at D10 (p=0.0001). Regarding clonogenic assays, there were more CFU-E colonies with DFX 3µM (p=0.04). Despite the low concentration of DFX, cells expressing DFX 3µM had a lower intracellular iron concentration measured by ICP-MS than control cells (p=0.019). Nevertheless, this decreased iron amount was not sufficient to activate cellular iron regulation by Iron Regulatory Proteins suggesting the absence of a direct effect of low dose DFX on iron homeostasis. Moreover, low dose DFX decreased intracellular and mitochondrial reactive oxygen species (ROS) at D14 (p=0.048 and p=0.03) and decreased the level of malonaldehyde (p=0.048), a product of lipid peroxidation. Then, we have investigated which signaling pathways were sensitive to DFX 3µM. We found an increased nuclear translocation of NFκB detected by both CM (p=0.04) and luciferase reporter assay (p=0.03). NFκB activation was absent in the knock-down (KD) of mitochondrial TRX (siTRX2) condition. Moreover, in non-iron overloaded medium condition, the level of ROS was not increased, and DFX in the TRX1 KD condition was not associated with NFκB activation. These results suggest that NFκB activation in this model is linked to TRX1 and regulated by an extremely fine control of ROS levels with a likely threshold effect.

Summary/Conclusions: Our study describes the pro-proliferative effects of low dose of DFX on erythroid progenitors in low risk MDS patients. These results provide a biological rationale for a clinical trial which will propose low dose of DFX in MDS patients, refractory to erythropoiesis stimulating agents.
E1179 EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC APPROACH OF MYELODYSPLASTIC SYNDROME
R. Invernizzi1,2, E. Travaglini1, R. Bastia1, I. Ambaglio1, F. Quaglia1, E. Boven1, M. G. Della Porta1, L. Malcovati1, M. Cazzola1
1IRCScs Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
2Division of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy

Background: According to WHO minimal morphological criteria for myelodysplastic syndrome (MDS) diagnosis, at least 10% of bone marrow (BM) cells of at least one hematopoietic lineage must show unequivocal dysplasia to be considered as dysplastic. Morphological abnormalities of erythroid cells include cytoplasmic Periodic acid–Schiff (PAS) positivity, but the diagnostic power of this cytochemical reaction is not yet fully clear.

Aims: The aims of our study were to evaluate the diagnostic significance of erythroblast PAS positivity in MDS and to investigate a possible correlation between levels of PAS positivity and other morphological and clinical features.

Methods: We retrospectively examined the results of the cytochemical PAS staining for glycogen in BM smears from 165 patients with MDS, 116 patients with non-clonal cytopenia and 49 healthy subjects. We developed a PAS score by counting 100 nucleated cells for the erythroid lineage and classifying them according to their degree of PAS reactivity. The discriminant power of both positivity rate and score for MDS identification was evaluated in comparison with that of the conventional morphological features of dyserythropoiesis; then, PAS positivity was included into the morphological scoring system we have previously defined (Leukemia 2015;29:66-75).

Results: PAS positive erythroblasts were observed in 104 (63%) MDS patients, 46 (40%) patients with non-clonal cytopenia, and 12 (24%) non-erythroid BM cells of BM smears. Erythroblasts PAS positivity in MDS and non-erythroid BM cells (p<0.001) or non-clonal cytopenias (p=0.0011) but not between healthy controls and non-clonal cytopenias (p=0.09). In MDS, both positivity rates (median 2%, range 0-33) and scores (median 2, range 0-53) were significantly higher than those in normal and pathological controls (p=0.0001 and p=0.0004 for positivity rate, p=0.0001 and p=0.0002 for score, respectively), without significant difference in relation to excess blasts or multilineage dysplasia. MDS patients with erythroblast PAS positivity rates and scores than MDS patients with ≤4% ring sideroblasts (RS) showed lower PAS positivity rates and scores than MDS patients with ≤4% RS (p=0.0332 and p=0.0412, respectively). In MDS, erythroblast PAS positivity was not influenced by SF3B1 mutation status.

In MDS, no significant relationship was detected between erythroblast PAS positivity and percentage of BM blasts, percentage of BM erythroblasts, dyserythropoiesis grading, or Hb levels, whereas an inverse correlation was noticed between PAS score values and inter-nuclear bridging (r=-0.23, p=0.0395). A ROC curve analysis allowed us to identify a PAS score value ≥1 (AUC=0.697, p=0.0008) and a PAS positive erythroblast percentage ≥1% (AUC=0.674, p=0.0034) as optimal cutoff to discriminate MDS patients from non-clonal cytopenias. Considering the most discriminant morphological features for dyserythropoiesis, the weight of both PAS positivity rate and score in the identification of BM dysplasia was lower than that of ring sideroblasts and megablasts, but higher than that of defective hemoglobinisation, nuclear lobulation, multinuclearity, cytoplasmic fraying, pyknosis, and inter-nuclear bridging. Integrating conventional parameters and PAS results significantly improved the sensitivity of our morphological scoring system.

Summary/Conclusions: The evaluation of BM erythroblast PAS positivity, easy to perform and inexpensive, may be useful in the work-up of patients with suspected MDS, especially if there is only unilateral dysplasia without ring sideroblasts or excess blasts.

E1180 A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
J. Á. Hernández Rivas1,*, B. Xicoy2, J. Bargay3, G. Sanz4, M.L. Amigó5, B. Arrizabalaga4, T. Bernal1, R. De Paz3, J. Sánchez2, B. Nomdedeu6, R. Invernizzi1,*, E. Travaglini1, R. Bastia1, I. Ambaglio1, F. Quaglia1, E. Boven1, M. G. Della Porta1, L. Malcovati1, M. Cazzola1, B. Slama7, S. Badre8, E. Gasal8, B. Mehta8, J. Franklin8
1University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany, 2Division of Hematology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece, 3Division of Hematology, Universitaetsklinikum Carl Gustav Carus der Technische Universitaet Dresden, Dresden, Germany, 4Department of Hematology, Universitaetsklinikum Carl Gustav Carus der Technische Universitaet Dresden, Dresden, Germany, 5Department of Hematology, Universitaetsklinikum Carl Gustav Carus der Technische Universitaet Dresden, Dresden, Germany, 6Department of Hematology, Universitaetsklinikum Carl Gustav Carus der Technische Universitaet Dresden, Dresden, Germany, 7Centre Hospitalier Departemental, Avignon, France, 8Amgen Inc., Thousand Oaks, United States

Background: There is a lack of PBO-controlled data for erythropoiesis-stimulating agents (ESAs) in MDS.

Aims: To evaluate darbepoetin alfa (DAR) in IPSS low/int-1 risk MDS (E1179).

Methods: Patients with MDS per WHO 2008 criteria with IPSS low/int-1 risk, anemia [hemoglobin (Hb)<10 g/dL], low transfusion burden, no previous treatment with ESAs or biologic response modifiers, and serum EPO<500mU/mL were randomized 2:1 to 24 weeks (wk) SC DAR 500 µg or PBO every 3 wk (Q3W), stratified by IPSS, then 48 wk open label (OL) DAR: follow-up is ongoing. Doses were withheld for Hb>12g/dL and decreased if Hb increased by >1.5 g/dL in 3 wk. Key endpoints were transfusion incidence and H-E per IWG 2006.

Results: Randomized patients [N=147] had median Hb of 9.3 (min-max:5.5-10.6) g/dL and median baseline EPO of 69 (min-max:4.3-497) mU/mL; WHO classification status and genotypes were similar in both arms. Key endpoints were transfusion incidence wk 5-24 was significantly reduced with DAR [DAR:36.1% vs PBO:59.2%, p=0.008]. In the 48-wk OL DAR period, 50.8% of patients had transfusions. More DAR patients achieved H-E in the double blind period [DAR:14.7% (11/75 evaluable) vs PBO:0% (0/35 evaluable), p=0.016]. In the 48-wk OL DAR period, 34.7% (34/98) of patients achieved H-E. Improved H-E and transfusion responses were seen with more favorable status for IPSS-R but not IPSS. In the 48-wk OL DAR period, dose frequency increased from Q3W to Q2W in 81% of patients; doses were held/reduced frequently. Safety results from this trial were consistent with the previous DAR phase 2 MDS trial, with similar AML rates in PBO and DAR arms.

Summary/Conclusions: In this phase 3, randomized, double-blind, PBO-controlled trial in anemic IPSS low/int-1 risk MDS patients, 24 wk of darbepoetin alfa Q3W significantly reduced transfusions and increased H-E rates with no new safety signals. Most patients met criteria to change to Q2W dosing during the 48-wk OL period, suggesting that Q2W dosing may offer more benefit. The true clinical benefit of darbepoetin alfa may have been underestimated due to the nature of IWG 2006 H-E criteria and trial design (Hb measured Q3W, dosing rules).

E1181 PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(SQ) AND TRANSFUSION INDEPENDENCY
1Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain, 2Department of Hematology, Hôpital Saint Louis, Paris, 3Department of Hematology, Centre Hospitalier Universitaire de Salamanca (Sanidad Castilla Y León), Salamanca, Spain, 4Department of Hematology, Hospital Germans Trias i Pujol (ICO Badalona), Badalona, Spain, 5Department of Hematology, Hospital Son Llatzer, Palma de Mallorca, Spain, 6Department of Hematology, Hospital Universitario La Fe, Valencia, Spain, 7Department of Hematology, Hospital de Cruces, Bilbao, Spain, 8Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain, 9Department of Hematology, Hospital La Paz, Madrid, Spain, 10Department of Hematology, Hospital Universitario Reina Sofia, Córdoba, Spain, 11Department of Hematology, Hospital Clinic, Barcelona, Spain, 12Department of Hematology, Hospital Universitario La Paz, Madrid, Spain, 13Department of Hematology, Hospital Universitario Miguel Servet, Huesca, Spain, 14Department of Hematology, Universitaetsklinikum Carl Gustav Carus der Technische Universitaet Dresden, Dresden, Germany, 15Department of Hematology, ICO Girona, Girona, Spain.
Background: Lenalidomide (LEN) is the first choice of treatment in low risk MDS patients with isolated del(5q) (MDS-del(5q)) and transfusion dependency (TD). Most of the low risk MDS-del(5q) patients diagnosed with anaemia and independent of transfusions developed TD or needed treatment for symptomatic anaemia early after diagnosis (median of 20 months, abstract 3180.ASH, 2016). LEN directly targets the del(5q) clone improving anaemia, quality of life and survival in these subset of patients. For these reasons, the use of LEN in patients with del(5q), anaemia and not TD seems to be very attractive. However, data about the use of LEN in MDS 5q- patients and transfusion independence (TI) are scanty, some retrospective studies suggest a benefit with the early use of LEN in this setting, but there is not already available any prospective and randomized study to confirm this likely advantage.

Aims: Our aims were to analyze efficacy and safety at week 12 of treatment with LEN vs Placebo in this setting of low risk MDS del(5q) patients with anaemia and not in TD at diagnosis

Methods: From 2010 to 2017, 47 patients have been included in the Sintra-Rev trial, a phase III, multicenter, randomized and double blind study with LEN (5mg/day) vs placebo [2:1 randomization] in Low – Int-1 risk (IPSS) MDS del(5q) patients with anaemia but TI. Preliminary results of efficacy (according to the IWG 2006 criteria for erythroid [HI-ER] and cytogenetic response [CyR]) and safety has been analyzed at week 12. Progression disease (DP) in the trial was defined as the development of TD.

Table 1.

<table>
<thead>
<tr>
<th>Age median</th>
<th>Gender M/F</th>
<th>Hb (g/dL)</th>
<th>Neutrophils (10^9/L)</th>
<th>Neutrophils in BM (%)</th>
<th>IPI risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>72 (37-89)</td>
<td>7/40</td>
<td>263 (104-1074)</td>
<td>2.18 (0.69-6.19)</td>
<td>18 (39-83)</td>
<td>Very low</td>
</tr>
</tbody>
</table>

Results: Main clinical characteristics are summarized in table 1, 85% were females, median age was 72 years (37-89) and most of patients (95%) had del(5q) as the only cytogenetic abnormality. Among 47 patients, only 38 were evaluable at week 12 (5 out of 38 discontinued the study, 3 due to DP, 1 due to toxicity and 1 for unknown reasons), 7 patients are currently receiving the first 12 weeks of treatment and 2 patients were excluded (screening failures). Regarding efficacy (w12), data from 36 patients were available. HI-ER was observed in 14/36 patients (39%), minor HI-ER (Hb increased <1.5g/dL) in 4/36 (11%), stable disease in 15/36 (42%) and PD (transfusion dependency) in 3 (8%). CyR was available in 30 patients: complete CyR was obtained in 12 (40%), partial CyR in 6 (20%) and no CyR in 12 (40%) patients. Safety information in 38 patients demonstrated that most patients (87%) developed any adverse events (AE) while only 42% of these were relevant (G3-4). Most G3-4 AE were hematological (neutropenia 38%) being non-hematological only in 5%. Seventeen percent of AE were reported in 5 patients: vestibular neuritis, congestive heart failure, polyarthritis, arterial hypertensive crisis, carpal arthritis, respiratory infection and chronic obstructive pulmonary disease exacerbation. All NAE were not related with the drug of study (LEN/Placebo).

Summary/Conclusions: In this study we confirm a high rate of erythroid and cytogenetic responses early after treatment with an adequate safety profile in the first 12 weeks of treatment with LEN or placebo.

E1182

MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM MDS ARGENTINEAN STUDY GROUP

A. L. Basquiera1, A. Enrico2, J. Arbelleiba1, E. Nucifora1, M. Iastrebnier3, G. Flores3, J. Gonzalez4, R. Crisp5, V. Novoa6, G. Alfonso7, M. de Dios Soler8, Y. Bestach9, I. Larrpa9, C. Beli10

1Hematology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires (CABA), 2Hospital Italiano de La Plata, La Plata, 3Sagrado Corazon, 4Hematology, Hospital Durand, Ciudad Autónoma de Buenos Aires (CABA), 5Hospital Nacional Prof A Posadas, Buenos Aires, 6Hospital Durand, Ciudad Autónoma de Buenos Aires (CABA), 7Hematology, Hospital Nacional Prof A Posadas, Buenos Aires, 8Hospital Curie, 9Instituto de Medicina Experimental (IMEX-CONICET), Ciudad Autónoma de Buenos Aires, Argentina, 10Laboratorio de Genetica Hematologica, Instituto de Medicina Experimental (IMEX-CONICET), Ciudad Autónoma de Buenos Aires (CABA), Argentina

Hematology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires (CABA), Hospital Italiano de La Plata, La Plata, Sagrado Corazon, Hematology, Hospital Durand, Ciudad Autónoma de Buenos Aires (CABA), Hospital Nacional Prof A Posadas, Buenos Aires, Hospital Durand, Ciudad Autónoma de Buenos Aires (CABA), Hematology, Hospital Nacional Prof A Posadas, Buenos Aires, Hospital Curie, Instituto de Medicina Experimental (IMEX-CONICET), Ciudad Autónoma de Buenos Aires (CABA), Argentina.

Background: Myelodysplastic syndrome (MDS) are the most frequent hematological malignancy in elderly patients. The impact of MDS burden on overall mortality remains controversial, moreover, after the incorporation of hypometabolism agents in the therapeutic armamentarium.

Aims: We aimed to analyze overall mortality and causes of death in our population of patients with MDS.

Methods: A retrospective analysis of patients with MDS reported to Argentinean MDS registry and a previous study from Academia Nacional de Medicina. Causes of death were classified in: acute myeloid leukemia (AML), infections, bleeding, solid tumor, cardiovascular, transplant related mortality (MRT), others and unknown. AML, infections and bleeding were considered as MDS-related mortality. Causes of death were analyzed using cumulative competitive events curves with Gray test and Fine-Gray for proportional hazard regression was used for the multivariate analysis.

Results: From 1981 to 2016, 1040 patients with MDS were recorded; 717 out of 1040 (69%) were diagnosed after 2006. Median age of patients was 70 years (range 14-96) with 58% (56%) being male. MDS was primary in 574 patients (94%). Median follow-up of 25 months (range: 1-170 months) for the surviving patients. The cumulative incidence of overall mortality was 20% at 12 months (95%CI 2-22), 37% at 24 months (95%CI 3-40) and 59% at 60 months (95%CI 5-63). The incidence of overall mortality did not significantly differ along the years of diagnosis (p=0.291) neither according to age group. Multivariate analysis for cumulative incidence of overall mortality found Charlson index (HR 1.38; p<0.001), sex (HR 1.45; p=0.014) and IPSS-R (HR 2.79; p<0.001) as prognostic variables. The main cause of death was AML accounting for 9% at 12 months (95%CI 7-11), 16% at 24 months (14-19) and 25% at 60 months (95%CI 22-26) of mortality for all patients. Infection and bleeding mortality remained the second and the third cause of death respectively. MDS-related mortality was 16% at 12 months (95%CI 13-18), 29% at 24 months (95%CI 26-32) and 44% at 60 months (95%CI 40-48); this incidence was not different by year of diagnosis. MDS-related mortality remained the main cause of death in all IPSS-R groups and in all Charlson index categories. Multivariate analysis for cumulative incidence of MDS-mortality found Charlson index (HR 1.29; p=0.02), IPSS-R (HR 2.88; p<0.001) and sex (HR 1.47;p=0.03) as independent variable. Age (p=0.034) and IPSS-R (p<0.001) were associated with AML-related mortality. A total of 56 patients underwent allogeneic transplant; cumulative incidence of MRT for all cohort was 0.5% at 12 months (95%CI 0.2-1.2) and 1.4% at 24 months (95%CI 0.8-2.4). Only male sex was associated with a higher cumulative incidence of mortality by solid tumor (p=0.001) and a Charlson index ≥2 was associated with higher cumulative incidence of cardiovascular mortality (p=0.021).

Summary/Conclusions: In this large cohort of patient with MDS we demonstrate that MDS-related causes are the leading cause of death along all IPSS-R groups. The absence of difference in mortality along the years of diagnosis highlights the necessity of better treatments for these patients.

E1183

PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN 105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK OF AML-EVOLUTION AND SURVIVAL

F. Marco De Lucas1, Z. Diez Gallarreta1, B. Blázquez1, P. Ieus1, B. Dávila1, C. Barreñetxea1, A. Blanco1, B. Barreira2, S. Herráez1, I. Capel3, I. Leal1, J. Uriarte1, C. Alonso Caballero1, J.L. Rodriguez1, J.A. Márquez1, J. A. Márquez1, 1Hematología, 2genetica, Hospital Universitario Basurto, 3Facultad De Medicina Uvp, Bilbao, Spain

Background: Diagnosis of myelodysplastic syndromes (MDS) remains a challenge, specially in patients with scant displastic morphology features and/or in the absence of cytogenetic changes. Multiparametric flow cytometry (MFC) findings have been recognized as a co-criterion for the diagnosis of MDS and have also demonstrated prognostic value in some studies. Nevertheless, this diagnostic tool is not fully implemented for the study of MDS in many centers and data from real life out of investigational studies are few.

Aims: To prospectively assess the value of MFC in the diagnosis of MDS in our center and correlate its findings to the clinical outcome of patients in terms of overall survival, transfusional needings, risk of hospitalization and evolution to acute leukemia.

Methods: We studied bone marrow samples from 105 consecutive patients submitted to our hospital between January 2013 and April 2015 because of one or more cytopenia and suspicion of MDS. Cytomorphology of every sample
was evaluated by at least two morphology experts and a consensus diagnostic of MDS was confirmed. MDS-suspected or MDS-excluded was emited. MDS was performed applying at least five-colour staining and a numerical score was calculated for every patient following criteria defined by Ogata et al (Blood. 2006 Aug 1; 108(3):1037-44), with a score >=2 suggesting MDS. Conventional karyotype and FISH employing probes to detect usual 5q-, 7q-, 8, 20q- and del7q by FISH (p=0.085). In the subset of patients with MDS-suspected but not confirmed by morphology, the presence of a MFC score >=2 was significantly associated with a poorer overall survival (log-rank p=0.012), with all MFC score 2 patients alive after a median follow-up of 35 months. There was also a trend to statistical association between MFC score and overall survival in the whole series of patients (log rank p=0.053). Interestingly, there was a striking difference in risk of evolution to AML according to MFC findings (log rank=0.013), with a 100% of patients free from this complication in the group of patients with MFC score <2.

Summary/Conclusions: MFC analysis of the bone marrow provides useful information in the diagnosis of MDS which can be specially helpful in the subset of patients with inconclusive morphological findings, showing a strong correlation in this group of patients with clinical outcome in terms of risk of evolution to AML and overall survival.

E1185
INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN MYELODYSPLASTIC SYNDROMES

M. Eaddy1, R. Fram1, D. Faller1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, 2Xcenda, Palm Harbor, United States

Background: Myelodysplastic syndrome (MDS) can be associated with immunologic disorders, including autoimmune cytopenia and Coombs positive or negative (C+) hemolytic anemia. Abnormally expanded T-cells can be detectable in the peripheral blood of patients with MDS and can be used as a diagnostic marker in MDS. We evaluated the prevalence and healthcare utilization (HCU) of US HR-MDS patients treated during routine care.

Methods: Newly diagnosed adult HR-MDS patients who initiated first-line therapy were identified from Optum, a large US claims database, between 1/1/08 and 10/31/15. HR status was based on ICD coding: ≥1 inpatient claim or ≥2 outpatient claims with ≥1 HR-MDS (ICD-9/10 code (ICD-9 code: 283.73; ICD-10 codes: D46.20, D46.21, D46.22). The first MDS claim served as the index date. Exclusion criteria included: lack of continuous enrollment in medical/pharmacy benefits in the 12 months prior to index date (baseline period), presence of other primary cancer, or receipt of any chemotherapy or SCT during baseline period, and MDS-related medical services were the main drivers of costs decreasing from Year 1 to Year 2. As treatment of HR-MDS continues to evolve, economic impact and HCU need to be further investigated in this patient population.

Table 1.

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average HCU</td>
<td>$17,337 (SD: $19,686)</td>
</tr>
<tr>
<td>Average PPPM cost</td>
<td>$17,361 (SD: $19,747)</td>
</tr>
<tr>
<td>Average PPPM costs decreased from $10,557 (SD: $11,164) to $6,530 (SD: $7,406) while non-MDS-related services decreased fairly constant in both years. Chemotherapy and supportive care medical services were the main drivers of decreased MDS-related medical costs, also decreasing from Year 1 to Year 2. Non-MDS-related costs accounted for a smaller portion of the overall medical PPPM costs ($6,124 [SD: $15,158]) and remained relatively similar in Years 1 and 2.</td>
<td></td>
</tr>
</tbody>
</table>
Summary/Conclusions: Treatment with IVIG of Cz hemolytic anemia and pancytopenia associated with T-cell immune-clones and MDS was safe and yielded high rates of durable response on all lineages and on hemolysis. Transfusion independency and reduction/discontinuation of corticosteroids for chronic hemolysis make this drug a valuable option not only in LR but also in HR conditions. Next, the 5-year OS rate was higher in the responders to IVIG: 53% compared to 30% (p=0.08).

Table 1.

E1186
DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES
1Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, 2Division of Population Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States, 3Hematology Unit, Sant’Eugenio Hospital, Rome, 4Division of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, 5Division of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, 6Hematology Unit, Sante Eugenio Hospital, Rome, 7Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, 8Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria, 9Department of Medicine I, University Hospital Dresden Carl Gustav Carus, Dresden, Germany, 10Institute of Hematology, Catholic University of Sacred Heart, 11Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, 12Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria, 13Department of Medicine I, University Hospital Dresden Carl Gustav Carus, Dresden, Germany, 14Institute of Hematology, Catholic University of Sacred Heart, 15Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, 16Department of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, 17Hospital Universitario de Canarias, 18Institute of Hematology, Catholic University of Sacred Heart, 19Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, 20Department of Internal Medicine V, University of Padua, 21Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, 22Clinica Ematologica, IRCCS AOUM San Martino IST, Genova, 23Department of Hematology, San Gerardo Hospital, Monza, 24Hematology Unit, Blood and Marrow Transplant Unit, Ospedale Ospedaliero di Imermini Regionale “Armando Businco”, Cagliari, Italy, 25Department of Hematology, University of Cagliari, Cagliari, Italy, 26Hematology Unit, Ospedale di Careggi, Firenze, 27Department of Hematology and Oncology, AOU Policlinico-Vulcania, 28Division of Hematology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States, 29Department of Internal Medicine, University of Padua, 30Department of Hematology, IRCCS Policlinico San Matteo Foundation, Pavia, 31Clinica Ematologica, IRCCS AOUM San Martino IST, Genova, 32Department of Hematology, San Gerardo Hospital, Monza, 33Hematology Unit, Blood and Marrow Transplant Unit, Ospedale Ospedaliero di Imermini Regionale “Armando Businco”, Cagliari, Italy, 34Department of Hematology, University of Cagliari, Cagliari, Italy, 35Academic Medical Center/University of Amsterdam, Department of Medical Psychology, Amsterdam, Netherlands

Background: The clinical presentation of myelodysplastic syndromes (MDS) is highly variable, and the ability to accurately predict outcomes is critical. Current prognostic systems for these diseases are based on traditional clinical, pathologic and laboratory indicators.

Aims: We aimed to develop and validate a new prognostic index for advanced MDS by including self-reported fatigue severity into a well-established clinical risk classification: the International Prognostic Scoring System (IPSS).

Methods: Untreated patients (n=280) were recruited at the time of diagnosis of advanced MDS from 37 hospitals in nine countries to create the index. The index was then applied to an independent cohort including pre-treated MDS patients from the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts (USA; n=189). Patients in both the International and DFCI cohorts were adults with newly-diagnosed intermediate-2 or high-risk MDS (advanced disease on the IPSS). Patients were enrolled regardless of age, comorbidity, performance status and progression status. All completed a baseline health-related quality of life assessment. Data from international and DFCI cohorts were independently collected and analyzed. Univariate and multivariate Cox proportional hazards (PH) regression analyses were performed to estimate hazard ratios with 95% Confidence Intervals (CIs). Discrimination and calibration were evaluated for both the development (internal validation) and independent DFCI datasets (external validation). Statistical significance for all tests was set as two-sided α=0.05.

Results: A new risk classification was developed, namely, the fatigue (FA)-IPSS(h). Whereas use of the standard IPSS in more advanced disease discriminates between two risk categories for untreated patients, the new fatigue FA-IPSS(h) classification was able to distinguish three survival outcomes for patients with distinct survival outcomes. Overall survival rates at 6 months, 1 year, and 2 years were markedly different among the three groups. To illustrate, one year survival was 80.3% (95% CI, 73.4;87.8), 60.5% (95% CI, 52.3;70.0) and 37.6% (95% CI, 23.9;59.1) for patients classified into Risk-1, Risk-2 and Risk-3 respectively. Median OS in DFCI data by FA-IPSS(h) risk was similar to that of the development cohort for each of the three risk groups, indicating good external calibration. Patterns of OS through 2 years were also distinct between risk groups as in the development cohort of untreated patients, with one exception: 2-year OS was similar for FA-IPSS(h) risk-3 and risk-2. Predictive accuracy of this new index was higher than the IPSS alone in both the development cohort (C-statistic, 0.61 vs 0.57) as well as in the independent cohort including pre-treated patients (C-statistic, 0.58 vs 0.54).

Summary/Conclusions: The FA-IPSS(h) is an additional prognostic tool that might enhance clinicians’ ability to provide more personalized treatment strategies both in untreated and pretreated advanced MDS patients. This analysis offers a model for integration of PROs in prognostic systems for patients with other cancers and advanced illnesses.

E1187
PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MARRROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: A SINGLE CENTRE STUDY
E. Giroak1, S. Maung1, K. Ewinski2, M. Jeffers2, B. MacDonagh3, J. Mchugh1, R. Desmond1, H. Enright1
1Department of Haematology, 2Department of Cellular Pathology, Tallaght Hospital, Dublin 24, Ireland

Background: Myelodysplastic syndromes (MDS) are defined in the WHO 2016 classification as a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, morphologic dysplasia in hematopoietic cells and peripheral cytopenia(s). They present as a diverse phenotype with some patients requiring mere observation while others require more intensive management due to significant marrow failure and the risk of development of acute leukaemia. The presence of significant marrow fibrosis has previously been shown to be a poor prognostic factor in patients with MDS, with reduced overall survival. Significant marrow fibrosis has also been associated with both the presence of the TP53 gene mutation and with p53 over expression, which is a known adverse prognostic risk factor in MDS patients.

Aims: To assess the presence of p53 expression in patients with moderate to severe marrow fibrosis (grade 2-3), observe its effect on overall survival in patients with marrow fibrosis, and determine whether the use of azacitadine had any impact on survival.

Methods: We conducted a retrospective study utilizing a hospital database of 247 patients with MDS diagnosed in a single center between 2000 and 2014. Of these patients, 200 had bone marrow trephine samples adequate for reticulin stain analysis, which was completed using the European consensus on grading bone marrow fibrosis (grades 0-3). P53 expression was examined using immunohistochemistry staining and assessed according to the modified quick scoring system. We then looked for an association between degree of marrow fibrosis and p53 expression. In patients with significant marrow fibrosis and p53 expression we examined overall survival and response to treatment with azacitadine.

haematologica | 2017; 102(s2) | 487
Results: Overall, no significant correlation was seen between expression of p53 and degree of fibrosis (p=0.25). However, degree of fibrosis predicted for overall survival in patients with p53 expression (median overall survival of 4 months in patients with both p53 over expression and significant fibrosis compared with median overall survival of 18 months in patients with p53 over expression without fibrosis, p=0.001). In patients who received azacitadine, those with high significant fibrosis and p53 expression had a significantly increased overall survival compared with those who did not receive azacitadine (4 month versus 1 month, p=0.002). Azacitadine treatment was not associated with increased survival in patients with p53 expression without fibrosis but these patients did have an overall increased survival compared to those with fibrosis (median survival 12 vs 37 months).

Summary/Conclusions: This study confirms that significant marrow fibrosis adversely affects overall survival in patients with MDS, including those with p53 over expression. Patients who received azacitadine had a significant increase in median survival. Although the numbers of patients who received azacitadine are small, the data suggests that patients with fibrosis may benefit from the use of azacitadine and large, randomized studies should be considered to study this further.

References

E1188

FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q) OR T8

M. Pereira1,2,*, G. Marques 3, J. Lima 3, R. Reis 3, A. Coelho 3, L. Jorge 3, M. Pereira1,2,*, G. Marques 3, J. Lima 3, R. Reis 3, A. Coelho 3, L. Jorge 3, 1Clinical Hematology Department, Coimbra University Hospital Centre, 2Faculty of Medicine, University of Coimbra, 3Clinical Pathology Department, 4Flow Cytometry Unit, Coimbra University Hospital Centre, Coimbra, Portugal

Background: Prognostication in Myelodysplastic Syndromes (MDS) using validated scores includes the detection of chromosomal aberrations by conventional karyotyping. When the latter is unavailable or unsuccessful, fluorescence in-situ hybridization (FISH) panels can be used. Although panels vary by laboratory, some of the most commonly used probes include the search for monosomy 5 or del(5q), monosomy 7 or del(7q), del(20q) and trisomy 8 (T8). In our Lab, FISH was historically performed on the source sample (Full Sample); since 2015, we have primarily performed the analysis on Fluorescence Activated Cell Sorting (FACS) separated blast cells.

Aims: In this study, we aim to analyze the benefit of using purified samples of blast cells for FISH analysis in MDS, when compared to full mixed cellularity samples.

Methods: We reviewed all samples analyzed in our laboratory between January 1st 2011 and February 28th 2017 in which a FISH panel was performed due to a suspicion of myelodysplasia, using probes for del(5q), del(7q), del(20q) and T8. The proportion of patients positive for the test, as well as the proportion of positive cells within a positive sample, were compared.

Results: We obtained valid results for 328 samples during the relevant time-frame, 39.6% of which were collected from female patients. FISH was performed after FACS in one third of samples (35.1%, n=115), starting in 2015. Considering the overall cohort, nearly a quarter of samples (23.8%) had at least one aberration in the four probes tested in this study. This proportion of aberrations was significantly higher in double in FACS compared to Full Sample (p<0.001). Del(5q) was present in 5.6% of the cohort; however, positivity was 8-fold higher in FACS patients, compared to Full Sample patients (12.3% vs 1.6%, p<0.001). Considering the percentage of positive cells in each sample, it doubled from 38.7±29.9% in the full sample to 71.8±28.1% after FACS, p<0.001. Del(7q) was similarly present in 5.7% of the cohort; however, in contrast, there were no relevant differences between FACS patients, 4.2% of whom had del(7q), and full sample patients (8.1%, p<NS). There were, however, differences in the percentage of positive cells within the sample, doubling from 32.1±11.2% in the full sample to 77.6±17.8% after FACS, p<0.001. Del(20q) was similarly present in 5.7% of the overall tested cohort; the asymmetry in results was marked, with a 36-fold higher proportion of positive findings after FACS (18.7%) compared to full samples (0.5%, p<0.001). The percentage of positive cells doubled from 15% in the single positive test in the full sample cohort, to an average of 35.5±22.2% after FACS. Finally, T8 was found in 10.2% in both full and FACS samples, p<NS. The percentage of positive cells once again doubled from 25.5±14.7% in the full sample to 53.3±28.1% after FACS (p=0.0008).

Summary/Conclusions: We found that one quarter of all patients who underwent a FISH panel workup for a suspected diagnosis of MDS presented with aberrations in at least one of the four selected probes, a proportion which was significantly lower (one fifth) when a full sample was analyzed, and significantly higher (one third) in FACS purified blast cells. Although the purification of the sample through FACS doubled the percentage of positive cells within each sample for all four probes, the likelihood of obtaining a positive result for del(7q) and T8 in the cohort was unaffected by the methodology used. In contrast, the use of a sorted sample greatly increased the proportion of positive findings in del(5q) and, especially, in del(20q), the two probes for which the basal positivity in full samples was lowest. The clinical value of this increased rate of detection of del(5q) and del(20q) remains unclear, since their prognostic utility has only been established for levels detectable by conventional karyotyping of a full sample.

E1189

COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NONERYTHROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS PATIENTS WITH ERYTHROID PREDOMINANCE

A. Sun1,2,*, Y. Yu1, T. Zhang1, Q. Wang1, D. Liu1, S. Chen1, D. Wu1,2
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background: Patients with erythroid predominance (50% erythroblasts, MDS-erythroid) compose a significant proportion of patients with MDS. The erythroid/myeloid subtype was divided from the AML category into MDS-erythroid by the 2016 WHO classification of myeloid neoplasms. At that time, there was no consensus on a more appropriate way of enumerating bone marrow (BM) blasts from TNCs or NECs in MDS-erythroid patients.

Aims: To clarify these questions, 1283 MDS patients were retrospectively analyzed in our center.

Methods: MDS-erythroid was observed in 27.0% of patients (346/1283), and these patients had similar clinico-pathological features and overall survival, with 93% cases of MDS with <50% ENCs.

Results: By calculating the percentage of BM blasts from NECs, 73 of 200 patients (36.5%) with MDS-erythroid who were diagnosed within WHO subtypes without excess blasts (EB) were moved into higher-risk categories and showed shorter OS than those who remained in the initial categories (P=0.041). Reclassification using the International Prognostic Scoring System-Revised (IPSS-R) by enumerating blasts from NECs, 40 of 168 (23.8%) MDS-erythroid patients with relatively lower risk were re-classified as higher-risk and had significantly poorer survival than those who remained in the lower-risk category (P=0.030). This was especially true for the intermediate risk group that was stratified by IPSS-R (unchanged patients vs shifted patients, P=0.007). However, the impact of enumerating BM blasts from NECs on classification and prognostication was not evident in all MDS patients.

Summary/Conclusions: In conclusion, our results suggested that enumerating the percentage of BM blasts from NECs significantly improved the prognostic assessment of MDS-erythroid, especially for patients within the intermediate risk group stratified by IPSS-R.

E1190

SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELODYSPLASTIC SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO STANDARD THERAPY

F. Schipperati1,2,*, A. M. Pelizzari1, E. Bor lenghi1, M. D’Adda1, E. Cerqua1, D. Marocolo1, G. Rossi1
1Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

Background: The discovery of danazol potential activity on telomere elongation in bone marrow failure has renewed interest in this drug. The treatment of cytopenia in myelodysplastic syndromes (MDS) and aplastic anemia (AA) patients who fail or are ineligible to standard therapies is an unmet medical need; however only dated reports on danazol use in this setting are available.

Aims: We report the results of treatment with danazol in patients with MDS and AA at a single institution.

Methods: From Jun-11 to May-15, danazol was administered to 31 consecutive patients (20 MDS and 11 AA). Criteria for treatment were non-severe AA (8), severe AA ineligible/refractory to immunosuppressive therapy or allogeneic transplantation (3), transfusion dependent (TD) lower risk MDS refractory to previous treatment (11), MDS with isolated thrombocytopenia <50x109/L (6) or with bone marrow hypoplasia and bicytopenia (3). Diagnosis was defined by WHO 2008 for MDS and according to Camitta (Blood 1975) for AA; response was assessed by IWG 2006 criteria.

Results: The characteristics of the patients are shown in the Table. All MDS patients and 8 AA patients were moved into higher-risk category by IPSS-R, except 2 and 3 patients respectively. Nineteen patients (12 MDS, 7 AA) received danazol at full dose (600mg daily). A 400mg daily dose was given to 12 patients, due to toxicity (4 MDS, 4 AA) or comorbidities (4 MDS). Median duration of treatment
was 19 months (mo) (1–66) in AA and 6 mo (1–60) in MDS. ORR was 73% and 50%, respectively. Age and hemoglobin levels impacted on response in AA. Hematological improvement was seen on all lines in 92% of cases, with a median time to best response of 3–5 mo on platelets and neutrophils and of 8–12 mo on hemoglobin. Interestingly, duration of response in MDS patients was significantly longer with a danazol dose of 600mg than with 400mg (p<0.001). Conversely, dosing did not impact on response to danazol in AA patients. Grade 2–3 toxicity was significantly higher in AA patients (p<0.05), 60% pretreated with IST. Adverse events included: hematotoxicity (3 G1, 1 G2, 3 G3), muscle pain/CPK elevation (3 G1, 2 G2), transient renal impairment (1 G1), hypoxemia (1 G1). Responders to danazol had a better survival in terms of OS and EFS in both groups (Figure 1).

Table 1.

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: Danazol was proved both effective and safe as treatment of cytopenia in MDS and AA patients refractory or ineligible to standard therapies. The daily dose of 600mg was more effective for MDS patients, whereas a lower dose of 400mg may have a better risk/benefit ratio in AA. Younger AA patients with less severe anemia were more likely to respond. Danazol use is particularly attractive in thrombocytopenic patients, where responses were rapid, but delayed responses may be expected also on anemia by using dana- zol for prolonged periods, when tolerated. Response to danazol is also poten- tially associated to a survival advantage, although these data should be con- firmed by larger prospective studies.

E1191

SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

Aims: We evaluated first-line treatment (1LT) choice and survival outcomes in a US cohort of HR-MDS patients engaged in routine care.

Methods: Newly diagnosed HR-MDS patients who were ≥18 years old and who had initiated 1LT were retrospectively identified from Optum, a large US claims database, between 1/1/2008 and 10/31/2015. HR status was based on ICD coding: ≥1 inpatient claim with an HR-MDS ICD-9/10 code (ICD-9 code: 238.73, ICD-10 code: D46.22, D46.20, G06.20), or ≥2 outpatient claims with ≥1 HR-MDS ICD-9/10 code. The first MDS claim served as the index diagnosis date. Exclusion criteria included: absence of continuous care for 12 months prior to index date (baseline period), presence of other primary cancer, or receipt of any chemotherapy or stem-cell transplant (SCT) during the baseline period. Exclusion criteria included: absence of continuous care for 12 months prior to index date (baseline period), presence of other primary cancer, or receipt of any chemotherapy or stem-cell transplant (SCT) during the baseline period. Follow-up ended after first HR-MDS claim (index date). For all treated HR-MDS patients with ≥60 days of follow-up on 1LT, 51% achieved transfusion independence. For all treated HR-MDS patients, median PFS and 2-year PFS rates were 12.3 months (95% confidence interval [CI]: 9.1, 14.9) and 27.0%, respectively. OS rate at 2 years was 59.1%. Patients who achieved transfusion independence had a higher rate of 2-year OS (65.2% vs 53.8%) and PFS (36.3% vs 25.7%), but neither were statistically significant.

Table 1.

<table>
<thead>
<tr>
<th>PFS from initiation of 1LT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
</tr>
<tr>
<td>Survival</td>
</tr>
<tr>
<td>OS</td>
</tr>
<tr>
<td>6 mo Focus</td>
</tr>
<tr>
<td>Intermediate</td>
</tr>
<tr>
<td>OS</td>
</tr>
<tr>
<td>2 yr Focus</td>
</tr>
<tr>
<td>OS</td>
</tr>
<tr>
<td>5 yr Focus</td>
</tr>
<tr>
<td>OS</td>
</tr>
<tr>
<td>10 yr Focus</td>
</tr>
<tr>
<td>OS</td>
</tr>
</tbody>
</table>

Results: 209 newly diagnosed HR-MDS patients initiating 1LT had outcomes identified; mean age was 73 years (standard deviation [SD]: 10.1) and 61.2% were male. In the 12 months prior to diagnosis, 27.3% of patients used MDS-directed supportive care (ie, colony stimulating-, erythrocyte-, or thrombopoietic growth factors; RBC or PLT transfusions; or hydroxyurea). 1LT with hypomyeloplas- tizing agents (HMAs) predominated in 89.5% of patients (azacitidine, 68.9% and decitabine, 20.6%); 8.6% of patients received an immunomodulator monotherapy; and 8.6% of patients underwent SCT during follow-up. Of the 169 treated HR-MDS patients with ≥60 days of follow-up on 1LT, 51% achieved transfusion independence. For all treated HR-MDS patients, median PFS and 2-year PFS rates were 12.5 months (95% confidence interval [CI]: 9.1, 14.9) and 27.0%, respectively. OS rate at 2 years was 59.1%. Patients who achieved transfusion independence had a higher rate of 2-year OS (65.2% vs 53.8%) and PFS (36.3% vs 25.7%), but neither were statistically significant.

Summary/Conclusions: Survival outcomes in routine clinical care were higher than reported in clinical trials, specifically in HR-MDS trials with azacitidine. Among patients able to achieve transfusion independence, a trend toward increased 2-year PFS and OS rates was observed, although statistical signifi- cance was not reached. Characteristics that contribute to variations in PFS and OS outcomes within the HR-MDS population need further investigation.

E1192

DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

Aims: To confirm pharmacokinetic (PK) and pharmacodynamic (PD) compa- rability of 20mg/m² IV-DAC administered D1-5 of a 28 day cycle with an entire cycle of ASTX727 given at the selected dose from phase I (35mg decitabine and 100mg of E7727).

Methods: Adult patients with Int-1/int-2 or HR MDS or Chronic Myelomonocytic Leukemia (CMML) were enrolled in a randomized cross-over Phase 2 study. Patients were randomized 1:1 to receive in the first 28 day cycle, either 5 days of IV-DAC or 5 days of ASTX727, followed by a cross-over to the other Cycle

Summary/Conclusions: Survival outcomes in routine clinical care were higher than reported in clinical trials, specifically in HR-MDS trials with azacitidine. Among patients able to achieve transfusion independence, a trend toward increased 2-year PFS and OS rates was observed, although statistical signifi- cance was not reached. Characteristics that contribute to variations in PFS and OS outcomes within the HR-MDS population need further investigation.
2. Cycles 3 forward were with ASTX727. PD were assessed with LINE-1 methylation measured on blood cells at baseline and days 8, 15, 21 and 28 in cycles 1 and 2. Full PK assessments of ASTX727 were performed on Days 1, 2 and 5 with sparse sampling on Days 3 and 4 and on Day 1 of IV-DAC. Modeling of 5 day exposures of ASTX727 and IV-DAC was created for each patient. Safety and clinical response were assessed on all patients.

Results: Of 50 randomized patients, 57 had matched PK and 46 had matched PD sample sets for the first 2 cycles. No significant differences were seen when comparing the randomized sequences for any parameters, so all assessments comparing ASTX727 and IV-DAC were performed independent of sequence. The geometric mean maximum demethylation was 9.9% for ASTX727 vs 8.4% for IV-DAC [Ratio = 1.18, p=0.04, 95% CI of 0.98-1.41]. The geometric mean AUC for IV-DAC was 161 ng*h/mL. The 5 day total geometric mean of the AUC (ng*h/mL) was 769 for ASTX727 and 805 for IV-DAC [(Ratio of oral over IV)=0.95, with a lower limit of 95% CI of 0.881]. Demethylation Cmax was higher for IV-DAC (189 ng/mL) than after ASTX727 (70 ng/mL) and 5.12 ng/mL). The Day 1 PK adverse events regardless of grade or causality were febrile neutropenia 34%, neutropenia 28%, thrombocytopenia 16%, fatigue 16%, and hypomagnesemia 18%. There were no reported GI adverse events greater than Grade 2 with ASTX727 regardless of relationship to treatment. A fixed dose oral administration of 35mg decitabine and 100mg E7727 (ASTX7727) emulates the AUC of IV-DAC over the 5 day treatment cycle and induces a similar degree of demethylation of LINE-1 sequences in blood cells compared to IV decitabine at 20mg/m2 dose. The preliminary safety profile is similar to what has been reported for IV-DAC and no major differences have been observed. All adverse events continue to be evaluated as the study data mature. This combination will be tested further as an alternative to parenteral administration of decitabine.

Summary/Conclusions: Patients treated with azacitidine (especially AML patients) had higher risk of infections during the first AZA cycle. All important infection predictive factors should be assessed before therapy. Patients possessing factors predictive for infection require special approach and predictive infection model should be developed in further analysis.

E1194
OVERALL SURVIVAL, INITIAL TREATMENT, AND TREATMENT DURATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME, A DETAILED POPULATION BASED STUDY
H. Rozema1,2, R. Kibbelaar2, N. Veeger2, E. Van Roon1,2, M. Hoogendoorn2
1Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen, 2Medical Centre Leeuwarden, Leeuwarden, Netherlands

Background: Population-based studies on myelodysplastic syndrome (MDS) containing detailed clinical information of patient characteristics, treatment and follow-up of the disease are scarce. Since 2005, all patients diagnosed with hematological malignancies in Friesland, a province in the Netherlands, are prospectively registered and followed by their clinicians in a population-based registry, the HemoBase. The registry provides representative population-based data on diagnosis, treatment and outcomes in an era where low-intensity treatment such as hypomethylating agents have become available for the elderly.

Aims: The objectives of this study were to determine the overall survival (OS) of patients with MDS and the effect of the variables gender, age, comorbidities, IPSS-R score (for MDS subtype according to WHO 2016 classification). Furthermore, the leukemia free survival (LFS), the initial treatment and the duration of first-line treatment were analyzed.

Methods: An observational, population-based study was performed using the HemoBase registry. The bone marrow biopsies and aspirates of all MDS patients diagnosed between 01-01-2005 and 31-12-2013 were independently and blindly reviewed by both the hematologist and hematologist-pathologist and classified according to the WHO 2016. Treatment categories were defined as intensive chemotherapy (IC) either combined or not combined with allogeneic stem cell transplantation, the hypomethylating agent azacitidine, the immunomodulatory agent lenalidomide, hydroxyurea or best supportive care (BSC) (blood transfusions, erythropoiesis-stimulating agents). Approval was obtained from the Medical Ethics Review Committee from Medical Centre Leeuwarden. Statistical analyses were performed with SPSS 19; survival analyses were used using Kaplan-Meier estimates.

Results: 217 patients (72.4% male, 66.8% >70 years old, median age 75 years, 27.2% Charison Comorbidity Index (CCI) score ≥3 at diagnosis) were included with a median follow-up duration of 70.2 months. 15.7% of the population had an IPSS score of ≥1.5 and 12.4% of the population had an IPSS-R score of ≥4.5. In 41.5% no cytogenetic information was available. MDS-RS, MDS-SLD/-MLD, MDS-EB, MDS-U and CMM were diagnosed in 11.5%, 14.7%, 36.4%, 27.2% and 10.1% of the population respectively. 18.4% showed progression towards acute myeloid leukemia (AML), IC, azacitidine, lenalidomide, hydroxyurea and BSC were the initial treatment in 5.1%, 13.8%, 1.4%, 9.7% and 66.4% of the patients respectively. Within 12 months 78.1% of all treated patients terminated their first-line therapy because of death (20.0%), refractory to treatment (18.3%) or disease progression (16.7%). A second treatment was initiated in 10.1% of patients. The median LFS was 18.2 months (95% CI: 12.6-23.8). The median OS of MDS patients in Friesland was 22.5 months (95% CI: 15.2-29.7). Univariate analysis showed an association between lower OS and male gender (HR for women: 0.54, p=0.008, 95% CI: 0.34-0.85), age >80 years (HR: 2.7, p<0.005, 95% CI: 1.6-4.6), CCI score ≥3 (HR: 2.0, p=0.011, 95% CI: 1.3-3.0), IPSS score ≥1.5 (HR: 2.3, p=0.004, 95% CI: 1.3-4.1), IPSS-R score ≥4.5 (HR: 5.7, p=0.0005, 95% CI: 2.4-2.4) and MDS subtype MDS-EB (HR: 1.8, p=0.016, 95% CI: 1.1-2.9).

Summary/Conclusions: This study provided complete and representative population-based data on overall survival and treatment of patients with MDS. Patients treated with azacitidine (especially AML patients) had higher risk of infections during the first AZA cycle. All important infection predictive factors should be assessed before therapy. Patients possessing factors predictive for infection require special approach and predictive infection model should be developed in further analysis.
suitable, but, at present, its safety is questioned in MDS patients. Furthermore, in clinical practice, danazol, an attenuated androgen, has been reported to have some ability to increase the platelet count in this context (Watell 1994; Chan 2002).

Aims: To assess efficacy and toxicity of danazol employed to improve severe thrombocytopenia in lower-risk MDS setting.

Methods: We retrospectively reviewed twenty-four patients affected by MDS and treated with danazol for thrombocytopenia. The initial dose was 600mg/day for all patients. The IWG criteria of response (Cheson 2006) were adopted. The outcome was observed every 3 months till 12th month. The overall response rate and the average platelet count or each time of observation were described. Progression free survival was estimated with the Kaplan-Meier product limit method, followed by the logrank test and by the Cox proportional-hazard regression.

Results: Of the 24 patients, 3 patients had a therapy-related MDS. At the starting time of danazol therapy, the IPSS was “low” in 9, “int-1” in 13 and “int-2” in 2 cases respectively; the IPSS-R was “very low” in 2, “low” in 11, “intermediate” in 7 and “high” or “very high” in 4 cases. In baseline at 14 patients the platelet count was lower than 20x10^3/mL, the average was 20x10^3/mL and the maximum value was 38x10^3/mL. The median dose was 600mg (range 200-600) also maintained at least up to 3 months (range 400-600). At 6 and 12 months the median dose therapy was 400mg (range 400-600 and 200-600 respectively). The response rate was 79.1% (19 responders on 24 treated). The average count increased as shown in Figure 1, over 60x10^3/mL after 6 months from the beginning of therapy and so maintained after 1 year. Only 3 patients lost the response at 187, 600 and 633 days respectively. The median survival was not reached in the presented series, and the probability to maintain the response is over 75% after two years from the beginning therapy in the responder patients (Figure 2). Adverse events recorded were as follows: moderate (grade 1 and 2) increase in transaminases in 4 cases (with reduction of danazol to 400mg/day in 2 of these); reversible cutaneous rash in 3 cases; amenorrhea in 1 case (the only fertile woman in the series); weight loss and loss of appetite in 1 case, weight gain in 1 case.

Summary/Conclusions: This series confirms the efficacy of danazol to improve platelet count in the most of patients with severe thrombocytopenia due to lower-risk MDS. In all patients with increased platelet count, the response was clinically significant. The median dose of 600mg should be maintained for at least 3 months to properly assess the effectiveness of therapy and then adjusted according to response and toxicity. The response may not be immediate, but seem to be reachable after 3-6 months of treatment. A responsive patients have short probability to loss the response, that may last for very long time. The toxicity profile of this drug is low. The mechanism of action of danazol in MDS patients remains unclear. Waiting for more information on the efficacy and safety of eltrombopag from the clinical trials in progress, danazol may be a good therapeutic option for these patients.
received supportive care with colony-stimulating factors (CSFs) (39.5% vs 28.5%) and either erythrocyte or platelet transfusions (69.8% vs 57.6%) during 1LT vs azacitidine-treated patients. Second-line therapy (2LT) was administered to 30 (14.4%) patients; the HMAs again predominated in 63.3% of patients (n=19). Of patients not receiving 2LT, 65 (31.7%) progressed to AML, 47 (22.9%) had <30 days of follow-up due to proximity to end of study (38 [80.9%] of these were on 1LT at end of study). 33 (16.1%) continued to receive some supportive care and, 21 (10.2%) died.

Summary/Conclusions: Most HR-MDS patients treated in routine care are treated according to guidelines, with the HMA, azacitidine, predominating. Underlying comorbidities and older age may influence whether or not to treat HR-MDS patients with 1LT. For treated HR-MDS patients, duration of 1LT did not differ with azacitidine and decitabine. However, use of certain MDS-related supportive care treatments varied by choice of HMA, with more decitabine-treated patients receiving CSFs and transfusions. Further research is needed to determine how these factors influence both clinical outcomes in a HR-MDS population.

E1197
APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING 8 TOOLS
S. Sandmann1,2, M. Karimi2, A. de Graaf3, B. van der Reijden3, E. Hellström-Lindberg4, J. Jansen3, M. Dugas1
1Institute of Medical Informatics, University of Münster, Münster, Germany, 2Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, 3Laboratory Hematology, RadboudUMC, Nijmegen, Netherlands

Background: For the use of next-generation sequencing in clinical routine same platform, on a different platform and expert-based review.

Methods: We aimed at developing a variant calling pipeline with both, high sensitivity and high PPV.

Aims: We aimed at developing a variant calling pipeline with both, high sensitivity and high PPV.

Results: When analyzing the training sets with only one of the eight variant calling tools and considering all variants - pathogenic as well as somatic - sensitivity ranges between 0.85 and 1.00 in case of set 1 and 0.47 and 0.99 in case of set 2. Although FreeBayes features highest sensitivity regarding both sets, it consistently features lowest PPV as well (set 1: 0.03, set 2: 0.02).

Combining the output of all variant calling tools leads to perfect sensitivity, while PPV is 0.03 for set 1 and 0.02 for set 2. Application of our apppreci8 pipeline led to a minor decrease in sensitivity (set 1 and set 2: 0.98), while PPV is significantly increased (set 1: 0.99, set 2: 0.94). The PPV of the apppreci8 output for both training sets is higher compared to each of the individual tools.

Analysis of the independent test set 1 leads to comparable results. Sensitivity of the individual tools ranges between 0.82 and 0.99, while PPV ranges between 0.02 and 0.91. Combining the output of all variant calling tools leads to sensitivity of 1.00 and PPV of 0.02. However, application of apppreci8 leads to variant calling results with sensitivity of 0.98 and PPV of 0.99. To test the robustness of our approach, we analyzed Roche 454 data, although the pipeline was exclusively trained on Illumina data. Regarding the individual tools sensitivity ranges between 0.91 and 0.99, while PPV ranges between 0.07 and 0.68. By combining the output of all variant calling tools, sensitivity increases to 0.99, while PPV is 0.05. Application of apppreci8 leads to sensitivity of 0.98 and PPV of 0.76.

Summary/Conclusions: To consider variant calling results in clinical routine, it does not seem appropriate to rely on the output of a single tool only. Instead, combining the output of several tools and applying a set of filters as it is done by our appreci8 pipeline leads to results with both high sensitivity and PPV. Nonetheless, variant calling results should, especially at allelic frequencies below 20%, always be viewed with criticism.

E1198
COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS ON THE EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH ADVANCED MDS
J. Cermak1,*, A. Vitek1, J. Maalouf-Soukupova1, M. Markova-Štastna1, P. Cetkovsky1
1Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic

Background: Hypomethylating agents (HMA) have been introduced as a promising agent in the treatment of elderly patients with advanced myelodysplastic syndromes (MDS) leading to a response in approximately 50% of patients. However, most of the patients relapse and estimated years survival is below 10%. Stem cell transplantation (SCT) still represents the only curative treatment even in elderly patients with advanced MDS and it is connected with long-term survival in 35-40% despite relatively high risk of transplant related mortality (25-30%).

Aims: The aim of the study was a retrospective analysis of results of the treatment of 59 elderly patients (50 years of age or older) with MDS RAEB-2 or with acute myeloid leukemia with multilineage dysplasia with less than 30% of bone marrow blasts (MDS RAEB-T according to the FAB classification) who received either HMA or underwent allogeneic SCT.

Methods: In the HMA group, 34 out of total 38 patients received azacitidine (Vidaza®) in the dose of 75mg/m2x7 every 28 days and 4 patients were treated with decitabine (Dacogen®) in the dose of 20mg/m2x5 every 28 days. Median number of cycles administered was 10.4 (range 3-31). An age and diagnosis matched transplanted group consisted of 21 patients, 9 patients were transplanted upfront, 12 patients were pretreated either with combination chemotherapy (10 patients) or with HMA (2 patients) and achieved CR prior to SCT. Ten patients received myeloablative conditioning and 11 patients were transplanted after reduced conditioning regimen.

Results: Hematologic response to HMA (CR,PR, hematologic improvement) was observed in 22 out of 38 patients in HMA group (57.9%), CR was achieved in 10 patients (31.8%). In SCT group, engraftment was reached in 20 out of 21 patients, 11 patients died after SCT ( 6 on complications related to SCT, 5 patients relapsed). No difference was observed between both the groups in 2 years estimated overall survival (OS), (42% for SCT vs 36% for HMA), a significant difference in favour of SCT was present in estimated 3 years and 5 years OS (42% and 38% for SCT vs 9% and 4% in HMA group, P=0.001). Median OS was 18.7 months in HMA treated group compared to 42.6 months in SCT group (P=0.02). In a recent analysis performed at 48 months after starting the treatment, 2 patients treated with HMA (5.3%) and 9 patients treated with SCT (42.8%) were alive, 23 patients in HMA group and 6 patients in SCT group relapsed. No significant differences in results and adverse effects of treatment were observed between patients aged 50-60 years and those older than 60 years in both HMA and SCT groups.

Summary/Conclusions: Our results confirm previous observations showing that despite a promising effect of HMA resulting in hematologic response in more than 50% of elderly patients with advanced MDS, allogeneic SCT still represents the only potentially curative treatment connected with long-term survival in a significant number of patients even in elderly MDS patients.
A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY, EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES

K. Ishizawa12, K. Usuki3, K. Ando4, Y. Ueda5, T. Kiguchi6, N. Uike78, Y. Onishi8, H. Iida9
1Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, 2Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, 3Department of Hematology, NTT Medical Center Tokyo, Tokyo, 4Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, 5Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, 6Department of Hematology, Chugoku Central Hospital, Fukuyama, 7Department of Palliative Care Medicine,Saga Medical Center Koseikan, Saga, 8Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, 9Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Background: Rigosertib, a novel phosphoinositide 3 kinase pathway inhibitor, induces G2/M arrest leading to the apoptosis of cancer cells and myeloblasts and is safe for and well tolerated by pts with low, intermediate-1, intermediate-2, or high-risk myelodysplastic syndromes (MDS).

Aims: The aims of the study were to assess the safety, efficacy, and pharmacokinetics of oral rigosertib and to determine the recommended dose (RD) for a Phase II clinical study in Japanese pts with recurrent/relapsed or refractory MDS.

Methods: We conducted a multicenter, open-label, Phase I clinical study of oral rigosertib. The key eligibility criteria were as follows: recurrent/relapsed or refractory MDS; age ≥20 or older; ECOG PS of 0 to 2; and no major organ dysfunctions. Rigosertib (280 and 560mg BID) was administered orally in one 21-day cycle (up to cycle 6) that consisted of the 14-day, twice-daily, oral administration term, followed by 7-day monitoring. The primary endpoint was dose-limiting toxicity (DLT). The secondary endpoints were 1) safety as assessed with adverse events (AEs) and laboratory results, 2) efficacy as assessed with the International Working Group 2006 criteria, and 3) pharmacokinetics.

Results: Between March 2013 and November 2014, 16 male and 3 female pts (median age: 70; range 25-80) were enrolled. ECOG PS was 0 in 7 pts and was 1 in 2 pts, and 3 and 6 pts were eventually assigned to the 280 and 560mg BID arms, respectively. According to the FAB classification, 4, 2, 2, and 1 pts were categorized to RAEB, RARS, RA, and RAEB-1, respectively. The prognostic factor according to IPSS was Int-1 risk in 4 pts (1 and 3 pts in the 280 and 560mg BID arms, respectively) and was Int-2 in 2 pts (2 and 3 pts in the 280 and 560mg BID arms, respectively). DLT occurred in 1 pt in the 280mg BID arm and in 2 pts in the 560mg BID arm: the former consisted of type 2 diabetes and grade 4 delirium, and the latter grade 5 urinary tract infection and grade 3 prolonged QT interval. Therefore, the RD for a Phase II clinical study in Japanese pts was determined to be 560mg BID. On day 11 of treatment, 1 pt in the 560mg BID arm died of grade 5 urinary infection whose relationship with the investigational drug was rated to “Definite”. The presumed cause of death was sepsis due to gastric shock caused by urinary tract infection. The mean counts of leukocytes, neutrophils, lymphocytes, and reticulocytes in the 280mg BID arm did not decrease along with increases in the number of cycles delivered but decreased slightly in the 560mg BID arm. Any changes of note were not found in other hematological items. One case of grade 3 neutropenia developed in the 280mg BID arm, and 1 case each of grade 3 laboratory abnormalities—increased alanine aminotransferase, increased aspartate aminotransferase, prolonged QT interval, neutropenia, and decreased hemoglobin—occurred in the 560 BID arm. The hematological remission rate was 11.1% (1 marrow CR, 1/9 pts), and the hematological improvement rate was 11.1% (1 HI-P: 1/9 pts). Among the PK parameters, inter-individual variability was observed in the Cmax and AUC. However, changes suggesting the accumulation of rigosertib during repeated oral administration (e.g., consistent increases in the Cmax and AUC) were not found.

Summary/Conclusions: The present chemotheraphy regimen of oral rigosertib was well tolerated. Our study indicates that the RD for a Phase II clinical study is 560mg BID in Japanese patients with recurrent/relapsed or refractory MDS.

E1200
NON-OVERLAPPING PROMOTER AND SUPER-ENHANCER DRIVEN PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA DISTINCT REGULATORY AXES

M. Fucili11, C. Lin11, M. Samur1, H. Avet-Loiseau11, K. Anderson1, J. Bradner4, N. Munshi1
1Dana Farber Cancer Institute, Boston, 2Baylor college of medicine, Houston, United States, 3Cancer research center, Toulouse, France, 4Novartis, Boston, United States

Background: We have previously reported that E2F1 and its heterodimerization partner DP1 promote MM tumor proliferation both in vitro and in vivo; and observed an inverse correlation between their expression and patient survival suggesting a role in MM pathogenesis. Moreover, E2F2 functional impairment by a dimerization inhibiting stapled peptide significantly affects myeloma tumor cell growth while sparing effect on normal components of bone marrow as well as normal plasma cells, suggesting an E2F2 dependency in MM cells.

Aims: In this study, our aim was to defined the regulatory landscape of E2F in MM to better understand how E2F1 and DP1 drive myeloma cell proliferation; and to define the relationship between promoter proximal transcription factor-associated gene expression and super-enhancer-driven transcriptional programs.

Methods: We integrated genetic perturbation with functional omics to define E2F role in MM. Global occupancy of E2F1 and DP1 in MM was evaluated by ChIP-seq analysis. E2F1 and DP1 genomic localizations were then integrated to MM reference genome. Enhancers and super-enhancers were mapped using ROSE2 (github.com/bradnerlab/pipeline). Read densities were calculated using bamliquidator (github.com/BradnerLab/pipeline/wiki/bamliquidator).

Results: Integration of E2F1 and DP1 genomic localization to MM reference genome revealed specific co-occupancy of the factors at promoters of active genes marked by H3K4me3, with a strong positive correlation between E2F1 and RNA Pol II increase at H3K4me3 binding sites. In contrast, active enhancers, as defined by promoter distal Mediator (MED1) peaks and marked by H3K27ac and BRD4, showed virtually no E2F binding. Prompted by these observations, we explored the transcriptional and functional interrelationship between E2F and BETs to identify their individual contribution to eventual functional effect in MM. Unbiased hierarchical clustering revealed distinct regulatory axes for E2F2 and BETs, with E2F2 predominantly localized to active gene promoters of growth/proliferation genes and BETs disproportionately at enhancer-regulated tissue specific genes confirming that these factors establish distinct target gene programs. At the extremes, we found less than 10% of genes were among the top 500 in BRD4 enhancer signal (i.e. SE-regulated) and top 500 E2F promoter signal. We hypothesized that the presence of BETs and E2F in distinct regulatory axes divides active genes in MM into those that can be selectively influenced by BET inhibition or E2F perturbation, but not both. In line with this we have observed that dual E2F and BET inhibition is synergistic for MM cell growth, both in vitro and in vivo.

Summary/Conclusions: In conclusions, our results highlight the existence of non-overlapping promoter and super-enhancer-associated dependencies in multiple myeloma, suggesting a sequestered molecular control that may be perturbed in cancer with potential for development of a promising therapeutic strategy.

E1201
ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND DISEASE SUBGROUPS

1Dana Farber Cancer Institute, Boston, United States, 2Cancer research center, Toulouse, France, 3Novartis, Boston, United States

In multiple myeloma (MM), next generation sequencing (NGS) has expanded our knowledge of genomic lesions, and highlighted a dynamic and heterogeneous composition. Despite a growing number of cases the full potential of NGS studies has not been exploited so far.

Myeloma and other monoclonal gammopathies - Biology

haematologica | 2017; 102(s2) | 493

Madrid, Spain, June 22 – 25, 2017
Aims: We used a custom target pulldown (TPD) approach on a large cohort of MM patients at diagnosis, with homogeneous treatment and long follow-up, to further our understanding of the landscape of driver lesions in MM and how this can be used to improve prognostication and disease classification.

Methods: We used a custom-designed SureSelect pulldown strategy (Agilent Biotechnologies) to target 246 genes implicated in MM or cancer in general; 2538 single nucleotide polymorphisms; the immunoglobulin heavy chain (IGH) locus. We sequenced unmatched DNA from CD138-purified plasma cells from 418 patients with a median follow-up of 5.4 years using Illumina HiSeq2000 machines. We applied algorithms developed in-house to detect driver genomic events, filtering out potential artifacts and germline variants. We then ranked each mutation on its likelihood of being oncogenic.

Results: We identified 197 driver events including genes, aneuploidies and IGH translocations (IGH-Tx), median of 6 per patient. Gene mutations where found in >99% of patients. At least one oncogenic mutation of a known driver gene previously identified (KRAS, NRAS, TP53, FAMM6C, BRAF, DIS3, PRAF3, SP40R, RPS4) was found in 64%, with a long tail of infrequently mutated genes with uncertain significance. Karyotypic class was assigned in 80% of patients, with 9% of hyperdiploid cases also showing an IGH-Tx (mostly t(4;14)). IGH-Tx and aneuploidies dominated the MM genomic landscape, KRAS and NRAS being the only point mutations present in the 15 most frequent drug events. Multivariate analysis by sparse Cox regression highlighted only four driver events with significant prognostic impact for both progression-free (PFS) and overall survival (OS): t(4;14) (HR 1.88, CI 1.25-1.84), amp(1q) (HR 2.63, CI 1.92-3.59), del(17p) (HR 2.55, CI 1.66-3.92), and rare mutations of ATP13A4 (HR 0.08, CI 0.01-0.65, mutated in 1.4% of patients). We found a significantly worse prognosis for increasing numbers of driver lesions in each patient (median OS 8.2 vs 3.5 years for <5 and >8 driver events, respectively). This was only partially explained by instances of additive effect or interactions between variables, which were very informative but not frequent. To better investigate these findings in the context of the genomic landscape of each case, we applied Bayesian clustering algorithms. The large number of driver events screened led to the identification of three clusters: in the largest one, some hyperdiploid and IGH-Tx cases clustered together, suggesting that secondary mutations and CNAs required for tumor progression are often shared between these two subgroups. We then identified two clusters both characterized by significantly lower number of mutations, but with opposing features. One was enriched for IGH-Tx, had the highest number of CNAs overall, showed higher prevalence of amp(1q), del(13), del(17p). TP53 mutations, and had a shorter median OS of 5.3 years. The other was mostly composed of hyperdiploid cases and showed fewest CNAs and mutations, with a good prognosis (median OS not reached).

Summary/Conclusions: We report on the first attempt towards the use of extended tumor genotype for a genomic classification of MM using innovative clustering algorithms. Despite the heterogeneity of the disease, we could identify disease subgroups with a distinct spectrum and number of driver events carrying different prognosis, supporting the introduction of genomics in the clinical approach to MM.

E1202

A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN PATIENTS WITH MULTIPLE MYELOMA

G. Ryland1,*, J. Markham1, K. Jones1, E. Aydogan1, T. Paperfuss2, M. Chin3, J. Hefferan3, K. O’Malley4, M. M. D. Devine4, E. Flynt4, Z. Yu5, M. Amatangelo5, M. Trotter6, H. Avelt6, L. O’Reilly7, C. Cooke8, M. MacDonald9, M. Reiter10, S. Shroff11, E. Aydogan1, T. Papenfuss2, M. Chin3, 1Pathology, 2Research, Peter MacCallum Cancer Centre, Melbourne, Australia, 3UCL Cancer Institute, 4Department of Haematology-Oncology, St Bartholomew’s Hospital, London, United Kingdom, 5Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia

Background: Assessment of gene mutations by next generation sequencing is now standard in patients with haematological malignancy. However, larger chromosomal aberrations (e.g. exon, gene and chromosome level gains and losses) also serve as critical prognostic indicators that guide therapeutic decisions. We used a novel method using a separate methodology such as conventional cytogenetics/FISH.

Aims: We aimed to develop and clinically validate a novel method for assessing genome-wide copy number changes using an existing hybridization-based targeted sequencing panel in order to provide further critical prognostic information and to augment the need for the next generation of clinical applications.

Methods: A custom Agilent SureSelect capture panel targeting 313 genes of relevance in myeloid and lymphoid malignancies was sequenced on an Illumina NextSeq (paired end 75bp reads) to a mean depth of 700x. An in-house bioinformatics pipeline was created to analyse probe counts from on-target and off-target regions, which also detected other large-scale changes introduced by RNAseq enrichment and sequencing by normalisation to a pooled reference comprising 10 normal controls. Three metrics for copy number calling were tested including a permutation-based statistic from circular binary segmentation, weighted mean and variance for the bins in each segmented region, and an MLPA-like test using reported copy numbers compared to controls. An interactive web-based graphical user interface was developed to visualise both large-scale and exon level amplification and deletions.

Results: We validated the approach on 45 samples from patients with multiple myeloma (predominantly advanced disease) with known copy number status as determined by conventional cytogenetics, FISH and MLPA. Our novel method detected numerous copy number changes that were outside the targeted region (through genome-wide mapping and analysis of off-target reads) such as del(1p) in 12 patients, gain(1q) in 15 patients and MYC amplification in 5 patients. Moreover our method was able to interrogate and resolve the complexity of changes on del(1p) including isolated deletions of FAM46C, CDKN2C and FAP1. Of 25 patients with a TP53 mutation, 20 had concomitant del(17p) detected by our assay, while 1 case had a del(17p) without mutation; both monosomally and biallelic TP53 aberration was associated with poor survival. Other findings in this cohort include frequent DIS3 mutations in patients with hyperdiploid and IGH-Tx cases (mostly with monosomy 13 and novel oncogenic copy number changes such as the high level amplification of KRAS in 1 case.

Summary/Conclusions: We have developed and demonstrated utility of a reliable workflow for genome-wide copy number assessment that can be implemented using existing targeted short read sequencing data, greatly extending the utility of this technology beyond the identification of novel genetic aberrations in patients with haematological malignancy. In the context of myeloma this can be used to report clinically relevant changes including deletions of 1p and 17p, and gains of 1q and 8q, as well as novel numerical chromosome aberrations.
80% power to detect gene expression changes and genomic variants associated in >2% of the study population. WES data identified the main cytogenetic groups, somatic variants, and significantly mutated genes. 28 significantly mutated genes were present in newly diagnosed samples (17 genes in >2% of samples). The main recurrent mutations included KRAS and NRAS, and negative regulators of the NF-kB pathway; however, novel genes were also identified. Using MCL-1 as a therapeutic target, we screened 2000 small molecular compounds to find novel small compounds that suppress growth of MM cell lines, and found that OSSL_325096 has strong anti-proliferative activity on MM cell lines (IC50 100-500µM). In this study, we evaluated anti-MM activity of OSSL_325096 through VCP inhibition, an ATP-competitive manner. Methods: OSSL_325096 were purchased from Princeton BioMolecular Research, Inc. (Princeton, NJ, USA). His-tagged human VCP (hVCP) cDNA was cloned and utilized to generate hVCP protein in vitro as previously described (Chou et al., PNAS, 2011, vol. 108(12): 4834-4839) to evaluate the VCP inhibition by OSSL_325096. In vivo analysis, MM xenograft model mice were intraperitoneally administered with vehicle or 50mg/kg of OSSL_325096 twice a week. Results: OSSL_325096 inhibited proliferation of MM cell lines, including one bortezomib-resistant cell line (Figure 1). OSSL_325096 induces apoptosis in these cell lines and primary MM cells purified from patients but not in PBMCs from healthy donors. OSSL_325096 treatment leads to accumulation of poly-ubiquinated proteins, cleavage of caspase-3, and up-regulation of CHOP in MM cell lines (Figure 2), suggesting this compound induces caspase-mediated apoptosis and ER-stress in MM cells. OSSL_325096 has a chemical structure similar to several known VCP inhibitors. Therefore, to evaluate the role of VCP in MM cell lines, we next performed knockdown of VCP. Knock-down of VCP induced apoptosis in MM cell lines, accompanied with accumulation of poly-ubiquinated protein. In-silico protein-drug binding simulation suggests possible binding of OSSL_325096 to the ATP binding site in VCP’s D2 domain. Indeed, in the cell-free ATPasase assay, OSSL_325096 showed dose-dependent inhibition of VCP’s ATPase activity (Figure 3). The IC50 of OSSL_325096 on ATPasase activity was 7-10µM, while IC50 of cell survival in MM cells was 0.1-0.8µM, suggesting that OSSL_325096 may have other anti-myeloma function in addition to VCP inhibition. RNA-sequencing of MM cells treated with OSSL_325096 revealed that several pathways including mTORC1 signaling, TNF signaling, and unfolded protein response, were activated by OSSL_325096. Finally, OSSL_325096 was administered to xenograft mice with MM cell tumors and inhibited the tumor growth in vivo (Figure 4).

Summary/Conclusions: The present data suggest that OSSL_325096 may be novel anti-myeloma drug candidate partially through its direct inhibition activity of VCP.

E1206
A NOVEL PREDICTIVE MODEL COMBINING UNCNRAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA
M. Samur1,2, A. Gulla1, M. Fulciniti1, R. Szalat1, A. Aktas Samur1, M. Shamas1, F. Magrangeas3, S. Minvielle4, K. Anderson1, G. Parmigiani1, H. Avet-Loiseau5, M. Samur1,2,*, A. Gulla1, M. Fulciniti1, R. Szalat1, A. Aktas Samur1, M. Shamas1, F. Magrangeas3, S. Minvielle4, K. Anderson1, G. Parmigiani1, H. Avet-Loiseau5, N. Munsli6
1Division of Hematology, 2Department of Internal Medicine, 3Department of Medical Oncology, 4Institut Paoli Calmettes, 5Institut de Recherche Thérapeutique, Nantes, 6Cancer Research Center of Toulouse, Toulouse, France

Background: M. Samur1,2, A. Gulla1, M. Fulciniti1, R. Szalat1, A. Aktas Samur1, M. Shamas1, F. Magrangeas3, S. Minvielle4, K. Anderson1, G. Parmigiani1, H. Avet-Loiseau5, N. Munsli6
1Division of Hematology, 2Department of Internal Medicine, 3Department of Medical Oncology, 4Institut Paoli Calmettes, 5Institut de Recherche Thérapeutique, Nantes, 6Cancer Research Center of Toulouse, Toulouse, France

Background: The majority of patients with MM do not achieve durable responses to first-line treatment. Novel agents, such as proteasome inhibitors and BCL-2 inhibitors, have demonstrated activity in MM. However, the identification of novel predictive models to distinguish patients who are likely to achieve durable responses to these agents is still needed. The present study was designed to develop a novel predictive model combining DNA copy number alterations (CNAs) and gene expression in newly diagnosed MM patients.

Methods: We performed an observational study of 147 newly diagnosed MM patients from 5 academic centers in France. MM samples were obtained at diagnosis, frozen, and stored at -80°C. Genomic DNA was extracted from peripheral blood mononuclear cells and subjected to whole-genome CNAs analysis (Illumina 244K or 550K SNP arrays). RNA was isolated from peripheral blood mononuclear cells and subjected to RNAseq analysis (Illumina HiSeq 2000). Initially, we performed a univariate analysis to evaluate the association of each CNA and gene expression with clinical outcomes. Then, we performed a multivariate analysis using the Cox proportional hazards model to identify genes that were significantly associated with progression free survival (PFS) and overall survival (OS) in newly diagnosed MM patients. Finally, we combined the selected genes with CNAs and used these into a risk score model to predict PFS and OS in newly diagnosed MM patients.

Results: The present data suggest that OSSL_325096 may be novel anti-myeloma drug candidate partially through its direct inhibition activity of VCP.

Summary/Conclusions: The present data suggest that OSSL_325096 may be novel anti-myeloma drug candidate partially through its direct inhibition activity of VCP.

E1206
A NOVEL PREDICTIVE MODEL COMBINING UNCNRAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

M. Samur1,2, A. Gulla1, M. Fulciniti1, R. Szalat1, A. Aktas Samur1, M. Shamas1, F. Magrangeas3, S. Minvielle4, K. Anderson1, G. Parmigiani1, H. Avet-Loiseau5, N. Munsli6

1Division of Hematology, 2Department of Internal Medicine, 3Department of Medical Oncology, 4Institut Paoli Calmettes, 5Institut de Recherche Thérapeutique, Nantes, 6Cancer Research Center of Toulouse, Toulouse, France

Background: The majority of patients with MM do not achieve durable responses to first-line treatment. Novel agents, such as proteasome inhibitors and BCL-2 inhibitors, have demonstrated activity in MM. However, the identification of novel predictive models to distinguish patients who are likely to achieve durable responses to these agents is still needed. The present study was designed to develop a novel predictive model combining DNA copy number alterations (CNAs) and gene expression in newly diagnosed MM patients.

Methods: We performed an observational study of 147 newly diagnosed MM patients from 5 academic centers in France. MM samples were obtained at diagnosis, frozen, and stored at -80°C. Genomic DNA was extracted from peripheral blood mononuclear cells and subjected to whole-genome CNAs analysis (Illumina 244K or 550K SNP arrays). RNA was isolated from peripheral blood mononuclear cells and subjected to RNAseq analysis (Illumina HiSeq 2000). Initially, we performed a univariate analysis to evaluate the association of each CNA and gene expression with clinical outcomes. Then, we performed a multivariate analysis using the Cox proportional hazards model to identify genes that were significantly associated with progression free survival (PFS) and overall survival (OS) in newly diagnosed MM patients. Finally, we combined the selected genes with CNAs and used these into a risk score model to predict PFS and OS in newly diagnosed MM patients.

Results: The present data suggest that OSSL_325096 may be novel anti-myeloma drug candidate partially through its direct inhibition activity of VCP.

Summary/Conclusions: The present data suggest that OSSL_325096 may be novel anti-myeloma drug candidate partially through its direct inhibition activity of VCP.

haematologica | 2017; 102(s2) | 495
Background: RNA has diverse sets of regulatory functions and a recent analysis of a Human Reference Genome set has identified a large number of non-coding transcripts. One of which, long intergenic non-coding RNA (lincRNA) with transcripts longer than 200 nucleotides, are located between the protein coding genes and do not overlap exons of either protein-coding or other non-lincRNA genes. lincRNAs have been considered to provide regulatory functions, however, their precise role and functionality remains unclear. In the immune system, lincRNAs are also implicated in the dysregulation of immune responses.

Aims: Here, we have studied lincRNAs using uniformly treated patients to show their impact on survival outcome in MM.

Methods: We performed RNA-seq on CD138+ MM cells from 360 newly-diagnosed patients and 18 normal plasma cells (NPM) and analyzed for lincRNA and protein coding genes. MM patient data included characteristic and clinical variables for each patient, and their respective receptors on marrow non-plasma cells (HLA-DR). Immunogenicity and antigenicity markers expression was described as percentage on the total of marrow plasma cells and non-plasma cells at 24 months (+/- 4 months, 16 samples). Half of these patients developed MM and were diagnosed as progressed SMM (16 samples vs control median 30.3%, range 5.8-71.4% and 6-12 months median 29.6%, range 0.2-89.7%, p<0.01) and LAG3 expression could be of clinical interest due to the current availability of checkpoint inhibitors drugs targeting these molecules. The results of this study should be confirmed on prospective studies with larger number of patients.

Summary/Conclusions: First, we observed an increase in in inflamed microenviron-
ment markers (increase in CD4+ and CD8+ cells in favor of CD4+ population and HLA-DR expression on plasmacellsm and non-plasmacells) during the course of SMM. Secondly, expression of T cell inhibition markers (PDL1, LAG3) was significantly augmented during disease progression. For the first time, we reported a comprehensive analysis of microenvironment modifications in a large number of MM samples and identified a dysregulated immune microenvironment were observed. In particular, increased in PDL1 and LAG3 expression could be of clinical interest due to the current availability of checkpoint inhibitors drugs targeting these molecules. The results of this study should be confirmed on prospective studies with larger number of patients.

E1208 IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS POST AUTOLOGOUS STEM CELL TRANSPLANT SHOWS PRESENCE OF CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRESSION AND OTHER CHECKPOINT MARKERS

Background: Multiple myeloma (MM) is a plasma cell malignancy that remains incurable, despite therapeutic advances. Immunotherapies have recently shown much promise in this and other cancers, and are under intense investi-
gation. Autologous stem cell transplantation (ASCT) is standard of care in young fit newly diagnosed patients. In the post-ASCT setting, the minimal dis-
ease burden and re-constituting immune system may be a favourable context for immunotherapies, including cellular therapy and checkpoint blockade. Autoimmune aimed to characterize immune cells in bone marrow (BM) of MM patients post-ASCT, to identify candidate immune checkpoint pro-
tiens for therapeutic targeting.

Methods: BM aspirates were obtained from patients with MM at 3 months post ASCT (n=28), and 6-12 months post ASCT (n=41) at University College Hos-
pital. Control BM aspirates were collected from healthy volunteers undergoing BM harvesting with the Anthony Nolan. Immunofluorescence surface staining was performed using antibodies to CD3, CD4, CD8, LAG-3, PD-1, HLA-DR, ICOS and the intracellular markers GzmB and Foxp3. All p-values indicate differences from normal donors unless otherwise stated.

Results: Using only the expressed lincRNAs, we developed a risk prediction signature using uniformly treated patients at time 0 was 93.2% (95% CI, 88.9% to 97.6%) and 71.1% (95% CI, 62.9% to 80.3%) in our patients having a low or high risk score. We then compared lincRNA sig-
nature with known expression signatures and improved the risk prediction for known expression signatures dramatically. We validated our results on inde-
pendent large cohort with newly diagnosed MM RNAseq data. When applied to patient cohort separated by other risk categorization including minimal resid-
ual disease status (MRD), cytogenetic risk status (del17p; t(4;14) and t(14;16)) and International Staging System (ISS), lincRNA signature was able to further identify patients with significant differential survival outcomes.

Summary/Conclusions: In summary, we report that lincRNAs have an inde-
pendent effect on survival outcome in MM and provides rationale for its use in risk stratification as well as to understand biological impact. Combined risk prediction with other risk features improve the prediction power and helps to create better classification in MM.
Background: Bone marrow stromal cells (BMSCs) interact with multiple myeloma (MM) cells in the bone marrow, and also create a permissive microenvironment for MM cell growth and survival. Recent evidence indicated that MM cell-BMSC communication via extracellular vesicles (EVs) plays an important role in the MM microenvironment.

Aims: In this study, we investigated the biological property of EVs and miRNAs in EVs derived from BMSCs, aiming to establish the emerging strategies to target MM microenvironment to prevent tumor growth and spread.

Methods: Bone marrow samples were obtained from MM patients (age 56 to 82, n=20) and monoclonal gammopathy patients (MGUS, age 44 to 82, n=13) in accordance with the Declaration of Helsinki and using protocols approved by the research Ethics Committee of Tokyo Medical University (IRB No. 2648), and BMSCs derived from MM patients (MM-BMSCs) and MGUS patients (MGUS-BMSCs) were isolated by the classical cell adhesion method. EVs were isolated from conditioned medium of BMSCs using a Exoquick-TC (SBI). The size of EVs was confirmed using a NanoSight LM10 (Malvern). The RNA from cells and EVs was profiled for 381 miRNAs using a TaqMan low-density array method.

Results: MM-BMSCs and MGUS-BMSCs had a fibroblast-like morphology in culture, and were homogeneously CD73+, CD90+, CD105+, CD34−, and CD45−. Cell viability of miRNA-overexpressed BMSCs were determined using WST-8 (Dojindo), and Apoptosis rates were determined using Caspase-Glo assays (Promega). To assess the effect of the inhibit on EV secretion, BMSCs were treated with 10 µM GW4869. Knockdown of PBK was performed using CRISPR-mediated knockout. The KMS-11 cells were subcutaneously injected to mice and the tumor volumes were observed every 3 to 4 days. Knockout of the pbk gene was determined using a log-rank test and survival curves plotted using the Kaplan-Meier method.

Summary/Conclusions: Our findings indicate that expression of PBK was associated with myeloma cell proliferation, while PBK was likely linked to tumor suppression. Increased phosphorylation of Thr 9 on PBK might contribute to proliferation in cells with PBKG. These results provide a novel insight into the mechanisms underlying myeloma cell growth and PBK regulates cell growth and survival in MM microenvironment.

Aims: The histone methyltransferases G9a/GLP represent new promising targets for the treatment of multiple myeloma. The histone methyltransferases G9a/GLP are 2 histone methyltransferases which catalyze mono- and dimethylation of histone 3 lysine 9 (H3K9). Importantly, G9a is overexpressed in several cancers, correlating with a poor prognosis.

Methods: Currently, data about the expression and role of G9a/GLP in MM is lacking. The aim of this study is therefore to investigate the functional role of G9a/GLP in MM pathogenesis.

Results: Our findings indicate that expression of PBK was associated with myeloma cell proliferation, while PBK was likely linked to tumor suppression. Increased phosphorylation of Thr 9 on PBK might contribute to proliferation in cells with PBKG. These results provide a novel insight into the mechanisms underlying myeloma cell growth and PBK regulates cell growth and survival in MM microenvironment.
E1212 CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPEUTIC OPPORTUNITIES

F. Seymour1,*, J. Cavenagh1, J. Gribben1

1Haematology-Oncology, Barts Cancer Institute, London, United Kingdom

Background: A bi-directional interaction exists between malignant cells and those of the immune microenvironment. This dynamic relationship results in gradual loss of clonal control associated with loss of cytotoxic lymphocyte (CTL) response. Mechanisms of immune escape are varied and include the induction of immune suppressive factors, notably the PD-1/PDL-1 axis. Multiple myeloma is a disease characterised by a pre malignant phase which can evolve into periods of asymptomatic and symptomatic disease. One possible mechanism for disease progression is progressive loss of immunological control. The malignant plasma cell has multiple potentially immune modifying effects including the expression of PDL1 and induction of a pro-tumour micro-environment. The role of CTLs is less well understood.

Aims: To undertake deep immune profiling of the CTL landscape in myeloma in order to establish whether features of immune dysregulation are present and to identify potential therapeutic opportunities.

Methods: Cryopreserved bone marrow from 18 patients with newly diagnosed and untreated myeloma and 9 controls were assessed using a 36 parameter mass cytometry panel. The panel was designed to assess 9 immune checkpoint regulators, 5 cytokines, and markers of proliferation and degranulation across multiple lymphocyte subsets. Samples were stimulated with CD3 and CD28 to assess functional subpopulations characterised by expression of multiple markers.

Results: The cytokine profile in newly diagnosed myeloma is shifted towards a pro-tumour microenvironment with particularly marked elevation of TGFβ throughout restimulated CTLs (36.4% v. 66.2%, p<0.0001). IFNg production is reduced in the restimulated myeloma effector population (0.33% v. 0.18%, p=0.0099). Stimulation restores the cytokine profile to match that of controls. Myeloma CTLs retain the capacity to proliferate and produce the constituents for cytotoxic granule formation, however elevated PD1 expression alongside other markers of exhaustion suggest a transition towards a exhausted phenotype is occurring. Strongly PD1 expressing populations in myeloma are larger (26% v.43%, p=0.05) and have increased rates of co-expression of CTLA4 (32%, 64%, p=0.0015), PD-L1 (26% v.47%, p=0.0198) and TIM3 (34% v. 56%, p=0.0241). Populations of CTLs from myeloma up-regulate expression of the TCR co-stimulatory molecules CD28 (74% total CD8), TIM3 (45% total CD8), PD-L1 (74% total CD8) and OX40 (33% total CD8) following stimulation.

Summary/Conclusions: Clear differences can be identified in the functional and phenotypic features of CTLs in myeloma compared to those of controls. The partial nature of these defects and the fact that reversibility can be demonstrated suggests that these cells have not yet reached the stage of irreversible exhaustion. Taken together this data suggests that targeting immune checkpoint regulators at an early disease stage, in order to optimise immunological function and reverse partial defects, is a viable therapeutic strategy to explore. PD1, PDL1, CTLA4 and TIM3 are all potent immune checkpoint targets. In addition the expression of both PD-L1 and OX40 in MM correlates with disease progression and suggests a potential role in the co-stimulation in order to up-regulate antigen specific CTL activity. Combining immunological blockade with other immune optimising agents may enhance the benefit, leading to greater malignant cell clearance.

E1213 P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA

Y. Arithara1,*, K. Takada1, Y. Kawano1, N. Hayasaka1, H. Nakamura1, S. Kikuchi1, Y. Kamihara1, K. Murase1, H. Ikeeda2, S. Iyama2, T. Sato2, K. Miyaniishi1, M. Kobune1, J. Kato1

1Department of Medical Oncology, 2Department of Hematology, Sapporo Medical University, Sapporo, Japan

Background: Reactive oxygen species (ROS) are normal byproducts of a wide variety of cellular processes. ROS have dual functional roles in cancer cell pathophysiology. At low to moderate levels, ROS act as signaling transducers to activate cell proliferation, migration, invasion, and angiogenesis. In contrast, high levels of ROS induce cell death. In multiple myeloma (MM), ROS overproduction is the trigger for apoptosis induced by several anticancer compounds, including proteasome inhibitors. However, no drugs that mainly affect oxidative stress are currently used for treatment of MM in the clinic. In MM, p53 status is an independent prognostic marker, since patients harboring p53 abnormalities are highly resistant to standard therapies, and the incidence of p53 mutations and deletions increases during disease progression. Therefore, restoration of p53 is an attractive strategy for treating advanced relapsed and refractory MM (RRMM) patients. CP-31398 (CP) is a small molecule that activates wild-type p53 or restores tumor-associated p53 mutants to wild type p53 function in multiple human cancer cell lines; this leads to cell cycle arrest and/or apoptosis. The growth of thymocytes and carline cells can be inhibited by p53-dependent induction of ROS, but it is not clear whether CP-induced cytotoxicity proceeds via a similar pathway.

Aims: Our study was aimed at evaluating the anti-myeloma activity of CP.

Methods: MM cell lines (MM1S, RPMI8226, U266, KMS5, OPM2, Delta47, Kato1) and freshly isolated primary MM cells from 20 patients were treated with IC50 concentrations of CP for 48 h. Subsequently, the inhibitory effect of CP on MM cell line growth was assessed using a WST-1 assay. In order to elucidate the cytotoxic mechanism of CP, immunoblotting and flow cytometry analysis were performed. Measurements of cytosolic and mitochondrial ROS were measured with CellROX Deep Red and MitoSOX Red. For quantification of ROS, cells were analyzed by flow cytometry and fluorescence microscopy. The therapeutic potential of CP was evaluated by its ability to suppress tumor growth in vivo using the subcutaneous RPMI8226 murine xenograft model for human MM.

Results: In this study, we have demonstrated that the p53-activating small molecule CP-31398 effectively inhibited the growth of MM cell lines and primary MM isolates from patients with IC50 values in the range of 2.51–11.2 μM. CP also suppressed the growth of MM xenografts in mice. Mechanistically, CP was found to induce intrinsic apoptosis in MM cells via increasing mitochondrial and cytosolic ROS production. Interestingly, CP-induced apoptosis occurs regardless of the cells' p53 status, suggesting that CP has additional mechanisms of action. In addition, we found that CP acted synergistic with the protease inhibitor carfilzomib (CFZ) in MM cells, providing a framework for further studies of CP alone and in combination with CFZ to improve the prognosis for MM patients.

Summary/Conclusions: Our findings indicate that CP could be an attractive candidate for treatment of MM even in patients with p53 abnormalities; this may identify an unmet clinical need, as such patients currently have a poor prognosis.
Results: Only N educated by SMM- and MM-MSC (both from patients at diagnosis, relapsed and refractory) significantly up-regulated Arg1. NOS2 and TNFα and exhibited suppressive effect with a reduction of T cell proliferation (p<0.001). By co-culturing educated-N with Human Brain Microvascular Endothelial Cells (HBMEC), we observed increased both tube length and number of branch points only in conditions where HBMEC were incubated with MM-MSC and MM-MSC-educated-N (p<0.05). Adding Bortezomib, Lenalidomide or Pomalidomide during co-culture of PBMC with MM-MSC, isolated N showed a significant reduction of pro-angiogenic activity but did not lose immunosuppressive ability. To examine if PB can play a role in MSC “activation”, before performing co-cultures with PBMC, we pre-treated HS-5 or HC-MSC with MM cell lines, PB cell treatment drove a healthy MSC to activate N in immunosuppressive and pro-angiogenic cells. Implanting of mixtures of fluorescently labeled MM cells and healthy- or MM-MSC into zebrafish, animals injected with PB and MM-MSC showed enhanced tumor colonization and growth compared with those injected with PB and healthy MSC.

Summary/Conclusions: A tumor microenvironment transformation from mgUS to MM is associated with progressive activation of MSC that have a pro-tumoral activity. Indeed SMM- and MM-MSC polarize N in immunosuppressive and pro-angiogenic N (N2) in vitro. In addition, MM-MSC facilitate MM growth in vivo confirming their central role in tumor progression.

E1215
LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT GENERATION FLOW SHOW PREDOMINANTLY CURED VSmgUS-LIKE MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE GTMM-TUSCAN GROUP FOR MANY MULTIPLE MYELOMA
A. Bacci1,*, A. Fantini2, F. Baccianti1, D. Candi1, D. Raspagliesi3, A. Neri4, M. Novelli5, M. Staderini2, G. Papini1, C. Zuanelli Brambilla1, B. Mecaccia1, G. Buda3, R. Caporale4, A. Bosi2, M. Petrinì2, M. Bocchia1
1Hematology Unit, University of Siena, Siena, 2Hematology, Azienda Ospedaliera Universitaria Careggi, Firenze, 3Hematology, University of Pisa, Pisa, 4Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

Background: CR is a prerequisite for long term responses, progression free survivals, and ultimately overall survivals and cure. In the era of novel agents, many MM patients can achieve stringent CR (sCR), i.e. disease disappearance at serological, immunohistochemical level plus negativity of free light chains (FLC). On the other hand most of these patients still will relapse and minimal residual disease (MRD) detection will play a crucial role in the very next future. Recently, two 8 colours tubes panel developed by the EuroFlow Consortium can detect MRD with an increased sensitivity and can be applied as standardized method to study multiple myeloma (MM) patients.

Aims: While many studies have looked at MRD status sequentially and soon after autologous or allogeneic stem cell transplantation with flow or molecular techniques, little is known about long term remission patients (>5-10 years) and in particular if more sensitive techniques such as NGS or NGS can still detect minimal disease in those patients. Aim of the study was to analyse patients with MM in >VGPR with next generation flow at >2 and >5 years of lasting remission.

Methods: Clinical assessment definition of CR status included serum and urine immunofixation, free light chain determination, imaging study with CT–PET, bone marrow biopsy. BM-MSC patients (M/F: 30/26), were studied with NGS at two GTMM centers between February 2016 and February 2017. 28/56 (50%) patients were in sCR at the moment of the study at a median of 40 months after therapy (range 3-140), 28/56 (50%) patients were in VGPR at study analysis according to new IMWG response criteria. N= 12, 25 and 44 patients had a remission disease >5 years, >2 years, and <5 years, respectively. Two tube assay incorporated 8 antibodies each: CD38, CD56, β2-Microglobulin, CD19, K-Anti-Kappa Anti-Lambda CD45 CD138, and CD38, CD28, CD27, CD117, CD81, CD45 and CD138 (OneFlow™ PCST and PCD, BD Biosciences) and were utilized to detect MRD level with a lyse-wash-and-stain gating strategy of BMSCs or healthy (FACSanto II, BD Biosciences). Accurate identification of BM plasma cells (PCs) and discrimination between phenotypically aberrant (aPC) and normal PC (nPC) were carried out after acquisition and analysis of >2 x 10⁶ cells (Diva 8, BD Biosciences).

Results: MRD+ status was detected in 23/56 (41%) of the patients. 4/12 (33%) were MRD positive at >5 years remission (2 sCR, 2 VGPR) (median 96 months range 72 – 186 months); 20/44 (45%) were positive at >5 years of remission (3 CR, 17 VGPR)[median 9.5 months range 3 – 46 months]. 9/25 (36%) were MRD+ and >2 years of remission (2 sCR, 7 VGPR) (median 46 months range 24 – 186 months). As expected being in sCR was correlated with a low MRD rate (14% of MRD positive patients after >5 years). Interestingly looking at long lasting remission, i.e. >5 years, the 4/14 patients that resulted MRD+ displayed aMGUS-like phenotype and high immunosuppressive activity. MM patients that display aMGUS-like phenotype after achieving a CR can have long lasting remissions meaning disease control. Patients in sustained CR after 2 years can have high percentage of MRD negativity. Larger studies are warranted to identify patients who need treatment consolidation or continuous treatment based on MRD+ status vs others who could stay treatment free with social and economical benefits.

E1216
THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS AND ENDOTHELIUM IN THE BONE MARROW NICHES
M.T. Palano1, N. Palatovonay2, I. Saltarella3, S. Garavelli1, M. Colombo1, F. Baccianti1, A. Neri4, R. Ria3, R. Chiaramonte1
1Scienze della Salute, 2Oncologia ed emato-oncologia, Università degli Studi di Messina, Messina, 3Medicina interna e Oncologia clinica, Università di Bari, Bari, Italy

Background: Angiogenesis is a hallmark of tumors, and it is a peculiar characteristic in bone marrow (BM) of multiple myeloma (MM) patients. MM is a still incurable disease that strongly depends on interactions with BM microenvironment. Endothelium of MM patients displays malignant behavior as compared to a healthy counterpart (1). MM displays a dysregulation of the Notch pathway due to Jagged ligands and Notch receptors overexpression. This condition brings to the generation of homotypic and heterotypic interaction loops that sustain MM-cell survival. Moreover, Notch may interact with BM resident cells, including osteoclasts and BM stromal cells (BMSCs), although its role in the crosstalk of MM and endothelium is still to be clarified.

Aims: The aim of this study is to investigate Notch role in MM crosstalk with endothelium exploiting 2D assays and 3D organoid systems to mimic tumor microenvironment (TME).

Methods: The Notch ligands, Jagged 1 and 2, were silenced in the MM cell line RPMI8226 (RPMI8226shJUG1/2) using an inducible lentiviral vector carrying two short hairpin RNAs targeting Jagged1 and 2. To mimic the endothelial compartment, sprouting endothelial cells (HPCAec) were used and for the stromal compartment, the GFP+HSS cell line. Matrigel and wound healing assays were set up to investigate Notch role in modulating the angiogenic potential of MM cells co-cultured with HPCAec and HPCAec motility in response to MM-derived soluble factors. To develop a TME-like system, a decellularized extracellular matrix (dECM) was used as a physiologic scaffold for organoid generation. dECM was produced by treating murine fibroblast NIH3T3 with ascorbic acid and was loaded with cells for organoids generation. We evaluated apoptosis of MM cells in single culture and co-culture with BMSCs or HPCAec by flow cytometry.

Results: Matrigel assay of HPCAec co-cultured with MM cells showed that direct contact increased angiogenic potential of HPCAec to form a grid of tubes; this effect is significantly reduced when HPCAec are co-cultured with RPMI8226shJUG1/2 cells, indicating a key role of Notch signaling in endothelial stimulation. Wound healing assay demonstrated that Notch signaling affects MM cell migration, reducing wound healing. Concerning the 3D-organoid generation, our results indicate that the decellularized dECM was a suitable scaffold. Moreover, apoptosis assays indicated that MM cells displayed an increased survival when cultured in the presence of BMSCs, that consistently with their recognized protective role; no significant difference in MM cell apoptosis was observed in the presence of endothelial cells. On the contrary, we have observed that endothelial cells were protected by MM cells suggesting that MM cells improve angiogenesis by preventing endothelial cells apoptosis.

Summary/Conclusions: These results indicate a novel role for Notch pathway in MM-EC crosstalk suggesting that the Notch pathway activation in MM cells can increase their proangiogenic potential. 3D-organoid mimics BM microenvironment and may be used as a novel tool to recapitulate the interactions of BM and tumor cells beyond the animal models.

References
E1218

ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE DISEASE IN A MURINE MODEL OF MYELOMA

A. Chantry1, A. Holly1, M. Fisher1, D. Jenny1, L. Michelle1, L. Darren1
1Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom

Background: The receptor tyrosine kinase c-Met, its ligand HGF, and their signalling pathway are believed to be implicated in the pathogenesis of multiple myeloma (MM). In myeloma patients with elevated levels of HGF their prognosis is known to be poor. Therefore, targeting these molecules or their pathway in such patients may be of great benefit. We hypothesised that ARQ-197 (Tivantinib), a small molecule c-Met inhibitor, would reduce myeloma cell growth and prevent myeloma-associated bone disease in a murine model.


Methods: In vitro assays were performed the effects of ARQ-197 (0.1563 μM - 5 μM) on myeloma cell proliferation, cytotoxicity and c-Met protein expression in the JJN3 human cell line. In vivo we intravenously injected NOD/SCID-γ mice with 106 JJN3 cells and 1 week later treated mice with either ARQ-197 (200mg/kg/day, 5 times per week by oral gavage) or vehicle for 2 weeks.

Results: ARQ-197 significantly inhibited both myeloma cell proliferation (p<0.001) and c-Met protein expression in the JJN3 cell line and in vivo intravenous administration of 5 μM ARQ-197 resulted in a significant reduction in cell proliferation (p<0.001) and an induction of cell death (p>0.001). In other experiments, when the inhibitor was co-administered in combination with BTZ (5 μM), myeloma cell proliferation was significantly reduced compared to treatment with BTZ alone (p<0.001). In summary, our results show that the disturbed genetic landscape of the 5T murine models shows heterogeneity and a partial overlap with multiple myeloma patients. The genetic defects affect pathways known to be involved in myeloma cell survival. The 5T models thus represent reliable models to study the characterized genetic defects.

Summary/Conclusions: E1221

CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE

T. Csikos1, H.-J. Prins1, E. Drent1, P. Poddighée2, S. Zweegman1, T. Mutis1, R. Groen1
1Hematology, 2Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands

Background: The bone marrow niche is a specialized microenvironment, which allows for the survival, growth and differentiation of hematopoietic stem and progenitor cells. This niche also provides the optimal growth conditions for hematological malignancies, such as multiple myeloma (MM). A complex interplay between cytokines, adhesion molecules, cell receptors and their ligands involved in stroma-mediated drug resistance, survivin and miRNA-101-3p axis in regulation of BMSCs-induced BTZ resistance in MM cells, thereby providing a rationale to further investigate the anti-myeloma activity of miR-101-3p in combination with BTZ as a potential therapeutic strategy in MM.

Aims: To unravel the role of the bone marrow mesenchymal stem/stromal cells (BMSCs) in MM cell growth, progression and drug resistance.

Methods: Hypothesizing that the interaction between MM cells and the BMSCs is bidirectional, we have compared BMSCMs from healthy individuals, mgUS, and MM patients and used our “humanized” bone marrow-like model to characterize the molecular impact of MM cells on BMSCMs. Finally, we have validated targets by generating HS-5 knock-out lines using CRISPR/Cas9 targeting.

Results: Analyzing the BMSCMs of healthy individuals, mgUS, and MM patients, we identified damaging mutations in Trp53, Rb1, Pik3ca, Fat3, Kdm6a and Kdm6b in MM cell-BMSCs co-cultures. Furthermore, miR-101-3p overexpression or silencing of survivin sensitizes MM cells to BTZ, thus providing a rationale to further investigate the anti-myeloma activity of miR-101-3p in combination with BTZ as a potential therapeutic strategy in MM.
E1222

THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VIVO AND IN VIVO MODELS OF MULTIPLE MYELOMA

F. Costa1,*, D. Toscani1, A. Chillemi2, V. Quarona2, M. Bolzoni1, V. Marchica1,3, M. Algarin1,2, M. Martin-Sánchez1, M-V. Mateos2, M. Garayoa2, E.M. Ocío1,2
Centro de Investigación contra el Cáncer (CIBICMCC), 2Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain

Background: PIM kinases are a family of serine/threonine kinases recently proposed as therapeutic targets in multiple myeloma. Recent work from our group has shown the dual antiyeligm and bone-protective effects of the pan-PIM kinase inhibitor, PIM447, and its in vitro synergism with current standards of care. Since myeloma remains an incurable disease, the preclinical evaluation of new drug combinations is of utmost importance, in order to support the development of future clinical trials. In this scenario, effective all-oral combinations are particularly attractive.

Aims: The aim of the present work has been the evaluation of the efficacy and mechanism of action of the all-oral triple combination PIM447 + pomalidomide + dexamethasone in preclinical in vivo and in vitro models of multiple myeloma.

Methods: In vitro cytotoxicity of PIM447, pomalidomide and dexamethasone alone or in double and triple combinations was evaluated on myeloma cell lines. The combination index (CI) was calculated with CalcuSyn software based on results from MTT assay. Effects on apoptosis and cell cycle were evaluated by flow cytometry. Glucose uptake was analyzed by incubation with 2-NBDG. The mechanism of action was explored by analysis of different protein levels by western blot. Finally, a pharmacomycyto model in CB17-SCID mice was employed for in vivo studies.

Results: Triple combination PIM447 + pomalidomide + dexamethasone showed a strong synergism (CI<0.3) in MM1S and RPMI-8226 cell lines. The efficacy of the combination in the SKMS-1 cell line was increased by pre-treatment with PIM447 + pomalidomide + dexamethasone remarkably reduced the levels of the glucose metabolism-associated enzyme hexokinase II and also reduced glucose uptake by cells. Finally, the efficacy of this combination was confirmed in a pharmacomycyto model in CB17-SCID mice, where it clearly reduced tumor growth as compared to single and double treatments.

Summary/Conclusions: Our preclinical data suggest that myeloma patients could benefit from treatment with the triple combination PIM447 + pomalidomide + dexamethasone and would support future clinical trials with this combination.

E1223

EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICA: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOLAST FORMATION IN MULTIPLE MYELOMA

F. Costa1,2, D. Toscani1, A. Chillemi2, V. Quarona2, M. Bolzoni1, V. Marchica1,3, M. Algarin1,2, M. Martin-Sánchez1, M-V. Mateos2, M. Garayoa2, E.M. Ocío1,2
Centro de Investigación contra el Cáncer (CIBICMCC), 2Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain

Background: Bone disease is the hallmark of multiple myeloma (MM). It is known that MM cells express CD38 and that a recently developed human anti-CD38 monoclonal antibody, Daratumumab (DARA), induces and mediates MM cell killing. However, the expression of CD38 and other functionally related ectoenzymes in the bone niche of MM patients and the potential effects of DARA on bone cells are still unknown.

Aims: The aim of this study was to define the expression profile of CD38, CD31, CD39, CD73 and CD203a on MM and bone niche cells. Then, the effect of DARA on bone cells was evaluated by in vitro osteoclastogenesis.

Methods: In order to evaluate the expression profile on the ectoenzymes, we firstly performed immunohistochemical analysis on bone biopsies in a cohort of 37 patients with MM and 14 with monoclonal gammopathy of uncertain significance (MGUS). The same antigens were analyzed by flow cytometry on primary MM cells, mesenchymal stromal cells (MSC), osteoblasts (OB), monocytes and microvesicles (MV). Then, we tested DARA effects, in the presence or absence of All-trans retinoic acid, compared with human IgG isotype control, on OC differentiation and function.

Results: MM cells showed a high expression of CD38 and were positive for CD31, CD39, CD73 and CD203a at variable levels. However, we did not find any significant difference in the expression of CD38 and related ectoenzymes between MM and MGUS patients. CD38 was expressed by monocytes and early OC progenitors but not by OB. Moreover, MSC lacked expression for CD73 and CD203a. Indeed, CD38 was lost during OC differentiation. Consistently, we found that DARA reacts with CD38 expressed by monocytes and its binding inhibits early in vitro osteoclastogenesis from total mononuclear cells. All-trans retinoic acid treatment increased the inhibitory effect of DARA on OC formation.

Summary/Conclusions: Our data suggest that DARA inhibits osteoclastogenesis, targeting monocytes and early progenitors. These observations provide a rationale for the use of an anti-CD38 antibody-based approach as treatment for MM-induced osteoclastogenesis.
enhancer of the TRIM33 signature that potently decreased the viability of the OMV-2 cell line. This study suggests that enhancing the TRIM33 gene signature could potentiate the tumor suppressive effect of TRIM33 and identify novel therapies for this subset of MM.

E1225
LONG NON-CODING RNAS EXPRESSION HETEROGENEITY AND FUNCTIONAL INVOLVEMENT IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A POTENTIAL THERAPEUTIC TARGET
A. Carrasco1, A. Casini2, T. Zappia3, T. Zappia4, S. D'Agostino3, D. Cilloni5, A. Melnick6, F. D'Auria1, F. Frassoni9, A. Neri10, L. Del Vecchio11, P. Musto12, D. Cilloni13, A. Caivano14
1Onco-hematology, Center for Applied Medical Research (CIMA), Pamplona, Spain, 2Department of Medicine, Weill Cornell Medical College, New York, USA, 3Department de Fundamentos Clinics, Universitat de Barcelona, Barcelona, Spain, 4Bioinformatics, 5Flow Cytometry Core, Center for Applied Medical Research (CIMA), 6Hematology, Clinica Universidad de Navarra, Pamplona, Spain

Background: Increasing amount of evidence indicates that deregulation of long non-coding RNAs (IncRNAs) is a common feature of cancer and therefore, its investigation may uncover new molecular oncogenic mechanisms. In multiple myeloma (MM), altered expression of small number of IncRNAs has been associated with decreased disease-free and overall survival, suggesting that these elements may play a more important role in MM than previously anticipated. Nevertheless, an extensive high-throughput analysis that characterizes the deregulation of IncRNAs in MM has not yet been performed.

Aims: We aim to characterize the IncRNA transcriptome of MM and its heterogeneity, and determine whether altered IncRNAs have a functional involvement in this disease.

Methods: Paired-end strand-specific RNA sequencing (ssRNA-seq) was performed in 38 purified plasma cell (PC) samples from MM patients, as well as in 5 tonsil PCs (TPCs) and in 3 bone marrow PCs (BMPCs) of healthy donors as controls. We also performed ssRNA-seq of populations from B cell differentiation (Naive, Germinal Center, Memory and PC). To study the heterogeneity of IncRNAs expression we performed sample level enrichment analysis (SLEA), in which each individual IncRNA was compared to BMPCs. To determine the epigenetic regulation of IncRNAs we used whole-genome bisulfite sequencing and CHIP-seq. shRNA-mediated knockdown using 2 different shRNAs and MTeh17F9 and MTeh17V (cell death) assays were utilized to study the functional effect of IncRNA overexpression.

Results: We identified 40,552 novel IncRNAs in MM samples that were present in at least 3 of the 38 patients. Principal component analysis demonstrated that TPCs and BMPCs cluster separately, suggesting that, in spite of being the same type of cells, their transcriptomes are very different. We observed that the expression of IncRNAs was more heterogeneous than that of coding genes. More importantly, SLEA showed 11,067 IncRNAs that were overexpressed and 5,601 underexpressed in >40% of patients. Thus, the number of deregulated genes analyzed by SLEA was much larger than the 70 lncRNAs that appeared associated with decreased disease-free and overall survival, suggesting that there is an extensive IncRNA expression heterogeneity in MM.

Conclusions: Our study demonstrates that the IncRNA transcriptome is a potential therapeutic target for MM. We identified 40,552 novel IncRNAs that are deregulated in MM, and characterized their expression heterogeneity. We also demonstrated that IncRNAs have a functional role, as shown by the significant effect of IncRNA overexpression on MM cell viability and movement. Finally, we analysed the effects of EphA3mAb in a MM mouse xenograft model.

E1226
ROLE OF EPHA3 IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A NOVEL TARGET THERAPY?
1Laboratory of Clinical Research and Advanced Diagnostics, IRCCS, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, 2Laboratorio di Oncologia, IRCCS - G. Gaslini Institute, Genova, 3Department of Medicine and Sciences of Aging, CESI-Met Aging Research Center and Division of Anatomic Pathology and Molecular Medicine, Chieti, 4Department of Stem Cell and Development, Istituto di Ricerche Genetico Gaetano Salvatore Biogemini, 5Department of Biological, University of Naples “Federico II”, Naples, 6Laboratory of Pre-clinical and Translational Research, 7Department of Oncology-Hematology, IRCCS, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy, 8Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia, 9Laboratorio Cellule Staminali post-natali e Terapie Cellulari, IRCCS - G. Gaslini Institute, Genova, 10Department of Clinical Sciences and Community Health, University of Milan and Hematology, Fondazione Ca Granda, Ospedale Maggiore Policlinico, Milano, 11Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, 12Scientific Direction, IRCCS, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, 13Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

Background: The tyrosine kinase Eph receptor A3 (EphA3) has recently emerged as a potential therapeutic target, since it has been overexpressed in many cancers, including some hematological malignancies (Keane et al. 2012). Furthermore, EphA3 has been found overexpressed not only in neoplastic cells, but also in the microenvironment of different human cancers, where its targeting inhibits tumor growth by disrupting supportive stroma and vasculature (Val et al. 2014).

Aims: Due to the absence of relevant information about the role of EphA3 in multiple myeloma (MM), we aimed to evaluate the expression of this molecule in primary bone marrow plasma cells (BMPCs) from MM patients and MM cell lines compared to healthy controls (HCs). In addition, using a “loss of function” approach by mRNA silencing and an anti-EphA3 monoclonal antibody (EphA3mAb), we studied the in vitro plasma cells (PCs) viability and movement. Finally, we analysed the in vivo effects of EphA3mAb in a MM mouse xenograft model.

Methods: EphA3 mRNA and protein where investigated in 15 MM BMPCs, 11 MM cell lines and 10 HCs by qRT-PCR and flow cytometry. The effects of EphA3 targeting by lentiviral RNA silencing (shRNA) and anti-EphA3mAb on PC trafficking and viability were studied by adhesion assay on fibronectin and on bone marrow stromal cells (BMSCs), invasion assays and proliferation MTS assay, respectively. Gene expression profiling (GEP) was performed in shEphA3 versus shControl cells. Furthermore, the effects of EphA3mAb were analysed in a MM xenograft model by measuring tumor size and by assessing angiogenesis, proliferation and apoptosis rate on tumor biopsies using immunohistochemistry (anti-CD31, anti-ki67 and TUNEL assay, respectively). Statistical significance was determined by the t-test or One-way ANOVA analysis.

Results: EphA3 was found overexpressed in primary MM BMPCs and MM cell lines when compared with HCs (figure 1A-B). The EphA3 loss of function by siRNA and by EphA3mAb significantly inhibited in vitro the ability of MM PCs to adhere to fibronectin, to BMSCs and to invade (figure 1C-E), without affecting cell proliferation and viability (data not shown). GEP showed that knockdown of EphA3 modulated some molecules that regulate adhesion, migration and invasion processes. Importantly, the treatment with EphA3mAb in vivo significantly reduced tumor size and inhibited angiogenesis, as revealed by decrease of CD31+ vessels at immunohistochemistry (data not shown).

Figure 1.
Summary/Conclusions: Our findings suggest that EphA3 is a novel regulator of MM PC trafficking, in part via effects on adhesion and invasion; its targeting using EphA3mAb inhibits tumor growth, possibly by reducing angiogenesis, though other possible mechanisms of tumor death cannot be excluded. These data, together with the favourable clinical properties of a humanized EphA3mAb reported in a phase I trial on acute myeloid leukemia and myelodysplastic syndrome (Swords et al. 2016), support EphA3 targeting as a new potential therapeutic opportunity for MM that warrant to be further investigated.

E1227
PROGNOSTIC SIGNIFICANCE OF AMP1Q21 IN MULTIPLE MYELOMA

T. Abramova1, T. Obukhova1, L. Mendeleva1, O. Pokrovskaya1, E. Gribanova1, M. Nareyko1, L. Grebenyuk1, O. Votyakova2, M. Solovev1, M. F. Firsina1, I. Nakastoev1, A. Grachev1, M. Kanaeva1, A. Danilina1, S. Kulkov1, M. Rusinov1, V. Savchenko1

1Hematology Research Center, 2N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation

Background: Multiple Myeloma (MM) is a genetically heterogeneous and complex disease with widely diverging survival times from months to years. Amplification of locus 1q21 (amp1q21) is among the most commonly reported genetic abnormalities in MM, but its prognostic value remains unclarified.

Aims: To define the frequency of amp1q21 in MM and its correlation with other chromosomal aberrations, clinical course and prognosis.

Methods: In 134 patients (pts) with newly diagnosed MM from December, 2009 to March, 2016, 67 male and 67 female, median age 57 years (30-81), we performed FISH with locus-specific and centromere DNA probes (XL 1p32/1q21, XL 1q42, XL 1t(11;14), XL 1t(4;14), XL 1t(14;16), XL 1t(14;20), XL 6t(6;14), XL cMYC BA, XL 5p15/9q22/15q22, XL P53 (MetaSystems), D13S25 (Cytocell). Induction therapy with bortezomib-based courses was initiated for 131 pts, 3 pts with smoldering MM remained under observation. Response was evaluated according to the IMWG criteria for 127 pts, because 4 pts died in induction. 48 pts were underwent ASCT. The median follow-up of group was 19.3 months (3.2 – 77.4). Progression was diagnosed in 69 pts, 12 in their FISH-analysis was performed also in disease progression.

Results: Chromosomal aberrations were revealed in 133 of 134 (99%) pts. T(14;1q32) was detected in 42.5% (57/134), hypodiploidy in 57.5% (77/134), hypodiploidy in 2.9% (3/134) pts. In 11.2% (15/134) a concurrent t(11g)1q21 and a trisomy were found. The IgH translocations t(11;14), t(4;14), t(14;16), t(14;20), t(6;14) were observed at a frequency of 16.4%, 12.7%, 3.7%, 2.2%, 0.7% respectively, chromosomal partner is not found in 6.7%. Del(13q) was detected in 40.3% (54/134), del(17p) in 12.7% (17/134), tMYC/8q24 in 17.2% (23/134). Amp1q21 was detected in 39.6% (53/134). We identified 3 copies of 1q21 in 32 (60.4%) and 3 copies 1q21 (4-7) in 21 (39.6%) pts. Cases with Amp1q21 had a high incidence of del(13q) (OR=2.71 (1.32-5.55); p=0.006) and as well as higher LDH levels (OR=2.27 (1.09-4.72); p=0.027). From 12 pts investigated in progression amp1q21 was found in 9 pts (75%); in 2 cases amp1q21 was not found at diagnosis and was revealed in disease progression only; in 7 cases - amp1q21 was detected at diagnosis and in progression, and its copy number did not change. The difference in response after induction between pts with or without amp1q21 was not statistically significant: OR – 11.8% versus 14.5%, VGPR – 39.2% versus 27.6%; PR – 37.2% versus 27.6%; therapy resistant 11.8% versus 30.3% (p=0.07). Pts with amp1q21 had significantly worse 5-year overall survival (OS) (43.5% vs 79.4%; p=0.07). According to copy number of 1q21 the 5-year OS pts carrying 3 or >3 copies of 1q21 were 67.3% and 20.9% (p=0.0016) (Figure 1). On multivariate analysis 3 copies of amp1q21 (HR=4.29, p=0.0094), tMYC/8q24 (HR=6.51, p=0.0082), del(17p) (HR=3.46, p=0.007) were found to be an independent adverse predictors of shorter OS.

Amp1q21 can appear in the course of MM, therefore FISH-analysis of locus 1q21 should be performed at diagnosis, as well as in disease progression.

E1228
ADAPTIVE IMMUNE RESPONSE IN PLASMA CELL DYSCRASIAS: IMMUNE PROFILING AND DETERMINATION OF CIRCULATING B CELL LEVELS AS A SURROGATE ASSAY FOR BONE MARROW TESTING

S. Drain1,*, P. Egan1, I. Deighan2, P. Elder3, T. Bjourson1, F. McNicholl3, S. Smith1, V. Pianta1, S. Gilmour1, S. Ho2, I. Swords1

1Stratified Medicine, C-trie, Ulster University, 2Clinical Biochemistry, 3Haematology Department, Altnagelvin Hospital, Derry, 4Haematology Department, Ulster Hospital, Belfast, United Kingdom

Background: Immune paresis is commonly identified in patients with plasma cell dyscrasias (PCD). Often, in newly presenting multiple myeloma (MM), it is associated with intractable infections for which the patient first seeks medical help. Furthermore, recent evidence suggests the importance of assessing levels of bone marrow (BM) derived B cells for risk stratification of the MM patients as reduced levels of B-cells in the BM have been associated with poorer outcomes and reduced progression free survival1. This cellular measure of adaptive immune function (ie: B cell enumeration) is, however, seldom analysed in the peripheral blood (PB) of patients with PCD.

Aims: This study was designed to examine measures of the adaptive immune response in PCD patients, by measuring relative and absolute numbers of T, B cell subset, NK and NKT cells at different stages of PCD, and to determine if the PB-B cell compartment can act as a surrogate marker for B cell enumeration in MM.

Methods: PB and BM lymphocyte subset analysis was performed on samples obtained from a range of PCD patients (n=70) using directly conjugated monoclonal antibodies (MAB) and multicolour flow cytometry, carried out on a FACSAria III cell sorter (BD, Oxford, UK). Serum protein electrophoresis was performed to identify and quantify paraproteins, and uninvolved Ig levels were quantified using a chemiluminescent immunoassay. sFLC were quantified using the Freelite assay on the SPAplus instrument (Binding Site, Birmingham, UK).

Results: Data is presented on 102 PB samples obtained from 70 PCD patients at different stages of disease, including monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and MM at diagnosis (MMD), throughout treatment (MMT) and at relapse (MMR). Quantification of circulating lymphocyte subsets showed reduced, absolute, numbers of B cells (56/102), T cells (19/102), TIL cells (32/102), CTLs (17/102), NK cells (32/102) and NKT cells (72/102). Furthermore, these reduced B cell levels were more frequently seen in the MMD and MMT groups (50% of samples) compared with the other PCD groups (10-25% of samples). Lymphocyte subset analysis was also performed on paired PB and BM samples from 14 patients with MM and a significant, positive, correlation was seen between relative numbers of B cells in both PB and BM (r=0.0001, r>0.94). No clearcut correlations were found between reductions in uninvolved sFLC levels, and numbers of cells involved in the adaptive immune response.

Summary/Conclusions: The results presented here are further evidence of immune paresis in PCD with specific effects seen at the cellular level. The highest frequency of reduction was in B lymphocytes and NKT cells, in keeping with reduced levels of circulating B cells, followed by T cells, particularly TIL cells which have a crucial role in B cell Ig production. Relative B cell levels in BM were significantly correlated with B cell levels in PB and we suggest that monitoring of B cell levels in the PB of PCD patients may serve as a surrogate assay for enumeration of B cells in BM.

References

E1229
NOVEL MONOCLOCALANTIBODY THERAPY TARGETING CD26 IN MULTIPLE MYELOMA

H. Nishida1, T. Suzuki1, M. Hayashi1, M. Sakamoto1, T. Yamada1

1Pathology, Keio University, School of Medicine, Tokyo, Japan

Background: Bone disease is a hallmark of multiple myeloma (MM) and targeting osteoclasts (OCs) to alleviate bone destruction is a component of the standard care for MM. CD26 is a 110-kDa cell surface glycoprotein with DPPIV enzyme activity and has well-defined roles in T cell activation and several tumor developments, including malignant lymphoma. However, little is known about the role of CD26 in regulating bone remodeling.

Aims: In this study, we examine the CD26 expression in human normal OCs and OCs of MM patients. We explore the function of CD26 in osteoclastogenesis (OC) and investigate the effects of humanized anti-CD26 monoclonal antibody (CD26mAb) on human OCG. We further define the molecular targets of CD26 signaling cascade in OCG and explore the therapeutic potential of CD26mAb for treating MM.
Methods: Human BM-HMCs derived from normal human subjects or MM patients were cultured with M-CSF plus sRANKL with or without GSK2606414 for OC formation for TRAP staining and functional assay. To assess the mechanisms of action of CD26Ab on OC, RANK signaling proteins were examined by immunoblotting.

Results: CD26 is expressed on normal human OCs and is intensely expressed on activated OCs in MM, M. ripheus and MIN. Blocking of CD26 inhibited antigen presentation in association with CD26 expression on monocyte-macrophage lineage cells. CD26 expression was accompanied by increased phosphorylation of MKK3/6 and p38MAPK, which is crucial for human OC differentiation with its downstream activation of microphthalmia-associated transcription factor (mTfMt). The effect of CD26 on OC function was dependent on the concentration of CD26. We counted the number of multinucleated OCs (>3 nuclei) by TRAP/CD26 staining and down-regulated the secretion of TRAP-5b and type I collagen. It decreased the size of OCs and the number of nuclei per OC, with significantly defective bone resorption activity. It was revealed that in the presence of CD26Ab, which blocked IDO expression on OC precursors cells, CD26 expression was specifically, rapidly inactivated and subsequently, its downstream miR125b phosphorylation was persistently inhibited. Thus, OC maturation with its bone resorption was impaired by suppressing the expression of TRAP and OC fusion proteins. In contrast, MKK3/6-p38MAPK-miR125b was not phosphorylated at all in immature OCs after RANKL stimulation, regardless of the absence or presence of CD26Ab. These results suggest that CD26Ab blocked RANKL induced p38MAPK phosphorylation in OC precursor cells, but not in OCs. The activation of other MAPKs including ERK and SAPK/JNK, or NFκB was rapidly induced in response to RANKL both in OC precursors cells and OCs. However, the absence or presence of CD26Ab did not directly affect mature OC functions. Next, although CD26Ab did not demonstrate direct inhibition of proliferation of MM cells, to further investigate the role of CD26 in MM cells in the BM, co-cultures of 11 MM cell lines with 11 MM cell lines with CD26-stained OCs were performed. We examined the expression of CD26 in CD26-stained MM cells. Although CD26 expression was only slightly detected in any of MM cell lines in mono-culture, CD26 expression level was upregulated in all MM cell lines, co-cultured with OCs by flow cytometry and immunohistochemistry. CD26 protein level in these cell lines was also increased by immunoblotting or ELISA. To further explore the CD26 expression in the BM, we used 12 human cell lines, co-cultured with CD26Ab. Interestingly, CD26Ab did not directly affect mature OC functions. Our data imply that the blockade of CD26 signaling with CD26Ab impairs the development of human functional OCs. Targeting CD26 in both OCs and MM cells with CD26Ab may be a promising novel therapeutic strategy in MM-associated bone disease and MM progression.

E1231

THE ANTI-MYELOMA ACTIVITY OF PERK KINASE INHIBITOR IN TARGETING MORE THAN 50 UPR-RELATED GENES INVOLVED IN THE PROLIFERATION OF MM CELLS

M. Dimopoulos1, T. Saracino1, T. Myrianthefs2, E. Kastritis1, N. Mavrianou1, N. Tankias1, E. Terpos1, M. Dimopoulos1

1National and Kapodistrian University of Athens, Athens, Greece

Background: Due to the immunoglobulin production, multiple myeloma (MM) plasma cells are dependent on the unfolded protein response process (UPR), which controls protein production and ensures its proper translation and folding. A study by Michallet et al (2011) showed that knockdown of one of the three well-known arms of the UPR, PERK (protein kinase R (PKR)-like ER kinase) in MM cells resulted in autophagic cell death. This outcome indicated the importance of PERK activation for the maintenance of plasma cell to myeloma cell but also its ability to impede the apoptotic effect. In this study we used a small ATP competitive molecular inhibitor, GSK2606414, that acts by targeting PERK enzyme activity in its inactive DFG conformation at the ATP-binding site. By displaying ≥385 fold selectivity over c-Kit, Aurora B, BRK and many other kinases.

Aims: In this study we aimed to use a small ATP competitive molecular inhibitor, GSK2606414, that acts by targeting PERK enzyme activity in its inactive DFG conformation at the ATP-binding site, while displaying ≥385 fold selectivity over c-Kit, Aurora B, BRK and many other kinases.

Methods: We initially screened 25 CD138+ MM patients and 6 human myeloma cell lines (HMCls) for PERK mRNA expression. Our results showed that PERK mRNA is highly expressed in almost all patients (5-10 fold higher than the mean PERK expression of HMCls).

Results: To test the effect of GSK2606414 on the proliferation of MM cells, 4 HMCls were treated with different doses of GSK2606414 at two time points (24 and 48 hours). Treatment of cells with 3-30μM GSK2606414 resulted in a dose-dependent inhibition of cell proliferation in all HMCls ranging for 20-95% of reduction of proliferative activity, thus, indicating the dependency of these cells on PERK activation. Treatment of H929 and L363 with GSK2606414 resulted in 40% and 30% reduced cell proliferation in H929 and L363 respectively compared to bortezomib-treated cells (87% and 42% respectively). In addition, the effect of GSK2606414 in combination with bortezomib in the proliferation of H929 and L363 cells was examined. As seen in the apoptosis assay, pretreatment of cells with GSK2606414 for 24 and 48 hours resulted in 25% and 15% increase in apoptotic cells by Annexin-V/PI staining respectively compared to the untreated cells. However, the most important finding was a significant synergistic effect of GSK2606414 with bortezomib in these cells. Specifically when H929 and L363 cells were treated with 5nM bortezomib in combination with 20μM GSK2606414, synergistic effect was seen where apoptotic cells reached 99% and 77% respectively, compared to bortezomib-treated cells (87% and 42% respectively). In addition, the effect of GSK2606414 in combination with bortezomib in the proliferation of H929 and L363 cells was examined. As seen in the apoptosis assay, pretreatment of cells with GSK2606414 for 48 hours resulted in 40% and 30% reduced cell proliferation in H929 and L363 respectively compared to bortezomib only treated cells. Under ER stress conditions, the activation of ATF6 and PERK/eIF2α leads to the induction of ATF4 translation and results in the upregulation of CHOP. To determine the gene target effects of GSK2606414, ATF4 and CHOP mRNA expression levels were determined in H929 cell line after 24 hour of treatment. Treatment with GSK2606414 alone did not alter the expression levels of CHOP but reduced more than 50% the expression levels of ATF4. When combined with bortezomib CHOP and ATF4 levels were reduced 20% and 60% respectively while treatment with bortezomib alone reduced the expression levels of CHOP and ATF4 by 50-100%. Changes in mRNA expression of 84 UPR-related genes were analyzed in H929 cells. Specifically H929 cells were pre-treated with GSK2606414 and then subjected to ER stress conditions by treatment with tunicamycin (TM). After 24 hours of treatment, 50 genes were found to be transcriptionally regulated by >5-fold in response to TM (ATF2, ATF3, ATF4, CHOP, CEBPα, CEBPβ, CEBPδ, CEBPB, CEBPβ, CEBPA, CEBPD, CREB3L3, CREB3L1, CEBPD, PPP1R15A, etc.) were downregulated by >5-fold, whereas 10 of these genes (HERPUD1, EIF2AK3, CREB3L3, HSPA2, HSPA1B, etc.) were upregulated similarly.
Summary/Conclusions: In conclusion, given the on-target pharmacological effects of PERK inhibitor on MM, development of PERK inhibitors may offer a therapeutic advantage that would affect MM pathogenesis and treatment.

E1232
ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE MYELOMA: MALIGNANT CO-OPTATION OF ARGININE AS NOVEL IMMUNE CHECKPOINT

A. Romano1,2, J. M. Garcia Manteiga3, V. Simone4, L. Parrinello4, L. Canziani1, E. Milan1, M. Ghizzinardi1, D. Tibulio2, G. Galliongo5, P. La Cava5, F. Cremaschi6, C. Concillo1, C. Musto6, F. Ciceroni6, F. Di Raimondo6, S. Cenci7
1Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, 2Division of Hematology and Bone Marrow Transplant Unit, Ospedale Policlinico e Vittorio Emanuele di Catania, 3Center for Translational genomics and Bioinformatics, San Raffaele Scientific Institute, Milano, 4Laboratory of Pre-clinical and Translational Research IRCCS, CROB Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), 5Division of Genetics and Cell Biology, Azienda Ospedaliera Policlinico e Vittorio Emanuele di Catania, 6Department of Oncology, San Raffaele Scientific Institute, Milano, Italy

Background: The bone marrow (BM) environment plays a crucial role in the incurable plasma cell (PC) malignancy multiple myeloma (MM). Our previous work showed that autocrine arginine (Arg) depletion in normal human marrow (bupa) sustains BM cell fitness through Arg depletion. On the other hand, MM is addicted to the autophagy receptor SQSTM1/p62. By inhibiting p62 translocation, we observed an increased Arg concentration and inhibited autophagy in MM cells.

Aims: We hypothesized that in MM HDNs sustain PC fitness sustaining p62 through environmental arginine deprivation. Methods: We integrated diverse unbiased and hypothesis-driven approaches: (1) gene expression profiles (GEP) of patient-derived circulating HDNs (60 MM, 30MSUS, 30 healthy controls), (2) metabolomic profiling by UHPLC/GC-MS of ad hoc collected BM and peripheral plasma (16 MM, 17 smoldering MM, 30MSUS, 29 controls), and (3) functional and expression in vitro studies on human MM cell lines. We validated our observations in primary MM cells using bioinformatic analysis of transcript expression levels detected by RNA-sequencing (RNA-seq) available from the open-access, public clinical and molecular database, the CoMMPass Researcher Gateway (http://research.thernmrf.org, vlA8, n=649).

Results: In vitro, selective and progressive arginine deprivation (range 1000-0 μM) in four MM cell lines (MSUS, U266, OPM2 and RPMI8286) activated the GCN2/CHOP axis, resulting in increased p62 and Bmp1 expression, increased ATP availability and immunoglobulin production. Conversely, stable lentiviral p62 silencing significantly reduced Bmp1 and ATp, and led to complete extinction of MM cell lines within 10 days of culture. Bioinformatic analysis of MMRF-Encompass trial data showed a positive correlation between p62 and Bmp1 expression. Increased Arg availability from the open-access, public clinical and molecular database was associated with increased Arg availability and decreased p62 expression.

Summary/Conclusions: Taken together, our findings disclose a novel envirommental circuit co-opted by MM evolution, whereby immunosuppressive HDNs sustain PC fitness through arginine deprivation to increase p62 and Bmp1 via the GCN2/CHOP pathway.

E1233
ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) CALCULATED BY CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY MORTALITY IN MYELOMA PATIENTS

E. Katodritou1,*, V. Palaska1, E. Giannopoulou1, S. Papadaki1, A. Gerofotis1, J. Martínez-López1,2, A. Leivas1,2,*, I. Rapado1,2, L. Fernández1, A. Pérez-Martínez3, J.J. Lahuerta2, J. Martínez-López1,2
1Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Center, 2Hematology, Hospital Universitario 12 de Octubre, 3Pediatrics, Hospital Universitario La Paz, Madrid, Spain

Background: Myeloma (MM) remains an incurable disease. Novel therapeutic strategies targeting drug resistant cells (DRC) and clonogenic tumor cells (CTC) are needed. Our group has conducted a phase I clinical trial with activated and expanded autologous NK cells (NKAES) in patients with refractory MM with a relevant clinical effect. Likewise, it has been possible to discriminate DRcs in MM by side population (SP) detection.

Aims: The aim of this study was to characterize DRC and to check the activity of NKAEs against these DRCs and CTCs while preserving the hematopoietic progenitor cell.

Methods: Flow cytometry of the side population was performed by Dye Cycle Violet efflux detection to characterize DRC of MM cell lines and bone marrow samples from MM patients. The side population was purified by sorting and characterized by RNAseq. NK cells from MM patients’ peripheral blood were expanded and cocultured with genetically modified K562-m15-4I8BL cells in order to obtain NKAES. The activity of NKAES against SP was evaluated by time lapse microscopy and the activity against CTCs was evaluated by methylcellulose assay. In vitro safety against CD34+ progenitors was evaluated by time-resolved fluorescence cytotoxicity with europium-TDA and cul- turability of methylcellulose with hydroxybutyric acid by co-culture.

Results: SP cells from both cell lines and samples from different stages of MM showed overexpression of stemness markers. Patient NKAES were shown to have much higher adhesion, migration and detection capacity of MM tumor cells than NK cells from the same patient. After SP purification by sorting, NKAES were also able to detect and coculture with the genetically modified K562-m15-4I8BL cells in order to obtain NKAES. The activity of NKAES against SP was evaluated by time lapse microscopy and the activity against CTCs was evaluated by methylcellulose assay. In vitro safety against CD34+ progenitors was evaluated by time-resolved fluorescence cytotoxicity with europium-TDA and culturability of methylcellulose with hydroxybutyric acid by co-culture.

Summary/Conclusions: NKAES have molecular characteristics of the tumor stem cell compartment in MM. Likewise, NKAES cells from MM patients could...
destroy drug resistant MM cells and clonogenic tumor cells with high efficiency, preserving CD34+ hematopoietic cells, and thus constitute an effective and safe therapy against MM.

E1235
UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS
S. Papamichos1, Laboratory of Oncology, Istituto Giovanni Gaslini, Genova, Italy

Background: Growing evidence suggest that production of soluble receptor activator of nuclear factor-kappa B ligand (sRANKL) directly by myeloma cells is causally related to accelerated bone loss in multiple myeloma (MM). Notably, sRANKL may be produced either by proteolytic cleavage of membrane-bound RANKL or by alternative splicing of TNFSF11 gene (TNFSF11 variant 2, sRANKL mRNA). Recent analysis argues against proteolytic processing of the membrane-bound form being the main mechanism of sRANKL production by myeloma cells. Accumulative data indicate that sRANKL mRNA presents a restricted transcriptional pattern, namely is expressed predominantly in malignant cell types. Accordingly, sRANKL mRNA (over)expression in primary MM cells and human MM cell lines has been validated in three independent studies. Furthermore it was recently demonstrated that sRANKL mRNA proximal promoter and first exon are of retroviral origin, residing within a large genomic cluster of transposable elements (TEs).

Aims: To unmask the TE-shaped transcriptional and epigenetic apparatus impelling the expression of sRANKL mRNA in a cell-type and cell-context-specific manner.

Methods: RepeatMasker software was used to reveal the presence of integrated TEs in the genomic segment comprising TNFSF11, TNFSF11 RNA-Seq data, generated by the GTEx project across 51 normal human tissues, were analyzed via GTeX Portal. TNFSF11 RNA-seq data from 4 bone marrow samples and 8 white blood cells samples, generated from the PRJEB4337 and PRJNA182351 BioProjects, were analyzed via the NCBI portal. TNFSF11 transcription factor (TF) ChIP-seq data were downloaded from the UCSC Genome Browser Database. Data on TNFSF11 proximal promoter methylation status in 63 cell lines were downloaded from the HAIb Methyl450 ENCODE track.

Results: RNA-Seq data from 51 normal human tissues show that sRANKL mRNA is expressed exclusively in testis, which is in accordance with the retroviral origin of the transcript. Data analysis from the PRJEB4337 and PRJNA182351 BioProjects further validates the null expression of sRANKL mRNA in normal human bone marrow and white blood cells. Methylation status of sRANKL mRNA promoter in 5 lymphoblastoid cell lines (LCLs) signifies that the retroviral promoter remains heavily methylated in these cell types. TNFSF11 TF ChIP-seq data show that 5 of 161 TFs can bind to the TE-derived sRANKL mRNA promoter region. Four of the five TFs (EBF1, PA5X, IKZF1, and PU.1) bind to this genomic segment exclusively in LCLs, signifying a cell-type specific transcriptional regulation. Notably, all 4 TFs are known to play a major role in normal and/or malignant lymphopoesis. Furthermore, IKZF1 and PU.1 represent direct targets of immunomodulatory drugs (IMiDs) for down-regulation.

Summary/Conclusions: Transcription of sRANKL mRNA is driven by a retroviral promoter which remains heavily methylated, thereby inactive, in normal lymphocytes. Epigenetic derepression of this promoter during the course of myeloma cell transformation, in the context of sRANKL mRNA by human myeloma cells represents a plausible scenario. Should the IKZF1 and the PU.1 TFs act as enhancers of sRANKL mRNA expression, directly contributing to upregulation of sRANKL production in MM, it is a tantalizing hypothesis that warrants further investigation because this type of transcriptional boost could be exploited for further treatment of MM. That Lenalidomide treatment downregulates the amount of sRANKL in the serum of patients with MM through inhibiting PU.1 expression (Breitkreutz et al., Leukemia 2008) is in accordance with the above and further raises the interest on the mechanisms promoting the anti-osteoclastogenic properties of IMiDs.

E1236
THE RATIO OF PATHOLOGICAL PLASMACYTES, ASSESSED BY 8-COLOR FLOW CYTOMETRY, PREDICTS RISKS OF DISEASE PROGRESSION IN MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND SMouldERING MULTIPLE MYELOMA
C. Brouzes1,*, L. Lhermitte1, C. Zaratzian1, M.O. Chandesris2, L. Frenzel2, 1Laboratory OncoHematology, 2Clinical Hematology, Necker Enfants Malades Hospital and Descartes University, Paris, France

Background: The ratio of pathological plasma cells (PP/PT) has been reported to be predictive in the context (Pérez-Perez et al. Blood 2007; 109:256–2592).

Aims: We undertook to test this in a single center study.

Methods: All patients undergoing bone marrow evaluation following identification of a monoclonal peak (at diagnosis or during follow-up) during a 7-year period with a diagnosis ofmUS (n=154) or SMM (n=56) and at least 6 months follow-up were analysed by 8-color FC (including 11 antibodies) from fresh whole blood or bone marrow. PP/PT ratios were considered high risk. Disease evolution was indicated by a necessity to treat.

Results: The 210 PP/PT ratios were on average 77% (10-100). Amongst the 154mUS patients, 24 had a ratio >95%, of which 8 (33%) evolved, compared to 9/130 (7%) with a ratio below 95%. Only 2 of these 8mUS demonstrated other high risk factors (a non-IgG monoclonal peak or a peak at >15g/L). Amongst SMM patients, 22/30 (73%) patients with a high ratio evolved, of which 9 (41%) had a non-IgG peak, compared to 10/26 (38%) evolution in SMM with low PP/PT ratios. The risk of evolution to active MM was significantly higher in patients with a PP/PT <95% group, in both hemmUS (p =0.0001) and overall (p =0.0004) groups. There was a discordance between PP/PT ratio and disease evolution in 11% (17/154)mUS patients and 23% (48/210) of the overall group but no other FC markers associated with an increased risk of evolution could be identified.

Summary/Conclusions: We confirm the clinical value of a simple, rapid, two-tubes FC quantification of the proportion of pathological plasma cells in the evaluation of the risk and kinetics of disease evolution immUS and SMM. It’s use allows identification of patients which require more frequent follow-up.
HAS been demonstrated, the synergistic cytotoxicity may be further exploited dosage of both drugs. Whilst the clinical efficacy of CAR and POM combinations schedule was maintained throughout BM microenvironment models using low demonstrated for the combination of CAR and POM and a maximal apoptosis be to start the administration of IMiDs a day before PIs to increase cells killing. overall suggest that the administration of IMiDs before PIs can improve efficacy. Consistently observed in IMiDs pre-exposure schedule. The superiority of this demonstrated for the combination of IMiDs and PIs and a maximal apoptosis using the median effect method of Chou Talalay, we evaluated the interactions: 1) MM cells cultured in complete medium, 2) MM cells suspended and active system, with potential contributions of both physical adhesion and intermediate dose and high dose. Since the BM microenvironment is a complex interacts with BMSCs in a transwell system. Myeloma and other monoclonal gammopathies - Clinical

ASSESSMENT OF THE IMPACT OF POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE COMMUNITY-BASED CONNECT MM REGISTRY

For the purpose of this study we used five bona fide MM cell lines (MM1.S, OPM-2, NCI-H929, KMS12.8M and U266), a human bone marrow stromal (BMS) cell line (HS-5 cells) and primary samples from newly diagnosed MM patients. Apoptosis analysis was done up to 48h after administration of the first drug. For each drug, three different concentrations were used: low dose, intermediate dose and high dose. Since the BM microenvironment is a complex and active system, with potential contributions of both physical adhesion and soluble factors, we used three experimental conditions to differentiate these interactions: 1) MM cells cultured in complete medium, 2) MM cells suspended in medium conditioned in the prior presence of BMSCs, or 3) MM cells co-cultured with BMSCs in a transwell system.

Clinical trials are needed to investigate the most effective schedule, which could be to start the administration of IMiDs a day before PIs to increase cells killing.

The Connect MM registry was used to assess impact of maintenance therapy on survival outcomes in pts with NDMM receiving ASCT.

Routine duration was from 100 days post-ASCT (no maintenance group) or start of maintenance until progressive disease, death, discontinuation, or data cutoff of January 7, 2016. End points were PFS, second PFS, OS, and safety. An exploratory analysis of the impact of baseline characteristics on survival outcomes was performed.

Table 1.

Results: A total of 1493 pts were enrolled in Cohort 1 from Sep 2009 to Dec 2011; 1450 were treated, 81% (n=1173) in a community setting. Of these, 432 (29%) met analysis criteria. Median follow-up was 39.3 months. Median age was 60 y (range, 24-78); 60% were men; and 86% were white. A total of 165 pts did not receive maintenance. Of 267 pts receiving maintenance, 213 (80%) received LEN-based maintenance; 30 (11%) received BORT-based maintenance, and LEN+BORT maintenance. Duration was from 100 days post-ASCT (no maintenance group) or start of maintenance until progressive disease, death, discontinuation, or data cutoff of January 7, 2016. End points were PFS, second PFS, OS, and safety. An exploratory analysis of the impact of baseline characteristics on survival outcomes was performed.

Table 1.
E1240
DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
A. Lakshman1, J. Abeykoon2, S. Kumar1, V. Rajkumar1, T. Kouris3, F. Buadi1, D. Dingli1, L. Martha4, W. Gonsalves1, A. Dispensieri2, R. Kyle5, Y. Lin6, R. Go7, R. Warsame1, M. Hobbs1, A. Fonder1, Y. Hwa1, S. Hayman1, S. Russell1, N. Leung1, M. Gertz1, P. Kapoor1
1Division of Hematology, Mayo Clinic, Rochester, United States

Background: Daratumumab-based combination Therapies (DCT) with bortezomib (V)/ lenalidomide (R)/ pomalidomide (P) and dexamethasone (d) have shown exceptional activity in relapsed and/or refractory multiple myeloma (RRMM) in trials. Experience outside of trials since the approval of Daratumumab (D) in 2015 is limited.

Aims: We aimed to review the outcomes of patients who received DCT at our institution.

Methods: Records of RRMM patients seen at Mayo Clinic, MN from December 2015–December 2016 were reviewed. Patients who received ≥ 1 cycle of DCT were included. Time-to-event analyses were done from date of starting DCT using Kaplan Meier method. Common terminology criteria for adverse events v4.0 were used to grade toxicities.

Results: Of 130 patients, 59% were males and median age at DCT initiation was 67 (43-93) years. ECOG performance score was ≥2 in 29%. Patients were classified as mSMART high (22%), intermediate (22%) or standard (56%) risk. Median time from diagnosis to initiation of DCT was 51.3 (5-156) months, and median number of prior therapies was 4 (1-14). Eighteen (14%) of patients were refractory to prior daratumumab monotherapy. Fifty-three (41%) responded D, 34 (26%) and 25 (19%) received DpD, Dpd and Dvd respectively. Eighteen (14%) patients received ‘other’ DCT. Median time to first response (≥ PR) was 3.1 months (95% CI 2.1-4.6). Overall response rate was 46%, [complete remission-2%, very good partial remission-18%, partial remission-26%]. Minimal response was seen in 17%, with clinical benefit rate of 62%. Median estimated progression-free survival (PFS) for quadruple refractory (n=28) MM was 2.8 months (CI 2.2-5.3) vs all survival (OS) from starting DCT was NR (CI 11.4-NR) (figure C). Median overall survival (OS) was 67 (43-93) years, ECOG performance score was ≥2 in 29%. Patients were refractory to prior daratumumab monotherapy. Fifty-three (41%) responded D, 34 (26%) and 25 (19%) received DpD, Dpd and Dvd respectively. Eighteen (14%) patients received ‘other’ DCT. Median time to first response (≥ PR) was 3.1 months (95% CI 2.1-4.6). Overall response rate was 46%, [complete remission-2%, very good partial remission-18%, partial remission-26%]. Minimal response was seen in 17%, with clinical benefit rate of 62%. Median estimated progression-free survival (PFS) for quadruple refractory (n=28) MM was 2.8 months (CI 2.2-5.3) vs 5.9 months (CI 4.9-NR) for the rest (p=0.008) (figure D). Grade 3 or higher hematological toxicities were seen in 42% of patients. Other toxicities included infections (37%), fatigue (31%), infusion reactions (16%) and diarrhea (10%).

Figure 1.

Summary/Conclusions: Metformin use was associated with a better progression-free survival and higher complete response rates after SCT in our MM cohort. A trend toward better overall survival was also noted in the Metformin group. Larger studies are needed to enhance our understanding of the clinical effect of metformin on MM.

E1241
IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA PATIENTS POST STEM CELL TRANSPLANT
N. Duma1, J. Vera-Aguilera1, J. Paludo1, Y. Wang1, T. Anagnostou1, A. Fonder1, F. Buadi1, S. Kumar1, M. Lacy1, S. Hayman1, A. Dispensieri1, M. Gertz1, D. Dingli1
1Hematology, Mayo Clinic, Rochester, United States

Background: Multiple myeloma (MM), a monoclonal plasma cell disorder, is one of the most common hematologic malignancies in the US. In preclinical studies, metformin demonstrated plasma cells cytotoxicity. However there is lack of studies translating the effect of metformin into the clinical setting.

Aims: Assess the clinical effect of metformin in patients with MM.

Methods: All MM patients who underwent stem cell transplant (SCT) at the Mayo Clinic Rochester from 2007 to 2012 were reviewed. Patients were grouped based on metformin use. Initial diagnosis at our institution and ≥12 months of follow up were required. Kaplan-Meier method and Cox regression were used for time-to-event and multivariate analysis.

Results: Out of 687 patients, 78 (11.4%) patients were using metformin at the time of MM diagnosis. Baseline characteristics in the metformin and no-metformin groups were similar. Median metformin dose was 2000mg daily and median duration of metformin use from MM diagnosis was 22 months. Patients on the Metformin group achieved higher rates of complete response after SCT (41% vs 29% p<0.02). Median progression-free survival (PFS) after SCT was longer in the Metformin group, 31.3 months (95% CI: 10.4-52.2) vs 16.6 months in the no-metformin group (95%CI: 14.5-18.7) p<0.04. There was a trend toward longer overall survival in the Metformin group, but it was not statistically significant (170 vs 106 months, p<0.10). In a multivariate analysis of metformin use, age, sex, international staging system (ISS), LDH and cytogenetics/FISH, the former was an independent predictor of PFS after SCT (OR: 0.38, 95%CI: 0.20-0.68, p<0.001).

Figure 1.

Summary/Conclusions: Metformin use was associated with a better progression-free survival and higher complete response rates after SCT in our MM cohort. A trend toward better overall survival was also noted in the Metformin group. Larger studies are needed to enhance our understanding of the clinical effect of metformin on MM.
and Nuclear Medicine, looking for focal bone lesions, bone marrow pattern and incidental findings. Details of the patients' demographics, myeloma diagnosis and treatment were collected from the medical records.

Results: Of the 33 patients, 24 were male. The median age was 64 years (range=43-86 years). One patient had a solitary plasmacytoma, the other 32 had myeloma (21 IgG, 3 IgA, 2 non-secretory, 4 light chain disease, 2 biclonal myeloma). Most had ISS stage I disease with a median platelet count of 170 (range 0-526). 21 patients had a bone marrow plasma cell burden of 10-60%, 10 patients >60% and 2 were unknown. Sixteen patients were diagnosed with smouldering myeloma and a ‘watch and wait’ policy was adopted. Eleven patients were treated with chemotherapy, 4 were entered into a clinical trial, one was offered palliative care and one was referred to our centre for autograft. WBMRI identified a focal lesion of disease in 30% of patients compared with 36% by PET-CT. This was not a statistically significant difference (p=0.18). In addition there was no statistically significant difference between PET-CT & MRI in detecting <3 or >3 lesions (p=0.705 and p=0.083 respectively). The apparent diffusion coefficient (ADC) at vertebrae L5 (using diffusion weighted MR imaging) was measured. This showed a strong correlation with the degree of bone marrow infiltration by plasma cells (r=0.64). An ADC of <600mm²/s had a negative predictive value of 93% for a bone marrow plasma cell infiltrate of >60%. There was also a significant difference (p=0.012) in the ADC between those with smouldering myeloma and those with symptomatic disease. It was noted that 9 scans resulted in incidental findings including pneumonia, adrenal lesions and one case of colocolcal resection.

Summary/Conclusions: We have shown no difference in PET-CT and WBMRI in detecting a myeloma defining focal bone lesion, or providing prognostic estimation of bone disease. Using MRI, a measure of the ADC at vertebrae L5 has been shown to be a semi-quantitative parameter that correlates with bone marrow plasma cell infiltration and distinguished between those with smouldering and symptomatic disease. In addition it is noted that whole body imaging has led to incidental findings of further pathology, including an unrelated malignancy, which may lead to useful clinical information or to further investigations and imaging which may not be needed.

E1243

PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN PATIENTS WITH AL AMYLOIDOSIS

G. Palladini1, G. Merlini1
1Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

Background: In multiple myeloma, Minimal Residual Disease (MRD) demonstrated by multiparameter flow cytometry (MFC) identifies subjects with significant challenges to achieve complete response (CR). The role of MRD in AL amyloidosis has not been assessed so far.

Aims: In the present study, we assessed the MRD by MFC in patients with AL amyloidosis who attained CR.

Methods: CR was defined as per current criteria (negative serum and urine immunofixation and normal free light chain ratio). For flow cytometry studies, bone marrow samples were processed following the EuroFlow Bulk Lysis Standard Operating Protocol and stained with the EuroFlow/MF MM MRD panel. At least 5x10⁶ events were measured using a FACSCanto II (USA) instrument. Data were analyzed using the Infinicyt software (Spain). Patients were identified as having residual disease if a discrepant population of plasma cells comprising ≥50 events was identified (10⁻⁵ limit of detection).

Results: Twenty-eight patients were tested (7 were found to have relapsed at the time of MRD assessment with monoclonal components detectable and MRD+ and 21 satisfied current criteria for CR. Nineteen (90%) had renal and 9 (45%) had cardiac involvement at diagnosis. More than 2 lines of therapy were required to achieve CR in 7 subjects. Median time to CR was 10 months (range: 3-82). Five patients (62%) had achieved cardiac response and 9 (50%) renal response at the time of CR. The median time from CR to MRD was 30 months (range: 6-148), this was not different in the MRD positive vs negative patients. A median of 1089 (range 256-2500) corresponding to 0.04% (range 0.02-0.3%) plasma cells with abnormal phenotype were detected in patients MRD+. No differences in organ involvement, cardiac and renal stage, type of therapy, number of treatments, and organ response at the time of CR was found between the two groups. However, improvement of cardiac function compared to the time of CR was observed in all 5 evaluable MRD- patients and in none of the 2 MRD+ patients (P=0.047). Compared to the time of CR, renal response was obtained in 7 MRD- subjects (84%) and in 4 (50%) MRD+ (P=0.153). Overall, further improvement of cardiac or renal function after CR was significantly associated with MRD+ (P=0.047).

Summary/Conclusions: This proof-of-concept study indicates that 43% of patients with AL satisfying current criteria for CR have detectable MRD. MRD positivity could in part explain persistence of organ damage is patients in CR.

E1244

RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS

R. Benjamin1, S. Schey1, A. Pagliuca1, G. Mufti1, M. Streetly1,3, R. Kazmi3, K. Raj1, M. McHale1, A. Hinds1, S. Rogatsky1, S. Hong1, K. Iskander7, L. Rosiñoł9,10, S. Schey1, A. Pagliuca1, G. Mufti1, M. Streetly1,3, R. Kazmi3, K. Raj1, M. McHale1, A. Hinds1, S. Rogatsky1, S. Hong1, K. Iskander7, L. Rosiñoł9,10
1Department of Myeloma, King’s College Hospital Foundation Trust, 2Guy’s, King’s and St Thomas’ School of Medical Education, King’s College London, 3Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, 4Department of Haematology, University Hospital Wales, Cardiff, United Kingdom

Background: High dose chemotherapy followed by autologous stem cell transplant (ASCT) remains the gold standard treatment in myeloma for young patients with AL amyloidosis who attained CR. A validation study in a larger cohort is ongoing. The possible impact of MRD should be considered in trials aiming at increasing organ response rate in patients in CR.

Methods: This analysis evaluated PN rates in ASPIRE (K [27mg/m²] lenalidomide [L]-dexamethasone [D] vs Rd) and ENDEAVOR (Kd [K 56mg/m²] lenalidomide [L]-dexamethasone [D] vs Rd). We evaluated treatment emergent grade ≥2 PN, patient reported outcomes (PROs; QLQ C30 pain, FACT/GOG neurotoxicity subscales), and progression free survival (PFS) in patients with a baseline history of PN (patients with grade ≥3 PN at baseline or grade 2 PN at baseline were excluded from the studies).

Results: In ASPIRE, grade ≥2 PN rate was low (8.0% [Kd] vs 8.0% [Rd]; Table). Pain subscale scores were similar between arms. Median PFS was longer with Kd vs Rd for patients with grade 2 PN at baseline. In ENDEAVOR, grade ≥2 PN rate during the study (prespecified key secondary endpoint) was significantly lower with Kd vs Rd (6.0% vs 32.0%, Table). Patients had significantly improved pain and neurotoxicity subscale scores with Kd vs Rd. PFS improved with Kd vs Rd in patients with baseline history of grade ≥2 PN (Table 1).

Table 1.

Summary/Conclusions: In ENDEAVOR, the rate of PN was significantly lower with Kd then with Rd: In ASPIRE, PN rate was similar for Kd and Rd. Improved pain and neurotoxicity subscale scores with K may be attributed to better disease control and/or lower PN rates.

E1245

EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING INDUCTION TREATMENT

I. Walker1,2, A. Coady3, I. El-Najjar 5, K. Wilson4, K. Cuthill1,2, W. Ingram4, M. Kazmierski2, K. Raj1, R. Benjamin1, S. Schey1, A. Pagliuca1, G. Mufti1, M. Streetly1,2, C. Bygrave4
1Department of Haematology, King’s College Hospital Foundation Trust, 2Guy’s, King’s and St Thomas’ School of Medical Education, King’s College London, 3Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, 4Department of Haematology, University Hospital Wales, Cardiff, United Kingdom

Background: Relapse occurs in approx. 50% of patients after ASCT. Factors associated with early relapse following ASCT are being identified to improve risk stratification.
patients at induction. A number of factors have been shown to correlate with overall survival (OS) at progression free survival (PFS) including depth of remission prior to ASCT, initial ISS stage and high risk cytogenetics. Emerging evidence has demonstrated that early relapse following ASCT is associated with reduced OS, and is not correlated with depth of pre-transplant response.

Aims: To characterise myeloma patients who relapsed within 12 months of ASCT, through baseline characteristics and transplant engraftment, and assess the impact of this early relapse on OS and PFS.

Methods: We performed a multicentre retrospective analysis of patients who underwent ASCT at 3 centres between 01/2009 – 02/2016 (London) and 06/2006 – 03/2013 (Cardiff). Baseline characteristics were reviewed and ASCT engraftment was assessed; by time to neutrophils 50 x 10⁹/ℓ and platelets ≥ 20 x 10⁹/ℓ. Post-transplant PFS & OS was calculated by time (months) from diagnosis to progression or death.

Results: 443 myeloma patients were identified, median age was 57 (r 31-73), 56% were male. 41% of patients were ISS stage 1, 34% stage 2, 25% stage 3. Cytogenetic data was available for 139 patients. 1st-line therapy prior to transplant was immunomodulatory drug (IMiD) based (THAL/LEN) for 318/443 patients & 24/443 were proteasome inhibitor (PI) based (BORT/CARF). In addition, 11 patients received combination PI and IMiD. Median time from start of therapy to ASCT was 10 months (r 3-109m), 67 patients progressed within 12m of ASCT (early progression). No statistical difference was found between <12m or >12m relapse for: age, gender, 1st line therapy, ISS stage, Hb, LDH, Ca or cytogenetic, confirming that this group is difficult to predict at baseline. Median OS from time of diagnosis was 103 months (95% CI 101 -137), median OS from start of ASCT was not reached, however 5-year OS was 68%. Patients with progressive disease within 12 months of ASCT, has significantly reduced median OS compared to patients with disease free > 12 months (95% CI 21- 39) compared to non-progressive patients (median OS:103m 95% CI 89-117) p=0.0005. Median OS from ASCT was reduced in early progression median OS:18m (95% CI 14-22m) vs progression > 12 months median OS:89 months (95% CI 79-89m) p<0.0005. 1st line therapy did not influence likelihood of PFS<12months, with no statistical difference between patients who received PIs, IMiDs or both 1st line (p=0.484).

A significant difference was observed in median time to platelet engraftment between the 2 centres. Increased time for platelets to reach >20 x 10⁹/ℓ was associated with reduced OS from ASCT for each centre HR 1.14 & 1.20 (p=0.046 & 0.03) for Cardiff or London centres respectively (Cox’s Method).

Summary/Conclusions: Early relapse following ASCT is a significant predictor of inferior OS in myeloma and difficult to predict from standard baseline characteristics. From our analysis; 1st line treatment prior to ASCT did not influence OS or PFS. There was an association between slow platelet engraftment following ASCT and PFS and OS. Possible explanations include: residual occult disease, toxicity of chemotherapy or patient somatral factors which facilitate disease resistance and impair normal haematopoiesis. All of these factors have been shown to drive relapse. RCTs are required to standardise bone marrow response assessment post ASCT, quantify remission status (using laboratory and imaging techniques) and definitively predict early relapse. Additionally, these studies will investigate further biological or genetic mechanisms driving early relapse to help identify novel therapeutic approaches in this extremely poor prognosis group.

E1246

PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)


1Haematology, Concord Repatriation General Hospital, Concord, Australia, 2National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 3Azienda Ospedale Niguarda Ca’ Granda Hospital, Milan, Italy, 4Cleveland Clinic Cancer Institute, Denver, 5Winship Cancer Institute of Emory University, Atlanta, United States, 6Royal Victoria Hospital at McGill University Health Centre, Montreal, Canada, 7Hospital Universitario de Salamanca, Salamanca, Spain, 8Dana-Farber Cancer Institute, Boston, United States, 9Hôpital Pitié-Salpêtrière APHP, UPMC Université, Paris, France, 10Pharmacyclics, LLC, and AbbVie Company, Sunnyvale, United States, 11University of Ulm, Ulm, Germany

Background: Anemia and fatigue are frequent indications for WM treatment. To date, patient-reported outcomes (PROs) have not been used to quantify benefits of any WM treatment. Ibrutinib (ibr), a first-in-class, once-daily inhibitor of BTK, is indicated in the EU for the treamtent of WM after ≥1 prior therapy or ≥12m relapse for: age, gender, 1st line therapy, ISS stage, Hb, LDH, Ca or cytogenetics, confirming that this group is difficult to predict at baseline. Median OS from time of diagnosis was 103 months (95% CI 101 -137), median OS from start of ASCT was not reached, however 5-year OS was 68%. Patients with progressive disease within 12 months of ASCT, has significantly reduced median OS compared to patients with disease free > 12 months (95% CI 21- 39) compared to non-progressive patients (median OS:103m 95% CI 89-117) p=0.0005. Median OS from ASCT was reduced in early progression median OS:18m (95% CI 14-22m) vs progression > 12 months median OS:89 months (95% CI 79-89m) p<0.0005. 1st line therapy did not influence likelihood of PFS<12months, with no statistical difference between patients who received PIs, IMiDs or both 1st line (p=0.484).

A significant difference was observed in median time to platelet engraftment between the 2 centres. Increased time for platelets to reach >20 x 10⁹/ℓ was associated with reduced OS from ASCT for each centre HR 1.14 & 1.20 (p=0.046 & 0.03) for Cardiff or London centres respectively (Cox’s Method).

Summary/Conclusions: Early relapse following ASCT is a significant predictor of inferior OS in myeloma and difficult to predict from standard baseline characteristics. From our analysis; 1st line treatment prior to ASCT did not influence OS or PFS. There was an association between slow platelet engraftment following ASCT and PFS and OS. Possible explanations include: residual occult disease, toxicity of chemotherapy or patient somatral factors which facilitate disease resistance and impair normal haematopoiesis. All of these factors have been shown to drive relapse. RCTs are required to standardise bone marrow response assessment post ASCT, quantify remission status (using laboratory and imaging techniques) and definitively predict early relapse. Additionally, these studies will investigate further biological or genetic mechanisms driving early relapse to help identify novel therapeutic approaches in this extremely poor prognosis group.

E1247

INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED, TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB


1Myeloma Unit, Division of Hematology, University of Torino, Torino, 2Italian Multiple Myeloma Network, GIMEMA, 3Unit of Clinical Epidemiology, AOU Città della Salute e della Scienza di Torino and CPO Piemonte, Torino, Italy, 4Myeloma Unit, Division of Hematology, University of Torino - Currently Takeda Pharmaceuticals Co., Torino, Zurich, Italy, Switzerland, 5Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands

Background: Cardio-vascular (CV) toxicities in patients (pts) with multiple myeloma (MM) may derive from comorbidities, MM itself and its treatment. Carfilzomib, an irreversible proteasome inhibitor, is approved as single agent or in combination with dexamethasone or lenalidomide-dexamethasone for relapsed MM.

Aims: We conducted an integrated analysis of CV adverse events (AE) in newly diagnosed, transplant-ineligible MM patients treated with Carfilzomib in 3 phase III studies (IST-CAR-506, IST-CAR-561, IST-CAR-601).

Methods: All pts were treated with 9, 28-day induction cycles with carfilzomib, cyclophosphamide (300mg²/m² on days 1,8,15) and dexamethasone (40mg weekly) (CCyd), followed by carfilzomib maintenance until progression or intol-

Results: Persistent fatigue was the main indication for treatment in 22/31 (71%) pts. Baseline PRO scores were lower for time sub-study vs randomized pts (Table). With a median of 17 months (mo) of treatment, most pts had clinically meaningful improvement in TS (≥7 points; 77%), AS (≥6 points; 84%), and EQ utility scores (≥0.08 points; 68%). Time to clinically meaningful improvement was prompt (1 mo for TS and 2 mo for EQ), corresponding with a 48% decline in median iMgM (median 20 g/l) after 4 weeks. In pts with baseline anemia (hemoglobin [Hb] ≤110 g/L), sustained Hb improvement increased with depth of response. At week 65, Hb levels significantly correlated with TS (r=0.507, P=0.01) and AS (r=0.519, P=0.008), and were marginal for EQ (r=0.39, P=0.054). Although iMgM levels did not significantly correlate with PRO scores, the benefit was similar in responders regardless of depth of response.

Table 1.
erance. Carfilzomib was administered i.v. at the dose of 36mg/m² on days 1, 2, 8, 15, 16 in the IST-CAR-506 trial; at 3 dose levels escalated from 45 to 70mg/m² on days 1, 8, 15, 16 in the IST-CAR-561 trial. AEs were graded based on NCI-CTCAE v4.

Results: 148 pts with a median age of 72 years were analyzed. At enrollment, 34% of patients had at least 1 cardiovascular risk factor; 20% had peripheral vascular disease (including hypertension in 13% patients), 19% diabetes and 5% chronic pulmonary disease. After a median follow-up of 21 months, at least 1 any grade CV-AE occurred in 45% of patients; any grade hypertension was reported in 17% of patients, dyspnea in 9%, and heart failure, arrhythmia and venous thromboembolism (VTE) in 6% of patients, each. Grade 3-5 CV-AEs occurred in 15% of patients; the most common being heart failure (4%), hypertension (3%), pulmonary edema (3%) and VTE (3%). Four (3%) fatal CV-AEs occurred: 1 case of heart failure, pulmonary edema, arrhythmia and VTE, respectively.

In this context, the CV toxicity was significant among pts. Patients with at least 1 CV risk factor at enrollment had a 4-fold increased risk of any CV-AE (odds ratio: 4.12; p=0.012) and peripheral vascular disease (odds ratio: 3.75; p=0.002) conferred the highest risk of developing CV-AEs.

Figure 1.

Summary/Conclusions: This update confirms the safety and efficacy of POM + LoDex following second-line LEN-based treatment failure in pts with RRMM. Hematologic AE rates improved, and median PFS was longer with third-line use than previously reported with POM + LoDex use in later treatment lines. In addition, achieving disease control of ≥ MR led to similar PFS rates as reaching ≥ PR.

E1249

“REAL WORLD” DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN REPEATED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP

E. Terpos1,*, E. Kadrioti2, M. Kotsopoulos2, I. Ntanasis-Stathopoulos1, P. Lampropoulou3, S. Papadaki2, M. Papathanasiou4, D. Stoumbos3, M. Gavriatopoulou1, P. Repousis3, E. Kastritis1, M.A. Dimopoulos1

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, 2Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, 3Department of Hematology, Metaxa Cancer Hospital, Piraeus, 4Department of Hematology and Bone Marrow Transplantation Unit, G. Papankiakoou General Hospital, Thessaloniki, Greece

Background: The overall combination of ixazomib, lenalidomide and dexamethasone (IRd) has been recently approved as a novel standard of care for relapsed/refractory multiple myeloma (RRMM). This was a retrospective, non-interventional study, which recorded IRd treatment data from patients with RRMM who participated in the name-patient program of ixazomib in Greece. The primary endpoint was the evaluation of proportion of patients achieving primary treatment response rates (PRR) and secondary endpoints included: treatment duration; time to response; duration of response; percentage of patients who experienced adverse events (AEs), need dose modification or treatment discontinuation; evaluation of PFS and TTP.

Results: Forty-one patients were included in the present study. Of those, 35 (85%) patients had received at least 3 cycles of IRd on the date of data analysis and thus they were included in the present report. The median line of previous therapies was one (range: 1-5); 71.4% (25/35) patients had received one prior treatment, while 20.0% (7/35),
5.7% (2/35) and 2.9% (1/35) received 2 and 3 or prior treatment lines, respectively. Overall, 82.9% (29/35) of patients had been exposed to proteasome inhibitors prior to IRd (77.1% to bortezomib and 8.6% to carfilzomib) and 48.6% (17/35) to IMiDs [31.4% (11/35) to thalidomide and 22.9% (8/35) to lenalidomide]. Autologous transplantation had been given in 42.9% (15/35) of patients. Median treatment duration was 7 months. Among 34 patients with available TTP data, median TTP was 17.1 months. Overall, 1841 patients (50.8%) had grade 3/4 AEs (Table). All grade neuropathy occurred in 9.8%, 28.2%, and 14.7% of patients in the LEN, BORT, and THAL cohorts, respectively. Treatment discontinuation rates due to AEs were similar in each cohort (LEN: 22.4%, BORT: 20.1%, and THAL: 21.2%). Rates of treatment-emergent AEs, 7 and 8 months, were similar across cohorts, occurring in 23.9% of patients in the LEN cohort, 21.2% in BORT, and 17.5% in THAL. Data on long-term responders will be presented at this meeting.

Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Grade 3/4 AEs</th>
<th>Grade 3/4 AEs</th>
<th>Grade 3/4 AEs</th>
<th>Grade 3/4 AEs</th>
<th>Grade 3/4 AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEN</td>
<td>5.3%</td>
<td>3.4%</td>
<td>2.8%</td>
<td>2.2%</td>
<td>1.7%</td>
</tr>
<tr>
<td>BORT</td>
<td>7.0%</td>
<td>4.6%</td>
<td>3.8%</td>
<td>3.4%</td>
<td>2.9%</td>
</tr>
<tr>
<td>THAL</td>
<td>7.2%</td>
<td>5.2%</td>
<td>4.4%</td>
<td>4.0%</td>
<td>3.5%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: LEN was generally well tolerated and the safety results were similar to published data. As expected, the occurrence of neutropenia, TCP, and VTEs were higher in patients in the LEN cohort, whereas neuropathy was more frequently reported in patients in the BORT cohort. VTEs were low in all cohorts. The occurrence of SPMs was generally low and comparable between cohorts.

E1250
EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY IN A LARGE COHORT OF PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB
1CIO Kön Bonn, University Hospital of Cologne, 2Kerpener Str. 62, Department of Internal Medicine, CIO Kön Bonn, University Hospital of Cologne, Cologne, 3Department of Medicine I, Hematology, Oncology & Stem Cell Transplant, University of Freiburg, Freiburg, 4Department of Medicine V, University of Heidelberg, Heidelberg, 5Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, 6Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, 7German Guideline Program in Oncology, German Cancer Society, Berlin, Germany

Background: Clinical outcome of multiple myeloma (MM) patients is heterogeneous and depends on various prognostic factors and available treatments. Although tremendous progress has been made in MM, so far, there is no national or international evidence-based guideline giving recommendations for clinical practice in the treatment of MM patients. In Germany, 14 Comprehensive Cancer Centers (CCC) are funded as ‘Centers of Excellence’ by the German Cancer Aid (DKH). All these Centers of Excellence are required to develop and provide in-house clinical pathways for standards in cancer care. These pathways include concise diagnostic and therapeutic instructions, reflecting available evidence-based recommendations. In addition, ongoing studies (in particular phase I / II) are part of clinical pathways, so that a rapid transfer of innovation is provided and patients gain access to new therapeutic approaches. The Centers of Excellence Network working group SOP has the goal to harmonize these hospital specific in-house clinical pathways differing in format, content, and level of evidence. The resulting pathway draft was discussed with experts from all 14 Centers of Excellence during face-to-face meetings, conference calls and two online surveys until consensus was reached. The resulting pathway draft was discussed with experts from all 14 Centers of Excellence during face-to-face meetings, conference calls and two online surveys until consensus was reached.

Aims: The project's objective is to harmonize diagnosis, treatment and follow-up of all MM patients in Germany by providing concise, freely available online clinical pathways.

Methods: The clinical pathway was prepared according to a methods handbook developed by the working group including recommendations for standardized methodology and evidence processing. Intensive collaboration of clinical and methodological experts in the multi-disciplinary working group, together with experts from both German Study Groups Multiple Myeloma and the German-speaking Multicenter Myeloma Group ensured clinically relevant and up-to-date clinical pathways. In a first step, four initial pathway drafts were discussed with experts from all 14 Centers of Excellence during face-to-face meetings, conference calls and two online surveys until consensus was reached. The project is funded by the DKH, No. 111493.
Results: During the development process, a number of similarities and discrepancies between centers as well as evidence gaps were identified. Intense discussion and literature searches resulted in a concise, harmonized clinical pathway, released by all 14 Centers of Excellence. This is freely available on the website ccc-netzwerk.de and provides a very decisive insight according to the current state of knowledge on the CCC-level (e.g. on the diagnostic algorithm, Fig. 1). The clinical pathway is well suited for informing patients and physicians about the most up-to-date, comprehensive medical treatment standards as well as innovative procedures. Furthermore, this project initiated the idea of developing a national evidence-based clinical practice guideline for MM in the frame of the German Guideline Program in Oncology.

Summary/Conclusions: The first clinical MM pathway developed and released by all 14 German CCCs/Centers of Excellence translates scientific evidence and expert knowledge into precise suggestions for MM patients in clinical practice. These suggestions might increase the quality of cancer care throughout Germany. To be up-to-date and to reflect latest research findings this clinical pathway will be updated every 18 months.

E1252

WT1 HETEROCLITIC EPITOPE IMMUNIZATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)

G. Koehne1, S. Devlin1, D. Chung1, H. Landau1, N. Korde1, S. Mailankody1, H. Hassoun1, A. Lesokhin1, N. Lendvai1, S. Giralt1, O. Landgren1

1Memorial Sloan Kettering Cancer Center, New York, United States

Background: The Wilms tumor 1 (WT1) protein is a tumor associated antigen that is a target for anticancer immunotherapy. We had previously demonstrated overexpression of WT1 in multiple myeloma (MM) cells by IHC, as well as for a mutation of a WT1 peptide fragment (RMFPNAPYL)HLA-A*0201 complex on the engagement interface between malignant plasma cells and T-cells in HLA-A*0201+MM pts using the high-affinity fully human IgG1 mAb ESK1. We report initial results from MM pts immunized with the WT1 heteroclitic peptide mixture galinpepimut-S (GPS) after autoSCT.

Aims: To determine the safety and potential efficacy of the WT1 heteroclitic peptide immunizer GPS administered in patients with multiple myeloma following autologous stem cell transplantation.

Methods: 16 MM pts underwent autoSCT with melphalan conditioning followed by (fbs) lenalidomide maintenance starting 3 months (mos) post-SCT. 13/16 pts presented with high-risk (HR) cytogenetics [t(4;14), t(14;16), del17p, 1q21/25 gain, t(4;14)]; response after ASCT, and maintenance therapy (yes vs no) were analyzed regarding their impact on the presence of PD before ASCT.

Aims of this analysis were: 1) To determine the safety and potential efficacy of the novel WT1 heteroclitic peptide vaccine galinpepimut-S (GPS) administered after autologous stem cell transplantation (ASCT) in MM patients with PD at time of ASCT; 2) To examine the impact of response before 1st ASCT (d > 100 days before ASCT) on the impact of PD at time of ASCT.

Results: Of 16 patients treated with GPS after ASCT, 11 (69%) had PD (≤100 days before ASCT) of whom 9 had PD ≤65 days. 7 out of 11 pd patients presented with HR cytogenetics (del17p, 1q21 gain, t(4;14)). Overall, 7 patients underwent a second ASCT (6 PD) with the second GPS cycle; 4 patients achieved SD and 1 CR, respectively. In summary, the preliminary results with GPS after ASCT indicate a high rate of PD ≤65 days before ASCT; however, the clinical impact of GPS on PD ≤65 days is still a matter of discussion.

Summary/Conclusions: The aim of this analysis was to determine the safety and potential efficacy of the novel WT1 heteroclitic peptide vaccine galinpepimut-S (GPS) administered after autologous stem cell transplantation (ASCT) in MM patients with PD at time of ASCT. The preliminary results indicate a high rate of PD ≤65 days before ASCT; however, the clinical impact of GPS on PD ≤65 days is still a matter of discussion.
Background: Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the proliferation of monoclonal plasma cells (PC) in the bone marrow. The natural history of active MM patients may be complicated in significant fraction by the occurrence of infections that can be related both to the development of therapy induced neutropenia (mainly due to high dose chemotherapy used in the setting of autologous stem cell transplantation or in salvage regimen) or to MM induced secondary immunodeficiency.

Aims: The aim of this study was to analyse the frequency, the type and the major risks factors of severe infections in our cohort of patients affected by MM and to understand the impact of these events on MM patient overall survival (OS).

Methods: A cohort of 341 patients affected by MM (104 with smouldering MM and 237 with symptomatic MM) followed from 1996 to 2016 was retrospectively studied for the presence of severe infections (si, defined by the need of hospitalization) during the natural history of the disease. Infections were classified as “not neutropenia related” or “neutropenia related” according to the Absolute Neutrophil Count > or <1,000/ml respectively. International Staging System (ISS) and Durie-Salmon (DS) were used for MM patients staging.

Results: In our cohort of patients, si were significantly associated to active MM (28.69% of symptomatic patients vs 3.85% of asymptomatic patients; p=0.001, c2=25,318). Among the 138 infective events occurred in 91 active MM patients, 38 (28%) were neutropenia related while remnant 100 not neutropenia related (72%). Furthermore, almost 44% of these events (61/138) developed during induction therapy, with 12 out of 61 (20%) being present at time of the diagnosis. Considering that majority of si was not neutropenia related and that these infective events involved most of active MM patients who developed si (68/91, 75%), our aim was to identify MM patient characteristics associated to the development of not neutropenia related si. Our results prove evidence that major features presented at the time of the diagnosis significantly associated to si were DS stage III (p=0.0004, c2=12,14), ISS stage III (p=0.0001, c2=21,11), age >70 years (p=0.0195, c2=5,455), bone marrow plasma cells >60% (p=0.034, c2=4,50), acute renal failure (p=0.0003, c2=13,010) or OS presenting with at least three of CRAB criteria (p=0.0123, c2=6,26). For what concern the impact of si on the natural history of the disease, patients who experienced infective event presented a reduced OS towards other patients (p<0.0001). Among infected patients no significant differences were reported referring to the number of infections (>1 or =1, p=0.11), while patients who developed exclusively neutropenia related infective events showed better OS towards patients who experienced not neutropenia related infections (p=0.0011).

Figure 1.

Summary/Conclusions: Severe infections represent an underestimated comorbidity in MM, characterizing all phases of the disease and not only refractory/relapsed patients receiving multiple lines of therapy. Considering that severe infections impact OS mostly in the setting of not neutropenia related infections, immunoglobulin replacement therapy or antibiotic prophylaxis may possibly have a protective role in high risk old patients characterized by ISS and DS stage III, bone marrow PC >60% and aggressive disease at the time of diagnosis.

E1255

EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE REAL-WORLD SETTING IN THE UNITED STATES

D. Lenihan1, R. Potluri2, H. Kanakamedala2, A. Dasgupta2, C. Chen3,4
1Vanderbilt University Medical Center, Nashville, 2SmartAnalyst Inc., New York, 3Bristol-Myers Squibb, Lawrenceville, United States

Background: Multiple myeloma (MM) is a disease of the elderly. The prevalence of cardiovascular (CV) comorbidities in the MM population is high. Past research suggests that MM is associated with a range of cardiac risks, and emerging evidence shows that both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) can have important CV sequelae. The improved efficacy of PI plus IMiD combination therapy (PI+IMiD) has resulted in its widespread adoption, which suggests that CV events may become a prominent concern in patients receiving PI+IMiD as contemporary treatment for MM.

Aims: To assess the risk of developing CV events in patients receiving anti-MM treatment and to test a specific treatment modality was associated with higher risk of a CV event.

Methods: Patients with ≥1 inpatient claim or ≥2 outpatient claims with a primary diagnosis code for MM who were treated with PI and/or IMiD drugs between Jul 2012 and Sep 2014 were identified in a large US claims database. The first claim for a PI or IMiD drug in this period was defined as the index date, which was preceded by 180-d continuous eligibility with no anti-MM treatment (baseline). Patients were divided into three cohorts based on the anti-MM treatment received: PI, IMiD, PI+IMiD. CV events of interest included cardiac arrhythmia, cardiac failure, venous thromboembolism (VTE), myocardial infarction, ischemic heart disease, and cerebrovascular disease, and were measured during anti-MM treatment. Kaplan–Meier methods were used to estimate the occurrence rate of a CV event, and multivariate Cox regression models were developed to identify prognostic factors of each CV event among patients treated with anti-MM therapies.

Results: 4288 patients met the eligibility criteria for inclusion in the study (57% male, median age 66 y, 41% with Charlson Comorbidity Index ≥2, mean duration of treatment 192 d; Table). 42% (n=1779) were treated with PIs, 38% (n=1624) with IMiDs and 20% (n=865) with PI+IMiDs. Patients receiving PI+IMiD were significantly younger and generally had lower prevalence of CV comorbidities than those receiving PI or IMiD (Table). Compared with patients on PI, the risk of developing VTE was 46% greater in patients on PI+IMiD (HR: 1.46; 95% CI: 1.09, 1.96). Compared with those on IMiD, the risk of developing cardiac failure and cardiac arrhythmia was 33% and 18% greater in patients on PI+IMiD (HR: 1.33; 95% CI: 1.03, 1.72; HR: 1.18; 95% CI: 1.00, 1.40). After 6 months of treatment, the rates of VTE were 8%, 10%, and 11% for patients on a PI, those on an IMiD and those on PI+IMiD, respectively. The corresponding rates for cardiac failure were 18%, 11% and 11% for PI, IMiD and PI+IMiD cohorts, and 21%, 16% and 22% for cardiac arrhythmia.

Table 1.

Summary/Conclusions: PI+IMiDs may be associated with incremental occurrence of specific CV events during treatment, and may result in specific CV events earlier during therapy than PIs or IMiDs alone. These highlight a need for treatments that do not exacerbate CV risks and are appropriate for patients with pre-existing CV conditions. The lower prevalence of baseline CV comorbidities and lower mean age in patients on PI+IMiDs suggest that prevalence of a CV comorbidity and age influences treatment choice. Further analysis may be necessary to better understand the impact of baseline CV comorbidities on choice of MM treatment.

E1256

LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

K. Kupas1,*, I. Kaspar1, V. Baecke2, K. Weise3
1Bristol-Myers Squibb, Munich, 2Ecker + Ecker GmbH, Hamburg, 3University of Tübingen, Tübingen, Germany

Background: Lenalidomide in combination with dexamethasone is approved globally for the treatment of multiple myeloma (MM). Although older pivotal regimens used lenalidomide combined with doxorubicin, cyclophosphamide and dexamethasone (LD), more recent studies have used lenalidomide plus low-dose dexamethasone (LD) for relapsed/refractory MM (RRMM), as the LD regimen demonstrated better survival with lower toxicity for the treatment of newly diagnosed MM.
Methods: We searched MEDLINE, EMBASE and Cochrane databases and key clinical trial registries for studies including adults with RRMM who had received ≥1 prior therapy and had a symptomatic relapse on their last treatment. Eligible studies evaluated LD (lenalidomide; 25mg on Day 1–21 of each cycle; dexamethasone; 160mg/cycle, not pulsed) or LD (Cycles 1–4: 480mg/cycle; Cycle 5+: 160mg/cycle, pulsed). Only those trials with designs and baseline patient characteristics that were similar to ELOQUENT-2 were eligible to enable comparisons in terms of overall survival; after ≥30 months of follow-up, the hazard ratio for LD vs VTD was 1.04 (95% CI 0.85–1.28). Tolerability was similar for LD vs VTD; after 16–25 months of follow-up, LD was associated with a statistically significantly increased risk of Grade 3/4 adverse events (AEs; relative risk [RR]: 1.10 [95% CI 1.01–1.18]). However, after ≥30 months of follow-up, LD was not associated with worse efficacy compared to VTD (RR: 1.02 [95% CI 0.91–1.05]); or RR: 0.37 [95% CI 0.21–0.67]; or RR: 1.03 [95% CI 0.95–1.12]) or serious AEs (RR: 1.08 [95% CI 0.97–1.20]); RR for AEs leading to discontinuation was 1.16 (95% CI 0.87–1.54).

Summary/Conclusions: Overall survival and safety were not significantly affected by different dosages of dexamethasone in combination with lenalidomide; thus, it is suggested that LD dosing is sufficient in this patient population. Further studies may provide additional evidence to inform clinicians and revision of international guidelines for dexamethasone dosing in RRMM.

Study funded by Bristol-Myers Squibb.

E1257

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTO-SCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP

I. Hus1,*, J. Manko1, D. Jawniak1, A. Jurczyszyński2, L. Uszynska-Zubekiewicz1, M. Sawicki1, G. Charlinski1, M. Razyn1, M. Rodzja1, A. Waszczyk-Golda1, J. Drozd-Sokołowska1, A. Galazka3, A. Sviderska4, B. Poglocke5, A. Pluta6, A. Druzd-Sitek11, N. Grzasko12, A. Kopinska13, A. Pasternak14, D. Błonska15, M. Hus6, A. Dmoszyńska1

1Clinical Transplantology, 2Hematology and Bone Marrow Transplantation, Medical University of Lublin, 3Department of Hematology, Collegium Medicum, Jagiellonian University, Cracow, 4Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, 5Department of Hematology, SSM, Torun, 6Department of Hematology, SS im. Rydygiera, Cracow, 7Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 8Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, 9Department of Hematology, WSK, Zielona Gora, 10Department of Oncological Hematology, SS, Brzozow, 11Department of Lymphoid Malignancies, Institute of Oncology, Warsaw, 12Department of Hematology, St. John of Dukla Lublin Region Cancer Center, 13Department of Oncology and Bone Marrow Transplant, Medical University of Silesia, Katowice, 14Department of Hematology, SPZOZ, MSWiA, Olsztyn, 15Department of Hematology, Collegium Medicum UMK, Bydgoszcz, Poland

Background: Three drug bortezomib-based regimens are nowadays generally recommended standard induction therapy for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The choice between different regimens depends on drug availability in particular countries, their toxicity profile and local preferences. Observations from routine practice might have though significant value to be reasons in this patient population. Further studies may provide additional evidence to inform clinicians and revision of international guidelines for dexamethasone dosing in RRMM.

Methods: From an initial bibliographic search yielding 5155 non-duplicate results and 619 registry results, 7 studies (8 publications) met the inclusion criteria (4 LD studies, 3 LD studies). Data for overall survival and tolerability from 1153 patients in the LD group and 353 patients in the LD group were analyzed. The median patient age was 63–68 years. Most patients were white, male and had an ECOG score of 0-1. LD was not associated with loss of efficacy in terms of overall survival; after ≥30 months of follow-up, the hazard ratio for LD vs VTD was 1.04 (95% CI 0.85–1.28). Tolerability was similar for LD vs VTD; after 16–25 months of follow-up, LD was associated with a statistically significantly increased risk of Grade 3/4 adverse events (AEs; relative risk [RR]: 1.10 [95% CI 1.01–1.18]). However, after ≥30 months of follow-up, LD was not associated with worse efficacy compared to VTD (RR: 1.02 [95% CI 0.91–1.05]; or RR: 0.37 [95% CI 0.21–0.67]; or RR: 1.03 [95% CI 0.95–1.12]) or serious AEs (RR: 1.08 [95% CI 0.97–1.20]); RR for AEs leading to discontinuation was 1.16 (95% CI 0.87–1.54).

Summary/Conclusions: Overall survival and safety were not significantly affected by different dosages of dexamethasone in combination with lenalidomide; thus, it is suggested that LD dosing is sufficient in this patient population. Further studies may provide additional evidence to inform clinicians and revision of international guidelines for dexamethasone dosing in RRMM.

E1258

HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE

A. Berni Wennakers1,*, M. V. Douduri Sahun2, E. Bonafonte Arruga3, A. Asensio Matas4, M. P. Martin Azara5, R. Alvarez Lipe1, L. Palomera Bernal2,1

1Neurology, 2Hematology, Hospital Clinico Universitario “Lozano Blesa” Zaragoza, Zaragoza, Spain

Results: The patients were 12 men and 7 women, aged 60±4 years (37–73 years). 10 patients were diagnosed with lambda FLC MM and 9 with kappa type. A total of 244 sessions were conducted, with an average of 11.6 sessions per patient (range 3–27) In all cases reduction of serum FLCs concentration was successful (90.3% reduction). At the end of treatment with HCO-HD, the reduction of lambda and kappa FLCs concentrations was 85% and 94%, respectively. The average reduction per dialysis session was 65% for lambda and 60% for kappa. 17 out of the 21 treated cases recovered sufficient renal function to become independent of dialysis (80.9% renal recovery). Renal recovery appears to be sustained over time. There was a significant reduction in between the two groups in terms of all FLCs concentrations and renal recovery. Our results confirm previous findings on the effectiveness of FLCs reduction by HCO-HD. Until randomized trials yield results, our highest priority is to provide guidelines on effective therapy for renal recovery in MM.
E1259
IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS
L.G. Rodríguez-Lobato1,*, C. Fernández de Larrea1, M.T. Cibeira1, N. Tovar1, J.I. Aróstegui2, L. Rosí1, M. Elena3, J. Yagüe4, J. Bladé1
1Department of Haematology, 2Department of Immunology, 3Department of Biochemistry, Hospital Clinic, Barcelona, Spain

Background: The presence of immunoparesis (IP) at diagnosis in several plasma cell disorders is a risk factor for progression, associated with an unfavorable outcome with reduced progression-free survival (PFS) and overall survival (OS). However, its impact in light chain (AL) amyloidosis has been evaluated only in few series, and when present it was associated with worse response and survival.

Aims: The aim of this study was to investigate the prognostic impact of IP in patients with newly diagnosed AL amyloidosis at a single institution.

Methods: We reviewed the clinical records of patients with AL amyloidosis diagnosed from January 2006 to December 2016. Sixty-nine patients (32F/37M; median age at diagnosis 62) with available immunoglobulin (Ig) measurements were the final study population. Initial baseline demographics, clinical and laboratory data, treatment and follow-up were collected. Median follow-up was 30.2 months. IP was defined as suppression of all uninvolved Ig below the lower reference value. PFS and OS were calculated from the date of diagnosis.

Results: Forty-three patients (62.3%) were transplant ineligible while 26 (37.7%) underwent an autologous stem cell transplantation (ASCT). The distribution of the monoclonal protein type by immunofixation at diagnosis was as follows: light chains only (46.4%), IgG (39.1%), IgA (10.2%) and IgM (4.3%). The predominant light chain isoform was lambda (79.7%). A very good partial response (VGPR) or better was achieved in 53.6% of patients. Three-year OS rate was 54.3%. IP was observed in 27.5% of the patients at diagnosis. Patients with IP had a higher bone marrow plasma cells (BMPC) infiltration (29 vs. 11, P<0.001). Also a trend towards a higher difference between involved and uninvolved free light chains was observed in the group of patients with IP (360.2 vs. 23.6, P=0.08). IP was more frequent in those who received an ASCT (57.9% vs. 42.1%, P=0.03). There were no changes in the frequency of IP comparing at diagnosis vs. post-ASCT settings (39.13% vs. 34.78%, P=.04).

Regarding its prognostic value, IP did not influence survival in the whole series. In the ASCT group, the presence of IP resulted in a significantly shorter PFS (median: 30.2 months vs. NR; P=0.019; Figure 1A) and OS (62.5 months vs. NR; P=0.097). In the group of patients with stage I and II of the Mayo risk stratification system of 2012 (Mayo12), the presence of IP resulted in a shorter PFS (21.8 months vs. NR; P=0.047; Figure 1B), but not significantly different in OS. Multivariate analysis restricted to the population of patients with stage I and II Mayo12, incorporating ASCT, BMPC and IP, indicate that IP retained its independent prognostic factor for worse PFS (HR=12.06; 95% CI, 1.9-75.7; P=0.008).

Summary/Conclusions: The presence of IP has a negative impact on survival, especially in the sub-group of patients in early stages of the disease. The presence of IP at diagnosis could be an additional powerful discriminatory prognostic indicator in the group of patients without advanced stage of the Mayo risk stratification system of 2012.

E1260
TREATMENT PATTERNS AND DURATION OF TREATMENT IN JAPANESE MULTIPLE MYELOMA PATIENTS RECEIVING SECOND LINE THERAPY WITH NOVEL AGENTS
G. Jun1,2,*, I. Mishiro1, H. Shinzo1, T. Skacel3, K. Iwasaki4, J. Soeda1
1Department of Haematology, 2Department of Immunology, 3Department of Biochemistry, Hospital Clinic, Barcelona, Spain

Background: The introduction of novel agents, such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) approved in 2006 and 2010, respectively, and/or autologous stem cell transplantation (SCT) are associated with improved overall survival of 60.6 months in Japanese multiple myeloma (MM) patients (pts) (Ozaki et al. Blood Cancer Journal 2015). However, the disease still remains incurable with disease relapse being inevitable after frontline therapy (FLT). Data regarding treatment patterns and duration of treatment (DOT) of Japanese pts with relapsed and refractory (RR) MM in routine clinical practice is limited.

Aims: This retrospective study aims to describe the treatment patterns and DOT of second-line therapy (SLT) with PI- and IMiD-based regimens and to assess factors that influence treatment choice and DOT of SLT in Japanese MM pts.

Methods: This is retrospective cohort study in pts with MM diagnoses with ICD-10-CM (C900) codes between April 2008 and January 2016 in Japan. This study used Japanese health insurance data provided by Medical Data Vision. MM pts receiving SLT were included. Index date was defined as the first observed claim for MM treatment and SLT was defined as switch to another drug combination>60 days or retreatment following a treatment gap of>90 days after starting FLT. Pts with salvage SCT were excluded. Observations were censored at loss to follow up, death or the end of study period. Kaplan-Meier analyses were performed to calculate DOT from the start of SLT. Welch’s test was used to test for statistical significance between groups.

Results: Among 956 pts receiving SLT, mean age was 68.8 years of age (yo); 65.3% were ≥65 yo at start of SLT; 54.2% were male. Most pts received lenalidomide (L)-based SLT (35.4%), followed by bortezomib (B)-based regimens (29.4%) and other regimens not containing novel agents (35.2%). Other regimens includes thalidomide, cyclophosphamide, etoposide, melphalan, vincristine, (iposomatis) doxorubicin, interferon, panobinostat, single-agent steroid; only 1.2% received B+L combination therapy. L+D and B+D were the most common (35.2% vs 21.7% in SLT. Majority of Japanese pts received B-based regimen in FLT among those receiving L+D and B+D SLT (77.2% vs 55.1%). Pts with peripheral neuropathy (PN) and renal insufficiency (RI) prior to SLT were 30.3% and 15.6%, respectively; those with PN were more likely to receive L+D compared to B+D (35.9% vs 21.3%, P=0.0047), but those with RI were not independently associated with treatment choice of SLT. Median DOT of L+D was longer than B+D (13.8 vs 6.9 months, P=0.0001); DOT was similar for those without a front-line SCT and receiving B+D FLT in both regimens (11.9 vs 11.9 months). PN and RI prior to SLT and age have not shortened the DOT in SLT. Additionally, 35.4% experienced PN during SLT among pts receiving L+D and B+D in SLT but there was no statistical significant difference of DOT between pts with and without PN. Median daily dose of L was 12.0mg; there was no significant difference of DOT between pts received at least and less than 12.0mg.

Table 1.

Summary/Conclusions: Among pts in SLT, 65% of Japanese pts obtained L- and B-based regimens. This observation is similar to the United States (Romanus et al. EHA 2016) and Europe (Raab et al. EHA 2015). Majority of pts not receive triplet-based regimen. Pts experienced PN in FLT were more likely to initiate L-based therapy in SLT and regimen type in SLT was correlated with DOT. Future research is needed to better understand treatment changes in routine clinical practice and the impact on pts’ outcomes, especially, after integration of novel agent-based triplet combinations as new standards of care in RRMM in Japan.

References

E1261
ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY
F. D’auria1,*, F. La Rocca1, V. Simeoni1, T. Statuto1, G. Pietrantuono1,

1Department of Haematology, 2Department of Immunology, 3Department of Biochemistry, Hospital Clinic, Barcelona, Spain
Background: Polyclonal antibodies against the conformational epitopes between the heavy and light chains (HLC) of immunoglobulin (lg) have been recently introduced as diagnostic tool in multiple myeloma (MM) and other monoclonal gammopathies. They separately identify the two different light chain types of each lg, allowing the quantification of the monoclonal component. HLC and HLC ratios may be particularly useful for monitoring the presence of monoclonal component in oligo-secretory MM or when it migrates in the β region, as frequently observed in IgA MM. The International Myeloma Working Group (IMWG) has published in 2016 new consensus criteria for assessing response and minimal residual disease (MRD) in MM, outlining the potential role of HLC assay in this setting and the need of its further investigation, particularly in patients achieving complete response (CR) and evaluation of minimal residual disease (MRD).

Aims: We conducted a single center, prospective study of HLC ratio, in comparison with free light chain (FLC) ratio, for the evaluation of MRD and its prognostic role in MM patients achieving CR after first line treatments including novel agents.

Methods: Twenty-five consecutive patients were evaluated. Mean age was 63 years (range 43-92), fourteen patients were males. Igλ iso-type was IgG or IgA in 14 and 11 patients, respectively, with 20 patients showing kappa and 5 lambda light chains. According to International Staging System, seven patients had stage I, ten stage II and eight stage III. Fourteen patients not eligible to autologous stem cell transplantation (AuSCT) received a bortezomib-based treatment mainly constituted by bortezomib, melphalan and prednisone combination (VMP), while eleven patients underwent AuSCT after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). With a median follow-up of 52 months (range 21-92), overall survival (OS) of the entire cohort was 68 months (95% CI 52-80). Progression-free survival (PFS) was 26 months (95% CI 18-34). HLC and FLC ratios were analyzed on serum samples at diagnosis and at the time of immunofixation negative CR (according to 2006 IMWG criteria), using Hevylite and Freelite commercial kits, respectively, on a SPAplus analyzer (Binding Site); IgGk/IgGλ, IgAk/IgAλ and k/λ ratios were then calculated.

Results: At CR time, we found seven (28%) samples still showing abnormal HLC ratio and fourteen samples (56%) with abnormal FLC ratio. Discrepancies between the two assays occurred in 11 patients. FLC assay normalization in 14 and 11 patients, respectively, on a SPAplus analyzer (Binding Site); IgGk/IgGλ, IgAk/IgAλ and k/λ ratios were then calculated.

Summary/Conclusions: To the best of our knowledge, this is the first study to analyze HLC ratios exclusively in MM patients in CR. While our preliminary data confirm the prognostic usefulness of FLC in this setting, currently they do not support a role for HLC as putative biomarker of MRD.

E1262
REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED/RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP

Methods: Patients were eligible for the study if they met the following criteria: pretreated RRMM patients with an ECOG performance status ≤ 2, age ≥ 18 years, MM according to 2003 IMWG criteria and treatment with daratumumab could be provided. In each center, 10 patients were enrolled. Daratumumab treatment was designed in 3 phases: 1) Induction therapy with daratumumab monotherapy (10 mg/kg IV weekly for 8 weeks); 2) Consolidation therapy with daratumumab plus lenalidomide for 4 weeks; 3) Maintenance therapy with daratumumab plus lenalidomide (or other approved PI) for at least 6 months. The primary endpoint of the study was safety and tolerability. The secondary endpoints included efficacy, OS, PFS, and response rate (RR) determined by the International Myeloma Working Group (IMWG) response criteria (2016).

Results: A total of 100 patients were enrolled in the study from 2016 to 2018. The median age at baseline was 62 years (range 31-91). The median number of prior treatments before the study inclusion was 4 (range 2-9). Daratumumab treatment duration was 4.4 months (range, 0-8 months). Sixteen patients (16%) had a ECOG performance status score 2 or lower. Data on treatment outcomes and complications were anonymously collected using electronic CRFs. The IMWG response criteria were applied.

Summary/Conclusions: In this real-world analysis we can confirm that daratumumab monotherapy is able to induce response in one third of highly pretreated and double refractory RRMM patients. Regarding safety, in contrast to the SIRIUS trial where no treatment discontinuations due to AEs occurred, 3/26 pts (11%) treated with daratumumab in clinical practice had their therapy interrupted due to complications.

E1263
REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE
A. Fournier1, A. Zomas1, E. Papakostas2, T. Do1, M. Russo3, R. D’Auriosten2, G. Schneidewind1

1EUCAN Medical Affairs, 2Global Market Access, Takeda, CH-8152 Glattpark-Opfikon (Zurich), Switzerland
Background: Multiple myeloma (MM) is the second most common haematologic malignancy after non-Hodgkin lymphoma, accounting for 13% of blood malignancies and 1% of all cancers1. The medical management of multiple myeloma has changed over the years and is influenced by multiple factors (e.g., evidence from clinical trials, drug approval status, level of drug reimbursement, guidelines), which vary across Europe. Information describing how physicians are managing MM in daily practice is required.

Methods: Physicians in Europe were requested to answer a series of questions on patient characteristics and treatment regimens of the last eight patients that they had treated during the month prior to answering the questionnaire, according to their patients’ medical charts. The questionnaire was conducted between January and June 2016. Data on 2564 patients with MM were available and are presented here. Countries were grouped into regions according to similar health care systems: Spain, Portugal, Italy and Israel (Southern Region, SR, n=1099); Austria, Netherlands, Belgium, Norway, Sweden, Switzerland and Finland (Central and Northern Region, CNR, n=776); Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Serbia, Slovakia (Eastern Region, ER, n=689). Analyses were descriptive.

Results: Patient characteristics were generally similar across regions, with the majority being <75 years old (69-76%), receiving frontline therapy at study inclusion (57-58%), and being ineligible for autologous stem cell transplant (ASCT) (53-59%). The median time from MM diagnosis to the time that the physician answered the questionnaire was higher in ER (19.5 months) than other regions (9.7-11 months) (Table). The majority of frontline regimens contained bortezomib, although this was lower in ER (51%) than in other regions (66-70%). The median duration of frontline therapy was longer in ER (4.5 months) than other regions (3.2 months). This difference was mainly driven by ASCT eligible patients having longer duration of therapy in ER (4.5 months) than other regions (2.9 months). The number of bortezomib injections in frontline therapy, however, was higher in SR and CNR (both 24) than in ER (18). The majority of second line regimens contained lenalidomide (57-64%) in all regions except ER, where bortezomib-based regimens were most frequent (38%). The median duration of second line therapy was shorter in SR and CNR than in ER (Table). Moreover, frontline line therapy, ASCT-eligible patients had shorter duration of therapy in ER and SR (3.2 months) than in CNR regions (4.5 months). The majority of later-line (3+) regimens were based on therapies that did not include bortezomib, lenalidomide or pomalidomide for all regions (57-68%). The exception of SR where pomalidomide (29.4%), lenalidomide (12.6%) and bortezomib (14%) were the preferred options. In this analysis conducted in Europe, treatment patterns differed in terms of regimens used and duration of therapies even though patient characteristics were generally similar across regions. This may in part be related to differences in healthcare systems.

Further research is required to understand how new therapies can be integrated into current treatment patterns and how these treatment patterns impact patient outcomes.

Table 1.

Summary/Conclusions: In this analysis conducted in Europe, treatment patterns differed in terms of regimens used and duration of therapies even though patient characteristics were generally similar across regions. This may in part be related to differences in healthcare systems. Further research is required to understand how new therapies can be integrated into current treatment patterns and how these treatment patterns impact patient outcomes.

E1264

FRAILTY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

N. Schutz1,*, M. Smietniansky1, D. Fantl1, V. Otero1

Background: Worldwide, life expectancy continues to rise. The treatment of elderly people with cancer poses special challenges that should be better addressed. Frailty is a geriatric syndrome associated with reduced functional reserve, impairment in multiple physiological systems, and reduced ability to regain physiological homeostasis.

Aims: To evaluate the impact of the level of frailty on early death and overall survival of elderly patients with multiple myeloma.

Methods: Retrospective study of 150 patients older than 65 years with a recent diagnosis of multiple myeloma from January 2006 to December 2012. Patients were treated with IMIDs, alkylating or bortezomib based chemotherapy on physician preference blind to the geriatric assessment. A check list for frailty burden measurement was used based on Edmonton frailty score and included: cognitive impairment, depressive disorder, polypharmacy, urinary incontinence, functional impairment, gait disturbance or falls, low weight or weight loss and previous hospitalization. Level of frailty was scored as the sum of each area involved. Record of all the variables were obtained from a retrospective review of the centralized and computerized medical records of the relevant hematologist. Univariate analysis were performed using STATA 13. Significant level was set at 0.05. OS and PFS were estimated using the Kaplan Meier method using Stata13 program Group differences according to frailty were investigated using the Cox proportional hazard model accounting for ISS, age, Charlson comorbidity index and treatment.

Results: From the 150 patients evaluated, 124 patients were included in the study. The median age was 77 years (range 65-98). Thirty one percent of the patients were older than 80 years, 51% were female. The median Charlson Comorbidity index was 2 (range 0-7), 28% had renal failure and 40% of the patients presented with Myeloma ISS 3. Sixty five percent of patients met at least one frailty criteria and 31% of patients were considered frail. The most common findings were polypharmacy, gait and functional impairment. Most patients were treated with IMIDs (47%); alkylating agents (33%) or bortezomib (14%). No significant difference in treatment according to frailty group (p=0.38). The median overall survival time was 75 months (95% CI 53-110), 39 months (95% CI 19-64) and 17 months (95% CI 5-37) for fit, vulnerable and frail patients respectively (log rank p=0.0002). Frailty was specially associated with early death [OR 8.2 (95% CI 1.9-34) p=0.007]. In the multivariate analysis a higher risk of death was observed related to age [ HR 1.07 (95% CI 1.02-1.12) p=0.002], number of frailty criteria [HR 1.13 (95% CI 1.02-1.24) p=0.001] and being ineligible for ASCT [HR 1.30 (95% CI 1.15-1.48) p=0.001]. Frailty criteria independently associated with death were incontinence polypharmacy and previous hospital admissions. Frailty was specially associated with early death [OR 6.2 (95% CI 1.9-34) p=0.0007].

Summary/Conclusions: This study shows that the prevalence of frailty syndrome is high and has a profound impact in early death. It is also independently associated with a worse prognosis. Frailty should be considered as part of the clinical assessment when treating elderly patients with myeloma.
of patients on dialysis, there is no significant difference between those receiving or not bortezomib. Median survival before 2008 was 54.82 months and rose to 82.30 months for patients treated after this date (p=0.05). Age (HR: 0.2819, CI 0.1375 to 0.5782), heart disease (HR: 0.3746, CI 0.1724 to 0.8141) and serum albumin (HR: 2.50 CI: 1.077 to 5.803) were identified as prognostic factors. Transplantation is a viable treatment option for good responders.

Summary/Conclusions: Prognosis of AL amyloidosis in dialysis is heterogeneous. Prognostic scoring integrating clinical biological data could identify the patient who may benefit the most dialysis. This results need to be matched by sex and age with non-dialysis and dialysis for another cause.

E1267

FDG-PET IN MULTIPLE MYELOMA: DUAL TIME POINT FDG UPTAKE IN FOCAL LESIONS CORRELATES TO RESPONSE TO CHEMOTHERAPY B. Oestergaard1,*, R. Taghvaei2, W.Y. Raynor2, M.Z. Zirakchian2, A. Nielsen3, J.T. Amsussen4, P. Holdgaard5, T. Plesner6, A. Alavi7, N. Abdigard8, P.F. Heilund-Carlsen9

1Hematology, Odense University Hospital, Odense, Denmark, 2Radiology, Hospital of the University of Pennsylvania, Philadelphia, United States, 3Nuclear Medicine, 4Radiology, Odense University Hospital, Odense, 5Nuclear Medicine, 6Hematology, Vejle Hospital, Vejle, Denmark

Background: Dual Time Point (DTP) 18F-FDG PET imaging has been shown to be useful in differentiating malignant from benign lesions in that increasing uptake from 1 to 3 hours is a characteristic feature of malignancy in contrast to inflammation.

Aims: The aim of this study was to evaluate the predictive role of DTP 18F-FDG PET/CT imaging in assessing response to chemotherapy in multiple myeloma (MM).

Methods: 23 patients with MM (21 male, aged 53-75 years) underwent 18F-FDG PET/CT in a prospective study (NCT02187731) before start of treatment and two months after high dose chemotherapy with stem cell support. All scans were performed at 60 and 180 minutes after tracer injection at Odense University Hospital and Vejle Hospital. Thirteen patients with ≥3 focal lesions of at least 10 mm were selected for analysis. Images were analyzed using an adaptive thresholding algorithm (ROVER software, ABX GmbH, Radeberg, Germany). Focal malignant lesions were localized in pre-treatment scans; maximum standard uptake value (SUVmax) and mean SUV (SUVmean) and partial volume corrected SUVmean (pvcSUVmean) were obtained for each lesion. The response to chemotherapy was classified as complete or partial in the post-treatment scan. A complete response was defined as a complete resolution of the lesion in the post-treatment scan. Lesions with partial response were present in the post-treatment scan. All statistical analyses were done in SPSS 24 using repeated measurements-ANOVA.

Results: Three-five focal lesions were evaluated in each patient. In the pre-treatment PET studies, the increase in SUVmean from 1 to 3 hours was significantly higher for lesions with partial response compared to those with complete response (27.7% vs 11.4%; P=0.050). Additionally, the increase in pvcSUVmax was more significant than the increase in SUVmean (+42.23% vs +12.0%; P=0.003). The increase in SUVmax of delayed scans was not significant (P=0.082).

Summary/Conclusions: These preliminary data show that a more significant increase of FDG uptake in delayed scans of DTP PET before treatment correlates with a good response to chemotherapy and a high likelihood of response in MM.

The increase in pvcSUVmean is a better index than those of SUVmean and SUVmax for this purpose.

E1268

UNDERSTANDING THE CONTRIBUTE OF THE NOTCH PATHWAY IN MULTIPLE MYELOMA BONE MARROW NICHE: A FOCUS ON EXTRACELLULAR VESICLES-MEDIATED COMMUNICATION M. Colombo1,2, F. Baccianti1, C. Lantone2, N. Moschini3, N. Platona3, S. Garavelli1, M.T. Palano1, R. Adami1, A. Neri3, V. Bollati2, R. Chiaramonte4, D. Piepoli5, L. Amighetti5, P.F. Høilund-Carlsen6

1Dept. of Health Sciences, 2Dept. of Clinical Sciences and community health, 3Dept. of Oncology and Hemato-Oncology, Università degli Studi di Milano, Italy

Background: Multiple myeloma (MM) is an incurable cancer stemming from malignant plasma cells. MM is characterized by a strong tropism to the bone marrow (BM), where tumor cells accumulate and establish complex interactions with the normal stroma, which in turn promotes tumour survival, drug resistance and the development of bone disease. The Notch oncogenic pathway provides a key contribute to the ability of MM cells to shape the BM niche, affecting both BM cell biology and the intercellular niche. Specifically, extracellular vesicles (EVs) have been reported as novel mediators in creating a supportive milieu for MM. Here we investigate the role of the activated Notch signalling in EV-mediated cross-talk.

Aim: The aim of this work was to further elucidate the role played by the Notch pathway in the shaping of the BM microenvironment to provide a supportive milieu for MM cells, with a focus on the contribution of EVs to the crosstalk between MM cells and the BM stromal cells.

haematologica | 2017; 102(s2) | 519

Madrid, Spain, June 22 – 25, 2017
Methods: We established two MM cell lines stably retaining the doxycycline-inducible pTRIPZ vector containing anti-Notch1 and Jagged1 shRNAs and a BM mesenchymal stromal cell line (BMSCS) line expressing shRNAs for Notch1 and Notch2. EVs were isolated by ultracentrifugation and used for functional assays and molecular analysis. qPCR was performed using SYBR Green. Apoptosis analysis was performed by flow cytometry; evaluation of protein expression was performed by Western blot or western immunoprecipitation. Summary/Conclusions: We present new insights in the pathophysiology of the rearranged BM niche represent the rationale for a Notch-directed therapy aiming to uncouple the crosstalk of MM with the surrounding microenvironment by inhibiting Notch signaling. 

E1269
THE USE OF CARFILZOMIB AND BORTezOMIB IN ROUTINE CLINICAL PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL COHORT STUDY IN MULTIPLE MYELOMA
B. Dure1,1, G. Cook2, H. Goldschmidt3, D. Kuten4, T. Zyczynski2, S. Popov5, M. Gooris6, C. Davis7, R. Vij8
1Cedars-Sinai Medical Center, Los Angeles, United States, 2University of Leeds, Leeds, United Kingdom, 3Heidelberg University Hospital, Heidelberg, Germany, 4Massachusetts General Hospital Cancer Center, Boston, 5Bristol-Myers Squibb, Lawrenceville, United States, 6Parexel, St Petersburg, Russian Federation, 7Washington University School of Medicine, St Louis, United States

Background: Multiple myeloma (MM) remains largely incurable despite improvements in clinical outcomes following the approval of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) (Rajkumar et al 2010). Previous findings were based on the evaluation of the median duration of therapy (DoT) with PIs and IMiDs (5 and 9 mo, respectively; Palumbo et al 2016) vs clinical trials (Stewart et al 2014). Understanding real-world use of therapies for relapsed/refractory (RR) MM is important to determine their position in the treatment paradigm.

Aims: In this subsequent PREAMBLE analysis, treatment patterns in patients (pts) with RRMM receiving bortezomib (bort) and carfilzomib (carfil) were evaluated to better understand the use of PIs in routine clinical practice.

Methods: PREAMBLE (NCT01838512) is an ongoing, observational, international cohort study exploring real-world treatment patterns and outcomes in pts with MM. Eligible pts were aged ≥18 yrs with diagnosis of RRMM who received at least one line of therapy and received treatment (index factors) by IMiDs or PIs and IMiDs (19), promoting their ability to boost tumor growth; interestingly, this effect is lost when EVs are isolated from MM cells where the Notch pathway was inhibited. Finally, EVs released by co-cultures of BMMCs and BM cells where the Notch pathway is blocked displayed a reduced ability to increase osteoclastogenesis compared with control culture. The results are particularly relevant due to the crucial role played by bone disease in MM progression.

Results: We present new insights in the pathophysiology of the rearranged BM niche represent the rationale for a Notch-directed therapy aiming to uncouple the crosstalk of MM with the surrounding microenvironment by inhibiting Notch signaling.
variable. Understanding the prognosis for a particular patient can help when selecting the intensity of treatment to be used and the frequency of reviews. The quantification of heavy/light chains pairs by the immunoassay Hevylite Heavy Chain (HLC) allows us a precise measurement of monoclonal and non-monoclonal immunoglobulins of the same isotype.

Aims: The aim of the study is to evaluate i) the impact of the “HLC ratio” defined as monoclonal immunoglobulin over isotype matched non-monoclonal immunoglobulin (involved/uninvolved HLC ratio or i/u HLC ratio), ii) the suppression on non-monoclonal pair denominated “HLC-matched pair suppression” and iii) the effect of “systemic immunoparesis” at diagnosis and at +100 days after autologous stem cell transplant (ASCT).

Methods: 85 patients (50 Male:35 Female) with a median age of 70 years (56-78) were followed (35 IgGK, 18 IgGL, 17 IgAK and 15 IgAL). The median follow-up of the patients was 19 (5-30) months. Sixteen patients (18%) presented ISS stage I, 15 (18%) with stage II and 54 (64%) with stage III disease. Thirty patients that reached ASCT were evaluated at +100 days after ASCT. Immunoglobulin heavy/light chains pairs (HLC) were assessed by Hevylite assays (The Binding Site). Clinical variables were evaluated for their impact on patient’s outcome. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier method and Cox regression. Statistical analysis was made with Prism 6.0.

Results: The median OS of the 85 patients was 54% and 26 patients deceased during the study due to MM. The median value of i/u HLC ratio was 80 (315.319.71). At diagnosis, a i/u HLC ratio>80 was significantly associated with worse OS (46 vs 61%, p=0.005) and shorter PFS (23% vs 42%, p=0.006). Severe HLC-matched pair suppression (i.e. more than 50% below the lower reference range) was identified in 68% of the newly diagnosed patients and was associated with significantly shorter OS (35% vs 81%, p=0.004) and PFS (21% vs 50%, p=0.013). Severe (>50%) systemic immunoparesis of non-monoclonal immunoglobulins was identified in 64% of the patients at diagnosis and was also significantly associated with shorter OS (32% vs 81%, p=0.030) but not with shorter PFS (26% vs 44%, p=0.306). The evaluation of other clinical variables on patient’s outcome are shown in table (see Table). In multivariate analysis, severe HLC-matched pair suppression and albumin were found as independent risk factors for OS whereas creatinine and i/u HLC ratio >80 were found as independent risk factors for PFS. In the post-ASCT evaluation of the patients, severe HLC-matched pair suppression reflects the persistence of clonal cells that is not associated with severe systemic immunoparesis.

Summary/Conclusions: Severe HLC-matched pair suppression and i/u HLC>80 are associated with worse OS and shorter PFS in MM patients suggesting a potential use of these parameters as prognostic biomarkers in newly diagnosed patients. Severe HLC-matched pair suppression is an independent risk factor for OS whereas i/u HLC>80 is independently associated with shorter PFS. In patients after ASCT, severe HLC-matched pair suppression reflects the persistence of clonal cells that is not associated with severe systemic immunoparesis.

E1272

SURVIVAL STRATIFICATION OF PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA)

R. Hajek1,*, M. Delforge 2, M. Raab 3, L. Pour 4, I. Špička 5, E. Gregora 6, J. Minářík 7, S. Gonzalez-McQuire 8, W. Bouwmeester 9, V. Maisnar 10
1Department of Haematoncology, University Hospital Ostrava, Ostrava, Czech Republic, 2Department of Hematology, UZ Leuven, Leuven, Belgium, 3Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany, 4Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, 51st Medical Department – Clinical Department of Haematology, University Hospital Charles University, 6Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, 7Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic, 8Amgen (Europe) GmbH, Zug, Switzerland, 9Pharminter International, Rotterdam, Netherlands, 10Department of Internal Medicine – Haematology, Charles University Hospital and Faculty of Medicine, Hirose Kralove, Czech Republic

Background: Established risk stratification tools in MM, such as the International Staging System (ISS) and the revised ISS, have improved overall survival (OS) estimates by combining the strongest known predictors of survival at diagnosis. There remains, however, a need for tools that use additional data available at relapse to improve risk stratification. We previously used real-world data from the Czech Registry of Monoclonal Gammapathies (RMG) to develop a RSA for estimating risk of death in patients with MM starting second line (2L) treatment. A multiple Cox regression model identified predictors of OS at 2L (Table); hazard ratios (HRs) for each predictor were multiplied to obtain an overall score for each patient. A K-adaptive partitioning for survival (KAPS) algorithm stratified patients into risk groups based on these scores.

Aims: To investigate how our RSA is affected by: 1) removing cytogenetic abnormalities (CAs) at diagnosis as an OS predictor, as these are not routinely measured in practice; 2) adding 2L treatment as a predictor, as 2L treatment type is likely to affect OS; 3) changing the number of stratification groups.

Methods: The analyses used data for 1418 patients aged ≥18 years who were diagnosed with symptomatic MM between May 2007 and April 2016 and who had started 2L. The Cox model was re-run for two sensitivity analyses: excluding CAs and adjusting for treatment received at 2L (adding bortezomib or lenalidomide vs other treatments as a predictor). The impact of different numbers of risk groups was assessed using KAPS.

Table 1.
Results: Results are shown in the Table. The model without CAs had similar HRs and predictors to the original; however, lactate dehydrogenase level at diagnosis was not identified as a predictor. Kaplan–Meier OS analysis showed separation between groups (median OS for the lowest [group 1] to the highest [group 4] risk group: 57.2, 29.4, 14.9 and 4.9 months), but the separation was weaker than when CAs were included in the model (median OS: 57.2, 28.8, 13.4 and 4.7 months). Despite 81% of patients in the RMS having no CA data, (‘missing’ CA was treated as a separate level in the original model), the fit of the model (measured using Akaike’s information criterion; Table) without CAs was worse than the original, reducing the accuracy of survival predictions. Adding 2L treatment as a predictor did not affect the model fit, indicating that OS predictions were not improved. KAPS analysis showed that a model with three groups for stratifying patients by risk of death was less effective than one with 4 or 5 risk groups. With group 1 as the reference, the HRs for OS were 2.4 and 8.1 for groups 2 and 3 in the three-group model (all \( p<0.001 \)), 2.1, 4.2 and 11.1 in groups 2–4 in the four-group model (all \( p<0.001 \)) and 1.8, 2.8, 4.9 and 10.5 for groups 2–5 in the five-group model (all \( p<0.001 \)). Using five risk groups was considered less practical in a clinical setting than the four-group model, which provides a clearer distinction in risk across groups.

Summary/Conclusions: These analyses indicate that our RSA incorporating data from diagnosis and relapse can identify patient groups with profoundly different survival expectations, regardless of 2L treatment type. CAs at diagnosis is a known OS predictor and, as expected, improves the strength of predictions. The practicalities of measuring CAs should be considered, but these data suggest that physicians should be encouraged to assess CAs at diagnosis; CAs at relapse may also be informative. Further validation of this model is required using other real-world and clinical trial data.

E1273
REAL-WORLD DATA ON MULTIPLE MYELOMA: A PROSPECTIVE NATIONAL REGISTRY IN URUGUAY ON 224 NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM 2012-2015
E. Riva1, V. Bove1, P. Villano1, M. Mori2, A. Noris2, P. Petruskevicius4, C. Córdoba2, A. Costa2, L. Díaz1
1Hematology Department, Hospital de Clinicas, Facultad de Medicina, 2Hematology, Centro Médico, Salto, 3Hematology Department, Asociación Española, 4President, Uruguayenian Society of Hematology, Montevideo, Uruguay

Background: The Uruguayan National Myeloma Registry is the first observational prospective Uruguay registry designed to document clinical characteristics of newly diagnosed multiple myeloma (MM), treatment and outcomes in a real-world setting. It collects detailed data on specific patients populations, limiting the generalizability of the evidence obtained.

Aims: To document current strategies of clinical characteristics at diagnosis, management, outcomes and treatment adverse effects of non-selected newly diagnosed MM patients in a recent period.

Methods: This registry includes all MM diagnosed from January 2012 in all institutions, nationwide. Smoking MM are not included. We present the analysis of the first 3 years of data collection. Information was obtained from medical records. Database includes clinical and laboratory characteristics, treatment, disease-related and treatment-related adverse events, response, progression free survival, overall survival and cause of death. Survival is obtained from the Uruguayan Ministry of Health database.

Results: With a 71% institutional coverage, 224 patients were included. Median age at diagnosis was 66 years (range 33-94 years), 54.5% were male; 10% were younger than 50 years and 34.5%, older than 70 years. Distribution according Ig subtype was: IgG 50.4%, IgA 23.3%, Light chains 18.7%, non-secretor 2.2% and IgM <1%. Most patients had advanced disease: 79.6% (Fig. 21/221), 48.6% ISS3 (86/177). Anemia (hemoglobin <10 g/dl) was present in 24.3%, osteolytic lesions in 89%, renal impairment (creatinine>2mg/dl) in 29.5% and hypercalcemia in 10%. Cytogenetics was evaluated in 150 patients; high risk features were detected in 63% by conventional cytogenetics and 19% by fluorescence in situ hybridization. First-line treatment included at least one of the new drugs (Thalidomide, Bortezomib or Lenalidomide) in 92% of patients ≤70 years and in 50% of >70 years. First-line response was available in 73%. Overall response rate (≥ PR) was 82.3%, VGR= 23.2% and CR=15.2%; 9.8% patients achieved stable disease and 7.9% were refractory. (Fig. 1.). Comorbidities and treatment-related toxicities were observed in 43.8% (47% in >70 y vs 41%). Most common adverse events were recurrent infections (28%), neuropathy (17%), thromboembolic events (54%) and grade 3-4 cytopenias (5%). Sixty out of 146 potential candidates have been transplanted as first line consolidation at the time of this analysis. After a median follow-up of 30 months, overall survival was 62.8% (median NR in ≤70 years and 32 months in >70 years) and median progression free survival (PFS) was 17 months.

Summary/Conclusions: This first national registry provides a thorough insight into the characteristics of MM patients in our country. With a high institutional coverage, we show MM characteristics at diagnosis are similar to other real-life reports. MM is detected in advanced stage with a high percentage of renal impairment. Diagnosis is performed according to international recommendations. First-line treatment is defined by local policies which restrict Bortezomib to high-risk cytogenetic features and/or renal impairment and do not provide Lenalidomide. Reasons for 59% potential candidates not receiving ASCI should be addressed in future research. This analysis provides relevant real-life information to plan strategies to improve MM management and perform high quality population-based research on the field.

Reference

E1274
REPRESENTATION OF MINORITIES, THE ELDERLY AND WOMEN IN MULTIPLE MYELOMA CLINICAL TRIALS
N. Duma1, J. Vera-Aguilera 1, M. Gonzalez 2, R. Parrondo 2, J. Paludo1, V. Mariotti2, Y. Wang1, R. Warsame1, R. Go1, A. Adjei3
1Hematology, Mayo Clinic, Rochester, 2Internal Medicine, Rutgers University, Newark, 3Mayo Clinic, Rochester, United States

Background: Multiple myeloma (MM) accounts for approximately 1% of all cancers and 10% of hematologic malignancies in the United States (US). MM occurs in all races but the incidence in African Americans is two to three times higher than in non-Hispanic whites. Many clinical trials (CT) lack appropriate representation of specific patients populations, limiting the generalizability of the evidence obtained.

Aims: Determine the representation of ethnic minorities, the elderly and women in MM CT.

Methods: Enrollment data from all therapeutic trials reported as completed in clinicaltrial.gov from 2000 to 2016 were analyzed. CT including other hematologic malignancies and with recruitment outside of the US were excluded. Enrollment fraction (EF) was defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database MM complete prevalence. Chi-square test was used to estimate differences in categorical data.

Results: Out of 177 MM CT, 78 (44%) reported ethnicity with a total of 12,055 enrollees. Out of those 78 CT, 52 (67%) were phase II, 15 (19%) phase III and 11 (14%) phase I. Most of the results were published from 2012 to 2016 (74%). Distribution by race, gender, age and comparison with the SEER MM prevalence data are described on Table. Forty-six (59%) trials were sponsored by industry, 7 (9%) by NCI and 25 (32%) were investigator initiated. Participation in CT varied significantly across ethnic groups, non-Hispanic Whites (NHW) were more likely to be enrolled in CT (EF of 0.23) than African Americans (AA) (EF of 0.08, p <0.0001) and Hispanics (H) (EF of 0.05, p <0.0001). Males had
a higher recruitment rate than females (58% vs 42%), but this could be explained by the higher incidence of MM in this subgroup. Enrollee’s median age was 62 years. Younger pts (<65 years) were more likely to be enrolled in CT than the elderly (66% vs 34%, p<0.0001). Industry sponsored trials were less likely to recruit AA compared with investigator initiated trials (7.6% vs 12%, p=0.0001).

Table 1.

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>CT</th>
<th>2013 MM Prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>10139</td>
<td>110.138</td>
</tr>
<tr>
<td>NA</td>
<td>1439</td>
<td>14.39</td>
</tr>
<tr>
<td>Other</td>
<td>2293</td>
<td>22.93</td>
</tr>
<tr>
<td>Native American</td>
<td>130</td>
<td>13.0</td>
</tr>
<tr>
<td>Other</td>
<td>2874</td>
<td>28.74</td>
</tr>
<tr>
<td>Total</td>
<td>12760</td>
<td>127.6</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Despite the higher incidence of MM in African Americans and the elderly, the former only represented 8.6% of the study participants and 66% of these were less than 65 years of age, perhaps lacking data in the tolerability of these new agents in our aging MM population. We also observed industry studies were less likely to recruit AA patients. Future trials should take extra measures to recruit participants that adequately represent the United States MM population.

E1275

EVALUATION OF TREATMENT INDUCED NEUROPATHY IN MULTIPLE MYELOMA AND ITS INFLUENCE ON PHYSICAL AND ROLE FUNCTIONING

B. Sidi Mohamed El Amine1,*, H. Asma1, O. Fouzia1, S. A. Najet1, Z. Zahia1
1Hematology department, University hospital of Sidi Bel Abbes, Sidi Bel Abbes, Algeria

Background: Peripheral neuropathy (PN) is a major dose limiting and potentially disabling adverse event of commonly therapeutically drugs used in the management of multiple myeloma (MM), including the immunomodulatory drugs (IMIDs, Thalidomide and Lenalidomide), and the proteasome inhibitor (Bortezomib).

Aims: The aims of this study were to (1) perform a psychometric evaluation of PN and (2) examine the prevalence of this complication and its influence on physical and role functioning of MM patients.

Methods: The FACT/GOG-Neurotoxicity (Ntx) subscale for assessing treatment induced PN was evaluated. The 11-item of this questionnaire was administered in 32 patients for internal reliability, construct validity, criteria validity, and compared to NCI grading adverse events (CTCAE version 3). Spearman rank correlation was calculated to determine the impact of PN on functional, physical and role functioning of MM patients, assessed by EORTC quality of life scale (EORTC QLO-C30). A Cronbach coefficient ≥ 0.8 is good. Spearman rank correlation is significant if p< 0.05 or r >0.5.

Results: Cronbach alpha coefficient for internal consistency of FACT/GOG-Ntx subscale was 0.92, and its correlation with the full CTCAE score as follows: P=0.0001. All the 11 items exhibited high correlations with the NTX subscale score (r= 0.65-0.79), and the Construct validity of NTX was good. According to FACT/GOG-NTX and NCI-CTCAE, 24 (75%) patients presented PN secondary to IMID or Bortezomib. The PN was severe in 14 (43, 7%) patients, especially those who received Bortezomib associated with IMIDs (71, 4%). PN did not influence the achievement of a very good response of MM to therapy neither a complete remission (P=0.6), but patients with high scores of NTX subscale have reduced functional activities, especially physical and role functioning (P=0.0001).

Summary/Conclusions: The 11-item FACT/GOG-Ntx subscale reliably and validly assesses Bortezomib/IMIDs induced PN. This complication is frequent and can alter the functional abilities of MM patients.

E1277

ANALYSIS OF THE CONNECT MM REGISTRY: TREATMENT OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED LENALIDOMIDE MAINTENANCE OR NO MAINTENANCE

1US Oncology Research, Rocky Mountain Cancer Centers, Denver, 2Mount Sinai Hospital, New York, 3Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, 4MD Anderson Cancer Center, Houston, 5US Oncology Research, Maryland Oncology Hematology, Columbia, 6Providence Cancer Institute, Southfield, 7Duke University Medical Center, Durham, 8Steeplechase Cancer Center, Somerville, 9University of South Carolina, Columbia, 10Wake Forest University School of Medicine, Winston-Salem, 11Celgene Corporation, Summit, 12Indiana University Simon Cancer Center, Indianapolis, United States

Background: Maintenance therapy post autologous stem cell transplant (ASCT) has been shown to improve clinical outcomes, including time to progression, progression-free survival (PFS), and overall survival (OS) in patients with newly diagnosed multiple myeloma (NDMM) (Sonneveld, N Engl J Med, 2012; McCarthy, N Engl J Med, 2012; Attal, N Engl J Med, 2012; Palumbo, N Engl J Med, 2014; Attal, ASCO, 2016). However, the effect of continued treatment on healthcare resource utilization (HRU) is mostly unknown. Connect MM Registry is a largely community-based, US prospective observational cohort study designed to characterize diagnosis, treatment patterns, and outcomes in patients with NDMM in clinical practice.

Aims: This analysis used the Connect MM registry to analyze the impact of maintenance therapy post ASCT on healthcare resource utilization in patients with newly diagnosed multiple myeloma (NDMM).

Methods: Adults patients with NDMM were eligible for enrollment in the registry within 60 days of diagnosis. Patients who completed induction and single ASCT were included in the analysis. HRU (hospitalization rates and median days) were analyzed by Kaplan-Meier.

Results: Of 1493 patients with NDMM enrolled in Cohort 1 from Sep 2009 to Dec 2011, 421 patients met the analysis criteria stipulated above. Of the 421, 266 (63%) did not receive maintenance therapy. Of those receiving maintenance, 180 (70%) were treated with LEN-only maintenance. The median age was 60 y (range, 24-78); 60% were men, and 86% were white. Baseline patient characteristics except serum

Background: Rearrangements of the immunoglobulin heavy chain (IGH) on chromosome 14 are identified by FISH in about 15-20% of patients (pts) with newly diagnosed multiple myeloma (MM). Historically there is no consensus on the significance of progress in these rearrangements: typically, t(4;14), t(14;16) and t(14;20) have high risk (HR), and t(11;14) have standard risk (SR). A recent study (Kaufman et al, Leukemia. 2016 30:633-9) suggests that t(11;14) may confer a worse prognosis.

Aims: To determine the prognostic significance of t(11;14) in a single-institution MM cohort.

Methods: 87 pts with t(11;14) by CD 138 selected FISH at diagnosis were identified, pts without symptomatic MM were excluded. Cox regression was used for statistical analysis. Progression free survival (PFS), and overall survival (OS) were evaluated in 32 patients for internal reliability, construct validity, criteria validity, and compared to NCI grading adverse events (CTCAE version 3). Spearman rank correlation is significant if p< 0.05 or r >0.5.

Results: Median age at diagnosis was 62 years, 45 pts (52%) were male, and 24 pts (27%) had ISS 3. All pts received either a proteasome inhibitor or an immunomodulatory agent, and 42 (48%) received triplet treatment as induction. Sixty-nine (79%) pts had ASCT, and overall response rate (ORR, partial response or better) post ASCT was 73%. For pts with HR FISH (defined as t(14;16), p53 del, 1q21 gain or 1p del) compared to SR FISH, the ORR post ASCT was 70% vs 77% (p=0.67). OS from diagnosis was 93% at 3 years, 74% at 4 years and 51% at 5 years. Seven patients (8%) developed plasma cell leukemia, and there was no association between HR and SR FISH (p=0.66).

Multivariate analysis, ISS stage was an independent risk factor for mortality; pts with stage 3 had 7.3 times (CI: 1.16-36.4) and 5.7 times (CI: 1.63-20.0) the risk of mortality than pts with stage 1 and 2. Having an ASCT reduced mortality by 87% (CI: 0.04-0.41).

Summary/Conclusions: Despite the use of novel therapies the OS at 5 years of our pts with MM was not significantly improved compared to SEER data from 1992-2013 (51% vs 48.5%). Pts with t(11;14) who had ASCT had increased survival compared to those who did not. Our results suggest that t(11;14) may confer a worse prognosis. Further prospective studies evaluating the risk of t(11;14) are warranted.
creatinine, calculated International Staging System stage, history of monoclonal gammopathy of unknown significance, presence of del(17p), and induction regimen were similar across groups. LEN-only maintenance significantly extended PFS compared to no maintenance (median 54.5 months vs 30.8 months; hazard ratio [HR]=0.98 [95% CI: 0.43, 0.79]; P=0.005; Table). OS was also significantly improved with LEN-only vs no maintenance (HR=0.45 [95% CI: 0.28, 0.73]; P=0.001). HRU results are detailed in the Table. The rate of hospitalization/100 person-years (PY) was similar across groups (P=not significant [NS], all comparisons) at the end of years 1 and 2. The median duration of hospitalization was numerically longer for patients who received no maintenance. Procedures/surgeries and concomitant medication use were similar across both groups at the end of years 1 and 2.

### Table 1

<table>
<thead>
<tr>
<th>Year</th>
<th>LEN-only Maintenance</th>
<th>HR</th>
<th>95% CI</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 0</td>
<td>0.98</td>
<td>0.43, 0.79</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>Year 1</td>
<td>0.45</td>
<td>0.28, 0.73</td>
<td>0.001</td>
<td></td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** For patients with NDMM, LEN-only maintenance significantly improved PFS and OS vs no maintenance with no apparent impact on HRU.

### E1278

**SERUM-FREE LIGHT-CHAINS (SFLC) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING MULTIPLE MYELOMA (LCMM)**


1Haematology, 2Clinical Biochemistry, Hospital 12 de Octubre, Madrid, 3Haematology, Hospital U de Salamanca, Salamanca, 4Haematology, Hospital Lozano Blesa, Zaragoza, 5Haematology, 6Hospital Morales Meseguer, Murcia, 7Haematology, Hospital U Son Llatzer, Mallorca, 8Haematology, Hospital Ger emulate, Hospitale General de Navarra, 9Haematology, Institut d'Oncologia Dr Josep Trueta de Girona, Girona, 10Haematology, Hospital U Ramon y Cajal, Madrid, 11Haematology, Hospital U de la Santa Creu i Sant Pau, Barcelona, 12Haematology, Hospital U La Paz, Madrid, 13Haematology, Hospital U Son Espases, Mallorca, 14Haematology, Hospital U San Carlos, Madrid, 15Haematology, Hospital Universitario de Canarias, Tenerife, 16Haematology, Clinica Universitaria de Navarra, Pamplona, Spain.

**Background:** Response and follow-up criteria in multiple myeloma (MM) are still based on the protein electrophoretic (PEP) quantification of the monoclonal protein (MP) in serum (s) or in urine (u). Monitoring MP by urine (u) PEP has a very low sensitivity for evaluating variations of small amounts of MP. Since 2001, serum free light-chain assays (sFLC) are available, with demonstrated clinical utility. Dejovic et al. have recently reported the usefulness of sFLC for evaluating response in LCMM.

**Aims:** In this work, we try to validate the use of sFLC assay in the context of GEM/PETHEMA clinical trials in order to evaluate the responses and its advantages in comparison to standard quantification of MP by PEP in serum (s) and in urine (u). The concordance between the classification of the response by uPEP / immunofixation (IF) and by FLCs (Kappa Index=0.425 [0.001]) in the Total Therapy 2 is demonstrated clinical utility. The normalization of the sFLC ratio (r) <0.101 observed in 35/98 (36%) patients after treatment, associated to a lower risk of progression (normal vs abnormal sFLCr: PFS 60 vs 39 months, P=0.038) but without impact in overall survival in our series. We also observed that an absolute value of sFLC greater than 50mg/L at treatment was associated with an increased risk of progression, regardless of the response achieved (PFS 60 vs 28 months, P<0.0001).

**Figure 1A.**

**Summary/Conclusions:** There is an acceptable agreement between both methods for response evaluation. The sFLC assays provide a greater sensitivity than the urine protein electrophoresis for monitoring low levels of disease in certain cases with measurable disease at diagnosis (isFLC ≥100) being useful for its follow-up, and also provide prognostic value as a predictor of progression.

### E1279

**TOPSPIN: A NOVEL ALGORITHM TO PREDICT TREATMENT SPECIFIC SURVIVAL IN CANCER**

J. Ubels1,2,3,*, E.H. van Beers1, A. Broijl2, P. Sonneveld2, M.H. van Vliet4, J. de Ridder1

1Center for Molecular Medicine, UMC Utrecht, Utrecht, 2Department of Hematology, Erasmus MC Cancer Institute, 3SkylineDx, Rotterdam, Netherlands

**Background:** In recent years many novel treatments have been introduced for Multiple Myeloma (MM), leading to an improved survival. However, this has also led to the need for a situation where many different treatment combinations are used, without a clear indication which patient will benefit most from which treatment. It is increasingly recognized that genetic heterogeneity between tumor influences treatment response. Patient outcomes may be improved by selecting the right treatment for the right patient at the moment of diagnosis. This requires the discovery of predictive markers, for example gene expression signatures, that can aid in this treatment decision. Here we present TOPSPIN (Treatment Outcome Prediction using Similarity between PatIeNts), a novel algorithm to discover such markers from tumor gene expression data. We use it to identify patients more likely to benefit from bortezomib.

**Aims:** This algorithm aims to develop a classifier that identifies a subset of patients that will benefit more from a treatment of interest than similar patients who receive a different treatment.

**Methods:** TOPSPIN aims to predict whether a patient will benefit (class 1) or not benefit (class 0) from a certain treatment of interest based on the gene expression profile of the patient. This algorithm relies on the idea that geneti- cally similar patients who received a different treatment should have a large difference in survival, given that genetic similarity is defined in a manner that is relevant to treatment response. This principle is used to identify prototype patients: patients who received the treatment of interest and have a larger than expected survival difference with the genetically most similar patients who received another treatment. Genetic similarity is defined separately for 10 581 gene sets based on Gene Ontology (GO) annotation. These prototype patients are used to define a classifier: new samples who exhibit a similar gene expression profile as these prototypes are also expected to benefit more from the treatment of interest. Here we use TOPSPIN to predict which patients will benefit from the proteasome inhibitor bortezomib. We combine tumor gene expression data from the Total Therapy 2, Total Therapy 3 and HOVON-65/GMMG–HD4 phase III clinical trials into one dataset comprising 910 patients, split into a bortezomib arm (n=407) and a non-bortezomib arm (n=503). Progression free survival is used as outcome measure. This dataset was split in a training set (n=606) and a test set (n=304). The test set is not used at any point in the training procedure and is only used for independent validation.

**Figure 1B.**
Results: We successfully identify gene sets that enable us to predict which patients will benefit most from bortezomib. The top 8 performing GO sets based on Hazard Ratio (HR) were combined to achieve the final classification. The training set 28.4% of patients are classified a class 1, resulting in an HR of 0.13 (p=7.1*10^-11) between the two treatment arms. More importantly, in an independent test set an HR of 0.47 (p=0.03) was found, as shown in Figure 1.

Figure 1. A Kaplan Meier of training set classification, showing a large survival benefit for patients receiving bortezomib in class 1 (red lines) but not in class 0 (blue lines). Innovation (B, Test)

Summary/Conclusions: This represents the first survey compiling both caregiver and patient experiences with AL amyloidosis. Alignment of caregiver with patient responses validates our patient-directed research. Patients with AL cardiac amyloidosis frequently receive misdiagnoses and sometimes receive incorrect treatment for the misdiagnosed condition. Disease awareness among all specialists is vital, especially among those to whom patients are initially referred due to the nature of their initial symptoms.

E1281

EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

M.A. Dimopoulos1, K. Weisel2, J. Kaufman3, P. Sonneveld4, M. Rizzo5, Y. Xu6, K. Fahrbach6, M. Gaudig7, M. Slavcev8, L. Dearden8, A. Lam8, 1National and Kapodistrian University of Athens, Athens, Greece, 2Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium, 3Karolinska University Hospital, Stockholm, Sweden, 4University Medical Center Utrecht, Utrecht, the Netherlands, 5Proteum Biosciences Inc, South San Francisco, CA, 6Mayo Clinic, Rochester, Rochester, NY, 7European Institute of Oncology, Milan, Italy, 8Janssen Global Services, LLC, Raritan, NJ, USA

Background: Daratumumab is a new monoclonal antibody aimed to improve outcomes in relapsed or refractory multiple myeloma (RRMM), and has been investigated in combination with lenalidomide plus dexamethasone (DRd), and with bortezomib plus dexamethasone (Dvd), in randomized controlled trials (RCTs), POLLUX and CASTOR, respectively. Although DRd and Dvd have been compared against current standard of care (SOC), namely Rd, and Vd, it is important to assess how daratumumab plus SOC compares with other routinely used treatment regimens and investigational regimens expecting regulatory approvals.

Aims: To understand delays, errors, and inconsistencies in the diagnostic pathway for patients with AL cardiac amyloidosis and validate using caregiver responses.

Methods: An online survey consisting of 36 questions (for patients) and 37 questions (for caregivers) was developed by the Amyloidosis Research Consortium (ARC) and distributed to the patient mailing lists of ARC, the Amyloidosis Foundation, and Amyloidosis Support Groups in January 2017. The survey was designed for patients with all forms of cardiac amyloidosis and their caregivers; however, the present analysis is limited to AL amyloidosis.

Results: In this subanalysis, 137 patients and 115 caregivers completed the survey. Most patient respondents were >55 years of age (n=111; 81.0%); of those, 16.1% (n=22) were >70 years of age. Composition of the population was 81.8% white/Caucasian (n=112), 2.2% Asian (n=3), 4.4% African American (n=6), 2.2% Latino (n=3), 5.1% other (n=7), and 3.6% unknown (n=5). Most patients had lived with their diagnosis for >1 year (17.5% [n=24] <1 year; 23.4% [n=32] 1-2 years; 29.2% [n=40] 3-5 years; 21.2% [n=29] 6-10 years; 8.8% [n=12] >11 years). A significant percentage of patients had multorgan involvement (54.7% [n=75] kidney; 29.9% [n=41] nerve; 14.6% [n=20] liver; 43.8% [n=60] heart) and the most recent data from POLLUX and CASTOR were extracted and then assessed RCTs of treatments for RRMM. The specific studies of interest were those that had investigated the efficacy of other treatment options considered to be comparable to DRd or DVd.

Network Comparator

<table>
<thead>
<tr>
<th>Network</th>
<th>Comparator</th>
<th>Past OR(DVd/DVd)</th>
<th>Past OR(DVd/DVd) better than multivariate*</th>
<th>OR(DVd/DVd)</th>
<th>DRd vs. Vd</th>
<th>DRd vs. Vd better than multivariate*</th>
<th>DRd vs. Rd</th>
<th>OR(DRd/Rd)</th>
<th>OR(DRd/Rd) better than multivariate*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRd vs. Vd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.59</td>
<td>0.38</td>
<td>0.77</td>
<td>0.59</td>
<td>0.38</td>
</tr>
<tr>
<td>DRd vs. Rd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.36</td>
<td>0.18</td>
<td>0.69</td>
<td>0.36</td>
<td>0.18</td>
</tr>
<tr>
<td>DVd vs. Vd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.36</td>
<td>0.18</td>
<td>0.69</td>
<td>0.36</td>
<td>0.18</td>
</tr>
<tr>
<td>DVd vs. Rd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.72</td>
<td>0.54</td>
<td>0.90</td>
<td>0.72</td>
<td>0.54</td>
</tr>
<tr>
<td>DRd vs. Vd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.36</td>
<td>0.18</td>
<td>0.69</td>
<td>0.36</td>
<td>0.18</td>
</tr>
<tr>
<td>DVd vs. Rd</td>
<td></td>
<td>Drake et al.</td>
<td>Drake et al.</td>
<td></td>
<td>0.72</td>
<td>0.54</td>
<td>0.90</td>
<td>0.72</td>
<td>0.54</td>
</tr>
</tbody>
</table>

*100% probability represent any value above 99.951%

Aims: Therefore, the objective of this analysis is to compare DRd and Dvd with other relevant treatment options via network meta-analysis (NMA) techniques.

Methods: A systematic literature review (SLR) based on searches of Medline, Embase, and the Cochrane Library was conducted to identify and then assess RCTs of treatments for RRMM. The specific studies of interest were those that had investigated the efficacy of other treatment options considered to be comparable to DRd or Dvd. Data from trials that met the SLR’s inclusion criteria and the most recent data from POLLUX and CASTOR were extracted and then included in a Bayesian NMA to allow for the indirect comparison.

Results: Data from RCTs identified by the SLR allowed formulation of two evidence networks. Network 1 included DRd and other immunomodulatory agent (IMiD)-containing regimens, and Network 2, contained Dvd and other
immunomodulatory agent (IMiD)-free regimens. Analysis using a fixed-effects model found that DRd compared with other IMiD-containing regimens in Network 1, and DVD compared with other IMiD-free regimens in Network 2 prolonged PFS and OS among patients RRMM (see Table 1).

**Summary/Conclusions:** In the absence of prospective head-to-head trials, NMA provides potentially important information on comparative effectiveness of different treatments. This NMA suggests that the combinations of DRd and DVD as front-line, active comparator PFS in patients with RRMM with similar trends found for OS when compared with other established and new regimens.

**E1282**

**TRENDS IN TREATMENT PATTERNS AND SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED 2011-2016 IN THE UNITED STATES USING AN ENHANCED ELECTRONIC HEALTH RECORDS DATABASE**

B. Ung1, S. Abouzaid1,*, Q. Ni1, K. Parikh1, A. Agarwal1

1Celgene Corporation, Summit, NJ, United States

**Background:** Over the past few years, the multiple myeloma (MM) treatment landscape has changed considerably. Immunomodulating (IMiD) drugs and proteasome inhibitors (PI) have emerged as mainstays of MM Tx. However, the limitations and lag time of available administrative claims databases make it difficult to assess current real-world trends in the Tx of MM.

**Aims:** The study aimed to describe trends in demographics, Tx patterns, and sequencing for newly diagnosed MM (ndMM) patients (Pt) in the United States (US) using an enhanced Electronic Health Records (EHR) database.

**Methods:** A retrospective observational study of ndMM Pts was conducted utilizing EHR from a nationally-representative database (Flatiron Health). The Flatiron MM provider network comprises over 260 clinics throughout the US. Pts with an ICD-9 (203.0x) or ICD-10 (C90.xx) diagnosis of MM between 01/01/2011–12/31/2016 were randomly selected into the study. Pts were excluded if they did not have ≥2 documented clinical visits during the study period. Diagnosis of MM was confirmed through review of unstructured chart data. Index date was defined as the Pt’s date of diagnosis with MM. ndMM Pts were defined as those without a MM Tx more than 14 days prior to their first diagnosis date. Start of first-line (1L) therapy was defined as the 1st episode of an eligible systemic Tx given after or up to 14 days before the index date. Regimen were defined using the 1st eligible drug episode plus other eligible drugs given within 28 days of each other. A maximum gap of 90 days was allowed within a given line of therapy (LOT) and was considered concluded the day beyond the start date of the next LOT.

**Results:** For the 3367 ndMM Pts identified, mean(SD) age was 68.5(11) years at the time of diagnosis, 45.9% were female, 57.6% were white, 14.7% African American, and 11.1% other race. The most common immunoglobulin (Ig) classes at diagnosis were IgG (51.8%) and IgA (18.9%). Median follow-up time for these groups was 471, 730, 928, 1132, and 610 days respectively. Among treated Pts, 205 (12.7%), 208 (28.2%), 109 (33.5%), and 98 (38.1%) received at least 1 stem cell transplant (SCT), respectively. Median follow-up time for ndMM Pts was 15.9 months. During the study period, 1611 received only 1 line (L) of Rx, 222 were treated with 2L, 325 with 3L, 252 with 4L+, while 442 (13%) received no Tx. Mean follow-up time for this groups was 471, 730, 928, 1132, and 610 days respectively. Among treated Pts, 205 (12.7%), 208 (28.2%), 109 (33.5%), and 98 (38.1%) received at least 1 stem cell transplant, respectively. Of Pts receiving 1L therapy, 984 (33.6%) received IMiD compound + PI, 715 (21.2%) received DRd, and 556 (19%) received IMiD compound-based therapy in 1L. The use of IMiD compound + PI in 1L increased during the study period for SCT and non-SCT Pts (NSCT) from 40.6% and 21.5% in 2011, to 66.7% and 46.8% in Pts diagnosed in 2016. In Pts who received a SCT (n=618), the most common 1L regimens were lenalidomide + bortezomib (<dexamethasone (Rx); n=217, 43.9%), cyclophosphamide + bortezomib + d (Rx; n=124, 21.9%), lenalidomide + d (Rx; n=70, 11.3%), and bortezomib + d (Rx; n=57, 9.2%). In NSCT Pts (n=2307), the most common 1L regimens were CyBord (13.2%), carfilzomib monotherapy (7.4%), lenalidomide + d (Vd; n=57, 9.2%). In 2L, the most common regimens were CyBord (13.2%), carfilzomib + d (Vd; n=43, 7.3%), and CyBord + d (Vd; n=35, 5.9%). In 3L, the most common regimens were CyBord (11.0%), carfilzomib + d (Vd; n=29, 4.4%), and CyBord + d (Vd; n=17, 2.6%). In 4L, the most common regimens were CyBord (7.9%), carfilzomib + d (Vd; n=20, 3.2%), and CyBord + d (Vd; n=12, 1.8%). In 5L, the most common regimens were CyBord (5.6%), carfilzomib + d (Vd; n=11, 1.7%), and CyBord + d (Vd; n=8, 1.2%).

**Summary/Conclusions:** At diagnosis, HLC pair suppression was observed in 72 (63%) patients, and SI in 52 (45%). The incidence of bloodstream infections during the study period was 23%; and 20 patients (18%) died within 6 months from diagnosis. We found a significant association between HLC pair suppression and both the incidence of bloodstream infections (OR: 6.10, 95% CI: 1.71-21.83; p=0.002) and early deaths (OR: 4.02, 95% CI: 1.10-14.66; p=0.03); by contrast SI had no significant association with either event (p=0.07 and p=0.3, respectively). Survival analyses demonstrated an association between bloodstream infections and shorter OS (50% vs 92%, HR: 7.43, 95% CI: 2.96-18.61, p<0.0001, Figure A). The risk of bloodstream infections was significantly higher among patients with HLC pair suppression vs those without suppression (34% vs 7%, respectively; HR: 5.12, 95% CI: 1.54-17.07, p=0.003, Figure B). In line with this, patients with HLC pair suppression had shorter overall survival (OS) compared to those without (76% vs 93%, HR: 3.47, 95% CI: 1.02-11.83, p=0.03). By contrast we found no association between SI and risk of infection (p=0.08) or survival (p=0.4).

Figure 1.

**Summary/Conclusions:** HLC pair suppression provides information on immune status and associates with an increased risk of bloodstream infections and early death in newly diagnosed MM patients. Our findings highlight the importance of recognizing this status at time of diagnosis, and suggest that HLC pair suppression may help guide clinical decisions about the need for adequate antimicrobial treatment during myeloma therapy.

**E1284**

**DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA**

D. Katalinic1,*

1Department of Internal Medicine, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia

**Background:** Daratumumab is a human IgGk monoclonal antibody which binds with high affinity to the CD38 molecule on the surface of multiple myeloma cells. It induces rapid tumor cell death through multiple immune-mediated mechanisms and showed encouraging results alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed multiple myeloma.

**Aims:** The primary end point of the study was progression-free survival (PFS). Patients were enrolled in a total of 134 patients (74 (54.5% white, mean age 65.4±18.2 years) with multiple myeloma who had received at least three lines of therapy to receive lenalidomide with dexamethasone (68 patients, control group A) or in combination with daratumumab (66 patients, therapy group B).
Results: At a median follow-up of 9.8 months in a protocol-specified interim analysis, 67 patients had disease progression or death were observed (in 18 of 66 patients (27.2%) in the group B vs 28 of 68 (41.1%) in the control group (p<0.001)). A significantly higher rate of overall response was observed in the group B than in the group A (68.7% vs 62.9%, p<0.001), as was a higher rate of complete response or better (39.2% vs 16.1%, p<0.001). The most common adverse events during the treatment was myelotoxicity (neutropenia in 68.6% of the patients in the therapy group B vs 42.1% of those in the control group A), anemia (in 21.5% vs 13.6%) and thrombocytopenia (in 13.8% vs 8.7%).

Summary/Conclusions: In patients with relapsed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone appeared active and resulted in significantly improved progression-free survival. However it was associated with a higher risk of myelotoxicity.

Summary/Conclusions: Our observations confirmed that FLC test has greater sensitivity than uIFE for detection of the monoclonal component, and that normalization of sFLC ratio is highly predictive of MRD negativity in patients with LCM/MMOSM. The proportion of negative sIFE samples increased with depth of MRD, but the FLC response did not appear to parallel with the depth of response in IIMM. We recommend that FLC test should be incorporated into the criteria for assessing treatment response using LCMM/OSMM as an alternative to 24-h uIFE, and both negative sIFE and normal rFLC are still useful for response assessment of residual clonal PCs in IIMM.

E1286 DARATUMUMAB IS AN EFFECTIVE AND SAFE SALVAGE THERAPY IN RELAPSED/REFRACTORY PATIENTS WITH MULTIPLE MYELOMA AFTER ALL-ALLOGENIC STEM CELL TRANSPLANTATION

E. Klyuchnikov1,*, U.-M. von Pein 1, F. Ayuk1, M. Christopeit 1, R. Adjalle 1, A. van Randenborgh1, C. Wolschke 1, N. Kroeger 1
1Department for Stem Cell Transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany

Background: Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma cells. The drug became the first monoclonal antibody as single agent therapy approved by the FDA for the treatment of multiple myeloma. The role of allo-SCT in myeloma patients (pts) remains unclear; nevertheless, the registry study of EBMT suggests an increasing rate of allografts in Europe in last years. Despite the potentially curative potential of this approach, the increased relapse rate and low PFS remain a central clinical problem.

Aims: In this single center retrospective analysis, we report on our experience on the use of daratumumab in relapsed/refractory myeloma pts after allo-SCT.

Methods: A total of 16 pts (male, n=9) with median age of 66 years (39-72) relapsing after allo-SCTs that had been performed during a period 2008-2015 at the University of Hamburg and received daratumumab as single agent salvage therapy. Before allografting 9 pts received one and 7 pts 2 autografts, respectively. All but one pt received at least 1 salvage therapy line prior to the allo-SCT. The allografts were performed from unrelated donors (MUD, n=9; MMUD, n=4) or matched related donors (MRD, n=3). The median of salvage lines post-transplant and prior to first daratumumab infusion was 3 (1-4). The salvage regimens included bortezomib, lenalidomide, pomalidomide and carfilzumib. Daratumumab infusions were started at a median of 21 months (0-30) after relapse/progress.

Results: The median number of infusions was 13 (3-22). A total of 16 and 15 pts were available to safety and efficacy evaluation, respectively. The safety was assessed according to the Common Toxicity Criteria (CTC). A total of 20 adverse events were observed in 16 pts: dyspnea (CTC1, n=3; CTC2, n=1), bronchospasm (CTC2, n=2) shivering (CTC1, n=3), cough (CTC1, n=1; CTC2, n=1), musculoskeletal pain (CTC1, n=4), acute coronary syndrome (CTC3, n=1), skin rush (CTC2, n=1), pressure on eyes (n=1). Two patients developed late onset infections (pneumonia and infection of urinary tract) followed by temporarily therapy interruption. We observed a decrease of Tregs (CD4+CD25high/CD127low) number from a median of 5.05% at start to 0.65% at day 21 after first daratumumab infusion in four pts. There were no cases of GVHD. The adverse events appeared in all pts after the first infusion, with improved tolerance of following infusions. There were no cases, where the therapy had to be stopped due to adverse events. Within a median follow-up of 32 months (1-45) from the relapse/progression 12 of 16 pts remain alive. Two pts died due to progress of myeloma and another 2 pts died due to severe infection/sepsis. A total of 9 of 15 evaluable pts responded (60%, PR, n=7, vgPR, n=2). The responses (decrease of paraprotein and/or free light chains; reduction of extramedullary tumor in 2 pt) occurred at a median of 7 days (7-75) after the first administration of daratumumab. The median response duration is 4.5 mo (1.5-8). Six pts show ongoing responses. All responding and 2 non-responding pts (stable disease) showed clinical improvement of constitutional symptoms.

Summary/Conclusions: Daratumumab demonstrated encouraging efficacy in relapsed/refractory pts with myeloma after allo-SCT. The administrations of the drug in these heavily pre-treated pts were associated with good safety profile and development mostly non-severe adverse events mostly after the first infusion. Further studies on the use of daratumumab in post-transplant setting are warranted.

E1287 PROGNOSTIC RELEVANCE OF VEGF AND VEGFR EXPRESSION IN CD138+/CD19- AND CD138+/CD19+ PLASMA CELLS FROM PATIENTS WITH MONOCLONAL GAMMOPATHIES

C. Geralsdes1,2,*, A.C. Gonçalves2,3, R. Alves2,3, E. Cortesão1,2,3, L. Ribeiro1, J.M. Nascimento Costa1,2, A.B. Sarmento-Ribeiro1,2,3
1Department of Hematology, Centro Hospitalar de Coimbra e Universitário de Coimbra (CHUC), 2Applied Medical Biology and University Clinic of Hematology, 3CIMAGO, 4University Clinic of Oncology, Faculty of Medicine University of Coimbra, Coimbra, Portugal

Figure 1.
Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of extracellular matrix remodeling and inflammatory cytokine generation with an important role in the bone marrow microenvironment of multiple myeloma (MM). Angiogenesis is heightened in the bone marrow of MM patients in parallel with tumor progression. Myeloma and stromal cells secrete angiogenic factors that include VEGF. Previous studies showed a high frequency of these genes in the expression of VEGF between plasma cells (PCs) and stromal cells from the same MM patient. However, no clear association with expression levels, phenotypic subtypes of PCs and prognosis was demonstrated.

Aims: The present study aimed to evaluate the expression levels of VEGF and VEGF receptor (VEGFR) on phenotypic subtypes of PCs in patients with multiple myeloma (MM) and to explore its role as diagnostic and prognostic biomarkers.

Methods: We include 128 patients with monoclonal gammopathies, 60 patients with newly diagnosed symptomatic MM and 68 with monoclonal gammopathy of uncertain significance (MGUS) and also from 11 non-neoplastic controls (11). The expression levels of VEGF and VEGFR on CD138+/CD19− (clonal PCs) and CD138+/CD19+ (non-clonal PCs). The results are presented as percentage of PCs expressing VEGF/VEGFR and as expression levels of this antiangiogenic molecules expressed in mean intensity of fluorescence (MIF). The effects of these parameters on progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier method. For statistical analysis, software IBM SPSS Statistics v22 was used. ROC curves were performed to assess the VEGF and VEGFR accuracy as diagnostic and prognostic biomarkers.

Results: In our cohort of patients, median age was 70 (39-86) years, 52% were male. We found increased expression levels of VEGF in CD138+/CD19− PCs from MM (80±7.5 MIF) compared to mgUS patients (61±7.6 MIF) (p=0.011), and also higher to the observed in CD138+/CD19+ PCs (39,92±1.74 MIF) in both populations of patients (p<0.001 and p=0.02, respectively). No difference was observed in the expression levels of VEGF in CD138+ in mmUS patients with VEGFR levels higher than 23.5 MIF in CD138+/CD19− PCs have higher probability to progress to MM [AUC 0.688 (95%CI 0.592-0.784), p<0.0001, 90% sensitivity, 56% specificity, 65% PPV, 84% NPV]. In mmUS patients, we also found an association between increased VEGF expression levels in CD138+/CD19− PCs (11%) and progression-free survival (PFS) (p=0.007) irrespectively of first line therapy (bortezomib-based regimens for fit patients or alkylating-based treatments for unfit patients). Interestingly, we also observed an increased percentage of CD138+/CD19+ PCs (21%) expressing VEGF in MM patients with a more favorable PFS (p=0.04) and OS (p=0.008).

Summary/Conclusions: The results of our investigation showed that CD138+/CD19− and CD138+/CD19+ PCs have differences in what concerns VEGF/VEGFR expression, not only in mmUS patients, but also immUS patients. The increased expression of VEGF in clonal PCs from MM compared to mgUS patients evidences the relevance of VEGF in myelomaogenesis. We also demonstrated a negative prognostic impact of an increased VEGF expression in CD138+/CD19− PCs, highlighting the role of VEGF in the survival and maintenance of clonal PCs and as a predictor of outcome in MM progression. The association between the percentage of CD138+/CD19+ PCs and survival supports the possibility that these cells may not be neutral players in the complex pathogenesis of MM. The results of our study should be further investigated in larger series of patients.

E1288

RACIAL DIFFERENCES OF FISH ABNORMALITIES IN MINORITIES WITH MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE

1Cabrini Medical Center, Chicago, Illinois 60641, USA, 2University of Chicago, Chicago, IL 60637, USA, 3University of Iowa, Iowa City, IA 52242, USA, 4Cabrini Medical Center, Chicago, Illinois 60641, USA, 5University of Chicago, Chicago, IL 60637, USA, 6Cabrini Medical Center, Chicago, Illinois 60641, USA, 7Cabrini Medical Center, Chicago, Illinois 60641, USA.

Background: Racial disparities of FISH abnormalities in multiple myeloma (MM) have been well described in whites (W) but partially described in minorities (M) (Paulus et al, ASH 2016, 4432).

Aims: To explore racial differences of FISH abnormalities using the largest cohort of minorities to date.

Methods: CD-138 selected FISH was done on 799 consecutive patients (pts). Pts without symptomatic MM, and biopsy ≥6 months after diagnosis were excluded. The abnormalities evaluated included standard and intermediate risk IGH rearrangements (IGH r), t(11;14), and high risk: t(14;20), t(1;14), del(13q), del 17p, 1q21. Chi-square was used for statistical analysis. Due to smaller numbers, all M (Hispanic (H), Black (B), Asian (A) and Other (O)) were included into the same group for statistical analysis.

Results: 482 pts were eligible, 343 (71%) were W, 52 (10%) H, 50 (10%) B, 19 (3%) A, and 18 (3%) O. Median age was 65 years, 54% were male, and 28% ISS stage 3. There were no were no statistically significant differences in FISH abnormalities between the M. Overall W had more abnormalities in IGH r, t(4;14), t(11;14), t(14;20). 1q21 gain compared to M. Most notably W had more IGH r (39% vs 28%, p=0.019) and t(11;14) (20% vs 12%; p=0.024). There were statistically significant differences between W and M in the high risk FISH abnormalities.

Summary/Conclusions: W had significant differences in FISH compared to M. W had more IGH r and t(11;14) than M, and there was no difference in high risk FISH abnormalities between W and M. This study confirms the biological racial disparities that exist in minorities with MM. Further studies with more inclusion of minorities are needed to elucidate these disparities and its effects on risk stratification and outcomes.

E1289

POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE DEXAMETHASONE AS MAINTENANCE INJECTION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MYELOMA (ALLG MM14)

1A. Kalff1,2,*, N. Kennedy3, J. Reynolds1, H. Quach4, P. J. Ho5, N. Horvath6, P. Mollee7, J. D’Rozario8, K. Taylor9, J. Estell10, A. Spencer11, 1Monash University, 2Alfred Hospital, Melbourne, Australia, 3Haematology Department, Alfred Hospital, 4St Vincents Hospital, Melbourne, 5Royal Prince Alfred Hospital, Sydney, 6Royal Adelaide Hospital, Adelaide, 7Princess Alexandra Hospital, Brisbane, 8The Canberra Hospital, Canberra, 9Haematology & Oncology, St Vincent’s Hospital, Sydney, 10Hills District Cancer Clinics of Australia, Brisbane, 11Concord Repatriation General Hospital, Sydney, Australia.

Background: Whilst the addition of dexamethasone to upfront therapy with Immunomodulatory (IMiD) agents is important to mediate rapid reduction in disease burden, preliminary findings suggest that the NK stimulatory effects of IMiD compounds are best harnessed without the co-administration of dexamethasone, and may be especially effective in the setting of minimal disease burden (in the maintenance setting for example) when some inherent immune recovery has occurred. However this has yet to be confirmed in a prospective clinical trial.

Aims: To evaluate the effect of maintenance with POM alone (Arm 1) versus POM-LoDEX (Arm 2) on progression free survival (PFS), overall survival (OS), and kinetics of response (overall response rate (ORR)) in relapsed myeloma (MM) patients refractory to lenalidomide (R-LEN) demonstrating stable disease (SD) or better after frontline IMiD® (ARV-LEN or IMiD® compounds) salvage treatment with pomalidomide (POM) and low dose dexamethasone (LoDEX) induction.

Methods: Multicentre, open-label, randomized phase 2 study of relapsed R-LEN patients who had received≥2 prior lines of therapy. POM 4mg days 1-21 (28 day cycle) was administrated alone or in combination with LoDEX (40mg weekly) as maintenance following an induction with 4 cycles of POM and LoDEX. Treatment continued until toxicity or progression. Peripheral blood samples for immune studies were collected pre-induction and prior to cycles 1, 3, 6 and 10 of maintenance.

Results: 154 patients from 11 sites were enrolled on to the study (M:F 80:74), with a median age of 67 years (range 35-88). Median number of prior lines of therapy was 4.5 (2-14). All patients had failed LEN (100%, 127 (82.5%) were also refractory to bortezomib (double refractory) and 94 (61%) had received a prior autologous stem cell transplant. 72 (47%) patients achieved SD or better with Arm 1, (RefRACTORY MYELOMA (ARM) 2 (15%) arm). ORR (≥PR) for all patients was 45.5% (≥MR) was 55.7% [MR=15 (9.7%)].
SUMMARY/CONCLUSIONS: In patients with relapsed myeloma, after initial disease control/debunking is achieved with POM-LoDEX induction, maintenance with single agent POM may be more effective for sustaining disease control than continuation of POM-LoDEX. Correlative studies are currently underway to further investigate the immunological mechanisms behind this observation.

E1290
POMALIDOMIDE IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, 2Department of Hematology, Theagenion Hospital, Thessaloniki, 3Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, 4Department of Hematology, 251 General Air-Force Hospital, Athens, Greece

Background: The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) is a perspective option for patients with end-stage relapsed/refractory multiple myeloma (RRMM). We analyzed efficacy and toxicity of Pom-Dex in all patients from the Czech Republic treated from June 2013 to december 2016.

Methods: Patients were eligible if they had been diagnosed with RRMM and had failed at least two previous treatments with bortezomib and lenalidomide. They were treated with start dose of Pom (4mg/day on days 1-21, orally) plus low-dose dexamethasone (40mg/day on days 1, 8, 15, and 22, orally) until disease progression or unacceptable toxicity. We analyzed TTP and OS together with toxicity. Also, univariate Cox proportional hazards model for OS was done for standard risk factors. One hundred and twenty-two patients with median age of 67 treated with Pom-Dex were evaluated. Median follow-up was 8.7 months. Median of previous treatment lines was 4.

Results: Median TTP of Pom-Dex treatment was 7.1 months (95% CI 5.3-8.6). Median OS was 19.0 months (95% CI 13.2-25.8). The most common grade 3-4 adverse events were neutropenia in 44%, anemia in 22% and thrombocytopenia in 24% of patients. Grade 4 infections were observed in 10% of patients. Patients with ECOG worse than 2, B2microglobulin higher than 5, ISS stage 3, low hemoglobin, low platelet count and presenting extramedullary mass had worse OS according to univariate Cox proportional hazards model.

Summary/Conclusions: Our analyses show that Pom-Dex treatment of Czech RRMM patients is effective, well tolerated and had better results than the registration study. Performance status and tumor burden seem to be main prognostic factors according to our model. Thus, our suggestion for clinical practice is to start pomalidomide treatment as soon as possible in case of MM relapse.

E1291
UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE
T. Bacon1,∗, M. Gaudig2, T. Ito1, A. Hadfield4, A. Rider4
1Janssen Health Economics & Market Access EMEA, Dublin, Ireland, 2Janssen-Cilag, Neuss, Germany, 3Janssen Health Economics & Market Access EMEA, High Wycombe, 4Adelphi Real World, Bollington, United Kingdom

Background: Multiple myeloma is a heterogeneous disease that accounts for approximately 10% of all haematological malignancies. While European treatment guidelines exist for multiple myeloma, there is limited understanding about the characteristics of patients with multiple myeloma in Europe and how these characteristics vary by disease stage. Numerous patient and disease-related factors can have an impact on treatment choice. Data surrounding these factors would help to better characterise European patients and inform management and treatment practices in multiple myeloma.

Aims: The aim of the current study is to describe multiple myeloma patients from 5 European countries (France, Germany, Italy, Spain, and the UK) across the disease continuum.

Methods: Data were drawn from the Adelphi Real World Multiple Myeloma Disease-specific Programme (DSP), which was conducted across France, Germany, Italy, Spain and Myeloma UK in Q1 2015. The Multiple Myeloma DSP is a real-world, cross-sectional survey that involves haematologists and haematologists who completed patient record forms for the next 8 multiple myeloma patients with whom they consulted. Study variables included patient demographics and background clinical information.

Results: A total of 262 physicians reported on 2,024 patients with multiple myeloma. Of these patients, 73.2% were receiving first-line treatment; the remaining 26.8% were receiving second-line treatment or later. The median age of multiple myeloma patients was 70 years, 58.4% were male, and most patients (88.5%) were white/Caucasian. Only 4.3% of patients had a family history of cancer. Patients had a mean height of 168.8 cm, a mean weight of 72.8 kg, and a mean body mass index of 25.5 kg/m². In terms of performance status, 79.8% of patients had an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1, whereas 20.2% had an ECOG status of ≥ 2. While 12.9% of patients had smouldering myeloma, 47.5% of patients had advanced stage (stage III) disease. The most common symptoms experienced by patients were anaemia (31.0%), bone pain (32.4%), fatigue/weakness (28.4%), and kidney impairment or failure (12.6%). Furthermore, 34.6% of patients had bone complications at some point in time. Over half (51.1%) of patients had comorbidities; of these, 22.8% had hypertension and 12.5% had diabetes. Overall, 33.7% of patients were considered ineligible for transplant. Variences in patient characteristics, both by country and by line of therapy, were observed.

Summary/Conclusions: Results from this analysis provide valuable insight into multiple myeloma patients in European countries. These findings can help to inform future treatment practices in Europe.

E1292
RAD REGIMEN AS INDUCTION BEFORE ASCT: OUTCOMES, SAFETY AND EFFECTS ON BONE METABOLISM AND ANGIOGENESIS; FINAL RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY GROUP
E. Terpos1,∗, E. Katodritou2, A. Symeonidis3, F. Zagouri1, A. Gerofotis2, G. Christopoulos2, M. Gavriatopoulou1, D. Christoulas4, A. Kourakis4, P. Konstantinidou2, E. Kastritsis, M.A. Dimopoulos1
1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, 2Department of Hematology, Theagenion Hospital, Thessaloniki, 3Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, 4Department of Hematology, 251 General Air-Force Hospital, Athens, Greece

Background: There is limited published data on the efficacy and safety of the combination of lenalidomide, adriamycin and dexamethasone (RAD) as induction therapy for newly-diagnosed myeloma (NDMM) patients who are eligible for autologous transplantation (ASCT).

Aims: The primary endpoint of this phase 2 study was the assessment of overall response rate (ORR) after 4 cycles of RAD induction in NDMM patients who are eligible for ASCT. Secondary endpoints included safety, progression-free survival (PFS), time to progression (TTP) and overall survival (OS). Exploratory endpoints included: i) the yield of stem cell collection after RAD; ii) the effects of RAD on biochemical markers of bone metabolism: CTX, TRACP-5b, bone-alkaline phosphatase (bALP), P1NP, osteocalcin, soluble RANKL, osteoprotegerin (OPG) and DKK1 (Dkk-1) and iii) the effects of RAD on angiogenic cytokines: angioptinin- (Angp) 1 & 2, angiogenin (Ang), VEGF and bFGF.

Methods: Lenalidomide was administered at a dose of 25mg, po, daily, on days 1-21 of a 28-day cycle; dexamethasone was given at a dose of 40mg po, on days 1,8,15, and 22 while adriamycin was administered as IV bolus infusion at a dose of 9mg/m², on days 1-4 of each cycle. Serum levels of the above markers of bone remodeling and angiogenesis were measured before and after 4 cycles of RAD, using ELISA methodology.

Results: Between November 2014 and February 2016, 45 patients (median age 64 years) were enrolled. Osteoclast lesions were present in 33 (73.3%) patients, while 3 (6.6%) had hypercalcemia (>11mg/dl). All but one patient completed 4 cycles of RAD. Best response included one (2.2%) CR, 8 (17.8%) VGPRs, 21 (46.7%) PRs, for an ORR of 66.7%, while 14 (31%) patients had
stabile disease and one progressed during the 4th cycle of treatment. After ASCT the ORR was 84.4% (6 (13.3%) patients achieved CR, 13 (28.9%) VGPR and 19 (42.2%) PR. Adverse events of grade 3 or 4 included mainly anemia (4 patients, 9%), neutropenia (3, 6.6%) and febrile neutropenia (one patient). After a median follow-up of 1.9 months (range: 1.0-24.9), 11 patients have progressed and 4 died (all had achieved less than VGPR post-ASCT). The PFS, TTP and OS rates at 12 months were 88.6%, 88.6% and 100%, respectively. Forty (89%) patients had adequate stem cell collection post-RAD induction (meanSD: 8.9±4.6 ±10 x10^6/kg CD34+ cells). Patients at baseline had elevated levels of CTX, TRACP-5b, sRANKL,OPG, Dkk-1, Ang, VEGF, VEGF-A, bFGF and reduced levels of Angp-1/Angp-2, bALP and P1NP compared to 30 healthy subjects of similar age and gender (p<0.01 for all comparisons). RAD therapy resulted in a reduction of circulating CTX (p=0.03), TRACP-5b (p=0.01), Ang (p=0.02), VEGF (p=0.01) and bFGF (p<0.01). Moreover, RAD increased serum levels of bALP (p=0.036), P1NP (p=0.028) and Ang-1/Ang-2 ratio (p=0.022). These alterations occurred irrespective of response, although patients who achieved at least VGPR tended to have more profound differences in the above parameters.

Summary/Conclusions: RAD resulted in successful induction for NDMM patients with an ORR of approximately 67% pre- and 84% post-ASCT. With a median follow-up of >1.5 year, the 12-month PFS rate and OS rates are high, as expected for patients with bone resorption and increased bone formation; the latter has not been previously described with lenalidomide-based regimens. Furthermore, RAD reduced angiogenic cytokines and this supports the action of the regimen also through the disruption of the interactions between myeloma and stromal cells.

E1293
MULTIPLE MYELOMA IN THE REAL WORLD: HOW THERAPEUTIC LANDSCAPE HAS CHANGED IN THE LAST 15 YEARS
F. Cocito1, V.V. Ferretti1, S. Mangiacavalli1, C.S. Cartia1, M. Ganzetti1, E. Fugazza1, B. Landini1, M. Catalano1, M. Cazzola1, A. Corso1
1Hematology, Policlinico S. Matteo, Pavia, Italy

Background: Therapeutic Multiple Myeloma (MM) scenario has completely changed in the last 30 years: conventional chemotherapy (CT) has been gradually abandoned and autologous stem cell transplantation (ASCT). Proteasome inhibitors as Bortezomib (Bor) and Immunomodulatory drugs as Thalidomide and Lenalidomide (Len) have become the new actors in MM treatment (Tx). Aims: to outline how the management of MM patients (pts) had changed in the last 15 years reporting the experience of a single center. Methods: Overall survival (OS) was measured from disease onset to death for any cause or last follow-up. Progression free survival (PFS) was defined as the time from first-line Tx to disease progression or last follow-up. Results: Median number of therapy lines was 2 (1-9). Among pts ≤65 yrs, 228/371 (61.8%) received ASCT as 1st line Tx. Patients >65 yrs were treated as follows: 16 (8.5%) received ASCT, 53 (28.2%) other therapies. As 2nd line tx to our pts received: 27 ASCT (8.9%), 115 Bor-based tx (38.1%), 48 Len-based tx (16%), 53 CT (17.5%) and 59 other therapies (19.5%). As 3rd line tx: 5 pts received ASCT (2.8%), 65 Bor-based tx (35.9%), 40 Len-based tx (20%), 9 CT (9%) and 10 other therapies (5%). The percentage of pts receiving a new drug in 1st line was 64% (338/525). This percentage was significantly different in pts treated before and after 2007 (42% vs 87%, p=0.001). Similar results were observed in 2nd line, 75% of pts treated before 2007 received a new drug and 90% after 2007 (p=0.002). Median PFS in pts ≤65 yrs was 7.6 yrs vs 4.8 yrs (p=0.001), of note considering pts ≤65 yrs treated before 2007 median OS was 5.5 vs 3.1 yrs (p=0.001) and after 2007 median OS was not reached vs 7.5 yrs (p=0.034).

Summary/Conclusions: Our real life data show how MM therapeutic scenario have changed during the last 15 yrs. The tremendous improvements observed in this study was mainly evident in older pts with a strong reduction of early mortality and median OS reaching, in the second time frame after year 2007, 7.5 yrs. For younger pts ASCT confirmed to be of great benefit in term of TTNT and PFS. Thus, considering the real advantage of new drugs a palliative approach is not anymore justified even in very old pts.

E1294
CUL4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS
A. Malanda1,2, A. Borankiewicz1,2, A. Szumera-Cieckiewicz3, M. Prochorec-Sobieszek3, K. Warzocha1, P. Juszczyński4, E. Lech-Maraneda1,2
1Department of Hematology, Institute of Hematology and Transfusion Medicine, 2Department of Hematology and Transfusion Medicine, Centre of Post-Graduate Medical Education, 3Department of Diagnostic Hematology, 4Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Background: Despite the clinical effectiveness of immunomodulatory drugs (IMiDs) in multiple myeloma (MM), neither their mechanisms of action nor the biomarkers that could identify patients who would benefit from IMiD treatment are yet known. While the identification of the IMiDs action via cerebel (CRBN), Ikaros (IKZF1) and Aiolos (IKZF3) was a milestone, the role of other pathways including CRBN and E3 ubiquitin ligase complex proteins (CUL4A, DBB1, Roc1) are not fully understood so far. Aims: The aim of this study was to: 1) evaluate CUL4A, IKZF1, IKZF3, MUM1 and IRF4 expression in bone marrow trephine biopsies obtained from multiple myeloma patients before treatment with thalidomide, 2) analyze the associations between the expression of these proteins and clinical characteristics and outcomes.

Methods: IHC staining for CUL4A, IKZF1, IKZF3, IRF4 and MYC expressions was performed in trephine biopsies obtained from 25 patients with multiple myeloma before the treatment initiation. The patients (20 females, 5 males, median age 68 years) were treated with thalidomide based regimens as a first line treatment. The patterns of proteins’ expression were scored independently by two hematopathologists on a 0-3 scale and the scored results were defined as ≥30 positive cells. Associations between studied proteins’ expression and clinical parameters were assessed using Fisher’s Exact Test for categorical variables and Mann-Whitney-Wilcoxon Test for continuous variables. Survival (PFS and OS) were estimated using the Kaplan-Meier method and censored using the log-rank test.

Results: Prior to treatment with thalidomide, 13 patients (52%) showed high expression (≥30%) of CUL4A protein. No associations between expression of CUL4A and other proteins were seen. Patients with high CUL4A expression more often presented low disease stage according to Durie-Salmon classification (p=0.02), beta-2-microglobulin level within normal ranges (P=0.07) and higher median platelet count (P=0.003) compared to patients with low CUL4A expression. Moreover, patients with high CUL4A expression before treatment showed longer PFS compared to those with low CUL4A expression (P= 0.03). Additionally, a significant association between high Aiolos expression and high median platelet count (p=0.03) was observed. Median platelet count was 800,000±200,000 in patients with high Aiolos expression and 600,000±100,000 in patients with low Aiolos expression. No other associations with clinical course of MM patients were seen. No associations between IKZF1, IKZF3, IRF4, MYC expression and patients’ characteristics or outcome were revealed.
Summary/Conclusions: In conclusion, our results suggest that CUL4A expression could serve as a prognostic marker for patients assigned to IMiDs containing regimens. Further analysis of the expression of other E3 ligase complex proteins in a larger patient cohort is in progress.

Acknowledgement: This work is funded by a grant No 2014/13/B/NZ5/03160 from National Science Centre.

Figure 1.

Results: 2-year Relapse-Free Survival in patients with MRD-negative status after ASCT was higher (p=0.05) than that in MRD-positive patients - 52.9% (95% CI: 35.5–70.5%) vs 37.2% (95% CI: 25.4–49.3%). The MRD-positivity significantly increases the risk of relapse (HR=1.7; 95% CI: 1.2–3.4; p=0.05). Two year cumulative probability of relapse after ASCT in patients with MRD-negative status, who had (n=15) and hadn’t received (n=10) maintenance therapy with Bortezomib was not different (p=0.58). Average time of relapse in MRD-positive patients who received maintenance therapy with Bortezomib was 5 months longer than in the group of patients without maintenance therapy - 12.3 months vs 7.8 months (p<0.0001). The MRD-positivity is an independent predictor of survival, which is influenced by the cumulative risk of death from both disease and secondary malignancies.

E1296

LONG-TERM OUTCOME OF MULTIPLE MYELOMA (MM) PATIENTS TREATED UP-FRONT WITH SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) - SINGLE CENTRE EXPERIENCE WITH 334 PATIENTS

J. Baticin1,2, S. Basic-Kinda1, B. Dreta1, I. Hude1, A. Ostojić1, D. Sertic1, R. Sverventi-Seiweth1, P. Roncevic1, I. Bojanic1, K. Gajdrov-Kuvezdic1, K. Dubravcic1, I. Ilic1, I. Aurer1, D. Nemec1
1Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, 2Medical School, University of Zagreb, 3Department of Transfusionology, 4Department of Pathology and Cytology, 5Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia

Background: ASCT after induction treatment has been standard of care for MM for almost 30 years. Some centers routinely perform two transplantation up-front (so-called tandem transplants), while others advocate postponing the second transplant until after progression. In recent years novel antimyeloma agents have significantly improved the prognosis of MM patients, thus casting further doubts on the value of the more aggressive tandem ASCT approach.

Aims: To describe long-term outcomes of MM patients treated with ASCT (single and tandem) in a single centre, while others advocate postponing the second transplant until after progression. In recent years novel antimyeloma agents have significantly improved the prognosis of MM patients, thus casting further doubts on the value of the more aggressive tandem ASCT approach.

Methods: This was a retrospective analysis of outcomes of 334 MM patients who underwent 470 ASCT procedures at our center between 1993 and 2014. During that period treatment policies changed from single to tandem to salvage second ASCT, as data from different clinical studies became available.

Results: 296 patients received VAD (vincristine, doxorubicin, dexamethasone) as induction therapy and 38 regimens based on immunomodulatory drugs or proteasome inhibitors. All received high-dose melphalan for pretransplant conditioning. Kaplan-Meier survival curves were compared using log-rank test. Statistical analysis was performed using SAS 9.4.

Figure 1.

Summary/Conclusions: Our results suggest that tandem ASCT is a very effective treatment modality that can partially substitute for the absence of expensive novel agents with low long-term and lethal toxicities. Tandem ASCT seems to result in superior OS and PFS in comparison to single or salvage second ASCT. More than 10% of patients treated with tandem ASCT experience very prolonged PFS.
showed an association of EMD with other adverse prognosis factors and unfavourable outcomes. Tools evaluating EMD role in pts undergoing autologous hematopoietic stem cell transplantation (ahsCT) are scarce.

Aims: We aimed to evaluate the clinical and laboratory characteristics of pts with EMD as well as its impact in outcomes of MM pts submitted to ahsCT (response to treatment, overall survival [OS] and progression-free survival [PFS]).

Methods: We analysed 155 MM pts submitted to ahsCT in our centre between January/2007 and December/2015, excluding second procedures. The assessment of response to treatment was based in the International Myeloma Working Group consensus criteria (2016). The median age of the cohort was 58 years (27–69), with 58% of males, and 80% of pts had the most common subtype was Igm (45%). In our cohort, Igs (29.7%) presented EMD at diagnosis, which was significantly higher compared to reports in the literature (p < 0.001; 95% CI 0.22–0.37). The more common involved sites were vertebral column (49%), ribs (13%) and pelvis (13%). EMD occurred more frequently in males (38 vs 18%; p = 0.012) and in pts with bone disease (80 vs 49%; p = 0.001), and in pts with R-ISS stage III than stage I II (82 vs 64%; p = 0.022) and without anaemia at diagnosis (28 vs 11%; p = 0.023). No other significant differences in characteristics at diagnosis were found between pts with and without EMD. Pts with EMD achieved lower complete response/very good partial response (CR/VGPR) proportions previously to ahsCT (30.4 vs 53.2%; p = 0.009), as well as at 100 days after ahsCT (D100) (41.3 vs 59.6%; p = 0.037). However, no differences were found concerning refractoriness to first line therapy or proteasome inhibitor (PI) treatment, despite EMD pts received a higher mean number of therapeutic lines previously to ahsCT (1.7 vs 1.4; p = 0.025). After a median follow-up of 46.6 months, the median OS was not reached for global cohort and both groups, and there was no difference between them (p = NS). The median PFS was 51.3 months for global cohort, with no differences seen between pts with and without EMD (50.2 vs 54.1; p = NS). Pts with EMD treated with a PI (57%) presented a higher OS (NR vs 15.3 months, p = 0.04), but with no impact in PFS (p = NS), and there were no differences concerning radiotherapy treatment (72%) or thalidomide maintenance after ahsCT (32%) (p = NS).

Summary/Conclusions: In our cohort, EMD prevalence was significantly higher than usually described in the literature. This observation was probably associated to a more carefully surveillance of EMD in ahsCT candidates. EMD was associated with a lower proportion of CR/VGPR previous to ahsCT and at D100 evaluation, even after a higher number of therapeutic lines, although we failed to demonstrate that EMD was an independent prognosis factor for PFS and OS. PI seem also to be the best first-line therapeutic approach for EMD pts. In conclusion, our study suggests that EMD is underdiagnosed in MM pts. It is necessary to achieve a better knowledge of the physiopathology of EMD, in order to define better treatment options that may overcome its negative impact in therapeutic response.

E1298
DIFFERENCES IN PATIENT AND DISEASE CHARACTERISTICS OBSERVED AT INITIATION OF FIRST-LINE AND INITIATION OF SECOND-LINE TREATMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA IN THE CZECH REPUBLIC

V. Maišner1,2,2, Z. Szabo3, W. Bouwmeester4, L. DeCosta5, L. Pour6,7, E. Gregora8, J. Minařík9,10, S. Gonzalez-McQuire3, R. Hájek11,12
1Department of Internal Medicine and Hematology, University Hospital Brno, 2Faculty of Medicine, Masaryk University, Brno, 3Amgen (Europe) GmbH, Zug, Switzerland, 4Pharmaceutical, International, Rotterdam, Netherlands, 5Amgen Ltd, Uxbridge, United Kingdom, 6Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 7Faculty of Medicine, Masaryk University, Brno, 8Department of Internal Medicine and Hematology, University Hospital Kralove Vinohrady, Prague, 9Department of Hematology- Oncology, University Hospital Otolouc and Palacký University Olomouc, 10Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, 11Department of Haematology- Oncology, University Hospital Ostrava, 12Faculty of Medicine, University of Ostrava, Czech Republic

Background: Tools such as the International Staging System (ISS) and the revised ISS (R-ISS) has been used to stratify risk of patients with MM disease with multiple myeloma (MM), enabling assessment of survival expectations. These tools are based on factors measured at diagnosis only; understanding the role of these factors at relapse is less clear. Patient characteristics change between first-line (1L) and second-line (2L) treatment. Predicting survival using tools that consider characteristics measured at diagnosis may only, therefore, become less relevant than other tools that consider factors measured at relapse. The Registry of Monoclonal Gammapathies (RMG) is a large haematological disease registry, collecting data from patients in the Czech Republic and Slovakia. Data from the RMG can be used to explore real-world characteristics, patients’ experiences throughout their disease course.

Aims: To explore how key characteristics of patients with relapsed MM evolve between initiation of 1L treatment and initiation of 2L treatment to better understand drivers of disease progression and death.

Methods: This non-interventional, observational, retrospective study used data collected prospectively from Czech patient charts available in the RMG. Adults (≥18 years old) initiating 1L treatment for MM between May 2007 and April 2016 were included (N=3027); those with smoldering MM were excluded. Patient and disease characteristics were extracted at initiation of 1L and of 2L treatment. Repeated measurements were available only for those who initiated 1L and 2L treatment (1L+2L group; N=1418); patients who did not start 2L treatment may have been in remission, lost to follow-up or had died. In conclusion, our study suggests that EMD is underdiagnosed in MM pts. It is necessary to achieve a better knowledge of the physiopathology of EMD, in order to define better treatment options that may overcome its negative impact in therapeutic response.

E1299
AN EARLY GOOD RESPONSE AFTER BORTEZOMIB-BASED INDUCTION REGIMENS REPRESENTS A SIGNIFICANT PREDICTOR FOR IMPROVED PFS IN NDMM PATIENTS

G. Rivoli1,2, M. Cea1, S. Aquino2, A. Dego1, N. Di Felice1, N. Bisso1, D. Avenoso1, R. M. Lemoli1, M. Gabbi1, L. Canepi1
1Clinica Ematologica, 2Ematologia 1, IRCCS San Martino IST, Genova, Italy

Background: Introduction of triplets-based induction regimens containing proteasome inhibitors (PIs) in clinical practice have led to higher response rates and prolonged life expectancy in newly diagnosed multiple myeloma (NDMM)
patients. Different studies have linked complete response (CR) with better PFS (progression-free survival), but not always with prolonged overall survival (OS), most likely due to the impact of novel agents in the management of relapsed-refractory patients. Overall, these observations suggest PFS as a more reliable predictor of clinical outcome. Also, the biological aggressiveness is emerging as a pivotal disease characteristic which affects clinical behavior and response to therapy. In this context, little is known about the association of response kinetics with survival outcomes.

**Aims:** In order to evaluate whether early achievement of a good quality response impacts on outcome, we retrospectively analyzed 87 NDMM patients treated at our institution with bortezomib containing regimens (BRs).

**Methods:** From 2004 to 2016, 87 patients with NDMM and measurable disease (serum and/or urine M protein) were treated with BRs. Both patients eligible and non-eligible for ASCT were included in the study; patients undergoing ASCT were censored at the time of transplant. Median age was 66 (range 32-87); males were 51 (59%); 72 (83%) patients were in III stage; median follow up was 30.7 months; median number of administered courses was 5 (range 2-9). PFS was defined according to IWG criteria. Cytogenetic risk evaluation performed by a standardized FISH panel, including del(17p), del(13q), t(11;14), t(4;14), was available in 37 patients (42.5%). Among these high risk abnormalities were identified in 20 patients. Early good response (EGR) defined an M protein reduction ≥75% after 2 courses of therapy. Survival curves were calculated for PFS and OS by Kaplan Meyer method, using log-rank test.

**Results:** PFS and OS were both assessed in patients who achieved EGR as well as in patients who did not. No significant differences were observed in terms of OS between the two groups, whilst PFS was significantly longer in patients achieving EGR (p=0.036, median PFS 44.7 vs 29 months, respectively). Next, we analyzed patients with high risk cytogenetic. Among these, EGR vs non-EGR patients reached a PFS of 43.7 and 18.7 months, respectively. Remarkable PFS differences between these two groups were not significant (p value=0.11).

**Summary/Conclusions:** Overall, our data demonstrate a significant impact of EGR on PFS in NDMM patients after BRs, irrespective of median age at diagnosis. In presence of high cytogenetic risk EGR is associated with prolonged PFS, although not significantly. Ongoing analysis on larger cohort of high risk patients will confirm the impact of EGR on PFS also in this group of patients. Based on our data kinetic of response, deriving from EGR assessment, may provide information on both disease aggressiveness as well as clinical outcome, thus representing a novel, surrogate marker for an early survival analysis, with favorable cost-effectiveness characteristics. In summary biological and clinical information deriving from EGR analysis combined with cytogenetic risk evaluation and patient-related (age, comorbidities) characteristics, may represent a useful tool to make clinical decisions. Further prospective evaluations are needed to include this marker in clinical practice.

**E1300**

**RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA**

K. Betts1, C. Chen2, M. Zichlin1, A. Brun2, J. Signorovitch1, D. Makenbaeva2,*

1Analysis Group, Inc., Boston, MA; 2Bristol-Myers Squibb, Inc., Plainsboro, NJ, United States

**Background:** In combination with lenalidomide (REVILIMID®) and dexamethasone (d), elotuzumab (EMPLICTI™, E), carfilzomib (KYPROLIS®, K), and ixazomib (NINLARO®, N) were recently approved for the treatment of relapsed/refractory multiple myeloma (RRMM). In randomized controlled trials, all three drugs showed a significant relative reduction in the risk of disease progression or death as compared to patients who received Rd. To date, there have been no head-to-head trials comparing ERd, KRd, and NRd relative to Rd.

**Aims:** To describe the time-specific progression-free survival (PFS) based on published Kaplan-Meier PFS curves for ERd, KRd, and NRd relative to Rd.

**Methods:** Individual patient-level data (IPD) were reconstructed from the published Kaplan-Meier PFS curves from the ELOQUENT-2 (ERd), ASPIRE (KRd), and TOURMALINE-MM1 (NRd) randomized, controlled, Phase III trials using digitization software and the methods described by Guyot, et. al. Using the reconstructed IPD, Kaplan-Meier survival curves were estimated for each arm within each trial. PFS curves were digitized by two independent researchers and 12 reconstructed curves were overlaid with the published data to validate the IPD. In each trial, the relative PFS benefit over time was calculated as the difference in the Kaplan-Meier PFS estimate of each triplet regimen and the Kaplan-Meier PFS estimate of Rd divided by the Kaplan-Meier PFS estimate of Rd: \( \frac{S_{ERd}(t) - S_{Rd}(t)}{S_{Rd}(t)} \). Where S(t) denotes the Kaplan-Meier PFS estimate at time t, and X denotes E, K, or N, respectively.

**Results:** IPD from the three randomized controlled trials was successfully reconstructed and validated. Numerically, ERd had the highest relative PFS over the initial 10 months of treatment and showed sustained benefit from month 24 onwards (Figure 1). At 12 months, the relative PFS benefit was 17.9% for ERd, 21.7% for KRd, and 9.7% for NRd. At 24 months, the relative PFS benefit was 45.1% for ERd, 34.3% for KRd and 24.1% for NRd. At 36 months, the relative PFS benefit was 39.9% for ERd and 19.1% for KRd. ERd had a higher relative PFS than NRd for almost the entirety of RRMM treatment. At the end of data availability, NRd and KRd showed no additional PFS benefit relative to Rd, while ERd showed a sustained benefit through 40 months. Data will be updated for the conference, where available.

**Figure 1.**

**Summary/Conclusions:** For the treatment for RRMM, ERd showed an early and sustained benefit in relative PFS which was maintained through 40 months. KRd and NRd showed initial benefits which faded by the end of data availability.

**E1301**

**POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY**

R. Wester1,*, A. Dinmohamed2,3, P. Sonneveld1, A. Brojil1, N. Blijlevens4

1Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam; 2Department of Research, Netherlands Comprehensive Cancer Organisation (KKNL), Utrecht; 3Department of Public Health, Erasmus University Medical Center, Rotterdam; 4Department of Hematology, Radboudumc, Nijmegen, Netherlands

**Background:** Patients with relapsed and/or refractory multiple myeloma (RRMM) have limited treatment options and a poor prognosis. Previous trials showed that pomalidomide combined with low-dose dexamethasone is effective in these patients with improvement in response and survival. These studies led to the approval of pomalidomide as third line treatment in patients with RRMM. And a, prospective analysis in a population-based registry was conducted to assess response and survival in patients with RRMM treated with a pomalidomide-based regimen. Also, we defined subgroups who benefit most of this treatment regimen.

**Methods:** Patients were eligible for pomalidomide if they received ≥2 prior lines of therapy including bortezomib, lenalidomide and alkylator therapy and developed progressive disease on their last therapy. This is a prospective analysis of patients registered at the nationwide Netherlands Cancer Registry. Treatment consisted of 4mg pomalidomide, day 1-21, combined with corticosteroids. Treatment was discontinued in case of progressive disease or unacceptable toxicity. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, response per risk group (based on cytogenetics and ISS at initial diagnosis) and response per age group (<65 vs >65 years).

**Summary/Conclusions:** For the treatment for RRMM, ERd showed an early and sustained benefit in relative PFS which was maintained through 40 months. KRd and NRd showed initial benefits which faded by the end of data availability.
Results: A total of 82 patients (median age 68 years [range: 43-88]) were included in this analysis. CRAB criteria included anemia in 23 patients (28%), renal insufficiency in 8 (9.8%), hypercalcemia in 13 (16%) and bone lesions in 54 (66%). Median time from diagnosis to start pomalidomide was 5.75 years [range: 0.8-18.4], median number of treatment cycles was 3 [range: 1-17]. At time of analysis 59 patients had stopped pomalidomide treatment: 24 patients had progressive disease, 10 had unacceptable toxicity, 6 patients were refractory, 4 patients died during treatment and 15 patients stopped due to various other reasons. Grade ≥3 hematological adverse events occurred in 11% of patients, 4% had neutropenic fever. Grade ≥3 non-hematological toxicities occurred in 57% of patients, including infection in 22%, gastrointestinal disorders in 5% and renal disorders in 5%. Of 69 patients evaluable for response ORR was 41%, with a partial response (PR) rate and a very good partial response (VGPR) rate of 36% and 4% respectively. Response based on age was not significantly different (p=0.426). Median PFS for all patients was 3.8 months (95% confidence interval [CI] 2.3-6.8). Patients >65 years had a longer PFS of 5.7 months (95% CI 2.3-8.0) versus 2.8 months (95% CI 1.9-6.6) in patients ≤65, however, this was not statistically significant (p=0.427) (figure 1). For patients achieving ≥PR, median PFS was 9.6 months (95% CI 5.7-not reached [NR]), as compared to 2.2 months (95% CI 1.9-6.8) among patients treated within 5 years after diagnosis (p=0.05). Data about previous treatment, ISS stage, cytogenetics at diagnosis and an update of OS will be presented at EHA.

Figure 1.

Summary/Conclusions: In this analysis the experience in clinical practice of patients with RRMM treated with a pomalidomide-based regimen is reported. These data support results shown in clinical trials. Preliminary data presented here suggest that older patients and patients with a long interval between initial diagnosis and pomalidomide treatment (indicating a less aggressive multiple myeloma) may benefit from this treatment.

E1302

INVOLVED/UNINVOLVED HEAVY/LIGHT CHAIN INDEX CAN PREDICT PROGRESSION IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM TRANSPLANT. PRELIMINARY EXPERIENCE

M. Espírio Martínez1,2, A. Arteche Lopez2, A. Arriero3, C. Muñoz-Callega3, A. Alegre Amor3, M.J. Blanchard Rodríguez2, F.J. López Jiménez2, L.M. Villar1

1Immunology, University Hospital Ramon y Cajal, 2Clinical Analisis, 3Haematology, University Hospital La Princesa, 4Immunology, University Hospital Madrid, Spain

Background: High-dose therapy followed by autologous peripheral blood stem transplant (APBSCT) has demonstrated to improve overall survival and progression-free survival with a high complete remission rate in multiple myeloma (MM) patients. However, most patients eventually present progression or relapse (P/R). Detection of P/R is mainly based on a significant increase of monoclonal protein (MC) or free light chains (sFLC). The identification of new biomarkers to early predict P/R might be clinically useful for an anticipated therapy.

Aims: The aim of our study was to evaluate the potential role of the Involved/Uninvolved Heavy/Light Chain index (I/Ui) in this setting.

Methods: We prospectively followed 44 MM transplanted patients: 19 with IgG-kappa isotype, 11 with IgG lambda, 9 with IgA-kappa and 5 with IgA-lambda. They were followed for 29.0±3.8 months (mean±standard error [SE]). Serial serum samples from each MM patients were collected periodically after APBSCT. Relapse or progression was defined according IMWG criteria. To identify factors that predict disease progression in MM transplanted patients, we studied heavy/light chains (HLC) pair quantification, sFLC and total immunoglobulins levels in serial serum samples collected during the follow-up. Involved/uninvolved index (I/Ui) was calculated using the monoclonal chain (Involved) as numerator and the polyclonal chain of the same class (Uninvolved) as denominator. The HLC ratio (HLC) was calculated as IgG/IgGκ or IgA/IgAκ with normal reference ranges established in 1.3-3.7 for IgG and 0.7-2.2 for IgA.

Results: In IgG MM patients, values of I/Ui were significantly increased in pre-relapse compared to basal samples (8.49±4.01 vs 2.23±0.67 p=0.012). By contrast, this index remained stable along follow-up in patients in complete remission (CR) or with a partial response (PR). However, the latter showed higher values of I/Ui ratio, suggesting that the presence of an M-component induces an increase of the uninvolved chain of the monoclonal isotype. Regarding IgA MM, we established a cut-off value of 2.0 for I/Ui that allowed the discrimination of patients at high risk of early progression (values above 2.0) from those in CR, whose levels of I/Ui are always below 2.0 (p=0.02).

Summary/Conclusions: Our results show that HLC pair measurement could detect progression or relapse and the increase of MC in transplanted MM patients earlier than other methods. Future studies will need to demonstrate the real value of the I/Ui index as a biomarker to anticipate progression in MM patients subjected to APBSCT.

E1303

MULTIPLE MYELOMA IMMUNOPHENOTYPIC REMISSION IS A SIGNIFICANT PREDICTOR OF PROGRESSION FREE SURVIVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION - PILOT STUDY

K. Beranova1,2, J. Radocha1, O. Soucek2, K. Machalkova1, J. Hanousek1, P. Zak1, V. Maisnar1

1I.V. interni hematologicka klinika, 2Institute of Clinical Immunology and Allergology, Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic

Background: Minimal residual disease in multiple myeloma assessed by multiparameter flow cytometry has become an increasingly important predictor of progression-free survival (PFS).

Aims: Our primary endpoint was to evaluate PFS in myeloma patients after stem cell transplantation who reached immunophenotypic CR (iCR) versus those who have not.

Methods: We prospectively evaluated prognostic importance of minimal residual disease detection by multiparameter flow cytometry (MFC) in multiple...
myeloma patients who underwent autologous stem cell transplantation from January 2014 until December 2016. All patients were uniformly treated with bortezomib based induction therapy followed by high dose chemotherapy (Melphalan 200mg/m²) and autologous stem cell transplantation. Minimal residual disease (MRD) status was determined by 8-colour MFC 1 month after autologous transplantation from bone marrow aspirate in all patients who achieved at least conventional VGPR or CR.

Results: We identified 56 patients who fulfilled the above mentioned criteria. 30 were males and 26 females, median age was 61.62.5% of patients (35/56 patients) achieved iCR, 37.5% of patients (21/56) did not. Median follow up of the cohort was 19 months (6-59), 32.1% of patients (19/56) relapsed during the follow-up period. 16.1% of patients (9/56) died. 22.9% (13/56 patients) in iCR and 47.6% (10/21 patients) not in iCR relapsed during the follow up. Patients in iCR showed significantly longer PFS with median 42 months than those in less than iCR with PFS median 29 months (p=0.0196, log-rank test). This was reflected also in hazard ratio of relapse (0.3565) iCR group.

Summary/Conclusions: Achieving immunophenotypic CR is clearly associated with longer progression free survival compared to conventional CR. Reaching iCR should be a goal of myeloma treatment.

E1304
REGULATION OF NORMAL AND MONOCLONAL IMMUNOGLOBULIN SECRETION BY CYTOKINES (S- SYNDECAN-1, BLYS & TGF-BETA-1) IN PATIENTS WITH IG-SECRETING B-CELL DISORDERS AT PRESENTATION. PROGNOSTIC IMPLICATIONS

E. Koulieris1, P. Papaioannou1,*, E. Nikolaiou2, M. Dafni2, S. Gidarakou2, T. Tzouen2, K. Aripis3, D. Maltezas1, P. Pats1, A. Kotsianti2, A. Koudouna1, E. Kastriti2, S. Sachanasi3, M. Angelopoulou1, G. Panagis1, E. Terpos4, P. Sifakis1, M. Dimopoulos5, P. Panayiotidis1, M.-C. Kyrtsonis1
1Hematology Section - 1st Department Of Propaedeutic Internal Medicine, Laikon General Hospital, Athens, Greece, 2Binding Site Ltd, Birmingham, United Kingdom, 3Immunology Laboratory, Laikon General Hospital, 4Therapeutic Clinic, Cliniche's,m Athens’s,Hospital, 5Hematology Clinic, Medical Center Psychico, Athens, Greece

Background: The most common neoplastic lymphoproliferative diseases that secrete paraprotein are multiple myeloma (MM), Waldenstrom’s Macroglobulinemia (WM) and chronic lymphocytic leukemia (CLL). The two first entities secrete paraprotein by definition, while serum free light chains (sFLC) are increased in 50% of CLL cases. Microenvironmental factors, such as soluble Syndecan-1 (ssynd-1) and BlyS normally promote lymphoplasmacytic differentiation as well as their secretory activity, whereas others, like TGFbeta1, inhibit differentiation as well as their secretory activity, whereas others, like TGFbeta1, inhibit

Results: At the time of diagnosis, Statistical analysis was performed by standard methods using the SPSS v22.0, software.

Results: The main correlations observed between the Ig levels secreted in the 3 diseases and cytokines studied, as well as their impact with regard to patients’ outcome, are shown in table.

Summary/Conclusions: sSynd1 in MM and BlyS in WM and CLL correlated with better outcome. By inhibiting both monoclonal and polyclonal Ig, TGFβ1 correlated in MM with both HLC and FLC ratios and differences. In addition, the aforementioned variables are prognostic with regard to patients’ outcome.

E1305
PATIENTS WITH MULTIPLE MYELOMA (MM) IN LONG TERM COMPLETE REMISSION (LTCR) AFTER AUTOLOGOUS TRANSCPLANT (APBSCT) EXPRESS A DISTINCTIVE IMMUNE PROFILE WITH POTENTIAL PROGNOSIS VALUE

A. Arteche-Lopez1,*, A. Alegre Amor2, A. Kreutzmann3, B. Aguado4, M. Espino Martinez2, L. M. Villan2, P. Sanz1, A. Arriero2, C. Muñoz-Calleja4
1Clinic Análisis, 2Haematology & Immunology, University Hospital La Princesa, 3Haematology, 4Immunology, University Hospital Ramon y Cajal, Madrid, Spain

Background: A small fraction of patients with MM could be considered potentially cured as long as they remain for more than six years in long term complete remission (MM-LTCR) after APBSCT. The exhaustive study of the immune status of these patients could highlight interesting information.

Aims: Here we present an observational study that evaluates the numbers and phenotype of T- and B-cells subsets in the peripheral blood (PB) of MM-LTCR patients. We also evaluated the correlation between the number of abnormal cells and those found in the initial diagnosis.

Methods: After approval by the ethics committee, we selected 13 patients diagnosed with MM, in sCR according to IMWG criteria for at least six years after APBSCT, and 15 healthy adults (HA) of similar ages as a comparative group. Group MM: 7 males and 6 females; median age: 61. Median follow up in sCR was 8 years (range 6-19). Group HA: 5 females and 10 males, median age 60 (36-78). Immunophenotype characterization was done using a comprehensive 8-color flow cytometry panel. Subpopulations of CD4+ and CD8+ T-cells from PB were quantified, including naïve, central and effector memory regulators.

Patients in iCR showed significantly longer PFS with median 42 months than those in less than iCR with PFS median 29 months (p=0.0196, log-rank test). This was reflected also in hazard ratio of relapse (0.3565) iCR group.

Summary/Conclusions: Achieving immunophenotypic CR is clearly associated with longer progression free survival compared to conventional CR. Reaching iCR should be a goal of myeloma treatment.

Table 1.

E1306
IMPACT OF THE AFFORDABILITY OF NOVEL AGENTS IN PATIENTS WITH MULTIPLE MYELOMA: REAL WORLD DATA ON CURRENT CLINICAL PRACTICE IN MEXICO

L. Tarín-Arzaga1,*, V. Martínez-Pacheco1, A. Gómez-De Leon1, P. Colunga
1PRACTICE IN MEXICO

Background: The MM-LTCR patients seem to express a distinctive immune “footprint” characterized by a decreased proportion of naïve T-cells and an increased percentage of effector T-cells, which probably exert a competent immune surveillance. Conversely, the increase in naïve B-cells may guarantee the humoral response homeostasis, including activation of normal plasma cells that might compete with myelomatous cells for normal bone marrow niches. The precise role of these refined immunological studies in the monitoring and therapeutic decisions in MM patients, and also in the duration of sCR, should be defined in the future.

Study partially performed with research grants from the spanish Leukemia and Lymphoma Foundation and Grant P11/00949P from the Fondo de Investigaciones Sanitarias and FEDER funds.
Background: The success of bortezomib and lenalidomide in improving outcomes as first-line therapies in multiple myeloma (MM) patients has been achieved at a very high cost. Treatment has become difficult to access for patients living in low to middle-income countries, as most receive assistance by public healthcare systems wherein novel drugs are unaffordable.

Aims: To compare the outcomes of MM patients who can afford private insurance and treatment in a private center (PrivC), with those managed in a public center (PubC), who do not have access to healthcare coverage and are treated on an out-of-pocket basis.

Methods: We analyzed records of 148 patients diagnosed with MM in two health sectors in Monterrey, Mexico, from October 2007 to July 2016; 77 (52%) from PubC, where the most common induction therapy was cyclophosphamide, thalidomide-dexamethasone, followed by thalidomide maintenance, and 71 (48%) from PrivC wherein bortezomib or lenalidomide-based induction and lenalidomide maintenance were used. We compared demographics, disease stage, response rate and survival among both groups.

Results: Median age, gender and frequency of immunoglobulin isotype did not differ significantly between the two groups. Patients treated in PubC were more likely to be diagnosed with advanced stage disease (ISS III 42% vs 26% p<0.05). Median follow-up was 36 months (range 3-120 months). Autologous transplantation was performed in 80% of the transplantation-eligible patients in PrivC and only in 31% of PubC. At least a very good partial response to induction therapy was achieved more often in the PrivC among transplantation-eligible (65% vs. 42%, p<0.05) and ineligible patients (66% vs. 41%, p<0.05). Overall survival was significantly higher in PrivC for transplantation-eligible (median 84 months, p<0.05) and ineligible patients (66% vs. 42%, p<0.05). Median follow-up was 36 months (range 3-120 months). Autologous transplantation was performed in 80% of the transplantation-eligible patients in PrivC and only in 31% of PubC. At least a very good partial response to induction therapy was achieved more often in the PrivC among transplantation-eligible (65% vs. 42%, p<0.05) and ineligible patients (66% vs. 41%, p<0.05). Overall survival was significantly higher in PrivC for transplantation-eligible (median 84 months, p<0.05) and ineligible patients (66% vs. 42%, p<0.05). Median follow-up was 36 months (range 3-120 months).

Summary/Conclusions: Stage at diagnosis, induction therapy and autologous stem cell transplantation were contributors to survival disparities between both groups. Treatment has become difficult to access for patients living in low to middle-income countries, as most receive assistance by public healthcare systems wherein novel drugs are unaffordable.

Background: Calreticulin (CALR) is a calcium (Ca2+) buffering chaperone mutation of which has recently been associated with essential thrombocythemia and primary myelofibrosis without JAK2 mutations. These mutations have been suggested to impair the Ca2+ buffering activity of Calreticulin due to a change of the negative charge in its C-terminal domain. Calreticulin is known to be important during megakaryocyte activity; however its role during megakaryopoiesis and the possible link of CALR mutations and abnormal megakaryocyte production due to impaired Ca2+ buffering activity in myeloproliferative neoplasms (MPNs) remains unclear.

Aims: Here we aim to understand how basal Ca2+ fluctuates during normal megakaryopoiesis and how CALR mutations could affect the basal Ca2+ levels in megakaryocytes in MPNs.

Methods: Ca2+ staining was performed using Flu-8 dye and Ca2+ basal level measured by flow cytometry. Changes in basal Ca2+ during megakaryopoiesis using two cellular systems, K-562 cells and mouse bone marrow cells, were measured each 24 hours. Further studies using CALR mutant cellular models were performed using the same methodology.

Results: Our results showed a characteristic behaviour of fluctuations of basal Ca2+ among different models. Changes in basal Ca2+ in megakaryopoiesis, where Ca2+ levels decrease in the last stage of megakaryocyte formation. These results suggest that Ca2+ reduction could be essential for megakaryopoiesis. In order to understand how CALR mutations affect basal Ca2+ levels, we compared different CALR types using flow cytometry analysis. These CALR types showed basal Ca2+ levels lower than the controls. Moreover, DAMI-CALR type1 did not show any significant reduction, suggesting possible differences in basal Ca2+ behaviour in CALR type2 mutation. We are currently working in the analysis of basal Ca2+ fluctuations during megakaryopoiesis in the presence of CALR mutations and preliminary results show abnormal basal Ca2+ levels throughout all the process of megakaryocyte differentiation.

Summary/Conclusions: Altogether, our findings indicate that basal Ca2+ could be an important element during megakaryopoiesis and CALR mutations found in MPN could impair the normal production of megakaryocytes due to changes in cellular Ca2+. Further analysis need to be done in order to understand the role CALR mutations and their effect in the Ca2+ buffering activity of CALR in MPNs.

THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS

Background: Myeloproliferative neoplasms (MPN) remain incurable regardless of advancement in the use of JAK2 inhibitor Ruxolitinib, which competence is unrelated to the JAK2V617F mutation.

Aims: We want to explore JAK1/2 inhibition dependency in correlation with activated JAK/STAT3 signaling and cell cycle in MPNs.

Methods: The immunoblotting has been used to analyze activation of JAK/STAT3, PI3K/AKT and MAPK signaling in JAK2V617F mutated HEL cells and granulocytes of MPN. The cell cycle and apoptosis of granulocytes are studied by flow cytometry.

Results: Concerning myeloproliferation, JAK1/2 inhibitors reduced the percentage of cells in G2M phase and increased apoptosis in JAK2V617F mutated HEL cells. Comparing to polycythemia vera (PV), the percentage of granulocytes is decreased in S and G2M phases of essential thrombocythemia (ET) and primary myelofibrosis (PMF) that demonstrated increased apoptosis. Hexamethylmelamine increased percentage of granulocytes in GoG1 phase of JAK2V617F positive, but reduced in JAK2V617F negative PMF, the later one similar to Ruxolitinib. JAK1/2 inhibitors reduced percentage of apoptotic granulocytes in JAK2V617F positive, but increased in JAK2V617F negative PMF. JAK1/2 inhibitors could not impair constitutive activation of JAK/STAT3 signaling in HEL cells as well as in granulocytes of JAK2V617F positive ET and PMF. Absence of JAK2V617F mutation supported dephosphorylation of JAK/STAT3 pathway by JAK1/2 inhibitors in ET, but not in PMF. JAK1/2 inhibitor...
Ruoxolitinib largely activates MAPK signaling in MPN, while slightly PI3K/AKT signaling in PV and JAK2V617F negative PMF. Specific JAK2 inhibitor Hexa-bromocyclohexane activates PI3K/AKT signaling in JAK2V617F positive ET, but reduced in JAK2V617F negative ET and PMF.

**Summary/Conclusions:** This observation support cross-talk between examined pathways, where inhibition of JAK/STAT3 signaling is compensated by activation of MAPK pathway irrespective of JAK2V617F mutation, while PI3K/AKT signaling demonstrates JAK2V617F dependence in MPN.

**E1309**

**CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISRUPTED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUOXOLITINIB?**

M. Barone 1, F. Ricci2, D. Forte3, D. Sollazzo1, M. Romano1, M. Spinsanti1, E. Ottaviani1, M. Cavo1, N. Vianelli1, P. Tazzari2, F. Paladini3, L. Catani1.

1Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology - University of Bologna, 2Department of Immunohematology and Blood Bank Service, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy

**Background:** Microparticles (MPs) are small vesicles (0.1-1 microm) deriving from plasma membrane budding during homeostasis and cell activation. MPs express antigens and contain constituents from cell of origin and are increased in conditions that are characterized by high cell turnover or death, particularly inflammatory, autoimmune, and neoplastic diseases. Myelofibrosis (MF) is a clonal neoplasia of the hematopoietic stem/progenitor cells characterized by diffuse extramedullary hematopoiesis, increased levels of MPN, and (PLT) activation. Mutations in 3 genes (JAK2, CALR, MPL) and chronic inflammation are the main pathogenic drivers of MF. Ruoxolitinib (RUX), a JAK1/2 inhibitor, suppresses both clonal myeloproliferation and release of proinflammatory cytokines, reducing splenomegaly and constitutional symptoms in around 50% of patients (pts). We hypothesized that MPs, as mediators of inflammation, could be overexpressed in MF and possibly predict responses to RUX.

**Aims:** This study aims to: 1) enumerate circulating MK and PLT-derived MPs of MF pts; 2) evaluate the effect of RUX on MPs production by PLT and MK; 3) investigate whether circulating MK and PLT MPs may be a biomarker of response to RUX.

**Methods:** EDTA-anticoagulated peripheral blood from healthy donors (HD, n=10) and JAK2V617F positive MF pts (n=12) at intermediate-2/high IPSS risk was collected at baseline and 3 and 6 months after RUX therapy and immediately centrifuged. MPs in normal platelets (normal MPN, JAK2V617F and CALR type I/II) and MPL S204F/P platelet-derived MPs were analysed in PLT poor plasma samples by flow cytometry (CytoFLEX, Flow Cytometer-Beckman Coulter). The instrument was calibrated with MEGAMIX Beads (Beckman Coulter) with various diameters to cover the MPs (0.5 and 0.9µm).

**Results:** At 3 and 6 months, 5 out of 12 pts achieved a spleen response (R) according to 2013-IWG-MRT criteria. At baseline, the mean percentage of MK-derived MPs was significantly decreased (29±6 vs 72±5; p<0.001) while that of PLT-derived MPs significantly increased (49±7 vs 11±1; p<0.001) in MF pts compared to HD. However, the mean percentage of MK-derived MPs from pts not achieving a spleen response (NR) was significantly decreased compared to R (17±6 vs 72±5; p<0.001). By contrast, the mean percentage of PLT-derived MPs significantly increased in NR compared to R (64±7 vs 37±5; p<0.05) and HD (64±7 vs 11±1; p<0.001). Of note, NR pts had significantly higher PLT number as compared to R (222±42 vs 172±45; p<0.05). No correlation was observed at baseline between the percentages of MK/PLT-derived MPs and platelet number, allele burden, splenomegaly, and constitutional symptoms. At 3 and 6 months, RUX did not significantly modify the mean percentages of MK- and PLT-derived MPs compared to baseline values.

**Summary/Conclusions:** At variance with HD, the majority of circulating MPs in JAK2V617F mutated MF pts at intermediate/2-high IPSS risk derived from PLTs. RUX therapy did not modify the MK/PLT-derived MPs pattern, suggesting that JAK1/2 inhibition does not seem to affect the pathways of MK/PLT MPs production or clearance. Most importantly, MPs evaluation at baseline is significant, ascribed to subsequent spleen reponse. Specifically, NR pts had increased percentages of PLT-derived MPs with a concomitant reduction of PLT number. This could be related to a state of PLT hyper-activation with hyper-production of MPs. Further studies are needed to confirm whether MPs may actually be considered a biomarker of disease activity and response to RUX.

**E1310**

**A COMPARATIVE FUNCTIONAL AND PHENOTYPIC PLATELET ANALYSIS AMONG GENETIC GROUPS OF ESSENTIAL THROMBOCYTHEMIA PATIENTS**

P. Papadopoulos1,2, 3, A. Al Asaad2, S. Smits2, I.M. De Cuyper3, E. Lierman2, M. Stoskus1, L. Gutierrez8, P. Vandenberghe8

1Department of Hematology, 2Department of Immunohematology and Blood Bank Service, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy, 3Department of Internal Medicine, University of Bologna, 4Department of Internal Medicine and Oncology, University of Bologna, 5Hematology “L. e A. Seragnoli”, University of Bologna, 6Immunohematology and Blood Bank Service, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy

**Background:** Microparticles (MPs) are small vesicles (0.1-1 microm) deriving from plasma membrane budding during homeostasis and cell activation. MPs express antigens and contain constituents from cell of origin and are increased in conditions that are characterized by high cell turnover or death, particularly inflammatory, autoimmune, and neoplastic diseases. Myelofibrosis (MF) is a clonal neoplasia of the hematopoietic stem/progenitor cells characterized by diffuse extramedullary hematopoiesis, increased levels of MPN, and (PLT) activation. Mutations in 3 genes (JAK2, CALR, MPL) and chronic inflammation are the main pathogenic drivers of MF. Ruoxolitinib (RUX), a JAK1/2 inhibitor, suppresses both clonal myeloproliferation and release of proinflammatory cytokines, reducing splenomegaly and constitutional symptoms in around 50% of patients (pts). We hypothesized that MPs, as mediators of inflammation, could be overexpressed in MF and possibly predict responses to RUX.

**Aims:** This study aims to: 1) enumerate circulating MK and PLT-derived MPs of MF pts; 2) evaluate the effect of RUX on MPs production by PLT and MK; 3) investigate whether circulating MK and PLT MPs may be a biomarker of response to RUX.

**Methods:** EDTA-anticoagulated peripheral blood from healthy donors (HD, n=10) and JAK2V617F positive MF pts (n=12) at intermediate-2/high IPSS risk was collected at baseline and 3 and 6 months after RUX therapy and immediately centrifuged. MPs in normal platelets (normal MPN, JAK2V617F and CALR type I/II) and MPL S204F/P platelet-derived MPs were analysed in PLT poor plasma samples by flow cytometry (CytoFLEX, Flow Cytometer-Beckman Coulter). The instrument was calibrated with MEGAMIX Beads (Beckman Coulter) with various diameters to cover the MPs (0.5 and 0.9µm).

**Results:** At 3 and 6 months, 5 out of 12 pts achieved a spleen response (R) according to 2013-IWG-MRT criteria. At baseline, the mean percentage of MK-derived MPs was significantly decreased (29±6 vs 72±5; p<0.001) while that of PLT-derived MPs significantly increased (49±7 vs 11±1; p<0.001) in MF pts compared to HD. However, the mean percentage of MK-derived MPs from pts not achieving a spleen response (NR) was significantly decreased compared to R (17±6 vs 72±5; p<0.001). By contrast, the mean percentage of PLT-derived MPs significantly increased in NR compared to R (64±7 vs 37±5; p<0.05) and HD (64±7 vs 11±1; p<0.001). Of note, NR pts had significantly higher PLT number as compared to R (222±42 vs 172±45; p<0.05). No correlation was observed at baseline between the percentages of MK/PLT-derived MPs and platelet number, allele burden, splenomegaly, and constitutional symptoms. At 3 and 6 months, RUX did not significantly modify the mean percentages of MK- and PLT-derived MPs compared to baseline values.

**Summary/Conclusions:** At variance with HD, the majority of circulating MPs in JAK2V617F mutated MF pts at intermediate/2-high IPSS risk derived from PLTs. RUX therapy did not modify the MK/PLT-derived MPs pattern, suggesting that JAK1/2 inhibition does not seem to affect the pathways of MK/PLT MPs production or clearance. Most importantly, MPs evaluation at baseline is significant, ascribed to subsequent spleen reponse. Specifically, NR pts had increased percentages of PLT-derived MPs with a concomitant reduction of PLT number. This could be related to a state of PLT hyper-activation with hyper-production of MPs. Further studies are needed to confirm whether MPs may actually be considered a biomarker of disease activity and response to RUX.
Results: 110 patients diagnosed with PMF according to WHO criteria between years 2013 and 2014 were included into this study. SNP-A analysis identified 77 chromosomal abnormalities in 61 patients (55.4%). These comprised the loss of heterozygosity (LOH) (59.7%), hemizygous deletions (23.4%) and copy number gains (16.9%). The most common aberrations in affected patients were: 9p LOH (55.7%), 20q deletion (11.5%), 1q duplication (4.9%), 19p deletion (4.9%), 1p LOH (3.2%) and 6q LOH (3.2%). NGS analysis detected 219 gene mutations (in a total of 27 genes) in 108 patients (98%). The most frequently mutated genes were: **JAK2** (62.9%), **CALR** (27.8%), ASXL1 (20.3%), **TET2** (16.6%), **MPL** (7.4%), <5% **ZRSR2**, **EZH2**, **DNMT3A**, **U2AF1**, **ETV6**, **SF3B1**, **IDH1**, **IDH2**. Recurrent specific mutations were detected in 10 genes. Sixty-two patients (57.4%) had more than one somatic mutation. Six patients (5.5%) had no **CALR**, **BCR** or **MPL** mutations and were defined as “triple-negative”. Previously not described ZRSR2 gene 12 bp insertion was identified in four patients (3.7%). The correlation analysis showed significant associations between 9p LOH and **JAK2** mutation (p=0.001); **ASXL1** mutations (p=0.011); 19p deletion and **CALR** mutations (p=0.004). Notably, the affected genes are located in core- responding affected chromosome regions, indicating disruption of both alleles by different biological mechanisms. KRAS and **ETV6** mutations were statistically associated with **ASXL1** mutations (p<0.001 and p=0.005, respectively) while **JAK2** and **CALR** mutations were mutually exclusive in all cases (p=0.001).

**Summary/Conclusions:** A number of associations between gene mutations and chromosomal aberrations was revealed in PMF. Co-presence of 9p LOH with **JAK2** and **CALR** mutations with 19p deletion indicate that further deregulation of these key signaling pathways may take place disrupting the second allele of the affected genes by different biological mechanism – LOH or deletion.

**E1312**

**FREQUENCY OF CONCURRENT BCR-ABL1, JAK2, CALR AND MPL MUTATIONS IN A COHORT OF 5,545 CASES WITH SUSPECTED MPN BY A DEEP SEQUENCING APPROACH**

S. Jeromin1,2, M. Meggendorfer1, A. Fasan1, C. Haferlach1, W. Kern1, T. Haferlach1
1Moffit Leukemia Laboratory, Munich, Germany
2Moffit Leukemia Laboratory, Munich, Germany

**Background:** Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by a **BCR-ABL1** fusion, whereas in about 90% of **BCR-ABL1** negative MPN a mutation in **CALR** or **MPL** can be detected. These genetic alterations are thought to be nearly mutually exclusive, however, an accurate frequency is still missing.

**Aims:** To determine the incidence of genetic markers occurring in parallel in a large cohort of patients with suspected MPN and characterize double mutated cases.

**Methods:** From July 2016 till January 2017 5545 samples were sent to our laboratory with suspected MPN. The male:female ratio was 1:1, and the median age was 60 years (range: 18-98 years). Median white blood cell count was 9x10⁹/l, hemoglobin level (Hb) was 15g/dl, and platelet count less 320x10⁹/l. All of these cases were analyzed by an amplicon deep sequencing approach for mutations in **JAK2** (exon12, exon14), **CALR** (exon9) and **MPL** (exon10) with a sensitivity of 1%. 3070 patients were additionally screened for **BCR**-**ABL1** fusion by a multiplex PCR approach. Samples that were double mutated for **JAK2**, **CALR** or **MPL** were analyzed by amplicon deep sequencing for additional mutations in 13 myeloid genes.

**Results:** In total 1775/5545 (32%) of suspected MPN patients showed **JAK2**, **CALR** and/or **MPL** mutations. 1438 (26%) were **JAK2** fusion identified 123 (4%) as CML cases. The 229 mutated cases presented mainly with Val617Phe (99%) and rarely with JAK2(V617F) mutations. 1438 (26%) were **JAK2** mutated cases primarily type 1 (54%) and type 2 (30%). **MPL** mutations were located at amino acid Trp515 in 96% of cases. Double mutated cases were present in 19/1775 (1%) cases: **JAK2/MPL** (63%), **JAK2/CALR** (32%), **CALR/MPL** (6%). In nearly all (97%) of the double mutated cases (67) the CALR mutation was detected with the higher load, whereas in **JAK2/MPL** double mutated cases the ratio was equal. Most of the patients (18/19) had one mutation with a load below 10% and could have been missed by other approaches. **BCR-ABL1** together with **JAK2** or **CALR** mutation was found in one patient, each (2.1%). In total 311/1775 (18%) of the 229 mutated cases (67) the **CALR** mutation was detected with the higher load, whereas in **JAK2/MPL** double mutated cases the ratio was equal. Most of the patients (18/19) had one mutation with a load below 10% and could have been missed by other approaches. **BCR-ABL1** together with **JAK2** or **CALR** mutation was found in one patient, each (2.1%). In total 311/1775 (18%) of the 229 mutated cases (67) the **CALR** mutation was detected with the higher load, whereas in **JAK2/MPL** double mutated cases the ratio was equal.

**Discussion:** The aim of the study was to evaluate a prognostic impact of **JAK2** and **CALR** mutations. One-third of the cases can be diagnosed having **BCR-ABL1** fusion and/or **MPL** mutation in an unselected cohort with suspected MPN. The frequency of double mutated **JAK2**, **CALR** and **MPL** cases is 1%. In CML cases **BCR-ABL1** fusion and **JAK2** or **CALR** mutation were detected in 2% of the patients. The impact of these parallel genetic events on the clinical course of the disease has to be evaluated in the future.

**E1313**

**COMPREHENSIVE ASSESSMENT OF MOLECULAR AND CYTOSKELETIC MARKERS OF PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS**

L. Polushkina1,2, I. Martynkevich1, V. Shuvaev1, E. Motyko1, M. Fominykh1, I. Krivolapov2, Z. Asaulenko2, L. Martynenko1, M. Ivanova1, N. Cybacova1, D. Shikhbabaeva1, A. Zhernyakova1, S. Voloshin1, S. Bessmelcev1, A. Chechetkin1
1Russian Research Institute of Hematology and Transfusiology, 2North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation

**Background:** According to resent reports the data of molecular and cytogenetic analysis (type or absence of driver mutation (DM), mutations in **ASXL1**, **EZH2**, **IDH1/2** genes, karyotype) is a promising tool for prediction of survival in primary myelofibrosis (PMF). Multiple combinations of genomic aberrations lead to clinical course and survival heterogeneity. The aforementioned factors need to be considered together to evaluate their mutual influence.

**Aims:** The aim of the study was to evaluate a prognostic impact of DM, mutational status of epigenetic regulation (ER) genes, karyotype and their combinations for overall survival (OS) in PMF patients.

**Methods:** We have examined 110 patients (pts) with PMF (34.5% males). Median (Me) age was 59 years (16-82). For all pts the detection of **JAK2**V617F was done. **JAK2** samples were tested for **MPL** 515 codon mutations and exon 9 mutations of **CALR** (direct sequencing). All pts except 4 underwent the analysis of mutations in **ASXL1**, **EZH2**, **IDH1/2** genes with high resolution melt- ing method followed by sequencing of probably mutated samples. Karyotype research was done for 48 (43.6%) pts.

**Results:** DM were detected in 81.8% pts: **JAK2** (50% - **CALR** (25.5%), **MPL** (6.4%) cases. No DM were found in 18.2% pts considered triple-negative (TN). Mutations in ER genes were detected in 20.8% pts. High risk (HR) chromosomal aberrations (Cyt) unfavorable CA (Del**CALR** (40%) and DiPSN along with muta- del(6)(q15), add(6)(p25), del(X)(q22), t(X;7)(p21;q11)) were found in 27.1% pts. Univariate analysis identified HR karyotype (hazard ratio (HR) 8.2, p<0.001), the absence of DM (HR 8.1, p<0.001) and nonsense and frameshift (hereinafter mut) (HR 2.9, p=0.018) but not missense mutations of **ASXL1** (p=0.378) as being prognostically detrimental for survival. **CALR** mutations had a favorable impact on survival with borderline significance (HR 0.3, p=0.052).

A multivariate analysis included TN, **CALR**, **ASXL1** status and karyotype as covariates revealed an inter-independent prognostic value of HR karyotype (HR=7.4, p<0.001) and **ASXL1** mut (HR=2.8, p=0.023). In Cox regression model considering the same covariates except karyotype TN status (HR=2.4, p=0.050) and **ASXL1** mut (HR=3.3, p=0.012) but not **CALR** mutations (HR=0.3, p=0.075) were significant for OS. **CALR** mutations became significant (HR=0.3, p=0.075) when only **ASXL1** mut were included as covariate (HR=3.9, p=0.004). When comparing groups divided by **CALR**/**ASXL1** status the shortest OS was noted **CALR**/**ASXL1** mut (HR=0.03) in 5 years, p=0.022. **CALR**/**ASXL1** wide type (wt) pts seem to have better OS than **CALR**/**ASXL1**wt (median not reached (with follow up period of 10.1 years) and 13.5 years, respectively, p=0.124). Median OS estimated in pts due to presence/absence of DM and **ASXL1** status.
was 0.9 years in TNASXL1wt. 3.6 years in TNASXL1wt, 13.8 years in DM(+)JASXL1wt and was not reached in DM(+)/JASXL1wt (with follow up period of 10.3 years) group (p<0.0001). Differences in OS depending on the ASXL1 status were statistically significant in the TN (p=0.007) but not for DM(+) group (p=0.788). The better OS was observed in ASXL1 wt pts with low risk (LR) karyotype (M 6.4 years, p=0.0005). There were no differences in OS of ASXL1 wt- HR, ASXL1 wt-LR and ASXL1 wt-HR pts (1.4 vs 1.6 vs 1.2 years, p=0.493).

Summary/Conclusions: The differences in OS were more statistically relevant in groups divided by TN/ASXL1 and karyotype/ASXL1 status. The presence of ASXL1wt significantly worsens OS in the TN group. OS in pts with any of the findings: HR karyotype or ASXL1wt – was significantly shorter than in cytogenetically favorable ASXL1 wt counterparts.

E1314

JAK2 HAPLOTYPE 46/1 (GGCC) HAS NO EFFECT ON THE PRIMARY RISK OF JAK2 V617F MUTATION, BUT IT STRONGLY POTENTIATES THE PROGRESSION OF GROWN ALLELE BURDEN IN MYELOPROLIFERATIVE NEOPLASMS

M. Stolyar1,2, O. Klímova3,4, M. Ivanov3,4, A. Gobenko1, S. Titov3,4, I. Likhovskova1,5
1Krasnoyarsk Branch of the Federal State-Funded Institution «National Research Center for Hematology» of the Ministry of Healthcare of the Russian Federation, 2Siberian Federal University, Krasnoyarsk, 3AO Vector-Best, 4Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, Novosibirsk, 5Federal Research Center “Krasnoyarsk Scientific Center of the Russian Academy of Sciences, Siberian Branch”, Krasnoyarsk, Russian Federation

Background: Several research groups have determined that the JAK2 46/1 (GGCC) haplotype in multiple ethnic groups is strongly associated with a pre-disposition to acquiring JAK2 V617F-positive MPNs. The role of the JAK2 46/1 haplotype in the natural evolution of the mutant JAK2 V617F allele burden in PV but not ET or PMF has been shown [Alvarez-Larrán A et al. Leukemia Research 2012, 36(3):324-326]. However, the data on the impact of the haplotype on the JAK2 V617F allele burden do not always agree. Using a highly sensitive test allowed to reveal a high prevalence JAK2 V617F among persons without symptoms of hematological disorders [Krichevsky S e.a. Blood Cells, Molecules and Diseases., doi: 10.1016/j.bcmd.2017.01.001]. Influence of haplotype 46/1 for such cases is not known. There are two competing hypotheses of "hypermutability" and "fertile ground" explaining the causes of the higher frequency of mutations of JAK2V617F in haplotype 46/1 carriers. The "hypermutability" hypothesis refers to an increased risk of primary mutation in carriers of haplotype 46/1. In this case, the increasing frequency of the haplotype in patients with low allele burden (<5%) must also be observed, including those individuals without evidence of hematological disorders.

Aims: Studying the relations of haplotype 46/1 and JAK2 V617F allele burden

Methods: The diagnosis of chronic myeloproliferative neoplasms was based on the WHO (2008) criteria. The cohort included patients with JAK2 V617F mutation: 100 patients with PV, 51 with ET, 14 with MF, 41 patients with unclassifiable MPN and 47 patients with asymptomatic V617F+ carriers. Among all patients, 17 patients were treated with hydroxyurea and 20 were treated with interferon. The control group included 100 healthy donors without JAK2 V617F mutation but no differences were observed from patients with the PMF. JAK2 V617F allele frequency was closely associated with MPN patients if the allele burden exceeds 5% (Fig. 1) regardless of the phenotype or the treatment. In this case with an increase in JAK2V617F allele burden the JAK2 V617F mutation significance increased. However, there was no significant difference in the JAK2 46/1 haplotype frequencies between patients with allele burden less than 5% and the control group.

Summary/Conclusions: No significant differences of the carrier haplotype frequency were observed between control group and patients with minimal allele burden (less than 5%) JAK2 2V617F have been observed. This is evidence against primary "hypermutability" hypothesis. A further increase in allele load is more pronounced in carriers of haplotype 46/1 that supports the "fertile ground" hypothesis. We hypothesize that DNA mutation JAK2V617F repair is down-graded in 46/1 haplotype carriers.

E1315

MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL PCR FOR JAK2V617F DETECTION IN PATIENTS WITH MYELOFIBROSIS (MF) OR ACUTE MYELOID LEUKEMIA SECONDARY TO MF AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)

S. Salmoiraghi1,*, C. Belotti, M.C. Finazzi, M.C. Micó1, A. Algarotti1, G. Finazzi1, M. Mascheroni1, A. Salvi1, A. rambald1,2, O. Spinelli1
1Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, 2Oncoology and Hematology, University of Milan, Milan, Italy

Background: Myelofibrosis (MF) is one of the BCR-ABL1-negative Chronic Myeloproliferative Neoplasms (MPNs), characterized by clonal expansion of abnormal hematopoietic progenitors and gradual replacement of normal bone marrow with fibrous tissue. MF patients’ prognosis is widely variable and the median survival can vary from a few months to many years. At present, Allogeneic Stem Cell Transplantation (ASCT) is the only curative treatment option for these patients. The most frequent phenotype-driving mutation in MF is the V617F mutation in the JAK2 gene. A high sensitive quantification of JAK2V617F mutation load can be useful to assess Minimal Residual Disease (MRD) in treatment directed to eradicate the malignant clone, such as ASCT. Droplet Digital PCR (ddPCR) is a quantitative approach for the detection of rare allele characterized by a high level of sensitivity and specificity.

Aims: To evaluate the efficacy of ddPCR JAK2V617F mutation detection assay in monitoring the MRD level at consecutive time-points in a small cohort patients who underwent an ASCT for MF or MF-derived Acute Myeloid Leukemia (s-AML) or secondary AML.

Methods: DNA from 9 patients affected by primary, secondary MF or s-AML were serially collected during the follow-up after ASCT (50-2500 days). These samples were investigated for hematologic chimerism by PowerPlex System (Promega, USA) and were also analyzed for JAK2V617F mutated alleles on total evaluated alleles.

Results: The JAK2V617F ddPCR mutation assay was able to detect low muta- tion load (up to 0.006%), confirming to be much more sensitive than ASO-PCR (0.5-2%). In 4 patients, early after transplantation, we observed by ddPCR a low level of MRD that progressively increased during the follow-up and anticipated a decrease in donor chimerism level and a worsening of clinical situation. In 2 patients, who showed a full donor chimerism and complete hematologic remission of the disease, very low levels of MRD (ranging from 1% to 0.006%) could be detected by ddPCR in the 2 years after ASCT. With a longer follow-up, a low molecular remission was achieved as demonstrated by ddPCR. In 2 patients, we observed a very early achievement of full donor chimerism and JAK2V617F molecular negativity (within 90 days post HSCT), also when evaluated by ddPCR.

Summary/Conclusions: The ddPCR proved to be a sensitive and accurate method in detecting JAK2V617F mutation. Therefore, this assay can be a valid tool for MRD monitoring in MF patients after ASCT. However, the use of this highly sensitive PCR should be considered with caution in the clinical management of transplanted patients to avoid inappropriate use of donor leukocyte infusion (DLI) and tampering of immunosuppression. A large
number of patients have to be studied with ddPCR to better understand the clinical significance of low mutation load.

E1316
S100A8/9 ACTIVATION OF MAPK PATHWAY IS SUPPORTED BY ITS RECEPTORS RAGE AND TLR4 IN POLYCYTHEMIA VERA
M. Kovačić1, C. Mitrovic-Ajić2, B. Beleslin-Cokić2, M. Diklić3, T. Subotić1, D. Dijukić4, S. Momiččolović2, D. Leković4,5, M. Gotić4,5, V. Cokić3
1Laboratory of neuroendocrinology, Institute for Medical Research, 2Clinic for Endocrinology, Diabetes and Metabolic Diseases, Genetic laboratory, Clinical Center of Serbia, 3Laboratory of experimental hematology, Institute for Medical Research, 4Clinic of Hematology, Clinical Center of Serbia, 5Medical Faculty, University of Belgrade, Belgrade, Serbia

Background: S100A8 proteins have been shown to regulate cell proliferation, excessively augmented in myeloproliferative neoplasms (MPN). S100A8/9 is produced by cells of myeloid origin as mediator of inflammation, while AKT and MAPK pathways mediate cell proliferation.

Aims: This study analyzed activation of AKT and MAPK pathways by S100A8/9 proteins in healthy controls and MPNs: polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), according to JAK2V617F and calreticulin (CALR) mutation status.

Methods: S100A8/9 factor is examined in granulocytes of MPN using immunochemistry to observe the presence of granulocytes is determined by flow cytometry. Mutations of JAK2V617F and CALR exon 9 are analyzed by DNA sequencing. Besides JAK2V617F+/PV patients, we formed per three groups of patients: JAK2V617F+; JAK2V617F/CALR+, and JAK2V617F/CALR- for ET and PMF.

Results: S100A8/A9 proteins demonstrated a common significant increase in plasma of MPN patients, whereas the presence of CALR mutation augmented S100A8/9 levels in granulocytes of ET and PMF patients. Activation of AKT pathway is generally reduced by S100A8/9 factor, further on ameliorated by inhibition of the receptor for advanced glycation end products (RAGE) in granulocytes of JAK2V617F+ and JAK2V617F+/CALR+ groups of ET and PMF patients, while it has been prevented by Toll-like receptor 4 (TLR4) inhibition in PV patients. MAPK pathway is significantly inhibited by S100A8/9 only in JAK2V617F+/ET patients and JAK2V617F+/CALR- PMF patients, partially prevented by TLR4 inhibition in PMF. Inhibition of TLR4 reduced S100A8/9 mediated AKT and MAPK pathways. In contrast, S100A8/A9 mediated MAPK activation has been significantly augmented by TLR4 and RAGE inhibition in PV patients. S100A8/9 stimulated granulocyte cycle arrest in G2M phase has been stopped by JAK1/2 inhibition.

Summary/Conclusions: S100A8/9 protein levels demonstrated stable elevation in MPN. The combination of inhibition of AKT pathway has been controlled by TLR4, whereas MAPK pathway activation by TLR4 and RAGE in PV, during treatment with S100A8/9.

E1317
MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL THROMBOCYTIAHMA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS)
G. Carreno-Tarragona1, I. Rapado1, R. Ayala1, A. Arenas1, J. Martínez-López1
1Haematology, Hospital Universitario 12 de Octubre, Madrid, Spain

Background: Essential thrombocythemia is one of the three classical phaeo- phia negative myeloproliferative neoplasms. It is frequently difficult to diagnose and some molecular markers are used as diagnostic criteria according to WHO classification. Despite this, a significant proportion of patients do not present a clonality marker.

Aims: To identify the mutational profile of ET negative for V617F and CALR mutations and to correlate it with clinical data.

Methods: A cohort of 22 ET negative for mutations in JAK2 (qPCR) and CALR (GENSCAN) was selected. Median age at diagnosis was 46 years (range: 14-88), male:female ratio 9:13; 2 patients had a record of thrombotic event prior to diagnosis, 4 patients had symptoms at the time of diagnosis, 3 patients suffered thrombotic event after diagnosis, 1 patient underwent transformation to AML. Median Hb, WBC and platelets at diagnosis were respectively 14.75g/dl, 8.5 x10^11/L and 720 x10^11/L. We performed targeted gene sequencing by NGS (Ion Torrent Proton System–Life Technologies) using a panel of 33 genes implicated in leukemia prognosis: X2 and I-stand test were used to find association between mutations and clinical data.

Results: On average, 97.94% of the target sequence showed a mean depth coverage around 2500. We discovered 17 non-synonymous mutations which were somatic single nucleotide variants (SNVs) and 1 a nucleotide deletion in coding regions. No mutations were detected in 9 samples (40.9%), 10 samples suffered from thrombotic event after diagnosis, 1 patient underwent transformation to AML. The samples with more than one mutation: one presented a CBL and two TET2 mutations, one two mutations in MPL and the other one mutation in TET2 and other in JAK2. No correlation was found between mutational profile and clinical data.

Summary/Conclusions: In ET, around 60% of patients present the JAK2V617F mutation, 15-30% show CALR mutations and around 5% present MPL mutations. In spite of this, there is still a significant percentage of ET patients without a molecular marker. Our study shows that the use of a NGS panel allows identifying markers of clonality as for example TET2. NGS also makes affordable to interrogate whole genes classically associated to ET, to detect mutations that were not found by traditional approaches. Finally, we can conclude, as previously described, that ET is an entity with a low mutational burden in comparison with other MPNs as primary myelofibrosis.
Background: We already demonstrated augmented proinflammatory IL-6 and angiogenic vascular endothelial growth factor (VEGF), hypoxia inducible factor-1α (HIF-1α) and endothelial nitric oxide synthase (eNOS) levels in myeloproliferative neoplasms (MPN).

Aims: To observe IL-6 activated signaling pathways during stimulation of angiogenic factors and their JAK-STAT dependence in MPN.

Methods: We analyzed phosphorylation of JAK/STAT3, PI3K/AKT and MAPK signaling by immunoblotting in HEL 92.1.7 cells (with JAK2V617F mutation) and granulocytes of MPN. The granulocyte cycle phases have been studied by flow cytometry.

Results: We demonstrated IL-6 stimulated angiogenic factors in HEL cells and HEL-derived macrophages, blocked by JAK-STAT inhibition for eNOS and HIF-1α. IL-6 stimulated JAK-STAT3 and angiogenesis related PI3-AKT signaling pathways in HEL cells, the later one prevented by JAK1/2 inhibition. Opposite to primary myelofibrosis (PMF), IL-6 activation of JAK2/STAT3 and PI3-AKT pathways has been prevented and enhanced by JAK1/2 inhibition, respectively in granulocytes of polycythemia vera (PV). Moreover, IL-6 inhibition of JAK-STAT3 and PI3-AKT pathways in essential thrombocytopenia (ET) has been prevented by JAK2 inhibitor in JAK2V617F positive ET granulocytes. JAK1/2 inhibitor Ruxolitinib upregulated IL-6 activators of MAPK pathway in MPN, in contrast to specific JAK2 inhibitor Hexabromocyclohexane. IL-6 mediated reduction in the percentage of HEL cells in G2M phase was inverted by Ruxolitinib that potentiated apoptosis and reduced the cell percentage in G0G1 phase both in HEL cells and granulocytes of PMF. It has been detected the cell cycle arrest of MPN granulocytes in S phase (DNA replication) after treatment with IL6, completely diminished by JAK1/2 inhibition.

Summary/Conclusions: Therefore, we concomitantly revealed that inflammation stimulated angiogenic factors and signaling pathways involved in cell proliferation, apoptosis and angiogenesis are regulated by JAK-STAT inhibition.

Myeloproliferative neoplasms - Clinical

E1320

PERCEPTION OF SYMPTOM BURDEN AND TREATMENT GOALS BETWEEN PHYSICIANS AND PATIENTS WITH MPNS: AN ANALYSIS FROM THE INTERNATIONAL MPN LANDMARK SURVEY

L. Foitz1,*, S. Koschmieder2, C.N. Harrison3, P. Guglielmelli4, T. Flindt5, M. Koehler6, J. Mathias7, N. Komatsu8, R.N. Boothroyd9, A. Spierer9, J. Perez Ronco10, G. Taylor-Stokes11, J. Waller11, R.A. Mesa12

1Laboratory of neuroendocrinology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia, 2Laboratory for endocrinology, Diabetes and Metabolic Diseases, Clinic for Hematology, Clinical Center of Serbia, 3Medical Faculty, University of Belgrade, 4Laboratory of experimental hematology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia

Background: The global MPN LANDMARK survey evaluated the patient (pt) and physician-reported impact of myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), among pts from 6 countries. We present an analysis comparing physician and pt perceptions of the impact of these MPNs.

Aims: To investigate differences between pt and physician perceptions of symptom burden, treatment goals, and disease management.

Methods: This was a cross-sectional survey of pts with MPNs and physicians treating pts with MPNs. Respondents completed the online survey measuring their perception of the impact of MPNs on symptom burden, disease management, and treatment goals. Pts and physicians were recruited independently.

Results: Pts (n=690) from Australia (n=10), Canada (n=64), Germany (n=149), Italy (n=106), Japan (n=84), and the UK (n=286) completed the survey (MF, n=223; PV, n=174; ET, n=302). Most pts had been diagnosed within ≤2 years of experiencing symptoms (73%); 56% were women. Physicians (n=219) were from the same countries; most were hematologists (54%) or hemato-oncologists (27%). Overall, 54% of pts reported having a prognostic score; however, 71% of physicians reported using a prognostic risk classification. Physicians assessed symptoms by proactively asking pts how they were feeling (43%) or asking about specific symptoms (37%); 11% waited for pts to mention symptoms. Importantly, only 26% of physicians used a validated symptom assessment form; 44% used their own rating method. Pts and physicians both agreed that pts with MPNs have a high symptom burden and that MF had a higher degree of burden on daily living. Interestingly, a higher proportion of physicians...
than pts felt that MPN symptoms have an impact on pt quality of life (92% vs 76%) and that pts had a substantial emotional burden associated with their disease. For instance, 34%, 29%, and 26% of pts with MF, PV, or ET reported feeling anxious or worried compared with 70%, 46%, and 36% of physicians reporting that their pts experience substantial anxiety or worry. Some pts did not recognize that their symptoms could be MPN related; for example, = one-fifth of pts did not think that their night sweats could result from their MPN (16% MF, 21% PV, 25% ET). Consistent with this, 60% of physicians indicated that pts could identify only few or some of their symptoms as MPN related. Pts and physicians were both concerned about reducing symptoms (pts: 70% MF; 61% PV; 53% ET; physicians: 80% MF, 55% PV, 60% ET); however, pts were also concerned about delaying MPN progression (58% MF, 57% PV, 66% ET; physicians: 43% MF, 28% PV, 37% ET; Figure 1). Compared with pts, physicians indicated a greater focus on prevention of vascular/thrombotic events in PV (66% vs 48%) and ET (80% vs 60%). Overall, only 27% of physicians felt they completely agreed with their pts on treatment goals; 66% felt they somewhat agreed. However, most pts (87%) were satisfied with their physician’s disease management/communication.

Summary/Conclusions: This study revealed a potential disconnect between physician and pt perceptions relating to communication and disease management, and an apparent lack of standardization in symptom assessment. Of note, some pts did not recognize that their symptoms could be MPN related and had different treatment goals than their physicians, indicating a need for improved pt education and pt-physician communication and a treatment plan that includes standardized monitoring of symptoms and agreement on treatment goals.

E1321

BASELINE QUALITY OF LIFE INDEPENDENTLY PREDICTS overall survival in the myelofibrosis: Key insights from the COMFORT-I STUDY

R. Scherber1,2, *H. Kosinòrek3, H. Geyer4, S. Verstovsek5, J. Sloan6, B. Langhais7, L. Padmos1, J. Palmer8, A. Fleischman7, A. Dueck3, R. Mesa1

1Hematology and Oncology, Mayo Clinic, Scottsdale, 2Hematology and Oncology, Mayo Clinic, Rochester, 3Hematology and Oncology, MD Anderson, Houston, 4Biostatistics, Mayo Clinic, Rochester, 5Hematology and Oncology, Oregon Health and Science University, Portland, 6Biostatistics, Internal Medicine, Mayo Clinic, Scottsdale, 7Hematology and Oncology, MD Anderson, Houston, 8Biostatistics, Mayo Clinic, Rochester, 9Hematology and Oncology, University of California Irvine, Irvine, United States

Background: Quality of life (QOL) is a critical aspect of cancer treatment and survival. A strong association exists between QOL and overall survival (OS) for numerous malignancies including breast, gastro-esophageal, colorectal, lung, prostate, ovarian, and head and neck cancer (Sloan 2012, Montazeri 2009, Nils-son 2017). Health care organizations have used symptom burden as a primary therapeutic endpoint when assessing the benefit of JAK inhibitors in myelofibrosis (MF) in clinical trials, although QOL was also considered. To date, little is known about the association of these items in regards to overall survival in MF.

Aims: To evaluate the prognostic relevance of QOL and symptom burden among patients with MF from the COMFORT-I study.

Methods: Data from the COMFORT-I trial of ruxolitinib (Verstovsek 2012) versus placebo was obtained from Incyte® for independent analysis. Association of total symptom burden (TSS; divided by the sample quartiles) and QOL (divided by the sample median) at baseline with OS among MF patients was estimated using the Kaplan-Meier method and tested using log rank tests and Cox regression. Symptom burden and QOL were assessed using the 5-symptom Global Health Status/QOL scale (Aaronson 1993), respectively. The PROMIS instrument was used to assess fatigue (Cella 2007).

Results: A total of 309 patients were available for analysis including 155 ruxolitinib-treated and 154 placebo-treated MF patients. Baseline demographics, disease-related variables, and calculated overall survival were similar to previous published results (Verstovsek 2015). Symptom Burden: When comparing OS by TSS quartiles at baseline, no significant associations in OS were observed (Figure 1A). Individual symptoms of bone or muscle pain, feeling full, pain under ribs on left side, abdominal discomfort, itchiness, or night sweats did not demonstrate significant associations when comparing OS by quartile symptom score. Baseline fatigue score demonstrated no difference in OS when stratified by median or quartiles. Global Health Status/QOL: Intention to treat analysis demonstrated significant survival advantage for patients with higher QOL at baseline (HR 1.47; p=0.02, Figure 1B). When censoring placebo patients at crossover, this hazard ratio improved to a HR 1.79 (p=0.008). Cox Proportional Hazards Modeling: Cox regression for survival analysis reached significance for items of age (p<0.001), sex (p<0.009), and QOL (p=0.009) when taking into consideration TSS, IPSS prognostic risk score, age, sex, COMFORT treatment arm, and QOL. When censoring for placebo patients at crossover, this analysis demonstrated that the same items remained significant (age [p<0.001], sex [p<0.001], and QOL [p=0.002]).

Summary/Conclusions: For the patients prospectively evaluated in the COMFORT-I trial, pre-treatment QOL is strongly prognostic for overall survival and MF-SAF high risk (Mesa 2006) or intermediate risk (IPSS scoring) for symptom burden score. Age, sex, QOL, and disease risk, age, sex, and treatment. Prior literature has confirmed the importance of QOL in prognosticating survival in other cancer types. However, this is the first study that has identified the key correlation among individuals with MF. Neither individual nor combined symptom scores at baseline appeared prognostic for overall survival, emphasizing the importance of QOL assessment in addition to symptom assessment. Weight loss (a prognostic factor for DIPSS scoring) was not included in this symptom burden assessment and may represent an independent factor associated with increased survival.

E1322

CHARACTERIZATION OF DISEASE AND OUTCOMES OF PATIENTS WITH MYELOFIBROSIS: A POPULATION BASED STUDY

J. He1, 2, M. Mehra1, J. Bussolari2, A. Rizo2, S. Mundle1

1Janssen Global Services LLC, 2Janssen Research & Development, LLC, Raritan, United States

Background: Myelofibrosis (MF) is a myeloproliferative neoplasm with profound negative effects on health related quality of life and survival. It is characterized by clonal myeloproliferation, ineffective erythropoiesis, bone marrow stromal changes, hepatosplenic extramedullary hematopoiesis, and aberrant cytokine expression. Although progress has been made in the understanding of the pathogenesis and management of MF, there are still unresolved issues regarding prognosis and causes of death.

Aims: This population-based study characterizes disease and outcomes in patients (pts) with MF by using the U.S. Surveillance, Epidemiology, and End Results (SEER) database.

Methods: We identified a total of 3,367 pts with primary myeloid fibrosis (PMF, ICD-O-3 morphology code as 9961/3 and primary site code as C420, C421 or C424) diagnosed between January 2000 to December 2013. Pts with missing survival status (n=753), pts lost to follow up (n=44), and pts with missing age record (n=1) were excluded. Kaplan-Meier analysis was performed to determine overall survival (OS) and cancer specific mortality. The effects of specific covariates on OS were analyzed using a Cox proportional hazards model.
Results: The study cohort comprised of 2,619 PMF pts. Median follow-up period was 28 months (interquartile range 9-57 years) with 60.6% (n=1,586) ≥ 65 years old. More than half of the pts were male (58.5%; n=1,531); 82.2% (n=2,153) were white, and 16.4% (n=430) were diagnosed between 2012 and 2013. The geographic distribution was as follows: East 14.8%, South 18.4%, West 54.2% and Midwest 12.6%. Median OS was 42 months (Figure 1). The hazard ratio of all-cause mortality for age was 1.05 (95% confidence interval [CI]) 1.04-1.05), for female vs male was 0.72 (CI 0.64-0.80), for nonwhite vs white 1.01 (CI 0.87-1.16), for unmarried vs married was 1.04 (CI 0.94-1.16), for patients diagnosed 2012-2013 vs 2000-2011 was 0.95 (CI 0.75-1.20). Compared to West, the hazard ratio of OS for East, South and Midwest was 1.05 (CI 0.90-1.22), 1.28 (CI 1.12-1.47), 1.03 (CI 0.88-1.19) respectively.

Summary/Conclusions: This population based study showed that the overall survival of pts with PMF was short. Older and male pts were associated with higher mortality risk. There were significant differences across geographic regions of the United States. Although there is a trend of improvement in the period of 2012 to 2013, the result is not statistically significant, partially due to short follow up. These findings underscore the continuing need for effective therapies for pts with MF.

E1323
SERUM ALBUMIN IS A STRONG PREDICTOR OF SURVIVAL IN MYELOFIBROSIS, INDEPENDENT OF IPSS, DISSP, AND DISSP+ SCORES
A.T. Kuykendall1,*, C. Talati1, D.A. Saltman2, K.L. Sweet2, E. Padron2, J.E. Lance2, A.F. Lis2, K.S. Zuckerman2, R.S. Komrokji2
1University of South Florida/Moffitt Cancer Center, 2Moffitt Cancer Center, Tampa, United States

Background: Albumin is the main protein in human plasma. Serum albumin (SA) is used as a surrogate marker of nutritional status and inflammation. The prognostic role of SA has been studied in many diseases, including hematologic malignancies. In myelofibrosis (MF), rouleutinib has been shown to improve SA levels in addition to other metabolic parameters. SA holds particular significance in MF given its ability to capture both nutritional status and inflammation level in a disease hallmarkd by hyperactive inflammatory pathways and constitutional symptoms.

Aims: We aim to closely evaluate the significance of SA in MF patients as it pertains to clinical presentation, laboratory correlations, disease genomics, comorbidities and outcomes.

Methods: We retrospectively reviewed an institutional database of 376 MF patients who presented to Moffitt Cancer Center between 1/1/1998 and 12/31/2012 and had available SA levels within 30 days of presentation. Laboratory values and prognostic scores were determined at time of first presentation. Overall survival (OS) was measured from time of first presentation until date of death or censored at time of last follow-up. Progression free survival (PFS) was defined as time from first presentation to development of acute myeloid leukemia (AML).

Figure 1.

Results: Our cohort of MF patients had median age of 67 and 69 at diagnosis and presentation, respectively. Most patients had primary MF (73%) with 11% and 16% having post-PV/PF and post-ET MF, respectively. First, we looked at the correlation between SA and other clinical factors. SA was positively correlated with hemoglobin (p<0.01) and platelet count (p<0.01), and negatively correlated with age (p<0.01), peripheral blast percentage (p=0.03), ferritin (p<0.01), prognostic scoring models (p<0.01 for IPSS, DIPPS and DIPSS+) and pack-year smoking history (p<0.01). SA did not correlate with spleen size or any specific somatic mutation, but negatively correlated with somatic mutation burden (p=0.03). On univariate regression, SA was associated with inferior PFS (HR: 0.31 [0.10-0.72], p<0.01) and OS (HR: 0.25 [0.17-0.36], p<0.01). Four cohorts were created based on SA: cohort I=SA 2.5-3.5 g/dL (n=31); cohort II=SA 3.6-4.0 g/dL (n=98); cohort III=SA 4.1-4.5 g/dL (n=182); and cohort IV=SA>4.5 g/dL (n=84). OS increased with increasing SA with median OS (in months) of 9.34, 25.3, 48.4, and undefined in cohorts I-IV, respectively. On focused comparison, each cohort was significantly different than all others. On multivariate analysis, the influence of SA on OS remained significant after controlling for prognostic scores (IPSS, DIPSS, DIPSS+) and comorbidities. For PFAA analysis, we found significant influence when controlling for IPSS and DIPSS+ but not IPSS alone.

Summary/Conclusions: SA level is independently prognostic in MF and correlates with variables known to hold prognostic value. Its representation of nutritional indices, inflammation, and comorbidities implies its usefulness in predicting outcome. Its incorporation into known prognostic scoring systems provides an improved ability to accurately capture low and high-risk subgroups.

E1324
CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING IN THE MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
W. A. Luidjes1,*, C. McNama1, A. Schuh1, A. Arruda1, M. Sukhal1, M. Thomas3, J.Y. Spiegel1, J.A. Kennedy2, T. Stockley2, H. Tsui2, R. Devlin1, N. Siddiqi1, H. Sibali1, D. Maze1, A. Schimmer2, K. Yee2, S. Chan2, S. Kamel-Reid2, V. Gupta3
1MPN program, Princess Margaret Cancer Centre, 2Hematology-Princess Margaret Cancer Centre, 3Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, 4Applied Molecular Oncology, Ontario Cancer Institute, University Health Network, Toronto, Canada, 5Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States, 6Department of Hematopathology, Toronto General Hospital, 7Molecular Diagnostics, Department of Pathobiology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, Canada

Background: Although Next Generation Sequencing (NGS) has helped characterize the complex genomic landscape of myeloid malignancies, its clinical utility remains not well defined. Funding for NGS testing by healthcare systems or third party payers is variable due to the lack of data on its utility in a routine care setting. At our centre, targeted sequencing (TAR-seq) is offered to all new patients referred for myeloid malignancies as part of the Advanced Genomics in Leukemia (AGILE) program.

Aims: In this study, we evaluate the impact of TAR-seq on the management of patients with a diagnosis of MPN or post-MPN acute myeloid leukaemia (MPN/AML).

Methods: All consenting patients referred to the MPN program at the Princess Margaret Cancer Centre between February 2015 and December 2016 with a suspected or confirmed diagnosis of MPN were evaluated (n=188). TAR-seq was performed on DNA extracted from peripheral blood (n=159, 85%) or bone marrow (n=29, 15%) using the TruSight Myeloid Sequencing Panel (Illumina), a targeted NGS panel of 54 genes (39 hotspot region; 15 complete coding region) implicated in myeloid malignancies. Reporting was focused to high quality exonic nonsonymous, intronic splice site, frameshift, nonsense and known pathogenic synonymous variants. Variants with global mean allele frequency >1% were identified using multiple population databases (1000 genomes, ESP, ExAC) and excluded. Each patient’s TAR-seq results were reviewed alongside their clinical information systematically by at least two hematologists with expertise in MPN, and disagreements were resolved by consensus.

Results: 179 patients fulfilled the 2008 WHO diagnostic criteria for MPN: 107 were diagnosed with myelofibrosis (MF), 26 with polycythemia vera (PV), 21 with essential thrombocythemia (ET), 11 with other MPN, 27 with unclassifiable MPN and 12 with MPN/AML. In 6 patients with ‘triple negative’ MPN, who lacked mutations in the driver genes JAK2, CALR and MPL, TAR-Seq confirmed clonal hematopoiesis through identifying other mutations. In 61 transplant-eligible patients with MF, 32 (52%) were considered to carry a high molec- ular-risk (RM) profile based on mutational burden, as defined in AML with t(8;21), EZH2, IDH1/2, SRSF2 or TP53; or a total of three or more mutations. Of these, 11 patients (34%) were considered for early transplant, three with Intermediate-1 and eight with Intermediate-2 risk, who were responding well to JAK 1/2

haematologica | 2017; 102(s2) | 543
E1325
IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
1Department of Hematology, University of Bologna, Bologna, 2Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, 3Department of Hematology, University of Verona, Verona, 4Division of Hematology, Ospedale Ferrarotto, University of Catania, Catania, 5Division of Hematology, Azienda Ospedaliera-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, 6Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, 7Division of Hematology, IRCCS AOU San Martino-IST, Genova, 8Division of Hematology, University of Ferrara, Ferrara, 9Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, 10Hematology and Clinical Immunology Unit, University of Padova, Padova, 11Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, 12Division of Hematology, ASST Spedali Civili di Brescia, Brescia, 13Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, 14Division of Hematology, Placenza, 15Division of Hematology, Casa Sollievo Sofferenza, San Giovanni Rotondo, 16U.O.S. Ematologia, Ospedale Nuovo Regina Margherita, Roma, Italy

Background: Charlson Comorbidity Index (CCI) and body mass index (BMI) are significantly associated with outcome in patients (pts) who receive continue treatment with tyrosine kinase inhibitors. Ruxolitinib (RUX) is the first JAK1/2 inhibitor that may induce spleen/symptom responses and improve quality of life in pts with myelofibrosis (MF). No data are yet available on the impact of comorbidities on pts treated with RUX.

Aims: To evaluate the impact of CCI and BMI on overall survival (OS) in a cohort of RUX-treated MF pts.

Methods: A multicenter observational study on WHO-defined MF treated with RUX according to standard clinical practice was conducted in 20 Italian Hematology Centers. Response to RUX was evaluated according to 2013 IWG-MRT criteria. OS was calculated from the date of RUX start to the time of death or last follow-up. Baseline parameters evaluated for correlation with OS were: blood count, spleen ≥10cm, marrow fibrosis grading, time from MF diagnosis to RUX start, transfusion dependency, mutation status, Total Symptom Score (TSS), CCI, and BMI.

Results: Between June 2011 and Apr 2016, 343 pts with PMF (51.9%), or post-ET (20.1%) / post-PV (28.0%) were treated with RUX in participating Centers. At RUX start, median age was 67.6 years (range 35.8-89.0) with a male prevalence (57.1%); International Prognostic Score System (IPSS) was inter- mediate in 55% (45.5% high 38.4%), transfusion dependency and spleen enlargement were present in 23.8% and 97.4% of pts, respectively (62.4% with spleen ≥10 cm). TSS was <20 in 131 pts (38.2%); 62 (18.1%) pts had a BMI<21 (corresponding to lower quartile). CCI was in 105 pts (30.6%), one in 74 pts (21.6%), two in 58 pts (16.9%) and 3 in 106 pts (30.6%). Follow-up from MF diagnosis was 3.6 yr (range 0.4-25.6) and median RUX exposure was 21.2 months (3-56.2). In multivariable Cox regression analysis, factors negatively correlating with OS from RUX start were: transfusion dependence (HR: 2.65; p<0.001), CCI ≥3 (HR: 1.67; p=0.031), BMI<21 (HR: 1.74; p=0.039), and IPSS (intm-2: HR: 3.19; p=0.057; high risk: HR: 6.83; p=0.001). Scoring values were assigned to OS at 3 years was 91.8%, 65.6% and 34.8% in group1, 2 and 3, respectively (log rank p<0.001) for a median OS of undefined, 66.7 and 22.8 months. Notably, while 88.7% of high IPSS risky pts clustered in group3, only 60.5% of pts in group1 were at intm-2 IPSS risk and 48.6% of pts in group2 were at high IPSS risk. The achievement of a spleen response at 6 months (39.2% vs 36.4%, p=0.71) was not influenced by lower BMI. However, pts achieving a spleen response at 6 months had significantly increased OS (Fig. 1A). Also, a higher CCI did not correlate with lower spleen response at 6 months (44% vs 34% of pts with CCI<3, p=0.11). The impact of higher CCI on survival was only mildly affected by the achievement of a spleen response at 6 months (Fig. 1B).

Figure 1.

Summary/Conclusions: Together with transfusion requirement, CCI and BMI may influence survival in RUX-treated MF pts. Taking into account these additional parameters may allow to better define survival probability beyond IPSS risk assessment. Unfavorable CCI and BMI did not hamper responses to RUX; also, the achievement of a spleen response counterbalanced the negative prognostic effects of a lower BMI.

E1326
ANALYSES OF 845 PATIENTS WITH PMF, PET-MF AND PPV-MF TREATED IN 35 GERMAN HEMATOLOGY CENTERS – A RETROSPECTIVE FIELD STUDY
B. Kragl1, C. Wassenberg2, H. T. Steinmetz3, G. Springer4, K. Jentsch-Ullrich5, A. Gaumann6, J. Dengler7, C. Junghanss1
1Department of internal medicine 3, Hematology, Oncology, Palliative Care, University Hospital Rostock, Rostock, 2Gefos Dortmund mbH, Dortmund, 3Gemeinschaftspraxis für Onkologie und Hämatologie, Köln, 4Hämato-Onkologische Schwerpunktpraxis, Stuttgart, 5Schwerpunktpraxis für Hämatologie und Onkologie, Magdeburg, 6Institut für Pathologie, Kauferinchen, 7Schwerpunktpraxis Onkologie, Heilbronn, Germany

Background: Primary myelofibrosis (PMF) as well as secondary post essential thrombocytemia (pET)-MF and post polycythemia vera (pPV)-MF are considered rare diseases associated with significant morbidity. Diagnostics and therapeutic options have significantly improved during the last decade by development of novel drugs, improvement of allogeneic stem cell transplantation (SCT) procedures and supportive care. Whereas the characteristics of PMF, pET-MF and pPV-MF patients (pts) participating in clinical trials are well analyzed, data are rare for the general MF population including patients not included in or eligible for clinical trials.

Aims: In order to gain a broader, more comprehensive data set on the general MF population we performed a questionnaire poll in 35 German hematology centers gathering characteristics on 845 pts who were currently under care.

Methods: A questionnaire asking for general patient and disease specific data as symptoms, quality of life, comorbidities, prognostic factors, past/ current treatment and blood count, degree of MF in bone marrow and transfusion frequency was designed. It was distributed to participating centers (n=35, mostly private offices) throughout Germany and analyzed centrally. Time period of collection
was 03/2013–12/2015. 845 pts were included i.e. a median of 20 pts (range 6–90 pts) per center.

**Results:**
Gender was equally distributed (50%/50%). Pts ages at initial diagnosis were as follows: <50 years (11%), 50–69 years (31%), ≥70 years (40%). Current age was ≥65y in 70% of all pts. PMF represented the largest MF cohort (77%), followed by Ph-MF (10%), PV-MF (7%) and unspecified (6%). Most pts (37%) had intermediate-1 disease (11% intermediate-2, 8% intermediate-3, <1% unknown). Current key blood values at time of diagnosis included abnormal thrombocyte counts (<50GPT/L; 5% <100GPT/L; 10% ≥450GPT/L) and elevated WBC >25,000/µl (11%). Presence of circulating blasts in the peripheral blood was documented in 11% of pts. Hemoglobin [g/dl] was ≥10 (68%), 8–10 (21%), <8 (8%), unknown for 3% of the pts. B. intermediate-2. The median of the intermediate-2 subgroup was present in 20% of the pts. Common symptoms included splenomegaly (60%), decreased fitness (41%) and weight loss (16%). Pruritus was present in 5% and night sweats in 9% of all pts. An individual Dynamic Prognostic Scoring System (DIPSS) score was calculable in 495 pts: 19% low risk, 52% intermediate-1, 23% intermediate-2 and 5% high risk disease. Concomitant cardiovascular risk factors were common, most often cardiac (54%). Most common medical treatments included cytostatic (37%), anticoagulation (25%), JAK-inhibitors (23%) and none (24%). Non-medical treatments were rare: stem cell transplantation (3%), splenectomy (2%) and spleen irradiation (3%). Only 31% of all pts received red blood cell transfusions, however 7% had received >90 units.

**Summary/Conclusions:**
Daily practice MF pts share several characteristics with MF trial cohorts (e.g. COMFORT). As expected the diseases were not as progressed as in the trials. Interestingly gender was equally distributed in our study. SCT was a rarely used treatment within this cohort whereas JAK2 inhibitors were frequently used.

---

**E1327**

**CALR MUTATION TYPE INFLUENCES THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA ACCORDING TO A COOPERATIVE STUDY BETWEEN TWO SPANISH CENTERS**

A. Aguin Blasco1, A. Sáez Salinas2, L. Bao Pérez1, J.M. González Martínez3, F.J. López Jaime1, L. Torres Miñana2, A. Mosquera Orgeira1, C. Bilbao Sieyro2, A. Abuín Blanco1,*, A. Sáez Salinas2, L. Bao Pérez1, J.M. González Martínez3, F. J. López Jaime1, L. Torres Miñana2, C. Bilbao Sieyro2

**Aims:**
The objective of this study is to understand the clinical meaning of CALR mutation type in ET.

**Methods:**
We analyzed 309 ET patients from two hospitals: H.C.U. Santiago de Compostela and H.U. of Gran Canaria Dr. Negrín. Dates of diagnosis were between 1/11-90 and 1/10-2016, and the median follow up was 6.88 years. Patients were treated according to local protocols. We collected clinical data of patients at diagnosis and during follow-up as well as events such as thrombosis, transformation to myelofibrosis (MF) or acute leukemia (AL). Thrombosis associated with diagnosis refers to those events happening from two years before to diagnosis until diagnosis. The statistical analyses were performed with R Core Team (2016) and IBM SPSS 21.0.

**Results:**
JAK2V617F mutation was present in 60.5% of the patients, 1.9% had MPL mutations, 14.5% were CALR type-1like, 11% were CALR type-2like and 11% were without a mutation. In three cases, we were not able to classify CALR mutation as type-1like or type-2like. With regard to the clinical events: 21 patients (6.8%) had thrombosis associated with diagnosis, and 34 (11%) at least 1 thrombosis since the diagnosis. Twelve patients suffered more than 1 thrombotic event. MF evolution was found in 18 patients (5.6%) and 2 cases transformed to AL. Since the diagnosis, 12 patients suffered more than 1 thrombotic event. All pts were treated at diagnosis, and repeated 6-9 months after the start of therapy. The objective of this study is to understand the clinical meaning of CALR mutation type in ET.

**Figure 1.**

**Summary/Conclusions:**
The type of driver mutation is associated with a different risk of thrombosis. Among the two types of CALR mutation, patients have similar clinical characteristics except for the risk of thrombosis which seems lower in CALR type-2like compared to type-1like. This finding shows the importance of studying the CALR mutation type in ET.

---

**E1328**

**MONITORING OF LEUKOCYTE-PLATELET AGGREGATES AND SELECTIN LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS**

D. Šefler1, P. Mišić1, N. Kraguljac-Kurvić1, S. Babić-Radulović1, V. Cokić1, A. Bogdanović1,2, D. Marković1, V. Knežević1, M. Golić1,2

**Aims:**
We prospectively analyzed the levels of leukocyte-platelet (Le-Plt) aggregates, along with levels of soluble selectins, in a group of pts with Ph-MPN at diagnosis and during therapy.

**Methods:**
Our study included 90 consecutive de novo Ph-MPN pts (37 polycythemia vera, 27 essential thrombocythemia, 26 primary myelofibrosis), diagnosed according to WHO criteria. According to therapy, pts were assigned as: hydroxyurea (HU) 7.8%, aspirin (ASP) 55.6%, hydroxyurea+aspirin (HU+ASP) 31.1%, although 5.6% of pts were without therapy. Neutrophil-platelet (Neu-Plt) and monocyte-platelet (Mo-Plt) aggregates were determined in whole blood samples (EDTA/CTAD) by flow cytometry. Aggregates were estimated as fraction (%) of CD42b+CD61+ neutrophils and monocytes. Plasma levels of E-, L- and P-selectin were determined by enzyme immunoassay. All analyses were performed on HU after achievement of partial or complete remission.

**Results:**
In all pts, mean levels of Neu-Plt and Mo-Plt aggregates at diagnosis were significantly elevated in comparison to control values (22.9% vs 8.9% and 13.0% vs 5.2% respectively, p<0.01). Mean concentration of soluble E-, L- and P-selectins were significantly higher in Ph-MPN than in control group (34.2 ng/mL vs 19.0 ng/mL; 274.8 ng/mL vs 1322.0 ng/mL and 294.0 ng/mL vs 69.8 ng/mL, respectively, p<0.01). Mean levels of Neu-Plt and Mo-Plt aggregates in response to therapy were significantly reduced compared to baseline levels (Figure). Significant reductions were observed for E-selectin levels in all three therapy groups and for P-selectin levels in HU and HU+ASP groups (Table). During the median follow up of 39 months from diagnosis of Ph-MPN, thromboembolic events occurred in 13.3% of pts (12/90), particularly: 0/7 on HU, 3/50 on ASP, and 9/28 on HU+ASP. In this subgroup we observed increased baseline levels of Neu-Plt and Mo-Plt as well as increased Aggregates levels in 9/12 pts, while all 12 pts who had increased levels of selectin, predominantly P-selectin. Retesting revealed that all 9 pts had thrombosis and increased Aggregates level at baseline, normalized those levels after therapy, while only 4/12 pts normalized soluble selectin levels.

**Background:**
Although the reduction of thrombotic risk is a primary goal of therapy in Philadelphia negative myeloproliferative neoplasms (Ph-MPN), even low risk patients (pts) may experience thrombotic events during the course of the disease. Some recent studies revealed a correlation between the occurrence of thrombosis and activation of blood and endothelial cells. However, not much information is available about influence of therapy on these parameters. Aims: We prospectively analyzed the levels of leukocyte-platelet (Le-Plt) aggregates, together with levels of soluble selectins, in a group of pts with Ph-MPN at diagnosis and during therapy. Methods: Our study included 90 consecutive de novo Ph-MPN pts (37 polycythemia vera, 27 essential thrombocythemia, 26 primary myelofibrosis), diagnosed according to WHO criteria. According to therapy, pts were assigned as: hydroxyurea (HU) 7.8%, aspirin (ASP) 55.6%, hydroxyurea+aspirin (HU+ASP) 31.1%, although 5.6% of pts were without therapy. Neutrophil-platelet (Neu-Plt) and monocyte-platelet (Mo-Plt) aggregates were determined in whole blood samples (EDTA/CTAD) by flow cytometry. Aggregates were estimated as fraction (%) of CD42b+CD61+ neutrophils and monocytes. Plasma levels of E-, L- and P-selectin were determined by enzyme immunoassay. All analyses were performed on HU after achievement of partial or complete remission. Results: In all pts, mean levels of Neu-Plt and Mo-Plt aggregates at diagnosis were significantly elevated in comparison to control values (22.9% vs 8.9% and 13.0% vs 5.2% respectively, p<0.01). Mean concentration of soluble E-, L- and P-selectins were significantly higher in Ph-MPN than in control group (34.2 ng/mL vs 19.0 ng/mL; 274.8 ng/mL vs 1322.0 ng/mL and 294.0 ng/mL vs 69.8 ng/mL, respectively, p<0.01). Mean levels of Neu-Plt and Mo-Plt aggregates in response to therapy were significantly reduced compared to baseline levels (Figure). Significant reductions were observed for E-selectin levels in all three therapy groups and for P-selectin levels in HU and HU+ASP groups (Table). During the median follow up of 39 months from diagnosis of Ph-MPN, thromboembolic events occurred in 13.3% of pts (12/90), particularly: 0/7 on HU, 3/50 on ASP, and 9/28 on HU+ASP. In this subgroup we observed increased baseline levels of Neu-Plt and Mo-Plt as well as increased Aggregates levels in 9/12 pts, while all 12 pts who had increased levels of selectin, predominantly P-selectin. Retesting revealed that all 9 pts had thrombosis and increased Aggregates level at baseline, normalized those levels after therapy, while only 4/12 pts normalized soluble selectin levels.
HEAT SHOCK PROTEIN 27 EXPRESSION IS INCREASED IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS AND MAY BE AFFECTING THEIR SURVIVAL


1Hematology department, 2Clinical Institute of Laboratory Diagnosis, Division of Molecular Diagnosis and Genetics, 3Department of Clinical Cytology and Cytometry, 4Pathology department, University Hospital Dubrava, Zagreb, Croatia

Background: Increased heat shock protein 27 (HSP27/HSPB1) expression and phosphorylation were observed in a large number of neoplastic diseases and they have mostly been associated with aggressive disease features and poor prognosis. There are only few reports investigating HSP27 in primary myelofibrosis (PMF), a myeloproliferative neoplasm characterized by high inflammatory state reflecting in debilitating clinical symptoms.

Aims: To analyze HSPB1 mRNA expression in patients with PMF and secondary myelofibrosis (SMF) and to correlate it with clinical and hematological features.

Methods: We analyzed HSPB1 relative expression in bone marrow aspirates of 26 patients with PMF, four patients with SMF and 13 controls using quantitative real time polymerase chain reaction (RT-PCR). Spleen size was assessed by palpation. Association with overall survival was analyzed in 27 PMF and SMF patients evaluated at the time of diagnosis. The Kuusalu-Wallits one way analysis of variance, The Mann Whitney U test, the Chi squared test, the Spearman rank correlation, the log-rank test and the Cox regression analysis were used, cut-off point for survival analyses was determined using the ROC curve analysis.

Results: Relative expression of HSPB1 differed significantly between diagnoses (P<0.001); it was significantly higher in patients with PMF and SMF than in control group (P<0.05 for both comparisons), but did not differ between PMF and SMF patients (non significant). Increased expression was associated with increase in the spleen size (P=0.009) and JAK2 V617F mutation (P=0.073). We did not detect significant associations with other disease specific features. Lower HSPB1 expression was associated with inferior overall survival in both univariate (HR 3.2; P=0.04) and multivariate analysis (HR 6.12; P=0.034) where effect was independent of age (non significant), gender (non significant) and the International Prognostic Scoring System (IPSS) score (HR 3.31; P=0.033).

Figure 1.

Summary/Conclusions: We have found elevation of blood and endothelial cell activation markers at baseline in Ph-MPN. Cytoreductive and antiaggregatory therapy reduced the mean level of Le-Plt aggregates and concentration of soluble selectins. In subset of pts with thrombosis, therapy lead to normalization of Le-Plt aggregate levels, with incompletely normalized soluble selectin levels. Even with normal Le-Plt aggregates, observed elevated selectin levels can explain persistent thrombotic risk due to intrinsic changes in relationship between blood and endothelial cells as a part of biology of Ph-MPN itself.

E1329
NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERATION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMOCYTHAEMIA MYELOFIBROSIS
B. Li1,*, Z. Xu1, T. Qin1, Y. Zhang1, J. Liu1, Z. Xiao1
1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China

Background: It is a consensus that the driver mutation is an independent prognostic factor in PMFs. Moreover, some non-driver mutations are found associated with initial, progression and prognosis in PMFs. However, a recent study from the AGIMM (AIRC- Gruppo Italiano Malattie Mieloproliferative) group showed that the type of driver mutation did not influence prognosis in post-PV/ET MF. These observations proved that there were indeed some differences in these two types of MF.

Aims: The aim of current study was to describe the non-driver mutation landscape and the molecular differences between the patients with PMF and those with post-PV/ET MF.

Methods: Targeted gene sequencing was carried out at diagnosis. We sequenced 190 genes across 62 patients, resulting in 229 high-confidence mutations. The average gene coverage was 95%. The average read depth was 540×. Also, 92% of targeted regions were covered with >20×. Every mutation identified in this study was then compared against these expected patterns and categorized into “oncogenic,” “possible oncogenic variants,” or “unknown significance”. Using copy number-adjusted VAF, we reconstructed the clonal architecture to establish whether a mutant gene was an ancestral or subclonal mutation. According to the statistically differences in VAF among gene mutations, subjects were classified as two different clonal architecture, namely clone+subclone(s) (P<0.05) or clonal.

Results: In PMFs, 42 (93.3%) patients had at least one non-driver mutation. Within the 17 patients lacking the driver mutations in JAK2/1617Fexon 12, MPLW515 and CALR, 2 had mutant genes (SH2B3 and PIAS3) involving in JAK-STAT pathway, 13 had mutations in other genes and 2 had no mutations. In Post-MFs, non-driver mutations were detected in 16 (94.1%) patients. There are no differences in the median number of non-driver mutations in PMFs vs. post-PV/ET MFs (3 vs. 3.18, P=0.865) and PMF patients with vs. without driver mutations (3 vs. 3.18, P=0.668). In PMFs, 12 non-driver genes were mutated in >5% of patients, namely ASXL1 33.3%, U2AF1 22.2%, TET2 15.6%, FAT1 15.6%, SETBP1 13.3%, SRSF2 8.9%, CUX1 8.9%, EP300 8.9%, FAT2 6.7%, NOTCH3 6.7%, EZH2 6.7%, and GATA3 6.7%. In post-PV/ET MFs, ASXL1 (41.2%) was the most frequent mutation, followed by TET2 (29.4%), U2AF1 and SRSF2 mutations were significantly more frequent in PMF than in post-PV/ET MF. Moreover, SETBP1 and FAT1 were mutated in PMF more often and not mutated in post-PV/ET MF. Figure 1 A-C show 3 illustrative patients. Clonal architecture was significantly different between PMFs and post-PV/ET MFs (Figure 1D). About 50% PMF patients were classified as clonal, however, most (87.5%) post-PV/ET MF patients were clone+subclone(s). In PMFs, driver mutation was an ancestral mutation with other non-driver mutations in 14 (31.1%) subjects as 2015-R02413 in Figure 1A. Moreover, driver mutation even was a subclonal mutation in 9 (16.7%) subjects as 2015-R02406 in Figure 1B.

Figure 1.

Summary/Conclusions: Both PMF and SMF patients have increased HSPB1 mRNA expression in their bone marrows which is associated with increased spleen size. Surprisingly, higher expression is also associated with improved overall survival which is independent of IPSS score. We speculate this to be due to atheroprotective properties of HSP27.

Table 1.

<table>
<thead>
<tr>
<th>Soluble selectin, µg/ml</th>
<th>HU (n=7)</th>
<th>p</th>
<th>ASP (n=5)</th>
<th>p</th>
<th>HU+ASP (n=26)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>hP-selectin (median)</td>
<td>157</td>
<td>0.016</td>
<td>150</td>
<td>0.034</td>
<td>154</td>
<td>0.031</td>
</tr>
<tr>
<td>lP-selectin (median)</td>
<td>226</td>
<td>0.035</td>
<td>230</td>
<td>0.048</td>
<td>229</td>
<td>0.046</td>
</tr>
<tr>
<td>E-Selectin (median)</td>
<td>238</td>
<td>0.035</td>
<td>232</td>
<td>0.048</td>
<td>236</td>
<td>0.048</td>
</tr>
</tbody>
</table>

E1330

In post-PV/ET MFs, 11 (64.7%) subjects showed that JAK2 mutation as an only ancestral mutation as G121517R00701 in Figure 1c.

Figure 1.

Summary/Conclusions: In conclusion, we found that the differences in non-driver mutation profile and clonal architecture between PMF and post-PV/ET MF. In addition, by applying a 190-gene panel we demonstrated some variants classified as “unknown significance”. And larger sample sizes may enable some of these to be reclassified in the future. The precise role of each mutation and their impact on MPN phenotype will require further studies.

E1331

DETERMINING MEANINGFUL CHANGE IN THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) v2.0 USING A COMBINATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES IN THE COMFORT-I TRIAL

A. Dueck1,*, R. Scherber2,3, H. Kosionek1, B. Langlais1, L. Padmos3, J. Palmere, S. Verostvskc4, J. Sloan5, G. Holly1, R. Mesa3, 1Mayo Clinic, Scottsdale, AZ, 2Oregon Health and Science University, Portland, OR, 3Mayo Clinic, Phoenix, AZ, 4MD Anderson, Houston, TX, 5Mayo Clinic, Rochester, MN, United States

Background: Symptom response was defined in the COMFORT-I trial as a 50% improvement from baseline at week 24 in the Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 total symptom score (TSS; Mesa J Clin Onc, 2013; 0 to 60 scale where 60 represents the worse symptom experience imaginable) with no minimum score requirement at baseline.

Aims: In this analysis of the phase III placebo-controlled COMFORT-I study we used distribution- and anchor-based approaches to investigate whether alternative change scores in the MFSAF v2.0 TSS could be meaningful relative to patient-reported quality of life (QOL).

Methods: One third and one half of the pooled standard deviations (SD) of scores and change scores (raw and percentage change) were used as distribution-based estimates. The anchor-based approach estimated meaningful changes (raw and percentage change) relative to the patient’s change in global health status/QOL (GH/QOL; 0=worst, 100=best) as measured by the EORTC QLQ-C30 where a decrease of 12.1 or more points was considered as deterioration; an increase of 7.6 or more points was considered as improvement; and all other changes were considered as stable based on change scores established in a multiple myeloma population (Kvam et al., Eur J Hem, 2011). Analysis of covariance (ANCOVA) was used to investigate whether estimated meaningful changes were consistent across the spectrum of observed baseline TSS. This model of TSS changes at week 24 included a continuous term for baseline TSS, a 3-level grouping factor for GH/QOL change (deterioration vs stable vs improvement), and an interaction term between baseline TSS and the GH/QOL grouping factor.

Results: 301 patients randomized to ruxolitinib [N=149] or placebo [N=152] completed TSS at baseline (45% female, median age 68 [range 40-91]). Median baseline TSS was 16.8 (range 0 to 52.7). Pooled SD at baseline and week 24 in TSS was 11.4 and 11.6, respectively, resulting in estimated meaningful changes of 3.8-5.8 points. For change and percentage change from baseline at week 24 in TSS, the pooled SDs were 9.8 and 75%, respectively, resulting in estimated meaningful changes of 3.3-4.9 points or 25%-38%. Among patients with TSS and QLQ-C30 data at baseline and week 24, 51 (23%) patients had deterioration, 61 (27%) were stable, and 110 (50%) had improvement based on QLQ-C30 GH/QOL changes. Mean (95% CI) changes in TSS for the three groups were 0.8 (-2.5 to 4.2), -1.4 (-3.8 to 0.8), and -6.8 (-9.0 to -4.6), and for percent changes 20% (-8% to 46%), 17% (-11% to 44%) and -34% (-45% to -22%). ANCOVA revealed that baseline TSS statistically significantly impacted meaningful change estimates (p=0.02). Figure 1 shows the estimated mean (95% CI) changes in TSS for the improved group of -20.8 (-26.4 to -15.1), -11.7 (-14.3 to -9.0), and -2.6 (-5.1 to -0.1) for baseline TSS of 50, 30, and 10.

Summary/Conclusions: Distribution- and anchor-based approaches suggest that changes as small as 3-6 points on a 0-60 scale of the MFSAF v2.0 TSS may be meaningful to patients. However, estimates of meaningful change appear to increase in magnitude for higher baseline scores, though in a way that a static percentage change criterion would either require too much change for lower baseline TSS or not enough change for higher baseline TSS. All analyses suggest that some changes in symptoms which do not meet a 50% improvement may still be meaningful to patients.

E1332

ERYTHROPOIESIS STIMULATING AGENTS CAN IMPROVE ANEMIA IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB

E. Crisà1,*, C. Daniela2, E.M. Elli3, E. Beggiato1, C. Frairia4, M. Cerrano1, G. Lanzarone1, M. Marchetti5, M. Mezzabotta6, M. Boccadoro1, D. Ferrero1

1Hematology Division, A.O. Città della Salute e della Scienza di Torino, University of Turin, 2Department of Clinical and Biological Sciences, University of Turin, 3Hematology Division, Ospedale San Gerardo, ASST Monza, 4Hematology, A.O. Ospedale Maggiore di Novara, Novara, 5SOC Oncologia, Ospedale Cardinal Massaia, Asti, 6Hematology Division, Ordine Mauriziano - Ospedale Umberto I, Torino, Italy

Background: Anemia is common in patients with myelofibrosis (MF) and it is one of the main cause of symptoms in this setting. Erythropoiesis stimulating agents (ESA) have been used in MF but mostly small series and no randomized trials have been published so far. Anemia response rate ranged between 23 and 60% in different reports (Cervantes et al. BJH 2004; Cervantes et al. BJH 2006; Tsira et al., Acta Haematologica 2007) and a larger study recently published by Cervantes group on 163 patients (Hernandez-Boluda JC. E et al, EJH 2016) showed a response rate of 50%. Ruxolitinib is currently approved for the treatment of intermediate 2 or high DIPSS/1PS2 risk MF and it is highly effective in reducing spleen size and controlling the symptoms of MF, thus resulting in a marked improvement in the patients' quality of life (Verstovsek S. et al, NEJM 2012). Harrison C. et al, NEJM 2012) and possibly a prolonged survival (Cervantes F. et al Blood 2016). However, one of ruxolitinib main side effects is anemia, which occurs in 40% of the patients and can be a limiting factor for treatment tolerability and thus compliance and optimal dosage, mostly in the first weeks of treatment.

Aims: To evaluate the efficacy and safety of combination therapy with ruxolitinib and ESA.

Methods: We retrospectively evaluated 32 patients who received concomitant therapy with ruxolitinib and ESA. ESA (epoetin alpha or zeta or darbepoetin) were given off-label after obtaining patient written consent and local pharmacy approval. Erythroid response was defined as transfusion independence with normal haemoglobin (HB), transfusin decrease of >50% or sustained HB increase of >2g/dl, partial response as a sustained HB increase of 1-2g/dl.

Results: We included 32 patients diagnosed with MF, 23.1% primary,36,4% secondary to PV and 42.3% to TE. 20 patients (62.5%) were male and median age at ESA start was 70 years (range 41-80). 87% of patients were an-cinate 2 and 13% at high risk according to DIPSS. Fifty-nine% of patients received epoetin alpha, 28% darbepoetin and 13% epoetin zeta. Median dose for epoetin alpha/zeta was 40000 U/week and for darbepoetin 150 mcg/week. Seven patients had started ESA treatment before ruxolitinib therapy, whereas 25 patients received both concomitantly, after ruxolitinib stabilization and prior to commencing or worsening of anemia. In particular, 5 were already RBC transfusion dependent before commencing ruxolitinib while 13 patients required red blood cell (RBC) transfusions only after treatment start. Overall ruxolitinib treatment worsened anemia leading to RBC transfusion requirement in 52% of patients. Median ESA start was 8.5 weeks (range 2.2-10.5). ESA treatment was not stopped due to ESA transfusion dependent. Median basal endogenous erythropoietin level was 58 UI/l (range 8-146 UI/l). Overall response rate was 87.6%, with 68.8% of erythroid response and 18.8% of partial response. Median time to response and median...
response duration were 4 and 31 months respectively. 23% of patients lost response after a median time of 16 months. Seventy-five% of patients responded to ruxolitinib in terms of spleen size, of whom 86.4% also achieved an erythroid response to ESA. A spleen increase during ESA treatment in patients responding to ruxolitinib was observed in 2 patients only.

No thrombotic events and no toxicity were reported over treatment with ESA. Successful treatment was effective in improving anemia in MF patients treated with ruxolitinib. We observed a high response rate in this patients series without significant toxicities. In particular no thrombotic event or no negative impact on response to ruxolitinib was reported. This results may be partially explained by the selection of patients with endogenous erythropoietin level below 250 U/l, but they could also suggest synergistic activity of ESA and ruxolitinib.

E1333
COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1–, INTERMEDIATE-2–, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY
F. Passamonti1–3, V. Gupta2, B. Martino3, L. Foltz4, A. Zaritksey5, H.K. Al-Aji6, R. Tavares7, M. Maffioli8, P. Raanan9, P. Giraldo10, M. Griesshammer11, C. Bouard12, J. Perez Ronco12, R. Tiwar113, A. M. Vannucchi14 1University of Insibria, Varese, Italy, 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada, 3Azienda Ospedaliera Bianchi-Melacrinino-Morelli, Reggio Calabria, Italy, 4St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada, 5Federal Almazov Medical Research Center of the Russian Ministry of Health, St. Petersburg, Russia, 6University Hospital of Halie, Halle (Saale), Germany, 7Universidade Federal de Goiania, Goiania, Brazil, 8Ospedale di Circolo e Fondazione Macchi, Varese, Italy, 9Rabin Medical Center, Petah Tikva, Israel, 10Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza, Spain, 11Johannes Wesling Clinic, Minden, Germany, 12Novartis Pharma AG, Basel, Switzerland, 13Novartis Healthcare Pvt. Ltd, Hyderabad, India, 14CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Background: RUX is a potent JAK1/JAK2 inhibitor that led to improvements in splenomegaly and symptoms and increased overall survival in pts with intermediate (Int)-1–, Int-2– and high-risk MF by the International Prognostic Scoring System (IPSS) in the phase 3 COMFORT studies. JUMP is a large, phase 3b, expanded-access trial in countries with no access to RUX outside a clinical trial and includes pts with IPSS Int-1–, Int-2–, and high-risk MF. To further evaluate RUX, we conducted an analysis assessing safety and efficacy of RUX by Dynamic IPSS (DIPSS) prognostic risk.

Aims: To compare the safety and efficacy of RUX in pts with DIPSS low/Int-1– vs Int-2– vs high-risk MF.

Methods: Eligible pts had IPSS high- or Int-2–risk MF, or Int-1–risk MF and a palpable spleen (>25 cm). Starting dose was based on baseline platelet (PLT) count (5mg bid [≥200x109/L], 15mg bid [100-200x109/L], or 20mg bid [>200x109/L]) and could be titrated during treatment. The primary endpoint was safety and tolerability of RUX. Changes in palpable spleen length and symptom scores were also assessed. DIPSS scores were determined using pt characteristics at baseline.

Results: Based on available pt data, DIPSS status was determined for 1840 of 2233 enrolled pts. JUMP included 893 low/Int-1–, 754 Int-2–, and 193 high-risk pts (primary MF, 57%, 63%, 62%) who started treatment ≥1 y before data cutoff (01 Jan 2016). Pts with higher-risk MF were older (62, 68, and 72 y), had lower Hb (<10 g/dL, 3%, 64%, 100%), and had higher blast counts (≥1%, 18%, 44%, 85%). Disease duration (50, 51, and 55 mo) and spleen size (12, 13, and 14.5 cm) were similar in all 3 groups. Most pts started at 20mg bid (68%, 57%, 59%) or 15mg bid (26%, 32%, 33%). Median exposure was 16, 11, and 29 mg. At data cutoff, most pts remained on treatment or had completed per protocol (70%, 56%, 45%). Main reasons for treatment discontinuation included adverse events (AEs; 15%, 17%, 15%) disease progression (6%, 11%, 11%), and death (2%, 5%, 11%). The most common hematologic grade 3/4 AEs were anemia (22%, 44%, 55%) and thrombocytopenia (11%, 18%, 25%), but these rarely led to discontinuation. Overall rates of nonhematologic grade 3/4 AEs were <2%, except for pneumonia (4.5%), pyrexia (2.3%), asthenia (2.2%), and dyspnea (2.2%). Infections in ≥5% of pts were pneumonia infection (6%), and nasopharyngitis (5.3%). Herpes zoster was reported in 4.8% of pts. At wk 48, 64% (226/355), 52% (121/232), and 50% (26/52) of pts had a ≥50% reduction from baseline in spleen length; 19% (68/355), 19% (43/232), and 23% (12/52) had ≥50% reductions. Best response in spleen length by wk 72 is shown in the Figure: 69%, 57%, and 51% of pts achieved ≥50% reductions. Median time to response was 4.7 wk (2.3-75 wk), 5.3 wk (2.6-80 wk), and 8.1 wk (3.1-72.3 wk). From wk 4 to wk 48, 39%, 43%–44%, and 48%–49% of pts achieved a clinically meaningful response on the FACT-Lym TS; proportions of responders on the FACT-Fatigue were 42%–49%, 46%–49%, and 55%–61%.

Figure 1.

Summary/Conclusions: RUX was safe and generally well tolerated. Interestingly, lower-risk pts received higher starting doses yet had lower rates of hematologic AEs. Additionally, lower-risk pts remained on treatment longer than higher-risk pts, with fewer discontinuations due to AEs. Lower-risk pts also achieved slightly better spleen size reductions and symptom improvement than higher-risk pts, suggesting that earlier RUX treatment may lead to greater benefits in pts with MF.

E1334
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10mg BID AND HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY
were based on baseline platelet (PLT) counts (≥50 to <100×10⁹/L, 100 to
Pts with high-, Int-2–, or Int-1–risk MF were eligible. Int-1–risk pts
in pts with MF.

Aims: A small cohort of pts in JUMP started at 10mg bid, and had the dose uptitrated during the first 8 wks to a mean average daily dose comparable to those of pts starting at higher doses, leading to safety and effi-
cacies consistent with those in the overall JUMP population. This alter-
native approach will be prospectively evaluated in anemic MF pts in the REALISE study (NCT029666353).

E1335 HYDROXYUREA IS ASSOCIATED WITH SKIN TOXICITY IN MYELOPRO-
FERATIVE NEOPLASMS: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL STUDY
F. Stiegelmann1,*, K. Wille2, S. Schauer1, H. Döhner3, K. Döhner1, M. Grieshammer2
1University Hospital of Ulm, Ulm, 2University of Bochum, Minden, Germany

Background: Until today, hydroxyurea (HU) remains the most commonly used cytoreductive drug in patients (pts) with classic myeoproliferative neoplasms (MPN), i.e. essential thrombocythemia (ET), polythemic vera (PV), and myelofibrosis (MF). However, mucosal lesions, cutaneous ulcers, and pre-carcinomatous skin alterations such as actinic keratoses are being considered as potential side effects of HU.

Aims: We sought to investigate the occurrence of skin toxicity in MPN pts under HU compared to other (non-HU) cytoreductive drugs in routine clinical practice.

Methods: Classic MPN pts regularly presenting at the outpatients centers of the University Hospital of Ulm and Johannes Wesling Clinic Minden were includ-
ed in our non-interventional study after having given informed consent. Skin alterations were evaluated prospectively between December 2010 and Novem-
ber 2016.

Results: In total, 151 MPN pts under cytoreductive therapy were included (ET, n=55; PV, n=55; MF, n=41). Primary MPN diagnosis was made between 1979 and 2012 at a median age of 55 years (range, 22-82). Median duration of the disease at baseline of the study was 6.3 years (0-32.6). Median prospective observation time for the total cohort within the study period was 5.3 years (0.4-
6.2). Most frequently used cytoreductive drugs were HU in 120 pts, followed by ruxolitinib in 9, anagrelide in 39, and pegylated Interferon-alpha (IFN-a) in 28 pts. Median cumulative HU exposure was 46 months (1-252), while the median cumulative treatment time for the corresponding drug in the HU pts was 24 months (1-267) [ruxolitinib: 22 months (2-64); anagrelide: 19 months (1-216); IFN-a: 64 months (1-267)]. Of 120 pts exposed to HU, 52 pts (43%) presented with skin abnormalities during the observational period occurring after a total HU treatment time of median 46 months (1-252). Sixteen of 120 pts (13%) discontinued HU due to skin toxicity (basal cell carcinoma, n=3; malignant melanoma, n=1). Although pts of the HU cohort were exposed longer to the drug compared to pts of the non-HU group, numbers of skin events in non-HU treated pts as follows: n=5 under IFN-a (local reaction after subcutaneous injection, n=3; actinic keratosis, n=1), and none under ruxolitinib. In 31/26 (2%) non-HU treated pts, occurrence of skin toxicity led to discontinuation of the corresponding cytore-
ductive drug. Interestingly, both skin ulcers as well as the single events ‘basal cell carcinoma’ and ‘actinic keratosis’ occurred under combination therapy with HU. Taken together, skin alterations occurred more frequently under HU compared to non-HU treatment (52/120 [43%] vs 9/126 [7%]; p=0.0001), and the

Summary/Conclusions: According to our prospective observation, skin toxicity was clearly associated with HU treatment compared to other cytoreductive drugs. This resulted in a higher rate of HU treatment termination due to skin toxicity. However, median exposure time to HU was longer compared to 126 pts with non-
HU treatment, and controlled clinical trials are necessary to provide more pre-
cise data on the occurrence and severity of skin toxicity under HU.

E1336 THE NEGATIVE PROGNOSTIC IMPACT OF BASOPHILIA, EOSINOPHILIA
AND MONOCYTOSIS AT DIAGNOSIS IN PRIMARY MYELOFIBROSIS
M. Pereira1,2,*, K. Hundarova2, J. Carda1,2, E. Cortesão1,2, R. Guilherme1,2, L. Ribeiro1, A.-B. Sarmento-Ribeiro1,2
1Clinical Hematology Department, Coimbra University Hospital Centre, 2Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Background: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) with a variable clinical presentation, from asymptomatic disease to rapidly progressive bone marrow failure and/or leukemic transformation; prognostic stratification using the DIPSS-plus score isolates patient cohorts with median survival ranging from 16 months to 185 months. The development of monocytosis during the course of PMF has been associated with a worse outcome, and absolute monocyte counts have been shown to be of prognostic value in other MPNs. Basophilia and eosinophilia are frequent findings in BCR-ABL-
positive MPNs, where they associate with an accelerated phase of disease, and seem to correlate with worse survival in myelodysplastic syndromes. However, the impact of these three findings at diagnosis in PMF remains unclear.

**Aims:** The aim of this work is to evaluate, at diagnosis, the prognostic impact of basophilia, eosinophilia and monocytosis in patients with PMF.

**Methods:** We identified all PMF patients diagnosed and followed-up in our Centre between January 1st 2005 and August 31st 2016 who still fulfill PMF criteria under the WHO 2016 diagnostic revision, have synchronous bone marrow (BM) and peripheral blood (PB) analyses dating from the time of diagnosis, and have complete charts with no missing data. After the exclusion of reactive causes, monocytosis was defined as an absolute count (AC) >1.0 G/L, eosinophilia an AC>0.6 G/L and basophilia an AC>0.2 G/L.

**Results:** We studied 55 evaluable patients (73% male) with a median age at diagnosis of 70.1±11.7 years old. At diagnosis, 20% of patients had monocytosis, with no significant differences according to gender or age. The median overall survival (OS) in PMF patients with monocytosis was 27.3 months, and twice as long (46.4 months) in patients without. A new calculated cut-off of 0.75 G/L was better able to stratify patients according to survival with a specificity of 74.1% (95% CI: 53.7-88.8%); 32.7% of patients had an AC above the cut-off, with a median OS of 27.9 months, compared to 64.4 months for patients under the cut-off. We identified 12.7% of patients with eosinophilia at diagnosis, with no differences according to gender or age. PMF patients with eosinophilia had a five-fold lower median OS compared with patients without (6.1 vs 32.5 months, respectively). We obtained a new cut-off of 0.25 G/L of eosinophils, which separated patients with a specificity of 77.8% (95% CI: 57.7-91.4%); 29.1% of patients had an eosinophil AC above the cut-off, with a median OS of 25.6 months, and 32.5 months in patients without. With a new cut-off of 0.25 G/L of basophils, with a specificity of 88.9% (95% CI: 70.8-97.64%), 20.0% of patients had a basophil AC above the cut-off and a median OS of 19.7 months, compared to 46.4 months for patients under the cut-off. Considering the whole cohort, 61.8% of patients had normal monocyte, eosinophil and basophil ACs; the median OS in these patients was 56.1 months, compared to 28.5 months in patients with an increase in at least one AC. Applying the new cut-offs, this difference in OS increased to 27.9 vs 64.4 months. Progression-free survivals were not calculated, since only 2 patients had BM- or PB-documented progression during follow-up.

**Summary/Conclusions:** We observed that the presence of monocytosis at diagnosis in PMF was associated with a halving of the median OS, while eosinophilia decreased the median survival to one-fifth; basophilia also contributed with a reduction in survival, of approximately 20%. The application of specific cut-offs calculated for the cohort improved the differentiation and stratification of patients, with moderate to high specificity, further clarifying the negative prognostic impact of these three variables, at diagnosis, in PMF. Our results show that even simple, inexpensive and readily available parameters can be used to predict survival in PMF patients, and suggest that their integration into established scores could further increase the prognostic accuracy of the latter.

**E1337**

**BLAST PHASE IN PH-NEGATIVE MYELOProliferative NeoplasmS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF 85 PATIENTS**

E. Roncoroni1, M. Bellini2, E. Rumi2, V. Ferretti1, D. Pietra1, C. Cavalloni1, M. Ciboddo2, I. Casetti2, P. Zappasodi1, P. Benvenuti2, C. Astori1, M. Cazzola1,2

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 2Department of Molecular Medicine, University of Pavia, Pavia, Italy

**Background:** Classic Ph-negative myeloproliferative neoplasms (MPN) include essential thrombocythaemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Clonal evolution can lead MPN patients in chronic phase (CP) to develop acute myeloid leukaemia (AML), called blast phase (BP); this event occurs at rates of approximately 1% in ET, 4% in PV and 20% in PMF over the first decade from MPN diagnosis. We observed that the presence of monocytosis at diagnosis in PMF was associated with a halving of the median OS, while eosinophilia decreased the median survival to one-fifth; basophilia also contributed with a reduction in survival, of approximately 20%. The application of specific cut-offs calculated for the cohort improved the differentiation and stratification of patients, with moderate to high specificity, further clarifying the negative prognostic impact of these three variables, at diagnosis, in PMF. Our results show that even simple, inexpensive and readily available parameters can be used to predict survival in PMF patients, and suggest that their integration into established scores could further increase the prognostic accuracy of the latter.

**E1337**

**TELOMER LENGTH IS REDUCED IN ESSENTIAL THROMBOCYTHAEMIA PATIENTS COMPARED TO AGE AND GENDER MATCHED HEALTHY CONTROLS**

S. Alimam1, J. Jie2, D. McLornan2, D. Radia1, G. Mufii2, C. Harrison1

1Haematology, Guys and St Thomas’ NHS Foundation Trust, 2Haematology, King’s College London, London, United Kingdom

**Background:** Essential thrombocythaemia (ET) is a clonal stem cell disorder, commonly diagnosed in the 6th or 7th decade of life. ET is associated with risk of thromboembolic events, hemorrhage, constitutional symptoms, progression to myelofibrosis and acute myeloid leukaemia. In over 85% of patients a clonal driver can be identified with mutations in JAK2 (50-60%), CALR (25-30%) or the thrombopoietin receptor (MPL) (3-5%); the remainder of patients are termed “triple negative” (TN). Telomeres are non-coding regions of DNA consisting of thousands of repeated sequences (TTAGGG) and are considered central to chromosomal integrity and genomic stability. In healthy adults, telomere length (TL) progressively shortens with age; therefore, TL is considered a marker of aging and genome stability. Hematopoietic cells in several hematological malignancies have been shown to be characterized by shortened TL.

**Aims:** Determine if there is TL shortening in patients with ET when compared to age and gender matched controls and establish the effects of cytoreductive therapy on TL in ET (JAK2 V617F and CALR mutated patients).

**Methods:** 100 patients were included in the study (27 with CALR, 35 JAK2V617F and two MPL515W mutations. 36 patients were TN). Most patients were female (70% 70/100); median age was 45 years (range 20 - 86 years).
TL was determined in peripheral blood mononuclear cells using a monochrome multiplex quantitative PCR based on the original methods described by Cawthon. All results were corrected for age and gender.

Results: Regardless of driver mutation status ET patients had significantly shortened TL compared with age and gender matched controls, p=0.0001. Considering individual mutation status these differences remained significant e.g. in JAK2(V617F) positive patients, TL was 0.007 and p=0.012 in TN patients. TL appeared more markedly short in the CALR cohort; for the 18 patients, whose TL was below the first centile, 55% (10/18) were CALR positive vs 28% (5/18) JAK2(V617F) positive vs 17% (3/18) who were TN. Concerning the potential impact of therapies 31/100 patients were treated with hydroxyace- tal (HOAC, eight of these had prior exposures to HC), 34/100 were not on cytoreductive therapy. Remaining treatments were ruxoli- tinib (5), busulphan (4), anagrelide (1) and vorinostat (1). Independent of mutation status there was significant TL shortening in untreated patients, p=0.05; however, upon evaluating the impact of cytoreductive therapy on TL we noted that ET patients with either current, or prior treatment had significantly short- ened TL, p=0.0015 and p=0.0001 respectively. Strikingly, there was no significant difference in TL in IFN patients who had no previous exposure to HC, p=0.2 but those ET patients currently on IFN but with prior HC exposure still had short TL.

Summary/Conclusions: We document for the first time that ET patients, when compared to age and gender matched healthy controls, have shortened TL. This shortening is more pronounced in CALR and JAK2(V617F) positive patients. Concerning therapy whilst present in untreated patients TL shortening was more pronounced in HC treated patients indicating that there may be a therapy effect as has been observed after HC treatment in sickle cell disease. Of note IFN treated patients had more normal TL suggesting that the disease related TF effects may be reversed by this agent.

E1339
NUTRITIONAL STATUS IN MYELOFIBROSIS: CORRELATES FROM THE COMFORT-1 STUDY
R. Scherber1,2,7, H. Kosiorsek3, H. Geyer4, S. Verostovský5, B. Langlais3, L. Padrones3, J. Palmer1, A. Dueck3, A. Fleischman6, R. Mensa1
1Hematology and Oncology, Mayo Clinic, Scottsdale; 2Hematology and Oncology, Oregon Health and Science University, Portland; 3Biostatistics, Internal Medicine, Mayo Clinic, Scottsdale; 4Hematology and Oncology, MD Anderson, Houston; 5Hematology and Oncology, University of California Irvine, Irvine, United States

Background: Nutritional status declines in most patients with myelofibrosis (MF). Sixty-seven percent of patients with MF lose weight over time and 27% of patients have a BMI decrease of at least one body mass index (BMI) category (Mesa et al. Blood. 2008;112(11):5224). MF also leads to deficient LDL and cholesterol levels compared to age matched controls (Mesa R A et al. Blood. 2007;110(11):2548). Both hypcholesterolemia (p<0.001) and weight loss>10% (p<0.001) have been associated with decreased survival in PMF patients (Mesa et al. Blood 2009 114:3918). JAK inhibitor therapy has been found to improve nutritional markers including weight, cholesterol, albumin, and leptin compared to placebo in the COMFORT-1 study (Mesa et al. Clin Lymphoma Myeloma Leuk. 2015 Apr; 15(4): 214–221; Verostovský et al. N Engl J Med 2012; 366:799-807). However, the correlation of these factors with other disease related variables and overall survival has not been established.

Aims: To evaluate the correlation, if any, between nutritional markers other variables collected in the COMFORT-1 study.

Methods: Data from the COMFORT-1 trial of ruxolitinib versus placebo was obtained from the Incyte for independent analysis. Data was analyzed for correlation with symptom burden and survival along with other variables. Symptom burden was assessed by the MF-SAF v2.0 (Mesa et al. Leuk Res 2009) for individual items and total symptom score (TSS).

Results: A total of 309 patients were available for analysis including 155 ruxolitinib treated and 154 placebo treated MF patients. At baseline, the average BMI was 24.9 (SD=4.5). Baseline demographic and other disease-related variables collected in the COMFORT-1 study.

Aims:

E1340
IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE PATIENTS
Tusaro1, A. Andrianov2, M. Scolari3, G. Santoro4, F. Spirito5, S. Leonetti6, Crescenzio7, R. Porrima8, A. Di Veroili9, N. Villiav8, A. Spadea8, A. Rago1, C. De Gregoris11, M. De Muro12, S. Felici13, M. Breccia13, E. Montefusco14, A. Bagnato15, G. Cimino16, M. G. Mazzucconi17, R. Latagliata18
1Department of Hematology, Belcolle Hospital, Viterbo, 2UOSD of Hematology, ASL Roma1, Ospedale Sante Spirito & Nuovo Regina Margherita, 3Department of Hematology, S. Giovanni Addolorata Hospital, 4Department of Cellular Biotechnology and Hematology, University of Rome “Sapienza”, 5Department of hematology and bone marrow transplantation, Azienda ospedaliera San Camillo-Forlanini, 6Department of Hematology, Azienda ospedaliera Sant’Andrea, 7Department of Hematology, University “Tor Vergata”, 8UOSS of Hematology, ASL Roma1, 9Department of Hematology, Regina Elena National Cancer Institute, Rome, 10Department of Hematology, Polo Universitario Pontino, Latina, 11Department of Hematology, Belcolle Hospital, Viterbo, 12Department of Hematology, Polo Universitario Pontino, Latina, 13Department of Cellular Biotechnology and Hematology,, University “La Sapienza”, 14Department of Hematology, Azienda ospedaliera Sant’Andrea, Rome, 15Department of Hema- tology, S. Giovanni Addolorata Hospital, Roma, 16Department of Hematology, Polo Universitario Pontino, Latina, 17Department of Cellular Biotechnology and Hematology,, University “La Sapienza”, 18Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

Background: To evaluate the prognosis of patients with Essential Thrombo- cytethemia (ET) in the first decade of the century we assessed retrospectively the thrombosis free survival (TFS) and the overall survival (OS) of the patients diagnosed from 01/01/2000 to 31/12/2009 and collected on the database of our group.

Aims: Diagnosis of ET was performed with PVSG, WHO 2001 or 2008 criteria, according to the date of the first observation. The whole population of 757 patients was then divided in two groups: the first (group I) with the diagnosis performed between 01/01/2000 to 31/12/2005 (334 patients), presented a medi- an follow-up of 111,9 months, the second (group II) diagnosed between
CUTANEOUS INVOLVEMENT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS—SINGLE-CENTER EXPERIENCE

J. M. Sanchez-Raga1,2,*, N. Knöpfel3, M.D.M. Escudero-Góngora3, F. Sartori2, B. Lopez1,2, I. Herraez2, M.D.C. Ballester2, M. Torres2, A. Martin-Santiago3, S. Sirhan1,*, C. Ross2, A. Orazi3
1Jewish General Hospital Montreal, Montreal, 2McMaster University, Hamilton, Canada, 3Weill Cornell Medical College, New York, United States

Background: Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) may present clinical dermatological manifestations at the time of diagnosis, as well as during the course of the disease. On the other hand, also its treatments can present skin side effects.

Aims: We have performed a dermatological review of a cohort of patients we follow-up at our center with the aim of assessing the cutaneous manifestations.

Methods: A randomized selection of patients with a diagnosis of essential thrombocytopenia and polycythemia vera was performed. We create a specific consultation in which a detailed history of each patient (sex, age, diagnosis, signs and symptoms, treatments and its duration) as well as a deep dermatological examination was done. All data was collected in an Excel database and analyzed using the SPSS system.

Results: 63 patients (54 ET and 9 VP) were reviewed. The most frequent skin lesions were xerosis and/or keratosis pilaris (76.2% patients), nail changes (41.3%), actinic keratosis (39.7%), hyperpigmentation of the skin (23.8%), pruritus (23.8%) and non-melanoma skin cancer (22.2%). In figure 1 we detail all the skin alterations that we have found.

Summary/Conclusions: Cutaneous involvement in MPNs is more frequent than expected and it is usually underdiagnosed. Some of these lesions could be prevented with the correct treatment of their pathology and adequate photographic measures. The results obtained support the recommendation of an annual review by a dermatologist in a systematic way, especially in patients with higher risk factors: low phototype, high sun exposure, past dermatological history and prolonged cytoreductive therapy.

Figure 1.
presentation with thrombocytosis. No central pathology review was planned for this stage of the study.

Results: A total of 122 patients (58 males and 64 females; 54% >60 years of age; 65% with LDH ≥200 μM/mL) with a clinical history indicative of ET were initially assessed. A majority of patients (76%) presented with suspected ET within the last 5 years, likely because it was more difficult for clinicians to identify patients with SM by biopsies collected within a year of presentation with thrombocytosis if they presented more than 5 years ago. Out of 122 patients, 48 met the hemoglobin and/or leukocytosis criteria outlined in the Carobbio algorithm, Figure. The BM examination was performed on 33 patients who met pre-specified criteria for the timing of bone marrow biopsy. About one third of the 33 patients met the WHO classification for ET and one third for PMF. While 2 of the remaining patients met criteria for PV, the rest were uncertain whether to represent true ET or early PMF, i.e. represented MPN-U (Figure 1).

Summary/Conclusions: Despite its methodological limitations, this initiative confirms that in real world clinical practice the Carobbio algorithm can be used to identify ET and early PMF and can be used in clinical algorithms to separate ET from PMF. It confirms the importance of hematologist-pathologist collaboration in reaching a final integrated diagnosis based on the WHO classification. These findings warrant investigation in larger prospective studies.

E1344
ZMYM2-FLT3 IS A RARE, RECURRENT, CYTOTHERAPIC FUSION IN MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA THAT IS RESPONSIVE TO FLT3 INHIBITION

M. Jawhar1,2, N. Naumann1, M. Knut2, B. Schneider3, M. Ghazzawi4, K.-A. Kreuzer2, M. Hallex3, A. Fabarius1, J. Score4, A. Chase2, W. Tapper2, A. Reiter5, N. Cross2

1Department of Haematology and Oncology, Medical Faculty Mannheim of University of Heidelberg, Mannheim, Germany, 2Faculty of Medicine, University of Southampton, Southampton, United Kingdom, 3Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

Background: Myeloid/lymphoid neoplasms with eosinophilia are characterised by diverse tyrosine kinase (TK) fusion genes, many of which can be effectively targeted by small molecule inhibitors. More than 70 TK fusions have been described, most of which are associated with visible cytogenetic abnormalities. However these fusions are rare, and the pathogenesis of the great majority of patients presenting as myeloid/hematologic neoplasm with eosinophilia (MPN-eo) remains unexplained. We hypothesized that some MPN-eo cases may be driven by hitherto undetected cryptic TK fusion genes.

Aims: To screen cases with MPN-eo for TK fusion genes and evaluate the significance of any novel fusions

Methods: PolyA RNA extraction from MPN-eo cases, RNA-Seq library preparation and 100bp paired-end sequencing was performed with multiplexing for a minimum of 75 million reads/sample using an Illumina HiSeq 2000. Bowtie, TopHat and TopHat-Fusion were used to align reads, resolve splice junctions, identify and filter potential TK fusions. Confirmation and screening of fusions was performed by RT-PCR and Sanger sequencing.

Results: Of 20 cases tested by RNAseq analysis, just one cryptic TK fusion was identified: ZMYM2-FLT3, predicted to arise as a consequence of an 8Mb inversion at 13q12. Unusually, both breakpoints fell within exons (ZMYM2 exon 20 and FLT3 exon 14, respectively) resulting in an in frame fusion. To test if this might be recurrent, we analysed 165 additional cases by RT-PCR. One additional positive case was detected, with similar but not identical breakpoints to the initial case. Case 1, a 48 year old female, presented with leukocytosis (30x10^9/L), eosinophilia (2x10^9/L, elevated serum tryptase (37µg/l), splenomegaly and a hypercellular bone marrow (BM). Cytogenetics was normal and FIP1L1-PDGFRα, KIT D816V and JAK2 V617F were all negative. In no other cases did the eosinophilia have a relationship to cytogenetic abnormalities.

Summary/Conclusions: As predicted by PK modeling and simulations analyzing PK of PAC-400mg QD was associated with higher Cmax and lower Cmin vs PAC-200mg BID in pts with MF from the PERSIST-2 trial. These differences appear to translate into an improved benefit/risk profile of PAC BID vs QD regimens.

Table 1.

| PK/PD MODELING COMPARING DIVIDED DIVING (200mg TWICE-DAILY [BID]) VS SINGLE DIVING (400mg ONCE-DAILY [QD]) OF PACRATINIB (PAC) IN PATIENTS WITH MYELOFIBROSIS (MF) ON THE PERSIST-2 PHASE 3 TRIAL |
|-----------------|-----------------|-----------------|-----------------|
| Cmin (Cminss) at weeks 12 and 24 were higher with BID regimen, and an absorption lag time. PAC QD was associated with higher Cmax and lower Cmin |

E1334
Validating the clinical utility of PK/PD modeling to select the PAC 200mg BID (Table). Median PAC plasma concentrations in myeloid neoplasms but the first FLT3 fusion that is cytogenetically cryptic. In one case presenting as MPN-eo, a novel TK fusion was identified, ZMYM2-FLT3, with a pause of 3 weeks due to pulmonary infection, leukocytes/eosinophils rapidly increased, but no other cases were collected up within weeks after restart of nilotinib. The patient has been maintained on nilotinib for 10 months (since re-start) and remains in complete hematologic remission.
E1345

COMPLETE HEMATOLOGIC AND CYTOGENETIC RESPONSE IN A PATIENT WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 ACTIVATED MYELOPROLIFERATIVE NEOPLASM RECEIVING INCBO54828

N. Daver1,*, V. Subbiah1, E. Asatiani2, S. Verstovsek1
1MD Anderson Cancer Center, Houston, TX, United States, 2Incyte Europe, Geneva, Switzerland

Background: Fibroblast Growth Factor Receptor (FGFR) inhibitors have demonstrated efficacy in solid tumors with FGFR pathway activation. INCBO54828, a novel, highly selective FGFR1, FGFR2, and FGFR3 inhibitor, is being assessed for the treatment of several advanced malignancies (AACR 2015; Abstract 771). 8p11 myeloproliferative syndrome is an aggressive myelo- proliferative neoplasm (MPN) associated with FGFR1 translocation on chromosome 8p11.

Aims: To describe the characteristics of a patient with FGFR1 activated MPN who achieved a complete hematologic and cytogenetic response with INCBO54828 in an ongoing phase 1/2 trial (NCT02393248).

Methods: In this 3-part, phase 1/2 dose-escalation and expansion trial, eligible adults had any advanced solid tumor (parts 1 and 3) or malignancy with FGFR1 FGFR1 activation (part 2). Had Eastern Cooperative Oncology Group performance status score ≤1 (part 1) or ≤2 (parts 2 and 3), and were refractory to prior therapy with no known effective standard therapy available to them. Patients received INCBO54828 orally on a 21-day cycle (2-weeks on/1-week off) starting at 0mg QD and increasing to 13.5mg QD.

Results: This 51-year-old male patient with 8p11 translocated MPN diagnosis (currently the only patient with MPN enrolled in this trial), presented with abnormal white blood cell (WBC) count (eosinophils, 15%; peripheral blood [PB] blasts, 4%) and abnormal platelet count (68×10^9/L). The patient had prior therapy with hydroxyurea. Bone marrow (BM) biopsy at study entry showed 95% cellularity, 1% BM blasts, adequate trilineage hematopoiesis, MF-1 fibrosis, and a complete cytogenetic response. After 4 months of treatment the patient was hospitalized for pneumonia and study treatment was held. The patient progressed to AML shortly after therapy interruption, with BM blasts increasing to 83% and evidence of clonal evolution (47,XY; +8,9,11,12q33 [3]/48 ide5, +19 [17]).

Summary/Conclusions: INCBO54828 showed efficacy in this patient with FGFR1 activated MPN using a 21-day (2-weeks on/1-week off) regimen. Continuous treatment may be necessary to sustain response and avoid rebound as has been seen with other kinase inhibitor therapies. A phase 2 trial has been initiated to evaluate INCBO54828 in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement (NCT0313172).

E1346

THE GRADE OF STROMAL CHANGES IMPACTS ON PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

U. Gianelli1,2, S. Fiori1, D. Cattaneo2, A. Bossi3, I. Cortinovis3, C. Bucelli3, N. Orofino2, A. Iurlo2
1Division of Pathology, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation and University of Milan, 2Oncometabolism Division, IRCCS Ca’ Granda Maggiore Policlinico Hospital Foundation, 3Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy

Background: Recently, a detailed grading system for the assessment of bone marrow stromal changes has been proposed in primary myelofibrosis, proved to be reproducible and adopted by the updated WHO 2016 classification.

Aims: In this study, we aim to evaluate any possible prognostic implications of this grading system in a series of patients with primary myelofibrosis.

Methods: The study involved 122 consecutive patients with primary myelofibrosis diagnosed between 1998 and 2015 at the Oncometabolism Division of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, for whom bone marrow trephine biopsy (more than 1 cm in length) performed at the time of first observation was available, together with complete clinical, laboratory and follow-up data.

Results: Reticulin myelofibrosis (MF), collagen deposition (Co) and osteosclerosis (Ost) were evaluated and graded from 0 to 3 in the bone marrow trephine biopsy for each patient at diagnosis. In detail, the stromal changes were graded as follows: bone marrow fibrosis: MF-0 in 9 cases, MF-1 in 60, MF-2 in 31 and MF-3 in 22; collagen deposition: Co-0 in 64 cases, Co-1 in 23, Co-2 in 21 and Co-3 in 14; osteosclerosis: Ost-0 in 72 cases, Ost-1 in 24, Ost-2 in 19 and Ost-3 in 7. Patients’ population was composed of 56 males and 66 females (M/F=1/1.2) with a median age at diagnosis of 68 years (range 30-85). Clinically, at presentation, anemia was present in 20 (16%) patients, leukocytosis more than 25×10^9/L was identifiable in 4 (3%) patients, and platelets count less than 100×10^9/L in 7 (6%) cases. JAK2 V617F mutation was detected in 81 cases (66%). Among the remaining 41 JAK2-negative patients, 4 and 27 carried MPL and CALR mutations, respectively; 10 out of 122 resulted “triple-negative”. According to the International Prognostic Scoring System, 38 cases were stratified as low risk, 51 as intermediate-1 risk, 21 as intermediate-2 risk, and the remaining 12 as high risk. By the time of the analysis, 21 (17%) patients had died: leukemic evolution occurred in 14 (11.5%) patients, whereas thrombotic or hemorrhagic events occurred in 25 (20.5%). Subsequently, a comprehensive grade of bone marrow stromal changes ranging from 0 to 9 allows us to distinguish 68 (72%) cases with low-grade stromal changes (total score: 0-4) and 34 (28%) with high-grade stromal changes (total score: 5-9). Clinically, patients with high-grade stromal changes presented more frequently with anemia, thrombocytopenia, leukocyto- tesis, peripheral blood blasts and increased lactate dehydrogenase levels. The grade of bone marrow stromal changes resulted strictly associated with the overall survival of the patients with low-grade and high-grade stromal changes (Log-Rank test: p=0.0002).

Summary/Conclusions: A detailed evaluation of the bone marrow stromal changes has important prognostic implications and can be used at diagnosis in the clinical stratification of the patients affected by primary myelofibrosis. Further studies are needed to test if the prognostic significance of this grading system remains during the follow-up.

E1347

INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS

1Department of Haematology, Zealand University Hospital, University of Copenhagen, Copenhagen, 2Incyte Europe, 3Departments of Clinical Epidemiology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 4Department of Occupational and Environmental Medicine, Bispebjerg Hospital, University of Copenhagen, 5Danish Knowledge Centre for Rehabilitation and Palliative care, University of Southern Denmark and Odense University Hospital, Odense, 6National Institute of Public Health, University of Southern Denmark, Copenhagen, 7Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Background: Studies reveal that patients with inflammatory bowel disease (IBD) may have increased risk of haematologica cancers. Moreover, Philadelphia negative chronic myeloproliferative neoplasms (MPNs) have previously been associated with autoimmune diseases, including IBD. Nevertheless, to our knowledge, the risk of IBD has not been investigated in patients with MPN.

Aims: We undertook a nationwide population-based matched cohort study, and investigated the risk of IBD in patients with MPN.

Methods: We used valid Danish national registries, covering more than 5 million inhabitants, and included all patients diagnosed with either essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), or unclassifiable myeloproliferative neoplasm (MPN-U) between 1994 and 2013. For each patient, 10 individually age- and sex-matched comparisons were included. Patients and comparisons were followed until first occurrence of any IBD diagnosis (ulcerative colitis or Crohn’s disease), death, emigration or end of 2013. Patients and comparisons with prior IBD were excluded from the analysis. Hazard ratios (HRs) between MPN patients and comparisons were estimated using cox regression models, and used as measure of the relative risk. The risk was only calculated if five or more individuals were included.

Results: Of the 8,210 MPN patients, 80 individuals were diagnosed with IBD during the study period; including 37 ET patients, 28 PV patients, 1 MF patient and 14 MPN-U patients. During a total risk time of 45,241 years, the rate of IBD per 1000 person years at risk was 1.8 (95% confidence interval [95% CI]: 1.4-2.2) for the MPN patients. The corresponding rate for the 81,326 comparisons was 0.8 (95% CI: 0.7-0.9). The 10-year risks of IBD for MPN patients and comparisons were 0.8% (95% CI: 0.6-1.0) and 0.4% (95% CI: 0.4-0.5), respectively. The overall HR of IBD was 2.4 (95% CI: 2.1-2.9) for MPN patients, with HRs of 2.6 (95% CI: 2.1-3.2) for ulcerative colitis and 2.4 (95% CI: 1.7-3.4) for Crohn’s disease. The risk of IBD was increased 2 to 3 fold among ET, PV and MPN-U patients, with HRs of 2.8 (95% CI: 2.1-3.7) for ET patients, 2.1 (95% CI: 1.6-2.7) for PV patients and 2.2 (95% CI: 1.3-3.7) for MPN-U patients.

Summary/Conclusions: Patients with MPN are at increased risk of IBD compared to the general population. The absolute risks of IBD are low, but abdominal discomfort may in few patients be caused by underlying IBD.
ESSENTIAL THROMBOCYTHEMIA WITH AQUAGENIC PRURITUS: AN ENTITY WITH MORE AGGRESSIVE CLINICAL AND BIOLOGICAL PROFILE AT THE DIAGNOSIS AND A HIGH MORBIDITY DURING THE FOLLOW-UP

C. Le Gall-Ianotto1,2,*, R. Le Calloch3, L.-M. Mollard4, L. Misery1, J.-C. Ianotto4
1Service dermatologie, CHU Brest - Hôpital Augustin Morvan, 2laboratory of interactions epithelium-neuromes, university of Brest, Brest, 3Service Hématologie, CHIC, Quimper, 4Service Hématologie, CHU Brest - Hôpital Augustin Morvan, Brest, France

Background: Polycythemia vera (PV) and essential thrombocythemia (ET) are Ph-negative myeloproliferative neoplasms in which arterial or venous thromboses and phenotypical evolutions (leukemia, myelofibrosis) are the most recurrent complications. Aquagenic pruritus (AP), induced by water contact, is a typical symptom of PV. However, we showed recently that ET patients also suffered from AP with clinical characteristics quite different from those observed in PV patients. In 2008, the presence of AP was associated with a lower risk of arterial thrombosis in PV patients. Aim: It seemed particularly interesting to analyse the clinical relevance and the prevalence of the presence of AP in ET patients for such a risk.

Methods: In this study, we used the OBENE observatory (Observatoire Brestois des NEoplasies myeloProlifératives), a register of MPN patients followed in our University Hospital in which biological and clinical data of 396 ET patients have been collected. This register was approved by a local ethical committee and registered in clinicaltrials.gov (NCT02897297). To avoid masked polycythemia Vera diagnostics, all JAK2 positive cases were analysed for testoic red mass cells if appropriate.

Results: Among the 396 ET patients, 42 (10.6%) suffered from AP. Interestingly, the median age at diagnosis of these patients was lower (51.6 vs 63.8%, p<0.0001). Furthermore, they presented more symptoms as erythrocytosis, hypercyclosis, constitutional symptoms and splenomegaly (p<0.01), ET patients with AP were more proliferative (more polypliytic but less thrombocytopenic) 0.04 vs 0.04, respectively). Concerning the overall survival of the patients, we have noted that there was less death in the group with AP than without AP (11.9 vs 32.5%, p=0.006) in spite of a longer follow-up (12.1 vs 7.7 years, p=0.002).

Summary/Conclusions: AP is classically associated to PV. But we confirmed here that AP is also present in ET. Furthermore, ET patients suffering from AP were more proliferative, more symptomatic at diagnosis but had also higher risk of thromboses and phenotypic evolutions than ET without AP. Despite that these patients have a higher overall survival. So, the presence of AP in ET with ET characterizes patients with high risk of morbidity (thrombosis, phenotypic evolutions).So as in PV, the presence of AP in ET patients at the time of diagnosis should be systematically identified.

ANAGRELIDE RESPONSE ACCORDING TO THE MOLECULAR PROFILE: SOMETHING TO CONCLUDE ON THE MECHANISM OF ACTION OF THE DRUG IN MYELOPROLIFERATIVE NEOPLASMS (MPN)?

M. Montero1, T. Knight1, M. Dominguez2, E. Camillo1, F. Márquez1, V. Escamilla1, P. Guerrero1, M. Suito1, A. Blum1, N. Alkadi1, J. González1, J. Falantes1, N. Rodríguez1, M. Martin1, I. Espigado1, J. Pérez-Simón1
1Haematology and haemotherapy Service, Hospital Universitario Virgen del Rocío, Seville, Spain

Background: Anagrelide is a useful drug in the control of thrombocythemia in MPN. Although it is known that in therapeutic levels it primarily influences in the post-mitotic phase of megakaryocytic development interfering with its complete maturation, its mechanism of action is still ill known.

Aims: To determine the diagnosis of MPN due to the discovery of driver mutations (JAK2, calreticulin and MPL) leads us in the present study to correlate them with the response to anagrelide in a group of patients treated with this drug, investigating the possible interference in the referred biological pathways.

Methods: 143 patients with MPN diagnosed in our centre between 1993 and 2015 were studied. The median age was 49 years, with 19 patients older than 60 years. 83% were female and 17% were male. The diagnosis was initially carried out based on the WHO criteria 2008 and subsequently reviewed the medical records with the new criteria of 2016. A molecular study on peripheral blood samples was carried out using quantitative allele-specific PCR techniques for JAK2, qualitative for MPL (L515V mutation) and Sanger sequencing of exon 9 for calreticulin. Type 1 mutation was considered at 52 bp deletion and type 2 at 5 bp insertion. In all patients, the goal of anagrelide therapy was to control thrombocythemia (platelet count below 600×10^9/L), with dosage within the range of efficacy and safety recommended in the datasheet. The results were analysed with the statistical software SPSS vs 15.0

Results: 80.5% of the patients were diagnosed with ET, 12.5% of PV, 3.5% of myelofibrosis and 3.0% of unclassifiable MPN. 59% of the patients had a V617F JAK2 mutation, with allelic load higher than 20% in 47.5% of the cases. 28.5% presented mutation in calreticulin; of which 50% were type 1 and 50% type 2. Only one patient had a mutation in MPL (2%), the remaining 6% being classified as “triple negative”. The median daily dose of anagrelide received was 1.5mg. 17.5% of the patients required more than 2mg for an adequate control, half of them being positive for mutations in calreticulin and the other 50% of the mutation V617F JAK2 with allelic load higher than 20%. 26% of the patients received daily dose of 1mg, being 70% positive for the mutation V617F-JAK2 with allelic load lower than 20%, although there were no statistically significant differences between the groups according to the mutational profile. 16% of patients discontinued treatment due to toxicity, with the most common adverse effects being mild (headache and palpatations).

Summary/Conclusions: Patients requiring higher doses of anagrelide present mutations in calreticulin or JAK2 V617F allelic load higher than 20% and patients with lower allelic load having greater sensitivity to the drug, with no statistically significant differences. It is possible that the first situation is associated with a greater pre-mitotic deregulation in the megakaryocyte where the drug does not interfere whereas the second one could be related to anagrelide interference through the JAK2 pathway in post mitotic maturation although larg-

E1349

E1530
THE DELAYED DIAGNOSIS OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) IS COMMON AND RESULTS IN A HIGH INCIDENCE OF POTENTIALLY PREVENTABLE THROMBOTIC COMPLICATIONS

C. Fosset1, C. Tiley2, B. Wylie2, M. Dean2, T. Armytage2, K. Melville2
1Medicine, Wyong Hospital, Kanwal, 2Haematology, Gosford Hospital, Gosford, Australia

Background: Ph-negative MPNs are a heterogeneous group of stem cell derived, clonal bone marrow disorders characterised by increased production of mature blood cells. Patients with MPNs are at significantly increased risk of thrombotic and haemorrhagic complications which are a major cause of morbidity and mortality. The early diagnosis and treatment of MPN may reduce the incidence of thrombotic complications and the associated morbidity and mortality.

Aims: We performed a study to determine if the delayed-diagnosis of MPN was common and the implications of any such delay.

Methods: The medical records of patients treated at our centre with a new diagnosis of MPN between January 2010 and June 2016 were audited. We determined the duration from first appearance of a full blood count (FBC) abnormality consistent with the diagnosis of MPN until the time of formal diagnosis. The occurrence of any thrombotic or haemorrhagic complications during this time was recorded.

Results: 143 patients were diagnosed with MPN, 35 with polycythemia vera, 79 with essential thrombocythemia, 25 with primary myelofibrosis and 13 with MPN-unclassifiable. Patients with PV had a median diagnostic delay of 156 days (range 0-2650 days) and 26% had potentially preventable events. Patients with ET had median diagnostic delay of 823 days (range 0-8731 days) and 23% had potentially preventable thrombotic events including 2 patients with multiple events. Patients with PMF had a median diagnostic delay of 196 days (range 0-3684 days) and 12% had potentially preventable thrombotic events. In MPN-U the median diagnosis delay was 1371 days (range 42-3255) and 31% of patients had potentially preventable adverse events.

Summary/Conclusions: Over 5.5 years we identified 143 patients with a new diagnosis of Ph-negative MPN within our centre. The overall median diagnostic delay was 723 days (0-8731) with delays of more than 12 months in ET, PV and MPN-U, and more than 6 months in PMF. 21% of patients had potentially preventable thrombotic events and 2.8% had potentially preventable haemorrhagic events. Earlier recognition of FBC abnormalities consistent with MPN and earlier intervention, would be expected to prevent many thrombo-haemorrhagic complications and reduce MPN-associated morbidity and mortality.

E1351
LONG-TERM AND LOW-DOSE BUSULFAN IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

R. Renso1, A. Aroldi1, P. Piottelli1, C. Gambacorti-Passerini2,3, E. M. Elli1
1Hematology Division, 2Clinical Research Unit, Hematology, San Gerardo Hospital, Monza, 3Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

Background: Therapeutic options for elderly patients (pts) with Essential Thrombocythemia (ET) resistant or intolerant to hydroxyurea (HU) are limited. Busulfan (BU) is a possible second-line treatment, but conventional schedule
Aims: We analysed efficacy, toxicity, risk of Myelofibrosis (MF) and leukemic evolution in 31 of 352 ET pts collected in our database, treated with an alternative long-term schedule of BU, defined by low-starting dose (4-6mg/week) up to CHR (evaluated according to ELN response criteria), followed by dose de-escalation overtime.

Methods: Non parametric tests, such as Mann-Whitney, Pearson Chi-square and Fischer’s exact tests, were used for statistical analysis of continuous and categorical variables. Survival curves were calculated by Kaplan-Meier method and compared with Log-rank (Mantel-Cox) test.

Results: 27/31 pts were evaluable for analysis (8 male, 19 female). Median age at diagnosis and at BU start were 71,3 and 79 years (yrs) respectively. We found these driver mutations: JAK2V617F in 15 pts (55.6%), Calreticulin in 8 pts (29,8%) and MPL in 1 patient (3,7%); 3 pts (11,1%) were triple negative. IPSET score at diagnosis was low-intermediate in 17 (63%) and high in 10 (37%) pts. 26 pts started BU as 2nd line treatment: 11 (42,3%) were intolerant and 15 (57,7%) were resistant to HU respectively. Only one received BU as 1st line treatment. They received BU for a median time of 47.67 months (range: 1.48 – 94.42). The median cumulative BU dose was 453mg (range: 32-1032). 22/27 pts (82.2%) obtained CHR, after a median time of 191 days. 6 pts (22.2%) presented hematological (5) and extra-hematological (1, cutaneous) side effects. Overall, 12 pts (44,4%) stopped BU: 4 for hematological toxicity, 4 for disease progression, 2 for drug intolerance/resistance; the remaining 2 not for drug-related side effects. After a median follow-up of 9.74 yrs (range: 1.82-27.05), 9 (33.3%) and 2 (7.4%) pts presented MF evolution and leukemic transformation respectively. The MF-free-survival (MFS) was 48.8% at 15 yrs and appears to be significantly lower than the entire series of ET pts (77.4% at 15 yrs; p=0,002; figure 1). Median MFS was 12.7 yrs for pts treated with BU, whereas it was not reached at 15 yrs in the entire series of ET. There were no statistically significant differences in principal statistical and clinical variables between “evolving-MF pts” and “not evolving-MF pts”, apart from lower hemoglobin value at BU start (11,5 vs 13,05 g/dl; p=0,05) and lower time of exposition to BU in MF subgroup (16 vs 53,7 months; p=0,026). Drug cumulative dose was the same in the two subgroups. Thrombotic complication after BU start were observed in 3 pts (11,1%). During time of analysis 5 pts (18,5%) died.

Summary/Conclusions: Our experience with an alternative long-term and low-dose BU administration is safe and effective in elderly patients with ET. 92.6% of them obtained CHR, with acceptable hematological and extra-hematological toxicity. We noticed a high rate of MF evolution with respect to global ET population, while the risk of leukemic transformation seems to be limited, considering that these pts were elderly and previously treated. Predictive factors for MF evolution should be analysed and confirmed in larger series.

Aims: The aim of this study was to find out if there is difference in frequency and type of thrombosis in JAK2 V617F positive patients according to their diagnosis, age, sex and V617F allele burden.

Methods: One hundred and eighty two JAK2 V617F positive patients diagnosed with polycythemia vera (PV) N=63, essential thrombocythemia (ET) N=83, and primary myelofibrosis (PMF) N=36 were included in the study. Patients in each group were additionally divided according to sex, age at diagnosis and first thrombosis. V617F allele burden was quantified in peripheral blood granulocyte DNA by real time PCR established by Larsen et al. Br J Haematol 2007;136:745.

Results: Among 182 patients observed, 66 (36%) experienced thrombosis, with arterial thrombosis being twice more frequent than venous thrombosis in all 3 studied groups. In ET group there was statistically significant difference in sex distribution (proportion of females=0.71), p<0.001. Statistically significant difference in age at diagnosis was observed between ET and PV/PMF patients without thrombosis (p<0.001); the youngest patients were those in ET group. The age at diagnosis of ET patients with thrombosis (65 years, range 23-92) was statistically different compared to ET patients without thrombosis (50 years, range 21-83), p=0.002. Our study showed that V617F allele burden in patients without thrombosis was statistically significantly different between ET (17.2%, range 4.2-55.2) compared to PV (43%, range 1.7-99.9) and PMF (37.1%, range 1.4-90.7), p<0.001. The same statistically significant difference for V617 allele burden was established in patients with thrombosis between ET patients (19%, range 1.4-84.5) and PV and PMF patients (42.5%, range 8.9-97.2 and 48.8%, range 1.6-99.8, respectively), p<0.001.

Summary/Conclusions: Our results confirm that arterial thrombosis is more frequent than venous thrombosis in JAK2 V617F positive patients. Female sex was prevalent only in ET group. The age at diagnosis in all studied groups was similar except for ET patients without thrombosis. There was no difference in the frequency and type of thrombosis among ET, PV and PMF patients with high heterogeneity in V617F allele burden between all studied groups regardless of the occurrence of thrombosis.
CD19Cre/Cre) mice were crossed with either C57BL/6 BLIMPflox/flox or C57BL/6 ABC-DLBCL phenotype.

**Aims:** To develop and characterize a transgenic mouse model of BLIMP-1 and p53.

**Methods:** A combination of studies was performed in mouse models (CD37/IL-6-deficient mice), and studies of DLBCL patient material using biochemical, immunological, genetic and microscopical approaches.

**Results:** We provided evidence that deficiency of CD37 induces the development of B cell lymphoma in vivo. CD37-deficient mice develop germinal center-derived B cell lymphoma in lymph nodes and spleen with higher incidence than Bcl2-transgenic mice. We discovered that CD37 interacts with SOCS3, and when absent drives tumor development through constitutive activation of the IL-6 signaling pathway. The importance of the IL-6 pathway was confirmed by investigating CD37×I6 double knock-out strains that were fully protected against lymphoma development. Our unpublished data shows discovery of inactivating CD37 mutations in patients with DLBCL. Importantly, loss of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) is directly correlated with activation of the IL-6 signaling pathway and with worse progression-free and overall survival.

**Summary/Conclusions:** Together, this study identifies tetranspan CD37 as a novel tumor suppressor that directly protects against B cell lymphomagenesis, and provides a strong rationale for blocking the IL-6 pathway in patients with CD37-negative B cell malignancies as therapeutic intervention.

**E1355**

**IDENTIFICATION AND CHARACTERIZATION OF THE LYMPHOMA INITIATING CELL (LIC) POPULATION IN AN ALCCL MOUSE MODEL**

A. Van Spriel1,* S. Schaaf1, S. Elfrink1, H. van Krieken1, C. Figdor1, S. van Deventer1, B. Scheijen1, A. Van Spriel1,*

1Radboud University Medical Center, Nijmegen, Netherlands, 2MD Anderson Cancer Center, Houston, United States

**Background:** B-Lymphocyte-Induced Maturation Protein-1 (BLIMP1)- and p53-inactivation contributes to the pathogenesis of a wide spectrum of malignancies, including diffuse large B-cell lymphomas. Nevertheless, there is lack of in vivo models that may be used for a better understanding of the biology and genomics of high-grade B-cell lymphomas characterized by dual loss of both BLIMP1- and p53.

**Aims:** To develop and characterize a transgenic mouse model of BLIMPI-p53 dual loss in B cells. To provide an in vivo model that mimics human ABC-DLBCL phenotype.

**Methods:** Cre recombinase under the control of CD19 promoter (C57BL/6 CD19CreCre) mice were crossed with either C57BL/6 BLIMPflox/flox or C57BL/6 p53flox/flox mice to achieve deletion of BLIMP or p53, respectively, in B cells. Secondly, CD19CreCre BLIMPflox/flox mice were crossed with CD19CreCre p53flox/flox mice to achieve dual deletion of BLIMP and p53 in B cells (CD19CreCreBLIMPflox/flox p53flox/flox, referred as CD19Bl-/p53-). Transgenic experimental mice (CD19Bl-/p53-) where characterized for clonal B cell infiltration using immunohistochemistry, flow cytometry, Southern Blotting, whole exome sequencing. MIT assay was used to test BTK-inhibitor-dependent cytotoxicity using CD19Bl-/p53-derived B220 cells.

**Results:** CD19Bl-/p53- mice presented with diffuse lymphadenomaligancies, splenomegaly, hepatomegaly (100%, 90.3% and 77.4%, respectively). Other clinical manifestations included presence of ascites and hind limb paralysis (12.0% and 19.3%, respectively). The CD19Bl-/p53- showed intestinal weight change as well as Blip-p53 mice expressing the CD19Cre recombinase, CD19/p53- or CD19Bl-/CD36, 469.5, 460.5, and 770, respectively. H.E. staining of CD19Bl-/p53-derived lymph nodes, defined a nodal architecture with a monomorphic population of large sized atypical lymphoid cells, multiple birefringent crystalloid inclusions, paranuclearly situated nucleoli. A prominent sinonasal dissemination was observed. Features were compatible with a high-grade lymphomas.

**Summary/Conclusions:** In vivo analysis confirmed positivity for B220 staining (TdT, Bcl6, CD138 and CD4, CD8 negative). Tumors were confirmed to be B220+IgM+, with either Igk- or Ig-lambda-restriction as demonstrated by flow cytometry; and either mono- or bidirectional involvement demonstrated by Southern blotting. Vimentin staining was observed in B220+ selected cells obtained from pathological lymph nodes of CD19Bl-/p53- mice and identified 143 SNVs. Non-synonymous somatic mutations were mapped on genes involved in the regulation of focal adhesion, PDGF signaling, p53-downstream pathway, and lipoprotein metabolism. B220+ cells selected from CD19Bl-/p53- derived lymphomas were implanted s.c. into recipient SCID/Bg mice, and presented with 100% engraftment, with a monomorphic lymphoid infiltration of B220+ and IgM+ cells. B220 positive cells were selected from the s.tumor and intravenous injected into recipient SCID/Bg (n: 10) and BL6/mice (n: 10). Engraftment was demonstrated in all transplanted mice where hepatomegaly and splenomegaly were observed. Infiltration of B220+ cells was documented within bone marrow, liver and spleen. Finally, we found that B220+ selected cells from lymph nodes harvested from CD19Bl-/p53- mice were sensitive to ibritinib.

**Background:** In 60% of anaplastic large cell lymphoma (ALCL) patients a translocation t(2;5) (p23;q35) is found, which results in NPM-ALK fusion gene expression and constitutive activation of the ALK tyrosine kinase. Immunophenotypic characterization of human ALCLs revealed highly CD30-positive cells of T- or Null-cell origin.

**Aims:** To characterize the origin of the lymphoma initiating cell population as well as NPM-ALK signal transduction in course of the disease remains unclear and needs to be characterized.

**Methods:** In this regard, we established a retroviral murine bone marrow transplantation model resembling human ALCL. Therefore we use an inducible Cre/IoxP system where NPM-ALK expression is restricted to early T-cells. We infected bone marrow of Lck-Cre transgenic mice with our MSCV-Stop-NPM-ALK/ires-EGFP vector and transplanted it into lethally irradiated non-irradiated C57Bl6 mice. With a latency of 4-5 months, mice developed CD30-positive lymphomas and died from neoplastic T-cell infiltration of lymphatic organs and bone marrow.

**Results:** Immunophenotypic analysis confirmed T-cell origin of the lymphomas with a heterogeneous contribution of all T-cell stages with mainly CD4+/CD8- double positive (DP) T-cells including all DN T-cell subpopulations as well as hematopoietic stem cells and lymphatic precursors. Staining of the T-cell sub-populations demonstrated high NPM-ALK expression in immature CD4+/CD8- double negative T-cells and undifferentiated CD4+/CD8+ double positive T-cells with highest expression of proliferation marker Ki67 as well as the activation markers CD25 and CD69. In the CD4+CD8- fraction, dual deletion of NPM and CD34 expression and constitutive activation of the CD4+CD8- double negative lymphoma population further more aberrantly expressed the T-cell receptor alpha/beta chain, which may allow these early T-cells to establish a systemic lymphoma. To further proof this hypothesis and identify the LIC population we performed secondary transplantations with sorted DN and CD4+CD8- T-cells as well as normal T-cells as controls. In primary transplantation, DN3/L3 lymphoma cells could give rise to secondary lymphomas, whereas sorted DN1, DN2, CD4+, CD8+ or CD4+CD8- transplanted lymphoma cells failed to establish serial lymphomas in recipient mice. Immunophenotypic analyses of secondary lymphomas caused by transplantation of the DN3 and DN4 lymphoma cells revealed CD4+ CD8- double positive CD4+ and CD8+ cells next to the DN3/DN4 population. However, we were not able to detect reinfestation of the DN3/DN4 cells to more immature DN1/DN2 lymphoma cells. To substantiate our findings, we performed microar-
Aims: To determine the relationship between HSP110 and the NF-kB pathway. Using immune-precipitation in DLBCL-non-DLBCL cell lines increases NF-kB signaling, indicating a tight interplay. Furthermore, shRNA silencing of HSP110 decreases the survival of ABC-DLBCL tumor sections and transcriptional analysis of ABC-DLBCL patient samples, compared to normal reactive lymph nodes by using IHC staining of a ral vector designed to infect highly efficiently non-permissive B cell lines. ShRNA specific for HSP110 was introduced through a lentiviral vector designed to infect highly efficiently non-permissive B cell lines. STAT3 inhibition as therapeutic strategy in symptomatic CD8+/CD16+/CD56- patients equipped with the CD16+/CD56- signature. The relationship between STAT3 activation and neutropenia Fas ligand related further supports to approach STAT3 inhibition as therapeutic strategy in symptomatic CD8+/CD16+/CD56- DLBCL-LGLL patients, obtaining the dual results of inducing apoptosis in leukemic LGL together with inhibition to Fas ligand mediated neutropenia.

Methods: The study was performed with ABC-DLBCL patient samples and several cell lines. STAT3 specific for HSP110 was overexpressed through a lentiviral vector designed to inject highly efficiently non-permissive B cell lines. We observed a high HSP110 expression in all ABC-DLBCL patient samples, compared to normal reactive lymph nodes by using IHC staining of ABC-DLBCL tumor sections and transcriptional analysis of ABC-DLBCL patient tumors. Furthermore, the RNA silencing of HSP110 decreases the survival of several ABC-DLBCL cell lines, and downregulates the expression of pro-survival factors such as BcL2 and BcL-XL. SiRNA silencing of HSP110 abrogates NF-κB signaling, which is the major oncogenic pathway in ABC-DLBCL cell lines. In accord with these results, over-expression of HSP110 in DLBCL and non-DLBCL cell lines increases NF-κB signaling, indicating a tight interplay between HSP110 and the NF-κB pathway. Using immune-precipitation in DLBCL cell lines and Duolink™ assays, we identified an in vitro and in cellulo interaction between HSP110 and Myd88, a critical protein of the NF-κB pathway that bears an activated mutation in many ABC-DLBCL patients and that is responsible for lymphoma aggressiveness. Finally, we demonstrate that HSP110 stabilizes the wild type as well as the mutated form of Myd88, therefore facilitating the chronic NF-κB pathway activation in those cells.

Summary/Conclusions: In conclusion, we identified HSP110 as a regulator of NF-κB signaling through Myd88 stabilization in ABC-DLBCL. This finding suggests that HSP110 is able to disrupt the NF-κB pathway in a variety of cell types and is critical for the development of neutropenia. Among CD8+ T-LGLL, immunophenotypic signature CD16+/CD56- was both associated to the presence of neutropenia and a STAT3 mutation (37 out of 41, 90.2% and 37 out of 41, 90.2%; p=0.0001 and 37 out of 41, 90.2%; p=0.001 respectively). Furthermore, by western blot we showed that high STAT3 tyrosine phosphorylation was observed in LGL obtained by CD8+ T-LGLL patients belonging to CD16+/CD56- subgroup was significantly higher as compared with other immunophenotypic groups. Provided this relationship between STAT3 mutation/activation and neutropenia, by RT-PCR we analysed Fas ligand expression, showing higher transcription levels in CD16+/CD56- CD8+ T-LGLL patients as compared to the not neutropenic patients belonging to the other immunophenotypes, both CD8+ T-LGLL and CD4+ T-LGLL (7.66±0.87, 2.4±0.22 and 2.35±0.28 arbitrary units, respectively; p<0.01). To confirm this relationship, in patient’s PBMCS treatment with STAT3 inhibitor Statico decreased both STAT3 phosphorylation and Fas ligand transcription as compared to the untreated conditions. In addition, IL-6 and IL-15 stimulation (which are known STAT3 activator) increased Fas ligand transcription levels (1.59- and 2.01-fold after IL-6 and IL-15, respectively) which is prevented by concomitant Statico. Treatment with STAT3 mutation and activation is mostly restricted to neutropenic CD8+ T-LGLL patients equipped with the CD16+/CD56- signature. The relationship between STAT3 activation and neutropenia is a possible mechanism to approach STAT3 inhibition as therapeutic strategy in symptomatic CD8+/CD16+/CD56- LGLL patients, obtaining the dual results of inducing apoptosis in leukemic LGL together with inhibition to Fas ligand mediated neutropenia.

E1356
HSP110 SUSTAINS MYD88-DEPENDENT NFkB SIGNALING IN ACTIVATED B CELL DIFFUSE LARGE B CELL LYMPHOMA
C. Boudesco1, S. Caussel1, A. Hamman2, E. Verhoyen3, L. Martin1, F. Jardin1, T. Fest1, O. Wolz6, A. Weber2, C. Garrido2, G. Jego1,2
1University of Burgundy, 2INSERM 1231, Dijon, 3INSERM U1111, Lyon, 4INSERM 918, Rouen, 5INSERM 911, Rennes, France, 6University of Tübingen, Tübingen, Germany

Background: Diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoproliferative disorder of B lymphocytes accounting for 30% of adult Non Hodgkin Lymphoma (NHL). Among DLBCL, Activated B Cell – DLBCL (ABC-DLBCL) is the most aggressive form and has a poor prognosis. Heat-shock proteins (HSPs) are molecular chaperons highly expressed in cancer cells and implicated in resistance to radio- and chemotherapy. Therefore, HSPs are envisioned as therapeutic targets in many cancers. Among the different HSPs, HSP110 has been recently identified as a pro-survival factor in germinal center DLBCL (GC-DLBCL), through stabilization of the GC-DLBCL oncogene Bcl-6.

Aims: Here, we have explored if HSP110 could also be involved in the survival of the most aggressive form of DLBCL

E1358
CYCLIN D2 OVEREXPRESSION RECAPITULATES MANTLE CELL LYMPHOMA IN MICE
T. Pieters1,2,*, S. T’Sas1, J. Morscio1, F. Matthijssens1, K. Lemeire1, T. Hochepied1,2,3,*, C. Vicenzetto1,2, M. Leoncin1,2, C. Calabretto1,2, G. Barilà1,2,*, A. Teramo1,2, G. Calabretto1,2, M. Leoncin1,2, C. Vicenzetto1,2, G. Barilà1,2,*, A. Teramo1,2, G. Calabretto1,2, M. Leoncin1,2, C. Vicenzetto1,2
1Dept of Medicine, Hematology and Clinical Immunology section, Padua University, Padua, Italy

Background: Mantle cell lymphoma (MCL) is a highly aggressive subtype of B-cell lymphoma that is characterized by a poor response to current treatment regimens. Most MCLs carry a prototypical translocation, t(11;14), which juxtaposes the CCND1 gene towards the immunoglobulin heavy chain (IGH) locus, resulting in cyclin D1 overexpression. Notably, a subset of MCL patients are cyclin D1 negative but instead overexpress cyclin D2 (encoded by CCND2) as a consequence of recurrent genomic rearrangements involving the CCND2 locus.
Aims: Here, we aim to recapitulate MCL in a mouse model of hematopoietic-specific overexpression of cyclin D2. Next, we want to use this preclinical mouse model to evaluate novel therapeutic strategies for the treatment of MCL.

Methods: To evaluate if cyclin D2 could act as a bona fide oncogene in the pathogenesis of MCL, we developed a conditional R26-driven Ccnd2 overexpression mouse model. For this, we used a targeting vector that contained a floxed stop cassette followed by the Ccnd2 gene and a EGFP/ luciferase reporter, which was subsequently targeted in mESCs using recombinase-mediated cassette exchange (RMCE).

Results: The resulting R26-Ccnd2 mice were crossed to VavCre mice to enable biallelic R26-driven overexpression of Cyclin D2 in the entire hematopoietic system. Interestingly, these mice developed large lymphomas starting from 36 weeks of age (Figure 1A), with tumor cells showing characteristic MCL immunophenotype (CD19+, CD5+, CD23-). Of note, these malignant B-cells were monomorphic small-sized cells with slightly irregular hyperchromatic nuclei and disseminated into other organs such liver, spleen and the gastrointestinal tract (Figure 1B). Infiltrating MCL cells were SOX11 positive, as evaluated by IHC, suggesting that these tumors indeed reflect a murine form of MCL. Noteworthy, the MCL cells from this mouse model also contain a luciferase reporter, allowing accurate in vivo tracing of tumor cells in xenograft experiments. These xenograft experiments can be used as preclinical models, in which bioluminescence is used to assess the tumor burden and to monitor tumor regression upon drug treatment.

Summary/Conclusions: In conclusion, our preliminary data suggest that modeling cyclin D2 in mice, mimicking the elevated cyclin D2 levels of human MCL patients with transliterations involving the CCND2 locus, is sufficient to form MCL.

E1359 HDAC6 INHIBITION INCREASES CD20 LEVEL BY STIMULATING TRANSLATION OF CD20 MRNA

A. Graczuk-Jarzynka1,1, M. Bobrowicz1,1, M. Dwojak1,1, J. Stachura1,1, E. Berthel2, B. Pyrzyńska1,1, M. Siernicka1,1, N. Miązek1,1, P. Zapała1,1, N. Dalla-Venezia2, J. Gołąb1

1Department of Immunology, Medical University of Warsaw, Warsaw, Poland
2Centre Léon Bérard – Centre de Recherche en Cancérologie de Lyon, Lyon, France

Background: HDAC6 (histone deacetylase, isoform 6) is a novel promising drug target for hematological malignancies. HDAC6 is an atypical member of HDAC family that regulates the acetylation status, and thus the function and cytosolic proteins, and has been explored therapeutically for its role in the process of protein degradation. HDAC6 mediates the transport of protein aggregates to the autophagic machinery to diminish their cytotoxicity. Thus, the disruption of the aggresome pathway, similarly to proteasome inhibition, results in a massive accumulation of misfolded protein aggregates and apoptotic cell death. As this strategy holds a considerable potential in aggressive B-cell tumors with a high rate of protein synthesis, HDAC6 inhibitors - are currently being tested in Phase I and II clinical trials in multiple myeloma and non-Hodgkin lymphoma. The results of preclinical studies show the increased efficacy of the combination of HDAC6 inhibitors with proteasome inhibitors in inducing stress-related cell death. The results of our studies show that HDAC6 inhibition in non-toxic concentrations significantly increases CD20 level on a protein level.

Aims: The aim of this study was to elucidate the mechanism of the regulation of CD20 expression by HDAC6.

Methods: We used qRT-PCR and Dual Luciferase Assays in order to determine the influence of HDAC6 on CD20 transcription. We used pulse-chase assays using widely used translation inhibitors – cycloheximide and homoharringtonine. We show that HDAC6 inhibition regulates CD20 level without affecting its transcription. Moreover, we demonstrate that HDAC6 inhibition increases translation of CD20 mRNA on polysomes without affecting general synthesis of novel proteins in the cell. However, our experiments suggest that the increased translation of CD20 mRNA is not a result of resumed translation of mRNA but rather a translation of newly synthesized mRNA.

Summary/Conclusions: Our study shows a new mechanism of the regulation of CD20 expression by increasing its translation. Moreover, we demonstrate a new role of HDAC6 protein. This finding has a potential clinical application, as HDAC6 inhibitor are being widely tested in different hematological malignancies. Further studies in order to identify other targets for HDAC6 are required.
is associated with an absence of relapse and thus defines a new group of very low risk patients. These findings provide important clues for future theranostic-driven therapies in MCL.

E1361

CLINICOBIOLICAL FEATURES OF B-CELL NEOPLASMS WITH CDK6 TRANSLOCATIONS: FREQUENT ASSOCIATION WITH MARGINAL-ZONE LYMPHOMA, CONTINGENT OF PROLYMPHOCYTIC CELLS AND TP53 ABNORMALITIES. A GFCH STUDY


1Laboratoire de genétique, Hôpital Robert Debre, Reims, 2Service d’Hématologie biologique, Hôpital Pitié-Salpêtrière, AP-HP, PARIS, 3Laboratoire d’Hématologie, Hôpital Robert Debre, Reims, 4UNIVERSITE PIERRE ET MARIE CURIE, Paris, 5Laboratoire de Cytogénétique, CHU Dijon, Dijon, 6CHU Strasbourg, Strasbourg, 7Laboratoire de Cytogénétique, Institut Universitaire du Cancer de Toulouse, Toulouse, 8Laboratoire de Cytogénétique Oncohématologique, CHU Grenoble, Grenoble, 9Laboratoire de Cytogénétique, Hôpital CAREMEAU, Nîmes, 10Laboratoire de Cytogénétique Onco-Hématologique, Hôpital Timone, Marseille, 11Unité de Génétique, CHU Bretonneau, Tours, 12Service de Genetique, Hôpital St Jacques, Besancon, France, 13Laboratoire de Cytogénétique Oncohématologique, Hôpital du Saint Sacrement, Quebec, Canada, 14Laboratoire d’Hématologie, Centre Hospitalier du Mans, Le Mans, 15Laboratoire Pasteur-CERBA, Val d’Oise, 16Laboratoire de Cytogenetique, Hôpital Necker – Enfants Malades, APHP, Paris, France

Background: Translocation involving the CDK6 gene is a rare but recurrent abnormality in B-cell neoplasms. Three different translocations have been described: t(2;7)(p11;q21), which is the most frequent, t(7;14)(q21;q32) and t(7;16)(q21;p11), leading to juxtaposition of CDK6 gene with IGK, IGH or IGL locus respectively.

Aims: The Groupe Francophone de Cytogenetique Hematologique (GFCH) collected 35 chronic B-cell disorders with CDK6 translocation in order to document the clinicobiological features of this uncommon aberration.

Methods: Clinical and biological data were gathered at diagnosis when available. A cytogenetical review was performed by 3 experts in 27/35 cases. FISH was used to detect IG or TRAD and CDK6 rearrangements, and recurrent abnormalities frequent in SMZL and CLL (trisomy 3, 12, deletions of 13q14 and 11q22/11q23 loci).

Results: Our cohort included 22 MZL and 13F, with a median age of 71 years. The involvement of CDK6 was confirmed in all cases. A t(2;7) IGK/CDK6 was found in 33/35 patients. One case had a t(7;14) IGH/CDK6, and one had a t(7;14)(q21;q11) involving the TRAD locus. There were 23 (66%) marginal-zone lymphoma (MZL), including 22 splenic MZL (SMZL) (including the t(7;14) TRAD), and 1 bronchus MALT type, 7 (20%) unclassified small B-cell lymphoma (USBCL) and 5 (14%) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Matutes score 4/5 (including the t(7;14)

Figure 1.
Background: NR4A1 (Nur77) belongs together with NR4A2 (Nur1) and NR4A3 (NOR-1) to the Nur77 family of nuclear orphan receptors. As immediate early- or stress response genes their expression is diverse as it is the cellular outcome upon activation. Recently, there has been attributed a pivotal role to NR4A1 and NR4A3 as tumor suppressors in AML in humans and mice. In our comprehensive NR4A4 expression analysis in various lymphomas we demonstrated a significant reduction of NR4A1 expression in aggressive lymphomas, which was associated with poor cancer-specific survival. Moreover, ectopic expression of NR4A1 in aggressive lymphoma cells resulted in induction of apoptosis.

Aims: In order to better dissect the role of Nr4a1 in lymphoid malignancies, we used a Mucy-driven mouse model of lymphomagenesis and crossed the EµMyc mouse with the Nr4a1-/− mouse. Survival and tumor formation were monitored and RQ-PCR was performed on selected tumor specimens, whereby genes, found to be associated with NR4A1 expression in the publicly available gene expression data set of DLBCLs generated by Lenz et al., were taken. The driver-function of Nr4a1 in lymphomagenesis at the premalignant stage was investigated by using apoptotic assays and by carrying out transplantations of tumor cells into wt recipients.

Methods: Kaplan Meier analysis was performed for survival and tumor formation in EµMyc Nr4a1+/+ (n=154), EµMyc Nr4a1−/− (n=84) and EµMyc Nr4a1+/− (n=59), respectively. For RQ-PCR selected tumor specimens from wt and EµMyc mice with (n=14) and without (n=17) Nr4a1 loss were used. For investigation of the role of Nr4a1 at the premalignant stage, mice aged 4 weeks (n=4 per genotype) were sacrificed and AnnexinV staining and cleaved-caspase3 assay were performed on cells isolated from the spleen and bone marrow. In vivo Nr4a1 loss was induced by tumor cell injection from Nr4a1−/− mice into the tail vein of wt mice. Kaplan Meier analysis was used for monitoring survival and tumor formation, and FACS analysis for analysis of bone marrow, spleen and tumor, respectively.

Results: EµMyc Nr4a1+/− mice showed decreased survival with a median of 92 days, whereas Nr4a1−/− mice died with a median of 45 days (p<0.001) and tumors developed faster with a median of 45 days for EµMyc Nr4a1−/−, vs 107 days for EµMyc Nr4a1+/+ (p<0.001). Both, survival (median=101 days; p=0.037) and tumor formation (median=66 days; p=0.001) gave intermediate values for EµMyc Nr4a1−/+ mice. Furthermore, EµMyc Nr4a1−/− mice showed a substantial response rates to rapamycin and analogs. Kaplan Meier analysis was performed for survival and tumor formation in EµMyc Nr4a1+/+ (n=154), EµMyc Nr4a1−/− (n=84) and EµMyc Nr4a1+/− (n=59), respectively. For RQ-PCR selected tumor specimens from wt and EµMyc mice with (n=14) and without (n=17) Nr4a1 loss were used. For investigation of the role of Nr4a1 at the premalignant stage, mice aged 4 weeks (n=4 per genotype) were sacrificed and AnnexinV staining and cleaved-caspase3 assay were performed on cells isolated from the spleen and bone marrow. In vivo Nr4a1 loss was induced by tumor cell injection from Nr4a1−/− mice into the tail vein of wt mice. Kaplan Meier analysis was used for monitoring survival and tumor formation, and FACS analysis for analysis of bone marrow, spleen and tumor, respectively.

Summary/Conclusions: Our results clearly demonstrate the influence of Nr4a1 loss on tumor formation and consequently survival in a Mucy-driven model of lymphomagenesis. Importantly, Nr4a1−/− seems to impact cell death early in B cell development, even ahead of malignant transformation. Additionally, Nr4a1−/− seems to be involved in driving immune responses towards an anti-inflamatory, tolerogenic phenotype, thereby facilitating tumor growth and in altering the tumor environment. Collectively, these data underpin the tumor suppressive function of Nr4a1 in aggressive lymphomas.

E1365 MUTATIONAL PROFILING OF HODGKIN- AND REED-STERNBERG CELLS (HSRC) OF CLASSICAL HODGKIN LYMPHOMA (CHL) ENRICHED FROM ARCHIVAL FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE SAMPLES

D. Juskevicius1,*, D. Jucker1, T. Dietsche1, V. Perrina1, C. Ruiz1, S. Dimhofer1, A. Tzankov1
1Institute of Pathology, University Hospital Basel, Basel, Switzerland

Background: chL can be cured in the majority of cases. However, ~10–20% patients die of the lymphoma after relapse or progressive disease. There are unmet needs for understanding the mechanisms that cause chL relapses, for development of new prognostic/predictive markers and effective targeted therapies. Comprehensive genetic characterization and advance in understanding the molecular pathways in CHL are indispensable to meet those needs. However, genetic information on chL is still scarce mainly due to difficulties of isolating malignant HSRC, whose overall frequencies in the affected tissues range from 0.1-5%. Formalin-fixed paraffin-embedded (FFPE) tissue archives are the most abundant source of clinically annotated tumor specimens. However, FFPE tissue usability is limited because of poor DNA quality and difficulty to enrich neoplastic cells. Therefore, new enrichment techniques are necessary to enable larger scale comprehensive genetic investigations of chL.

Aims: Our aims were: 1) to develop a technique for HSRC enrichment from the archival formalin-fixed paraffin embedded tissue; 2) to reliably detect genetic aberrations in the genomes of enriched tumor samples and to use this information for development of new prognostic and predictive markers as well as for better understanding of the genetic background of chL.

Methods: We have developed a novel high-throughput method for marker-based enrichment of archival FFPE tissue-derived HSRC nuclei by fluorescence-assisted sorting of cells (FACS). Genomic DNA extracted from sorted nuclei was used for identification of mutations in 68 genes that are frequently mutated in lymphomas by targeted high throughput sequencing (HTS). Chromosomal copy number aberrations were investigated by the Agilent SurePrint 180k microarray.

Results: Enzymatically extracted FFPE tissue-derived cell nuclei retain their karyotypic structure and can be used for analysis with microarray and next generation sequencing. Mutations of STAT6, PIM1, SOCS1, KMT2D occurred in almost 18% (218 of 12) of genes. Additionally, individual cases contained copy number aberrations such as gain of chr2 (CREL locus), focal deletions of chr4, chr7, chr16 and chr19 affecting genes such as JAK3, CDKN2D, MAP2K3 and NOTCH3. Taken together our study demonstrates that DNA extracted from the enriched cell populations is suitable for wide-scale genetic profiling.

Summary/Conclusions: A novel rare-cell-enrichment technique is suitable for genetic chL studies and opens the possibility for the wider use of archived tissue.
LACK OF STAT1 PREDISPOSES TO A DIFFUSE LARGE B-CELL LYMPHOMA-LIKE DISEASE

S. Tripolt1,*, C. Schnekenleithner1, A. Hoelbl-Kovicic1, G. Heller2, V. Sexl1
1Institute of Pharmacology and Toxicology, Veterinary University of Vienna, 2Department of Medicine I, Medical University of Vienna, Vienna, Austria

Background: The highly conserved JAK-STAT signaling pathway regulates proliferation, differentiation, apoptosis and immune responses. Activating mutations in STAT3 are considered to drive the development of diffuse large B-cell lymphomas (DLBCL). STAT1 is a critical counter-player of STAT3. Of note, many STAT1 target genes are frequently altered or mutated in DLBCL patients, such as SOCS-1, B2M, PDL1, CARD11, CIITA and BCL6. We observed that the loss of STAT1 suffices to provoke spontaneous haematopoietic tumors in mice.

Aims: We aimed at investigating the underlying mechanisms of spontaneous hematopoietic tumor formation in STAT1-deficient mice.

Methods: We characterized the spontaneous haematopoietic tumors by FACS and morphological analysis. To identify the cell of origin for the disease, we performed bone marrow transplantation assays. We high-purity FACS-sorted individual cell populations of diseased STAT1-deficient mice and transplanted them into recipient mice. Ex vivo, the tumors were characterized for lineage-specific surface marker expression and identified as B-cells. Malignant B-lymphoid STAT1-deficient cell lines were established and expression levels of typical lymphoid-specific tumor suppressor and promoter genes were assessed by qPCR. In parallel, Stat<sup>-/-</sup> cell lines were used for RNA-seq analysis to identify the signaling pathways driving disease. RNA-seq data were compared to publicly available RNA-seq data from different hematological malignancies.

Results: STAT1-deficient mice develop a myeloid hyperplasia that manifests with an incidence of 60% and is characterized by the absence of Rigi. Transplantation of bone marrow unmasked the development of a B-cell malignancy, which can be transferred by CD19<sup>+</sup> cells. The malignant B-cells arising in Stat<sup>-/-</sup> mice can be maintained in vitro and display alterations in gene expressions that are typically found in human DLBCL such as IRF4, PRDM1 and P53. RNA-seq analysis revealed features shared with human DLBCL: increased reads a local tumor suppressor gene network, which was repressed and TP53 and CD72 (PDL1) and decreased expression of SOCS-1, Cdkn1a and B2m and PRDM1. Low levels of Stat1 together with low levels of p16<sup>NK4A</sup> correlate with a reduced life expectancy in DLBCL patients.

Summary/Conclusions: Loss of STAT1 in B/c B-cells provokes a myeloid hyperplasia which masks a B-cell malignancy resembling human DLBCL. DLBCL patients with low levels of STAT1 have a poorer prognosis if they lack the tumor suppressor p16<sup>NK4A</sup>.

MOLECULAR HETEROGENEITY OF MANTLE CELL LYMPHOMA

O. Cédile1,*, M.C. Hansen1, L.H. Ebbesen2, H.H.N. Bentzen2, M. Thomassen3, O. Cederqvist4, M. Nørgaard5, C.G. Nyvold1,*, M.C. Hansen1, L.P. Christiansen1, L. Hansen1, C. H. Lawrie1,7,10
1Haematology-Pathology Research Laboratory, Department of Haematology, Odense University Hospital, Odense C, 2Department of Haematology, Aarhus University Hospital, Aarhus C, 3Department of Clinical Genetics, 4Department of Pathology, 5Department of Haematology, Odense University Hospital, Odense C, Denmark

Background: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by t(11;14)(q13;q32) leading to constitutive cyclin D1 overexpression and cell cycle deregulation. The survival is still poor, especially for patients resistant to first-line drugs. Although patients are brought in remission, relapses often occur with disseminated lymphoma, which is more difficult to treat. There is a need for a better understanding of the clonal heterogeneity of this disease and to identify new signaling pathways with genes which could be targeted by novel drugs or be used as biomarkers to predict response to treatment.

Aims: To address the genetic heterogeneity in MCL in paired patient samples at diagnosis and relapse.

Methods: Highly pure malignant B-cell populations were isolated using fluorescence-activated cell sorting in four patients diagnosed with MCL. In addition T-cells were sorted from the same patients as paired non-malignant control samples. RNA was performed on both the malignant B-cell population and paired T-cells (13 samples in total). Mutations were detected in parallel with CLC Biomedical Workbench 2.5 (Qiagen) and MuTect 1.04 (Broad Institute) (coverage ≥ 20, population allele frequency<0.01) and evaluated for their significance with the online COSMIC (Wellcome Trust Sanger Institute), dbSNP and PubMed databases. Exon sequence from informed consent was approved by the National Ethical Committee.

Results: Our data highlighted in each patient persistent gene modifications between diagnosis and relapse. We confirmed gene mutations already well-known in B-cell malignancies (e.g. TP53, NOTCH1 and MYD88). Interestingly, aberrations not previously described in the COSMIC database, were observed with high allele frequency both at diagnosis and at relapse. This included genes in B-cell signaling (e.g. transcriptional repressor SPEN associated to NOTCH pathway regulation and blockage of the precursor B-cell differentiation), inflammatory response (e.g. IRG1), genes found in invasive carcinoma (e.g. integrin β4), and BCL6. Mutations in these genes were associated with cell proliferation or hit in putative drivers, new gene modifications as well as loss of previous ones could be observed at relapse. For example, genes involved in embryonic development and cell fate (e.g. the transcription factor SOX1) and genes involved in inflammation (CCL13) were not previously correlated to MCL and were novel at relapse. This suggests that a modified malignant clone has evolved and progressed. No gene modification was observed to be shared by all four patients. However, aberrations in the same signaling pathways were identified across individuals. From allele frequency distribution detected with MuTect we could detect discrete clonal or competing subclonal involvement: A patient harbored one major discrete clone at diagnosis while at relapse two clones were identified, whereas in another patient presented a diffuse clonal pattern at diagnosis and a more discrete biallelic pattern at relapse.

Summary/Conclusions: Our work shows examples of molecular progression from diagnosis to relapse in MCL and supports the heterogeneous nature and genetic complexity of this disease. We confirm mutations in genes already known as involved in the B-cell signaling pathways. This adds valuable knowledge to the biological understanding of MCL which is pivotal in the era of precision medicine.

NOVEL TARGET GENES OF DEREGULATED MRNAS IN DLBCL REVEALED BY ENDOGENOUS AGO2 PAR-CLIP

M. Fernandez-Mercado1,2, E. Larrea1, I. Cerbeiro1, I. Goicoechea1, O. Echaniz1, J. Buratti5, Y. Luo1, M. Araujo-Bravo5,6, M. Landthaler5,9, C. H. Lawrie1,7,10
1Oncology, Biodonostia HRI, 2Biomedical Engineering, School of Engineering, University of Navarra, 3Haematology and Haemotherapy, Donostia University Hospital, 4Computational Intelligence Group, University of the Basque Country (UPV/EHU), 5San Sebastian, Spain, 6Julien Buratti Bioinfo Consult, Plaisir, France, 7Computer and Biological Systems Biomedicine, Biodonostia HRI, San Sebastian, 8Ikerbasque, Basque Foundation for Science, Bilbao, Spain, 9Medical Systems Biology, Max Delbrück Center for Molecular Medicine, 10University of Oxford, Oxford, United Kingdom

Background: Aberrant expression of microRNAs (miRNAs) is a widespread phenomenon in cancer. However, the functional complexity of such techniques is the need for exogenously produced tagged proteins. In parallel, we have recently demonstrated that over-expression in pre-B cells or haematopoietic stem cells leads to oncogenic transformation (Costinean, 2006; O’Connell, 2008). Given their relevance, DLBCL and mir-155 were chosen as models for the present study.

Aims: We set ourselves to adapt PAR-CLIP technique to allow non-engineered cells to be used based on IP of endogenous levels of Ago2. In addition, we also aimed at testing the minimum number of input cells needed for miRNA target identification.

Methods: Two DLBCL cell lines (ABC-type RIVA, and GC-type SUD-HL10) were transfected with lentiviral vectors that encoded mir-155. In parallel, we transfected these cells with an inhibitor of mir-155 or with a scrambled sequence, as experimental controls (for reducing the number of false positives). Cells were then stably selected with puromycin, and grown in the presence of 100 μM 4SU for 18 h. Different amounts of these cells (300M, 50M and 10M) were then irradiated to cross-link the RNA to RNA-binding proteins. PAR-CLIP was then performed on cell lysates using anti-Ago2 mAbs for IP. The original protocol (Hafner, 2010) was modified to eliminate radioactive labelling. The reverse transcription was performed using SuperScript Small RNA Sample Kit v1 and the sequencing performed on an Illumina HiScanSQ system. After deduplication and alignment, T-to-C variants (indicative of miRNA-dependent binding) were called using wavClusteR.

Results: Endogenous Ago2 IP, followed by a radioactive-free modified PAR-CLIP, protocol yielded sufficient RNA for building libraries for NGS irrespectively of cell input. Samples gave an average ~9.7 x10<sup>6</sup> aligned reads/library. There were an average of 7,370 PAR-CLIP clusters mapping to coding genes (range 4,675 - 11,004, correlating with the number of input cells, r=0.82). In all exper-
...imental conditions we found that a number of the captured genes corresponded to experimentally validated targets of miR-155. Crucially, ontology analysis of the PAR-CLIP-captured genes demonstrated an enrichment of genes involved in haematopoietic and/or lymphomagenesis pathways.

**Summary/Conclusions:** To fully understand the role of a particular miRNA in a specific malignancy, it is essential to identify its target genes in a relevant cellular context. Using a haematopoietic malignancy model of high clinical interest, we have developed an optimized method for interrogating the miRNA:mRNA interface (targetome) within a cellular system without the need of ectopically expressed Ago2, keeping physiological levels of the core component of the RISC complex unaffected. Moreover, our optimized protocol allowed us to reduce the number of input cells, therefore opening the exciting possibility of interrogating the targetome of patient primary samples.

**E1369**

**DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA**

A. Matas-Céspedes1, A. Vidal-Crespo1, V. Rodríguez1, C. Rossie2, G. Roué1, A. López-Guillermo3, E. Giné3, A. Westreer4, C. Bezonm5, E. Campoo6, D. Colomer7, S. Balasubramanian5, C. Chu6, P. Doshi5, P. Pérez-Galan1

1Hematology-Oncology, IDIBAPS, Barcelona, Spain, 2Hematology-Oncology, Centre de Recherche en Cancérologie de Toulouse (CRCT), Toulouse, France, 3Hematology-Oncology, Hospital Clinic, Barcelona, Spain, 4R&D, Janssen, Spring House, PA, United States

**Background:** Daratumumab (DARA) is a first-in-class human monoclonal antibody that targets the CD38 epitope and is approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) patients. DARA is currently being evaluated in phase II clinical trials as monotherapy in patients with R/R Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL). In vitro, DARA induced long-term growth inhibition through high-affinity mediated mechanisms in MM, including Antibody-Dependent Cellular Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC) (de Weers M. J Immunol, 2011) and Antibody-Dependent Cellular Phagocytosis (ADCP) (Overdiik MB. Mabs, 2015). In Chronic Lymphocytic Leukemia (CLL), DARA induces killing mainly via ADC and ADCP (Matas-Céspedes A. Clin Cancer Res, 2016). Furthermore, Immunomodulatory effects (Krnickj J, Blood, 2016) and modulation of the enzymatic activity of CD38 (Lammerts van Bueren J. Blood, 2014) have been described to contribute to its antitumor activity.

**Aims:** To evaluate the activity of DARA on MCL and FL cells as monotherapy and in combination with current therapies, both in vitro and in vivo.

**Methods:** ADC, CDC and ADCP activities were assessed by calcein release or flow cytometry. Penetration of DARA was analyzed in a 3D model by Selective Plane Illumination Microscopy (SPIM). Molecules per cell were analyzed using Qifikit and flow cytometry. In vivo activity was assessed in prophylactic and therapeutic set ups using SCID mice subcutaneously (sc) or intravenously (iv) injected with 1x10^7 of MCL or FL cells. Mice were treated (human IgG control or DARA) with two different schedules: prophylactic (3 doses of 10mg/kg one dose per week) or therapeutic (20/10/10/10mg/kg, one dose per week). For the combination regimens in FL, sc injected SCID mice were treated following the therapeutic schedule in combination with Rituximab (20/10/10/10mg/kg, one dose per week) and/or CHOP (initial unique dose).

**Results:** DARA (0.0001-1µg/mL) induced ADC in a dose-response manner on MCL (n=6) and FL (n=4) cell lines in the presence of PBMCs in vitro. Moreover, DARA induced significant levels of ADCP at 1µg/mL on MCL (n=6) and FL (n=4) cell lines in the presence of murine macrophages in vitro. However, DARA did not induce significant CDC in any of these models due to a high expression of the complement inhibitors CD46, CD55 and CD59, and insufficient number of CD38 molecules per cell. In a 3D model of FL, SPIM analysis revealed a maximum penetration of DARA at 1µg/mL after 48h of treatment. We tested DARA activity in vivo in two different mouse models (sc and iv) of MCL and FL. In the prophylactic setting, DARA completely prevented the outgrowth and induced tumor regression of MCL (n=6) and FL (n=6) subcutaneous tumors. In the therapeutic setting, DARA significantly increased the overall survival of mice and reduced organ infiltration of tumor cells both in the MCL (n=10) and in the FL (n=10) systemic xenograft models. In addition, the combination of DARA with Rituximab/CHOP regimen in FL, resulted in a synergistic reduction of tumor growth (n=7-10).

**Summary/Conclusions:** DARA shows encouraging cytotoxic activity in MCL and FL cells, with significant activity in the presence of external effectors in vitro. In vivo, DARA exerts unique and substantial effects as single agent on MCL and FL tumor cell growth in different mouse models and contributes to potent therapeutic efficacy in combination with current approved therapies. These results warrant further studies of DARA in the clinical setting for these conditions.

**E1370**

**ECTONUCLEOTIDASES CD39/CD73 ARE HIGHLY EXPRESSED ON ATLL CELLS AND RESPONSIBLE FOR GENERATING AMP/ADENOSINE**

Y. Nagate1, S. Ezeo1, J. Fujita1, M. Ichii1, J. Toda1, K. Oritani1, Y. Kanakura1

1Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan

**Background:** Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell neoplasm, linked to the human T-cell lymphotropic virus, HTLV-1. Patients with ATLL are often at the risk of opportunistic infections. It might be possible that the immunocompromised state could be induced by the function of ATLL cells having similar phenotypes with regulatory T cells (Tregs). However, difficulties of in vitro studies using primary tumor cells have hampered the progress of ATLL research, and it is still controversial whether ATLL tumor cells have the immunosuppressive characteristics.

**Aims:** In this study, we analyzed the roles of molecules expressed in ATLL cells associated with immunosuppressive functions of Tregs.

**Methods:** The protocol of this study was approved by the Investigational Review Board of Osaka University Hospital. Peripheral blood mononuclear cells (PBMCs) were collected from 8 asymptomatic HTLV-1 carriers and 20 ATLL patients (3 with smoldering type, 5 with chronic type, and 12 with acute type) after getting informed consent. PBMCs from 3 ATLL patients were separated into CD4+CD7-CADM1+ ATLL cells and adjacent CD4+ CD7+CADM1- normal T cells using Fluorescence-activated Cell Sorter (FACS), and total RNA sequencing experiments were conducted. And we also examined the expression patterns of CD39 and CD73 in ATLL patients or carriers or each type of ATLL patients.

**Results:** We compared whole transcriptome of ATLL cells and normal CD4+ cells. Bioinformative analyses showed that many genes associated with immunosuppressive functions of Tregs were elevated or downregulated in ATLL cells. Among these genes we focused on CD39, CD73 and CD26, because recently it has been reported that extracellular adenosine, which is catalyzed by CD39, expressed in human Tregs, and CD73, expressed in murine but not in human Tregs, has strong anti-inflammatory function and plays major role in T-reg-mediated immunosuppression. Therefore, we investigated the expression of CD39 and CD73 in ATLL cell lines and primary tumor cells. We found that all of 4 ATLL cell lines expressed CD39, but not CD73 just as human effector Tregs. In contrast, the expression patterns of CD39 in 20 ATLL patients were various (Table) and interestingly, some ATLL tumor cells express CD73. Also in asymptomatic carriers, we could detect CD39 and/or CD73 positive on CD7+CADM1+ abnormal fraction of CD4+ cells. CD26, expressed in human naive but not in effector Tregs, was negative in all cell lines and primary cells except for abnormal cells in one smoldering patient. Next, the role of CD39 and/or CD73 in ATLL cells was assessed. Extracellular ATP is converted into AMP by CD39. As expected, CD39+ ATLL cells converted significantly more ATP than CD39- ATLL cells, which was not possible with normal effector Tregs. Conversely, mass spectrometry analysis of AMP/adenosine concentration indicated the activity of CD39 mediated AMP hydrolysis was very slow; less than 10% of 1mM AMP was converted to adenosine by CD73+ ATL cells, indicating that the aberrant expression of CD73 could not efficiently increase adenosine synthesis.

**Table 1.**

<table>
<thead>
<tr>
<th>Molecule</th>
<th>ATLL Cells</th>
<th>Normal Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD39</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>CD73</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>CD26</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** In this study, we showed that about two thirds of ATLL samples were CD39+CD73+ just as effector Tregs and have comparable level of ATPase activity as Tregs, which are expected to play some immunosuppressive function in ATL patients. Recently it is also reported that in exhausted CD8+ T cells in cancer patients, CD39 is co-expressed with PD-1. CD39 expression in ATLL cells may also have some roles in immunosuppression and thus in the escape from anti-tumor immunity.

**E1371**

**Abstract withdrawn.**

**E1372**

**ACTIVATION OF SYK TYROSINE KINASE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO-GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)**

K. Tsukamoto1,2, W. Harriet3,4,5, J. Sandrine1,3, M. J. Dyer1,2,3

1Cancer studies, 2Molecular and Cell Biology, 3The Ernest Waudby and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom

**Background:** The B-cell receptor (BCR) pathway is implicated in the survival...
and proliferation of several B cell malignancies. BTK is a key regulator of this pathway. In a preliminary clinical study, STRO-001 showed therapeutic activity in relapsed/refractory DLBCL of the Activated B-cell phenotype (ABC-DLBCL) (Walter et al Blood 127pp 411-419, 2016). However, median treatment duration in ABC-DLBCL was only 3 months due to progressive disease and development of resistance. Two acquired resistant mutations (C481S and R665W) have been reported as dominant negative mechanisms to BTK inhibition in CLL but resistance mechanisms in DLBCL have not been fully elucidated.

Aims: To determine resistance mechanisms in the ABC-DLBCL TD8 cell line and determine new rational combinations to take into the clinic with ONO/GS-4059.

Methods: The ABC-DLBCL sensitive ABC-DLBCL cell line TD8 was cloned ONO/GS-4059 and ibrutinib resistant TD8 cell lines (TM8RO and TM8RI) were used for this study. TM8RO has PLC\gamma2 R665W whilst TM8RI lacks both BTK C481S and PLC\gamma2 R665W. Cell viability and apoptosis after compound treatment were assessed using Cell titer Glo assay and Annexin V / PI staining. Ex vivo whole blood samples were collected from the peripheral blood of healthy volunteers and from 12 patients with diffuse large B-cell lymphoma (DLBCL), 3 activated B-cell (ABC) DLBCL, and 4 mantle cell lymphoma (MCL) cell lines with EC50 values ranging from 0.17-13 nM. STRO-001 has only modest effects on naive B-cells, but exhibits more potent cell killing in activated human B-cells that have upregulated CD47 expression (similar CD47 expression as SU-DHL-6 cell line). CD47 cell surface expression is required for STRO-001 cytotoxic activity but expression level, as measured by antibody-binding capacity, does not correlate with in vitro potency (R2=0.4154). STRO-001 exhibits dose-dependent tumor growth inhibition in rituximab-resistant SU-DHL-6 xenografts starting at 2.5 mg/kg weekly x 3 doses. The standard of care combination of bendamustine/ rituximab (BR) + STRO-001 further improves tumor suppression in SU-DHL-6 xenografts compared to vehicle (p<0.001) starting at a single STRO-001 dose of 3 mg/kg, with a single 10 mg/kg dose resulting in tumor regression for up to 64 days post treatment. STRO-001 treatment 14 days post tumor inoculation was used to evaluate disease progression in the SU-DHL-6 xenograft model. Jeko-1, demonstrate potent anti-tumor activity compared to vehicle (p<0.001) starting at a single STRO-001 dose of 3 mg/kg, with a single 10 mg/kg dose exhibiting improved survival, with most animals healthy and disease free at the time of sacrifice 135 days post inoculation. STRO-001 demonstrated B-cell depletion in cynomolgus monkeys, confirming the intended pharmacodynamic effect. Myelosuppression was observed at the highest dose but there was no evidence of off-target toxicity.

Table 1.
formed following the BIOMED-2 design and protocol. All PCR experiments were done in duplicates, and cases were considered PCR+ when both duplicates showed the same clonal pattern, ruling out false positivity (pseudoclonal pattern) often seen in paucicellular samples.

Results: We confirm that FCM and PCR are more sensitive than CM. Indeed, every CM+ cases (n=16) was also FCM+ and/PCR+ while 13 cases were PCR+ but CM+. A total of 269 samples showed similar results by FCM and PCR with presence (n=22) or absence (n=247) of lymphomatous cells whereas 25 samples were classified as suspicious by at least one technique. Eleven samples were FCM+ but PCR-. False negative (FN) PCR results can be explained in part by extensive somatic mutation in IG genes, preventing optimal amplification of the targeted VDJR regions. BCL-2 targets less prone to somatic mutations, such as IGL, should therefore be evaluated. Conversely, 21 samples were PCR+ but FCM-. Absence of FCM detection might have resulted from the presence of very large lymphomatous cells outside the scope of analysis. Also, rapid cell death is an issue with FCM (preventing detection of the underdosed targeted VDJR region). Thus, molecular techniques often systematically require intact cells. Most of the difficulties encountered with both methods are due to occul blood contamination and poor cellularity, leading to low-intensity clonal signals by PCR and inconsistent clusters of events with FCM. In addition discordant results between FCM and PCR might be explained by sampling heterogeneity. Considering those limitations, it seems highly advisable to choose the best suited method for the follow-up according to the results at diagnosis.

Summary/Conclusions: Our results suggest that a multimodal investigation using FCM and PCR is necessary for improved detection of leptomeningeal dissemination in B-cell malignancies. It seems premature to make clinical decisions based on a single technology. Both methods, which suffer limitations that need to be acknowledged, are complementary and should be performed at diagnosis. Specific limitations of each one of them should be taken in consideration for follow-up studies.

E1376
THE SYK INHIBITOR R406 DRAMATICALLY INCREASES THE SENSITIVITY OF GCB AND ABC DLBCL CELL LINES TO THE BCL-2 INHIBITOR VENETOCLAX

Background: The BCL-2 inhibitor venetoclax demonstrated significant single-agent activity in recent clinical trials of relapsed/refractory chronic lymphocytic leukemia (CLL). However, results in other B-cell malignancies characterized by BCL-2 overexpression have not been equally impressive. This particularly refers to diffuse large B cell lymphoma (DLBCL), where only 18% of patients responded to treatment with venetoclax in a recent phase I clinical trial (Davis MS et al, J Clin Oncol. 2017).

Aims: Investigate whether the SYK inhibitor R406 can increase sensitivity of DLBCL cell lines to venetoclax.

Methods: The following cell lines were used: Ly4, Ly1, Ly7, Ly18, DHL4, Toledo and BJAB (all GCB DLBCL) and U2932, DHL2, Ly3, Ly10, HBL1 and TMD8 (all ABC DLBCL). The percentage of apoptotic cells was determined by Annexin V/FITC staining and flow cytometry analysis. Expression of BCL-2 family members was determined by immunoblotting or qR-PCR analysis.

Results: In a recent study, we showed that MCL-1 increases the resistance of anti-IgM stimulated CLL cells to venetoclax, and that SYK inhibitors can effectively overcame this resistance by blocking B cell receptor (BCR)-mediated MCL-1 upregulation (Bojarczuk K et al. Blood. 2016). Since constitutive activation of the BCR pathway has been described in both ABC and GCB DLBCL (Davis RE et al, Nature 2010; Chen L et al, Cancer Cell. 2013), we investigated whether treatment with the SYK inhibitor R406 can sensitize DLBCL cells to venetoclax. Single-agent venetoclax had only modest activity against most DLBCL cell lines at concentrations ranging up to 0.25 μM (Figure 1). Substantial apoptosis induction (>20%) was observed in only 2 GCB (Ly1 and Ly18) and 2 ABC (U2932 and Ly10) cell lines. R406 as single agent had almost no effect on tumor cell viability, with only one cell line showing >20% apoptosis induction (HBL1). However, addition of R406 to venetoclax resulted in a dramatic increase in the number of apoptotic cells in six of the investigated cell lines (Ly18, DHL4, U2932, Ly10, HBL1 and TMD8). A synergistic effect was also observed with Ly1 using a lower concentration of venetoclax, whereas no effect or only an additive effect was observed in the remaining cell lines (Ly4, Ly7, Toledo, BJAB, DHL2 and Ly3). Among these, only Toledo expressed similar levels of BCL-2 to venetoclax sensitive cell lines whereas the levels of BCL-2 in the other cell lines were extremely low or undetectable. To understand the mechanisms how R406 increases the sensitivity of DLBCL cells to venetoclax, we evaluated changes in the expression of MCL-1 and other antiapoptotic BCL-2 family proteins that have been associated with venetoclax resistance. Five of the seven R406 + venetoclax sensitive cell lines (Ly1, DHL4, U2932, HBL1 and TMD8) showed a 20-45% reduction in MCL-1 levels following 24 hours culture with 2μM R406, whereas no changes were observed in Ly18 and Ly10. However, a substantial reduction in A1 levels was observed in Ly18 and U2932 cells, whereas no substantial changes in A1 and BCL-xL expression were detected in any of the other investigated cell lines. Finally, we also investigated the effects of R406 on expression of HRK, which is a proapoptotic BCL-2 family member that was recently shown to be induced by SYK inhibition in a subset of GCB DLBCLs (Chen L et al, Cancer Cell. 2013). A substantial increase in HRK expression (140-640%) was observed in 5 of the 7 R406 + venetoclax sensitive cell lines (Ly1, Ly18, DHL4, U2932 and TMD8).

Figure 1.

Summary/Conclusions: These data show that the SYK inhibitor R406 can significantly increase the sensitivity to venetoclax in the vast majority of BCL-2 positive DLBCL cell lines. The mechanisms of action require further investigation, but are likely to involve downregulation of MCL-1 and upregulation of HRK in a substantial proportion of cases.

E1378
VB EXPRESSION ASSESSMENT AND CLONALITY DETECTION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) BY FLOW CYTOMETRY (FCM) AND NEXT GENERATION SEQUENCING (NGS): A COMPARISON OF BOTH METHODS

Background: VB repertoire analysis can distinguish monoclonal from polyclonal (reactive) T-cell proliferations. The molecular quantification of clonal T-cell receptor (TR) gene rearrangements can also be used to record minimal residual disease (MRD) in T-cell malignancies. TR clonality can either be assessed by FCM employing VB antibody panels covering ~70% of the normal human TR VB repertoire or by molecular techniques like NGS with primers that amplify virtually all possible VB-Vβ rearrangements. T-PLL is the most common (post-thymic) T-cell leukemia. Clonal TR gene rearrangements are detected in virtually all T-PLL by FCM or PCR from peripheral blood (PB) or bone marrow samples.

Aims: To compare the results of parallel TRB-based clonality analyses by FCM and NGS in T-PLL.

Methods: We investigated diagnostic PB leukocytes of 73 T-PLL patients with median lymphocytes at 66% (range 13-93; harboring T-cells at 97% (55-100)), FCM of surface (not intracellular) VB expression was assessed by the IOTest Beta Mark kit (Beckman Coulter). Libraries for NGS were prepared using 100ng of DNA via a 2-step PCR and sequenced on the Illumina MiSeq (2x250bp, v2) with a median coverage of 17,908 reads (range 1,125–41,193)/sample. In the first PCR TRB rearrangements were amplified using TRB BIOMED-2 V- and J-regions primers (van Dongen et al, Leukemia 2003). In the second PCR step, sequencing adaptors and sample-specific barcodes were added. Annotation of V, D, and J-regions of TR sequences was done using ARREST/Interrogate (Bystry et al, Bioinformatics 2016).

Results: In all samples one or two dominant clonal TRB rearrangements were detected by NGS and represented in median by 83% of reads (range 15-90%). In 36/73 (49%) of these cases, also FCM demonstrated clonality. Interestingly, in 8/36 (22%) of cases the dominant VB by FCM differed from the molecular clonotype. In 5 of these cases the discrepancy was most likely accountable to a non-functional TRB clone detected by NGS corresponding to a bi-allelic TRB rearrangement with the second non-functional allele being preferentially identified by NGS. In 37/73 (51%) of cases no reactivity with one of the Vβ antibodies was seen. In 16 (43%) of these cases this could be attributed to expression of a TRB rearrangement for which the appropriate Vβ antibody was not present in the FCM panel. In another 12 (33%) of these cases a non-productive TRB rearrangement represented the dominant NGS clonotype. However, in further 9 cases (24%), the functional TRB clonotype (TRBV 5-6, 6-5, 25-1, 18-20, 1-27) was not detected by FCM despite theoretical coverage. Of note, overall 10/73 T-PLL (14%) lacked surface TRa/β chain expression.

Summary/Conclusions: T-cell clonality is detected by TRB NGS in all T-PLL, whereas FCM-based VB repertoire analysis identifies a dominant single VB
**E1377**

**IRF4 EXPRESSION IS ASSOCIATED WITH RESPONSE OF MANTLE CELL LYMPHOMA TO BRUTON’S TYROSINE KINASE INHIBITORS**

H.P. Thompson1, D.L. Tucker2, S.A. Rule1, C.V. Hutchinson1, 2

1Institute of Translational and Stratiﬁed Medicine, Plymouth University, Peninsula Schools of Medicine and Dentistry, 2Clinical Haematology, Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, United Kingdom

**Background:** Mantle cell lymphoma (MCL) responds poorly to conventional chemotherapy. Inhibitors of Bruton’s tyrosine kinase (BTK) have unexpectedly shown signiﬁcant clinical effect; however despite this success, approximately one third of MCL patients have primary resistance to the drug, and patients who initially respond to treatment frequently acquire secondary resistance and aggressive relapse of the disease. Understanding how BTK resistance or sensitivity is mediated can identify new targets for therapy or predictive biomarkers of response. Using an in vitro model system we have identiﬁed the transcription factor IRF4 as a sensitive indicator for BTK response in MCL cell lines and primary samples.

**Aims:** To identify molecules or pathways responsible for resistance to BTK inhibitor-drugs in mantle cell lymphoma using cell line models and primary cells.

**Methods:** Primary cells and validated MCL cell lines (REC-1, GS19, Jeko-1, JVM2) were cultured either alone, or together with murine stromal cells (with or without CD40L transfection). The BTK sensitive REC-1 cell line was continuously treated with BTKi to generate an acquired resistance model. Cultures were treated with BTKi drugs: ibritinib or acalabrutinib in the presence or absence of B-cell receptor or CD40L stimulation, and their sensitivity or resistance to treatment was determined using ﬂow cytometry to assess proliferation (Ki67), apoptosis (Annexin-V), or phosphorylation of BTK (pY223). Changes affecting downstream proteins were determined by protein expression or phosphorylation analysis (immunoblotting) and by mRNA expression (RT PCR).

**Results:** Each MCL cell line showed basal phosphorylation of BTK (Y223) and its downregulation in response to BTKi; this downregulation was an early and speciﬁc response (mRNA downregulated after 4 hours, and protein expression after 8 hours). Furthermore in REC-1 cells with acquired partial resistance to BTKi, the downregulation of IRF4 was signiﬁcantly less than in the parental cell line. Finally in vitro co-culture of REC-1 cells with CD40L prevented IRF4 downregulation; this could be rescued by co-culturing with primary MCL cells, which included in vitro CD40 induced proliferation, survival, prevented BTKi-induced IRF4 downregulation and protected the cells from BTKi-induced death. These ﬁndings were conﬁrmed using ex vivo samples from treated patients (n=7) analysed before and during BTKi treatment. IRF4 was downregulated in 6 samples from patients shown to be clinically responding to BTKi and was not downregulated in 1 refractory case. The expression of IRF4 is upregulated in patients with clinical response.

**Summary/Conclusions:** BTK inhibition in primary samples led to early and speciﬁc downregulation of IRF4, which correlated with clinical response to BTKi. The sensitivity of MCL cell lines was dependent on their ability to downregulate IRF4 in response to BTKi. These results indicate that the sensitization to BTKi can be achieved by downregulation of IRF4. Additionally, these results suggest that the sensitivity to BTKi can be achieved by downregulation of IRF4.

**E1378**

**LOSS OF TPL2 KINASE ACCELERATES MYC-INDUCED LYMPHOMAGENESIS**

E. Stagakis1,2, D. Vyrta1, H. Papadaki3, E. Drakos3, A. Eliopoulos1

1Laboratory of Molecular and Cellular Biology, Medical School, University of Crete, 2Department of Hematology, University Hospital of Heraklion, 3Department of Pathology, Medical School, University of Crete, Heraklion, Greece

**Background:** While MYC (8;14)(q24;q32) translocation was initially identiﬁed as a hallmark of Burkitt lymphoma, a number of other B-cell neoplasms are associated with MYC deregulation. These MYC-driven non-Hodgkin lymphomas have aggressive clinical behavior and respond poorly to treatment. However, MYC-dependent lymphomagenesis is believed to require additional oncogenic alterations, such as deregulation of genes that counteract the proapoptotic functions of MYC. TPL2 is a MAP3 kinase with an obligatory role in inﬂammatory signal transduction on the MEK/ERK axis but little is known about its involvement in B-lymphocyte biology and lymphomagenesis.

**Aims:** The aim of this study is to deﬁne the impact of and the mechanism by which TPL2 kinase affects MYC-induced lymphomagenesis.

**Methods:** CD19+ positive B lymphocytes were isolated from peripheral blood of human healthy individuals and mouse B cells from spleens of WT (C57BL/6) and lymphomagenic mice engineered to overexpress c-myc in B cell progenitor cells under the control of the IgH chain enhancer. Mouse pre-B lymphocytes were isolated from bone marrow by ﬂow cytometric cell sorting. Differentiation status of lymphomas was analysed by ﬂow cytometry using B220, IgM and IgD antibodies. The TPL2 RNA and protein expression levels were assessed by qPCR and Western blot analysis, respectively. The extent of apoptosis was estimated by immunohistochemical evaluation of activated caspase-3 in parafﬁn embedded mouse lymphoma tissues and by flow cytometry using Annexin and 7AAD staining of ex vivo cultured lymphoma cells following cytokine deprivation.

**Results:** TPL2 RNA levels were found dramatically decreased in various human Burkitt lymphoma cell lines as well as in 7 primary Burkitt lymphoma biopsies compared to B lymphocytes of healthy individuals. In line with this finding, both pre-B and B lymphomas derived from Eμ-myc mice express very low levels of TPL2 RNA and protein levels, compared to pre-B and splenic B lymphocytes isolated from WT mice. Interestingly, pre-B and B lymphocytes of healthy (premalignant) Eμ-myc mice express TPL2 in comparable levels to their WT counterparts, suggesting that the reduction of TPL2 expression in lymphomas is an additional oncogenic alteration. In this regard, genetic ablation of TPL2 in Eμ-myc mice (Eμ-myc/tpl2−/−) signiﬁcantly shortened their survival to 92 days from 140 days of Eμ-myc/tpl2+/+ mice (p<0.005). Eμ-myc/tpl2−/+ mice also displayed a trend to develop more pre-B lymphomas compared to Eμ-myc/tpl2+/+ mice. This may be attributed to the decreased TPL2 expression in mouse pre-B lymphocytes, while it is upregulated in mature B-lymphomas. Finally, Eμ-myc/tpl2−/− lymphomas displayed reduced levels of apoptosis.

**Summary/Conclusions:** This study reveals a novel pathway during MYC-driven lymphomagenesis. We show that MYC deregulation imposes selective pressure in favor of clones with decreased expression of TPL2 kinase. This process seems to be advantageous for the malignant clone, since genetic ablation of TPL2 in the Eμ-myc mouse model accelerates MYC-induced lymphomagenesis likely by contributing to apoptosis resistance.

**E1379**

**LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRONAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA**

F. Marchesi1,2, G. Regazzò2,3, A. Sacconi2,3, M. Spagnuolo2, S. Donzelli2, F. Palombi1, M. Marino2, C. Ercolani2, A. Di Benedetto2, G. Biandino2, A. Mengarelli1, M. G. Rizzo2

1Department of Stem Cell Transplant, 2Epigenetic and Oncogenomic Unit, Translational Research Area, 3Regina Elena National Cancer Institute, Rome, Italy

**Background:** Up to 40% of Diffuse Large B-Cell Lymphoma (DLBCL) patients still have recurrence following treatment failure or disease relapse after conventional chemotherapy. Therefore, the search of novel non invasive biomarkers able to early identify these patients is warranted in order to offer a different therapeutic approach. Recently, bodily fluids have emerged as an important source of information.
mation in several diseases analyzable by liquid biopsies, representing minimally invasive methods for precision diagnostics and prognosis. Blood extracellular microRNAs (miRNAs) are under investigation as novel biomarkers. While tissue miRNAs in DLBCL patients have been extensively studied, only few reports, and limited to a small subset of miRNAs, evaluated the role of circulating/serum miRNA as potential prognostic factors.

Aims: To identify and validate a serum miRNA signature with prognostic value in a cohort of newly diagnosed DLBCL patients.

Methods: This is a on-going prospective non interventionist study on a cohort of newly diagnosed de novo DLBCL patients uniformly treated with six courses of R-CHOP (Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisone). Serum samples of patients were collected at diagnosis and after the end of treatment. Treatment response was evaluated by standard Cheson criteria. The expression profile of selected circulating miRNAs described as associated with lymphoid malignancies by us (let-7c/miR-99a/miR-125b cluster) and by previously published studies (miR-22, miR-18a and miR-20a) was evaluated by quantitative real time polymerase-chain reaction (qRT-PCR). Serum samples collected at diagnosis of the first 18 patients enrolled into the study. 

Results: Our results showed that the expression level of serum miR-22 as well as let-7c/miR-99a/miR-125b cluster was significantly higher at diagnosis, in patients unresponsive to R-CHOP treatment when compared with responsive patients. On the contrary, miR-18 and miR-20 levels appeared to be not significantly associated to treatment response. In addition, a global expression profile of circulating miRNAs was evaluated in serum samples derived from a smaller cohort of patients (n=4) by first-line chemo-immunotherapy. Interestingly, we found a striking difference in miRNA modulation upon treatment between unresponsive and responsive patients. In particular, we found 31 miRNAs significantly modulated after R-CHOP in the group of responsive patients, including miR-22. In contrast, this miRNA subset did not show remarkable expression changes in unresponsive patients. Moreover, we performed a study interrogating The Cancer Genome Atlas (TCGA) database about miRNA expression levels in samples of DLBCL patients. We found that the only available data are relative to the miRNA expression levels in tumor tissue samples of 47 out of 58 DLBCL patients. Kaplan Meier method and log-rank test revealed a signature of 13 miRNAs with potential prognostic value. Among these we found that miR-22, also emerged as modulated in our genome-wide analysis, was linked to risk of disease recurrence.

Summary/Conclusions: These preliminary data suggest that the serum miR-22 as well as miR-99a/let-7c/miR-125b cluster are of potential interest as non–invasive biomarkers to predict therapeutic response in DLBCL patients. Ongoing experiments in a wider cohort of patients are aimed to confirm these results and unveil potential miRNA signature with predictive value.

E1380 INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL
E. Viventhrarajaa1, J. Grimbien1, A. Braunn1
1Centre for Haematology-Oncology, Barts Cancer Institute, London, United Kingdom

Background: Since the discovery and utilisation of the Type-I anti-CD20 antibody Rituximab, many have tried to enhance the efficacy of anti-CD20 antibodies in order to improve first-line treatment of B cell malignancies, leading to the development of more potent anti-CD20 antibodies. To date, the exact biological role of CD20 and the mechanism of anti-CD20 antibody action remains unclear. However, CD20 has been shown to be involved in the store operated calcium (Ca2+) system. This complex has the ability to facilitate mitochondrial permeabilisation, resulting in reduced mitochondrial function. Basal oxidative phosphorylation (OxPhos), ATP production, and maximal and spare respiratory capacity of cells can be calculated as a measure of mitochondrial function.

Aims: i) Assess and compare intracellular calcium concentration following treatment with anti-CD20 antibodies ii) Evaluate mitochondrial function of cells following treatment with anti-CD20 antibodies iii) Assess whether cytotoxicity of Type-I and Type-II anti-CD20 mAbs can be enhanced by exploiting cellular metabolism

Methods: We established a panel of four DLBCL cell lines (Karpas422, Pfeiffer, OCI-LY7 and SU DLH). Following a 24-hour treatment with one of four anti-CD20 antibodies (Rituximab) and three Type-II anti-CD20 antibodies (BHII2, Obinotuzumab and Tositumomab), intracellular calcium concentration was quantified and visualised using imaging flow cytometry. Next, we used the XF Seahorse Mitro Stress Test to reveal bioenergetic profiles of the cell lines following a 24-hour treatment with the same antibodies. We used Metformin to inhibit oxidative phosphorylation (OxPhos) and then characterised the bioenergetic profile of our cell panel lines again, this time to assess how combining each anti-CD20 antibody with an OxPhos inhibitor affected mitochondrial function. Metformin was also used to reduce the mitochondrial membrane potential (MMP) across our panel of cell lines. We confirmed MMP reduction by staining cells with JC-1, a chameleon dye used as an indicator of MMP and analysed samples using flow cytometry. Under the same conditions, we conducted clonogenic survival assays to see whether cytotoxicity of anti-CD20 antibodies could be enhanced by manipulating metabolism.

Results: Intracellular calcium concentration was decreased across our panel of cell lines following a 24-hour treatment with all Type-II anti-CD20 antibodies in our panel. This decrease was not observed following treatment with the Type-I anti-CD20 antibody Rituximab. Treatment with anti-CD20 antibodies resulted in a significant increase in the maximal respiratory capacity of our panel of cell lines; cells were able to produce more ATP in response to oxidative stress. Conversely, pharmacological inhibition of OxPhos impaired mitochondrial function, causing a significant reduction in basal OxPhos and in maximal respiratory capacity. Under this condition, cells were unable to increase ATP production in response to oxidative stress. We also show that treatment combining Metformin with either Type-I or Type-II anti-CD20 antibodies prevents the increase in maximal respiratory capacity observed with anti-CD20 antibody treatment alone. When analysing the clonogenic survival of cell lines, we have found that only the cytotoxicity of Type-II anti-CD20 antibodies is enhanced by simultaneously treating cell lines with Metformin.

Summary/Conclusions: Our data show for the first time that when cells are treated with Type-II CD20 antibodies, intracellular calcium is decreased. Intracellular calcium remains unchanged following treatment with Rituximab. Next, we show anti-CD20 antibody treatment causes cells to increase maximal mitochondrial respiratory capacity to compensate for reduced basal mitochondrial function. We show that inhibition of OxPhos disables the cells from being able to compensate for the reduced mitochondrial respiratory capacity and as a result, cells lose their ability to increase ATP production in response to oxidative stress. Moreover, our data show that combining Metformin with Type-II CD20 antibodies leads to enhanced cytotoxicity, with a significant reduction in clonogenicity in our panel of DLBCL cell lines.

E1381 CYCLIN D1 ONCOGENIC OVEREXPRESSION LEADS TO A GLOBAL TRANSCRIPTIONAL DOWNREGULATION IN MALIGNANT LYMPHOID CELLS
R. Albero1, A. Enjuanes2, S. Demajo3, G. Cavello4, M. Pino5, N. Garcia6, C. Capdevila7, H. Suarez-Cisneros7, K. Karube4, S. Bela8, I. Martin-Subero1, E. Campo9, P. Jares9
1IDIBAPS, Barcelona, Spain, 2Genomics Unit, IDIBAPS, 3Molecular Biology Core, Hospital Clinic, Barcelona, Spain, 4University of the Ryukyus, Okinawa, Japan, 5Hospital Clinic, Barcelona, Spain

Background: Cyclin D1 is an oncoprotein frequently overexpressed in human cancers. In hematological neoplasms, mantle cell lymphoma and multiple myeloma are clear examples of deregulated cyclin D1 expression. It plays a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored.

Aims: In this study, we investigate the transcriptional role of cyclin D1 in lymphoma stem cell. The study identified cyclin D1 oncogenic overexpression in B cells as a model of the first steps in MCL oncogenesis.

Methods: Chromatin immunoprecipitation (ChIP) followed sequencing was performed in four established MCL cell lines. RNA-sequencing (RNA-Seq) and information from histone ChIP-Seq were correlated with genomic intervals displaying cyclin D1 binding. Transcriptional downregulation was studied through cytometric RNA total quantification in lymphoblastic cyclin D1-overexpressing models and DNA Pol II ChIP-Seq.

Results: Endogenous cyclin D1 showed widespread binding to active promoter regions and its overexpression was responsible for a global transcriptional down-regulation. Cyclin D1, instead of showing specific gene activation, seems to globally decrease cell transcription. Mantle cell lymphoma and multiple myeloma cell lines displayed an inverse relation with cyclin D1 quantity. This transcriptional effect was associated with increased RNA polymerase II pausing in promoters due to cyclin D1-overexpression. Mantle cell lymphoma and multiple myeloma cell lines displayed an inverse relation with cyclin D1 quantity. This transcriptional effect was associated with increased RNA polymerase II pausing in promoters due to cyclin D1-overexpression.

Summary/Conclusions: This mechanism expands the oncogenic cyclin D1 functions and places the transcriptional machinery as a potential therapeutic target in cyclin D1 overexpressing tumors.

E1382 MICROENVIRONMENTAL EXPRESSION OF IMMUNOREGULATORY MOLECULES AND CYCLIN D1 CLASSICAL CYTOGENETIC PROGNOSIS
O. Novosad1, N. Svergun2, O. Skachkova2, O. Gorbach2, N. Khranovska2, I. Kryachok1
1Oncohematology, 2Experimental Oncology, National Cancer Institute, Kiev, Ukraine

Background: Over the past decade, new biologic insights have revealed a key role of tumor microenvironment in the pathogenesis of classical Hodgkin’s lymphoma (cHL). cHL infiltrating cells produce cytokines and growth factors that provide essential stimulatory signals for survival and proliferation of Hodgkin’s and Reed–Sternberg cells. Moreover, clinical behavior of cHL may be directly regulated by the cross-talk between tumor cells and infiltrating immune cells.
Aims: The aim of our study was to estimate the role of microenvironment expression of immunoregulatory molecules (PD-1 ligands, IDO) and cytokines (TGF-β, IL-13) in clinical outcome of cHL.

Methods: 74 patients (median age: 44, range: 17-71 years; males: 22, females: 52) were included in the study. 55.4% of patients were diagnosed with an early stages of HL, while 44.6% - with advanced stages. ABVD or BEACOPP (14 courses) were administered as a 1st line therapy. 78.3% of patients achieved remission (CR/PR), while 8.1% had progression of disease during the therapy. We recorded 14.8% relapses in patients after the 1st line therapy during the follow-up period (median duration – 36 months; range 6–66 months). PD-L1, PD-L2, IDO, TGF-β, IL-13 mRNA expression levels were analyzed in fresh pre-treatment lymph nodes biopsies using qRT-PCR.

Results: Expression of PD-L1 ligands was heterogeneous across the samples and did not depend on histological variant or stage of cHL. Only 12.1% of patients (9/74) were PD-L1 negative and all but one of those cases had a CR and a long-term remission. Patients with PD-L1 overexpression tended to have a higher rate of relapse, comparing to low PD-L1 expression (p=0.1). We did not find any significant association between PD-L2 expression level and clinical outcome of cHL. Expression levels of IDO, TGF-β, IL-13 were evaluated in 38 cHL samples. 18.4% (7/38) patient were IDO positive and 81.6% (31/38) - IDO negative. The presence of IDO expression was associated with a higher risk of relapse in cHL patients (p=0.008). 85.7% (6/7) and 23.3% (7/30) of relapses were observed during the follow-up period in IDO+ and IDO- patients, respectively (p<0.05). The patients with double negative expression of PD-L1 and IDO were noted to have a favourable outcome of cHL. 5-year event-free survival (EFS) rate was 80% for double negative PD-L1+/IDO- patients vs 20% for double positive PD-L1+/IDO+ patients (p=0.008). IL-13 was expressed at various levels depending on the stage of cHL with the highest expression levels in advanced stages. A trend for a higher risk of relapse was observed for HL patients with increasing level of IL-13 (p=0.23). TGF-β expression levels were analyzed in a 1st line therapy. 78.3% of patients achieved EFS in cHL patients with HRs of 6.7 [95% (CI) 1.3-2.1, p=0.04].

Summary/Conclusions: Our results suggest that tumor microenvironment plays an important role in clinical behavior of cHL. Hence, better understanding of molecular mechanisms of interaction between tumor and immune cells probably can provide us with a novel promising strategy for relapsed/refractory cHL treatment.

E1383
AN IN VIVO TRACEABLE AND MULTIPLYING CRISPR/CAS9 GENOME EDITING SYSTEM
L. Cheng1, Y. Li2, H. Sun2, Y. Liu1, Y. Liu2
1Department of Hematology and Research Laboratory of Hematology, 2State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University, Chengdu, China

Background: Gene gain of function and loss of function mutations, oncogene overexpression, gene amplification, chromosome deletion and epigenetic changes, may lead to lymphoma onset. The CRISPR-Cas9 genome editing system has become a feasible tool for exploring the functions of specific genes in various diseases. As an example, we show that the CRISPR-Cas9 genome editing system has become a feasible tool for exploring the functions of specific genes in various diseases. Eμ-myc HSPCs retrovirally transduced with sgp53 and Cas9 were simultaneously mutating multiple gene efficiencies were validated in vivo. Eμ-myc HSPCs retrovirally transduced with sgp53 and Cas9 were transplanted into sublethally irradiated C57/BL6 mouse.

Results: Co-transduced cells can be tracked by the expression of GFP protein and multiple sgRNA can be efficiently introduced to the GFP-labeled cells for simultaneously mutating multiple genes or deleting a large chromosome fragment. Further we applied this system for both in vitro and in vivo genome editing. As an example, we show that Eμ-myc driven lymphoma onset in vivo.

Summary/Conclusions: This traceable and multiplexing CRISPR/Cas9 system might be useful for various genome editing applications.

E1384
Abstract withdrawn.

E1385
HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20 IMMUNOTHERAPY IN VIVO
M. Bobrovec1, D. Dwojak1, J. Stachura1, M. Angelikia1, P. Beata2, S. Marta2, N. Miazek1, P. Zapala1, J. Golab1, M. Winiarska1
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland

Background: Down-regulation of CD20, a molecular target for monoclonal antibodies, constitutes a clinically significant issue leading to decreased efficacy of anti-CD20-based therapeutic regimens. The epigenetic modulation of CD20 coding gene (MS4A1) has been proposed as a mechanism for the reduced therapeutic efficacy of anti-CD20 antibodies and confirmed previously with clinically available non-specific histone deacetylase pan-inhibitors (HDACs). However, the identification of particular HDAC isoforms involved in CD20 regulation seems to be of paramount importance. Since the use of pan-HDAC is associated with substantial side effects, especially difficult to manage in elderly and frail patients, the new specific HDAC6 inhibitors are currently being tested in multiple myeloma and non-Hodgkin lymphoma. They have already been shown to sensitize tumor cells to proteasome inhibitors and novel kinase inhibitors e.g. ibritinib and demonstrated promising results in in vitro studies in chronic lymphocytic leukemia (CLL).

Aims: HDAC6 has been known for its regulatory role in protein degradation. We have previously reported that inhibition of proteasome activity can effectively increase CD20 levels in tumor cells. In our study we tested the hypothesis that selective HDAC6 inhibition sensitizes tumor cells to immunotherapy with anti-CD20 monoclonal antibody (mAbs) by regulating CD20 expression level.

Methods: We assessed the influence of HDAC6 inhibition in a panel of different subtypes of human lymphoma cell lines (Burkitt, DLBCL: both EBV+ and EBV- cells) on CD20 expression using flow cytometry and Western blotting. We confirmed our observations in primary samples from the patients with CLL, known to express low CD20 levels. Moreover, we performed cytotoxic assays using flow cytometry in order to assess complement-dependent cytotoxicity (CDC) as well as apoptosis. We used HDAC6-specific chemical inhibitors (tubacin, trichostatin A and clinically tested ricolinostat), as well as HDAC6 shRNA assay. We also performed animal studies using SCID mice injected with Burkitt CD20+ lymphoma cell line s.c. and treated with rixinimab i.p. We used both the pharmacological ( i.p. administration of ricolinostat) and genetic (cells stably transduced with HDAC6 shRNA ) approach.

Results: The results of our studies demonstrate that HDAC6 inhibition significantly increases CD20 level and sensitizes tumor cells to rituximab- and ofatumumab-induced CDC, as well as to direct cytotoxicity of obinutuzumab. In vivo settings HDAC6 inhibition potentiated the efficacy of rituximab by significantly reducing tumor size and prolonging the survival of the mice.

Summary/Conclusions: Our results clearly indicate that HDAC6 inhibition sensitizes tumor B-cells to anti-CD20 immunotherapy. Therefore, we propose HDAC6 inhibition with specific inhibitors as an effective strategy to be associated with the therapy with anti-CD20 mAbs. This strategy seems to be highly promising in CLL patients, often expressing very low CD20 level and do not fully benefiting from immunotherapy.

The work was supported by National Science Center 2013/09/N/ZN3/01407 (MB), 2015/16/T/NZ600034 (MB), 2014/13/N/NZ600281 (MS), 2015/18/E/ NZ600702 (MW), 2013/11/B/ZS02/0340 (BP), Polish Ministry of Science and Higher Education grant IP2011 060271 (MW), DI2011 021241 (MB). DI 2014007344 (NM) and DI2013 006643 (AD), the Medical University of Warsaw grant 1M19/PM/112D/14/14 (MB) and Horizon 2020 Programme, project 692180-STREAM-H2020-TWINN-2015 (JG).

E1386
NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T CELL LYMPHOPROLIFERATIONS: A CELAC NETWORK STUDY
M. Chemminiot1,2, J. Bruneau3, G. Malamut4,5, N. Guean5, D. Sibon1,2, N. Broussoux3, L. Hermite4,5, R. Delarue1, A. Marçais1, F. Suarez1,2, E. Macintyre6, V. Asnafi6, F. Lhospice7, C. Bonnafous7, A. Trinquand 6, L. Lhermitte 6, N. Brousse 3, L. Frenzel 12, R. Delarue 1, N. Miazek1, P. Zapala1, J. Golab1, M. Winiarska1
1Hematology Unit, Necker Hospital - Paris Descartes – Sorbonne Paris Cité
Background: Primary gastrointestinal (GI) T-cell lymphoproliferations (T-CL) are heterogeneous entities, which diagnoses are difficult to perform. T-CL include aggressive lymphoma such as enteropathy-associated T-cell lymphoma (EATL) as well as indolent monoclonal lymphoproliferations. Refractory coeliac disease type II (RCDII) is one of the indolent clonal T-CL that complicates coeliac disease (CD) and may evolve toward an overt EATL. The differential diagnosis of RCDII from CD and RCDI is difficult and essentially based on negative expression of sCD3 and CD8 and the presence of a clonal TCR rearrangement. Lymphocytes from RCDII are dependent for survival on IL-15, which reprograms T lymphocytes towards a cytotoxic NK phenotype.

Aims: We thus studied the expression of NKp46 on a representative panel of GI T-CL to assess its diagnosis and prognosis value.

Methods: Using formalin-fixed paraffin-embedded tissue biopsies, we assessed NKp46 expression by immunohistochemistry (IHC) and investigated its clinical and biologic significance on 177 intestinal, 11 lymph node and 7 other biopsies from 84 CD or RCD patients (RCDI, n=20; RCDII, n=40), 44 GI T-cell lymphoma patients (EATL, n=25; monomorphic epitheliotropic intestinal T-cell lymphoma, MEITL, n=4; indolent T-LPD, n=15), 11 healthy patients and 5 patients with a GI inflammatory environment as controls.

Results: By doing ROC analysis on number of cells expressing NKp46 on GI-TCL we identify that 25 intra-epithelial lymphocyte (IEL) per 100 epithelial cells (EC) clearly separates RCDII from CD and RCDI patients, with a good positive and negative predictive values (100 and 95% respectively). In healthy controls, CD or RCDI patients, NKp46 was only expressed on scattered IEL (median 3%, 0-15). Based on NKp46 expression the overall survival is poor if over 25% of IEL are positive for NKp46 (OS-5years 96.4% vs 72.8%, P=0.0004) (Figure 1A). Among patients with GI T-cell lymphoma, we show that NKp46 was expressed in most of aggressive lymphoma (EATL 80%, n=20/25 and MEITL 100%, n=4/4). On the other hand, NKp46 was not expressed on indolent T-LPD (n=15). The NKp46 expression was also associated with a poor prognosis in GI-TCL patients (OS-5years 50.5% vs 5.4%, P=0.0011) (Figure 1B).

Summary/Conclusions: The NKp46 expression in more than 25 IEL per 100 EC by IHC analysis can easily identify RCDII from CD and RCDI. Furthermore, the NKp46 expression is associated with aggressive forms of GI T-cell lymphoma. Finally, the NKp46 expression was strongly associated with shortened survival. Thus NKp46 provides a new biomarker for both diagnosis and prognosis in GI-TCL.

Figure 1.

E1387

HIGH EXPRESSION LEVELS OF MIR23A CLUSTER IN DLBCL ANTAGONIZE INDUCTION OF APOPTOSIS

N. Freytag1, C. Pommerenke2, Y. Merkhofer1, J. Anibas Arranz2, D. Kube3, H. Dreuxler2, H. Quentmeier2, S. Eberth1,1

1Junior Research Group Molecular Cancer Research, 2Department of Human and Animal Cell Lines, Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, 3Haematology and Oncology, University Medical Center Göttingen, Göttingen, Germany

Background: The microRNA cluster MIR23A, which encodes for the mature microRNAs miR-23a, miR-27a and miR-24, was shown to be deregulated in many different malignancies including subtypes of B cell non-Hodgkin lymphoma (B-NHL). Furthermore, high expression of miR-23a was correlated with poor overall survival in diffuse large B-cell lymphoma (DLBCL) patients (Wang et al., Med Oncol. 2014) indicating that miR-23a might act as an onco-miR (tumor promoting microRNA) in this entity. However, both targets and function of the MIR23A cluster in B-NHL remain unknown.

Aims: This study aims to elucidate the role of the MIR23A cluster as a potential onco-miR in DLBCL by identification of the lymphoma-specific targetomes of miR-23a and miR-27a and subsequent analyses of associated functions.

Methods: We used a DLBCL model cell line U2932 K1, which has a low basal expression level of MIR23A cluster, was used for the lentiviral-based generation of clones overexpressing miR-23a, miR-27a, or a scrambled control. Differentially expressed genes (DEG, fold-change ≥2, p-value <0.05) between samples were determined by mRNA sequencing (RNA-Seq). miR-23a and miR-27a targetomes were identified by immunoprecipitation of AGO2-bound miRNA (AGO2-RIP) followed by RNA-Seq. MicroRNA targets had to be enriched >2-fold with a p-value <0.05. Validations were performed by qPCR and immunoblotting.

Gene set enrichment analyses (GSEA) and GO-term analyses were applied on identified targetomes and DEG to predict microRNA associated functions. Apoptosis was assessed by Annexin-V staining followed by FACS analyses as well as in immunoblot.

Results: Overexpression of miR-23a and miR-27a, respectively, in a DLBCL model cell line resulted in global alterations of gene expression (so-called indirect targets) with a substantial overlap of 104 of DEG affected by both microRNAs. Using AGO2-RIP, 26 novel direct targets of miR-23a, and 20 novel direct targets of miR-27a were identified. GSEA and GO-term analyses of direct and indirect targets indicated that the MIR23A cluster might regulate processes in apoptosis. Moreover, BBC3 which encodes the pro-apoptotic protein PUMA was one of the identified direct targets of miR-23a. As expected induced apoptosis and miR-27a overexpression failed to induce PUMA on protein level. Importantly, functional analyses confirmed that miR-23a overexpression reduces and high levels of miR-27a significantly attenuate the ability of DLBCL cells to undergo apoptosis in response to DNA damage.

Summary/Conclusions: We demonstrate that high levels of miR-23a and miR-27a can promote apoptosis induction of apoptosis in a lentiviral model cell line. This might be one possible explanation why DLBCL patients with high miR-23a expression levels have a worse overall survival rate than patients with low levels. Thus, future studies should address the suitability of the MIR23A cluster as biomarker and potential target in DLBCL.

E1388

PLASMA CELLS ARISE FROM DIFFERENTIATION OF CLONAL LYMPHOCYTES AND SECRETIE IGM IN WALDENSTRÖM MACROGLOBULINEMIA

D. Talaulikar1,2,*, J.H. Lim1, J. Wang2, N. Hein2, A. El-Ayoubi2

1Haematology, Canberra Hospital, 2Australian National University, Canberra, Australia

Background: Waldenström Macroglobulinemia (WM) is an indolent non-Hodgkin lymphoma characterized by bone marrow infiltration with malignant plasma cells (LPLs), and a smaller number of plasma cells (PCs). The malignant plasma cells (SMPCs) show abnormal clonal heavy chain gene (IgH), 56% SMPCs express CD138, characteristic of plasma cells (PCs). The SMPCs express CD38 and Ig-1 and are negative for CD19 and CD20, these findings are found in 56% SMPCs, and 75% SMPCs have monoclonal IgM. The malignant plasma cells (SMPCs) have more IgM and worse overall survival compared to SMPCs with less IgM. The pathological SMPCs lack of proliferation and they are still dependent for IgM production despite the relative lack of proliferation of this remains uncertain. Cell culture studies showed that PCs alone were primarily responsible for IgM production despite the relative lack of proliferation and eventual cell death in MWCL-1 (~65% plasma cells remained after 72
hours and produced 8.7 – 9.3 X 10^3 ng/ml of IgM). PCs isolated from BCWM.1 increased to 130% and produced 2.5 – 2.8 X 10^3 ng/ml of IgM. LPLs from both cell lines proliferated in culture (~ 130 – 140% in MWCL-1 and ~170 – 200% in BCWM.1 at 72 hours), gave rise to the more differentiated PCs (7.5 – 9.0% of PCs at 72 hours in MWCL-1 and 1.2 – 1.4% of PCs in BCWM.1), and secreted smaller amounts of IgM than PCs (3.5 – 5.0 X 10^3 ng/ml in MWCL-1 and 0.3 – 0.7 X 10^3 ng/ml in BCWM-1).

**Summary/Conclusions:** Our analysis of the 2 WM cell lines provides evidence to support the common hypothesis that malignant PCs arise from the clonal malignant LPL population, and are primarily responsible for IgM secretion in WM.

---

**E1389**

**LMP-1 MEDIATED UPREGULATION OF IL-2Rα PROMOTES LYMPHOMA-GENESIS AND CHEMOTHERAPY RESISTANCE IN NATURAL KILLER-T-CELL LYMPHOMA AND COULD BE A POTENTIAL THERAPY TARGET**


1Medical oncology, 2Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

**Background:** Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal, especially for advanced-stage or relapsed diseases. Our previous study demonstrated the prognostic value of IL-2Rα in NKTCL, but the role of IL-2Rα in the lymphomagenesis and chemotherapy resistance and its interactions with EBV in NKTLK remain to be investigated.

**Aims:** This study investigated the mechanism of IL-2Rα expression in NKTCL, and explored the role of IL-2Rα in lymphomagenesis and chemotherapy resistance and its potential role of anti-IL-2Rα treatment in NKTCL.

**Methods:** Expression of IL-2Rα was measured in NK-92 (LMP-1 weak expression) and SNK-6 (LMP-1 strong expression) cell lines by western blot, quantitative real-time PCR, enzyme-linked immunosorbent assay, and flow cytometry, respectively. LMP1-harboring lentiviral vectors were transfected into NK-92 cells to examine the correlation between LMP1 and IL-2Rα expression. Proteins in the downstream pathways of LMP1 signaling were measured in NK-92 cells transfected with LMP1-harboring or negative control vectors as well as in SNK-6 cells. Then IL-2Rα-harboring lentiviral vectors were transfected into both NK-92 cells and SNK-6 cells to examine the cell proliferation by CCK8, apoptosis by staining with Annexin V and detected by flow cytometry (FCM), cell cycle distribution by FCM analysis, and IC50 values exposed to three chemotherapy drugs (adriamycin, gemcitabine, and asparaginase) by MTT. Finally anti-IL-2Rα antibody was added to investigate its ability of reversal of drug resistance.

**Figure 1.**

**Results:** Expression of IL-2Rα was significantly higher in SNK-6 cells than in NK-92 cells, at both protein and mRNA levels. Expression of IL-2Rα was remarkably upregulated in NK-92 cells transfected with LMP1-harboring lentiviral vectors compared with those transfected with negative control vectors. Proteins in the MAPK/NF-κB pathway were upregulated in LMP1-expressing NK-92 cells compared with the negative control. Selective inhibitors of those proteins induces significant downregulation of IL-2Rα expression in LMP1-expressing NK-92 cells as well as in SNK-6 cells. When comparing with those transfected with negative control vectors, cell growth was significantly increased in both NK-92 and SNK-6 cells transfected with IL-2Rα-harboring lentiviral vectors, and the cell cycle assay displayed a significant decrease in the percentage of cells in the G0/G1 phase (p<0.05) and an increase in the percentage of cells in the S phase (p<0.05), while apoptosis was not affected. Subsequent western blot tests demonstrated that cyclin A, B, and CDK1, 4 were involved in the regulation of cell cycle with overexpression of IL-2Rα. The IC50 values to all three chemotherapy drugs were significantly increased after overexpression of IL-2Rα, which can be fully reversed by addition of anti-IL-2Rα antibody.

**Summary/Conclusions:** IL-2Rα expression was upregulated in NKTCL by LMP-1-mediated activation of MAPK/NF-κB pathway. IL-2Rα can promote NKT-cell proliferation partially through regulation of cell cycle and induce chemotherapy resistance, which can be reversed by anti-IL-2Rα antibody, indicating the potential role of IL-2Rα as a therapy target in NKTCL.

---

**E1390**

**LENALIDOMIDE (LEN) DRIVES PROGRAMMED DEATH-1 (PD1) PATHWAY UPREGULATION IN A TUMOR MICROENVIRONMENT (TME) MODEL OF ACTIVATED LOW-GRADE LYMPHOMA CELLS**


1Unità di Ricerca Biotecnologica, Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), 2Tumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo School of Medicine, Palermo, 3Unità di Ricerca Biotecnologica, Azienda Sanitaria Provinciale di Cosenza, 4Unità di Ricerca Biotecnologica, Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), 5Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, 6Biotechnology Research Unit, ASP of Cosenza, Aprigliano (CS), 7Biotechnology Research Unit, ASP of Cosenza, 8Hematology Unit, Department of Oncology and Hemato-Oncology, A.O. of Cosenza, 9Centre of Excellence for Biomedical Research and Department of Internal Medicine, 10Centre of Excellence for Biomedical Research and Department of Internal Medicine, University of Genova, 11Molecular Pathology Unit, and Department of Experimental Medicine, IRCCS-A.O.U. San Martino-IST and University of Genova, Genova, 12Department of Onco-Hematology, Hematology Unit, A.O. of Cosenza, Cosenza, 13Department of Health Science, Human Pathology Section, Tumor Immunology Unit, University of Palermo School of Medicine Palermo, Palermo. 14Hematology Unit, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Reggio Calabria, 15Department of Oncology and Hemato-Oncology and Hematology Unit, University of Milano Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 16Department of Oncology and Hemato-Oncology and Hematology Unit, University of Milano Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano. 17Molecular Pathology Unit, IRCCS-A.O.U. San Martino-IST, Genova, 18Department of Experimental and Clinical Medicine, University of Catanzano Magna Graecia, Catanzano, 19Scientific Direction, IRCCS-A.O.U. San Martino-IST, Genova, 20Hematology Department, Anunnziata Hospital of Cosenza, Cosenza, Italy

**Background:** PD1 binding to its ligand PDL1 inhibits TCR/BCR signaling; impairs activation, and effector functions of T- and B-cells; induces T-cell exhaustion; and ultimately provokes tolerance towards cancers. PD1 is expressed on Hodgkin lymphoma (HL) and B-cell non-HLTLT-cells. The TME may play an essential role in maintaining PD1-induced immune exhaustion. LEN is an oral immunomodulator (IMID) with direct antineoplastic activity and immune modulation. In vitro coculture of T-cells and tumor cells in the TME enabled cytolysis in experimental models Preclinical findings indicate that combination of IMIDs with immune checkpoints inhibitors may promote therapeutic synergy and long-term antitumor immunity to improve clinical outcome.

**Aims:**

1) To better characterize the PD1, PDL1 and the lesser-known PDL2, phenotype in peripheral neoplastic CD19+ lymphocytes and T-cell subsets in patients with low-grade B-cell lymphoma. PD1 expression was similarly increased in both immunocompetent and autologous activated T-cells (AAT) coculture of patient T-cells with anti-CD3/CD28 beads, rIL2 and with PBMCs. Cultures were monitored daily until sizeable clumping was observed and tested for PD1 and ligand expression. In selected experiments LEN provided the role of Cl cells was added to cell cultures.

**Methods:** Samples obtained from patients attending participating Hematology Units were used to determine PD1, PDL1, PDL2 phenotype (%SEM) by Flow cytometry (FC). Autologous activated T-cells (AAT) were obtained by in vitro co-culture of patient T-cells with anti-CD3/CD28 beads, rIL2 and with PBMCs. Results: Twelve cases of lymphoma were evaluated for PD1, PDL1 and PDL2 expression on malignant B- and T-cells by FC. The expression of PD1 and PDL2 was similarly expressed, while PDL1 was almost undetectable on B-cells. Levels of PD1 expression on CD3+ cells were variable across samples, however they were significantly higher than those expressed on malignant B-cells. Significantly higher PD1 expression and very low levels of ligands were detected in both CD4+ and CD8+ cells. Co-culture of patient T-cells with AAT led to the role of the TME in supporting the PD1 axis; and 3) to determine whether LEN influences PD1 or cognate ligand expression.

**Results:** Expression of IL-2Rα was significantly higher in SNK-6 cells than in NK-92 cells, at both protein and mRNA levels. Expression of IL-2Rα was remarkably upregulated in NK-92 cells transfected with LMP1-harboring lentiviral vectors compared with those transfected with negative control vectors. Proteins in the MAPK/NF-κB pathway were upregulated in LMP1-expressing NK-92 cells compared with the negative control. Selective inhibitors of those proteins induces significant downregulation of IL-2Rα expression in LMP1-expressing NK-92 cells as well as in SNK-6 cells. When comparing with those transfected with negative control vectors, cell growth was significantly increased in both NK-92 and SNK-6 cells transfected with IL-2Rα-harboring lentiviral vectors, and the
on CD3+ cells was unaffected by AAT, although the expression of both ligands remained unchanged. CD3+ cells showed a significant increase in PD1 expression by LEN compared to untreated cells. CD3+ cells and may contribute to reactivation of PD1 signaling under treatment. The PD1 pathway may be potentially targeted to overcome both the intrinsic and LEN-induced exhaustion phenotype.

Aims: To investigate if ATO targets BCL6 and inhibits the proliferation and growth of BCL6-dependent DLBCL.

Methods: BCL6-dependency of a panel of DLBCL cell lines (i.e. OCI-Ly1, OCI-Ly7, SU-DHL-6, OCI-Ly18 and Pfeiffer) was determined based on their sensitivity to proliferation inhibitory activity of the BCL6 inhibitor 79-6 (Calbiochem). The effects of ATO and cisplatin as single agent or in combination on cell viability and apoptosis of DLBCL cells were examined with MTT assay and flow cytometric analysis. Expression of BCL6 and its target genes was examined with quantitative RT-PCR and western immunoblotting. The therapeutically efficacious ATO treatment was also examined in a DLBCL (OCI-Ly7) xenograft mouse model.

Summary/Conclusions: ATO targets BCL6 for proteosomal degradation and inhibits the proliferation and growth of BCL6-dependent DLBCL.

E1393
PROTEOMIC PHOSPHOSITE ANALYSIS IDENTIFIED CRUCIAL NIPA SERINE RESIDUES FOR NPM-ALK-MEDIATED TRANSFORMATION A. Gengenbacher1,*, A. Rudorf1,2, T. Poggio1, C. Rummelt1, S. Kreutmair1, V.I. Dumpt1, J. Dyuster2, A.L. Illert2
1Dept. of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, 2German Cancer Consortium (DKTK), Heidelberg, 3Center for Biological Systems Analysis, University of Freiburg, Freiburg, Germany

Background: Anaplastic large-cell lymphoma (ALCL) is an aggressive non-Hodgkin lymphoma that occurs mainly in children and younger adults. Patients typically show an advanced stage disease as well as an aggressive disease pattern with extralymphatic manifestations. At the molecular-genetic level, 60% of the patients with systemic ALCL exhibit a translocation t(2;5)(p23;q35), which leads to the expression of the NPM-ALK fusion protein. Under the control of the NPM promoter, ALK activation causes increased and autonomous proliferation. Nuclear interaction partner of ALK (NIPA) was first identified as a new interaction partner of the oncopogene NPM-ALK in a yeast-2-hybrid screen which defines an E3-SCF ligase and is physiologically involved in cell cycle regulation at the transition from G2 phase to mitosis. It has already been shown in preliminary studies that co-expression of NIPA with the oncogenic tyrosine kinase NPM-ALK results in the constitutive phosphorylation of NIPA (Illert et al., 2012a). Until now, the specific signal transduction pathway, the crucial phosphorylation sites as well as the functional effect of the pathological NIPA phosphorylation in NPM-ALK-induced lymphomagenesis still remain unclear. Molecular insights into the induced phosphorylations of the kinase NIPA may help to identify new druggable targets for therapeutic implications.

Aims: In the present study, we investigated the molecular mechanisms as well as the functional impact of the NPM-ALK-induced NIPA phosphorylation.

Methods: For this purpose, biochemical methods with ALCL cells were used to examine functional effects of constitutive NIPA phosphorylation. Moreover, we performed a "proteomic-phosphosite-analysis" to identify crucial NPM-ALK specific phosphorylation sites in NIPA. Based on these results, phospho-deficient NIPA mutants were generated to investigate the functional effect of this phosphorylation: MTI proliferation- and Softagar-Assays were performed after retroviral infection of Ba/F3 and primary Nipa-deficient MEF cells with NPM-ALK and the respective phospho-deficient NIPA to reveal transformation and growth ability.

Results: It has already been shown, that cell cycle dependent NIPA phosphorylation at critical serine residues 354, 359 and 395 leads to dissociation of the interaction partners, which were able to bind within the NPM-ALK binding region of NIPA. This result was further substantiated by generation of a AAΔ310-402 mutant, where NIPA phosphorylation is completely abolished. To further prove biological significance of the identified residies, phospho-deficient mutants were established and transformation assays were performed. Here we were able to show drastically impaired cell proliferation in co-transfected cells with silenced upstream kinase residues 338, 344, 370, 381 and 387 upon NPM-ALK expression.

Summary/Conclusions: Taken together, we identified five phosphorylation sites in NIPA to be highly upregulated upon NPM-ALK expression. However,
NPM-ALK mediated NIPAs-phosphorylation of those sites did neither change the SCFH2/21 complex formation nor influence the NIPA localization at the nuclear pore complex, but silencing of these NIPA Serine/Threonine residues led to significantly reduced proliferation and altered transformation ability of Ba/F3 and primary MEF cells. Further analyses will shed some light into the mechanisms underlying these findings and evaluate NIPA as a possible new treatment option for ALCCL.

**E1394**

**APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B CELL LYMPHOMAS**

1Department of Hematology, Hospital Universitari Mutua de Terrassa, Terrassa, 11Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, 12Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain, 13Department of Hematology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, 14Department of Pathology, 15Department of Hematology, Hospit clinically in clinical practice. Although the importance of COO is well established on the expression of 20 genes, have been developed to facilitate COO assign- ment in clinical practice. Although the importance of COO is well established.

**Aims:**

Therefore, we aimed to comprehensively study the implication of the CXCR4 - CXCL12 axis in bone marrow infiltration process of aggressive lym phoma and to analyse the effects of CXCR4 antagonists on cell growth and migration of aggressive lymphoma cells in vitro.

**Methods:**

To determine whether CXCR4 and CXCL12 expression have any effects on the bone marrow infiltration process of aggressive lymphomas, we performed gene expression analysis on bone marrow biopsies of our diffuse large B-cell lymphoma patient cohort. Therefore, we used 63 bone marrow specimens, whereby 52 bone marrow biopsies were taken at time of diagnosis. Additionally, we generated a novel CXCR4 antagonist -named WK1- by modification of the side chain of AM070 - a commercially available CXCR4 antag onist. We treated various aggressive lymphoma cell lines (U2932 and RI-1 as ABC-DLBCL and BL2 and Raji as Burkitt lymphoma lines) with CXCR4 antag onist and to analyse the effects of CXCR4 antagonists on cell growth and migration of aggressive lymphoma cells in vitro.

**Results:**

These data strongly suggest that CXCR4 and its ligand CXCL12 is implicated in the bone marrow infiltration process of diffuse large B-cell lymphomas. Additionally, our in vitro results indicate that treatment of lymphoma cells with CXCR4 antagonists might be a promising new thera peutic intervention to eliminate lymphoma cells.

**E1395**

**CXCR4 AND CXCL12 ARE IMPLICATED IN BONE MARROW INFILTRATION PROCESS OF AGGRESSIVE B CELL LYMPHOMAS AND THEIR INHIBITION SUPPRESSES LYMPHOMA CELL GROWTH IN VITRO**

A. Deutsch1, B. pursche1, B. Ehlal1, M. Zoidl2, K. Kechter3, E. Steinbauer3, M. Sedej3, H. Greinix1, K. Prochazka3, T. Wrodnigg3, C. Beham-Schmid3, P. Neumeister1

1Hematology, Internal Medicine, 2Organic Chemistry Technical University Graz, 3Pathology, 4Experimental and Clinical Pharmacology, Graz, Austria

**Background:**

The chemokine receptor CXCR4 together with its prime ligand CXCL12 plays a pivotal role in tumorigenesis of solid and haematological neo-plasms. Our comprehensive study on the CXCR4 expression in aggressive lymphoma demonstrated that high CXCR4 expression was associated with poor clinical course of aggressive lymphoma patients.

**Aims:**

Therefore, we aimed to comprehensively study the implication of the CXCR4 - CXCL12 axis in bone marrow infiltration process of aggressive lymphoma and to analyse the effects of CXCR4 antagonists on cell growth and migration of aggressive lymphoma cells in vitro.

**Methods:**

To determine whether CXCR4 and CXCL12 expression have any effects on the bone marrow infiltration process of aggressive lymphomas, we performed gene expression analysis on bone marrow biopsies of our diffuse large B-cell lymphoma patient cohort. Therefore, we used 63 bone marrow specimens, whereby 52 bone marrow biopsies were taken at time of diagnosis. Additionally, we generated a novel CXCR4 antagonist -named WK1- by modification of the side chain of AM070 - a commercially available CXCR4 antag onist. We treated various aggressive lymphoma cell lines (U2932 and RI-1 as ABC-DLBCL and BL2 and Raji as Burkitt lymphoma lines) with CXCR4 antag onist and to analyse the effects of CXCR4 antagonists on cell growth and migration of aggressive lymphoma cells in vitro.

**Results:**

These data strongly suggest that CXCR4 and its ligand CXCL12 is implicated in the bone marrow infiltration process of diffuse large B-cell lymphomas. Additionally, our in vitro results indicate that treatment of lymphoma cells with CXCR4 antagonists might be a promising new thera peutic intervention to eliminate lymphoma cells.

**Summary/Conclusions:**

These data strongly suggest that CXCR4 and its ligand CXCL12 is implicated in the bone marrow infiltration process of diffuse large B-cell lymphomas. Additionally, our in vitro results indicate that treatment of lymphoma cells with CXCR4 antagonists might be a promising new therapeutic intervention to eliminate lymphoma cells.

---

**Table 1.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ABC</th>
<th>BCL2</th>
<th>UNC</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDL, μmol/L</td>
<td>2.3/3.2 (2/3)</td>
<td>2.1/2.3 (2/2.1)</td>
<td>2.4/2.7 (2/3)</td>
<td>0.023</td>
</tr>
<tr>
<td>LDL, μmol/L</td>
<td>1.1/1.5 (1.1/1.3)</td>
<td>1.2/1.3 (1.1/1.1)</td>
<td>1.3/1.5 (1.1/1.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>90/95 (90/92)</td>
<td>92/94 (90/92)</td>
<td>94/100 (92/95)</td>
<td>0.012</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>13/15 (13/14)</td>
<td>14/16 (13/15)</td>
<td>15/17 (14/16)</td>
<td>0.008</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.7/1.0 (0.7/0.8)</td>
<td>0.8/0.9 (0.7/0.7)</td>
<td>0.9/1.2 (0.8/1.0)</td>
<td>0.009</td>
</tr>
</tbody>
</table>

**Note:**

ABC: ABC subtypes; BCL2: BCL2 subtypes; UNC: UNC subtypes.
**E1396**

EPSTEIN-BARR VIRUS LOAD IN PLASMA IS AN EARLY BIOMARKER OF HIV-RELATED LYMPHOMA

J. Muncunill1, M.J. Baptista1, A. Hernandez-Rodriguez2, J. Dalmau3, O. Garcia1, G. Tapia4, M. Moreno1, J.-M. Sancho1, J. Martinez-Picado5, J.-M. Ribera1, E. Felu1, J.-L. Mate1, J.-T. Navarro1

1Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, 2Department of Oncology, Hospital Universitari Germans Trias i Pujol, 3AIDS Research Institute-IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, 4Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 5AIDS Research Institute-IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.

**Background:** Epstein Barr virus (EBV) has been detected in the tumor cells of some non-Hodgkin lymphomas (NHL) and Hodgkin lymphomas (HL) and detectable EBV loads have been found in the plasma of immunocompetent patients with HL. In HIV-related lymphomas the importance of EBV load as potential lymphoma biomarkers has been scarcely studied.

**Aims:** We aimed to evaluate the usefulness of EBV load in plasma as lymphoma biomarker in HIV-infected patients.

**Methods:** One hundred and fifteen patients with NHL (HIV-infected = 57 and HIV-uninfected=34) and HL (HIV-infected= 16 and HIV-uninfected= 8) were studied. EBV loads were determined in plasma by means of a commercial real-time PCR technique (EBV PCR kit, Qiagen GmbH, Hilden, Germany) at lymphoma diagnosis and in two serial samples of HIV-infected patients also at one year before diagnosis (N=11) and at complete response (CR) (N=34). EBER expression was studied by in situ hybridization in tumor biopsies. The following clinical and biological parameters were collected from records: age, gender, date of lymphoma diagnosis, ECOG score, extranodal and bulky disease, B symptoms, Ann Arbor stage, serum lactate dehydrogenase and beta2-microglobulin. International Prognostic Index (IPI), HCV and HBV serology, history of opportunistic infection and of AIDS-defining illness, onset of combination antiretroviral therapy, CD4-counts, HIV loads, type and date of response, relapse date, last follow up or death date. McNemar’s test and Wilcoxon test were used to compare quantitative and qualitative variables, respectively. Survival analyses were performed using the Kaplan-Meier method. P-values of less than 0.05 were considered statistically significant.

**Results:** At diagnosis, EBV loads were detectable in more HIV-infected patients than HIV-uninfected (48% vs 14%, P=0.002) and in more HL cases than NHL (70% vs 26.3%, P=0.006). In HIV-infected patients, detectable EBV load was associated with EBER expression, 66.6% of the patients with detectable EBV loads had EBER-positive tumors and 92% of the patients with undetectable EBV loads had EBER-negative tumors (P=0.003). All the remaining clinical and biological features were not associated with detectable EBV load in plasma. In HIV-uninfected patients, associations between EBV load and EBER expression (P=0.006) and EBV load and HIV infection (P=0.017) were observed. From 16 out of 34 (47%) HIV-infected patients with detectable EBV loads at lymphoma diagnosis, 15 had undetectable EBV loads at CR (P=0.001) (Figure 1). The exception was one patient with HL whose EBV load substantially decreased at CR but was still detectable. Moreover, 4 out of 7 HIV-infected patients with detectable EBV loads at diagnosis had detectable loads one year before diagnosis, and no patient with negative EBV loads at diagnosis had detectable loads before it, pointing EBV load can be used as an early biomarker of lymphoma. EBV loads at diagnosis had neither impact on overall survival nor progression-free survival.

**Summary/Conclusions:** EBV-load in plasma can be used as early biomarker of lymphoma in HIV-infected patients since EBV-loads can be detected up to 1 year before lymphoma diagnosis and are virtually undetectable at lymphoma CR.

This work was supported by 2014 SGR225 (GRE) from CERCA Programme/Generalitat de Catalunya, and by funds from Josep Carreras International Foundation, “la Caixa” Foundation and Celgene Spain.

---

**E1397**

CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA

A. Teramo1,2, E. Ciabatti3, G. Tarini3, I. Petrin3, G. Barilà1, G. Calabretto1,2, C. Vicenziello1,2, M. Leoncin1,2, C. Ercolin1, A. Cabrello2, S. Galimberti3, R. Grossi3, N. Pisaniti3, G. Semenzato1,2, R. Zambello1,3

1Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, 2Venetian Institute of Molecular Medicine, 3Department of Experimental Medicine, Section of Hematology, 4Department of Translational Research and New Technologies in Medicine, 5Department of Informatics, University of Pisa, Pisa, Italy

**Background:** T-cell large granulocyte leukemia (T-LGLL) is a rare heterogeneous T-cell neoplasia whose leucemic cells usually express the γδ T-cell receptor (TCR); only a small subset of cases expresses the γδ TCR denoting the TCRγδ LGLL. Currently, among the different LGL diseases, TCRγδ LGLL remains less studied and several clinical and laboratory data already described in TCRγδ-LGLL have not yet been explored in TCRβ-LGLL.

**Aims:** The aims of this work were 1) to characterize TCRγδ-LGLL defining STAT mutational pattern and CDR3 repertoire diversity/clonal composition (clonotype) and 2) to evaluate correlations among LGL phenotype, mutations, TCR rearrangement and clinical presentations.

**Methods:** In this work 11 patients affected by TCRγδ-LGLL were included. Sanger sequencing was used for mutational analysis on hot-spot regions in the two genes more frequently mutated in LGL disorders, STAT3 and STAT5b. Immunophenotype of LGL clone was defined by flow cytometry analysis. CDR3 repertoire and frequency distribution of TCR gamma gene rearrangements were analyzed by IGH sequencing.

**Results:** Our results showed that TCRγδ LGLL had a high incidence of STAT mutations, 9 out of 11 patients carrying STAT3 or STAT5b mutations in a mutually exclusive pattern. At variance from CD8+ TCR αβ LGLL and CD4+ TCR βα LGLL, STAT3 mutations were present only in the first being more characterized by STAT3 mutations. The latter by STAT75b. TCRγδ LGLL patients were characterized by both the mutations. Thus, TCRγδ LGLL showed features shared by CD8 and CD4 TCRαβ-LGLL. Consistently, TCRδ LGLL showed the same correlation between immunophenotype and kind of mutation observed in TCRγδ-LGLL: γδLGL patients with CD16+CD56- LGL immunophenotype were characterized by STAT3 mutations (as in CD8+ T-LGLL), while γδLGL patients with CD56+ LGL immunophenotype by STAT75b mutations (as in CD4+ T-LGLL). Moreover, we observed that patients with γδLGLs positive for Vδ2 showed usually indolent course, while Vδ1 was linked to a more symptomatic disease (4 out of 5 symptomatic patients were Vδ1+), whereas no correlation was found between mutational pattern and clinical course. By NGS of TCR gamma gene, we observed that all patients were clonal but two, showing a polyclonal pattern borderline with clonality percentage defined by sequencing kit criteria. Interestingly, these two last patients were the only two patients without STAT mutations. As far as the remaining cases are concerned, among STAT75 mutated patients (n=4), 3 were polyclonal and one biclonal, while STAT5b mutated patients (n=5) were more frequently monoclonal (4/5 monoclonal and 1/5 biclonal). In terms of clonal rearrangements, Vg3-Jg1/2, Vg9-Jp9 and Vg8Jg1/2 were the combination usages most frequently detected. Concerning the clonotype repertoire, CDR3 sequences of the immunodominant clone expressed in each single patient were sequenced, with low frequency in almost all the other γδ patients and two different CDR3 sequences were found shared, each one in different patients at frequency >10% of the total rearrangements.

**Summary/Conclusions:** Our data indicate that TCRγδ LGLL can be considered at the interface, sham of the two types of TCRαβ-LGLL, sharing with CD8 T-cell and CD4+ TLLGL mutational features. As already described in TCRαβ-LGLL, also in γδLGL disease a decreased diversity of TCR repertoire was demonstrated. However, in these γδLGL patients STAT mutations do not correlate with a symptomatic clinical behavior while STAT5b mutations seems to be more frequently linked to monoclonal nature of the LGL lymphoproliferation. Rather, the marker Vδ1 appears to be correlated to symptomatic disease.

---

**E1398**

INCREASED EXPRESSION OF IRF8 IN TUMOR CELLS INHIBITS THE GENERATION OF TH17 CELLS AND PREDICTS UNFAVORABLE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS

Q. Li1,*, W. Zhong1

1Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China, Guangzhou, China

**Background:** The immunological pathogenesis of diffuse large B cell lymphoma (DLBCL) remains elusive. Searching for new prognostic markers of DLBCL is a crucial focal point for clinical scientists.

**Aims:** The aim of the present study was to examine the prognostic value of interferon regulatory factor 8 (IRF8) expression and its effect on the development of Th17 cells in the tumor microenvironment of DLBCL patients.

**Methods:** Flow cytometry, immunohistochemistry, and quantitative real-time PCR were used to detect the distribution of Th17 cells and related cytokines and IRF8 in tumor tissues from DLBCL patients. Two DLBCL cell lines (OCI-
LY10 and OCI-LY1) with IRF6 knockdown or overexpression and two human B lymphoblast cell lines were co-cultured with peripheral blood mononuclear cells (PBMCs) in vitro to determine the effect of IRF8 on the generation of Th17 cells. Quantitative real-time PCR and Western blotting were used to investigate the involvement of retinoic acid receptor-related orphan receptor gamma t (RORγt) in the effect of IRF8 on Th17 cell generation. The survival of 67 DLBCL patients was compared to the Kaplan-Meier method and the log-rank test.

Results: The percentage of Th17 cells was lower in DLBCL tumor tissues than in PBMCs and corresponding adjacent benign tissues. Relative expression of interleukin (IL)-17A was lower, whereas that of interferon (IFN)-γ was higher in tumor tissues than in benign tissues. Co-culture with DLBCL cell lines inhibited the generation of Th17 cells in vitro. IRF8 upregulation was detected in DLBCL tumor tissues, and it was associated with decreased DLBCL patient survival. Investigation of the underlying mechanism suggested that IRF8 upregulation inhibited Th17 cell generation by suppressing the effect of RORγt on CD4+ T cells.

Summary/Conclusions: Our findings suggest that IRF8 expression in the tumor microenvironment inhibited the generation of Th17 cells through its antagonistic effect on RORγt in the DLBCL tumor microenvironment, suggesting that it could be a prognostic factor for DLBCL.

E1399
GENOMIC PROFILING OF BCL2 AND MYC DOUBLE EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA
V. Dirse1,2,*, J. Drachneris3, U. Mickys3, M. Stoskus1, L. Griskevicius1,2
1Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, 2Department of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 3National Center of Pathology, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania

Background: Diffuse large B cell lymphoma (DLBCL) is an aggressive disease featuring heterogeneous genetic, phenotypic and clinical characteristics. Recently, a negative prognostic impact of double expression of BCL2 and MYC (double expressor (DE)) lymphoma) has been identified in several studies. SNP array (SNP-A) studies have already led to the identification of novel genomic aberrations in ABC and GCB subtypes of DLBCL whereas similar analysis has not been done in DE and non-DE DLBCL.

Aims: To characterize the landscape of genomic aberrations in DE and non-DE DLBCL groups using SNP-A and interphase fluorescence in situ hybridization (FISH).

Methods: Immunohistochemical and FISH analysis was performed on tissue microarray of formalin fixed paraffin embedded (FFPE) tumor tissue samples using Bcl2 (124, DakoCytomation) and MYC (Y69, Epitomics) antibodies and FISH MYC (ZytoVision), Bcl2 (Abbott/Vysis), Bcl6 (Abbott/Vysis) break-apart probes and MYC/IgH (ZytoVision) double fusion probe. Intronum HD-complete genotyping assay with the HumanCytoSNP SNP-FPPE-12 BeadChip (Illumina Inc., San Diego, CA, USA) was performed for genomic analysis of the aberrations.

Results: A cohort of 91 primary DLBCL patients diagnosed between 2004 and 2012 was selected for the study. Immunohistochemical evaluation was informative in 87/91 patients (95.6%). Double expression of BCL2 and MYC was found in 22/87 patients (25.3%). FISH analysis revealed that 81% of DE cases were informative for MYC, 56 cases for Bcl2, and 65 cases for Bcl6. 2 cases (11.4%) were positive for MYC translocation, 14 (25%) for Bcl6, and only 3 (4.6%) were positive for Bcl2. No cases of FISH MYC and bcl2 double positive DLBCL were identified. Genomic DNA from FFPE tumor tissue for SNP-A was available for 67/87 patients. SNP-A data detected in total 329 genomic abnormalities not corresponding to known copy number polymorphisms (89% of all the patients, 59/66). These comprised 164 (50%) hemizygous and 2 (1%) homozygous deletions, 60 (32%) gains, 41 (12%) trisomies and 16 (5%) monosomies. The most common aberrations were 1p deletion, 1q gain, 6q deletions and 16q gains (29.8% were detected in >3 aberrations). A whole-genome SNP array (SNP-A) analysis revealed that 60/67 patients (89%) had at least one SNP-A aberration, 37/66 (56%) patients. Both DE and non-DE DLBCL groups had equal rate of aberrations per case (~5 aber/case) and shared the most common aberrations – 1p deletion and 1q gain. In contrast, 11q deletion was more common in DE, while 6q and 17q deletions were more prevalent in the non-DE group. No statistically significant genomic aberrations were observed in common karyotypes in non-DE group than in DE (16 vs 6 cases, respectively). Cases with MYC positive (FISH) and MYC gain (SNP-A) had the median number of two chromosomal aberrations with an exception of two MYC positive cases with complex karyotypes. These two cases shared the same 9q, 11q 14q deletions and the monosomy of chromosome 19. Finally, of the 7 cases with normal SNP-A karyotype, BCL6 FISH-positive marker was detected in 3 patients.

Summary/Conclusions: SNP-A analysis highlights the genomic differences between the DE and non-DE DLBCL. Our finding of MYC positive (translocations and/or gains) association with low complexity karyotype status may suggest MYC to be an early initiating genetic event.
vival (OS). The efficacy of R-CHOP was evaluated according to Cheeson criteria by performing standard hematochemical and instrumental (TC and FDCG-PET) tests and defining complete remission (CR), partial remission (PR), non response or progressive disease (PD). Genomic DNA was extracted from peripheral blood of 80 pts. SNPs analysis was performed by an Affimatrix array. To date, 21 SNPs from 19 candidate genes (ABC21, ABC1, ABC2, ABC2G, CYB5A, DAPK1, FGR2A, GSK283, GSTP1, IL11, NCF4, NOQ1, NOQ2, RAC2, TNF, TOP2A, TP53, TUBB) involved in pharmacokinetics and pharmacodynamics of R-CHOP (www.pharmkb.org) selected and analysed in relation to R-CHOP efficacy. Univariate and multivariate logistic regression analyses were performed to evaluate associations between SNPs and clinical/pathological characteristics or survival parameters (PFS and OS).

Results: Median age was 63 years. There were 37 men and 43 women. 47.5% of pts were in stage I-II, 52.5% of pts in stage III-IV. 27.5% of pts had bulky disease, 43.8% of pts had involvement of extranodal site. 47.5% of pts had pathological LDH value. According to the revised IPI, 15% of pts were in the low risk group, 58.7% in the intermediate, and 28.3% in the high risk group. IC50-values of sensitive cell lines (JeKo-1, WeCr, NCI-H929) was analyzed by Western Blot analysis.

CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB

L. Fischer1,*, A. Mayer1, M. Irger1, B. Freysoild1, Y. Zimmermann1, G. Hutter1, W. Hiddemann1, M. Dreyling1, G. Hutter1, A. Mayer1, M. Irger1, B. Freysoldt1, Y. Zimmermann1, G. Hutter1, W. Hiddemann1, M. Dreyling1

1Dept. of Medicine III, Univ. Hospital Grosshadern/LMU; Experimental Leukemia and Lymphoma Research (ELLF), Munich, Germany

Background: Mantle cell lymphoma (MCL) is characterized by k(11;14) resulting in a constitutive cyclin D1 overexpression. The cyclin D1-CDK4/6 complex inactivates Rb through phosphorylation, leading to G1/S-phase transition. Therefore, inhibition of CDK4/6 is an efficient and rational approach to overcome cell cycle dysregulation in MCL.

Aims: We evaluated the efficiency of the novel CDK4/6 inhibitor abemaciclib in various MCL cell lines and in primary MCL cells in combination with cytarabine (AraC) and ibrutinib.

Methods: MCL cell lines (Granta 519, JeKo-1, Mav-1, Mino) and primary MCL cells were exposed to abemaciclib alone and combined with AraC or ibrutinib. MCL cells were pretreated with abemaciclib and exposed to AraC or ibrutinib with or without consecutive wash-out of the CDK4/6 inhibitor. Proliferation and viability were measured by trypsin blue staining and Cell Titer Glo assay.

Figure 1. Methods: The study included 26 patients (15 males and 11 females; age 36-92, median 67) with the diagnosis of AITL established on the basis of WHO 2008 diagnostic criteria. LN, BM and peripheral blood lymphocytes were tested for T-cell clonality according to BIOMED-2 protocol with subsequent fragments analysis on ABI PRISM 3130 (Applied Biosystems). The material was examined at the diagnosis and at various stages of patient’s treatment. In 5 patients selection of CD8+ and CD4+ populations of PB lymphocytes was performed with MidiMACS and MiniMACS Separators using CD4+ and CD8+ Microbeads (Miltenyi Biotec).

Results: Clinical TCR and TCRB gene rearrangements were not detected in the BM of the LN of AITL patients. In 6 of the 26 patients (23%) clonal products found in LN matched those from PB and BM. In 8 patients (30%) at least one of the clonal products isolated from the BM and/or PB mismatched the clonal products isolated from the LN. In 12 patients (46%) clonal rearrangements found in the PB and BM were complete different from those identified for LN. Thus, at the diagnosis and at various stages of patient’s treatment. In 5 patients selection of CD8+ and CD4+ populations of PB lymphocytes was performed with MidiMACS and MiniMACS Separators using CD4+ and CD8+ Microbeads (Miltenyi Biotec).

Conclusion: We observed that R-CHOP has a potent effect against AraC treatment in all sensitive cell lines, due to an ongoing 1st G1-arrest (Mip: 10.19; 32.15 nm Mip abemaciclib / 3.33 µM AraC). In contrast, simultaneous exposure to abemaciclib had a protective effect against AraC treatment in all sensitive cell lines, due to an ongoing 1st G1-arrest (Mip: 10.19; 32.15 nm Mip abemaciclib / 3.33 µM AraC). Sequential administration of abemaciclib and ibrutinib had synergistic or additive effects in sensitive cell lines (Cis: JeKo-1 = 0.24; Mav-1 = 0.19; Mino = 0.03 32.15 nm Mip abemaciclib / 2.5 µM ibrutinib), whereas the simultaneous administration of both showed additive effects at most (Cis: JeKo-1 = 0.10; Mav-1 = 0.1; Mino = 0.09 32.15 nm Mip abemaciclib / 2.5 µM ibrutinib). In primary MCL cells abemaciclib had no impact on cell death or sensitization since no cell proliferation was observable and cells where resting in G1-phase.
CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA SHOWED FREQUENT MYC EXPRESSION AND AGGRESSIVE CLINICAL BEHAVIOR

Methods: A total of 350 cases of DLBCL were reviewed 4 university hospitals from 2004 to 2012. Review of the histologic features along with immunohistochemical study for BCL1, BCL2, BCL6, CD5, CD10, CD23, MUM1, MYC, Ki-67 and EBV in situ hybridization was performed. Florescent in situ hybridization (FISH) for MYC rearrangement and amplification was also performed. The results were compared with DLBCL-NOS (N=195).

Results: Thirty cases of CD5+ DLBCL were retrieved among 350 cases of DLBCL (8.6%), which showed predominance of female (20/30), elderly (mean age 64), and extranodal presentation (16/30). Richter transformation was suspicious in 1 case. BM and PB derived-monoclonality and EBV was negative in all. Most cases (22/30) belong to non-GCB subtype by Hans classifier. Rearrangement of MYC was found in 2 cases and amplification was found in one. Compared with DLBCL-NOS, CD5+ cases revealed significantly higher expression of MYC, BCL6, IRF4/MUM1, MYC, Ki-67 and EBV in situ hybridization was performed. Double expression of both BCL2 and MYC was found in 9 of 30 cases (30%). Also, CD5+ DLBCL showed more frequent bone marrow involvement, advanced stages and high international prognostic index (all p<0.05). In unvariable survival analysis, CD5+ DLBCL revealed significantly shorter progression free survival (median 8.2 months) compared with DLBCL-NOS (median 6.8 months) (p<0.05).

Summary: We performed the first extensive study of CD5+ DLBCL in Korea. The incidence, clinical presentation, and pathologic features including cell of origin coincide with previous reports from western population or Japan. However, frequent high expression of MYC without chromosomal structural alteration was a unique finding in our study. Expression of CD5 should be routinely investigated in DLBCL to find this particularly aggressive subtype.

MICROVESSEL DENSITY IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMAS

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common and one of the most heterogeneous lymphomas. Therefore, it is critical to further stratify cases of DLBCL into biologically similar and clinically meaningful subgroups, which will not only guide prognostic assessment and facilitate therapeutic decisions but also stimulate further research to understand the pathogenesis and development of these subtypes. In addition, the development of personalized therapies for lymphoma based on the analysis of a number of different kinds of tumors has indicated that microvesSEL quantification may be useful in predicting disease outcome.

Aims: The aim of this study was to examine the relationship between microvesSEL density (MVD) as a parameter of tumor angiogenesis, and the immunophenotype in patients with diffuse large B-cell (DLBCL) lymphomas.

Methods: We retrospectively identified cases of DLBCL diagnosed between January 2010 and January 2016 at our Institution. The following large B cell lymphoma subtypes were excluded from this analysis: post-transplant lympho-proliferative disorders with a DLBCL morphology, Primary Mediastinal large B cell lymphoma, and plasma cell neoplasms. Using this cohort, we analyzed a total of 123 patients with a mean age of 64 years (range 21-91).

Table 1: Comparison of data: HIV associated lymphoma and HIV associated RBLP.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Median (range)</th>
<th>CD30 positive large B cell lymphomas</th>
<th>Burkitt lymphomas</th>
<th>Hodgkin lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>5(2-75)</td>
<td>38</td>
<td>37</td>
<td>37</td>
</tr>
<tr>
<td>Viral load (copies/ml)</td>
<td>Median (range)</td>
<td>7(0-10 000)</td>
<td>7(0-10 000)</td>
<td>7(0-10 000)</td>
</tr>
<tr>
<td>576</td>
<td>12 000 - 10 000</td>
<td>12 000 - 10 000</td>
<td>12 000 - 10 000</td>
<td>12 000 - 10 000</td>
</tr>
<tr>
<td>18</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
</tr>
<tr>
<td>576</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
</tr>
<tr>
<td>18</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
<td>12(6-30)</td>
</tr>
<tr>
<td>576</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
<td>1(1-10)</td>
</tr>
</tbody>
</table>

123p-value<0.001, Children excluded from CD4 count analysis.

Summary: In the setting of HIV, reactive conditions may mimic lymphoma and vigilance is needed in the confirmation of monolymphocytosis. Patients with RBLP presented at a younger age when compared to their counterparts with lymphoma. They had extremely high VL with higher CD4 counts, suggesting this may be a feature of early HIV disease and the possibility of a seroconversion type illness should be considered.
Microvessel quantification was performed by immunohistochemical staining, using monoclonal antibodies against platelets/endothelial cell adhesion molecule-CD31. A total of 82 cases of de novo DLBCL treated with R-CHOP were included in the training set for further analysis. There were 45 men and 37 women, with a median age of 57 years (range, 16-84); 35 patients (43%) presented with B symptoms, and 49 (60%) had advanced Ann Arbor stages. Most of the patients had a good performance status (Eastern Cooperative Oncology Group score 0-1, 87%), elevated serum lactate dehydrogenase level (61%), and low or low-intermediate International Prognostic Index (IPI) risk (IPI score 0-2, 63%). Involvement of multiple extranodal sites (≥2) was seen in 22% of cases, and bulky disease in 32% of cases.

Results: The median follow-up time was 47 months. Among the 82 cases in the training set, CD30 was positive in 24 cases (29%). No difference in response rate was observed between CD30 positive and CD30 negative patients. Patients with CD30+ DLBCL showed a significantly superior OS and PFS compared with CD30− patients. The 5-year OS was 79% in patients with CD30+ vs 59% in CD30− (P<0.05); 5-year PFS was 82% in patients with CD30+ vs 63% in CD30− (P<0.05). In patients with CD30 positive diffuse large B cell lymphomas we found a smaller number of vessels compared with patients CD30 negative (fig.1, p<0.05).

E1407

ANTIGEN SELECTION PROMOTES CLONAL CYTOTOXIC T-CELL RESPONSES: HIGH-THROUGHPUT IMMUNOGENETIC EVIDENCE

E Stalika1, C. Galigalidou1, A. Papalexandri2, N. Stavroyianni2, I. Batsis2, I. Sakellari1, A. Anagnostopoulou2, N. Maglaveras3, I. Chouvarda3, M. Papaioannou4, K. Stamatopoulos1, A. Hadzidimitriou1

Introduction: T-LGL leukemia is a malignancy of T cells with a characteristic CD3+CD8+CD57+ phenotype. The borders between polyclonal and monoclonal T-LGL lymphoproliferations are not sharply demarcated, but rather present a transition from a polyclonal cytotoxic response towards an immunodominant proliferation of more than one immunodominant clonotype. In this study, we aimed to determine the clonal status of T-LGL leukemia: for this case, the donor blood was analyzed as were two blood samples from the son spanning 5 years were analyzed; and, (ii) a patient with T-LGL leukemia of donor cell origin developing after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia-positive acute lymphoblastic leukemia: for this case, the donor blood was analyzed and two blood samples: 1 was PCR-negative/RQ-brd, 5 were PCR-brd/RQ-brd, 2 were PCR-brd/RQ-negative. Overall, considering the 167

E1408

MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES

I. Della Starza1,2, M. Cavallo1, L.A. De Novi1, E. Genuardi2, B. Mantoan2, D. Drandi2, L. Monitillo2, E. Ciabatti3, S. Grassi4, A. Gazzola5, C. Mannu5, A. Vardi2, N. Stavroyianni2, S. Ferrero2, I. Del Giudice3

Background: In B-cell non-Hodgkin lymphomas, minimal residual disease (MRD) is a highly valuable tool for the direct assessment of the reduction of the disease burden. In 2009, the four laboratories of the Fondazione Istituto LinfoMi (FIL) - FIL MRD network - started a collaborative effort to harmonize and standardize their methodologies, performing QC (Quality Control) rounds twice a year for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD assessment.

Methods: Between February 2010 and November 2016, in the context of 14 QC rounds, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR), BCL2/IGH rearrangement was analyzed by nested PCR (Gribben, 1993) and by RQ-PCR (Ladetto, 2000). Clonality assessment was performed using an IGHV multiplex consensus PCR (Ladetto, 2003) and a second PCR assay (derived from Ladetto, 2000; Donoval, 2000). All analyses were conducted and interpreted according to the “EuroMRD Consortium” guidelines (van der Velden, 2007).

Results: The sensitivity and the accuracy of each molecular analysis was tested, reaching a uniform sensitivity of 10–5 and a quantitative range for RQ-PCR of at least 10–8. Ninety-thousand analyses were carried out as described (Ladetto, 2000). Between February 2010 and November 2016, in the context of 14 QC rounds, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples; 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR). Between 2010 and 2016, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR). BCL2/IGH MBR rearrangement was analyzed by nested PCR (Gribben, 1993) and by RQ-PCR (Ladetto, 2000). Clonality assessment was performed using an IGHV multiplex consensus PCR (Ladetto, 2003) and a second PCR assay (derived from Ladetto, 2000; Donoval, 2000). All analyses were conducted and interpreted according to the “EuroMRD Consortium” guidelines (van der Velden, 2007).

Results: The sensitivity and the accuracy of each molecular analysis was tested, reaching a uniform sensitivity of 10–5 and a quantitative range for RQ-PCR of at least 10–8. Ninety-thousand analyses were carried out as described (Ladetto, 2000). Between February 2010 and November 2016, in the context of 14 QC rounds, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR). Between 2010 and 2016, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR). Between 2010 and 2016, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR). Between 2010 and 2016, the FIL MRD Network labs received 188 BM (114 FL and 74 MCL) samples: 167 were analyzed by both nested polymerase chain reaction (PCR) and real-time quantitative PCR (RQ-PCR).
samples analyzed by both methods, 83% (139/167) of these were classified as +/+ or -/- by all the FIL laboratories. The remaining 28/167 (17%) were the samples that showed discordant results in the inter-lab assessments: while in 17 cases the "borderline status" was defined alternatively by only one method, 11 resulted brd samples by both techniques (11/167, 6.6%) (Fig.). Given that the 167 samples were tested in three replicates across the 4 labs, a total of 12 replicates/sample were analyzed: 31 brd samples were thus identified, 13 of which brd by both approaches. Of 156 evaluations performed on the 13 brd, 69/156 (44%) resulted PCR-positive and 87/156 (56%) PCR-negative, 58/156 (37%) were RQ-PNQ and 98/156 (63%) RQ-negative.

Summary/Conclusions: Despite the high inter-lab reproducibility in the MRD analysis that can be obtained and maintained by the QC round strategy, samples with the lowest MRD levels can still represent a challenge: 17% (28/167) of our series resulted brd, showing discordant results in inter-lab assessments; 39% of them (11/28) remained brd even applying both methods. The results did not change even increasing the number of replicates/sample. Thus, although representing a minority, brd samples are still problematic, especially when a clinically oriented interpretation is required. As the combined use of standard methods does not totally solve this problem, alternative, novel, methods such as digital PCR and NGS need to be tested in this context.

E1409
RH OA GLY17 VAL MUTATION AND T-CELL CLONALITY ANALYSIS IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Y. Sidorova1, 2*, N. Chernova2, I. Yakutik1, S. Smirnova1, N. Ryzhikova1, E. Nikulina1, M. Alekseenko2, O. Glinshchikova1, M. Sinitsyna3, A. Kovrigina3, E. Zvonkov2, A. Sudarikov1
1Department of Molecular Hematology, 2Department of Lymphoma Chemotherapy, 3Department of Pathology, National Research Center for Hematology, Moscow, Russian Federation

Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of T-cell lymphoma, characterized by generalized lymphadenopathy, hypergammaglobulinemia, and autoimmune manifestations. Interpretation of histological and immunohistochemical data can be difficult due to the small number of tumor cells surrounded by abundant polymorphonuclear infiltrate. AITL could often be misdiagnosed as reactive processes and other lymphomas, including Hodgkin’s lymphoma. T cell clonality assessment plays an important role in AITL diagnosis. However, ambiguous clonality results may be obtained. Recently discovered somatic RH OA Gly17Val mutation is present in 53-71% of angioimmunoblastic T-cell lymphomas. We compared the efficiency of T-cell clonality testing and quantitative allele-specific PCR RH OA Gly17Val mutation assay in different tissues for AITL diagnosis.

Aims: To correlate the number of RH OA Gly17Val mutated cells in lymph nodes, blood, bone marrow and skin of AITL patients with corresponding T cell clonality results.

Methods: Lymph nodes (LN), skin biopsies, blood and bone marrow (BM) samples were studied for 40 patients with AITL. The male/female ratio was 25/15, median age was 65 years (36-92). To evaluate T-cell clonality rearranged TCRG and TCRB gene rearrangements were PCR-amplified according to BIO-MED-2 standardized protocol and analyzed by capillary electrophoresis on ABI PRISM 3130 (Applied Biosystems). Sensitivity of T-cell clonality assay was limited to 10% of clonal T-cells of the total T-lymphocytes in the sample. Gly17Val mutation was analyzed by quantitative allele-specific (qAS) TaqMan Real-Time PCR assay. The detection level of this method was 1% of mutated cells in the total cell population.

Results: The clonal TCR gene rearrangements in LN were found in 37 of 40 patients (92%). RH OA (Gly17Val) mutation in LN was revealed in 60% (24 of 40) patients. T-cell clonality was detected in 26 of 28 primary samples of BM, but in 12 of 26 patients (46%) clonal TCR rearrangements were not matched in length with rearrangements detectable in LN. Number of cells with RH OA mutation was highest in the LN (in average 26.7% of the total cells), while in the bone marrow RH OA mutation was undetectable (in 7 patients), or detected in 10 patients in a small amount (in average 2% of the total cells). Combined histological investigation, T-cell clonality and RH OA (Gly17Val) testing showed BM lesion in 76% of patients (13 of 17) with at least one of the methods. Blood and bone marrow samples examined simultaneously showed slightly higher numbers of RH OA positive cells in the blood than in the BM in 5 of the 7 RH OA positive patients. Significant percentage of cells with a RH OA mutation (in average 25% of the total cells) was revealed in 5 of 6 skin samples from RH OA positive patients. We have found good correlation (Spearman’s Rho=0.8198, p-level <0.00001) between T-cell clonality (matching with LN clonal peaks) and the number of RH OA positive cells in the AITL samples (n 51). Skin, blood and bone marrow samples with the T cell clonality peaks that differ from those found in the LN were also negative for the presence of cells with RH OA (Gly17Val) mutation.

Summary/Conclusions: RH OA (Gly17Val) point mutation is detected in LN by allele-specific PCR in 60% of patients with AITL. The percentage of tumor cells in BM is low (averaging less than 2% of the total cells). However, combined molecular and histological data suggest that BM may be involved in most patients. Extent of T cell clonality (matching with LN clonal peaks) correlates with the amount of cells having a RH OA mutation. T-cell clonality in BM, skin, spleen, etc. with rearrangements not matching those identified for the LN should be considered reactive and possibly associated with autoimmune process or antiviral response.
E1410
USEFULNESS OF CHITOSITRIOSEDASE ACTIVITY, CCL18/PARC, 7-KETO-CHOLESTEROL AND GLYCOSYPHOSINGOSINE CONCENTRATIONS FOR SCREENING OF LYSSOMAL STORAGE DISEASES
P. Irum1,2, J. Gębaila1,2,3, L. Lopez de Frutos1,2, P. Giraldo1,2,4
1Centro de Investigación Biomédica en Enfermedades Raras (CIBER-ER), 2Unidad Investigación Trasclacional. Hospital Universitario Miguevert Servei, Instituto de Investigación Sanitaria Aragón (IIS Aragon), 3Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 4Fundación Española de Estudio y Terapéutica de la Enfermedad de Gaucher y Otras Lisosomales (FEETEG), Zaragoza, Spain

Background: Gaucher (GD), Niemann-Pick Type A/B (NPA/B), Niemann-Pick Type C (NP-C) and Lysosomal acid lipase deficiency (LALD) are lysosomal storage diseases (LSDs) difficult to diagnose due to the great heterogeneity of signs and symptoms, including haematological disorders, sometimes common to several pathologies, and the consequent alteration of biomarkers.

Aims: To assess the diagnostic utility of Chitositriosefda activity (ChT), CCL18/PARC, 7-ketocholesterol (7KC) and glycosyphosingosine (Lyso-Gb1) concentrations in previously mentioned LSDs.

Methods: ChT activity, CCL18/PARC and 7KC concentrations were measured in 146 plasma samples from subjects with suspected LSD (32 GD, 7 NPA/B, 90 NP-C and 17 LALD) received in our laboratory. In addition, a new biomarker, the Lyso-Gb1 concentration, was evaluated in 83/146 of previous mentioned subjects. 19 of them with confirmed LSD diagnosis. ChT was evaluated using a fluorogenic substrate, CCL18/PARC concentration was measured with ELISA and 7KC and Lyso-Gb1 by liquid chromatography followed by tandem mass spectrometry.

Results: A total of 9/32 (28%) samples with suspected GD showed high ChT and/or 7KC, 29/32 samples with suspected NP-C had high 7KC and/or 7KC and/or high CCL18/PARC, 4/9 confirmed GD status; the rest were 1 NPA/B, 1 NP-C and 2 carriers of NP-C. Only 3/47 (6%) with suspected NPA/B and altered biomarkers were confirmed. Among the 23/90 (26%) with suspected NP-C and some elevated biomarker four were diagnosed of NP-C, and two carriers showed some biomarker higher than cutoff. Of the 8/17 (47%) referred to LALD suspicion with some elevated biomarker six were affected. All GD confirmed patients show high levels of Lyso-Gb1 whereas none of the other cases showed elevation for mentioned biomarker.

Summary/Conclusions: The screening of three biomarkers: ChT activity, CCL18/PARC and 7-ketocholesterol concentrations (the latter not applicable in GD) is a powerful tool to identify patients at high risk of suffering from LSDs which should undergo confirmatory diagnostic tests. In this line we have would reduced the number of cases needing confirmatory diagnostic test from 146 to 43 (29%) and 19/43 (44%) were positive for LSDs. Lyso-Gb1 concentration can allow the unambiguous identification of all the GD patients but is not useful for the other LSDs.

E1411
THE VALUE OF SOLUBLE IL-2R ALPHA SUBUNIT MEASUREMENT IN CSF OF CHILDREN WITH HEMOPHAGOCYTIC LYMPHOPHILOSITCITOSIS (HLH): PRELIMINARY OBSERVATIONS
1Translational Research Unit, IIS-Aragon. CIBERER, ISCIII, 2ADIPOFAT, Instituto Aragones de Ciencias de la Salud, 3Translational Research Unit, IIS-Aragon., 4FEETEG, Fundacion Española Estudio y Terapéutica Enfermedad de Gaucher, Zaragoza, Spain

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening clinical syndrome due to a severe hyperinflammatory response. HLH is typically characterized by a very wide spectrum of clinical findings. Central nervous system affection “CNS disease” has been frequently described at presentation of HLH, during course of disease, or as isolated CNS-HLH that could precede other systemic clinical manifestations by months to years.

Aims: To study the value of CSF soluble interleukin-2 receptor alpha subunit (sIL-2Rα) assay as a marker of CNS affection in children with HLH.

Methods: In this descriptive, observational study done at Alexandria University Children’s Hospital, we analyzed the clinical data of a group of patients diagnosed as HLH. After informed consent was obtained, data was collected from patients who have undergone clinical examination, brain MRI, routine CSF analysis for evaluation of CNS-HLH, and sIL2Rα measurement in the CSF (Quantikine Human CD25/IL-2Rc Immunnoassay, R&D Systems). Patients were considered as “CNS-HLH positive” when they had either neurological manifestations, abnormal findings on MRI or routine CSF analysis (elevated proteins &/or pleocytosis) and as “CNS-HLH negative” when they did not show any of these findings.

Results: We analyzed the data of 9 HLH patients; 4 females and 5 males. Their age ranged from 2 months to 13 years with a median of 5 months. Six patients had genetic diseases predisposing to HLH [Griscelli syndrome type II (GSI) & Chediak-Higashi syndrome (CHS)], and 3 other patients were diagnosed according to HLH-2004 diagnostic criteria and presumed to be of familial form (FHL). Out of the 9 patients, only 5 patients (55.6%) showed clinically evident neurological manifestations; 5 patients (55.6%) had elevated CSF proteins &/or pleocytosis, and 4 patients (44.4%) had an abnormal brain MRI. Overall 7 out of the 9 patients (77.8%) were “CNS-HLH positive” versus only 2 (22.2%) “CNS-HLH negative” according to classical criteria. Interestingly, the geometric mean of CSF sIL2Rα in CNS-HLH positive group was lower than in CNS-HLH negative group (734 vs 1952 pg/ml, p = 0.094). Moreover, CSF protein level and cell counts did not statistically correlate with CSF sIL2Rα level. Several patients showed interesting observations. Among the patients with confirmed FHL (6/7 HLH-2004 diagnostic criteria fulfilled, NK cell activity not tested), the one with the highest observed CSF sIL2Rα level (17329 pg/ml), a 2 months old infant, was “CNS-HLH negative”, but had severe bilateral papillidemia (discovered during workup for suspected autoinflammatory disorder). The second patient, a 3.5 year old with a 3 year history of a “CNS-HLH positive” infant also had a relatively elevated CSF sIL2Rα of 220 pg/ml. On the other hand, 2 twin sisters evaluated at the age of 3 months for HLH secondary to CNS (positive family history, grey hair, hypogammaglobulinemia) showed neuro- logical or radiological evidence of HLH, but had positive routine CSF analysis (elevated protein & pleocytosis) and CSF sIL2Rα (600 & 800 pg/ml).

Summary/Conclusions: We hypothesize that routine CSF sIL2Rα level assay could enhance earlier & better detection of CNS-HLH in children especially in familial HLH, and genetic forms. As far as we know, only one previous study reported the diagnostic and prognostic value of CSF sIL2Rα levels, as well as its value for follow up of CNS disease.

E1412
GAUCHER DISEASE PATIENTS EXHIBIT A HIGH EXPRESSION OF LIPOCALINE (LCN2) AS POSSIBLE BIOMARKER OF RESIDUAL DISEASE Activity: EXPLORATORY STUDY AND CORRELATION WITH OTHER CYTOKINES
M. Andrade-Campos1,*, M.P. Garcia Sobreviela2,3, B. Medrano Engay3, P. Irum1, J. Gervas Aруga3, M. Arbones2,3, P. Giraldo1,4
1Translational Research Unit, IIS-Aragon. CIBERER, ISCIII, 2ADIPOFAT, Instituto Aragones de Ciencias de la Salud, 3Translational Research Unit, IIS-Aragon., 4FEETEG, Fundacion Española Estudio y Terapéutica Enfermedad de Gaucher, Zaragoza, Spain

Background: Gaucher Disease (GD) is characterized by a latent chronic inflammation with macrophage activation status expressed by an increase of pro-inflammatory cytokines, hyperferritinemia, hypergammaglobulinemia, altered calcium homeostasis and metabolic syndrome. Even patients under ERT do not fully revert this status and their risk to develop bone crisis, iron metabolism alterations, autoimmune disorders and neoplasms remain higher. This observation has led to the creation of the minimal-residual-disease-activity concept. Monitorization of patients through chitotriosidase and CCL18/PARC has become essential however there are patients whom never normalize while others developed bone crisis/ complications after long-time under therapy and normal values. One of the key features for chronic inflammation is the anemia; this is characterized by hyperferritinemia and a common feature diagnosed in GD1 patients. Lipocaline (LCN2), a cytokine released by adipocytes, mononuclear cells and neutrophils with expression on endothelial cells, hepatocytes and other cells, has been involved into the monocyte polarization and perpetuation of the inflammatory state. Based on this, we have performed an exploratory study assessing LCN2 expression in GD patients.

Aims: To explore the Lipocaline (LCN2) expression as biomarker for disease activity in type 1 Gaucher Disease patients under different circumstances.

Methods: We have performed an exploratory study on 18 GD1 patients distributed in two cohorts. Cohort A was composed by 6 patients: 2 naïve (N) (without undergo replacement therapy) and 3 patients undergoing cholinesterase inhibition therapy. Patients were classified into two different groups: Cohort A and Cohort B. For this cohort sera samples were obtained for LCN2 determination and also a panel of cytokines (IL-10, IL-13, IL-4, IL-6, IL-7, Mip1a, Mip1b y TNFα), and general hematological and metabolic parameters. Starting at beginning of ERT and after one year on it. Data were incorporated into a database for this porpoise including demographic and clinical available data. All patients have signed an informed consent for the use of their samples and ethical approved were obtained form institutional board of FEETEG foundation. In order to be compared to results of other trials or homologous, all the patients showed increased levels of serum LCN2, the overall mean value for the initial sample was 171, 88 (66,72-261,72). As cohorts the differences among individuals were significant (Cohort A: p<0.02 and cohort B, p<0.01). Naive
patients exhibit the higher values. In general 9 patients showed a reduction on LCN2 levels while 7 showed an increase and one the value was stable. All patients showed a reduction in ferritin and chitotriosidase, however a fully correlation with LCN2 expression were not founded. Globally there were no statistically differences, but as individual T-test showed a difference between both measures (p=0.027). A detailed description an analysis will be presented in case of acceptance.

**Summary/Conclusions: **Lipocaline expression is increased in GD1 patients in general, a correlation with other cytokines expression to establish the role of this biomarker is warranted.

E1413

COMPARISON OF TREATMENT AND OUTCOMES BETWEEN ACQUIRED PRIMARY AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA

S.H. Wai1,2, J. H. Ng3, W.C. Ten4, J. Quek2, H. T. Mya5
1Monash University, Melbourne, Australia; 2Singapore General Hospital, Singapore, Singapore

**Background:** Thrombotic thrombocytopenic purpura (TTP) is a rare disease that is fatal if untreated. While the main treatment modality is plasmapheresis, immunosuppressants also play a crucial role in the treatment of TTP.

**Aims:** Our aim is to compare the clinical characteristics, treatment and outcomes of patients with acquired primary TTP to those with secondary TTP (i.e. autoimmune and malignancy/hematopoietic stem cell transplant (HSCT) related).

**Methods:** We reviewed all patients with TTP who received plasmapheresis at our institution from 1st Jan 2008 to 31st Jan 2017. Clinical and laboratory characteristics, treatment, response to treatment and complications were recorded.

**Complete remission (CR) was defined as platelet count normalization, partial remission (PR) as platelet count doubling and >30 x 10⁹/L, and the rest as unsatisfactory/mortality (UM).**

**Results:** Of 41 cases of TTP, 24% (n=10) was primary, 44% (n=18) was secondary to autoimmune diseases, 27% (n=11) was secondary to malignancy or HSCT, 5% (n=2) was related to DRESS syndrome and acute pancreatitis. The median age was 47(±18) years and it was predominately female (81%). About two-thirds of the cases presented with neurological symptoms (66%), renal dysfunction (56%) and fever (59%). Only 12 patients (29%) had TTP pentad. Proportionate to incidence of secondary TTP, 85% required immunosuppressive treatments and 51% (n=22) were in PR in 15% (n=6) mortality rate at end of treatment was 41% (n=17) and at end of follow-up was 46% (n=19).

Comparison of demographics, clinical presentation, treatment and outcomes between acquired primary TTP and secondary TTP are shown in table below.

<table>
<thead>
<tr>
<th>Table 1.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary TTP</strong></td>
</tr>
<tr>
<td><strong>Age (median, range)</strong></td>
</tr>
<tr>
<td><strong>Female (%)</strong></td>
</tr>
<tr>
<td><strong>Neuropsychological symptoms (%)</strong></td>
</tr>
<tr>
<td><strong>Renal dysfunction (%)</strong></td>
</tr>
<tr>
<td><strong>Fever (%)</strong></td>
</tr>
<tr>
<td><strong>Placenta vena (median, range)</strong></td>
</tr>
<tr>
<td><strong>Hematocrit (%)</strong></td>
</tr>
<tr>
<td><strong>Von Willebrand factor (%)</strong></td>
</tr>
<tr>
<td><strong>C-reactive protein (%)</strong></td>
</tr>
<tr>
<td><strong>Immuno Globulin (%)</strong></td>
</tr>
<tr>
<td><strong>Renal replacement therapy (%)</strong></td>
</tr>
<tr>
<td><strong>Thrombocytopenia (%)</strong></td>
</tr>
<tr>
<td><strong>Malignancy (%)</strong></td>
</tr>
<tr>
<td><strong>Major hemorrhage (%)</strong></td>
</tr>
<tr>
<td><strong>Days of hospitalisation (median, range)</strong></td>
</tr>
<tr>
<td><strong>TTP</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** Our aim was to compare the characteristics, treatment and outcomes of patients with acquired primary TTP to those with secondary TTP (i.e. autoimmune and malignancy/hematopoietic stem cell transplant (HSCT) related). A total of 41 patients were included, median age was 47(±18) years and it was predominately female (81%). About two-thirds of the cases presented with neurological symptoms (66%), renal dysfunction (56%) and fever (59%). Only 12 patients (29%) had TTP pentad. Proportionate to incidence of secondary TTP, 85% required immunosuppressive treatments and 51% (n=22) were in PR in 15% (n=6) mortality rate at end of treatment was 41% (n=17) and at end of follow-up was 46% (n=19).

**Comparison of demographics, clinical presentation, treatment and outcomes between acquired primary TTP and secondary TTP** are shown in table above.

E1415

LOW DOSE RITUXIMAB IS A USEFUL ADDITION TO CORTICOSTEROIDS FOR EVANS SYNDROME IN CHILDHOOD

A. Gomez-De Leon1,*, P. Colunga Pedraza 1, P. Santana-Hernandez 1, J. Quek2, H. T. Mya3
1Hematology, Hospital Universitario Dr. Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Mexico

**Background:** Autoimmune hemolytic anemia (wAIHA) is an infrequent autoimmune disorder with a high response rate to corticosteroids, albeit relapses are common. Low-dose rituximab has been used successfully in autoimmune hemolytic anemia in an effort to increase response duration, while reducing adverse effects and costs associated with a traditional rituximab dose and prolonged prednisone exposure.

**Aims:** To evaluate the safety and efficacy of low-dose rituximab combined with corticosteroid treatment in newly diagnosed patients with wAIHA.

**Methods:** We performed a single-center, prospective, single-arm, open-label study in adult patients with newly diagnosed primary or idiopathic wAIHA from 2013-2016 using high dose dexamethasone (40mg IV days 1-4) followed by low-dose rituximab (1g/kg PO dose +1mg/kg PO day 1, 3, 5, 7, 9, and 11). A total of 8 patients were included, median age was 32 years (range 15-81). All patients had response at day +28 (50% CR rate); median time to response was 12 days (range 3-17). During follow-up, CR was achieved in 7 patients (median time to CR: 3 months, range 1-8). Response was evaluated at day +28, months +6 and +12. Informed consent was obtained from all participants.

**Results:** Eight patients were included, median age was 32 years (range 18-42), 6 were female. Median Hb at diagnosis was 5.8 g/dL (range 4.8-8.2 g/dL). All patients had response at day +28 (50% CR rate); median time to response was 12 days (range 3-17). During follow-up, CR was achieved in 7 patients (median time to CR: 3 months, range 1-8). All patients remained steroid-dependent and relapsed after 12 months, achieving a stable PR after re-treatment with low-dose rituximab. Furthermore, two patients had new-onset immune thrombocytopenia (IT; Fisher-Evans’ syndrome), without hemolysis 6.5 and 8 months.
after diagnosis. Two patients were diagnosed with systemic lupus erythematosus during follow-up, they remained in CR. Twelve-month CR rate was 80% (5 evaluable patients). One patient experienced grade 3 neutropenia two months after the last rituximab infusion that resolved without complications. Estimated relapse-free survival was 80% at 2 years (60% if IT is considered). No patient had a spleenectomy performed.

Summary/Conclusions: This small study reports favorable outcomes for patients with newly diagnosed wAIHA treated with low-dose rituximab, and adds 8 patients with similar responses to the 7 cases previously published by the Italian group in 2012 and 2016. These results may be comparable to standard doses of rituximab, with a lower cost, and deserves further inquiry. The emergence of additional autoimmune phenomena (SLE, Evans’ syndrome) is unpredictable and can be an obstacle for appropriate data analysis in prospective AIHA studies.

E1416
INFECTIOUS COMPLICATIONS IN PRIMARY AUTOIMMUNE NEUTROPENIA OF CHILDHOOD
T. Palianopoulos 1, A. Gkoutsias 1, N. Chaliasos 1, A. Makis 1, 2
1Department Of Pediatrics, University Hospital Of Ioannina, Ioannina, Greece

Background: Primary autoimmune neutropenia (PAN) of childhood is caused by the action of antibodies against membrane antigens of neutrophils leading to their peripheral destruction. Despite the low neutrophil counts, it is characterized by minor intermittent infections with rare severe bacterial episodes, which can be a significant cause of morbidity.

Aims: The retrospective evaluation of the incidence and characteristics of infectious complications in children with PAN from one reference academic center in Greece.

Methods: The study included the clinical and laboratory findings of children with PAN, who were diagnosed in our department in the last eight years (2008-2016). We included children who had neutropenia lasting over 3 months with a positive test for neutrophil antibodies, using the granulocyte immunofluorescence test, the granulocyte agglutination test and the monoclonal antibody immobilization of granulocyte antigen test. Laboratory evaluation for nutritional deficiencies, infections, systemic autoimmune diseases or malignancies was negative. Clinical data related to the occurrence of bacterial infections and treatment, hospitalization and outcome were collected and analyzed.

Results: 48 children with PAN were enrolled; 28 were boys, the median age was 14.5 months (range 5-96) and median follow-up time was 20 months (range 4-93). 19 children (39.6%) all suffering from severe neutropenia (0.5 x 10^9/L) had to be hospitalized 25 times for bacterial infections; 4 for pneumonia, 7 for acute otitis media, 1 for mastoiditis, 7 for urinary tract infections, 4 for bacterial infections of unspecified site, 1 for perianal abscess and 1 for cellulitis, all with good outcome with proper antibiotic treatment. The average number of hospitalizations due to infections was 0.52/patient and the rate was 0.56/1000 patient-days. G-CSF was administered in 2 children due to severe infection, while 8 children received antibiotic chemoprophylaxis.

Summary/Conclusions: Although rare, infections are an important clinical issue in the management of children with severe PAN, sometimes requiring hospitalization. Early signs of infection should be promptly recognized and accordingly treated.

E1417
NEW EPO-RECEPTOR MUTATION IN A -17 YEAR OLD WOMAN WITH ERYTHROCYTOSIS
B. Robredo 1, L. Lo Riso 1, B. Lopez 2, L. Florensa 2, L. Arenillas 2, B. Belosillo 2, C. Ballester 1, A. Perez 1, A. Sampol 1, M.A. Duran 1
1Hematology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 2Laboratorio Citología Hematólogica, Hospital Universitario Son Espases, Palma de Mallorca, Spain

Background: Erythrocytosis is defined when red cell, hematocrit (Hct) and hemoglobin (Hb), are elevated above normal limits. Causes of erythrocytosis can be primary and secondary. Secondary causes are divided into congenital and acquired. There is a group of patients with idiopathic erythrocytosis.

Aims: We present a case report of a novel EPO-Receptor mutation.

Methods: We present a case report of a 17-year-old woman with erythrocytosis. In the control blood test she had hemoglobin of 18.6g/dl and hematocrit of 62%. We contacted the patient and she attended hematology consultations for study and treatment with phlebotomy. The patient had no known drug allergies or toxic habits. She had no known comorbidities and was treated by phlebotomy. At evaluation she referred chronic headache without other symptoms. The physical examination was normal. At that time, three possible diagnose were suspected. Firstly, primary erythrocytosis, polycythemia vera (PV). In this disease, the bone marrow produces many red cells and the JAK2 V617F mutation has been demonstrated in the majority of patients. Exon 12 mutation has been described in patients with PV who did not have the JAK2 V617F mutation. The erythropoietin (EPO) level is undetectable as a compensatory mechanism. In our patient, JAK2 V617F mutation and exon12 mutation were negative and the EPO levels were undetectable (<1.5). The bone marrow aspirate and the bone marrow biopsy were normal. These results show that this patient doesn’t present PV, due to she only fulfilling one diagnosis criteria of PV. Secondly, acquired secondary erythrocytosis can be produced as a compensatory mechanism, including: cardiac or pulmonary disease, smoking, renal artery stenosis, sleep apnea/hypventilation and malignant tumors. In the patient, pulmonary function test, abdominal ultrasound and kidney function were normal. Endogenous erythropoietin colonies were positive. Due to the test results, we ruled out the diagnosis of acquired secondary erythrocytosis. Finally, congenital secondary erythrocytosis. Genetic abnormalities have been identified in congenital causes of erythrocytosis. The congenital erythrocytosis are divided into two sets according to EPO levels. If the EPO levels are normal or increased, the patient could present high oxygen-affinity hemoglobin because of biphosphoglycerate mutase deficiency or mutations in the genes in the oxygen sensing pathway. However, if the EPO levels are decreased, the patient could present an erythropoietin-receptor mutation. Our patient presented undetectable EPO levels and the EPO-receptor mutation was requested. The patient has been treated with phlebotomies and aspirin due to headache with good evolution. In this moment, she presents hematocrit levels of 46.8%.

Results: The test revealed an EPO-receptor mutation (c.1275_1290dup), which had never been described before.

E1418
FAMILIAL HEMOPHAGICOTIC LYMPHOHISTIOCYTOSIS IN CHILDREN
Z. Salcioglu 1,2, G. Aydoğan 1, F. Akci 1, C. Bayram 1, A. Ayciçek 1, G. Ozdemir 1, 1Pediatric Hematology and Oncology Clinic, Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey

Background: Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive disorder characterized with uncontrolled activation of T-helper lymphocytes and macrophages and over-release of inflammatory cytokines. The only curative treatment is hematopoetic stem cell transplantation (HSCT).

Aims: This study evaluates the clinical and laboratory data of children with FHL. Thirty five FEL cases followed and treated at our clinic between 2005 and 2017 were retrospectively evaluated in our study.

Methods: Information of patients were retrieved from patient files and from the records contained in the electronic information processing environment created after 2005. All patients were treated with HLH-2004 protocol. HSCT was performed in nine patients.

Results: Twenty one of the cases were boys and fourteen were girls. The age at presentation for patients was two week-three years (mean 6.2 months). There was a history of consanguineous marriage in 26 of the families (74%). Fever, anemia, and hypertriglyceridemia were present in all HLH cases. Hepatomegaly was detected in 74%. Splenomegaly was more frequent in patients (87.7%). Thrombocytopenia was detected in all patients. All patients had neutropenia and thrombocytopenia. Hyperferritinemia was present in 94%/ of patients. Only nine patients found to have hemophagocytosis in the cytological evaluation of the CSF(25.7%). Mutation analysis were performed in 94% of patients. Only nine patients found to have hemophagocytosis in the cytological evaluation of the CSF(25.7%). Mutation analysis were performed in 18 patients and of these, 10 had PRF1, 5 had UNC13D, and 3 had STX11 gene mutation. All patients were treated with HLH-2004 protocol. Of the 22 children who were placed in first remission. HSCT was performed in 9 patients (%25.7). The overall mortality rate was 57% (20 cases) in our series. Twenty children died opportunistic infection (10%) or of disease progression (10%).
Summary/Conclusions: In conclusion, FHL is a disease with high mortality rates and the only curative treatment is HSCT. Donor search for HSCT must be started and HSCT should be performed after the remission.

E1419

ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA

M. Economou1,*, A. Teli1, D. Adamidou2, A. Taparkou1, E. Farmaki1, P. Kanellos1, I. Mavroudi1, C. Pontikoglou1, H. Papadaki1
1Department of Haematology, University of Crete School of Medicine, Heraklion, Greece

Background: Chronic idiopathic neutropenia (CIN) is an acquired disorder of granulopoiesis characterized by an unexplained, prolonged reduction in the number of neutrophils and a generally benign and uncomplicated course. Neutropenia in CIN has been mainly attributed to increased apoptotic death of the granulocytic progenitor cells due to abnormal production of pro-inflammatory cytokines and pro-apoptotic mediators. Activated T-lymphocytes with a skewed oligoclonal/monoclonal profile and myelosuppressive properties have also have a major role in the pathophysiology of CIN.

Aims: Monocyte subpopulations display a prominent role in innate immunity but also mediate pro-inflammatory responses and T-cell activation. The monocyte subsets have never been studied in CIN. The aim of the present study was to evaluate the monocyte subsets, namely the classical CD14++/CD16-, intermediate CD14+*/CD16- and non-classical CD14+*/CD16++ cells as well as the monotypic CD14+/CD15+/DR/holoTC/CD33+/CD11b- fraction of the myeloid derived suppressor cells (iMDSC), in CIN patients.

Methods: We have studied 25 patients fulfilling the well-defined diagnostic criteria for CIN and 10 age and sex-matched healthy individuals. Three-colour flow cytometry was used to assess the peripheral blood monocytes subsets in the gate of CD14 positive cells and five-colour flow cytometry for the evaluation of the myeloid derived suppressor cells in the gate of cells with intermediate/high FSC/SSC properties.

Results: The mean number of neutrophils and monocytes in CIN patients was 117±6x496/µl and 412±130/µl, respectively (range 200-1800 and 700-2000/µl, respectively). The proportion of classical CD14++/CD16+ cells was significantly decreased in CIN patients (79.6%±7.6%) compared to the healthy individuals (87.9%±3.7%) (P=0.0009). In contrast, a significant increase was observed in the proportion of CD14+ positive cells in CIN patients (16.81%±6.75%) compared to the controls (7.97%±3.16%) (P=0.0001). This increase was due to the higher proportion of the intermediate CD14+*/CD16* but not the non-classical CD14+*/CD16++ monocyte subsets in CIN patients (12.74%±5.28% and 4.05%±2.51%, respectively) compared to controls (7.05%±2.47% and 2.73%±1.39%, respectively) (P=0.0014 and P=0.1383, respectively). Furthermore, the proportion of CD14+*/CD15+/DR/holoTC/CD33+/CD11b- MDSCs was significantly increased in the patients (6.18%±3.92%) compared to the healthy controls (2.73%±1.39%) (P=0.0412).

Summary/Conclusions: CIN patients display increased proportion of circulating intermediate CD14+*/CD16+ monocytes that may have a role in the aberrant inflammatory responses commonly seen in these patients. The increased proportion of the intermediate CD14+*/CD16* monocyte subset may play a role in the suppression of T-cell activation. Isolation of the above cell populations and transcriptome studies are currently in progress in our laboratory.

E1420

DIAGNOSTIC VALUE OF CELL BOUND AND CIRCULATING ANTI-NEUTROPHIL ANTIBODY DETECTION IN PEDIATRIC NEUTROPENIA

1Flow Cytometry Service, IRCCS Foundation Ca’ Granda Ospedale Maggiore Poligimico, Milan, 2Azienda Ospedaliero Universitaria di Novara, 3Azienda Ospedaliera Civica di Cristina e Benfratelli, Palermo, 4Flow Cytometry Service, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milan, 5Azienda Ospedaliero Universitaria Policlinico Giovanni XXIII, Bari, 1Department of Clinical Sciences and Community Health, Milan, Italy

Background: Chronic benign neutropenia (CBN) of patients includes primary autoimmune (pAIN) and chronic idiopathic (cAIN) neutropenia. A diagnosis of CIN is supported by the absence of demonstrable anti-neutrophil antibodies that can be detected free in the serum and bound to neutrophils with the Indirect- and Direct-Granulocyte Immunofluorescence Test (I-GIFT, D-GIFT), respectively. Conclusive evidence is lacking on the diagnostic value of the D-GIFT, whose performance requires specific laboratory expertise, may be logistically difficult and hampered by very low neutrophil count in patient samples.

Aims: This study investigated whether the evaluation of D-GIFT improves the diagnostic accuracy of pediatric neutropenia.

Methods: I-GIFT and D-GIFT were performed by flow cytometry in 533 children including 174 (33%), 162 (30%), 81 (15%), 51 (10%) and 65 (12%) cases with pAIN, CIN, secondary autoimmune (sAIN), post-infection (PIN) and non-autoimmune (nAIN) neutropenia referred to this laboratory during 2002-2014, respectively.

Results: Using highly specific median fluorescence intensity cut-off values calculated by ROC curves, a positive D-GIFT was found in 49% of CIN patients, who showed similar clinical features as those included in the pAIN group. In 44% (272) CIN patients I-GIFT was repeated 2-3 times in a year, resulting positive in 12% (27) and 2% (5) patients at the second and third screenings, respectively. Interestingly, 10% (71) of the latter 14 patients showed a positive D-GIFT at the first serological screening.

Summary/Conclusions: D-GIFT evaluation improves the diagnostic accuracy of pediatric neutropenia. This can reduce the need for expensive and invasive investigations in CBN patients.

E1421

INAPPROPRIATE TREATMENT COULD MASK COBALAMIN DEFICIENCY: ROLE OF METHYLMALONIC ACID EVALUATION

R. Angel P.1,*, P. Sarda2, M. Serra3, J.M. Querol4, E. Zapico1, J. Remacha1, S. Payan1, A. Ramos-Aviles1
1Hematology, 2Biochemistry, Hospital de Sant Pau, Barcelona, Spain

Background: Metabolic markers of cobalamin (Cbl) deficiency, such as methylmalonic acid (MMA) and homocysteine (Hcy) enable us to diagnose Cbl deficiency. They differentiate Cbl deficient patients from those with low serum cobalamin levels (LB12), but without a real Cbl deficit. Hcy evaluation is fully automated and available in many laboratories, whereas MMA determination is cumbersome and measured in few laboratories. Routinely, Hcy is used to differentiate LB12 patients because a good concordance has been reported between Hcy and MMA. However, in a study involving few cases, 26.3% patients with LB12 and normal Hcy showed high MMA levels.

Aims: To evaluate the characteristics of patients with LB12 and normal Hcy and high MMA levels.

Methods: A prospective study was carried out in our University Hospital. Hcy levels were determined in LB12 (level <15pmomol/l) patients with normal folate parameters for 18 consecutive months. MMA was assessed in those with normal Hcy. Serum B12, serum and red cell folate, and Hcy levels were evaluated using commercial automated methods. Hyperhomocysteinemia was defined by serum Hcy >17µmol/l. MMA serum was assessed by using mass spectrophotometer and an increase in the MMA level was considered when MMA was >0.4nmol/l.

Results: A total of 237 patients with LB12 and normal Hcy were observed. In 27 (11.4%) MMA levels could not be determined. MMA levels were normal in 147 (70%). In 63 patients, MMA was increased (30%), including 25 cases (12%) with MMA >0.8nmol/l. In 48 out of 63 patients (76%), data on previous treatment were available. Of them, 40 (83.3%) patients had previously received inappropriate treatment (40% receiving folate) and 5 no previous Cbl treatment (10.5%). Only, 3 patients (6.25%) were treated with an adequate Cbl dosage.

Summary/Conclusions: MMA was increased in 30% of LB12 patients with normal Hcy. Most of these patients (83.3%) were erroneously treated, including 40% receiving folate. As a consequence, in most of these cases this erroneous treatment decreased Hcy levels to normal values, but cobalamin deficiency was masked and could deterioration, especially when folate treatment was used without and adequate cobalamin replacement.

References

E1422

Abstract withdrawn.

E1423

RITUXIMAB IN AUTOIMMUNE HEMOLYTIC ANEMIA OF INFANCY

M. Economo1,*, I. Teili1, D. Adamidou2, A. Taparkou1, E. Farmaki1
1Aristotle University of Thessaloniki, 2Blood Bank, Hippokration General Hospital, Thessaloniki, Greece

Background: Chronic idiopathic neutropenia (CIN) is an acquired disorder of granulopoiesis characterized by an unexplained, prolonged reduction in the number of neutrophils and a generally benign and uncomplicated course. Neutropenia in CIN has been mainly attributed to increased apoptotic death of the granulocytic progenitor cells due to abnormal production of pro-inflammatory cytokines and pro-apoptotic mediators. Activated T-lymphocytes with a skew...
Background: Autoimmune hemolytic anemia (AIHA) is not commonly seen in childhood, and is extremely rare in infancy. Absence of guidelines renders management of the disease difficult in children – and even more so in infants.

Aims: Aim of the report is to present a number of cases of infantile AIHA, refractory to conventional treatments, demonstrating response in administration of rituximab.

Methods: The report concerns four infants (3 baby girls and one baby boy) who presented with AIHA. Data including demographics, personal and family medical history, immunologic assessments, previous treatments and response to rituximab were studied.

Results: Age at diagnosis of AIHA was 4-6 months. In 3 cases, cases number 1, 2 and 3, and in case number 4, the condition became apparent upon the 2nd-3rd week of life. In all 4 cases, the patients were not previously associated with anaemia. The condition was refractory to conventional treatments, administrating transfusions, and intravenous immunoglobulin (maximum dose 60g/kg), repeated doses of intravenous methyl-prednisolone (30mg/kg) followed by oral predniolone (max 5mg/kg), all failing to achieve sustained response. Rituximab was administered at 370mg/m² in 4 weekly infusions. In 3 infants 5 monthly infusions followed. stabilization of hemoglobin and improvement of hemolysis parameters were observed after the 3rd-4th weekly infusion in all infants. In 3 patients (no 1,2,3) CD19+ and CD20+ B-cell assessment before and after rituximab administration was performed. Complete elimination (<1%) was observed in all patients after the 1st-2nd infusion. Despite B cells returning to normal 11 months after treatment, infant no 1 remained in clinical remission during follow-up (22 months post treatment). Infant no 2 remained in clinical remission for the 16 month post treatment follow-up, despite B cell normalization. Infant no 3 relapsed following B cell normalization, 11 months after rituximab administration. Infant no 4 did not undergo B cell measurements and relapsed one year after completing rituximab therapy. The 2 patients that relapsed were re-treated with 4 rituximab infusions: patient no 3 remained well for the 18 month follow-up, whereas patient no 4 remained well for 10 years – again relapsing and receiving her 3rd rituximab treatment with good response for the remaining 7 month follow-up.

None of the patients presented with adverse reactions during the infusions or with severe infections as a result of immunosuppression. However, infant no 1 developed asymptomatic progressive IgG hypogammaglobulinemia 11 months after initial exposure to rituximab, eventually requiring IVIG administration.

Summary/Conclusions: Rituximab administration in refractory AIHA seems to be efficacious and safe in infants. However, close follow-up is warranted in order to ensure absence of long term complications, including the risk of post-treatment hypogammaglobulinemia, when the drug is administered at such young ages.

E1424
EARLY LESSONS FROM WHOLE-EXOME SEQUENCING IN THE CLINICAL DIAGNOSIS OF RARE INHERITED ANAEMIAS
1Molecular Haematology Unit, 2BRC Molecular Diagnostic Centre, Oxford University Hospitals NHS Trust, 3Comprehensive Biomedical Research Centre, Weatherall Institute of Molecular Genetics, University of Oxford, 4Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Background: Targeted re-sequencing has recently been adopted for the rapid diagnosis of anaemia patients whose disease is likely to have a genetic basis, however, currently results remain inconclusive in 30-60% of cases. Whole-genome sequencing (WGS), provides more uniform coverage than amplification-based panels and is allied to an unbiased approach offering the opportunity to explore both coding and non-coding regions. It is also possible to use WGS data to detect copy number variation with good resolution and sensitivity. Therefore WGS has the potential to offer an accurate molecular diagnosis in a proportion of unsolved anaemia cases and may therefore be a superior initial approach. Furthermore, WGS is likely to lead to the identification of novel genes involved in pathogenic and normal erythropoiesis.

Aims: It is aimed to undertake WGS in a set of patients in whom targeted re-sequencing had not been able to identify a molecular cause for the inherited anaemia, in an attempt to increase the diagnostic yield of the molecular analysis to enable correct diagnostic and clinical management of anaemia patients. We also demonstrate the benefit of using WGS over targeted resequencing given the difficulty of designing comprehensive gene panels and is allied to an unbiased approach offering the opportunity to ensure absence of long term complications, including the risk of post-treatment hypogammaglobulinemia, when the drug is administered at such young ages.

Summary/Conclusions: These results illustrate the overlap in phenotypic abnormalities existing among these conditions and the importance of providing an accurate molecular diagnosis to enable correct diagnostic and clinical management of anaemia patients. We also demonstrate the benefit of using WGS over targeted resequencing given the difficulty of designing comprehensive gene panels and keeping them up-to-date as new candidate genes are identified.

E1425
CONGENITAL ERYTHROCYTOSIS: DISCOVER OF A NEW MUTATION
J. Barradas1,2, P. Rocha1, C. Dantas Rodrigues2,1, C. Constanço1, M. Reis Andrade1, C. Bento2, H. Matos Silva1
1Serviço de Hematologia Clínica, Centro Hospitalar Tondela-Viseu, Viseu, 2Serviço de Hematologia Clínica, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal

Background: Congenital erythrocytosis (CE) is a rare hereditary disorder of red cell production, characterized by an absolute increase in red cell mass with elevated hematocrit and hemoglobin levels not accompanied by increased EPO production and subsequent erythropoiesis. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of erythropoiesis and it was co-segregated with the erythocytosis phenotype. That gene plays an important role in the regulation of
Results: Patient distribution was: TTP 13, HUS 8, sTMA 23. ADAMTS13 was determined in 28 patients (low 8, high 20). Clinical and laboratory parameters of each group and univariate analysis are summarised in table 1. All patients received 1mg/kg/day steroids on admission and started plasma exchange. Patients in the TTP group showed increased levels of LDH, schistocytes, bilirubin, and a low platelet count which was associated with bleeding. They also required a higher number of plasma exchanges to recover. Five patients relapsed, 4 with low ADAMTS13 level. 4 patients were splenectomized and received immunomodulators. One patient received only plasma exchanges when relapsed. One patient died immediately after diagnosis before receiving plasma exchange. HUS group patients had higher creatinine level which was associated with oliguria and dialysis requirement. Neurological symptoms were more frequent as well. Two patients progressed to renal failure and one was transplanted. Two other patients received eculizumab and 1 relapsed when treatment was interrupted during pregnancy. sTMA patients showed more cardiac events and fever. Main triggering causes were: 6 malignant hypertension, 5 systemic lupus erythematosus, 4 neoplasia, 3 pancreatitis, 2 pregnancy, 1 tuberculosis, 1 glomerulonephritis, 1 dermatomyositis. Six patients died (4 cancer related). In the multivariate analysis, high LDH level was significantly associated with relapse (p=0.012) while the number of schistocytes showed a trend to statistical significance (p=0.063).

Summary/Conclusions: ADAMTS13 determination is a useful tool in TMA differential diagnosis. A high LDH level, and also the probable number of schistocytes, could be valuable to predict relapse in TMA patients.

E1427

CHILDREN WITH CHRONIC-REFRACTORY AUTOAMUNE CYTOPENIAS: A SINGLE CENTER EXPERIENCE

T.H. Karapınar1,*, E. Durgun1, Y. Oymak1, N. Gülez2, Y. Ay1, F. Genel2, S. Gözmen1, E. Serdaroğlu3, S. Aydın Köker1, E. Töret1, C. Vergin1

1Pediatric Hematology and Oncology, 2pediatric immunology, 3pediatric nephrology, Dr. Behçet Uz Children Training and Research Hospital, Izmir, Turkey

Background: Autoimmune cytopenias are a group of heterogeneous disorders characterized by immune-mediated destruction of one or more hematopoietic lineage cells. They can be idiopathic or occur as a manifestation of other underlying disorders, such as autoimmune diseases, immunodeficiency, autoimmune lymphoproliferative syndrome, tumors, medications or infections. Aims: The aim of this study was to evaluate the clinical course and significance of autoimmune cytopenias due to immunodeficiency or autoimmune diseases in children followed up at our hospital.

Methods: A total of 337 files of information belong to patients with chronic or refractory autoimmune cytopenias were evaluated retrospectively at our hematology department between February 1997 and September 2015. Ultimately, patients with immune deficiency or autoimmune diseases (23 patients) were included in this study. Data were analyzed using SPSS 15.0. The results are presented as the mean, SD, median, absolute number, or percentage.

Results: Two third of the patients were male (69%) and third were female (31%). The median age of diagnosis was 3.1 years (between 6 months-16 years) and the ratio of male/female was 1.3. The median duration of following was 2.6 years (between 4 months and 18.5 years). A total of 13 patients (56.5%) had single-lineage cytopenias and 10 (46.5%) had multi-lineage cytopenias. Shows last diagnosis of the patients. In 10 of the patients, first cytopenias had been diagnosed than the primary diseases were diagnosed after median 2 months (between 0 and 77 months). Only one patient firstly had diagnosed as CVID, cytopenia has developed after years. All of the patients were treated with corticosteroids or intravenous immune globulin (IVIG) as first-line treatment. Ten patients needed second or further-line immunosuppressive therapies including rituximab, methylprednisolone, and chloroquine. A total of 8 patients (34.7%) recovered from autoimmune cytopenias after the treatment of primer disease. That diseases were diagnosed as systemic lupus erythematosus in 4 patients, hypogammaglobulinemia in 3 patients, and celiac disease in 1 patient. Cytopenias have counted in 14 of the patients. One patient had homozygous CVID died.

Summary/Conclusions: Cytopenia may be the first finding of an immunodeficiency or autoimmune disease and primary disease may be diagnosed in the clinical course. Early diagnosis is important because of beginning to the early treatment of underlying disease.
**Results:**

Shortly before and from 24 patients following HLH-diagnosis; in 13 patients a rapid phenotypic screening was intended to investigate potential utility of a rapid phenotypic screening in diagnostics of suspected HLH.

**Methods:** Flow cytometric files for 42 patients with hM were retrieved from archive of the Department of Clinical Pathology and Cytology, Karolinska University Hospital. The patients were diagnosed and treated for hM-HLH at the Hematology Center of the same hospital, between 2009 and 2016. Tissue samples (bone marrow, peripheral blood, lymph nodes) were analyzed according to standard procedures, using monoclonal antibodies (BD, DAKO, Beckman Coulter, BioLegend). Cells were acquired using 4-color Canto A or 8-color Canto II cytometers (BD), and analyzed with BD FACSDIVA software. Neoplastic clones of myeloid or lymphoid character were excluded from reanalysis for the purpose of this study. Bone marrow samples were obtained from 31 patients shortly before and from 24 patients following HLH-diagnosis; in 13 patients paired BM samples were available.

**Results:** Patient characteristics are presented in table 1. Bone marrow B-cell lymphophasia was observed in 57% patients before and 74% after HLH diagnosis. Decreased amounts of NK-cells were noted in 48% patients at both time points. T-cell lymphopenia before HLH diagnosis was noted in 60% patients with myeloid malignancy but in only 25% cases of lymphoid malignancy, whereas in established HLH the respective figures were 27% and 46%. CD4/CD8 ratio was skewed-to-normal in both myeloid and lymphatic tumors before HLH was diagnosed. In cases of continued hyperinflammation, patients with myeloid tumors showed dominance of CD4+ cells but no such difference was noted in lymphoid disease. Loss of lineage specific markers of non-neoplastic T-cells was a constant feature in lymphoid malignancy, whereas aberrant expression of lymphatic markers (CD2, CD7, CD56) on myeloid cells was uniform in patients with myeloid tumors. Monocytosis was more often observed in myeloid as compared to lymphoid tumors at HLH onset (40% vs 31%), although it was of non-neoplastic character. However, monocytopenia was also noted in cases of established HLH, in 10% of myeloid malignancies and 15% of lymphatic malignancy cases.

**Table 1.**

<table>
<thead>
<tr>
<th>Platelets disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E1430</strong></td>
</tr>
</tbody>
</table>

**BLEEDING IN PRIMARY IMMUNE THROMBOCYTOPENIA: WHO ARE MOST AT RISK?**

U. Doobareet, S. Hodges, R. Nandigam, A. Newland, D. Provan

**Background:** Primary Immune Thrombocytopenia is a rare disorder in which patients are at risk of bleeding due to autoimmune-mediated platelet destruction. This study focused on describing the prevalence and types of bleeding events around the time of ITP diagnosis and after, as well as identify any factors that can potentially influence the risk of bleeding.

**Methods:** Data from the United Kingdom Immune Thrombocytopenia Registry were analysed for this study. The registry obtained its data from about 70 centres around the UK. Descriptive and logistic regression statistical techniques were used for this study.

**Results:** This analysis was based on 2365 (57.8% females) participants who are part of the Registry. The median age at diagnosis was 50 years (IQR 32, 66) and 77% of these patients were of European ethnicity. The commonest comorbid conditions was hypertension (23%). Median platelet count was 19 (IQR: 5, 53). Eighty percent had a platelet count below 30x10^9/L around ITP diagnosis. The most common bleeding events were skin-related (46.5%) and to the oral cavity (14.4%). About 70% of the cohort experienced at least one bleeding event at some point after diagnosis. After ITP diagnosis the most common bleeds were again skin-related (34.3%) and oral cavity bleeding (14.8%). Epistaxis had risen from 11.6% before diagnosis to 17.7%. Bleeding at other sites did drop. However, the prevalence of intracranial haemorrhage rose from 0.9% pre-diagnosis to 1.2% after diagnosis. Prednisolone (79%) and ivIg (43%) were the most used drugs followed by rituximab (26%) among those who were treated. Romiplostim (15%) and Eltrombopag (9%) are used too but not any more than mycophenolate (18%) and azathioprine (22%). Fourteen percent of the cohort had a splenectomy at some point. Age but not gender or ethnicity were found to be associated with having a bleeding event around the diagnosis of ITP. Patients older than 60 years old are less likely to experience a bleed than older adults (>70 years), who were most at risk. Platelet counts, expectedly, was associated with bleeding with those presenting with a platelet of <30x10^9/L were at higher risk. No comorbid illness or cotherapies were found to be associated with bleeding events.

**Summary/Conclusions:** The frequency of bleeding decreased for most sites but for some others a slight increase has been observed since ITP diagnosis. It is possible that bleeding events may have been recorded more accurately or observed more closely and over a longer period of time since diagnosis. However, control of bleeding was an issue after the diagnosis of ITP. Future analysis selfinforming its findings by time periods would be beneficial in describing if bleeding events were better controlled over the last few years, especially after the introduction of new therapeutic agents and the publication of the internal consensus report on the diagnosis and management of primary ITP.

**E1431**

**A MULTICENTRE, SINGLE ARM, OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ELTROMBOPEG IN PATIENTS WITH SEVERE PERSISTENT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) WITHIN SIX MONTHS OF DIAGNOSIS**

H. Tran, R. Bird, S. Chunilall, T. Brighton, J. Reynolds, S. He, C. Mazis, R. Hall, P. Shuttleworth, A. Grigg

1Clinical Haematology, The Alfred Hospital, 2Clinical Haematology, Monash University, Melbourne, 3Clinical Haematology, Princess Alexandra Hospital, Brisbane, 4Clinical Haematology, Monash Health, Melbourne, 5Clinical Haematology, Prince of Wales Hospital, Sydney, 6Clinical Epidemiology and Preventative Medicine, Monash University, 7Clinical Haematology, Austin Hospital, Melbourne, Australia

**Background:** Patients with acute ITP who fail or are dependent on steroids or intravenous immunoglobulin (ivIg) are often committed to splenectomy or protoclastic immunosuppression. Splenectomy is potentially curative but not without operative risk with many patients reluctant to undergo surgery, while the response to immunomodulation is often suboptimal with significant side effects. Although effective, to date, there is no published studies evaluating the benefit of eltrombopag among steroid dependent or resistant, non-splenectomised ITP patients diagnosed within 6 months.

**Aims:** To evaluate the efficacy and safety of eltrombopag in patients with severe “acute” and persistent ITP within 6 months of diagnosis.

**Methods:** A multicentre, single arm open label study involving 39 patients with recent diagnosis (<6 months of ITP onset) with platelets <30x10^9/L despite a daily dose of prednisolone of 1mg/kg for at least 2 weeks from diagnosis OR (b) requiring prednisolone ≥10mg daily and/or recurrent doses of ivIg to maintain a platelet of ≥30x10^9/L within 6 months of diagnosis. Prior splenectomy was not a requisite.

**Summary/Conclusions:** In the presented cohort, quantitative shifts could be observed in BM samples around the time of HLH onset. However, different patterns were observed between patients affected by lymphoid or myeloid malignancies, which may indicate disease-specific impact on BM microenvironment. Further study will be carried out to confirm findings in a large, possibly prospectively collected patient group. Control group of patients with respective malignancies but without HLH will be included.
Patients with platelets <10x10^9/L will commence on eltrombopag 75mg daily with a dose that is increased by 25mg every 2 weeks to maximum of 150mg daily (patients of East Asian heritage should have a maximum eltrombopag dose of 100mg daily) if the platelet count remains ≤30x10^9/L or there is clinically significant bleeding every 2 weeks. The dose can be progressively weaned to zero over the subsequent 6 weeks if clinically appropriate. The primary endpoint was overall response rate (ORR) at week 12, defined as the proportion of patients achieving complete response (CR; platelet >100x10^9/L), partial response (PR; platelet >50x10^9/L) or minor response (MR; platelet ≥20x10^9/L with ≥25% reduction in the dose intensity of concomitant ITP therapy compared with screening). The protocol specified a 1-sided 5% level binomial test of the null hypothesis that ORR at week 12 ≤30% and reporting of a 90% two-sided confidence interval (CI).

**Results:** Of the 39 patients enrolled, 46% were women, median (Q1, Q3) age was 52 (38, 65) years, median (Q1, Q3) duration of ITP diagnosis was 12.2 (4.2, 24.5) months, and median (Q1, Q3) screening platelet count was 21(13, 34) x10^9/L. Prior treatments included steroids (95%), IVIG (58%), and immunosuppression (28%). 35 patients (90%) completed 12 weeks of treatment, 4 (10%) discontinued eltrombopag prior to week 12 [3 required new ITP therapy; 1 died due to pancytopenia]. The median (Q1, Q3) dose of eltrombopag at week 12 was 50 (50, 100)mg daily. The median (Q1, Q3) dose of steroid at week 12, zero (0, 5)mg daily. At week 12, the ORR was 64% (<0.0001; 90% CI: 51-77%); CR, MR, PR rates were 41%, 15% and 8% respectively and the median (Q1, Q3) platelet count among responders was 168 (98, 252)x10^9/L. At week 12, the ORR was 64% (95% CI: 50-77%); CR, PR, MR, CR rates were 41%, 15% and 8% respectively and the median (Q1, Q3) platelet count among responders was 168 (98, 252)x10^9/L.

There were no other adverse events or deaths.

**Summary/Conclusions:** The majority of patients with ITP diagnosed for ≤6 months had a favourable overall response rate to eltrombopag and the drug was generally well tolerated. Longer-term follow up data (beyond 6 mos) will be presented at the meeting.

**E1432**

**A NOVEL RUNX1 MUTATION IN FAMILY WITH FAMILIAL PLATELET DISORDER WITH PREDISPOSITION TO ACUTE MYELOGENOUS LEUKAEMIA**

L. Krupkova1, M. Divoka2, B. Ludikova2, J. Kucerova1, M. Holzerova1, A. Hlusi1, T. Szotkowski1, T. Papajik1, D. Kucera2, D. Pospisilova2

1Department of Hemato-oncology, 2Department of Pediatrics, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

**Background:** Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML) is a clinically heterogeneous group of rare disorders with autosomal dominant inheritance. Germline mutations in RUNX1 plays a role in the pathogenesis of ITP. RUNX1 mutation in FPD/AML is associated with 30-50% lifetime risk of developing myeloid malignancy. In the patient with pancytopenia, possible causes of leukemogenesis can be presented at the meeting.

**Methods:** Platelet aggregation was measured on 4-channel aggregometer APACT 4004, with platelet rich plasma (PRP) in response to adenosine diphosphate (ADP), collagen, epinephrine and adrenalin in the presence of nilotinib, eltrombopag and aspirin. Germline mutations in RUNX1 were identified as causative lesions in several families with FPD/AML. RUNX1 plays a key role in megakaryocyte maturation and differentiation also and plazidation and platelet formation. In FPD/AML, RUNX1 mutations are very heterogeneous and often specific to individual pedigrees, most commonly involving exons 3-5 in the RHD domain near the N-terminus of RUNX1. The presence of RUNX1 mutation in FPD/AML is associated with 30-50% lifetime risk of developing AML. Clonal hematopoiesis can be detected in >80% of asymptomatic FPD/AML. Clonal hematopoiesis can be detected in >80% of asymptomatic FPD/AML. Future studies of these miRNAs in relation to initiation of treatment with defined clinical outcomes as treatment response/ remission after initiation of treatment will clarify their potential as biomarkers for treatment response.

**Support:** IGA-LF-2017-007, NPU LO 1304
NORDIC COUNTRY PATIENT REGISTRY FOR IMMUNE THROMBOCYTOPENIA (NCPRITP): A COHORT OF PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN DENMARK, SWEDEN, AND NORWAY

C. Christiansen1, S. Bahmanyar2, W. Ghanima3, N. Kristensen1, S. Stryker1, J. Acuavella1, K. Ketin5, M. Nargaard1, H. Sørensen1

1Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Clinical Epidemiology Unit & Center for Pharmacoepidemiology, Department of Medicine, Carambula, Stockholm, Sweden, 3Department of Medicine, St. Olof Hospital Trust, Fredrikstad, Norway, 4Center for Observational Research, Agena Inc, San Francisco, 5Center for Observational Research, Agena Inc, Thousand Oaks, United States

Background: Immune thrombocytopenia (ITP) is a rare disease characterized by isolated platelet counts and an increased tendency to bleed. As yet, there have been no large, multi-country, population-based cohorts established to describe its long-term clinical course and investigate the effectiveness and safety of related therapies.

Aims: To describe the establishment of the NCPRITP and the characteristics of patients enrolled.

Methods: Encompassing Denmark, Norway, and Sweden, the NCPRITP started as a population-based post-authorisation safety study to assess the long-term safety of romiplostim in treating ITP. It includes patients with prevalent chronic idiopathic thrombocytopenia (cITP – ITP lasting >6 months) as of 04/01/2009 and incident cITP diagnosed from 04/01/2009-12/31/2014, confirmed through medical record review. Since the start of the registry, guidelines have changed to define cITP as ITP lasting >12 months. For consistency, incident cases of ITP for a duration of >6 months will continue to be accrued through 2019. Through linkage of data from the national health registries and medical record review, the registry has rich clinical information for all enrolled ITP patients, as well as comorbidities (including scores according to the Charlson Comorbidity Index [CCI] – a validated tool developed to predict 1-year mortality), treatments, lab values (e.g., platelet counts), and complete follow-up for several clinical outcomes of interest (e.g., clinically significant bleeding, the need for rescue therapies, and thromboembolic/thrombotic events). Alternatively, available bone marrow samples are restained and reexamined for reticulin and collagen content to assess Thiele’s myelofibrosis (MF) grading.

Results: The NCPRITP includes 3,749 patients with confirmed cITP (35% Danish, 51% Swedish, and 14% Norwegian), with a female preponderance (58%) and median age of 56 years at cITP diagnosis. Forty-one percent of the cohort was prevalent at study inclusion; 59% represent incident cITP patients. Median follow-up time thus far is 4.3 years. At study enrollment, 24% had a platelet count <50×10⁹/L, 16% were splenectomized, and 41% had at least one previous ITP therapy (mainly oral glucocorticoid steroids). The majority (68%) of the cohort had no underlying conditions included in the CCI at study enrollment, but 8% had a CCI score of 3 or higher, indicating severe comorbidity. Of note, based on hospital diagnoses of specific comorbidities recorded within 5 years before study enrollment, 9% had diabetes, and 18% had a history of hypertension. Currently, 718 bone marrow samples from 566 patients have been retrieved.

Summary/Conclusions: The NCPRITP provides an example of how, within the Nordic countries’ uniform health care systems, registries can be established to study the clinical course of rare diseases such as ITP and the safety of drugs used to treat these patients.

EPIDEMIOLOGY OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS IN RUSSIAN FEDERATION (RESULTS OF REGISTRY OF NATIONAL HEMATOLOGIC ASSOCIATION)

A. Melikyan1, E. Pustovaya1, M. Kalina1, E. Volodicheva2, T. Kaporskaya3, R. Ilia4, T. Babaeva5, O. Bekker6, V. Bogova7, E. Zdolna8, I. Zlotova9, I. Kontovleva10, O. Pyykalova11, I. Sokolova12, N. Fedorova13, I. Shchetnovaya14, T. Kolosheinova15, E. Egorova1, S. Kulikova2

1St. Petersburg Clinical Hospital Trust, Saint Petersburg, Russia, 2Consultative, Moscow Regional Clinical Research Institute of Hematology, 3Department of Medicine, Kirov Research Institute of Hematology and Blood Transfusion, 4Hematology, Regional Clinical Hospital, Tula, 5Hematology, Regional Clinical Hospital, Kirov, 6Hematology, Russian Research Institute of Hematology and Transfusionology, Saint Petersburg, 7Consultative, Moscow Regional Clinical Research Institute of Hematology, 8Hematology, City hospital No1, Omsk, 9Hematology, Republican Oncology Hospital, Syktyvkar, 10Hematology, Regional Clinical Hospital, Amurk, 11Hematology, Regional Clinical Hospital, Khabarovsk, 12Biostatistics and information systems, National Research Center for Hematology, Moscow, Russian Federation

Background: Primary immune thrombocytopenia (ITP) is a rare disease. The incidence of ITP is not well estimated in Russia and worldwide. Due to WHO information it varies from 1.6 to 3.9/100 000 person-years in adults. The gender and age-associated results in Russia and abroad are discussed and differ in several investigations.

Aims: to describe its long-term clinical course and investigate the effectiveness and safety of related therapies.

Methods: The NCPRITP includes 3,749 patients with confirmed cITP (35% Danish, 51% Swedish, and 14% Norwegian), with a female preponderance (58%) and median age of 56 years at cITP diagnosis. Forty-one percent of the cohort was prevalent at study inclusion; 59% represent incident cITP patients. Median follow-up time thus far is 4.3 years. At study enrollment, 24% had a platelet count <50×10⁹/L, 16% were splenectomized, and 41% had at least one previous ITP therapy (mainly oral glucocorticoid steroids). The majority (68%) of the cohort had no underlying conditions included in the CCI at study enrollment, but 8% had a CCI score of 3 or higher, indicating severe comorbidity. Of note, based on hospital diagnoses of specific comorbidities recorded within 5 years before study enrollment, 9% had diabetes, and 18% had a history of hypertension. Currently, 718 bone marrow samples from 566 patients have been retrieved.

Summary/Conclusions: The NCPRITP provides an example of how, within the Nordic countries’ uniform health care systems, registries can be established to study the clinical course of rare diseases such as ITP and the safety of drugs used to treat these patients.
while not receiving rescue treatment, was 78 (range, 0–350) weeks. Incidence of bleeding symptoms (WHO grades 1–4) decreased from BL (66%) to 1 y (15%). AEs were reported in 47 (94%) pts, most frequently nasopharyngitis (n=13, 26%), constipation (n=12, 24%), fatigue (n=12, 24%), diarrhea, arthralgia, urinary tract infection, cataract and cough (all n=11, 22%). Serious AEs occurred in 24 (48%) pts, most frequently (>5%) cataracts (n=7, 14%), pneumonia (n=5, 10%), and urinary tract infection (n=3, 6%). The most frequent AEs with suspected relationship to study drug were cataracts (n=4, 8%), headache, fatigue, and increased ALT, AST and bilirubin (all n=3, 6%).

**E1439**

**CHILDHOOD IMMUNE THROMBOCYTOPENIA: A NATIONWIDE COHORT STUDY ON CONDITION MANAGEMENT AND OUTCOMES**

N. Aladjidi1,*, C. Nordon2,*, G. Leverger 1, T. Leblanc 3, L. Grimaldi-Bensouda2

1Haematology Unit, 2Molecular Genetic Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

**Background:** Little is known about the management of pediatric ITP in real life, that is, routine clinical practice. Moreover, the predictive value of these factors upon disease outcome was explored individually and therefore the confounding effect of associated exposures remains unknown.

**Aims:** With this nationwide prospective cohort study, our objectives were to explore (1) the factors associated with treatment initiation (vs. watchful waiting) in children with primary immune thrombocytopenia (ITP) followed in routine clinical practice and (2) the predictors of chronicity at 12 months.

**Methods:** Between 2008 and 2013, 23 centers throughout France consecutively included 257 children aged 6 months to 18 years and diagnosed with primary ITP over a 5-year period. Data on ITP clinical features along with medical management were collected at baseline and 12 months. Multivariate logistic regressions were used to determine (1) and (2) as defined above, providing odds ratio (OR) with 95% confidence intervals (95%CI).

**Results:** 137 (53%) children were males, median age was 4.6 years, median platelet count was 7×109/L, and 214 (81%) patients initiated medication. Factors independently associated with treatment initiation included platelet counts <10×109/L (p=0.0001) and mucocutaneous bleeding symptoms at baseline (p=0.001). At 12 months, data were available in 211 (82%) children, of whom 168 (77%) had recovered. Predictors of chronicity included female gender (OR=2.2; 95% CI=1.0–4.8), age ≥10 years (OR=2.6; 95% CI=1.1–6.0) and platelet counts ≥10×109/L (OR=3.2; 95% CI=1.5–6.9).

**Summary/Conclusions:** In routine clinical practice, the decision to apply a watchful-waiting strategy seems to be driven by platelet counts even in the absence of bleeding symptoms, resulting in treatment being initiated in more than 80% of the children surveyed. Overall, younger children with ITP showed good prognosis, with lower platelet counts and, to a lesser extent, male gender predicting more favorable outcomes.

**E1440**

**SIROLIMUS FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME: A SINGLE CENTRE EXPERIENCE**

M. Miano1,*, A. Rotulo1, E. Palmisani1, A. Grossi2, F. Pierri1, M. Calvillo1, C. Micalizzi1, P. Terranova1, E. Cappelli1, T. Lanza1, M.T. Giamo1, I. Ceccherini1, C. Dufour1, F. Fioredda1

1Haematology Unit, 2Molecular Genetic Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

**Background:** The treatment of chronic relapsing immune thrombocytopenia purpura (ITP) is not well established due to the lack of evidence-based data, and is particularly challenging in children who are more at risk of severe side effects secondary to prolonged steroid therapies. Sirolimus has been shown to be effective in patients with ITP secondary to ALPS1 and in very few patients with primary disease or secondary to ALPS-like syndromes2.

**Aims:** The aim of this study is to evaluate the outcome and toxicity of patients with ITP either primary or secondary to ALPS-like syndromes, with or without involvement of other cell lineages.

**Methods:** We retrospectively evaluated charts of patients followed in our Unit for ITP primary or secondary to ALPS-like syndromes. Patients with ALPS were excluded. ALPS-like was defined as the presence of at least one absolute or primary additional criterion for ALPS. Complete response (CR) and partial response (PR) were defined as a platelet count ≥100×109/L and ≥30×109/L and at least 2 fold increase of the baseline count, respectively.

**Results:** 23 children aged 0-12 yrs (median 6) with primary ITP (7) or secondary to an ALPS-like disorder (16), were treated with Sirolimus. Seven patients (30%) with ALPS-like also had an Evans syndrome (ES), due to the association of leukopenia (1), or to the presence of tilinear cytopения (4). Four patients with ALPS-like were found to have mutations on PI3KCD, CTLA4, TACI, and CARD11 gene. All patients, but one treated in first-line, received Sirolimus as second (4), third (14) or fourth (4) line treatment, respectively. 18 patients had previously failed Miconofenolatometofine (MMF) therapy. Overall, 17/23 (74%) patients achieved a response that was complete and partial in 12 (52%) and 5 (22%) respectively. 2 cases. Children with monoclinar-IPT achieved a response in 11/16 (68%) cases, in particular 4/7 (57%) and 7/9 (77%) patients with primitive or secondary disease, respectively. 12 out of 18 (66%) patients who failed MMF therapy responded to Sirolimus rescue. Three patients (13%) reported toxicity consisting of ovari cysts (2) and gastrointestinal issues (1) that required the interruption of the treatment in 2 cases.

**Summary/Conclusions:** To the best of our knowledge this is the largest cohort of patients with ITP or ES other than ALPS-treated with Sirolimus, that showed to be safe and effective in most cases, including patients who previously failed
MMF treatment. Therefore, it can be considered as an alternative therapeutic option in the setting of ITP non only for patients with an underlying diagnosis of ALPS but also for the ones with primitive disease or with an ALPS-like disorder.

References


E1441

ASSESSMENT OF ROMIPLOSTIM SELF-ADMINISTRATION BY PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA AND CAREGIVERS FOLLOWING RECEIPT OF HOME ADMINISTRATION TRAINING (HAT) MATERIALS: A PROSPECTIVE STUDY

M. Schipperus1,*, G. Kaira2, L. Taylor3, S. Wetten4, J. Bennett5, G. Kreuzbauer5, A. Boshier6, A. Seesaghur4

1Department of Haematology, Haga Teaching Hospital, The Hague, Netherlands, 2AHEPA University Hospital, Thessaloniki, Greece, 3Royal London Hospital, London, 4Amgen Limited, London (Uxbridge), United Kingdom, 5Amgen (Europe), Zug, Switzerland, 6Amgen Limited, Cambridge, United Kingdom

Background: A HAT pack was designed as an additional risk minimization tool to support healthcare providers (HCPs) in selecting patients and training of patients/caregivers to mitigate medication error risk when self-administering romiplostim subcutaneously, a thrombopoietin-receptor agonist against which is approved in the European Union (EU) to treat chronic immune thrombocytopenic purpura (ITP) refractory to other treatments.

Aims: To estimate the proportion of adult patients and caregivers who administered romiplostim correctly after HAT pack training.

Methods: This non-interventional, cross-sectional study enrolled 40 patients/caregivers and was conducted at 12 centres in Austria, Belgium, France, Germany, Greece, The Netherlands, Spain, and The United Kingdom, from 7 July 2014 to 20 November 2015. HCPs directly observed adults >18 years of age with chronic ITP or caregivers new to administering romiplostim in the act of product administration at the first standard-of-care (SoC) 4-week visit after HAT pack training. Correct administration of romiplostim (primary endpoint) was defined as dose accuracy within 10% margin of error between prescribed and administered romiplostim doses, and correct romiplostim reconstitution and successful injection, and no HCP intervention during administration to correct patient/caregiver error. All analyses were descriptive and no formal hypothesis was tested.

Results: Of the first SoC visit, 4 weeks (range: 2-8 weeks) after HAT pack training, 35 patients/caregivers (87.5%) administered romiplostim correctly. The dose accuracy was within 10% margin of error for all patients. HCP intervention was required in 5 instances: 1 patient did not ensure all romiplostim was dissolved, 1 patient and 1 caregiver needed verbal encouragement, 1 patient needed nursing intervention to read the correct dose from the vial due to poor eyesight, and 1 caregiver needed guidance with syringe and vial connection. Further follow-up data was available for only 2 of these 5 patients/caregivers; they both administered romiplostim correctly at a voluntary subsequent visit.

Summary/Conclusions: Given that this study was conducted on a convenience instead of random sample of patients, generalizability of the results may be limited. Direct observation can be susceptible to observation bias and to the Hawthorne effect with the patients/caregivers acting differently when observed. Nonetheless, the success of most patients and caregivers in correctly administering romiplostim after HAT pack training suggests that self-administration of romiplostim is a feasible option for suitable romiplostim-treated ITP patients.

E1442

FCTIA 131 H/R (A>G) RECEPTOR GENE POLYMORPHISM IN PATIENTS OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

A. Tripathi1,*, D. Yadav1, A. Kumar2

1Clinical Hematology, 2K.G. Medical University Lucknow India, Lucknow, India

Background: Primary Immune Thrombocytopenia (ITP) is an autoimmune hematologic disorder characterized by isolated thrombocytopenia (<100,000/cmm) in the absence of other causes or disorders that may be associated with thrombocytopenia. The predominant mechanism is enhanced peripheral destruction of autoantibody coated platelets through binding of Fc portion of antibody with the Fcy receptors on cells of reticuloendothelial system mainly monocytes/macrophages.

Aims: This study was aimed to investigate the association of polymorphisms in FCTIA 131 H/R (A>G) gene with Primary Immune thrombocytopenia (ITP).

Methods: Genotyping for the FCTIA 131 H/R (A>G) was performed using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) in 70 ITP patients and 70 healthy controls.

Results: The mean age of patients and control was 29.5±13.86 yrs and 27.9±8.89 yrs respectively. Male/Female ratio in patients and control was 1:2. Under additive model, the heterozygous genotype (AG) of the FCTIA 131 H/R (A>G) polymorphism shows the significant association with ITP, (Odds Ratio 2.41 (95% CI, Lower - 1.19 Upper 4.90 P- value 0.0149)) whereas the homozygous mutant genotype (GG) had no significant association with ITP (Odds Ratio 2.47 (95% CI, Lower - 0.63 Upper 9.72 with P- value 0.2979)). Under dominant model, the Odds Ratio was 2.42 (95% CI, Lower - 0.34 Upper 0.94) with the significant P- value 0.0167. Mutant allele (G) frequency was 37.85% in patients and 25.71% in controls (Odds ratio 1.76 1.05-2.93 with the p-value 0.0297).

Summary/Conclusions: The study shows the association of heterozygous genotype (AG) of FCTIA 131 H/R (A>G) with ITP. The dominant model also shows significant association with ITP. We conclude that mutant allele (G) in FCTIA 131 H/R (A>G) gene polymorphism may have impact on susceptibility to ITP.

E1443

SHORT- AND LONG-TERM RESULTS OF FIRST LINE THERAPY WITH PULSED HIGH-DOSE DEXAMETHASONE IN ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE SINGLE-CENTER REPORT

L. Crucitti1,*, S. Canton1, R. Cairini1

1Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda, Milano, Italy

Background: Immune thrombocytopenia (ITP) is an autoimmune disorder mediated by clearance of antibody-opsonized platelets (pt) by spleen macrophages. Pulsed high-dose dexamethasone (HD-DXM) has proved to be effective in adult patients (pts) with primary ITP resulting in controlled studies in 89% short-term response and a relapse-free survival (RFS) of 58% at 50 months (mos) (Mazzucconi, Blood 2007).

Aims: To assess the short-term and sustained response rates of adult ITP pts receiving pulsed HD-DXM in everyday clinical practice.

Methods: Charts of pts with ITP - as defined by Rodeghiero, Blood 2009 - treated with HD-DXM were reviewed. DXM was administered according to the schedule of 40mg/day for 4 consecutive days to be repeated every 21 days for a maximum of 6 courses. A reduced-dose schedule of 20mg/day for 4 days was preferred for elderly/diabetic pts. Pts who had completed at least 3 courses were included in the analysis. Response to HD-DXM was classified according to IWP definitions (Provan, Blood 2010); therefore, steroid-dependent pts were considered as non-responders even if pt counts increased to safe levels during HD-DXM and were included only in the analysis of short-term response, but not evaluated for long-term response. Short-term response rate was determined at completion of the whole course of treatment. Relapse was defined as a pt count decrease ≤20x10^9/L after initial response achievement and RFS was defined as the time interval between last course administered and the date of relapse, censoring pts alive or dead without relapse. Follow-up was defined as the time between diagnosis and last available assessment. The probability of RFS was calculated using the Kaplan-Meier method.

Results: A total of 45 pts (M: 21) were eligible for analysis; median age at treatment was 60 yrs (range 18-87) and median time between diagnosis and treatment start was 3 days (range 0-4686). Pts received a median of 5,15 courses (range 3-6); 27/45 completed 6 courses: 21/45 received the full dose of 40mg/day (=960mg total dose) while 6/45 received the reduced dose of 20mg/day (=480mg total dose). Median total DXM dose was 800mg/IWG along with 1st DXM course were required in 11/45 pts. In between courses, no bleeding complications were observed and no emergency therapies were required. Short-term response was achieved in 39/45 (87%); complete response (CR) in 28/45 (62%), response (R) in 7/45 (16%); 4/45 (9%) pts were classified as steroid-dependent ITP and excluded from subsequent analysis. Long-term response off therapy, lasting for a median time of 28 mos (range 5-80) without relapses was observed in 25/35 responding pts (71.5%; CR in 18/25, R in 7/25 at last follow-up) with a RFS of 51% at 50 mos (Fig. 1). Median pt count at last

Figure 1.
follow-up was 102x10^9/L (range 54-336). Disease duration of less than 3 mos prior to therapy start was associated with better outcome (log rank p=0.049, Fig.2) with a median RFS not reached; median RFS for pts treated after 3 mos of diagnosis was 31 mos [OR: 3.8 (CI 95% 0.9-16.3), p=0.067].

**Methods:** We performed a retrospective single-center study. From November 2009 until March 2015, a total of 168 patients from our Hematology Unit were prescribed oseltamivir due to clinical suspicion of influenza. A total of 120 patients were excluded because they had received myelotoxic chemotherapy within 30 days of diagnosis or died prior to therapy start. We observed a significant increase in platelet counts (2).

**Results:** Patients were divided into those with proven influenza (n=34) and without influenza (n=14). Median age was 58.0 and 59.5 years, respectively. Treatment consisted of 75mg oseltamivir bid for 5 days, with the exception of 3 patients in the proven influenza group receiving 150mg bid for 10 days (allo-genic stem cell transplant recipients). We observed a significant increase in the mean platelet count after treatment with oseltamivir (1702±95 x10^9/L vs 190±103 x10^9/L, p=0.04). As in the previous study (2), this effect was independent of whether influenza was diagnosed (Table 1). In addition, we did not discern significant fluctuation in platelet counts when treatment was immediately interrupted after a 30-day time lapse (184±100 x10^9/L vs 182±91 x10^9/L).

Table 1.

<table>
<thead>
<tr>
<th>Platelet counts (x10^9/L)</th>
<th>with a clinical suspicion of influenza</th>
<th>without a clinical suspicion of influenza</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>182±91</td>
<td>184±100</td>
<td>0.39</td>
<td></td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** Our study confirms the effect of oseltamivir on increasing platelet counts regardless of influenza infection. Although an increase in platelet counts related to the viral syndrome healing is not ruled out, the lack of long-term fluctuations after the end of treatment may indicate a late inhibition that contributes to reduction in platelet clearance via the hepatic receptor.

**References**

**E1445**

**CLINICAL UTILITY OF CARDIAC MRI IN IMMUNE MEDIATED THROMBOCYTOPENIC PURPURA**

F. Alwan1,*, D. Mahdi1, S. Mc Gucken1, J. P. Westwood1, M. Thomas1, J. Moon2, 1Haematology Department, University College London Hospital, 2Cardiac Imaging Department, Barts Heart Centre, London, United Kingdom

**Background:** Immune Mediated Thrombotic Thrombocytopenic Purpura (TTP) is a life threatening thrombomicroangiopathy caused by acquired antibody mediated inhibition of ADAMTS13. Cardiac complications are a common cause of death in patients diagnosed with TTP. This study evaluated if there was a specific cardiac MRI finding which could aid in the diagnosis of TTP.

**Aims:** To evaluate if TTP patients have a specific cardiac abnormality on MRI.

**Methods:** A retrospective review evaluating the value of cardiac MRI in TTP. Between November 2008 and November 2014 whilst being treated for an acute episode of immune mediated TTP. All patients had troponin-t measurement on admission and a transthoracic echocardiogram within 72 hours of presentation. All patients were treated for their TTP episode with plasmapheresis, steroids and Rituximab. Two cardiologists reported each MRI scan and only agreed, unequivocal findings were considered.

**Results:** The median age of patients was 49 (range 13-75), 71% of whom were women. Two patients had a diagnosis of hypercholesterolemia prior to TTP diagnosis but otherwise there was no previous cardiac history. 71% of patients had a raised troponin-t at presentation (normal <14ng/ml). Two patients developed bradycardia and one atrial fibrillation during their acute admission.

**Background:** Immune thrombocytopoenia (ITP) is an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet counts. MEFV gene mutations are responsible for Familial Mediterranean Fever (FMF) a hereditary autoinflammatory disease characterized by recurrent febrile inflammatory attacks of serosal and synovial membranes. MEFV gene’s protein product, pyrin or marenostrin, play an essential role in the regulation of inflammatory reactions. MEFV gene mutations are associated with recurrent febrile attacks of serosal and synovial membranes.

**Methods:** A retrospective review evaluating the value of cardiac MRI in TTP. Between November 2008 and November 2014 whilst being treated for an acute episode of immune mediated TTP. All patients had troponin-t measurement on admission and a transthoracic echocardiogram within 72 hours of presentation. All patients were treated for their TTP episode with plasmapheresis, steroids and Rituximab. Two cardiologists reported each MRI scan and only agreed, unequivocal findings were considered.

**Results:** The median age of patients was 49 (range 13-75), 71% of whom were women. Two patients had a diagnosis of hypercholesterolemia prior to TTP diagnosis but otherwise there was no previous cardiac history. 71% of patients had a raised troponin-t at presentation (normal <14ng/ml). Two patients developed bradycardia and one atrial fibrillation during their acute admission.

**References**

**E1446**

**THE FREQUENCY AND CLINICAL SIGNIFICANCE OF MEVF GENE MUTATIONS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**

I. Kaygusuz Atagunduz1,*, C. Keklikkiran2, T. Toptas1, O. Kara1, A. Sezgin1, F. Gecgel1, T. Ozgumus1, T. Fratiol Tugular1

1Hematology, Internal Medicine, Marmara University Hospital, Istanbul, Turkey

**Background:** Immune thrombocytopoenia (ITP) is an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet counts. MEVF gene mutations are responsible for Familial Mediterranean Fever (FMF) a hereditary autoinflammatory disease characterized by recurrent febrile inflammatory attacks of serosal and synovial membranes. MEVF gene’s protein product, pyrin or marenostrin, play an essential role in the regulation of inflammatory reactions. MEVF gene mutations are associated with recurrent febrile attacks of serosal and synovial membranes. MEVF gene mutations are associated with recurrent febrile attacks of serosal and synovial membranes.

**Methods:** A retrospective review evaluating the value of cardiac MRI in TTP. Between November 2008 and November 2014 whilst being treated for an acute episode of immune mediated TTP. All patients had troponin-t measurement on admission and a transthoracic echocardiogram within 72 hours of presentation. All patients were treated for their TTP episode with plasmapheresis, steroids and Rituximab. Two cardiologists reported each MRI scan and only agreed, unequivocal findings were considered.

**Results:** The median age of patients was 49 (range 13-75), 71% of whom were women. Two patients had a diagnosis of hypercholesterolemia prior to TTP diagnosis but otherwise there was no previous cardiac history. 71% of patients had a raised troponin-t at presentation (normal <14ng/ml). Two patients developed bradycardia and one atrial fibrillation during their acute admission.

**References**
group and 56 (24-76) in the control group. Overall MEFV mutation prevalence was 25.9% (21/81) in the study group and 42.7% (46/186) in the control group, (p=0.963). MEFV mutation distribution prevalence was similar in both gender groups among ITP patients and their presence did not alter the age of disease onset, (p>0.05). Similarly, presence of mutations did not change the platelet count at diagnosis, the number of treatment courses, the rate of patients undergoing splenectomy and primary steroid resistance. Although statistically not significant, there was a trend towards a better overall response to steroids in patients carrying MEFV mutations, %94.7 vs%82.8,(p=0.28) respectively. The median time to loss of response to steroids was 60 (10-124) months in patients with mutations and 42 (19-24.6) months in patients without MEFV mutations, (p=0.001). The median time to splenectomy was 101 (42.5-159.5) months in the MEFV mutation carriers and 51 (46-56) months in the non-carriers, (p=0.48). Time to loss of response to splenectomy was 38 (12-90.9) months in mutation carriers and 54 (14.9-93.1) months in non-carriers, (p=0.42).

Summary/Conclusions: To the best of our knowledge, our study is the first to address the possible association between MEFV mutations and the severity of ITP. MEFV mutation carrier rates were similar in both ITP and control groups. Although MEFV carrier state had no effect on clinical features of ITP, mutation carriers tended to have a better overall response to steroid treatment, stayed longer in remission, had a longer time to splenectomy and relapsed earlier after splenectomy.

E1447
PD-1 AND CTLA-4 POLYMORPHISMS AFFECT THE SUSCEPTIBILITY AND CLINICAL FEATURES OF CHRONIC IMMUNE THROMBOCYTOPENIA
R. Ino1,*, T. Kasamatsu1, Y. Kitamura1, K. Honma1, T. Nagashima1, N. Takahashi2, M. Gotoh1, M. Takizawa3, A. Yokohama4, H. Handa3, T. Saitoh1, H. Murakami1
1Department of Hematology, Graduate School of Health Sciences, 2Gunma University, 3Department of Hematology, Blood Transfusion Service, Gunma University Hospital, Maebashi, Gunma, Japan

Background: The programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) play a critical role in immune checkpoint pathways. The PD-1 negatively regulates self-reactive T and B cells in peripheral immune tolerance. The CTLA-4 antagonizes the binding of CD28 to its ligands including CD80 and CD86, and inhibits T cell activation. Previous studies have shown the lower expression of serum soluble PD-1 and CTLA-4 mRNA in patients with chronic immune thrombocytopenia (cITP) than healthy individuals. Single nucleotide polymorphisms (SNPs) of PD-1 and CTLA-4 have been reported to be associated with susceptibility of some autoimmune diseases; however, the possible association between these immune checkpoint SNPs and cITP risk remain controversial and obscure.

Aims: In order to explore the role of PD-1 and CTLA-4 in the pathogenesis of cITP, we investigated the impact of PD-1 and CTLA-4 SNPs on the susceptibility and clinical features of adult cITP.

Methods: We extracted the genomic DNA from 141 cITP patients and 223 healthy controls, and determined 3 PD-1 SNPs (-606G/A, -7209C/T, A215V) and 4 CTLA-4 SNPs (-1722T/C, -1577G/A, +49A/G, +6230G/A) by using the polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) method. The severity of bleeding tendency and thrombocytopenia was assessed according to the previously described criteria by Han JJ. The response criteria, ‘‘corticosteroid dependence,’’ severe cITP, and ‘‘refractory cITP’’ were obtained according to the criteria of the International Working Group. The characteristics and laboratory data of cITP patients with CTLA-4 and PD-1 polymorphisms were compared by using the Mann-Whitney U test for continuous variables and the chi-square test for categorical variables. This study was approved by the Institutional Review Board of Gunma University Hospital (Approval #E160007).

Results: The minimum platelet count of all clinical course ranged from 0 to 98×109/L with a median count of 13×109/L. Eighty-six patients (61.0%) had bleeding tendency and 24 patients (17.0%) had severe thrombocytopenia (< 10×109/L). Eighty-six patients (61.0%) received the treatment with corticosteroid, and 10 patients (7.7%) were corticosteroid-dependent. Twenty-three patients (16.4%) were controlled to healthy controls, the higher frequency of PD-1 >7209 TT genotype (low producer) was observed in cITP patients (12.8% vs 4.5%, p=0.004). There were no significant differences in CTLA-4 SNPs between cITP patients and healthy controls. In cITP patients, PD-1 >7209 TT genotypes (low producer) was significantly associated with high frequency of treated patients, treated patients with corticosteroid, and corticosteroid-dependent patients compared with CC & CT genotype (high producer) (94.4% vs 71.5%, 94.4% vs 57.7% and 52.9% vs 23.8%; p=0.043, 0.003 and 0.188, respectively). On the other hand, CTLA-4 +49AA genotype (high producer) was significantly associated with low bleeding tendency and AG & GG genotype (low producer) (27.3% vs 63.8%, p=0.017). CTLA-4 -1577 AA genotypes (high producer) was significantly associated with low bleeding tendency and steroid treatment than AG & GG genotype (low producer) (20.0% vs 63.8%, p=0.017). CTLA-4 +49AA genotype and low producer group, and M. Mitrovic1,2,*, S. Matic3, J. Bodrozic1, M. Smiljanic1, J. Jelicic1, D. Antic1,2, M. Todorovic - Timanic2, D. Tomin1,2, I. Elezovic1,2, N. Suvajdic1,2
1Clinic of Hematology, CCS, 2Faculty of Medicine, University of Belgrade, 3Clinic for Digestive Surgery, Center for Nuclear Medicine CCS, Belgrade, Serbia

Background: Splenectomy may lead to a good response in 60-80% of adults with corticosteroid refractory immune thrombocytopenia (ITP). However, in the era of new drugs the proper selection of patients for splenectomy is essential to optimizing treatment outcomes. Accordingly, it is important to identify pre- or post-operative parameters that are able to predict the response to splenectomy.

Aims: To identify the pre- and postoperative parameters predictive of successful splenectomy in ITP.

Methods: We retrospectively analyzed 130 ITP patients (median age 43 years, range 19-74; 84/39 female/male; median time from diagnosis to splenectomy 19 months, range 2-132; median number of pre-splenectomy therapies 2, range 0-10; number of hospitalizations 2, range 0-4). MEFV mutation prevalence was 86% (112 patients); 13/130 (112.5%) patients had mutations in the MEFV gene. MEFV mutation distribution prevalence was similar in both gender groups (39.0% vs 35.3%, p=0.56). MEFV mutation distribution prevalence was similar across age (p=0.64). The median time to splenectomy was 101 (42.5-159.5) months in the non-carriers, (p=0.48).

Summary/Conclusions: In cITP patients, PD-1 +7209 TT genotypes (low producer) was significantly associated with higher minimum platelet count than AG & GG genotype (22.5 vs 14.0 ×109/L, p=0.048).

E1449
FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GERMANY
M. Reiser1,*, M. Welslau2, K. Josten3, H. Dietzfelbinger4, A. Kuhn5
1PIOh Koeln, Koeln, 2Gemeinschaftspraxis Dr. Klausmann, Dr. Welslau, Aschaffenburg, 3Hämatologie und Onkologie, Helios Kliniken Praxis, Wiesbaden, 4Haematologisch-onkologische Schwerpunktpraxis, Herrsching, 5Amgen GmbH, München, Germany

Background: In the European Union, the thrombopoietin-receptor agonist romiplostim (Nplate®) is recommended since January 2016 for treatment of ITP in patients who are refractory to other treatments (e.g. corticoids, immunoglobulins).

Aims: The aim of this study was to assess the use of romiplostim in clinical practice in Germany.

Methods: This multicentre, prospective and retrospective observational study (PLATEAU) involving 50 German sites and 363 (18.3%) of whom romiplostim (Nplate®) enrolled ITP patients ≥18 years who received at least one dose of romiplostim in routine clinical practice, with an observation period of 2 years following romiplostim initiation. Endpoints included patient demographics, romiplostim use, platelet counts, adverse
drug reactions (ADRs), and other clinically relevant parameters. We report results from a full data analysis.

**Results:** A total of 59 patients were enrolled (49.4% male; 54% aged 65 years or above) from 38 sites; 22 of them were excluded due to protocol violations (e.g., incomplete documentation, inclusion criteria not met). Of the 137 remaining patients (the full analysis set, FAS), 102 completed the 2-year observation period from the time of platelet counts to levels maintained between 50 and 250 x 10^9/L over time, regardless of the splenectomy status of the patients; most of them were non-splenectomized. The product was well tolerated and achieved a non-splenectomized. The product was well tolerated and achieved a median count remained in a range between 87.5 x 10^9/L and 145.5 x 10^9/L. Since the start of romiplostim therapy, 59 patients (35.8%). The overall number of ADRs was 112 in the FAS, affecting 57 patients (27.0%). The most frequent ADRs were gastrointestinal (10.2%) and neurological (11.7%) ADRs, followed by constitutional symptoms (10.9%). Adverse drug reactions pertaining to bone/blood marrow affected 2.9% of patients (vascular/thrombotic events, bone marrow fibrosis), whereas bleeding as an ADR was seen in 0.7% of patients. The exposure-adjusted rate of bleeding events (grade 3 or 4) per 100 patient-years in the FAS was 7.2 before treatment initiation vs. 4.0 after starting the treatment. The rate of ITP-related hospitalization per 100 patient-years decreased from 23.3 before the start of therapy to 15.5 since the start of the therapy.

**Summary/Conclusions:** This study of routine clinical practice in Germany showed that treatment with romiplostim in ITP patients resulted in a rapid increase of platelet counts to levels maintained between 50 and 250 x 10^9/L over time, regardless of the splenectomy status of the patients; most of them were non-splenectomized. The product was well tolerated and achieved a decrease in the rate of ITP-related hospitalization.

**E1450 THE CLINICAL UTILITY OF NEUROPSYCHOLOGY TESTING IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA**

F. Alwan1,*, S. Tayabali1, D. Mahdi1, M. Thomas1, J.P. Westwood1, L. Cipolotti2, M. Scully1
1Haematology Department, University College London Hospital, 2Neuropsychology Department, National Hospital for Neurology and Neurosurgery, London, United Kingdom

**Background:** It is well recognized that neurological manifestations are common in thrombotic Thrombocytopenic Purpura (TTP) however research into the neuropsychological impact of the disease is lacking despite evidence suggesting patients who experience clinical illnesses are at high risk for long-term cognitive impairment.

**Aims:** To review the clinical utility of neuropsychology testing in thrombocytic thrombocytopenic purpura.

**Methods:** Between 2010 and 2015, all patients within a single tertiary hematol-ogy center with a confirmed diagnosis of TTP were reviewed as outpatients after their acute episode. Those with persisting, non-physical or psychological symptoms underwent cerebral MRI scanning and were referred for neuropsychological assessment. The Wechsler Adult Intelligence Scale (WAIS) IQ test was used to assess factors including verbal IQ and performance IQs.

**Results:** 18 patients were included. 89% were female with a median age of 51 (16-67 years). 56% were Caucasian, 33% Afro-Caribbean and 11% of South Asian ethnic origin. 33% had experienced TIA or stroke-like symptoms during the acute episode vs. 29% had no neurological symptomatology during their initial presentation. The most common symptom leading to neuropsychology review was problems with concentration, experienced by 89% of patients. 44% had problems with memory, 39% felt depressed and 33% had anxiety issues. The median time from acute TTP episode to neuropsychology review was 29 months. Based on the WASH-Ill review into consideration, one patient had a normal assessment. 50% (n=9) were found to have mild cognitive impairment, 33% (n=6) mild-moderate impairment and 11% (n=2) significant impairment. The two cases with significant impairment had a widespread pattern of dysfunction whilst in the other cases the most concerning impairments were sub-acute infarction or microhaemorrhages.

**Summary/Conclusions:** Persisting psychological symptoms after an acute TTP episode are highly suggestive of underlying cognitive impairment as a result of cerebral sub-acute infarction or microhaemorrhages.

**E1451 FIVE NEW CASES OF HERMANSKY-PUDLAK SYNDROME: IDENTIFICATION OF NOVEL GENETIC VARIANTS IN HPS4 AND HPS3 ASSOCIATED TO RELEVANT CLINICAL COMPLICATIONS**

J. Bastida1,*, G. Gonzalez-Porras1, M. Llozano2, R. Benito3, K. Janusz3, N. Bermejo3, M. Karkukak5, M. Trapero6, M. del Rey7, Y. Yuce1, J. Hernandez-Sanchez3, V. Palma-Barquero2, V. Vicente2, J. Hernandez-Rivas1, J. Rivera2
1Department of Haematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, 2Department of Haematology and Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hématologia, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, 3Department of Haematology, IBSAL, IBMCC, CIC, Universidad de Salamanca-CSIC, Salamanca, 4Department of Haematology, Hospital San Pedro de Alcántara, Caceres, Spain, 5Department of Medical Genetic, Sakarya University Training and Research Hospital, Sakarya, Turkey, 6Department of Haematology and Biomedical Sciences, University College Dublin, Dublin, Ireland

**Background:** Hermansky-Pudlak syndrome (HPS) is an inherited platelet dis-order characterized by bleeding diathesis, oclocutaneous albinism and some-times serious clinical complications. Heterogeneous clinical symptoms and a large numbers of possible genetic culprits (9 HPS genes, >110 exons) compli-cate unequivocal HPS diagnosis.

**Aims:** To assess the clinical and platelet phenotype in five patients with HPS sus-picion and to identify their genetic defect(s) using high-throughput sequencing (HTS).

**Methods:** We studied 5 patients from 3 families (2 Spanish, 1 Turkish) present-ing with oclocutaneous albinism. Clinical records were reviewed and bleeding scored with ISTH-BAT. Platelet phenotyping (only Spanish patients) included: platelet aggregation, GPs expression and granule secretion, 14C-serotonin uptake and whole mount electron microscopy. Patients DNAs were analyzed by HTS using a 71 gene panel.

**Results:** and laboratory findings in these patients are shown in Table 1. The Spanish patients (P1,P2,P5) showed impaired platelet aggregation to mild agonists and reduced platelet dense granules. In family 1 (F1), HTS identi-fied a heterozygous, potentially harmful, c.2054delC (p.Pro685Leu fs*17) vari-ant in HPS4. One sister (P1) had Crohn’s disease and severe gastrointestinal (GI) bleeding. This variant had been reported in a 46yr Asian patient with pul-monary fibrosis (Bachi EB, Am J Hum Genet 2004). A novel missense homozygous HPS4 variant, c.272T>C (p.Leu91Pro), was found in two Turkish siblings (F2). One had severe GI bleeding requiring colectomy (P4) and the other devel-oped pulmonary fibrosis. Patient 5, suffering from mild GI bleeding, bears a heterozygous novel variant in HPS3 (c.2464C>T, p.Arg822X) and, most likely, an additional unrevealed mutation.

**Table 1.**

<table>
<thead>
<tr>
<th>Family</th>
<th>Locus</th>
<th>Syndrome</th>
<th>Other clinical features</th>
<th>HPS4-BAT</th>
<th>HPS3-BAT</th>
<th>Phenomena</th>
<th>Phenomena</th>
<th>Phenomena</th>
<th>Phenomena</th>
<th>Variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>HPS4</td>
<td>Pseudo-</td>
<td>platelet agglutination</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>c.2054delC (p.Pro685Leu fs*17)</td>
</tr>
<tr>
<td>P2</td>
<td>HPS4</td>
<td>Pseudo-</td>
<td>platelet agglutination</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>c.2054delC (p.Pro685Leu fs*17)</td>
</tr>
<tr>
<td>P3</td>
<td>HPS4</td>
<td>Pseudo-</td>
<td>platelet agglutination</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>c.2054delC (p.Pro685Leu fs*17)</td>
</tr>
<tr>
<td>P4</td>
<td>HPS4</td>
<td>Pseudo-</td>
<td>platelet agglutination</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>c.2054delC (p.Pro685Leu fs*17)</td>
</tr>
<tr>
<td>P5</td>
<td>HPS4</td>
<td>Pseudo-</td>
<td>platelet agglutination</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>absent</td>
<td>c.2054delC (p.Pro685Leu fs*17)</td>
</tr>
</tbody>
</table>

**Summary/Conclusions:** HTS facilitates genetic confirmation of HPS diagno-sis, and may help investigating phenotype-genotype relationships in HPS. The novel p.Leu91Pro variant in HPS4 associates with severe clinical phenotype. Funding: JMB: Genrica Regional de Salud [GRS 1370/A16]; JR: ISCIII & Feder (P114/01956), Ciberer CB15/00055, Sociedad Española de Trombosis y Hemostasia.

**E1452 CHARACTERIZATION OF PLATELET ACTIVATION MARKERS IN EARLY PREECLAMPSIA**

D. Angelov1,2, K. Engan1,2, F. Ni Ainle1,2,3,4,5
1UCD Conway SPHERE Research Group, 2School of Medicine, University College Dublin, 3Department of Haematology, Rotunda Hospital, 4Department of Haematology, Mater Misericordiae University Hospital, 5School of Molecular and Biomedical Sciences, University College Dublin, Dublin, Ireland

**Background:** Preeclampsia is a serious pregnancy complication with poten-tially life-threatening consequences for both mother and baby, diagnosed when new onset hypertension and proteinuria develops after 20 weeks gestation. Early onset preeclampsia (EOP; onset <34 gestational weeks), is associated with higher maternal and fetal risks than late onset preeclampsia. At the extreme end of the severity spectrum, HELLP syndrome is characterised by...
hemolysis, elevated liver enzymes, and low platelets. Previous studies have demonstrated enhanced platelet activation in pregnant women with pre-eclampsia, using cell surface markers and platelet microparticles 1. Although severe pre-eclampsia is associated with increased inflammatory markers in vitro, levels of platelet activation do not necessarily correlate with severity of disease 2.

Aims: To assess the presence, and degree, of platelet activation in a cohort of patients with early onset pre-eclampsia (EOP), HELLP syndrome, and to correlate this with evidence of vivo coagulation activation using D-UM.

Methods: Plasma samples from patients with EOP were accessed from a clinical biobank. Platelet activation markers were characterized using ELISA assays measuring platelet factor 4 (PF4), soluble glycoprotein VI (sGPVI) and neutrophil activating peptide-2 (NAP-2). Platelet microparticles (CD42a+ microparticles) were measured by flow cytometry. Platelet activation biomarker levels were adjusted by platelet count and expressed as /10^8 platelets/ml. All data was analysed using GraphPad Prism 7. Parameters were reported as means±SEM.

Results: Plasma samples from 19 individual patients were included. Patients with HELLP syndrome demonstrated significantly greater numbers of CD42a+ microparticles when corrected for platelet count compared with those without HELLP syndrome (598±10^3 vs 20±10^3, p<0.001). Similarly, patients with HELLP syndrome demonstrated increased levels of sGPVI than those without HELLP; corrected for platelet count (2.57±0.96 vs 1.22±0.12, p=0.04). There was no difference in NAP-2 or PF4 levels between those with HELLP and those without HELLP, nor between severe and moderate pre-eclampsia patients. Severe pre-eclampsia patients in this cohort had a D-dimer level of 3.7±10.774 µg/ml compared with non-severe patients 1.85±3.501 µg/ml (p=0.337).

Summary/Conclusions: The results of this study demonstrate a positive correlation between severity of pre-eclampsia and platelet activation, as measured by levels of platelet-derived microparticles and platelet GPVI expression. A number of events, currently labelled traits, have evaluated the role of low-dose aspirin therapy as prevention for pre-eclampsia, and there is Grade 2B evidence for its use in those at risk of severe pre-eclampsia 3. The evidence of enhanced platelet activation in our study provides rationale for the efficacy of aspirin in this setting, and the potential for novel antiplatelet agents to be studied for the same indication.

E1453 PRIMARY ITP IN ADULTS TREATED WITH ELTROMBOGAP: A RETROSPECTIVE STUDY USING DATA FROM THE UNITED KINGDOM ADULT IMMUNE THROMBOCYTOPENIA REGISTRY.

D. Provan1,*, U. Doobaree1, A. Newland1, J. Fleming2
1Haematology, Barts and The London School of Medicine and Dentistry, London, UK
2Haematology, Novartis, Cambridge, Surrey, United Kingdom

Background: Primary ITP is an autoimmune disorder associated with a reduced peripheral blood platelet count. Although many patients are relatively asymptomatic, many suffer with bruising, mucosal bleeding and quality of life issues. Current line treatment has remained unchanged for decades and until recently, second-line therapy has been unsatisfactory, using empirical treatments. The recently approved thrombopoietin receptor agonists eltrombopag and romiplostim have transformed patient care and these agents are licensed second-line therapies in adults.

Aims: To describe the adult patients receiving eltrombopag using data from the UK Adult ITP Registry. In particular we were interested in understanding the mean dose used, number of prior therapies, median length of treatment with eltrombopag, median counts at baseline before treatment and at six months following treatment, and sustained response in patients who have received eltrombopag.

Methods: The UK Adult ITP Registry involved more than 70 UK collaborating centres, coordinated by The Royal London Hospital. In this study we analysed data from all patients receiving eltrombopag and analysed these using various statistical techniques.

Results: The total number of patients evaluated was 129. The median age at diagnosis was 49.4 years (26.9-66.4). There were 74 males (57.4%) and 55 females (42.6%). 29 patients (22.4%) had undergone prior splenectomy. The median age at eltrombopag initiation was 59.5 years (37.0-70.7 years). The median time from ITP diagnosis to eltrombopag initiation was 1.6 years (0.7-2.3 years). The majority of patients started eltrombopag between 2013 and 2016 (63.3%) and 8% started eltrombopag within the first 6 months and between 6 to 12 months of ITP diagnosis, respectively. Most patients had received prior ITP therapies. Some 10 patients (7.8%) had received one prior ITP therapy and 99 patients (77%) had received three or more prior therapies before starting eltrombopag. The commonest prior therapies were corticosteroids in 110 patients (87%); IVig 91 patients (72%); rituximab 68 patients (54%); romiplostim 47 patients (37%); and immunosuppressors 71 patients (56%). At baseline, prior to starting eltrombopag, the median platelet count was 21±10^9/L (10-54) and the majority of patients (64.5%) had platelets less than 30±10^9/L. The mean platelet count at 6 months was 206±210^9/L and at 1 year was 288±540^9/L. The median dose of eltrombopag used was 50mg/day. The median course length on eltrombopag was 14.7 (IQR: 4, 67) weeks. After initiation, 53 (41%) remained on eltrombopag as a monotherapy whereas 27 (21%) had other ITP treatment concurrently with eltrombopag. Forty nine (38%) changed treatment after eltrombopag, of which prednisolone (47%), IVig (35%), romiplostim (21%) and splenectomy (18%) were noted. Thirty patients (24%) stopped treatment with eltrombopag after a median course length of 23 months (15-54). Of these, 27 patients (21%) were unresponsive soon after a brief episode of response. In short, 64% (60%) had a sustained response to eltrombopag (among patients who remained on eltrombopag at follow-up).

Summary/Conclusions: The patient characteristics of those receiving eltrombopag appear to be typical of adult ITP. Only 10 patients (7.8%) were on eltrombopag as a second line therapy. Three quarters had received 3 or more prior therapies before starting eltrombopag despite its licence as a second line therapy. As clinicians become more familiar with its use, a greater proportion of patients are likely to receive eltrombopag as a second line therapy.
E1455
PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS
C. Morel1, A. Tichelli2, A. Wieland-Greguare-Sander3, A. Angelillo-Scherrer3, A. Rovó3,*
1Faculty of Medicine, University of Bern, Bern, 2University Hospital of Basel, Basel, 3University Hospital of Bern, Bern, Switzerland

Background: Immune thrombocytopenia (ITP) is characterized by severe thrombocytopenia due to autoantibody- and cell-mediated peripheral platelet destruction and attenuated thrombopoiesis. Despite a higher risk for bleeding, thromboembolic events (TEE) have been observed.

Aims: We aimed to investigate the prevalence and type of TEE and the potential risk factors in adult ITP patients.

Methods: Retrospective cohort study, including all ITP patients followed in our clinic between 01/1990 and 05/2016. Information on gender, age, date of ITP diagnosis, platelets count, type and clinical form of ITP, type of ITP treatments and its response, severe bleeding and follow up time were collected. Furthermore we evaluated date of first appearance, number and type of thromboembolic events, cardiovascular risk factors, date and cause of death. We assessed and compared risk factors of ITP patients with and without TEE in univariate and multivariate analysis.

Results: Medical files of 480 patients registered as ITP were reviewed; 42 patients were excluded from the analysis (not fulfilling the ITP criteria according to Rodghegroh et al. Blood 2009). In total 438 patients were retained for analysis, 10% out of them (44 patients) presented ≥1 TEE after ITP diagnosis. Within these patients, in total 54 TEE occurred: 34 venous (61%), 19 arterial (34%) and 3 arterial and venous (5%) thrombotic events. The most frequent venous TEE were pulmonary embolism, deep vein thrombosis, and superficial vein thrombosis; arterial TEE were cerebrovascular insults, myocardial infarction and peripheral artery thrombosis. At time of TEE, 43% of patients were on treatment with corticosteroids, 14% with thrombopoietin receptor agonists (TPO-ra) and 18% were off-treatment. In the univariate analysis, older age at diagnosis (>50 years, P=0.015), longer interval since ITP diagnosis (P=0.009), ≥2 treatment lines (P=0.0002), TPO-ra at time of thrombosis (P=0.027), non-response to first-line treatment (P=0.010), smoking (P=0.011), arterial hypertension (P=0.005), and obesity (P=0.041) revealed to be significant. The multivariate analysis model showed that older age at diagnosis (RR, 2.272; 95% CI, 1.167-4.426; P=0.016), ≥2 treatments (RR, 2.539; 95% CI, 1.305-4.941; P=0.006), persistent or chronic ITP (versus acute, P=0.01), TPO-ra at time of thrombosis (P=0.027), smoking (RR, 2.622; 95% CI, 1.250-5.499; P=0.011) were independent risk factors for TEE. When the variable “number of treatments” (<2 versus ≥2) was excluded from the multivariate model, having a splenectomy increased the risk for TEE. The cumulative incidence of TEE at year 1, 5, 10, 15 and 20 years since diagnosis of ITP was 6.2% (95% CI, 4.1-9.3), 11.9% (95% CI, 8.3-17.0), 15.8% (95% CI, 11.1-22.4), 24.2% (95% CI, 16.9-34.7) and 32.8% (95% CI, 22.8-47.3) respectively (Figure). Death occurred in 7/44 (16%) patients with TEE, and in 12/394 (3%) patients without TEE (P=0.001). Most frequent causes of death were infection (32%) and bleeding (21%).

Figure: Cumulative incidence of thromboembolic events with 95% confidence interval.

Methods: We performed a prospective study in 4 ITP patients who exhibited no response to standard therapies (steroid, IVIG and/or splenectomy) and smokers were more likely to develop TEE. The knowledge about the risk of thromboembolic events in adult ITP patients could have an impact on management attitude for patients at risk.

E1456
OSELATAMIVIR FOR THE TREATMENT OF ITP PATIENTS NOT RESPONDING TO CONVENTIONAL TREATMENT: BIOLOGICAL CHARACTERIZATION AND CLINICAL RESPONSES
1Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, 2Hospital de Jerez, Jerez de la Frontera, 3Hospital Universitario Reina Sofía, Córdoba, 4Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, 5Hospital Infanta Cristina, Badajoz, 6Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Grupo de Investigación CB15/00055 del CIBERER, ISCIII, Murcia, Spain

Background: Oseltamivir phosphate, a drug that conventionally serves as an antiviral sialidase inhibitor classically prescribed for the treatment of patients with influenza, has shown to induce an increase in platelet counts in 2 patients with primary immune thrombocytopenia (ITP) (1,2). A previous study has suggested a mechanism of Fcγ receptors (FcγR)-independent platelet clearance in ITP patients with anti-Glycoprotein (GP) Ia autoantibodies (3). However, little is known about the exact response mechanism of this drug in ITP, TEE. Aims: To analyze the biological features and clinical responses following oseltamivir treatment in patients that are non-responders to conventional treatments.

Table 1.

Patients' characteristics

Age (years) | Male/female | Previous treatment | Platelet count (×10⁹/L) | Before | Before
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>78.5</td>
<td>78.5</td>
<td>78.5</td>
<td>78.5</td>
<td>78.5</td>
<td>78.5</td>
</tr>
</tbody>
</table>

Methods: We performed a prospective study in 4 ITP patients who exhibited no response to standard therapies (steroid, IVIG and/or splenectomy) and showing relevant platelet desialylation levels. Patients were given off-label oseltamivir at the referring physician’s discretion. Desialylation of GP platelet surface was examined via flow cytometry (FC) analysis, with fluorescein-conjugated Ricinus Communis Agglutinin I (RCA-1), which binds galactose residues only if the terminal sialic acid has been removed. FC data are expressed as fold change compared to control samples. Additionally, patients’ sera were incubated with normal human platelets to analyze the ability to induce desialylation of normal platelets. Analysis of plasma proteins was performed by Western blot (FXI, FXII) and HPLC (transferrin). Platelet autoantibody specificity was achieved by using Western blot (RCA-1) and HPLC (IgG4, IgM). Results: Patients’ characteristics are summarized in Table 1. Two patients achieved complete platelet response (>100x10⁹/L) after oseltamivir treatment. The oral dose was 75mg twice daily, for a variable duration (5 days in one case and 4 months in the other showing response criteria since the third week of from start) combined with low doses of other treatments (azathioprine or romiplostim). A sustained platelet response was observed after 4 weeks of the sial-
idase inhibitor discontinuation. Patients with no response after oseltamivir treatment (n=2) were given similar doses for 5 days. Patients with response had antibodies directed solely to GPIb and had greater platelet loss of sialic acids. Moreover, their sera induced significant desialylation of normal platelets. However, no desialylation in patients’ plasma proteins was detected. Biological analysis after treatment discontinuation (median of 3 weeks), revealed a sustained sialylation level of platelet glycoproteins over time, particularly in patients with sustained platelet response.

Summary/Conclusions: Chronic ITP patient with anti-GPIbα autoantibodies who do not respond to conventional therapies and exhibit significant platelet desialylation may achieve a complete response to treatment with oseltamivir.

References

E1457
BORTEZOMIB THERAPY IS ASSOCIATED WITH SIGNIFICANT RESOURCE IMPLICATIONS FOR BOTH PATIENTS AND PROVIDERS: RESULTS OF A TIME-IN-MOTION STUDY
M. Tatarczuch1, K. Ramasamy1, A. Peniket1, M. Sultanova1, G. Vallance1, F. Panitsas1
1Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Background: Bortezomib is a proteasome-inhibitor, which has improved outcomes in multiple myeloma (MM). Its use is approved within the UK NHS. Bortezomib is frequently administered as a subcutaneous injection in a hospital day treatment unit. Whilst the administration of a subcutaneous injection is brief, the process for the patient travelling to hospital, assessment and waiting for the delivery of the injection can take considerable time. From a patient perspective, significant amount of time spent without economic activity and travel costs add up during the course of therapy. From the health-care provider the process of safely administering bortezomib has significant resource implications beyond those of drug procurement.

Aims: We set up a time-in-motion study to evaluate the costs to health care provider and patients during bortezomib therapy to estimate the ‘real-world’ cost of delivering bortezomib therapy.

Methods: Retrospective data collection was undertaken, using electronic prescribing records for patients treated between July 2014 - August 2016. Travel distance and time was estimated using Google maps and costed using HMRC mileage (an approved costing of mileage used for taxation purposes). The NHS schedule of service costs was used to estimate the cost of bortezomib administration. Cost of delivery of Bortezomib for healthcare providers is a sum of these individual costs.

Results: We identified 127 patients who incurred a total of 2 134 visits whilst receiving Bortezomib therapy at the Churchill Hospital in Oxford during this 2 year period. Median age was 70 years-old (yo) (39-95); Male 74 patients (58%) 53 patients (42%). We restricted the analysis to 110 patients who started and completed therapy during the study period. Median number of patient visits was 16 (range 11-52). The median travel distance (return journey) for each patient was 33 miles (53 km) (range: 1.2-224 mi; 1 9-360 km). Median travel time was 90 min (range: 8-300 min). The range travel cost per patient was £8.35-£13.20. Twenty-seven patients (21%) required use of specialist hospital transport services, which resulted in 295 transport-episodes (14%) in total. In order to assess the time spent in the day therapy unit, a subgroup of 589 patient-episodes were analysed to assess time from arrival to administration of Bortezomib: the median time from patient registration to bortezomib administration was 63 min (range: 5-433 min). Pharmacy cost for preparation of Bortezomib was £50 per dose. The cost of delivery of bortezomib (not including cost of drug) was £1160 per cycle, which equated to a total median cost of £4640 per patient (range: £890-£15,080). Drug procurement costs for Bortezomib is estimated at an additional £12,261 per course of therapy (BNF 2016). Delivery costs therefore added an additional 38% to the procurement costs.

Summary/Conclusions: We provide the first time-in-motion data on myeloma patients treated with Bortezomib. The ‘real-world’ cost of delivering therapy is 37% higher than the drug-costs alone. In addition the impact on patients is substantial: over a two year period 127 patients required 2 134 visits with a median time in the day unit of 63 minutes and a median travel time of 90 minutes per visit. Our data highlights the burden of both time and economic costs to patients during therapy. Novel oral proteasome inhibitors offer the potential to reduce this resource impact in the future. This data could be used by health care providers and reimbursing agents for economic modeling of the potential benefits of oral proteasome inhibitors.

E1458
HOSPITAL CARE AT HOME ADMINISTRATION OF SUBCUTANEOUS AZACITIDINE IS FEASIBLE AND PREFERRED BY PATIENTS COMPARED TO HOSPITAL ADMINISTRATION: A FRENCH REGIONAL HEMATOLOGY NETWORK EXPERIENCE
M. Touati1,2,3, M.P. Gounin1, S. Moreau1, S. Lefort1, E. Belfet-Frayssé4, C. Brillat5, M. Jacquenot6, G. Maillan7, A. Daulange8, I. Joussain9, L. Jeannet2, Z. Boutalbi1, E. Dumond Wilbaux2, D. Bordesoule1, A. Jacquot1
1ServicelméHématologie Clinique et Thérapie Cellulaire, 2Réseau Hématologie, Centre Hospitalier Universitaire, Limoges, 3Oncologie et Radiothérapie, Centre Hospitalier, Brive-la-Gaillarde, 4Service d’Hospitalisation à Domicile, Centre Hospitalier Universitaire, Limoges, 5Service d’Hospitalisation à Domicile, Relai Santé Oncoré, Brive-la-Gaillarde, 6Service d’Hospitalisation à Domicile, Sanité Service Limousin, 7Pharmacie Centrale, Centre hospitalier Universitaire, Limoges, 8Pharmacie Centrale, Centre Hospitalier, Brive-la-Gaillarde, 9Service d’Hospitalisation à Domicile, CRFF 23, Noth, France

Quality of life, palliative care, ethics and health economics
Background: In France, azacitidine (AZA) is indicated for the treatment of adult patients affected by Myelodysplastic Syndrome with intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS), Chronic Myelomonocytic Leukemia (CMLL) with 10-29% medullary blasts and Acute Myeloblastic Leukemia (AML) with 20-30% blasts. It’s also a drug treatment of adult AML patients over 65 years with >30% of medullary blasts. Azacitidine is a hypomethylating agent administered by subcutaneous route. Though itidine is a hypomethylating agent administered by subcutaneous route. Though it is considered by some to be an alternative to conventional chemotherapy in elderly patients, several concerns such as the high costs of such care with the medical personnel workload. Limousin is a region with the oldest population of France and with a very low population density. There is one university hospital and two local state-run hospitals each with a hematology department. In 2010, we started a randomized and patient blinded trial aimed to evaluate, as primary end point, the efficacy and safety of opioid and benzodiazepine agent combination plus LIA in patients that underwent BMAB for hematological malignancies. Two secondary end points were: 1) define if patients who already underwent BMAB without LIA prefer sedoanalgesia; 2) sedoanalgesia can influence the outcomes to minimize the frequent hospital visits that these treatments require. This organization includes the three previously mentioned hospitals, four HaH structures, and three central pharmacies with an integrated preparation unit for cancer treatments. From 2009 to 2015, a total of 11,367 infusions were administered at home for 464 pts. In 2016, we demonstrated the feasibility of ESCADHEM and the medico-economic interest of such care with the medico-economic interest of such care with the medico-economic interest of such care with the medico-economic interest of such care with the medico-economic interest of such care. The aim was to minimize the frequent hospital visits that these treatments require. The overall satisfaction rate was 95%.

Aims: Our work aimed to demonstrate that HaH administration of AZA is feasible and well preferred by patients compared to hospital administration.

Methods: Chemotherapy at home obeys to strict rules. The first chemotherapy cycle (C1) and the first injection (D1) of subsequent cycles were administered at the outpatient care unit. The following injections were administered at the patient’s home and carried out by HaH, according to a predefined procedures (Fig 1) to comply with safety rules essential to the protection of the professional, the patient, the entourage and the environment. Subcutaneous AZA injections were administered at 101 out of 244 pts (51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur- sedoanalgesic placebo plus LIA (standard group, 48.6%) or oral fentanyl citrate 200 mcg plus oral midazolam 5mg in addition to LIA (combo-group, 51.4%) dur-

Results: Between 2009 and 2015, a total number of one-hundred-sixteen (n=116, Table 1) were enrolled in the study. Nine (n=9) patients did not meet inclusion criteria and were excluded. Fifty-two (n=52) patients were randomized and assigned to standard group and fifty-five (n=55) to combo group. Fifty-eight (n=58) patients were administered at a dose of 75mg/m^2 for 7 days of each 28-day cycle. Among all pts, 110 were males and 59 females with a median age of 75 years (range 41-92) there are 88 (52%) MDS patients and 81 pts (48%) with AML. Patients received a median number of 5 cycles (1-41) and 26 injections of AZA (1-244) at home. The total duration of HaH management lasted from less than 1 day to more than 3.4 years with a mean of 6.3 months. During the period of HaH administration of AZA, 101 pts (60%) had to return to the local hospital for a non programmed rehospitalization. 90% of the time the patient needed a transfusion, 4% because of infection and 6% for other reasons.

Summary/Conclusions: Administration of oral analgesia and anxiolysis is a safe and feasible option to be used in outpatient setting: sedo-analgesia is very effective in reducing pain during the biopsy and diminishes the anticipatory anxiety related to a painful procedure. Patients should have the possibility to choose between local anesthesia alone or sedo-analgesia plus local anesthesia.

Table 1.

Table 1. Baseline characteristics of patients undergoing BMAB

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Standard group</th>
<th>Combo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70 (65-75)</td>
<td>75 (70-80)</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>65/35</td>
<td>52/48</td>
</tr>
<tr>
<td>Disease (AML/MDS)</td>
<td>60/40</td>
<td>50/50</td>
</tr>
<tr>
<td>Number of cycles</td>
<td>5 (1-10)</td>
<td>5 (1-10)</td>
</tr>
<tr>
<td>Number of injections</td>
<td>20 (10-30)</td>
<td>25 (15-35)</td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: This important number of subcutaneous injections (n=6369) in a large cohort (n=169) over a period of time of 6 years activity show that home administration of subcutaneous AZA is feasible without serious adverse event. The first satisfaction survey demonstrates a high rate of sati-faction by all patients (20% with AML/MDS) treated by injectable chemotherapy.

E1459

USE OF COMBINED ORAL FENTANYL CITRATE (ACTIQ®) AND MIDAZOLAM AS PREMEDICATION FOR BONE Marrow Biopsy in Patients with Hematological Malignancies: A Randomized Controlled Patient Blinded Clinical Trial

C. Cerchione1,*, M. Picardi1, N. Pugliese1, R. Della Pepa1, A. Gravett1, A. Casoria1, L. Catalano1, D. Nappi1, G. Giancia2, G. Pettinato2, F. Pane1, V. Martellini1

1Hematology, Ematologia e trapianto/au federico ii, 2Anatomia Patologica, AOU Federico II, Napoli, Italy

Background: Bone marrow aspiration and biopsy (BMAB) is a painful procedure done in patients with hematological malignancies (HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED

AS PREMEDICATION FOR BONE MARROW BIOPSY IN PATIENTS WITH

A. AML/MDS) that home administration of subcutaneous AZA is feasible without serious adverse event. The first satisfaction survey demonstrates a high rate of satisfaction by all patients (20% with AML/MDS) treated by injectable chemotherapy.

E1460

ASSESSMENT OF THE ECONOMIC IMPACT OF HORSE-ATG IN SWEDEN FOR APLASTIC ANAEMIA

R. Desmond1, R. Pelfault de Latour2, A. Risitano3, K. Sutton4, E. Remak5, R. Horvath6, V. Katkade6,*, C. Charbonneau7

1Hematology, Tallaght Hospital, Dublin, Ireland, 2Hematology, Saint Louis Hospital, Paris, France, 3Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy, 4Modeling & Simulation, Evidera, London, United Kingdom, 5Modeling & Simulation, Evidera, Budapest, Hungary, 6Pfizer, Philadelphia, United States, 7Pfizer, Paris, France

Background: Aplastic anaemia (AA) is a rare, potentially fatal haematopoietic stem-cell disorder that can either be inherited or acquired. AA is graded according to disease severity, from non-severe to very severe and is linked to immunemediated responses such as the generation of auto-antibodies. Cases of severe and very severe AA are considered to be a hematological emergency requiring urgent treatment. Extended hospitalisations and the cost of treatments and disease management are associated with the economic impact of AA.

Table 1. Baseline characteristics of patients undergoing BMAB

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Standard group</th>
<th>Combo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70 (65-75)</td>
<td>75 (70-80)</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>65/35</td>
<td>52/48</td>
</tr>
<tr>
<td>Disease (AML/MDS)</td>
<td>60/40</td>
<td>50/50</td>
</tr>
<tr>
<td>Number of cycles</td>
<td>5 (1-10)</td>
<td>5 (1-10)</td>
</tr>
<tr>
<td>Number of injections</td>
<td>20 (10-30)</td>
<td>25 (15-35)</td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: Administration of oral analgesia and anxiolysis is a safe and feasible option to be used in outpatient setting: sedo-analgesia is very effective in reducing pain during the biopsy and diminishes the anticipatory anxiety related to a painful procedure. Patients should have the possibility to choose between local anesthesia alone or sedo-analgesia plus local anesthesia.

E1460

ASSESSMENT OF THE ECONOMIC IMPACT OF HORSE-ATG IN SWEDEN FOR APLASTIC ANAEMIA

R. Desmond1, R. Pelfault de Latour2, A. Risitano3, K. Sutton4, E. Remak5, R. Horvath6, V. Katkade6,*, C. Charbonneau7

1Hematology, Tallaght Hospital, Dublin, Ireland, 2Hematology, Saint Louis Hospital, Paris, France, 3Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy, 4Modeling & Simulation, Evidera, London, United Kingdom, 5Modeling & Simulation, Evidera, Budapest, Hungary, 6Pfizer, Philadelphia, United States, 7Pfizer, Paris, France

Background: Aplastic anaemia (AA) is a rare, potentially fatal haematopoietic stem-cell disorder that can either be inherited or acquired. AA is graded according to disease severity, from non-severe to very severe and is linked to immune-mediated responses such as the generation of auto-antibodies. Cases of severe and very severe AA are considered to be a hematological emergency requiring urgent treatment. Extended hospitalisations and the cost of treatments and disease management are associated with the economic impact of AA.
Aims: To assess cost-effectiveness of ATGAM (horse antithymocyte globulin) in comparison to rabbit antithymocyte globulin (r-ATG) in the treatment of moderate to severe aplastic anemia (sAA) patients in Sweden.

Methods: A semi-Markov state-transition cohort model was developed to estimate longer-term (up to 5 years) clinical and economic outcomes for patients with AA receiving either ATGAM or r-ATG as first-line IST treatment. The following key assumptions were included in the model: responders who relapse are assumed to be re-treated with no expected change in survival. Patients who do not respond to first-line treatment move onto a second-line treatment comprised of either IST, IST + eltrombopag or hematopoietic stem cell transplantation (HSCT). Although response rates are lower, those who respond to second-line treatment are assumed to have the same outcomes as those who respond to first-line. Patients who continue to not respond receive standard supportive care with a significant decrease in expected survival. Efficacy data for ATGAM and r-ATG were obtained from published literature. Adverse events were not included due to lack of evidence of any difference between the two comparators. Medication, administration, and disease management costs were obtained from published literature, publicly available sources and clinical expert opinion. As resource utilization for disease management changes over time and differs considerably between responders and non-responders, three distinct phases have been included in the model: short-term (first 6 months post-IST administration), medium-term (6-12 months) and long-term (greater 1 year), for patients in either of the response categories.

Results: Response to treatment was calculated to be seen in 67% of ATGAM patients’ vs 35% in r-ATG (accounting for mortality). Over 5 years, the model estimated that patients gained 4.15 life-years (3.28 quality-adjusted) on ATGAM vs 3.52 (2.56) on r-ATG. Short-term disease management costs were estimated to be SEK 880,144 (€96,816) in responders vs SEK 1,264,016 (€139,041) in non-responders. Medium and long-term costs also followed the same pattern. Overall costs (drug plus disease management), were significantly lower for patients receiving ATGAM vs r-ATG; making ATGAM cost-saving by being both more effective and less costly than r-ATG. When considering treatment costs only (including cyclosporine and HSCT), the model estimated a cost of SEK 107,097/life-year gained (approx. €11,781) and SEK 135,655/quality-adjusted life-year (approx. €14,922), showing ATGAM is highly cost-effective. The analysis showed that when treatment and disease management costs are considered, ATGAM dominates r-ATG as the gain in QALYs and LYs are achieved at a lower cost. Therefore making ATGAM cost-saving with greater health benefits in comparison to r-ATG.

Summary/Conclusions: Due to improved treatment response, survival, and quality of life outcomes, the model shows that ATGAM is at least more cost-effective, if not cost-saving, in comparison to r-ATG for the treatment of patients with aplastic anemia.

E1462 A CLINICAL AUDIT OF NUTRITIONAL SCREENING AND SUPPORT OF HOSPITALIZED PATIENTS WITH HEMATOLOGIC DISEASES

A. Stamoul1, A. Liaskas1, I.-G. Tzanninis1, E. Kanioura1, D. Politis1, L. Poulia2, N.-A. Viniou1, K. Konstantopoulos2, P. Diamantopoulos1.* 11st Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens. 2Clinical Nutrition Department, Laikon General Hospital, Hematology Department, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Background: Poor food intake is a common problem in patients with hematologic diseases. Recurrent infections and chemotherapy complications are some of the possible causes. Malnutrition is correlated to slow recovery, prolonged hospitalization, and higher mortality. Audits about the nutritional support of hospitalized patients may detect significant failures in patient care and help towards the correct application of the international guidelines.

Aims: We performed a prospective observational audit on hospitalized patients with hematologic diseases to investigate their nutritional status and whether they received the appropriate nutritional support.

Methods: The initial population consisted of 122 consecutive patients with hematologic diseases admitted from March 31, 2016 to June 8, 2016 in two Hematologic Units of a Tertiary University Hospital in Athens, Greece. We designed a special questionnaire based on the Malnutrition Universal Screening Tool (MUST) with additional questions on demographic, somatometric and medical data (Table 1). The questionnaire was applied by 6th-year medical students to all patients within 48 hours of admission. Patients were classified as high, intermediate, and low-risk per the MUST score and were reassessed at prede- fined intervals. During nutritional interviews we examined the food intake and the nutritional interventions (nutritional supplements, enteral or parenteral nutrition) applied.

Results: Ninety-three patients were included in the final analysis (5 refused to participate, 22 were excluded due to short-term hospitalization, 2 were absent during reassessment). Forty-one (38%) patients had a MUST score ≥2 (high risk) but none of them received nutritional supplements. One patient was supported with parenteral nutrition (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Table 1: Patients’ characteristics and results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, N (%)</td>
</tr>
<tr>
<td>Age (years), median (range)</td>
</tr>
<tr>
<td>Gender (M/F)</td>
</tr>
<tr>
<td>BMI (kg/m²), median</td>
</tr>
<tr>
<td>% of unexplained weight loss in past 6 months, median (range)</td>
</tr>
<tr>
<td>Disease, N (%)</td>
</tr>
<tr>
<td>Lymphoproliferative disorders</td>
</tr>
<tr>
<td>Acute leukemia</td>
</tr>
<tr>
<td>Myeloproliferative disorders</td>
</tr>
<tr>
<td>Benign hematologic disorders</td>
</tr>
<tr>
<td>No confirmed diagnosis</td>
</tr>
<tr>
<td>Patients receiving nutritional support, n (%)</td>
</tr>
<tr>
<td>Recipient chemotherapy/radiotherapy, N (%)</td>
</tr>
<tr>
<td>Reported food intake (last 5 days), n (%)</td>
</tr>
<tr>
<td>Increased</td>
</tr>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>Decreased</td>
</tr>
<tr>
<td>Serum albumin levels on admission/discharge, g/dL, median (range)</td>
</tr>
<tr>
<td>Other variables: estimated food intake in 3 days, reduced appetite, type of diet, calorie intake, duration of hospitalization, ECOG score, recent surgery, dysphagia, nausea, muscositis, infection, neurological deficits, head trauma etc.</td>
</tr>
<tr>
<td>*65 year-old woman with 12% weight loss over the last month, BMI=21.5 m², albumin=2.9 g/L, a hospital-acquired infection and no food intake.</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our audit revealed a lack of nutritional support of the hospitalized patients. A meeting with the involved health professionals was organized and an oral presentation of the results and the possible causes (lack of sensitization of the staff, high regimen cost, shortness of staff) was performed. Proposals to change the current situation were made such as detection of high risk patients by medical students and further assessment by a nutritional specialist. A brief MUST-based questionnaire was also proposed to be used for all patients upon admission. A re-audit was programmed and is already in progress.
E1463
ASSESSING REAL-WORLD TREATMENT PATTERNS, OUTCOMES AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) POST AUTOLOGOUS STEM CELL TRANSPLANT ACROSS EUROPE

J. Ashcroft1, G. Taylor-Stokes2, S. Dhansani3, D. Judge4,5
1Mid-Yorkshire Hospitals NHS, Wakefield, 2Adelphi Real World, Bollington, United Kingdom, 3Celgene International, Boudry, Switzerland

Background: Autologous stem cell transplant (ASCT) is the standard of care for first line (1L) treatment (tx) for patients (pts) with MM of deemed suitable fitness to safely undergo the procedure. More recently introduced tx options have significantly increased the life expectancy of pts with MM and continue to provide further promise for the future in this devastating disease. The increasing therapeutic armamentary across the MM pathway allows for varied tx patterns providing both potential differences in outcomes and healthcare resource use (HCRU).

Aims: The aim of the analysis was to determine current management of pts in the post ASCT setting, assess outcomes of pts and HCRU.

Methods: A retrospective chart review was conducted in France, Germany, Italy, Spain and the UK. Data collection took place in Q1 2017. Physicians provided data on consecutive pts with MM who had undergone an ASCT as part of 1L tx or on after 1st January 2014, to specifically examine the HCRU post 1L ASCT. Data collected pertained to pt characteristics, b patterns, duration of tx and outcomes (including time to progression (TTP) and best response achieved (IMWG updated criteria), HCRU in terms of hospitalizations, additional supportive drugs prescribed and healthcare professional (HCP) visits. Pt records included in this interim analysis were completed by Feb 2017, with data collection continuing in all countries.

Results: 214 record forms have been reviewed to date. Pts’ mean age at diagnosis was 59 (±7.8 SD) years; 43% female and 57% male. Mean duration from diagnosis, to receiving an ASCT was 9.6 months (+13.3 SD). Of the pts included in the study, 62%, 28% and 8% had received 1st, 2nd and 3rd line tx respectively. In the 1L setting, 72% of pts did not receive any drug therapy post ASCT, 21% received consolidation and 8% maintenance therapy. Of the pts who did not receive maintenance therapy, 42% and 34% went onto receive 2L and 3L drug therapy respectively; whereas, only 24% of pts who received maintenance therapy went onto 2L, and none onto 3L. The most frequently prescribed regimens at 1L maintenance were Lenalidomide (82%), Bortezomib (12%) and Thalidomide (12%).

Summary/Conclusions: The sample is reflective of the pt demographics data reported in Raab et al. 2016. Furthermore, the TTP for pts not receiving any active ongoing tx post ASCT in this real-world study is comparable to findings in literature. Additional data exists on HCRU post ASCT. This study demonstrates that there is ongoing HCRU impact even if pts are not receiving any active ongoing tx post first ASCT. Prolonging the remission period post ASCT may therefore spread the marginal cost of HCRU whilst simultaneously enhancing a pt’s quality of life by deferring future tx lines.

E1465
THE COST-EFFECTIVENESS OF PEGASPARAGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS

S. Basu1, P. Llin2, C. Rowntree3, V. Sahai4
1Shire, London, United Kingdom, 2Shire, Cambridge, United States, 3University Hospital of Wales, Cardiff, 4University of Manchester, Manchester, United Kingdom

Background: Asparaginase is a key component in the multi-agent chemotherapeutic regimen for the treatment of children, adolescents, and adults with acute lymphoblastic leukaemia (ALL). Compared to native asparaginase (native ASP), pegaspargase (PEG-ASP) has a longer half-life, can be given less frequently, and is less immunogenic, which leads to fewer hypersensitivity reactions. In the UK, patients with newly diagnosed ALL are treated with PEG-ASP followed by Erwinia-derived asparaginase (ERW-ASP) in cases of hypersensitivity, based on the UKALL protocols. Although native ASP is no longer used as the first choice of asparaginase therapy, it was the standard of care before PEG-ASP was available. A cost-utility analysis (CUA) was conducted to evaluate overall cost-effectiveness of PEG-ASP in comparison to native ASP when utilized as part of antineoplastic combination therapy for treating newly diagnosed ALL in children, young people, and adults.

Aims: To evaluate the cost-effectiveness of a treatment strategy including PEG-ASP in a multi-agent in patients with newly diagnosed ALL compared to regimens that include native ASP.

Table 1.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Total Cost</th>
<th>Incremental Cost</th>
<th>ICER (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG-ASP &gt; ERW-ASP</td>
<td>7,871</td>
<td>5,224</td>
<td>3,647</td>
</tr>
<tr>
<td>ERW-ASP &gt; Native ASP</td>
<td>5,360</td>
<td>2,731</td>
<td>1,075</td>
</tr>
<tr>
<td>Native ASP &gt; ERW-ASP</td>
<td>2,509</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Methods: In line with accepted National Institute for Clinical Excellence (NICE) methodology, a combined decision tree and health state transition Markov model was developed to compare treatment sequences starting with PEG-ASP versus native ASP, followed by ERW-ASP in case of hypersensitivity. Although ERW-ASP is not used first-line in the United Kingdom, alternative switching scenarios could be clinically possible, and therefore all scenarios were modeled. Paediatric, young adult (≤25 years), and adult (26-65 years) patients were modelled separately using the UKALL 2003 and UKALL14 protocols, respectively. Further splits were made between high-, intermediate-, and standard-risk patients in the paediatric model, between patients aged ≤40 vs ≥41 years and patients eligible vs not eligible for transplant in the adult model. Key model parameters (survival, risk of hypersensitivity) were based on published data and clinical expert input. In the base-case analysis, overall survival and event-free survival were assumed to be equivalent for PEG-ASP, native ASP, and ERW-ASP. With 1,000IU/m² dosing (per UKALL protocols) used for PEG-ASP, the 2,000 IU/m² dosing (per non-SmpC) of PEG-ASP was examined, as well as variations in comparative survival and hypersensitivity rates. Incremental cost-effectiveness ratios (ICER), defined as incremental costs/quality-adjusted life years (QALYs) gained, were produced.
Results: The base-case scenario demonstrated that PEG-ASP followed by ERW-ASP dominated (i.e., was both less costly and more effective than) native ASP followed by ERW-ASP in adults, children, and the whole (combined) population (Table). Scenario analyses highlighted the robustness of the cost-effectiveness results. Differences in total QALYs between PEG-ASP and native ASP were driven primarily by the difference in hypersensitivity rates.

Summary/Conclusions: This analysis demonstrates that PEG-ASP, as part of multi-drug chemotherapy, is a cost-effective treatment option compared to native ASP for treating ALL in children, young people and adults with newly diagnosed ALL.

E1466

IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/ GDC-0199) MONOTHERAPY

W. Weise1,2, R. Saitz1, L. Noe2, R. Kamalakar2, J. Gdovin2, M. Verdugo2, S. Kim2, R. Humerickhouse2, S. Stilgenbauer3

1The University of Texas MD Anderson Cancer Center, Houston, 2AbbVie Inc, North Chicago, United States, 3Department of Internal Medicine III, Ulm University, ULM, Germany

Background: Chronic lymphocytic leukemia (CLL) is associated with reduced health-related quality of life (HRQoL), with progressive severe fatigue being a particularly relevant burden. Disease-related symptoms, toxic effects of therapy, and the awareness of living with an incurable disease can have a profound impact on HRQoL. Venetoclax (VEN) is an oral BCL-2 inhibitor that has demonstrated deep and durable responses in relapsed/refractory (R/R) CLL patients.

Aims: To assess whether Venetoclax has a sustained impact on health related quality of life among patients with relapsed/refractory CLL based on a second interim analysis (first interim results through week 24) of patients treated with VEN monotherapy.

Methods: Patients ≥18 years of age with R/R CLL who received VEN monotherapy until disease progression, unacceptable side effects, or discontinuation for any other reason. Patient-reported HRQoL measures included the EORTC QLQ-C30 and EORTC QLQ-CLL16, which were assessed at Baseline (BL), at 4 weeks and every 12 weeks thereafter. Mean change in the HRQoL measures from BL to each assessment are reported. Clinical relevance was based on minimum important difference (MID) of values from BL at different assessment points. The lower bound of 5–10 point changes, considered a “little” change for EORTC-QLQ-C30 and 10% of MID acceptance for both measures.

Results: Clinically meaningful improvements from BL were observed early and were sustained through week 96 in VEN treated patients in the EORTC-QLQ-C30 global health status and the role, social, and emotional functioning scales. Improvements in VEN treated patients in EORTC-QLQ-CLL16 disease effects, social problems, and future health worries scores were statistically significant and exceeded the MID at all assessment points. Furthermore, early and sustained improvements in fatigue through week 96 were seen in both EORTC-QLQ-C30 and EORTC-QLQ-CLL16 (Table 1). The changes observed in patient EORTC-QLQ-CLL16 future health views were considered large (>20 points) at Weeks 12, 24, and 48.

Table 1.  

Summary/Conclusions: These updated interim results suggest that patients receiving VEN monotherapy experienced early and sustained clinically relevant improvement in several key aspects of functioning and HRQoL for up to 96 weeks in a very symptomatic and difficult to treat patient population. These results are important to consider when making treatment decisions in the R/R settings.

E1467

WHICH HAEMATOLOGICAL CONDITIONS CAN THIRD YEAR MEDICAL STUDENTS RECOGNISE INTERPRETING FULL BLOOD COUNT RESULTS?

S. Lovato1,2, J. Arnold1,2

Summary/Conclusions: These updated interim results suggest that patients receiving VEN monotherapy experienced early and sustained clinically relevant improvement in several key aspects of functioning and HRQoL for up to 96 weeks in a very symptomatic and difficult to treat patient population. These results are important to consider when making treatment decisions in the R/R settings.

E1468

LONGITUDINAL ASSOCIATIONS BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTHCARE UTILIZATION IN AL AMYLOIDOSIS

M. Baylis1, T.P. Quock2, S.D. Guthrie2, M.K. White1, K.L. McCausland1,*

1Optum, Lincoln, 2Prothena Biosciences Inc, South San Francisco, United States

Background: Light chain (AL) amyloidosis is a rare, complex disease associated with significant organ dysfunction, disability, and death. AL amyloidosis patients interact with the healthcare system in a myriad of ways; however, few studies have quantified healthcare utilization (HCU) in this condition.

Aims: To prospectively examine the association between health-related quality of life and healthcare utilization among patients with AL amyloidosis.

Summary/Conclusions: This group of medical students found it difficult to correctly diagnose some of the haematological conditions presented, even though they had studied all the conditions before, however the use of a “Team Based Learning” approach where students could discuss the cases in small groups did improve their results. Interestingly for two conditions, for CML and Multiple myeloma the number of correct answers was the same for i-RAT and t-RAT, possibly the students who responded correctly during the i-RAT were concentrated in fewer groups. To the author’s knowledge this is the first study on the effect of applying the Team Based Learning method to haematology teaching. This study showed that TBL could be a useful teaching tool to improve teaching of haematological conditions in medical schools, however the size of the sample was small and the results should be validated with a bigger study.
Methods: A non-interventional, longitudinal online study was conducted among patients with AL amyloidosis who were recruited with assistance from patient advocacy groups. Initial (n=341) and six-month follow-up (n=226) surveys assessed demographics, disease and treatment characteristics, and health-related quality of life (HRQoL), measured by the SF-36v2® Health Survey physical and mental component summary scores (PCS and MCS). HCU (e.g., outpatient doctor’s visits, emergency room [ER] visits, hospitalizations, and insurance coverage) was measured during the six-month follow-up. Prevalence of HCU and its bivariate associations with patient characteristics were evaluated. Multivariable logistic regression models were used to test for associations between HRQoL and having an ER visit or hospitalization in the past six months.

Results: Overall, visits with specialists and other healthcare providers during the previous six months were nearly ubiquitous (92.0% and 94.6%, respectively). Collectively, 56.0% of patients reported having ≥1 ER visit or hospitalization. ER visits and hospitalizations were not associated with the numbers or types of organs affected by the disease or the duration of disease. There were significant associations between PCS and ER visits (p < 0.05) and between both PCS and MCS and hospitalizations (p < 0.05 for all) based on multivariable analyses.

Summary/Conclusions: There is a lack of real-world evidence regarding HCU among patients with AL amyloidosis. This research identified longitudinal associations between HRQoL and HCU, indicating there is potential for using HRQoL surveys as screening tools to predict future HCU for AL amyloidosis patients. The development of prediction models for HCU in AL amyloidosis should consider incorporating HRQoL, as well as disease staging and treatment type.

E1469

SAFETY, FEASIBILITY AND EFFECTIVENESS OF ELECTRICAL MUSCLE STIMULATION IN HOSPITALIZED PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENIC STEM CELL TRANSPLANTATION AND INTENSIVE CHEMOTHERAPY

D. Kadrić-Mulindwa1, A. Klostermann1,*, M. Bewarerder1, J. Bittenbring1, M. Pfreundschnu1
1Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany

Background: Autologous and allogeneic stem cell transplantation (HSCT) or intensive chemotherapy are the only treatment option for many patients with haematological malignancies. Even after complete remission many patients are physically and psychologically impaired because of intensive treatment and weeks of immobilisation. Electrical muscle stimulation (EMS) is a verified training tool to prevent muscle decline in seniors and helps improving physical performance in patients with chronic diseases.

Aims: This prospective, randomized and controlled study tested the safety, efficacy and feasibility of EMS in 72 patients (EMS=42, control=30) undergoing autologous HSCT (n=21), allogeneic HSCT (n=17) and intensive chemotherapy (n=34).

Methods: A Myopuls 2000 device (Curatec Services Gmbh) was used. Target training time was 15 minutes 5 days a week on both thighs and arms from start of therapy (T1) to time of discharge (T2). Adverse events and treatment adherence were documented. Impact on psychological and physical functioning was evaluated using the Multidimensional Fatigue Inventory (MFI), the EORTC QLQ-C30, the Short Physical Performance Battery and the 6 Minute Walking Distance (6MWD) and 30m T2.

Results: Seven patients died in the EMS- (n=4) and control-group (n=3). 6 of 42 EMS patients withdrew because of sepsis (n=4) or loss of motivation (n=2). 32 patients from the EMS group completed our study with 22 accomplishing >66% of the pre-set training time. EMS related adverse events were hematological (n=1) and muscle pain (n=2). No bleeding events (WHO bleeding scale=1) or ventricular arrhythmias occurred. Difference in 6-minute walking distance between both groups was 23 meter (p=0.2). SPPB test results differed by one point (p=0.08). MFI and EORTC QLQ-C30 both favoured the EMS group, but showed no statistical significance.

Summary/Conclusions: EMS is feasible and safe in patients undergoing intensive chemotherapy regimens. It also may improve physical fitness, fatigue and quality of life, indicated by favourable test results in the EMS group. To verify positive effects of EMS in patients with haematological malignancies, further research is needed, with more patients and sham EMS stimulation.

E1470

MYELOMA PATIENT VALUE MAPPING: A DISCRETE CHOICE EXPERIMENT

J. Galinsky1,*, S. Fifer2, S. Richard1
1Research, Myeloma UK, Edinburgh, United Kingdom, 2Research, Community and Patient Preference Research, Sydney, Australia

Background: Myeloma is a life threatening haematological cancer. Although myeloma is responsive to treatments, there remains no cure. In recent years, there have been improvements in survival due to the use of high dose therapies, stem cell transplant, and other novel therapies. However, while myeloma patients are living longer, they are also living with symptoms and treatment toxicity. Therefore, myeloma patients face difficult decisions about the benefits and risks of treatment. The purpose of this study was to assess myeloma patient preferences for treatment.

Aims: The study aimed to answer the following questions: What treatment attributes do myeloma patients value? What is the relative importance of different types of treatment and the associated risks? What is their willingness to accept? What risk-benefit trade-offs characterise patients’ decision-making around treatment options, including not to treat? What, if any, influences and predictive factors are in the way patients assess benefits and risk?

Methods: Participants were 475 Myeloma patients in the UK. Data were collected using discrete choice experiments (DCEs) through an online survey. The DCEs presented patients with a traditional treatment choice experiment (e.g., treatment A vs treatment B), focusing on the clinical benefits of treatments and the associated risks. The attributes and levels of the attributes were selected based on previous research, literature review and expert opinion. The DCE data were modelled using a Latent Class Model (LCM), and the effect of demographic characteristics were also examined.

Results: Findings revealed two classes (groups) of patients with different preferences for attributes. Patients in class one placed greater importance on overall survival and mild-to-severe side effects, whereas patients in class two placed greater importance on how the treatment was administered and the cost/insurance coverage. For patients in class two, the cost saving effects were significant.

Summary/Conclusions: Findings from this study suggest that not all myeloma patients value the same treatment features equally. This finding has important implications for healthcare policy decision-makers and could be used to guide future healthcare policy decisions around the value of new myeloma medicines. For example, to establish more patient-aligned endpoints in clinical trials or as evidence which is incorporated into the Heath Technology Assessment process.
E1472
QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS
B. Sidi Mohamed El Amine¹1, H. Asma¹, Z. Zahaia¹, M. Naima², M. Nemra³
¹Hematology department, University hospital of Sidi Bel Abbes, Sidi Bel Abbes, ²Hematology department, University hospital of Tlemcen, Tlemcen, ³Hematology department, Hospital of Mascara, Mascara, Algeria

Background: Thyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myelogenous leukemia (CML), but little is known about quality of life (QoL) of the patients.

Aims: The purpose of this study is to evaluate QoL of CML patients receiving TKIs, a disease requiring strict daily compliance with taking these drugs orally, as well as regular clinical and biological controls.

Methods: The study included patients with CML followed in three hospitals in west Algeria between 2004 and 2016. The measure of QoL was performed by the tool of functional assessment of chronic illness therapy (Functional Assessment of Chronic Illness Therapy, FACIT) for leukemia. We have established QoL scores given by the questionnaire, FACIT, consisting of three levels: TOI for leukemia trial outcome index, FACT-G for general score, and FACT-LEU for the total score of leukemia. Specific areas of the questionnaire were associated with QoL of patients such as fatigue and ability to work. The correlation between the total QoL score and QoL scores given by Spearman’s test. The test is significant if p<0.05.

Results: 67 patients with CML have agreed to answer to the questionnaire of QoL, medications in use, and their side effects. The mean QoL of the patients was 93.7 (out of 124 total points) for the TOI, 77.2 (out of 108) for the FACT-G, and 128.9 (out of 176) for the FACT-LEU. Patients who presented with TKIs side effects had a low score of QoL (p=0.0006), especially when these effects are severe (p=0.003). Stopping TKIs medication was noted in 41.3% of patients with severe side effects. Severe fatigue was observed in 14 (22.9%) patients, having low QoL scores in all scales (p<0.0001). 44 (65.8%) patients were able to work with higher QoL scores in the three FACIT scales (p<0.0001, Spearman correlation).

Summary/Conclusions: QoL is an important aspect in the management of CML, its assessment is necessary and must be regular. The ability to work and fatigue are important components of QoL of patients receiving TKIs and should be specifically taken into account during the treatment. Adverse effects of TKIs can interfere with QoL of patients and can lead to discontinuation of CML therapy.

E1473
QUALITY OF LIFE AND EMPLOYMENT AFTER AN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A MEXICAN POPULATION
L. Rivera-Fong ¹, A. Riveros Rosas¹, C. Banjet¹, L.M. Valero Saldaña², R. Robles García¹, L. Traeger³, S. Rivas-Vera², J.L. Aguilar Ponce⁴, O. Galindo Vázquez², B.L. Acosta Maldonado²
¹Psicología y Salud, Universidad Nacional Autónoma de México., ²Hematology, National Cancer Institute, Mexico City, Mexico, ³Health psychology, Harvard University, Massachusetts, United States, ⁴Oncology, National Cancer Institute, Mexico, ⁵Psicología, Universidad Nacional Autónoma de México., Mexico City, Mexico

Background: Hematopoietic stem cell transplantation (HSCT) is a consolidation therapy for multiple hematological malignances and its goal include patients achieve levels of quality of life (QOL) similar that general population. However, studies developed in Europe and United States have shown that patients on long-term follow-up after HSCT reported lower levels of QOL, more unemployment and lower household income than before the procedure. These relationships have not been examined in Mexican HSCT patients.

Aims: To describe the QOL (EORTC-QLQ), level of employment and household income in Mexican patients on follow-up after HSCT

Methods: This was a cross-sectional study with patients ≥18 years old with at least one year of follow up after HSCT at the National Cancer Institute, Mexico.

Results: 30 participants were included, with a median age of 34 years (range 20-60), 56% male, and 41% married. Regarding educational level 68.7% had basic education, 25% had a college education and 6.3% postgraduate education. Mean time after HSCT was 36 months, 10% had active chronic graft versus host disease (GVHD). Patients reported moderate to high levels of QOL (Table 1). With respect to employment, 52% had a job (56% had a full time job, 13% work part-time and 31% had an informal job) and 48% were unemployed (50% could not find a job and 50% did not want to have a job). Finally, 56% had lower household income than before HSCT.

Summary/Conclusions: Mexican patients showed similar or higher levels of QOL in comparison with samples from other countries, with the exception of higher impact in emotional QOL and better social QL in our sample. Additionally, a substantial minority of patients were unemployed and over half had lower household income after HSCT. More work is needed to identify risks associated with changes in QOL, employment status and income among long-term survivors of HSCT.
Summary/Conclusions: Anthracycline therapy was responsible for more deaths in B cell lymphoma in a dose-dependent manner. More intensive blood sugar monitoring and control should be recommended to B cell lymphoma patients, especially those who received anthracycline treatment.

E1475 THE COST-EFFECTIVENESS OF LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CHINA

J. Lu1,*, S. Hu2, P. X. Gu3, Y. Feng4
1Peking University People's Hospital, Peking University Institute of Hematology, Beijing, 2Fudan University School of Public Health, Shanghai Health Development Research Center, 3Cellgene China, Shanghai, 4Department of Pharmacy, Beijing Hospital, Beijing, China

Background: The introduction of lenalidomide plus dexamethasone (RD), and bortezomib-containing regimens, has improved the management of relapsed or refractory multiple myeloma (rMM) in China. However due to the absence of both head-to-head (direct) comparative efficacy and local cost data, stakeholders still face hard choices to make when choosing one therapy over another. Indirect treatment comparisons and health economic modeling can help support local decision-making by enabling the incorporation of country-specific unit cost data, in the comparison of cost-effectiveness of one treatment vs another where treatments have not been directly compared in clinical trials.

Aims: To assess the cost-effectiveness of RD relative to bortezomib/dexamethasone (VD) and bortezomib/cyclophosphamide/dexamethasone (VCD) for rMM in Chinese patients.

Methods: The Markov-based decision analytic model was constructed to simulate lifetime health benefits and direct medical costs associated with RD, VD, and VCD for rMM in Chinese patients. A systematic literature review was conducted (in both Chinese and English databases, from 2005 to 2016) to obtain efficacy data of the three treatment regimens. The risk of progressive disease associated with RD and VD were estimated from available Chinese trials. The efficacy of VCD and the mortality associated with progressive disease after treatments with RD and VD were lacking in China, therefore were estimated from the published international randomized clinical trials. Published quality of life data was adapted to Chinese rMM patients with health utility adjustment. The model took into account (i) drug acquisition costs, (ii) treatment administration costs, (iii) for Chinese urban residents, (iv) indirect costs, (v) cost of adverse events management based on a survey of seven MM centers across China, and (vi) rMM management costs estimated from a Chinese real-world hospital setting. Quality-adjusted life years (QALY) and direct medical costs in the model were discounted at 3% per annum. Base case analysis calculated incremental cost-effectiveness ratios (ICERs) per QALY for RD relative to VD and VCD, respectively, from the Chinese healthcare payer’s perspective. One-way sensitivity analysis and probabilistic sensitivity (PSA) with 5,000 Monte Carlo simulations assessed the impact of the model uncertainty on the cost-effectiveness of RD. A scenario analysis was conducted by meta-analyzing the published international randomized trials for the efficacy associated with RD, VD, and VCD, to verify the base case analysis.

Results: Based on the model simulation without discounting survival outcomes over a lifetime horizon, RD could obtain longer average PFS years than VD (2.37 vs 0.78) and VCD (2.37 vs 1.36). RD was associated with longer duration of remission compared to VD (1.41) and VCD (1.40) without any differences in costs ($494,060 vs $272,135 vs $272,135 vs $244,220) both than VD and VCD. The ICERs per QALY for RD relative to VD ($149,706) and VCD ($150,774) were less than the cost-effectiveness threshold of China (three times of estimated 2016 China GDP per capita $166,920/QALY, $1= €0.138). The cost-effectiveness of RD was also lower than the mortality and/or utility risk associated with the progressive disease after treatment. The scenario analysis generated comparable ICER per QALY associated with RD relative to VD ($120,974) and VCD ($117,191), therefore supports the robustness of base case analysis.

Summary/Conclusions: The local data-based health economic model estimates that RD could gain longer PFS and OS with acceptable cost-effectiveness when compared to VD and VCD in Chinese rrMM patients.

E1477 OVARIAN TISSUE CRYOPRESERVATION IN PEDIATRIC AND ADOLESCENT PATIENTS UNDERGOING CANCER CHEMOTHERAPY AND/OR HEMATOPOIETIC STEM CELL TRANSPLANTATION

A. Kinoshita1,*, R. Ooyaama1, D. Keino 1, Y. Matsuoka1, Y. Koto1, T. Mori1, N. Suzuki1, M. Sumikura1, 1Pediatric Hematology/Oncology, 2Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan

Background: Ovarian tissue cryopreservation (OTC) and subsequent re-implantation is the only option available for fertility preservation in prepubertal females, but this approach remains unestablished in pediatric and adolescent patients with cancer. After the experience of OTC for more than 200 patients with primary ovarian failure and more than 50 patients with breast cancer in our center over 5 years, we have started OTC for pediatric and adolescent cancer patients since 2015.

Aims: To define safety and benefits of OTC in pediatric and adolescent patients with undergoing cancer chemotherapy and/or hematopoietic stem cell transplantation.

Methods: From December of 2015 to February of 2017, OTC was performed in 6 girls (median age 14 years, range 11-15): 2 patients with myelodysplastic syndrome, 2 with lymphoma, 1 with acute lymphoblastic leukemia, and 1 with primary immunodeficiency. Indications for OTC were 5 hematopoietic stem cell transplantation and 1 sterilizing chemotherapy. Two patients with myelodysplastic syndrome and 1 with immunodeficiency received no previous chemotherapy and the other 3 had received prior chemotherapy. Laparoscopy was used to collect a one of ovarium that was frozen by vitrification method. Results: Collectively collected ovarian tissue were harvested in 6 patients, were not studied without major postoperative complications and this procedure did not delay chemotherapy or hematopoietic stem cell transplantation. Histological analysis of ovarian tissue revealed primordial follicles, even in the patients with previous cancer chemotherapy. No malignant cells were identified. Median post-harvest
Methods: Between October 2016, and January 2017, we did a cross-sectional survey of individuals receiving at least 3 months of ongoing treatment for MM at our department. The survey included the 11-item COST measure (financial toxicity score range 0-44). A paper survey was offered to eligible patients on arrival for routine follow-up visits or treatment, and participants were asked to respond either during or after their visit or at home. Completed surveys were returned to the research team and the data were analyzed by a statistician. The COST questionnaire was validated with internal consistency (Cronbach’s coefficient) and item correlation (Pearson’s r coefficient) tests, especially those of Quality of life (EORTC QLQ 30).

Results: Of 47 patients approached for the study, 44 individuals completed the survey and 40 (91%) were insured. Analysis of the internal consistency of the COST questionnaire showed an overall Cronbach’s alpha coefficient of 0.84. According to COST data, 26 (59,1%) patients have a score>22. Patients with financial difficulties have a negative impact on their quality of life (P=0, 02, r=0, 32), and low scores of physical and role functioning (P<0,001, r>0, 5), 29 (68%) patients feel financially stressed, and 23 (52, 3%) did not control their financial situation. After a logistic regression, lower household income (P=0,009) and Poor response to treatment (P=0, 0037) were associated with higher financial burden as measured with the COST score.

Summary/Conclusions: Despite insurance and free care, financial toxicity is common in many myeloma patients, especially those with lower income and refractory disease. Strengthened collaboration among patients and health-care stakeholders is needed to promote healthcare reforms that promote high value and affordable myeloma care.

E1418

THE IMPLICATIONS OF NON-PROPORTIONAL HAZARDS FOR THE MEASUREMENT OF SURVIVAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT: CURRENT APPROACHES AND THE ROLE OF RESTRICTED MEAN SURVIVAL TIME

G. Monnickendam1,2, J. McKendrick1, M. Zhu1, Y. Su2, X. Zhang3

1PRMA Consulting, Fleet, United Kingdom, 2Global Health and Value, Pfizer, New York, United States

Background: Median survival and hazard ratios (HR) calculated from Cox proportional hazard (PH) models for progression-free survival (PFS) and overall survival (OS) are the principal endpoints in the assessment of new cancer drugs. The advent of novel agents, including immuno-oncologics, has seen increasing reports of non-proportional hazards (non-PH). When non-PH are present, it is challenging to evaluate the true clinical significance of survival differences even if median and overall survival measures do not represent the comparative benefit over the full period of observed data. In such situations, additional metrics such as restricted mean survival time (RMST) may be valuable.

Aims: To determine current methods used by health technology assessment (HTA) agencies when non-PH are observed in assessments of new cancer drugs.

Methods: Methodological guidelines published by 10 HTA agencies in 8 major developed countries (Australia, Canada, France, Germany, Italy [Emilia Romagna, Veneto], Spain, Sweden, and the United Kingdom [NICE, SMC]) and by international organizations for health technology assessment (HTA) (e.g., British National Formulary, United Kingdom [NICE, SMC]) and by international organizations for health technology assessment (HTA) (e.g., British National Formulary, United Kingdom [NICE, SMC]) were reviewed to establish recommended approaches for presenting survival benefit from clinical trials, particularly the use of RMST when non-PH were not reported.

Results: To determine how these guidelines are implemented in practice, published HTA reports were examined across the 8 countries for 23 oncology agents (including 4 in hematology) approved by FDA and EMA since 2014, to identify instances where testing for non-PH was conducted and RMST data reported.

Results: Guidelines from only 2 agencies (PBAC in Australia and NICE in the UK) described formal testing for non-PH. Testing was reported in 3 (of 4) NICE assessments and 4 (of 10) PBAC assessments. For the hematology drugs, non-PH testing was conducted in 3 (of 4) NICE assessments; it did not hold in 2 instances. Of the agencies (from France, Germany, Italy and Spain), which focus on comparative clinical benefit, only 1 (GENESIS in Spain) discussed the concept of RMST in their guidelines; most guidelines presented these differences as hazard ratios (HR) without further testing. Testing was reported in 15 (of 23) NICE and 4 (of 10) PBAC assessments. For the hematology drugs, non-PH testing was conducted in 3 (of 4) NICE assessments; it did not hold in 2 instances. Of the agencies (from France, Germany, Italy and Spain), which focus on cost-effectiveness, all except the TLY in Sweden include RMST in their guidelines; RMST was reported in 13 (of 81) HTA assessments from those countries. Of the 3 hematology drugs where non-PH was tested within the NICE pathway, only 1 (of 3) TLY in Sweden where non-PH was reported RMST (utilized during economic model sensitivity analyses). Non-PH is not a widely reported issue in US guidelines; however, the ICER has acknowledged it and PH testing was conducted in both ICER reports in oncology.

Discussion: RMST is not widely reported in clinical trials or incorporated into assessments by HTA agencies except by UK NICE. RMST as a metric to assess OS has played a role in assessing clinical benefit within the context of HCA assessments, although not consistently within countries (across drugs) or across countries (for the same drug), as was seen with the hematology agents. As treatments for cancer expand to new classes and indications, instances of non-PH will likely increase; alternative survival metrics such as RMST may have an increasingly important role to play in describing survival benefit in such cases.

E1479

FINANCIAL TOXICITY OF THE MANAGEMENT OF MULTIPLE MYELOMA

B. Sidi Mohamed El Amine1,2, H. Asma1, O. Fouzia1, S.A. Najet1, Z. Zahia1

1Hematology department, Universitary hospital of Sidi Bel Abbes, Sidi Bel Abbes, Algeria

Background: Advances in supportive care and the development of novel treat- ments have helped to double the life expectancy of patients with newly diag- nosed multiple myeloma (MM). Financial toxicity is increasingly recognized as adversely affecting the quality of life and medication adherence, and patients with MM might be particularly vulnerable because of extended treatment dura- tion.

Aims: Our aim was to measure financial toxicity and its effects on patients undergoing treatment for MM.

Methods: We introduced a weekly multi-disciplinary chemotherapy prescribing meeting in 2013 with the aims of improving prescribing safety, minimising time spent prescribing in clinic & reducing patient waiting times. Present at each meeting is a Haematology Specialist Pharmacist, Haematology CNS, Consultant & Specialist Registrar. Chemotherapy is planned a week in advance on ChemoCare (an electronic chemotherapy prescribing package). Chemotherapy is prescribed & immediately screened by the pharmacist; oral chemotherapy is collected from pharmacy by a CNS prior to clinic. All prescription queries are resolved during this meeting. Deferred oral chemotherapy can be returned to pharmacy stock, minimising waste. Intravenous chemotherapy is pre-planned with authorisation on the day of treatment if the patient is fit to proceed.

Results: In the first 2 years to the care pathway, we focussed on delivery of care to myeloma patients receiving oral chemotherapy, including setting up a nurse-led clinic. Data have been collected to assess service impact, particularly on patient satisfaction. The latter was assessed using a patient survey. Between July-Dec 2014, 66 patients received oral chemotherapy in the Myeloma Con- sultant-led clinic, Lenalidomide based regimens accounted for 86% of the oral regimens prescribed. On average, 7 patients per week were on maintenance therapy. During this period 8% of chemotherapy courses were deferred due to low blood counts or side-effects. Drugs were not wasted due to the pharmacy agreement.

Results: A patient satisfaction survey was undertaken from Jan-June 2015, post-introduction of the nurse-led clinic paired with the MDT chemotherapy pre- scripting meeting. Patients were asked about a wide-range of quality parame- ters. Results showed 89% of patients noted a reduction in wait times & 89% felt they spent more time in consultations as a result. All patients noted they spent more time with the nurse specialist & benefited from not attending phar- macy. All patients rated the service as more efficient.

Summary/Conclusions: The MDT approach to prescribing & dispensing oral chemotherapy & supportive medication has streamlined our way of working & led to greater efficiency for both staff & patients. The new model has changed the way we treat MM patients. It has led to greater efficiency for both staff & patients. The new model has changed the way we treat MM patients.
E1481
DISEASE SEVERITY AND SLOWER PSYCHOMOTOR SPEED IN ADULTS WITH SICKLE CELL DISEASE
E. Novelli1,2, D. Jorgensen3, A. Metti2, M. Butters2, C. Rosano2
1Medicine, Vascular Medicine Institute, University of Pittsburgh, BST E1240, 200 Lothrop St., 2University of Pittsburgh, Pittsburgh, United States

Background: Psychomotor slowing is common in children with sickle cell disease (SCD), but little is known about its severity in adult patients. While the primary risk factor for psychomotor slowing in SCD is the presence of stroke, there has been mounting evidence that cognitive impairment also occurs in patients without a history of overt or silent stroke. Risk factors for cognitive impairment in patients with SCD without stroke are, however, not completely known, particularly in relationship to the SCD genotype.

Aims: We conducted a cross-sectional study to quantify psychomotor slowing, measured with the Digit Symbol Substitution Test (DSST), a pencil and paper test of executive function, in relationship with disease severity in adult patients with SCD attending an outpatient clinic. We also examined whether demographic, behavioral, physiologic, and pathologic factors that are known to be related to SCD severity and cognitive function in other settings are also related to psychomotor speed in these patients.

Methods: Genotype was used to group patients with SCD (n=88, age: 36.3 years, 33 males) in “severe” (homozygous for the mutated sickle hemoglobin HbS [HbSS], or compound heterozygous with β+ thalassemia [HbSβ+] or “moderate” groups (compound heterozygous for HbS with either HbC [HbSC], or β-thalassemia [HbSβ-β-])). Standardized DSST scores based on published norms were used to define mild cognitive impairment, defined as ≤1.5 standard deviations (SD) below the DSST T-score (T-scores had a mean of 50 and SD of 10).

Results: Among our patients, 56 (63%) had a “severe” genotype and 32 (27%) had a “moderate” genotype. Mild cognitive impairment was detectable in both the “severe” and the “moderate” group (30% and 9%, respectively, age-adjusted p=0.15). Compared to the “moderate” group, those in the “severe” group, had significantly lower DSST scores (age, sex and education adjusted p-value<0.006), independent of adjustment for factors that differed between groups: hemoglobin, ferritin, hydroxyurea use, blood pressure parameters and stroke history. Results were similar after excluding patients with stroke.

Table 1. Predictors of DSST T-score

<table>
<thead>
<tr>
<th>Predictor variable</th>
<th>Severe</th>
<th>Moderate</th>
<th>P1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>33.7</td>
<td>40.9</td>
<td>0.009</td>
</tr>
<tr>
<td>Male sex*</td>
<td>21 (37.5%)</td>
<td>12 (37.5%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Education (years)</td>
<td>13.1</td>
<td>13.2</td>
<td>0.80</td>
</tr>
<tr>
<td>Mild Cognitive Impairment*</td>
<td>17 (30.4%)</td>
<td>3 (9.4%)</td>
<td>0.14</td>
</tr>
<tr>
<td>DSST T-score</td>
<td>47.6</td>
<td>41.5</td>
<td>0.006</td>
</tr>
<tr>
<td>O2 Saturation (%)</td>
<td>95.7</td>
<td>98.1</td>
<td>0.14</td>
</tr>
<tr>
<td>WBC count (X109/L)</td>
<td>9.7</td>
<td>9.3</td>
<td>0.87</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>9.2</td>
<td>11.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Platelet count (X109/L)</td>
<td>344.1</td>
<td>263.3</td>
<td>0.16</td>
</tr>
<tr>
<td>Reticulocytes (%)</td>
<td>1.7</td>
<td>1.1</td>
<td>0.51</td>
</tr>
<tr>
<td>LDH (IU/L)</td>
<td>32.1</td>
<td>269.2</td>
<td>0.18</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>111.6</td>
<td>403.4</td>
<td>0.05</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.7</td>
<td>0.8</td>
<td>0.91</td>
</tr>
<tr>
<td>SBP (mm/Hg)</td>
<td>111.3</td>
<td>118.9</td>
<td>0.03</td>
</tr>
<tr>
<td>DBP (mm/Hg)</td>
<td>68.8</td>
<td>73.5</td>
<td>0.02</td>
</tr>
<tr>
<td>MAP (mm/Hg)</td>
<td>83.1</td>
<td>88.6</td>
<td>0.03</td>
</tr>
<tr>
<td>Hydroxyurea use*</td>
<td>32 (57.1%)</td>
<td>10 (31.2%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Opiate use*</td>
<td>15 (26.8%)</td>
<td>10 (31.2%)</td>
<td>0.57</td>
</tr>
<tr>
<td>Transfusion history*</td>
<td>17 (31.5%)</td>
<td>5 (16.1%)</td>
<td>0.15</td>
</tr>
<tr>
<td>Stroke history†</td>
<td>10 (18.2%)</td>
<td>2 (6.2%)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

* Mean (SD) unless otherwise noted. † Age-adjusted. P1 statistically significant differences between severe and moderate groups.

Summary/Conclusions: Psychomotor slowing in SCD differs in relationship to genotype; this difference appears unrelated to history of stroke or severity of anemia and other risk factors examined cross-sectionally. Although relatively infrequent, mild cognitive impairment was also detectable in adults without a less severe genotype. Longitudinal studies of SCD should include all diseases genotypes, and examine factors that would reduce the risk of cognitive impairment in each subgroup.
E1483

MICROSTRUCTURAL ANALYSIS OF RETINO-CHOROID LAYERS USING OPTICAL COHERENCE TOMOGRAPHY IN ADULT PATIENTS WITH SICKLE CELL DISEASE

G. Graziaidei1,*, L. Dell'Arti2, G. Barteselli3, F. Viola4, L. Riva2, E. Carini5, S. Franzonni2, A. Invernizzi2, L. Duca2, M.D. Cappellini6,7,8,9,10

1Rare Disease Medical Specialties, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 2Eye Clinic, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 3Genentech, Inc, South San Francisco, United States, 4Eye Clinic, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 5Unita’ Operativa di Oculistica, Ospedale Fatebenefratelli, 6Eye Clinic, Luigi Sacco Hospital, University of Milan, 7Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 8Rare Disease Center, Internal Medicine Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Background: Retinopathy is one of the ophthalmological complications of patients with Sickle cell disease (SCD), due to microvascular occlusions; occasionally, proliferative sickle cell retinopathy (PSR) can lead to severe vision loss.

Aims: a. to analyze macular alterations in patients with Sickle Cell Disease (SCD) by spectral-domain optical coherence tomography (SD-OCT), using the automated software for retinal segmentation; b. to investigate relationship between OCT abnormalities and the severity of proliferative sickle cell retinopathy (PSR); c. to elucidate the role of potentially contributory systemic factors on the development of macular thinning.

Methods: This is a prospective, observational case-control study. Ophthalmological evaluation, fluorescein angiography and SD-OCT were performed. Central and temporal retinal layers were measured by the SD-OCT Automatic Segmentation software. SCD eyes were divided into two groups based on the presence of visible macular thinning areas. Clinical data and blood samples were collected.

Results: Thirty consecutive adult SCD outpatients were studied (median age 38.7±9.89 [M.F 12:18], including 9 patients with Sickle Cell Anemia (SCA), 17 with Sickle Cell β°-Thalassemia and 4 HbS/HBc. One HbS/HbC and 4 HbS/HbC. HbS/HbC and HbS/HbC. More severe PSR was present in 16/59 eyes (29%). The prevalence of temporal macular thinning was higher (10/16) in eyes with more severe PSR (62.5%). Both inner and outer retinal layers thinning of the foveal region and of the central and temporal macula was found in the overall SCD patients compared with normal controls (p<0.001). SCD eyes with patchy retinitis pigmentosa showed sharper Staining Center, Intact of inner retinal nerve fiber layer (INL) and outer plexiform layer (OPL) in the temporal region. Univariate analysis revealed a significant correlation between patchy areas of severe retinal thinning on OCT and SCD need for transfusions, need for chelation, HbF, ferritin, and transferrin saturation (p<0.025) with the most predictive variables for retinal thinning as assessed after multivariate regression analysis were the need of chelation (p=0.0187) and the HbF (p=0.0775). More specifically, the odds of retinal thinning is 94.2% lower when chelation is present, and the odds of retinal thinning decreases by 12.9% when HbF increases by 1 unit.

Summary/Conclusions: Early identification of chronic hepatic disease sometimes pauci-symptomatic in terms of VOCs but able to lead to advanced stage and progressive fibrosis is crucial for suitable clinical management to avoid cirrhosis in SCD patients. The combination of TE with specific serum markers (GGT, ALP, albumin) is a valid tool to early detection of sickle hepatopathy.

E1484

NON ABLATIVE TRANSPLANT CONDITIONING WITH TREOSULFAN IS CURATIVE IN A MURINE MODEL OF SICKLE CELL DISEASE

D. Devadasan1, C.-W. Sun2, T. Townes2, F. Goldman3

1Pathobiology and Molecular Medicine theme, Department of Graduate Bio-medical Sciences, 2Department of Biochemistry and Molecular Genetics, 3Department of Pediatrics, University of Alabama at Birmingham, Birmingham, United States

Background: Hematopoietic stem cell transplantation (HSCT) for patients with sickle cell disease (SCD) is curative, though significant toxicity from myeloablative conditioning regimens decrease transplant toxicity and are preferable in non-malignant disorders. Novel approaches have been proposed including targeted depletion of stem cells (ACK2), co-stimulation blockade (anti-CD40L), and combination therapy with less toxic alkylating agents (Treosulfan).

Aims: Optimize non-myoablative conditioning in a murine model of SCD that allows for sufficient donor RBC chimerism.

Methods: Control (AA) and SCD (SS) animals were treated with varying conditioning regimens (+/− rescue with AA or SS marrow), including Treosulfan (2-5g/kg), ACK2 (100-500ug/kg), anti-CD40L, and low-dose radiation, alone or in combination. Short and long-term toxicities, including survival, were monitored over a 12 month period. Hematologic effects were determined by assaying CBCs, reticulocytes, bone marrow (BM) cellularity and RBC chimerism (iso-electric focusing). Myeloid/lymphoid chimerism was monitored by FACS combined with droplet-digital PCR. Renal tubular function was assessed by measuring urine osmolality, and moribund animals underwent necropsy to assess organ damage.

Results: Erythropoietic hyperplasia was noted in the BM of SS, relative to AA mice. Treosulfan, in a dose-dependent manner, decreased BM cellularity and induced cytopein in AA and SS mice. AA mice were able to tolerate Treosulfan at non-ablative doses of 6g/kg. In contrast, SS mice were unable to tolerate doses of 3g/kg unless RBC transfused by d+3. At 3g/kg dose, erythroid engraftment was transient in SS transplanted mice and most often absent by 2 months post-transplant, with only 25% of animals having sustained RBC chimerism at one year. In SS mice achieving 50% AA in peripheral blood, fertility was preserved, while the majority of SS mice 12 months post-transplant were incapable of age-matched controls. ACK2, anti-CD40L, or low-dose radiation, in combination with Treosulfan (3g/kg), failed to improve engraftment. In contrast, increasing Treosulfan to 3.6g/kg resulted in donor-erythroid chimerism at 3 months post-transplant in all mice, with improvement in hematologic parameters and normalization of hypertrophic kidneys. These animals are currently being observed for fertility, organ toxicity and survival.

Summary/Conclusions: SCD mice closely mimic human disease in phenotype and ablative conditioning intolerance. Treosulfan, at sub-myoablative dosing, sustained erythroid chimerism and reversed the SCD phenotype. Our data suggest that pre-transplant conditioning with Treosulfan alone may be permisive for engraftment, in an allogeneic and gene-corrected autologous clinical transplant setting.
in just under half of patients. A new diagnosis of sickle cell anemia was made during the admission (53/161; 32.9%), followed by infective complications including pneumonia. The most common diagnosis causing the admission was vaso-occlusive crisis (161/161; 100%), Staphylococcus aureus (2/11; 18.2%) and other enteric Gram-negative pathogens (6/11; 54.5%), followed by Haemophilus influenzae type b in 6/11 (54.5%).

Summary/Conclusions: The presence of microscopich encephalopathy is very common in SCD patients and is associated with a history of TEE, which is also frequent in SCD. There seems to be a permanent activation of the coagulation mechanism in SCD. In SCD patients with SCIs and a history of TEE, apart from clotting factors and natural inhibitors there seems to be a contribution of platelets and cellular elements, possibly sickle cells. The impact of chronic hydroxyurea treatment on the pathogenesis of silent infarcts and TEEs needs further evaluation.

E1486
Abstract withdrawn.

E1487
INVASIVE BACTERIAL INFECTIONS IN GAMBIAN PATIENTS WITH SICKLE CELL ANEMIA IN AN ERA OF WIDESPREAD PNEUMOCOCCAL AND HAEMOPHILUS INFLUENZA TYPE B VACCINATION

G. Soothill1,2, S. Darboe2, G. Bah3, L Bolainde4, A. Cunningham5, S. Anderson6
1Royal Free Hospital, London, United Kingdom, 2Medical Research Council Unit Gambia, Fajara, Gambia, 3Imperial College London, London, United Kingdom

Background: Bacterial infections cause significant morbidity and mortality in patients with sickle cell anemia, especially in populations without reliable access to antimicrobial prophylaxis and treatment. The long-standing use of penicillin prophylaxis and vaccination for Streptococcus pneumoniae and Haemophilus influenzae type b in resource-rich settings has minimised the additional risk of invasive bacterial infections associated with sickle cell anemia. However, these interventions are not routinely implemented in much of Africa, despite this region having the greatest burden of disease, with over 80% of people with sickle cell anemia born on the continent. The Gambia has well established vaccination programmes for pneumococcal and Haemophilus influenzae type b, which is rare in the region. There is little data on the identity of bacterial infections in African sickle cell anemia populations, and we believe (until this study) there were no data from countries with comprehensive vaccination programmes against Streptococcus pneumoniae and Haemophilus influenzae type b.

Aims: Primary: to determine the predominant pathogens causing invasive bacterial infections in a population of sickle cell anemia patients admitted to the Medical Research Council Unit Gambia. Secondary: to review the characteristics of this sickle cell anemia population.

Methods: A retrospective analysis of the clinical and laboratory records relating to 161 admissions of 126 patients with sickle cell anemia admitted to the Medical Research Council Unit Gambia over a five-year period (between April 2010 and April 2015) when there was high coverage of pneumococcal and Haemophilus influenzae type b vaccination.

Results: Pathogenic bacteria were cultured from blood in 11 of the 131 admissions which had blood cultures taken (8.4%, 95% CI 4.5-14.1%). The most frequent organism isolated was Salmonella typhimurium (6/11; 54.5%), followed by Staphylococcus aureus (2/11; 18.2%) and other enteric Gram-negative pathogens (2/11; 18.2%) and there was one case of Haemophilus influenzae non-type b bacteremia (1/11; 9.1%). No cases of bacteremia caused by Streptococcus pneumoniae or Haemophilus influenzae type b were identified. The most common diagnosis causing admission was vaso-occlusive crisis (53/161; 32.9%), followed by infective complications including pneumonia (16/161; 9.9%) and osteomyelitis (12/161; 7.5%). The median length of admission was five days and the median age of patients was five years (IQR: 2-13 years). A new diagnosis of sickle cell anemia was made during the admission in just under half of patients.

Figure 1.

E1488
THE ASSOCIATION OF IGF-1 AND IGFBP-3 SERUM LEVELS AND GENE EXPRESSION WITH THE PATHOGENESIS OF INFLAMMATION IN SICKLE CELL DISEASE

N. basul1, E. karanah2, E. Ak3, S. Una1,3
1Pediatri, merins University Pediatric Department, 2Mersins University Pediatric Hematology Department, Mersin, Turkey

Background: Sickle cell disease (SCD) is one of the chronic inflammatory diseases. Serum markers of inflammation have provided evidence for a state of chronic inflammation in sickle cell disease (SCD). Inflammation promotes endothelial adherence to sickle erythrocytes.

Aims: To investigate the serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels and gene expression in the pathogenesis of inflammation in sickle cell disease and to determine its role in painful crises.

Methods: A total of 71 patients aged 2 to 18 years, who were followed with the diagnosis of SCD in our department, were included in the study between April 2012 and April 2013. Patients were divided into two groups; Group 1: Patients who had a painful crisis during the study (41 patients, mean age: 11.5 years) and Group 2: Patients who were in steady state during the study (30 patients, mean age: 11 years). Blood samples were taken from the patients for complete blood count, serum levels of C-reactive protein (C-RP), interleukin-1 β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), IGF-1, IGFBP-3 and IGFBP-3 gene expression.

Results: When the patients in both groups were compared in terms of serum IGF-1 level; serum IGF-1 levels were normal in all patients (100%) in group 2 and 33 patients (80.5%) in group 1, and the difference was considered to be statistically significant (p <0.001). When the groups were compared in terms of serum IGFBP-3 level; serum IGFBP-3 level in Group 2 was found to be significantly lower in Group 1 (p <0.001). Also, when the patients were examined for IGF-1 and IGFBP-3 gene expression, no significant difference was found between the groups (Table 1). A negative correlation was found between leukocyte level and IGF-1 in group 1, and IGF-1 gene expression and CRP in group 2. Serum IGFBP-3 and IL-6 levels were found to be significantly lower in patients without any painful crisis than those with painful crisis in the last year (p <0.05).

Table 1.
Summary/Conclusions: The clinical manifestations of SCD were thought to be associated only with hemoglobin polymerization for a long time. However, recent studies have shown that SCD is a chronic inflammatory disease. The pro-inflammatory cytokines and IGFBP are in a state of equilibrium in the human body. It has been reported that IGFBP-1 plays a major role in the production of NO, which is produced in the endothelium and causes a vasodilatory response, and that it increases antioxidant systems and reduces oxidative stress, thereby decreasing inflammation by reducing pro-inflammatory cytokines. In our study, we found that the serum levels of IGFBP-1, an important growth factor that has not been studied previously in SCD and has recently been evaluated on the effects of treatment, decreased in SCD patients with painful crisis compared to patients in steady state. It was also found that the levels of inflammatory cytokines, evaluated during the same period, such as IL-6 and TNF-α increased. In conclusion, IGFBP-1 was thought to play a role especially in the pathogenesis of acute inflammation in SCD.

References:
3. Performed with a grant from Team for Children.

E1489
UNIVERSAL NEWBORN SCREENING FOR SICKLE CELL DISEASE: PRELIMINARY RESULTS OF THE FIRST YEAR OF A MULTICENTRIC ITALIAN PILOT PROJECT
M. Martella1, L. Cattaneo2, G. Viala1, S. Azzera1, A. Cappelli1, E. Baraldi3, C. Zorlino2, N. Maseri1, A. Biondi2, G. Basso1, R. Colombatti1, L. Sainati1
1Clinic of Pediatric Hematology Oncology, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, Italy. Padova, Italy
2Pediatric Clinic, Università degli studi Milano-Bicocca-Fondazione MBBM, Monza, Monza
3Neonatal Intensive Care, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, Italy. Padova, Italy

Background: Sickle cell disease (SCD) is the most common monogenic disease worldwide. Although it is most prevalent in Africa, in parts of the eastern Mediterranean and Asia, as a result of migration, the prevalence is also continuously increasing in central and northern Europe. It is established that early detection and appropriate prophylactic measures prevent potentially fatal complications and many European countries have already introduced newborn screening programs for SCD. In Italy it is estimated that 6.5% of the total population is represented by carriers of hemoglobinopathies, nevertheless, there isn’t a national newborn screening program for SCD nor a plan to establish it. Selective newborn screening programs for SCD are currently active in three regions of Italy, and a pilot universal newborn screening was terminated due to lack of funding. Furthermore, the hospitalization rate for SCD patients is still not clearly defined. Since May 2016 a pilot program of universal newborn screening for SCD is active at the birth center of the Department of Women and Child-Health in Padova, which has about 3,500 births a year. In September 2016 the screening program was extended to San Gerardo Hospital in Monza, also located in Northern Italy, with centralization in Padova for samples analyses.

Aims: To study the feasibility and efficacy of a universal newborn screening for SCD and to evaluate SCD epidemiology in the areas of Padova and Monza.

To identify S gene carriers and affected newborns for a timely taking in charge and to provide genetic counseling for the family. To reduce morbidity and management costs of children with SCD.

Methods: Guthrie cards collected after parents’ informed consent, from an unselected cohort of newborns, are analyzed by HPLC (Variant Newborn Screening-NBS-BioRad). The abnormal hemoglobin fractions identified by HPLC are confirmed by molecular analysis of the β-globin gene (HBB) by PCR and sequencing of the DNA extracted from the dried blood spot. Genetic counseling is offered to the families of infants carriers of the S gene, after notification of the result; families of all infants with SCD are contacted within two months for enrollment in comprehensive care.

Results: Over a period of nine months and five months 1364 and dried blood spots were collected in Padova and Monza respectively. Two families in Padova and 19 in Monza refused the test. The ethnic origin of newborns was similar in the two sites: 64.08% were children of Italian couples, 8.21% of mixed couples and 21.26% of foreign couples in Monza. None of the two sites: 64.08% were children of Italian couples, 8.21% of mixed couples and 21.26% of foreign couples in Monza. None of the two sites: 64.08% were children of Italian couples, 8.21% of mixed couples and 21.26% of foreign couples in Monza. None of the two sites: 64.08% were children of Italian couples, 8.21% of mixed couples and 21.26% of foreign couples in Monza.

Table 1. Summary of screening results.

<table>
<thead>
<tr>
<th>Location</th>
<th>Number of newborns</th>
<th>Sex</th>
<th>Number of newborns</th>
<th>Sex</th>
<th>Number of newborns</th>
<th>Sex</th>
<th>Number of newborns</th>
<th>Sex</th>
<th>Number of newborns</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Padova</td>
<td>1364</td>
<td></td>
<td>45</td>
<td></td>
<td>12</td>
<td></td>
<td>13</td>
<td></td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Monza</td>
<td>19</td>
<td>19</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

From birth. Our preliminary data confirm and support the need for a universal newborn screening that should be extended to the whole country.

E1490
EXTENDING ACCESS TO CARE FOR CHILDREN WITH SICKLE CELL DISEASE THROUGH TELEHEALTH
J. Kanter1, J. Mcelligott1
1Pediatrics, Medical University of South Carolina, Charleston, United States

Background: Sickle Cell Disease (SCD) is the most common inherited blood disorder in the United States and is highly prevalent in South Carolina. Previous work using administrative databases have shown that 25% of affected individuals live in the more rural PeeDee region and seek acute care from community hospitals. As a result, many of these patients have travel >90 minutes for routine SCD care. Due to the difficulty in travel, many patients from this region are seen at frequent intervals with management costs of children with SCD. Moreover, the primary aim of the pilot was to evaluate the feasibility and acceptability of using a telehealth clinic to provide SCD care for children living in a designated rural area. The secondary aims were to improve the clinic adherence for patients living in the rural PeeDee region, decrease the burden of care and expense of travel for affected families and improve Hydroxyurea acceptability and uptake.

Methods: The Medical University of South Carolina (MUSC) Center for Telehealth agreed to sponsor the necessary equipment including the video communication system, moveable camera and tele-stethoscope. A regional partner was identified in the target area willing to host the telehealth clinic. Nurses and Advanced Practice Providers were trained in using the equipment and also trained in spine palpation techniques which cannot be performed using the telehealth system. A local hospital was also identified where routine laboratories can be performed for children seen in the local clinic. Pediatric patients currently seen at the central academic center (MUSC) living in this region were contacted to assess their interest in coming to the telehealth clinic.

Results: The pediatric SCD telehealth clinic was initiated in November, 2014 and data reflects the first 16 months of practice. There were originally 21 patients identified from MUSC of whom 4 families declined interest in participating. Two additional children with known SCD were referred from the local pediatric group for the telehealth clinic who had been designated as “lost to follow up (LTFU).” The clinics were originally scheduled monthly however three were cancelled during the first 16 months and a total of 13 clinics were conducted. There were 64 total visits scheduled of which 50 visits were completed. The overall no-show rate was 14% (range 0-34%) and six clinics had a no-show rate of 0%. The scheduling rate was 78% (range 60-100%). The primary aim was to assess the feasibility and acceptability of a telehealth clinic measured by patients’ and families’ adherence to scheduled appointments. Of the 14 patients with SCD at the beginning of the study, 9 (64%) (9/14) have continued participating in clinic (defined as attending more than 3 clinics in the 16-month period). Prior to starting the telehealth clinic, 10 of the 19 patients had only been seen once in the previous calendar year and 5 of those patients had not been seen in >18 months. Three new patients were started on Hydroxyurea. Two additional referrals to the telehealth clinic were made during the first 13 months (young adults with SCD who had been LTFU for over 3 years). These young adults were seen once by telehealth and then referred to MUSC for the young adult clinic.

Summary/Conclusions: The pediatric SCD telehealth clinic met its primary aim and has continued monthly operations. Hydroxyurea initiation has improved and decreased travel has been welcomed by participating families. Challenges have included equipment issues, difficulties in post-clinic care coordination and assuring caregivers received discharge information. Future directions include a tele-tele Health program from children with SCD at risk for stroke and additional telehealth clinics for adults with SCD that will be utilized for both routine care as well as acute care through the state sickle cell network, (SC). This approach will both harness the resources of the state to approach SCD and will also use a technology-based approach to increase education of providers.

E1491
EMERGING NEED FOR SICKLE CELL DISEASE NEWBORN SCREENING IN ITALY, A EUROPEAN COUNTRY WITH INTENSE MIGRATION FLUXES
D. Venturé1,2, G. Russo3, L. Sainati3, L. De Franceschi2, F. Fagioli5, G.L. Form6, O.T.B.O. SITE-AIEOP 7

1Pediatrics, Medical University of South Carolina, Charleston, United States
Background: The incidence of the Sickle Cell Disease (SCD) has increased in Europe because of the high rate of migration from areas in which carriers of the sickle cell allele account for 19-27% of the entire population. Although SCD is endemic in Southern Italy, the recent migration fluxes spread SCD all over Italy with the number of carriers at about 6.5% of the whole population. The distribution of SCD patients has dramatically changed. The large part of resident immigrants are young with a high fertility rate. Neonatal screening combined with timely diagnostic testing, parental education and comprehensive care management can reduce morbidity and mortality of SCD. Up to now, a national newborn screening program for SCD is not active in Italy and only few pilot studies have been carried out (Ballardini E et al. Blood Transfus. 2013 Apr; 11(2): 245-9; Venturelli D et al., Blood Transfusion 2014; 12: 346-51; Rolfa R et al. Clin Lab 2014; 60 (12): 2089-93).

Aims: To provide recommendation for newborn screening program for SCD in Italy.

Methods: A panel of experts was identified by Italian Society of Thalassemia and Hemoglobinopathies (SITE) and Italian Onco-Hematology Pediatrisation Association (AIEOP). The panel has rigorously reviewed the literature (from 1990 to 2016), the existing recommendations/guidelines of other countries where newborn screening programs already exist and the database system of the AIEOP's Recommendations Assessment, Development and Evaluation) was used to score levels and grades of evidence. The working group produced the draft guideline, and the final version has been revised by external (international) reviewers and the national patients association (UNITED).

Results: The recommendations were divided into five sections according to the newborn screening program as well as: 1) testing of newborns and specific screening methods, 2) evaluation of screening results for a definitive diagnosis, 3) enrollment of affected newborns in comprehensive care programs, 4) evaluations of the efficacy of follow-up and interventions, and assessment of the benefit to the patient, family, and society. The on line access for recommendations will be available for clinicians and healthcare providers.

Summary/Conclusions: The recommendations for SCD newborn screening program will be an important tool in the evaluation of strategic new born screening panel at national level; (ii) to early identify patients to be treated in comprehensive SCD centers and (iii) to produce epidemiological data required for future design of SCD map in Europe.

E1492
GENETIC HEMOLYTIC MARKER IN SICKLE CELL ANAEMIA
P. Pereira Nascimento1,2, L. Souza Torres 3, D. Grung Humberto da Silva 1, J. Viviane Okumura1, E. Belini Junior2, C. Lopes de Castro Lobo3, C. Regina Bonini-Domingos1
1) Departamento de Biologia, Instituto de Biociências, Letras e Ciências Exatas - Ilicile/UNESP - São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil, 2)Medicina - UFMS/CPTL, Universidade Federal de Mato Grosso do Sul, Três Lagoas, 3) HEMORIO, Instituto de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil

Background: The heterogeneity and complexity of the phenotypic profile among individuals with sickle cell anemia (SCA) its one of the principals focus of current research. The SCA, a homozygous condition for Hb S, is a hereditary haemolytic anemia with severe clinical consequences. The intravascular hemolysis is a chronic clinical subphenotype and has been associated as an independent risk factor related to complications such as pulmonary hypertension, leg ulcer and more recently with progression of vasculopathies. Researches has already shown that the heterogeneity of the hemolytic profile can be due to the presence of different beta S-globin gene cluster haplotypes among the individuals, which suggests the participation of genetic factors in the characterization of this subphenotype. Thus, search for genetic variants has been a promising strategy to assist in the individualization of treatments, and favoring clinical evolution. Recent studies showed that the presence of at least one rs7203560 SNP allele (G) of the NPLR3 gene plays a protective role at hemolysis in individuals with SCA, suggesting this variant as a genetic marker of hemolysis. The association between categorical variables (with or without use of HC and different SNP genotypes) by cell-free Hb levels was performed by univariate covariance analysis (GLM), followed by Fisher’s Post Hoc, considering the gender and age co-variates. Statistic software was used and assumed p <0.05 as significant.

Results: Evaluating the recessive model (GG / GT versus TT), we found a significant difference between the different genotypic patterns (p=0.026), and not found in the dominant model. Therefore we performed an analysis of the normalization of SNP in the variation of cell-free Hb levels and hemolysis markers commonly used as hemolysis parameters (relative reticulocytes, the enzymes lactate dehydrogenase and aspartate aminotransferase and unconjugated bilirubin), and we found that the individuals genotypic profile was responsible for 50.7% of the variance of Hb, suggesting that the SNP may play a role in characterizing the hemolytic profile of our patients with SCA.

Summary/Conclusions: The SNP here studied is located in the intronic region of the NPLR3 gene, where the main regulatory elements of the alpha globin gene cluster (HS-48, HS-30 and HS-33) are also found. Studies have already suggested that the protective effect of the G allele of the SNP on the hemolytic activity is probably related to the role of this genetic variant in the expression of the alpha globin genes. Its promising that additinal analyzes in other ethnic groups and models of hemolytic anemias, such as those of an acquired character are realized. This is one of our next step in the attempt to suggest this variant as a genetic marker capable of assisting in the characterization of the hemolytic and prognostic profile of people with SCA.

E1493
ASSESSMENT OF INTERNATIONAL DAY HOSPITALS/INFUSION UNITS FOR THE EVALUATION AND TREATMENT OF SICKLE CELL DISEASE
L. De Castro1,2, J. Jonassaint2
1) Internal Medicine, University of Pittsburgh Medical Center, 2) Internal Medicine, UPMC, Pittsburgh, United States

Background: A Sickle Cell Disease (SCD) Day Hospital is defined as a “dedicated facility for the treatment of SCD uncomplicated painful crises, operating on principle-based pain management”. SCD Day Hospital/Infusion Units (SCD-DH/IU) play a positive role in improving pain management, preventing emergency room visits, hospitalizations, and readmissions. No study to date has systematically surveyed the availability, organization, diagnostic tools/therapy provided, and number of SCD patients treated at these facilities as well as compared these facilities’ practices based on location.

Aims: To evaluated and compare availability and characteristics of key SCD-DH/IU components with the overarching goal of enhancing and standardizing across facilities, guidelines and standard of care and help supporting the development of alike outpatient-care units at other health care institutions and countries.

Methods: A Web-based survey was developed and link to the survey sent via email in September 2016 and January 2017, to 120 health care providers (80 in the USA and 40 in other countries) identified via the Global Sickle Cell Disease Network as caring for individuals with SCD. Responses were collected between September 4 and February 10, 2017. Data was analyzed by descriptive statistics and T tests using Graphpad.

Results: Fifty seven surveys were completed (41% response rate) from 51 unique institutions. Responses from the USA sites, 27 (53%) were, mostly, from long-standing sickle cell institutions in the East, West, and South. Non USA sites, 15 (29%) included Canada, Oman, France, Kuwait, and England. Location of nine sites (18%) was not available. Data from only 42 sites showed: 34 (81%) sites reported having an SCD-DH/IU facility. Thirty-one (73%) sites care for 200 or more individuals with SCD, including 17(40%) caring for more than 400 SCD patients. Self-standing units accounted for 30% of SCD-DH/IU, while most (63%) were part of a multi-speciality unit. Only three site operated 24 hours/day, 7 days/week, while 30% of the sites functioned Monday-Friday, 8am-5pm. Half of the SCD-DH/IU sites treat 1-3 SCD patients, 30% treat more than 10 daily. Treatments available at SCD-DH/IU varied among sites. All performed blood tests, but not all were able to provide IV hydration, IV pain management, and blood transfusions. SCD-DH/IU data such as utilization, therapy outcomes, and admissions/readmissions were tracked by 74% of the sites, only 44% have standard post-discharge/follow-up procedures. ¾ of those were Non-USA sites. Most (69%) sites provide individualized care plans for pain management. Only 23% use Patient Controlled Analgesia (PCA). Most 85% allowed direct hospital admission for patients initially evaluated in the SCD-DH/IU. Seven (19%) sites do not have a dedicated provider (MD/PNP) available to triage SCD patients presenting to the SCD-DH/IU. Twenty (48%) sites do not have a psychologist available to address patients’ psychosocial issues, 21 sites have only a SW, one has only a psychologist, and six neither available. When presented with three different clinical scenarios, sites significantly differed in services availability. Data analyzed based on geographical location, i.e. USA vs Non-USA showed similar trends for high use of data tracking in the USA sites; but higher availability of triage medical staff in Non-USA sites. Notably, 50% of Non USA sites, only treated patients 18 years and younger, p=0.003.
Summary/Conclusions: This is the first study highlighting key healthcare practice data for the small but significant number of SCD Day Hospital/Infusion Units around the globe. Our data suggest that among institutions with SCD-DH/IU there is no consensus regarding clinical practice or data collection. We conclude that there is a significant need to further evaluate SCD DH/IU patient-based value, and to develop operational standards / benchmarks to ensure dissemination, adaptability, and sustainability of these alternative care models.

E1494

REDUCED SERUM HAEMOPEXIN LEVELS IN HAEMOGLOBIN SC DISEASE OCCUR INDEPENDENTLY FROM THE DEGREE OF HAEMOLYSIS

F. Vendrame1,*, L. Marani1, S. Saad1, F. Costa1, K. Feutrín1
1Hematology and Hemotherapy Center, Unicamp, Campinas, Brazil

Background: In intravascular haemolysis, saturation of haptoglobin leads to haemoglobin oxidation and the release of free haem, which is scavenged by haemopexin. In sickle cell patients, this factor has been shown to be decreased in patients with sickle cell disease (SCD). The aim of this study was to evaluate haemopexin levels in children with sickle cell disease (Santiago et al., 2016) and to investigate if haemopexin levels are affected by haemolysis, but intravascular haemolysis does not predominantly affect haemopexin levels.

Methods: Forty HbSC patients (age range 25-68 years, 15 men) and 40 HbAA controls (age range 18-66 years, 28 men) participated in this study. Exclusion criteria were pregnancy, other cause of haemolysis, history of blood transfusion and HbAC disease. Forty HbSC patients (age range 25-68 years, 15 men) and 40 HbAA controls (age range 18-66 years, 28 men) participated in this study. Exclusion criteria were pregnancy, other cause of haemolysis, history of blood transfusion and HbAC disease.

Results: As expected, serum LDH, total and indirect bilirubin, and reticulocyte counts were increased in HbSC patients (P<0.0001). Despite this, no significant difference in total circulating haem was found between HbSC and HbAA (39±2.6 vs 35±1.8 μM respectively, P=0.30), contrary to what has been reported in other haemolytic diseases. Haemoglobin (Hb) was higher in the HbAA group when compared to the HbSC group (15±0.2 vs 12±0.3 g/dL), and considering World Health Organization definitions of anemia for men (Hb below 13 g/dL) and women (Hb below 12 g/dL), 20 (50%) patients in our HbSC cohort were not anaemic, thus fulfilling criteria for compensated haemolysis. HbSC patients with compensated haemolysis were not significantly different from their anaemic counterparts, with similar reticulocyte counts, LDH, bilirubin, haemoglobin (9.83±1.4 mg/dL, 7.73±9.13 g/dL, P=0.10), and total haem levels (33.92±2.4 vs 37.55±2.9 μM, P=0.30).

Summary/Conclusions: Despite the putative importance of reduced haemopexin in the pathophysiology of sickle cell disease, HbSC patients do not always present with haemopexin deficiency, regardless of the intensity of the haemolytic state, and possibly to due to the lesser importance of intravascular haemolysis. Our data suggest that non-anaemic HbSC patients may be equally affected by haemolysis, but intravascular haemolysis does not predominantly regulate haemopexin production. We suggest that excessive free haem and low haemopexin probably represent a lesser contribution to the pathophysiology of complications found in this subgroup of sickling disorders.

E1495

ASSOCIATION OF TOLL-LIKE RECEPTOR 2 GENE POLYMORPHISM WITH THE INCIDENCE OF BACTERIAL INFECTIONS IN SICKLE CELL DISEASE

K. Tozatto-Maio1,2,3,*, R. Girot4, C. Mariaselvam5,6, M. Bennabi5,6, A. Ruggeri1,2, B. Cappelli1,2, R. Krishnamoorty5, B. Pinto Simões3, I. Diagne7, E. Gluckman1, Albert Royer, Dakar, Senegal

Background: Despite antimicrobial prophylaxis and immunization, bacterial infection remains a leading cause of morbidity and mortality in sickle cell disease (SCD) patients. Functional hyposplenism/asplenia partially explains their susceptibility, since even young SCD children with normal spleen are at raised infectious risk. Toll-like receptors (TLR), that recognize pathogen molecular patterns, are at the forefront of immune protection. The interaction between TLR and infectious diseases in SCD patients has never been explored.

Aims: To evaluate if functional polymorphisms in TLR confer susceptibility/resistance to infections in SCD.

Methods: 160 SCD patients followed either in France (n=110) or Senegal (n=56) with recorded history of infections were tested for SNPs in TLR-1, TLR-2, TLR-4, TLR-6 and TLR-10 by TaqMan 5'-nuclease assay for their association with infectious history. Comparisons between groups were evaluated by x² or Fisher exact T-test with Bonferroni corrections of P-value (Pc); associations were measured by odds ratio (OR).

Results: 76 patients were positive for at least one bacterial infectious episode (IP) and 84 had no infection (NIP). Eleven IP had more than one episode of infection. Median age was 25 years (range 4-49) for IP and 23 years (range 3-52) for NIP with no distribution bias in gender (P=0.24). All patients had vaccinations against Streptococcus pneumoniae and Haemophilus influenza B, and patients under 10 years had received penicillin prophylaxis. Ethiological agent was identified in 58 cases with encapsulated bacteria (EB) occurring in 35; the most common agents consisted of Mycobacterium tuberculosis, Streptococcus pneumoniae, Salmonella spp, Escherichia coli and Klebsiella pneumoniae. Sites of infection included respiratory tract (n=24), bone and joints (n=21), blood stream (n=17), urinary tract (n=11), central nervous system (n=8) and abdominal (n=5). TLR-2 rs49669480 TA genotype was less represented in IP than in NIP [45% vs 98%, OR=0.02, 95%CI=0.01-0.09, Pc<0.003] and in particular TLR-2 rs49669480 TA genotype was significantly less frequent in the group of patients infected by EB as compared to NIP+IP with other known etiological agents [51% vs 85%, OR=0.19, 95%CI=0.08-0.44, Pc<0.003]. Other TLR SNPs, genotype and haplotype showed no significant difference between groups.

Summary/Conclusions: rs49669480 TA genotype apparently confers protection against infections especially for EB. Given the previously demonstrated association of AA genotype with exacerbated expression of inflammatory cytokines as well as association of T allele with lower expression of cytokines, it is tempting to postulate that TA genotype can be considered as a compromise between deleterious effects of over inflammatory response (TLR-2 AA genotype) and under response (TLR-2 TT genotype) to infectious agents. Such balanced selection effect is probably reflected by the observed deviation from HWE.

Table 1.
**Stem cell transplantation - Clinical**

E1496

**HIGH PROGNOSTIC VALUE OF PRE-SCT MOLECULAR MINIMAL RESIDUAL DISEASE ASSESSMENT BY WT1 GENE EXPRESSION IN AML TRANSPLANTED IN CYTOLOGIC COMPLETE REMISSION**

A. Candoni1,*, M.E. Zannier1, E. Bertoli1, F. De Marchi1, E. Simeone1, C. Fili1, J. Wang1, Y. Wang1, C. Yan1, Y. Sun1, F. Tang1, X. Zhang1, X. Huang1

1Hematology and BMT Unit, 2Immunohematology and Transfusion Unit, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China, Beijing, China

**Aims:** We analyzed the outcome of allogeneic Stem Cell Transplantation (allo-SCT) in AML patients according to molecular Minimal Residual Disease (MRD) at the pre transplantation (pre-SCT) workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms’ tumor gene (WT1), according to LeukemiaNET validated method.

**Methods:** 122 consecutive AML patients received allo-SCT while in cytotropic Complete Remission (cCR), between 2005 and 2016, at our Center. The median age at SCT was 53 years (18-70). The quantitative analysis of the WT1 gene expression (bone marrow samples) was available in 100% cases, both at diagnosis (100% overexpressing WT1 with a mean of 8607±8187 copies/10⁴ Abelson) and before allo-SCT (81/122: 66.6%; MRD-WT1-negative and 41/122- 44% MRD-WT1 positive cases at the pre-SCT workup).

We evaluated pre-SCT Overall Survival (OS), Disease Free Survival (DFS) and Relapse Rate, according to MRD-WT1 pre-SCT status.

**Results:** Both OS, DFS and DFS were significantly better in patients who were MRD-WT1 negative (WT1<250 copies) at the time of SCT compared with those who were MRD-WT1 positive (WT1>250 copies), with a median OS and DFS not reached in the MRD-WT1 negative group and 9 and 8 months, respectively, in the MRD-WT1 positive group (OS log-rank p=0.0001; hazard ratio 3.29, 95% confidence interval [95% CI]:2.0-5.36; DFS log-rank p=0.0001; HR=3.73, 95% CI=2.0-6.72). The relapse rate after allo-SCT was 15% (12/81) in pre-SCT MRD-WT1 negative cases and 44% (18/41) in MRD-WT1 positive cases (p=0.0073). At univariate analysis, MRD-WT1 negativity before allo-SCT and grade 2 acute GVHD were significant prognostic factors for improved OS and DFS. However, at multivariate analysis, MRD-WT1 negativity before allo-SCT was the only independent prognostic factor for improved OS and DFS.

**Summary/Conclusions:** These data show that pre-allo-SCT molecular MRD evaluation through WT1 expression is a powerful predictor of post-SCT outcome (OS, DFS, relapse rate). Patients with both cCR and a MRD-WT1 negative outcome have been reported to identify patients, transplanted in cCR, who are at high risk of relapse and who could be considered for conditioning regimen intensification and/or for the use of alternative strategies (e.g. lymphocyte infusion, tapering of immunosuppression, azacitidine or new target drugs).

E1497

**GOOD IMMUNOLOGICAL RECONSTITUTION IN ADULTS WITH ACUTE LEUKEmA AFTER ALFA-BETA TCR/CD19+ DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HSCT)**

L. Prezioso1, L. Bononini1, C. Schifano1, I. Manoli1, I. Manfra1, A. Spolzino1, G. Sammarelli1, L. Craviotto1, M. Sassi2, M. Soli2, F. Aversa1

1Hematology and BMT Unit, 2Immunohematology and Transfusion Unit, Parma, Italy

**Background:** Haplo-HSCT based on the infusion of high numbers of T cell depleted (TCD) hematopoietic progenitor cells and no post-transplant immunosuppression controls both graft rejection and GVHD in patients with acute leukemia. One major remaining issue is the delay in the post-transplant immunological reconstitution because of the minimal residual T lymphocytes in the graft and in vivo ATG-linked T cell depletion. Current studies are focusing on rebuilding posttransplant immunity to improve clinical outcomes separating GVHD from favourable donor immune responses. Selection of αβ+ T cells retains in the graft NK, dendritic cells, monocytes and γδT lymphocytes. Under this approach, a rapid immunological reconstitution and very promising outcome have been reported in pediatric patients.

**Aims:** With the aims of confirming these results in adults, we tested this approach in adults with acute leukemia.

**Methods:** Thirty-two patients, median age 51 years (range 19-74), with AML (n=25), ALL (n=5) entered to study. Twenty were in CR (12 CR1; 8 CR2); 12 in advanced-stage disease at transplant. Conditioning consisted of ATG 1.5mg/kg from day -13 to -10, Treosulfan 12 gr/qm from -9 to -7, Fludarabine 30mg/m² from -6 to -2 and Thiopeta 5mg/kg on days -5 and -4. PBPCs from haplo-donor (3 mothers, 9 siblings, 13 sons/daughters and 7 cousins) under-went αβTCR/CD19+ depletion by CliniMACS. No post-transplant immunosuppression was given. Ganciclovir was given over the conditioning regimen in the 22 patients who were CMV seropositive; L-AmB was used as anti-mold active prophylaxis over the neutropenic phase.

**Results:** Grafts contained a median of 11x10⁶/kg (range 5-19) CD34+ cells, 4.3x10⁶ CD3-Tcells/kg (range 1-36), 4.6x10⁴/kg (range 0.4-62) αβ+ T cells, 4x10⁹/kg CD19+ cells/kg (range 1-34), 5x10⁸ B cells/kg (range 1.5-32) and 22x10⁶ CD56NK cells/kg (range 5-91). All patient achieved a full donor sustained engraftment. Median time to reach 500 neutrophils and 20,000 platelets was 13 (range 10-18) and 11 days (range 6-30), respectively. Two patients developed and died from severe acute GVHD. One of them had received the highest dose of αβ+ T cells (3.7x10⁶/kg) and the second one affected by 6GPDH deficiency experienced a late onset hepatic GVHD. Eight patients had skin limited grade II aGVHD that required short course steroids. Only two patients have so far developed mild cGVHD that recovered completely after steroid and cyclosporin treatment. Tending to confirm our working hypothesis, there was a rapid, sustained increase in peripheral blood T-cell subpopulations (Fig. 1). Naïve and memory T-cell subsets increased significantly over the first year after transplantation. B-cell reconstitution was rapid and sustained and immunoglobulin serum levels normalized within 3 months. CMV reactivation only occurred in 15% (2/12 in relapse, 3/20 in CR) of the 30 patients who were at risk (positive 2 or more CMV reactivations). One with unfavorable serology (donor negative into recipient positive) developed and died of CMV disease 8 months after transplant. Relapse was the main cause of failure (8/12 in relapse, 3/20 in CR). NRM was 15% (4/12 in relapse, 4/20 in CR), 13 patients survive at a median follow-up of 29 months (range 5-53).

**Summary/Conclusions:** The infusion of αβ/CD19-depleted grafts confirmed a fast immunologoical reconstitution also in adults. Relapse is still a major concern in patients already in relapse at transplantation.
23 patients showed prompt recovery of neutrophils and platelets. So far, despite the infusion of higher numbers of T-cells, no increase of GVHD was apparent. Similar after both types of mobilization. No graft failures were observed and all patients engrafted with prompt recovery of granulocytes >0.5 x 10^9 L at a median of 19 days (0-27) and platelet recovery >50 x 10^9 L at day 13 (0-23). Acute graft-versus-host disease (GVHD) grade 1-4 was observed in 6 out of 23 patients, 2.3% (0.5-4.4) and 1.3% (0.2-25.9) respectively, 2.5% (0.5-4.4) versus 2.3% (0.2-25.9) versus 1.4% (0.2-5). The unmanipulated grafts were infused according to local protocol and contained a median of 3.5 x 10^6/kg CD34+ cells (range:1.9-6.5). All patients engrafted with prompt recovery of granulocytes >0.5 x 10^9 L at a median of 19 days (0-27) and platelet recovery >50 x 10^9 L at day 13 (0-23). Acute graft-versus-host disease (GVHD) grade 1-4 was observed in 6 out of 23 patients, including 2 with grade 3 and no grade 4. Chronic extensive GVHD was observed in 9 patients.

Summary/Conclusions: Stem cell mobilization by sc PFX is feasible in HLA identical sibling donors with limited side effects and results in sufficient numbers of CD34+ cells for transplantation. While absolute numbers of CD34+ cells were higher after G-CSF mobilization, the subset of phenotypic stem cells was similar after both types of mobilization. No graft failures were observed and all 23 patients showed prompt recovery of neutrophils and platelets. So far, despite the infusion of higher numbers of T-cells, no increase of GVHD was apparent.

A FEASIBILITY STUDY OF THE FULL OUTPATIENT CONDUCT OF HEMATOPOIETIC TRANSPLANTATIONS IN PERSONS WITH MULTIPLE SCLEROSIS USING AUTOTRANSPLANTATION OF PHOTODYNAMICALLY CRYOPRESERVED HEMATOPOIETIC STEM CELLS

G.J. Ruiz Arguelles1, A. Leon Peña2, M. Leon Gonzalez1, A.K. Nuñez Cortés1, J.C. Olivares Gazca1, J. Vargas Espinosa1, E. Medina Ceballos1, Y. Cantero Fortiz1, J.A. Arizaga Berber1, M.S. Torres Priego1, A. Ruiz Arguelles1, M. Ruiz Arguelles1, R. Ruiz Delgado1, G. Ruiz Reyes1, M. Priesca Marin1, G. Ruiz Delgado1 1Hematología, Centro de Hematología y Medicina Interna, Puebla, Mexico

Background: With the goal of immune system reset, autologous hematopoietic stem cell transplantsations have been done in patients with multiple sclerosis (MS). Aims: With the goal of immune system reset, autologous hematopoietic stem cell transplantations have been done in patients with multiple sclerosis (MS).

Methods: 131 consecutive patients with MS were autografted in a single center using non-frozen peripheral blood stem cells, on an outpatient basis and conditioning with cyclophosphamide (Cy) and rituximab. The protocol was registered in ClinicalTrials.gov identifier NCT02674217. The PBSC mobilization schedule was done with Cy and Filgrastim (G-CSF). Intra venous Cy (50mg/kg) was delivered on days -11 and -10. Sustanunato C-CSF (10ug/Kg/BID) was delivered on days -9 to -1. The apheresis procedure was performed on day -2. The apheresis objective was to reach at least 1 x 10^6 viable CD34+ cells/kg. As outpatients and after collecting the PBSC, intra venous Cy (50mg/kg) was delivered over a 120 minute period, on days -2 and -1 followed by MESNA (1000mg/m2 over a 180 minute period). After the intravenous Cy, oral ondasetron, oral cotrimoxazole, oral fluconazole and oral acyclovir were used in all patients until granulocytes were greater than 0.5x10^9 L. After the recovery of the granulocytes, patients were given rituximab (375mg/m2 over 3 hours) and subsequently rituximab (100mg) every two months over a 12-month period. The cumulative dose of Cy is 200mg/Kg.

Results: 80 females and 51 males were included; median age was 47 years. 26 have PPMS, 42 RRMS, and 61 SPMS. All procedures were started on an outpatient basis and two persons were admitted to the hospital during the procedure. In order to obtain at least 1x10^6/kg viable CD34 cells, one to four apheresis were performed (median 1). Total number of viable CD34+ cells infused ranged between 1 and 9.6x10^6/kg (median 2.2). Patients recovered and 100% of patients on median day 9 (range 6 to 12). Two individuals needed red blood cells but none needed platelet transfusions. There were no transplant related deaths and the 125 month overall survival of the patients is 100%. In a subset of 78 persons followed for 3 months or more the EDSS (Expanded Disability Status Scale) was assessed three months after the graft and means diminished from 5.2 to 4.9. The EDSS score improved in 33 patients (42.3%), remained stable in 29 (37.1%) and worsened in 16 (20.5%). Best results of EDSS were found in Relapsing Remitting (82%) and Primary Progressive (80%) type of MS compared to Secondary Progressive (71.4%).

Figure 1.

Summary/Conclusions: It is possible to conduct autotransplants for patients with MS employing non-frozen peripheral blood stem cells and outpatient conduction. Additional information is needed to assess the efficacy of these procedures in the treatment of patients with MS.

E1501 VEDOLIZUMAB IN STEROID REFRACTORY INTESTINAL GASTRIF-VER-SUS-HOST DISEASE A.E. Myhre1,*, J.D. Kristiansen1, K.E.A. Lundin2, L.T.N. Osnes3, D.J. Warren4, K. Bremnes5, M. Korsnes2, K. Drevon3, E. Sandsvåg1 1Hematology, 2Gastroenterology, 3Immunology, 4Medical Biochemistry, Oslo University Hospital, Oslo, Norway

Background: Steroid refractory intestinal graft-versus-host disease (GVHD) is an important complication after allogeneic hematopoietic cell transplantation (allo-HCT), and treatment options are limited. We have previously described successful treatment of this condition with the antibody vedolizumab, targeting the homing of allogeneic T-cells to the intestinal mucosa by inhibiting the binding of T-cell integrin α4β7 to mucosal addressin MadCAM-1.

Aims: Explore outcome of all patients treated with vedolizumab in our department.

Methods: Prospective case series of 13 patients with steroid refractory gastrointestinaleal GVHD. Patients received 300mg of intravenous vedolizumab at weeks 0, 2 and 6, followed by infusions every 8 weeks if deemed necessary.

Figure 1.

Summary/Conclusions: It is possible to conduct autotransplants for patients with MS employing non-frozen peripheral blood stem cells and outpatient conduction. Additional information is needed to assess the efficacy of these procedures in the treatment of patients with MS.
Results: All 13 patients experienced clinical responses, which were confirmed by endoscopies and in mucosal biopsies. 10 patients (77%) achieved a clinical response within 28 days, and half of these were complete responses. At last follow-up 10 patients (77%) had achieved sustained complete responses, 2 patients (15%) had responded partially and 1 patient (8%) suffered disease progression. 7 patients (54%) were alive after a median follow up of 35 weeks. The causes of death were transplantation related toxicity, GVHD in other target organs and infectious complications. Increased relative counts of CD25++/CD127low regulatory T-cells prior to treatment were observed in peripheral blood of 7 of 9 evaluable patients, and the relative counts decreased in all 7 patients during follow-up.

Summary/Conclusions: Our results indicate that vedolizumab may effectively treat steroid refractory cases of intestinal GVHD and is well tolerated. The mechanism of action is believed to be inhibition of allo-reactive T-cells interacting with intestinal endothelial cells. It is unclear why regulatory T-cells were increased in our steroid refractory GVHD patients and subsequently normalized. This might imply a response to the alloreactive inflammation and subsequent redistribution to affected tissues and/or its resolution after successful treatment.

E1502
RISK FACTORS, OUTCOMES AND CHARACTERIZATION OF ‘AUTOLOGOUS GRAFT VERSUS HOST DISEASE’: THE MAYO CLINIC EXPERIENCE
T. Aranagusto1, J. Paludo1, M.M. Patnaik1, M.R. Litzow1, D.A. Gastineau1, N. Duma1, F.K. Buadi1, L.F. Porrata1, G. Goyal1, J.S. Lehman1, S.K. Hashmi1, S.S. Kenderian1
1Hematology/Medical Oncology, Mayo Clinic, Rochester, United States

Background: Graft versus Host Disease (GVHD) is a common complication of autologous stem cell transplantation (SCT) which is caused by the recognition of recipient antigens by the donor T lymphocytes. Acute GVHD remains a major cause of morbidity and mortality and half of the cases are refractory to steroids. The development of GVHD after autologous SCT (ASCT) is a poorly understood phenomenon. While some experts suggest that such an entity does not exist, some ASCT recipients develop clinical and histo-pathological changes similar to GVHD after allogeneic SCT.

Aims: In this analysis, we aimed to elucidate the factors that affect the outcomes of patients with autologous GVHD.

Methods: This is a retrospective analysis of patients that received ASCT at Mayo Clinic between January 2006 and December 2016. Autologous GVHD was defined as the development of clinical and histo-pathological findings indicative of GVHD in ASCT recipients, as determined by pathology review. Survival was estimated and compared using the Kaplan Meier and Log rank tests. The study was approved by the institutional review board.

Results: Between 2006 and 2015: 3,891 consecutive patients underwent ASCT. Of these, 35 patients (0.9%) developed symptoms suggestive of GVHD warranting biopsies. In 19 of these 35 patients (54%), the histopathological changes were consistent with GVHD. The most common underlying disease in patients with developed GVHD was multiple myeloma (14 patients, 73.7%) and the most common conditioning regimen used was melphalan (16 patients, 84.2%). The median age at ASCT was 61.9 (range 49.2-72.6) years and the median time from disease diagnosis to ASCT was 3.1 (0.3-9.6) years. The median number of prior therapeutic regimens was 2 (range 1-7). GVHD manifested with gut involvement in all 19 patients, skin involvement in 8 patients (42.1%) and liver involvement in 2 patients (10.5%). The median time to symptom onset was 11 (range 3-80) days and the median time to GVHD diagnosis was 12 (range 2-162) days. Most patients (14, 73.7%) had grade 3 or 4 GVHD and the clinical grading correlated with the histopathologic grading in all patients. GVHD was treated with autologous GVHD. 5 (26.3%) died due to complications of GVHD or its treatment. Delay in initiation of steroids beyond 1 week was associated with lower response rates to treatment (30.8% vs 69.2%, p=0.03), longer duration of symptoms of GVHD (median 28 vs 4 days, p=0.02), and a trend towards worse 1-year OS (64.5% vs 83.3%, p=0.1). Higher steroid doses (≥5 mg/kg) were associated with a trend towards better complete response rates (76.9% vs 23.1%, p=0.5), although this difference did not reach statistical significance.

Table 1.

Summary/Conclusions: Our findings suggest that autologous GVHD is associated with significant mortality and early initiation of treatment with steroids results in improved outcomes. Further studies into the mechanisms of the disease are warranted.

E1503
CNS DEMYELINATION AFTER HAPLO-HSCT AND ITS ASSOCIATION WITH THE IGG INTRATHECAL SYNTHESIS INDEX AND ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY IN CEREBROSPINAL FLUID
X. Zhao1, Q. Wang1, J. Zhang1, X. Zhu1, Y. He1, L. Xu1, W. Han1, H. Chen1, Y. Chen1, F. Wang1, J. Wang1, Y. Zhang1, X. Mo1, Y. Chen1, Y. Wang1, Y. Chang1, L. Xu1, K. Liu1, X. Huang1, X. Zhang1, Y. Wang1, X. Mo1, Y. Chen1, Y. Wang1
1Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China

Background: Haploidentical haemopoietic stem cell transplant (haplo-HSCT) is an upfront and effective therapy for haematological patients, but it usually has many complications such as neurological complications. As one of the neurological complications following haplo-HSCT, immune-mediated demyelinating diseases of the central nervous system (CNS) seriously affect the patient quality of life. However, the incidence, risk factors and pathogenesis of CNS demyelination are not very well understood.

Aims: To analyse the incidence, risk factors, and prognosis of CNS demyelination after haplo-HSCT.

Methods: A study was conducted in 1,526 patients who underwent haplo-HSCT between January 2013 and June 2016. The definition of CNS demyelination during haplo-HSCT was confirmed by neurologic signs, MRI abnormality corresponding to the neurologic signs, abnormal CSF studies and the presence of systemic GVHD or the response to immunosuppressive therapy (Grauer O et al. Brain. 2010; 133(10): 2852-2865, Chronic graft versus host disease. 612 | haematologica | 2017; 102(s2)
these biomarkers, suggesting they strongly reflect patients' physiological status. Alk-p was dropped out in the multivariate analysis. Prediction models for day-100 and 2-years TRM, based on only HCT-CI, had AUCs of 56.4 and 58.6, respectively. The introduction of both albumin and CrCl, separately or combined, resulted in incremental improvement in AUC, topping at 66.1 (+17% increase) and 63.2 (+8% increase), for day-100 and 2-years TRM, respectively (Figure panel b). The improvement was maintained in all conditioning and donor subgroups.

Results: Thirty patients developed CNS demyelination after haplo-HSCT. The cumulative incidences of the diseases at 100 days, 1 year and 2 years post transplantation were 0.6%, 1.6% and 2.3%, respectively. The mean age at the time of presentation was 26.5 years (range, 10-52 years), and the mean time from transplant to the onset of neurologic symptoms was 216 days (range, 17-844 days). Nineteen patients received a corticosteroid pulse, five patients received immunoglobulin, and six patients received supportive treatment and an antiviral medication in immunosuppressive symptoms improved in all patients. The mean duration from the time of improvement to deterioration was 5 days (+4). In univariate analysis, we found that BBB permeability and the CSF IgG intrathecal synthesis index were related to the occurrence of CNS demyelination (p<0.1). In multivariate analysis, the CSF IgG intrathecal synthesis index (OR=1.017; 95% CI: 1.003-1.031; p=0.019) and CSF myelin oligodendrocyte glycoprotein antibody (OR=12.059; 95% CI: 1.141-127.458; p=0.038) were independently associated with the onset of CNS demyelination. We also studied the possible pathogenesis of CNS demyelination. Immune reconstitution (the cell proportion of CD19+B cells, CD3+ T cells, CD4+ T cells), the count of leukocytes, lymphocytes, monocytes and platelets, as well as the level of immunoglobulins A, G and M +30 days, +60 days, and +90 days after H SCT showed no significant differences between CNS demyelination and no demyelination (P>0.05). The probabilities of overall survival showed no significant differences between patients with and without demyelination.

Summary/Conclusions: The CSF IgG intrathecal synthesis index and CSF anti-myelin oligodendrocyte glycoprotein antibody are independently risk factors for the onset of CNS demyelination after haplo-HSCT and have no influence on long-term survival. Immune reconstitution may not be pathogenesis of CNS demyelination.

**E1504**

**BASELINE CREATININE CLEARANCE AND ALBUMIN ARE POWERFUL RISK FACTORS FOR ALLOGENEIC TRANSPLANTATION RELATED MORTALITY**

R. Shouval1, N. de Jong2, J. Fein1, E. Braakman2, A. Broens3, J. Kuipers3, N. Shem-Tov1, I. Danyleska1, R. Yerushalmi1, A. Shimon1, A. Nagler1, J. Cornelissen2

1Hematology Division, Chaim Sheba Medical Center, Tel-HaShomer, Ramat-Gan, Israel, 2Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

**Background:** The follow up along allogeneic hematopoietic stem cell transplantation (HSCT) varies between individuals. Baseline comorbidities, commonly scored by the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), are important determinants of transplant risk. However, their prognostic utility varies and only partially accounts for transplantation-related mortality (TRM). Standard pre-HSCT laboratory carries objective physiologic information which can be used for TRM risk estimation.

**Aims:** Determine the value of pre-HSCT estimated creatinine clearance (CrCl), albumin, and alkaline phosphate (Alk-p) for TRM prediction.

**Methods:** The study population included 1,217 patients from two European centers. Indications for transplantation and conditioning regimes were diverse. Donors were either HLA-matched sibling donors (54%), matched unrelated donors (30%), or 9/10 HLA-mismatched unrelated donors (15%). The impact of CrCl, albumin, and Alk-p on TRM was evaluated in a univariate and multivariate analysis. Disease status, donor-recipient sex mismatch, donor type, cytomegalo virus serostatus, and conditioning intensity. Relapse was considered a competing event for TRM. The predictive benefit of adding the laboratory markers to the HCT-CI score was estimated by calculating the area under the receiver operating curves (AUC) of TRM prediction models, with and without the biomarkers.

**Results:** Patients had a median age of 55 years and HCT-CI scores of 0 (24%), 1-2 (39%), and ≥3 (37%). A cut-off of CrCl<60 ml/min, albumin<3.5 g/dl, and Alk-p>180 IU/l corresponded with 8.8%, 8.3%, and 6.5% of the population, respectively. CrCl and albumin were associated with increased risk and higher cumulative incidence of day-100 TRM, disease status, donor-recipient sex mismatch, donor type, cytomegalo virus serostatus, and conditioning intensity. Relapse was considered a competing event for TRM. The predictive benefit of adding the laboratory markers to the HCT-CI score was estimated by calculating the area under the receiver operating curves (AUC) of TRM prediction models, with and without the biomarkers. Results: Donors were either HLA-matched sibling donors (54%), matched unrelated donors (30%), or 9/10 HLA-mismatched unrelated donors (15%). The impact of CrCl, albumin, and Alk-p on TRM was evaluated in a univariate and multivariate analysis. Disease status, donor-recipient sex mismatch, donor type, cytomegalo virus serostatus, and conditioning intensity. Relapse was considered a competing event for TRM. The predictive benefit of adding the laboratory markers to the HCT-CI score was estimated by calculating the area under the receiver operating curves (AUC) of TRM prediction models, with and without the biomarkers.

**Results:** Patients had a median age of 55 years and HCT-CI scores of 0 (24%), 1-2 (39%), and ≥3 (37%). A cut-off of CrCl<60 ml/min, albumin<3.5 g/dl, and Alk-p>180 IU/l corresponded with 8.8%, 8.3%, and 6.5% of the population, respectively. CrCl and albumin were associated with increased risk and higher cumulative incidence of day-100 TRM, disease status, donor-recipient sex mismatch, donor type, cytomegalo virus serostatus, and conditioning intensity. Relapse was considered a competing event for TRM. The predictive benefit of adding the laboratory markers to the HCT-CI score was estimated by calculating the area under the receiver operating curves (AUC) of TRM prediction models, with and without the biomarkers. Results: Donors were either HLA-matched sibling donors (54%), matched unrelated donors (30%), or 9/10 HLA-mismatched unrelated donors (15%). The impact of CrCl, albumin, and Alk-p on TRM was evaluated in a univariate and multivariate analysis. Disease status, donor-recipient sex mismatch, donor type, cytomegalo virus serostatus, and conditioning intensity. Relapse was considered a competing event for TRM. The predictive benefit of adding the laboratory markers to the HCT-CI score was estimated by calculating the area under the receiver operating curves (AUC) of TRM prediction models, with and without the biomarkers.

**Results:**

**Summary/Conclusions:** Pre-transplantation CrCl and albumin are powerful risk factors for TRM. Deviations from normal ranges were frequent in our cohort, making them useful prognostic markers. We report for the first time the role of CrCl in HSCT prognostication, rather than the traditional HCT-CI cut-off of Creatinine >2mg/dl, which is rare in HSCT population (<1% in our cohort). We also corroborate albumin’s important prognostic role. Incorporation of these simple biomarkers can improve pre-transplant risk stratification and potentially be used as a tool for treatment personalization.

**E1505**

**CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS**

F. Guolo1, P. Mineto1, P. Minetto1, M. Clavio1, F. Galaverna2, D. Guardo1, M. Clavio1, D. Guardo1, E. Coviello1, N. Colombo1, N. Colombo1, F. Ballerini1, F. Ballerini1, M. Miglino1, C. Di Grazia2, A.M. Riolto2, R.M. Lemoli2, M. Gobbi1, M. Miglino1, R.M. Lemoli1, M. Gobbi1, A. Bacigalupo2

1Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, 2Division of Hematology and Bone Marrow Transplantation, IRCCS AOI San Martino-IST, Genova, Italy

**Background:** Allogeneic bone marrow transplantation (BMT) offers the only chance of cure for patients with advanced acute myeloid leukemia (AML). High levels of pre BMT minimal residual disease (MRD) have been reported to predict relapse risk in patient transplanted in first complete remission (CR). WT1 expression levels and multicolor flow cytometry (MFC) are the most common tools to evaluate MRD.

**Aims:** Here, we analyzed the role of pre-BMT MRD assessment as predictor for the post-transplant relapse risk in patient transplanted beyond first CR.

**Methods:** We retrospectively analyzed the outcome of 92 consecutive AML patients receiving allo-BMT in 2nd (CR2) or 3rd (CR3) Pre-BMT MRD was evaluated by WT1 expression and MFC. Median age at transplant was 45 years. Disease phase was CR2 in 63 patients (68%) and CR3 in 29 (32%). Risk group according to European Leukemia Net (ELN) at diagnosis was low in 28 patients (30%), intermediate in 44 (48%) and high in 20 (22%). Sixty-six patients (71%) received myeloablative conditioning, whereas 26 (29%) were conditioned with reduced intensity regimen. Stem cell source was HLA-identical (HAPLO) in 24 (26%) and alternative donor in 50 (54%). Median follow-up was 64 months (95% CI 39.8-88.2 months). A powerful MRD FMC was defined by the presence of at least 1x10^4 residual leukemic cells at four or eight (since 2011) color flow-cytometry. WT1 copy

**Figure 1.**

**Summary/Conclusions:** Pre-transplantation CrCl and albumin are powerful risk factors for TRM. Deviations from normal ranges were frequent in our cohort, making them useful prognostic markers. We report for the first time the role of CrCl in HSCT prognostication, rather than the traditional HCT-CI cut-off of Creatinine >2mg/dl, which is rare in HSCT population (<1% in our cohort). We also corroborate albumin’s important prognostic role. Incorporation of these simple biomarkers can improve pre-transplant risk stratification and potentially be used as a tool for treatment personalization.
number/Abl copy number 250x10^4 was used as cut-off value for abnormal WT1 expression.

Results: Relapse occurred in 30 patients (33%) and two years non-relapse mortality was 29%. Three-year estimate of OS was 47.9% (median 19 months). The survival probability was significantly affected by donor source (better for HAPLO, p<0.05), ELN at diagnosis (better for ELN low risk, p<0.01), MRD status, BMT donor source and MRD status (better for WT1-based MRD, p<0.03 for MFC based MRD) and CR status at BMT (better for CR2, p<0.05).

Specifically patients transplanted in a MRD negative status had comparable OS irrespective of ELN at diagnosis (2-years OS of 62.2% and 52.7% among MFC MRD negative patient with ELN risk low or intermediate/high, respectively, Fig.1). The predictive value of MRD resulted independent from all other analyzed variables, although patients with positive MRD undergoing HAPLO BMT had a slightly better outcome. Multivariate OS analysis revealed that MRD status (evaluated by any method) was the only independent predictor of OS (p<0.05 for both). Pre BMT MRD was also a strong predictor of cumulative incidence (CI) of relapse in competitive risk analysis (p<0.01 and p<0.03, respectively, for WT1 and MFC MRD). Multivariate CI of relapse analysis showed that donor source and MRD significantly influenced relapse risk (p<0.05 and <0.01, respectively).

Aims: There are limited data concerning the impact of specific HLA mismatches on patient outcome and we therefore interrogated the EBMT database in order to characterize the impact of mismatch on transplant outcome.

Methods: 937 patients with AML in CR1 or CR2 underwent transplantation utilizing a RIC regimen using a 9/10 mismatched unrelated donor between 2001-2015. Of these 264 were transplanted using a donor mismatched at HLA-A, 127 were mismatched at HLA-B, 292 mismatched at HLA-C, 180 mismatched at HLA-DQ and 74 mismatched at HLA-DR. 85% of patients received in vivo T cell depletion.

Results: The 2 year leukemia free survival (LFS) for the whole cohort was 45% and the 2 year overall survival (OS) was 50%. The corresponding non-relapse mortality was 26%. Pre BMT MRD was also a strong predictor of cumulative incidence of relapse (CI) of relapse in competitive risk analysis (p<0.01 and p<0.03, respectively, for WT1 and MFC MRD). Multivariate CI of relapse analysis showed that donor source and MRD significantly influenced relapse risk (p<0.05 and <0.01, respectively).

Summary/Conclusions: To our knowledge this is the largest to date studying the impact of specific HLA mismatch on the outcome of adults undergoing a RIC allograft from an adult unrelated donor. Recipients of HLA-A, B, C, DRB1 and DQ mismatched allografts demonstrated equivalent outcomes. Patient/donor CMV disparity is an important adverse prognostic factor in HLA mismatched transplants. These data have the potential to inform donor selection in allo-mandatory adults with AML undergoing a RIC allograft who lack a 10/10 matched donor.

E1506 IMPACT OF ALLELE SPECIFIC PATIENT:DONOR HLA DISPARITY ON OUTCOME OF REDUCED INTENSITY TRANSPLANTS PERFORMED USING HLA MISMATCHED UNRELATED DONORS: ON BEHALF OF THE ALWP OF THE EBMT

C. Craddock1,*, M. Labopin2, D. Niederwieser3, J. Cornelissen4, B. Afanasyev5, C. Maertens6, J. Ganser11, B. Savani12, M. Mohty13, A. Nagler14
1Department of Haematology, University of Birmingham, Birmingham, United Kingdom, 2Department of Haematology, EBMT Saint Antoine Hospital, Paris, France, 3Oncology and Haematology, University Hospital Leipzig, Leipzig, Germany, 4Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands, 5First State Pavlov Medical University of St Petersburg, St Petersburg, Russian Federation, 6Haematology, University Hospital Gasthuisberg, Pilsen, Czech Republic, 7Haematology, University Hospital Gasthuisberg, Leuven, Belgium, 8Centre de Recherche en Cancérologie de Marseille, Marseille, France, 9Karolinska University Hospital, Stockholm, Sweden, 10Division of Stem Cell Transplantation and Immunotherapy, University Medical Center Schleswig-Holstein, Kiel, 11Haematology, Hanover Medical School, Hanover, Germany, 12Department of Medicine, Vanderbilt University, Tennessee, United States, 13Haematology, St Saint Antoine, Saint Antoine, France, 14Chaim Sheba Medical Center, Tel Hashomer, Israel

Background: Allelic gene stem cell transplantation (allo-SCT) represents an increasingly important curative treatment strategy in adults with acute myeloid leukemia (AML), consequent upon both the increased availability of unrelated donors and the advent of reduced intensity conditioning (RIC) regimens. Although optimal outcomes are achieved in patients transplanted using an unrelated donor matched at 10/10 HLA-A, B, C, DRB1, DQ alleles it remains the case that many undergo transplantation using a donor matched at only 9/10 HLA alleles.

Methods: Retrospectively analyzed 986 acute leukemia patients undergoing allo-HSCT from Jan.2006 to Mar.2014 in our hospital. After allo-HSCT, 896 AL patients were periodically monitored the minimal residual disease(MRD) including: bone marrow smear, leukemia-associated immunophenotype (LAIP), leukemia specific or related fusion genes, and donor chimerism through multi-parameter detection to evaluate disease status. Patients were given IFN-α-2b 2-3 million units/day by subcutaneous injection for preemptive treatment once a relapse tendency was detected, such as: increasing proportion of blast in bone marrow between 3–5%, or MRD>1.0×10^3, or leukemia specific fusion gene transform negative to positive, or dynamic increasing copy number of WT1 more than 200 copies/10^4 abl, or decreasing of donor chimerism(≤90%). There were 98 patients who presented increasing tendency of MRD and were enrolled in this study. Among them, 31 patients received IFN-α-2b preemptive therapy, and 67 patients received non-IFN-α-2b therapy as such: immunosuppresant, traditional DLI or DC-CIK immunotherapy.

Results: There were no significant differences in disease characteristics between two groups. For the 31 patients who received IFN-α-2b pre-emptive therapy(IFN group), the median time of IFN-treatment was 60 days (range: 5–720 days), Twenty five patients had responded to the treatment without progression to hematological relapse (response rate 80.6%). 2 patients developed to hematological relapse again after temporary response; 3 patients had no response and eventually progressed to hematological relapse. Regarding 67 patients who received non-IFN-α-2b therapy, 45 patients failed to the treatment and progressed to hematological relapse at a median time of 35 (range: 6–940) days. There was significant difference of RR between two group (P=0.0001). 31 patients of IFN group tolerate well and no patient terminated therapy due to adverse reactions. In the IFN group, 11 patients (35.5%) were followed-up more than 5 years after allo-SCT; 6 patients 19.4% with aGvHD and 14-45.2% with limited cGvHD. The median follow-up time was 21-4.5-78.5 months. 22 of 31 cases of IFN group maintained disease-free survival. The 5-year overall survival rate (OS) and the leukemia-specific disease-free survival rate were 37.2% and 62.5% respectively.
free survival rate (LFS) of IFN group were 47.0%±13.9% and 38.7%±13.1% respectively. However, the 5-yr OS and LFS of non IFN group were 14.5%±10.7% and 12.5%±9.4% respectively. The difference were significantly (P<0.000, P=0.002 respectively). Patients with GVHD had significantly better response than patients without GVHD (88.9% vs 53.8%, P=0.043, P <0.05).

Summary/Conclusions: IFN-α-2b pre-emptive therapy can effectively prevent high risk patients with relapsing tendencies for disease progression post allo-HSCT. Further large-scale investigation is warranted.

E1508
PREDICTING SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. THE GATMO SCORE
1Hematology, Transplant Unit, Hospital Privado de Cordoba, Cordoba, 2Hematology, Transplant Unit, Hospital Italiano de Buenos Aires, 3Hematology, Transplant Unit, Instituto Alexandre Fleming, 4Hematology, Transplant Unit, Fundacion Favaloro, 5Hematology, Transplant Unit, Hospital Italiano de La Plata, La Plata, 6Hematology, Transplant Unit, Hospital Italiano de Buenos Aires, 7Hematology, Transplant Unit, Hospital Italiano de Buenos Aires, 8Hematology, Transplant Unit, Hospital Universitario Austral, Derqui, Argentina, 9Hematology, Transplant Unit, Hospital Privado de Cordoba, Cordoba, 10Hematology, Transplant Unit, Sanatorio Anchorena, 11Hematology, Transplant Unit, Hospital Britanico, Buenos Aires, 12Clinica Medica, Hospital Universitario Austral, Derqui, Argentina, 13Clínicas BMTR, Department of Medicine, Medical College of Wisconsin, Milwaukee, United States

Background: Several attempts to predict mortality after autologous stem cell transplantation (ASCT) have been made, like Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) score, originally described by Sorror for allo-geneic HSCT. There is no score applicable to the clinical practice that integrates comorbidities with other patient characteristics.

Aims: To describe a comprehensive score that combines comorbidities with other factors and analyse the impact of this score in OS and NRM after ASCT in a cohort of patients transplanted in Argentina.

Methods: We retrospectively reviewed a cohort of 1453 medical records of adult patients who record an ASCT in our centres between October 2002 and August 2016, for Multiple Myeloma or Lymphoma. We compared NRM and Relapse with CI, OS with KM and long term MVA with fine-Gray or Cox regression.

We included in the score all the factors that remained significant after MVA for NRM, and assigned a score of 1 if the Hazard ratio (HR) was around 2 (1.5-2.5) and 2 if it was around 3 (2.6-3.5).

Results: Mean age was 50.7 years (range 15-74); 57% were male, 52% had Multiple Myeloma, 29% Non Hodgkin Lymphoma and 19% Hodgkin Lymphoma. Forty-seven percent were in CR, 50% in PR and 3% SD/PD; 14% received three or more chemotherapy lines before transplant (heavily pre-treated).

Regarding comorbidities, 62% had low HCT-CI score (score 0), 26% intermediate risk (1-2) and 12% high risk (≥3). Median follow up was 1.1 years (range 0-120), with all patients having a neutrophil count <1x109/l. The reasons for HDC-ASCT were: male patients (1 point), age ≥55 years (1 point), heavily pre-treated (1 point), HCT-CI ≥3 (1 point) and Non Hodgkin Lymphoma (2 points).

One hundred and seventy eight patients (12%) had a score of 0, 460 (32%) 1, 381 (26%) 2, 241 (17%) 3, 137 (9.5%) 4 and 47 (3.5%) ≥5. The hazard ratio for NRM increased proportionally with the score (1 2.2, 2 3.5, 3 4.6, 4 10.1 and ≥5 32.3). Patients were grouped as low risk (LR) with a score 1-2, intermediate risk (IR) score 1-3 (75%) and high risk (HR) ≥3 (13%). The score was significantly associated with early NRM (day 100: 1.1% vs 1.9% vs 9.2 for LR, IR and HR respectively), long term NRM (1-3 years 1.1-1.1% vs 2.9-4.1% vs 15-20%, respectively, p<0.001) (figure 1) and OS (1-5 years 93-78% vs 91-67% vs 73-50% respectively, p<0.001) (figure 2). No significant association was observed with relapse rate.

Figure 1.

Summary/Conclusions: We found that GATMO score had a significant association with long term OS due to an increase in NRM. All end-point risks increased proportionally with the score. This observation should be confirmed in larger series.

E1509
A RETROSPECTIVE ANALYSIS OF PATIENT CHARACTERISTICS AND RISK FACTORS FOR ADMISSION TO THE INTENSIVE CARE UNIT (ICU) FOLLOWING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT)
L. Jeyaraj Nallathambi1,*, T. Freeman1, S. Williams1, V. Potter1, R. Benjamin1, K. Cuthill1, S. Devereux1, P. Patten1, D. Yallop1, S. kassam1
1Haematology, Kings college hospital, London, United Kingdom

Background: HDC-ASCT is a standard treatment modality for patients with myeloma and lymphoma. It carries a low, but significant risk of morbidity and mortality. Given that the upper age limit for patient selection continues to increase, it is important to have an objective way of assessing patient suitability for HDC-ASCT. Admission to the ICU is an ominous clinical event post HDC-ASCT and carries a high risk of mortality. There are currently no standard assessment tools to predict the risk of morbidity and mortality.

Aims: To review the incidence and cause of ICU admission in patients receiving HDC-ASCT and identify pre-transplant factors that may be predictive of transplant morbidity and mortality.

Methods: All patients receiving HDC-ASCT for myeloma and lymphoma at King’s College Hospital, London between July 2015 and December 2016 were included. Data cut off was 1st February 2017. Electronic patient records were used to collect data on baseline patient characteristics, comorbidities and performance status. The Charlson comorbidity index (CCI) and haematopoietic cell transplantation comorbidity index (HCTCI) were calculated. Univariate analysis of variables was performed using Graph Pad Prism version 5.03. A p value <0.05 was considered significant.

Results: 869 patients received HDC-ASCT. The median age was 58 years (23-74). Patient characteristics are shown in the table (See Image). Thirteen patients (7.6%) required ICU admission at a median of 14 days post cell infusion (range 5-85), with all patients having a neutrophil count <1x109/l. The reasons for ICU admission included sepsis (n=12), severe mucositis/colitis (n=11), renal failure (n=7), hypotension and arrhythmias (n=5), respiratory distress (n=4), liver failure (n=1). The median number of days spent in ICU was 9 (range 2-16). Five patients required single organ support (non-invasive ventilation, 2; inotrope support, 2; haemofiltration; 1) and 2 required only management of

Table 1.
fluid balance. Six patients required multi-organ support (non invasive ventilation/intubation, haemofiltration and inotropic support) and all died. Four patients died within 30 days of HDC-ASCT and had not engrafted neutrophils at the time of death. Two patients died late at day +120 and day +93 post HDC-ASCT. The latter had both successfully engrafted neutrophils but subsequently became neutropenic. Causes of death were neutropenic sepsis (3), cerebrovascular accident (1) and acute liver failure (1) versus host disease (1). By univariate analysis none of the baseline parameters, comorbidities or conditioning regimens were predictive of ICU admission. The only parameter for which there was a trend for significance was baseline cardiac ejection fraction (EF) <50% (p=0.05). Three patients that required ICU had an EF <50% and 2 were on heart failure medications prior to HDC-ASCT. Two of these 3 patients died.

Summary/Conclusions: In this retrospective series, the risk for ICU admission and death following HDC-ASCT was 7.6% and 3.5% respectively. All patients requiring more than one organ support died. The only predictor of ICU admission was baseline cardiac function but this would need confirmation in a larger series. Patient selection remains challenging with no definite tool to predict ICU admission or death.

E1510
AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BENDA-EAM (BENDAMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN) IN AGGRESSIVE NON HODGKIN AND HODGKIN'S LYMPHOMA
T. Noesslinger1, R. Simanek1,*, M. Panny1, E. Koller1, M. Moestl1, F. Keil1
1Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria

Background: Autologous Stem Cell Transplantation (ASCT) is standard of care in relapsed diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders (relapsed Hodgkin’s disease, 1st line mantle cell lymphoma (MCL) or T-cell lymphoma). BCNU, Etoposide, Ara-C, Melphalan (BEAM) is a standard conditioning regimen, but BCNU is known to be associated with interstitial pneumonia (range 2 to 20%) and an increased risk of death compared with other regimens.

Aims: Therefore a less toxic conditioning protocol might improve the results in lymphoma patients. Bendamustine showed promising results in B- and T-cell lymphoma and lymphoma and dose escalation is safe and feasible. Here we report promising results with bendamustine replacing BCNU in the BEAM regimen described as Benda-EAM, previously published in a phase two dose finding study (Visani, Blood 2011).

Methods: Forty-one patients with Hodgkin’s (HL)(n=9) or Non-Hodgkin (n=32) lymphoma were consecutively treated with Benda-EAM (bendamustine on two consecutive days at a dose of 200mg/m2 per day). Eleven patients were diagnosed with DLBCL, ten patients with MCL, six patients with follicular lymphoma (FL), three patients with T-cell lymphoma (TCL) and two patients with greyzone lymphoma (GZL). Twenty-seven patients were male and fourteen female with a median age of 52 years (range 22-71) and 25% were above the age of sixty.

The median lines of previous therapies were 2 (range 1-4).

Results: All patients had chemosensitive disease and before transplantation, 34 patients (83%) were in complete (CR) and 7 (17%) in partial remission (PR). A median number of 4,20*10⁶CD34+ cells/kg (range: 1,60-13,30) were infused. All patients showed engraftment with a median time to achieve an absolute neutrophil count >0.5 *10⁹/L of 10 days (range 8-13) and to platelets >20*10⁹/L of 12 days (range 7-110). The median time of fever was 5 days (range: 0-15).

The median number of days on G-CSF was 7 (range 4-15) and in median 2 units of red blood cells and 5 units of platelets had to be transfused. The median duration of hospitalization was 25 days. The common grade 3 and 4 toxicity during the whole treatment period was diarrhea (n=18), mucositis (n=7), infections (n=9) and febrile neutropenia (n=6), followed by nausea (n=4) and cardiologic toxicities (n=3). No severe pulmonary or renal toxicities were observed and no transplant related mortality occurred. After a median follow-up of 43 months 22 patients (56%) are still in CR, while 19 patients (44%) showed no evidence of disease. Median time of 3 years engraftment (range 2-29 months). Until today nine patients received an additional autologous transplantation. Eleven patients (27%) have died (3 DLBCL, 3 HL, 2 MCL, 1 GZL, 1 TCL and 1 FL), all due to lymphoma progression. Thus the 1- and 2-year PFS are 73.2% and 57.9% and the 1- and 2-year OS 85.4% and 79.4%, respectively.

Summary/Conclusions: In conclusion Benda-EAM is feasible with a quite promising outcome. Currently an international randomized phase II trial comparing Benda-EAM with BEAM is recruiting. So far fifty-five of 110 planned patients are randomized and first results are expected for 2018.

E1511
THROMBOTIC MICROANGIOPATHY WITH CONCOMITANT AGVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK FACTORS, SEVERE OUTCOME AND TREATMENT EXPERIENCE
X. Liu1, Q. Wang1, Y. He1, X. Zhu1, J. Zhang1, L. Xu1, W. Han1, H. Chen1, Y. Chen1, F. Wang1, J. Wang1, Y. Zhang1, X. Mo1, Y. Chen1, Y. Wang1, Y. Chang1, L. Xu1, X. Liu1, X. Huang1, X. Zhang1
1Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)- associated thrombotic microangiopathy (TA-TMA) is a significant complication after allo-HSCT. acute graft-versus-host disease (aGVHD) is one of the risk factors for the occurrence of TA-TMA, and some patients may develop both. Although there has been sufficient information available on aGVHD and TA-TMA, TMA with concomitant aGVHD after allo-HSCT remains not well understood.

Aims: To explore the possible risk factors for the occurrence and mortality of TMA with concomitant aGVHD and to investigate outcomes and treatments of this disorder after allo-HSCT.

Methods: This study was based on patients who underwent allo-HSCT at Peking University People’s Hospital from January 2008 to December 2016. We included patients who showed refractory diarrhea and underwent endoscopy and biopsy. The diagnosis of TA-TMA and aGVHD were mainly based on the probable-TMA criteria (Byung-Sik Cho et al. Transplantation 2010;90:918-926) and endoscopic appearance and histologic findings (Thomas Hematopoietic Cell Transplantation, Fifth Edition, 2016), respectively. The potential risk factors affecting TMA with concomitant aGVHD occurrence and markers associated with the death of these patients were identified using uni- variate and multivariate Cox analysis. The cumulative incidence of relapse, non-relapse mortality (NRM), overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and were compared by the log-rank test.

Results: Among all 3,992 allo-HSCT recipients, 276 patients showed refractory diarrhea and underwent endoscopy; of these patients, 50 (1.3%) were diagnosed with TMA with concomitant aGVHD and were enrolled in the case group, and 150 (5.80%) were enrolled in the control group. The two groups matched well with regard to baseline characteristics. Based on the nested case-based control study, grade III-IV aGVHD (P=0.000), AKI (P=0.033) and hypertension (P=0.028) were significant independent risk factors associated with the occurrence of TMA with concomitant aGVHD. Considering the case group only, our data suggested that a haptoglobin level below normal (P=0.013), a maximum volume of diarrhea >2500 ml/d (P=0.015) and bloody diarrhea (P=0.049) were significant markers for death in both univariate and multivariate analysis. Among the case group and control group, the 9-year OS rates were 52% and 81% (P=0.001), respectively; the 9-year DFS rates were 50% and 65% (P=0.345), respectively; the 9-year cumulative incidence rates of NRM were 44% and 16% (P=0.001), and those of relapse were 6% and 19% (P=0.010), respectively. To further study the treatments of patients with TMA and aGVHD, we calculated the OS and found that plasma exchange (PE) use (PE=0, 62.5%; PE 0, 38.9%; P=0.156) had no significant influence on the patient outcome.

Summary/Conclusions: This study demonstrated that patients diagnosed with TMA with concomitant aGVHD after allo-HSCT had a significantly lower OS, higher NRM, and a lower incidence of relapse. The risk factors associated with the occurrence and mortality of TMA with concomitant aGVHD may help us assess the prognosis of patients. The findings also suggested that PE use may be ineffective to these patients.

E1512
SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY QUANTITATIVE RT-PCR IN CORE BINDING FACTOR AML ON TRANSPLANTATION OUTCOMES
B.oran1,*;K.Patel2;D.Marin1,Q.Bashir1,S.Ahmed1,A.Aoulos1,S.Ciurea1,J.Chen1,K.Rezvani1,U.Popat1,E.Shall1,R.Rampling2
1Stem Cell Transplantation and Cellular Therapy, 2Hematopathology, The University of Texas MDACC, Houston, United States

Background: Despite the well-defined role of minimal residual disease (MRD) monitoring in core binding factor (CBF)-AML after intensive chemotherapy, there has been, to date, a paucity of data assessing the clinical utility of MRD monitoring before allogeneic stem cell transplantation (HSCT).

Aims: We investigated the prognostic impact of MRD monitoring by real-time quantitative polymerase chain reaction (RT-PCR) for RUNX1/RUNX1T1 and
CBFB-MYH11 transcript levels at HSCT on transplant outcomes in AML patients with CBF abnormalities.

Methods: We included 61 AML patients with CBF at diagnosis that underwent their first HSCT in complete remission (CR) from January 2007 through May 2016. Of 61, 19 (31%) had t(8;21) chromosomal translocation and 42 (69%) inv(16)(t;16;16). Disease status at HSCT was CR1 in 19 (31%) and CR2 in 42 (69%). Conditioning regimen was myeloablative in 23 (37%) patients, reduced intensity in 19 (31%) patients, and reduced intensity in 19 (31%) patients. Donors were matched related (MR) in 24 (39%), matched unrelated (MUD) in 26 (43%), and haploidentical in 11 (18%) patients. Hematopoietic stem cell sources were peripheral blood (n=22), bone marrow (n=22) and cord blood (n=7). Conditioning regimen was myeloablative in 38 (62%) and reduced intensity in 23 (38%) patients. Donors were matched related (MR) in 24 (39%), matched unrelated (MUD) in 26 (43%), and haploidentical in 11 (18%) patients. Conditioning regimen was myeloablative in 38 (62%) and reduced intensity in 23 (38%) patients. Conditioning regimen was myeloablative in 38 (62%) and reduced intensity in 23 (38%) patients. Conditioning regimen was myeloablative in 38 (62%) and reduced intensity in 23 (38%) patients. Conditioning regimen was myeloablative in 38 (62%) and reduced intensity in 23 (38%) patients.

Results: The incidence of acute GVHD (≥grade II) and chronic GVHD of acute GVHD. All patients engrafted and three patients developed delayed or haplo-identical donor (n=2). After a median follow-up of 66.3 months (range, 20-110 months) patients with a median age of 41 years (range, 20-59 years) were included.

E1514 PROGNOSTIC VALUE OF PET/CT PRIOR TO AUTOLOGOUS HCT IN RELAPSED / REFRACTORY LYMPHOMA

M. Damla1,2, G. Syed1, G. Gmait3, H. Salama1, K. Abuelgasim1, M. Al-Zahrani1, S. Ghazi2, A. Heijaz1, A. Alaskan1
1Oncology, King Abdullahaz Medical City, 2King Abdullahaz Medical City, Riyadh, Saudi Arabia

Background: Positron Emission Tomography /Computed Tomography (PET/CT) is emerging as a powerful prognostic tool in the management of Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). A number of retrospective single center cohorts have reported that a positive PET/CT prior to autologous Hematopoietic Stem Cell Transplantation (HSCT) is an adverse factor associated with higher relapse risk. However, important heterogeneity is noted in these studies due to differences in timing of PET/CT prior to HSCT as well as different metabolic activity threshold (i.e. Deauville ≤2 vs ≤3). At our institution, we perform PET/CT within 4 weeks prior to HCT and after all intended salvage therapy is administered.

Aims: We sought to further investigate the prognostic value of PET/CT in relapsed / refractory lymphoma patients prior to HCT.

Methods: After due IRB approval, patients who received autologous HCT at our institution for relapsed / refractory lymphoma between 2010 - 2016 were identified. All variables were retrospectively extracted. PET/CT reports were reviewed and metabolic activity was assigned per Deauville criteria. Patients with primary CNS lymphoma were excluded. Refractory disease indicates disease progression prior to commencing planned first line therapy. Categorical and continuous variables were compared using Chi-squared and Wilcoxon tests, respectively. Time to end point analysis was computed using the method of Kaplan and Meier with log rank tests. Competing events were computed using Grey’s method considering non relapse mortality as a competing event for relapse. Analysis was computed using JMP software, version 11.

Results: A total of 53 patients underwent HCT for relapsed / refractory lymphoma with 80% of the cohort having HL. Median follow up of the entire cohort was 26.8 months (0.6-70.5). Cumulative incidence of relapse (CIR), progression free survival (PFS) and overall survival (OS) at 2 years was 37.9%, 56.1% and 74.8%, respectively. A PET/CT status pre-HCT. A total of 47 patients had pre-HCT PET/CT and were evaluable for further analysis. Median time from PET to HCT was 17 days (6-59). There were no significant differences between the cohorts based on age at HCT, gender, underlying diagnosis, relapsed/refractory status, time to relapse, number of salvage regimens, number of salvage cycles, use of immunotherapy as part of salvage and post HCT immunotherapy use as maintenance. Considering Deauville ≤3 as complete metabolic response (CMR), 2-year CIR was 16.7% vs 60.5% for PET negative vs PET positive patients (p=0.0021). 2-year PFS was significantly higher in PET negative vs PET positive patients at 72% vs 39.5%, respectively (p=0.035). 2-year OS was similar irrespective of PET status (p=0.49). Considering Deauville ≤2 as CMR, there was only a trend towards decreased CIR for metabolically negative scans (p=0.096). Significance of these results remained unchanged after excluding NHL cases. B. Relapse post HCT: Median time to relapse post HCT for patients...
was 109 days (55-395) vs 271 days (55-449) for PET positive vs PET negative patients, respectively. Mortality post relapse was lower in the remaining patients achieving long term disease control with immunotherapy alone (57%), allogeneic HCT (29%) and combination chemotherapy (14%). Median follow up of patients with long term disease control was 1093 days (177-1271). Causes of death post HCT relapse was progression of disease in all cases.

Summary/Conclusions: Despite inherent limitations of this analysis, we present a number of important observations: 1. Deauville score ≤3 is an appropriate cutoff for metabolic activity pre-HCT and is associated with significantly decreased relapse and improved PFS. 2. PET positive status will better identify patients who may benefit from maintenance strategies post HCT. 3. Time to relapse in PET positive patients is significantly shorter highlighting the need for early initiation of pre-emptive maintenance therapy. 4. Long term disease control is possible in a high proportion of patients despite relapse post HCT. These important observations require further study.

E1515
COMPARISON OF OUTCOMES AFTER DONOR LYMPHOCYTE INFUSION WITH OR WITHOUT PRIOR CHEMOTHERAPY FOR MINIMAL RESIDUAL DISEASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
X.-D. Mo1,*, X.-H. Zhang1, L.-P. Xu1, Y. Wang1, C.-H. Yan1, H. Chen1, Y.-H. Chen1, W. Han1, F.-R. Wang1, J.-Z. Wang1, K.-Y. Liu1, X.-J. Huang1
1Peking University People’s Hospital, Institute of Hematology, Beijing, China

Background: Minimal residual disease (MRD) can predict impending relapse after allogeneic hematopoietic stem cell transplantation (allo-HSTC). Thus, MRD-directed immunotherapy may be a reasonable option for relapse prophylaxis. However, lymphodepletion therapy prior to lymphocytopenia and immunodeficiency (Chemo-DLI) can decrease the tumor burden, and immunotherapy should preferably be started in patients with leukemia with relatively low tumor burden. However, some patients who are MRD-positive may refuse or are unable to receive chemotherapy prior to DLI. Few studies have compared the clinical outcomes of Chemo-DLI and DLI alone in patients who were MRD-positive after allo-HSTC.

Aims: The efficacy of DLI without chemotherapy was investigated and compared with that of Chemo-DLI in patients who were MRD-positive after allo-HSTC.

Methods: We enrolled 115 consecutive patients who received either DLI (n=20) or Chemo-DLI (n=95) during the same time period for each DLI recipient, three recipients matched for age at the HSTC, underlying diseases, and the year of the HSTC were randomly selected from the Chemo-DLI cohort (n=60).

Results: The 2-year cumulative incidence of severe acute graft-versus-host disease (GVHD) and chronic GVHD was comparable between the groups. Fifteen (30%) patients vs 47 (78.3%) patients in the DLI and Chemo-DLI groups turned MRD negative, respectively. The 2-year cumulative incidences of relapse and non-relapse mortality after intervention were 30.7% versus 39.6% (P=0.582) and 10.3% versus 6.0% (P=0.508) in the DLI and Chemo-DLI groups, respectively. The 2-year probabilities of disease-free, overall, and GVHD-free/relapse-free survival after preemptive intervention were 58.9% versus 54.3% (P=0.862), 69.3% versus 78.1% (P=0.361), and 44.4% versus 35.1% (P=0.489) in the DLI and Chemo-DLI groups, respectively. In multivariate analysis, the intervention method did not significantly influence the clinical outcomes.

Summary/Conclusions: In summary, preemptive DLI alone may be effective for patients who are MRD-positive and may be a potential alternative for patients who refuse or are unable to receive Chemo-DLI after HSTC.

E1516
DIFFERENTIAL PROGNOSTIC IMPACT OF HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX (HCT-CI) ON TRANSPLANT OUTCOMES BY STEM CELL SOURCES
Y. Adams1,*, K. Sagou1, Y. Yamaga1, N. Fukushima1, K. Ozeki1, A. Kohno1
1Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan

Background: The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been proposed to predict the probability of nonrelapse mortality (NRM) and survival (OS) in allo-HCT recipients. However, the impact of HCT-CI on clinical outcomes in single unit umbilical cord blood transplantation (UCBCT) has not been investigated extensively.

Aims: The purpose of this single-center retrospective study was to investigate the impact of HCT-CI on NRM in UCBT.

Methods: We retrospectively analyzed a cohort of 144 consecutive adult patients who received first allogeneic HSTC between July 2008 and December 2016 in our hospital. One patient was excluded from this analysis due to inadequate data regarding comorbidities before HSTC. Patients were divided into the UCBT group (n=82) and the non-UCBT group (n=53). Two-year OS and 1-year NRM were defined as the primary endpoints.

Results: Pre-transplant parameters, such as gender, diagnosis, and the phase of disease, were comparable between the two groups. The median follow-up durations were 562 days and 627 days for the non-UCBT group and the UCBT group, respectively. The most frequent comorbidity was mild hepatic comorbidity (22%), followed by mild or severe pulmonary comorbidities and active infections (16%). For the non-UCBT group, 2-year OS rates for HCT-CI scores of 0, 1-2 and ≥3 were 70% (n=43), 63% (n=30), and 31% (n=17), respectively (P=0.014). For the non-UCBT group, 1-year NRM rates for HCT-CI scores of 0, 1-2 and ≥3 were 10%, 17%, and 35%, respectively (P=0.026). For the UCBT group, 2-year OS rates for HCT-CI scores of 0, 1-2 and ≥3 were 78% (n=26), 46% (n=13), and 69% (n=14), respectively (P=0.38). For the UCBT group, 1-year NRM rates for HCT-CI scores of 0, 1-2 and ≥3 were 9.0%, 15%, and 7.1%, respectively (P=0.75). In multivariate analysis, the HCT-CI score of ≥3 was significantly associated with lower OS (p=0.005; hazard ratio 2.6) and higher NRM (p=0.015; hazard ratio 3.1) for the non-UCBT group, but not for the UCBT group. There was no significant difference in the cumulative incidences of grade 2 to 4 acute GVHD between the non-UCBT group (41%) and the UCBT group (33%; P=0.51). Similarly, there was no significant difference in the cumulative incidence of grade 3 to 4 acute GVHD between the non-UCBT group (8.8%) and the UCBT group (6.1%; P=0.80). The cumulative incidence of extensive chronic GVHD was significantly higher in the non-UCBT group compared with the UCBT group. (38% vs 3.8%; P=0.001) Although not significant, patients in the non-UCBT group were more likely to have the systemic steroid therapy compared with those in the UCBT group. (54% vs 34%; P=0.084).

Figure 1.

Summary/Conclusions: UCBT showed good OS with the low incidence of NRM even in patients with high HCT-CI scores. These results indicate that a single unit umbilical cord blood might be a promising stem cell source for patients with multiple comorbidities. Further studies are needed in order to validate these results.

E1517
LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIAL
Y. Wang1, Y.-J. chang1, X.-J. huang1
1Peking university people’s hospital, beijing, China

Background: Anti-thymocyte globulin (ATG)/granulocyte colony-stimulating factor (G-CSF)-represented regimen produces essentially universal engraftment with limited relapse and favorable survival, albeit with relatively high rates of graft-versus-host disease (GVHD), especially after HCT from maternal donor or collateral relatives. While use of high-dose, post-transplant cyclophosphamide (PT/Cy) results in low rates of GVHD and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure. Thus, novel strategies are needed to refine each approach: under Beijing protocol including ATG and G-CSF, reducing GVHD without abrogating GVLF effect is a major priority.

Aims: In order to benefit patients at high risk of developing GVHD without abrogating engraftment and GVLF effects, we sought to develop a novel procedure in TCR haplo-HCT with intensified conditioning containing ATG and G-CSF followed by lower-dose of PT/Cy. In addition, the current study attempt to establish a murine model and focus on Treg cells to clarify the immunological mechanisms for GVHD prevention by the new strategy.

Methods: We performed a prospective pilot study of HLA haploidentical cell transplantation with intensified conditioning including G-CSF and ATG, followed by two lower doses of PT/Cy (14.5mg/kgx2 doses; designated as Group A). Outcomes were compared with those of 160 controls from matched-pair analysis who undergone haploidentical HCT from other donors than mother or collateral relatives at the same time period (Group B) as well as with those of 46 historical controls undergoing HCT from mother or collateral relatives at earlier time period (Group C). In addition, the current study attempt to establish a murine model and focus on Treg cells to clarify the immunological mechanisms for GVHD prevention by...
the new strategy. Trial registration: The study is registered at www.clinicaltrial.gov as NCT02412423.

Results: We found that low dose PT/Cy combined with ATG could alleviate GVHD in mice and could increase the number of Treg cells while have no effects on CD4+ or CD8+ T cells. A total of 40 patients with myelodysplastic syndrome (MDS) and leukemia undergoing haploidentical HCT from maternal or collateral donors were enrolled in the study. The cumulative, 100-day incidence of acute GVHD, grades II-IV, in Group A (17%; 95% CI, 5%–29%) was significantly lower than both that in Group B (33%; CI, 25%–41%; P = 0.04) and that in Group C (56%; CI, 42%–70%; P < 0.001). The 1-year probabilities of NRM (5%; CI, 0%–12%), OS (84%; CI, 88%–100%), and LFS (83%; CI, 70%–96%) in Group A were similar to that in Group B, but was significantly lower than that of Group C (28%; CI, 15%–41%; P = 0.006; 65%; CI, 51%–79%; P = 0.02; and 65%; CI, 51%–79%; P = 0.04, respectively).

Summary/Conclusions: Low dose PT/Cy can enhance the protective effect of ATG (G-CSF on GVHD. Conditioning with ATG/G-CSF and low-dose PT/Cy might be a feasible option for patients undergoing HLA haploidentical, T-cell replete HCT, in particular for those with high GVHD risk.

E1518

HEPATITIS B REACTIVATION IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS: 22 YEARS EXPERIENCE OF A SINGLE CENTRE

A. Murt1, T. Elverdi2, A. Salihoglu2, A.E. Eskazan2, M.C. Ar2, S. Ongoren Aydin2, Z. Baslar2, T. Soysal2,*

1Internal Medicine, 2Hematology, Cerrahpasa Medical Faculty, Istanbul, Turkey

Background: Reactivation of inactive viruses is an important complication of haematopoietic stem cell transplantation (HSCT). Suggestion of strategies to combat this problem will probably decrease transplant related mortality and morbidity.

Aims: Aim of this study is to evaluate the clinical progress and risk factors for reactivation in HSCT patients who were infected with hepatitis B virus (HBV) with the prospect of developing recommendations for a better clinical care.

Methods: Patient files and electronic records of 561 patients who received HSCT between 1994 and 2015 at the Bone Marrow Transplantation Centre of Cerrahpasa Medical Faculty were retrospectively evaluated. A total of 66 patients with HBsAg (n=15; 12 autologous, 3 allogeneic) and anti-HBc IgG positivity (n=51; 29 autologous, 22 allogeneic) were included in the study. Cases were grouped according to transplant types (allogeneic or autologous) and anti-HBc and HBsAg positivity (HBsAg positive or negative) to calculate relative risks and cumulative incidences of HBV reactivation.

Results: Four (26%) of the 15 patients with HBsAg positivity showed HBV reactivation in an average of 13 months following HSCT. While cumulative incidence of reactivation was 7% at day 60, it went up to 16% and 44% at days 270 and 730 following HSCT, respectively. In Anti HBc- IgG positive group, allogeneic HSCT (n=22) was a higher risk factor for reactivation (31.8%) than autologous HSCT (n=29, 6.8%). Relative risk of reactivation in the allo-transplanted patients who were anti-HBc IgG positive and anti-HBs negative was 6.8 when compared to anti-HBc negative patients (n=9, 55% vs n=13, 10%; 95% CI: 1.3–46.5). Cumulative incidence of reactivation in anti-HBc IgG positive anti-HBs negative patients (isolated anti HBc IgG positivity) was 11% at day 10, 33% at day 133, 50% at day 400 and going up as high as 75% at day 940.

Summary/Conclusions: The results of our study indicate that HBsAg positive patients undergoing autologous or allogeneic HSCT should receive prophylaxis at least one year posttransplant. Anti-HBc IgG positive patients carry the risk of reverse seroconversion, with receivers of allogeneic HSCT having higher risk than those of autologous HSCT. Patients who are anti-HBc IgG positive and anti-HBs negative should receive prophylaxis for HBV if allogeneic HSCT is to be performed. However, close follow-up seems to be acceptable rather than a prophylactic treatment for anti-HBc IgG positive patients undergoing autologous HSCT.

E1519

ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WAS RELATED TO LESS INPATIENT COST COMPARED TO CORD BLOOD TRANSPLANTATION

N. Kurtla1,*, Y. Yokoyama1, T. Kato1, H. Nishikii1, M. Sakata-Yanagimoto1, N. Obara1, Y. Hasegawa1, S. Chiba1

1Department of Hematology, University of Tsukuba, Tsukuba, Japan

Background: The number of allogeneic HSCT from alternative donors such as cord blood (CB) and haploidentical donor (haplo) is increasing especially after introduction of post-transplant cyclophosphamide (PT/CY) as GVHD prophylaxis for haplo. Although comparison of the survival benefit between CB and haplo with PT/CY has been made by several groups, there is little information about the medical cost and the hospitalization period of HSCT from alternative donors.

Aims: We evaluated the medical costs and the hospitalization period related to allogeneic HSCT in order to clarify the impact of donor sources and other clinical factors on these outcomes.

Methods: Patients (n=134) with hematological malignancies who underwent allogeneic HSCT between January 2013 and December 2016 in University of Tsukuba Hospital were included. The days of the initial hospitalization (from the beginning of the conditioning regimen to discharge), the whole initial inpatient costs and the costs of transfusion during the initial hospitalization was retrospectively analyzed.

Results: The median age of the patients was 46 (range, 16–67) years. The diagnoses were AML (n=66), ALL (n=31), MDS (n=17), lymphoma (n=11), and others (n=9). Twenty-seven patients were transplanted from MRD, 37 from MUD, 22 from haplo with PT/CY, and 48 with single-unit CB. The median initial inpatient cost was €49179 (IQR, 37030–66923), the median transfusion cost was €11500 (IQR, 9500–15250), and the median length of initial hospitalization was 55 (IQR, 44–75) days. CB showed significantly higher inpatient cost (median, €69985, P = 0.008 vs CB), MUD (median, €39262, P < 0.001 vs CB), and haplo (median, €30683, P = 0.005 vs CB) (Figure). Also, the transfusion cost was highest in CB (median, €22750) compared with haplo (median, €12866, P = 0.001 vs CB), MUD (median, €12699, P = 0.001 vs CB), and MED (median, €13118, P < 0.001 vs CB). The median hospitalization days were 67 in CB, 61 in haplo (P = 1.0 vs CB), 46 in MUD (P = 0.001 vs CB), and 49 in MUD (P = 0.01 vs CB). Among the clinical variables such as diagnoses (acute leukemia or others), refined disease-risk index (low/intermediate or high), donor source (MUD, MED, haplo, or CB), age, first or second HSCT, intensity of conditioning (RIC or MAC), with or without comorbidity, graft failure, GVHD III-IV, and admission to the intensive care unit (ICU), multiple regression models revealed CB (P < 0.001), admission to ICU (P = 0.001), and MAC (P = 0.05) were the factors that increased the initial inpatient cost. The transfusion cost was increased by CB (P = 0.001), graft failure (P < 0.001), admission to ICU (P = 0.001), and MAC (P < 0.001). CB (P = 0.001), haplo (P = 0.003), and GVHD III-IV (P = 0.01) were selected as factors associated with longer hospitalization period.

Figure 1.

Summary/Conclusions: Although HSCT from alternative donors was related to the higher initial inpatient cost and longer hospitalization, the impact on those outcomes was more significant in CB than haplo with PT/CY. The higher inpatient cost of CB was partly attributed to delayed hematological recovery which lead to its larger demand for transfusion. The strategy to improve hematological recovery will be needed to reduce the medical cost especially in CB. The larger scale investigation is necessary for better cost-effectiveness in HSCT.
plant from HLA-matched donors, of which included 13 ISD and 12 MUD. Chemorefractory disease at transplantation was more common in the haplo-HSCT group as compared to that in the HLA-matched HSCT cohort (P = 0.005). No significant between-group differences were observed with respect to distribution of age and sex, histological subtype, bone marrow involvement, aaIPI score, chemotherapy regimen and relapse after ASCT.

Results: Median age of patients at allo-HSCT was 33 years (16-58). Over a median follow-up of 23 months, 27 out of the 48 patients (56%) were alive. Progression free survival (PFS) rate at 2-years in the haplo-HSCT and HLA-matched HSCT groups was 52.1% and 56.6%, respectively (P = 0.75); 2-year overall survival (OS) rate was 52.8% and 57.8%, respectively (P = 0.83). Cumulative incidence of relapse (IR) was 41.7% and 35.0% (P = 0.37), while non-relapse-mortality (NRM) was 21.7% and 35.0%, respectively (P = 0.32). Collectively, these results showed no significant difference with respect to major allo-HSCT endpoints between the haplo-HSCT and HLA-matched-HSCT groups. On multivariate analyses, older age (> 45 years), primary chemorefractory disease (CR) at transplantation, and disease status at transplantation were independent risk factors for poor OS. Non-CR at transplantation was considered as competing risk and were compared using the Gray’s test. In a multivariate analysis, the Cox proportional hazard model was used to analyze OS, using the following variables: age, sex, disease status at allo-HSCT, time from diagnosis to allo-HSCT, and disease intensity. Other variables considered as overall survival (OS), relapse, and non-relapse mortality (NRM) were not significant for poor OS.

Summary/Conclusions: Haplo-HSCT is an option for patients with R/R aggressive NHL without appropriate donors. The outcomes are comparable to those of HLA-matched HSCT, particularly in younger patients with R/R NHL without appropriate donors.

E1521

HAPOIDENTICAL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING REGIMEN COULD SERVE AS AN OPTIONAL SALVAGE THERAPY FOR YOUNGER PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA

H. Huang1,*, X. Xiao1, Z. Jin1, D. Wu1
1Soochow University, Suzhou, China

Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) has a well-established role in the treatment of refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (NHL). However, whether patients with R/R aggressive NHL, in the absence of appropriate HLA-matched donors, can benefit from haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is yet to be elucidated. Herein, we evaluated clinical outcomes of haplo-HSCT in patients with R/R aggressive NHL.

Aims: To evaluated clinical outcomes of haplo-HSCT in patients with R/R aggressive NHL.

Methods: Among 235 patients who had undergone haplo-HSCT, aGVHD occurred in 45 patients. Expression of PPARγ mRNA in healthy controls was significant and lower than that in patients after allo-HSCT within 90 days (P < 0.05). The expression of PPARγ mRNA held steady in non-GVHD patients within 90 days after allo-HSCT, and was significantly lower in GVHD group than in non-GVHD group (P = 0.05). The expression of IFNγ and TNF-β increased in aGVHD patients and were negatively correlated with PPARγ mRNA expression (P < 0.05). The experiment of MLR shows that PPARγ agonist rosiglitazone above concentration of 25μM had dose-dependent inhibition effect to proliferation of lymphocytes.

Summary/Conclusions: Low expression of PPARγ is associated with aGVHD occurrence and degree. PPARγ agonist can inhibit the proliferation of lymphocytes, which may be a new way to treat aGVHD.

E1522

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA HARBOURING INV(3)/(Q21;Q26.2)/T(3;3)Q21;Q26.2)

1Department of Hematology, Kanagawa Cancer Center, Yokohama, 2Department of Hematology, Kanazawa University Hospital, Kanazawa, 3Department of Hematology, Toranomon Hospital, 4Division of Hematopoietic stem cell transplantation, National Cancer Center Hospital, 5Department of Hematology, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo, 6Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, 7Department of Hematology, Sapporo Medical University, Sapporo, 8Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, 9Division of Hematology- Oncology, Japanese Red Cross Society Nairita Hospital, Nairita, 10Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, 11Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, 12Department of Hematology, Tokyo Women’s Medical University, Tokyo, 13Japanese Data Center for Hematopoietic Cell Transplantation, 14Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, 15Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

Background: Acute myeloid leukemia (AML) with inv(3)/(q21;q26.2) is categorized as AML with recurrent genetic abnormality in the WHO classification, accounts for approximately 1%-2% of AML, and is characterized by resistance to chemotherapy and poor clinical outcomes. Therefore, the presence of this chromosomal abnormality in AML is an indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, outcomes of AML with inv(3)/(q21;q26.2) remain unclear.

Aims: We retrospectively examined the impact of inv(3)/(q21;q26.2) on the outcomes of allo-HSCT in patients with AML.

Methods: Clinical data were collected from the registry database of the Japan Society for Hematopoietic Cell Transplantation. We selected patients with AML harboring inv(3)/(q21;q26.2), who were aged ≥16 years and underwent their first transplantation between January 2000 and December 2014. We analyzed outcomes as overall survival (OS), relapse, and non-relapse mortality (NRM) for the patients underwent allo-HSCT. OS was estimated using the Kaplan-Meier method and compared using the log-rank test. Relapse and NRM were considered as competing risk and were compared using the Gray’s test. In a multivariate analysis, the Cox proportional hazard model was used to analyze OS. The following variables, age, sex, disease status at transplantation, and disease intensity were taken for allo-HSCT from diagnosis, donor source, conditioning regimen, additional monosomy of chromosome 7 or partial deletion of long arm of chromosome 7 and type of 3q abnormality.

Results: Of 15025 patients with AML who were aged ≥16 years and who underwent first transplantation, inv(3)/(q21;q26.2) was identified in 23 patients (0.15%). The median age of patients who underwent HSCT was 33 years, range (16-58). Twenty-three patients had received transplant from haploidentical donors, while twenty-five patients received transplant from HLA-matched donors, of which included 13 ISD and 12 MUD. Chemorefractory disease at transplantation was more common in the haplo-HSCT group as compared to that in the HLA-matched HSCT cohort (P = 0.005). No significant between-group differences were observed with respect to distribution of age and sex, histological subtype, bone marrow involvement, aaIPI score, chemotherapy regimen and relapse after ASCT.

Results: Median age of patients at allo-HSCT was 33 years (16-58). Over a median follow-up of 23 months, 27 out of the 48 patients (56%) were alive. Progression free survival (PFS) rate at 2-years in the haplo-HSCT and HLA-matched HSCT groups was 52.1% and 56.6%, respectively (P = 0.75); 2-year overall survival (OS) rate was 52.8% and 57.8%, respectively (P = 0.83). Cumulative incidence of relapse (IR) was 41.7% and 35.0% (P = 0.37), while non-relapse-mortality (NRM) was 21.7% and 35.0%, respectively (P = 0.32). Collectively, these results showed no significant difference with respect to major allo-HSCT endpoints between the haplo-HSCT and HLA-matched-HSCT groups.

Results: Among 23 patients who had undergone haplo-HSCT, aGVHD occurred in 45 patients. Expression of PPARγ mRNA in healthy controls was significant and lower than that in patients after allo-HSCT within 90 days (P < 0.05). The expression of PPARγ mRNA held steady in non-GVHD patients within 90 days after allo-HSCT, and was significantly lower in GVHD group than in non-GVHD group (P = 0.05). The expression of IFNγ and TNF-β increased in aGVHD patients and were negatively correlated with PPARγ mRNA expression (P < 0.05). The experiment of MLR shows that PPARγ agonist rosiglitazone above concentration of 25μM had dose-dependent inhibition effect to proliferation of lymphocytes.

Summary/Conclusions: Low expression of PPARγ is associated with aGVHD occurrence and degree. PPARγ agonist can inhibit the proliferation of lymphocytes, which may be a new way to treat aGVHD.

Figure 1. Methods: 23 patients with R/R aggressive NHL who had undergone haplo-HSCT in our center between January 2004 and December 2015 were included, and data were retrospectively analyzed. 25 patients with R/R aggressive NHL who received HLA-matched HSCT during the same period constituted the control group for this analysis. All patients received myeloablative conditioning (MAC). The median age of patients who underwent HSCT was 33 years, range (16-58). Twenty-three patients had received transplant from haploidentical donors, while twenty-five patients received transplant from HLA-matched donors, of which included 13 ISD and 12 MUD. Chemorefractory disease at transplantation was more common in the haplo-HSCT group as compared to that in the HLA-matched HSCT cohort (P = 0.005). No significant between-group differences were observed with respect to distribution of age and sex, histological subtype, bone marrow involvement, aaIPI score, chemotherapy regimen and relapse after ASCT.
(HR, 2.03; 95% CI, 0.99-4.14; P=0.05) were risk factor with marginal significance for poor OS.

Summary/Conclusions: These findings revealed that AML with inv(3)/t(3;3) had dismal outcome even after allo-HSCT. Multivariate analysis suggested that a myeloablative conditioning regimen might improve the transplantation outcome.

E1523

PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)

P. Han1, B. Dhakal1, A. D’souza1, R. Thompson1, M. Hamadani1, M. Pasquini1, S. Chhabra1
1Medical College of Wisconsin, Milwaukee, United States

Background: Melphalan (MEL) is the most commonly used conditioning agent in AHCT for MM and exhibits a dose response relationship (Nath CE Br J Clin Pharmacol. 2010 May; 69(5):484). PG-free MEL (Evomela™) has longer stability in solution, results in a slightly higher systemic exposure compared with standard MEL and eliminates propylene glycol administration during high dose melphalan-based conditioning. This agent was shown to be bioequivalent to conventional melphalan leading to successful myeloablation and engraftment in MM pts receiving AHCT with no transplant related mortality or unexpected toxicity leading to its FDA approval (Hari P Biol Blood Marrow Transplant. 2015 Dec; 21(12):2100). Published studies thus far have used PG-free MEL in 2 consecutive daily doses of 100mg/m2/day while a single daily conditioning dose of 200mg/m2 (MEL200) is most commonly used in clinical practice.

Aims: Determine the safety and PK variability of high dose PG-free MEL 200mg/m2 in patients undergoing AHCT for MM

Methods: Open-label phase II study in which 10 serial blood samples at specific time points for the PK evaluation of melphalan were collected immediately prior to and after receiving single 200mg/m2 dose of PG-free MEL on day -2 as a 2mg/ml solution. The primary objective was a descriptive analysis of melphalan PK while secondary objectives included the response rates, engraftment and the toxicity and safety profile of PG-free MEL conditioning.

Results: As of Feb 2017, a total of 24 pts. were enrolled (63% male) with a median age of 67 years (range 46-72), including 23 (96%) who received upfront AHCT and 1 (4%) after relapse (Figure 1). High-risk cytogenetics was present in 6 (25%) pts 25% were in ISS stage 3. Disease status at transplant was complete remission (CR) in 4 (17%), very good partial remission (VGPR) in 12 (50%) and PR in 8 (33%). AHCT was performed entirely as outpatient in 25% of patients who underwent AHCT at Tel-Aviv Sourasky Medical Center and were alive 24 weeks after the transplant. In each patient we documented the absolute lymphocyte counts (ALC) starting 2 weeks after the transplant until the 24th post-transplant week. We used flow cytometry to characterize the lymphocyte sub-populations in lymphocytes derived from 20 randomly selected patients, assayed apoptosis by DiO6 binding and used fluorescence anti-MO2 monoclonal antibody to detect the MO2 epitope by flow cytometry. The probability of OS and of DFS was estimated by the Kaplan-Meier method. The log-rank test was used to compare survival distributions.

Results: The ALC was recorded at least once-weekly between the 2nd and 24th post-transplant weeks for each of the 105 study participants. The median ALC during the first 2-16 weeks was 1.4 X109/μL (range: 0.3 to 4.1) and varied considerably in a single patient. After the 16th week, the ALC stabilized and divided the cohort into those with high (n=54, median=1.9 X109/μL; range: 1.0 to 3.1) and low (n=51, median=0.9 X109/μL; range 0.15 to 1.25) ALCs. Patients with low ALCs were slightly younger, but in all other patient or disease characteristics there were no differences between the two groups. Remarkably, the CD4+ subpopulation was low across all patients, and the difference in ALCs was primarily in the CD8+ subpopulation which remained low in half of the patients and normal or above normal in others. Interestingly, patients with prolonged lymphopenia had higher rates of apoptosis in freshly obtained lymphocytes and the expression levels of MO2, a CD14-derived epitope that protects the cells from apoptosis correlated with lymphocyte counts. Patients with high ALCs during 16-24 post-transplant weeks had longer DFS (P=0.07) and OS (P=0.04) compared to patients with low ALCs. In a multivariable analysis low ALC at 16 to 24 post-transplant weeks was the strongest predictor for shorter OS.

E1524

IMPAIRED LYMPHOCYTE RECONSTITUTION AFTER AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH APOPTOSIS OF CD8+ T CELLS AND PREDICTS ADVERSE CLINICAL OUTCOME

U. Rozovsky1,2, B. Tartakovsky3, S. Frank1, E. Zigman-Hofman4, M. Yeshurun3, S. Trestman3, E. Naparstek6
1Hematology, Davidoff Cancer Center, Beilinson Campus, Petah Tikva, 2Tel Aviv University, 3Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, 4Scheinfeld Hospital, Beilinson Campus, 5Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, Petah Tikva, 6Hematology, Assuta Medical Centers, Tel Aviv, Israel

Background: In patients undergoing autologous stem cell transplantation (ASCT), faster recovery of the lymphocyte counts has been associated with longer disease-free survival (DFS) and longer overall survival (OS). We noticed that the post-transplant lymphocyte counts fluctuated significantly during the first post-transplant weeks and wondered what the clinical significance of this observation is, and what dictates the lymphocyte counts over time.

Aims: Describe the kinetics of post-ASCT lymphocyte reconstitution in a single patient and across patients. Determine whether activation of anti-apoptotic pathways are associated with faster recovery of the lymphocyte counts.

Methods: We reviewed the medical records of 105 consecutive patients with lymphoma (Non-Hodgkin’s lymphoma and Hodgkin disease) or multiple myeloma who underwent ASCT at Tel-Aviv Sourasky Medical Center and were alive 24 weeks after the transplant. In each patient we documented the absolute lymphocyte counts (ALC) starting 2 weeks after the transplant until the 24th post-transplant week. We used flow cytometry to characterize the lymphocyte sub-populations in lymphocytes derived from 20 randomly selected patients, assayed apoptosis by DiO6 binding and used fluorescence anti-MO2 monoclonal antibody to detect the MO2 epitope by flow cytometry. The probability of OS and of DFS was estimated by the Kaplan-Meier method. The log-rank test was used to compare survival distributions.

Results: The ALC was recorded at least once-weekly between the 2nd and 24th post-transplant weeks for each of the 105 study participants. The median ALC during the first 2-16 weeks was 1.4 X109/μL (range: 0.3 to 4.1) and varied considerably in a single patient. After the 16th week, the ALC stabilized and divided the cohort into those with high (n=54, median=1.9 X109/μL; range: 1.0 to 3.1) and low (n=51, median=0.9 X109/μL; range 0.15 to 1.25) ALCs. Patients with low ALCs were slightly younger, but in all other patient or disease characteristics there were no differences between the two groups. Remarkably, the CD4+ subpopulation was low across all patients, and the difference in ALCs was primarily in the CD8+ subpopulation which remained low in half of the patients and normal or above normal in others. Interestingly, patients with prolonged lymphopenia had higher rates of apoptosis in freshly obtained lymphocytes and the expression levels of MO2, a CD14-derived epitope that protects the cells from apoptosis correlated with lymphocyte counts. Patients with high ALCs during 16-24 post-transplant weeks had longer DFS (P=0.07) and OS (P=0.04) compared to patients with low ALCs. In a multivariable analysis low ALC at 16 to 24 post-transplant weeks was the strongest predictor for shorter OS.
remaining, both CD4+ and CD8+ subpopulations remained low and these patients were prone to develop relapse. These findings underscore a putative function of CD8+ T-cells in eliminating post-transplant residual disease and maintaining the patients disease free.

E1525

COMPARISON OF TECAM AND BEAM HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA: EFFICACY AND TOXICITY

F. Sahin1,*, P. Patir1, N. Akad Soyer1, R. Duruso2, G. Saydam1, M. Tobu1, M. Tomboluglu1, F. Vural1
1Hematology, Ege University Hospital Internal Medicine, 2Public Health, Ege University, Bornova, Turkey

Background: High-dose chemotherapy conditioning regimens followed by autologous hematopoietic stem cell transplantation (AHSCT) generally provide good results in relapsed and refractory lymphomas.

Aims: Limited data are available to guide the choice of conditioning regimen before AHSCT for patients with lymphoma. We evaluated the efficacy and safety of TECAM and BEAM regimens as conditioning with autologous stem cell support in patients with relapsed/refractory lymphomas.

Methods: From July 2011 to October 2016, 64 pathologically confirmed lymphoma patients underwent AHSCT with BEAM (n=32) or TECAM (n=32) regimens in Hematology Division of Ege University Faculty of Medicine. Patients were considered as high risk at diagnosis or with relapsed or refractory diseases for eligibility for AHSCST. The two groups were well matched in terms of age, gender, histology. Patients were conditioned with TECAM (thiotepa [40mg/m2 x four days], etoposide [200mg/m2 x four days], cyclophosphamide [60mg/kg x one day], cytarabine [200mg/m2 x four days] and melphalan [80mg/m2 x two days]) or BEAM (carmustine [300mg/m2 x one day], etoposide [200mg/m2 x four days], cytarabine [200mg/m2 x four days] and melphalan [140mg/m2 x one day]) regimens.

Results: The estimated 22-months overall survival for the TECAM and BEAM groups were 53% and 63%, respectively (p=0.41). The estimated 22-months progression-free survival in the BEAM group (59%) was relatively inferior to the TECAM (74%) group, but the differences were not significant (p=0.98). Cardiotoxicities were relatively more common in the BEAM group. No differences were observed in the time to hematopoietic recovery, the duration of hospitalization, hematological and nonhematological toxicities.

Summary/Conclusions: We conducted a single-center retrospective on lymphoma patients undergoing AHSCT, comparing efficacy and toxicity of TECAM and BEAM conditioning regimens. These two regimens are all optional high-dose chemotherapy with favorable efficacy and acceptable toxicity.

E1526

GENETIC MARKERS OF THE NEUTROPHENIA DURATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

E. Nazarova1,*, M. Horobryh2, V. Sharadov1, V. Demjanova1, N. Zorina2, N. Mineeva3, I. Paramonov3
1Laboratory of Immunology of Leukemia, 2Department of chemotherapy and bone marrow transplantation, 3Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation

Background: The successes achieved in the treatment of multiple myeloma (MM) in the past few years, associated with the use of high-dose chemotherapy, and with the use of new drugs. Using high-regimes with subsequent autologous hematopoietic stem cells (auto-HSCT) has increased both overall and progression-free survival of patients with MM, as well as improved quality of life. In most cases, patients in the early post-transplant period have severe toxic and infectious complications of varying severity that requires resource-intensive supportive care. The duration of the period of hematopoiesis hypoplasia is dependent on many factors, and an average of 14-16 days. In turn, the attachment of infectious complications in some cases adversely affect the duration of neutrophenia.

Aims: To evaluate the possible association of the immune response genes mutation status to the duration of neutropenia after autologous transplantation of peripheral blood stem cells in patients with multiple myeloma.

Methods: The study included 19 patients with multiple myeloma at the age of 32 to 67 years (median - 52 years) who underwent autologous transplantation of hematopoietic stem cells after conditioning regimen with high-dose melphalan. Among surveyed: 8 men and 11 women. In accordance with staging for Durie-Salmon (DSS) system in patients following stages of MM were installed: stage 1A in one patient (5.2%), stage 2A - in 12 patients (63.2%), stage 2B - in two patients (10.5%) and stage 3A - in four patients (21.1%). In the pre-transplantation period partial remission of the disease was achieved in seven patients (36.8%), very good partial remission - in eight patients (42.1%) and complete response in four patients (21.1%). Genotyping of polymorphisms of the innate immune response genes TLR2 (rs5743708), TLR3 (rs3775291), TLR6 (rs5743810), TLR9 (rs5743836), IL1β (rs2869762), IL4 (rs2243250), IL6 (rs1800795), IL10 (rs1800871), IL17A (rs2275913), CD14 (rs34424920), TNFα (rs1800629), FCGR2A (rs1801274) was performed by polymerase chain reaction with allele-specific primers (Lifeh, Russia) at the time of diagnosis.

Results: Depending on the duration of the neutropenia period all examined are divided into two groups. The first group included 10 patients with MM who have early observed recovery (within the first 13 days, 11-13 days), the number of leukocytes ≥1000 cells per ml after auto-HSCT. The second group consisted of nine patients with agranulocytosis held more than two weeks (≥14 days, 14-19 days). When comparing the genotyping data found that a longer period of neutropenia after autologous HSCT was significantly associated with the presence of genotype of MM patients homozygous wild-type allele A gene IL17A at position -197 (OR 13.15, 95%CI: 0.60-28.34, p=0.03) and with a predominance of heterozygous mutant allele C of the gene IL1β at position -31 (OR 8.17, 95%CI: 1.03-67.94, p=0.04).

Summary/Conclusions: Our findings point to immune response genes involved in the rate of recovery of hematopoiesis in MM patients after autologous HSCT. Identification of the wild-type allele in intron gene IL17A (G-197A) and mutant allele in intron gene IL1β (T-31C) will predict the risk of prolonging the period of agranulocytosis and, consequently, the risk of post-transplant complications, and develop a personalized strategy of managing them.

E1527

SUCCESSFUL TREATMENT WITH GRANULOCYTE TRANSFUSION AND EARLY NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC TRANSPLANT PATIENTS WITH FEBRILE NEUTROPENIA

A. Ünal1,*, L. Kaynar1, N. Kem1, A. Birekul1, E.E. Turak1, S. Sivgin1, B. Eser1, M. Çetin1
1Erciyes University Medical School, Kayseri, Kayseri, Turkey

Background: Febrile Neutropenia is very severe and urgent early complication after bone marrow transplantation before engraftment. Infection delays engraftments. In this study we retrospectively evaluated the effect and outcome of Granulocyte transfusion on febrile neutropenia and neutrophil engraftment in patients receiving allogeneic transplantation.

Aims: Between 2015-2016, five patients receiving allogeneic bone marrow transplantation (BMT) were treated with granulocyte transfusion at the time of febrile neutropenia before engraftment. They were given antibi-

Summary/Conclusions: Figure 1. Granulocyte was collected from unrelated and same blood groups donors. Mean infused granu-
ulocyte counts were 3.6x10^3/μl (1.3-4.6x10^3/μl/day). Twenty-four hours after granulocyte transfusion, mean neutrophil counts were 0.6x10^3/μl (0.4-0.8x10^3/μl/d). Neutrophil counts were 2.6x10^3/μl (1.7-2.6x10^3/μl/d), after 48 hour. After 72 hours, neutrophil counts were 3.4x10^3/μl (2.1-4.5x10^3/μl/d). After 48 days of granulocyte transfusion, neutrophil counts were normal levels (>0.5x10^3/μl/d).

Summary Conclusions: Granulocyte transfusions during the febrile neutropenia, helped to better overcome febrile neutropenia periods in allogeneic transplant patients before engraftment. In addition, granulocytes transfusion also may help early neutrophil engraftments.

E1528
DEFIBRITODE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCULSIVE DISEASE AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION; A SINGLE CENTER EXPERIENCE
B. Antnme1,2, I. Sasmaz1,2, B. Karagun1, M. Serbst1
1Pediatric Bone Marrow Transplantation Unit, Department of Pediatric Hematology, Adana Acibadem Hospital, 2Pediatric Hematology, Cukurova University, Adana, Turkey

Background: Hepatic veno-occlusive disease (VOD) is a common and serious complication of hematopoietic stem cell transplantation (HSCT) in children. We aimed to assess prospectively the use of prophylactic defibrotide in pediatric patients undergoing HSCT.

Aims: We aimed to assess prospectively the use of prophylactic defibrotide in pediatric patients undergoing HSCT.

Methods: In this study, 113 patients who underwent HSCT were given defibrotide prophylaxis as 25mg/kg per day in four divided intravenous infusions over 24h, starting on the same day as the pretransplantation conditioning regimen. The mean duration of use of defibrotide is 25 days as a prophylaxis.

Results: In this study, 113 patients were recruited, 66 male patients and 47 female patients, with the average of 9.1 years, range 1-20; 8% infants, 55% children and 37% adolescent. There were 50 patients with thalassemia major, 41 patients with leukemia; 11 patients with aplastic anemia, one patient with Diamond Blackfan anemia, two patients with congenital dyserythropoietic anemia, one patient with osteopetrosis, four patients with familial hepatic phosphatase deficiency, two patients with severe immune deficiency and one patient with Kostman syndrome. All transplants were allogeneic. No serious side effects were seen. In eight patients developed clinical VOD (Seattle criteria). In these patients, defibrotide dose was increased to a treatment dose of 40-60mg/kg per day. One infant patient with Kostman syndrome died due to hepatic and pulmonary veno-occlusive disease. After 36 months of follow up, 7 patients who developed VOD are being well and no patient have transplant related complications.

Summary Conclusions: Hepatic veno-occlusive disease, which is caused by hepatocyte and sinusoidal vessel endothelium damage, can occur early after HSCT, and in its severe form, may lead to liver failure, hepatorenal syndrome, portal hypertension, and eventually death from multiorgan failure. In this prospective study, we demonstrated that the use of defibrotide is safe and effective in preventing and treating VOD in pediatric patients at high risk.

E1529
ACUTE RENAL IMPAIRMENT IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS, A PREDICTOR OF MORTALITY
A.J. Mahdi1,2, D. Foxwell1, G. Scott1, D. Davies1, K. Wilson1, W. Ingram1
1Department of Haematology, 2Department of Nephrology, University Hospital of Wales, Cardiff, United Kingdom

Background: Allogeneic stem cell transplant (ASCT) remains the only curative option in many malignant and non-malignant conditions. There remains however, uncertainty of morbidity and mortality. One risk, acute kidney injury (AKI), can result from drug toxicity and/or haemodynamic instability from sepsis and/or graft vs host disease (GVHD). Existing reports on the impact of AKI have concentrated on patients undergoing mainly myeloablative (MA) conditioning alone, whereas those undergoing reduced intensity conditioning (RIC) transplants have reported outcomes from limited patient numbers.

Aims: To investigate the incidence, causes and consequences of AKI in patients undergoing ASCT, including survival.

Methods: The prospectively maintained database of the South Wales Blood and Marrow Transplant programme which serves 77% of the Welsh population, was interrogated to identify patients undergoing ASCT from January 2010 to December 2015. Patients received ciclosporin as GvHD prophylaxis to 100 mg/kg for 60 days. Causes of AKI were assigned after independent review. AKI was defined as a rise in serum creatinine by ≥0.3 mg/dl within 48 hours from baseline. AKI was further classified as acute tubular necrosis, non-oliguric acute renal failure and oliguric acute renal failure.

Results: A total of 229 patients were identified (17% children, 45% adolescents, 45% adults). Pre-existing renal impairment was uncommon (mean eGFR 92ml/min, range 45-143ml/min). During the first 100 days, no differences were seen in mean eGFR in survival vs non-survival groups (75 and 80ml/min respectively, p=0.23). Amongst all patients, AKI incidence in the first 100 days was greater in the non-survival group (93.2% vs 80.6%, p=0.02). On multivariate analysis, AKI event in the first 100 days and HLA mismatch (>8/8) were independent factors predicting mortality (p=0.02 and p=0.04 respectively). Recipient age and gender, ASCT indication, score of hypertension, CAV1 status, donor sex, stem cell source and conditioning regimen (MA vs RIC) were not statistically significant (p=0.05). Within the first year of ASCT, pre-terminal AKI was noted in 29% (n=23) of all patients dying (n=59) with sepsis accounting for nearly non-relapse causes (Death (n=15) of the patients alive, only 11% had chronic renal impairment. Chronic GvHD was associated with these patients (73%) one of whom was dialysis dependent.

Summary Conclusions: AKI is very common post ASCT. Chronic renal failure is uncommon in long-term survivors. AKI is however a prominent event preceding death. Consistent with other reports AKI and HLA mismatch predicted inferior outcomes. Poor survival from AKI probably reflects physiological strain from other complications (e.g. sepsis and GVHD). Early recognition and treatment of AKI are important measures in the supportive care of patients with AKI.

E1530
PREDICTIVE INDEXES FOR ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER EXPERIENCE
J. Zanabili Al-Sibai1,*, M.P. Palomo Moraleda1, A.J. González Huerta1, T. Arias Fernández1, L.R. Morais Bras1, L.F. Ávila Idrovo1, C. Castaño Fernández1, A. Solé Magdalena1, S. González Muñiz1, A.P. González Rodríguez1
1Hematology, HUCA, Oviedo, Spain

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often associated with complications such as graft-versus-host disease (GVHD), resulting in poor outcome, relapse and death. Introduction of reduced intensity conditioning (RIC) regimens and improvements in supportive care, have allowed offering allo-HSCT to more and older patients (pts). A balanced risk-benefit approach of candidates for allo-HSCT is the key for maximizing chances of cure with acceptable quality of life.

Aims: Compare the potential utility of two pretransplant predictive models: PAM (pretransplant assessment of mortality; Parimon et al, AIM 2006) and HCT-CI (HCT comorbidity index; Sorror et al, Blood 2005), in our cohort of pts.

Methods: We retrospectively studied 154 pts, 86 (55.8%) were males with a median age of 51 years (range: 15-68), who underwent allo-HSCT in our center between May 2005 and December 2014. Patients’ baseline diseases were: acute myeloblastic leukemia (24%), multiple myeloma (22.7%), non Hodgkin lymphoma (11.7%), acute lymphoblastic leukemia (11%), myelodysplastic syndrome (9.1%), chronic lymphocytic leukemia (5.2%), Hodgkin lymphoma (3.9%), aplastic anemia (3.9%), myelofibrosis (3.9%), chronic myloid leukemia (1.3%), Waldenström macroglobulinemia (1.3%) and others (1.8%). Eighty (51.9%) pts received cells frommatched siblings, seventy (45.5%) from unrelated donor (n=59) with matched related donor (n=24). Twenty (13%) pts received RIC regimens. Stem cell source were: peripheral blood (n=86), bone marrow (n=63) and umbilical cord (n=5). Median and maximum follow-up were 31 and 228 months, respectively.

Figure 1.

Results: After allografting, 57.1% pts had complications, the most frequent were: infections (45.5%), followed by nephrotoxicity (25.3%), hepatotoxicity (12.3%), pulmonary toxicities (9.7%) and cardiotoxicity (3.9%). Eighty-two per- cent of pts with high/very high risk group of PAM score presented complications vs 46% of pts included in low/intermediate risk (p<0.001). Regarding GVHD, 41.6% and 31.2% of pts developed aGVHD (grades II to IV) and cGVHD, respectively. PAM score was a good predictor for aGVHD risk: 38.1% of pts with low/intermediate risk had aGVHD versus 59.3% of pts with high/very high risk p<0.001. Amongst all pts, acute GvHD (n=26) was 24%. Causes of NRM included infections (45.8%), hemorrhage (10%), pulmonary toxicities (16%), second neoplasia (14.6%), GVHD (6.25%), cardiotoxicity (2%) and hepatic toxicity (2%). PAM score effectively risk-stratified pts for NRM: 17%, 24.7%, 45.8%, and 50%
E1531

ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK PERIPHERAL T-CELL LYMPHOMAS

H. Huang1,2, Y. Jiang1, Q. Wang1, T. Xu1, X. Chen1, Z. Jin1, D. Wu1
1Soochow University, Suzhou, China
222 nd Congress of the European Hematology Association

BACKGROUND: Peripheral T-cell lymphomas (PTCLs) often carry poor outcomes with conventional chemotherapy, and hematopoietic cell transplantation (HCT) can benefit patients with PTCL. Recent retrospective studies have reported that autoHCT as consolidation can offer a durable survival benefit in high-risk patients with first complete or partial response, and alloHCT could result in long-term disease control for relapsed and refractory patients.

AIMS: To explore questions about the optimal timing for stem cell transplantation and relative efficacy of auto-HCT versus alloHCT.

METHODS: We conducted a retrospective review of 67 patients with peripheral T-cell lymphoma who underwent autologous HCT (autoHCT, n=43; median age 40 years) or allogeneic HCT (alloHCT, n=24; median age 36.5 years) from 2004 to 2016.

RESULTS: With a median follow-up of 27 months, 5-year PFS and OS of auto-HCT patients were 49% and 57%, respectively. Among alloHCT recipients, the 5-year PFS and OS were 54% and 55%, respectively. When considering incidence of disease relapse or progression (CIR) and nonrelapse mortality (NRM), the 5-year CIR and 1-year NRM of alloHCT recipients were 38% and 18%, respectively, and 58% and 7% of autoHCT patients, respectively. There were no differences between autoHCT and alloHCT on 5-year PFS (P=0.499), OS (P=0.566), CIR (P=0.555) and NRM (P=0.202). When specifically examining recipients in primary refractory disease, 3-year PFS rates of autoHCT and alloHCT were 20% and 49% (P=0.054), 3-year OS rates were 20% and 53% (P=0.042), respectively.

Figure 1.

Summary/Conclusions: This analysis shows that HCT can benefit patients with high-risk PTCL in both remission and primary refractory setting. The outcomes did not differ significantly between autoHCT and alloHCT approaches, but alloHCT recipients in primary refractory disease resulted in significantly better outcomes than autoHCT patients. So, we favor proceeding to alloHCT if patients with PTCL in primary refractory disease.

E1532

IMPACT OF BASELINE BILIRUBIN ON SURVIVAL IN PATIENTS WITH HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME RECEIVING DEFIBROTIDE: POST-HOC ANALYSIS OF EXPANDED-ACCESS PROTOCOL FINAL DATA

P. Richardson1,2, A. Smith2, B. Triplett3, N. Kerman4, S. Grupp5, J. Antin6, L. Lehmann7, S. Giralt8, W. Liang9, R. Hume9, W. Tappe9, R. Soiffer7
1Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 2Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, 3Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, 4Pediatric BMT Service, Memorial Sloan Kettering Cancer Center, New York, 5Pediatric Oncology, Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, 6Center for Stem Cell Transplantation, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, 7Center for Stem Cell Transplantation, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 8Memorial Sloan-Kettering Cancer Institute, New York, 9Jazz Pharmaceuticals, Inc., Palo Alto, United States

BACKGROUND: Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable, potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) conditioning. VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved in the European Union to treat severe hepatic VOD/SOS post-HSCT and in the United States to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT. Prior to approval, defibrotide had been available in the United States via an expanded-access program.

AIMS: A post-hoc analysis of final data from the defibrotide expanded-access program was used to explore Day +100 survival post-HSCT based on bilirubin-level categories at the time of study entry.

METHODS: Patients in the defibrotide expanded-access program had VOD/SOS diagnosed by investigators using Baltimore criteria (bilirubin ≥2mg/dL and ≥2 of: hepatomegaly, ascites, ≥5% weight gain), modified Seattle criteria (≥2 of: bilirubin ≥2mg/dL, hepatomegaly, or ascites and/or≥5% weight gain), or biopsy; bilirubin ≥2 was not required for modified Seattle criteria or biopsy. MOD (renal and/or pulmonary) was permitted. After informed consent, defibrotide treatment (25mg/kg/day) was recommended for ≥21 days. Here, Day +100 survival was explored by bilirubin level at study entry using categories that are part of the European Society for Blood and Marrow Transplantation (EBMT) proposed grading scale for adults (≥2 to ≤3mg/dL, ≤3 to ≤5, ≤5 to ≤8, and >8), as well as bilirubin <2mg/dL, which is not part of the scale but has been reported in children with VOD/SOS.

RESULTS: There were 1000 HSCT patients enrolled, between December 2007 and September 2016, with a confirmed diagnosis of VOD/SOS and receiving ≥1 dose of defibrotide, 512 patients had MOD. Median age was lowest in patients with bilirubin <2 (4.5 years); 19% of patients; median age was 16 years in the bilirubin ≥2 to <3 group (53.5% of patients) and 13.5 in the ≥3 to <5 group (20.4% of patients); median age in other groups ranged from 15 to 17 years. Kaplan-Meier estimated Day +100 survival in all HSCT patients was 58.9%, with 85.6% in patients with BR <2; other bilirubin groups were older and survival estimates decreased (Table 1). In the pediatric (aged ≤16 years) and adult (aged >16 years) patients, patterns were similar (Table 1). Estimated survival rates were lower for patients with MOD across all groups. Of all 1000 HSCT patients with confirmed VOD/SOS, 210 (21%) had treatment-related AEs (TRAEs). The TRAEs in >2% of patients were pulmonary hemorrhage (4.6%), gastrointestinal hemorrhage (3.0%), epistaxis (2.3%), and hypotension (2.0%).

Table 1. Day +100 Survival (Kaplan-Meier, N=1000).

<table>
<thead>
<tr>
<th>Bilirubin (mg/dL)</th>
<th>All HSCT Patients</th>
<th>Age ≤16 Years</th>
<th>Age &gt;16 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤2</td>
<td>190</td>
<td>85.6%</td>
<td>53.3%</td>
</tr>
<tr>
<td>2 ≤ ≤3</td>
<td>535</td>
<td>55.5%</td>
<td>67.3%</td>
</tr>
<tr>
<td>3 ≤ ≤5</td>
<td>204</td>
<td>42.7%</td>
<td>58.8%</td>
</tr>
<tr>
<td>5 ≤ ≤8</td>
<td>42</td>
<td>33.3%</td>
<td>22.0%</td>
</tr>
<tr>
<td>&gt;8</td>
<td>39</td>
<td>33.3%</td>
<td>17.2%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This post-hoc analysis found that higher bilirubin levels were generally associated with lower Day +100 survival. These results should be interpreted with caution, as only 1 EBMT criterion was analyzed. MOD was also associated with lower Day +100 survival. The results suggest that diagnosis and treatment of VOD/SOS, before bilirubin becomes markedly elevated, may be associated with improved outcome.

Support: Jazz Pharmaceuticals.

E1533

LONG-TERM FOLLOW-UP OF A PROSPECTIVE TRIAL OF INTENSIFIED CHEMO-IMMUNOTHERAPY WITH AUTOLOGOUS OR ALLOGENIC STEM CELL TRANSPLANTATION IN PATIENTS AFFECTED BY PERIPHERAL T-CELL LYMPHOMA

P. Corradini1,2, U. Vitol1, A. Rambaldi1, R. Miceli1, F. Patriarca2, A. Gallamini2, F. Benedetti1, G. Todeschini1, G. Rossi2, F. Salvi1, B. Bruno2, C. Tarella1, S. Pileri2, A. Dodero1
1Department of Medical Oncology, IRCCS Istituto Nazionale dei Tumori, Milano, 2Hematology, Azienda Ospedaliera Universitaria Città della Salute, Torino, 3Hematology, Ospedale Papa Giovanni XXIII, Bergamo, 4Statistical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 5Hematology,
Cancellations for donor-related reasons and the following factors: donor sex, grounds and inability to contact the donor. We examined associations between distinguished 3 categories: donor medical reasons, donor withdrawal on personal grounds and donor pull-out on personal grounds and 4% (n=9) due to uncontactable donors. Donor reasons accounted for 38% of cancellations (n=216, 6.8% of requested donors), of which 69% (n=148) happened for medical reasons, 27% (n=59) for donor pull-out on personal grounds and 4% (n=9) due to uncontactable donors. The medical reasons for withdrawal were varied but the most frequent health issues were obesity and cardiovascular disease. Analyses of factors affecting donor reasons showed that donor sex and time on the register were not associated with donor fitness or withdrawal rate. Age had no impact on donor pull-out, but it was significantly associated with medical eligibility and donors who were patients. Donor pull-out was more frequent for donors who were shown a significant association with blood donor reliability score (p=0.028, score 5 vs others). In 48 cases (8%) there were mixed reasons where TCs had other donor options and pursued them because of issues such as donor availability for ideal dates or CMV mismatches.

Summary/Conclusions: In our registry patient-related issues accounted for more than half of cancellations at a late stage in the stem cell donor pathway. Cancellations for donor reasons were unusual (6.8% of requested donors), which figure compares favourably with international data (12.4% of requested donors, WMDA Annual Report 2015). This is likely due to the fact that most BBMR donors are regular blood donors: few donors withdrew for personal reasons. Medical reasons for frequent cause of cancellation for donor reasons. Further work is underway to allow earlier or reduced deferral of medically unsuitable donors such as control of high blood pressure and to explore personal reasons which cause donors to withdraw. This study should provide reassurance to TCs that BBMR provide reliable and accessible stem cell donors.

E1535 POLIMORPHISM IN TGFβ1 GENE PREDISPOSES TO RELAPSE AND DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE GRADES III-IV

N. Meggges1, P. Kocyi, V. Telek1, K. Balassa1, L. Varga1, A. Bors1, P. Micsenyi1, G. Mathei1, A. Batai1, E. Torobygi1, L. Gopcsa1, L. Lengyel1, A. Barta1, A. Tor1, T. Masszi1, H. Andrikovics1
1Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, 2School of PhD Studies, Semmelweis University, 3Department of Haematology and Stem Cell Transplantation, St. Istvan and St. Laszlo Hospital, 4Department of Pathophysiology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the most effective treatment option for certain hematologic malignancies. Cytokines play a well established role in the mechanism of acute GvHD (aGvHD), which is one of the most significant complications following hematopoietic stem cell transplantation (HSCT).

Methods: We examined the association of recipient and donor TGFB1 -1347T>C polymorphism in the outcome of HSCT.

Aims: The aim of this study was to investigate the role of TGFB1 -1347T>C polymorphism in the outcome of HSCT.

Results: We did not find any association between recipients’ TGFB1 -1347T>C polymorphism and HSCT outcome. However, in patients whose unrelated donors carried homozygous TGFB1 -1347TT variant, aGvHD grades III-IV occurred more frequently (aGvHD grade III-IV: 28.9% vs aGvHD grade 0-II: 9.6%, p=0.006). Similar finding was observed on a subgroup of patients with acute leukemia: in aGvHD grade III-IV 37.5%, while in grade 0-II 11.5% of patients had TT genotype (p=0.022). Donor TT genotype did not influence the relapse rate significantly. Patients with MUD carrying TT genotype had lower overall survival (OS) that of donors bearing at least one C variant, but the differences were not reach statistical significance (OS at 40 month for CC and CT variant donors: 45.3% and for TT donors: 26.2%). In case of sibling donors, we did not find association between recipient or donor genotype and aGvHD, but relapse rate was increased if donor had at least one T variant (n=115, 67.9% vs 32.1%, p=0.028).

Summary/Conclusions: Our findings suggest that TGFB1 -1347T>C polymorphism in HSCT donors might influence the development of aGvHD in unrelated and the relapse rate in related HSCT.
E1536
EARLY AND LATE LOST OF PROTECTIVE ANTIBODY LEVELS AGAINST MEASLES, MUMPS AND RUBELLA IN PATIENTS GIVEN ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION
J. Bögeholz1,*, E. Haralambieva2, M.G. Manz1, U. Schanz1, A.M. Müller1
1Hematology, 2Pathology, University Hospital Zurich, Zurich, Switzerland

Background: Live-vaccines should be avoided in the early period following allogeneic hematopoietic cell transplantation (HCT), due to a possible uncontrollable proliferation of the attenuated strains. The post HCT immune system is severely compromised by pharmacological immunosuppression and disruption of lymphoid tissues by conditioning and donor T cell alloreactivity. Patients frequently lost their antibody-based immunity against measles, mumps, and rubella after receiving allogeneic HCT.

Aims: Here, we studied the dynamics of antibody (AB) titers against measles, mumps, and rubella post-HCT.

Methods: We retrospectively analyzed serial AB titers in 240 patients who underwent allogeneic HCT from related and unrelated HLA-matched donors from 2002-2014 at our center. AB titer against measles, mumps and rubella were measured prior to HCT, at 6 months (m), and every year (y) post-HCT.

Results: Most patients had protective AB titers (measles 90%, mumps 86%, rubella 92%) prior to HCT. AB protection against mumps was lost in a substantial proportion of patients after HCT (protective AB titers in 72%@y1, 56%@y5, 50%@y8), comparing to AB against measles, which persist more frequently (protective AB titers in 85%@y1, 74%@y5, 73%@y8). We found a faster lost of protective AB in the first years for patients given a myeloablative condition (MAC) in comparison to patients with reduced condition (RIC), but the proportion of seropositive patients became more equal over time (Figure 1 displays the percentage of seropositive patients to Measles AB given MAC or RIC during 8 years post-HCT). The proportion of patients who retained protective AB titers at 5y post-HCT was higher in recipients of mobilized peripheral blood compared with bone marrow (BM) grafts (measles p=0.01, mumps=0.06, rubella=0.08). For rubella, absolute AB titers were available. Patients with lymphoid malignancies, ongoing GVHD and pharmacological immunosuppression had a steeper decline of rubella AB titers as compared to patients with myeloid malignancies.

Summary/Conclusions: We found a marked decline of AB titers post-HCT with loss of protection in a substantial proportion of patients. Surprisingly, BM grafts did not provide better AB protection post-HCT, despite their higher content of (donor) plasma cells. Together with the observations that (i) patients with lymphoid malignancies (who have received (B-) lymphocyte targeted therapies prior to HCT) had lower AB levels, while (ii) those given reduced intensity conditioning have a higher percentage of protective AB levels in the first years, our data suggest, that residual host plasma cells significantly contribute to AB production during the first years post-HCT. In opposite, the loss of protective AB levels in later years after transplantation was independent of the toxicity of the conditioning regime and may be a effect of weakening signaling for host plasma cells or late donor alloreactivity.

E1537
MICA AND NKG2D POLYMORPHISMS HAVE A SIGNIFICANT IMPACT ON GRAFT VERSUS HOST DISEASE AFTER HLA-MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
M.-J. Apithy1, A. Charbonnier2, J. Desoutter1, P. Morel2, J.-P. Marolleau2, N. Guillaume1

1Hematology and Histocompatibility, 2Hematology and cellular therapy, University Medical Center, AMIENS, France

Background: MICA (MHC class I polypeptide-related sequence A) is a highly polymorphic gene closely linked to the HLA-B locus. It encodes a cell stress inducible glycoprotein, which mediates an activator signal towards the NKG2D receptor expressed on NK-cells, CD8+ T-cells and NKT-cells. MICA polymorphisms have been shown to influence NKG2D signaling. Indeed, a methionine to valine change at position 129 in exon 3 categorized the MICA alleles into strong (MICA-129 met) and weak (MICA-129 val) binders of NKG2D receptor. 5 repetitions of COT with 1 additional nucleotide insertion (G) in exon 5 designed the MICA A5.1 alleles with a premature stop codon. Moreover, NKG2D polymorphisms identified alleles associated with a low (NKC3 C/C and NKC4 C/C) or high cytotoxic activity (NKC3 G/G and NKC4 T/T).

Aims: In this study, we hypothesized that polymorphisms at the MICA and NKC2D loci are associated with adverse outcomes in HSCT.

Methods: Here, we evaluated whether recipient MICA and donor NKG2D polymorphisms (respectively MICA-129, MICAAS.1 and NKC3, NKC4) could influence the incidence of acute and chronic graft versus-host disease (GVH), overall survival (OS) and relapse free survival (RFS) on 124 patients undergoing allogeneic hematopoietic stem cell transplantation using an HLA-matched donor (10/10).

Results: In an univariate model, recipient MICA A5.1 heterozygosity (p=0.030) and donor NKC4 C/C polymorphism (p=0.013) are associated with the increase of incidence of acute GVH (grade I to IV). Recipient MICA A5.1 heterozygosity is also associated with chronic GVH (p=0.04) while Recipient MICA-129 val/val tends to be a risk factor of chronic GVH without being statistically significant. These polymorphisms have no significant impact on OS and RFS in our study (median of follow up=15 months; range 0.2-49 months).

Summary/Conclusions: Our data suggest that a MICA or NKG2D low activity status can be related to an increase of acute GVH according to a mechanism that remains to be elucidated, maybe by a low cytotoxic activity on recipient dendritic cells.

Figure 1.

Summary/Conclusions: We found a marked decline of AB titers post-HCT with loss of protection in a substantial proportion of patients. Surprisingly, BM grafts did not provide better AB protection post-HCT, despite their higher content of (donor) plasma cells. Together with the observations that (i) patients with lymphoid malignancies (who have received (B-) lymphocyte targeted therapies prior to HCT) had lower AB levels, while (ii) those given reduced intensity conditioning have a higher percentage of protective AB levels in the first years, our data suggest, that residual host plasma cells significantly contribute to AB production during the first years post-HCT. In opposite, the loss of protective AB levels in later years after transplantation was independent of the toxicity of the conditioning regime and may be a effect of weakening signaling for host plasma cells or late donor alloreactivity.

E1538
STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING USING TIMED SEQUENTIAL BUSULFAN IMPROVES OUTCOMES IN OLDER AML AND MDS PATIENTS.
B. Oran1,*, R. Saliba1, S. Ahmad1, A. Alousi1, S. Cirea1, C. Hosing1, I. Khouri1, D. Marin1, A. Olson1, Q. Bashar1, Y. Nieto1, K. Rezvani1, P. Kebriaei1, B. Valdez1, E. Shpall1, B. Andersson1, R. Champlin1, U. Popat1

1Hematology and Transplantation Cell Therapy, The University of Texas MDACC, Houston, United States

Background: We previously reported 6% 100 day NRM with a MA fludarabine (Flu) and busulfan (Bu) in older patients with a median age of 60 years. MA dose of Bu in this timed sequential (TS) regimen was administered over a longer period of time. To assess its impact on survival, we compared the outcomes of older patients treated with the TS Bu (TS cohort) and the reduced intensity conditioning with Flu/Bu regimen, which is used as standard (ST) for older patients at our center ST cohort.

Aims: To assess its impact on survival, we compared the outcomes of older patients treated with the TS Bu (TS cohort) and the reduced intensity conditioning with Flu/Bu regimen, which is used as standard (RIC cohort) for older patients at our center.

Methods: Patients in the TS cohort received Flu 80mg/m2/day on day -13 and -12 and Flu 40mg/m2/d followed by IV Bu on day -6 to -3, dose adjusted to achieve a total Bu course AUC of 16,000μmol-min based on PK studies. Patients in the ST cohort received Flu 40mg/m2/d day followed by IV Bu daily for 4 days (day -6 to -3) dose adjusted to achieve AUC of 16,000μmol-min. Patients with AML or MDS were eligible for the study if they had adequate organ function, had matched related or unrelated donor and were treated between Jan 2012 and Se.

Results: Patient characteristics including age, sex, disease status, cytogenetic risk group, donor type, graft source CMV status and comorbidity were similarly distributed between the two cohorts. Median age was 66 and 65 years in TS-MAC and RIC cohorts respectively. Overall survival (OS) and progression free survival (PFS) were significantly better in the TS-MAC cohort. This was due to a reduction in the disease progression without any increase in the TRM. After adjusting for other covariates, the multivariate analysis for PFS confirmed a reduction in the disease progression without any increase in the TRM. After adjusting for other covariates, the multivariate analysis for PFS confirmed that TRM was not significantly different between the two cohorts.

Table 1.

Summary/Conclusions: The myeloablative timed sequential Bu regimen improves survival and appears promising in older patients with AML/MDS. The myeloablative timed sequential Bu regimen improves survival and appears promising in olderpatients with AML/MDS.
E1539

HAPOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DEPLETION OF TCR αβ (+) IN CHILDREN: ERCIES PEDIATRIC BMT CENTER

M. Karakucuk1, E. Unal1, E. Yilmaz1, A. Ozcan1, S. Kose1, G. Ucan1, T. Patiroglu1,* 1Department of Pediatrics, Division of Pediatric Hematology Oncology, Erciyes University, Faculty of Medicine, Kayseri, Turkey

Background: Recently, haploidentical hematopoietic stem cell transplantation (HSCT) poses an alternative option for patients without a suitable donor. Erciyes Pediatric BMT Center is the first pediatric center for haploidentical HSCT with depletion of TcR αβ (+) in Turkey.

Aims: We would like to share our pediatric experience with a follow up period of up to four years.

Methods: All children who underwent haploidentical HSCT in our center from December 2012 to February 2017 were included in the study. Total 51 haploidentical HSCT in 44 children (17 relapsed/refractory AML, 9 relapsed/refractory ALL, 4 SAA, 4 HLH, 2 Fanconi aplastic anemia, 2 Gisciroid sydrome, 1 JMML, and 5 SCID) were performed. Transplantation-related mortality (TRM) was 13.7%. The regimen included ATG, Fludarabine, Thiotepa, Melphalan. Mycophenolate mofetil (MMF) was given as GvHD prophylaxis if the graft contained ≤5 x10^5 TCR αβ (+).

Results: The mean number of TCRαβ depletion was 9.3x10^6/kg. The median number of apheresis was 2 (1-4) performed after chemotherapy and G-CSF mobilization in most cases, 19 pts were mobilized. The median of previous lines was 2 (1-9). The stem cell collection was performed on day 8 after chemotherapy and G-CSF mobilization in most cases. In 35 pts the median dose was 3.7x10^6/kg. In 35 pts we observed no GvHD, 40 pts had grade I-II GvHD, and 6 pts had grade III-IV GvHD. The regimen included ATG, Fludarabine, Thiotepa, Melphalan. MMF was given as GvHD prophylaxis if the graft contained ≤5 x10^5 TCR αβ (+). The mean day of discharge was 34th day of HSCT. The long term follow up was performed in 18 patients. The analysis of the immune reconstitution of the patients transplanted in haploidentical HSCT group showed a rapid immune reconstitution for CD3+ T cells 732 (range 126-2432) mm3; for CD4+ helper T cells 92 (range 1-419); for CD8+ cytotoxic T cells 310 (range 95-2235) mm3 at 28th day of HSCT. Ten out of 14 patients (71%) are alive, with a median follow up of 24 months (range 1 to 49 months). Overall survival was 65%, in these group.

Summary/Conclusions: Our primary results underline that haploidentical HSCT with depletion of TcR αβ (+) can be an option in experienced center in countries in which unrelated donor programs are not satisfactory, as in Turkey. The availability of a haploidential donor in most families is a potential advantage. Moreover probably more potent graft-versus-tumor effect can be induced with haploidential HSCT.

E1540

SECONDARY MYELODYSPLASTIC SYNDROME AND/OR ACUTE LEUKEMIA INCIDENCE AFTER AUTOLOGOUS TRANSPLANTATION FOR LYMPHOMA PATIENTS IS CONNECTED WITH DECREASE OF HEMATOPOIETIC RESERVE

M. Tmien1,2, M. Trnkova1, D. Pohlreich1, B. Vackova1, Z. Gasova2, R. Pytlík1, P. Blahova1,2 1Charles University General Hospital, 2Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Background: Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/AML) is one of the most important long term complication of high dose therapy (HDS) with autologous stem cell transplantation (ASCT). The factors usually described to be associated with sMDS/AML development are pretreatment, HDS itself, radiotherapy, age and recently the evidence of TP53 mutations (Wong, Nature 2015) or clonal hematopoiesis (Gibson, JCO 2016) before ASCT.

Aims: To analyze our center’s experience in the treatment of TA-TMA with defibrotide.

Methods: We identified 17 TA-TMA episodes treated with defibrotide in 16 allo-FSC recipients.

Results: The risk of sMDS/AML was 4.0% at 10y after ASCT and was connected with heavier pretreatment, which leads to the decrease of BM reserve, hematopoietic clonal development. The lower dose of CD34+ cell, used routinely to use BM progenitor cell and prolonged platelet engraftment could be considered as critical markers of these biological processes.

E1541

USE OF DEFIBROTIDE TO TREAT TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

M. Martinez-Munloz1,2, A. Larío1, G. Bautista1, J. Bueno1, B. Navarro1, A. Baguesa1, J. Cabrera1, R. Duarte1 1Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Majadahonda, Spain

Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe early transplant complication which results from endothelial injury and it exhibits characteristics of an atypical hemolytic uremic syndrome. Beyond removal or treatment of precipitating factors and, more recently, treatment with eculizumab, TA-TMA remains a therapeutic challenge. Defibrotide, with marked protective effects on the endothelium and the potential to restore thrombofibrinolytic homeostasis in small vessels, may be considered a therapeutic option for TA-TAM.

Aims: To analyze our center’s experience in the treatment of TA-TMA with defibrotide.

Methods: We reviewed all cases of TA-TMA treated with defibrotide in our allo-genetic transplant recipients between October 2008 and November 2016. All cases had non-immune hemolytic anemia with high LDH, low haptoglobin and negative Coombs test, >2 hct by high power field and thrombocytopenia (<50 x10^9/L or <50% of normal baseline). Cases without signs of renal or pulmonary involvement were excluded.

Results: We identified 17 TA-TMA episodes treated with defibrotide in 16 allo-genetic transplant recipients: 9 men; median age 38 years old (16-57); 10 single-cord blood plus third-party donor cells [Bautista G, 2009], 3 HLA-identical siblings and 3 unrelated donors; 3 myeloablative conditioning regimen, 10 with total body irradiation (Table 1). Co-morbid risk factors at the time of TA-TMA onset were: calcineurin inhibitor treatment in all cases (13 cyclosporin, 4 tacrolimus), acute GvHD grade III/IV in 8 cases, 3 CMV reactivations and 3 severe fungal (1 pulmonary aspergillosis, 1 Scedosporium Prolificans septicaemia) or bacterial (1 E Coli sepsis) infections. Median onset of TA-TAM was on day +43 after transplant (2-566), 11 cases of early onset (<2 months) and 6 of late onset. Nine episodes were probable TA-TMA without organ dysfunction, 8 had renal failure and 2 presented with concomitant diffuse alveolar hemorrhage. First line replacement of calcineurin-inhibitors for basiliximab or other
Background: We performed multi-center retrospective study to validate the prognostic impact of HSCT-CI on transplant outcomes in a cohort of aplastic anemia patients undergoing allo-HSCT.

Aims: We applied the HCT-CI to 140 patients with severe aplastic anemia (SAA) who underwent allogeneic HCT at the Asan Medical Center, Seoul, and Haeundae Paik Hospital, Busan, Korea between April 1995 and March 2013. Required data were retrieved from Asan medical center and Haeundae Paik Hospital BMT Registry Database. We stratified the patients based on comorbidities, as assessed by HCT-CI. Post-transplant outcomes were evaluated in terms of overall survival (OS) and event-free survival (EFS). Event was defined as graft failure including primary and secondary, relapse, donor lymphocyte infusion, and death.

Results: The median age of including patients was 31 year-old (range, 31-61 year-old) and male was 81 patients (58%). HCT-CI score was 0 in 92 patients (65.0%), 1-2 in 34 (24.3%), and ≥3 in 14 (10.2%). The most prevalent comorbidity captured by the HCT-CI was infection (n=20, 14%) followed by moderate/severe hepatic comorbidity (n=10, 7%). During a median surviving post-HCT follow-up period of 45.5 months (range, 4-1178.4 months), 32 patients (24%) died and 20 (14%) experienced primary or secondary graft failure. The 10-year probability of OS and EFS was 73.4% and 68.3%, respectively. OS and EFS was significantly different according to HCT-CI score; the OS for HCT-CI 0, 1-2, and ≥3 at 4 years was 84.1%, 68.6%, and 60.6%, respectively (P=0.007). The EFS for HCT-CI 0, 1-2, and ≥3 at 4 years was 76.5%, 60.0%, and 56.3%, respectively (P=0.019). Multivariate analysis after adjustment for other variables demonstrated that higher HCT-CI score were associated with increased OS and EFS as judged by increasing hazard ratio compared to patients with HCT-CI score of 0 (Table 1).

Summary/Conclusions: In conclusion, our data indicate that the presence of pre-transplant comorbidty assessed by HSCT-CI may predict worse outcomes after allo-HSCT in severe aplastic anemia.
plant-related toxicity. The median hospitalization time (20, range 14–70 vs 20, range 14–53, p=0.72) and the consecutive number of re-admissions after discharge (27% vs 35%, p=0.35) were also similar between Neupogen® and Nivestim® groups. In the group of HEALTHY DONORS, 95 were mobilized with Neupogen® and 122 with Nivestim®. Donor characteristics were equivalent between groups, and no severe adverse events were registered in any of them. Mean of CD34+ cells collected/kg of recipient body weight was 7.8x10^6/kg for Neupogen® vs 6.26x10^6/kg for Nivestim® (p=0.02). The minimal target cell dose (2x10^6/kg) was collected in all donors. 8.5% of donors mobilized with Nivestim® failed to achieve the optimal cell dose (4x10^6/kg) compared with 13% in the Neupogen® group (p=0.025). All recipients were successfully transplanted. All donors for haploidentical transplants (N=25) were mobilized with Nivestim®; none with Neupogen®. There were no other transplant differences. Platelet and neutrophil engraftment were comparable between the two groups, as well as transfusion requirements and infectious complications after transplant. The incidence of grade 1 to 4 acute graft-versus-host disease was different (Neustim®65.5% vs Neupogen® 67.7%; p=0.7). The hospitalization period was similar in Neupogen® and Nivestim® groups, (30 days, range 16-102; 30 days, 16-136, respectively).

Table 1. Characteristics and main results comparison in patients who underwent autologous stem cell transplantation

<table>
<thead>
<tr>
<th>Results</th>
<th>Neupogen® (n=115)</th>
<th>Nivestim® (n=86)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD45+e4+IL-7 in peripheral blood, median (%)</td>
<td>30.70 (7-119)</td>
<td>29.16 (6-108)</td>
<td>0.26</td>
</tr>
<tr>
<td>Total cell count x10^6</td>
<td>3.45x10^6</td>
<td>3.27x10^6</td>
<td>0.62</td>
</tr>
<tr>
<td>Donor lymphodepletion, n (%)</td>
<td>21 (18%)</td>
<td>26 (30%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Median number of CD34+ cells/kg of recipient body weight</td>
<td>7.8x10^6</td>
<td>6.26x10^6</td>
<td>0.02</td>
</tr>
<tr>
<td>Absolute neutrophil count (x10^9/L)</td>
<td>2.9</td>
<td>3.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Platelet count (x10^9/L)</td>
<td>135</td>
<td>139</td>
<td>0.7</td>
</tr>
<tr>
<td>Volume of apheresis (L)</td>
<td>5</td>
<td>7</td>
<td>0.05</td>
</tr>
<tr>
<td>Infusion of neutrophil engraftment (th/L)</td>
<td>3</td>
<td>3</td>
<td>0.7</td>
</tr>
<tr>
<td>Transplant-related complications, n (%)</td>
<td>7 (6%)</td>
<td>9 (11%)</td>
<td>0.4</td>
</tr>
<tr>
<td>No. of patients with grade 2–4 acute GvHD</td>
<td>12 (11%)</td>
<td>16 (19%)</td>
<td>0.3</td>
</tr>
<tr>
<td>No. of patients with severe GvHD</td>
<td>8 (7%)</td>
<td>11 (13%)</td>
<td>0.5</td>
</tr>
<tr>
<td>Hospital stay, median (range), days</td>
<td>30 (16-102)</td>
<td>30 (16-136)</td>
<td>0.7</td>
</tr>
<tr>
<td>Median number of days of neutropenia</td>
<td>7</td>
<td>7</td>
<td>0.8</td>
</tr>
<tr>
<td>Median number of days of platelet nadir</td>
<td>14</td>
<td>14</td>
<td>1.0</td>
</tr>
<tr>
<td>Median number of days of G-CSF treatment</td>
<td>6</td>
<td>6</td>
<td>1.0</td>
</tr>
<tr>
<td>Median number of days of transfusions</td>
<td>7</td>
<td>7</td>
<td>1.0</td>
</tr>
<tr>
<td>Median number of days of hospital stay</td>
<td>30</td>
<td>30</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Although prospective data are still required, our study supports that the use of the Filgrastim biosimilar Nivestim® has a similar efficacy and safety as mobilization agent compared with the originator Neupogen®.

E1544

PERIPHERAL BLOOD STEM CELL DONATION IN OLDER SIBLING DONORS: IS IT SAFE?

K. Balassa1,*, A. Peniket1, R. Danby1, R. Pawson1
1Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Background: The introduction of reduced intensity conditioning regimens has led to an increase in allogeneic haematopoietic stem cell transplantation (HSCT) in older patients with a consequent increase in age of family members who are asked to donate HSCs for them. Such donors are expected to have more comorbidities than younger donors and careful assessment of their suitability to donate is required.

Aims: Our aim is to assess the frequency and nature of issues concerning the eligibility of related peripheral blood stem cell donors seen at Churchill Hospital, Oxford between 2012 and 2016. We wished to examine the influence of age and the nature of any extra interventions required to establish donor suitability.

Methods: For clinical data collection donors’ notes were reviewed and analysed retrospectively. A separate template was used in all cases for sibling donor selection and screening.

Results: During the study period 90 related donors were screened, of whom 1 declined to proceed because of his concerns regarding G-CSF safety, 2 were excluded due to pre-existing medical conditions and 2 were defined medically inelible during work-up, and finally 85 donors donated PBSCs to their relatives (36% of allogeneic HSCT performed at our centre). The median donor age was 51 years (range 25-71, n=17 over 60). Nearly half of the donors (44%) took regular medications. Two thirds (67%) suffered from at least one significant comorbidity (25% hypertension, 24% back problems, 16% asthma, 9% cardiovascular conditions, 9% diabetes mellitus, 8% autoimmune disease). The presence of comorbidities was significantly associated with age (p=0.033). 59% travelled abroad, of whom 14% visited a malarial area within a year of a donation. Based on donors’ history or examination findings, 47% needed extra blood tests on top of the mandatory tests before the clearance, including malaria (31%) and haemoglobinopathy screening (13%). 13% underwent specific haematology investigations e.g. BMA, molecular studies. Additional imaging studies were performed in 13%. In 16% specialist opinion was sought from other specialties with concerns regarding donor fitness or safety. 13 out of 85 cases were handled as planned deviation from our standard eligibility criteria. The collected median CD34+ dose was 5.73x10^6/kg (range 1.76-22.45). Collection was completed in one day in 54%, in two in 44% and in three in 2%. Male (p=0.017) and younger donors (p=0.041) were more likely to achieve stem cell yield in one day. The stem cell dose was higher for collections being successful in one day (median 6.5 vs 5.03, p<0.001). Citrate related toxicity was the most common complication of the apheresis procedure (52%). The only documented serious complication affected a 69-year old donor who was hospitalized on 3rd day of G-CSF treatment with chest and abdominal pain and troponin rise, but investigations excluded acute coronary syndrome or other significant acute pathology and she managed to donate successfully with no further issues.

Summary/Conclusions: Peripheral blood stem cell collection seems to be safe among sibling donors, who are significantly older than unrelated donors. With careful assessment and planning even individuals with significant co-morbidities can donate successfully. The demographic trend and its implications should be considered when planning resources in HSCT programmes.
was 2 (1-5). There were 5 (19%) graft failure cases. Acute GVHD appeared in 8 (32%) patients, all of them achieved grade 3; chronic GVHD occurred in 7 (27%). Patients with a MC had better overall survival 77.6% than patients with relapse after allo-HSCT (22%). Remission was achieved in 16 (48%) patients with relapses. However, 5 patients relapsed again. Acute GVHD was developed in 8 cases (22%). Nineteen patients died from relapse and 1 patient died from aGVHD in remission. Disease-free survival in patients with MC and in patients with relapses was 78.6% and 26.2%, respectively.

Summary/Conclusions: The prognosis of hematological malignancies is poor if relapse is established after allo-HSCT. DLI protocol as preventive therapy must be created for improving long-term results in high risk patients. Prevention is better than cure.

E1546
MEMORY T CELLS DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANPLANTATION AS A SAFE PROCEDURE TO IMPROVE T-CELL RECONSTITUTION
S. Cortez 1,*, R. De Paz 1, M. Gasior1, A. Martínez1, Y. Mozo2, B. Rosích2, J. Valentín1, A. Sastre2, A. Pérez 2
1Hematology, 2Pediatric Hematology-Oncology, Hospital Universitario La Paz, Madrid, Spain

Background: Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for patients with hematologic malignant diseases. Haploidentical transplantation with extensive ex vivo T cell depletion of the graft, has demonstrated to prevent graft versus host disease (GVHD), but the major disadvantage has been the development of graft failure, relapse and infections due to delayed immune reconstitution. A selective T cell depletion method that removes Donor cells expressing CD45RA+ in haploidentical donors, which are responsible for GVHD, as well as preservation of T cells CD45RO, is a novel therapy that may provide functional T cells with anti-infection, anti-leukemia and anti-rejection properties.

Aims: We describe the outcome of CD45RA+ cell depletion of donor lymphocytes infusions, in patients with poor prognosis and high risk of relapse after hematopoietic stem cell transplantation.

Methods: Patients with hematologic diseases with poor prognosis who lacked an HLA matched donor were included. The recipients received a CD45RA-depleted haploidentical transplantation, on day 0 they received a first graft with a median CD34+ cell dose of 6.4x10⁶/Kg (range 5x10⁶/Kg-9x10⁶/Kg), on day +1 they received a CD45RA-depleted graft. After transplantation studies of chimerism, quantification of lymphocyte subsets as well as control for viral infections were made to all patients.

Results: We present the results of six patients with a median age of 11 years (range 4-18 years), diagnosis included B-Cell acute lymphoblastic leukemia (n=2), T cell acute lymphoblastic leukemia (n=1), acute myeloblastic leukemia (n=2), aplastic anemia (n=1), these patients received a selective CD45RA-depleted haploidentical transplantation. The follow up after HSCT, three patients had persistent lymphopenia, four patients developed infections caused by CMV, norovirus, HHV-6, BK virus and toxoplasma, one patient had increasing levels of mixed chimerism and one had graft failure. These patients were treated with infusions of 16 aliquots of cryopreserved CD45RO+ haploidentical donor lymphocytes, the CD45RA+ cells depletion was made using the clinMACS system. The median dose of CD45RO+ cells was 1,02x10⁶/Kg, starting at a dose of 0.002x10⁶/Kg and 0.01x10⁶/Kg (range 0.005x10⁶/Kg-0.03x10⁶/Kg), on day +13 in 5 patients we observed a progressive increase in T cells count to the total amount of PCR product and to derive universal formulas for the chimerism calculation excluding stutter percentage.

Aims: We have evaluated the safety and efficacy of new conditioning regimen with sequential intensive chemotherapy (FLAG-IDA) followed by conditioning of Flu-Bu(3).

Methods: The study was designed and developed in two separate transplantation centers in Rui Jin Hospital (RJH, Shanghai) and Institut Paoli-Calmettes (IPC, Marseille) respectively. A total of 47 refractory AML patients with median bone marrow blast of 38% (1-90%) and median age of 41 (16-62) were enrolled. Thirteen patients received transplantation with mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donor while 18 and 16 with matched unrelated or haplo-identical donors. All patients received FLAG + 3-days idarubicin (12mg/m² in RJH or 10mg/m² in IPC) and then received Flu-darabine (5 days) with IV Busulfan (3-days) with a 7-day interval. The GVHD prophylaxis regimens were CsA+MMF+ATG (RJH) or post-cyclophosphamide (IPC).

Results: With a median follow-up of 8 months (1-70m), a total of 14 patients relapsed with a median time of relapse at 4.8 months (2.1-18.1) and most of the relapses involved first relapse within the first 12 months after transplantation. A total of 24 patients died due to relapse (n=12) or non-relapsed mortality (NRM, n=12). The estimated 3-year relapse rate (RR) and NRM were 42.0±9.2% and 25.9±6.5% respectively. The estimated 3-year OS and DFS were 43.6±7.8% and 42.2± 7.8%. In the primary multivariate analysis (including age, cycles of pre-transplantation chemotherapy, bone marrow blasts, cytogenetics and treatment center), only bone marrow blast ≥35% and age over 40 were associated with disease-free survival and relapse respectively while there was no significant difference between RJH and IPC in terms of transplantation outcome in uni- and multivariate analyses.

Summary/Conclusions: Our primary data demonstrated a promising outcome with FLAG-IDA chemotherapy as debulking therapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML and clinical trial with larger patients cohort is warranted.
patient DNA and donor DNA. The percentage of donor chimerism as well as stuffer percentage was calculated using standard formula.

Results: Fifty transplant cases with stuffer peaks were evaluated: 18 homozygous; 15 heterozygous with both alleles showing detectable stuffer; 17 heterozygous with one stuffer visible only. Stuffer percentage and standard deviation were calculated in each case for donor DNA sample and for four bone marrow DNA samples from recipient with established complete donor chimerism taken during the time. It was found that the contribution of the stuffer-peaksto the total amount of product ranges from 1.2% to 11% (SD was no more than 1.5% for each locus) for markers with appreciable stuffer-bands and seems to be locus-specific constant for each patient. Assuming the stuffer percentage as a locus- and 13.63% as the constant (for the same PCR conditions) we derived a formulae for recipient DNA percentage: Actual recipient's%=(apparent rec./total DNA ratio - stuffer/total DNA ratio)*100% (special formulas for hetero- and homozygous on fig.1). To test these formulae the panel of DNA samples with mixed chimerism from 50 to 97% estimated by independent stuffer-free method. The result of this estimation based on “stutter-complicated” markers (using proposed formulae) conventional “stutter-free” markers appeared to be the same (SD<1%).

Summary/Conclusions: The use of formulae described may circumvent the absence of the “stuffer-free” informative markers for mixed chimerism estimation.

E1550

PERIPHERAL BLOOD STEM CELL (PBSC) HAPLOIDENTICAL TRANSPLANTATION VERSUS MISMATCHED UNRELATED DONOR TRANSPLANTATION: A SINGLE UK CD34+ CELL CENTRE EXPERIENCE

J. O'Sullivan1, K. Parraress2, D. McLornan2, D. L. Hugues2, V. Potter4, M. Streetley1,4, M. Gallagher1, I. Walker4, M. Kazmi2, A. Kulasekarara1, J. Marsh1, G. Muffi1, T. Pagliuca2, K. Raj1

Haematologist, Guy's and St Thomas' NHS Foundation Trust, 2Haematology, Southend University Hospital NHS Foundation Trust, 3Haematology, Guy's and St Thomas' NHS Foundation Trust, 4Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom

Background: Haploidentical (Haplo) and mismatched unrelated donor transplantation (MMUD) are potential alternatives for those without a fully matched available donor. Recent collaborative and single centre studies suggest that haploidentical donor outcomes are comparable to unrelated donor outcomes in the T cell-replete setting.

Aims: In this single centre review, we aimed to compare outcomes of T cell-replete haploidentical allogeneic stem cell transplantation with mismatched unrelated donor allogeneic stem cell transplantation.

Methods: From January 2010 to December 2015, 38 patients underwent T cell-replete HLA-matched haploidentical transplantation with post transplantation cyclophosphamide given on days +3 and +4 given as graft versus host disease (GvHD) prophylaxis. These were retrospectively compared with 45 patients underwent single HLA-locus mismatched unrelated donor transplantation with alemtuzumab as GvHD prophylaxis. Data was censored at time of last contact in 2016. Analysis was performed using SPSS v23.0 and R 3.3.2 software.

Results: The median recipient age was similar in both groups; 51 (19-69) years in Haylo and 50 (28-74) years in MMUD transplants, p=0.012; 68.7% of all patients were male. Non-Caucasian ethnicity comprised 63.2% of Haylo versus (vs.) 15.6% of MMUD transplants, p<0.001. Myelodysplasia (MDS)/acute myelomonocytic leukaemia (AML) was the commonest transplant indication in both groups (60.5% of Haylo and 93.6% of MMUD transplants). The disease risk index (DR1) in this subgroup was overall low/intermediate in 69.2% and high/very high in 26.2% (unknown in 4.6%). Reduced intensity conditioning was used in all but two Haylo (6.4%) and 4 MMUD transplants. Patients were followed up for a median of 544 days with a similar 2-year overall survival of 61.5% (95% confidence interval, CI, 52.4 – 69.3%) and 58% (95% CI 48.8-66%) and 3-year overall survival of 56.4% (95% CI 45.8 – 65.6%) and 48.9% (95% CI 41 – 56.2%) in Haylo and MMUD transplants respectively, p=0.67. Overall progression free survival (PFS) at 2 years was 53.3% (95% CI 44-61%) and 40.1% (95% CI 34-46%) in Haylo and MMUD transplants respectively, p=0.31. In those with MDS/AML, the 2-year progression-free survival was 64.2% (95% CI 49-75%) in Haylo vs 38.5% (95% CI 33-43%) in MMUD transplants, p=0.1. In Haylo and MMUD transplants, the 3-year cumulative incidences of non-relapse mortality were 25.5% (95% CI 12-41%) and 31.2% (95% CI 18-45%) respectively, p=0.61 and the incidences of relapse were 25.6% (95% CI 12-41%) and 34.8% (95% CI 20-49%) respectively, p=0.51. Median time to neutrophil engraftment was 18 and 12 days and for platelet engraftment 21 and 12 days in the Haylo and MMUD transplants respectively. Engraftment was successful in 89.4% (Haylo) and 95.5% (MMUD) patients. The incidence of acute GvHD was 42.1% in Haylo and 35.6% in MMUD transplants respectively. Engraftment was successful in 89.4% (Haylo) and 95.5% (MMUD) patients. The incidence of chronic GvHD occurred in 15.8% of Haylo and 8.9% (MMUD). Chronic GvHD occurred in 15.8% of Haylo and 33.3% of MMUD transplants, p=0.067. Chronic GvHD did not impact overall or progression free survival in either transplant group.

Conclusions: Haploidentical allogeneic transplantation when compared with T cell-deplete mismatched unrelated donor transplantation showed high engraftment rates, low rates of severe acute and chronic GvHD and comparable overall survival, non-relapse mortality and relapse rates. We suggest that T cell-replete haploidentical transplantation is a safe and acceptable alternative when a matched unrelated donor is unavailable.

E1551

IMPACT OF ABO BLOOD GROUP INCOMPATIBILITY ON THE OUTCOME OF RECIPIENTS UNDERGOING ALLOGENIC TRANSPLANTATION: EXPERIENCE IN OUR CENTER BETWEEN 2013 AND 2016

G.A. Méndez Navarro1,*, G. Moreno Jiménez1, F.J. López Jiménez1, A. Jiménez Martin1, S. López González1

1Servicio de Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain

Background: ABO blood group compatibility is not an essential requirement or priority in the selection of the allogenic bone marrow donor, unlike what happens in solid organ transplant; thereby, up to 30-50% of allogeneic transplantation shows ABO incompatibility1, but its clinical impact is controversial. It’s accepted that it may provoke hemolytic reactions and delayed erythocyte engraftment. Nevertheless, its influence in leukocyte and platelet engraftment, graft-versus-host disease (GvHD), and overall survival is not fully elucidated yet2.

Aims: To describe the experience in our center in allogenic transplantation with ABO mismatching and its relation with hemolytic events (HE), red blood cell
(RBC) recovery, neutrophil and platelet engraftment, pure red cell aplasia (PRCA), acute GVHD, relapse and event-free survival (EFS).

Methods: We retrospectively studied allogeneic transplants performed from January 1, 2013 to December 31, 2016. We collected the baseline variables reflected in Table 1 and analyzed the incidence of HE, neutrophil and platelet engraftments, RBC recovery, PRCA (defined as anemia with transfusion requirement and reticulocytes <1% in day +80 without other cytopenias), acute GVHD, relapse of the background disease and survival (at 6, 12 and 24 months) in the ABO compatible groups (ABOc) and in the incompatible (ABOi), the latest divided into major, minor and bidirectional disparity.

Results: A total of 133 transplants were included, with a mean follow-up time of 16.4 months. The median age was 52 years and there were 79 males and 54 females. Diagnoses were mainly AML (n=72), ALL (n=19) and NHL (n=11) (see Table 1). 60 received low intensity and 73 myeloablative regimens. They were HLA identical (n=44), unrelated donor (n=50), haploidentic (n=38) and cord (n=1) and, in most cases, hematopoietic progenitors were obtained from mobilized peripheral blood (90.2%), 4.4% (n=59) presented some type of ABOi: major (n=26), minor (n=25) and bidirectional (n=8). The product was processed in order to prevent hemolysis in only 7 cases (red cell depletion in 4 and deplasmatization in 3). There were 23 hemolytic (18 immediate and 5 delayed) -mostly mild- events, which appeared predominantly in patients with ABO-incompatibility (38.96%) vs 50% in major disparity, 28% in minor and 37.5% in bidirectional- vs ABOi (2.7%) and this difference was statistically significant (p<0.001). No differences were observed in the neutrophil graft between the ABOc group and the ABOi group, nor in the platelet engraftment; in contrast, we found a statistically significant effect on the time to erythrocyte recovery (mean: 49.94 days in ABOi vs 24.69 in ABOc; p=0.032). Only 6 cases of PRCA were documented (all in ABOi). The occurrence of acute GVHD did not differ significantly among the groups (52% in ABOc vs 53.5% in incompatibles) nor in its severity. We have not found differences either in the rate of relapse (24.8% vs 19.1%) nor in the survivals at 6, 12 or 24 months (66.1% vs 78.8%, 48.2 vs 47.2% and 38.4 vs 39.4%, respectively).

Table 1.

<table>
<thead>
<tr>
<th>Table 1.</th>
<th>Gender</th>
<th>Male (n=74)</th>
<th>Female (n=59)</th>
<th>Total (n=133)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Mean (SD)</td>
<td>51 (12)</td>
<td>53 (13)</td>
<td>52 (12)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AML</td>
<td>72</td>
<td>44</td>
<td>116</td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>19</td>
<td>9</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>NHL</td>
<td>11</td>
<td>10</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engraftment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophil</td>
<td>60</td>
<td>25</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Platelet</td>
<td>73</td>
<td>48</td>
<td>121</td>
<td></td>
</tr>
<tr>
<td>RBC</td>
<td>60</td>
<td>30</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GVHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: In our study ABO-mismatched transplants have shown a greater number of hematolytic events and red cell aplasia, as well as a greater delay in achieving erythrocyte recovery. However, we have not found an association with delayed neutrophil and platelet recoveries, increased acute GVHD, relapse or worse OS in the ABO incompatible group, in keeping with most previous reports**, although the absence of effect might be as well be related to an insufficient study power due to low sample size.

References
6. The occurrence of acute GVHD did not differ significantly among the groups (52% in ABOc vs 53.5% in incompatibles) nor in its severity. We have not found differences either in the rate of relapse (24.8% vs 19.1%) nor in the survivals at 6, 12 or 24 months (66.1% vs 78.8%, 48.2 vs 47.2% and 38.4 vs 39.4%, respectively).

E1553
LOW BLOOD CONCENTRATION OF TACROLIMUS CAN BE A RISK OF GRAFT FAILURE AFTER CORD BLOOD TRANSPLANTATION
A. Fujimoto1,*, T. Ishikawa1
1Hematology, Kobe City Medical Center General Hospital, Kobe, Japan

Background: Peripheral blood stem cell transplantation (PBSCT) is one of the main strategies for the treatment of malignant hematological diseases. Toll-like receptors (TLRs) are present on various immune cells including natural killer cells, monocytes, macrophages, T lymphocytes and B lymphocytes. Ten different TLRs have been evaluated in humans. TLRs play a central role in immune surveillance and in the initiation of the inflammatory response. The expression of TLRs genes and their association with outcome in patients treated with PBSCT remains under study.

Aims: The objective of the current study was to investigate association between expression of TLRs genes and hematopoietic recovery and rate of infections in patients treated with PBSCT.
Methods: The evaluation of TLRs expression genes were performed in 40 patients who underwent PBSCT. The median age of patients was 54 years (range: 25-65 years). There were 15 patients with multiple myeloma (MM), 20 patients with non-Hodgkin lymphomas (nHLs) and 5 patients with Hodgkin lymphoma (HL). Peripheral blood samples were taken before megachesmotherapy with autologous stem cell transplantation and at time of hematopoietic recovery in patients. The mRNA expression of TLRs receptors was assessed by real-time PCR using inventoried TaqMan® Assays from Life Technologies/ThermoFisher. Beta glucoronidase (GUSB) served as endogeous control. Reaction was performed in 7500 Real Time PCR instrument (LifeTechnologies) using Gene Expression MasterMix (LifeTechnologies/ThermoFisher). Comparative Cq method (***) was used to compare expression among patients with and healthy controls. Statistical analysis was conducted using STATISTICA 12 software (StatSoft, Polska).

Results: The mRNA expression of TLR2 and TLR9 was significant higher in patients after PBSCT than before PBSCT procedure (ΔCt TLR2 1,4209±1,0461 vs 1,7877±1,4974 and ΔCt TLR9 117,853±141,0870 vs 289,788±271,98) (p<0,05).

Table 1.

<table>
<thead>
<tr>
<th>CATEGORIZE</th>
<th>n</th>
<th>GENDER</th>
<th>MEAN YEARS OLD</th>
<th>EAEMATOLOGICAL DISEASE</th>
<th>MBG</th>
<th>Leucopenic cytopenias:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>23</td>
<td>Male</td>
<td>43,75±7,86</td>
<td>HAEMATOLOGICAL DISEASE</td>
<td>41</td>
<td>CMCL:</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>Female</td>
<td>43,75±7,86</td>
<td></td>
<td>13</td>
<td>MN:</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>ANAIF:</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>ANAIF</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>ANAIF</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GBVs/RBC</th>
<th>VES</th>
<th></th>
<th>MO</th>
<th>MEDIAN RBC</th>
<th></th>
<th>MEDIAN RBC DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>114±12 (108-368)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIAN HGB</th>
<th>MEDIAN RBC</th>
<th>MEDIAN PLT</th>
</tr>
</thead>
<tbody>
<tr>
<td>11,4±12 (108-368)</td>
<td>3,94±1 (3,8-4,00)</td>
<td>210±1 (180-240)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Correlation of high RBC and GVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>HGB vs RBC</td>
</tr>
<tr>
<td>P=0,058</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This exploratory analysis of final study data, earlier defibrotide initiation post-VOD/SOS diagnosis significantly improved Day +100 survival, confirmed by the Cochran-Armitage test (P<0.001). No specific day provides a clinically meaningful cutoff for better Day +100 survival, suggesting that later intervention retains value if treatment must be delayed.

Support: Jazz Pharmaceuticals.
Aims: RDW values were evaluated at the day of infusion (RDW 0), we choose this point in time to evaluate the tissue injury and inflammation secondary to the conditioning regimen, in order to evaluate if there is a major incidence of GVHD.

Methods: We retrospectively evaluated 103 patients who had undergone allo-HSCT for different indications at our center, with a median follow up of 12.8 months (0-235) at our center. The population consisted of 59 males and 44 females, the median age was 43.7 years. The RDW was collected from the hemogram at the day of the HSCT cell infusion, before it was performed (table 1). The IBM SPSS STATISTICS program was used for all statistical analyses. Differences were considered statistically significant when p<0.05. The median of RDW values in our study was of 16.4 (11.2-38.5). The areas under the receiver operating characteristic (ROC) curves of RDW were ≤18.4 and >18.4 for the selection of the increased RDW cutoff. We evaluated the association of increased RDW (>18.4) with the development of GVHD. A survival analysis of the association of different levels of increased RDW was performed. A subgroup analysis of the Haploidentical HSCT patients (N=13) was also evaluated.

Figure 1.

Results: The presence of increased RDW >18.4 was strongly associated with an increased risk of developing acute GVHD (p=0.009) being present in 80% of the patients. In the haploidentical HSCT subgroup an increased RDW >16 was associated with acute GVHD. (p=0.044). There was no association of chronic GVHD with elevated RDW at day 0 (p=0.563). The survival analysis didn’t found an association of high RDW levels with mortality or survival (p=0.301) but a tendency to an increased survival was show between the RDW level subgroups. (figure2). Where a higher RDW seems to have a better survival, but this should be evaluated in a wider sample.

Summary/Conclusions: RDW at day 0 is a feasible predictor factor of Acute GVHD, most likely as a secondary surrogate marker of inflammation secondary to the conditioning regimen. The presence of other factors contributing to the RDW increase (secondary to other comorbidities) cannot be ruled out; but by itself RDW it’s an easy and affordable prognosis marker for aGVHD that should be further evaluated.

E1556

COMPARISON OF THE BEEAM CONDITIONING REGIMEN AND THE BEAM CONDITIONING REGIMEN IN THE AUTOLOGOUS TRANSPLANTATION FOR HL AND NHL

S. Lozenov1,2, P. Ganeva1, B. Spassov1, Y. Petrov1, G. Arnaudov1, G. Mihaylov1

1NSHATHD, Sofia, Bulgaria

Background: The BEAM has established itself as a standard of care conditioning regimen in the autologous lymphoma HSCT setting for most transplant centres in Europe. Yet however various other regimens are being compared with it in order to achieved better safety profile, better OS and DFS, in order to improve results with chemoresistant and unfavourable patients. One such regimen is the BeEAM (bendamustine, etoposide, cytarabine, melphalan).

Aims: We aimed to compare the efficacy of the BEAM and BeEAM conditioning regimens and to compare there myelotoxicity profile.

Methods: We evaluated retrospectively 114 patients, receiving auto-HSCT at the National Specialized Hospital for Active Treatment of Hematological Diseases in Sofia for relapsed/refractory HL or NHL for the period from 1.01.2013 to 1.07.2016 with a follow-up of patients up to 1.11.2016. 92 of the patients received BEAM and 22 received BeEAM. 2 and 3 year OS and DFS were compared, CR rates and the average time periods to hematological recovery.

Results: The OS at 2 and 3 years respectively was 86.1%, 86.1%, for BeEAM and 78%, 71% for BEAM, the DFS at 3 years was 76.4% in BeEAM and 73.2% BEAM, provided that the differences did not have statistical significance. The CR rate was 63.63% in the BeEAM group versus 50% in the BCNU group. 22.72% of the patients receiving BeEAM in SD or in diseases progression achieved CR versus 10.86% respectively for the BEAM group. The mean time to hematological recovery for neutrophils was 11.27 days (BeEAM) versus 10.24 days (BEAM) and 12.64 days (BeEAM) versus 11.12 days (BEAM) for platelets.

Figure 1.

Summary/Conclusions: BeEAM appears to be a non-inferior alternative conditioning regimen to the standard BEAM, it shows a trend towards higher myelotoxicity, but also a trend towards better short-term results in chemoresistant patients.

E1557

DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS: CORRELATION OF ALLEY-LEVEL HLA MATCHING WITH OUTCOME AND WHICH CORD BLOOD UNIT WILL BECOME DOMINANT

M. Westendorp1,2, D. Hogge1, K. Song1, S. Narayanan1, S. Nantel1, R. Broady1, M. Barnett1, C. Tozz1, A. Genio1, Y. Abou Moudri1, D. Sanford1, M. Power1, D. Forrest1, S. Heather1, N. Thomas1

1Leukemia/BMT Program of BC, Vancouver General Hospital, Vancouver, Canada

Background: Umbilical cord blood (UCB) has been used for alternative donor transplantation for the past 3 decades. Graft failure is not uncommon due to higher degrees of histoincompatibility between recipient and UCB units and fewer hematopoietic precursors in the product. To improve engraftment rates, especially in larger (i.e. adult) patients (pts), two UCB units can be used. Double UCB transplantation (DUCBT) is being utilized at many centres although it has been noted that, while both units may contribute to engraftment, only one unit becomes “dominant” – i.e. persists to provide long-term hematopoiesis. A variety of predictors of which unit will become dominant have been suggested, primarily the unit that is more closely HLA-matched or the unit with the highest total nucleated cell (TNC) count.

Aims: To determine the likelihood of engraftment, incidence of GVHD, influence of TNC count and HLA mismatch on survival and selection of the dominant cord following DUCBT in adults with high-risk hematologic disorders.

Methods: A retrospective review was performed of adult pts undergoing DUCBT at the referral centre for British Columbia. Recipients signed informed consents for all clinical trials in which they participated. HLA typing at A, B, C and DRB1 loci was done on all pts using high-resolution allele-level testing (HRT). HRT was available at these 8 loci for both UCB units in 25/31 pts; for the remaining units, class I typing was done by serology. UCB units selected had to be ≥4/6 match at A, B, C, DRB1 by HRT. Combined TNC count for the units had to be ≥30x10^9/kg recipient weight. Conditioning was Fludarabine 40mg/m^2 x4 and TBI 150 cGy x8; GVHD prophylaxis was Tacrolimus/Mycophenolate. Pts received G-CSF 300 mcg s.c. daily from day +1. Outcomes were compared using Fisher’s exact test.

Results: Between 06/09 and 09/16, 31 pts underwent DUCBT - 11 males, 20 females with median age 50 years (range 19-59). Diagnosis was acute myeloid leukemia (AML; n=12), acute lymphoid/ mixed phenotype leukemia (n=7), chronic lymphoproliferative disease (n=5), MDS (n=4) or other (n=3). All 31 pts recovered ANC>0.5x10^9/L at median of 20 days (range 14-72). Platelet count reached >20x10^9/L in 26/31 pts at median of 38 days (range 24-188). Acute GVHD developed in 26/31 pts (84%) and chronic GVHD in 17 of the 26 pts (65%) that survived to day +100. Seventeen pts (55%) remain alive, in contin-
uous remission at median follow-up of 3 years (range 0.5-7.0). Ten pts (32%) experienced non-relapse mortality from GVHD (5 pts), infection (4 pts) or unknown cause (1 pt). Four pts (13%) have relapsed at 3.5, 10 and 12 months.

Outcomes for pts when the best cord unit match was 0-2 antigen-mismatched (Ag-M/M) were superior (8/12 alive and well) to those when the best unit was 3 Ag-M/M (3/9 alive and well; p=0.20). Unexpectedly, 6/9 pts whose best unit was >4 Ag-M/M were alive and well. Information on the dominant cord was available on 19 pts (Table 1); in 15/19 pts, the dominant cord was the same or a better HLA match compared to 4/19 with a dominant cord that was an inferior HLA match (p<0.001). However, the TNC was of less importance with the lower TNC unit being dominant as frequently as the higher TNC unit for each HLA match category (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>HLA Match</th>
<th>Higher TNC</th>
<th>Same TNC</th>
<th>Lower TNC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Better</td>
<td>0 (0%)</td>
<td>8 (42%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Same</td>
<td>3 (16%)</td>
<td>4 (22%)</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Worse</td>
<td>2 (11%)</td>
<td>1 (5%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: DUCBT is effective in adults with life-threatening hematologic disorders. With current UCB inventories, conditioning therapies and supportive care, graft failure is rare - even in adults. The discrepancy between the UCB unit and the patient is a better predictor than the TNC regarding which unit will become dominant. Pts receiving well-matched UCB units (0-2 Ag-M/M) may have better outcomes than pts receiving 3 Ag-M/M units although successful outcomes can be seen even with a high degree (>4 Ag-M/M) of HLA incompatibility.

E1558

CLINICAL ANALYSIS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 46 ACTIVE RELAPSED AND REFRACTORY ACUTE PEDIATRIC LEUKEMIA

L. Yuan1, S. Xue1, J. Wang1.

1Department of Hematology, Aerospace Center Hospital, Beijing, China

Background: Given the dismal prognosis for relapsed and refractory (R/R) acute leukemia, many physicians discourage offering hematopoietic stem cell transplantation (HSCT) to adults with bone marrow (BM) blasts over 25%. Therapeutic recommendations for pediatric subjects with a similar situation are not available.

Aims: With no significant alternative managing options for these patients, more data are required to make an informed and patient tailored decision.

Methods: We retrospectively analyzed the preliminary outcome of 46 active R/R pediatric AML or ALL relapsing or refractory in maintenance or consolidation phase who underwent allogeneic HSCT from 2010-2016.

Results: Out of 46 patients, 21 patients had good-risk AML (FAB M0/M1/M3), 12 had poor-risk AML (FAB M2/M4/M5), 4 had high-risk ALL and 9 had low-risk ALL.

Conclusions: Our outcomes for pediatric patients with relapsed/refractory AML/ALL are comparable to other reports for similar patient populations. However, it is not clear if bone marrow recipients are at a disadvantage compared to peripheral blood stem cell recipients. Further study is warranted.

E1560

OUTCOMES OF PATIENTS RELAPSING FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML IN FIRST CR: SINGLE CENTER EXPERIENCE

D. Pastore1, P. Carluccio1, M. Deila1, A. Ricco1, A. Russo Rossi1, M.S. De Candia1, A. Mestice1, V. Carluccio1, V. P. Gagliardi1, S. D’Agostino1, C. Pasciolla1, G. Specchia1, G. Albano1, G. Specchia1

1Hematology with Transplantation-University Policlinico, Bari, Italy

Background: Allogeneic stem-cell transplantation (SCT) is a curative therapy for patients with AML but disease relapse continues to be the most common cause of treatment failure. There is no standard therapy for relapse after SCT and treatment results are very poor. Treatment options range from supportive care through chemotherapy and donor lymphocyte infusion (DLI) up to a second SCT from the same or a different donor.

Aims: We report a retrospective study of 36 patients AML relapsed patients following allogeneic stem cell transplantation in first remission.

Methods: Between 2000 and 2016, 130 adults with AML in first CR underwent allo-SCT. We identified 36/130 patients (27%) who had relapsed and proceeded to review the management and outcomes of these patients; the incidence of relapse was 20% and 54% after myeloablative and reduced intensity conditioning, respectively. The median time to disease relapse after allo-SCT was 11 months (range 5-48); 15/36 (41%) of relapsed patients suffered aGVHD grade II-IV or extensive cGVHD. At time of relapse 15/36 (41%) patients were still taking immunosuppressive treatment, which was immediately suspended.

Figure 1. Short-term reconstitution in BM and PBSC recipients with and without Post-HSCT-Cy.

Summary/Conclusions: Lymphocyte recovery was impaired for the PTCy groups in the immediate post-HSCT period but quickly recovered. The mechanism of induction of immunity using PTCy on the +3rd day is limited to deletion of alloreactive T-cell clones, but also affects other leukocyte subpopulations (B cells, monocytes, granulocytes). The use of PTCy at +3, +4 a day is immunologically safe method for prevention of GVHD.

E1559

POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE AFFECT T-CELL RECONSTITUTION IN BONE MARROW, BUT NOT IN PERIPHERAL BLOOD STEM CELLS RECIPIENTS

E. Mikhailova1,2, M. Drokov1, J. Davydova2, L. Kuzmina1, N. Popova1, D. Dubnyak1, V. Vasilyeva1, O. Koroleva1, Z. Konova1, N. Kapranov2, I. Galtseva2,4

1Department of Hematology, Aerospace Center Hospital, Beijing, China; 2Laboratory of immunophenotyping, National Research Center for Hematology, Moscow, Russian Federation

Background: Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many patients with hematologic malignancies. Occurrence of complications and mortality after allo HSCT still high and it’s strongly associated with immune reconstitution. Despite the wide-spread of Post-Transplant High-Dose Cyclophosphamide (PTCy) immune reconstitution and immunological safety of this method is still poorly understood.

Aims: Evaluated immune reconstitution profile in patients who received HSCT with and without PTCy.

Methods: 62 patients who underwent allogeneic PBSCST in our institution were analyzed in 2 groups; patients with PTCy (n=28) and without PTCy (n=34). The total cohort had 22 males and 40 females, and had median age of 33 years (range 18-61). All patients had hematological malignancy. 21 patients under- went myeloablative conditioning and 41 patients non-myeloablative. In 41 patients received bone marrow transplant. The GVHD prophylaxis consisted of a combinations of ATG-PTCy-CSa-MMF (n=10), ATG-PTCy (n=5), Mono- PTcyCSA-MTX (n=2), ATG-CSa-MMF-MTX (n=20), CSa-MTX (n=2), ATG-CSa-MTX (n=2). In 21 patients received PBSCT. The GVHD prophylaxis consisted of a combinations of ATG-PTCy-CSa-MMF (n=4), ATG-PTCy (n=8), ATG-CSa-MMF-MTX (n=8), ATG-CSa-MTX (n=1). 21 patients had progression disease before transplantation, this could affect the results. Immune reconstitution profile was tested via serial flow cytometry analysis of peripheral blood on day +14, +30, +60 and +90 after allo-HSCT. Anti-CD3 FITC, anti-CD14PE, anti-CD45 PE-Cy7, anti-CD16PE, anti-CD56 PE, anti-CD45 Per-CP-CY5.5, anti-CD4 PE-Cy7, anti-CD19 APC, anti-CD8 APC-Cy7; anti-CD62L FITC (BD Biosciences, USA); anti-CD14PE, anti-CD16PE, anti-HLA-DR APC (ebioscience, USA) were used for analysis.

Results: In a bone marrow recipients the number of CD4+ cells was significantly lower when using PTCy (see Figure 1). On day 14 CD4+ cells count for bone marrow recipients was 42,62±9,99; on day 30 - 114,29±42,36; on day 60 – 140,81±52,53; on day 90 - 126,83±26,12. On day 14 CD4+ cells count for PBSC recipients was 47,47±19,99; on day 30 – 114,29±42,36; on day 60 – 148,08±58,22; on day 90 - 162,93±62,94. At the same time when using the PBSCT transplant number of CD4+ cells was not significantly different.

Summary/Conclusions: This may validate decision making on if this special approach is beneficial or not.
Results: The patients were subdivided into three groups according to the salvage treatment received: palliative/supportive care (PSC group, n=5, 25%), intensive chemotherapy alone (CHT group, n=18, 50%) and chemotherapy with immunotherapy (donor lymphocyte infusion or second SCT) (IT group, n=9, 25%). Median age at the start of treatment from relapse was 10, 20 and 25 days in the PSC, CHT and IT groups, respectively. In the IT group, 3 patients (16%) achieved a CR and 4 (22%) died during reinduction chemotherapy. In the IT group, 6 (66%) pts achieved a second CR after chemotherapy and DLI/second allo-SCT and 3 (34%) died of treatment toxicity. In the whole patient sample, median overall survival (OS) was 7 months (range 2-74), being 4, 5, 13 months in the PSC, CHT and IT group, respectively. Estimated 1-year and 2-years overall survival was 14%, 15%, 40% and 0%, 0%, 12% in the PSC, CHT and IT groups, respectively. In our experience, 3 independent factors for a longer OS after chemotherapy and immunotherapy have been identified: the absence of previous acute or chronic GvHD (HR=2.7p<0.001), a longer interval between the allo-SCT and relapse than 12 months (HR=1.2, p=0.005) and age less than 40 years (HR=1.3, p=0.005).

Summary/Conclusions: This study shows that salvage chemotherapy (with DLI or second allo-SCT) provides the best results and should be offered, whenever possible, to patients with AML who relapse after allo-SCT performed in first CR. Patients undergoing chemotherapy alone had a poorer outcome. Our results emphasize the need to schedule a prospective protocol combining cytoreductive treatments and immunotherapy in patients with AML relapsing after allo-SCT.

Methods: We used a cohort of patients with plasma cell dyscrasias who underwent autologous stem-cell transplant with conditioning melphalan 200, Busulfan-Melphalan 140 or melphalan 100 in hemodialysis regimen in which cyclosporine was not applied (2007-2011) and another cohort in which was applied from 2012 to 2016. We did not collect 2012 or 2013 because the measure of cryotherapy was being implemented. It consists of administering ice poles to the patient who must chew before, during and after the infusion of melphalan. The t-Studen and Chi square method was used to estimate the rates of incidence and the baseline characteristics. The regression logistic method was used to the multivariate and univariate analysis. Hazard ratios and 95% were estimated with the use of logistic regression model.

Results: The baselines characteristics can be seen in table 1. All patients in both groups had OM. In the cryotherapy and non-cryotherapy groups, the distribution was respective: grade I 20% vs 16%, grade II 40% vs 10.8%, grade III 31.4% vs 59.4% and grade IV 8.5% vs 13.5%. We observed a reduction in the incidence of severe mucositis (grade III and IV) in the group in which cryotherapy was used against the cohort in which it was not (40% vs 72.9%, p=0.005). The need for morphine was also lower in the cryotherapy group (64% vs 72%, p=0.149). The use of parenteral nutrition was lower in the non-cryotherapy group (8.5% vs 13.5%, p=.07). The prevalence of fever was predominant in the cryotherapy group (51% vs 43%, p=.048), but and infection was documented on more occasions in cryotherapy group (27% vs 81%, p=0.04). The median number of days the patients were discharged from the cryotherapy group was lower (+14 vs +15 median days, p=0.39) and the mortality at day 100 was higher in the non-cryotherapy group (0% vs 8%, p=0.24).

Decreased mucositis degree was associated in both univariate and multivariate analysis only with cryotherapy (p= 0.01 and p=0.0003). Hazard ratio was 0.81 (IC 95% 0.06-0.55).

Table 1.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CRYOTHERAPY</th>
<th>NON-CRYOTHERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender F/M (%)</td>
<td>51/49</td>
<td>49/51</td>
</tr>
<tr>
<td>Age Median</td>
<td>66</td>
<td>67</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In our center, cryotherapy reduces significantly the severity of mucositis. The use of morphine and parenteral nutrition and other complications do not present such a drastic decline, probably because they influence the gastrointestinal mucositis, which is not combatted with cryotherapy. With this results, we are encouraged to continue to include cryotherapy in our protocols.
Background: Haploidentical stem cell transplantation (HSCT) is an alternative for patients without HLA matched donors. However, primary graft failure (PGF) and graft versus host disease are still limitations derived from alloreactivity due to HLA mismatch. T cell depleting approaches (in-vivo with post-transplant cyclophosphamide (PT-Cy) or ex-vivo with graft engineering) and surveillance for anti HLA antibodies are strategies intended to reduce these complications. PGF has a high mortality, and treatment with a second graft is not well defined in terms of donor, source, graft engineering or conditioning.

Aims: Our objective is to describe the incidence and risk factors of PGF and treatments if needed.

Methods: We retrospectively analyzed 40 consecutive patients who underwent HSCT from 2014 to 2016: unmanipulated for 20 adults and graft engineering for 20 children (CD34 selection/TCRab depletion, n= 6; and CD34 selection/CD45RA depletion, n=14). The stem cell source was mobilized peripheral blood in all cases. GCSF was systematically used from day 5 until engraftment. We used descriptive statistical methods for analysis.

Results: Patient characteristics are described in Table 1. Conditioning regimen was Bu-Flu-Cy (n=18, adults), Thio-Bu-Flu (n=2, adults), Flu-Mel-Thio for all pediatric patients. ATG was used in 6 children and TLI in 14 children. All adult patients were given PT-Cy. Only one adult patient had high tier donor specific anti HLA antibodies and was desensitized with plasma exchange, Rituximab and IVIG before transplantation. All patients engrafted before day 28 and no PGF diagnosis was established in our serie. We found that 4 patients (3 children, 1 adult) required a boost of CD34 selected graft from the same donor for secondary GF and poor graft function.

Summary/Conclusions: PGF incidence described in literature is 5-10%, we did not find any primary graft failure in our serie. Desensitization therapy appeared to be effective in one patient with anti HLA antibodies. All CD34 boosts were performed for secondary graft failure/poor graft function due to treatment toxicities or viral infections. Unfortunately, analysis of causes and risk factors for secondary GF requires a larger number of patients to be determined.

E1564

RESULTS OF HAPLOIDENTIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA: A SINGLE CENTER EXPERIENCE

Z. Gulbas1,*, D. Cekdemir1,2, J. Dora1,2, E. Er1,2
1Bone Marrow Transplantation Department, 2Anadolu Medical Center, Kocaeli, Turkey

Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies and nonmalignant hematologic disorders. However, only about a third of candidates for allo-HSCT have HLA-matched siblings. For patients who lack HLA-matched siblings, partially HLA-mismatched (haploidentical) related donors are good alternative sources of stem cells for allo-HSCT.

Aims: In this retrospective, single center study we evaluated safety and efficacy of haploidentical allo-HSCT compared to those of HLA-matched allo-HSCT in patients with lymphoma.

Methods: A total of 81 lymphoma patients (Hodgkin and NonHodgkin) with a mean age of 42 years who underwent allo-HSCT (HLA matched n=46, haploidentic n=35) between July 2010 and July 2016 were analyzed. All patients received Cyclophosphamide (Cy) 50mg/kg i.v. on days +3 and +4. All patients initiated CsA day +5, and then adjusted according to the plasma levels. In addition to CsA, all haploidentical allo-HSCT recipients received MMF until day +35. Results: There were no significant differences in age, sex, diagnosis, disease status up-front HSCT, or transplant characteristics between the groups except a higher median number of stem cells infused in haploidentical group (p=0.004). The median follow-up was 13 months for haploidentical group and 12 months for HLA-matched group. Outcomes of patients are summarized in Table 1. Summary/Conclusions: Our results suggest that haploidentical allo-HSCT is a safe treatment modality in patients with relapsed lymphoma who lack HLA-matched siblings. The major problem are seems to be viral infections. Future challenges remain in improving post-transplant immune reconstitution and finding the best approach to reduce the incidence and severity of viral infections, while preserving graft-versus-lymphoma effect to prevent the recurrence of the underlying disease.
Stem cell transplantation - Experimental

E1566
ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL BLOOD AND UBMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT
C. Besley1, E. Kotsiou1, R. Petty1, A. Sangaranigam2, C. Chelala2, E. Ghazaly1, R. LeDieu1, J. Gribben1, J. Davies1
1Centre for Haematology Oncology, 2Centre for Tumour Biology, Barts Cancer Institute, London, United Kingdom

Background: Immunomodulatory drugs (IMiDs), such as lenalidomide provide a tool to enhance both direct anti-tumor and graft-versus-tumor effects after allogeneic haematopoietic stem-cell transplantation (AHSCT). However, early clinical experience with IMiDs after AHSCT using adult peripheral blood (APB) as a stem cell source has been limited by induction of graft-versus-host disease. Characterization of the mechanisms by which IMiDs can modulate alloresponsiveness of T-cells from different cell sources could facilitate more effective use of these drugs in the setting of AHSCT.

Aims: To use in vitro modelling to identify changes in alloresponses of APB and umbilical cord blood (UCB) T-cells after exposure to the widely used IMiD lenalidomide.

Methods:

Figure 1. BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT

E1567
USING MARKER GENES ANALYSIS INSTEAD OF MLR ASSAY FOR IDENTIFICATION OF FUNCTIONAL CD4+FoxP3+ REGULATORY T CELLS IN GVHD PROPHYLAXIS
1Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, 2Institute of Biochemical Science, National Taiwan University, Taipei, 3Department of Life Science, Fu-Jen University, New Taipei City, Taiwan, Republic of China

Background: There are two types of CD4+CD25+FoxP3+ regulatory T cells (Tregs), natural Treg cells (nTreg): developing in thymus, and induced Treg cells (iTreg) arising from CD4+ naïve T cells. The iTreg cells have been considered important for maintenance of immunological tolerance and correlate with the occurrence of GVHD in some studies. Establishing a quick method to identify the functional iTreg cells is worthy of focusing. Five to ten percent Tregs could be found in human CD4+ T cell and should be expanded via in vitro culture. In order to improve the efficiency of Treg cells for the prevention of GVHD, we attempt to establish a relatively quick analytic method to identify the functional iTreg cells, and then to curtail the iTreg cells harvest time for clinical use. Therefore, using qPCR for marker genes analysis instead of MLR (mixed lymphocyte reaction) assay is an important issue.

Methods: Mouse splenocytes were prepared from mouse spleen. Human PBSC were prepared from peripheral blood (PB) of healthy donors by Ficoll-Hypaque density gradient centrifugation. All T cells were isolated by negative selection, then CD4+ naïve T cells were harvested. CD4+ naïve T cells were activated with anti-CD3/CD28 beads in the presence of IL-2, TGF-β and retinoic acid (RA) containing RPM1640 medium. The protocol is showed in Fig. 1.

Results: Seven genes for qPCR analysis were used to identify the functional iTreg cells. We used the different proportions of iTreg cells in total naïve T cells for 7 genes expression analysis and MLR assay to investigate the relationship between gene expression on alloresponses of T-cells. The iTreg cell gene expression analysis were showed in Fig. 2. It indicated that the different proportion of iTreg cells could show the different expression profile of these genes. Obviously, the FoxP3 gene expression increased in a great level. Based on our previous...
experiments, iTreg cells induction could be TGF-b1 dependent. After different amount of TGF-b1 induction, the genes expression profile also showed the coincidence of the data in Fig.2 (Fig.3). Using the same iTreg populations, MLR assay have been investigated for 5 days. The T cell suppression percentage would be dependent on the iTreg cells proportion (Fig.4A and B). It indicated that the gene expression levels can represent the biological function of iTreg cells. It’s the better way to identify the iTreg cells. Further, we have used PBMCs for iTreg cell induction, the marker genes expression analysis also showed in Fig.5. After comparing with IL-2 cultured T cells, the gene expressions revealed the difference in between iTreg cells and un-induced T cells.

**Summary/Conclusions:** Our study showed that MLR assay should spend 3 to 5 days for identification of the functional iTreg cells, however, the marker genes analysis took only one day for that. Besides, MLR assay is a more complicated method than qPCR analysis. Using simple analysis for human iTreg cells functional identification could save the time for clinical application and might prevent GVHD occurrence effectively.

**E1568**

**OXIDANT-ANTIODIANT SYSTEM IN PATIENTS WITH MULTIPLE MYELOMA**

L. Aleksanian1,*, L. Rybakova1, S. Kapustín1, S. Gritsaev2, S. Bessmel'tsev2

1Biochemistry laboratory, 2Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation

**Background:** Multiple myeloma (MM) is one of the most widespread malignant B-cell lymphoproliferative disorders and is characterized by a clonal proliferation of atypical plasma cells in bone marrow or, less frequently, in extramedullary locations synthesizing monoclonal immunoglobulins. Currently, autologous hematopoietic stem cell transplantation (auto-HSCT) is recognized as the standard method of treatment for young patients (≤65 years old) with MM. Moreover, the best auto-HSCT results are observed in patients who have received new medication (thalidomide, bortezomib, and lenalidomide) during induction therapy and who have achieved at least a very good partial response, which leads to a significant increase in overall survival. However, studies reflecting the impact of this kind of treatment on the dynamics of oxidant-antioxidant indicators are virtually non-existent. At the same time, the possibility of treating developing diseases by prescribing medication makes the problem highly relevant.

**Aims:** The aim of the study was to investigate the state of OS-AOS in patients with MM during auto-HSCT.

**Methods:** We studied 20 patients (11 men and 9 women, mean age 49 years) who followed auto-HSCT after high-dose melphalan. The control group consisted of 50 age- and sex-matched healthy persons. The plasma levels of malonic dialdehyde in MM patients were not significantly different from that in the control group. At the same time, ceruloplasmin plasma level as well as catalase activity were significantly increased in patient group (p<0.05), whereas the level of non-protein thiol groups was decreased. The results of the study indicate a high frequency of occurrence of disturbance of the condition of OS-AOS in patients with MM. The imbalance in the functioning of this system is not entirely eliminated in the process of treating the patients with MM using auto-HSCT. The question of the necessity and methods of the possible correction of OS-AOS in patients with MM, particularly during auto-HSCT, requires further study.

**E1569**

**SURFACE RECEPTOR EXPRESSION PROFILE DEFINES ALLOREACTIVE DONOR CD8+ T-CELLS AFTER MURINE ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION**

C. Bäuerlein1, M. Qureischi1,*, C. Brede1, A.-L. Jordán Garrote1, S.S. Riedel1, C. Graf1, H. Einsele1, P.G. Schlegel3, R.S. Negrin4, A. Beilhack1

1Medical Department II, University Clinics Wuerzburg, Wuerzburg, 2Würzburg University, Institute of Pathology, 3University Clinics Würzburg, Department of Pediatrics, Würzburg, Germany, 4Division of Bone & Marrow Transplantation, Department of Medicine, Stanford University, United States

**Background:** Acute graft-versus-host disease (aGVHD) is a severe and often life-threatening inflammatory complication of allogeneic hematopoietic cell transplantation (allo-HCT). aGVHD is mediated by alloreactive donor T cells attacking the gastrointestinal tract, liver, and skin of the host. Efficient strategies to improve aGVHD-related morbidity and mortality will rely on more precise methods than preemptive immunosuppression to consistently predict aGVHD and abrogate disease manifestation without exposing patients to an unwarranted risk for infectious complications. Recent insights into the multistep-pathophysiology of aGVHD provide a good basis for the development of new tests to identify individual patients at risk before the onset of aGVHD.

**Aims:** As pathologic T cell responses rely on spatiotemporally defined programs of T cell activation, acquisition of effector functions, and homing to GVHD target tissues it appeared attractive to assess receptor expression profiles of peripheral blood T cells as potential predictive markers.

**Methods:** Therefore, we characterized the surface receptor expression profile of peripheral blood donor lymphocytes early after allo-HCT in two independent murine models across minor histocompatibility antigens (miHAg) with multicolor flow cytometry. C57Bl/6 (H-2b, Thy1.1+) or B10.D2 (H-2d, Thy1.1+) T cells plus bone marrow cells were transplanted in conditioned (8Gy) miHAg mismatched BALB/c (H-2b, Thy1.2+) and syngeneic C57Bl/6 (9Gy) or BALB/c (H-2d, Thy1.1+) recipients. To identify suitable predictive markers, we compared the expression pattern of allo-HCT recipients to syngeneic HCT recipients and untreated wild type controls.

**Results:** Comparing a panel of T cell surface receptors, we found the homing markers 043B7 integrin, and P- and E-selectin ligand highly up-regulated on alloimmune peripheral blood donor CD8+ T cells at peak time points of cell migration. The combination of these homing markers with the activation markers CD25 and CD69 at later time points and low expression levels of L-selectin allowed to define alloreactive donor T cells.

**Summary/Conclusions:** Based on this data we propose that alloreactive CD8+ T cells can be identified in miHAg allo-HCT recipients upon their homing receptor expression pattern as soon as six to ten days before the onset of aGVHD.
**Thalassemias**

**E1570**

**SOLUBLE FORM OF TRANSFERRIN RECEPTOR IS ASSOCIATED WITH AGE AT DIAGNOSIS AND RISK OF THERAPEUTICAL INTERVENTION AND IRON OVERLOAD IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA**

A. Meloni1,*, A. Spasiano 2, P. Ricchi2, L. Pistoia 1, A. Carrà 3, C. Cosmi 4, L. Pistoia2, P. Cinque1, A. Filosa1

1AORN A. Cardarelli, Naples, 2Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 3AORN Monaldi-Cotugno-CTO, Naples, Italy

**Background:** The soluble transferrin receptor (sTfR), that fully reflects the narrow erythropoietic activity, was found to have not only a striking diagnostic accuracy in predicting the risk of extramedullary haematopoiesis (EMH), but also in scoring disease severity in non-transfusion-dependent thalassemias (NTDT).

**Aims:** We retrospectively evaluated the relationship between sTfR and some fundamental events in the life and in the management of patients with NTDT.

**Methods:** We considered 111 NTDT patients with four genetic entities of NTDT: homozygous or compound heterozygous state for β-thalassemia, triplicated a genotype associated with β heterozygosity, deletional HbH, and combination of a β defect plus a β chain variant. sTfR was measured with a commercially available kit. A group of patients was enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) network and underwent hepatic iron overload assessment by the T2* Magnetic Resonance Imaging (MRI) technique.

**Results:** The group with homozygous or compound heterozygous for β-thalassemia had the higher sTfR levels. sTfR values were negatively related to age at diagnosis ($R=-0.462, P<0.0001$), and to age at first transfusion ($R=-0.703, P<0.0001$). At ROC curve a sTfR>5.3mg/L discriminated the patients with a previous history of occasional transfusions. sTfR values were significantly higher in splenectomized patients. sTfR values were negatively related to age at splenectomy ($R=-0.328, P=0.044$) and in unsplenectomized patients a significant positive correlation was found between sTfR values and spleen diameter ($R=0.572, P<0.0001$). sTfR values were negatively related to age at starting chelation therapy ($R=-0.564, P=0.044$). Patients never chelated showed significantly lower sTfR values than patients under chelation therapy (see Figure). sTfR values were significantly correlated with serum ferritin levels ($R=0.321, P<0.0001$), but no with LIC values.

**Figure 1.**

**Summary/Conclusions:** Low serum ferritin values, even in the normal range, do not per se exclude cardiac and hepatic iron overload, although decreasing the risk. Before to consider a reduction of the chelator dose in patients whose serum ferritin levels have reached the target, a MRI scan should be performed in order to measure iron levels in the different organs.

**E1571**

**LOW SERUM FERRITIN LEVELS DO NOT PROTECT FROM CARDIAC AND HEPATIC IRON IN PATIENTS WITH THALASSEMIA MAJOR**

A. Meloni1,*, A. Spasiano2, P. Ricchi2, L. Pistoia1, A. Carrà3, C. Cosmi4, A. Meloni1, A. Spasiano2, L. Pistoia1, A. Carrà3, C. Cosmi4


**Background:** The estimation of serum ferritin levels is the most commonly employed test to evaluate iron overload in Beta Thalassemia Major (TM).

**Aims:** The aim of this multicenter study was to assess the distribution of serum ferritin levels in a cohort of well treated TM patients and the possible protective role of really low levels versus iron accumulation in the heart and in the liver.

**Methods:** We considered 1548 TM patients regularly transfused and chelated consecutively enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) Network. Myocardial and hepatic iron burdens were quantified by the T2* technique. For the heart a multislice approach was adopted in order to calculate segmental and global T2* values. Hepatic T2* values were converted into liver iron concentration (LIC) values.

Remarkably, clean serum ferritin levels <500ng/ml were found in 342 (22.1%) patients. Three groups were identified on the basis of mean serum ferritin levels. Both transaminases were significantly lower in patients with serum ferritin <500 ng/ml and between 500 and 1000 ng/ml versus patients with serum ferritin ≥1000 ng/ml. Among patients with serum ferritin <500 ng/ml, 9.1% showed hepatic iron (LIC ≥3mg/g dw). Cardiac and hepatic iron levels were significantly lower in patients with serum ferritin <500 ng/ml than in the other two groups and in patients with ferritin between 500 and 1000ng/ml versus patients with serum ferritin ≥1000 ng/ml (see Figure). Compared to patients with serum ferritin levels <500 ng/ml, the other two groups showed a significant higher risk of cardiac iron overload (odds ratio-OR=2.03, P=0.002 for patients with ferritin 500-1000 ng/ml and OR=5.96, P<0.0001 for patients with ferritin ≥1000 ng/ml) and of hepatic iron overload (OR=3.44, P=0.0001 for patients with ferritin 500-1000 ng/ml and OR=25.43, P<0.0001 for patients with ferritin ≥1000 ng/ml).

**Figure 1.**

**Summary/Conclusions:** Low serum ferritin values, even in the normal range, do not per se exclude cardiac and hepatic iron overload, although decreasing the risk. Before to consider a reduction of the chelator dose in patients whose serum ferritin levels have reached the target, a MRI scan should be performed in order to measure iron levels in the different organs.

**E1572**

**ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS IN CHILDREN AND ADOLESCENTS WITH B-THALASSEMIA: RELATION TO LIPID PEROXIDATION, IRON OVERLOAD AND VASCULAR DYSFUNCTION**

A.A. M. Adly1,*, N.H. Elsherif1, A.A.R. Ismail2, Y.A. Ibrahim3, G. Niazid4, S.H. Elmetwally1

1Pediatric Hematology&oncology, Faculty of Medicine, Ain Shams University, Cairo, 2Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, 3Radiology Department, Faculty of Medicine, Ain Shams University, Cairo, 4Radiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

**Background:** Patients with β-thalassemia major (β-TM) are under significant iron driven oxidative stress. Ischemia modified albumin (IMA) is an altered type of serum albumin that forms under conditions of oxidative stress and an independent predictor of major adverse cardiovascular events.

**Aims:** To measure the levels of IMA in 45 children and adolescents with β-TM compared with 30 healthy controls and assess its relation to lipid peroxidation, vascular complications and subclinical atherosclerosis.

**Methods:** β-TM patients without symptoms of heart disease were studied focusing on transfusion history, chelation therapy, serum ferritin, malondialdehyde (MDA) and IMA levels. Echocardiography was performed and carotid intima-media thickness (CIMT) was assessed in order to measure iron overload in the different organs.

**Results:** IMA and MDA levels were significantly higher in β-TM patients compared with controls (p<0.001). IMA was higher among patients with heart disease and pulmonary hypertension (PH) risk than those without. Serum IMA and MDA levels were elevated among patients with serum ferritin ≥2500μg/L compared with patients below this cutoff. TM patients compliant to chelation had a significantly lower IMA levels than non-compliant ones. Receiver operating characteristic (ROC) curve analysis revealed that a cutoff value of IMA at 75 U/mL could differentiate β-TM patients with PH risk with 90% sensitivity,
91.4% specificity and positive predictive value of 75% and negative predictive value 97%; area under the curve 0.883 (95% confidence interval 0.752-0.959). In addition, the cutoff value of α-IMA at 17.5 U/mL could differentiate β-TM patients with heart disease with 80.5% sensitivity, 88.9% specificity and positive predictive value of 96.7% and negative predictive value 73.3%; area under the curve 0.887 (95% confidence interval 0.750-0.962). Significant positive correlations were found between IMA levels and disease duration (r=0.311, p=0.045), white blood cell count (r=0.322, p=0.031), serum alanine aminotransferase (r=0.388, p<0.01) and aspartate aminotransferase (r=0.382, p<0.037). IMA and MDA levels were positively correlated (r=0.503, p<0.001) and there was a significant positive correlation between these two markers and mean serum ferritin (IMA; r=0.543, p<0.001 and MDA; r=0.367, p<0.01) among TM patients. IMA levels were positively correlated to TRV (r=0.621, p<0.008), while negatively correlated to ejection fraction (r=0.412, p<0.014) and fractional shortening. Both IMA and MDA were positively correlated to CIMT (r=0.607, p<0.001 and r=0.371, p<0.01, respectively).

Summary/Conclusions: Our results highlight the role of oxidative stress in the pathophysiology of vascular complications in thalassemia. IMA could be useful for screening of β-TM patients at risk of cardiopulmonary complications and atherosclerosis because its alteration occurs in early subclinical disease.

E1573
SERUM N-TERMINAL PRO-BRAIN NARIUETIC PEPTIDE LEVEL AND ECHOCARDIOGRAPHIC TISSUE Doppler ABNORMALITIES IN PATIENTS WITH Beta THALASSEMA MAJOR
M. El-Tagui1, I. Mahmoud2, H. Aghal1, S. Mohamed1, M. El-Ghamrawy1, 1Pediatrics, 2Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

Background: Heart disease remains the major cause of morbidity and mortality in thalassemia patients. Multiple pathologies have been implicated in the development of cardiac dysfunction in these patients including: cardiac iron overload leading to right ventricular diastolic then left ventricular systolic dysfunction, chronic anemia and tissue hypoxia. Because congestive heart failure is the main cause of death in these patients, early recognition of cardiac dysfunction may be useful in modifying therapy in a timely manner. Tissue Doppler imaging (TDI) assessment of serum brain natriuretic peptide (BNP) level may be promising tools for such a purpose.

Aims: This study aimed to assess serum NT-proBNP level and echocardiographic tissue doppler abnormalities among a cohort of Egyptian beta thalassemia major patients and to detect possible associations between them as well as other disease variables including iron overload.

Methods: Thirty beta thalassemia major patients with a mean age of 12.93±2.07 years regularly followed up at Pediatric Hematology Clinic, Cairo University and thirty aged matched healthy control subjects were included. Conventional, M-Mode and TDI echocardiography were performed to all patients and control subjects in addition to cardiac magnetic resonance (CMR) for studied patients. Serum NT-proBNP level was measured using enzyme linked immunosorbant assay (ELISA).

Results: Tissue doppler imaging revealed a significant difference of ratio of the early (e’) to late (a’) right ventricular filling velocities (Rv e’/a’ ratio) between cardiac and non-cardiac iron overloaded patients reflecting early diastolic dysfunction in cardiac iron overloaded patients. Myocardial performance index of left ventricle (LV TEI index) by TDI showed significant difference in cardiac iron overloaded patients compared to non cardiac iron overloaded patient (mean=0.74±0.04 with p value<0.003) indicating decrease in ventricular relaxation due to iron overload and restrictive cardiomyopathy. SerumBNP level was significantly higher among patients compared to controls (mean 99.18±72.43 pg/ml versus 18.93±9.65 pg/ml respectively with p value <0.001) and among cardiac iron overloaded patients compared to non cardiac iron overloaded (mean 212.31±57.89 pg/ml versus 64.75±26.69 pg/ml respectively with p value <0.001). We found positive correlation between level of BNP and frequency of the blood transfusion/year, Rv/e’a’ and LV TEI_TD index with (p value 0.006, <0.001 and 0.030 respectively) denoting early diastolic impairment in asymptomatic thalassemia patients.

Summary/Conclusions: Asymptomatic thalassemia major patients under chelation therapy may have diastolic and or systolic dysfunctions that could not be detected by conventional echocardiography but could be highlighted by TDI. CMR, TDI and serum BNP level measurement are promising tools for accurate assessment of cardiac functions and iron overload in thalassemia patients.

E1574
PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES IN NORTHERN GREECE. 15 YEARS REPORT
S. Theodorou1, 1Thalassemia Centre, Laikon General Hospital, Athens, 2Obstetric Department, Aristotle University, Thessaloniki, Greece

Background: Hemoglobinopathies constitute the most frequent monogenic disorders worldwide and thalassemias are the most frequent genetic disorders among Greeks. In the Thalassemia Prevention Program in Northern Greece, 15% of the population are carriers of the Hb S mutation. The rate of β-thal carriers could be as high as 15-20% in some areas. The risk of giving birth to an affected child depends on the incidence of the thalassemic gene and this may vary from 1/24 to 1/150 in married couples. The National Program for prevention of Thalassemia was established in 1973. Through population screening and prenatal diagnosis programs Greeks and immigrants are screened and counselled.

Aims: We report our findings on prenatal diagnosis of thalassemias and hemoglobinopathies in Northern Greece over a 15 year period (2001-2015).

Methods: During the 15 year period, a total of 33,837 subjects were screened for hemoglobinopathies, including as couples or as individual patients. 3,659 couples were screened for hemoglobinopathies. In 371 couples both partners carried an abnormal Hb gene and counseling was offered and 329 pregnancies were found at risk of giving birth to an affected child. The genes interactions were in 245 pregnancies at risk for thalassemia major offsprings and 84 for sickle cell disease ones. Prenatal diagnosis was offered in 12 weeks of gestation (n=298), in few cases by amniotic fluid sampling (n= 21) collected at 16-18 weeks. Few late carriers were tested by fetal blood sampling at 20 week of gestation(n=5).

Results: The remaining 42 pregnancies involved couples who were double heterozygotes for mutations that did not cause severe clinical disease and were exempted from prenatal diagnosis. The gene interactions were as follows β-thal/o thal, β-thal in combination with Hb E-Saskatoon or D-Punjab, HbE/HbE, Hb E-Saskatoon with carrier of HbS, and Hb O/ Hb O, O thal or thal in combination with D Punjab, Hb Brugg/β-thal, silent β-thal silent β-thal -91. 91% of the couples were of Greek origin, and 9% were immigrants from the Balkan Peninsula, Egypt, and Asia Minor. We had an average of 15-32 prenatal diagnosis per year.

E1575
THE IMPACT OF LIVER STEATOSIS ON THE ABILITY OF SERUM FERRITIN LEVELS TO PREDICT LIVER IRON CONCENTRATION AMONG NON TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS: A CROSS-SECTIONAL EVALUATION
P. Ricchi1, A. Meloni2, L. Spasiano1, L. Pistoia2, P. Preziosi3, A. Filosa1, A. Pepe1
1AORN A. Cardarelli, Naples, 2Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 3Ospedale “Sandro Pertini”, Rome, Italy

Background: Fatty liver is a common abnormality encountered in western countries among patients undergoing imaging of the abdomen and is associated to systemic inflammation and to increased ferritin levels, frequently unrelated to systemic iron overload.

Aims: We analyzed the impact of the presence of fatty liver in the parameters of iron overload among our patients with Non Transfusion dependent Thalassemia (NTDT).

Methods: 111 patients with NTDT were cross-sectionally evaluated; the diagnosis of liver steatosis was ultrasound-based (US). In all patients ferritin levels and serum alanine aminotransferase (ALT) to serum aspartate aminotransferase (AST) ratio were assessed. Liver iron concentration (LIC) measurements were available for 64 patients (54%) who underwent a magnetic resonance Imaging (MRI) scan within the Myocardial Iron Overload in Thalassemia (MiOT) network.

Results: Liver steatosis was frequently (35.5%) encountered among our patients with NTDT and was significantly more prevalent in males with respect to females (49.0% vs 24.6%, p<0.008). Patients with liver steatosis had significantly higher values of ALT, AST, ALT/AST ratio and ferritins than those without, but LIC values were comparable (Table 1). At ROC curve analysis, an ALT/AST ratio >0.89 predicted the presence of liver steatosis with a sensitivity=0.872 and a specificity = 0.901 (P<0.001). Overall, ferritin levels positively correlated with LIC values (R=0.558, P<0.001) but in patients without steatosis there

haematologica | 2017; 102(s2) | 641
was a strong relationship between ferritin and LIC values (R=0.656, P<0.0001) while in patients with steatosis the correlation was moderate (R=0.428, P=0.05).

Table 1.

Summary/Conclusions: Our data show that liver steatosis affected also patients with NTDT and should be suspected in presence of a ALT/AST ratio >0.89. Recently, serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding chelation therapy when MRI is unavailable in patients with (NTDT) have been provided. Our data show that the presence of liver steatosis may lead to overestimate the magnitude of iron burden and may be responsible for anticipating or exceeding chelation treatment in patients with NTDT in absence of a LIC evaluation.

E1576

CIRCULATING CELL-FREE DNA (cfDNA) AND INEFFECTIVE ERYTHROPOIESIS IN BETA-THALASSEMIA INTERMEDIA

D. Tavazzi1, G. Graziadei2, A. Marcon2, L. Duca2, I. Nava2, M.D. Cappellini3,*, M. Sampietro3
1Dip. Scienze Cliniche e di Comunità, Università degli Studi di Milano, 2Dipartimento di Medicina Interna, Fondazione IRCCS Cà Grande PoliChinico di Milano, 3Dip. Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy

Background: Low concentrations of circulating cell-free DNA (cfdNA) are found in the plasma of healthy individuals and increase in a number of conditions dependent on clinical severity, including cancer, chronic inflammation, autoimmune diseases and trauma. The mechanisms of release of cfdNA in the bloodstream are not well understood: DNA could originate from cells undergoing apoptosis/necrosis in tissues or from cells released in the blood and subsequently lysed. Also the tissue origin of cfdNA is mainly unclear. It has been suggested that cfdNA, at least after bone-marrow transplantation, could be mostly of hematopoietic origin. This finding prompted us to explore whether cfdNA is increased in patients with ineffective erythropoiesis (IE), a condition characterized by the over-proliferation and lysis/removal of erythroid precursors. This situation is common in thalassemias, mainly in non transfusion-dependent patients (NTDT).

Aims: The present study was designed i) to evaluate the behaviour of cfdNA in IE caused by beta-thalassemia, and ii) to assess whether cfdNA could be useful to quantify IE.

Methods: We studied 49 beta-thalassemia intermedia (TI) patients (mean age 41 years, range 16-65), 23 of whom were splenectomized. No evidences of tumor, trauma or autoimmune diseases have been observed in any patient at the time of the study. Eighteen healthy subjects were also included as control group. The study was approved by the local ethical committee. DNA was extracted by QIagen silica-based micro-spin columns from 200 mL of K3EDTA plasma. cfDNA concentration determined fluorometrically using the fluorescent dye PicoGreen. Biochemical and hematologic parameters were determined in all patients as a part of laboratory routine. Reticulocytes and peripheral erythropoiesis in TI patients as a part of laboratory routine. Reticulocytes and peripheral erythropoiesis in TI patients.

Results: We studied 49 beta-thalassemia intermedia (TI) patients (mean age 41 years, range 16-65), 23 of whom were splenectomized. No evidences of tumor, trauma or autoimmune diseases have been observed in any patient at the time of the study. Eighteen healthy subjects were also included as control group. The study was approved by the local ethical committee. DNA was extracted by QIagen silica-based micro-spin columns from 200 mL of K3EDTA plasma. cfDNA concentration determined fluorometrically using the fluorescent dye PicoGreen. Biochemical and hematologic parameters were determined in all patients as a part of laboratory routine. Reticulocytes and peripheral erythropoiesis in TI patients as a part of laboratory routine. Reticulocytes and peripheral erythropoiesis in TI patients.

Correlations of cfdNA were found between sTfR (r=0.45, p=.0014) and GDF15 (r=0.56, p<.0001). Correlations of cfdNA were found between sTfR (r=0.45, p=.0014) and GDF15 (r=0.56, p<.0001). Notably, correlations with EBL (r=0.75, p=0.0001), AST (r=0.58, p=0.0036) and uncorrected bilirubin (r=0.54, p=0.0083) were observed only within the SPX group and not in non-SPX.

Summary/Conclusions: In this study we found that plasma cfdNA rises in TI patients compared to controls. Its concentration appears to correlate with both the amount of IE and the number of EBL and the lysis of circulating erythroid precursors (both increased after splenectomy). We obtained preliminary evidences that circulating cfdNA concentration may be a suitable indicator of erythropoietic activity in TI patients. Results need to be extended on larger samples of patients’ population to investigate the possible use of plasma cfdNA as a feasible and reliable biomarker to describe/monitor the severity of IE and TI complications.

E1577

LEFT VENTRICULAR HYPERTRABECULATION BY CARDIAC MAGNETIC RESONANCE IN THALASSEMIA INTERMEDIA PATIENTS: FREQUENCY AND PROGNOSTIC ROLE

A. Meloni1,*, F. Macaione2, L. Pistoia1, S. Pulini3, V. Santamaria4, M. Benni5, L. Sardella6, A. Barison1, G. Peritore7, V. Postiano1, S. Novo2, A. Pepe1

Background: Differentiation of left ventricle non-compaction (LVNC) from hypertrabeculated LV due to a negative heart remodeling in thalassemia intermedia (TI) can depend on the selected CMR criterion. The recently proposed Piga’s criterion (NC/C ratio threshold of >2.5, Am J Haem 2012) seems to have a low specificity to identify the true LVNC in TI. Anyway, the Piga’s criterion could easily detect a negative heart remodeling in TI patients.

Aims: The aim of our study was to prospectively assess whether the Piga’s criterion had a prognostic role for adverse cardiovascular outcomes in TI patients.

Methods: We studied prospectively 168 TI patients (81 males, mean age 38.32 ±11.61 years) consecutively enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) Network. Standard cine steady-state free precession sequences were acquired and used for the calculation of biventricular function parameters (short-axis) and for the calculation of the thickness of the non-compacted and the compacted myocardium (three diastolic long-axis views) in all 16 segments. The maximal NC/C ratio was considered. Late gadolinium enhancement (LGE) images were acquired to detect myocardial fibrosis.

Results: Eight patients were excluded because a cardiac complication was present at the first CMR. The baseline mean age of the considered 161 TI patients was 38.32±11.61 years and 81 patients were males. The study population was divided into two groups: patients with Piga’s positive criterion (n=15, 9.31%) and with Piga’s negative criterion (n=146, 90.68%). No significant differences were found between the two groups in terms of demographic features and CMR parameters. The mean follow-up time was 57.50±21.87 months. Sixteen new cardiac events were recorded: 1 heart failure, 10 supraventricular arrhythmias and 5 pulmonary hypertension. Due to numerical reasons, it was possible to perform a Cox regression analysis only for arrhythmias and cardiac complications globally considered. Patients with Piga’s positive criterion had a significantly higher risk of developing arrhythmias (hazard ratio=HR=7.19, 95% CI=2.02-25.51; P=0.002) and cardiac complications (HR=3.86, 95% CI=1.8-11.36, P=0.025). The figure shows the Kaplan-Meier survival curves. The Piga’s positive criterion remained a significant prognosticator also in a multivariate models including previous and resolved events (14 cardiac complications, of which 7 arrhythmias) (HR for arrhythmias=23.67; HR for cardiac complications =7.09).

Summary/Conclusions: Based on our data a NC/C ratio ≥ 2.5 provides prognostic information for patients with TI about the risk of developing cardiac complications.

E1578

NITRIC OXIDE DYSREGULATION IN BETA-THALASSEMIA MAJOR: RELATION TO PULMONARY HYPERTENSION

M. Eshinawaya1,2,*, A. Elneaguia3, A. Ghanemii, M. Wagyia2
1Pediatric Hematology, Sultan Qaboos University Hospital, Muscat, Oman, 2Pediatric Hematology, Faculty of Medicine, 3Hematology, Medical Research Institute, 4Clinical Pathology, Faculty of Medicine, Alexandria, Egypt

Background: Pulmonary hypertension (PH) is emerging as one of the most devastating complications of beta-thalassemia major. Chronic hemolysis and iron overload constitute a major source of strong oxidative stress. Free heme radicals and red cell membrane elements resulting from hemolysis have a negative effect on the intrinsic nitric oxide (NO) production and arginine available.

Figure 1.
ability. Deficiency of both biochemical mediators promotes vasoconstriction of the pulmonary vasculature resulting in further endothelial dysfunction, with subsequent intensified reduction of nitric oxide. The role of nitric oxide dysregulation is well-studied in non-transfusion dependent thalassemias and in sickle cell disease, but yet not very well-characterized in beta thalassemia major.

Aims: The aim of our work is to study the relation between intrinsic nitric oxide level and the evolution of pulmonary hypertension in beta thalassemia major.

Methods: This is a case-control study, including all patients with beta thalassemia major above 12 years of age, undergoing follow up in pediatric hematology and in medical research institute, university of Alexandria, Egypt throughout a period of 6 months from 1st of July till 31st of December 2016. All patients were screened for pulmonary hypertension by echocardiography, and those who have high tricuspid regurgitant jet velocity (TRV>2.5m/sec.) underwent cardiac catheterization.

Results: The present study included 52 thalassemic patients, 28 males and 24 females. Their age ranged between 11 and 26 years. The patients were subdivided into two groups (17 patients with pulmonary hypertension (PH), proven by cardiac catheterization and 35 patients without pulmonary hypertension). Nitric oxide level (measured by ELISA) was significantly lower in patients as a whole compared to controls [median of 19 micromol/L versus 30 micromol/L] (p=0.02). Similarly, nitric oxide was significantly lower in PH group compared to non-PH patients (p=0.001). In addition, there was a statistically significant negative correlation between serum NO level and serum ferritin level in all patients (r=-0.444, p<0.001).

Summary/Conclusions: In conclusion, NO reduction might contribute significantly to the development of pulmonary hypertension in patients with beta thalassemia major. This effect could be related to the degree of hemolysis, iron overload and the duration of disease. Further studies on the adverse pathophysiological effects of nitric oxide deficiency in beta thalassemia major e.g. its relation to coagulopathy and platelet aggregation are recommended.

E1579

Abstract withdrawn.

E1580

SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR DIAGNOSIS OF EARLY MYOCARDIAL DISEASE IN EGYPTIAN BETA THALASSEMIA MAJOR PATIENTS

A.A.G. Tantawy1,*, N.M. Habeeb2, N.H. Elshefie2, E.M. Hasan1, A. Abdelhameed1 1Pediatric Hematology&oncology, 2Cardiology departement, faculty of medicine, Ain Shams University, Cairo, Egypt

Background: The new parameters of cardiac function, derived from two-dimension speckle-tracking echocardiography could be useful for an early diagnosis of cardiac involvement in transfusion dependent β-TM patients.

Aims: In this cross sectional study, our goal was to detect early myocardial disease in transfusion dependent β-TM patients using Echocardiography (Speckle Tracking) to assess its specificity and sensitivity in comparison with cardiac MRI T2*. Methods: This cross sectional study included 30 transfusion dependant β-thalassemia patients aged between 11-20 years recruited from the Pediatric Hematology & Oncology Unit, Children Hospital, Ain Shams University. All included patients were subjected to detailed medical history(inclusion transfusion, chelation, hepatitis C virus history with calculation of mean serum ferritin in last 2 years) Radiological investigation included Echocardiography (Tissue Doppler and Speckle Tracking);MRI T2* were done.Cardiac afection by speckled was defined as decreased longitudinal strain less than 11 percentage or affection of any segment less than 11 percentage.

Results: Cardiac afection by speckled echocardiography was found in 10 patients(33.3%), 8 of them (80%) had normal ejection fraction and normal shortening fraction, while 9 had iron overload by Cardiac MRI T2*. Patients with mean serum ferritin ≥2000 ng/mL in the last 2 years prior evaluation showed a significantly lower longitudinal strain (GLPSLAX) (P=0.043) which was further proved by a significantly negative correlation with the mean serum ferritin (P=0.002). No significant differences were found between both splenectomized and non splenectomized patients as regard speckle tracking echocardiographic measures. The ROC curve analysis revealed that GLPS A4C a cutoff value of ≤21% was able to detect β-thalassemia patients having myocardial disease by cardiac MRI T2* with a sensitivity of 87.50% and specificity of 63.64%. Patients with cardiac iron overload by MRI T2* had significantly lower GLPSLAX &GLPS A4C and higher Ao Diam than those without cardiac iron overload (P=0.016, P=0.008, P=0.047 respectively). No significant difference between beta thalassemia patients with cardiac affection and those without cardiac affection as regard the duration of the disease, type and compliance of chelation therapy.

Summary/Conclusions: Although, Magnetic Resonance Imaging T2* technique is considered the reference standard for cardiac iron overload, its routine use is limited by its high costs, poor availability. We demonstrated in this study an abnormal global longitudinal strain despite preserved LV systolic functions among BTM patients; thus speckle tracking echo techniques might be considered as an alternative effective method to detect early myocardial disease before evident systolic dysfunction.

E1581

Efficacy, Safety and Genetic Basis of Variability of Response to Hydroxyurea Therapy in Beta Thalassemia: A Systematic Review

S. Khalil

1Pathology, fauji Foundation Hospital/Foundation University Medical College Rawalpindi, 2Hematology, Hemophillia Centre, Rawalpindi, Pakistan

Background: Pharmacological agents such as hydroxyurea promote fetal hemoglobin production via a reactivation of γ-genes. In β-thalassemia there is an imbalance in globin chains which could be ameliorated by the newly synthesized γ-chains which neutralize the excess α-chains and therefore improves symptoms.

Aims: Systematic review of literature to evaluate the efficacy, safety and the genetic basis of variability of response to hydroxyurea therapy in beta-thalassemia patients.

Methods: Research sources used were: MEDLINE (PubMed), EMBASE (Ovid) and Cochrane from June 1993 till June 2016. Eligible articles were reviewed and data including patients’ characteristics, duration of treatment, outcome, toxicity and impact of genetic mutation on response to hydroxyurea therapy was extracted. Major responders were those who became transfusion independent after hydroxyurea treatment, partial responders had significant decline in transfusion requirements, poor responders did not respond to hydroxyurea therapy. Statistical analysis software package 16 was used for data analysis.

Table 1.

<table>
<thead>
<tr>
<th>Type of Beta Thalassemia</th>
<th>Major Response</th>
<th>Partial Response</th>
<th>Poor Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-thalassemia major</td>
<td>35 (32%)</td>
<td>35 (32%)</td>
<td>15 (14%)</td>
</tr>
<tr>
<td>β-thalassemia intermedia</td>
<td>50 (47%)</td>
<td>45 (42%)</td>
<td>15 (14%)</td>
</tr>
</tbody>
</table>

Results: Thirty eligible studies comprising of a total of 1822 patients with beta thalassemia were identified. Of these (n=9, 30%) evaluated the major effect of hydroxyurea therapy on beta thalassemia major patients, (n=11, 36%) evaluated beta thalassemia intermedia patients while (n=10, 34%) included both beta thalassemia major and thalassemia intermedia patients. Mean age of patients was 13.5 years. Mean duration of hydroxyurea therapy was 3.4 years. The mean hydroxyurea dose was 10mg/kg per day (8.15mg/kg). Table I showing number and percentage of patients having major, partial and poor response to hydroxyurea therapy. Only (n=12, 36%) studies evaluated the role of underlying genetic mutation on hydroxyurea response, out of these (n=6, 50%) studies found no significant correlation while (n=6, 50%) showed a positive correlation between common genetic mutations and hydroxyurea response. Hydroxyurea was found to be well tolerated, only (n=9, 01%) had transient myositis/epis.

Summary/Conclusions: Hydroxyurea is an effective and well-tolerated agent in the management of β-thalassemia (both intermedia and major). It reduces blood transfusion requirements either partially or completely in majority of patients. No significant correlation between response to therapy and underlying genetic mutation was found. More studies are required to fully establish the association of genetic mutation to drug response.

E1582


M. El Samahy1, A. Tantawy1,*, A. Adly1, E. Ismail1, A. Ahmed1, Y. Nousef1 1AinShams university, Cairo, Egypt

Background: Glucose metabolism disturbances, among other end-organ pathologies, are a common feature of β-thalassemia major (β-TM). Pancreatic iron overload and diabetes mellitus (DM) are common in β-TM patients. However, the relationship between iron stores and glucose disturbances is not well defined. Continuous glucose monitoring system (CGMS) enables more diagnostic accuracy and a better achievement of an optimal glycemic control.

Aims: To assess the pattern of glucose homeostasis in patients with β-TM and detect early impairment in glucose metabolism and prediabetic state in β-thalassemia patients comparing oral glucose tolerance test (OGTT) and CGM system.

Methods: This cross sectional study was conducted on 200 patients β-TM patients. Patients were studied focusing on transfusion history, transfusion index, iron chelation therapy and compliance to chelation. Complete blood picture, markers of hemolysis, serum ferritin and random blood glucose (RBG) were measured. Patients with RBG ≥140mg/dL were subjected to OGTT, inser-
mellitus. The percentage of diabetic patients diagnosed by CGMS was signific-
antly higher than that with OGTT (p = 0.012). According to CGMS readings, 10
of the 13 patients with diabetes had abnormal HbA1c readings of diabetic
range (6.5-9.9%) while 5 of the 7 patients with impaired glucose tolerance had
HbA1c readings in the prediabetic range (5.5-6.1%). Serum ferritin were sig-
nificantly higher among patients with RBG ≥140mg/dL (p(= 0.001). It was noted
that 76% of patients with RBG ≥140mg/dL were noncompliant and 75% of
patients on desferrioxamine therapy had RBG ≥140mg/dL. There was a signif-
icant positive correlation between HbA1C% and FBG among the studied thalas-
semia patients with elevated RBG ≥140mg/dL, while HbA1C% was nega-
tively correlated with fasting C-peptide. Serum ferritin was positively correlated
with RBG. As regards CGMS data, HbA1C was positively correlated to maxi-
mum blood glucose, average blood glucose, SBG blood glucose and area under
the curve≥140mg/dL. The only significant independent factor for elevated
RBG ≥140mg/dL was serum ferritin.

Summary/Conclusions: The use of CGMS in the diagnosis of early glycemc
abnormalities (prediabetes) among patients with β-TM appears to be promising
and superior to other known diagnostic modalities namely OGTT and HbA1c.

E1585
ASSOCIATION OF SP1 POLYMORPHISM IN THE COLLAGEN TYPE I ALPHA 1 (COL1A1) GENE WITH OSTEOPOROSIS IN CHILDREN WITH
BETA-THALASSEMA
M. Hesham1,*, N. Khalifa2, M. Zakaria1, N. Elbazz2, D. AbdElElmonem2
1Pedicatri, 2clinical pathology, Zagazig University Hospital, Zagazig, Egypt

Background: Osteoporosis is a progressive bone disease that is characterised
by a decrease in bone mass and density that leads to an increased risk of frac-
ture. Early detection of mutation at the Sp1-binding site on the COL1A1 gene is
mandatory in order to initiate preventive therapy before the occurrence of frac-
ture. Aims: To study the relationship between SP1 polymorphism in the collagen
type I alpha 1 gene and the development of osteoporosis in patients with Beta
thalassemia.

Methods: A prospective case control study was carried out in the Outpatient
Clinic of Hematology Unit of Pediatric Department and Clinical Pathology Depart-
ment at Zagazig University Hospitals on forty thalassemic patients (21 females
&19 males) aged 6-18 years during their regular follow-up visits (22 patients
with thalassemia major and 18 with thalassemia intermedia) and forty age-
and sex-matched healthy children as a control group. All patients and control were
subjected to full medical history, thorough clinical examination and laboratory
investigations in the form of complete blood count, Hb electrophoresis, Calcium
evel Serum ,alkalin phosphatase, Bone Density by DXA, Serum osteocalcine
level and COL1A1 gene polymorphism by using polymerase chain reaction
restriction fragment length polymorphism technique (PCR-RFLP).

Results: There was highly significant difference between thalassemia patients
and control group as regards serum levels of calcium, osteocalcin and alkaline
phosphatase and DEXA results but no significant difference between thala-
semia major and thalassemia intermedia patients. As regard COL1A1 geno-
type there was high percentage of heterozygous Ss (GT) and homoyzygous ss
( TT) genotype in beta thalassemia major 55.63%, 13.67% than thalassemia
intermedia 50.6%, 0%, respectively. There was significant relation between
COL1A1 genotypes and Calcium level (p=0.02). But there was no significant
relation between COL1A1 genotypes and osteocalcin, alkaline phosphatase lev-
els and DEXA among studied groups.

Summary/Conclusions: SP1 polymorphism in collagen gene could be of clini-
ical value in identifying the thalassemic patients at risk of developing osteo-
porosis.

E1586
UNUSUAL MOLECULAR MECHANISMS IN THE ORIGIN OF ALPHA-THA-
LASSEMA
J. Ferraó1, M. Silva1, L. Gonçalves1, S. Gomes1, P. Loureiro1, A. Coelho1,
A. Miranda2, F. Feuane3, A. Batalha Reis3, F. Pina4, R. Maia5, P. Krölstrom5,
E. Monteiro6,7, J. F. Lacerda6,8, J. Lavinha9,1, J. Gonçalves1,10, P. Faustino11,11,
1Departamento de Genética Humana, Instituto Nacional de Saúde Doutor
Ricardo Jorge (INSD), 2Departamento de Promoção da Saúde e Doenças não
Transmissíveis, INSA, 3Serviço de Patologia Clínica, Hospital São Francisco
Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, 4Serviço de Hemato-
Oncologia, Hospital do Espírito Santo de Evora, Evora, 5Unidade de Hema-
tologia, Hospital de D. Estefânia, Centro Hospitalar de Lisboa Central, 6Fac-

Table 1.

| Table 1. |
Background: Hemoglobin (Hb) is a protein responsible for oxygen transport from lungs to the entire body. It is composed by four globular subunits - the globins - each with a central core containing a heme molecule. Globins are encoded by the alpha- and beta-globin gene clusters located at 16p13.3 and 11p15.5, respectively. The pattern of globin gene expression during development is precisely controlled by the interaction of cis-regulatory genomic regions (located in close proximity to and far from genes) with trans-activating/silencing factors within permissive chromatin domains. Distally upstream of the X-globin genes and/or their distal MCSs give rise to X-thalassemia, one of the most common genetic recessive disorders worldwide, due to a reduced rate of alpha-globin chain synthesis. The severity of the pathology is variable ranging from a very mild microcytic hypochromic anemia to a moderately severe anemia associated with the formation of X-tetramers resulting in HbH disease or an even higher reduction or complete absence of a-chains resulting in hemoglobin Bart’s hydrops fetalis, a condition generally incompatible with life.

Aims: The main objectives of this work were to characterize the molecular lesions underlying ten Portuguese cases of unusual alpha-thalassemia/HbH disease and to establish their origin and functional consequences.

Methods: After exclusion the most frequent molecular lesions associated with alpha-thalassemia, Multiplex Pigment-dependent Probe Amplification (MLPA) using the SALSA MLPA P140B Hba kit (MCR-Holland) was used to search for DNA deletions in the subtelomeric region of chromosome 16p. Additionally, specifically designed synthetic MLPA probes, as well as gap-PCR and Sanger sequencing were performed for more accurate deletion breakpoint mapping.

Results: We have found five distinct deletions and one indel, all in heterozygosity. The deletions range from approximately 3.3 to 323 kb and two of them are novel. The three larger deletions remove the entire a-globin cluster whereas the others remove totally or partially the distal regulatory elements keeping the a-globin genes structurally intact. The indel comprises the deletion of the MCS-R2 regulatory element and the insertion of a singular 39 bp DNA fragment possibly originating from a complex rearrangement involving chromosome 3. Finally, no a-globin gene cluster deletion or point mutation were found in a patient whose Hb electrophoresis was very unusual case of acquired alpha-thalassemia associated with a myelodysplastic syndrome.

Summary/Conclusions: Our study widens the spectrum of molecular lesions and unusual molecular mechanisms by which alpha-thalassemia/HbH may occur and emphasizes the importance of diagnosing large deletions to provide patients with appropriate genetic counseling.

E1587

Abstract withdrawn.

E1588

VALUE OF HBA2 IN THE DIAGNOSIS OF BETA-THALASSEMINA MINOR “ATTENTION TO THE GRAY ZONE”

L. Reivas1, L. Magalhães Maia1, E. Cunha1, J. Pereira1, A.C. Oliveira1, C. Bento1, M.L. Ribeiro1

1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Background: The homozygosity for the alternative splicing mutation HBB: IVSI-6 (C>T) is the most frequent genotype of beta thalassemia intermediate in our population and was even termed “beta thalassemia intermediate type Portuguese” (Tamagnini et al., 1983). The IVSI-6 (C>T) carriers (heterozygous) are characterized by mild hypochromia and microcytosis, with a moderately increased in HbA2, that may be even less than 3.5%. The correct identification of these carriers is important, especially when facing a couple who intends to have children.

Aims: To evaluate the percentage of individuals with hypochromia and microcytosis and HbA2 between 3.2% and 3.4%, who are beta thalassemia carriers, alerting for the need to adapt the cut-offs of HbA2 values to the genetic background of different populations.

Methods: Parameterized search of all the consecutive individuals evaluated in our laboratory from January 2007 to January 2016. The inclusion criteria were the simultaneous presence of hypochromia and microcytosis (adjusted to the age) and HbA2 values between 3.2% and 3.4% inclusive. The exclusion criteria were the presence and/or clinical information of sideropenia or sideropenic anemia, hemoglobin variants or alpha thalassemia. Sequencing of the entire HBB gene was performed by Sanger Sequencing.

Results: Respecting the inclusion and exclusion criteria we have identified 43 individuals with hypochromic and microcytic anemia, HbA2 ≥3.2% and ≤3.4%, in which the HBB gene mutations were screened. Among the 43 subjects, nineteen presented HbA2=3.2% (19/43), eleven HbA2=3.3% (11/43) and thirteen had HbA2=3.4% (13/43). The IVSI-6 (T>C) mutation was identified in 2 subjects with HbA2=3.2% (10%), 5 with HbA2=3.3% (45%) and 7 with HbA2=3.4% (54%). No other HBB gene mutations were detected. The remaining individuals were classified as probable alpha thalassemia and suggested continuation of the study, if warranted.

Summary/Conclusions: We have identified 14/43 (32%) individuals as beta thalassemia carriers who, for the conventional cut-off of HbA2 ≥3.5%, would not have been diagnosed. Based on this data, we propose that individuals with hypochromia and microcytosis, with normal or slightly elevated RDW, without sideropenia, with HbA2 between 3.2-3.4%, should be screened for mutations in the HBB gene, in order to rule out beta thalassemia carriers due to Beta+, mutations. As HBB IVSI-6 (T>C) mutation is one of the most frequent beta thalassemia mutations in Portugal, and in Mediterranean basin, it is necessary to deep evaluation of the classic rule of HbA2=3.5% for the diagnosis of beta thalassemia minor may undergo diagnose this pathology and lead to an incorrect genetic counseling.

E1589

DIAGNOSIS OF HEMOGLOBINOPATHIES BY CAPILLARY ZONE ELECTROPHORESIS: EXPERIENCE WITH 925 CASES

P. Tripathi1,*, H.P. Pati1, R. Saxena1

1Dept of Hematology, All India Institute of Medical Sciences, New Delhi, India

Background: Hemoglobin capillary zone electrophoresis is a relatively newer technique as compared to HPLC for detection of abnormal hemoglobins. We share our first hand experience of using Capillary 2 Flex piercing instrument for diagnosis of hemoglobinopathies as a primary diagnostic modality

Aims: The main aim was to evaluate a new technology for diagnosis of hemoglobinopathy.

Methods: The capillary 2 Flex piercing instrument with Phoresis software for hemoglobin electrophoresis at alkaline pH was evaluated at our centre over a period of 1 year. A total of 925 sample runs were included in the analysis. The equipment was assessed on the following parameters: ease of operation, pre-analytical factors, identification, quantification and precision of hemoglobin variants including the rare variants. Further, we evaluated if capillary zone electrophoresis can be useful as a single method for diagnosis of hemoglobinopathies.

Results: The automation provided by capillary zone electrophoresis eased the problem of errors during sample preparation. The option for low sample volume mode is a great help in samples from children. The instrument could readily identify all common hemoglobins and the diagnosis was straightforward in 829 (89.7%) cases. In the rest 96 (10.3%) cases, the sample was required to be rerun because it lacked Hb A or Hb A2. This posed inconvenience because the electrophoretic zones get displaced and have to be derived after mixing it with normal sample. The machine is not specifically standardized for cord blood samples hence we are not performing tests on neonatal cord blood sample. The instrument could separately identify Hb E from Hb F which is a big scorer over HPLC, however, we found mild high Hb A2 both in heterozygous and homozygous Hb E cases (heterozygous Hb E, n-28 mean Hb A2- 3.9% and homozygous Hb E, n-7 and mean Hb A2- 4.2%) leaving the doubt whether some adducts are still left. Identification of small peaks of Hb H could be difficult and requires other modalities to confirm. Two cases where Hb H was strongly suspected clinically and HB H inclusion test was positive showed small peaks of HB H (1.2% and 0.9%) on HPLC. Hemoglobins falling into the same zone (eg Hb D- Punjab and Hb Q India) needed identification with second modality. Whenever encountered with problem of identifying certain abnormal peak, we resorted to HPLC for confirmation. Spectrum of hemoglobin variants encountered (n-298 cases, rest 627 showed normal results) in the study is listed in table below.

Table 1.

<table>
<thead>
<tr>
<th>Type of Hemoglobin</th>
<th>No of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb A</td>
<td>281</td>
</tr>
<tr>
<td>Hb A2</td>
<td>29</td>
</tr>
<tr>
<td>Hb A3</td>
<td>5</td>
</tr>
<tr>
<td>Hb G</td>
<td>2</td>
</tr>
<tr>
<td>Hb H</td>
<td>2</td>
</tr>
<tr>
<td>Hb Hb</td>
<td>2</td>
</tr>
<tr>
<td>Hb Hb2</td>
<td>2</td>
</tr>
<tr>
<td>Hb Hb4</td>
<td>2</td>
</tr>
<tr>
<td>Hb Hb6</td>
<td>2</td>
</tr>
<tr>
<td>Hb Lepore</td>
<td>2</td>
</tr>
<tr>
<td>Hb O</td>
<td>2</td>
</tr>
<tr>
<td>Hb C</td>
<td>2</td>
</tr>
<tr>
<td>Hb E</td>
<td>2</td>
</tr>
<tr>
<td>Hb E 4</td>
<td>2</td>
</tr>
<tr>
<td>Hb E 6</td>
<td>2</td>
</tr>
<tr>
<td>Hb F</td>
<td>2</td>
</tr>
<tr>
<td>Hb F 4</td>
<td>2</td>
</tr>
<tr>
<td>Hb F 6</td>
<td>2</td>
</tr>
<tr>
<td>Hb Hb</td>
<td>2</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Capillary zone electrophoresis is an alternative method for hemoglobinopathy. However, since the diagnosis of Hemoglobin variants mandates confirmation by a second method, HPLC cannot be replaced completely. Based upon the availability, workload and cost effectiveness, any of these two methods can be used as primary modality.
We retrospectively reviewed consecutive clinical and laboratory analysis for TTP. Siderosis was considered: JAK II mutation analysis for myeloproliferative diseases such as polycythemia vera if outside of the normal laboratory range. We examined whether less than 150,000 platelets and platelet count, and whether these were documented and further investigated. Thrombophilia testing is routinely sent despite limited evidence linking to arterial thrombosis in a younger cohort.

**Methods:** Mice were anesthetized with sodium pentobarbital and a midline laparotomy was then performed on a heating pad. Blood supply for left lateral and median lobes of liver (approximately 70% of the liver mass) was interrupted by cross-clamping the hepatic artery and portal vein with a microvascular anastomotic clip for 90 min. Then a clip was taken off to provoke the reperfusion of hepatic blood flow, which was monitored on the surface of left lateral lobe by Laser Doppler flowmetry (ALF21, Advance Co, Tokyo, Japan). The hepatic blood flow was measured again 24 h after reperfusion and mice were then sacrificed for analysis. It has been well known that histological and histochemical changes of liver tissue of control mice (WT) and VWF-gene deleted (knock-out; KO) mice (from The Jackson Laboratory, Bar Harbor, ME), all of which were 8-12 weeks of age, healthy and fertile. Excess blood loss was not observed in all mice (WT or KO) during whole surgical process.

**Results:** As compared to WT mice, restoration of hepatic blood flow was significantly greater in VWF-KO mice at 24 h after reperfusion (WT; 61 ± 17% vs KO; 87 ± 17%, expressed as the percentage of pre-ischemic value). Consistent with the hepatic blood flow, the time-course analysis of serum alanine aminotransferase (ALT) at several time points after reperfusion revealed the lesser liver damages of KO mice (WT, 689±3270 and 1313±621 IU/L vs KO; 3043±1320 and 478±330 IU/L, at 3 h and 24 h after reperfusion, respectively). In addition, histological analysis confirmed that neutrophil infiltration in the liver tissue of KO mice was significantly reduced as compared to WT mice at 24 h after reperfusion. These impaired hepatic blood flow and ALT values as well as intensified neutrophil infiltration in WT mice were significantly improved to an extent comparable to those of KO mice by the bolus injection of recombinant human ADAMTS13 (3 µg/mouse equivalent to 2800 U/kg, n=12) just prior to the I/R operation.

**Summary/Conclusions:** Our results altogether indicate that VWF-dependent inflammatory responses within neutrophil recruitment at ischemic sites are involved in pathophysiology of hepatic I/R injury, and functional regulation of VWF by ADAMTS13 may serve as a promising therapeutic option for hepatic I/R injury.

**E1592**

PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) RELATED THROMBOSIS IN 230 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. A 6 YEARS SINGLE EXPERIENCE CENTER

M. Baile1, A. Vega1, M. López-Parra1, M. Sánchez-Barba2, N. Arraitibie1, B. Rodríguez1, M. Sastre1, Ó. Del Rey1, A.A. Martín1, M. Cabrero1, J.R. González-Porras1, J.M. Bastida1

1Hematology, Hospital Universitario de Salamanca. 2Estadística, University of Salamanca, Salamanca, Spain

**Background:** The use of peripherally inserted central catheters (PICCs) is widely extended in patients with hematological malignancies, not only to be treated with chemotherapy, blood cell transfusions, but also parenteral nutrition support or frequent analytical extractions. However, catheter-related thrombosis is one of its main complications. There are a few studies that evaluate this complication. We reported the experience of the PICC-related thrombosis (PRT) in our center.

**Aims:** To analyze the incidence of PRT, describe the clinical characteristics and management of these patients and identify the risk factors of PRT.

**Methods:** We performed a prospective chart review of 230 adult patients diagnosed with hematological malignancies, in whom, experimented nurses tunneled PICCs with different technique: blind Seldinger from 2010 to 2014 and guided by ultrasonography (US) from 2015 to 2016. PRT diagnosis was confirmed by Doppler US. Statistical analysis was performed using the SPSS program (v.20).

**Results:** The median age was 58 years (14-86) and 55.7% of the patients enrolled in the study were male. The most frequent hematological malignancies were: Non-Hodgkin’s lymphoma (NHL=105; 45.7%) myeloid malignancies (acute myeloid leukemia and myelodysplastic syndrome=10; 26.1%), acute lymphoblastic leukemia (ALL=22; 9.6%), multiple myeloma (MM=19; 8.3%) and Hodgkin lymphoma (HL=17; 7.4%). In 188 patients (82%), PICC was tunneled when the active disease was presented. Only 51 patients (22%) received thromboprophylaxis based on low molecular weight heparin (LMWH=27), aspirin (ASA=21) or vitamin K antagonist (VKA=3). PICCs were tunneled guided by US in 127 patients (55.2%), and the main location of tip catheter was in cava-right atrium region (66%). The overall incidence of PRT was 7% (n=16). The main diagnoses related to PRT were ALL (6), NHL (5), other hematological malignancies (2) and solid tumors (3). All except one catheter (15/16=94%) were tunneled. Fourteen patients (88%) were treated by chemotherapy based in L-asparaginase (L-ASA), immunomodulatory drugs or other treatment combined with corticosteroids. The median onset of PRT was 26 days, (range: 0-230) and 8 of them (50%) in the first 30 days after insertion. In 11 cases (69%) PICCs were removed within 72 hours of PRT and treated with LMWH to a median of 4 months (range: 1-11). During follow-up, no patient had progression of thrombosis, or pulmonary thromboembolism. Finally, in the univariate analysis ALL, HL and L-ASA had significant impact on
A STUDY OF VENOUS THROMBOEMBOLISM SUSCEPTIBILITY LOCI FACTOR XI, ABO AND FIBRINOGEN IN A PORTUGUESE POPULATION SAMPLE
L. Manco1,*, C. Silva2, P. Martinho3, T. Fidalgo2, A.B. Sarmento2,3, M.L. Ribeiro1,3
1Research Center for Anthropology and Health (CIAS), 2Faculty of Medicine, University of Coimbra, 3Serviço Hematologia Clinica, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal

Background: Venous thromboembolism (VTE) is a multifactorial disease caused by inherited risk factors and complex gene-gene and gene-environment interactions. VTE results from the development of a thrombus, usually in the deep veins of the leg (deep vein thrombosis, DVT) that can subsequently embolise to the lung (pulmonary embolism, PE). Classical inherited risk factors for VTE in European-ancestry populations include protein C and S deficiencies, factor V Leiden and prothrombin gene mutation (FII G20210A). Several other common and low-frequency susceptibility variants, mainly single nucleotide polymorphisms (SNPs) in loci ABO, FXI, FII, FV, FGG, GP6, KNG1, PROC, SLCA4A2, STXBP1, TSPAN15 and VWF, have been also found robustly associated with VTE. However, in the Portuguese population the genetic background for VTE for most of these genetic susceptibility variants remains to be evaluated.

Aims: To investigate the association of five SNPs in the loci ABO (rs2519093 and rs18767179), FXI (rs2036914 and rs2289252) and FGG (rs2066865) with VTE in a sample of Portuguese patients.

Methods: A retrospective (2012-2015) case-control study with 119 cases of unprovoked VTE and 148 healthy controls of Portuguese origin was conducted, to evaluate allele frequencies of the five risk VTE alleles in the Portuguese population and to assess the association between these alleles and the risk for VTE. FXI (rs2036914 and rs2289252) and FGG (rs2066865) SNPs were genotyped by real-time PCR with TaqMan probes. ABO rs2519093 and rs1876719 SNPs were genotyped by restriction fragment length polymorphism (RFLP). PLINK software was used to determine the allelic frequencies, concordance with Hardy-Weinberg equilibrium (P>0.05) for all SNPs. The association between risk alleles and VTE through logistic regression, in the additive model, estimating OR with 95% confidence intervals (95% CI) and p-values. The association between the cumulative number of risk alleles and the risk of VTE was assessed through Pearson χ2 using the Simple Interactive Statistical Analysis software (SISA).

Results: The estimated risk allele frequencies in the overall study population sample were: 0.212 for FGG rs2066865 (T), 0.62 and 0.50 for FXI rs2036914 (C) and rs2289252 (T), respectively, and 0.295 and 0.417 for ABO rs2519093 (T) and rs1876719 (C), respectively. The genotype distributions were in agreement with Hardy-Weinberg equilibrium (P>0.05) for all SNPs. There was no significant deviation from the Hardy-Weinberg equilibrium (p=0.29) among controls (n=272). ABO genotyping concordance was 99.6% (171/173). The overall frequency of VTE associated with any of the two risk alleles was 0.076 (11/145) and 0.147 (22/149) for FXI and FGG, respectively. The risk allele ABO rs2519093 T (0.62) was significantly associated with VTE (p=0.015, OR=2.31; and 0 vs 2 or more risk alleles: X²=12.2, p=0.0048, OR=3.36).

Summary/Conclusions: Our data suggest that the alleles FGG rs2066865 T and ABO rs1876719 C may contribute to the VTE susceptibility in the Portuguese population. The absence of significant associations for the remaining loci could be the result of a limited statistical power, consequence of a modest effect size of polymorphisms or lower sample sizes, or because of differences in genetic backgrounds between populations.

E1594

PEdiatric VEnous THROMBOEmBOLISM: iNCiDENCE, RiSK FACTORS AND MANAGEMENT OF HOSPITALIZED PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL
P. Raheja1,*, P. Olivera1, V. Pons1, E. Johansson1, T. Canals1, F. Bosch1, A. Santamaria1
1Hematology Department, Vall d’Hebron University Hospital, Barcelona, Spain

Background: Venous thromboembolism (VTE) is a considered a rare event in childhood. In spite of this, the incidence of VTE is on the rise in hospitalized patients. Medical progress in the treatment of critically ill patients has increased the use of central venous catheters (CVC) and intervention procedures particularly in children with cardiac defects and malignant disease. Therefore VTE is increasingly recognized as a major secondary complication of advanced tertiary care in inpatients and children.

Aims: To study the incidence, demographics, risk factors, diagnostic tests, therapy, and complications of pediatric acute VTE in our tertiary care hospital.

Methods: A retrospective single-center study of patients<18 years of age who were discharged from January 2014 to December 2016 by using diagnostic codes for acute VTE from our hospital database. We studied demographic characteristics, clinical presentation, diagnostic tests, risk factors, treatment strategies and outcome.

Results: We report an incidence rate of 10.7 cases per 10,000 patient-years (70 acute VTE events / 21,892 discharge cases over a 3-year period). Patients were predominantly male (57%). Mean patient age was 3.3 years, with the greatest proportion of cases in children (89%) in the infants (95%), while children above 1 year comprised 37% and neonates (<1 month) formed 8.6% of our sample. Patients were mostly born at term (71.4%), although 45.7% of the neonatal and infant cases were premature. Catheter-related (CVC-VTE) comprised 55.7% of VTE cases. On the other hand, non-catheter-related (NCR) diagnoses were more intracranial in 35.3% of patients. In VTE due to extreme deep vein thrombosis (DVT) in 29% and intracardiac in 19.3%. Only 3 cases of NCR-pulmonary embolism (PE) and 2 cases of NCR-upper extremity DVT were reported. Doppler ultrasound was the most common diagnostic test used (75.7%), followed by MRI, CT and CT angiography in equal proportions. Critically ill patients encompassed most of the cases (88%). Mean duration of hospitalization was 89 days (range 2-156) and time from admittance to VTE diagnosis was 25.6 days. A large proportion had congenital heart defects (32.9%) requiring interventional procedures. Half of the patients (51.4%) had surgery around the time of VTE diagnosis. Malignancy was identified in 5 cases (2 of which were CVC-VTE). Transient triggers such as infection (12 cases), and use of aspiraginase (2 cases) were also reported. Most patients were not tested for thrombophilia (n=44, 62.9%) since they were classified as provoked VTE and from those who were tested 10% were diagnosed with a thrombophilia. ABO rs2519093 T allele for one patient initiated anticoagulant therapy: 78.6% (n=52) were initially treated with low molecular weight heparin (LMWH) and while most continued treatment with LMWH, 8.6% (n=6) received vitamin K antagonists and 8.6% received direct oral anticoagulants. LMWH dosing was adjusted using anti-Xa assays (AXA) in 85.7% of cases, documenting a median of 5 AXA per patient. Mean duration of treatment was 5.8 months. Recurrence rate was 17%, half of which were in patients with CVC-VTE. On the other hand, bleeding rate was 15.7% most of which were mild (10%) or provoked bleeds (4.3%). Mortality was 10%, although cause of death was not directly related to VTE in any of the cases.

Summary/Conclusions: Pediatric VTE is a substantial complication arising from tertiary care hospitalization where critically ill infants are at greater risk. Potential risk factors of VTE include use of CVCs, patients with complex congenital heart defects, surgical procedures, infection and malignancy. Further studies on VTE prophylaxis and identification of VTE predictors in a critical care setting are required.

E1595

CELL-BASED EVALUATION OF CHANGES IN COAGULATION ACTIVITY INDUCED BY ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
M. Tsunaka1,*, T. Koyma1, H. Nitoh1, T. Naito1, M. Itoh2, H. Hasegawa1, H. Morikawa3, A. Teraoka3, S. Kato3, S. Nishikido3,1
1Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan
2Institute of Biomedical Research and Innovation, Tokyo, Japan
3Department of Surgery, Tokyo Medical and Dental University, Tokyo, Japan

Background: Idarubicin IDR, cytarabine (AraC), and tamibarotene (Am80) are effective for treatment of acute myeloid leukemia (AML). In leukemia, the incidence of venous thromboembolism or disseminated intravascular coagulation is associated with induction chemotherapy.

Aims: How some drugs for the treatment of AML affect the procoagulant activity is unclear. Thereby, in this study, we investigated the procoagulant effects of IDR in comparison with AraC and Am80.

Methods: Procoagulant effects of IDR, AraC, and Am80 were investigated in a vascular endothelial cell line EAHy926 and AML cell lines HL60 (AML M2), NB4 (AML M3, APL), and U937 (AML M5, focusing on tissue factor (TF), phosphatidylserine (PS), and thrombomodulin (TM)). Normal human plasma-based recalcification time assay, flow cytometric analyses, and RT-PCR are applied for the evaluation.

Results: IDR induced procoagulant activity on the surface of vascular endothelial and AML cell lines. Expression of TF antigen, TM antigen, and PS were induced by IDR on the surface of each cell line, whereas expression of TF and TM mRNAs were unchanged. Increased TF and PS expression may overcome increased TM expression and the overall effect may be procoagulant. Conversely, Am80 decreased TF expression and procoagulant activity, and increased TM expression on NB4 cells. In NB4 cells, we observed downregulation of TF mRNA and upregulation of TM mRNA by Am80. But Am80 did not sufficiently inhibit anticoagulant activity on NB4 cells when applied simultaneously with IDR.

Summary/Conclusions: These data suggest IDR may induce procoagulant activity in vessels by apoptosis through PS expression and/or TF expression on vascular endothelial and AML cell lines. Am80 may suppress procoagulant transcriptional regulation of TF expression and induction of TM expression. Our methods could be useful to investigate changes in procoagulant activity induced by antineoplastic drugs.
DESCRIPTION OF THROMBOTIC EVENTS AND/OR PREGNANCY LOSS IN A COHORT OF HOMOZYGOUS CARRIERS FOR THE C46T POLYMERASE IN THE F12 GENE

S. Martin Rodríguez1, L. D. Weiss, with mean,: R. Vidal1, C. Blas1, J. M. Alonso-Dominguez1, A. Garcia Raso2, P. Llamas1
1Hematology, 2Health Care Institute, Fundación Jiménez Díaz, Madrid, Spain

Background: The intrinsic pathway of coagulation is initiated by a serine protease named factor XII (FXII) in a reaction involving the contact system and triggers fibrin formation through activation of factor XI. In vitro, FXII triggers activation of the classic complement pathway and initiates the fibrinolytic system via plasma kallikrein mediated urokinase activation, whereas in vivo its role is more relevant in the extrinsic pathway-T polymorphism in the 5’ untranslated region of the F12 gene (F12 C46T) is associated with lower levels of FXII. Its frequency varies widely across populations and ethnic groups, ranging from 0.18 in the Spanish population to 0.67 among Japanese. Homozygosity for the C46T polymorphism of the F12 gene has proved to be an independent risk factor for thrombosis and unexplained recurrent spontaneous abortion. However, the precise role of this polymorphism as a thrombotic risk factor is controversial, and the evidence for an association between F12 C46T, venous thromboembolism (VTE) and myocardial infarction is weak.

Aims: To describe the occurrence of thrombotic events and/or pregnancy losses and the existence of other risk factors for thrombosis in a cohort of homozygous individuals for F12 C46T.

Methods: We retrospectively analyzed all the homozygous F12 C46T cases diagnosed in our laboratory from January 2015 to January 2017. Allelic discrimination PCR with TaqMan® B probes was performed to detect homozygous individuals for F12 C46T mutation. The following variables were collected: age, gender, race, cardiovascular risk factors (CVRF) (hypertension, diabetes mellitus, dyslipidemia, smoking and overweight), history of cancer, VTE (type, recurrent), arterial thrombosis, familial history of thrombosis, number of pregnancy losses and other inherited/acquired thrombophilia.

Results: 122 cases were evaluated: 45 (36.8%) male and 77 (63.12%) female. Mean age: 46.2 years (1-86). Race: 65.57% caucasian, 13.1% american, 2.4% black, 1.6% asiatic, 4.1% other. Decreased factor XII plasma levels were found in 81.42% of them, with mean factor XII levels 53.73% (27.5-107.5). Overall, 34.48% of the subjects had at least one thrombotic event. Type of thrombosis: 64.4% VTE and 35.6% arterial thrombosis. One (26.7%) or more than one (46.7%) additional thrombotic risk factors were found in women with any thrombotic event. Presence of one or more CVRF was found in 66.7%. Family history of thrombosis was found in 16%, whereas 13% had a recent or active malignant neoplasm. Among women, 28.57% and 12.98% had one and more than one pregnancy loss respectively. Additional thrombotic risk factors were found in 30% of them. Familiar history of thrombosis was found in 57.6%. Many patients had a medical (non-surgical) index admission with 58.5% admitted as an emergency, 7.1% admitted for surgery and 34.4% for medical reasons. The majority of patients had orthopedics and urology admissions. In 526 HAT cases, root cause analysis (RCA) revealed that 101 (19.2%) were deemed preventable and 367 (69.8%) were not thought to be preventable. The remaining 57 cases had the index admission outside of our trusts, largely having orthopaedic procedures which were not included in further analysis.

Of 394 HAT cases with sufficient data, 80 (20.3%) had a preventable cause. The remaining 22 (5.6%) were receiving delayed TP, 9 receiving delayed IF, 26 having no TP given though indicated and 18 not having a VTE risk assessment. Some cases of insufficient TP were deemed due to underestimating standard patient >90kg. Off 394 HAT cases, 37 patients had contraindications to TP. 166 had TP failure i.e. full TP given and in 102 TP was not indicated. 9 patients were on full anticoagulations at time of index admission.

Summary/Conclusions: HAT rates remain stable and the majority are through clinical and laboratory reasons. Key errors implicated are failure to perform a timely VTE risk assessment and action with appropriate thromboprophylaxis. Full integration of electronic patient records with electronic prescribing modules may reduce further these errors.

THROMBOSIS DURING INFANCY AND NEWBORN PERIOD: AN UNRESOLVED ISSUE

F. Gumruk1,*, S. Aytac1, I. yaman bajin1, B. Kuskonmaz1, S. unal1, S. yigit2, M. yurakok2, M. cetin1
1Hematology, 2Health Care Institute, Fundación Jiménez Díaz, Madrid, Spain

Background: Reported incidence of thrombosis is higher among newborn infants that can be explained by age related deficiency of anticoagulants, overproduction of procoagulants and deficiency/dysfunction of fibrinolysis in addition to exposure to multiple risk factors and wide use of catheters which may eventually lead to the transient prothrombotic phenotype in this age group.

Aims: Our aim is to evaluate clinical and laboratory data, risk factors, outcomes of patients (<1-12 months) and newborns (<1 month) with thrombosis in our center.

Methods: Our database revealed 752 children having various types of thrombosis between January 2003 to December 2015 and 77 out of 752 were diagnosed thrombosis under one year of age. We retrospectively evaluate their clinical and laboratory results and further analyze their thrombotic files.

Results: There were 51 male and 26 female with a median age of 4 months (0-12 months) in this group. Among 77 thrombotic events 22 (28%) were observed during the neonatal period (<1 month) with a male predominance (n=15, 68%) and from these 22 events were arterial thrombosis (purpurea fulminans(1), cerebral(1)) whereas 4 intracardiac, 5 sinusovenous and 11 venous thrombosis (deep veins(4), renal veins(3), portal veins(3) cerebral vein(1)) were noted. In 2(9%) thrombosis was diagnosed on the first day of life and 11 out of 22 patient had underlying risk conditions such as prematurity(3), perinatal hypoxia(2), necrotizing enterocolitis(1), congenital cardiac disorders(3), congenital nephrotic syndrome(1) and adrenal insufficiency(1).Moreover 6 out of these 22 thrombotic event catheter insertion was the associated risk factor and 4/22 had infection. Factor V Leiden mutation was found to be homozgyous in 1/18 and normal in 17/18. Heterozygous prothrombin 20210A mutation were detected in 1 out of 18 and homozygous MTHFR C677T mutation was found in 3/13 patient. Half of them (12/54) were initially treated with LMWH and TPA were used as a thrombolytic agent in 5 case without any complication. In 2(9%) of patients there had an amputation, 5 patient deceased; one because of sepsis and the rest 4 had primary disease and thrombosis. The site of location in 55 thrombotic events during the infancy period involved deep venous thrombosis (22), cerebral sinusovenous thrombosis (10),cardiac(8), portal(3), renal(1) veins and cerebral arterial (7),femoral arterial(3),abdominal aortic thrombosis(1).In this group 42(76%) out of 55 had an underlying disorder and most common associated risk factor for this age group was inserted catheter related thrombosis, infection and surgical operations. Initial treatment choice was LMWH in 25(45%) and during the follow up period 10 had to change treatment, 21 resolved, 10 had parsiel thrombosis, 4 deceased and 10 loss to follow up.

Summary/Conclusions: During the first month of life thrombotic complications are 40 times higher than at any other pediatric age. As previously reported venous thrombosis which mainly affect the limbs, the right atrium and right veins are more frequently seen than arterial thrombosis in newborn infants with a male predominance is compatible with our findings. In the absence of randomized clinical trials the choice of anticoagulation and the duration of treatment for this age group is still controversy beside the complex mechanism and a high mortality&morbidty rate. Although clinical and laboratory data of neonates were compatible with infants, treatment choices differ between these two groups and it seems that thrombolytic treatment was tend to be used more commonly in the neonates without any complication.
Background: Soluble fibrin monomer complexes (SFMC) are the early marker of thrombophilia that represent the complexes of monomeric fibrin with fibrinogen or their products of degradation (FDP). SFMC levels are not directly affected by therapy with thrombolytic agents. Detection of SFMC formed due to the activation of blood clotting by thrombin reveals a pathological process in the early, preclinical stages.

Aims: We explored the quality difference between the SFMC fraction obtained from acute ischemic stroke patients and one year post acute phase of stroke in the absolutely the same patients.

Methods: SFMC fraction was obtained from each tested groups: 35 healthy donors as well as 66 patients with atherothrombotic ischemic stroke (AIS) and 56 patients with cardioembolic ischemic stroke (CIS) during the acute phase of disease; 56 patients with AIS and 56 patients with CIS one year past acute phase. SFMC were collected from blood plasma of each tested subtypes of ischemic stroke by incubation with 0.78% o-phenanthroline per 5 min. For Size-exclusion chromatography SFMC in volume 1 ml was applied on Healthcare Life Sciences “HiLoad 16/60 Superdex 200 pg” column.

Results: Results suggest presence of proteins with Mr from 45 up to 330 kDa in SFMC fraction. The content of SFMC was similar for all stroke fractions with some exception. The difference between results of separation of stroke fractions and fractions obtained from healthy donors was obvious. Mostly the proteins content of the SFMC fraction is similar for stroke and healthy fractions. But amount of the proteins as mean peaks high is different (Figure 1). In fact, the first three peaks which correspond to the 330, 280 and 250 kDa of chromatogram of SFMC are common for all tested fractions and were verified only in their height. Accordingly, the most widely represented variations peaks of AIS, even a year after stroke soluble fibrin monomer complex content was higher comparing to the healthy donors index. Healthy donors also had some of these complexes, but in trace amounts. For acute CIS situation was similar as for AIS, but post one year it get closer to healthy donors.

STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC MYELOPROLIFERATIVE NEOPLASMS

V.M. Popov1,2, M. Andreescu1, M. Omer3, A. Trifa4, F. Miha1, C. Drag5, G. Patrino1, M.G. Moise5, T. Savopo6, E. Koves7, H. Bumbac8, A.M. Viadareanu9

1Haematology, Colentina Clinical Hospital, 2Biophysics and Biotechnology Department, 3Haematology, UMF Carol Davil, Bucharest, Romania

Background: Patients with chronic myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia (CML) have a variety of structural and functional abnormalities of platelets. Many of them have thrombotic or hemorrhagic complications. Platelet function is influenced by changes in membrane fluidity (MF) which has an important role in the expression of platelet receptors, modulating the activity of protein membrane.

Aims: The importance of reactive oxidative species (ROS) in alteration function of platelet membrane and expression of platelet receptors in patients with MPNs and CML.

Methods: We present a retrospective study on 36 cases MPN (20 JAK2-positive MPN) and 24 CML admitted in Colentina Clinical Hospital Bucharest. The determination of platelet membrane fluidity was performed by fluorescence anisotropy measurements using as marker 1-(4-trimethylammoniumphenyl)-1-phenyl-1,3,5-hexatriene p-toluenesulfonate (TMA-DPH). We analyzed the fluorescence anisotropy of platelet membrane and correlate the result of with a...
different kind of treatment. Production of ROS was examined using fluorochrome method with DCFDA and Fluorochrome spectrofluorometer. Platelet receptor expression was analyzed by flowcytometric method studying adhesion marker (CD 42 and CD 42b) and aggregation marker (CD61, CD41).

Results: Patients with MPN and JAK2 mutation present a high level of fluorescence anisotropy compared to the JAK-negative group. Median value for JAK2 positive group was 147.2 (95% CI for median value 157.7-150.6) vs JAK2 negative MPN group 130.8 (124.6-138.3) p<0.001. There are no differences between CML and MPN group. Our results confirm that fluorescence anisotropy is influenced by medication taken. MPN patients who have taken Hydroxyurea alone had a high-low fluorescence anisotropy than the patient who have taken both association Hydroxyurea and Anagrelide; median value and 95% CI for median value 151 (137.1-156.8) vs 136 (126-137.5) p=0.03. A patient who have treatment with tyrosin kinase inhibitor (TKI) - Sprycel or Glivec, had a low level of fluorescence anisotropy, median value and 95% CI for Hydroxyurea group 151 (137.1-156.8) vs TKI group value 138 (124.4-147.8) p=0.04. No differences of fluorescence anisotropy was observed between the group of patients who received JAK inhibitor (Jakavi) or Hydroxyurea. The CD42b expression is low in patients versus controls (median: 17.87% vs 94.16%, P<0.01), there is no difference in the CD42a value range (P=0.51). The CD26/CD41 expression (GP IIb-IIIa) presents also lower values in patients (median: CD 61= 94.3%; CD 41=71.13%) vs controls (median: CD 61= 98%; CD 41=93,17%), statistical significance obtained only for CD61 expression. Production of ROS is higher for patients with MPNs and CML patients compared with healthy controls. CML patients in accelerate or blast phase have higher level of ROS production compared with patients with MPN in chronic phase (1.23 ± 1.09, p=0.03). Our results of anisotropy measurements did not reveal any influence of ROS in MF modifications (0.15 vs 0.13, without statistical significance) or with platelet receptor expression.

Summary/Conclusions: The presence of JAK 2 mutation in MPN patient is associated with a low fluidity of platelet membrane. Association of Anagrelide or TKI inhibitor is associated with lower level of fluorescence anisotropy. The fluidity of platelet membrane could be an important parameter which influenced the expression of platelet receptor. We have to observe in the future if this group with high level of fluorescence anisotropy had a high risk of thrombosis. All these results will be verified in a higher patients lot and need to be checked any correlation between modification of fluidity membrane production ROS and expression of microparticles platelet derived.

E1603

USE OF ROTATIONAL THROMBOELASTOGRAPHY TO PREDICT CENTRAL VENOUS CATHETER RELATED VENOUS THROMBOSIS IN CHILDREN: PRELIMINARY RESULTS

T. Bayhan1,*, B. Oguz2, F. Gumruk1, M. Cetin1, A. Gunes3, I.Y. Bajin1, F.N. Kalkan1, S. Unal1

1Department of Pediatric Hematology, 2Department of Radiology, Hacettepe University, Ankara, Turkey

Background: Central venous catheters (CVCs) have been widely used in hospitalized children. CVC related venous thrombosis (VTE) is one of the most dangerous complications. Frequency. In pediatric age group exact risk factors for CVC related venous thrombosis (VTE) have not been shown yet. Rotational thromboelastography (ROTEM®) measures clot formation and stability and can be used to guide prophylactic treatment.

Aims: We aimed to predict CVC related venous thrombosis via ROTEM parameters in in pediatric age group patients.

Methods: Study included patients who required CVC insertion due to any reason and who were not on any anticoagulation treatment during the week before the CVC insertion. On the day of CVC insertion clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), and alpha angle (AA) were measured for intrinsic (INTEM), extrinsic (EXTEM), and fibrinogen (FIBTEM) pathways via ROTEM. At one week of insertion and at removal of CVC, Doppler ultrasound imaging was performed to the vein that catheter was removed.

Results: A total 14 patients were included in the study. Median age was 3.9 years (range: 1-17.8 years). Ten (71%) of the patients had jugular vein, four (29%) patients had femoral CVC. Median duration until removal of CVC was 15.5 days (7-56). Thrombosis was detected in one patient (7%) at first week of CVC insertion (Patient 10). When the the ROTEM parameters were examined, this patient had lowest CT and highest AA in EXTEM, and the highest AA in INTEM, indicating more pro-coagulant status (Table 1). Also patient 14 had similar AA, as patient 10 in EXTEM and INTEM but was not found to develop thrombosis by the 18th day of insertion. However, CVC of that patient wasn’t removed yet.

Table 1.

<table>
<thead>
<tr>
<th>Table 1.</th>
<th>Baseline patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT</td>
<td>Clotting time, CFT</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In this study we reported our preliminary results. We detected thrombosis only in one patient and compared to this limited sample size, we may suggest that CT and AA in EXTEM, and AA in INTEM prior to insertion of CVC may be predictive for catheter related thrombosis development. Such patients with pro-coagulant findings at ROTEM prior to CVC insertion may need prophylactic anti-coagulation. The results in a larger sample size will be more definitive to make a conclusion.

E1604

THE POTENTIAL ROLE OF ANTEINEOPLASTIC DRUGS IN THE PREDICTION OF THROMBOTIC RISK IN ONCOLOGIC PATIENTS IN ADDITION TO THE KHORANA SCORE

E. Gomez1,*, P. Garcia-Ramirez1, A. Zabalza1, M. Montoya1, M. Alvarezolos1, M. Bordon2, M. P. Millaclay1, B. Signes1, T. Galicia1, M.V. Aznair1, A.M. Redondo2, M.J. Paloma1, M.L. Antelo1

1Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain

Background: Venous thromboembolism (VTE) is common in patients with cancer. Several risk factors (related with patient, tumour and treatment) have been already identified. Thromboprophylaxis (TP) with low molecular weight heparin (LMWH) is associated with a reduction of symptomatic VTE but without clear benefit in survival as the number of major bleedings is increased. In primary TP in newly diagnosed cancer patients starting chemotherapy (CT), a risk assessment model (based on clinical and laboratory variables) was developed (the Khorana score). Many patients with intermediate risk (without thromboprophylaxis indication according to Khorana-based clinical guidelines) develop VTE episodes. Factors as tissue factor-bearing micro particles and D-Dимер levels in addition to leauidomide, platin and gencitabine-based therapies are associated with VTE high risk. Its efficacy as a predictive tool is a matter of debate.

Aims: This retrospective observational study is aimed to assess the Khorana score efficacy in predicting the VTE risk and analyze some treatment related factors as predictive complementary tools.

Methods: We analyzed the demographic and characteristic, the Khorana score and the antineoplastic treatment of oncologic patients diagnosed of pulmonary embolism (PE) from December 2010 until December 2016 at the Complejo Hospitalario de Navarra. At baseline, the Khorana score classified patients as ‘low risk’ (0 points) ‘intermediate risk’ (1-2 points) or ‘high risk’ (≥3 points) for VTE.

Results: 102 oncologic patients were diagnosed of PE. Patient baseline characteristics are showed in table 1. In 27.5% (n=28) PE diagnosis preceded to cancer diagnosis, in 62.5% (n=27) PE occurred at least 1 month beyond the end of antineoplastic treatment and in 46.1% (n=47) PE was diagnosed during the treatment (chemotherapy +/- radiotherapy). In this last group the median time from the treatment beginning and EP diagnosis was 3 months (0-46). The stratification according to the Khorana score (at baseline) was: ‘low risk’ 21.3%, intermediate risk 61.7%, and high risk 17%. In the intermediate risk group (n=29) the drug-based therapy was: 44.8% platín (n=13), 6.9% gencitabine (n=2), 2.5% leauidomide (n=1) and 48.3% non-related-thromboembolic treat-

Summary/Conclusions: Nearly 2/3 of Khorana intermediate risk patients developed a PE while on antineoplastic treatment and inside this group over 50% were treated with well-recognized high thrombosis-risk drugs. The inclusion of antineoplastic drugs in a predictive thromboembolic model in oncologic patients could improve the benefit-risk of the use of LMWH prophylaxis in some patients without a high risk Khorana score but however at high risk of thrombosis. More prospective studies are needed to analyse the benefit of antithrombotic prophylaxis in oncologic patients receiving outpatient chemotherapy treatment.
Transfusion medicine

E1605

CLINICAL OUTCOMES AND UTILIZATION OF BLOOD BANK RESOURCES OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), HEMOLYTICUREMIC SYNDROME (HUS), AND OTHER MICROANGIOPATHY REACTIONS: A 16-YEARS EXPERIENCE

C.-T. Lee1,2, C. Thow1, K.P. Lim3, S.T. Lim3, J. Mah3, N.N. Zhang3, M.L. Tung1, L.K. Tan1, Y.S. Lee1,2,3
1Department of Haematology-Oncology, National University Cancer Institute Singapore, 2 Yong Loo Lin School of Medicine, National University Singapore, 3Blood Transfusion Service and Blood Donation Centre, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore

Background: TTP, HUS and other thrombotic microangiopathy are rare, complex clinical syndromes which are characterized by thrombocytopenia, microangiopathic haemolytic anaemia, (MAHA) and systemic thrombosis. The introduction of plasma exchange (PEX) has dramatically reduced the mortality of these patients, and has become standard of treatment. Although the clinical outcome of these conditions is heterogeneous, with multiple clinical complications and prolonged hospital stay, there is no previously published data to provide measurement of blood bank and hospital resource utilization associated with its clinical management.

Aims: We performed a retrospective cohort study of 42 consecutively treated patients with MAHA and analyzed their clinical and laboratory characteristics, treatment outcomes and plasma product utilization.

Methods: Medical records of these patients treated from 2002-2017 were reviewed. We used the standardized criteria based on the consensus on standardization of terminology in TTP to define clinical response. (Scully et al J Thromb Haemost 2017).

Results: In our series, the causes and number (% of MAHA were TTP-HUS (18.42%), autoimmune disorder-associated MAHA (13.31% i.e. 9 SLE and 4 Sjögren’s syndrome), cancer-related MAHA (4, 9.5%), drug-induced (3, 7.1%), post-transplant and infection-related microangiopathy (4, 9.5%). The average number of PEX sessions required to achieve overall clinical response in TTP, autoimmune-associated MAHA, HUS and drug-induced microangiopathy was 18.2±17.9, 11.5±7.6, 13.0±8.7 and 7.3±6.7, respectively. The mean follow up time was 40.8 months. 5 patients (11.6%) died during the course of treatment in index hospitalization, 12 (27.9%) were refractory to PEX and 24 patients (55.8%) responded to PEX, and 1 patient was lost to follow up. For the patients who were finally treated successfully with PEX, and was palliated eventually. For the refractory cases, 7 patients were given Rituximab, 5 achieved clinical response while the others were given Vinristine (n=3) and Cyclophosphamide (n=2), achieved clinical response with a median of 15 days from the time second line agents were used. The 1 year overall survival of those who received second line treatment compared to patients who responded to only PEX and standard of care was 59% and 80% (p=0.51), respectively. The overall 1 year survival of the entire cohort is 74% which is comparable to the Oklahoma registry. The mean length of hospital stay was 30 days (median 27 days), 5 patients (11.6%) required red blood cell transfusion and 4 patients (9.5%), seizures (11.9%), cardiovascular complications like myocardial infarction and stroke (16.7%), and nosocomial infection (16.7%). 30% of the cohort required temporary dialysis support for acute kidney injury while 38% of them ended up required lifelong dialysis. With regards to the cost of plasma units, consumables and PEX procedure, the calculated mean cost was Singapore Dollar (SGD) 25275.95 ($16991.17) (SD20885.91 ($14035.02) per patient.

Summary/Conclusions: The clinical outcome in terms of survival in our cohort is in keeping with that of other registry and cohort (Hovinga et al Blood 2010). Our data which demonstrate the health care resource utilization show that management of these patients is expensive. While small in terms of incidence, it poses an economic burden disproportionate to its overall size.

E1606

HEPATITIS E VIRUS: INVESTIGATION IN NORTH ITALIAN BLOOD DONORS

L. Raffaelli1, M. Spredaio1, B. Fogliani1, G. Guarnoni1, S. Brambilla1, S. Fumagalli1, D. Prati1
1Transfusion Medicine and Hematology, ASST-Lecco, Lecco, Italy

Background: Hepatitis E virus (HEV) is a major cause of acute hepatitis worldwide and the most common cause of transmission safely. Recent data from Europe showed a HEV IgG prevalences of 6.8% in German blood donors, 27% in Dutch blood donors, and 52% in an hyperendemic area in the South of France.

Aims: The aim of this study was to determine the prevalence of anti-HEV reactivity and HEV viremia in Italian blood donors, in order to estimate the risk of transmission.

Methods: Nearly 10,000 samples were collected from anonymized, unpaid donors at the “Lecco processing and validation blood center” (Lombardy, Italy) from June to July 2016. Samples were tested individually (individual-donation nucelic acid test [ID-NAT]) for HEV RNA using the Procleix HEV assay (95% limit of detection 7.9 IU/mL). Initial TMA-reactive samples were retested and considered positive if the retest result was reactive. For the serology study, a subset of 2000 donations was tested for HEV IgG using DiaPro HEV ELISA kit (Diagnostic BioprobesSrl, Milano, Italy). HEV IgG and IgM were analyzed in ID-NAT positive samples at the time of donation and in the follow up, collected one year after the index donation.

Results: The prevalence of IgG anti-HEV in north Italian blood donors was 7.4%. Nine out of 9,726 donor samples gave reactive values by the ID-NAT assay for HEV RNA. Among them, only one sample was confirmed to be reactive in additional TMA tests. None of the 9 HEV RNA initially reactive samples had circulating IgM or IgG antibodies against HEV. The only repetitive reactive donor showed a IgM and IgG seroconversion, indicating primary HEV infection. Therefore, we estimated that the risk of receiving a potentially infectious blood unit is of 1:10000 (upper bound of the 95% confidence interval, 1:1700).

Summary/Conclusions: The clinical impact of HEV infection among blood recipients remains to be determined. The clinical impact of HEV infection among blood recipients remains to be determined.

E1607

SHORT-TERM ADMINISTRATION OF RECOMBINANT HUMAN ERYTHROPOIETIN DECREASES B CELL IN HUMAN PERIPHERAL BLOOD

T. Nagashima1, A. Yokohama2, M. Awata1, Y. Kanai1, K. Murata1, R. Ino1, K. Kikuchi1, K. Honma1, N. Gotoh2, T. Kasamatsu1, H. Handa1, T. Saitoh1, H. Murakami1
1Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 2Blood Transfusion Service, 3Department of Hematology, Gunma University Hospital, Maebashi, Gunma, Japan

Background: Erythropoietin (EPO) is hematopoietic factors participating in red blood cell production, and accelerates proliferation and inhibits apoptosis of erythroblasts. It is reported that EPO has pleiotropic effects including anti-apoptotic action for some cells, antioxidant action, vasculatization action, and promoting cell division in addition to stimulation of erythropoiesis as well, whereas there are conflicting results of small cohorts as to its effect on blood immune cells.

Aims: We analyzed peripheral white blood cell subsets in patients who received one bolus administration of recombinant human erythropoietin (H+UEPO) to examine the effect of EPO on human immune system.

Methods: One hundred nineteen autologous blood donors (male/female 62/57) in Gunma University Hospital were enrolled in this study after written informed consent. All the patients had no infections or inflammation. Forty nine patients were treated with H+UEPO (Epoetin alpha or Epoetin beta (24,000 IU, respectively)) once after blood donation because of low hemoglobin concentration and 70 were not treated. Peripheral blood samples were obtained at the time of the first phlebotomy and after 1 week from the same patient. We measured the number of WBC, lymphocytes, myeloid dendritic cells (mDC), plasmacytoid dendritic cells (pDC), CD4+ T cells, CD8+ T cells, Natural killer (NK) cells, B cells, monocytes, and neutrophils of peripheral blood before and after H+UEPO administration by flow-M/FM and histology. Absolute number and percentage of lymphocytes in WBC decreased significantly after H+UEPO administration from 1885.0±520.0/µl to 1798.7±439.0/µl, in absolute number (p=0.019), and from 33.2±8.57% to 30.0±7.32% in percentage (p=0.023). The numbers of whole WBC, mDC, pDC, monocyte and neutrophil did not change significantly. In respect of lymphocyte subsets, absolute number of CD8+ T cell, NK cell and B cell significantly decreased from 358.9±925.70/µl to 311.5±210.9/µl (p=0.04), from 290.6±157.6/µl to 257.4±141.8/µl (p=0.01) and from 289.3±192.4/µl to 239.9±158.2/µl (p<0.01), respectively. Regarding B cell subsets, absolute number of naive B cell and IgD CD27- B cell significantly increased from 171.3±93.5/µl (153.0±84.2/µl) and from 164.1±13.6/µl to 129.2±17.6/µl (p=0.045), respectively. Moreover, other B cell subsets, such as transitional B cells, memory B cells and marginal zone B cells, also showed a trend of decrease. However, percentages of naive cell and IgD CD27+ B cell in total B cell did not change. These suggested that whole B cell decreased, not a specific subset of B cell. In non treatment group, there was no change of lymphocytes.

Summary/Conclusions: These findings suggested that just one administration of H+UEPO influenced human immune system, especially via reduction of B cell in peripheral blood, with unknown mechanism so far.
Background: At most centers, the majority of patients who request bloodless medicine are members of the Jehovah’s Witness (JW) faith. But, there are no standard, established guidelines to manage pancytopenia in these patients, nor are there many studies to inform optimal treatment approaches. The most troublesome patients who request bloodless medicines are patients with hematologic malignancy. The treatments of these patients are considerable challenges. They have not only problems of severe pancytopenia, but also require intensive chemotherapy. Since 2000, our hospital has been a bloodless center. This study was retrospectively analyzed for hematologic malignancies and aplastic anemia with bloodless treatments in Soonchunhyang university hospital.

Aims: This study was retrospectively analyzed for hematologic malignancies and aplastic anemia with bloodless treatments in Soonchunhyang university hospital.

Methods: A retrospective review of medical records was performed of 44 patients with hematologic malignancies and aplastic anemia who request bloodless medicine from January 2006 to December 2015 at Soonchunhyang university hospital.

Results: Of 44 patients, 48% were men (n=21) and 52% were women (n=23). The median age of the study population at the time of diagnosis was 62 years (range 16-87). Thirteen patients (29.5%) were acute leukemia, 15 (34.1%) patients with non-Hodgkin’s lymphoma (NHL), 2 (4.5%) patients with chronic myeloid leukaemia (CML), 4 (9%) patients with myelodysplastic syndrome (MDS) and 4 (9%) patients with multiple myeloma (MM). Thirty one patients were treated with chemotherapies and 13 patients were treated with supportive care only. Among 44 patients 27 patients were died. Most common cause of attribution to death was anemia (92.5%). And Chief complaint at death was dyspnea (88%). Median survival of acute leukemia was 1 month (95% CI, 0.4-1.59).

Table 1.

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>Number of Patients</th>
<th>Survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute leukemia</td>
<td>13</td>
<td>1 (0.4-1.59)</td>
</tr>
<tr>
<td>NHL</td>
<td>15</td>
<td>1 (0.4-1.59)</td>
</tr>
<tr>
<td>Chronic myeloid leukaemia (CML)</td>
<td>4</td>
<td>1 (0.4-1.59)</td>
</tr>
<tr>
<td>MDS</td>
<td>4</td>
<td>1 (0.4-1.59)</td>
</tr>
<tr>
<td>Multiple myeloma (MM)</td>
<td>31</td>
<td>1 (0.4-1.59)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In bloodless treatment, CML, MM and lymphoma had a relatively good prognosis. However, AML and MDS were showed a poor prognosis. Therefore, further studies are needed to improve survival for bloodless patients with hematologic malignancies.

E1610

RED BLOOD CELLS (RBC) AND PLATELET (PLT) TRANSFUSIONS IN TRANSPLANTED AND NOT-TRANSPLANTED PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

E. Baldoumi1, V. Papadopoulos2, V. Kalaitzidou1, A. Syrigou1, C. Lalayanni1, M. Papadionasiou1, D. Malloulli1, C. Smias1, I. Sakellari1, A. Anagnostopoulou1, D. Sotiropoulos1

1Haematology Department & BMT Unit, George Papanicolaou Hospital, 2Hematology Department, Papageorgiou General Hospital, Thessaloniki, Greece

Background: Patients with hematological malignancies require often and prolonged hospitalisations during the course of their treatment, in part due to increased and frequent transfusion demands.

Aims: The objective of the study was to assess the factors affecting transfusion needs in a Hematology Department (bone marrow transplant unit- BMTU, post-transplant unit-PTU, hematology clinic).

Methods: The patients that were hospitalized between 1/1/2015 and 31/12/2015 were analyzed. Data regarding the underlying disease, the disease status, type of transplant, duration of marrow aplasia and donor-patient blood group mismatch were obtained from the medical records. The analysis was restricted to the transfusion of packed RBCs and units. Differences between groups were assessed using non-parametric statistics (Kruskall-Wallis and Mann-Whitney U-test).

Results: There were 523 admissions of 256 different patients. Complete data for analysis could be obtained for 487 admissions of 237 patients (92.6% of patients, 93.1% of admissions), corresponding to 10,673 days of hospitalization. Total number of blood products transfused was 2284 packed RBC units, 13883 PLT units (apheresis platelets counted as 5 units). Values are reported as median (range), unless otherwise specified. In the BMTU, the type of transplant was correlated with transfusion needs: number of RBC units transfused per admission was 2 (1-5) for autologous transplanted (AUTO) patients, 4 (1-28) for allo-transplanted (ALLO) (no difference between sibling and matched unrelated donors), and 7 (1-14) for haplo-identical transplants (HAPLO), p=0.001. Platelet units requirements were respectively 15 (5-45) for AUTO, 20 (5-205) in ALLO and 50 (30-130) for HAPLO, p=0.001. The length of stay was 18 (13-23) days in AUTO, 22 (16-44) in ALLO, 30 (29-40) days in HAPLO transplantation, p<0.001, while the duration of aplasia in days was 9 (4-19) in AUTO, 13 (5-32) in ALLO and 25 (20-38) in HAPLO, p<0.001. The longer duration of aplasia and hospitalization was correlated with greater transfusion needs. In the PTU there was no statistically significant difference in transfused RBC or PLT units with regard to transplant type. Disease status (response versus active disease) was only correlated with RBC units transfused in PTU [2 (1-29) vs 6 (1-56) units respectively, p=0.006]. Donor – patient blood group mismatch correlated with increased transfusion demands in BMTU for RBCs [4 (1-28) vs 2 (1-5), p<0.001] and PLTs [25 vs 15, p=0.001]. In hematology clinic, the underlying disease was correlated with transfusion needs in RBC and PLTS, as shown in table 1. Patients with AML had the higher needs in RBCs and PLTs, whereas patients with lymphoma had the lowest needs in RBC transfusions. Disease status was not correlated with transfusion needs. The duration of aplasia was correlated with the number of RBC units (Pearson’s r=0.66, p<0.001, r²=0.435) and of PLTS transfused (Pearson’s r=0.78, p<0.001, r²=0.61).

Table 1. Units transfused in hematology clinic

<table>
<thead>
<tr>
<th>Disease Status</th>
<th>RBCs</th>
<th>PLTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td>4 (1-28)</td>
<td>2 (1-5)</td>
</tr>
<tr>
<td>Response</td>
<td>6 (1-56)</td>
<td>50 (30-130)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The main determinants of transfusion requirements are the duration of aplasia, the type of transplant and the disease, with myeloid malignancies requiring more transfusions. The establishment of haplo-identical transplantations has increased the transfusion needs due to longer period of aplasia.

E1609

PREOPERATIVE ANEMIA: A SINGLE INSTITUTION EXPERIENCE IN SPAIN

G. Pinto1, F. Ruiz1, I. Page1, G. Yumi1, G. Moreno1

1Hematology, Hospital Ramon y Cajal, Madrid, Spain

Background: Preoperative anemia is considered as a strong predictor of postoperative red cell transfusions, and has also been linked to increased morbidity and mortality in surgical patients, but it is frequently overlooked.

Aims: The objective of this study was measure of real impact of preoperative anemic patients in terms of decreasing blood cells transfusions.

Methods: We analyzed 85 patients undergoing elective surgery in subgroups of high or low risk of bleeding. All the patients were referred from pre-anesthesia consultation for performing a 4-week hematological protocol in order to optimize the hemoglobin level to a near normal value. We identified the underlying cause of anemia and offered the treatment according to the etiology. The primary outcome was the response to therapy defined as reaching the Hb level >13 gr/dL or increasing of >2 gr/dL from basal level, and the rate of blood transfusion.

Results: Mean age was 70.4 years, with a male-female ratio of 1:2, and the patients were divided into 2 groups according to the bleeding risk: high risk 74% (hip and knee replacement, cystectomy, colostomy, maxillofacial surgery), and low risk 26% (mastectomy, gynecology or spine surgery), with a median hemoglobin of 10.9% and 10.1%, respectively. A diagnostic workup was performed in order to provide appropriate treatment: iron deficiency anemia (83.9%), anemia of chronic disease (10.3%), folate or vitamin B12 deficiency (5.8%). The patients with iron deficiency anemia received oral (62%) or intravenous iron (38%), and all patients had to change from oral to intravenous iron by intolerance or poor response. The response to treatment was reached by 44.7% of patients, in an average time of 26.4 days. The rate of blood transfusion was 18% in good responders (0.5 packed red blood cells per patient) and 63% in poor responders (1.6 packed red blood cells per patient).

Summary/Conclusions: The treatment strategies of preoperative anemia period, and the effort to reach a near to normal hemoglobin level, could minimize the amount of red blood cell transfusion the patients will be exposed in the postoperative period. Our data provide evidence about the effectiveness of a prompt evaluation and correction of preoperative anemia in a maximum time of 4 weeks.

Table 1. Units transfused in hematology Department

<table>
<thead>
<tr>
<th>Disease Status</th>
<th>RBCs</th>
<th>PLT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (1-2)</td>
<td>3 (0-9)</td>
<td>1 (0-7)</td>
</tr>
<tr>
<td>3 (0-15)</td>
<td>2 (0-4)</td>
<td>0 (0-3)</td>
</tr>
<tr>
<td>1.5 (0-8)</td>
<td>1.5 (0-10)</td>
<td>1 (0-6)</td>
</tr>
<tr>
<td>1 (0-15)</td>
<td>1 (0-15)</td>
<td>1 (0-15)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The main determinants of transfusion requirements are the duration of aplasia, the type of transplant and the disease, with myeloid malignancies requiring more transfusions. The establishment of haplo-identical transplantations has increased the transfusion needs due to longer period of aplasia.
Background: Patients suffering from Acute lymphoblastic leukemias (ALLs) harboring t(9;22) genetic abnormality are classified very high risk (VHR)-ALLs displaying poor clinical outcome irrespective of intensive chemotherapies and tyrosine kinase inhibitor treatment. Development of new adjutant therapeutics will provide great value. HQ17(3)-induced rapid cell demise, characterized by oxidative stress, loss of membrane integrity, mitochondrial membrane potential disturbance and nuclear DNA fragmentation. Neither pan-caspase inhibitor nor Nec-1 (RIP-1 inhibitor) protected SUP-B15 cells from HQ17(3)-induced cell death. The cell death program elicited by HQ17(3) is caspase-independent, and is different from the RIP1-mediated controlled necroptosis.

Aims: To investigate the characters of, and the molecular pathways involved in the HQ17(3)-induced non-classical death on VHR-ALL SUP-B15 cells and help design potential therapeutic strategies for the VHR-ALLs.

Methods: Cell growth inhibition in response to HQ17(3) w/wo inhibitors was analyzed by flow cytometry for cell death. Lysosomal protease inhibitors (AEBSF (serine protease inhibitor), pepstatin/CA074-Me (cathepsin D/B inh.)) or autophagy inhibitor 3MA (used in combination with HQ17(3)) in some experiments. Acidine orange stain and confocal microscopy are used to visualize the changes of acidic vesicles. Autophagic flow in response to HQ17(3) was revealed by aggregation of ectopically expressed EGFP-LC3. Western blot analysis were used to reveal expression of Beclin-1. Nuclear accumulation of apoptosis inducing factor (AIF) was revealed by fluorescence microscopy.

Results: Enlarged acidic vesicles accumulated soon after HQ17(3) treatment, and diminished when cell death ensued. HQ17(3)-induced cell death could not be attributed to caspase sensitive apoptosis for the VHR-ALLs. HQ17(3) enhanced apoptosis as revealed by aggregation of ectopically expressed EGFP-LC3. Inhibition of apoptosis by Bafilomycin A1 or knockdown the essential autophagy-related Beclin-1 by shRNA could partially attenuate HQ17(3)-induced cell death. Further, HQ17(3) treatment gave rise to early ER stress as revealed by enhancement of eIF2α phosphorylation and up-regulation of ER chaperone Gp78. HQ17(3)-induced nuclear translocation of AIF, in compatible with mitochondria disturbance and caspase-independent cell death thereafter.

Summary/Conclusions: In Ph+-ALL SUP-B15 cells, HQ17(3) acts in multi-facet: a) lead to oxidative stress and perturb mitochondria membrane permeabilization (LMP) as caspase inhibitors did not attenuate the cell death. HQ17(3) enhanced autophagy as revealed by aggregation of ectopically expressed EGFP-LC3. Inhibition of autophagy by Bafilomycin A1 or knockdown the essential autophagy-related Beclin-1 by shRNA could partially attenuate HQ17(3)-induced cell death. Further, HQ17(3) treatment gave rise to early ER stress as revealed by enhancement of eIF2α phosphorylation and up-regulation of ER chaperone Gp78. HQ17(3)-induced nuclear translocation of AIF, in compatible with mitochondria disturbance and caspase-independent cell death thereafter.
acquired results were compared with those derived from the first ALL diagnosis. Results: The median age of the study group was 36 (range: 0.4-785×10⁹/L), the median blasts count in the bone marrow was 21.9% of CD4+ cells, p=0.0001), but no difference was observed in the proportion of CD40+ positive CD8+ T cells (p=0.49).

**Summary/Conclusions:** Multiplex IHC enables ample cyometric evaluation of different immune cell subtypes in their original microenvironmental context of the bone marrow. The TMA format not only allows analysis of tens of BM samples in parallel but also serves as a retroactive, easy-access archive for any follow-up studies. Ph+ ALL BM is characterized by a decrease in the CD4+CD8+ ratio and an increase in the proportion of CD4+CD45RO+ T cells in comparison with the non-leukemic controls. The proportion of PD1-expressing T cells is also elevated. However, the heterogeneity between patients is marked. The analysis of other marker panels is presently ongoing, as well as correlation to clinical and treatment outcome parameters.

**PB1614**

**IMMUNOLOGICAL CHARACTERIZATION OF PH+ ALL BONE MARROW BY MULTIPLEX IMMUNOHISTOCHEMISTRY**

H. Hohrtain1, O. Brück1, S. Blom2, R. Turkki2, A. Ribeiro2, M. Sinisalo3, P. Kovanen4, O. Kalli2, T. Pellinen5, K. Porka2, S. Mustjoki1

1Hematology Research Unit, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, 2Institute for Molecular Medicine Finland (FIMM), Helsinki, 3Division of Hematology, Tampere University Hospital, Tampere, 4Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, 5Hematology Research Unit, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland

**Background:** The treatment results in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have improved significantly in the era of tyrosine kinase inhibitors (TKIs). However, many patients relapse despite having received intensive treatments with initially favorable responses. TKI therapy is known to modulate the immune system, and it may play a critical role in keeping the leukemia under control. However, little is known about the status of the immune system in patients with Ph+ ALL. Especially with the emerging immunotherapies in sight, it is vital to chart the immunological landmarks that could help us direct the treatment towards a more personalized course.

**Aims:** To characterize the immunological microenvironment in Ph+ ALL bone marrow (BM) by multiplex immunohistochemistry (IHC).

**Methods:** Ph+ ALL BM biopsies from the diagnosis stage were collected from Helsinki University Hospital and Tampere University Hospital (N=31). BM biopsies from non-leukemic (NL) controls (N=14) were used as a reference. Samples were hematopathologically evaluated and a tissue microarray (TMA) was constructed by selecting two BM cores with high leukemic cell infiltration per patient. The TMA sections were stained with both fluorescent and chromogenic dyes for six markers and nuclei simultaneously enabling cyometric analysis at cellular resolution. Marker panels included T and B lymphoid cells, NK and dendritic cells, macrophages as well as myeloid derived suppressor cells. Furthermore, we analyzed immune checkpoint molecules (PD-L1, PD-L2, HLA-G, HLA-A,B,C) and ligands (PD-1, PD-L1) as well as various activation markers (granzyme B, CD45RO, CD25, CD27, CD69). After the staining, the cells were segmented and analyzed using the image analysis software CellProfiler and the cell analysis software FlowJo.

**Results:** The CD4+/CD8+ ratio was lower in Ph+ ALL BM versus NL BM (1.3 [interquartile range (IQR) 1.0-1.9] vs 2.0 [IQR 1.7-2.4], p=0.0134) indicating that there are relatively more CD8+ T cells in the leukemic than in the non-leukemic bone marrow. The ratio of memory CD4+CD45RO+ T cells in Ph+ ALL BM versus NL BM was elevated (21.0% [IQR 16.7-28.5] vs 13.0% [IQR 8.7-15.9] of CD4+ T cells, p=0.0044). The difference in memory CD8+CD45RO+ T cells was not significant (p=0.36). Further analysis of the T cell phenotype showed increased proportion of both PD1+positive helper T cells and PD1-positive cytotoxic T cells in Ph+ ALL BM vs NL BM (27.9% [IQR 17.5-30.1] vs 6.9% [IQR 5.7-8.9], of CD4+ cells, p=0.0001 and 28.8% [IQR 13.2-38.0] vs 14.9% [IQR 9.6-18.7], of CD8+ cells, p=0.0107). The ratio of CD40-positive helper T cells was also higher in Ph+ ALL BM (27.1% [IQR 21.6-33.25] vs 18.5% [IQR 14.8-

**Figure 1.**
Results: The prevalence of the CDKN2A deletion in all studied population was 24.5% (27 cases). The frequency of homozygous deletions was 70% (in 19 cases), homozygous deletion was 30% (in 8 cases). CDKN2A deletion was detected in 14 (52%) patients with precursor-B phenotype, in 11 cases (41%) with T-ALL and in 2 (7%) cases with biphenotypical ALL. Our study demonstrated that CDKN2A deletion had no significant association with age, sex, WBC counts, BM blasts, risk stratification groups, complete remission (CR) and relapse rate in B-cell ALL. We didn’t reveal any significant differences in OS, clinical and laboratory dates between groups of patients with homozygous and heterogeneous deletion of the CDKN2A deletion. The analysis for T-ALL has detected that CDKN2A deletion was strongly associated with high WBC count (the median is 86×10^9/L, p=0,000), with high level of lactate dehydrogenase (LDH) level (the median is 3026 E/L, p=0,0004) and no associating with CR and replace incidence was found. We didn’t revealed relationship between CDKN2A deletion and ALL, TEL/AML1 rearrangement, MYC translocation, TP53 mutation and IAM2. CDKN2A deletion didn’t have statistically significant impact on outcome of patients. The five-years CR rate was 92% in patients with without deletion and 85% (p=0,35); DFS was 92% and 65% (p=0,07), respectively. OS for T-ALL patients with and without deletion was 90% and 80% (p=0,63); DFS was 100% and 62% (p=0,24), respectively. (Figure 1).

Summary/Conclusions: We were unable to demonstrate prognostic value of the CDKN2A deletion in adult ALL patients and did not find significant association between deletion of the CDKN2A gene and with known cytogenetic prognostic factors. However patients with T-cell ALL and CDKN2A deletion had a more aggressive initial clinical features (high level WBC and LDH), but it didn’t associate with poor outcomes including overall survival.

Deletion of CDKN2A is not adverse prognostic factor in adult ALL treated according to protocol RALL-2009.

PB1616

FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS


1All Research Group, Josep Carreras Leukaemia Research Institute (IJC), 2ICO-Germans Trias i Pujol Hospital, 3Josep Carreras Leukaemia Research Institute (IJC), Badalona, 4ICO-Duran I Reynals Hospital, Hospital del Llobregat, 5ICO-Josep Trueta Hospital, Girona, 6Donostia University Hospital, Donostia, 7Virgen de la Victoria Hospital, Málaga, 812 October Hospital, Madrid, 9Vall de Hebron Hospital, Barcelona, 10Alcante General Hospital, Alicante, 1112 October Hospital, Madrid, 12Son Llatzer Hospital, 13Son Espases Hospital, Mallorca, 14Barcelona Clinic Hospital, Barcelona, 15Virgen del Rocio Hospital, Sevilla, 16USAL-BNADN, Salamanca, 17La Fe Hospital-Biobanco de la Fe, 18La Fe Hospital, Valencia, Spain

Background: Recurrent 9p21 deletions involving CDKN2A/CDKN2B locus are frequent in ALL. The very few data regarding their prognostic significance in adult T-ALL have shown that homozygous deletions of the CDKN2A/CDKN2B locus are associated with improved overall survival (OS).

Aims: We precisely characterized the copy number status (CNA) of CDKN2A/CDKN2B locus by discriminating deletions in A or B gene in order to elucidate its clinical impact separately.

Methods: Samples from 30 adult T-ALL cases included in high-risk protocols from the PETHEMA group were analyzed by CytoScan array (Affymetrix). Additionally, we set up a genomic qPCR to screen for CDKN2A and CDKN2B deletions in A or B gene in order to discriminate deletions in A or B gene.

Results: qPCR results showed that most of the 9p21 losses corresponded to homozygous deletions in both genes (36%, 19/53), while heterogeneous deletions corresponded to 5.7% (3/53) and different CNA status on 41% (21/53) of the samples. Global alterations in CDKN2A/B locus were found in 32% (17/53) of patients. We also obtained 32% of patients in whom we corroborate the findings obtained by qPCR. The resolution of the array allowed us to distinguish between homozygosis in CDKN2A and heterozygosis on CDKN2B. The FISH analysis corroborated the homozygous deletion in the CDKN2A/B locus in all the cases analyzed. With that, we ask for clinical implications of CDKN2A/B CNA status in 49 cases with adequate follow-up. Median OS for patients with homozygous deletions in both genes (36%, 19/53), while heterozygosis deletions in samples with few or not enough quality DNA (n=53) were analyzed by CytoScan array (Affymetrix). Additionally, we set up a genomic qPCR to screen for CDKN2A/CDKN2B locus by discriminating deletions in A or B gene in order to elucidate its clinical impact separately.

Results: We examined the rate of apoptosis of CEM-C7 (T-ALL), CEM-1 (F-ALL), MOLT-4 (T-ALL), RS4-11 (B-ALL) cell lines and primary ALL blasts from patients with different cytogenetic and molecular features. We tested the expression of the caspase-9, poly ADP-ribose polymerase (PARP), nuclear Forkhead Class box O3a (FOXO3a) and BCL-2 interacting mediator of cell death (BIM) using western blot assay. We established the xenograft mouse model to examine the anti-leukemic effect of butein in vivo. We found that butein promoted FOXO3a localization, enhanced the binding of FOXO3a on the BIM gene promoter and then increased the expression of BIM. Moreover, we showed that FOXO3a knockdown significantly decreased the apoptosis of butein, whereas overexpression of FOXO3a enhanced the butein-induced apoptosis. However, overexpression of FOXO3a mutation (C-terminally truncated FOXO3a DNA-binding domain) decreased the apoptosis by butein through decreasing the expression of BIM. Furthermore, treatment with butein was highly efficacious in vivo, with enhanced reduction of tumor burden in a xenograft model of ALL.

Summary/Conclusions: Our results therefore demonstrate the therapeutic potential of butein for ALL via FOXO3a and caspase-dependent apoptotic pathways.

PB1617

BUTEIN KILLS ACUTE LYMPHOBLASTIC LEUKEMIC CELLS IN VITRO AND IN VIVO THROUGH FOXO3A AND CASPASE-DEPENDENT APOPTOTIC PATHWAYS

Y.-L. Tang1, L.-B. Huang1

1Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Background: Acute lymphoblastic leukemia (ALL) is a common hematological malignancy in children. Discovering and developing effective chemotherapeutic drugs are needed for ALL.

Aims: In this study, the anti-leukemic effect and the potential molecular mechanisms of butein on ALL were investigated.

Methods: We examined the rate of apoptosis of CEM-C7 (T-ALL), CEM-1 (F-ALL), MOLT-4 (T-ALL), RS4-11 (B-ALL) cell lines and primary ALL blasts from patients with different cytogenetic and molecular features. We tested the expression of the caspase-9, poly ADP-ribose polymerase (PARP), nuclear Forkhead Class box O3a (FOXO3a) and BCL-2 interacting mediator of cell death (BIM) using western blot assay. We established the xenograft mouse model to examine the anti-leukemic effect of butein in vivo. We found that butein promoted FOXO3a localization, enhanced the binding of FOXO3a on the BIM gene promoter and then increased the expression of BIM. Moreover, we showed that FOXO3a knockdown significantly decreased the apoptosis of butein, whereas overexpression of FOXO3a enhanced the butein-induced apoptosis. However, overexpression of FOXO3a mutation (C-terminally truncated FOXO3a DNA-binding domain) decreased the apoptosis by butein through decreasing the expression of BIM. Furthermore, treatment with butein was highly efficacious in vivo, with enhanced reduction of tumor burden in a xenograft model of ALL.

Summary/Conclusions: Our results therefore demonstrate the therapeutic potential of butein for ALL via FOXO3a and caspase-dependent apoptotic pathways.

PB1618

GENOMIC LANDSCAPE AT DIAGNOSIS AND RELAPSE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA.

O. Theisen1, C. Godon1, F. Riaillard2, C. Thomas2, A. Grain2, Y. Le Bris1, N. Robillard3, M. C. Béne1, M. Eveillard1

1Hematology Laboratory, 2Pediatric Oncology, Nantes University Hospital, Nantes, France

Background: Childhood acute lymphoblastic leukemia (ALL) is the most common of pediatric malignancies, but intensive chemotherapy now allows to obtain complete remission in over 90% of the cases. Nevertheless, 1 out of 5 children develop relapse.

Aims: In order to identify new markers prognostic of relapse, we analyzed SNP arrays of paired diagnosis and relapse samples from 8 B-ALL children.

Methods: The cohort included 3 males and 5 females, aged between 6 months and 21 years old (median age 4 years old). Bone marrow samples were analyzed by SNP array (Affymetrix®) performed on cryopreserved cells at diagnosis and relapse investigated copy number alterations (CNAs) and loss of heterozygosity (LOH). TP53 mutation was studied on paired samples by Sanger sequencing.

Results: CNAs were detected in the EGIL classification between diagnosis and relapse. Diagnostic cytogenetics prognosis was good for 3 children, poor for 3 (AmpAML, KNMT2A and complex caryotype) intermediate for 2 (normal karyotype). Three patients showed additional karyotypic anomalies at relapse. SNP array showed a mean of 10 CNA and 3 LOH at diagnosis and relapse. 2 CNA and 0.6 LOH modulations at relapse. Seven of the 8 patients presented modulation in CNA and LOH during evolution with a median of 4. Some anomalies observed by cytogenetics were refined by SNP analysis, notably all chromosomal gains and losses were recovered and precisely located. More-
over, a t(4;8) translocation was found to be more complex with 7 and 8 CNA on chromosomes 4 and 8. Patients with the most CNA and LOH also had a complex karyotype. Anomalies were observed in hot spot regions in 8p (encompassing CDKN2A/2B, PAX5 and JAK2) for 5 patients and 12p (including ETV6) for 3. Stable CNA were observed in the JAK/STAT pathway in 2 patients (JAK2) and LOH in the RAS/Mapk pathway (NRAS) in 1. Using the genetic classification of Moorman et al based on SNP array for 8 genes at diagnosis (IKZF1, CDKN2A/2B, PAR 1, BTG1, EBF1, PAX5, ETV6 and RB1), SNP reclassified our patients in 3 of good prognosis and 5 of poor prognosis, with a median of 2 CNA for the 8 genes of interest. The 2 patients with cytogenetic intermediate prognosis would thus probably have been considered for a more intense therapeutic regimen, i.e. allogeneic stem-cell transplantation. Moreover, SNP showed that 2 patients acquired an IKZF1 deletion, also of poor prognosis, while none of the children had TP53 mutation at diagnosis nor relapse.

Summary/Conclusions: SNP array allowed to identify additional anomalies (compared to karyotype) in all children tested and changed the prognostic value of diagnostic anomalies. Moreover, the identification of anomalies in the JAK/STAT pathway could indicate a treatment by tyrosine kinase inhibitors, which would possibly have positively modified outcome. Taken together, this new technology combined with classical analyses at diagnosis might modify therapeutic options in childhood ALL, especially in the subgroup with a normal karyotype.

PB1619
SCREENING OF NUDT15 GENE VARIANTS IN CHILDREN WITH ACUTE LYMPHOBластIC Leukemia
D. Aslar Oner1,*, D.F. Aktin1, K. Stipali1, M. Mumcuoglu1, N. Oner Battaloglu1, S. Tasdelen1, U. Ezer1, S. Emir1, E. Kurekci1
1Lössante Hospital, ANKARA, Turkey

Background: In cells, while DNA bases can be protected by double helix formation and nucleosome packaging, deoxynucleobase triphosphates are unprotected, thus, are vulnerable to damage. One of the enzymes which are responsible for removing damaged nucleotides is Nudix hydrolase15 (NUDT15). NUDT15 works as a negative regulator in thiopurine metabolism. Thioguanines are active metabolites of thiopurines. Mechanisms of action of thioguanines are described in the literature, but the role of NUDT15 is not described. At the moment, NUDT15 inhibits incorrect base pairing and apoptosis through catalysis of thioguanine hydrolysis. Tanaka et al. reported that NUDT15 is a possible additional factor that may influence thiopurine toxicity. They reported that NUDT15 works as a negative regulator in thiopurine metabolism. Thioguanines are active metabolites of thiopurines. Mechanisms of action of thioguanines are described in the literature, but the role of NUDT15 is not described.

Aims: The aim of this study was to retrospectively and prospectively analyze bone marrow cells of children with T-ALL, to determine a frequency of recurrent cryptic chromosomal aberrations and to assess their impact on event free (EFS) and overall survival (OS).

Methods: Bone marrow cells of all patients were analyzed at the time of diagnosis by combination of conventional and molecular cytogenetic methods. For detection of the most frequent known chromosomal changes, i.e. rearrangements of TCR loci (TRA-14q11, TRB-7q34, TRG-7p14) and TLX3 gene (9q35), deletion of CDKN2A (9p21) and amplification of ABL1 (9q34), interphase FISH with locus-specific probes (Dako, Abbott Molecular) was used. Complex chromosomal rearrangements were proved by multicolor FISH and multicolor banding (24X/CyteX/Cyte Probe Kit; MetaSystems) or CGH-SNP array (SurePrint G3 CGH+SNP 4x44K Plus; Agilent). For OS and EFS Kaplan-Maier analysis with Mantel Cox test was done.

Results: During the years 1996-2016 we examined archival material of 64 children with T-ALL (19 girls and 45 boys, median age 8.25 years). In total, chromosomal aberrations were detected in 86% of patients. The most frequent aberration was deletion of CDKN2A gene, which was found in 35/64 patients (19x homozygous, 16x heterozygous). Rearrangements of TCR loci were detected in 17/64 children (11x TRA, 6x TRB). TLX3 gene rearrangement was established in 15/64 patients. No aberration of TRG gene and amplification of ABL1 were found. Complex chromosomal aberrations were proved in 12/64 children. In two cases, isochromosome of the long arm of chromosome 9 was found. 48 patients are living in the first/second complete remission. Relapse of the disease occurred in 17 patients, 16 children died. Best outcome (EFS and OS) was associated with TRA translocations (p<0.05). Patients with TLX3 rearrangement had significantly shorter OS and EFS (p<0.05).

Summary/Conclusions: Using molecular cytogenetic methods cryptic recurrent aberrations were proved in vast majority of patients. Rearrangement of TLX3 gene was related to poor outcome in contrast to TRA translocations associated with more favorable course of the disease. Our work attempts to clear up the significance of chromosomal aberrations related to childhood T-ALL in order to facilitate the patients’ stratification into cytogenetic prognostic groups and to identify patients at an increased risk of relapse similarly like it has been adopted in p-B-ALL.

Supported by grants RVO:VF-N64165, GACR-P302/12/G157 and NPU I nr.L01604

PB1620
COMPREHENSIVE MOLECULAR CYTOGENETIC ANALYSES OF BONE MARROW CELLS IN 64 CHILDREN WITH T-ALL REVEALED PROGNOSTICALLY RELEVANT RECURRENT FINDINGS
L. Lizova1,*, Z. Zemanova1, E. Prihodova1, L. Pavlistova1, K. Svobodova1, E. Mejslikovu2, O. Hrusak2, P. Luknarova2, I. Janotova3, L. Sramkova3, J. Stary1, K. Michalova1
1Center of Oncogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, 2CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 3Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital , Prague, Czech Republic

Background: T-ALL represents 15% of newly diagnosed children with ALL and it is a clinically and genetically heterogeneous disease. Despite the use of intensive chemotherapy, relapse occurs in almost 25% of patients whose outcome remains dismal. Visible chromosomal aberrations are seen in approximately half of the cases, while cytogenetically cryptic aberrations are observed in almost all cases of T-ALL. However, prognostic implication of majority of them still remains unclear.

Aims: The aim of this study was to retrospectively and prospectively analyze bone marrow cells of children with T-ALL, to determine a frequency of recurrent cryptic chromosomal aberrations and to assess their impact on event free (EFS) and overall survival (OS).

Methods: For detection of the most frequent known chromosomal changes, i.e. rearrangements of TCR loci (TRA-14q11, TRB-7q34, TRG-7p14) and TLX3 gene (9q35), deletion of CDKN2A (9p21) and amplification of ABL1 (9q34), interphase FISH with locus-specific probes (Dako, Abbott Molecular) was used. Complex chromosomal rearrangements were proved by multicolor FISH and multicolor banding (24X/CyteX/Cyte Probe Kit; MetaSystems) or CGH-SNP array (SurePrint G3 CGH+SNP 4x44K Plus; Agilent). For OS and EFS Kaplan-Maier analysis with Mantel Cox test was done.

Results: During the years 1996-2016 we examined archival material of 64 children with T-ALL (19 girls and 45 boys, median age 8.25 years). In total, chromosomal aberrations were detected in 86% of patients. The most frequent aberration was deletion of CDKN2A gene, which was found in 35/64 patients (19x homozygous, 16x heterozygous). Rearrangements of TCR loci were detected in 17/64 children (11x TRA, 6x TRB). TLX3 gene rearrangement was established in 15/64 patients. No aberration of TRG gene and amplification of ABL1 were found. Complex chromosomal aberrations were proved in 12/64 children. In two cases, isochromosome of the long arm of chromosome 9 was found. 48 patients are living in the first/second complete remission. Relapse of the disease occurred in 17 patients, 16 children died. Best outcome (EFS and OS) was associated with TRA translocations (p<0.05). Patients with TLX3 rearrangement had significantly shorter OS and EFS (p<0.05).

Summary/Conclusions: Using molecular cytogenetic methods cryptic recurrent aberrations were proved in vast majority of patients. Rearrangement of TLX3 gene was related to poor outcome in contrast to TRA translocations associated with more favorable course of the disease. Our work attempts to clear up the significance of chromosomal aberrations related to childhood T-ALL in order to facilitate the patients’ stratification into cytogenetic prognostic groups and to identify patients at an increased risk of relapse similarly like it has been adopted in p-B-ALL.

Supported by grants RVO:VF-N64165, GACR-P302/12/G157 and NPU I nr.L01604

PB1621
ADULT PRIMARY ACUTE LEUKEMIA SAMPLES WITH CHROMOSOMAL TRANSLocations GROW WELL IN IMMUNODEfICIENT MICE, BUT ARE DIFFICULT TO TRANsDUCE WITH LENTIVIRUS
B.C. Heckl1,*, M. Carlet1, M. Grunert1, B. Vick12, C. Roof12, C. Junghani3, K. Spiekermann2,4, W. Hiddemann2,4, I. Jeremias1,2,5
1AGV, Helmholtz Zentrum Muenchen, 2German Cancer Consortium , 3Department of Internal Medicine III, University, Rostock, 4Internal Medicine in Prague and Motol University Hospital , Prague, Czech Republic

Background: Acute leukemia (AL) is a severe disease of the hematopoietic system and associated with a poor outcome for patients. Patient derived xenograft (PDX) mouse models provide an attractive tool to engraft and grow primary tumor cells. In contrast to culture growth, samples can be monitored in a consisting
microenvironment. This powerful tool provides the baseline for further experiments like preclinical treatment trials or biology studies. While good engrafment rates were published for primary pediatric ALL samples, engrafment rates of adult ALL samples might be inferior, but remain largely elusive. Aims: This study aimed to determine engrafment and growing ability of primary adult ALL samples in immunodeficient mice. Genetic engineering was performed to evaluate transduction efficiencies by lentiviruses in PDX ALL cells. Methods: Primary adult ALL and AML samples were transplanted into NGS mice in the absence of total body irradiation. Both frozen as well as fresh patient material was used. Human CD45 and human CD38 were stained in blood to monitor successful engrafment. Mice were sacrificed before coming down with leukemia. Isolated cells from bone marrow and spleen were analyzed by flow cytometry. Genetic engineering was performed using lentiviral vector systems and monitored by expression of fluorochrome markers and flow cytometry. Results: Engraftment and growth was successful in NGS mice in 12 out of 15 primary adult ALL samples. Frozen samples showed a longer median engrafment time than fresh samples which would already be isolated with an average time of 75.29 days. Generally, the engrafment time varied from 47 days up to 166 days and was shortened for slow samples over several passages. Genetic engrafment was successfully performed using lentiviral transduction to introduce expression of fluorescent colours for cell marking and monitoring in further experiments. Lentiviral transduction was performed in 8 ALL samples with BCR-ABL rearrangement and 2 ALL-F4 ALL samples. Adult ALL PDX samples with chromosomal translocations showed very low transduction rates around 1%. Three AML samples with ALL-F6, MLL-A9 and MLL-AF10 translocation were analysed for this study. Interestingly and in contrast to ALL, transduction efficiency for AML rearranged samples was high with up to 60%. These values are similar to non-rearranged ALL samples having transduction rates between 30% up to 80%.

Summary/Conclusions: In summary, we observed a high engrafment rate of primary adult ALL samples in immunodeficient mice which was above what we anticipated from the literature. Therefore fresh samples can be transplanted with lentiviruses with identical high transduction efficiency as pediatric samples, with an age independent exception of ALL PDX cells with BCR-ABL or MLL translocations.

PB1622
SYNERGIC CHEMOTHERAPEUTIC EFFECT OF MENADIONE COMBINED WITH EPIGALLOCATECHINE-3-GALLATE OR DOXORUBICIN IN A HUMAN CELLULAR MODEL FOR ACUTE LYMPHOCYTIC LEUKEMIA WITH MOUSOMY 7 FOLLOWING TREATMENT OF RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA
A. Garaımi1,2,*, I. T. Tofte1, R. M. Babes1, C. Ganea1, I. Baran1
1Department of Biophysics, “Carol Davila” University of Medicine and Pharmacology, Bucharest, 2Department of Hematology, Coltea Clinical Hospital, Bucharest, Romania

Background: Epigallocatechine-3-gallate (EGCG) and menadione (vitamin K3; MD) are known as potent apoptotigs in cellular models for acute lymphocytic leukemia (ALL) –Jurkat T cells. Aims: The goal of this study was to explore the chemotherapeutic potential of MD combined with EGCG or DOX, and to determine whether there is a synergic interaction between these agents that could significantly enhance their antitumor effect in a cellular model of ALL. We investigated the antiproliferative effect, and apoptosis induction, EGCG:MD and MD:DOX respectively on human leukemia Jurkat lymphoblasts. Some underlying cellular mechanisms were also scrutinized.

Methods: Cells suspensions of Jurkat lymphoblasts were treated at various concentrations of EGCG, MD and DOX. Clonogenic survival was evaluated as the colony forming capacity in 96-well plates. Cell cycle and apoptosis/necrosis were determined by flow cytometry using the fluorescent indicators propidium iodide and Annexin V-FITC/7-AAD, respectively. Determination of oxidative stress, opening of the mitochondrial permeability transition pore. The combination EGCG:MD induced cell cycle arrest in G2/M and S phases in a synergic manner.

Summary/Conclusions: Our results support the notion that the combinations EGCG:MD and MD:DOX exert a strong synergic antiproliferative effect in human leukemia Jurkat cells and encourage further studies to test the clinical utility of this association in ALL therapy.
Results: ASI amphetamine morphology showed 5% of blasts. However, detailed 8- color flow cytometry according to the EuroFlow protocols revealed no cells with BCP-ALL-specific immunophenotype, but several subsets of BCP with aberrant 45X, 65% and 65% expression of TdT and CD19 were observed in 8% of mononuclear cells of T-ALL patients, Jurkat and HUT-78 cell lines. After apoptosis inhibitor was applied, chidamide inhibits the transduction and translation to c-FLIP gene. When apoptosis is inhibited, chidamide upregulates the expression level of receptor-interacting protein 3 (RIP3) and the phosphorylation level of mixed lineage kinase domain-like (MLK). After treatment with chidamide, the phosphorylation level of RIP3 was significantly increased in Jurkat and HUT-78 cell lines. Chidamide induces necroptosis in Jurkat and HUT-78 cell lines by down regulating the transcription and translation of c-FLIP gene. Chidamide induces necroptosis in Jurkat and HUT-78 cell lines via the classical NF-κB signaling pathway.
Background: Intrachromosomal amplification of chromosome 21 (iAMP21) defines a rare subtype of pediatric acute lymphoblastic leukemia (pALL) occurring in approximately 2-3% of cases. The patients are older (median age is 9 years), usually have low white blood cell counts and show high relapse risk with standard therapy. Thus, it has been proposed to include ALL with iAMP21 as a distinct entity in the WHO classification of hematological malignancies.

Aims: To assess the frequency as well as the clinicopathological and genetic characteristics of ALL with iAMP21 in one of the three national diagnostic centers of pALL in Hungary. We sought to determine additional genetic aberrations associated with this rare entity.

Methods: Between 2008-2016, 175 samples of pALL patients were tested with FISH for BCR-ABL1, ETV6-RUNX1 and MLL translocations. When available, bone marrow karyotyping was used to verify the abnormal results. In one case with iAMP21, multiplex ligations-dependent probe amplification (MLPA) was used to verify the cytogenetic aberrations as well as to detect associated copy number alterations.

Results: Among the 175 samples screened with FISH, three showed evidence of iAMP21 (1.7%). Case 1 was a 16-year-old male who presented with thrombocytopenia and hepatosplenomegaly. Flow cytometry (FCM) showed common ALL phenotype with the expression of CD13 and CD33. FISH showed >10 RUNX1 signals in clusters in leukemic blasts, while karyotyping demonstrated r(21) with 7q deletion and +X. The lesions were verified by MLPA, which additionally revealed biallelic RUNX1 and RUNX1 deletions. The patient was treated with ALL-IC BFM 2002 standard risk protocol. Following remission, isolated meningeal relapse occurred, for which he received radiotherapy. The patient died with recurrent meningeal disease without bone marrow involvement after 52 months. Case 2 was an 11-year-old girl, who presented with symptoms suggesting osteomyelitis of the tibia with unremarkable blood count. MRI showed multiple lesions in vertebrae as well as meningeal involvement of the spinal cord. Bone marrow biopsy and biopsy of the left tibia showed diffuse infiltration of lymphoblasts with only 5% leukemic cells in bone marrow aspirates. FISH detected 6-8 copies of RUNX1 in leukemic blasts, while karyotyping yielded only normal bone marrow cells. She was commenced on ALL-IC BFM 2002 standard risk and was later switched to high risk protocol. She is in complete remission after 14 months. Case 3 was an 11-year-old boy who presented with anemia and thrombocytopenia. FCM showed ALL with common phenotype with two populations; one being strong CD19+/CD66c+ and one with dim CD19+/CD66c-. FISH showed >10 RUNX1 signals in clusters in 95% of cells, while 52% showed BCR-ABL1 positivity. Bone marrow karyotyping yielded metaphases of poor quality (Figure 1).

Figure 1.

Summary/Conclusions: ALL with iAMP21 is a rare subtype with distinct clinicopathological characteristics. Presenting with only mildly elevated WBC in older children is typical, relapses are frequent if standard risk chemotherapy is administered. Association with BCR-ABL1 translocation is rare, having been reported in only 4 cases. Observing BCR-ABL1 translocation in a sub-population of leukemic cells is an intriguing phenomenon; it indicates that this translocation may occur as a secondary event even after leukemic transformation has commenced.
PB1629

COMPLETE REMISSION WITH BLINATUMOMAB IN TWO PATIENTS WITH SKIN RELAPSED B-CELL ACUTE LEUKEMIA

H. Lerey1, M.-L. Julien1, E. Forcade1, G. Labourel1, R. Tabrizi1, P.-Y. Dumas1, M. Robles1, A. Chauvel1, B. Vergier1, N. Milpied1, A. Pigneux1, T. Leguay1

1CHU Bordeaux Haut Lévêque, pessac, France

Background: Blinatumomab is a bispecific T cell–engager (BiTE) antibody (CD19/CD3) indicated in relapsed/refractory B-cell Acute Lymphoid Leukemia (t(1;19)) (Topp et al.). Extra-medullary relapse is a rare event occurring in only 8% of the patients, of whom only 1.4% present a skin relapse which harbor a dismal prognosis (Gokbuget et al.).

Aims: Herein, we report the efficacy of Blinatumomab in two patients presenting with extra-medullary relapse of ALL.

Methods: The first patient (a 40-year-old man) was diagnosed a CD19+ Ph - B-ALL in 2009. He received a chemotherapy regimen according to the GRAALL protocol (Huguet et al.) until complete remission (CR). In 2015, he presented with a maculopapular rash of the right leg and the left flank, and two enlarged inguinal lymph nodes. Cutaneous relapse was attested by examination of skin biopsy specimen showing a blastic dermal infiltration harboring a CD10+, Tdt+ phenotype. The second patient was a 50-year-old male who presented, in 2016, a CD19+ B-ALL Ph- Ikaros- without central nervous system involvement. He obtained a first CR after GRAALL induction with negative MRD (IgH) but he relapsed 3 months later with a maculopapular rash of his chest. The skin biopsy revealed a blastic dermal infiltration. These two patients with skin relapse received the same chemotherapy (CPOPRAALL 2007 regimen) (Domenach et al.), with no efficacy (cutaneous blastic infiltrate). Both patients received one cycle of Blinatumomab from day 1 to day 28, at 28 µg per day, in an attempt to achieve CR before allogeneic stem cell transplantation, as previously described.

Results: At day 5 of Blinatumomab, an important non pruritic maculopapular rash occurred in both patient, in the same area of the initial cutaneous involvement. Interestingly, it decreased after day 8. No new drug introduction or infection (bacterial, viral or parasitic) was documented in the days preceding or during Blinatumomab infusion. A skin biopsy performed at day 6 of Blinatumomab showed a prominent dermal CD3+ lymphocytic infiltrate with a perivascular, but also a peri-nervous distribution (on the first patient’s specimen only). Few lymphocytes marginated at the basement membrane and rare basal necrotic keratinocytes were also noted but without blast for the first, although few residual blastic cells were observed on the second’s. One month later, another skin biopsy showed a CR without lymphocytic infiltrate. The medullar CR was confirmed at the molecular level (MRD negative). The first patient received allogenic stem cell transplantation (SCT) from a matched related donor one month later. He presented an acute and chronic GVHD, and is now in complete remission with a follow-up of 7 months. The second is still waiting for a SCT.

Summary/Conclusions: These observations confirm the strong efficacy of Blinatumomab in t(-)/B-ALL. We observed a T-cell dermal recruitment 6 days after Blinatumomab initiation clinically mimicking skin GVHD. However, we couldn’t find specific histological features of GVHD, but only an “inflammatory dermal syndrome” as described in relapsed B-ALL with cutaneous infiltration suggesting promising activity in extra-medullary relapse. Further studies are required to confirm a Blinatumomab-based strategy in extra medullary relapsed B-ALL. This may provide a better understanding of how cytolytic synapses between T lymphocytes and intradermal blasts happen and the underlying homing mechanisms involved.

PB1630

A NOVEL METHOD FOR MINIMAL RESIDUAL DISEASE ANALYSIS IN PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: MODIFIED BIOMED-2 POLYMERASE CHAIN REACTION FOR IMMUNOGLOBULIN HEAVY CHAIN ARRANGEMENT

D. Katoh1,*, M. Nakamura1, M. Morita1, H. Maruoka2, A. Fujimoto1, M. Robles1, A. Chauvel1, B. Vergier1, N. Milpied1, A. Pigneux1, T. Leguay1

1Shire, Cambridge, United States, 2Shire, Zählerweg, Switzerland

Background: Recent studies have demonstrated the clinical importance of minimal residual disease (MRD) monitoring in adult acute lymphoblastic leukemia (ALL) as well as pediatric ALL. However, patient-specific polymerase chain reaction (PCR)-based MRD assessment, one of the most commonly recognized methods, is not widely used in clinical practice because it is expensive, time consuming, and technically difficult. Therefore, we modified the BIOMED-2 protocol, PCR for immunoglobulin heavy chain (IgH) rearrangement, to assess MRD in ALL easily and readily in our hospital.

Aims: The aim of this study was to examine the clinical utility of monitoring MRD by the modified BIOMED-2 PCR for IgH rearrangement in patients with Philadelphia-negative (Ph- ALL).

Methods: We enrolled 54 patients diagnosed with Ph (-) ALL between 2006 and 2016 in our hospital. IgH rearrangement was detected in 35 patients using the standard BIOMED-2 PCR protocol. Patients who received palliative chemotherapy, never achieved remission (blasts <5%), or had no follow-up MRD data were excluded. Finally, data from 27 patients with Ph (-) ALL were analyzed. We assessed MRD with the modified BIOMED-2 PCR for IgH using bone marrow samples collected after each chemotherapy session. Patients’ MRD statuses were classified as follows: Early MRDneg (100% vs 72.9% vs 20%; p=0.001) (Figure 1). Patients undergoing transplantation derived better prognosis than those receiving chemotherapy alone in the late MRDneg group (100% vs 40%; p=0.028), whereas there was no difference in the early MRDneg group (100% vs 100%; p=0.48).

Table 1. Patient characteristics by MRD status as assessed with the modified BIOMED-2 PCR for IgH protocol.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MRDneg Group (100%)</th>
<th>MRDpos Group (72.9%)</th>
<th>Late MRDneg Group (20%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>38</td>
<td>38</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>16–73</td>
<td>16–73</td>
<td>16–73</td>
<td></td>
</tr>
<tr>
<td>Male/Female</td>
<td>21/23</td>
<td>8/14</td>
<td>4/16</td>
<td></td>
</tr>
<tr>
<td>WBC (×10^4/μL)</td>
<td>B &gt;3; T &gt;10</td>
<td>B &gt;3; T &gt;10</td>
<td>B &gt;3; T &gt;10</td>
<td></td>
</tr>
<tr>
<td>Cyto genetic risk</td>
<td>Hypodiploidy, complex karyotype</td>
<td>Hypodiploidy, complex karyotype</td>
<td>Hypodiploidy, complex karyotype</td>
<td></td>
</tr>
</tbody>
</table>
| Treatment outcomes in adult Ph- ALL and patients with late MRDneg might derive a high survival benefit from allogeneic transplantation. Finally, the accuracy and reliability of the modified BIOMED-2 PCR for IgH were confirmed with a comparison to quantitative real-time PCR for BCR-ABL using samples from patients with Philadelphia-positive ALL (data not shown).

PB1631

SYSTEMATIC LITERATURE REVIEW OF PEGASPARGASE FOR THE TREATMENT OF NEWLY DIAGNOSED ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

E. Hooper1,*, A. Wiatry1, D. Bollag2

1Shire, Cambridge, United States, 2Shire, Zährerweg, Switzerland

Background: Asparaginase is a component of a multi-agent chemotherapy regimen widely used in clinical practice for adults with acute lymphoblastic leukemia (ALL). Since 2006, pegaspargase (PEG-ASP) has been the gold standard asparaginase for the treatment of pediatric ALL as it offers equivalent efficacy to native E. coli L-asparaginase (native ASP), with less frequent dosing,
an IV administration option, and improved immunogenicity. Clinical outcomes in the adult ALL population are less well understood.

**Aims:** To assess the relative clinical benefit of PEG-ASP vs native ASP in 1st line treatment in newly diagnosed adult ALL patients in terms of event-free survival (EFS) and overall survival (OS). Safety outcomes were also examined.

**Methods:** A systematic literature search was conducted using a standardized search algorithm within the National Library of Medicine PubMed database to identify available evidence for newly diagnosed patients treated with adult ALL protocols that use PEG-ASP or native ASP. Randomized, observational, and cohort studies were included, with the predefined clinical outcomes of event-free-survival (EFS) and overall survival (OS). Data was pooled with 95% confidence intervals (CIs) calculated using the logit transformation.

**Results:** A total of 30 studies were identified that met the pre-specified inclusion criteria, with 10 studies providing data for PEG-ASP and 23 studies for native ASP. The pooled estimate of 2-year EFS for adult ALL patients treated in 1st line with asparaginase was 48.0% (95% CI: [10.8; 85.2]) for PEG-ASP and 66.1% (95% CI: [53.8; 77.6]) for native ASP. Similarly, the pooled estimate of 2-year OS was 64.5% (95% CI: [61.5; 67.5%]) for PEG-ASP and 46.8% (95% CI: [33.6; 60.1]) for native ASP. In very high risk ALL patients, the pooled estimate of 5-year OS was 57.1% (95% CI: [52.4; 61.7%]) for PEG-ASP and 35.3% (95% CI: [21.7; 51.7]) for native ASP. Findings for safety outcomes were consistent with product labeling for both asparaginases.

**Summary/Conclusions:** The systematic literature review highlights a positive clinical effectiveness profile for PEG-ASP in regards to EFS and OS in the treatment of newly diagnosed adult ALL patients with less frequent administration and similar safety profile as compared with native ASP.

**PB1632**

**A COMPREHENSIVE ANALYSIS OF PATIENT- AND THERAPY-RELATED FACTORS AFFECTING THE TOXICITY OF PEGYLATED-ASPARAGINASE FOR THE TREATMENT OF ADULT ACUTE LYMPHBLASTIC LEUKEMIA**

P. Minetto1,*, N. Bisso1, F. Guolo1, M. Clavio1, E. Coviello1, D. Guardo1, N. Di Felicile1, F. Canale1, L. Manconi1, F. Ballerini1, M. Miglino1, R. M. Lemoli1, M. Gobbi1

1Clinic of Hematology, Department of Internal Medicine (DIMI), University of Genoa, IRCSS AOU San Martino-IST, Genoa, Italy

**Background:** The application of pediatric regimens in the treatment of adult acute lymphoblastic leukemia (ALL) has led to a significant improvement in patients outcome. However, concerns about the feasibility of more intensive therapies and of the use of pegylated L-Asparaginase (PEG-ASP) in adult patients have emerged. Some patient-related risk factors as high BMI or hepatic steatosis have been already identified as risk factors, but few data are available on the synergic toxic effect from other concomitant drugs.

**Aims:** The aim of the present study was to evaluate the incidence of PEG-ASP related adverse events in a cohort of adult ALL patients in order to identify potential patient and therapy-related risk factors contributing to toxicity.

**Methods:** Since 2013, 21 adult ALL patients received PEG-ASP therapy in our institution. Median age was 44 (range 19-76): 12 patients were treated in front-line setting (7 according to a full pediatric protocol) whereas 9 patients received therapy for relapsed/refractory neoplasm. We retrospectively analyzed each single course which included PEG-ASP administration as an independent event, accounting 41 episodes. Patients' features (age, BMI, disease status) and concomitant therapies were accurately analyzed as factors potentially affecting PEG-ASP toxicity. The incidence of major thrombotic/bleeding complications and grade III/IV hepatic or pancreatic toxicity was analyzed; toxicity grading and management of PEG-ASP related complications were performed according to guidelines recently published by Stock et al.

**Results:** No grade III/IV pancreatic, thrombotic or hemorrhagic adverse events were observed. A total of 8 episodes of grade III/IV hepatic toxicities were observed. In 3 cases, grade IV toxicity was observed. Those patients experienced unexplained severe weight gain and painful epaulegomy, a clinical picture resembling sinusoidal occlusive disease, ultrasonography showed acute liver steatosis. All 3 patients receiving concomitant therapy with idarubicin, vincrisine, and vancomycin. In univariate analysis, the incidence of grade III/IV hepatic toxicity was significantly higher when concomitant chemotherapy with at least 2 mg/sqm cumulative dose of vincristine (p = 0.044, HR 4.75) or at least 16 mg/sqm cumulative dose of idarubicin (p = 0.046, HR 1.45) was administered. Steroids therapy determined a borderline increase in toxicity risk (p = 0.068, HR 1.27). An increase in toxicity was observed only in those receiving daunorubicin, cyclophosphamide, cytarabine, methotrexate and 6-mercaptopurine (Table 1). Among concomitant antibiotic therapies, vancomycin administration seemed to increase the incidence of grade III/IV hepatic toxicity (p = 0.02, HR 1.863). No significant increase was observed with carbapenems and azoles (Table 2). Receiving PEG-ASP with active leukemia or a high BMI (>25) were not related with an increased incidence of grade III/IV hepato-toxicity (Table 1). Notably, none of the patients undergoing full pediatric induction (who received the highest doses of PEG-ASP), regardless of age (ranging from 21 to 55) experienced grade III/IV hepatotoxicity.

**Summary/Conclusions:** Our data show that the toxicity profile of PEG-ASP in adult patients is overall manageable. However, serious warnings emerge from our experience. Concomitant drugs and their timing of administration may play a crucial role in significantly contributing to PEG-ASP hepatic toxicity. In order to attempt to reduce toxicity, anthracyclines with shorter half-life, i.e. daunorubicin instead of idarubicin, should be used. A particular attention should be paid when administration of concomitant antibiotic therapy is required.

**PB1633**

**COST OF CARE FOR ADULT PATIENTS WITH RELAPSED ACUTE LYMPHBLASTIC LEUKEMIA WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT IN GERMANY**

Y. Su1,*, S. Schmitte2, A. Navarro3, L. Mayerhoff4, S. Pneu5, M. Lehne6, F.R. Lobaczka1

1Pfizer Inc., New York, United States, 2Pfizer Deutschland GmbH, 3Elsevier Health Analytics, Berlin, Germany

**Background:** Adult ALL is a rare but frequently fatal disease. Many patients who respond to initial therapy experience a relapse. For relapsed ALL (rALL), hematopoietic stem cell transplant (HSCT) is a potentially curative treatment option. HSCT is associated with added costs, however, which could impact overall healthcare budget.

**Aims:** This retrospective observational study aims to determine the cost of care and the impact of HSCT on total cost for adult rALL patients from a German payers’ perspective.

**Methods:** A German claims database with a representative sample of approximately 7 million individuals insured within the German statutory health insurance and continuously observable over a period of 6 years was used as data source. Costs for these data (adult ALL patients 18 years and older) with a new diagnosis of ALL (ICD-10-GM code: C91.0*) between January 1, 2011 and December 31, 2015 and a relapse after remission to initial treatment were identified. Mean health care cost per patient per quarter, the smallest unit of time available in the database, was determined by whether or not patients had an HSCT after relapse. Costs were considered from the perspective of the German statutory health insurance and included costs for prescription medicine as well as outpatient and inpatient healthcare encounters.

**Results:** Of the total 116 incident adult ALL patients identified, 29 (25%) were determined to have had a relapse and 11 underwent HSCT after relapse (38%). Patients with an HSCT appear to incur higher cost than those without HSCT in each of the quarters after relapse was diagnosed (Table 1), with the highest in the first quarter after relapse, but decreasing in subsequent quarters. Inpatient cost accounted for the majority of the cost for the first three quarters for both HSCT and non-HSCT patients, but for HSCT patients. The number of patients in the HSCT cohort remained relatively stable, while the non-HSCT cohort had only half the patients left by the third quarter post relapse.

**Table 1. Costs in € per patient (with and without HSCT) by quarter after relapse**

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Index quarter (relapse)</th>
<th>O1</th>
<th>O2</th>
<th>O3</th>
<th>O4</th>
<th>O5</th>
<th>O6</th>
<th>O7</th>
<th>O8</th>
<th>O9</th>
<th>O10</th>
<th>O11</th>
<th>O12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N mean</td>
<td>% inpatient cost</td>
<td>N mean</td>
<td>% inpatient cost</td>
<td>N mean</td>
<td>% inpatient cost</td>
<td>N mean</td>
<td>% inpatient cost</td>
<td>N mean</td>
<td>% inpatient cost</td>
<td>N mean</td>
<td>% inpatient cost</td>
<td></td>
</tr>
<tr>
<td>HSCT (29)</td>
<td>18</td>
<td>24.676</td>
<td>81%</td>
<td>10</td>
<td>23.323</td>
<td>52%</td>
<td>11</td>
<td>10.760</td>
<td>67%</td>
<td>9</td>
<td>11.154</td>
<td>73%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>35.915</td>
<td>82%</td>
<td>20</td>
<td>54.147</td>
<td>38%</td>
<td>10</td>
<td>17.006</td>
<td>68%</td>
<td>18</td>
<td>10.125</td>
<td>64%</td>
<td></td>
</tr>
<tr>
<td>Non-HSCT (87)</td>
<td>21</td>
<td>24.146</td>
<td>81%</td>
<td>10</td>
<td>23.323</td>
<td>67%</td>
<td>11</td>
<td>10.760</td>
<td>71%</td>
<td>9</td>
<td>11.154</td>
<td>73%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>35.915</td>
<td>82%</td>
<td>20</td>
<td>54.147</td>
<td>38%</td>
<td>10</td>
<td>17.006</td>
<td>68%</td>
<td>18</td>
<td>10.125</td>
<td>64%</td>
<td></td>
</tr>
</tbody>
</table>
Summary/Conclusions: The results of this study inform the magnitude of cost in Germany associated with adult rALL patients with or without an HSCT after relapse. The cost estimates provide a benchmark against which new treatment options for rALL can be compared. For future studies, it would be important to determine the magnitude of benefit such as long-term survival and other health consequences associated with HSCT as well.

PB1634

RETROSPECTIVE STUDY OF ADULT ALL IN MEXICO CITY: FIRST REPORT OF THE WORKING GROUP ON ACUTE LEUKEMIA

Background: The prognosis of adult acute lymphoblastic leukemia (ALL) is dire, with a long-term survival of 40-50%. This disease entity is probably more frequent in the Latino population. Several studies have reported a worse prognosis in Hispanics with ALL as well as a greater incidence of the Ph-like genetic signature; however, the data is inconclusive in the Mexican population and there are no existing large multicenter series of ALL patients in Mexico that analyze survival.

Aims: The aim of this study was to describe the incidence, clinical and biological characteristics as well as the survival of ALL patients in 5 referral hospitals in Mexico City.

Methods: A working group known as the Grupo de Trabajo de Leucemia Aguda (GTLA), was created as a result of an initiative of the Mexican Group for the Study of Hematology (Agrupación Mexicana para el Estudio de la Hematología) to promote acute leukemia research in Mexico. This is the first report of the GTLA which includes 5 referral hospitals in Mexico City. A retrospective, multicenter descriptive study of adult ALL patients treated between 2009 and 2015 was conducted.

Results: We included 559 adults in 5 centers in Mexico City. Their median age was 28 years (14-81): adolescents and young adults (AYA) 67.3%; adults 24.7% and elderly adults 8.1%. Tumor lysis syndrome was detected in 9.8% of patients. Cytogenetic information was unavailable in 45% of cases due to lack of access or growth in metaphase. Among cases that could be analyzed, a normal karyotype was the most frequent (70.5%), followed by Ph+ (16.7%). Patients were considered high-risk in 52.1% cases. The most frequently used drug protocol was Hyper-CVAD, in 47% of cases. Complete remission (CR) was achieved in 67.1% of patients, and 18% required a second cycle for CR, while 13% were primarily refractory. A mortality rate during induction was registered as 10.6%, and there were 11.4% deaths while in CR. Among patients in CR, 59.1% relapsed. At the time of analysis, 26.7% of patients were alive, with a median OS of 12.97 months and a DFS of 16 months. Only 5.7% were able to reach a second complete remission (≥CR2) and 12.5% in 18 patients received an autologous hematopoietic stem cell transplant (AlloHCT). OS at 3 years was 22.1% and by age group: AYA 25.7%, adults 17.4% and elderly adults 0% (p=0.0001). On multivariate analysis, significant risk factors for OS were the age group, ECOG, the presence of the tumor lysis syndrome and liver function test abnormalities while protective factors included earlier CR and AlloHCT.

Summary/Conclusions: Outcomes are poor in adult ALL patients treated in these referral centers in Mexico City. This may be explained by the high incidence of AYA patients and the low frequency with which they are treated with regimens containing L-asparaginase. The incidence of the Philadelphia chromosome is lower than reported, which could be due to a real difference between populations or due to aspects related to cytogenetic techniques. Based on these results, the GTLA’s objectives will be: to standardize diagnostic testing (immunophenotype and cytogenetics), improve early CR rates, standardize support care to decrease deaths during induction as well as treatment-related deaths, and increase the percentage of patients treated with AlloHCT. Studies to determine the prevalence of the Ph-like genetic signature will be of great relevance in our population.

ClinicalTrials.gov Identifier: NCT029909104TRIAL

PB1635

IMPACT OF DISEASE STATUS ON OUTCOMES OF ALOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REFRACTORY AND RELAPSED ACUTE LYMPHOBlastic LEUKEMI

J. Cao1, X. Zhu1, A. Sun1, H. Qiu1, Z. Jin1, M. Miao1, D. Wu1,2*, X. Tang1,2,3*

1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background: Refractory or relapse remains a major obstacle in improving outcomes of patients with acute lymphoblastic leukemia (ALL). And allogeneic hematopoietic stem cell transplant (allo-HSCT) was the only curative treatment option for these patients. However, whether an allo-HSCT was performed in status of advanced stage or in setting of remission after salvage chemotherapy, there is no standard of care.

Aims: To evaluate the impact of disease status on the outcomes of allo-HSCT in the treatment of patients with refractory and relapsed ALL.

Methods: 92 patients with refractory and relapsed ALL, including 19 cases in advanced stage (nonremission, NR) and 33 cases in more than or equal to second complete remission (≥CR2), received allo-HSCT after myeloablative conditioning regimen in our department.

Results: 51 patients engrafted successfully. The transplantation-related mortality (TRM) rate of NR and ≥CR2 was 10.5% vs 12.1% (P=0.815). The incidence of aGVHD was 52.6% vs 57.6% (P=0.730), including 42.1% vs 33.3% (P=0.527) with mild (grade I-II) and 10.5% vs 24.3% (P=0.399) with severe (grade III-IV) aGVHD. The incidence of cGVHD was similar also (41.6% vs 57.9%, P=0.660). With a median follow-up of 12(1.8-44.5) months, the cumulative relapse rate of NR and ≥CR2 was 47% vs 34.3% (P=0.426) respectively. The estimated 2 year overall survival (OS) and 2 year leukemia-free survival (LFS) rate were 42.6% vs 45.7% (P=0.487) and 46.3% vs 46.2% (P=0.571) respectively. Multivariate Analysis results showed that cGVHD was independent favorable risk factor for OS and LFS of R/R ALL. For relapsed patients, OS was significantly better with first CR duration≥6 month and time to transplants ≥2 months.

Summary/Conclusions: Allo-HSCT is an effective salvage treatment option for patients with refractory and relapsed ALL. Our retrospective analysis showed that R/R ALL with different status prior transplant had similar outcome post transplantation.

PB1636

THE FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF IKZF1 DELETIONS IN ADULT PH-POSITIVE AND PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED IN RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA STUDIES

G. Baskhava1, B. Biderman1, O. Gavvin1, K. Zarubina1, I. Lukyanova1, E. Stepanova1, V. Troitskaya1, A. Sudanko1, E. Parovichnikova1

1Hematological Research Center under the Ministry of Health, Moscow, Russian Federation

Background: The incidence of IKZF1 gene deletions is approximately 20% in adult patients with BCR-ABL1-negative B-cell ALL and 70–80% in BCR-ABL1-positive ALL. These mutations are associated with poor prognosis in patients with Ph-negative ALL, but not in patients with Ph-positive ALL, suggesting that IKZF1 deletions may be more prognostically valuable in patients with Ph-negative ALL.

Aims: To evaluate the frequency and prognostic impact of mutation status of IKZF1 in patients with de novo BCR-ABL1-negative and BCR-ABL1-positive B-cell acute lymphoblastic leukemia.

Methods: The study included 149 adult patients (median age 27, range 17–66; m:f=15:21) with newly diagnosed BCR-ABL1- neg B-cell ALL and 15 patients (median age 34 years, range 22–68; m:f=6:9) with BCR-ABL1- pos B-cell ALL, who were enrolled in Russian acute lymphoblastic leukemia (RALL) - 2009 [ClinicalTrials.gov public site; NCT01193893] and RALL-2012 protocols since Feb 2010 till Sep 2016 and Aug 2009 till Feb 2017, respectively. Intragenic deletions of IKZF1 were detected using breakpoint-specific fluorescent cent multiplex polymerase chain reaction according to the procedure described by [Aurelie Caye et al, Haematologica, 2013]. DNA for PCR was extracted from leukemia cells of frozen bone marrow samples.

Results: The IKZF1 deletions were detected in 7 (47%) of 15 patients with BCR-ABL1- pos ALL (3 cases with del 4-7 (43%), 2 – del 2-7 (28%), 1 – del 2a-8 and 1 – del 4-8 (14%)). The median follow-up time in 15 patients was 18 months (range: 4-79 month). Five patients died (33%) after relapse or progression of the disease, and 10 patients are alive. Overall survival (OS) for BCR-ABL1- pos B-cell ALL patients with IKZF1 mutations and without was 37.5%, and 57,1% (p=0.77), relapse - free survival (RFS) - 25% and 33.3% (p=0.88), respectively. In patients with BCR-ABL1- neg ALL the IKZF1 deletions were revealed in 8 (22%) of 36 patients (4 cases with del 4-7 (50%), 2 - del 2-7 (25%), 1 – del 2-8 (12.5%) and 1 in patient all types of deletions were determined (del 4-7, del 4-8, del 2-7, del 2-8)). The median follow-up time in 36 patients was 22 months (range: 0.5-84 month). 4 patients died of the disease (11%) and 2 of infections, 30 patients are alive. OS for patients with BCR-ABL1- neg ALL with IKZF1 mutations and without was 100% and 60.2% (p=0.77), RFS - 75% and 40.2% (p=0.74), respectively. IKZF1 mutations seemed to be of poor prognosis for BCR-ABL1-
pos ALL and, on the contrary, more favorable for BCR-ABL1- neg ALL, though not statistically significant. Having or not IKZF1 mutations, all BCR-ABL1- pos ALL patients are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Regarding BCR-ABL1-neg ALL: though the group of patients is small, we can suggest that IKZF1 mutation did not appear to influence survival due to different chemotherapy principal in RALL -- 2009 -- non-intensive but not-interruptive therapy with low numbers of HSCT.

Summary/Conclusions: Our results show that GMALL-based protocol yields good overall survival in adults patients in a low income country, despite major adaptations. On the other hand, overall survival of AYA patients treated with BFM-based protocol was surprisingly poor, specially because of ineffective intensive but not-interruptive therapy with low numbers of HSCT.

Background: Despite being the most common childhood cancer, nearly one half of ALL cases occurs in adults. Recently, it has been suggested that more intensive protocols may improve survival in adolescents and young adults (AYA).

Aims: Compare results of patients treated with BFM-based protocol to those treated with GMALL-based protocol, in a developing country.

Methods: This is a single center retrospective study which included all newly diagnosed adult ALL patients admitted between May/2012 and October/2016. Initially, patients aged 18-39 years (AYA group) were treated with BFM ALL 2009-based protocol and those aged 40-59 years were treated with GMALL 2003-based protocol. Since September 2013, because of high toxicity, only patients under 30 years were eligible for BFM-based treatment. Major adaptations were: (1) native E. coli l-asparaginase was substituted for peg-asparaginase, and (2) GMALL irradiation therapy was postponed to maintenance phase. BCR/ABL1 positive patients received standard chemotherapy plus Imatinib. Negative MRD was defined as <0.01% by flow cytometry. Overall survival was estimated by Kaplan-Meier method. Competing risk analysis was carried out for cumulative incidence of death in CR1 or not in CR1. This study was approved by local Ethics Committee.

Results: Thirty five patients were included, 21 of them started BFM-based treatment and 14 started GMALL-based protocol. During the first three months, 7 patients migrated from BFM to GMALL-based treatment because of toxicity and were analyzed separately. Median age was 21 years (18-38) for BFM-based group, 44 years (30-57) for GMALL-based, and 33 years (21-38) for de-escalated. Male predominance was observed (71%), not different between groups. T-phenotype was more frequent than expected, representing 50% of BFM-based, 50% of GMALL-based and 29% of de-escalated groups. BCR/ABL1 was detected in 14% of BFM-based, 23% of GMALL-based and 14% of de-escalated groups (p=0.85). Seven patients (2 BFM and 5 GMALL) underwent allogeneic stem cell transplantation in first remission. Of all 35 patients, 31 achieved complete remission after first induction phase. With median follow-up of 18 months, 1-year overall survival (OS) was 60% for all patients (39% for BFM-based, 75% for GMALL-based and 86% for de-escalated groups – p=0.04; BFM-based versus other protocols). Cumulative incidence (CI) of death in first complete remission (CR1) at 12 months was 18%, not different between groups. CI of death at 12 months in non-CR1 (relapsed or refractory) patients was 39% for BFM-based, 7% for GMALL-based and 0% for de-escalated groups – BFM-based versus other HR 2.6; p=0.13. Among 31 patients who achieved CR1, MRD data was available for 26 (74%) of these at the end of first induction. OS at 18 months for CR1 patients with negative MDR after first induction was 74%, compared to 52% in MRD+ (Figure 1).

Summary/Conclusions: Our results show that GMALL-based protocol yields significant association between other C1A1 and Fok1 gene polymorphisms and development of treatment-related skeletal complications in children with acute lymphoblastic leukemia.

Background: Cure rates for childhood acute lymphoblastic leukemia (ALL) have approached 90% with therapeutic advances over the last several decades. Many treatment related long-term complications including impaired physical growth, neurocognitive dysfunction, emotional and occupational difficulties, cardiac abnormalities, hypertension, secondary neoplasms, decreased bone mineral density (BMD) and osteonecrosis have been observed as the number of survivors increased. Bone infiltration of leukemic cells, corticosteroid exposure, poor nutrition, low vitamin D levels, poor muscle mass, genetic predispositions contribute to the development or worsening of bone pathologies during therapy that may result in osteoporosis, fracture and osteonecrosis.

Aims: In this study, we aimed to investigate whether vitamin D receptor and collagen protein gene polymorphisms, which are important in bone mineral and matrix formation, have effects on bone turnover in patients with ALL.

Methods: Fifty children with ALL who were diagnosed and treated with BFM-95 protocol (25 girls, 25 boys) between 1998-2008 and 96 healthy children at Dokuz Eylul University Medical School were enrolled in this study. Polymorphisms of vitamin D receptor (VDR) Fok1 gene and the collagen Col1A1 gene were studied from peripheral blood samples of the patients that were collected before initiation of chemotherapy protocol. After genomic DNA extraction, VDR Fok1 gene and colloidal Col1A1 gene polymorphisms were analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The data including age, sex, leukemia risk group, presence or absence of relapse were all noted. Bone marrow density and markers of bone metabolism including serum calcium, phosphorus, serum alkaline phosphatase, parathyroid hormone and 25-OH D vitamin levels were all screened before initiation of maintenance treatment.

Results: The distribution of Fok1 and Col1A1 gene polymorphisms was similar both in the patient group and healthy control group. The frequency of gene polymorphisms in the patient group were 8% F, 46%FF and 46%FF for the Fok1 genotype and 62%GG, 26%GT and 12%TT for the Col1A1 genotype. Out of 50 patients, 16 (32%) patients were found to have skeletal diseases like osteopenia (16%), osteoporosis (12%) and osteonecrosis (8%). The Fok1 genotype and Col1A1 genotype polymorphisms were similar in both group of patients with or without skeletal diseases. The frequency of osteopenia was significantly higher in the male group (p=0.049) and the frequency of osteonecrosis was significantly higher in patients older than 10 years old (p=0.001). There was no significant association between Fok1 and Col1A1 gene polymorphisms and leukemia subtype, risk group or relapse rate.

Summary/Conclusions: It has recently become more important to prevent treatment-related complications that we see as a consequence of high cure rates in ALL. In this context we have investigated whether there is a relationship between gene polymorphisms and treatment related skeletal diseases like...
outcomes, osteoporosis and osteonecrosis. We have not detected a significant association between Fok I and Col1A1 gene polymorphisms and frequency of skeletal complications. Studies investigating the possible underlying genetic susceptibilities to certain complications are important not only for better management of complications but also for development of new individual patient-specific treatment modalities.

PB1639  OUTCOME OF ADOLESCENTS AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC PROTOCOL: MONOCENTRIC STUDY

I. Frikha1,*, M. Medhaffer1, S. Hedjji1, R. Kharrat1, M. Chaari2, G. Kassar1, M. Ghribi1, H. Bellaâ1, L. Ben Amor1, F. Kallek1, C. Kallel1, M. Elbourn1
1Hematology, 2Laboratory of Hematology, Hedi Chaker Hospital, Sfax, Tunisia

Background: Several retrospective studies have confirmed that adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) treated with pediatric protocols have better outcomes than similarly aged patients treated with adult protocols.

Aims: We reported results and feasibility of a pediatric-based protocol (EORTC 58951) in adolescents and young adults.

Methods: From January 2000 to December 2015, 72 patients aged 16 to 30 years with newly diagnosed ALL were treated, in the department of clinical hematology of Hedi Chaker Hospital, according to the pediatric protocol EORTC 58951. Further leukemia characteristics (Sex, White Blood cell count, Blasts phenotype, Cytogenetic results), we studied the protocol results: response to therapy, incidence of neurologic complications, as well as hematologic, psychological and social complications.

Results: Seventy two AYAs ALL were treated with the pediatric protocol. The patients were 45 males and 27 females (SR=1.68). A WBC>100 G/L was noted in 32% of the patients at diagnosis. Twenty two patients (30%) were PPR. Nine patients (13%) were treated according AR1 arm, 39 patients (54%) according AR2 arm and 24 patients (33%) according VHR arm induction. CR rate was 57% after one course and 94% after 2 courses. Induction death was noted in 3% and post-induction death was noted in 13%. Twenty four patients were given remission induction protocol; 5 patients were eligible for allelogeneic stem cell transplantation (SCT), among them 15 patients had a familial donor and 10 patients were allograft (42%) and only 4 patients still in CR (2 patients died by GVH and 4 patients relapsed). Relapse was observed in 22 patients (32%), among them 12 during the first year of treatment. The median follow up was 101 months (8.4 years). The five years OS and EFS were respectively 50 and 50.4%.

Summary/Conclusions: The results of this pediatric based study show that response to therapy and prognostic in adolescent and young adults were better than those treated with adult protocols and tolerability of chemotherapy is acceptable. However OS and EFS, better than adult ALL treated by adult protocol (OS:14%, EFS=14%:local study) was not satisfactory because the high toxic mortality rate.

PB1640  SEVERE PSYCHIATRIC DISTURBANCES DURING THERAPY IN PEDIATRIC ALL

O. Tsiopu1,*, N. Tourkanton1, A. Kattamis1
1Hematology-Oncology Unit, 1st Department of Pediatrics, “Aghia Sofia” Children’s Hospital, University of Athens, Athens, Greece

Background: Psychiatric disturbances are not uncommon in patients with cancer. Their pathogenetic mechanisms are variable and comprise consequences of the therapy, underlying disease, as well as personality characteristics. These disturbances are frequently associated with the use of corticosteroids, which is an essential component of the treatment for children and adolescents with Acute Lymphoblastic Leukemia (ALL).

Aims: This study aimed to investigate the incidence of severe psychiatric disturbances in patients treated for childhood ALL.

Methods: We report the results of a retrospective analysis of the incidence of severe psychiatric disturbances, defined as behavioral and psychological changes which lead to dangerous or erratic behaviors requiring use of psychiatric medications, in patients treated for childhood ALL. All patients were treated in a single institution and followed the same chemotherapy protocol, according to which, corticosteroids are administered initially during the “induction” phase and then in multiple subsequent pulses.

Results: Seventy patients (mean age:4.04 years old, range:1-16) were treated in two protocols: Prot. I and Prot. II. During the observation period, 9 (12.8%) children (6 boys, 3 girls) of mean age 12.3 years old (range: 10-15) experienced psychiatric - neurological symptoms and/or mental disorders, which included major depressive disorder, withdrawal, first psychotic episode, disorientation, visual hallucinations, mood swings and behavioral outbursts. In 27 patients (38.6%), 6 at the Intermediate Risk group and 2 at the High Risk group) experienced disturbances during the reinduction phase, while treated with dexamethasone at 10 mg/m2 for 21 days. Two patients of the High Risk group presented with behavioral effects one during the second HR2 block. Patients who had symptoms of major depression were treated with either fluoxetine, or/and risperidone, or/ and escitalopram for a period of time ranging from 5 days to 6 months. One patient experienced a psychotic episode during reinduction (Prot.II,phase 2) with aggression and violence towards others and had to be treated immediately with intramuscularly haloperidol and diazepam. All of our patients are alive and in remission, 7 off therapy for a period of 3 years, and 2 receiving maintenance therapy. Statistical analysis showed that severe psychiatric disturbances were observed more frequently in older patients and they were more common with the administration of dexamethasone than with prednisolone.

Summary/Conclusions: Severe psychiatric disturbances are not infrequent in adolescents and young adults receiving therapy for ALL. Awareness of this complication, appropriate parental education for identifying early signs, and prompt therapeutic interventions are essential for optimal outcome. Further studies are required for identifying patients at risk and best use of chemotherapeutic agents and of dexamethasone.

PB1642  ASSESSMENT OF DEPRESSION AND SELF-CONCEPTION IN CHILDREN WITH ALL-TREATMENT

G. Aydogan1,*, N. Kovâkî1, F. Akici1, Z. Saliçgül1, H. Sen1, N. Ozdemir1, C. Özyar1, A. Aytac2
1Pediatric Hematology, Kanuni Sultan Suleyman Education And Research Hospital, Istanbul, Turkey

Background: Leukemia is the most prevalent pediatric malignancy with acute lymphoblastic leukemia (ALL) being the most common accounting for 75% of leukemia cases with about 24000 newly diagnosed children each year worldwide. Treatment of ALL requires long course chemotherapy ranging up to 48 weeks.

Aims: The study aimed to assess children with leukemia and healthy children. The study was conducted in 245 children with leukemia and 25 healthy children aged 9-16 years. Children with leukemia were evaluated at the time of diagnosis, end of induction treatment and end of consolidation treatment, just before the maintenance treatment, respectively. Psychological data including depression and self-conception were assessed by Child Depression Scale and Self-Concept Scale. The changes in psychological conditions due to long stay at the hospital were investigated. Demographic data included age, sex, school achievement, parents education, socioeconomic condition, loss of first degree relatives.

Methods: The study included children with leukemia and 25 healthy children aged 9-16 years. Children with leukemia were evaluated at the time of diagnosis, end of induction treatment and end of consolidation treatment, just before the maintenance treatment, respectively. Psychological data including depression and self-conception were assessed by Child Depression Scale and Self-Concept Scale. The changes in psychological conditions due to long stay at the hospital were investigated. Demographic data included age, sex, school achievement, parents education, socioeconomic condition, loss of first degree relatives.

Results: The prevalence of depressive disorder in children with leukemia at the end of induction and at the end of consolidation treatment was significantly increased. Self-Concept Scales were found lower in these patients.

Summary/Conclusions: The children with ALL receive long course chemotherapy and become distanced from their family, school and milieu and as a result, these patients are vulnerable to psychological problems. They are more depressive and have lower self-conception comparing to healthy children. It is important to provide psychological support to these children in addition to their chemotherapy.
Department of Clinical Institute Fundeni during 2010-2017 and received chemotherapy according to protocol ALL BFM 1995 and ALL BFM 2002, established after framing in the risk group.

Results: Over a period of 8 years in our department 280 patients with ALL received L-asparaginase in the induction phase. Neurological manifestation suggestive for bleeding or thrombotic events occurred in 9/280 (3.21%) patients. 2 patients were treated according to protocol ALL BFM 1995 and 7 patients were treated according to protocol ALL BFM 2002. M/F ratio was 4/5. Patients had an interval between 3 and 15 years (median age 9 years). All patients had thrombotic events after starting administration of L-asparaginase during induction. Most had clinical symptoms after the fourth dose of L-Asparaginase. Clinical manifestations were accompanied by hypofibrinogenemia (<100 mg/dl) especially in patients who experienced bleeding. The patients who experienced thrombosis had decreased levels of antithrombin III, protein C and increased D dimer levels.

The diagnosis of cerebral venous sinus thrombosis (CVST) is typically based on clinical suspicion and imaging confirmation. At 5 of these patients neuroimaging tests (CT/MRI) documented CVST after developing neurological symptoms; one of the patients suffered major complication (extended brain injury) and died. All patients with ALL and thrombotic events received low-molecular weight heparin (LMWH) for 3 to 6 months. A follow-up CT or MRI at 3 to 6 months after diagnosis was made to assess for recanalization of the occluded cortical veins/sinus. Survival in the patients with CVST was 84.61%, 1 patient with ALL and hemostasis alteration had intracerebral hemorrhage (ICH) with rapid progressive neurological deterioration to death. 1 patient had pulmonary embolism associated with clotting disorders and severe sepsis and he died. 2 patients had clinical manifestation (headache, confusion and seizures) and clotting disorders (decreased levels of antithrombin III, protein C, fibrinogen and increased D dimer levels), but with normal brain imaging. Survival in the cohort was 77.7%.

Summary/Conclusions: Thrombotic events have occurred in all patients during induction. Clinical manifestation were depending on size, duration and thrombosis, from headaches, seizures or focal neurological deficits. Severe sepsis association was an additionally risk factor for thrombotic and bleeding events in patients with ALL. Screening for genetic prothrombotic defects diagnosis prior to initiating chemotherapy may represent a way to reduce thrombotic or bleeding events and appropriate management of hemostasis disorders that occur during the treatment.

PB1643

INCIDENCE AND SURVIVAL OF CHILDHOOD LEUKEMIA IN ARMENIA: A POPULATION-BASED ANALYSIS

M. Tatulyan1, S. Daghashyan1, L. Krmoyan1, A. Zakaryan1, L. Vagharshakyan1, L. Sahakyan1

1Pediatric hematology/oncology department, Hematology Center after prof. Yeolyan, Yerevan, Armenia.

Background: Leukaemia is the most common cancer in children. Childhood leukaemia incidence and survival varies globally, and this could be associated with the different risk factors, genetics, and improvement in diagnosis and treatment. Armenia is considered to be a mono ethnic nation.

Aims: We aimed to quantify the incidence of and mortality from acute leukaemias among children population in Armenia and their variation with gender, age, year of diagnosis.

Methods: In this work we included children diagnosed with de novo acute leukaemia, 0–18 years of age from 2006 to 2016. The initial data for this survey have been derived from ambulance/dispensary cards, hospitalization journals, and clinical data from the Registry of Blood Diseases at the R.Yeolyan Hematology Center, Yerevan, Armenia. The data has been supplemented by the data from the Registry of Oncological Diseases of the V. Fanarjyan NCO, as well as from death certificates. The demographic data has been obtained from the National Statistics Board of Republic of Armenia. The obtained data has been statistically analyzed using EPI INFO-2002 program.

Results: A total of 277 cases of childhood acute leukaemia were identified, 174 (62.2%) were male. The overall incidence of leukaemia was 3.4 per 100 000 children-years. The higher incidence rates were noted in 2007, 2012, 2010 (accordingly 4.0, 4.0 and 3.9), and the lower rates in 2011, 2014, 2009 (accordingly 2.4, 2.4 and 2.9). There are three registered regions in Armenia— Lori, Vayots Dzor and Tavush with higher incidence rate (respectively 0.020, 0.026 and 0.030 per 100 000 children). 83.8% of patients whom are alive. The 5-year survival rate was 72%, 100%, and 100% among children diagnosed at 3–7, 7–13, and 13–18 years of age, respectively. The study indicated that the children diagnosed between ages of 3 and above had the lowest risk of mortality and higher survival rates.

Summary/Conclusions: This is the first general population study to describe the incidence of and mortality from childhood acute leukaemias in Armenia during 2006-2016. It forms the basis for quality assessment of acute leukaemia treatment in Armenia and offers a unique opportunity for population-based research. Age at diagnosis remained to be a crucial determinant of the survival variation of various acute leukaemia patients, after adjusting for sex, race, therapy, primary tumor sites, immunophenotype, and year of diagnosis. Further research is warranted to dissect the effects of age-dependent biological and environmental processes on this association.

PB1644

LONG-TERM SURVIVAL OUTCOMES OF ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBlastic LEUKEMIA PATIENTS TREATED WITH IMATINIB OR DASATINIB

G. Vahdati1, A. R. Jeong1, Z. Ghaznavi2, W. Hsiao2, V. Tulipul1, M. Akinari3

1Department of Internal Medicine, LAC+USC Medical Center, 2Keck School of Medicine, University of Southern California, 3Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, United States

Background: Acute lymphoblastic leukemia (ALL) with positive Philadelphia chromosome (Ph+) is a unique subset of ALL with poor prognosis. Recent studies have demonstrated improved survival outcomes in adult patients with Ph+ ALL with the use of tyrosine kinase inhibitors (TKIs) along with chemotherapy. However, there are very few studies that describe the comparative effectiveness of various TKIs in this patient population.

Aims: To characterize long-term survival outcomes including leukemia-free survival (LFS) and overall survival (OS) for Ph+ adult ALL patients treated with imatinib versus dasatinib.

Methods: Retrospective chart review was conducted at our institution. Patients >= 18 years old and diagnosed with Ph+ ALL between 2002 and 2015 were included. Analysis was done by intent to treat for patients initiated with imatinib or dasatinib at the time of Ph+ diagnosis. The primary endpoints were 2-year LFS and OS and secondary endpoints were complete molecular response (CMR; BCR-ABL1/ABL1 ratio < 0.01% by PCR) and major molecular response (MMR; BCR-ABL1/ABL1 ratio < 0.1% by PCR).

Results: Among 46 patients with Ph+ ALL, 74% (n=34) were in imatinib group and 17% (n=8) in dasatinib group. 9% were treated with other or no TKI (1 ponatinib and 3 with no TKI). Thirty-eight percent (n=13) of patients in imatinib group and 13% (n=1) in dasatinib group switched to a different TKI due to adverse effects or failure to achieve remission. There was a trend towards increased 2-year LFS for patients on dasatinib (HR 0.40, 95% CI: 0.14-0.11, p=0.09) and no difference in 2-year mortality (HR 1.00 95%CI: 0.46-2.17, p=0.99). Molecular response data was available for 61% (n=28) of patients; 75% of imatinib group achieved CMR or MMR (65% CMR) compared to 76% of dasatinib group (63% CMR) (p=0.98) (Figure 1).

Figure 1.

Summary/Conclusions: In conclusion, dasatinib, compared to imatinib, in combination with chemotherapy, may prolong LFS in patients with Ph+ ALL and may be a suitable first-line agent. Large, randomized studies are needed to better define a detailed treatment protocol in this high-risk patient population.

PB1645

OUTCOME OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A MIXED COHORT OF PEDIATRIC AND ADULT PATIENTS WITH KMT2A-AFF1 ACUTE LYMPHOBLASTIC LEUKEMIA

T. L. Gindina1, N. Mamea1, O. Paina1, O. Pirgova1, O. Slesarchuk1, Y. Gudzhnikova1, A. Alyanskiy1, S. Bondarenko1, L. Zubarovskyaya1, B. Afanasev1

1R.M. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Department of Hematology, Transfusiology and Center for the Study of Blood Diseases, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, United States

Background: Acute lymphoblastic leukemia with poor-risk translocation t(4;11)(q21;q23)/KMT2A-AFF1 occurs in all age groups with a clear dominance in children, especially up to 1 year. To date, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered to be potentially curative treatment in high-risk acute leukemia patients, including the above-mentioned.

Aims: To evaluate the prognostic impact of the different clinical and cytogenetic characteristics on the results of allogeneic hematopoietic stem cell transplantation in KMT2A-AFF1 acute lymphoblastic leukemia patients.

Methods: Retrospective analysis of treatment results was performed for a mixed cohort of the patients with KMT2A-AFF1 ALL who received allo-HSCT, including haploidentical one at our University over 2008 to 2015. Twenty-one patients (12 females and 9 males aged from 3 months to 48 years; median 18.9 years) were examined.

Figure 1.
Results: Eight of 21 (38%) patients exhibited an isolated (t(4;11)) translocation, additional chromosome abnormalities (ACA) were revealed in 11 (52%) patients, including 8 (42%) subjects with 3 and more chromosome aberrations. In univariate analysis, significance was shown for clinical stage at HSCT (1st remission vs other stages, 75% vs 0%; p<0.001 for OS; 58% vs 0%, p<0.001 for EFS), complex chromosomal aberrations (<3 abnormalities vs ≥3 abnormalities, 58% vs 13%, p=0.04 for OS; 46% vs 0%, p=0.04 for EFS). According to multivariate analysis, the clinical stage at HSCT (HR 26.8, 95% CI 3.28-218.80; p=0.002 for OS; HR 11.18, 95% CI 2.92-42.80 p=0.0004 for EFS) was only independent prognostic factor for clinical outcome.

Summary/Conclusions: The study has shown the stage of disease at the moment of allo-HSCT to be independent prognostic factor in a mixed cohort of KMT2A-REFI ALL patients treated with HSCT. The good results of allo-HSCT can be obtained using a haploidentical transplantation from parents that removes the problem of searching the HLA-matched donors in the Registers and, therefore, greatly simplifies the therapy.

PB1646
DERMATOLOGIC COMPLICATIONS ASSOCIATED WITH TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ACUTE LEUKEMIA
K. Zarubina¹, O. Gavrilina¹, E. Parovichnikova¹, V. Troitskaya¹, A. Sokolov¹, E. Chelysheva¹, A. Turkina¹, E. Usikova¹, A. Abramova¹, G. Baskhaeva¹, I. Lukyanova¹, V. Savchenko¹
¹Department of chemotherapy of hemoblastosis and depression of hemopoiesis, National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Despite of targeted effects of tyrosine kinase inhibitors (TKIs), they are not absolutely selective in relation to their target. Hair pigmentation is regulated by factors including the interaction of the ligand stem cell factor (SCF) with its class III receptor tyrosine kinase, c-kit. Hair depigmentation observed during therapy TKI with action directed against class III receptor tyrosine kinase (PDGFRα, PDGFRβ, C-KIT, CSF1R, FLT3). But other TKI such as BCR/Abl TKI can also inhibit class III receptor tyrosine kinase without non-targeted actions. Skin reactions are the most common observed during the epidermal growth factor-receptor tyrosine kinase inhibitor treatment.

Aims: To describe the spectrum of skin and hair reactions in patients with acute leukemias (Ph+/Ph- acute lymphoblastic leukemia and acute myeloid leukemia) during the treatment by second-generation TKI (bosutinib), third-generation TKI (ponatinib) and multikinase inhibitor (sorafenib).

Methods: From 2016 to March 2017 6 patients (pts), age 24-53 (median 29,5), 1 male, 5 female, received second or third line therapy with target tyrosine kinase inhibitors in National Research Center for Hematology. One pt (pt 1) with AML had been receiving chemotherapy (decitabine, cytarabine, irinotecan) with continuous treatment of sorafenib. Three pts who have taken second-generation TKI (bosutinib), third-generation TKI (ponatinib) and multikinase inhibitor (sorafenib) they were not serious. Temporarily dose reduction or interrupting of TKI therapy led to complete regression of dermatological side effects, temporarily discontinuation of TKI therapy was required only in three (50%) cases. In the other cases the treatment was continued. The therapy was restarted in all pts with temporarily discontinuation after skin lesions disappearing (Figure 1).

Summary/Conclusions: Dermatological adverse events in acute leukemia pts who have taken second-generation TKI (bosutinib), third-generation TKI (ponatinib) and multikinase inhibitor sorafenib they were not serious. Temporarily dose reduction or interrupting of TKI therapy led to complete regression of skin lesions. Restarting TKI at full dose did not lead to dermatological adverse reactions reappearing. Moreover, the temporary cancellation did not reduce its effectiveness.

Figure 1. Results: All of the 6 patients who had taken second-generation TKI (bosutinib), third-generation TKI (ponatinib) and multikinase inhibitor sorafenib developed dermatologic reactions (skin rash or grey hair). Generalized maculo-papular skin rash grade II evolved after two weeks of sorafenib treatment in pt 1. Both patients on ponatinib therapy developed localized maculo-papular skin rash grade I in pt 2 after 8 weeks of therapy. In pt 3 after 6 weeks of ponatinib treatment grey hair observed. Skin rash with pigmentation grade I evolved in pt 3 after 12 weeks of therapy. Pt 4 had grey hair after 12 weeks second-generation TKI (bosutinib) treatment. Palmoplantar erythrodysesthesia syndrome grade II and hair and total skin depigmentation were evolved after 2 weeks and after 4,5 months respectively observed during the ponatinib treatment. Pt 5 (with psoriasis anamnesis) Pt 6 developed localized maculo-papular skin rash grade I after 5 weeks of sorafenib treatment. Despite of all patients developed dermatological side effects, temporarily discontinuation of TKI therapy was required in only three (50%) cases. In the other cases the treatment was continued. The therapy was restarted in all pts with temporarily discontinuation after skin lesions disappearing (Figure 1).

Summary/Conclusions: Dermatological adverse events in acute leukemia pts who have taken second-generation TKI (bosutinib), third-generation TKI (ponatinib) and multikinase inhibitor sorafenib they were not serious. Temporarily dose reduction or interrupting of TKI therapy led to complete regression of skin lesions. Restarting TKI at full dose did not lead to dermatological adverse reactions reappearing. Moreover, the temporary cancellation did not reduce its effectiveness.
SEVERE HYPOFIBRINOGENEMIA ASSOCIATED WITH IMATINIB AND PREDNISONE THERAPY IN PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

M. Sciumè1,*, N. S. Fracchiolla1, G. Reda1, R. Cassin1, V. Mattiello1, A. Corteleezzi1
1Oncohematology Division, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation and University of Milan, Milan, Italy

Background: Hypofibrinogenemia associated to acute lymphoblastic leukemia (ALL) is rare and usually due to L-asparaginase. Consumption coagulopathy or therapy-related hematotoxicity are other possible explanations. Severe hypofibrinogenemia, not linked to the causes listed, was rarely reported and a role of steroid therapy on fibrinogen metabolism was suggested. Aims: Our aim was to identify the incidence of severe hypofibrinogenemia during induction phase in a cohort of consecutive ALL patients and to assess its impact on clinical decision-making.

Methods: In order to avoid confounding factor due to L-asparaginase, we revised our cohort of Philadelphia chromosome–positive (Ph+) ALL that we treated according to pediatric-type therapy program (imatinib, intensive chemotherapy without L-asparaginase) for patients aged 18-65 years and through LAL021-B protocol (imatinib, prednison) for patients ≤65 years. We retrospectively analyzed coagulation tests on admission and during induction therapy of all Ph+ALL patients diagnosed at our Institution from 2004.

Results: Twenty-one Ph+ALL were identified: 17 patients were younger than 65 years, while the remaining 4 patients had a median age of 74 years (66-76). No alteration of plasma fibrinogen during induction was observed in younger patients. Severe hypofibrinogenemia (≤100 mg/dl) was detected in 3 out of 4 Ph+ALL over 65 years. In these patients induction consisted of prednison 40 mg/dl and imatinib 1 to 45 and imatinib at the fixed dose of 800 mg/dl. On admission hemoglobin levels were ≤10 g/dl in all patients, leucocytes counts were 2×10⁹/L (blasts 15%), 8×10⁹/L (blasts 30%) and 18×10⁹/L (blasts 61%), while platelet count was reduced in 2 cases (6×10⁹/L and 6×10⁹/L). Coagulation tests were normal (fibrinogen median level 380 mg/dl). Severe hypofibrinogenemia developed between 6 and 15 days after beginning treatment and lasted between 4 and 48 days. Fibrinogen nadir ranged from 47 to 100 mg/dl (median 61 mg/dl); reduced plasma fibrinogen levels at functional tests were also confirmed to immunological assays. During fibrinogen nadir, D-dimer was positive in all patients, but stable compared to the outset. Antithrombin, coagulation factors, activated partial thromboplastin and prothrombin time, common liver function tests remained in a normal range; platelet counts showed a trend to normalization. Early clearance of peripheral blood blasts was observed and when hypofibrinogenemia appeared no blast cells were detectable. At the end of induction bone-marrow evaluation demonstrated the absence of BCR-ABL transcript by qualitative RT-PCR. There were no bleeding events and only one patient received a prophylactic transfusion of fresh-frozen plasma (10 ml/kg) for fibrinogen <50 mg/dl on two occasions. Normal fibrinogen levels (≥165 mg/dl) were recovered at the end of steroid therapy.

Summary/Conclusions: We observed severe hypofibrinogenemia in Ph+ALL patients older than 65 years treated with imatinib and high-doses steroid, while normal fibrinogen levels were detected in younger Ph+ALL during intensive chemotherapy plus imatinib. In our experience, hypofibrinogenemia was not associated to major bleeding events, although its clinical significance should be investigated in larger series. Fibrinogen may recognize multiple metabolic pathways, also unrelated to in vivo coagulation and fibrinolysis; the correspondence between steroid treatment and hypofibrinogenemia seems to suggest that glucocorticoids may alter some steps in fibrinogen kinetics and could be considered as a cause of acquired hypofibrinogenemia.

LATE EFFECTS OF CHEMORADIOTHERAPY ON THE ENDOCRINE SYSTEM IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

G. Aydogan1,*, S. Ettan1, F. Akci1, Z. Saliogiulu1, A. Akcay1, T. Akcay1, H. Sen1, N. Ozdemir1, C. Bayram1, A. Aydick1
1Pediatric Hematology, KANUNI SULTAN SULEYMAN EDUCATION AND RESEARCH HOSPITAL, Istanbul, Turkey

Background: Over the past four decades treatment of childhood acute lymphoblastic leukemia has been modified with the aim of achieving high survival rate while reducing the risk of the life threatening late-effects and promoting risk-based follow-up care of survivors.

Aims: The aim of our study is evaluation of late effects of chemotherapy and cranial radiotherapy on the endocrine system in children with acute lymphoblastic leukemia.

Methods: Forty-eight patients, who were diagnosed and treated for ALL between 1997-2007 in Istanbul Kanuni Sultan Suleyman Education and Research Hospital Pediatric Hematology-Oncology Clinic and have disease-free for at least 5 years after cessation of treatment, were evaluated prospectively. The study form included each patients age, gender, weight, height, target height, parental height, treatment protocol, stage of puberty, bone age, TSH, free T4, LH, FSH, estradiol or testosterone, IGF-1 and IGFBP-3 levels. Annual rate of growth was evaluated for each patient. The patients with inadequate growth rate and delayed bone age were subjected to growth hormone stimulation test with clonidine.

Results: Mean age of the patients was 14.4±2.85 (10.5-22.4) years. Thirty-one of patients had prophylactic cranial radiotherapy; five of them 18 Gy and twenty-six had 12 Gy CRT. Fifteen of the 48 patients were diagnosed with at least one endocrinological disorder. Six patients had lower height (<-2 SD), three patients had a body mass index >30kg/m². Bone age delayed in two patients. Four patients had IGF-1 value below <-2SD and two patients had inadequate levels of growth hormone. Tanner stage of the patients were appropriate for their ages except for one patient with hypergonadotrophic hipogonadism and one patient with pubertas precox. Subclinical hypothyroidism was detected in two patients.

Summary/Conclusions: Significant late effects may develop over time in children treated for ALL. For this reason long-term follow-up of these children is necessary. Because of the awareness of the late effects the treatment modified to reduce their impact on clinical decision-making.
Acute myeloid leukemia - Biology

PB1650

MUTATIONAL ANALYSIS OF 231 DE NOVO AML PATIENTS BELOW 60 YEARS WITH CURATIVE THERAPY

A. Folta1,*, I. Jeziskova1, D. Dvorakova1,2, N. Tom2, M. Culen1,2, Z. Kosarova2, J. Mayer1,2,4, Z. Racil1,2,4

1University Hospital Brno, 2Masaryk University, Brno, 3Institute of Hematology and Blood Transfusion, Prague, 4On behalf of CELL, Brno, 5University Hospital Pilsen, Pilsen, 6University Hospital Olomouc, Olomouc, 7University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

Background: Acute myeloid leukemia (AML) is an aggressive cancer disease of the myeloid lineage of blood cells, characterized by rapid growth of undifferentiated myeloid precursors. Analysis of the spectrum of somatic mutations in leukemic cells may help to improve the identification of individual prognostic subgroups of patients as well as to observe clonal evolution in the course of AML treatment.

Aims: The aim of the project is to identify somatic alterations in genes related to AML using next generation sequencing (NGS) in large cohort of AML patients from Czech Republic and to determine their frequency and mutual coexistence. Methods: The analyzed group consists of 231 de novo consecutively diagnosed AML patients with curative therapy below 60 years from five hematological centers. The NGS libraries are prepared from peripheral blood samples from diagnosis using ClearSeq AML panel (Agilent Technologies) and sequenced on MiSeq and NextSeq machines (Illumina). As positive are determined mutations with variant allele frequency (VAF) at least 2%

Results: At least one somatic mutation (median 2; range 0-6) was identified in 204 (88.3%) patients with de novo AML. In total, 526 recurrent mutations in 19 genes were identified. The most frequently mutated genes were: FLT3 91/231 (39.4%; from this FLT3-ITD 69/231 [29.9%] and FLT3-TKD 22/231 [9.5%]), NPM1 90/231 (39.0%; mutation type A 71/90 [78.9%], type B 11/90 [11.1%], other types 10/90 [10.0%]), DNMT3A 68/231 (29.4%; mutations in codon R882 49/68 [72.1%]), NRAS 51/231 (22.0%; the most frequent mutation G12D 17/51 [22.0%]; 11/51 patients [21.6%] contain more than one mutation in NRAS gene), IDH2 35/231 (15.2%) and CEBPA 35/231 (15.2%). The analysis also identified mutations in rarely mutated genes U2AF1, SF3B1, EZH2 and SETBP1 in 4/231 (1.7%), 4/231 (1.7%), 1/231 (0.4%) and 1/231 (0.4%) samples, respectively (Figure 1).

Summary/Conclusions: The results of mutational analysis of large cohort of AML patients show high heterogeneity of detected mutations. Surprisingly we have detected high percentage of patients with mutations in gene NRAS. Together with sequencing results from the time of remission/relapse/resistance of the disease, the data will enable to get more complex view on the development of AML in time.

Supported by Ministry of Health of the Czech Republic, grant nr. 15-25809A, and by project MUNIA/1106/2016. All rights reserved.

PB1651

INHIBITION OF LIN28B IMPAIRS LEUKEMIA CELL GROWTH AND METABOLISM IN ACUTE MYELOID LEUKEMIA

J. Zhou1,*, J.-Y. Chooi1, J.-Y. Qian1, S.-H. M. Toh1, T.Z. Tan1, P.S. Chong1, W.-J. Chng1

1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

Background: Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. 2. The relapse is postulated to be due to leukemia stem cells (LSCs), which is different from normal hematopoietic stem cells (HSCs). LIN28B is microRNA regulator and stem cell reprogramming factor. 3. Overexpression of LIN28B has been associated with advanced human malignancies and cancer stem cells (CSCs), including AML. However, the molecular mechanism by which LIN28B contributes to the development of AML remains largely elusive.

Aims: 1. To study the function role of LIN28B in cell proliferation, cell cycle and colony formation ability of AML cells. 2. To systematically dissect transcriptional signaling mediated by LIN28B on whole genome level. 3. To determine the key targets of LIN28B in AML. 4. To explore the function of LIN28B in AML in vivo.

Methods: 1. We modulated LIN28B expression in AML and non-leukemic cells and investigated functional consequences in cell proliferation, cell cycle and colony forming assays. 2. We performed a microarray-based analysis for LIN28B targeting cells and interrogated gene expression data with different bioinformatic tools. 3. AML mouse xenograft model was used to examine the in vivo function of LIN28B.

Results: We first showed that increased LIN28B expression was associated with worse survival in AML patients. We demonstrated that targeting LIN28B in AML cells resulted in cell cycle arrest, inhibition of cell proliferation and colony formation, which was induced by de-repression of let-7a miRNA. On the other hand, overexpression of LIN28B promoted cell proliferation. Mechanistic studies revealed that inhibition of LIN28B induces metabolic changes in AML cells. IGF2BP1 was confirmed to be a novel downstream target of LIN28B via let-7 miRNA. Notably, silencing LIN28B led to slow tumor growth in vivo.

Summary/Conclusions: In conclusion, these results uncover a novel mechanism of an important regulatory signaling, LIN28B/let-7/IGF2BP1, in leukemogenesis and provide a rationale to target this pathway as effective therapeutic strategy.

Figure 1. Distribution of gene mutations with VAF ≥2% in AML cohort. Each column represents one patient (n=231). Each row represents one gene described on left, on the right is shown the number of patients with mutations in rarely mutated genes

Figure 1. Results: Patients were segregated in 2 groups: Relapse patients (Group 1: 32.2%, 11/34) and no relapse patients (Group 2: 67.6%, 23/34). Group 1 presented MRD NPM1 positive in 9/11 (82%) of patients, the time from NPM1 to relapse was 4.6 months (1.6-24), NPM1 mean was 1.7 (0.03-9). Group 2 presented MRD NPM1 negative (~0.02% y or 1 determination) in 21/23 (91%) patients. Univariate analysis was performed and our results show that age, leukocyte, LDH and MRD NPM1 are prognostic factors for cumulative incidence of relapse (Figure 1).
PB1654

AT101 ELIMINATES AML STEM CELLS VIA ACTIVATION OF INTRINSIC APOPTOTIC PATHWAY AND PARTICIPATION IN DNA DAMAGE RESPONSE

X. Bing1, Z. Lei2, Z. Yong1, C. Kari3, S. Pengcheng2, L. Yin2, D. Manman1, J. Zhui4, W. Xiannong2, L. Peng4

1The First Affiliated Hospital of Xiamen University, Xiamen, 2Nanfang Hospital, Southern Medical University, Guangzhou, 3Nanfang Hospital, Southern Medical University, Xiamen, 4Southern China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou, China

Background: Leukemia stem cells (LSCs) are considered as the main reason for treatment failure and relapse in acute myeloid leukemia. Overexpression of Bcl-2 anti-apoptotic proteins is associated with the survival and self-renewal of LSCs.

Aims: To observe the effect for AT101 to eliminate AML stem cells and its underlying mechanism.

Methods: Use CD34+CD38−CD123+KG1α and primary AML CD34+ cells as research object.

Results: In this study, we demonstrated that AT101, a BH3 mimetic pan-Bcl-2 inhibitor, was significantly and effectively cytotoxic towards CD34+CD38−CD123+KG1α and primary AML CD34+ cells, with slight effect on CD34+ normal hematopoietic cells. And the mechanism was closely associated with activation of intrinsic apoptotic pathway, such as loss of mitochondrial membrane potential and caspase activation, along with disturbance of DNA damage response. Further analysis on AML patients’ clinical characteristics revealed that the ex vivo efficacy of AT101 in primary samples was significantly correlated to hyperleukocytosis or FLT3-ITD mutation. Besides, AT101 exhibited exciting effect on CD34+ blasts from patients who are old or cannot achieve CR after induction therapy.

Summary/Conclusions: In conclusion, together, these findings provide potentiality for the use of AT101 to treat relapse and refractory AML as alternative salvage regime in the future, including those clinically characterized by one or more adverse prognostic abnormalities.

PB1655

COOPERATIVE EFFECT OF CHIDAMIDE AND CHEMOTHERAPEUTIC DRUGS INDUCE APOPTOSIS BY DNA DAMAGE ACCUMULATION AND REPAIR DEFECTS IN ACUTE MYELOID LEUKEMIA STEM AND PROGENITOR CELLS

X. Bing1, L. Yin2, D. Manman1, C. Kari3, S. Pengcheng2, Z. Yong1

1The First Affiliated Hospital of Xiamen University, Xiamen, 2Huizhou Municipal Central Hospital, Huizhou, 3Nanfang Hospital, Southern Medical University, Guangzhou, 4Nanfang Hospital, Southern Medical University, Xiamen, China

Background: Lots of conventional chemotherapeutic drugs are confirmed to take part in DNA damage generation and initiation of DNA damage response, ultimately leading to apoptosis. However, they fail to completely eliminate leukemia stem cells (LSCs) on account of higher DNA repair capacity of cancer stem cells than bulk cancer cells, which become the root of resistance and recurrence. Thus, new strategy to eliminate LSCs in AML is urgently needed.

Aims: To observe the effect of low dose chidamide in combination with chemotherapeutic agents on eliminating AML stem cells.

Methods: We used a novel benzamide-type HDAC inhibitors, chidamide, in combination with DNA-damaging agents (daunorubicin, irubidacin and cytara- bine) to treat CD34+CD38−KG1α cells and primary refractory or relapsed AML CD34+ cells.

Results: Here, we report that low dose chidamide, a novel benzamide-type HDAC inhibitors, which selectively targeted HDAC 1, 2, 3, 10, could enhances cytotoxicity of DNA-damaging agents (daunorubicin, irubidacin and cytara- bine) in CD34+CD38− KG1α cells and primary refractory or relapsed AML CD34+ cells, reflected by inhibition of cell proliferation and induction of apoptosis in vitro. Mechanistically, these effects were associated with DNA damage accumulation and repair defects. Co-treatment with chidamide and DNA-damaging agents IDA gave rise to production of YH2-A, inhibited ATM, BRCA1, checkpoint kinase 1 (Chk1) and 2 (Chk2) phosphorylation. Finally, the combination initiated caspase-3 and PARP cleavage and ultimately induced CD34+CD38− KG1α cells apoptosis. Further analysis on AML patients’ clinical characteristics revealed that the ex vivo efficacy of chidamide in combination with IDA in primary CD34+ samples was significantly correlated to peripheral blood WBC counts at diagnosis, while status, LDH level, karyotype had no effect, indicating that the combination regimen of chidamide and IDA could rapidly diminish tumor burden in a patient with R/R AML.

Summary/Conclusions: These findings provide preclinical evidence for low dose chidamide in combination with chemotherapeutic agents to treat recurrent/resistant AML as an alternative salvage regimen, especially those possessed stem and progenitor cells.

PB1656

NEW CANDIDATE GENES USEFUL TO PREDICT THE RISK OF RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA

J. Nando1, M.C. Fontana1, G. Marcioni1, C. Papayanand1, S. Lo Monaco1, G. Simonetti1, A. Padella1, E. Ottaviani1, S. Paoli1, M.C. Abbenante1, L. Bertamini1, G. Martinelli1, L. Bertamini1

1University of Bologna, Bologna, Italy

Background: Nowadays, Acute Promyelocytic Leukemia (APL) is a disease entity with a very high rate of cure and an estimated 2-year overall survival of 97%. Early death, rather than resistant disease so common in all other subtypes of AML, has emerged as the major cause of treatment failure, and relapse is a very rare occurrence.

Aims: To observe the effect for AT101 to eliminate AML stem cells and its underlying mechanism.

Methods: Use CD34+CD38−CD123+KG1α and primary AML CD34+ cells as research object.

Results: In this study, we demonstrated that AT101, a BH3 mimetic pan-Bcl-2 inhibitor, was significantly and effectively cytotoxic towards CD34+CD38−CD123+KG1α and primary AML CD34+ cells, with slight effect on CD34+ normal hematopoietic cells. And the mechanism was closely associated with activation of intrinsic apoptotic pathway, such as loss of mitochondrial membrane potential and caspase activation, along with disturbance of DNA damage response. Further analysis on AML patients’ clinical characteristics revealed that the ex vivo efficacy of AT101 in primary samples was significantly correlated to hyperleukocytosis or FLT3-ITD mutation. Besides, AT101 exhibited exciting effect on CD34+ blasts from patients who are old or cannot achieve CR after induction therapy.

Summary/Conclusions: In conclusion, together, these findings provide potentiality for the use of AT101 to treat relapse and refractory AML as alternative salvage regime in the future, including those clinically characterized by one or more adverse prognostic abnormalities.
AN INVESTIGATION INTO THE ROLE OF S100A8 AND S100A9 IN ACUTE MYELOID LEUKAEMIA

S. Chaudry1,*, T. Chevassut1, H. Stewart1
1Brighton and Sussex Medical School, Brighton, United Kingdom

Background: Acute myeloid leukemia (AML) is the a haematological malignancy characterised by the over proliferation and block in differentiation of clonally expanded leukaemia potential bone marrow such as S100A8 could assess the progression and remission of AML.

Aims: To determine whether a hybridisation-based enrichment approach overcomes the difficulties associated with these genes, and permits the generation of high quality (sufficient de-duplicated depth) data to allow these targets to be accurately interrogated.

Methods: We utilised a hybridisation-based enrichment approach for library preparation in combination with a SureSeq myPanel™ NGS Custom AML panel. The library was then sequenced using a 2x150 bp read length protocol on an Illumina MiSeq®.

Results: Here we present the coverage and variants generated from numerous research samples for each of these difficult to sequence genes. The results clearly show that this approach can reliably detect and accurately size (including low allele frequency) insertions and deletions of up to 52 bp in CALR (exon 9), SNVs and deletions in CELBPA with a de-duplicated depth in excess of 2000x as well as ITDs of between 24 and 201 bp in FLT3.

Summary/Conclusions: This approach is suitable for the analysis by NGS of these difficult genes and therefore removes the requirements for supplementary approaches to analyse these difficult genes, such as Sanger sequencing (CEBPA) and fragment analysis (CALR and FLT3).

PB1661

ASSOCIATION OF MiRNA EXPRESSION PROFILES WITH FUNCTIONAL AND MOLECULAR ACUTE MYELOID LEUKAEMIA CATEGORIES

C. Sargas1,*, M. Llop2, M. C. Alonso3, R. Ayala4, M. E. Onecha5, M. Ibañez2
2Hospital Arnau de Vilanova, Valencia, 4Hospital 12 de Octubre, Madrid, Spain

Background: Development of high-throughput technologies such as Next Generation Sequencing (NGS) allowed the identification of recurrent mutated genes in Acute Myeloid Leukemia (AML), and new molecular markers which help refine patients classification in different risk groups.

Epigenetic alterations such as aberrantly expressed microRNAs (miRNAs) also play an important role in the development and progression of AML. miRNA control processes such as cell development, differentiation, proliferation and apoptosis. Therefore, aberrant miRNA expression can affect signaling and metabolic pathways, directing cancer cell biological behavior.

Recently, several studies have classified AML according to different criteria. AML was proposed in 2013 a new classification where genes are grouped according to their biological function. Moreover, Pappaemmanuil et al. suggested in 2016 a new classification based on molecular markers with not overlapping categories.

Aims: Our aim is to explore the miRNA profile of NK-AML and to find expression profiles associated with the categories proposed by TCGA and Pappaemmanuil et al. Associations of miRNA expression profiles with altered categories could help understand the molecular mechanisms that lead to leukemogenesis.

Methods: CD34+ cord blood progenitor cells from 5 healthy donors and 7 CD34+ NK-AML samples with >70% blasts were obtained. Total RNA from these samples was hybridized onto an Array miRNA 3.0 chip (Affymetrix) in order to identify deregulated miRNAs. The most deregulated miRNAs were validated by qRT-PCR (miScript) in an independent cohort of 73 patients. Muta-
tional analysis was performed by Next Generation Sequencing using the AML Community Panel with the Ion Torrent System (Life Technologies).

Results: We found a profile of 6 miRNAs up-regulated and 61 miRNAs down-regulated in NK-AML vs CD34+ cells. Validation by qRT-PCR confirmed that miR-494 (p=0.028) and miR-499 (p=0.035) were up-regulated in NK-AML vs CD34+ (p=0.022), miR-99a (p=0.001), miR-146b (p=0.031), miR-15b (p=0.006) and miR-20b (p=0.001) were down-regulated in NK-AML. Interestingly, some of the deregulated miRNAs were significantly associated to a functional category according to the TCGA classification. Therefore miR-146b was down-regulated in AML with mutations in myeloid transcription factors (p=0.025). Low expres-
sion of this miRNA causes the activation of the factor signaling pathway, which increases transcription. miR-4668 was down-regulated in AML with mutations in activation pathways genes (p=0.004). Several target predictors propose RASGEF1A and BRAF as targets of this miRNA. Thus, under-expression of this miRNA could cooperate with mutations leading to the activation of signaling pathways. Regarding to Pappaemmanuil’s molecular classification, miR-494 was up-regulated in IDH2-R172T category (p=0.009). High levels of this miRNA are associated with lower expression of TET, specially TET1. Therefore, high levels of miR-494 could contribute to the hypermethylation signature of IDH (AFM) AML.

Summary/Conclusions: In conclusion, the mutational landscape of significant functional and molecular groups in AML is accompanied by miRNA deregulation, which could cooperate in the development of this hematologic malignancy.

PB1662

PROTEOMIC APPROACH TO IDENTIFY MOLECULAR TARGETS OF HALOFUGINONE IN ACUTE MYELOID LEUKEMIA

L. Cândido1,*, C. Silva2, D. Moreno1, C. Thomé3, A. Nagler4, E. Rego5
1Hematology Division of the Department of Internal Medicine, School of Medicine of University of São Paulo, 2Laboratory of Experimental Animal Studies, Faculty of Medicine of Ribeirão Preto - University of São Paulo, 3Hematology Division of the Department of Internal Medicine, University of São Paulo, Ribeirão Preto, Brazil, 4Hematology Division and Cord Blood Bank, Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel, 5National Institute of Science and Technology on Cell-Based Therapy, School of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Background: Halofuginone (HF) is a halogenated derivative of Febrifugine, which is a molecule isolated from the plant Dichroa febrifuga. It has been demonstrated that Halofuginone exhibits anti-fibrotic, anti-cancerogenic, anti-inflammatory and pro-apoptotic effects. Previously, we have reported that treatment with HF has anti-leukemic properties in vitro and in vivo in acute promyelocytic leukemia (APL), reducing tumor growth through the induction of apoptosis and by stimulating the synthesis of the TGF-β protein and activating its downstream targets. In addition, HF presented anti-angiogenic effects by modulating the level of pro and anti-angiogenic factors including VEGF. However, it is still unknown whether HF has anti-leukemic properties in different subtypes of acute myeloid leukemia (AML) and HF targets were not determined yet.

Aims: Evaluate the anti-leukemic effect of HF on other AML subtypes than APL and investigate its targets using a proteomic approach.
Methods: AML cell lines Kasumi-1, THP-1, MV-4-11, U937 and OCI-AML3 were treated in vitro with HF at concentrations ranging from 25 to 1000 ng/ml. The % of apoptotic cells, the distribution of cells in different cell cycle phases, and the HF IC50 was determined for each cell line. We used the Proteome ProfilerTM Array – HumanPhospho-Kinase Array to verify the possible tyrosine kinases and signaling pathways that could be modulated by HF. To analyze the in-vitro effect of HF, THP-1 (ThP-1) and Kasumi-1, and THP-1 cells transfected with 5'-ido-2' deoxyuridine (5'-idUDR) (iUDR) and NOD.Cg-Prkdcscid Ibrgim1Wjl/Sjcl (NSG) mice, which were then treated with intra-peritoneal injections of HF at a dosage of 150 mg/Kg daily for 14 days. The leukemic infiltration of the peripheral blood was quantified by flow cytometry every 2 weeks (using a anti-human CD45).

Results: HF IC50 values ranged from 125.58 ng/ml in Kasumi-1 to 786.15 ng/ml in THP-1 cells. Kasumi-1 cells halted in the S phase of the cell cycle when treated with HF, displaying a significant decrease in proliferation, while no effect was observed for THP-1 cells. Corroborating our in-vitro observation indicating resistant of THP-1 cells towards HF, we did not detect significant differences in overall survival (OS) of NSG mice transplanted with THP-1 cells treated with vehicle or HF (mean OS of 70.5 and 68 days, respectively; p = 0.24). In contrast, the mean OS for NSG mice transplanted with Kasumi-1 cells treated with HF was significantly prolonged compared to the control group (144 versus 94.5 days; p = 0.007). The proteomic analysis identified significant decrease upon treatment with HF of four phosphorylated-proteins in both cell lines: Phospholipase C gamma 1 (PLCγ1), Proline-rich tyrosine kinase 2 (PYK2), Endothelial nitric oxid syntase (eNOS) and Signal transducer and activator of transcription 3 (STAT3 Y705), thus suggesting that these proteins are primary targets of HF. In addition, the protein target of rapamycin (TOR) was downregulated only in THP-1, while the levels of STAT3 S727 and STAT5αβ were significantly decreased by HF treatment only in Kasumi-1 cells. This comparative analysis suggests that the sensitivity to HF may be dependent on inhibition of STAT3/5 pathway.

Summary/Conclusions: In summary, our results suggest that HF may be effective against core binding factor leukemias and, that the methodology based on a Phospho-Kinase Array is useful to identify drug molecular targets.

PB1663

DNA METHYLATION AND HYDROXYMETHYLATION PROFILING IS CAPABLE TO DISTINGUISH AML SAMPLES WITH DISTINCT MUTATIONS IN DNA METHYLATION REGULATORY GENES

H. Hajkova1, S. Vorakova1, Z. Krejci1, A. Herovska1, P. Cetkovsky2, C. Salezek1

1Department of Genomics, 2Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Background: Aberrant DNA methylation as well as hydroxymethylation is a hallmark of acute myeloid leukemia (AML). Mutations of DNA methylation regulatory genes (DNMT3A, IDH1, IDH2 and TET2) are present in approximately 40-50% of AML. These mutations are often present together with the exception of TET2 and IDH1/2 as well as IDH1 and IDH2, which are usually mutually exclusive. Aims: We aimed to perform DNA methylation, hydroxymethylation and gene expression profiling in clearly defined subgroups of AML patients with distinct mutations in DNA methylation regulatory genes to see whether there is a clear epigenetic and gene expression signature.

Methods: We accomplished DNA hydroxymethylation and methylation profiling in 12 AML samples at diagnosis and in CD34+ cells of 3 healthy controls by MethylationEPIC array (Illumina) covering 850,000 CpGs. AML samples were chosen based on their mutational status and divided into 4 groups: DNMT3A+ (n=3), IDH1+ (n=3), DNMT3A+/IDH1+ (n=3) and IDH2+ (n=3). The remaining DNA methylation regulatory genes as well as CEBPA were unmethylated. 1 μg of genomic DNA was treated with TrueMethyl Seq kit (CEQX) to convert DNA through oxidative bisulfite (oxBS) and bisulfite (BS) treatment. This approach allows us to determine whether CpG is methylated or rather hydroxymethylated. We also performed gene expression profiling on the same samples by HumanHT-12 v4 Expression Array (Illumina).

Results: We performed hierarchical clustering analysis of oxBS β-values (corresponding to DNA methylation levels) of 830 304 CpGs (with detection P<0.05) and observed clear separation of 4 groups according to mutational status – DNA methylated (IDH1+, IDH2+ and CD34+ as well as IDH1+/CD34+). Interestingly, only positive DNA methylation scores with IDH1+ and CD34+ normal strongly suggest that there is a cumulative effect of these two opposing mutations (Figure 1). We found out that genes hydroxymethylated in IDH1+ samples are enriched for genes from HOX gene family (P=0.043), and genes involved in JNK cascade (comprising of evolutionarily conserved MAP kinases). The gene expression data did not reveal any cluster coherent with methylation subgroups, only CD34+ normals clustered together.

Figure 1.

Summary/Conclusions: We explored that AML patients with clearly defined mutational background exhibit distinct DNA methylation as well as hydroxymethylated profiles. The presence of two mutations that have the opposing effect on DNA methylation pattern (DNMT3A and IDH1) is linked to mixed DNA methylation patterns, which prevents unambiguous assignment to one cluster. Further, our data support that IDH1+ and IDH2+ represent distinct biological entities. On the contrary, gene expression profile did not support separation of samples into different mutational subgroups. We plan to enlarge the patients’ cohort and validate the most promising genes involved in selected pathways. Supported by Ministry of Health of the Czech Republic, grant nr. 15-25809A, and by the project for conceptual development of research organization (00023736) from the Ministry of Health of the Czech Republic.

PB1664

RNA-MEDIATED CORRECTION OF ABBERRANT DNA METHYLATION AT THE P15 LOCUS

M. Li1, M. Borchelli2, P. Cascino1, N. Habib2, A. Di Russo1

1University of Eastern Piedmont, Novara, Italy, 2 Imperial College London, Hammersmith Campus, London, United Kingdom

Background: P15 (a.k.a cell cycle dependent kinase inhibitor 2B; CDKN2B; INK4B) is a methylation sensitive gene located on chromosome 9p21 and commonly found silenced during Myelodysplastic Syndrome (MDS) progression to Acute Myeloid Leukemia (AML). P15 encodes for a cyclin-dependent kinase inhibitor increasingly expressed during granulomonocytic maturation (Teoffi et al., Exp Hematol 2000). P15 deletion or promoter methylation has been shown to independently correlate with disease progression and poor patient prognosis (Tien et al., Br J Hematol 2001). Additionally, P15 overexpression was also sensitive to regulation by myeloid-specific transcription factor PU.1 (Schmidt Blood 2004).

As MDS evolution to AML includes both myeloid proliferation and blocked differentiation stages, restoration of the natural P15 transcript will provide not only valuable information regarding disease progression but may also alleviate some of their characteristic symptoms.

Aims: Currently available demethylating agents approved for therapeutic applications, e.g. 5-azacytidine and decitabine, have major side effects of high toxicity and non-specific DNA methylation that limit their clinical application. Therefore, the aim of this study is to achieve RNA-mediated correction of the aberrantly methylated P15 locus using small activating RNAs (saRNAs; Li et al, PNAS 2006).

Methods: Myeloid Leukemia cell lines HL-60, KG1a, and K562 were screened for basal p15 expression by western blotting and qRT-PCR. As the P15 gene body. SaRNAs were introduced into cell lines through electroporation, and re-activation of the locus was measured in parallel. HEK293 cells serve as positive control in all studies. SaRNAs were designed against the proximal promoter, first exon, and intron regions of the P15 gene body. SaRNAs were introduced to cell lines through electroporation, and re-activation of the locus was measured at the transcript level by qRT-PCR and protein level by western blotting. Changes in P15 promoter level methylation were determined by Methylation Specific PCR.

Results: Transfection of saRNAs into the HL60 cell line showed upregulated p15 expression 24 and 48 hrs post-transfection. Analysis of ANRIL after saRNA-transfection showed no concomitant changes, suggesting locus-specific activity of the saRNAs. Future experiments will elucidate the mechanisms of saRNA activation of P15 gene expression and genome-scale specificity of saRNAs.

Summary/Conclusions: There is much interest in using RNA molecules as a therapeutic tool (Kole et al., Nat Rev Drug Discovery 2012; Reebye et al., Hepatology 2014). Introduction of such an approach offers greater advantages over...
existing hypomethylating-based protocols: a) high gene specificity b) lower cytotoxicity and c) absence of drug-based off-target side-effects. In the short term, this research can lead to the identification of novel key regulators of leukemogenesis and new targets for therapeutic treatments; in the long term pave the way for development of RNA-based gene demethylating agents for cancer treatment.

PB1665
JQ1 AND CURCUMIN COMBINED TREATMENT SHOWS SYNERGIC EFFECTS IN MLL-REARRANGED LEUKEMIA CELL LINES
P. Vitullo1,*, P. Leoncini1, V. Tocco1, M. Pigazzi2, K. D’Ovidio1, D. Montagna3, R. Rota1, A. Bertaina1
1Oncohaematology, Bambino Gesù Children Hospital, Roma, 2Pediatrics-Oncoematology, University of Padova, Padova, 3Pediatrics, Policlinico San Matteo, Pavia, Italy

Background: MLL-rearranged leukemia accounts for □ 70% of infant and □ □ 10% adult acute leukemias, featuring a particularly poor prognosis and high risk of relapse. Our main field of study is AML, in which nearly 50% of total cases accounts for t(9;11) translocation, the remaining 50% predominantly includes t(6;11)(q27;q23), t(10;11)(p12;q23), t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). A 2% of AML total cases, however, is characterized by t(4;11) translocation, which is a marker of bad prognosis and it’s, so far, poorly characterized. A key feature of MLL-rearranged leukemia is cMyc overexpression, a well-known oncogene involved in several types of cancer. JQ1 is a novel molecule, which prevents cMYC expression binding an important bromodomain protein, BRD4. Moreover, Curcumin, a natural compound, inhibits HATs enzymes preventing lysine 14 acetylation on histone H3 (AcH3K14), a particular residue which is bind by BRD4 to exert its function.

Aims: We would like to explore a potential synergic effect between JQ1 and Curcumin molecules in the attempt to develop a novel therapeutic alternative to standard chemotherapy and to deeply investigate features underlying the molecular pathogenesis in pediatric MLL-rearranged pediatric AML.

Methods: Four human leukemia cell lines with MLL fusion protein have been employed in this study: RS4-11, MV4-11 expressing MLL-AF4 and THP1, MOLM13 expressing MLL-AF9 fusion genes. 5μM and 10μM Curcumin were employed in this study: RS4:11, MV4:11 expressing MLL-AF4 and THP1, MOLM13 expressing MLL-AF9 cell lines respectively, while 250nM JQ1 was used to treat all the cell lines. After 2 days of treatment, either with single treatment or with the combination of drugs in both MLL-AF4 cell lines, meanwhile in MOLM13 cells it was 64±2 and 87±2 for curcumin and JQ1, respectively and 76±2 for their combination (P<0.005). The THP1 cells did not showed any significant modulation in the proliferation. We decided to focus our study on t(4;11) translocated cells, considering the more intense effect of the combined drugs on previous analysis. qRT-PCR and western blot experiments revealed a synergic effect of the 2 experimental drugs on both apoptosis and proliferation gene related (bcl2, caspase3, Parp, cdkn1a) as well as on the effect of the drugs (cMyC, AcH3K14). Finally, in MLL-AF4 cell lines, curcumin and JQ1 together induced a significant decrease in mir-99a expression.

Summary/Conclusions: Our data demonstrated that curcumin and JQ1, inhibiting HATs and BRD4 respectively, exert a more intense synergic effect on MLL-AF4 than in MLL-AF9 cells. Increased apoptosis together with a decreased proliferation rate, prompted us to investigate on molecular pathway in which targets of these drugs are involved. Intriguingly, we found a significant decrease in cMyc, bcl2 and AcH3K14 expression, confirming that both curcumin and JQ1 have a synergic effect. Additionally, we revealed a significant reduced expression of mir-99a, a well know oncomiR reported to act as negative regulator of differentiation and involved in drug-resistance, typically up-regulated in pediatric AML and ALL.

PB1666
TP53β AND TP53Γ EXPRESSION LEVELS IN RELATION TO NPM1 AND CEBPA MUTATIONS
K. Miaty,A. Bartoszewsk-Kubik1, E. Bielinska1, M. Morgut-Klimkowska1, O. Haus1
1Department of Clinical Genetics, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland

Background: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder with the presence of diverse genetic abnormalities in hematopoietic stem cells. The most frequent alterations in normal karyotype AML (NK AML) are mutations in exon 12 of nucleophosmin gene (NPM1). Until now 56 different mutations of NPM1 exon 12 have been described, mostly insertions. The NPM protein plays an important role in cell cycle and apoptosis control. It cooperates with several proteins, among them with p53 and ARF. The median levels of functional nuclear p53 protein are reduced in NPM1 and FLT3 ITD mutant samples. TP53 encodes a tumor suppressor protein which consists of transactivation, DNA-binding and oligomerization domains. Due to alternative splicing it may exist in 13 different isoforms. Alternative splicing of intron 9 leads to production of 2 different proteins, p53β and p53γ, without oligomerization domain (stop codon is localized in exon 9b). These isoforms can be present in acute myeloid leukemia (AML) cells, p53β binds to BAX promoter and can induce apoptosis independent from p53 wt. p53 has influence on activation of CEBPA which is associated with cell cycle regulation, especially cell cycle arrest and plays also role in cell differentiation. Generally, it is a transcription factor expressed during myeloid lineage development, from progenitor cells to mature granulocytes. Various mutations of CEBPA gene are described. Among them N-terminal and C-terminal mutations, mostly insertions and deletions, are often present.

Aims: The goal of the study was to assess mutational status of NPM1, CEBPA and FLT3 in association with TP53beta and TP53gamma expression levels.

Methods: 75 NK AML patients were included in the study. NPM1, CEBPA and FLT3 gene mutations were analyzed by direct sequencing. TP53β and TP53γ expression levels were assessed by real time PCR. Expression levels were analyzed with ΔΔCt method, with ABL as a control gene and K562 cell line as a calibrator.

Results: In all 75 cases, TP53β and TP53γ transcripts were detected. 36 patients had NPM1 mutations, 25 had CEBPA mutations or known polymorphisms, and 25 had FLT3 ITD mutation. Assessed median expression level of TP53β was much higher (∆ΔCt 43.11) than TP53γ (∆ΔCt 10.85; p<0.05). Furthermore, expression level of TP53γ in CEBPA mutated group (∆ΔCt 11.4) was significantly lower than in CEBPA wt group (∆ΔCt 17.7) (p=0.03). We have not found any other important correlation between mutations of studied genes and TP53 expression. We also classified patients according to median expression value of TP53, to two groups: with overexpression or with low expression. Haematological and clinical features, such as white blood cells count (WBC), blasts count in bone marrow or patient age did not depend on TP53 isoform expressions. However, statistical analysis showed important difference between WBC count in NPM1mutated and NPM1wt groups.

Summary/Conclusions: Obtained results may suggest a clinical importance of simultaneous analysis of TP53 isoform expression and mutations in CEBPA gene. It may be hypothesized that a changed sequence of the latter gene might influence TP53 isoform expression and in consequence regulate the cell cycle.

PB1667
EXPRESSION PROFILE OF EPIGENETIC MODULATORS IN ACUTE MYELOID LEUKEMIA OF INTERMEDIATE RISK
C. Bilbao Sieyro1,2,*, Y. Florida Ortega1, C. Rodriguez Medina1, S. Gamrani1

Figure 1. In apoptosis analysis, a synergic effect was detected for all 4 cell lines, similarly cell cycle evaluation showed a significant accumulation of cells at SubG1 phase (2-8 fold) (Figure 1). XTT metabolic assay showed a reduction in proliferation percentage: 65±5 for curcumin and JQ1 single treatment and 59±5 for combination of drugs in both MLL-AF4 cell lines, meanwhile in
Background: Whole-genome sequencing has revealed acute myeloid leukemia (AML) as a very complex and dynamic disease. Epigenetic modulation is among the functional categories of the mutational landscape in AML. According to recent reports, suppression of the epigenetic reader BRD4 with small-molecule inhibitors (BET-i) results in antileukemic activity. Clinical trials are being developed, however, so far, identification of those patients that may benefit from this therapy is not possible as changes in mRNA BRD4 levels seem to be not specific enough. It has been recently suggested that antileukemic effect of BET-i could be due to c-myc suppression and that also high Bcl-2 levels may target those patients that would benefit of BET-i. We believe that establishing the expression profile of epigenetic modulators in AML may help in the identification of patients that could benefit from BET-i.

Aims: We wanted to get a better insight regarding the expression profile of epigenetic modulator in AML of intermediate risk by studying: 1) expression levels of EZH2, ASXL1, BRD4, c-myc and Bcl-2 in a consecutive series of AML patients; 2) correlation between mRNA and protein levels; 3) Determining BRD4 binding to the c-myc promoter through chromatin immunoprecipitation (CHIP).

Methods: Our series consisted of 104 consecutive patients with a mean age of 55.8 years (range 15-79 years) diagnosed and treated between 2005-2016 at the Hospital Universitario de Gran Canaria Dr. Negrín with a median follow up of 12 months. Gene expression analysis was carried out through real time PCR in a LightCycler 480 Instrument II (Roche) using GUS a control gene. Results were normalized with a cDNA pool from bone marrow of 10 healthy donors which was introduced as internal control in each experiment. Western blot were performed to determine protein levels for BRD4, c-myc and Bcl2. CHIP studies for BRD4 were carried out in HL60 cell line. For statistical analysis the SPSS (v.15.0) software was used.

Results: ASXL1 levels were positively associated with EZH2 ( Spearman’s= 0.285, p=0.021) and BRD4 with c-myc (Spearman’s coefficient=0.420, p<0.001), Bcl2 (Spearman’s=0.471, p<0.001) EZH2 (Spearman’s=0.4565, p=0.008) and ASXL1 (Spearman’s=0.9495, p<0.001). Survival analysis considering 50th percentile as a cut-off value for BRD4 expression indicated that patients with higher levels had a 2.9 times better overall survival (median overall survival OS, of 27 months, 95% CI 15.1-38.9) compared to those with low expression (median OS 12 months, 95% CI 0.4-23.7), although the association was not statistically significant (p=0.196) probably due to the limited series size. Protein levels of Bcl2 and c-myc correlated with those of mRNA, but not for BRD4, although other antibodies should be tested in order to confirm these results. CHIP analysis in HL60 cell lines confirmed the binding of BRD4 to c-myc promoter.

Summary/Conclusions: The positive association observed between EZH2 and ASXL1 agrees with the fact that both cooperate in the epigenetic repressive complex PRC2. The finding of expression of BRD4 in the mRNA and protein forms correlates with the reported binding of BRD4 to the c-myc enhancer regions and our CHIP analysis also support so. Further studies in a larger series are necessary to confirm the relationship between higher BRD4 levels and better overall survival. Finally, future analysis should be done to determine whether patients with higher BRD4 expression levels determine a subgroup with better response to BET-i.

PB1686
FLOW CYTOMETRY IMMUNOPHENOTYPING IN CEBPA-DM DE NOVO AML. BIOLOGIC AND PROGNOSTIC RELEVANCE.
M. Fernandez1,2, M. Prattorona1, A. Gambot1, C. Estivill1, J. Esteve2, O. Salameh1,3, M. Tormo1, M. Arna2, B. Bellocchio1, L. Zamora1, S. Vives1, R. Guardia1, S. Brunet1, J. Sierra1, J. Nordemede1
1Hematology, Hospital de la Santa Creu i Sant Pau, 2Hematology, Hospital Clinic, 3Hematology, Hospital de la Vall d’Hebron, Barcelona, 4Hematology, Hospital Clinico, Valencia, 5Hematology, ICO Hospitalit, L’Hospitalet de Llobregat, 6Hematology, Parc de Salut Mar, Barcelona, 7Hematology, ICO Badalona, Badalona, 8Hematology, ICO Girona, Girona, Spain
Background: CEBPA is a transcriptional co-factor of RUNX1 which play a major role in the fate decisions associated with physiologic myelopoesis. Biallelic CEBPA mutations (dm) define an homogeneous molecular subgroup which is associated with a favorable outcome. CEBPA mutations may be transmitted in the germline giving rise to clusters of familial leukemias.
Aims: To analyze the immunophenotypic findings assessed by multiparametric flow cytometry in a consecutive series of de novo CEBPAdm AML.
Methods: 16 de novo AML patients with CEBPAdm who where enrolled on the AML-03 and AML-12 protocols of the Spanish CETLAM cooperative group were included in this study. The immunophenotypic analysis was performed on erythrocyte-lysed bone marrow (BM) samples obtained at diagnosis. Antigenic expression of leukemic cells was systematically analyzed by multiparametric flow cytometry using four-color staining. The antibodies studied were: CD45, CD34, HLA-DR, CD10, CD20, CD19, CD2, CD33, CD7, CD117, CD66, CD13, CD64, CD36, CD56, CD14, CD123, CD61, CD42b, glyco- phorin, CD71, CD11b, myeloperoxidase, CD79a, Td7, lysosome and lactoferrin. At least 10.000 events/tube were measured. Analytical gates were established according to CD45 reactivity and to FSC/SSC pattern. Positivity threshold was established at 20%. The FACS-DIVA, Paint-a-Gate and Infinicyt software programs were employed for analysis. Amplification of overlapping PCR products covering the whole CEBPA coding sequence followed by Sanger sequencing were used to investigate CEBPA mutations. FLT3-ITD, NPM1, MLL, PTD2, WT1 and GATA2 mutations were also investigated by conventional PCR-based molecular methods.
Results: Antigen reactivity was as follows: CD45 (39/39,100%), CD15 (35/39, 90%), CD34 (36/39,92%), HLA-DR (39/39,100%), CD33/39,100%), CD2 (2/39,5%), CD7 (36/39,92%),CD117(39/39,100%), CD13/37/39,95%), CD56 (39,13%), CD36 (6/39, 15%), CD123/39,100%), CD14 (1/39,0,02%), CD71/39,39,97%), myeloperoxidase (38/39, 97%). In nine cases CD36 and/or CD56 expression on leukemia blasts was greater than 20% Those CD36/CD56+ cases had a shorter overall survival and leukemia free survival (see graph). Four out five tested CD36/CD56+ cases also showed GATA 2 mutations. An additional CD36/CD56+ case had a FLT3-ITD. In three out 39 cases (7%) a population showing cytoplasmic CD79a reactivity was detected (8%, 11%, 14% of the neoplastic population, respectively). Two of those cases had also a FLT3-ITD.

Figure 1.
Summary/Conclusions: CEBPAadm cases showed an homogeneous immunophenotype with positivity for CD45, CD7, CD34, CD123, CD117, HLA-DR, CD71, CD33, CD13 and CD15. CD36 and/or CD56 overexpression was detected in a subgroup of cases (9/39, 23%) with an adverse outcome. The current findings suggest that CD36 and CD56 reactivity should be investigated in larger series of CEBPAadm AML cases. Small leukemic populations with B-cell markers are not uncommon in CEBPAadm AML (3/39, 7%).

PB1669
PROTEOME CHANGES IN ACUTE MYELOID LEUKEMIA PATIENTS BEFORE AND AFTER INDUCTION TREATMENT
L.F. Restrepo Rodriguez1,*, S. Rothlisberger1
1Biomedical Engineering, Instituto Tecnologico Metropolitano, Medellin, Colombia
Background: Acute myeloid leukemia (AML) is a malignant disorder of hematopoietic stem and progenitor cells (HSPCs), characterized by the accumulation of immature blasts in the bone marrow and peripheral blood (PB) of affected patients. Standard induction therapy, based on cytosine and an anthracycline, leads to complete remission in approximately 50% to 75% of patients, depending on prognostic factors, such as age or the presence of certain gene or chromosomal changes. In spite of favorable primary response rates, only approximately 20% to 30% of the patients enjoy long-term disease survival.
Aims: Our aim was to compare the protein expression profile of peripheral blood mononuclear cells (PBMCs) of AML patients at time of diagnosis and after induction therapy.
Methods: PB samples were taken from seven AML patients in Medellin-Colombia before and after concluding the induction therapy. Informed consent was obtained prior to sample collection. PBMCs were isolated from the 14 blood samples using a Histopaque-1077 solution. Cells were resuspended in lysis buffer (0.5% Triton x-100, 50 mM Tris-HCL pH 8.0, 150 mM NaCl, 1 mM EDTA, protease inhibitor) and proteins precipitated with trichloroacetic acid. Protein lysate were separated by 2D SDS-PAGE (pI 3–10 NL), and stained with SYPRO®Ruby. The proteomes were compared using PDQuest™ Advanced 8.0.1 Software. Protein spots of interest were those with a fold change of +/- 1.5 and p <0.05.

Madrid, Spain, June 22 – 25, 2017
haematologica | 2017; 102(s2) | 673
Results: Image analysis revealed an average of 464 protein spots in PB samples taken at time of diagnosis, and an average of 346 spots in PB taken after induction therapy, reflecting changes in protein expression due to treatment. Comparing the proteins, we found 11 spots that differed significantly (fold change of +/- 1.5 and p <0.05). Of these, seven proteins were up-regulated and four were down-regulated at time of diagnosis (before treatment) compared to after induction treatment. Nine of these spots correspond to low molecular weight proteins (<40 kDa) and 2 spots have a molecular weight between 40-60 kDa. Based on the molecular weight and isoelectric point information of these spots we were able to search for proteins reportedly involved in leukemia, in order to propose possible identities (see Table 1). In terms of biological processes, four proteins (eIF5B, HSP27, 14-3-3 protein zeta/delta, and GST-P) are involved in the regulation of apoptosis. The F-actin-capping protein subunit beta could also be of interest, as reorganization of F-actin reflects unique characteristics of the differentiation process in promyelocytic leukemia cells. RuvB-like 2 is a positive regulator of histone acetylation and DNA repair. GRBP2 is a protein involved in the MAPK pathway. Transaldolase is part of the pentose-phosphate pathway. Annexin II is a key glycolytic enzyme; however, it has been shown to be a multifunctional protein involved in cancer. It promotes cell proliferation by also regulating the MAPK and PI3K pathways. Transaldolase is part of the pentose-phosphate pathway. Annexin II acts in angiogenesis and has multifaceted role in human health and disease.

Table 1.

Summary/Conclusions: The protein expression profile of AML patients changes after induction treatment. We found 11 spots that differed significantly, and propose possible identities for these. Further analyses are pending in order to experimentally establish the identities and correlate with response to treatment.

PB1670

AMP-ACTIVATED PROTEIN KINASE ACTIVITY INTERFERES WITH OVER EXPRESSION OF NUCLEOPHOSMIN IN CYTARABINE-INDUCED CHEMORESISTANT AML CELLS

D. Kim1,2,*, N.K. Kim1,2, J. Kang1,2, C.S. Park1,2, H.G. Yi3

1Hypoxia-related Disease Research Center, 2Pharmacology, 3Internal Medicine, Inha University School of Medicine, Incheon, Korea, Republic Of

Background: Cytarabine is a chemotherapeutic drug used alone or in combination with other anticancer drugs to treat acute myeloid leukemia (AML). New treatment strategies are emerging to enhance the anti-cancer effect and decrease the toxicities. Nucleophosmin (NPM1 or B23) is a ribosomal protein located on promyelocytic leukemia and multifunction in cancer development and protein synthesis. AMP-activated protein kinase (AMPK) is a critical energy sensor to regulate homeostasis and plays a potential role for anti-cell proliferation activity. Aims: We investigated the effects of AMPK activation on the cell death (apoptosis) and viability of AML cells treated with low or high concentration of cytarabine, an anti-leukemic drug, to predict the mechanisms responsible for AML cells chemoresistance.

Methods: The HL-60 (FAB M2) cells were exposed to the different drug combinations including cytarabine and AMPK activators. The molecular mechanisms of AMPK activation were investigated by western blotting. The cell viability and apoptosis were assessed using cell counting kit-8 assay and flow cytometry.

Results: We found that cell apoptosis (36.27 ~ 42.11%) showed little dependence on cytarabine concentrations (10, 100, and 1000 mM), while the overexpression of NPM1 overexpression level with drug dependence, indicating the drug-induced cell resistance. In the same point, cytarabine also inhibited the phosphor-activity (Thr172) and expression level of AMPK, which has mTOR-p70S6K pathway-repressor activity. As expected, single cytarabine treatment increased the ratio of p-mTOR/mTOR and p-p70S6K/p70S6K. Co- treatment of AMPK activator (phenformin or AICAR) in cytarabine-treated HL-60 AML cells inhibited significantly the induction of NPM1 overexpression level with the decrease of phosphor-activities of mTOR and its substrate p70S6K, resulted in the accelerated cell apoptosis.

Summary/Conclusions: Our results suggest that the higher concentration of cytarabine induces NPM1 overexpression, and that AMPK activation might be used to sensitize AML cells to cytarabine with the control of NPM1 expression levels. These modulations to standard therapeutic strategies could actually enable the reduction of the chemotherapeutic dose, therefore reducing their toxicity and adverse effects.

( Correspondence to H.G Yi and CS Park; Medical Research Center No. 2014009392 )

PB1671

QUERCETIN REGULATES TELOMERE-BINDING PROTEINS EXPRESSION OF POT1, TRF1, TRF2 TO INHIBIT PROLIFERATION AND INDUCE APOPTOSIS IN AML THP-1 CELLS

S. Cui1, X. Wu2, Z. Wang1, Y. Guo2, R. Xu1,*

1Hematology Department, Affiliated Hospital of Shandong University of TC,M, 2The 1st Clinical College , Shandong University of TC,M, Jinan, China

Background: Leukemia cells are limitless cell sources for initiation and maintenance of leukemia. Telomere-binding proteins are key regulators for various diseases, including leukemia. Therefore, targeting telomere-binding proteins is considered as a promising therapeutic strategy for treatment of leukemia.

Aims: We aimed to explore whether quercetin, a natural flavonoids, could regulate telomere-binding proteins expression to inhibit proliferation and induce apoptosis in acute myeloid leukemia(AML) THP-1 cells.

Methods: 1. In vitro: (1) We cultured human AML THP-1 cells. (2) The cells were treated with different concentration of quercetin for 24/48 h, and the cell viability was measured by cell counting kit-8(CCK-8) to determine the IC50 of quercetin (Q). (3) The cell cycle distribution was measured by Annexin V-FITC/PI double staining flow cytometry(FCM). (4) The protein expression levels of POT1, TRF1, TRF2 were measured by western-blotting. (5) The mRNA expression levels of POT1, TRF1, TRF2 were measured by real-time fluorescent quantitative polymerase chain reaction(RT-qPCR). 2 In vivo: (1) Established AML/NOD/SCID model based on THP-1 cell line in NOD/SCID mice, and treated with optimal quercetin concentration 40mg/(kg*d) for 4 weeks by tail vein injection. (2)We observed the changes of mice survival status, peripheral blood and bone marrow cell morphology and organ histopathology by microscopy before and after treatment with quercetin. (3) The cell cycle distribution and apoptotic rate of spleen cells were measured by Annexin V-FITC/PI double staining FCM. The protein expression levels of POT1, TRF1, TRF2 were measured by immunohistochemistry(IHC) staining.

Results: In this study, we found that quercetin significantly suppressed THP-1 cells proliferation in dose- and time-dependent manner. Treatment with quercetin significantly increased the G1 phase arrest rate. Furthermore, the protein expression levels of POT1 and TRF1 increased and the protein expression level of TRF2 decreased. The mRNA expression levels of POT1, TRF1, TRF2 were consistent with their protein expression levels, respectively.

Summary/Conclusions: Our results demonstrate that quercetin has anti-leukemia activity. It is mediated by regulating telomere-binding proteins expression of POT1, TRF1 and TRF2. Taken together, our findings support the concept that quercetin is a promising therapeutic strategy for treatment of leukemia.
signs or symptoms of DS is crucial, however specific biological therapies to counteract the syndrome are still not available.

Peroxisome proliferator activated receptor gamma (PPARγ) is a ligand-dependent transcription factor and a member of the nuclear receptor superfamily, which is expressed in normal monocytes, various leukemias, and epithelial malignancies. PPARγ is highly induced in differentiating myeloid cells and subsequently contributes to their differentiation. Differentiation induction of APL cells is associated with increased expression of specific adhesion molecules and inflammatory cytokines, which may promote activation, migration, and adhesion of these cells.

Aims: Here, we studied the effect of PPARγ agonists on the adhesion of a human leukemia cell line (HL-60) to endothelial cells.

Methods: Differentiation was determined by an increase in reactivity with the CD11b antibody. For the adhesion assay, the Matrigel transwell system was used.

Results: HL-60 cells were differentiated into macrophage-like cells by a PKC activator, 12-O-Tetradecanoylphorbol-13-acetate (TPA). During the differentiation of HL-60 cells, PPARγ agonists activate TPA-induced CD11b expression. However, PPARγ agonists completely blocked TPA-induced ICAM-1 expression of endothelial cells, which resulted in the inhibition of adhesion of HL-60 cells to endothelial cells. These responses also were reversed by PPARγ antagonist (GW9662), indicating that PPARγ agonists inhibits the adhesion of the HL-60 cells to endothelial cells through a PPARγ dependent mechanism.

Summary/Conclusions: These results suggest that PPARγ agonists inhibit TPA-induced adhesion signal in the between HL-60 cells and endothelial cells, and may control differentiation syndrome in APL patients.
Summary/Conclusions: Expression of p53 assessed by immunohistochem- istry is a fast, specific, and readily available tool for prognostic evaluation of AML. A high expression of p53 (H-score >60) was related to a lower overall survival in de novo AML.

PB1675
Abstract withdrawn.

PB1676
LONG-TERM FOLLOW-UP OF SALVAGE TREATMENT FOR RELAPSED AML WITH CLADRIBINE, HIGH DOSE CYTARABINE AND IDARUBICIN K. Mayer1,∗, C. Hahn-Ast1, K. Schwab1, A. Glasmacher1, I. Schmidt-Wolf2, P. Brossart3, M. von Lilienfeld-Toal1
1Medical Clinic III, 2University Hospital Bonn, Bonn, Germany

Background: Despite improving response rates in induction treatment for AML during the last years the outcome for relapsed or refractory AML is still poor. Currently, no standard therapy exists for patients with relapsed AML. Furthermore, CR rates are lower than in newly diagnosed patients and range between 15% and 50%. There is evidence that clonal evolution after a follow-up of 5 years.

Aims: Therefore, testing the combination of 2CdA, AraC and idarubicin (CAI) seems reasonable. Here we present the final analysis from our single-center phase II trial evaluating the safety and efficacy of CAI in relapsed AML patients after a follow-up of 5 years.

Methods: Patients with relapsed AML after at least 6 months of remission and ECOG 0-2 were included. Chemotherapy regime consisted of two courses of 2CdA 5 mg/m²/12 h, d 1-3, AraC 1000 mg/m²/12 h, d 1-3 and idarubicin 8 mg/m²/d, d 1-3. After 8 patients, the prolonged duration of neutropenia especially in course 2 prompted us to change the protocol by 1 application of growth factors from day 15 onwards, and 2) omission of idarubicin from the 2nd course. The primary endpoint was the overall remission rate and safety of CAI.

Results: Because of slow recruitment the study was stopped after 20 patients. The median age was 63 years. 40% were female. 19/20 (95%) patients were included in the first relapse after at least 6 months of CR following 1st line therapy for AML. 1/20 (5%) patient was included with a second relapse. In 14/20 patients cytogenetic data at the time of relapse were available, according to the ELN-risk-group 2017 3/14 (22%) had favorable cytogenetic changes, 9/14 (64%) intermediate and 2/14 (14%) belonged to the adverse cytogenetic group. The performance status was good in most patients (ECOG 0 in 10%, ECOG 1 in 80%), but reduced (ECOG 2) in 2 (20%) patients. After the first course, CR/CRi was achieved in 60% and PR in 10% of patients. Median duration of remission after induction therapy was 19-41 days. Treatment grade 3 or 4 non-hematologic toxicity was infection seen in 85% of courses. Nausea occurred in 30%, hepatotoxicity, mucositis and diarrhea in 11% of courses. Cardiac or renal toxicities grade 3/4 were not observed. Two patients (10%) died due to infection. Six patients received a second course of CAI/CA. Altogether, 6 patients were refractory. Nine patients (48%) proceeded to allogeneic stem cell transplantation after induction therapy with CAI. Of those, 4 patients are still alive and free of leukemia and one patient died in CR 88 months after salvage-therapy accounting for a 5-year survival rate of 55%.

Summary/Conclusions: Combination therapy with CAI in relapsed AML patients is feasible and induces good response rates. Combined with allogeneic stem cell transplantation, long-term survival can be achieved. However, infection rates are a serious complication warranting intensive supportive care.
pts., according to ELN (Doehner, 2017). In 2 pts it was not evaluable. Molecular analysis was available in 17/19 NK, NPM1 was mutated in 5 cases, with (2) or without (3) FLT3-ITD mutation.

**Results:** The total number of cycles administered was 231 (median 3.5; range 1-20). In 37/48 evaluable pts (2 (ongoing, 1 early and 6 aplastic deaths), overall response rate (ORR) and complete remission (CR) rate were 51.3% and 32%, respectively. Partial response (PR) and hematological improvement were achieved in 5.3% and in 13.5%, stable disease in 29.9% and failure in 19% of pts, respectively. Median time to best response was 3.5 months (range 1-8.5). Median response duration was 5.3 months (1-18+ ms). Relapse/disease progression was observed in 42% of responders. ORR was 21.4%, 47.3% and 77% in adv, NK and int-ref respectively (P=0.0289). After a median follow-up of 6.5 months, median survival was 8.4 months and projected OS at 1 and 2 y was 43%±9 (SEM) and 30%±12 (SEM). Treatment was fairly well tolerated except for a high incidence of infections (46 episodes in 231 cycles) particularly during the first 3 cycles (29% vs 11%) (p=0.0072). Pneumonia was the most frequent infection (46%), followed by sepsis (28%). It was more frequent during the first 6 cycles [14% vs 4%: p 0.012] when 44% of cases were of suspected fungal origin (3 probable aspergillosis and 4 possible IFI). Death occurred in 24 pts (52.2%): 12 (50%) of disease progression, 1 of early CNS hemorrhage and 11 (45.8%) of infection. In the first 3 months, infections were responsible for 46.7% of deaths. Pulmonary IFI were fatal in 57% of cases. These figures are higher than those reported by Cashen (JCO 2010) where the frequency of pneumonia was 11%.

**Summary/Conclusions:** These preliminary data confirm, in a population based setting, the high efficacy of decitabine and its longer time to response (more than that of CT). However infections complications were more frequent than expected and often fatal, particularly during treatment. Since pneumonia, especially IFI, was the major cause of death, the adoption of routine antimicrobial prophylaxis may be considered in order to reduce early mortality and further improve the results.

**PB1679**

CLOFARABINE, CYTARABINE AND MITOXANTRONE FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA – INTERIM RESULTS OF A PROSPECTIVE PHASE 2 STUDY

H. Gill1,*, H. W. Ip2, S. F. Yip3, B. Kho4, H. Lee5, V. Ma5, J. Lau6, C. K. Lau7, S. Y. Lin8, R. Wong9, W. Li10 Y. L. Kwong1

1Medicine, The University of Hong Kong, 2Pathology, Queen Mary Hospital, 3Medicine, Tuen Mun Hospital, 4Medicine, Pamela Youde Nethersole Eastern Hospital, 5Medicine, Princess Margaret Hospital, 6Medicine, Queen Elizabeth Hospital, 7Medicine, Tseung Kwan O Hospital, 8Medicine, United Christian Hospital, 9Medicine and Therapeutics, 10Climical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong

**Background:** In unsellected patients with acute myeloid leukaemia (AML) in first relapse or refractory to primary daunorubicin / cytarabine therapy, complete remission (CR) rate is merely 20 - 30%. In patients <60-years old, CR rates of about 55% may be achieved.

**Aims:** We tested in a multicenter prospective phase 2 study the efficacy and safety of clofarabine, cytarabine and mitoxantrone (CLAM) in AML patients in first relapse or refractory to first-line daunorubicin / cytarabine induction therapy.

**Methods:** Consecutive patients aged 18 to 65 years in first relapse or refractory to first-line dose-intensified daunorubicin / cytarabine were recruited. Bone marrow pathology and karyotype at diagnosis and relapse were centrally reviewed. Next-generation sequencing of a myeloid panel of 67 genes was performed. Re-induction CLAM comprised clofarabine (40mg/m²/day, days 1-5) and mitoxantrone (12mg/m²/day, days 3-5). Bone marrow assessment was done on day 28 using standard criteria. Treatment toxicity was evaluated using the Eastern Cooperative Oncology Group Common Toxicity Criteria (ECOG-CTC). Survivals were determined using Kaplan Meier method. The primary outcome was the response on day 28. Secondary outcomes were treatment toxicity, leukaemia-free and overall survivals.

**Results:** In this interim analysis, 24 patients (14 men, 10 women) with a median age of 44.5 (19-66) years were treated. Karyotypic and genetic profiles were: normal karyotype (N=8) (NPM1 mutation, N=1; FLT3-ITD, N=8), t(8;21)(p22;q22) (N=4) (KIT D816V mutant, N=1), inv(16)(p13.2;q22) (t(16;16)(q22;p13.2)22) (N=1) (KIT D816V mutant, N=1), t(15;17) (N=1), t(9;11)(p21;32) (N=1), trisomy 13 (N=1), near-tetraploidy (N=1), and complex karyotype (N=1). Twenty patients (83.3%) responded (CR, N=16; CR with incomplete hematopoietic recovery, N=4). Eight responding patients underwent allogeneic haematopoietic stem cell transplantation. Grade 3/4 haematologic toxicity was observed in 46 (21.6%) pts, with 12 (6.0%) grade 3/4 hepatotoxicity was observed in 17 (70.8%) and 2 (8.3%) patients respectively. Grade 1/2 rash was observed in 4 patients (20%). Cardiotoxicity or treatment-related mortality was not seen. With a median of follow-up of 4 (1-32) months, 6 patients relapsed. The 12-month overall and leukaemia-free survivals were 81.7% and 66.8% respectively.

**Summary/Conclusions:** CLAM resulted in a high CR rate for AML in first relapse or refractory to first-line induction therapy, which was associated with an acceptable toxicity profile.

**PB1680**

FATAL EVOLUTION IN THE FIRST 96 HOURS OF PATIENTS DIAGNOSED WITH ACUTE LEUKAEMIA: ANALYSIS OF A SERIES OF 346 CONSECUTIVE CASES OF ACUTE LEUKAEMIA

S. Martin-Batista1,*, J. M. Rayá,† T. Martín-Santos1, B. Soría1, R. Arcas1, M. Moreno1, S. Lakhwan1,‡ B.-J. González-González1,‡ M.-T. Hernández-García1
1Hematology and Hemotherapy, Hospital Universitario de Canarias, La Laguna, Spain

**Background:** The very early death of a newly diagnosed acute leukemia (AL) patient is very frustrating, and there are very few published works (except for the case of acute promyelocytic leukemia, APL) analyzing this circumstance and the features of these patients.

**Objectives:** was to study the main characteristics of patients with acute leukemia who died within the first 96 hours after diagnosis in our centre in the last 15 years.

**Methods:** We studied all cases of acute leukemia diagnosed in our institution between April 2002 and January 2017, focusing on the analysis of those who died within the first 96 hours after diagnosis. In this subset of patients, we collected data concerning clinical presentation, hemogram, biochemical parameters, coagulation status, performance of a bone marrow aspirate, acute leukemia subtype, started therapy, initiation or not of induction chemotherapy, time elapsed from diagnosis to death (hours), and cause of death, among others.

**Results:** A total of 346 consecutive cases of acute leukemia were recorded in this period of time: 222 of acute myeloid leukemia (AML, 64%) and 124 of acute lymphoblastic leukemia (ALL, 36%). Thirty-three patients were diagnosed of acute promyelocytic leukemia (15% of all AML). Those patients who died in the first four days after the diagnosis were only seven (2%), with a median of 45 hours (range 21-96) between clinical and analytical findings. These cases are shown in the Table 1. They were 5 men and 2 women with a median of 57 years (range 22-91). Two of the seven patients had an APL (6% of all diagnosed APL). All patients showed leukocytosis, but hyperleukocytosis was only recorded in 2/7 patients, and severe thrombocytopenia (Plt ≤ 20 x109/L) in 3/7. There was possibility of bone marrow aspiration only in 4/7 cases. Coagulopathy was detected in four of six patients, including criteria for disseminated intravascular coagulation (DIC) in three cases. The exitus took place in the Intensive Care Unit in 5 cases, while it occurred in the Hematology facility in two.

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
</table>

**Summary/Conclusions:** In our experience, about 2% of patients with acute leukemia die within the first 96 hours after diagnosis (including 6% of APL). Clinical and analytical features of this subset of patients are very heterogeneous, although AML clearly predominate on ALL. More extensive and multicenter studies are needed to deepen into the circumstances conditioning this early fatal course of the disease.

**PB1681**

PRIMARY Posaconazole PROPHYLAXIS IN ACUTE MYELOID LEUKAEMIA - A SINGLE CENTER REAL LIFE EXPERIENCE

T. Fıratlı Tuğlular1,*, T. Özgümüş1, T. Elibol1, F. Pepedi Tannkulu1,‡, F. Gençeli1, A. Sezgin1, Y. İpek1, B. Ertuğrung Şengel, A. Tekin1, B. Kömürcü1, H. Bilginer1, C. Mutlu2, T. Toştap1, I. Ağaçgündüz1, Z. Odabaş1
1Hematology, Marmara University, Istanbul, 2Hematology, Dr Ersin Arslan Research & Training Hospital, Gaziantep, 3Infectious Diseases and Clinical Microbiology, Marmara University, Istanbul, Turkey

**Background:** Invasive fungal infections (IFI) are a major cause of mortality and morbidity in acute myeloid leukemia (AML) patients receiving remission induction therapy, and relapsed/refractory AML patients. Posaconazole prophylaxis has shown the greatest benefit in preventing IFI in AML. AML.

**Aims:** We present the data of our real-life experience in AML patients under PP. Methods: We have retrospectively reviewed the data from 82 AML patients...
receiving 105 cycles of chemotherapy between June 2012 and December 2016 in Mainz University Perioperative Research and Training Hospital. Median patient age was 50 years (18-73); and there was no significant gender difference (38 female vs 44 male (46% vs 54%). All patients had active disease, 78 (74.3%) of them received 3+7 (idarubicine - ara-c), 25 (23.8%) of them FLAG-Ida, 1 patient received EMA and 1 patient received CLARA chemotherapy protocol. Acute promyelocytic leukemia was excluded from the analysis. All patients received posaconazole as oral suspension at the dose of 200 milligrams three times daily starting on the first day of chemotherapy. Prophylaxis was continued until marrow regeneration, or occurrence of IFI, or onset of adverse events, or discontinuation due to other reasons. All fungal infections were classified as possible, probable, or proven according to European Organization for the Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG) consensus criteria.

**Results:** Mean posaconazole prophylaxis duration was 20±13 (1-68) days. This duration was 29.7 days (16-50) in patients receiving prophylaxis until marrow recovery. In patients receiving prophylaxis in 8.9 (9-34) days IFI under prophylaxis and 12.7 days (1-68) in prophylaxis discontinuations due to adverse events and other reasons. Posaconazole prophylaxis was administered until marrow recovery without IFI (clinical success rate) in 42 of 105 (40%) chemotherapy cycles. In 18 cycles prophylaxis was stopped after diagnosis of IFI (7/17). Discontinuations were due to adverse events in 6 cycles (5.7%), and to other reasons (diarrhea, intolerance of oral medication, recurrent high grade fever, death) in 39 cycles (37.1%). IFI incidence under effective posaconazole prophylaxis was 28.1% (18/64). Total clinical failure rate was 60% (63/105). IFI was diagnosed with pulmonary nodules in 12 of 18 patients (66.6%, EORTC-MSG: probable), with galactomannan positivity in 3 patients (16.6%; EORTC-MSG: probable), and with fungal culture in 3 patients (16.6%; EORTC-MSG: proven). Data from 70 patients were available for mortality analysis. In patients receiving effective posaconazole prophylaxis, all-cause mortality rate at day 100 was (8/44; 20.4%) significantly lower than patients unable to continue posaconazole prophylaxis (12/26; 46.1%) (p=0.0023). In the subset of patients receiving prophylaxis as planned; there was no statistically significant difference in IFI incidence between previously untreated AML (13/46; 28.2%) and relapsed/refractory AML (5/18; 27.7%).

**Summary/Conclusions:** In our real-life experience, we have demonstrated early effective prophylactic posaconazole prophylaxis. Although our IFI rate was comparable to other real-life data, our clinical failure rate was slightly higher. This is probably due to compliance issues, since in many chemotherapy cycles (37.1%) posaconazole was discontinued due to other reasons such as drug intolerance. Although not as effective as in the clinical trials; our data still supports the use of posaconazole prophylaxis in high risk AML patients.

**PB1682**

**CLINICAL AND PROGNOSTIC VALUE OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS IN ROUTINE CLINICAL PRACTICE – SINGLE CENTER EXPERIENCE**

A. Radzhabova1, S. Voloshin1, I. Martynykevich1, V. Shuvav2, M. Ivanova3, E. Motyko1, N. Cybakova1, L. Polushkina1, D. Shikhtababaev1, N. Poltkhona1, S. Tyranova1, M. Zenina1, S. Kudryashova1, A. Chechetkin1

1Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation

**Background:** Detection of FLT3 gene mutations in acute myeloid leukemia (AML) now recognized as an unfavorable factor that affects the disease course, emerging the risk of relapses and overall survival (OS) shortening. Although about 30% of AML patients harbor one of the FLT3 gene lesion, at present there are no internationally standardized assays to quantify FLT3 mutation burden and no results of randomized clinical trials intended to individualize AML treatment based on FLT3 status. Some hematologists advocate to allo-SCT as consolidation in FLT3 ITD+ patients, but this way could be hard in frail and old patients and in countries with low access to transplant techniques. On the other hand, the development of target drug therapy – FLT3-kinase inhibitors gives us a new hope for improvement in the treatment results of such poor-prognosis subset of AML patients.

**Aims:** To assess the frequency of FLT3 gene mutations and its impact on clinical survival of the patients with acute myeloid leukemia (AML) in routine clinical practice.

**Methods:** We have analyzed FLT3 gene mutation frequencies, complete blood count (CBC) parameters, karyotype and survival outcomes per FLT3-mutation status in 199 patients with AML (83 male / 116 female). The median age at diagnosis was 52 years (20-86 years). To determine FLT3 gene mutations we used the method of polymerase chain reaction (PCR) with subsequent restriction. FLT3 gene mutations were classified as internal tandem duplication (FLT3-ITD) and point mutation in the “A-loop” (FLT3-TKD). Statistical analysis was included Kruskal-Wallis ANOVA and Kaplan-Meier curves.

**Results:** We observed next FLT3 gene mutations rates: FLT3-ITD - 22.6% (45/199), FLT3-TKD 5.5% (11/199), FLT3-ITD and FLT3-TKD in combination 1.0% (2/199), other 70.8% (141/199) patients had no mutations (FLT3-). CBC data at the time of diagnosis were as follows (median [max-min]): - FLT3-TKD: Hb 9.7 (3.7-13.0) g/dl, WBC 40.3 (0.6-400.0) x 109/L, blasts 80% (21-100), platelets 60 (2-140) x 109/L; - FLT3-TKD: Hb 10.2 (5.8-12.8) g/dl, WBC 62.4 (1.7-362.0) x 109/L, blasts 68% (23-100), platelets 55 (12-115) x 109/L; - FLT3-ITD+TKD: Hb 5.8, 8.4 g/dl, WBC 37.0, 157.0 x 109/L, blasts 65%, 86%, platelets 38, 186 x 109/L; - FLT3: Hb 9.0 (2.8-14.0) g/dl, WBC 12.9 (1.0-260.0) x 109/L, blasts 64% (20-103), platelets 63 (1-334) x 109/L; Significant differences across the groups were seen only in W.E.L blasts. Chromosomal aberrations were revealed in 38% of FLT3-ITD, 64% of FLT3-TKD, none of FLT3-ITD+TKD and 51% of FLT3- patients. All patients received chemotherapy (7+3, 5+2, HAM). Transplantation of hematopoietic stem cells (SCT) was performed in 28 (allo/auto 17/11) (14%) patients: FLT3-ITD allo-3; FLT3-TKD allo-1, auto-1; FLT3-allo-13, auto-10. We found significant (p=0.00024) differences regarding to OS between FLT3-ITD, FLT3-TKD and FLT3- patients (Figure 1). Median survival times were: 5.1 months for FLT3-TKD, 7.1 months for FLT3-TKD and 13.0 months for FLT3- patients.

**Figure 1.**

**Summary/Conclusions:** We confirmed the role of FLT3 gene mutations as an unfavorable factor for AML patients in routine clinical practice by own experience. The investigation of qualitative assessment potential and target therapy value especially in SCT ineligible FLT3 gene mutations positive patients has of great value for AML management.

**PB1683**

**TARGETING ENDOTHELIAL DYSFUNCTION FOR PROTECTION FROM ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN PATIENTS WITH ACUTE LEUKEMIA AND CO-MORBID ISCHEMIC HEART DISEASE**

T. Lymanets1, I. Skrypnyk1, G. Maslov1

1Chair of Internal Medicine #1, Ukrainian Medical Stomatological Academy, Poltava, Ukraine

**Background:** Cardiotoxicity of chemotherapeutic drugs, in particular anthracycline antibiotics (AA), is one of the biggest problems in treatment of patients with acute leukemia (AL). Chemotherapy with AA is accompanied by systemic endothelial dysfunction, increasing the cardiovascular toxicity risk and promoting vascular complications. Patients with co-morbid ischemic heart disease (IHd) are at extremely high risk of myocardial injury and in need of anthracycline cardiotoxicity (AC) prevention.

**Aims:** To assess the effectiveness of L-arginine in the prevention of endothelial dysfunction as a predictor of acute AC in patients with AL and co-morbid ischemic heart disease.

**Methods:** A total of 66 patients with newly diagnosed acute leukemia (acute lymphoid leukemia – 7 patients, acute myeloid leukemia – 59 patients) and co-morbid ischemic heart disease were included in the study. The cohort consisted of 43 (65%) males and 23 (35%) females, age of 54–72 years, ECOG I-II. The duration of IHD ranged from 3 to 15 years. Chemotherapy (CT) schemes of 34 (51.5%) males and 32 (48.5%) females, age of 54–72 years, ECOG I-II. The cohort consisted of 34 (51.5%) males and 32 (48.5%) females, age of 54–72 years, ECOG I-II.

**Results/Conclusions:** In our real-life experience, we have demonstrated early effective prophylactic posaconazole prophylaxis. Although our IFI rate was comparable to other real-life data, our clinical failure rate was slightly higher. This is probably due to compliance issues, since in many chemotherapy cycles (37.1%) posaconazole was discontinued due to other reasons such as drug intolerance. Although not as effective as in the clinical trials; our data still supports the use of posaconazole prophylaxis in high risk AML patients.
Results: In the debut of AL prior to the CT in all 66 (100%) patients the increased activity of total NOS in 3.8 times compared with the norm (p<0.001) was noted, with simultaneously reduced concentration of [NO2] in 1.5 times relatively normal values (p<0.05) (Table 1). As a result of two CT courses of remission induction in patients of group I the tendency to reduce the total NOS activity compared with its level before treatment was observed. At the same time the significant decrease of [NO2] in 1.8 times relatively normal values (p <0.01) and a trend to lower their content in 1.2 times compared with the data before treatment (p<0.05) was noted. These changes constitute the violation of NO-dependent vasodilation mechanism and endothelial dysfunction intensification. Provided achieving low cumulative dose of AA in patients of group II on the background of AC prevention with L-arginine showed a significant decrease in 1.9 times the total NOS activity (p<0.001) with a simultaneous tendency to increase concentration of [NO2] in 1.3 times (p>0.05) compared to that before treatment.

<table>
<thead>
<tr>
<th>Indicators of NOS and NO2 in AL in CT dynamics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I - Phase baseline</strong></td>
</tr>
<tr>
<td>Healthy (n=16)</td>
</tr>
<tr>
<td>pts</td>
</tr>
<tr>
<td>1st course</td>
</tr>
<tr>
<td>210±140</td>
</tr>
<tr>
<td>235±180</td>
</tr>
<tr>
<td>240±180</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Thus, during the CT with the inclusion of AA without L-arginine in patients with AL and co-morbid IHD we observed the depletion of NO synthesis and production, accompanied by endothelial dysfunction impairment. The additional appointment of L-arginine on the background of CT can restore synthesis of NO and, respectively, the mechanism of NO-dependent vasodilation, thus reducing the risk of early anthracycline cardiotoxicity development.

PB1684

CLINICAL CHARACTERISTICS AND SURVIVAL OUTCOMES IN ACUTE ERYTHROID LEUKEMIA (AML-M6): AML/MDS WORKING PARTY STUDY OF KOREAN SOCIETY OF HEMATOLOGY


1Internal Medicine, Kyung-Hee University Medical Center, 2Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 3Internal Medicine, Seoul National University College of Medicine, Seoul, 4Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, 5Internal Medicine, Korea University School of Medicine, Anam Hospital, Seoul, 6Internal Medicine, Pusan National University Hospital, Busan, 7Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 8Internal Medicine, Yonsei University College of Medicine, 9Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 10Internal Medicine, Gachon University Gil Medical Center, Incheon, 11Internal Medicine, Inje University Busan Paik Hospital, Busan, 12Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea, Republic Of

Background: Acute erythroid leukemia is a morphologically distinct and rare entity designated as M6 in FAB classification. In Korea, patients with AML-M6 have been treated as acute myeloid leukemia with intensive chemotherapy whenever possible rather than as myelodysplastic syndrome. The 2016 revision of the WHO reclassified erythroid/myeloid subtype (a case with ≥50% BM erythroid precursors and ≥20% myeloblasts among non-erythroid cells) to MDS category based on the close biological and genetic relationships between them. Aims: The aims of this multi-center study were to characterize clinical characteristics and treatment outcomes in patients with newly diagnosed acute erythroid leukemia.

Methods: Clinical data from newly diagnosed M6-AML patients between 2002 and 2012 at 11 academic centers were retrieved from the electronic registry data of AML/MDS working party of Korean Society of Hematology. Conventional cytogenetic analysis was performed on metaphase cells prepared from bone marrow aspirate by G-banding technique. Patients were classified according to the UK MRC cytogenetic risk criteria and the International Prognostic Scoring System (IPSS) risk groups for MDS based on karyotypes. Survival curves were analyzed using the Kaplan-Meier method and compared with a log-rank test. A p-value <0.05 was considered statistically significant.

Results: A total of 84 patients with AEL (M6-AML) as defined by 2008 WHO classification criteria were included in this study. The median age at diagnosis was 55 years with following distribution: age ≤ 49, 34 patients (40.5%); age 50 – 59, 17 (20.2%) patients; 60 – 69, 19 (22.6%) patients; age ≥70, 14 (16.7%) patients. There were 50 (59.5%) males and 34 (40.5%) females. Median hemoglobin, white blood cell count, and platelet count were 8 g/dL, 3.69 × 10^9/L, and 58 × 10^9/L, respectively. Peripheral blood blasts were observed in 55 (65.5%) patients. Cytogenetic results were available in 80 patients. Among them, karyotype was normal in 43 (53.8%) and complex in 13 (15.5%) patients. Trisomy 8 was observed in ten (12.5%) patients. Monosomies of chromosome 5 and 7 were observed in five (6.2%) and four (5.0%) patients, respectively. Four (5.0%) patients had t(9;22)(q34;q11.2). Cytogenetic risk group assignment to UKMRC criteria were intermediate in 63 (78.8%) patients, and poor in 17 (21.2%) patients. Seventy-two (85.7%) patients received induction chemotherapy and 55 patients (76.4%) achieved complete remission. Nineteen patients received two or three cycles of induction chemotherapy. Thirty-eight patients (45.2%) underwent autologous hematopoietic stem cell transplantation (HSCT): 8 patients, matched-sibling donor; 15 patients, matched-unrelated donor; 5 patients, alternative donor were used. Treatment-related mortality of HSCT was observed in five (17.9%) patients. Fourteen (16.7%) among the study patients relapsed. The median overall survival (OS) of total 84 study patients was 21 months. Patients with intermediate risk karyotype showed better median OS than those with poor risk karyotype (22 months vs 7 months, P=0.020). The median OS was similar in patients with good and intermediate IPSS, but significantly worse in patients with poor IPSS (21 months, 27 months, 7 months, respectively, P=0.026) (Figure 1).

Figure 1.

Summary/Conclusions: Patients in this study were younger than previous studies. The most common aberrations in chromosomes are trisomy 8, followed by numerical changes in chromosome 5 and 7. The median in total patients was 21 months with many patients received intensive treatment, including HSCT in 45.2% of patients. We also confirmed that patients with poor-risk karyotypes had very poor median OS of 7 months. Therefore, we suggest that although erythroid/myeloid subtype is similar to the MDS with excess blast, treatment decision might be carefully considered according to the karyotype risk.

PB1685

PREGNANCY ACCUMULATES UNFAVORABLE MOLECULAR GENETIC AML AND SHOULD BE CONSIDERED AS A POOR PROGNOSTIC FACTOR

V. Troitskaya1,*, E. Parovichnikova1, A. Sokolov1, A. Kokhno1, Z. Fidarova1, A. Sidorova1, O. Gavrilha1, G. Galstian1, A. Bazhenov1, L. Kuzmina1, M. Drokov1, S. Makhinya1, O. Latishkevich1, A. Zvereva2, A. Olenev3, O. Korobitsyna4, A. Korobkin4, V. Savchenko1

1National Research Center for Hematology, 2Centre of Family Planning and Reproduction, 3City Clinical Hospital №24, Moscow, 4Chelyabinsk regional hospital, Chelyabinsk, Russian Federation

Background: Acute myeloid leukemia (AML) during pregnancy – is a rare clin-
trical condition that limits the possibility to conduct large prospective clinical studies. All publications present small retrospective data and case reports. Most of them conclude that pregnancy doesn’t affect the prognosis of acute leukemia. 

**Aims:** To assess the pregnancy, as independent prognostic factor, in non APL AML-patients (pts), prospectively treated within Russian AML multicenter studies. 

**Methods:** From 1990 to 2017 y the Russian Acute Leukemia study group has treated 33 with de novo AML pregnant women (Me-27 (21-42) yrs), AML was diagnosed in the 1st trimester in 1 woman (3%), in the IIInd 15 (45,5%), in the IIIInd 17 (51,5%). Molecular genetic risk group was estimated in 27/33 pts: 52% (n=14) were referred to the intermediate risk group and 48% (n=13) to the poor prognosis. High risk group comprised complex karyotype (n=5), -7/7q(del7) (n=4), translocations involving gene MLL (n=2). 

**Results:** One pt at the 1st trimester medical abortion was conducted and 11 women delivered at the gestation age of 34-40 weeks before chemotherapy (CT). 21 pregnant women received CT, that was started at 23 (14-32)nd weeks of gestation. Classical cytogenetics were applied in all of pts: either with daunorubicin (45-60 mg/m²), or mitoxantrone (10 mg/m²), or idarubicin (12 mg/m²) regarding the treatment study-protocol. 

**Summary/Conclusions:** Our results demonstrated almost half of women, who were AML diagnosed during pregnancy, are referred to the poor molecular genetic prognostic group; they demonstrated very low OS and DFS with their improvement after allo-BMT. 

**PB1686**

CLOFARABINE IN RELAPSED-REFRACTORY ACUTE MYELOGENOUS LEUKAEMIA: A SINGLE CENTRE EXPERIENCE

B. Scappini1,2, G. Gianfaloni1, M. Armento2, F. Manneli1, C. Iutini1, M. Piccioni2, C. Biasiotti2, F. Fanconi2, M. Di Gioia2, A. Bosi2

1Haematology, AOUI Careggi Florence, 2Haematology, University of Florence, Florence, Italy

**Background:** Clofarabine has been shown to be effective in AML patients, mainly in induction therapy at high dose cytarabine. 

**Aims:** On the basis of these reports, we tested clofarabine in association with high dose cytarabine in relapsed/refractory AML patients, selecting cases of primary refractoriness to at least two induction therapies, relapsed but refractory to a standard re-induction treatment, or very early relapse. 

**Methods:** From March 2016 to June 2016 we treated 67 patients with a regimen including clofarabine at 22.5 mg/m² daily on days 1-5, followed after three hours by cytarabine at 1 gr/m² daily on days 1-5. Among the 67 patients, 24 were in first relapse, 29 in second or third relapse, 14 with resistant disease. The mean age was 54 years (range: 36-77 years). 

**Results:** 20/67 patients achieved a complete remission (29.9%), 4/67 a partial response (6%), 38/67 had resistant disease (56.7%), 3/67 died of complications during the aplastic phase (4.4%). The most frequent non haematologic adverse events were: transient liver toxicity (41% grade 1-2, 11% grade 3-4) skin rash (33%), vomiting (28%), diarrea (15%). Comparing with other salvage strategies, clofarabine showed a significant difference regarding bone marrow recovery (median time to ANC recovery 21 days). Febrile neutropenia was observed in 58 cases (85%), with bacterial infections microbiologically documented in 20 patients (29%) and 2 cases (3%) of fungal infections. The median overall survival of the whole cohort was 115 days, with a median event-free survival of 111 days. Among the responding patients, 16 (24%), underwent allogeneic bone marrow transplantation; in these selected patients, median overall survival was 185 days.

**Summary/Conclusions:** These results suggest that the clofarabine-ARA-C regimen was able to induce a response in about one third of this particularly poor prognostic category of patients, with a safety data consistent with previously reported salvage therapies. Nevertheless, long term results remain still and completely unsatisfactory. Further studies, with different combinations or in more selecting conditions, are warranted.

**PB1687**

PRESENCE OF MULTIPLE DRIVERS IN THE SELECTION OF HIGH AND LOW INTENSITY CHEMOTHERAPY IN AML

B. Pandya1, A. Hadfield2, B. C. Medeiros3, S. Wilson1, E. Berrak1, T. Bailey2, S. Flinders1, A. Rider2, L. Horvath1

1Astellas Pharma Inc., Northbrook, United States, 2Adelphi Real World, Cheshire, United Kingdom, 3Stanford University, Stanford, United States

**Background:** Data on the key drivers of initial treatment choice for patients diagnosed with acute myeloid leukemia (AML) in the United States is limited. The use of age as a selection driver of induction therapy is well established; however, there is limited data and a knowledge gap about additional factors driving treatment selection. 

**Aims:** This analysis explored the key physician drivers, which led to the selection of high- and low-intensity induction therapy in AML patients. 

**Methods:** Data from the Adelphi AML Disease Specific Programme, a real-world, cross-sectional survey conducted between February–May 2015, was analyzed. A total of 61 hematologists/oncologists provided additional information about their management and treatment choices for AML patients via survey. Each physician was provided a pre-specified list of 16 patient characteristics. Via two separate questions, they were asked to select those considered important when choosing high and low intensity chemotherapy for their AML patients. Characteristics were analyzed descriptively and ranked based on the frequency of mention from highest to lowest. 

**Results:** The top three drivers for decision making when selecting high and low intensity treatment were: patient age, performance status and presence of comorbidities. More than 60% of physicians would prescribe high-intensity treatment for patients aged <65, with a good performance status or with no comorbid conditions. Over half of physicians would consider those who are eligible for a stem cell transplant or have a mutation in the CEBPA gene to be eligible for high-intensity chemotherapy (Table 1). Low-intensity chemotherapy was considered by more than 60% of physicians as being the most appropriate treatment for patients aged ≥65, with a poor performance status or increased number of comorbid conditions. A total of 38% of physicians would likely consider low-intensity chemotherapy if the patient was ineligible for a stem cell transplant or had had previous cancers or exposure to radiation/chemotherapy in the past. 

**Table 1. Top 5 patient characteristics considered by physicians when choosing high- or low-intensity treatment in AML.**
Background: IRAIN which is produced from the insulin-like growth factor type 1 receptor (IGF1R) implicated locus is a newly identified IncRNA. There are very little knowledge about the specific role of this IncRNA in tumorogenesis presses. Recent studies were revealed that IRAIN is down-regulated in leukemia cell lines and viral expression of the IRAIN IncRNA inhibits tumor cell migration, suggesting a tumor suppressor function for this transcript.

Aims: In this study, we attempted to examine the expression level of IRAIN in different cytogenetic subtypes of AML patients.

Methods: Using quantitative polymerase chain reaction (qPCR) the expression level of IRAIN were analyzed in bone marrow specimen of AML patients (n=76) and healthy individuals (n=18).

Results: IRAIN expression was found to be remarkably decreased in AML patients compared with healthy individuals (p= 0.02). Significant IRAIN down-regulation was observed in all FAB types except for the M3 (p= 0.11). When we analyzed the expression level of IRAIN in different cytogenetic subtypes of AML patients the statistically down-regulation of IRAIN was observed only in poor prognosis AML patients (p=0.008).

Summary/Conclusions: Our results suggest that down-regulation of IRAIN IncRNA might play a role in the AML development and hence may be a potential prognostic factor and serve as therapeutic target for AML treatment.

PB1689

PERFORMANCE OF THE LEUKOSTRAT® CDX FLT3 MUTATION SIGNAL RATIO ASSAY TO DETECT INTERNAL TANDEM DUPLICATION AND TYROSINE KINASE DOMAIN MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

A. Osgood1,*, E. Shakeri2, V. Atkinson1, N. Kha3, C. Simon4, J. Thomas1,2, S. Muller1, A. Osgood1

1Invivochrome Technologies, San Diego, United States, 2Product Development, Invivochrome Technologies, 3Laboratory for Personalized Molecular Medicine (LabPMM), San Diego, United States, 4Laboratory for Personalized Molecular Medicine (LabPMM), Kawasaki, Japan

Background: Acute myeloid leukemia (AML) in general has a poor prognosis. Assessment of the mutation status of the FLT3 (fms related tyrosine kinase 3) receptor gene in AML is the most important prognostic indicator of disease outcome, which is often substantial, as many studies in AML have shown that the presence of FLT3 activating mutations portends a poor prognosis. The LeukoS- trat® CDX FLT3 Mutation Assay targets regions of the FLT3 gene to identify internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations. Since this assay is a signal ratio (SR) assay with a validated cutoff of 0.05, demonstration of international harmonization of results is paramount. FLT3 ITD mutations are caused by duplication and insertion of a portion of the FLT3 gene that includes the region in and around the juxtamembrane region of the FLT3 gene. These mutations vary in both the location and the length of the inserted duplicated DNA sequence. ITD mutations result in constitutive autophosphorylation and activation of FLT3. FLT3 TKD mutations are usually caused by nucleic acid substitutions and/or deletions that result in a change in the amino acid sequence in this highly-conserved catalytic center. TKD mutations, such as D835 and I836 substitutions and deletions, result in constitutive autophosphorylation and activation of FLT3.

Aims: To assess the performance of the Invivochrome® LeukoStrat® CDX FLT3 Mutation Assay.

Methods: White blood cells were removed from peripheral blood after 30 minutes of centrifugation at 2000 x g to create leukocyte depleted blood (LDB). Various ratios of four ITD positive cell lines, with insert sizes from 21 bp to 279 bp, and one TKD positive cell line, with a D835 substitution mutation, were created over a wide range of signal ratios (0.02 to 1.83) and added to the LDB. Mononuclear cells were isolated from the contrived LDB samples. DNA was extracted and amplified via PCR. The amplicons were analyzed via capillary electrophoresis. The assay measured the ratio of signals from mutation against a background of a wild type. A FLT3 mutation was detected (and reported as positive) if the mutant:WT type SR met or exceeded the clinical cut-off of 0.05. Proprietary software calculated the SR and reported positive or negative. Clinical specimens were de-identified by LabPMM in San Diego. DNA from thirty specimens was tested by three laboratories: LabPMM LLC in San Diego, LabPMM GmbH in Germany and LabPMM Gk in Japan.

Results: The analytical performance of the LeukoStrat® CDX FLT3 Mutation Assay was evaluated using contrived LDB samples, with known FLT3 mutations. For limit of blank (LoB), the SR was 0.00 in the ITD assay and 0.00 to 0.01 in the TKD assay, which is well below the clinical cutoff SR of 0.05. The limit of detection in the ITD assay detected allelic ratios of 0.03, 0.05, and 0.53 above the LoB SR in more than 95% of samples for insertions sized at 30 bp, 126 bp and 279 bp, respectively. The limit of detection in the TKD assay detected an allelic ratio of 0.05 above the LoB. For precision and reproducibility, the SR%CV was within 3-14% across ITD and TKD mutation types regardless of reagent lots, equipment, or operator.

There was 100% agreement between all three clinical LabPMM laboratory sites.

Summary/Conclusions: This robust assay produced a SR%CV less than 15% regardless of reagent lot, equipment or operator. The high reproducibility between the three laboratories on three different continents provides evidence that the Invivochrome® LeukoStrat® CDX FLT3 Mutation Assay is an internationally standardized assay.

PB1690

CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA

S. Tousson1,*, N. Rekab, F. Lamraoui1, S. Oukid1, K.-M. Benlabd1, H. Brahimi1, M.T. Abad1

1Hematology, EHS ELCC CAC, Bilda, Algeria

Background: Acute Myeloid leukemia is classified into different prognostic groups according to their cytogenetic profile; AML with t (8; 21) or inv(16) (16; 16) called AML CBF belong to a prognostic group of low-risk; they represent 15% to 20% of the AML.

Aims: The aim of this study is to present clinical, cytogenetic features and outcome of this group of patients (pts) in an emerging country.

Methods: Cytologic diagnosis of AML CBF is completed by immunophenotypic and cytogenetic analysis; t(8; 21), inversion 16(t;16) and del16q22. Induction treatment: Daunorubicin 45 to 90 mg/m² day (d1-d3)+Cytarabine 100 mg/m² (d1- d7) (with progressive doses if major leukocytosis). Assessment between d 21 and d 28 by bone marrow analysis; If failure a study of the donor cells is under-taken by Genexa- bine high dose 3 m²/12 h d1, d3, d5. Central nervous system prophylaxis for patients (pts) with AML4, M5 and hyperleukocytosis forms. Consolidation: Cytarabine high dose: 2 to 3 curies; low dose of chemotherapy for pts older than 55 years or pts presented severe toxicity at the first induction. Research of FLT3 and residual disease is not available in our laboratory; hematologic stem cell transplantation (HSTC) was proposed for all pts; if no compatible donor, 3 courses of Cytarabine high doses was instituted.

Results: From 2010 to 2016, cytogenetic analysis was performed in all cases of AML of which 58% with 16 0.18% of LAM - CBF were diagnosed. The male to female ratio was 0.5. Average age was 37 years (16-72); t (8;21) was found in 28 pts (16 M,12F); inversion (16)(p13.11;q22.1); t(16;16)(p13.11;q22.1) and del16q22 were found in 30 pts (12M,18F), respectively in 27 pts, 2 pts and 1 pt. Four cases of del (16)(p13) were associated with inv(16). For inv(16), FAB subtypes were AML4 (26). AML2 (1) and 3 AML; For t(18;21), there was 26 AML2 and 2 AML4. Evaluation of induction: not evaluable: 13 cases, Complete Remis- sion (CR): 38 cases (65,5%); for 7 cases in failure , a second induction was proposed, we obtained 2 CR. 15 pts were transplanted. Outcome: 27 pts are alive in CR of which 12 transplanted . 31 pts died of which 18 toxic deaths ( 15 after induction treatment and 3 after engraftment). Median overall survival for inv(16): 11 months vs 15 months for t(8;21) (p=0.87).

Summary/Conclusions: In our study, the frequency of the CBF AML is closer than those described in another Algerian study and literature: 18.6% vs 15.4% and 20% respectively; a slight predominance of the inv 16 ot t (16; 16) identical translocation (21). Our results are in accordance with our study and lower than the CALGB study. We noted less relapse compared with literature. Relapses were observed in pts with poor prognostic factors: age, leukocytosis and failure to first induction. Regarding the favorable prognosis of AML CBF, our results are bad because the high rate of toxic deaths. The CBF AML are characterized by low risk of relapse. At the time of diagnosis, but with a 30% relapse rate essentially when associate poor prognosis factors such as a kit mutation that increases the risk to 70%, mutation FLT3, advanced age, the leukocytosis, severe thrombocytopenia and additional cytogenetic abnormalities.

PB1691

FLOW CYTOMETRY ANALYSIS SOFTWARE FOR REMOTELY LOCATED HAEMATOLOGISTS

M. Kelly1,2

1Haematology Department, Our Lady's Childrens Hospital Crumlin, Dublin, Ireland

Background: Current flow cytometry software packages are unsuitable in cases where the interpreter of the data isn’t physically located at the computer with the software installed. This is particularly disadvantageous in urgent situations, such as in the diagnosis of acute leukemia.

Aims: Develop a tool to allow haematologists to analyse flow cytometry data from anywhere on any internet-enabled device e.g. tablet, smartphone, laptop, PC.

Methods: We came up with principles a new software package should adhere to: 1. should be accessible from any Internet-enabled device e.g. iPad, Android phone, Blackberry, laptop; 2. should not require installation; 3. FCS data should be anonymised; 4. data transfer should be secure and encrypted; 5. software must include all basic functionality of flow cytometry software e.g. dot plot graphics, histogram graphics and gating 6. should put collaboration to the forefront e.g. analysis can be instantly linked to a web URL.

Results: The resulting software package is a web app which is accessible from any internet-enabled device e.g. smartphone, tablet, laptop or PC. On mobile devices such as an iPad, touch is used for drawing of gates, selection of quadrants, selections of parameters etc. On laptop’s and PCs, these are drawn via
the mouse or keypad. The software utilises the latest strides made in web technologies to respond to the varying screen sizes of devices, and display suitably sized graphs and gating information accordingly. Collaboration between parties is facilitated - a lab technician running the sample can upload the sample and the web app is available at https://www.redmatterapp.com as gating, can take place immediately and can then be instantly shared via a web URL. No sensitive file data is displayed within the platform. All data transfer happens via SSL encryption.

WEB TECHNOLOGIES TO RESPOND TO THE VARYING SCREEN SIZES OF DEVICES, AND DISPLAY SUITABLY SIZED GRAPHS AND GATING INFORMATION ACCORDINGLY. COLLABORATION BETWEEN PARTIES IS FACILITATED - A LAB TECHNICIAN RUNNING THE SAMPLE CAN UPLOAD THE SAMPLE AND THEN BE INSTANTLY SHARED VIA A WEB URL. NO SENSITIVE FILE DATA IS DISPLAYED WITHIN THE PLATFORM. ALL DATA TRANSFER HAPPENS VIA SSL ENCRYPTION.

Figure 1.

Summary/Conclusions: The latest web technologies can be effectively harnessed to enhance flow cytometry analysis and allow for faster, more accessible and more collaborative analysis. Within the field of haematology in particular, this opens up the option of remote diagnosis - a haematologist need not be in the lab, or even in the same country, to deliver a diagnosis.

PB1692
FLAG-IDA IN THE TREATMENT OF ACUTE LEUKAEMIA: SINGLE-CENTER EXPERIENCE
M.I. Goyanes Martin1,*, M.A. Canales Albindenda1, M. Fabra Urdiol1, M.D.M. Meijon Ortigueira1, V. Jimenez Yuste1
1Hematology, Hospital La Paz, Madrid, Spain

Background: A variety of different treatment regimens have been studied in an effort to improve outcomes of patients with relapsed or refractory acute myeloid leukemia (RR-AML), there appears to be no single superior approach. Spanish studies usually use the FLAG-IDA protocol (Fludarabine 30 mg/m2 days 1-4, Idarubicin 12 mg/m2 days 1-3, ara-C 2 mg/m2 days 1-5) in these patients.

Aims: To evaluate our response rates and the survival with FLAG-IDA protocol.

Methods: Descriptive study of a case series of patients with acute leukemia who received intensive induction chemotherapy with FLAG-IDA protocol at our hospital between January 2007 and December 2016. Biodemographic, histopathological, cytogenetic and molecular results and previous treatment were recorded. We analyzed the response rate, the 30-day mortality rate and the overall survival.

Results: 65 patients received treatment with FLAG-IDA protocol between 2007-2016, 36 of them female, with an average age of 53.4 years (DS=±23.3). We treated with this protocol mostly patients with relapsed or refractory acute myeloid leukemia (RR-AML) (primary refractory or resistant AML as defined by not achieving complete remission after 1 cycle of intense induction therapy); 60% (n=38) of patients had a RR-AML, 37% (n=23) of them were relapsed AML during chemotherapy and 6% (n=4) refractory disease. Based on European Prognostic Score (EPISO) for patients with RR-AML, 61% of them had a poor prognosis (10-14 points), 36% had an intermediate prognosis (7-9 points) and only 3% had a favorable prognosis (1-6 points). The next important group, 25% (n=17) were MDS patients transformed to AML. We had 9% (n=6) patients with treatment related AML and 6% with other acute leukemia (3 cases of refractory ALL and 1 case of biphenotypic leukemia). We observed a global response rate of 63%: 51% (n=33) of patients had a complete response (CR) and 12% (n=8) partial response, 17% (n=11) did not have a response and 20% of patients were not evaluated after to receive the treatment because they had a early death. The 30-days mortality rate was 21.5% (n=14), similar to the mortality rate observed in patients. We can see in the overall survival curve (picture 1) that most patients died first months after treatment, after that patients remain alive and we achieve a plateau. The median overall survival was 82 days (standard deviation: 25 days). 10 patients were alive when we analyzed the data (Figure 1).

Summary/Conclusions: Most AML patients ultimately die from their disease. In our case serie none died by any other cause. We had a similar response rate, mortality and overall survival that other groups in our country. Despite a variety of salvage therapy options, like FLAG-IDA protocol, prognosis in patients with RR-AML is generally poor and treatment is very complex.

PB1693
BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS - UNSUAL PRESENTATIONS AND UNFAVOURABLE OUTCOMES
M. Guenova1,*, A. Michova1, T. Dikov1, Y. Georgieva1, B. Spassov1, K. Prisadashka2, M. Balabanova2, V. Kaleva3, G. Balatzenko1
1National Specialised Hospital for Active Treatment of Hematological Diseases, 2Alexandrovska University Hospital, Sofia, 3University Hospital St.Marina, Varna, Bulgaria

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. Most patients (90%) with BPDCN have skin lesions and involvement of DS, peripheral blood, bone marrow, and lymph nodes. Very few cases have been described with lack of skin and or bone marrow manifestations at the time of diagnosis.

Aims: To characterise the clinical presentation and clinical outcomes of a cohort of consecutive patients with a rare blastic plasmacytoid dendritic cell neoplasm in a single institution.

Methods: Patients diagnosed with BPDCN at the National Hematology Hospital between 2010 and 2016 were retrieved from the database. The diagnosis was confirmed by morphology and immunophenotyping by flow cytometry and/or immunohistochernistry, according to 2008 WHO Classification of Hematopoietic Neoplasms. The relevant clinicopathologic features were reviewed.

Results: We identified 8 adult patients at a median age of 70 years (range: 37-84 years) with a male:female ratio of 6:2 (75%:25%) and only 1 child. Mean platelets 116.10^9/L. LDH was generally elevated with a mean of 962.8 U/L. At diagnosis the skin was involved in 5/9 patients. Five patients developed acute leukemia presentation with 40-95% of bone marrow infiltration. Interestingly, in 4 pts (50% of adult pts) the initial presentation affected other tissues and organs such as testis, bronchial wall, stomach and periorbital soft tissues, however, only the latter one case presented with a leukemic picture. Biopsies revealed diffuse, monomorphous infiltrate of medium-sized blast cells with irregular nuclei, fine chromatin with ≥1 nucleoli, scant and agranular cytoplasm, without angioinvasion or coagulation necrosis. Immunophenotype generally demonstrated CD45+, CD4+, CD56+, CD123+. No standard therapies were applied. Patients received CHOP or HyperCVAD or AML-induction therapy. However, response rates in adult patients were low and the mean OS was 2.6 months (ranging from early deaths before any treatment could be initiated to 10 months).

Summary/Conclusions: BPDCN is a rare aggressive disease that typically affects elderly patients. The most commonly affected non-hematopoietic organ is the skin, however any other organ or tissues can also be involved. Response to therapy if any is relatively short and long-term prognosis is poor despite of the site of presentation. Larger scale studies are warranted to understand the pathophysiology of the disease and to find optimal management.

Acknowledgements: Partial support by the National Science Fund.
Background: Western hospitals have achieved First Complete Remission (CR-1) and Overall Survival (OS) rates of 90% and 60% for children with Acute Myeloid Leukemia (AML), Intensified regimen of standard chemotherapy along with precise risk classification and improvements in supportive care are mainly attributed to this achievement.

Aims: We analyzed clinical data of our pediatric AML patients treated at KFSH&RC from 2005 to 2015 in order to assess the outcome of our treatment efforts including Hematopoietic Stem Cell Transplantation (HSCT).

Methods: A total of 155 pediatric patients with AML were registered at our institution from 2005 to 2015. 55.5% (86) were boys with a F:M ratio of 1.2:1 and median age at diagnosis 5.5 years (Min: 1.months, Max: 13.8 years). 12 patients were excluded from further analysis for not being able to complete induction. Following the Children’s Oncology Group (COG) Doxorubicin’s syndrome, 7.7% (11 of 143) had concomitant malignancies. 85.7% (120 of 143) were CNS-1, 27.4% (20 of 73) had MLL Gene rearrangement, 21.2% (14 of 66) were positive for TEL/AML1/ RUNX1/RUNX1T1 and 22% (13 of 59) had PML/RAR (P-Value: 0.044), Post-Induction BM Classification M-3 (P-Value: 0.034) and AML High Risk (P-Value: 0.003) were found to be significantly associated with Relapse. Age at diagnosis, or Time to CR-1 were not found to have any association with relapse. 51.9% (27 of 52) who relapsed, went for HSCT. With a median follow-up of 6.8 months, five year overall survival for our cohort of patients was (0.567±0.046); significantly poor (P-Value: 0.001) in relapsed (n=52, 0.170±0.051) compared to non-relapsed (n=82, 0.862±0.041); resulting in a five year overall survival of 0.472±0.044. Among relapsed group (n=52), five year overall survival was significantly better (0.160±0.073) for those who received HSCT (27) who did not (n=25, 0.114±0.073, P-Value: 0.029). Five year overall survival was also significantly better for Non-Relapse group (n=31, 0.828±0.070) compared to relapsed patients (n=27, 0.160±0.073, P-Value: 0.003) who did not receive HSCT (n=15).

Summary/Conclusions: The results of our treatment efforts are in conformity with the western literature. Precise risk classification can be a vital predictor in planning for first line and salvage therapies including HSCT for pediatric patients with AML.

PB1695

IS HIF-2 ALPHA A POOR PROGNOSIS FACTOR IN HUMAN ACUTE MYELOID LEUKEMIA? A SINGLE CENTER ANALYSIS - PRELIMINARY RESULTS

J. Dybko 1,*, D. Urbaniaik-Kudja 1, D. Szymczak 1, O. Haus 1,2, B. Jazwiec 1, M. P. Michalak 1, M. Kulczokowski 1
1Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, 2Department of Clinical Genetics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Background: Hypoxia-inducible transcription factors (HIF) are well known regulators of cellular response to hypoxia. HIFs control functional, metabolic and vascular adaptation to hypoxia on transcriptional level. HIF-1 alpha has been also described to be responsible for solid tumors chemoresistance, invasion, metastasis and relapse. The role of HIFs in leukemias has not been established yet. First report of poor outcomes of antileukemic treatment linked with overexpression of HIF-1α has been published. Moreover another HIF subunit - HIF-2 alpha - has been described in mouse model as increasing myeloid preleukemic cell proliferation and accelerating disease progression with reduced survival. On this background, we found interesting if HIF-α expression is associated with myeloid leukemia causes of progression in human. We have tried to find a connection between AML cell percentage expressing HIF-2 alpha and first line chemotherapy results.

Aims: The aim of the study was to determine the role of HIF-2 alpha in human AML.

Methods: We analyzed a 26 primary AML patients group (median age 54.5 (21-77), F/M – 13/13). The group consisted of 21 AML-NOS cases, 2 AML cases with inv(16), one case with t(6;9) and one with t(9;11) according WHO classification. ELN cytogenetic risk stratification divided the group into intermediate-1, intermediate-2 and adverse cases in 10, 12 and 4 patients respectively. Leukemia was treated with Daunorubicin, Cytarabine and Cladribine based first line chemotherapy. We collect bone marrow and blood samples before chemotherapy and blood samples alone 48 hours after chemotherapy start. In all samples leukemic blasts were counted and determined by flow cytometry and the subpopulation of HIF-2 alpha positive blasts was estimated as well. Volunteer bone marrow donors were the control group in this study and the CD34+ HIF-2α+ subpopulation was assessed in their bone marrow samples during the routine harvest procedure. The study was approved by the local Ethics Committee.

Results: After the first line chemotherapy 15 patients achieved complete remission (CR-group) and 11 did not (NR group). We did not find significant differences between the groups regarding patients age, the mean percentage of blasts in bone marrow and blood before the treatment, the percentage of HIF-2 alpha positive blasts in BM and blood before and 48 hours after the treatment start (data not shown). But the analysis of the percentage of HIF-2 alpha positive blasts in blood before and 48 hours separately in CR and NR groups revealed quite different dynamics. In CR group the mean percentage of HIF-2 alpha positive blasts was 14.65 (+33.32) and 8.48 (+11.63) before and after chemotherapy respectively (p=NS); In NR group the values were 11.74 (+22.6) and 24.01 (+33.68) respectively (p=0.007). The Cox analysis revealed HIF-2 alpha positive blasts in blood after chemotherapy to be proportional to death probability (p=0.0036) (Figure 2).

PB1696

RARE BCR/ABL FUSION PROTEINS AND THEIR CLINICAL SIGNIFICANCE INTO PH+ ACUTE MYELOID LEUKEMIAS

M. Pedimonte 1,*, T. Ottone 1, V. Alfonsod 2, A. Ferrarin 1, E. Conte 1, M. Divona 2, M. P. Bianchi 1, M. R. Ricciardi 1, S. Mirabili 1, R. Licchetta 1, F. Falco 1, A. Campagna 1, L. Cicconi 1, G. Galassi 1, S. Pelliccia 1, A. Lepore 1, F. Lo Coco 2, A. Tafuri 3
1Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, 2Department of Clinical Genetics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Background: The Philadelphia (Ph) (t(9;22)(q34.1;q11) results in an oncogenic BCR/ABL gene fusion, representing the hallmark of chronic myeloid leukemia (CML), although it has been also described in acute lymphoblastic (ALL) and myeloid (AML) leukemia. Three main different transcripts have been described (p210, p190 and p230), but rare atypical BCR breakpoints outside the cluster regions have been also reported and their clinical significance is under investigation. Atypical transcript p190 e6a2 is a rare fusion protein associated with aggressive phenotype and dismal prognosis. The breakpoint in BCR intron 6 is responsible for increased kinase activity and greater transforming potential because of the partial loss of the Guanine Exchange Factor (GEF) domain, completely absent in p190 proteins. This truncation could increase the BCR/ABL oncogenic activity.

Aims: In this report we describe rare cases of Ph+ AML patients with the atypical p190 e6a2 isoform.

Methods: Routine morphologic, immunophenotypic and genetic analyses were carried out in all samples at diagnosis. cDNA extracted from bone marrow was synthesized from 1 μg of total RNA. Most common AML genetic alterations were investigated and a quantitative RT-PCR (qRT-PCR) for p190 transcripts was performed. qRT-PCR assay for FLT3-ITD and p190 e6a2 transcript were sequenced to confirm BCR/ABL fusion.

Results: Case 1. A 78-years old male was admitted at our hospital with clinical and laboratory features allowing to make the diagnosis of AML. No evidence of a preceding CML (spleenomegaly or basophilia) was found. The karyotype on G-banded metaphases was 46,XY, t(9;22)(q34.11) detected. The molecular analysis was carried out on a first-line treatment based on daunorubicine. The molecular biology analysis revealed the simultaneous presence of the common p190 e1a2 and the rare e6a2 isoforms (Figure 1A). Because of persistent panmyelopenia and presence of blasts, according to the molecular data, he was then switched to TKIs treatment. Nevertheless, after 2 months, the patient was still active and a second line treatment was started. The patient was treated with Daunorubicine, Cytarabine and Cladribine based first line chemotherapy. The bone marrow failure and blood samples before chemotherapy and blood samples alone 48 hours after chemotherapy start. In all samples leukemic blasts were counted and determined by flow cytometry and the subpopulation of HIF-2 alpha positive blasts was estimated as well. Volunteer bone marrow donors were the control group in this study and the CD34+ HIF-2α+ subpopulation was assessed in their bone marrow samples during the routine harvest procedure. The study was approved by the local Ethics Committee.

Results: After the first line chemotherapy 15 patients achieved complete remission (CR-group) and 11 did not (NR group). We did not find significant differences between the groups regarding patients age, the mean percentage of blasts in bone marrow and blood before the treatment, the percentage of HIF-2 alpha positive blasts in BM and blood before and 48 hours after the treatment start (data not shown). But the analysis of the percentage of HIF-2 alpha positive blasts in blood before and 48 hours separately in CR and NR groups revealed quite different dynamics. In CR group the mean percentage of HIF-2 alpha positive blasts was 14.65 (+33.32) and 8.48 (+11.63) before and after chemotherapy respectively (p=NS); In NR group the values were 11.74 (+22.6) and 24.01 (+33.68) respectively (p=0.007). The Cox analysis revealed HIF-2 alpha positive blasts in blood after chemotherapy to be proportional to death probability (p=0.0036) (Figure 2).
consolidation chemotherapy was postponed, relapsing without reach the already planned transplantation. At the most karyotype was 46XY, t(9;22)(q34;q11) and the molecular biology showed the presence of p190 e6a2 and e6a2 isoforms and FLT3-ITD mutations with a low mutant allelic burden (Figure 1B). Salvage chemotherapy was then performed, allowing at this time to obtain disease remission and further allogeneic transplantation. Nevertheless, the patient died 5 months later for transplant complications. qRT-PCR assays performed in diagnosis sample showed the main clone FLT3-ITD accompanied by subclones with p190 e1a2 and e6a2 isoforms. These data indicate a clonal selection process and the expansion of a resistant clone with their OS was dismal. So HMA could be a good clinical option in a selected population of relapsed patients, especially in those not suitable for allogenic bone marrow transplantation, in whom the prognosis is generally extremely poor. Further studies are needed to determine which are the cytogenetic subsets of patients who could benefit from such a salvage chemotherapy.

PB1698
OMITTING CYTARABINE FROM CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA REDUCES TOXICITY AND NOT EFFICACY
C. Laiyann1, G. Karavallakis1, E. Gavrilaki1, A. Lazariou1, M. Iskas1, A. Syrigou1, M. Papathanasios1, G. Papaioannou1, A. Athanasiadou1, A. Papalexandri1, C. Vadikoliou1, N. Stavroyiann1, R. Saloum1, A. Anagnostopoulou1
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

Background: The introduction of retinoic acid (ATRA) has changed the treatment paradigm in Acute Promyelocytic Leukemia (APL). Combination of ATRA protocol based cytotoxic chemotherapy and APL-specific therapy has shown high efficacy in Spanish and Italian studies. However, early mortality resulting from coagulation disorders remains high. Furthermore, AraC administration during consolidation is questioned and often limited to high-risk patients.

Aims: We aim to compare the efficacy, tolerance and toxicity between 2 consecutive treatment protocols that differed in AraC administration during consolidation.

Methods: We studied clinical characteristics, prognostic factors, response to treatment, toxicity, outcome and outcomes in APL patients treated in our Department during the last decade. All patients received induction with AIDA (Idarubicin, 44 ATRA until day 14, 2-2 and 2-2 and 2-2) and 2-year maintenance therapy. Protocol 1 included 2 cycles of consolidation with anthracyclines/AraC. Protocol 2 was implemented the last 5 years and included 3 cycles of anthracyclines and AraC only in high-risk patients (PETHEMA LPA2005).

Results: APL was diagnosed in 35 patients, of whom 2 patients older than 80 years did not receive treatment and were not included in the analysis. The rest 18 male: 15 female patients aged 37-75 years old presented at diagnosis with: thrombocytopenia (22), leukocytosis (6), impaired performance status/PS > 2 (10), lactate dehydrogenase >400 IU (17), increased d-dimers (33), low fibrinogen (11), fibrinogen <1 mg/dl (5). Five patients died during induction from severe differentiation syndrome (2), bleeding (2) and infection (1). In the multivariate analysis, these patients had significantly impaired PS (3, p=0.005), older age (median of 59 years, p=0.014) and lower fibrinogen (median of 0.9 mg/dl, p=0.05). Among 28 patients eligible for the comparison, all patients achieved complete remission (CRs (80%). Protocol 2 (Arac) was applied to 16 patients and 2 to 12 patients. Complete molecular remission was achieved after a median of 2 chemotherapies (1-3). Efficacy could not be compared between protocols because there was only 1 relapse in Protocol 2, refractory to chemotherapy, ATRA, arsenic trioxide and allogeneic transplantation. However, there were significant differences in tolerance and toxicity. Patients in Protocol 1 had significantly higher transfusion needs compared to Protocol 2 (p<0.001): 9(2-15) versus 1(0-17) red blood cell and 11(3-32) versus 2(0-10) platelet transfusion. Duration of grade 4 leukopenia was significantly higher in Protocol 1 [16(5-19) versus 9(0-18) days, p=0.002]. The same was true for neutropenia (p=0.04) and resulted to higher infection rates in Protocol 1 (58% versus 17%, p=0.03), including 2 aspergillosis and 1 fatal sepsis. 10-year overall survival probability was 73.1%, with no difference between Protocols.

Summary/Conclusions: Our study confirms that early mortality is a significant issue in APL, in particular for older patients. AraC can be safely omitted from treatment of low- and intermediate-risk patients, resulting in significantly reduced toxicity.

PB1699
DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OFAML PATIENTS <60 YEARS OLD VERSUS ≥60 YEARS OLD
B.C. Medeiros1,2, B. Pandya2, A. Hadfield2, S. Wilson2, C. Buif2, T. Bailey3, S. Flanders3, R. Rieder3, L. Horvat2, J. Pike3
1Stanford University, Stanford, 2Astellas Pharma Inc., Northbrook, United States, 3Adelphi Real World, Cheshire, United Kingdom

Background: There is limited real-world data in patients with acute myeloid leukemia (AML) that looks at presenting disease characteristics and subsequent treatment decisions made for patients <60 and ≥60 years of age in the United States (US).

Aims: This analysis examined the characteristics of patients <60 years of age and ≥60 years of age at the point of AML diagnosis and further investigated subsequent treatments.

Methods: Data from the Adelphi AML Disease Specific Programme, a real-world, cross-sectional survey conducted between February-May 2015, were analyzed. A total of 61 hematologist/oncologists provided data on their 457 AML patients treated at various stages of AML. Disease characteristics upon
initial AML diagnosis including symptoms, performance status, and physician-determined prognostic category were taken from physician-completed patient record forms. Details about subsequently prescribed AML treatment were also taken from this data source. Treatments for n=15 (3.3%) patients were reassigned as high or low intensity following evaluation of physician treatment selection. Post-hoc T-tests and Chi-Squared/Fisher’s exact tests were used to determine differences between groups.

Results: Table 1 shows key presenting characteristics of AML patients <60 and ≥60 years old. According to physicians, those patients <60 years of age were significantly more likely than those ≥60 years of age to have de novo AML, a performance score of 0 versus ≤1 at diagnosis, more tests conducted to establish the diagnosis and a more favorable prognosis at baseline, according to physician perception. Following initial diagnosis, patients <60 years of age were 1.65 times more likely than patients ≥60 years of age to be initiated on high-intensity induction treatment: 67% (n=143) of patients <60 years of age were at risk for the worst prognosis (p<0.001). All other patients received low intensity treatment irrespective of age. The most common high intensity treatment given was a cytarabine-based regimen and the most common low intensity treatments were low dose cytarabine-, decitabine- or azacitidine-based regimens.

Table 1. Disease characteristics of patients <60 and ≥60 years of age at diagnosis of AML.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>&lt;60 years old (n=244)</th>
<th>≥60 years old (n=243)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>129 (65%)</td>
<td>117 (48%)</td>
</tr>
<tr>
<td>Pathophysiologic</td>
<td>Anemia</td>
<td>208 (86%)</td>
<td>209 (86%)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Leukocytosis ≥10</td>
<td>208 (86%)</td>
<td>209 (86%)</td>
</tr>
<tr>
<td>Performance status</td>
<td>ECOG score ≥2</td>
<td>31 (13%)</td>
<td>43 (18%)</td>
</tr>
<tr>
<td>Diagnostically negative</td>
<td>False</td>
<td>1 (0.4%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Generalized prognostic category</td>
<td>Poor</td>
<td>44 (18%)</td>
<td>42 (17%)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>84 (46%)</td>
<td>84 (35%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Not determined</td>
<td>7 (3%)</td>
<td>12 (5%)</td>
<td>0.207</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The age of an AML patient at initial diagnosis appeared to play a significant role in the diagnostic, prognostic and treatment intensity decisions made by AML-treating physicians in the US. The estimated performance and prognostic status tend to be considerably better for younger patients and consequently, they were more likely to receive the most aggressive yet more effective high intensity treatments currently available to treat AML.

A UNIQUE PRESENTATION OF ACUTE PROMYELOCYTIC LEUKEMIA: AORTOILIAC OCCLUSIVE DISEASE (LERICHE SYNDROME)
S. Berk 1,*, M. Günaltılı2, S. Sadrı1, A. E. Eşkazan1, Z. Başlar1, T. Soysal1
1Haematology, 2Molecular Genetics, The Republican Research Center for Radiology, Ankara, Turkey

Background: Acute promyelocytic leukemia (APL), FAB M3 subgroup of acute myeloid leukemia is known for its association with haematological disorders. Compared to bleeding thrombosis is a less commonly encountered complication of AML. Thrombosis of major arteries is a rare form of presentation.

Aims: A case, who applied with acute lower limb ischemia and diagnosed with APL and aortoiliac occlusive disease (Leriche syndrome), is presented.

Methods: A 53-year-old female patient presented with weakness, loss of appetite and pain in the lower extremities. She had diabetes mellitus (DM) regulated with metformin, hyperlipidemia (HL), and smoking history. Physical examination revealed general paleness and ischemia around big toe of the right foot. Laboratory studies revealed leukopenia, neutropenia, anemia, thrombocytopenia, elevated D-Dimer. A bone marrow aspiration and biopsy was done to enlighten the etiology of pancytopenia. The pathological examination of the bone marrow revealed abundant granular blasts (78%) and Auer rods. The patient was diagnosed with APL, hypergranular classical form. t(15;17) was positive with fluorescence in situ hybridization. All-trans retinoic acid (ATRA) plus idarubicin treatment was started. In few days of ischemia progressed and encompassed 2nd, 4th and 5th toes together with the big toe (Figure 1 on the left). Monophasic flow pattern (proximal stenosis?) was detected in bilateral common femoral arteries in lower extremity venous doppler ultrasonography. CT angiography, abdominal aorta and bilateral common iliac arteries were observed to be occluded from L3 vertebra level till 1.5 cm after aortic bifurcation (Figure 1 on the right). Low-molecular-weight heparin therapy was started. According to rheumatological tests and tests for lupus anticoagulant, anticardiolipin and antiphospholipid antibodies, anti-beta-2 glycoprotein-1, protein C-S, Antithrombin III and homocysteine levels, methylenetetrahydrofolate reductase, Factor V Leiden and prothrombin gene mutations no cause of tendency to thrombophilia could be determined. Echocardiography was normal. The patient was transferred to Cardiovascular Surgery Department for axillofemoral bypass operation.

Figure 1.

Results: In APL 80% of thrombotic events occur before treatment or during induction. Acute lower limb ischemia as an initial feature of APL is very rare
which makes our case unique. Thrombotic risk factors in APL include high leukocyte count, presence of coagulation disorder, ATRA+chemotherapy+antifibrinolytic therapy and ATRA syndrome. None of these were seen in the presented case. The effects of known predisposing risk factors to thrombosis meaning DM, HL and smoking cannot be ruled out. But development of acute thrombosis concomitant with APL diagnosis points out to the relationship between these two entities.

Summary/Conclusions: Current literature knowledge is based on case reports and 9 patients with APL who presented with acute lower limb ischemia were reported yet. As far as we know our case is the first APL case presenting with aortoiliac occlusive disease (Leriche syndrome).

PB1702
A CASE OF THERAPY-RELATED ACUTE LEUKEMIA WITH MIXED PHENOTYPE WITH BCR-ABL1 AFTER TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

D. Yang1,*, J. Lee2, S. R. Cho3, Y. S. Kim4, J. R. Cho5, M. H. Kim6
1Laboratory Medicine, Kosin University Gospel Hospital, Busan, 2Yeongam-gun Public Health Center, Yeongam, 3Laboratory Medicine, Ajou University School of Medicine, Suwon, 4Internal Medicine, Kosin University Hospital, Busan, 5Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic Of

Background: Although therapy-related acute leukemia (tAL) is a well-recognized clinical syndrome and is increasing owing to the prolonged survival of patients treated with chemotherapy, tAL with mixed phenotype is extremely rare.

Aims: Here, we report a rare case of tAL with mixed phenotype with BCR-ABL1 after achieving complete remission (CR) of Diffuse Large B-Cell Lymphoma (DLBCL).

Methods: A 57-year-old woman was diagnosed as DLBCL. The patient received six cycles of R-CHOP regimen with G-CSF injected after each cycle and achieved CR. The patient was readmitted to the hospital after a follow-up examination revealed the presence of immature cells in the blood.

Results: Her complete blood count findings were as follows: hematocrit, 35.1%; hemoglobin, 116 g/L; platelet count, 129×10^9/L; and white blood cell count, 2.41×10^9/L, with 4% blasts, 26% segmented neutrophils, 3% band neutrophils, 39% lymphocytes, and 26% monocytes. Bone marrow aspirations revealed 40.7% myeloblastic blasts with medium cell size, ovalaround shape, vesicular nuclei, fine chromatin patterns, and basophilic cytoplasm. On cytochemical staining, these blasts were positive for PAS and NSE staining, but were weakly positive for MPO staining. Flow cytometric analysis showed that the blasts were positive for both T-lymphoid and myeloid markers (CD3+, CD4+, CD19, CD20, CD11b, CD14, CD15, CD19, CD20, CD61, CD117, and TDT). Immunophenotyping results fulfiled the diagnostic criteria of T/myeloid biphenotypic leukemia based on the scoring system of the EGIL and WHO classifications. Multiplex reverse transcriptase PCR(using Hema Visionkit (Bio-Rad Laboratories) revealed the presence of minor BCR-ABL1 (e1a2) fusion transcripts. Chromosome analysis of bone marrow cells failed because of insufficient mitotic cells. Immunoglobulin heavy chain rearrangement and TCR gene rearrangement were not detected on bone marrow aspirate.

Summary/Conclusions: Mixed phenotype acute leukemia is an uncommon subtype that comprises 0.5%-1% of leukemia. T/myeloid phenotype is rare and represents 35% of all MPAL cases. The risk of secondary malignancies after lymphoma treatment is relatively increased for leukemia. AML, ALL, MDS, CML and chronic myelomonocytic leukemia are reported secondary hematological malignancies. Until now, only one case of tAL with mixed phenotype after lymphoma has been reported worldwide. To the best of our knowledge, this is the second case of tAL with mixed phenotype after DLBCL. This case is also unique because the BCR-ABL1 has not been described in the literature for patients with tAL with mixed phenotype, after hematologic malignancy. According to the 2017 WHO classification, tAL can be attributed to radiation, alkylating agents, or topoisomerase II inhibitors. Our patient did not receive radiation therapy but previously received cyclophosphamide and doxorubicin. Therefore, this is the first case of tAL with mixed phenotype and BCR-ABL1 after alkylation agent and topoisomerase II inhibitor therapy for DLBCL.

PB1704
CLINICAL, CYTOMORPHOLOGIC AND IMMUNOPHENOC/IMMUNOHISTOCHEMICAL CHARACTERISTICS OF PATIENTS WITH BLASTIC PLASMOCYTOID DENDRITIC CELL NEOPASIS - DIAGNOSTIC AND THERAPEUTIC DILEMMA

A. Vidošíc1, M. Vrijevic2, D. Tomini1, N. Suvajdžic Vuković1, V. Milošević1, I. Djunic1, M. Mitrovic1, N. Colovic1, N. Kraguljac Kurtović1, M. Perunicic Jovanovic1, B. Mihaljevic1
1Clinic of Hematology, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia
2Department of Medical Biochemistry, University of Belgrade, Belgrade, Serbia

Background: Blastic plasmocytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive haematological malignancy that originates from clonal proliferation of plasmacytoid dendritic cells and their precursors. BPDCN is rare, represents less than 1% of acute leukemias. The disease has two patterns of presentations: cutaneous and leukaemic. The main histological differential diagnosis includes: cutaneous NK/T-cell lymphoma; cutaneous T-cell lymphoma with co-expression of CD56 and CD56+ acute myeloid leukemia with monocytic differentiation.

Aims: The aim of study was to analyze heterogeneity of BPDCN differential diagnosis, especially with regards to clinical, immunological and cytomorphological characteristics of blastoid cells in terms of the optimal treatment.

Methods: During period 2010-2016. at the Clinic of Hematology, eight patients with BPDCN were diagnosed (M/F 6/2; average age 43 yrs, range 26-60yrs).

Results: In the blood count, average concentration of Hb was 108g/l (range 87-154); WBC 6,38x10^9/l (range 2,6-12); Plt 147,8x10^9/l (range 20-282). Hemorrhagic diathesis was registered in 3/8; splenomegaly existed in 3/8 (average diameter 166mm, 140-200mm); and hepatomegaly existed in 3/8 (average diameter 132 patients of AML at a tertiary health care facility in India, treated during 2010-2017. Results from commercially available molecular assays for detection of specific translocations by RT-PCR and of adequate samples of karyotype analysis were compared.

Results: In AML patients, out of those tested 50.6% had chromosomal abnormalities detected by karyotyping while 30% had a positive detection with RT-PCR. The concordance rate in AML was found to be 56.3%. In a large number (31 in AML) karyotyping provided additional information in the form of detection of deletions, additions and hyper-diploidy (Table 1).

Table 1.

Summary/Conclusions: RT-PCR cannot substitute conventional cytogenetic analysis due to the absence of a broad based application for detection of aberrations other than translocations. However, given its efficiency and reliability it can have a complimentary role in prognosis assessment.

PB1705
CROSS-SECTIONAL ANALYSIS OF CONCORDANCE RATES BETWEEN KARYOTYPING AND RT-PCR IN ACUTE MYELOID LEUKEMIA; REAL WORLD CHALLENGES

D. Katoch1,*, Y. Uday1, T. Verma1, R. Kapoor1, S. Das1, V. Nair1
1Hematology, Army Hospital (Research & Referral), Delhi, India

Background: Translocation and chromosomal anomalies have prognostic implications in acute myeloid leukemia (AML). Cytogenetic analysis assumes great importance in their diagnosis and treatment stratification which are assessed by karyotyping and/or reverse transcriptase polymerase chain reaction (RT-PCR). Given the decreasing prevalence of karyotyping on sample quality, more and more centers are now relying on RT-PCR to detect specific translocations. Varying rates of concordance between Karyotyping and RT-PCR have been reported and no consensus has prevailed. Given the resource constraint, it is economically non-viable to perform both for prognosis in real world scenarios. The aim of study was to analyze heterogeneity of BPDCN differential diagnosis, BCR-ABL1 after alkylating therapy for DLBCL. Therefore, given its efficiency and reliability it can have a complimentary role in prognosis assessment.
Results: Four pts were treated with 3+7 chemotherapy. Complete remission (CR) was achieved in 3 pts, and treatment was continued according to the HIDAC and IDAC protocol. The duration of remission was 3, 8 and 11 months respectively, followed with relapse and letal outcome. One of the pts died within first 0.5 months after BPDCN was diagnosed. Three pts, treated with HyperCVAD, are alive and in CR with duration of 1, 3 and 10 months respectively. The continuation of the treatment within the programme of allogeneic stem cell transplantation is planned in 2 pts.

Summary/Conclusions: BPDCN diagnostics is difficult due to the heterogeneity of immunological characteristics of disease. Aggressive course of disease with median survival of 12-18 months, in the view of the unique treatment recommendations indicates necessity of further clinical investigations on larger patients groups.

Background: DLBCL is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for about 33% of all NHL cases. However, the healthcare burden associated with DLBCL has not been extensively studied in a US population.

Aims: We evaluated the costs of care and healthcare utilization (HCU) of DLBCL patients treated during routine care in the US.

Methods: The Optum claims database was used to identify adult patients (≥18 years old) with newly diagnosed DLBCL between 01/01/08 and 10/31/15. DLBCL diagnosis was based on ≥1 inpatient claim or ≥2 outpatient claims with DLBCL diagnosis codes, with the index date being the first DLBCL claim. Patients were followed from index date until end of continuous enrollment, death, or end of study period (12/31/15) for the assessment of HCU and costs. DLBCL-related and non-DLBCL-related HCU and costs incurred during follow-up were evaluated. DLBCL-related HCU and costs were medical claims with a primary diagnosis of DLBCL or DLBCL-related treatment (chemotherapy, radiation, stem cell transplant [SCT], supportive care) and pharmacy claims for DLBCL treatment. Proportions of patients with HCU were reported. Costs were calculated as per-patient-per-month (PPPM) costs and reported as mean and standard deviation (SD). Patients with a capitated payment plan were excluded from the cost analysis.

Results: 1,267 treated DLBCL patients were identified. Over the follow-up period, 66.0% of patients had ≥1 inpatient admission, with more patients having a non-DLBCL-related than DLBCL-related admission (Table 1). 60.0% of patients had ≥1 emergency room visit over the follow-up period; visits were predominately for non-DLBCL-related admissions. Nearly all patients had ≥1 physician office visit (92.4%) and other outpatient visits (99.6%). The mean PPPM costs incurred during the follow-up period was $11,890 (SD: $11,515) (Table 1), and costs were higher in Year 1 ($14,402, SD: $10,951) than in Year 2 ($4,190, SD: $8,076). About 55% of costs overall were related to DLBCL medical services ($6,532 PPPM, SD: $6,457). DLBCL-related medical PPPM costs decreased substantially from Year 1 ($8,327, SD: $5,925) to Year 2 ($1,443, SD: $4,349). This decrease was driven by the decreases in chemotherapy and supportive care medical services from Year 1 to Year 2. Non-DLBCL-related medical costs accounted for about 42% of the overall PPPM costs ($4,955, SD: $7,210); and a decrease was observed from Year 1 ($5,640, SD: $7,468) to Year 2 ($2,447, SD: $5,456). Inpatient admission was the main component of non-DLBCL-related costs, and associated costs decreased from Year 1 to 2.

Table 1.
PB1706

PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

S. Rožman1, I. Grabnar2, S. Novaković3,4*, 1Pharmacy Department, Institute Of Oncology Ljubljana, 2Department of Bio-pharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, 3Department of Molecular Diagnostics, 4Department of Medical Oncology, Institute Of Oncology Ljubljana, Ljubljana, Slovenia

Background: Rituximab dosing is based on evidence from clinical practice rather than from consideration of pharmacokinetics and factors influencing individual exposure. Clinical use of rituximab can be improved through a more individualized treatment.

Aims: The objective of this investigation was to typify rituximab pharmacokinetics in 29 newly diagnosed patients with the diffuse large B-cell lymphoma who received rituximab in combination with cyclophosphamide, doxorubicin, vincristine and methylprednisolone every three weeks. The association of rituximab pharmacokinetics with clinical outcome was also investigated.

Methods: Rituximab serum levels were defined by enzyme-linked immunosorbent assay and assessed by a population pharmacokinetic analysis applying the non-linear mixed effects modelling.

Results: A 2-compartment model comprising linear non-specific clearance of 0.260 L/day (95% CI: 0.257 – 0.265) and specific clearance decay of 0.278 L/day (95% CI: 0.181 – 0.390) was recognized to target-mediated drug disposition of rituximab was considered to describe the data. The non-specific clearance was found to be lower in older patients and those with lower body weight. Additionally, the central compartment volume was higher in males. An unambiguous association of clinical response with rituximab pharmacokinetics has been detected. The rate constant of specific clearance decay was 0.143 day⁻¹ (95% CI: 0.0478 – 0.418) in patients with no disease progression, while in patients with disease progression it was 0.822% lower (95% CI: 33.4 – 95.0).

Summary/Conclusions: These results imply that time-changes in clearance could serve as a predictive marker of response to rituximab. Our findings prove the rationale for studies evaluating higher doses of rituximab in selected patients.

PB1707

HOW 18FDG PET/TC CAN IDENTIFY BONE MARROW INFLTRATION IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA

S. Pellegrino1, M. Petretta3, S. Del Vecchio1

1Department of Advanced Biomedical Sciences, 2Department of Clinical Medicine and Surgery, 3Department of Translational Medical Sciences, University Federico II, Naples, Italy, AOU Federico II Naples, Naples, Italy

Background: Bone marrow infiltration (BMI) evaluation plays a key role in lymphoma staging, treatment and prognosis. The role of PET/TC in the assessment of BMI is still controversial, especially in non-Hodgkin’s lymphoma (NHL).

Aims: To evaluate the role of 18F-FDG PET/TC in bone marrow infiltration for the diagnosis of Non-Hodgkin Lymphoma, we compared 18F-FDG PET/TC visual and quantitative analyses with bone marrow biopsy in NHL patients.

Methods: Fifty patients with newly diagnosed NHL from February 2011 to February 2016 were retrospectively analyzed. Of these, 26 (group A) patients had aggressive NHL and 24 (group B) indolent NHL. To detect BMI on the posterior compartment, we evaluated: 1) two maximal standardized uptake values (SUVmax, cut-off >2.5), and 3) Deauville score (categorical). Each method was applied in the whole patients cohort, in group A and in group B. Images were blindly reviewed separately by 3 nuclear medicine physicians. PET/TC results were compared with the bone marrow biopsy performed after imaging in all patients. The basis was used to evaluate the increment in net benefit (NB) obtained considering the Deauville score over a biopsy-all strategy.

Results: The prevalence of a positive biopsy was 38% in whole cohort, 19% in group A and 56% in group B. In the whole cohort, specificity, specificity and accuracy were 60%, 58% and 51% for SUVmax; and 47%, 81% and 68% for Deauville score. In group A, sensitivity, specificity and accuracy were 0%, 76% and 62% for SUVmax; 5%, 95% and 85% for SUVmax; 50% and 60% for SUVmax; and 20%, 71% and 62% for Deauville score. In group B, sensitivity, specificity and accuracy were 100%, 100% and 58% for SUVmax; 50%, 55% and 95% for SUVmax; and 50%, 55% and 95% for SUVmax; and 50%, 55% and 95% for Deauville score. At probability threshold equal to the prevalence of a positive biopsy, the increase in NB by Deauville score was 0.11 in the whole cohort, 0.22 in group A and 0.33 in group B. In this latter group, biopsying patients on the basis of the Deauville score is a strategy that reduced the biopsy rate by 24%, without missing any BMI.

Summary/Conclusions: FDG-PET/TC visual analysis has a limited value for detecting BMI in patients with NHL, while quantitative analysis by Deauville score provides a higher diagnostic performance. Noteworthy, the high positive predictive value in patients with indolent NHL suggests a potential role of FDG-PET/TC in avoiding bone marrow biopsy in this subtype of lymphoma.

PB1708

LOW ALBUMIN LEVEL CORRELATES WITH POORER SURVIVAL OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: SERBIAN LYMPHOMA GROUP EXPERIENCE

J. Jelicic1, D. Antić2, M. Todorovic Balint2, B. Andjelic2, O. Marković3, I. Petrović3, V. Nikolać3, Predila3, V. Djurasinovic4, A. Sretenovic5, V. Vukovic5, M. Smiljanic1, B. Mihaljevic2

1Clinic of Hematology, Clinical Center of Serbia, 2Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, 3Clinical Hospital Center “Bezanijska Kosa”, University of Belgrade, Belgrade, 4Clinic of Oncology, University Clinical Center Niš, 5Clinic of Hematology, Clinical Center Niš, Serbia

Background: Current prognostic scores are not sufficient to define high risk patients with diffuse large cell lymphoma (DLBCL). Besides parameters included in the International Prognostic Index (IPI), other clinical and laboratory parameters have been investigated as potential prognostic markers. However, contradictory data have been reported.

Aims: The aim of this study was to evaluate prognostic significance of clinical and laboratory parameters on the overall survival (OS) of patients with DLBCL.

Methods: A total of 393 patients (188 females/205 males) with the median age 62.4 years were identified. All patients were initially treated with rituximab plus CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or CHOP like protocols.

Results: Ann Arbor stage I, III, and IV had 56 patients (14.2%), 142 (36.1%), 71 (18.1%) and 124 (31.6%), respectively. Bulky disease had 99 patients (25.2%). B symptoms 263 patients (66.9%), and poor performance status was ascribed to the European Cooperative Oncology Group (ECOG) ≥2 had 82 (20.9%). Bone marrow involvement was present in 68 patients (17.3%). Low IPI risk was present in 194 patients (49.4%), low intermediate in 86 (21.9%), high intermediate in 77 (19.6%), and high in 36 (9.2%). Median absolute lymphoma mass was 36g/l (range 0.07-236g/l), absolute monocyte count (AMC) was 0.64X10⁹/l (range 0.06-5.8x10⁹/l), AMC/AMC was 2.3 (range 0.07-37.0x10⁹/l), hemoglobin level was 125g/l (range 57-421g/l), platelet level was 274X10⁹/l (range 50-584X10⁹/l), C-reactive protein was 10.2 mg/l (range 0.10-438mg/l), erythrocyte sedimentation rate (ESR) was 30mm/h (range 2-636mm/h), and albumin level was 38g/l (range 20-51g/l).

Complete remission (CR) was achieved in 288 patients (73.3%), partial remission (PR) in 58 (14.8%), stable disease (SD) in 5 (1.3%) and progressive disease in 42 (10.7%). Disease relapse was confirmed in 59/348 patients (17.0%). OS was influenced by the presence of B symptoms (p=0.004, 95% CI 1.263-4.458), ECOG ≥2 (p<0.0001, 95% CI 1.489-2.222), and albumin level (p=0.004, 95% CI 0.905-0.953). Optimal cut-off point for albumin level was 34g/l, and was determined by Receiver operating characteristic (ROC) curve (AUC 0.699, 95% CI, 0.629-0.770, p<0.0001). The prognostic value of IPI was highly statistically significant for OS (p<0.0001, 95% CI, 1.545-2.236). However, other analyzed parameters did not influence OS. Multivariate analysis among significant parameters (presence of B symptoms, IPI, and albumin), has pointed to IPI (HR 1.81, p<0.0001, 95% CI, 1.489-2.222), and albumin level (HR 1.77, 95% CI, 1.164-2.69, p=0.008) as the most important parameters that influenced survival.

Summary/Conclusions: Although IPI is widely used as a prognostic index in DLBCL, it cannot fully recognize high-risk patients. Pretreatment albumin level may represent a useful tool in order to discriminate high-risk patients and is likely to add significant information to the IPI.
Methods: The Optum claims database was used to identify adult patients (≥18 years old) with newly diagnosed DLBCL between 01/01/08 and 10/31/15. DLBCL diagnosis was based on ≥1 inpatient claim or ≥2 outpatient claims with DLBCL diagnosis codes, with the index date being the first DLBCL claim. Patients were followed from index date until end of continuous enrollment, death, or end of study period (12/31/15). Treatment patterns and response to treatment were assessed within the study group. Possible remission was defined as no additional chemotherapy and no supportive care use or receipt of supportive care <30 days after end of line of therapy (LOT) for <30 days. Lack of remission was defined as receipt of supportive care >30 days after end of LOT for >30 days. Progression was defined as initiation of another LOT or evidence of supportive care >30 days after end of a LOT.

Results: Of the 2,216 patients selected into the study, 1,267 (57.2%) initiated 1LT, and median (interquartile range [IQR]) time to therapy was 0.7 (0.4–1.1) months. The majority of patients received combination (87.7%) single-agent (12.3%) chemotherapy. R-CHOP (60.5%) was the most frequently used combination chemotherapy, while rituximab monotherapy comprised 67% (8.2%) of single-agent use in 1LT. Median (IQR) duration of 1LT was 4.2 (2.3–4.5) months. At the end of 1LT, 64.0% (n=811) had evidence of remission, 15.0% (n=190) progressed, and 1.2% (n=15) had no evidence of remission. Second-line therapy (2LT) was initiated by 159 patients who progressed after 1LT; 29.6% received a single agent, and 70.4% received combination chemotherapy. In 2LT, rituximab (12.6%) remained the top single agent used, while bendamustine+rituximab (15.7%) and R-CHOP (8.2%) were the most common combinations; 82% of patients received stem cell transplant. Median (IQR) duration of 2LT was 2.1 (1.2–3.8) months. Of the 2LT patients, 44.0% (n=70) had evidence of remission, 26.4% (n=42) progressed, and 3.1% (n=5) had no evidence of remission. 34 patients who progressed after 2LT received third-line therapy (3LT); 29.4% received a single agent, while 70.6% received combination chemotherapy. In 3LT, rituximab (5.9%), etoposide (5.9%), and carboplatin (5.9%) were the most common single agents, while bendamustine+rituximab (20.8%) and etoposide+carboplatin+rituximab (17.6%) were the most common combinations; 8.8% of patients received stem cell transplant. Median (IQR) duration of 3LT was 3.5 (0.9–5.2) months. Following 3LT, 32.4% (n=11) had evidence of remission, 29.4% (n=10) progressed, and 5.9% (n=2) had no evidence of remission.

Summary/Conclusions: DLBCL treatment in routine clinical care aligns with guidelines. Most patients received rituximab in combination with chemotherapy. A small proportion of patients received single-agent chemotherapy in 1LT. As expected, remission rates decreased with subsequent lines of therapy. Some patients were untreated; therefore, subsequent studies should explore reasons for lack of treatment.

PB1710

TP53 GENE MUTATIONS IS A PREDICTOR OF HIGH GRADE B-CELL LYMPHOMA PROGRESSION

A. Misurina1,*, V. Misurin2, S. Kravchenko1, A. Kovrigina1, A. Misyurin2, E. Baryakh2, A. Magomedova1, E. Nesterova1, E. Pushkova1, J. Finashulina2, A. Vayskova1
1National Research Center for Hematology, 2Federal State Institution “Russian Ministry of Health Russian Federation diagnosis of high grade B-cell lymphoma; 41%, B cell lymphoma; 29%, MPN; 18%, MDS; 12%). Solid tumor was 5% was chronic, 38% was smoldering, 5% was acute, 29% was lymphoma type. Median overall survival was 30 months in carrier, 10 months in acute, 8 months in lymphoma, and smoldering was not available. In all HTLV-1 seropositive patients, the occurrence of primary malignant neoplasm was 32%, they were all carrier or smoldering. Among them, 53% was hematology malignancy (T cell lymphoma; 41%, B cell lymphoma; 29%, MPN; 18%, MDS, 12%). Solid tumor was 47% (lung cancer; 33%, prostate cancer 13%, colon cancer; 13%, renal cell cancer; 13%). Four patients with HTLV-1 carrier who developed primary malignant neoplasm received standard chemotherapy for the neoplasm, and after the chemotherapy they developed 3 acute type and 1 smoldering type ATL.

Summary/Conclusions: In our cohort, the occurrence of primary malignant neoplasm with HTLV-1 seropositive patients was significantly high. Chronic HTLV-1 infection might associate with reduction of cytotoxic T cells and an increased risk of developing other malignancy. Furthermore, cytotoxic chemotherapy for primary malignant neoplasm might reduce cytotoxic T cells for HTLV-1 and exacerbate ATL conditions.

PB1712

Abstract withdrawn.

PB1713

THIOTETA BUSULFAN CYCLOPHOSPHAMIDE, A TOXIC CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM LYMPHOMA: REMISSION OR INFECTION

P.-E. Debureaux1, B. Royer1,2, B. Gruson1, P. Votte3, M. Joris1, G.L. Damaj4, J.-P. Marolleau1,5, L. Delphine1,5,
1First Department of Internal Medicine, Division of Hematology and Oncology, KANSAI MEDICAL UNIVERSITY, Osaka, Japan

Background: The correlation between HTLV-1 infection and malignant neoplasm other than ATL remains unknown. Some previous studies have indicated that the frequency of primary malignant neoplasms in patients with HTLV-1 seropositive is higher than HTLV-1 seronegative.

Aims: To clarify the correlations between HTLV-1 infection and malignant neoplasms other than ATL.

Methods: We retrospectively analyzed 203 patients with HTLV-1 seropositive who were diagnosed between 2006 and 2015 at Kansai Medical University Hospital.

Results: Among 203 patients (median age 62 years: range 19 to 86 years), 43% was carrier and 57% was diagnosed with ATL. According to clinical subtype, 5% was chronic, 38% was smoldering, 28% was acute, 29% was lymphoma type. Median overall survival was 30 months in carrier, 10 months in acute, 8 months in lymphoma, and smoldering was not available. In all HTLV-1 seropositive patients, the occurrence of primary malignant neoplasm was 32%, they were all carrier or smoldering. Among them, 53% was hematology malignancy (T cell lymphoma; 41%, B cell lymphoma; 29%, MPN; 18%, MDS, 12%). Solid tumor was 47% (lung cancer; 33%, prostate cancer 13%, colon cancer; 13%, renal cell cancer; 13%). Four patients with HTLV-1 carrier who developed primary malignant neoplasm received standard chemotherapy for the neoplasm, and after the chemotherapy they developed 3 acute type and 1 smoldering type ATL.

Summary/Conclusions: In our cohort, the occurrence of primary malignant neoplasm with HTLV-1 seropositive patients was significantly high. Chronic HTLV-1 infection might associate with reduction of cytotoxic T cells and an increased risk of developing other malignancy. Furthermore, cytotoxic chemotherapy for primary malignant neoplasm might reduce cytotoxic T cells for HTLV-1 and exacerbate ATL conditions.

Summary/Conclusions: Mutations in TP3 gene - a significant predictive factor of early disease progression in high grade B-cell lymphoma.
Background: CNSL represent 4% of primary central nervous system (PCNSL) and secondary CNS lymphoma (SCNSL) occur in 7% of systemic lymphoma. Overall survival (OS) and progression free survival (PFS) have dramatically increased in PSNL since the introduction of Methotrexate high doses and ASCT usually conditioning with TBC (Thiotepa, Busulfan and Cyclophosphamide). The studies usually tend to recommend TBC/ASCT in front line for patients under 60 years old. Median age at ASCT was 58 years (23-66). 22 of 24 were DLBCL and 2 follicular lymphoma and there were 15 PCNSL and 9 SCNSL. All but one, received 1 or 2 lines of chemotherapy (with high doses Methotrexate in first or second line) before ASCT. 15% were in complete response (CR) and 9 in partial response (PR) before TBC/ASCT. Median duration of hospitalisation was 33 days (15-78 d) and of aplasia was 14 days (7-37 d). Median follow-up was 10 months (0-73). At the end of follow up 5 patients have died. Among the 3 patients older than 60 years in PR before ASCT, 1 patient treated with R-CHOP and PFS were respectively 78% and 73%. Surprisingly (Table 1), we noted an important rate of toxicity (100% with 66% ≥grade 3) with a TRM=21%. Neurological adverse events (37%; 9 patients with 4 comas) and infections (100% with ≥grade 3) were predominant. We documented 2 CMV reactivations and 5 funga- 

ginal infections (3 candida, 1 aspergillus and 1 cryptococcus).

We observed 5 deaths (4/5 older than 60 years) in first 3 months due to a septic cho- 

coc, 4 associated with a persistent comat and 2 with an acute respiratory distress syndrome.

Summary/Conclusions: To our knowledge, there is one of the biggest retro-

spective cohort concerning TBC/ASCT in CNSL. If TBC seems to give interest-


ing response rates (72% CR), we noted an unacceptable toxicity compared to other used conditionings (for example TRM with Thiotepa Carmustine is 1%). Our high toxicity rates (66%≥grade 3), especially in elderly patients, with neurological adverse events and infections (with unusual microorganismal agents) lead us to disavow the use of TBC before ASCT.

TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH RISK AND HIGH-INTERMEDIATE RISK GROUPS I. Kriačok,1,7 K. Filonenko,2 A. Martynchyk,2 I. Titorenko,2 I. Stepashyna1, O. Aleksey,3 I. Dyiagy,3 E. Kushcheyevych,5 Z. Martina3, V. Kozlov6

1Hématologie Clinique, CHU Amiens, Amiens, 2Hématologie Clinique, Hôpital Saint-Louis, Lomونов, 3JUPCO, CHU Amiens, Amiens, 4Hématologie Clinique, Chu Calen, 5EA4666, CHU Amiens, Amiens, France

Aims: We report in this multicenter retrospective study our experience con-


tering TBC/ASCT and its main toxicities.

Methods: All patients treated with TBC/ASCT for PCNSL or SCNSL from August 2010 to November 2016 in our centers were researched by using CHIMOS® software. TBC combined Thiotepa (250mg/m2/d from d-9 to d-7) Busulfan (3.2mg/kg/d from d-6 to d-5 and 1.6mg/kg/d on d-4) and Cyclophos-


pamide (60mg/kg/d on d-3 and -2) followed by ASCT transplantation at d0. Clinical data were extracted from the medical records. We measured OS and PFS from the date of ASCT and transplant related mortality (TRM) (defined by death occurred 3 months after ASCT). Results: 24 patients, without any major co-morbidity, were included. Median age at ASCT was 58 years (23-66). 22 of 24 were DLBCL and 2 follicular lymphoma and there were 15 PCNSL and 9 SCNSL. All but one, received 1 or 2 lines of chemotherapy (with high doses Methotrexate in first or second line) before ASCT. 15% were in complete response (CR) and 9 in partial response (PR) before TBC/ASCT. Median duration of hospitalisation was 33 days (15-78 d) and of aplasia was 14 days (7-37 d). Median follow-up was 10 months (0-73). At the end of follow up 5 patients have died. Among the 3 patients older than 60 years in PR before ASCT, 1 patient treated with R-CHOP and PFS were respectively 78% and 73%. Surprisingly (Table 1), we noted an important rate of toxicity (100% with 66% ≥grade 3) with a TRM=21%. Neurological adverse events (37%; 9 patients with 4 comas) and infections (100% with ≥grade 3) were predominant. We documented 2 CMV reactivations and 5 fungal infections (3 candida, 1 aspergillus and 1 cryptococcus).

Table 1.

PB1714

TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH RISK AND HIGH-INTERMEDIATE RISK GROUPS I. Kriačok, K. Filonenko, A. Martynchyk, I. Titorenko, O. Aleksey, I. Dyiagy, E. Kushcheyevych, Z. Martina, V. Kozlov

1Hematology, Kobe City Medical Center General Hospital, 2Hematology, Nishikobe medical center, 3Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan

Background: Using of Rituximab-containing regimens, as the «gold standard» of survival (OS) and progression free survival (PFS), showed significant improvement in the treatment results throughout all prognostic groups. The “real-life” treatment approaches vary depending on financial support of health-care system in different countries. Unfortunately, treatment results in patients with DLBCL from high and high-intermediate risk groups are still unsatisfying. Aim: Aim of our study was to compare efficacy and toxicity of different treatment approaches in patients with DLBCL from high risk and high-intermediate risk groups.

Methods: Prospective cohort study was initiated in 2014 in three Ukrainian centers. Patients with newly diagnosed DLBCL and ≥3 risk factors according to international IPI were treated according to “investigators decision”, including NLR and other variable interacting with NLR. Results: High NLR group was associated with old age, poor performance status (PS), elevated lactate dehydrogenase, and more advanced prognostic indices than low NLR group. High NLR group had a low complete response (CR) rate compared to low NLR group (57.5% vs 81.4%, p=0.004). However, the high NLR as prognostic index was not confirmed in multivariate analysis, which showed strong interaction between NLR and PS. The model composed of NLR and PS could stratify the patients into low-, intermediate-, and high-risk groups for overall survival (OS). Multivariate analysis, compared to low risk group, the hazard ratios of intermediate and high risk groups on OS were 1.871 (p=0.019) and 2.733 (p=0.004).

Summary/Conclusions: High NLR is associated with poor treatment response and unfavorable clinical features in DLBCL. The prognostic model using NLR and PS can predict more precisely the prognosis of this population and needs to be validated in the independent cohort.

PB1716

HIGH SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR ARE ASSOCIATED WITH A POOR PROGNOSIS IN CASES OF RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

M. Morita1, D. Kato1, A. Tanaka2, M. Nakamura1, A. Fujimoto1, Y. Yabushita1, Y. Irie2, Y. Ono2, A. Hashimoto2, N. Hiramoto1, S. Yoshikawa1, N. Yonetani1, A. Matsuishi1, H. Hashimoto1, R. Sinzato2, I. Ishikawa1

1Hematology, Kobe City Medical Center General Hospital, 2Hematology, Nikoshiko medical center, 3Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan

Background: The prognosis is extremely poor for cases of relapsed/refractory peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), and there
are no established predictors of prognosis. Although serum soluble interleukin-2 receptor (sIL-2R) levels are associated with clinical outcomes in newly diagnosed patients with PTCL-NOS, it remains unclear whether sIL-2R levels can predict prognosis in patients with relapsed/refractory PTCL-NOS.

Aims: This study evaluated whether sIL-2R levels at the time of salvage chemotherapy were associated with prognosis in cases of relapsed/refractory PTCL-NOS.

Methods: We retrospectively analyzed 45 patients with relapsed/refractory PTCL-NOS who received salvage chemotherapy at our institutions (1996–2016). All patients received CHOP or CHOP-like therapy as their initial treatment. The primary outcome was defined as overall survival (OS), which was calculated from the date of the salvage chemotherapy to the date of death from any cause or the last follow-up.

Results: The median age at salvage chemotherapy was 68 years (range: 37–86 years). The median sIL-2R level was 3,476 U/mL (range: 260–24,400 U/mL). Receiver operating characteristic curve analysis revealed that the optimal sIL-2R cut-off value for predicting OS was 2,283 U/mL (area under the curve: 0.672, 95% confidence interval [CI]: 0.421–0.923). Thus, we defined patients with serum sIL-2R levels of ≥2,283 U/mL as the high sIL-2R group and the other patients as the low sIL-2R group. The two groups had similar clinical characteristics at the salvage chemotherapy, with the exception of their international prognostic index (secondary IPI) and performance status (PS). The high sIL-2R group had significantly higher secondary IPI (≥2,000) and poorer PS (≥2). Eight patients were alive at the time of the analysis, with a median follow-up of 55 months (range: 2–136 months). The 2-year OS among all patients was 25.1% (95% CI: 13.6–38.5), and the high sIL-2R group had significantly poorer 2-year OS (10.9%, 95% CI: 2.8–25.4 vs 50.0%, 95% CI: 24.5–71.0, P < 0.001). A multivariate analysis was performed using the following factors: serum sIL-2R levels (high vs low), secondary IPI (≥2,000) vs ≤2,000) (Figure 1).

Figure 1. Overall survival according to serum sIL-2R levels.

Summary/Conclusions: Serum sIL-2R levels are a useful predictor of prognosis in cases of relapsed/refractory PTCL-NOS, especially among patients with low secondary IPI risk.

PB1717

AUTOIMMUNE DISEASES ARE NOT ASSOCIATED WITH INFERIOR PROGNOSIS IN PATIENTS WITH MALIGNANT LYMPHOMA

Y.-H. Shih1,*, C.-L. J. Teng1, H.-C. Lin1, W.-L. Hwang1
1Division of Hematology/Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China

Background: Previous epidemiological studies have shown that autoimmune diseases increase the risk of lymphoma development. Immune dysregulation could be the possible underlying pathogenesis. Whether autoimmune diseases deteriorate outcome of lymphoma patients, however, remains unclear.

Aims: The objective of this study is to compare the clinical outcome among lymphoma patients with and without autoimmune diseases.

Methods: From January 2008 to November 2016, we retrospectively reviewed medical records of 913 newly diagnosed lymphoma patients. From these 913 lymphoma patients, 34 (3.71%) patients were diagnosed to have autoimmune diseases before their lymphoma identification. Among these 34 patients, six patients were lost to follow-up, and total of 28 lymphoma patients with pre-existing autoimmune diseases were finally analyzed. For the further comparison, 56 lymphoma patients without pre-existing autoimmune diseases who were adjusted for age and gender were considered to be the control group. Response rate, progression-free survival (PFS), and overall survival (OS) were compared between these two groups of patients.

Results: Rheumatoid arthritis was the most common autoimmune disease in lymphoma patients (11/34; 32.3%). The complete remission rate for lymphoma patients with and without autoimmune diseases were 72.0% and 83.3%, respectively (P=0.178). The PFS for patients with and without autoimmune diseases were 44.3±32.1 months and 50.9±28.6 months, respectively (mean±standard deviation; P=0.334). These two groups of patients had similar OS time as well (46.4 ±31.5 months vs 52.9±28.0; mean±standard deviation; P=0.337). Univariate analysis did not show autoimmune diseases were associated with inferior OS in lymphoma patients (crude hazard ratio: 1.32; 95% confidence interval: 0.43–4.07; P=0.627).

Summary/Conclusions: The results of this case-control study showed the autoimmune disease was not a poor prognostic factor for lymphoma patients.
Background: Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin’s lymphoma. Two independent prognostic scoring systems have been developed at the Memorial Sloan-Kettering Cancer Center (MSKCC) and the International Extranodal Lymphoma Study Group (IELSG). The former considers age and Karnofski’s performance status (PS) as prognostic parameters (JCO. 2006;24:5711). The latter includes age, Eastern Cooperative Oncology Group (ECOG) PS, the presence of deep lesions, serum lactate dehydrogenase (LDH) and total protein levels in the cerebrospinal fluid (CSF)(JCO 2003;21:256). Neither of the two systems has been verified in the Asian population, leading to concerns regarding applicability in this region.

Aims: This study was conducted to test the prognostic power of the 2 systems in PCNSL patients in Taiwan. In addition, we analyzed the parameters of the IELSG system to figure out the most powerful prognostic factors and then established a new scoring system.

Methods: The medical records of patients with tissue-proven PCNSL were retrieved from 15 academic hospitals in Taiwan through January 2002 to December 2011. They were Stratified into different groups according to the MSKCC or the IELSG system and the overall survivals (OS) were evaluated. All parameters in the IELSG system were checked by multi-variable analysis to establish a new scoring system.

Results: When the IELSG scoring system was applied, the 2-year OS in low, intermediate and high-risk groups were 78.3%, 43.9% and 37.5% respectively with a crossover in the latter 2 groups (Figure 1A). When the patients were stratified by the MSKCC scoring system, the 2-year OS of class I, II and III were 65%, 68% and 20% (Figure 1B), respectively. We conducted single-variable analysis of the 5 parameters included in the IELSG scoring system and were 65%, 68% and 20% (Figure 1B), respectively. We conducted single-variable analysis of the 5 parameters included in the IELSG scoring system and only age and ECOG PS were statistically significant. In the multi-variable analysis of the 5 parameters included in the IELSG scoring system and the overall survivals (OS) were evaluated. All parameters in the IELSG system were checked by multi-variable analysis to establish a new scoring system.

Background: The incidence of lymphomas is increasing with age. Many aggressive lymphomas are now considered to be curable. All fit patients, even elders, are candidates for optimal treatment with a curative intent. Diffuse Large B Cell Lymphoma (DLBCL) is the most common non-Hodgkin Lymphoma, with 60% of curative rates after standard R-CHOP regimen. Patients that relapse can be rescued with salvage treatment in 20-30%. The elders are not considered for full standard treatment in many systems. Geriatric scales are starting to being used to stratify patients and offer them individualized treatments. The use of GSCF for neutropenia prophylaxis is not a standard of care in this population.

Aims: The objectives of this study were: 1) Validate CIRS score in a DLBCL cohort; 2) Analyze the impact of CIRS score in OS; 3) Analyze the impact of GSCF prophylaxis in neutropenia fever.

Methods: Between November 2008 and November 2015, 41 DLBCL patients with ≥60 years at diagnosis from a single institution and homogeneously treated with R-CHOP were analyzed. Patients were evaluated for comorbidities with Cumulative Illness Rating Scale (CIRS). CIRS score was used to detect the most unfit population and evaluate the average of admissions stay and the impact on OS. The CIRS scale was adjusted by removing the hematological question since all our patients were diagnosed with a hematologic malignancy. The cut-off point for CIRS score was selected using a ROC analysis. Neutropenic fever (NF) events were recorded and the use of GSCF in prophylaxis were analyzed, as well as the admission days for adverse events.

Results: In our series, 20 patients (48%) were males. Median age at diagnosis was 73 years old (range 60-90) With a median follow-up of 32 mo. (range 0-96), the median PFS was 51 months and the OS was 61 mo. The patients were stratified by the R-IPI and the NCI-IPI. The R-IPI and the NCI-IPI. The ROC analysis showed a scoring of 5.5 in CIRS to identify two different risk groups, with an AUC of 70.5%, a sensitivity of 87% and a specificity of 48% (p=0.02). In the low risk group, with CIRS <6 (n=17), 7 (41%) patients were admitted with a mean of stay of 6,2 days (range 1-16) vs the high-risk group with CIRS >6 (n=24). Of this group, 11 (45%) patients were admitted with a mean of stay of 10,6 days (range 1-62), p=0.035. The CIRS scale was also used to discriminate two OS groups; the low risk showed a median OS not reached vs 29 mo. the high-risk group, with a Hazard ratio of 2,68 (95%CI:1.031-5,882, p= 0.042). NF was the most common ER visit, n=18 (36%). Of the 18 patients with NF, 10 (55%) were prescribed with GCSF prophylaxis mid cycles. Of all patients with GCSF (n=43) only 10 (24%) NF were reported. 11/17 patients (65%) who didn’t use GCSF prophylactic had an NF episode. The Odds ratio (OR) for the patients under prophylaxis was 0,232 (CI 95%: 0.085-0,634, p=0,004) (Figure 1).

Figure 1.

Summary/Conclusions: The OS and the PFS in our sample is similar as described in larger studies. The days of admissions adjusted to the CIRS scale give us a tool to help physicians to discriminate patients with DLBCL that will have prolonged admissions when treated with the standard of care. The CIRS scale also help separate two distinct OS curves, giving physicians a new tool to help discriminate worse prognostic patients, making them good candidates for adapted therapies. The use of GSCF prophylactic can protect the elderly patients from NF, and should be used in all patients in this category.

PB1721

PRIMARY ADRENAL LYMPHOMA: A SINGLE-CENTER EXPERIENCE
L. Yuan1, L. Sun2, W. Du3, Y. Zhao1,*
1Department of Hematology, 2Department of Pathology, 3Department of Oncology, Chinese PLA General Hospital, Beijing, China

Background: Primary adrenal lymphoma (PAL) is rare, with slightly more than 250 cases currently described in the English-language literature. In current classifications, there is not yet a consensual definition of PAL.

Aim of the study: To report a large single-center clinical case series of primary adrenal lymphoma (PAL) in terms of clinical presentation, pathological and imaging features, and treatment outcome.

Methods: We performed a retrospective analysis of 21 patients diagnosed with PAL who presented to our center between January 2005 and January 2015.

Results: Median age at presentation was 48 years (range: 27–73) with a male-to-female ratio of 6:2. Bilateral and right-sided adrenal involvement were seen in 12/21 and 7/21 patients, respectively. Adrenal insufficiency (AI) was seen in

Figure 1.

Summary/Conclusions: The OS and the PFS in our sample is similar as described in larger studies. The days of admissions adjusted to the CIRS scale give us a tool to help physicians to discriminate patients with DLBCL that will have prolonged admissions when treated with the standard of care. The CIRS scale also help separate two distinct OS curves, giving physicians a new tool to help discriminate worse prognostic patients, making them good candidates for adapted therapies. The use of GSCF prophylactic can protect the elderly patients from NF, and should be used in all patients in this category.

PB1721

PRIMARY ADRENAL LYMPHOMA: A SINGLE-CENTER EXPERIENCE
L. Yuan1, L. Sun2, W. Du3, Y. Zhao1,*
1Department of Hematology, 2Department of Pathology, 3Department of Oncology, Chinese PLA General Hospital, Beijing, China

Background: Primary adrenal lymphoma (PAL) is rare, with slightly more than 250 cases currently described in the English-language literature. In current classifications, there is not yet a consensual definition of PAL.
follow-up are warranted to confirm these preliminary data.

alterations in blood pressure and lipid profile. Larger cohorts of pts and longer prior regimens. However, the quality and time of response does not seem to rate and produces rapid responses regardless of the number and quality of progression of disease. Follow-up is still ongoing.

Background: Myeloid neoplasms following solid organ transplantation are needed. However, few studies about the incidence and impact on survival of HMs following solid organ transplantation have been conducted in Asian countries.

Aims: The aim of this study was to identify the incidence, characteristics, risk factors and prognosis of HMs in solid organ transplant recipients at our institution.

Methods: Clinical data of patients undergoing kidney, liver and heart transplantation at Hokkaido University Hospital were retrospectively reviewed. Kaplan-Meier analysis was performed for the cumulative incidence rates (CI) of HMs, graft survival and patient survival. Patient’s characteristics were compared between groups by the student t-test or K-squared test.

Results: A total of 16 cases of HMs were identified, 9 post-transplant lymphoproliferative disorder (PTLD) cases (5 EBV-positive PTLD and 4 EBV-negative PTLD), 4 acute myeloid leukemia (AML), 1 myelodysplastic syndrome (MDS), 1 myeloproliferative neoplasm (MPN) and 1 recurrent non-Hodgkin lymphoma. The CI of PTLD were 1.1%, 1.5% at 10 years in kidney transplant recipients (n=352), 0.92%, 2.6% at 5 years in liver transplant recipients (n=287) and 29% at 1 year heart transplant recipients (n=5), respectively (P<0.0001). AML/MDS and MPN developed only in liver recipients, and CI were 2.3% at 5 and 10 years (P<0.01). There was no difference in background factors other than transplanted organ type between recipients with HMs and without HMs. Patients with EBV-positive PTLD (n=5) were younger (P<0.05) and had less extranodal diseases (P<0.05) compared with EBV-negative PTLD (n=4). All patients with monomorphic PTLD (n=4) were treated with chemotherapy combined with rituximab and had been in remission.

Aims: The incidence of PTLD in solid organ transplant recipients in Japan is comparable to that in Western countries, whereas the incidence of myeloid neoplasms is higher in liver transplant recipients. PTLD dose not have a negative impact on the prognosis of solid organ transplant recipients under appro- priate management, while myeloid neoplasms are known to be fatal. We examined a clinical approach for myeloid neoplasms following solid organ transplantation are needed.

Summary/Conclusions: The incidence of PTLD in solid organ transplant recipients in Japan is comparable to that in Western countries, whereas the incidence of myeloid neoplasms is higher in liver transplant recipients. PTLD dose not have a negative impact on the prognosis of solid organ transplant recipients under appro- priate management, while myeloid neoplasms are known to be fatal. We examined a clinical approach for myeloid neoplasms following solid organ transplantation are needed.

By contrast, the present study showed that ibritinib may have an anabolic effect, including altering haemoglobin and lipids levels. Larger cohorts of pts and longer follow-up are warranted to confirm these preliminary data.
variate analysis was performed for the OS. Elevated LDH level, stage ≥3, PS ≥2, ≥2 cranial sites, IPI≥3, BCL6 negative (IHC), and MYC rearrangement (FISH) were significant factors in the female patients; however, PS ≥2 and IPI≥3 were significant factors in the male patients. Univariate analysis was also performed for PFS. Elevated LDH level, PS ≥2, IPI≥3, BCL6 negative (IHC), and MYC rearrangement (FISH) were significant factors in the female patients; however, PS ≥2 was the only significant factor in the male patients. Multivariable analyses were then performed using these factors in the Cox proportional hazard model. MYC rearrangement (FISH) [hazard ratio (HR): 9.13, 95% confidence interval (CI): 2.33–35.77, P=0.0015], and IPI ≥3 were identified as independent significant prognostic factor for OS in the female patients with DLBCL. Furthermore, MYC rearrangement (FISH) (HR: 2.47, 95% CI: 1.87–327.8, P=0.01494), and elevated LDH level were identified as independent significant prognostic factor for PFS in the female patients with DLBCL. On the other hand, PS ≥2 was identified as the only significant prognostic factor for OS (HR: 44.27, 95% CI: 6.71–292.2, P<0.001), but not for PFS in the male patients with DLBCL. Five of seven female patients with DLBCL and MYC rearrangement died from lymphoma progression. The median OS in the female patients with DLBCL and MYC rearrangement was 8.0 months (range: 1–35 months) compared to 21.5 months in those without MYC rearrangement (range: 1–79 months, P=0.003). On the other hand, in the male patients (n=13) with DLBCL, MYC rearrangement was not significantly associated with poor OS (Figure 1).

Summary/Conclusions: These results suggest that MYC rearrangement by FISH is significantly associated with very poor OS and PFS in the female patients with DLBCL but not the male patients with DLBCL. On the other hand, PS ≥2 is significantly associated with poor OS in the male patients with DLBCL.

PB1725
ASSESSING THE RISK FOR PERFORATION IN DIFFUSE LARGE B-CELL LYMPHOMA INVOLVING THE INTESTINES USING COMPUTED TOMOGRAPHY CHARACTERISTICS.
N. Sardi1, A. Sherban1, U. Bendet1, E. Luttwak1, Y. Herishanu1, C. Perry1, I. Aviv1
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Background: Around 40% of all Diffuse Large B-Cell Lymphoma (DLBCL) cases involve extra-nodal sites, the most common being the gastro-intestinal (GI) tract. DLBCL patients with intestinal involvement are particularly prone to develop GI perforation, which might be life threatening and entail significant morbidity. Identification of patients at risk for perforation may promote the performance of pre-emptive surgical resection of the involved segment. Although computed tomography (CT) scan is widely used at diagnosis, incorporation of CT results into the risk stratification of perforation has not yet been performed.

Aims: To determine risk factors for perforation in patients with DLBCL and intestinal involvement, with an emphasis on CT findings.

Methods: A retrospective single center study, including all consecutive DLBCL patients that presented with intestinal involvement between 2005 and 2016. The analysis included clinical, laboratory, pathological, and radiological parameters. Cases with DLBCL of the stomach were excluded.

Results: Forty-nine cases (30 men, 19 women) were included. Median age of the entire cohort was 64 years (54.5–77 IQR). Early stage (1, 2) according to the Lugano system was reported in 35% of cases. Small intestine involvement was most frequent (31%), followed by large intestine and ileo-colic (23 and 16%, respectively). Forty-three (88%) patients underwent CT scan at diagnosis. Most lesions were defined radiology as concentric (n=27, 63%) (as opposed to eccentric), and transmural (n=31, 74%) (as opposed to non-transmural). Of note, 98.3% of the 27 concentric lesions were also transmural, compared with 31% (8/26) of eccentric lesions. The median length and wall thickness of the involved site were 9.3 cm (5.8–13.5) and 15 mm (10–20), respectively. Ten (20%) patients developed an intestinal perforation. Six of the perforations (60%) involved the small intestine, 3 (33%) occurred at diagnosis prior chemotherapy, and 4 (40%) occurred within the first 21 days post therapy. All perforated lesions were concentric and transmural, with a median length of 11.2 cm. Eight (80%) patients underwent an urgent operation due to GI perforation, including 3 that resulted in an ostomy. Perforation led directly to 2 (20%) deaths. Perforation resulted in delayed administration of chemotherapy in 50% of cases (n=5). A univariate regression analysis found a higher risk of perforation in patients presenting with a concentric lesion (p=0.001, HR=36.4, CI 25.9–53.3) and a transmural lesion (p=0.008, HR=1.06, CI 1.017–1.116). Each extra centimeter to the length of the GI segment involved was associated with a 6% increase in the risk for perforation. There was no association between sex, age, performance status, hemoglobin, LDH, albumin, iron, ferritin, KI67, disease stage, anatomical location nor the involved site wall thickness and risk of perforation.

Summary/Conclusions: DLBCL patients presenting with an involvement of a long intestinal segment, especially with a concentric, transmural lesion, are at higher risk for perforation. These patients should be considered for a preemptive surgical resection, dependent on lesion site and operative risk.
Elevated LDH (HR 3.92, 95% CI: 1.61-9.51, p=0.003) (Table 1). To R-CHOP were: B-symptoms (HR 1.94, 95% CI: 1.05-3.61, p=0.034) and 317 patients treated with R-CHOP, risk factors at diagnosis for having PRD (CI 95% 0.19-1.80) and median OS 1 month (CI 95% 0.19-2.42). Among the patients who were treated with palliative intention, median PFS was 1 month. One died during transplant due to septic shock and 4 were not rescued with current salvage therapies, and in this setting DLBCL must currently in CR at 7 months. Median PFS was 2 months (CI 95% 1.2-2.7) and low in 4 patients (40%). Stem cell harvest was performed after 2 cycles. Successful mobilization was defined as achieving 10^6 PBSC/kg in a CD34+ cells x 10^6/kg. The G-CSF (Lenograstim) infusion started per protocol at day 6 at the dose of 5 µg/kg.

Results: Among the 44 primary refractory patients, 15 (34%), with a median age of 76 years (range 63-91), were considered unfit, 11 received supportive treatment. Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for these patients. Aims: We aimed to study the clinical features and outcome of patients diagnosed of DLBCL, homogeneously treated with R-CHOP/R-CHOP-like first line regimen, who have primary refractory disease (PRD). Methods: Three hundred and sixty-seven patients were diagnosed of DLBCL between January 2004 to August 2016 in our center. 317/367 (86.3%) were treated with R-CHOP or R-CHOP-like in first line. Forty-four (13.9%) patients had PRD and 39 (12.3%) progressed during the follow up. Survival curves were estimated using the Kaplan-Meier method and compared using the Log-Rank test. Univariate analyses were performed by Chi square test and multivariate analyses by Cox proportional hazard regression model. Results: Among the 44 primary refractory patients, 15 (34%), with a median age of 76 years (range 63-91), were considered unfit, 11 received supportive care and 4 were treated with palliative chemotherapy (cyclophosphamide and prednisone). Twenty nine (66%) were eligible for salvage therapy and consolidation with ASCT. Characteristics of those 29 patients at the time of salvage therapy were: median age 50 years (range 21-71), males 19 (65.5%), ECOG 2-4 16 (55.2%), Ann Arbor stage III-IV 23 (79.3%), B-symptoms 9 (31%), bulky disease (20.7%), extranodal involvement 20 (68%), leptomeningeal infiltration 4 (13.8%), high LDH 19 (65.5%), MIPI score was high in one patient (10%), intermediate in 5 patients (50%) and low in 4 patients (40%). Stem cell harvest was performed after 2 cycles. Successful mobilization was defined as achieving ≥10^6 PBSC/kg in a CD34+ cells x 10^6/kg. The G-CSF (Lenograstim) infusion started per protocol at day 6 at the dose of 5 µg/kg.

Results: All patients completed the scheduled treatment (4 cycles). The ORR was 90%. CR 90% and PD 10% (1 patient). Overall, the rates of successful mobilization and the proportion of patients achieving a total PBSC yield of ≥2x10^6/kg were 100%, and the median PBSC yield was 10 x 10^6/kg (range 3-20x10^6/kg). The median time to stem cell harvest was 17 days (range 14-19). The median number of apheresis to achieve the PBSC target was 1 and only 1 patient (10%) required a second collection procedure. Pleiexafor was not used. 86% of patients underwent high dose chemotherapy according to RBAC protocol (Fotemustine 150 mg/mq on days -7, -6, Etoposide 200 mg/mq) and Rituximab 375 mg/mq day 1, Bendamustine 70 mg/mq day 2-3, Cytoxan 500 mg/mq day 2-3-4) for 4 cycles. 90% had a stage IV disease; MIPI score was high in one patient (10%), intermediate in 5 patients (50%) and low in 4 patients (40%). Stem cell harvest was performed after 2 cycles. Successful mobilization was defined as achieving ≥10^6 PBSC/kg in a CD34+ cells x 10^6/kg. The G-CSF (Lenograstim) infusion started per protocol at day 6 at the dose of 5 µg/kg.

Results: All patients completed the scheduled treatment (4 cycles). The ORR was 90%. CR 90% and PD 10% (1 patient). Overall, the rates of successful mobilization and the proportion of patients achieving a total PBSC yield of ≥2x10^6/kg were 100%, and the median PBSC yield was 10 x 10^6/kg (range 3-20x10^6/kg). The median time to stem cell harvest was 17 days (range 14-19). The median number of apheresis to achieve the PBSC target was 1 and only 1 patient (10%) required a second collection procedure. Pleiexafor was not used. 86% of patients underwent high dose chemotherapy according to RBAC protocol (Fotemustine 150 mg/mq on days -7, -6, Etoposide 200 mg/mq) and Rituximab 400 mg/mq on days -5, -4, -3, -2 and Melphalan 140 mg/mq on day -1) with infusion of at least 5 x10^6/kg of PBSC. The median day for neutrophils recovery (ANC ≥0.5 x10^9/L) was 11 and 26 and platelet recovery (ANC >500/mmc, Plts >50,000/mmc) was 11 and 26 days. There was no engraftment failure. Most frequent adverse events (according to CTCAE grading) during therapy were hematological: neutropenia (100%, all 3-4), thrombocytopenia (100%, 60% G3-4), anemia (100%, 50% G3-4). Among non hematological toxicities, 20% of patients had febrile neutropenia (G3-4), 20% mucositis (G1-2), 20% lung infec- tions (G3), 10% hyperglycemia (G3). After a median follow up of 43 months the OS and PFS were 90% and 80% respectively. Summary/Conclusions: In the relapsed/refractory setting and in MCL patients ineligible for high dose chemotherapy, RBAC has been proven to be an efficacious induction and mobilization regimen also in transplant eligible MCL patients with an encouraging safety profile. Further investigations are needed to assess the optimal role of RBAC within the standard first line treatments.

PB1729

THE SAFETY OF LIPOSOМAL CYTARABINE IN CENTRAL NERVOUS SYSTEM INFILTRATION BY HAЕMATOLOGICAL MALIGNANCES

P. Garcia-Ramirez1,*, D.P. Millan-Lluis1, T. Galicia1, M.C. Mateos1, J.M. Arguiñano1, M. Alvarelles1, M.C. Montoya1, B. Signes1, M.L. Antelo1

1Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain

Background: Central nervous system (CNS) involvement, both leptomeningeal and parenchymatous conveys a poor prognosis in haematological malignancies. As well as systemic chemotherapy that crosses hematocerebral barrier, intrathecal (IT) chemotherapy has become an attractive approach because of direct action in the cerebrospinal fluid (CSF). Liposomal cytarabine (Depocyt®) is a liposomal formulation containing cytarabine (Ara-C) in CSF for an extended period of time (>14 days). This permits to decrease the frequency of lumbar punctures, without losing efficacy and minimizing the patient’s discomfort.

Table 1.

Patients with DLBCL refractory to first line R-CHOP are not rescued with current salvage therapies, and in this setting DLBCL must be considered an incurable disease with a very short survival, similar to that of patients treated with palliative care. Patients with B symptoms and elevated LDH at diagnosis have a significant higher risk to be refractory to R-CHOP. It is imperative to identify early these patients and to design new therapies for them.
Aims: The objective of this retrospective, observational study is to evaluate the efficacy and safety of liposomal cytarabine in patients with CNS infiltration by haematological malignancies.

Methods: 36 consecutive patients with haematological disease and risk of CNS infiltration underwent flow cytometry (FC) analysis of CSF in a single center from December 2014 to December 2016. CNS involvement was assessed by baseline routine CSF cytology, 8-color flow cytometry or MRI imaging. Along with systemic therapy, all patients considered positive were treated.

Results: Data from 36 patients were analysed. A total of nine patients were considered to have CSF involvement, all of them detected by FC. Of note, all of them were considered negative for CSF infiltration by standard cytology. Three additional patients had MRI changes suggestive of brain involvement by the malignancy. The median age of this 12 patients was 52 years (range 16-69), 58.3% were female. Diagnosis was B-cell lymphoproliferative disorder 41.7% (CLL, Burkitt, DLBCL), ALL 25%, AML 25% and multiple myeloma 8.3%. The median number of doses per patient was 6.5 (SD 1.7). CSF clearance was achieved after a median of 1 dose (range 1-3) or 20 days (range 16-86). Overall rate of CNS response was 100%. Two patients (16.7%) had leptomeningeal involvement during the IT treatment. The overall AE incidence was 66.7%. The most common AE include: headache, peripheral sensory neuropathy, back pain and nausea. Severe neurotoxicity has been encountered in four patients: cauda equina syndrome in 2 cases, myelopathy, bilateral optic neuropathy and neuritis in 1 patient each. Treatment had to be discontinued in 3 patients because of side effects but this did not lead to relapse. The median time to AE occurrence was 6 cycles (range 4-7) or 110 days (range 33-227). The incidence and severity of AE seemed to increase with the cumulative number of cycles administered. In most patients neurologic complications resolved or improved with time.

Summary/Conclusions: use of liposomal formulation of cytarabine for IT administration has become an effective option for the treatment of leptomeningeal involvement by haematological malignancies. Neurological AE are reversible; however, they accumulate and worsen with time, thus precluding long-term use.

PB1730
RETROSPECTIVE ANALYSIS OF OUTCOMES FOR ELDERLY PATIENTS WITH STAGE 3 AND 4 DISEASE HIGH-GRADE DLBCL WITH REDUCED CYCLES OF R-CHOP OR R-GCVP: A 7 YEARS SINGLE-INSTITUTE EXPERIENCE.
K. Joshi1, K. Leung2, C. Page2, A. Rajic3, F. Masieri4, N. Gill5, J. Morgan2, A. Hodson1, M. Prahladan1
1Haemato oncology, Ipswich Hospital/ Addenbrookes Hospital, Cambridge, 2Haematology, Ipswich Hospital, 3Molecular Biotechnology Unit, University of Suffolk, Cambridge, United Kingdom

Background: The most common high-grade lymphoma malignancy in adults is Diffuse Large B-Cell Lymphoma (DLBCL), which has an increasing incidence (2). Over 40% of patients with DLBCL are above the age of 70, and the comorbidities in this age-group present significant challenges and complexities with regards to selecting and implementing treatment regimens (2).

Aims: We present a retrospective analysis of outcomes for patients with high-grade DLBCL (stage 3 or 4 disease) who have received fewer than 6 cycles of full-dose R-CHOP or R-GCVP because of poor tolerability or disease progression with treatment.

Patients and Methods: Retrospective data were collected from the cancer registry for all newly-diagnosed DLBCL patients who received R-CHOP or R-GCVP chemotherapy, with data collected from Jan 2010 to Feb 2017 from Ipswich hospital NHS trust, United Kingdom. Patients who completed 6 cycles of chemotherapy were excluded. Interim PET-CT scan/staging CT scan was done to assess the disease response to therapy after 2 cycles of chemotherapy. The main baseline characteristics collected were age, sex, ECOG Performance Status, Ann-Arbor Stage and IPI risk stratification. The primary end point was progression-free survival (PFS) from first course of treatment. Secondary end points were overall progression-free survival (OPFS), overall survival (OS), and the reasons for premature ceasing of treatment based on graded toxicity according to NCI-CTCAE 4.0.

Results: Out of 87 patients, 12 patients were identified that fulfilled the inclusion criteria. The median age of patients was 72 years (range: 64-88 years), sex distribution was 7 male: 5 female, ECOG PS was 0-2 in 10 (83%) and ≥3 in 2 (17%) of the patients, Ann-Arbor Stage was 3 in 6 patients (50%) and 4 in 6 patients (50%), and IPI score was 3 in all 12 patients. 11 patients received R-CHOP and 1 patient received R-GCVP. The median length of treatment was 3.5 years (range: 1-6 years). The overall response rate was 55% and median number of assessment and 75% at end of treatment assessment scan. The complete and partial response rates at the end of the treatment were 58% and 17% respectively. Progression free survival was 73% at 2 years (8 out of 11 patients) and 50% at 3 years (4 out of 8 patients). The median overall survival of deceased patients (out of 12) was 9.5 months (range: 2-42 months) and the median overall survival of living patients (8 out of 12) is at 40.5 months (range: 27-84 months).

Conclusion: DLBCL treated with less than 6 cycles of full dose R-CHOP or R-GCVP chemotherapy may achieve sustained long-term remission in selected patients with high IPI and significant co-morbidity. Further research on disease characteristics including molecular profile is needed to elucidate selected populations who may achieve long-term remission with shorter cycles of chemotherapy. Further insights may derive, for example, from analysis of polymorphism of folate pathway genes and/or of NF-kb, which have been previously suggested as pharmaco-genomic targets in lymphoid neoplasms. A risk stratification model needs to be developed to reduce drug toxicity and other short and long term treatment related complications so as to improve patient experience, and pharma-economic benefits.

PB1731
MULTIPLE NEOPLASMS CONSIST OF SOLID CANCER AND NON-HODGKIN LYMPHOMA
K. Natori1,*, D. Nagase1, S. Ishihara1, A. Shibuya1, Y. Mitsui2, Y. Kuraishi1, H. Izumi1
1hematology and Oncology, Toho University Medical Center, Oota city, Japan

Background: Malignant lymphoma is a ninth cause of death in Japan. And non-Hodgkin lymphoma(NHL) occupied more than 90%. We experienced cases and will report that we experienced multiple neoplasms consisting non-Hodgkin lymphoma. We experienced 176 cases.

Aims: We aimed for epidemiology and prognosis improvement of malignant neoplasms including NHL. We want to look for a hint of the early detection.

Methods: We intended for multiple neoplasms 340 cases including hematological malignancy. We reviewed 190 cases of multiple neoplasms including malignant lymphoma. In 190 cases, NHL case were 176 cases. The examination factors are type of the hematological malignancy, gender, the age at onset of the first cancer, interval with the second cancer, treatment strategy. The definition of multiple neoplasms followed Warren & Gates theory. And as for the diagnosis of synchronous and metachronous diagnosis into 2 groups. By date analysis, metachronous type interval is more than 6 months. About statistical examination, we used SPSS statistics version21.

Results: All cases are 176 cases, consist of male 108 cases, female 68 cases, synchronous type 45 cases, metachronous type 131 cases. Double neoplasms 149 cases, triple neoplasms 25 cases, quadple neoplasms 2 cases. The median age was 7 yrs (ranged51-93yrs), the synchronous type 70yrs (ranged 51-88yrs), the metachronous type was 73yrs (ranged 57-93yrs). The counterpart of malignancies, Hodgkin’s lymphoma 1 case, myelodysplastic syndrome 3 cases, acute myeloid leukemia 8 cases, multiple myeloma 4 cases, gastric cancer 36 cases, colon cancer 32 cases, lung cancer 26 cases, renal cell carcinoma 6 cases, prostate cancer 12 cases, breast cancer 14 cases, urinary bladder cancer 5 cases, uterin cancer 7 cases, esophangeal cancer 9 cases, hepato-cellular carcinoma 12 cases. In double neoplasms was 149 cases, metachronous type was 112 cases. The median age of first diagnosis, 68yrs (ranged43-85yrs), the second cancer were 74yrs (ranged57-89yrs). About interval between solid cancer and NHL, median interval time was 58M, solid cancer presence case was 53 cases, interval was 81M (ranged 7-564M), hematological malignancy presence case was 59 cases interval was 55M (ranged 8-364M). The cause of death was that 15 cases were solid cancer, 72 cases were hematological malignancy and 6 cases were accident. The median overall survival was 18M (ranged 1-211M), synchronous type 14M (ranged 2-132M), metachronous type 22M (ranged 1-116M).

Summary/Conclusions: In the case of a double cancer including solid cancer and NHL, the first cancer occurs in elderly. Diagnosis of malignant neoplasms incidence is over 30% (32.2%). The important point is that 3 years are required for careful observation at the time of malignancy diagnosis. It is necessary to discover at the early stage. So it could be a lot of treatment options from formalin neoplasms. We think that a diagnosis is improved.

PB1732
RETROSPECTIVE EVALUATION ON Efficacy and Feasibility of R-CODOX-M/IVAC REGIMEN IN AGGRESSIVE DLBCL
E. Covello1,*, P. Minetto1, F. Guolo1, D. Guardo1, M. Gambella1, F. Ballerini1, R. M. Lemoli1, M. Gobbi1
1Haematology, IRCCS San Martino, Genova, Genova, Italy

Background: Diffuse Large B Cell Lymphoma (DLBCL) is an heterogeneous group of diseases. The aggressive behavior can be predicted by clinical risk scores, immunohistochemistry and cytogenetic. Among DLBCL, double hit lymphomas are characterized by the expression of two oncogenes, MYC and BCL2, which are considered positive in the case of double neoplasms. While R-CHOP is the current gold standard of care for DLBCL, it is not curative on this subset of patients due to high resistant rates.
phomas (DHL) and double or triple-protein-expression lymphomas (DPLs, TPLs) display a worse outcome. R-CHOP, which is the frontline treatment for DLBCL, showed a poor outcome in high risk IPI patients and DHLs or DPLs. From January 2011 in our centre (IRCCS AOU San Martino Hospital–IST, Genoa, Italy) R-CODOX-M/IVAC regimen has been adopted as first line in patients with aggressive DLBCL, defined by at least one among these features: high tumour burden, DPLs, IPI score >3 or by the presence of at least 1 extranodal site.

Aims: Our aim was to define the efficacy and feasibility of this frontline strategy and eventually identify the subgroups of patients who may benefit from this approach.

Methods: We retrospectively analyzed 20 patients affected by aggressive DLBCL treated with R-CODOX-M/IVAC. R-CODOX-M consists of rituximab 375 mg/sqm day 1, cyclophosphamide 800 mg/sqm day 1, 200 mg day 2-5, doxorubicin 40 mg/sqm day 1, vincristine 1.4 mg/sqm, methotrexate 6700 mg/sqm. IVAC-R contains rituximab 375 mg/sqm, iophosphamide 1500 mg/sqm day 1, etoposide 60 mg/sqm day 1-5, cytarabine 2000 mg/sqm bid day 1-2. In both cycles CNS prophylaxis was administered. According to Ann Arbor classification, 11 patients were on stage IV, 1 on stage III, 3 in stage I and 5 in stage I. Twelve patients had B symptoms. Median IPI score was 3. Eleven patients had DPLs and 4 of them had TPLs. Overall survival (OS) was calculated from the time of diagnosis to the time of death or last follow-up.

Results: After a median follow-up of 28 months, 5 patients died (25%). OS at six and twelve months was 89.4 and 70.4%, respectively, median not reached (NR). Complete remission was achieved in 11 patients (55%), partial remission in 2 patients (10%). The overall response rate was 98%. Three patients (18%) were alive without disease. There were 12 patients with a twelve months was 88.9 and 64.8%, respectively, not significantly lower than non-DPLs patients (p=n.s., median NR). In patients with Ann Arbor stage III or IV, OS at six and twelve months was 90.9 and 80.6% (median NR). In patients with IPI score >3, OS at six and twelve months was 78.8 and 45% (median 12 months). The main toxicity during CODOX-M was grade >2 mucositis, 63% of patients. Infections occurred in 71% of patients. Renal and liver toxicity was mainly of low grade and was observed respectively in 38% and 50% of patients. Median severe neutropenia was 4.5 days (range 0-16) and median severe thrombocytopenia was only 1 day (range 0-21). Most patients (56%) needed transfusion support. In IVAC regimen, the main toxicities were the hematological one with 7 days of median duration of severe neutropenia (range 3-10), and 7 days (range 6-23) of thrombocytopenia. Seventy-five patients required transfusion support. Infections occurred in 42% of patients. We observed few case of grade >2 mucositis (17%), renal toxicity (8%) and liver toxicity (17%).

Summary/Conclusions: R-CODOX-M/IVAC is a generally well tolerated regimen, with acceptable toxicity profile in the setting of aggressive DLBCL. Results in our cohort suggest a potential benefit for DPLs, whereas higher IPI scores retains a negative prognostic impact. The next step of the study will be retrospective FISH evaluation of C-MYC, BCL2 and BCL6 translocations, for lacking impact of body mass index (BMI) on overall survival (OS) or progression-free survival (PFS) of diffuse large B cell lymphoma (DLCLB). Many factors like treatment response, cycles of chemotherapy and consolidation radiation did not make significant difference to the survival. Prevention of early mortality may improve the outcome of this disease. Gastrointestinal bleeding in treatment is rare but with high mortality.

PB1734

STOMACH DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE

M.-T. Sung1,*, L.-W. Chiu1, S.-N. Huang2, A.-C. Feng3, M.-C. Wu1, P.-Y. Chen1, C. Hsiao-Hsiang1, T.-D. Tan1
1Department of Hematology and Medical Oncology, 2Office of Epidemiology and Biostatistics, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan, Republic of China

Background: Primary gastric diffuse large B cell lymphoma is a rare type of diffuse large B cell lymphoma. Immunochemotherapy followed by consolidation radiation is the cornerstone of treatment. However, the cycles of chemotherapy and the role of consolidation radiation are still under debate.

Aims: To review and analyze the treatment experience of newly diagnosed primary gastric diffuse large B cell lymphoma. We presented the treatment outcome of our institution.

Methods: We retrospectively reviewed medical records from Jan 2005 to Dec 2014 from our institution. 30 patients with primary gastric diffuse large B cell lymphoma were included. Clinical characteristics, treatment regimens, treatment response, treatment modality, and survival were analyzed.

Results: From Jan 2005 to Dec 2014, there were 30 patients with primary gastric diffuse large B cell lymphoma. Median age was 65 years of age. 53% (n=16) of patients were male. All 30 patients (100%) have received chemotherapy. 13 of them (43%) have received involved field radiation therapy (IFRT). RCHOP or RCEOP was administered in 86% (n=26) of patients. Complete response (CR) rate was 80% (n=24), 5-year survival was 86%. In patients who achieved complete remission (CR) (n=24), 5-year survival for 4 cycles of chemotherapy was 88% vs 86% (p=0.42), respectively. For addition of IFRT in CR patients, 5-year survival for IFRT vs no IFRT were 83% vs 90% (p=0.03), respectively. Treatment-related mortality (TRM) was 10% (n=3) and primary relapse or recurrent disease was 10% (n=3). All of them are non-CR patients. Gastrointestinal bleeding which required admission occurred in 10% (n=3) of patients. In patients who developed GI bleeding, 2 of them were non-CR patients and they all died. No patient died of disease relapse after complete response.

Summary/Conclusions: In our series, the 5-year survival was good. In patients who achieved CR, cycles of chemotherapy and consolidation radiation did not make significant difference to the survival. Prevention of early mortality may improve the outcome of this disease. Gastrointestinal bleeding in treatment is rare but with high mortality.

PB1735

IMMUNOHISTOCHEMISTRY BIOMARKERS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY

T. Mendes1,*, F. Mousinho1, P. Sousa E Santos1, E. Viegas2, A. P. Gomes1, F. Falcão2, F. Lima1
1Clinical Hematology, 2Pharmacy Department, Faculty of Pharmacy, University of Lisbon, Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal

Background: Diffuse Large B-cell Lymphoma (DLBCL) is a heterogeneous group of lymphomas with variable clinical presentation. The International Prognostic Index (IPI) is the most important tool to identify subgroups with different survival, however, certain biological markers seem to have a prognostic value relevant and independent of IPI.
Aims: To analyze the evolution of patients diagnosed with DLBCL and the expression of BCL2, BCL6 and MYC.

Methods: We conducted a retrospective study that included hospitalized patients with de novo CD20+ DLBCL, with expression of BCL2+, BCL6+, BCL2/BCL6, MYC/BCL2, MYC/BCL6 treated with regimens containing rituximab, from February 2012 to November 2016. Samples were analyzed by immunohistochemistry. Statistical analysis with the SPSS V17.0 program.

Results: We included 43 patients with a median age of 65 years (22-97), 59.5% male, 45.2% had IPI 0-2, 54.8% had IPI 3-5, 26.2% stage I-II, 73.8% stage III-IV, 61.9% had extranodal disease and 23.8% bulky disease. Ki-67 was elevated in all patients who did this evaluation (n=28). In 13 patients was identified BCL2 expression in 6, and 21 patients had co-expression of BCL2/BCL6, 1 patient had MYC/BCL2 and 1 had MYC/BCL6. The R-CHOP regimen was first line treatment in 92.8% of patients. The ORR was 82.5%, with 65% of CR, 15% PR and 17.5% PD. Of those patients who received second line treatment, 8 expressed BCL2/BCL6, 4 BCL2, 2 BCL6, 1 MYC/BCL2, and 1 MYC/BCL6. Of 15 patients who received third line treatment 5 expressed BCL2/BCL6, 1 BCL2 and 1 MYC/BCL6. The average time to next treatment (TNT) was 5.2 months (0.5-19) for second line and 4.9 for third line. Mortality rate was 45.2%. With a median follow-up of 18.6 months (3-58.6), the overall survival was 24.6 months (3-62).

Summary/Conclusions: The identification of biomarkers by immunohistochemistry is a relatively inexpensive process, which, when well elaborated and interpreted, allows to find in a safe way, subgroups of patients at high risk, who benefit from more aggressive 1st line therapy and, whenever possible, from the Inclusion in clinical trials with new drugs.

PB1736
INVESTIGATION ON TREATMENT STRATEGY, PROGNOSTIC FACTORS, AND RISK FACTORS FOR EARLY DEATH IN ELDERLY TAIWANESE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
S.-F. Cho1,*, Y.-C. Liu1, H.-H. Hsiao1, Y.-F. Tsai1, H.-C. Wang1, T.-C. Liu1
1Department of Hematology and Oncology, 2Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung city, Taiwan, Kaohsiung city, Taiwan, Republic of China

Background: Given that the population of elderly cancer patients, including those with diffuse large B-cell lymphoma(DLBCL), is increasing, the management of cancer in the elderly has emerged as an increasingly common problem.

Aims: This study aimed to investigate the treatment strategy, prognostic factors, and risk factors of early death in elderly patients (age ≥65 years) with DLBCL in the rituximab era.

Methods: Elderly patients diagnosed with DLBCL between 2008 and 2014 were enrolled for analysis.

Results: There were 145 elderly patients with DLBCL diagnosed between 2008 and 2014. After excluding patients with primary central nervous system DLBCL (n=9) and incomplete data (n=3), a total of 133 patients (64 male and 69 female) with a median age of 74 years (range 65 to 94 years) were enrolled in the present study. Patients at a younger age and with better performance status were more likely to receive intensive frontline treatment. The median progression-free survival (PFS) and overall survival were 15 and 21 months, respectively. Anthracycline-containing chemotherapy achieved a higher remission rate and showed a trend toward better overall survival at the expense of a higher risk of severe neutropenia. Multivariate analysis revealed that very old age (≥81 years), a high-risk age-adjusted international prognostic index (aIPI) score, and bone marrow involvement were associated with poorer PFS and overall survival. Progression of lymphoma was the major cause of death in the study population. In addition, approximately 25% of patients died within 120 days of their diagnosis. The risk factors for early mortality included very old age, a high-risk aIPI score, and bone marrow involvement. The appearance of symptoms or signs of tumor lysis syndrome at diagnosis was associated with a trend toward early death.

Summary/Conclusions: Treatment of elderly patients with DLBCL remains a challenge, and comprehensive co-evaluation to tailor therapeutic interventions and offer the best supportive care may reduce complications and improve the clinical outcome of these patients.

PB1737
TREATMENT OUTCOME OF MONOMORPHIC EPITHELIOIDIC INTESTINAL T-CELL LYMPHOMA: EXPERIENCE FROM AN ASIAN CAN- CELER
M.-T. Sung1,*, M.-Y. Lee2, M.-C. Wu1, T.-D. Tan1
1Department of Hematology and Medical Oncology, 2Department of Pathology and Laboratory Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan, Republic of China

Background: Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), previously type II enteropathy-associated T-cell lymphoma(EATL), primarily occurred in Asian countries. It is refractory to chemotherapy and the prognosis is poor. Intensive chemotherapy has been proposed to improve treatment outcome.

Aims: We examined the treatment outcome of MEITL in our institution.

Methods: We retrospectively searched our institutional database from 1996 to 2014 for intestinal T-cell lymphoma. Medical records were reviewed and the patients were classified on the basis of WHO-2016 classification. Patient’s characteristics, treatment modalities, response and survival were collected and analyzed.

Results: Ten patients with intestinal T-cell lymphoma were identified. One patient had enteropathy-associated T-cell lymphoma (EATL) presenting with celiac sprue. Five patients had intestinal T-cell lymphoma, NOS. Four patients were diagnosed with monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). For patients with MEITL, median overall survival was 7.9 months (4.2-15.0 months). Median age was 46 years of age. Bowel perforation was the initial presentation in 3 patients (3/4, 75%). One patient was treated with chemotherapy with CHOP regimen, while another patient underwent surgery alone. The remaining two patients were treated with regimens containing chemotherapy alone (one with CHOP, the other with BFM-90 protocol). Only one patient (1/4, 25%) entered complete response. Of concern, the unique patient achieved complete response received surgery followed by chemotherapy with Berlin-Frankfurt-Munster(BFM)-90 protocol. Remission duration was 10.3 months. He passed away 15.0 months after remission because of relapsed lymphoma.

Summary/Conclusions: Though the prognosis of MEITL is poor, operation followed by high dose chemotherapy such as BFM-90 protocol may have better treatment response, response duration and survival. It deserves further investigation.

PB1738
OSTEOPONTIN AS PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA
G.I. Barranco Lampón1,2,*, E.B. Ruiz García3, E.A. Fernández Figueroa2,3, M.S. Rivas Vera1, C. Lorne Maladonado5, R. Quezada López4, E. Cortés4, J.L. Aguilar Ponce4
1Hematology, 2Translational Medicine, Instituto Nacional de Cancerología, 3Facultad de Medicina, Universidad Nacional Autónoma de México, 4Pathology, 5Internal Medicine, Instituto Nacional de Cancerología, Ciudad de México, México

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. It is a heterogeneous disease whose prognosis depends on the histological subtype (central, extranodal, non-centrogeminal), as well as other factors such as age, clinical stage, extranodal disease, ECOG scale and levels of lactate dehydrogenase (LDH) identified by established scales (IPI, NCCN-IPI). Osteopontin (OPN) a protein that is secreted by various cells and fulfills physiological functions, when produced by neoplastic cells favors tumor growth and metastasis. This has been corroborated in different types of cancer and there are few reports of cases of patients with DLBCL in which the tumor expresses osteopontin, characteristically these cases have presented an aggressive clinical behavior with extranodal disease.

Aims: To evaluate the expression of osteopontin in neoplastic lymphocytes and their association with overall survival; the percentage of patients who expressed osteopontin at diagnosis; the association between the expression of osteopontin and the histological subtype (germinial center, non-centrogeminal, unclassifiable); the association between osteopontin expression and age, elevation of DHL, ECOG scale, clinical stage, extranodal invasion and the application of the IPI and NCCN-IPI scales.

Methods: Tissue samples were obtained from DLBCL patients diagnosed at the Instituto Nacional de Cancerología between December 2014 and January 2016. Morphologic and immunohistochemistry features were studied on paraffin-embedded tissue microarray (TMA). Single antibody staining was performed for OPN. OPN expression was semiquantitatively assessed by three different pathologists scoring the proportion and intensity of stained cells. Positive cases were defined as cases with osteopontin expression in the nucleus or cytoplasm of the tumor cell. Age, ECOG, clinical stage, LDH, extranodal invasion, histological subtype, IPI and NCCN-IPI score were independently documented. Overall survival (OS) analysis was performed by the Kaplan-Meier method, the comparison between different curves was performed using the log-rank test; for the analysis of the relationship between variables we used the X2 test with a statistical significance of p <0.05.

Results: 81 patients were evaluable. 43.2% of the cases were positive for OPN in neoplastic cells. The mean survival of patients with positive OPN was 14.8 months versus 16.5 months for patients with no OPN expression (p=0.025). OPN positivity was not significantly associated with increased age, impaired functional status (ECOG 2,3,4), advanced clinical stage (III, IV), increased LDH or extranodal invasion (including central nervous system); neither was it associated with a specific histological subtype. Survival significantly decreased in patients with increased LDH (p=0.000137), ECOG 2,3,4 (p=0.047). Survival decreased significantly as the risk measured by the IPI and NCCN-IPI scales increased (p=0.000001, p=0.000013 respectively) with an average survival of 18.6 months for the low-risk group, compared with 6.4 months for the high-risk group (Figure 1).
Results:

Overall response rate, with appropriate selection of combination chemotherapy regimens, was improved. This also applies to patients with SCNSL in subgroup analysis. Longer follow up of patients will be needed to further demonstrate an overall survival benefit.

Summary/Conclusions: Our findings demonstrate that approximately half of the cases evaluated express OPN at diagnosis and tend to have a lower survival rate, however, a longer follow-up time is needed, as well as other studies that discriminate between different isoforms or post-translational modifications of osteopontin to determine if this trend can reach significance. By demonstrating OPN expression by neoplastic cells we can devise new protocols that validate its usefulness as a surrogate marker of tumoral activity in DLBCL using non-invasive techniques (e.g., quantification of serum levels), which would improve surveillance of these patients.

Figure 1.

Summary/Conclusions: This single centre study demonstrated that patient selection, based upon comorbidities and performance status, for high dose combination chemotherapy in the treatment of PCNSL improves 30 day mortality, often associated with death from myelosuppression due to chemotherapy. The overall response rate, with appropriate selection of combination chemotherapy regimens, was improved. This also applies to patients with SCNSL in subgroup analysis. Longer follow up of patients will be needed to further demonstrate an overall survival benefit.

Figure 1.

Summary/Conclusions: This single centre study demonstrated that patient selection, based upon comorbidities and performance status, for high dose combination chemotherapy in the treatment of PCNSL improves 30 day mortality, often associated with death from myelosuppression due to chemotherapy. The overall response rate, with appropriate selection of combination chemotherapy regimens, was improved. This also applies to patients with SCNSL in subgroup analysis. Longer follow up of patients will be needed to further demonstrate an overall survival benefit.
criteria at the outset and analyzing the possible features of laboratory TLS. Although dosing did not always follow BSH guidelines, we did respond to biochemical deterioration. The majority of patients with HD developed acute kidney injury despite rasburicase. Doses were increased in response to creatinine increases, albeit not as per guideline. It is notable that despite lower than the recommended doses of rasburicase, 6/8 patients with lab TLS did not progress to clinical TLS, and none required dialysis. The guideline is a good tool for the risk stratification and treatment of patients at risk of TLS. In clinical practice 100% compliance is hard to achieve. Responding to trends in creatinine may explain why, despite lower than recommended doses, our outcomes were still good. It would be interesting to see if further work with larger numbers of patients would support this. Since this audit was completed, the ePrescribing system has been altered to improve practice and a re-audit is planned.

PB1742

PROGNOSTIC IMPACT OF SYNCHRONOUS MULTIPLE PRIMARY MALIGNANT TUMORS ON NEWLY DIAGNOSED LYMPHOMA PATIENTS

S. Nishikawa1,2, S. Okuno1, K. Suzuki1, S. Kurashash1, I. Sugura1
1Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, 2Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan

Background: Synchronous multiple primary malignant tumors (sMPMTs) are occasionally diagnosed during screening for a newly diagnosed malignant neoplasm. Lymphoma is one of the most common hematological malignancies, and number of lymphoma patients with sMPMTs seems to grow as the population ages. Since the standard chemotherapy for lymphoma takes a few months, treatment strategy sometimes comes to an issue.

Aims: To answer a clinical question of how to handle sMPMTs in the treatment of lymphoma, we investigated prognostic significance of sMPMTs and suitable treatment strategy for a newly diagnosed lymphoma with sMPMTs.

Methods: We retrospectively analyzed patients with malignant lymphoma newly diagnosed between 2009 and 2015. The definition of sMPMTs was patients who were also diagnosed as a solid tumor within 6 months of the diagnosis of lymphoma. Therapeutic strategy was according to physician’s choice. Impact of sMPMTs on treatment outcome of lymphoma was analyzed. Also, relation between treatment of lymphoma and concomitant solid tumors was closely analyzed.

Results: Total of 505 lymphoma patients was included. Median age was 69 (range 20-99). The most common diagnosis was diffuse large B-cell lymphoma (63%), and patients with aggressive lymphoma accounted for 77% (391/505). High risk disease, which was defined as international prognostic score 3 or higher, accounted for 36% (184/505). sMPMTs were identified in 16 patients (3%). There was no difference of distribution between patients with and without sMPMTs regarding age, grade of lymphoma, and disease risk. The overall survival (OS) and disease-free survival (DFS) were not significantly different between the two groups (with sMPMTs: 53% and 47% vs without sMPMTs: 77% and 61% at 3 years, P=0.20 and P=0.31). Cumulative incidence of lymphoma relapse was similar between the two groups (with sMPMTs 29% vs without sMPMTs 27% at 3 years, P=0.28). In multivariate analyses, age (75 years<) and disease risk (high) were identified significant risk factors for OS, and age was an only significant risk factor for DFS. Existence of sMPMTs was not a significant risk factor for either OS or DFS (OS: HR 1.29, 95% CI 0.52-3.20, P=0.58; DFS: HR 1.06, 95% CI 0.49-2.27, P=0.88). Among 16 patients with sMPMTs, half of the patients had high-risk lymphoma, and half of the solid tumors were gastric cancer. Treatment was initiated for the disease which was diagnosed earlier in all patients except one. Interval from diagnosis to the first treatment was significantly shorter in patients whose lymphoma was treated earlier (median 11 days vs 38.5 days, P=0.004). OS was not significantly different according to the sequencing of treatment (lymphoma earlier: 59% vs Solid tumor earlier: 40% at 3 years, P=0.84). In 8 of 10 patients whose lymphoma was treated earlier, treatment of lymphoma was interrupted for the treatment of the solid tumors. Interruption of treatment had no significant effect on OS (interuption+: 60% vs interruption-: 50% at 3 years, P=0.13).

Summary/Conclusions: Existence of sMPMTs was not a significant risk factor for newly diagnosed lymphoma patients. It is important to provide adequate treatment for both lymphoma and solid tumor at physician’s discretion.

PB1741

IMPLICATION OF BASIC VALUES OF VITAMIN D IN THE CLINICAL COMPLICATIONS OF PATIENTS WITH NON-HODGKIN LYMPHOMA IN ACTIVE CHEMOTHERAPY TREATMENT

R. Martos1,2, I. De Vicente1, M. Yuste1, L. Bermejo2, A. Pascual2, P. Beltran2, N. Patrignani2, P. Llamas3
1Hematology, Hospital General Villalba, Collado Villalba, 2Hematology, Hospital Universitario “Infanta Elena”, Valdemoro, 3Hematology, Hospital Universitario “Fundación Jimenez Diaz”, Madrid, Spain

Background: The incidence and prevalence of Non-Hodgkin’s Lymphoma B (NHL-B) has increased in recent years, reaching approximately 3-7 cases / 100,000 habitants. For this reason, the number of patients who receive chemotherapy treatment is also considerably higher; this implies a greater presence of adverse events. In many of these patients, baseline vitamin D values at the time of diagnosis are decreased, and may be related to the development of the tumor pathology, also to the severity of the adverse events.

Aims: To assess the implication of vitamin D values in the development of relevant clinical complications in patients diagnosed with NHL-B receiving chemotherapy. To determine its clinical evolution after correcting the vitamin deficiency.

Methods: Retrospective study (January 2013-January 2017), which includes patients diagnosed with NHL-B with histological confirmation. We analyze demographic parameters (age, sex), histological subtype of NHL-B according to WHO classification, laboratory values of vitamin D (cut-off values: optimal 25-66 pg/mL; low 25-18 pg/mL or very low <18 pg/mL), adverse effects: hematological, toxicity, infection, gastrointestinal toxicity, hospital admissions and exitus. A subanalysis of complications was performed in patients with vitamin D deficiency vs. those with normal levels versus those with corrected levels.

Results: 68 patients were analyzed, and 57 cases (84%) were valid because they had vitamin D determination in the 8 weeks near the diagnosis. The distribution was: 58% (n=33) 25-66 pg/mL; 12% (n=9) 25-18 pg/mL; 20% (n=13) <18 pg/mL. Hematological toxicities were higher for the subgroup with decreased vitamin D values at the time of diagnosis, and may be related to the development of the tumor pathology, also to the severity of the adverse events.

Conclusions: The determination of vitamin D levels should be routinely included in the diagnosis in patients with NHL-B because could be a modifiable risk factor in the complications of this patients.
Bleeding disorders (congenital and acquired)

PB1743

GLOBAL HEMOSTATIC ASSAY AT DIFFERENT TARGET ACTIVITY OF FACTOR VIII AND FACTOR IX

K. Yoo, K. Han

Background: On reports addressing hemophilia B patients bleed less common and less intensively than hemophilia A, it has been expected that the hemostatic level of factor IX (FIX) activity can be lowered as that of factor VIII (FVIII) activity.

Aims: We compared the hemostatic efficacy of the different hemostatic level of FIX and FVIII activity using global hemostatic assay.

Methods: A total of 17 severe hemophilia patients without inhibitor, aged more than 15 years were subjected; 12 hemophilia A patients and 7 hemophilia B patients. Factor concentrates were injected to reach the target activity of 60% in hemophilia A and 40% in hemophilia B which is given by Korean health insurance guideline. All patients were in non-bleeding state and kept the wash-out period of 3 days for hemophilia A and 5 days of hemophilia B. Before and on 15 minutes after injections, we conducted one-stage factor assay, thrombin generation assay (TGA), thromboelastography (TEG) and clot-wave form analysis (CWA).

Results: Median ages of hemophilia A and hemophilia B patients were 28 and 33 years old. Baseline FVIII:C and FIX:C were 0.6 and 1.8% and they rose after injection rose to 70.8% and 49.8%. The dosage of FVIII concentrates and recombinant FIX concentrates were 28.4 IU/kg and 50.7 IU/kg. In vivo recovery (IVR) in A hemophilia and A hemophilia B patients recorded 2.43% and 0.91% respectively. Peak thrombin of FVIII and FIX were 451.3 nM and 376.6 nM (P=0.108, normal range, 458 nM±60). TEG index of FVIII and FIX were -1.60 [-1.74 to -1.46] and -3.77 [-4.00 to -3.54] respectively. All except one boys were Caucasians and had PIT 2.8 and 3.02BU/ml. All except one boys were Caucasians and had PIT 2.8 and 3.02BU/ml. Two patients were low responders (14,3%) with FVIII:C 1.4% and 2.2% and FVIII:C 2.7% and 3.3%.

Summary/Conclusions: Global hemostatic assay indicates even though IVR of FVIII and FIX are normal, less amount of FIX is insufficient to normalize hemostatic parameters in comparison with FVIII.

PB1744

THE RATE OF SUCCESSFUL IMMUNOTOLERANCE INDUCTION IN HAEMOPHILIA A BOYS TREATED WITH OCTOCOG ALFA - THE EXPERIENCE OF POLISH PAEDIATRIC HAEMOPHILIA CARE CENTRES

K. Kołtan1,2,*, A. Klukowska3, P. Laguna3, W. Badowska4, W. Balwierz5, A. Kołtan1,2,*, A. Klukowska3, P. Laguna3, W. Badowska4, W. Balwierz5,6

Background: From 2011 to 2016 in all Polish Paediatric Haemophilia Care Centres (inhibitor; INH) is the most challenging complication of haemophilia replacement therapy (HRT). It occurs in up to 30% of severe haemophilia A (HA) patients. Data published recently indicate that immunotolerance induction (ITI) is effective in 62–77% of cases.

Aims: To assess the rate of successful ITI in boys with severe HA treated with full length recombinant FVIII (octocog α) in all Polish Paediatric Haemophilia Care Centres between 2011-2016.

Methods: From 2011 to 2016 all Polish Paediatric Haemophilia Care Centres 14/18 (15.9%) boys with severe HA on prophylaxis or on demand treatment with octocog α developed INH after 3 - 489 (median 20) exposure days (EDs). Twelve of them (85.7%) were high responders with the peak inhibitor titre (PIT) ≤ 58, 716.8 (median 20.1) BU/ml. Two patients were low responders (14.3%) and had PIT 2,8 and 3.02BU/ml. All except one boys were Caucasians and only one had a positive family history of INH formation. Characteristics of patients is given in Table 1.

Results: INH titres prior to ITI were 1.2 - 37 (median 6.75) BU/ml. One of low responders eliminated INH spontaneously, 1 patient is waiting for ITI initiation. ITI with octocog α was initiated in 12/14 boys after 0.2 to 8.2 (median 2.0) months from INH diagnosis and completed in 9 patients. Three patients are still on ITI. INH eradication was observed in 7/9 (77.8%) of those who completed ITI. Eradication of INH was not achieved in 2 patients; both have already started prophylaxis with activated prothrombin complex concentrate (APCC). The remaining 3 patients are still on ITI. All 7 patients after successful ITI were put back on prophylaxis with octocog α.

Summary/Conclusions: 1. Octocog α is effective in induction of immunotoler- ance in severe haemophilia A boys who developed inhibitor on prophylaxis with octocog α.

Table 1. Characteristic of patients.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)</th>
<th>Initial FVIII</th>
<th>Prothrombin inhibitor</th>
<th>Time to diagnosis</th>
<th>Treatment</th>
<th>Surgery</th>
<th>High level of anti-INH during</th>
<th>INH after ITI</th>
<th>Outcome</th>
<th>platelet transfusion</th>
<th>fibrinogen</th>
<th>first day of injection</th>
<th>mth</th>
<th>outcome</th>
<th>treatment</th>
<th>ADP</th>
<th>TRAP</th>
<th>collagen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7.2</td>
<td>0.2</td>
<td>1.2</td>
<td>2.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.2</td>
<td>0.2</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.2</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.2</td>
<td>3.5</td>
<td>1.5</td>
</tr>
<tr>
<td>2</td>
<td>8.4</td>
<td>0.5</td>
<td>1.1</td>
<td>3.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.5</td>
<td>0.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.5</td>
<td>3.5</td>
<td>1.5</td>
</tr>
<tr>
<td>3</td>
<td>9.6</td>
<td>0.3</td>
<td>1.3</td>
<td>2.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.3</td>
<td>0.3</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.3</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>3.5 mth</td>
<td>1.5</td>
<td>0.3</td>
<td>3.5</td>
<td>1.5</td>
</tr>
</tbody>
</table>

CD, on demand; P, prophylaxis; CVA, central venous access; N, no; V, yes; mth, month.
dyslipidemia treatment were made upon data from literature and patient’s findings. Multidisciplinary approach in this setting is needed. Bleeding risk is not connected only with platelet count, but also with their function and degree of splenomegaly. Liver function can also be disturbed and can influence hemostasis. Pregnancy in our patient did not cause health state deterioration and there were no clinical findings of Niemann Pick disease in newborn.

PB1746
SINGLE CENTRE FX DEFICIENCY EXPERIENCE
Z. Basilar1,*, S. Sadri1, I. Erdogan1, M.C. Ar1
1Internal medicine- Hematology, Istanbul University, Cerrahpasa Medical Faculty, istanbul, Turkey

Background: Factor X is a vitamin K-dependent serine protease that works at the crossroads of the extrinsic and intrinsic pathways to cleave prothrombin into thrombin. Inheritance pattern of factor X deficiency is autosomal recessive, with heterozygote patients most often remaining asymptomatic or having only a mild bleeding phenotype. (1) Homozygous individuals may experience haemorrhagic symptoms, including easy bruising, haematuria, soft-tissue haemorrhages, haemarthroses, recurrent epistaxis, and menorrhagia (2) Congenital factor X deficiency is among the most rare factor disorders. We present here our experience with patients having congenital factor X deficiency.

Aims: We aimed to present our experience with rare FX deficiency in our centre.

Methods: There are currently 4 patients with factor X deficiency (F:M: 3/1) that are followed at our centre.

Results: First patient is 40 years old man who got his diagnosis at the age of 31 years following a gastrointestinal bleeding. He was treated with fresh frozen plasma (FFP) at that time. His FX was found: 5%. Two years later underwent a planned tooth operation under the coverage of prothrombin complex concentrate (PCC) (Table 1). Three years after the tooth extraction he underwent an intraocular lens operation under PCC prophylaxis. No complication was observed while on PCC treatment.

Table 1.

<table>
<thead>
<tr>
<th>weight (kg)</th>
<th>PCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operation day</td>
<td>750 unit</td>
</tr>
<tr>
<td>2nd day</td>
<td>500 unit</td>
</tr>
<tr>
<td>4th day</td>
<td>500 unit</td>
</tr>
<tr>
<td>6th day</td>
<td>250 unit</td>
</tr>
</tbody>
</table>

Our second patient is a woman who was diagnosed at the age of 3 because of recurring gum bleeding. She has been treated with FFP replacement throughout her childhood and adolescence due to recurring nose and soft tissue bleeds as well as menorrhagia. She was first referred to our hospital at the age of 42 due to soft tissue bleeding. Given the lack of health insurance she mainly received FFP and tranexamic acid tablets during most of her bleeding attacks. However, PCC of 1000 unit for two days had to be used for her excessive vaginal bleeding irrespective to FFP. Her number of annual bleeding is 15-20 times in a year and most of them are gum bleeding and rarely vaginal bleeding. Third and 4th patients were referred to our centre because of prolonged the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) and received the diagnosis of FX deficiency.

Summary/Conclusions: Bleeding phenotype differs in a wide range in patients with congenital FX deficiency. Secondary causes including amyloidosis should be excluded especially in patients receiving diagnosis at advanced ages. Usually the factor level does not correspond to the severity of the bleeding phenotype. Therefore bleeding pattern of the patients with FX deficiency should be carefully observed and considered while planning a prophylactic treatment with PCCs to prevent the risk for thrombosis and unnecessary utilisation of PCCs. FFP and PCCs replacement continue to be the source for FX in bleeding patients or in individuals requiring prophylaxis. Recently, a FX concentrate has entered the market in the USA and the European Community.

PB1747
IMPROVEMENT OF THE SURVIVAL FOR LIFE-THREATENING HEMORRHAGE WITH HEMOPHILIA PATIENT
K.S. Lee1,*, J.Y. Kim2, J.K. Seo2, S.Y. Hyun3
1Kyungpook National University School of Medicine, 2Kyungpook National University Children’s Hospital, Daegu, 3Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic Of

Background: In life threatening hemorrhage such as brain and abdomen, several important factors are affect for improving the survival. One tenth (223) of hemophilia patients in Korea lived in Daegu city and Kyungpook province and have treated in our treatment center.

Aims: We reviewed the case of life threatening hemorrhage and our unique care of hemophilia patients for 34 years.

Methods: Korea Hemophilia Foundation was established in 1991. After that all factor concentrates were free to all hemophilia patients. Home treatment are available for rapid administration of factor concentrate of full required amount. Rapid transportation to emergency room are available for immediate operation. Hot line of mobile phone between patient and doctor for 24 hours are available for emergency care. Monthly group education has done. Prophylactic treatment was started to all who had a life threatening hemorrhage history in taxon since 1996. But HIRA permitted officially in 2008.

And then recovery rate test was done for the optimal blood level for life threatening hemorrhage patient. Continuous infusion with every 2 to 4 hours reconstitution dilution fluid has been done for preserve in vitro factor activity to all surgery cases.

Results: Thirty five events were intracranial hemorrhage in 17, general surgery in 9 and orthopedic surgery in 9. Age distribution was 0-32 yr (mean: 24.8 yr). Severity was severe (16), moderate (7) and mild (5). Time interval between first symptom and arrival at ER were 15 min to 10 days (mean: 1.7days). We confirmed in vivo factor activity within permissible level in all patients. All recovered from hemorrhage or surgery and are healthy, but one had limb-girdle and one had mild neurologic sequelae for more than 10 years follow-up period.

Summary/Conclusions: Education, financial support, home and prophylactic treatment, hot-line, individual pharmacokinetics with effective blood level and fresh concentrate during continuous infusion are important factors to improve the survival of surgery case.

PB1748
CAN BLEEDING SCORE AND FACTOR LEVELS DETERMINE HEMOPHILIA CARRIERS?
Y. Ay1,*, A. Çakı2, S. Okur Açı1, E. Töre3, T. Hilkay Karapınar1, Y. Oymak1, S. Gözmen1, C. Vergin1
1Division of Pediatric Hematology, 2Department of Pediatrics , Dr. Behçet Uz Children Disease and Surgery Training and Research Hospital, İzmir, 3Division of Pediatric Hematology, Balikesir Ataölçuk State Hospital, Balikesir, Turkey

Background: Hemophilia A and B are X-linked recessive hemorrhagic disease. Due to this type of inheritance, males are usually affected, but girls are carriers. Factor levels are usually detected around 50% because only one chromosome is affected in carriers. Inconsistently, it has been reported that factor activity can be detected in a wide range of 22% -116% as a result of random inactivation (lyonization) of one of two X chromosomes. It is specified that factor levels may be very low due to excessive inactivation in a significant part of the hemophilia carriers, which creates a risk of bleeding in carriers.

Aims: In this study, we aimed to investigate the role of bleeding score and factor levels in detecting hemophilia carriers.

Methods: Bleeding Assessment Tool (BAT) for hereditary factor deficiencies of the International Society on Thrombosis and Haemostasis (ISTH/SSC) were applied to the mother and sisters of 32 hemophilia patients who were followed-up in Dr Behçet Uz Children’s Diseases and Surgery Training and Research Hospital. Mothers whose at least one of the other members of the family and their sons had hemophilia, mothers with more than one hemophilic son and girls whose father had hemophilia were evaluated as an obligate carrier. Sisters or mothers who do not meet the obligatory carrier criteria but whose siblings or sons are hemophilic were identified as possible carriers. Factor activity of obligate or probable carriers was studied after their informed consent was obtained.

Results: Thirty-two mothers and 13 sisters of hemophilia patients were included in this study. The mean age was 31.6 (4-57) years. Three of the patients were mild, 3 were moderate, 23 were severe hemophilia A; 2 were severe and 1 had moderate hemophilia B. Twelve were obligate and 33 were probable carriers. Only seven in 45 (15.5%) probable and obligate hemophilia carriers had high bleeding scores (≥4). Those with high bleeding scores, three were obligate carriers and four were probable carriers. The mean factor activity of 12 obligate and 18 probable carriers were 78.9% (20.8%>189%). Factor activities of the three obligate carriers with high bleeding scores were 77%, 80% and 98%, respectively. Factor activities of the three probable carriers with high bleeding scores were 58.5%, 69.3% and 112%, respectively. The median bleeding scores of four probable and one obligate carriers with low factor activity (<60%) were 2.8 (1-4).

Summary/Conclusions: Measurement of factor activity seems to be insufficient to detect hemophilia carriers. ISTH/SSC-BAT may help to determine the carriers. However, a larger study is needed to understand the diagnostic value of the BAT.

PB1749
FETAL INTRACRANIAL HEMORRHAGE AS A PRESENTING FEATURE OF SEVERE CONGENITAL FACTOR VII DEFICIENCY: THE NEED FOR EARLY PROPHYLAXIS
M. Elshinawy1,*, A. Airawa2, Y. Wali2
1Pediatric Hematology, SQUH, University of Alexandria, Oman, Egypt, 2Pediatric Hematology, Sultan Qaboos University Hospital, Muscat, Oman

Background: Congenital factor VII (FVII) deficiency is a rare autosomal reces-
sive bleeding disorder, with an estimated prevalence of 1:300,000. Compared to western countries, rare bleeding disorders (RBDs) are relatively common in Oman, owing to high rate of consanguinous marriage.

**Aims:** To discuss an interesting case of severe congenital factor VII deficiency and to explore the need for early prophylaxis.

**Methods:** Case report and retrospective data analysis of all children diagnosed with inherited coagulation factor deficiencies in Pediatric Hematology Unit, Sultan Qaboos University Hospital, Muscat, Oman from January 2009 till December 2016.

**Results:** We report a male full term baby, delivered by cesarean section. His older sister is a known case of severe congenital factor VII deficiency. Antenatal scans of this baby revealed two intracerebral hematomas and dilated cerebral ventricles. Postnatally, the diagnosis of severe congenital FVII deficiency was confirmed. CT scan revealed obstructive hydrocephalus at the level of aqueduct of Sylvius (Figure 1). At day 10 of life, ventriculo-peritoneal shunt has been done successfully under cover of recombinant activated factor VII replacement therapy. Afterwards, the patient has been initiated on rFVIIa prophylaxis at a dose of 30 µg/kg three times weekly. In our center, deficiencies of fibrinogen, FV, FVII, FX and FXIII were diagnosed in 22 pediatric patients (10 males and 12 females), accounting for 11.1% (22/198) of all children with inherited coagulation factor deficiencies. The age range from 1 day to 6 years and consanguinity is found in 19/22 cases (86.4%). Hypofibrinogenemia, FV and FVII deficiency are the commonest RBDs, diagnosed in 8, 6 and 5 patients respectively. As an initial presentation, intracranial hemorrhage occurred in 7/22 cases (31.8%). Three patients with FV, FVII and FXIII deficiencies suffered from global developmental delay due to severe intracranial hemorrhage. As regards management, 4 patients with severe FV deficiency and one with severe FXIII deficiency are on fresh frozen plasma (FFP) and recombinant FXIII prophylaxis respectively. Other patients receive on-demand therapy.

**Summary/Conclusions:** Children with RBDs constitute more than one tenth of cases of hereditary coagulation factor deficiencies in our center. They have some unique features in terms of severity, clinical profile and the need for prophylaxis early in life. We recommend establishing a national/regional registry of RBDs to identify the magnitude and the peculiar genotype-phenotype correlations of such rare, yet significant disorders.

**PB1750**

THE ASSOCIATION OF BLOOD TYPE WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH VENTRICULAR ASSIST DEVICES

T. Kanellopoulopou1, M. Albérito1, A. Apostolou1, M. Fidirikou1, S. Georgantis1, E. Kabana1, M. Katafigioti1, P. Litras1, A. Makrigianni1, N. Matoula1, E. Papadaki1, G. Soufla1, E. Zalachori1, T. Kostelidou1

1Department of Haematology and Blood Transfusion, Onassis Cardiac Surgery Centre, Athens, Greece

**Background:** Patients who have implantation of continuous flow ventricular assist devices (VAD) as a bridge to heart transplantation are subjected to complications secondary to pump support. The use of antiplatelets either alone or in combination with anticoagulation is necessary to avoid clot formation and pump thrombosis. However, a proportion of patients reveal an increasing risk of bleeding episodes. A possible reason of this situation could be that high shear forces lead to devastation of high molecular weight von Willebrand factor (vWF) making it functionally inactive and resulting in acquired von Willebrand disease (vWD). People with blood type O have lower baseline vWF levels and this abnormality could exacerbate the bleeding risk of patients with blood type O with VAD, resulting in more frequent bleeding episodes and need for transfusions.

**Aims:** The aim of current study was to investigate the possible association of blood type with acquired VWD induced by VAD, with the need for transfusions.

**Methods:** In this retrospective study, 17 patients who had a VAD implant in our hospital in a six-month period were included for analysis. The investigation of underlying vWD was estimated by ristocetin-induced platelet aggregation (RIPA) using classical light transmission aggregometer.

**Results:** Six patients (35.3%) had left-VAD (L-VAD) implantation while the others had biventricular VAD implantation (BiVAD). The mean age was 42.41 years (SD±15.33) and 9 patients (52.9%) were male. Female patients had VAD implantation at younger age than male (p<0.001). The mean follow-up after VAD implantation was 15 months (SD±11.88). At the time of analysis, 13 patients (76.5%) were alive, 2 patients (11.8%) had died while 2 patients (11.8%) had been heart-transplanted. Eight patients (47.1%) had blood type O, 8 patients (47.1%) had blood type A and a patient (5.9%) had AB. Mean RIPA before VAD implantation was 59.3% (SD±14.76) while after VAD implantation was 47.29% (SD±15.47), whereas the decrease was no statistically related. No statistical correlation was found between RIPA among different blood types. Among patients with blood type O, the need for blood transfusions was associated with the duration of having the VAD implantation in months (p<0.001) while the need for fresh frozen plasma (FFP) transfusions was associated with RIPA before VAD implantation (p=0.016). In non-blood type O patients no statistical correlation was found with the need for transfusions with RIPA percentage or median follow-up of patients.

**Summary/Conclusions:** It has been shown by several studies that patients with VAD show a decrease in vWF increasing the bleeding risk. Thus the best antiplatelet treatment and/or anticoagulation that those patient needs, remains challenging. In our study, there was a decrease in mean RIPA percentage after VAD implantation and patients with blood type O had lower RIPA before implantation. However, none of these measurements was statistically significant. The blood type O patients showed an increased need for transfusions in correlation with the duration of VAD implants and an increased need for FFP in correlation with RIPA baseline. Our study has limitations due to the small population and the fact that vWF was not estimated within the different blood groups at baseline and after VAD implantation.
Bone marrow failure syndromes incl. PNH - Clinical

PB1751
ACQUIRED PURE RED CELL APLASIA ASSOCIATED WITHLYMPHOPROLIFERATIVE DISEASES IN ERYTHROPOIETIN-REACTIFY ANEMIA PATIENTS ON DIALYSIS
K. Yoshinaga1,*, N. Mori1, M. Owahishi2, M. Iishi3, M. Shiseki1, T. Tanaka1
1Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan

Background: Erythropoietin-refractory anemia is a serious problem and complicatedcauses should be ruled out in patients on dialysis. Acquired pure red cell aplasia (PRCA) may be hidden behind anemia of chronic kidney disease. Recently it was reported that PRCA patients with large granular lymphocyte frequently had STAT3 mutations (Oie ZY et al. J Hematol & Oncol 2013, Ishida F et al. Cancer sci 2014). Molecular or flow-cytometric analysis is useful for detecting a small amount of abnormal lymphocytes.

Aims: We conducted this study to determine the clinical characteristics and STAA3 mutations of patients with acquired PRCA on dialysis with lymphoproliferative diseases.

Methods: In our hospital, 4 patients were diagnosed as having acquired PRCA on dialysis with lymphoproliferative diseases after 2005. Patients were retrospectively studied for presenting feature, laboratory data, and clinical course. Surface markers of lymphocytes were examined by flow cytometric analysis, and T-cell receptor (TCR) rearrangements were examined by Southern blot analysis. Mononuclear cells were separated after obtaining written informed consent. STAT3 (Y640F and D661Y) mutations were examined by allele-specific PCR. Current study was conducted within the guidelines and with the approval of the institutional ethics committee.

Results: In spite of adequate administration of erythropoietin colony-stimulating factor, all four patients required blood transfusion due to erythropoietin-refractory anemia. Median leukocyte and lymphocyte counts at diagnosis were 4650/mL (range, 3180-4850) and 1794 mL (range, 1183-2859), respectively. Two patients (Cases 1 and 2) had low percentage of CD4+ CD8+ by flow-cytometry and TCR C beta1 and gamma rearrangements by Southern blot analysis. Another patient (Case 3) had high percentage of gamma-delta T cell component (66.2%) with TCR delta rearrangement. The other patient (Case 4) had high CD16+CD56+ NK cell percentage without TCR receptor rearrangement. The serum levels of interleukin 6 (range, 5-19 years). Of the 4 patients, only one patient (Case 3) had the mutations of the STAT3 gene (Y640F). This patient first received cyclophosphamide but he did not respond to the therapy. He subsequently received cyclosporine (CyA). The other three patients received CyA as an initial therapy, and it was effective in all 4 patients. Median follow-up were 7 years from diagnosis, and two patients died during follow-up period. One patient (Case 4) died of cardiac failure 7 years from the diagnosis. Another patient (Case 2) developed diffuse large B-cell lymphoma 5 years after the administration of CyA. He was treated with R-CHOP chemotherapy and complete remission (CR) was achieved. Although he had been in CR, he died of refractory pancytopenia with infection, 2 years after the lymphoma onset. The other two patients are still alive without blood transfusion for 6 and 7 years.

Summary/Conclusions: A proportion of erythropoietin-refractory anemia patients with hematologic malignancies may benefit from flow-cytometric and TCR C beta and gamma rearrangements analysis. This method of lymphocytes was useful for diagnosis of acquired PRCA associated with lymphoproliferative diseases. Further accumulations of patients were required for understanding the pathogenesis of lymphoproliferative diseases causing acquired PRCA on dialysis.

PB1752
ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: TREATED BY CYCLOSPORINE A OR CORTICOSTEROIDS: SIMILARITY EFFICIENCY
X. Wu1,*, S. Wang1, W. Shen1, G. He1, J. Li1
1Hematological Department, The First Affiliate Hospital, Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Background: Adult pure red cell aplasia (PRCA) is a syndrome characterized by a severe normocytic anemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. Immunosuppressive therapy has been used as the initial treatment for acquired chronic PRCA.

Aims: This study is aimed to evaluate the efficacy of cyclosporine A, and/or corticosteroids, and possible factors influencing it.

Methods: 34 cases of PRCA were retrospectively analyzed at our institution. Clinical data of 23 inpatient cases and 11 outpatient cases since 2009 October were collected. These patients were treated by cyclosporine A (CsA), and/or corticosteroids (CS), or other immunosuppressive agents if become refractory and relapsed.

Results: 31 patients were evaluated in our institution (one patient lost to follow-up and two patients with short observation period). The remission induction therapy included CsA (n=13), CS (n=13), or a simultaneous combination of CsA (n=5). The initial response rate of CsA alone, CS alone, combination of CS and CsA were 69.2%, 46.2%, 80%, respectively (P=0.422). There was no statistical difference in response rate and CR rate between CsA-containing group and CS group, although the patients treated with CsA had a better response than those treated with CS (response rate 72.2% vs 46.2%, P=0.262; CR rate 33.3% vs 23.1%, P=0.696). Including patients who had crossed over from other treatment groups, the cumulative response rate of CsA, CS, combination of CS and CsA was 73.7% (14/19), 46.7% (7/15), 83.3% (5/6), respectively (P=0.193); the cumulative rate of CR was 26.3% (5/19), 26.7% (4/15), 66.7% (4/6), respectively (P=0.202). In 23 refractory and relapsed PRCA patients, 8 out of 12 (66.7%) refractory patients and 4 out of 11 (36.4%) relapsed patients achieved remission. The response rate of treatment with traditional immunosuppressive agents (CS and/or CsA) was higher than other immunosuppressive agents (65.0% vs 20%, P=0.014).

Summary/Conclusions: CsA and/or CS are effective similarly in treating PRCA. All patients with relapse or refractory PRCA, there were no satisfactory treatment measures if CsA and/or CS were not be administered or un-effective. It was still needed to explore a more effective therapy for them.

PB1753
REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS
S. Wang1,*, X. Wu1, G. He1, W. Shen1, J. Li1
1Hematological Department, The First Affiliate Hospital, Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Background: There is little data about the influence of infection of HBV on the therapy of aplastic anemia.

Aims: This article is aimed at assessment the HBV reactivation risk in HBSAg positive patients with AA receiving CsA and/or ATG.

Methods: We analysis the clinical data of 60 AA patients with HBV infection out of 201 cases of AA from our center at AA diagnosis during the recent 3 years, and laboratory test data such as levels of liver enzyme, HBV DNA in serum, HBSAg positive patients who will receive IST with AA as they had high rate (41.6%) of HBV reactivation. HBV infection were found no influence to the clinic course in AA and antiviral therapy had no influence to the effect of IST.

PB1754
MULTICENTER RESULTS OF SCHWACHMAN-DIAMOND SYNDROME PATIENTS
S. Unal1,*, N. Kalkan1, T. Celkan2, G. N. Ozdemir2, N. Ozbek3, N. Yarali4, N. Guleray5, M. Celini6, F. Gumruk6, N. Akarsu1
1Hacettepe University, Division Of Pediatric Hematology, Ankara, Turkey 2Cerrahpasa University, Department of Pediatric Hematology, Istanbul, 3Ankara Çocuk Sagligi ve Hastalikleri Hematoloji-Onkoloji Uygulamasi ve Arastirma Hastanesi, Ankara Çocuk Sagligi ve Hastalikleri Hematoloji-Onkoloji Uygulamasi ve Arastirma Hastanesi, 4Gazi University, Department of Pediatric Hematology, 5Hacettepe University, Medical Faculty, Ankara, 6Hacettepe University, Department of Pediatric Hematology, Istanbul, Turkey

Background: Shwachman-Diamond syndrome (SDS) is an autosomal recessively inherited disease characterized with neutropenia, exocrine pancreas insufficiency, failure to thrive and skeletal abnormalities. In approximately 90% of the patients, the molecular defect is related to SBDS gene mutations. The classical triad is present in one-forth of the patients and a high degree of suspicion is required in order to make the diagnosis. In this study, molecular work-up to patients with suspected SDS were made and the clinical and laboratory findings that predict the SDS diagnosis were investigated.

Aims: Aim of the study was to find out the predictive clinical and laboratory characteristics of SDS patients.

Methods: The patients who were sent to Hacettepe Inherited Bone Marrow Failure Center for molecular work-up between June 2015 and August 2016 were evaluated with clinical and laboratory data obtained from a standardized patient registry form.
Results: Molecular work-up was performed in 20 patients referred to our center with a suspected diagnosis of SDS. Of these 20 patients (12 girls), 4 (20%) (3 boys) were found to have mutation in SBDS gene. The median age of these patients was 3.2 years (1-18). Of the 4 patients with genetically verified SDS, 1 (25%) had history of chronic diarrhea and pancreas atrophy was detected in ultrasonography of that patient. Another patient (25%) with SDS had skin rash and mononuclear cell infiltration with Langerhans type histology. Three patients (75%) had anemia associated to neutropenia, and 1 patient (25%) had pancytopenia at presentation. On the other hand, the patients who were referred with a suspicion of SDS but was found to have no mutation, 43% had neutropenia, 25% had bicytopenia, 10% had pancytopenia. The patients of the latter group had failure to thrive in 25% of the patients and chronic or persistent diarrhea was present in 25% of this group. There was no statistically significant difference in the clinical and laboratory parameters of the genetically verified SDS patients and patients without SDS but was referred with SDS suspicion.

Summary/Conclusions: Although, there was no statistically significant difference in the clinical and laboratory parameters of the genetically verified SDS patients and patients without SDS but was referred with SDS suspicion, this might be attributed to the small sample sizes. Compatible with the previous literature data, SDS is a cryptic disorder and the classical triad is not commonly fulfilled in most of the patients. On the other hand, failure to thrive/growth retardation was three times more common in patients with SDS. Thus, in patients neutropenia, accompanying failure to thrive/growth retardation might be an indicative to make molecular work-up for SDS. Additionally, not only neutropenia, but bicytopenia or pancytopenia might be the hematological presentational findings of SDS.

PB1755
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND APLASTIC ANAEMIA – DATA FROM THE SPANISH PNH REGISTRY
S. De La Iglesia1,2, M. Morado2, B. Arzamalaga3, A. Gonzalez4, D. Beneitez2, M. López Rubio1, V. Recasens2, E. Salido3, A. Urquia3, I. Rodrigues1, L. Herráiz1, X. Martín1, C. Chávez1, A. Lemes1, C. Acosta1, A.M. Villegas4, G.D.E. SEHH12
1Hematology, H. Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, 2Hematology, H. Universitario La Paz, Madrid, 3Hematology, Hospital de Torrevieja, Alicante, 4Hematology, H. Universitario de Canarias, Santa Cruz, Madrid, 6Hematology, H. Universitario Príncipe de Asturias, Madrid, 7Hematology, H. Universitario Miguel Servet, Zaragoza, 8Hematology, H. Clínico Universitario Virgen de la Arrixaca, Murcia, 9Hematology, H. Universitario Donostia, Bilbao, 10Hematology, H. Universitario Germans Trias i Pujol, 11Hematology, H. Parc Tauli, Barcelona, 12Hematology, SEHH, Madrid, Spain

Background: Aplastic anaemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) are included, together with other pathologies, within the bone marrow failure syndromes. In the present study these clinical entities should be understood as independent pathologies, due to the extremely frequent evolution among them and with other BMFS, along with the development of new clones in the context of haematopoietic stem cell’s genetics.

Aims: The aims of this study were analyzing and comparing the behaviour of Aplastic anaemia who suffered from PNH with pancytopenia with respect to that of patients who were initially diagnosed of AA and who later developed a PNH clone.

Methods: A clinical form was elaborated and distributed among the investigators of the PNH Spanish Registry. Clinical, laboratory and treatment data of the patient were asked. Soon after, a descriptive analysis of the data was performed.

Results: 34 patients were recruited and analyzed (12 women and 22 men). Their age interval ranged from 2 to 87 years, and all of the patients suffered from either PNH with pancytopenia and/or AA with a developing PNH clone. The average age at the time of initial diagnosis was 28.5 years old (4m-72y). The failure to thrive was present in 20 patients with pancytopenia (1), moderate AA (16), severe AA (10), very severe AA (7). 15 patients presented a PNH clone in their granulocytes and/or monocytes at the time of diagnosis, being 24% the average of such clone (0.08-95%) and less than 2% in 7 patients. All of the cases that identified SDS, 1 (25%) had history of chronic diarrhea and pancreas atrophy was detected in ultrasonography of that patient. Another patient (25%) with SDS had skin rash and mononuclear cell infiltration with Langerhans type histology. Three patients (75%) had anemia associated to neutropenia, and 1 patient (25%) had pancytopenia at presentation. On the other hand, failure to thrive/growth retardation was three times more common in patients with SDS. Thus, in patients neutropenia, accompanying failure to thrive/growth retardation might be an indicative to make molecular work-up for SDS. Additionally, not only neutropenia, but bicytopenia or pancytopenia might be the hematological presentational findings of SDS.

Summary/Conclusions: Clonal evolution in AA is frequently associated with the development of a PNH clone at the time of diagnosis, throughout the pathogenic natural course or even after disease’s resolution. The development of such clone has been related to better prognosis in AA right after the immunosuppressive therapy (IST). Our experience demonstrated the presence of hermolysis in at least half of the cases, making it necessary in these patients treatment with eculizumab, generally obtaining a very good response.

PB1756
AUTOIMMUNE CYTOPENIAS IN PRIMARY IMMUNODEFICIENCY DISEASES: SINGLE CENTER EXPERIENCE
T. Patroglu1, M. Canserver2, F. Bektas2
1Pediatric Hematology, 2Pediatric Immunology, Erciyes University Medical Faculty, Kayseri, Turkey

Aims: Primary immunodeficiency diseases (PID) are associated with hematologic complications such as autoimmune hemolytic anemia (AIHA) and thrombocytopenia (ITP). The most common autoimmune cytopenia is ITP. Although ITP is observed in 7.6% of patients with PID, AIHA is seen at 4.8%. Also, we aimed to present the patients who had autoimmune cytopenias and PID.

Methods: Fifty six PID patients who were followed at the Pediatric Immunology Department of Erciyes University Medical Faculty (they were analyzed genetically) were evaluated retrospectively. Autoimmune cytopenias such as ITP and AIHA were detected in 9 (5.16) of the patients (combined immunodeficiency:4 patients, common variable immunodeficiency: 2 patients, hyper immunoglobulin E syndrome:1 patient, X-linked lymphoproliferative :1 patient, chronic granulomatous disease:1 patient). ITP was detected in 8 of 9 patients and AIHA was also detected in 6 patients. In four patients (LRBA deficiency: 2 patients, hyper IgE: 1 patient and OCS:1 patient), both ITP and AIHA were observed. Immunosuppressive therapy with steroid, cyclosporine, mycophenolate mofetyl and intravenous immunoglobulin were given to all patients. Bone marrow transplantation was performed to the four patients. However, five patients died because of immunodeficiency.

Results: There is a paradoxical situation between PID and autoimmunity. The reduction of central and peripheral tolerance is held responsible for autoimmunity in PID.

Summary/Conclusions: As a conclusion, we wanted to point out autoimmune cytopenias in patients with PID and the requirement of multidisciplinary approach for treatment.

PB1757
HEAVY METAL LEVELS IN PATIENTS WITH FANCONI APLASTIC ANEMIA
T. Bayhan1,*, E. Ördenb, S. Unal1, F. Gürnuk1, S. Çelinkaya1, E. Cırak2, I. Eker3
1Division of Pediatric Hematology, Hacettepe University, 2Department of Pharmaceutical Toxicology, University of Health Sciences, 3Pharmacologist, Retired, Ankara, 4Division of Pediatric Hematology, University of Aylan, Aylan, Turkey

Background: Fanconi aplastic anemia (FAA) is a rare, autosomal recessively inherited bone marrow failure disorder. Various congenital anomalies may accompany disease and various complications including malignancy and endocrinopathies may develop during the course.

Aims: Heavy metal levels in patients with different chronic disorders have been investigated, however, up to our knowledge there is no literature data on the heavy metal levels in patients with FAA. Heavy metal levels in patients with different chronic disorders have been investigated, however, up to our knowledge there is no literature data on the heavy metal levels in patients with FAA.

Methods: Study was performed between July 2015 and April 2016 among patients with FAA and the results were compared with age and gender matched healthy group (16 volunteers). Plasma copper (Cu), cobalt (Co), selenium (Se) levels were measured in patients with FAA.

Results: Total of 17 patients with FAA were included in the study. Median age was 9 years (1 – 30), female to male ratio was 8/9. One patient had undergone stem cell transplantation, four patients were transfusion dependent. When we compared patients with FAA and age/sex matched healthy group (16 volunteers) Cr and Cu levels were higher and Se level was lower in FAA group significantly (Table 1). In the present study, because those clinical entities could be understood as independent pathologies, due to the extremely frequent evolution among them and with other BMFS, along with the development of new clones in the context of haematopoietic stem cell’s genetics.

Table 1. Heavy metal levels in patients with PID and control group.

<table>
<thead>
<tr>
<th>Heavy Metal</th>
<th>FAA</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromium</td>
<td>17.4 (9.2-35.4)</td>
<td>5.3 (3.0-7.5)</td>
</tr>
<tr>
<td>Cobalt</td>
<td>1.10 (0.9-3.9)</td>
<td>1.10 (0.9-3.9)</td>
</tr>
<tr>
<td>Copper</td>
<td>187.2 (150-250)</td>
<td>187.2 (150-250)</td>
</tr>
<tr>
<td>Selenium</td>
<td>68.5 (46.6-86.5)</td>
<td>68.5 (46.6-86.5)</td>
</tr>
</tbody>
</table>

FAA: Fanconi aplastic anemia.
In our study we found chromium and cobalt levels higher in patients with FAAs than control group. In-vitro studies have revealed that FAA cells are more sensitive to chromium toxicity. With larger number of participants, chromium and cobalt levels and clinical association should be investigated in further studies. Lower Se level in patients with FAAs may be related with oxidative stress in these patients.

PB1759

A RARE ASSOCIATION: EBSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER AND PURE RED CELL APLASIA

S. Berk1,*, M. Günaltılı2, S. Sadri1, M. C. Ar1, T. Soysal1

1Haematology, 2Internal Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

Background: Lymphoproliferative disorders (LPD) constitute a heterogeneous group of diseases related to expanding polyclonal or monoclonal lymphoid cells in the setting of immune dysfunction. Ebstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell LPD spectrum. EBV associated LPDs (EBV-LPD) are more commonly encountered after stem cell and organ transplantations. Pure red cell aplasia (PRCA) is an uncommon disorder characterized by a severe normocytic anemia due to erythroblastopenia in an otherwise normal bone marrow. PRCA may be primary or develop secondary to viruses, autoimmune diseases, hematological malignancies, thymoma, solid tumors and drugs.

Aims: A case, who was diagnosed with EBV-LPD and developed PRCA during follow-up, is presented.

Methods: A 75-year-old woman with pain in upper and lower extremities applied to our center in February 2016. Her past medical history was unremarkable except for rheumatoid arthritis. On physical examination bilateral cervical, submandibular, axillary lymphadenopathies (LAP) and splenomegaly were detected. Laboratory tests revealed normochronic normocytic anemia, elevated serum lactate dehydrogenase and acute phase reactants. Positron emission tomography (PET) showed supra- and infradiaphragmatic malignant lymph nodes and splenic involvement. An excisional biopsy of cervical LAP was performed. Pathological examination showed CD20 (+) and CD30 (+) large B cells in the interfollicular area. EBV early RNA signals were checked by in-situ hybridization and viral transcripts were detected. Diagnosis of EBV-LPD was made. During diagnostic work-up deepening of anemia with reticulocytopenia, increased transfusion requirement and inadequate response to transfusion necessitated a bone marrow aspiration and biopsy. Pathological examination of the bone marrow was compatible with PRCA. Parvovirus IgM and DNA was negative; IgG was found to be positive. Because of the lack of response to steroids, Rituximab was given (375 mg/m2, weekly). Anemia and transfusion requirement increased. Parvovirus IgM turned negative. Virological test for parovirus B19 its association with EBV is rare. PRCA can develop before the diagnosis, during the course and after the remission of LPD. In our case we observed PRCA in the follow-up period of EBV-LPD.

Summary/Conclusions: On the basis of EBV-LPD being more common in transplant setting our case was thought to be unique due to the absence of transplantation or immunosuppression history. This case report points out to the possibility of coexistence of two rare diseases, EBV-LPD and PRCA.
Chronic lymphocytic leukemia and related disorders - Biology

PB1760
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAÍVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
1Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy, 2MD Anderson Cancer Centre, Houston, United States, 3Università di Padova, Padova, Padova, 4IRCCS Ca’ Granda Policlinico – Università degli Studi, Milano, 5Ospedale San Bortolo, Vicenza, 6A.O. Città della Salute e della Scienza S. Giovanni Battista, Torino, 7Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, 8Azienda Ospedaliera Universitaria Senese, Siena, 9Università La Sapienza, Policlinico Umberto I, Rome, 10Ospedale Niguarda, Milano, 11Azienda Ospedaliera di Cosenza, Cosenza, 12Ospedale Fugliese – Ciacco, Catanzaro, 13Ospedale Belcolle, Viterbo, 14IRCCS Centro di Riferimento Oncologico del Basilea, Rionero in Vulture, 15Ospedale A. Businco, Cagliari, 16Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, 17Ospedale C. G. Mazzoni, Ascoli Piceno, Italy

Background: Patients affected by chronic lymphocytic leukemia (CLL) that have trisomy 12 (+12) on FISH analysis have unique clinical and biological features. In a prior analysis (Autore F, ASH 2016) of 487 patients with +12 compared to 816 patients with negative FISH, patients with +12 had a significantly higher prevalence of elevated LDH, β-2-microglobulin, and ZAP70 positivity, CD38, CD49d positivity and unmutated IGHV as compared to patients with negative FISH. They also showed shorter progression free survival (PFS), treatment free survival (TFS) and overall survival (OS).

Aims: To identify clinical and laboratory features that predict disease progression and survival in treatment-naïve patients with +12 CLL.

Methods: This study included 487 treatment-naïve patients with +12 CLL from 16 academic centres, diagnosed between January 2000 and July 2016. A cohort of 250 patients with +12 CLL followed at a single US institution was used as external validation. Data were summarized as medians and 25th and 75th percentiles. Chi-square test or Fisher’s exact test were used to compare categorical variables, while Wilcoxon-Mann-Whitney-Test was applied for continuous variables. The survival analysis was based on the Kaplan-Meier method and the log-rank test was used to compare survival curves. A Cox model was used for multivariate analysis of the impact of different factors on survival. P-values lower than 0.05 were considered statistically significant (STATA 12.0) and reported as two-sided. We analysed also CLL-specific survival considering events deaths due to the haematological disease.

Results: Parameters associated with shorter PFS, TFS, OS and CLL-specific survival on univariate analysis were IGHV, LDH, β-2-microglobulin and Rai stage; age, ZAP70 and CD38 associated with OS only; on multivariate analysis were LDH, β-2-microglobulin, Rai stage and ZAP70; LDH, β-2-microglobulin and age associated with OS. On multivariate analysis high LDH was the sole parameter significantly associated with all shorter outcomes, along with elevated β-2-microglobulin, which associated with worse outcome.

Summary/Conclusions: Our study on 487 patients with +12 CLL and the analysis on 250 patients of the validation cohort showed that patients with +12 and elevated LDH have shorter PFS, TFS, OS and CLL-specific survival.

PB1761
THE PERCENTAGE OF CELLS WITH ABNORMALITIES IN FISH STUDIES CONFRONS PROGNOSTIC INFORMATION IN CLL PATIENTS
I. González-Gascón Y Marín1,*, M. Hernández-Sánchez2, A.E. Rodríguez-Vicente2, C.C. Muñoz Novas1, M. S. Infante1, C. Heras1, M.A. Foncallas1, K. Marín1, J.M. Hernández Rivas2, J.A. Hernández1,1 Hospital Universitario Infanta Leonor, MADRID, 2IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain

Background: Genomic aberrations detected by FISH have become one of the most important and widely used prognostic factor for chronic lymphocytic leukemia (CLL) patients. In addition several publications have described that patients with a higher percentage of abnormal nuclei have a worse outcome.

Aims: To analyze the effect of the percentage of abnormal nuclei detected by FISH (13q deletion (13q-), 11q deletion (11q-), 17p deletion (17p-)) on OS and time to treatment (TTFT).

Methods: We studied a non-selected cohort of 650 consecutive CLL cases from a local database with a median follow up time of 50 months (0-346). The cut-off point for the percentage of abnormal nuclei for each alteration was detected by dividing the variable into deciles, and selecting the most efficient cut-point, and based on previous publications.

Results: FISH detected aberrations in 85% of the cases (442/650). The most frequent abnormality was 13q-, observed in 302 patients (47%), but as a sole alteration in 212 cases, followed by +12 (106 patients, 16%), 11q- (83 patients, 13%), and 17p- (33 patients, 5%). As expected, the group of patients with 13q- as a sole abnormality was the one with the better OS (195 months) followed by the group of patients with normal FISH (160 months), +12 (124 months), 11q- (56 months) and 17p- (46 months), consistent with the Dohner hierarchical classification (Döhner H et al. NEJM 2000). Similar results were observed in TTFT: 13q- as sole abnormality (106 months), normal FISH (112 months), +12 (29 months), 11q- (10 months), 17p- (10 months). The best predictive cut-off point that divided patients according to its prognosis was different for each alteration. We confirmed that a high percentage of cells carrying the deletion is associated with a significantly worse TTFT in cases with 17p, 13q, and 11q deletions, and a significantly shorter OS in cases with 17p deletion. We observed a similar trend for OS in cases with 13q and 11q deletions, probably not significant because of the low number of patients included, compared to previous studies. We observed the same trend in patients with +12. The Table 1 summarizes these findings. Probably with a higher number of cases and a longer follow up, it could have also been possible to reach statistically significant differences in the subgroups in which it was not objectet.

Table 1.

<table>
<thead>
<tr>
<th>FISH abnormality</th>
<th>Number of cases</th>
<th>Overall survival (months)</th>
<th>P</th>
<th>Time to first treatment (months)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>13q deletions</td>
<td>212</td>
<td>160</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17p deletions</td>
<td>121</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11q deletions</td>
<td>104</td>
<td>56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal FISH</td>
<td>115</td>
<td>195</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Not only the type of cytogenetic abnormality but also the percentage of abnormal nuclei detected by FISH are important factors in the prognosis of CLL patients.
Background: Chronic Lymphocytic Leukemia (CLL) pathogenetic mechanisms have not been fully elucidated yet. However, genetic and epigenetic alterations seem to be involved in the pathogenesis and extensive clinical heterogeneity of the disease. DNA methylation in CpG sites of a gene promoter, which may affect the chromatin structure as well as gene transcriptional activity, is a crucial epigenetic modification in CLL. RAD21 gene is involved in DNA repair and its encoded product acts as basic subunit of the Cohesin protein complex that regulates the cohesion and proper separation of sister chromatids during mitosis or meiosis.

Aims: We investigated the methylation status of RAD21 gene promoter and its possible implication in CLL pathogenesis and the formation of CLL cytogenetic aberrations.

Methods: The study included 105 CLL patients and 17 healthy donors (controls). Total genomic DNA extraction was performed from bone marrow or peripheral blood sample of all patients and controls. Methylation analysis of RAD21 gene promoter was carried out using the new technology of MethylScreen™ in the CFX96Biorad Real-Time PCR system. For this purpose, we used EpTect Methyl II PCR Assay which enables us to calculate the methylation and unmethylated fraction after simultaneous digestions with specific restriction enzymes. Analytical sensitivity was determined on unstimulated and stimulated with CpG-oligonucleotide DSP-30 bone marrow cells of CLL patients. FISH analysis was carried out using the commercial CLL set probes for detection of the most common abnormalities of the disease including deletions of 1p13 (TP53), 11q22.3 (ATM) and 13q14.3/13q34 (D13S319/13q34) regions and trisomy 12 (CEP 12).

Results: Among the 105 CLL patients, 21 patients exhibited a normal karyotype also confirmed by FISH and 84 patients showed chromosome aberrations detected by karyotypic or/fish analysis. Methylation study was successful in all healthy donors and in 101 out of 105 CLL patients. All healthy donors had normal unstimulated RAD21 gene promoter. On the contrary, 25.74% (27/105) of CLL patients carried >10% cells with methylated CpG islands in RAD21 promoter, which was significantly increased compared to controls (p=0.039, χ²=4.25, df=1). RAD21 methylated cell fraction varied among patients. More specifically, 9% of patients (10/101) showed 11-50% methylation rate, 10.89% (11/101) 51-75% and 30% (31/101) showed high methylation rate score, >90% of the analyzed cells. Stratification of patients according to cytogentic findings showed that the promoter of RAD21 was methylated in 28.57% of patients (8/21) with normal karyotypes and 25% of patients (20/80) with abnormal karyotypes. In detail, methylation in RAD21 promoter was present in 33.33% of patients with trisomy 12 (3/9), 33.33% (4/12) with trisomy 13, 25.81% (8/31) with del(13q) in 20% (2/10) with del(6q) and in 12.5% (2/16) with del(11q). Based on karyotypic complexity, RAD21 promoter was methylated in 18.18% (4/22) of patients with a single chromosome aberration, 26.09% (6/23) with two chromosome aberrations and 25.71% (9/35) of patients with complex karyotype (>3 aberrations).

Summary/Conclusions: Methylation of RAD21 gene promoter, which leads to transcriptional inactivation and consequently inhibition of RAD21 expression, seems to be implicated in CLL pathogenesis and the formation of specific chromosomal aberrations. Carcinification of the epigenetic landscape of CLL may help in the design of new targeted therapeutic agents.

PB1763

ROLE OF KEAP1-NRF2 PATHWAY GENETIC VARIABILITY IN THE SUSCEPTIBILITY AND PROGNOSIS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

S. Marín1,2,3, I. Garay2,3, K. Azuara2, A. Ribeiro2,3,4,5, T. Tenreiro1,5, R. L. T. R. Antunes1,2, R. Alves2,3,4, J. Jorge2,3, A. Pires2,3, L. Jorge5, G. Marques5, L. Barroso6, A. Gonçalves2,3,4, A.B. Sarmento Ribeiro1,2,3,4

1Hematology Department, 2Lab. of Experimental Genetics, and 3Center for Investigation on Genes, Environment and Oncology, 4CIN-IBILU - Coimbra University, 5Pathology Department, 6Coimbra University Hospital - CHUC, Coimbra, Portugal

Background: Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western adult population. Although advanced age, white ancestry, and family history of hematologic malignancies are risk factors, the etiology of CLL still unknown. One of the mechanisms associated with the development of this pathology is related to the oxidative stress (OS) resulting from an imbalance between the production of reactive oxygen species (ROS) and their disposal by the antioxidant defenses. The number factor erythroid 2-like gene 1 (NFE2L2) and its suppressor, the Kelch-like ECH-associated protein 1 (KEAP1) gene, plays a central role in ROS balance. Changes in these genes, whether due to somatic mutations or genetic variants (SNPs), have been associated with some hematological diseases. However, the role of NFE2L2 and KEAP1 genes polymorphisms in susceptibility and prognosis of CLL is not studied.

Aims: To assess the role of two SNPs in the NFE2L2 and KEAP1 genes on CLL susceptibility, their influence on prognosis/survival, and their correlation with clinical and laboratory characteristics of patients.

Methods: Genetic variants rs13001694 (NFE2L2) and rs11085735 (KEAP1) were genotyped by tetra-primers-AMPS-PCR in 176 patients with CLL and 261 controls. The role of these genes polymorphisms in CLL susceptibility and their association with clinical and laboratory characteristics as well as with therapy response was assessed by logistic regression analysis and/or by Fisher’s exact test. The influence on prognosis and survival was performed through Kaplan-Meier survival curves by estimating the progression free survival (PFS) and overall survival (OS).

Results: The results showed that individuals with the GG genotype (NFE2L2) are at higher risk of developing CLL (Odds ratio (OR): 2.032; 95% confidence interval (CI): 1.234-3.351; P=0.004). In addition, the genotypic profile (GP) GG / CC (NFE2L2 / KEAP1) is a risk factor (OR: 2.186; 95% CI: 1.273-3.744, p=0.003) for the development of CLL while the AA / CC profile constitutes a protective factor (OR: 0.634, 95% CI: 0.407-0.984, p=0.037). In contrast, patients with genotype AG (NFE2L2) and/or CC (KEAP1) had a higher rate of complete response to rituximab therapy regimens (NFE2L2 AG: OR 1.6, 95% CI 1.063-2.463, p=0.037; KEAP1 CC, OR 1.2, 95% CI 1.041-3.477, p=0.045). NFE2L2 / KEAP1 AG / CC: OR 1.9, 95% CI 1.843-4.485, p=0.017) and with fludarabine (NFE2L2 / KEAP1 AG / CC: OR 1.5, 95% CI 1.119-3.887, p=0.026).

Finally, the overall survival of CLL patients appears to be influenced by the genotypic profile of NFE2L2 / KEAP1 (GP AG / AC patients have a lower mean survival of 22 months [13.3 ± 10.2 months], compared with others GPs [19.8 ± 13.3 months], p=0.037]), while progression-free survival seems to be influenced by the KEAP1 genotype [patients with CC genotype have a longer mean survival (198.0 ± 13.6 months) than patients with AA and AC genotypes (85.3 ± 13.4 months); p=0.023].

Summary/Conclusions: This study suggest that genetic polymorphisms in NFE2L2 and KEAP1 genes might be risk factors for CLL development and may constitute novel genetic markers for therapy response (namely regimes with rituximab and fludarabine) as well as prognostic markers, by influencing overall survival and progression free survival in CLL patients. The authors declare no conflicts of interest.

PB1774

EVALUATION OF BASAL CHROMOSOME ABERRATIONS AND MICRONUCLEUS FREQUENCY IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND THEIR ASSOCIATION WITH GENOTROPHIC MARKERS

M. Palmisani1,2, C. Stanganelli2, P. Dos Santos3, B. Brizuela3, F. Stella3, R. Bezerra1, I. Slavutsky3, M. González Cid1

1Laboratorio de Mutagénesis, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, 2División Patología Molecular, Instituto de Investigación Clinica Academia Nacional de Medicina, 3Unidad de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, 4Servicio de Hematología, Htal. Teodoro Alvarez, Buenos Aires, Argentina

Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, with variable clinical presentation and evolution. Two major subtypes can be distinguished, mutated (M) and unmutated (UM), characterized respectively by a high or low number of somatic hypermutations in the variable region of immunoglobulin genes and different outcome. Cytophgetic and FISH (fluorescence in situ hybridization) analysis has been employed as a different forms to evaluate genomic instability.

Aims: In this study, we have analyzed the basal frequency of CA and MN in untreated CLL patients. Results were evaluated in relation to different prognostic factors.

Methods: A total of 67 untreated CLL patients (36 males; mean age: 66.6 years; range: 42-83 years; Rai stage: 0: 27%; I-II: 59%; III-IV: 14%), and 6 normal controls, were studied. Chromosome analysis was performed on stimulated peripheral blood lymphocytes cultures. For each patient, CAs were evaluated on 50 cells stained with 10% Giemsa and the MN frequency was assessed on 50 cells stained with 10% Giemsa and the MN frequency was assessed on 50 cells stained with 10% Giemsa and the MN frequency was assessed on 50 cells stained with 10% Giemsa and the MN frequency was assessed on 50 cells stained with 10% Giemsa.
Results: An increased number of CAs, including chromatid breaks and dicentrics, in CLL patients (6.59±3.5%) compared to controls (0.25±0.04%) (p=0.021) was observed. A tendency to increased CA frequency in cases with abnormal (8.18±6.1%) compared to normal karyotypes (5.67±4.4%) (p=0.08) was also found. The analysis taking into account FISH risk groups showed a higher frequency of CA in patients with deletions 11q22 and/or 17p13 associated to poor outcome (8.54±4.9%), than those with no alterations or 13q14 deletion related to a better outcome (5.64±3.9%) and cases with +12 with an intermediate prognosis (5.4±3.5%). By MN analysis, an increased frequency in CLL patients (2.81±1.5%) compared to controls (0.67±3.0%) (p=0.0001) was found. Patients with +12 presented the highest percentage of MN compared to the other two groups (~1.3-fold), indicating the aneugenic effect of this alteration. The evaluation according to the IGVH mutational status showed similar frequencies for CAs and MN in M-CLL (6.25±5.2% and 2.8±4.9%, respectively) and UM-CLL (6.25±5.8% and 2.7±3.1%, respectively). No association between CA and MN frequencies and clinical parameters was found.

Summary/Conclusions: Our results confirm the presence of basal genomic instability in untreated CLL patients as measured by both CA and MN techniques. To our knowledge, this is the first analysis of these parameters taking into account prognostic factors of the disease. Cases with deletions 11q22 and/or 17p13 had the highest value of CA and those with +12 showed the highest frequency of MN, reflecting different mechanism of DNA damage.

PB1765

B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE

A. Lečerovská1, Ľ. Pospíšilová1, Š. Pospíšilová2, M. Šmída1,2
1Central European Institute of Technology (CEITEC), Masaryk University, 2Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic

Background: CD20 monoclonal antibodies (mAbs) are a standard of care for B-lymphoid malignancies. Yet, their clinical efficacy is quite variable and many patients relapse, while their malignant cells express very low density of CD20 on the cell surface. In spite of being used for 20 years as a therapy target, little is known about the biology and regulation of CD20 inside the cell.

Aims: The aim of this proposal was to investigate the intracellular mechanisms regulating expression of CD20 antigen.

Methods: Diverse cell and molecular biology techniques were used, including flow cytometry analysis, real-time PCR and RNA sequencing.

Results: We show that treatment of B cells with different CD20 mAbs initiates a signaling cascade within the cells that is partially distinct from classical B-cell receptor signaling machinery and does not involve BCR proximal proteins. Importantly, it results in a prompt downregulation of CD20 expression. Through chromosome exposure to gradually increasing doses of monoclonal antibodies, we generated cell lines that are resistant to additional treatment with mAb. Notably, these cells are resistant also to any of the available anti-CD20 antibodies even at very high concentrations as shown by dose-response experiments. This resistance is sustained for long period and maintained even upon many rounds of cell passages. We could observe that these cells downregulated CD20 protein from the cell surface and that this effect was not just due to its internalization. Instead, we detected a defect in CD20 transcription as measured by quantitative real-time PCR. Flow cytometry analysis of other surface markers showed a strong upregulation of CD55 and CD59, known inhibitors of complement activation. The combination of CD20 loss together with the increase of CD55 and CD59 is responsible for the complete resistance to the mAbs. We have then analyzed changes in overall gene expression by performing RNA sequencing and quantitative real-time PCR. We have identified several interesting genes whose expression was altered in our resistant cells when compared to their parental counterparts. Among the most interesting hits was a strong downregulation of the transcription factor NFkB, which was measured more than 10-fold lower in the rituximab or ofatumumab resistant cells. We could confirm this result in multiple independent experiments. We have postulated that anti-CD20-triggered signaling results in the inactivation of NFkB probably due to the block in NFkB transcription. To test this hypothesis, we have treated the cells with phorbol ester PMA, which nonspecifically activates NFkB. Indeed, cells treated with PMA managed to rapidly upregulate CD20 on their cell surface.

Summary/Conclusions: In summary, CD20 triggering by therapeutic mAbs initiates apoptosis in circulating cells that change that result in downmodulation of CD20 expression. Further analysis of detailed intracellular mechanisms regulating CD20 is warranted in order to propose novel interrogation nodes that might modulate CD20 surface density and thereby enhance the therapeutic potential of CD20 monoclonal antibodies.

This research has been financially supported by the Ministry of Education, Youth and Sports of the Czech Republic under the project CEITEC 2020 (L16010) and by the research grant AZV-MZ-CR 15-33651A/4-2015 and grant MUNI/A-1106/2016.

PB1766

DIFFERENTIAL EXPRESSION PATTERNS OF CHEMOKINE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA

A. Tempescul1,*, C. Berthou1, H. Saad1, V. Olivier1, B. Boutahar2, M. Zdrengea1,2, Y. Renaudineau1, C. Bagacean1,2, A. Tempescul1,*, C. Berthou1, H. Saad1, V. Olivier1, B. Boutahar2, M. Zdrengea1,2, Y. Renaudineau1, C. Bagacean1,2
1Clinical Hematology, 2Laboratory of Immunology, Teaching Hospital Breast, Breast, France, 3Clinical Hematology, Oncology Institute “Ion Chiricuta”, Cluj-Napoca, Romania

Background: Chemokines and their receptors are involved in the regulation of cell recruitment, survival, proliferation, and trafficking, all these processes crucial in the pathogenesis of chronic lymphocytic leukemia (CLL). Comprehensive profiling of chemokine receptors in CLL and its subgroups according to prognostic relevance is missing.

Aims: To characterize the chemokine expression pattern in CLL patients and subgroups according to clinical course and cytogenetic aberrations.

Methods: We studied the gene expression pattern of 16 canonical and 4 atypical chemokine receptors in peripheral blood mononuclear cells (PBMC) of CLL patients (n=88) and healthy subjects (n=34) by using SmartChip quantitative RT-PCR (WaferGen Bio-systems). The expression of CXCR3, CXCR4, CXCR5, CXCR7, and CCR7 was confirmed by flow cytometry.

Results: Among deregulated receptors, 5 receptors (CCR7, CCR10, CXCR3, CXCR4, CXCR5) were up-regulated and 9 receptors (CCR2-CR6, CCR8, CCR9, CXCR1, CXCR2, CXCR6) were down-regulated in CLL. The most deregulated receptor did not differ between CLL and controls (P>0.05). In patients with del(17p) associated with a poor prognosis, we observed higher mRNA levels of CXCR6, CXCR7 and CCR10 comparing to del(13q). On protein level, the percentage of neoplastic B cells positive for CXCR4, CXCR5, and CXCR7 was higher and percentage of CXCR7 lower than on normal B cells (P<0.05). In patients with CLL a marked increase in MFI of CXCR4 (P<0.001) and CCR7 (P<0.001) on CLL cells was detected compared to healthy subjects.

Summary/Conclusions: Our results provide a complete picture of expression patterns of chemokine receptors in PBMC of CLL patients and prognostically relevant subgroups. Further studies are needed to clarify how chemokine receptor network affects neoplastic development and progression.


PB1767

RESIDUAL SERUM CONCENTRATIONS OF RITUXIMAB ARE ASSOCIATED WITH RELAPSE RATE IN CHRONIC LYMPHOCYTIC LEUKEMIA

A. Tempescul1,*, C. Berthou1, H. Saad1, V. Olivier1, B. Boutahar2, M. Zdrengea1,2, Y. Renaudineau1, C. Bagacean1,2
1Clinical Hematology, 2Laboratory of Immunology, Institute of Molecular Biology NAS RA, Yerevan, Armenia, 3Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic

Background: Rituixmab is an anti-CD20 chimeric monoclonal antibody approved in first-line treatment of patients with chronic lymphocytic leukemia (CLL), in association with chemotherapy. Rituximab displays a time-dependent pharmacokinetic with a high variability between patients that is primarily related to target mediated elimination.

Aims: Rituixmab pharmacokinetics has been associated with clinical response but there is no data on its association with patients’ evolution after immunochemotherapy, which is the aim of the present study.

Methods: Residual serum concentrations of rituximab were determined by an enzyme-linked immunoabsorbent assay (ELISA) for 35 CLL patients before each infusion, administered every 28 days at T0, T1, T2, T3, T4, T5. Response and relapse criteria were evaluated according to the International Workshop on Chronic Lymphocytic Leukemia guidelines.

Results: Patients were assigned to two groups related to time to relapse. The first group (n=7), had an early relapse in less than 3 years, the second group (n=28), in more than 3 years. A lower residual serum rituximab concentration was observed in patients with an early relapse and statistical significance was reached for the values obtained after the 3rd cycle (T3) (p=0.02). Concerning the area under the curve (AUC), the difference was significant across all the values obtained after the first (AUCmeanT1=1.28±1.01 mlg/L·day, AUCmeanT5=2.79±1.93 mlg/L·day, p=0.02). Additionally, the residual rituximab serum concentration between T2 and T5, superior at 70µg/ml, is associated with a long response time, with a sensitivity of 100% and a specificity of 52%. Low residual serum rituximab concentrations in the early relapse subgroup were associated with a lower residual residual rituximab concentration in patients with CLL has an impact on clinical evolution after treatment. This study provides data that sustains the need of rituximab serum concentration adaptation in certain CLL patients, in order to reduce relapse risk.
PB1768

ACTIVITY OF THE CD19 ANTIBODY MOR208 IN COMBINATION WITH IBRUTINIB, IDELALISIB OR VENETOCLAX IN VITRO

R. Bochammer1,2, B. Bauer1, S. Steidl1, J. Endell1
1Pharmacology, MorphoSys AG, Planegg, Germany
2Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany

Background: CD19 is broadly expressed across B-cell malignancies, including chronic lymphocytic leukemia (CLL). MOR208 is an Fc-enhanced CD19 antibody mediating potent antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and direct cytotoxicity. Single agent MOR208 has shown promising activity in clinical studies.

Aims: We investigated the in vitro cytotoxicity of MOR208 when combined with the tyrosine kinase inhibitors (TKIs), ibrutinib and idelisib, and the BCL-2 inhibitor, venetoclax.

Methods: The CLL cell line MEC-1 was treated with 0.3–10 μM ibrutinib, idelisib or DMSO (control) for 7 days or 3–10 μM venetoclax or DMSO for 24 hours. Inhibition of proliferation, cytotoxicity and impact on CD19 expression were then assessed. ADCC assays with MOR208 incorporated a fixed number of primary human natural killer cells from healthy volunteers as effector cells. By contrast, the number of target cells was reduced according to antiprofилiative or cytotoxic effects of the TKIs or venetoclax. Dose-dependent ADCC activity of MOR208 was analyzed by flow cytometry. Cytotoxic effects were studied in at least three independent experiments.

Results: Ibrutinib and idelisib induced only moderate direct cytotoxicity on MEC-1 target cells but had strong antiprofилiative effects. In contrast, venetoclax induced strong cytotoxicity on MEC-1 target cells within 24 hours. Both effects led to reduced tumor target cell numbers in the subsequent ADC assays. CD19 expression was largely unaffected by all three drugs. The addition of MOR208 to idelisib or venetoclax treated target cells resulted in enhanced maximum ADC when compared with single agent MOR208. EC50 values remained unaltered in TKI or venetoclax treated conditions compared with the DMSO control. Calculations according to Chou-Talalay yielded combination indices below 1 for all three drugs, thus confirming synergistic activity.

Summary/Conclusions: The cytotoxic effect of MOR208 was synergistically enhanced when combined with ibrutinib, idelisib or venetoclax in vitro. These promising data provide a strong rationale for combination of MOR208 with these agents in future clinical trials.

PB1769

LYMPOCHYTE EXHAUSTION AND THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA – FRIENDS OR FOES?

E. Grywalska1, J. Rolinski1, M. Pasiarski2, M. Mielenk1, E. Fitas1, S. Gozdz3
1Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, 2Clinic of Hematology and Bone Marrow Transplantation, 3Clinic of Clinical Immunology, Holy Cross Cancer Center, Jan Kochanowski University, Kielce, Poland

Background: Chronic lymphocytic leukemia (CLL) is a disease characterized by the presence of morphologically mature monoclonal lymphocytes B with CD19+CD5+CD23+ phenotype in lymphoid tissue, peripheral blood and bone marrow. The course of CLL is chronic by default. Of note, however, is its heterogeneity. Programmed cell death protein 1 and its ligand 1 (PD-1, PD-L1) as well as CD200 and CD200 receptor (CD200R) are major inhibitory receptors regulating T cell exhaustion, i.e. a state of T cell dysfunction. The role of lymphocyte exhaustion in the natural history of CLL is still a matter of discussion.

Aims: The aim of this study was to determine the percentages and absolute numbers of exhausted lymphocytes B and T in peripheral blood and bone marrow of CLL patients. Moreover, we analyzed relationship between the number of PD-1-positive, PD-L1-positive, CD200-positive, and CD200R-positive lymphocytes and established prognostic factors in CLL.

Methods: The study included 60 untreated patients with CLL and 20 healthy subjects. The immunophenotype of peripheral blood mononuclear cells (in both groups) and bone marrow cells (solely in the CLL group) was determined by means of flow cytometry.

Results: Patients with CLL showed higher frequencies and absolute number of exhausted B lymphocytes CD19+PD-1+ (p<0.0001), CD19+PD-L1+ (p<0.0001), CD19+CD200+ (p<0.0001) and CD19+CD200R+ (p<0.0001), as well as higher frequencies and absolute number of exhausted T helper lymphocytes CD4+PD-1+ (p=0.0021), CD4+PD-L1+ (p=0.0032), CD4+CD200+ (p=0.0027), CD4+CD200R+ (p=0.0062) and exhausted T cytotoxic lymphocytes CD8+PD-1+ (p=0.0036), CD8+PD-L1+ (p=0.0029), CD8+CD200+ (p=0.0038), CD8+CD200R+ (p=0.0073) than the controls in the peripheral blood. Similar observations were done in the bone marrow samples (p<0.0001, p<0.0001, p=0.0001, p=0.0134, p=0.0182, p=0.0263, p=0.0169, p=0.0261, p=0.0362, p=0.0293, and p=0.0379, respectively). Enhanced exhaustion of peripheral blood and bone marrow lymphocytes was associated with higher Rai stage, increased concentration of lactate dehydrogenase and beta-2 microglobulin, and more rapid progression of the disease. The number of lymphocytes B CD19+ZAP-70+ correlated positively with the number of CD19+PD-1+ B cells, CD4+PD-1+ T cells, and CD8+CD200+ T cells.

Summary/Conclusions: The study confirmed the association between unfavorable prognosis and high expression of exhaustion markers in CLL patients. Determination of PD-1+, PD-L1+, CD200+ and CD200R+ lymphocytes T and B cells constitutes valuable diagnostic tool, completing cytomeric evaluation of CLL.

PB1770

HSP70 AND HSF1 GO HAND IN HAND AND HAVE A ROLE IN THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA NEOPLASTIC B CELLS

F. Raggi1,2, F. Federica1,2, Y. Martin1,2, S. Severin1,2, V. Tramaro1,2, L. Martelletti1,2, A. Visentin1,2, E. Scamozzani1, S. Imbergamo1, M. Faccio1,2, F. Piazza1,2, G. Semenza1,2, L. Trenti1,2
1Dipartimento di Medicina, Università di Padova, 2VIMM Istituto Veneto di Medicina Molecolare, Padova, Italy

Background: B-cell Chronic Lymphocytic Leukemia (CLL) is a neoplastic disorder characterized by the accumulation of clonal B cells in peripheral blood, bone marrow and lymphoid tissues. CLL is a clinically and biologically heterogeneous disease. As a consequence, novel biological and cytogenetic features have become increasingly important in predicting prognosis at the time of diagnosis and the research for molecules involved in apoptosis resistance and increased survival of neoplastic B cells is still ongoing.

Aims: We recently found that the Heat Shock Protein of 70kDa (HSP70) is overexpressed in Chronic Lymphocytic Leukemia (CLL) B cells. Considering the pro-survival role of HSP70 in cancer, we were aimed at characterizing this protein and its master regulator, the Heat Shock Factor 1 (HSF1), within the pathogenetic mechanisms leading to CLL.

Methods: HSP70 and HSF1 expression levels were evaluated by Western blotting (WB) analysis in leukemic and normal B cells. HSP70 and HSF1 protein levels were correlated to IGHV mutational status and ZAP70 protein expression in CLL patients. HSP70 and HSF1 levels were also analyzed in neoplastic cells obtained from patients undergoing ibrutinib based regimen by WB analysis. Moreover, HSP70 and HSF1 localization was analyzed by subcellular protein fractionation followed by WB analysis. The effects of HSP70 and HSF1 inhibition by Zafirlukast and Fisetin were evaluated by Annexin V/Propidium iodide flow cytometry test and WB analysis of PARP cleavage.

Results: We demonstrated that HSP70 and HSF1 are overexpressed in leukemic vs normal B cells and their expression levels correlate to poor prognosis in CLL. We also analyzed HSP70 and HSF1 levels in patients following in vivo ibrutinib based regimen, observing a positive correlation between these two protein expression levels and moreover we observed that these two protein levels decreased after therapy. We found that at steady state both HSP70 and HSF1 are localized in the nucleus of CLL B cells. HSP70 and HSF1 inhibition was proved to be effective in inducing a dose-dependent in vitro apoptosis of CLL cells.

Summary/Conclusions: HSP70 and HSF1 overexpression and correlation with poor prognosis in CLL patients underline their pivotal role in the regulation of leukemic B cell survival. HSP70 and HSF1 both correlation and reduction in CLL patients following in vivo ibrutinib regimen let us hypothesize a role of these proteins in the progression of the disease. In normal B cells HSP70 and HSF1 are both localized into the nucleus after stress conditions, however we found both HSP70 and HSF1 localized into the nucleus of CLL B cells at steady state, suggesting a constitutive activation of these proteins in CLL. Although HSP70 has been extensively linked to cancer, little progresses have been made in bringing HSP70 inhibitors to the clinic, because of their potential off-target effects. For this reason we tried an alternative approach by targeting the HSP70 major regulator, HSF1. We observed that both inhibitors, Zafirlukast and Fisetin, lead to an in vitro dose dependent cell apoptosis. These data demonstrate HSP70 and HSF1 involvement in the pathogenesis of CLL and identify HSP70/HSF1 axis as a target for new therapeutic strategies.

PB1771

OVEREXPRESSION OF GENE FOR HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3 IS A PREDICTOR OF RESISTANCE TO FLUDARABIN-BASED CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

V. Vukovic1,2, D. Antić1,2, T. Karan-Djurasevic1, N. Milic3, M. Todorovic-Bainit1,2, J. Bila1,2, B. Andjelic1,2, V. Djurasovic1,2, A. Sretenovic1, M. Smiljanic1, J. Jelicic1, M. Dencic-Fekete1, M. Perunicic-Jovanovic1, N. Kraguljac-Kurtovic1, S. Pavlovic1, B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, University of Belgrade, 3Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, 4Institute for Medical Statistics and Informatics, Medical Faculty, University of Belgrade, Belgrade, Serbia
Background: Human concentrative nucleoside transporter 3 (hCNT3) belongs to a family of nucleoside transporters involved in fludarabine cellular uptake. It has been reported that overexpression of SLC28A3 gene encoding hCNT3 predicts poor response to fludarabine-based chemotherapy. However, the mechanisms by which elevated expression of SLC28A3 mediates fludarabine resistance are still elusive.

Aims: The aim of the study was to examine possible influence of SLC28A3 gene overexpression on treatment response to fludarabine-cyclophosphamide therapy (FC) in patients with chronic lymphocytic leukemia.

Methods: We retrospectively analysed data from 54 CLL patients diagnosed and treated at Clinic for Hematology, Clinical Center of Serbia from 2003 to 2013. Blood samples were prospectively collected and analysed for biological and molecular features, as well as standard laboratory parameters. The expression of SLC28A3 gene was analyzed in peripheral blood mononuclear cells by RT-qPCR methodology, using TaqMan chemistry and Abl as endogenous control gene. Quantification of target gene expression was made by comparative ddCt method using HLA-BL cell line as the calibrator. All analyses were done prior to any treatment.

Results: Median age at diagnosis was 57 years (range 38-75). All patients were treated with fludarabine-based chemotherapy. 45% (3%) in the first treatment line. Overall response rate to the first line therapy was 81%, equally distributed on complete and partial responses (CR and PR), while the remainder included the same number of patients with stable disease (SD) and progressive disease (PD) (5, 9.6%). Most of the patients (42, 78%) relapsed during the follow up. At the time of the last follow up 14 (26%) patients were still alive, 35 (65%) were dead, and 5 (9%) were lost to follow up. Median overall survival was 76 months.

In the group of patients who received FC in the first treatment line (43/54), median expression of SLC28A3 mRNA in patients who experienced CR, PR, SD, and PD was 0.036±0.030, 0.092±0.03-0, 033±0.025 and 0.157±0.257, respectively. The level of SLC28A3 expression was not associated with the IGHV mutation status. Patients who experienced PD to FC treatment overexpressed gene for hCNT3 compared to patients who achieved CR (p=0.013) and PR (p=0.05). We detected a significantly higher level of SLC28A3 expression in patients who experienced PD to FC treatment in comparison to patients who achieved CR (p=0.013) and PR (p=0.05).

Summary/Conclusions: Overexpression of SLC28A3 gene predictor of resistance to treatment with FC chemotherapy. Further studies are warranted to confirm these findings.

PB1772

THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT

N. Bilous1,*, I. Abramenko1, A. Chumak1, I. Dyagil2, Z. Martina2
1Clinical Immunology, 2Hematology, Research Center for Radiation Medicine, Kiev, Ukraine

Background: Generally, chronic lymphocytic leukemia (CLL) is considered to be a non-radiogenic form of leukemia. We previously found some clinical and biological features of CLL in group of clean-up workers of Chornobyl NPP accident indicated unfavorable disease course, as such high frequency of solid tumors and Richter transformation, mainly unmutated status of heavy chain variable region (IGHV) genes with increased usage of IG VH V-1-69 and IG VH V-21 (Abramenko et al., 2008). Analysis of genetic features of leukemic cells in IR-exposed CLL patients may provide an additional data on the possible causal relationship with IR.

Aims: The aim of the study was to analyze TP53, NOTCH1 and SF3B1 mutations in CLL patients, suffers of Chornobyl NPP accident to clarify the possible pathogenetic relationship between IR and CLL development

Methods: TP53, NOTCH1, and SF3B1 mutations were analyzed in 106 CLL patients who have been exposed to ionizing radiation (IR) due to Chornobyl NPP accident (83 clean-up workers, 16 inhabitants of radionuclide contaminated areas, and 7 evacuees) and in 130 IR non-exposed CLL patients as the control group. TP53 gene mutation analysis was performed for exons 3 to 10. NOTCH1 mutations and SF3B1 mutations were analyzed in the hotspot regions of these genes were the vast majority of CLL-specific lesions were reported: c.720delG, p.L240fsX20 (14%) of NOTCH1 gene, and in exons 14, 15 and 16 of SF3B1 gene, correspondingly.

Results: We found TP53 and SF3B1 mutations with similar incidence in both groups – in 11.3% and 10.0% of IR-exposed patients, and in 12.7% and 11.5% of IR non-exposed CLL patients, respectively. In contrast, NOTCH1 mutations were found in IR-exposed patients with lower frequency in IR-exposed patients in comparison with the control group (6.7% vs 17.7%; p=0.012). Other features were found among IR-exposed CLL patients also. Specifically, TP53 mutations were seen with equal frequency among mutated (11.1%) and unmutated (11.8%) IGHV cases in IR-exposed CLL patients, while the tendency to prevalence of TP53 mutations in unmutated compared with mutated IGHV cases was found in the control group (14.1% and 5.6%, correspondingly; p=0.178). In IR-exposed group SF3B1 mutations were combined with mutations in TP53 almost in half of detected cases. In opposite, in the control group we observed reported earlier mutual exclusivity between SF3B1 and TP53 lesions (p=0.001 in comparison between observed groups). Among IR-exposed CLL patients we found two different cases with identical rare mutation of TP53 gene - c.665C>T substitution leading to change proline to leucine at codon 222 (Pro222Leu). This substitution is very likely to represent inherited TP53 mutation, which may influence CLL development under IR exposure.

Summary/Conclusions: In summary, our data suggest that TP53 abnormalities are involved in CLL development in sufferers of the Chornobyl NPP accident and also a possible interaction between inherited IR sensitivity caused by mutation in TP53, radiation and CLL development.

Background: Personalized Cancer Medicine is rapidly developing field that includes predictive medicine, preventive medicine and various personalized or individualized therapies, e.g. labeled “precision medicine”. One particular challenge is that origin of each cancer is a clonal event evolving into tumor heterogeneity. We focus on Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma and Follicular lymphoma (FL) that are currently considered incurable. Although current treatment regimens are effective for many patients, CLL and MM cancer eventually relapse. Current challenges in using therapies against CLL and MM includes design of optimal treatment for individual patients based on characterization the tumor and its intratumor heterogeneity as observed by whole genome sequencing. Efficient therapies require a personalized approach that combines targeting lymphoma cells and the tumor microenvironment by restoring the patient’s own anti-tumor immunity. One solution to this challenge is the so-called “n-of-one” studies where protocols are organized with diagnostically based patient stratification to individualized treatments (n=1).

Aims: To introduce individualized treatment for patients against available therapies, we aim to established cell-based assays and drug sensitivity platform at NCMM, University of Oslo and Oslo University Hospital. To establish a pipeline for direct drug sensitivity screening in CLL and MM (WP1-Path A). To Complement the results from WP1-Path A, with Signaling pathway analysis (WP2-Path B) towards testing in xenografted mice and individualized treatment in n-of-one clinical trials. To Offer patients with intractable CLL and MM individualized treatment with an effective combination of targeted therapies.

Methods: We culture CLL cells with combination of feeder cells that express CD40L, APRIL and BAFF for 24 hours stimulation. We perform drug sensitivity screening with Prestimulated CLL cells in 384 well formats without feeder cells. We culture MM cells in 384 well format for drug sensitivity in response to T help cells prestimulation in the presence of IL2. To support high-throughput drug sensitivity screening, we use cell-based assays such as CellTiter-Glo® proliferation assay and CellTox™ Green Cytotoxicity Assay to define drugs that inhibit cancer cell growth. Additional methods such as cell proliferation assay, CellTox Green, apoptosis and oxidative stress (glutathione release) are also applied. We also use established cell barcoding on CLL/MM for flow cytometry (7-AAD/BrDU cell proliferation and Caspase®9 apoptosis assay).

Results: Standard Curve for cell proliferation, CellTiter-Glo assay has been performed for MM/CLL cells. Time course measurement using cell proliferation, CellTox-Green assay for CLL cells (stimulated and soluble CD40 ligand-activated) has been performed. 48,72 hrs (and 5 days) using cell proliferation, CellTox-Green assay for M2 cells has been performed. Benzalkonium chloride (BzCl2) is used as Positive control. Endpoint measurement using CellTiter-Glo assay for CLL and MM cells was performed with cell density of 5000. Dose Response curve for 50 drugs has been generated for CLL patients (n=4) and MM (n=4) (Figure 1).

Figure 1.

Summary/Conclusions: We perform drug sensitivity screening to select potential drug candidates and pathway inhibitors through an approach where we directly assess patient samples. Selected drug candidates will first be validated by bioassays and further cytometry to assess effects on intracellular mitogenic pathways (phosphoflow-based approach). We propose to use the drug sensitivity screening platform to identify and validate drug candidates for xenografting and “n-of-one” clinical trial studies.
Background: The mutational status of the immunoglobulin heavy variable (IGHV) genes is established as one of the most important prognostic molecular genetic markers in chronic lymphocytic leukemia (CLL). It divides the CLL patients into two subsets with a different clinical course, mutated (M-CLL) and unmutated (U-CLL). U-CLL is delineated with a cutoff value of 98% identity with the closest germ line of IGHV genes. The shaping of the CLL IGHV gene repertoire is relied on a different genetic background and environmental factors. In addition, a strong bias in the use of individual genes and subgroups between normal and malignant B-cells and presence of highly homologous “stereotyped” heavy complementary-determining region 3 (VDJ) is shown, which suggests the role of a specific antigen in the pathogenesis of disease.

Aims: In this study, we analyzed the mutation status and pattern of IGHV, IGHD and IGKJ gene usage in Macedonian CLL patients.

Methods: Ninety-seven consecutive CLL patients that presented at the University Clinic of Hematology–Skopje in the period between 2011-2013, were included in the study. IGHV mutation status and gene repertoire were analyzed using two databases: IMGT/V-QUEST tool and IgBLAST software. The stereotyped subset assignment was performed using ARResT/AssignSubset tool (Bioinformatics Analysis Team).

Results: We found that 44.3% of the cases belonged to M-CLL and 55.7% to U-CLL, with a progressive disease dominant in the U-CLL subset. Both groups were comparable regarding the age and gender distribution. Only 39% of the M-CLL patients presented with a progressive disease, compared to 74% of the U-CLL patients (p<0.05). The comparison of median time to the first treatment (TFT) between M-CLL and U-CLL (39 months versus 8 months, respectively) showed a statistically significant difference between the groups (p=0.01). Most frequently expressed IGHV genes were: IGHV3 subgroup (44.3%), IGHV1 (28.9%), IGHV4 (23.7%), IGHV5 (2.0%), and IGHV12 (2.0%). Among 32 different IGHV genes, 8 genes were found (V1-4, V6-19, V3-21, V3-23, V3-30, V3-33, V3-48 & V4-34) in 58.8% of all cases, revealing a strong bias in IGHV gene expression in CLL. IGHV1-69 was the most frequently expressed gene of all (16.5%), and exclusively found in the U-CLL group demonstrating a frequency of 29.6%. The IGHV3-21 was detected with a low frequency of 4.1%, as reported for CLL patients from other Mediterranean countries. The distribution of IGHD subgroups was as follows: IGHD3, 52.6%; IGHD2, 17.5%; IGHD6, 13.4%; IGHD1, 7.2%; IGHD4, 7.2%; and IGHD5, 2.09%. The most frequent IGJH gene was IGJH4 (49.4%), followed by IGJH3 (23.7%), IGJH1 (11.4%), IGJH2 (3.1%), and IGJH12 (2.0%). In 10.1% of the cases, the VHCDR3 amino acid sequences belong to previously defined stereotyped clusters. Only one of the rearrangements with stereotyped VH-CD3 belonged to the M-CLL subset.

Summary/Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. Results on IGHV-IGHD-IGHKJ gene usage in our study are comparable to the previously reported from Mediterranean countries. The high frequency of V1-69gene and low frequency of IGHV3-21 in our CLL patients that originate from a small geographic region further promotes the geographic bias in the use of IGHV genes and points to an important role in antigen stimulation in the pathogenesis of the CLL subsets. Our findings indicated a lower expression of the stereotyped BCR region than those previously reported (~30%), but they were comparable with the results reported for the Serbian CLL patients (10.1% versus 15.3%, respectively), in the only previous published study of this kind from Western Balkans.

PB1774

MUTATIONAL STATUS, IMMUNOGLOBULIN HEAVY VARIABLE GENES PATTERN AND STEREOTYPED RECEPTORS REPERTOIRE OF MACEDONIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

I. Panovska-Stavridis1,*, S. Trpkovska-Terzieva1, R. Angelovic1, O. Karanfilski1, T. Sotirova1, A. Stojanovic1
1University Clinic of Hematology–Skopje, Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, Skopje, Macedonia, The Former Yugoslav Republic Of

Table 1. Genotype distributions for FCGR2A & FCGR3A in patients with CLL.

<table>
<thead>
<tr>
<th>FCGR2A/FCGR3A</th>
<th>Complete Response n=48(53.7%)</th>
<th>Partial Response n=50(55.7%)</th>
<th>No Response n=6(11.1%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCGR2A 131H/R</td>
<td>2(0.6%) (12.2%) 6(12.7%)</td>
<td>18(36.0%) (36.0%) 29(58.0%)  4(8.0%) (8.0%) 5(10.0%) (10.0%)</td>
<td>2(0.4%) (0.4%) 1(2.0%)</td>
<td>0.809</td>
</tr>
<tr>
<td>FCGR3A 158V/V</td>
<td>8(20.5%) (20.5%) 11(33.3%)</td>
<td>12(33.3%) (33.3%) 33(82.5%)  2(5.1%) (5.1%) 1(2.0%) (2.0%)</td>
<td>4(10.0%) (10.0%)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our results are similar with previously published reported results in other studies in CLL patients, but in contrast with the results for follicular lymphoma (FL), which showed that high-affinity FCGR2A-158V/V variant was associated with the highest response rates in FL patients treated with rituximab. These findings could be explained with the different mechanism of action of rituximab in CLL compared to lymphoma patients or could be due to the variations in selected patient’s population.

PB1775

MUTATIONAL STATUS, IMMUNOGLOBULIN HEAVY VARIABLE GENES PATTERN AND STEREOTYPED RECEPTORS REPERTOIRE OF MACEDONIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

I. Panovska-Stavridis1,*, S. Trpkovska-Terzieva1, R. Angelovic1, O. Karanfilski1, T. Sotirova1, A. Stojanovic1
1University Clinic of Hematology–Skopje, Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, Skopje, Macedonia, The Former Yugoslav Republic Of

Table 1. Genotype distributions for FCGR2A & FCGR3A in patients with CLL.

<table>
<thead>
<tr>
<th>FCGR2A/FCGR3A</th>
<th>Complete Response n=48(53.7%)</th>
<th>Partial Response n=50(55.7%)</th>
<th>No Response n=6(11.1%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCGR2A 131H/R</td>
<td>2(0.6%) (12.2%) 6(12.7%)</td>
<td>18(36.0%) (36.0%) 29(58.0%)  4(8.0%) (8.0%) 5(10.0%) (10.0%)</td>
<td>2(0.4%) (0.4%) 1(2.0%)</td>
<td>0.809</td>
</tr>
<tr>
<td>FCGR3A 158V/V</td>
<td>8(20.5%) (20.5%) 11(33.3%)</td>
<td>12(33.3%) (33.3%) 33(82.5%)  2(5.1%) (5.1%) 1(2.0%) (2.0%)</td>
<td>4(10.0%) (10.0%)</td>
<td>0.010</td>
</tr>
</tbody>
</table>
Chronic lymphocytic leukemia and related disorders - Clinical

PB1776
LAMBDA LIGHT CHAIN RESTRICTION – USEFUL FOR HAIRY CELL LEUKEMIA PROGNOSTICATION? J. Araujo1,2, M. Sobrinho-Simões1, S. Afonso1, F. Principe1, J.E. Guimarães1 1Hematology, Centro Hospitalar de São João, Porto, Portugal

Background: Hairy cell leukemia (HCL) patients have near-normal life expectancies since the introduction of purine nucleoside analogues. However, HCL remains a chronic, often relapsing disease in which maximizing treatment-free survival (TFS) is the main goal.

Aims: Prognostication is not standardized in HCL, emphasizing the relevance of the characterization of HCL populations.

Methods: We retrospectively analysed 40 patients (90% men), diagnosed between 1997 and 2016, with a median follow-up of 6 years.

Results: At presentation, the median age was 58 years and 69% of patients were symptomatic - fatigue (53%), B symptoms (50%), bleeding (14%), abdominal discomfort (6%) and severe infection (22%). The commonest cytopenia was thrombocytopenia (70%), with median platelet count being 66x10^9/L. Monocyte counts below 0.1x10^9/L were observed in 61% of patients. Splenomegaly was observed in 63% of the patients and 21% had abdominal lymphadenopathies. The majority of the patients (88%) was treated with cladribine in first line, achieving an overall response (OR) rate of 100% and a complete response (CR) rate of 38%, of which 67% were classified as minimal residual disease (MRD)-negative CR. Retreatment was required in 33% of the patients, of which the majority received cladribine. The median time-to-next-treatment (TNT) from first to second line was 3 years. The OR rate for second-line treatment was 91%, 50% achieving CR, of which 33% were classified as MRD-negative CR. Only 5% of the patients required further treatment lines. Even the presence of scarce hairy cells in the bone marrow precluded classification of response as CR. This might have contributed to the low CR levels observed in our patients. As post-treatment bone marrow biopsies were available in only 24 patients, response analysis was restricted to these patients. All of these 24 patients had bone marrow fibrosis at diagnosis, which reverted when and in whom first CR was obtained. Median overall survival (OS) was not reached and, at 10 years, the OS was 90%. Four deaths occurred, all unrelated to HCL. Regarding prognostication, a trend to a longer TFS, albeit no statistically significant, was observed in patients achieving CR (namely MRD negative) and without thrombocytopenia at presentation. Excitingly, the 61% of patients with kappa (k) light-chain restriction (LCR) displayed a significantly higher TFS than the 39% with lambda (λ) LCR (p=0.04, Wilcoxon-Gehan test). To the best of our knowledge, there are no published reports on prognostic value of LCR in HCL (Figure 1).

Summary/Conclusions: If multicentre studies corroborate our findings, LCR may be of use in the prognostication/risk stratification of HCL. Similarly with multiple myeloma and other hematological malignancies, lambda (λ) LCR appears to correlate with worse prognosis, leading to a shorter TFS.

PB1777
CLINICAL EFFICACY AND LONG-TERM OUTCOMES OF SPLENECTOMY IN CHRONIC LYMPHOCYTIC LEUKEMIA Y. Yevstakhievych1,2, I. Yevstakhievych1, O. Vygovska1, M. Semerak1, V. Loginsky1 1Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine, L’viv, Ukraine

Background: Chronic lymphocytic leukemia (CLL) is often accompanied by splenic rupture and acute intra-abdominal bleeding.

Methods: The clinical efficacy and long-term outcomes of splenectomy in patients with CLL were evaluated. Splenectomy was performed at the Clinical Department of Hematology, Centro Hospitalar de São João, Porto, Portugal, 1Hematology, Centro Hospitalar de São João, Porto, Portugal

Results: Splenectomy was effective in 37 patients (90.2%): abdominal discomfort disappeared, hemolysis stopped and hemoglobin levels normalized or increased, platelets numbers normalized or increased. Splenectomy was ineffective in 3 patients with CLL associated with ITP: amid elimination of abdominal discomfort the platelets number did not increase significantly (2 patients), while in 1 patient despite increase in platelets number leukemia progression was observed. One (2.4%) patient with CLL and AIHA died on 3rd day after surgery because of acute adrenal insufficiency. The analysis of late effects of splenectomy in patients with CLL showed that average life expectancy after the surgery comprised 111.6 months within observation period between 11 and 277 months. In patients with CLL immune cytopenias the average life expectancy after surgery was shorter and equal to 60.7 months within the observation period between 2 and 361 months.

Summary/Conclusions: Splenectomy remains an effective method of treatment of patients with CLL. Companied by severe thrombocytopenia and immune cytopenia. Long-term results of splenectomy in patients with CLL without cytopenia are better than in patients with CLL and cytopenias. Aggressive hemolysis, large spleen covered in perisplenic adhesions, amid portal hypertension and thrombocytopenia are considered to be special surgical risk factors in this patients.

Figure 1.

Summary/Conclusions: If multicentre studies corroborate our findings, LCR may be of use in the prognostication/risk stratification of HCL. Similarly with multiple myeloma and other hematological malignancies, lambda (λ) LCR appears to correlate with worse prognosis, leading to a shorter TFS.

PB1778
MONOCLONAL B-CELL LYMPHOCYTOSIS IN THAI POPULATION: PREVALENCE AND IMMUNOPHENOTYPIC CHARACTERISTICS P. Kongti1, J. Chantakarn1, W. Limsoppitak1, N. Wansorn2, T. Smuthiwatt1, W. Udornprasertkit1, S. Issaragrisil3 1Hematology, 2Pathology, Faculty of Medicine Thammasat University, Pathumthani, 3Cancer Cytogenetic and Molecular Diagnostic, Chulabhorn Research Institute, 4Hematology, Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok, Thailand

Background: Monoclonal B-cell lymphocytosis (MBL) is characterized by the presence of <5X10^9 clonal B-cells/L in peripheral blood (PB) in otherwise healthy subjects, in the absence of symptoms and signs of a B-cell lymphoproliferative disorder (LPD). MBL is considered a precursor to chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Aims: To study the immunophenotypic features and prevalence of MBL in healthy Thai individuals.

Methods: Peripheral blood (PB) samples from 616 healthy Thai individuals (313 female), 18-80 year-old with normal lymphocyte counts were immunophenotyped using high-sensitive flow cytometry, based on 5-color staining and the screening for >5x 10^9 total PB leucocytes. The initial PB samples were screened for clonal B cells using MultiMix Triple-Color Reagent (Kappa Light Chains/FITC, Lambda Light Chains/RPE and CD19/RPE-Cy5). In those cases in which a clonal B cell population was detected by imbalance of sIgK:sIgL ratio of >3:1 or <1:3, were further tested for CDS, CD23, CD20 and CD79a expression.

Results: Of total 616 subjects, MBL was found in 8 cases (1.2%) including 3 and 5 female and male cases respectively. Among 40 years or older, MBL was found in 5 out of 448 cases (1.1%). Compared with non-MBL group, subjects in high-count MBL were significantly older (mean age 55 years versus 50 years; p=0.01) and had a significant higher number of absolute and B-lymphocyte count (median 3.1 versus 1.6 X10^9/L; p=0.03 and 0.35 versus 0.16 X10^9/L; p=0.02, respectively) while the median white blood cell count was not different between 2 groups. Also, there were more subjects in MBL group who had family history of lymphoproliferative diseases (LPD), 37% vs 0% (p<0.01) and influenza vaccination within 2 years (50% vs 8.7%; p=0.003). Among 8 cases with MBL clone, 6 cases had low-count MBL (<0.5X10^9 clonal B-cells/L) while only 2 cases had high-count MBL (>0.5X10^9 clonal B-cells/L). All 8 cases had persistent positive of MBL clone after tested was repeated within 3 months after the initial test. In follow up test, only 1 case with initial high-count MBL had decrease number of B cell clone and became low count MBL. There was not significant different in age between subjects in low and high-count MBL group. Six cases had typical CLL phenotype MBL clone (CD5+, CD23+, CD20+ and dim and light chain restriction). Whereas 1 case had atypical CLL phenotype MBL (CD5+, CD23+, CD20+ and light chain restriction but CD23-), and 1 case had non-CLL phenotype MBL (CD20+ but CD5-). In univariate analysis, age (RR 4.19; 95%CI 1.0-17.7; p=0.049), absolute lymphocyte count (RR 2.76; 95%CI 1.01-4.87; p=0.047), family history of LPD (RR 122; 95%CI 51.1-293.4; p<0.001) and...
influenza vaccination (RR 10.47; 95%CI 2.54-43.07; p=0.003) were associated with increased risk of developing MBL. After adjusted for age, only history of influenza vaccination and family history of LPD were an independent risk factor for developing MBL with age adjusted RR of 9.75 (95%CI 2.3-40.5; p=0.002) and 92 (95%CI 56.3-149.5; p<0.001), respectively.

Summary/Conclusions: MBL prevalence in Thai population is much lower than previously reported. It more frequent in elders and associated with family history of LPD and influenza vaccination. Although uncommon, the presence of high-count MBL warrants further investigations to define the biological and clinical significance in term of LPD transformation and long-term survival.

PB1779

SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGICAL FEATURES OF 9 CASES FROM THE ERIC REGISTRY

I. Del Giudice1, A. Visentin2, L. Trentini3, M. Flogarag3, C. Cavallioni4, E.M. Oriolod4, M. Mattsson5, S. Raponi6, C. Illan7, L. Caffo1, M.S. De Prozo1, I. Denzler8, N. Peragine9, P. Mariglia9, C. Semenzato10, A. Guarini10, E. Montserrat9, R. Fineman7, A. Aviv8, O. Rouvio9, R. Ruchlem1, A. Braester11, D. Najib12,

1Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, 2Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Padua, Italy, 3Hematology, Medicine Clinic, Falun Hospital, Falun, Sweden, 4IRCCS, Policlinico San Matteo, Pavia, Italy, 5Department of Hematology, Uppsala University Hospital, Uppsala, Sweden, 6Department of Molecular Medicine, Hematology, Sapienza University, Rome, Italy, 7Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain

Background: Spontaneous clinical regression in chronic lymphocytic leukemia (CLL) is rare (1% per year). We previously reported on the clinico-biological features of 9 Binet stage A CLL patients from our Center in Rome who experienced a persistent spontaneous clinical regression of the disease at a median time of 11 years to the last follow-up. In 5/9 cases the lymphocyte count was <4 x 10^9/L at diagnosis, median time from diagnosis to clinical regression was 3.6 x 10^9/L (1.3-4.9), with a persistent small CLL clone (CD19+CD5+CD23/light chain restricted: 44%, range 5-60%). Biologic features included negative CD38, mutated IGHV, often with VH3-30 and variable expression of IgVH3-21, +12 in 1 case. No patient had undergone treatment, except for one diagnosed in 2009 who received FCR for disease progression in 2013 (lymphocytes 107 x 10^9/L).

Aims: To conduct a retrospective collection of clinical data and biologic information on CLL spontaneous regressions and to make them accessible for future research.

Methods: A registry of spontaneous CLL regressions (absence of lymphopenopathy, splenomegaly and constitutional symptoms, peripheral blood (PB) lymphocytes <4 x 10^9/L in the absence of any previous treatment) was launched within the ERIC consortium.

Results: So far, 9 CLL patients showing a spontaneous regression have been reported and 8 have been formally registered, 7 from Italy and 2 from Sweden. Six were males and 3 females, with a median age of 57 years at diagnosis (range 51-82), stage Binet/Rai A0 in 6, A1 in 2 and B1 in 1. The median lymphocyte count at diagnosis was 14.1 x 10^9/L (5.3-51.9). Biologic features included: mutated IGHV in 8/8 with VH3-30 (2), VH3-21, VH3-15, VH3-24, VH3-31, VH4-34, VH4-59; CD38 -30% in 6/8; ZAP70 <20% in 4/8; FISH (7 cases): del13q in 7, del17p in 1. The median lymphocyte count at regression was 3.16 x 10^9/L (1.3-4.9), with a persistent small CLL clone (CD19+CD5+CD23/light chain restricted: 44%, range 5-60%). No patient had undergone treatment, except for one diagnosed in 2009 who received FCR for disease progression in 2013 (lymphocytes 107 x 10^9/L). A patient needed IBR interruption or dose reduction. All pts displayed severe impairment of collagen-induced aggregation upon IBR. Reduction of maximal aggregation by IBR. Associated bleedings and platelet dysfunction may be caused by chronic lymphocytic leukemia (CLL) with del 17p or TP53 mutation or for antithrombotic therapies.

Summary/Conclusions: Our study showed minor bleedings in pts treated with IBR. A severe impairment of collagen-induced aggregation was caused by IBR and was counteracted by amelioration of ADP-induced aggregation, with IBR. A severe impairment of collagen induced aggregation upon IBR. Reduction of maximal aggregation by IBR. Associated bleedings and platelet dysfunction may be caused by chronic lymphocytic leukemia (CLL) with del 17p or TP53 mutation or for antithrombotic therapies.
Background: Hairy cell leukemia (HCL) accounts for approximately 2% of all leukemias and is associated with pancytopenia, splenomegaly, and recurrent infections. Therapy with the purine analogues cladribine (2CdA) or pentostatin (2’deoxycoformycin), has been most effective and both agents have achieved equivalent results in HCL. In this regard cladribine given as a single course, achieves a high response rate. Several alternative dosing schedules have been reported, but they were not identical with the standard regimen. This study compared either as a “fixed daily dose” or “weight based dose” for 5 or 7 days. Seeding that excellent results are obtained using 2CdA in all schedules used, it now seems very important to focus on reducing therapy induced toxicity, related mostly to development of neutropenia, immunosuppression and severe infections.

Aims: In this retrospective study, we summarized the Israeli experience with HCL over the past 30 years, and analyzed demographic data, relevant laboratory and clinical parameters with special emphasis on outcome after first line treatment with cladribine.

Methods: We collected retrospective data on patients with HCL from 12 medical centers in Israel, followed and treated during 1985-2015. The study was approved by local institutional IRBs of each medical center.

Results: Data from the medical records of 202 patients with HCL was summarized. Mean follow up was 7.5 years (0.1-40), with a 5 and 10 years’ overall survival of 96% and 90.62% respectively. The median age at diagnosis was 53 years, and most (81.77%) were males. In terms of ethnicity: 88.3% of patients were Jews (52.2% Ashkenazi and 36.1% Sephardic Jews) while 11.7% were Arab, Druz or others. First line therapy with cladribine was given to 159 patients (80.71%); other therapies 9.14%, while 1.1% did not receive any treatment. The median time from HCL diagnosis to treatment with 2CdA was 5.9 years. IV therapy was given to 62% of patients and 38% received it SC. Complete remission rates, progression-free survival and overall survival were not significantly different between the two schedules. In univariate analysis: Sex, ethnicity, dose, patient weight, and treatment duration (5-7 days) had no impact on outcome, but patients older >65 years had a shorter survival. Infectious complications requiring hospitalization was reported in 50.3% of all treated patients (54%, post IV and 47% post SC delivery; p=0.40). Median days of hospitalization were 8 for both groups (p=0.05), and the length of NADIR was 18 and 20 days for IV and SC delivery respectively (p=0.33).

Summary/Conclusions: This study is the first comprehensive summary of the natural history involving a large cohort of HCL patients with long follow up. These results serve as validation of previous reports relating to HCL and confirm that the excellent outcome achieved after a single course of treatment with 2CdA is independent of schedule and method of drug delivery. In addition, patient ethnicity was insignificant.

PB1782

CHRONIC LYMPHOCYTIC LEUKEMIA: CHANGES IN CLINICAL STAGE DISCRIMINATE PATIENTS WITH DIFFERENT OUTCOME WITHIN THE IWCLL PARTIAL RESPONSE CATEGORY

E. P. Vicente1,2,3, M. Martinez2, A. Soler2, C. Cuellar2, A. Mora4, R. Bosch1,2, J. Herranz1, G. Guasch1,3,4, G. Esquivol1, M. Granell1, S. Saavedra3, J. Sierra1, R. Martino3, C. Morenci2,3

1Department of Hematology, 2Laboratory of Oncology/Hematology and Transplantation, 3Institute of Biomedical Research, 4Hematology, Hospital Sant Pau, Barcelona, Spain

Background: Over the last decades, progress in chronic lymphocytic leukemia (CLL) treatment has resulted in an impressive increase in overall survival (OS). In CLL, as in other tumors, response to therapy overcomes negative prognostic factors and is the most important predictor of survival. Clinical stages reflect tumor load and correlate with OS both at diagnosis and over the course of the disease (Rai et al, Blood 1975).

Aims: To determine whether changes in clinical stage discriminate patients with different outcome within IWCLL response categories, particularly the heterogeneous (PR) group. (Ellekilde et al. Blood 2008).

Methods: Two-hundred twenty-nine patients with CLL were retrospectively evaluated. Median follow-up was 91 months (range, 2-390). CLL diagnosis was based on IWCLL criteria. Endpoints were time to next treatment (TTT) and OS. TTT and OS curves were estimated by the Kaplan-Meier method and differences between groups were assessed by the log-rank test. Response was determined according to IWCLL recommendations and by changes in clinical stage. A landmark analysis was performed in ninety-two patients in whom a PR was achieved at any time during the course of the disease, using the time when a PR was achieved as “time 0”.

Results: From the series of 229 patients, those who achieved a better IWCLL degree of response after first line of therapy had a better OS than those with an inferior response (p=0.001). With a median follow up of 91 months (range, 2-390), the median survival in patients who achieved complete remission (CR) was 214 (95% CI: 123-305) vs 134 (95% CI: 79-189) and 91 (95% CI: 60-122) in the subcategories that failed to achieve remission and failed to therapy, respectively (Figure 1A). Among patients in PR (n=66), after a median follow-up of 42.5 months (range 1-201), those patients with stage A disease at the time of response evaluation (PR Binet A) had significantly better outcome than those whose stage was Binet B/C (median survival 63 vs 43 months; p=0.047). Interestingly, when the analysis was restricted to response assessment after first line therapy (n=229), patients who achieved PR Binet A did not have significant differences in OS compared to those patients who were in CR (median survival were 164 and 214 months respectively; p<0.001); on the contrary, patients in PR Binet B/C had a similar outcome than those who did not respond to treatment (median survival 81 and 91 months respectively). Similar results were observed in the outcome of patients with PR subclassified according to Rai clinical stage.

Figure 1.

Summary/Conclusions: Changes in clinical stage provide reliable information on the degree of response to therapy in patients with CLL, particularly those in the IWCLL PR category. This study supports the use of clinical stages as a complementary and simple tool to assess response in patients with CLL, both at the end and over the course of treatment.

PB1783

INCIDENCE OF THYROID GLAND DISORDERS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

A. Tombak1,*, M. A. Ucar1, R. Gen2, M.A. Sungur3

1Hematology, 2Endocrinology, Mersin University, Mersin, 3Biostatistics, Duzce University, Duzce, Turkey

Background: Frequency of autoimmune complications like immune anaemia or immune thrombocytopenia has increased in patients with chronic lymphocytic leukaemia (CLL). However, there is no data in the literature investigating the relation of the other autoimmune disorders including thyroid gland diseases with CLL.

Aims: We aimed to investigate the presence, features and frequencies of thyroid disorders in patients with CLL.

Methods: Thyroid function tests, thyroid autoantibodies (antithyroglobulin antibody [anti-TG], antithyroid peroxidase antibody [anti-TPO]), thyroid ultrasonographies (USG) and scintigraphies of CLL patients were performed. Demographic data, Rai-stages, and thyroid disorders were recorded.

Results: One hundred CLL patients were included into the study (65 male, mean age was 62±10.4). Free T3 (FT3) was within normal limits in 96 cases (96%), was low in 2 cases (2%), was high in 2 cases (2%); free T4 (FT4) was normal within normal limits in 89 cases (89%), was low in 7 cases (7%), was high in 4 cases (4%); TSH was within normal limits in 90 cases (90%), was low in 7 cases (7%), was high in 3 cases (3%). Anti-TPO and anti-TG were positive in 10 cases (11.8%) and in 18 cases (21.2%), respectively. While USG was normal in 36 cases, multinodular goiter (MNG) in 21, chronic thyroiditis in 20, MNG associated with thyroiditis in 10, uniodular goiter (UNG) in 8, UNG associated with thyroiditis in 4, and diffuse goiter in 1 case were determined by USG. Toxic adenoma in 3 cases, toxic MNG in 2 cases, and thyroiditis in 1 case were determined in 6 patients in whom thyroid scintigraphy was performed for hyperthyroidism. After evaluation of all the tests; while no thyroid disease was determined in 33 of the cases (33%), MNG in 25 (25%), thyroiditis according to the results of USG in 12 (12%), UNG in 11 (11%), Hashimoto thyroiditis in 9 (9%), toxic MNG in 3 (3%), subclinical hyperthyroidism in 3 (3%) cases, subclinical hypothyroidism in 1 case (1%), lymphocytic thyroiditis in 1 case (1%), toxic UNG in 1 case (1%), and euthyroid sickle syndrome in 1 case (1%) were determined. The patients were divided into 2 groups according to their Rai-stages and ages. Accordingly; Rai-stage 0 - I - II (n=80) and Rai-stage III - IV (n=20), <65 years (n=56) and ≥65 years (n=44). Anti-TPO positivity was similar in 2 Rai-stages groups and in both sexes (p=0.507, p=0.223, respectively). However, anti-TPO positivity was statistically different between age groups; anti-TPO was positive in 3 patients in <65 years old age group, and was positive in 7 patients in ≥65 years old age group (p=0.049). Anti-TG was positive in 7 patients in <65 years old age group,
and was positive in 11 patients in ≥65 years old age group (p=0.053). There was a statistically significant difference in thyroid function tests according to the Rai-stages, ages and sexes.

Summary/Conclusions: We determined that incidence of hypothyroidism or hyperthyroidism associated with all reasons do not increase in patients with CLL when compared with general population. However, we also determined that the incidence of Hashimoto thyroiditis was higher than general population (incidence of Hashimoto thyroiditis in general population is 2-5%). Anti-TG positivity was also higher than general population (positivity of anti-TG in general population is 5-20%). In addition, the positivity of 2 antibodies increased with advanced ages. Patients with CLL—especially the elderly cases— in both sexes and in all Rai-stages should be examined for thyroid gland disorders, mainly for Hashimoto thyroiditis.

PB1784

CLINICAL-BIOLOGICAL CHARACTERISTICS, TREATMENT OUTCOME AND SURVIVAL OF SMALL LYMPHOCYTIC LYMPHOMA PATIENTS: A REAL-LIFE EXPERIENCE

S. Sachanas1,2, G. Pangalis1, M. Moschogiannis1,3, K. Kalpadakis3, M. Angelopoulou3,4, C. Kyrtsonis3,5, V. Bartzi2, X. Yiakoumi1, E. Koulieris5,6, P. Tsirkinidis1, M. Psyllakis4, H. Papadakis3, K. Korkolopoulou6, D. Rontogiannis3, T. Vassilakopoulos1

1Hematologic, Athens Medical Center/Phychikon Branch, Athens, 2University Hospital, University of Crete, Heraklion, 3Hematologic, Laikon General Hospital, University of Athens, Athens, 4Hematologic, University Hospital, University of Crete, Heraklion, 5Pathology, Laikon General Hospital, University of Athens, 6Pathology, Evangelismos General Hospital, Athens, Greece

Background: Studies of B-SLL published to date have included heterogeneous groups of patients(pts) and did not use modern diagnostic criteria, or included pts who had in fact chronic lymphocytic leukemia. Outside the context of clinical trials, SLL pts are treated heterogeneously and thus there are no data concerning the impact of different treatment approaches on response and survival. In the updated WHO classification it is pointed out that there are a subset of cases with lymph node(LN) involvement by SLL in which proliferation centers(PCs) were not observed and pts in whom lymphadenopathy was <1.5 cm showing a better prognosis

Aims: To: a)record clinical, biological features and treatment strategy in a selected group of SLL pts diagnosed in our centers b)correlate clinicopathological characteristics and treatment with response and survival c)detect possible differences in terms of response and survival between SLL pts according to LN characteristics (size of LN and presence of PCs)

Methods: Pts diagnosed with SLL from 2007 up to now fulfilling the diagnostic criteria of SLL 2008 WHO classification were included. Clinical and biological data were recorded at diagnosis as well as treatment related variables, such as type of treatment, response and patient survival. Moreover, LN features such as the size, and the presence of PCs were also studied. PCs containing prolymphocytes and paraimmunoblasts, surrounded by a dark background of small lymphocytes.

Results: 47 pts were analysed. Pts median age was 69y (range, 40-87) with no gender predominance (24male/23female). According to Binet staging system 12, 19 and 9 were classified as A, B and C stage respectively while according to Ann Arbor staging system 26 (89%) had advanced disease stage. 11 pts presented with bulky lymphadenopathy, 11 had splenomegaly and 4 had B-symptoms. LN biopsies were performed in 37 out of 47 pts. All pts underwent bone marrow (BM) biopsy with a median BM infiltration of 45% (0-97%). Pts were identified in 19 out of 24 pts in whom data were available, while 31 pts were presented with LN >1.5 cm as measured in CT. The estimated 10 y -OS was 80% while median TFS was 5.3 mos. Age and ECOG performance status were the only parameters that were statistically significant in terms of survival (p=0.019 and p=0.013 respectively). Pts with LN≥1.5cm and pts in whom there were no detectable PCs tended to have better survival. 24 pts (51%) were in need of therapy and most of them were treated with oral drugs. System attraction: the study was proposed to 91 consecutive patients, independently of age, level of education and internet accessibility, and 72.5% of patients agreed to participate to the study. The main reason of refusal was older age and scant internet/technology knowledge. In 3 cases with no access to internet, but with interest to participate in the project, the questionnaires were administrated through tablet, before the scheduled visit, by a dedicated nurse. Patient compliance: a global response of 58.2% was observed; 48 patients responded at least once and 23 at all scheduled time points. In each case, all questionnaires were fully completed. At this timepoint we cannot yet evaluate system effectiveness as the study is still ongoing. However, ad interim data (Table 1) suggest that patients who interrupt questionnaires ful- filling are those with younger age, more intense working activity and experi- encing no changes in disease status (e.g. untreated cases or those in remis- sion). In particular, patients who were under treatment during the question- naire administration period, showed a higher adherence compared to those in follow up, both previously treated or not (80% versus 26%, p=0.05).

Summary/Conclusions: Outside the context of clinical trials SLL pts were treated mostly with lymphoma immunochemotherapeutic protocols while mild treatment approaches resulted in significant responses. LN features such as size and presence of PCs tended to have prognostic significance. Further analysis in larger series of pts is on the way.

PB1785

HEMSIGHT TO ASSESS PATIENT REPORTED OUTCOMES OF PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA IN DAILY CLINICAL PRACTICE

G. Reda1, B. Fattizzo1,2, R. Cassin1, E. Saluzzo2, E. Flesopherger2, V. Mattielo2, M. Sciume1, E. Ferretti1, C. Andersen3, E. Oliva4, A. Cortelezzii2

1Oncohematology Department, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Italy, 2Oncohematology Department, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Italy, 3Department of Hematology Roskilde University Hospital, Roskilde, Denmark, 4Azienda Ospedaliera “Bianchi Melacrinio Morelli”, Reggio Calabria, Italy, Reggio Calabria, Italy

Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, with a median age at diagnosis between 67 and 72 years. The therapeutic landscape of CLL is changing rapidly with the advent of small molecules acting as B-Cell Receptor (BCR) signaling inhibitors. In this setting, long term oral therapy may lead to the reduction in compliance, with a possible impact on effectiveness. Moreover, long-term follow-up may highlight complications, such as drug-related adverse events that, together with the disease itself, may impact quality of life (QoL). Patient Reported Outcomes (PROs) in daily clinical practice is a resource-intensive procedure and may be affected by low adherence, risk of recall bias and difficulties in establishing reproducible procedures. HemInsight, a project conceived in 2010 for myeloproliferative neoplasms in haematological centres in Denmark, enables patients to periodically submit PROs online to be combined to the medical records.

Aims: HemInsight was implemented at our Centre to collect PROs from CLL patients in daily practice.

Methods: HemInsight incorporated the EORTC QLQ-C30, EORTC QLQ-CLL 16, SF-36, and the eight-item Morisky Medication Adherence Scale (MMAS-8) questionnaires to collect PROs and their changes during various stages of CLL (diagnosis - progression – treatment). PRO assessments were scheduled for the patients who received regular reminders by email to complete the tasks. The following measurements will be assessed: system attraction (percentage of CLL patients adhering to the project); patient compliance in filling out questionnaires; system efficiency (number of alerts related to QoL worsening and number of questionnaires not submitted) and system effectiveness (significant differences in changes in QoL scores from diagnosis to response/relapse, changes of therapeutic approach/action following an alert, changes in adherence of therapy).

Results: At the time of the present report, 74 patients with a CLL diagnosis have been enrolled, 15 of whom were newly diagnosed. Fourteen patients underwent cytoreductive therapy and 2 are under treatment with novel oral drugs. System attraction: the study was proposed to 91 consecutive patients, independently of age, level of education and internet accessibility, and 72.5% of patients agreed to participate to the study. The main reason of refusal was older age and scant internet/technology knowledge. In 3 cases with no access to internet, but with interest to participate in the project, the questionnaires were administrated through tablet, before the scheduled visit, by a dedicated nurse. Patient compliance: a global response of 58.2% was observed; 48 patients responded at least once and 23 at all scheduled time points. In each case, all questionnaires were fully completed. At this timepoint we cannot yet evaluate system effectiveness as the study is still ongoing. However, ad interim data (Table 1) suggest that patients who interrupt questionnaires fulfilling are those with younger age, more intense working activity and experiencing no changes in disease status (e.g. untreated cases or those in remission). In particular, patients who were under treatment during the questionnaire administration period, showed a higher adherence compared to those in follow up, both previously treated or not (80% versus 26%, p=0.05).

Summary/Conclusions: In conclusion, HemInsight is a useful tool for QoL evaluation in CLL patients. Provisional data suggest a higher compliance of those patients who feel that they need a closer contact with the clinician, both for individual disposition or disease status.

Table 1.
PB1786
HEALTHCARE COST OF MEDICARE PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
C. Reyes1,*, G. Gauthier2, L. Schmerold1, A. Guerin2
1Genentech, Inc., San Francisco, United States, 2Analysis Group, Inc., Montreal, Canada, 3Analysis Group, Inc., New York, United States

Background: Chronic lymphocytic leukemia (CLL) is the most prevalent form of leukemia in industrialized countries, accounting for 20% to 30% of all leukemia cases. CLL affects mainly elderly patients, with a median age at the time of diagnosis reported to be 71 years. Although CLL is not curable, disease symptoms and progression may generally be controlled with adequate pharmacologic treatments. Bendamustine-based regimens have long been used in the management of CLL patients but few studies have analyzed the comorbidity- and/or adverse event (CAE)-related healthcare costs in elderly patients receiving these regimens in a real-world setting.

Aims: To describe all-cause and CAE-related healthcare costs of elderly patients with CLL treated with a bendamustine-based regimen in second or later lines of therapy in a real-world setting.

Methods: A retrospective cross-sectional cohort study design was used. Adult patients who received a bendamustine-based regimen in second or later lines of therapy on or after January 2010 were identified from the Medicare Limited Data Set (LDS) 5% Standard Analytic Files (data availability: 1999–2014). The index cohort was defined as the index date for the first of the studied bendamustine-based regimens. Selected patients were required to be continuously enrolled in their Medicare plan for ≥6 months before and ≥3 months after the index date – unless the patient died during the first 3 months after the index date. Patient cohorts were determined based on the treatment initiated on the index date: (1) rituximab monotherapy (BR cohort) and (2) bendamustine monotherapy (bendamustine cohort). Healthcare costs, including inpatient, emergency room, outpatients and CLL-drug costs, incurred while treatment with the index treatment were described for each cohort. For each medical cost component, all-cause and CAE-related costs were summarized. Healthcare costs were adjusted for inflation (2016 USD) and reported per-patient-per-month (PPPM).

Results: A total of 275 patients were included in the BR cohort and a total of 100 patients in the bendamustine cohort. Most patients (61.8% in the BR cohort and 65.0% in the bendamustine cohort) were male and the mean age was approximately 75 years old. During the 6 months prior to the index date, patients in the BR and bendamustine cohorts were similar in terms of comorbidity profile; mean Charlson comorbidity index was 3.53 in the BR cohort versus 3.68 in the bendamustine cohort (p=0.58). During treatment in total all-cause healthcare costs were $14,520 PPPM for the BR cohort and $13,125 PPPM for the bendamustine cohort – outpatient costs (mainly driven by CLL-drug costs) represented the largest cost component. CAE accounted for a relatively large portion of the total all-cause healthcare costs; 58.3% for the BR cohort and 66.9% for the bendamustine cohort.

Summary/Conclusions: In this population of elderly patients previously treated for CLL, healthcare costs incurred during relapsed treatment with bendamustine-based regimens were high and a large portion of the costs were driven by comorbidity and/or adverse event-related costs. Results also suggest that the addition of rituximab to bendamustine does not appear to be a major cost factor.

PB1787
THE ROLE OF MAINTENANCE THERAPY IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
A. Kuvshinov1,*, S. Voloshin1, I. Martynek1, A. Garifullin1, E. Kleina1

1Russian Scientific Research Institute of Hematology and Transfusionology, Saint-Petersburg, Russian Federation

Background: The inclusion in the treatment program of new drugs (including new monoclonal antibodies and targeted therapies) allowed the majority of patients with chronic lymphocytic leukemia (CLL) to achieve disease remission (complete or partial) after combined therapy. So, at now, the urgent task is long-term preservation and the deepening of the therapeutic response, if it is possible.

Aims: To achieve increasing the depth of remission and increase the duration of its preservation. MT may be a means of control over the minimal residual disease and the method of its eradication.

Methods: The conducting of MT with patients with CLL allows to achieve increasing the depth achieved remission and increase the duration of its preservation.

PB1788
MULTISITE PERFORMANCE EVALUATION STUDY OF THE BD ONEFLOW LYMPHOID SCREENING TUBE
B. Balasa1,*, C. Green2, J. Kendall2, D. Gladding2, C.J. Fox2, D. Van Hoof2, V. Fraser2, A. Doherty3, D. Tielemans4, L. Wolfe5, K. Judge6
1Medical Affairs, 2BD Biosciences, San Jose, United States, 3BD Biosciences, Oxford, United Kingdom, 4BD Life Sciences, Erembodegem, Belgium, 5BD Clinical Corporate Critical Development, Sparks, Maryland, United States

Background: The BD OneFlow solution for diagnostic screening of chronic lymphoproliferative disorders (CLPDs) includes a standardized flow cytometry approach based on the EuroFlow (EF) Consortium liquid reagent system. The BD OneFlow solution enables reproducible identification and discrimination of normal from aberrant mature cell populations by combining standardized assays, setup reagents, and protocols. The BD OneFlow LST (Lymphoid Screening Tube) is intended for flow-cytometric immunophenotyping of normal and aberrant mature lymphocyte populations of B, T, and NK lineages in specimens (peripheral blood, bone marrow, and lymph node) from patients with hematological disorders. BD OneFlow LST acquisition and analysis template version 1.0 was revised to version 2.0 to include determination of lymphocytes as a percentage of total leukocytes. The FCS files from evaluable specimens of the original LST clinical trial were retrospectively used to assess the BD OneFlow LST v2.0.

Aims: The objective of this study was to reprocess the FCS files from all the evaluable specimens previously collected using LST template v1.0 in the original clinical study to demonstrate equivalency between the investigational BD OneFlow LST system and the comparator EF liquid reagent system on a BD FACSCanto II flow cytometer with the 4-2H-2V CE-IVD configuration and LST template v2.0.

Methods: The FCS files using LST v1.0 template from the original clinical study included de-identified remnant peripheral blood (n=123), bone marrow (n=53), and lymph node (n=31) specimens from patients and healthy donors. Specimens were analyzed using BD OneFlow LST template v2.0.
were collected in EDTA or heparin anticoagulants or PBS (for lymph nodes) at three external study sites. Informed consent was not required in this clinical study. All specimens in the original study were simultaneously stained with investigational BD OneFlow LST and comparator EF liquid reagents within 24 hours of collection and were acquired within 60 minutes of staining. In the current study, analyses were performed on a BD FACSCanto II instrument using LST v2.0 template and BD FACSDiva software version 6.0.1. For all endpoints, specimens were categorized as normal or follow-up needed. If follow-up was needed, specimens were categorized as B-, T-, NK-, or other-cell lineage. Overall agreement, negative agreement, and positive agreement, along with their one-sided lower 95% confidence limits, were calculated. For quantitative (percent) comparison of defined cell populations, Deming regression (slope and intercept analysis) was performed between the BD OneFlow method and the EF method.

Results: The BD OneFlow LST system compared to the EF system gave 100% (207 of 207) overall agreement (lower 95% CI: 98.6%) in delineating patients into normal (no follow-up) or follow-up, and 100% overall agreement in identifying B-, T-, and NK-types of each immunoglobulin class. For all cell lineages, the BD OneFlow and EF methods agreed for follow-up vs no-follow-up (normal) and for all cell lineages from specimens that required follow-up. Furthermore, compared to the BD Hematological System, the BD OneFlow LST system met the acceptance criteria for the quantitative comparison (Deming regression) of the defined cell populations.

Summary/Conclusions: The multisite performance evaluation of the BD OneFlow LST system and the comparator EF liquid reagent system was consistent in identifying abnormal from normal mature populations in patients with CLPDs. BD OneFlow LST is fit for in vitro Diagnostic Use. CE Marked to the European in Vitro Diagnostic Medical Device Directive 98/79/EC. 23-19566-00.

PIB1789

IMMUNOGLOBULIN HEAVY/LIGHT CHAIN ASSAY DETECT IMMUNE DYSREGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

L. Magal1, A. Braester2, D. Najibi2, A. Avivi3, Y. Herishanu5, M. Yukle4a, L. Shvidel7, N. Rahimi-Levene9, R. Ruchheimer9, A. Arad10, A. Pollack10, J. Tadmor11

1Almog Diagnostic, Park Shoham, 2Hematology Unit, Galilee Medical Center, Nahariya, 3Hematology Unit, Ziv, Medical Center, 4Hematol. 5Medical Center, Haemek Medical Center, Afuila, 6Department of Hematology, Soursky Medical Center, Tel Aviv, 7Hematology Unit, Meir Medical Center, Kfar Saba, 8Hematology Unit, Kaplan Medical Center, Rehovot, 9Hematology Unit, Assaf Harofeh Medical Center, Zerifin, 10Department of Hematology, Shaare Zedek Medical Center, 11Department of Hematology, Hadassah University Hospital, Jerusalem

Background: Chronic lymphocytic leukaemia (CLL) is frequently accompanied by immune dysregulation. Hypogammaglobulinaemia is the most important associated immune defect and all three classes of immunoglobulins (IgG, A and M) are involved. Recently, a novel assay for detecting heavy/light chain (hevy/light) and their ratios has been described (HLC), which improves immunoglobulin detection and monitoring in plasma-cell dyscrasias by quantitating the different light chain types of each immunoglobulin class. The frequency and biological role of this assay has as yet not been studied in CLL.

Aims: To study the frequency of abnormal Heavy Light chain assay, in CLL patients.

Methods: This is an observational, multi-center study performed in collaboration with the Israeli CLL Study Group involving 10 medical centers in Israel. The cohort included patients with CLL as well as healthy volunteers. All patients studied had complete clinical database available and all medical records were examined and then summarized. Serum samples were analyzed for levels of: IgG1, IgG2, IgG3, IgG4, IgA kappa, IgA lambda, IgM kappa, IgM lambda and Free light chain: kappa (K) and lambda (L) ratio of K/L and calculation of ratios of monoclonal/polyclonal immunoglobulin (HLC ratio).

Results: The total cohort consisted of 126 “treatment-naive”, patients with CLL and 26 healthy volunteers. Mean age was 64 years, 64% were males and 78% and Binet stage A, while 19% and 3% were stages B or C respectively. Significant number of patients had hypogammaglobulinemia identified. The HLC assay was identified in 122 patients (96.9% CI: 98.6%). Thrend Binet stage and elevated LDH levels. Abnormal lambda FLC was observed 26 (21%) patients and only in one (4%) healthy control. Abnormal free light chain ratio (FLC) was present in 39 patients (32%), with a mean value of 4.22 (0.11-62.15) while only 1 (4%) was observed in healthy controls (mean value of 1.76 (0.25-2.3)) and was associated with more advanced Binet stage and elevated LDH (p=0.003).

Summary/Conclusions: CLL cells may produce light chains, or as shown here abnormal intact immunoglobulins (heavy and light chains). HLC levels were associated with advanced stage and adverse prognostic parameters. These findings lend support for the considerable potential of the HLC assay in the evaluation of clinical status in patients with CLL.

PIB1790

INFLUENCE OF TREATMENT ON CONCENTRATION OF CYTOKINES IN BLOOD OF PATIENTS WITH HAIR CELL LEUKAEMIA

N. Pelemyi1a, B. Barinka1a, V. Matlani2, O. Danysh1, Y. Vtygvska1a, Z. Maslyk1, G. Loginsky1, V. Loginsky1

1SI “Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine”, 2Danylo Halytsky Lviv National University, Lviv, Ukraine

Background: A pathogenic role and prognostic value of cytokines in treatment of patients (pts) with hairy cell leukaemia (HCL) are not finally established. Aims: to define the concentration of cytokines such as TNFa, IL-6, sIL-2R, TGFβ1 in serum of HCL pts before and after treatment with IFNα or 2-CdA and to estimate the relationship with blood count indexes in HCL pts.

Methods: The study group consisted of 26 primary pts with the classic variant of HCL (median age - 47 years). A control group consisted of 12 healthy persons (median age - 50 years). The concentration of cytokines was measured using a validated commercial ELISA kits.

Results: Median of TNFa content in serum of HCL pts before treatment was substantially lower (3.57 pg/ml) than in healthy persons (8.56 pg/ml; p=0.275), however levels of IFNα for IFNα or 2-CdA did not influence TNFa level. Median of TGFβ1 concentration in serum of HCL pts was also significantly lower, than in healthy persons (265.52 and 156.82 pg/ml respectively; p=0.0004). Reliable increase of TGFβ1 concentration was observed only after 2-CdA therapy (928.33 pg/ml; p=0.281). Cross-correlation relationship was revealed between the TGFβ1 concentration and the level of haemoglobin (r=0.23; p=0.1) as well as with leucocyte count in HCL pts (r=-0.24; p=0.09). Median of IL-6 content in serum of HCL pts before treatment was higher, than in healthy persons. Ther- apy with IFNα or 2-CdA reduced IL-6 level to the control values. Certain cross-correlation relationships were revealed between the IL-6 level and percentage of lymphocytes in bone marrow (r=-0.24; p=0.01). On the other hand - a considerable amount of lympho- cytes in peripheral blood of HCL pts (r=0.24; p=0.09). Median serum concentra- tion of sIL-2R (24.73 ng/ml) in HCL pts more than 20-fold exceeded such control group (1.15 ng/ml; p=0.0000005). Cross-correlation relationship was revealed between the percentage of hairy cells in bone marrow and sIL-2R level in serum (r=-0.27; p=0.08). Obtained results may be an evidence of pre-dominant secretion of sIL-2R by tumor cells in HCL pts.

Summary/Conclusions: New data regarding pathogenetic relationship between production of certain cytokines and features of hematopoiesis in HCL pts was obtained. Between the blood level of some cytokines in HCL pts and efficiency of treatment a relationship was revealed, which is possible to use for prediction of clinical course of this disease. Moreover sIL-2R level in blood possibly can serve as a marker of tumour activity in classic type of HCL.

PIB1791

PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA – CLINICAL BENEFITS OF ACHIEVING A DEEP RESPONSE TO FIRST-LINE THERAPY

J. Samp1,*, A. Guerin2, R. Foster3, B. Meissner1, A. Rokito3, S.H. Enschede1, G. Gauthier2

1AbbVie, Inc., North Chicago, United States, 2Analysis Group, Inc., Montreal, Canada, 3Analysis Group Inc., New York, United States

Background: In recent years, there have been advances in the treatment of CLL with the approval of several novel oral agents that show improvement in PFS and OS. Additionally, some agents induce a deep response indicated by complete remission (CR) and/or minimal residual disease negativity (MRD-). However, there is limited data on the benefits of achieving a deep response in a real-world setting.

Aims: This study aimed to characterize PFS and OS for patients who achieved a deep response to first-line therapy for CLL.

Methods: Patient-level data were collected between July and August 2016 from 33 oncologists/hematologists in the United States. Oncologists/hematologists provided patient level clinical data obtained from patient charts among CLL patients who initiated first-line therapy for CLL between January 2010 and December 2014. Selected patients were categorized into 2 cohorts based on their best response; patients who achieved CR and patients who did not achieve CR (non-CR). The non-CR cohort included patients with partial remis- sion (PR), stable disease (SD) and progressive disease (PD). iwCLL 2008 cri- teria were provided to guide physicians’ assessment of treatment response. The target sample size for each response type was a priori determined based
on distribution of response in clinical trials. Data on disease progression and mortality was provided by the treating oncologist/hematologist. PFS and OS were compared using univariate and multivariate Cox proportional analyses between the CR and non-CR cohorts (OS multivariate analyses were not conducted due to the small number of events). An additional analysis was conducted to examine the benefits of achieving MRD- versus not achieving MRD among patients who achieved CR or PR. Results: Data was collected on 330 CLL patients, including 179 patients in the CR cohort and 151 patients in the non-CR cohort (120 patients with PR, 25 with SD, and 6 with PD). Most patients were male, in their early sixties, and had an ECOG status of 0/1 at the time of initiating first-line therapy. The median observation period was approximately 30 months. There were 43 (24%) patients in the CR cohort and 75 (50%) patients in the non-CR cohort who progressed/died (Table 1). Patients in the non-CR cohort had an >2-fold higher hazard of progression/death (adjusted hazard ratio [HR]=2.30, p<0.05) and death (unadjusted HR=2.61, p<0.05) compared to patients in the CR cohort. Among patients who achieved CR or PR, 84 patients achieved MRD- and 62 patients did not; 14 (17%) patients who achieved MRD- and 27 (44%) patients who did not achieve MRD- progressed/died. Patients who did not achieve MRD had an over three-fold higher hazard of progression/death compared to patients who achieved MRD- (adjusted HR=3.75, p<0.05). No death events were observed among patients who achieved MRD- while 4 (6%) events were observed among those who did not achieve MRD-.

Table 1

Summary/Conclusions: Findings from this real-world study suggest that achieving CR is associated with improved PFS and OS compared to patients who do not achieve CR. Furthermore, significantly better outcomes were observed among patients who achieved MRD- compared to those who did not achieve MRD- but still achieved CR or PR. This suggests that deep response may be an important clinical parameter to consider in the treatment of CLL.

PB1792

ANTICD ANTIBODY MICROARRAY FOR MORPHOLOGY EXAMINATION OF CIRCULATING LEUKEMIA AND LYMPHOID CELLS

S. Kuznetsova1,2,*, A. Khvastunova1, A. Zakirova1, O. Fedyanina1,2, S. Pavlovic3, B. Mihaljevic1,2

1Centre for Pediatric hematology, oncology and immunology, 2Centre for theoretical problems of physico-chemical pharmacology, Moscow, Russian Federation

Background: Matching the morphology with immunophenotype for individual leukocytes is a major issue in diagnostics of leukemia and lymphoma due to the absence of a method for simultaneous cluster of differentiation surface antigen detection and full leukocyte morphology analysis. This problem can be solved by using a leukocyte-binding antibody microarray.

Aims: We describe an anti-CD antibody microarray on a transparent support for leukocyte sorting and a method for preparation of the microarray-bound cells for high-resolution morphology analysis. The aim of the work was to demonstrate, that the leukocyte binding is highly specific and that the microarray-bound peripheral blood mononuclear cells both from healthy donors and patients with B-cell leukemias and lymphomas are morphologically identical to the same cells in blood smears.

Methods: Anti-CD antibodies were immobilised on plastic coverslips in spots 2 mm in diameter. In order to study the peripheral blood mononuclear cells (PBMC) for the mononuclear fraction separated by density gradient from peripheral blood are incubated with the microarray in non-mixing conditions at 4°C. After the unbound cells are washed away the microarray-bound cells are dried in a cytocentrifuge and stained after May-Grünwald-Giemsa for morphology examination. Using this technique we have studied the PBMC from 56 healthy donors and 77 patients with leukemias and lymphomas: chronic lymphocytic leukemia (CLL, 37 patients), hairy cell leukemia (HCL, 22 patients), splenic marginal zone lymphoma (SMZL, 7 patients), mantle cell lymphoma (MCL, 2 patients), follicular lymphoma (FL, 1 patient), 5 patients with multiple myeloma (MM), 2 patients with large granulocytic lymphoma (LGL) leukemia and one patient with acute myeloid leukemia (AML)2.

Results: Non-specific cell binding both inside and outside the spots is below 5%. Due to the non-mixing incubation the density of the cells bound to an anti-CD antibody permits to determine the proportions of cells positive for the corresponding CD antigen with high correlation with flow cytometry. The patterns of the binding densities of the anti-CD-captured PBMC for CLL, HCL and SMZL patients clearly differ both from those for normal PBMC and from each other and agree well with the reported immunophenotypes of corresponding neoplastic cells. Both normal and pathologic microarray-bound PBMC after the proprietary drying procedure are morphologically identical to the same cells in a smear. In cases when pathologic cells are morphologically and/or cytochemically distinct, the anti-CD antibody microarray permits to determine their percentage and immunophenotype by analysing the relative amount of these cells captured by the antibodies against all the CD antigens. The results of such analysis of neo-plastic PBMC for the patients with leukemias and lymphomas agree with flow cytometry results for the same patients including CLL, HCL, and CD2 and CD11c in CLL. CD56 in MM. The amount of hairy cells determined morphologically on the microarray varied from 20 to 97% of all anti-CD19-captured cells and 2 to 80% of all lymphocytes and was in good agreement with the percentages of cells with CD19/CD103 and CD19/CD11c coexpression determined in the peripheral blood of the same patients by flow cytometry.

Summary/Conclusions: The microarray works as a “sorted smear” with cells positive for certain surface CD antigens localised in a predetermined area and permitting to apply any standard smear-oriented technique to the microarray-captured cells. Combined analysis of the pathologic cells’ immunophenotype, cytochemistry, and cytochemistry-immunophenotyping permits to perform complete blood cell examination and can be used in cases of any controversies between morphology, cytochemistry and immunophenotyping. The work is partially supported by 16-34-01030 and 16-04-00282 grants from RFBR.

PB1793

COMPARATIVE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA, PROGRESSION-RISK SCORE AND MD ANDERSON CANCER CENTER 2011 SCORE: REAL WORLD DATA FROM A SINGLE INSTITUTION

V. Vukovic1,2, A. Antic1,2, T. Karan-Djurasevic3, N. Milic4, M. Todorovic-Balint1,2, J. Djurasic1,2, V. Djurasicovic1,2, A. Sretenovic1, M. Smajilovic1, J. Belicic1, M. Dencic-Fekete1, M. Perus-Jenic-Kolic1, N. Krajacic-Kovacic1, S. Pavlovic3, B. Mihaljevic1,2

1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, University of Belgrade, 3Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, 4Institute for Medical Statistics and Informatics, Medical Faculty, University of Belgrade, Belgrade, Serbia

Background: In recent times, several powerful prognostic scores have been developed in order to predict to first treatment (TTFT) and overall survival (OS) of patients with chronic lymphocytic leukemia (CLL). Within the context of international prognostic index for chronic lymphocytic leukemia (CLL-IPI) developed by The International CLL-IPI working group was found to predict OS and TTFT, while the rest of two scores- progression-risk score (PRS) and MD Anderson Cancer Center Score 2011 (MDACC 2011) have been developed for prediction of TTFT in early stage CLL patients.

Aims: The aim of this study was to compare CLL-IPI, PRS and MDACC 2011 prognostic scores based on their impact on TTFT, treatment response (TR), progression-free survival (PFS) and OS of 54 treated CLL patients.

Methods: We retrospectively analyzed data from 54 consecutive CLL patients diagnosed and treated at Clinical Center of Serbia, Clinical Center Score 2011 (MDACC 2011) have been developed for prediction of TTFT from 2003 to 2013. Blood samples were prospectively collected and analyzed for clinical and laboratory parameters. The three scores were retrospectively calculated using formulas from the original articles (International CLL-IPI working group, Lancet 2007), for CLL-IPI, published in 2010, for PRS, and Villers et al, J Clin Oncol 2011, for MDACC 2011 score), and, then, correlated with TTFT, TR, PFS and OS of patients from the studied cohort.

Results: Median age at diagnosis was 57 years (range 38-75). All patients were treated with fludarabine-based chemotherapy, 45% (83) in the first treatment line. Overall response rate to the first line therapy was 81%, equally distributed on complete and partial responses. Most of the patients (42, 78%) relapsed during the follow up. At the time of the last follow up 14 (26%) patients were still alive, 35 (65%) were dead, and 5 (9%) were lost to follow up. Median overall survival was 76 months. Lower score values for all the three scoring systems (CLL-IPI, PRS, and MDACC 2011) correlated with longer TTFT (p<0.05 for all). Cox regression analysis revealed that CLL-IPI and PRS are significant predictors of TTFT (p=0.003, RR=1.4, 95%CI 1.1-1.7 and p=0.019, RR=1.4, 95%CI 1.1-1.9, respectively), while MDACC 2011 was of borderline significance (p=0.052). In the multivariable analysis PRS emerged as the most significant predictor of TTFT among the three examined scores (p=0.041, RR=1.35, 95%CI 1.01-1.81). Regarding TR, only PRS appeared to have borderline statistical significance (p=0.052), showing that patients with lower score value may achieve better TR. Lower CLL-IPI can predict longer PFS after the first line treatment (p=0.007, RR=1.7, 95%CI 1.2-2.57), as well as PRS (p=0.039, RR=1.35, 95%CI 1.03-1.72) and MDACC 2011 (p=0.012, RR=1.4, 95%CI 1.01-1.91). MDACC 2011 has not shown to have influence on PFS. Multivariable analysis confirmed PRS to have the strongest predictive value of all the three scores regarding duration of PFS (p=0.039, RR=1.8, 95%CI 1.02-3.1). Furthermore, CLL-IPI and PRS were found to be significant predictors of OS (p=0.005, RR=1.4, 95%CI 1.1-1.8 and p=0.037, RR=1.5, 95%CI 1.02-2.34), respectively. MDACC 2011 was not shown to have influence on OS.

Summary/Conclusions: CLL-IPI and PRS were identified as significant predictors of TTFT, as well as of duration of TR and OS. Further studies are warranted to confirm these findings.
MULTISITE PERFORMANCE EVALUATION STUDY OF THE BD ONEFLOW B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS T1 (B-CLPD T1) PANEL
B. Rukavina1,*, C. Green2, J. Kendall2, D. Gladding2, I. Racoma2, D. Van Hoof2, F. Oreliz2, A. Chen3, V. Fraser2, A. Doherty3, D. Tieleman3, L. Wolfe4, K. Judge1
1Medical Affairs, 2BD Biosciences, San Jose, United States, 3BD Biosciences, Oxford, United Kingdom, 4BD Life Sciences, Erembodegem, Belgium, 5BD Clinical Corporate Development, Sparks, Maryland, United States

Background: The BD OneFlow solution for B-cell chronic lymphoproliferative diseases (B-CLPDs) incorporates a standardized flow cytometry approach based on the EuroFlow (EF) Consortium liquid reagent system. The BD OneFlow solution enables reproducible identification and discrimination of distinct B-cell populations by combining standardized assays, setup reagents, and protocols. The previously launched BD OneFlow LST (Lymphocyte Screening Tube) is intended for flow-cytometric immunophenotyping of normal (no follow-up required) and aberrant (follow-up required) mature lymphocyte populations of B, T, and NK lineages in specimens from patients with hematological disorders. The BD OneFlow B-CLPD T1 is being developed to work in conjunction with BD OneFlow LST for the immunophenotyping of B cells and distinguishing chronic lymphocytic leukemia (CLL) from other B-CLPDs such as atypical CLL, follicular lymphoma, mantle cell lymphoma, etc.

Aims: The objective of this study was to demonstrate equivalency (accuracy) between the investigational BD OneFlow LST and BD OneFlow B-CLPD T1 system and the corresponding comparator EF liquid reagent system on the BD FACSCanto II flow cytometer using BD FACSDiva software.

Methods: De-identified remnant peripheral blood (PB) (n=70) and bone marrow (BM) (n=31) patient specimens were collected in EDTA or heparin anticoagulants at four external study sites and tested within 26 hours of draw. Informed consent was not required in this clinical study. Specimens were stained with BD OneFlow LST in combination with OneFlow B-CLPD T1 tubes and comparator EF liquid reagents. Acquisition and analysis were performed on a BD FACSCanto II instrument using BD OneFlow LST and B-CLPD T1 template in BD FACSDiva software v8.0.1. Categorization of samples with normal B-cell populations into CLL (typical) or other B-CLPDs, overall agreement, negative agreement, and positive agreement, along with their one-sided lower 95% confidence limits, were calculated. For qualitative categorization of relative fluorescence intensity (positivity or negativity) of the aberrant cell populations, overall agreement with one-sided lower 95% confidence limits was calculated.

Results: All evaluable specimens were identified by the OneFlow LST as having B-cell populations requiring follow-up by both methods. Compared to the EF system, the BD OneFlow LST in combination with the BD OneFlow B-CLPD T1 system (n=101) gave 100% (101 of 101) overall agreement in classifying patients as having CLL (54 of 54 concordant) and in identifying patients with other B-CLPD diseases (47 out of 47 concordant) with a lower 95% CI of the overall agreement of 97.4%. The BD OneFlow B-CLPD T1 system, compared to the EF system, gave 100% (101 of 101) concordant agreement for the qualitative assessment of abnormal (positive) and normal B-cell populations, overall agreement with one-sided lower 95% confidence limits was calculated.

Summary/Conclusions: The multisite performance evaluation between the BD OneFlow system (LST and B-CLPD T1) and the comparator EF system in specimens from patients with CLL from other B-CLPDs, including presumptive cases of atypical CLL. The BD OneFlow B-CLPD T1 is a fully standardized and validated system for aiding in the diagnosis of CLL from other B-CLPDs in PB and BM specimens.

PB1795
COMBINED PATTERNS OF IGHV REPERTOIRE AND MOLECULAR ALTERATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA- SINGLE CENTER EXPERIENCE
S. Bakalova1,*, L. Cevreska1, A. Dimovski2, M. Ivankovski1, M. Popova-Labacevska1, D. Dukovski1, B. Kocosi1, I. Panovska-Stavridis1
1Hematology, University clinic for Hematology, 2Faculty of Pharmacy, University “Ss. Cyril and Methodius”, Skopje, Macedonia, The Former Yugoslav Republic Of

Background: The specific determining factors for malignant progression in Chronic lymphocytic leukemia (CLL), remaining unknown.

Objectives: To investigate the potential existence of unique cytogenetic profiles associated with specific IGHV gene repertoires that could be associated with an increased risk of progression in CLL.

Methods: For this purpose, molecular analysis of well-established cytogenetic alterations of chromosomes 11, 12, 13, 14 and 17 together with the pattern of rearrangement of the IGHV genes were performed in 100 CLL cases.

Results: Our results based on molecular analysis from 100 subjects living in the same geographical area, show the presence of three major groups of clones with distinct but partially overlying configurations of IGHV gene usage, IGHV mutational status and cytogenetic alterations. These included a group which mainly consisted of clinical advanced stage CLL with a skewed but different IGHV-associated IGHV gene repertoire (VH1-69 associated with HD3 gene and H64 gene) which is frequently associated with complex karyotypes and poor-prognosis cytogenetic alterations, a second group enhanced in clones expressing specific IGHV subgroups (VH3-23 associated with HD2 genes and HJ6 gene) with no or isolated good-prognosis cytogenetic alterations and a third group of clones with intermediate features, with prevalence of mutated IGHV genes, and higher numbers of del(13q)+ clones.

Summary/Conclusions: These findings suggest that the specific IGHV repertoire and IGHV mutational status of CLL B-cells may adjust the type of cytogenetic alterations acquired and their clinical significances. Further long-term follow-up studies investigating the IGHV gene repertoire of CLL clones in distinct geographic areas or microenvironments are required to validate our findings and discard or confirm the potential role of some antigen-binding BCR specificities contributing to clonal evolution.

PB1796
PROGNOSTIC SIGNIFICANCE OF SERUM BAFF, APRIL, TACI AND BCMA LEVELS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
I. Barke Mentese1,*, Z.A. Yeging2, S. Goksen3, Z.N. Ozkok4, M. Yagci2
1Internal Medicine, 2Hematology, Gazi University Faculty of Medicine, Ankara, Turkey

Background: B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of CD5+ B cells in the peripheral blood and bone marrow. Prognosis of B-CLL is highly variable which depends on certain prognostic parameters. Novel prognostic markers and risk assessment models are fundamental to identify high risk patients who may need early treatment. The two tumour necrosis factor family proteins BAFF (TNFSF13B) and APRIL (TNFSF13) and their receptors [BAFF-R (TNFRSF13C), TACI (TNFRSF13B), BCMA (TNFRSF17)] play a critical role in the survival of normal B cells.

Aims: In this study, we aimed to investigate the impact of serum BAFF, TACI, APRIL and BCMA levels on prognosis of B-CLL.

Methods: A total of 129 newly diagnosed CLL patients [median age: 64 (39-88); M/F: 85/44] and 26 healthy volunteers were enrolled in this study. Serum BCMA, TACI, BAFF and APRIL levels were measured at diagnosis using enzyme-linked immunosorbent assay (ELISA). The association with conventional prognostic markers and impact on survival were evaluated.

Results: Serum BAFF, TACI and BCMA levels were significantly lower in the patient group (p=0.05) (Table 1). Serum BAFF [(p=0.008; r=0.236)] and BCMA [(p=0.042; r=0.183)] levels were negatively correlated with Rai stage and serum BAFF level was higher in low-risk patients based on modified Rai staging system (p<0.05). The CD38 positive patients (p=0.06; 0.17(0.1-0.86) vs 0.13(1.0-1.07)). Age (p=0.002), Rai stage (p=0.05) and Modified Rai stage (p=0.051) were the significant factors which had an impact on overall survival in multivariate analysis.

Table 1.
Background: Constitutive activation of B-cell receptor signalling appears to be essential for the proliferation of malignant B cells. Bruton’s tyrosine kinase (BTK) has been identified as an essential component of the B-cell receptor signalling pathway. Ibrutinib is an orally administered BTK inhibitor that antagonises B cell receptor, chemokine & integrin mediated signalling.

Aims: We report our experience of using ibrutinib to treat relapsed/refractory B-cell chronic lymphocytic leukaemia (B-CLL) and mantle cell lymphoma (MCL) in a busy U.K. District General Hospital (DGH) serving a population of 600,000.

Methods: 26 patients were commenced on ibrutinib for relapsed/refractory B-CLL or MCL between August 2014 & December 2016. 16 patients had B-CLL and 10 patients had MCL. Patients with B-CLL were commenced on 420mg daily; those with MCL received 540mg daily. The median age at which ibrutinib was commenced was 71.1 years (range 50-85). The median age of patients with B-CLL was 71.1 years (range 50-80) and for MCL was 71.6 years (range 54-85). The median number of prior lines of therapy decreased over the time period from 3.2 in 2014 to 1.2 in 2016. The mean interval between diagnosis and first ibrutinib treatment was 6.3 years (B-CLL) and 6.5 years (MCL). The average number of co-morbidities in both groups was similar: 1.4 in B-CLL and 1.5 in MCL. After May 2015 all patients received aciclovir and co-trimoxazole prophylaxis. Response to ibrutinib was assessed by clinical examination and blood results; imaging and bone marrow examination were conducted at the clinician’s discretion.

Results: The median follow up was 15.5 months for B-CLL patients and 8 months for MCL patients. The median survival of all patients who did not receive anti-viral and pneumocystis prophylaxis was 5 months and the median survival for those who did receive prophylaxis was not reached (p=0.0001). The median survival of patients who received ibrutinib treatment was 17 months; the median survival in those who had received just one prior line of treatment was not reached (p=0.0085). In the B-CLL cohort there was no difference in survival between those with and without 17p/p53 deletion. 11/26 patients experienced side effects: 8 had grade 1 and 2 side effects (diarrhoea, drug rash, cardiac arrhythmias) which were easily controlled. 3 patients had grade 4 side effects (1 severe arthropathy, 2 intracranial haemorrhage - one of which was fatal). 4 of the 16 (25%) with B-CLL and 5 of the 10 (50%) with MCL died during the period of follow-up. Causes of death were: intra-cerebral haemorrhage (1), unrelated cancer (1), disease progression (2), disease progression +sepsis (2), sepsis alone (3). Of the remaining 17 patients, 14 continue to receive ibrutinib, 2 (B-CLL) were switched to idelalisib+Rituximab (for grade 4 toxicity) & 1 went on to have an allogeneic transplant (MCL).

Summary/Conclusions: Though our cohort of patients is small, our experience shows that the use of prophylaxis with co-trimoxazole and aciclovir is associated with improved overall survival. Moreover, patients who received fewer lines of prior treatment had a better survival. Patients with 17p/p53 deleted B-CLL responded as well as those without a deletion. Ibrutinib is a very effective therapeutic option in patients with relapsed CLL and MCL.

PB1799
THE VALUE OF RITUXIMAB ADDITION TO CHEMOTHERAPY TREATMENT OF REAL-WORLD CLL PATIENTS: A 15 YEAR SINGLE CENTER EXPERIENCE
L. Van Der Straten1,*, A.G. Dinmohamed2,3,4, J.K. Doorduijn2, P.E. Westerweel1, A.W. Langerak2,3, A.P. Kater1, M.-D. Levin1
1Internal Medicine, Albert Schweitzer Hospital, Dordrecht, 2Haematology, Erasmus Medical Center, Rotterdam, 3Research, Netherlands Comprehensive Cancer Organization, Utrecht, 4Immunology, Erasmus Medical Center, Rotterdam, 5Haematology, Academic Medical Center, Amsterdam, Netherlands

Background: The addition of the monoclonal antibody rituximab to chemotherapy has been shown to improve progression free survival and overall survival in prospective trials in CLL patients. However, CLL patients participating in clinical trials may not be fully representative of the overall patient population in clinical practice as there is selection due to study availability, willingness to participate and various in- and exclusion criteria. To date, the efficacy of rituximab added to standard chemotherapy in first line and relapsed CLL patients has been poorly validated in observational studies in unselected real-world CLL patients.

Aims: To evaluate the efficacy of rituximab-chemotherapy (R-CTX) compared to chemotherapy (CTX) in a real-world CLL population.

Methods: All patients from a large teaching hospital diagnosed with immunophenotypically confirmed CLL in the period from 1-1-2000 up to 1-9-2015 were analyzed for this study and were categorized into two groups (1) those treated with CTX and (2) those who were treated with R-CTX. The clinical treatment of patients was evaluated based on the “treatment-free interval” (TFI), defined as the time from stop of chemo/immuno/therapy to start of next treatment. Patients who did not need next treatment were censored at time of last follow-up or death. In addition, overall survival (OS) for patients treated in the period which chemotherapy was the only available option, was compared to patients treated before the rituximab era (before and after 1-1-2006, respectively).

Results: A cohort of 375 CLL patients was studied, of whom 124 CLL patients (33%) required treatment in the observation period. The median age at first-line therapy was 67 years; 55% and 45% of these patients received first line CTX or R-CTX, respectively, and 47% of these patients required a second or later line of (R-)CTX. In total 221 treatment periods of (R-)CTX were studied with respect to treatment-free interval, 124 first-line, and 97 courses of retreatment. In the first-line treatment group 12 (10%) and 24 patients (19%) were treated with purine-analogue-based schedules without or with R respectively, i.e. (R-)fludarabine or (R-)fludarabine plus cyclophosphamide, 25 (28%) and 31 patients (25%) were treated with chlorambucil/CVP-based regimens without or with R respectively, and two patients (2%) were treated with CHOP and R-bendamustin. The median TFI for patients treated with CTX was 31 months (95%CI; 20 – 42 months) and was significantly better in the R-CTX group where the median TFI was 17 months (95%CI; 12 – 22 months) (HR=0.40, 95%CI 0.22 – 0.73). In second or later lines of treatment 15 (11%) and 11 patients (11%) were treated with purine-analogue-based schedules without or with R respectively, i.e. (R-)fludarabine or (R-)fludarabine plus cyclophosphamide, 24 (25%) and 31 patients (32%) were treated with chlorambucil/CVP-based regimens without or with R respectively, and 11 patients (15%) were treated with other treatment modalities, i.e. (R-)CHOP or (R-)bendamustin. The median TFI for CTX was 27 months (95%CI; 18 – 52 months) vs 55 months for R-CTX (95%CI; 41 months – NR), HR 0.47 (95%CI 0.15 – 0.90) for subsequent lines. OS for patients treated in the R era was 48 vs 35 months for patients treated before the introduction of rituximab.

Summary/Conclusions: Our study shows that the addition of rituximab improved treatment free interval in first- and subsequent lines and prolonged overall survival in a cohort of CLL patients receiving treatment in routine clinical ‘real world’ practice.
Ibrutinib was administered at a dose of 420 mg/d.

Results: Infectious complications were observed in 16 patients (37.2%). These included, for example, upper respiratory tract infection, bronchitis, pneumonia, urinary-tract infections, pharyngitis. The conducted analysis showed a statistically significant correlation between the concentration of IgM in the blood serum (before ibrutinib administration) and infectious complications during these therapy (p<0.05). The average IgM concentration in patients with complications was considerably lower when compared to people who did not experience any complications. The patients (n=3, 6.98%) with complications at the moment of ibrutinib therapy had statistically significant lower IgM concentration (p<0.05) compared to patients who did not have complications (n=11, 26.1%). In patients with complications at the moment of ibrutinib therapy, the average IgM level was significantly lower (p<0.05) compared to patients without complications. The correlation coefficient between the concentration of IgM and the occurrence of infection was confirmed in 13 patients (33%) in the other group.

Summary/Conclusions: The preliminary results of our prospective study, performed using a routine, not highly sensitive flow cytometry approach, highlight a possible association between (clinical?) MBL and prostate cancer (PC). Though several studies have described the association between CLL and various types of neoplastic disorders, only few data exist about the risk of non-hematologic cancer in individuals with MBL, in particular, no association between MBL and prostate cancer (PC) has been so far reported.

Aims: To study prospectively the frequency of CLL-like MBL clones in patients affected by PC compared to healthy males of the same ages, after our previous observation of an apparently increased MBL incidence at baseline in a cohort of patients with PC, originally studied to detect lymphocyte abnormalities possibly induced by radiotherapy (RT).

Methods: We enrolled 34 consecutive patients affected by PC (mean age 74 years, range 58-91), naïve for chemotherapy (sixteen previously treated with hormone-therapy). All patients were planned to receive whole-pelvis RT with radical (n. 23) or salvage (n. 11) intent. Fifty-four healthy males (mean age 71 years, range 58-91) naïve for chemotherapy were selected as controls. Median prostate specific antigen (PSA) value before RT was 10 ng/ml. CTRL group included 30 healthy males (mean age 71 years, range 58-91), naïve for chemotherapy (sixteen previously treated with hormone-therapy). All patients were planned to receive whole-pelvis RT with radical (n. 23) or salvage (n. 11) intent.

Results: In healthy subject group, only one (8.8%) individual was detected, showing a very small clone (1 cells/µl). A significant difference was not statistically significant (p=0.2).

Table 1.

<table>
<thead>
<tr>
<th>Prostate cancer (n. 24)</th>
<th>Median WBC (range)</th>
<th>Median White Cell Count (range)</th>
<th>Median B-cells (range)</th>
<th>MBL n. (%)</th>
<th>Absolute MBL clone value (clone/µl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n. 64)</td>
<td>7577 (3100-12900)</td>
<td>2257 (300-1010)</td>
<td>201 (28-484)</td>
<td>3.8%</td>
<td>294, 254, 1970</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The preliminary results of our prospective study, performed using a routine, not highly sensitive flow cytometry approach, highlight a possible association between (clinical?) MBL and PC, never described before and probably warranting further investigation in a larger number of patients.
Chronic myeloid leukemia - Biology

PB1802
IDENTIFICATION OF NOVEL MUTATIONS IN CANCER-RELATED GENES IN HUMAN ERYTHROLEUKEMIA K562 CELL LINE BY NEXT-GENERATION SEQUENCING
M. Pegoraro1,2,3, M. Kurkowski1, M.M. Machnicki1,2, I. Solarska3, K. Borg3, M. Rydzanicz3, P. Stawinski2, R. Ploski2, T. Stoklosa1
1Department of Immunology, Medical University of Warsaw, 2Postgraduate School of Molecular Medicine, 3Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, 4Department of Medical Genetics, Medical University of Warsaw, Warsaw, Poland

Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by reciprocal chromosomal translocation (t(9;22)(q34;q11), resulting in the formation of the BCR-ABL fusion oncogene. One of the most used CML in vitro model is the K562 cell line with the BCR-ABL1-positive human erythroleukemia cell line derived from a female patient with CML in blastic phase (CML-BP) and representing an important tool for the studies of malignant hematopoiesis in last decades. Although K562 karyotype was described several times, detailed genomic analysis of this cell line is not yet available and to our best knowledge there are no publications yet describing complex genomic landscape of K562 cells.

Aims: The aim of our study was to determine the mutational landscape of K562 cell line using next-generation sequencing (NGS). Additionally classical fluorescence in situ hybridization (FISH) with BCR and ABL1 probes was performed to confirm cytogenetics.

Methods: The K562 cell line was purchased from DSMZ (Braunschweig, Germany). We analyzed almost 1300 genes implicated in human cancer using custom designed capture (SeqCap EZ, NimbleGen, Roche) followed by high-throughput sequencing on Illumina HiSeq 1500. Common variants (>1%) gathered in ESP6500 and 1000 genomes projects and our internal exome database were filtered out and the subsequent analysis was focused on putative protein damaging variants with the frequency in the database from NHLBI GO exome sequencing project less or equal to 0.01. We used different bioinformatic tools for variant effect prediction (eg. PolyPhen-2, SIFT, IntOGen). Mutations were confirmed with Sanger sequencing. FISH was performed using commercially available probes (Vysis, Abbott, USA), that identifies BCR-ABL1/ABL1-BCR fusion genes.

Results: Sequencing and bioinformatic analysis revealed 88 variants with potential biological significance. We detected Q136fs*13 mutation in TP53, which has already been described in K562 cell line previously by ATCC, but we have also identified several new mutations in genes involved in tumorigenesis and drug resistance (Table 1). Moreover, cytogenetic analysis showed both multiplication of the BCR and ABL1 genes and amplification of the BCR-ABL1 fusion gene (Ph chromosome is present in at least four additional copies).

Table 1. Selected prominent mutations identified in K562 cells.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>SCN1A Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP53 q13.4q25.3</td>
<td>NM_001283144.2</td>
</tr>
<tr>
<td>ASXL1 p.V907X</td>
<td>NM_03385.5</td>
</tr>
<tr>
<td>TP53</td>
<td>NM_002492.2</td>
</tr>
<tr>
<td>BRAF p.V600E</td>
<td>NM_005298.2</td>
</tr>
<tr>
<td>KIT p.D819V</td>
<td>NM_002631.3</td>
</tr>
<tr>
<td>SRC</td>
<td>NM_004746.3</td>
</tr>
</tbody>
</table>

Summary/Conclusions: We describe several new mutations in such genes as ASXL1, BRCA1 or MLH1 in one of the most frequently used cell line in leukemia research, K562 erythroleukemia. Our results confirm high level of genomic instability in the blastic phase of CML represented by the K562 cell line, which has already been described in K562 cell line previously by ATCC, but we have also identified several new mutations in genes involved in tumorigenesis and drug resistance (Table 1). Moreover, cytogenetic analysis showed both multiplication of the BCR and ABL1 genes and amplification of the BCR-ABL1 fusion gene (Ph chromosome is present in at least four additional copies).

PB1803
INVESTIGATION OF POLYMORPHISMS RELATED TO MIR-608 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
N. Ryabchikova1, G. Safuanova1, I. Minniakhmetov2, A. Sultanbaev1, E. Khusnutdinova2
1Bashkir State Medical University, 2BG USC RAS, UFA, Russian Federation

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the expression of the BCR-ABL oncoprotein, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of BCR-ABL, has unprecedented efficacy for the treatment of CML. Several cellular and genetic mechanisms of imatinib resistance have been proposed, including overexpression of the BCR-ABL gene, the tyrosine kinase domain mutations, pharmacokinetic and pharmacodynamic factors.

Aims: The purpose of this study was to investigate miRNA-608 role in response to therapy with tyrosine kinase inhibitors (Imatinib). In this study, we analyzed rs9762 SNP located in a miRNA-608 binding site of 3’UTR of BCR-ABL gene and rs4919510 SNP in the mature sequence of miR-608 in CML patients with different response to tyrosine kinase inhibitor therapy. These polymorphisms disrupt the negative effect of miR-608 on its target BCR-ABL. Our study demonstrated that individual based investigations may be important to evaluate the BCR ABL kinase. We also provide the promising clinical relevance as a candidate drug for treatment of BCR ABL resistant leukemia patients.
FLUORESCENCE IN SITU HYBRIDIZATION SIGNAL PATTERNS AND INTRACHROMOSOMAL BCR-ABL1 AMPLIFICATION ANALYSIS IN IMATINIB-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA PATIENTS USING TRICOLOR DUAL FUSION PROBE

K. Bommannan1,*, S. Naseem1, N. Varma, P. Malhotra2, J. Binota1, S. Varma2
1Hematology, 2Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Background: Conventional cytogenetics is a common modality for tyrosine kinase inhibitor (TKI) response assessment in chronic myelogenous leukemia (CML) patients. There is no consensus regarding the use of conventional bone marrow (BM) cytogenetics or peripheral blood (PB) metaphase fluorescence in situ hybridization (FISH) during follow-up. The routine dual colour FISH probes are less sensitive to reliably identify der(9) deletions during follow-up. BCR/ABL/ASS1 tri-colour dual fusion (TCDF) probe is highly sensitive and specific in identifying der(9) deletions.

Aims: Our aim was to identify the I-FISH fusion patterns of BCR/ABL/ASS1 TCDF probe and correlate the patterns with patient-specific molecular genetic parameters.

Methods: This was an ethically approved study conducted at a government-funded tertiary care institute. From January 2015 to June 2016, PB I-FISH analysis was performed on European LeukemiaNet defined imatinib-resistant CML patients using BCR/ABL/ASS1 TCDF probe (Abbott Laboratories, Abbott Park, Illinois, USA). The residual BCR-ABL1 transcript load was monitored in international scale (BCR-ABL1%) using an automated cartridge-based Genxpert system (Cepheid, Sunnyvale, CA, USA).

Results: On analyzing 37 adult patients, all had residual Philadelphia (Ph) chromosome (100%). Classic Ph fusion pattern was seen in 33 (89%), der(9) chromosome 9 [der(9)] deletions in 25 (67.5%) and supernumerary Ph chromosomes in 11 (30%) patients. Coexistence of classical fusion and der(9) deletions were seen in 21 patients (57%), whereas 8 patients (22%) had a mutual existence of classical fusion, der(9) deletions and supernumerary Ph chromosomes. None had Ph amplification. Figure 1 demonstrates the I-FISH patterns seen in a 43-year-old male diagnosed with CML-CP and had progressed to blast crisis at his 72nd month of imatinib therapy. In this Figure red, yellow and white arrows indicate blast cells without Ph chromosome, Ph+ blast with a loss of residual ABL1 on der(9) classical and random signal overlap, respectively. A mean (± S.D) of 29% (± 30) and 18% (± 17) der(9) deleted cells were seen amongst patients with b2a2 and b3a2 BCR-ABL1 transcript types, respectively and this difference was statistically significant (p=0.008).

There was also a significant difference in the disease transformation status according to the percentage of der(9) deleted cells (p=0.03). In this regard, patients with progressive disease (accelerated phase/blast crisis progression) had a mean (± S.D) of 47% (± 35) der(9) deleted cells in comparison to 19% (± 20) such cells in patients without disease transformation. In addition, patients with Ph duplication/triplication had a mean (± S.D) BCR-ABL1r levels of 49.47% (± 40.19) in comparison to BCR-ABL1r levels of 16.00% (± 19.99) in patients without these anomalies and this difference was also statistically significant (p=0.029).

Background: Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm (MPN). It is characterized by a reciprocal (9:22)(q34;q11.2) resulting in the fusion oncogene BCR/ABL in a hemopoietic stem cell. Clinical features are absent in nearly 20-40% of patients at diagnosis time. Hence, laboratory suspicion is crucial. Peripheral blood shows leukocytosis with left shift and “myelocyte bulge”, absolute eosinophilia, and absolute basophilia invariably present.1-3 The demonstration of the Philadelphia (Ph) chromosome with cytogenetic analysis, or BCR/ABL fusion gene by qRT-PCR will confirm the diagnosis (typical CML).

Aims: In order to gain accuracy when BCR/ABL qPCR is ordered, we review myeloproliferative hematimetric parameters, with special focus in basophilia, before performing molecular analysis.

Methods: We retrospectively reviewed 299 BCR-ABL qPCR requests received at our laboratory between January 1, 2015 and January 1, 2017. 80% of the total requests were ordered by haematologists physicians, 13.46% by other medical specialities (11.5% internal medicine) and 7.7% from the laboratory. Complete blood cell count (CBC) were analysed by ADIVA 2120. Neutrophilia was defined in our laboratory as absolute neutrophil count of >7.7 x10^9/L, and basophilia was defined as absolute basophil count of >0.2 x10^9/L. A total of 299 requests for PCR of BCR-ABL were reviewed by laboratory hematologists, 167 (55.78%) performing tests. The clinical data were classified according to the criteria of Hema-tologo neoplasms criteria. We reviewed clinical history, previous CBC and PB if necessary for this screening. We performed 235 test (78.6%) and 64(21.4%) were considered inadequate according former criteria. qRT-PCR p210 was performed and if a negative result was obtained with high CML suspicion qRT-PCRp190 and qRT-PCRp230, such as cytogenetic studies were performed. The statistical analysis was performed with STATA.

Results: 235 BCR/ABL by PCR tests were performed and 24 (10.21%) resulted positive. 167 (71.06%) were placed for neutrophilia; 41 (17.87%) for thrombocytosis and 26 (11.07%) for other criteria (eosinophilia, monocytosis, splenomegaly or combined). Among 24 positive cases 100% presented basophilia at diagnostic time and 91.66% (22/24) presented basophilia and neutrophilia. Two cases without neutrophilia at diagnosis were CML with extreme trombocytosis. We found 33 cases with basophilia among 235 patients. 24 cases (72.73%) were diagnosed of CML and 9(27.27%) resulted in other MPN Ph- or unclassifiable MPS/MDS neoplasm. Our results show that when CML is suspected, basophilia>0.3 x10^9/L has a 100% sensitivity and 95.75% specificity. ROC curve for basophilia as a screening test before performing BCR/ABL PCR is 0.984 (Figure 1).

Summary/Conclusions: Our results show that basophilia should be carefully investigate when CML is suspected, with high sensitivity (100%) and specificity (95.75%). In cases no CML with basophilia >0.3 x10^9/L, further investigation should be performed in order to diagnose a MPN Ph- or MDS/MPN. Even basophilia is well stablished as nearly universal in CML 1,3,4, this study reveals it is not always pursue enough, when clinicians ask for a molecular study.

Figure 1.
of fundamental medicine, Lomonosov Moscow State University, Moscow, Russian Federation. 3Medical faculty, Tashkent Medical Academy, Tashkent, Uzbekistan

Background: Data concerning the impact of BCR-ABL del. c.1086-1270 on TKI resistance in CML is still controversial. This mutation was first described by Curvo et al. (2008) and was thought to confer TKI resistance. However computer modeling performed by Meggyesi N. et al. (2012) revealed disruption of ATP binding site in mutated tyrosine kinase therefore abrogating enzymatic activity. Nevertheless pathogenic effect of BCR-ABL p.R362fs*21 could be attributed to the formation of heterodimer with “wild type” Bcr-Abl p210 as described by Poulikakos P.I. et al. (2011).

Aims: To assess the impact of BCR-ABL del. c.1086-1270 (p.R362fs*21) on TKI resistance in CML patients from Russian Federation.

Methods: 33 male and 49 female CML patients (age 24-80) with BCR-ABL transcript level >0.1% were included in the study. BCR-ABL del. c.1086-1270 was estimated by nested PCR followed by Sanger sequencing. Initial screening for deletions was performed by means of fragment analysis (Applied Biosystems 3130).

Results: 92 RNA (cDNA) samples isolated from peripheral blood of 82 CML patients were tested. BCR-ABL del. c.1086-1270 (p.R362fs*21) was found in 32 patients (39%). 15 out of 32 (47%) patients with deletion were TKI sensitive while 17 (55%) were TKI resistant. In one TKI resistant case BCR-ABL del. c.1086-1270 was accompanied by BCR-ABL c.844G>C p.E282Q point mutation not described so far (Figure 1). This mutation was found in BCR-ABL del. c.1086-1270 transcript only and was absent in “wild type” Bcr-Abl p210 transcript amplified from the same patient.

Figure 1.

Summary/Conclusions: BCR-ABL del. c.1086-1270 could be found in almost half of CML patients and have no evident impact on the induction of big molecular response in TKI sensitive cases. Our observation that independent c.844G>C p.E282Q point mutation expressed on the same BCR-ABL transcript with deletion c.1086-1270 (p.R362fs*21) being absent in “wild type” transcript strongly contradicts the hypothesis, that del. c.1086-1270 could be generated by alternative splicing of “wild type” BCR-ABL transcript.

PB1808

PEROXIREDOXIN II ACTIVITY HAS IMPORTANT ROLES TO CONTROL ABL TYROSINE KINASE ACTIVITY IN STIS TREATED CML PATIENTS AND ITS POTENTIAL APPLICATION IN IMATINIB RESISTANCE

E.S. Yoo1,*, Y.-C. Mun1, J.-Y. Ahn1, J.-W. Huh1, C.-M. Seong1

1Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic Of

Background: Therapies targeting the redox environment such as over-expression of antioxidants or antioxidant treatment, could inhibit tumor cell growth even resistant cells. Bcr-Abl oncopgene is known to induce high levels of intracellular ROS which may further induce genomic instability with malignant transformation even if the erythroid cells are removed. Variable expression of antioxidant enzymes in leukemia, with limited studies with variable results so far. Altered redox biology in leukemia also has implications for therapeutics.

Aims: We investigated the roles of PRX II in CML primary cells at diagnosis and remission during signal transduction inhibitor (STIs), and tested the same with cell growth by MTT assay, BCR/ABL expression by western blot analysis, changes of intracellular ROS level and antioxidant enzymes such as peroxiredoxin (Prx) 1, 2, 3 using immunoblot assay according to different concentrations of IM between 0 to 10 µM in time dependent manner (24 hours/48 hours). We also repeatedly investigated the effects of IM therapy using PRXII overexpressed K562 cells by transfection.

Results: Three BCR-ABL1 positive cell lines showed significant change in cell viability. Intracellular ROS level, eradication of BCR/ABL oncogene and levels of Prx2 during IM treatment with different response each other in degree and pattern by IM exposure. The levels of BCR-ABL1 oncogene were slightly decreased in Prx2 overexpressed K562 cells. Moreover, Prx2 overexpressed K562 cells showed further down-regulation of Bcr-Abl oncoprotein by IM treatment.

Summary/Conclusions: Our findings may contributes to find a new pathway on which TKIs are working besides the mechanisms of ATP binding competitively, blocking the binding of ABL-kinase and substrate resulting apoptosis of Ph+ cells. In addition develop the new strategies to overcome the situation of the IM/Nilotinib resistance in CML positive disease in the future. The importance of the roles of ROS and its PRX II, antioxidant enzymes in CML is further established by our work.

PB1809

FUNCTIONAL CHARACTERISTICS OF ERYTHROID PROGENITOR CELLS OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH IMATINIB AND NILOTINIB

T. Perekhrestenko1,*, I. Sviezhentseva2, D. Bilko2, N. Tretiiak1, I. Dyagil3

1blood disease, State Institution «Institute of Hematology and Transfusionology of NAMS of Ukraine», 2center of molecular and cell research, University of Kyiv Mogila Academy, 3department of hematology and transplantology, State instutute ‘National Research Center of Radiation Medicine, Kyiv, Ukraine

Background: It is believed that chronic myeloid leukemia arises as a result of myeloid progenitor cell malignancy. There are changing of proliferative activity in granulocyte-macrophage and erythroid hematopoiesis germs in patients bone marrow. Currently we don’t have definite results regarding tyrosine kinase inhibitors influence on erythropoietic cell characteristics of patients with CML.

Aims: The aim of study was to determine functional characteristics of erythroid progenitor cells of patients with chronic leukemia treated with Imatinib and Nilotinib.

Methods: We studied 300 bone marrow samples from 75 patients: with initial diagnosis of CML (n=7), patients receiving drug imatinib (n=47) and patients who taking nilotinib (n=21). We provide studying of erythroid mononuclears in semisolid in vitro and in vivo cultures. For in vitro culture we used special gel capsule, allowing cytokines and growth factors of mouse body affect human mononuclear cells. For in vitro culture we added 20% fetal calf serum, 30 ng/ml erythropoietin, and 20 ng/ml minterleykin-6 and interleukin-9. Cultivation was provided 14 days, then counted the number of erythroid colonies and provided their morphological studies.

Results: The results showed that the increase of erythroid progenitor cells proliferation rates and the reduction of differentiation rates as a result of the parallel cultivation of patients’ bone marrow cells in vivo and in vitro happen irrespective of the presence of cytokines and growth factors in a normal microenvironment of these cultures. In addition, we showed that bone marrow cells of CML patients form erythroid colonies, when placed in the animals’ body without previous leuvenous anemia. Moreover, correlational relationship was found between the number of erythroid colonies and the number of leukemic cells in the patients bone marrow. It was established that the acquisition of leukemic clone cells resistance to TKI is characterized by increased proliferative activity irrespective of soluble microenvironment factors as well as the culture medium in the erythropoietin presence.

Summary/Conclusions: The normal microenvironment factors not effect on the erythroid progenitor cell proliferation independence of the response to TKI therapy. This may explain the fact that we don’t have an increase the number of erythroid cells in patient bone marrow compared to culture in vitro. In addition, the ability of erythroid progenitor cells to form colonies in the absence of erythropoietin in culture can serve as an additional prognostic factor in the formation of resistance to TKI.

PB1810

DEVELOPMENT OF FRAGMENT ANALYSIS MULTIPLEX-PCR METHOD TO DETECT TRANSCRIPTS OF BCR-ABL FUSION GENE IN CHRONIC MYELOID LEUKEMIA

L. Reguilón-Gallego1,*, F. Ferrer-Marín1, R. Cifuentes1, V. Vicente1, R. Toral-Montoya1

1Hematología y Oncología Médica, Hospital Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Murcia, Spain

Background: Chronic myeloid leukemia (CML) is a myeloproliferative, clonal and acquired hematological disease that is included within myeloproliferative neoplasms (WHO 2016). Its main characteristic is the presence (95% of the
cases) of a small chromosome denominated Philadelphia chromosome, coming from the reciprocal translocation between the chromosomes 9 and 22. Depending where the break-point occurs, different isoforms of the fusion gene BCR-ABL may appear. For the diagnosis of CML, detection of BCR-ABL rearrangement is crucial; and molecular biology techniques, such as RT-PCR, may be the only data at that point, but most current RT-PCR methods for detecting BCR-ABL are designed and optimized for detecting the majority forms (e1a2 and in 3a2) without distinguishing between them. Characterization of the transcript is not necessary for the diagnosis but permits follow-up at the molecular level and differentiate between different BCR-ABL isoforms at the time of the CML diagnosis could be taken into account in future studies to investigate its role into the prognosis.

Methods: 34 CML patients BCR-ABL positive by qRT-PCR and 1 negative control patient by PB18111 and PB1812. For this study, we have used the physicians at the University Hospital of Besançon as the main source of patients.

Results: BCR-ABL fusion RNAs were detected in all patients (34/34), on the other hand, we did not detect BCR-ABL on the negative control. The main isoform identified was e1a2 (detected in 22 out of 34 patients, 64.7%). Twelve patients were positive for e13a2 BCR-ABL isoform (35.3%). Interestingly we identified 7 patients (20.5%) with co-expression of e1a2 and e13a2 isoforms, being in all these cases the e14a2 isoform mainly expressed.

Summary/Conclusions: RT-PCR combined with capillary electrophoresis is regarded as a sensitive technique for the detection of different isoforms of BCR-ABL and may be included as a BCR-ABL first screening. Quantification with qRT-PCR might only be done in positive samples. Unfortunately we could not detect any isoform besides the majority ones, due to the size of our cohort. Finally, our study validates previous studies on the main BCR-ABL isoforms (e14a2 and e13a2) percentage detected in CML patients.

PB1811
Abstract withdrawn.

PB1812
PDGF AND BDNF PLASMA LEVELS IN CML PATIENTS BEFORE AND AFTER INITIATION OF TKI THERAPY
Z. Litwińska1,*, K. Łuczkowska1, E. Pius-Sadowska1, A. Sobuś1, E. Paczkowska1, B. Machaliński1
1Laboratory of Hematology, GHEST Lyon, Bron Cedex, 2Laboratory of hematology, Hôpital Desgenettes, Lyon, 3Laboratory of Hematology, GEST, BRON, 4Department of Cyto genetics and molecular biology, 5Department of cyto genetics and molecular biology, GHSD, Lyon, France

Background: Myeloproliferative neoplasms (MPN) include on the one hand chronic myeloid leukemia defined by the presence of Philadelphia chromosome and BCR-ABL remodeling, and on the other hand MPNs without Philadelphia chromosome (Polycythemia vera [PV], essential thrombocytopenia [ET] and primary myelofibrosis [PMF]). V617F JAK2 mutation is the main recurring genetic abnormality in these pathologies (1). It can be found in 95% of PV and 50% of ET and PMF (2). The 2016 WHO classification makes no proposal of an entity where it would include BCR-ABL and JAK2. However, 28 of those cases were described in a 2013 literature review (9). Most patients developed either a V617F JAK2 mutation during treatment by tyrosine kinase for a BCR-ABL+CML; or a BCR-ABL+CML during treatment for a V617F JAK2+MPN (3,4,5,6,7). A very small number of patients showed coexistence of those two mutations (8).

Aims: We report a 62y old woman patient with chronic myeloid leukemia with late discovery of JAK2.

Methods: Clinical presentation: A 62-year-old man with no notable medical history was admitted in 2009 for CML. After failure of first line treatment by Imatinib in 2009 (poor tolerance and incomplete molecular response), treatment by Nitotinib was initiated in 2012 allowing for, to this day, good molecular response despite poor digestive tolerance in the form of dyspepsia. Ever since 2009, a second MPN was suspected. V617F JAK2 mutation was found positive (9). A very small number of patients showed coexistence of those two mutations (8).

Results: BCR-ABL fusion RNAs were detected in all patients (34/34), on the other hand, we did not detect BCR-ABL on the negative control. The main isoform identified was e1a2 (detected in 22 out of 34 patients, 64.7%). Twelve patients were positive for e13a2 BCR-ABL isoform (35.3%). Interestingly we identified 7 patients (20.5%) with co-expression of e1a2 and e13a2 isoforms, being in all these cases the e14a2 isoform mainly expressed.

Summary/Conclusions: RT-PCR combined with capillary electrophoresis is regarded as a sensitive technique for the detection of different isoforms of BCR-ABL and may be included as a BCR-ABL first screening. Quantification with qRT-PCR might only be done in positive samples. Unfortunately we could not detect any isoform besides the majority ones, due to the size of our cohort. Finally, our study validates previous studies on the main BCR-ABL isoforms (e14a2 and e13a2) percentage detected in CML patients.
**Chronic myeloid leukemia - Clinical**

**PB1814**

**E14A2 TRANSCRIPT IS ASSOCIATED WITH HIGHER PROBABILITY OF DURABLE TREATMENT FREE REMISSION IN CML PATIENTS**  
M. D’Adda1,*, F. Schieppati1, E. Morello2, G. Ruggeri3, E. Cerqui1, S. Ferrari1, C. Bottelli1, A. Passi1, G. Rossi1  
1Hematology, 2USD Centro Trapianto Midollo Adulti, 3Laboratorio Analisi, ASST Spedali Civili di Brescia, Brescia, Italy

**Background:** TKIs discontinuation in CML-CP patients with deep molecular response (DMR) are feasible, safe and 40-60% of them maintain treatment free remission (TFR); sokal risk score and duration of TKI-therapy were significantly associated with molecular relapse, according to Euro-Ski and STIM1 trials. While it is known that patients with e14a2 achieve earlier, deeper and more durable responses compared to those with e13a2, few information is available on the influence of the type of bcr-abl transcript on TFR duration.

**Aims:** Here we describe our single center experience of TKI discontinuation in CML-CP patients with sustained DMR

**Methods:** Bcr-abl transcripts were determined by RQ-PCR analysis performed in accordance with EAC protocol (Gabert et al, Leukemia 2003) and to the standards of the Italian national network Labnet. All 174 CML-CP patients presently followed at our institution according to ELN guidelines and treated with 1st or 2nd TKIs were analysed: 103 (59%) had e14a2 and 69 (40%) e13a2 transcript (in 2 pz bcr-abl were not detectable). Criteria for TKI discontinuation was sustained DMR (MR4 or better) for at least 2 years. After TKI withdrawal, RQ-PCR for BCR-ABL was performed every month during the first year and every 2 months thereafter. TKI treatment was reintroduced immediately if DMR loss occurred. TFR was defined as the time between the date of TKI cessation and the date of restarting treatment for DMR loss or, if TKI was not resumed, the date of the last contact.

**Results:** Forty-nine patients, 25 male and 24 female, discontinued TKI treatment. At the time of discontinuation median age was 63 years (43-85), median time from TKI start 113 months (30-172), median duration of sustained DMR 60 months (24-153). Sokal distribution was 49%, 29% and 20% for low, intermediate and high risk (one patient was not evaluable). Among our 174 patients 39% (40/103) of all e14a2 patients and 13% (9/69) of all e13a2 discontinued TKI (P 0.0002, chi square). Thirty-six patients discontinued imatinib (11 of them with previous INF treatment), 13 stopped nilotinib (8 in first line, 5 in second line treatment). Median follow up after treatment discontinuation was 19 months (3-76), including 31 patients with follow up > 12 months. Thirty (61%) patients lost DMR. Median time off-therapy for these patients was 3 months (2-8), and only 1 lost DMR after 6 months. Therapy was restarted in all 13 patients (2 in MR1, 4 in MR2, 7 in MR3), 10 achieved a second DMR after a median interval of 2 months (1-7); 2/13 patients are in M3 after 7 and 12 months, 1 patient is not yet evaluable. Univariate analysis showed no difference in relapse risk according to age, gender, type and duration of TKI, duration of stable DMR and sokal score risk. Ten out of 11 patients treated with INF before imatinib remained in TFR. Of note, the type of bcr-abl transcript was significantly linked to DMR loss: after TKI discontinuation, 32/40 e14a2 patients (78%) maintained DMR vs 4/6 e13a2 patients (42%) (p 0.03). After 12 months 78% (+/-6% CI95%) of e14a2 and 41,6 (+/-17% CI95%) of e13a2 patients were still in TFR (log-rank: P=0.033) (see Figure 1). Using multivariate analysis the type of bcr-abl transcript and previous INF treatment correlated with DMR loss (p 0.012 and p 0.033). One patient died during follow up in DMR for CML-unrelated cause.

**Figure 1.**

---

**Figure 1.**

---

**Figure 1.**
Summary/Conclusions: in e14a2 CML patients the probability of discontinuation of sustained DMR is significantly higher as compared with e13a2 patients. Moreover, after discontinuation, e14a2 have significantly lower probability of DMR loss than e13a2. These data confirm that e14a2 transcript is associated with a more favorable CML disease profile than e13a2 (Jain et al., Blood 2016); in addition they show that e14a2 is a favorable prognostic factor for TFR maintenance.

PB1815

COMPARATIVE ANALYSES OF NILOTINIB VS HIGH-DOSE IMATINIB VS SUSTAINING STANDARD-DOSE IMATINIB IN PATIENTS WITH CP CHRONIC MYELOID LEUKAEMIA FOLLOWING SUSTAINED MOLECULAR RESPONSE TO FIRST-LINE IMATINIB

S.-S. Park1,2,3, S.-H. Kim1, R. Woodman3, T. Szczudlo3, J. Joo4, E. Misyurina4, A. Misyurin1,2

1Leukemia Research Institute, The Catholic University of Korea, 2Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of; 3Novartis Pharmaceuticals Corporation, East Hanover, United States, 4BMT Program, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 5Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, 6Kyungpook National University Hospital, Daegu, 7Ajou University School of Medicine, Suwon, 8Dong-A University, College of Medicine, Busan, 9Kyung Hee University College of Medicine, Anyang, 10Kangbuk Samsung Hospital, Seoul, Korea, Republic Of

Background: Imatinib (IM) and its generic form are widely used as one of the standards of care for chronic phase (CP) chronic myeloid leukemia (CML). Although it was shown that both nilotinib and dasatinib have a significantly higher starting rate of MR4.5 than standard-dose IM for the treatment of patients who have suboptimal molecular responder to IM had a trend for achieving a MR4.5 more frequently, 1cacy than standard-dose IM for the treatment of patients who have suboptimal molecular responder to IM.

Methods: 105 patients with CML in chronic phase (CP) who received TKI were enrolled in this study between 2014 and 2015. Nine patients with newly diagnosed CML in CP prior to TKI treatment were added as control. Patients underwent echocardiography to evaluate 3values of tricuspid regurgitation pressure gradient (TRPG), which relates to severity of PH. Patients with TRPG values >31mmHg were suspected of PH onset according to European Society of Cardiology criteria. All patients gave informed consent.

Results: Patients were divided into 3 groups by the TKIs they used at the time of study enrollment; 37 patients on imatinib, 30 on nilotinib and 38 on dasatinib (Table 1). In imatinib group, patients’ age was significantly higher, and duration of treatment was also longer than those of the 2nd generation TKIs. Echocardiography revealed mean values of TRPG as 22.7, 23.1 and 23.4mmHg in imatinib, nilotinib and dasatinib groups, respectively (p=0.887), and these values were higher than that in the newly diagnosed CML patients (19.0mmHg), though without significance (p=0.38). Nine of the 105 patients (8.6%) presented with an elevated TRPG>31mmHg, suggesting the presence of PH; 1 of 37 (2.7%) in imatinib group, 3 of 30 (10.0%) in nilotinib group, and 5 of 38 (13.2%) in dasatinib group. Three patients complained of dyspnea, while the remaining 6 were asymptomatic. We found no apparent risk factors associated with TRPG elevation, however, there were trends toward correlation of age and TRPG values in nilotinib and dasatinib treated patients, and treatment duration and TRPG values in nilotinib treated patients. Imatinib dosage tended to inversely correlate with TRPG value, suggesting that imatinib might decrease pulmonary arterial blood pressure in a dose-dependent manner.

Table 1.

Summary/Conclusions: PH is a rare but life-threatening adverse event for dasatinib-treated patients, and its definitive diagnosis is made by cardiac catheterization. However, cardiac catheterization is too invasive for PH screening of the many patients with TKIs who do not have any symptoms. Our study, by using echocardiography, detected TRPG elevation not only in dasatinib treated patients (13.2%) but also in imatinib (2.7%) and nilotinib (10%), including patients without any symptoms. This indicates possible PH onset among patients treated with imatinib or nilotinib, as well as with dasatinib. Although TRPG values obtained by echocardiography might not be fully compatible with those by cardiac catheterization, the results suggested that noninvasive echocardiography is sensitive for screening PH and is also effective for easily screening groups of patients with suspect subclinical PH among patients treated with any available TKIs. Careful screening with echocardiography is necessary especially for older patients who have received TKIs for a long time.

PB1816

COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB

M. Minami1, T. Miyamoto1, K. Akashi1

1Department of Medicine and Bioinformatic Science, Kyushu University, Fukuoka City, Japan

Background: Pulmonary hypertension (PH) has been reported as a serious adverse event in chronic myeloid leukemia (CML) patients treated by dasatinib. French group reported incidence of PH diagnosed by cardiac catheterization as 0.45% (13 of 2,900 patients) in symptomatic patients treated with dasatinib. Dasatinib-related PH usually resolves after cessation of treatment, but it can be fatal, as two deaths in France and one in Japan have been documented.

Aims: To clarify the incidence of tyrosine kinase inhibitor (TKI)-related PH, we noninvasively screened CML patients who have been given imatinib, nilotinib or dasatinib by echocardiography.

Methods: 105 patients with CML in chronic phase (CP) who received TKI were enrolled in this study between 2014 and 2015. Nine patients with newly diagnosed CML in CP prior to TKI treatment were added as control. Patients underwent echocardiography to evaluate 3values of tricuspid regurgitation pressure gradient (TRPG), which relates to severity of PH. Patients with TRPG values >31mmHg were suspected of PH onset according to European Society of Cardiology criteria. All patients gave informed consent.

Results: Patients were divided into 3 groups by the TKIs they used at the time of study enrollment; 37 patients on imatinib, 30 on nilotinib and 38 on dasatinib (Table 1). In imatinib group, patients’ age was significantly higher, and duration of treatment was also longer than those of the 2nd generation TKIs. Echocardiography revealed mean values of TRPG as 22.7, 23.1 and 23.4mmHg in imatinib, nilotinib and dasatinib groups, respectively (p=0.887), and these values were higher than that in the newly diagnosed CML patients (19.0mmHg), though without significance (p=0.38). Nine of the 105 patients (8.6%) presented with an elevated TRPG>31mmHg, suggesting the presence of PH; 1 of 37 (2.7%) in imatinib group, 3 of 30 (10.0%) in nilotinib group, and 5 of 38 (13.2%) in dasatinib group. Three patients complained of dyspnea, while the remaining 6 were asymptomatic. We found no apparent risk factors associated with TRPG elevation, however, there were trends toward correlation of age and TRPG values in nilotinib and dasatinib treated patients, and treatment duration and TRPG values in nilotinib treated patients. Imatinib dosage tended to inversely correlate with TRPG value, suggesting that imatinib might decrease pulmonary arterial blood pressure in a dose-dependent manner.

Table 1.

Summary/Conclusions: PH is a rare but life-threatening adverse event for dasatinib-treated patients, and its definitive diagnosis is made by cardiac catheterization. However, cardiac catheterization is too invasive for PH screening of the many patients with TKIs who do not have any symptoms. Our study, by using echocardiography, detected TRPG elevation not only in dasatinib treated patients (13.2%) but also in imatinib (2.7%) and nilotinib (10%), including patients without any symptoms. This indicates possible PH onset among patients treated with imatinib or nilotinib, as well as with dasatinib. Although TRPG values obtained by echocardiography might not be fully compatible with those by cardiac catheterization, the results suggested that noninvasive echocardiography is sensitive for screening PH and is also effective for easily screening groups of patients with suspect subclinical PH among patients treated with any available TKIs. Careful screening with echocardiography is necessary especially for older patients who have received TKIs for a long time.

PB1817

DYNAMICS OF BCR-ABL1 MUTATION ACQUISITION AND LONG-TIME MUTATION-ASSOCIATED RESISTANCE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED BY TYROSINE KINASE INHIBITORS: RUSSIA, 2006-2016

V. Tikhonova1,2, Y. Finashutina1, L. Kesaeva1, Y. Stroylova3, N. Kasatkina1, E. Misyurina4, A. Misyurin1,2

1Lab of recombinant tumor antigens, N.N.Blokhin Russian Cancer Research Center, 2Center for Molecular Medicine, M. Sechenov First Moscow State Medical University, 3Clinical City Hospital 52, Moscow, Russian Federation

Background: While chronic myeloid leukemia (CML) can successfully be treated with tyrosine kinase inhibitors (TKIs), mutations in the BCR-ABL1 kinase domain are the most prevalent cause of TKI resistance. More than 100 BCR- ABL1 kinase domain point mutations with various frequencies of incidence, domain positions and implications on TKI response in CML are associated with
TKI resistance. Here we present our data concerning prognostic significance of BCR-ABL1 kinase domain mutations dynamics in Russian CML patients according the follow-up study having been performed during the last 10 years.

**Aims:** To determine the frequency dynamics of BCR-ABL1 mutations in CML patients and its prognostic significance.

**Methods:** In this study we have included 1077 TKI resistant CML patients from 112 hospitals from 77 Russian cities having been observed during the period from 2006 to 2016. BCR-ABL1 kinase domain point mutations in mRNA samples from peripheral blood cells were analyzed by means of PCR followed by Sanger sequencing. Statistical analysis was performed using SPSS 22.0 (IBM, USA) and Excel 2013 (Microsoft, USA). Critical p-value was set to 0.05.

Results: 1077 TKI resistant CML patients were analyzed, among them were 41.5% men (n=447) and 58.5% women (n=630), median age – 50 (from 15 to 74). BCR-ABL1 mutations were found in 30.8% (332/1077) CML pts. We have detected a total of 415 mutations in 332 patients, giving rise for 58 different mutation variants. Mutation associated resistance rate was higher in women compared to men in 46 cases (24% of all mutations). F317L and H396R mutations were statistically more frequent in women, meanwhile T315I mutation prevailed in men group (Pearson’s χ2=0.05). It was of a sudden that BCR-ABL1 mutation distribution significantly varied according the particular CML pts city location throughout the different regions of Russia. Although for the period from 2006 to 2016 there were no detectable changes in mutation frequency spectrum (Pearson’s χ2 is 0.062), the total amount of mutations associated with TKI CML resistance has decreased from 36.6% in 2006-2008 to 24.95% in 2013-2016, but still remained significant. For particular mutations the following dynamics was detected: frequency of imatinib-resistant mutations decreased gradually from 2006 to 2016, while the rate of F317L and F359V mutations underlying resistance to second generation TKI increased in 2013-2016. T315I mutation rate expanded to the maximal level in 2014 and abruptly decreased afterwards. This tendency change may be the consequence of the second generation TKIs and other therapeutic strategies involvement into clinical practice.

**Summary/Conclusions:** As different BCR-ABL1 kinase domain mutations are associated with various types of mutation associated resistance to TKI treatment, the detection of trends in mutation distribution in CML patients receiving TKI treatment is very important for long time treatment strategy decision making, and management of resistance. We believe here the regional difference of mutation profiles should also be considered. Therefore, to enable correct triggering of particular types of TKI for CML treatment it is necessary to obtain data of when, which and where a particular type of BCR-ABL1 mutation is prone to appear in a distinguished cohort of CML pts.

**PB1818 IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID LEUKEMIA TREATED FRONTLINE WITH Nilotinib**

F. Castagnetti1,*, G. Gugliotta1, M. Breccia2, F. Stagno3, M. D’Adda4, L. Levato5, F. Cazzola6, E. Abruzzese7, A. Rossi-Rossi1, R. Calabria1, M. Paccagnella8, G. Gugliotta1, G. Alifano2, A. Gil9, M. Deininger13, D. Niederwieser10, F. Castagnetti1,*, G. Gugliotta1, M. Breccia2, F. Stagno3, M. D’Adda4, L. Levato5, F. Cazzola6, E. Abruzzese7, A. Rossi-Rossi1, R. Calabria1, M. Paccagnella8, G. Gugliotta1, G. Alifano2, A. Gil9, M. Deininger13, D. Niederwieser10

**Introduction:** The East German Study Group conducted a phase I study to identify the starting dose for the randomized phase II study which tested the combination of IM and HU has been tested in vitro and showed a additive suppression of CML CFU-GM cells. Combinations of tyrosine kinase inhibitors (TKIs). The combinations of IM and HU have been widely used to treat CML prior to the era of targeted treatment. HIGHER MOLECULAR RESPONSE RATE AT 6 MONTHS COMPARED TO IMATINIB (IM) 400MG IN PATIENTS WITH CML1ST CP RESULTS IN A PROLONGED PFS.” PB1819

**Background:** Imatinib (IM) monotherapy remains an acceptable option to treat advanced phase CML patients with chronic myeloid leukemia (CML) in the chronic phase (CP). Hydroxyurea (HU) is effective in controlling elevated white blood cell counts and has been widely used to treat CML prior to the era of tyrosine kinase inhibitors (TKIs). The combinations of IM and HU have been tested in vitro and showed a additive suppression of CML CFU-GM cells. Combinations of IM and HU was introduced in CML patients treated frontline with nilotinib (NIL).

**Aims:** To assess the impact of BCR-ABL1 transcript type on molecular response in newly diagnosed adult CML patients treated frontline with nilotinib (NIL).

**Methods:** An analysis of 345 CML patients at diagnosis (chronic phase) enrolled within 3 multicentric prospective studies of the GIEMEA CML Working Group (NCT00602092, NCT01353891) was performed. The initial treatment was NIL 300 mg Bid or NIL 400 mg Bid. Definitions: major molecular response (MMR), BCR-ABL1IS ratio < 0.1%, deep molecular response (MRD0), BCR-ABL1IS ratio < 0.01% with >10,000 ABL1 copies; progression, transformation to advanced phases; death, at any time and for any reason. Cumulative incidences of response were estimated under consideration of competing risks (progression, death) and compared by Gray test. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared by log-rank test.

**Results:** Patients expressing rare transcripts (e1a2 or e19a2; n=7) and patients with unknown transcript type (n=10) were excluded: 328 patients were evaluable: 38% e13a2, 19% e14a2, 53% e13a2 transcript and 3% expressing both transcripts. No significant differences in age, gender, Sokal or EUTOS long-term survival score distribution, presence of clonal chromosomal abnormalities in Ph+ cells, or NIL dose were observed. The median follow-up was 60 months (range 24-82 months). The response rates and the survival probabilities were uniformly lower in patients with e13a2 transcript compared to patients with e14a2 transcript (N=174), but the differences were not significant: MMR by 12 months, 66% vs 72%, p=0.244; MRD0 by 36 months, 56% vs 66%, p=0.067; estimated cumulative incidence of MMR, 82% vs 88%, p=0.135; estimated cumulative incidence of MRD0, 60% vs 69%, p<0.101; estimated PFS, 88% vs 93%, p=0.547; estimated OS, 89% vs 94%, p=0.232. The response rates and the survival probabilities of patients co-expressing the e13a2 and the e14a2 transcripts (N=30) were similar to or even better than the ones of e14a2 patients. Grouping together the patients with e14a2 transcript alone and the patients with co-expression of both transcripts (N=174+30=204), and comparing their outcome to patients with e13a2 transcript alone (N=133), better outcome was observed (cumulative incidence of MMR and MRD0, p=0.050 and p=0.036, respectively), but no outcome differences emerged (PFS and OS, p=0.340 and p=0.276, respectively).

**Summary/Conclusions:** Lower molecular response rates in patients with e13a2 transcript were observed and the differences were small and mostly not significant. No outcome differences were detected. Further studies in larger patient cohorts are required in order to clarify whether including the transcript type in the calculation of the baseline risk scores may improve prognostic stratification, and whether NIL or second generation TKIs should be preferred as first-line therapy in patients aiming at treatment-free remission.
Three patients (2 IM/HU, 1 IM) were lost to follow-up. As prospectively designed, all available IM/HU patients (n=77) were included in the analysis. According to the study protocol, patients from the CML IV study were to be added to obtain equal numbers for analysis. To arrive at a total of 77 IM patients, from study IV another 49 patients were selected by propensity score matching. The median age of the 154 patients was 55 years (range 18 – 82). The ELTS prognostic score was favorable for 141 patients and was high in 3 (5.7%), intermediate in 35 (24.8%) and low in 98 (69.5%), with no significant differences between treatment groups.

Results: The 5-year overall survival (OS) / progression-free survival (PFS) probabilities were 90.4 and 86.7% in the IM/HU and twice 84.9% in the IM arm respectively. With IM/HU, the probabilities of complete cytogenetic response (CCR) at 6, 12, and 18 months were 54.3, 84.0, and 93.7%, In the IM arm, the corresponding numbers were 70.4, 84.9, and 83.3% (p<not significant). Primary endpoint was MMR rate at 18 months. There was no significant difference between IM/HU (65.8%) and IM (66.0%). At 6 months, MMR in the IM/HU group was 41.1% (p=0.383) and at 12 months 41.9 (IM/HU) vs 58.9% (not significant). Time to event analyses of OS and PFS did not result in significant differences; neither did group comparisons between the probabilities of CCR and MMR. The median HU dose was 500mg (range 152-3000); the median IM dose was 400 mg (range 145-617mg). All numbers of adverse events in general or of adverse events of grade 4 were not different between the two arms, but cumulative incidences showed an earlier occurrence in the IM/HU than in the IM arm (p= 0.0343, Gray test)

Summary/Conclusions: Compared to imatinib only, the combination of Imatinib and HU resulted in a lower MMR rate at 6 months but a similar MMR rate at 18 months. Furthermore, IM/HU was associated with more early adverse events. There was no indication of a beneficial effect in the treatment of CML patients in 1st chronic phase using the combination of IM with HU.

PB1820
A MULTICENTER, OBSERVATIONAL, AMBISPECTIVE STUDY EVALUATING EFFICACY AND SAFETY OF GENERIC IMATINIB COMPARED TO GLEEVEC IN CHRONIC MYELOGENIC LEUKAEMIA IN CHRONIC PHASE - 3 MONTHS RESPONSE ANALYSIS

10Universidade Federal de São Paulo, 11Instituto de Estudos e Pesquisas São Lucas, São Paulo, 12Universidade de Campinas, Campinas, Brazil

Background: The efficacy of branded imatinib (Gleevec) in the first-line treatment of chronic myeloid leukemia (CML) has been demonstrated in several clinical studies. However, there is currently a lack of data on the long-term efficacy and adverse events of generic formulations of imatinib. In Brazil, CML patients have been treated in the public health system with generic imatinib since June 2013. Aims: The present study aims to evaluate the efficacy and safety of generic imatinib in the treatment of CML in comparison with the reference drug (Gleevec) in the first three months of imatinib treatment. Methods: This is a multicenter, observational, ambispective, cohort-type study. The study was initiated in January 2015 with the intended participation of 17 Brazilian centers. In the prospective group, were selected chronic phase CML patients who started their first-line treatment with generic imatinib between January 2015 and October 2016, whereas retrospective group was treated with Gleevec between January 2010 and December 2011. All patients started imatinib less than six months from diagnosis. Study data were collected and managed using REDCap electronic data capture tools. Demographic data were collected at diagnosis: age, gender, Sokal, Hasford, EUTOS score, comorbidities, cytogenetics, BCR-ABL transcript type. The definition of the responses followed the CML clinical criteria. Adverse events were assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.3, 2010. Statistical analysis: SPSS version 21.0 was used applying the chi-square and t-test, when adequate. All analysis considered p-value <0.05 as significant.

Results: Ten centers were included and 177 patients in the retrospective group and 68 patients in the prospective group so far. For this preliminary analysis, response data from 132 patients were available (47 from prospective and 85 from the retrospective groups). The median age of patients was 54 years in the prospective group and 46 years in the retrospective group (P=0.12). Sokal score in the prospective group was 1.22 and in the retrospective group 1.09 (P=0.14). The probability of achieving complete cytogenetic responses was 42.5% in the prospective group and 42% in the retrospective group (P=0.48). There was no difference between the groups concerning gender, Hasford, EUTOS scores, ECOG, blood cell counts at diagnosis and before starting imatinib and BCR-ABL transcripts. Regarding responses, there was no difference in the hematologic, composite cytogenetic responses and rate of BCR-ABL transcripts >10% at three months. However, there was a higher rate of failure at three months according to the ELN 2013 criteria in the prospective group (14.9% versus 4.7% Gleevec group, P=0.04). There was no significant difference in grade 3 and 4 hematological and non-hematological toxicity, but there was one early death in the prospective group (acute peripheral arterial occlusion and renal failure). Four patients discontinued imatinib: one from Gleevec group (resistance) and three from the generic group due to intolerance (1) and resistance (2).

Summary/Conclusions: According to ELN-2013 criteria, there was a higher rate of failure in the prospective group (generic imatinib) at three months, but no difference in toxicity. The register is ongoing; the confirmation of this data and the impact in prognosis will be evaluated in the long-term follow-up, after increasing the number of patients.

PB1821
COMPLEX ADDITIONAL CHROMOSOME ABERRATIONS IN PH-POSITIVE CELLS IMPACT ON CHRONIC MYELOID LEUKAEMIA PATIENTS’ SURVIVAL IN THE ERA OF TYROSINE KINASE INHIBITORS
M. Fominykh1,*, O. Shuhov2, I. Martynkevich1, V. Shuvaev1, E. Chelysheva2, A. Turykina1
1Clinical department, Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, 2Clinical department, National Research Center for Hematology, Moscow, Russian Federation

Background: Additional chromosomal aberrations (ACA) as marker of clonal evolution in chronic myeloid leukemia (CML) patients were previously noted in association with resistance to therapy. The presents of ACA have been associated with a worse prognosis for survival in the pre-TKI era. The ACA classiffication proposed earlier was based only on its frequencies. Whereas ACA’s clinical impact had not yet been clearly established.

Aims: The aim of our study was to evaluate the long-term impact of the ACA presence in Ph-positive cells in CML patients on TKI treatment results.

Methods: 30 patients with ACA in Ph-positive cells treated in our center from 2005 to 2015 years were included in this study. Cytogenetic analyses of at least 20 Giemsa-banded bone marrow metaphases were interpreted per ISCN 2013. We analyzed overall survival (OS) and cumulative incidence of CML-related death on TKI treatment. Cox regression was used for multivariate survival analysis, that included next covariates: number of ACA, type of ACA, age, TKI type, CP or AP at diagnosis. OS was estimated by Kaplan-Meier method with log-rank test for comparison. Cumulative incidence of CML-related death was estimated into consideration the presents of competing risks (CML-unrelated death) using Gray’s test for comparison between groups.

Results: Median follow-up period in ACA group (n=30) was 51 months (3-124). ACA at diagnosis were detected in 16 (53%) of 30 patients. Chronic phase was diagnosed in 23 (77%) patients. Accelerated phase was defined in 7 (23%) patients. In that group treatment of 6 patients was started with Imatinib and Dasatinib was given initially for one patient. »Major-route» ACAs (trisomy 8, +7(22)(9;22)(q34;q11), (17)(10), trisomy 19) was detected in 16 (53%) of 30 patients. Complex aberrations (2 ACA and more) were revealed in 7 (23%) patients, 4 patients from this group had »major-route» ACA. 10-years OS in the whole ACA group was 67%, 10-years cumulative incidence of CML-related death was 23%. Number of ACA (p=0.03, HR=13.2) and age (p=0.03, HR=1.14) had statistical significance influence on survival by regression analysis. 10-years OS was 31% and 77% (p<0.05) in patients with complex ACA and single ACA respectively, 10-years cumulative incidence of CML-related death was 54% for patients with complex aberrations versus 10% for single ACA patients (p<0.05) (Figure 1).

Figure 1.

Summary/Conclusions: Our results showed that TKI treated CML patients with complex ACAs have a higher risk of progression and death in comparison with single-ACA patients.
BCR/ABL1 TRANSCRIPTION ERRORS IN CP-CML PATIENTS TREATED WITH GI AS THE 2-ND LINE THERAPY

I. Dmytrenko1, V. Fedorenko2, Z. Martina2, V. Sholoyo2, T. Syhalytchynko1, Z. Minchenko1, I. Dyagi2
1Immunogenetic Laboratory, 2Hematology and Transplantology Department, National Research Center for Radiation Medicine, Kyiv, Ukraine

Aims: To explore the HRQoL profiles of patients with CML in the chronic phase (CP) who were treated with front-line imatinib or nilotinib, in order to assess the relationship between early response and HRQoL outcomes.

Methods: A prospective, longitudinal, single center study was conducted to assess the response to treatment with imatinib or nilotinib and the HRQoL profile of patients who were newly diagnosed with CML-CP and enrolled into ENESTchina study. Responses based on molecular and cytogenetic outcomes were measured according to the European LeukemiaNet recommendations, and patient-reported HRQoL profile was measured by the SF-36 health survey.

Results: Fifty-nine patients were randomly assigned to receive imatinib (n=31) or nilotinib (n=28). In multivariate analysis, the use of nilotinib was identified as an independent factor affecting the achievement of optimal response at 6 months (OR=3.9, 95% CI, 1.0-14.9; P =0.043) and 12 months (OR=5.6, 95% CI, 1.7-17.9; P =0.004). With a median follow-up of 60 months, the probabilities of failure-free survival (all P values <0.001) and progression-free survival (all P Values <0.05) at 5 years were significantly higher in patients who achieved optimal response at 3, 6, or 12 months than those who achieved non-optimal response (waring or failure), and overall survival rate at 5 years was significantly higher in those who achieved optimal response at 12 months (P =0.047). Achieving optimal response at 12 months was associated with better role limitation caused by physical health problems (P =0.0019) and role limitations due to emotional problems (P =0.0110) and was the sole factor associated with significantly improving physical component summary over time (P =0.0160). In addition, achieving optimal response at 6 months had a tendency of high physical functioning (P =0.0674), social functioning (P =0.0571), and role limitations due to emotional problems (P =0.04), and higher education level were also associated with better HRQoL subscales.

Summary/Conclusions: Achieving optimal response at 12 months was associated not only with longer overall survival and less treatment failure and disease progression, but also better HRQoL in newly diagnosed patients with CML-CP on front-line tyrosine kinase inhibitor.
SECOND-LINE TYROSINE KINASE INHIBITORS IN CHRONIC PHASE - CHRONIC MYELOGENOUS LEUKEMIA (CML-CP)

J. Cortes,1,2,3,4 L. Huynh,2,5 P. Brandt,3 M. DerSarkissian,4 G. Zaccardelli,1,2 D. Dala,3,4 J. Hussein,2,3,4 M. S. Duh2,5

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 2Epidemiology, Analysis Group, Inc., Boston, 3Novartis Pharmaceuticals Corporation, East Hanover, United States

Background: Achieving deep molecular response, ≥4.5-log reduction (MR4.5; BCR-ABL1 on the International Scale [IS] ≤0.0032%), is one of the important prerequisites for achieving treatment-free remission. Limited information is available on comparative rates of MR4.5 between nilotinib and dasatinib in second-line (2L) CML.

Aims: This study aims to investigate to time to achieving MR4.5 and major molecular response (MMR; ≥3-log reduction or ≤0.1% in BCR-ABL1 on IS) in CML-CP patients (pts) treated with nilotinib vs dasatinib in 2L.

Methods: A retrospective chart audit study was conducted to recruit oncologists (N=141) globally to conduct a retrospective medical chart audit. Physicians were instructed to select up to 4 pts who met the following criteria via a random letter generation scheme for the first letter of pt’s last name: diagnosed with CML-CP at age ≥18 years, initiated 2L nilotinib or dasatinib between 1/1/11 and 12/31/13, and had ≥12 mos of follow-up data after initiating 1L TKI. Multivariate Cox proportional hazards models accounting for country clustering random effects were used to assess the effect of nilotinib vs dasatinib on time to MR4.5 and MMR, adjusting for age, gender, Sokal risk score at diagnosis, hydroxyurea use before 1L TKI, 1st vs 2nd generation TKI as 1L, and reasons for 1L TKI discontinuation. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were reported. Adverse events (AEs) were also described.

Results: The study included 236 pts from Australia, Brazil, France, Germany, Italy, and Netherlands treated with nilotinib (N=115[49%]) or dasatinib (N=121[51%]) in 2L. Both groups had a similar mean follow-up of 23 mos, mean age of 57 years, and were 35% female. 8% of 2L nilotinib and 22% of 2L dasatinib pts were reported. The univariate Cox model showed that nilotinib had a non-significantly higher rate of achieving MR4.5 than dasatinib (32% vs 31% at 24 mos for 2L nilotinib and 2L dasatinib respectively, based on the Kaplan Meier estimator; unadjusted HR=1.09, 95% CI [0.87, 1.38], p=0.46); however, after multivariate adjustment, nilotinib reached a significantly higher rate of achieving MR4.5 (adjusted HR=1.36, 95% CI [1.07, 1.73], p=0.01) than dasatinib. Among those who achieved MR4.5, 45% of nilotinib pts maintained MR4.5 for ≥1 year vs 39% of dasatinib pts (p=0.60). Additionally, high-risk Sokal score (HR=0.31; 95% CI [0.14, 0.72], p=0.01) and resistance to 1L TKI (HR=0.60; 95% CI [0.42, 0.88], p=0.01) were inversely associated with achieving MR4.5.

There was no significant difference in MMR achievement between 2L TKI groups. Over 3 times more dasatinib pts experienced pleural and pericardial effusion AEs than nilotinib pts (9.9% vs 2.6%, p=0.02). One nilotinib pt had ischaemic heart disease AE vs none for the dasatinib group (p=0.49).

Summary/Conclusions: This retrospective chart audit study suggests that 2L nilotinib may be associated with a higher rate of MR4.5 than 2L dasatinib in CML-CP. Our results should be taken with caution as this study is susceptible to unmeasured confounding and biases due to its retrospective and observational nature. Rigorous clinical assessment in a prospective setting is needed to conclusively rates of patients achieving MR4.5.

PB1826

COMPUTATIONALLY INTELLIGENT PREDICTION OF CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA

Z. Cojbasic1, I. Cojbasic2,3,4, L. Macukanovic-Golubovic2,3, M. Vucic3,4

1Mechanical Engineering Faculty, University of Nis, 2Clinic of Hematology, Clinical Center Nis, 3Faculty of Medicine, University of Nis, 4Clinic of Hematology, Clinical Ceter Nis, Nis, Serbia

Background: Computational intelligence has been applied to a wide range of medical problems, and has already proven their strong potentials in medicine. Despite that, applications in hematology are still scarce.

Aims: In this study we have developed novel ANFIS neuro-fuzzy prognostic models on base of morphometric and clinical data, to enable better prediction of complete cytogenetic response (CCgR) for patients with chronic myeloid leukemia.

Methods: This prospective study included a consecutive series of patients with chronic myeloid leukemia (CML) who were started on imatinib therapy. Analysis was performed on 224 patients from 1/2011 to 12/2016, as the outcome variables. A total of 40 patients on imatinib therapy were included in the final analysis. Of these, 25 (62.5%), 29 (72.5%), and 32 (80%), respectively, achieved CCgR at 6, 12, and 18 months after initiation of imatinib. Computationally intelligent neuro-fuzzy models that were developed included EUTOS score on diagnosis and one of the following morphometric parameters: microvascular density, length of the minor axis, area or circularity of the blood vessel. Adaptive neuro-fuzzy systems represent a specific combination of artificial neural networks and fuzzy logic, thus combining the learning ability of artificial neural networks with the knowledge representation capability of fuzzy logic systems. ANFIS (Adaptive Neuro Fuzzy Inference System) consists of two input ANFIS model were respectively 75%, 75% and 75.5%, while area under curve on ROC graphs were 0.776, 0.829 and 0.875 respectively.

PB1827

A NATIONWIDE OBSERVATIONAL STUDY OF PONATINIB IN CHRONIC MYELOCYTIC LEUKEMIA OUTSIDE CLINICAL TRIALS

A. Shacham Abulafia1,2,3, R. Ratzon2, D. Lavie4, Y. Volchek5, R. Ram2,3, I. Hellman2,6, L. Shargian7, A. Gourevitch8, E. Chubar9, M. Koren-Michowitz2,10, I. zibershats11, P. Raanani12, U. Rozovsky12

1hemato-oncology, Rabin Medical Center, Petah Tikva, 2Sackler School of Medicine, Tel Aviv University, 3Department of Hematology, Hadassah-Hebrew University Medical Centre, Jerusalem, 4Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, 5Bone Marrow Transplantation Unit, Sourasky Medical Center, Tel Aviv, 6Department of Hematology, Meir Medical Center, Kfar Saba, 7Bone Marrow Transplantation Unit, Rabin Medical Center, Petah Tikva, 8Hematology Institute, Sorko University Medical Center, Beer-Sheva, 9Hematology unit, HaEmek Medical Center, Afula, 10Department of hematology, Assaf Harofeh Medical Center, Zeriffin, 11Department of hematology, Wolfson Medical Center, Holon, Israel

Background: In December 2014 the oral tyrosine kinase inhibitor (TKI), ponatinib was granted an accelerated approval by the FDA based on promising results from the phase II PACE (Ponatinib Ph-ALL and CML evaluation) trial. Yet, nowadays the use of this drug is limited because of safety issues, most notably the increase in severe vascular complications. Pre-ponatinib treatments: Patients received at least one other TKI and most received at least two different TKI...
based regimens (N=28, 76%). Nine patients (25%) underwent hematopoietic stem cell transplantation (HSCT) prior to ponatinib. The time that lapsed from diagnosis until ponatinib initiation ranged considerably (from 1 to 215 months, median 47 months). *Indications for ponatinib switch:* 26% of patients (N=9) switched to ponatinib because T315I mutation was detected. The remaining switched either because of progressive disease, i.e. accelerated (N=5, 14%) or blastic (N=6, 17%) phases, and 14 (39%) because they experienced loss of previous molecular or cytogenetics response. Only 5% (N=2) switched because of unacceptable side effects to previous treatments. Treatment with Ponatinib: Patients received ponatinib for a median time of 14 months (range: 1 to 5). The drug started at the recommended dose of 45 mg/day only in 60% (N=22) of patients and in 24% of them (N=9) the dose was reduced during treatment. The median survival time of patients with ponatinib was 38 months (95%CI: 30 to 47 months) (Figure 1). Patients died because of cerebrovascular event (N=1), sepsis (N=2) or graft vs host disease that developed shortly after HSCT. Response assessment: Response assessment was available for 32 patients (86%). Seventy percent (N=22) achieved molecular response, of which 60% (N=13) achieved at least major molecular response. The median time to maximal response was 7 months (range: 3 to 28 months). Drug discontinuation: Twenty four percent (N=9) discontinued ponatinib after a median of 7 months (range: 1 to 18 months) because of disease progression (N=6) or severe adverse effects in two patients (cerebrovascular event and myocardial infarction surviving at 5 years was 91%.

**Summary/Conclusions:** In our cohort ponatinib was almost always used in patients who experienced treatment failure to previous TKIs. Still, molecular response was achieved in most patients, even in those with progressive disease in accelerated or blastic phases. The vast majority of patients received reduced doses of ponatinib and although more than one third of patients were at-risk for vascular events, only two patients developed serious life-threatening vascular episodes. In heavily pre-treated patients, ponatinib is effective and safe and can be considered even in patients with cardiovascular risk factors.

**PB1828**

**MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOPANCYTHIA AT THE ONSET**


1Laboratory of Cyogenetics and Molecular Biology, 2National Specialised Hospital for Active Treatment of Hematological Diseases, 3Alexandrowska University Hospital, Sofia, Bulgaria

**Background:** Generally, chronic myeloid leukemia (CML) and essential thrombocythemia (ET) are characterized by distinctive clinical and laboratory character-istics, including the spectrum of genetic abnormalities - Philadelphia chromosome (Ph) and BCR-ABL fusion transcripts in CML and JAK2, CALR or MPL gene mutations in ET. Therefore, even in the presence of overlapping fea-tures in some cases, the correct diagnosis can be assigned. However, in rare cases Ph chromosome and BCR-ABL fusion transcripts can be found in oth-erwise typical cases of CML. The number of reported cases in the recent course of the disease and the response to tyrosine kinase inhibitors (TKI) in such patients with BCR-ABL1-positive thrombocytopenia is largely unknown.

**Aims:** To report the clinical course and response to TKI in patients (pts) with CML presenting with isolated thrombocytopenia at the onset.

**Methods:** In total, 31 pts with Ph(+) and/or BCR-ABL(+) isolated thrombocytopenia and a moderate or absent leukocytosis were retrieved from the hospital database. The cohort comprised 17 females and 14 males, at a median age of 47 years (range 23-86). Diagnosis was based on bone and blood marrow morphologic and differential, cytogentic and/or molecular testing according to the WHO criteria (2008). Molecular monitoring was carried out using Xpert BCR-ABL Monitor or Xpert BCR-ABL Ultra tests (Cepheid). In total, follow up data for at least 6 months (mean 65 months) are available for 25 patients treated with TKI as a first-line therapy.

**Results:** At diagnosis the median leukocyte count was 22 x10⁹ (range 6-36) and platelet count – 1316 x10⁹ (range 770-2815). Splenomegaly was found in 5 pts (16%). Only one patient was diagnosed in accelerated phase as the remaining presented in chronic phase at diagnosis. Interestingly, 4 pts (12.9%) had a history of an antecedent solid tumor. All patients enrolled in the study were BCR-ABL1(+): cs2a2 (n=16) or b2a2 (n=15). Karyotypes were available in 22 patients and classical Ph was found in 16 of them (69%), with variants (21.7%) a cryptic translocation was detected as well as a variant Ph in the remaining 2 pts (8.7%). Imatinib was used as a first line therapy in 15 pts and optimal response was achieved in 53.3% (n=8), while 5 were switched to a second line, and 2 - to a third line therapy. First-line treatment with nilotinib in 10 pts resulted in optimal response in 80% (n=8). In those with optimal molecular response (MR) was achieved in 80% (n=20), including deep MR in 56% (n=14). One pt was lost of follow up after optimal response was registered. No response was documented in 4 pts (16%) and progression to blast crisis developed in 2 of them. The mean OS was estimated 143 months and the cumulative propor-tion surviving at 5 years was 91%.

**Summary/Conclusions:** Interestingly, CML presenting with isolated thrombo-cytosis at diagnosis in our cohort had high proportion of antecedent malignan-cies and high incidence of cryptic Ph translocation without any specific correla-tion with the transcript types. However, the clinical course and molecular response to TKI therapy was similar to the reported in CML in general.

Acknowledgements: Partial support by the National Science Fund.

**PB1829**

**BCR-ABL1 MOLECULAR RESPONSES AT 12-18 MONTHS USING THE QUANTIDEX QPCR BCR-ABL1 IS KIT PREDICT LONG-TERM EVENT-FREE SURVIVAL IN PATIENTS WITH TKI-TREATED CML**

J. Brown1,*, A. Ruskin1, I. Beldor1, M. Fahey1

1Asuragen, Austin, United States

**Background:** Detection of BCR-ABL1 e13a2 or e14a2 transcripts (major break-point rearrangements, or translocations, also known as the Philadelphia chro-mosome) is important in CML monitoring tumor burden. The International Scale (IS) was established to standardize reporting relative to a common baseline. As newer TKI therapies create deeper responses, analytical sensitivity has become a critical topic in investigations into TKI discontinuation, where researchers require a clinically validated assay that calls a molecular reduction (MR) of ≥4.5 logs below baseline (i.e. MR4.5 or 0.0032%IS). To clinically validate the QuantideX qPCR BCR-ABL1 IS Kit and to reaffirm the clinical utility of BCR-ABL1 RT-qPCR monitoring in patients with (0;22) positive CML, a correlation between molecular response (MR) values and long-term outcome was determined.

**Methods:** The QuantideX qPCR BCR-ABL1 IS Kit uses standard TagMan chemistry to quantitate BCR-ABL1 and the ABL1 reference gene. Associated software reports an international scale BCR-ABL1 value and a log-transformed MR value, with a 3 log-reduction from pre-treatment baseline repre-sented as 0.1%IS or MR3.0. Three laboratories performed BCR-ABL1 testing on banked RNA specimens from 96 chronic phase CML patients from 2 hos-pitals drawn 12-18 months after starting TKI therapy. Clinical events (TKI therapy change, loss of complete hematologic or cytogenetic response, pro-gression to accelerated phase or blast crisis, kinase domain mutation, or death) were recorded through 36x4 months after starting TKI therapy. Two operators per site also tested serially-diluted reproducibility samples (range MR1.0 to MR4.0) in multiple replicates over 5 days. The 95% LOD for the assay was defined as the median measured%IS value of 4 analogous serially-diluted specimens.

Results: 51 patients had MR<3.0 at 12-18 months post-TKI. Of these 51 patients who did not achieve a major molecular response (MMR), 20 had a subsequent clinical event, 17 had no event, and 14 were lost to follow-up (LFU). 45 patients had MR≥3 at 12-18 months post-TKI. Of these 45 patients who did achieve MMR, 8 had an event, 28 had no event, and 9 were LFU. Kaplan-Meier survival curves demonstrated a 22% prolongation of event-free survival (95% CI 2%>42%) at 3 years between the two MR groups [p=0.028; 58% (95% CI 44%>75%) for MR<3 vs 80% (95 CI 68%>93%) for MR≥3]. Specimens with MR values ranging from MR1 to MR4 showed an average%CV of 2.8%. Day to day agreement was high with MR SD by operator ranging from 0.000 to 0.080. Site to site agreement was high with MR SD by site ranging from 0.000 to 0.069. The 95% LOD for both transcripts (e13a2 & e14a2) was MR4.7 (0.0022%IS), allowing sensitive detection of the MR4.5 cutoff that defines “complete molecular response” in ongoing treat-ment-free remission clinical trials.

**Summary/Conclusions:** The QuantideX qPCR BCR-ABL IS Kit has excellent reproducibility and analytical sensitivity, and the achievement of MR3 (major molecular response) by this assay predicts prolonged event-free survival in TKI-treated CML patients.
PB1830

SHOULD SWITCHING TO SECOND GENERATION TKIS BE A RULE IN PATIENTS WITH CP-CML AFTER 3-6 MONTHS OF IMATINIB TREATMENT? RETROSPECTIVE ANALYSIS OF CML PATIENTS TREATED IN A SINGLE BRAZILIAN CANCER CENTER

A.P.S. Ferreira1,2,*, F.S. Seguro1,2, A.B. Medina1, A.N.R. Abdoo2, F.V.R. Maciel2, L.Y. Okada1, I. Benedit1

1Hematology, Hospital das Clinicas da Faculdade de Medicina da USP, 2Hematology, Instituto do Cancro do Estado de Sao Paulo, Sao Paulo, Brazil

Background: Early molecular response is an important predictor for survival and therapy-free remission in chronic myeloid leukemia (CML). The current guidelines define BCR-ABL1 <10% at 3 months and/or 1-10% at 6 months as warning signs; however, it is not clear if switching imatinib to second generation TKIs in this scenario improves responses and overall survival in patients outside clinical trials.

Aims: To analyze the proportion of patients with major molecular response (MMR) at 12 months according to the molecular response at 3 and 6 months in a cohort of CML population, not enrolled in clinical trials and treated only with imatinib. Also evaluate the incidence of molecular responses log3.0, log4.0 and log4.5 at any time in patients who did not switch to second generation TKIs.

Methods: Retrospective analysis of all 226 patients diagnosed with CML from January 2007 until January 2015 in our hospital. The exclusions criteria were: advanced phases, inclusion in clinical trial, treatment with second-generation TKI in the first 12 months (due to toxicity or failure). The molecular response was evaluated according ELN recommendations: RQ-PCR assessment of BCR-ABL1 levels every 3 months until achievement of MMR, with molecular evaluation every 3-6 months afterward. All samples were analyzed in the same laboratory which was standardized since 2007.

Results: In the first cohort, 150 patients with CML chronic phase were analyzed. Optimal molecular responses by the ELN at 3 and 6 months were predictors of MMR by 12 months (94% vs 6%, p<0.0001 at 3m, 89.3% vs 10.7%, p<0.0001 at 6m), but there was no overall survival benefit. A second cohort with 119 patients received only imatinib, with a medium follow-up time of 71 months (13-117m), MMR was achieved by 60% of this imatinib-only group after 12 months and by more than 90% after 36 months (Figure 1). Patients with BCR-ABL1 <10% at 3 months and/or <1% had a higher probability of achieving MMR3, MMR4 and MMR4.5 at any time.

Summary/Conclusions: Our study shows that around 30% of the patients that do not fail to imatinib at the first year of treatment may be late responders. Not all patients should change therapy, if they have not reached MMR at 12 months. Molecular response at 3 at 6 months might guide the decision to switch TKI, but patient’s comorbidities, possibility of discontinuation and cost of therapy should also be considered.

PB1831

PREDICTIVE PARAMETERS FOR IMATINIB FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

D. Lekovic1,2,*, M. Gočić1,2, B. Zivojinovic1, N. Milic3, J. Jovanovic1, L. Okada1, I. Benedit1

1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, 3Institute for Medical Statistics, University of Belgrade, Belgrade, Serbia

Background: Development of tyrosine kinase inhibitors (TKIs) has significantly changed natural course of chronic myeloid leukemia (CML) and increased 10 year overall survival from 10-20% to 80-90%. Until recently, imatinib was the standard first-line treatment in CML. In 2013, nilotinib and dasatinib were approved as alternative front-line options. However, none of three TKI has been shown to have a clear survival advantage so this raised a debate on treatment selection. The early identification of patients expecting poor outcome is crucial for offering an alternative TKI regimen.

Aims: to analyze predictive parameters for Imatinib response as first-line treatment of CML patients.

Methods: The study was conducted on 168 consecutive patients with chronic phase of Ph+ CML who were diagnosed and treated at single university hospital from December 2000-January 2015. Following data were analyzed in terms of treatment response to Imatinib: demographic characteristics; currently used prognostic scores (Sokal, Hasford, EUTOS); liver and spleen size; laboratory parameters; influence of comorbidities analyzed by three scores (ACE 27, HCl- CI, SCIRS); occurrence of second malignancies; conventional cytogenetic parameters, duration of therapy, cytogenetic responses, overall survival (OS) and outcome.

Results: The mean age at diagnosis was 48±14.4 years (range: 18-74) with 87.5% of patients<65 years. The OS at 5 and 10 years was 97% and 91% respectively. Overall response to imatinib treatment was as the follows: 131 patients (78.8%) achieved complete cytogenetic response (CCyR), 24 patients (8.3%) minorCyR, 16 patients (9.5%) had no cytogenetic response, 2 patients (1.2%) had hepatic toxicity verified by liver biopsy in the first six months of Imatinib treatment and 1 patient (0.6%) was lost from follow-up. After achievement of CCyR, 25 patients (19%) had a progression of disease by losing CCyR or development of AP/BC. Median time to progression was 24 months (range 12-102). After the median follow up of 87 months in 61 patients (36.3%), the Imatinib failure was verified. All three prognostic scores (Sokal, Hasford, EUTOS), age, gender, hemoglobin level, leukocyte and platelet count, splenomegaly, eosinophils and basophils in peripheral blood were not found to be statistically significant for the Imatinib failure. Cox regression analysis identified hepatomegaly (p<0.001), leukocytosis10x109/L (p=0.001), blood blasts>1% (p=0.002) and presence of additional cytogenetic aberrations (ACAs) (p=0.002) as a predictors of Imatinib failure. Accordingly, we assigned risk scores based on hazard ratios (HR) to hepatomegaly (HR=4.089; 2 points), leukocytosis ≥5x109/L (HR=3.158; 1 point), blasts in peripheral blood ≥1% (HR=2.912; 1 point), and presence of ACAs (HR=11.110; 2 points). A final 3-tiered prognostic model named IMA-FAIL was thus developed, as low (score 0), intermediate (score 1-3), and high risk (score ≥4), according to which imatinib failure had 17% (8/47) of patients in low, 34.9% (30/88) in intermediate and 76.7% (23/30) in high risk group (HR=3.973, 95% CI for HR 2.237-7.053, p<0.001). In addition, presence of comorbidities as well occurrence of second malignancy were not predictors for Imatinib failure.

Summary/Conclusions: Hematologists are facing with challenge of making decision which TKI to choose upfront with increasing a chance to achieve best possible response. The new score allows better selection of patients who are suitable for treatment with Imatinib and may-give the guideline decision for front-line treatment of CML.

PB1832

A MULTICENTRE AUDIT OF SYMPTOMS AND QUALITY OF LIFE IN IRELAND CML PATIENTS ON TYROSINE KINASE INHIBITORS

J. Garry1,*, P. Murphy1, J. Quinn1, P. Thornton1, J. Sargent3, M. McClorey4, A. Fortune5, M. Fay5, N. Herlihy5, D. Angelo5, K. Fadalla6, C. Cotter6

1Haematology, Beaumont Hospital, 2Haematology, James Connolly Memorial Hospital, Dublin, 3Our Lady Of Lourdes Hospital, Drogheda, Ireland, 4Haematology, Our Lady Of Lourdes Hospital, Drogheda, 5Haematology, Mater Misericordiae University Hospital, 6Haematology, St. Vincent’s University Hospital, Dublin, Ireland

Background: The development of tyrosine kinase inhibitors (TKIs) over the last 20 years has dramatically improved the outcomes for patients with every stage of chronic myeloid leukaemia (CML). Since the approval of the first TKI, imatinib, in 2001, there are now currently 5 oral TKIs available. Three are approved for frontline use (imatinib, dasatinib and nilotinib) and 2 others (bosutinib and ponatinib) approved for intolerance or failure of prior TKI. Because CML patients remain on TKIs, it is important to determine if patients are continuing treatment and how well they are coping. It is important to identify if patients who are experiencing a worse quality of life as well as to identify patterns that may impact on treatment adherence.

Aims: The aim of this audit was to determine the impact of TKIs on symptom burden and QoL in CML patients currently on TKIs in Ireland. The audit was also to identify if patients are continuing TKI treatment and what patterns of non-adherence might be identified.

Methods: Across 7 centres in Ireland, a total of 87 CML patients currently on TKIs were identified. The mean age was 60 years with an equal sex distribution (44 male, 43 female). All of these patients were in chronic phase. 79% of patients were in MMR (major molecular remission) at the time of survey. 53 patients were on imatinib, 19 patients on nilotinib, 13 on dasatinib and 2 on bosutinib. Patients from the 7 centres were surveyed at varying time periods between July 2015 and Feb 2017. Patients were contacted by phone. Symptom burden and QoL were assessed using the MD Anderson Symptom Inventory (MDASI) tool.

Results: Among 70 patients currently on TKIs, 88% (61) of patients were on TKIs. Of these patients, 66% (39) were on first line TKI treatment. Of the 88% of patients who were on TKI treatment, 43% (37) reported experiencing at least one symptom, the most common symptoms were tiredness, pain and loss of appetite (11% each). The most common symptoms which interfered with daily activities were fatigue (27%), pain (22%) and weight loss (22%). Of patients, 5% (4) reported symptoms which interfered with their work. 42% (35) of patients had taken a sick day over the last 2 weeks due to symptoms. 64% (55) of patients had taken medication to control their symptoms.

Summary/Conclusions: This is the first audit in Ireland that measures the impact of TKIs on quality of life and symptom burden in CML patients currently on TKIs. The most common symptoms were fatigue, pain and weight loss. Overall, 42% of patients had taken a sick day over the last 2 weeks due to CML-related symptoms. Although the majority of patients reported that their symptoms were controllable, 42% of patients took medication to control their symptoms and 42% reported that their symptoms interfered with their work. This suggests that patients are managing these symptoms in their daily lives and may benefit from additional support to improve their quality of life. This audit is important as it highlights areas where patient support could be improved and is a call to action for healthcare professionals to assess the impact of TKIs on patient quality of life and symptom burden.
Results: Of the 87 patients surveyed, the most commonly prevailing symptoms were fatigue (72.4%), peripheral oedema (48.3%), disturbed sleep (46%), myalgia (43.7%) and dry mouth (39.1%). The least common symptoms were nausea (20.7%) and vomiting (6.9%). Almost half (49.4%) of patients reported at least 1 severe side effect (a score of 7 or more). The more severe side effects were drowsiness (mean score 6.3), myalgia (mean score 6), fatigue, nausea and vomiting (mean score 5.7 each). There was no significant difference in prevalence or severity among the different TKIs. As regards the perceived interference of symptoms on daily functioning, only 29% reported a score of 7 or more in at least 1 of the 6 interference items (i.e. general activity, mood, work, relations with others, walking and enjoyment of life), and only 14% reported that their enjoyment of life was severely affected (score of 7 or more). Of note, exactly two thirds of patients reported little or no interference with their enjoyment of life (score of 0-3).

Summary/Conclusions: As demonstrated in this audit, patients with CML on ITK frequently experience chronic adverse events (CTAE) and many patients taking second generation TKIs did not appear to have any difference in frequency or severity of symptoms or in QOL compared to patients on ima-tinib. Despite excellent survival results obtained with TKIs since 2001, an emphasis needs to be placed on symptom burden and QOL. The potential for adverse events with long term therapy may result in dose adjustments, treatment discontinuation, or nonadherence, all of which may negatively affect treatment efficacy. Therefore, assessment of QOL and the symptom burden experienced by patients with CML is useful to facilitate individual treatment decisions and to improve outcome as well as to evaluate the efficacy of emerging therapies.

PB1833

Cost-effectiveness of a Therapeutic Education Program (TPE) for Patients with Chronic Myeloid Leukemia and Treated by Tyrosine Kinase Inhibitors

M. Kur-Cordier1*, A. Chan Hew War2, L. Cochard3, M.-L. Fontoura4, V. Blazejewski5, P. Lenain6, R. Van7, F. Basuyau7, M. Daoquauet8
1Pharmacy, Centre Henri Becquerel, ROUEN, 2Pharmacy, Hopital Saint Louis, PARIS, 3Pharmacy, CHU de Caen, CAEN, 4Hematology, Centre Henri Becquerel, 5Pharmacy, CHU de Rouen, ROUEN, France

Aims: Within our cancer centre, an TPE program on ITK in the management of CML has been authorized since 2011. We conducted a pharmacoeconomic study to evaluate the TPE clinical impact on responses to TKI in patients with CML (based on recommendations from European Leukemia Net) and also the costs in terms of use of care.

Methods: Over the 12-month follow-up period, the study population consisted of 2 groups of CML patients monitored in our centre: - Intervention group (n=18) (IG) : Patients who benefited of TPE sessions on TKI between January 2013 and August 2015 - “Matched controls” group (n=18) (CG): Patients who benefited only from the usual care, matched to the “intervention” group. The method of pairing the 2 groups of patients according to the age at diagnosis, sex, the molecule used in first line and the prognostic risk according to the score of Sokal was used. The main criteria of efficacy was the MMR. The considered costs were: the cost of the TPE program, estimated on the basis of the French health insurance reimbursement per patient and the costs associated with the use of “supplementary” care (examinations, consultations and additional hospitalizations). The point of view was from French health insurance.

Results: Over the 12-month follow-up period, the number of patients in MMR was similar between the 2 groups (9 in IG versus 8 in CG). However, the average time to obtain the MMR was significantly shorter in IG (6.9 months±3.8) than in CG (11.3 months±2.1) (p <0.05). The mean duration of MMR maintenance over the 12-month follow-up period was significantly longer in IG (3.2 months±3.5) than in CG (1.5 months±1.9) (p <0.05). Regardless of the use of additional care, unexpected hospitalizations were significantly more numerous in CG than in IG (4 versus 0). Thus, costs associated with use of additional care were significantly lower in IG (€ 3,566) than in CG (€ 12,709). Thus, € 250 invested (annual allowance per patient) in the TPE saves € 508 in the use of care and reduces the time required to obtain a MMR by 4.4 months.

Summary/Conclusions: Thus, TPE is clinically and economically beneficial in our study population. By increasing the patient capacity to adapt to the treatment through the development of skills and adaptation processes, TPE reduces the costs of seeking care while improving the clinical response to treatment with a faster and more sustainable major molecular response.

PB1834

Role of Allo-HSCT in the Treatment of Patients with T315I Mutation in the TKI ERA

J. Smadja1, A. Cheval1, E. Mosnier2, N. Shukhov2, M. Barabanshchikova1, T. Ginodia1, I. Barhatov1, I. Martynekevich1, V. Shuavaev2, A. Turkina2, B. Afanaseveny1
1R.M. Gorbacheva Institute of Pediatric Oncology Hematology and Transplantation St. Petersburg State Medical I. Pavlov University, St.Petersburg, 2National research center for hematology of ministry of healthcare,Russian Federation, Moscow, 3Russian Research Institute of Hematology and Transfusionology, St.Petersburg, Russian Federation

Background: Resistance to tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) is frequently caused by point mutations in the BCR-ABL kinase domain, including the gatekeeper mutant T315I, which confers a high degree of resistance to all currently approved tyrosine kinase inhibitors except ponatinib. The role of allo-HSCT in such patients is still disputable.

Aims: To evaluate the results of different treatment modalities in CML patients with T315I mutation.

Methods: Retrospective analysis of 53 BCR-ABL T315I –positive CML patients (pts) was done. Allogeneic bone marrow transplantation (allo-HSCT) was made in 16 pts, 37 pts received only pharmacological therapy (21 pts received TKI as monotherapy or in combination with hydroxyurea, interferon-α or chemotherapy). At the time of T315I detection 29 (55%) pts were in CP, 19 (36%) pts had AP and 5 (9%) pts were in BC. Median (Me) age at the time of mutation detection was 47 years (15-76) (38 years in HSCT-group), 2 pts were in BC at the time of HSCT, 5 pts were in AP, 7 pts were in CP22. The number of points on EBMT scale: 3-4 points – 12(75%) pts, 5-7 points – 4(25%) pts. 11 (69%) pts received more than 2 lines TKIs before HSCT. In allo-HSCT group 11 (69%) pts had unrelated donors. Conditioning regimen in 13 (81%) pts had reduced intensity, in 3(19%) pts had MAC. Me time to HSCT after T315I detection was 10 months (1-38). Mutation analysis was performed by Sanger sequencing. Overall survival (OS) was estimated by Kaplan-Meier method with log-rank test for comparison between groups. Cox regression was used for multivariate survival analysis that included next covariates: age, phase on the time of mutation detection, performance of allo-HSCT, time to T315I detection from TKI start.

Results: Me follow-up time after T315I detection was 21 months (1-100). 5-years OS in whole group was 42% (Figure 1A). According to multivariate analy- sis only CML phase at the time of mutation detection significantly affect to survi-vival in whole group. All pts in BC (n=5, 2 in HSCT group and 3 in non-HSCT group) died within first year after T315I indication wherein Me survival time was 1.3 month (Figure 1B). 5-years OS in non-HSCT group (n=37) was 42% with Me survival time 2.8 years. 5-years OS after allo-HSCT (n=16) was 37% with Me survival time 5 months (Figure 1C). All living patients after allo-HSCT are in deep molecular response. There was no significant difference in 5-years OS between TKI (n=21) and non-TKI (n=16) pharmacological therapy (non-HSCT) groups (42% and 47% respectively, p=0.53) (Figure 1D).

Figure 1.

Summary/Conclusions: Detection of T315I mutation in TKI-resistant patients is extremely unfavorable factor for survival, especially in the advanced phase CML, and it is a great reason for switching to ponatinib or other new potential investigated drugs if possible. Allo-HSCT can be a potential option for this group of patients in case of good selection taking into consideration transplan-t risk, especially for patients in CP 22.

PB1835

Thyroid Functional Status in Patients with Chronic Myeloid Leukemia on TKIs - Single-Center Results

M. Dragičević1,2, I. Urošević1,2, M. Đokić1,2, I. Bajkic1,2, T. Ićin2,3, I. Perićić1,2, A. El Fara2,1
1Clinic for Hematology, 2Faculty of Medicine, University of Novi Sad, 3Clinic for Endocrinology, Diabetes and Metabolic Diseases, Novi Sad, Serbia

Background: Thyronine kinase inhibitors (TKI) as target specific compounds profoundly changed the outcome in patients with chronic myeloid leukemia (CML). TKI-induced thyroid dysfunction is now recognized as a common toxicity associated with some TKI. In the previous decade, cases of thyroid dysfunction have been reported in patients treated with different TKIs.

Aims: To evaluate the thyroid functional status in CML patients treated with imatinib and nilotinib.

Figure 1.
imatinib remains a good first choice for patients presenting with CML. Aims: Patients with chronic myeloid leukaemia (CML) treated with Tyrosine Kinase Inhibitors (TKIs) have relative survival rates of up to 90% that of age-matched controls. Patients achieving complete cytogenetic responses (CCyR) within 2 years of starting imatinib have survival rates equivalent to the general population. Newer TKIs are associated with faster and deeper treatment responses, but have a more toxic side effect profile as well as being more costly. Aims: This study looks at the 11 year experience of a single teaching hospital treating a population of almost one million and presents the response and survival data of this unscreened population of patients with CML treated with imatinib as initial therapy. Methods: A retrospective case record review was undertaken on CML patients identified from the regional cytogenetics department. Imatinib was available for routine prescription in the UK from 2003, so a 11-year period from 2003 to 2014 was selected to allow for adequate follow-up. Results: In total 83 patients were newly diagnosed in this time period. Four patients, treated on SPIRIT2 with dasatinib as initial therapy, have been excluded from the subsequent analysis, leaving 79 patients treated initially with imatinib 400mg daily. The median age at diagnosis was 53 years (range 13-93) with 74% of patients. The median follow up was 5 years (range in living patients 29-163 months). Fifteen patients have died (19%). The median age at diagnosis of these was 73 years. Two deaths were transplant-related, both in patients who had failed available TKIs and had mismatched transplants. The only treated patient who died of accelerated disease was intolerant of all TKIs and unfit for transplant. Three patients died of other malignancies (ovarian, bowel and melanoma). Seven patients were transplanted. Of the surviving 5, 2 had sibling transplants early in the TKI era, 2 had MUD transplants after failing imatinib prior to the availability of second line drugs, and one failed to make an adequate response to imatinib then nilotinib and received a second transplant. A selected population, up front imatinib with appropriate response (BCRABLABL ratio <0.01, MMR). An MMR was achieved by 60/79 (76%) patients. Of the 19 without MMR, 1 is lost to follow-up, and 9 have died, of which only one death was due to accelerated CML in a patient intolerant of all TKIs. Of those 9 patients living not in MMR, 8 have a CCyR. Three are elderly patients, one patient has taken a pragmatic approach: three are related to patient compliance, two to treatment limited by severe side effects and one had TKI interruption to facilitate cancer treatment. Of the sixty patients in MMR, 40 achieved this on standard dose imatinib. Four patients required increased dose of imatinib, 11 were switched to second line TKI and 5 were transplanted. A complete molecular response (BCRABLABL ratio <0.001, CMR) was achieved by 10 patients, six on standard dose imatinib. Summary/Conclusions: This data shows the real life experience of patients treated for CML in the TKI era. At six years follow up, the overall survival was 86% which is remarkably similar to that of the IRIS trial patients. Using an intention to treat analysis, a selected population with appropriate escalation of treatment where response is unsatisfactory achieves an MMR rate of 76%. This offers reassurance that where appropriate monitoring is feasible, imatinib remains a good first choice for patients presenting with CML.
adverse event (AEs), the 5-year event-free survival (EFS) and 5-year overall survival (OS) were all evaluated. Clinical features of the patients in different age groups are summarized in Table 1.

**Results:** The patient cohort consisted of 94 patients with median age of 53.4 years (range 18-78), with a slight predominance of females of 53.2%. There were more patients with intermediate and high Sokal scores in the EP group than in the groups MA and YA (p<0.001). To the contrary of that, most patients with high EUTOS score were observed in the group YA compared to MA and EP groups (p<0.001). The three groups were balanced regarding Euro score. The median duration of imatinib therapy was the longest in MA group (61.4 months vs 40.6 months in YA and 38.2 months in EP patients p<0.001). Furthermore, median follow-up duration was also the longest in MA group (64.3 months vs 48.5 months in YA and 44.7 months in EP patients p<0.001).

The rates of complete cytogenetic response (CCyR) were similar in all three analysed groups (80.6% in YA, 85.8% in MA and 75.9% in EP, p=0.328) while rates of complete cytogenetic response were the highest in the MA group (83.3% vs 63.3% in YA and 57.1% in EL, p=0.001). The percentages of patients switched to second-generation TKIs were similar in all three groups (36.7% in YA vs 33% in MA vs 32.1% in EP, p=0.559). There were the most of non-hematological AEs all grades in EP group (25% vs 13.3% in YA and 13.8% in MA, p=0.005). Hematological AEs also were common in EP group but not statistically significant (17.8% vs 10% in YA and in 12.1% in MA, p=0.156). The 5-years EFS in the MA group (88% (95% CI 82.1-96.9)) was significantly higher than in YA group (65.3% (95%CI 59.1-71.8)) and in EP group (60.2% (95%CI 49.5-73.7)). The 5-years OS in the EP group (74.7% (95% CI 65.9-89.0)) was significantly lower than in YA group (93.1% (95%CI 87.2-99.5)) and in MA group (90.8%) (95%CI 85.8-97.8). The number of deaths, both CML related or not, was the largest in the EP group (25% vs 13.3% in YA and 13.8% in MA, p<0.001).

### Table 1. Clinical features of the patients in different age groups.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Male</th>
<th>Female</th>
<th>Median Age (years)</th>
<th>Immature/Intermediate</th>
<th>Median Follow-up (months)</th>
<th>Median Duration of Imatinib Therapy (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>36</td>
<td>54</td>
<td>57.8</td>
<td>46.3</td>
<td>61.4</td>
<td>61.4</td>
</tr>
<tr>
<td>YA</td>
<td>51</td>
<td>43</td>
<td>55.1</td>
<td>44.5</td>
<td>50.6</td>
<td>40.6</td>
</tr>
<tr>
<td>EP</td>
<td>17</td>
<td>77</td>
<td>57.1</td>
<td>43.5</td>
<td>44.7</td>
<td>38.2</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Results of this study indicate that age at diagnosis impacts the course of chronic myeloid leukemia treated with imatinib. The best clinical outcomes have middle age patients in terms of the highest rates achieved optimal therapeutic response and longer survival without events and overall survival. The degree of therapeutic responds in the elderly is comparable with that observed in younger patients, but the presence of comorbidity and more frequent occurrence of adverse events were affecting relatively lower overall survival. Although it might be expected that younger patient population has a better clinical outcome than patients middle age, a possible cause of poor outcomes is probably a late diagnosis at an advanced stage of the disease.

---

**Enzymopathies, membranopathies and other anemias**

**PB1389**

CHARACTERIZATION OF HEMATOPOIETIC SAMPLES FROM PYRUVATE KINASE DEFICIENCY PATIENTS


1LACISEP (Advanced Therapies Unit), CIEMAT/CIBERER, 2LACISEP (Advanced Therapies Unit), CIEMAT, Madrid, Spain, 3Hematopoietic Innovative Therapies, CIEMAT, Madrid, Spain, 4Fondazione IRCCS Ca’ Granda, UO Oncodemologia, UOS Fisiopatologia delle Anemie, Ospedale Maggiore Policlinico, Milano, Italy, 5Instituto de Investigación contra la leucemia Josep Carreras, 6Hospital de Sant Pau, Barcelona, 7Hematología y Hemoterapia, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

**Background:** Pyruvate Kinase Deficiency (PKD) is an autosomal recessive disease caused by mutations in the PKLR gene. PKD produces chronic non-spherocytic hemolytic anemia, which can be fatal during early childhood and may result in lifelong transfusion dependence that in some instances persists despite therapeutic splenectomy. Although not considered a standard-of-care, allogeneic bone marrow transplantation has been curative in a limited number of cases. These findings, and the evidence that PKLR gene mutations are likely the sole etiology of the disorder, make PKD a candidate for gene therapy. Our lab has developed a therapeutic Orphan Drug lentiviral product (EMA: EU/3/14/1330; FDA: DRU-2016-5168) for the treatment of PKD and is working to develop an efficient and safe gene therapy clinical trial for the treatment of PKD.

**Aims:** In order to improve this new treatment, a more deep knowledge of the disease and its associated pathophysiology is necessary.

**Methods:** To characterize the hematopoietic profile of this disease, we have standardized flow cytometry protocols to perform both a qualitative and quantitative study of different population subsets. These included subsets of the hematopoietic stem cell compartment, erythroid progenitors, reticulocytes, mature erythrocytes and other mature lineages. Human routine samples consisted of peripheral blood, bone marrow and cord blood from PKD patients. In addition, xenogenic engraftment studies in immunodeficient (NSG) mice were also performed.

**Results:** Flow cytometry studies showed a clear imbalance in the erythroid populations. On the other hand, human PKD progenitors were able to engraft into NSG mice demonstrating that the disease does not likely impair hematopoietic stem cell capabilities.

**Summary/Conclusions:** Pyruvate Kinase Deficiency (PKD) is an autosomal recessive disease caused by mutations in the PKLR gene. Our lab has recently developed a therapeutic Orphan Drug lentiviral product for the treatment of PKD. In order to improve this new treatment, we are also working to deep into the knowledge of the disease and its associated pathophysiology. Flow cytometry studies have shown a clear imbalance in the erythroid populations. Functionally, results in NSG mice we have demonstrated that the disease does not likely impair hematopoietic stem cell capabilities.

---

**PB1840**

OSMOTIC GRADIENT EKTACYTOMETRY: A VALUABLE SCREENING TEST FOR HEREDITARY SPHEROCYTOSIS AND OTHER RED BLOOD CELL MEMBRANE DISORDERS

M.D.M. Marfú Pereira1, E. Llaudet Planas1, V. Rizzuto1, J.L. Vives Corrons1

1Red Blood Cell Pathology and Hematopoietic Defects, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

**Background:** Red blood cell (RBC) membrane disorders constitute one of the major causes of chronic hereditary hemolytic anemia. Main RBC membrane disorders, namely hereditary spherocytosis (HS), hereditary elliptocytosis (HE) and hereditary stomatocytosis (HST), alter membrane cohesion, membrane mechanical stability, and RBC volume, respectively. As a consequence, RBC deformability is compromised leading to their premature removal from circulation, manifested as hemolytic anemia. New generation osmotic gradient ektacytometry has become a powerful procedure for measuring red cell membrane deformability and therefore for the diagnosis of red blood cell membrane disorders.

**Aims:** The aim of this study is to evaluate osmotic gradient ektacytometry as an adequate assay to perform screening of membranopathies, focusing on the differential diagnosis between HS and non-spherocytic membrane defects such as HE and dHSt.

**Methods:** A total of 75 patients with chronic hemolytic anemia oriented as hereditary RBC membrane disorders (hemoglobin disorders discarded and negative Coombs test) were included during a period comprised between January 2015 and August 2016. Normal controls were obtained from blood donors. Osmotic gradient ektacytometry was performed using the osmoscan module of the Laser-assisted Optical Rotational Deformability Cell Analyzer: LoRRCa MaxSis (RR Mechatronics). Evaluation of osmoscan parameters

---
robustness for HS diagnosis was performed using the receiver operating characteristic (ROC) curve analysis. The optimal cut-off was determined as the one with the highest likelihood ratio. Statistical analysis was operated with GraphPad Prism.

Results: Specific patterns of osmotic LoRRCa MaxSis were observed for each individual membranopathy. All HS curves were bell shaped but two different profiles were identified both presenting increased Omin, and decreased Elmax and AUC. HE curves showed a characteristic trapezoidal shape with a decreased Elmax, Omax and AUC. dHSt curve was bell shaped with a specific decrease in Othyer and a slight increase in Elmin. Reference ranges for each osmotic parameter were established with 171 healthy subjects and compared with the values of the parameters obtained from the different RBC membrane disorders. ROC curve analysis was performed for HS and each one of the non-HS groups separately. The results determined that Elmax was the parameter that better separated HS from normal controls and dHSt, while the Omin was the best to separate HS from HE. The optimal Elmax cut-off to differentiate HS from normal controls had a sensitivity of 94.46% (specificity 99.42%), while the optimal Omin cut-off to differentiate HS from HE was >159.0 (sensitivity 95.38%, specificity 85.71%). Expressing the results as% of variation in relation to the mean of our normal controls, the best combination of parameters for HS diagnosis would be Elmax <3% and Omin >5.2%. This combination of Elmax and Omin >5.2% was used as criteria to classify all the 246 samples included in the present study, and the result showed 62 samples detected as HS and 184 as no-HS. Of the 62 patients identified as HS, 61 were real HS (specificity 98.38%) and 1 was an HE. On the other hand, 4 HS patients were identified as non-HS (sensitivity 93.85%).

Conclusion: We can conclude that, the inclusion of LoRRCa osmocsm as a screening test in RBC membrane diagnostic workflow will signify an important advance for the accurate diagnosis of HS patients, as well as for the identification of HE and specially dHS patients.

PB1842
RARE RED BLOOD CELL ENZYMOPATHIES INDUCED CHRONIC NONSPHEROCYTIC HEMOLYTIC ANEMIA: NEXT GENERATION SEQUENCING BASED APPROACH

M. Jamwal1,*, A. Aggarwal1, P. Sharma1, D. Bansal2, P. Malhotra3, A. Maitra4, D. Bansal1

Background: Red blood cell enzymopathies are mostly inherited autosomal recessive monogenic disorders. Mutations in the genes encoding red blood cell enzymes could lead to chronic nonspherocytic hemolytic anemia (CNSHA). The clinical manifestations are jaundice, cholelithiasis, splenomegaly, with usually normocytic normochromic hemolytic anemia. Phenotypes vary from having fully compensated hemolysis (without anaemia) to severe hemolytic anemia requiring regular transfusions. Definitive diagnosis is difficult when biochemical test results are not consistent/fail to identify defects. Molecular diagnosis by gene-by-gene approach is expensive, time consuming and cumbersome as testing for multiple genes is required. A gene-by-gene approach is expensive, time consuming and cumbersome as testing for multiple genes is required. Molecular diagnosis by gene-by-gene approach is expensive, time consuming and cumbersome as testing for multiple genes is required.

Aims: The patients with HS were diagnosed according to clinical findings for hemolytic anemia, splenomegaly and spherocytes in peripheral blood. Hemoglobin, reticulocyte count, total/direct bilirubin, spherocytes in blood smear (BS), EMA binding test, OF test, and cryohemolysis test were obtained from patients and control groups. Correlation between EMA, OF and cryohemolysis tests were evaluated.

Results: Twenty-five male, 17 female HS patients aged between 1.0-19.0 years and 38 male, 47 female healthy controls were evaluated. There were no differences between both groups in terms of age and sex (Table 1). The median (range) values of hemoglobin (%), reticulocyte count (%), mean corpuscular volume (fl), MCHC (%) and total bilirubin level were seen in Table 1. Besides MCV value, there were no other significant differences between control and patients (Table 1). The median MCF of HS patients was significantly lower than that of healthy controls while cryohemolysis and osmotic fragility were higher in HS patients than healthy controls (Table 1). There were moderate concordence between cryohemolysis and EMA test (r=0.355, p<0.001). The sensitivity of EMA was 92.86%, specificity was 82.35%, PPV was 72.22, NPV was 98.46. EMA was superior diagnostic test to osmotic fragility. (sensitivity 95.38%, specificity 85.71%). Expressing the results as% of variation in relation to the mean of our normal controls, the best combination of parameters for HS diagnosis would be Emax <3% and OMmin >5.2%. This combination of Emax and OMmin >5.2% was used as criteria to classify all the 246 samples included in the present study, and the result showed 62 samples detected as HS and 184 as no-HS. Of the 62 patients identified as HS, 61 were real HS (specificity 98.38%) and 1 was an HE. On the other hand, 4 HS patients were identified as non-HS (sensitivity 93.85%).

Conclusion: We can conclude that, the inclusion of LoRRCa osmocsm as a screening test in RBC membrane diagnostic workflow will signify an important advance for the accurate diagnosis of HS patients, as well as for the identification of HE and specially dHS patients.

Table 1. Comparison of Clinical and Laboratory Findings in Hereditary Spherocytosis groups and Healthy Controls

<table>
<thead>
<tr>
<th>Parameter</th>
<th>HS patients (n=62)</th>
<th>Healthy Controls (n=184)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/F</td>
<td>25:37</td>
<td>100:84</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.6 (0.1-19.0)</td>
<td>12.0 (2.0-20.0)</td>
<td>0.416</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apo (ng/mL)</td>
<td>8.4 (1.0-21.0)</td>
<td>12.0 (2.0-20.0)</td>
<td></td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>32.0 (27.0-35.0)</td>
<td>32.0 (27.0-35.0)</td>
<td></td>
</tr>
<tr>
<td>MCV (fl)</td>
<td>61.3 (58.3-65.0)</td>
<td>61.3 (58.3-65.0)</td>
<td></td>
</tr>
<tr>
<td>MCH (pg/cell)</td>
<td>22.0 (19.0-25.0)</td>
<td>22.0 (19.0-25.0)</td>
<td></td>
</tr>
<tr>
<td>Emax (%)</td>
<td>92.86</td>
<td>82.35</td>
<td></td>
</tr>
<tr>
<td>OMmin (%)</td>
<td>98.46</td>
<td>98.46</td>
<td></td>
</tr>
<tr>
<td>Tcrit (%)</td>
<td>15.0 (10.0-20.0)</td>
<td>15.0 (10.0-20.0)</td>
<td></td>
</tr>
<tr>
<td>EMA (%)</td>
<td>72.22</td>
<td>72.22</td>
<td></td>
</tr>
<tr>
<td>OF (%)</td>
<td>98.46</td>
<td>98.46</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: In this study EMA-FC was more sensitive and specificity than osmotic fragility. However specificity and PPV of cryohemolysis was higher than other test. Also we showed moderate concordance cryohemolysis and EMA test. Although high sensitivity and specificity of EMA test there were need to use other tests together with family history of patient, physical examination, evaluation of blood smear and several tests for HS diagnosis.

PB1843
ADVANCES IN DIAGNOSIS OF HEREDITARY HEMOLYTIC ANEMIAS: THERMOGRAVIMETRY COUPLED WITH CHEMOMETRICS

R. Risoli1, S. Materazzi2, F. Sorrentino1, L. Maffei1, C. Boffi2, P. Caprar1,*, D. Roppel1

1Department of Chemistry, Sapienza University of Rome, 2Thalassemia Unit, S. Eugenio Hospital, 3Haematology, Oncology and Medical Medicine, Istituto Superiore di Sanità, Rome, Italy

Background: The differential diagnosis of hereditary hemolytic anemia is generally carried out by applying different diagnostic protocols depending on the specific congenital erythrocyte defects. Thermogravimetric analysis (TGA) coupled with chemometrics has recently been proposed as a rapid and cost effective diagnostic tool for β-thalassemia screening. This model, consisting of Parallel Factor Analysis-Discriminant Analysis (PLS-DA), permitted the discrimination of thalassemic patients and healthy individuals, using thermogravimetric curves of blood samples [1].

Aims: In this study, the capability of thermogravimetry in conjunction with a mutal-
tivariate statistical analysis was investigated for the screening of hereditary hemolytic anemias due to different erythrocyte defects.

**Methods:** Whole blood samples collected in K$_2$EDTA were obtained, after informed consent, from patients suffering from congenital hemolytic anemias and were analyzed using the thermobalance TGT7 (Perkin Elmer) without any pretreatment and the resulting curves were compared with those of healthy individuals. Two groups of hereditary hemolytic anemias were considered: the hemoglobinopathies (sickle cells anemia and thalassemia) and the erythrocyte membrane defects (hereditary elliptocytosis and hereditary spherocytosis).

**Results:** The characteristic profile of the blood sample thermal decomposition and the first derivative (DTG) of the TG curve showed that blood 2 samples from anemic patients were clearly distinguished from those of healthy individuals as a result of different amounts of water and corpuscular fraction. The chemometric approach based on Principal Components Analysis (PCA) allowed a quick identification of differences between healthy and anemic patients in order to point out a model of prediction in patients with heterogeneous congenital hemolytic disorders.

**Summary/Conclusions:** The achieved results allow to consider the coupling TGA/Chemometrics as a promising diagnostic approach to provide a high-throughput and sensitive tool to obtain an early detection of hereditary hemolytic anemias using only a few microliters of blood without any pretreatment and with an hour of analysis time.

**PB1844**

**DEVELOPMENT OF A POINT-SCORING SYSTEM FOR EARLY DIAGNOSTIC TESTING IN GAUCHER DISEASE: APPLICATION OF FINDINGS FROM THE GAUCHER EARLIER DIAGNOSIS CONSSENSUS DELPHI INITIATIVE**

S. Salek$^1$, J. D. Kuter$^2$, A. Mehta

$^1$School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, $^2$Center for Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, $^3$Department of Haematology, Royal Free Hospital, UCL School of Medicine, London, United Kingdom

**Background:** In the Western hemisphere, Gaucher disease (GD) type 1 is the most common GD phenotype, but the prevalence of GD type 3 is increasing. The order of signs and symptoms of the different GD phenotypes ranges from fatal perinatal to asymptomatic adult disease, and the heterogeneity of its presentation contributes to both misdiagnosis and delays in diagnosis by clinicians unfamiliar with the disease. The Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative determined which signs and patient co-variables are regarded by experts in GD as most indicative of GD types 1 or 3 in the early stages.

**Aims:** From the findings of the GED-C expert consensus, to generate a simple web-based point-scoring system (PSS) suitable for use across clinical specialities, that provides guidance based on patients' presenting signs as to whether GD diagnostic testing is appropriate.

**Methods:** An anonymous three-round Delphi process, conducted among a global panel of 22 expert physicians, established consensus on which signs and co-variables may be important in early GD type 1 and, separately, in early GD type 3. In round 1, free-text responses provided by the panel were categorized and consolidated into summary factors by the non-voting co-chairs. In round 2, the factors were rated for importance by the panel using a 5-point Likert scale (1 = not important, 3 = important, 5 = extremely important). Any factors assigned an importance score of ≥3 by >75% of respondents were then rated for agreement in round 3, using a 5-point Likert scale (1 = strongly disagree, 3 = neither agree nor disagree, 5 = strongly agree). Consensus was defined as a score of ≥4 by >67% of respondents. Factors meeting this threshold were classified as major; all other factors were classified as minor. The co-chairs defined value ranges corresponding to mild, moderate or severe forms of five of the major signs of GD (anaemia, hepatomegaly, hyperferritinaemia, splenomegaly and thrombocytopenia). Panel members indicated whether they regarded each range as consistent with a GD diagnosis. This information was used in combination with the classifications of signs and co-variables as major or minor to create a prototype PSS.

**Results:** The achieved results allow to consider the coupling TGA/Chemometrics as a promising diagnostic approach to provide a high-throughput and sensitive tool to obtain an early detection of hereditary hemolytic anemias using only a few microliters of blood without any pretreatment and with an hour of analysis time.
PB1846
CHARACTERISTICS AND MANAGEMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA: A SINGLE CENTER STUDY WITH 32 CASES
A.F. Yilmaz1, H.D. Kiper Unal1, T. Yuksel Karalı2, M. Kılıç3, F. Gediz1, K.B. Bayman Payzin1
1Hematology, 2Internal Medicine, Izmir Katip Celebi University Ataturk Research and Training Hospital, Izmir, Turkey

Background: Autoimmune hemolytic anemia (AIHA) is characterized by red blood cell destruction mediated with autoantibodies against RBC antigens. Most common type is warm AIHA which can be either idiopathic or secondary to underlying disorders with immune disturbance. Determining the optimal therapy is a challenge because of insufficient data from prospective controlled trials.

Aims: To evaluate the clinical characteristics, treatment responses and outcomes of our AIHA patients.

Methods: The clinical data of 32 patients with AIHA diagnosed and treated in our center between 2008 and 2016 were retrospectively analyzed.

Results: Median age at diagnosis of AIHA was 45 years (range:20-74), Male:female ratio was 1/1.3. 24 of 32 patients (75%) had primary AIHA and 8 (25%) had secondary AIHA with underlying disorders as SLE in 2 patients, mixed connection tissue disease (MCTD) in 2, psoriatic arthritis in 1, chronic lymphocytic leukemia (CLL) in 1, marginal zone lymphoma in 1 and, chronic HCV infection in 1. Median Hemoglobin (Hb) level was 7.4 g/dl and 5 patients also had thombocytopenia (<15000) beside hemolytic anemia. Mean LDH level was 544, indirect bilirubin was 2.7, reticuloocyte was 11.3%. 18/32 patients (56%) required transfusion. In all patients who required treatment (94%) corticosteroids were the first-line therapy with an initial response rate of 93%. Median steroid duration was 3 months ranging from 1.5 to 96 months. Relapse was occurred in 15 of 30 patients who received steroid (50%) with the median time to relapse (TTR) of 12 months (range:5-72 months). 11/30 patients (37%) required second-line therapy; seven had undergone splenectomy, three received rituximab, and one received danasum. All of the patients who undergone splenectomy had CR in first month and relapse after splenectomy was seen in 5/7 patients (71%) with a median duration of 60 months. Of 3 patients who were treated with standard dose of Rituximab; two achieved CR and one did not achieve any response. One of two rituximab-responsive patients relapsed at 26. and 60. months and re-treated by rituximab; still following with CR for 16 months.

Summary/Conclusions: Although corticosteroids are the first choice of initial treatment of AIHA, most of the patients relapse at follow up. Steroid dependency and intolerance are also challenging. Splenectomy is still a considerable option for second-line therapy because of its high response rates and long remission durations. Rituximab is the other effective second-line therapy option with similar response rates to splenectomy. Until prospective studies will be performed, retrospective data would help the clinicians to choose best treatment algorithm for AIHA.

PB1847
THE IMPACT OF THE REORGANIZATION OF THE PATIENT CARE PROCESS FOR GAUCHER DISEASE IN HEALTH SYSTEM
F. Blanco-Favela1, R. Silva-Garcia2, E. Avila-Arreguin3
1Hematology, 2Internal Medicine, 3Universidad de México, Ciudad de México

Background: Gaucher disease (GD) is a multisystemic disease of lysosomal storage that is caused by deficient activity of the glucocerebrosidase enzyme resulting from a recessive autosomal hereditary mutation in the β-glucocerebroside gene. The accumulation of glucocerebrosidase in the lysomes damages the hematological, skeletal, and nervous systems and leads to three varieties of the disease: type 1, which is non-neuropathic, and types 2 and 3, which are neuropathic. In Mexico, the process by which patients with lysosomal disease is followed was cared for was recognized by the Clínicas de Referencia Nacional y Grupos de Expertos en Enfermedades Lisosomales (National Reference Clinics and Expert Groups on Lysosomal Diseases (EGLDs)), who created the Guías de Práctica Clínica (Clinical Practice Guidelines) for GD.

Aims: To evaluate the results obtained for 39 patients diagnosed with type 1GD (25 women and 14 men) through the National Reference Clinics and EGLDs.

Methods: The clinical case of 39 patients was analyzed and the number of patients treated with and without complications, improved care, and optimized the use of resources.

Results: Four of the 39 patients were found to have been incorrectly diagnosed with GD, the remaining 35 patients completed the treatment goals, which included an antihemolytic remission rate of 75% and a remission rate of 82% for the β-glucocerebrosidase gene. The patients were treated with imiglucerase enzyme at 60 U/Kg every 14 days. The enzymatic activity in the β-glucocerebrosidase and the chitotriosidase was determined. We determined the optimal treatment for 39 patients. In the hemoglobin and platelet concentrations, we observed that the degree of hepato- splenomegaly, bone density, and skeletal pain was reduced.

Summary/Conclusions: This reorganization of patient care successfully reduced complications, improved care, and optimized the use of resources and costs of GD treatment.
Gene therapy, cellular immunotherapy and vaccination

PB1849
DEMONSTRATION OF FUNCTIONAL SIMILARITY OF PROPOSED BIOSIMILAR ABP 798 TO RITUXIMAB
H. McBride1,*, G. Maher1, H. Swee2, I. Foltz2, J. Cannon1, S. Kuhns1
1Biosimilars Development, Amgen Inc., Thousand Oaks, United States, 2Biosimilars Development, Amgen British Columbia, Burnaby, Canada

Background: Proposed biosimilars undergo comprehensive structural and functional characterization before they can be studied in confirmatory clinical trials. ABP 798 is being developed as a biosimilar to rituximab. The originator of rituximab would be warranted to reveal the mechanism and clinical significances of these delayed effects on the levels of G-CSF itself as well as of other cytokines which could affect on the neuroregenerative potential. Further studies would be warranted to reveal the mechanism and clinical significances of these delayed effect of G-CSF or mobilized PBSCs.

Aims: To check if MYD88 participates in activating PRAME expression in leukemia cell lines.

Methods: Three cell lines were used for incubation with anti-PRAME antibody: chronic myeloid leukemia cell line K562 with high PRAME expression level (645%), acute monocytic leukemia cell line THP-1 with intermediate PRAME expression level (2,92% relative to ABL) and acute myeloid leukemia cell line NOMO-1 with low PRAME expression level (0,98%). After 1 and 4 hours of experiment in K562 cell line PRAME expression level (2,92% relative to ABL) and acute myeloid leukemia cell line THP-1 with intermediate PRAME expression level was increased in 1,1 and 2,5 fold under control. In THP-1 line PRAME expression level was increased in cell during lipopolysaccharide-treatment conditions. Role of MYD88 in this process still be unknown.

Results: After 1 and 4 hours of incubation total RNA was extracted and PRAME and MYD88 expression levels were measured.

Summary/Conclusions: We conclude that LPS after binding with TLRs initiates activating signal to PRAME gene via MYD88.

PB1851
MYD88 IN PRAME GENE ACTIVATION
V. Misyurin1,*, N. Lyzhko1, A. Misyurina2, J. Finashutina1, V. Tikhonova1, L. Kesaeva1, O. Solopova1, N. Kasatkina1, M. Baryshnikova1, E. Misyurina2, A. Prokopiev1, A. Misyurin1
1*N.N.Blokhin Russian Cancer Research Center" Ministry of Health, 2National Research Center for Hematology, 3City Clinical Hospital No52 Moscow Health Department, 4Moscow state Academy of Veterinary Medicine and Biotechnol- ogy - MVA by K. I. Skryabin, Moscow, Russian Federation

Background: PRAME is the most frequently expressed non-X-chromosomal cancer-testis gene in solid and hematological cancer. It is important, because PRAME often has a bad prognostic significance. In early studies was found that PRAME frequently coexpressed in translocation-harboring (like t(8;21), t(15;17) and t(9;22)) haematological diseases. Authors supposed that chimeric genes are activators of PRAME expression. But in large cases with normal karyotype PRAME is also expressed. Another reason for PRAME expression is promoter demethylation. But demethylating agents cannot activate PRAME expression in hematological cells taken from healthy donor. So presence of chimeric genes and methylation status only are not enough to explain why PRAME can be expressed in high level. Wadelin et al. found that PRAME expression level was increased in cell during lipopolysaccharide-treatment conditions. Role of MYD88 in this process still be unknown.

Aims: To check if MYD88 participates in activating PRAME expression in leukemia cell lines.

Methods: Three cell lines were used for incubation with anti-PRAME antibody: chronic myeloid leukemia cell line K562 with high PRAME expression level (645%), acute monocytic leukemia cell line THP-1 with intermediate PRAME expression level (2,92% relative to ABL) and acute myeloid leukemia cell line NOMO-1 with low PRAME expression level (0,98%). All cell lines were incubated in RPMI 1640 with addition of LPS in final concentration 10 ng/ml. After 1 and 4 hour of incubation total RNA was extracted and PRAME and MYD88 expression levels were measured.

Results: After 1 and 4 hours of incubation in K562 cell line PRAME expression level was increased in 2,7 and 7 fold under control, respectively, and MYD88 expression level increased in 1,1 and 2,5 fold under control. In THP-1 line PRAME expression level was increased in 20 and 25 fold, respectively, and MYD88 expression level was increased in 5,5 and 6,5 fold. In cell line NOMO-1 PRAME expression level was increased in 10 fold after 1 hour and in 14 fold after 4 hours, and MYD88 expression level was increased in 2,4 and 3,2 fold after 1 and 4 hours of experiment, respectively. Strong correlation between MYD88 and PRAME expression levels was observed (Pearson correlation coefficient 0,98).

Summary/Conclusions: We conclude that LPS after binding with TLRs initiates activating signal to PRAME gene via MYD88.
Hematopoiesis, stem cells and microenvironment

PB1852

PD-1 IS HIGHLY EXPRESSED ON MEMORY T-CELL SUBSETS RESIDING IN BONE MARROW BUT NOT IN PE-RIPHERAL BLOOD IN HEALTHY INDIVIDUALS

N. Popova1,*, M. Drokov1, A. Kuchmiry2, A. Vdovin3, J. Davydova3, L. Kuzmina1, D. Dubnayk1, E. Mikhailova1, V. Vasilyeva1, O. Koroleva1, Z. Konova1, I. Galtseva2, G. Efimov2, E. Parovichnikova1, V. Savchenko1

Bone marrow transplant department, 2Laboratory of post-transplant immunology, 3Laboratory of immunophenotyping, National Research Center for Hematology, Moscow, Russian Federation

Background: Recently memory T lymphocytes were shown to be a highly heterogeneous cell compartment comprising different phenotypes, functional activities, gene expression profiles and survival capacities. Phenotypically due to the differentiation stage and functional activities memory CD8+ T cells can be divided into four cell memory subsets (Tem, Tcm, Tcl, Ttm), central memory (Tcm) effector memory (Tem) and terminal effector (Tte) and reside in bone marrow (BM) as long-lived persistent T cells [Mahnke YD et al., 2013]. Programmed cell death protein 1 (PD-1) is well known as a negative immune regulator of T cells that has detrimental effects on anti-viral, anti-tumor immunity, mediates tissue tolerance to protect against immune-mediated tissue damage. Currently anti-PD1 immunotherapies are among the most effective anti-cancer immunotherapies available. PD1 pathway blockade is a key pathogenic mechanism [Bousiques VA et al., 2014]. Understanding the influence of PD-1 pathway on memory T-homeostasis in BM might be critical for improving treatment of patients with cancers and hematological malignancies, but is still not well understood.

Aims: To evaluate PD-1 expression on distinct memory T cell subsets in BM and PB of healthy donors.

Methods: The first portion of BM and a sample of PB were obtained from healthy donors (n=10, m=6, f=4) with age 37.5 (22-53) years old. Numbers of white blood cells (WBC) in BM and PB samples were evaluated by Sysmex XE-2100 hematology analyzer. 1*10^6 of WBC (excluded nucleated red blood cell) from BM and PB were stained using “lyse-wash-stain” standard protocol. The CD8-APC-Cy7, CCR7-PE-Cy7, CD28-PE, CD45R0-FITC, PD1-APC antibodies were used for cell activation and staining and 7-AAD was used for to discriminate dead cells during flow cytometry.

Results: PD1 expression by T memory cell subsets is shown in the Table 1 (median with interquartile range). The percentage of PD1+ cells within Tcm CD8+ subset was 34.2%, 8.03% in BM versus 10.4%, 1.23% in PB. Similar trend was observed in other subsets: Tscm, Tem, Ttm, Tte. Median of PD1+ CD8+ cells were 3.8%, 1.015%, 22.7%, 7.39%, 42.7%, 7.86%, 21.9%, 4.047% and 2.6%, 0.41%, 6.6%, ≤2.59%, 12.7%, ≤1.25%, 8.9%, ≤0.825% in BM and in PB respectively.

Summary/Conclusions: We found higher frequencies of PD-1 expressing memory BM T cells comparing to PB. This might point to the important roles of PD-1 in regulation of memory T cells homeostasis in BM. In physiological conditions PD-1 is thought to neutralize self-reactive naïve T cells that in its turn leads to restraining T cells activation and blockade the development of autoimmunity in BM. On the other hand low expression of PD1 on T cells in PB can be explained by needs the opportunity for prompt reactivity with pathogens that also provide normal «robust control» and prevent developing of a disease.

PB1853

BONE MARROW STROMAL CELLS MAY HAVE GENETIC ABBERRATIONS AND ARE CAPABLE TO GAIN THEM IN A CULTURE

I. Barkhatov*,1, N. Tsvetkov1, D. Ershov1, T. Gindina1, A. Shakirova1, M. Nikolaeva1, A. Potter1, L. Zubarovskaya1, B. Aftanaysyev1

1R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov Saint Petersburg State Medical University, St.Petersburg, Russian Federation

Background: Stromal microenvironment poses a key role in the regulation of both normal hematopoiesis and its reconstitution after hematopoietic stem cell transplantation (H SCT). Recent data supports the idea that bone marrow stromal cells (BMSC) also have genetic aberrations and may tightly involved in the pathogenesis of HSCT complications. These findings justify the need for more detailed study of genetic aberrations in BMSC.

Aims: The aim of this study was to evaluate genetic aberrations in BMSC and check the ability to gain them in coculture system.

Methods: The interaction of BMSC with hematopoietic tumor cell lines bearing specific genetic aberrations (BCR-ABL fusion transcript for K-562 and JAK2 V617F mutation for Uke-1 cell line) was investigated in stroma cells harvested from 17 patients and 8 healthy donors. We performed cultivation of BMSC in the coculture with tumor cells using semipermeable membrane plates with different pore size (0.4 μm and 3.0 μm) in order to exclude direct cell-to-cell contact. We looked also for existing specific genetic aberrations (point mutations and fusion transcripts) in BMSC of patients with the respective aberration in their leukemic clone. For this purpose we used both karyotyping (17 patients) and QP-PCR method. BMSC were examined by flow cytometry to evaluate the possible contamination with cells of hematopoietic lineage.

Results: We investigated the BMSC karyotype in seven patients and only one case led to a remarkable finding. The clonal chromosomal rearrangement t(1;7) was detected in 25% of BMSC metaphases. Interestingly, this aberration was not detected in patients’ leukemic cell line. We also examined BMSC from leukemia patients bearing recurrent genetic abnormalities and in one case the leukemia-specific marker was detected by QP-PCR - we observed expression of ETV6-RUNX1 gene (=0.02%) in BMSC by patient with (12;21) acute lymphoblastic leukemia. At the moment of BMSC culture initiation ETV6-RUNX1 expression in patient’s bone marrow was detected at high level (ETV6-RUNX1/ABL1=100:521%). Before carrying out DNA extraction BMSC were harvested after the second passage and no contamination with CD45+/CD34+ cells by flow cytometry was observed (50,000 events collected from the sample). When BMSCs and Uke-1 cell line were cocultured by using 3.0 μm pore the BMSC population also detected the Jak2V617F mutation (alleles burden = 30,39%). We reproduced similar experiments with the K-562 cell line and got similar results - CD45+ cells were also detected in BMSC population (= 30%). Moreover we detected CD45+ non-cellular particles by flow cytometry analysis. Implying K-562 cells are not likely to cross the semipermeable membrane (3,0 μm pores versus 20,0 μm cells as measured during microscopy). Besides BCR-ABL gene expression in BMSC was detected by QP-PCR (BCR-ABL/ABL1=100:19%). We repeated same test with 0.4 μm pore inserts and without them in order to check implication of cell-to-cell interaction. We didn’t obtain any similar results with smaller pores, but the fusion transcript was detected in BMSC population when these two cell populations weren’t devided. Both findings point out at possible horizontal gene transfer mediated by membrane vesicles larger than 0.4 μm and direct whole cell fusion.

Summary/Conclusions: Our data stands for the existence of horizontal gene transfer between leukemic clone and BMSC. This process seems to be mediated by membrane vesicles larger than 0.4 μm in size, though cell fusion can also take place. We also confirmed the fact BMSCs can bear clonal genetic rearrangements which are not specific to tumor cell populations. These findings show tight interaction between tumor and microenvironment cells and can partly explain nature of PCR-based MRD persistence in complete remission.

PB1854

CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND METABOLIC FACTORS IN CHILDHOOD CANCER SURVIVORS

E. Athanassopoulou1, G. Martimianakis1, K. Kourkouri1, M. Stratiagki1, E. Karkas1, N. Kizilas1, M. Nikolaou1

1Pediatric Hematology - Oncology, University Hospital of Heraklion, University of Crete, Heraklion, Greece

Background: Circulating Endothelial Progenitor Cells (CEPCs) play a significant role in the maintenance of vascular integrity, balancing the coagulation mechanism and modulating the immune system by regulating the leukocyte trafficking, as well as controlling the vascular tone. Additionally, it is well-established, that patients who underwent chemotherapy have increased incidence of hypertension and obesity. Nevertheless, numerous studies have shown a negative correlation between CEPCs and obesity, underlying poor vascular reparation.

Aims: The study of CEPCs in children who received chemotherapy for Acute Lymphoblastic Leukemia (ALL) and solid tumors (ST) and the investigation of their levels in correlation with patients Body Mass Index (BMI) and blood pressure (BP) regarding the time following treatment.

Methods: Circulating endothelial progenitor cells (CEPCs) were investigated in children with ALL (n=77), ST (n=81) and children with malignancies as control group (n=71) were studied. Four colour flow cytometry was performed to determine the subpopulations CD34+CD45negdimCD133+, CD34+CD45negdimVEGFR2+ and CD34+CD45negdim-CD133+VEGFR2+ of CEPCs. The BMI of the patients was calculated and the body surface was standardized by the age and gender. Normal weight defined with BMI percentile over 5th and below 85th percentile, and over-weight/obesity over 85th percentile. The systolic blood pressure (BP) was measured and the percentile was calculated specified by the age, gender and height. Normal BMI was defined with BMI percentile over 5th and below 85th percentile, and over-weight/obesity over 85th percentile. The statistical analysis was conducted using t-test (Holm-Sidak) and Sway ANOVA (Tukey’s multiple comparisons test).
Results: The mean values of CEPCs subpopulation CD34+CD45negdimVEGF-R2+ estimated in ALL, ST and Controls were 0.00308(SE=0.00072), 0.00613(SE=0.00146) and 0.002953(SE=0.0004) respectively. The mean percentage of CD34+CD45negdimCD133+VEGF-R2+ between the ST and Controls was 0.00331(SE=0.00072), 0.00499(SE=0.00113) and 0.002663(SE=0.00037). The correlation of the above showed statistical significant difference of CD34+CD45negdimVEGF-R2+ between the ST and Controls (OR=0.23, 95CI of diff 0.031974, 0.95 CI of diff 1.976e-005 to 0.002672). In ALL the levels of CD34+CD45negdimVEGF-R2+ the 1st year after treatment completion were 0.0458(SE=0.0026), during 1-3years 0.00315(SE=0.00066) and >3 years 0.003423(SE=0.00081). The levels of CD34+CD45negdimCD133+VEGF-R2+ during the 1st year after chemotherapy was 0.0092 (SE=0.00371), 1-3 years 0.00034(SE=0.00063) and >3 years 0.00336(SE=0.00081). Statistical significant results were calculated for the levels of CD34+CD45negdimVEGF-R2+ in ST group between the groups <1 year and over years post treatment(Mean Diff 0.007747, 95 CI of diff 0.0002441 to 0.01525). The study of body weight in ALL and ST groups in relation with CEPCs showed no statistical significant difference, although a negative trend between obesity and CEPCs was found in the ALL group and a positive one in the ST group. The same trend also appeared in BP between ALL and ST regarding the CEPCs, with hypertensive patients in ALL group having higher levels of CEPCs than the ST hypertensive individuals.

Summary/Conclusions: The higher levels of CEPCs were estimated in ALL and ST just after treatment completion with a gradual decrease as time passes. The highest percentages of CEPCs were evaluated in ALL patients with normal weight and blood pressure in contrast with the solid tumor group. Further investigation is necessary to highlight the importance of these data.

PB1855
HEMATOLOGICAL PARAMETERS IN NATIVE HIGHLANDERS OF LADAKH AGED 4-19 YEARS
S.K. Das1,*, Y. Uday1, D. Katoch1, V. Nair2
1Hematology, Army Hospital (Research & Referral), New Delhi, India
Background: High altitude (HA) has always intrigued physiologists because of the remarkable ability of man to adapt to the hostile environment. Hematological changes associated with HA exposure is believed to be driven by hypobaric hypoxia of HA. Majority of the studies on HA physiology and hematological adaptation have focused on the hematological adaptation in lowlanders visiting HA or have compared the hematological profile of native highlanders from Andes and Tibet with those of the neighboring lowlanders. These studies have mostly been directed towards adult population with no or little reference to children and adolescent age groups. Moreover these studies have been mostly on the highlanders of Andes and Tibet with no data on Indian highlanders.

Aims: We aimed at assessing hematological parameters in native highlanders in the age group of 4- 19 yrs and compare the same with Indian lowland population as well as native highlanders from Ladakh and Tibet. The study was designed to analyze the hematological parameters in Ladakhi kids during the first year after chemotherapy with a suspected MDS.

Methods: A total of 390 native highlanders of Ladakh in the age group of 4-19 yrs with no history of travel to lowland were taken for the study. A written informed consent was taken from the parents of all the subjects before starting interviewing them for the laboratory investigations. After taking antispec precautions, blood samples were drawn from the antecubital vein and complete hemogram including red blood cell indices were measured. The study subjects were stratified into five age groups (less than 5y, 5-8y, 8-10y, 10-12y, 12-15y and children more than 15y). Appropriate statistical analysis was done to compare the hematological parameters between the stratified age groups as well as between boys and girls.

Results: A total of 197 girls and 193 boys were included in the study. The mean age of the subjects was 128.8±0 (means2SD) months. The mean hematocrit value increased with age (38.68±2.51% in <5 yrs age group to mean age of the subjects was 128±80 (mean±2SD) months. The mean hematocrit value was significantly higher than those in girls (35.96±2.94%). The mean platelet count in boys was significantly higher than in girls (p=0.0003) (Figure 1).

Summary/Conclusions: The hematological adaptation of Ladakhi kids is different as compared to other native highlanders. There is also a significant difference in the hematological response to hypobaric hypoxia with growing age and between boys and girls.

PB1856
AGE VARIATION OF B-CELL PRECURSORS IN BONE MARROW: NORMAL VALUES AS A REFERENCE FOR MDS IN BRAZIL
1Hematology - Hemotherapy Center, University of Campinas, Campinas, 2Laboratory of Hematology, Hospital Albert Einstein, Sao Paulo, 3Laboratory of Experimental Oncology, Federal University Of Santa Catarina, Florianopolis, 4Laboratory of Cytometry, Hospital Aamaral Carvalho, Jau, 5Laboratory of Hematology, DASA, 6Laboratory of Hematology, Laboratorios Fieuro, Sao Paulo, 7Laboratory of Hematology, Children's Cancer Hospital, Barretos Cancer Center, Barretos, 8Pathology, University of Campinas, Campinas, Brazil
Background: Decrease of bone marrow (BM) B-cell precursors (BCP) is an important diagnostic feature in myelodysplastic syndromes (MDS). Moreover, their number is associated with patients’ overall survival. However, BCPs vary with age in normal BM.

Aims: In a multicenter study from the Brazilian Group of Flow Cytometry we analyzed the variation of BCPs in normal BM according to age, antibody combinations used for quantification and reproducibility after a centralized reanalysis. We set up a reference pattern of normal values for evaluation of patients with a suspected MDS.

Methods: In a retrospective study including 10 centers we retrieved analyses of BM donors and cases examined for elucidation of transitory reactive cytopoiesis presenting a normal BM immunophenotyping. BCPs were enumerated as CD19/CD34/CD45/CD10 cells (panel 1 or CD19/CD34/CD45 cells (panel 2), among the total nucleated cells and as percentage among CD34+ cells. Statistical multiple regression to analyse the dependence of BCS from the variables analysed.

Results: 134 cases were included. Panel 1 was applied in 106 cases (all centers) and panel 2 was used in 28 cases (3 centers). Age range: 10 months to 89 years. In the same age range, values for panel 2 were lower than those for panel 1. In multiple regressions % BCP/totals cells “log age” (years) – 0.313 (for panel 2)+correction factor for labs +1.873. The correction factor for labs was 0 to 0.40. Age explained alone 49.6% of the variance of BCPs/totals cells, while “laboratory” explained 5.2% and panel used explained only 0.8%. Age explained only 24.9% of the variance of BCPs/CD34+ cells.

Table 1.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>% of total CD34+ cells</th>
<th>BCP/total cells</th>
<th>BCP/CD34+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-6 (n=19)</td>
<td>3.65% (1.5 - 5.1)</td>
<td>2.8% (3.5-3.8)</td>
<td>62.1% (22.8-62.6)</td>
</tr>
<tr>
<td>7-18 (n=19)</td>
<td>1.43% (0.25 - 3.2)</td>
<td>0.4% (0.02-1.8)</td>
<td>41.5% (3.1-64.5)</td>
</tr>
<tr>
<td>19-55 (n=70)</td>
<td>0.84 (0.07-2.76)</td>
<td>0.12% (0.08-2.0)</td>
<td>20.8% (2.4-60)</td>
</tr>
<tr>
<td>&gt;55 (n=35)</td>
<td>0.97% (0.06-2.48)</td>
<td>0.08% (0.02-6.6)</td>
<td>12.9% (1.5-52.2)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: In a normal population BM B-cell precursors varied mainly with age, but were also dependent on technical peculiarities of operators and equipments. Analysis by phenotype and as percentage of total cells was more accurate and less susceptible to variation.

PB1857
PERIOSTIN/BIGH3 RATIO AS A PROGNOSTIC MARKER OF IDIOPATHIC THROMBOCYTOPENIA AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION FOR THE PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA
Y.J. Lee1,*, S.K. Sohn1, J.-H. Kim2, T.I. Park3, J.Y. Ham4
1Department of Oncology/Hematology, 2Biochemistry and Cell biology, 3Pathology, 4Laboratory, Kyungpook National University Hospital, Daegu, Korea, Republic Of
Background: Disrupted hematopoiesis is life-threatening complication of allo- geneic hematopoietic cell transplantation (allo-HCT). The interactions of haematopoietic stem/ progenitor cells (HSPCs) and bone marrow (BM) microenvironment, niche(s), control the homeostasis of BM. TGF-b induced gene 3 (BIG3), one of BM extracellular matrix (ECM) which is produced by niche cells maintain the homeostasis and regeneration of BM.

Aims: We analyzed the relationship between the idiopathic thrombocytopenia after allo-HCT and the BM expression of periostin as the only paralogue of BIG3H.

Methods: We reviewed twenty patients who transplanted with matched sibling donor for acute myelogenous leukemia at Kyungpook National University Hospital from January 2010 to August 2015. BM biopsy specimens at the time of day 28, day 90, day 180, and 3 at day 365. There was no significant difference between idiopathic thrombocytopenia and the expression of BIG3H or Periostin (p=0.128) However, BM with idiopathic thrombocytopenia manifested the low periostin/BIG3H ratio (p=0.007). Acute GVHD was observed in 12 patients (60%) and chronic GVHD developed in 13 patients (65%). The development of thrombocytopenia dose not differ according to acute and chronic GVHD (p=0.847) (Figure 1).

Figure 1.

Summary/Conclusions: The periostin/BIG3H might represent the status of BM niche during the homeostasis and regeneration of hematopoiesis. High periostin/BIG3H ratio could predict the recovery of the idiopathic thrombocytopenia.

PB1859

LABEL-FREE IMAGING BY AUTO-FLUORESCENCE PERMITS IDENTIFICATION OF ERYTHROID PRECURSORS IN BONE MARROW AND DETECTS CHANGES OF SOLUBILITY OF HEMOGLOBIN IN ERYTHROCYTES

I. Lorand-Metze 1,2, F. Borges da Silva 3, M. Falconi 1, K. Metze 3,2

1Hematology - Hemotherapy Center, 2National Institute of Photonics applied to Cell Biology (INFABIC), 3Pathology, University of campinas, Campinas, Brazil

Background: In the fluorescence lifetime imaging (FLIM) technique, the image contrast is created by determining the delay of the fluorescence photon emis- sion at each pixel of the image and transforming it in pseudo-colors. This delay, also called lifetime depends on the type of molecules and their physicochemical characteristics.

Aims: We investigated the utility of this technique for the characterization of erythropoietic cell line and changes in the solubility of hemoglobin.

Methods: We used unstained BM smears of 24 normal BM and 8 megaloblastic anemia patients and unstained peripheral blood smears of 10 patients with sickle cell anemia. Images were captured by a confocal microscope with a HPM-100-40-Hybrid detector and excitation at 405 nm (diode laser,80 MHz). In order to create equivalent images of the cytological smears, pseudo-colors were attributed to different lifetime ranges. Images were compared with May-Grünwald-Giemsa (MGG) stained smears.

Results: FLIM created highly contrasted images, where different cell types could be easily recognized by their similarity with MGG images. Erythrocytes exhibited the shortest lifetimes (210.4±42.1 ps). Normal shaped erythrocytes in smears of sickle cell patients showed similar values (214.6±31.1 ps), whereas crenated erythrocytes as well as drapanocytes revealed significantly elevated values (314.2±66.7 ps and 312.5±67.0 ps respectively). Regarding erythro- poiesis, the cytoplasm of erythroblasts showed significantly shorter lifetimes (623.5±271.2 ps) than that of myeloblasts (835.9±198.4 ps) and the same was the case when comparing the nuclei (erythroblasts: 895.4±262.8 versus myeloblasts: 1166.4±287.9 ps). The same differences could be found in megaloblastic anemia. There were no significant differences between the FLIM val- ues of the different cell types between normal hemopoiesis and megaloblastic anemia.

Summary/Conclusions: The FLIM technique is easily applicable on unstained routine smears and revealed images of good quality permitting cell identification. It allowed also to distinguish between erythroid and myeloid precursors and indicates the major physico-chemical changes during the process of falcination.

PB1858

ASSOCIATION WITH OMENN SYNDROME AND CYSTINURIA: CASE REPORT

T. Patiroglu 1,2, M. Cansever 2, S. Coskun 3, M. Karakucuk 1, N. Baydilli 4

1Pediatric Hematology, 2Pediatric Immunology, 3Pediatric Nephrology, 4Urology, Erzurum University Medical Faculty, Kayseri, Turkey

Background: Omenn syndrome is one type of combined immunodeficiency, characterized with hepatosplenomegaly, lymphadenopathy, recurrent infections and has an autosomal recessive pattern of inheritance. T lymphocyte count can be very low to none. Cystinuria is renal reabsorption defect of dibasic amino acids, inherited autosomal recessive. Because cysteine solubility is lower than other amino acids cysteine stones are formed in kidneys. In the lit- erature, no association was found between Omenn Syndrome and cystine stone history.

Methods: 5 months old girl applied to the Pediatric Immunology Department of Erzurum University Children Hospital with skin eruption. There was no family history for immune deficiency and no consanguineous marriage between moth-

er and father. Patient had one sibling who is healthy. Patient was not performed with BCG or other live vaccines. In her physical examination, we observed exfoliative erythroderma and hepatomegaly. In laboratory examination, leuko- cyte count 6540/mm³, absolute neutrophil count 2270/mm³, absolute lymphocyte count 1560/mm³, absolute eosinophil count 2220/mm³, serum Ig level 171mg/dl, IgA level 5.81mg/dl, IgM level 24.5mg/dl, IgE level 1270 mg/l were found. B lymphocyte count 1902/mm³, NK count 332/mm³ were found respectively. Blood sample of patient was sent to Erasmus for genetic analysis. The patient had no full-match family donor. Hence, hap- loidentical bone marrow transplantation from her father was planned. In prepara-

ation for bone marrow transplantation, bilateral kidney stones were showed in abdominal CT. Cystinuria was detected in urine and thought to be bilateral cy- steine Stone. Percutaneous nephrolithotomy operation was performed, then the patient was given scholl solution. Stone analysis revealed to be cystine stone.

Results: Association with two different diseases inherited autosomal recessive is very interesting. Challenging incident that can be caused by a reason or it can be only coincidence. In Omenn Syndrome is known to be sequencing alteration of cysteine and tyrosine amino acids. Perhaps, cysteine stones took form as a result of this alteration.
on Table 1. There are three deaths because of refractory diseases. Five patients needed treatment for the first disease and nine patients needed treatment for the second disease. Four patients had treatment for both diseases.

Table 1.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Number of Patients</th>
</tr>
</thead>
</table>

Summary/Conclusions: occurrence of two malignancies in the same patient can be a challenge for the hematologist. Findings of the second disease can be attributed to the fist disease or considering them to be results of treatment. Follow up and initiation of treatment in those patients can be more complex than usual. As far as origin is concerned there are conflicting reports in the literature supporting a common or different cells of origin. Recording of these cases and biobanking can be of great interest for understanding mechanisms of hematologic neoplasms.

Background: The prognosis of Hodgkin lymphoma (HL) has improved significantly with the implementation of a risk-adapted treatment that combines chemo and radiotherapy. Although this approach has led to the greatest advance in disease response, the benefit in terms of overall survival (OS) has been jeopardized by long term toxicity. The identification of risk factors is crucial to assign each patient to a well defined risk group and prevent under or overtreatment, minimizing the risk of relapse and long term toxicity.

Aims: To analyze the risk factors associated with survival in HL treated with an ABVD based regimen that restricted radiotherapy only to bulky disease.

Methods: We retrospectively analyzed HL patients diagnosed in 4 centers in Tarragona area (Catalonia, Spain), between 1995 and 2015, treated uniformly according to a local protocol. Patients were assigned into 4 groups: G1: favorable early stage: ABVDx6 cycles, G2: Bulky early stage without other risk factors: ABVDx6+IFRDT. G3: unfavorable early stage (B symptoms) and advanced stage without bulky disease: ABVDx8, G4: Bulky advanced stage: AVBDx8+IFRDT

Results: A total of 183 patients were analyzed with a median follow up of 82 months [range 1-244]. Male/female ratio was 1.29. Median age was 36 years [range 16-82]. Complete response was achieved in 160 patients (87.4%). The estimated OS at 20 years for the whole group was 62.7%. Kaplan–Meier method and log rank test were used for survival analysis. Cox proportional hazard model was used for univariate analysis to identify predictive factors for OS. Factors with significance (p <0.05) were considered for multivariate Cox regression. In univariate analysis, worse OS was found in patients with increased LDH, non-NS subtype, albumin <3.5 g/dL, B symptoms, HIV+, advance stage and ESR >50 mm (log rank p=0.012; p=0.049; p=0.024; p=0.002; p=0.005; p=0.004 and p=0.001 respectively). The multivariate Cox regression analysis identified B symptoms and ESR >50 mm as independent prognostic factors for OS (p=0.002; p=0.006 respectively). These variables allowed us to identify 3 patient groups: low (no risk factors), intermediate (either B symptoms or ESR>50 mm) and high risk (both risk factors), with significant differences in OS. Estimation for OS was uniformly analyzed at 216 months (18 years), which is the shortest follow up period for patients in the low risk group. Patients in the low, intermediate and high risk groups had an estimated OS of 85.7%, 65% and 40.1% (p<0.001) (Figure 1).

Figure 1. B symptoms and ESR>50mm are independently associated with OS. The combination of these factors can stratify patients in low, intermediate and high risk groups with significant differences in OS, regardless their clinical stage.
ADVANCED HODGKIN LYMPHOMA PATIENTS WITHOUT LARGE TUMOR MASS – A NEW PROGNOSTIC SCORE IDENTIFIES PATIENTS WITH FAVORABLE OUTCOME

Background: ABVD and escalated BEACOPP are still the standard of care in patients with advanced Hodgkin Lymphoma (HL). The use of escalated BEACOPP gives better disease control but it is associated with more acute and late toxic effects. The identification of patients who require more or less aggressive initial approach remains the main goal for many investigators in the field of HL.

Aims: The aim of this study was to identify among patients with diagnosed advanced HL, which subgroup which should not be considered for more aggressive approach than ABVD.

Methods: A retrospective study was performed on 149 patients classical HL, diagnosed in the period June 1997-December 2011. All the patients were in clinical stage III or IV and didn’t have any tumor lesion of 5 cm or more in its longest diameter. The standard of initial care was 6-8 cycles of ABVD followed by radiotherapy. Prognostic relevance of age more than 45 years, gender, CS IV, presence of B symptoms, IPS score, ESR>50 mm/h, lymphopenia (lymphocytes <600/mm³ or <8% of WBC count) were examined.

Results: The median age of analysed patients was 37 (range 17-80). The median follow up was 98 months. For the whole group 5-year event free survival (EFS) was 63.1% and 5-year overall survival (OS) was 80.6%. In univariate analysis, worse OS was found in patients older than 45 years (5-year OS 66.7% vs 87.8%), patients with CS IV (5-year OS 70.2% vs 87.0%), B symptoms (5-year OS 77.1% vs 89.1%), ESR>50 mm/h (5-year OS 75.0% vs 89.5%), lymphopenia (5-year OS 66.5% vs 84.6%) (log rank: p=0.001, p=0.006, p=0.040, p=0.003, p=0.007, p=0.010, respectively), while gender, anaemia and leukocytosis didn’t influence OS (log rank: p=0.303, p=0.714, p=0.522, respectively). Worse EFS was found in patients with CS IV (5-year EFS 50.0% vs 70.7%, log rank p=0.002), IPS>3 (5-year EFS 63.8% vs. 73.2%), (log rank: p=0.006) and lymphopenia (5-year EFS 50.0% vs 66.7%, log rank p=0.025), while age, gender, B symptoms, ESR>50 mm/h, anaemia and leukocytosis didn’t influence EFS (log rank: p=0.078, p=0.437, p=0.068, p=0.151, p=0.384, p=0.158, respectively). The multivariate Cox regression analysis showed that identified age more than 45 years, ESR>50 mm/h and lymphopenia as independent prognostic factors for OS, while only IPS was identified as an independent factor for EFS. Afterwards, we performed survival analysis with aggregate scores of identified negative prognostic factors for OS for each patient. Since there was no difference in OS in intergroup analysis, groups 1 and 2 were formed. Patients with at least one negative prognostic factors were merged. Finally, we developed prognostic model for identifying patients at low (0 factors), intermediate (1 factor) and high risk (2-3 factors) for poor outcome (p<0.000). According to this model, in the examined group 34 (22.8%) patients had low, 64 (43.0%) intermediate and 51 (34.2%) high risk for poor outcome, with 5-years OS of 100%, 84.3% and 60.8%, respectively.

Summary/Conclusions: According to the score which we developed, ABVD is very effective in the subgroup of advanced HL patients without large tumor mass and without identified risk factors.
**Methods:** In study were included 85 previously untreated patients, presented with classical HL between 2002 and January 2016. This retrospective study did not require approval by the Local ethical committee. Inclusion criteria were: a histologically confirmed diagnosis of classical HL, the presence of a fixed in paraffin before treatment a lymph node sample or other diseased tissue, the minimum follow-up was not less than 18 months.

**Results:** In the study population (n=85) identified 30 (35%) histological samples bcl-2+, and 55 biopsies (65%), bcl-2. Group bcl-2+ patients had a lower response rate after ABVD chemotherapy - only 24 (28%) patients achieved CR or better result, as compared with 49 patients (57.6%) of the bcl-2 group. Three-year event-free survival (EFS) in bcl-2+ patients had lower 82% vs 96% in bcl-2 group (p=0.018). Multivariate analysis with the Cox proportional-hazard model with the inclusion of bcl-2+, CD30 +; bcl-2+ / CD30 +, age 45 and older, B-symptoms, III-IV stage, anemia, decreased serum albumin, increased LDH, leukocytosis revealed that the expression of bcl-2 on RFS was an independent factor of poor prognosis. 3 year EFS was 52% vs 90% in bcl-2 population (p=0.022; RR=1.4). The greater relative risk was observed in a population with double expression of bcl-2 and CD30, where the 3-year EFS was 47% (p=0.012; RR=1.6).

**Summary/Conclusions:** The expression of bcl-2 on HRS cells can be an independent prognostic factor, co-expression of bcl-2 and CD30 can be viewed as a more powerful factor of poor prognosis than bcl-2+ cells.

PB1866

**SURVIVAL ANALYSIS OF PATIENTS WITH CLASSICAL HODGKIN’S LYMPHOMA TREATED WITH ABVD: RESULTS FROM TWO REFERRAL CENTERS IN MEXICO CITY.**

G.P. Agreda-Vásquez1, A. F. Ramirez-Ibarguen2, E. Crespo-Solís3,*

1Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 2Department of Hematology, Instituto Nacional de Cancerología, Mexico City, 3Department of Hematology and Oncology, Hospital Regional de Alta Especialidad de Ciudad Victoria, Victoria, Mexico

**Background:** Classical Hodgkin’s lymphoma (cHL) is a neoplastic disease with a favorable prognosis since 85% of patients can be considered cured with current treatment strategies. Combined chemotherapy with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) has been the standard therapy for over 20 years. Epidemiological information and the regimen’s results as first-line therapy in Mexico are limited.

**Aims:** The aim of this study was to conduct a survival analysis in adult patients from two referral centers in Mexico City.

**Methods:** This is a retrospective analysis of all patients with cHL treated at the Instituto Nacional de Cancerología and the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, between 2009 and 2013. The study was approved by the local Ethics Committee.

**Results:** We included a total of 193 patients with a de novo diagnosis and initially treated with ABVD: 60.6% of cases were male, with a median age of 36 years (17–81 years), 71.5% were diagnosed in late clinic stages (CS). The most frequent histopathological subtypes were: nodular sclerosis and mixed cellularity (46.3% and 46.9%; respectively). The observed overall response rate (ORR) was 85.7% (Complete response (CR) was 78.2%). The RR was 90% in early CS vs 83.8% in late CS (CR rate was 84% vs 75.8%; respectively, p=0.23). Univariate analysis by logistic regression in the early CS group revealed that having a Lymphocyte:Monocyte ratio <1 presents an independent favorable factor of better event-free survival (EFS) [OR 0.150 (95%CI 0.018–1.274; p=.082)]. In the group in late CS, we found that the lymphocyte percentage tended to favor CR [OR 1.048 (95%CI 0.994–1.105; p=.081)] and the opposite was observed in terms of the absolute monocyte count [OR 0.999 (95%CI 0.998–1.000; p=0.082)]. Median follow-up was 35 months (9–96 months), 10.9% of cases had died at last follow-up, and median overall survival (OS) of the entire cohort had not been reached at the time of analysis (5-year OS, 87.1%). However, at the time of this analysis, the group of patients in complete remission had a greater OS than the group that did not achieve CR (p=0.0001). With Cox multivariate analysis of OS according to CS, we detected that in the group in early CS none of the analyzed factors were significant, while in the late CS group, age >45 years was an independent risk factor [HR 6.9 (95%CI 1.80–26.60; p=0.005)] and achieving CR had a protective effect [HR 0.02 (95%CI 0.004–0.108; p=0.0001)].

**Summary/Conclusions:** Although OS medians had not been reached at the time of analysis, it is noteworthy that CR (84%) in early CS is lower than that reported in the literature and no related prognostic factor has been identified. The role of lymphocytes and monocytes may prove to be significant in larger series with a longer follow-up.

PB1867

**OUTCOME OF PD-1 BLOCKADE IN PATIENTS WITH RELAPSED HODGKIN LYMPHOMA AND ACTIVE GRAFT-VERSUS-HOST DISEASE**

A. Minson1,2, G. Douglas1, A. Grigg1

1Haematology, Austin Health, Heidelberg, Australia

**Background:** Efficacy of PD-1 (programmed death-1) inhibitors in relapsed/refractory Hodgkin lymphoma (HL) has been established, but their role in relapse after allologeneic stem cell transplant (alloSCT) remains controversial due to the perceived risk of exacerbating graft-versus-host disease (GVHD). The literature is largely limited to case reports in patients with no or quiescent GVHD.

**Aims:** To define the outcome of PD-1 inhibitor therapy and subsequent management in patients with concomitant biopsy proven active GVHD and progressive HL after alloSCT.

**Methods:** We describe the treatment and management of two patients in our centre.

**Results:** Case 1 had both extensive bony, lung and nodal HL with active skin, pleuropericardial and liver GVHD 6 months after donor leucocyte infu- sion (DLI) and immunosuppression withdrawal and 24 months after sibling alloSCT. Fifty% of the standard pembrolizumab dose (100mg) produced a PET partial response after 5 weeks but with concomitant biopsy proven, severe exacerbation of liver GVHD. The latter was managed with prednisolone, everolimus, ursodeoxycholic acid (UDCA) and subsequently tacrolimus with gradual but substantial improvement in liver function over the next 5 months (Figure 1) in the absence of further PD-1 blockade, but with progression of lymphoma. Pembrolizumab 50mg was then given with lymphoma response but again a significant (but less severe) flare of liver GVHD occurred. Subsequent 25mg doses failed to prevent lymphoma progression. Reintroduction of 50mg doses approximately each 6 weeks for 4 doses with prophylactic everolimus, low dose prednisolone and ruxolitinib, has resulted in ongoing substantial but incomplete PET responses with associated stable liver GVHD. Case 2 had progressive mediastinal and pulmonary HL despite DLI-induced extensive liver and skin chronic GVHD 38 months post sibling alloSCT. Initial therapy consisted of optimisation of liver GVHD with 8 weeks of UDCA and prednisolone with improvement in liver indices (Figure 1). Pembrolizumab 50mg was then given, together with sirolimus and ruxolitinib as GVHD ‘prophylaxis’, resulting 5 weeks later in complete metabolic remission on PET. Concomitantly liver GVHD was aggravated (See Figure 1) together with pancycopenia and narrow hypoplasia attributed to an immune-mediated phenomenon. Despite addition of tacrolimus and increased steroids, he remains with severe liver dysfunction and pancycopenia 10 weeks after the single dose of PD1 inhibitor therapy.

**Summary/Conclusions:** PD-1 inhibitors can exert powerful graft vs HL effects even in patients with progression in the context of active GVHD, but at the expense of substantial GVHD exacerbation. Further exploration of approaches such as individualised dose titration according to response and concomitant prophylaxis and prophylactic therapy with non-calcineurin based immunosuppression which may not mitigate the anti-lymphoma effect will help evaluate whether durable responses with tolerable toxicity is possible in this context.

**Figure 1.**

**Summary/Conclusions:** PD-1 inhibitors can exert powerful graft vs HL effects even in patients with progression in the context of active GVHD, but at the expense of substantial GVHD exacerbation. Further exploration of approaches such as individualised dose titration according to response and concomitant prophylaxis and prophylactic therapy with non-calcineurin based immunosuppression which may not mitigate the anti-lymphoma effect will help evaluate whether durable responses with tolerable toxicity is possible in this context.
PB1868

PROGNOSTIC VALUE OF THE RED CELL DISTRIBUTION WIDTH IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA

A. Knežović1, V. Perišić2, L. Zibarić, S. Sinčić-Petricič1
1Comunity Health Centre Đakovo, Faculty of Medicine, University of Osijek, Osijek, Croatia, 2Department for Pathophysiology, Faculty of Medicine, University of Osijek, Osijek, Croatia, 3Nephrology, Department for Pathophysiology, University Hospital Centre Osijek, Faculty of Medicine, University of Osijek, Osijek, Croatia, Osijek, Croatia

Background: The current gold standard for risk stratification in Hodgkin lymphoma (HL) is the International Prognostic Score. There are certain molecular and immunohistochemical prognostic markers in patients with HL, but their cost and technical constraints make such an application in routine impractical and expensive. Therefore, prognostic models for classic HL (CHL) that are inexpensive, simple, and easy to perform and interpret are needed. The red blood cell distribution width (RDW) is a simple, inexpensive, and independent prognostic factor for EFS that may improve the ability of risk stratification in CHL patients. RDW ratio is a simple, inexpensive, and independent prognostic factor for EFS that may improve the ability of risk stratification in CHL patients.

Aims: The aim of this study was to analyze the prognostic significance of RDW in CHL patients.

Methods: We retrospectively analyzed data from 54 cHL patients diagnosed from 2005 to 2016 at the University Hospital Center Osijek, Osijek, Croatia. We evaluated disease outcomes, overall survival (OS) and event-free survival (EFS), and demographic, clinical and laboratory factors affecting outcomes. Univariate analysis and Cox regression analysis were used.

Results: The median age of patients was 36 years, 29 were men (54%). Higher RDW levels (%) were found in patients with advanced Ann Arbor clinical stage (15.34 ± 2.28 vs 13.12 ± 1.3, P < 0.001) and in those with poor response to therapy (15.65 ± 3.37 (progression) vs 16.68 ± 2.09 (partial remission), 13.95 ± 1.82 (complete remission), P = 0.008). Patients with RDW values of >14.5% (cutoff value calculated by receiver-operating characteristic) had a significantly worse two-year EFS (62.4% vs 90.4%, P = 0.009) but did not differ significantly in terms of OS (P = 0.2). Univariate analysis revealed that a high RDW (>14.5) was correlated with poor EFS (P = 0.019). Multivariate Cox regression analysis showed that RDW >14.5% was an independent prognostic factor for EFS (hazard ratio [HR] 3.801, 95% confidence interval [CI] 1.4-11.4, P = 0.05). The RDW allowed further bordering statistically significant risk stratification in patients who were considered to be at low risk on the basis of an International Prognostic Score less than 4 (P = 0.053).

Summary/Conclusions: High baseline RDW is an independent prognostic marker of poor outcome in patients with CHL. RDW ratio is as simple, inexpensive, and independent prognostic factor for EFS that may improve the ability to identify high-risk patients with CHL. It could be an easily available and inexpensive marker for the risk stratification in patients with CHL.

PB1869

HIGH FREQUENCY OF SECONDARY MALIGNANCIES IN PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA: A SINGLE INSTITUTIONAL EXPERIENCE

L. Issenbaum1, M. Van den Bergh1, E. Wang2, B. Schable1, Z. Ma1, L. Zhang1, L. Sokol1
1Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 2Internal Medicine, University of South Florida, Tampa, United States

Background: Large granular lymphocyte (LGL) disorders represent a spectrum of aberrant T-cell or natural killer cell lymphocytic proliferations. LGLL is classified as associated with autoimmune conditions and bone marrow (BM) failure disorders. SM has been reported in association with LGLL in about 10%.

Aims: The aim of this study is to evaluate the impact of SM on the clinical course of LGLL.

Methods: This is a retrospective study of LGLL patients evaluated at Moffitt Cancer Center between January 1995 and May 2016. The clinical and pathological criteria consist of LGL count > 0.5 k/μL with T-cell receptor gene rearrangement. Lower absolute number of clonal circulating LGLs with characteristic immunophenotype associated with BM involvement, cytopenias, and/or associated symptoms were also diagnostic. Patients with myelodysplastic syndrome were excluded. Survival analysis was performed using the Kaplan-Meier method with log-rank test. Chi-square and T-test were used to analyze association among various variables. Significant P-value was considered < 0.05.

Results: Out of 668 screened patients with LGL expansions in peripheral blood, 261 met criteria for LGLL, of which 38% were hematological and 80% arose prior to onset of LGLL. Most common solid secondary malignancy included skin cancer (14%), prostate cancer (12%), and breast cancer (12%), while most common hematological secondary malignancy consisted of non-Hodgkin lymphoma (17%) and chronic leukemia (14%). 5-year overall survival (OS) for all LGLL patients was 75% and 10-year OS 63%. There was a statistically significant difference in 5-year OS between LGLL patients with a secondary malignancy compared to without (p = 0.049), but no difference between both groups in 10-year OS. Patients diagnosed with a secondary malignancy prior to LGLL had worse 5-year OS (p = 0.031) and 10-year OS (p = 0.05) compared to all other LGLL patients.

Summary/Conclusions: This study showed that the frequency of a secondary malignancy is higher than previously described, especially with onset prior to diagnosis of LGLL. Even though median age of LGLL is around 60 years, it appears that age itself cannot explain this phenomenon. Our results suggest that having a secondary malignancy is a poor prognostic factor in LGLL patients.

PB1870

BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY WITH SUBSEQUENT RITUXIMAB SUPPORTING THERAPY IN RUSSIAN SUBJECTS WITH RELAPSING OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS

1Russian Medical Academy for Postgraduate Education of Ministry of Health, 2Scientific Medical Surgical Center n.a.I.V.Pyrogov, Moscow, 3Regional Clinical Hospital, Tula, 4Regional Clinical Hospital, Orenberg, 5Moscow Scientific Research Oncology Institution n.a.P.A. Gertzen, Moscow, 6Volgograd Regional Clinical Oncology Dispensary1, Volgograd, 7Regional Clinical Hospital, Irkutsk, 8Atlas Medical Center, Moscow, 9Novosibirsk State Regional Clinical Hospital, Novosibirsk, 10Regional Clinical Hospital, Krasnoyarsk, 11Clinical Trial Support, Smolensk, Russian Federation, 12Astellas Pharma Europe, Middle East and Africa, Chertsey, United Kingdom

Background: Combination of bendamustine and rituximab has been established in many international guidelines as treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL).

Aims: Objectives of this study were to evaluate the effectiveness, safety, and tolerability of bendamustine/rituximab combination followed by rituximab maintenance therapy for relapsed or refractory (R/R) iNHL patients in the Russian Federation.

Methods: Adult subjects (≥18 yr), diagnosed with R/R iNHL according to local diagnostic standards, and were enrolled in this prospective observational study. Intravenous therapy was administered in 2 stages (Figure 1): a combination therapy stage followed by a rituximab supporting therapy stage for subjects who achieved complete response (CR) or partial response (PR) during the combination therapy stage. Overall response rate (ORR) was assessed after
3 (Evaluation 1) and 6–8 (Evaluation 2) 28-day cycles. Data from the full analysis set (FAS) were used for the primary analysis and the per-protocol (PP) set for a subgroup analysis. Safety/tolerability was a secondary endpoint and was assessed in the safety analysis set (SAF). Response assessments used the LOCF method for substitution of missing data; overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan–Meier estimates, safety/tolerability was assessed by adverse event (AE) frequency and description using descriptive statistics.

**Results:** Of the 102 subjects enrolled between June 2012 and October 2015, 83 subjects (52M/31F; median age 59 yr [range: 27–84]) with various NHL histology; subjects with mantle cell lymphoma [n=4], diffuse large B-cell lymphoma [n=2], and follicular lymphoma transformation [n=1] were excluded from the PP population due to deviation from the INHL inclusion criteria. Most study subjects were heavily pretreated with a median number of 2 prior lines of therapy before entering the study (range: 1–6). At Evaluation 2, ORR in the FAS was high (n=80; 69.0%) with 35 (44.2%) subjects achieving CR (confirmed, n=20 [24.1%]; unconfirmed, n=15 [18.1%]) and 23 (27.7%) achieving PR; ORR (defined as [CR+CR unconfirmed +PR]) in the PP population was 70.8% (Table 1). For FAS patients, at follow up (17 mo) neither median OS nor PFS had been reached; 2-year OS was 88.9% (95% CI: 79.7–98.0%) and 2-year PFS was 87.9% (95% CI: 80.7–95.7%). In the SAF, 31 of 96 subjects (32.3%) reported ≥1 AE. Decreased neutrophil count, decreased white blood cell count, and infections were the most commonly reported AEs and serious AEs. Twelve deaths occurred: 5 due to disease progression (n=2) or relapse (n=3), 5 were not related to lymphoma or occurred during remission, 1 cause of death was unknown, and 1 subject died from hyperthermia and respiratory failure, which was the only death in the study considered related to combination therapy.

**Summary/Conclusions:** Bendamustine plus rituximab therapy followed by rituximab maintenance therapy was generally well tolerated and demonstrated clinical effectiveness in Russian RR patients with INHLs. Although a number of subjects with aggressive lymphomas were included in the FAS, the ORR rate was not considerably different from the PP population (ORR: 69.9% [FAS] vs 70.8% [PP]).

**PB1871**

**PROGNOSTIC VALUE OF G8 SCREENING TOOL IN PATIENTS WITH INDOLENT B-CELL LYMPHOPLASERATIVE NEOPLASMS – A SINGLE CENTRE EXPERIENCE**

Z. Cvetkovic1,2,*, A. Novkovic1, Z. Djumic3, T. Bibic1, A. Ivanovic1, N. Milutinovic1

1Department of haematology, Clinical Hospital Center Zemun, 2Medical Faculty University of Belgrade, Belgrade, Serbia, 3Department of haematology, Medical Faculty University of Belgrade, Belgrade, Serbia

**Background:** Indolent B-cell lymphoproliferative neoplasms (B-LPN) are malignant diseases of advanced age. The most common among them, follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL) together represent about 40% of all B-LPN. However, as indolent B-LPN are most often the slow-growing diseases, an approach “watch and wait” is often recommended. But, when treatment is necessary, the advanced patients’ age indicate the need for geriatric assessment (GA) in aim to indentify functional, cognitive, social, nutritional and psychological parameters of the general health status. G8 screening tool (G8) is recognized as fast, easy to perform and sensitive test for selecting the group of fit elderly patients capable for curative treatment approach. Although incorporated in routine oncological practice, GA and G8 are not widely evaluated in hematological practice, so far.

**Aims:** To evaluate the impact of G8 screening tool on clinical outcome and survival of elderly patients with indolent B-LPN ≥70. The most common among them, follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL) together represent about 40% of all B-LPN. However, as indolent B-LPN are most often the slow-growing diseases, an approach “watch and wait” is often recommended. But, when treatment is necessary, the advanced patients’ age indicate the need for geriatric assessment (GA) in aim to indentify functional, cognitive, social, nutritional and psychological parameters of the general health status. G8 screening tool (G8) is recognized as fast, easy to perform and sensitive test for selecting the group of fit elderly patients capable for curative treatment approach. Although incorporated in routine oncological practice, GA and G8 are not widely evaluated in hematological practice, so far.

**Patients and methods:** From June 2012, 45 males and 44 females with median age at diagnosis 74.6 years (range: 60–84) were treated with FLT (24 FL, 26 MZL) and chronic lymphocytic leukemia (CLL) with ofatumumab (1st dose: 300 mg, 2nd-8th doses: 1000 mg) up to 8 weekly infusions. Ofatumumab is a humanized, high affinity mAb that specifically targets CD20 to induce a more potent complement-dependent cytotoxicity if compared to rituximab. We designed this multicenter, open-label, single-arm phase 2 trial addressing activity and safety of ofatumumab monotherapy in patients with relapsed/refractory (R/R) SMZL.

**Aims:** The primary objective is the activity of ofatumumab in terms of complete response (CR) rate. Secondary objectives aim at evaluating the safety and tolerability of the regimen and exploratory endpoints investigate biological features potentially related with response to ofatumumab.

**Methods:** All patients provided written informed consent. Eligibility criteria include: R/R SMZL; ≥1 prior line of therapy after ≤2 prior line of therapy; <50% of chemotherapy exposure; ≥1 AE; and extended interval of ≥2 months. Aiming to evaluate the potential of ofatumumab monotherapy, at least 43 patients should be recruited. A safety analysis was planned after the enrolment of the first 10 patients. With an expected rate of adverse events (AEs) of 13%, if less than 3 AEs leading to withdrawal from treatment are reported, the accrual will be stopped.
continue to the planned 15 patients (interim analysis). Here we present safety analysis results.

Results: Ten patients (6 males, 4 females; median age: 69.5 years, 9 ≥65 years, 1 <65 years) were analyzed for safety. Eight patients were previously treated with rituximab, 26 adverse events (AEs) occurred in 7 patients, with only 5 grade 3-4 AEs. Ten AEs were drug-related, 30% were of grade 3. Three AEs occurred: hypersensitivity, n=2, both related to sunitinib, and lab test abnormality, n=1, unrelated to study drug. No AEs leading to treatment withdrawal were reported and no patients died on study. Hematological and biochemical abnormalities included: neutropenia (any grade 6 cases, grade 3–4: 4), thombocytopenia (grade 1–2: 3 cases), lymphopenia (grade 1–2: 2 cases), leukopenia (grade 1–2: 5 cases), 1 case of GO (grade 1, at baseline grade 2). 10 cases of ALP increase (all grade 1–2), 1 case each of AST, ALT and bilirubin increase (all grade 1). Preliminary response assessment in these 10 patients documented 5 CR, 4 Partial Responses (PR), and one patient with progressive disease (PD) at the end of treatment.

Table 1: List of AEs.

<table>
<thead>
<tr>
<th>Drug-related AEA</th>
<th>N of events grade 2–3</th>
<th>Non-drug related AEA</th>
<th>N of events grade 2–3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia</td>
<td>5</td>
<td>Anemia</td>
<td>1</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>1</td>
<td>Neutropenia/leukopenia</td>
<td>1</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>1</td>
<td>Lymphopenia</td>
<td>1</td>
</tr>
<tr>
<td>Neurotoxicity</td>
<td>1</td>
<td>Diaphoresis</td>
<td>1</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>1</td>
<td>Pain/sensations</td>
<td>1</td>
</tr>
<tr>
<td>Bone pain</td>
<td>1</td>
<td>Insomnia</td>
<td>1</td>
</tr>
<tr>
<td>Rash</td>
<td>1</td>
<td>Ataxia</td>
<td>1</td>
</tr>
<tr>
<td>GGT increase</td>
<td>1</td>
<td>Alanine transaminase</td>
<td>1</td>
</tr>
<tr>
<td>ALP increase</td>
<td>1</td>
<td>Bilirubin increase</td>
<td>1</td>
</tr>
<tr>
<td>All grade 2</td>
<td>22</td>
<td>All grade 3</td>
<td>0</td>
</tr>
<tr>
<td>All grade 4</td>
<td>7</td>
<td>All grade 5</td>
<td>0</td>
</tr>
<tr>
<td>Other grade 2</td>
<td>1</td>
<td>Other grade 3</td>
<td>0</td>
</tr>
<tr>
<td>Other grade 4</td>
<td>2</td>
<td>Other grade 5</td>
<td>0</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Ofatumumab is safe and generally well-tolerated even in elderly patients with R/R SMZL. No cases of unexpected adverse drug reactions were documented. In a series of patients largely pre-treated with rituximab, ofatumumab resulted in a 90% overall response rate, 50% being CR. Complete results of the interim analysis will be presented at meeting.

PB1873

TREATMENT PATTERNS AND TREATMENT RESPONSE IN PATIENTS WITH FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL CARE – A UNITED STATES ELECTRONIC MEDICAL RECORD DATABASE STUDY

I. Parraga1,*, E. Gimeno 1, F. García Pallerols1, B. Sanchez Gonzalez1, M. Suarez2, A. Mestre2, M. Ferraro1, E. Abella1, L. Martinez1, C. Pedro1, E. Torres1, J. Maiques3, L. Colomo4, C. Besseres, A. Salar1
1Hematology department. Hospital del mar, Barcelona. Grup de recerca aplicada en Hematologia PSMAR, 2Nuclear Radiology department, 3Radiology department, 4Pathology department. Hospital del Mar, Barcelona, Spain

Background: Follicular lymphoma (FL) is an indolent lymphoid B neoplasm corresponding to 20–25% of non-Hodgkin lymphomas (NHL). Bone marrow biopsy (BMB) is part of standard work-up in indolent NHL since up to 40–70% of cases have bone marrow involvement. This fact is important because the role of bone marrow involvement in aggressive NHL. However, its role in low-grade indolent lymphomas such as follicular lymphoma remains controversial.

Aims: To analyze retrospectively the diagnostic accuracy of PET-CT in comparison with BMB in the initial staging of new FL in a single centre in daily practice.

Methods: One hundred and thirty-six patients with de novo FL have been diagnosed in our institution from June 2005 to October 2016. Of them, 64 who underwent both BMB and PET-CT before treatment were evaluated. The BMB was evaluated by hematologist and the interpretation of PET-CT images was interpreted by a nuclear radiologist. Positive BMB was defined as the presence of CD20+ CD10– Bcl-2+ lymphoid infiltration. No molecular biology techniques were done in the bone marrow tissue. PET-CT bone marrow involvement was defined as an elevated FDG uptake in the bone marrow than those in liver or mediastinum.

Results: Thirty-five male and 29 female were included. The median age at diagnosis: 58 years (range 23-84). Thirty-four patients had grade 1-2 FL and 30 grade 3a FL. Bone marrow involvement was diagnosed in 33 of 64 patients (51.1%) by BMB. Out of the 17 patients with positive PET-CT, 4 had negative BMB. Out of 33 patients with positive BMB, 13 had a positive PET-CT (Table 1). The sensitivity and specificity of PET-CT was 39% and 87%, respectively. The positive predictive value and negative predictive value was 76.5% and 57%, respectively.

Table 1. Detection of BMO involvement: BMB and PET-CT results.

<table>
<thead>
<tr>
<th></th>
<th>BMB –</th>
<th>BMB +</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET –</td>
<td>27 (87%)</td>
<td>20 (61%)</td>
<td>47 (73%)</td>
</tr>
<tr>
<td>PET +</td>
<td>4 (13%)</td>
<td>13 (39%)</td>
<td>17 (27%)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>31 (100%)</td>
<td>33 (100%)</td>
<td>64 (100%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our study shows a very low sensitivity of PET-CT in the daily practice. These results contrast with those reported in some recent studies in aggressive lymphoma. However, the high positive predictive value raises the question about the usefulness of BMB in these PET-CT positive cases. In our opinion, with the current data, BMB should be performed in indolent NHL patients.

PB1875

SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN FOLLICULAR LYMPHOMA USING A UNITED STATES ELECTRONIC MEDICAL RECORD-BASED COHORT

A. Galaznik1,*, J. Bell 1, L. Hamilton2, A. Ogbonnaya2, A. Raju2, K. Hennenfent2, M. Eaddy2, Y. Shou1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, 2Xcenda LLC, Palm Harbor, United States

Newly diagnosed FL patients aged ≥18 years were selected from one large, national US EMR database, between 01/01/08 and 07/31/15 if they had ≥2 FL outpatient records with FL diagnosis codes. The median follow-up for this cohort was 5.1 years. Those in liver or mediastinum.

Aims: To analyze retrospectively the diagnostic accuracy of PET-CT in comparison with BMB in the initial staging of new FL in a single centre in daily practice.

Methods: One hundred and thirty-six patients with de novo FL have been diagnosed in our institution from June 2005 to October 2016. Of them, 64 who underwent both BMB and PET-CT before treatment were evaluated. The BMB was evaluated by hematologist and the interpretation of PET-CT images was interpreted by a nuclear radiologist. Positive BMB was defined as the presence of CD20+ CD10– Bcl-2+ lymphoid infiltration. No molecular biology techniques were done in the bone marrow tissue. PET-CT bone marrow involvement was defined as an elevated FDG uptake in the bone marrow than those in liver or mediastinum.

Results: Thirty-five male and 29 female were included. The median age at diagnosis: 58 years (range 23-84). Thirty-four patients had grade 1-2 FL and 30 grade 3a FL. Bone marrow involvement was diagnosed in 33 of 64 patients (51.1%) by BMB. Out of the 17 patients with positive PET-CT, 4 had negative BMB. Out of 33 patients with positive BMB, 13 had a positive PET-CT (Table 1). The sensitivity and specificity of PET-CT was 39% and 87%, respectively. The positive predictive value and negative predictive value was 76.5% and 57%, respectively.

Table 1. Detection of BMO involvement: BMB and PET-CT results.

<table>
<thead>
<tr>
<th></th>
<th>BMB –</th>
<th>BMB +</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET –</td>
<td>27 (87%)</td>
<td>20 (61%)</td>
<td>47 (73%)</td>
</tr>
<tr>
<td>PET +</td>
<td>4 (13%)</td>
<td>13 (39%)</td>
<td>17 (27%)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>31 (100%)</td>
<td>33 (100%)</td>
<td>64 (100%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our study shows a very low sensitivity of PET-CT in the daily practice. These results contrast with those reported in some recent studies in aggressive lymphoma. However, the high positive predictive value raises the question about the usefulness of BMB in these PET-CT positive cases. In our opinion, with the current data, BMB should be performed in indolent NHL patients.

PB1875

SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN FOLLICULAR LYMPHOMA USING A UNITED STATES ELECTRONIC MEDICAL RECORD-BASED COHORT

A. Galaznik1,*, J. Bell 1, L. Hamilton2, A. Ogbonnaya2, A. Raju2, K. Hennenfent2, M. Eaddy2, Y. Shou1
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharm-
Background: FL is a heterogeneous disease, and clinical presentation is highly variable. The Follicular Lymphoma International Prognostic Index (FLIPI-2) identifies prognostic factors at diagnosis but does not predict in whom and when to initiate first-line therapy (1LT). Recommended therapies for 1LT vary by stage, symptomatology, and tumor burden but include monotherapy with rituximab (R) or in combination with other chemotherapies. Survival of FL patients in the R era has greatly improved, but few studies have evaluated survival outcomes in patients seen in routine clinical care.

Aims: This study aimed to evaluate survival outcomes in patients with newly diagnosed FL patients seen in routine clinical care.

Methods: A retrospective study was conducted in which the presence of ≥1 inpatient record or ≥2 outpatient records with FL diagnosis codes were used to identify newly diagnosed FL patients from a large US EMR database, a part of a US EMR data base, between 01/01/08 and 07/31/15. The study index date was the first FL record. Patients who subsequently initiated 1LT for FL were followed from the date of treatment initiation until death, loss to follow-up, or end of study (09/30/15) for the evaluation of the survival outcomes. Median progression-free survival (PFS) (defined as initiation of second-line therapy, evidence of supportive care >30 days after the end of a line of therapy, or death), median overall survival (OS), and PFS and OS rates at 2 years following initiation of 1LT were evaluated using Kaplan-Meier analyses.

Results: 1,346 newly diagnosed FL patients who initiated 1LT met the patient selection criteria. 47.7% were male, and the mean age was 65.4 years (SD: 12.7). At baseline, 16.6% of patients had a Charlson Comorbidity Index of ≥2, and the most common comorbidities were diabetes (14.5%) and chronic pulmonary disease (11.2%). 1LT consisted of both monotherapy (38.6%) and combination therapy (61.4%). For monotherapy, R was the predominant agent used (85.1%) for first-line therapy, bendamustine+R (43.8%) and R-CHOP (24.6%) were the most common. Kaplan-Meier analysis revealed that the 2-year OS and PFS rates (from initiation of 1LT) were 86.9% and 64.6%, respectively. Median OS was not reached, and median PFS was 48.1 months (95% confidence interval: 39.4, 58.4).

Summary/Conclusions: The 2-year OS and PFS rates in this newly diagnosed FL patient cohort who received 1LT (the majority of which was R-based) were consistent with expectations in a post-R era. Future analysis will explore the differences in clinical characteristics and survival outcomes for patients who received R monotherapy and various R-combination therapies.

Reference

PB1876
Abstract withdrawn.

PB1877
RITUXIMAB MAINTENANCE AFTER R.BENDAMUSTINE FOR PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA: A REAL LIFE STUDY IN SOUTHERN ITALY ON BEHALF OF RETE EMATOLOGICA PUGLIESE

Background: Results from phase 3 “Stil” and “BRIGHT” trials demonstrated the effectiveness of the combination Bendamustine-Rituximab (BR) compared to R in patients with advanced follicular lymphoma (FL). BR has been frontline treatment in advanced follicular lymphoma (FL), emphasizing BR as a standard strategy in this subset of patients. However, only few studies investigated the efficacy and safety of R maintenance after frontline BR, indicating a global beneficial effect of R administration in term of PFS but not OS, in keeping with a good toxicity profile even over two years of treatment.

Aims: In this study, we evaluated the role of maintenance therapy with R after induction with BR in previously untreated FL, and compared its efficacy and safety profile with recent publicly available results of “Stil” trial.

Methods: Patients were treated with a maximum of 6 cycles of B-R (Bendamustine 90 mg/m2 8days 1+2), Rituximab 375 mg/m2 every 28 days followed by 2 additional cycles of Rituximab monthly. Patients showing complete response [CR] or partial response [PR] were then allowed to receive R maintenance [375 mg/m2] administered every two months. To date 118 pts (65 women and 53 men) with FL have been recorded. Median age was 61 years (range 28-86); 15 (13%), 41 (35%), 62 (52%) pts had respectively stage II, III and IV; median number of nodal areas was 4, bone marrow involvement was found in 56 (47%) pts, and median FLIPI was 3.

Results: Among the 118 pts, 94 were evaluable for response and safety. The overall response rate [ORR] was 89.2% with 83 pts achieving a remission after BR therapy. The CR rate was 84.4%, 7 pts had partial response, 5 pts (6.1%) had stable disease, whereas 3 (3.5%) showed no response to BR and had a progressive fatal disease. All of the pts achieving remission received the full planned 2 years Rituximab maintenance treatment and, among them, 24 pts (28.9%) were administered with R over the first two years. Primary adverse events recorded were of grade 3 and 4 in 25% of cases. Infectious (grade 3-4) and neutropenia (grade 3) were the most common adverse event, no additional unexpected toxicities were observed, whereas no occurrence of secondary malignancy was registered so far.

Summary/Conclusions: Our data, compared with recent reports about the role of Rituximab maintenance, support the efficacy of BR as backbone treatment of choice in previously untreated advanced FL. These results, moreover, are in line with those of other studies indicating that Rituximab standard maintenance and also over 2 years for FL appears safe and well tolerated, with no additional toxicities.

PB1878
Abstract withdrawn.

PB1879
ROLE OF F-18 FDG-PET/CT IN DETECTING LYMPHOMATOUS BONE MARROW INVOLVEMENT IN THE INITIAL STAGING OF PATIENTS WITH LYMPHOMA

Background: The role of F-18 FDG-PET/CT in the assessment of bone marrow involvement in the staging of newly diagnosed patients with lymphoma was reviewed in the Recommendations of Lugano Classification. They conclude that if a PET/CT is performed, a bone marrow biopsy is no longer indicated for a routine staging of Hodgkin lymphoma (HL) and most diffuse large cell lymphoma (DLBCL). Data are insufficient in follicular lymphoma (FL) and bone marrow biopsy is always recommended.

Aims: We study the value of F-18 FDG-PET/CT for the detection of bone marrow involvement in the initial staging of patients with lymphoma.

Methods: Newly diagnosed patients with HL, DLBCL and FL who underwent F-18 FDG PET/CT and bone marrow biopsy for initial staging between January 2007 and June 2016 were included. We analyze sensitivity, specificity and concordance of PET/CT compared with bone marrow biopsy. In discordant cases, we review if there was any difference in the staging.

Results: 161 patients were included, 69 DLBCL (38 male, 31 female, median age 59 years), 44 HL (24 male, 20 female, median age 32 years), 48 FL (23 male, 25 female, median age 65 years). Four of the 44 patients with HL had bone marrow infiltration in bone marrow biopsy (BMB+) and PET/CT detected bone marrow involvement in all of these patients. PET/CT was positive in bone marrow biopsy (BMB+) in 7 of the 40 patients without bone marrow infiltration in bone marrow biopsy (BMB-), these patients had bone marrow lesions on locations other than iliac crest. Six of the 7 patients were in advanced stage regardless of bone marrow involvement and a patient had sternal involvement by contiguity. Seven of the 69 patients with DLBCL had BMB+, 6 patients with DLBCL and 1 patient DLBCL and FL. PET/CT had detected bone marrow involvement in all of them. Sixty-two patients of 69 DLCL did not have bone marrow infiltration by biopsy (BMB-), but nine of them had BMB+PET+. Seven of the 9 patients were in stage IV because of extranodal involvement of other organs. One patient had primary brain lymphoma. Patient of jaw bone and metastatic involvement by contiguity. Fourteen patients of 48 patients with FL had BMB+. Of these 14 patients with bone marrow involvement by biopsy, 5 patients had BMB+PET- and PET/CT could not detect another extranodal involvement in three of these five patients. Of the 34 patients without bone marrow infiltration by biopsy BMO-, 8 patients had PET-TAC+, and 6/8 could be classified in stage IV regardless of bone marrow involvement (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>BMB+</th>
<th>BMB-</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET+</td>
<td>PET-</td>
</tr>
<tr>
<td>PET+</td>
<td>PET-</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>specificity</td>
</tr>
<tr>
<td>100%</td>
<td>82.5%</td>
</tr>
<tr>
<td>94%</td>
<td></td>
</tr>
<tr>
<td>64.2%</td>
<td></td>
</tr>
<tr>
<td>86.6%</td>
<td></td>
</tr>
<tr>
<td>72.9%</td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Our series confirms that PET/CT is useful to detect bone marrow involvement in the initial staging of Hodgkin Lymphoma and DLBCL as well as to avoid bone marrow biopsy in these histological variants of lymphoma. In follicular lymphoma, PET/CT did not detect more than one third of patients with bone marrow infiltration by biopsy. These results support the histological assessment of bone marrow in the initial staging of follicular lymphoma.
Background: The combination of bendamustine (B) and rituximab (R) is an effective and well tolerated treatment for B-cell malignancies. However, previous reports have shown a higher incidence of lymphopenia and secondary infectious complications in patients treated with BR than in patients treated with other chemoimmunotherapy regimens.

Aims: We performed a retrospective analysis at our institution in patients treated with BR with or without R maintenance, with the aim of determining the incidence of the infectious adverse events (AEs) and of identifying potential predictors factors.

Methods: We collected data from 65 patients with B-cell non-Hodgkin lymphoma (NHL) who received at least two cycles of BR±R maintenance between 2010 and 2016 at our institution. The AEs – including neutropenia (N), neutropenic fever (NF), lymphopenia, infections episodes and the occurrence of second tumors - were recorded according to the CTCAE v4.0 grade score. We compared the patients with or without infections recording if patients did not. Univariate analysis with Fisher’s exact test was used to evaluate the potential risk factors.

Results: The median age at the first treatment cycle was 66 years (range 36-89), 33 patients (50%) were 66 years, 27 (41%) were male, 53 (82%) had advanced disease with or without B symptoms and 37 (60%) had bone marrow involvement. Thirty (46%) patients had follicular lymphoma, 17 (26%) mantle cell lymphoma, 11 (17%) marginal lymphoma, 5 (7%) diffuse B-cell lymphoma and 4% other indolent lymphomas. Thirty two patients (49%) received BR as first line treatment, 51% as second line and above. Bendamustine was administered either at the dosage of 90 or 90 mg/m² on days 1, 2 and R was administered at a dose of 375 mg/m² or iv, on day 1. Therapy was administered every 4 weeks up to 6 courses. Twenty nine patients (46%) received R maintenance every 8-12 weeks for two years. The mean number of cycles administered was 5 (range 2-6), 13 patients (20%) discontinued treatment due to toxicity: 8/13 for non-hematologic toxicity. Primary or secondary G-CSF prophylaxis was administered to 25 patients (38%), while the prophylaxis with trimetropin-sulfametoxazole against Pneumocystis jiroveci pneumonia was given to all patients. Twenty two patients (34%) had at least one infection, Bacterial pneumonia was identified in 6/22 patients, varicella zoster virus infection in 4/22, cytomegalovirus reactivation in 2/22 and other infections in 10 patients. At univariate analysis, the infectious AEs were associated only with lymphopenia during the second cycle (p=0.043) and with neutropenia during the second, third and fourth cycle (p=0.026, p=0.003, p=0.018, respectively). No correlation with age, line of treatment and G-CSF administration was documented. Other AEs were: grade 3/4 neutropenia (14%), lymphopenia (3%), grade 3/4 lymphopenia (80%). We reported also a 5% incidence of second tumors after treatment (lung cancer in 2 patients and prostate cancer in 1).

Summary/Conclusions: In our analysis, BR±R maintenance confirms a toxicity profile similar to that reported in previous experiences. According to our results, an early lymphopenia and neutropenia (after two cycles) are predictive factors for infections AEs and for premature treatment discontinuation. Twenty% of patients discontinued treatment mostly because of the early withdrawal due to infectious complications. These data raise the question on the role of antibacterial, antiviral and primary G-CSF prophylaxis in all patients treated with BR.

Background: Indolent Non Hodgkin Lymphomas (INHL) are slow growing lymphomas that usually arise from follicular centres. They are characterized by slow appearance and progression of symptoms compared to aggressive non Hodgkin lymphoma (NHL) namely Diffuse large B-cell Lymphoma (DLBL). Small percentage of INHL might transform to aggressive NHL.

Aims: We aim to describe the clinical characteristics, prognosis and risk of transformation to aggressive Lymphoma in INHL. In this analysis we consider FLIPI 0-1 and the obtainment of complete remission. In multivariate analysis we evaluated the potential risk factors.

Methods: All patients diagnosed with INHL between Jan 2003 to Jan 2017 were retrospectively reviewed. Clinical and laboratory data at time of diagnosis including gender, age, lactate dehydrogenase level (LDH), pathological subtypes (including induction CT scan) were studied. Extraneous involvement was confirmed either by histopathological studies or CT and PET/CT scan. Transformation to aggressive lymphoma was confirmed by histopathological studies. Patients were followed and overall survival rate was calculated. Mean survival times were calculated using Kaplan-Meier method.

Results: Among 265 patients diagnosed with INHL, only 88 patients (33.20%) confirmed to have INHL. 54 patients (61.4%) were males and 34 patients (38.6%) were females. Their ages at diagnosis ranged from (29-83) years with a mean (SD) of 59.26 (12.39). Among these patients, 45 patients (51.1%) had small lymphocytic lymphoma / chronic lymphocytic leukemia (CLL), 20 patients (22.7%) had follicular lymphoma (FL), 15 patients (17%) had marginal zone lymphoma (MCL), 6 patients (6.8%) had mantel cell lymphoma (MCL) and 2 patients (7.8%) had unspecified NHL. Mean age of MZL (53.2 years) and FL (55.3 years) were significantly lower than mean age of MCL (58 years) and CLL (62.77 years). 22 patients (23.9%) had extra nodal involvement. There were significant differences in sites involvement of NHL subtypes characterized by slow appearance and progression of symptoms compared to aggressive non Hodgkin lymphoma (NHL) namely Diffuse large B-cell Lymphoma (DLBL). There was significant association between INHL subtypes and transformation to DLBL. 7 from 20 patients with FL (35%) and 4 from 45 patients with CLL (8.9%) had transformed to DLBL. Mean LDH level (886.1 U/L) in patients with transformation to DLBL was significantly higher than mean LDH level (490.7 U/L) in other patients, (P-value=0.004). There was a significant association between mean age and mean lymphocytic lymphoma / chronic lymphocytic leukemia (CLL) subtypes and extra nodal sites involvement. (P-value=0.001). 60% of patients with MCL, 20% of patients with FL and 8.9% of patients with CLL had extranodal sites involvement. 11 patients (12.5%) from all INHL had transformed to DLBL (P-value=0.02). 7 from 20 patients with FL (35%) and 4 from 45 patients with CLL (8.9%) had transformed to DLBL. Mean LDH level (886.1 U/L) in patients with transformation to DLBL was significantly higher than mean LDH level (490.7 U/L) in other patients, (P-value=0.004).

Summary/Conclusions: Prevalence of INHL among patients with NHL in Northern Jordan is 33.2%. The most common INHL subtypes in our patients were
CLL (51.1%) and FL (20.7%). These findings are significantly different from Saudi Arabia and Western Countries in which FL is the most common subtype. FL and CLL are associated with higher risk of transformation to DLBCL. High LDH level is considered a risk factor for transformation to DLBCL in our patients. MCL is associated with significantly lower mean survival time than other NHL subtypes.

PB1883

OCULAR ADNEAXAL LOW GRADE LYMPHOMA TREATMENT OUTCOMES AND LONG TERM FOLLOW UP: A SINGLE CENTRE EXPERIENCE

N. Elmuşharâf1,2, C. Bloodworth1, B. Skippen2, M. Hourihan2, T. Parmar2, D. Morris2, C. Lane3, C. Rowntree1
1Haematology, 2Ophthalmology, 3Radiology, University Hospital of Wales, Cardiff, United Kingdom

Background: Ocular adnexal lymphoma (OAL) accounts for 1-2% of Non-Hodgkin Lymphomas (NHL) and 8% of all extra-nodal sites. The majority of cases, >95%, are of B cell origin and 80% are low grade lymphomas. Secondary ocular involvement occurs in approximately 2.4-5.3% of patients with advanced systemic NHL. Marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma is reported in approximately 50% of patients. Current treatment options for low grade OAL include radiotherapy and chemotherapy. Chlamydia Psittaci DNA has been reported in up to 80% of tumor biopsies from patients with OAL suggesting a possible value of anti-Chlamydia Psittaci antibiotic therapy.

Aims: To report a single centre’s experience in the outcomes of patients diagnosed with OAL over a 13 year period.

Methods: A Retrospective cohort of patients with low grade OAL treated in a single Centre between 2003 and 2016 was analyzed. Chemotherapy was the first choice of therapy until 2008, afterwards radiotherapy became the first line treatment for OAL.

Results: A total of 20 patients with OAL were identified. 60% (12/20) of patients were females with a median age of 61.5 years (range 45-85 years). 80% (16/20) had unilateral disease at presentation. MALT lymphomas comprised 75% (15/20). Follicular NHL 15% and CLL/SLL 10%. Only 10% (2/20) had a prior diagnosis of NHL. At presentation 20% (4/20) had evidence of disease recurrence, mainly extra-ocular and 50% (3/6) suffered complications related to high grade and 1 patient subsequently died as a consequence of their disease. 33% (2/6) patients treated with radiotherapy experienced disease recurrence, mainly extra-ocular and 50% (3/6) suffered complications related to radiotherapy in the form of dry eyes and cataract. Median follow up was 9.5 years (range 1-14 years). Overall survival was 95% (19/20) with an event free survival of 65% (13/20) (Table 1).
immunoglobulin heavy chain rearrangement (CDR2 / CDR3 of [IGH]) in PB, bone marrow and affected organs. All diagnoses were classified according to WHO (2016 revision). In addition, we performed an autonomy test in most patients.

**Results:** Among the 56 patients, 26 were men (46.4%) and 30 women. The median age at diagnosis was 64 years (37-92). The most frequent subtype was marginal zone lymphoma (17 patients, 30.4%), followed by MALT: 10 pulmonary (17.9%), 10 gastric (17.9%), 5 cutaneous (8.9%), 5 ORL (8.9%), 2 (3.6%), 1 hepatic, 1 thyroid and 1 lacrimal gland (1.8%) and nodal marginal zone lymphoma (3 patients, 5.4%). Five of them presented with multifocal disease (8.9%). Fifty percent (28) had a clinical stage III / IV and 32 patients (57.1%) had a low risk of diagnosis (FLIPI 0-1). We found an antigenic stimulus in 11 patients (Helicobacter pylori, Sjögren’s syndrome, Hashimoto’s thyroiditis). The molecular study of MALT1 was performed in 25 patients and 3 presented the translocation (12%). Six of seventeen cases (35.3%) showed light rearrangements. Anti-nuclear antibodies were positive in 15 of 32 patients (46.9%), whereas 16 of 32 patients (50%) had serological IgH rearrangements. Antinuclear antibodies were positive in 15 of 32 patients (46.9%), whereas 16 of 32 patients (50%) had serological IgH rearrangements. At the time of diagnosis was demonstrated in 100% of Tiacci HCL case series.

**Aims:** To evaluate the efficacy and safety of the bendamustine-rituximab association in a group of patients with follicular lymphomas previously exposed to rituximab (OPL). The study was approved by the Oncologic Ethics Committee and by all of the participating centres. All patients acceded to the treatment through the compassionate use program.

**Methods:** Retrospective analysis of patients with relapsed FL treated with BR in 7 spanish hospitals on behalf of the Spanish Lymphoma Group (GELTAMO). A total of 402 patients were previously treated with rituximab in 166 (41.4%) cases, with a median follow-up of 15 months (6-92). The median age was 60 years (38-87) and the median progression-free survival (PFS) was 6 months (2.9-5.4). Toxicity: No treatment-related death was recorded. 42% received cotrimoxazole prophylaxis and 36% of patients. Response: The overall response rate was 95.1% (65.8% CR-iCR / 29.3% PR). With a median follow-up of 26 months (6-92) the median response duration was 41.9 months (32.8-51). The median progression-free survival (PFS) was 67 months (27.4-86.5) with no impact neither by the number of previous treatments (1 vs 2) (P=0.69) nor by the age (<70 vs ≥70) (P=0.9). Patients who received maintenance with rituximab after BR had a significantly longer median PFS than without rituximab (NR vs 23 months) (p=0.004). Toxicity: No treatment-related death was recorded. 43% received rituximab prophylaxis and 35% opportunistic infections were recorded (1 P. jirovecii pneumonia in a patient without prophylaxis).

**Summary/Conclusions:** BR has a high efficacy and a good safety profile in this series of patients with relapsed FL previously exposed to rituximab. The number of previous treatments (1 vs ≥2) and the age had no impact in the results.
Results: In all patients we got complete responses (CR) with no tumor detectable by endoscopy or biopsy after initial treatment, but after 2 years one of them relapsed and required immunochemotherapy. The most common acute toxicities were fatigue and nausea, in our patients. In any case late toxicities were observed. The overall survival was 100% after 2 years.

Summary/Conclusions: In selected patients who are not responsive to HP sterilization, definitive radiotherapy can be an efficient therapy with tolerable complications, preservation of stomach and sustained response over time.

Infectious diseases, supportive care

PB1889

USE OF LIPEGFILGRASTIM IN CLINICAL PRACTICE FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN LYMPHOMA PATIENTS: INTERIM RESULTS OF A PAN-EUROPEAN NON-INTERVENTIONAL STUDY

N. Cascavilla1,2, T. Wrobel2, E. Hatzimichael3, E. Wojciechowska-Lampka4, P. Mazz5, K. Kargar6, M. Lenzhofer7
1Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy, 2Wroclaw Medical University, Wroclaw, Poland, 3University Hospital of Ioannina, Ioannina, Greece, 4MSC Cancer Center and Institute, Warsaw, Poland, 5SS Annunziata Hospital, Taranto, Italy, 6Hospital Center of Wallonie Picarde, Tournai, Belgium, 7Schwarzhach Hospital, Schwarzhach im Pongau, Austria

Background: Lipegfilgrastim (Lonquex®) is a long-acting fixed-dose glycopeylated granulocyte colony-stimulating factor administered once per chemotherapy cycle. It has been available in Europe since 2013. It was proven to be non-inferior with regard to duration of severe neutropenia compared with pegfilgrastim in breast cancer patients. However, data in patients with hematological malignancies are limited.

Aims: We aimed to evaluate the effectiveness of lipegfilgrastim in the cycle following the first lipegfilgrastim-supported treatment cycle in lymphoma patients.

Methods: This is a prospective observational cohort study. Patients with different tumor types treated with cytotoxic chemotherapy (CT) who received lipegfilgrastim in primary prophylaxis (PP) or secondary prophylaxis (SP) are being included in this study. CT dose modifications and neutropenia-related events are recorded and analyzed. Evaluation of effectiveness in the cycle following the first lipegfilgrastim-supported CT cycle in a lymphoma subpopulation is presented here.

Results: At the time of the interim analysis (December 2016), 249 patients diagnosed with lymphoma have been included. Mean age±standard deviation of lymphoma patients was 61.6±15.6 years and 56.6% were male. For the majority of patients (81.1%), intended use of lipegfilgrastim was in PP. Exposure to lipegfilgrastim has been documented for 228 patients with an average of 4.76 cycles per patient. Data on CT dose modifications and neutropenic events following the first lipegfilgrastim-supported cycle were available for 144 and 167 patients, respectively. CT dose was never omitted. CT dose delays were observed in 8.0% (PP) and 18.8% (SP) of patients and CT dose reductions in 4.5% (PP) and 12.5% (SP) of patients. In the first lipegfilgrastim-supported cycle, febrile neutropenia was recorded in 4.5% (PP) and 3.0% (SP) of patients; severe neutropenia was recorded in 7.5% (PP) and 9.1% (SP) of patients. Throughout the treatment, 22 (9.6%) patients exposed to lipegfilgrastim reported at least 1 adverse drug reaction (ADR). The most common ADRs were myalgia and musculoskeletal pain. Serious ADRs were reported by 11 (4.8%) patients.

Summary/Conclusions: Lipegfilgrastim is effective and well tolerated in the real-world setting in lymphoma patients, administered either in PP or SP. The results suggest that lipegfilgrastim administered in PP might give better outcomes in terms of dose delays and dose reductions than when administered in SP.

PB1890

TUBERCULOSIS IN ACUTE LEUKEMIA- AN ANALYSIS OF CLINICAL CHARACTERISTICS AND IMPACT ON MANAGEMENT IN 25 PATIENTS

C. Singh1,2, A. Jain2, G. Prakash2, P. Malhotra2, S. Varma1
1Internal Medicine, 2Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India

Background: Patients with acute leukemia represent an immune-compromised population, with innate, humoral and cellular immune paresis. These patients are thus at high risk of development of new infections and reactivation of chronic infections. Despite the high prevalence of tuberculosis in the general population in endemic countries, it is rarely suspected and diagnosed in patients with acute leukemia.

Aims: To study the clinical manifestations of tuberculosis in patients with acute leukemia, as well as the impact of infection in the management of leukemia.

Methods: A hospital database search was done to identify cases of acute leukemia and tuberculosis between a study duration of January 2013 to January 2017. All the medical records of the identified cases were retrieved from the central records department. A systemic analysis of characteristics pertaining to acute leukemia, treatment regimen, chemotherapy response, site of tuberculosis infection, mode of diagnosis and treatment response to anti-tuberculous therapy was conducted.

Results: A total of 25 patients with acute leukemia were identified who were also diagnosed with tuberculosis. 10 patients had Acute Myeloid Leukemia, 7 had Acute Promyelocytic Leukemia, 5 had Acute Lymphoblastic Leukemia, 2 had Mixed Phenotypic Leukemia while 1 had Myeloid Sarcoma. The mean interval between diagnosis of tuberculosis and acute leukemia was 37.2 weeks, with 2 patients being diagnosed after completion of therapy of acute leukemia.
and one patient was diagnosed post mortem. The most common organ involved was the lung, which was seen in 80% of patients and 20% of patients had disseminated tuberculosis. The development of tubercular infection led to alteration of therapy for the acute leukemia in 24% of cases, while it was postponed in 44% of cases. In particular, hypomethylating agents were used successfully in two patients with AML as bridge therapy to high dose chemotherapy. 76% of patients were cured of tuberculosis, 6% of patients required additional therapy and 3 patients could not receive adequate therapy for tuberculosis. 3 patients went on to undergo HSCT post treatment for tuberculosis, and none had a flare of the disease post transplant. Summary/Conclusions: The presence of tuberculosis infection in patients of acute leukemia has an impact on the overall management of the patient and strategies such as utilization of hypomethylating agents as bridge therapy may help in successful management of the leukemia. A high index of suspicion is required to suspect and diagnose the presence of tuberculosis as the manifestations are more commonly attributed to fungal infections or to the leukemia per se. These patients usually have a frequent polymicrobial infection and the presence of tuberculosis infection does not forego treatment options such as HSCT or high dose chemotherapy for these patients.

PB1891
INCIDENCE OF BACTEREMIA BY MULTI-RESISTANT BACTERIA IN HEMATOLOGY PATIENTS. A DESCRIPTIVE EPIDEMIOLOGIC STUDY FROM A THIRD LEVEL HOSPITAL
A. Nieto Vazquez.1 2
1Hematology, SERGAS. Hospital Alvaro Cunqueiro, Vigo, Spain
Background: In recent years the incidence of multi-resistant bacteria (MRB) infections have notably increase. These infections are especially serious in hematological patients because of the immunosupression derived from their illness and their treatments. This increase is related to a high mortality rate and high health costs due to the severity of the infections and the difficulty in setting adequate therapy due to the lack of new antibiotics against these pathogens.
Aims: Define the MRB infections incidence and ways of presentation. As a secondary goal we try to determine if the isolation of these MRB has affected our empiric antibiotic therapy decision.
Methods: We retrospectively collected all positive blood stream cultures from hematologic patients from January 2012 to December 2016. We studied the characteristics, clinical features and pathogen isolates of our patients when the blood cultures were obtained.
Results: 1085 positive blood stream cultures were collected in 382 patients. The main characteristics of the patients are shown on Table 1.

PB1892
INFECTIONS PRESENTING IN THE BONE MARROW IN HIV POSITIVE PATIENTS AND THEIR MORPHOLOGICAL ASSOCIATIONS – SIX YEAR DATA FROM AN INDIAN TERTIARY CARE HOSPITAL
R. Gupta1,*, S.L. Jain1, P. Sobti2
1Pathology, Maulana Azad Medical College, 2Pathology, Apollo hospital, Delhi, India
Background: Centre of Disease Control enlists more than 20 infections considered as Acquired Immunodeficiency Syndrome(AIDS) defining. Progression of the disease and falling CD4 counts are the most important risk factors in acquiring these infections. Most of the cases present with non specific symptoms including fever, respiratory and gastrointestinal manifestations . A bone marrow examination is helpful in establishing the diagnosis in many of these cases.
Aims: The aim of this study was to evaluate the incidence of marrow infections in HIV positive patients and to study their morphological spectrum.
Methods: This is a six year retrospective study carried out in a tertiary care hospital in North India. All bone marrow aspirates and biopsies from HIV positive patients were retrieved and evaluated for the presence of infectious etiology. Cytochemical stains like Acid Fast Bacillus, Periodic Acid Schiff, Gomori Methenamine Silver and Mucicarmine were performed wherever needed. The associated morphological features which may assist diagnosis were noted.
Results: Bone marrow samples (either aspirates or biopsies or both) were available in 185 HIV patients. Out of these, fifty three cases (33.5%) were associated with infections. The most common infection in these patients was Mycobacterium Tuberculosis (22.7%). In addition, five cases of Histoplasmosis (2.7%), two cases of Cryptococcosis, two cases of Leishmania donovani, and one case of Plasmodium falciparum, Parvovirus and Microfilaria each were noted. The morphological spectrum associated with infections in these cases included lymphoplasmacytic infiltrate(68%), granulomas(66%), macrophage infiltration, hemophagocytosis, gelatinous marrow transformation and marrow hypoplasia. Two cases of M tuberculosis were associated with maturation arrest in the bone marrow. One case of Tuberculosis was associated with Non Hodgkin’s Lymphoma. Myelodysplasia was seen in association with Leishmania infection.
Summary/Conclusions: A wide spectrum of infections may be observed in HIV positive patients in the bone marrow. Bone marrow aspirate and biopsy are essential, rapid and cost effective techniques to arrive at the right diagnosis in such cases. Features like hypoplasia, myelodysplasia and maturation arrest may be attributable to infections.

PB1893
UTILITY OF BONE MARROW BIOPSY IN FEVER OF UNKNOWN ORIGIN: A CRITICAL ANALYSIS OF A RETROSPECTIVE SERIE
H.N. Fernandez - Leyva1,*, J. Bosworth1, M. Offer1, N. Ansar1
1Haematology, Friemly Park Hospital, Surrey, United Kingdom

Background: The utility of bone marrow biopsy trephine (BMT) as a diagnostic tool in patients with fever of unknown origin (FUO) is a subject of controversy and debate. BMT has been shown to be safe and useful in patients with HIV/AIDS but its value in immunocompetent patients has not been sufficiently assessed. It’s reported the use of diagnostic BMT as a rapid decision-making tool in patients with HIV/AIDS and FUO in the proper clinical setting. A BMT demonstrated infection-related evidence prior to positive bone marrow culture in 75% of cases. Special stains and blood cultures had similar diagnostic yield, but BMT offers faster results. Thus, this procedure assists in clinical decision-making and the refinement of treatment in a more timely manner.

Aims: To determine the utility of Bone marrow biopsy (BMT) in FUO patients.

Methods: We reviewed retrospectively the bone marrow biopsy results of the patients who underwent BMT from January 2010, to December 2016. Demographic, laboratory, diagnostic and outcome data were collected and retrospectively analyzed. We identified 31 patients who fulfilled the accepted classic Petersdorf criteria for FUO. The cohort included immunocompromised and immunocompetent patients.

Results: The BMT contributes to the diagnosis in only four cases (12.9%). In two patients (6%) the histology revealed the presence of granuloma and/or lymphohistiocytic aggregates; one secondary hemophagocytosis (3.2%) and one mastocytites infiltrate (3.2%). Six patients had a previous diagnosis of HIV/AIDS (19%). Sub-analyse in HIV/AIDS patients revealed positive BMT culture in 2 of the patients (6.4%). Cultures demonstrated Mycobacterium tuberculosis and Mycobacterium avium intracellular. There was one case in which a patient was known in culture but that had a negative of ‘direct examination’. The associations most likely related factor to contribute to the diagnosis in HIV/AIDS was male predominance (58% odds ratio [OR] 2.95; 95% CI, 1.19-4.25), clinical lymphadenopathy (OR 4.97; 95% CI, 1.90-2.44) or anemia (OR, 1.7-21.3; P<0.01), and ≥3 organ system dysfunction (P<0.001, respectively), positive inotropic support (P<0.01), and mechanical ventilation (P<0.001). By using multivariate logistic regressions, the independent risk factors were mechanical ventilation (OR, 9.0; 95% CI, 1.7-21.3; P<0.01), and organ system dysfunction (P<0.001). The mortality for hematologic cancer was higher mean PRISM3 score (165.9± 4 vs 122.8± 6; P=0.51) and higher risk of sepsis (39.3% vs 13.0%; P<0.05) compared to solid organ cancer patients.

Summary/Conclusions: These results revealed the current status of ICU care for pediatric cancer patients in a tertiary hospital in Korea. Further improvement of supportive care and earlier effective intervention should be translated in gradual reduction in mortality rate in these population.

PB1895
EFFICACY AND SAFETY OF TIGECYCLINE IN FEBRILE NEUTROPHIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND CARBAPENEM RESISTANCE: A MULTICENTRE RETROSPECTIVE STUDY FROM CHINESE PEOPLE
X. Bing1,*, H. Linsi2, G. Guoshu3, L. Zhifeng1, S. Pengcheng2, G. Xutao4, W. Yang1, L. Jia2, J. Jiaob3, Z. Yong3
1The First Affiliated Hospital of Xiamen University, Xiamen, 2Nanfang Hospital, Southern Medical University, Guangzhou, 3Huizhou Municipal Central Hospital, huizhou, 4Nanfang Hospital, Southern Medical University, Xiamen, China

Background: Tigecycline has broad spectrum activity against multidrug-resistant (MDR) bacteria, but few investigations of tigecycline in febrile neutropenic (FN) patients with malignancy are available.

Aims: This study attempts to investigate the efficacy and safety of tigecycline in FN and carbapenem resistant patients with hematologic malignancies.

Methods: The study of 109 patients with hematologic diseases and FN were retrospectively analyzed. They are unresponsive to carbapenems for 3~5 days before receiving tigecycline (loading dose 100 mg; then 50 mg every 12 hours). Clinical response to treatment was defined as clinical cure, improvement or failure. Meanwhile, the adverse events were documented.

Results: The median duration of neutropenia was 15 days (ranged from 1 to 83d). Out of 109 patients, 96 (88.1%) had respiratory infection, while 33 (30.3%) had bloodstream infection. The total response rate of tigecycline was 65.1%. The bacterial eradication rates and bacterial hypotheical eradication were 25.9% and 24.1%, respectively. The clinical effective rate was 85.7% when tigecycline was administered for more than 9 days, while just 48.3% when administered for less than 9 days (p<0.001). Patients with bloodstream infection got a worse efficacy than those without (41.2% vs 69.6%, p=0.024). For patients whose absolute neutrophil counts were less than 0.1×10^9/L, the clinical effective rate was 89.6% vs 86.4%, p=0.19. The side-effects were well tolerated. No lethal adverse events were observed.

Summary/Conclusions: Our results demonstrated tigecycline was effective and safe for patients unresponsive to carbapenems with FN, combination and prolonged duration of tigecycline is recommended, and these results need to be further studied.

PB1894
THE OUTCOME OF PEDIATRIC CANCER PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT OF A TERTIARY HOSPITAL IN Gwangju-Chonnam, Korea
H. Kook1,*, G. Kim1, J.-S. Choi1, H.-J. Choi1, H.-J. Bae1
1Pediatrics, Chonnam National University Hwasun Hospital, Hwasun-gun, Korea, Republic Of

Background: Recent advances in supportive care have considerably improved the prognosis of pediatric cancer patients. However, the use of aggressive cancer treatment is also associated with complications and life-threatening events that result in admissions to the intensive care unit (ICU).

Aims: This study aimed to analyze the outcome of pediatric cancer patients admitted to the ICU.

Methods: A retrospective analysis of 84 ICU admissions of cancer patients <21 years old between May, 2004 and Aug, 2016 at Chonnam National University Hospital (CNUNH) was undertaken. The risk factors for short-term outcome (survival at the time of discharge from the ICU) were analyzed. After excluding scheduled perioperative admissions, the records of 81 admissions (75 patients) were reviewed.

Results: Hematologic cancer patients represented 71.6% of admissions. The mortality rate decreased obviously (59.8%, 12.2±8.6; P<0.001) compared to solid organ cancer patients.

Summary/Conclusions: Our results demonstrated the outcome of pediatric cancer patients admitted to the ICU is better than those of previous report.
Methods: A retrospective cytological study of bone marrow aspirates from 95 patients with HMS (n=27), HMS+HIV (n=8), HMS+HIV/HEV (n=11) and HMS+intestinal parasitosis (n=49) has been performed.

Results: Bone marrow cellularity was normal in all the groups studied except in HMS+HIV patients, in which the cellularity was very diminished (statistically significant difference, p<0.01). Most frequent alterations observed in all samples (HMS and HMS+other entities) that could define the HMS-bone marrow cytological pattern, were: - Erythroid hyperplasia with dyserythropoiesis, which is reflected in a decreased myeloerythroid ratio. - Increased eosinophils percentage. - Increased lymphocytes percentage. - Increased plasma cells percentage and detection of Mott cells in a significant proportion of samples from all series (48.1% of HMS samples). Quantitative results for these samples are summarized in Table 1. Lymphocytosis was significantly increased in HMS+HIV/HCV bone marrow (p=0.04). Significant detection of atypical lymphocytes (>4%) varied widely between the groups, ranging from 14.8% of HMS bone marrows to 75.0% of HMS+HIV bone marrows (statistically significant difference, p<0.01). There was no lymphocytosis in any case. No quantitative or qualitative alterations were detected in megakaryocytes, except for a slight decrease in HMS+HIV/HCV bone marrows (statistically non-significant difference) (Figure 1).

Table 1. Quantitative results (mean±standard deviation).

<table>
<thead>
<tr>
<th>Reference values</th>
<th>HMS</th>
<th>HMS+HIV</th>
<th>HMS+HIV/HCV</th>
<th>HMS+HIV/HEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myelocytes/monocytes ratio</td>
<td>3.3±1.0</td>
<td>2.5±0.8</td>
<td>2.4±0.6</td>
<td>2.5±0.9</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>&lt;5</td>
<td>12±0.9</td>
<td>9±0.9</td>
<td>12±8.3</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>33±0.5</td>
<td>30±2.9</td>
<td>27±0.5</td>
<td>25±2.0</td>
</tr>
<tr>
<td>Plasma cells (%)</td>
<td>54</td>
<td>30±2.7</td>
<td>31±2.1</td>
<td>46±1.0</td>
</tr>
</tbody>
</table>

Summary/Conclusions: As far as we know, this is the largest series of HMS bone marrow analyzed. Identification of common cytological findings in all the groups studied allows defining a characteristic cytological pattern for HMS. The reason for these findings could be related to an aberrant chronic immune response caused by a continuous exposure to malaria parasites. Only bone marrows of HIV coinfected patients present additional specific alterations (decreased cellularity and high proportion of atypical lymphocytes). Some authors hypothesize that HMS could eventually evolve to chronic lymphocytic leukemia, hairy cell leukemia or splenic lymphoma with villous lymphocytes, so a special follow-up would be advisable for those patients with a high proportion of atypical lymphocytes.

PB1897

ACUTE APPENDICITIS IN LEUKEMIA PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING THE NEUTROPHILIC PHASE Q. Zhang1, Q. Jiang1, Y. Zhou1, Q. Mai1, K. Tsui2, Z. Wei2, J. Majaw2

Background: Infectious complications arising from the gastrointestinal tract is common in neutropenic patients with hematologic malignancies, especially during HSCT.

Aims: Sequential analysis of 776 HSCTs in single center, totally 10 cases of acute appendicitis were found out, the treatment and outcome were further analyzed.

Methods: The HSCT patients who occurred acute appendicitis during 10d~+60d in the Hematological Department of Nanfang Hospital from Jan. 2005 to July 2016 were analyzed. Patients were enrolled in our study based on the Modified Alvarado Scoring combined with ultrasonography (the MASS total score of 1–4: acute appendicitis very unlikely; Score 5–7: acute appendicitis probable; Score 8–10: acute appendicitis definite. # R: negative; *: positive.

Summary/Conclusions: Acute appendicitis occurring during the neutropenic phase in HSCT patients could be diagnosed by the MASS and ultrasonography, and such cases could be cured by conservative therapy. This study could provide a further choice for the diagnosis and treatment of acute appendicitis in leukemia patients of HSCT.

PB1898

EPIDEMIOLOGY OF BLOODSTREAM INFECTIONS IN NEUTROPENIC AND NON-NEUTROPENIC PATIENTS WITH MALIGNANCY N. Raja1,2, S. Gupta3,*, B. O’Neill3

Background: Blood stream infections (BSI) in patients with malignancies remain associated with significant morbidity and mortality. The choice of an empirical antibiotic regimen is usually based on the local epidemiology of the microorganisms and their antibiotic resistance profile. Antimicrobial guidelines for the management of sepsis in cancer patients in East Sussex Healthcare Trust (ESHT) recommend piperacillin/tazobactam as monotherapy and gentamicin is added in case of septic shock. Vancomycin is also added as a first line therapy if there is a suspicion of central line sepsis. Alternative therapies are cefazidime or meropenem plus aminoglycoside.

Aims: We intend to review the aetiology of BSI and check the effectiveness of the antibiotics used in ESHT in cancer patients.

Methods: This retrospective study was conducted at ESHT from January 2006 to December 2015. Demographic and laboratory data were collected from the Pathology information system.

Results: A total of 640 episodes of BSI occurred in 297 patients (159 male). Of the 297 patients, 239 had haematology malignancies while 54 had solid organ tumour. Four patients had both. The neutrophil count was <1 cells/109 /L in 383 episodes and majority of BSI occurred in this group. A total of 802 organisms (477 and 325 organisms from neutropenic and non-neutropenic respectively) were isolated. Among Gram negative organisms, more than 91% isolates were sensitive to ceftazidime or meropenem plus aminoglycoside. Resistance caused by a continuous exposure to malaria parasites. Only bone marrow analyzed. Identification of common cytological findings in all the groups studied allows defining a characteristic cytological pattern for HMS. The reason for these findings could be related to an aberrant chronic immune response caused by a continuous exposure to malaria parasites.

Figure 1. # R: negative; *: positive.
PB1899

CHANGING TREND IN LOCAL BACTERIAL EPIDEMIOLOGY: EXPERIENCE IN ACUTE LEUKEMIA PATIENTS HOSPITALIZED IN SINGLE HEMATOLOGY UNIT

C. Buquicchio1,¹, L. Ciuffreda1, G. De Santos1, C. Germano1, M. Leo1, M.T. Santeramo1, R. Miccilo1, G. Tarantini1

¹Ematologia, SC Ematologia con trapianto, Barletta, Italy

Background: The intense chemotherapeutic regimens and hypometabolic agents to treat acute leukemia induce prolonged neutropenia with high risk of infections.

Aims: To analyze local microbial epidemiology we studied patients admitted to our ward.

Methods: All 100 cases of Acute Leukemia (AL) admitted in our ward from August 2013 to February 2017 received prophylactic antibacterial therapy with fluoroquinolones and were analyzed for weekly routine tissue culture screening and serial blood culture for fever. Six patients were LymphoidAL and 94 were Myeloid AL. 41 patients were not eligible for intensive chemotherapy (for age and comorbidities) and were treated with hypometabolic agents, while 59 were younger than 65 years and were treated with induction /consolidation chemotherapy 3 plus 7 regimen. Median age was 58 years with range from 27 to 88 years old.

Results: We found 28 patients (28%) bacterial septic shock during fever, of which 20 cases (71%) in particular 65% E.Coli, 15% Enterobacter, 10% Klebsiella, 5% Stenotrophomonas, 5% Pseudomonas; while 8 patients (29%) had a gram positive septic shock (S.Haemoliticus 38%, S.capitis 25%, S. hominis 25%, S epidermidis 12%). During intensive chemotherapy and prolonged severe neutropenia we took over the major incidence of septic shock (23 patients 82%) than hypometabolic treatment in particular decaitbone (5 patients 18%). During 2013 we had 3 mortal septic shock for multiresistant gram-klebsiella and Pseudomonas. Since than we adopted in our ward, isolation of patients with gram negative (klebsiella or pseudomonas )tissue culture positive, hygienic and sanitary practices with closing room for 48 hours and hand disinfection before entering and after leaving any patients room. We noticed a change of bacterial infections incidence in these 3 years in our ward...reduction klebsiella/pseudomonas multiresistant infections and emergency of E.coli and Staphilococcus septic shock not multiresistant.

Summary/Conclusions: More epidemiological analysis in several haematological ward are necessary to understand if is a changing local microbial epidemiology or is the different management of neutropenic patients with acute leukemia and/or a different antimicrobial strategy to determine this changing trend.

PB1900

UK SINGLE-CENTRE SERVICE EVALUATION TO DESCRIBE THE IMPACT ON HEALTHCARE RESOURCE USE OF LOCAL ANTIMYCOBACTERIAL PROPHYLAXIS AND TREATMENT PROTOCOLS IN THE MANAGEMENT OF HIGH- RISK PATIENTS WITH NEUTROPENIA

D. Furry1,², H. Ahré, G. Nock1, E. Taymor1

¹Poole Hospital, Poole Hospital NHS Foundation Trust, Poole, ²Merck Sharp & Dohme Ltd, Merck Sharp & Dohme Ltd, Hoddesdon, ³pH Associates, pH Associates, Marlow, United Kingdom

Background: Patients with neutropenia, including those with haematologic malignancies, are at high risk of invasive fungal infections (IFI). Pre-2014, there were no formal written guidelines but the guidance at Poole Hospital NHS Foundation Trust specified the use of posaconazole oral suspension for primary prophylaxis in all high-risk patients except those with acute lymphoblastic leukaemia (ALL). In 2014 formal guideline changes included the introduction of the tablet formulation of posaconazole, use of micafungin as first line empirical therapy and a focus towards improving diagnostics to guide management.

Methods: An interim analysis of high-risk adult patients with prolonged neutropenia aged ≥18 years at initiation of antifungal prophylaxis/treatment was carried out. Retrospective data on patient characteristics, antifungal prophylaxis and treatment, IFI-related diagnostic tests, hospital attendance/admission during antifungal prophylaxis were collected for 12-month periods before and after 2014 (Cohort 1: 2013; Cohort 2: 2015). Anonymised data was entered into the Fungal Service Evaluation Tool (FSET) and this data was analysed using descriptive statistics.

Results: The evaluation included 24 patients in Cohort 1 (median age 66.8 [interquartile range (IQR): 47.5–72.2] years; 16 [67%] male; 5 [21%] ALL) and 22 patients in Cohort 2 (median age 66.8 [IQR: 51.7–73.4] years; 13 [59%] male; 1 [5%] ALL). At least one line of antifungal prophylaxis was recorded in 22 (92%) patients in Cohort 1 and 17 (71%) in Cohort 2. Posaconazole was the most commonly prescribed antifungal in Cohort 1 (18/24 [75%]) and Cohort 2 (17/22 [71%]). Other agents used included liposomal amphotericin B, fluconazole, and itraconazole. There were no patients in Cohort 1 and 2 (9%) patients in Cohort 2 (overall 4%) who experienced a BIFI: 1 was defined as confirmed and 1 as suspected. The mean 12 month costs per patient for all resource utilisation (including antifungal drug costs, hospitalisation costs [including admissions and attendances], investigations and tests) was £28,903 in Cohort 1 and £21,934 in Cohort 2 (Figure 1). Hospitalisation costs were a key determinant of overall costs, which is common in the management of people with complex underlying disease. There were 4 (17%) patients in Cohort 1 and 1 (5%) in Cohort 2 who had a period of ITU associated stay, which typically has greater costs than general wards. The most common investigations/tests were blood cultures (Cohort 1: mean 13.8; Cohort 2: mean 10.7) and chest x-ray (Cohort 1:mean 4.0; Cohort 2: mean 2.5), which are in-line with routine clinical practice. Once implemented, the guideline was adhered to in the management of 19 patients (86%) in Cohort 2.

Summary/Conclusions: These data show that rates of breakthrough IFI are low in complex patients receiving antifungal prophylaxis/treatment. Furthermore, the results in Cohort 2 indicate that the switch to recommending posaconazole tablets did not result in an increase in the mean cost per patient of antifungal prophylaxis and shows a lower overall mean cost per patient. A larger cohort study over a longer period is warranted to confirm these findings.

Figure 1. Breakdown of mean 12 month resource utilisation costs for cohorts 1 and 2.

Background: Patients with neutropenia, including those with haematologic malignancies, are at high risk of invasive fungal infections (IFI). Pre-2014, there were no formal written guidelines but the guidance at Poole Hospital NHS Foundation Trust specified the use of posaconazole oral suspension for primary prophylaxis in all high-risk patients except those with acute lymphoblastic leukaemia (ALL). In 2014 formal guideline changes included the introduction of the tablet formulation of posaconazole, use of micafungin as first line empirical therapy and a focus towards improving diagnostics to guide management.

Methods: An interim analysis of high-risk adult patients with prolonged neutropenia aged ≥18 years at initiation of antifungal prophylaxis/treatment was carried out. Retrospective data on patient characteristics, antifungal prophylaxis and treatment, IFI-related diagnostic tests, hospital attendance/admission during antifungal prophylaxis were collected for 12-month periods before and after 2014 (Cohort 1: 2013; Cohort 2: 2015). Anonymised data was entered into the Fungal Service Evaluation Tool (FSET) and this data was analysed using descriptive statistics.

Results: The evaluation included 24 patients in Cohort 1 (median age 66.8 [interquartile range (IQR): 47.5–72.2] years; 16 [67%] male; 5 [21%] ALL) and 22 patients in Cohort 2 (median age 66.8 [IQR: 51.7–73.4] years; 13 [59%] male; 1 [5%] ALL). At least one line of antifungal prophylaxis was recorded in 22 (92%) patients in Cohort 1 and 17 (71%) in Cohort 2. Posaconazole was the most commonly prescribed antifungal in Cohort 1 (18/24 [75%]) and Cohort 2 (17/22 [71%]). Other agents used included liposomal amphotericin B, fluconazole, and itraconazole. There were no patients in Cohort 1 and 2 (9%) patients in Cohort 2 (overall 4%) who experienced a BIFI: 1 was defined as confirmed and 1 as suspected. The mean 12 month costs per patient for all resource utilisation (including antifungal drug costs, hospitalisation costs [including admissions and attendances], investigations and tests) was £28,903 in Cohort 1 and £21,934 in Cohort 2 (Figure 1). Hospitalisation costs were a key determinant of overall costs, which is common in the management of people with complex underlying disease. There were 4 (17%) patients in Cohort 1 and 1 (5%) in Cohort 2 who had a period of ITU associated stay, which typically has greater costs than general wards. The most common investigations/tests were blood cultures (Cohort 1: mean 13.8; Cohort 2: mean 10.7) and chest x-ray (Cohort 1:mean 4.0; Cohort 2: mean 2.5), which are in-line with routine clinical practice. Once implemented, the guideline was adhered to in the management of 19 patients (86%) in Cohort 2.

Summary/Conclusions: These data show that rates of breakthrough IFI are low in complex patients receiving antifungal prophylaxis/treatment. Furthermore, the results in Cohort 2 indicate that the switch to recommending posaconazole tablets did not result in an increase in the mean cost per patient of antifungal prophylaxis and shows a lower overall mean cost per patient. A larger cohort study over a longer period is warranted to confirm these findings.
Iron metabolism, deficiency and overload

PB1901
REAL-LIFE FEASIBILITY OF AN IRON CHELATION PROGRAM WITH DEFERASIROX IN MYEOLOGYOSPLASIA AND OTHER ACQUIRED CHRONIC ANEMIAS: A SINGLE CENTRE EXPERIENCE
G. Bertani1,2, M. Riva1, E.B. Volpato1, E. Ravano1, I. Cuppari1, A. Mazza1, P. Usardi1, R. Cazzani1
1Haematology, Ospedale Niguarda Ca' Granda, Milano, Italy

Background: Prolonged red blood cell (RBC) transfusion support in patients affected by myelodysplastic syndrome (MDS) and other chronic anemias may cause vital organs damage due to accumulation of non-transferrin-bound iron with consequent increased oxidative stress. Retrospective studies have shown that iron chelation may prevent aforementioned mechanisms and improve survival in low-risk MDS patients. Iron chelation is usually recommended in patients who received at least 20 RBC units and/or have a serum ferritin level of 1000 ng/ml or higher. Deferasirox, an oral iron chelator, has widely replaced the use of deferoxamine, due to its greater manageability, especially in the elderly. However, an high dropout rate of approximately 50% of patients within one year was observed in the majority of clinical studies, the leading cause of discontinuation being gastrointestinal (G.I.) and renal toxicity and skin rash.

Aims: We aimed at evaluating the real-life feasibility of a program of prolonged iron chelation in a population of acquired chronic anemia patients. Thus, we performed a retrospective analysis to evaluate which is the percentage of patients who in our centre actually receive and tolerate deferasirox treatment, among the cohort of eligible patients.

Methods: Deferasirox treatment is considered at our centre in patients affected by MDS or other forms of chronic anemia (excluded chronic bleeding) who fulfill criteria for iron chelation (high transfusion burden, ≥20 RBC units and/or a serum ferritin ≥1000 ng/ml). Starting dose is usually 10 mg/kg, titrated up to 20-30 mg/kg as tolerated. The cohort of patients transfused at our centre during 2015 and 2016 was considered for analysis. Causes of unsuitability and of treatment discontinuation were extracted from our database.

Results: Our cohort consisted of 58 patients, mainly affected by MDS (45 pts); other diagnosis were myelofibrosis (6 pts), NHL (2) and multifactorial anemia, not related to blood cancer (7). Only 38 out of 58 potentially eligible patients were assigned to iron chelation (see the Figure 1). The leading cause of ineligibility in our cohort was a reduced life expectancy (5 pts), due to the hematologic disease itself or to comorbidities, and pre-existing renal failure (4). Importantly, in 6 cases patients were not offered iron chelation without a specific clinical reason: half of them (3/6) were non-MDS patients. Furthermore, 13/38 patients had to interrupt the treatment, due to toxicity (mainly renal failure, fol-lowed by gastrointestinal toxicity, see flow-chart). Overall, 25/58 (43%) poten-tially eligible patients, i.e. heavily transfused patients, initiate and continue an iron chelation program at our centre. The main cause for treatment discontinuation in our cohort was renal failure, while we had less difficulties in managing G.I. adverse events. Renal toxicity of deferasirox is known to be reversible; however, in patients with pre-existing compromise and those who concurrently take nephrotoxic drugs, treatment may be difficult to carry on.

Figure 1.

Summary/Conclusions: Our data are in line with literature. However, there is still room for improvement, especially in the category of non-MDS patients, who are often under-treated. Furthermore, the introduction of a new formulation of deferasirox, which is forthcoming, may hopefully reduce G.I. toxicity and improve tolerance and patients adherence to therapy.

PB1902
NONINVASIVE TRANSCUTANEOUS SPOT-CHECKING OF TOTAL HEMOGLOBIN FOR THE SCREENING OF ANEMIA IN CAMBODJAN CHILDREN FROM REMOTE RURAL AREAS
J. Perez De Oteyza1,2, L. Fernandez de la Fuente2, C. Montero1, L. Trives2, A. Jayo3, R. Guiote2, B. Santos2, A. Rodriguez2, J. Marin2, L. Sierra2, S.P. Gonzalez2, E. Martinez2, J. Rodriguez2, A. Perez2, A.I. Sanz2, X. Santos Heredero2
1Hematology, Hospital Universitario Madrid Sanchinarro, 2Clinical Sciences, 3Basic Sciences, Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain

Background: Previous studies have reported a high prevalence of anemia among school-aged children from Cambodia, ranging from 21 to 64%. Although iron deficiency accounts for the majority of cases, additional nutritional and non-nutritional etiologies have been identified. Children living in rural or remote areas, with limited access to health facilities, are at high-risk of developing anemia, and therefore, painless, fast, and reduced cost screening tests are needed.

Aims: The aim of our study is to evaluate the role of a portable device for transcutaneous noninvasive spot-checking of total hemoglobin (SpHb) in children living in remote locations.

Methods: Transcutaneous noninvasive spot-checking of total hemoglobin (SpHb) was performed in children attending summer-school camps at 12 different locations in Cambodia. SpHb was measured in fingertips by using size adapted optic sensors. For the purpose of the study, three age groups were defined as follows: Group 1 =less than 5 years, group 2 =5 to 11 years, and group 3 =11 to 14 years.

Results: A total of 476 otherwise healthy children were analyzed. Mean SpHb value was 11.9 ±0.3 g/dl (range 9-16 g/dl). Overall, the prevalence of anemia in the entire population was 34.5%. Anemia was present in 3/31 (16.1%) of the children within group 1, 9/78 (11.7%) in group 2, and 54/81 (47%) in group 3. (p=0.039, two sided Pearson’s Chi square). There were no differences in the prevalence of anemia by gender in groups 1 and 2. In group 3, anemia was significantly more prevalent in females 32/65 (49.2%) than in males 22/48 (31.4%), p=0.035.

Summary/Conclusions: Taken together, our results demonstrate the feasibility of noninvasive transcutaneous spot-checking of total hemoglobin (SpHb) for the screening of anemia in children from remote rural areas with limited access to health services. Our results also confirm the high prevalence of anemia in this population.

PB1903
IRON DEFICIENCY ANEMIA IN INFANTS AND YOUNG CHILDREN
S.K. Park1,2, S.K. Kim2, E.Y. Joo2
1pediatrics, Ulsan University Hospital, Ulsan, 2pediatrics, Inha University college of medicine, Incheon, Korea, Republic Of

Background: Iron deficiency anemia in infants and young children is easy to underdiagnose. Anemia and iron deficiency are usually corrected after aged 2-3 years old, but it causes complications. There is a association between IDA and impaired neurocognitive function and exercise intolerance, even after treatment of IDA. Therefore, preventing the progression of iron deficiency is especially important during infancy and early childhood, when increased vulnerability is associated with rapid growth and development, especially of the brain.

Aims: To detect iron deficiency anemia early and to reduce the adverse impact by IDA, we assessed the characteristics of infants and young children with IDA, those at risk for IDA and those exhibiting associated characteristics of severe anemia.

Methods: Among 1,782 children with IDA aged 6 months to 18 years-old, we retrospectively analyzed medical records and laboratory data of 1,361 subjects aged 6–23 months with IDA who had been diagnosed between 1996 and 2013. We excluded patients with CRP ≥5 mg/dL.

Results: IDA was predominant in boys (2:1.41) during infancy and young child-hood. Peak incidence was at 9 to 12 months of age. Only 7% of subjects were brought to the hospital with symptoms and/or signs of IDA, while 23.6% in subjects with severe IDA. LBW infants with IDA shows low adherence with iron supplementation. In a multivariate analysis, risk factors of severe anemia in infants included prolonged breastfeeding without iron fortification [odds ratio (OR) 5.70] and low birth weight (OR 6.49).

Summary/Conclusions: Many clinicians did not consider IDA as a real problem, so many children with IDA were not followed up. LBW infants need more attention, as the increase adherence of iron supplementation. For early detection of IDA, nutritional assessment should be evaluated in every infants and iron batteries in high risk infants (LBW infants, prolonged breastfeeding, picky eater and/or symptoms of IDA) at health screening visit.
THE ROLE OF ZINC PROTOPORPHYRIN IN THE DIAGNOSIS OF SIDEROPENIC ANEMIA

Aims: Determine the cut-off value of ZPP for the diagnosis of IDA. Evaluate the value of ZPP for the differential diagnosis between IDA and anemia due to inflammatory diseases (AID).

Methods: We have analyzed in our lab, from 1st to 15th February 2017, all the consecutive samples (pediatric and adult) with anemia (as defined by WHO) which had sedimentation rate (SR) and serum ferritin evaluations. We have defined three different groups: IDA: Anemia and Ferritin <20μg/L; AID: Anemia, Ferritin >20μg/L and SR>20mm/h; Group control (GC): Normal levels of hB adjusted by age and sex, as defined by WHO, Ferritin 20-120μg/L and SR<20mm/h. ZPP measurement was performed by hematochemistry (AVIV, Biomedica, Inc.). Data were analyzed by SPSS v20.0 using Wilcoxon W and Man-Whitney to examine differences between groups and receiver-operating characteristic (ROC) analysis to determine the cut-off values of ZPP. We considered a p-value <0.05 statistically significant.

Results: We have identified 204 samples that fulfilled the inclusion criteria: 104 with IDA, 51 with AID and 49 from control patients. IDA group: 73% female (F); mean age 32.3y in F [1-78], 28y in males (M) [1-78]; mean hB was 10.6g/dL [SD 1.4]; mean ferritin was 9.3 μg/L [SD 4.85] and ZPP was 214.1 μmol [SD 121.3]; mean SR was 20.0 mm/h [SD12.9]; AID group: 75% F; mean age 47y in F [2-91] and 22y in M [1-85]; mean hB 11.0 g/dL [SD 1.2]; mean ferritin 150.3 μg/L [SD246.2] and ZPP 136.7 μmol [SD 107.8]; mean SR 47mm/h [SD 21]; GC: 69.4% F; mean age 44.8y in F [1-79], and 37y in M [2-65 years]; mean hB 13.8 g/dL [SD 0.9]; mean ferritin 71.9ug/L [SD 49.9] and ZPP 78.6 μmol [SD 26.8]; mean SR 14mm/h [SD 4]. The mean serum ZPP in IDA and AID was significantly higher than in GC (95% CI; p<0.0005). The ROC analysis showed 83.7% sensitivity and 85% of specificity to identify IDA for ZPP ≥100.3 μmol (W=0.933) and 69% sensitivity and 70% of specificity to identify AID for ZPP ≥140.0 μmol (W=0.749) when compared with GC.

Summary/Conclusions: We have concluded that ZPP is a valid, quick, easy and cheap parameter to diagnose IDA in clinical practice, and we have defined in our cohort of patients a ZPP cut off of ≥100.3 μmol as diagnostic of IDA with 83.7% sensitivity and 85% of specificity, independent of age. In AID patients we found a cut-off value of ≥140.0 μmol, but with a low sensitivity and specificity. In our study ZPP was not a reliable method to differentiate IDA from AID. This could be due to a sample selection bias (since clinical data were missing and the number of patient with AID was substantially lower than with IDA). It would be important to enlarge the AID sample in order to obtain a more reliable result.

Summary/Conclusions: Hyperferritinemia was present in vast majority (97%) of them. We would like to emphasize that serum ferritin level fluctuates and can differ significantly from one day to another. Ferritinemia should be repeatedly measured in cases of suspected HLH. Serum concentrations of TNF-α, IL-6, IL-8, and IL-10 were frequently elevated in the examined hM-HLH patients. IL-8 concentration was in half of all tested patients at the time of HLH diagnosis. However, IL-10 concentration was above reference range only in 12% of patients (7 of 58).

Table 1. Inflammatory cytokines in patients with newly diagnosed hM-HLH.

Summary/Conclusions: Hyperferritinemia at the time of HLH diagnosis was common in Swedish adult patients with hM-HLH. Hyperferritinemia ≥500 μg/L was present in vast majority (97%) of them. We would like to emphasize that serum ferritin level fluctuates and can differ significantly from one day to another. Ferritinemia should be repeatedly measured in cases of suspected HLH. Serum concentrations of TNF-α, IL-6, IL-8, and IL-10 were frequently elevated in the examined hM-HLH patients. IL-8 concentration was in half of all tested patients at the time of HLH diagnosis. However, IL-10 concentration was above reference range only in 12% of patients (7 of 58).

Table 1. Inflammatory cytokines in patients with newly diagnosed hM-HLH.
blood films are iron deficient pictures with the characteristic finding of reduced Haemoglobin (Hb), MCV and MCH. Above certain thresholds, the blood film adds little or no value to the CBC in these patients, apart from correlating with the iron studies results or suggesting iron studies when unavailable. One initiative used to manage the workload was based on this logic and aimed to reduce the blood film review rate using IT3000 technology (Roche).

Methods: An algorithm was designed in IT3000 to encourage testing and treatment for iron deficiency using a series of automated educational comments, while minimising unnecessary laboratory work. The impact that this algorithm had at WSCL was investigated by retrospective analysis of all the patient results from 1st November 2015 to the 1st of May 2016.

Results: In the first six months of operation, WSCL performed 232,192 CBCs and 30,204 blood films with an average review rate of 13.01%. Had this algorithm not been employed, 2,434 extra blood films would have been reviewed, bringing the review rate up to 14.05%.

Summary/Conclusions: Incorporation of an algorithm specific for iron deficiency in IT3000 has significantly reduced the review rate without any negative impact on patient care.

PB1907

THE RELATIONSHIP ENDOTHelial MICROPARTICLES AND ASYMMETRIC DIMETIL ARGinine IN CHILDREN WITH IRON DEFICIENCY AND IRON DEFICIENCY ANEMIA

S. Kim1, S.Y. Cho1,*, T.S. Park1

1Kyung Hee University Hospital, Seoul, Korea, Republic Of

Background: Iron deficiency anemia and iron deficiency without anemia increase the risk of atherosclerosis by increasing oxidative stress and inflammation. Endothelial dysfunction is an important factor of the pathogenesis of atherosclerosis.

Aims: Endothelial micro particles (EMP) are considered as markers of endothelial dysfunction. Asymmetric dimetil arginine (ADMA) is known as another marker of endothelial dysfunction. In this study; we aimed to evaluate circulating EMPs and ADMA in children with iron deficiency and iron deficiency anemia and to disclose iron deficiency with the strongest relation with EMPs, ADMA and carotid atherosclerosis.

Methods: This study included 30 children with iron deficiency anemia, 30 children with iron deficiency without anemia and 30 healthy children whose anthropometrics measurements were recorded. Hemoglobin, serum iron level, iron binding capacity, ferritin, and lipid profile were studied. Circulating EMPs (CD144, CD146, and CD105) were measured by flow cytometry. ADMA was measured by ELISA. The carotid artery intima media thickness (CIMT) and left ventricular mass index (LVMI) were measured using echocardiography.

Results: CD144 and CD105 EMP levels were lower in the iron deficiency without anemia group than in the control group and statically lower than in the iron deficiency anemia group (p<0.05). There were no significant differences in ADMA level between groups. Any significant variety in ADMA level was not observed between groups. CIMT was negative correlated with ferritin and high density lipoprotein and positive correlated with body weight.

Summary/Conclusions: In this study, endothelial dysfunction which occurs as a result of iron deficiency were observed. According to our result, CD144 and CD105 EMP levels in the iron deficiency without anemia group were lower than the iron deficiency anemia and control group; these levels in iron deficiency anemia group were higher than control group. In addition, when the level of ferritin has decreased, CIMT has increased. This study show that CD144 and CD105 may be related to endothelial dysfunction which occurs by iron deficiency.

PB1908

INVESTIGATION OF IRON METABOLISM FOR REGULATING MEGAKARYOPOIESIS AND PLATELET COUNT ACCORDING TO THE MECHANISMS OF ANEMIA

S. Kim1, S.Y. Cho1,*, T.S. Park1

1Kyung Hee University Hospital, Seoul, Korea, Republic Of

Background: Iron deficiency anemia (IDA) is characterized by depletion of total body iron stores. By contrast, chronic inflammation makes iron unavailable for hematopoiesis through a cytokine-mediated cascade, resulting in anemia of chronic disease (ACD). However, the laboratory data regarding the regulatory role of iron metabolism on platelet count has not been fully discussed yet.

Aims: In this study, we investigated the relationship between iron status and platelet production according to different anemic mechanisms representing different iron metabolism.

Methods: The study included total of 759 blood specimens from 537 different patients. The complete blood count with various CBC index were measured using Advia 2120 (Siemens, USA). Biochemical indexes including iron level were estimated using Toshiba chemical analyzer (Toshiba, Japan).
Myelodysplastic syndromes - Biology

PB1910
ROLE OF PRO-PHAGOCYTIC CALRECTICULIN AND ANTI-PHAGOCYTIC CD47 IN MDS AND MPN MODELS TREATED WITH AZACYTIDINE OR RUXOLITINIB
K. Bejerman1,*, C. E. Bird1, J. Simmonds1, C.R. Rinaldi1
1School of life Sciences, Collage of Science, 2Lincoln Institute of Health, University of Lincoln, Lincoln, United Kingdom

Background: Myelodysplastic syndrome (MDS) and Myeloproliferative neoplasms (MPN) are clonal myeloid disorders with the tendency to progress into acute myeloid leukaemia. Previous studies in solid tumours have shown an increase in expression of both pro-phagocytic calrecticulin (CALR) and anti-phagocytic CD47, as they act in response to one another, reflecting a possible apoptosis vs survival mechanism in response to chemotherapy.

Aims: The aim of our study is to assess the changes in CALR and CD47 levels during treatment of MDS and MPN with azacitidine (AZA) or ruxolitinib (RUXO), in a series of model cell systems.

Methods: CALR and CD47 gene and protein expression was measured in MDS cell line models (MOLM-13 and SKM-1), MPN cell line models (HEL-92 and GDM-1) and in an intermediate MDS/MPN cell line (K562) before and after treatment with AZA and RUXO. Drug titrations were completed, resulting in dosing regimens of 0.05µM/ml for both AZA and RUXO, with re-drugging occurring at 24 hours. Cells were then harvested, cDNA was synthesized for use in qPCR and protein levels determined by Western blot analysis.

Results: When treated with AZA, MDS cell models showed a 7-10 fold increase in CALR expression and 4-6 fold increase in CD47 expression. In contrast, the MDS/MPN intermediate cell model (K562) showed a 4.5 fold increase in CALR but only a 0.5 fold increase in CD47 expression. In the MPN model HEL-92, a 9-fold increase in CALR and 4-fold increase in CD47 was seen, whereas in the other MPN model (GDM-1 cells) expression was more evenly matched between CALR and CD47 (5.3 and 4.8 fold increases, respectively). After treatment with RUXO, MPN models showed a 9.5-16 fold increase in CALR expression and a 6-9 fold increase in CD47, which would be expected as RUXO is used to treat MPN in humans. When the MDS/MPN cell model or pure MDS models were treated with RUXO, the ratio of CALR/CD47 decreased substantially (with CALR expression only increased 2.4-3.7 fold compared to CD47 increasing 5.3 fold). This ratio is also seen in the MPN model HEL-92, where CALR/CD47 increased 3.4 fold compared to CD47 increasing 5.3 fold.

Summary/Conclusions: In line with results in solid tumours, we have shown that treatment for MDS and MPN leads to an up-regulation of CALR and CD47 but to a lesser extent, CD47 in cell lines models. The ratio of CALR/CD47 seems to correlate with specific treatment response, significantly increasing when given diseases models are treated with the appropriate drug. We postulate a role of CALR expression in leukaemia cell phagocytosis, with CD47 co-expression in phagocytic CD47, as they act in response to one another, reflecting a possible apoptosis vs survival mechanism in response to chemotherapy.

PB1911
GENETIC VARIANTS OF MSH3 AND BLM GENES MAY INFLUENCE MYELODYSPLASTIC SYNDROME SUSCEPTIBILITY AND PROGNOSIS
M.S. Melo1, L. Balancal1, A. Barbosa Ribeiro1,2, A.C. Gonçalves1,2, R. Alves1,2, E. Cortesão1,2, C. E. Bird1, L. Ribeiro1, L. Mota-Vieira4, A.B. Sarmento-Ribeiro1,2,3,4,*
1Servicio de Hematologia, Hospital Universitario 12 de octubre, Madrid, Spain, 2Laboratory of Molecular Biology and Immunodiagnosis, Hospital de la Princesa, Madrid, Spain, 3Clinical Hematology Department, Hospital Universitario 12 de octubre, Madrid, Spain, 4Department of Medical Genetics, Hospital Universitario 12 de octubre, Madrid, Spain

Background: Heterozygous deletion of RPS14 occurs in isolated interstitial deletion of chromosome 5q in patients with myelodysplastic syndrome (MDS). 5q- MDS has been linked to impaired erythropoiesis and it is characterized by a constant macrocytic anaemia and normal or high platelet counts associated with hypolobulated megakaryocytes. Previous studies have detected reduced RPS14 expression in more than 50% of 5q- MDS patients. Recently, the pivotal role of RPS14 in human erythropoiesis during 5q- MDS pathology has been demonstrated: RPS14 haploinsufficiency produces the activation of p53 and its target p21 in erythroid cells, resulting in cell cycle arrest and apoptosis. Based on these results, non-5q- patients expressing low levels of RPS14 will be potentially benefitted by lenalidomide therapy. In this work, we explore the origin of the altered RPS14 expression in non-5q- patients and its potential link with 5q- pathology.

Aims: The objective of this work was to explore the origin of RPS14 low expression in non-5q- MDS patients and its link with 5q- pathology. In order to do this, we assessed potential mutations in RPS14 gene. We also studied expression changes in other key genes involved in the development of the 5q- disease, including the tumour suppressor gene SPARC and the putative tumour suppressor gene CSNK1A1, contained in the commonly deleted region. Moreover, other 32 genes related with MDS disorders were evaluated in relation with RPS14 levels. Finally, in order to establish if this group of patients could be benefitted by lenalidomide therapy, p21 expression levels were also analysed.

Methods: DNA and RNA were extracted from the bone marrow of 89 non-5q- MDS patients. Ten controls and nine 5q- MDS patients were used as negative and positive controls, respectively. RPS14, SPARC, CSNK1A1 and p21 mRNA levels were analysed by real time PCR using Taqman probes and a 7500 RT PCR System. β-glucuronidase gene was used as endogenous reference to normalize data. Samples were classified by RPS14 expression levels and differences in SPARC, CSNK1A1 and p21 expression mean values between the two groups were analysed using the Mann-Whitney U test. RPS14 and 32 genes expression were also analysed using ICGC Proton data.

Results: Non-5q- patients expressing low levels of RPS14 presented higher survival probability in the IPSS lower risk group. This data, in addition with a tendency for increased p21 expression, suggests that this group could be benefitted by lenalidomide therapy. Nevertheless, we did not observe a significant association between RPS14 expression and other HR-MDS genes, including those involved in bone marrow stromal niche. Furthermore, we did not observe a significant association between any mutation in RPS14, discarding alterations in the adjacent genes commonly deleted in 5q- MDS patients. In addition, the majority of patients analysed did not present any mutation in RPS14 gene. Only two MDS patients showed mutations upstream, downstream or within intronic regions of the gene. The origin of the remaining low RPS14 expression remains to be elucidated. In the future, we plan to perform a microarray analysis in these patients in order to establish if this group of patients benefitted by lenalidomide therapy.

Summary/Conclusions: Although the important role of RPS14 in MDS pathol-
ogy has been recently demonstrated, the origin of RPS14 downregulation in about 50% non-5q- patients remains unknown. Our results suggest that the origin of RPS14 decreased expression is not related to genomic alterations in 5q region. Further studies are necessary in order to establish a link with 5q-pathology and demonstrate the potential use of lenalidomide in this group of patients.

**PB1913**

**INTEREST OF THE XN-10® ANALYZER TO SCREEN FOR MEYELODYSPLASTIC SYNDROMES ON COMPLETE BLOOD COUNTS**

R. Boutaut1, P. Peterlin2, M. Boubaya3, S. Tremblais1, M. De Oliveira1, Y. Le Bris1, C. Godon1, O. Theisen1, M.C. Béné1, M. Eveillard1,*

1Hematology Laboratory, 2Hematology clinic, Nantes University Hospital, Nantes, 3Clinical research, Avicennes University Hospital, Avicennes, France

**Background:** A prospective study was performed over one year in order to investigate whether suspected myelodysplastic syndromes (MDS) could be detected on a complete blood counts (CBC), the fastest laboratory investigation, performed on the recently developed XN-10® (Sysmex, Kobe, Japan).

**Aims:** The primary end point was to discriminate MDS patients from normal samples and the secondary end-point was to distinguish MDS with excess blasts (MDS-EB), MDS with multilineage dysplasia (MDS-MLD), MDS with single lineage dysplasia (MDS-SLD) and MDS with ring sideroblasts and sideroblasts and blasts (MDS-RAEB). In all these MDS subgroups by comparison with controls as described by the WHO 2016 classification.

**Methods:** One hundred and thirteen patients were enrolled in the study, for whom a diagnosis of MDS was concluded based on CBC, bone marrow smears examination and karyotype. All patients were free of treatment, including transfusions, at inclusion. They were 63 men and 50 women with a median age of 82 years (range 36-96 yo). CBC were performed on a Sysmex analyzer XN-10®, including classical parameters (hemoglobin level, Mean Corpuscular Volume (MCV), reticulocytes, platelets, neutrophils and extra-parameters i.e. platelets by fluorescence (PLT-F), immature platelets fraction (IPF%), immature reticulocytes fraction (IRF%) and the neutrophils median position). The three axes as well as their dispersion (Neut-WX). For comparison with normal values, results from 707 healthy subjects over 50 years old, for whom CBC were performed on the same analyzer and generated no flag, were used. All had parameters within the normal range according to age. According to the WHO, 37 patients were classified as MDS, 35 EB, 33 MDS-EB, 18 MDS-SLD, 9 MDS-RAEB, 10 MDS-RAEB-1 and 3 MDS-RAEB-2.

**Results:** Almost all non-healthy parameters were significantly decreased from the healthy cohort. The median level of hemoglobin was 9.92±1.96 g/dL (p<0.0001), the median MCV (99,24±10,56 fL p<0,0001), reticulocyte counts 44,3x109/L (range 8-165,9; p=0,041) and IRF% 16,7% (range 2,4-50,9; p<0,0001). The median platelet count was 194±128x109/L (p=0,0001) and the median IPF% 8,8% (1,2- 42; p=0,0001). Among leucocyte parameters, the MDS median neutrophil count was significantly lower at 3,08±2,58x109/L (p<0,001) while Neut-WX was significantly higher (35F71±p<0,0001). The latter, allowed to predict a diagnosis of MDS with 73% sensitivity and 97% specificity. For patients over 50 years old, 4 parameters (Neut, Neut-WX, hemoglobin level and MCV) in a score allow to diagnose MDS with 92% sensitivity and 81% specificity. When considering MDS subgroups, although each of them was significantly different from controls for hemoglobin levels, MCV and IPF% and (p<0,0001), they could not be discriminated between the subgroups of MDS with single lineage dysplasia and ring sideroblasts, platelet counts were similar to those of controls, yet significantly higher than for MD-EB or MDS-MLD (p=0,004 and p=0,029 respectively). Moreover, neutrophils counts were significantly lower in MDS-DML or MDS-EB than in MDS-SLD.

**Summary/Conclusions:** This study demonstrates that a simple CBC allows to screen for MDS using a multiparameter score including Neut-WX. Blood smear examination should be performed in this situation even if the XN-10® analyzer does not raise any alarm, especially in unknown patients older than 50.

**PB1914**

**PROGRESSION SCORE FOR ACUTE LEUKEMIA – A NEW PROGNOSTIC SCORE IN MDS**

E. Cortesio1,2, A-C. Goncalves1, A.R. Tenneiro2, A. Ribeiro1,2, C. Geraldes1,2, N. Costa e Silva3,4, L. Ribeiro2, J. Nascimento Costa5, A.B. Sarmento-Ribeiro1,2,*

1Applied molecular biology and clinic university of medicine, Faculty of Medicine of University of Coimbra, 2Hematology, 3Clinical Pathology, Centro Hospitalar e Universitário de Coimbra (CHUC), Portugal, 4Histology and Embryology, 5Clinical university of oncology, Faculty of Medicine of University of Coimbra, Coimbra, Portugal

**Background:** Since 1987, the International Prognostic Scoring System (IPSS) has been the standard for stratifying patients with Myelodysplastic Syndrome (MDS). Although other models were proposed to improve this stratification, some issues remain, notably the identification of low-risk patients with poor prognosis who may benefit from earlier and/or aggressive therapy.

**Aims:** The aim of our work was the conception of a new prognostic score in MDS, including in the cellular and molecular disease characteristics.

**Methods:** Our sample consisted of 102 patients diagnosed with MDS de novo. The median age was 74 years (22-89), with a 0.8 Male to Female ratio. The subtypes, according to the World Health Organization 2008, were Refractory Cytopehania with Multilineage Dysplasia (RCDM) (n=52), Refractory Cytopehania with Unilineage Dysplasia (RUCD) (n=12), Refractory Anemia with Excess Blasts type 1(RAEB-1) (n=8), RAEB-2 (n=8), Refractory Anemia with Ring Sideroblasts (n=6), 5q- syndrome (n=4) and Chronic Myelomonocytic Leukemia (n=12). The IPSS based stratification was: low (n=37), intermediate-1 (n=39), intermediate-2 (n=10) and high (n=1). Several variables were analyzed: cytogenetic, (mosaicism, karyotypic anomalies classically reported in MDS, and p53, by PCR-MS, and evaluation of expression levels of regulatory molecules of apoptosis BCL-2, BAX, TRLAIL, R1, R2, R3, FAS, Survivin, Caspase 3, Cit C, Glycop and p53, by BC.

**Results:** In the 60-month follow-up, 11 patients progressed to Acute Myeloblastic Leukemia (AML), 7 with RAEB-2-2 with RCMD, 1 patient with RAEB-1 and another with CMMML. These patients had a higher% of ring sideroblasts and blasts; higher scores on IPSS, IPSS-R and WPSS; lower platelet counts, higher erythropoietin levels and greater expression of CD34 / CD117 / IL-12 / TNFa and molecular characteristics (methylation profile of genes p15, p16, DAPK, R1, R2, R3 and R4 performed by PCR-MS, and evaluation of expression levels of regulatory molecules of apoptosis BCL-2, BAX, TRAIL, R1, R2, R3, FAS, Survivin, Caspase 3, Cit C, Glycop and p53, by BC.

**Summary/Conclusions:** In conclusion, we believe that this score may contribute to evaluate the risk of progression to AML, by reflecting the heterogeneity of MDS and its multifactorial etiology. The coexistence of many altered variables not only contributes to the etiopathogenesis of MDS but also allows the assessment of potential leukemic transformation.

**PB1915**

**CORRELATION OF PATIENT PROGNOSIS WITH PU.1 AND JDP2 PROVIDES POTENTIAL NOVEL PROGNOSTIC/DIAGNOSTIC MARKERS IN MDS**

R. Simpson1, A. Goddard1, J. Lally1, M. Simmonds1, C. Rinaldi2, A.B. Sarmento-Ribeiro1,2

1University of Lincoln, 2University of Lincoln and United Lincolnshire Hospital Trust, Lincoln, United Kingdom

**Background:** PU.1 is a key transcription factor in haematopoiesis that plays important roles in various haematological malignancies. Previously, significant down-regulation of PU.1 has been reported in high risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) patients.

**Aims:** We hypothesised PU.1 mRNA function we investigated the gene expression of PU.1 and JDP2 (Jun dimerization protein-2), a member of the activating protein-1 protein family located downstream of PU.1, in bone marrow from 12 MDS patients stratified according to IPSS-R score (6-low, 3-intermediate, 3-high risk), 1 AML patient and 10 normal controls.

**Methods:** Samples were enriched for the mononuclear fraction by Ficoll separation. Total RNA was extracted and analysed by Real Time PCR for PU.1 and JDP2 expression relative to the housekeeping gene GAPDHusing the 2-ΔACT method. Western blot has been performed using anti-PU.1 and anti-JDP2 (Abcam)according to manufacture instructions.

**Results:** We revealed both PU.1 and JDP2 were down regulated in MDS. In addition, our data suggests that PU.1 and JDP2 expression inversely correlates with disease, with expression of these genes consistently reducing according to IPSS-R groups. Furthermore, a positive correlation of PU.1 and JDP2expression versus R=0.9333, p=0.0004 , provides additional evidence that suppression of JDP2 by PU.1 could contribute to the pathogenesis of AML. Notably, PU.1 and JDP2 do not correlate to the same extent in normal HSCs, indicating that cofactors are required for PU.1 to exert its JDP2-regulating function and that such cofactors are not present under normal conditions. To confirm that JDP2 suppression is a direct result of reduced PU.1 we performed PU.1-knockdown in AML cells by stably expressing PU.1 short interfering RNAs versus control cells. These analyses reveal only a partial reduction in JDP2 expression when analysed by RT-PCR and Western blot, suggesting a more complex regulatory mechanism. Additionally, both PU.1 and JDP2 expression was recovered by treatment with azacitidine, which is routinely used to treat MDS, suggesting an interaction between MDS and PU.1-JDP2 expression.

**Summary/Conclusions:** PU.1 and JDP2 expression correlates with patients prognosis highlighting a potential role as new diagnostic and prognostic markers in MDS.
PB1916
DECREASED EXPRESSION OF DECORIN, A WNT-PATHWAY RELATED PROTEIN, IN MESENCHYMAL STEM CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
K. Pavlaki1,2, A. Batsali1, M. Lazaris1, S. Mastrodemou1, M. Ximeri1, C. Pontikoglou1, H. Papadaki1
1Department of Haematology, University of Crete School of Medicine, Heraklion, Greece

Background: Myelodysplastic syndromes (MDS) are clonal disorders of the haematopoietic stem cells (HSCs) characterized by inefficient bone marrow (BM) haemopoiesis and increased risk for leukemic evolution. Ineffective BM haemopoiesis in MDS has also been linked with an abnormal microenvironment that may sustain or even induce the aberrations within the HSC compartment. We have previously shown that the stroma progenitor cells, namely the mesenchymal stem cells (MSC), in MDS patients display impaired clonogenic and proliferative potential, reduced haemopoiesis supportive capacity and down-regulation of the canonical Wnt-signaling pathway.

Aims: Decorin, a small leucine-rich proteoglycan, and galectin-3, a member of β-galactosidase specific lectin family, are components of the extracellular matrix of the BM microenvironment. Both proteins have been implicated in the canonical Wnt-pathway participating therefore in cell growth and proliferation. The aim of the study is to assess the expression of decorin and galectin-3 in MSCs of MDS patients, evaluating their implication in the abnormal Wnt-signaling previously reported in MDS.

Methods: BM MSCs were isolated from 12 patients with lower risk MDS aged 51 to 75 years (median 67.5 years) and 12 haematologically healthy subjects aged 50 to 73 years (median 63.3 years), after informed consent. The study has been approved by the Ethics Committee of the University Hospital of Heraklion. BM MSCs were characterized according to international system for human cytogenetic nomenclature (ISCN) criteria, expanded and re-seeded for two passages (P). Total RNA was extracted from culture-expanded P2 MSCs and amplified by real-time PCR for the evaluation of decorin and galectin-3. Relative gene expression was calculated by the ΔCT method.

Results: A statistically significant decreased expression of decorin was identified in MSC of MDS patients (mean 1.338, SD 0.84) compared to the healthy individuals (mean 1.830, SD 0.71, (P<0.05). Galectin-3 expression was also decreased in MDS patients (mean 0.6758, SD 0.50) compared to controls (0.9395, SD 0.50), although not at a statistically significant levels.

Summary/Conclusions: MSCs from MDS patients display statistically significant decreased expression of decorin and a tendency towards decreased expression of galectin-3 in BM MSCs compared to healthy individuals. These preliminary data indicate that extracellular matrix proteins may have a role in the disturbed Wnt-pathway signaling and abnormal MSC function in MDS patients. The underlying mechanisms are currently under investigation.

PB1917
CLINICAL FEATURES, CYTOGENETIC STUDY AND OUTCOME OF ADULT MYELODYSPLASTIC SYNDROMES: REVIEW OF 101 CASES, A SINGLE CENTER EXPERIENCE IN ALGERIA
S. Taoussi1,*, Y. Bouchakor-Moussa1, M. Abad1
1Hematology, EHS ELCC CAC, Blida, Algeria

Background: Myelodysplastic syndromes (MDS) are heterogeneous disorders defined as clonal diseases involving hematopoietic stem cells and even characterized by cytopenias, with a high risk of leukemic transformation. Morphological analysis of peripheral blood (PB) and marrow aspirates or bone marrow biopsies is the first step that ensures a diagnosis of MDS. Cytogenetic studies are important means of defining different prognostic groups and even of showing how patients are eligible for this or that treatment. We conducted the first study including conventional karyotyping and fluorescent in situ hybridization (FISH) for MDS in our country.

Aims: Our study was aimed to evaluate outcome of MDS regarding IPSS and IPSS-R classification in an emerging country.

Methods: Between January 2012 to December 2016, 101 patients with MDS were consecutively diagnosed. Frequent genetic abnormalities in MDS were screened by R-banding karyotype and metaphasic and interphasic FISH using a panel including six probes (5q-,7q-,20q-, del(17p13), MLL, Inv(3) t(3;3). Patients were stratified into risk groups according to IPSS and IPSS-R scores; survival probabilities were estimated using the Kaplan-Meier method.

Results: Among these 101 pts, 58 were male with a sex ratio=1.35; range in age is from 18 years to 94 years with a median of 61, 6 years. Median hemoglobin level was 8.0 (29-150), more than 60% of patients had severe anaemia mainly in the low risk group; the median absolute neutrophil count was 3 G/L (0.060-13.5), and the median platelet count was 144 G/L (5-659). Median bone marrow blast value was 4% (0-18). Cases were classed by cytology morphology FAB as RA (n=45), REAB (n=34), RARS (n=16), other (n=6). Classification by WHO included CRDU (n= 31 of which RA : 18, RT : 10, RN : 3), CRDM (n= 16), RAEB-1 (n=22), RAEB-2 (n= 13), RARS (n= 15), Isolated 5q- (n=4). Among 101 patients, cytogenetic abnormalities by R banding karyotype (n= 84) and FISH (n=101) were found in 41 cases (41%) distributed as single anoma-
Myelodysplastic syndromes - Clinical

PB1918

CLINICAL EVOLUTION OF ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES

G. Pinto1,*, P. Herrera1

1Hematology, HOSPITAL RAMON Y CAJAL, Madrid, Spain

Background: Acute myeloid leukemia (AML) with myelodysplasia-related changes (MRC) is usually classified associated to worse clinical course and poor prognosis compared other AML subtypes. Differences between treatment modalities according to age, and the response to treatment, would help to provide specific anti-AML treatment in this difficult scenario.

Aims: The objective of this study is analyze the clinical features and course of patients with AML with MRC, in order to evaluate the impact of different therapeutic regimens in this subgroup.

Methods: We report an unicentric retrospective study of 76 patients with AML with MRC, over the past ten years in a single institution in Spain. We analyzed the overall survival (OS) among the subgroup of patients with over or under 65 years, and the different types of treatment that has been offered.

Results: Median age was 69 years with a male predominance, and 66% was preceded by a known myelodysplastic syndrome with a median interval of 18 months to progress to AML. The more frequent genetic abnormalities in descending order were trisomies, del(5q), and del(7q)-7. The patients aged >65 and <65 were 70% and 30%, respectively. The patients aged >65 received DNA hypomethylating agents (40%), anthracycline-cytarabine combinations (9%), low-dose cytarabine or hydroxyurea (17%), and supportive measures (34%). The patients aged <65 received induction chemotherapy with anthracycline-cytarabine combinations so as to continue with post-consolidation management with allogeneic transplantation, but the 44% died over the induction chemotherapy (OS: 2.2 months). The OS in patients aged <65 was 20.2 months in chemotherapy plus allogeneic transplantation. The OS in patients aged >65 was 10.3 months in the group of anthracycline-arac combinations, 3.81 months in the DNA hypomethylating agents group, 2.8 months in the low-dose of AraC/hydroxyurea, and 0.5 months in supportive measures group (Figure 1).

Results:

The objetive of this study is analyze the clinical features and course of patients with AML with MRC, in order to evaluate the impact of different therapeutic regimens in this subgroup.

Methods: We report an unicentric retrospective study of 76 patients with AML with MRC, over the past ten years in a single institution in Spain. We analyzed the overall survival (OS) among the subgroup of patients with over or under 65 years, and the different types of treatment that has been offered.

Results: Median age was 69 years with a male predominance, and 66% was preceded by a known myelodysplastic syndrome with a median interval of 18 months to progress to AML. The more frequent genetic abnormalities in descending order were trisomies, del(5q), and del(7q)-7. The patients aged >65 and <65 were 70% and 30%, respectively. The patients aged >65 received DNA hypomethylating agents (40%), anthracycline-cytarabine combinations (9%), low-dose cytarabine or hydroxyurea (17%), and supportive measures (34%). The patients aged <65 received induction chemotherapy with anthracycline-cytarabine combinations so as to continue with post-consolidation management with allogeneic transplantation, but the 44% died over the induction chemotherapy (OS: 2.2 months). The OS in patients aged <65 was 20.2 months in chemotherapy plus allogeneic transplantation. The OS in patients aged >65 was 10.3 months in the group of anthracycline-arac combinations, 3.81 months in the DNA hypomethylating agents group, 2.8 months in the low-dose of AraC/hydroxyurea, and 0.5 months in supportive measures group (Figure 1).

Summary/Conclusions: The AML with MRC patients is a group with difficult treatment decisions and poor prognosis, in whom only the chemotherapy plus allogeneic transplantation treatment manage long-term survival. In patients aged >65, there is not a significant difference among groups, although the chemotherapy with anthracycline-cytarabine seems to reach a better OS versus other available treatments.

PB1919

SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRAC'TORY MYELODYSPLASTIC SYNDROMES: A MULTICENTER, OPEN-LABEL, PHASE I STUDY

M. Ogura1,2,*, Y. Kobayashi3, S. Kubonishi4,5, M. Hidaka6, T. Uchida2,

1Department of Hematology, Tokai Central Hospital, Kamakigahara, 2Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, 3Department of Hematology, National Cancer Center Hospital, Tokyo, 4Department of Hematology, Okayama University Graduate School of Medicine, 5Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, 6Department of Hematology, Red Cross Society Himeji Hospital, Himeji, Japan

Background: Rigosertib, a novel phosphoinositide 3-kinase pathway inhibitor, selectively induces the apoptosis of cancer cells and is safe and well tolerated in pts with recurrent/relapsed or refractory MDS.

Aims: We conducted a multicenter, open-label, Phase I study of intravenous rigosertib to evaluate its safety, efficacy, and pharmacokinetics and to determine the recommended dose (RD) for Japanese pts.

Methods: The key eligibility criteria were as follows: recurrent/relapsed or refractory MDS; age: 20 or older; FAB classification (RA, RARS, RAEB, RAEB-t, and CMML), excluding patients with IPSS low- or Int-1 risk with respect to RA; ECOG PS of 0 to 2; no major organ dysfunction; and written informed consent. Patients received 1,200 and 1,800 mg daily was administered intravenously for 72 h, followed by 11-day monitoring in one 14-day cycle. The primary endpoint was dose-limiting toxicity (DLT). The secondary endpoints were 1) safety as assessed with adverse events (AEs) and laboratory results; 2) efficacy as assessed with the International Working Group 2006 criteria; and 3) pharmacokinetics.

Results: Between June 2012 and February 2015, 7 male and 2 female pts (median age: 70; range: 63-84) were enrolled, and 3 and 6 pts were eventually assigned to the 1,200 and 1,800 mg arms, respectively. According to the FAB classification, 6, 2, and 1 pts were categorized to RAEB, RAEB-t, and RA, respectively. There were 4 pts in the 1,200 mg arm and 2 in the 1,800 mg arm. In the 1,200 mg arm, 3 cases of grade 3/4 neutropenia, 2 cases of grade 3/4 thrombocytopenia, and 2 cases of grade 3/4 leucopenia were observed. No cases of grade 3/4 anemia were observed. Three cases of grade 3/4 renal toxicity were observed. No cumulative effects were observed in the two arms. The Cmax values in the 1,200 and 1,800 mg arms were 5.99±1.50 and 6.74±2.39 μg/mL, respectively. The AUC 0-∞ values were 314.6±142.7 and 324.8±83.9 μg × hr/mL, respectively. The clearance values were 0.94±0.21 and 1.01±0.37 L/hr, respectively. The M1/M2 values were 0.45±0.14 and 0.42±0.15, respectively. The half-life values were 10.5±2.0 and 13.1±2.7 h, respectively.

Summary/Conclusions: This Phase I study showed that intravenous rigosertib (1,800 mg daily) for consecutive 72 h was well tolerated, indicating that this is the RD for Japanese pts. No deaths occurred during the study period. However, 5 pts died during follow-up, 4 of whom died from primary disease progression. Furthermore, 1 pt died of grade 5 bacterial pneumonia that was rated to “Unrelated”. In the 1,200 mg arm, 2 cases each of grade 3/4 thrombocytopenia, grade 4 neutropenia, and grade 3/4 leucopenia, as well as 1 case of grade 3 lymphopenia developed. In the 1,800 mg arm, 3 cases of grade 3/4 leucopenia, 2 cases each of grade 3/4 lymphopenia, grade 4 thrombocytopenia, and grade 3/4 neutropenia, as well as 1 case each of grade 3 lymphopenia, increased C-reactive protein, erythropenia, and hypochloremia developed. Three cases of SAEs, including grade 4 meningitis, grade 4 sepsis, and grade 3 catheter-related infection, developed in the 1,800 mg arm. Stable disease was obtained in 2 pts in the 1,800 mg arm. Hematological remission, hematological improvement, and cytogenetic response were not obtained in the two arms. The Cmax values in the 1,200 and 1,800 mg arms were 5.99±1.50 and 6.74±2.39 μg/mL, respectively. The AUC 0-∞ values were 314.6±142.7 and 324.8±83.9 μg × hr/mL, respectively. The Summary/Conclusions: This Phase I study showed that intravenous rigosertib (1,800 mg daily) for consecutive 72 h was well tolerated, indicating that this is the RD for Japanese pts with MDS similar to a Phase II study in the U.S. Based on these clinical outcomes, Japanese pts with MDS are participating in a global randomized Phase III study to compare rigosertib with physicians’ choice of treatment.

PB1920

IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE

G. Nitrato Izzo1, A. Gagliardi1, L. Mastrullo1

1Department of Oncology, Naples, 2Department of Hematology, National Hospital Organization L’Aquila Medical Center, L’Aquila, 3Division of Medical Oncology, Hematology, and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan

Background: Azacitidine (AZA) improves long-term outcomes of higher-risk MDS patients and is now the reference frontline therapy of higher-risk MDS not eligible for allogeneic stem cell transplant. Azacitidine (AZA) improves long-term outcomes of higher-risk MDS patients and is now the reference frontline therapy of higher-risk MDS not eligible for allogeneic stem cell transplant. Anemia is the most common symptom of MDS and most patients become transfusion-dependent with the risk of iron overload. Deferasirox is an orally available iron chelator administered once-daily in transfusion-dependent patients with various chronic anaemias. Its efficacy has been established in controlled clinical trials.

Aims: We report our experience on using the azacitidine in patients with high-risk MDS, evaluating the efficacy and safety. Concomitant treatment with deferasirox was performed in a routine clinical setting following Consensus Guidelines on Iron Chelation Therapy.

Methods: In our Institution from October 2009 to January 2017 we have...
treated 32 elderly patients (19 male and 13 female, median age 76 years, r. 71-88) affected by HIGH-RISK MDS (IPSS INT-2/HIGH). Patients received subcutaneous azacitidine at 75mg/m2(2) daily for 7 days every 4 weeks. All patients completed at least 6 cycles of therapy. 12/30 (40%) patients underwent more than 8 cycles of therapy. 18/30 patients underwent as well iron chelation therapy with deferasirox receiving a starting dosage of 10 mg/kg/day, subsequently titrated according to serum ferritin (SF) measured monthly.

Results: Complete response (CR), partial response (PR), and hematologic improvement (HI) were observed in 2 (7%), 5 (17%), and 12 (40%) patients, respectively. The median number of cycles to clinical response was 4 (range 4-8). The 2-year rate of transformation to acute myeloid leukemia-free survival was 48%. Five serious adverse events occurred in five patients with one fatal outcome. 16 out of 18 patients who showed any hematologic response (CR+PR+HI) meeting International Working Group 2006 criteria had also performed deferasirox therapy. No increased toxicity was noted when deferasirox was used concomitantly with azacitidine.

Summary/Conclusions: Our results confirm the effectiveness of the therapy with azacitidine in HIGH-RISK MDS elderly patients with acceptable toxicity profile. Peripheral cytopenias were the most commonly occurring adverse event, with gastrointestinal adverse events and injection site reactions being the most commonly occurring non-haematological adverse events. In conclusion, azacitidine is an important agent for use in the treatment of elderly patients with MDS. Furthermore concurrent use of deferasirox in patients with iron overload seems to significantly improve the hematologic response by reducing transfusion requirement.

PB1921
EXPLORING THE RISK OF RED CELL ALLOIMMUNIZATION IN MYELODYSPLASTIC SYNDROMES: TO WHAT EXTEND COULD CYTOTOGENETIC ANALYSIS AT DIAGNOSIS PREDICT THIS RISK?
1. Koutsavlis1,*, J. Falconer2, J. Fleming3, H. Roddie1
1Haematology, 2Blood Transfusion Service, 3Cytogenetics Service, NHS LOTHIAN, Edinburgh, United Kingdom

Background: Red cell alloimmunization poses a huge burden for the blood transfusion services as it may be associated with crossmatching difficulties, haemolytic transfusion reactions and potentially severe clinical consequences for the transfused patient. Collectively, alloimmunization appears to be higher in patients with myelodysplasia (MDS) and chronic myelomonocytic leukaemia (CMML) with a rate somewhat around 15%. Identification of patients at risk of developing alloantibodies would be of clinical significance as antigen negative red cells could be crossmatched in advance for use in clinical practice. Largely, studies have failed to predict this cohort of patients and little is known regarding identifiable risk factors.

Aims: To this end, we focused on exploring the cytogenetic profile from patients with MDS and CMML along with demographic characteristics as risk factors for alloimmunization.

Methods: A retrospective analysis was performed in 360 transfused patients with MDS (74.4%) and CMML (25.6%) registered in our local database between 1980 and 2016. Prognostic variables (age, sex, disease subtype) were assessed using a multivariate prediction model in SPSS statistical software. Cytogenetics at diagnosis were available in 228 of the above patients and uni-variate analysis was performed separately.

Results: The mean age at diagnosis was 73 years (range 20-95) with 58.3% male patients. Overall, 45 patients (12.5%) formed 76 antibodies [88 alloantibodies, 8 autotransfusions] with 42% of them developing more than 1 antibody. 5 additional patients developed autoantibodies without alloantibodies. Alloantibody specificities were as follows: E (22 cases), C (8), K (7), Cw/Jka/Kpa (5 cases each), Lua (4), e/Fya (3 cases each), M (2), c/D/Chido/Bga (1 case each). Collectively, alloantibodies against the RH and Kell systems encountered in 69% of this cohort. 6 out of 8 patients with anti-C had also developed a second alloantibody. In a model, none of the above mentioned variables reached statistical significant level as predictors for immunization; age (p=0.59), sex (p=0.07), MDS WHO subtype (p=1.0). 228 patients had known cytogenetics at diagnosis. Normal profile (46, XY or 46, XX) was encountered in 58.8%. Similarly, univariate analysis of this cohort (normal versus abnormal cytogenetics) showed cytogenetic analysis to be superior to 1+ with no statistical significant point (p=0.64). Further sub-group analysis was performed to explore whether the risk was increased in patients with poor or very poor cytogenetics as per IPSS-R. Descriptive statistics showed; very good/ good risk cytogenetics 69.7%, intermediate 12.7% and poor/ very poor 17.5%. Logistic regression analysis revealed no association between cytogenetic groups and risk of alloimmunization (p=0.89, p=0.96 and p=0.84 respectively).

Summary/Conclusions: The rate of alloimmunization in our cohort of patients was 12.5%, slightly lower compared to published studies. The most common alloantibody found was anti-E. Prognostic variables included in analysis (age, sex, disease subtype) did not reach statistical significance. Further sub-group analysis revealed no association between cytogenetic profile and risk of alloimmunization and further studies are needed to investigate other possible risk factors. Prophylactic RH and Kell antigen matched cells, when possible, would be a reasonable strategy until further knowledge is acquired.

PB1922
PROGNOSTIC MARKERS THAT PREDICT THE OUTCOME OF REDUCED INTENSITY CONDITIONING TRANSPLANT IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE
S. Elashwah1,*, S. Shama2, H. Kamel3, M. Samra4, E. Azmy1
1Clinical Hematology, 2Medical Oncology, Mansoura University, Mansoura, 3Clinical Hematology, 4Medical Oncology, Cairo University, Cairo, Egypt

Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic diseases, characterized by a clonal abnormality of hematopoietic stem cells. The incidence of MDS is age-dependent. The treatment approach is to categorize patients into lower or higher risk MDS and to select a suitable treatment accordingly. HCT offers potentially curative therapy for patients with MDS. Reduced intensity conditioning (RIC) regimen was used to reduce the toxicities associated with transplant procedure. The main concept of RIC relay upon adoptive immunotherapy especially in the low risk patients allowing the graft versus leukemia to occur.

Aims: This study aimed to investigate the demographic, anatomic and peripheral blood cell transplantation adverse effects and the intensity of alloimmunization in adult patients with MDS, the effect of different prognostic factors on outcome and the effect of chronic GVHD according to IPSS risk.

Methods: A retrospectively study analyzed the fifty-one patients with MDS who underwent transplantation at the BMT unit at Nasser Institute during a period of 8 years. The significance of patient age, performance status, disease status, blood group, risk status, prior splenectomy and history of transfusion at the time of enrolment were involved in this study. The patients were stratified as lower risk or high risk patients based on the IPSS classification. The potential immunosuppressive effects of current use of deferasirox in patients with iron overload seems to significantly improve the OS for low and high risk MDS group (p= 0.02 and 0.03 respectively). The 5-year estimate for DFS of the whole group was 28.6%. On univariate analysis the presence of cGVHD significantly reduce relapse (p=0.029).

Summary/Conclusions: The presence of cGVHD significantly improved OS and reduced the risk of relapse in patients with MDS. We also found that the presence of cGVHD significantly improved OS especially in high-risk patients group, which suggests that the GVLT effect may be beneficial in high-risk patients who do not receive intensive preparative regimens.

PB1923
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH MYELOPOIESIS STIMULATING AGENTS IN REAL-LIFE EXPERIENCE: AN UPDATE FROM RECAMDS
C. Cerchione1,*, O. Vitagliano1, R. Della Pepa1, G. Cerciello1, A.E. Pareto1, M. Di Perna1, I. Soriente1, P. Danise1, A.M. D’Arco2, F. Afflitt01, F. Pane1
1Hematology, Ematologia e trapianto/au federico ii, Napoli, 3Hematology, Ospedale Umberto I, Napoli, 3Hematology, Ospedale Umberto I, Nocera Inferiore (SA), 4Ematologia e trapianto/au federico ii, Napoli, Italy

Background: Erythropoiesis stimulating agents (ESAs) are the frontline treatment in low-risk anemic MDS patients and an employment of this therapy in the pretransplantation or delay the need for RBC transfusion, hypothetically by slowing the disease course. It’s matter of debate whether the clinical response is a result of proliferation and maturation of the dysplastic clone or stimulation of residual normal erythropoiesis by ESAs. Only a small percentage of patients with MDS respond to ESAs due to their limited effects on the proliferation of erythroid precursors. The incidence of MDS is age-dependent. The treatment approach is to categorize patients into lower or higher risk MDS and to select a suitable treatment accordingly. HCT offers potentially curative therapy for patients with MDS. Reduced intensity conditioning (RIC) regimen was used to reduce the toxicities associated with transplant procedure. The main concept of RIC relay upon adoptive immunotherapy especially in the low risk patients allowing the graft versus leukemia to occur.

Aims: This study aimed to investigate the demographic, anatomic and peripheral blood cell transplantation adverse effects and the intensity of alloimmunization in adult patients with MDS, the effect of different prognostic factors on outcome and the effect of chronic GVHD according to IPSS risk.

Methods: A retrospectively study analyzed the fifty-one patients with MDS who underwent transplantation at the BMT unit at Nasser Institute during a period of 8 years. The significance of patient age, performance status, disease status, blood group, risk status, prior splenectomy and history of transfusion at the time of enrolment were involved in this study. The patients were stratified as lower risk or high risk patients based on the IPSS classification. The potential immunosuppressive effects of current use of deferasirox in patients with iron overload seems to significantly improve the OS for low and high risk MDS group (p= 0.02 and 0.03 respectively). The 5-year estimate for DFS of the whole group was 28.6%. On univariate analysis the presence of cGVHD significantly reduce relapse (p=0.029).

Summary/Conclusions: The presence of cGVHD significantly improved OS and reduced the risk of relapse in patients with MDS. We also found that the presence of cGVHD significantly improved OS especially in high-risk patients group, which suggests that the GVLT effect may be beneficial in high-risk patients who do not receive intensive preparative regimens.
PATIENTS WITH PRIMARY MDS
IMMUNOSUPPRESSIVE THERAPY AS FIRST-LINE TREATMENT OF PB1925

The aim of these study is to better define cases of MDS transforming to ALL. Methods: We describe a series of 4 cases of MDS/CMM with evolution to acute lymphoblastic leukaemia. These events are very rare and are to date only published as single cases. Aims: The aim of this study is to better define cases of MDS transforming to ALL. Methods: We describe 4 cases of patients suffering from MDS who in the course of the disease presented with ALL. Three of these cases presented in 1 centre, the other, all cases were documented in a 17-year time span. We than performed a literature research including at the moment 37 cases of MDS transforming to ALL described as case reports.

Results: Subtypes of MDS are varying from low risk MDS with deletion (5q) (del(5q)) to refractory anaemia with excess of blasts in transformation (RAEB-T), classified as AML in newer WHO classifications (2008 and 2016) and CMMML, classified as MDS/MPN nowadays. Even if MDS subgroups are manifold, cytogenetic results are less so. Two of the 4 patients described demonstrated KMT2A rearrangements, 1 already at MDS presentation, the other at ALL presentation. One patient presented with del(5q). Of the 37 cases we identified in the literature, 7 presented with del(5q) and 2 showed with anomalies of the 11q23 locus. Summary/Conclusions: KMT2A is known to be a gene involved in myeloid neoplasms as well as in acute lymphoblastic leukaemia. In a small series of cases we identified in the literature, 7 presented with del(5q) and 2 showed with anomalies of the 11q23 locus. Summary/Conclusions: The effectiveness of immunosuppressive therapy in MDS associated with a variant of the disease, bone marrow cellularity and the bone marrow lymphoid infiltration. The greatest effect of the immunosuppressive therapy can be expected in patients with hypoplastic MDS and accumulation of lymphocytes in the bone marrow biopsy.
Juvenile myelomonocytic leukemia (JMML) is a chronic malignant myeloproliferative disease of early childhood

Background: Juvenile myelomonocytic leukemia (JMML) patients in Turkey, in terms of time of diagnosis, clinical characteristics, muta
tional studies, clinical course and treatment strategies.

Myelodysplastic syndrome (MDS) constitutes a heterogeneous group of hematopoietic stem cell disorders, characterized by peripheral blood cytopenias in the presence of a dysplastic myeloperoxidase bone marrow. This biological heterogeneity is reflected in the clinical course, ranging from an indolent disease to entities with high risk of progression to AML and dismal prognosis. Genetic and epigenetic abnormalities are at the core of myeloid neoplasias biologic heterogeneity is reflected in the clinical course, ranging from an indolent disease to entities with high risk of progression to AML and dismal prognosis. Genetic and epigenetic abnormalities are at the core of myeloid neoplasias biologic heterogeneity is reflected in the clinical course, ranging from an indolent disease to entities with high risk of progression to AML and dismal prognosis. Genetic and epigenetic abnormalities are at the core of myeloid neoplasias
patients. All patients required erythropoiesis stimulating agents and 9 patients received treatment with azacytidine (AZA) including all the Int-2 patients and 3 lower risk patients who progressed to a higher risk MDS. Estimated cumulative survival at 46 months was 67% with a median OS not reached and median follow-up time of 34 months. Patients receiving AZA revealed a trend towards survival benefit (mean survival 54.2 vs 50 months, independent of IPSS and R-IPSS, not significant). A recent study revealed that 75.6% of patients had at least one gene mutation and it was most frequently related to DNA methylation genes (n=14), particularly in TET2 (n=7 patients) and DNMT3A (n=6 patients, 7 different mutations). We found a statistically significant difference between mutations in these genes and lower absolute neutrophil counts (Mean 0.47 G/L ± 0.94 vs 1.8 G/L ± 0.42; p=0.001). The most frequently mutated genes were related to signal transduction pathways (n=11; JAK1, JAK2, NRAS, CBL, GATA2, SH2B3, CSFR). Patients with these mutations had significantly lower serum EPO levels (p <0.001; median 32.35 vs 42.70 U/L, respectively). Furthermore, patients with such mutations demonstrated a clear discrepancy in analysis, with a median OS of 19 months vs 27 months (p<0.001), being these results independent of the IPSS and R-IPSS risk groups. We were also able to identify a trend towards worst survival in patients with previously described high risk mutations (TP53, EZH2, ASXL1, RUNX1 and ETVB genes).

Summary: We conclude that the most frequently detected mutations were related to DNA methylation genes, as described in the literature, which was independent of the IPSS risk group, being observed in both low-risk and high-risk patients. These results raise the question whether hypomethylating agents may also be of benefit for lower-risk patients. We also identified a trend with signal transduction pathways which was related to a clear survival disadvantage across all risk groups of the IPSS and R-IPSS. This unveiled the question we may be facing a shift towards the molecular level in MDS risk stratification and if therapies targeted to such molecules may improve the outcome of these patients.

**PB1930 CLINICAL FEATURES, CYTOGENETIC STUDY AND OUTCOME OF ADULT MEYLODYSPLASTIC SYNDROMES: REVIEW OF 101 CASES, A SINGLE CENTER EXPERIENCE IN ALGERIA.**

S. Taoussi1,*, Y. Bouchakor-Moussa1, M.T.T. Abad1
1Hematology, EHS ELCC CAC, Blida, Algeria

**Background:** Myelodysplastic syndromes (MDS) are heterogeneous disorders defined as clonal diseases involving hematopoietic stem cells and even characterized by cytopenias, with a high risk of leukemic transformation. Morphological analysis of peripheral blood (PB) and marrow aspirates or bone marrow biopsies is the first step that ensures a diagnosis of MDS. Cyto genetic studies are important means of defining different prognostic groups and even of showing how patients are eligible for this or that treatment. We conducted the first study including conventional karyotyping and fluorescence in situ hybridization (FISH) for MDS in our country.

**Aims:** Our study was aimed to evaluate outcome of MDS regarding IPSS and IPSS-R classification in an emerging country.

**Methods:** Between January 2012 to December 2018, 101 patients with MDS were consecutively diagnosed. Frequent genetic abnormalities in MDS were screenable by conventional karyotyping, metaphase and interphase FISH using a panel including six probes (5q-,7q-;20-, del(17p13), MLL, Inv(3) (t;3:3). Patients were stratified into risk groups according to IPSS and IPSS-R scores; survival probabilities were estimated using the Kaplan-Meier method.

**Results:** Among these 101 pts, 58 were male with a sex ratio=1,35; range in age is from 18 years to 94 years with a median of 61,6 years. Median hemoglobin value was 80 G/L (29-150), more than 60% of patients had severe anaemia mainly in the low risk group; the median absolute neutrophil count was 3 G/L (0,060-13,5), and the median platelet count was 144 G/L (5-659). Median bone marrow cellularity was 50%, only 52% had normal bone marrow infiltration. Median age was 63,5 years (range: 49-69), male/female ratio was 9/5. According to IPSS, 12 out of 14 patients were high-risk (2 int-2 (1-1), 11/14 had >10% blast cells (EB-2). According to our centre protocol, we treated 11 patients with EB-2 and 1 patient with EB-1 with hypercellular bone marrow) with a debulking therapy. This was I.C. in 6 patients and 5-AZA in 6 patients. Two patients treated with EB-1 did not receive any therapy pre-transplant. However, both of them are not evaluable, due to early mortality. Transplant conditioning was RIC in 11/14 patients, myeloablative in 3 cases. The donor was a sibling in 9/14, MUD in 5/14. Four out of six patients treated with I.C. achieved a pre-transplant CR (83.3%), compared to one out of six in the 5-Aza cohort (17%). Four patients experienced a relapse post HCT, after a median of 8,5 months (4-11). With a median follow up of 21 months (6-68), post transplant RR was 4/12 (33.3%) and was not influenced by debulking therapy (I.C. vs 5-Aza, p=0,54), nor by pre-transplant disease stage (CR vs noCR, p=0,22). In fact, 3 out of 6 patients treated with I.C. achieved a CR, but only 1 out of 6 treated with 5-Aza relapsed after transplant. Three out of four patients who subsequently relapsed had received I.C transplant; type of transplant was not associated with relapse (P=1,0). The only variable that showed a trend for reduced RR was MUD transplant (p=0,08).

**Summary/Conclusions:** Extreme caution must be used in considering our data, given the very small patients number. In our cohort, pre-transplant intensive debulking chemotherapy, although obtained an high rate of CR, showed no effect in preventing relapse. Larger studies are necessary to assess the real utility of I.C. in this subset of frail patients.

**PB1932 IRON CHELATION THERAPY IN MEYLODYSPLASTIC SYNDROMES AND IN OTHER TRANSPLANT-DEPENDENT CHRONIC ANEMIAS: RETROSPECTIVE STUDY OF 69 PATIENTS FROM A SINGLE INSTITUTION**

C. Finelli1,*, C. Clissa2, M. Barraclou1, C. De Maio1, M. Stanzani1, S. Parini1, S. Paolini1, C. Bosi2, M. Cavo1
1Hematology, S.Orsola-Malpighi University Hospital, Bologna, 2Hematology, S. Salvatore Hospital, Pesaro, 3Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy

**Background:** Although several recent guidelines recommend iron chelation therapy (ICT) for iron overload in transfusion-dependent patients (pts) with lower-risk myelodysplastic syndromes (MDS), several barriers may limit the initiation or the continuance of ICT: older age, comorbidities, poor tolerance and compliance.

**Summary/Conclusions:** Our results are in agreement with those previously published regarding demographic features; distribution of pre-transplant cytogenetic abnormalities and prediction of survival. Myelodysplasias are among the most difficult hematological diseases to treat. Treatment of low risk and high risk myelodysplasia are completely different, the last group carrying a great risk of leukemic transformation. For all these reasons, application of the new tools to R-IPSS is necessary. This model has revealed that in emerging countries where few therapeutic means are available, hence the need to predict the prognosis of these diseases in order to better target treatments. To the best of our knowledge, it is the first study conducted in our country.
of a diagnosis of iron overload, age: 74 (23-96) yrs, with transfusion-dependent anemia, received ICT, because

Methods:
From October 1997, in our Institution, 69 pts (48 males), median age: 74 (23-96) yrs, with transfusion-dependent anemia, received ICT, because of a diagnosis of iron overload, i.e. both a transfusion history of at least 20 units of RBC and a serum ferritin (SF) higher than 1000 ng/ml.

Results: 40 pts (58%) were affected by lower-risk MDS (IPSS risk: low or intermediate-1) but were considered for ICT because of responsiveness to hypomethylating therapy and/or eligibility for allogeneic SCT. 16 pts (23.2%) were affected by other diseases (chronic myelomonocytic leukemia: 2 pts; idiopathic myelofibrosis: 3 pts; aplastic anemia: 9 pts; pure red cell aplasia (PRCA): 2 pts). 45 pts (65.2%) received deferasirox (DFX) as first-line treatment, 12 pts (17.4%) received DFO after a previous treatment with deferoxamine (DFO), while 9 pts (13%) received DFO and 3 pts (4.3%) received DFO after DFX because of contraindications to DFX or toxicity. Median time from diagnosis to the start of ICT: 18 months. Median number of RBC transfusions before the start of ICT: 37.5. Median SF level pre-ICT: 1964 ng/ml; median SF after ICT (last value): 1858 ng/ml; median duration of ICT: 12 (range 1-230) months. 36 pts (52.2%) continued ICT for a period >12 months, and 25 pts (36.2%) for a period ≥24 months. 27 pts (39.1%) showed a drop of SF ≤500 ng/ml, 11 pts (15.9%) showed a drop of SF <500, 13 pts (18.8%) showed an increase of SF >500, in spite of ICT, and 18 pts (26.1%) showed an increase of SF >5000. 12 pts (17.4%) achieved a SF value <1,000, and 48 pts (69.6%) a SF value <2,500. Adverse events possibly related to DFX were observed in 30 pts (43.5%): renal (increase of serum creatinine): 14 pts (20.3%) (grade >2: 1 pt: 1.4%); gastrointestinal : 14 pts (20.3%) (grade >2: 1 pt: 1.4%); cutaneous: 2 pts (2.9%) (grade >2: no pts). Permanent discontinuation of ICT: 40 pts (58%), because of toxicity (16 pts: 23.2%), worsening of clinical condition (6 pts: 8.7%), discontinuation of transfusions (9 pts: 13%), allogeneic transplantation (9 pts: 13%). 5 pts (7.2%) (4 MDS and 1 PRCA) (with DFX: 4 pts; with DFO: 1 pt) showed an erythroid response following ICT, after 2, 4, 7, 32 and 112 months, respectively, and one of them (with PRCA) achieved complete remission. 35 pts (50.7%) died, because of infection (9 pts), AML (4 pts), cachexia (4 pts), other neoplastic diseases (3 pts), hemorrhage (2 pts), heart failure (2 pts), stroke (2 pts) and other causes (9 pts). 10 pts (14.5%) are still receiving ICT.

Summary/Conclusions:
In conclusion, in our experience ICT appears feasible and effective, in terms of reduction of SF and OS, even in a population of elderly pts, if carefully selected.

Myeloma and other monoclonal gammopathies - Biology

PB1933

VCAM-1 AS A NOVEL DRUG THERAPY TARGET OF BONE MARROW MESENCHYMAL STEM CELLS IN MULTIPLE MYELOMA

A. Ortiz-Ruz1,2, C. Alica1, L. Alejandr2a, M.Mº Luiz2, L. Maria3, G. Miguel1, M.-L. Joaquín1

Background: Multiple myeloma is characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment. The pathogenesis of MM is complex, in part, in physiological interactions between myeloma cells and the mesenchymal stem cells (MSC). The interactions between myeloma cells and bone marrow cells are established through surface receptors (e.g. integrins, cell adhesion molecules, etc.), which determine tumor growth, survival, migration and drug resistance. Mesenchymal stromal cells modulate the pattern of myeloma markers on the cellular surface in vitro towards a less differentiated phenotype. However, the exact mechanism by which mesenchymal stromal cells carry out their functions is not yet fully understood.

Aims: To evaluate the effect of MSCs from healthy donors and myeloma patients over malignant plasma cells and the molecular changes produced for the recognition each other.

Methods: Interactions between both cell types were studied through different co-cultures studies. We evaluate differences between cultivating primary MSC cells and MM cell line RPMI 8226. Pathological MSCs were extracted from the bone marrow of newly diagnose MM patients. On the other hand, purified healthy MSCs will be isolated from donor patients. Pathological or healthy MSCs were cultured and co-cultured 24h after seeding with MM plasma cells RPMI 8226 for duplicates at 24, 48 and 72h. The phenotypical and molecular effect of the interaction of both cells were characterized by viability through trypan blue, cell apoptosis percentage (7AAD) and variations on expression of cell surface proteins (MSCs: CD90, CD105, CD106 and CD54. MM cell: CD138, CD49d, CD11a) using flow cytometry, and statistically analyzed with GraphPad.

Results: We observed a decrease of apoptosis of MM plasma cells when are in co-culture with pathological MSCs at short-term (24h, 7AAD positive cells MM alone: 4.8%, MM in co-culture: 0.4%) and mid-term (72h, 7AAD positive cells MM alone: 16.4%, MM in co-culture: 10.7%) compared with MM plasma cells alone. However MM plasma cells not decreases the level of apoptosis at mid-term with healthy MSCs in co-cultures (72h, 7AAD positive cells MM alone: 16.4%, MM in co-culture: 18.0%). The molecular analysis showed a correlation between MSCs lack of protection over MM plasma cells and the decrease in the levels of expression of VCAM-1 (CD106).

Summary/Conclusions: As reported in literature CD106 expression increase when MSCs are co-cultured with plasma cells. Adhesion of tumor cells to BMSC activates many pathways resulting in upregulation of cell cycle and anti-apoptotic proteins. MM pathophysiology is supported by a strong interaction between CD106/CD49d. Changes in VCAM-1 and VLA-4 expression have been demonstrated in cell lines assays, and were corroborated with primary cells in the context of MSCs protection over MM plasma cell. Thus, MM pathological MSCs did not change VCAM-1 levels and MM plasma cell protection be held. However, healthy MSCs have the capacity to modulate the VCAM-1 in mid-term to avoid the protection effect. Therefore, these results suggest MSCs VCAM-1 as potential drug therapy target in MM disease.

PB1934

RALA AND RALB MEDIATE CELL SURVIVAL INDEPENDENTLY OF ONCOCERGIC RAS AND PROVIDE POTENTIAL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA

M. Seibold1, T. Stühmer1, N. Schmied1, D. Brünnert1, A. Mottock2, E. Leich2, A. Rosenwald2, C.-J. Scholz2, M. Chatterjee1, H. Einsele1, R.C. Bargou4, M.-L. Joaquín2

Background: Genetic mutations and the bone marrow microenvironment contribute to disease progression, aggressive phenotype, and shorter survival in multiple myeloma (MM). Oncogenic RAS is one of the most common mutations in MM. Pathway activation through oncogenic RAS is associated with promotion of disease progression and shorter survival. Cell survival and proliferation in MM are mainly mediated via classical signaling pathways such as MEK/ERK and PI3K/Akt. Since there is a lack of specific RAS-inhibitors for clinical use, it is important to identify and analyze associated pathways, which may provide useful alternative targets for MM therapy. The small GTPase Ral has previously
been implicated in putative downstream signaling of RAS, and may therefore promote proliferation and survival in drug-resistant MM cells.

Aims: We used shRNA-mediated knockdown of RAiA and RAiB isoforms to appraise their role as potential therapeutic targets and to analyze their dependence on important signaling pathways, which regulate MM cell survival and proliferation. Because oncogenic RAS is a potential activator of the Rap pathway, we investigated the roles of Rap signaling in MM in order to assess its role as an independent prognostic factor.

Methods: Immunohistochemical stainings of bone marrow trephines of MM patients and Western analysis of primary MM cell and MM cell lines were performed to evaluate Rap protein expression. Transient or stable knockdown of RAiA or RAiB was achieved by electroporation of MM cell lines and the effect on MM cell survival was measured with flow cytometry using annexin V/propidium iodide staining. RAi pulldowns were applied to test potential dependence of Rap activation on oncogenic RAS. Furthermore, RNA sequencing was performed to compare RAi and Rap gene expression signatures after respective knockdowns.

Results: Both Rap isoforms were expressed in primary MM cells and MM cell lines, with RapA showing the most prominent and consistent protein expression levels. ShRNA-mediated knockdown of RAiA strongly induced apoptosis in two thirds of the tested cell lines, whereas RAiB depletion did impair MM cell survival in less than half of the cell lines. Western analysis revealed no alteration of classical Rap pathway activation after RAi knockdown. Rap activity appears to be independent of oncogenic KRAS or NRAS. In addition, RNA sequencing revealed differing gene expression signatures for RAi and Rap.

Summary/Conclusions: Rap and its effector network constitute potential therapeutic targets in MM, which are activated independently of oncogenic K- or NRAS. Therefore, investigation of the functional network of Rap may be important to identify useful clinical targets.

PB1935

CXCR4 MUTATIONS FOUND BY USING DEEP SEQUENCING WITHOUT SORTING B CELLS, AND PROGNOSTIC IMPLICATION IN WALDENSTROM MACROGLOBULINEMIA

S.-M. Kim1,2, D.W. Shin1, K. Im1, S.M. Hwang1, J.-A. Kim2, H.S. Park2, D.S. Lee1
1Cancer Research institute, 2Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of

Background: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytoid lymphoma with IgM monoclonal gammapathy. Most of WM harbor MYD88 L265P and one third of WM with MYD88 present CXCR4 mutations. Currently, frequency of CXCR4 mutations and its clinical implication is not reported in Asian patients with WM.

Aims: We investigated the profiles of CXCR4 and MYD88 mutation in correlation with prognostic implication. To detect minor cell population with CXCR4 mutation, we adopted a ultra-deep sequencing strategy for CXCR4, which can detect specific variants <1% of the cell population.

Methods: Allele-specific PCR for MYD88 was performed on 37 patients with WM, along with 161 patients with B-cell neoplasms [diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL)]. Deep-sequencing for CXCR4 and interphase fluorescent in situ hybridization (FISH) for 6q deletion was performed on 31 patients with WM. Clinicopathologic features were compared among 3 groups according to MYD88 and CXCR4 mutation status (Group 1, MYD88 WT and CXCR4 WT; group 2, MYD88WT and CXCR4-mutation; group 3, MYD88L265P and CXCR4-Mutation; statistical comparison, Fisher exact test, one-way ANOVA).

Results: MYD88 L265P mutation was detected in 81.3% (26/32) patients with WM, 10.8% (9/83) in patients with DLBCL, 9.5% (6/63) in patients with CLL, 0% (0/15) in patients with B-ALL, and 0% in 200 healthy persons. Among the 31 WM patients, 6 patients have CXCR4 mutation (19.4%) in the c-terminal domain (Figure 1); 1 frameshift mutation and 5 nonsense mutations. Twelve (40%) patients, however, were not found to be positive cases. All of them had MYD88 L265P mutation. FISH revealed 6q21 deletion in 14 patients (43.8%), and IGH rearrangement in 9 patients (28.1%). There was no correlation among cytogenetic aberrations and genetic mutation (MYD88 and CXCR4). IgM levels of group 2 (MYD88WT and CXCR4WT) were significantly higher than that of group 1 (MYD88WT and CXCR4-mutation) (P=0.024). Meanwhile, IgG level was significantly lower in group 2 WT and MYD88 WT, which was not statistically significant (P=0.410). There were no death events in group 3 (MYD88L265P and CXCR4-Mutation) patients during the research period.

Summary/Conclusions: The frequency of CXCR4 mutation in Korean WM was similar to those of Caucasian. We suggest that ultra-deep sequencing using deep-sequencing can detect CXCR4 mutation in WM with sensitivity of less than 1%. CXCR4 mutation in patients with MYD88 WT and CXCR4 WT showed higher IgM level and lower survival, suggesting an adverse prognostic implication. This is the first report on CXCR4 mutation in Korean WM patients.

Figure 1.
THE ROLE OF NEUROTROPHINS AND ANGIOGENIC CYTOKINES IN THE PATHOPHYSIOLOGY OF PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA

K. Luczkowska1, Z. Litwińska1, E. Pius-Sadowska1, A. Sobus1, E. Paczkowska1, B. Machaliński2
1Department of General Pathology, Pomaranian Medical University in Szczecin, Szczecin, Poland

Background: The introduction of new treatment modalities has changed significantly the prognosis of multiple myeloma (MM) patients. The novel drugs and schemes of treatment of MM have contributed to substantial extend of the overall survival time of patients. However, the administration of some of the treatments is associated with peripheral neuropathy, which is a serious and common side-effect problem, which is the drug-induced peripheral neuropathy. The mechanism of the development of the peripheral neuropathy is poorly understood. Nevertheless, one of its potential cause, could be inadequate concentrations of crucial trophic factors, including neurotrophic and angiogenic factors, which are responsible for proliferation, differentiation, survival and death of neuronal and nonneuronal cells.

Aims: The aim of this study was to elucidate the potential relationship between concentration of neurotrophic and angiogenic factors and development of peripheral neuropathy in the natural clinical course of the disease and, especially, induced by treatment regimen: VMP (bortezomib, melphalan, prednisone) or VTD (bortezomib, thalidomide, dexamethasone) in patients with MM.

Methods: Peripheral blood samples were collected from patients classified into two groups: i) patients with multiple myeloma, without neuropathy and before therapy; and ii) patients with peripheral neuropathy 3 or 4 grade induced in the course of VMP or VTD therapy. The control group consisted healthy age-matched subjects. Assessment of concentrations of neurotrophins (BDNF, NSE) and angiogenic factor (PDGF) were performed using Luminex technology, which utilize microbeads coated with fluorescently labeled antibodies.

Results: Concentration of BDNF, PDGF and NSE were significantly decreased in patients after treatment regimen involving VMP or VTD who have developed peripheral neuropathy grade 3 or 4, compared with patients with newly diagnosed MM without neuropathy, before therapy and control healthy group. Additionally, plasma levels of both neurotrophins and PDGF in patients before therapy were higher, then in control group. Obtained results may be caused by the changes in an activity of the transcription factor NF-κB during the treatment of MM, since reduction of NF-kB concentration is associated with decrease in the transcription of genes encoding BDNF, NSE and PDGF.

Summary/Conclusions: Alterations in the concentration of BDNF, PDGF and NSE suggest the cause and effect relationship between these factors and the development of neuropathy in patients with MM. Comprehensive elucidation of this phenomenon may contribute to the extension of the knowledge concerning the pathogenesis of neuropathy, and might well lead to reduction of the incidence of polyneuropathy in MM patients in the future.

PB1938

INFLUENCE OF XRCC5, XRCC4, NFKB2, AND BIRC5 GENES POLYMORPHISMS IN THE RISK AND PROGNOSIS OF MONOCLONAL GAMMAPATHIES

L. Balanço1, M. S. Mata1, A.C. Gonçalves1,2, R. Alves1, C. Geraldes1,2,3, A.C. Gonçalves1,2
1Hematology, Shengjing Hospital of China Medical University, Shenyang, China; 2Hematology, The University of Texas, MD Anderson Cancer Center, Houston, United States

Background: Monoclonal gammapathies (MG) are a group of disorders characterized by the proliferation of monoclonal plasma cells, which produce and secrete monoclonal immunoglobulin (M protein). Symptomatic multiple myeloma (MM) is defined by the clonal proliferation of plasma cells. MM is consistently preceded by a pre-neoplastic entity, called monoclonal gammapathy of undetermined significance (MGUS), with an intermediate phase of indolent multiple myeloma (MMi). This disease is a heterogeneous hematological neoplasm characterized by the proliferation of clonal, long-lived plasma cells within the bone marrow (BM) secreting monocolonal proteins and by the presence of so-called CRAB criteria and/or biomarkers of malignancy (as clonal BM plasma cells > 60%, involved/uninvolved serum free light chain ratio > 100, > 1 focal lesion in MRI studies). Genetic instability and several molecular abnormalities are hallmarks of MM cells. Alterations in DNA repair pathways, namely abnormal activity of non homologous end-joining (NHEJ) repair pathway, are involved in the disease onset and progression. Moreover, it has been observed that virtually all primary MM samples have constitutive nuclear factor-κB (NF-κB) pathway activity, having this pathway a well-established role in MM pathogenesis.

Aims: To explore the tumor suppressive role of in NHEJ repair pathway (XRCC5, XRCC4) and in NF-κB pathway (NFKB2, and BIRC5) may have impact in MG susceptibility and prognosis.

Methods: In the present, a hospital-based case-control study, we analyzed eight polymorphism in four genes (XRCC5, XRCC4, NFKB2, and BIRC5), by genotyping 189 individuals (63 MG patients and 126 controls) using TaqMan qPCR. Results are expressed in terms of frequencies of allele, genotype, haplotype, and genotypic profiles, and their correlation with MG susceptibility. The strength of association between polymorphisms and disease risk was assessed by odds ratio (OR) with 95% confidence interval (95%CI) calculated by logistic regression. We also investigated the association of these SNPs with overall survival through Kaplan Meier curves. All statistical analyses had a significance levels of 95%.

Results: In the patient group, 51% (32/63) of the individuals were females and 49% (31/63) were males; the mean age was 70.11±10.25 years old. Among the control group, 52% (65/126) of the individuals were females and 48% (61/126) were males, and the mean age was 69.90±10.06 years old. Most of patients were diagnosed with multiple myeloma (84%, 53/63) and the remaining ones (16%, 10/63) were diagnosed with smoldering multiple myeloma. According to the ISS classification, 43% (27/63) of patients are in stage III. The data analysis revealed two associations of the studied gene polymorphisms with MG. First, the analysis by gender stratification suggested a decreased predisposition to MG in male carriers of NFKB2 rs12769316 GA and GA genotypes (OR 0.346, 95%CI 0.124–0.965, p=0.043). Second, we observed that patients with BIRC5 rs9904341 CC genotype had a highly significant lower overall survival (recessive model: HR 4.89, 95%CI 5.06 199.70, p<0.01). BIRC5 GGC haplotype (rs4789551, rs9904341, and rs8073069) was found in one patient and absent in controls.

Summary/Conclusions: The present study suggests that NFKB2 gene variant (rs12769316, allele A) may be associated with MG susceptibility in males, and BIRC5 (rs9904341) CC genotype may negatively influence MG prognosis. Nonetheless, further studies are needed to validate these findings, enlighten the role of genetic polymorphisms in MG susceptibility and prognosis.

PB1939

SILENCE OF LONG NONCODING RNA MALAT1 BY RNA INTERERENCE INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN MULTIPLE MYELOMA

H. Liu1, Z. Gong1, W. Yang1
1Hematology, Shengjing Hospital of China Medical University, Shenyang, China; 2Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, United States

Background: Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by abnormal proliferation of monoclonal plasma cells in bone marrow leading to various end-organ damages. Altered long non-coding RNAs (lncRNAs) levels can result in aberrant expression of gene products that may contribute to cancer biology. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an evolutionarily highly conserved mRNA-like IncRNA was originally identified with high expression in metastatic non-small-cell lung cancer and reported to be up-regulated in many other cancers. However, the function of MALAT1 in MM remains unknown.

Aims: Our study aimed to evaluate the role of MALAT1 on proliferation as well as apoptosis in MM cells in vitro and tumorigenic ability in vivo, following transfection with MALAT1-specific short hairpin RNA (shRNA) expression plasmids.

Methods: Levels of MALAT1 in human myeloma cell lines were detected by real-time polymerase chain reaction (RT-PCR) analysis. The effects of MALAT1 shRNA in MM were investigated in vitro and in vivo.

Results: We found that MALAT1 was high expressing in RPMI8226 and U266 cell lines. Knockdown of MALAT1 by shRNA significantly inhibited the proliferation through cell cycle arrest at G1 phase and induced apoptosis, which was closely associated with activation of caspase-3/9, downregulation of Bcl-2 and upregulation of Bax. Study in vivo revealed that silencing of MALAT1 delayed the tumor growth and led to apoptosis in mice bearing xenograft.

Summary/Conclusions: MALAT1 may serve as a promising novel therapeutic target in human MM. Notably, the inhibition of MALAT1 by shRNA may prove to be an effective genetic therapeutic strategy for MM treatment.

PB1940

LONG NON-CODING RNA MEG3 FUNCTIONS AS A COMPETING ENDORNS RNA TO REGULATE PTEN EXPRESSION BY SPONGING MIR-181A IN MULTIPLE MYELOMA

L. Chen1, H. Bai1, H. Zhu1, X. Shen1, J. Li1, W. Yu1
1the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Background: Long non-coding RNA maternally expressed gene 3 (MEG3) plays a critical role in cancer progression and metastasis. However, the overall biological role and regulatory mechanism of MEG3 in multiple myeloma (MM) development and progression remains largely unknown.

Aims: To explore the tumor suppressor role of IncRNA MEG3 in MM and further reveal the mechanism of MEG3 functions as ceRNA to contribute to MM pathogenesis.

Methods: MEG3 expression was measured in MM patients by real-time PCR.
The effect of MEG3 on cell apoptosis, cell proliferation and angiogenesis were gained from CGH-8, flow cytometric analysis and transwell invasion assays in MM cell lines ARP-1 and LP-1. Insights of the mechanism of competitive endogenous RNA (ceRNA) were gained from bioinformatic analysis, luciferase reporter assays and RNA binding protein immunoprecipitation (RIP) assay.

**Results:** MEG3 expression was significantly decreased in MM patients with advanced stage disease (ISS II and III) and in patients with an abnormal serum FLC ratio. Overexpression of MEG3 promoted cell apoptosis and inhibited cell proliferation, migration and angiogenesis in MM ARP-1 and LP-1 cell lines. Furthermore, MEG3 increase the expression of phosphatase and tensin homolog (PTEN) and consequently inhibit MM cell proliferation and angiogenesis through sponging miR-181a in MM patients with a median of 91.8 and 181 and 181a expression by PTEN by p < 0.05.

**Summary/Conclusions:** MEG3 functions as a tumor suppressor in MM. High expression of MEG3 is a marker for good survival. We reveal a novel mechanism that MEG3 as a ceRNA of the PTEN gene by competing for miRNA-181a binding sites and thereby regulate the expression of the PTEN mRNA.

**PB1941**

**IMPROVE RISK-STRATIFICATION OF multiple MYELOMA PATIENT WITH MICROFLUIDIC DEVICES**

C. Li¹, L. Gao¹, Y. Zeng¹, X. Zhang¹, J. Zhong¹.

¹University of Southern California, Los Angeles, United States

**Background:** Cytogenetic alterations are required for risk stratification of multiple myeloma (MM); however, current pathology assays performed on bone marrow samples directly can produce false negatives due to the unpredictable distribution and rarity of MM cells. A more accurate method is needed for MM diagnosis and risk-stratification. We develop a new microfluidic device to facilitate CD45 depletion for enhancing the detection of cytogenetic alterations in plasma cells.

**Aims:** Improve accuracy of risk stratification for multiple myeloma patients

**Methods:** Bone marrow samples from 48 MM patients were divided into two parts each. One part was directly detected by classic flow cytometry and FISH while the other part was first enriched by microfluidic size selection and then underwent CD45-cell depletion (MF-CD45-TACs). The enriched samples were then analyzed by flow cytometry and FISH and compared to the classical analysis.

**Results:** MF-CD45-TACs significantly increased the percentage of CD38+/CD138+ cells to 37.7±20.4% (P < 0.001) compared to 10.3±6.5% in the marrow. After the MF-CD45-TACs enrichment the detection rate of IgH rearrangement, del(13q14), del(17p) and 1q21 gains rose to 56.3%(P < 0.001), 37.5%(P < 0.001), 22.9%(P < 0.001) and 41.7%(P < 0.001), respectively, all significant increases compared to untreated samples.

**Summary/Conclusions:** We have developed a rapid, simple assay for improved diagnostics and risk-stratification for MM. With more precise diagnostics, the clinical outcomes of MM will be significantly improved.

**PB1942**

**SERUM FREE LIGHT CHAIN RATIO IS AN INDEPENDENT RISK FACTOR FOR PROGRESSION IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE**

R. Sert¹, B. Salih Ertel¹, 2, S. Bessmeltsev², E. Kleina³, ¹Immunohaematology laboratory, 2Russian Institute of Haematology and Transfusion, 3Laboratory of molecular genetics, Saint-Petersburg, Russian Federation

**Background:** Monoclonal gammapathy of undetermined significance (MGUS) is a premalignant plasma cell proliferative disorder found in approximately 3% of the general population 50 years of age and older. MGUS is associated with progression to multiple myeloma or related malignancy at a rate of 1% per year. Thus the risk of malignancy for a 50-year-old patient with a 25-year life span is 25%.

**Aims:** We hypothesized that the presence of monoclonal free kappa or lambda immunoglobulin light chain in monoclonal gammapathy of undetermined significance (MGUS), as detected by the serum free light chain (FLC) assay is now available for clinical practice. The risk of progression in patients with an abnormal FLC ratio was significantly higher compared with patients with a normal ratio, and was independent of the size and type of the serum monoclonal protein. Inclusion of FLC ratio in the clinical staging system (International Staging System II and III) further improved diagnostics and risk-stratification for MM. With more precise diagnostics, the overall survival of patients with newly diagnosed and refractory/relapsed multiple myeloma is the overall survival of patients with newly diagnosed and refractory/relapsed multiple myeloma and the effect of expression of MDR genes such as MDR 1, MRP 1, BCRP, LRP on the overall survival of patients after treatment with bortezomib.

**Methods:** Bone marrow aspirates of 30 patients (30 men and 18 women) aged 48 to 77 years (median 60 years) with stage III MM by classification Durie-Salmon were studied. 15 patients were included in a group of newly diagnosed (ND) MM. 15 patients were in group of a clinically refractory/ relapsed (RR) MM. The bone marrow in this group of patients was studied after treatment with alkylating agents and at the time of registration of resistance to the given therapy. In the future, all patients were treated by bortezomib - containing chemotherapy regimens. mRNA expression studied genes were determined by semi-quantitative polymerase chain reaction reverse transcription. The degree of expression was assessed by semi-quantitative visual assessment from 0 (no electrophoretic migration of RNA band), 1 (no migration on the gel strip), 2 (weak glow of the transcript), 3 (moderate strength of the transcript), 4 points (bright glow of the transcript). The overall survival (OS) was analyzed by the Kaplan-Meier method, with the use of Cox-Mantel test. Differences were considered statistically significant at p < 0.05.

**Results:** In both groups of patients had comparable expression of all studied MDR`s genes. The development of clinical resistance to treatment with alkylating agents were accompanied by an increase in mRNA expression of all studied genes. However, the statistically significant increase the expression of the mRNA LRP gene only (the average intensity of the expression of mRNA LRP gene in ND MM 0.9±0.24, with RR MM 1.93±0.34, p < 0.05). The MDR 1 mRNA expression was 1.50±0.34 in the group of ND MM and 1.67±0.31 in the group of RR MM, p<0.05. The expression of mRNA of MRP 1 and BCRP are 1.07±0.21 and 1.63±0.15 respectively before treatment and increased to 1.73±0.31 and 2.13±0.35 respectively in the group of RR MM, p<0.06. OS was negatively associated with high LRP gene expression only in group of ND MM (median of OS in patients with high LR gene expression was 5.8 months and in those with low LR expression was 31 months).

**Summary/Conclusions:** High expression of LR gene is associated with worse overall survival in patients with newly diagnosed MM treated with bortezomib-containing chemotherapy programs. "Genetic resource MDR" in MM is due mainly to the initial multidrug resistance. The treatment of MM by alkylating drugs increase the existing at the time of diagnosis of MDR activity of genes.

**PB1944**

**ASSOCIATIONS OF IL-1, IL-4 AND TGF-B1 POLYMORPHISMS WITH CYTOTYPIC PROFILES IN PATIENTS WITH MULTIPLE MYELOMA**

A. Pavlova¹, I. Pavlova¹, L. Bubnova², S. Bessmeltsev², E. Kleina³, A. Garfulin¹, I. Martynevich¹, S. Voloshin¹, A. Chechukin¹, ¹Haematology clinic, ²Russian Institute of Haematology and Transfusion, Saint-Petersburg, Russian Federation, ³Laboratory of molecular genetics, Saint-Petersburg, Russian Federation

**Background:** Multiple myeloma (MM) is a plasma cell malignancy characterized by complex cytogenetic and molecular genetic aberrations. These cytogenetic abnormalities occur at different stages of the disease. The chromosome ploidy status and Ig rearrangements are two genetic criteria that are used to help stratify patients into prognostic groups.

**Aims:** The aim of the study was to analyze correlation between cytogenetic profiles and some cytokine genotypes in 24 patients with MM (Caucasoid inhabitants of the North-West region of Russia).

**Methods:** Genomic DNA was extracted from the peripheral blood; gene geno-
typing (IL-4, TGF-β1, IL-1α, IL-1β) was performed by PCR-SSP; study of cytogenetic abnormalities was performed by standard GTG-method and interphase FISH analyses with DNA probes: LSI 13(RB1)13q14, IGHI/CCND1, IGHI/FGFR3, LSI TP53 (17q13.1); p-values less than 0.05 were considered statistically significant. Results: Previous results allow us to describe some cytokine genotype markers associated with the development of MM (IL-1α-889 TT, IL-1β-3962 TT, IL-6-174 GG and IL-6 n565 GG; gr. 1) as additional negative prognostic markers but IL-4 -33 CC and TGF-β1 codon 25 GG genotypes as additional positive prognostic markers (gr. 2). However, in some MM patients we found presence of negative and positive markers together (mixed markers; gr. 3). We analyzed cytoprofiles in MM patients with different prognostic markers in their genotypes (Table 1).

The frequency of abnormal cytogenetic transformations in the 2nd gr. was noticeably lower compared to patients from the 1st and 3rd gr. (0.11 vs 0.78 vs 0.67 respectively; p<0.05). Similarly, significant differences in the frequency between patients with positive prognostic markers and normal cytoprofleic profile (0.59) compare to MM patients negative (0.22) or mixed (0.33) genotypes but normal cytoprofiles were also observed (p<0.05). In the 1st gr. frequency of cytogenetic abnormalities was noticeably higher compare to patients with normal profile (0.78 vs 0.22; p<0.05). Vice versa, in patients with positive prognostic markers the frequency of normal cytoprofleic profiles was remarkably higher (0.89) compared to patients with aberrations (0.11; p<0.05).

Summary/Conclusions: Thus, our results allow to describe IL-1α-889 TT, IL-1β-3962 TT, IL-6-174 GG and IL-6 n565 GG as markers associated with the presence of cytogenetic abnormalities in MM patient cells. However, IL-4 -33 CC and TGF-β1 codon 25 GG genotypes as additional negative prognostic markers in patients with MM from the North-West region of Russia. Although, if MM patients have both negative and positive prognostic markers associated with the development of multiple myeloma (mixed genotype) it seems that the chance of finding cytogenetic abnormalities is much higher compared to patients with positive prognostic markers only.

PB1945

CORRELATION DEPENDENCE OF CHRONIC LYMPHOPROLIFERATIVE DISORDERS, MULTIPLE MYELOMA FROM CHANGES OF IMMUNE RESPONSE GENES PROFILE

E. Nazarova1, V. Shardakov1, A. Nagovitsina1, E. Zotina2, I. Dokshina2
1Laboratory of Immunogenetics, N. N. Petrov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation

Background: Hematological malignancies are multifactorial diseases in the development of which play a role as environmental factors and genetic determinants. The latter include the presence in human genome of allelic variants of the regulatory regions of the innate immune response genes. At present time, they are considered as real risk factors for the development of these diseases in a person with a certain set of genetic variants. Their distribution among the population corresponds to the population laws and has its ethno-geographic features. Analysis of the individual associations of genes polymorphic variants involved in the implementation of the immune response does not sufficiently complete answer about their role in the formation of predisposition to the development of chronic lymphoproliferative disorders (CLD) and multiple myeloma (MM). It is noted that in the pathogenesis of hematological diseases contribute significantly to certain combinations of immune response genes.

Aims: Analysis of interactions between genes based on the distribution of immune response genes combinations in chronic lymphoproliferative disorders and multiple myeloma.

Methods: The study included 176 patients aged 22-86 years (median - 61 year), identifying themselves as Caucasians residing in one region in the north-east of the Russian Federation. This group consisted of 80 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (45%), 72 with multiple myeloma (41%), 10 with diffuse large B-cell lymphoma (6%) with marginal zone lymphoma (3%) four with mantle cell lymphoma (2%), three with lymphoplasmacytic lymphoma (2%) and one patient with follicular lymphoma (1%). Genotyping of polymorphism of the innate immune response genes TL2R (rs5743708), TL3R (rs3775291), TL6R (rs5743810), TL9R (rs5743836), IL1b (rs2856841), IL2 (rs2069762), IL4 (rs2243520), IL6 (rs1800795), IL10 (rs1800896), IL17A (rs775913), IL17F (rs34442450), TNFR2 (rs000496), FCGR2A (rs1801274) was performed by polymerase chain reaction with allele-specific primers (LifeTech, Russia). Analysis of interactions between genes was performed using nonparametric GMDR program (Generalized Multifactor-Dimensionality Reduction) [Liu X.Y. et al., 2007, http://www.healthsysvirginia.edu/internet/addiction-genomics/Software/]

Results: In the analyzed group of patients with CLD and MM identified almost 78 753 combinations of multi-locus genotypes of the 13 immune response genes is 1 594 323 theoretically possible, indicating the non-random nature of the combination of allelic variants of analyzed genes. A statistically significant two-, three-, four-, five-, six-, seven- and eight-loci model of inter-gene interactions at the investigated hematological malignancies: - IL4 (C-589T) and CD14 (C-159T) (χ²=8.39, p=0.0038); - IL4 (C-589T) and CD14 (C-159T) and IL6 (C-174G) (χ²=12.14, p=0.0005); - IL4 (C-589T) and IL17A (G-197A) and CD14 (C-159T) (χ²=17.30, p=0.0001); - IL4 (C-589T) and IL17A (G-197A) and TLR9 (C-1241T) and IL6 (C-174G) (χ²=16.88, p<0.0001); - IL4 (C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF-α (C-308A) and CD14 (C-159T) and IL2 (T-330G) (χ²=16.98, p<0.0001); - IL4 (C-589T) and IL17A (G-197A) and IL10 (C-819T) and TNF-α (C-308A) and TLR9 (T-1237C) and CD14 (C-159T) and IL2 (T-330G) and TLR9 (T-1237C) and CD14 (C-159T) and IL2 (T-330G) and IL1b (T-31C) and TLR9 (Ag753Gln) (χ²=16.88, p<0.0001).

Summary/Conclusions: The findings suggest an important role of immune response genes in the development of a number of chronic lymphoproliferative disorders and multiple myeloma, and can later be used as diagnostic and prognostic markers of different types of hematological malignancies. In addition, the research of genomics markers is a real tool not only for clarifying the pathogenesis of hematological malignancies, but also for determining their high and low risk of hematological malignancies studied, but also to determine their prognostic significance in the clinical course of these diseases.
Myeloma and other monoclonal gammopathies - Clinical

PB1948
Abstract withdrawn.

PB1949
IMPACT OF RENAL IMPAIRMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA IN A REAL WORLD SETTING
V. Bove1, F. Villano1, L. Díaz1, E. Riva1
1Hematología, Hospital de Clínicas, Montevideo, Uruguay

Background: Renal impairment (RI) is a frequent complication of patients with newly diagnosed multiple myeloma (NDMM), reported in 15-40% with 10% requiring hemodialysis (HD). It is associated with higher early mortality (EM) and lower overall survival (OS). Early diagnosis and treatment with new agents improve these results.

Aims: Analyze renal response, OS and EM in NDMM with RI and compare them to patients with MM without RI.

Methods: All consecutive and unselected NDMM patients treated at Hospital de Clínicas, Montevideo, Uruguay, from January 2011 to June 2015 were included. Our database was completed prospectively and included clinical and laboratory characteristics of the disease, treatment, treatment-related adverse events, response, HD requirement, renal response and mortality. Diagnosis of MM, response to treatment and degree of renal function recovery were based on the International Myeloma Working Group criteria. RI was defined as an estimated glomerular filtration rate (eGFR) <40 ml/min/1.73m², calculated by MDRD (Modification of Diet in Renal Disease) equation. Patients whose RI was explained by other causes were excluded. Early treatment was defined by initiation within 7 days after diagnosis. EM was defined as death within 3 months of diagnosis.

Results: MM was diagnosed in 52 patients, median age was 67 years (range 39-90), 61.5% were male, 38.5% had RI. The characteristics of the patients and front-line treatment are shown in Figure 1.

Overall response to first line treatment was 70% for those with RI (CR 20%) and 68.8% in patients without RI (CR 15.4%). Treatment related adverse effects were higher in patients with RI (45% vs 28.2%), being polyneuropathy the most common side effect. Patients with RI required more dose adjustments (40% vs 6.3%). Renal response: 50% reversed RI, 10% achieved renal PR and 40% renal CR, all before the 4th month from diagnosis; 77.8% started early treatment and 70% received bortezomib (bz). Patients whose RI did not reverse had had late initiation of treatment in 78% and 40% received bz. Six patients (30%) remained in chronic HD, all had late initiation of treatment. Two of the 6 patients who required HD at diagnosis obtained later independence; both received bz and one was consolidated with autologous stem cell transplantation. Impact of RI on OS and EM: median OS in patients with RI was not significantly different to that of MM without RI (35.3 vs 43.3 months, p=0.346). Patients without RI had higher OS compared to those who had reversible renal failure and those who never recovered (43.3 vs 40.9 and 12 months, respectively, p=0.031). OS was higher in patients with RI who received bz vs other therapeutic schemes (42.5 vs 25.8 months, p=0.137). With a mean follow-up of 26 months, mortality was 40% and 28.1% in patients with and without RI, respectively. EM were also higher in patients with RI at diagnosis (50% vs 22.5%). The main cause of EM was infection in both groups.

Summary/Conclusions: RI was frequent in NDMM and was associated with advanced disease and higher tumor mass (>90% stage III Durie-Salmon and ISS3), revealing a late diagnosis. Prompt institution of treatment and use of bz relates to higher recovery of renal function and dialysis independence. Although toxicity and dose adjustments were higher in patients with RI this was not associated with lower response to treatment. Reversal of renal failure associates with better OS, similar to those without RI at diagnosis. EM are more prevalent in patients with RI at diagnosis. Even when the number of patients is small, this real life data supports the need of planning local strategies that lead to early diagnosis and initiation of treatment, which are crucial to reduce morbidity and mortality associated to RI in NDMM.

PB1950
THE EXPRESSION OF THE TRYPThASE POSITIVE MAST CELLS AND THE LEVELS OF IL-17, CORRELATE WITH ANGIOGENIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA
M. Kokonozaki1, C. Papadaki2, R. Vyzoukaki1, A. Stavroulaki3,*, M. Devetzoglou4, A. Papadopoulou1, I. Liapis6, A. Bola1, M. Alexandakis5
1Laboratory of Haematology, University Hospital of Heraklion, 2Department of Internal Medicine, 3Department of Haematology, Venizelion Hospital, 4Department of Haematology, University Hospital of Heraklion, 5Medical School, University of Crete, Heraklion, Greece

Background: Angiogenesis in the bone marrow plays a very important role in the progression of multiple myeloma(MM). The procedure of angiogenesis is stimulated by several factors such as VEGF, FGF-2 and metalloproteinases that are secreted straight from the tumor cells. The presence of IL-6 in the microenvironment, induces the production and the secretion of several angiogenic factors that activate inflammatory cells of the matrix, like macrophages and mast cells to secrete more angiogenic factors. IL-17 is among the most important cytokines that have an important role in the development of myeloma tumor. IL-17 is a proinflammatory cytokine that is secreted primarily by CD4 (activated memory cells) and stimulate macrophages, fibroblasts and other cells that release several cytokines. It has been reported that IL-17, induces angiogenesis in humans by stimulating the migration of vessel endothelial cells and adjusting the production of various proangiogenic factors. In a previous study, it was found that increased levels in stage II and stage III, resolved after therapy. Additionally, blocking the receptor of IL-17, with an antibody, cancels the effects of IL-17.

Aims: Aim of this study is to assess the relationship of the MCD and IL-17, in angiogenesis of MM, as well as their correlation with known angiogenic factors in disease progression.

Methods: We studied 52 newly diagnosed patients with MM. 32 women and 20 men, aged 67±9.6 years. According to the ISS stage, 19 were stage I, 17 stage II and 16 stage III. Regarding the type of paraprotein that had been found, 31 IgG, 17 IgA and 4 patients with light chains. 20 age and sex-matched healthy volunteers, were used as controls. Serum samples and bone marrow biopsy samples were obtained from all patients prior to the initiation of treatment. Patients with impaired hepatic and renal function, chronic or acute infections, chronic inflammatory or autoimmune disorders or other malignancies were excluded from the study. We also excluded patients who were taking anti-inflammatory drugs, corticosteroids or bisphosphonates. IL-17, bFGF and ANGIO1-2 were measured in patients’ serum with ELISA method according to the manufacturer’s instructions. The MCD assessed after immunohistochemical staining using monoclonal antibody to mast cell tryptase. The MCD was measured in three hot spots (maximum vasculature area) x 100 and then we measured mast cells x 400, using a graduated slide which corresponds to an area of 0.0625 mm². MCD was calculated as mean MCD / HPF.

Results: Statistically significant differences between patients and controls were observed in all measured parameters, MCD (p<0.001), bFGF (p<0.01) and ANGIO1-2 (p<0.01). All parameters were increased in parallel with ISS stages (p<0.001) in all cases. Finally, the MCD and IL-17 correlated significantly with all the measured parameters (p<0.001).

Summary/Conclusions: The mast cells increase in the bone marrow(BM) of patients with MM. They release several transmitters that promote direct and indirect the development of various angiogenesis progression of MM also accompanied with increased angiogenesis in BM. In conclusion, mast cells and angiogenic factors seem to be important elements in the development of MM and become potential targets for the treatment and prognosis of the disease.

Figure 1. Characteristics of patients and overall survival according to renal function.

Overall response to first line treatment was 70% for those with RI (CR 20%) and 68.8% in patients without RI (CR 15.4%). Treatment related adverse effects were higher in patients with RI (45% vs 28.2%), being polyneuropathy the most common side effect. Patients with RI required more dose adjustments (40% vs 6.3%). Renal response: 50% reversed RI, 10% achieved renal PR and 40% renal CR, all before the 4th month from diagnosis; 77.8% started early treatment and 70% received bortezomib (bz). Patients whose RI did not reverse had had late initiation of treatment in 78% and 40% received bz. Six patients (30%) remained in chronic HD, all had late initiation of treatment. Two of the 6 patients who required HD at diagnosis obtained later independence; both received bz and one was consolidated with autologous stem cell transplantation. Impact of RI on OS and EM: median OS in patients with RI was not significantly different to that of MM without RI (35.3 vs 43.3 months, p=0.346). Patients without RI had higher OS compared to those who had reversible renal failure and those who never recovered (43.3 vs 40.9 and 12 months, respectively, p=0.031). OS was higher in patients with RI who received bz vs other therapeutic schemes (42.5 vs 25.8 months, p=0.137). With a mean follow-up of 26 months, mortality was 40% and 28.1% in patients with and without RI, respectively. EM were also higher in patients with RI at diagnosis (50% vs 22.5%). The main cause of EM was infection in both groups.

Summary/Conclusions: RI was frequent in NDMM and was associated with advanced disease and higher tumor mass (>90% stage III Durie-Salmon and ISS3), revealing a late diagnosis. Prompt institution of treatment and use of bz relates to higher recovery of renal function and dialysis independence. Although toxicity and dose adjustments were higher in patients with RI this was not associated with lower response to treatment. Reversal of renal failure associates with better OS, similar to those without RI at diagnosis. EM are more prevalent in patients with RI at diagnosis. Even when the number of patients is small, this real life data supports the need of planning local strategies that lead to early diagnosis and initiation of treatment, which are crucial to reduce morbidity and mortality associated to RI in NDMM.
PB1951

HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE US: FINDINGS FROM PREAMBLE

D. Kuter1, C. Chen2,*, S. Khare3, S. Perez4, T. Zyczynski2, C. Davis2, R. Vij5

1Massachusetts General Hospital, Boston, 2Bristol-Myers Squibb, Lawrenceville, United States, 3Mu Sigma, Kamataka, India, 4Mu Sigma, Northbrook, 5Washington University School of Medicine, St. Louis, United States

Background: Proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and treatments involving both a PI and an IMiD (PI+IMiD) are the principal therapies for treating relapsed/refractory multiple myeloma (RRMM). The widespread adoption of these treatments may come with high healthcare resource utilization (HCRU), of which key drivers are reported in past research. It is important to further understand HCRU by different treatment modalities in real-world practice settings.

Aims: To evaluate HCRU in patients receiving different treatment modalities for RRMM.

Methods: US patients with RRMM, aged ≥18 y, with at least one prior therapy who initiated treatment with a PI, IMiD or IMiD+PI within 90 d before or 30 d after study enrollment (index therapy), were identified from PREAMBLE, an ongoing, prospective, multinational, non-interventional observational study. Patient data collected at each healthcare provider (HCP) visit, over a 3-y period or until the end of patient follow-up, included clinic/physician office visits; home healthcare, hospital outpatient and emergency room visits; and hospitalizations. Demographics and baseline characteristics were summarized using descriptive statistics. HCRU and its associated costs were analyzed using a standard per-1000 patients-per-month metric.

Results: 287 patients (median age 66 y; 56% male) were enrolled in the US. At the time of data cut-off (Sep 2016), 136 (47%) were still in the study and 151 (53%) had withdrawn; 92 (61%) of those withdrawn had died. Median (range) follow-up was 12.7 (0.5–41.0) mo. At study entry, patients were divided into three cohorts based on index therapy: PI (n=162, 56%; carfilzomib n=82/162; bortezomib n=80/162), IMiD (n=74, 26%; pomalidomide n=32/74; lenalidomide/thalidomide n=42/74), and PI+IMiD (n=51, 18%; carfilzomib and/or pomalidomide n=17/51; other n=34/51). The three groups were similar with regard to sex, race, disease status, ISS stage, comorbidities and number of prior therapies (Table 1).

Table 1. Patient characteristics and risk stratification.

The median duration of treatment (mDoT) was longer for patients on IMiD (6.4 mo), but shorter for those on PI (4.2 mo) or PI+IMiD (4.4 mo). In the PI cohort, carfilzomib had a shorter mDoT than bortezomib (3.5 vs 4.7 mo). Of 3220 total HCP visits, the most common type was clinic/physician office (2732, 85%), followed by hospitalization (210, 7%) and hospital outpatient (54, 5%). Mean per-1000 patients-per-month total visits were higher for PI+IMiD (876) than for PI (750) and IMiD (494). This remained true for clinic/physician office, hospital outpatient and home healthcare/other. Patients on PI had more visits for management of MM treatment-related events (16%) than those on PI+IMiD (10%) or IMiD (7%) (Table 1). Notably, among patients on PI, those on carfilzomib had high mean per-1000 patients-per-month total visits (827), with per-1000 patients-per-month emergency room visits (18) and hospitalizations (78) higher than any other treatment; 19% (175) of visits were made for management of treatment-related events.

Summary/Conclusions: Routine management of MM and treatment-related events drive HCRU, which may differ by treatment. Hospitalizations and hospital outpatient visits remain key drivers of HCRU in MM, which highlights an unmet medical need for effective therapy with better safety profiles.

PB1952

ASSOCIATION OF SERUM HEAVY/LIGHT CHAIN PAIR SUPPRESSION WITH RISK FACTORS FOR PROGRESSION IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING MYELOMA

I. Isola1,*, M.T. Sanz2, M.T. Cibeira1, L. Rosioli3, E. Lozano1, J.I. Aróstegui3, M. Elena4, N. Tovar1, J. Yagüe3, E. Mogas2, J. Bladé1, C. Fernández de Larrañaga1

1Hematology (Amyloidosis and Myeloma Unit), Hospital Clinic de Barcelona, 2Immunology, Hospital de la Santa Creu i Sant Pau, 3Immunology (Amyloidosis and Myeloma Unit), 4Biochemistry (Amyloidosis and Myeloma Unit), Hospital Clinic de Barcelona, Barcelona, Spain

Background: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are conditions that usually precede symptomatic multiple myeloma (MM). Risk stratification is crucial, considering the heterogeneous progression rate among these patients and the chemoprevention trials encouraged for high risk individuals. A number of prognostic factors for progression have been identified. In this sense, the novel Hevlity assay now enables us to accurately measure each isotype-specific heavy and light chain (HLC). Recently, isotype-specific uninvolved HLC pair suppression was described as an independent predictor of progression to MM in patients with MGUS. The role of Hevlity as a prognostic factor in SMM is less investigated.

Aims: The aim of the present study was to analyze the impact of HLC pairs in a series of patients with high risk MGUS and SMM and their relationship with other previously described risk factors.

Methods: Forty-four patients diagnosed with high risk MGUS or SMM at a single institution from March 2014 through April 2016 were prospectively included in the present study. Patients were stratified according to the Mayo Clinic and the Spanish PETHEMA group models. Samples at diagnosis were tested for HLC concentrations for the three pairs (IgG, IgM and IgA) by immunonephelometry.

Results: The clinical characteristics and risk stratification of patients were summarized in Table 1.

Table 1. Patient characteristics and risk stratification.

An abnormal HLC-pair ratio was detected in 96% of MGUS and 94% of SMM patients, with no differences depending on the heavy chain isotype. A highly abnormal HLC ratio (<0.02 or >45) was present in 9 patients (1 with MGUS and 8 with SMM), HLC-pair suppression (i.e., Igκ-x in patients with Igκ-gammapathy) was more frequent in patients with SMM (83% vs 46%, p=0.02). Severe HLC-pair suppression (≥50% below lower level of normal) was present in 12 (27%) patients, the majority of which had a diagnosis of SMM (83%). Severe HLC-pair suppression was significantly associated with a highly abnormal (<0.125 or >8) serum free light chain (FLC) ratio (p=0.004), abnormal/normal bone marrow plasma cell ratio >0.95 (p<0.001) and immunoparesis (p=0.005), being present in 6 (66%) of the 7 patients with high risk SMM. Suppression of the other isotypes (i.e. IgA or IgM HLC pairs in a patient with IgG gammapathy) was identified in 33 (75%) patients, namely in 18 (69%) patients with MGUS and 15 (83%) patients with SMM (p=0.48), and was not significantly
associated with other risk factors for progression. Severe suppression (>50% below lower level of normal) was significantly more frequent in SM patients (33% vs 8%, p=0.04) and was associated with highly abnormal FLC ratio (p<0.001), abnormal/normaI plasma cell ratio >0.95 (p=0.001), severe HLC-pair suppression (p<0.001) and highly abnormal HLC ratio at diagnosis (p<0.005). The ‘evolving’ pattern of the serum M-protein was identified in 12 patients (28% vs 7, p<0.001) and it was significantly associated with either severe suppression of the HLC-pair or of the other isotypes. After a median follow-up of 18 months (range, 6-35) progression to symptomatic MM was observed in 3 patients. All 3 had a diagnosis of SMM with an “evolving” pattern, highly abnormal HLC-ratio and severe HLC-pair suppression.

Summary/Conclusions: The findings presented in this study indicate that highly abnormal HLC ratio, severe suppression of the HLC-matched pair, and other isotype HLC pairs are associated with known risk factors for disease progression in patients with high risk MGUS and SMM. The HLC assay could become a valuable tool in the risk stratification of these patients.

PB1953
EXTRAMEDULLARY MYELOMA IN THE “NOVEL AGENTS ERA”:
OUTCOME, HETEROGENEITIES AND PECULIARITIES OF A COHORT OF 84 PATIENTS RETROSPECTIVELY ANALYSED IN A MONOCENTRIC EXPERIENCE

L. Torti1,2, A. Morelli1, F. BaccP, P. Di Bartolomeo1
1Department of Hematology and Bone Marrow Unit, Pescara, 2Section of Hematopathology, Department of Hematology and Oncological Sciences, S. Orsola-Malpighi Hospital, Bologna, Italy

Background: Extramedullary disease is an uncommon manifestation in multiple myeloma (MM) and can either accompany newly diagnosed disease or develop with disease progression or relapse. Extramedullary myeloma (EMM) seems to have a different pathogenesis from its much more frequently encountered medullary counterpart, showing often a poor prognosis. EMM clinical situations are extraordinarily heterogeneous and their management is challenging. This includes organ or tissue involvement resulting from hematogenous-spread and/or bone involvement originating from different kind of bones. Aims: We evaluated the impact of this disease features on patients’ outcome in the context of novel-agents.

Methods: We reviewed patients presenting EMM (median age 60, range 30-76) describing clinical and biological features (Figure 1B). Our aim was studying the prognosis of bone-related extramedullary-disease (bEMD) and its relationship with soft-tissue related EMM (sEMD) in MM patients in our institution.

Results: 42 bEMD and 42 sEMD patients treated at Our Department between 2007 and 2016 were included in this study. Of the first group 10 presented EMM at diagnosis and 32 at relapse as well as 7 and 35 respectively of the second series. 31 among sEMD were dead and 11 were alive, 20 of bEMD patients were dead and 22 were still alive. EM was diagnosed using imaging techniques such as PET-CT (35%) or magnetic resonance MRI (65%). Biopsies showed the lesion was accessible (82%). The treatment was heterogeneous and all patients had received either thalidomide or bortezomib in the first-line of therapy. We showed that sEMD cohort has a significantly poorer survival compared to bEMD patients (median OS from diagnosis of EMM of 13 versus 58 months, P<0.001). Finally lung, liver (parenchymal) and skeletal involvement in sEMD patients has shown a poorer outcome when compared to skin and lymph nodes masses respectively median OS of 12 and 10 months versus 18 and 15 months P <0.001). Conversely among bEMD group there wasn’t a significant advantage of outcome regarding the different bones involved. Kaplan-Meier estimates were used for survival analysis and differences between survival-times in patient subgroups were tested using the log-rank test (Figure 1A).

Interestingly extramedullary-spread can be triggered by an invasive-procedures (surgery) or by a bone-fracture. In our population we have a case of breast-plasmodcytoma diagnosed accidentally after reconstructive breast-surgery; where Polymerase Chain Reaction of infiltrated breast tissue was positive, aggressiveness of the lesion was the high expression of integrins and CD56 is involved. In our population absence of CD56 protein was shown in 56% of sEMD group and in 15% of bEMD case-series. Aims: The findings presented in this study indicate that highly abnormal HLC ratio, severe suppression of the HLC-matched pair, and other isotype HLC pairs are associated with known risk factors for disease progression in patients with high risk MGUS and SMM. The HLC assay could become a valuable tool in the risk stratification of these patients. PB1954

DINAMIC PREDICTIVE FACTORS FOR A BETTER STRATIFICATION OF PATIENTS WITH R-ISS II NEWLY DIAGNOSED MULTIPLE MYELOMA

M. Offidani1,2, L. Corvatta1, L. Maracol1, K. Garvey1, S. Gentili1, S. More1, M. Mori1, P. Toni1
1Clinici di Ematologia AOU Ospedali Riuniti di Ancona, Ancona, Italy
2Background: Revised International Staging System (R-ISS), combining the ISS score with cytogenetics and serum LDH, represents the most recent prognostic model for stratifying newly diagnosed multiple myeloma patients into three different survival groups. Although data for R-ISS development have been obtained from patients enrolled in clinical trials, this prognostic score has been validated also in real-life scenario (Tandon et al., 2017). In both non-clinical trial setting and IMWG experience, the majority of patients (about 65%) belonged to the intermediate risk group (R-ISS II) that, probably, needs better prognostication.

Aims: The aim of this study was to search for a closer stratification of MM patients with R-ISS II, taking into consideration dynamic aspects, such as therapeutic strategy and response to therapy.

Methods: We investigated the impact of variables, such as initial therapy, response to therapy and maintenance therapy, on PFS and OS in 108 newly diagnosed MM patients classified as R-ISS stage II, diagnosed between 2005 and 2015, who received novel agents such as immunomodulatory drugs and proteasome inhibitors. Score weights of the prognostic factors, found to be significant according to Cox regression model, were determined based on the regression coefficients.

Results: Median age of the 108 patients was 69 years (range 44-93) and 35% of them were older than 75 years. Thalidomide- and lenalidomide-based regimens were administered to 12% and 28% of patients, respectively, whereas 60% of the patients received bortezomib (54%) or carfilzomib-based (6%) regimens as induction therapy. Thirty-eight percent of the study population underwent ASCT and 40% received maintenance therapy. Regarding the response to therapy, at least CR, VGPR and PR were documented in 35%, 66% and 87% of patients, respectively. Five-year PFS and OS were 31% and 65%, respectively, similar to those reported by IMWG. Patients who did not achieve a CR, showed a significantly shorter 5yr-PFS (27% vs 50%; HR=2.9, 95%CI=1.6-4.5; p<0.0001) and 5yr-OS (53% vs 80%; HR=2.8, 95%CI=1.3-5.9; p=0.006) compared to those who did. Moreover, a significant better 5yr-PFS and OS was found in patients receiving maintenance therapy, compared to those who did not receive maintenance therapy (48% vs 20%; HR=1.9, CI95%=1.2-3.3; p=0.010) whereas initial therapy did not affect the outcome. Assigning a value to the variables found to be significantly related to survival measures, according to the above methods, patients were stratified into the following two groups: low-risk (LR), including 38 patients with score 0-1, i.e. patients achieving CR and receiving maintenance therapy (score 0) or achieving CR but not receiving maintenance therapy (score 1); high-risk (HR) group, including 70 patients with score 2-3, i.e. not achieving CR, who underwent maintenance therapy (score 2) or not achieving CR and not receiving maintenance (score 3). Five-year PFS of HR-ISS patients was significantly shorter (median 7 vs 12 months, p<0.001) compared to those who did not receive maintenance therapy (48% vs 20%; HR=1.9, CI95%=1.2-3.3; p=0.010).
the outcome of those achieving a CR and undergoing long-term therapy, is comparable with the outcome of the R-ISS I group. On the other hand, patients not achieving CR have a poor outcome, similar to those in the R-ISS III group. Therefore, these patients should require personalized therapy, aimed to achieve CR and to maintain therapy continuously.

PB1955
THE IMPACT OF THE UPDATED IMWG DIAGNOSTIC CRITERIA IN A REAL-LIFE SMM COHORT: A SINGLE CENTER EXPERIENCE
V. Pl vụmmens1,2, F. Ofner1
1Hematology, Ghent University Hospital, Ghent, Belgium

Background: Recently, an update of the diagnostic criteria for smoldering multiple myeloma (SMM) & multiple myeloma (MM) was published by the Interna-
tional Myeloma Working Group (IMWG). In addition to CRAB criteria, 3 bio-
markers of disease were introduced being (i) the presence of >60% clonal bone marrow plasma cells (BMPC), (ii) a serum free light chain ratio (FLC-ratio) >100 & (iii) the presence of ≥1 focal lesion on whole-body MRI (WBMRI). The intro-
duction of these biomarkers has been shown to identify patients having a 70-80% risk of progression to MM over a 2-year time period.

Aims: To evaluate the impact of IMWG criteria in routine practice, focussing on (i) the prevalence of these biomarkers, (ii) the diagnostic strength of BMPC estim-
ates alone, respectively (FLC-ratio >100) and (iii) the added value of dynamic contrast-enhanced WB-MRI (DCEMRI) in the evaluation of SMM patients.

Methods: We retrospectively identified 28 SMM cases diagnosed between 01/01/09-31/12/14. Sufficient data for analysis was available for 25 patients. All patients underwent standard clinical & laboratory evaluation, bone marrow examination & WBMRI (T1- & T2-weighted sequences, diffusion-weighted sequences & dynamic contrast-enhanced sequences using time intensity curves). Time to progression (TTP) is defined as time from diagnosis until MM development. Overall survival (OS) is defined as time from diagnosis until death from any cause. Survival analysis was performed using a Kaplan-Meier method & significance was tested using the log-rank algorithm. Group analysis was performed using non-parametric rank-based analysis & correlation was calculated using the Pearson coefficient. Reported p-values are 2-sided with a signifi-
cance level of 5%.

Results: Median follow-up was 64.1 months (analysis performed on 01/02/2017). No patients had a FLC-ratio >100 at time of diagnosis. Also, no patients with >60% of clonal BMPCs were seen. In 20 patients BMPC counts using both aspirate & biopsy were available. Analysis showed a significant higher estimate of BMPC levels using biopsy (14.8%, SD 4.99) versus aspirate (8.45%, SD 6.59) (p=0.02). Sensitivity of bone marrow aspirate was calculated to be 30% consid-
ering the 10% BMPC cut-off. Correlation between bone marrow aspirate & biopsy was found in 26.6% of cases. WBMRI-positivity was seen in 9 patients (36%). Progression was seen in 7/9 patients (78%) where only 1/16 WBMRI-negative patients (6.3%) developed MM (p=0.001). Median TTP was 19.9 months versus not reached (p=0.001). Of 13 cases, 26% was seen in dynamic contrast-enhanced WBMRI (DCEMRI) in the evaluation of SMM patients.

No significant difference concerning progression risk was however seen between WBMRI- & biopsy positive patients being DCEMRI-positive (5/19, 26.3%) or -negative (4/19, 73.7%) (p=0.317). Median follow up for both groups was 48.6 months. DCEMRI- was positive in 14 patients (56%) thus identifying 5 additional WBMRI-negative patients with measurable bone marrow involvement. No significant difference concerning progression risk was however seen between WBMRI- & biopsy positive patients being DCEMRI-positive (5/19, 26.3%) or -negative (4/19, 73.7%) (p=0.317). Median follow up for both groups was 48.6 months. DCEMRI- was positive in 14 patients (56%) thus identifying 5 additional WBMRI-negative patients with measurable bone marrow involvement. No significant difference concerning progression risk was however seen between WBMRI- & biopsy positive patients being DCEMRI-positive (5/19, 26.3%) or -negative (4/19, 73.7%) (p=0.317). Median follow up for both groups was 48.6 months. DCEMRI- was positive in 14 patients (56%) thus identifying 5 additional WBMRI-negative patients with measurable bone marrow involvement. No significant difference concerning progression risk was however seen between WBMRI- & biopsy positive patients being DCEMRI-positive (5/19, 26.3%) or -negative (4/19, 73.7%) (p=0.317). Median follow up for both groups was 48.6 months. DCEMRI- was positive in 14 patients (56%) thus identifying 5 additional WBMRI-negative patients with measurable bone marrow involvement. No significant difference concerning progression risk was however seen between WBMRI- & biopsy positive patients being DCEMRI-positive (5/19, 26.3%) or -negative (4/19, 73.7%) (p=0.317). Median follow up for both groups was 48.6 months. DCEMRI- was positive in 14 patients (56%) thus identifying 5 additional WBMRI-negative patients with measurable bone marrow involvement.

Summary/Conclusions: Our data support the actual recommendation of antithrombotic prophylaxis in IMIDs-based regimens, especially in association with high dose of dexamethasone. We recommend the use of a risk factor model including obesity and previous history of thromboembolic disease or cancer, in order to guide the appropriate thromboprophylaxis measures.

PB1957
A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
P. Richardson1,2, M. Attali3, J. San Miguel4, F. Campana5, S. Le-Guenec6, A.-M. Huî6, M.-L. Rissee5, K. Anderson4
1Medical Oncology, Dana-Farber Cancer Institute, Boston, United States, 2Insti-
tut Univ. du Cancer Toulouse Oncopole, Toulouse, France, 3Clinica Universidad de Navarra, Navarra, Spain, 4Sanofi, Cambridge, United States, 5Sanofi, Vit-
y-Alfortville, France

Background: Treatment for refractory or relapsed and refractory multiple myelo-
a is challenging. Cell-free plasma cell neoplasms of Richter’s equivalent (CLL, FL) or derived from the extrapolation of data from many studies.

Aims: The aim of this study is to analyze the development of VTE in a large co-
hort of MM patients, treated for 25 years in a single institution, to assess risk factors suggested to be associated with VTE, derive measures, and confirm the role of other risk factors in the development of VTE.

Methods: Four hundred and one consecutive patients diagnosed with MM in a tertiary University Hospital between 1991 to 2015 were included. Data about VTE development, patient characteristics, myeloma-related factors, treatment, and thromboprophylactic measures were retrospectively recorded. Multivariable correlates of VTE were assessed using Cox proportional haz-
ards analysis.

Results: The median age at diagnosis was 68 years (range 24-90 years), and 47% were males. The results concerning treatment are extracted from 374 patients who were symptomatic when receiving myeloma treatment. Among the 164 patients that received IMIDs-based regimen, 27% did not receive any antithrombotic treatment, due to the lack of strong recommendations at the beginning of the use of IMIDs-based regimens. On the other hand, the most common thromboprophylaxis was set with LMWH (54%), followed by low doses of aspirin (13%) and anti-vitamin K (VKA) (8%). Median follow of the risk of VTE was 7 years (range, 1-293) and VTE occurred in 11% of patients, with a median time from diagnosis of 10 months. IMIDs based-regimen demonstrated to be a risk factor associated with higher estimate of VTE. Other factors that have also demonstrated to be independently associated with a higher risk for VTE were: BMI ≥30 kg/m², prior Stroke or TIA, prior malignant neoplasm, and the use of high dose of dexamethasone.

Summary/Conclusions: Our data support the actual recommendation of antithrombotic prophylaxis in IMIDs-based regimens, especially in association with high dose of dexamethasone. We recommend the use of a risk factor model including obesity and previous history of thromboembolic disease or cancer, in order to guide the appropriate thromboprophylaxis measures.
LONG TERM SURVIVAL OF IGM MULTIPLE MYELOMA AND WALDENSTRÖM’S MACROGLOBULINEMIA PATIENTS
M. Kraj1,2,3, R. Pogloś2, B. Krusk1, K. Warzocha2, M. Prochorec-Sobieszek1
1Department of Diagnostics for Hematology, 2Department of Transfusion Medicine, 3Department of Hematology, Institute of Hematology and Transfusion Medicine , Warsaw, Poland

Background: IgM multiple myeloma (MM) and Waldenström’s macroglobulinemia (WM) are two hematologic malignancies with the common finding of monoclonal gammopathy. IgM MM is a rare and poorly characterized disease.

Aims: The paper presents clinical and laboratory results of long term observation of 15 IgM MM patients selected from a group of 889 MM patients (1.6%) diagnosed and treated for several years at the Institute of Hematology and Transfusion Medicine in Warsaw as well as 15 WM patients investigated and treated at the same period of time at our hospital.

Methods: For analysis of serum proteins new Hevylite and Freelite tests (Binding Site Ltd Birmingham, UK) were applied as well as immunofixation using Sebia (Lisses, France) reagents. Fresh and archived frozen serum samples were used for the study.

Results: The clinical presentation of IgM MM patients is heterogenic starting with typical form for non IgM MM through predominant form with characteristic hyperviscosity syndrome and severe disease course to slow and latent form with survival time up to dozens of years. In 2 patients diagnosis of IgM MM was preceded by a 3-year period of monoclonal gammopathy of undetermined significance (MGUS) while in 4 patients (27%) diagnosis of WM was preceded by a 108, 84, 78, 9 months period of IgM MGUS. Median real overall survival of IgM MM patients was 50 months, 5 patients (33%) survived above 7 years and 13 patients (86.6%) above 12 years. Median survival of WM patients was 108 months, 7 patients (47%) survived above 10 years, 3 patients (20%) survived above 15 years. Lytic bone lesions were found in 11 (73%) IgM MM patients and in 3 (20%) WM patients. Urine monoclonal free light chains (FLC) detected by immunofixation was present in 60% of IgM MM patients and in 60% of WM patients. Serum monoclonal free light chains (SLC) and urinary FLC were concordant in all assessed IgM MM and WM patients. In IgM MM the suppression of uninvolved IgM was 15 months and in patients with normal polyclonal IgM 55 months (p<0.01).

Summary/Conclusions: 33% of IgM MM patients survive above 7 years and 13% above 12 years while 47% of WM patients survive above 10 years and 20% above 15 years. Suppression of uninvolved polyclonal IgM (detectable by using HLC test) at the time of IgM myeloma diagnosis is unfavorable prognostic factor.
These new agents, with their own specific safety and side effect profiles, are likely to add to the challenges already experienced by health care providers in their management of patients with MM.

PB1961

THE EXPRESSION OF APRIL BY MULTIPLE MYELOMA CELLS AND THEIR ROLE IN THE EVOLUTION OF MULTIPLE MYELOMA

A. Kekalo1, F. P. Kanellou2, R. Vyzoukaki3, M. Kokonozaki2, C. Pappa4, M. Devetzoglou2, A. Styridaki2, F. Psarakis3, M. Alexandrakis3
1Pathology, Venizelion Hospital, 2Blood bank, 3Laboratory of Haematology, University Hospital of Heraklion, 4Department of Internal Medicine, Venizelion Hospital, Deptartment of Haematology, University Hospital of Heraklion, 5Blood bank, Venizelion Hospital

Aims: The aim of this study was to study the role of APRIL expression in multiple myeloma cells and their bone marrow patients with MM and their possible association with cell proliferation markers.

Methods: We studied 42 newly diagnosed patients with MM, 19 women and 23 men, aged 64,14,10,4 years. According to the ISS stage, 14 were stage I, 11 stage II and 17 stage III. Regarding the type of paraprotein that had been found, 23 were lambda and 19 gamma with light chains. Serum samples from bone marrow biopsy samples were obtained from all patients prior to the initiation of treatment. Patients with impaired hepatic and renal function, chronic or acute infections, chronic inflammatory or autoimmune disorders or other malignancies were excluded from the study. We also excluded patients who were taking anti-inflammatory drugs, corticosteroids or bisphosphonates. 20 age and sex-matched healthy volunteers were used as controls. The levels of IL-6 and IL-10 in the serum were measured by ELIZA. Bone marrow infiltration by neoplastic plasma cells was calculated in%. The expression of cell proliferation index was calculated in BM biopsy sections with immunohistochemical techniques. The expression of APRIL was also calculated with immunohistochemistry. For the control of the process we used positive control. The assessment of the staining was checked in the optical microscope, over the whole surface of each sample and had to do with the cytoplasm of tumor cells. It was dotted with brown ting. Non-specific staining was observed at the other cellular components of BM. The degree of staining was evaluated as the percentage of neoplastic plasma cells and according to the intensity of staining in four-grade scale 0: negative, +1 weak, +2 moderate and +3 intense staining. Then the proportion of plasma cells stained for each type of staining separately was calculated using the H-score method (Histoscore), based on the formula:% *% * 1+2+3% *. Our aim is to prove if the intensity of expression is associated with disease stage.

Results: Statistically significant differences were observed between patients and controls for all parameters measured (p<0.001 in all cases). All values of the measured parameters increased in parallel with the ISS stages of the disease. BM infiltration was 0.00 <0.001, Ki-67 p<0.01, IL-10 <0.001, IL-6, p<0.001. Eventually APRIL correlated significantly with all measured parameters e.g. BM infiltration r=0.386, p<0.01, with Ki-67 r=0.390 p<0.01 IL-10 r=0.497 p<0.001, IL-6, r=0.484 p<0.001.

Summary/Conclusions: Increased expression of APRIL ligand plays an important role in development and pathology of MM and may be an important therapeutic target in the treatment of MM.

PB1962

DEVELOPMENT OF SECOND PRIMARY MALIGNANCY AFTER TREATMENT WITH LENALIDOMIDE: A SINGLE CENTRE EXPERIENCE

F. McPlin1, E. Groarke1, S.W. Maung1, R. Desmond1, J. McHugh1, H. Enright1
1Haematology, Tallaght Hospital, Dublin 24, Ireland

Methods: A database of patients (n=137) treated with lenalidomide in the specified timeframe was created from pharmacy records. A search of the hospital’s patient management system was performed to identify: (1) type and date of primary haematological diagnosis, and (2) type and date of second malignancy based on histology. An analysis of the data was performed to establish: (1) incidence of SPM, (2) latency between primary haematological malignancy and SPM, (3) latency between starting lenalidomide and SPM, (4) types and subtypes of SPM.

Results: The majority of patients were treated for Multiple Myeloma (67%). Other primary haematological malignancies included myelodysplastic syndrome(MDS), Non-Hodgkin Inphoma(NHL), and Idiopathic myelofibrosis(IMF). The incidence of SPM post-treatment with lenalidomide for multiple myeloma and IMN was 2%>10% over a 25 year period [5]. This study demonstrates a higher incidence (12%), however it includes patients treated for other primary haematological malignancies. This data demonstrates a similar incidence of SPM to previous studies (8%) post-treatment with lenalidomide [1 - 3]. Haematological malignancy was the commonest SPM however this differs from other studies which showed a higher incidence of solid tumours (29%) [6]. We found t-MDS/AML and skin malignancy to be the most significant SPMs. This is in agreement with some published reports [4, 5]. No analysis was made of patient specific risks or disease specific risks. This data supports the conclusion that the risk of SPM must be considered before commencing a patient on lenalidomide therapy.

References

PB1963

SOLITARY PLASMACYTOMA. A SINGLE-CENTRE RETROSPECTIVE STUDY

K. Velazquez Kennedy1, C. Martinez-Gejo Román1, M.J. Blanchard1, F.J. López Jiménez1
1Haematology, Hospital Ramón y Cajal, Madrid, Spain

Background: A solitary plasmacytoma (SP) is a rare neoplastic mass of monoclonal plasma cells that can either be localized in bone (solitary plasmacytoma of bone, SPB), or soft tissue (extramedullary plasmacytoma, EMP), without evidence of multiple myeloma (MM). The median age at diagnosis is 65 years. Some patients present a monoclonal band (MB) at diagnosis, and a proportion progresses to MM. The low incidence of this entity has prevented reaching definite conclusions with regards to prognostic factors and treatment.

Aims: In this study we retrospectively analysed the clinical presentation, treatment and outcome of all patients with SP treated in our centre in order to establish relevant prognostic clinical features and management options.

Methods: Between 1985 and 2016, 27 patients with SP (20 SPB, 7 EMP) were treated in Ramon y Cajal Hospital (Madrid), with a median follow up of 8 years. The time to relapse, progression to MM or death was measured in months. The progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The comparison of PFS and OS was made using the Log Rank test. Student’s t test was used to compare the average expression at diagnosis. To determine the association between the presence of MB or the subtype of SP, and progression to MM, we used Fischer’s exact test. All statistical analysis was performed with the software SPSS 24.0.

Results: The average age at diagnosis was 56 years (range 18-81) for SPB, and 72 ±5 for EMP (p=0.05), with a male:female ratio of 2.4:1. The most frequent location was the axial skeleton (80%) for SPB, and the airway in the case of EMP (57%). In most cases, the initial symptom of SPB had been pain...
Risk groups were defined based on the overall score. To provide optimal patient care, each OS predictor were multiplied to obtain an overall score for each patient. At the start of 2L were identified using Cox regression analyses. Hazard ratios for overall survival (OS) from the time of 2L were initiated. Predictors of OS from the 2L, and previous treatment outcomes to stratify patients based on their risk of death at initiation of 2L; treatment with bortezomib or lenalidomide provided similar outcomes independent of risk group. Use of our RSA at 2L would support physician decision making to improve patient specific care.

PB1964

RISK STRATIFICATION ALGORITHM USING REAL-WORLD DATA FROM PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: DESCRIPTION OF CLINICAL OUTCOME BY TREATMENT REGIMEN

R. Hajek1,*, M. Delforge2, M. Raab3, J. Radocha4, J. Straub5, W. Bouwmeester6, Z. Szabo1, L. Pour6, S. Gonzalez-McQuire1, V. Maisnar6

1Department of Haematology, University of Ostrava, Ostrava, Czech Republic, 2Department of Hematology, UZ Leuven, Leuven, Belgium, 3Department of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany, 4Department of Medicine, Charles University Hospital and Faculty of Medicine, Hradec Kralove, 5Departments of Internal Medicine and Hematology, Prague General Teaching Hospital, Prague, Czech Republic, 6Pharmerit International, Rotterdam, Netherlands, 7Amgen (Europe) GmbH, Zug, Switzerland, 8Department of Internal Medicine, University Hospital Brno and Faculty of Medicine, Brno, Czech Republic

Background: Estimation of survival for patients with RRMM, requires prognostic tools that define the relative risk of death after first relapse. We recently developed a risk stratification algorithm (RSA) using real-world data from the Czech Registry of Monoclonal Gammopathies (RMG). Our RSA uses patient and disease characteristics at diagnosis and at initiation of second-line treatment (2L), and previous treatment outcomes to stratify patients based on their overall survival (OS) expectations from initiation of 2L treatment (Hajek et al. Blood 2016). The value of such an algorithm depends on its validation but also on understanding the evidence that explains these differences in survival expectations.

Aims: To describe 2L treatment patterns by RSA group and to report OS, progression-free survival (PFS) and response by treatment received in 2L per RSA risk group.

Methods: Data were collected from the Czech RMG for patients aged ≥18 years who were diagnosed with symptomatic MM between May 2007 and April 2016 and in whom 2L treatment had been initiated. Predictors of OS from the start of 2L were identified using Cox regression analyses. Hazard ratios for each OS predictor were multiplied to obtain an overall score for each patient. Risk groups were defined based on the overall score. To provide optimal patient stratification, cut-offs of the score were estimated using K-adaptive partitioning for survival (KAPS) analysis.

Results: Data from 1418 patients were analysed. KAPS analysis defined four groups based on risk of death: low (LR; score ≤ 4.1; n=403), intermediate-low (ILR; score 4.2–10.3; n=635), intermediate-high (IHR; score 10.4–20.1; n=237) and high (HR; score ≥20.2; n=143) risk. Median OS (months) was 57, 29, 13 and 5 for the LR, ILR, IHR and HR groups, respectively. Following stratification, compared with patients in the lower risk groups, a higher proportion of those in the HR group had LDH levels above 360 U/L and an Eastern Cooperative Group Performance Status of ≥ 4 at initiation of 2L. Treatments received at 2L were similar across all risk groups, with bortezomib and lenalidomide being the most common 2L treatments. Patients who received bortezomib at 1L were often given lenalidomide or thalidomide at 2L and those who received thalidomide at 1L were frequently given bortezomib at 2L. This suggests that 2L treatment choice was not defined by the underlying risk of death for each patient, but rather by the type of previous treatment. For patients receiving lenalidomide at 2L, median OS (months) from start of 2L was 57, 29, 13 and 6 (Figure 1), and median PFS (months) was 18, 12, 8 and 3 in the LR, ILR, IHR and HR groups, respectively. A very good partial response or better (VGPR+) was reported for 29.3%, 31.0%, 18.7% and 16.9% of patients in the LR, ILR, IHR and HR groups, respectively. For patients receiving lenalidomide at 2L, median OS (months) was 48, 29, 14 and 5, and median PFS (months) was 20, 12, 10 and 3 for patients in the LR, ILR, IHR and HR groups, respectively. A VGPR+ was reported for 33.6%, 22.9%, 26.0% and 7.1% of patients in the LR, ILR, IHR and HR groups, respectively.

PB1965

LACK OF CD56 EXPRESSION IN MULTIPLE MYELOMA PATIENTS WITH RISS 2 DISEASE IS ASSOCIATED WITH WORSE PROGNOSIS AND ABOLISHED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION

M. Skerget1,*, B. Skopeč1, H. Podgornik1, D. Zontar1, K. Rebersek1, T. Furlan1, P. Cermelj1

1Department of Hematology, University Clinical Center Ljubljana, Ljubljana, Slovenia

Background: Multiple myeloma (MM) is a hematologic disease in which accumulation of malignant plasma cells and high levels of monoclonal protein and free light chains lead to bone marrow failure, hypercalcemia, lytic bone lesions and renal failure. Myeloma cells are distinguished from normal plasma cells by an aberrant immunophenotype. They express CD56, which is present in 70–80% and can be used to distinguish myeloma cells by flow cytometry. The expression of CD56 is constant throughout the course of the disease. The lack of CD56 expression in myeloma cells decreases the adherence of myeloma cells to the cell matrix and is associated with higher levels of bone marrow infiltration and peripheral blood involvement, higher incidence of extramedullary disease, renal insufficiency, Bence Jones protein, plasma cell leukemia and t(11;14). The lack of CD117 expression is associated with higher levels of bone marrow infiltration, renal impairment, elevated β2-microglobulin and cytogenetic...
aberrations including t(11;14), t(4;14) and del(13q). CD28 expression is present in 15 – 45% of patients and is associated with unfavorably cytogenetic changes including t(4;14) and del(17p) and shorter PFS and OS despite aHCT.

Aims: Aim of our retrospective study was to evaluate the impact of CD56, CD117 and CD28 expression on clinical characteristics and PFS in newly diagnosed MM patients treated with bortezomib based induction therapy.

Methods: We retrospectively analyzed 110 newly diagnosed MM patients from our national registry that had data available at the time of diagnosis. Immunophenotype was determined using a panel consisting of CD19/CD38/CD45/CD56/CD138 to distinguish and to enumerate MM cells. Monoclonal antibodies directed against CD20, CD28, and CD117 were used additionally. All samples were routinely tested for the presence of recurrent chromosomal aberrations, i.e. del 1p, amp1q, del6q, amp15q, del13, del17, t(4;14), t(14;16) and t(11;14) using commercially available DNA probes.

Results: We found no association between CD56 expression and age, gender, elevated LDH or RISS stage. We found a strong association between lack of CD56 expression and light-chain only or asymmetric myeloma. There was an association between CD28 expression and female gender (Table 1). In multivariate analysis including age, elevated creatinine, RISS, aHSCT , CD28, CD56 and CD117 expression, CD56 expression was associated with a 47% reduced hazard for progression (Exp(B)=0.527, p=0.03). Other factors with statistically significant impact on progression were aHSCT and age. In patients not undergoing aHSCT lacking CD56 expression in comparison to those with an aberrant CD56 expression, the difference in PFS was statistically significant with a PFS of 8 vs 18 Month (Log Rank p=0.088, Breslow p=0.046). When stratified according to RISS stage, only patients in stage 2 disease had a significant reduction in PFS with lack of CD56 expression.

Summary/Conclusions: CD56 expression was a prognostic for PFS only in the patient cohort not undergoing aHCT. As previously reported CD28 seems to aggravate the negative impact of CD56 negativity. We propose CD56 expression to be used as a prognostic marker in patients with RISS stage 2 disease and to be possible these patients should undergo aHCT.

PB1966 AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA IN GERMANY – REAL-WORLD DATA FROM A NATIONWIDE, MULT-INSTITUTIONAL SURVEY IN 2015-2016

M. Merz1, L. Kellermann2, W. Poenisch3, U. Mahlknecht4, S. Fries5, H. Goldschmidt6

1Klinik für Innere Medizin V, Universitätssklinikum Heidelberg, Heidelberg, 2OnkologinformationsService, Freiburg, 3Universitätsklinikum Leipzig, Leipzig, 4Innere Medizin Hämatologie und Internistische Onkologie, Kplus-Gruppe GmbH – St. Lukas Klinik, Solingen, 5Onkologische Schwerpunktpraxis, Barnberg, 6Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, Germany

Background: A nationwide, multi-institutional survey was performed in 2015 and 2016 to analyse routine practice for myeloma patients outside clinical trials in Germany.

Aims: We aimed to investigate implementation of autologous stem cell transplantation (ASCT) into treatment of patients with newly diagnosed or relapsed/multiple myeloma (MM) in Germany.

Methods: The analysis is based on a database built from university hospitals (UH), community hospitals (CH), office-based hematologists (OBH). Anonymized data were collected online based on retrospective chart review. The goals of this study were to evaluate the emergency department visits not related to MM care and by online personal checks. We investigated which institutions initiated treatment in patients with ASCT, which were the characteristics for patients not-considered eligible for transplantation, how stem cell mobilization was performed, how many patients dropped out before planned transplantation and what were the frequencies of tandem ASCT and ASCT for relapsed disease.

Results: Data from 515 patients from 51 centres were available for the first half of 2015 and from 867 patients from 52 centres for the first half of 2016. There were 40% (2015) and 32% (2016) pts considered as eligible for ASCT in 1st line. Although the proportion of patients older than 69 years was not significantly different between health care providers in 2015 and 2016 (2015: 47%UH, 60%CH, 49%OBP / 2016: 54%UH, 56% CH, 47%OHP), patients were considered more often transplant-eligible in UH (2015: 49% / 2016: 53%) than in CH (2015: 29% / 2016: 21%) or OBH (2015: 45% / 2016: 28%). In first-line treatment, 52% of patients eligible for SCT received mobilization chemotherapy in addition to induction therapy. More than 80% of patients were mobilized with a cyclophosphamide-based chemotherapy in combination with G-CSF for stem cell mobilization in 2015 and 2016. Most participating institutions aimed at collection of three sufficient stem cell transplants (2015: 48% / 2016: 46%). Once patients completed stem cell mobilization, 92% continued to high-dose chemotherapy and 92% of them received ASCT. A large number of patients were treated with tandem ASCT in 1st line. In 2015, 8% of patients and 1% of patients in 2016 were considered eligible and were ultimately treated with ASCT for relapsed disease. The most frequent reason for transplant-eligible patients not receiving ASCT were withdrawal of patients consent (first-line: 15%, second-line: 39%).

Summary/Conclusions: With our current analysis of a nationwide survey performed with different health care providers in Germany we demonstrate that implementation of ASCT is strongly influenced by the institution initiating primary therapy. Age does not seem to impact usage of ASCT compared to concomitant disease or patients’ and doctors’ preferences. Patients patients require collect three autologous transplants, enabling a possible tandem ASCT and ASCT for relapsed disease.
PB1968
EFFECTIVENESS AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE FROM TURKEY
G. Saydam1, N. Soyer1, P. Patir1, A. Uysal1, M. Duran1, R. Durusoy2, F. Sahin1, F. Vural1, M. Tobu1, M. Tombuloglu1
1Hematology, Ege University Internal Medicine, Bornova, 2Public Helath, Ege University Medical School, 3Hematology, Ege University Hospital Internal Medicine, Izmir, Turkey

Background: Lenalidomide, an immunomodulatory drug, was approved for treatment of relapse/refractory multiple myeloma (RR-MM). In Turkey, we have used the combination of lenalidomide and dexamethasone (RD) for RR-MM patients after 2010. Therefore, we analyzed efficacy and safety of RD in Turkish patients with RR-MM.

Aims: We aimed to evaluate the outcome and the tolerability of the RD in patients with RR-MM who had been treated under the standard clinical practice between October 2010 and June 2016.

Methods: This is a retrospective, single center study. Patients’ clinical and laboratory data were collected from patient files. The overall and progression free survival (OS and PFS) were estimated using the Kaplan–Meier method.

Results: A hundred and twenty patients (71 male and 49 female) enrolled in the study. The median age at the start of RD was 64 years (29-84) and the median number of previous line of treatment was 1 (1-4). Seventy-two patients (60%) received RD as second-line therapy and 51 patients (42.5%) treated with autologous stem cell transplantation (ASCT). With regard to the initial dose of lenalidomide, 82 (68.3%) of the patients received the recommended dose of 25 mg per day for 21 days in a cycle of 28 days. Objective response (≥PR) was observed in 87 patients (72.5%); 23 patients (19.2%) achieved CR. The median follow-up was 14 months (range, 1–72 months), and the median DOR was 19 months (range, 12.4-25.6 months). Median OS and PFS were 32 months (95% CI, 15.8-48.1 months) and 21 months (95% CI, 15.8-26.1 months), respectively. In the multivariate analysis, the independent prognostic factors for OS and PFS were treated with previous ASCT, patients who achieved at least PR, patients receiving RD for more than 12 cycles. Adverse events occurred in 69 of patients (57.5%). Hematological and non-hematological adverse events were found at the same rate (n=47, 39.2%). The treatment discontinued due to AE was 11.7% (14 patients). The overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 0.93 (95% CI, 0.04-4.60). The rate of anaemia was 12.5% and thrombocytopenia was 9.2% in all grades. Penemania (15.8%), fatigue (14.2%) and herps infections (0.8%) have been reported as most frequent non-hematological side effects.

Summary/Conclusions: RD is a safe, well tolerated and effective treatment in patients with RR-MM. Good response, previous ASCT and using more than 12 cycles are associated with better survival. Higher OS and PFS and ORR seems to be related to using RD in the first relapse. Adverse events are manageable and lower with prophylaxis.

PB1969
OPTIMIZING THE MANAGEMENT OF NON-HEMATOLOGICAL ADVERSE EFFECTS RELATED TO LENALIDOMIDE IN RELAPSED MULTIPLE MYELOMA PATIENTS. ONE CENTER EXPERIENCE
M. Moya-Arnao1, M. V. Cabanas-Prienera1, M. J. Moreno Belmontes1, M. Berganzo1, C. Martinez Marin1, E. Ferrero-Kaplan–Meier methods, Log–rank test was used to evaluate the variables affecting OS and PFS (univariate analysis). Cox proportional hazards regression was used for multivariate analysis to analyze the independent variables affecting PFS and OS.

Results: One-hundred and twenty patients (71 male and 49 female) enrolled in the study. The median age at the start of RD was 64 years (29-84) and the median number of previous line of treatment was 1 (1-4). Seventy-two patients (60%) received RD as second-line therapy and 51 patients (42.5%) treated with autologous stem cell transplantation (ASCT). With regard to the initial dose of lenalidomide, 82 (68.3%) of the patients received the recommended dose of 25 mg per day for 21 days in a cycle of 28 days. Objective response (≥PR) was observed in 87 patients (72.5%); 23 patients (19.2%) achieved CR. The median follow-up was 14 months (range, 1–72 months), and the median DOR was 19 months (range, 12.4-25.6 months). Median OS and PFS were 32 months (95% CI, 15.8-48.1 months) and 21 months (95% CI, 15.8-26.1 months), respectively. In the multivariate analysis, the independent prognostic factors for OS and PFS were treated with previous ASCT, patients who achieved at least PR, patients receiving RD for more than 12 cycles. Adverse events occurred in 69 of patients (57.5%). Hematological and non-hematological adverse events were found at the same rate (n=47, 39.2%). The treatment discontinued due to AE was 11.7% (14 patients). The overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 0.93 (95% CI, 0.04-4.60). The rate of anaemia was 12.5% and thrombocytopenia was 9.2% in all grades. Penemania (15.8%), fatigue (14.2%) and herps infections (0.8%) have been reported as most frequent non-hematological side effects.

Summary/Conclusions: RD is a safe, well tolerated and effective treatment in patients with RR-MM. Good response, previous ASCT and using more than 12 cycles are associated with better survival. Higher OS and PFS and ORR seems to be related to using RD in the first relapse. Adverse events are manageable and lower with prophylaxis.

PB1970
PROLONGED THROMBOPROPHYLAXIS IN PATIENTS TREATED WITH LENALIDOMIDE AND DEXAMETHASONE DOES NOT SEEM STRICTLY MANDATORY TO PREVENT LATE THROMBOTIC EVENTS
C.S. Cartia1,2, S. Mangiacavalli3, V.V. Ferretti1, F. Cocito1, M. Ganzetti1, E. Fugazza1, B. Landini1, M. Catalano1, M. Cazzola1, A. Corso1
1Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

Background: The aim of this study was to evaluate the risk factors for venous thromboembolism (VTE) in patients treated with Lenalidomide plus Dexamethasone (LD) using the population-based population. The study was conducted in a single, tertiary-care center in Italy.

Methods: The primary endpoint was the occurrence of a late VTE, defined as an event that occurred more than 30 days after the last dose of Lenalidomide and/or Dexamethasone. The secondary endpoints were the occurrence of a VTE in the first 30 days and the proportion of patients who received at least 6 months of prophylaxis.

Results: A total of 103 patients (pts) treated with LD were included in the analysis. The median age was 66 years (range 55-80), the median time from diagnosis to lenalidomide starting was 33.3 months (range 0.3-159.9 months), and the median duration of Lenalidomide treatment was 4.6 months (range 0.4-65.2 months) with the following response: ≥PR 56%, CR 7%. Table 1 shows type and distribution of risk factors and the occurrence of a late VTE.

Methods: We retrospectively reviewed a consecutive cohort of patients with RRMM receiving Rd (R: 25 mg on days 1 through 21; d: 40 mg on days 1, 8, 15, and 22) in 28-day cycles until progression or unacceptable adverse effects, from 2011-2016. All patients received thromboprophylaxis with low-molecular-weight heparin (LMWH) (Enoxaparin 40 mg subcutaneous daily) the first 4 cycles; thereafter, patients were switched to aspirin 100 mg in a day prophylaxis. Enoxaparin 7500 anti-Xa IU once-daily dose was employed if enoxaparin was suspended. Clonazepam dose to treat dystonia was 0.5 mg twice daily. Data were analyzed with SPSS statistical v 22.0.

Results: Between 2011 and 2016 a total of 65 patients received Rd in our center. Baseline characteristics are shown in Table 1. Patients received a median of 2 previous regimens (range 1-6). 51.5% of the patients had undergone one previous autologous stem-cell transplantaion (ASCT). Rash occurring in 12.3% of patients (grade 2), all of them were concurrently receiving enoxaparin. All rashes resolved switching the enoxaparin to bemiparin, maintaining same dose of lenalidomide. Neither treatment with esteroids or antihistaminic were administrated. Dystonias were reported in 23.1% of patients (grade 2), all of them disapperated after treatment with clonazepam without lenalidomide dose reduction.

Table 1.

Summary/Conclusions: Rash and dystonias are frequent adverse effects of immunomodulatory drugs (IMiDs), particularly lenalidomide, often leading to treatment discontinuation and decreasing the potential benefits to patients. According to our data, the rash could be due to synergism between enoxaparin and lenalidomide. In most cases, switch LMWH letting not to reduce lenalidomide dose in order to optimize the benefit of the treatment. Clonazepam, a benzodiazepine, is useful to treat dystonias related to lenalidomide.
0.4-6 months). No hemorrhagic events were observed during LMWH. Cumulative incidence of VTE was 11.7% (12/103 pts), similar to that previously reported in the literature in patients with continuous TP. The median time of patients developing or VTE occurrence was 12.2 months (range 1-88.2 months), with only one patient developing early VTE among our group. In detail we observed 10 deep vein thrombosis (83%), 1 pulmonary embolism (8.5%), 1 myocardial infarction (8.5%). Most of patients developing VTE had good disease control (≥PR 83%, ≥TP 10 pts). Concomitant adverse events (AE) was registered in 41.1% of pts (5/12). Most common concomitant AE were infections of respiratory tract (3 pts) and gastrointestinal AE (2 pts). The median number of risk factors for VTE in patients developing or not thrombosis was similar (2.5 vs 2, p=0.092).

Table 1. Baseline distribution of risk factors for thrombosis in the population on study.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;65</td>
<td>60%</td>
</tr>
<tr>
<td>Age &gt;65</td>
<td>40%</td>
</tr>
<tr>
<td>Female</td>
<td>20%</td>
</tr>
<tr>
<td>Male</td>
<td>80%</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>15%</td>
</tr>
<tr>
<td>Heart failure</td>
<td>10%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This study shows that LMWH is effective and well tolerated for early VTE prophylaxis during Lenalidomide plus low dose Dexamethasone. Incidence of late VTE without TP maintenance is similar to that reported with long-term antiplatelet therapy. We found no difference in factors predisposing for thrombosis among patients developing or not VTE, with a non negligible proportion of concomitant adverse events observed nearby VTE occurrence.

PB1971
ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE REAL WORLD
1Clinical Laboratory Department, Yokohama City University Hospital, 2Department of Hematology and clinical Immunology, Yokohama City University School of Medicine, 3Department of Hematology, Saiseikai Yokohama Nanbu Hospital, 4Department of Hematology, Yokohama City University Medical Center, 5Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, 6Department of Hematology, Fujisawa City Hospital, Fujisawa, 7Department of Hematology / Oncology, Yamato Municipal Hospital, Yamato, 8Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, 9Department of Hematology, Yokosuka City Hospital, Yokosuka, 10Department of Hematology, Yokohama City University School of Medicine, Yokohama, Japan

Background: Many new agents for multiple myeloma (MM) were launched during the last decade, and the clinical trial using such new agents showed promising results for MM patients. However, clinical course of elderly patients with newly diagnosed MM (NDMM) in the real world is different from the results of clinical trial.

Aims: We examined the clinical parameter to assess survival in elderly patients with NDMM in clinical practice.

Methods: We performed a retrospective study involving 125 elderly NDMM patients from April 2012 to September 2015. Patients aged 60 years or older, who were ineligible for autologous stem cell transplantation, were selected. The study included 57 males and 68 females, with median age at diagnosis of 74 years (range 60-95 years). ECOG performance status at diagnosis were 0-1, 67; 2-4, 28. We collected pretreatment parameter at diagnosis as follows; monoclonal protein type (IgG/60; IgA:32; IgD:1; B.J.P:38; non-secretory:2), light chain (kappa: 72; lambda: 52; unknown 1), hemoglobin level (mean 8.9 g/dL [range 5.8-15.2]), estimated glomerular filtration rate (eGFR) (mean 49.3 mL/min [range 3.6-114.2]), calcium level (mean 10.0 mg/dL [range 8.7-20.2]), albumin level (mean 3.4 g/dL [range 1.0-5.0]), beta-2-microglobulin (mean 5.1 mg/L [range 1.6-51.5]), involved/uninvolved serum free-light chain (FLC) ratio (mean 143.8 [1.83-21133]), cytogenetic abnormalities by using fluorescence in situ hybridization (FISH) [none, 53; t(4;14), 7; del(17p), 14; t(4;14) & del(17p), 5; t(4;14) & t(14;16) & del(17p), 1].

Results: Of 125 patients, 76 patients received bortezomib based therapy (VMP: 49; VD: 21; VCD, 6), 6 patients received lenalidomide based therapy (Ld, 6). 10 patients were received MP therapy, 19 patients received dexamethasone therapy (high dose, 16; low dose, 3), 1 patient received radiation therapy as first line therapy, and 13 patients received only supportive care due to their fragility. After induction therapy, the overall response rate (at least partial response, PR) was 52.7% (stringent complete response (sCR) 0.3%, CR 4.5%, very good PR 16.1%, PR 29.5%). Overall survival (OS) was 74.5% at 1 year, 66.2% at 2 years with median follow-up of 19 months (range 1-52) for patients who were still alive at the date of last contact and 14 months (range 1-52) for entire cohort. Death occurred in 41 patients during the follow-up period. International staging system (ISS), with ISS1, 19; ISS2, 42; ISS3, 60; N/A, 4, can divide elderly patients into three distinct survival groups (P<0.001) (Figure 1A). Univariate and multivariate analysis showed a lower OS was associated with eGFR lower than 40 ml/min (HR 2.279, 95%CI 1.152-4.510) (Figure 1B) and serum calcium level greater than 11 mg/dL (HR 3.036, 95%CI 1.412-6.529) (Figure 1C). Among 80 patients with FISH data, survival of those with t(4;14) or del(17p) or t(14;16) was not statistically different (P=0.394). Survival of patients treated with bortezomib or lenalidomide as an induction therapy was better, while not statistically significant (P=0.066) than those who were not.

Figure 1.

Summary/Conclusions: This study shows that LMWH is effective and well tolerated for early VTE prophylaxis during Lenalidomide plus low dose Dexamethasone. We recognised increase of the number of the yearly diagnosed patients with myeloma 2.48% of patients the actual date of diagnosis was before 2011 but 3.56% of patients the date of diagnosis was before 2011 and 3.56% of patients starting the right treatment. The patients were categorised according to age, gender, ISS stage, R-ISS stage, first line therapy and response. We recognised increase of the number of the yearly diagnosed patients with myeloma 2.48% of patients the actual date of diagnosis was before 2011 but the actual date of diagnosis was before 2011 and 3.56% of patients starting the right treatment. The patients were categorised according to age, gender, ISS stage, R-ISS stage, first line therapy and response.

PB1972
RETROSPECTIVE ANALYSIS OF 121 MULTIPLE MYELOMA PATIENTS USING THE R-ISS PROGNOSTIC STAGING SYSTEM AND RESPONSE TO FIRST LINE OF TREATMENT
R. Ghonema1, S. AlShemmari1, R. Pandita2, M. Hasanean1, M. Al-Drees1
1Hematology, Kuwait cancer control centre, Kuwait, Kuwait

Background: The International Myeloma Working Group has developed the R-ISS (Revised International Staging System) as a simple and powerful prognostic staging system. We collected the LDH level and the cytogenetics of a group of patients and studied the difference between the ISS (International Staging System) and the R-ISS (Revised International Staging System) for those patients.

Aims: To evaluate and compare between the ISS and the R-ISS for a group of patients treated in Kuwait Cancer Control Centre.

Methods: A retrospective analysis of the data collected from 121 patients registered as multiple myeloma from 2011 to 2015. Of the patients presented to our centre after initial work up and starting the right treatment. The patients were categorised according to age, gender, ISS stage, R-ISS stage, first line therapy and response.

Results: Of the 121 patients, 2.4% of patients the actual date of diagnosis was before 2011 but 3.56% of patients starting the right treatment. The patients were categorised according to age, gender, ISS stage, R-ISS stage, first line therapy and response.

haematologica | 2017; 102(s2) | 785
even both. First line treatment 55% of the patients received Bortezomib based triple therapy 22% received CT (Cylophosphamide, Thalidomide, Dexamethasone), 7% RD (Lenalidomide, Dexamethasone), 3% CyBord (Cylophosphamide, Bortezomib, Dexamethasone), 3% RV (Lenalidomide, Bortezomib), 2% Thal-Dex (Thalidomide, Dexamethasone), 2% RT (Local Radiotherapy), 2% Watchful Wait, 1% MP (Melphalan, Prednisone) and 3% for treatment and lost follow up.

Table 1.

<table>
<thead>
<tr>
<th>BSS stage</th>
<th>% of patients</th>
<th>BSS stage</th>
<th>% of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1</td>
<td>34%</td>
<td>Stage II</td>
<td>35%</td>
</tr>
<tr>
<td>Stage III</td>
<td>47%</td>
<td>Stage IV</td>
<td>36%</td>
</tr>
<tr>
<td>MGUS</td>
<td>2%</td>
<td>MGUS</td>
<td>2%</td>
</tr>
<tr>
<td>Unknown</td>
<td>4%</td>
<td>Unknown</td>
<td>4%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Applying the RISS system to myeloma patients is a significant and easy method to categorise myeloma patients, a significant number of patients in Kuwait are diagnosed as stage III, with median age of 56 years although the use of novel therapies shows excellent response to most of them.

PB1973

FEASIBILITY/PHASE II STUDY OF MYELOABLATIVE BEAM ALLOGENIC TRANSPLANTATION FOLLOWED BY ORAL IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH HIGH RISK MYELOMA

E. Scott1,*, R. Maziarz1, S. Dreumont1, C. Gasparetto2
1Hematology and Oncology, Oregon Health and Science University, Portland
2Hematology and Oncology, Duke University, Durham, United States

Background: While the role of allo-HCT in MM remains controversial several studies have shown encouraging PFS and OS with this treatment even in patients with high-risk myeloma (HRM). HRM manifests with early relapses and refractoriness. Median OS is 2.5 years despite aggressive therapy with novel agents. Post auto-HCT maintenance with lenalidomide is considered standard of care, but post allo-HCT maintenance presents unique challenges and has not been well studied. Ixazomib (Ixa) is a new oral proteasome inhibitor with good oral bioavailability, is active in refractory resistant patients, and is a promising agent in the maintenance setting.

Aims: Here we present preliminary results for this trial. The primary objective is safety defined as day 100 transplant related mortality (TRM), and safety of Ixa maintenance (incidence of grade III-IV GVHD and Ixa related toxicity). Other objectives include determination of efficacy (ORR, PFS, MRD for CR), the ability to start Ixa, and quality of life.

Methods: The protocol was approved by a local institutional review board and ethics committee. The study was conducted in accordance with the Declaration of Helsinki. All subjects provided written informed consent prior to treatment. Eligibility criteria include: age ≤65; relapsed MM previously treated with autologous HCT; bortezomib and an immunomodulatory agent (IMiD); at least one high-risk criterion: deletion (del)17p, t(4;14), t(14;16), (14;20), (13q), or t(14;16), 13q deletion by conventional karyotyping, hypodiploidy, high-risk GEP, B2M >5.5mg/l, plasmablastic morphology (>2%). At study entry 2 subjects were in VGPR, and 4 in PR. Three subjects received 8/8 HLA matched MUD, and 3 received sibling donor HCT. GVHD prophylaxis with tacrolimus and methotrexate was given in 3 subjects with the addition of methylprednisone in 3 subjects. Both subjects started Ixa (at day 139 and 128) and remained on therapy for 198 days and 59 days respectively; both discontinued for disease progression. Three subjects remain on study, and have not started Ixa. At day 100 post HCT, 4 of 6 subjects were evaluable for response. All had a deepening of response; 3 VGP, 1 CR. One subject died from BEAM-allo related complications; namely acute stage 4 GVHD (skin and gut), and disseminated adenovirus infection (day 29). Grade 3/4 adverse events include: febrile neutropenia(3); colitis(3); diarrea(3); infection(4); staph bacteriemia(2); E.coli bacteriemia(1); adenovirus viremia(1); neutropenia(4); thrombocytopenia(4); acute GVHD(1). Ixa related toxicities include grade 3 neutropenia(2), thrombocytopenia(1), pneumonia(1), nausea and vomiting(1).

Summary/Conclusions: Although this is very early data, it is the first clinical trial to report the use of BEAM conditioning followed by Ixa maintenance for relapsed HRM. Thus far stopping rules have not been met, with expected toxicities occurring.

PB1974

EPIDEMIOLOGY OF MULTIPLE MYELOMA. THE GRANADA MYELOMA REGISTRY

R. Rios Tamayo1,*, D. Sánchez-Rodríguez2, J. Sainz Pérez3, J.J. Jimenez Meleno4, M. Sánchez Pérez5, M. Jurado Chacón6
1Hematology, University Hospital Virgen de las Nieves, 2Hematology, FIBAO, 3Hematology, GENYO, 4Medicine Preventive, University of Granada, 5Cancer Registry, Andalusian School of Public Health, Granada, Spain

Background: The Granada Myeloma Registry is the second largest single-institution population-based registry (Ríos-Tamayo et al, 2015) of multiple myeloma (MM) referenced to date. Here we update and point out the epidemiological variables of interest.

Aims: To highlight the importance of the epidemiological perspective in the knowledge and outcome of MM.

Methods: From January 1985 to February 2017 all consecutive patients diagnosed with MM at our institution have been registered, including clinical, biological and socio-demographic variables, as previously reported. A comprehensive approach to comorbidity was recorded as well as diagnostic and treatment delay. Overall survival (OS) was estimated by the Kaplan-Meier method.

Results: 700 patients have been included in the registry, 343 men (49%) and 357 women. All cases have their place of residence in the Granada province. The median age was 67 years (range: 12-93). The race was Caucasian in 98.9%. In relation to occupation, 18.4% were skilled or elementary agricultural workers. Only 9% had a previously documented precursor disease (solitary plasmacytoma, monoclonal gammopathy of undetermined significance , or smoldering MM), and 14 patients (2%) remain alive with smoldering MM without progression. The subtype of MM is IgG 55.6%, IgA 24.8%, Light Chain Only 15.9%, Non-secretory 3%, IgD 0.8% and IgM 0.2%. The International Staging System was known in 378 patients (19.9%), 1 (25.7%), and 3 (48.4%). Baseline performance status (ECOG) was: 0 (4.7%), 1 (41.1%), 2 (26.7%), 3 (21.7%), and 4 (5.9%). Comorbidity was assessed in 498 patients: 30.6% of patients were obese at the moment of diagnosis. 8.2% had other previously known or synchronous neoplasm. 150 patients (30.1%) had three or more comorbidities. Median diagnostic delay was 4.1 months (0.1-80) and median treatment delay was 13 days. 44 patients (6.3%) were very unfit and they did not receive active treatment. Information about stem cell transplant is available in 606 cases: 151 of them (24.9%) received a first autologous transplant. Median OS for the whole cohort was 43.1 and 22.4 months for patients younger than 65 years or 65 years or older, respectively (p=0.001). For patients diagnosed in 2010 or later, median OS is not reached for younger than 65 and 40.4 months for the elderly (p=0.001). Information about the main cause of death is available in 230 patients: 101 (43.9%) of them died by infection.

Summary/Conclusions: MM is a very heterogeneous disease from a clinical, biological and epidemiological perspective. The distribution by sex is identical. Farmer is the most frequent occupation. Almost one in three patients are obese, and one in ten had another prior or associated neoplasm. Infection is the leading cause of death. Information derived from population-based registries may help to complement data from clinical trials.

PB1975

REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA

M. Ziff1,*, S. Cheessman1, C. Kyriakou1, A. Mehta1, X. Papanikolaou1, N. Rabin1, R. Popat1
1University College London Hospitals NHS Foundation Trust, London, United Kingdom

Background: Ixazomib (Ixa) is a novel oral proteasome inhibitor (PI) approved in combination with lenalidomide and dexamethasone (IRD) for the treatment of relapsed/refractory multiple myeloma (MM). This was based on the TOUR-MALINE-MM1 trial which demonstrated a progression free survival benefit over HD. However real world use often differs to clinical trials due to heterogeneous patient selection, more flexibility with dosing intensity and country specific prescribing practices/funding restrictions.

Objectives: We characterise real world use of IRD by demographics, response rate (RR) and progression free survival.

Methods: This was a retrospective review of patients sequentially treated with IRD at a large UK Haematology Centre. Patients received Ixa 4mg D1, 8, 15 with lenalidomide (dose as per label) days 1-21 and dexamethasone 40mg weekly or as tolerated every 28 days until disease progression or intolerance. In some cases, Ixa was added later to RD. RR and PFS were assessed according to IMW criteria and haematological toxicities graded by CTCAE 4.0 criteria.

Results: Up to 31 th October 2016, 30 patients were treated with the IRD schedule. Median age was 65 years (32-75), male (57%), ISS: stage I 18 (60%), stage II 4 (13%), stage III 8 (27%). 2 Patients had a median of 2 (2-5) prior lines of therapy. All patients had previous treatment with a proteasome inhibitor (PI) (29 bortezomib, 5 carfilzomib) and 8 (27%) were refractory to a PI. 3 (10%) had prior lenalidomide and all remained sensitive. 23 (77%) had a prior autol...
re-escalated back onto dexamethasone and alkylator (IV/oral) based regimes of 2nd and 3rd line IMiD therapy that these salvage regimes are highly effective.

Summary/Conclusions: This real world dataset highlights differences in patients treated in routine practice to trials. No patients were treated at first relapse due to funding restrictions, whereas most in the trial were. Patients had up to 5 prior lines, all had prior PI exposure and a higher proportion were PI refractory (33% vs 2%) which correlated with a worse outcome. Nevertheless the overall efficacy of our study (ORR 70.8%; median PFS 19.23 months) was comparable to the TOURMALINE-MM1 trial which had an ORR of 78.3% and median PFS of 20.6 months in the Ixa group.

PB1976

EFFICACY AND TOLERABILITY OF LENolidOIDE AND POMALIDoMIDE IN RELAPSED/REFRACTORY MYELOMA PATIENTS IN A REAL WORLD STUDY

G. Adams1, M. Collins1, C. Kyriakou1, R. Ayto1
1Haematology, Northwick Park Hospital, London, United Kingdom

Background: New agents have revolutionised the treatment of multiple myeloma. Immunomodulatory drugs (IMiD) such as lenalidomide and pomalidomide are effective in relapsed refractory multiple myeloma (RRMM) with successful salvage, contributing to the observed long duration of local therapy compared to national averages. Pomalidomide was highly effective at prolonging PFS. All continued to maintain their response. The median duration on treatment was 15 months. (Local-cohort). Lenalidomide-treatment was well tolerated with 5 (20.8%) patients experiencing grade 3-4 neutropenia and thrombocytopenia and 1 patient experiencing grade 4 anaemia. This resulted in Ixa dose reductions in 16 (16.7%) patients. Ixa was stopped in 1 patient due to adverse events.

Results: We collected data on 46 patients treated between 2011-2014 with lenalidomide, 17 whom progressed to receive pomalidomide. The median age at initial diagnosis was 67 years, with median age at starting lenalidomide 77 years (range 36-94). This gave an average of 5 years from diagnosis to commenced lenalidomide (range 1-15 years). Myeloma subtypes included IgG 28/46, IgA 2/46, IgA / IgG 1/46, light chain disease 4/46 and 3 with IgD and non-secretory myeloma. High risk cytogenetics [17p+, (4;16), t(14;20), hypodiploidy, chromosome 1 abnormalities] were identified in 9/46 and 16/46 were high-risk based on biomarker staging (ISS). All patients had at least 1 preceding line of therapy before starting lenalidomide, average 2 lines (range 1-6). Prior treatment included alkylating agents/steroid duplets, thalidomide combinations, bortezomib-based therapy and autograft. National average for the% of patients reaching cycle 26 was 16% compared to 31% in our cohort. The median number of cycles in those who progressed to pomalidomide was 12.8 (n=17), which is double that of the national average reported in seminal trials. These patients had few treatment breaks and treatment was well tolerated (pomalidomide duplets or triplets).

Summary/Conclusions: We conclude from this real-world retrospective review of 2nd and 3rd line IMiD therapy that these salvage regimens are highly effective. Patients on lenalidomide monotherapy post triplet/duplet induction were often re-escalated back onto dexamethasone and alkylator (IV/oral) based regimens with successful salvage, contributing to the observed long duration of local therapy compared to national averages. Pomalidomide was highly effective at rescuing patients failing lenalidomide-based regimens and well tolerated.

PB1977

APPLICATION OF CONDITIONING REGIMEN WITH BUSULFAN AND CYCLOPHOSPHAMIDE IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

Y. Xu1, C. Fu1, Z. Yu2, W. Yao2, S. Jin2, L. Yan2, J. Zhang2, X. Zhu2, A. Sun2, D. Wu1
1Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 2The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China

Background: Busulfan is the most commonly used drug in conditioning regimens for hematopoietic stem cell transplantation: and high-dose melphalan (MEP) is the standard conditioning regimen in autologous stem cell transplantation (ASCT) for multiple myeloma. Studies have shown that in ASCT for multiple myeloma, conditioning regimens containing busulfan is effective as HD.

Aims: Evaluate the safety and efficacy of BUCY (busulfan and cyclophosphamide) conditioning regimen for autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM).

Methods: We retrospectively analyzed the clinical data of 72 MM patients who received transplantation in the Hematology Department of the First People’s Hospital of Soochow University from May 2012 to June 2015. Among them, 36 patients underwent BUCY regimen while the others received high dose melphalan. Those were compared between the two groups including the complication rates, hematopoietic reconstitution and the post-transplantation efficacy.

Results: There were no significant differences in age, stage, induction therapy, mobilization method between the two groups. The transplantation-related adverse events were similar in both groups but the incidence of pulmonary infections and bloodstream infection were slightly higher in BUCY group. The median time to neutrophil engraftment in the BUCY and HDM groups were 10(8-17) days versus 10(9-13) days, taking the same time on average (P=0.046). On the other hand, the median time to platelet engraftment was 10(8-18) versus 11(9-47) days accordingly (P=0.017). The TRM in both group was 2.7%. The SGR/CR rates after ASCT (47.2% and 50.0%) were higher than those before it (38.9% and 26.6%), in both groups. In the BUCY group, the median follow-up was 12.5 (0-26) months. Six patients (16.7%) underwent disease progression. The 2-year progression-free survival (PFS) rate was 68%. Correspondingly, in the HDM group, the median follow-up time was 23 (0-38) months. Fifteen patients (41.7%) developed disease progression and the 2-year PFS rate was 55%.

Summary/Conclusions: The BUCY regimen is a safe and effective therapy for ASCT in patients with multiple myeloma. Besides, BUCY regimen is not inferior to HDM regimen. In conclusion, BUCY regimen may replace HDM regimen as a standard conditioning regimen for ASCT in multiple myeloma.

PB1978

MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT, 12 CASES AND REVIEW OF THE LITERATURE

G. Varga1, M. Mikala2, L. Ogoscza3, Z. Csukly1, P. Reményi1, G. Szombath1, Z. Oroszi1, V. H. Andrikková1, M. D. Balogh2, B. Timár1
1Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 2Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, 4Heart and Vascular Center, Division of Diagnostic Imaging, 51st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

Background: Central nervous system (CNS) propagation is a rare event in multiple myeloma (MM), but may become more prevalent as newer treatment options allow patients to have a prolonged life expectancy and with this comes the selection of increasingly aggressive clones.

Aims: We reviewed 12 MM cases with CNS involvement treated in two hospitals. Methods: Statistical analyses were performed using the SPSS (version 20.0) software package.

Results: Between 2008 and 2015 twelve MM patient developed CNS involvement which presented in all cases at relapse. The median age at diagnosis and at CNS presentation were 55.5 and 57.4 years. At first presentation nine had ISS 3, one ISS 2 and two ISS 1 stage disease, two patient presented original plasma cell leukaemia. FISH showed 1q amplification in 4, 13q deletion in 4, 10(9-13)days, taking the same time on average (P=0.046). On the other hand, the median time to platelet engraftment was 10(8-18) versus 11(9-47) days accordingly (P=0.017). The TRM in both group was 2.7%. The SGR/CR rates after ASCT (47.2% and 50.0%) were higher than those before it (38.9% and 26.6%), in both groups. In the BUCY group, the median follow-up was 12.5 (0-26) months. Six patients (16.7%) underwent disease progression. The 2-year progression-free survival (PFS) rate was 68%. Correspondingly, in the HDM group, the median follow-up time was 23 (0-38) months. Fifteen patients (41.7%) developed disease progression and the 2-year PFS rate was 55%.

Summary/Conclusions: The BUCY regimen is a safe and effective therapy for ASCT in patients with multiple myeloma. Besides, BUCY regimen is not inferior to HDM regimen. In conclusion, BUCY regimen may replace HDM regimen as a standard conditioning regimen for ASCT in multiple myeloma.

Results:

Between 2008 and 2015 twelve MM patient developed CNS involvement which presented in all cases at relapse. The median age at diagnosis and at CNS presentation were 55.5 and 57.4 years. At first presentation nine had ISS 3, one ISS 2 and two ISS 1 stage disease, two patient presented original plasma cell leukaemia. FISH showed 1q amplification in 4, 13q deletion in 4, 10(9-13)days, taking the same time on average (P=0.046). On the other hand, the median time to platelet engraftment was 10(8-18) versus 11(9-47) days accordingly (P=0.017). The TRM in both group was 2.7%. The SGR/CR rates after ASCT (47.2% and 50.0%) were higher than those before it (38.9% and 26.6%), in both groups. In the BUCY group, the median follow-up was 12.5 (0-26) months. Six patients (16.7%) underwent disease progression. The 2-year progression-free survival (PFS) rate was 68%. Correspondingly, in the HDM group, the median follow-up time was 23 (0-38) months. Fifteen patients (41.7%) developed disease progression and the 2-year PFS rate was 55%.

Summary/Conclusions: The BUCY regimen is a safe and effective therapy for ASCT in patients with multiple myeloma. Besides, BUCY regimen is not inferior to HDM regimen. In conclusion, BUCY regimen may replace HDM regimen as a standard conditioning regimen for ASCT in multiple myeloma.
progression was 23.9 (3-65) months. Eight patients presented with cerebral nerve palsies, 2 with paraplegia, 1 with headaches, and 1 with headache. CSF cytospin or flow cytometry was positive in 7, MRI or CT supported the diagnosis in 4 patients. Treatment consisted of combination chemotherapy, intrathecal chemotherapy, cranio-caudal radiotherapy and imids with various success. The PFS and OS from CNS progression was 63 and 125 days. Two patients survived for over a year (427 and 776 days), both responded in terms of CNS symptoms to imid-based combination therapy and one had cranio-caudal radiotherapy (Figure 1).

Summary/Conclusions: CNS progression in MM has a particularly poor prognosis as it represents a late stage of an aggressive relapse which often shows chemo-refractoriness. The differential diagnosis includes infection, autoimmune or vascular diseases of the CNS as well as paraneoplasia and drug toxicity. The CNS penetration of the effective myeloma drugs is poor except for the imids, and drugs with CNS availability are usually not very effective in refractory MM.

PB1979 DARATUMUMAB: CHALLENGES OF INTEGRATING THIS NEW THERAPY INTO STANDARD CARE L. Little1,2, R. Powles1 1Haemato-Oncology, Cancer Centre London, Parkside, London, United Kingdom  Background: Daratumumab (Darzalex) is the first anti-CD38 human Monoclonal Antibody approved for Multiple Myeloma (MM). Targeting the CD38 antigen on the surface of MM cells it causes apoptosis, and has an immune modulated tumour lysis effect. Success in Clinical trials meant that this drug, administered as single agent, or in combination with other novel therapies (Lenalidomide or Bortezomib), received accelerated FDA Approval in the US. It is now being introduced into standard hospital care.  Aims: Daratumumab presents unique challenges to the delivery of risk managed care, due to effects on some blood and bone marrow testing, and to the Infusion Related Reactions (IRRs) seen at the outset of treatment. This poster will highlight important aspects of the treatment pathway for this new therapy, from a single centre perspective.  Methods: We outline the pathways integrated at MDT level; patient characteristics and adverse event profiles of the 15 myeloma patients we have treated with Daratumumab, in a standard service setting.  Results: Daratumumab affects certain pathology tests so samples should be clearly identified. Relevant laboratory teams need to be aware of the methods used to process samples. Daratumumab binds to CD38 on Red Blood Cells, and therefore with Cross Match Compatibility testing and Antibody Screening. Obtaining RBC Products for patients receiving Darra will take longer, requiring up to 48 hours’ notice. Cross match samples taken prior to treatment provide the National Blood Service Laboratory with a baseline antigen profile to aid selection of suitable blood products. Dara is detected during Paraprotein Electrophoresis; and therefore with Cross Match Compatibility testing and Antibody Screening. Daratumumab affects Immunophenotyping by masking the CD38 epitope used to identify plasma cells by flow cytometry; special kits are available using a different CD38 epitope thus dealing with this issue. Infusion Related Reactions (IRRs) have been reported in over half of patients receiving Daratumumab. 95% of these were seen at the first dose. Typically involving the upper respiratory tract and include rhinitis, cough, wheeze, bronchospasm, laryngospasm and chest pain. More rarely they include rash, fever, and nausea. Reactions can be grade 1-4 so it’s important that the patient is closely monitored where there is quick access to specialist staff, resuscitation equipment and respiratory support in a high dependency setting. Staff training is important and patients need to be aware that they report all new symptoms so the infusion is interrupted immediately and the IRRS treated and re-started at a lower rate when the symptoms have resolved. Premedication is given one hour prior to infusion and patients with a history of COPD receive extra support. Patient characteristics. Total: 15. (Table 1).  Table 1  | Age  | Gender | Number of prior treatments | Regimens | Disease outcomes  |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Range/Hr</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27-33</td>
<td>Male: 8</td>
<td>5</td>
<td>Single-agent Dara</td>
<td></td>
</tr>
<tr>
<td>31-11</td>
<td>Female: 4</td>
<td>3</td>
<td>Dara with Lenalidomide</td>
<td></td>
</tr>
<tr>
<td>26-56</td>
<td></td>
<td></td>
<td>Dara with Bortezomib</td>
<td></td>
</tr>
<tr>
<td>24-54</td>
<td>Mean: 45</td>
<td>2-4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary/Conclusions: Education, to include Blood Transfusion, Protein and Histopathology laboratory, and High Dependency Unit staff, in the key aspects of monitoring and risk management are an important part of integrating this new therapy to the treatment pathway for myeloma patients. Daratumumab is likely to become an important treatment for improving both Outcomes and Quality of Life for Myeloma patients going forward.

PB1980 MULTIPLE MYELOMA IN HIV+ PATIENTS LITERATURE REVIEW AND OWN CASE A. Leighton1,2,*, A. Pivnik1, M. Tumanova1, G. Dudina1, E. Sergeeva1 1Oncohematology, MKNC, 2Internal Medicine, RUDN, Moscow, Russian Federation  Background: Multiple myeloma (MM) and HIV infection in AIDS stage until now its considered not to be associated. Recently new ideas appear in the literature such as influence of HAART on the treatment outcomes of MM in HIV negative patients.  Aims: To find literature sources on multiple myeloma in HIV positive patients and elucidate the problem of this association. evaluate the impact of HAART in multiple myeloma.  Methods: Patients were retrospectively identified out of 39 cases of MM and HIV from Pubmed/Medline from 1983 to 2017, and own case reported.  Results: Patients with MM and HIV infection did not differ significantly from the MM in HIV-negative with respect to age, gender, stages and renal function. Effects of HAART on levels of serum M-protein HAART itself has been reported to decrease M-protein in an HIV+ patient with MM. We determined whether HAART alone, in the absence of MM treatment, had any effects on the level of serum M-protein in HIV+MM patients. Depending on the interval between the discovery of the HIV infection HAART treatment initiation, and the diagnosis of MM and initiation of its treatment. The overall and progression-free survival of HIV+MM patients on HAART appeared to be superior to that of HIV-negative MM patients. The survival of the HIV+ MM patients were also superior to that of non-HIV-MY patients reported in the literature. The majority of HIV+ MM patients who had long-term follow-up in our study did not show clinical symptoms of MM and were free of serum-M protein after primary MM therapy in the presence or absence of HAART and maintained treatment with HAART alone. Although MM is not an AIDS-defining illness, meta-analyses of large population studies reveal an increased risk of MM in HIV/AIDS patients. HIV infection is commonly associated with B cell hyperproliferation, as indicated by polyclonal hyperglibulinemia and the development of various autoantibodies. This is presumed to be usually due to these CD4 deficient patients’ inability to control Epstein-Barr virus infections, which immortalize B cells. This may help to explain the increased incidence of MM in HIV+ patients. However, HIV cannot infect B lymphocytes or plasma cells, nor drive their malignant transformation. Some authors are going to state that treatment of multiple myeloma in HIV seronegative patients with HAART in combination with chemotherapy (Geling Lia and co-authors, Leukemia Research, 2014). A 38-year-old Russian male presented at the Moscow clinical Center in 2015 with pronounced ossalgya and inability to move. Total protein 135 g/l with 81.7 g/l of IgG-k M-protein and no presence of Bence Jones protein. Bone skeletal survey showed multiple generalized lytic lesions. Bone marrow aspirate and biopsy showed 46% plasma cells. Serum creatinine – 104 mmol/l. HIV and hepatitis C (genotype 1a) screening test were positive, confirmed with Western blot analysis. The CD4 count was 290 cells, HIV viral load 37 copies/ml, hepatitis C viral load 14.2 million copies. He was started on HAART, combined with chemotherapy 5 courses of CDP+CVP+MP and 7 V-MP. In 2017 total serum protein– 97.3 g/l, M-protein 31.2 g/l, serum creatinine 63.0 mmol/l. Now he is active with no bone pain receives Pegasus and lamivudine (Table 1).  Summary/Conclusions: Patients with MM and HIV infection did not differ significantly from the MM in HIV-negative with respect to age, gender, stages and renal function, and treatment with addition of HAART.Recently was reported that HAART itself may reduce and even remove m-gradient in HIV positive
patients. It is considered to include HAART in HIV negative patients with MM. The problem of MM and HIV/AIDS association remains unclear and needs to be elucidated.

Table 1.

PB1981

OPTIMIZATION OF APPROACHES FOR STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA: PRACTICAL CONSIDERATIONS

O.-L. Lee1,2

1Haematology, Royal Adelaide Hospital, 2Haematology, SA Pathology, Adelaide, Australia

Background: Autologous stem cell transplant (ASCT) is a well-established treatment for myeloma. However, the optimal strategy for stem cell mobilization remains undefined. The goal of mobilization is to collect adequate stem cells for at least 2 ASCT (4x10^6/kg), with the minimum apheresis sessions and toxicities such as febrile neutropenia.

Aims: We aim to compare stem cell mobilization using granulocyte colony stem cell factor (GCSF) only (steady state), high dose cyclophosphamide (4 g/m2) with GCSF or low dose cyclophosphamide (2 g/m2) with GCSF.

Methods: We performed a retrospective analysis of 79 patients mobilized with GCSF only from mid-2014 to Aug 2016 with 32 patients mobilized using high dose cyclophosphamide and 23 patients with low dose cyclophosphamide during a similar period.

Results: Patients undergoing steady state collection required a median of 2 days for adequate collection, in comparison to 1 day for both high and low dose cyclophosphamide. Addition of plerixafor was required in 27.8% of patients on steady state collection, in contrast to 3.1% and 15% of patients on high and low dose cyclophosphamide respectively. The mean yield of CD34+ x 10^6/kg cells collected was 53.9, 9.14 and 8.5 for steady state, high and low dose. There was no significant difference in time to engraftment despite a lower dose of CD34+ cells infused for the steady state cohort. Admission for febrile episodes was observed in 50% of patients mobilized with high dose cyclophosphamide, as compared to 13% of patients on the lower dose regime and none in the steady state cohort. Patients mobilized with cyclophosphamide had a longer interval between stem cell collection and transplant (median of 20, 42 and 34 days respectively for steady state, high dose and low dose). However, we observed that 60.7% patients with steady state mobilization had increases in their myeloma markers during this period, in contrast to biochemical improvement in 50% of patients mobilized with high dose cyclophosphamide and 26% with low dose cyclophosphamide.

Summary/Conclusions: All 3 strategies for stem cell mobilization have their own merit. Steady state mobilization is safe and yields sufficient stem cells; however, patients require more apheresis sessions. Moreover, more than a quarter require additional therapy with plerixafor. Of concern, greater than half of these patients have increased myeloma markers during the interval between stem cell mobilization and mobilization which may potentially affect outcomes. Mobilization with high dose cyclophosphamide yield more CD34+ cells but with increased toxicities- 50% of patients required admission for febrile episodes. Conversely, half of these patients had improvement in their myeloma markers. The use of low dose cyclophosphamide for mobilization resulted in lower admission rates (13%), however, plerixafor is required in a fraction. In light of these findings, we propose that patients who have not achieved at least VGPR should be mobilized with cyclophosphamide, the dosage dependent on their individual risks.

PB1982

MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA PATIENTS BY FLOW CYTOMETRY: A SINGLE CENTER EXPERIENCE

S. Sizikova1,2, N. Prorokina3, B. Batoro4, G. Ushakova1, V. Sergeevicheva1, A. Gilevich1, I. Kruchkova1

1Hematology and bone marrow transplantation, 2Laboratory of immunology, 3Laboratory of cell immunotherapy, Research Institute for Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Background: Multiple myeloma (MM) is a malignant disease characterized by an increased number of clonal (abnormal) plasma cells in the bone marrow (BM). High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (SCT) is used for the treatment of young MM patients and produces a high rate of complete remissions (CR). Recent trials with novel agent combinations alone have also resulted in high CR rates, even among old patients, high-risk patients and relapse/refractory MM. Unfortunately, most patients have a recurrences of the disease. This is due to the persistence of residual tumor cells, known as minimal residual disease (MRD), responsible for tumor relapse.

Aims: BM samples from 51 MM patients who had achieved partial or complete response or were resistant after chemotherapy, including autologous SCT, were evaluated by multiparameter flow cytometry (MFC). The study was conducted to assess the quality of remission, the correlation between the number of abnormal cells of BM and other signs of disease activity, readiness of patients for autologous SCT.

Methods: The study included 51 patients MM, average age - 54 years (36-70 years), who underwent assessment of MRD from November 2014 to February 2017. According to the classification Durie-Salmon the vast majority of patients (n=40) had III stage of complexity of disease (CR) and 11 patients - II. Response to treatment was assessed according to standard EBMT criteria At the time of MRD assessment 20 patients were in CR, 8 had a partial response (PR) and 5 had a minimal residual disease; 5 patients had a primary MM, 3 patients were in the 1st relapse. Most of the patients were undergoing high-dose chemotherapy with autologous SCT (n=42). Re-evaluation of MRD after therapy was managed to hold in 36 patients at a mean of 3,1 months (1,9-5,7, min-max). Analysis was performed using a FACS Cantoll flow cytometer (BD) and FACSDiva software (BD). Instrument performance was checked daily by recording fluorescence intensity with calibrating beads (Cytometer Setup and Tracking from BD Biosciences). Whole BM was estimated using combination of surface and intra-cellular staining CD38/CD56/CD27/CD117/CD81/CD19/CD45/cytLambda/CD138/cytKappa. The sensitivity of our panel MRD is 0.01% (i.e. 10^-4).

Results: Among patients in CR (n=20) confirmed the absence of MRD in 6 patients, but 14 CR patients were MRD positive. MRD was detected in all patients with PR and resistant disease (n=31). The relative content of abnormal plasma cells in CR patients with MRD positive (n=14) was significantly lower than that in PR/resistant patients (n=31): 0.0085% (0.026-0.271%) versus 1.5% (0.203 -5.9%), pU=0,000092. PR patients (n=8) had a lower relative content of abnormal plasma cells (as expressed tendency), than patients with resistant disease (n=15): 0.286% (0,177-1,129%) versus 1.48% (0,90-8,0%), pU=0,053. Besides the relative content of abnormal plasma cells in PR/resistant patients (n=31) correlated with the serum M-gradient concentration (r=0,42; p=0,019) and narrow plasma cells (r=0,54; p=0,0017).

Summary/Conclusions: Currently, we can consider that MFC could be considered as the method of choice for MRD monitoring in MM. If the disease is measured, then, indeed, enough to evaluate only the M-gradient level of serum. If the M-gradient is not defined, it is necessary to assess the number of abnormal plasma cells in the BM and strive for the high-quality responses at the time of transplantation. And also it can help us to regulate duration of maintenance therapy.

PB1983

AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS

M. Stadterini1, C. Nozzoli2, E. Antonioni1, I. Donini2, I. Cutini2, A.S. Guarerra1, M. Di Gioia1, A. Gozzini2, S. Guidi2, A. Bosi1, R. Saccardi2

1Hematology Department, 2BMT Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

Background: Autologous stem cell transplantation (ASCT) is currently approved as a “gold standard” first line treatment for multiple myeloma (MM) patients (pts) under 65 year old but the procedure could also be considered feasible in fit elderly patients based on several retrospective studies. The aim of our study was to retrospectively evaluate the tolerability and the efficacy of high dose chemotherapy followed by ASCT in selected ≥65 year old MM population.

Methods: We retrospectively analyzed consecutive MM pts aged 65 or older who underwent upfront ASCT at our institution from January 2009 to November 2012. We evaluated the patient receipt of induction therapy, intensity of toxicities and/or immunomodulatory drugs (bortezomib and/or thalidomide based), followed by high-dose cyclophosphamide plus G-CSF and subsequently underwent peripheral blood stem cells (PBSC) collection.
Results: Overall we analyzed 36 pts: 21 males and 14 females (median age 66, range 65-70); 23 had IgG MM, 4 had IgA MM and 9 had light chain MM. Induction therapy was bortezomib-based (bortezomib in combination with dexamethasone, VD, in 7, or VD plus thalidomide in 26 pts) for a median of 4 cycles (range 3-6), 2 patients received thalidomide plus dexamethasone (6-12 cycles). PBSC were collected after high-dose cyclophosphamide (2 μg/kg in 2 pts, 3 μg/kg in 11 pts, 4 μg/kg in 22 pts) plus G-CSF, plerixafor was administered in 4 pts. Three pts also received lenalidomide and dexamethasone to improve the depth of response before ASCT. At the time of conditioning, among 34 evaluable pts, 8/34 pts were in complete response/strigent complete response (CR/SCR), 19/34 in very good partial response (VGPR), 5/34 in partial response (PR) and 2/34 in stable disease (SD). The conditioning regimen consisted of melphalan 140 mg/m2 in 11 pts or 200 mg/m2 in 24 pts. A median number of 4.11 x10^6 CD34+ cells/Kg was reinfused (range 2.09-10.44). The most frequent complication was fever (9 pts) with gram negative bacteremia documented in 3/9 and gram positive bacteremia in 1/9. Other complications were represented by 1 case of atrial fibrillation and 3 cases of pneumonia and 1 case of VZV reactivation. All 35 pts achieved neutrophils recovery after a median of 12 days (range 8-25) and platelets recovery after a median of 13 days (range 8-45) after transplant. No grade 3-4 toxicities were recorded. No transplant-related mortality was recorded within 100 days post transplantation. Thirty-five pts received ASCT, among 28 evaluable pts, 10/28 pts in VGPR and 4/28 pts in PR. Three pts underwent tandem ASCT. After a median follow-up of 32 months (range 3-96) among 33 evaluable pts, 20 experienced disease relapse and 7 deaths occurred. Median PFS and OS were 21 and 40 months.

Summary/Conclusions: Our data support the use of ASCT as an effective and safe first-line treatment approach also in elderly MM pts. A careful patient selection is needed to reduce the toxicity of the procedure.

PB1985
CHARACTERIZATION OF A SERIES OF PATIENTS WITH PLASMA CELL LEUKEMIA
P. Bettencourt Medeiros1,*, R. Berganini1, F. Trigo1, J. E. Guimarães1
1Servicio de Hematología Clínica, Centro Hospitalar de São João, EPE, Porto, Portugal

Background: Plasma cell leukemia (PCL) is a rare malignancy characterized by the proliferation of monoclonal plasma cells in the bone marrow and ≥2x10^10 or ≥20% plasma cells in the peripheral blood. It is an aggressive disease, with a median survival of 7 to 11 months. Due to its rarity, it is difficult to design prospective studies or randomized trials in PCL, so collecting and publishing data from the largest number of cases is essential for the understanding of PCL's pathophysiology and outcome.

Aims: To characterize a series of PCL patients, in order to obtain data with the potential to be used as prognostic factors and to improve clinical outcomes.

Methods: Single-center, observational, retrospective study including all PCL cases admitted in our hospital between 2007 and 2016. Data regarding demographics, clinical characteristics, laboratory results, treatment, follow-up and mortality were collected and analyzed using Statistical Package for Social Sciences (21st version), searching for significant associations (p<0.05) with overall survival (OS) and progression free survival (PFS).

Results: 15 patients were included, with a median age of 58 years. Most patients were male (80%) and had PS ECOG 0-1 (93.3%) at presentation and primary PCL (80%). Median hemoglobin (Hb) and platelets values were 8.5 g/dl and 74x10^10/L, respectively. Median plasma cell percentage was 37.3% (peripheral blood) and 60% (bone marrow). IgG heavy chain was present in 33.3% and lambda light chains in 53.3% of cases. Most patients had total serum calcium ≥4.5mmol/L (60%), total proteins ≥65g/L (66.7%), monoclonal component ≥30g/L (53.3%), albumin ≥35g/L (60%), creatinine clearance ≥50ml/min (66.7%), elevated β-2 microglobulin (93.3%), ISS III (80%), R-ISS III (73.3%) and at least 1 cytogenetic change associated with poor prognosis in multiple myeloma (86.7%). Ten (66.7%) patients received bortezomib-based chemotherapy and nine patients (60%) were submitted, at least, to an autologous stem cell transplantation (ASCT). Complete response (CR) or very good partial response (VGPR) were achieved, after chemotherapy, in 53.3% and, after ASCT, in 88.9% of patients. Mortality rate was 66.7%, with median PFS of 5 months and median OS of 4 months. In univariate analysis, OS was significantly associated with albumin ≤ 35g/L, splenomegaly and R-ISS III; PFS was significantly associated with platelets ≤100x10^9/L, splenomegaly and lambda light chains. In multivariate analysis, only the presence of splenomegaly kept its association with OS, none of the characteristics associated with PFS kept their significance. Chemotherapy followed by ASCT and the achievement of, at least, VGPR after chemotherapy and ASCT were associated with longer OS and PFS.

Summary/Conclusions: This study's retrospective design and the small sample limit the strength of our data and our conclusions. Interesting results were obtained regarding pre-treatment prognostic characteristics and the association of improved OS and PFS with treatment response and ASCT execution. More studies are necessary to determine the clinical relevance of this findings and the best treatment strategies in PCL.

PB1986
OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
D. Delgado1,*, A. Gil1, N. Gobano1, M. Diaz1, H. Guillen1, A. Vazquez1, B. Pinedo1
1Hematología, Hospital universitario de Guadalajara, Guadalajara, Spain

Background: MM-003 study has presented a median PFS of 4.0 months and median OS was 13.1 months overall for Pomalidomide and low doses of dexamethasone in RRMM patients. Those results were better when a third drug was added (Poma-Dexa, Poma-Cyclophosphamide-dexa, and Poma-Bortezomib-dexa, ORR 38.9, 64.7 and 85%; PFS 4.4, 9.5, 10.7 months respectively).

Aims: To evaluate the response at therapy with pomalidomide plus dexamethasone in RRMM, and to analyze the efficacy of another drug in high risk MM.

Methods: We reported the clinical experience of the 8 patients treated with pomalidomide and dexamethasone. In patients with high risk MM (cytogenetic, extramedullary myeloma or plasmatic cell leukemia) pomalidomide and dexamethasone have had poor response. In both pts in the bone marrow and third drug (cyclophosphamide or Bortezomib) and we have obtained the best results.

Results: We have used pomalidomide and dexamethasone in 4 patients and poma-dexa-cyclophosphamide in 3 patients (extramedullary myeloma) and
PB1888

INTERNATIONAL OPPORTUNITIES TO COMPARE 'REAL WORLD' DATA FROM MYELOMA REGISTRIES: BASELINE CHARACTERISTICS, FIRST-LINE THERAPIES AND EARLY OUTCOMES FROM AUSTRIA AND AUSTRALIA/NEW ZEALAND

K. Bergin1,*, R. Weger2, E. Moore3, Z. McQuilten3, E. Wood4, W. Willenbacher4, A. Spencer1
1Hematology, Alfred Health-Monash University, Melbourne, Australia, 2Oncotyrol Center for Personalized Cancer Medicine, Innbruck, Austria, 3Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, 4Hematology & Oncology, Medical University Innsbruck, Innsbruck, Austria

Background: Most outcome data for multiple myeloma (MM) come from clinical trials which can not necessarily be extrapolated to 'real world' patients. More information is needed on patients treated in the 'real world' and in a wider range of settings.

Aims: To compare and contrast baseline characteristics, investigations, and initial therapies in different geographical regions, Australia/New Zealand (ANZ) and Austria, through first analysis of data from two established MM registries on behalf of the steering committees of the Australian and New Zealand Myeloma and Related Diseases Registry and the Austrian Myeloma Registry.

Methods: Analysis of data from newly diagnosed MM patients enrolled on the Austrian Myeloma Registry (AMR) and the ANZ Myeloma and Related Diseases Registry (MRDR) from 2012-2017.

Results: Available data from 250 and 691 patients from the AMR and ANZ MRDR, respectively, were included. DEMOGRAPHICS: The AMR cohort was younger (median age m/f: 63.5:64 years vs 65.5:66 yrs on the AMR and MRDR, respectively). The proportion of female:male patients was similar between the AMR and MRDR (m/f: 56%/44% and 61%/39%, respectively). PRESENTATION: IgG myeloma was the most common subtype in both registries (m/f: 64%/55% and 55%/58%, respectively) with more light chain only disease on the AMR (m/f: 26%/33% vs 20%/19%). Presence of documented preceding plasma cell dyscrasias was similar (m/f: 21%/19% vs 19%/16% on the AMR and MRDR, respectively). INVESTIGATIONS: A higher proportion of patients underwent MRI (m/f: 51%/58% vs 25%/27%) and skeletal survey (SS) (78% vs 60%) on diagnosis on the AMR than the MRDR, respectively. Baseline laboratory investigations were similar, however, patients on the MRDR demonstrated higher median LDH (m/f: 176:178 vs 187:186 units/L) and serum calcium (m/f: 2.34:2.28 vs 2.41:2.45 mmol/L) but decreased serum albumin (m/f: 39:39g/L vs 35:35g/L) when compared to the AMR. STAGE: ISS staging was similar on both registries with ISS stage 2 being most common in both cohorts (m/f: 42%/37% vs 40%/40%, on the AMR and MRDR, respectively) while ECOG performance status at diagnosis was lower in the MRDR cohort (ECOG1 m/f: 43%/44% vs 81%/78%, on the AMR and MRDR, respectively). FIRST LINE THERAPY: First line therapy was predominantly bortezomib (Velcade - V) based on both registries (81% vs 85%). Vidalenezamethone (D) was the most common on the AMR (29%) followed by V/thalidomide/D (VTD) (25%) with PFS and OS being calculated since the first time the PB morphology was observed in the bone marrow aspiration, in the outset at newly diagnosed patients or in relapsed patients.

Summary/Conclusions: This pilot study between the AMR and ANZ MRDR demonstrates many similarities but also highlights significant differences, particularly in first line therapy and depth of response. Future studies between the AMR and MRDR will provide a platform for ongoing international benchmarking.

PB1897

PROGNOSTIC SIGNIFICANCE OF PLASMABLASTIC PLASMA CELLS IN THE ERA OF NOVEL AGENTS IN MULTIPLE MYELOMA

A. Machet1,*, S. Guidez1, T. Systchenko1, A. Bobin1, S. Bouyer2, C. Tomowiak1, P. Sonneveld3, H. Avet-Loiseau4, X. Leleu1
1Hematology, 2Hematology Laboratory, University Hospital Center, Poitiers, France, 3Hematology, University of Rotterdam, Rotterdam, Netherlands, 4Laboratory for Genomic in Myeloma, Institut Universitaire du Cancer, Toulouse, France

Background: Plasmaablastic (PB) feature of plasma cells in multiple myeloma (MM) has long been identified as poor prognosis. Interestingly it does not take part of International Revised Scoring System (R-ISS). Similarly, the prognostic impact in the era of novel agents and novel classes in MM is unknown. Finally, the percentage of PB in the bone marrow to which a poor prognosis develop is unclear.

Aims: To assess which modality of treatment of plasmaablastic MM was associated with longer progression free survival (PFS) and overall survival (OS).

Methods: We have performed a retrospective analysis of all MM in our center from May 2005 to November 2016, and sought for MM with plasmablastic features, characterized by immature cells with high proliferative index rate. The PFS and OS were calculated since the first time the PB morphology was observed in the bone marrow aspiration. In the outset at newly diagnosed patients or in relapsed patients.

Results: 65 patients with PB were included. Adverse cytogetic per IMWG criteria was reported in 6 patients, del17p x3, t(4;14) x3, and one with both. 33.8% were ISS 3, and 23.1% R-ISS 3. Extramedullary disease (EMD) was reported in 40%. 35 patients (53.8%) were in first-line therapy. The overall response rate with any triplet-based treatment containing always a proteasome inhibition and IMiDs or alkylator was 49.2%, with 29.2% VGPR and 4.6% CR. The median PFS and OS were 6.9 and 14.9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65). PFS and OS were 6,9 and 14,9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65).

Summary/Conclusions: Plasmaablastic MM with PB triplet-based treatment containing always a proteasome inhibition and IMiDs or alkylator is associated with poor prognosis. Adverse cytogetic per IMWG criteria was reported in 6 patients, del17p x3, t(4;14) x3, and one with both. 33.8% were ISS 3, and 23.1% R-ISS 3. Extramedullary disease (EMD) was reported in 40%. 35 patients (53.8%) were in first-line therapy. The overall response rate with any triplet-based treatment containing always a proteasome inhibition and IMiDs or alkylator was 49.2%, with 29.2% VGPR and 4.6% CR. The median PFS and OS were 6.9 and 14.9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65). PFS and OS were 6,9 and 14,9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65).

PB1898

DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA AFTER ASCT: USEFULNESS OF IMMUNEASYSS

A. Andrade-Campol,1, 2, L. Floress3,4, E. Colorado Ledesma2, P. Giraldo3, 1Translational Research Unit - Hematology, IIS-Aragon, CIBERER, 2Hematology, 1Translational Research Unit - Hematology, IIS-Aragon, CIBERER, 3Hematology, Miguel Servet University Hospital, 4Translational Research Unit, IIS-Aragon, CIBERER, IISCIII, Zaragoza, Spain

Background: The Free Light chain immunoassay (FLC) (Bindingsite, Birming-
ham, UK) is part of the mandatory response assessment for MM, the role of the Heavy/ Light chain immunoassay (HLC) is under investigation. Also relapses in MM patients are frequent, autologous stem cell transplantation (ASCT) is the standard consolidation therapy and there is an interest to detect early relapses of multiple myeloma. We hypothesized that the combination of these techniques could permit to detect early biological (non-symptomatic) relapses (EBR) in this setting.

Aims: To analyze the usefulness of HLC and FLC to detect EBR in MM after ASCT.

Methods: A retrospective study was performed following these criteria: all patients diagnosed of secretory MM, in our center, and treated (including ASCT), between May 2011-August 2015; the protocol for follow-up included FLC, HLC, serum and urine electrophoresis (SPE, UPE), pre-ASCT, after 12 weeks, and after 12 months. A total of 791 patients were included. Adverse cytogenetic per IMWG criteria was reported in 6 patients, del17p x3, t(4;14) x3, and one with both. 33.8% were ISS 3, and 23.1% R-ISS 3. Extramedullary disease (EMD) was reported in 40%. 35 patients (53.8%) were in first-line therapy. The overall response rate with any triplet-based treatment containing always a proteasome inhibition and IMiDs or alkylator was 49.2%, with 29.2% VGPR and 4.6% CR. The median PFS and OS were 6.9 and 14.9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65). PFS and OS were 6,9 and 14,9 months as a whole, respectively. The median PFS was greater when treatment combined bortezomib, lenalidomide and dexamethasone: 36.1 months (95% CI: 0.99-5.66) vs 24.1 months (95% CI: 1.5-3.65).
weeks and every 3 months later (minimum follow-up: 6 months). EBR was defined as 25% on M-protein increase (any amount for patients on CR/SR) and/or ≥20mg/dl FLC increase, and/or 25% involved HLC increase with normal ratios. For urine, an increase >500mg/24 hrs of involved free-chain protein.

Results: Fifty-five patients were registered. Median follow-up 47 months. MF ratio: 29/26, mean age 59.3 ± 33.71. Immunoglobulin subtype: IgG-Kappa: 41.8% (23), IgG-Lambda: 23.6% (12), IgA-Kappa: 16.4% (9), IgA-Lambda: 7.3% (4), Bence-Jones-Kappa: 3.6% (2), Bence-Jones-Lambda: 7.3% (4). Durie-Salmon Stage: IA: 13.5% (7), II-A: 32.7% (17), III-A: 44.2% (23), III-B: 9.6% (5), missing-data 3 case. All patients received Bortezomib based therapy and MEL200 as ASCT conditioning. Status pre-ASCT: minimal response: 12%, Partial response (PR), 50.0%, very-good-PR (VGPR): 28.0%, complete response (CR): 6% and string response (SR): 4.0%. After ASCT, evaluation reveals that 13.0% achieved SR, 30.4% VGPR and 39.1% PR. During follow-up, 34/50 (68%) patients who achieved at least PR after ASCT, had a clinical relapse/progress, median PFS 41 months (31.5-50.5). EBR were detected in 28 patients, of them 22/34 (64.7%) early-relapsed patients at median time 8.0 (2-22) months before symptomatic relapse. The EBR were detected by FCCr (36.7%), HCCr (22.7%), FLC+SPE (4.5%), FCC+IFX (9.1%), FCC+HLC+SPE (13.6%), FCC+HLC+SPE+UPE (13.6%).

Summary/Conclusions: Both FLC and HLC are useful tools to detect EBR in more than 50% of patients in our cohort ahead other techniques.

PB1990

EARLY MORTALITY (<6 M) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: COMPREHENSIVE INTERVENTION

V. Martínez-Robles1,*, B. Ballina1, S. Cerdà1, N. de las Heras1, M. Fuentes1, L. Villalobos1, J. Rodríguez-Ciriza1, F. Ramírez1, F. Escalà1,1Hematología, Complejo Asistencial Universitario de León, LEON, Spain

Background: Early mortality in the first 6 to 12 months from diagnosis is well recognized in newly diagnosed multiple myeloma (NDMM) patients, with rates in the real-world setting of around 20-30%.

Aims: In a retrospective analysis of the causes of death performed by the end of 2012 we identify 2 different causes in the 2 consecutive periods analyzed. In the first period (1998-2006) the main cause was MM progression and in the second (2006-12) was secondary to serious infectious complications. Additional analysis were done after it an can identify a patient and infectious profiles. Main risk factors from the patient were: age (over 75), suboptimal treatment and renal failure (calculated ClCr<50 ml/min). The infectious occurred mainly in the first 3 months from diagnosis and principally polymicrobial and multiresistant infections.

Methods: After this analysis several measures were taken to reduce this high early mortality: 1) To promote the ambulatory regime both in diagnosis and for the rapid assessment of complications to avoid or shorten income and to reduce the nosocomial-behaviour infection complications. 2) Early initiation of “optimal” anti-myeloma treatment. 3) Get infectious prophylaxis in patients over 75.

Results: From the patient were: age (over 75), suboptimal treatment and renal failure (calculated ClCr<50 ml/min). The infectious occurred mainly in the first 3 months from diagnosis and principally polymicrobial and multiresistant infections.

Summary/Conclusions: Infectious complications and progression of MM have been the main cause of early mortality in patients with NDMM. Identifying potential “modifiable” variables and acting on them improves the short-term prognosis of patients with NDMM like: Supportive treatment to prevent infectious complications (avoid unnecessary hospitalization, antibiophylaxis) and rapid access to optimal antiMM treatments. These improvement of short-term

PB1991

FIRST LINE USE OF NOVEL AGENTS BEFORE AUTOLOGOUS SCT HAS A POSITIVE IMPACT ON TIME TO SECOND PROGRESSION AND SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDER 70 YEARS

S. Gassiot1,2, C. Motél1,3, M. Mogrades1, Y. Gonzalez4, M. Garcia-caro1, J.-M. Ribera1,2, A. Orfali1,2
1Hematology, Hospital Germans Trias i Pujol - ICO, Badalona, 2Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 3Universitat Autònoma de Barcelona, Badalona, 4Hematology, Hospital Dr Josep Trueta, Girona, Spain

Background: Most clinical trials for multiple myeloma (MM) patients using novel agent-based regimens before autologous stem cell transplantation have shown improvement in response rates and progression-free survival, however they have failed to identify a significant overall survival (OS) benefit.

Aims: Our aim is to analyze the potential impact of initial induction in the feasibility of these same agents second line and other major factors affecting OS in a real clinical practice setting.

Methods: Newly MM patients less than 70 years of age diagnosed between December 1999 and December 2009 were prospectively registered. Patients were assigned to a first cohort if they received conventional chemotherapy (CC) induction regimens with new agents available at relapse or to a second cohort if received novel agents based first line treatment (NA).

Results: The overall response rate after completing first line treatment for all the 154 eligible patients was 85%, 79% in CC compared to 94% in NA (P=0.012).

Very good partial response or better for NA was significantly higher than for CC in terms of (39% vs 29%, P=0.012). Patients in NA demonstrated not only a superior median progression-free survival (2.8 years vs 1.6 years, P=0.03) but also superior median progression-free survival from diagnosis to second progression – PFS2 (5.2 years vs 2.7 years, P=0.003).

In both cohorts PFS1 and PFS2 represented more than 50% and 80% of life expectancy respectively. It could be hypothesized that CC patients would obtain more benefit than NA patients of second-line therapy, as they would be naïve to the novel agents used at relapse, but this is not the case. The use of thalidomide and/or bortezomib induction did not reduce the efficacy of these same agents second line. Indeed, these patients also had the best second responses that also contributed to longer PFS2 periods. After a median follow-up of 6.97 years, clear differences in OS were observed (7.97 years for NA compared to 3.35 years in CC, P<0.001). Despite the fact that better risk patients in the NA group were more likely to remain in first or second response, relapsed and refractory patients in this group still presented longer survivals beyond second relapse than patients in the CC group (Figure 1).

Figure 1. 

Summary/Conclusions: New agent based first line induction treatments in newly diagnosed MM patients provide benefits beyond first progression free survival that contribute to a significant improvement in OS.

PB1992

SAFETY AND EFFICACY OF NOVEL AGENTS IN VERY ELDERLY MULTIPLE MYELOMA PATIENTS (AGED 80 YEARS OR MORE): A REPORT BY THE RETE EMATOLOGICO OGLIESETI GROUP

N. Sgherza1,*, A. P. Falcone1, A. Iacobazzi2, G. Palumbo3, B. Rossini4, G. Mele5, P. Curci6, L. Ciuffreda7, G. Polimeno8, G. Rossi1, G. Tarantini7, G. Specchia6, A. Melpignano5, V. Pavone4, S. F. Capalbo3, A. Guarini2, N. Cassignelli1
1Hematologia, Complejo Asistencial Universitario de León, LEON, Spain

Aims: To promote the ambulatory regime both in diagnosis and for the rapid assessment of complications to avoid or shorten income and to reduce the nosocomial-behaviour infection complications. 2) Early initiation of “optimal” anti-myeloma treatment. 3) Get infectious prophylaxis in patients over 75.

Results: 343 pac NDMM were treated between 1998 and 2015 (127 in the 1st period, 115 in the 2nd: 242 pts before 2013; and 101 in the 3rd period: 2013-15). The median age at dx was 74 years (39-100). The number of patients died <6m was 77. 60 died before 6 months: 55 before 2013 (29 in the 1st period (22.8%) and 26 in the 2nd (22.6) and 5 after 2013 (5.0%). Of these, 60, 37 had a severe infectious complication. The main cause of mortality before 2013 was infectious complications, (14 of 28 early death in the first period and 22 of 6 in the second). Severe pneumococcal infections were infrequent (11%) In the 3rd period, mortality <6m was reduced by 77% (22% vs 5%) (p<0.001); There was only 1 severe infection (OS) in this period (CMV reactivation, probably Pneumocystis pneumonia). After this analysis several measures were taken to reduce this high early mortality: 1) To promote the ambulatory regime both in diagnosis and for the rapid assessment of complications to avoid or shorten income and to reduce these nosocomial-behaviour infection complications. 2) Early initiation of “optimal” anti-myeloma treatment. 3) Get infectious prophylaxis in patients over 75.

Summary/Conclusions: Infectious complications and progression of MM have been the main cause of early mortality in patients with NDMM. Identifying potential “modifiable” variables and acting on them improves the short-term prognosis of patients with NDMM like: Supportive treatment to prevent infectious complications (avoid unnecessary hospitalization, antibiophylaxis) and rapid access to optimal antiMM treatments. These improvement of short-term

Figure 1 (large graphic; legends: red: pre2013; blue: post2013).
Background: Multiple Myeloma (MM) is mainly a disease of the elderly and the very elderly patients (80 years of age or more) comprise one third about of all MM patients. This subset of patients suffer from concomitant disabilities and/or comorbidities and require a different and more individualized therapeutic approach, including the novel agents.

Aims: The aim of our study is to verify safety and efficacy of novel agents with the reliability to maintain a good quality of life and obtain a maximal disease control.

Methods: Patients from 8 Hematology Centers of the “Rete Ematologica Pugliese (REP)” were included in this study. Between January 2011 and December 2016, 71 patients (MF: 42/29) with a median age of 82 years (range 80-91) were diagnosed as newly symptomatic MM. Of the entire study population, 40 (66%) patients showed an ECOG score lower than 2. According to immunoglobulin heavy and light chain isoatypes, patients had IgG-k (n=23), IgG-λ (n=16), IgA-k (n=14), IgA-λ (n=6), micromolecular κ (n=8) and λ (n=4) chains. On the basis of ISS, patients were classified as I (n=4) score, II (n=23) and III (n=44) score, respectively. When CRAB features were considered, bone lesions represented the most frequent (n=43, 60.6%) clinical manifestations, while splenomegaly and renal failure were found in 35 (49.3%) patients and 2 (2.8%) patients, respectively. Majority of patients (n=49, 69%) showed at least 1 comorbidity requiring specific treatments, and 11 patients (15.5%) showed more than 3 comorbidities. Patients were treated according to Bortezomib-based regimens (VMP, VCD and VD) (n=45; 63.4%), Lenalidomide-based regimens (MP and MPT) (n=5; 7%). Only 13 patients (18.3%) did not receive any novel agent.

Results: Based on IMWG criteria, 15 patients (21.1%) achieved a CR, 15 patients (21.1%) a VGPR and 15 patients (21.1%) a PR. Fourteen patients (19.7%) and 12 (17%) patients experienced a SD and a PD, respectively. As second line of treatment, Bortezomib was used in 14 (33.3%) patients, Lenalidomide in 17 (40.5%) patients and Thalidomide in 3 (7.2%) patients. Height patients (19%) were treated with old drugs (Melphalan, Cyclophosphamide or Bendamustine). Pomalidomide was used as third line-therapy in 3 patients. After 72 months (median 32.5 months) of treatment, the median overall survival was 53.3 months (25 (28.2%) died. Last follow-up from 13 patients was unavailable. Hematological and extra-hematological toxicities were similarly distributed (18.3% and 18.3%, respectively) and usually weak/moderate. Neuropathy was the most common toxicity reported (n=7, 9%). Of patients treated only with novel agents (n=58), hematological and extra-hematological toxicity was observed in 14% and 16% patients, respectively.

Summary/Conclusions: We showed that all MM patients can be treated by novel agents independently of the age. Results from our study show that particularly very elderly and frail patients can benefit from these drugs by prolonging their life expectancy and maintaining a good quality of life.

Biorzotem-Melphalan-Prednisone versus MP as Initial Treatment for Very Elderly Patients with Newly Diagnosed Multiple Myeloma


1Department of Internal Medicine, 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, United States

Background: While hematopoietic malignancies are found at increased rates in individuals with acquired immunodeficiency syndrome (AIDS), comorbidity of multiple myeloma (MM) and human immunodeficiency virus (HIV) is less common, leading to a paucity of expertise in the treatment of individuals with these co-morbid conditions. Prior to the advent of highly active anti-retroviral therapy (HAART), autologous stem cell transplant (ASCT) was relatively contraindicated for MM patients with HIV due to issues associated with stem cell harvest and the risk of opportunistic infections. With the widespread use of HAART for control of HIV, high dose chemotherapy and ASCT is now the preferred treatment for relapsed lymphoma, the leading hematopoietic malignancy associated with HIV/AIDS. It stands to reason that MM patients with HIV on HAART may benefit equally from aggressive combination treatment of chemotherapy and ASCT.

Aims: This study seeks to evaluate the clinical course and treatment outcomes of patients with HIV and MM treated with high dose therapy and ASCT.

Methods: A single center retrospective case-series study was performed. Data from patients who were HIV-positive and on HAART undergoing ASCT for treatment of MM between January 2000 and June 2016 were collected and analyzed.

Results: The following Table 1 lists patient characteristics. All were male with average age 53.2 years. All were diagnosed with HIV prior to diagnosis of MM and were appropriately treated with HAART prior to ASCT. All patients had viral load <50/uL prior to ASCT; however all patients recovered CD4 counts after ASCT. Five of four patients who had CD4 >200/uL and one patient had CD4 <50/uL prior to ASCT; however all patients recovered CD4 counts after ASCT (and most with improved CD4 count). Adequate CD34(+) stem cells were collected. Patients received high dose melphalan (200 mg/m2) followed by ASCT. HAART was continued during ASCT. Patients experienced usual ASCT toxicities including diarrhea, mucositis, and neutropenic fever. One patient developed sepsis and small bowel obstruction, which resolved with antibiotics and conservative management. All patients had normal neutrophil and platelet engraftments. Post-ASCT responses were complete remission (2 patients), very good partial remission (1), partial remission (1) and minimal response (1). All patients are currently alive without relapse or progression 1-4 years from ASCT and receiving post ASCT maintenance with lenalidomide.

Table 1.

PB1993

Efficacy of Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma in HIV-Positive Patients – a Case-Series

B. Ni1, A. Rosko2, D. Benson2, S. Devine2, C. Hofmeister2, Y. Efebera2

1Department of Internal Medicine, 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, United States

Background: While hematopoietic malignancies are found at increased rates in individuals with acquired immunodeficiency syndrome (AIDS), comorbidity of multiple myeloma (MM) and human immunodeficiency virus (HIV) is less common, leading to a paucity of expertise in the treatment of individuals with these co-morbid conditions. Prior to the advent of highly active anti-retroviral therapy (HAART), autologous stem cell transplant (ASCT) was relatively contraindicated for MM patients with HIV due to issues associated with stem cell harvest and the risk of opportunistic infections. With the widespread use of HAART for control of HIV, high dose chemotherapy and ASCT is now the preferred treatment for relapsed lymphoma, the leading hematopoietic malignancy associated with HIV/AIDS. It stands to reason that MM patients with HIV on HAART may benefit equally from aggressive combination treatment of chemotherapy and ASCT.

Aims: This study seeks to evaluate the clinical course and treatment outcomes of patients with HIV and MM treated with high dose therapy and ASCT.

Methods: A single center retrospective case-series study was performed. Data from patients who were HIV-positive and on HAART undergoing ASCT for treatment of MM between January 2000 and June 2016 were collected and analyzed.

Results: The following Table 1 lists patient characteristics. All were male with average age 53.2 years. All were diagnosed with HIV prior to diagnosis of MM and were appropriately treated with HAART prior to ASCT. All patients had viral load <50/uL prior to ASCT; however all patients recovered CD4 counts after ASCT (and most with improved CD4 count). Adequate CD34(+) stem cells were collected. Patients received high dose melphalan (200 mg/m2) followed by ASCT. HAART was continued during ASCT. Patients experienced usual ASCT toxicities including diarrhea, mucositis, and neutropenic fever. One patient developed sepsis and small bowel obstruction, which resolved with antibiotics and conservative management. All patients had normal neutrophil and platelet engraftments. Post-ASCT responses were complete remission (2 patients), very good partial remission (1), partial remission (1) and minimal response (1). All patients are currently alive without relapse or progression 1-4 years from ASCT and receiving post ASCT maintenance with lenalidomide.

Table 1.
Summary/Conclusions: Multiple myeloma patients with concurrent HIV infection that is controlled on HAART tolerate ASCIT for treatment of myeloma as well as myeloma patients without HIV infection and have generally good outcomes.

PB1995

FEASIBILITY OF USING GLOBAL FDG UPTAKE IN BONE MARROW TO ASSESS TREATMENT RESPONSE IN MULTIPLE MYELOMA

Aims: A novel method using CT segmentation to determine global bone marrow activity portrayed by FDG uptake was used to achieve a comprehensive understanding of disease burden in patients with MM before and after therapy.

Methods: Prospective FDG-PET/CT data of 23 MM patients between ages of 50 and 76 (mean=64.3, males=21, females=2) were collected from Odense University Hospital (NCT02187731) and included scans before initiation of treatment and at end of treatment (EOT) two months after high dose chemotherapy with stem cell support. All scans were conducted 60 min after intravenous injection of 4 MBq/kg of FDG. Images were analyzed using an iterative thresholding algorithm that delineates a continuous region based on Hounsfield units from the CT data (OsiriX software; Pixmeo SARL; Bernex, Switzerland), allowing for segmentation of the total skeleton on a fused PET/CT image. This enabled the quantification of FDG uptake representing the entire skeleton, providing a global SUV measure that considers all bone marrow involvement. Global SUV/mean scores were compared before and at EOT using a two-tailed paired t test.

Results: A decrease in marrow FDG uptake was observed at EOT compared to baseline in most patients. The calculated global SUV/mean uptake decreased after initiation of treatment in 17 (73.9%) of the cases and increased in 6 (26.1%) of the cases. The change was analyzed using the observed statistical difference of the dependent means before and after treatment (P=0.0053).

Summary/Conclusions: We assessed the effects of treatment in MM patients using a novel technique for global quantification of FDG uptake in the bone marrow and skeleton and found lower global uptake at EOT. However, a limitation of this study was the use of a semi-quantitative PET/CT scan. Global assessment rather than focal analysis of discrete lesions represents a robust and straightforward method of determining total disease activity that potentially will be of value in treatment evaluation, disease monitoring and prognostication in multiple myeloma.

PB1996

VALUE OF MYELOMA PROGNOSTIC INDICES IN ERA OF NOVEL DRUGS IN TRANSPLANT SETTING

Background: Multiple myeloma (MM) is characterized by plasma cell proliferation and expansion primarily in the bone marrow. Modern assessment of MM using FDG-PET has so far mostly been limited to the analysis of focal lesions, requiring subjective interpretation to determine overall disease activity.

Aims: A novel method using CT segmentation to determine global bone marrow activity portrayed by FDG uptake was used to achieve a comprehensive understanding of disease burden in patients with MM before and after therapy.

Methods: Prospective FDG-PET/CT data of 23 MM patients between ages of 50 and 76 (mean=64.3, males=21, females=2) were collected from Odense University Hospital (NCT02187731) and included scans before initiation of treatment and at end of treatment (EOT) two months after high dose chemotherapy with stem cell support. All scans were conducted 60 min after intravenous injection of 4 MBq/kg of FDG. Images were analyzed using an iterative thresholding algorithm that delineates a continuous region based on Hounsfield units from the CT data (OsiriX software; Pixmeo SARL; Bernex, Switzerland), allowing for segmentation of the total skeleton on a fused PET/CT image. This enabled the quantification of FDG uptake representing the entire skeleton, providing a global SUV measure that considers all bone marrow involvement. Global SUV/mean scores were compared before and at EOT using a two-tailed paired t test.

Results: A decrease in marrow FDG uptake was observed at EOT compared to baseline in most patients. The calculated global SUV/mean uptake decreased after initiation of treatment in 17 (73.9%) of the cases and increased in 6 (26.1%) of the cases. The change was analyzed using the observed statistical difference of the dependent means before and after treatment (P=0.0053).

Summary/Conclusions: We assessed the effects of treatment in MM patients using a novel technique for global quantification of FDG uptake in the bone marrow and skeleton and found lower global uptake at EOT. However, a limitation of this study was the use of a semi-quantitative PET/CT scan. Global assessment rather than focal analysis of discrete lesions represents a robust and straightforward method of determining total disease activity that potentially will be of value in treatment evaluation, disease monitoring and prognostication in multiple myeloma.

PB1997

WHICH ORGAN SHOULD WE BIPSY TO DIAGNOSE AL AMYLOIDOSIS?

Background: Light chain (AL) amyloidosis is a deposition disease with can affect many organs and with a variable but usually bad, prognosis. Therapy requires a quick and correct diagnosis. Accurate identification of amyloid deposition and of the amyloid subtype in tissue biopsies is thus mandatory. Random biopsies of easily accessible tissues such as subcutaneous fat, gingivae or rectum are usually recommended but sensitivity of this approach is low.

Aims: To present our experience with tissue biopsies performed in 62 consecutive patients diagnosed of AL amyloidosis in our center.

Methods: We reviewed all tissue biopsies performed during the study period (2004-2017) in 62 consecutive patients diagnosed of AL amyloidosis at the same center. A bone marrow (BM) biopsy was performed per protocol in all cases. Decisions on biopsies were taken considering organ involvement and accessibility: skin, lymph nodes, lung or tongue biopsies were performed when lesions were seen on clinical or X-ray examinations, cardiac biopsies in the presence of increased NT-proBNP (N-terminal natriuretic peptide) levels and typical echocardiographic findings, kidney biopsies in patients with nephrotic syndromes. Biopsies were stained with Congo Red and read under polarized light with a Texas filter. Subtyping of the amyloid was done using anti-kappa, anti-lambda, anti-TTR and anti-A antisera.

Results: Of 62 patients, no biopsy was positive for AL amyloid, no further biopsies were performed unless necessary for therapeutic decisions.

Summary/Conclusions: A novel method using CT segmentation to determine global bone marrow activity portrayed by FDG uptake was used to achieve a comprehensive understanding of disease burden in patients with MM before and after therapy.

PB2001

VALUE OF MYELOMA PROGNOSTIC INDICES IN ERA OF NOVEL DRUGS IN TRANSPLANT SETTING

Table 1.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Biopsies</th>
<th>AL-amyloidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>59</td>
<td>25 (42.5%)</td>
</tr>
<tr>
<td>Intestine/Rectum/ Stomach</td>
<td>10</td>
<td>7 (70%)</td>
</tr>
<tr>
<td>Skin</td>
<td>2</td>
<td>2 (100%)</td>
</tr>
<tr>
<td>Sural nerve</td>
<td>3</td>
<td>3 (100%)</td>
</tr>
<tr>
<td>Total biopses</td>
<td>130</td>
<td>91 (69.3%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Prognosis in AL amyloidosis is slowly improving with the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis. We do not perform random biopsies of tissues such as fat or gingivae due to low sensitivity. In our hands, biopsy limited to the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis. We do not perform random biopsies of tissues such as fat or gingivae due to low sensitivity. In our hands, biopsy limited to the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis. We do not perform random biopsies of tissues such as fat or gingivae due to low sensitivity. In our hands, biopsy limited to the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis.
PB1998

A COMPARISON OF CYCLOPHOSPHAMIDE-GLUCOCORTICOIDS AND LENALIDOMIDE-DEXAMETHASONE AS TREATMENT FOR MULTIPLE MYELOMA IN FIRST RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

R. Sterrett1, A. Figueiredo2, R. Mallick3, N. Kekre1, H. Atkins1, A. McCurdy1,2
1Department of Medicine, University of Ottawa, 2Ottawa Hospital Research Institute, 3School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, 4Clinical Epidemiology Program, Ottawa Hospital Research Institute, 5Division of Hematology, The Ottawa Hospital, Ottawa, Canada

Background: The optimal management of relapsed Multiple Myeloma (MM) with respect to therapeutic combinations and sequence remains controversial and is actively evolving. Many commonly used regimens have not been directly compared. These agents vary widely in cost, and knowledge of their relative efficacy is of particular importance in regions where cancer medicines are publicly funded.

Aims: We sought to compare the efficacy and safety of two commonly used regimens for relapsed MM using historical cohorts from a single transplant center.

Methods: A retrospective observational study was performed between January 1991 and November 2016 to compare the efficacy of cyclophosphamide and dexamethasone/prednisone (Cylo), or lenalidomide and dexamethasone (Len-Dex) for relapsed MM post autologous stem cell transplant (auto SCT). The primary outcome was Time to Next Treatment 2 (TTNT2), defined as time from first relapse requiring therapy after auto SCT to second relapse requiring therapy. The secondary outcome was overall survival, defined as time of diagnosis to death from any cause. Outcomes were assessed by Kaplan-Meier methods and overall differences determined by log rank test. Hazard ratios were calculated for individual treatment groups and compared by univariate and multivariate logistic regression.

Results: A total of 243 patients underwent treatment for MM at first relapse post autologous transplant. Of these, 139 were included in this analysis: 88 Cylo and 51 Len-Dex. Patient demographics and disease characteristics were similar between each group for age, sex, subtype of MM and ISS Stage (p>0.05). Vincristine, Doxorubicin and Dexamethasone (VAD) was the most common treatment at diagnosis for the Cylo group (68%), whereas bortezomib-based therapy was the most common for the Len-dex group (76%) (p=0.0001). No differences were observed in overall response rate or depth of response based on induction therapy between both groups. Median time to first relapse requiring treatment after auto SCT was longer in the Cylo group (36 months vs 25 months (p=0.0008). The median TTNT2 was similar for the two groups: 12.2 months (IQR, 4.56-27.96) for Cylo and 12.1 months (IQR, 4.80-29.16) for Len-dex (p=0.52). However, after adjusting for standard patient and disease related factors in a multivariate model, TTNT2 was shorter for Cylo compared to Len-dex (HR 2.29, 95% CI, 1.17 – 4.51; p=0.016). The median overall survival was 84 months for Cylo and 75.6 months for Len-dex (p<0.31). In the multivariate analysis, overall survival was not different for Cylo compared to Len-dex (HR 0.99; CI 0.42 – 2.34; p=0.99). There was no significant difference in rates of hospitalization, infection, or grade 3 adverse events between the two groups (Figure 1).

Figure 1. Survival curves.

Summary/Conclusions: In this observational study of patients with relapsed multiple myeloma post autologous stem cell transplantation, Lenalidomide-dexamethasone was associated with longer TTNT2 compared with Cylophosphamide-glucocorticoids. However, there was no difference in overall survival. Cyclophosphamide is considerably less expensive than the novel agents. In an era when fiscally sustainable care for MM remains a challenge, further prospective studies are required to compare cyclophosphamide with novel agents in the management of relapsed multiple myeloma.

PB1999

CLINICAL IMPACT OF THE PLASMA LENALIDOMIDE CONCENTRATION AND THE ANALYSIS OF ANTI-TUMOR IMMUNE RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE AND DEXAMETHASONE THERAPY

T. Kobayashi1, M. Miura2, T. Nioka3, Y. Fujioka3, M. Abumyra3, S. Ikeda1, T. Yoshio4, Y. Kameoka1, H. Nishikawa3, N. Takahashi1
1Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 2Pharmacy, Akita University Hospital, Akita, 3Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan

Background: Lenalidomide (Len) and dexamethasone (DEX) combination therapy is now the standard treatment of multiple myeloma (MM). Len has both a direct effect on MM cells and an immunomodulatory effect and recently many drugs are combined with Ld therapy to expect the synergistic anti-tumor immune response. However, adverse events (AEs) make continuation of Ld therapy difficult for some patients especially for elderly patients.

Aims: To investigate the safe and effective plasma concentration of Len and the anti-tumor immune response change in MM patients treated by Ld therapy.

Methods: Forty patients (18 men and 22 women) were enrolled in this study. Median age was 75.5 years old (range 61-86). Len was administered on days 1–21 of a 28-day cycle, and DEX, on days 1, 8, 15, and 22. The plasma concentrations of Len just before oral administration and 1, 2, and 4 hr thereafter were analyzed by using liquid chromatography-tandem mass spectrometry. Before and after Ld therapy, peripheral blood mononuclear cells (PBMCs) of MM patients were isolated from whole blood by Ficoll-Hypaque density-gradient centrifugation. PBMCs were stained with the fluorescent dye-conjugated antibodies against surface markers and intracellular cytokine production by flow cytometry. Intracellular cytokine production of IFN-γ, TNF-α, IL-2 and CD107a molecule was detected after stimulation with PMA/ionomycin for 5 hours in the presence of protein transport inhibitor Golgi stop (BD Bioscience). Analysis was performed using LSR Fortessa (BD Biosciences) and Flowjo version 10.2 software (TreeStar). This study protocol was approved by the Ethics Committee of Akita University Hospital, and all recipients gave written informed consent.

Results: 21 patients showed renal impairment (RI) necessary to adjust initial Len dosage. Adverse cytogenetics of del17p and t(4;14), detected by using fluorescence in situ hybridization, were found in 2 and 4 patients, respectively. The median initial dosage of Len was 15 mg and DEX 20 mg. The overall response rates were 68.6% and the 2-year progression-free survival was 70.8% at a median follow-up of 26.5 month. Grade 3 to 4 nonhematologic AEs were observed only in 8 patients. We estimated the AUC0-24 of Len by using formula as we previously reported (Ther Drug Monit 2014) and the cut-off value of the area under the curve was 2545.16ng•hr/ml (sensitivity 81.8%, specificity 80%) and non-hematologic AEs 3023.6ng•hr/ml (sensitivity 78.9%, specificity 62.5%). After Ld therapy, naïve subset of CD4 and CD8 T cells and monocytic MDSC were observed after Ld treatment. On the other hand, effector memory subset and intracellular cytokine productions of IFN-γ, TNF-α, IL-2, and CD107a of CD4 and CD8 T cells increased significantly (Figure 1).

Summary/Conclusions: Len can be administered safely even in elderly patients with RI by using the estimated AUC0-24 of Len as a prediction marker of AEs. Enhanced cytokine production and increased memory subset of T cells were observed after Ld treatment.

PB2000

THE ROLE OF EXPRESSION CD56 ON BONE MARROW PLASMA CELLS AND EXTRAMEDULLARY PLASMA CELLS IN PATIENTS WITH MULTIPLE MYELOMA

M. Firsova1,2, L. Mendeleva1, A. Kovringa2, M. Soloviev1, O. Pokrovskaya1, M. Nareiko1, L. Kuzmina3, V. Sevchenko1
1Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastosis, 2Pathology department, 3Bone Marrow Transplantation Department, 4National Research Center for Hematology, Moscow, Russian Federation
Background: The myeloma cells interact with the bone marrow microenvironment by several adhesion molecules. One of them is CD56 (a neural cell-adhesion molecule N-CAM) – a membrane glycoprotein, a member of the immunoglobulin superfamily, expressed on the surface of malignant plasma cells of patients with multiple myeloma (MM). Decreased expression of CD56 is considered as one of the possible factors, that help tumor cells to spread outside the bone marrow.

Aims: To evaluate the impact of CD56 expression on the rate of overall survival (OS) in MM patients with extramedullary disease (EMD).

Methods: The study included 32 patients with primary MM (17 males, 15 females) 23-77 years old (median value: 52 years old). The disease was diagnosed in accordance with the IMWG criteria (2014). 17 patients had EMD, including 14 patients with soft-tissue plasmacytomas associated with bone and 3 patients with extramedullary foci in the neck area, in the stomach, in the liver. In all cases a tumour biopsy and bone marrow trephine biopsy were performed, that confirmed the presence of malignant plasma cell infiltration. Paraffin block slices from trephine biopsy material and tumour biopsy material were used to perform an immunohistochemistry (IHC) analysis with an antibody to CD56. Kaplan-Meier survival curves were generated, statistical analysis was done using the program «Statistica» ver.10.

Results: In patients with plasmacytomas the IHC analysis of trephine biopsy material showed CD56+ in 59% cases vs 73.4% in patients without EMD. Five-year OS in patients with CD56+ in the bone marrow was 90%, which was significantly higher (p=0.04) than that of the patients with CD56- - 0% with follow-up of 5 to 61 months (median 20 months, Figure1). Expression of CD56 on the surface of extramedullary MM cells was found in 76.5% patients. OS in the group of patients with CD56+ in extramedullary MM cells and in bone marrow cells (n=9) was 67% which was significantly higher (p=0.04) than that in the group of patients (n=4) with CD56+ in extramedullary MM cells and CD56- in bone marrow cells – 50%. Simultaneous lack of CD56 in extramedullary MM cells and in bone marrow cells was observed in 3 patients with 2 of them died of progression in 31 and 51 months. However simultaneous expression of CD56 in extramedullary MM cells and in bone marrow cells was observed in 9 patients with median follow-up of 40 months and 1 patient died of progression after 47 months.

Figure 1. Probability of overall survival in patients depending on CD56 expression in bone marrow.

Summary/Conclusions: CD56 expression in bone marrow plasma cells significantly increases the OS rate in MM patients regardless the presence or absence of plasmacytomas. Double CD56 negativity both in extramedullary and bone marrow MM cells is a poor prognostic factor with high risk of early relapse and death.

PB2001

BENDAMUSTINE-BORTEZOMIB-DESAMETASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

C. Cerchione1,*, L. Catalano1, A. E. Pareto1, S. Basile1, L. Marano1, I. Peluso1, L. Simeone1, O. Vitagliano1, S. Palmieri2, S. Rocco2, F. Ferrara2, F. Pane1

1Department of Hematology, Zaporizhzhia Regional Clinical Hospital, 2Department of Internal diseases, 3Department of Pathophysiology, 4Department of Pro彼得ropeus of Internal Disease, 5Scientific medical-laboratory center, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine

Background: Bendamustine is a bifunctional alkylating agent, with low toxicity, proved to be effective in relapsed, refractory and in newly diagnosed Multiple Myeloma (MM).

Aims: It has been evaluated efficacy and tolerance of Bendamustine, in combination with bortezomib-dexamethasone (BVD) in patients with relapsed and refractory MM (rMM), whose prognosis is particularly severe. A regional prospective real-life analysis of patients with rMM who had been treated with BVD as salvage therapy has been performed.

Methods: 56 patients (31 M/25 F, Table 1), with rMM, median age at diagnosis 57.3 years (r. 36-82), median age at start of treatment 61.8 years (r.37-83) treated with several lines of treatments (median 6, r. 2-11), every other to the drugs previously received (also Bortezomib), received BVD (Bendamustine 90 mg/sqm days 1,2, Bortezomib 1.3 mg/sqm days 1,4,8,11, Dexamethasone 20 mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression. ISS was equally distributed, and cytogenetic was evaluable in 12 patients, including 1 del13q and one del17q. All the patients had previously been treated with schedule containing bortezomib and IMIDs, and 30% had also received radiotherapy. 67% of them had undergone at least to a single auSCT. All patients were relapsed and refractory to last therapies received in SD, which can be considered as an impressive result in this subset of rMM patients. In particular, for 11 patients, BVD was, after having achieved at least a PR, a bridge to second auSCT, and for two patients a bridge to alloSCT. Median time to response was 1.2 months (r.1-3), median OS from diagnosis was 62.7 months (range 6-151), median OS from start of Bendamustine was 9.8 months (range 2-36).

Table 1

<table>
<thead>
<tr>
<th>Total patients</th>
<th>56</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>31</td>
</tr>
<tr>
<td>Female</td>
<td>25</td>
</tr>
<tr>
<td>Median age, years</td>
<td>57.3 (36-82)</td>
</tr>
<tr>
<td>at diagnosis, (range)</td>
<td>61.8 (37-83)</td>
</tr>
<tr>
<td>at start of BVD, (range)</td>
<td></td>
</tr>
<tr>
<td>Previous regimen</td>
<td></td>
</tr>
<tr>
<td>median. no. (range)</td>
<td>6 (2-11)</td>
</tr>
<tr>
<td>FISH analysis</td>
<td>12/56</td>
</tr>
<tr>
<td>negative</td>
<td>10</td>
</tr>
<tr>
<td>del1q</td>
<td>1</td>
</tr>
<tr>
<td>del11q</td>
<td>1</td>
</tr>
<tr>
<td>Previous therapies: no. of patients(%)</td>
<td></td>
</tr>
<tr>
<td>Bortezomib</td>
<td>56 (100%)</td>
</tr>
<tr>
<td>IMIDs</td>
<td>56 (100%)</td>
</tr>
<tr>
<td>Autologous SCT</td>
<td>38 (67%)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: BVD has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT.

PB2002

VE-CADHERIN IN MULTIPLE MYELOMA: AN INDEPENDENT PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL

B. Samur1,2,*, Y. Kolesnyk3, V. Syvolap4, A. Abramov5

1Department of Hematology, Zaporizhzhia Regional Clinical Hospital, 2Department of Internal diseases, 3Department of Pathophysiology, 4Department of Pro彼得ropeus of Internal Disease, 5Scientific medical-laboratory center, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine

Background: Endothelial damage and perivascular infiltrates are vital in the development of multiple myeloma. Recent studies have found that endothelial dysfunction might be result in multiple myeloma progression and adverse effects of drug implementation. On the other hand, there is a direct correlation between microvessels density in multiple myeloma and parameters of disease progression. Endothelial cells participate in inflammatory events leading to atherosclerosis by regulating endothelial cell permeability via the expression of adhesion molecules localized at the endothelial junction, which plays critical roles in angiogenesis, neovascularization, neoplasm development, stem cells mobilization, and endothelial integrity. Indeed, VE-cadherin chiefly organizes the opening and closing of the endothelial barrier. It was evaluated in 12-cadherins, as a transmembrane protein probably modulates intensity of angiogenesis in multiple myeloma and may be useful in prognosis. However, the predictive role of VE-cadherin as a prognostic factor for survival of patients after treatment of multiple myeloma is not still clear.

Aims: To evaluated the survival prognosis value of circulating VE-cadherin for progression-free survival in patients with multiple myeloma in complete or partial remission.

Methods: One hundred twelve out subjects with multiple myeloma were...
enrolled in the study. Diagnosis and staging of multiple myeloma were defined by current clinical practice guidelines. To be achieving remission chemotherapy with bortezomib, thalidomide, dexamethasone, cyclophosphamide, melphalan, anthracyclines was used accordingly contemporary clinical guidelines. All subjects were at complete or partial remission at baseline. Observation period was up to 12 months. ELISA method for measurements of circulating level of VE-cadherin was used.

Results: Medians of circulating levels of VE-cadherin in subjects without progression of multiple myeloma (n=89) and subjects with progression (n=23) during 12 months were 0.92 ng/ml (95% confidence interval [CI]=0.66-1.19 ng/ml) and 1.77 ng/ml (95% CI=1.47-2.07 ng/ml) (p=0.0002). The best VE-cadherin cutoff value for predicting progression free survival was 1.31 ng/ml with AUC value 0.839 (p=0.0001), the sensitivity and specificity were 77.8% and 61.5% respectively. The presence of high levels of serum VE-cadherin was significantly correlated to a shorter progression-free survival (PFS). In a multivariate analysis along with clinical and biologic prognostic parameters, high serum VE-cadherin level (>1.31 ng/ml) was an independent adverse prognostic variable for PFS (median PFS 9.93 (IC=16.11-71.1) months vs 7.35 (IC=5.75-8.95) months (p=0.02).

Summary/Conclusions: The serum VE-cadherin level is a valuable biomarker for predicting treatment response and an independent prognostic factor for progression-free survival for patients with multiple myeloma.

PB2003

THE UTILITY OF FACS PURIFICATION OF PLASMA CELLS FOR FISH ANALYSIS IN MONOCLONAL GAMMOPATHIES

M. Pereira1,2,.*, G. Marques3, J. Lima3, R. Reis3, A. Coelho3, L. Jorge3, J.J. Lima3, F. Rodrigues3, L. Pinto4, R. Alves5, C. Lopes6, L. Almeida7, J. Sancan8,9, A. Coelho3,1, M. Pereira1,2,*. 1Clinical Hematology Department, Coimbra University Hospital Centre, 2Faculty of Medicine, University of Coimbra, 3Clinical Pathology Department, 4Flow Cytometry Unit, Coimbra University Hospital Centre, Coimbra, Portugal

Background: Despite the prognostic value of chromosomal aberrations, conventional metaphase karyotyping in monoclonal gammopathies (MG) is often uniform to in situ hybridization (FISH) is a simple, quick and effective technique for the detection of cytogenetic aberrations that can overcome this limitation. However, the signal of interest is frequently diluted by the noise of the mixed cellularity of the sample, originating both false negatives and false positives. Fluorescence-activated cell sorting (FACS) of the target cells enables a focused application of FISH on pathologically significant cells – such as the PC in MG – reducing the confounding noise. This is particularly relevant when the percentage of pathologic cells in the sample is low, such as in monoclonal gammopathy of undetermined significance (MGUS) where, by definition, there are less than 10% PC in the bone marrow.

Aims: This study aims to analyze the utility and effectiveness of FACS purification of PC for the cytogenetic workup of MG by FISH.

Methods: We analyzed all FISH studies performed in our laboratory, in individual patients, on clonal interphase FACS-separated bone marrow PC, between the 1st June 2015 and the 15th September 2016. The probes used in our standard MG panel were del(1p32), amp(1q21), t(4;14) and del(17p13.1) (TP53 gene) and, starting in April 2016, t(14;16). We had previously established 20 000 cells per sample as the minimum (and sufficient) number of cells needed to get a confident application of all 5 probes in our lab.

Results: After the exclusion of samples diluted with peripheral blood, we identified 102 patients with FACS separated purified PC. An average of 165 3932270 516 PC were separated per patient, and 98 of the cohort (96.1%) had a sufficient number of cells for the hybridization of at least one FISH probe; all 5 probes were applied in 30% of patients, 4 in 50%, 3 in 12% and 2 in 8%; the motives underlying the selection of fewer than all 5 probes in samples with a sufficient number (>20 000) of cells included the individual decision of the assisting physician and, for t(14;16), the date of the study. Considering only those studies performed after the introduction of t(14;16), all 5 probes were used in 67.2% of patients; we were able to apply four or more probes in 80% of patients with 1% or less bone marrow PC according to flow cytometry. The median age of the 98 patients with a FISH result was 63.6 years old (37.8 to 87.3), and 56.1% were male; 41.8% eventually received a diagnosis of MGUS and 58.2% of multiple myeloma (MM), with an identical median age (64.2±6.9 vs 63.0±10.8 years old, p=NS). We found that 16.3% (of 92) were positive for t(14;14), 12.2% (of 90) for del(17p13.1), 5.6% (of 90) for del(1p32) and 41.1% (of 90) for amp(1q21); t(14;16) was not identified in any of the 30 patients in whom the probe was used. The t(4;14) translocation was present in 22.4% of MM and 7.7% of MGUS patients (p=0.058), and del(17p13.1) was found in 18.5% vs 2.8% in MGUS and MM (p=0.03). del(1p32) (5.6% vs 5.6%, p=NS), del(1q21) (46.3% vs 33.3%, p=NS) and amp(1q21) (46.3% vs 33.3%, p=NS) were identically distributed across diagnoses. We observed that 40.4% of MM and 65.8% of MGUS patients were positive for 20% of less of the tested aberrations, while 54.4% vs 34.2% were positive for 20 to 50%, and 3.5% vs 0% were positive for over 50% of the aberrations.

Summary/Conclusions: We have found that the application of FISH probes in FACS-separated PC is highly efficient with a robust yield, providing a large enough sample for the application of at least two probes in over 95% of patients, irrespective of bone marrow plasmacytosis; in fact, we obtained an average of 165 000 pure PC per patient, which is more than 8-fold higher than the number we consider invariably sufficient to apply 5 probes, which we achieved in at least 80% of patients.

PB2004

CLINICAL SPECTRUM AND EVOLUTION OF MONOCLONAL GAMMOPATHY ASSOCIATED NEUROPATHY VERSUS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PATIENTS

J.M. Byun1,*, I. Kim2, S.-H. Baek3, J.-J. Sung2, Y. Koh2, D.-Y. Shin2, S.-S. Yoon2, S. Park1, C.-S. Kim5 1Seoul Metropolitan Government Seoul National University Boramae Medical Center, 2Seoul National University Hospital, 3Korea University Anam Hospital, Seoul, 4Inje University Haeundae Paik Hospital, Busan, 5Incheon Medical Center, Incheon , Korea, Republic Of

Background: Paraproteinemic neuropathy (PPN) refers to a disorder of the peripheral nervous system associated with a monoclonal gammopathy (MG). It is known that about 10% of idiopathic peripheral neuropathies are of this type. Unfortunately, PPN is often underdiagnosed or confused with chronic inflammatory demyelinating polyneuropathy (CIDP), subsequently leading to inappropriate management. Since progression of neuropathy is associated with possible malignant conversion of underlying monoclonal gammopathy, it is important to recognize underlying hematological conditions.

Aims: We aimed to determine whether the clinical characteristics and course differed in patients with PPN compared to those with CIDP in order to identify factors useful for differential diagnosis.

Methods: This study was carried out at Seoul National University Hospital, which is a tertiary academic center. During the period between January 2005 and December 2016, patients with 1) monoclonal gammopathy of undetermined significance (MGUS), and 2) CIDP were identified. Those with previous history of cancer or autoimmune disease requiring treatment with immunomodulatory agents were excluded from analyses. In the end, a total of 18 MGUS patients and 34 CIDP patients, with complete set of data including clinical physical examinations, electrodagnostic studies, and laboratory test results, were enrolled.

Results: In both groups, males were predominant. IgG MG was most common (55.6%) in our cohort. PPN appeared to be mainly sensory regardless of heavy chain or light chain. Compared to PPN patients, CIDP patients were associated with motor symptoms manifesting as motor weakness (50.0% vs 91.2%, p=0.001) and ataxia (44.4% vs 61.8%, p=0.043) (Table 1). There were equal number of axonal type neuropathy and demyelinating type neuropathy in patients with PPN, and there were no differences in type of neuropathy between various immunoglobulin subclasses. However, demyelinating type PPN was associated with more severe clinical presentations, including more dysesthesia, pain and sensory symptoms. During median follow-up of 49 months, 2 PPN patients developed overt hematologic malignancies: 1 case of Waldenstrom macrogammopathy and 1 case of AL amyloidosis. None of them showed malignant transformation within 8 months of neuropathy development, and were associated with worsening neuropathic symptom at the diagnosis of hematologic malignancy. There were no differences between the two groups with regards to overall survival.

Table 1. Clinical characteristics of all enrolled patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PPN (n=18)</th>
<th>CIDP (n=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.0 (52.0-73.0)</td>
<td>67.0 (53.0-79.0)</td>
</tr>
<tr>
<td>Gender</td>
<td>12M/6F</td>
<td>29M/5F</td>
</tr>
<tr>
<td>Heavy chain</td>
<td>IgG (55.6%)</td>
<td>IgG (61.8%)</td>
</tr>
<tr>
<td>Light chain</td>
<td>IgA (33.3%)</td>
<td>IgM (14.7%)</td>
</tr>
<tr>
<td>Sensory vs Motor</td>
<td>15/3</td>
<td>18/16</td>
</tr>
<tr>
<td>Dysesthesia</td>
<td>9/9</td>
<td>13/21</td>
</tr>
<tr>
<td>Pain</td>
<td>13/5</td>
<td>14/20</td>
</tr>
<tr>
<td>Sensory symptoms</td>
<td>14/4</td>
<td>17/17</td>
</tr>
<tr>
<td>Motor symptoms</td>
<td>3/15</td>
<td>2/33</td>
</tr>
<tr>
<td>Motor weakness</td>
<td>9/9</td>
<td>14/20</td>
</tr>
<tr>
<td>Ataxia</td>
<td>1/17</td>
<td>5/29</td>
</tr>
<tr>
<td>Serum VE-cadherin level (ng/ml)</td>
<td>1.31 (1.07-1.63)</td>
<td>1.31 (1.07-1.63)</td>
</tr>
<tr>
<td>AUC value</td>
<td>0.839</td>
<td>0.839</td>
</tr>
</tbody>
</table>

haematologica | 2017; 102(s2) | 797
Summary/Conclusions: Although both PPN and CIDP patients suffer from sensorimotor symptoms, CIDP patients were more often associated with superimposed motor symptoms. Among PPN patients, demyelinating type neuropathy seems to be associated with more severe clinical presentations. Worsening of neuropathic symptoms in PPN patients warrants a high level of suspicion of malignant transformation of underlying disease.

PB2005
MOLECULAR GENETIC CRITERIA PREDICTING THE EFFICIENCY OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Z. Minchenko1, O. Dmytrenko2, A. Chechetkin1, Z. Chubukina1, A. Schmid1, V. Khomenko2, M. Lukach1, V. Khromchenko1
1Immunogenetic Laboratory, National Research Center for Radiation Medicine of National Academy of Medical Science of Ukraine, 2O.O. Bogomolets National Medical University, 3Hematology and Transplantation Department, National Research Center for Radiation Medicine of National Academy of Medical Science of Ukraine, 4Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine

Background: Global gains in treatment of MM using auto-PBHSCT testify to heterogeneity of long-term outcomes of transplantation - different term of the achievement and duration of complete remission, progression-free survival (PFS), overall survival (OS). These facts determine individual approach to the patient and the choice of therapeutic tactics.

Aims: Finding molecular genetic criteria of predicting the effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) for improving of algorithm of multiple myeloma (MM) patients cure at various stages of treatment.

Methods: The study involved 61 patients with MM and relapse and primary therapy resistant patients. Molecular cytogenetic, immunogenetic, hematological and statistical methods were used.

Results: Since appearance of genetic abnormalities in the malignant plasma cells is one of the pathogenic mechanisms of the disease, genetic support of patients is essential. It was determined that the carriage of the allele HLA-DQB1*02 in MM patients is associated with a high risk of high-dose chemotherapy resistance (F=4.83, p=0.028; OR=1.75, p=0.038), and achieving remission after auto-PBHSCT is associated with carriage of haplotype HLA-C*06 - HLA-DQA1*01:01 (F=4.87, p=0.028; OR=7.34, p=0.05). Abnormalities of chromosomes 4, 11, 13, 14, 16 and 17 were determined in 35 of 61 (57%) MM patients with complicated disease course and minimal therapy response. Significant alterations were revealed in the presence of two or more abnormal clones (23 patients (37.7%), Ro Sparim=0.42, p < 0.05), deletion of chromosome 17 (17 patients (27.9%), Ro Sparim=0.41, p < 0.05), deletion/mosaicism of chromosome 13 (10 of 15 patients surveyed, Ro Sparim=0.30, p < 0.05), the translocation t(4;14) (4 patients (6.6%), Ro Sparim=0.50, p < 0.02).

Summary/Conclusions: The results indicate the necessity of introducing the molecular genetic support into protocol of examination MM patients on various stages of treatment with auto-PBHSCT.

PB2006
THE INFLUENCE OF MINIMAL RESIDUAL DISEASE AND TUMOR LOAD ON THE PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS
A. Garifullin1,*, S. Voloshin1, A. Kuvshinov1, Z. Chubukina1, A. Schmidt1, S. Bessmeltsev1, A. Chechetkin1
1Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation

Background: Use of modern drugs and their combinations in the complex antmyeloma therapy (induction, high-dose therapy (HDT) with autologous stem cell transplantation (ASC-T), consolidation and maintenance therapy) to improve efficacy of treatment and duration of responses. Despite the achievement of complete response (CR) many patients has a relapse which is caused by activation of residual clonal plasma cells.

Aims: To define influence of induction therapy regimens, HDT with ASCT to the frequency of Minimal Residual Disease (MRD) negative status and estimate a role MRD in duration of Progression Free Survival (PFS) in multiple myeloma (MM) patients.

Methods: We analyzed 52 patients with MM (median age 55 years, male/female – 2:1:1). The induction therapy with Bortezomb-based regimens (VD, OVD, VMP, PAD) was used in 38/52 (69%) patients, Immunomodulator-based regimens (Thal+D, RD, VRD, PomD) – in 14/52 (27%), chemotherapy – in 2/52 (4%). ASC-T is carried out 31 (59.6%) patients. Primary tumor cells phenotype and MRD were detected by S-color flow cytometry. Clonal plasmatic cells were detected by markers: CD38, CD138, CD45, CD19, CD20, CD27, CD56 (Beckman Coulter, Brea, USA 2017). MRD-negative status considered in identifying less than 1 tumor cell in 10000 (0.01%).

Results: MRD-negative CR was reached in 23.8% (10/42) patients after 4-6 cycles of therapy. The frequency of MRD-negative status in the “Bortezomb group” was 31% (8/28), in the “Immunomodulator group” – 7.7%, (1/13) (Chi-square p=0.1; p > 0.05). The general frequency of MRD-negative CR after HDT with ASCT was 33.3% (7/21). The carrying out HTD with ASCT allowed to MRD eradication in 36.4% (4/11) patients. One patient with a “light chain” myeloma lost MRD-negative CR after HTD with ASCT that led to development of a clinical relapse after 6 months. Carrying out a maintenance therapy with bortezomib or lenalidomide didn’t allow to achieve MRD-negative status in patients with MRD-positive response. On the contrary, achieve MRD-negative status promoted to increase of PFS. The PFS median in MRD-negative group of patients (n=36. 21 CR, 6 VGP4, 9 PR) was 21 months, in the MRD-negative group (n=16) – 66 months (p=0.008). The PFS median patients with CR was higher in the MRD-negative group than in the MRD-positive group (66 and 48 months, respectively, p=0.0045). The tumor load is also a strong prognostic factor like MRD status. Patients who attained low-level MRD had of benefit in the duration of PFS: -0.01% - 66 months, 0.01%-1% - 48 months at 0.1%-1% - 22 months, >1% - 10 months (p=0.0009) (Figure 1).

Summary/Conclusions: The frequency of achievement MRD-negative doesn’t depend from program of induction therapy, HDT with ASCT and maintenance therapy. Negative prognostic role of MRD status independent from clinical response. Presence of MRD after treatment to associated with decrease of PFS and early relapse. Control of MRD allows to increase of PFS and can be done by means of modern drugs and its combinations, HDT with ASCT and maintenance therapy. Impact of MRD requires further studies, especially after HDT with ASCT.

PB2007
QUALITY OF RESPONSE AS PREDICTOR OF SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN REAL LIFE MULTIPLE MYELOMA PATIENTS IN A SINGLE INSTITUTION
A. Pinho1,*, A. Roque1, E. Cortesio1, J. Espadana1, A. B. Sarmento1, C. Gerais1, M. L. Ribeiro1
1Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra, 2Faculty of Medicine and Cimago, University of Coimbra, Coimbra, Portugal

Background: High dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is the standard treatment approach for younger patients with multiple myeloma (MM). Since the introduction of proteasome inhibitors and immunomodulatory drugs in MM treatment more patients achieve durable responses and better disease control before ASCT.

Aims: To evaluate the association between the depth of response before ASCT and survival outcomes in a cohort of patients with MM.

Methods: Retrospective analysis of patients with MM treated with HDC and ASCT between 2007 and 2016 in a single institution. All patients received autologous stem cell support after conditioning with high dose melphalan (200 mg/m2 and 140mg/m2 for patients with renal insufficiency). Response was assessed 100 days after ASCT according to the International Myeloma Working Group response criteria. The Kaplan-Meier method was used to estimate progression free survival (PFS) and overall survival (OS) and comparison between groups was performed by log-rank test. The prognostic factors of survival were analyzed by Cox regression univariate and multivariate analysis.

Results: We included 195 MM patients, mainly males (57.9%) with a median age at ASCT of 61 years (28-71). The most prevalent subtype was IgG k (44%). The median number of previous therapeutic lines was 1 (1-4) and the majority of patients (61%) received bortezomib as part of first-line regimen. Patients undergone ASCT within a median of 10 months after diagnosis. With a median follow-up time from ASCT of 28.55 months (2.8-121.4), OS at 2 years was 79.8% (95% CI 74.2-85.4) and the median PFS was 51 months (95% CI 44.2-57.7). The unadjusted survival rates of patients with different levels of responses were as follows: complete response (CR) – 81.9% (75.6-88.2), very good partial response (VGPR) – 55.2% (48.6-61.8), partial response (PR) – 31.5% (25.2-38.8), disease progression/relapse (PD) – 10.4% (7.1-13.7), death – 16.4% (12.6-20.3).

Summary/Conclusions: The frequency of achievement MRD-negative doesn’t depend from program of induction therapy, HDT with ASCT and maintenance therapy. Negative prognostic role of MRD status independent from clinical response. Presence of MRD after treatment to associated with decrease of PFS and early relapse. Control of MRD allows to increase of PFS and can be done by means of modern drugs and its combinations, HDT with ASCT and maintenance therapy. Impact of MRD requires further studies, especially after HDT with ASCT.
5 years was 83.8% and 68.9% and PFS was 74.8% and 37.3%, respectively.

Before ASCT, 101 patients (51.8%) achieved very good partial response (VGPR) or better (≥VGPR) and 94 patients (48.2%) a partial response (PR). The patients in ≥VGPR presented significantly longer OS (median OS not reached vs 96.9 months, p=0.023) and PFS (58.5 vs 41.2 months, p=0.003) compared with those in PR. At 100 days after ASCT, 107 patients (54.9%) presented ≥VGPR, 79 (40.5%) PR and 7 (3.6%) progressive disease or death. Two patients were not assessed due to loss of follow-up. The group of ≥VGPR showed superior OS (median OS not reached vs 72.4 months, p=0.023) and PFS (58.5 vs 34.7 months, p=0.007) compared to the PR group. We did not find statistically significant differences in survival of patients who achieved ≥VGPR before or after ASCT. Univariate analysis indicates that depth of response before and after ASCT (≥VGPR vs PR) are significant predictors of OS (HR 0.49; 95% CI 0.31-0.80, p=0.004 and HR 0.49; 95% CI 0.30-0.81, p=0.005) and PFS (HR 0.50; 95% CI 0.27-0.92, p=0.026 and HR 0.49; 95% CI 0.27-0.90, p=0.021).

Multivariate regression models confirmed that these factors retain their prognostic value after adjustment for age, International Staging System stage and number of previous lines of treatment.

Summary/Conclusions: These findings provide evidence for quality of response as a predictor of OS and PFS after ASCT in patients with MM. Outcome after ASCT seems to be better for MM patients who achieve deep responses (at least VGPR) before or after transplant. Our results support the use of more effective induction regimens in order to improve initial response as this may correlate with higher response rates and survival post-ASCT.

PB2008
LEPTOMENINGEAL INFILTRATION SCREENING SHOULD BE PERFORMED IN PATIENTS DIAGNOSED WITH PLASMA CELL LEUKAEMIA
M.Q. Salas1*, V. Clapes2, N. Garcia1, C. Baca3, R. Velasco4, E. Gamundi5, M.Q. Salas1,*, V. Clapes2, N. Garcia1, C. Baca3, R. Velasco4, E. Gamundi5, A. Sureda M.Q. Salas1*, V. Clapes2, N. Garcia1, C. Baca3, R. Velasco4, E. Gamundi5, A. Sureda

Background: Plasma cell leukaemia (PCL) is a rare and aggressive plasma cell (PC) disorder characterized by the presence of circulating plasma cells. PCL can either originate de novo (dPCL) or as secondary PCL (sPCL) in patients with relapsed/refractory multiple myeloma (MM). PCL has a more aggressive clinical presentation than MM with a more frequent extramedullary involvement, such as leptomeningeal infiltration. However, because of the low incidence of this entity, most clinical data come from small retrospective studies.

Clinical diagnostic criteria of PCL are today under review and the incidence of leptomeningeal infiltration is unknown.

Aims: We aimed to study the clinical features with special emphasis in the incidence of leptomeningeal infiltration in patients diagnosed with PCL in our centre.

Methods: Seventeen patients were diagnosed of PCL between 2008 to 2016 in our centre. PCL was defined based on criteria from the Chronic Leukaemia Myeloma Task Force, by the presence of ≥2x10⁹/L peripheral blood PC or plasmacytosis in our centre. PCL was defined based on criteria from the Chronic Leukaemia Myeloma Task Force, by the presence of ≥2x10⁹/L peripheral blood PC or plasmacytosis in our centre. PCL was defined based on criteria from the Chronic Leukaemia Myeloma Task Force, by the presence of ≥2x10⁹/L peripheral blood PC or plasmacytosis in our centre.

Results: Seventeen patients with PCL were included. Six (35.3%) were dPCL and eleven (64.7%) sPCL. Median age at diagnosis was 57 years (range 35-78) and 8 (47.1%) were males. Clinical and analytical features at the moment of diagnosis are recorded in Table 1.

Table 1.

Five (29.4%) patients presented with leptomeningeal infiltration; in three of them it was diagnosed at the time of the diagnosis of PCL. All the patients had neurological features. Thirteen (76.4%) patients were able to start a curative treatment: VD in 7 (53.8%) patients, VTD in 2 (15.4%), VAD in 1 (7.7%), D-PACE in 1, MTX-ARAC in 1 patient and RD in the remaining one. Three patients received intrathecal treatment. The intention-to-treat response was: 2 (15.4%) CR, 2 PR, 7 (53.8%) refractory disease/progression and 2 non-evaluable. Of the 2 (15.4%) patients achieved enough response (2 CR) to undergo an autologous stem cell transplant (ACST) and only 1 to undergo an allogenic-SCT. With a median follow up of 4 months for all the patients included, median of PFS was 3 (CI 95% 0.47-4.76) months and median of OS was 4 (IC 95% 0.47-7.53) months.

Summary/Conclusions: Prospective multicenter studies are required to provide a better understanding of the pathogenesis of PCL. Staging procedures should include lumbar puncture or magnetic resonance at diagnosis when extramedullary involvement is suspected. Intrathecal prophylaxis with cytarabine, metotrexate and dexethasone is not today a standard of care for patients with PCL.

PB2009
MANAGEMENT AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA IN REAL-WORLD SETTINGS IN BULGARIA, CROATIA AND SLOVAKIA
1Clinic for Hematology, University Hospital Sofia, Sofia, Bulgaria, 2School of Medicine, Merkur University Hospital, Zagreb, Croatia, 3Department of Hematology, Transfusiology, University Hospital, Bratislava, Slovakia, 4Kantar Health, Paris, France, 5Hemetsberger medical services, Vienna, Austria, 6Amgen (Europe) GmbH, Zug, Switzerland, 7Amgen (Europe) GmbH, Vienna, Austria

Background: The multiple myeloma (MM) treatment (Tx) landscape is rapidly evolving, with varying Tx practice patterns and access schemes across countries. However real-world (RW) data describing patient (pt) management, MM Tx use and outcomes in some Eastern European Countries are limited.

Aims: To understand the characteristics, management, Tx patterns and outcomes of pts with symptomatic MM in a RW setting in Bulgaria (BG), Croatia (HR) and Slovakia (SK).

Methods: Data were collected within a cross-sectional (X) and retrospective (R) phase of a chart review in 6 countries between June/15 and June/16 by oncologist-hematologists who managed at least 15 pts with MM per month (mo) and were responsible for initiating MM Tx. Data from 3 countries with limited access to MM Tx are shown. In the X-phase, data included characteristics and current Tx by line of therapy for all pts with MM seen during a 3-week observation period, regardless of pts’ Tx status and strategy. In the R-phase, data included pt and disease characteristics at diagnosis, Tx response, comorbidities and outcomes by Tx line. Pts were selected in reverse chronological order and those who had completed specific lines of active Tx within the past 3 mo were included as follows: 3 pts in first line (1L), 4 pts in second-line (2L) and 7 pts in third or higher lines. Analyses were descriptive.

Results: In the X-phase, 7 physicians from BG, 6 from HR and 5 from SK contributed to the X-phase. In BG, pts contributed 43, 39 and 44 pts respectively. Of those, 51% and 52% of pts were <65 years; 41%, 35% and 38% were 65-75 years. Only 4 pts (from BG) were enrolled in clinical trials. Median time since diagnosis was 24, 31 and 54 mo in BG, HR and SK respectively. In BG, fewer pts received stem cell transplantation (SCT) than in HR and SK (8% vs 24% and 36%). The proportion of pts that had received SCT at any point increased from 1L to 2L (3% to 19%, 7% to 35% and 9% to 54% in BG, HR and SK respectively). 82% of pts in BG, and 70% both in HR and SK were currently receiving Tx (Table 1), while 17%, 30% and 25% of pts respectively, were treated previously. Only 4 pts (1 in BG and 3 in SK) had never been treated. In the R-phase, 6 physicians from BG and 3 from HR contributed to the R-phase analysis. In BG, pts included 43, 39 and 44 pts respectively. Of those, 51% and 52% of pts were <65 years; 49%, 36% and 39% were 65–75 years. Depth of response, as assessed by physicians, decreased in BG with each additional line of Tx, but remained stable or increased in HR and SK: 43%, 55% and 50% of pts achieved at least a very good partial response (≥VGPR) in 1L, while 13%, 54% and 69% achieved ≥VGPR in 2L. The most common (≥2%) adverse events (AEs) and comorbidities in 1L were anaemia (23% in HR, 43% in SK) and neutropenia (43%) and thrombocytopenia in SK (21%). Mostly, these AEs did not impact on Tx.

Summary/Conclusions: These findings suggest a high unmet need for access to more effective and innovative Tx options with manageable safety profiles in these countries. In particular, in BG where bortezomib- and chemotherapy-based regimens are the only treatments used, pts might be re-treated with the same agents, which may explain why most do not achieve ≥VGPR from 2L. In HR and SK, sustained or increased rates of ≥VGPR in 2L may be due to the use of newer or different agents from those used in 1L and to the fact that most pts had previously received a SCT. These RW data provide useful input for economic evaluations of new MM agents to include in earlier Tx lines in these countries.
Background: Multiple myeloma (MM) patients refractory to proteasome inhibitors, IMiDs or both, have an extremely poor prognosis. Moreover, they frequently fail to respond to further therapies, and represent a major challenge in everyday clinical practice.

Aims: With this in mind, we treated 12 patient with relapsed MM with a single shot of medium dose melphalan (60 mg/m2) between October 2010 and January 2016.

Methods: The median age was 72 years (range, 62 – 79) and the median time from initial diagnosis to melphalan treatment was 51 months (range, 24 – 144). Patients were heavily pretreated with a median number of 3 prior lines of therapy. All patients were refractory to the previous therapeutic regimens and had failed to respond or were refractory to regimens containing bortezomib. Seven patients (60%) had previously received at least one IMiD, 8 (67%) autologous stem cell transplantation (ASCT) and 1 allogeneic stem cell transplantation (1 Escherichia coli bacteremia, 1 fever of unknown origin, 1 erysipelas). We observed 3 cases of gastrointestinal toxicity (1 bleeding, 1 subocclusion, 1 mucosal ulceration), 2 cases of clinically documented infection (1 Escherichia coli bacteremia, 1 fever of unknown origin, 1 erysipela) and 2 deep vein thrombosis. Response was assessed between six and eight weeks after melphalan therapy. Overall, 10 out of 12 patients had a response (1 complete response, 3 very good partial response, 2 partial response and 4 stable disease); only 2 had progressive disease. Median overall survival was 11 months (range, 2 – 37). 10 of 12 patients relapsed after a median time of 5 months (range 2-12). Concerning two patients not relapsed, 1 patient died in partial response 8 months after therapy of other causes; 1 patient is still alive, in complete remission 18 months after melphalan. He underwent ASCT and maintenance with lenalidomide.

Summary/Conclusions: Many patients refractory to proteasome inhibitors, IMiDs or both, have an extremely poor prognosis. Moreover, they frequently fail to respond to further therapies, and represent a major challenge in everyday clinical practice.

Aims: In this report, we describe our retrospective experience on the administration of lenalidomide 25 mg every other day for patients with MM and RI.

Methods: From March 2014 to February 2016, 19 consecutive patients, 11 female and 8 male, with a median age of 63.3 years (range: 49-81) affected by advanced, resistant and progressive MM (median number of previous treatment lines: 3, range : 1-5, all including bortezomib) with concomitant renal failure not in dialytic support (median calculated CICr 36.4 ml/min, range : 18-66) were treated, after informed consent, with monthly 21-day courses of 25 mg lenalidomide every other day and dexamethasone (20-40 mg on days 1-8-15-22, every 28 days).

Results: Disappearance of urinary light chain and reduction of serum creatinine (complete response) were detected in 7 patients (36.8%); 3 patients (15.7%) had a very good partial response, 3 (15.7%) had a partial response, 4 of them (21.0%) were in stable disease, whereas 2 patients (10.5%) had signs of progressive disease. Overall response ratio was 68.2%. More than half of the patients (11/19, 57.8%) had a renal response (median calculated CICr 51.5 ml/m2/min, range 20-148). Median progression free survival was 10.4 months (range 3-18 months). No patient experienced grade 4 myelotoxicity; four patients required red cell transfusions for grade 3 anemia. No SAE occurred during treatment.

Summary/Conclusions: Dose adjustment RI-related of Lenalidomide is recommended in most guidelines, but there is no a leading scheme with a proven effectiveness more than others. These preliminary observations point to a significant therapeutic effect of lenalidomide, at the dose of 25 mg every other day for 21 days, in more than half of a small population of patients with advanced MM and renal impairment, with not negligible logistic and economic advantages. However, these results should be validated by controlled studies involving larger number of patients.

PB2011

LENALIDOMIDE AT THE DOSE OF TWENTY-FIVE MG EVERY OTHER DAY IN PATIENTS AFFECTED BY MULTIPLE MYELOMA AND RENAL FAILURE: A REAL-LIFE EXPERIENCE

C. Cerchione 1,*, L. Catalano 1, A.E. Pareto 1, D. Nappi 1, L. Peluso 1, K. Ferrara 1, M. Di Perna 1, I. Zacheo 1, F. Pane 1
1Hematology, OARMN Pesaro, Pesaro, Italy

Background: Lenalidomide, available as oral compound, is an IMiD with both antiproliferative and immunomodulatory activity which is largely used in the management of newly diagnosed, relapsed or refractory MM and as maintenance therapy after autologous stem-cell transplantation. Due to its renal route of excretion, it is mandatory to adjust lenalidomide dose in patients with RI, guided by Creatinine Clearance (CICr), in order to impede a systemic prolonged exposure that could boost myelosuppression. With normal renal function, lenalidomide reaches its maximal plasma concentration after a median time of 0.6-1.5 h, and it is primarily metabolized by the liver and eliminated unchanged in the urine. Changes in renal function can significantly affect the pharmacokinetics of lenalidomide. In patients with RI, the half-life of lenalidomide increases up to 9 hours if moderate/severe renal impairment is present (creatinine clearance <50 or <30 ml/min, respectively). In the latter cases a reduction of the daily dose is recommended. Dose adjustment based on RI severity decreases the daily amount of lenalidomide from 15 up to 5 mg (in patients undergoing dialysis); other studies include a schedule with 10 or 15 mg every other day. However, there is no theoretical assumption against the possibility that protracting the time of full standard doses can be equally effective and tolerated by patients requiring reduced doses.

Aims: In our series, we evaluated the feasibility of the dose adjustment of lenalidomide every other day in MM patients with RI and the efficacy of this approach.

Methods: From March 2014 to February 2016, 19 consecutive patients, 11 female and 8 male, with a median age of 63.3 years affected by MM (median number of previous treatment lines: 3, range : 1-5, all including bortezomib) with concomitant renal failure not in dialytic support (median calculated CICr 36.4 ml/min, range : 18-66) were treated, after informed consent, with monthly 21-day courses of 25 mg lenalidomide every other day and dexamethasone (20-40 mg on days 1-8-15-22, every 28 days).

Results: Disappearance of urinary light chain and reduction of serum creatinine (complete response) were detected in 7 patients (36.8%); 3 patients (15.7%) had a very good partial response, 3 (15.7%) had a partial response, 4 of them (21.0%) were in stable disease, whereas 2 patients (10.5%) had signs of progressive disease. Overall response ratio was 68.2%. More than half of the patients (11/19, 57.8%) had a renal response (median calculated CICr 51.5 ml/m2/min, range 20-148). Median progression free survival was 10.4 months (range 3-18 months). No patient experienced grade 4 myelotoxicity; four patients required red cell transfusions for grade 3 anemia. No SAE occurred during treatment.

Summary/Conclusions: Dose adjustment RI-related of Lenalidomide is recommended in most guidelines, but there is no a leading scheme with a proven effectiveness more than others. These preliminary observations point to a significant therapeutic effect of lenalidomide, at the dose of 25 mg every other day for 21 days, in more than half of a small population of patients with advanced MM and renal impairment, with not negligible logistic and economic advantages. However, these results should be validated by controlled studies involving larger number of patients.
Results: From March to December 2016 we admitted 57 pts with RI and monoclonal component (29 F, 28 M, 41-83 yrs range), 20 are known MM pts and 37 de novo pts. We diagnosed 11 de novo MM, 13 known MM with a de novo RI, 12 diabetes related RI, 3 amyloidosis, 16 other causes.

Summary/Conclusions: The implementation of the International Myeloma Working Group Recommendations in a routine clinical practise confirmed its feasibility and utility in his optimal workload of MM pts. We obtained diagnosis of RI within 4 days, both in known and in de novo MM pts, with a positive impact on reduced hospitalization, unnecessary dialysis and steroids overtreatment.

PB2013

NOCARDIOSIS PROVOKED BY NOVEL AGENTS AT RELAPSED MULTIPLE MYELOMA: CASE SERIES

Z. Bolaman1, A. Turgutkaya1, E. Ceylan2, B. Gültüken Korkmazgil3, M. Telli3, C. Karaman4, I. Yavasoglu1

1Adult Hematology, 2Pulmonology, 3Microbiology, 4Radiology, Adnan Menderes University Medical Faculty, Aydin, Turkey

Background: The proteosome inhibitors and immunomodulatory drugs which are used in MM treatment enhance the risk of infection by several mechanisms. Nocardial infections are rare in Turkey.

Aims: Here, we present three relapsed myeloma cases which developed nocardia pneumonia.

Methods: Case-1: 66 year old man, who has a history of autologous SCT 4 years ago and lenalidomide usage because of IgG kappa type myeloma, has been prescribed bortezomibe for the relapse of the disease. He was immunocompromised not only because of the myeloma, and also because of the diabetes and renal failure without dialysis. He was admitted to the hospital because of the productive cough. His lymphocyte count was 1290/mm3 and flow-cytometric analysis showed CD5:<8% and CD20:<1%. Thorax CT showed 39x39x45 mm mass like lesion. Bronchoscopy examination showed branched bacillus via modified acid-fast and Gram stain. This typical morphological appearance was defined as Nocardia spp. Imipenem/cilastatin treatment started and control CT was performed. Case-2: 71 year old woman, who has a diagnosis of IgG kappa type myeloma; this situation tends to provoke rare opportunistic infections such as nocardiosis. Thus, in these patients; it is significant to follow the lymphocyte count closely and to keep in mind that kind of rare microorganisms.

Results: From March to December 2016 we admitted 57 pts with RI and monoclonal component (29 F, 28 M, 41-83 yrs range), 20 are known MM pts and 37 de novo pts. We diagnosed 11 de novo MM, 13 known MM with a de novo RI, 12 diabetes related RI, 3 amyloidosis, 16 other causes.

Summary/Conclusions: The proteosome inhibitors and immunomodulatory drugs which are used for the treatment of MM make T cell dysfunction and considering B cell dysfunction is also present because of the nature of the disease; this situation tends to provoke rare opportunistic infections such as nocardiosis. Thus, in these patients; it is significant to follow the lymphocyte count closely and to keep in mind that kind of rare microorganisms.

PB2014

LENALIDOMIDE IN PATIENTS WITH DIALYSIS-DEPENDENT END STAGE RENAL FAILURE (ESRF) AND MULTIPLE MYELOMA

P. Di Ciaccio1,*, S. Ling1

1Department of Haematology, Liverpool Hospital, Sydney, Australia

Background: Lenalidomide is an oral immunomodulatory medication with clinical efficacy in relapsed/refractory and treatment naïve multiple myeloma (MM),Sq- myelodysplasia and lymphoma. Lenalidomide is eliminated predominantly unchanged by urinary excretion. Renal impairment is common in MM (15-40%) and approximately 10% of MM requires dialysis. However, there is a paucity of clinical safety data of Lenalidomide in ESRF. There is evidence that Lenalidomide can be safely used in patients with moderate and severe renal dysfunction with dose adjustment. However, published data in hemodialysis-dependent patients is limited to a handful of patients across small retrospective analyses and case reports. Patients with ESRF have generally been excluded from clinical trials investigating Lenalidomide. Phase III trials in the relapsed setting (MM-009, MM-010) excluded patients with a serum creatinine >221μmol/L. The FIRST trial (MM-020), investigating upfront use, excluded patients dependent on dialysis. There is no accepted clinical standard on the most appropriate dosing of Lenalidomide in dialysis. The manufacturer has provided guidelines, being 5mg daily, day 1-21, every 28 days (equivalent to 105mg per cycle). There is alternate well-cited pharmacological dosing that the more appropriate starting dose is likely 15mg per 3 times per week, given post-dialysis (equivalent to 135mg per cycle). Aims: To provide real-world evidence of an institutional experience of the use of Lenalidomide in dialysis-dependent MM.

Methods: We performed a retrospective audit of our in-centre experience with treating dialysis-dependent MM with Lenalidomide and included patients who completed at least one cycle of therapy. Patients were assessed for haematological toxicity, significant infective complications, thrombosis, disease response and progression-free survival. Best response was stratified by IMWG criteria. Patients’ baseline characteristics, prior therapies, cytogenetics and FISH data were collected.

Results: We identified 5 patients treated between 2010 and 2017, aged between 54 to 73 years old. All patients had relapsed/refractory MM and dialysis dependent ESRF. The median number of prior therapies was two. One patient had (11,14) on FISH and died from progressive disease. Dose schedules are shown in the Table 1. Almost all patients experienced grade III-IV haematological toxicity and 60% had grade III-IV infection. There was a positive correlation between dose and toxicity, and furthermore there appeared to be an inverse relationship between age and tolerated dose. Haematological toxicities and infection were ameliorated by dose adjustment in most instances. There was no drug related mortality, however one patient died of progressive disease. Four of the five patients were prescribed aspirin thromboprophylaxis, with no proven thrombotic complications seen. Where possible to assess, the ORR was 75% (3/4), with 2 patients achieving a very good partial response (VGPR), 1 partial response and 1 progressive disease. The lowest starting dose in this cohort was 10mg twice/week and the maximum dose was 25 mg three times/week.

Table 1.

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>66</td>
<td>72</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Renal Function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>229</td>
<td>228</td>
</tr>
<tr>
<td>Albumin</td>
<td>32</td>
<td>33</td>
</tr>
<tr>
<td>Proteinuria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>32</td>
<td>33</td>
</tr>
<tr>
<td>Myeloma Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG kappa type myeloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td>1290/mm3</td>
<td>1290/mm3</td>
</tr>
<tr>
<td>Flow-cytometric analysis</td>
<td>CD5:&lt;8% and CD20:&lt;1%</td>
<td>CD5:&lt;8% and CD20:&lt;1%</td>
</tr>
<tr>
<td>BCR-ABL</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CT Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenalidomide dose</td>
<td>105mg per cycle</td>
<td>105mg per cycle</td>
</tr>
<tr>
<td>CT Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bortezomib</td>
<td>10mg twice/week</td>
<td>10mg twice/week</td>
</tr>
<tr>
<td>Prednisone</td>
<td>10mg twice/week</td>
<td>10mg twice/week</td>
</tr>
<tr>
<td>Response</td>
<td>PoCR</td>
<td>VGPR</td>
</tr>
<tr>
<td>Toxicity</td>
<td>grade III-IV</td>
<td>grade III-IV</td>
</tr>
</tbody>
</table>
| Summary/Conclusions: Our experience builds on the emerging evidence that reduced dose of Lenalidomide can be safely prescribed for dialysis-dependent MM with clinical efficacy. Our cohort had most patients on dialysis only. There was significant variation of dose-related tolerability between patients. However, toxicity was manageable with diligent monitoring and dose adjustment.

haematologica | 2017; 102(s2) | 801
PB2015

STUDY USE OF 18-F FDG PET / CT SCANNING INTO THE FIRST FOLLOW UP OF PATIENTS WITH MULTIPLE MYELOMA AND ASSOCIATION WITH BIOCHEMICAL RESPONSE

K. Vallejo Luna1, M. Simó2, J. Montoro3, C. Palacio3, M. Junquera4, M. Girone1ola Mesa4, 5

1Hematology, Vall d’Hebron Institute of Oncology, 2Department of Nuclear Medicine, 3Department of Clinical Diagnostic, 4Department of Hematology, Hospital Universitario de Vall d’ Hebron, Barcelona, Spain

Background: Positron computed tomography (PET / CT) with 18F fluoro-deoxyglucose-labeled glucose (FDG) is a reliable technique with high sensitivity and specificity for assessing skeletal involvement and recent studies propose it as a method for predicting treatment response in multiple myeloma. Conventionally, the response is measurable by the monoclonal component in both serum and urine and Minimal residual disease (MRD) by flow cytometry has been established as a mandatory tool. The studies are aimed at combining the measurement of paraprotein with imaging tests that help to promptly define response or failure to the treatment.

Aims: The primary endpoint was the correlation of the biochemical response with the FDG PET/CT in a second evaluation after first line treatment. The secondary endpoint was the correlation between MRD and second FDF PET/CT.

Methods: We included in this retrospective and observational study at University Hospital Vall d’Hebron, all patients with newly MM and PET/CT before to start a first line treatment and a second PET/CT when completing treatment. PET/CT were analyzed by the department of Nuclear Medicine with experience to grade the lesions in MM, were evaluated and categorized into positive or negative according to the criteria proposed by Zamagni, et al. The biochemical response was defined according to the standard IWG response criteria.

Results: Eighteen patients (8 males and 10 females) with untreated MM entered, seven patients were classified with ISS III, fifteen had a good performance status, none presented renal lesion, only 16% had hypercalcemia and 66% showed immunorepressurization. Ten patients were IgG isotype, six were classified as light chains myeloma and two patients were oligosecretors. Seventeen patients had bone marrow infiltration with a median of 42% plasmatic cells. Two patients had a extramedullary plasmocytoma and nine had an anormo ratio of light chains. Seventeen patients were treated with bortezomib-based regimens, (median 5.5 cycles) included VTD, MPV, VLD and VD. After treatment, for fourteen patients achieved complete response, two partial response and two had progressive disease. PET/CT was positive in all patients pretreatment, 15 focal lesions, 2 diffuse bone marrow involvement plus focal lesions and 1 involvement of bone marrow alone. Twelve patients had more than 3 focal lesions and two had extramedullary disease. At the end of first line treatment PET/CT was negative in eight patients (44%) and fourteen had complete biochemical response (78%). 62% of the patients with negative PET/CT showed negative flow minimal residual disease (MRD) and biochemical complete response. Two patients had PET/CT with progression disease and corresponded to a biochemical progression.

Summary/Conclusions: The correlation between PET/CT and biochemical response obtained after treatment was positive in patients with complete response. We found discordant data in two patients with oligosecretory myeloma. No correlation was shown between PET/CT and flow MRD. Are necessary more long term studies that include greater number of patients to confirm the negative PET/CT is an image technique that could be a tool to follow up patients after the first line treatment added to the evaluation of the biochemical response.

PB2016

MULTIPLE MYELOMA IN BORNEO SARAWAK: A DEVELOPING WORLD’S EXPERIENCE

T.S. Lum1, 2, L. P. Chew1
1Hematology Unit, Medical Department, Sarawak General Hospital, Kuching, Malaysia

Background: Sarawak, is the largest state of Malaysia situated on the island of Borneo. Sarawak General Hospital is the tertiary referral center of Sarawak (serving a population about 1 million people). It is 980 km away from its main hematology/transplant referral center in Kuala Lumpur, Malaysia, which is accessible only by airplane. Hence, treatment of patients with multiple myeloma in this part of the state is a big challenge due to its geographical constraint.

Aims: To identify demographics and clinical characteristics of patients with multiple myeloma; To establish treatment and outcome of patients with multiple myeloma.

Methods: This is a retrospective study examining basic characteristics and clinical outcomes of patients diagnosed with multiple myeloma between 2010 and 2016 in Sarawak General Hospital. Patients’ case notes were traced and the relevant information was entered into a pre-designed data collection form. Data was analysed and interpreted via IBM SPSS Statistics version 24.0.

Results: There were a total of 63 patients with the male to female ratio of 3:2. The median age for patient was 61 years old (range 31 to 86 years old). Majority of them were local natives of Iban or Bidayu descendants (n=32, 50.8%) followed by Chinese (n=20, 31.7%) and Malays (n=11, 17.5%). Most common type of multiple myeloma is of IgG variant (n=27, 42.9%). The most common myeloma related organ or tissue impairment (ROTI) are anaemia (n=54, 85.7%) followed by bone lesion (n=48, 77.8%), renal impairment (n=27, 42.9%) and hypercalcaemia (n=18, 28.6%). More than half presented late with Dure Salmon stage III disease (n=34, 54%). Majority of patients were treated with dexamethasone/thalidomide (n=25, 39.7%). Sixteen patients (25%) received bortezomib based treatment. Three patients (n=3, 4.8%) undergone bone marrow transplantation. Thirty five patients died (n=35, 55.6%). Median survival time was 21 months (95% CI: 16.26). One year, two years and five years survival rate was 67.4%, 43.6%, 31.6%. Patients who were 60 years old and above have lower median overall survival (20 months) compared to patients who were 60 years and below (36 months) even though they are not statistically significant (p=0.565).

Summary/Conclusions: Baseline characteristics of patients with multiple myeloma in Sarawak are similar to the rest of Asia. However, our median an overall survival was comparatively lower to our counterparts. Limitation wise, due to logistic and economic reasons, we do not have good access to cytogenetic and genetic profiling that enables us to prognosticate patients accordingly.

PB2017

A RETROSPECTIVE AND PROSPECTIVE AUDIT OF RADIOLOGICAL INVESTIGATIONS FOR SUSPECTED CASES OF PLASMA CELL DYSKRASIAS/MYELOMA IN THE ALTNAGEVIN AREA HOSPITAL

G. Baker1, *, N. Cunningham1
1Haematology, Western trust, Londonderry, United Kingdom

Background: The updated NICE guidelines for diagnosis and management of myeloma (2016) suggests whole-body MRI as first-line imaging for people with suspected myeloma and consideration of MRI/CT/PET in newly diagnosed myeloma to assess for bone disease or EM plasmacytoma.

Aims: Our aims were to ascertain; 1) Our current practice regarding radiological investigation for myeloma (2) Whether additional diagnostic information was gained using CT/MRI imaging (3) Since its release, is the trust compliant with the NICE guidance (4) The estimated cost of meeting the current NICE guidance compared to the NICE guidance for imaging in plasma cell dyskrasias/myeloma for suspected multiple myeloma.

Methods: This retrospective and prospective audit included all patients having a skeletal survey performed for suspected multiple myeloma within the Alt-nagevin Area Hospital (AAH). Retrospectively from 10/2/15 until 9/2/16 data was collected using the advanced search feature of the Spectra IDS7 PACS system. The ‘Reason for examination’ for each study was then analysed and those ordered for reasons other than suspected myeloma were excluded. Each case was analysed individually and any follow up MRI/CT/NMB imaging performed in the 6 month period following the skeletal survey were included in the data collection. The same information was gathered prospectively from 10/2/16-30/5/16 following the NICE guidance. 54 skeletal surveys where performed for suspected myeloma.

Results: The indications for requesting imaging is shown in Table 1A. No WB MRI/CT was performed in this period. 26 patients had new lytic lesions on skeletal survey. 23 patients had further imaging in the form of MRI or CT following skeletal surveys. All the positive MRI findings offered additional diagnostic information - including examples of missed multiple spinal deposits. The results of imaging are summarised in Table 1B. The false negative rate for skeletal surveys was 39% and the false positive rate was 22%. Following NICE guidance publication 23 patients had skeletal surveys performed for suspicion of myeloma between 10/2/16 and 30/5/16. The indications are summarised in Table 1C. No WB imaging was performed. 5 patients had positive skeletal surveys. 6 patients had subsequent CT/MRI imaging. A skeletal survey was reported normal with a subsequent MRI showing multiple spinal deposits. The imaging results are summarised in Table 1D.

Table 1.
economic model for imaging with WB MRI. In addition it reviews evidence which links time to diagnosis to survival and myeloma related complications. The NICE guidance offers clear evidence that WB-MRI should be the investigation modality of choice for suspected myelomatous disease. It offers a diagnostic and cost-effective strategy that will ensure health improvements for myeloma patients. This audit offers further evidence of the diagnostic accuracy of MRI imaging. At present failure to comply with NICE guidance will lead to delayed diagnosis of myeloma in certain patients and potential patient harm. Therefore I offer a business and health improvement case for the Western Trust to instigate WB-MRI imaging for all suspected myelomatous bony disease.

PB2018
TONI DEBRE FANCONI SYNDROME DURING MYELOMA, ABOUT 8 CASES
R. Cherif1,*, B. Salah Eddine1
1Hematology, Central Hospital Mohammed Seghir Nekkache, Algiers, Algeria, Algiers, Algeria

Background: The cast nephropathy with cylinders is the most frequent renal complication of the myeloma, which results from a catabilism of the light chains by the tubular cells and can lead a tubular chronic suffering showing itself by a syndrome of acquired Toni-Debré-Fanconi marked by a glycosuria, a phosphaturia, an aminoaciduria, a sometimes severe and sometimes revealing hypokalemia.

Aims: We reporting some observations informed by Multiple Myeloma complicated with a Fanconi syndrome.

Methods: From January 2016 to December 2010: 78 cases of Multiple Myeloma were brought together, whose circumstance of discovery 22 cases with renal failure, it’s was a evolutes complications in 12 cases; and in 10 cases it’s discovered at diagnosis. The renal achievement is dominated by Tubule disease in 11 cases, Randall syndrome 8 cases, and Nephrotic syndrome 3 cases. The tubule disease of Fanconi is suspected at only 8 patients: in front of the presence of a glycosuria (without associated diabetes) and a frank proteinuria in the majority of the cases, with a hypophosphatemia and a fickle hypokalemia.

Results: The clinico-epidemiological and immuno-biological characters of these 8 patients are the following ones: - The median age is of 64 years (39-76), sex ratio 3. - The osseous pains and the muscular cramps dominate the clinical presentation with constant diffuse demineralization in the radiology. - The patients were classified (according to the Salmon-Durie classification): III B (3 cases) and II B (5 cases). - The mononclonal immunoglobulin observed: IgG kappa: 4cases, IgA kappa: 2cases, light chain kappa: 2cases. - With a Bence Jones proteinuria isotype kappa and a glycosuria in the majority of the cases. - The gravity of the renal failure, based on the clearance of the creatinine: with an average clearance of 16,19 ml/min (4-37): several in 5cases, terminal in 3cases. - We note more of hypocalcaemia while the hypercalcemia is noted in a single case, the hypophosphatemia is found in half of the cases. The therapeutic is double: - Symptomatic: alkaline hydration, correction of the metabolic disorders and sometimes the renal extra purge (indicated in 3cases). - Specific: chemotherapies VAD 7cases, a patient died by cardio-vascular complication.

Under treatment the recovery of the renal function is obtained in 3 cases, to the rests of the patients persists a stable renal failure.

Summary/Conclusions: The Syndrome of Fanconi is a frequent and often formidable complication during Myeloma, observed to 30-40% of the patients in an autopsie series. It is necessary to think to it in front of any renal achievement in myeloma of kappa light chain with renal glycosuria, a generalized aminoaciduria and a hypophosphatemia resulting respectively from a defect of the transport of the glucose, from amino acids and from phosphates by the renal proximal tubule. To improve the osseous and renal appearances, it is necessary to realize a calcic supplementation, phosphorous and by the vitamin D active, as well as the correction of the acidose and a specific treatment reducing the excretion renal of the light chains.

PB2019
DEPP RESPONSES WITH CARFLIZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE
V. Pedersen1, G. Rossi1, D. Garino1, A. Mele1, P. Curci1, A. Giordano2, S. Citino1, G. Specchia1, V. Pavone1,*,
1Hematology and TMO, Hospital Card. G. Panico, Tricase (LE), 2Haematology and TMO, Policlinico di Bari, Bari, Italy

Background: Carfilzomib is a new proteasome inhibitor with in contrast to the reversible binding of bortezomib, binds irreversibly and selectively to its target: the chymotrypsin-like activity of the 20S proteasome. The phase IB/II PX-171-006 study was the first study in which carfilzomib was combined with lenalidomide and dexamethasone. In the phase I dose-escalation part the maximum plateau dose was established as well tolerated and in the phase II part the study focused the efficacy and toxicity in the subgroup treated with maximum planned dose. The ASPIRE trial showed superior response rates and progression free survival for carfilzomib-lenalidomide-dexamethasone compared with lenalidomide-dexamethasone in relapsed/refractory Multiple Myeloma patients. Aims: The aims is explore the efficacy and tolerability of carfilzomib-lenalidomide-dexamethasone in relapsed/refractory Multiple Myeloma patients in real life.

Methods: All patients received carfilzomib 20/27 mg/m2 days 1,2,8,9,15 and 16; lenalidomide 25 mg days 1-21 and dexamethasone 20 mg days 1,2,8,9,15,16, 22 and 23, according to post approval access protocol. After 2, 4, 6 cycles the responses, disease progression and toxicity were assessed using the International Myeloma Working Group Uniform Response Criteria and WHO score respectively.

Results: From January 2016 to February 2017 in hematology “Cardinale G.Panico Hospital” and “Bari Policlinico”, treated 15 relapsed/refractory Multiple Myeloma patients with carfilzomib-lenalidomide-dexamethasone. Six patients male (40%), 9 female (90%), mean of age 62 years (range 38-79); 10 (66%) and 5 (34%) relapsed/refractory multiple myeloma respectively. Median time from diagnosis to carfilzomib-lenalidomide-dexamethasone was 46 months (range 12-92); median of prior therapy was 3 (range 1-6); 9 (60%) received autologous transplantation while 1 (6%) allogeneic; 11 (73%) prior therapy with lenalidomide; 15 (100%) prior therapy with bortezomib; 2 (14%) prior therapy with pomalidomide (Table 1). Eleven (73%) patients achieved after 2 cycles a response ≥PR, of these 3 VGPR. After 4 cycles, 5 (33%) and 1 (7%) have obtained at least a VGPR and CR respectively (Figure 1). Three patients were not evaluated for treatment discontinuation because of rapid progression disease and died during first cycle with a median of 5 prior lines therapy. Most grade 3-4 adverse events were haematological and well manageable, 10 (80%) trombocitopenia and 5 (35%) neutropenia grade 3-4. Dyspnea, fatigue and pyrexia were higher but were mostly grades 1 and 2. Only 2 patients developed respiratory failure and pneumonia while cardiac failure, ischemic heart disease and hypertension not were detected.

Table 1. Baseline patient characteristics.

<table>
<thead>
<tr>
<th>MEAN OF AGE, years (range)</th>
<th>RELAPSED</th>
<th>REFRACTORY</th>
<th>MULTIPLE MYELOMA, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>62 (58-79)</td>
<td>11 (60)</td>
<td>5 (34)</td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td>4 (46)</td>
<td>2 (22)</td>
<td></td>
</tr>
<tr>
<td>IgA</td>
<td>7 (46)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMBDA</td>
<td>3 (30)</td>
<td>11 (80)</td>
<td></td>
</tr>
<tr>
<td>MICROMOLECULAR</td>
<td>3 (30)</td>
<td>11 (80)</td>
<td></td>
</tr>
<tr>
<td>STAGING (N)</td>
<td>I</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 (96)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>MEDIAN TIME FROM DIAGNOSIS TO KRD, months (range)</td>
<td>46 (12-92)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDIAN OF PRIOR THERAPY, lines (range)</td>
<td>3 (1-6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRIOR TRASPANT, n (%)</td>
<td>9 (96)</td>
<td>1 (10)</td>
<td></td>
</tr>
<tr>
<td>AUTOLOGOUS</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>ALLOGENEIC</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>PRIOR THERAPY, n (%)</td>
<td>11 (77)</td>
<td>15 (100)</td>
<td></td>
</tr>
<tr>
<td>LENALIDOMIDE</td>
<td>11 (77)</td>
<td>15 (100)</td>
<td></td>
</tr>
<tr>
<td>BORTHEZOMIB</td>
<td>7 (47)</td>
<td>8 (53)</td>
<td></td>
</tr>
<tr>
<td>POMALIDOMIDE</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: Carfilzomib-lenalidomide-dexamethasone is a powerful and efficacy association in relapsed/refractory Multiple Myeloma patients, which allows the achievement of deep responses from the first cycle of therapy. Non haematological adverse events of grade 3 or higher were reported in only 2 patients.
Background: Carfilzomib is an epoxysketone proteasome inhibitor of second generation, proved to be effective in relapsed and refractory Multiple Myeloma (rMM), whose prognosis is particularly severe.

Methods: 21 patients (12 M/9 F, Table 1), with rMM, median age at diagnosis 62 years (r. 47-75), median age at start of treatment 65 years (r. 53-81) treated with several lines of treatments (median 3, r. 2-10), included 2 patients refractory to Bortezomib, underwent to KRD regimen (ASPIRE trial schedule: Carfilzomib starting dose 20 mg/sqm on days 1,2 of cycle 1, target dose 27 mg/sqm thereafter; Lenalidomide 25 mg on days 1 through 21; Dexamethasone 40 mg on days 1,8,15 and 22, every 28 days) for a median treatment cycles of 2 (r 1-8). ISS was equally distributed, and cytogenic was evaluable in 8 patients, and in particular one del13q14 1q gain, one del 13q14 and one t(11;14). 86% of patients had previously been treated with schedule containing bortezomib and in particular one del13q14 1q gain, one del 13q14 and one t(11;14). 86% of patients had under- gone at least to a single auSCT.

Results: Carfilzomib was well tolerated, with grade 2 anemia in 28% of patients, without necessity blood transfusions; 5% grade 1 and 9.5% grade 3 neutropenia (no ospedalization was required); 33% grade 2, 19% grade 3 and 5% grade 4 thrombocytopenia, without hemorrhagic events and necessity of transfusions. Concerning severe extrahematologic toxicity, it was observed grade 1 pneumonia in 47% of patients, treated by common antibiotic drugs; grade 2 Hypertension in 24% of patients; grade 3 arrhythmias in 5% of patients; grade 2 dyspnea in 5% of patients; grade 1 fatigue in 9.5% of patients. According to IMWG criteria, after a median follow-up of 3 months (r.1-13), ORR was 66.7% (14/21 : 8 VGPR, 6 PR) with 3 progressive diseases and 2 patients in stable disease, which can be considered as an impressive result in this subset of rMM patients. In particular, for 1 patient, KRD was, after having achieved at least a PR, a bridge to second auSCT. Median time to response was 2 months (r.1-4), median OS from diagnosis was 47 months (9-170 range), median OS from start of Carfilzomib was 3 months (range 1-13).

Table 1.
Background: The treatment of patients with multiple myeloma (MM) has dramatically changed over the past decade due in part to the development of new agents and myeloma-specific targets. Nowadays, new effective treatments exist for patients with RRMM not responding to bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with RRMM, but synergistic effects have been noted when combined with dexamethasone.

Aims: To show our experience with the use of 28-day cycles of pomalidomide (4 mg/day on days 1–21, orally) plus low-dose dexamethasone (40 mg/day weekly, orally) (Pom/dex) in RRMM.

Methods: This is a retrospective study performed between May 2014 and January 2017 in the Hospital of Guadalajara (Spain). Eight patients (3M, 5F), with a median age of 67 years (range, 40–81), diagnosed with MM were included. Four were classified as high-risk myeloma (Patients 1–4). Patient 1 (P1) had plasma cell leukemia and received Pom/dex plus bortezomib; Patient 2 (P2) presented complex karyotype and received Pom/dex after three previous regimens and an autologous transplantation; Patient 3 and Patient 4 (P3 and P4) had extramedullary plasmacytoma and received Pom/dex/local radiotherapy. The eight patients of this study had failed to bortezomib and lenalidomide-based therapy, and received Pom/dex until disease progression or unacceptable toxicity. Pom/dex was associated with ciclophosphamide in two patients, and with bortezomib in another two patients. The primary endpoint was progression-free survival (PFS).

Results: The median number of prior regimens was 2 (range, 1–4) and five of eight patients (62.5%) had previously received autologous transplantation. Median time from diagnosis to Pom/dex was 51.5 months (range, 28–155). Patients received a median of 6 cycles of Pom/dex (range, 2–16). In the whole series, the median follow-up was 60.5 months (IQR: 50.0–80.25), and median PFS was 11 months; 75% of patients had not progressed after 5 months, and 50% of patients after 11 months. The overall response rate was 87.5% in one patient (P1) (discontinued therapy for non-response). In standard-risk MM patients, median follow-up was 61 months (IQR: 46.25–140.25), and median PFS was 13 months; 75% of patients had not progressed after 2 months, and 50% of patients after 13 months. Regarding the high-risk group of patients, P1 achieved complete response after 6 cycles of Pom/dex/bortezomib; P2 achieved PFS of 11 months; P3 achieved plasmacytoma resolution after 6 cycles of Pom/dex plus local radiotherapy; P4 abandoned Pom/dex after 3 cycles due to severe neutropenia and sepsis. In this group median follow-up was 60.5 months (IQR: 56.3–79.8), and median PFS was 6 months; 75% of patients had not progressed after 5 months, 50% of patients after 6 months, and 25% of patients after 11 months. Regarding adverse events, they were present in two patients: one had neutropenia, and the second one pneumonia plus pulmonary venous thromboembolism. Both of them died (Figure 1).

Summary/Conclusions: In our experience, Pom/dex regimen has prolonged PFS of patients with RRMM, with an improvement of health-related quality of life. This regimen has been even valuable in high-risk patients who received Pom/dex after ≥2 treatment regimens. Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option as a standard of care for patients with RRMM who have poor prognosis and a high need for effective treatments.
of time. The period of observation was 1 year or longer in most patients. Sixteen patients with idiopathic leukaemcytosis were analyzed in this study. Neutrophils or mononuclear cells were collected after obtaining written informed consent from the 16 patients. Neutrophils from peripheral blood were purified by dextran sedimentation followed by hypotonic lysis and centrifugation with Ficoll-Conray. Mononuclear cells were isolated from bone marrow by Ficoll-Conray gradient centrifugation. DNA was isolated using the QIAamp DNA blood mini kit (Qiagen, Valencia, CA, USA). Mutations within hot spots of the CSF3R, JAK2, CALR, SETBP1, ETNK1, CBL, TET2, ASXL1, EZH2, IDH1/IDH2, DNMT3A, U2AF1, and CEBPA genes were analyzed by direct sequencing in both directions using a 3730XL DNA Analyzer (Life technologies, Carlsbad, CA, USA) and/or allele-specific polymerase chain reaction analysis. Total RNA extraction and reverse transcription polymerase chain reaction (RT-PCR) were performed between the EV6 and ABL1 genes in 10 patients. BCR/ABL1 gene was analyzed by RT-PCR or fluorescence in situ hybridization in 8 patients. The current study was conducted within the guidelines and with the approval of the institutional ethics committee.

Results: JAK2 V617F mutations were found in one of the 16 patients with idiopathic leukaemcytosis. No mutations were found in the other genes in the 16 idiopathic leukaemcytosis patients. EV6-ABL1 fusion gene was detected in one of the 10 patients. No BCR/ABL1 fusion gene was detected in the 8 patients. One patient with idiopathic leukaemcytosis, patient with JAK2 V617F mutation has developed PV. Another patient with sustained leukaemcytosis for 20 years showed cytogenetic abnormalities during observation and has developed Philadelphia chromosome negative CML (Ph-CML). EV6-ABL1 fusion gene was detected in this patient. Another patient with normal karyotype progressed to blast crisis of Ph-CML (-6 months) or recognized by cytogenetic abnormalities. Of the remaining 13 patients with idiopathic leukaemcytosis, one resolved the disease and twelve had a stable disease.

Summary/Conclusions: Idiopathic leukaemcytosis comprises heterogeneous conditions. JAK2 mutations and cytogenetic abnormalities are predictive of progression to hematological neoplasms.

PB2025
EVALUATION OF EXPRESSION OF MiRNAs ISOLATED MICROVESICLES OF PATIENTS WITH MYELOFIBROSIS ASSOCIATED WITH DISEASE
L. Rodrigues1*, J. Barros1, A. Nonino1, C. Mascaréns1,2
1Biotecnologia, Universidade Católica De Brasília, Brasília, Brazil
22 nd Congress of the European Hematology Association

Background: Myelofibrosis is a hematological disease inserted in the group of myeloproliferative neoplasias. It has as main characteristic fibrosis of the bone marrow, consequence of a variety of pathological changes presented in the medullary microenvironment. The development of the disease is related to the clonal expansion of myeloid stem cells, abnormal expression of cytokines, hypercellularity of myeloid lines and also extramedullary hematopoiesis. The pathophysiology of myelofibrosis involves the activation of signal transduction pathways, which may occur due to genetic rearrangements and mutations that alter the structure of protein tyrosine kinases, making hematopoietic progenitor cells independent or hypersensitive to cytokines, generating anomalous cellular behavior. Myelofibrosis is a hematological disease inserted in the group of myeloproliferative neoplasias. It has as main characteristic fibrosis of the bone marrow, consequence of a variety of pathological changes presented in the medullary microenvironment. The development of the disease is related to the clonal expansion of myeloid stem cells, abnormal expression of cytokines, hypercellularity of myeloid lines and also extramedullary hematopoiesis. The pathophysiology of myelofibrosis involves the activation of signal transduction pathways, which may occur due to genetic rearrangements and mutations that alter the structure of protein tyrosine kinases, making hematopoietic progenitor cells independent or hypersensitive to cytokines, generating anomalous cellular behavior.

Aims: Recent studies have shown that microRNAs produced by the cells of the organism may be associated with the cellular communication process due to their structure and action that microRNAs may regulate the function of this component are able to regulate diverse cellular processes. The expression of some microRNAs is associated with hematopoietic processes such as the transformation of myeloid, erythroid and megakaryocytic progenitors. These can regulate the hematopoiesis of normal stem cells and also of compromised progenitors, having implication in the pathogenesis of the disease. The development of the disease is related to the clonal expansion of myeloid stem cells, abnormal expression of cytokines, hypercellularity of myeloid lines and also extramedullary hematopoiesis. The pathophysiology of myelofibrosis involves the activation of signal transduction pathways, which may occur due to genetic rearrangements and mutations that alter the structure of protein tyrosine kinases, making hematopoietic progenitor cells independent or hypersensitive to cytokines, generating anomalous cellular behavior.

Methods: MicroRNAs were isolated from the plasma by ultracentrifugation methods. Quantitative and qualitative technology was possible for the detection of specific microRNAs. Assays by qPCR were performed to evaluate the expression of specific microRNAs.

Results: We used the miRNAs described in the literature as influential in the process of hematological disorders. They are: miR-146b, miR-150, miR-29a and 155. After analysis of miRNA differential expression, miR-29a and miR-155 were less expressed in MF patients compared to healthy donors (P <0.02 and P <0.03), and miR-223 did not Present a statistically significant difference. Data on miR-29a corroborate in part with the literature, since the data presented here relate to miRNA carried by VEs rather than serum / plasma. However, low levels of miR-29a expression are related to aberrant auto-renewal of hematopoietic progenitor cells, thus indicating that VEs may contribute to this mechanism. As for miR-155, the data obtained do not corroborate with the literature and, possibly, the VEs do not participate in a stable disease.

Summary/Conclusions: miRNAs present in the microvesic content may collaborate in the cellular communication process in myeloproliferative disorders and induce hematopoietic disorders.

PB2026
COMPREHENSIVE STUDY OF BCR/ABL GENE EXPRESSION IN PROGRESSION OF “CLASSIC” MYELOPROLIFERATIVE DISORDERS
1N.Blokhin Russian Cancer Research Center, 2N.Blokhin Russian Cancer Research Center, 3GeneTechnology LLC, Moscow, Russian Federation, 4Leeroy Management, Russia, 5LN.Blokhin Russian Cancer Research Center, Moscow, Russian Federation

Background: Classic myeloproliferative disorders (MPDs) also known as chronic myeloproliferative diseases (CMDs), include several clonal hematological diseases (such as polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF)), which are negative for (9;22) translocation, result to BCR/ABL chimeric gene expression. Characterization of JAK2V617F mutation, deletion in 12 exon of JAK2 gene, MPL W515L/K mutation, mutation in calreticulin gene (CALR) contributed a lot to understanding of molecular pathogenesis of MPDs. However, developed molecular mechanisms underlying the progression of MPD remains unclear. Several cases of MPDs with detected BCR/ABL expression were described repeatedly in previous publications. The phenomenon of simultaneous coincidence of mentioned molecular markers in each clinical case requires comprehensive study.

Aims: The aim our work was to investigate BCR/ABL expression in therapy resistant MPD patients with disease progression.

Methods: Peripheral blood samples 175 patients with progressive MPD and 67 patients with primary MPD was used as a biological material for experiments. Qualitative and quantitative analysis of BCR/ABL gene (p190, p210, p230) was performed by two-step PCR and real-time PCR. JAK2, JAK2-e12, MPL, CALR mutations were determined by direct sequencing and allele-specific PCR, RAG1 and RAG2 expression was analyzed by real-time PCR.

Results: 175 patients with progressive MPD were analysed: 35(20%)- PV, 38(22%)- ET, 102(58%)-PMF. BCR/ABL gene expression was identified in 47 cases (32.83%). We found 44 cases with BCR/Abi/p210, 3 cases with BCR/Abi/p190, and no cases of BCR/Abi/p230. We have observed hepatomegaly (17/43- 40%) and elevated WBC in BCR/ABL positive cases. JAK2V617F mutation was identified in 139 patients, deletion in 12 exon of JAK2 gene was found in 2 patients. One case with MPL W515L mutation and 11 cases with CALR mutation were identified, Group of primary MPD patients (N= 67)- 26(47%)-PV, 21(38%)-ET, 8(15%)-PMF, contained 55/67(82%) patients with JAK2V617F mutation. Expression of BCR/ABL/p210 was detected only in 2/55(3.6%). We also found that expression levels of key components of V(D)J recombinase RAG1 and RAG2 in granulocytes is higher in Jak2V617F mutation positive MPD patients(46/49- 94% cases) compared to healthy donors (3/42- 7%).

Summary/Conclusions: The normal rearrangement of immunoglobulin receptors in maturing B-lymphocytes depends on JAK-kinases activation. Therefore we suppose that activation of key components of V(D)J recombinase (RAG1/RAG2) could lead to appearance of additional clone with chimeric BCR/ABL due to increased tension of Jak-STAT pathway. The expression of BCR/ABL gene could be the possible reason for MPD progression and should be considered as an indication for complementary therapy.
Background: Myeloproliferative neoplasms (MPNs) are a group of chronic myeloid cancer characterized by overproduction of mature hematopoietic cells. Mutations in one of three genes; Janus kinase 2 (JAK 2), myeloproliferative leukemia virus (MLV) and Janus-associated cytokine receptor-like protein 2 (CALR), have been described in most patients with BCR-ABL negative MPNs. JAK2 mutations are present virtually all cases of Polycythemia Vera and 50-60% of prMF and Essential Thrombocythemia (ET). Recently, mutations in CALR gene were found in 50-80% of JAK2 and MPL mutation negative ET and prMF patients.

Aims: To evaluate immunohistochemical results of CALR gene mutation in the bone marrow samples of the JAK2V617F mutated and JAK2V617F wild type Primary Myelofibrosis (pMF) patients.

Methods: Bone marrow biopsy samples from 32 patients previously diagnosed as primary myelofibrosis with known JAK V617F mutation status were evaluated from archives of Marmara University Pathology Laboratory. Bone marrow samples of two patients were already known as CALR mutated by PCR analysis. Bone marrow samples of three JAK2 wild type and CALR mutated ET, two JAK2 wild type, CALR mutated prMF patients and two CALR wild type ET patients were used as positive and negative control tissues for CALR immunohistochemistry. Immunohistochemistry: 4-μm unstained sections of each bone marrow biopsy specimens were cut onto electrostatically charged glass slides. Immunohistochemistry was performed on an automated immunostainer (Ventana BenchMark Ultra; Ventana Medical Systems, Inc). CALR antibody (clone CAL2, Diana, Germany) staining used a 1:100 dilution. Any cytoplasmic staining of the cells with CAL2 antibody was considered positive immunostaining.

Results: We studied 32 bone marrow specimens of primary myelofibrosis with 15 (47%) of them having JAK2 V617F mutation and 17 (53%) of them lacking JAK2 V617FMutation. CALR immunoreactivity was seen in 8 (25%) of all pr MF, 5 (25%) in CALR mutant patients and CALR was seen in 8 (47%) of patients with PMF. CALR is negative for JAK2V617F mutation. CALR immunoactivity was not seen in patients with PMF myelofibrosis who are positive for JAK2V617F mutation. CALR immunoreactivity was seen in 3 (100%) of patients with ET and 2 (100%) of patients with known CALR mutation. CALR immunoreactivity was seen in patients with CALR wild type ET patients. We observed that CAL2 immunostaining was seen mainly in the cytoplasm of the small and large megakaryocytes, and atypical megakaryocytes as found in fibrotic PrMF. Pale immunostaining was seen in myeloid and erytroid cell precursors. This immuno staining also stained some small cells appearing as micromegakaryocytes. Immunohistochemical stain easily detects the CALR mutation by staining of megakaryocytes in formalin-fixed bone marrow biopsy specimens. This method would be a easy, rapid, and cost effective way to detect CALR mutations in daily routine hematopathology biopsy evaluation of the myeloproliferative patients.

Summary/Conclusions: We assume that the studied gene expression changes reflect the metabolic processes in the bone marrow progenitor cells. Probably JAK2 V617F mutation leads to more favorable microenvironment and reduced willingness to autophagy, causing the index shift HIF1α/2α. We found reduced of mRNA CALR expression in blood cells at MPN and this fact require further investigation.
PB2030
DETECTION OF THE MUTATIONS IN GENES JAK2 AND MPL IN THE DIAGNOSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS
K. Boboev1,*, K. Karimov1, A. Mohammad1
1Institute of hematology and blood transfuzion, tashkent, Uzbekistan

Background: Chronic myeloproliferative diseases is a group of clonal Ph-negative hematological diseases, which include erythremia (polycythemia Vera, PI), chronic megakaryocytic leukemia (essential thrombocytopenia, ET) and subleukemicmyelosclerosis (primary myelofibrosis, PMF), chronic idiopathic myelofibrosis. The origin of these diseases is linked to transformation of hematopoietic stem cells, the result is the excessive production of mature cells of erythroid, granulocytic and megakaryocyte shoots with relatively long course of the disease. The frequency of occurrence of mutation V617F of gene JAK2 exon 12 and MPL gene varies in different literature.

Aims: Determination of the frequency of occurrence of mutations in genes JAK2 and MPL and identifying the importance of the verification of these diseases.

Methods: The study included 350 patients with chronic myeloproliferative diseases — with polycythemia Vera 150 patients, with essential thrombocytopenia 78, with chronic idiopathic myelofibrosis 55 and 67 patients were examined with the purpose of differential diagnosis with Ph(-) Chronic myeloproliferative diseases. The age of patients ranged from 20 to 70 years, median age was 54 years. Isolation DNA of patients was carried out using a set of reagents "AmpliPrep Ribo-prep" (OOO Interlaboriservice, Russia). The concentration and purity of isolated DNA was determined by Nano Drop 2000 instrument (USA). Detection of gene mutation JAK2V617F and MPL gene was carried out by standard polymerase chain reaction on a thermal cycler 2720 "Applied Biosystems" (USA), using a set of "Litech" (Moscow).

Results: The result of the research showed that the incidence of the V617F mutation in JAK2 was varying in patients depending on the type of disease. In polycythemia Vera the mutation V617F in the JAK2 gene was identified in 147 patients (98,3%), with essential thrombocytopenia in 42 patients of the 78 (54,6%), with chronic idiopathic myelofibrosis in 27 patients of 55 (49,1%). In 67 patients with no hematological profile, which examined with the purpose of differential diagnosis with Ph(-) chronic myeloproliferative diseases, V617F in JAK2 was detected in 6 (8,6%), which allowed to confirm Ph(-) Chronic myeloproliferative diseases. A mutation in exon 12 of the JAK2 gene was detected in 2 of 33 (2,9%) of those surveyed V617FJAK2-negative patients exclusively diagnosed with polycythemia Vera. The MPLV615L mutation gene was detected in polycythemia Vera and chronic idiopathic myelofibrosis 2.2% (1 of 41) and 2% (1 of 52) of patients.

Summary/Conclusions: Thus established, our data confirm that mutations in the genes JAK2 and MPL are highly specific diagnostic markers in patients with Ph-negative chronic myeloproliferative diseases.

PB2031
ASSOCIATION OF MYELOPROLIFERATIVE NEOPLASM AND LYMPHOPROLIFERATIVE DISORDER IN 3 PATIENTS
B. Fouche1,*, M. Dudez2, M. Daniel2, S. Girard2, C. Froelich2, F. Mestrallet2, I. Tigaud3, S. Hayette4, A. Belhabri5, M.P. Pages2, L. Vila6,7
1Laboratoire, Hopital d’instruction des armées Desgenettes, 2Laboratoire, Groupement Hospitalier EST, 3laboratoire, Groupement hospitalier Sud, 4department of cytogénetics and molecular biology, Groupement Hospitalier EST, 5department of oncology and hematology, Centre Leon Barard, 6laboratoire, Groupement Hospitalier EST, 7laboratoire, Centre Léon Bérard, Lyon, France

Background: Lymphoproliferative disorders (LPD) and myeloproliferative neoplasms (MPN) are two very different sets of hematological pathologies. However, several studies have shown that the risk for LPD onset in patients with MPN is higher than in the general population (1)(2). No single LPD seems to be more at cause and all MPN are likely to present the onset of an associated LPD.

Aims: We present 3 cases diagnosed in the Department of Hematology, Groupement Hospitalier Est, Lyon, France, of patients bearing an association of MPN and LPD: an essential thrombocytopenia (ET) with myeloma, ET with marginal zone lymphoma and a chronic myeloid leukemia with chronic lymphoid leukemia.

Methods: Diagnosis have been made thanks to cytology of peripheral blood, bone marrow aspirate and biopsy and confirmed by cytogenetic and molecular biology techniques.

Results: Case number 1. A 68 year old woman known to have essential thrombocytopenia as a MPN, with V617F mutation of the JAK2 protein kinase. After 19 years of treatment by Hydrea, she developed a splenomegaly, anemia and slight lymphocytosis of 4.77 G/L. The blood smear; the bone marrow aspirate and biopsy examination revealed myelofibrosis evolution and an infiltration by 30% of a small sized clonal lymphoid population CD20+, CD5- Medullar karyotype was normal: 46, XX[10].In conclusion the ET has evolved into myelofibrosis and is associated with a lymphoproliferative syndrome, possibly marginal zone lymphoma.No additional treatment has been implemented. Case number 2. A 64 year old woman know to have ET with V617F mutation of the JAK2 protein kinase treated by acetic salicyclic acid. 5 years after, she presented with IgG kappa type monoclonal gammapathy up to 28 g/L, without any associated clinical manifestations nor cytopenia. Medullar blood was diluted but showed slightly atypical plasmocytes remaining under 10%.Myeloma was diagnosed anyway and the patient received 5 cures of Velcade-Melphalan-Prednissone which resulted in complete remission. The MPN remains stable to this day. Case number 3. A 62 year old man with chronic lymphoid leukemia, treated by six cycles of R-FC. While in remission since 2 years, hemogram shows hyperleucocytosis (WBC: 18.3 G/L) with thrombocytopenia (platelets: 1866 G/L) without anemia (Hb: 13.7 g/dL).Blood smear examination reveals 3% of myeloma and basophilia (3,66 G/L).BCR-ABL transcript is positive in 43% and karyotype points out a 9;22 translocation. (46, XY, t (9 ;22) (q34 ;q11) nuc ish (BLX3, BCRx3,ABL.con BCRX2)(48/100).) Before starting Nilotinib, cytoreductive treatment by Hydrea was decided. Treatment is under way.

Summary/Conclusions: The three cases described highlight the diverse situations observed in cases of combined MPN/LPD pathologies. MPN with secondary onset of LPD are most frequently encountered, as was the case with patients 1 and 2. Cases of preexisting LPD and late onset MPN are rare (1), and cases of simultaneous discovery of both pathologies even more so (3). Several hypotheses have been formulated to explain the frequency of onset of these pathological associations: genomic instability due to JAK2 protein kinase activation, or due to BCR-ABL mutation, or exposure to cytotoxic chemotherapy or radiations (3).
Myeloproliferative neoplasms - Clinical

PB2032

CLINICAL AND ANALYTICAL DIFFERENCES BETWEEN CALR TYPE-1 AND CALR TYPE-2 MUTATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS: A SINGLE CENTRE STUDY

M. Sobas1, M. Olejniczak1, I. Andrasiak2, M. Kryszelewski3, B. Jazwiec1, J. Rybka1, T. Wrobel1, K. Kulczewski1
1Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 2WroMedica Research Center, 3Wroclaw Medical University, Wroclaw, Poland

Background: The JAK2V617F is a major molecular marker in myeloproliferative neoplasms (MPN) and is harbored in about 50-60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Recently, CALR mutation was described in ET and PMF. JAK2V617F mutation was considered as a marker for disease severity and transformation. There are two main variants of CALR mutation: type 1 (a 52-bp deletion) and type 2 (a 5-bp insertion).

Aims: To compare clinical and analytical data of ET and PMF patients with CALR type-1 vs CALR type-2 mutation.

Methods: We performed a single center study on 471 patients: 87 PMF and 384 ET. The JAK2V617F mutation was analyzed in DNA from peripheral blood leukocytes by PCR ARMS method. In all JAK2V617F negative patients detection of CALR mutation was performed by fragment length analysis and the results were confirmed by sequencing. Statistical data analysis was performed using the Statistica 12.5 software for Windows.

Results: From 384 ET patients 254 were JAK2V617F positive (66%), 80 were CALR positive (21%) and 51 were JAK2V617F and CALR negative (13%). From CALR positive patients: 36 (51%) had type-1, 34 (45%) type-2 mutation, and 10 (12%) type-3 mutation. From 87 PMF patients 56 were JAK2V617F positive (61%), 18 were CALR positive (21%) and 13 (15%) were JAK2V617F and CALR negative. From CALR positive groups: 13 (72%) had type-1 and 5 (28%) had type-2 mutation. Compared with ET carrying JAK2V617F mutation, patients ET CALR type-1 (positive type-1 plus type-2) had lower hemoglobin (13.3 vs 14.5 g/dL, p<0.001), leukocyte count (8.2 vs 9.7 G/L, p<0.001), higher platelet counts (507 vs 800 G/L, p=0.001) and with no significant differences in frequency of thrombosis. In ET, CALR mutation was associated with increased odds of myelofibrotic transformation (odds ratio [OR]=2.61; 95% CI: 1.28 - 5.34; p=0.009) comparing with JAK2V617F positive patients. Patients ET CALR type-1 had higher leukocyte counts than ET CALR type-2 mutation (9.6 vs 7.3 G/L, p; 0.008), but we did not find significant differences in hemoglobin, platelet counts, frequency of thrombosis or myelofibrotic transformation. Within PMF, no significant differences were observed. Moreover in PMF, there was no significant differences between the JAK2V617F, CALR type-1 and type-2 mutation status respect to the International Prognostic Score System (IPSS).

Summary/Conclusions: In our population, the frequency of JAK2 and CALR mutation was similar to previously described. 2. Compared patients with ET carrying JAK2V617F positive, ET CALR type-1 (positive type-1 plus type-2) had higher platelet count but no higher frequency of thrombosis was observed. 3. Myelofibrotic transformation was more frequent in ET CALR positive versus JAK2V617F positive patients. 4. ET patients CALR type-1 versus type-2 had higher leukocyte count but there were no more significant differences between these two groups. 5. There were no significant differences within PMF group (to small number of patients). 6. In PMF patients, there was no relations between IPSS and mutational status (JAK2V617F, CALR type-1 and type-2).

PB2033

ESSENTIAL THROMBOCYTHEMIA: STUDY OF TREATMENT LINES REQUIRED. EXPERIENCE OF A SINGLE CENTER

1Hematology, 2Hospital Clínico Universidad de la Arrixaca, Murcia, Spain, 3Internal Medicine, Hospital Clínico Universidad Virgen de la Arrixaca, Murcia, Spain

Background: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that shows similar survival prognosis as general population, with a very low rate of transformation to myelofibrosis and acute leukemia. There are different treatments for these patients with optimal responses at first. For the first line, it is usually treated with hydroxyurea, although in young patients it is usually replaced by anagrelide / interferon. There are publications of hydroxyurea side effects, especially cutaneous, but there are not many studies about how many lines of treatment are needed to control the disease.

Aims: Study type and lines of treatment needed in patients with ET in a cohort of patients from January 1997 to January 2017.

Methods: We studied patients diagnosed of essential thrombocythemia in one area of the region of Murcia from January, 1997 to January, 2017. Those who started treatment and those who needed change were analyzed, either by resistance or by intolerance.

Results: In our area we have registered a total of 152 patients diagnosed with ET. Of these, 71% (108 patients) have required at least one treatment line. Table 1 shows the number of treatment lines required for the control of the disease. As it is shown in the Table, more than 20% of treated patients needed a second line and 6.5% required more than 2 times. At last, Table 3 shows current treatment of ET patients.

Table 1. Number of line treatment required for disease control.

<table>
<thead>
<tr>
<th>Treatment lines</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>76 (70,3)</td>
</tr>
<tr>
<td>2</td>
<td>23 (21,2)</td>
</tr>
<tr>
<td>3</td>
<td>7 (6,48)</td>
</tr>
<tr>
<td>4</td>
<td>1 (0,92)</td>
</tr>
<tr>
<td>5</td>
<td>1 (0,92)</td>
</tr>
</tbody>
</table>

Table 2. Drugs used in patients with ET.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyurea</td>
<td>99</td>
</tr>
<tr>
<td>Anagrelide</td>
<td>31</td>
</tr>
<tr>
<td>Interferon</td>
<td>10</td>
</tr>
<tr>
<td>Busulfan</td>
<td>4</td>
</tr>
<tr>
<td>Melphalan</td>
<td>1</td>
</tr>
<tr>
<td>Danazol</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 3. Current treatment of ET patients.

<table>
<thead>
<tr>
<th>Current treatment</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>34 (29 never treated, 5 no currently)</td>
</tr>
<tr>
<td>in treatment</td>
<td>108</td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td>76</td>
</tr>
<tr>
<td>Anagrelide</td>
<td>22</td>
</tr>
<tr>
<td>Interferon</td>
<td>6</td>
</tr>
<tr>
<td>Busulfan</td>
<td>1</td>
</tr>
<tr>
<td>Danazol</td>
<td>1</td>
</tr>
<tr>
<td>Hydroxyurea + Anagrelide</td>
<td>2</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This study highlights that, although ET has a very good prognosis, there is a significant percentage of patients that will need a change of treatment, either because of resistance or intolerance.

PB2034

THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA

A. Zhermiakov1, I. Martynkevich1, V. Shuvav1, L. Polushkina1, M. Fominky1, V. Udal'eva1, I. Zotova1, D. Shichabaeva1, S. Voloshin1, S. Bessmeltsev1, A. Chechenlik1, K. Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation

Background: Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence [JAK2V617F, MPL, CALR] or its absence (triple-negative status (TN)) in ET supposed to impact on the clinical course, thrombosis rate and ET prognosis.

Aims: The aim of this study was to investigate interactions between the presence of molecular marker, thrombosis/bleeding rates and the OS in ET.

Methods: Outpatient’s charts of 240 ET patients, who had been diagnosed with ET at our institution according to WHO 2008 criteria. The following data were assessed: complete blood count, bone marrow biopsy results, bone marrow cytogenetic, the restriction fragment length polymorphism (RFLP) results used for JAK2V617F detection, in case of JAK2V617F-negative status the PCR-RFLP (MPL detection) and the direct sequencing (CALR detection) results. Different thrombotic/bleeding complications rates were analyzed. The OS in ET patients was compared according to molecular markers revealed.

Results: According to their mutational status 182/240 (75.9%) patients (pts) were JAK2V617F-positive (JAK2+), 30/240 (12.5%) – CALR-positive (CALR+), 17/30 pts (56.7%) had both JAK2+ and CALR+ status. Only two pts were MPL-positive (MPL+) (0.8%). TN were 26/240 pts (10.8%). Among 240 pts 183 (76.3%) hadn’t any thrombotic complication or bleeding event (no complications/NC), 57/240 (23.7%) had complications. 49/57 (85.9%) reported arterial or/and venous thrombosis, stroke or heart failure (thrombosis+). JAK2+ and CALR+ patients had lower hemoglobin (12.9±0.5 G/L vs 13.6±0.5 G/L, p=0.003) and higher platelet counts (1067±280 vs 1001±200, p=0.008), but we did not find significant differences in hemoglobin, platelet counts, frequency of thrombosis or myelofibrotic transformation. Within PMF, no significant differences were observed. Moreover in PMF, there was no significant differences between the JAK2V617F, CALR type-1 and type-2 mutation status respect to the International Prognostic Score System (IPSS).

Table 3. Current treatment of ET patients.
median platelet count as follows: 742x10^9/l (thrombosis+) and 937x10^9/l (hemorrhage+) (p=0.003). No significant statistical differences in median hemoglobin and leukocyte count (p=0.75 and p=0.47) were detected. There were more than a half pts older than 60 years in groups NC (51%) and thrombosis+ (59%) and in group hemorrhage+ only 36% (p<0.001). Cardiovascular risk factors were reported in 24% pts (NC), 69% pts (thrombosis+) and 36% pts (hemorrhage+) (p=0.001). There were no significant statistical differences in follows risk factors as thrombosis+>1000x10^9/l and leukocytosis+>11x10^9/l (p=0.85 and p=0.72). No significant differences in OS among groups NC, thrombosis+ and hemorrhage+ (p=0.12) were found (Figure 1).

**Summary/Conclusions:** Leukocytosis >1x10^9/l and thrombocytosis >1000x10^9/l cannot be assessed as independent thrombosis risk factors in ET. JAK2V617F mutation was associated with increased risk of thrombotic complications in ET. CALR mutations were correlated with lower thrombosis risk and better OS rate, comparing to JAK2+ and TN status despite the fact of CALR+ patients had higher platelets level. Along with common thrombosis risk factors (age >60 and cardiovascular risk factors) mutational status may help to identify ET course and to optimize individual therapy option choice.

**Figure 1.**

**Table 1.**
of JAK2 V617F by droplet digital PCR as standard of care. The British Committee for Standards in Haematology recommends that suspected MPN cases have investigation of JAK2 exon 12, CALR and MPL genes if JAK2 V617F is negative.

Aims: The aim of the project was to improve the MPN service by substituting sequential analysis of individual target regions within the JAK2, CALR and MPL genes with a single assay, and to increase the number of genes available for analysis.

Methods: A commercial next generation sequencing (NGS) gene panel (Oxford Gene Technology, SureSeq Myeloid Panel), coupled with the Illumina MiSeq platform was validated and implemented. The gene panel utilizes hybridization based enrichment technology and consists of 25 MPN-related genes. During the validation stage the following were enriched and analysed: 29 positive control samples with 30 known pathogenic variants, 30 negative control samples without known pathogenic variants in the JAK2, CALR and MPL genes, and 24 MPN samples of unknown mutational status. Thus so far over 200 clinical samples have been analysed and reported since the service was introduced in October 2016.

Results: The panel has successfully identified: a large range of known pathogenic variants at high sensitivity (JAK2 V617F variant allele frequency 1%, CALR Type I frameshift variant allele frequency 3%), a potential alternative driver mutation in a known low level JAK2 V617F positive patient, a rare MPL exon 4 pathogenic variant and also the detection of low level CALR pathogenic variants, which would not have been detected by Sanger sequencing analysis. In one patient the panel identified the presence of two different JAK2 exon 14 pathogenic variants in cis (JAK2 V617F and JAK2 C618R). The JAK2 C618R predicted the hybridization of the probe binding site of the JAK2 V617F ddPCR assay which had to lead a false negative result by ddPCR. The validation procedure also explored coverage and limits of sensitivity, potential chemistry specific artefacts and identified common polymorphisms for all 25 genes.

Summary/Conclusions: The panel has replaced the current sequential analysis of CALR, MPL and JAK2 exon 12 in JAK2-positive patients and reduced turn-around-times with increased accuracy and sensitivity compared to Sanger sequencing and fragment analysis. Our current clinical service operates on a two tier system whereby clinicians can request analysis of the full 25 gene panel or a 4 gene subset (JAK2, CALR, MPL, CBL as an in silico analysis).

PB2037
IN JAK2V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS, BLEEDING RISK CORRELATES WITH ALLELE BURDEN
I. Bertozzi1,*, E. Cosi1, C. Santarossa1, G. Bogoni1, F. Fabris1, M.L. Randi1
1Dep. Internal Medicine - DIMED, University of Padova, Padova, Italy

Background: Myeloproliferative neoplasms (MPN) are characterized by the presence of JAK2V617F mutation that is almost invariably associated with polycythemia vera (PV), but also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). JAK2V617F-positive patients display different laboratory and clinical features from JAK2 wild-type, but no clear correlation was found between the JAK2V617F allele burden and natural history of the disease. The most common causes of morbidity and mortality in MPN are thrombotic and hemorrhagic complications, albeit bleedings are less frequent than thrombosis and mostly represented by minor hemorrhagic events (epistaxis, menorrhagia and gingival hemorrhage). The impact of different allele burden on bleeding risk is uncertain.

Aims: Aim of our study is to explore whether there is an association between JAK2V617F allele burden and hemorrhagic complications in a large cohort of MPN diagnosed and followed in a single center.

Methods: We selected 253 MPN (121 ET = 47.8%, 124 PV=49% and 8 PMF=3.2%) carrying JAK2V617F mutation. The median follow-up of patients was 8.8 years (0.1 – 37.3 y). Complete medical history and anti-thrombotic drugs use were recorded. Hemorrhagic complications were classified as “major” or “minor” in agreement with ISTH criteria. The patients were categorized into four groups according to the amount of JAK2 mutant allele, (1st quartile 1-25%, 2nd quartile 26-50%, 3rd quartile 51-75% and 4th quartile 76-100%). Nominal variables were compared with X² test or Fisher’s exact where indicated. Survival has been evaluated only for groups with different prevalence of events during follow-up and were calculated with the Kaplan Meier method and compared by Log Rank test.

Results: Three patients (1.2%) bled at diagnosis (1 major and 2 minor hemorrhages) while 27 (11.8%) suffered for hemorrhages during follow-up (10 major and 17 minor). Prevalence of hemorrhages results higher in 4th quartile compared both to 2nd (p=0.003) and to 1st (p<0.001) quartiles. Hemorrhages-free survival was significantly better in the 1st quartile compared both to 2nd (p=0.004) and to 1st (p<0.001). The incidence rate of hemorrhages are respectively 0.7/100 paty/s for 1st quartile, 0.65/100 paty/s for 2nd quartile, 1.26/100 paty/s for 3rd quartile and 3.23/100 paty/s for 4th quartile with a IRR of 5 and of 4.6 for the 4th quartile respectively versus 2nd and 1st one. No statistically significant different had been observed in the use of anti-thrombotic drugs among patients of the different quartiles.

Summary/Conclusions: Risk factors for hemorrhage in MPN are not well defined, and there is no risk estimation model for this outcome. Acquired von Willebrand disease, entity of platelet increased count and aspirin use have been implicated in bleeding occurrence. Previous reports fail to demonstrate a correlation between JAK2 mutation and bleeding risk. In contrast, in our cohort we found a significantly higher incidence of bleeding manifestations during follow-up in patients with higher allele burden. Interestingly no differences were seen in administration of anti-thrombotic drugs among quartiles, suggesting an independent role of JAK2 allele burden in the different distribution of hemorrhagic events.

PB2038
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
M. Napolitano1,*, S. Siragusa1, M. Santoro1, M.R. Lanza Cariccio1, M. Bonò1, F. Di Piazza2, A. Russo3, V. Accurso1
1UO Ematologia, 2Laboratorio di genetica e oncologia molecolare, 3UO Oncologia, University Of Palermo, Palermo, Italy

Background: The JAK2V617F allele burden (JAK-AB) plays a central role in chronic myeloproliferative neoplasms (cMPNs); its presence has also been advocated in the differential diagnosis of cMPNs and as independent risk factor for venous thromboembolic complications. New treatment with Ruxolitinib may decrease JAK-AB but at the present, it is not clear the clinical advantage of this approach.

Aims: Primary aim of the current study was to evaluate at diagnosis the JAK-AB in patients with Philadelphia negative cMPNs, in order to evaluate any association with standard demographic, clinical and laboratory parameters with particular reference to thrombotic risk.

Methods: Peripheral blood samples from patients with Ph-negative cMPNs were collected, DNA from leukocytes was analysed for JAK-2 (V617F) gene mutation with amplification-refractory mutation system (ARMS) PCR, subsequently a real-time quantitative polymerase chain reaction (qRT-PCR) for JAK2V617F allele burden measurement was applied. A multivariate analysis was then performed to evaluate any association of AB with demographic and clinical data.

Results: One hundred and twelve patients with Philadelphia negative cMPNs were investigated: 52 females with a median age at diagnosis of 69 years (range: 18-85 years), 50 males with a median age of 68 years (range: 18-82 years). Thirty-four patients had Essential Thrombocytopenia (ET), fifty-two had Polycythemia Vera (PV) and twenty-six had primary myelofibrosis (PMF). JAK-2 AB of patients with an age of <69 years and ≥69 years, was respectively evaluated. Patients older than 69 years showed a significantly higher JAK2-AB . JAK-AB was significantly reduced in ET, when compared to PV and PMF. No correlation was found between median values of allele burden and PSS and DIPSS scores. In patients with PV (n=52), a significant correlation was observed between allele burden and WHO2008 scoring system. No significant correlation was found between allele burden and thrombotic risk according to IPSET-t and IPSET-ET for PV and ET, respectively. Patients with a previous history of thrombosis had the highest JAK2-AB. In PMF, a positive correlation between JAK-AB and grading of fibrosis was found only for the highest grades (PMFIII and IV). JAK-AB had a positive correlation with splenomegaly in PMF.

Summary/Conclusions: Our report cannot confirm any correlation between allele burden and thrombotic risk, according to currently adopted scoring systems. Previous history of thrombosis is however associated with the highest AB in all cases.

PB2039
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA
M. Napolitano1,*, S. Siragusa1, M. Santoro1, F. Di Piazza2, M. Bonò1, S. Mancuso1, A. Russo2, V. Accurso1
1UO Ematologia, 2Laboratorio di genetica e oncologia molecolare, University Of Palermo, Palermo, Italy

Background: Idiopathic erythrocytosis (IE) is a relatively rare finding characterized by an increased red blood cell mass without an identifiable cause. Diagnosis of IE is based on the exclusion of primary and secondary erythrocytosis including JAK2-wild-type polycythemia Vera (PV).

Aims: In the current study, we report clinical features and laboratory data able to discriminate IE from PV, at diagnosis.

Methods: We have here analyzed clinical and laboratory parameters, including JAK-2 46/1 haplotype, from patients with a confirmed diagnosis of IE and PV, followed at our department from January 2010 to December 2015. Data were statistically analyzed, nominal variables were compared with X² test and continuous variables with the Mann-Whitney test.

Results: Overall, 40 patients with IE and 93 patients with PV were included in the current analysis (Table 1). Spleenomegaly and itch were reported only in a small percentage of patients with IE. History of thrombosis and cardiovascular events was positive in one case with IE. JAK-2 (V617F) and exon 12 mutations were negative in all patients with IE, while JAK-2 46/1 haplotype was found at heterozygous state in 18 patients and at homozygous state in 2 patients with IE.

haematologica | 2017; 102(s2) | 811
### Table 1.

<table>
<thead>
<tr>
<th>Patients</th>
<th>PV</th>
<th>IE</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>MALE 2 (51.6±49.7)</td>
<td>35 (50.9%)</td>
<td>0.600</td>
<td></td>
</tr>
<tr>
<td>FEMALE 1 (50.7±37.2)</td>
<td>44 (60.5%)</td>
<td>0.196</td>
<td></td>
</tr>
<tr>
<td>MEAN AGE AT DIAGNOSIS, YEARS</td>
<td>67.6±3.5</td>
<td>70.3±3.4</td>
<td>0.007</td>
</tr>
<tr>
<td>MEAN CAJAL CYTOGENETIC RESULT</td>
<td>4q12</td>
<td>4q12</td>
<td>0.600</td>
</tr>
<tr>
<td>DCH</td>
<td>4q12</td>
<td>4q12</td>
<td>0.600</td>
</tr>
<tr>
<td>MEAN MRCB CNT X100</td>
<td>17 (8.2±1.4)</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>MEAN Ht/100</td>
<td>17 (8.2±1.4)</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>MEAN Ht/100</td>
<td>17 (8.2±1.4)</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>MEAN PLT X100</td>
<td>53 (21.4±11)</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>Ht/100</td>
<td>53 (21.4±11)</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>MEAN TIME-OF-THROMBOCYTHEMIA</td>
<td>49.4±3.5</td>
<td>49.9±3.3</td>
<td>0.962</td>
</tr>
<tr>
<td>MEAN TIME-OF-THROMBOCYTHEMIA</td>
<td>49.4±3.5</td>
<td>49.9±3.3</td>
<td>0.962</td>
</tr>
<tr>
<td>MEAN TIME-OF-THROMBOCYTHEMIA</td>
<td>49.4±3.5</td>
<td>49.9±3.3</td>
<td>0.962</td>
</tr>
<tr>
<td>MEAN TIME-OF-THROMBOCYTHEMIA</td>
<td>49.4±3.5</td>
<td>49.9±3.3</td>
<td>0.962</td>
</tr>
</tbody>
</table>

The fusion genes of rearrangements of PDGFRα and B genes were detected by RT-PCR. Immunophenotype analysis was carried out by flow cytometry. Most of all cases were treated with IM and followed up.

**Results:** The diagnoses included 27 cases of MPN, 1 case of AML-M2 and 1 case of non-hodgkin lymphoma. 21 cases were PDGFRα rearrangement, the other 8 were PDGFRβ abnormal, 7 of 8 were EP fusion gene, one of which concurrent with DEK-CAN fused gene, and the eight had MYO18A-PDGFRB. 7 cases of the 8 PDGFRβ rearrangement had a primary abnormality with t(5;12)(q33;p13) and the other one had a secondary abnormality of AML-M2. PDGFRα and B genes rearrangement detected by FISH and multiple-RT-PCR were positive. The immunophenotypical analysis showed myeloid or lymphoid. These cases achieve rapid and durable remissions, IM.

**Summary/Conclusions:** In summary, patients with significantly anemia and eosinophilia should be screened for the presence of PDGFRα and B rearrangements. The dual-color FISH is a simple approach and should be added into the diagnostic work-up because these patients respond to imatinib therapy, and sustained responses have been observed. The OS of PDGFRα and B abnormal was similar with a previous report in a western population and another Chinese hematology center.

---

**PB2040**

**PLATELET AGGREGATION STUDY OF ESSENTIAL THROMBOCYTHESIA TREATED WITH ANAGRELIDE**

Y. Hiramatsu1,*, K. Furukawa2, K. Mizuhara1, T. Sakayori3, Y. Fujiwara1, N. Mochizuki1, S. Kubonishi1, Y. Komiyama1

1Department of Hematology and Oncology, 2Department of Pathology and Clinical Laboratory, Japanese Red Cross Society Himeji Hospital, Himeji, 3Hemostasis Product Engineering, Sysmex Corporation, Kobe, Japan

**Background:** Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by thrombocytosis and abnormal megakaryocytic proliferation. Patients with elevated platelet count are considered to be a high-risk group for thromboembolic and/or hemorrhagic complications. In Japan, anagrelide treatment was recently approved for the 1st line as a cell reduction therapy on ET. Even now, there are few study whether the risk of thrombosis has decreased after anagrelide treatment. Moreover, the platelet count problem uncertainty remains what is the best practice to follow when the platelet count in platelet-rich plasma (PRP) exceeds about 600 x 10^9/L, in the recent recommendation for the standardization of light transmission aggregometry by the platelet physiology subcommittee of Scientific and Standardization Committee /International Society of Thrombosis and Hemostasis.

**Aims:** The aim of this study was to characterize the platelet aggregating (PA) in patients with ET. We would also clarify whether there were any changes of hemostatic side effect and platelet aggregability before and after treatment with anagrelide.

**Methods:** This study has been conducted with blood sample obtained from six healthy subjects, compared to 18 consecutive patients with ET. None of the patients was taking anticoagulants or cytoreductive agents. We also studied six anagrelide-treated patients with ET. Whole blood aggregometry (WBA) and LTA using PRP were performed. ADP-induced PA or collagen-induced PA used natural count PRP and platelet count adjusted PRP with platelet-poor plasma. Data were compared in the groups using the Tukey-Kramer test. This study was approved by the Ethical committee of our hospital. All study procedures were performed in accordance with the Declaration of Helsinki.

**Results:** The result of WBA was not obtained, because the filter was obstructed by giant platelets. In the natural PRP, even over 900 x 10^9/L, the platelet aggregability was markedly increased compared with the control (ADP-induced PA: p=0.023, collagen-induced PA: p=0.001), but, was not significantly different (ADP-induced PA: p=0.703, collagen-induced PA: p=0.986) in the count-adjusted PRP. These results were not confirmed in cases with platelet counts of less than 600 x 10^9/L. There was no decrease in platelet aggregation before and after treatment with anagrelide (ADP-induced PA: p=0.3403, collagen-induced PA: p=0.514).

**Summary/Conclusions:** In the ET patients with platelet counts more than 900 x 10^9/L, the platelet aggregation by LTA with natural count PRP was remarkably accelerated and this data seemed to reflect the disease state. Although treatment with anagrelide showed cyto-reductive effect without any hemorrhagic complication in patients with ET, it did not fully reduce platelet aggregability.

---

**PB2043**

**A SINGLE CENTRE EXPERIENCE OF MASTOCYTOSIS**

G. Özkan1,*, Ö. Tepe2, N. Demir1, Ö. Arslan1, S. Erdem1, O. Doğan1, N. Büyükabab2, C. Baykal3, R. Tanaka1, M. Naçlı4, A.S. Yavuz1

1Hematology, 2Pathology, 3Dermatology, 4Endocrinology and Metabolism, Istanbul Medical Faculty, Istanbul, Turkey

**Background:** Mastocytosis considered as a subcategory of myeloid neoplasms based on World Health Organization (WHO) 2016 classification, is characterized by expansion and accumulation of abnormal clonal mast cells in
one or more organs. KitD816V mutation and other KIT mutations play as driver mutations in the pathogenesis of disease. KitD816V mutation is positive in 80% of systemic mastocytosis patients. Recent studies show that high allele burden of KitD816V and high serum tryptase levels correlate with aggressive disease. Recently the importance of CD30 expression on neoplastic mast cells has been confirmed. CD30 is expressed aberrantly on neoplastic mast cells in patients with advanced systemic mastocytosis.

Aims: In this study we aimed to present demographic data, clinical follow-up and treatment of patients with mastocytosis and identify the impact of KitD816V allele burden and expression of CD30 by mast cells in systemic mastocytosis.

Method: We performed a retrospective study on 54 adult patients with mastocytosis (24 female, 30 male; mean age:44.1±13) who fulfilled WHO criteria between 2006 and 2016. These patients comprise cutaneous mastocytosis (CM) (n=10), indolent systemic mastocytosis (ISM) (n=30), smoldering systemic mastocytosis (SSM) (n=2), aggressive systemic mastocytosis (ASM) (n=4), systemic mastocytosis (SM) (n=3), mast cell leukemia (MCL) (n=4) and mast cell activation syndrome (MCAS) (n=1).

Results: At diagnosis, age of patients with advanced disease was higher than ISM and SSM group (p=0.001). Most frequent symptom of disease was skin lesion (urticaria pigmentosa) (%64). Skin lesions were significantly higher in patients with ISM and SSM than with advanced disease (p<0.009). But B symptoms were significantly higher in advanced disease variant (p=0.013). Anemia, trombocytopenia, elevation of ALP and GPT, hypalbuminemia were significantly higher in advanced disease than in ISM and in SSM. Osteoporosis was higher in patients with ISM and SSM than with advanced disease, %56 and %18 respectively. KitD816V mutation was detectable in peripheral blood in 33 of 40 patients with mastocytosis (%82) with a median Ct value 36±4. Median Ct value was significantly lower in advanced SM (Ct: 32±5 ) than in SM and SSM (Ct: 36±4 ) (p=0.028) showing a significantly higher allele burden. Expression of CD30 on mast cells in bone marrow biopsies with immunohistochemistry investigation was detectable in 20 of 32 systemic mastocytosis patients (62%). There was no significant difference expression of CD30 on mast cell between patients with ISM (%65) (13/20) and advanced SM (%87) (7/8) (p=0.371). There was no significant correlation between elevated serum tryptase level and CD30 expression (p=0.11).

Summary/Conclusions: The definition of disease subcategories in systemic mastocytosis is important for choosing the treatment modality (cytoreduction or allogeneic stem cell transplantation vs treatment of the mediators symptoms) for the individual patient. CD30 is a diagnostic marker and also a possible therapeutic target.

PB2045

COMPARISONS OF PATIENT MANAGEMENT IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY


1Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, 2Head of Campaigns and Advocacy, Leukaemia CARE, Worcester, 3Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, 4Queens Centre, Castle Hill Hospital, Cottingham, 5MPN Voice, London, 6Adelphi Real World, Bollington, 7Haematology Franchise, Novartis Pharmaceuticals, Camberley, United Kingdom

Background: Patient (Pts) with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocytosis (ET), experience a substantial disease burden. The international MPN LANDMARK survey evaluated the patient-reported impact of MPNs in pts across 6 countries and identified current treatment strategies in these pts.

Aims: To analyze differences in treatment strategies used by physicians and pts to manage their MPN between the UK and the Rest of Surveyed World (ROSW).

Methods: A cross-sectional survey was conducted in Australia, Canada, Germany, Italy, Japan, and the UK. The Internet-based survey was administered separately to MPN patients and treating physicians (the two samples were not linked). Observed differences between the UK and ROSW are described in terms of treatment patterns and patient physician communication.

Results: A total of 699 pts (UK, n=286; ROSW, n=413) and 219 physicians (UK, n=31; ROSW, n=188) completed the survey. UK physicians were more likely to refer to 10 or more patients rather than delay at diagnosis of PV or ET. A greater proportion of ROSW physicians reported they would observe >25% of patients at diagnosis (UK - 54% MF, 30% PV, 37% ET; ROSW - 51% MF, 48% PV, 50% ET). No difference was observed in the most commonly received treatments for each disease, but a greater proportion of UK patients reported receiving treatments than ROSW. This difference was greatest in PV and ET than MF. For MF the most commonly received treatments were ruxolitinib (UK 55%, ROSW 50%), aspirin (UK 53%, ROSW 37%), hydroxyurea (HU) (UK 31%, ROSW 28%) and transfusion (UK 27%, ROSW 23%), for PV they were aspirin (UK 83%, ROSW 58%), phlebotomy (UK 76%, ROSW 67%) and HU (UK 63%, ROSW 36%) and for ET they were aspirin (UK 94%, ROSW 52%), HU (UK 62%, 30% ROSW) and anagrelide (UK 14%, ROSW 18%). Physician reported data on treatments prescribed demonstrated a similar pattern as a greater proportion of UK physicians reported using treatments than ROSW. UK physicians reported that their patients were more likely to ‘often’ disagree with their primary treatment recommendation than ROSW (18% vs 7%) but despite this UK patients were more likely to be ‘completely’ satisfied with their physicians understanding and support of their treatment goals (UK, 51%; ROSW 35%). Patients rated who they thought should be the main decision maker on a scale of 1 (the patient) to 10 (the physician). UK patients were slightly more inclined to be involved in treatment decisions (mean: UK, 6.25; ROSW, 7.01). UK physician supported this as more ‘agreed strongly’ with the statement ’I involve my MPN patients in treatment decisions’ (UK, 39%; ROSW 28%).

Summary/Conclusions: In comparison with ROSW UK physicians were more likely to prescribe drug treatments for ET/PV. Interestingly, UK patients desired to be more involved in treatment decisions, and this was reflected in the physician’s perspective to involve their patient in treatment decisions more. UK patients were also more likely to disagree with their physician on primary treat-
ment recommendations. However, this had no impact on satisfaction suggesting that UK patients welcome an open discussion on treatment options with their physician. These data highlight the importance of maximizing patient physician communication in order to improve patient satisfaction with treatment in the UK.

PB2046
ANALYSIS OF EMERGING MOLECULAR SIGNATURES AND ASSOCIATED CLINICAL FEATURES IN MPN
S. H Al Shemmari1,*, R. Rajan2
1Department of Medicine, Kuwait University, 2Bone Marrow and Stem Cell Transplant Lab, Kuwait Cancer Center, Kuwait, Kuwait

Background: Myeloproliferative neoplasms (MPNs) are a group of clonal hematological disorders that arise from transformation of a multipotent hematopoietic stem cell which includes polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). Driver mutation's confer growth advantage on the cancer cell and most is selected in the tissue microenvironment within which the neoplastic cells arise. Three-quarters of these patients carry the unique JAK2V617F mutation, JAK2 exon 12 mutations are found in 5% of patients with PV, MPL exon 10 mutations are present in about 5% ET/PMF and CALR mutations are found in 50-70% patients with ET/PMF.

Aims: In this study we investigated the prevalence of these so called driver mutations in patients with MPN's from January 2007 – January 2017 reported in our center.

Methods: We analyzed 3000 samples with suspected MPN for JAK2V617F mutation by ARMS-PCR and their allele burdens were reported by RQ-PCR. We have screened a cohort of 500 patients for JAK2/MPL/CALR mutations by a sequential molecular analysis which includes PCR, RT-PCR and fragment analysis.

Results: JAK2V617F mutation is present in 50% of patients with MPN. Among 600 cases submitted for sequential molecular analysis identified 372 cases with JAK2V617F mutation, 70 cases with CALR mutation, and 6 cases with MPL mutations. Allele burden study on JAK2V617F positive patients revealed that patients with ET has the lowest allele burden, those with PV an intermediate one and those with PMF showed the highest burden. Measurement of JAK2V617F allele burden by RQ-PCR for a PMF case after allogeneic transplant (AST) reported that allele burden of 2.9% after 20 days of transplant and a negative result after 60 days of transplant vs 13% before AST. CALR mutation is found in ET and PMF that are mutually exclusive with JAK2V617F and MPL exon 10 mutations in ET whereas 2 cases with PMF found to be positive for JAK2V617F and CALR mutations. We found 40 cases with a 52-bp deletion, 4 cases with a 14bp deletion and 26 cases with a 5bp insertion. CALR variants reported in our cohort were 54% type 1 and 46% type 2 mutations. We found a tendency towards older age among type 2 carriers compared to type 1 carriers (median age at diagnosis: 75 years vs 52 years) or compared to non-type 2 carriers (median age at diagnosis: 57 years vs 80 years). Similarly, platelet count at diagnosis tended to be higher in the subgroup of type 2 mutation carriers than in patients with the type 1 mutation while hemoglobin levels and white blood cell count were lower compared to those with non-type 2 mutation. The mutual allele burden of JAK2V617F/CALR exon 11d mutations of two PMF patients found as 10%/65% and 15%/55% respectively. In our cohort, 10% of the patients with CALR mutation had anemia, 21% had splenomegaly, and 43% had megakaryocytes at time of diagnosis. Compared with JAK2 V617F-positive ET and PMF, CALR-mutant ET and PMF are clinically correlated with lower WBC, leukocyte and hemoglobin counts, higher platelet counts, and a reduced risk of thrombosis.

Summary/Conclusions: This is the first large cohort study on the genetic landscape of patients with MPN. Molecular testing for JAK2/MPL/CALR genes as molecular marker's for MPN's, allows the diagnosis of 95% of patients with MPN's, allows the diagnosis of 95% of patients with MPN. As a novel mutation, CALR testing also has a prognostic significance and it was not mutually exclusive with JAK2V617F mutation. Measurement of JAK2 V617F allele burden early after transplantation is an important predictive parameter in monitoring patients following this treatment. The knowledge of driver mutations can provide valuable information for diagnosis and prognosis, which ultimately can be highly useful for clinical decision making for the management of patients with MPN.

PB2047
IMPACT OF THE TYPE OF CALR MUTATIONS ON THE CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS
E. Lisina1,*, P. Butylin1, N. Siordia1, A. Silyutina1, A. Zaritskey1
1Federal Almazov North-West Medical Research Centre, St. Petersburg, Russian Federation

Background: In 2013, in the majority of JAK2V617F negative patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF) have been identified mutations in the 9 exon of CALR gene. Described more than 30 different mutations, subdivided into two subtypes: deletions (type I) and insertions (type II). There are data on the phenotypic effects, depending on the version of CALR mutations. However, the prognostic significance of mutations CALR is still insufficiently clear.

Aims: To assess the impact of the type I and type II mutations of CALR on the clinical and laboratory features of ET and PMF.

Methods: A multicenter retrospective study was carried out. Samples of peripheral venous blood was obtained from 149 patients with ET (n=76) and PMF (n=73). Patients that were negative for JAK2V617F and MPL515L/K mutations were studied for CALR mutations presence as described in original paper (T.Klampf, 2013). CALR Mutations were detected in 34 patients with ET (10 - men, 24 - women) and 25 patients with PMF (13 - men, 12 - women). Statistical data processing was carried out in the program STATISTICA for Windows 6.0.

Results: The frequency of mutations CALR was comparable in patients with ET and PMF (44.7% and 35.6%). Mutations of type II is 2 times more common in ET than with the TFM. 17.1% vs 9.6% (p=0.178). Mutations of type I detected in ET, in 18 cases - in PMF, type II in 13 cases - in ET and 7 - in PMF. The median of follow-up period of patients with ET with type I mutation was 36 months (3-87), with type II - 22 months (2-90). In PMF, the median of follow-up in the group with type I mutation was 46 months (3-133), type II - 77 months (4-115). Hematological parameters in patients with ET showed higher levels of WBC in patients with type I mutation (p=0.043), the level of Hb in this variant was lower (p=0.009). In PMF levels of Hb were similar in the studied groups. Type of mutations had no significant effect on the number of WBC in patients with PMF. However, PLT was higher in PMF patients with type II mutations (p=0.014). Spleen size in ET patients on the time of the diagnosis date was slightly different: in type I - 106.5mm, type II - 116.9mm (p=0.076). The type of mutation in our study had no effect on the stratification according to the IPSET. Also there were no significant differences in assessing of the effect of therapy. Spleen size on the time of the diagnosis date in PMF patients with type I mutation were slightly larger (180.9mm vs 169.9mm). Revealed moderate pronounced fibrotic changes of the bone marrow (BM) in patients with type I CALR mutations (p <0.005). CALR mutation type had no influence on the distribution of patients with PMF, depending on the risk groups on the scale of IPSS and DIPSS.

Summary/Conclusions: The effect of the type of CALR mutation on the clinical and laboratory features of the ET and PMF has found. Type of CALR mutations in our study had no effect on the number of PLT in ET, but have a value for this index in PMF. Type I mutations in ET accompanied higher WBC level and a lower level of Hb. The published studies have not shown the influence of the type of mutation in the Hb level and the number of WBC in ET. An important observation was the detection of the effect of type I mutation on development fibrotic changes of BM in PMF. Our data are consistent with previously published studies that showed no effect on the stratification of patients according to the scale on the IPSS.
Background: Patients with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), experience a substantial disease burden. The international MPN LANDMARK survey evaluated patient-reported impact of MPNs across 6 countries.

Aims: To analyze differences in disease and symptom burden of MPN patients between the UK and the Rest of World (ROW).

Methods: A cross-sectional survey was conducted in Australia, Canada, Germany, Italy, Japan, and the UK. The internet-based survey was administered separately to MPN patients and treating physicians (the two samples were not linked). Observed differences between the UK and ROW are described in terms of symptom burden.

Results: A total of 699 pts (UK, n=286; ROW, n=413) and 219 physicians (UK, n=136; ROW, n=83) completed the survey. UK patients reported more symptoms than those in ROW (9.02 vs 5.95 respectively). A higher proportion of UK patients reported experiencing symptoms compared with ROW (e.g., fatigue and tiredness UK - 87% MF and PV, 86% ET vs. ROW – 64% MF, 39% PV, 45% ET). Patients rated symptom severity from 1 (not severe at all) to 10 (worst possible). The UK was higher than ROW for the three most common symptoms; fatigue and tiredness (mean: UK 6.73, ROW 6.18), difficulty sleeping (mean: UK 6.06, ROW 5.38) and loss of concentration (mean: UK 6.01, ROW 5.67). This difference was not observed when physicians were asked to rate symptom severity. An overall symptom burden was calculated as a function of all patient-reported symptoms. UK patients were disproportionately represented in the high symptom burden group (UK 43% vs. ROW 16%) followed by an average overall symptom burden score of 40.1 compared with 24.1 among ROW patients. UK patients were also more likely to have been classified with a high risk score at diagnosis (UK 22% vs ROW 9%). Despite the consistently greater symptom burden experienced by UK patients, little difference was observed in patient satisfaction with their healthcare and medication. The internet-based survey (UK 81% satisfied vs ROW 90%) and disease management (UK 87%, ROW 90%) were also less likely to disagree with the statement 'My doctor understands how much my condition impacts my life' (UK 39% vs 22% ROW). UK physicians had more MPN patients under their care than ROW (mean patients under care in last 12 months: UK 25, ROW 15). UK patients and adult UK patients were also more likely to agree with the statement 'There is not enough time during the appointment to discuss all of the symptoms a patient is experiencing' (UK 74% vs ROW 54%).
Background: The vast majority of myeloproliferative neoplasms (MPNs) patients are characterized by a molecular genetic background and by variable symptoms reflecting disease burden that may correlate with prognosis.

Aims: To study the impact of driver gene mutations; Janus kinase 2 (JAK2), calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) on disease burden and correlating mutational status with symptom severity calculated by MPN10 score, degree of bone marrow (BM) fibrosis, clinical characteristics and survival in MPNs patients.

Methods: Time-weighted MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) was assessed as mean/median of 10 items: fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pains, abdominal discomfort, weight loss and fever. JAK2W617F and exon12 mutations were performed by allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) while CALRexon9 insertion/deletion and MPL W515exon10 mutations were assessed by allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) while high-resolution melting (HRM).

Results: 93 MPNs patients (48 males and 45 females): 18 polycythemia vera (PV), 41 essential thrombocytopenia (ET), 25 primary myelofibrosis (PMF), 9 post-ET/PMF, 15 ET, 2 PV, 4 PMF and 2 post ET-MF. Median age at diagnosis was 55 years (17-75 years) in PV, 44 (19-75) years vs 56 (34-70) years and 56 (20-75) years, respectively (p<0.001). JAK2 mutation was positive 53/93 (57%); 16 (90%) PV patients, 9 (36%) ET, 2 PV, 4 PMF patients (p<0.001). CALR mutation was positive in 4/14 (30%) (12%) and 14 ET, 3 PMF, 2 post ET-MF patients (p<0.001). MPL mutation was positive in 2/93 (2%) and 23/36 (1/4) PMF patients, 0 (0%) post-ET/PV/PMF patients. 23/36 (95%) patients were triple negative; 15 ET, 2 PV, 4 PMF and 2 post ET-MF. Median MPN10 score was 21 (4-45) in ET versus 37.5 (25-56) in PV, 54 (15-80) in PMF and 59 (45-75) in post-ET/PV/PMF (p<0.001). From 52 patients with BM fibrosis, 6 (15%) were triple negative vs 33 (85%) mutant patients (p=0.007). Among 52 patients with splenomegaly, 7 (13.5%) patients were triple negative vs 45 (87%) patients with a positive mutational status (p<0.001). Median MPN10 score was 48 (5-76) in JAK2 positive patients vs 25 (4-80) in JAK2 negative (p<0.001) and was 22.5 (4-65) in CALR mutants vs 35 (5-80) in CALR negative (p<0.001). Median MPN10 score was 21 (10-48) in triple negative patients vs 40 (4-80) in MPNs JAK2/CALR/MPL mutants (p<0.001). After a median follow-up period of 36 months (6-102), progression free survival (PFS) and overall survival (OS) of the whole cohort was 85% and 95%, respectively. PFS of JAK2 positive vs negative patients was 62% vs 0% (p<0.001), PFS of CALR positive vs negative patients was 100% vs 78% (p=0.067). PFS of triple negative vs mutant patients was 100% vs 75% (p=0.004). OS of JAK2 positive vs negative patients was 85% vs 100% (p=0.011). OS of CALR positive vs negative patients was 100% vs 92% (p=0.197). OS of triple negative vs mutant patients was 100% vs 90% (p=0.015) (Figure 1).

Summary/Conclusions: MPN10 score is directly affected by JAK2 and CALR positivity and can be used as a major predictor of survival in MPNs patients. Triple negative ET patients in our cohort have significantly lower MPN10 score, show lower incidence of BM fibrosis and splenomegaly which may indicate a more indolent disease course.

PB2053

FINAL RESULTS FROM PEN-PV STUDY, A SINGLE-ARM PHASE 3 TRIAL ASSESSING THE EASE OF SELF-ADMINISTRATING ROPEGINTERFERON ALFA-2B USING A PRE-FILLED PEN IN POLYCYTHEMIA VERA PATIENTS


1Hematology and Hemostaseology, Medical University Vienna, 2AOP Orphan Pharmaceuticals AG, Vienna, Austria, 3Clinic of Hematology, University Multi-profile Hospital for Active Treatment “Sveti Georgi”, Plovdiv, Bulgaria, 4Teaching Unit of Hematology Department, University Hospital in Krakow, Krakow, Poland, 5Clinical Hematology Clinic, Multi-profile Hospital for Active Treatment “Sveta Marina”, Varna, Bulgaria, 6Department of Internal Medicine II, Kaposi Mor County Teaching Hospital, Kaposvar, Hungary, 7Samara Kalinin Regional Clinical Hospital, Samara, Russian Federation, 8Department of Clinical Hematology, University Hospital Hradec Králova, Hradec Kralove, Czech Republic, 9Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, 10Department of Hematology, Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy, Ukraine, 11First Department of Internal Medicine, Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, Bulgaria, 12Clinic of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic, 13Department of Hematology, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark, 14Centre d’Investigations Cliniques, Hôpital Saint-Louis and Université Paris Diderot, Paris, France

Background: Interferon-alpha (IFNa) based therapies have been successfully used in myeloproliferative neoplasms for over thirty years. A known burden for long-term therapy applying IFNa in otherwise fit outpatients is the frequency of hospital visits for product administration. Ropeginterferon alfa-2b (ROMP) (AOP2014) is a novel long-acting monopegylated IFNa allowing initially bi-weekly and, in long-term maintenance, monthly administration. To further improve on convenience and compliance, a pre-filled, dose-adjustable pen was developed for patient self-administration at home.


Methods: The study was performed in 18 sites in 8 European countries. Patients were eligible who completed the AOP2014-arm in the PROUD-PV study (12 months of treatment). A total of 7 visits was scheduled within 3 months (i.e. supervised self-administration at site, following first self visit at study site). Patients were eligible who completed the AOP2014-arm in the PROUD-PV study (12 months of treatment). A total of 7 visits was scheduled within 3 months (i.e. supervised self-administration at site, following first self visit at study site). Patients were eligible who completed the AOP2014-arm in the PROUD-PV study (12 months of treatment). A total of 7 visits was scheduled within 3 months (i.e. supervised self-administration at site, following first self visit at study site).

Results: A total of 36 patients were enrolled and received the AOP2014 pen for self-administration. The mean age was 58.5 years (range 37 to 77 years), 23/36 (63.9%) were male patients and a large proportion of patients (15/36 (41.7%)) had at least one major comorbidity. Baseline data was available on 32/36 patients (88.9%). Patients achieved full success at Visit P7 (supervised visit at study end). 80.6% (29/36) of patients had achieved full success, defined as no technical problems with the pen experienced by the patient during the injection, and no early withdrawal of the pen (before injection was complete), both observed by the investigator. At the second supervised visit the full success rate was 91.7% (33/36). The majority of observations resolved after the second supervised visit. Only 5 patients (13.9%) needed one additional supervised visit prior using the pen correctly in a home-setting. All patients had achieved full success at the final supervised visit at study end.

The patients responded favourably to the use of the pre-filled pen for the administration of AOP2014 and the accompanying instructions. Based on the Investigator’s assessment, no patients exhibited any visible pain or physical discomfort, appeared to be dissatisfied when using the pen or exhibited any frustraton. As per patient report, 100% of patients achieved full success at the final supervised visit at study end.

Summary/Conclusions: UK patients perceive a higher symptom burden than ROSW in terms of frequency and severity. While UK physicians agree with regards to frequency, they didn’t perceive a greater symptom severity in their patients compared to ROSW physicians. Patient/physician disconnect was unlikely to be the cause as satisfaction was high and similar to that in ROSW. However, UK physicians not only have more patients under their care than their ROC counterparts, they are also more likely to feel that they don’t have enough time to discuss all symptoms. This is likely to be impacting on the ability of patients and physicians to communicate fully on symptoms and to agree on the best disease management plan.
PB2054  
**JAK2, CALR and MPL MUTATIONS: CORRELATION WITH PHENOTYPIC DISEASE AND HISTOPATHOLOGICAL FEATURES OF BONE BIOPSY**

H. J. Campo Palacio1, M.J. Ramírez Sánchez1, A.M. Rodríguez Fernández2, L. Hermosín Ramos1, B. Bellosillo Paricio1, E. Camillo Cruz1

1Haematology, 2Pathology, Jerez De La Frontera Hospital, Jerez De La Frontera, 3Pathology, Hospital del Mar, Barcelona, 4Haematology, Hospital Virgen del Rocío, Sevila, Spain

**Background:** Drivers mutations JAK2, CALR and MPL are mutually exclusive in Essentials thrombocytopenia (ET) and these are included in the diagnostic criteria of mieloproliferative neoplasms (MPNs). Consistent with know literature, the molecular characterisation have implications in the phenotipic disease and it might be interesting to study if they are associated with the histopathological characteristics of bone marrow biopsy.

**Aims:** The purpose of this work is analyse the correlations between clinical, biological and histological characteristics of bone marrow biopsy and the mutational status (JAK2, CALR, MPL).

**Methods:** The study included 76 patients with ET diagnosed according to WHO criteria at the Haematology Department from Hospital de Jerez from January 2005 to December 2015. We examined the prevalence, and clinical and laboratory correlations of JAK2/CALR/MPL mutations. To evaluated the histology, one pathologist with expertise in haematopathology review the bone marrow biopsies corresponding to 44 patients with ET. We incluyed only bone marrow biopsies of at least 10 mm in length and/or minimum 8 inter-trabecular areas. The pathologist only had access to age and gender data. Mutations JAK, CALR and MPL were analysed by PCR real time and sanger sequencing.

**Results:** There where 55 (72%) patients JAK2, 12 (15.5%) patients CALR, one patient MPL and 9 (11.8%) patients triple-negative (TN). The main clinical and biological features of patients are show in Table 1A. As can be seen, a 75% of patients belonged a high risk group, 18 (23%) patients presented thrombotic events before diagnosis and only 4 (5.3%) during the evolution. Clinical and molecular characteristics of patients as age, sex, hemoglobin level and stratification of risk were statistically significant. (Table 1A). Thromboembolic events seemed to be more frequent in patients with JAK2 mutation, although statistical significace was not achieved. The correlation between histopathological characteristics and mutational status are shown in Table 1B.

We observed differences between the presence of laxes groups of megacaryocytes according with the mutational status and there were more frecuently in patients with JAK2 mutation, although statistical significance was not achieved. The correlation between histopathological characteristics and mutational status are shown in Table 1B. We incluyed only bone marrow biopsies of at least 10 mm in length and/or minimum 8 inter-trabecular areas. The pathologist only had access to age and gender data. Mutations JAK, CALR and MPL were analysed by PCR real time and sanger sequencing.

**Results:** There where 55 (72%) patients JAK2, 12 (15.5%) patients CALR, one patient MPL and 9 (11.8%) patients triple-negative (TN). The main clinical and biological features of patients are show in Table 1A. As can be seen, a 75% of patients belonged a high risk group, 18 (23%) patients presented thrombotic events before diagnosis and only 4 (5.3%) during the evolution. Clinical and molecular characteristics of patients as age, sex, hemoglobin level and stratification of risk were statistically significant. (Table 1A). Thromboembolic events seemed to be more frequent in patients with JAK2 mutation, although statistical significace was not achieved. The correlation between histopathological characteristics and mutational status are shown in Table 1B.

We observed differences between the presence of laxes groups of megacaryocytes according with the mutational status and there were more frecuently in patients with JAK2 mutation, although statistical significance was not achieved. The correlation between histopathological characteristics and mutational status are shown in Table 1B.

**Summary/Conclusions:** In our study we can confirm that there are differences between clinical and laboratory finding according with mutational status, as shown in previous studies. The most consistent finding of this study was the presence of laxes groups of megacaryocytes significantly higher in those with CALR mutations. The major limitations of this study include a small number of patients and biopsies available to analysed, this might be the mayor causes for the lack of the data demonstrating clinical and histological relevance. But our results should not be underestimated because, to our knowledge, this is the second study thas has investigated this relation.

---

**PB2055**

**CLINICAL IMPLICATION OF QUANTITATIVE JAK2 V617F ANALYSIS WITH DROPLET DIGITAL PCR IN MYELOPROLIFERATIVE NEOPLASMS**

E. Lee1, K. J. Lee2, H. Park2, J. Y. Chung2, M.-N. Lee3, M.H. Chang4, J. Yoo5, H. Lee1, S.-Y. Kong5, H.-S. Eom1

1Hematology, 2National Cancer Center, Goyang, 3Green Cross Laboratories, Yongin, 4Oncology-Hematology, 5Laboratory Medicine, National Health Insurance Service Ilsan Hospital, 6Laboratory Medicine, National Cancer Center, Goyang, Korea, Republic Of

**Background:** JAK2 V617F is the most common genetic mutation in myeloproliferative neoplasms (MPN) and included in the major diagnostic criteria. Beyond the description of existence, quantification of mutational load is proposed as a useful information to classify subgroups of MPN and to predict prognosis. Droplet digital PCR (ddPCR) is a novel assay which has an advantage in accurate and reproducible quantitative analysis.

**Aims:** This study was planned to verify the correlation of ddPCR with pyrosequencing in diagnosis of MPN and to investigate clinical implication of the mutation burden in disease course.

**Methods:** Between 2012 and 2016, peripheral blood or bone marrow samples were obtained from 56 patients at diagnosis and every 3 months after enrollment. Inclusion criteria were 1) older than 20 years, 2) who were newly diagnosed with MPN and 3) diagnosed with MPN before, not met the indication of JAK2 inhibitor treatment yet. JAK2 V617F mutation was detected by pyrosequencing as diagnostic work-up. The ddPCR was performed using the same samples with pyrosequencing to prove correlations between assays and to establish a detection sensitivity cutoff. Clinical aspects and hematologic profiles of enrolled patients were reviewed.

**Results:** The lowest value of measured JAK2 V617F allele by ddPCR except negative samples in our study was 0.01%, which was approximately 0.07 copies/μL of mutant allele. Some discrepancies were observed from 0.0001% to 0.01% concentration between the expected and measured values in ddPCR detection sensitivity assay. 0.1% was determined as the cutoff. Forty-two patients (75%) were positive for JAK2 V617F by pyrosequencing and 46 (82.1%) were positive by ddPCR. The mean mutated allele at diagnosis was 37.5%±30.08%. With ddPCR, the mean was 40.7%±31.2%. Pyrosequencing and ddPCR were highly correlated (r=0.9712, P<0.001). JAK2 V617F burden measured with ddPCR was significantly different by subgroups (P<0.001). In comparison of one disorder with another, polycythemia vera (PV) had more amount of mutant allele than essential thrombocytosis (ET) (P=0.001), however, differences between PV-myelofibrosis (MF) and ET-MF were not statistically significant. Follow-up samples were available in 12 patients and 8 were JAK2 V617F positive. Among them, reduction of mutant burden after treatment was observed in 6 patients (75%). JAK2 V617F burden showed initial reduction in a MF patient treated with JAK2 inhibitor, however, after dose reduction for toxicities, the JAK2 V617F mutation increment with hematologic aggravation was discovered. Mutation burden decrease showed a tendency consistent with hematologic improvement.Hematologic characteristics and JAK2 V617F load at the initial diagnosis and follow-up after treatment (Table 1, Figure 1).

**Table 1.**

<table>
<thead>
<tr>
<th>Pl. No</th>
<th>Source</th>
<th>Subgroup</th>
<th>Initial JAK2 V617F load</th>
<th>Follow-up JAK2 V617F load</th>
<th>Difference</th>
<th>Initial CR</th>
<th>Follow-up CR</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PV</td>
<td>ET</td>
<td>57.04</td>
<td>37.07</td>
<td>19.97</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
<tr>
<td>2</td>
<td>PV</td>
<td>PV</td>
<td>46.81</td>
<td>39.13</td>
<td>7.68</td>
<td>100.00</td>
<td>79.60</td>
<td>JAK2</td>
</tr>
<tr>
<td>3</td>
<td>PV</td>
<td>PV</td>
<td>61.56</td>
<td>41.35</td>
<td>20.21</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
<tr>
<td>4</td>
<td>PV</td>
<td>PV</td>
<td>50.00</td>
<td>40.95</td>
<td>9.05</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
<tr>
<td>5</td>
<td>ET</td>
<td>ET</td>
<td>11.56</td>
<td>3.49</td>
<td>8.07</td>
<td>100.00</td>
<td>78.90</td>
<td>JAK2</td>
</tr>
<tr>
<td>6</td>
<td>ET</td>
<td>ET</td>
<td>20.32</td>
<td>16.25</td>
<td>4.05</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
<tr>
<td>7</td>
<td>ET</td>
<td>ET</td>
<td>16.25</td>
<td>12.50</td>
<td>3.75</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
<tr>
<td>8</td>
<td>ET</td>
<td>ET</td>
<td>50.00</td>
<td>40.95</td>
<td>9.05</td>
<td>100.00</td>
<td>100.00</td>
<td>JAK2</td>
</tr>
</tbody>
</table>

* Data from the first follow-up sample.  † Data from the next follow-up sample in the same patient.

**Figure 1.**

![Figure 1](image-url)
Summary/Conclusions: Quantitative analysis of JAK2 mutation using ddPCR was highly correlated with pyrosequencing and might reflect clinical treatment response.

PB2056

CLINICAL IMPACT OF JAK2 AND CARLETICULIN GENE MUTATIONS ON PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

M. Napolitano1, *, S. Siragusa1, S. Mancuso1, M. Santoro1, V. Leone2, C. Marinò2, F. Di Plaizza1, A. Russo1, V. Acciai1, C. Beltrami2, A. Rizzi2,1
1UO Ematologia, University Of Palermo, Palermo, 2Oncemoclinica, ASP Local Hospital, Trapani, 3Laboratorio di genetica e oncologia molecolare., 4UO Oncologia, University Of Palermo, Palermo, Italy

Background: JAK2 (V617F) gene mutation is found in approximately 60% of patients with Essential Thrombocythemia (ET), while 5-10% of JAK2 (V617F) negative ET patients carry MPL gene mutations involving codon 515. Recently, mutations at the exon 9 of calreticulin (CALR) gene have been identified in approximately 50% of patients with ET, unmutated for Jak2 and MPL.

Aims: Primary aim of the current study was to analyse the prevalence of JAK2, MPL and CALR gene mutations in patients with ET; secondary aim was to evaluate the impact of gene mutations on clinical features of ET at diagnosis.

Methods: A cohort of consecutive patients with a diagnosis of ET followed between January 2013 and June 2016 were considered. JAK2 (V617F) gene mutation was detected by PCR testing; MPL and CALR mutations were analysed by direct sequencing methods. Thrombotic risk score was calculated according to European Leukemia Net recommendations. Data were statistically analyzed.

Results: Overall, 148 patients were included: 107 (72.30%) had JAK2 (V617F) gene mutation (JAK2+), 12 (8.10%) carried a mutation at exon 9 of CALR gene (CALR+), 2 (1.70%) a combination of codon 515 of MPL gene, 26 (17.58%) patients were not mutated for JAK2, CALR and MPL genes (triple negative). JAK2+ subjects, compared to JAK2+ patients, had a younger age at diagnosis: median 48 years (25-92) in CALR+ patients vs 72 years (18-93, respectively. Patients with MPL mutation had a median age of 82 years while triple-negative subjects had a median age of 59 years (23-89). The median score for thrombotic risk was 0 in CALR+ patients and 1 in JAK2+, MPL+ and triple negative patients. The distribution of International Prognostic Score for Essential Thrombocythemia (IPSET) categories was also statistically significantly different (p=0.003) for the three groups. The percentage of high-risk patients was 0 in JAK2+, 7% (2/29) in JAK2+ group, and 13 (30/236) in the triple negative group. The IPSET1 model also stratified patients with statistically significant difference (p=0.001) among the three groups: the percentage of high-risk patients was 16, 66 (22/135) in the CALR+ group, 82, 35% (88/107) in the JAK2+ group, and 33, 89(29) in triple negative group. CALR+ patients belonged more frequently to the low intermediate risk group than JAK2+ patients (80% versus 17.5%, p=0.05). The incidence of thrombotic events at diagnosis of ET was 0 in the CALR+ group, 28.3% (30/107) in the JAK2+ group and 23.07% (6/26) in the triple negative group. The median overall survival was not reached in any group.

Summary/Conclusions: CALR+ patients with ET are phenotypically distinct from JAK2+ and triple negative patients. We can speculate a potential protective role of CALR mutation given the absence of thrombosis in IPSS and IPSET1 high-risk patients.

PB2057

RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE FROM THE EAST OF ENGLAND

J. Russell1, D. Sparksman2, A. Dicu3, K. Maw2, C. Gomez2, M. Mangi2, J.E. Park1, *, I. Hwang1
1Pediatrics, AJOU University School of Medicine, Suwon, Korea, Republic Of

Background: Children with Down syndrome (DS) have a 10- to 20-fold increased risk of developing leukemia. But some patients don’t suffer leukemia even they have significant numbers of blast cell in their peripheral blood. These patients have anemia at diagnosis, which is not a condition called Transient myeloproliferative disorder(TMD), and it is a disease entity unique to DS newborns and is defined as the morphologic detection of blasts in DS less than three months of age.

Aims: This study gathered DS patients to find some difference between leukemia and TMD, to determine TMD, and only 1 patient progress to Acute Myeloid Leukemia(AML) in 98 days of his life. Other 6 patients have blast cell in their blood after three months of life, and underwent chemotherapy due to hematologic malignancy. All patients with leukemia has anemia at diagnosis, which is not found in TMD patients(p=0.018). In 7 Leukemia patients, 3 was acute Lymphoblastic Leukemia(ALL), 4 was Acute Myeloblastic Leukemia(AML). All patients with leukemia has anemia at diagnosis, which is not found in TMD and ALL patients, even it didn’t confirm former examination.

Summary/Conclusions: DS Patient who has blast in their peripheral blood before 3 months of life need closely follow up their Complete Blood Count and Chromosome analysis to find whether TMD progresses to leukemia.

PB2058

MONITORING OF TRANSIENT MYELOPROLIFERATIVE DISORDER AND LEUKEMIA IN DOWN’S SYNDROME: A SINGLE UNIVERSITY HOSPITAL STUDY

T. Park1, *, I. Hwang1
1Pediatrics, AJOU University School of Medicine, Suwon, Korea, Republic Of

Background: Children with Down syndrome (DS) have a 10- to 20-fold increased risk of developing leukemia. But some patients don’t suffer leukemia even they have significant numbers of blast cell in their peripheral blood. These patients have anemia at diagnosis, which is not a condition called Transient myeloproliferative disorder(TMD), and it is a disease entity unique to DS newborns and is defined as the morphologic detection of blasts in DS less than three months of age.

Aims: This study gathered DS patients to find some difference between leukemia and TMD, to determine TMD, and only 1 patient progress to Acute Myeloid Leukemia(AML) in 98 days of his life. Other 6 patients have blast cell in their blood after three months of life, and underwent chemotherapy due to hematologic malignancy. All patients with leukemia has anemia at diagnosis, which is not found in TMD patients(p=0.018). In 7 Leukemia patients, 3 was acute Lymphoblastic Leukemia(ALL), 4 was Acute Myeloblastic Leukemia(AML). All patients with leukemia has anemia at diagnosis, which is not found in TMD and ALL patients, even it didn’t confirm former examination.

Summary/Conclusions: DS Patient who has blast in their peripheral blood before 3 months of life need closely follow up their Complete Blood Count and Chromosome analysis to find whether TMD progresses to leukemia.

PB2059

INFECTIONOUS EVENTS IN A COHORT OF PATIENTS WITH MYELOFIBROSIS UNDER TREATMENT COMPARING RUXOLITINIB WITH CONVENTIONAL THERAPY, A MONOCENTRIC EXPERIENCE OF 22 PATIENTS RETROSPECTIVELY ANALYSED

L. Torti1, *, M. Morelli1, F. Scocca1, D. Di Bartolomeo1
1Department of Hematology and Bone Marrow Unit, Pescara, 2Section of Hematopathology, Department of Hematology and Oncological Sciences, S. Orsola-Malpighi Hospital, Bologna, Italy
Background: Treatment with the Janus-activated kinase (JAK) 1 and 2 inhibitor ruxolitinib decreases constitutional symptoms and spleen size in myelofibrosis. However accumulating evidences suggest that the drug also exerts substantial immunosuppressive activity. The impressive clinical activity of ruxolitinib is predominately mediated by its profound anti-inflammatory effects modulating dendritic cell (DC) function resulting in impaired CD4+ and CD8+ activity. Several studies have shown that Ruxolitinib affects different cytokines (IL1, IL6 and TNFα/α) and other immune processes and has been linked to increased incidence of opportunistic and no opportunistic infections. Herein we report our experience at our Centre.

Aims: In our retrospective study we analysed myelofibrosis patients treated with Ruxolitinib and cyto reduce treatment with Hydroxurea and supportive therapy followed in our Department from 2012 to 2016 to evaluate rate of infections developed.

Methods: We reviewed 22 patients presenting myelofibrosis (median age 72, range 60-86) describing clinical and biological features (Table 1). Our aim was to describe the composition of infections identified with conventional treatment and with Ruxolitinib. They were 11 treated with JAK inhibitors and 11 with Hydroxurea taken orally, similar for age and clinical features.

Results: A total of 22 patients consecutively diagnosed were included in this analysis. There were 15 primary and 7 secondary myelofibrosis patients. According to the Dynamic International Prognostic Scoring System (DIPSS) 8 were low risk, 10 were intermediate risk and 4 were high. A total of 5 documented infections were identified throughout the evaluation period, 4 were grade 1 and one grade 2. They are various including oral herpes simplex reaction, pneumonia, recurrent viral flu syndromes, esophagitis fungal and urinary infections. All of them were present in the subgroup of patients undergoing therapy with Ruxolitinib (45%) after a medium time of 8 months from beginning of therapy (range 3-10). No patients received any anti-infective prophylaxis. Median total daily dose of ruxolitinib was 10 mg (range 5-20). All of this infections were low risk, one was grade 2. They are various including oral herpes simplex reaction, pneumonia, recurrent viral flu syndromes, esophagitis fungal and urinary infections. None of patients were treated with concomitant immunosuppressive therapy. 3 of this patients presented renal impairment (median creatinine clearance of 46 ml/min).

Summary/Conclusions: These data in our small series of patients suggest a higher incidence of ruxolitinib associated infections observed in clinical practice compared to traditional treatment. Immunosuppressive effect of Ruxolitinib is reported and the use of this drug in the transplant setting with beneficial effects on alloreactivity and on graft versus host disease is becoming more common. These patients might benefit from receiving prophylactic therapy with antiviral drugs or antibiotics or antifungal therapy or in alternative by careful monitoring. Finally nowadays physicians and patients should be aware of potential risks of using ruxolitinib including the risk of infections.

In summary, infections can occur in patients treated with ruxolitinib but are generally mild. Generally infections were non-life threatening and managed with appropriate supportive care. However larger studies are needed to confirm these observations.

PB2060

THE JAK2V617F MUTATION AND LEUKOCYTOSIS AS RISK FACTORS FOR INCIDENCE OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA

E. Simonovic1,*, V. Colic1

1Internal Medicine, General Hospital Leskovac, Leskovac, Serbia

Background: Polycythemia vera (PV) is a clonal, chronic, progressive myeloproliferative disease, caused by transformation of pluripotent hematopoietic stem cell. It is a malignant hematological disease that leads to excessive proliferation of erythroid, myeloid and megakaryocytic elements in the bone marrow. Essential thrombocythemia (ET) is a clonal disorder of unknown etiology characterized by a multipotent hematopoietic stem cell, and it is characterized by enhanced formation of megakaryocytes in the bone marrow and for no apparent cause, by markedly increased platelet counts in peripheral blood. PV and ET belong to a group of Philadelphia chromosome negative myeloproliferative neoplasms. Thrombotic and hemorrhagic complications are the most common cause of morbidity and mortality in patients with PV and ET. It is thought that the mechanisms that lead to thrombosis in MPN are the following: increased blood cell mass, abnormal platelet function and the phenomenon of spontaneous aggregation. The contribution to the incidence of thrombosis: increased level of products that are formed in the activation of platelets (thromboxane, p-selectin); increased production of microparticles that are parts of various cell membrane structures of platelet origin; JAK2V617F mutation. In patients with MPN there is increased activity of the coagulation system due to the resistance to the anticoagulant function of thrombomodulin.

Aims: The aim of this study is to monitor JAK2V617F mutations and leukocytoses as potential risk factors for the development of thrombotic complications in patients with polycythemia vera and essential thrombocythemia.

Methods: During the five-year period we monitored the occurrence of thrombotic complications in 56 patients (of both sexes, aged between 30 and 78 years), being diagnosed with PV and 22 patients (of both sexes, aged between 38 and 79 years) being diagnosed with ET. We used methods of clinical, laboratory, ultrasound and CT scans. With regard to the risk factors we followed the presence of JAK2V617F mutations and leukocytoses.

Results: Leucocyte count ranged from 5.2-27.1 x 10⁹/L. The highest leucocyte count was recorded in the group of patients with PV (p=0.01). JAK2V617F mutation was also statistically more significantly present in patients with PV. The highest percentage of thrombotic complications (arterial and venous) was found in the group of patients with ET, which was statistically more significant relative to PV. Thrombotic complications in those groups were more frequent in patients with undetectable JAK2V617F mutation, but statistically significant difference was present only in the group with PV. Thrombotic complications were in both groups more frequent in percentage with JAK2V617F positive patients, but without statistical significance. It is believed that activated neutrophils bind to platelets by influencing the increased expression of tissue factor activity, as well as the activation and damage of the endothelial cells, especially with JAK2V617F positive patients.

Summary/Conclusions: Leukocytosis and JAK2V617F may be considered as potential risk factors for the incidence of thrombosis in patients with PV and ET. Further follow-up of those patients, as well as a larger number of subjects are needed.

PB2061

RISK FACTORS FOR INCIDENCE OF HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES

E. Simonovic1,*, L. Macukanovic-Golubovic2

1Internal Medicine, General Hospital Leskovac, Leskovac, 2Internal Medicine, Clinic of Hematology, Niš, Serbia

Background: Myeloproliferative neoplasms (MPN) are the group of clonal, malignant hematopoietic stem cell disorders, characterized by the proliferation of one or more blood lines with normal or nearly normal maturing in the bone marrow and in extramedullary hematopoietic organs. Hemorrhagic syndrome is a complication that occurs in about a quarter of patients with PV and even 60% of patients with ET. Bleeding may complicate the clinical course of the IMF. In patients with PV it is manifested in the form of petechiae and ecchymoses, or may be life-threatening as uncontrollable esophageal bleeding. Bleeding occurs due to ineffective megakaryocytopenia, retention of platelets in the large spleen, qualitative...
platelet disorders, acquired deficiency of factors V and VWF, disseminated intravascular coagulation.

**Aims:** The aim of this study is to monitor the count of erythrocytes, leukocytes and platelets, as well as hemoglobin and hematocrit values as potential risk factors for the incidence of hemorrhagic complications in patients with chronic myeloproliferative neoplasms.

**Methods:** During the three-year period we monitored the occurrence of hemorrhagic complications in 139 patients of both sexes, aged between 30 and 87 years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were classified into the following groups: 1. Group with polycythemia vera (PV) (61); 2. Group with essential thrombocytemia (ET) (22.8%); followe by PV patients (37.1%) and PMF pts (49.6%) (p<0.01).

**Results:** The highest percentage of hemorrhagic complications were in the group of patients with ET and IMF (p<0.01), followed by the group with MPNs (p<0.05). In all three groups, the incidence of hemorrhagic complications in patients older than 65 years of age was higher (p<0.001). The erythrocyte count ranged from 4.65-8.89 x 10^12/L, leukocyte count 1.2-27.1 x 10^9/L and the platelet count ranged from 10.2-1986.6 x 10^9/L. Hemoglobin levels ranged from 176-210 g/L, and hematocrit from 0.58 to 0.83 L/L. The highest erythrocyte count, the highest hemoglobin and hematocrit values, as well as the highest leukocyte count was recorded in the group of patients with PV and MPNs (p<0.001) and the lowest in the group of patients with IMF (p<0.01). Among the group of patients with MPNs there was no statistically significant difference in those parameters. In the group of patients with PV and MPNs hemorrhagic complications were more frequent in percentage in patients with leukocytosis and erythrocytosis, but without statistical significance. The highest platelet count was found in the group of patients with ET and MPNs (p<0.001), and the lowest in the group of patients with IMF (p<0.01). Among the group of patients with PV and MPNs there was no statistically significant difference with regard to platelet count. Hemorrhagic complications were more frequent both in patients with platelet count below 10x10^11/L (p<0.05) and in patients with platelet count over 1000x10^9/L (p<0.01). The increase in platelet count influences the adsorption of larger von Willebrand multimers on the platelet mem-brane, thus having an effect on their elimination from circulation and degradation.

**Summary/Conclusions:** The platelet count can be considered a significant parameter for monitoring the risk of hemorrhagic complications in patients with myeloproliferative neoplasms, particularly with ET and IMF. Deviation from the count of leukocytes, erythrocytes, hemoglobin and hematocrit values may be considered as a potential risk factor for bleeding in patients with myeloproliferative neoplasms, but further follow-up and a larger number of subjects are needed. The age of the patient can also be considered as a risk factor for the incidence of hemorrhagic syndrome in those patients. The follow-up of patients with unclassified myeloproliferative neoplasms has been particularly important, which showed a high prevalence of hemorrhagic complications, and with the purpose of their further differentiation.

**PB2062**

**CLINICAL RELEVANCE OF JAK2V617F MUTATIONAL LOAD IN PATIENTS WITH PHILIPADIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS FROM REPUBLIC OF MACEDONIA (SINGLE-CENTER EXPERIENCE)**

M. Popova-Labachevska1,*, L. Cevreska1, A. Dimovski1, M. Ivanovski1, D. Dukovski1, B. Kocosi1, A. Eftimov1, S. Trakova1, I. Panovska-Stavridis1

1Hematology, University Clinic of Hematology, Skopje, Macedonia, The Former Yugoslav Republic Of

**Background:** Polycythemia vera (PV), essential thrombocytemia (ET), and primary myelofibrosis (PMF) are Philadelphia chromosome negative myeloproliferative neoplasms (MPN) characterized by the expression of an acquired activated JAK2V617F mutation. Up to date, it remains controversial how one mutation can lead to expression of three different clinical MPN phenotypes. However, several studies have shown that the JAK2V617F allele burden may correlate with specific MPN entity.

**Aims:** In order to further clarify these observations, we evaluated the JAK2 mutational status and its clinical implications in 233 JAK2 V617F+ patients with different MPNs from the Republic of Macedonia.

**Methods:** We conducted a single center retrospective study which included 223 patients with JAK2V617F+MPN diagnosed according to WHO criteria, with median follow-up period of 4 years. The verification of the JAK2V617F mutation was analyzed with the Real Time PCR method using the Larsen protocol. Based on the mutational load patients were divided in three groups: first with <10% mutational load, second with 10-50% load and third with >50% mutational load. The correlation of the allele burden with various clinical parameters was done by the independent student’s t-test using Statgraphics 4.3 software.

**Results:** Our study showed that median allele burden was lowest in patients with ET (22.8%), followe by PV patients (37.1%) and PMF pts (49.6%) (p<0.01). A higher mutation burden (>50% vs <10%) was associated with advanced age (67.5 vs 58.5 years and 65 vs 58 years in ET and PMF pts respectively), with higher leukocyte count (17.3 vs 9.6 x 10^9/L and 13.8 vs 12.4, and 9.8 vs 8.8 in ET, PV and PMF pts respectively), with elevated erythrocyte count (5.76 vs 4.85 and 5.59 vs 4.52 in ET and PMF pts respectively), and with higher hemoglobin level (g/dL) and platelet count 10^9/L (15.45 vs 14.35 and 1071.5 vs 860.5 in ET patients respectively) (p<0.05 for all comparisons)

**Background:** Chronic neutrophilic leukemia (CNL) is a rare BCR-ABL1-negative myeloproliferative neoplasm (MPN) with only 200 patients reported to date according to the WHO criteria. These cases are characterized by a high number of mature neutrophils in peripheral blood (PB), a hypercellular bone marrow due to neutrophilic granulocyte proliferation and hepatosplenomegaly. None standard of care exist for CNL; most patients are palliated with hydroxyurea, interferons, splenectomy or splenectomy.

**Methods:** On May 2015 a 76 aged male patient presented at our Institution with fatigue, night sweats, neutrophilic leukocytosis (neutrophils 42.080/mmc, immature granulocytes <5%), and symptomatic splenomegaly (277x127x200 mm). To exclude myelofibrosis with myeloid dysplasia and profound erythrocytopenia, reticulocyte fibrosis was minimally present. Molecular profiling demonstrated no mutations of JAK2 or CALR and polymerase chain reaction (PCR) studies for t(9;22) and BCR-ABL fusion, was negative.

The patient was initially treated with hydroxyurea with a provisional diagnosis of prefibrotic phase of primary myelofibrosis (PMF), but symptoms worsened and the therapy was interrupted after 9 months for progressive anemia (Hb 9.9 gr/dl) and thrombocytopenia (82.000/mmc); meanwhile polymerase chain reaction (PCR) studies revealed the presence of CSF3R T618I mutation, suggesting diagnosis of CNL. By taking into account the activity of ruxolitinib in refractory CNL patients, we decided to start this drug. The initial dose was 5 mg twice daily with a gradual increase in the dose to 20 mg twice daily when platelet count became normal.

**Results:** After a follow-up of 6 months after initiation of ruxolitinib therapy, symptoms resolved, hemoglobin and platelet levels improved (PLT 186,000/mmc), leukocytosis persisted (WBC 24.600/mmc), and the patient achieved a dramatic response with fatigue, night sweats, neutrophilic leukocytosis (neutrophils 42.080/mmc, immature granulocytes <5%), and symptomatic splenomegaly (277x127x200 mm). Marrow biopsy was hypercellular (100%) with myeloid hyperplasia, mild myeloid dysplasia and profound erythrocytopenia; reticulocyte fibrosis was minimally present. Molecular profiling demonstrated no mutations of JAK2 or CALR and polymerase chain reaction (PCR) studies for t(9;22) and BCR-ABL fusion, was negative.

The patient was initially treated with hydroxyurea with a provisional diagnosis of prefibrotic phase of primary myelofibrosis (PMF), but symptoms worsened and the therapy was interrupted after 9 months for progressive anemia (Hb 9.9 gr/dl) and thrombocytopenia (82.000/mmc); meanwhile polymerase chain reaction (PCR) studies revealed the presence of CSF3R T618I mutation, suggesting diagnosis of CNL. By taking into account the activity of ruxolitinib in refractory CNL patients, we decided to start this drug. The initial dose was 5 mg twice daily with a gradual increase in the dose to 20 mg twice daily when platelet count became normal.

**Results:** After a follow-up of 6 months after initiation of ruxolitinib therapy, symptoms resolved, hemoglobin and platelet levels improved (PLT 186,000/mmc), leukocytosis persisted (WBC 24.600/mmc), and the patient achieved a dramatic reduction in spleen size (209x119x74 mm).

**Summary/Conclusions:** Current data suggest that constitutively active JAK-STAT signaling plays a central role in the pathogenesis of BCR-ABL1-negative myeloproliferative neoplasms (MPNs); our experience suggests that ruxolitinib may be a valuable therapeutic option for CNL patients. The use in CNL patients can induce partial responses by improving marrow function and reducing splenomegaly and lymphadenopathy. However, this diagnosis has been more defined since the oncogenic mutations of prefibrotic phase of primary myelofibrosis (PMF), but symptoms worsened and the therapy was interrupted after 9 months for progressive anemia (Hb 9.9 gr/dl) and thrombocytopenia (82.000/mmc); meanwhile polymerase chain reaction (PCR) studies revealed the presence of CSF3R T618I mutation, suggesting diagnosis of CNL. By taking into account the activity of ruxolitinib in refractory CNL patients, we decided to start this drug. The initial dose was 5 mg twice daily with a gradual increase in the dose to 20 mg twice daily when platelet count became normal.

**Results:** After a follow-up of 6 months after initiation of ruxolitinib therapy, symptoms resolved, hemoglobin and platelet levels improved (PLT 186,000/mmc), leukocytosis persisted (WBC 24.600/mmc), and the patient achieved a dramatic reduction in spleen size (209x119x74 mm).

**Summary/Conclusions:** Current data suggest that constitutively active JAK-STAT signaling plays a central role in the pathogenesis of BCR-ABL1-negative myeloproliferative neoplasms (MPNs); our experience suggests that ruxolitinib may be a valuable therapeutic option for CNL patients. The use in CNL patients can induce partial responses by improving marrow function and reducing splenomegaly and lymphadenopathy.
PERIPHERAL BLOOD CELL STUDY FROM PATIENTS WITH FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: WHAT SHOULD WE EXPECT?

D. Subirá1,*, H. Guillén1, C. Fernández Maqueda2, Á. Gil1, D. de Miguel1, S. Maegawa1, S. Tatekawa1, Y. Chinen1, T. Tsukamoto1, M. Yamamoto-Sugitani1, T. Kobayashi1, T. Taki1, Y. Shimura1, M. Maegawa1, T. Kobayashi1, T. Takeyama1, Y. Chinen1, Y. Shimura1, M. Yamamoto-Sugitani1, T. Kobayashi1, T. Taki1, S. Horikie1, M. Taniwaki1, J. Kuroda1

1Haematology, Kyoto prefectural university of medicine, Kyoto, Japan
2Haematology, Hospital Universitario Puerta de Hierro, Madrid, Spain

Background: Follicular lymphoma (FL) may evolve to diffuse large B-cell lymphoma (DLBCL) and interactions between neoplastic cells and immune tumour microenvironment have been involved in this process. However, the potential value of the peripheral blood study to identify FL patients at high risk of progression is less known.

Aims: To describe the peripheral blood findings of patients with FL and DLBCL at diagnosis, and to investigate whether a particular lymphoid distribution could be associated with aggressive disease.

Methods: The study (performed between September 2012 and January 2017) included 52 patients (50% female) with a median age of 70.5 years (71% >60 years). Patients were newly diagnosed with FL (n=1), Grade 1 FL (n=12), Grade 3 FL (n=11), and DLBCL not otherwise specified (n=28). In situ FL and Grade 1 FL were grouped as low-grade FL. Most patients with FL (11/13 low-grade FL and 8/11 Grade 3 FL) had clinical stages III/IV. Patients with primary or secondary immunodeficiency and those who had already received corticosteroids or chemotherapy were excluded from this study. A whole blood sample was studied at diagnosis of lymphoma and prior to the start of therapy, using multicolour flow cytometry immunophenotyping and a standard stain-lyse-wash protocol. A single monoclonal antibody panel including reagents against CD19, CD20, CD22, kappa, lambda, CD3, CD4, CD8, CD56 and CD45 was used, and a minimum of 300,000 events were acquired on the flow cytometer. Results were expressed as the absolute number/ml of monocytes, lymphocytes, T cells, CD4, CD8 and NK cells. Polyclonal and monoclonal B lymphocytes were also identified.

Results: No difference in the distribution by sex or age was found between patients with FL and DLBCL. A low cell count in at least one lymphocyte population was detected in 35/52 patients (67.3%). 100% of cases had a low number of polyclonal B cells (<100/ml). Comparison of low-grade FL, grade 3 FL and DLBCL did not show any statistically significant difference regarding monocytic CD45, CD4 and total T cells. Low-grade FL and DLBCL showed the highest number of differences, involving lymphocytes (257±1243 versus 1495±657, p=0.001), NK cells (381±312 versus 204±167, p=0.03), the CD4:CD8 ratio (1.5±4.29 versus 2.06±1.44, p=0.002), and circulating mononuclear B cells, for both percentage (15.2±23.23 versus 1.94±23, p=0.001) and absolute number (869±1758 versus 18.75±54.67, p<0.001). Grade 3 FL and DLBCL also showed a different CD4:CD8 ratio (1.16±0.45 versus 2.06±1.44, p=0.001), with a trend toward significance regarding CD4 T cells (413±184 versus 685±457, p=0.077). Grade 3 FL had a lower number of polyclonal B cells as compared to DLBCLs (864±41 versus 105±102, p=0.048). There was a high expression of membrane B cells was higher in low-grade FL than in grade 3 FL, in both percentage (15.2±23.23 versus 4.58±28.48, p=0.008) and number (869±1758 versus 43.3±69.91, p=0.002) of monoclonal B cells. The number of lymphocyte sub-populations was different as well: in low-count was higher in grade 3 FL than in low-grade FL (p=0.03).

Summary/Conclusions: The peripheral lymphocyte profile in patients with FL and DLBCL is heterogeneous, but B-lymphopenia and CD4:CD8 ratio deviations are frequent findings. Regardless of clinical stage, low-grade FL had more circulating lymphoma cells and preserved lymphocyte populations than grade 3 FL. Further studies are warranted to confirm these exploratory findings and determine their clinical implications.

Non-Hodgkin & Hodgkin lymphoma - Biology

PB2064

HYDROCHLORIDE INDUCES MULTIDRUG RESISTANCE IN A NOVEL MANTLE CELL LYMPHOMA-DERIVED CELL LINE KUMP-YU1

T. Takimoto1,*, H. Nagoshi1, S. Maegawa1, S. Tatekawa1, T. Tsukamoto1, Y. Chinen1, Y. Shimura1, M. Yamamoto-Sugitani1, T. Kobayashi1, T. Taki1, S. Horikie1, M. Taniwaki1, J. Kuroda1

1Haematology, Kyoto prefectural university of medicine, kyoto, Japan

Background: Mantle cell lymphoma (MCL) is cytogenetically and molecularly characterized by chromosomal translocation t(11;14)(q13;q32) for deregulated cyclin D1 (CCND1) overexpression, and has remained as one of hard-to-treat subtypes of non-Hodgkin lymphomas (NHLs).

Aims: The development of novel therapeutics for MCL has been urgently needed, therefore, this study investigated the potency of PDPK1 as a therapeutic target molecule in MCL cells.

Methods: Four MCL-derived cell lines (MINO, Jeko-1, JVM-2 and Z138 cells), three diffuse large B-cell lymphoma (DLBCL)-derived cell lines (KPUM-MS3, KPUM-UH1 and A3/KAW cells) and a Burkitt lymphoma (BL)-derived cell line (Namalwa) were utilized in this study. Patient-derived biopsy specimens were obtained with informed consent and subjected to the immunohistochemical (IHC) staining of phospho- (p-) PDK1 Ser241. Cell proliferation was assessed by a modified MTT assay. Antibodies utilized for Western blotting was performed for evaluating protein expression levels of PDK1, p-PDK1Ser241, p-RSGK2Ser227, and RSK2. BX-912, a specific inhibitor for PDPK1, was purchased from Selleckchem (USA). RNA interference of PDPK1 was performed by transfection of short hairpin RNA (shRNA) or small interfering RNA (siRNA) in MCL cell lines by means of nucleofection (Lonza, Switzerland).

This study was approved by the institutional review board of our institute.

Results: By means of IHC examination, our study revealed that PDPK1 was generally active in various types of B-cell lymphoid neoplasms. The in vitro treatment with BX-912 for 48 hours resulted in the dose-dependent inhibition of cell proliferation in all four MCL cell lines (IC50 0.9~2.5 mM), and this inhibitory effect of BX-912 was more profound in MCL cell lines compared with three DLBCL cell lines (IC50 3.7~17.0 mM) and a BL cell line (IC50 2.9 mM). In addition, the flow cytometric analysis revealed that the growth inhibition of MCL cells by PDPK1 blockade with BX-912 was at least partly mediated through the induction of apoptosis. As the molecular sequelae, PDPK1 blockade by BX-912 resulted in dephosphorylation of RSK2 and AKT activity or CCND1 expression was unaltered by BX-912 treatment in MCL cells. By gene knock-down of PDPK1 by RNA interference using three different short hairpin RNAs, further validated that the reduction of PDPK1 protein caused the inactivation of RSK2 and the growth inhibition in MCL cell lines. Finally, when combined with various agents that are utilized for the treatment of MCL, such as doxorubicin, etoposide, fludarabine, bortezomib, or ABT263, BX-192 showed additive/synergistic growth inhibitory effects in MCL cell lines.

Summary/Conclusions: Collectively, our study suggested that PDPK1/RSK2 signaling axis is the potential therapeutic target in MCL.

PB2066

THE ACQUISITION OF RESISTANCE TO BENDAMUSTINE HYDROCHLORIDE INDUCES MULTIDRUG RESISTANCE IN A NOVEL MANTLE CELL LYMPHOMA-DERIVED CELL LINE KUMP-YU1

T. Takimoto1,*, H. Nagoshi1, S. Maegawa1, S. Tatekawa1, T. Tsukamoto1, Y. Chinen1, Y. Shimura1, M. Yamamoto-Sugitani1, T. Kobayashi1, T. Taki1, S. Horikie1, M. Taniwaki1, J. Kuroda1

1Haematology, Kyoto prefectural university of medicine, kyoto, Japan

Background: Bendamustine hydrochloride (BH) has been one of the most promising phototoxotrophic mantle cell lymphoma (MCL), however, its mechanisms of action and the mechanisms for the acquisition of resistance to BH have not been fully clarified.

Aims: We tried to identify the underlying mechanisms for BH resistance to develop the strategy to overcome BH resistance.

Methods: This study was conducted in accordance with the Declaration of Helsinki and with the approval of the Institutional Review Board. Patient’s sample was obtained along with the written informed consent. We firstly established a novel MCL-derived cell line, KUMP-YU1, from circulating lymphoma cells of a 77-year-old male patient with MCL. A BH-resistant subline of KUMP-YU1 (KUMP-YU1R) was established by continuous exposure to BH with gradual escalation of its concentration from 5 μM up to 50 μM for about 8 months. Cyto- genetic analysis was performed by double color-fluorescence in situ hybridization and spectral karyotyping (SKY). The comparative gene expression profile (GEP) and the ingenuity canonical signal pathway analyses between of KUMP- YU1 and KUMP-YU1R were performed to identify the differential gene expression pattern along with the acquisition of BH resistance. Cell viability was evaluated by a modified MTT assay.

Results: SKY analysis revealed that both primary tumor cells and KUMP-YU1 had complex karyotype including three-way translocation (8;14;11) (q24;q32;q32) involving cyclin D1, and a novel deletion of cyclin D3. Flow cytometric analysis of the comparative gene expression profile in KUMP-YU1R compared with KUMP-YU1 cells, including 312 upregulated more than 1.5-fold and 160 downregulated less than 0.67-folds in KUMP-YU1R cells. The ingenuity canonical signal pathway analysis based on the GEP results sug-
gested that KPUM-YY1R cells harbored the distinct gene expression patterns in MDR1, a gene for p-glycoprotein (P-gp) of drug transporter molecule, MGST1, a member of glutathione S-transferase (GST) families, and argininosuccinate synthetase 1 (ASS1), a rate-limiting enzyme for arginine biosynthesis. The upregulation of MDR1 (P-gp) and MGST1 were confirmed by Western blot or RT-PCR analysis in KPUM-YY1R compared with KPUM-YY1. Importantly, the addition of P-gp inhibitor or GST inhibitors, such as ethacrynic acid, at least partly restored the sensitivity to BH in KPUM-YY1R cells, indicating the functional significance of the upregulation of MDR1 and MGST1 in the development of BH resistance in MCL. In addition, BH-resistance cells were also found to express decreased mRNA level of ASS1 whereas relative expression of other lysosomal enzymes and biotin transporters were not significantly different compared with those in parental cells. }

**Summary/Conclusions:** This study revealed that the multiple molecular mechanisms overlappingly underlie the development of BH resistance, therefore, the acquisition of BH resistance potentially leads multidrug resistance in MCL cells. In future, KPUM-YY1R cells could be developed to study tumor suppressor roles and its loss has been associated with clinical aggressiveness in various cancers.

**PB2067**

**COMPARISON OF OVERALL SURVIVAL ACCORDING TO BONE MARROW ASPIRATION RESULTS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA**

J.Y. Choi1,*, K.-W. Kang1, J.H. Kim1, D.S. Kim1, E.S. Yul1, S.R. Lee1, H.J. Sung2, S.J. Kim2, C.W. Choi1, B.S. Kim1, Y. Park1

1Division of Hematology and Oncology, Korea University School of Medicine, 2Division of Hematology and Oncology, Samsung Medical Center, Seoul, Korea, Republic Of

**Background:** Bone marrow (BM) biopsy with or without aspiration is usually included in the staging workup for patients with non-Hodgkin’s lymphoma (NHL). According to the National Comprehensive Cancer Network guidelines, BM biopsy is mandatory for lymphoma, but aspiration is optional. Moreover, the role of BM aspiration is controversial. Other studies have shown that BM aspiration morphologically or flow cytometry is often inconsistent with biopsy and is less likely to detect lymphoma than biopsy. There are no clear guidelines regarding which patients are positive in BM aspiration and negative in biopsy.

**Aims:** The aim of this study was to establish guidelines through a comparison of the overall survival (OS) of patients with NHL using morphological method.

**Methods:** We performed a retrospective analysis of BM involvement in patients with newly diagnosed NHL in the Korea University Hospital from January 1991 to December 2016. OS was compared according to the BM groups, which were divided into three groups: the group without BM involvement in both BM aspiration and biopsy, the group with atypical lymphocytes only in BM aspiration, and the group with BM involvement in biopsy regardless of BM aspiration results. Atypical lymphocytes were identified as positive in BM aspiration if they displayed cleaved nuclei, vacuolation, and granulation including lymphoid aggregates, atypical nuclei, lymphoid presentation of mature B-cell neoplasm, and lymphoma associated hemophagocytic lymphohistiocytosis. Reactive changes, or relative lymphocytosis were excluded. OS was assessed using the Kaplan-Meier method, and the log-rank test was used for comparison between the groups. Multivariate analysis were performed using a Cox proportional hazards model.

**Results:** In total, the data of 1,773 patients, of which 391 patients had indolent NHL and 1,382 patients had aggressive NHL, were reviewed. Of the 1,773 patients, 1,148 (64.7%) yielded negative results on both BM aspiration and biopsy, 30 (1.7%) yielded positive results with atypical lymphocytes only in BM aspiration, and 190 (10.7%) yielded positive results in BM biopsy. Remaining 405 patients were excluded owing to inadequate results in BM aspiration and/or biopsy. Median follow-up duration was 37.62 months (range, 0-288).

At the time of Kaplan-Meier survival analysis, OS was significantly worse for patients with BM involvement in biopsy compared with those with no BM involvement, vacuolation and granulation including lymphoid aggregates, atypical lymphoid presentation of mature B-cell neoplasm, and lymphoma associated hemophagocytic lymphohistiocytosis. Reactive changes, or relative lymphocytosis were excluded. OS was assessed using the Kaplan-Meier method, and the log-rank test was used for comparison between the groups. Multivariate analysis were performed using a Cox proportional hazards model.

**Summary/Conclusions:** This study suggests that the detection of morphologically atypical lymphocytes only in BM aspiration, but not in biopsy, is not a significant predictor of OS. Therefore, even if atypical lymphocytes are detected during BM aspiration in patients with NHL, it may not be sufficient to judge the BM involvement and predict the OS of these patients.
development but more importantly, to monitor accurately response to R-CHOP and relapse from this therapy. The tumors at different stages of response to R-CHOP therapy are being analyzed and compared from lipidomics, metabolomics and proteomics point of view. Primary analysis indicate very distinctive metabolomics and lipidomic profiles between relapsed and non treated tumors.

Summary/Conclusions: Combining IVIS and MSI allow us for a better understanding of the disease and the treatment effects and the possible mechanisms allowing tumor cells to escape therapy. We are currently investigating in more details these different lipidomics, metabolomics or proteomics signatures between the different stages of DLBCL response to R-CHOP treatment in order to identify new candidates for alternative therapies.

PB2069
THE PROGNOSTIC ROLE OF INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION IN HODGKIN’S LYMPHOMA.

T. Skrypka1,*, O. Novosad1, N. Svergun2, O. Skachkova2, O. Gorbach2, V. Solovev3, N. Khrapovskaya2, I. Kryachok1

1Oncohematology, 2Experimental Oncology, National Cancer Institute, 3Thoracic surgery, Clinical Hospital No.18, Kiev, Ukraine

Background: Indoleamine 2,3-dioxygenase (IDO) is an inducible enzyme that catalyzes the initial and rate-limiting step in tryptophan along the kynurenine pathway. IDO is a key factor maintaining immune tolerance and expression and it correlates with poor clinical outcome in different types of cancer and hematological malignancies. It also plays a role in a lot of pathophysiological processes, such as antitumor and antimicrobial defense. IDO causes immunosuppression in the tumor microenvironment by tryptophan breakdown. Although, only several reviews have been made to evaluate IDO expression value and its expression value in hematological malignancies.

Aims: The aim of the study was to assess the impact of the IDO expression on clinical outcome in Hodgkin’s lymphoma (HL). Methods: A total number of 35 patients with HL were included in the group (10 males and 25 females; median age; 17-60 years, range; 38.5 years). Early stages (I-II) and advanced stages (III-IV) were diagnosed in 48.5% (17/35) and 51.4% (18/35) of patients, respectively. B-symptoms had 37.1% (13/35) of patients at the time of diagnosis. Patients were treated with ABVD/BEACOPP (14/esc) and radiation therapy. The mRNA expression level of IDO was measured in pre-treatment tumor tissue specimens from HL patients using real-time qPCR analysis.

Results: For 35 patients with HL, the overall response rate after the first-line therapy was 88.6% (31/35). Progression of the disease during the therapy was observed in 11.4% of patients (4/35). Among the patients, who achieved a remission, 9 had relapses. In our study, only 20% (7/35) of HL patients were IDO-positive (IDO+), while the majority of cases in the group (80%, 28/35) were IDO-negative (IDO–). There were no significant differences in IDO expression between histological subtypes of HL. We also did not find any association between stage of disease and IDO expression in our study. Patients with the absence of IDO expression tended to have a better response to the 1st line chemotherapy compared to Hodgkin’s lymphoma (HL).

Aims: We aim to analyze the impact of secondary chromosomal abnormalities on treatment outcome in pediatric Burkitt leukemia.

Methods: Patients with BL presenting to Children Cancer Hospital in Egypt-CCHE from July 2007 till end of December 2015, were reviewed for karyotyping, cMYC status by FISH using break apart probes, and secondary chromosomal abnormalities. These results were correlated with survival analysis.

Results: In 47 cases, seven BL patients were diagnosed and treated during the study period according to the FAB/LMB 96 protocol. Majority were males (77.3%) and above 10 years of age at presentation (42%). Associated central nervous system involvement was diagnosed in 32.9% of the patients. LDH more than 2 times the upper limit was seen in 79.5%, and 52.3% of the patients suffered from tumor lysis syndrome at presentation. Immunohistochemistry for B-cell karyotyping in 46 cases demonstrated translocation of the MYC and IGH genes in 54 patients (86%) while translocation of the IKG and IGL were found in 2 (3%) and 7 (11%), respectively. Secondary chromosomal abnormalities were detected in 40 (60%) patients, with 5 or more abnormalities in 4 patients, 3 chromosomal abnormalities in 22 patients, and 2 abnormalities in 20 all patients. The most common secondary common chromosomal abnormality was duplication of chromosome 1q which was found in 16 patients. Other secondary chromosomal abnormalities included structural abnormality of chromosome 14q other than MYC translocation (6 patients), chromosome 6q deletion (4 patients), chromosome 13q deletion (3 patients), marker chromosome (3 patients), loss of chromosome 17p (2 patients), isochromosome 9q (2 patients), translocation of chromosome 13, trisomy 13 and trisomy 9 in one patients each. Relapse or tumor progression on chemotherapy was seen in 16% of the whole group of patients. The 5 year OS was 57.7%, while 5 year EFS was 51.6%. When comparing incidence of relapse in relation to karyotype abnormalities, we found that nine out of 16 (56.2%) patients having complex karyotype experienced relapse whereas relapse occurred in only 6 (12.5%) patients having non-complex karyotype (p-value= 0.005).

Summary/Conclusions: The frequency of secondary chromosomal abnormalities in our series is in concordance with other publications with duplication 1q being the most common, followed by deletion 6q, 13q, and 17p. Complex karyotype was significantly associated with higher incidence of relapse and poor outcome.

PB2071
IGHV SOMATIC MUTATION PROFILE AS PATHOGENETIC SIGNATURE IN SPLENIC MARGINAL ZONE LYMPHOMA AND SPLENIC DIFFUSE RED PULP LYMPHOMA.

H.L. Julhakyan1,*, B. Biderman1, L. Al-Radi1, I. Yakutik1, S. Korzhova1, A. Kovrigina1, A. Sudarkin1, V. Savchenko1

1National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow , Russian Federation

Background: Splenic lymphomas (SLs) are rare chronic lymphoproliferative neoplasms with a very indolent clinical course and a non-characteristic phenotype and karyotype. They mainly are SMZL and SDRPL that are characterized by a B-cell lymphoma and characterized by a peculiar morphology with micronodular pattern of infiltration, biphasic cytology, and the almost constant presence of marginal zone differentiation. Splenic diffuse red pulp lymphoma has been introduced as a provisional entity but differential diagnosis with other SLs is needed to be made especially when considering the therapeutic approach in this disease.

Aims: The aim of our study to determine the immunoglobulin variable heavy chain (IGHV) gene usage and somatic mutation patterns in a series of SMZL and SDRP patients.

Methods: We studied 24 patients with SMZL, 40 patients with HCL and 10 patients with SDRPL. Diagnosis was based on standard Western criteria. Within all patients, the diagnosis was based on peripheral blood and BM findings. The baseline clinical and laboratory features as well as follow-up and outcome were recorded for every patient. Rearranged IGHV genes were amplified essentially in reactions that contained only one of the 5' leader region primers for the indicated VH region. All PCR reactions were performed using appropriate positive and negative controls. The rearranged VH genes identified for each case seemed to represent functional rearrangements because no stop codons or crippling mutations were identified.

Results: A comparison of the VH genes to reported germline sequences in SMZL revealed that 6 cases used VH1 and 8 cases used VH3. All VH genes were in germline or near germline configuration, whereas in 20 cases (83.3%), IGHV genes were somatically mutated. We have shown no differences in clinical and laboratory characteristics, immunophenotype, outcome or overall survival when comparing mutated and unmutated cases of SMZL. A comparison of the VH genes to reported germline sequences in SDRPL revealed that five cases used the VH3 family VH gene segments and five the VH4 family, one of case with unmutated IGHV genes. Summary/Conclusions: Our analysis also showed the selective use of VH1 and VH3 families in SMZL cases. A high proportion of SMZL cases were represented at a lower frequency (8.33% and 25%, respectively). The present study may revealed that SMZL and SDRPL derive from different cellular origin and may use in different diagnostic.

PB2070
SECONDARY CHROMOSOMAL ABNORMALITIES AND THEIR IMPACT ON TREATMENT OUTCOME IN PEDIATRIC BURKITT LEUKEMIA.

S.I. Salem1,*, H. Abdelrahman2, M. Tantawy2, S. Talaat2, R. Hamdy2

1Clinical Pathology, Pediatric Oncology, NCJ, Cairo University and Children Cancer Hospital Egypt-CCHE, 2Clinical Pathology, 3Research Department, Children Cancer Hospital Egypt, 57357, Cairo, Egypt

Background: Burkitt leukemia (BL) constitutes around 13.5% of pediatric malignancies. Burkitt non leukemic lymphoma is a high proliferative tumor involving the MYC gene to one of the immunoglobulin genes. The clinical significance of secondary chromosomal abnormalities associated with this characteristic translocation remains unknown.
PB2072

CELL OF ORIGIN ASSIGNMENT USING IMMUNOHISTOCHEMISTRY IS INFLUENCED BY BCL-2 EXPRESSION IN DLBCL PATIENTS TREATED WITH CHEMOTHERAPY AND IMMUNOTHERAPY

R. Yassin1, A. Hejazi3, A. Ahmed3,4, M. Damlaj1,4,*

COO assignment using IHC demonstrated superior Figure 1.

with chemotherapy or Lymph2Cx assay, DLBCL can be assigned as germinal center (GCB) or non-germinal center (Non-GCB) subtype. However such assays remain cumbersome or unavailable for routine clinical care. Immunochemistry (IHC) algorithms, such as the one proposed by Hans et al., are easy to use tools but demonstrated variable concordance to gene expression profiling. Importantly, cell of origin (COO) assignment appears to influence overall survival (OS) but not progression free survival (PFS). Furthermore, antiapoptotic BCL-2 oncogene expression confers prognostic significance in GCB DLBCL but its significance in Non-GCB is unknown.

Aims: To examine the prognostic impact of cell of origin (COO) assignment in conjunction with BCL-2 expression in a cohort of DLBCL patients.

Methods: After due IRB approval, adult patients diagnosed with DLBCL and treated at our institution between 2010 – 2015 were identified. Clinical and pathologic variables were retrospectively abstracted. IHC expression was deemed positive if >30% of staining was observed. Cell of origin analysis was determined by the Hans criteria. All patients were treated with combinational chemotherapy containing rituximab. Patients who died prior to receiving therapy were excluded. Categorical and continuous variables were compared using Chi-squared and Wilcoxon tests, respectively. Time to end point analysis was computed using the method of Kaplan and Meier with log rank. Relapse, progression or death was considered an event for PFS estimation. Analysis was computed using JMP software, version 11.

Results: A total of 122 patients were identified and analyzed. Median follow up of the cohort was 21.8 (1.47 – 107) months, during which OS was 73.5% and PFS was 59.9%. Stratified by IPI, 2-year OS was 85%, 76.3%, 72% and 49.5% for low, low-intermediate, high-intermediate and high risk patients, respectively (p=0.006). After stratifying patients to GCB and Non-GCB, base-line characteristics between the strata with regards to gender, age, stage, extranodal disease, lactate dehydrogenase (LDH), International Prognostic Index (IPI) and BCL-2 expression were not significantly different.

At 2-years, PFS was significantly higher for GCB vs Non-GCB at 72.5% vs 48.6%, respectively (p=0.006). After stratifying patients to GCB and Non-GCB, base-line characteristics between the strata with regards to gender, age, stage, extranodal disease, lactate dehydrogenase (LDH), International Prognostic Index (IPI) and BCL-2 expression were not significantly different.

At 2-years, PFS was significantly higher for GCB vs Non-GCB at 72.5% vs 48.6%, respectively (p=0.006). After stratifying patients to GCB and Non-GCB, base-line characteristics between the strata with regards to gender, age, stage, extranodal disease, lactate dehydrogenase (LDH), International Prognostic Index (IPI) and BCL-2 expression were not significantly different.

Importantly, cell of origin (COO) assignment appears to influence overall survival (OS) but not progression free survival (PFS). Furthermore, antiapoptotic BCL-2 oncogene expression confers prognostic significance in GCB DLBCL but its significance in Non-GCB is unknown.

Summary/Conclusions: COO assignment using IHC demonstrated superior FIG 1.

PFS for GCB over non-GCB however this was mitigated by BCL-2 expression. This raises questions regarding the currently presumed pathogenesis of the different subtypes and how to utilize the currently available targeted therapies including BCL-2 inhibitors. These observations warrant further study.
real-time polymerase chain reaction (qRT-PCR) was used to confirm the results of six upregulated and two downregulated lncRNAs. Bioinformatic analysis (gene ontology analysis, pathway analysis and network analysis) was performed to predict the biological functions and potential mechanisms of the differentially expressed lncRNAs in GCB DLBCL.

Results: We demonstrated that 21,539 lncRNAs were expressed in all samples analyzed, of which 1,548 lncRNAs were upregulated and 2,671 lncRNAs were downregulated in GCB DLBCL cell lines (OCI-ly1 and OCI-ly19) (±2.0-fold, P<0.05). Pathway analysis indicated that 64 pathways corresponded to upregulated transcripts, and 62 pathways corresponded to downregulated transcripts (P<0.05). In addition, an lncRNA-mRNA co-expression network was constructed to identify potential target genes related to the 3 upregulated and 2 downregulated lncRNAs.

Summary/Conclusions: Our data suggested that lncRNAs may play an important role in the pathogenesis of GCB DLBCL, and profile of lncRNAs may be used as a potential biomarker in the diagnosis of DLBCL and predicting its clinical outcome.

PB2075
FLOW CYTOMETRY IN EVALUATION OF EXTRANODAL LYMPHOMA PRESENTING AT UNUSUAL LOCATIONS COMPARED TO NODAL LYMPHOMAS
P. Prakhar1, M. Choudhury2, S. Sharma2
1Pathology, Lady Hardinge Medical College, New Delhi, India, 2Pathology, Lady Hardinge Medical College , New Delhi, India

Background: Immunophenotyping is a fundamental step in the diagnosis of hematological lymphomas arising at extranodal sites. It can present significant diagnostic challenges due to their morphological diversity. In recent years flow cytometry (FCM) has proven useful in the evaluation of nodal and extranodal lymphoproliferative disorders on samples obtained by surgical specimens or fine needle aspiration cytology (FNAC). For years FNAC has been used for initial evaluation of suspected hematolymphoid neoplasms. Flow cytometry can additionally help in identifying B or T cell nature of neoplastic cells, clonality in case of B-cell neoplasms and any aberrant phenotype. The possibility of detecting CD20 status can help in initiating targeted therapy without undergoing tissue biopsy to do so. FNA cytology with Flow cytometry can serve as a replacement for open biopsy and may help in eliminating the need for more invasive procedures. In this study FCM analysis on cytological specimens, including nodal and extranodal mass from GIT, Thyroid, Kidney, Breast, Tonsil, cerebrospinal fluid and ascitic fluid, was performed.

Aims: The aim of our study was to evaluate the efficacy of flow cytometer for the evaluation of extranodal and nodal lymphomas on 40 patients.

Methods: The current study was prospectively conducted on 40 patients with a clinical suspicion of hematolymphoid neoplasms. Samples for flowcytometric immunophenotyping (FCI) were obtained by fine needle aspiration (FNA) or by tissue scraping along with samples for cytomorphological, histological and immunostaining evaluation. Samples collected in isotone were submitted for FCM on 5-color Beckman Coulter FC-500, using a set of mature and distinct markers. The aim was to use a panel of markers to identify the disease.

Results: In our study 30 cases were lymphomas. Flowcytometric immunophenotyping conducted on extranodal sites included 25 cases which could not be categorized by FCI. As per World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues 2008 most common lymphoma at extranodal sites was lymphomas (12 DLBCL, 10 FL, 5 SLL, 3 MZL, 2 MCL) the CD4 T subset testing the expression of CD26 and CD39, 12 DLBCL, 10 FL, 5 SLL, 3 MZL, 2 MCL (the CD4 T subset testing the expression of CD26 and CD39).

Summary/Conclusions: The results of our study show the phenotypic variations in the microenvironments of different types of lymphoma emphasizing of DLBCL the similarity with HL the difference with FL and other NHL. They also suggest a link between a activated environment (CD38+) and a high CD39, which, in addition to a low CD26, could enhance the generation of adenosine and, therefore, an increased immune suppressive activity. The profile by FC of TCD4 T infiltrating can characterize lymphomas in its environment indicating also signals and biological mechanisms representative of possible therapeutic target.

PB2076
POSSIBLE ROLE OF FLOW CYTOMETRY TO CHARACTERIZE INFILTRATING CD4 CELLS IN THE MICRO ENVIRONMENT OF LYMPHOMA TISSUE SAMPLES
R. Di Gaetano1,2, D. Belvini1, B. Callegari1, M.A. De Benedetto1, E. Pilotto1, R. Sartori1, G. Tagariello1
1Haematology Castelfranco Veneto, 2Pathology Castelfranco Veneto, Azienda USLLS 2 Marca Trevigiana, Castelfranco Veneto (TV), Italy

Background: In our previous work (Di Gaetano et al, Ann Haematol, 2014) we analyzed by flow cytometry (FC) the rich infiltrating characterizing the microenvironment of Hodgkin lymphoma (HL) mainly comprised of CD4 T lymphocytes . We confirmed that the majority of these CD4 T expressing the antigens (CD38) is the subset CD4+CD26+CD38+. We also identified the subset CD4+CD26-CD38+ to identify the neoplastic cellular pattern in HL. A subset connectable to regulatory T (Treg) cells, because the low expression of CD26 (DPP4) added to the presence of CD39 (NTPDase) may be responsible for the generation of adenosine, which plays a major role in T-regulated immunosuppression.

Aims: We wanted to test if this subset may also characterize T infiltrating lymphocytes the lymph nodes of Non-Hodgkin’s lymphomas (NHL) and to verify the expressions of the two enzymatic markers (CD26 and CD39) in microenvironments of HL and NHL analyzed by FC.

Methods: In 2016 we analyze by FC in lymph nodes of 6 HL and in 32 NHL (12 DLBCL, 10 FL, 5 SLL, 3 MZL, 2 MCL) the CD4 T subset testing the expression of CD26 and CD39.

Results: In CD4 T HL, CD39 is expressed in 44% of the subset and the increased presence (50%) of CD4+CD26+CD38+ cells is confirmed. Compared with HL, the cells of DLBCL are not statistically (Student t test) different: CD38 (64 vs 55; p=0,39), CD26+CD38+ (50 vs 46; p=0,66 ), CD39 (44 vs 59; p=0,15 ). While HL and FL cells are significantly different: CD38 (64 vs 23; p<0,05 ), CD26+CD38+ (50 vs 18; p<0,05 ), CD39 (44 vs 23; p<0,05 ). The other three types of NHL, few in number, show a tendency to a significant difference compared with DLBCL.

Summary/Conclusions: The our data show the phenotypic variations in the microenvironments of different types of lymphoma emphasizing of DLBCL the similarity with HL the difference with FL and other NHL. They also suggest a link between a activated environment (CD38+) and a high CD39, which, in addition to a low CD26, could enhance the generation of adenosine and, therefore, an increased immune suppressive activity. The profile by FC of TCD4 T infiltrating can characterize lymphomas in its environment indicating also signals and biological mechanisms representative of possible therapeutic target.
the clone of B lymphocytes involved in cancer. This may support that leukemic cells may contribute to create an environment to characterize an immune-subversive environment and to facilitate immune escape mechanisms. FC analysis of CD26 and CD39, markers likely connected with the adenosinergic pathway, in PB26 patients with CD was observed in plasma cell variant. In hyaline vascular CD, the percentage of blood vessel area was increased to 15.1±1.4% (p<0.05). Patients with hyaline vascular CD had a significantly lower percentage of vessels (10±1.0%) compared to the control group. In patients with hyaline vascular CD, the percentage of vessel area was lower than in patients with plasma cell variant (not statistically significant). In 5 patients (25%) with hyaline vascular CD, the percentage of vessel area was higher - 12.3±1.5% (p<0.05) and did not differ from levels in patients with plasma cell variant.

Summary/Conclusions: The highest index of vessel density in the lymph node variant was observed in the plasma cell variant. In hyaline vascular variant, the index was characterized by significant variability, which could reflect the heterogeneity of this type of the disease. Increased density of blood vessels in the lymphoid tissue may be considered as a possible target for angiogenesis inhibitors, especially in patients with progressive disease.

PB2081

PROGNOSTIC SIGNIFICANCE OF IMMUNOHISTOCHEMICAL MARKERS IN R-CHEM TREATED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

Aims: We aimed to find distinctive histologic or immunohistochemical findings to better differentiate PMLBCL and CHL of the mediastinum.

Methods: A total of 32 cases of mediastinal B-cell lymphomas consisting of PMLBCL (N=16), CHL (N=13), and gray zone lymphoma (N=3) were collected from 6 university hospitals from Korea. Immunohistochemistry (IHC) for various cell lineage markers and EBV in situ hybridization were performed to confirm the diagnosis, and additionally, expression of P63, GATA3 and cyclinE was investigated.

Results: Most clinical features were overlapped between PMLBCL and CHL except more frequent disease progression and mortality in PMLBCL (p<0.05). In pathologic review, presence of epithelioid granuloma favored CHL (p=0.078), whereas fine reticulated fibrosis was unique for PMLBCL (p<0.001). By IHC, P63 was predominantly positive in PMLBCL (15/16) than CHL (2/11) with the highest diagnostic power (p<0.001). GATA3 was expressed in the majority of CHL (9/12) compared with PMLBCL (0/16) (p<0.001). Expression of cyclinE was rarely found in a minor population of PMLBCL.

Summary/Conclusions: Expression of P63 in the tumor cells, even focal, is the most helpful feature to distinguish PMLBCL from mediastinal CHL. Additional diagnostic markers include GATA3 in CHL and reticular fibrosis in PMLBCL.
nancy in adults. The role of immunophenotype variability for the therapeutic outcome has long been the cornerstone for DLBCL management strategy.

**Aims:** To evaluate the immunophenotypic characteristics of DLBCL and the prognostic significance of specific biomarkers such as bcl2, bcl6, CD 10 and MUM1, in a population-based cohort of patients treated with R-CHOP.

**Methods:** We performed a retrospective assessment of all cases of DLBCL diagnosed at our institution between 2005-2013. The immunohistochemical expression patterns of all DLBCL patients were analyzed and correlated with the therapeutic response to R-CHOP regimen.

**Results:** The study included 101 patients diagnosed with DLBCL, with a median age at diagnosis of 57.1 years (19-90 years) and male/female ratio of 1.3/1. Ninety-one patients were eligible for R-CHOP treatment. The median follow-up was 41 months. Out of the 90 cases analyzed by immunohistochemistry CD 10, BCL2, BCL6 and MUM1 expression was found in 17.6%, 50.5%, 72.7% and 81.8% of cases, respectively. Negative expression for CD10, as well as positive expression of BCL2, were adverse prognostic factors for 3-years overall survival (OS) and disease free survival (DFS) (OS for bcl2: 72.3 vs 89.7, p<0.05, OS for CD10: 84.1 vs 75.1, p<0.05). BCL6 and MUM1 expressions, however, did influence neither OS nor DFS.

**Summary/Conclusions:** This study confirms the prognostic value of a multi-marker assessment which includes bcl2, bcl6, CD 10 and MUM1 expression for patients R-CHOP therapy.

---

**Other Non-malignant hematopoietic disorders**

**PB2082**

**LYMPHOID NEOPLASMS: A REALLY IMPORTANT TRIGGER IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS**

V. Martínez Robles1,*, S. Calleja2, B. Ballina1, S. Cerdá1, S. Fernández-Ferrero1, F. Escalante1, F. Ramos1, J.A. Rodríguez-García1

1Hematology and Hemotherapy, 2Immunology, Complejo Asistencial Universitario de León (CAULE), León, Spain

**Background:** Triggered by several conditions Hemophagocytic lymphohistiocytosis (HLH) is an unusual, aggressive and life-threatening dysfunction caused by an excessive immune activation. It has become more recognized over the past decade. HLH was first described in 1939 by Scott and Robb-Smith, next case was reported in 1952 by Farquhar and Claireaux describing two infant siblings with progressive and lethal cytopenias, hepatosplenomegaly, and fevers with autopsy showing hemophagocytosis. A lengthy and unstoppable activation of antigen-presenting cells (macrophages, histiocytes) and CD8+ T and NK cells is characteristic. This condition leads to an important hyperinflammatory situation and organ damage including splenomegaly, fever, cytopenia, hypertriglyceridermia and/or coagulopathy. Histiocyte Society (HS) criteria have been applied for diagnosing HLH, however not all of them are usually showed at the presentation. This disease can be described in two different scenarios: primary (usually in children, genetic, and known as familial form) and secondary (acquired). It can be triggered by a large variety of events that disrupt immune homeostasis. When we talk about triggers, we can divide them in two broad categories, those that cause immune activation and those that lead to immune deficiency. Lymphoid neoplasms can be both.

**Aims:** Due to the lack of publications about HLH secondary to Lymphoid Neoplasms (LN), we would like to analyze the casuistry of our hospital and making a comparison with the current literature.

**Methods:** We conducted a retrospective analysis through medical files of all patients with suspected diagnosis of HLH between 1994 and 2017 in our inpatient ward. Clinical features, age, diagnostic criteria proposed by the HS, etiology, treatment and evolution were analyzed. In our study 18 out of 50 patients met the requested criteria for HLH diagnosis.

**Results:** We report 10 LN secondary cases (4 males, 6 females). The median age at diagnosis was 60,5 years, ranged between 46 and 80 years. In all of them, but in one, who presented long-term pancytopenia, symptoms were developed very fast. The most frequent causes of consultation were cytopenia and general syndrome. In two of them HLH was diagnosed with LN relapse, in one patient during a transformation from a low-grade B-cell lymphoma to DLBCL (Diffuse large B-cell lymphoma), in 6 of them we diagnosed LN and HLH concomitantly, and in the last one coinciding with a Richter Syndrome. Four of 10 were secondary to T-cell neoplasm. All patients met 5 or more HS diagnostic criteria. In only 3 of them HLH was healed. One patient is still in remission. Nine died, 7 of them due to HLH complications. Treatment was chemotherapy (depending on their LN) in almost all of them. Fluctuations were detected among activity HLH parameters due to LN response. Detailed characteristics of patients are shown in Table 1.

**Table 1.**
Summary/Conclusions: HLH triggered by LN is diagnosed in older patients than other causes secondary HLH (46-60 vs 4-8 y/o in our center), we think this is because in our experience there are not children or Young adult in HLH due to LN group. We would like to highlight that although LN is a very common HLH trigger there are a few works describing them in the literature, that is why we would like to spread our experience. We would like to emphasize in the importance of considering this possibility in the face of a patient with fever which does not respond to antibiotics and has not clarified citopenia, as well as the importance of conducting cheap and very profitable test such as ferritin or tryglycerides level when symptoms or clinical features of lymphoid neoplasm are not concordant with the expected evolution.

Figure 1.

Summary/Conclusions: The creation of these new networks allows strengthening the links between the various actors involved in the field to improve care and answer transversal questions. In this way, MaRIH pilot concerted actions to all its members around immunohematological rare diseases by: 1- increasing the visibility of the actors on the web or during events. The MaRIH website includes all the informations of the members as well as recommendations and events (www.marih.fr), 2- communication and training. MaRIH organizes two annual events, one for patients and another one for professionals. Moreover, MaRIH sends clinical cases by email to professionals and produce an annual webcast, 3- pushing forward research development and epidemiological surveillance. Thanks to his research project manager, MaRIH facilitates the submission and the set-up of new registries or clinical studies. In the future, MaRIH will continue and futher develop all these actions, in close collaboration with the French Ministry of health.

PB2084

CLINICAL FEATURES AND ETIOLOGY OF PATIENTS WITH THROMBOTIC MICROANGIOPATHIES

Ü. Ergin1,*, N. Özü1

1hematology, saglik bilimleri university, izmir, Turkey

Background: Thrombotic microangiopathy (TMA) is a heterogeneous group of disease that has a fatal pattern of endothelial damage. TMA can be found in association with diverse clinical conditions such as carcinoma metastasis, malignant hypertension, infections, and TTP (thrombotic thrombocytopenic purpura). TTP is a rare, life-threatening multisystem disease, characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, renal dysfunction, and neurological disorders.

Aims: The purpose of this study is to evaluate the etiology associated with TMA. Methods: All of the six TMA patients who were newly admitted to our clinic in two months period were enrolled in this study. Effectiveness, response, adverse effects and safety of plasmapheresis were evaluated using laboratory and clinical findings. (See Table 1).

Results: First patient presented with cachexia, thrombocytopenia, and TMA. He did not respond to plasmapheresis and corticosteroid treatment. We diagnosed carcinoma metastasis and liver metastasis, respectively, through bone marrow biopsy and PET (positron emission tomography). We thusly ascertained that TMA was due to carcinoma unknown primary. The second patient presented with general neurological findings like Guillain-Barre Syndrome and paraplegia with renal failure, thrombocytopenia, and TMA. After PLEX and corticosteroid treatment, laboratory and neurological clinical recovery were observed after one month. The third patient had chronic obstructive pulmonary disease and pneumonia in anamnensis. It was diagnosed with chronic obstructive pulmonary disease in January 2016 and was informed on the update status of research on their disease as well as to help patients in daily common problems (sport, psychological, transfusion…). Pushing forward research development and epidemiological surveillance: the network has appointed a research project manager for its scientific and strategic committee to support, provide stability for and add value to research centre activities. The research project manager watch out for calls for tender, set-up of new registers and continually monitor the regulations for research centre activities. The research project manager, MaRIH facilitates the submission and the set-up of new registries or clinical studies. In the future, MaRIH will continue and futher develop all these actions, in close collaboration with the French Ministry of health.
Presented with acute renal failure with malignant hypertension. We performed hemodialysis together with PLEX treatment. Because his diagnosis was acute renal failure, malignant hypertension, and TMA. The fifth patient presented with epistaxis and sepsis. He had chronic TTP diagnosis for two years ago. We diagnosed the patient as relapse TTP. Early treatment against infection and PLEX increased his platelet counts as early as the second day of treatment. The sixth patient presented with a fever that had been going on for five days. We treated the patient with PLEX together with the corticosteroid. Because his ADAMTS13 level was very low and he had 35% schistocytes.

**Table 1.**

**Summary/Conclusions:** We diagnosed our first patient with carcinoma unknown primary, who did not respond to PLEX and corticosteroid treatment. The results we received for that patient indicate that PLEX with corticosteroid treatment alone, remain ineffective in cancer-related TMA patients. Etiology of our second patients TMA was idiopathic. His clinical and laboratory findings improved rapidly in response to PLEX and pulse corticosteroid treatment. One viral infection induced TMA patient had anaphylactic reaction receiving his 8th PLEX. Allergic reactions should always be kept in mind when administering PLEX. One patient with TMA and malignant hypertension-induced renal failure was successfully treated with PLEX, hemodialysis and antihypertensive treatment. We successfully treated our bacterial infection and sepsis-induced TTP patients with PLEX and antibiotic administration. In second TMA patient, we coupled PLEX with high dosage corticosteroid treatment even though he had an infection. For he had high histocytost count and atypical neurological findings. ADAMTS 13 activity may only be a guide for diagnosis of TTP, but it is unreliable for a definitive one. In conclusion, diagnosis of TTP and other TMA is difficult. Etiology, clinical features, laboratory findings should all be taken into account when diagnosing TMA. While it is established that ADAM TS13 deficiency is the major cause in acquired TTP, finding the etiology of other TMA’s is determinant for a successful treatment of the latter.

**PB2085**

**HAEMOLYSIS AS SCREENING TEST IN LYSSOMAL STORAGE DISEASES**

L. López De Frutos1,2,*, J. J. Cebolla1,3,4, P. Irún1,2,3, P. Giraldó1,2,3

1Unidad de Investigación Traslacional. Hospital Universitario Miguel Servet, Fundación Española para el Estudio y Terapéutica de la Enfermedad de Gaucher y Otras Lisosomas (FEETEG), 2Unidad de Investigación Traslacional. Hospital Universitario Miguel Servet, Centro de Investigación Biomédica en Red En Enfermedades Raras (CIBERER), 3Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain

**Background:** Lysosomal storage disorders (LSDs) are a group of rare inherited metabolic diseases, whose clinical hallmark is organomegaly among others, due to progressive accumulation of several non-catalyzed products inside the lysosomes. This storage leads to intracellular oxidative stress status triggering oxidized metabolites production as oxytetros, which are related to apoptosis and cellular eriposis, as well as haemolysis dysregulation.

**Aims:** To evaluate the link between LSDs and haemolysis and if it could be used as a screening test in LSDs.

**Methods:** The osmotic resistance test (ORT) was evaluated in 150 samples of plasma. To evaluate the link between LSDs and haemolysis and if it could be used as a screening test in LSDs. The analysis shown that haemolysis at 0.48% of NaCl allow us to sort out controls vs LSDs-C/LSDs-P (AUC 0.729) whereas no significant differences were observed between LSDs-C and LSDs-P (p-value>0.05).

**Summary/Conclusions:** According to our results the ORT test is an useful screening test in LSDs.

**PB2086**

**CLINICAL SIGNIFICANCE OF ELEVATED SERUM COBALAMIN (VITAMIN B12) LEVELS**

I. Yaman Bajin1,*, E. Sabancı2, S. Akyan2, S. Aytac1, M. Çetin1, F. Gümrük1

1Pediatric Hematology, 2Pediatrics, Hacettepe University, Ankara, Turkey

**Background:** Hypercobalaminemia is a frequent but underestimated abnormality. Elevated serum cobalamin levels may be a sign of a wide range of disorders like solid neoplasms, hematological disorders like chronic lymphocytic leukemia, polycythemia vera, hyperesoinophilic syndrome as well as liver and kidney diseases.

**Aims:** We aimed to evaluate the underlying disorders of the patients with high cobalamin levels (>1000 pmol/l) between 01.02.2016- 01.02.2017 in Hacettepe University Pediatric Hematology Department.

**Methods:** We investigated the patient records of the patients examined between 01.02.2016- 01.02.2017 in our department and included the patients with serum cobalamin levels higher than 1000 pmol/l. We excluded the patients who are taking Vitamin B12 supplement.

**Results:** There were 46 patients with serum cobalamin levels higher than 1000 pmol/l out of 14367 patients seen between 01.02.2016- 01.02.2017 in our department. The reason to check the cobalamin levels were anemia, neutropenia and thrombocytopenia in most of the patients. Only 2 patients were referred to our department because of hypercobalaminemia. The underlying disorders were found to be leukemia in 3 patients (Acute lymphoblastic leukaemia (ALL) n:1, acute myeloblastic leukaemia (AML) n:1, large granular lymphocytic leukaemia (LGLL) n:1), myelodysplastic syndrome (MDS) in 2 patients, isolated thrombocytopenia in 4 patients, isolated neutropenia in 7 patients, bicytopenia in 4 patients, aplastic anemia in 2 patients, cobalamin metabolism defects in 10 patients, hypereosinophilia in 2 patients, polisitemia in 1 patient, cystic fibrosis in 1 patient, HIV in 1 patient, FMF (familial mediterranean fever) in 1 patient, chronic kidney failure in 2 patients, sickle cell anemia in 1 patient, factor V Leiden in 1 patient, LGLL in 1 patient and episitemia in 1 patient.

**Summary/Conclusions:** An observed elevation of cobalamin merits the a full diagnostic work up to assess the presence of an early diagnostic marker of these diseases. When we look at the patients except hematological neoplasm and cytopenias, most of the underlying reasons is associated with inflammation or infection, cobalamin was found to be elevated as an acute fase reactant. A certain approach is needed whether to determine the potential indications to search for high serum cobalamin levels and to determine the practical clinical strategy when elevated cobalamin levels discovered.

**PB2087**

**THE HEMATOLOGIC FINDINGS OF INHERITED METABOLIC DISEASE; THEY ARE MORE THAN EXPECTED**

I. Yenicesu1,*, A.E. Sai2, I. Okur2, Z. Kaya1, F.S. Ezgu2, U. Kocak1, L. Tumer2

1Pediatric Hematology, 2Gazi University, Faculty of Medicine, Ankara, Turkey

**Background:** Inherited metabolic diseases are pathological conditions that generally develop as a result of impairment of the production or breakdown of protein, carbohydrate and fatty acids. Hematological problems are some of the most frequently observed findings of inherited metabolic diseases. These may be seen together with other systemic findings or sometimes as the first and only diagnostic finding of the disease. Early determination of hematological findings has a positive effect on the prognosis of metabolic diseases.

**Aims:** The aim of this study is to evaluate the incidence of hematological findings in inherited metabolic diseases since there are a few studies about the true incidence in literature.

**Methods:** Three hundred eighteen patients who were being followed-up within the previous 6 months at Gazi University Department of Pediatric Nutrition and Metabolism, Turkey, were included in the study. Patients’ hematological findings were taken from Department of Pediatric Nutrition and Metabolism and hospital data-processing records. Since patients were in different age groups, hematological findings were compared with normal values for each patient’s age group. The hematological findings were classified under seven main groups; anemia, thrombocytopenia, polycythemia (n=1), thrombocytosis (n=1), isolated neutropenia (n=1), bicytopenia (n=1), and four vitamin B12 deficiency anemia. Leukocytosis (n=1), thrombocytosis in 1 patient, isolated neutropenia in 7 patients, bicytopenia in 4 patients, isolated neutropenia in 2 patients, cobalamin metabolism defects in 10 patients, hypereosinophilia in 2 patients, polisitemia in 1 patient, cystic fibrosis in 1 patient, HIV in 1 patient, FMF (familial mediterranean fever) in 1 patient, chronic kidney failure in 2 patients, sickle cell anemia in 1 patient, factor V Leiden in 1 patient, LGLL in 1 patient and episitemia in 1 patient.

**Summary/Conclusions:** An observed elevation of cobalamin merits the a full diagnostic work up to assess the presence of an early diagnostic marker of these diseases. When we look at the patients except hematological neoplasm and cytopenias, most of the underlying reasons is associated with inflammation or infection, cobalamin was found to be elevated as an acute fase reactant. A certain approach is needed whether to determine the potential indications to search for high serum cobalamin levels and to determine the practical clinical strategy when elevated cobalamin levels discovered.

**PB2088**

**THE HEMATOLOGIC FINDINGS OF INHERITED METABOLIC DISEASE; THEY ARE MORE THAN EXPECTED**

I. Yenicesu1,*, A.E. Sai2, I. Okur2, Z. Kaya1, F.S. Ezgu2, U. Kocak1, L. Tumer2

1Pediatric Hematology, 2Gazi University, Faculty of Medicine, Ankara, Turkey
Hematotoxic Effects of Generic Triazole Fungicides Tebuconazole on Wistar Hannover Rats

T. Userko, V. Shulyak, N. Nedopityanska, M. Prodanchuk
1IL Medved's Research Center of Preventive Toxicology, Food and Chemical Safety, Ministry of Health, Kiev, Ukraine

Background: Pesticides are extensively used in agriculture today. Fungicides based on derivatives of triazole are the most widespread all over the world. Tebuconazole (TB) is one of the most frequently used substance of this group. Literature review confirms that triazole fungicides have the ability to cause different hematotoxic effects.

Aims: Since 2007-2016 years we have investigated 10 test-substances of generic tebuconazoles (purity up to 97%) from different manufacturers with purpose to assess their hematotoxic action on males Wistar Han rats peripheral blood in the subchronic 90-days oral toxicity study (according to SOP and OECD 408 recommendations in compliance with GLP).

Methods: The Wistar Han males were randomly allotted to four groups. The input controls of peripheral blood parameters were conducted after a period of animals acclimatization. The goal was to evaluate the physiological state of the Wistar Han rats and the blood picture before treatment. Doses 0; 10; 50; 200 mg/kg/bw/day were defined and were the same in all studies. Blood samples for hematological measurements were examined at 4, 9, 13 weeks after TB exposure in the same groups of animals throughout the experiment. Hemo- globin (HGB) concentration, hematocrit (HCT), total amount of erythrocytes (RBC), leukocytes (WBC) and platelets (PLT), mean corpuscular hemoglobin (MCH) were evaluated.

Results: As a result, all generic TBs on high toxic doses level (200 mg/kg/bw/day) had shown the tendencies for quantitative hematological changes. TBs mainly provoked the significant decrease of HGB concentration and RBC count on 4th and 9th weeks of exposure. Morphological changes of RBC (anisocytosis) were seen too. It means that generic TBs had anemic effect. In general, changes of hematological parameters were not principally significant and did not differ from control values at 13th weeks of experiments, except two TB's, which had shown significant decrease of HGB. Also some of generic TBs lead to decrease (leukopenia) or increase (leukocytosis) of leu- koocytes count in peripheral blood. In case of generic pesticides, the presence of impurities can demonstrate various hematotoxic action. Also the adverse effects on peripheral blood of males Wistar Han rats were observed at a dose of 50 mg/kg/bw/day and demonstrated the lesions of red blood. But abovementioned changes were not so clearly expressed. Any adverse hematotoxic effects at 10 mg/kg/bw/day dose were not observed in all studies.

Summary/Conclusions: As a conclusion, due to our results the triazole fungi- cides generic tebuconazoles have hematotoxic action. They induce anemia in Wistar Han rats and quantitative white blood cells changes. Today it is very impor- tant to investigate the hazardous effects of pesticides on the blood system.

PB2089

What We Can Do To Make a Standardization and Harmonization of APTT?

M. Pamukcuoglu, M. Falay, M. A. Ucar, F. Ceren, S. Dagdas, G. Özel
1Pediatric Hematology, Dokuz Eylül University, Izmir, Turkey

Background: Transfusion enhanced many kind of complication in patients therefore peri-operative coagulation monitoring was suggested before the sur- gical procedures. The patients who have chronic anemia are at risk of bleeding. Also there are some diseases which had bleeding events in surgical procedure or spontaneously. We should detect these kind of diseases and we should examine the correct measure of active parsiel thromboplastin time (APTT) before surgical pro- cedure by detecting the mild oromoderate deficiencies of plasma factor levels and by eliminating the lupus anticoagulant from plasma. This was caused to the make the importance of APTT reagents.

Aims: We tried to show the importance of APTT reagents and how to reach the correct measure of APTT in this study.

Methods: We are planning to examine 300 patients, 109 of 300 patients were included as patients. APTT levels were calculated ATL-TOC analyzer by using three different reagents.First reagent was HemosIL LAPTT-SP which was sensitive against both plasma factors and lupus anticoagulant. It contains mix of collagen and collagen and normal range of APTT- SP was 25-43.6 s. Second reagent was Hemosil SynthA Si-SS which was sensitive against only plasma factors. It contains mix of collagen and phospholipids by composed of sintehetic or animal collagens and reagents and also several studies compared APTT reagents which was included silica, ellagic acid and phospholipids by composed of syntethic or animal orgninated and several studies determined a target level of APTT for looking at the plasma factors levels. If we want to get a correct result of APTT, ranges of APTT must be determine according to reagents which was used in APTT devices and APTT reagents must be sensitive against borderlines cases who had a mild or moderate low levels of factors and the presence lupus anticoagulant. We need further studies to make a standardization and harmonization of APTT.

PB2090

Acquired Pure Red Cell Aplasia in an Adolescent: Could it Be Anything Else?

S. Yılmaz Bengoal, Ö. Tüfecki, M. Erdem, D. Kızımlıoğlu, H. Ören
1Pediatric Hematology, Ege University, Izmir, Turkey

Background: Pure red cell aplasia (PRCA) is a syndrome characterised by normocytic (sometimes macrocytic), normochromic anemia with severe retic- ulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow. PRCA may be congenital, in the form of Diamond-Blackfan Anemia, or acquired which is rather rare in childhood. An immune mechanism interrupting erythroid differentiation is responsible in primary autoimmune PRCA, on the other hand secondary acquired PRCA may be associated with autoimmune/immune vascular disorders, infections, lymphoproliferative dis- orders, hematological malignancies, solid tumors and drugs.

Aims: Here we report a 16-year-old male with acquired pure red cell aplasia who was treated successfully with steroids and cyclosporine after elimination of the secondary causes.

Methods: Case: An 16-year-old boy presented with a history of pallor and fatigue noticed three months prior to admission. He had been diagnosed with immune thrombocytopenia when he was 5 years old and had been in remission since that time. There was no history of blood transfusion, chronic illness or any other medication. His physical examination revealed pallor and a 2/6 sys- tolic murmur with no other abnormalities. Complete blood count revealed severe macrocytic anemia and reticulocytopenia with hemoglobin:2.2 g/dL, hematocrit: 22.2%, mean corpuscular volume:108.7 fL, red blood cell: 0.57x1012/L, reticulocyte: 0.2% and mild leukopenia and lymphopenia. Peripheral blood smear showed macrocytic red cells with occasional tear drop cells. Stool for occult blood was negative. The direct and indirect antiglobulin tests were negative Serum bilirubin, LDH, haptoglobin, liver function tests and renal function tests were in normal limits. Hemoglobin F was 2.9%. Bone mar- row aspiration showed red cell hypoplasia, without dysplasia or giant pronor- moblasts and normal myeloid and megakaryocytic series. A high resolution computed tomography of chest ruled out thymoma. Serum immunoglobulins revealed low IgA with normal IgG and IgM levels. Anti-nuclear antibody was elevated to 1:640. Anti-dsDNA, anti-Jo1, anti-Sm, anti-SSA, anti-SSB, anti-nucleolar, anti-Scl-70, anti-RNP, anti-U1-RNP, anti-Glc-3BP, anti-Ro-52 and anti-La antibodies as well as Parvovirus B19 DNA and other serologic markers including antibodies to HIV and hepatitis A, B and C were all negative. He was transfused with erythrocytes and discharged with a hemoglobin level of 7.2 g/dL. On his follow-up, hemoglobin levels were observed to decrease again. A diagnosis of primary acquired PRCA was considered and prednisone was initiated at a dose of 1 mg/kg/day. Aplastic crisis appeared and Hemosil synthetic APTT was started to maintain through levels of 150-250 ng/mL. His hemoglobin level gradually increased and reached to 12 g/dL and leukopenia and reticulocy- topenia resolved completely. Prednisone was tapered after 4 weeks and stopped. He is still on cyclosporine treatment and has been transfusion free with stable hemoglobin levels in the second month of his treatment.

Results: Primary acquired PRCA is very rare in childhood, secondary causes must be eliminated for definitive diagnosis. Our patient was found to have lym- phopenia, low immunoglobulin A level and positive anti-dsDNA in further inves- tigations, yet these results are not sufficient for a specific diagnosis like common variable immune deficiency or systemic lupus erythematosus. Therefore we must be elliminated for definitive diagnosis. Our patient was found to have lym- phopenia, low immunoglobulin A level and positive anti-dsDNA in further inves- tigations, yet these results are not sufficient for a specific diagnosis like common variable immune deficiency or systemic lupus erythematosus. Therefore we must be elliminated for definitive diagnosis.
Summary/Conclusions: Immunosuppressive therapy including cyclosporine with or without steroid has been reported as the most effective treatment in primary acquired PRCA. Consistently, we had a dramatic response to immunosuppressive therapy in our patient.

PB2091
APLASTIC ANEMIA IN CHILDHOOD: A TEN YEARS’ SINGLE CENTER EXPERIENCE
A. Apsemidou1,*, T.-S. Tziola1, A. Tragiannidis1, E. Chatzipantelis1, M. Papageorgiou1, L. Damianidou1, T. Papageorgiou1, T. Koletsa2, A. Giannopoulos3
1Pediatrics-Pediatric Hematology/Oncology, 2Pathology, 3Pediatrics-Pediatric Cardiology, AHEPA University Hospital, Thessaloniki, Greece

Background: Aplastic anemia in childhood is a rare, life-threatening disorder, characterized by peripheral blood pancytopenia and a hypocellular bone marrow without signs of dysplasia or fibrosis. Acquired aplastic anemia needs to be distinguished from inherited bone marrow failure syndromes or myelodysplastic syndromes.

Aims: The aim of this study is to assess the clinical and laboratory findings at the time of diagnosis, the treatment approach and the outcome of children with aplastic anemia treated in our department during the past decade.

Methods: This retrospective study evaluated 9 children with aplastic anemia, who were treated and followed up in the Pediatric Department of AHEPA, during the period 2006-2016.

Results: We identified 9 children with aplastic anemia. The patients’ population included 6 (66.7%) males and the mean age at admission was 9.7 years. At the time of diagnosis, the average neutrophil count was 750/mm³, the Hb count was 8.4mg/dl and platelets count was 8770/mm³. In all of our cases aplastic anemia was acquired, expect one case of Fanconi anemia. Predisposing risk factors (including drugs exposure, viral infections, chemicals) were identified in 4 patients. Among the 9 studied patients, 3 (33.3%) had severe anemia, 2 (22.2%) severe and 2 (44.5%) had very severe aplastic anemia. All of the patients received immunosuppressive therapy (consisting of antithymocyte globulin, cyclosporine A and steroids), 2 remained transfusion independent, 4 underwent bone marrow transplantation-2 from a matched related donor and 2 from a matched unrelated donor. One patient with refractory disease received, as an alternative first line therapy, eltrombopag. Complete response was achieved in 22.2%, partial response was achieved in 22.2%, relapse occurred in 11.1% and 44.5% of the patients had refractory disease. The overall survival was 77.8%.

Summary/Conclusions: A remarkable progress has been made during the past decades in the understanding of pathogenesis and management of children with aplastic anemia. Bone marrow transplantation from a matched related donor is the recommended first line therapy resulting in an excellent survival rate that exceeds 90%. In the future the development of targeted strategies for aplastic anemia will further improve outcome and diminish the disease’s late complications.

PB2092
CAUSES OF IRON DEFICIENCY ANEMIA IN THE HEMATOLOGY CLINIC – SINGLE CENTER EXPERIENCE
M. Ionita1,*, I. Ionita1, D. Calamar1, D. Oroș1, V. Todorescu1, C. Ionita1, C. Sorice1, H. Ionita1
1Hematology, University of Medicine and Pharmacy Victor Babes Timisoara, Timisoara, Romania

Background: Iron deficiency anemia (IDA) is the common nutritional deficiency worldwide. The studies concerning various causes of IDA in adult men are rare, although it is assumed that chronic gastrointestinal blood accounts for the majority.

Aims: Of the study is to evaluate retrospectively adult men with IDA that were hospitalized in our Hematology Clinic.

Methods: Two hundred fifteen male with IDA were enlisted at this study from January 2005 to december 2015. Anemia was defined as Hg <13g/dL using the WHO criteria. IDA was considered present if serum ferritin was 15 ng/mL combined with serum iron concentration <30ug/dL with a transferrin saturation of <10%. Complete physical examination, the history of the disease and fecal occult blood test (FOBT) of three spontaneously passed stools was done in all patients. All patients had complete blood count, serum and total iron binding capacity, and a serum ferritin level. Most patients underwent esophagastroduodenoscopy (EGD). Colonoscopy was performed if lesion that caused IDA was not found, and/or FOBT was positive. The abdominal CT scan were performed according to clinician’s recommandation together with other tests related with blood lost.

Results: The median age was 62 (range 32 to 85) years old. 168 of 215 (78.13%) men with IDA had symptoms such as fatigue, dizziness, or digestive complaints. The history of prior gastrectomy, hemorrhoid, that probably had caused IDA were reported in 32 (14.88%), 43 (20.0%), patients, respectively. FOBT was positive in only 65 (30.23%) subjects. 170 (79.06%) patients underwent EGD. The most common findings from EGD were gastritis (48 patients) and peptic ulcer (39 patients). Seventy eight (36.27%) patients were found to have upper gastrointestinal disorders (20 patients with erosive gastritis, 19 gastric ulcer, 16 duodenal ulcer, 23 gastric cancer. Eighty-nine (41.39%) patients underwent colonoscopy. That showed 44 clinically important lesions that probably caused IDA; colon cancer in 17 (7.90%) patients, colon polyp in 10 (4.65%) patients and hemorrhoid in 17 (7.90%) patients. Concerning malignant lesions which are responsible for IDA, the malignant lesions were found more frequent in patients older than 50 years accounting for 20.45% (27/132 patients) and patients younger than 50 years 17.80% (13/73 patients).

Summary/Conclusions: This study demonstrated that gastrointestinal blood loss is the main cause of IDA in adult men, and that there is a high rate of malignancy in men older than 50 years.

PB2093
IMPACTS OF CLINICAL AND BIOCHEMICAL PARAMETERS ON KEY HEMATOLOGICAL INDICES IN ADULTS: A COHORT STUDY
C.-C. Chih1,*, M.-H. Lin2, Y.-H. Yang3, C.-E. Huang4, H.-Y. Tsou5, C.-C. Hsu1, Y.-Y. Wu1
1Department of Medicine, 2Center of Excellence for Chang Gung Research Datalink, 3Department of Traditional Chinese Medicine, Chang-Gung Memorial Hospital, Chiayi, Chiayi, Taiwan, Republic of China

Background: Studies in Caucasians have shown that values of hematological parameters could be affected by a wide variety of factors, most notably age and gender. However, parallel work in different ethnic populations, especially from Asia-Pacific region, is lacking. Importantly, it remains largely unknown whether some fundamental variables such as nutritional status, lipid profile, and hepatitis infection (either HBV or HCV) also affect the variation of values in hemogram.

Aims: Therefore, we conceptualize this study to explore through several key parameters regarding their potential impacts on the changes of hemogram.

Methods: Adult individuals aged 18 or older from several adjacent villages in Yun-Lin County, located in the central part of western Taiwan, who came to our hospital for annual health exams were screened for the current study. The work, retrospective in nature, was approved by institutional IRB. Information on age, gender, hemogram, levels of total cholesterol (TC), triglyceride (TG), apolipoprotein B (Apo B) as well as albumin, and results of serological testing for hepatitis B and C infection, was obtained from a centralized digital data base. All the clinical data, after given a coding number for each case, were encrypted and provided to the investigators without identifiable personal information. We analyzed the impacts of various parameters on several key hematological indices.

Results: Overall, 26,497 individuals were included in the current analysis after excluding those with hemogram data fell outside of normal range. Carriers of either hepatitis B (HBV) or C (HCV) who had abnormal liver function (defined by elevated levels of aspartate transaminase or alanine transaminase) were excluded as well. Age, gender, and serum levels of TC, Apo B, and albumin all significantly impacted most key hematological profiles. As the levels of TC and Apo B correlated well with each other (correlation coefficient r=0.82211, p<0.0001, Pearson’s correlation), we did not incorporate TC in our multi-variate analysis. Several key variables were found to influence some hematological indices in the multi-variable regression model. Increasing age and male gender negatively affected the platelet count, whereas higher Apo B level was associated with elevated platelet count. Surprisingly, hepatitis C carriers with normal hepatic function had slightly higher platelet number than non-HCV carriers. Gender and serum albumin level were the major determinants of variation in hemoglobin level. Total white cell count increased with male gender and elevating Apo B level but was inversely correlated with change in age and serum albumin level (Table 1).

Table 1.

Summary/Conclusions: The hematological indices are influenced by a wide variety of factors, especially age, gender, and serum level of Apo B. As age,
Apo B, while cell count, and platelet count all impose risk of thromboembolism, further work exploring the interactions and impacts of these parameters on the development of cardiovascular diseases should be mandatory.

PB2094

UNUSUAL DISTRIBUTION OF INTERLEUKIN-10 C-592A GENE POLYMORPHISM IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA FROM NORTH-WESTERN RUSSIA

S. Bessmeltsev1, I. Zotova2, S. Gritsaev2, A. Pavlova3, S. Bessmeltsev2

1Laboratory of Biochemistry, 2Russian Research Institute Of Haematology And Transfusiology, Saint-Petersburg, Russian Federation, 3Laboratory of Immuno-hematology, Russian Research Institute Of Haematology And Transfusiology, Saint-Petersburg, Russian Federation

Background: Primary immune thrombocytopenia (ITP) is a rare hematological disease with unknown etiology. It is characterized by heterogeneity of the laboratory parameters as well as the features of clinical manifestation. DNA polymorphism of several cytokine genes has been suggested to modulate the risk of ITP development or/and treatment response in distinct population groups. There is no data on the prevalence of cytokine gene polymorphisms in ITP patients from the North-Western region of Russia (NWR).

Aims: To establish the features of genotypes distribution for several cytokine promoter gene polymorphisms in ITP patients from NWR.

Methods: A total of 68 patients (59 women and 9 men) with chronic primary ITP were involved in the study. The median age of the group was 57 years (range: 24-77). The mean duration of ITP was 7 years (2-48). In 19 (32.2%) women, ITP was diagnosed before 30 years old; 26 (38.2%) patients (5 men and 21 women) were diagnosed at age 30-50 years; 23 (33.8%) patients (8 men and 19 women) developed ITP after 50 years old. The control group consisted of 240 healthy persons originated from NWR. Nucleotide variations in the genes coding for interleukin (IL) -1b (-31T/C), IL-6 (-174G/C), IL-10 (-592C/A) and tumor-necrosis factor alpha (TNFA -308 G/A) were discriminated by PCR and subsequent restriction analysis (PCR-RFLP). Intergroup differences in genotype frequencies were assessed by Fisher’s exact method. Odds ratios (OR), their 95% confidence intervals (CI) and p-values were calculated by using the GraphPad Prism 5.0 software.

Results: The frequency of the IL-10 -592CC genotype was slightly increased in the ITP group when compared to controls (65.7% vs 54.0%; OR=1.6, 95% CI: 0.9-3.1, p=0.05). Interestingly, this variant of the IL-10 gene was more prevalent among women than men with ITP (71.2% vs 25.0% respectively; OR=7.4, 95% CI: 1.4-40.5, p=0.016). When compared to controls, the IL-10 -592CC genotype was significantly overrepresented in the group of women with ITP (71.2% vs 54.0%; OR=2.1, 95% CI: 1.1-4.2, p=0.044). On the contrary, in the group of affected men we observed the increase of persons who had IL-10 -592A allele (75.0% vs 66.0% in control group; OR=1.5, 95% CI: 0.7-3.3, p=0.15). Genotype frequencies for other studied genes were similar between the patients and control group as well as between women and men with ITP. We have also found almost 2-fold increase of the IL-1b -31CC frequency in women diagnosed before 30 years old compared to other patients (15.8% vs 8.2% respectively; OR=2.1, 95% CI: 0.4-10.5, p=0.39). The presence of the TNFA -308AA allele was more often seen in patients diagnosed before 50 years old (26.7% vs 8.7% in other ITP patients; OR=3.8, 95% CI: 0.8-18.8, p=0.12).

Summary/Conclusions: We suggest that the IL-10 -592CC genotype is associated with increased risk of ITP in women from NWR. On the other hand, the IL-10 –592A allele could be involved in pathogenesis of ITP in men. Further studies are needed to clarify the significance of TNFA and IL-1b gene polymorphism in ITP development.

Platelets disorders

PB2095

COMBINED TREATMENT OF AZATHIOPRINE AND ROMIPLOSTIM IN PATIENTS ITP REFRACTORY TO STEROIDS OR THROMBOPOIETIN ANALOGS

M. E. Mingot-Castellano1, I. Sánchez-Bazán1, J. Diez-Pastor1

1Hematology, Regional University Hospital of Málaga, Málaga, Spain

Background: More than 70% of patients with Immune Primary Thrombocyto-penia (ITP) respond to steroids, but 40 to 70% relapse in the first year follow-up. The use of romiplostim in this group is effective, although 8% failure has been described. In recent literature, there are clinical cases and small series describing the potentiating effect of combined treatment with thrombopoietin analogues and immunosuppressive drugs such as steroids, cyclophosphamide and rituximab. We have not found references to the combined use of azathioprine (AZA) and romiplostim (ROM).

Aims: To describe our experience in the combined use of azathioprine and romiplostim as a rescue treatment in patients with acute or newly diagnosed ITP refractory to corticosteroids or corticosteroid-dependence and refractory to maximal doses of romiplostim monotherapy.

Methods: We analyzed patients with newly diagnosed or persistent ITP, with corticosteroid-dependence or refractory to steroids and refractory to romiplostim, both in monotherapy. We have considered refractoriness to steroids not reaching platelets higher than 30x10^9/L. Corticosteroid-dependence as the need for ongoing or repeated doses administration of corticosteroids for at least 2 months to maintain a platelet count at or above 30 x10^9/L and/or to avoid adverse effects. We considered refractoriness to romiplostim not get platelets greater than 30x10^9/L with 10mcg/kg/week for at least 3 consecutive weeks. All patients have been diagnosed in a single center with the same physician responsible for the treatment and follow-up. The initial doses of AZA was 100mg/days (2mg/kg/day) and ROM 10mcg/kg/week. Patients have been evaluated every week until platelets were higher than 30x10^9/L for 2 consecutive weeks, after this they were reviewed monthly.

Results: We treated 4 patients (75% female) with a median age at diagnosis of ITP of 53 years old (RIQ: 20-61 years). Treatments received prior to the use of the combination of AZA and ROM were polyspecific immunoglobulins (Ig), cyclophosphamide and rituximab. Responses to steroids and romiplostim in monotherapy were: • Median dexamethasone cycles (40mg/days x 4 days) was 2.5 (2-4 cycles, IQR). The initial dose of prednisone was 1-2mg/kg/days with a median treatment day of 31.5 days (28-60 days, IQR). The type of response to steroids was PR with corticoste-pendence in one patient, 3 patients NR. • Median time from ITP diagnosis and romiplostim indication was 9.5 weeks (7-48 weeks, IQR). Median platelet counts at the start of romiplostim was 6x10^9/L (2-13x10^9/L, IQR). The median platelet count achieved at maximal doses of romiplostim for at least 2 consecutive weeks was 10x10^9/L (3-19x10^9/L, IQR). Once established the refractoriness to romiplostim, we maintained ROM 10mcg/kg/week and AZA was initiated at 100mg/day. The median time from romiplostim indication to the association with azathioprine was 9.8 weeks (5.5 to 15 weeks, IQR). The median time to response after initiation of combination of AZA and ROM was 21 days (15-35 days, IQR). The types of response were: • One patient did not respond after 60 days of romiplostim treatment. • 1 patient with RC maintains for 7 months in the absence of active treatment. The combined was necessary during 6 months. • 2 CRs still undergoing combined dose reduction (current dose romiplostim 2mcg/kg/week and azathioprine 50mg id). Median platelets from onset of dose reduction 169x10^9/L (128-176x10^9/L, IQR). Duration of RC, 7 and 14 months. Non adverse events have been described in combination treatment.

Summary/Conclusions: The use of azathioprine and romiplostim in combination could be a safe and effective alternative in subjects refractory to steroids or corticosteroid-dependence and thrombopoietin analogs alone. More studies are needed to clarify the mechanism of complementation between the two drugs.

PB2096

AGONIST-INDUCED PLATELET REACTIVITY CORRELATES WITH BLEEDING IN HEMATO-ONCOLOGICAL PATIENTS

B. Batman1,2, E. R. van Bladel1, M. van Hamersveld2, P.C. Pasker - de Jong1, S.J. Korporaal2, R.T. Urbanus3, M. Roest1, L.A. Boven1, R. Fijnheer1,3

1Internal Medicine, 2Department of Clinical Chemistry, Meander Medical Center, Amersfoort, 3Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, Netherlands

Background: Prophylactic platelet transfusions are administered to prevent bleeding in hematologic-oncological patients. However, bleeding still occurs, despite these transfusions. This practice is costly and not without risk. Better predictors of bleeding are needed and flow cytometric evaluation of platelet function might aid the clinician in identifying patients at risk of bleeding. This evaluation can be performed within the hour and is not hampered by low platelet count.
Aims: Our objective was to assess a possible correlation between bleeding and platelet function in thrombocytopenic hematopoietic patients.

Methods: Inclusion was possible for admitted hematopoietic-oncology patients aged 18 years and above after written informed consent. Furthermore, an expected need for platelet transfusions was necessary. Bleeding was graded according to the WHO bleeding scale. Platelet reactivity to stimulation by either adenine diphosphate (ADP), crosslinked-collagen-related peptide (CRP-XL), PAR-1- or PAR4-activating peptide (AP) was measured using flow cytometry.

Results: A total of 114 evaluations were available from 21 consecutive patients. Platelet reactivity in response to stimulation by all four studied agonists was inversely correlated with significant bleeding. Odds Ratio’s (OR) for bleeding were 0.23 for every unit increase in median fluorescence intensity (MFI) [95% Confidence interval (CI) 0.11-0.73] for ADP; 0.59 [0.40-0.87] for CRP-XL; 0.59 [0.37-0.94] for PAR1-AP and 0.43 [0.23-0.79] for PAR4-AP. The platelet count was not correlated with bleeding (OR 0.99 [0.96-1.02]).

Summary/Conclusions: The ex vivo-induced platelet reactivity was significantly correlated to bleeding. Platelet function testing could provide a basis for a personalized transfusion regimen, in which platelet transfusions are limited to those at risk of bleeding.

PB2097 TUMOR NECROSIS FACTOR-A AND TUMOR NECROSIS FACTOR-B SINGLE NUCLEOTIDE POLYMORPHISM AND CHRONICITY IN EBRYONIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA

N. El-Ghargawi, G. Shahin, A. Eid, N. Diaa, M. El-Ghamrawy

1Clinical and Chemical Pathology, 2Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt

Background: Although the etiology of immune thrombocytopenic purpura (ITP) remains unclear, both genetic and environmental factors may contribute to the development of disease. Tumor necrosis factor alpha & beta (TNF-α and TNF- β) are key cytokines that play a role in regulation of cell differentiation, proliferation and death, as well as in inflammation, innate and adaptive immune responses, and have been implicated in a wide variety of human diseases. We hypothesized that inflammatory cytokine genes polymorphisms (TNF-α and TNF- β) in ITP pediatric patients may play a fundamental role in pathogenesis of the disease and may be the base for future specific immunomodulatory therapies for chronic ITP (cITP) in children.

Aims: The current case-control study aimed at detecting TNF-α (-308 G/A) and TNF-β (+252 A/G) genes polymorphism in Egyptian children with cITP and studying their possible association with chronic evolution of the disease.

Methods: The current study included 80 Egyptian cITP patients at Pediatric Hematology Unit, Cairo University (mean age 7.08±3.64 years) and 100 matched unrelated healthy controls. Genotyping was performed using polymerase chain reaction restriction fragment length polymorphism technique (PCR-RFLP).

Results: TNF-α genotyping revealed that wild G/G, heterozygous G/A and homozygous A/A genotypes among cITP patients were 81.2%, 16% and 3.8% respectively versus 79%, 20% and 1% in control group, while TNF- β wild A/A, heterozygous A/G and homozygous G/G genotypes among cITP patients were 55%, 40% and 5% respectively versus 60%, 28% and 12% in control group, with no statistically significant difference between both groups. Patients having homozygous TNF-α or TNF-β genotype showed statistically significant higher mean age, longer disease duration & lower mean platelet count (p=0.005, 0.024 and 0.008 respectively). TNF-α polymorphism was more frequent among unresponsive patients compared to responsive patients with statistically significant difference. Calculated risk estimation revealed that combined genes polymorphism conferred three fold increased risk of development of cITP (OR=3.491, 95% CI: 1.235-9.869, p=0.015).

Summary/Conclusions: We hereby report a strong association between combined polymorphisms of both TNF-α & TNF-β genes and susceptibility to chronicity of ITP in Egyptian children. Further studies for gene polymorphisms which could affect the pathogenesis of ITP and facilitate the development of new therapeutic modalities are recommended.

PB2098 PROGNOSTIC FACTORS IN PRIMARY IMMUNE THROMBOCYTOPENIA OF CHILDREN

A. Gkoutias1, T. Palianopoulos1, E. Papapi1, E. Papapetrou3, C. Tsoussi3, N. Chaliasos1, A. Makis1

1Department of Pediatrics, 2Department of Internal Medicine, 3Hematology Laboratory, University Hospital of Ioannina, Greece, Ioannina, Greece

Background: Primary immune thrombocytopenia (ITP) is an immune disorder with varied course. According the duration of the disease, it is distinguished in newly diagnosed (<3 months), persistent (3-12 months) and chronic (>12 months). International studies have highlighted prognostic factors for each form of ITP. However, such studies have yet to be performed in Greece.

Aims: The evaluation of clinical and laboratory parameters and the identification of prognostic markers for the three forms of the disease in children with ITP from an academic reference center in Greece.

Methods: This retrospective study included 57 children with ITP in the past 13 years, aged 1-16 years (median age 5.2). The following data were recorded: age, gender, preceding infection, bleeding type, duration of symptoms and platelet count at the diagnosis, treatment, disease course and immunological markers and comparison was made among the three types of ITP.

Results: 39 children had newly diagnosed, 4 had persistent and 14 had chronic disease. Due to the small number of children with persistent form they were incorporated in the group of children with newly diagnosed ITP. In chronic ITP children are more likely be above 10 years of age (p=0.015) and to have gradual initiation of the disease (p=0.001) compared with newly diagnosed/persistent group (57% vs 21% and 79% vs 9%, respectively). Recent history of infection was found mainly in newly diagnosed/persistent group (70% vs 21%, p=0.013). Platelet count below 10 x 10^9/L at diagnosis was found more frequently in newly diagnosed/persistent group (79% vs 36%, p=0.01). Similar, but not statistically significant difference, was found with mucosal bleedings (70% vs 50%, p=0.81). Children with newly diagnosed/persistent disease had less frequently impaired immunological markers (12% vs 65%, p<0.01). Children received most frequently intravenous gamma globulin and/or corticosteroids (p<0.05). None of the children exhibited severe spontaneous bleeding.

Summary/Conclusions: Even though ITP in children is usually a self-limited disease, with rare serious bleeding complications, the newly diagnosed/persistent and the chronic form of the disease are characterized by different predictive parameters that can be used in clinical practice.

PB2099 CANCER-ASSOCIATED IMMUNE THROMBOCYTOPENIA

G. Pinto1, P. Herrera1

1Hematology, Hospital Ramon y Cajal, Madrid, Spain

Background: Cases of cancer-associated immune thrombocytopenia (IT) have been reported recently, but there are few reports and case series that describe clinical features and response to treatment.

Aims: We report our experience of 10 years at a single hospital in Spain, in patients with IT concurrent with neoplasia.

Methods: We identified the patients by data search of hospital records from 2006 to 2016, with diagnosis of IT with previous diagnosis of cancer, not related with chemotherapy or radiotherapy, not suggestive of bone marrow infiltration, drug-induced, infection of disseminated intravascular coagulation. For the diagnosis, the examination of number of children with bone marrow was not mandatory.

Results: The two most common cancers associated with IT were bladder and lung neoplasms, but the occurrence of prior cancer (third part of patients) was not uncommon. The IT can appear at any stages of cancer, and it is mainly detected at the first two years after the diagnosis when the patient have been in acceptable antitumoral response. They usually manifest with very low platelet count <20,000, but not always with evident clinical bleeding. The response to therapy was fast and complete with corticoids (usually in the first week) in the majority of patients, but some cases require the combination second line with immunoglobulins or thrombopoietin receptor agonists, and in the follow-up, the response was persistent without recurrence in the first year post-treatment (Table 1).

Table 1.  

summary/Conclusions: The CAIT is a rare hematological paraneoplastic syndrome that occur in solid tumors, usually associated to low platelet count but without life threatening bleeding, requiring therapy with corticosteroids as first line, and generally related with a benign clinical course with a rapid and persistent response.

PB2100 THE ROLE OF MEAN PLATELET VOLUME IN NEONATAL SEPSIS: A RETROSPECTIVE CASE CONTROL STUDY IN A LEVEL III NEONATAL INTENSIVE CARE UNIT

A. Srivivasan1, A. Ameer1, M. Marron-Convin1

1Pediatrics, Harlem Hospital Center, New York, United States
Background: Sepsis is a relatively common diagnosis in the neonatal period. Apart from blood cultures which are the gold standard, C-reactive protein (CRP), total white blood cell count (WBC) and the ratio of immature to mature neutrophils (I/T) are considered to be useful markers of sepsis in the neonatal period. There are a few studies that show that mean platelet volume (MPV) is elevated in infectious disease processes.

Aims: The aim of this study was to investigate whether mean platelet volume is increased in neonates with sepsis.

Methods: Only term neonates were included in the study. Exclusion criteria included: (a) Any neonate born with a genetic defect, (b) Any neonate with suspected immunodeficiency, (c) Any neonate requiring surgery in the post-natal period, (d) Neonates admitted to NICU for hyperbilirubinemia, (e) Neonates requiring extensive resuscitation at birth resulting in documented Hypoxic Ischemic Encephalopathy or requiring transfer to a Regional Perinatal Center. Medical records were reviewed from March 2015 to June 2016 and a total of 114 eligible neonates were included in the study and they were divided into 2 groups: group A: (neonatal sepsis) defined by either culture positivity and/or clinical features plus treatment with antibiotics exceeding 48 hours) and 75 healthy controls (as defined by neonates in whom antibiotics were never started or discontinued when cultures were negative for 48 hours and the absence of clinical features of sepsis). Total white blood cell count, C-reactive protein, immature to total neutrophil count and mean platelet volume values were compared drawn on two occasions (first within 24 hours and the second between 24 to 48 hours after delivery) were compared between the two groups.

Results: There was no statistically significant difference in the mean platelet volume between the study group and the control group (p value 0.9 in the first 24 hours and p value of 0.55 in the 24-48 hour sample). There was however, a statistically significant difference between immature to total neutrophil count and C-reactive protein on both samples (p value <0.0001) (Table 1).

Summary/Conclusions: In our study there was no statistically significant difference in the mean platelet volume values between neonates with sepsis and healthy controls. C-reactive protein and immature to total neutrophil count continue to be reliable markers of neonatal sepsis.

Results: A total of 48 patients confirmed to have tTPP with an ADAMTS13 <5% underwent line insertion: 94 central venous catheter lines were inserted: 40% femoral, 60% internal jugular vein. The median number of lines inserted per patient episode was 3, with a range of 1-5. Median presenting platelet count for first line insertion was 25x10^9/L (IQR 9-26 x10^9/L). 70% of lines were inserted by critical care and the remaining 30% by interventional radiology. Platelet transfusion was not administered pre line insertion and any bleeding complications were documented during or after line insertion. 5 patients had ‘excessive oozing at the insertion site’ documented, within the first 24 hours of insertion, for which no intervention was required. There were no deaths related to line insertion.

Summary/Conclusions: In conclusion, this study shows no significant bleeding risk associated with central venous catheter insertion in thrombocytopenic patients presenting with TTP. The results support guidance against prophylactic platelet transfusion in this setting and provide reassurance for teams tasked with central line insertion in this critically unwell patient group.
D receptor (VDR) polymorphisms in the development of autoimmune diseases. Vitamin D affects both innate and adaptive immune responses that have been blamed in immune thrombocytopenia (ITP) pathogenesis.

**Aims:** The aim of this study is to assess the association of vitamin D receptor gene polymorphism BsmI in cases of adult primary immune thrombocytopenia.

**Methods:** Vitamin D receptor polymorphism BsmI (rs1544410) was detected by Polymerase Chain Reaction followed by Restriction Fragment Length Polymorphism (PCR-RFLP). Deoxyribonucleic acid (DNA) samples were extracted from peripheral blood of 40 ITP patients and 60 geographically and ethnically matched healthy controls.

**Results:** Statistically significant difference was found in the BsmI polymorphism between ITP patients and controls ($\chi^2 = 8.77$, P value=0.01). The BsmI polymorphism B allele was higher in ITP group than that in controls but in statistically insignificant difference ($\chi^2 = 2.125$, P=0.145). bb genotype played a protective role in ITP incidence.

**Summary/Conclusions:** This is the first published report on VDR gene polymorphisms in adult primary ITP patients. The BsmI genotype was associated with increased risk for ITP incidence with no obvious effect on bleeding severity, platelet count nor site of bleeding.

**PB2104**

**A SURVEY OF THE TREATMENT OF THE PREVENTION OF NAIT IN THE UK AND IRELAND**

D. O’Keeffe1, V. Broderick1,*

1UHL, Dept of haematology, Limerick, Ireland

**Background:** Neonatal alloimmune thrombocytopenia (NAIT) is caused by maternal antibodies generated against alloantigens carried on fetal platelets, which cross the placenta and induce destruction of platelets in the fetus. In most cases the maternal immunisation is triggered by exposure to fetal platelets at delivery. As a result, the clinical presentation tends to be more severe in subsequent pregnancies.

**Results:** Aims: We set out to establish if there is consistency in the management of the prevention of NAIT across Ireland and the United Kingdom (UK).

**Methods:** A survey was set up on Survey Monkey and all members of the UK-Ireland Haematology group were contacted by email with a link to the survey in January 2015. In total 90 individual Specialists were contacted across 70 centres.

**Results:** 30 responses were received to the following questions. Who manages the prevention of NAIT in your centre? 34% of respondents stated that it was managed jointly by haematologist/feto-maternal specialists, with 26% responding it was overseen solely by haematologists and 40% solely by feto-maternal specialists. Secondly what risk stratification each respondent used to decide risk of NAIT in the current pregnancy? 82% stated that they took into account multiple risk factors but 18% stratified risk based only on the outcome of previous pregnancy. Thirdly how many groups do you define after risk stratification? 60% identified 3 strata of risk (standard, high and very high) with 40% classifying two.

**Summary/Conclusions:** Aims: To evaluate management and results of pregnancy and delivery on pregnant ITP women and on their offspring.

**Summary/Conclusions:** To evaluate whether patients with chronic ITP and H. pylori infection exhibit higher ROS levels compared to patients with chronic ITP and no H. pylori infection and whether there are statistically significant differences between the two groups.

**Methods:** We studied 29 patients with chronic ITP (median age 39 years) hospitalized in the Clinic of Hematology, Filantropia City Hospital, Craiova, Romania, between 2014 and 2016 (informed consent obtained). All patients were diagnosed with ITP, other causes of thrombocytopenia having been ruled out by bone marrow aspiration. The patients were divided in two groups: patients with ITP and H. pylori infection (group A) and patients with chronic ITP without H. pylori infection (group B). Intracellular ROS levels were used to indicate the presence of a H. pylori infection and reactive oxygen species were evaluated by FORT (Free Oxygen Radicals testing) test from a single drop of capillary blood, at the time of diagnosis, before the administration of any drug (the normal value of FORT is considered less than 2.3 mmol/L H2O2), using a CR3000 analyzer (Callegari SpA, Parma, Italy). The differences between the two groups were assessed using the Student T-test and a p-value of less than 0.05 was considered statistically significant.

**Results:** Group A consisted of 11 patients positive for H. pylori, whereas group B included 18 patients with no H. pylori infection. ROS levels, measured by the FORT test, were elevated in both groups (between 2.8 – 3.6 mmol/L H2O2). However, statistically significant differences were found in favour of group A, with higher ROS values than group B. The A group also associated lower platelet counts and more patients pertaining to this group relapsed in comparison to group B.

**Summary/Conclusions:** In chronic ITP, increased levels of ROS are associated with elevated autoantibody production. Autoantibodies are involved in platelet destruction via a high immunogenic activity. On the other hand, association of H. pylori infection, via chronic inflammation, led to a supplementary increase in ROS levels and increased platelet destruction.
50.8% of women received corticosteroids, immunoglobulins (IVIG) (16.9%), rituximab (6.8%) and splenectomy (8.4%) as ITP treatments between or before new pregnancies. On the other hand, 26.4% of women needed treatment for ITP during pregnancy, mainly steroids (13.5%) and IVIG (10.2%). The median platelet-count nadir during pregnancy was 74 x 10^9/l (IQR, 36-172). 127 (47%) pregnancies suffered from non-haemoatomatic platelet levels (less than 50 x 10^9/l) with 73 (27.0%) women who achieved less than 30 x 10^9/l. 56 (20.7%) women exhibited hemorrhagic symptoms, being 30 (11.1%) of them severe bleedings.

Regarding type of delivery, this was vaginal in 63.4% of pregnancies and cesarean sections 30.5%. Median platelet count at delivery was 110 x 10^9/l (IQR, 70-181). 43 patients (23.4%) experienced 57 bleeding episodes. We only observed 48 cases (20.4%) of neonatal thrombocytopenia among 235 living newborns.

Summary/Conclusions: Our results are comparable to previously reported studies. No severe bleeding complications during pregnancy and/or delivery were observed in our case series. Rate of neonatal thrombocytopenia, and therefore, newborn bleeding is low.

PB2107

ANALYSIS OF THE DEMOGRAPHIC, CLINICAL, LABORATORY AND TREATMENT-RELATED DATA OF ITP PATIENTS IN GREECE BASED ON THE NATIONAL ITP REGISTRY OF THE HELLENIC SOCIETY OF HAEMATOLOGY


1Department of Haematology, Venizeio-Pananeio General Hospital, 2Information Systems Unit Center of Information and Communications Technologies, University of Crete, 3Department of Haematology, University of Crete School of Medicine, Heraklion, 41st Department of Propaedeutic Medicine, 51st Department of Medicine, National and Kapodistrian University of Athens (NKUA), 6Department of Haematology, Gennimatas General Hospital, Athens, 7Department of Medicine, University of Patras, 8Department of Haematology, Anticancer Hospital of Peiraiα “Metaxa”, Peiraeas, 9Department of Haematology, General Hospital of Chania “Agios Georgios, Chania, 101st Department of Internal Medicine, 111st Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 12AHEPA University Hospital, 132nd Department of Internal Medicine, Aristotle University of Thessaloniki, 14Hospital of Patras “St Andrew”, Patras, Greece

Background: Immune thrombocytopenia (ITP) consists of various acquired disorders caused by autoantibodies against platelets resulting in increased platelet destruction and impaired thrombopoiesis. ITP is characterized as primary when an underlying etiology cannot be identified and secondary when a certain etiology exists. Data concerning ITP characteristics at a national level are limited.

Aims: The purpose of the study was to access systematically the demographic, clinical, laboratory and treatment-related data of ITP in Greece based on the national database (ITP registry) operated and supported by the Hellenic Society of Haematology.

Methods: Patient data were collected over 2013-2016. The data source is a unique database initiated and managed by the Haematology Department of the University of Crete (UoC) and supported by the Center of Information and Communications Technologies of the UoC. The registry has been configured for national and regional base usage considering hospitals as the core unit. A retrospective review of all consecutive admissions to a single tertiary center between 2009 and 2015. Only patients who required plasma exchange were included. Patients’ symptoms and their duration were reviewed in addition to presenting anti-ADAMTS13 IgG antibody levels and ADAMTS13 antigen levels, both of which have previously been found to have prognostic significance.

Results: 106 patients (68% female) were included with a median age of 48. 58% were Caucasian and 19.8% Afro-Caribbean. The mortality rate was 7% (n=8). 47% of patients had neurological symptoms on presentation, 24% reported a bleeding history and 12% a recent infection. The most common presenting symptoms were headache (27.4%), bleeding (24%) spontaneous bruising/ petechial hemorrhage (19.8%), abdominal pain (16.2%). The majority of patients presented with thrombotic symptoms (70.9%). The main manifestations were cutaneous bleeding (64%), oral cavity bleeding (20.9%), epistaxis (8.9%), menorrhagia (7.8%) and gastrointestinal bleeding (5.5%). 430 patients (61.78%) had primary ITP and 266 (38.22%) secondary ITP. Among these secondary ITP cases, 44.2% were related to infectious agents, 25.74% to drugs, 17.17% to collagen vascular diseases and 12.87% to cancer. Patients with positive ANA antibodies with no evidence of any underlying diseases were included in the primary ITP group. The main patient comorbidities were hypertension (22.6%), thyroid disease (12.32%) and cardiovascular disease (10.17%). Treatment was given in 620 women (70.19%) with 109 IgG level (less than 50 x 10^9/l). The majority of patients (85%) responded to the initial treatment. Follow-up data for more than one year are available in 259 patients (133 with persistent ITP and 126 with chronic ITP). Splenectomy has been performed in 59/696 patients (8.47%).

Summary/Conclusions: Primary ITP is more frequent than secondary ITP in Greece, the disease displays two peaks at the ages of 19-30 and 71-80 years, presents a female predominance and high frequency of hemorrhagic symptoms. Thrombotic complications are mainly based on anti-ADAMTS13 antibodies and/or increased ADAMTS13. Registration and follow-up of larger number of patients and evaluation of response to various treatments are anticipated to extend our knowledge on the pathophysiology and natural history of ITP and may also reveal peculiarities at local level.

PB2108

PRESENTING SYMPTOMS AFFECT OUTCOME IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

J. Khwaja1,2, F. Alwan1, C. Vendramini3, K. Langley4, M. Thomas5, J.P. Westwood1, M. Scully6

1Haematology Department, University College London Hospital, 2Haemostasis Research Unit, University College London Hospital, London, United Kingdom

Background: Whilst immune mediated Thrombotic Thrombocytopenic Purpura (TTP) has classically been suspected by the presence of a pentad of symptoms (microangiopathic haemolytic anaemia, fever, disturbed neurological function, renal failure, thrombocytopenia), the limitations of this have long been recognized and a wide variety of symptoms are seen on initial presentation.

Aims: A retrospective review of the significance of specific symptoms and their duration on mortality.

Methods: A retrospective review of all consecutive admissions to a single tertiary center between 2008 and 2015. Only patients who required plasma exchange were included. Patients’ symptoms and their duration were reviewed in addition to presenting anti-ADAMTS13 IgG antibody levels and ADAMTS13 antigen levels, both of which have previously been found to have prognostic significance.

Results: 106 patients (68% female) were included with a median age of 48. 58% were Caucasian and 19.8% Afro-Caribbean. The mortality rate was 7% (n=8). 47% of patients had neurological symptoms on presentation, 24% reported a bleeding history and 12% a recent infection. The most common presenting symptoms were headache (27.4%), bleeding (24%) spontaneous bruising/petechial hemorrhage (19.8%), abdominal pain (16.2%). The majority of patients presented with thrombotic symptoms (70.9%). The main manifestations were cutaneous bleeding (64%), oral cavity bleeding (20.9%), epistaxis (8.9%), menorrhagia (7.8%) and gastrointestinal bleeding (5.5%). 430 patients (61.78%) had primary ITP and 266 (38.22%) secondary ITP. Among these secondary ITP cases, 44.2% were related to infectious agents, 25.74% to drugs, 17.17% to collagen vascular diseases and 12.87% to cancer. Patients with positive ANA antibodies with no evidence of any underlying diseases were included in the primary ITP group. The main patient comorbidities were hypertension (22.6%), thyroid disease (12.32%) and cardiovascular disease (10.17%). Treatment was given in 620 women (70.19%) with 109 IgG level (less than 50 x 10^9/l). The majority of patients (85%) responded to the initial treatment. Follow-up data for more than one year are available in 259 patients (133 with persistent ITP and 126 with chronic ITP). Splenectomy has been performed in 59/696 patients (8.47%).

Summary/Conclusions: Primary ITP is more frequent than secondary ITP in Greece, the disease displays two peaks at the ages of 19-30 and 71-80 years, presents a female predominance and high frequency of hemorrhagic symptoms. Thrombotic complications are mainly based on anti-ADAMTS13 antibodies and/or increased ADAMTS13. Registration and follow-up of larger number of patients and evaluation of response to various treatments are anticipated to extend our knowledge on the pathophysiology and natural history of ITP and may also reveal peculiarities at local level.
PB2109

NOVEL TECHNIQUES FOR MONITORING GALNZMANN THROMBOASTHENIA PATIENT UNDERGOING SURGICAL INTERVENTIONS
A. Barg1,2, H. Hauschner1,2, M. Misgav1,2, E. Avishai1, N. Rosenberg1,2, G. Kenet1,2
1Institute of thrombosis and hemostasis, Sheba medical center, 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Background: Glanzmann thrombasthenia (GT) patients undergoing surgical procedures are often treated by platelet transfusion. However many GT patients who have been previously exposed to platelets may form antibodies either against the missing glob3 antigen or directed against MHC-class molecules thus hampering the efficacy of care. Due to the rarity of disease there is paucity of data regarding platelet transfusion protocols during the perioperative period. We herein describe our experience with monitoring the proportion of donor platelets following transfusion, and their contribution to whole blood clot formation.

Aims: To describe the use of flow cytometry (FC) analysis in order to detect donor transfused platelets in a GT patient undergoing a minor surgical procedure and to assess the correlation between FC analysis and the results of Rotational thromboelastography (ROTEM).

Methods: A nine year old female patient with GT underwent teeth extraction. The patient received platelet transfusion around the procedure. Complete blood counts, ROTEM, FC to detect the number of donor platelets and their ADP dependent activation, were sampled and followed till 7 days post teeth extraction.

Results: Prior to teeth extraction upon injection of local anesthetics patient developed a buccal hematoma probably owing to local blood vessel penetration. The patient did not experience any post extraction bleeding. Hematoma was absorbed within several days. Post transfusion platelet FC demonstrated 20.6% donor platelets equivalent to 55,620 donor platelets. Platelets activation was determined following ADP addition by examination CD62 antigen expression. Seven days post platelet transfusion FC demonstrated 2.6% equivalent to 8,658 donor plantlets. The decline in the number of active platelets was associated with a reduced clot firmness (MCF) and lower α-angle as assessed by ROTEM (Figure 1).

Figure 1.

Summary/Conclusions: Clinical decision making in patients with GT may be aided by application of novel techniques, evaluating the number of active donor platelets and actual clot formation. This data may help making more knowledgeable decisions as for the need for further platelet transfusion or for the need for rFVIIa. Thus leading to improved monitoring and better patients’ care.

PB2111

CLINICAL SIGNIFICANCE OF IMMATURE PLATELET FRACTION MEASUREMENT IN THROMBOCYTOPENIC DISORDERS DURING PREGNANCY
R. Coll1,2, A. Marull1, M. Sagüés1, N. Kelleher1, O. Jimenez1, C. Morales-Indiana1, M. Serrando1
1Hematology Department, Institut Català de la Salut, Girona, Spain

Background: Thrombocytopenia is the second most common hematologic abnormality during pregnancy and is usually a benign condition. The challenge to the clinician is to weigh the risks of maternal and fetal bleeding complications against the benefits of diagnostic tests and interventions. This condition can also be associated with several diseases, either pregnancy specific or not, such as preeclampsia, HELLP syndrome, or idiopathic thrombocytopenic purpura (ITP). The differential diagnosis between ITP and gestational thrombocytopenia is clinically important with regard to the fetus, due to the risk of neonatal thrombocytopenia. The immature platelet fraction (IPF) is young cells that have recently been released into the circulation, and are considered indicators of bone marrow recovery. They contain a higher concentration of RNA than mature platelets. Measure of immature platelet fraction (IPF) has been suggested as a less invasive and early diagnostic test in the study of thrombocytopenic disorders. Immature platelet fraction can be currently measured by fully automated hematology analyzers providing clinical utility for diagnosing and monitoring thrombocytopenia.

Aims: The aim of this is to know whether IPF can be a useful parameter in pregnant women with thrombocytopenia to predict the potential risk of bleeding.

Methods: Pregnant women with thrombocytopenia were selected (2015-2016); a total of 25 patients (mean age: 33 yrs, range 19-43 yrs) were examined with platelet count <100.000 platelets/L. Venous whole-blood samples were collected into Vacutainer EDTA-K2E tubes (Becton Dickinson and Company, Plymouth, UK). Complete blood counts and immature platelet fraction (%IPF) were immediately analyzed within 2 h of blood withdrawal by Sysmex XN20 system (Sysmex Corporation, Kobe, Japan). Novel PLT-F channel uses fluorescent light and stains platelets specifically with Oxazine Dye (Fluorescent Fluorocell). Platelet counting was performed on an automated hematology analyzer and was repeated to confirm the results.

Results: Mean platelet count was 73.000 platelets/L (range of 69-91) and IPF mean was 11% (2.5-23.4). Lab test Hemoglobin shows a mean of 95,17 g/L (range of 83-100) and hematocrit a mean of 0.30 (0.30-0.35). The IPF% was <10% in 11, which means a 44% of the patients. 14 patients bleed during or after labor, 56% among all the patients in this study. Related to this group, 11 patients had IPF <10%; 3 of bleeding patients showed an IPF >10%. All pregnant women with an IPF <10% (11/11) bleed as a complication. Pregnant women with thrombocytopenia and patients with bleeding has a higher risk of bleeding during and/or after labor compared with pregnant women with an IPF>10% (Fisher 12,41, p=0,001). 5 (20,83%) patients among all of them were under treatment (earlier or during labor); 3 (12,5%) with steroids and 2 (8,33%) with other methods.

Summary/Conclusions: Status of c-mpl in ITP is ambiguous. Significant level of positivity in patient group who did not have splenectomy might the useful for splenectomy indication.
Summary/Conclusions: Thrombocytopenia is a potential risk of bleeding during the labor. A high IPF indicates either consumptive or recovering thrombocytopenic disorders, such as immune thrombocytopenic purpura, while low IPF is characteristic of bone marrow suppression states. Although not directly used in clinical decision making, the reference range is critical to the introduction of new parameters and the interpretation of laboratory results. Our results suggest that the laboratory evidence parameter in the measured and a level <10% might be an independent bleeding factor which can be useful for detecting high risk pregnant patients. It should be corroborated in further studies.

PB2112

DOES EARLY RESPONSE TO FIRST LINE CORTICOSTEROID THERAPY PREDICT REQUIREMENT FOR SECOND LINE THERAPY IN IMMUNE THROMBOCYTOPENIC PURPURA? N. El Husseiny,1* S. Kucukyurt Kaya1,2, S. M. Bakanyan1,2, T. Hacibekiroglu2,2, A. Akinci1, S. Gündüz2, S. Mara2, A. Senturk Yikilmaz1,2, I. Dilek1,2
1Department of Hematology, Ankara Yildirim Beyazit University, 2Department of Hematology, Ankara Atatürk Training and Research Hospital, Ankara, Turkey

Background: Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease that is characterized by increased destruction of platelets by autoantibodies. ITP is characterized by mucocutaneous bleeding. Rarely, life-threatening bleeding such as central nervous system bleeding can occur. Typically, patients have isolated thrombocytopenia. The diagnosis of ITP is one of exclusion. Corticosteroids are chosen as a first-line therapy for adult patients who require treatment. Responses to first line therapy with corticosteroids is about 80% with approximately 20% to 30% long term complete remission. Most patients finally relapse, requiring second-line therapy. Aim: Our aim was to investigate potential criteria of early platelet response to corticosteroid therapy in achieving long term complete remission.

Methods: We retrospectively evaluated 43 ITP patients who were followed-up at our institution. All patients’ thrombocyte counts were below 30 x10^9/L at diagnosis. All patients received initially methylprednisolone (MP) 1 mg/kg/day. For patients who responded with platelet count ≥150 x10^9/L methylprednisolone was tapered over 3 months. Those who were unresponsive to MP or relapsed after a complete response, were treated with second line therapies that splenectomy or medical treatment agents. The platelet counts of the patients on day 0, 3 and 7 were evaluated by complete blood counts and were confirmed with the platelet function analysis. Effectiveness of first line therapy on day 3 and 7 were compared in terms of second line therapy requirement or not. A platelet count of >30 x10^9/L on day 3 and >100 x10^9/L on day 7 was considered as a complete response. Vaccination against encapsulated organisms was given and imaging was done to detect accessory spleen before splenectomy.

Results: Baseline characteristics of the cohort of 43 patients with an initial diagnosis of ITP are shown in Table 1. The mean age at diagnosis was 51 years (18-84) with female/male: 25/18. All patients presented with severe thrombocytopenia (platelet counts below 30.0 x10^9/L). Most patients presented with mucocutaneous bleeding (n=39), only three patients had genitourinary or gastrointestinal bleeding and one patient had lymphaticoreticular and aspiration and biopsy was done in 14 (%32.6) patients due to various reasons mainly, failure to respond to ITP treatment (7 patients) and advanced age (7 patients). On third and seventh day of MP therapy, median platelet counts were 30x10^9/L (2.0 x10^9/L - 150 x10^9/L) and 100 x10^9/L (1.0 x10^9/L - 347 x10^9/L), respectively. Numbers on day 7th in each group compared, a significant association was found in correlation analysis (p<0.05). 21 patients (%48.8) required second line therapy which were splenectomy (76.2%) or medical treatment (23.8%). Medical therapy consisted of rituximab, splenectomy or medical treatment agents. The platelet counts of the patients after a complete response, were treated with second line therapies that starting second therapy then weekly for 3 months. At the end of third month the response to second line therapy was considered according to the following criteria; complete response (CR) PLT>100 x10^9/L, partial response (PR), PLT=30-100 x10^9/L, no response (NR), PLT<30 x10^9/L.

Results: Regarding FcγRIIa-131 R/H gene polymorphism in distribution in the 100 patients; 28 patients (28%) had wild HH genotype, 41 patients (41%) have heterozygous HR genotype and 31 patients (31%) have homzygous mutant genotypes (RR). In our study, the 100 ITP patients included showed wild type of FcγRIIIa (V158F) gene polymorphism. By the end of month 3 of the second line therapy, 18 patients (44.4%) carried FcγRIIIa HR genotype and 7/18 patients (38.9%) carried FcγRIIa RR genotype. Out of the 18 patients who achieved CR, 27/107 patients (37%) achieved NR and 20/100 patients (20%) achieved NR. Among the 50 patients who treated with rituximab; 18 patients (36%) achieved CR, 19 patients (38%) achieved PR and 13 patients (26%) achieved NR. Out of the 18 patients who achieved CR, 8/18 patients (44.4%) carried FcγRIIIa RR genotype and 7/18 patients (38.9%) carried FcγRIIa HR genotype. Among FcγRIIa polymorphism, 13 patients (26%) achieved NR. Out of the 18 patients who achieved CR, 8/18 patients (44.4%) carried FcγRIIIa RR genotype and 7/18 patients (38.9%) carried FcγRIIa HR genotype.

Summary/Conclusions: The higher platelet count achieved early (end of week 1, 2, and 3) after rituximab is suggestive for a better response later (at end of M3). FcγRIIIa RR genotype is predictive for better response to rituximab in ITP patients.

PB2114

IMMUNE THROMBOCYTOPENIA, EGYPTIAN EXPERIENCE WITH STUDY OF IL-17,ILGF-B, IL-35 AND IL-12 CYTOKINES IN CHRONIC AND PERSISTENT IMMUNE THROMBOCYTOPENIA PATIENTS N. El Husseiny,1* 1kasr al aini hospital, cairo, Egypt

Background: The role of T cells in the pathophysiology of immune thrombocytopenia (ITP) is heterogeneous and complex. It has been studied in active and reactive ITP but not to same extend in chronic and persistent type.

Aims: In this study we review the demographic features of 150 immune thrombocytopenic Egyptian patients and for cases who were chronic and persistent with negative both autoimmune screen and virology for hepatitis B and C

Methods: We measured IL-12, IL-17, IL-35 and TGF-β by ELISA to assess role of cytokines and T cells in the pathophysiology of ITP.

Results: Our results revealed Chronic and persistent cases who fulfilled the criteria for cytokine assay were 45 cases with a mean (± SD) age of 31.6±8.78 years. Thirty two patients were included in this study. Observation and a week later, eight patients presented with mucous bleeding (17.8%) and five patients presented with mucosal bleeding (11.1%). Eight patients presented with mucous bleeding (17.8%) and five patients presented with mucosal bleeding (11.1%). Eight patients presented with mucous bleeding (17.8%) and five patients presented with mucosal bleeding (11.1%). Eight patients presented with mucous bleeding (17.8%) and five patients presented with mucosal bleeding (11.1%). Eight patients presented with mucous bleeding (17.8%) and five patients presented with mucosal bleeding (11.1%). All cases were carriers of anti platelet and polymer antibodies and showed positive reaction to another immunesuppression medication. No correlation between measured cytokines and platelet count.

Summary/Conclusions: The higher expression of IL-12 and IL-35 is due to persistently higher TH1 activity which explain continuation of the disease while lower expression of IL-17 and IL-35 cytokines can't predict the course of disease.

883 Haematologica | 2017; 102(12)
PB2115

SWITCH OF TPO-MIMETICS IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: FLORENCE MONOCENTRIC EXPERIENCE

C. Biagiotti1,*, V. Carrail, F. Bocchi1, A. Bossi1
1Hematology, Careggi Hospital, Florence, Italy

Background: Primary immune thrombocytopenia (ITP) is an immune-mediated condition characterized by isolated thrombocytopenia, with peripheral blood platelet count < 100,000/μl in the absence of an identifiable underlying cause of thrombocytopenia. Clinical studies in patients with ITP demonstrated that thrombopoietin (TPO) mimetics increase platelet production and can outpace platelet destruction.

Aims: We evaluated patients treated with both TPO-mimetics.

Methods: From November 2008 and February 2017, 65 patients were treated with TPO-mimetics with a median follow up of 29 months (1-96); 39 patients underwent therapy with Romiplostim and 26 to Eltrombopag. In our study we evaluated 18 patients who received both therapies: among patients treated at first with Romiplostim, 10 patients (9F; 1 M) switched to Eltrombopag and 8 patients (3 M; 5 F) switched from Eltrombopag to Romiplostim. In the group of 10 patients treated at first with Romiplostim, 5 patients started Eltrombopag because no responders, 3, for loss of response and 2 patients because of adverse events. In the group of 8 patients at first treated with Eltrombopag, 4 patients didn’t obtain any response with Eltrombopag and switched to Romiplostim, 1 patient underwent to Romiplostim for loss of response and 3 patients because of adverse events.

Results: Among patients switched from Romiplostim to Eltrombopag, 2 achieved complete response, 4 response and 4 were no responders; among patients switched from Eltrombopag to Romiplostim, 4 obtained complete response, 3 response, 1 was no responder.

Summary/Conclusions: Romiplostim and Eltrombopag stimulate the TPO-R but have different mechanisms of action, therefore, in our limited experience switching from one thrombopoietic receptoragonist to the other could be beneficial in clinical practice for patients with severe chronic immune thrombocytopenia who failed to respond or experienced adverse events to the first treatment.

PB2116

COEXISTENCE OF GLANZMANN’S THROMbasthenia AND MAPLE SYRUP URINE DISEASE: IMPLICATIONS FOR HEMOSTATIC MANAGEMENT

M. Elshinawy1,*, A. Alrawas2, Y. Wali2
1Pediatric Hematology, SQUH, Alexandria University, Muscat, Oman, Egypt, 2Pediatric Hematology, SULTAN QABOOS UNIVERSITY HOSPITAL, Muscat, Oman

Background: In Oman, autosomal recessive disorders are relatively commoner than western communities due to the high prevalence of inter-tribal marriage. Unfortunately, some patients have got more than one autosomal recessive genetic disorder, owing to complex consanguinity which might further complicate proper management plans.

Aims: To report a case of combined Glanzmann’s thrombasthenia and MSUD, and to review the existing data of platelet function disorders in Oman.

Methods: Case report and retrospective data analysis of all cases with confirmed or suspected platelet function disorders in Pediatric Hematology Unit, Sultan Qaboos University Hospital, Muscat, Oman from January 2006 till December 2016.

Results: A 3-year-old girl who is a known case of MSUD. Her parents are double first cousins (from both maternal and paternal sides). At the age of 3 months, she required Gastrostomy tube (G-tube) insertion. Preoperatively, full blood count and coagulation screen were perfectly normal. Unfortunately, she developed profuse bleeding at the site of G-tube insertion, followed by massive hematemesis. The patient received multiple blood products, but bleeding didn’t stop. As an emergency measure, recombinant activated factor VII (rFVIIa) was given and resulted in cessation of bleeding. Platelet aggregation studies revealed defective aggregation with ADP, arachidonic acid, collagen and epinephrine which is consistent with Glanzmann’s thrombasthenia. The diagnosis was confirmed by platelet aggregation assay which showed no activity with CD41 and CD61, indicating absent GpIIb/IIIa complex. The patient experienced a severe bleeding phenotype, which is further complicated by multile coexisting factors, including the recurrent episodes of metabolic crises which provoked worsening of platelet function, the development of platelet refractoriness at the age of 1 year, and the need for recurrent invasive procedures such as G-tube and central line insertion. Currently, the bleeding episodes are managed by rFVIIa at a dose of 120-180 μg/kg/dose. Excluding von Willebrand disease, we have 38 cases of confirmed or suspected platelet function disorders in our center, including 15 cases with Glanzmann’s thrombasthenia, 7 cases with Bernard-Soulier syndrome, 5 cases with May–Hegglin anomaly and 11 cases of suspected, yet unconfirmed platelet storage pool deficiency.

Summary/Conclusions: In conclusion, children with platelet function disorders still have plenty of unmet needs, ranging from deficient accurate diagnostic facillities, to lack of evidence-based management guidelines. The coexistence of another hereditary disorder may result in mutual management difficulties of both diseases. In developing countries, proper registry is needed to establish optimum care of such rare disorders.

PB2117

ASSESSMENT OF PLATELET REACTIVITY TO ASPIRIN AND CLOPIDOGREL WITH POINT-OF-CARE VERIFYNOW® ASSAY AND TWO ALTERNATIVE METHODS IN PATIENTS WITH CEREBRAL ANEURYSMS TREATED WITH ENDOVASCULAR PROCEDURES

D. Velasco-Rodríguez1,*, R. Vidal1, S. Martín Herrero1, T. Castaño Bonilla1, A. García Raso2, M. Martínez-Galdames2, P. Llamas1
1Hematology, 2Health Care Institute, 3Neuroradiology, Fundación Jiménez Díaz, Madrid, Spain

Background: Stent thrombosis and hemorrhage are the main complications after endovascular procedures for cerebral aneurysm treatment. Identifying an optimal pre-procedure response to antiplatelet therapy is essential to guarantee a successful result. A high variability in the individual responses to the anti-agregant effect of aspirin and, specially, with clopidogrel has been reported. The VerifyNow® System (Accutrendm, San Diego, CA, USA) performs a turbidimetric-based optical detection of induced platelet aggregation in response to major antiplatelet agents (P2Y12 inhibitors, aspirin, GP IIb/IIIa inhibitors).

Aims: 1) To measure the antiplatelet effect of aspirin and clopidogrel with the point-of-care VerifyNow® assay in patients with brain aneurysms before undergoing endovascular treatment. 2) To compare the results with two alternative methods: impedance aggregometry, and PFA-100.

Methods: 38 patients with cerebral aneurysms, scheduled for elective endovascular procedure, were included in the study. All of them had started taking aspirin at a dose of 100 mg daily and clopidogrel at a dose of 75 mg daily 7 to 10 days before testing aspirin and clopidogrel sensitivity. The following functional tests were performed in all of them before the procedure: 1) VerifyNow® assay: Aspirin Reaction Units (ARU) <550 and P2Y12 Unit Reaction Units (PRU) <200 were considered to be good response to aspirin and clopidogrel respectively. PRU >85 was considered hyper-response to clopidogrel. 2) Impedance aggregometry from whole blood (Multiplate® analyzer, Roche Diagnostics, Mannheim, Germany): arachidonic acid (AA), adenosine diphosphate (ADP) and thrombin receptor activating peptide (TRAP) were used as agonists. TRAP was used to determine baseline platelet function. Aggregates with TRAP and ADP >47 U were considered good responses to aspirin and clopidogrel respectively. 3) PFA-100: an overall assessment of platelet function was performed using epinephrine-collagen (COL/EPI) and ADP-collagen (COL/ADP) cartridges. Although COL/ADP is not an appropriate method to evaluate the effect of thienopyridines, we performed it to analyze which hyper-responders to clopidogrel detected by VerifyNow® were also identified with PFA-100.

Results: The results of platelet function testing with three different methods are summarized in Table 1. None of the patients showed thrombocytopenia. Good response to aspirin was observed in 84.21%, 97.36% and 93.75% of the patients using VerifyNow®, Multiplate® and PFA-100 respectively. Good response to clopidogrel was detected in 86.84%, 38.88% and 62.5% of the patients using VerifyNow®, Multiplate® and PFA-100 respectively. VerifyNow® identified 6 (18.75%) aspirin-resistant patients. However, PFA-100 and Multiplate® showed a significant aspirin-mediated platelet dysfunction in 5 of them. Low response to clopidogrel was detected by VerifyNow® in 5 (13.15%) patients consistent with Multiplate® results. VerifyNow® identified 10 patients with excessive response, but only 2 of these results were reproduced by Multiplate® or COL/ADP. Multiplate® detected 19 patients (50%) with suboptimal response to clopidogrel, although these results did not correlate with those obtained by VerifyNow®.

Table 1.

<table>
<thead>
<tr>
<th>VerifyNow®</th>
<th>Multiplate®</th>
<th>PFA-100</th>
</tr>
</thead>
<tbody>
<tr>
<td>550 ARU</td>
<td>&lt;200 PRU</td>
<td>&lt;47 U</td>
</tr>
<tr>
<td>85 PRU</td>
<td>&gt;47 U</td>
<td>&gt;47 U</td>
</tr>
<tr>
<td>200 ARU</td>
<td>&gt;47 U</td>
<td>&gt;47 U</td>
</tr>
<tr>
<td>&gt;85 PRU</td>
<td>&gt;47 U</td>
<td>&gt;47 U</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The effect of aspirin can be accurately measured by platelet aggregation and PFA-100 (with COL/EPI); however, VerifyNow® seems to identify a higher number of poor responders. Multiplate® assay using only
ADP is not good enough to detect clopidogrel-mediated platelet dysfunction since it is not specific for the P2Y12 receptor. The addition of PG1 to the ADP test may increase its sensitivity. VerifyNow® assay seems to overestimate the effect of clopidogrel, since hyper-response data are not reproduced by other techniques. According to our results, a high interindividual variability in response to clopidogrel is observed.

Background: Thrombopoietin-receptor agonists (TRA), romiplostim and eltrombopag, are part of the treatment of chronic immune thrombocytopenia (ITP), resistant to first line therapy (corticosteroids and/or immunoglobulins) and with a significant bleeding risk. Both are approved for adult patients, but only eltrombopag was approved for pediatric use. When used before splenectomy, these treatments may serve as a bridge for surgery or even postpone/avoid the procedure.

Aims: We wanted to evaluate the impact of gestational age by determining variants in platelet volume parameters according to gestational weeks.

Methods: Medical records were prospectively reviewed during pregnancy in 38 preterm infants admitted to First University Hospital from January 2001 to December 2007. Study group consisted of only one-hour-old newborns delivered in the clinics of Department of Gynecology, and Obstetrics of our hospital. The exclusion criteria included those with maternal history of antepartum haemorrhage, chorioamnionitis, fever, sepsis, preeclampsia and hypertension; and perinatal history of twin-to-twin transfusion syndrome, feto-maternal transfusion, injury and infection. A hundred and ninety-three newborns with apparent health problems were excluded from our study. Study group comprised 398 preterm infants born between 26-37 gestational weeks, and 63 healthy term (38 gestational weeks) infants. MPV, and PDW values were obtained within the first hours after birth. Blood samples were placed into tubes with EDTA, and analyzed in ADVIA 120® (Japan) hematology analyzer using suitable kits. Data were expressed as mean±standard deviation. Platelet counts, and volume were indicated for each gestational week, and groups of 24-31, 32-36, 37, and 38 weeks. One-way analysis of variance (ANOVA) was used for statistical analysis, and p<0.05 was accepted as the level of statistical significance.

Results: In our study, patients with ET had increased ROS 2008 revised WHO criteria (informed consent obtained). All analysis were performed after diagnosis and before the start of therapy. The JAK2V617F mutation was detected by allelic specific polymerase chain reaction (PCR) testing. ROS levels were detected by flow-cytometry using a Cy Flow Space Sysmex flow-cytometer and a DFCDFA Cellular ROS Detection Assay Kit. Studied parameters were compared both to healthy controls and to each other. Exclusion criteria were pregnancy of any condition associated with an increased oxidative state (alcohol consumption, smoking, diabetes mellitus, hyperlipidemia, chronic renal failure, human immunodeficiency, cirrhosis, and active infection), use of antioxidants or iron supplementation. Data analysis was performed using Flow Max software. The differences between the two groups were assessed using the Student T-test and a p-value of less than 0.05 was considered statistically significant.

Results: The study group involved 12 females and 11 males, with a median age of 48 years. All patients had increased ROS levels at diagnosis compared to healthy controls. Eleven patients had JAK2V617F mutation and twelve were JAK2V617F mutation negative. Significantly higher ROS levels were found in JAK2V617F positive patients compared to JAK2V617F negative patients. In our study, patients with ET had increased ROS levels. Cases with JAK2V617F mutation associated higher ROS levels compared to those without JAK2V617F mutation. In our future research, we will focus on the follow-up of these patients for a period of four years and we will try to observe if increased ROS levels enhanced genomic instability and transformation to acute myeloid leukemia.

Background: The evaluation of platelet count and platelet volume according to gestational age is limited. In hematological evaluation not only platelet (PLT) counts but also 3 important platelet volume parameters (mean platelet volume [MPV], platelet distribution width [PDW], plateletcrit [PCT]) are also taken into consideration.

Aims: We established the reference ranges of platelet and platelet index in Turkish preterm and term infants. Platelet counts, and platelet volumes continually change as gestational age increases. Increases in platelet counts, and PCT, while decreases in MPV and PDW were detected. The gestational age-related changes in PLT patterns may reflect maturation of platelet regulation.

Results: The study group comprised 398 preterm infants born between 26-37 gestational weeks, and 63 healthy term (38 gestational weeks) infants. Blood samples from all cases were obtained within the first hours after birth. Blood samples were placed into tubes with EDTA, and analyzed in ADVIA 120® (Japan) hematology analyzer using suitable kits. Data were expressed as mean±standard deviation. Platelet counts, and volume were indicated for each gestational week, and groups of 24-31, 32-36, 37, and 38 weeks. One-way analysis of variance (ANOVA) was used for statistical analysis, and p<0.05 was accepted as the level of statistical significance. We established the reference ranges of platelet and platelet index in Turkish preterm and term infants. Platelet counts, and platelet volumes continually change as gestational age increases. Increases in platelet counts, and PCT, while decreases in MPV and PDW were detected. The gestational age-related changes in PLT patterns may reflect maturation of platelet regulation.
Background: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction and suppressed platelet production. ITP may occur concurrently or precede the occurrence of SLE, which would have great diagnostic significance. ITP may also be the first early sign of the disease. Few studies have addressed the risk of systemic lupus erythematosus (SLE) after ITP.

Methods: All patients diagnosed with ITP and with a platelet count <100×10^9/L between September 2002 and January 2017 were included in the study. Patients were retrospectively reviewed for diagnosis of SLE, and inclusion criteria included only those patients who had initial ANA screen at the time of the first presentation of ITP. All patients with the diagnosis of SLE at the time and before the presentation of primary ITP were excluded from the study.

Results: This study included a total of 58 patients (43 females and 15 males) who were followed up for a period of 14 years. Their age at the baseline ranged from 16 to 65 years with a mean (SD) of 31.4 (13.3). ANA was positive in 11 (19.0%) patients. Over the period of follow up, 9 (15.5%) patients developed lupus. The incidence was 13.3% among males and 16.3% among females, with no significant difference (p-value=0.786). There was significant association between ANA and lupus in both genders. Only one patient with negative ANA and 81.8% of patients with positive ANA developed lupus (P<0.005).

Summary/Conclusions: SLE developed in patients with primary ITP in with initial positive ANA titer at presentation. The results suggest that patients with initial positive ANA are at risk for development SLE. Thus, follow up after primary ITP diagnosis with positive ANA titer is of great importance as the risk of SLE is significant.

PB2122
TREATMENT OF REFRACTORY IMMUNE THROMBOCYTOPENIA WITH THROMBOPOIETIN RECEPTOR AGONISTS: OUR EXPERIENCE IN CHILDHOOD

J. Zanabili Al-Sibai1, T. Arias Fernández1, M.P. Palomo Moraleda1, L.R. Morais Bras1, C. Castañón Fernández1, L.F. Ávila Idrón1, A. Solé Magdalena1, S. González Muñiz1, M.A. Fernandez Rodríguez1

1Hematology, HUCA, Oviedo, Spain

Background: Immune thrombocytopenia (ITP) is an autoimmune disease in which antibodies develop against platelets (plts) and dysregulation of cellular immunity result in premature destruction of plts and impaired plt production. For most affected children, ITP is a self-limiting disease. Approximately, 10% of plts require treatment.

Aims: To estimate the risk of SLE after ITP in adult Jordanian patients.

Methods: All patients diagnosed with ITP and with a platelet count <100×10^9/L between September 2002 and January 2017 were included in the study. Patients were retrospectively reviewed for diagnosis of SLE, and inclusion criteria included only those patients who had initial ANA screen at the time of the first presentation of ITP. All patients with the diagnosis of SLE at the time and before the presentation of primary ITP were excluded from the study.

Results: This study included a total of 58 patients (43 females and 15 males) who were followed up for a period of 14 years. Their age at the baseline ranged from 16 to 65 years with a mean (SD) of 31.4 (13.3). ANA was positive in 11 (19.0%) patients. Over the period of follow up, 9 (15.5%) patients developed lupus. The incidence was 13.3% among males and 16.3% among females, with no significant difference (p-value=0.786). There was significant association between ANA and lupus in both genders. Only one patient with negative ANA and 81.8% of patients with positive ANA developed lupus (P<0.005).

Summary/Conclusions: SLE developed in patients with primary ITP in with initial positive ANA titer at presentation. The results suggest that patients with initial positive ANA are at risk for development SLE. Thus, follow up after primary ITP diagnosis with positive ANA titer is of great importance as the risk of SLE is significant.

PB2123
INVESTIGATION OF PLATELET FUNCTIONS IN PSEUDOTHROMBOCYTOPENIA

B. Oncel1, S. Cėsu2, K. Oncel3, E. Calisken3, S. Cangur4

1Hematology, 2Internal Medicine, 3Medical Microbiology, 4Biostatistics, Duzce University Faculty Of Medicine, Duzce, Turkey

Background: Pseudothrombocytopenia (pseudoTCP), is incorrectly detection of low platelet counts in automatic blood counter devices and is most frequently caused by ethylene diamine teta-asetic acid (EDTA) induced platelet clumping and in vitro agglutination. Therefore, pseudoTCP which accounts 15-30 of thrombocytopenic admissions, actually is not associated with a bleeding tendency. Diagnosis may be detected with a careful investigation of peripheral blood smears (PBS) by experienced clinicians but in centers which does not have these facilities; misleading of worried patients through advanced centers could happen. The objective of this study was to compare the platelet function analyzer (PFA-100™) for all patients who are referred to our clinic as thrombocytopenia (TCP, plt <150 x10^3/µL) and 11 healthy controls (plt>150 x10^3/µL).

Methods: Platelet functions were measured as collagen-ADP and collagen-epinephrine closure times (ColADP and ColEPI) by Platelet Function Analyzer (PFA-200™) for all patients who are referred to our clinic as thrombocytopenia (TCP, plt <150 x10^3/µL) and 11 healthy controls (plt>150 x10^3/µL). Median age was 54 (IQR:37-68) for thrombocytopenic subjects and 37 (%63) of them were female. Median Plt count was 61 x10^3/µL (IQR:30-90) in TCP group but WBC and Hb were not different from control subjects. Subjects referred with TCP were grouped with PBS as pseudoTCP and real-TCP. There was no difference in terms of Plt, MPV, PCT, WBC and Hb between these groups but age was younger (median age 46 vs 62, p<0.05) and PDW was higher in pseudoTCP group (med 17.6 vs 16.8, p<0.01). ColEPI and ColADP measures were significantly lower (med 125 vs 287 for ColEPI, med 84 vs 224 for ColADP, p<0.001 for both) at pseudoTCP group. The capacity of ColEPI and ColADP values in predicting pseudoTCP were analyzed using ROC curve analysis. We found that, when the manufacturer’s recommended cut-off value (150 s) was used, the sensitivity and specificity were 74.4% and 95%, with overall accuracy of 81.4% for ColEPI (AUC 0.813, 95%CI: 0.684-0.933). Similarly sensitivity and specificity were 79.5%, and 95%, with overall accuracy of 84.7% for ColADP using manufacturer’s cut-off value of 100 s (AUC 0.878, SD:0.055, p<0.001, 95%CI: 0.770-0.986).

Summary/Conclusions: We concluded that, running PFA tests for everybody with thrombocytopenic counts, could be used for differentiation of pseudoTCP and realTCP in centers which does not have conditions for proper BS. Especially long close times excludes pseudoTCP with a high specificity and could make clinicians quick decisions for further investigations.

PB2124
FUNCTIONAL ADHESION MOLECULES (CAMs) AS MARKERS OF PSEUDOTHROMBOCYTOPENIA

B. Oncel1, 2, S. Cėsu, K. Oncel3, E. Calisken3, S. Cangur4

1Hematology, 2Internal Medicine, 3Medical Microbiology, 4Biostatistics, Duzce University Faculty Of Medicine, Duzce, Turkey

Background: Pseudothrombocytopenia (pseudoTCP), is incorrectly detection of low platelet counts in automatic blood counter devices and is most frequently caused by ethylene diamine teta-asetic acid (EDTA) induced platelet clumping and in vitro agglutination. Therefore, pseudoTCP which accounts 15-30 of thrombocytopenic admissions, actually is not associated with a bleeding tendency. Diagnosis may be detected with a careful investigation of peripheral blood smears (PBS) by experienced clinicians but in centers which does not have these facilities; misleading of worried patients through advanced centers could happen. The objective of this study was to compare the platelet function analyzer (PFA-100™) for all patients who are referred to our clinic as thrombocytopenia (TCP, plt <150 x10^3/µL) and 11 healthy controls (plt>150 x10^3/µL). Median age was 54 (IQR:37-68) for thrombocytopenic subjects and 37 (%63) of them were female. Median Plt count was 61 x10^3/µL (IQR:30-90) in TCP group but WBC and Hb were not different from control subjects. Subjects referred with TCP were grouped with PBS as pseudoTCP and real-TCP. There was no difference in terms of Plt, MPV, PCT, WBC and Hb between these groups but age was younger (median age 46 vs 62, p<0.05) and PDW was higher in pseudoTCP group (med 17.6 vs 16.8, p<0.01). ColEPI and ColADP measures were significantly lower (med 125 vs 287 for ColEPI, med 84 vs 224 for ColADP, p<0.001 for both) at pseudoTCP group. The capacity of ColEPI and ColADP values in predicting pseudoTCP were analyzed using ROC curve analysis. We found that, when the manufacturer’s recommended cut-off value (150 s) was used, the sensitivity and specificity were 74.4% and 95%, with overall accuracy of 81.4% for ColEPI (AUC 0.813, 95%CI: 0.684-0.933). Similarly sensitivity and specificity were 79.5%, and 95%, with overall accuracy of 84.7% for ColADP using manufacturer’s cut-off value of 100 s (AUC 0.878, SD:0.055, p<0.001, 95%CI: 0.770-0.986).

Summary/Conclusions: We concluded that, running PFA tests for everybody with thrombocytopenic counts, could be used for differentiation of pseudoTCP and realTCP in centers which does not have conditions for proper BS. Especially long close times excludes pseudoTCP with a high specificity and could make clinicians quick decisions for further investigations.
PB2124

MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA. SINGLE CENTER EXPERIENCE

C. Ionita1, I. Ionita1, D. Calamari-Popovici1, D. N. Oros1, M. Iordache1, M. Ionita1, I. Pascu1, M. Iftose1, H. Ionita1
1 UMF “Victor Babes” Timisoara, Timisoara, Romania

Background: The investigation and management of patients with Chronic immune thrombocytopenic purpura (ITP) varies widely. Although many treatments have been recommended for ITP, there are no evidence-based recommendations for when different treatments should be used, or when any treatment should be used rather than managing a patient by observation alone.

Aims: To evaluate the treatment of ITP patients in Department of Hematology, County Hospital, Timisoara.

Methods: A retrospective study for 350 ITP patients was performed. Patients demographics, medical history, current treatments and side effects, were abstracted from the patient’s medical charts for the 15 months prior to their most recent visit.

Results: The mean age was 45.6 years with 58% women and 42% men. Median time from the diagnosis of ITP to the start of the observational period was 23 months. Regardless of the presence of bleeding symptoms, for majority of patients we started treatment based on plateled count. Treatment was considered when platelet counts are less than 20x10^9/L in patients without bleeding, and less than 30x10^9/L in patients with bleeding. Prior to the observational period, 36% of patients had been splenectomized and the most reported treatment was corticosteroids. During the observational period, 72% of all patients were treated. The most frequent reasons given for treatment were platelet count (58%), followed by bleeding symptoms (42%). Corticosteroids represented 52% of treatments, followed by IVlg (20%), azathiprine (12%) rituximab and 8% IVIG. Splenectomies (8% of patients) and platelet transfusions (27% of patients) were performed during the observational period. In the patient survey, 52% of participants were 60 years of age or older and the duration of disease was more than 10 years in 43% of patients. The minimum platelet counts were less than 10x10^9/L in 49% of patients. The most common symptoms of ITP was fatigue (45%). Approximately 60% of patients reported at least one side effect associated with ITP treatment. The side effects were most frequently associated with corticosteroid use (43%). Overall, 40% of patients required hospitalization. Mean duration of hospitalization was 13.5 days.

Summary/Conclusions: The retrospective study of 350 patients provides the results of treatment practices in our country. It showed that bleeding symptoms remained quite frequent among patients with chronic ITP. Corticosteroids were the most widely used treatment.

PB2125

IMMUNOLOGICAL THROMBOCYTOPENIC PURPURA AND PREGNANCY: A RETROSPECTIVE STUDY OF 89 PREGNANCIES IN 59 PATIENTS

H. Brahimi1,*, S. Taoussi1, Z. Bouchetara1, K. Rekrouk1, M. T. Abad1
1 Hematology, EHS ELCC CAC, Blida, Algeria

Background: Immunological thrombocytopenic purpura (ITP) occurs for about 1 case for 1000 pregnancies. The risk of onset, aggravation or relapse of ITP during pregnancy is not clearly established.

Aims: The aim is to describe the prevailing ITP progression profile in pregnant women and to evaluate the risk of neonatal thrombocytopenia in two situations, when ITP was known before pregnancy and when ITP was discovered for the first time during pregnancy.

Methods: It is a retrospective study carried out in the hematology department of CAC Blida, Algeria, between 1993 and 2016. All patients (pts) who had a pre-pregnancy ITP or thrombocytopenia during pregnancy attached to an ITP were included.

Results: The development of 89 pregnancies (PG), including two twins, occurred in 59 women was analyzed. There were one PG in 40 pts, 2 PG: 13 pts, 3 PG: 5 cases, 4 PG: 1 case and 5 PG: 1 case. Of the 59 pts: in 42 cases it was a history of ITP before pregnancy (group 1: G1) with a history of splenectomy in 9 patients, and in 17 cases it was ITP discovered on the occasion of Pregnancy (group 2: G2). The average age at diagnosis=26.7 years (7-44) and that at delivery=30.4 years (19-44). The mean platelet count at diagnosis: G1: 34000 / µL, G2: 47000 / µL. In the first group (G1): At the beginning of pregnancy the ITP was chronic in 30 cases, newly diagnosed in 1 case, persistent in 2 cases and transient cured in 7 cases; treatments previously received were: corticosteroid therapy (n=34), splenectomy (n=9), Danazol (n=1), cyclosporine in 1 case and cyclophosphamide in 1 case, abstention in 7 pts, 2 of whom required corticosteroids during pregnancy. The status of the ITP at the beginning of each pregnancy was: out of treatment (n=8), corticosteroid dependence (n=5), non-response (n=7), PR (n=11), CR (n=24). In the second group (G2): the discovery of thrombocytopenia was in the first trimester (T) in 4 cases, in the second T in 6 cases and in the third T in 7 cases: 17 pts had platelet counts <80000 /µL and were included due to the persistence or even worsening and / or necessity to resort to treatment of thrombocytopenia after delivery. In both groups: in 26 pts (G1:16; G2: 10) variable dose and duration of treatment were required during pregnancy; at delivery, 19 patients needed a treatment, out of them, a bolus of corticosteroids (n=1) transfusion of platelets (n=4), immunoglobulins in 4 cases and transfusion of platelets alone in 4 cases. At birth, thrombocytopenia was observed in 40 pregnancies (50.6%): platelets <30000 / µL (n=7), between 31000 and 50000 /µL (n=13), between 51000 and 100000/µL (n=20), between 100000 and 150000/µL in 2 cases. All pregnancies were completed: 14 by caesarea section, one for thrombocytopenia, with an average platelet count=95000 / µL and 75 by natural delivery with a mean platelet count=100000 / µL with 4 deaths born, one anencephaly and 88 newborns. No hemorrhagic syndrome was observed in pregnancy; two postpartum hemorrhages were seen in G2 group. Eleven newborns (5 in G1 and 6 in G2) were thrombocytopenic with platelet count <20000/µL in 4 cases; between 20000 and 50000/µL in 7 cases; neonatal thrombocytopenia occurred during the first 7 days. Only 4 newborns were treated, one by corticosteroid and 3 by immunoglobulins, with a good progression and only one of the untreated is always followed for thrombocytopenia.

Summary/Conclusions: The de novo ITP appearing during pregnancy is an etiological eventuality to be evoked in front of a thrombocytopenia of the pregnant woman after elimination of the other causes related to the pregnancy and in front of the non-resolution after the delivery. The pre-existing ITP does not necessarily.
QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MULTIPLE MYELOMA

B. Sidi Mohamed El Amine,1 H. Asma,1 F. Ouzia,1 S.A. Najet1, C. Malkia1, Z. Naima1, Z. Zahia1

1Hematology department, University hospital of Sidi Bel Abbès, Sidi Bel Abbès, Algeria

Background: Multiple myeloma (MM), the second most common hematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known about health-related quality of life (QoL) of patients with MM.

Aims: This study aimed to (1) Determine symptom prevalence in patients with MM on disease-modifying treatment, and identify the range and nature of these symptoms within the dimensions of physical, psychological, social well-being. (2) Measure the QoL of patients. (3) Compare the above-mentioned parameters to the general population.

Methods: Adults with multiple myeloma attending the hematology day unit in hematology department from November 2016 to January 2017 were eligible for inclusion in a cross-sectional. Consenting patients completed 2 validated questionnaires: 1) the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplement-ed by the myeloma-specific module (EORTC QLQ-MY20).

Results: Forty-seven patients were included for analysis: 51, 1% were male and 48.9% were female. Mean age was 64.7 years (range 42-82, standard deviation 11.3). The QoL scores were significantly lower than the general population (54.7 vs 71.2). The most commonly reported physical symptoms were pain (72%), fatigue (70%) and insomnia (66%). About 61% of the patients were burdened by financial worries. On multivariate analysis, a good performance status (PS≤1) and a response of the disease to therapy (at least a partial response) were associated with high scores of QoL (P=0.01, P=0.03 respectively).

Summary/Conclusions: Patients with MM have a lower QoL than the general population and are symptomatic across physical, psychological and financial domains. They represent a polysymptomatic patient cohort with a complexity of need that merits a holistic multidisciplinary approach, and consideration of specialist symptomatic or palliative care review.

QUALITY OF LIFE IN ANEMIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

N. Romanenkov,1 S. Bessmeltsev1, A. Romanenkov2, N. Potikhonova1, M. Zenina1

1Clinical Hematology, Russian Research Institute of Hematology and Transfusiology, 2Neurology, Children Hospital of St. Olga, Sankt-Peterburg, Russian Federation

Background: Anemia is a common complication of patients with hematological malignancies (HM), which may progress undergoing antitumor treatment significantly decreasing hemoglobin concentration and occur symptoms as fatigue, dizziness, palpitations, dyspnea markedly reduce patient activity, resulting in impaired Quality of Life (QoL).

Aims: To compare of QoL in HM's patients with different grades of anemia.

Methods: In this study were included following patients (n=326) in the age of 19-82 (Me=65) years: myelodysplastic syndrome (n=37), acute myeloid leukemia (n=20), acute lymphoid leukemia (n=7), primary myelofibrosis (n=23), chronic myeloid leukemia in blast crisis (n=6), multiple myeloma in I and III st. (n=128), Non-Hodgkin's lymphoma in III IV st. (n=40) and chronic lympho-cytic leukemia in B or C st. (n=67). Patients were examined: 1) clinical blood test (hemoglobin concentration) to assess anemia's grade; 2) the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale to measure of QoL. The FACT-An questionnaire consists of a general questionnaire (FACT-G), measuring domains of physical well-being (PW), social/family well-being (SF), emotional well-being (EW), functional well-being (FW), anemia-specific questionnaire – Anemia subscale (AnS), measuring fatigue-associated items – Fatigue subscale (FS) and non-fatigue-associated items – Non-Fatigue subscale (NFS). Patients were divided into six groups according to the Hb concentration: 1) the first group – Hb was 4.0-6.4 g/dl (Me=5.7 g/dl); 2) the second – Hb 6.5-7.9 g/dl (Me=7.2 g/dl); the third – Hb 8.0-9.4 g/dl (Me=8.6 g/dl); the forth – Hb 9.5-10.9 g/dl (Me=10.8 g/dl); the fifth – Hb 11.0-11.9 g/dl (Me=11.4 g/dl); the sixth – Hb 12.0-14.4 g/dl (Me=13.0 g/dl). The sixth group was control.

Results: In the first group of patients (n=34) with severe anemia grade 4 QoL was revealed too poor; number of points in the subscale of PW was 14.0±0.9, in SF/W – 14.2±0.7, EW – 10.3±0.9, FW – 18.5±2.0, AnS – 41.2±1.6, FS – 27.8±1.3, NFS – 13.4±0.6. In the second group of patients (n=53) with anemia grade 3 QoL was poor too; in PW – 13.3±0.8, in SF/W – 14.4±0.6, EW – 9.9±0.7, FW – 18.2±0.6, AnS – 38.5±2.3, FS – 26.8±1.7, NFS – 12.0±0.7. In the third group of patients (n=72) with anemia grade 2 QoL in the subscale of PW was 11.5±0.7, in SF/W – 14.0±0.5, EW – 8.6±0.6, FW – 16.9±0.5, AnS – 36.1±1.9, FS – 25.5±1.4, NFS – 11.6±0.6. In the forth group of patients (n=70) with anemia grade 1 QoL in the subscale of PW was 11.3±0.7, in SF/W – 14.3±0.6, EW – 6.4±0.8, FW – 16.0±0.7, AnS – 34.7±1.6, FS – 23.7±1.0, NFS – 11.7±0.6. In the fifth group of patients (n=41) with anemia grade 0 QoL in PW was 11.1±0.9, in SF/W – 14.9±0.8, EW – 7.6±0.6, FW – 16.4±0.5, AnS – 34.6±2.2, FS – 23.7±1.6, NFS – 10.9±1.7. In the sixth group of patients (n=56) without anemia QoL in the subscale of PW was 11.7±0.7, in SF/W – 13.6±0.6, EW – 6.4±0.5, FW – 14.8±0.7, AnS – 23.4±1.5, FS – 14.9±1.0, NFS – 8.4±1.6.

Summary/Conclusions: QoL was found too poor in patients with Hb <8.0 g/dl. QoL wasn’t satisfactory in patients with Hb 8.0-11.0 g/dl. But the QoL improvement were greater in patients with Hb levels >11.0-12.0 g/dl (p<0.05). These data suggest that early correct anemia with red blood sells transfusions and erythropoiesis-stimulating agents can improve QoL in a clinically meaningful way.
Summary/Conclusions: The exercise shows that using local input changes the number of patients potentially influenced by local evaluations related to the access for LMWH treatment for CAT. Tinzaparin was found to be a cost effective LMWH over VKA in 6 European Countries as well as in Canada, when local medication costs were used. This was in contrast to the conclusion in the US. Not using localized or regionalized cost inputs could potentially lead to misinterpretations about cost effectiveness of CAT treatments.

PB2129
MINIMIZING THE RISK OF MUCOSITIS IN HEMATOLOGIC PATIENTS WITH TOPICAL PRODUCTS
I. Ursuleac1*, Z. Varady1, A. Enache1, A. A. Tomescu2, R. Dragun2, D. Coru1
1Hematology, 2Fundeni Clinical Institute, Bucharest, Romania

Background: Mucositis is a frequent severe complication associated to aggressive therapies of hematological malignancies with chemotherapeutic drugs and radiation (therapy), conditioning therapy in stem cell transplants. Regularly occurs at 3 to 10 days after chemotherapy and about 6 to 8 weeks after radiotherapy. It is self-limited within 2-4 weeks, but in some cases the patient is vulnerable to systemic infections (bacterial and fungal). It could also compromise the optimal timing and dosage of the chemotherapy schedule, induce psychosocial distress, prolong hospitalization and finally, higher costs.

Aims: Evaluating the efficacy of Gel X® in chemotherapy induced mucositis. GelX® is a topical product that contains Zinc gluconate-taurine, with bacteriostatic and anti-inflammatory effecy, easy to use for the patient, in order to prevent and reduce pain and severity of oral ulcers, making a barrier for mucositis.

Methods: A retrospective analysis of 77 adult patients: 17 with hematological treatments and 60 with allelogeneic stem cell transplantation. 17 were diagnosed and treated between January 2015 and December 2016 with various hematological malignancies (5 AML, 2 ALL – 1 Ph positive, 2 blastic phases of CML, 3 AILT (CHOP/DA-EPOCH), 2 DLBCL (RCHOP), 1 FL (RCPV), 1 MM (radiotherapy), 1 Hodgkin disease (ABVD). Treatment regimens used for acute leukemias/blastic phases of CML were: 3+7 (3 cases), MEC (1 case), high doses ARA-C (1), GMALL protocol (1), HyperCVAD (1), Idarubicine and APA-C(1) HD-MTX(1) GelX® was indicated as prophylactic treatment for eight patients, because the risk of mucositis was high (aggressive chemotherapy, bad oral condition, risk of prolonged neutropenia). Curative treatment of grade 3-4 mucositis was indicated for 10 patients (one was initially treated with curative intention and after that with prophylactic treatment). In 60 patients (59 hematological malignancies, 1 unrelated, 4 haplo and 21 sibling) GelX® was prescribed for treating grade 3-4 mucositis. For the 35 cases with unrelated allograft transplant (21 AML, 4 ALL, 2 SA, 2ATLL, 2 MMM, 2 CML, 1 MDS, 1 BH), 16 cases of grade 3-4 mucositis has appeared. The conditioning regimen was mieloablative (14 cases) and reduced intensity (21 cases). There were 21 cases of sibling allografts (SAML, 3 ALL, 1 ATLL, 5 LMH, 1 CLL, 2 SAA, 2 CML, 1 mycosis) with 10 cases of mucositis grade 3-4. The regimens used were 6 mieloablative and 15 nonmieloablative. 3 from 4 cases of haplo-transplant with nonmieloablative conditioning (2MDs, 1 AML and 1 SAA) had grade 3 mucosis.

Results: GelX® induced a reduction in the grading of mucositis (grad 1-2) and a shorter period of evolution (5 days) versus grade 3-4 mucositis and prolonged duration of oral lesions for those with curative treatment. From 60 patients allografted, 30 patients experienced grade 3 and 4 mucositis with a medium duration of five days. All of them received GelX® as prophylactic treatment.

Summary/Conclusions: Prophylaxis is the key of successful evolution in mucositis (time to heal shorter than 10 days). Identifying candidates for mucositis is mandatory and the product should be applied starting with the chemotherapy (or in the first 24 hours on the onset of chemotherapy) in order to minimize the risk of mucositis appearance.

PB2130
EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK IN RARE HEMATOLOGICAL DISEASES
M.D.M. Mahu Pereira1*, V. Gutierrez Valle1, J.L. Vives Corrons1, B. Gubius2, P. Giralt2, B. Balak2
1Red Blood Cell Pathology and hematopoietic defects Unit, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, 2Laboratoire Hospitalier Universitaire de Bruxelles - ULB, Brussels, Belgium, 3Service d’Hématologie Séniors, Hôpital Saint-Louis - Université Paris, Paris, France

Background: Almost all hematological disorders are rare diseases, affecting less than 1 in 2000 individuals, justifying their inclusion in a European Reference Network (ERN). ERN are networks created following the Directive 2011/24/EU on cross border health care, which include nationally recognized Centers of Expertise aiming to ensure the same level of access to health services of patients with rare diseases. As a result, by a rare disease network created within the ERN on Rare Hematological Diseases (RHD), from a joint effort of the European Network on Rare and Congenital Anaemias (ENERCA), the European Hematology Association (EHA), and European hematology patient organisations represented in both the EURORDIS European Patient Advocacy Groups (ePAGS) and the EHA Patient Organisations Workgroup. EuroBloodNet gathers 66 highly skilled and multidisciplinary healthcare teams in 15 Member States, and advanced specialized medical equipment and infrastructures which will facilitate concentration of resources for the design, validation and implementation of high-quality and cost-effective services aimed at facing the challenges of RHD. Aims: To improve EuroBloodNet’s mission to improve the healthcare for RHD patients, to promote guidelines and best practice, to improve training and education of healthcare providers, to improve access for LMWH treatment for CAT. Tinzaparin was found to be a cost effective approach as it can be easily used for the patient, in order to prevent and reduce pain and severity of oral ulcers, making a barrier for mucositis.

Methods: ERN are networks created following the Directive 2011/24/EU on cross border health care, which include nationally recognized Centers of Expertise aiming to ensure the same level of access to health services of patients with rare diseases. As a result, by a rare disease network created within the ERN on Rare Hematological Diseases (RHD), from a joint effort of the European Network on Rare and Congenital Anaemias (ENERCA), the European Hematology Association (EHA), and European hematology patient organisations represented in both the EURORDIS European Patient Advocacy Groups (ePAGS) and the EHA Patient Organisations Workgroup. EuroBloodNet gathers 66 highly skilled and multidisciplinary healthcare teams in 15 Member States, and advanced specialized medical equipment and infrastructures which will facilitate concentration of resources for the design, validation and implementation of high-quality and cost-effective services aimed at facing the challenges of RHD. Aims: To improve EuroBloodNet’s mission to improve the healthcare for RHD patients, to promote guidelines and best practice, to improve training and education of healthcare providers, to improve access for LMWH treatment for CAT. Tinzaparin was found to be a cost effective approach as it can be easily used for the patient, in order to prevent and reduce pain and severity of oral ulcers, making a barrier for mucositis.

Results: Tinzaparin was found to be a cost effective approach as it can be easily used for the patient, in order to prevent and reduce pain and severity of oral ulcers, making a barrier for mucositis.

Summary/Conclusions: The exercise shows that using local input changes the number of patients potentially influenced by local evaluations related to the access for LMWH treatment for CAT. Tinzaparin was found to be a cost effective LMWH over VKA in 6 European Countries as well as in Canada, when local medication costs were used. This was in contrast to the conclusion in the US. Not using localized or regionalized cost inputs could potentially lead to misinterpretations about cost effectiveness of CAT treatments.

PB2131
2016 REVISION OF WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOETIC AND LYMPHOID TISSUES: IMPACT ON INVESTIGATING PATIENTS WITH ISAEMIC STROKE
C. Philip1*, J.D. Pandian2, M.J. John1, P.N. Sylaja3, A. Mathew1, S. Kaul4, D. Khurana5, M. Padma6, D. Arora2, A. Singh6
1Clinical Haematology, 2Neurology, Christian Medical College & Hospital, Ludhiana, 3Neurology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, 4Neurology, Nizam’s Institute of Medical Sciences, Hyderabad, 5Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, 6Neurology, All India Institute of Medical Sciences, New Delhi, India, 7Neurology, Massachusetts General Hospital, Boston, United States

Background: Under diagnosis related to the earlier hemoglobin (Hb) or hematocrit (Hct) diagnostic criterion is one reason to the 2016 revision of the diagnosis of PV in the World Health Organization (WHO) classification of Tumours of Haematopoietic and Lymphoid Tissues. Bone Marrow Biopsy (BM) and molecular markers (JAK2) are recommended to establish the diagnosis in those with the lower threshold(Arber DA et al,2016). This potentially could result in increased numbers and costs of investigations. The lower thresholds are aimed to identify those previously referred to as masked PV (mPV) who have been recognized to have an increased cost of investigations. The lower thresholds are aimed to identify those previously referred to as masked PV (mPV) who have been recognized to have an increased cost of investigations. The lower thresholds are aimed to identify those previously referred to as masked PV (mPV) who have been recognized to have an increased cost of investigations. The lower thresholds are aimed to identify those previously referred to as masked PV (mPV) who have been recognized to have an increased cost of investigations. The lower thresholds are aimed to identify those previously referred to as masked PV (mPV) who have been recognized to have an increased cost of investigations.

Aims: To determine number of patients with young strokes with potential PV application of the 2016 revised WHO criteria for PV. Methods: We undertook an analysis of records of patients with ischemic stroke from participating sites in the Indo-US Stroke Registry and Infrastructure Development Project. This registry enrolled adult patients admitted with imaging-confirmed ischemic stroke <2 weeks after symptom onset. The Indo-US Stroke Registry and Infrastructure Development Project, includes 5 geographically diverse centers in India and one in USA. The registry data was entered into a web-based electronic database. From January, 2012 to March, 2014, 2076 patients with new onset ischemic stroke were evaluated in the Indian arm of the Indo-US Stroke Registry. We compared the incidence of polycythemia as per the 2016 revision against the earlier (2008) Hb diagnostic criterion.

Results: There were 24 (1.2%) patients with potential PV which was revised to 33 (1.6%) patients with PV following the 2016 criterion. The McNemar test determined that there was a statistically significant difference in the proportion of polycythemics, p= 0.000. Considering the potential of comorbidities in the elderly to confound the association of polycythemia with Ischaemic stroke, we...
Madrid, Spain, June 22 – 25, 2017
separately analyzed only those with young stroke (Age <45). In this cohort
there were 420 patients. A total of 6 (1.4%) patients had potential PV based on
the 2008 Hb criteria. On applying the 2016 revision; 37 (8.8%) patients fulfilled
the Hb criteria. An exact McNemar’s test determined that there was a statistically significant difference in the proportion of polycythemics, p=.000. Separate
analyses by gender was not significant in females, P=0.5; but significant in
males, p=.000. There were an additional 29 males with the revised criteria for
polycythemia. The impact of cost in influencing treatment decision from
resource limited countries with predominant out of pocket health expenditure
has been earlier reported (Philip C et al, 2015). This revision promotes the routine use of BM and JAK-2. In our analysis we estimate this new criterion would
add to the costs to each patient ( 7000 per our centre estimate).
Summary/Conclusions: The present data shows that there exists a significant
difference in the incidence of polycythemia in thrombosis (Ischaemic Stroke) on
applying the revised criteria. The requirement to additionally investigate them
with BM and molecular markers for PV has potential economic implications.
PB2132

PATHOPHYSIOLOGICAL MECHANISMS INVOLVED IN THE
DEVELOPMENT OF ANEMIA IN PATIENTS WITH NON-HODGKIN’S
LYMPHOMA
M.-A. Gaman1,*, A. Papoi2, A. M. Gaman3,4
1”Carol Davila” University of Medicine and Pharmacy, Bucharest, Bucharest,
2University of Medicine and Pharmacy of Craiova, 3Hematology, Filantropia
City Hospital, 4Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Background: Non-Hodkin’s lymphomas (NHL) are a group of heterogenous
malignant lymphoid disorders that associate anemia either from diagnosis or
during the evolution of the disease. The anemic syndrome can be present at
the moment of diagnosis or can develop during the evolution of non-Hodgkin’s
lymphomas, with negative effects on the therapeutic regimen due to reduction
of intensity and density of drug doses, overall survival and quality of life of these
patients. Various pathophysiological mechanisms responsible for the development of anemia are depicted in literature: pro-inflammatory cytokines and hepcidin action on iron metabolism and erythropoiesis, bone marrow failure caused
by infiltration of malignant lymphomatous cells, cytopenias secondary to
chemotherapy, immune peripheral destruction of red blood cells, iron and folate
deficiency due to chronic bleeding.
Aims: To evaluate the prevalence of anemic syndrome in patients with nonHodgkin’s lymphomas and the pathophysiological mechanisms involved in the
development of anemia.
Methods: A retrospective study was conducted on 85 patients (informed consent obtained) with non-Hodgkin’s lymphoma, who were admitted to the Clinic
of Hematology, Filantropia City Hospital, Craiova, Romania, in between 2013
and 2015, in order to evaluate the prevalence and pathophysiological mechanisms involved in the development of anemia in this study group.
Results: In our study group, the median age at diagnosis of non-Hodgkin’s lymphoma was 64 years, sex distribution was males:females=1,3, and the rural to
urban area index=1,2. 85,88% of patients had B type NHL and 14,12% T type
NHL. 20% of NHL were indolent lymphomas, aggressive lymphomas in 54% cases and very aggressive lymphomas in 26%. NHL repartition on stage of disease
revealed: type I – 2.35%, type II – 18.81%, type III – 57.64%, and type IV –
21.16%. In our study group, 84% of patients enrolled had anemia, with the anemic
syndrome affecting the 50-59 years and 70-79 years age groups. 59.73% of
patients had anemia at diagnosis and 40.27% of patients developed anemia during the evolution of NHL. The pathophysiological mechanisms involved in the
development of anemia were: perturbations of iron metabolism and erythropoiesis
under pro-inflammatory cytokines and hepcidin actions (47.25%), bone marrow
failure induced by lymphomatous infiltration (25%), anemia induced by
chemotherapy (18.05%), and autoimmune hemolysis (9.7%). Five patients with
anemia induced by chemotherapy and three patients with lymphomatous infiltration of the bone marrow also associated iron and/or folate deficiency.
Summary/Conclusions: In our study, anemia was present in 84% of NHL cases, more frequently found in patients that associated comorbidities and
belonged to the 50-60 years and 70-80 years age groups. In half of the cases,
anemia was moderately severe. 47.25% of patients had simple chronic anemia
due to perturbations of the iron metabolism and of erythropoiesis, and 25% of
patients presented anemia due to bone marrow failure. Chemotherapy lead to
an anemic syndrome in 18.05% of cases, whereas hemolysis of autoimmune
cause was responsible for 9.7% of cases of anemia diagnosed. The management of anemia is extremely important in patients with NHL because it influences the administration of chemotherapy (dose intensity and density), prognosis and quality of life.
PB2133

SAFETY OF RITUXIMAB BIOSIMILAR (NOVEX®) IN THE ROUTINE USE
TREATMENT IN ARGENTINA.
G. Milone1,*, M. I. Penna2, F. Fernandez2, E. Spitzer2, S. Millan3, S. Mariani3,
N. Español3, R. Gomez2

1Hematología, Centro Médico Hematológico, 2Laboratorio Elea, Buenos Aires,
Argentina, 3Mabxience, Madrid, Spain

Background: Novex® is a biosimilar by design of the reference product
Mabthera®/Rituxan®. Novex® was approved in Argentina following ANMAT’s
Biosimilar guidelines, having the same indications as the reference product,
and is commercialized by Laboratorio Elea. As part of its Risk Management
Plan (RMP), Laboratorio Elea implements an active pharmacovigilance program
as defined in Argentina regulation. Periodically reports ANMAT RMP status and
results.
Aims: To describe frequency and pattern of adverse events during the use of
NOVEX® in treatments registered along an active pharmacovigilance program
in order to oversee the safety profile of NOVEX® in the real clinical practice
and maintain the benefit-risk evaluation.
Methods: A treatment Registry for NOVEX® was implemented from the beginning of NOVEX® commercialization as part of the RMP. The Data Lock Point
for this report is Jan 31st, 2017. Physicians prescribing NOVEX® were requested to fill a form indicating age and gender, treatment start date, treated pathology, dosing and dose frequency. Such data was recorded in a database. After
a preset time, physicians were contacted by Laboratorio Elea to ask them about
the treatment outcome and Adverse Event occurrences. If adverse events were
detected they reported each occurrence as Individual Case Safety Report
(ICSR), they were registered using the MedDRA dictionary (version 19.1) for
its codification.
Results: The total number of participating physicians was 151. During this period,
they reported 638 treatment initiations, 389 of which had at least 1 follow up point
and were included in further analysis. 53% male. Mean age 64.1 years. Hematological indications were more than 90%. More than 90% of indications were
approved indications. Nevertheless, we detected off-label use. Total cycles
received for any approved indication had a mean number of 5.7. Total received
Individual Case Safety Reports were 17, indicating a relative frequency of 4.4%
of Individual Case Safety Report. Occurrence rates were 1.2 Individual Case
Safety Report per 100 administered cycles, and 0.020 per 100 treatment days.
Eleven Individual Case Safety Reports were classified as serious (SAE) because
they had at least one manifestation that prolonged hospitalization, endangered
life or was death-associated. The most frequent AE reported was acute reaction
related to infusion (9 cases), followed by cardiovascular manifestations (2 arrhythmia, 1 cardiac failure and 1 ischemic stroke), infections (1 pneumonia, 1 progressive multifocal leukoencephalopathy), neurologic (1 paresthesia), cytopenias
(1 pancytopenia) and cutaneous (1 bullous dermatitis).
Summary/Conclusions: The activities developed under this active pharmacovigilance program showed great value allowing us not only to monitor the
adverse event pattern but also to detect off-label use as part of real life treatments. This report showed a similar safety profile to that of the reference product
concluding that NOVEX®, in terms of tolerability, is similar to the reference
product. Pharmacovigilance is cornerstone in the development of biologicals,
especially biosimilars, as a tool to assist in the knowledge about their safety
profile.
PB2134

DEPRESSION AS THE PRESENTING SYMPTOM OF CENTRAL NERVOUS
SYSTEM LYMPHOMAS IN NORTHWESTERN TURKEY
E.G. Umit1,*, D.B. Esen1, M. Baysal1, A.M. Demir1
1Hematology, Trakya University Faculty of Medicine, Edirne, Turkey

Background: PCNSL represents approximately 4 percent of newly diagnosed
primary central nervous system (CNS) tumors, with an age-adjusted incidence
rate of four cases per million persons per year. Most cases of non-AIDS related
PCNSL are diagnosed in patients between 45 and 65 years of age, with a median age at diagnosis in the fifth decade. The most notable risk factor for the
development of PCNSL is immunodeficiency including HIV infection, iatrogenic
immune suppression, and congenital immune deficiencies. Antecedent flu-like
or gastrointestinal illnesses or a history of autoimmune diseases were reported.
Presenting symptoms may include focal neurologic deficits, neurophyschiatric
symptoms, signs of increased intracranial pressure, seizures or ocular symptoms. Neurophyschiatric symptoms like depression, apathy, psychosis, confusion, memory impairment, slowness of thought are generally undernoticed or
underestimated due to the increased rates of depression and tendancy towards
antidepressant use. Diagnosis is based on imaging of the central nervous system (CNS), ideally with contrast-enhanced magnetic resonance imaging (MRI),
cerebrospinal fluid (CSF) analysis, unless contraindicated due to elevated
intracranial pressure The radiographic lesion tends to be a solitary non-hemorrhagic mass, situated in the deep white matter adjacent to the ventricular
surface.
Aims: We aimed to evaluate the presence of depression and antidepressant
use before the diagnosis of CNS lymphoma and emphasize the duration
between the diagnosis of depression and lymphoma.
Methods: Data of 40 patients with CNS lymphoma were evaluated in a retrospective manner. From their national health records, prescription for antidepressant and anxiolytic drugs with their psychiatric diagnosis, time before the diagnosis
of CNS lymphoma, the branch of the prescribing physician, presenting symptoms

haematologica | 2017; 102(s2) | 845


from their medical files, type and treatment of lymphoma and survival were recorded. OECD international statistics as well as Turkish Statistical Institute data for national antidepressant use were collected and interpreted.

Results: Of the 40 patients, 14 were male (35%) while 26 were male (65%). Mean age was 60.5 years (38-78), 7 patients were alive (17.5%). Method for diagnosis was radiological imaging (magnetic resonance imaging) in 27 patients (67.5%) while in 13 patients, diagnosis was supported with histopathological confirmation (32.5%). Mean survival was 8.6 months (2-24 months). As the complaint for medical help seeking, 4 patients presented with neurophysiologic symptoms while 16 patients presented with headache (40%) and 20 patients (50%) presented with neurologic defects. On the other hand, prior to lymphoma diagnosis, 7 patients were diagnosed as anxiety disorder and 13 as depression (total, 19 patients, 47.5%) and were prescribed antidepressant and anxiolytic medications. The mean duration between prescription of antidepressants and diagnosis of lymphoma was 2.6 months (0-10 months). Within the patients who were on antidepressants, 6 were female and 14 were male.

Summary/Conclusions: OECD Health at a Glance data revealed that in 2013, the defined dose per 1000 per day is 35, range of Europe is 21-88. According to our data of Ministry of Health, use of antidepressants in the general population is 10.52%, mostly in women. Within these patients, 42.37% were anxiety disorders and 22.99% were depression. In the last five years’ statistics, 30% of our population was prescribed for an antidepressant. The major group of physicians prescribing these medications was family and general physicians (>45%). The most striking finding of our study was the majority of male patients receiving antidepressants before the diagnosis of CNS lymphoma with a mean delay of diagnosis as 2.6 months (0-10 months). Depression and anxiety disorders are the leading causes of disability and the importance of organic and underlying conditions should not be underestimated relying on the increasing need of antidepressants.

PB2135

IMPACT OF U.S. FDA APPROVAL OF LENALIDOMIDE MAINTENANCE THERAPY IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION ON TOTAL HEALTHCARE COSTS

K. Parikh1, J. Xie2, C. Chen3, C. Yang4, A. Farrukh5, P. Cockrum1, A.B. Agarwal1, S. Abouzaid1

1Corning Corporation, Summit, NJ, 2Analysis Group, Inc, Los Angeles, CA, 3Analysis Group, Inc, Boston, 4Analysis Group, Inc, Boston, MA, 5Analysis Group, Inc., Los Angeles, CA, United States

Background: Lenalidomide maintenance therapy after autologous hematopoietic stem cell transplant (auto-HSCT) in the first-line treatment has been shown to improve progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM) patients.

Aims: This study assessed the budget impact of the United States (U.S.) Food and Drug Administration (FDA) approval of lenalidomide maintenance therapy on total healthcare costs of a U.S. health plan.

Methods: An economic model was developed to estimate the incremental (additional) total plan costs (in 2016 USD) of maintenance therapy in each year for the first 3 years after lenalidomide monotherapy (R) maintenance therapy approval. The number of post auto-HSCT adult MM pts eligible for initiating maintenance therapy was estimated from published epidemiological data and an analysis of Connect® MM Registry data. Clinical endpoints for R-maintenance, including time on treatment, PFS and OS, were obtained from a meta-analysis of published clinical trials (CALGB, IFM, and GIMEMA). The use of common off-label maintenance therapies was considered. Types of costs included in the model were drug, drug administration, adverse events (AE), AE monitoring, one-time progression and terminal care costs.

Results: In a hypothetical U.S. health plan with 1 million members, the number of adult MM pts eligible to initiate post-ASCT maintenance therapy was estimated to be 28. Among them, 14.8 pts initiated R-maintenance in Year 1, 15.2 in Year 2, and 15.3 in Year 3, representing an incremental increase of 2.9%, 4.2% and 4.4% after R-maintenance therapy approval, respectively. After considering additional costs of maintenance, as well as potential offsets resulting from delayed progression the incremental total healthcare costs by year are listed in the Table. Results were consistent across all total plan, per patient per year, and per member per month costs. Deterministic sensitivity analysis showed that the model results were robust to the variations of key model inputs.

Table 1.

Summary/Conclusions: Approval of lenalidomide monotherapy for maintenance after auto-HSCT in the first-line treatment of MM has minimal impact on total plan costs, primarily due to the small incident population and the already common use of lenalidomide in post auto-HSCT maintenance.

PB2136

LAPAROSCOPIC APPROACH CAN EXTEND THE INDICATIONS OF SPLENECTOMY: ANALYSIS OF 31 CONSECUTIVE PATIENTS WITH MALIGNANT HEMOPATHIES

A. Salaroli1,2, B. Cadere2, C. Spillebout1, M. Vercruyssem1, A. de Wind3, M. Maerevel1, G. Dapri1, G. B. Cadere1, D. Bron1

1Department of Hematology, Institut Jules Bordet, ULB, 2Department of Digestive Surgery, Hôpital St Pierre, 3Department of Pathology, Institut Jules Bordet, ULB, Brussels, Belgium

Background: Surgical resection of large spleens may eliminate a significant amount of tumor, allow definite diagnosis of malignant disorder, ameliorate abdominal symptoms and resolve cytopenia. However, because of short term perioperative events (25%) and long term immunosuppression (increased risk of infections caused by encapsulated bacteria) physicians can be reluctant to choose splenectomy, especially in older patients or patients with comorbidities. The role of laparoscopic splenectomy (LS) in patients with hematologic malignancies is still unclear. Nevertheless, the ageing of the world’s population and the increased incidence of Non-Hodgkin’s Lymphoma are increasing the indications for splenectomy, requiring a well-tolerated and less invasive procedure.

Aims: The aim of this review is to analyze our single-center experience of LS performed for malignant Hemopathies. Results are compared with LS for benign splenomegaly and the risk of locoregional dissemination or inadequacy of fragmented histological sample were analyzed.

Methods: We retrospectively analyzed 50 patients who underwent LS between 2005 and 2016 at Saint-Pierre Hospital. Any splenectomy was used in 12 patients whereas in the remaining 38 cases, a semi-lateral position was chosen. All the patients received the triple vaccination (Streptococcus pneumoniae, type B Haemophilus influenzae, and Neisseria meningitidis). Patients characteristics, safety data such as early (<30 days) and late (>30 days) morbidities and mortality and efficacy (hematologic recovery, accuracy of histological diagnosis) were analyzed.

Results: 19 patients underwent splenectomy for benign hemopathies (SBH) and 31 patients for malignant hemopathies (SMH). Non-Hodgkin’s lymphomas (12) and idiopathic myelofibrosis (10) were the most common causes of splenectomy followed by chronic lymphocytic leukemia (7), hairy cell leukemia (1) and hodgkin’s lymphoma (1). Patients’ age (67 +/- 12 years, ranging from 36 to 87 in SMH, and from 11 to 71 in SBH), prior abdominal surgery (18/31) and spleen volume (1515 +/- 662 mL, ranging from 220 to 3000 mL in SMH, and from 90 to 1500 mL in SBH) were significantly higher in the SMH group (p <0.05). There was no significant difference in surgical time (150 vs 146 min, p=0.8), blood losses (243 vs 402 mL, p=0.26) and duration of hospitalization (5.4 vs 7.5 days, p=0.19) between SMH and SBH. No case of locoregional dissemination was experienced. The early morbidity of the SBH group was 10% and 13% for the SMH group (p=1). Late morbidity was 0% in the SBH group and 13% in the SMH group (p=0.26). This could be explained by a combination of underlying disease and immunosuppression (2 sepsis and 2 deep vein thrombosis). There was one conversion to open surgery and perioperative mortality in each group (p=1). There was no significant difference in efficacy of splenectomy, with respectively 83% and 79% (p=0.91) or quality of histological sample for pathologic report of SBH and SMH. In the SMH group out of 31 patients received a pre-surgical corticosteroid treatment, with a pre-surgical platelets level of 156 +/- 108 x 10^3 /ml, white blood cell level of 15696 +/- 18950 /ml and Hemoglobin level of 10.1 +/- 1.6 g/dL. Regarding the efficacy of LS in correcting hypersplenism in the SMH, a significant difference in term of platelets recovery after 1 month from the surgery was shown in patients efficiently Vs inefficiently operated (respectively 387 +/- 125 Vs 138 +/- 90 x 10^3 /ml, p <0.05). The median follow up is 39 +/- 37 months and 80% achieved a hematological recovery.

Summary/Conclusions: LS is a safe and less-invasive procedure in patients affected by Malignant Hemopathies. This approach is also well tolerated in older patients (median 67yrs) and in patients with large spleen (1515 +/- 660 ml), extending the indication for laparoscopic SHM even in older patient and in patients with high volume spleen. Compared to historical data, LSy for Malignant Hemopathies shows better early and late morbidities. Our data shows however a trend for higher late morbidity in the SMH group, warranting a careful long term follow-up in this subset of patients.

PB2137

ARE WE AWARE OF ANXIETY AND DEPRESSION IN PATIENTS WITH NEWLY DIAGNOSED ACUTE LEUKEMIA?

M.H. Dogu1,*, R. Eren1, N. Nizam2, O. Yokus1, E. Suyan1

1Hematology, Internal Medicine, Istanbul Education Research Hospital, Istanbul, Turkey

Background: Acute leukemia poses a high risk of stress for the patient during the process of diagnosis. The process after the diagnosis is challenging for the
Background: Three years ago, a unit for autologous bone marrow transplant for hematological patients has been established in Shaare Zedek medical center. The patients meet with the doctors for the treatment plan usually following the diagnosis. From the point of view of a part of the patients, the process appears simple, short term, and promises cure. In reality, the process is long term, including aggressive chemotherapy prior to the transplant. The treatment is highly aggressive and toxic with many physical and mental side effects for the patient and her/his family. The transplant process requires hospital admission for about a month in an isolation room. No one is allowed in the room except for close relatives and the medical staff. The social worker, part of the caring staff, accompanies patients and families from the initial diagnosis through this taxing and stressful process. Most patients are young, average 45 years, in the middle of their careers, from a broad spectrum of occupations, education as well as social status, representing Israeli society.

Aims: 1. To accompany and empower patients by means of giving them tools to cope with the transplantation process which is a crisis situation in the midst of their lives. 2. To teach patients self-awareness. 3. Promote quality of life for the patients especially during the stay in the isolation room by way of creating a safe domain.

Methods: The following tools had been utilized: 1. The “Empowerment method”. An advanced view of the powers and experiences of patients that constitute resources in addressing crisis. 2. Work of hope- finding unique meaning in life crisis.

Results: This work is based on therapeutic conversations that took place inside the isolation room with about 30 patients, mostly men, average age was 50, during the past three years. With the understanding that a patient goes from the public sphere to a private one -the isolation room- my entrance into the room was based on the ability and willingness of the patients to go into a treatment dialogue at that point and time. From the narratives of the patients, a few themes were extracted that were repeatedly discussed by most patients. 1. Fear of death 2. Post-traumatic issues 3. Fear of isolation 4. The issue of relationships. 5. Mind and body. 6. Children. 7. Faith. 8. Closure

Summary/Conclusions: From the therapy sessions it appears that the central issue facing the patients is coping with the process of their life and the coping with it. The process of treatment helps patients to go from the private sphere back to the public one.

Recommendations: It seems essential for the patients in the isolation room, undergoing autologous bone marrow transplant, to have therapy sessions with a qualified social worker as part of the holistic care. ‘Having a room of his own’ in the process enables an opportunity to examine the inner self esteem and strengths of the patients thereby patients learn to contribute to themselves from themselves.
Sickle cell disease

PB2140

HYPOXÆA INHIBITS MYELOID DIFFERENTIATION VIA NITRIC OXIDE SYNTHASE

T. Subotički1, O. Mitrović Ajtić1, M. Diklić2, S. Vignjević Petrinović1, M. Budeč1, D. Djillali3, J. Salić3, V. Čokić1

1Laboratory of neuroendocrinology, 2Laboratory of experimental hematology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia

Background: Hypoxæa and nitric oxide (NO) inhibit erythroid differentiation, while hypoxæa is NO-releasing agent used in therapy of sickle cell diseases.

Aims: To study the mechanism of hypoxæa inhibition of erythroid differentiation by exploring NO synthase (NOS) dependence.

Methods: The erythroid differentiation is studied by methylcellulose colony assay in mice, whereas presence and activation of endothelial NOS (eNOS) by immunocytochemistry and immunoblotting, respectively in K562 erythrocytic cell line.

Results: In ex vivo experiments, mice exposed 7 days to hypoxæa demonstrated significant decrease in the number of nucleated cells per femur, partially reversed by NOS inhibitor N-nitro L-arginine methyl ester hydrochloride.

Summary/Conclusions: The results indicate that hypoxæa inhibits erythropoiesis, and NO is essential for hypoxæa-mediated inhibition of erythroid differentiation.

PB2141

SLEEP DISORDERED BREATHING IN CHILDREN AND ADOLESCENT WITH SICKLE CELL DISEASE: IMPACT ON EXECUTIVE FUNCTION AND PROCESSING SPEED INDEX

M. Koebel1, J. Kawadler2, H. Stotesbury3, P. Balfour2, F. Kirkham1

1UCL Great Ormond Street Institute of Child Health https://www.ucl.ac.uk/ich, London, United Kingdom, 2Developmental Imaging & Biophysics, UCL Great Ormond Street Institute of Child Health https://www.ucl.ac.uk/ich, London, United Kingdom

Background: Studies in non-syndromic children have shown that sleep-disordered breathing (SDB) increases the risk of neuropsychological deficits and neuronal brain injury. Few authors have investigated the role in cognitive deficits of SDB and the associated hypoxia in children with sickle cell disease (SCD). Snoring and SDB are very common in children with SCD and may affect cognitive function in very young children. Previous data suggested that executive function was worse in older children with SCD and low mean overnight oxygen saturation.

Aims: We aim to investigate if SDB could be a potential factor contributing to developmental problems in cognition in children and adolescent with SCD.

Methods: We have followed up children and adolescents in the Sleep Asthma cohort who underwent Polysomnography at two different time points (1) 2006-2009 and (2) 2011-2014 and compared the sleep data with subsequent neuropsychological assessment.

Results: Worse performance was found for processing speed: PSI (p<0.01) and general intelligence (p<0.05) compared to controls without SDB. SDB, measured as apnea and hypoxia index (i.e. AHI >3%) and is correlated with worse executive function, as well as worse cognitive scores (i.e., executive function, p=0.01 and PSI: p=0.05). Table 1.

Summary/Conclusions: SDB symptoms seem to worsen into adolescence and therefore, might have a neurodevelopmental impact if left untreated; appropriate intervention might improve cognition and quality of life.

PB2142

LUNG FUNCTION IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL ANEMIA: A COMPARISON BETWEEN UK AND ITALY

C. De Pieri1*, M. Arigliani1, R. Colombatti2, L. Sainati1, K. Vecchiato3, S. Ndroo3, P. Gogo1, B. Insua4

1Department of Clinical and Experimental Medical Sciences, University Hospital of Udine, Udine, 2Clinic of Pediatric Hematology-Oncology, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, 3University of Trieste, Trieste, Italy, 4Department of Pediatrics, Evelina Children’s Hospital, London, United Kingdom

Background: Acute and chronic respiratory complications are common in sickle cell anemia (SCA). Subjects with SCA often have a progressive decline of lung function with age that could be influenced by the quality of healthcare and other environmental factors, such as the level of exposure to air pollution.

Aims: To compare lung function, evaluated cross-sectionally through spirometry, in children and adolescents attending sickle cell centers in UK and Italy.

Methods: Anthropometry and spirometry were recorded in patients with SCA (SS,SSβ*) aged 6-17 years of African ancestry followed at the Evelina Children’s Hospital, London, UK, and at the University Hospitals of Padova and Udine, northeast of Italy. Subjects from the British cohort lived in an urban area while those from Italy came from urban and non-urban areas. Exclusion criteria were the presence of SCA-related morbidity within the last two weeks and the inability to perform a spirometry meeting the European Respiratory Society acceptability and reproducibility criteria (Miller, Eur Respir J 2005;26:319–338), modified for children (Kirkby, Pediatr Pulmonol 2008;43:1233–1241). Portable spirometers (Pony FX, Cosmed-IT, Easy-on PC, NDD-CH) were used. Z-scores of anthropometric and spirometric data were derived, respectively, from CDC2000 and from the Global Lung Initiative 2012 predictive equations for African Americans (Quanjer, Eur Respir J 2012; 40:1234–1243). Spirometry patterns were classified as normal, obstructive (zFEV1/FVC<1.64) or restrictive (zFVC<1.64+zFEV1/FVC ≥ -1.64). Differences between groups were assessed by t-tests and considered statistically significant for p values <0.05.

Results: A total of 101 children and adolescents were included (n. 62 in UK; n.39 in Italy; 42% girls; age-range: 6.2-17.9 years). We didn’t find significant differences in mean spirometry indices between the SCA cohort from London and northeast Italy (Table 1). Nevertheless while an obstructive spirometric pattern was more common in the British cohort compared to the Italian one (respectively 22.5% vs 7.7%), the picture was the opposite for the restrictive pattern (respectively 11.2% and 20.5%) (Table 1). In the whole sample age was negatively correlated with both zFEV1 (Spearman’s rho=0.20) and zFVC (Spearman’s rho=-0.24).

Table 1.

<table>
<thead>
<tr>
<th>Index</th>
<th>Sickle cell UK</th>
<th>Sickle cell ITA</th>
<th>Diff between means (5% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td>0.55 (95%)</td>
<td>0.61 (95%)</td>
<td>-0.4 (0.0 to 3.8)</td>
</tr>
<tr>
<td>zFEV1</td>
<td>-0.41 (z&lt;20)</td>
<td>-0.40 (z&lt;20)</td>
<td>0.01 (-0.2 to 0.3)</td>
</tr>
<tr>
<td>FVC</td>
<td>0.55 (95%)</td>
<td>0.61 (95%)</td>
<td>-0.06 (0.0 to 0.1)</td>
</tr>
<tr>
<td>zFVC</td>
<td>-0.41 (z&lt;20)</td>
<td>-0.40 (z&lt;20)</td>
<td>0.01 (-0.2 to 0.3)</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Lung function of pediatric subjects with SCA living in London and in the northeast of Italy is overall comparable. Obstructive lung disease is more common among subjects with SCA living in London than in urban and non-urban areas in Italy. Differences in the level of exposure to ambient air pollution and in the prevalence of allergies between the rural and urban environment might have contributed to this finding and need to be further investigated.

PB2143

SICKLE CELL DISEASE: A NEW DISEASE IN MADRID

E. J. Bardon-Cancho1, M. Garcia-Morin1, B. Ponce-Salas1, Y. Aguilar-de la Red1, A. Pérez-Corral2, G. Pérez-Rus2, E. Dulín3, C. Beléndez1, E. Celá1

1Section of Pediatric Hematology and Oncology, Department of Pediatrics, 2Department of Hematology, 3Newborn Screening Laboratory (Community of Madrid), Hospital General Universitario Gregorio Marañon - Facultad de Medicina - Universidad Complutense de Madrid, Madrid, Spain

Background: Sickle cell disease (SCD) was scarcely diagnosed 2 decades ago in Spain, and the Community of Madrid is a paradigm of the adjustments that had to be implemented to attend an increase of cases due to immigration.

Aims: The aim of our study was to find out the prevalence of SCD in the referral sickle cell newborn screening of the Community of Madrid, in addition to the demographic characteristics of these patients. The secondary objectives were to obtain the frequency of specific treatments or prophylaxis accomplished by these patients, and the reasons for loss to follow-up.

Summary/Conclusions: SCD is a multifactorial disease that affects all aspects of life, from family, to community and society, and it is a challenge to treat and manage.
Methods: The study is observational, univentric, descriptive and retrospective, carried out in February 2017 in a tertiary hospital in the Community of Madrid, Spain. All patients diagnosed with SCD and who had attended at least once to the hematology clinic for this reason were included. Demographic characteristics (date of birth, gender, country of birth) and clinical characteristics (genotype, therapy and update in follow up, like alive, deceased or lost patient) were collected. Written informed consent was signed by patients or legal guardians in accordance with the Declaration of Helsinki. The study was approved by the hospital Ethical Committee. Statistical analyses were performed using SPSS version 18.0. Quantitative variables were reported as median or mean value and range, while categorical variables were expressed as absolute value and percentage.

Results: The total number of SCD patients included was 209. Ratio boy/girl is 1.3. Most of patients were born in Spain (85%), although 8% and 5.26% were born in Africa or America respectively. Seventy percent of the progenitors came from Africa and 24% from America. Ninety two percent of those SCD patients born in Spain were detected in the first days of life due to universal screening detection implemented in Community of Madrid since 2003. Median age at first diagnosis was 1.42 years (0-21.4). Median age at the end of inclusion was 9.91 years (range 0.13 to 35.14). SS or S/Betathal was reported in 86%. In addition, 2.39% associated allel gene deletion, and 1 (0.48%) glucose 6 phosphate dehydrogenase deficiency. No patient had congenital throracic diathesis. Eighteen patients (8.65%) had human leucocyte antigen (HLA) identical siblings. Hydroxyurea was added to standard treatment in 65 patients (31%) of which 47 continue to be treated to date. Penicillim prophylaxis was communicated in 165 patients (79%). Vitamin-D prophylaxis was initiated in 128 children. Crossmatch prior to pleroen transplants were performed in 25 cases (12%) and 9 children (4%) underwent splenectomy. None of these patients had sepsis or meningitis. Cholecystectomy was performed in 9 cases (4%). There were 18 progenitor stem cell transplantations (8.61%) performed between 2.09 to 13.97 years of age (median 6.77 years). Ten patients remained on treatment 1 year post the transplant and 1 attained a marrow reversion. One patient died of graft-versus-host disease. Patients lost in follow up summed up 128: 23 for emigrating to other countries, 65 for continuing the monitor of their diseases in other centers or in adults units and 31 for unknown reasons (1.3%).

Summary/Conclusions: Early diagnosis like universal neonatal screening allows an effective health education, and antibiotic and osteopenia prophylaxis with vitamin D and general and specific vaccination can be started.

PB2144
COMPLEMENT ACTIVATION IN PATIENTS WITH SICKLE CELL DISEASE IS ASSOCIATED WITH HIGHER HBS LEVELS
E. Gavriliak1,*, M. Mainou2, I. Christodoulou2, E.-E. Koravou1, A. Paleta1, T. Touloumenidou1, A. Papalexandri1, A. Anastasiadou1, C. Apostolou2, P. Klironikas2, A. Anagnostopoulou1, E. Vlachaki2
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, 2Adults Thalassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

Background: Older studies have suggested activation of the alternative pathway component (APC) in sickle cell disease (SCD). Despite the renewed interest in SCD therapeutics, little is known about APC activation in the clinical setting of SCD, possibly due to the complexity of complement diagnostics.

Aims: We investigated firstly, whether complement activation can be detected in the sera of asymptomatic SCD patients using a simple functional assay, secondly whether it is associated with clinical parameters and thirdly whether it can be blocked in vitro by the complement inhibitor eculizumab.

Methods: Consecutive asymptomatic SCD patients were enrolled prospectively from November 2016 to January 2017. Patient history, clinical and laboratory data were recorded. Complement activation was detected in patient sera using the modified Ham test, a cell proliferation assay based on the susceptibility of a PNH (paroxysmal nocturnal hemoglobinuria)-like cell line to complement activated serum. Normal human serum (NHS) was used as a negative control and lipopolysaccharides (LPS)-incubated normal serum as a positive control. All samples were tested in triplicates and twice. Eculizumab containing serum (ECU) was collected from a PNH patient within 60 minutes after the infusion and used to test complement blockade by eculizumab in the modified Ham test.

Results: Thirty-two children with HbSS SCD aged 6 to 12 years (mean age= 9.03) and 35 controls (mean age= 9.14) were enrolled. Patients and controls were matched for gender (F 53% vs 61%), ethnicity (African 30 vs 29%), % of children born in Italy (81 vs 80%), number of years lived in Italy (8.09 vs 8.31) and Socio-Demographic Index (5.15 vs 4.59). Children’s Performance in (Z scores) at Visuospatial, Boston Naming, Phonological Fluency and Semantic Fluency Tests are shown in Figure 1. The results overall showed significant differences between patients and controls in inhibition and planning (p= 0.001 and 0.001 respectively) and in verbal tasks that involved Executive Functions more (i.e. phonological fluency) (p=0.004). The poorer verbal performance of children with SCD was not associated to visible lesions to Broca’s area. In fact only 9 patients presented Silent Infarcts that were all in the white matter, in watershed areas. Regression analyses showed that in children with SCD inhibition skills explained unique variance in phonological fluency, suggesting that poor executive control

Figure 1.
Summary/Conclusions: Our results suggest that complement dysregulation is evident in asymptomatic SCD patients with increased HbS levels, an important tool in everyday clinical practice. APC activation during a painful crisis and the role of hydroxyurea need to be further investigated in larger series validating the role of different functional assays. Effective inhibition of complement activation in vitro is promising for future studies in selected patients.

PB2145
THE ROLE OF EXECUTIVE DYSFUNCTIONS IN THE VERBAL LANGUAGE DEFICITS OF CHILDREN WITH SICKLE CELL DISEASE
B. Arfe1, M. Montanaro2, E. Mottura2, R. Manara3, M. Scallitini1, G. Basso2, L. Sainati2, R. Colombatti2
1Department of Psychology, University of Padova, 2Clinic of Pediatric Hematology Oncology, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, Italy, 3Department of Radiology, University of Salerno, Salerno, Italy

Background: Children with Sickle Cell Disease (SCD) frequently present impairment of general and specific neurocognitive functions, even in the absence of clear neurological damage at brain neuroimaging. Verbal language deficits are also common, but the etiology of poor performance in the verbal domain is still not clear. The ability to speak and communicate verbally relies on a complex interaction of cognitive and linguistic functions as well as on environmental factors, like bilingualism or second language (L2) learning. The majority of children with SCD in Italy are of immigrant families whose first language is not Italian. These children thus perform poorly in tests assessing the verbal domain with adverse impact on school performances.

Aims: To evaluate if verbal language deficits in bilingual children with SCD are mainly due to linguistic and environmental issues or to impairment of executive functions.

Methods: In this study a cohort of bilingual children with SCD and social-demographically matched healthy controls recruited from elementary schools of the same school, performed an extensive battery of tests to assess naming skills, phonological and semantic fluency, attention and Executive Functions (inhibition and planning skills) and visuo-spatial skills (Boston naming test, phonological and semantic fluency tests, Flanker task, Eithorn test, PMA spatial relations subscale). All tests were administered in Italian. A composite index considering parental education and employment was used to match socially, demographically and environmental factors, like bilingualism or second language (L2) learning. The majority of children with SCD in Italy are of immigrant families whose first language is not Italian. These children thus perform poorly in tests assessing the verbal domain with adverse impact on school performances.

Aims: To evaluate if verbal language deficits in bilingual children with SCD are mainly due to linguistic and environmental issues or to impairment of executive functions.

Methods: In this study a cohort of bilingual children with SCD and social-demographically matched healthy controls recruited from elementary schools of the same school, performed an extensive battery of tests to assess naming skills, phonological and semantic fluency, attention and Executive Functions (inhibition and planning skills) and visuo-spatial skills (Boston naming test, phonological and semantic fluency tests, Flanker task, Eithorn test, PMA spatial relations subscale). All tests were administered in Italian. A composite index considering parental education and employment was used to match socially, demographically and environmental factors, like bilingualism or second language (L2) learning. The majority of children with SCD in Italy are of immigrant families whose first language is not Italian. These children thus perform poorly in tests assessing the verbal domain with adverse impact on school performances.

Aims: To evaluate if verbal language deficits in bilingual children with SCD are mainly due to linguistic and environmental issues or to impairment of executive functions.

Methods: In this study a cohort of bilingual children with SCD and social-demographically matched healthy controls recruited from elementary schools of the same school, performed an extensive battery of tests to assess naming skills, phonological and semantic fluency, attention and Executive Functions (inhibition and planning skills) and visuo-spatial skills (Boston naming test, phonological and semantic fluency tests, Flanker task, Eithorn test, PMA spatial relations subscale). All tests were administered in Italian. A composite index considering parental education and employment was used to match socially, demographically and environmental factors, like bilingualism or second language (L2) learning. The majority of children with SCD in Italy are of immigrant families whose first language is not Italian. These children thus perform poorly in tests assessing the verbal domain with adverse impact on school performances.
and 19% never experienced an indicator of pain crisis. Patients take initiative (37%), irritability (27%) and appetite (20%) are early symptoms and increase during the period of January 10, 2017 through March 1, 2017. Community-based organizations were leveraged. The survey was open for access to home to manage the onset of an acute crisis and the top 5 home strategies reported were: prescription pain medication (15%), sleep/rest (15%), apply heat using heating pad/blanket/bath/shower (13%), increase fluid intake (12%), and finally avoid stress (9%). Further it is clear, that people living with SCD are motivated to try a new therapy that could provide “significant relief” and “prevent symptoms from happening” due to their SCD.

PB2146

UNDERSTANDING MEDICAL HISTORY, LIFESTYLE AND NEEDS FOR FUTURE THERAPIES FOR PEOPLE LIVING WITH SICKLE CELL DISEASE - IMPLICATIONS FROM A PATIENT SURVEY

A.M. Leitgeb1, M. Robinson2, C. Herder1, L. Jendeberg1

1Modus Therapeutics, Stockholm, Sweden, 2Micromattie Consulting Inc, Oviedo, Florida, United States

Background: Sickle Cell Disease (SCD) is an inherited blood disorder affecting millions of people. Sevuparin/DF02 is being developed to treat people suffering from SCD and is currently in clinical phase 2 for the treatment of the acute painful crisis in hospitalized SCD patients with intravenous infusion. This is called the Resolve program. In a second program called EASE, sevuparin/DF02 will be investigated as an on-demand treatment of early symptoms of painful sickle cell crisis in an at-home setting via a subcutaneous injection. Searching in the literature and discussing with health care providers, it becomes clear that little is known about how the SCD patients sense these early symptoms of a painful crisis. In order to gain increased understanding of how people living with SCD experience daily life, coping with disease, support by health care providers and the demand for new therapies, a patient survey addressing these areas was conducted.

Aims: The aim with this survey was to gain deeper understanding of different aspects of life with SCD by providing a channel for patients to air their own views. The outcome will provide important information and, in combination with future feasibility studies, will guide the design of the first clinical study aimed at treating the early symptoms of pain crises in SCD patients.

Methods: A 29-question survey was created to gather input on a wide variety of topics related to the lives of people living with SCD. This questionnaire was developed by Modus Therapeutics AB, Sweden, in conjunction with Micromattie Consulting Inc., USA. Experts and leaders of community-based organizations participated in two focus group sessions to ensure that the text and structure were ethical and appropriate for the intended purpose. The survey was hosted at www.modustopatientsurvey.com. Patients answered the survey directly, or had their views entered in by a caregiver. The answers are anonymous. During the initial period, survey promotion occurred within the Sickle Cell Warriors online community and later, additional connections within the network of community-based organizations were leveraged. The survey was open for access during the period of January 10, 2017 through March 1, 2017.

Results: An interim analysis was conducted on January 31, 2017. Basic demographic data is presented in Table 1. Responders were located mainly in the United States. Medical history related questions indicate that fatigue (40%), aches/pain (37%), irritability (27%) and appetite (20%) are early symptoms and increase just before the onset of a pain crises. However, 7% reported infrequent signs and 19% never experienced an indicator of pain crisis. Patients take initiative at home to manage the onset of an acute crisis and the top 5 home strategies reported were: prescription pain medication (15%), sleep/rest (15%), apply heat using heating pad/blanket/bath/shower (13%), increase fluid intake (12%), and finally avoid stress (9%). Further it is clear, that people living with SCD are motivated to try a new therapy that could provide “significant relief” and “prevent symptoms from happening” due to their SCD.

Table 1.

<table>
<thead>
<tr>
<th>Number of responders</th>
<th>Age</th>
<th>Female</th>
<th>Male</th>
<th>African American/African descent</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>70</td>
<td>4-7 years</td>
<td>80%</td>
<td>20%</td>
<td>97%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The survey collected feedback about topics for which the patient is the best source of information. It is obvious that people with SCD are willing to self-medicate by subcutaneous injections and that there is a need for new tools and medications. With support from the answers from the survey, specific aspects will be considered while designing a first clinical study for subcutaneous sevuparin/DF02 administration to treat early symptoms of painful crisis in an at-home setting.

PB2147

LONG-TERM USE OF HYDROXYUREA IN CHILDREN AND ADOLESCENTS WITH SICKLE/ßETA THALASSEMIA

M. Economou1,*, A. Teisl1, E. Papadopoulo1, A. Papastergiopoulos1, S. Theodoridou2, F. Papachristou1

1Aristotle University of Thessaloniki, 2Blood Bank, Hippokration General Hospital, Thessaloniki, Greece

Background: Hydroxyurea (HU) has lately been used in the treatment of patients with severe sickle cell disease (SCD). Despite documented benefits on laboratory and clinical parameters in SCD patients, there are few reports about drug’s long-term safety and efficacy in pediatric patients with SCD – even more so in the rare patient subgroup of sickle/ßeta thalassemia.

Aims: A prospective, long term evaluation of HU efficacy and safety in children and adolescents with sickle/ßeta thalassemia (S/b thal).

Methods: Ten patients with S/b thal aged 3.5-18 years were followed for a 6 year period (Jan 2011- Dec 2016). HU was given at a daily dose that ranged from 10 to 20 mg/kg, with a mean of 14.1 mg/kg. Laboratory follow-up consisted of WBC, Hb, Ht, RBC, reticulocyte count and PLT count measured every 2 weeks until dose escalation to a stable dose, biochemistry assessed every 2 months and Hb F measured every 2-3 months. Patients were clinically evaluated prior to HU treatment and every 12 weeks during the study period. Evaluated data on clinical course included frequency of vaso-occlusive crises, hospitalizations and transfusions, as well as presence of severe clinical events. Hematologic toxicity of hydroxyurea was defined as a more than 20% decline in baseline in Hb, as an absolute neutrophil count of less than 1,000/µl and/or a PLT count of less than 80,000/µl. Moreover, presence of alopecia, rash, skin hyperpigmentation or headache was reported as drug-related toxicity.

Results: A significant reduction in vaso-occlusive crises as compared to prior to HU treatment was noted (median: 1 episode per year before HU, range: 0-2.5 vs median: 0.24 episodes per study year after HU, range: 0-1.33, p=0.011). A significant reduction in hospitalizations was also reported (median: 1 per year before HU, range: 0-3.2 vs median: 0.16 per study year after HU, 0-0.83, p=0.005). None of the patients presented with severe clinical events such as acute chest syndrome, avascular bone necrosis, stroke or splenic sequestration during the study period. With regards to hematological parameters, a significant increase in HbF (10.2±6.5% vs 16.6±7.1%, p=0.02), MCV (66.1±3.9fl vs 59.3±8.4fl, p=0.001) and MCH (20.9±1.2pg vs 25.3±2.2pg, p=0.001), as well as a decrease in reticulocyte count (7.7±3.3% vs 5.0±1.9%, p=0.039), WBC count (9,566±3,674/µl vs 7,466±3,460/µl, p=0.009) and PLT count (333,778/µl±170,227 vs 272,111±160,304/µl, p=0.007) was noted. Concerning adverse events, one patient presented with mild transaminasemia, one with elevation of serum creatinine levels and one with pancytopenia. Due to persistent pancytopenia HU treatment was discontinued in the last mentioned patient, but was restarted a year later due to frequent vaso-occlusive events - despite the patient being put on transfusions after initial HU discontinuation. Besides the pancytopenia episode, the rest of the mentioned toxicities were significant and dose-dependent.

Summary/Conclusions: The study indicates that HU has an overall safe profile and results in a marked improvement of clinical course in pediatric S/b thal patients.
IN VITRO AND IN VIVO EVIDENCES OF SICKLING REVERSAL INDUCED BY REHYDRATION WITH HIGH K+ ISOTONIC SOLUTION

O. I. Ajayi1, O. O. Obioru2, F. O. Zimbode1
1Physiology, 2Medical Lab Science, University of Benin, Benin city, Nigeria

Background: Erythrocyte sickling and adhesion are favoured by cellular dehydration, which increases the rate of hemoglobin polymerization and cell sickling. Potassium ion (K+) co-transport and calcium-activated potassium channel (Gardos channel) mediate erythrocyte dehydration in sickle cell disease and β-thalassemia. We investigated the in-vitro and in-vivo effects of various concentration of K+ ions in physiological solutions (PSS) as well as in cocus necrrifera water (CNw) which is known for its natural high potassium content and isotonicity.

Aims: This study was aimed at ascertaining the efficacy of high potassium isotonic solutions in rehydrating sickling cell and possibly reversing the sickling phenomenon at in vivo and in vitro situations.

Methods: 1. Erythrocytes from twenty sickle cell anemia (SCA) as well as forty healthy subjects were studied. One part was treated with sodium metabisulphite (Na2S5O7) to induce maximum sickling as controls while the other was subjected to different high concentrations of K+ in PSS as well as Cocos necrrifera water (40mM, 80mM and CNw - 65mMOL/L) respectively. The procedure was repeated for the normal HB AA subjects. Also, both groups of subjects were given 10ml/kg body weight of coconut water to drink as a single dose for the in-vivo experiment. Blood samples were collected longitudinally before and after the oral ingestion, at 1hr and at 24hrs for analysis of red cell indices as well as stained blood films used to ascertain the percentage sickled erythrocytes count before and after the treatment in both cases.

Results: Maximum percentage counts of sickled cells after the addition of Na2S5O7 (45%) were observed which decreased significantly (P<0.05, respectively) to about 2% with Cocos necrrifera and 10% with 80mM K+PSS. The count in 40mM K+PSS was not statistically significant. In both HB AA and SS subjects, MCHC slightly but not significantly remained the pre-injection sample (P>0.05, respectively) while MCHC increased significantly in both groups as early as 1hr and sustained till the 24th hour. MCHC was equally raised in the in-vitro samples (P<0.05, respectively). The morphology of red cells also indicated a lesser count of sickled red cells after the oral ingestion Summary/Conclusions: Cocos necrrifera water and other high potassium ion solutions can activate the rehydration of sickled erythrocytes by probably de-activating the Gardos channel to increase the mean corpuscular haemoglobin concentration (MCHC) and thereby restoring the normal red cell shape. We suggest a probable pharmacological value of the cocus necrrifera water as well as other formulated high potassium but isotonic fluids in SCA management.

IN VITRO AND IN VIVO EVIDENCES OF SICKLING REVERSAL INDUCED BY REHYDRATION WITH HIGH K+ ISOTONIC SOLUTION

O. I. Ajayi1, O. O. Obioru2, F. O. Zimbode1
1Physiology, 2Medical Lab Science, University of Benin, Benin city, Nigeria

Background: Erythrocyte sickling and adhesion are favoured by cellular dehydration, which increases the rate of hemoglobin polymerization and cell sickling. Potassium ion (K+) co-transport and calcium-activated potassium channel (Gardos channel) mediate erythrocyte dehydration in sickle cell disease and β-thalassemia. We investigated the in-vitro and in-vivo effects of various concentration of K+ ions in physiological solutions (PSS) as well as in cocos necrrifera water (CNw) which is known for its natural high potassium content and isotonicity.

Aims: This study was aimed at ascertaining the efficacy of high potassium isotonic solutions in rehydrating sickling cell and possibly reversing the sickling phenomenon at in vivo and in vitro situations.

Methods: 1. Erythrocytes from twenty sickle cell anemia (SCA) as well as forty healthy subjects were studied. One part was treated with sodium metabisulphite (Na2S5O7) to induce maximum sickling as controls while the other was subjected to different high concentrations of K+ in PSS as well as Cocos necrrifera water (40mM, 80mM and CNw - 65mMOL/L) respectively. The procedure was repeated for the normal HB AA subjects. Also, both groups of subjects were given 10ml/kg body weight of coconut water to drink as a single dose for the in-vivo experiment. Blood samples were collected longitudinally before and after the oral ingestion, at 1hr and at 24hrs for analysis of red cell indices as well as stained blood films used to ascertain the percentage sickled erythrocytes count before and after the treatment in both cases.

Results: Maximum percentage counts of sickled cells after the addition of Na2S5O7 (45%) were observed which decreased significantly (P<0.05, respectively) to about 2% with Cocos necrrifera and 10% with 80mM K+PSS. The count in 40mM K+PSS was not statistically significant. In both HB AA and SS subjects, MCHC slightly but not significantly remained the pre-injection sample (P>0.05, respectively) while MCHC increased significantly in both groups as early as 1hr and sustained till the 24th hour. MCHC was equally raised in the in-vitro samples (P<0.05, respectively). The morphology of red cells also indicated a lesser count of sickled red cells after the oral ingestion Summary/Conclusions: Cocos necrrifera water and other high potassium ion solutions can activate the rehydration of sickled erythrocytes by probably de-activating the Gardos channel to increase the mean corpuscular haemoglobin concentration (MCHC) and thereby restoring the normal red cell shape. We suggest a probable pharmacological value of the cocus necrrifera water as well as other formulated high potassium but isotonic fluids in SCA management.

Knowledge of Sickle-cell Disease in Haute-Normandie, Socio-Demographic Context and Health Characteristics: Interest of the Implementation of a Patient Education in Sickle Cell Disease

A.M. Bobes Fernández1,2,3,*, B. Ponce1,2, Y. Aguilar1,2, C. Garrido1,2, M. García-Morín1,2, C. Beléndez1,2, E. Cela1,2
1Hospital Gregorio Marañón, 2Facultad de medicina, Universidad Complutense de Madrid, 3Hospital Clínico San Carlos, Madrid, Spain

Background: Sickle cell anemia (SCA) is a genetic disease causing a severe disease manifestation by painful crisis but which can also be marked by organ complications. Mortality is still happening at a young age. Many of these complications may be better taken care of if treated early. The best way to manage this disease is probably through Patient Education (PE). The aim of the project was to highlight the education and awareness of sickle cell disease in order to improve the knowledge of the disease.

Methods: Fifty patients (male / female ratio 0.92) out of 123 (40.6%) responded, mean age 33±10.5 years (SS genotypes [66%], SC[25%], S-beta-thalassemia [9%]). 56% of them were born outside of Metropolitan France, 36% came from French speaking African countries. Age range was 18±10.9 years. Despite the fact that their education has been disrupted by the disease for the majority (69.4%) and 73% of them have been satisfied with their level of education, 18% of patients who have never left school or have a primary / middle school level and 4% were illiterate. 68% of the patients had a job or were students. 48% of patients reported to practice physical activity at least once weekly. Tobacco was consumed on a daily basis by 14%, alcohol 2% and 4% for cannabis. Self-assessment of health status was 6.9 / 10, self-assessment of morale of 7.8 / 10 and impact of the disease on daily life was estimated at 5.4 / 10. The mean age at which specialized follow-up was started was 11±9 years. 88% of the subjects stated that they understood everything the doctor said during consultation. Missed appointments were reported by 26% which was justified by forgetfulness, lack of will or physical incapacity. Regarding sources of information regarding SCA, patients declared asking their specialist first and then looking on the internet. 68% of subjects had a first-degree relative suffering from the same disease, 71% were able to talk about the disease with their family. While the triggers of crises and the management of crises were well-identified by patients (average scores of 13.8 and 12/20), “standards” were not met with chronic complications, prenatal diagnosis, and long term treatment (mean scores respectively of 7.4, 4.2 and 2.2 / 20). Average score on the whole questionnaire was 9/20. Most patients showed interest in PE (52.1%) vs 31.3% that claimed were not interested. 17.7% did not decide.

Summary/Conclusions: A majority of SCA adults followed in Haute-Normandie are first-generation migrants. Even if the disease has heavy impact on everyday life and school access, their education level appeared correct. PE sessions will therefore be focused on chronic complications, prenatal diagnosis, and the long term treatment. The majority of adults with SCA are motivated by PE, we will have to adapt to a heterogeneous population in terms of educational level, ethnic origin and knowledge of the disease.

Start treatment with Cholecalciferol 25000IU/month. Regarding second levels of vitamin D, we have divided patients into those who presumably have the treatment against children who do not. We present the results in the following Table 1.

Table 1.
Background: Patients with sickle cell disease (SCD) may require repeated red blood cells (RBCs) transfusion, putting them at risk from minor blood group alloimmunization and the development of delayed haemolytic transfusion reactions. Aims: We reported a prevalence of recognized DHTR syndrome in patients with SCD.

Methods: We reviewed the cases of DHTR in SCD patients in a 5-year period (2010-2016). A total of 10 patients had a clinical picture compatible with DHTR and underwent treatment with high dose steroids, intravenous immunoglobulins (IVIG) or erythropoietin. Any patient received Rituximab.

Results: The most common indications for transfusion were anemia due to vasocclusive sickle cell crisis or preoperative anaemia optimization. The cohort received partial exchange transfusion and transfusionally matched RBCs. Before transfusion the median of Hb level was 69 g/L (baseline range 80g/L) and the nadir at haemolysis episode was 38 g/L. Ht was 21.9%, WBC was 17.3 x 109/L and mean LDH 1290 IU/L. The median time to develop DHTR was seven days after the transfusion and approximately 6 days after the surgical interventions (range: 4–12 days) and all cases presented with symptoms of anaemia, jaundice, tiredness and tachycardia. The median age was 29 years with female predominance (6:4). Blood cultures were negative in 80% of patients and only positive in 2 cases, 30% of patients tested positive for viral infection on PCR. Mortality rate in our series was low (zero). Pain episodes and other complications associated with DHTR was treated as required and four cases were successfully monitored in HDU. One patient required noninvasive ventilations and inotropic support. Two patients received RBCs transfusion as packed RBCs. Possibly as their previous DHTR mimics an acute vaso-occlusive crisis. In all cases haemoglobin stabilized and improved, symptoms resolved and patients were discharged on small course of oral antibiotics (median admission 6 days).

Summary/Conclusions: The symptoms of DHTR can easily be mistaken for other SCD complications, including infection and vaso-occlusive crisis. The diagnosis of DHTR is based on clinical suspicion, when there is a rapid Hb drop after a recent RBC transfusion with clinical signs of haemolysis. To support the diagnosis, laboratory tests (serial FBCs, haemolysis screen, DAT, measurement of Hb S levels) and exclusion of other aetiologies are useful. Whenever a DHTR is suspected, further RBC transfusion should be withheld unless absolute necessary, as it may precipitate acceleration of the hemolytic reaction. Patients in whom the diagnosis of DHTR is missed may receive repeat transfusions, which may contribute to the complications associated with SCD. The use of more extensive phenotypic matching of blood and minimizing RBC transfusion help to prevent DHTR. The present series emphasis the importance of early recognition of symptoms and signs in correlation with a recent history of RBC transfusions, as DHTR can be a potentially life-threatening complication.

HBS MONITORING ON TOSOH G8 IN VARIANT HBA1C MODE IN CASE OF URGENT RCE

Background: Pre- and post-transfusion HbS levels are used to document the efficacy of red blood cell exchange (RCE) in patients with sickle cell disease (SCD). In case of urgent RCE a 24/7 STAT analysis, with the ability to identify and quantify hemoglobin (Hb) S, is warranted.

Aims: We evaluated the use of Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 (Tosoh Europe, Amsterdam, The Netherlands) for this purpose, using the variant HbA1c mode. Results were compared to our routine CZE Minicap Flex Piercing (Sebia, Lisses, France).

Methods: Within- and between-run imprecision were assessed using a sickle cell trait and a sickle cell anemia sample, aliquoted and stored at -80°C, twice daily for 10 replicates for ten days. A linearity study was performed using duplicate measurements of a dilution set of 11 samples (HbS range: 0% - 88%). Additionally, a comparison study was conducted between TOSOH G8 and Minicap Flex Piercing using 32 whole blood left-over HbS samples (HbS range: 9% - 93%). Data analysis was performed using Microsoft Excel Analyze-it version 4.6.3. and differences were considered as statistically different if the P-value was <0.05.

Results: Within- and between-run imprecision were <2% and an acceptable linearity was observed. Passing-bablok regression analysis comparing TOSOH G8 and Minicap Flex Piercing showed an acceptable correlation coefficient of 0.98 (P<0.05). A Bland and Altman plot detected a slope and intercept of 0.94 (95% CI: 0.92 - 0.96) and 0.057 (95% CI: -2.5 to 1.3), respectively. Differences in HbS results between TOSOH G8 and Minicap Flex Piercing ranged from -8.76% to +0.36% (mean difference: -3.54%). More specifically, for samples with a HbS concentration <25% HbS results on TOSOH G8 differed between -0.34% to +0.36% compared to Minicap Flex Piercing. For samples with a HbS concentration >25%, differences in HbS results ranged from -8.76% to -0.43%.

Summary/Conclusions: In our clinical laboratory, TOSOH G8 is used in variant HbA1c mode to quantify HbA1c. Previous studies demonstrated reliable HbS identification using TOSOH G8 in variant Hba1c mode. Our study showed good analytical performance for HbS quantification using TOSOH G8. Good correlation with Minicap Flex Piercing system was found, although results were statistically not interchangeable. Our results suggest that TOSOH G8 in variant Hba1c mode generates lower HbS results in samples with a high HbS concentration (>25%) compared to our routine analyzer. However, the goal of RCE is to achieve a post-transfusion HbS level of 30% or less. Therefore, results obtained with TOSOH G8 are clinically acceptable to monitor post-transfusion HbS levels. Importantly, HbS on TOSOH G8 can only be requested in case of urgent RCE. Our routine hemoglobinopathy screening will still be performed using CZE Minicap Flex Piercing in combination with CE-HPLC Variant 1TM.
SICKLE CELL PAIN IN CHILDREN: TARGETS FOR ADMINISTRATION OF ADEQUATE INITIAL ANALGESIA

A. Rushd1,*, A. Ramanathan2, B. Inusa3
1KCL, 2GSTT, 3Paediatric haematologist, Guys St Thomas Hospital, London, United Kingdom

Background: Acute pain is a hallmark presentation in sickle cell disease (SCD) and frequently requires attendance to the emergency department (ED).

Aims: Here we report our findings following a complete retrospective audit cycle, documenting the timeliness of analgesia administration and post-treatment pain review as per National Institute of Clinical Excellence and College of Emergency Medicine guidelines, in children with SCD presenting to a single inner city London ED over a 1.4 month period.

Methods: In 2014, we evaluated 48 patient records of children presenting to the ED, with respect to mild, moderate and severe pain scores, time of analgesia administration and pain review. Completing the audit cycle, 97 records were re-audited in 2015. A total of 145 admission records were evaluated.

Results: In 2014 the ED met CEM criteria for the timeliness of analgesia administration in 100% of severe and 95% of the moderate pain category; however fell 33% short of NICE standards. Pain review was poorly performed, identifying an area for improvement. Proportions meeting the aforementioned criteria fell significantly in 2015, except review of moderate pain, which increased by 25%.

Summary/Conclusions: We conclude CEM guidelines promote timely administration of analgesia in patients with severe pain; however mild pain may be overlooked. NICE avoids this discrimination. Thus we recommend combining the mild and moderate pain categories to acknowledge the fluctuating nature of sickle pain and its tendency to rapidly escalate. In addition, we reiterate the need for regular pain reviews. This is important in ensuring analgesia is closely titrated to pain level.

PB2156

EFFECT OF SUSTAINED-RELEASE SUPPLEMENTATION OF L-ARGININE AMONG CHILDREN WITH SICKLE CELL DISEASE IN FEDERAL TEACHING HOSPITAL GOMBE, NORTH EASTERN NIGERIA

O. Erhabor1,*, V.D. Knox2, S. Abubakar3, S. Yuguda3
1Haematology and Blood Transfusion Science, Usmanu Danfodiyo University Sokoto, Nigeria, Sokoto, Nigeria, 2Department of Biochemistry and Molecular Pharmacology, West Virginia University Medical School, Morgantown, United States, 3Department of Haematology, Federal Teaching Hospital Gombe, Gombe State, Nigeria , Gombe, Nigeria

Background: Sickle cell disease is a global public health problem. As of 2013 about 3.2 million people have sickle-cell disease with 176,000 deaths

Aims: In this present study, we investigated the effect of 8 weeks, low dose supplementation of sustained-release of nitric oxide generating L-arginine supplement (350mg) given two times daily on the full blood count, L-arginine, nitric oxide, pantocathic acid, plasma malondialdehyde, glutathione and total antioxidant capacity of children with sickle cell disease.

Methods: This study included children with sickle cell disease (HbSS) aged 1-14 years with mean age 7.45±0.0±0.50613 years presenting to the sickle cell clinic unit of Federal Teaching Hospital Gombe, Gombe State. Subjects received sustained release oral L-arginine supplementation of 350mg twice daily for 8 weeks.

Results: L-arginine and nitric oxide levels were significantly higher among sickle cell disease children. There were no statistically significant differences between the baseline and post L-arginine supplementation in the PCV, WBC, RBC and LYM levels of subjects (p>0.05). There was a statistically significant difference between the baseline and post L-arginine supplementation in the MCV, MCH, MCHC, PLT, NEU, EOS, MON and RDW-SD levels of subjects (p<0.05). The L-arginine and nitric oxide levels were significantly higher post supplementation compared to baseline levels (p=0.002 and 0.000 respectively).

Summary/Conclusions: The total antioxidant capacity of children with sickle cell disease significantly increased post supplementation compared to baseline levels among sickle cell disease subjects with vaso-occlusive crisis (p=0.001, 0.01 and 0.05 respectively). The pantocathic acid and malondialdehyde levels at baseline were significantly higher than the post supplementation levels among subjects with vaso-occlusive crisis (p=0.002 and 0.000 respectively). The total antioxidant capacity and glutathione levels were significantly higher post supplementation compared to baseline levels among the sickle cell subjects (p> 0.05 and 0.000 respectively). The baseline plasma malondialdehyde level was significant higher that the post supplementation levels among the sickle cell disease subjects. There is need for more effort and resources to be dedicated to research especially in supplementation studies involving a larger population aimed at establishing specific treatment for sickle cell disease. It is recommended that L-arginine supplementation be included in the management of patients with sickle cell disease particularly those with vaso-occlusive crisis. We observed a statistically significant negative correlation between the L-arginine levels and the red cell count among sickle cell disease subjects (r=-0.350, p=0.043).
Summary/Conclusions: L-arginine supplement should be made available in the paediatric emergency unit, clinic and pharmacy department in high risk communities to obviate the negative effects during vaso-occlusive crisis and potentially reduce the length of stay in the hospital. L-arginine, nitric oxide, total antioxidant capacity, malondaldehyde and glutathione levels should be routinely monitored in sickle cell disease patients particularly those presenting with vaso-occlusive crisis.

Stem cell transplantation - Clinical

PB2157

THE EFFECT OF BODY MASS INDEX ON OUTCOME AFTER UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA ON BEHALF OF EUROCORD, PDWP

A. Paviglianiti1,2,*, A. Ruggeri1,2,3, J.H. Dalle4, G. Michel5, F. Locatelli6, C. Kenzey1,2, F. Volt1,2, C. Jubert7, A.P. Iori8, W. Barberi8, I. Yakoub-Agha9, H. Bittencourt10, M. A. Diaz11, Y. Bertrand12, H. Rafii12, K. Tozatto Maio12, H. Hayashi12, V. Rocha12,13, P. Bader14, E. Gluckman12

1EUROCORD, Hopital Saint Louis, Paris, France, 2MONACORD, Centre Scientifique de Monaco, Monaco, Monaco, 3Haematology and Hematology, Sapienza University, Rome, Italy, 4Department of Pediatric Hematology-Oncology, IRCSS Ospedale Bambino Gesù, Rome, Italy, 5Pediatric Onco-Hematology Department, Hôpital des Enfants, Bordeaux, France, 6Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, 79UAM allo-CSH CHRU, Hôpital HURIEZ , Lille, France, 10Hematology-OncoLOGY Division, C.H.U. Saint-Justine, University of Montreal, Montreal, Canada, 11Hematology Department, Hospital Infantil Universitario Nino Jesus, Madrid, Spain, 13Institute of Hematology and Oncology Paediatrics, Hospices Civils de Lyon, Lyon, France, 13Hospital Sino Libanès, San Paulo, Brazil, 14Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents of Frankfurt, Frankfurt, Germany

Background: Body mass index (BMI) may influence outcome after allogeneic transplantation. Previous studies have demonstrated that being obese or underweight may have a detrimental effect on survival rates after chemotherapy induction in children with acute leukemia. However, the impact of BMI of transplanted patients on survival is still not clear, with conflicting results being reported on this issue.

Aims: To analyze the effect of BMI on UCBT outcomes in children with acute leukemia

Methods: We retrospectively analyzed 517 patients aged from 2 to 20 years with acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Patients were classified according to BMI as: normal (5th-85th percentile), underweight (<5th percentile), overweight (85th-95th percentile) and obese (>95th percentile) by using growth charts for age and gender.

Results: Sixty-one percent (n=314) of patients were in the normal category, 12% (n=63) were underweight, 15% (n=80) overweight and 12% (n=60) obese. All patients received single-unit UCBT after a myeloablative conditioning regimen. Diagnosis was acute lymphoid leukemia in 70% (n=363) and acute myeloid leukemia in 30% (n=154). Median age at UCBT was 7.4 years (range 2-19.6). Cytomegalovirus (CMV) serology was positive in 45% patients; 60% of patients were male. Most patients (92%) were in complete remission at UCBT. Median follow-up was 52 months (range 2-201). Total body irradiation (>6 Gy) was used in 58% of cases; antithymocyte globulin (ATG) in 68% of cases. Median infused total nucleated cell (TNC) dose was 4.2x10^7/Kg (0.3-17.8); 56% of patients received a graft with 0-1 HLA mismatch donor. Four-year overall survival (OS), leukemia-free survival (LFS) and graft-versus-host disease-free, relapse-free survival (GRFS), neutrophil engraftment, NRM and chronic GVHD between the 4 groups identified according to BMI was identified. Conversely, acute GVHD was 44.3% (33.3-58.8%) for underweight, 36% (31.4-41.8%) for normal, 26.2% (18.1-38%) for overweight and 23.3% (14.7-37.1%) for obese (p=0.03). Among patients underweight who experienced acute GVHD (n=27), 37.5% had grade III-IV acute GVHD with gut involvement. In multivariate analysis, infused TNC dose>4.2x10^7/Kg was associated with higher neutrophil engraftment (HR=1.46, CI 95% 1.01-1.43, p=0.02), higher incidence of acute grade II-IV GVHD (HR=2.8, CI 95% 1.4-5.6, p=0.003) and female gender (HR=1.5, CI 95% 1.0-2.3, p=0.03) was associated with higher NRM. ATG use (HR=1.6, CI 95% 1.05-2.31, p=0.03) was associated with higher relapse incidence. Moreover, ATG use and a positive CMV serology were associated with worse OS (HR=1.6, CI 95% 1.15-2.17, p=0.04 and HR=1.3, CI 95% 1.01-1.69, p=0.001, respectively) and LFS (HR=1.15, CI 95% 1.01-1.32, p=0.03 and HR=1.3, CI 95% 1.04-1.72, p=0.02, respectively). Infused TNC >4.2x10^7/Kg (HR=1.5, CI 95% 1.07-2.14, p=0.02), lack of ATG in the conditioning (HR=2.72, CI 95% 1.6-3.1, p<0.001) and BMI <5th percentile (HR=1.8, CI 95% 1.19-2.78, p<0.001) were associated with higher incidence of acute grade II-IV GVHD.

Summary/Conclusions: In conclusion, we did not find association of obesity with transplant outcomes in this study population. However a BMI <5th percentile at UCBT was found to be associated with higher risk of acute GVHD, highlighting the importance of nutritional status before UCBT.
PB2158
PROSPECTIVE PHASE II STUDY OF REDUCED TOXICITY CONDITIONING CONSISTED OF HIGH DOSE CYTARABINE, FLUDARABINE, CYCLOPHOSPHAMIDE +/- TOTAL BODY IRRADIATION FOLLOWED BY ALLOGENIC STEM CELL TRANSPLANTATION
S. Kasahara1,*, H. Nakamura2, Y. Kaneda1, Y. Ikomasa2, E. Takada3, Y. Shibata1, T. Matsumoto2, M. Nakamura2, S. Ninomiya2, J. Kitagawa2, H. Goto2, T. Harasawa2, M. Sawada3, T. Takahashi1, K. Saito1, M. Shimizu2, H. Tsurumi2,1Hematology, Gifu Municipal Hospital, Gifu, Japan, 2Hematology, Gifu University Graduate School of Medicine, 3Hematology, Gifu Red Cross Hospital, 1Internal Medicine, Gihoku Kosei Hospital, Gifu, Japan

Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT) using reduced intensity conditioning (RIC) has been widely applied to elderly or frail patients who are not eligible for conventional conditioning regimen. However, benefit provided by reduced toxicity has been often offset by increased incidence of relapse. So far, the optimal conditioning for those patients has not been established.

Aims: Here, to investigate whether addition of high dose cytarabine (AraC) to RIC regimen consisting of fludarabine (Flu) and cyclophosphamide (Cy) +/- total body irradiation (TBI) can be available for elderly or frail recipients, phase II study has been designed.

Methods: This study was conducted from April 2011 to December 2015. The protocol was approved by each institutional review board (Trial identifier: UMIN000007281). Patients aged 55 to 70, or patients who have some organ damage or a history of SCT aged from 20 to 54 with hemato logic malignancies were enrolled after obtaining written informed consent. Bone marrow (BM), peripheral blood (PB), or cord blood (CB) was used as stem cell sources. Preconditioning regimen consisting of 30 mg/m² of Flu for 5 days (total 150 mg/m²), 4 g/m² of AraC for 2-4 days (divided by 2 daily), total 8-16 g/m² and 50mg/kg of Cy for a day. Four day of TBI was used for all CB transplant recipients, whereas 2 day of TBI was used in other stem cell sources except in BM recipients according to each institution policy. Calcineurine inhibitors (cyclosporine or tacrolimus) and short term methylprednisolone were used as GVHD prophylaxis. Donor cell engraftment and 60 day-survival were assessed as a primary end point to evaluate feasibility of this protocol.

Results: Thirty nine patients including 7 recipients with a history of SCT were enrolled. Median age was 61 (28-86), 21 were male, and 18 were female. Nineteen were acute myeloid leukemia, 11 myelodysplastic syndrome, 6 malignant lymphoma and 3 acute lymphoblastic leukemia. Donors were 4 matched related PB, 8 matched unrelated BM, 5 1-Ag/allele-mismatched unrelated BM, and 22 2-Ag-mismatched CB. Thirty seven (94.9%) patients have passed 60-day-point post-transplant. In 38 (97.4%) recipients, engraftment was obtained, a patient died before engraftment due to sepsis caused by enterococcus faecium (male CB recipient, 55y, day15). Median neutrophil recovery to over 500/μl was obtained on day 19 (16-38). Fourteen blood stream infections (13 bacteremias and 1 candidemia) judged as grade 3 toxicity and 2 cases (1 sepsis and 1 endocarditis) were not according to institutional policy. Calcineurine inhibitors (cyclosporine or tacrolimus) and short term methylprednisolone were used as GVHD prophylaxis. Donor cell engraftment and 60 day-survival were assessed as a primary end point to evaluate feasibility of this protocol. Patients conditioned with BEAM or CFM-TBI had a complete remission (5 acute coronary syndrome, 1 myocarditis) and 2 had pulmonary toxicity. The CI of non-2nd neoplastic complications at 10 year was 10% (1-25%, CI 95%). No differences were detected between the two conditioning regimens regarding non-neoplastic complications. (See Figure 1).

Summary/Conclusions: RIC using Flu/high dose AraC/Cy +/- TBI was well tolerated with acceptable low toxicities and was sufficient to allow donor cell- engraftment post allo-SCT for elderly or frail patients with hematologic malignancies. Longer follow up and another prospective study enrolling more patients are required to evaluate the eventual survival benefit by reducing relapse.

PB2159
LATE COMPLICATIONS OF CONDITIONING REGIMENS (CYCLOPHOSPHAMIDE - TOTAL BODY IRRADIATION vs BEAM) FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA
S. Novelli1,*, A.C. Caballero1, A. Monter1, G. Gomez Segura1, I. Garcia Cadenas1, A. Esquirol1, R. Martino1, J. Sierra1, J. Briones1,1Hematology, Hospital Regional de Málaga, Málaga, Spain

Background: Autologous stem cell transplantation (ASCT) is a frequently used procedure for the treatment of patients with relapsed non-Hodgkin lymphoma (NHL). While chemotherapy-based regimens are now commonly administered, total body irradiation (TBI) was largely used in the past. The current conditioning regimen in our center is BEAM (a combination of carmustine (BCNU), etoposide, cytarabine and melphalan) although we also have a large experience with cyclophosphamide (CFM)-total body irradiation (TBI) since this was the usual conditioning until year 2000.

Aims: To analyze the cumulative incidence of secondary neoplastic complications (grade 3-4 infections, cardiovascular and pulmonary toxicity) after the two conditioning regimens (CFM-TBI vs BEAM) for ASCT.

Methods: We performed a retrospective analysis of patients with NHL that received an ASCT between October 1992 and December 2012. The late complications were defined as those to other previous comorbidity or to aging. Statistical analysis was performed using the IBM SPSS Statistics version 21.0. Cumulative incidences were estimated using EZR version 1.27 (Saitama Medical Center, Jichi Medical University, Omiya, Japan), a graphical user interface for R (version 3.1.1).

Results: A total of 105 autografted patients were analyzed. Patient’s characteristics are in Table 1. The median follow up since ASCT was 73 months (0 – 274 months). Thirty-one percent (n=33) of patients were conditioned with CFM-TBI. The overall 5-years survival (OS) was 68.3% (58-77% - CI 95%) and the 5-year disease free survival (DFS) was 52% (42 61% - CI 95%). There were no differences regarding OS and DFS between the two conditioning regimens. The 5-years cumulative incidence (CI) of relapse was 0.48 (0.37-0.57. CI 95%). We detected 10 secondary neoplasm (myelodysplasia n=1, skin carcinoma n=2, lung carcinoma n=3, oropharyngeal carcinoma n=1, intestinal adenocarcinoma n=1, renal neoplasia n=1, bladder neoplasia n=1). The median time for the neoplastic event was 10.5 years (0-18.5 years). The CI of secondary neoplasias (2nd neoplasia) at 10 years was 10% (1-20%, CI 95%) and at last point of follow up (18.5 years) was 40% (13%>63%, CI 95%). There were no differences in the CI of 2nd neoplasias between BEAM and CFM-TBI. Non-neoplastic complications were present in 10% of patients (n=11). Three cases were infections grade 3-4 related to ASCT. Six cases had cardiac complications (5 acute coronary syndrome, 1 myocarditis) and 2 had pulmonary toxicity. The CI of non-2nd neoplastic complications at 10 year was 10% (1-25%, CI 95%). No differences were detected between the two conditioning regimens regarding non-neoplastic complications. (See Figure 1).

Table 1. Patient’s characteristics.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Frequency (%)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genitourinary</td>
<td>51.0</td>
<td>52%</td>
</tr>
<tr>
<td>Histology</td>
<td>Diffuse Large Cell Lymphoma</td>
<td>40 58%</td>
</tr>
<tr>
<td></td>
<td>Follicular Lymphoma</td>
<td>65 42%</td>
</tr>
<tr>
<td>Response pre- ASCT</td>
<td>Complete Remission: 58</td>
<td>59%</td>
</tr>
<tr>
<td></td>
<td>Partial remission: 46</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stable disease: 2</td>
<td>1%</td>
</tr>
<tr>
<td>Number of Lines pre-ASCT</td>
<td>Less than 5</td>
<td>106/48%</td>
</tr>
<tr>
<td></td>
<td>More than 5</td>
<td>6%</td>
</tr>
<tr>
<td>Conditioning</td>
<td>Flu/TBI: 13</td>
<td>31/ 69%</td>
</tr>
</tbody>
</table>

Summary/Conclusions: Autologous stem cell transplantation offers long disease free survival for half of the patients with a high risk non-Hodgkin lymphoma. In our series, patients conditioned with BEAM or CFM-TBI had a comparable incidence of neoplastic and non-neoplastic events.

PB2160
THE MANAGEMENT OF RELAPSED HODGKIN’S LYMPHOMA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: DONOR LYMHOYCTE INFUSION AND BRENTUXIMAB.
I. Sánchez Bazán1,*, A.L. Contento Gonzalo1, M.J. Pascual Cascón1, I. Sánchez Bazán1,*, A.L. Contento Gonzalo1, M.J. Pascual Cascón1, A.R. Martín Cerezo1, M.A. Cuesta Casas1, A.I. Heiniger Mazo1,1Hematology, Hospital Regional de Málaga, Málaga, Spain

Background: Hodgkin’s lymphoma, is an heterogeneous malignancy wich is possible to cure. For those patients who relapse, chemotherapy followed by an autologous transplantation (autoTPH) is the only possible to cure. Autologeneic transplantation (alo-SCT) is used for patients in relapse after auto-SCT or those with refractory advanced disease. Since 2012, with the experience of the Baltimore group, our Center has chosen the haploidentical family donor as a source for aloeSCT in Hodgkin’s disease. Despite the promising results, the rate of relapse is between 25 and 35%, and there is not standard-ized treatment for this situation.

Aims: To analyze the outcome of post-transplant relapse treatment of haploident donor haematopoetic progenitors (haploTPH).

Figure 1.

Summary/Conclusions: Autologous stem cell transplantation offers long disease free survival for half of the patients with a high risk non-Hodgkin lymphoma. In our series, patients conditioned with BEAM or CFM-TBI had a comparable incidence of neoplastic and non-neoplastic events.
Methods: We studied 19 patients with the diagnosis of Hodgkin’s lymphoma in our center between August 2004 and July of 2013. All of them were submitted to haploSCT with a median follow-up of 495 days (1455-1054).

Results: The median age was 32 years (21-60). 44% (8 patients) relapsed. 60% of them (5 patients) were nodular sclerosis histological subtype and 40% (3) ILC (latticocyte predominance). 2 patients (25%) were diagnosed in stage IV and 75% (6 patients) were grade 1 or 2. A total of 29 patients received treatment. Before transplantation was 5.5 (4-7); Compared to the median of the non-relapsed group (4-11). 5 patients (60%) of the patients who relapsed had reached haploTPH in complete remission and 40% in partial remission, we did not observe differences related to the pre-SCT status. Peripheral blood was used as progenitor source in 75% (6) of the patients who relapsed and in 70% (7) in the non-relapsed group. 38% of the whole group of patients, had a donor/recipient KIR alloreresitivity without differences between the two groups of the study. 88% (7) of the relapses occurred before 6 months of the SCT. The mean time to relapse was 316 days (range 181-446). Between the 8 relapsed patients, 3 of them presented moderate cutaneous affection, and one of them suffered hepatic graft versus host disease stage III, with adequate evolution after treatment.

Summary/Conclusions: Is possible to treat patients who relapsed after haploidentical stem cell transplantation with Brentuximab+DLI, with a very good tolerance. We observed cutaneous graft versus host disease in most of the patients who reached completed response after DLI. Despite this findings, we need multicentric studies to perform standarized treatments and protocols.

PB2161 CONDITIONING REGIMENS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA – LEED vs MCEC

H. Shimizu1,*, C. Naitoh2, Y. Osaki1, Y. Miyazawa3, K. Toyama2, H. Koiso1, M. Akiyama1, H. Shima1, K. Toyama2
1Hematology Department, University of Medicine, Fukuoka, Fukuoka, Japan
2Department of Malignant Hematologic, Hokkaido University, Sapporo, Japan
3Department of Medical Oncology, Keio University, Tokyo, Japan

Background: High-dose chemotherapy before ASCT has been established as an effective treatment option for high-risk patients with chemo-sensitive ML. Although the therapeutic efficacy of this strategy highly depends on the conditioning regimens before ASCT, the appropriate regimen has been controversial. Thus, we performed a multi-center retrospective study of ASCT recipients with ML to compare the safety and efficacy of the conditioning regimens LEED and MCEC, which are widely used in Japan.

Aims: The primary objective was to determine the preferable conditioning regimen before ASCT: LEED or MCEC.

Methods: This study analyzed 127 adult patients who underwent ASCT for LEED or MCEC as the conditioning regimen against chemo-sensitive ML at four institutions in Japan between 1997 and 2015. Any type of pathological diagnosis was considered. The LEED regimen consisted of 140 mg/m² cyclophosphamide (days −4 to −3), and 40 mg/kg body dexamethasone (days −1 to 4). The MCEC regimen consisted of 200 mg/m² Methotrexate (days -4 and -3), 300 mg/m² carboplatin (days 7 to −4), 500 mg/m² etoposide (days −6 to −4), and 50 mg/kg cyclophosphamide (days 7 to −3). Fisher’s exact test was used to compare binary variables. OS rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Cumulative incidence table of relapse and non-relapse mortality (NRM) was estimated using the stratified Gray test. The Cox proportional hazards regression model was used for multivariable analysis of OS. Values of p <0.05 were considered significant.

Results: Of the 127 patients, 76 were male and 51 were female, and the median age was 32 years (range 18 to 68 years). Underlying diseases were DLBCL in 74 patients, mantle cell lymphoma in 16, other B-cell lymphoma in 14, Hodgkin lymphoma in 9, and T-NK-cell lymphoma in 14. The disease status at the time of transplant was first complete remission (CR) in 68, advanced CR in 27, and partial remission in 32. As the conditioning regimens before ASCT, 81% (103) of the patients received the LEED regimen, and 19% (24) the MCEC regimen. No significant differences in patient characteristics, disease features, or transplant procedures were present between the two groups except for the following three factors: (1) ASCT in the longer period (2007-2015) in the LEED group compared with the MCEC group (72% vs 13%; p<0.01); (2) fewer patients with advanced disease before ASCT in the LEED group (47% vs 59%; p<0.01); and (3) less frequent radiation therapy before ASCT in the LEED group (17% vs 37%; p=0.02). The 5-year OS rates were not significantly different between the LEED and MCEC groups (77% vs 88%; p=0.35). Likewise, both the 5-year OSs of relapse and NRM were similar in the two groups (NRM: 1% vs 3% (p=0.61), RR: 1% vs 5% (p=0.71). In multivariate analysis that included the transplant periods, rituximab administration, and radiation therapy as independent variables, two or more prior regimens was extracted as an independent unfavorable prognostic factor for OS, but not conditioning regimens. Regimen-related toxicities within 100 days after ASCT were less frequent in grade 3-4 nausea (56% vs 78%; p<0.01), vomiting (4% vs 28%; p<0.01), diarrhea (36% vs 56%; p=0.02), and liver dysfunction (4% vs 36%; p<0.01) were significantly decreased in the LEED group. The 5-year OSs of secondary MDS/AML were similar between the two groups (4% vs 3%; p=0.62).

Summary/Conclusions: Our findings demonstrated that both the LEED and MCEC regimens showed sufficient anti-lymphoma effect as conditioning regimens before ASCT, with a 5-year OS rate of more than 70% in patients with chemo-sensitive ML. However, the LEED regimen is considered more preferable in comparison with the MCEC regimen based on the low frequency of severe regimen-related toxicities. A large-scale prospective study is warranted to confirm these findings.
PB2163
IMPROVEMENT IN BIVENTRICULAR CARDIAC MECHANICS NOTED IN PATIENTS UNDERGOING MYELOABLATIVE AUTOLOGOUS-HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ALamyloidosis
S. Heitner,1,2 C. Portell,2. E. Scott
1Knight Cardiovascular Institute, 2Department of Medicine, 3Knight Cancer Institute, Oregon Health and Science University, Portland, United States

Background: Primary amyloidosis (AL) is characterized by extracellular deposition of insoluble protein fibrils often with multisystem organ involvement. The Mayo staging model for determining prognosis in patients with cardiac amyloidosis takes into account troponin, NT-proBNP, and serum free-light chain difference in order to stage patients prior to undergoing autologous hematopoietic stem cell transplant (Auto-HCT). Since amyloidosis often involves the kidneys, serum biomarkers that require renal clearance are less reliable in the setting of significant renal dysfunction. 2D-echo and strain imaging offer non-invasive modalities for identifying early cardiac changes independent of renal function. These changes may also precede symptom improvement as assessed by NYHA classification.

Aims: Our hypothesis is that strain imaging is a feasible biomarker for cardiac response after Auto-HCT in AL amyloidosis.

Methods: Seven patients with biopsy-proven AL amyloidosis who were treated with a Melphalan based myeloablative regimen and Auto-HCT were evaluated retrospectively. Each patient underwent 2D-echo up to 36-days prior to treatment followed by repeat 2D-echo within 14-months. Strain imaging was performed using Echolnsight®. Chart review was conducted to determine associated NYHA functional classification and Mayo staging. Statistical analysis was performed using SPSS.

Results: Of the 7 patients studied, 3 were Mayo stage I, 2 stage II, 1 stage III, and 1 stage IV. The median follow-up from transplant was 47.4 months. There was one death at 20.4 months. The mean NYHA classification at baseline was 2.3 and after transplant was 1.9. Longitudinal, radial and circumferential left ventricular strain (LV) were evaluated, but only the global longitudinal strain (GLS) showed an improvement (baseline -14.69%; follow-up -16.84%; mean absolute improvement 2.15%; p <0.05). There wasn’t significant change in left ventricular ejection fraction (LVEF) (Figure 1).

PB2164
AN ABSOLUTE NUMBER OF CD34+ CELLS IN BLOOD AS A PREDICTOR OF A SUCCESSFUL HARVEST OF HEMATOPOIETIC STEM CELLS IN DIFFERENT MOBILIZATION REGIMENS
I. Galtseva,1 Y. Davydova,1 T. Gaponova,1 N. Kapranov,1 L. Kuzmina,1 V. Troitskaya,1 E. Zvonkov,1 E. Parovichnikova,1 L. Mendeleeva,1 V. Savchenko1
1Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Autologous stem cells transplantation (ASCT) has become necessary part in therapy of hematological diseases. Transfusion of at least 2x10^6 CD34+ HSCs per kg of patient’s weight allows achieving an adequate hematopoiesis after high-dose chemotherapy. The most optimal is to collect 2-10^5 CD34+ cells/kg with single harvest apheresis. Different mobilization regimens are used for optimal collection of CD34+ HSCs. We demonstrate that there is a clinically meaningful number of significant renal dysfunction. 2D-echo and strain imaging offer non-invasive modalities for identifying early cardiac changes independent of renal function. These changes may also precede symptom improvement as assessed by NYHA classification.

Aims: Our hypothesis is that strain imaging is a feasible biomarker for cardiac response after Auto-HCT in AL amyloidosis.

Methods: Seven patients with biopsy-proven AL amyloidosis who were treated with a Melphalan based myeloablative regimen and Auto-HCT were evaluated retrospectively. Each patient underwent 2D-echo up to 36-days prior to treatment followed by repeat 2D-echo within 14-months. Strain imaging was performed using Echolnsight®. Chart review was conducted to determine associated NYHA functional classification and Mayo staging. Statistical analysis was performed using SPSS.

Results: Of the 7 patients studied, 3 were Mayo stage I, 2 stage II, 1 stage III, and 1 stage IV. The median follow-up from transplant was 47.4 months. There was one death at 20.4 months. The mean NYHA classification at baseline was 2.3 and after transplant was 1.9. Longitudinal, radial and circumferential left ventricular strain (LV) were evaluated, but only the global longitudinal strain (GLS) showed an improvement (baseline -14.69%; follow-up -16.84%; mean absolute improvement 2.15%; p <0.05). There wasn’t significant change in left ventricular ejection fraction (LVEF) (Figure 1).

Summary/Conclusions: We demonstrate that there is a clinically meaningful improvement in cardiac mechanics one year after Auto-HCT, despite no alteration in LVEF. This metric may prove useful in assessing organ response, especially when serum biomarkers are less reliable. Changes in left ventricular GLS occur independent of pre-transplant Mayo stage, although prospective studies are needed for confirmation. We further believe that improvements in RVFWS may predict clinical improvement.

PB2165
QUANTIFICATION OF CD34+ CELL AND ITS VIABILITY OF FRESH OR CRYOPRESERVED NUCLEATED CELLS BY IMAGE-BASED CELL COUNTER IS COMPARABLE TO STANDARD FLOW CYTOMETER
1Department of Pediatrics, 2Blood & Marrow Transplantation Center, 3Department of Internal Medicine, Hanyang University Medical Center, 4NanoEntek, Seoul, Korea, Republic Of

Background: As a standard method for quantification of CD34+ stem cells, flow cytometry has been widely used. However, it has some limitations such as
expensive instrumentation, high reagent costs, and poor reproducibility between technicians and laboratories.

Aims: We developed and assessed an instrument performance of a newly-developed image-based microscopic cell counter (ADAM II™) for enumeration of CD34+ cell and its viability.

Methods: We used samples of fresh and cryopreserved nucleated cells from G-CSF-mobilized peripheral blood stem cells (PBSCs) as well as cord blood (CB). We assessed the reproducibility and linearity of the new device and compared numbers and viabilities of CD45+ cells and CD34+ cells determined with the ADAM II™ and flow cytometer.

Results: Each analysis used 10 aliquots from one sample to assess the reproducibility of ADAM II™ with expected (y) = 1.473 ± 0.077 × 172.06 ± 1.20 (CD45+) 0.08–0.56 CD34+(%)/CD45. The number of CD45+ cells determined by ADAM II™ was sufficiently accurate over the expected range, and the intra-assay coefficient of variation (CV) was ≤10.8%. The linearity of CD45+ count was confirmed over a range of dilutions (0.59–200 cells/μl) of sample. Linearity was excellent (R²>0.988). The numbers and viabilities of CD45+ cell and CD34+ cell obtained with the ADAM II™ were highly correlated with those obtained with the flow cytometer (R²>0.9841, P<0.0001). In all samples from fresh/cryopreserved PBSC and fresh/cryopreserved CB, there were no significant differences in total numbers and viabilities of CD45+ cell and CD34+ cell counts by the ADAM II™ and flow cytometer.

Summary/Conclusions: The newly developed image-based microscopic cell counter (ADAM II™) appears to be suitable for quantification of CD34+ cell and its viability of fresh or cryopreserved PBSCs or CBs.

PB2166

EXTRACORPOREAL PHOTOPHERESIS IN STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE I. Sakellari1, I. Batis1, E. Gavrilaki1, A. Panteliadou1, A. Lazaridou1, K. Leontopoulos1, D. Mallouri1, A. Bountia1, V. Constantinou1, E. Yannaki1, C. Smial2, A. Anagnostopoulos1

1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

Background: Extracorporeal photopheresis (ECP) has been incorporated in the management of graft-versus-host disease (GVHD) post allogeneic hematopoietic cell transplantation (allo-HCT) in many centres. The introduction of ECP as an early second-line treatment in steroid-dependent or refractory patients with acute GVHD (aGVHD) remains under study. The rationale of its early use is based on the low incidence of complete responses to corticosteroids and the profound immunosuppression caused by traditional secondary treatments.

Aims: Based on our long-lasting experience in chronic GVHD, we aimed to prospectively assess the role of ECP in this high-risk population.

Methods: We enrolled consecutive patients with steroid-dependent or refractory grade (gr) II-IV aGVHD post allo-HCT from January 2013 to August 2016. All patients with unrelated or haploidentical donors received thymoglobulin (ATG) 5mg/kg as prophylaxis. Post-transplant GVHD prophylaxis included cyclosporine – methotrexate in myeloblastic and cyclosporine – mycophenolate mofetil in reduced toxicity or intensity regimens. ECP was commenced after assessment of response to 5 days of steroid treatment according to our protocol: 2 sessions/week for 1 month, 1 session/2 weeks for 3 months, evaluation of response and 1 session/month for 6 months.

Results: We studied 20 patients, aged 35 (18-65), post allo-HCT with myeloblastic (14), reduced toxicity (4) and intensity (4) conditioning, from sibling (3), matched (8) or one locus mismatched (8) volunteer unrelated and haploidentical (3) donors. Disease risk index was high (10), intermediate (9) and low (1). Acute GVHD was observed at day +17 (8-50) in 15 patients, late-onset at +130 (110-160) in 4 patients and induced at +38 post donor lymphocyte infusion in a relapsed AML patient. Skin, intestine and liver involvement was evident in 6 patients, skin and intestine in 10 and skin only in 4 patients. Nine patients (2 with GrI, 7 with GrII, 2 with GrIII) were steroid-dependent and 11 (8 with GrIII, 3 with GrIV) steroid-refractory. ATG was administered simultaneously with ECP initiation in 14 and 13 respectively and other viral infections were found in 5 patients. Cumulative incidence of bacterial infections were found in 17 patients, fungal in 2, CMV and EBV reactivation in 14 and 13 respectively and other viral in 5 patients. Cumulative incidence (CI) of chronic GVHD was 77.4±1-year. 1-year CI of aGVHD-related mortality was 29%. 1-year overall survival (OS) was 53% and significantly increased in patients with improved OS, irrespectively of other factors. Optimal timing of intervention, frequency, duration and tapering schedule of ECP need to be investigated in future studies.

Summary/Conclusions: Our study supports that ECP should be considered early in the course of steroid-dependent or refractory aGVHD, before significant irreversible end organ damage has been established. Optimal timing of intervention, frequency, duration and tapering schedule of ECP need to be investigated in future studies.

PB2167

RAPID RECONSTITUTION OF NK1 CELLS IS ASSOCIATED WITH THE LOWER INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENIC TRANSPLANTATION X. Zhao1, X. Xu1, Y. Chang1, X. Huang1

1Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China

Background: The balance between immunostimulation and immunoregulation in T cell immunity is achieved by a Th1/Th2/T3r/T1 and CD4+CD25+ regulatory T (Treg) cell paradigm.

Aims: We investigated the production of type1 (IFN-gamma, NK1), type2 (IL-13, NK2), type3 (TGF-beta, NK3) and regulatory cytokines (IL10, NKr) from human peripheral blood to discuss the cytokine paradigm of NK cells in human allogeneic hematopoietic stem cells transplantation (allo-HSCT).

Methods: Forty patients undergoing haploidentical (n=27) and HLA-identical sibling (n=13) allo-HSCT between August 2009 and December 2009 were enrolled in this analysis after being originally selected using a protocol exploring the association of reconstituted donor derived NK1/NK2/NK3/NKr cells to GVHD and CMV reactivation.

Results: Expansion of NK2 and NK3 were found post allo-HSCT compared to healthy donor. The levels of NKr reconstituted to donor’s level since day 15 post allo-HSCT, and the levels of NK1 in recipients post transplantation were consistently lower compared to donors levels until day 60 post allo-HSCT. Multivariate analysis showed that the higher levels of NK1 by day 15 were associated with lower overall acute GVHD (HR 0.157, 0.039-0.642, P=0.010) as well as II-IV acute GVHD (HR 0.260, 95%CI, 0.064-1.053, P=0.059). Meanwhile, the higher levels of NK1 by day 15 correlated with lower CMV reactivation (HR 0.101, 0.005-0.348, P=0.003).

Summary/Conclusions: These results indicate that rapid reconstitution of NK cells, especially NK1 cells would be help to prevent the development of graft-versus-host disease as well as CMV reactivation after allogeneic transplantation.

PB2186

BORTEZOMIB FOR STEROID-REFRACTORY RITUXIMAB AUTOIMMUNITY AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION M. Zine1, T. Khaid1, S. Kafka1, D. Bonney1, S. Hughes1, S. H. Lunn1, R. Wynn1

1Bone Marrow Transplant Unit, Royal Manchester Children’s Hospital, Manchester, United Kingdom

Background: Therapy of post-transplant autoimmunity manifestations remains a challenge. Many cases are steroid and rituximab refractory and continuing intensified immune suppression increase the risk of infection in the post-HSCT patient. In our institution, we have used bortezomib as our third agent after failure of steroids or rituximab, or in cases of steroid-dependence since Bortezomib appears to be effective in cases with refractory autoimmunity.

Aims: In our series, we assessed the therapeutic response to proteasome inhibitor in 4 cases of post-transplant refractory autoimmunity.

Methods: Three of the 4 patients treated with bortezomib developed autoimmune cytopenia (autoimmune haemolytic anaemia AIHA (n=2), AIHA with acquired red Cell aplasia (n=1)). At least 2 therapy lines had failed to resolve the cytopenia. One to two courses of Bortezomib were administered at a dose of 1.3 mg/m2 at day 1, 4, 8, 11 each course. In two cases this treatment was combined with immunosuppressive agents: Mycophenolate mofetil (MMF) alone in one case and associated with sirolimus in the other case.

Results: Resolution of autoimmune cytopenia was observed in the three cases after a median of 33 days from the first day of administration. The fourth case received 1 course of Bortezomib for persistent anti-enzyme antibodies after allogeneic transplant for Wolman disease. Therapeutic response was obtained after 25 days reflected by a complete regression of circulating anti-enzyme antibodies. In all cases, no Bortezomib related toxicity was noticed. The response was maintained in all cases.

Table 1 summarizes the clinical data and the results of the four cases.

Table 1

<table>
<thead>
<tr>
<th>Case</th>
<th>Diagnosis</th>
<th>Age at diagnosis (y)</th>
<th>Treatment</th>
<th>Rituximab</th>
<th>Response to rituximab</th>
<th>Bortezomib</th>
<th>Response to bortezomib</th>
<th>Duration of response</th>
<th>Successful treatment</th>
<th>Successful bortezomib</th>
<th>Total duration of treatment</th>
<th>Successful therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AIHA</td>
<td>22 (20-30)</td>
<td>Rituximab</td>
<td>2</td>
<td>NR</td>
<td>NR</td>
<td>2</td>
<td>4</td>
<td>NR</td>
<td>NR</td>
<td>6</td>
<td>NR</td>
</tr>
<tr>
<td>2</td>
<td>AIHA</td>
<td>33</td>
<td>Rituximab</td>
<td>2</td>
<td>NR</td>
<td>NR</td>
<td>2</td>
<td>4</td>
<td>NR</td>
<td>NR</td>
<td>6</td>
<td>NR</td>
</tr>
<tr>
<td>3</td>
<td>AIHA</td>
<td>39</td>
<td>Rituximab</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>2</td>
<td>4</td>
<td>NR</td>
<td>NR</td>
<td>6</td>
<td>NR</td>
</tr>
<tr>
<td>4</td>
<td>AIHA</td>
<td>18</td>
<td>Rituximab</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>2</td>
<td>4</td>
<td>NR</td>
<td>NR</td>
<td>6</td>
<td>NR</td>
</tr>
</tbody>
</table>
POST-THAW CELL COUNT PREDICTS ENGRAFTMENT RATE IN CORD BLOOD TRANSPLANTATION

K. Isobe1, K. Kohi1, R. Kawahito1, T. Itabashi1, M. Yanagi1, K. Sasaki1, K. Watanabe1, M. Morii1, Y. Arakawa1, R. Hanada1
1Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan

Background: The infused cell count in cord blood transplantation (CBT) is an important element for engraftment; however, the number in the prior reports has been based on the pre-thaw cell count. Therefore, the association between post-thaw cell count and engraftment rate, especially in pediatric patients, is unclear.

Aims: The aim of this study is to reveal the association between post-thaw cell count and engraftment rate in pediatric patients in the setting of CBT at our institution.

Methods: We retrospectively reviewed the medical records of 78 patients who underwent CBT between June 1998 and April 2016. We excluded the cases of CBT that required rescuing after engraftment failure.

Results: Underlying disease was acute leukemia (AL) in 63 (ALL: 38; AML: 25) patients, chronic myeloid leukemia in one, malignant lymphoma (ML) in two, myelodysplastic syndrome (MDS) in three, aplastic anemia in one, and others (such as primary immunodeficiency syndrome) in eight. In terms of conditioning regimens, myeloablative conditioning was administered to 62 patients and reduced intensity conditioning was administered to 16 patients. The median age at CBT was 3 (range: 0–19) years, and the median follow-up period was 896 (range: 47–6236) days. The engraftment rate was 84.6%, primary engraftment failure was observed in 11 patients (AL: seven; ML: one; MDS: one; neutroblatoma, one; and others, one) and secondary graft failure was observed in one patient (severe congenital neutropenia). The engraftment rate was 55.1%, and 32 patients had died (cause of death: progressive disease in 19 patients). We analyzed the data on 34 patients of whom both of pre- and post-thaw CD34+ cell counts in the cord blood samples were available. The median post-thaw CD34+ cell count was 1.60 x 10^6/kg in the patients who achieved engraftment and 1.01 x 10^6/kg in the patients who did not achieve engraftment. No statistically significant difference was observed between these two groups (p = 0.30). When we defined the cut-off value of the pre-thaw CD34+ cell count as 1.2 x 10^6/kg in the patients who were infused with CD34+ cells more than the cut-off value, the specificity and sensitivity of graft failure was 79.3% and 60%, respectively. When we defined the cut-off value of the post-thaw CD34+ cell count as 0.7 x 10^6/kg in the patients who were infused with CD34+ cells more than the cut-off value, the specificity and sensitivity of graft failure was 96.6% and 40%, respectively.

Summary/Conclusions: We concluded that the risk of graft failure is more precisely predicted by the post-thaw than pre-thaw CD34+ cell count and that if the post-thaw CD34+ cell count is more than 0.7 x 10^6/kg, the risk of graft failure is very low.

PB2170

COLONY-FORMING CAPACITY OF HEMATOPOIETIC STEM CELLS MOBILIZED INTO PERIPHERAL BLOOD WITH VINIRELBINE AND GRANULOCYTE COLONIES STIMULATING FACTOR

V. Balashova1, I. Kostroma2,*, I. Zapreeva2, V. Rugal’1, S. Bessmeltsev2, A. Chechetkin2, S. Griticaev2
1Laboratory of Leukemia Study, 2Hematological Clinic, Russian Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation

Background: One of the alternative method to mobilize stem cells from bone marrow to peripheral blood is using of vinorelbin with granulocyte colony stimulating factor (G-CSF). The specific features of vinorelbine are absence of hospitalization necessity and predictability of leukocytapheresis’ optimal time. But there is not enough data to conclude whether vinorelbine is safe for haematopoietic stem cells mobilization.

Aims: The aim of the study was to determine the colony-forming capacity of hematopoietic stem cells mobilized into peripheral blood with vinorelbine and G-CSF.

Methods: Data of 11 patients with multiple myeloma (MM) and 1 patient with Hodgkin lymphoma (HL) were analyzed. Vinorelbine was injected IV in dose 50-70 mg (35 mg/m2). Daily lenograsit dose was 10 mcg/kg. The number of BFU-E, CFU-GM, CFU-GMME and CFU-Macrophage in patients’ group was 207, 180, 14 and 9 accordingly. The results were not significantly different from control group data: 168, 170, 10 and 12 accordingly; p>0.05.

Summary/Conclusions: We conclude that mobilization regimen with vinorelbine in combination with G-CSF does not damage colonyforming capacity of hematopoietic stem cells.

PB2171

URIC ACID LEVEL MIGHT BE A PROGNOSTIC INDICATOR FOR SURVIVAL IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE

N. Mandaş Şanlı1,*, S. Şvgım1, L. Kaynar1, B. Eser1, M. Cetin1, A. Ünal1
1Hematology and Bone Marrow Transplant Center, Erzinc University School of Medicine, KAYSERI, Turkey

Background: Uric acid (UA) is an abundant aqueous antioxidant that accounts for almost two thirds of all free-radical-scavenging activity in human serum. It is released from injured cells during conditioning for allogeneic hematopoietic stem cell transplantation (AHSCT).

Aims: The aim of this study was to evaluate the prognostic impact of pre-transplant uric acid levels on survival and mortality in allogeneic HSC patients.

Methods: We retrospectively analyze 273 patients with hematologic diseases undergoing AHSCT. The patients were categorized as patients with acute leukemia, myelodysplastic syndrome, lymphoma patients and other hematologic disease diagnoses. A serum uric acid concentration 3.4 mg/dl was considered hypouricemia. Pretransplantation uric acid, creatine, total protein and albumin were analyzed. Univariate, multivariate Cox regression models and Kaplan–Meier curves were performed to uric acid, creatine, total protein and albumin associated with disease-free survival (DFS) over all survival (OS), early non relaps mortality (+30 day) and late non relaps mortality (+100 day).

Results: Pretransplantation low uric acid levels were detected in 57 % (2.08) mean of UA levels were significantly associated with DFS (HR: 0.52; p = 0.027). None of the creatine, total protein and albumin were significantly associated with DFS (HR: 0.98; p = 0.98, HR: 0.87; p=0.60, HR: 1.15; p = 0.66 ). There was no significant association between UA, creatine, total protein and albumin levels and overall survival (HR: 0.84; p = 0.48, HR: 2.10; p = 0.057, HR: 0.88; p = 0.52, HR: 0.78; p = 0.26), early relapse mortality (HR: 1.38; p=0.54, HR: 2.16; p = 0.29, HR: 0.61; p = 0.25, HR: 0.53; p = 0.13 ) and late non-relapse mortality (HR:0.57; p=0.35, HR: 0.21; p=0.29, HR: 1.04; p = 0.94, HR: 1.07; p = 0.92).

Summary/Conclusions: Uric acid is a natural antioxidant compound. UA reacts with oxygen-derived free radicals and becomes oxidized. Since humans are unable to catabolize UA to the more soluble compound allantoin due to lack of urate oxidase or uricase, the serum UA concentration is higher in humans than almost all other mammals. However, this high UA level in humans has been regarded as being beneficial in the presence of elevated oxidative stress. Our study supports that the uric acid is an antioxidant compound. Further in vitro and in vivo studies evaluating the effects of urate oxidase or uricase on disease outcomes in patients with hematologic malignancies undergoing chemotherapy may be warranted.

PB2172

RISK FACTORS FOR HERPES SIMPLEX VIRUS-1/2 VIREMA AND CLINICAL OUTCOMES FOLLOWING UNMANIPULATED HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION

F.-F. Tang1, L.-P. Xu1, X.-H. Zhang1, H. Chen1, Y.-H. Chen1, X.-D. Mo1, Y.-Q. Sun1, K.-Y. Liu1, X.-J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology, 2Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Background: Herpes simplex virus(HSV)-1/2 can still be reactivated after allogeneic hematopoietic stem cell transplantation (allo-HSCT) even when the prophylactic acyclovir is used. However, the risk factors for HSV-1/2 viremia and the clinical outcomes following unmanipulated haploidentical HSCT remain unknown.

Aims: The aim of this study was to explore the risk factors for HSV-1/2 viremia and the clinical outcomes following haploidentical HSCT.

Methods: Nineteen patients with HSV-1/2 viremia and fifty-seven patients without HSV-1/2 viremia were included in this prospective study. The risk factors for HSV-1/2 viremia included HLA disparity ≥2 loci and to evaluate clinical outcomes following haploidentical HSCT.

Results: Patients with HSV-1/2 viremia and fifty-seven patients without HSV-1/2 viremia were selected using the case-pair method after haploidentical HSCT were enrolled. We analysed the risk factors for HSV-1/2 viremia and compared clinical outcomes between the two patient groups.

Discussion: The risk factors for HSV-1/2 viremia included HLA disparity ≥2 loci (p = 0.049) and cytomegalovirus (CMV) reactivation (p=0.028). The incidences of platelet engraftment, oral mucositis and severe haemorrhagic cystitis (HC) in patients with and without HSV-1/2 viremia were 77% and 94% (p=0.003),
78% and 13% (p=0.000), and 25% and 6% (p=0.04), respectively. Moreover, the median time to platelet engraftment in patients with and without HSV-1/2 viremia was 25 d(range, 11–80 d) and 17 d(range, 8–67 d) (p=0.004). In a multivariate analysis, HSV-1/2 viremia was associated with delayed platelet engraftment(p=0.038), a higher incidence of oral mucositis(p=0.000) and severe HC (p=0.038). However, HSV-1/2 viremia was not associated with non-relapse mortality (34.0% ± 11.6% vs 31.5% ± 26.0%, p=0.26), leukoencephalopathy-free survival (60.9% ± 57.9%, p=0.46) and overall survival (61.2% vs 60.7%, p=0.37) (Figure 1).

**Summary/Conclusions:** Our data suggest that Flu/Mel-based RIST was a promising strategy for patients with hematologic malignancy, irrespective of (?) donor or stem cell sources. However, GRFS and OS of MDS were significantly worse than those of AL, and MDS is strongly associated with high NRM even with RIST. This indicates that we should pay more attention to NRM in MDS.

**Background:** Hemorrhagic cystitis (HC) is a serious complication occurring after allogeneic hematopoietic stem cell transplantation (HSCT) more frequent on haploidential (haplo) HSCT, with an incidence of 10% to 70% (Silva et al Haematologica 2010;95(7):1183–1190) associated mainly with the effect of cytotoxic agents such as Cyclophosphamide (Cy). The conditioning regimen, BKPyV infection and graft versus host disease have an implication in the incidence. Other authors related the reactivation of CMV and a previous transplantation as risk factors to HC development (Ruggen et al Transplant Infectious Disease 2015;17:822–830).

**Aims:** With this study we aim to describe the HC incidence and risk factors in all haplo-HSCT performed in the Canary Islands.

**Methods:** We analyzed all consecutive haplo-HSCT from family donors performed at our Hospital between 2013 and 2016. The conditioning regimen used for the transplant was the Hopkins haplo protocol with high dose Cy (50 mg/kg on days 3 and 4) post-transplantation (PTCy). We used as HC prophylaxis intense hydration on the Cy administration day and the following 24 hours (using bladder wash only in 1 patient with cardiac dysfunction) and perfused MESNA at 100% of Cy dose beginning 15 minutes before the Cy administration on 16 pts and at 20% of the last dose at 0, 4 and 8 hours on all pts. We used SPSS V.23 to determine the cumulative incidence (CI) of HC.

**Results:** We performed 20 haplo-HSCT, of which 10 were males (1 was transplanted 3 times) and 8 were women. The mean age was 40 (range 16–64). The pts presented the following diagnosis: AML (10), ALL (1), EH (5), NHL (3), AM (1). 45% of pts received the haplo-HSCT in remission, 50% with refractory disease and 5% of pts did not receive previous treatment. 6 pts developed HC (36.5% CI at day +80) (Figure 1a) with a median time from haplo-HSCT to onset of 23 days (range 3-42), 1 (17%) was grade I, 1 (6%) grade II and 1 (17%) grade IV. The grade I case did not received the MESNA infusion like most of the other pts. 12 pts received Cy pre- and post-transplant and only 8 pts received PTCy. The CI at day +80 for the pts with PTCy was 33.3% and for Cy pre- and post-transplant 38.3% (Figure 1b). We found no statistically significant difference on the CI of HC between these two groups. The development of HC was related to Cy in 1 patient, who suffered from this complication on the second and third haplo-HSCT. For the rest of the pts (after day +30) the HC was related to BKPyV infection, as a consequence of the immunosuppression state of the patient, we also observed all these pts had positive serum viral load for CMV.

**Summary/Conclusions:** The incidence of HC associated to post-HSCT high Cy dose in our series is 15% lower than other ones. Most of them on grade 1 or 2 and without mortality associated. The risk of HC is high, particularly in the setting of highly pre-treated patients (especially those undergoing a 2nd transplant). The development of HC after day +30 is evidently associated to BKPyV as a contributing factor for continuous inflammation and CMV reactivation (as an immunosuppression marker). In our study, HC did not have an impact on the overall or disease-free survival of high-risk patients after haplo-HSCT. The HC remains frequent with a high morbidity in particular when it is severe, often causing prolonged hospitalization and resource use. We need further studies to recognize the at-risk population early.
OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANTATION AFTER TREATMENT WITH THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB

F. Ramdohr1, G.-N. Franke1, M. Jentzsch1, W. Pönisch1, C. Michael1, S. Heym1, S.-Y. Wang1, G. Behre1, S. Leiblein1, S. Schwind1, D. Niedenwieser1, V. Vucinic1

1Dept. Hematology & Clinical Oncology, University of Leipzig, Leipzig, Germany

Background: Although the Bruton tyrosine kinase (BTK) inhibitor ibrutinib significantly improves the prognosis of CLL patients (pts), allogeneic hematopoietic stem cell transplantation (HCT) remains the only curative option for the underlying disease. Data on pre-transplant treatment of CLL with ibrutinib are very limited.

Aims: Here we present our experience of HCT in pts previously treated with ibrutinib.

Methods: 11 CLL pts (median age at HCT 57 years [p], range 52-66 y) treated between 2014 and 2016 in our unit with non-myoeloblastic (nma) HCT after ibrutinib were included. Ibrutinib treatment lasted median 4.03 months (range 1-28). Conditioning regimen was Fludarabin 30 mg/m² on day -4 to -2 followed by 2 Gy total body irradiation. Disease status at HCT was Binet B (n=3) or Binet C (n=8). Two pts had Richter’s transformation (RT) diagnosed before nma-HCT. Ten pts were in partial remission (PR) at nma-HCT (PR1 n=4; PR2 n=3; PR3 n=2, PR4 n=1) while one was in first relapse. Donors were human leukocyte antigen (HLA) matched related (n=3, MRD) or HLA-matched unrelated (n=8, MUD). Pts received median 3 lines of therapy (range 1-6) including ibrutinib before transplantation. Classical cyto genetic analysis and fluorescence in situ hybridization (FISH) was carried out for every pt. Five pts had a deletion (del)(17p13) and one a del(11q22.3).

Results: The average overall survival (OS) for all pts was 471 days (range 36-812) (Figure 1). The average OS of patients with del(17p13) was 379 days (range 66-628) compared to 456 days (range 36-812) for those without del(17p13, p=0.98). OS was not significantly influenced by the stem cell source (MUD vs MRD, p=0.63) or remission status PR1 vs >PR1 (353 vs 472 days, p=0.79). Non-matched CMV-Status (negative recipient and positive donor or positive recipient and negative donor) had an OS comparable to that of matched CMV-Status (p=0.73). Pts above the median age had a lower OS although this didn’t reach significance (p=0.39). EFS was median 125 days (range 26-628). Pts with or without a TP53 alteration had a similar EFS (p=0.91). Pts undergoing MRD-HCT had better EFS than those undergoing MUD transplantation (p=0.055). CMV-Status or age>median had no prognostic influence on the EFS (p=0.83 and p=0.39 respectively). Non-relapse mortality (NRM) was 32% at 10 months (Figure 1), which was consistent with a previous publication from our group (30% at 4y). The acute GVH Grade 3-4 was present in 3 pts (27.2%).

Summary/Conclusions: Impact of chimerism in different T-helper subsets still need further investigation. We will continue our research and further results will be reported later.

ADIPOSE TISSUE CHANGES IN LYMPHOMA PATIENTS IN THE PERI TRANSPLANTATION PHASE

J. Jabbour1,2, B. Manana3, M. Tahrihadjène4, C. Saadeh5, C. Maya3, A. Bazbarbach6, D. Blaise6, J. El Cheikh3,*

1Clinical Nutrition, American University of Beirut Medical Center, Beirut, Lebanon, 2Ecole Doctorale Sciences de la vie et de la santé, Aix Marseille Université, Marseille, France, 3Division of Hematology/Oncology, 4Bone Marrow Transplantation Program, 5Department of Radiology, American University of Beirut Medical Center, Beirut, Lebanon, 6Programme de Transplantation et Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

Background: Abdominal Visceral Adipose Tissues (VAT) have been shown to have inflammatory activity and have been used to predict cancer outcomes. The ratio of VAT/Total Adipose Tissues (TAT) is a negative predictor of progression free survival in Lymphoma patients on chemotherapy. This study aims to assess the changes in the VAT/VAT ratio of stem cell lymphoma recipients in the peri-transplantation phase.

Methods: Institutional Review Board approved this retrospective study for adult patients (age≥16 years) having B and T lymphoma who underwent Stem Cell Transplantation (SCT). Each patient was imaged by PET/CT scan pre-SCT and in the first 3 months post transplantation. A cross sectional image was analyzed at the level of the L3 to calculate VAT, TAT and Waist Circumference (WC). Data was analyzed by gender since body composition parameters differed significantly between the two categories in the literature.

Results: The study sample consisted of 91 patients [mean age: 37.5±13.5 years, n=52 (57%) males, n=81 (87%) autologous SCT, n=12 (13%) allogeneic SCT, median overall survival in months: 12 in males and 19 in females]. Death was observed in 6 (11.5%) males and 1(2.4%) female. Patient characteristics were similar across gender categories except for weights (kg) and Body Mass Index (kg/m²): 88.1 and 26.8 vs 62.2 and 25.0, in males and females respectively (p>0.05). Changes from pre-SCT to 3 months post SCT revealed that TAT and VAT decreased with mean differences of 33±56 cm² (p<0.01) and 7.0±36 cm² (p=0.17) in males and 16±44 cm² (p=0.01) and 4±14 cm² (p=0.056) in females, respectively. Waist circumference decreased significantly with mean

Summary/Conclusions: Impact of chimerism in different T-helper subsets still need further investigation. We will continue our research and further results will be reported later.
differences of 3.9±4.9 cm and 2.8±4.4 cm in males and females, respectively (p<0.01). VAT/TAT witnessed a slight increase in males and reduction in females (p>0.05). In multivariate analysis, no significant associations were shown with mortality and progression rates (Figure 1).

Figure 1.

Summary/Conclusions: This study provides data on the evolution of adipose tissues parameters in the peri-transplantation phase. VAT, VAT and WC decrease within 3 months post transplantation. Future studies should evaluate the associations of these parameters with major outcomes on larger sample sizes.

PB2178
NON RELAPSE MORTALITY (NRM) ANALYSIS IN 93 UNRELATED DONOR TRANSPLANTATION - SINGLE CENTRE EXPERIENCE - HLA HAPLOTYPE ROLE?
P. Mensah-Gianowski1,2, B. Piątkowska-Jakubas1,2, A. Radziszewska2, A.B. Skotnicki1,2
1Department of Haematology, Krakow University Hospital, 2Department of Haematology, Collegium Medicum Jagiellonian University, Krakow, Poland

Background: Unrelated donor stem cell transplantation has a curative potential against haematological malignancies. However there are concerns about associated risk of non-relapse mortality. We performed a retrospective single centre study of causes of non-relapse mortality over four year period - 2012-2016.

Aims: Purpose of the study was to analyse non-relapse mortality (NRM) in patients subjected to unrelated donor transplantation in four-year-period: 2012 to 2016 - 93 transplant procedures in 86 patients.

Methods: Study cohort was analysed - relapse rate and non-relapse mortality were assessed. Causes of both - early and late NRM were studied.

Results: There were 23 relapses in the group of assessed patient cohort (24.7%). 7 patients underwent the second transplant - five patients - because of AMR relapse; T - because of severe GVHD; 1 patient with graft failure. Out of re-transplanted 7 patients - 3 patients are alive - 2 patients with graft failure and one with post-transplant AML relapse in 2nd CR. Out of 93 procedures of unrelated donor transplantation there were 16 cases of death - assumed as non relapse mortality NRM (17%). There were 9 early deaths (before day +100) - 6 cases in patients with relapsed/refractory acute leukaemia without remission after conventional chemotherapy. These patients were subjected to sequential conditioning with cytreduction phase. Active disease and highly active conventional chemotherapy. These patients were subjected to sequential conditioning with cytreduction phase. Active disease and highly active antileukaemic treatment can be reason for higher treatment related toxicity and elevated risk of death. Later two patients developed infectious bacterial complications with septic shock. In one patient - antiviral treatment refractory CMV encephalitis with massive macrophage activation syndrome was diagnosed. Analysis of NRM after day 100 revealed 7 affected patients. All these patients GVHD 2-4 was diagnosed previously, accompanied by transplant associated microangiopathy (TAM) and infections - both viral and fungal. Additionally to factors connected to NRM - age, comorbidity score, patient/donor HLA allelic and antigen and sex mismatches, HLA patient/donor haplotypes were analysed. It was possible to categorise 15 out of 16 NRM patients into 5 HLA class II haplotype groups connected with autoimmune diseases in Caucasian population - rheumatoid arthritis and lupus erythematosus: DRB1 01:01 DQB1 05:01 (6 patients), DRB1 03:01 DQB1 02:01 (4 patients), DRB1 11:01 DQB1 03:01 (3 patients), DRB1 15:01 DQB1 06:02 (2 patients), DRB1 04:01 DQB1 03:02 (1 patient).

Summary/Conclusions: Based on these results we create working hypothesis that HLA class II haplotype may predispose to severe post-transplant infectious or/and non-infectious complications and affect the risk of NRM. Because small number of analysed patients and documented high frequency of these haplotypes in population, further analysis is required.

PB2179
HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH HIGH DOSE CYCLOPHOSPHAMIDE POST-TRANSPLANT IN HIGH RISK HEMATOLOGIC MALIGNANCIES: RISK FACTOR AND OUTCOME ANALYSES IN OUR CENTER
J. Viedma1,*, M. Saez-Perdomo1, M. Perera1, A. Suarez1, J. Lopez1, C. Medina1, L. Guerra1, M. T. Gómez-Casares1, H. Luzardo1, T. Molero1, S. Jimenez1
1Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

Background: Allogenic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for a variety of hematological malignancies. However, a lack of HLA-identical sibling donors or unrelated donors has restricted the application of allo-HSCT in hematological malignancies. Haploidentical HSCT (Haplo-HSCT) offers the benefits of rapid and nearly universal donor availability and, in the past decade, has been accepted worldwide as an alternative treatment for patients with hematological malignancies who do not have an HLA-identical sibling donor or who require urgent transplantation.

Aims: The purpose of this study was to investigate the incidence, causes and factors influencing overall and transplant-related mortality after Haplo-HSCT.

Methods: We analyzed all consecutive patients receiving Haplo-HSCT from family donors at our hospital from 2013 to 2016. The conditioning regimen used for the transplant was the Hopkins haplo protocol with high dose Cy (50 mg/kg on days 3 and 4) posttransplantation. We classified the patients before the Haplo-HSCT according to disease risk index (DRI), ECOG, Sorror score and EBMT risk score to evaluate the correlation between the physical state of the patients before the transplant and the survival (overall mortality (OM) and transplant-related mortality (TRM)). We used SPSS V.23 to calculate the cumulative Mortality incidence by the KM test and the Cox proportional hazards model.

Figure 1.

Results: We performed 20 haplo-HSCT. 10 were males (1 was transplanted 3 times) and 8 were females mean age of 40 (range 16-64). Diagnosis: AML (10), ALL (1), EH (5), NHL (3), AM (1). Forty five percent of patients received the haplo-HSCT in remission, 50% with refractory disease and 5% of patients did not receive previous treatment. Of the 20 patients from our series, 12 died post transplant with an OM of 60%. The cumulative incidence (CI) of OM was 15% at 1 month (m), 35% at 3 m, 45% at 6 m, 55% at 1 year, and 40% at 2 and 3 years (Figure 1a). When we analyzed the OM depending on the different physical status scores we found no statistically significant differ-

862 | haematologica | 2017; 102(s2)
ence between OM from the different states of EBMT (p=0.356) and DRI (p=0.07), however we found a statistically significant difference for ECOG (p=0.028) (Figure 1b) and Sorror (p=0.016). On a pairwise analysis the OM we found no statistically significance for EBMT, and found a statistically significant difference between the patients with low-high DRI (p=0.01), intermediate-high DRI (p=0.001), ECOG 0-1 (p=0.046) and Sorror 0-5 (p=0.003). The multivariate analysis showed that ECOG 2 vs 0 (p=0.013, HR=4.65); Sorror 2-3 vs 0-1 (p=0.041, HR=19.55) and Sorror 4-5 vs 0-1 (p=0.005, HR=282.48) were significantly related with a higher incidence of OM. Five patients died of infection (41.67%), 3 of disease progression (25%), 1 of relapse (8.33%) and 3 of other causes (25%). Six patients died of TRM (50%).

The CI of TRM was 10.5% at 1 m and 31.6% at 3 m. 6% at 6 m, 1% at 2 years and 3 years (Figure 1c). When we analyzed the TRM depending on the different physical status scores we only found a statistically significant difference between TRM incidence from the different states of ECOG (p=0.038) (Figure 1d) and no statistically significant difference for EBMT (p=0.366), DRI (p=0.372) and Sorror (p=0.342). The multivariate analysis we found statistically significant differences between ECOG 1-2 (p=0.018) and EBMT 1-5 (p=0.046), for Sorror we found a marginal statistical significant difference between 0-1 (p=0.052), 0-2 (p=0.052) and 0-5 (p=0.052), for DRI we found no statistically significant difference. On the multivariate analysis we found no statistically significant correlation between TRM and the physical status scores.

Summary/Conclusions: Despite the fact that Sorror, EBMT and DRI scores are widely evaluated to establish the risk of patients undergoing HSCT, in our experience ECOG remains a useful score for assessing the risk of TRM on patients receiving Haplo-HSCT. We think further studies with a larger sample would be necessary to confirm our results.

PB2180

A SIMPLIFIED METHOD OF CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS WITH OVER 10% GRANULOCYTE CONCENTRATION FOR LESS THAN 36 MONTHS


1Transfusion and Cell Therapy; 2Hematology, Aomori prefectural central hospital, Aomori; 3Gastroenterology and Hematology, Hirosaki University Hospital, Hirosaki, Japan

Background: The long-term stability of cryopreserved peripheral blood stem cells (PBSCs) is an important concern for patients experiencing disease relapse. However, the quality of long-term cryopreserved PBSCs stored at -80°C by using simplified method has not been elucidated in detail. Cryopreserved PBSCs undergo cell damage and decrease in viability, and those containing granulocytes might influence cell loss.

Aims: The aim of this study was to evaluate the effect of cryopreservation for less than 36 months and the number of granulocytes in the cryopreserved PBSC products on CD34+ cells.

Methods: We examined the effects of cryopreservation on the viability of CD34+ cells that were stored for less than six months and those stored for 7–24 months, and 25–36 months, and the change of CD34+ cell viability with higher granulocyte content. We also evaluated the correlations between the number of granulocytes in the cryopreserved PBSC products and the time to engraftment of leukocytes or platelet. Informed consent was obtained prior to the procedure from all the patients following institutional guidelines.

Results: A total of 65 PBSC samples were collected. We compared three groups based on the cryopreservation period: (1) less than 6 months, (2) 7–24 months, and (3) 25–36 months. The median (range) viability of CD34+ cells after thawing was 81.8% (58.2–94.4), 80.5% (56.6–92.8), and 76.1% (54.5–89.6) in the three groups, respectively. No significant difference in the viability of the cells in either frozen period was observed (p=0.14, respectively). We compared the effect of granulocyte concentration (over 10% concentration against less than 10% concentration) on CD34+ cells viability. The median (range) viability of CD34+ cells containing >10% granulocytes was 76.6% (54.5–93.0%), and that for cells containing <10% granulocytes was 82.1% (59.1–94.4%), respectively. There was significant difference in the viability of CD34+ cells between the two groups (p=0.02, respectively). Second, we analyzed 81 autologous PBSC transplants after stored at -80°C by using simplified method. We divided the two groups based on the granulocyte concentration (over 10% concentration against <10% concentration). No significant difference in the days to leukocyte >1.0x10^9/L and to platelet >20x10^9/L in either granulocyte concentration was observed. However, the median (range) time to platelet >50x10^9/L containing >10% granulocytes was 27.2 (12–87), and that for cells containing <10% granulocytes was 20.3 (10–51), respectively. There was no significant difference in the days to platelet >50x10^9/L between the two groups (p=0.04, respectively).

Summary/Conclusions: Long-term cryopreservation represents a means of holding a potential therapeutic modality in reserve for use at a future date. In this study, PBSCs can be safely stored for at least 36 months with a simplified method at -80°C. The loss of the viability of CD34+ cells was greater when the granulocyte content was over 10% than in cells with less than 10% of granulocytes. The effect of reduced CD34+ cells viability seems important for engraftment. Difference in the day to platelet >50x10^9/L between the two groups based on the granulocyte concentration (over 10% concentration against <10% concentration) was observed. Thus, a lesser granulocyte content could give a more reliable graft with better quality. Further research is necessary to observe the effect of long-term cryopreservation period and granulocyte content on the viability of stored CD34+ cells.

PB2181

LYMPHOCYTE RECONSTITUTION AFTER ALOGENIC TRANSPLANTATION, DOES EARLY RECOVERY HAVE ANY INFLUENCE IN SURVIVAL RATES?

V. Verduzo1, M.A. Correa Alonso1, V. Rubio Sanchez1

1Hematology, Hospital Jerez de la Frontera, El Puerto de Santa Maria, Spain

Background: Immune reconstitution after AloTPH has significant influence on the procedure final success. Studies have established that early lymphocyte recovery can influence survival rates, associated to a reduction in mortality unre- lated relapse (NMR) and, in some studies, also to a reduction in relapse rate.

Aims: Analyze our patients survival rates in terms of lymphocyte reconstitution in absolute value on day +30 and +60 post-HSCT. Check if there is any relationship between the number of transfused CD34+ progenitors and LT3+ and see if that possible link affects the speed of recovery after transplant + lymphocyte count.

Methods: Analysis of the lymphocyte recovery in a retrospective study of 63 of 71 patients transplanted (ALO, and Haplo Unrelated Donor) by AML and ALL between 2008–2015. (8 died before the day+60). Table 1 shows the characteristics of the pre-transplanted patients and analyze the influence of the parameters of the infused product (CD34x10^6 and LTx10^9/kg r), type of transplant, GVHD presentation, treatment and reactivation of CMV on the recovery of absolute lymphocyte numbers in s+30 and +60 days post transplantation using as cut off <0.3x10^9/ml. We have analyzed the ratio of the number of lymphocytes on day +60 with survival after transplantation. It has made a statistical - analysis of OS and DFS in relation to the number of lymphocytes on day +30 and +60 with Kaplan Meier compared the results with long-rank test and subsequent analysis of the variables collected with Cox Regression.

Results: After analyzing the product infused we observe a relationship between LT and lymphocyte recovery on day+30 (p=0.057), and day +60 (p=0.059, cor=0.257) but not with the CD34x10^6. Table 2 shows the patient characteristics in lymphocyte absolute count in the day +60. We analyzed the overall survival (OS) and disease - free survival (DFS) and a decrease in OS with statistical difference was evident in patients with <.300 (p=0.0029) on day +60 and day+30 (p=0.05), a decline also in DFS, with no statistically significant difference (p=0.1). Multivariate analysis to determine which factors could influence the lymphoid recovery on day +60 and SG, we observed that the type of unrelated donor, myeloablative conditioning and ATG administration can influence a delay in a recovery. No differences were observed in the rest of the variables.

Table 1.

Summary/Conclusions: A delay in lymphocyte recovery is associated with a decrease in survival rates in our patients. Measures favoring an accelerated lymphocyte recovery (privileged use of thymoglobulin, adequate donor selection, and transplantation modality) could affect the post-transplant survival. It appears that the amount of infused product could play an important role in reconstitution, so it would be a factor to take into account prior to infusion.
**PB2182**

**SUCCESFULL AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER VELCADE-BASED REFRACTORY MULTIPLE MYELOMA PATIENTS**

V. Martínez-Robles1, B. Ballina1, S. Cerda1, N. de las Heras1, J.A. Rodriguez-García1, F. Escalante1

1Hematología, Complejo Asistencial Universitario de León, LEON, Spain

**Background:** The optimal induction treatment for Newly Diagnosed Multiple Myeloma Patients needs combinations with Bortezomib-Based (Bor-based) schemes. Primary Refractory patients include patients with progressive disease or rapid (<60 d) relapse after these optimal induction approach have a very bad prognosis. Lenalidomide-Dexamethasone (LenDex) were usually the next step in the treatment of these patients, until the recent introduction of triplets combination LenDex-based. Autologous Stem Cell Transplantation (ASCT) have proven efficacy in NDMM younger patients that have got at least a partial response (PR) after the induction therapy. There are few data about toxicity and response of ASCT in primary refractory patient that can obtain a response with LenDex rescue treatment.

**Aims:** Analysis of tolerance, response and overall survival of ASCT-candidates that are primary refractory to Bor-Based induction treatment.

**Methods:** Retrospective analysis of our database. From 2010 to Nov-2016, 53 ASCT-Candidates (for 1st or 2nd ASCT procedures) were included. Median Age for diagnosis was 62 (46-71). Median Age for ASCT procedure was 63 (46-72). 12 of these 53 patients (22.6%) were considered primary refractory and had considered candidate to get Bor-Based conditioning. 6 of them (50%) were woman. Characteristics of Disease: IgG kappa (4), IgG-lambda (3), IgA kappa (3), IgA lambda (1), Light Chain lambda (1). ISS II/III/IV: 5/2/5. Induction treatment: VelDex (4), VTD (6), VCD (2). Median of cycles administered: 6 (2-8). Best Response to induction treatment: >PR (6), Minimal Response (1), progression (1). Median age at ASCT: 62 (49-70). All of them received Melphalan 200 mg/m2 as conditioning treatment.

**Results:** Morbidity or mortality (M&M) (0%) of ASCT procedure in refractory patients is similar to non-refractory patients. After a median follow up of 46 months from diagnosis for all ASCT-candidates group, the refractory patients get an overall survival of 46.2 months (3-72 m). Any of them have relapsed yet. 2 of them are in biological relapse without need of treatment.

**Summary/Conclusions:** Patients refractoriness to induction may receive ASCT after a rescue treatment LenDex based, as is effective in this group conversion of refractory disease to remission. New combinations (triplet) with new drugs with LenDex-based treatment may improve the responses rates and overall survival before and after of ASCT procedure in this group.

**PB2183**

**SAFETY AND EFFICACY OF TBF CONDITIONING IN PATIENTS UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE SINGLE CENTER EXPERIENCE.**

R. Massoud1, N. Moukalled1, B. Haffarr1, A. Zahreddine1, A. Bazarbachi1, J. El-Cheikh1

1Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

**Background:** The optimal intensity of myeloablation with a reduced-toxicity conditioning (RTC) regimen to decrease relapse rate after allogeneic stem cell transplant (allo-SCT) without increasing non-relapse mortality (NRM), has not been well established.

**Aims:** In this retrospective study at the American University of Beirut medical center (AUBMC) we aimed to evaluate the outcomes of patients who underwent allo-SCT with thiotepa, busulfan and fludarabine (TBF) as RTC.

**Methods:** We included twenty four consecutive patients with hematological malignancies who received TBF as conditioning for allo-SCT from January to December 2016. All patients and transplant characteristics are listed in Table 1. All patients received the myeloablative conditioning regimen consisting of thiotepa(5mg/kg/day) infused on day -7 and -6, fludarabine(30mg/m2/day) was infused on day -5 to day -2, and busulfan(130mg/m2/day) was infused on day -5 to day -3. All patients received 2.5mg/kg/day intravenous rabbit antithymocyte globulin (ATG) on days -2 and -1. GVHD prophylaxis for patients transplanted from haploidentical donors consisted of post-transplant cyclophosphamide 50mg/kg/day on day +3 and day +5, cyclosporine started at 3 mg/kg/day on day +6 and readjusted according to level, and mycophenolate mofetil 500mgx4/day started on day+6 to +28. Patients transplanted from mismatched related donor, received cyclosporine as of day +1.

**Results:** Twenty three patients(96%) engrafted, with 14 days (range, 10-18) and 13 days (range, 8-48) as median time for neutrophil and platelet engraftment respectively. One patient who underwent haploidentical donor transplant with persistent disease for AML (karyotype 45,XY,-7) failed to engraft and died due to disease progression on day+22. After a median follow up of 10 months (range, 1-22) post-allo-SCT, the cumulative incidence of Gradell-Iv acute GVHD (aGVHD) was 26%. One patient developed chronic limited GVHD (cGVHD). All the complication post allo-SCT are listed in table 1. Five patients (24%) relapsed post allo-SCT at a median of 163 days (range, 55-384), of log-rank test (1%) died due to disease progression and two were successfully salvaged and are in complete remission (CR) with full donor chimerism (FDC) at last follow up. Two patients developed JC virus progressive multifocal leukoencephalopathy, one of them made a full recovery and the other died in CR. The day 100 NRM was 0%. At last follow up 20 patients (83%) are alive in CR, with negative minimal residual disease and FDC.

**Table 1.**
and 74.5% and PFS was 76.8% and 58.2%, respectively. Before ASCT, 60 patients (72.3%) were in CR and 23 (27.7%) were in PR. After ASCT, 4 patients were not assessed for response due to early death by toxicity. Of the remaining, 70 (88.6%) achieved a CR, 4 (5.1%) a PR and 5 (6.3%) failed to respond. Patients in CR before ASCT presented significantly longer PFS compared with those in PR (107.9 vs 44.0 months, p=0.01). Besides that, patients that obtained CR after ASCT also had longer OS and PFS compared with those in PR (107.9 vs 8.0 and 107.9 vs 7.3 months, p<0.001). However, these patients had significantly lower PFS compared to patients that continued in CR after ASCT (45.3 vs 107.9 months, p=0.041). Univariate analysis indicated that remission status prior to ASCT (CR vs PR) is a significant predictor of PFS after ASCT (HR 0.39; 95% CI 0.19-0.82, p=0.013). Multivariate Cox regression model showed that this factor retains prognostic value after adjustment for age, histological subtype, Ann Arbor stage and number of previous lines of treatment.

Summary/Conclusions: Our results highlight the relevance of the obtained CR after ASCT in the OS. Furthermore, we conclude that patients with NHL who are in CR before ASCT have a better PFS than those in PR before ASCT. Additionally, continued CR after ASCT may also be an important prognostic factor. Our results suggest that the use of more effective induction regimens in order to improve initial response may be advantageous in terms of clinical benefits post-ASCT.

PB2185
AUTOLOGOUS STEM CELL TRANPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE
S. K. Toprak1,*, E. Atilla1, P. Ataca Atilla1, S. Civriz Bozdag1, M. Kurt Yuksel1, P. Topcuoglu1, T. Demirer1, O. Arslan1, M. Ozcan1, M. Araci2, O. Ilhan1, H. Akan1, H. Namazian1, V. Atilla1, A. K. Kurnaz1, A. Uysal1, G. Gurpinar1, S. Ahmet1
1Ankara University School of Medicine, Department of Hematology, Ankara, Turkey
2Florence Nightingale Hospital, Istanbul, Turkey

Background: Mantle cell lymphoma accounts for relatively small proportion (3%-10%) of non-Hodgkin lymphoma. High-dose chemotherapy (HDT) and autologous-sterm cell transplantation (ASCT) has played a critical role in the treatment of mantle cell lymphoma. Regardless of that, mantle cell lymphoma remains largely a relapsing/remitting disease.

Aims: Our aim is to present our mantle cell lymphoma patients who underwent ASCT.

Methods: We retrospectively evaluated our 21 mantle cell NHL patients. The patients were followed after ASCT for relapse.

Results: Patients were followed by a median time of 66.9 months (range, 6-170 months). The median age at diagnosis was 45 (range, 18-69), female to male ratio 5/16. The stages and MIPi scores at diagnosis were as follows: 5% stage I, 19% stage III, 76% stage IV; Low MIPi 29%, intermediate MIPi 48% and high MIPi 23%. First line treatments were R-CHOP for 6 cycles in 6 patients (29%) and R-CHOP for 3 cycles followed by R-DAHP in 15 patients (71%). The median time to ASCT was 20 months (range, 7-45 months). All patients were in at least partial remission at the time of ASCT. The transplant conditioning regimen was CBV in 5 patients (24%) and R-/ICE in 5 patients (24%), R-/BEAM in 11 patients (52%). Six patients (29%) achieved complete remission. Four patients (19%) died within three months of ASCT due to infection. Eleven patients (52%) was relapsed with a median time of 39 months (range, 4-123 months). Ten patients received BORID (bortezomib, rituximab, dexamethasone) and 1 patient received lenalidomide as salvage therapy and six of them achieved complete remission. Three patients underwent allogeneic hematopoietic stem cell transplantation as well as two patients underwent autologous transplantation.

Summary/Conclusions: ASCT is a part of initial treatment strategy in fit patients with mantle cell lymphoma however 19 patients in our series had transplant related toxicity. Today, novel agents may present a less intensive approach for achieving response.

PB2186
ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH AUTISM
A. Gomes1,*, A. B. Mafra1, A. Zanette1, V. Rocha1
1Hematopoietic Stem Cell Transplantation, Hospital Sirio Libanes, Sao Paulo, Brazil

Background: Autism Spectrum Disorders (ASD) are severe heterogeneous neurodevelopmental abnormalities characterized by dysfunctions in social interactions and communication skills, restricted interests, repetitive and stereotyped verbal and non-verbal behaviors. The etiology of ASD remains unknown, but recent studies suggest a possible association with altered immune responses and ASD. Inflammation in the brain and Central Nervous System has been given HSCT. All children with MDS should be referred for allogeneic HSCT.

Aims: The evaluation of the benefits of HSCT in patients with ASD.

Methods: We describe two cases of patients with ASD who underwent HSCT for acute lymphoblastic leukemia (ALL) and whose symptoms were markedly decreased like an improvement of social interaction, communication, and behavior.

Results: The first patient is an 11-year-old girl with ASD who was diagnosis with Ph-positive ALL in October 2011 (at the end of treatment, BCR-ABL remained positive). She underwent a matched sibling HSCT in March 2015. The conditioning regimen was total body irradiation (TBI) and cyclophosphamide in the 20-month follow-up period, we observed improvement in social interaction, communication, and behaviors. According to The Childhood Autism Rating Scale – CARS, prior to HSCT, she had a score of 39 (Severe Symptoms of ASD Disorder), and she currently scores 30 (Mild-to-Moderate Symptoms of ASD). The second case is a 7-year-old boy with ASD, Asperger Syndrome, who was diagnosed with ALL in September 2012. He presented with bone marrow and testicular relapse in May 2015 and underwent a matched unrelated HSCT in November 2015. The conditioning regimen was Etoposide, ATG and TBI. During the 12-month follow-up period, we observed improvement in social interaction, communication, and behaviors. According to CARS, prior to HSCT he had a score of 30 (Mild-to-Moderate Symptoms of ASD), and he currently scores 24 (Minimal-to-No Symptoms of ASD). There is no treatment for ASD thus every effort to minimize the symptoms are valuable. In both cases, social interaction was significantly increased, and the aggressive behaviors decreased. Clinical cases have reported responses in autistic children receiving HSCT.

Summary/Conclusions: Several incurable neurological disorders have shown benefits with cellular therapy. Thus, autism should be explored as an indication. Clinical studies are an immediate need to fully explore its potential in autism.

PB2187
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE FROM TURKEY
D. Atay1,*, F. Erbay1, A. Akca1, G. Ozturk1
1Pediatric Hematology Oncology Bone Marrow Transplantation Unit, Acibadem University Medicine Faculty, Istanbul, Turkey

Background: Myelodysplastic syndrome (MDS) in childhood is a rare disorder and hematopoietic stem cell transplantation (HSCT) is the only known curative treatment option. However, there exist few reports regarding the outcome of transplantation for children with various types of MDS.

Aims: We analyzed the outcome of pediatric patients who underwent HSCT.

Methods: We reviewed retrospectively 14 pediatric MDS patients who received HSCT at a single center. Median age at time of HSCT of the patients was 3 years (range, 1-14 years). The median disease duration from diagnosis to transplantation ranged from 1 to 3 to 36 months with a median of 10 months. Five patients had primary and one had secondary MDS. Four patients had juvenile myelomonocytic leukemia (JMLM) and 4 patients had myelodysplastic related acute myeloid leukemia (MDR-AML). Diagnostic cytogenetics included monosomy 7 (n=2), trisomy 8 (n=3), KRAS (n=1) or normal/other (n=8). Patients received a median of 6.8x106 CD34+ cells/kg. Eight patients received a bone marrow, 5 had peripheral blood graft and one an unrelated cord blood (UCB) transplant; five patients were transplanted from a matched sibling donor (MDS), 5 from a matched unrelated donor (MUD) and 4 from haploidentical donor. Conditioning regimen consisted of busulfan/cyclophosphamide in MDS/MUD patients. Patients transplanted from MUD and UCB also received antithymocyte globulin (ATG) for 3–5 days pretransplantation. Haploidentical transplantation was performed with RIC regimen and TCRα/β CD3 depletion.

Results: Graft failure occurred in three patients with JMLM (n=1), secondary MDS (n=1) and MDR-AML (n=1). Failure was the main cause of treatment failure in children with JMLM given HSCT.

Summary/Conclusions: This data demonstrate that especially children with primary MDS may achieve encouraging OS and RFS following HSCT.

Relapse remains the main cause of treatment failure in children with JMLM given HSCT. All children with MDS should be referred for alloHSCT soon after diagnosis.
Thalassemias

PB2188

RELATIONSHIP BETWEEN URIC ACID LEVELS AND CARDINAL FINDINGS IN A LARGE COHORT OF Β-THALASSEMA MAJOR: GENDER-RELATED DIFFERENCES

A. Meloni¹, C. Vassalle², L. Pistola¹, T. Gippolito³, M. G. Bisconte³, G. Palazzoli³, M. P. Sacchetti³, N. Dello Iacono⁶, R. Ndreu¹, A. Olivi¹, V. Positano¹, A. Pepe¹

¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Azienda Ospedaliera Regionale San Carlo di Polenta, Potenza, 3Azienda Ospedaliera Cosenza - Presidio Ospedaliero “Annunziata”, Cosenza, 4Modena, Pollicino di Modena, 5Pollicino Umberto 1, Roma, 6Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy

Background: Iron overload, secondary to recurrent transfusions and ineffective erythropoiesis, induces oxidative stress in thalassemia (TM). Uric acid (UA), a major blood antioxidant, may act either as an antioxidant or pro-oxidant.

Aims: Our aim was to evaluate the role of UA in TM and its association with cardiac iron, dysfunction, fibrosis, and complications, and cardiovascular risk factors in a large cohort of TM patients of both sexes.

Methods: 397 TM patients (200 men, mean age 32±8 years) enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) Network were considered. Myocardial and hepatic alterations in this study were quantified by the T2* technique. Atrial dimensions and biventricular function were quantified by cine images. Late gadolinium enhancement (LGE) images were acquired to detect myocardial fibrosis.

Results: As expected, UA resulted significantly higher in male respect to female TM patients (4.7±4.1 vs 4.0±1.0 mg/dL, P=0.001). UA levels directly correlated with BMI (R=0.25, P=0.003), and triglycerides (TG) (R=0.20, P=0.005) in female patients. Moreover, female which presented myocardial fibrosis showed higher levels of UA (4.4±3.1 vs 3.9±0.9 mg/dL, P=0.03). The multiple regression model identified BMI (T-value 3.7, P=0.003), TG (2.1, P=0.04) and cardiac fibrosis (2.5, P=0.01) as independent correlates of UA level in women. In men, UA levels were positively correlated with BMI (R=0.17, P=0.02), TG (R=0.38, P<0.001), and inversely with HDL (R=−0.20, P=0.006) and glycemia (R=−0.15, P=0.04). Interestingly, UA was also directly correlated with global heart T2* values (R=0.3, P=0.001). After multivariate analysis adjustment, global heart T2* (T-value 3.6, P<0.001), and BMI (T=1.9, P=0.05) remained as independent determinants of UA in male TM patients.

Summary/Conclusions: UA levels correlate with factors related to metabolic dysfunction in TM patients of both sex, while a more strong correlation between UA and cardiac fibrosis was observed only in females, and a direct relationship between UA and T2* global heart only in males. The differences in male and female TM patients imply some gender-specific mechanisms, providing biochemical basis for the epidemiological differences between sexes.

PB2189

CHARACTERIZATION OF HEMORHEOLOGICAL ALTERATIONS IN Β-THALASSEMA BY A CHEMOMETRIC APPROACH

P. Caprari¹, C. Bozzi¹, S. Materazzi², R. Risoli²

¹Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, ²Department of Chemistry, “Sapienza” - University of Rome, Rome, Italy

Background: Several studies reported a high incidence of thromboembolic events in β-thalassemia, more frequent in thalassemia intermedia than in regularly transfused thalassemia major. In these patients a chronic hypercoagulable state is evident and the red blood cells exhibit impaired flow properties that facilitate micro-circulatory disorders.

Aims: Since many abnormalities described in thalassemia may determine rheological alterations, in this study we have investigated the viscoelastic profiles of red blood cells from patients with β-thalassemia.

Methods: Blood samples from 45 β-thalassemia patients and 48 healthy individuals, after informed consent, were analyzed. Hemorheological profiles were investigated at 37 °C at native and normalized hematocrit. The evaluation of RBCs viscoelastic properties was performed by determining storage modulus G’, loss modulus G’’ and complex modulus G* in oscillation mode as a function of angular frequency ω in the range 0.1-10 Hz. Multivariate statistical analysis was performed on the resulting G’, G’’ and G* curves and Principal Components Analysis was used as display method.

Results: The hemorheological profiles of patients affected by β-thalassemia and healthy subjects showed significant differences and the chemometric analysis allowed to draw a clearly identification of anemic status according to viscoelastic profile. Increased G’, G’’ and G* modula were observed in thalassemic patients demonstrating a reduction in deformability and impaired flow properties.

Summary/Conclusions: In this study a characterization of haemorheological alterations in thalassemia patients has been performed by a chemometric approach. The achieved results permit to consider the viscoelastic properties as promising predictive new indices of microvascular damage in β-thalassemia and to explain the increased incidence of vascular complications in these disorders.

PB2190

HEPATITIS E IN TRANSFUSION-DEPENDENT THALASSEMA PATIENTS, IN GREECE. A SINGLE CENTER EXPERIENCE

P. Klonizakis¹, G. Gioula¹, A. Meldrou¹, M. Exindari¹, G. Karavalkis², C. Apostolou², E. Gigi¹, E. Vetsis¹, A. Kotsi¹, E. Vlachaki¹

¹Aristotle University of Thessaloniki, ²Papanikolaou General Hospital, Thessaloniki, Greece

Background: Hepatitis E (HE) is nowadays considered an emerging disease that may be a threat in both developing and industrialized countries all over the world. The causal agent is a RNA virus, transmitted mainly through the fecal-oral route. Nevertheless, there are additional patterns of transmission, including the transfusion of infected blood products. The risk of developing chronic HE infection following transfusion of infected blood–derived products is higher among immune-compromised individuals. Transfusion-dependent Thalassemia patients consist a distinct category of immune-compromised patients, but the data regarding transfusion-transmitted HE infection are limited for this group of patients. Accordingly, there is, as yet, no consensus on whether blood products should be systematically screened for markers of the HE virus.

Aims: The aim of this study was to assess the status of Hepatitis E infection in a transfusion-dependent Thalassemia patients, followed up in a single Thalassemia Unit, in Northern Greece.

Methods: Over a one-month period, we retrospectively evaluated 96 consecutive patients, from a registry of 150 adult TDT patients followed at a single Thalassemia Unit, in Northern Greece. The mean age of the study population was 28±10 years, 42% were male and 58% female. According to the patients’ blood transfusion history, the participants had been transfused with 47.376 blood units during the last 14 years, whereas during the last year the same patient population had been transfused with 3.384 blood units. The detection of HEV RNA was performed by Real-Time RT-PCR method (hepatitisE2/ceer-Tools kit. Applied Biosystems ABI), according to the instructions. The detection of HEV was based on the identification of the “a” region of ORF2. The detection of IgG anti-HEV antibodies and their titration were performed in 92/96 samples using a commercially available enzyme-linked immunosorbent assay kit (CUSABIO BIOTECH kit), according to the manufacturer’s instructions.

Results: HE RNA was not detected in any of the 96 samples, whereas the IgG anti-HEV antibodies were also negative in all measured samples. The negative HEV RNA, in all the participants of this study, indicates the absence of an active HE infection, whereas the negative IgG anti-HEV antibody titre implies that there was no history of previous HE infection. According to the literature, IgG antibodies may be detectable following an HE infection for a time period that varies from one year to 14 years.

Summary/Conclusions: This is the first assessment of the HE virus seroprevalence in the population of TDT patients in Greece, over the last two decades. Our results suggest that TDT patients are not at a high risk for HE infection. Further studies are necessary to evaluate the clinical importance of the transfusion-transmitted HE infection in TDT patients and clarify whether screening of blood donors is necessary for countries with a lower or higher prevalence of HE.

PB2191

Abstract withdrawn.

PB2192

A PRELIMINARY STUDY OF THE CARDIAC EFFECT OF PPAR GAMMA IN BETA THALASSEMA MAJOR WITH IRON OVERLOAD

P.M. Eldredreawy¹, P.N.A. Hamed¹, D.D. Ehlinley², D.O. Ghallab³, M.A. Khalifa¹

¹Hematology, ²Clinical Pathology, Alexandria Faculty of Medicine, Alexandria, Egypt

Background: Peroxisome proliferator–activated receptor (PPAR) agonists have been shown to improve insulin resistance, dyslipidemia, and thyroid hormone receptors. PPAR-gamma is a master transcriptional regulator involved in the expression of probably hundreds of genes. One of PPAR gamma gene polymorphisms is Pro12Ala which is present in at least 80% of the patients. The Pro12Ala polymorphism may reduce the risk of cardiovascular complications. Consistently, Ala12 allele carriers were found to have lower carotid intima-media thickness and reduced risk of myocardial infarction in type 2 diabetes patients. Pharmacological agonists of PPAR-gamma leads to a molecular
switch providing alleviating myocardial injury through modulating oxidative, inflammatory and apoptotic signaling pathway.

Aims: Our aim was to investigate the frequency of Pro12Ala polymorphism (substitution of proline to alanine at codon 12 in exon B of PPARγ gene in Egyptian β-thalassemia major (β-TM) with iron overload. Untreated transfusion induced iron overload in thalassemia major is fatal, usually as a result of cardiac complications.

Methods: 30 β-TM patients and 10 healthy volunteer matched for age, sex and body weight were involved in this study. β-TM patients followed up was in the “outpatient clinic of Hematology unit, at Alexandria main university hospital”. Seventeen were males and thirteen were females with ages ranging from 16 – 39 years (21.5±5.44). Blood samples from β-TM patients and healthy controls were analyzed for PPARγ gene polymorphism using polymerase chain reaction-restriction fragment length polymorphism.

Results: The mean value of serum ferritin in β-TM was 4976.30±2216.41 ng/L which was significantly higher than that in controls (102.60±12.69 ng/mL). The mean value of ejection fraction were 62.23±3.46% and 63.80±4.34 in controls and respectively. Pro12Ala polymorphism was present in 2 out of 30 (6.67%) β-TM patients with osteoporosis. One patient had heterozygous 12Ala polymorphism and the other had homogygous 12Ala polymorphism. Both had normal body mass index, lipid profile, ejection fraction and elevated serum ferritin (4923 ng/L in heterozygous patient and 4886 ng/L in homogygous patient). Ejection fraction was 70% in heterozygous patient and 68% in homogygous patient. Only one male control (10%) has homogygous 12Ala polymorphism (Table 1).

Table 1. Comparison between the two studied groups according to PPAR gamma genotyping

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Cases (n = 30)</th>
<th>Control (n = 10)</th>
<th>x²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>28</td>
<td>1</td>
<td>10.00</td>
<td>0.003</td>
</tr>
<tr>
<td>Sex</td>
<td>male</td>
<td>female</td>
<td>15.76</td>
<td>0.002</td>
</tr>
<tr>
<td>Body mass index</td>
<td>19.8±1.30</td>
<td>20.2±1.30</td>
<td>1.41</td>
<td>0.05</td>
</tr>
<tr>
<td>Ferritin (ng/ml)</td>
<td>8486±2216.41</td>
<td>4976.30±2216.41</td>
<td>12.57</td>
<td>0.002</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>12.7±1.28</td>
<td>11.5±0.89</td>
<td>3.92</td>
<td>0.05</td>
</tr>
<tr>
<td>LDH (u/l)</td>
<td>330±221.6</td>
<td>215±121.7</td>
<td>6.67</td>
<td>0.01</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>70±5.2</td>
<td>68±4.3</td>
<td>2.02</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Summary/Conclusions: This study suggests that Pro12Ala polymorphism may have a cardioprotective effect in Egyptian thalassemic patients since we find the highest value of ejection fraction among the two positive cases. Further studies on a larger population of patients are still needed to confirm this finding.

PB2193
THALASSEmia MAJOR AND INTERMEDIA IN PATIENTS OLDER THAN THIRTY-FIVE YEARS - FROM A FATAL TO A CHRONIC DISEASE
O. Pasvolsky1,*, L. Shargian Alon1, P. Raanani1
1Beilinson Hospital, Petach Tikva, Israel

Background: During the past four decades beta thalassemia major (TM) and beta thalassemia intermedia (TI) have transformed from a universal cause of death at a young age, into a chronic disease, with a constantly increasing life expectancy. This is attributed, amongst others, to the use of improved chelation therapy. Since prolongation of life expectancy has occurred only in recent years, there is little data regarding the older population with TM and TI.

Aims: There is little data regarding the older population with TM and TI. Aims: Since prolongation of life expectancy has occurred only in recent years, this is attributed, amongst others, to the use of improved chelation therapy. Since prolongation of life expectancy has occurred only in recent years, there is little data regarding the older population with TM and TI.

Methods: Aims: Theta thalassemia major is fatal, usually as a result of cardiac complications.

Results: Between 2006 and 2016, 14 adult patients older than 35 years with TM (n=10) & TI (n=4) were treated and followed in our center. Median patients’ age was 37 (range, 35-51) years, with 66% males and 50% of Arab ethnicity. Most of the patients had at least high school education (85%), and 78% were employed. Thirteen patients (all TM patients and 3 out of the 4 TI patients) were treated regularly with blood transfusions. All patients received chelation treatment. Median hemoglobin (Hb) levels and mean corpuscular volume (MCV) levels were lower in patients with TI compared to TM (8.1 vs 10 g/dl, p=0.02 and 72.4 vs 84 fl, p=0.04, respectively). Median LDH levels and indirect bilirubin levels were higher in patients with TI compared to TM (603 vs 330 u/L, p=0.004 and 2.02 vs 1.1 mg/dl, p=0.06, respectively) indicating increased hemolysis. All patients underwent splenectomy and had secondary thrombocytosis. All but two patients were treated with at least two different chelation modalities, either as single agent, including subcutaneous (SC) or intravenous (IV) deferoxyamine (DFO), deferiprone (DFP), or deferasirox (DFX), or as various combination therapy options. The median number of chelation treatment lines was 3. All patients treated with chelation suffered from at least one adverse event, necessitating temporary discontinuation and usually substitution of treatment. The median number of adverse events was 1.5 per patient. Nine patients (64.2%) had good compliance with current chelation therapy. Four patients with acute heart failure secondary to cardiac iron overload, and all four improved with intensified chelation treatment. Four TM patients (40%) were hypothyroid, half of them requiring thyroid hormone replacement therapy. All TM patients had hypogonadism. All females had amenorrhea and were treated with hormone replacement therapy, and none of them tried to conceive. Six of the seven male TM patients were treated with monthly testosterone injections, and three of them fathered children. All TM patients had osteoporosis, and three TI patients (75%) had metabolic bone disease. Figure 1 shows the relative rates of symptomatic cardiac iron overload and endocrine dysfunction in the cohort. Three patients (21.4%) had significant liver overload according to liver T2* MRI, necessitating chelation treatment intensification. None of the patients in our cohort underwent allogeneic hematopoietic stem cell transplantation and none developed secondary malignancy during follow-up.

Summary/Conclusions: Advances in the treatment of thalassemia patients have enabled the majority of these patients prolonged survival into adulthood. However, this has brought a new set of challenges for both patients and healthcare. This study delineates the challenges faced while treating adult patients with TI and TM in the new era.

PB2194
EVALUATION OF LIVER IRON CONCENTRATIONS IN CHILDREN WITH BETA THALASSEMIA INFECTED WITH HEPATITIS C VIRUS BEFORE AND AFTER SPIRULINA THERAPY
M. El-Shanshory1,*, M. Awad1, R. El-Shafay2, A. Alikhawany3
1Pediatrics, 2Radiology, Faculty of Medicine, Tanta University, 3Pediatrics, Ministry of Health, Tanta, Egypt

Background: Magnetic resonance imaging (MRI) assessment of liver iron concentration (LIC) is necessary for quantitative staging of iron overload in children with β-Thalassemia. There is no enough evidence about the effect of spirulina therapy on LIC.

Aims: To assess LIC by MRI in multi-transfused β-Thalassemic children infected with HCV before and after Spirulina Therapy.

Methods: Thirty multi-transfused β-thalassemic children infected with HCV, were subjected to clinical evaluation, appropriate laboratory investigations and assessment of LIC by MRI. They were classified according to LIC into mild
EVALUATION OF THREE AUTOMATIC DEVICES FOR HEMOGLOBINOPATHY DIAGNOSTICS IN MULTI-ETHNIC POPULATIONS

PB2196

Aims: As the latter device is new to the market a multisite precision study was performed testing the reproducibility of the system across three test sites (Leiden, Genoa and London) using the same set of samples for several following days. The results between these three sites were compared and evaluated. Moreover we have tested the capacity to detect the most common structural haemoglobin variants, such as HbS, Hbc, HbD, HbE and less common Hb variants important to be diagnosed in multi-ethnic populations found in the U.K., The Netherlands and Northern Italy as well as elevated HbA2, as indicator for beta-thalassemia carriers.

Methods: Hb variant separation using he Variant II HPLC (BioRad), the Capilarys2 capillary electrophoresis (Sebia) and the most recently introduced HPLC, Premier Hb9210™ High Resolution HPLC of Trinity Biotech (Menarini). Molecular analysis to verify the hemoglobin variants found.

Results: We present the data of the comparison studies using the replicates of the three different sites for the Premier Hb9210™ and of 100 normal samples and 217 patient samples for a variety of beta-thalassemia trait and haemoglobin (Hb) variants, including the molecular data of the beta-thalassemia mutations and Hb variants.

Summary/Conclusions: All three apparatuses identified the common Hb variants and beta-thalassemia trait in carriers, homo- hetero- and compound hemoglobinopathies with the expected sensitivity and specificity. The Premier Hb9210™ HPLC for the diagnosis of beta-thalassemia trait shows comparable reproducibility determined by quantitation on the three different sites using the same samples and is suitable for the analysis of samples suspected of having hemoglobinopathy and the diagnosis of beta-thalassemia trait or Hb variants.

Background: Frequent transfusions required for beta-thalassemia major patients cause iron overload. Without the appropriate chelation therapy, iron toxicity can cause significant heart, liver and endocrine morbidity. Aims: In this case series we estimated the safety and efficacy of iron chelation with the combination of deferoxamin (DFX) and deferoxamine (DFO) in transfusion dependent thalassaemia (TDT) patients attending the Thalassemia Unit in a tertiary hospital in Athens, Greece.

The combination treatment was well tolerated without adverse events or effects on liver and kidney function. The combination treatment was better tolerated without adverse events or effects on liver and kidney function.
of PRBC transfusion was 23 yrs. The average number of transfusion in last at first transfusion was 7 months & 11 months respectively. The average years yrs. Majority of patients (56%) were male. The average age at diagnosis and blood transfusions were included in the study. Compare the ferritin level with T2* MRI finding. Aims: There is scarcity of clinical, biochemical and radiological data showing cardiac and hepatic iron assessment of young adults with (TDT) at recently established adult thalassemia clinic at PGIMER, Chandigarh.背景: 肝脏超声和MRI技术在评估肝脏硬化方面有其局限性。MRI不能用来评估心脏铁负荷。α-珠蛋白基因突变是地中海贫血的主要原因。地中海贫血基因检测使用多个方法，包括MLPA、Southern blotting、PCR和测序。但是，TDT患者中异质性高，需要综合性评估。目的: (i)比较α-珠蛋白条带和MLPA，(ii)定义TDT患者中铁负荷的临床和放射学特征，(iii)根据预测的铁负荷选择合适的治疗方法。(iv)研究背景和目的: 意大利西西里岛卡塔尼亚(CT)大学医院血液科的Ghadri-Najar等，发表了“CT和地中海贫血亚型患者丙氨酸转移酶和铁负荷相关的研究”。该研究是第一项研究，旨在评估地中海贫血患者中铁负荷和丙氨酸转移酶的相关性。研究背景: 丙氨酸转移酶是监测铁负荷的生物标记物。 研究目的: 比较α-珠蛋白条带和MLPA，定义TDT患者中铁负荷的临床和放射学特征，根据预测的铁负荷选择合适的治疗方法。

Methods: 研究分为两部分: 第一部分使用α-珠蛋白条带条带，第二部分使用MLPA。

Results: 研究共有104名患者，其中74名是地中海贫血患者，30名为HbE患者。

Conclusion: 该研究提供了TDT患者铁负荷的临床和放射学特征，为治疗决策提供了依据。

Figure 1.

PB2200

THALASSEMIA IN MADRID: A PICTURE OF THE CURRENT SITUATION

E. J. Bardón-Cancho1,*, M. García-Morín2, Y. Aguilar-de la Red2, F. F. Pe-Salas1, G. Perez-Rus3, C. Pascual1, E. Dulin1, C. Beléndez1, E. Cela1

1Section of Pediatric Hematology and Oncology, Department of Pediatrics, 2Department of Hematology, 3Newborn Screening Laboratory (Community of Madrid), Hospital General Universitario Gregorio Marañón - Facultad de Medicina- Universidad Complutense de Madrid, Madrid, Spain

Background: Diagnosis of thalassemia (Thal) in a Mediterranean country as Spain, could be thought as endemic, but few data are available so far. Moreover, attention to hemoglobinopathies is focused on sickle cell disease.

Aims: The aim of our study was to find out the prevalence of Thal and clinical significant hemoglobinopathies other than sickle cell diseases in a referral center for newborn sickle screening, in addition to the demographic characteristics of these patients. The secondary objectives were to obtain the frequency of specific treatments or prophylaxis accomplished by these patients, and the reasons for loss to follow-up.

Methods: The study is observational, unicentric, descriptive and retrospective, carried out in December 2016 in a tertiary hospital in the Community of Madrid, Spain. All patients diagnosed with Thal and other not sickle-hemoglobinopathies who had attended at least once to the hematology clinic were included. Demographic characteristics (date of birth, gender, country of birth) and clinical ones (genotype or Thal type, therapy and update in follow up, like alive, deceased or lost patient) were collected. Written informed consent was signed by patients or legal guardians in accordance with the Declaration of Helsinki. The study was approved by the hospital Ethical Committee. Statistical analyses were performed using SPSS version 18.0. Quantitative variables were reported as median or mean value and range, while categorical variables were expressed as absolute value and percentage.

Results: The total number of patients included was 31 (9 Thalassemia Major (TM), 1 Thalassemia Intermedia (TI), 21 other not sickle-hemoglobinopathies). The center follows 209 sickle patients, which leads to a ratio sickle/not sickle of 6.74 (Table 1). Ratio boy/girl is 1.21 for all group. Most of patients were born in Spain (90.32%), although 6.45% were born in Asia and one patient was born in Rumania. Considering the parents, 32% were born in Europe, 25% from Asia, and 12% from America. 92% of those patients born in Spain were detected in their first days of life due to universal screening detection implemented in Madrid since 2003. Median age at first diagnosis was 0.70 years (0-16.35). Median age at the end of inclusion was 9.39 years (range 1.90 to 35.44). 35% of them had molecular genotyping for diagnostic confirmation. The test of 10 patients with Thal had HLAA identical siblings. Quelation treatment was added to standard treatment to all the patients with Thal: 7 received deferasirox, 3 were treated with deferoxamine and 2 with deferiprone; 2 of the patients required double quelation. Two out of 10 patients with Thal underwent...
splenectomy. None of these patients had sepsis or meningitis. Three Thal patients underwent progenitor stem cell transplantations and they remain on complete chimerism in the present moment. Patients lost to follow-up summed up 14; 3 emigrated to other countries, 2 continue the monitor of their diseases in other centers or in adults units and 7 for unknown reasons. There was one death (3.22%) for a cause unrelated to his illness.

Table 1.

Summary/Conclusions: Early diagnosis derived from universal neonatal screening for sickle cell disease allows an effective health education and prompt therapy to other hemoglobinopathies, and a correct and thorough follow-up of these patients.

PB2201
PREVALENCE AND CAUSES OF CLOTTING TIMES PROLONGATION IN PATIENTS WITH TRANSFUSION DEPENDENT BETA THALASSEMIA
I. Tartaglione1,*, M. Caiazza1, A. Bonadies1, D. Roberti1, M. Casale1, S. Scianqueta1, F. Rossi1, S. Perrotta1
1Dipartimento della Donna, del Bambino e della Chirurgia generale e specialistica, Università della Campania “Luigi Vanvitelli”, Naples, Italy

Background: Thalassemia is traditionally known to be a thrombophilic, rather than hemorrhagic, disorder. In spite of this, prolongation of clotting times are often reported. Understanding if there is a real risk of bleeding, and what this risk can be associated to, is crucial, especially in relation to the frequent referral to surgery (e.g. for splenectomy, cholecistectomy). Hepatopathy due to iron overload or HCV infection has been addressed as a main cause of this finding, even though disorders in the clotting profile are often reported also in patients with no alterations of hepatic function. The impairment of factors XI and XII often reported has been hypothesized to be secondary to intravascular haemolysis or multiple transfusions (Caocci et al, Acta Haematol 1978, Mcfadyen et al, Ann Hematol 2014), but no data are available to confirm this supposition.

Aims: To determine the prevalence of clotting disorders in a group of Transfusion dependent Thalassemia (TDT) patients and to assess the correlation with hepatopathy, degree of the hemolysis, transfusion frequency, erythroblastosis, iron chelation.

Methods: TDT patients followed at our center for whom clotting tests were available were included. From chart review data were collected regarding clotting times, demographics, disease history, comorbidities and concomitant medications, iron chelation therapies, iron overload (serum ferritin, LIC, cardiac T2*), liver function tests, hemolysis parameters, hemorocromocitometric values. Patients on anticoagulation therapy were excluded.

Results: 22 TDT patients (female 55,35%) were enrolled in our study, mean age 26.02±13.38 years, 17 of them were pediatric. In 20/56 patients (35,71%) prolongation of clotting time was found: this included both prolonged INR (23,21%) and prolonged aPTT ratio (25%); 7 patients (12,5%) had both prolonged INR and aPTT. Subgroup with clotting disorder (group A) was compared to subgroup with clotting times within normal ranges (group B) using T-Test. No differences were found in terms of sex, age, genotype, transfusion interval, hemolysis degree, comorbidities, HCV infection included, iron overload, liver function, erythroblastosis and platelets levels, nor in history of thrombotic complications. No patients had history of hemorrhagic disease. Pretransfusion Hb was lower in patients with prolonged clotting times (p=0.045); none of the patients in Group A was splenectomized (p=0.042).

Summary/Conclusions: In our population clotting disorders were not correlated with hepatic disease, nor hemolysis or transfusions. The mild correlation with lower Hb values and with the lacking splenectomy could be consistent with the known effect of low Ht on lab procedures for clotting tests. In relation to this observation in patients with altered coagulation tests the repetition of clotting test after blood transfusion could be advisable to overcome the low Hb effect.

PB2202
COMPOUND HETEROZYGOSITY FOR HAEMOGLOBIN ADANA AND A-THALASSEAEMIA IN GREECE. CLINICAL PHENOTYPE AND GENETIC COUNSELING
S. Theodoridou1,*, A. Telì2, E. Yfantì3, T.-A. Vyzantiadìs4, M. Economou2
1Thalassemia Unit, Hippokration General Hospital, 2First Department of Pedi- atrics, Aristotle University, Thessaloniki, 3Thalassemia Centre, Laikon General Hospital, Athens, 4First Microbiology Department, Aristotle University, Thessa- loniki, Greece

Background: Haemoglobin (Hb) Adana (HBA2q.C.179>A) in interaction with deletional and nondeletional α-thalassaemia mutations leads to HbH disease commonly to thalassaemia intermedia with clinical manifestations varying from asymptomatic forms to severe anemia. First line screening tests are unable to detect the highly unstable variant. Aims: We report two cases of Hb Adana co-inheritance with the α-thalassaemia 3.7 kb deletion - the only α-thal and Hb Adana double heterozygosity cases diagnosed in subjects of Greek origin. Methods: The first case concerns a 3 year old girl, born from parents referred for genetic counseling at the 11th week of a second gestation. The mother showed an Hb of 10.7g/dl, MCV 80.7 fl, MCH 26.4 pg, Hb A2 2.8% and Hb F 1%, with positive inclusion bodies, and her ethnic (Greek) and regional background was of high risk for thalassaemia. The partner came from the same region, and he showed an Hb of 13.8g/dl, MCV 8.10 X 10^12/L, MCH 73.1 fl, MCH 23.5 pg. Hb A2 2.4% and Hb F 2.3%, while her ferritin levels were 228ng/ml and inclusion bodies were found. On clinical examination she was found to be of normal weight and height for her age, but presented with paleness, icteric sclera and mild splenomegaly. Genetic analysis revealed that the mother carried the α-thalassaemia 3.7 kb deletion defect. The father carried the rare non deletional Hb Adana. As suspected from the haematologi- cal data, their offspring was a compound heterozygote for Hb Adana variant in trans to a 3.7 α+ thal deletion. The second case concerns a 17-year-old boy, diagnosed with Hb Adana co-inheritance with the α-thalassaemia 3.7 kb deletion at the age of 8 years. At diagnosis, findings were compatible with a very mild phenotype and growth was not impaired. The boy retained a mild hypochromic macrocytic anemia (Hb~10g/dl, MCV 71 fl, MCH 23 pg, RDW 18.6%, reticulo- cytosis 5%), until age 11, at the age of 11 transfusion initiation was decided due to marked splenomegaly and limited weight and height gain. For the following years he was transfused approximately once a month, neces- sitating chelation therapy. Weight, height and pubertal development were normal by the age of 15, but splenomegaly persisted. Splenectomy was decided and transfusions were stopped shortly afterwards. During the following months the boy retained an Hb of 9.5 g/dl; however, he complained of constant fatigue and impaired physical activity and asked to get back on a transfusion program. Results: In both cases diagnosis was incidental highlighting the mild pheno- type. However, the co inheritance of Hb Adana with the 3.7 kb α+ thal deletion is rare, with only the presenting cases in Greece, and in a few other families in Turkey, Southeast Asia, Philippines and Albania. The clinical phenotype of the combination seems to be a mild disease with a non-transfusion-dependent thalassaemia intermedia phenotype. Nonetheless, clinical severity prediction is always a difficult issue and phenotypes may change overtime as demon- strated by the second case described above.

Summary/Conclusions: Long follow-up of such rare cases is necessary in order to gain as much information as possible, so as to offer the best manage- ment to the patients and the most accurate genetic counseling.
Thrombosis and vascular biology

PB2203
ANTITHROMBOTIC EFFECTS OF PEPTIDE PGPL IN EXPERIMENTAL THROMBUS FORMATION
M. Grigorjeva1, L. Lyapina1, T. Obergan1
1Biology, Lomonosov Moscow State University, Moscow, Russian Federation

Background: Previously, it was established that proline- and glycine-containing peptides have fibrinolytic, anticoagulant activity, inhibit platelet aggregation and thrombin activity in vitro and in vivo. Besides, it is known that short peptides of this family also have antithrombotic effects.

Aims: To study the influence of Pro-Gly-Pro-Leu (PGPL) and amino-acid leucine on fibrinolytic and anticoagulant blood activity, platelet aggregation and to estimate their possibility to reduce the formation of experimental blood clots.

Methods: Experiments were carried out on white rats (200–250 g) according to the ethical principles of the Helsinki Declaration. Peptide PGPL (1 mg/kg), leucine (0.33 mg/kg - equivalent to its content in PGPL) and saline (control rats) were intranasal entered to rats within 3 days. 1 hour after the last drugs administration we induced the formation of thrombus in n=15 guineaïs (Wesserly model). The degree of thrombus formation was estimated on thrombus weight. Fibrinolytic activity and activity of tissue-plasminogen activator (t-PA) of blood plasma were measured by fibrin plate method. Anticoagulant activity (APTT-test) and ADP-induced platelet aggregation were detected by standard methods.

Results: Our experiments demonstrated that preliminary intranasal administration of PGPL (before formation of thrombus) leads to increase of APTT, fibrinolytic and t-PA activity on 18%, 62%, 35% accordingly from control rats. Besides, we observed the decrease of platelet aggregation. Also we indicated the reduction of thrombus weight in PGPL-treated rats on 68.5% comparatively with control rats. The thrombus weight after leucine treatment decreased on 30% compared with control rats. But administration of leucine did not change of haemostasis system parameters.

Summary/Conclusions: Thus administration of PGPL enhanced of anticoagulant, fibrinolytic and antiplatelet activity in rats blood plasma. PGPL pretreatment lead to prevention of experimental venous thrombus formation. Therefore, PGPL may be used as a perspective anticoagulant and fibrinolytic agent with direct antithrombotic effect.

PB2204
TREATMENT AND OUTCOME OF THROMBOTIC MICROangiopathy IN MALAYSIA
Y.Y. Yap1, K.B. Law1, P.A.B. Zulkarnain1, S. Carlo1, R. Ramli1, J. Sathar1, K.M. Chang1
1Department of Haematology in Ampang Hospital, Ministry of Health, Selangor, Malaysia

Background: Thrombotic Thrombocytopenic Purpura (TTP) is a potentially lethal disease that there is still no promising cure in this era. The ADAMTS-13 deficiency or defect in the disease has enabled clinician to recognize another entity which is Thrombotic Microangiopathy (TMA). This entity includes TTP, typical Haemolytic Uraemic Syndrome (HUS), Cancer associated TMA, Atypical HUS, Post-transfusion TMA, SLE related TMA and Transplant TMA.

Aims: This study is to focus on the treatment among the TMA and the outcome of the disease.

Methods: The data was collected from year 2012 to 2016 from Ampang Hospital via the electronic hospital information system (EHIS) and external records traced from Haemostasis laboratory in Ampang Hospital as well as from other hospitals nationwide.

Results: There were total of 243 suspected TMA cases, encompassing 97 (39.9%) males and 146 (60.1%) females. The median age for this cohort was 34 years. Only 54 (24.15%) patients were diagnosed as TTP based on ADAMTS-13 activity ≤10%. Treatments were evaluated by using complete case details from Ampang Hospital cohort (69 cases). From this cohort, only 59 cases had ADAMTS-13 activity testing. There were 24% Primary Acquired TTP, 5% typical HUS, 3.4% atypical HUS, 3.4% Pregnancy TMA, 3.4% SLE related TMA, 20.3% Transplant TMA, 1.7% Cancer associated TMA and 37% TMA of other causes. The average plasma exchange was given 4 cycles and was higher in patients with ADAMTS-13 activity ≤10% (11.4 cycles) as compared to those with ADAMTS-13 >10% (7.7 cycles).

No infectious diseases were transmitted as a result of plasma exchange or plasma infusion. Treatments used in the patients included immunosuppressant therapy like cyclophosphamide (26%), mycophenolic acid (19%), prednisolone (14%), methotrexate (10%), mycophenolate mofetil (22%), vincristine (26%). The survival outcome seemed to be worse among the transplant TMA in comparison to other groups (log-rank, p<0.0001). Transplantation was also associated with higher odds of death among TMA cases (OR: 14.8571, 95% CL: 1.7385, 126.9707). Those with confirmed TTP was inevitably doing better compared to other groups (log-rank, p=0.0299). The odds of death was 4.36 times higher in patients with ADAMTS-13 activity >10% (OR: 4.36, 95% CL: 1.0961, 17.3714), indicating secondary TTP may have inferior treatment and disease outcomes than primary TTP like congenital or acquired TTP. Besides, the complications of the disease were also evaluated which revealed 26.6% of renal failure and 52.2% of neurological deficit. Furthermore, 8.7% were complicated by Venous Thromboembolism, either provoked or spontaneous. The odds of relapse is 2.9 times higher given the ADAMTS-13 activity ≤10% to ADAMTS-13 activity >10%.

Summary/Conclusions: This study illustrated that the standard treatment like plasma exchange and immunosuppressant therapy are only effective in genuine TTP whereas those masquerading TTP (TMA) would be more challenging to be tackled in terms of improving the outcome. The task to investigate other types of TMA prospectively will be highly desirable in the future.

PB2205
ANTIPHOSPHOLIPID ANTIBODY PROFILE AND ORGAN INVOLVEMENT IN CRITICALLY ILL PATIENTS WITH AUTOIMMUNE DISEASES
P. Zambrano1,2, J. Aponte1, A. Sanchez2, M.T. Ospina2, Y. Forero1, J. Carrizosa3, E. Aviles4, A. Cartagena1, C. Zapata1, C. Gamboa1
1Universidad de La Sabana, 2Hospital Universitario de la Samaritana, 3Fundación Santa Fe De Bogotá, Bogotá, 4Universidad de La Sabana, Bogotá, Colombia

Background: Antiphospholipid antibodies (APA) are a group of proteins direct-ed against the phospholipids of cell membranes, such as cardiolipins or phospho-lipid binding proteins. APA presence provokes microvascular, arterial or venous thrombotic events indicating somehow the relationship between the immune system, the hemostatic system, and the inflammatory response. It has been suggested that their presence in a critically ill patient is related to thrombotic manifestations, organ dysfunction, and death.

Aims: The aim of this study was to evaluate the prevalence of antiphospholipid antibodies in critically ill patients with autoimmune diseases and the rate of organ involvement.

Methods: Retrospective and descriptive study of patients admitted to the intensive care unit of Hospital Universidad de la Samaritana between 2008 and 2016, in Bogotá, Colombia.

Results: A total of 79 patients were found to have systemic lupus erythematosus (SLE), antiphospholipid syndrome and vasculitits. 17 patients (22%) were positive for antiphospholipid antibodies. Of these, 76% were women and mean age was 38 years (18-63 years). APA profiles showed positivity with control distribution: one positive antibody, n=9 patients (53%) (lupus anticoagulant antibody being the most common), two positive antibodies in n=4 patients (23%) and three positive anti-bodies in n=4 patients. Anemia (100%), monocytosis (64%), thrombocytopenia (40%) and prolonged INR (17%) were found in 88% of patients on admission to the ICU. In descending order, other organ involvement was found to be: pulmonary and renal dysfunction (70%), shock (53%), central nervous system involvement (41%), cardiovascular (23%), and gastrointestinal (22%). 82% of this cohort had positive anti-nuclear antibodies (ANA) and 23% anti-cytoplasmic antibodies (ANCA). 100% of patients had elevated C-reactive protein (CRP), and APA score average was 11 points (Table 1).

Table 1.

Summary/Conclusions: Hematologic, renal and pulmonary involvement are the most commonly compromised in patients with antiphospholipid antibodies presenting with autoimmune diseases in the ICU. Based on these results, a prospective study is proposed in order to evaluate the presence of APA and their impact on mortality and multi-organ dysfunction in these patients.

PB2206
PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODY AND HBA1C IN T2DM WITH DIABETIC VASCULAR COMPLICATIONS
T. U. Nwagha1, O. Agye1
1Haematology & Immunology, University Of Nigeria Teaching Hospital, Enugu, Nigeria

haematologica | 2017; 102(s2) | 871.

Madrid, Spain, June 22 – 25, 2017
Background: Antiphospholipid antibodies (APLs) have been implicated in vascular (atherosclerotic, venous or both) thrombosis. Diabetes Mellitus (DM), as a disease entity has been associated with hyper-coagulable and pro-thrombotic states, with studies showing an increased procoagulant state and thrombotic events especially in poorly controlled Type 2 Diabetes Mellitus (T2DM). Aims: The aim of the study is to assess the APLs and HbA1c levels and evaluate the correlation between APLs levels and HbA1c in T2DM patients with diabetic vascular complications.

Methods: This was a cross-sectional study of subjects with T2DM attending the diabetic clinic of University of Nigeria Teaching Hospital. A total of two hundred and ten (210) subjects were recruited for this study. There were grouped into microvascular complications: T2DM, uncomplicated T2DM and health control. Each had 70 subjects matched for sex and age. Lupus anticoagulant (LA) was assayed using DRVVT (thrombocyte GmbH Austria) IgGβ2GPI-ACA was assayed using ELISA test kit (Genway Bio-tech San Diego USA), HbA1C was assayed using D10TM haemoglobin analyzer. Ethical clearance was obtained from the ethical committee UNTH.

Results: The prevalence of LA was 7.1%, 4.3% and 4.3% for complicated T2DM, uncomplicated and healthy control subjects respectively, while the prevalence of IgG-B2GPI ACA was 4.3% in all groups. The mean HbA1C were 8.2(1.5), 8.0 (1.7), 5.6 (0.38) for complicated, uncomplicated T2DM and control subjects respectively. ANOVA showed a significant difference in mean position on the risk of acute coronary syndrome (ACS).

Summary/Conclusions: The study did not find any causal or other association between T2DM and the occurrence of APLS positivity, however, APLS may be a significantly aggravating factor for vascular complications especially in poor control T2DM.

Background: von Willibrand factor antigen level (vWF: Ag) was shown to contribute to the risk of cardiovascular disease. vWF Thr789Ala single nucleotide polymorphism is thought to affect factor level and function. Aims: This study was designed to investigate the genetic variants at that position on the risk of acute coronary syndrome (ACS).

Methods: The study included 112 patients of ACS; 31 with unstable angina (UA) and 81 with myocardial infarction (MI) as well as 118 healthy controls. vWF: Ag level was measured by ELISA. The gene analysis was carried out by polymerase chain reaction using restriction fragment length polymorphism (RFLP-PCR) principles.

Results: vWF:Ag levels were significantly higher in MI (111.6±24.77 IU/dl) and UA (110.27±23.44 IU/ml) patients compared to healthy controls (71.13±13.72 IU/dl). p < 0.001 for both groups. The frequency of patients with UA (80.6%) were Ala789 homozgyous, 5.6% were Thr789Ala heterozygous and 12.9% were Thr789 homozygous. Regarding the MI group, Ala789 genotype was in 34.6%, Thr789Ala genotype was the predominant genotype and was seen in 48.1% of patients and Thr789 homozygous was present in 17.3% of patients. The genotype frequency in the control group was as follow: 47.1% were Ala789 homozygous, 33.1% were heterozygous and 19.5% were Thr789Ala heterozygous and 12.9% were Thr789 homozygous. The genotype distribution was significantly different among the 3 groups, p<0.001, and between the groups with UA and MI, p < 0.001. Ala789 homozygous genotype was an independent risk factor for UA while the Thr789Ala genotype was shown as an independent risk factor of MI. Summary: vWF Thr789Ala polymorphism is independent risk factor for UA and has significant impact on the type of myocardial ischemia. It should be incorporated in a risk assessment model to identify individual patient risk and guide the management plan.

Background: The influence of fibrinogenase isolated from the Antarctic scallop Adamussium colbecki on platelet aggregation and blood coagulation.

Methods: Fibrinogenase from the crude tissue extract of A. colbecki was isolated by three-step procedure and characterized by Blue-Sepharose followed by affinity chromatography on Blue-Sepharose and size exclusion chromatography on Superdex 75- PG. Platelet aggregation was determined by AT-02 aggregometer (Medtech, RF). The platelet count was adapted to 2.5x10^5 platelets/μL with platelet-poor plasma. Then, fibrinogen (12.5 μg/mL or 6.25 μg/mL) was added 2 min before the addition of the platelet aggregation inducer (5x10^{-7} M ADP). The changes in light transmittance were continuously monitored during 8 min, and the percentage of aggregation, in the presence of the samples, was calculated comparing the transmittance against the controls. Activated partial thromboplastin time (APTT) and prothrombin time (PT) were assayed using INTEM and EXTEM, respectively.

Results: According to our result investigated enzyme inhibited ADP-induced platelet aggregation and the inhibition increased with increasing concentration of the enzyme. Data analysis revealed a significant (p<0.05) inhibition of ADP-induced platelet aggregation by 80.5% for 12.5 μg/mL of fibrinogenase and by 31% for 6.25 μg/mL of fibrinogenase dose. The fibrinogenase induced platelet aggregation by hydrolyzing the α-chain of fibrinogen to prevent fibrinogen from combining with fibrinogen receptor on platelet membrane. In addition, fibrinogen degradation products may act as competitive inhibitors of platelet–fibrinogen bridging formation. We also investigated the effect of fibrinogenase on blood coagulation by determination of APTT and PT. According to our result APTT increased in 2.25 and 1.25 times at the concentration of fibrinogenase of 12.5 μg/mL and 6.25 μg/mL, respectively. The fibrinogenase also prolonged PT from 18 s to 68 s when the concentration of enzyme was 6.25 μg/mL.

Summary/Conclusions: Further investigations of fibrinogenase from A. colbecki are interesting and would probably help to develop new therapeutic agents to treat thrombotic disorders.
and aPTT, therapeutic level of the drug and creatinine measurement, within the emergency and control laboratory tests in patients that receive DOACs.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Apixaban</th>
<th>Rivaroxaban</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>percentage</td>
<td>35.9%</td>
<td>31.8%</td>
<td>22%</td>
</tr>
<tr>
<td>toxicity</td>
<td>3.3%</td>
<td>6.9%</td>
<td>10%</td>
</tr>
<tr>
<td>thrombophiles</td>
<td>1.6%</td>
<td>2.5%</td>
<td>6%</td>
</tr>
<tr>
<td>percentage out of therapeutic range</td>
<td>8.4%</td>
<td>24.5%</td>
<td>22%</td>
</tr>
<tr>
<td>prolonged PT</td>
<td>8.4%</td>
<td>2.5%</td>
<td>80%</td>
</tr>
<tr>
<td>prolonged aPTT</td>
<td>16.9%</td>
<td>21%</td>
<td>4%</td>
</tr>
<tr>
<td>Bleeding</td>
<td>(31): 15.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>percentage</td>
<td>34.3%</td>
<td>20.8%</td>
<td>7.8%</td>
</tr>
<tr>
<td>prolonged PT</td>
<td>8.3%</td>
<td>22.5%</td>
<td>100%</td>
</tr>
<tr>
<td>prolonged aPTT</td>
<td>25%</td>
<td>35.3%</td>
<td>80%</td>
</tr>
<tr>
<td>moderate therapeutic range</td>
<td>177</td>
<td>142</td>
<td>154</td>
</tr>
<tr>
<td>median serum creatinine</td>
<td>Imq/ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>median age</td>
<td>81</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PB2210

HEREDITARY RISK FACTORS OF VENOUS THROMBOEMBOLISM IN YOUNG WOMEN TAKING ESTROGEN DRUGS
A. Chechulova1, S. Kapustín2, S. Karpic3, V. Shimelava2, V. Soldatenvk4, L. Papayam, V. Soroká1, P. Chechulová1
1Vascular surgery, Dzhanedzhele Research Institute of Emergency Medicine, St. Petersburg, 2Russian Research Institute of Hematology and Transfusiology, 3Dzhanedzhele Research Institute of Emergency Medicine, St. Petersburg, St. Petersburg, Russian Federation

Background: Estrogens are recognized as the most common risk factor of venous thromboembolism (VTE) in young women. The cumulative risk of VTE in patients taking estrogens is significantly increased in carriers of inherited thrombophilia. However, the known hereditary risk factors – mutations FV Leiden and FII 20210A could be detected in only 20-30% of patients with VTE.

Aims: To identify the most common hereditary risk factors of VTE in young women taking estrogen drugs.

Methods: We examined 133 young women with acute VTE (mean age 37.4 years; 16-45), who were genotyped by PCR-RFLP method for DNA polymorphism in 9 genes: FI-A Thr312Ala, FI-B -455 G/A, FII 20210 G/A, FV 1691 G/A, FXI 46 C/T, FXI-A Val34Leu, PAI-1 675 4G/4G – 36.7%, 42.9% and 27.9%; EPSCR 219Ser/Gly – 16.7%, 19.0% – 13.3%, 14.3% and 13.1%; TPA 311bp Ins/Ins – 16.7%, 28.6% and 31.1%; PAI-1 675 4G/4G – 36.7%, 42.9% and 27.9%; EPCR 219Gly/675Gly – 16.7%, 19.0% and 23.0%; EPSCR 219Gly/675Gly – 3.3%, 7.1% and 0.0%; FXI-A 46TT – 13.3%, 0.0% and 9.8%; FXII-A 34Leu/Leu – 3.3%, 21.4% and 9.8%. Significant differences between the groups have been detected only for the FXIII-A 34Leu/Leu variant, with a stronger risk factor for anticoagulation >0.05 and was not significant. The majority knew of prothrombin test and p value was 0.03, less than alpha value of 0.05 and was significant. On the contrary, Majority does not know about anti-Xa assay, p-value=0.02, <0.05, was also significant. Their affirmative response on the mode of action as one of the differences showed a p=0.001, <0.05, was significant. On the contrary, the non-affirmative response to drug and food interaction, p=0.03, was also significant. Based on results of the statement analysis, the variables were ranked according to the value of their mean. All except one variable had p-values of <0.05. The statement “Do you think anticoagulation therapy/prophylaxis is clinically important” had the highest mean of 4.60 and had a high degree of agreement. The statement “Should hospital inpatient with >3 days admission routinely receive anticoagulation?” had the lowest mean of 2.27 with a p-value of 0.015 had a low degree of agreement.

Summary/Conclusions: There is a need to upscale knowledge attitude and practice of the use anticoagulants agents especially the NOACs through well-articulated CME educational activities. A limitation of this study is the relatively small number of study participants and some sub specialties that were not reflected in this survey.

PB2214

INTERLEUKIN -10 GENE POLYMORPHISMS AND THE RISK OF UNPROVOKED DVT IN EGYPTIAN PATIENTS
H. Eshlity1, G. Shaheen2, E. Elmoamly1
1Internal medicine- clinical Hematology Unit, 2Clinical pathology, Kasr Al-Ainy school of medicine- Cairo university, Cairo, Egypt

Background: Thrombosis is often multifactorial, caused by both genetic and acquired risk factors. The inflammatory process is linked to pathogenesis of venous thrombosis. Venous thrombosis is considered to be mediated by an imbalance in proinflammatory as compared with anti-inflammatory mediators. One of the important anti-inflammatory cytokine is interleukin-10 (IL-10) with important immunoregulatory functions. Primarily, IL-10 counterbalances the potentially harmful effects of tumor necrosis factor α (TNFα) and other pro-inflammatory mediator such as IL-1b, IL-6, and IL-8 from monocytes/macrophages. Three important single nucleotide polymorphisms (SNP) have been identified as potentially affecting IL-10 expression, including: 1082 A/G, 819 C/T, and 592 C/A. Studying the association between genetic polymorphisms of anti-inflammatory cytokines such as IL-10, and venous thrombosis may suggest using of polymorphisms as a predictive genetic marker of future VTE.

Aims: The objective of this study was to evaluate a possible association between IL-10-1082A/G, and -592C/A polymorphisms with DVT.

Methods: The study was conducted on 115 patients with symptomatic DVT proved by venous duplex ultrasound; divided into two cohorts: group A included

1Haematology & Immunology, 2Internal medicine, University Of Nigeria Teaching Hospital, Enugu, 3Internal medicine, Abia state Teaching Hospital, Umunhua, 4Internal medicine, Nnamdi Azikiwe Teaching Hospital Nnewi, Awka, 5Internal medicine, Federal Medical Center , Abakiliki, 6Internal medicine, Amaku Specialist hospital, Awka, Nigeria
60 patients with unprovoked DVT, and group B included 55 patients with provoked DVT. Gene mutations for IL-10 -1082AG, and -592CA were performed using PCR-restriction fragment length polymorphism assay. We studied the association between IL-10 gene polymorphisms and occurrence of either provoked or non-provoked DVT. We also investigated the link between these polymorphisms and the recurrence of DVT and family history of DVT.

Results: In group B (provoked DVT), as compared with group A (unprovoked DVT) the gene polymorphism distribution was statistically significant different (Table 1).

Summary/Conclusions: IL-10L1082AG gene polymorphism is associated with risk of unprovoked DVT, however it is not associated with either risk of recurrence or positive family history.

PB2215
CATASTROPHIC ANTI-PHOSPHOLIPID SYNDROME TRIGGERED BY SEPSIS. A PROSPECTIVE CASE STUDY HIGHLIGHTING BIOLOGICAL CONCEPTS AND MANAGEMENT STRATEGIES IN THIS COMPLEX AND LIFE THREATENING DISEASE
M. Hu1
1Haematology, Liverpool Hospital, Sydney, Australia

Background: Catastrophic antiphospholipid syndrome (CAPS) is a rare and life threatening event characterized by widespread intravascular thrombosis and multi-organ failure. Typically it is CAPS associated with bleeding diathesis, but it has been reported in cases with severe thrombocytopenia and acquired prothrombin inhibitors. APS auto-antibodies are heterogeneous and may undergo post-translational modification during antigen stimulation altering its pathogenicity and thrombotic risk. Sepsis and associated disseminated intravascular coagulation is known phenomenon where cytokines influence pro-coagulant and anti-coagulant pathways on multiple levels, induce haemostatic chaos.

Aims: Define the role of sepsis in triggering life threatening CAPS, and highlight the management strategies used in this highly complex and fatal disease.

Methods: Prospective case study illustrating two separate atypical CAPS presentations and the management strategies employed. 1st episode (2015): 54F with long standing 27 years of triple positive APS, pro-thrombotic history with recurrent thrombosis despite optimal anticoagulation. Her pro-thrombotic episode occurred as respiratory diathesis which progressed with severe headaches. Subsequent investigations demonstrated multiple atrumatic intra-cranial haemorrhages followed by concurrent extensive cerebral venous thrombosis. 2nd episode (2017): She presented with subdural haemorrhage, preceded by fever and respiratory symptoms. She then developed pleuritic chest pain and dyspnoea after temporary cessation of anticoagulation for 24 hours. Imaging confirmed multiple pulmonary emboli with areas of infarction. Respiratory symptoms worsened with progressive interstitial ground glass changes on CT consistent with atypical pulmonary infection. Shortly after low therapeutic anti-coagulation she developed acute abdominal pain and hypertension. CT revealed significant bilateral adrenal haemorrhages. Management Strategies: (A) Rapid reduction in APS pathogenic auto-antibodies via plasma exchange, B cell depletion therapy and immuno modulation. (B) Treatment of underlying infectious trigger. (C) Judicious anticoagulation with anti-Xa monitoring and (D) long term hydroxychloroquine and statin therapy. 22 nd Congress of the European Hematology Association

Results: The two life threatening presentations of CAPS were triggered by an infectious event, supporting the biological concept that anti-phospholipid antibodies can be immune modulated altering his pathogenic capabilities creating haemostatic havoc. There are similarities and a degree of overlap with sepsis and the pathophysiology behind disseminated intravascular coagulopathy. Rapid reduction in the pathogenic auto-antibodies using combination plasma exchange, immuno modulation and B cell depletion therapy is effective in this acute setting. Judicious anticoagulation and treatment of the precipitating infection is important in turning off the immune response driving this life-threatening condition.

Summary/Conclusions: CAPS is rare and life threatening, often triggered by an infectious event, trauma or temporary cessation of anticoagulation. It requires prompt recognition and timely commencement of therapy.

PB2216
HAEMATOLOGICAL CORRELATES OF ISCHEMIC STROKE AND TRANSIENT ISCHEMIC ATTACK : LESSONS LEARNED
H. Gunasekara1, I. Pathirag2
1Health, Teaching Hospital- Kegalle, Kegalle, 2Health, Provincial Department of Health Services, North Western Province, Sri Lanka

Background: Haematological abnormalities are known to cause Ischemic Stroke or Transient Ischemic Attack (TIA). The identification of haematological correlates plays an important role in management and secondary prevention.

Aims: The objective of this study was to describe haematological correlates of stroke and their association between stroke profile. The haematological correlates screened were Lupus Anticoagulant, Dysfibrinoginemia, Paroxysmal nocturnal haemoglobinuria (PNH), Sickle cell disease, Systemic Lupus Erythematosus (SLE) and Myeloproliferative Neoplasms (MPN).

Methods: A cross sectional descriptive study was conducted in a sample of 152 stroke patients referred to haematology department of National Hospital of Sri Lanka for thrombophilia screening. Following tests were performed to assess each hematological correlates (Table 1).

Table 1

<table>
<thead>
<tr>
<th>Haematological correlate</th>
<th>Tests performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lupus anticoagulant</td>
<td>Anti-DX, Anti-Hen, Test and Kaolin-activating test</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>Blood count (Hb), Blood protein, and Antithrombin III</td>
</tr>
<tr>
<td>Paroxysmal nocturnal haemoglobinuria (PNH)</td>
<td>Blood count (Hb), Blood protein, and Antithrombin III</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus (SLE)</td>
<td>Blood count (Hb), Blood protein, and Antithrombin III</td>
</tr>
<tr>
<td>Myeloproliferative Neoplasms (MPN)</td>
<td>Blood count (Hb), Blood protein, and Antithrombin III</td>
</tr>
</tbody>
</table>

Results: Among study sample, 134 patients had strokes and only 18 had TIA. The recurrence of stroke/TIA was observed in 13.2% of patients. The majority of the cases (96.7%) had no evidence of haematological thrombotic event. One fourth of patients had past thrombotic events while 12.5% had family history of thrombosis. Out of haematological correlates screened Lupus anticoagulant was the most common haematological correlate (n=16) and dysfibrinogenaemia(n=11) had the next high prevalence. One patient was diagnosed with Essential thrombocythaemia and one with SLE. None of the patients were positive for screening tests done for sickle cell disease and PNH.

Summary/Conclusions: The haematological correlates were identified in 19% of our study sample. Among stroke profile only presence of past thrombotic events were statistically significant correlates associated with haematological disorders (P=0.004). Therefore hematomatological disorders appear to be an important factor in etiological work up of stroke patients particularly in patients with past thrombotic events.

PB2217
ANTIPLATELET AND FIBRINOLYTIC EFFECTS OF ARGinine-CONTAINING PEPTIDES IN HEALTHY RATS AND RATS WITH METABOLIC SYNDROME
Y. Song1, M. Grigorjeva2, T. Obergaran3
1I.M.V.Lomonosow Moscow State University, Moscow, Russian Federation

Background: Currently, the number of diabetes, hypercholesterolemia, metabolic syndrome (MS) patients has increased sharply in the world. MS is metabolic disorders with increase of cholesterol and glucose levels, dyslipemia, endothelial dysfunction. This is accompanied by an increase in blood clotting, including platelet aggregation strengthening and reducing the activity of the plasminogen activator. Thus, the MS may predispose to venous thrombosis. It is known that, regulatory oligopeptides involved in the conservation normal functional activity of coagulation, anticoagulation, insular systems of the organism, fat metabolism. It is also known that some amino acids, particularly arginine, improve rheological properties of blood and reduce platelet aggregation. In a study the effect of tripeptides Pro-Arg-Gly and Gly-Arg-Pro, containing arginine in the molecule, on platelet aggregation and tissue plasminogen activator (t-PA) activity in a healthy organism and the development of the experimental MS.

Methods: Experiments were carried out on Wistar rats weighing 300-350 g in accordance with the ethical principles of the Helsinki Declaration. Two groups of animals were used: healthy rats and rats with experimental MS. Peptides were intranasal injected in doses of 1 mg / kg once daily for 5 days. 0.85% NaCl solution was injected to control rats in the same time frame. MS in rats was caused by a hyper-cholesterol fat-rich diet (FD) for 6 weeks. Blood samples were taken from the jugular vein 1 hour after the last drug administration. Activity of t-PA (fibrin plate method) and ADP-induced platelet aggregation (standard method) were measured in blood plasma.

Results: The intranasal administration of peptides Gly-Arg-Pro, and Pro-Arg-Gly to healthy animals resulted a reduction of platelet aggregation by 23% and 57% compared with control. Both peptides induced enhancement t-PA activity of 2 or 3.5 times respectively. In rats with experimental MS these effects were preserved, besides, platelet aggregation was decreased by 27% (Pro-Arg-Gly) and 38% (Gly-Arg-Pro) compared with the control.
Summary/Conclusions: We concluded that intranasal administration of tripeptides Pro-Arg-Gly and Gly-Arg-Pro to organism of healthy rats and in rats with experimental MS show anticoagulative and fibrinolytic effects of the blood. Thus, arginine-containing peptides could potentially be used as antithrombotic drugs that protect the organism from the blood coagulation and thrombus formation.

PB2218
THE PRINCIPAL COMPONENT ANALYSIS USING CALIBRATED AUTOMATED THROMBOGRAM PARAMETERS AS A POTENTIAL QUALITY CONTROL FOR MEASURING PROCOAGULANT ACTIVITIES OF IMMUNOGLOBULINS


Background: The calibrated automated thrombogram (CAT) is a method to monitor the generation of thrombin. It can be described by four variables; lag time, peak time, time to peak, and velocity index. Currently, due to thromboembolic event related risks of immunoglobulins, the CAT is widely used to quantify the thrombogenic potential associated with immunoglobulin manufacturing processes and products. However, there is currently no officially approved method for such assessments and even this results are highly variable in inter-laboratories comparison. In this study, to obtain a summary score, we applied the principal component analysis (PCA) for these four outcomes measured from CAT method. The PCA is a statistical procedure concerned with elucidating the covariance structure of a set of variables. In particular it allows us to identify the principal directions in which the data varies.

Aims: In this study, our interest is to apply PCA method in order to find appropriate dose related with CAT variables and to reduce variation of procoagulant values in Immunoglobulin products.

Methods: The CAT are measured in a 96 well plate fluorometer equipped with a 390/460 filter set and a dispenser. Usually experiments are carried out in triplicate. During the measurement, a dedicated software program, Thromboscope compares the readings from the trigger wells and the calibrator wells, calculates thrombin concentration and displays the thrombin concentration in time. Outcomes from CAT were analyzed in the principal component analysis (PCA) which is a statistical procedure that allows us to summarize high dimensional data with a smaller number of representative variables that collectively explain most of the variability. Statistical analyses were performed with R 2.5.

Results: Four variables measured from CAT have different distribution and too large variations. For example, the mean of each variable (lag time, peak time, time to peak, and velocity index) are 24.86(8.01), 80.16(94.52), 31.28(9.78), 19.08(28.86), respectively. Therefore, to remedy such high variability among variables and to find a score, PCA method is applied. Then the dose values calculated based on the PCA scores have mean 0.393 and a much smaller variation (sd=0.583) (Table 1).

Summary/Conclusions: The PCA value showed a good agreement with four CAT outcomes and less variation. The PCA method could be used to monitor the process of immunoglobulin manufacturing.

PB2219
PRIMARY THROMBOPHILIA IN MÉXICO XII: MISCARRIAGES ARE MORE FREquent IN PERSONS WITH THE STICKY PLATELET SYNDROME


Background: The sticky platelet syndrome (SPS) is an inherited condition which leads to arterial and venous thrombosis. There is scant information about the association between the SPS and obstetric complications.

Aims: To assess the relationship of the SPS and fetal loss in a single institution.

Methods: The obstetric history of all the consecutive female patients prospectively studied along a 324 month period, in a single institution with a history of thrombosis and a clinical marker of primary thrombophilia was reviewed.

Results: Between 1989 and 2016, 268 consecutive patients with a clinical marker of primary thrombophilia and a history of arterial or venous thrombosis were studied; of these, 108 were female patients. Within this subset of thrombophilic female persons, 77 (71%) had been pregnant at some moment. Twenty eight of these 77 patients (37%) had had a spontaneous abortion and 24 out of these (86%) were found to have the SPS. On the other hand, in a subset of 73 female patients with the SPS who had been pregnant, 32% had miscarriages. These figures are significantly higher than the prevalence of abortions in the general population of pregnant women (9.8% chi square=7.47; p=0.0063). Accordingly, the relative risk of having a miscarriage is 2.66 times higher in female patients with the SPS than in the general population (p=0.0014) (Figure 1).

Summary/Conclusions: In México, female patients with the SPS experience significantly more spontaneous abortions than the general population. Since the treatment of the SPS is simple and effective and could in turn prevent adverse obstetric outcomes, its investigation in women studied because obstetric complications may be useful and deserves further research.

PB2220
CROSS-SECTIONAL ANALYSIS OF VENOUS THROMBOEMBOLISM IN YOUNG INDIAN MALES; NEW INSIGHTS INTO AN OLD PROBLEM

S.K. Das1,2, Y. Desai3, R. Kappor4, T. Verma5, S. Das6, V. Nair7

Background: Venous thromboembolism (VTE) comprising of deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the major cardiovascular causes of death along with MI and stroke. Though earlier work has suggested that DVT is rarer in Asian population, recent studies have revealed that this might not be so. Most of the studies conducted in Asia in general and India specifically has been on hospitalized patients with minimal representation of young healthy individuals.

Aims: We aimed at studying the disease variables of VTE in young healthy males of Indian origin and compare the same with other Indian studies as well as the global statistics.

Methods: Hospital records of 176 Color Doppler Flow Index (CDFI) and /or Contrast Enhanced Computed Tomography (CECT) proven VTE patients being followed up in a tertiary care hospital was analyzed retrospectively to document cause (provoked/ unprovoked), venous systems involved, thrombophilia profile, duration of anti-coagulation and recurrence.

Results: Among the study population, 49.8% had a provoked VTE. 90.9% subjects had DVT, mostly of the lower limb, 15.3% had PE with DVT, 2.8% had PE alone and 6.2% had splanchnic vein thrombosis including portal vein thrombosis. In the subjects who had undergone thrombophilia profile, 41.9% had Protein C, 58.1% Protein S and 25.9% Antithrombin III deficiency. Lupus anti-coagulant screen was positive for 13% of the screened subjects. The average time of anti-coagulation was 12 months with majority (98.2%) patients taking Vitamin K antagonist. The recurrence rate in our study population was found to be 11.4% (Table 1).

Summary/Conclusions: Young Indian males have different disease variables
for VTE as compared to western population. The exact pathophysiology of such differences needs to be studied further to formulate strategies for effective screening and prevention.

Table 1.

PB2221

A PRELIMINARY STUDY ON THE EFFECTS OF AMPHIBIAN CRUDE SKIN SECRETIONS ON SOME PARAMETERS OF HEMOSTATIC SYSTEM

I. Nikolaeva1, O. Marushchak1, O. Osyko1, T. Halenova1, O. Savchuk1
B. Dönmez Demir4, N.M. Christiansen5, M. Ziegler5, H. Özdağ4, M. Ziegler5

Background: A lot of bio-chemical compounds from secretion of the amphibian skin glands with various biological activities have been isolated and characterized. Several recent studies indicate that amphibian skin secretions can be a source of molecules affecting the platelet activity. We are interested to look for other bioactive components of the amphibian skin which exhibit ability to influence on diverse parameters of hemostatic system.

Aims: We performed a preliminary study of the some effects of amphibian crude skin secretions on hemostasis.

Methods: Adult specimens (both sexes) of Bombina bombina, Bombina variegata, Bufo bufo, and B. bufo viridis were collected from outdoors in Kyiv region of Ukraine. The crude skin secretions were collected by washing with ultrapure water and centrifuged to remove debris. The supernatants were lyophilized and kept at −20 °C till use. In the experiments we used fresh prepared water solution of lyophilized skin secretions. Protein concentration was determined by Bradford method with BSA as a standard. Rabbit platelet-rich plasma (PRP, 2x10^6 cells/mL) and platelet-poor plasma were obtained following standard protocols. Platelet fraction (PF) was purified by gel-filtration on Sephadex G 50 column. Platelet aggregation was measured by aggregometer AT-02 (Medtech, Russia). Coagulation parameters (prothrombin time (PT), thrombin time (TT), as well as activated partial thromboplastin time (APTT)) were measured by coagulometer (Rayto, RT-2201C) using corresponding commercial kits (Renam, Russia).

Results: The lyophilized B. bufo skin secretions in dose-dependent manner induced platelet aggregation in both PRP and purified PF; its final concentration of 50 mg of total protein/mL caused the same effect as 5x10^-6M ADP. These results indicated that skin components acted directly on platelets, maybe through their surface receptors. The lyophilized skin secretions of B. variegata and Bufo bufo also activated platelet aggregation but their effects were lower than B. bufo skin secretions. The skin secretions from all studied amphibian did not influence on PT and TT except B. viridis which prolonged TT by 40%. The values of APTT were significantly enhanced in 3.4 and 2.3 times under the influence of crude skin secretions (final concentration of 0.2 mg total protein/mL, plasma) of B. bombina and B. variegata, respectively.

Summary/Conclusions: The obtained results indicate the prospects of the search for potential modulators of hemostatic system among the amphibian skin bioactive compounds. To establish their physiological and functional mechanisms of action, the further purification and characterization of components from the skin gland secretions are necessary.

PB2222

PLASMINOGEN-DEFICIENT PATIENTS

H. Kuzilok1,*, G.N. Özdemir2, G. Dikme1, B. Köş1, G. İskelili3, B. Dönmez Demir4, N.M. Christiansen5, M. Ziegler5, H. Özdağ4, V. Schuster5, T. Celkan1

1Istanbul University Cerrahpasa Medical Faculty, Pediatric Hematology-Oncology, 2Kanuni Sultan Süleyman Education and Research Hospital, Pediatric Hematology Oncology Dept., 3Istanbul University, Cerrahpasa Medical Faculty, Ophthalmology, Istanbul, 4Ankara University, Biotechnology Institute, Ankara, Turkey, 5University of Leipzig, Leipzig, Germany

Background: Congenital plasminogen (Plg) deficiency is a rare autosomal recessive disorder that leads to the development of ligneous membranes on mucosal surfaces.

Aims: Here we report our experience with local and intravenous fresh frozen plasma (FFP).

Methods: Our cohort consisted of 14 patients and their 8 first-degree relatives. The patients have been diagnosed between 3 months and 18 years of age, and the median age at the time of first clinical manifestation was 4.5 months (range 3 days to 12 months).

Results: Conjunctivitis is the main complaint, hydrocephalus and hearing loss follow. In 10 patients, ligneous membranes were surgically removed but all recurred. Nine patients were treated with intravenous and conjunctival FFP. Two patients had no complaints after treatment. Most patients needed transfusion with FFP every three weeks. Only one patient had severe endophthalmitis and local treatment with corticosteroids before treatment. Two female patients at the age of 7 and 9 years had undergone multiple surgeries for ligneous conjunctivitis despite being treated with FFP. The response rate to FFP treatment was 6/9 (66%). Another 8-year-old female with severe bronchial membranes was treated with FFP and t-PA through bronchoscopy. Venous thrombosis did not occur in any of the patients. Nine had consanguineous parents. The genetic evaluation of our patients revealed heterogenous mutations as well as polymorphisms.

Summary/Conclusions: The diagnosis and treatment of Plg deficiency is challenging, and there is no consensus on treatment. Topical and iv FFP may be used with clinical outcome.

PB2223

THE TREATMENT OF HEREDITARY TROMBOPHILIA DURING PREGNANCY

M. Thedehsiou1,*, I. Ionita1,2, E.-C. Budai1,2, C. Hategan1, D.-N. Oros1,2, E.-C. Fenes1, R.-S. Burim1, H.-M. Ionita1,2

1Hematology, Spitalul Clinici Municipal de Urgenta Timisoara/Municipal Emergency Hospital Timisoara, 2Hematology, Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania

Background: Thrombophilias are genetic conditions that increase the risk of thromboembolic disease. The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. The most common complication is venous thromboembolism.

Aims: This study is conducted in order to assess the importance of treatment during pregnancy for women with hereditary thrombophilia, the risks of not treating the disease or treating incorrectly.

Methods: This study includes a total of 207 women, from which 83% were treated with low molecular weight heparin and Aspirin during pregnancy regardless if it was their first pregnancy or not and the rest 17% remained untreated during pregnancy. The success of the treatment is based on the completion of the pregnancy and the good health of the fetus.

Results: A total of 207 women were included into the study, 172 were treated with low molecular weight heparin and Aspirin while 35 were treated with just Aspirin. Out of 172 patients in the low molecular weight heparin group 155 managed to give birth which accounts for a 90% success rate with a reported case of fetal growth restriction and 2 cases of abruptio placentae. In the remaining 17 women which represent the 10% of the treated patients were unsuccessful in completing their pregnancy with 14 women presenting pregnancy loss on the first trimester and 2 having late fetal loss, only one case of preeclampsia was recorded. Out of the 35 women who did not receive treatment with low molecular weight heparin and only with Aspirin, 21 managed to complete their pregnancies representing the 60% out of which 2 cases presented with Abruption and 4 cases with fetal growth restriction, out of the 14 women who represented the 40% who were unsuccessful in completing their pregnancies 7 cases were recorded during the first trimester while 3 more had late fetal loss and 4 cases of preeclampsia.

Summary/Conclusions: Women treated for thrombophilia had a lower percentage of fetal loss than their no treatment group counterparts. There is an urgent need for appropriate guidelines for these patients in our medical center.

PB2224

LEARNING ABOUT VALIDATIONS OF THE DVT SCREENING TEST IN PATIENTS WITH SUSPECTED UPPER LIMB THROMBOSIS:
A PERSPECTIVE FROM THE CLINICAL PRACTICE

H.N. Fernandez - Leyva1,2

1Haematology, Croydon University Hospital, London, United Kingdom

Background: Deep vein thrombosis (DVT) of the upper limbs represents 1-4% of DVT, most of them related to central venous catheter and / or malignancy. Thrombosis involving the deep veins (ie, subclavian, axillary, brachial) can lead to complications as pulmonary embolism (PE) and long-term sequelae. PE from upper extremity sources accounts for about 6% of cases. Initial treatment in acute context include fibrinolysis and subsequent anticoagulation (Grade 2C). When symptomatology is mild and/or onset of symptoms undocumented (>2 weeks), minimum anticoagulation 3 months is recommended. If there are associated anatomical abnormalities, the possibility of surgical vascular thoracic decompression must be assessed.
Aims: To ascertain D-dimer diagnostic accuracy for upper extremity DVT. 
Methods: A retrospective audit was undertaken to determine the aetiology and clinical presentation on patients who UDVT at presentations. Patients with a formal malignancy confirmed before the diagnosis was excluded. A D dimer (DD) with a cut off cut off levels validated for lower limb DVT was performed. 
Results: A total of 18 patients was identified in the period of 2012 to 2016. All the cases investigations included Doppler US or CT/MRI and in 30% of the patients the thrombosis was confirmed via contrast venography as a reference standard test. The gender predominan was male in this group the symptomatology were related to physical efforts in a 60% (Paget-Shroetter Syndrome) whereas in female serie the predominant was thrombotic defects (factor V Leiden).

Summary/Conclusions: In 50 white laboratory rats weighing 200-230 g according to the ethical principles of the Helsinki Declaration. Anti-coagulant and antithrombotic effects of LMWH or HMWH were studied in two rat models of thrombosis – thrombosis in v. jugularis (Wessler) and thrombosis in arterio-venous shunt (direct registration of blood pressure). The α–AA diglyco-drogteroxetin (DET – 1mg/kg), α–AA azaprosin (PZ – 2mg/kg), LMWH or HMWH (40 USP/kg) were injected in v. jugularis. Saline was administered in control rat groups. The thrombus were formed 15 or 180 min after substances injected. The degree of thrombus formation (TF) was detected in ball (Wessler model) and by time of TF (arterio-venous shunt model). In blood plasma of the activity of PT, AT, thrombin were determined. The process was repeated for different anticoagulants and combinations with various anticoagulant and fibrinolytic agents.

Aims: Study of the influence of low molecular weight heparin (LMWH, 4.4 kD) and high molecular weight heparin (HMWH) and their combinations with various α–adrenoreceptor antagonists on blood coagulation during many years. The study of the influence of low molecular weight heparin (LMWH, 4.4 kD) and high molecular weight heparin (HMWH) and their combinations with various anticoagulant and fibrinolytic agents.

Methods: Experiments were performed on 50 white laboratory rats weighing 200-230 g according to the ethical principles of the Helsinki Declaration. Anti-coagulant and antithrombotic effects of LMWH or HMWH were studied in two rat models of thrombosis – thrombosis in v. jugularis (Wessler) and thrombosis in arterio-venous shunt (direct registration of blood pressure). The α–AA digydro-grotoxetin (DET – 1mg/kg), α–AA azaprosin (PZ – 2mg/kg), LMWH or HMWH (40 USP/kg) were injected in v. jugularis. Saline was administered in control rat groups. The thrombus were formed 15 or 180 min after substances injected. The degree of thrombus formation (TF) was detected in ball (Wessler model) and by time of TF (arterio-venous shunt model). In blood plasma of the activity of PT, AT, thrombin were determined. The process was repeated for different anticoagulants and combinations with various anticoagulant and fibrinolytic agents.

Summary/Conclusions: Thus we confirmed that LMWH (as one, as in combination with α–adrenoreceptor antagonists) has definite advantages over the degree of coagulation in blood plasma. The study of the influence of low molecular weight heparin (LMWH, 4.4 kD) and high molecular weight heparin (HMWH) and their combinations with various anticoagulant and fibrinolytic agents.

Effects: Thrombolytic therapy among clinicians in South East Nigeria. A pretested validated questionnaire was administered to clinicians in five tertiary hospitals in the southeast Nigeria. The questionnaire was designed to assess their knowledge of anticoagulant therapy. The questionnaire was administered consecutively on clinicians in the participating centers. The following institutions participated in the survey: University of Nigeria Teaching Hospital, Enugu, Internal medicine, Abia state Teaching Hospital, Umuahia, Internal medicine, Nnamdi Azikiwe Teaching Hospital Nnewi, Awka, Internal medicine, Federal Medical center , Abakiliki, Internal medicine, Amaku Specialist hospital, Awka, Nigeria

Background: In the absence of anticoagulation therapy, the risk of Venous thromboembolism; deep-vein thrombosis (DVT) and pulmonary embolism (PE) in medically ill patients is comparable to that in moderate-risk surgical patients. Previous studies have revealed grossly inadequate knowledge and a dismal practice of anticoagulation among healthcare workers in some resource poor countries. Prophylactic anticoagulation is under-prescribed in Nigeria, South Africa, as well as in many other countries in Africa.

Summary/Conclusions: This study aimed to evaluate the practice of anticoagulant therapy. It will also document the frequency of drug-induced complications resulting from the use of anticoagulants and presence of an anticoagulation policy in the hospitals surveyed.

Methods: This is a multicentre cohort survey of the practice of anticoagulant therapy in blood coagulation during many years. The study of the influence of low molecular weight heparin (LMWH, 4.4 kD) and high molecular weight heparin (HMWH) and their combinations with various α–adrenoreceptor antagonists on blood coagulation during many years.
Results: A total of 528 clinicians were involved in the survey. There were more males (378 (71.6%)) than females, 150 (28.4%) the clinicians who practiced for less than 5 years are in the majority 189 (35.8%), and those with 15-20 years of practice 46(8.7%) are in the minority. Only 52 of the respondents (9.8%) claimed their institutions had an anticoagulation policy while 274 (51.9%) of them said there was no such policy and 168 (31.2%) do not know of any policy. Unfractionated heparin was the most frequently used (96.8%) and fondaparinux was the most infrequently used (42%). Most of the prescriptions were done by younger clinicians who are the highest in number. The consultants prescribed heparin and warfarin most, with the newer anticoagulants taking the rear position. Only 193 (36.6%) of the respondents routinely prescribed anticoagulation therapy when indicated. 412 (78%) of respondents believe the risk of anticoagulation outweighs the benefits while 439 (83.1%) identified cost as an important variable in prescribing anticoagulation agent. Anti-coagulation prophylaxis was the most frequently used for patients immobilized or bedridden (94.1%); malignancy and atrial fibrillation were the most infrequent reasons for using anticoagulation agents (50.6%). A total of 63 respondents (11.9%) were not satisfied and 219 (41.5%) were not very satisfied with the laboratory monitoring tool available in their institutions. Bleeding is the most common complication of anticoagulation while the least encountered complications are skin and jaw necrosis among the respondents.

Summary/Conclusions: This survey has shown the lack of anticoagulation policies among the centers that participated. Our survey has also shown deficiencies in the areas of practice of anticoagulation among the clinicians in the Southeast of Nigeria. These gaps can be remedied by continuous medical education and by the establishment of anticoagulation policies.

Transfusion medicine

PB2229
UMBILICAL CORD BLOOD PLASMA INFUSION PROMOTES BLOOD CELL RECOVERY IN INPATIENTS WITH ACUTE LEUKEMIA UNDERGOING CHEMOTHERAPY
Y. Lu1,*, X. Zhang1, X. Li2, Y. Zou1, Z. Lin1
1the third Affiliated Hospital of Sun Yat-Sen University, 2 The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Background: Umbilical cord blood plasma (UCBP) is separated from umbilical cord blood. UCBP contains a variety of hematopoietic growth factors which can stimulate hematopoiesis.

Aims: The aim of this work is to explore the influence of UCBP infusion on blood cell recovery in patients with acute leukemia undergoing chemotherapy.

Methods: Patients with the diagnosis of acute leukemia were included in this study and they were randomly distributed to experimental group and control group. Patients in experimental group received infusion of 100ml UCBP with the same ABO and Rh blood type every day after chemotherapy for five days and patients in control group received placebo for the same time. Blood routine were tested every day until WBC >4×109/L and PLT >20×109/L.

Results: 25 patients were included in the study of which 23 were brought into statistics. 13 patients were in experimental group and 10 in control group. There were no difference in age, gender and dose intensity of chemotherapy between the two groups (P>0.05). The average recovery time of the blood neutrophil granulocyte >0.5×109/L in experimental group and control group were respectively (8.53±3.26) days versus (12.92±4.75) days (P<0.05) and that of PLT >20×109/L was respectively (9.24±3.88) days versus (13.15±5.76) days (P<0.05). No UCBP transfusion-related side effects were found.

Summary/Conclusions: UCBP administration is safe as treatment for cytopenia and could promote blood cell recovery in patients with acute leukemia undergoing chemotherapy.

PB2228
TOWARD BETTER BLOOD TRANSFUSION PRACTICE: A SUCCESSFUL RED BLOOD CELL UTILIZATION TOOLS IN A TERTIARY CARE HOSPITAL
A. Aly1,*, G. Mawad1, E. Alzaabi1, A. Aly1,2
1Mafraq Hospital, Abu Dhabi, United Arab Emirates

Background: The need for blood in hospitals continues to exceed the volume collected by the transfusion services. The gross over-ordering of blood, in excess of actual and anticipated needs leads to substantial costs and a burden to the transfusion services. In addition, over-ordering leads to non-availability of cross-matched units for other patients who might be in urgent need of transfusion.

Aims: We are aiming to reduce the Cross-match-to-transfusion ratio (C:T ratio) & improve blood utilization in Mafraq Hospital.

Methods: In 2011 the ordering practice at Mafraq Hospital, a designated Trauma Centre, had been evaluated. Data collected retrospectively over a one year period and a C:T ratio was adopted by the American Association of Blood Bank was calculated for all various sub-specialities including Surgery, Internal Medicine, Pediatrics and Obstetrics and Gynecology. All procedures related to hospital transfusion practice have been retrieved and re-evaluated to address gaps. Policy of maximum surgical blood ordering (MSBO) was implemented based upon both results of audits and by discussion and agreement between medical teams. Focused training and education has been followed to increase the awareness of the health care workers. Plus monitoring of C:T ratio on monthly basis, blood bank team had arranged meetings with the departments that were over-ordering cross-matches to explain that group & save test is a safe, effective and financially beneficial strategy. Communicating with the physicians had been the most challenging aspect of implementing the policy changes. Regular audits had been conducted to measure the compliance and effectiveness of the blood management practice.

Results: Compared to the international guidelines, C:T ratios in 2010 was beyond the acceptable target and ranged between 2.5 to 3.2 highlighting the over-ordered cross-matched blood in certain sub-specialties. This practice of ordering was probably because of the fear that blood will not be available, if needed. Following implementation of control and continuous monitoring measures while establishing proper procedures such as transfusion guidelines, administration of blood and blood products and Maximum Surgical Ordering Practice, Mafraq blood bank supported by the Transfusion and Tissue & Quality & Patient Safety Committees, achieved a great success in reducing C:T ratio <2 all through 2016 Figure 1. The reduction of C:T ratio had improved blood inventory control and reduced the workload of the blood bank staff. Because fewer units of cross-matched PRBC are being ordered, the blood bank has been able to decrease the number of expired units &reducing money loss Figure 1. The savings in technologist time is particularly significant since the blood bank is most of the time at a minimal staffing level.
IN VKA REVERSAL AND OFF-LABEL INDICATIONS
SAFETY AND EFFICACY OF A PROTHROMBIN COMPLEX CONCENTRATE
PB2230
M. Marcos Jubilar1, J.A. García Erce2, N. Martínez Calle1, J.A. Paramo1, R. Figueroa1, S. Villar1, M. Quintana3
1Hematology and Hemotherapy, Clínica Universidad de Navarra, 2Hematology and Hemotherapy, Complejo Hospitalario de Navarra, Pamplona, 3Intensive Medicine, Hospital Universitario La Paz, Madrid, Spain

Background: Prothrombin complex concentrates (PCC) are highly purified mixtures of plasma coagulation factors that contain vitamin K dependent and anticoagulation factors, they are approved for urgent reversal of vitamin K antagonists (VKA). Massive bleeding-associated coagulopathy guidelines include PCC in their management, although as an off-label indication.

Aims: The aim of the present work is to evaluate safety and efficacy of PCC in a case series of VKA reversal and refractory coagulopathy associated with major bleeding.

Methods: Retrospective review of cases treated with a four-factor PCC between January 2010 to January 2016 in two tertiary University Hospitals. As safety endpoints we evaluated infusion reactions and incidence of thromboembolic events by self reported registry. The efficacy endpoints were studied in two separate cohorts: 1) INR correction for VKA reversal and 2) coagulopathy correction and early mortality (24 hours) in major bleeding coagulopathy.

Results: 328 patients were included (47.25% male), median age 78 years (range 19-102), PCC was used in the following cases: 1) 66.67% in VKA reversal (181 patients due to hemorrhage and 33 prior to emergent surgery), mean dose of PCC 1333.51 IU; 2) 30.54% in refractory coagulopathy in major bleeding (30 patients due to refractory bleeding protocol activation, 43 patients in hepatitis C-related coagulopathy and 25 patients in bleeding not related with any of previous reasons); 3) 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients. 0.003% of non-hemolytic febrile reactions (NHFR) have been recorded during transfusions without individual matching to non-refractory patients.

Summary/Conclusions: There is a tendency to order blood in excess, either by asking for an increased number of units or as a standby precautionary measure. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use.

PUBLIC USE DATA

PB2231
TRACEABILITY OF RED BLOOD CELLS IN A HOSPITAL TRANSFUSION LABORATORY
M. Tserga1, A. Argyrou1,*, S. Nikolopoulou1, A. Gafou1
1Blood Bank, General and Oncology Hospital “Agioi Anargyroi”, Athens, Greece

Background: According to European legislation (2002/98/EC, 2005/61/EC) as a requirement of hemovigilance system traceability (confirmation of final destination of blood components in hospitals) information should be kept for 30 years, improving the quality and safety of the transfusion process. Various methods are available from simple paper–based procedures to full electronic blood tracking systems. The ideal goal is to trace the final fate of 100% of the red blood cell (RBC) units, from donor to recipient and vice versa.

Aims: To check the ability to trace each individual unit from donor to recipient or disposal in our hospital.

Methods: To ensure compliance, the minimum traceability data set for retention is a mix of 1) Wards’ paper files (file of transfusions and/or patient records: 14/2 wards respectively), 2) HTL electronic records and paper records. The transfusion practitioner is responsible for the collection and maintenance of traceability data.

Results: During the year 2016, the number of RBC units transfused in our hospital was 2128. The traceability status of the transfused units is shown in the Table 1.

Table 1.

Summary/Conclusions: Although we are satisfied that the results represent a reasonably accurate working model of the current situation, the trail of a unit is less reliable after blood has left the HTL. 1. Patients’ notes to provide traceability are not totally reliable. It is apparent that the ward staff plays a key role part in the chain and this highlights the need for them to receive training to emphasize the importance of their contribution to hospital compliance. 2. The indications are that the essential requirements on traceability are not fully met by the current laboratory computer system. A configuration is needed to produce a report which lists components which have been assigned for use but do not have an entry for return to stock or final fate. Ongoing problems will be referred to the Hospital Transfusion Committee. 3. For the longer term ultimately only effective IT system in both wards and HTL can ensure total traceability and we recommend the inclusion of electronic tracking system in the National Blood Donor Registry Programme (EMAR).

PB2232
NON-HEMOLYTIC FEBRILE POST-PLATELET-TRANSFUSION REACTIONS IN HEMATOLOGICAL PATIENTS
A. Rakhmani1,2, E. Mikhailova1, I. Dubinkin1, V. Troitskaya2, O. Kalmikova3, M. Danilevskaya1, T. Gaponova1
1Clinical Research Department of processing and cryopreservation of blood cells, 2Clinical Research department of chemotherapy and bone marrow depression, 3Scientific clinical laboratory quality control and safety of transfusions, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

Background: Platelet concentrate (PC) transfusions are the main method of thrombocytopenia correction in hematological patients, but multiple transfusions could trigger alloimmunity and refractoriness to transfusions.

Aims: Comparison of post-transfusion reactions in hematological patients with individual matching and without individual matching receiving PC transfusion support.

Methods: In 2015-2016, we observed 948 hospitalized patients, who received 12,344 PC transfusions. Individual matching of PCs was performed by cross-matching on the Galileo-Neo (Immucor) analyzer. Statistical processing was performed using the chi-squared test with Yates’ correction.

Results: 107 of 948 patients developed refractoriness to PC transfusions (12% of total patients). Out of them, 21 patients received 389 PC transfusions without individual matching. 86 patients with individual matching transfusion 1705 PC transfusions. During transfusions without individual matching to non-refractory patients, 0.003% of non-hemolytic febrile reactions (NHFR) have been record-

PB2233
Figure 1.

Summary/Conclusions: There is a tendency to order blood in excess, either by asking for an increased number of units or as a standby precautionary measure. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use. Adherence to MSBO & transfusion guidelines, hospital can achieve C:T ratios below 2.0. The introduction of strategies for improved blood utilization can lead to significant reductions in blood use.
ed, after matching to refractory patients the frequency was 0.002%. Before matching to refractory patients, the frequency of NHFR was (0.03%) (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Status</th>
<th>Patients</th>
<th>Transfusion</th>
<th>Post-transfusion reactions</th>
<th>% of all transfusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory with matching</td>
<td>2067</td>
<td>2</td>
<td>0.002</td>
<td>1.04</td>
</tr>
<tr>
<td>Refractory before matching</td>
<td>21</td>
<td>1</td>
<td>0.002</td>
<td>1.04</td>
</tr>
</tbody>
</table>

Summary/Conclusions: The frequency of NHFR in groups with refractoriness with individual matching is significantly lower (10 fold) compared to groups with refractoriness before the matching (P<0.01).

PB2233

RARE DONORS AND MALARIA

A. Berzuini1,*, B. Foglieni1, M. Spreafico1, D. Prati1
1Department of Haematology and Transfusion Medicine, Ospedale A. Manzoni, Lecco, Italy

Background: Migratory flows of sub-saharan (SSA) persons throughout the world are expected to continuously increase. A significant proportion of SSA citizens are affected by Sickle Cell Disease (SCD), condition requiring repeated blood transfusions. Many centuries of malaria pressure have induced in SSA natives, homeostatic selection of peculiar haematologic characteristics, such as the absence of high frequency red cell antigens (defining a rare blood) that cannot be found in donors of European descent so that many SCD transfused patients experience the fearful occurrence of red cell alloimmunization. For these reasons haematologists are expecting to access to Rare Blood Banks in order to assure a full match between donor and recipient’s blood, that may be obtained from donors sharing the same ethnicity. Unfortunately SSA donor recruitment is counteracted by the widespread diffusion of infections contracted before migration: one of these is malaria. In SSA malaria may occur subclinically and is characterized by a slow antibody clearance. This peculiar condition, the so-called semi-immunity, has been induced by a strong genetic pressure, and is a kind of co-evolutionary process characterized by the co-existence and persistence of small entity of Plasmodium genome with relative antibodies. Molecular techniques are unreliable to detect a small number of Plasmodia, which may otherwise be sufficient to induce a transfusion transmitted malaria (TTM). The serologic assessment, despite the low specificity, remains the most sensitive and reliable method to detect the semi-immune status in blood donors (1).

Aims: The aim of this study was to assess the prevalence of malaria immunity in a cohort of healthy SSA citizens.

Methods: Since 2010 in our Department of Haematology and Transfusion Medicine we recruited 184 SSA citizens, in good health, who agreed to underwent clinical and laboratory investigations to become a blood donor. All of them were born in SSA Africa and lived there for at least the first 5 years of life. 70% of subjects didn’t recognize any previous malaria fever. The last travel/stay in Africa was more than 5 years (26.3 yrs), and 9% of returning people had received prophylaxis. Malaria serology was determined by a commercial enzyme immunoassay kit (Malaria EIA Ab, BioRad). Results: Overall 75% of persons were positive for malaria antibodies. Serologic positivity was found in 75% of persons no more exposed in 5 recent years and even in 83% (19/23) persons settled in Italy since 10-20 years. Serologic positivity was present in 100% of people from Benin, 85% from Burkina Faso, 78% from Ivory Coast and Cameroon, 63% from Senegal. We followed antibody concentration in 50 persons (136 assays), and we observed a slightly negative trend that, in most cases, was followed by a prolonged phase of low antibody levels, 4/50 became negative after three years.

Summary/Conclusions: The identification of malaria antibodies is essential in SSA native donors and, by far, irreplaceable in order to avoid the risk of TTM. Until pathogen inactivation techniques will become available, we have a very low expectation to introduce SSA blood in Blood Bank inventories. Haematologists have to wait some years for the forthcoming SSA second generation that will allow to fully match the entire SCD patient community.

REFERENCE


PB2234

EFFICACY AND INFLUENCE OF IRON CHELATION THERAPY ON RED BLOOD CELL TRANSFUSIONS

A. Parvu1,2,*, M. Iancu2, A. Vasiache2, T. Torok2, I.-A. Zsodlos1, M. Zdrengeha1, L. Petrov2, C. Seles2, L. Urion2, A. Todorica1, C. Truica1, A. Bojan1
1Hematology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 2Hematology, Prof. Ion Chitici" Oncological Institute, 1IT, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, 3Hematology, Baia-Mare County Hospital, 4Hematology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Baia-Mare, Romania

Background: Chelation therapy is recommended for transfused patients that have an elevated serum ferritin level (over 1000 microg/l), evidence of iron overload or received over 20 units of red blood cell transfusions (RBCT). Deferasirox showedefficacy and safety in maintaining or reducing body iron (assessed by liveriron concentration or serum ferritin).Iron chelation therapy was associated with hematopoiesis improvement in transfusion-dependent patients and interrupution of Deferasirox treatment of transfusions dependent myelodisplastic patients produced loss of erythroid response.

Aims: Aim of the study: to assess the results of Deferasirox efficacy, side effects and to study if the number of RBCT decreased after starting Deferasirox.

Methods: We have done a retrospective, transversal study including all the adult politransfused patients treated with Deferasirox in three counties Hema-tology Departments of Nord-West Romanian hospitals. Criteria of Deferasirox treatment: over 20 RBCT, serum ferritin level over 1000 microg/l.

We created a data collection sheet including: demographics, information on patients’ disease, serum ferritin level at start of and during treatment, Deferasirox dose, data about dose modification, adverse effects of Deferasirox and their management, reasons for treatment discontinuing, evaluation of comorbidities that could increase serum ferritin level, number of RBCT before and after starting the treatment.

Results: We included 40 politransfused patients treated with Deferasirox, age average 63. The diagnosis included meiodysplastic syndromes (most of patients), thalassemia, other anemias. Myelodysplastic patients were treated with low dose chemotherapy, epigenetic treatment, RBCT and Deferasirox. The main points of transfused patients were transfused. The baseline value of ferritine was between 1075 - 6187 microg/l. Deferasirox dose: 20-30 mg/kg. There was a significant reduction in serum ferritine from baseline for all the patients. Ferritine median at start, 3631 microg/l decreases at 1537 microg/l after 6 months of treatment and at 894 microg/l after 12 months of treatment. There were 8 patients that had decreased levels of ferritine, but during infectious episodes the ferritine increases for a short period of time. Digestive adverse events appeared in three cases (two cases of diarrhea and one case of digestive hemorrhagic episode). In all these cases the treatment was temporarily discontinu- ed. In three cases, treatment was stopped because low ferritin level (under 500 microg/l). RBCT were administered before (mean 2.43 units/month) and after starting Deferasirox (mean 1.39 units/month), the difference is statistically significant (Student Test, t(39)=6.98, p<0.001). After starting Deferasirox treat- ment mean number of RBCT decreased, mean of differences (95% CI) was 1.04. We reviewed the group of 23 patients treated with Deferasirox less than 12 months, and the patients treated more than 12 months, 15 patients. In both groups the difference of RBCT means (before and after the start of the treat- ment) are statistically significant (Student Test, t(23)=8.12, p<0.001) and for the patient treated more than 12 months (Student test, t(15)=3.03, p=0.008).

Summary/Conclusions: Analyzing our group of 40 patients, Deferasirox proves to be effective and safe. Adverse effects that determined a temporary stop of the treatment were mild/medium short time digestive reactions. The number of red blood cell transfusion significantly decreased after starting Deferasirox treatment.

PB2235

LIBERAL VS RESTRICTIVE COMPARATIVE TRANSFUSIONAL STUDY IN ONCOLOGICAL POPULATION

M.I. Touzón Andión1,*, M. Gestal 1, A. Varela1, M. Castro1, C. Moineo1, R. García de Villascausa1
1Transfusion , Centro Oncológico de Galicia, La Coruña, Spain

Background: Allogeneic transfusion therapy is perhaps one of the most widely used treatments without good evidence support, despite many years of appli- cation in clinical practice. This, coupled with blood shortages, the impossibility of determining zero risk, the lack of evidence that transfusion may increase con- sumption or decrease tissue oxygen debt and the existence of an association with an increase in morbidity and mortality have favoured that we join efforts towards its optimal use.

Aims: Optimal use in our adult oncological population and evidence that restric- tive transfusion (TR, Hb 7-9 g/dl) is not greater or lowero the liberal transfusion (TL, Hb 8-10 g/dl), keeping hemoglobin in safe levels for the patient.

Methods: A research was performed from October 1st, 2015 through Decem- ber 31st, 2016. We analyzed the proportion of patients receiving packed red cells (CH) and the number of units transfused as well post-transfusion control in order to describe the outcome of the CH versus TL strategies in the cancer population under the study.

Results: See Table 1.

Summary/Conclusions: The results obtained in our series of 311 cancer
patients indicate that the restrictive strategy has been equally effective and probably superior to the liberal one maintaining Hb at a safe level in each patient, as well as quality of life and comfort in a subgroup with advanced and terminal cancer.

Table 1.

<table>
<thead>
<tr>
<th>Transfusion Therapy</th>
<th>Patients ((N))</th>
<th>Hb Pre (g/L)</th>
<th>Hb Post (g/L)</th>
<th>yield CH (g/vis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT</td>
<td>192</td>
<td>8.1</td>
<td>9.1</td>
<td>1.0</td>
</tr>
<tr>
<td>LT</td>
<td>97</td>
<td>7.4</td>
<td>9.4</td>
<td>1.0</td>
</tr>
<tr>
<td>PWC</td>
<td>22</td>
<td>8.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TPF</td>
<td>111</td>
<td>8.8</td>
<td>9.2</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Hb Pre: Pre-transfusional haemoglobin; Hb Post: Post-transfusional haemoglobin; PWC: Patients without post transfusion Hb leve; TPF: Total Patients Transfused; X-: half haemoglobin.

PB2236

HIGH RISK OF HBV INFECTION IN VACCINATED POLYTRANSFUSED CHILDREN

M. El-Sayed1,*, D. Soydemir1, M. Yanaşık1, A. Akcay2, G. Ozturk3

1Pediatric Department, Ain Shams University, Faculty of Medicine, 2Microbiology Department, Faculty of Medicine (for girls), Al-Azhar University, 3Community Medicine Department, National Research Center, Cairo, Egypt

Background: Children receiving chemotherapy for neoplastic diseases are still susceptible to Hepatitis B virus (HBV) infection despite the national HBV vaccination program coverage for all infants since 1992. Aims: This study aimed to analyze immunity against HBV and occurrence of HBV breakthrough infections in polytransfused children who had been vaccinated during infancy.

Methods: The study included 89 children with hematological disorders and malignancies, who were categorized into group (A): 37 receiving chemotherapy (M:F 20:17; mean age:7±4.0) and group (B): 52 polytransfused children (M:F 31:21; mean age:7±6.3). A matched healthy control group (n=162) was also included. All patients and controls had received their primary vaccination against HBV in infancy. Quantitative anti-HBs were tested for patients and controls. Patients’ sera were tested for HBsAg, anti-HBc, and HBV-DNA (nested PCR for sums, core, e & x regions).

Results: Levels of anti-HBs between 10-100 IU/L and ≥100 IU/L were found among 13.5% and 21.6% [group (A)], 44.2% and 11.5% [group (B)] and 32.1% and 10.5% of controls respectively. There was a significant difference in HBsAb between patients receiving chemotherapy (group A) and both groups B patients (p=0.008) and controls (p=0.032). However, no difference was found between polytransfused children [group (B)] and controls.

HBsAg positive was 21 (67.7%) children under chemotherapy [group (A)] compared to 10 (32.2%) polytransfused children [group (B) (p=0.0005). Overall, 49 patients (55%) were HBV-DNA positive; 44 c-region positive, 7 s-region positive, 2 positive for both c and s-regions and one positive for c and x-regions. Of those, only 21 patients (42.8%) were also positive for HBsAg; while 28 (47.2%) had occult HBV infection (HBsAg-negative). There was no significant difference between patients receiving chemotherapy [group (A)] and polytransfused children [group (B) (p=0.157), regarding the rate of HBV DNA. Anti-HBs ≥10 IU/L coexisted in 38.7% (12/31) of HBsAg positive patients and 49% (24/49) of HBV-DNA positive patients.

Summary/Conclusions: Children with neoplastic diseases vaccinated during infancy were at a high risk for HBV infection. The effect of immunosuppression on the HBV protective level favored overt HBV infection in children receiving chemotherapy. The co-existence of anti-HBs with HBsAg and/or HBV-DNA demonstrated a possible residual transfusion-transmission risk with mutant HBV strains.

PB2237

THE ISOHEMAGGLUTININ TITERS OF BLOOD BANK DONORS: THE EXPERIENCE OF ISTANBUL FACULTY OF MEDICINE

Z. Karakas1,*, D. Soydemir1, M. Yanaşık1, A. Akcay2, G. Ozturk3

1Pediatric Hematology-Oncology, Istanbul University Istanbul Medicine Faculty, 2Pediatric Hematology-Oncology, Acibadem University, 3Pediatric Hematology-Oncology, Acibadem University, Istanbul, Turkey

Background: Isohemagglutinins that develop against ABO blood group antigens are very important in transfusion and transplantation medicine. Today, 30-40% of allogeneic stem cell transplantsations are ABO incompatible transplantation, 20-25% of which are major, 20-25% are minor and remaining bi-directionally incompatible transfusion. Our study; based on the knowledge that isohemagglutinins play an important role in blood transfusion policies in patients undergoing ABO incompatible hematopoietic stem cell transplantation (HSCT) has been shaped by the assumption that each healthy blood bank donor may be potential transfusion donors for ABO incompatible HSCT transplant recipients.

Aims: In this study, we investigated the isohemagglutinin titer values of the individuals with A, B and O blood groups; the distribution of the isohemagglutinin titters according to the decades and gender. Also we examined the possibility of determining the isohemagglutinin cut off value in Turkish society.

Methods: One thousand five voluntary blood donors (48 female, 957 male), randomly chosen from the donors, providing the criteria to be a standard blood donor in Blood Center Department, Istanbul Faculty of Medicine were studied. This study was approved by the Ethics Committee of Istanbul Medical Faculty. In the donor population group; blood group A (%40) was the most common and blood group AB was the rarest blood group. According to the Rh D phenotypes; 85% of the population was Rh D positive and 15% of the population was Rh D negative. The frequency of our blood group was determined similar with other European countries. The most common age range of one thousand five voluntary blood donors, including the same rate individuals with blood group A, B and O, was the age range between 26 and 35 years. Forward and reverse blood group determination were performed to these donors and also we identified the Anti-B IgM and Ig G isohemagglutinin titer values for blood group A;

Anti-A Ig M and Ig G titer values for blood group B;

eventually both Anti-A Ig M / Ig G and Anti-B Ig M / Ig G isohemagglutinin titer values for blood group O by using column agglutination methods. Statistical analysis was performed with NCSS (Number Cruncher Statistical System) 2007 (Kaysville, Utah, USA).

Results: While the titer value of Anti-A Ig M isohemagglutinin was 1:128 for female individuals with blood group B; the titer values of both Anti-B Ig M (1:128 and 1:256) , Anti-B Ig G (1:1024) and Anti-A Ig M (1:256) isohemagglutinins were statistically significance in female individuals rather than male ones. The levels of isohemagglutinin in the blood groups A, B and O are shown in Table 1.A,B. There was no statistical difference in anti-B IgG and IgM titters in blood group A, anti-A IgG and IgM titters in blood group B and anti-A IgG and IgM titters in blood group O between males and females(p>0.05). However Anti-B IgG and IgM antibody titters were higher in females than males in donors with blood group O respectively p=0.017 (p<0.05) and p= 0.001 (p<0.01) (Figure 1.A,B).

Table 1.

<table>
<thead>
<tr>
<th>Anti-B Ig M Titer</th>
<th>Anti-B Ig G Titer</th>
<th>Anti-A Ig M Titer</th>
<th>Anti-A Ig G Titer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:128</td>
<td>1:256</td>
<td>1:256</td>
<td>1:256</td>
</tr>
</tbody>
</table>

Figure 1.

Summary/Conclusions: Female individuals of blood bank donors participated in our study have higher isohemagglutinin titer values rather then male individuals. Recurrent blood group incompatibility in pregnancy, invasive diagnostic and therapeutic approaches for risk analysis in fetal examination during pregnancy, perinatal complications causing fetomaternal hemorrhage after pregnancy or during birth and lastly autoimmune diseases cause the enhancement of isohemagglutinin titer values in female individuals. Regarding the gender differences; nutrition, vaccination and recurrent blood transfusion history of blood bank donors also affect and change the isohemagglutinin titters of individuals. Population specific isohemagglutinin titer values play a key role in blood donation policy of patients undergoing hematopoietic stem cell transplantation. Consequently; we predict that Turkish community-specific isohemagglutinin cut off titer values can be identified and we will hope our knowledge on this issue in the future with the increase of research is going to increase further.

PB2238

THE NEW METHOD OF PURIFICATION FACTOR COAGULATION VIII N. Shurko1,*, T. Danysh1, V. Novak2

1laboratory biochemistry of blood, 2Hematology, State Institution «Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine», Lviv, Ukraine

Background: The human plasma of blood can be transfused directly to patients or pooled and fractionated into plasma protein products. Plasma contains about 60-80 g/l of protein, of which about 95% are used for many therapeutic prod-
Thrombotic microangiopathies are a group of rare diseases characterized by non-immune microangiopathic hemolytic anemia, thrombocytopenia, and involvement of organs of varying intensity, mainly renal and CNS damage. TTP and HUS are the most important forms of TMA and without adequate treatment administered early are associated with high morbidity and mortality. Aims: To review our experience in the management of the primary TMA and to raise a series of questions that perhaps could improve the approach of these pathologies

Methods: We made a retrospective, descriptive analysis of ten cases diagnosed of primary thrombotic microangiopathy (TTP n=5, typical HUS n=3; atypical HUS n=2) over the last eight years, 70% of which were women with an average age between 40-60 years. Only three cases had previous records of autoimmune diseases (MTCRD, RA and HIV), all of which would eventually develop TTP. We requested ADAMTS13 levels on all cases, they were low (<5-10%) only in those patients diagnosed with TTP, and on the other hand confirming the positivity for Shiga toxin in those patients who eventually developed typical HUS.

Results: Regardless of the diagnosis, 10-12 plasma exchanges were performed to improve the biological parameters of hemolysis, requiring the placement of a central catheter, most commonly at the right jugular vein (70%) due to the lower risk of thrombotic and infectious complications. Although renal involvement is frequent in HUS, only two of the patients required dialysis without recovery of baseline renal function. Is to be noted the part played by the approval in 2011 of eculizumab and how patients eight years ago suffered a torpid course, requiring a greater number of plasmapheresis and the side effects this carries. However, we still do not know its repercussions out of indication. In our study it was used in a patient with a diagnosis of TMA associated with an infection with good evolution, although perhaps this result is due only to the natural evolution of the disease. Another controversial point is the use of antibiotics and possible harm to the diagnosis made.

Summary/Conclusions: The results of the study are helpful to identify and understand the complication of adverse donor reactions though the incidence of reactions in the blood donor is lower than in other studies. Donor age and donation status were strong possibilities of complications.

PB2240
HAEMOVIGILANCE REPORTS OF ADVERSE BLOOD DONOR REACTION AMONG VOLUNTARY BLOOD DONORS IN TERTIARY CARE HOSPITAL IN KATHMANDU, NEPAL

B. Nepal1

1Blood Bank, Grande International Hospital, Kathmandu, Nepal

Background: Voluntary blood donation is widely considered to be safe with very minimum chance of adverse reaction, which may occur during or after the end of phlebotomy procedure.

Aims: To identify and understand the complication of adverse donor reactions though the incidence of reactions of blood donation among blood donor in the tertiary care hospital in Nepal

Methods: This is a prospective study done among voluntary blood donors at Grande International Hospital, Kathmandu, Nepal from February 2013 to March 2015. The outlines of reported and communicated adverse donor reaction were also collected after the blood donation from voluntary blood donors in different locations including outdoor and in-house blood donation drive.

Results: In the present study 6,955 whole blood donors were included, during the period of 2 years, 105 (1.50%) adverse donor reactions were reported. Majority 89(84.76%) of adverse donor reactions were mild in nature such as, sweating; 27(25.72%), Light headedness; 19(18.09%), Nausea and vomiting; 15(14.28), Allergy and bruises;11(10.47%), Sore arm; 9(8.58%) and hematoma; 6(7.62%) while 16 (15.24%) were severe adverse reactions similarly, anaphylaxis; 11(10.49%), Loss of consciousness; 3(2.85%) and convulsive syncope;2(1.90%). Markers of the adverse donor reaction were age, sex, pulse, weight, blood pressure and donation status. Age and first time status were related with significantly higher risk of adverse reaction with 18-23 years old at higher risk compared to 24-55 years old. First time donors were at higher risk compared to repeated volunteer donors.

Summary/Conclusions: The use of eculizumab out of indication in typical HUS and whether the improvement in the picture is due to the drug or by natural evolution of the disease. Thrombotic microangiopathy in patients diagnosed with typical HUS. The use of antibiotics and possible harm to the diagnosis made.
Index of authors

A
Abad, L, P510
Abad, M, E985, PB1690, PB1917, PB1930, PB2125
Abáigar, M, P318, P655, E1169
Abali, H, P281
Abalo Perez, L, PB1806
Abarrategi, A, P264, P657
Abashkaroun, M, E1060
Abaza, Y, P207
Abadessa, G, E1400
Abbenante, M, E882, PB1657
Abboud, C, P319
Abd El-Maksoud, M, E1411
Abdelaziz, R, E926
Abdelkader, H, PB2052
Abdelmoaty, M, PB2052
AbdElmonem, D, E1585
Abdelrahman, H, PB2070
Abdel-Rahman, H, PB1658
Abdi, J, E1217
Abdo, A, PB1830
Abdulkadyrov, K, PB2034
Abdullaev, A, PB1807
Abdurahmanova, N, E1050
Abe, Y, E1285
Abecassis, L, P370
Abel, G, E1186
Abella, E, E1223
Abeykoon, J, E1240
Abildgaard, N, S501, E1267, E1367, PB1995
Abonour, R, P349, E1239, E1277
Abou Elmagd, E, PB2236
Abou Mourad, Y, P581, E1557
Abou Zah, A, P550
Aboukhalil, Z, S140
Abouzaid, S, E1277, E1282, PB2135
Abraham, M, P269
Abrahams, C, P328, E1373
Abramenko, I, PB1772
Abramov, A, PB2002
Abramova, A, PB1646
Abramova, T, E1227, E1295
Abranches, P, E1044
Abru, M, P157
Abrisqueta, P, S461, P298, E995, E1002, E1027, E1394
Abruzzese, E, S485, P256, P604, P705, E1042, E1043, E1067, PB1818
Abubakar, S, PB2196
Abuelgasim, K, E1514, PB2072
Abuín Blanco, A, E1327
Abumiya, M, E1053, PB1999
Accardi, F, E1223
Accordi, B, E1011
Accurso, V, PB2038, PB2039, PB2056
Acharya, S, P257
Achenbach, H, P704
Acosta, C, PB1759
Acocea, B, E1473
Acquavella, J, E1435
Adachi, S, P531
Adachi, Y, E1516
Adami, R, E1268
Adamidou, D, E1414, E1423, E1574
Adamo, A, E821
Adamopoulos, I, E1266
Adams, G, PB1976
Adams, J, E1007
Adams, R, E875
Adams, S, P526
Addada, J, PB1797
Abeday, T, P669
Ades, L, P657
Adjalle, R, E1286
Adjei, A, E1274
Adly, A, P398, E1572, E1582
Adrienne, D, P174
Advani, A, S793, P201, P203, P519, P525, P547
Advani, R, P571
Advani, V, P417
Afanasiev, B, E1154, E1506, PB1645, PB1834, PB1853
Afonso, S, PB1776
Agajanian, R, E1248
Agami, R, P153
Agarwal, A, S460, P349, E1239, E1282, PB2135
Agarwal, A, P194
Agarwal, S, P675, E1139
Agathangeliadis, A, E997
Agbuduwe, C, E938
Aggarwal, A, PB1841
Aggarwal, S, P533
Aggarwal, S, E1049
Agha, H, E1573
Aglic, D, PB1745
Agirre, X, P300, P325, E1225
Aglietta, M, P322
Agnelo, H, E1374
Agorasti, A, PB2197
Agostinelli, C, E1408
Agostini, C, E1254
Agouli, I, S131
Agrawal, M, S463, E864, E868
Agrawal, T, P552
Agreda-Vázquez, G, PB1866
Agresta, S, E471
Agrippino, R, P166
Aguadé-Gorgorió, J, S437
Aguado, B, E1305, E1565
Aguir, R, S126
Aguilar, C, P655, E1014
Aguilar, Y, PB2149
Aguilar-de la Red, Y, PB2143, PB2200
Aguilar-Guisado, M, S804
Aguilar Martínez, P, S453, P289
Aguilar Ponce, J, E1473, PB1738
Aguilera, C, PB1727
Aguilera Gomez, C, E957
Aguinaco, R, PB1861
Aguinaco Culebras, R, E1426
Aguirre, X, P679
Aguzzi, C, P667
Agwu, O, PB2206
Agyol, Y, PB2027
Ahn, I, S1689
Ahn, I, S427
Ahn, J-Y, PB1808
Ahmed, A, E1582
Ahn, C, PB2218
Ahmed, S, S450, S792, P739, E914, E1512, E1538
Ahn, J, PB2218
Ahmed, J, S1588
Ahn, J-S, S491, P6168
Ahn, J, PB1684
Ahn, JY, PB1808
Ahmed, S, S491
Aichler, M, S809
Aid, Z, S427
Airaud, F, P712
Airoldi, I, E1226
Aji, A, S128
Ajayi, O, PB2148
Aka, E, E1488
Akad Soyer, N, E1525
Akagi, T, PB2180
Akalestos, A, P337
Akan, H, PB2185

haematologica | 2017; 102(s2) |
Cabezón, M, P696, E831
Cabras, A, E1207
Cabrera, C, E1165, E1397
Cabrera, J, E972, E1541, B1885
Cabro, M, P318, P655, E1169, E1592
Cacace, F, P1707
Cacuelli, L, P631
Cacciagù, S, E1123
Cacciola, E, P358, PB2040
Cacciola, R, P358, PB2040
Cadenas, B, E1156
Cadière, B, P2136
Cadière, G, P2136
Cadierski, L, E1471
Cair, G, E1508
Cairns, D, S407, S781
Cairv, R, S111, P722, E1195, E1443, PB1901, PB1931
Cajano, A, E1226
Çakıl, A, PB1748
Cakmaki, H, PB1754
Calabrese, C, P658
Calabretto, G, E1357, E1397
Calabria, A, S128
Calabriug, M, S790
Calado, D, S125
Calafio, V, S111, PB2063
Calamar, D, PB2092
Calamar-Popovic, D, PB2124
Calansanz, M, S461, P198, P205, P696, E1027
Calbi, V, S128
Caldas, C, P713
Calderon-Cabrera, C, S804, P318
Calderini, A, E1270
Calderon, M, P393
Caliskan, E, S1165, PB2123
Caliskan, Ü, E1270, PB1927
Calistri, E, E485, P604
Call, J, P633
Call, T, P254
Callahan, J, P699, P701, E1343
Callanan, M, E1360
Calle Primo, C, S1879
Calle, M, E1051
Calleja, B, PB2076, PB2077
Calleja, S, P696
Callet-Bauchu, E, P1247
Calvaruso, G, P290
Calvillo, M, P234, P575, E1440
Calvo, J, S140
Camacho, L, P694
Cametti, G, P685
Campana, F, PB1957
Campanati, A, E1136
Campanini, N, E1223
Campbell, H, P668
Campbell, P, E1201
Campbell-Drew, M, PB2045, PB2051
Campillo, N, P543
Campion, L, E1360
Campion, L, P163
Campisi, S, PB2153
Campo, E, S115, S117, P244, P296, P300, P325, E1137, E1369, E1381
Campo Palacio, H, PB2054
Campos, P, PB1674
Campos, R, P721, E1456
Campr, V, P218
Campos, P, PB1674
Campos, R, P721, E1456
Canafoglia, L, P636, E1136
Canal, A, PB1933
Canale, F, PB1632
Canales, M, S469, E1563
Canales Albendea, M, S775, PB1692
Canals, T, E1594
Cancado, R, S454
Cancelas, J, S149
Cancelli, V, P218
Cancian, L, S119
Candi, V, E941, E1215
Cândido, L, PB1662
Candoni, A, S111, E1496, PB1697
Canepa, L, S410, P322, E1299
Cañete Sánchez, A, E1103
Cangini, D, E1012
Cangur, S, PB2123
Caniglia, M, S775
Canioti, D, S105, P709, E1360
Cañizo, C, P316
Canli, O, S809
Cannella, P, S775
Cano, I, E856
Canon, J, PB1849
Cano, I, E856
Cao, J, E931, PB1635
Cao, X-N, S449, P507, P725, E833
Cao, X, S103
Capecchi, G, P256, P358, P610, E1042, E1186
Caola, A, S779
Capalbo, S, PB1877, PB1992
Caparrós, E, P660
Capdevila, C, E1381
Capell, I, E1183
Capelli, D, S779
Capocci, E, P351
Capodanno, I, S485, P604, PB1818
Caporale, R, E1215
Caporariello, N, E1214
Cappelli, A, E1489
Cappelli, B, E1495
Cappelli, E, P234, E1440
Cappellini, M, S128, P396, E1483, E1576
Cappuccini, I, P277
Capuzzo, J, S779
Capuzzo, A, S630
Caporali, P, PB1843, PB2189
Caprio, S, P168
Carabia, J, P298, E995, E1002
Carciofalo, C, P671
Caraffini, V, S419, E879
Caramazza, D, P351
Caramella, D, P671
Caramella, M, P351
Caravita di Toritto, T, E1247
Carabat-Ham, I, S113
Carbon, C, P722
Carbonnel, D, PB1653
Carbonell, F, E1027
Carcassi, C, P256
Christopoulos, G. E1292
Christoulas, D, S130, S415, E1292
Chromik, J, P666
Chu, S-T, E1567
Chuah, C, E1292
Chubak, E, PB1827
Chubukina, Z, PB2006
Chubukov, V, P614
Chumak, A, PB1772
Chung, C, PB2165
Chung, D, E1252
Chung, J, E984, E1070
Chung, K, P372, E922
Chung, N-G, S422
Chung, W, E1248
Chunilal, S, E1431
Chupryna, M, E1127
Chyla, B, S771, P682
Ciabatti, E, E1048, E1318, E1397, E1408
Ciancia, G, E1459
Cibeira, M, E1259, PB1952
Cibien, F, P715
Ciboddo, M, PB1827
Cibulskis, C, P236
Cicala, D, PB1647
Cicalese, M, S128
Ciccarone, M, E1123
Ciccone, G, P214, E1247
Cicconi, L, E908, PB1696
Ciabatti, E, E1048, E1318, E1397, E1408
Ciancia, G, E1459
Cibeira, M, E1259, PB1952
Cibien, F, P715
Ciboddo, M, PB1827
Cibulskis, C, P236
Cicala, D, PB1647
Cicalese, M, S128
Ciccarone, M, E1123
Ciccone, G, P214, E1247
Cicconi, L, E908, PB1696
Cicco, G, S773, P587
Coble, C, E1293, PB1970
Cockrum, P, PB2135
Codorin, E, P607
Coe, A, P285
Coelho, A, E1033, E1188, E1586, PB2003
Coelho, A, PB1820
Coenen, J, S501
Cojbasic, I, PB1823, PB1826, PB1838
Cojbasic, Z, PB1826
Colado, E, S115, E1316, E1319, E1328, PB2140
Colado, E, S115, PB1758
Colaiuta, E, P763
Colakovic, F, PB1837
Cole, C, P680
Colisman, M, E888
Cifuentes, R, PB1810
Cigalini, E, S433, P365
Cillero Pastor, B, PB2068
Cillo, D, P658, P667, E1226, E1332
Ciminello, A, P722
Ciminelli, M, PB1877
Cinni, G, E1325, E1340
Cimmuneli, M, S413
Ciminelli, C, E1292
Cinabo, F, E1254
Cinqueto, M, S412, S772
Cohen, M, S451
Cohen, M, PB2073
Coffey, G, S773, P587
Cogle, C, E923
Cogo, P, PB2142
Cohen, J, S412, S772
Cohen, M, S451
Cohen, M, PB2073
Colland, F, P635
Collins, A, P276, E874, PB2057
Collins, G, S412, S775, E1476
Collins, M, PB1976
Collins, R, S471, P552
Collins, S, P343
Collin-大型系统-MAIN-A, E1361
Collard, G, S420
Colman, B, P609
Colombatti, R, E1164, E1489, PB2142, PB2145
Colombo, M, E1216, E1268
Colombo, N, E854, E915, E933, E1505
Colomer, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P429
Colovic, F, PB1800
Colotti, S, E941, E946
Colonna, M, PB1647
Colombo, N, E854, E915, E933, E1505
Colomer, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, P, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Colovic, F, PB1800
Colombo, N, E854, E915, E933, E1505
Colore, D, S115, P696, E1369
Colombo, L, PB1726, PB1874
Colonna, M, PB1647
Coloredo, M, P554
Colordo Ledesma, E, P1989
Dobbin, J, PB1637
Dobrenic, M, E971
Dobson, R, P587
Docherty, S, P276
Dodero, A, E1533
Doehner, H, P248
Dogán, Ö, PB2043
Doger, F, PB2110
Dogné, J-M, P230, E964
Dogu, M, P281, PB2137
Doherty, A, PB1788, PB1794
Döhner, H, P182, P208, P535, P700, E864, E868, E870, E1084, E1335
Dokal, A, E869
Dokić, M, PB1835
Dokmanovic, L, PB1612
Dokshina, I, PB1945
Dolatshad, H, S122
Dolnik, A, P182, P248, P535, E864, E888
Dolph, M, E945
Doma, E, P749
Domanska-Czyz, K, P162
Domenichini, C, P599, E1048
Domingo Domenech, E, E957, PB1727
Domingo-Reinés, J, E893
Dominguez, D, E831
Dominguez, P, P297
Domínguez, A, P205
Domínguez, M, E1349
Dominietto, A, S796
Dominoni, F, E1207
Donadieu, J, E1102, PB2083
Donato, B, P369
Donnini, I, PB1983
Donnini, L, PB1983
Donnier, J, S478, P208, E856, E910
Domenichini, C, P599, E1048
Domingo Domenech, E, E957, PB1727
Domingo-Reinés, J, E893
Dominguez, D, E831
Dominguez, P, P297
Dominguez, M, E1349
Dontscher, H, E1387, PB1623
Dreyling, M, S470, S776, E1402
Drize, N, E1092, E1096, E1098
Droin, N, S427, P268
Drokov, M, E1545, E1559, PB1685, PB1852, PB2176
Drozd-Sokolowska, J, E1193, E1257
Drummond, M, P699, P701, E1343
Drzazgic, S, E1257
Du, W, PB1721
Duan, M, P356
Duarte, B, PB1674
Duarte, D, E875
Duarte, G, PB1674
Duarte, R, S807, E1541
Duarte, S, E1110
Dubinski, I, PB2232
Dubnyak, D, E1545, E1559, PB1852, PB2176
Dubois, O, E624
Dubovsky, J, S492
Dubi, E, E1483, E1576
Ducastelle-Leprêtre, S, E906, E1150
Duces, A, PB2045, PB2051
Ducou Le Pointe, H, P716
Dudakov, J, S446
Dued, M, P21813, PB2031
Dudina, G, PB1980
Dueck, A, P359, P377, E1321, E1331, E1339, PB2050
Duell, J, S470
Duffy, K, E875
Dufour, A, E885
Dufour, C, P232, P234, P575, P717, E1440
Dugas, M, E1197
Duh, M, P285, P286, PB1825
Duhamel, A, E1135
Düehrens, U, P534, P582, E1118
Dujmovic, D, E971
Dukovski, D, E1471, PB1775, PB1795, PB2062
Duly, R, P217
Dulleck, P, PB2053
Dullege, A, S435
Dulin, E, PB2143, PB2200
Duma, N, E1241, E1274, E1276, E1288, E1502
Duma, V, E1127
Dumas, P-Y, PB1629
Dumee, B, P677
Dunesioli, C, S131
Dumit, V, E1393
Dummer, R, P637
Dunon, S, E1197
Dumond Wibaux, E, E1458
Dumons, S, P712
Dunaeva, E, PB2035
Dunbar, M, S473, P675
Dunn, R, E905, E1176
Dunning, A, P295
Dong, D, E847
Dong, V, E912, E947
Duprez, E, P183
Dupuy, C, P268
Duque, J, E1074
Durakovic, N, S795
Durán, M-A, P703, E1341, E1417, E1555
Duran, M, PB1968
Duran-Ferrer, M, S117, P300
Durand, J-M, P716
Durbin, E, P279
Durcan, E, E1159
Durechova, K, S461, P238
Durgun, E, E1427
Duran, M, S501
Durst, B, S782, P349, P687, E1239, E1269, E1277
Dürig, J, S775
Durinikova, A, PB1650
Duro, R, PB1984
Durot, E, E1001
Fielding, A, S802, P160, P164, E1476
Fieschi, C, PB2083
Fifer, S, E1470
Fiddor, C, E1353
Figueiredo, A, PB1998
Figuera, A, E1470
Figdor, C, E1353
Figueiredo, A, PB1998
Figueroa, M, E1315
Figueroa, R, S444, PB2230
Fijnheer, R, PB2096
Filaci, G, P586, E1390
Filì, C, E1496, PB1697
Fillerova, R, PB1766
Filocamo, M, E1077
Filonenko, K, E1127, PB1714
Filosa, A, P290, P393, P399, E1570, E1575
Finashutina, Y, PB1710, PB1817, PB1851, PB2026
Finazzi, G, P760, P766, P393
Finazzi, M, E1315
Finck, B, E1147
Finelli, C, E1496, PB1697
Finazzi, G, P760, P766, E1315
Finazzi, M, E1315
Finck, B, E1147
Finelli, C, P586, P667, PB1932
Fischer, A, E1025
Fischer, A, P350
Fischer, J, P585, E1025
Fischer, L, E1402
Fischer, M, P648
Fischer, T, P535, E865
Fischer, U, S436
Fischer von Weikersthal, L, S464
Fitch, A, E1218
Fitzgibbon, J, P303, P532
Fitzgibbon, J, P303, PB1785
Fiz, F, P283
Flachs, E, E1347
Flaherty, L, P526
Flanagan, L, P548
Flanders, S, PB1687, PB1699
Flasinski, M, S789
Fleischman, A, P377, E1321, E1339
Fleischman, R, P279
Fleming, J, P81921
Fleming, J, E1453
Fleming, S, E848, E929
Fletcher, T, P319
Fleury, I, S468
Flevari, P, E1485
Flicek, P, S117
Flick, E, P349
Flickinger, Z, S439
Flinn, J, S777, E1130
Flintrop, M, S789
Floegang, M, PB1779
Florschutz, A, S502
Floride, M, S468, S772
Flowers, C, S492
Flynt, E, E1203
Foa, R, S111, S800, P166, P306, E976, E989, E1000, E1017, E1408, PB1779, PB1818, PB1880
Fodor, W, S790
Fogli, M, P607
Fogliatto, I, PB1820
Fogliani, B, E1606, PB2233
Foglietta, M, E999
Folber, F, E841
Foli, A, P684, E1243
Folkvaljon, Y, E972
Foltmann, M, E1251
Follo, M, E1335
Follas, G, S469, S776, P276, E938
Folta, A, PB1650
Folz, I, PB1849
Foltz, L, P702, P706, E1320, E1333, E1334
Fominykh, M, E1313, PB1821, PB2034
Foncillas, M, E1038, PB1761
Foncuberta, C, E1508
Fonder, A, P573, E1240, E1241
Fong, E, P620
Fonseca Moutrelle, A, PB2155
Font, L, S790
Fontana, D, P570
Fontana, M, E882, E989, PB1657
Fontana, R, E967
Fontaneli, G, E946
Fontcuberta, J, P759, P765
Fontoura, M-L, PB1833
Foon, K, P634
Forcade, E, S798, PB1629
Forcella, D, E1145
Forcina, A, S806
Forconi, F, S770, P587, E996
Forde, E, E873
Fordham, N, P270
Forero, Y, PB2205
Forero-Torres, A, P633, E1142
Forés, R, E972, PB1885
Forestieri, G, P282
Forrest, D, P581, E1557
Forslund, A, P186
Forsyth, C, E1350
Forsythe, A, E925, E945
Fort, D, E1109
Forth, E, E1020
Fornecker, L, P105, P217
Forni, G, P400, E1482, E1491
Forno, B, PB1913
Foroni, L, S423
Forrest, D, P581, E1557
Forrest, D, E1309
Forstpointner, R, S775
Forst, A, P295
Forsthofer, R, S775
Forsyth, C, E1350
Forsythe, A, E925, E945
Fort, D, E1109
Forth, E, E1020
Fortune, A, PB1832
Foster, K, P264
Foster, R, E1035, PB1791
Foster, T, P258
Fotiou, D, P337, E1266
Fotzi, I, P714
Foucar, K, E923
Foucher, B, PB1813, PB2031
Fouzia, O, E1275, E1479, PB2126
Fowler, A, P276
Fowler, N, S772, E1129
Fox, C, PB1788, PB1959
Fox, C, S770, P245, P589, E1037
Fox, M-L, P703
Foxwell, D, E1529
Framoni, D, E908
Kueenburg, E, P343, E1250
Kuendgen, A, E937
Kufer, P, E867, E877
Kugler, S, E1449
Kuhlen, M, S116
Kuhn, A, E1449
Kuhnert, G, S515
Kuhns, S, PB1849
Kuhr, K, S812
Kuper, R, P677
Kupers, J, E1504
Kuklik-Roos, C, S809
Kukreti, V, P680
Kulagin, A, S498, P718
Kulanda, T, E1154
Kulibaba, T, E1154
Kulbiczkowski, K, E1553, PB1695, PB2032
Kulikov, S, E836, E853, E860, E1067, E1240, E1241
Kulis, M, S117, P300, P325, E1225
Kulvait, V, E1166
Kumagai, T, P263
Kumar, A, S451, PB2150
Kumar, A, S451
Kumar, A, E987
Kumar, B, P186
Kumar, N, E974
Kumar, P, E974
Kumar, S, S101, S408, S460, P331, P338, P673, P675, E1240, E1241
Kumode, T, E1100
Kunihisa, S, P360
Kunisch, M, S137
Kuroda, J, E959, PB2065, PB2066
Kurosawa, S, E1139
Kurt Yuksel, M, P281, PB2185
Kurtovic, S, PB1837, PB2078
Kurtovic-Kozanic, A, PB1837
Kuwabara, J, E959, PB2065, PB2066
Kuwabara, S, S137
Kurtz, D, E1269, PB1844, PB1951
Kutlar, A, S454
Kuvshinov, A, PB1787, PB2006
Kuykendall, A, E608, E1323
Kuzmina, L, E982, E1092, E1096, E1098, E1154, E1159, P685, PB1852, PB2000, PB2049, PB2154, PB2176
Kuznetsova, S, PB1792
Kvistad, E, E1424
Kwak, D-H, P551, P561
Kwak, J-Y, P259, E954, E1054, E1062, E1069, E1070
Kwak, L, P635
Kwei, L, P672
Kwiatkowski, J, S451, S814
Kwon, J, E1069
Kwon, M, E1113
Kwong, Y-L, P371, P725, E1234, E1278
Kyriakopoulou, L, PB1860
Kyrtonnis, M, PB1849, PB2107
L
La Cava, P, E1214, E1232
La Nasa, B, S129, P256
La Rocca, F, E1226, E1261
La Sala, E, S111
Laademan, A, S129, P666
La Belle, C, P510
Labbé, B, S1860
Labopin, M, S493, S579, S798, P379, P384, P388, E1506
Labotka, R, S338
Laboure, G, P1862
Ladage, J, E1406
Ladetto, M, S778, P304, E1408
Ladirign, C, S809
Lajemel, N, S371
Ladogana, S, S360
Lai, G-M, PB1719
Lai, K, S256
Lai, S, PB1852
Lai, Y-Y, P507, S511, P725, E833, PB1677
Lakshman, A, E1240
Lai, L, S492
Lal, J, E1278
Lalayanni, C, E1610, PB1698, PB2102
Lally, J, PB1915
Lam, A, P687, E1281
Lam, A, E1424
Lamagna, M, P400
Lamanna, M, S144, P755
Lambilliotte, A, S131
Lambrechts, D, E1220
Lammens, T, P156, E1114
Lampropoulou, R, S796
Lampropoulou, R, E1249, PB2107
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee, J</td>
<td>P333, E984, PB1993</td>
</tr>
<tr>
<td>Lee, J</td>
<td>E1361, E1549</td>
</tr>
<tr>
<td>Lemeire, K</td>
<td>S438, E1358</td>
</tr>
<tr>
<td>Lemay, A</td>
<td>PB1755</td>
</tr>
<tr>
<td>Lemmy, G</td>
<td>P636</td>
</tr>
<tr>
<td>Lemoli, R</td>
<td>P283, E854, E915, E919, E933, E1043, E1299, E1505, PB1632, PB1732</td>
</tr>
<tr>
<td>Lenain, F</td>
<td>P345, PB1833</td>
</tr>
<tr>
<td>Ledahl, U</td>
<td>E1110</td>
</tr>
<tr>
<td>Lennai, N</td>
<td>E1252</td>
</tr>
<tr>
<td>Leneus, A</td>
<td>S129</td>
</tr>
<tr>
<td>Lengyel, L</td>
<td>E1535</td>
</tr>
<tr>
<td>Lennihan, D</td>
<td>E1255</td>
</tr>
<tr>
<td>Lermve, D</td>
<td>E295</td>
</tr>
<tr>
<td>Lennard, A</td>
<td>P225</td>
</tr>
<tr>
<td>Lentzsch, S</td>
<td>S101, S459</td>
</tr>
<tr>
<td>Lenz, G</td>
<td>S776</td>
</tr>
<tr>
<td>Lenza, H</td>
<td>PB1889</td>
</tr>
<tr>
<td>Lee, M</td>
<td>PB1899</td>
</tr>
<tr>
<td>Leon, E</td>
<td>P536</td>
</tr>
<tr>
<td>Leon Gonzalez</td>
<td>E1500, PB2219</td>
</tr>
<tr>
<td>Leon Peña, A</td>
<td>E1500, PB2219</td>
</tr>
<tr>
<td>Leoncin, M</td>
<td>E1254, E1357, E1397</td>
</tr>
<tr>
<td>Leoncini, P</td>
<td>E917, E1167, PB1665</td>
</tr>
<tr>
<td>Leonore, G</td>
<td>PB2162</td>
</tr>
<tr>
<td>Leon, S</td>
<td>PB1707</td>
</tr>
<tr>
<td>Leon, V</td>
<td>PB2056</td>
</tr>
<tr>
<td>Leonetti Crescenzi</td>
<td>S1340</td>
</tr>
<tr>
<td>Leong, T</td>
<td>S82016</td>
</tr>
<tr>
<td>Leoni, P</td>
<td>P636, E1136, PB1954</td>
</tr>
<tr>
<td>Leontopoulos, K</td>
<td>PB2166</td>
</tr>
<tr>
<td>Lepkov, S</td>
<td>P220, E1133</td>
</tr>
<tr>
<td>Leporace, A</td>
<td>P616, PB1696</td>
</tr>
<tr>
<td>Leppa, S</td>
<td>S776</td>
</tr>
<tr>
<td>Lefretre, S</td>
<td>S856</td>
</tr>
<tr>
<td>Leroy, H</td>
<td>PB1629</td>
</tr>
<tr>
<td>Lesokhin, A</td>
<td>E1252</td>
</tr>
<tr>
<td>Lessene, G</td>
<td>S175</td>
</tr>
<tr>
<td>Lessi, F</td>
<td>E930, PB1697, PB1728</td>
</tr>
<tr>
<td>Lezly, C</td>
<td>E1001, E1361</td>
</tr>
<tr>
<td>Lezai, A</td>
<td>S472, P508</td>
</tr>
<tr>
<td>Leuchtnner, N</td>
<td>E992</td>
</tr>
<tr>
<td>Leung, A</td>
<td>P167</td>
</tr>
<tr>
<td>Leung, K</td>
<td>P167</td>
</tr>
<tr>
<td>Leung, M</td>
<td>PB1730</td>
</tr>
<tr>
<td>Leung, N</td>
<td>P331, P673, E1240</td>
</tr>
<tr>
<td>Leung, T</td>
<td>P167</td>
</tr>
<tr>
<td>Leung, W</td>
<td>P509</td>
</tr>
<tr>
<td>Leux, C</td>
<td>P217</td>
</tr>
<tr>
<td>Levati, G</td>
<td>E1030</td>
</tr>
<tr>
<td>Levato, L</td>
<td>P605, E1021, PB1818</td>
</tr>
<tr>
<td>Leverger, G</td>
<td>S427, P716, E1439</td>
</tr>
<tr>
<td>Leverison, J</td>
<td>S460, P189, P675</td>
</tr>
<tr>
<td>Lesvesque, H</td>
<td>PB2150</td>
</tr>
<tr>
<td>Leveta, G</td>
<td>PB2195</td>
</tr>
<tr>
<td>Leovin, M-D</td>
<td>S501, P340, P677, PB1798</td>
</tr>
<tr>
<td>Levine, B</td>
<td>S477</td>
</tr>
<tr>
<td>Levine, J</td>
<td>S477, P517</td>
</tr>
<tr>
<td>Leviss, A</td>
<td>P667</td>
</tr>
<tr>
<td>Levis, M</td>
<td>S110, P560, E940</td>
</tr>
<tr>
<td>Levitas, A</td>
<td>E1073</td>
</tr>
<tr>
<td>Levy, A</td>
<td>PB1987</td>
</tr>
<tr>
<td>Levy, M</td>
<td>S793, P201, E1464</td>
</tr>
<tr>
<td>Lemawodowski, K</td>
<td>P611</td>
</tr>
<tr>
<td>Leyighton, A</td>
<td>PB1980</td>
</tr>
<tr>
<td>Leys, R</td>
<td>S501</td>
</tr>
<tr>
<td>Lhertier, V</td>
<td>E856</td>
</tr>
<tr>
<td>Lherninette, L</td>
<td>E1236, E1386</td>
</tr>
<tr>
<td>Lhospice, F</td>
<td>E1386</td>
</tr>
<tr>
<td>Li, A</td>
<td>P405</td>
</tr>
<tr>
<td>Li, B</td>
<td>E1330</td>
</tr>
<tr>
<td>Li, C</td>
<td>E856</td>
</tr>
<tr>
<td>Li, C</td>
<td>PB1941</td>
</tr>
<tr>
<td>Li, C</td>
<td>P167</td>
</tr>
<tr>
<td>Li, C</td>
<td>P662</td>
</tr>
<tr>
<td>Li, D</td>
<td>P663</td>
</tr>
<tr>
<td>Malatesta, R, P168</td>
<td>Maragno, A, P175</td>
</tr>
<tr>
<td>Malavasi, F, E1223, E1237</td>
<td>Maral, S, PB2112</td>
</tr>
<tr>
<td>Malciokova, L, S122, S123, P355, E1179</td>
<td>Marani, L, E1494</td>
</tr>
<tr>
<td>Malecka, A, P613</td>
<td>Marano, L, PB1707, PB2001</td>
</tr>
<tr>
<td>Malek, E, E1248</td>
<td>Marantz, J, S498</td>
</tr>
<tr>
<td>Malenda, A, E1294</td>
<td>Marasco, V, S806</td>
</tr>
<tr>
<td>Malerba, L, PB2010</td>
<td>Marçais, A, E1386</td>
</tr>
<tr>
<td>Maiffait, R, S141</td>
<td>Marcatti, M, S806</td>
</tr>
<tr>
<td>Maifianto, A, E1247</td>
<td>Marocà, S, E831</td>
</tr>
<tr>
<td>Malhotra, P, PB1805, PB1841, PB1890, PB2199</td>
<td>Marcelli Graziosi, B, E967</td>
</tr>
<tr>
<td>Maii, R, P189</td>
<td>Marcellini, S, PB2106</td>
</tr>
<tr>
<td>Malikova, O, PB2126</td>
<td>Marcher, C, P193, E932</td>
</tr>
<tr>
<td>Malikova, O, PB220, E1133</td>
<td>Marchesi, F, P760</td>
</tr>
<tr>
<td>Malinge, S, E1223</td>
<td>Marchesi, F, E1145, E1379</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marchesini, M, P321</td>
</tr>
<tr>
<td>Mallo, M, E1294</td>
<td>Marchetti, M, P760, P766</td>
</tr>
<tr>
<td>Malo, M, E831</td>
<td>Marchetti, M, E1332</td>
</tr>
<tr>
<td>Mallouri, D, PB2166</td>
<td>Marchetti-Laurent, C, E829</td>
</tr>
<tr>
<td>Malonda, A, E1294</td>
<td>Marchica, V, E1223</td>
</tr>
<tr>
<td>Malloum, K, E1248</td>
<td>Marco De Lucas, F, E1183</td>
</tr>
<tr>
<td>Malenda, A, E1237</td>
<td>Marcon, A, E1247</td>
</tr>
<tr>
<td>Malenda, A, E1248</td>
<td>Marcon, C, S433, P365</td>
</tr>
<tr>
<td>Malenda, A, E1294</td>
<td>Marconi, G, E882, E898, PB1657</td>
</tr>
<tr>
<td>Malena, R, P189</td>
<td>Marcos Jubilar, M, S444, PB2230</td>
</tr>
<tr>
<td>Malick, R, PB1998</td>
<td>Marcoat, N, P536</td>
</tr>
<tr>
<td>Mallm, J-P, P663</td>
<td>Marcucci, G, P186</td>
</tr>
<tr>
<td>Malinverni, R, P649</td>
<td>Marcus, R, S774, S775</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mardiros, A, P523, E840</td>
</tr>
<tr>
<td>Malis, R, E1304</td>
<td>Marekovic, I, S795</td>
</tr>
<tr>
<td>Malis, R, E1304</td>
<td>Marfa, S, P532</td>
</tr>
<tr>
<td>Malizas, J, S785, S786</td>
<td>Margaritis, D, P280</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mariana, A, P154</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mariani, S, PB2133</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mariaselvam, C, E1495</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mariglia, P, E989, E1000, PB1779</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marimpietro, D, E1237</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marin, D, S792, P739, E914, E1512, E1538</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marin, J, PB1902</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marin, K, PB1761</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marin, L, E887</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marinakis, T, E895</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marinello, P, S783, P344</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marini, I, P364</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marini, S, E1080, PB1763, PB1904, PB1929, PB2044</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marino, C, PB2056</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marino, M, E1379</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mariotti, V, E1048, E1274</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Maris, M, S793</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marit, G, P345</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marjanovic, I, PB1612</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Mark Toye, A, P391</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markaki, E, PB1854</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markavarn, B, E1057</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markham, J, E1202</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markiewicz, M, P741</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markova, J, S150</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markova-Štastna, M, E1198</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markovic, O, E970, PB1708</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Markovic, D, E1328</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marks, D, S802, S817, P164, P525</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marmolejo, J, S107, E1135, E1537, PB1713</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marotta, P, E1226</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marojuje, A, PB2083</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marquez, F, E1349</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marquez, J, A, E1183</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marquez-Maiewer, F, P765</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marquez-Matito, A, P213</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marr, N, P717, PB1647</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marr, R, S811</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marrero, C, P376</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marron-Conwin, M, PB2100</td>
</tr>
<tr>
<td>Malinverni, R, E831</td>
<td>Marsh, J, E1550</td>
</tr>
<tr>
<td>Subotićki, T, E1308, E1316, E1319, PB2140</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Subramanian, P, P169, E837, E843</td>
<td></td>
</tr>
<tr>
<td>Such, E, P316, P318, P696, PB1661</td>
<td></td>
</tr>
<tr>
<td>Sud, A, P295</td>
<td></td>
</tr>
<tr>
<td>Sudarkov, A, E860, E1403, E1409, E1548, PB1636, PB1807, PB2071, PB2176</td>
<td></td>
</tr>
<tr>
<td>Suessbier, U, P266</td>
<td></td>
</tr>
<tr>
<td>Sugai, T, E1148</td>
<td></td>
</tr>
<tr>
<td>Sugawara, N, P642</td>
<td></td>
</tr>
<tr>
<td>Sugimoto, K-I, E1058, E1066</td>
<td></td>
</tr>
<tr>
<td>Sugimoto, M, E1590</td>
<td></td>
</tr>
<tr>
<td>Sugita, J, E859, PB1723</td>
<td></td>
</tr>
<tr>
<td>Sulč, E, P316, P318, P696, PB1661</td>
<td></td>
</tr>
<tr>
<td>Sule, A, E903</td>
<td></td>
</tr>
<tr>
<td>Sulima, S, S417, S439</td>
<td></td>
</tr>
<tr>
<td>Suljović Hadžimesić, E, PB2078</td>
<td></td>
</tr>
<tr>
<td>Sultanbaev, A, PB1803</td>
<td></td>
</tr>
<tr>
<td>Sultanova, M, E1457</td>
<td></td>
</tr>
<tr>
<td>Sumril, A, S412</td>
<td></td>
</tr>
<tr>
<td>Sun, A, E931, E1189, E1507, PB1635, PB1977</td>
<td></td>
</tr>
<tr>
<td>Sun, D-W, E1484</td>
<td></td>
</tr>
<tr>
<td>Sun, H, P155</td>
<td></td>
</tr>
<tr>
<td>Sun, J, P356</td>
<td></td>
</tr>
<tr>
<td>Sun, J, PB1897</td>
<td></td>
</tr>
<tr>
<td>Sun, K, E1146</td>
<td></td>
</tr>
<tr>
<td>Sun, L, PB1721</td>
<td></td>
</tr>
<tr>
<td>Sun, Y, P682</td>
<td></td>
</tr>
<tr>
<td>Sun, Y, P753</td>
<td></td>
</tr>
<tr>
<td>Sun, Y, E1498</td>
<td></td>
</tr>
<tr>
<td>Sun, Y-Q, S449, P725, E1101, PB2172</td>
<td></td>
</tr>
<tr>
<td>Sufi, G, E1088</td>
<td></td>
</tr>
<tr>
<td>Sung, H, P223, PB2067</td>
<td></td>
</tr>
<tr>
<td>Sung, J, J, PB2004</td>
<td></td>
</tr>
<tr>
<td>Sung, M-T, PB1734, PB1737</td>
<td></td>
</tr>
<tr>
<td>Sungur, M, PB1783</td>
<td></td>
</tr>
<tr>
<td>Superti-Furga, G, S133</td>
<td></td>
</tr>
<tr>
<td>Suphapeetiporn, K, E975</td>
<td></td>
</tr>
<tr>
<td>Surano, M, P736</td>
<td></td>
</tr>
<tr>
<td>Sureda, A, E997, PB2008</td>
<td></td>
</tr>
<tr>
<td>Sureda Baiari, S, PB1727</td>
<td></td>
</tr>
<tr>
<td>Suri, G, E974</td>
<td></td>
</tr>
<tr>
<td>Surkus, W, P566</td>
<td></td>
</tr>
<tr>
<td>Surralles, J, S144, P580</td>
<td></td>
</tr>
<tr>
<td>Sutherland, H, P581</td>
<td></td>
</tr>
<tr>
<td>Sutter, U, P700</td>
<td></td>
</tr>
<tr>
<td>Sutton, D, P761</td>
<td></td>
</tr>
<tr>
<td>Sutton, K, E1460</td>
<td></td>
</tr>
<tr>
<td>Sutton, L, E1001</td>
<td></td>
</tr>
<tr>
<td>Sutton, L-A, P242, P244</td>
<td></td>
</tr>
<tr>
<td>Sutton, R, P154, E848</td>
<td></td>
</tr>
<tr>
<td>Suturkova, L, E1471</td>
<td></td>
</tr>
<tr>
<td>Suvajdić, N, E1448</td>
<td></td>
</tr>
<tr>
<td>Suvajdić Vuković, N, E948, PB1612, PB1704</td>
<td></td>
</tr>
<tr>
<td>Suzorov, A, E1244</td>
<td></td>
</tr>
<tr>
<td>Suzorov, D, PB1925</td>
<td></td>
</tr>
<tr>
<td>Suyani, E, PB2137</td>
<td></td>
</tr>
<tr>
<td>Suzuki, S, P698</td>
<td></td>
</tr>
<tr>
<td>Suzuki, H, S123, S799</td>
<td></td>
</tr>
<tr>
<td>Suzuki, H, E1229</td>
<td></td>
</tr>
<tr>
<td>Suzuki, K, S101, P334</td>
<td></td>
</tr>
<tr>
<td>Suzuki, K, P531</td>
<td></td>
</tr>
<tr>
<td>Suzuki, K, PB1742</td>
<td></td>
</tr>
<tr>
<td>Suzuki, K, P171</td>
<td></td>
</tr>
<tr>
<td>Suzuki, N, E1477</td>
<td></td>
</tr>
<tr>
<td>Suzuki, S, E1210</td>
<td></td>
</tr>
<tr>
<td>Suzuki, T, E962</td>
<td></td>
</tr>
<tr>
<td>Suzuki, Y, P171</td>
<td></td>
</tr>
<tr>
<td>Suzuki, Y, P642</td>
<td></td>
</tr>
<tr>
<td>Svatoš, M, P711</td>
<td></td>
</tr>
<tr>
<td>Svenkovtova, A, S801</td>
<td></td>
</tr>
<tr>
<td>Svensson, M, S805</td>
<td></td>
</tr>
<tr>
<td>Svensson, T, S805</td>
<td></td>
</tr>
<tr>
<td>Svergun, N, E1382, PB2069</td>
<td></td>
</tr>
<tr>
<td>Sverrisdóttir, I, S442, P678</td>
<td></td>
</tr>
<tr>
<td>Svetlana, G, P311</td>
<td></td>
</tr>
<tr>
<td>Sviezhentseva, I, PB1809</td>
<td></td>
</tr>
<tr>
<td>Svitina, S, P308</td>
<td></td>
</tr>
<tr>
<td>Svoboda, J, P566</td>
<td></td>
</tr>
<tr>
<td>Svobodova, K, PB1820, PB1936</td>
<td></td>
</tr>
<tr>
<td>Svobodova, V, E1004</td>
<td></td>
</tr>
<tr>
<td>Swanink, R, S422</td>
<td></td>
</tr>
<tr>
<td>Sweat, R, P184</td>
<td></td>
</tr>
<tr>
<td>Sweat, H, PB1849</td>
<td></td>
</tr>
<tr>
<td>Sweet, K, P608, E1323</td>
<td></td>
</tr>
<tr>
<td>Swerdlov, A, P295</td>
<td></td>
</tr>
<tr>
<td>Swan, A, E923</td>
<td></td>
</tr>
<tr>
<td>Swiderska, A, E1257</td>
<td></td>
</tr>
<tr>
<td>Swieringa, F, P760</td>
<td></td>
</tr>
<tr>
<td>Swinkles, D, P293</td>
<td></td>
</tr>
<tr>
<td>Swoboda, J, P182</td>
<td></td>
</tr>
<tr>
<td>Swords, R, S471</td>
<td></td>
</tr>
<tr>
<td>Sy, Q, S456</td>
<td></td>
</tr>
<tr>
<td>Sychevskaïa, K, E1403</td>
<td></td>
</tr>
<tr>
<td>Syed, C, PB2204</td>
<td></td>
</tr>
<tr>
<td>Syed, G, E1514</td>
<td></td>
</tr>
<tr>
<td>Sykes, D, S428</td>
<td></td>
</tr>
<tr>
<td>Sykes, S, P528</td>
<td></td>
</tr>
<tr>
<td>Sykora, K-W, P382</td>
<td></td>
</tr>
<tr>
<td>Sykorova, A, P218</td>
<td></td>
</tr>
<tr>
<td>Sykla, P, PB2131</td>
<td></td>
</tr>
<tr>
<td>Symeonidis, A, S415, E1180, E1266, E1292, PB2107</td>
<td></td>
</tr>
<tr>
<td>Syrigou, A, E1610, PB1698</td>
<td></td>
</tr>
<tr>
<td>Sysoeva, E, E1161</td>
<td></td>
</tr>
<tr>
<td>Sytchenko, T, PB1863, PB1987</td>
<td></td>
</tr>
<tr>
<td>Syulap, X, PB2002</td>
<td></td>
</tr>
<tr>
<td>Szabo, Z, E1298, PB1964</td>
<td></td>
</tr>
<tr>
<td>Szabolcs Toka, K, PB2009</td>
<td></td>
</tr>
<tr>
<td>Szalat, R, E1206</td>
<td></td>
</tr>
<tr>
<td>Szarcev Szc, K, P243, P656</td>
<td></td>
</tr>
<tr>
<td>Szatkowski, D, S501</td>
<td></td>
</tr>
<tr>
<td>Szczepanek, A, PB1800</td>
<td></td>
</tr>
<tr>
<td>Szczepanek, D, PB1800</td>
<td></td>
</tr>
<tr>
<td>Szczepański, T, PB1624</td>
<td></td>
</tr>
<tr>
<td>Szczudło, T, PB1815</td>
<td></td>
</tr>
<tr>
<td>Szczygieł, K, E827</td>
<td></td>
</tr>
<tr>
<td>Szelagowski, M, E1508</td>
<td></td>
</tr>
<tr>
<td>Szer, J, P369</td>
<td></td>
</tr>
<tr>
<td>Szeremet, A, E1262</td>
<td></td>
</tr>
<tr>
<td>Szmiłgelska-Kaplon, A, P235</td>
<td></td>
</tr>
<tr>
<td>Szoke, A, P699, P701, E1343</td>
<td></td>
</tr>
<tr>
<td>Szombathelyi, G, PB1978</td>
<td></td>
</tr>
<tr>
<td>Szatkowski, T, E1432, PB1650</td>
<td></td>
</tr>
<tr>
<td>Szudy-Szczepak, A, E888</td>
<td></td>
</tr>
<tr>
<td>Szumera-Ciećkiewicz, A, E1294</td>
<td></td>
</tr>
<tr>
<td>Szydło, R, S617</td>
<td></td>
</tr>
<tr>
<td>Szydlowski, M, E886</td>
<td></td>
</tr>
<tr>
<td>Szymanski, G, E1178</td>
<td></td>
</tr>
<tr>
<td>Szyniecak, D, PB1695</td>
<td></td>
</tr>
<tr>
<td>Szynkcyk, A, PB1800</td>
<td></td>
</tr>
<tr>
<td>T Carson, R, E1358</td>
<td></td>
</tr>
<tr>
<td>Tabrizi, R, P388, PB1629</td>
<td></td>
</tr>
<tr>
<td>Tacchetti, P, S410, E1238</td>
<td></td>
</tr>
<tr>
<td>Tachavani, K, E1076</td>
<td></td>
</tr>
<tr>
<td>Tachi, N, P689</td>
<td></td>
</tr>
<tr>
<td>Tachibana, T, PB2173</td>
<td></td>
</tr>
<tr>
<td>Taddele, D, E866</td>
<td></td>
</tr>
<tr>
<td>Tadmor, T, E1034, PB1781, PB1789</td>
<td></td>
</tr>
<tr>
<td>Tadokoro, K, E1072</td>
<td></td>
</tr>
<tr>
<td>Tafuri, A, S411, PB1612</td>
<td></td>
</tr>
<tr>
<td>Tagariello, G, PB2076, PB2077</td>
<td></td>
</tr>
<tr>
<td>Taghi, R, E1207</td>
<td></td>
</tr>
<tr>
<td>Tahara, H, E291</td>
<td></td>
</tr>
<tr>
<td>Tahani, F, E1428</td>
<td></td>
</tr>
</tbody>
</table>

**LXXVI | haematologica | 2017; 102(s2)**

22nd Congress of the European Hematology Association
Late Breaking Oral Session

LB2600

This abstract is part of the Presidential Symposium

NOVEL SMALL MOLECULE INHIBITORS CO-TARGETING CK1A AND P-TEF-B DISRUPT SUPER-ENHANCERS AND ERADICATE ACUTE MYELOID LEUKEMIA IN A MOUSE MODEL

W. Minzel,1 I. Alkalay,1 A. Finkl,1 A. Venkatachalam1, E. Hung1, D. Li2, J. Vaccara2, F. Mercun2, M. Oren3, E. Pikarsky1, Y. Ben-Neria1

1Immunology and Cancer Research, Hebrew University of Jerusalem, Jerusalem, Israel, 2Chemistry, WuXi AppTec, Shanghai, China, 3BioTheryX Inc, San Diego, United States, 4Molecular Cell Biology, Weizmann Institute, Rehovot, Israel

Background: Whereas p53 is mostly non-mutated in AML, various oncogenic pathways, frequently through enhancing the activity of its major antagonist Mdm2, suppress its activity. We have previously shown that genetic ablation of CK1α robustly activates p53 (doi:10.1038/nature09673). However, with no selective CK1α inhibitors for in vivo use, the therapeutic value of CK1α inhibition in hematological malignancies cannot be validated.

Aims: To develop small molecule CK1α inhibitors and assess their effect in mouse models of human leukemia.

Methods: CK1α inhibitors were identified via cell-based screening based on p53 activation. We focused on a small class of pyrazole-pyrimidine scaffolds, which through extensive medicinal chemistry yielded derivatives with high affinity binding, validated by crystallography studies, potent CK1α inhibitory activity and a good pharmacokinetic profile. Anti-leukemic activity was assessed by oral treatment in mouse models of AML. MLL-AF9 and Bcr-Abl Blast Crisis

Results: We first demonstrated the inhibitors’ anti-leukemic effect by single oral dose treatment, robustly inducing p53 activation and blast cell cytoreduction (Figure 1).

Figure 1.

These inhibitors distinguished leukemic from normal hematopoietic stem cells: they did not affect normal hematopoietic CFUs, but eliminated leukemic CFUs at an IC50 <9nM. We tested the long-term oral therapeutic effects of the inhibitors in MLL-AF9 leukemia. Whereas all vehicle-treated mice succumbed to the disease within a month, 40-50% of inhibitor-treated mice survived with no signs of disease up to 5 months’ observation, nor had the surviving mice any sequel of long-term treatment; all had normal blood counts and normal organ morphology and histology. Long-term leukemia control with possible cure, attesting to eradication of LSCs and preservation of normal HSPCs was demonstrated by transplanting leukemia-treated BM into lethally irradiated mice: all transplanted mice recovered and none showed any evidence of residual disease within 6 months. To elucidate the mechanisms by which the inhibitors distinguished leukemic from normal hematopoietic cells, we profiled the kinome affinity of the inhibitors and further studied their signaling effects in vitro and in vivo. We found that CK1α inhibitors having potent anti-leukemia activity are distinguished from less active analogues by their capacity to co-target CDK9 and P-TEF-B. We selected major anti-apoptotic leukemia oncogenes including Mdm2, Bcl-2 and Mcl-1. They were highly inhibited by the analogues, similar to P-TEF-B DISRUPT, super-enhancers, and activation of DNA damage response (HDRAX) and p53

the dramatic therapeutic effect of co-targeting CK1α and P-TEF-B in leukemia.

Summary/Conclusions: We developed a new class of small molecule inhibitors that co-target CK1α and P-TEF-B. These inhibitors induce very rapid, robust induction of p53 in synergy with shutdown of leukemic super-enhancers, resulting in a lasting, powerful and specific anti-leukemic therapeutic effects in vivo, with cure potential.

LB2601

CRYPTIC INSERTIONS OF IMMUNOGLOBULIN LIGHT CHAIN ENHANCER REGIONS ACTIVATE CCND2 AND CCND3 IN CYCLIN D1-NEGATIVE MANTEL CELL LYMPHOMAS


1IDIBAPS, Barcelona, 2Universidad de Oviedo, Oviedo, Spain, 3The Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, 4Department of Medical Oncology, University of Würzburg, Würzburg, Germany, 5Massachusetts General Hospital and Harvard Medical School, Massachusetts, 6Cleveland Clinic Foundation, Cleveland, 7University of Nebraska Medical Center, Omaha, NE, United States, 8University of Toronto and Toronto General Hospital, Toronto, 9Department of Pathology, City of Hope National Medical Center, Duarte, CA, United States, 10VU University Medical Center, Amsterdam, Netherlands, 11HMS Laboratory, Leeds Teaching Hospitals NHS Trust, St James’s Institute of Oncology, Leeds, United Kingdom, 12Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, 13Barcelona Supercomputing Center, Spain, 14Genómica-Centro for Genomic Regulation, 15HM-Médecin del Mar, 16Hospitalet de Barcelona, Barcelona, Spain, 17Institute of Human Genetics, University of Ulm, Ulm, 18Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, 19Institute of Pathology, Eberhard-Karls-University of Tübingen, Tübingen, Germany, 20National Cancer Institute, National Institutes of Health, Bethesda, United States

Background: Mantle cell lymphomas (MCL) are characterized by the primary translocation t(11;14)(q13;q32) involving CCND1 and IGH genes in virtually all cases. Recently, a small subset of cyclin D1-negative (cyclin D1−) MCL has been recognized. About half of these cases have CCND2 gene rearrangements and overexpression of this gene. However, the only oncogenic events in cyclin D1−cyclin D2−MCL still remain elusive.

Aims: To identify potential mechanisms driving the pathogenesis of cyclin D1−cyclin D2−MCL.

Methods: We investigated 66 cyclin D1−/SOX11+MCL cases by a combination of fluorescence in situ hybridization (FISH), gene expression profiling by Affymetrix U133+2.0 and qPCR (n=51), and copy number arrays (n=47) (Agilent CGH 1M, Affymetrix Oncoscan and 500K). Six cases were investigated by gDNA sequencing, 4 sequencing 13 mate-pair whole-genomes, 4 whole exomes, and 1 whole-genome sequencing. The male/female ratio was 2.5:1 and median age at diagnosis 66 years.

Results: Most cyclin D1−MCL (49/51, 96%) showed overexpression of other GI cyclins: CCND2 in 33/35 (94%), CCND3 in 12/25 (48%), and moderate overexpression of both CCNE1 and CCNE2 in 4/23 (11%). CCND2 rearrangements were detected by FISH in 25/33 cases (76%) with CCND2 overexpression, but the remaining CCND2− cases and those with CCND3 overexpression did not show CCND2, CCND3 and IG rearrangements using currently used break-apart probes. Interestingly, by mate-pair whole-genome and whole-exome sequencing analyses we discovered cryptic insertions of IG light chain regions including the enhancer regulatory elements (2 IGK and 1 IGL) near CCND3 gene in the three cases with cyclin D3 overexpression. These rearrangements were confirmed by FISH sequencing and FISH with specifically designed probes to recognize the translocated rearranged regions in genome, using FISH models 6 additional cases with cryptic IGK-CCND3, as well as 3 cases with IGK-CCND2 juxtaposition in tumors with high levels of CCND3 and CCND2, respectively. Taken together, 74% and 18% cases corresponded to cyclin D2− and cyclin D3+ MCL respectively, whereas 6% showed overexpression of CCNE1 and CCNE2 without IG rearrangements. The whole-genome analyses with CCNE1 and CCNE2 overexpression identified 29 somatic protein-coding mutations, 42 complex structural variants and 24 copy number alterations (including CDK2NA and RB1 homozygous deletions) but no rearrangements involving any of the IG genes or G1 cyclins. The global genomic profile of 47 cyclin D1−MCL was highly complex, without similarities to 102 conventional SOX11+ MCL, with significantly more gains at 7p and 18q in the cyclin D1−MCL. Moreover, 32% cases had chromothripsis at least in one chromosome.

Summary/Conclusions: We have identified a novel IG light chain locus-associated rearrangement, consisting of cryptic insertion of IG enhancer near CCND3 gene. This rearrangement is associated to cyclin D2− and cyclin D3+ MCL. Similar rearrangements of IGK enhancer region into CCND2 gene. Both rearrangements were aberrations indicated by cytogenetics and FISH break-apart approaches. Overall, 65/66 (98%) MCL had G1 cyclin overexpression. The detection of these rearrangements with custom probes will allow for diagnostics and therapy of this subset of MCL.

Single-door inhibitor effects treated for 4hrs (EM Western blot and blood smear) and 16hrs (tissue records), in heavily leukemic mice, showing strong cytodestruction in the spleen and bone marrow and pro-apoptotic signaling of leukemia inhibition in vivo (CK1α) and α, confirmed by RNA Pol II phosphorylation (CK1α and α) induction and activation of DNA damage response (HDRAX) and p53

Figure 1.
Background: 1q (1q21 gain) is a common high-risk subtype of multiple myeloma (MM), which drives MM progression, confers drug resistance, and correlates with inferior outcome. However, the molecular mechanism underlying the adverse prognostic roles of 1q remains largely unclear. Recently, 1q has been linked to hypoxia and resulting drug-resistant gene expression.

Aims: To understand the function and clinical significance of hypoxia-induced factor-1β (HIF-1β), a gene located in the 1q21 region, in MM and hypoxic microenvironment.

Methods: The relationship between 1q or HIF-1β and Btz response or overall survival (OS) was analyzed in patients with newly-diagnosed MM (NDMM). Western blot and qPCR analyses were performed to determine expression of HIF-1β and other 1q21 genes in 1q+ cells, or drug-resistant MM cells, or under hypoxia. The function of HIF-1β was evaluated using genetic means and pharmacological inhibitors.

Results: In a cohort of 180 NDMM patients, median OS (mOS) was 29 and 43 months for cases with (w) or without (w/o) 1q (P=0.038), among which 24.3, 43.3, and 43.8 months for 1q copy number ≥3, ≥2, and (P=0.030), respectively; whereas Btz-based therapy displayed a marked increase in response rate: mOS, it failed to improve mOS of 1q patients significantly (28.5 and 33.9 months for patients w or w/o Btz treatment, P=0.983); in contrast, Btz treatment dramatically prolonged mOS in patients w vs w/o 1q (53.7 and 28.5 months, P=0.016). To explore the molecular basis for the adverse effect of 1q on prognosis, expression of the 1q genes related to drug resistance was examined. Notably, robust expression of HIF-1β at protein level was found in 1q+ MM cells, while no difference observed in other 1q21 genes (e.g., PSMD4, CKS1B). Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia-induced factor-1β (HIF-1β), a gene located in the 1q21 region, in MM and hypoxic microenvironment.

Conclusion: Together, these findings argue that HIF-1β represents a potential target for treatments, as these cells have the capacity to potentiate the graft versus leukemia effect with a minimum risk for graft versus host reactions. Indeed, the abundance of circulating NK cells has been inversely correlated with the probability to develop (aGvHD). CD69 is a C-type lectin expressed on the surface of certain immune cell progenitors as well as activated mature leukocytes. CD69 expression was related to shorter OS (P=0.027). In the in vitro study, HIF-1β was markedly upregulated in MM cells acquired drug-resistance against Btz and lenalidomide, while no changes observed in other 1q21 genes (e.g., PSMD4, CKS1B). Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia-induced HIF-1β expression was associated with activation of NF-κB, which was prevented by the IKK inhibitor parthenolide, leading to restoration of Btz sensitivity in Btz-resistant cells (Figure 1).

Summary/Conclusions: Together, these findings argue that HIF-1β represents a potential target for treatments, as these cells have the capacity to potentiate the graft versus leukemia effect with a minimum risk for graft versus host reactions. Indeed, the abundance of circulating NK cells has been inversely correlated with the probability to develop (aGvHD). CD69 is a C-type lectin expressed on the surface of certain immune cell progenitors as well as activated mature leukocytes. CD69 expression was related to shorter OS (P=0.027). In the in vitro study, HIF-1β was markedly upregulated in MM cells acquired drug-resistance against Btz and lenalidomide, while no changes observed in other 1q21 genes (e.g., PSMD4, CKS1B). Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia-induced HIF-1β expression was associated with activation of NF-κB, which was prevented by the IKK inhibitor parthenolide, leading to restoration of Btz sensitivity in Btz-resistant cells (Figure 1).

Summary/Conclusions: Together, these findings argue that HIF-1β represents a potential target for treatments, as these cells have the capacity to potentiate the graft versus leukemia effect with a minimum risk for graft versus host reactions. Indeed, the abundance of circulating NK cells has been inversely correlated with the probability to develop (aGvHD). CD69 is a C-type lectin expressed on the surface of certain immune cell progenitors as well as activated mature leukocytes. CD69 expression was related to shorter OS (P=0.027). In the in vitro study, HIF-1β was markedly upregulated in MM cells acquired drug-resistance against Btz and lenalidomide, while no changes observed in other 1q21 genes (e.g., PSMD4, CKS1B). Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia-induced HIF-1β expression was associated with activation of NF-κB, which was prevented by the IKK inhibitor parthenolide, leading to restoration of Btz sensitivity in Btz-resistant cells (Figure 1).

Summary/Conclusions: Together, these findings argue that HIF-1β represents a potential target for treatments, as these cells have the capacity to potentiate the graft versus leukemia effect with a minimum risk for graft versus host reactions. Indeed, the abundance of circulating NK cells has been inversely correlated with the probability to develop (aGvHD). CD69 is a C-type lectin expressed on the surface of certain immune cell progenitors as well as activated mature leukocytes. CD69 expression was related to shorter OS (P=0.027). In the in vitro study, HIF-1β was markedly upregulated in MM cells acquired drug-resistance against Btz and lenalidomide, while no changes observed in other 1q21 genes (e.g., PSMD4, CKS1B). Ectopic expression of HIF-1β in 1q− cells reduced sensitivity of Btz. Hypoxia-induced HIF-1β expression was associated with activation of NF-κB, which was prevented by the IKK inhibitor parthenolide, leading to restoration of Btz sensitivity in Btz-resistant cells (Figure 1).
University of Texas MD Anderson Cancer Center, Houston, United States, 1Department of Medicine, University of Montreal, Maisonneuve-Rosemont Hospital CIUSSS East, Montreal, Canada, 2Department of Medicine, University of Minnesota, Minneapolis, United States, 3Department of Medicine, McMaster University, Hamilton, Canada, 4Institute of Haematology, Royal Prince Alfred Hospital & Sydney University, Sydney, Australia, 5Medizinische Klinik und Poliklinik Universitätsklinikum Würzburg, Würzburg, Germany, 6Department of Internal Medicine Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States, 7Department of Oncology, Oslo University Hospital, Oslo, Norway, 8Global Drug Development, Novartis Pharma AG, Basel, Switzerland, 19PK Sciences, 20Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, United States, 21Hôpices Civils de Lyon, Université de Lyon, Lyon, France, 22Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, United States

Background: CTL019 is an investigational chimeric antigen receptor (CAR) T-cell therapy with a high rate of durable complete responses (CRs) and a manageable safety profile in a previously reported single-center trial in adult patients (pts) with R/R DLBCL. Aims: Results of a planned interim analysis of a single-arm, open-label, multicenter, global phase 2 trial of CTL019 in pts ≥18 y with R/R DLBCL (JULIET; NCT02445248) are reported. Methods: Industry-manufactured CAR T cells were provided to pts at 27 centers on 4 continents using a global supply chain. Pts had received ≥2 lines of chemotherapy and had disease progression after or were ineligible for autologous hematopoietic cell transplantation (AutoHCT). Autologous CAR T cells were transduced using a lentiviral vector encoding an anti-CD19 CAR, expanded, cryopreserved, shipped, and infused at study sites. The primary endpoint (centrally reviewed by an independent review committee) was best overall response rate (ORR: CR + partial response [PR]). Results: 141 pts were evaluated. Following restaging, bridging therapy, and lymphodepleting chemotherapy (fludarabine 25 mg/m²/cyclephosphamide 250 mg/m²/day × 3 days or bendamustine 90 mg/m²/day × 2 days), 85 pts received a single dose of CTL019 transduced cells (median, 3.1 × 10⁸ [range, 0.1-6.0 × 10⁸] cells). Median time from infusion to data cutoff (20 December 2016) was 9.7 months (range, 0.1-39.4 months). 3 pts died from disease progression within 30 days of infusion. CRS occurred in 57% of responders. Cytokine release syndrome (CRS) was graded using the Penn grading scale and managed by a protocol-specific algorithm. CRS occurred in 57% of pts with grade 3/4 CRS. Median time from initiation to data cutoff (20 December 2016) was 1.78 months (range, 0.1-25.8 months). Complete response (CR) + partial response (PR) was achieved in 33% of pts (21% CR, 12% PR). 13% of pts had grade 3/4 neurologic adverse events (AEs), managed with supportive measures. CRS and other AEs were effectively and reproducibly managed by appropriately trained investigators.

Background: T-cell acute lymphoblastic leukemia (T-ALL) is a disease of T-cell progenitors, which mainly affects children and young adults. Numerous genomic alterations such as NOTCH1/FBXW7 mutations, TAL1/SCL expression or SILT/TAL deletions lead to survival, proliferation and differentiation block in T-ALL cells. Interactions between leukemic cells and their microenvironment also contribute to T-ALL pathogenesis. Cell-cell contacts - Delta-Like/Jagged-Notch1, integrin LFA1/ICAM1 - and secreted factors - such as interleukin 7 and TAL1/SCL expression - are key pathways that affect the course of the disease. T-ALL cells settle in various environments such as thymus, blood, bone marrow (BM), pleura or lymph nodes, which differ in terms of cell content, extracellular matrix and secreted factors. To what extent these distinct niches imprint niche-specific features on T-ALL cells is not well understood.

Aims: Compare the growth of leukemic cells from human and mouse T-ALL in various BM sites. Uncover novel mechanisms of chemoresistance, in relation with the BM microenvironment.

Methods: We used grafts of human and mouse T-ALL in immune-deficient and normal mice, respectively. We explored the behavior of leukemic cells ex-vivo and in vivo to determine whether they differ in their interaction with the host body (femurs, Thorax and Tail vertebrae). We tested their respective chemoresistance to conventional drugs (dexamethasone, vincristine, cytarabine).

Results: We observed that mouse and human T-ALL develop slowly in tail vertebrae BM compared to thorax vertebrae and femur BM. T-ALL recovered from tail BM display lower cell surface marker expression and decreased metabolism and cell cycle progression, demonstrating a dormancy phenotype. Functionally tail-derived T-ALL exhibit a deficient short-term ex vivo growth and a delayed in vivo propagation. These features are non-cell autonomous as T-ALL from tail and thorax share identical genomic abnormalities and functional disparities disappear in vivo and in prolonged in vitro assays. Importantly tail-derived T-ALL display a higher intrinsic resistance to conventional chemotherapy, i.e. vincristine, sulfate and cytarabine, but not to dexamethasone. T-ALL recovered from gonadal adipose tissues or from co-cultures with adipocytes share metabolic, cell cycle and phenotypic or chemoresistance features with Tail-derived T-ALL.

Summary/Conclusions: These results demonstrate that BM sites differentially impact T-ALL propagation. Differences derived from adipose tissue is associated with quiescence and decreased response to cell cycle dependent chemotherapy indicating that adipocyte-rich aged BM or pathologies enhancing BM adipocyte content may help leukemia escaping drug treatment.
**Index of authors**

| A | Alkalay I LB2600  
|   | Anak O LB2604  
|   | Andreadis C LB2604  
|   | Arcangeli M-L LB2606  
|   | Awasthi R LB2604 |
| B | Bachanova V LB2604  
|   | Balas A LB2603  
|   | Ballerini P LB2606  
|   | Baruchel A LB2606  
|   | Beà S LB2601  
|   | Beltran S LB2601  
|   | Ben-Neriah Y LB2600  
|   | Bishop MR LB2604  
|   | Borchmann P LB2604 |
| C | Cahu X LB2606  
|   | Calvo J LB2606  
|   | Campo E LB2601  
|   | Chang B LB2605  
|   | Chen B LB2605  
|   | Clot G LB2601 |
| D | Dai Y LB2602  
|   | Daniel M LB2605  
|   | de Jong D LB2601  
|   | de Leval L LB2601  
|   | Delabesse E LB2606  
|   | Delabie J LB2601 |
| E | Espinet B LB2601 |
| F | Ferreira L LB2605  
|   | Ferry JA LB2601  
|   | Fink A LB2600  
|   | Fleury I LB2604  
|   | Foley SR LB2604  
|   | Fu K LB2601 |
| G | Gao S LB2602  
|   | García de Soria VG LB2603  
|   | Gomes A LB2605  
|   | González-Farré B LB2601  
|   | Gutiérrez-Abril J LB2601 |
| H | Ho PJ LB2604  
|   | Holte H LB2604  
|   | Hei ED LB2601  
|   | Hung E LB2600 |
| J | Jaffe ES LB2601  
|   | Jäger U LB2604  
|   | Jaglowski S LB2604  
|   | Jin F LB2602 |
| K | Kurochkin I LB2605 |
| L | Lachmann A LB2605  
|   | Landman-Parker J LB2606  
|   | Law K LB2605  
|   | Leblanc T LB2606  
|   | Lemischka IR LB2605  
|   | Li D LB2600  
|   | Liu X LB2602  
|   | López-Otin C LB2601 |
| M | Ma’ayan A LB2605 |
| N | Navarro A LB2601 |
| O | O’Connor SJ LB2601  
|   | Oren M LB2600  
|   | Ott G LB2601 |
| P | Pacaud L LB2604  
|   | Papatsenko D LB2605  
|   | Pereira C-F LB2605  
|   | Pérez García Y LB2603  
|   | Pfumio F LB2606  
|   | Pikarsky E LB2600  
|   | Poglio S LB2606  
|   | Puente XS LB2601 |
| Q | Quintanilla-Martinez L LB2601 |
| R | Relano M LB2603  
|   | Ribera-Cortada I LB2601  
|   | Rosenwald A LB2601  
|   | Rymkiewicz G LB2601 |
| S | Salaverria I LB2601  
|   | Salles G LB2604  
|   | Satija N LB2605  
|   | Schuster SJ LB2604  
|   | Siebert R LB2601  
|   | Sun J LB2602  
|   | Sun Y LB2602  
|   | Swerdlow SH LB2601 |
| T | Tai F LB2604  
|   | Tam C LB2604  
|   | Torrents D LB2601  
|   | Tselingiri K LB2603 |
| U | Uzan B LB2606 |
| V | Vacca J LB2600  
|   | Valdés-Mas R LB2601  
|   | Venkatachalam A LB2600 |
| W | Waller EK LB2604  
|   | Wang X LB2602  
|   | Wang Z LB2605  
|   | Weisenburger D LB2601  
|   | Westin J LB2604  
|   | Woroniecka R LB2601  
|   | Wu C LB2602 |
| Y | Yang P LB2602  
|   | Ye L LB2602  
|   | Yu X LB2602 |